Sglt-2 US20110237527 T JJ I-UN
inhibitors US20110237527 T NNS O
, US20110237527 T , O
methods US20110237527 T NNS O
of US20110237527 T IN O
making US20110237527 T VBG O
them US20110237527 T PRP O
, US20110237527 T , O
and US20110237527 T CC O
uses US20110237527 T VBZ O
thereof US20110237527 T NN O
. US20110237527 T . O

The US20110237527 A DT O
present US20110237527 A JJ O
invention US20110237527 A NN O
relates US20110237527 A VBZ O
to US20110237527 A TO O
compounds US20110237527 A NNS O
which US20110237527 A WDT O
are US20110237527 A VBP O
inhibitors US20110237527 A NNS O
of US20110237527 A IN O
sodium US20110237527 A NN I-UN
dependent US20110237527 A JJ I-UN
glucose US20110237527 A JJ I-UN
co-transporter-2 US20110237527 A NN I-UN
( US20110237527 A ( O
SGLT-2 US20110237527 A NNP I-UN
) US20110237527 A ) O
. US20110237527 A . O

These US20110237527 A DT O
compounds US20110237527 A NNS O
are US20110237527 A VBP O
used US20110237527 A VBN O
in US20110237527 A IN O
the US20110237527 A DT O
treatment US20110237527 A NN O
of US20110237527 A IN O
various US20110237527 A JJ O
disorders US20110237527 A NNS O
, US20110237527 A , O
including US20110237527 A VBG O
diabetes US20110237527 A NNS O
, US20110237527 A , O
impaired US20110237527 A VBD O
glucose US20110237527 A JJ O
tolerance US20110237527 A NN O
, US20110237527 A , O
insulin US20110237527 A NN I-UN
resistance US20110237527 A NN O
, US20110237527 A , O
retinopathy US20110237527 A NN O
, US20110237527 A , O
nephropathy US20110237527 A JJ O
, US20110237527 A , O
neuropathy US20110237527 A JJ O
, US20110237527 A , O
cataracts US20110237527 A NNS O
, US20110237527 A , O
hyperglycemia US20110237527 A NN O
, US20110237527 A , O
hyperinsulinemia US20110237527 A NN O
, US20110237527 A , O
hyperchlolesterolemia US20110237527 A NN O
, US20110237527 A , O
elevated US20110237527 A VBD O
blood US20110237527 A NN O
level US20110237527 A NN O
of US20110237527 A IN O
free US20110237527 A JJ O
fatty US20110237527 A JJ O
acids US20110237527 A NNS O
or US20110237527 A CC O
glycerol US20110237527 A NN O
, US20110237527 A , O
hyperlipidemia US20110237527 A NN O
, US20110237527 A , O
hypertriglyceridemia US20110237527 A NN O
, US20110237527 A , O
obesity US20110237527 A NN O
, US20110237527 A , O
wound US20110237527 A IN O
healing US20110237527 A NN O
, US20110237527 A , O
tissue US20110237527 A NN O
ischemia US20110237527 A NN O
, US20110237527 A , O
atherosclerosis US20110237527 A NN O
, US20110237527 A , O
and US20110237527 A CC O
hypertension US20110237527 A NN O
. US20110237527 A . O

Aptamers WO2014102213A1 T NNS O
inhibiting WO2014102213A1 T VBG O
the WO2014102213A1 T DT O
enzymatic WO2014102213A1 T JJ O
activity WO2014102213A1 T NN O
of WO2014102213A1 T IN O
tyrosinase WO2014102213A1 T NN I-UN
. WO2014102213A1 T . O

The WO2014102213A1 A DT O
invention WO2014102213A1 A NN O
relates WO2014102213A1 A VBZ O
to WO2014102213A1 A TO O
a WO2014102213A1 A DT O
DNA WO2014102213A1 A NN O
aptamer WO2014102213A1 A NN O
that WO2014102213A1 A WDT O
can WO2014102213A1 A MD O
inhibit WO2014102213A1 A VB O
the WO2014102213A1 A DT O
enzymatic WO2014102213A1 A JJ O
activity WO2014102213A1 A NN O
of WO2014102213A1 A IN O
tyrosinase WO2014102213A1 A NN I-UN
for WO2014102213A1 A IN O
the WO2014102213A1 A DT O
conversion WO2014102213A1 A NN O
of WO2014102213A1 A IN O
tyrosine WO2014102213A1 A NN O
into WO2014102213A1 A IN O
L-DOPA WO2014102213A1 A NNP O
and WO2014102213A1 A CC O
dopaquinone WO2014102213A1 A NN O
, WO2014102213A1 A , O
and WO2014102213A1 A CC O
to WO2014102213A1 A TO O
the WO2014102213A1 A DT O
dermatological WO2014102213A1 A JJ O
and WO2014102213A1 A CC O
cosmetic WO2014102213A1 A JJ O
uses WO2014102213A1 A NNS O
thereof WO2014102213A1 A NN O
. WO2014102213A1 A . O

Anti-acne WO2011001165A3 T JJ O
formulations WO2011001165A3 T NNS O
containing WO2011001165A3 T VBG O
a WO2011001165A3 T DT O
dialkyl WO2011001165A3 T NN O
sulphosuccinate WO2011001165A3 T NN O
and WO2011001165A3 T CC O
salicylic WO2011001165A3 T JJ O
acid WO2011001165A3 T NN O
. WO2011001165A3 T . O

Pyrrolopyridazine EP1254907B1 T NNP O
compound EP1254907B1 T NN O
. EP1254907B1 T . O

A EP1254907B1 A DT O
pyrrolopyridazine EP1254907B1 A NN O
compound EP1254907B1 A NN O
represented EP1254907B1 A VBN O
by EP1254907B1 A IN O
the EP1254907B1 A DT O
general EP1254907B1 A JJ O
formula EP1254907B1 A NN O
( EP1254907B1 A ( O
I EP1254907B1 A PRP O
) EP1254907B1 A ) O
or EP1254907B1 A CC O
a EP1254907B1 A DT O
pharmacologically EP1254907B1 A RB O
acceptable EP1254907B1 A JJ O
salt EP1254907B1 A NN O
thereof EP1254907B1 A NN O
. EP1254907B1 A . O

( EP1254907B1 A ( O
In EP1254907B1 A IN O
the EP1254907B1 A DT O
formula EP1254907B1 A NN O
, EP1254907B1 A , O
R1 EP1254907B1 A NNP O
is EP1254907B1 A VBZ O
C¿2-6 EP1254907B1 A NNP O
? EP1254907B1 A . O

alkenyl EP1254907B1 A NN O
, EP1254907B1 A , O
C2-6 EP1254907B1 A NNP O
halogenoalkenyl EP1254907B1 A NN O
, EP1254907B1 A , O
optionally EP1254907B1 A RB O
substituted EP1254907B1 A VBN O
C3-7 EP1254907B1 A NNP O
cycloalkyl EP1254907B1 A NN O
, EP1254907B1 A , O
or EP1254907B1 A CC O
optionally EP1254907B1 A RB O
substituted EP1254907B1 A VBN O
C1-6 EP1254907B1 A NNP O
alkyl EP1254907B1 A NN O
substituted EP1254907B1 A VBN O
by EP1254907B1 A IN O
C3-7 EP1254907B1 A NNP O
cycloalkyl EP1254907B1 A NN O
; EP1254907B1 A : O
R EP1254907B1 A NNP O
? EP1254907B1 A . O
2¿ EP1254907B1 A CD O
is EP1254907B1 A VBZ O
C¿1-6 EP1254907B1 A NNP O
? EP1254907B1 A . O

alkyl EP1254907B1 A NN O
; EP1254907B1 A : O
R EP1254907B1 A NNP O
? EP1254907B1 A . O
3¿ EP1254907B1 A CD O
is EP1254907B1 A VBZ O
hydroxymethyl EP1254907B1 A VBN O
, EP1254907B1 A , O
C¿2-6 EP1254907B1 A NNP O
? EP1254907B1 A . O

aliphatic EP1254907B1 A JJ O
acyloxymethyl EP1254907B1 A NN O
, EP1254907B1 A , O
optionally EP1254907B1 A RB O
substituted EP1254907B1 A VBN O
( EP1254907B1 A ( O
C6-10 EP1254907B1 A NNP O
aryl EP1254907B1 A NN O
) EP1254907B1 A ) O
carbonyloxymethyl EP1254907B1 A NN O
, EP1254907B1 A , O
( EP1254907B1 A ( O
C1-6 EP1254907B1 A NNP O
alkoxy EP1254907B1 A NN O
) EP1254907B1 A ) O
carbonyloxymethyl EP1254907B1 A NN O
, EP1254907B1 A , O
formyl EP1254907B1 A NN O
, EP1254907B1 A , O
carboxy EP1254907B1 A NN O
, EP1254907B1 A , O
( EP1254907B1 A ( O
C1-6 EP1254907B1 A NNP O
alkoxy EP1254907B1 A NN O
) EP1254907B1 A ) O
carbonyl EP1254907B1 A NN O
, EP1254907B1 A , O
or EP1254907B1 A CC O
optionally EP1254907B1 A RB O
substituted EP1254907B1 A VBN O
( EP1254907B1 A ( O
C6-10 EP1254907B1 A NNP O
aryl EP1254907B1 A NN O
) EP1254907B1 A ) O
oxycarbonyl EP1254907B1 A NN O
; EP1254907B1 A : O
R EP1254907B1 A NNP O
? EP1254907B1 A . O
4¿ EP1254907B1 A CD O
is EP1254907B1 A VBZ O
optionally EP1254907B1 A RB O
substituted EP1254907B1 A VBN O
C¿6-10 EP1254907B1 A NNP O
? EP1254907B1 A . O

aryl EP1254907B1 A NN O
; EP1254907B1 A : O
and EP1254907B1 A CC O
A EP1254907B1 A DT O
is EP1254907B1 A VBZ O
imino EP1254907B1 A JJ O
, EP1254907B1 A , O
oxygen EP1254907B1 A NN O
, EP1254907B1 A , O
or EP1254907B1 A CC O
sulfur EP1254907B1 A NN O
. EP1254907B1 A . O
) EP1254907B1 A ) O

The EP1254907B1 A DT O
pyrrolopyridazine EP1254907B1 A NN O
compound EP1254907B1 A NN O
is EP1254907B1 A VBZ O
highly EP1254907B1 A RB O
effective EP1254907B1 A JJ O
in EP1254907B1 A IN O
inhibiting EP1254907B1 A VBG O
the EP1254907B1 A DT O
secretion EP1254907B1 A NN O
of EP1254907B1 A IN O
gastric EP1254907B1 A JJ O
hydrochloric EP1254907B1 A JJ O
acid EP1254907B1 A NN O
, EP1254907B1 A , O
protecting EP1254907B1 A VBG O
the EP1254907B1 A DT O
gastric EP1254907B1 A JJ O
mucosa EP1254907B1 A NN O
, EP1254907B1 A , O
and EP1254907B1 A CC O
the EP1254907B1 A DT O
like EP1254907B1 A JJ O
. EP1254907B1 A . O

It EP1254907B1 A PRP O
is EP1254907B1 A VBZ O
useful EP1254907B1 A JJ O
as EP1254907B1 A IN O
a EP1254907B1 A DT O
medicine EP1254907B1 A NN O
, EP1254907B1 A , O
especially EP1254907B1 A RB O
a EP1254907B1 A DT O
preventive/remedy EP1254907B1 A NN O
for EP1254907B1 A IN O
ulcerative EP1254907B1 A JJ O
diseases EP1254907B1 A NNS O
. EP1254907B1 A . O

Use US7902261 T NNP O
of US7902261 T IN O
fingolimod US7902261 T NN O
or US7902261 T CC O
salt US7902261 T NN O
. US7902261 T . O

Quinoline US20110263620 T NNP O
compounds US20110263620 T NNS O
and US20110263620 T CC O
their US20110263620 T PRP$ O
use US20110263620 T NN O
for US20110263620 T IN O
treating US20110263620 T VBG O
viral US20110263620 T JJ O
infection US20110263620 T NN O
. US20110263620 T . O

Quinoline US20110263620 A NNP O
compounds US20110263620 A NNS O
of US20110263620 A IN O
formula US20110263620 A NN O
( US20110263620 A ( O
I US20110263620 A PRP O
) US20110263620 A ) O
: US20110263620 A : O
in US20110263620 A IN O
which US20110263620 A WDT O
A US20110263620 A NNP O
, US20110263620 A , O
B US20110263620 A NNP O
, US20110263620 A , O
D US20110263620 A NNP O
, US20110263620 A , O
E US20110263620 A NNP O
, US20110263620 A , O
F US20110263620 A NNP O
, US20110263620 A , O
G US20110263620 A NNP O
, US20110263620 A , O
R1 US20110263620 A NNP O
, US20110263620 A , O
R2 US20110263620 A NNP O
, US20110263620 A , O
R3 US20110263620 A NNP O
, US20110263620 A , O
X US20110263620 A NNP O
, US20110263620 A , O
Y US20110263620 A NNP O
, US20110263620 A , O
n US20110263620 A RB O
, US20110263620 A , O
p US20110263620 A NN O
, US20110263620 A , O
and US20110263620 A CC O
q US20110263620 A NNS O
are US20110263620 A VBP O
defined US20110263620 A VBN O
herein US20110263620 A NNS O
. US20110263620 A . O

Also US20110263620 A RB O
disclosed US20110263620 A VBN O
is US20110263620 A VBZ O
a US20110263620 A DT O
method US20110263620 A NN O
for US20110263620 A IN O
treating US20110263620 A VBG O
a US20110263620 A DT O
viral US20110263620 A JJ O
infection US20110263620 A NN O
with US20110263620 A IN O
a US20110263620 A DT O
compound US20110263620 A NN O
of US20110263620 A IN O
formula US20110263620 A NN O
( US20110263620 A ( O
I US20110263620 A PRP O
) US20110263620 A ) O
. US20110263620 A . O

Pharmaceutical CN101129948B T JJ O
composition CN101129948B T NN O
for CN101129948B T IN O
treating CN101129948B T VBG O
gynecology CN101129948B T NN O
hysteromyoma CN101129948B T NN O
and CN101129948B T CC O
processes CN101129948B T NNS O
for CN101129948B T IN O
producing CN101129948B T VBG O
same CN101129948B T JJ O
. CN101129948B T . O

2- CA2745063A1 T JJ O
( CA2745063A1 T ( O
piperidin-1-yl CA2745063A1 T JJ O
) CA2745063A1 T ) O
-4-heterocyclyl-thiazole-5-carboxylic CA2745063A1 T JJ O
acid CA2745063A1 T JJ O
derivatives CA2745063A1 T NNS O
against CA2745063A1 T IN O
bacterial CA2745063A1 T JJ O
infections CA2745063A1 T NNS O
. CA2745063A1 T . O

Medicine CN101011548A T NNP O
for CN101011548A T IN O
treating CN101011548A T VBG O
ringworm CN101011548A T NN O
of CN101011548A T IN O
the CN101011548A T DT O
nails CN101011548A T NNS O
and CN101011548A T CC O
preparation CN101011548A T NN O
method CN101011548A T NN O
thereof CN101011548A T NN O
. CN101011548A T . O

Clofarabine CN102138896B T NNP O
injection CN102138896B T NN O
and CN102138896B T CC O
preparation CN102138896B T NN O
method CN102138896B T NN O
thereof CN102138896B T NN O
. CN102138896B T . O

Antimicrobial US20080015189 T JJ O
photoinactivation US20080015189 T NN O
using US20080015189 T VBG O
chalcogen US20080015189 T JJ O
analogs US20080015189 T NNS O
of US20080015189 T IN O
benzo US20080015189 T NN O
( US20080015189 T ( O
A US20080015189 T DT O
) US20080015189 T ) O
phenoxazinium US20080015189 T NN O
dyes US20080015189 T NNS O
. US20080015189 T . O

Compositions US20080015189 A NNS O
and US20080015189 A CC O
methods US20080015189 A NNS O
for US20080015189 A IN O
the US20080015189 A DT O
use US20080015189 A NN O
of US20080015189 A IN O
photoactivatable US20080015189 A JJ O
antimicrobial US20080015189 A JJ O
chalcogen US20080015189 A NN O
analogs US20080015189 A NNS O
of US20080015189 A IN O
benzophenoxazinium US20080015189 A JJ O
dyes US20080015189 A NNS O
in US20080015189 A IN O
the US20080015189 A DT O
treatment US20080015189 A NN O
of US20080015189 A IN O
infections US20080015189 A NNS O
are US20080015189 A VBP O
provided US20080015189 A VBN O
. US20080015189 A . O

Enteric CN1759844A T NNP O
coated CN1759844A T VBD O
preparation CN1759844A T NN O
of CN1759844A T IN O
Clarithromycin CN1759844A T NNP O
. CN1759844A T . O

An CN1759844A A DT O
entenic CN1759844A A JJ O
clamycin CN1759844A A NN O
and CN1759844A A CC O
its CN1759844A A PRP$ O
preparing CN1759844A A NN O
process CN1759844A A NN O
are CN1759844A A VBP O
disclosed CN1759844A A VBN O
. CN1759844A A . O

Said CN1759844A A NNP O
enteric CN1759844A A JJ O
clamycin CN1759844A A NN O
contains CN1759844A A VBZ O
one CN1759844A A CD O
or CN1759844A A CC O
more CN1759844A A JJR O
units CN1759844A A NNS O
and CN1759844A A CC O
each CN1759844A A DT O
unit CN1759844A A NN O
is CN1759844A A VBZ O
composed CN1759844A A VBN O
of CN1759844A A IN O
a CN1759844A A DT O
core CN1759844A A NN O
prepared CN1759844A A VBN O
from CN1759844A A IN O
clamycin CN1759844A A NN O
and CN1759844A A CC O
one CN1759844A A CD O
or CN1759844A A CC O
more CN1759844A A JJR O
medicinal CN1759844A A JJ O
excipients CN1759844A A NNS O
and CN1759844A A CC O
an CN1759844A A DT O
enteric CN1759844A A JJ O
polymer CN1759844A A NN O
film CN1759844A A NN O
coated CN1759844A A VBN O
on CN1759844A A IN O
the CN1759844A A DT O
surface CN1759844A A NN O
of CN1759844A A IN O
said CN1759844A A VBD O
core CN1759844A A NN O
. CN1759844A A . O

Delivery US20080003219 T NN O
of US20080003219 T IN O
an US20080003219 T DT O
ocular US20080003219 T JJ O
agent US20080003219 T NN O
. US20080003219 T . O

Improved US20120009168 T VBN O
emulsifying US20120009168 T NN O
system US20120009168 T NN O
for US20120009168 T IN O
nutraceutical US20120009168 T JJ O
compositions US20120009168 T NNS O
. US20120009168 T . O

phosphodiesterase US7531540 T NN O
type US7531540 T NN O
4 US7531540 T CD O
inhibitors US7531540 T NNS O
; US7531540 T : O
to US7531540 T TO O
treat US7531540 T VB O
respiratory US7531540 T NN O
disorders US7531540 T NNS O
, US7531540 T , O
skin US7531540 T FW O
disorders US7531540 T NNS O
like US7531540 T IN O
psoriasis US7531540 T NN O
and US7531540 T CC O
atopic US7531540 T NN O
eczema US7531540 T NN O
; US7531540 T : O
low US7531540 T JJ O
toxicity US7531540 T NN O
, US7531540 T , O
high US7531540 T JJ O
bioavailability US7531540 T NN O
, US7531540 T , O
no US7531540 T DT O
significant US7531540 T JJ O
side US7531540 T NN O
effects US7531540 T NNS O
; US7531540 T : O
2- US7531540 T JJ O
{ US7531540 T ( O
4- US7531540 T JJ O
[ US7531540 T NN O
( US7531540 T ( O
4aS,8aR US7531540 T CD O
) US7531540 T ) O
-4- US7531540 T NN O
( US7531540 T ( O
3,4-dimethoxyphenyl US7531540 T JJ O
) US7531540 T ) O
-1-oxo-4a,5,8,8a-tetrahydro-1H-phthalazin-2-yl US7531540 T FW O
] US7531540 T FW O
-piperidin-1-yl US7531540 T FW O
} US7531540 T ) O
-acetamide US7531540 T NN O
. US7531540 T . O

Pharmaceutical US20110065719 T JJ O
formulations US20110065719 T NNS O
containing US20110065719 T VBG O
flavouring US20110065719 T VBG O
substances US20110065719 T NNS O
with US20110065719 T IN O
improved US20110065719 T JJ O
pharmaceutical US20110065719 T JJ O
. US20110065719 T . O

Method EP2149584A1 T NNP O
for EP2149584A1 T IN O
enhancing EP2149584A1 T VBG O
immune EP2149584A1 T JJ O
response EP2149584A1 T NN O
with EP2149584A1 T IN O
peptide EP2149584A1 T NN O
. EP2149584A1 T . O

An EP2149584A1 A DT O
object EP2149584A1 A NN O
of EP2149584A1 A IN O
the EP2149584A1 A DT O
present EP2149584A1 A JJ O
invention EP2149584A1 A NN O
is EP2149584A1 A VBZ O
to EP2149584A1 A TO O
provide EP2149584A1 A VB O
a EP2149584A1 A DT O
safe EP2149584A1 A JJ O
and EP2149584A1 A CC O
effective EP2149584A1 A JJ O
method EP2149584A1 A NN O
for EP2149584A1 A IN O
enhancing EP2149584A1 A VBG O
an EP2149584A1 A DT O
immune EP2149584A1 A JJ O
response EP2149584A1 A NN O
and EP2149584A1 A CC O
a EP2149584A1 A DT O
medicament EP2149584A1 A NN O
for EP2149584A1 A IN O
preventing EP2149584A1 A VBG O
or EP2149584A1 A CC O
treating EP2149584A1 A VBG O
Alzheimer EP2149584A1 A NNP O
disease EP2149584A1 A NN O
comprising EP2149584A1 A VBG O
amyloid EP2149584A1 A JJ I-UN
β EP2149584A1 A NNP I-UN
peptide EP2149584A1 A NN I-UN
that EP2149584A1 A WDT O
induces EP2149584A1 A VBZ O
an EP2149584A1 A DT O
enhanced EP2149584A1 A JJ O
immune EP2149584A1 A NN O
response EP2149584A1 A NN O
. EP2149584A1 A . O

An EP2149584A1 A DT O
amyloid EP2149584A1 A JJ I-UN
β EP2149584A1 A NN I-UN
peptide EP2149584A1 A NN I-UN
or EP2149584A1 A CC O
a EP2149584A1 A DT O
portion EP2149584A1 A NN O
thereof EP2149584A1 A NN O
with EP2149584A1 A IN O
addition EP2149584A1 A NN O
or EP2149584A1 A CC O
insertion EP2149584A1 A NN O
of EP2149584A1 A IN O
cysteine EP2149584A1 A NN O
and EP2149584A1 A CC O
a EP2149584A1 A DT O
method EP2149584A1 A NN O
for EP2149584A1 A IN O
enhancing EP2149584A1 A VBG O
an EP2149584A1 A DT O
immune EP2149584A1 A JJ O
response EP2149584A1 A NN O
using EP2149584A1 A VBG O
the EP2149584A1 A DT O
peptide EP2149584A1 A NN O
or EP2149584A1 A CC O
a EP2149584A1 A DT O
method EP2149584A1 A NN O
for EP2149584A1 A IN O
enhancing EP2149584A1 A VBG O
an EP2149584A1 A DT O
immune EP2149584A1 A JJ O
response EP2149584A1 A NN O
using EP2149584A1 A VBG O
the EP2149584A1 A DT O
peptide EP2149584A1 A NN O
together EP2149584A1 A RB O
with EP2149584A1 A IN O
an EP2149584A1 A DT O
adjuvant EP2149584A1 A NN O
. EP2149584A1 A . O

A EP2149584A1 A DT O
medicament EP2149584A1 A NN O
for EP2149584A1 A IN O
preventing EP2149584A1 A VBG O
or EP2149584A1 A CC O
treating EP2149584A1 A VBG O
Alzheimer EP2149584A1 A NNP O
disease EP2149584A1 A NN O
comprising EP2149584A1 A VBG O
an EP2149584A1 A DT O
amyloid EP2149584A1 A JJ I-UN
β EP2149584A1 A NN I-UN
peptide EP2149584A1 A NN I-UN
or EP2149584A1 A CC O
a EP2149584A1 A DT O
portion EP2149584A1 A NN O
thereof EP2149584A1 A NN O
that EP2149584A1 A WDT O
induces EP2149584A1 A VBZ O
an EP2149584A1 A DT O
enhanced EP2149584A1 A JJ O
immune EP2149584A1 A NN O
response EP2149584A1 A NN O
. EP2149584A1 A . O

A EP2149584A1 A DT O
DNA EP2149584A1 A NN O
vaccine EP2149584A1 A NN O
, EP2149584A1 A , O
that EP2149584A1 A WDT O
may EP2149584A1 A MD O
have EP2149584A1 A VB O
the EP2149584A1 A DT O
same EP2149584A1 A JJ O
effect EP2149584A1 A NN O
, EP2149584A1 A , O
comprising EP2149584A1 A VBG O
the EP2149584A1 A DT O
gene EP2149584A1 A NN O
encoding EP2149584A1 A VBG O
an EP2149584A1 A DT O
amyloid EP2149584A1 A JJ I-UN
β EP2149584A1 A NN I-UN
peptide EP2149584A1 A NN I-UN
or EP2149584A1 A CC O
a EP2149584A1 A DT O
portion EP2149584A1 A NN O
thereof EP2149584A1 A NN O
that EP2149584A1 A WDT O
induces EP2149584A1 A VBZ O
an EP2149584A1 A DT O
enhanced EP2149584A1 A JJ O
immune EP2149584A1 A NN O
response EP2149584A1 A NN O
with EP2149584A1 A IN O
addition EP2149584A1 A NN O
or EP2149584A1 A CC O
insertion EP2149584A1 A NN O
of EP2149584A1 A IN O
cysteine EP2149584A1 A NN O
. EP2149584A1 A . O

A US7053095 T DT O
pyridyl-2yl-4- US7053095 T JJ O
[ US7053095 T JJ O
1,2,3-triazole US7053095 T JJ O
] US7053095 T NN O
derivatives US7053095 T NNS O
therapeutic US7053095 T JJ O
agent US7053095 T NN O
for US7053095 T IN O
treating US7053095 T VBG O
cancer US7053095 T NN O
, US7053095 T , O
glomerulonephritis US7053095 T NN O
, US7053095 T , O
diabetic US7053095 T JJ O
nephropathy US7053095 T NN O
, US7053095 T , O
hepatic US7053095 T JJ O
fibrosis US7053095 T NN O
, US7053095 T , O
pulmonary US7053095 T JJ O
fibrosis US7053095 T NN O
, US7053095 T , O
hyperplasia US7053095 T NN O
, US7053095 T , O
restenosis US7053095 T NN O
, US7053095 T , O
skin US7053095 T NN O
disorders US7053095 T NNS O
. US7053095 T . O

The US7053095 A DT O
compounds US7053095 A NNS O
of US7053095 A IN O
the US7053095 A DT O
present US7053095 A JJ O
invention US7053095 A NN O
are US7053095 A VBP O
potent US7053095 A JJ O
inhibitors US7053095 A NNS O
of US7053095 A IN O
transforming US7053095 A VBG I-UN
growth US7053095 A NN I-UN
factor US7053095 A NN I-UN
( US7053095 A ( I-UN
“TGF” US7053095 A NNP I-UN
) US7053095 A ) O
-β US7053095 A VBP O
signaling US7053095 A VBG O
pathway US7053095 A NN O
. US7053095 A . O

Composition CN101085216A T NN O
containing CN101085216A T VBG O
biological CN101085216A T JJ O
polysaccharide CN101085216A T NN O
and CN101085216A T CC O
biological CN101085216A T JJ O
polysaccharide CN101085216A T NN O
wine CN101085216A T NN O
made CN101085216A T VBN O
from CN101085216A T IN O
the CN101085216A T DT O
same CN101085216A T JJ O
. CN101085216A T . O

Compositions US20090148541 T NNS O
and US20090148541 T CC O
methods US20090148541 T NNS O
for US20090148541 T IN O
the US20090148541 T DT O
treatment US20090148541 T NN O
of US20090148541 T IN O
seborrhea US20090148541 T NN O
. US20090148541 T . O

Modulators US8497271 T NNS O
of US8497271 T IN O
G US8497271 T NNP I-UN
protein-coupled US8497271 T JJ I-UN
receptor US8497271 T NN I-UN
88 US8497271 T CD I-UN
. US8497271 T . O

The US8497271 A DT O
present US8497271 A JJ O
disclosure US8497271 A NN O
is US8497271 A VBZ O
generally US8497271 A RB O
directed US8497271 A VBN O
to US8497271 A TO O
compounds US8497271 A NNS O
which US8497271 A WDT O
can US8497271 A MD O
modulate US8497271 A VB O
G-protein US8497271 A NNP I-UN
coupled US8497271 A JJ I-UN
receptor US8497271 A NN I-UN
88 US8497271 A CD I-UN
, US8497271 A , O
compositions US8497271 A NNS O
comprising US8497271 A VBG O
such US8497271 A JJ O
compounds US8497271 A NNS O
, US8497271 A , O
and US8497271 A CC O
methods US8497271 A NNS O
for US8497271 A IN O
modulating US8497271 A VBG O
G-protein US8497271 A NNP I-UN
coupled US8497271 A VBD I-UN
receptor US8497271 A NN I-UN
88 US8497271 A CD I-UN
. US8497271 A . O

Medicine CN1824041A T NNP O
and CN1824041A T CC O
food CN1824041A T NN O
dual CN1824041A T JJ O
purpose CN1824041A T NN O
nutritive CN1824041A T JJ O
product CN1824041A T NN O
for CN1824041A T IN O
preventing CN1824041A T VBG O
and CN1824041A T CC O
treating CN1824041A T VBG O
computer CN1824041A T NN O
vision CN1824041A T NN O
syndrome CN1824041A T NN O
and CN1824041A T CC O
its CN1824041A T PRP$ O
manufacturing CN1824041A T NN O
method CN1824041A T NN O
. CN1824041A T . O

Medicine CN101396488A T NNP O
for CN101396488A T IN O
treating CN101396488A T VBG O
chronic CN101396488A T JJ O
faucitis CN101396488A T NN O
. CN101396488A T . O

Secondary US20130053325 T JJ O
Structure US20130053325 T NNP O
Stabilized US20130053325 T NNP O
NMDA US20130053325 T NNP I-UN
Receptor US20130053325 T NNP I-UN
Modulators US20130053325 T NNPS O
and US20130053325 T CC O
Uses US20130053325 T VBZ O
Thereof US20130053325 T NNP O
. US20130053325 T . O

Disclosed US20130053325 A VBN O
are US20130053325 A VBP O
compounds US20130053325 A NNS O
having US20130053325 A VBG O
enhanced US20130053325 A VBN O
potency US20130053325 A NN O
in US20130053325 A IN O
the US20130053325 A DT O
modulation US20130053325 A NN O
of US20130053325 A IN O
NMDA US20130053325 A NNP I-UN
receptor US20130053325 A NN I-UN
activity US20130053325 A NN O
. US20130053325 A . O

Oral CN1939271A T JJ O
preparation CN1939271A T NN O
containing CN1939271A T VBG O
erythrocin CN1939271A T NN O
and CN1939271A T CC O
its CN1939271A T PRP$ O
making CN1939271A T NN O
method CN1939271A T NN O
. CN1939271A T . O

Bacterial US20090022819 T JJ O
extracts US20090022819 T NNS O
cultured US20090022819 T VBN O
in US20090022819 T IN O
thermal US20090022819 T JJ O
waters US20090022819 T NNS O
for US20090022819 T IN O
the US20090022819 T DT O
treatment US20090022819 T NN O
of US20090022819 T IN O
dry US20090022819 T JJ O
skin US20090022819 T NN O
. US20090022819 T . O

Method EP1496883A1 T NNP O
for EP1496883A1 T IN O
treating EP1496883A1 T VBG O
ileus EP1496883A1 T NN O
with EP1496883A1 T IN O
an EP1496883A1 T DT O
alpha-ketoalkanoic EP1496883A1 T JJ O
acid EP1496883A1 T NN O
, EP1496883A1 T , O
ester EP1496883A1 T NN O
or EP1496883A1 T CC O
amide EP1496883A1 T NN O
. EP1496883A1 T . O

Preparation WO2005105098A3 T NN O
for WO2005105098A3 T IN O
the WO2005105098A3 T DT O
treatment WO2005105098A3 T NN O
of WO2005105098A3 T IN O
cancer WO2005105098A3 T NN O
. WO2005105098A3 T . O

The WO2005105098A3 A DT O
invention WO2005105098A3 A NN O
relates WO2005105098A3 A VBZ O
to WO2005105098A3 A TO O
a WO2005105098A3 A DT O
combination WO2005105098A3 A NN O
preparation WO2005105098A3 A NN O
, WO2005105098A3 A , O
effective WO2005105098A3 A JJ O
against WO2005105098A3 A IN O
cancer WO2005105098A3 A NN O
cells WO2005105098A3 A NNS O
, WO2005105098A3 A , O
comprising WO2005105098A3 A VBG O
, WO2005105098A3 A , O
as WO2005105098A3 A IN O
active WO2005105098A3 A JJ O
substance WO2005105098A3 A NN O
, WO2005105098A3 A , O
at WO2005105098A3 A IN O
least WO2005105098A3 A JJS O
one WO2005105098A3 A CD O
1-diethylaminoethyl-3-quinoxalin-2-one WO2005105098A3 A JJ O
derivative WO2005105098A3 A NN O
of WO2005105098A3 A IN O
formula WO2005105098A3 A NN O
( WO2005105098A3 A ( O
I WO2005105098A3 A PRP O
) WO2005105098A3 A ) O
, WO2005105098A3 A , O
where WO2005105098A3 A WRB O
R1 WO2005105098A3 A NNP O
and WO2005105098A3 A CC O
R2 WO2005105098A3 A NNP O
independently WO2005105098A3 A RB O
= WO2005105098A3 A VBZ O
H WO2005105098A3 A NNP O
, WO2005105098A3 A , O
methyl WO2005105098A3 A NN O
, WO2005105098A3 A , O
ethyl WO2005105098A3 A NN O
, WO2005105098A3 A , O
propyl WO2005105098A3 A NN O
, WO2005105098A3 A , O
butyl WO2005105098A3 A NN O
, WO2005105098A3 A , O
or WO2005105098A3 A CC O
R1 WO2005105098A3 A NNP O
and WO2005105098A3 A CC O
R2 WO2005105098A3 A NNP O
together WO2005105098A3 A RB O
= WO2005105098A3 A VBD O
a WO2005105098A3 A DT O
cycloalkyl WO2005105098A3 A NN O
compound WO2005105098A3 A NN O
, WO2005105098A3 A , O
R3 WO2005105098A3 A NNP O
= WO2005105098A3 A NNP O
methoxy WO2005105098A3 A NN O
, WO2005105098A3 A , O
ethoxy WO2005105098A3 A NN O
, WO2005105098A3 A , O
hydroxy WO2005105098A3 A NN O
, WO2005105098A3 A , O
H WO2005105098A3 A NNP O
, WO2005105098A3 A , O
C1-C4 WO2005105098A3 A NNP O
alkyl WO2005105098A3 A NN O
, WO2005105098A3 A , O
or WO2005105098A3 A CC O
halogen WO2005105098A3 A NN O
and WO2005105098A3 A CC O
n= WO2005105098A3 A JJ O
1 WO2005105098A3 A CD O
, WO2005105098A3 A , O
2 WO2005105098A3 A CD O
or WO2005105098A3 A CC O
3 WO2005105098A3 A CD O
, WO2005105098A3 A , O
or WO2005105098A3 A CC O
a WO2005105098A3 A DT O
pharmaceutically-acceptable WO2005105098A3 A JJ O
salt WO2005105098A3 A NN O
of WO2005105098A3 A IN O
said WO2005105098A3 A VBD O
derivatives WO2005105098A3 A NNS O
and WO2005105098A3 A CC O
an WO2005105098A3 A DT O
effective WO2005105098A3 A JJ O
amount WO2005105098A3 A NN O
of WO2005105098A3 A IN O
a WO2005105098A3 A DT O
cytostatic WO2005105098A3 A JJ O
anti-cancer WO2005105098A3 A NN O
agent WO2005105098A3 A NN O
, WO2005105098A3 A , O
such WO2005105098A3 A JJ O
as WO2005105098A3 A IN O
a WO2005105098A3 A DT O
compound WO2005105098A3 A NN O
of WO2005105098A3 A IN O
the WO2005105098A3 A DT O
oxysterol WO2005105098A3 A NN O
or WO2005105098A3 A CC O
polyphenol WO2005105098A3 A NN O
classes WO2005105098A3 A NNS O
, WO2005105098A3 A , O
or WO2005105098A3 A CC O
a WO2005105098A3 A DT O
mixture WO2005105098A3 A NN O
comprising WO2005105098A3 A VBG O
selenium WO2005105098A3 A NN O
and WO2005105098A3 A CC O
L-cysteine WO2005105098A3 A JJ O
and/or WO2005105098A3 A NN O
L-glutathione WO2005105098A3 A NNP O
, WO2005105098A3 A , O
or WO2005105098A3 A CC O
a WO2005105098A3 A DT O
mixture WO2005105098A3 A NN O
comprising WO2005105098A3 A VBG O
B-complex WO2005105098A3 A NNP O
vitamins WO2005105098A3 A NNS O
, WO2005105098A3 A , O
in WO2005105098A3 A IN O
particular WO2005105098A3 A JJ O
with WO2005105098A3 A IN O
the WO2005105098A3 A DT O
vitamins WO2005105098A3 A NNS O
B1 WO2005105098A3 A NNP O
, WO2005105098A3 A , O
and/or WO2005105098A3 A NN O
B6 WO2005105098A3 A NNP O
and/or WO2005105098A3 A NN O
B12 WO2005105098A3 A NNP O
, WO2005105098A3 A , O
with WO2005105098A3 A IN O
the WO2005105098A3 A DT O
exception WO2005105098A3 A NN O
of WO2005105098A3 A IN O
cis- WO2005105098A3 A NN O
or WO2005105098A3 A CC O
oxaliplatin WO2005105098A3 A NN O
and WO2005105098A3 A CC O
irinotecan WO2005105098A3 A JJ O
. WO2005105098A3 A . O

Cialis CN1742732A T NNP O
drop CN1742732A T NN O
pilles CN1742732A T NNS O
and CN1742732A T CC O
preparing CN1742732A T VBG O
method CN1742732A T NN O
therefor CN1742732A T NN O
. CN1742732A T . O

Nano CN1857309A T NNP O
silver CN1857309A T NN O
spray CN1857309A T NN O
for CN1857309A T IN O
women CN1857309A T NNS O
and CN1857309A T CC O
its CN1857309A T PRP$ O
preparing CN1857309A T NN O
method CN1857309A T NN O
. CN1857309A T . O

Skin US20100197802 T NNP O
dressings US20100197802 T NNS O
. US20100197802 T . O

Three-ring EP2781520A1 T JJ O
pi3k EP2781520A1 T NN I-UN
and/or EP2781520A1 T NN O
mtor EP2781520A1 T NN I-UN
inhibitor EP2781520A1 T NN O
. EP2781520A1 T . O

Novel US20110105470 T NNP O
Lapachone US20110105470 T NNP O
Compounds US20110105470 T NNP O
And US20110105470 T CC O
Methods US20110105470 T NNP O
of US20110105470 T IN O
Use US20110105470 T NNP O
Thereof US20110105470 T NNP O
. US20110105470 T . O

Modified CN102652744A T VBN O
injection CN102652744A T NN O
containing CN102652744A T VBG O
13 CN102652744A T CD O
compound CN102652744A T NN O
vitamins CN102652744A T NNS O
and CN102652744A T CC O
preparation CN102652744A T NN O
method CN102652744A T NN O
thereof CN102652744A T NN O
. CN102652744A T . O

Restoring US7393825 T VBG O
balance US7393825 T NN O
in US7393825 T IN O
vascular US7393825 T JJ O
tone US7393825 T NN O
without US7393825 T IN O
systemic US7393825 T JJ O
effect US7393825 T NN O
in US7393825 T IN O
normal US7393825 T JJ O
vasculature US7393825 T NN O
; US7393825 T : O
administration US7393825 T NN O
of US7393825 T IN O
minimal US7393825 T JJ O
amounts US7393825 T NNS O
of US7393825 T IN O
nitric US7393825 T JJ O
oxide US7393825 T JJ O
donors US7393825 T NNS O
and/or US7393825 T VBP O
guanyl US7393825 T JJ O
cyclase US7393825 T NN O
activators US7393825 T NNS O
. US7393825 T . O

Method CA2758948A1 T NNP O
for CA2758948A1 T IN O
the CA2758948A1 T DT O
induction CA2758948A1 T NN O
of CA2758948A1 T IN O
a CA2758948A1 T DT O
reward CA2758948A1 T NN O
response CA2758948A1 T NN O
by CA2758948A1 T IN O
modulation CA2758948A1 T NN O
of CA2758948A1 T IN O
dopaminergic CA2758948A1 T JJ O
systems CA2758948A1 T NNS O
in CA2758948A1 T IN O
the CA2758948A1 T DT O
central CA2758948A1 T JJ O
nervous CA2758948A1 T JJ O
system CA2758948A1 T NN O
. CA2758948A1 T . O

GPE US7041314 T NNP O
analogs US7041314 T NNS O
and US7041314 T CC O
peptidominetics US7041314 T NNS O
. US7041314 T . O

Sulfonamide EP1981845A2 T NNP O
derivatives EP1981845A2 T VBZ O
to EP1981845A2 T TO O
treat EP1981845A2 T VB O
infection EP1981845A2 T NN O
with EP1981845A2 T IN O
hepatitis EP1981845A2 T NN O
c EP1981845A2 T NN O
virus EP1981845A2 T NN O
. EP1981845A2 T . O

Substituted US7279498 T VBN O
aryl US7279498 T JJ O
amides US7279498 T NNS O
as US7279498 T IN O
IP US7279498 T NNP I-UN
antagonists US7279498 T NNS O
. US7279498 T . O

Compounds US7279498 A NNS O
effective US7279498 A JJ O
as US7279498 A IN O
IP US7279498 A NNP I-UN
receptor US7279498 A NN I-UN
modulators US7279498 A NNS O
, US7279498 A , O
particularly US7279498 A RB O
IP US7279498 A NNP I-UN
receptor US7279498 A NN I-UN
antagonists US7279498 A NNS O
, US7279498 A , O
that US7279498 A WDT O
are US7279498 A VBP O
of US7279498 A IN O
the US7279498 A DT O
formula US7279498 A NN O
I US7279498 A PRP O
: US7279498 A : O
wherein US7279498 A NN O
A US7279498 A NNP O
, US7279498 A , O
R1 US7279498 A NNP O
, US7279498 A , O
R2 US7279498 A NNP O
, US7279498 A , O
R3 US7279498 A NNP O
and US7279498 A CC O
R4 US7279498 A NNP O
are US7279498 A VBP O
as US7279498 A IN O
defined US7279498 A VBN O
in US7279498 A IN O
the US7279498 A DT O
specification US7279498 A NN O
; US7279498 A : O
and US7279498 A CC O
individual US7279498 A JJ O
isomers US7279498 A NNS O
, US7279498 A , O
racemic US7279498 A JJ O
or US7279498 A CC O
non-racemic US7279498 A JJ O
mixtures US7279498 A NNS O
of US7279498 A IN O
isomers US7279498 A NNS O
, US7279498 A , O
and US7279498 A CC O
pharmaceutically US7279498 A RB O
acceptable US7279498 A JJ O
salts US7279498 A NNS O
or US7279498 A CC O
solvates US7279498 A NNS O
thereof US7279498 A VBP O
. US7279498 A . O

Improving WO2008000669A1 T VBG O
tolerance WO2008000669A1 T NN O
to WO2008000669A1 T TO O
anti-inflammatories WO2008000669A1 T NNS O
. WO2008000669A1 T . O

Stabilized CN1895251A T VBN O
nalmefene CN1895251A T JJ O
hydrochloride CN1895251A T NN O
injection CN1895251A T NN O
and CN1895251A T CC O
its CN1895251A T PRP$ O
preparation CN1895251A T NN O
. CN1895251A T . O

Novel US20090012069 T NNP O
Antidiabetic US20090012069 T NNP O
Compounds US20090012069 T NNP O
. US20090012069 T . O

5- US7745450 T JJ O
[ US7745450 T JJ O
1- US7745450 T JJ O
( US7745450 T ( O
hydroxymethyl US7745450 T NN O
) US7745450 T ) O
propyl US7745450 T NN O
] US7745450 T JJ O
amino-7-benzylamino-3-isopropyl US7745450 T NN O
( US7745450 T ( O
methyl US7745450 T NN O
, US7745450 T , O
ethyl US7745450 T NN O
) US7745450 T ) O
pyrazolo US7745450 T NN O
[ US7745450 T JJ O
4,3-d US7745450 T JJ O
] US7745450 T NN O
pyrimidine US7745450 T NN O
for US7745450 T IN O
inhibiting US7745450 T VBG O
cell US7745450 T NN O
proliferation US7745450 T NN O
, US7745450 T , O
cancer US7745450 T NN O
, US7745450 T , O
or US7745450 T CC O
psoriasis US7745450 T NN O
, US7745450 T , O
rheumatoid US7745450 T JJ O
arthritis US7745450 T NN O
, US7745450 T , O
lupus US7745450 T NN O
, US7745450 T , O
diabetes US7745450 T VBZ O
, US7745450 T , O
multiple US7745450 T JJ O
sclerosis US7745450 T NN O
, US7745450 T , O
restenosis US7745450 T NN O
, US7745450 T , O
polycystic US7745450 T JJ O
kidney US7745450 T NN O
disease US7745450 T NN O
, US7745450 T , O
graft US7745450 T NN O
rejection US7745450 T NN O
, US7745450 T , O
and US7745450 T CC O
neurodegerative US7745450 T JJ O
diseases US7745450 T NNS O
. US7745450 T . O

Neutral WO2012092160A3 T JJ O
human WO2012092160A3 T JJ O
milk WO2012092160A3 T NN O
oligosaccharides WO2012092160A3 T NNS O
to WO2012092160A3 T TO O
promote WO2012092160A3 T VB O
growth WO2012092160A3 T NN O
of WO2012092160A3 T IN O
beneficial WO2012092160A3 T JJ O
bacteria WO2012092160A3 T NNS O
. WO2012092160A3 T . O

Pyrrolidinyl CN1636978A T NNP O
metalloprotease CN1636978A T NN I-UN
inhibitor CN1636978A T NN O
and CN1636978A T CC O
its CN1636978A T PRP$ O
application CN1636978A T NN O
. CN1636978A T . O

The CN1636978A A DT O
present CN1636978A A JJ O
invention CN1636978A A NN O
is CN1636978A A VBZ O
pyrrolidinyl CN1636978A A JJ O
matrix CN1636978A A JJ I-UN
metalloprotease CN1636978A A NN I-UN
inhibitor CN1636978A A NN O
and CN1636978A A CC O
its CN1636978A A PRP$ O
application CN1636978A A NN O
. CN1636978A A . O

One CN1636978A A CD O
kind CN1636978A A NN O
of CN1636978A A IN O
powerful CN1636978A A JJ O
matrix CN1636978A A JJ I-UN
metalloprotease CN1636978A A NN I-UN
inhibitor CN1636978A A NN O
is CN1636978A A VBZ O
provided CN1636978A A VBN O
to CN1636978A A TO O
treat CN1636978A A VB O
disease CN1636978A A NN O
with CN1636978A A IN O
abnormal CN1636978A A JJ O
matrix CN1636978A A JJ I-UN
metalloprotease CN1636978A A NN I-UN
activity CN1636978A A NN O
expression CN1636978A A NN O
effectively CN1636978A A RB O
. CN1636978A A . O

E.g. US7105705 T NNP O
, US7105705 T , O
dodecahydroadhyperforin US7105705 T NN O
and US7105705 T CC O
acetyloctahydroadhyperforin US7105705 T NN O
, US7105705 T , O
for US7105705 T IN O
use US7105705 T NN O
in US7105705 T IN O
the US7105705 T DT O
treatment US7105705 T NN O
of US7105705 T IN O
depression US7105705 T NN O
and US7105705 T CC O
Alzheimer US7105705 T NNP O
's US7105705 T POS O
disease US7105705 T NN O
. US7105705 T . O

Oxidation CN103272223A T NNP O
prevention CN103272223A T NN O
health CN103272223A T NN O
care CN103272223A T NN O
capsule CN103272223A T NN O
and CN103272223A T CC O
preparation CN103272223A T NN O
method CN103272223A T NN O
thereof CN103272223A T NN O
. CN103272223A T . O

Natural CN103330807A T JJ O
drug CN103330807A T NN O
composite CN103330807A T NN O
, CN103330807A T , O
and CN103330807A T CC O
preparation CN103330807A T NN O
method CN103330807A T NN O
and CN103330807A T CC O
purpose CN103330807A T JJ O
thereof CN103330807A T NN O
. CN103330807A T . O

Stable WO2006135932A3 T JJ O
fixed-dose WO2006135932A3 T JJ O
formulations WO2006135932A3 T NNS O
containing WO2006135932A3 T VBG O
a WO2006135932A3 T DT O
combination WO2006135932A3 T NN O
of WO2006135932A3 T IN O
antivirals WO2006135932A3 T NNS O
, WO2006135932A3 T , O
method WO2006135932A3 T NN O
for WO2006135932A3 T IN O
producing WO2006135932A3 T VBG O
thereof WO2006135932A3 T JJ O
using WO2006135932A3 T VBG O
dry WO2006135932A3 T JJ O
granulation WO2006135932A3 T NN O
. WO2006135932A3 T . O

Methods CA2592407A1 T NNS O
of CA2592407A1 T IN O
treating CA2592407A1 T VBG O
pain CA2592407A1 T NN O
. CA2592407A1 T . O

The CA2592407A1 A DT O
present CA2592407A1 A JJ O
invention CA2592407A1 A NN O
is CA2592407A1 A VBZ O
directed CA2592407A1 A VBN O
to CA2592407A1 A TO O
methods CA2592407A1 A NNS O
and CA2592407A1 A CC O
compositions CA2592407A1 A NNS O
for CA2592407A1 A IN O
inducing CA2592407A1 A VBG O
, CA2592407A1 A , O
promoting CA2592407A1 A VBG O
or CA2592407A1 A CC O
otherwise CA2592407A1 A RB O
facilitating CA2592407A1 A JJ O
pain CA2592407A1 A NN O
relief CA2592407A1 A NN O
. CA2592407A1 A . O

More CA2592407A1 A RBR O
particularly CA2592407A1 A RB O
the CA2592407A1 A DT O
present CA2592407A1 A JJ O
invention CA2592407A1 A NN O
discloses CA2592407A1 A VBZ O
the CA2592407A1 A DT O
combination CA2592407A1 A NN O
of CA2592407A1 A IN O
a CA2592407A1 A DT O
nitric CA2592407A1 A JJ O
oxide CA2592407A1 A NN O
donor CA2592407A1 A NN O
and CA2592407A1 A CC O
an CA2592407A1 A DT O
opioid CA2592407A1 A JJ O
analgesic CA2592407A1 A NN O
in CA2592407A1 A IN O
the CA2592407A1 A DT O
therapeutic CA2592407A1 A JJ O
management CA2592407A1 A NN O
of CA2592407A1 A IN O
vertebrate CA2592407A1 A NN O
animals CA2592407A1 A NNS O
including CA2592407A1 A VBG O
humans CA2592407A1 A NNS O
, CA2592407A1 A , O
for CA2592407A1 A IN O
the CA2592407A1 A DT O
prevention CA2592407A1 A NN O
or CA2592407A1 A CC O
alleviation CA2592407A1 A NN O
of CA2592407A1 A IN O
pain CA2592407A1 A NN O
, CA2592407A1 A , O
particularly CA2592407A1 A RB O
moderate CA2592407A1 A JJ O
to CA2592407A1 A TO O
severe CA2592407A1 A VB O
pain CA2592407A1 A NN O
. CA2592407A1 A . O

In CA2592407A1 A IN O
particular CA2592407A1 A JJ O
, CA2592407A1 A , O
the CA2592407A1 A DT O
nitric CA2592407A1 A JJ O
oxide CA2592407A1 A NN O
donor CA2592407A1 A NN O
is CA2592407A1 A VBZ O
a CA2592407A1 A DT O
slow-release CA2592407A1 A JJ O
nitric CA2592407A1 A JJ O
oxide CA2592407A1 A NN O
donor CA2592407A1 A NN O
or CA2592407A1 A CC O
is CA2592407A1 A VBZ O
formulated CA2592407A1 A VBN O
to CA2592407A1 A TO O
provide CA2592407A1 A VB O
a CA2592407A1 A DT O
sustained CA2592407A1 A JJ O
release CA2592407A1 A NN O
of CA2592407A1 A IN O
a CA2592407A1 A DT O
low CA2592407A1 A JJ O
dose CA2592407A1 A NN O
of CA2592407A1 A IN O
nitric CA2592407A1 A JJ O
oxide CA2592407A1 A NN O
. CA2592407A1 A . O

Compounds US20110086813 T NNS O
for US20110086813 T IN O
treating US20110086813 T VBG O
bacterial US20110086813 T JJ O
infections US20110086813 T NNS O
. US20110086813 T . O

The US20110086813 A DT O
present US20110086813 A JJ O
invention US20110086813 A NN O
relates US20110086813 A VBZ O
to US20110086813 A TO O
a US20110086813 A DT O
novel US20110086813 A JJ O
class US20110086813 A NN O
of US20110086813 A IN O
guanine US20110086813 A JJ O
nucleotide US20110086813 A IN O
analogs US20110086813 A NNS O
which US20110086813 A WDT O
inhibit US20110086813 A VBP O
RelA US20110086813 A NNP I-UN
and US20110086813 A CC O
Relseq US20110086813 A NNP O
synthetic US20110086813 A JJ O
activity US20110086813 A NN O
and US20110086813 A CC O
which US20110086813 A WDT O
possess US20110086813 A JJ O
anti-bacterial US20110086813 A JJ O
activity US20110086813 A NN O
. US20110086813 A . O

Topical WO2007094605A1 T JJ O
preparation WO2007094605A1 T NN O
composition WO2007094605A1 T NN O
containing WO2007094605A1 T VBG O
a WO2007094605A1 T DT O
thiourea WO2007094605A1 T JJ O
derivative WO2007094605A1 T NN O
for WO2007094605A1 T IN O
preventing WO2007094605A1 T VBG O
or WO2007094605A1 T CC O
treating WO2007094605A1 T VBG O
pruritic WO2007094605A1 T JJ O
or WO2007094605A1 T CC O
irritant WO2007094605A1 T JJ O
skin WO2007094605A1 T NN O
diseases WO2007094605A1 T NNS O
. WO2007094605A1 T . O

Condensed EP2116538A1 T VBN O
tetrahydroquinoline EP2116538A1 T JJ O
derivative EP2116538A1 T NN O
and EP2116538A1 T CC O
use EP2116538A1 T NN O
thereof EP2116538A1 T NN O
for EP2116538A1 T IN O
medical EP2116538A1 T JJ O
purposes EP2116538A1 T NNS O
. EP2116538A1 T . O

The EP2116538A1 A DT O
problem EP2116538A1 A NN O
of EP2116538A1 A IN O
the EP2116538A1 A DT O
present EP2116538A1 A JJ O
invention EP2116538A1 A NN O
is EP2116538A1 A VBZ O
to EP2116538A1 A TO O
provide EP2116538A1 A VB O
a EP2116538A1 A DT O
compound EP2116538A1 A NN O
having EP2116538A1 A VBG O
a EP2116538A1 A DT O
GR EP2116538A1 A NNP I-UN
selective EP2116538A1 A JJ O
binding EP2116538A1 A NN O
activity EP2116538A1 A NN O
, EP2116538A1 A , O
which EP2116538A1 A WDT O
shows EP2116538A1 A VBZ O
less EP2116538A1 A JJR O
action EP2116538A1 A NN O
on EP2116538A1 A IN O
other EP2116538A1 A JJ O
nuclear EP2116538A1 A JJ I-UN
receptors EP2116538A1 A NNS I-UN
such EP2116538A1 A JJ O
as EP2116538A1 A IN O
progesterone EP2116538A1 A NN I-UN
receptor EP2116538A1 A NN I-UN
( EP2116538A1 A ( O
PR EP2116538A1 A NNP I-UN
) EP2116538A1 A ) O
, EP2116538A1 A , O
mineralocorticoid EP2116538A1 A JJ I-UN
receptor EP2116538A1 A NN I-UN
( EP2116538A1 A ( O
MR EP2116538A1 A NNP I-UN
) EP2116538A1 A ) O
and EP2116538A1 A CC O
the EP2116538A1 A DT O
like EP2116538A1 A JJ O
. EP2116538A1 A . O

Atorvastatin CN102138910B T NNP O
calcium CN102138910B T NN O
tablets CN102138910B T NNS O
and CN102138910B T CC O
preparation CN102138910B T NN O
method CN102138910B T NN O
thereof CN102138910B T NN O
. CN102138910B T . O

Glucagon EP2079688B1 T NNP I-UN
receptor EP2079688B1 T NN I-UN
antagonist EP2079688B1 T NN O
compounds EP2079688B1 T NNS O
, EP2079688B1 T , O
compositions EP2079688B1 T NNS O
containing EP2079688B1 T VBG O
such EP2079688B1 T JJ O
compounds EP2079688B1 T NNS O
and EP2079688B1 T CC O
their EP2079688B1 T PRP$ O
pharmaceutical EP2079688B1 T JJ O
use EP2079688B1 T NN O
. EP2079688B1 T . O

Glucagon EP2079688B1 A NNP I-UN
receptor EP2079688B1 A NN I-UN
antagonist EP2079688B1 A NN O
compounds EP2079688B1 A NNS O
are EP2079688B1 A VBP O
disclosed EP2079688B1 A VBN O
. EP2079688B1 A . O

Mixed DE102009026357A1 T JJ O
oxide DE102009026357A1 T JJ O
dispersion DE102009026357A1 T NN O
in DE102009026357A1 T IN O
water DE102009026357A1 T NN O
, DE102009026357A1 T , O
where DE102009026357A1 T WRB O
mixed DE102009026357A1 T JJ O
oxide DE102009026357A1 T NN O
contains DE102009026357A1 T VBZ O
silicon DE102009026357A1 T NN O
, DE102009026357A1 T , O
sodium DE102009026357A1 T NN O
, DE102009026357A1 T , O
and DE102009026357A1 T CC O
either DE102009026357A1 T DT O
potassium DE102009026357A1 T NN O
, DE102009026357A1 T , O
calcium DE102009026357A1 T NN O
, DE102009026357A1 T , O
phosphorus DE102009026357A1 T NN O
and/or DE102009026357A1 T NN O
magnesium DE102009026357A1 T NN O
, DE102009026357A1 T , O
useful DE102009026357A1 T JJ O
to DE102009026357A1 T TO O
manufacture DE102009026357A1 T VB O
or DE102009026357A1 T CC O
prepare DE102009026357A1 T VB O
a DE102009026357A1 T DT O
food- DE102009026357A1 T JJ O
, DE102009026357A1 T , O
pharmaceutical- DE102009026357A1 T JJ O
or DE102009026357A1 T CC O
cosmetic DE102009026357A1 T JJ O
product DE102009026357A1 T NN O
. DE102009026357A1 T . O

Stabilized WO2012127431A1 T JJ O
compositions WO2012127431A1 T NNS O
of WO2012127431A1 T IN O
tetrahydrobiopterin WO2012127431A1 T NN O
. WO2012127431A1 T . O

PAR-1 US20120121706 T JJ I-UN
Activation US20120121706 T NNP O
by US20120121706 T IN O
Metalloproteinase-1 US20120121706 T NNP I-UN
( US20120121706 T ( O
MMP-1 US20120121706 T NNP I-UN
) US20120121706 T ) O
. US20120121706 T . O

Matrix US20120121706 A NNP I-UN
metalloproteases US20120121706 A NNS I-UN
( US20120121706 A ( O
MMPs US20120121706 A NNP I-UN
) US20120121706 A ) O
play US20120121706 A VBP O
many US20120121706 A JJ O
important US20120121706 A JJ O
roles US20120121706 A NNS O
in US20120121706 A IN O
normal US20120121706 A JJ O
and US20120121706 A CC O
pathological US20120121706 A JJ O
remodeling US20120121706 A NN O
processes US20120121706 A VBZ O
including US20120121706 A VBG O
atherothrombotic US20120121706 A JJ O
disease US20120121706 A NN O
, US20120121706 A , O
inflammation US20120121706 A NN O
, US20120121706 A , O
angiogenesis US20120121706 A NN O
and US20120121706 A CC O
cancer US20120121706 A NN O
. US20120121706 A . O

This US20120121706 A DT O
invention US20120121706 A NN O
relates US20120121706 A VBZ O
to US20120121706 A TO O
the US20120121706 A DT O
activation US20120121706 A NN O
of US20120121706 A IN O
protease-activated US20120121706 A JJ I-UN
receptor-1 US20120121706 A JJ I-UN
( US20120121706 A ( O
PAR-1 US20120121706 A NNP I-UN
) US20120121706 A ) O
by US20120121706 A IN O
endogenous US20120121706 A JJ O
platelet US20120121706 A NN O
MMP-1 US20120121706 A NNP I-UN
collagenase US20120121706 A NN I-UN
on US20120121706 A IN O
the US20120121706 A DT O
surface US20120121706 A NN O
of US20120121706 A IN O
platelets US20120121706 A NNS O
. US20120121706 A . O

Exposure US20120121706 A NN O
of US20120121706 A IN O
platelets US20120121706 A NNS O
to US20120121706 A TO O
fibrillar US20120121706 A VB O
collagen US20120121706 A NN O
converts US20120121706 A VBZ O
the US20120121706 A DT O
surface-bound US20120121706 A JJ O
pro-MMP-1 US20120121706 A JJ I-UN
zymogen US20120121706 A NN O
to US20120121706 A TO O
active US20120121706 A JJ O
MMP-1 US20120121706 A NNP I-UN
, US20120121706 A , O
which US20120121706 A WDT O
promotes US20120121706 A VBZ O
aggregation US20120121706 A NN O
through US20120121706 A IN O
PAR-1 US20120121706 A NNP I-UN
, US20120121706 A , O
MMP-1 US20120121706 A NNP I-UN
is US20120121706 A VBZ O
shown US20120121706 A VBN O
to US20120121706 A TO O
cleave US20120121706 A VB O
the US20120121706 A DT O
PAR-1 US20120121706 A NNP I-UN
extracellular US20120121706 A JJ I-UN
domain US20120121706 A NN I-UN
at US20120121706 A IN O
a US20120121706 A DT O
novel US20120121706 A JJ O
site US20120121706 A NN O
, US20120121706 A , O
which US20120121706 A WDT O
then US20120121706 A RB O
strongly US20120121706 A RB O
activates US20120121706 A VBZ O
Rho-GTP US20120121706 A JJ O
signaling US20120121706 A NN O
pathways US20120121706 A NNS O
, US20120121706 A , O
cell US20120121706 A NN O
shape US20120121706 A NN O
change US20120121706 A NN O
and US20120121706 A CC O
motility US20120121706 A NN O
, US20120121706 A , O
and US20120121706 A CC O
MAPK US20120121706 A NNP I-UN
signaling US20120121706 A NN O
. US20120121706 A . O

Blockade US20120121706 A NN O
of US20120121706 A IN O
MMP-PAR US20120121706 A NNP O
1 US20120121706 A CD I-UN
suppresses US20120121706 A NNS O
thrombogenesis US20120121706 A NN O
under US20120121706 A IN O
arterial US20120121706 A JJ O
flow US20120121706 A JJ O
conditions US20120121706 A NNS O
and US20120121706 A CC O
inhibited US20120121706 A JJ O
thrombosis US20120121706 A NN O
in US20120121706 A IN O
animals US20120121706 A NNS O
. US20120121706 A . O

These US20120121706 A DT O
studies US20120121706 A NNS O
provide US20120121706 A VBP O
a US20120121706 A DT O
link US20120121706 A NN O
between US20120121706 A IN O
matrix-dependent US20120121706 A JJ O
activation US20120121706 A NN O
of US20120121706 A IN O
metalloproteases US20120121706 A NNS I-UN
and US20120121706 A CC O
platelet-G US20120121706 A JJ O
protein US20120121706 A NN I-UN
signaling US20120121706 A VBG O
and US20120121706 A CC O
identify US20120121706 A VB O
MMP-1/PAR-1 US20120121706 A NNP O
as US20120121706 A IN O
a US20120121706 A DT O
new US20120121706 A JJ O
target US20120121706 A NN O
for US20120121706 A IN O
the US20120121706 A DT O
treatment US20120121706 A NN O
and US20120121706 A CC O
prevention US20120121706 A NN O
of US20120121706 A IN O
arterial US20120121706 A JJ O
thrombosis US20120121706 A NN O
and US20120121706 A CC O
other US20120121706 A JJ O
thrombotic US20120121706 A JJ O
diseases US20120121706 A NNS O
. US20120121706 A . O

Amoxicillin-clavulantes CN101077348A T NNS O
sustained CN101077348A T VBD O
release CN101077348A T NN O
tablets CN101077348A T NNS O
. CN101077348A T . O

Pharmaceutical CN101040860A T JJ O
composition CN101040860A T NN O
for CN101040860A T IN O
treatment CN101040860A T NN O
of CN101040860A T IN O
lower CN101040860A T JJR O
urinary CN101040860A T JJ O
tract CN101040860A T NN O
diseases CN101040860A T NNS O
. CN101040860A T . O

Jiadifenin WO2006019673A3 T NNP O
analogs WO2006019673A3 T NNS O
and WO2006019673A3 T CC O
uses WO2006019673A3 T VBZ O
thereof WO2006019673A3 T NN O
. WO2006019673A3 T . O

The WO2006019673A3 A DT O
present WO2006019673A3 A JJ O
invention WO2006019673A3 A NN O
provides WO2006019673A3 A VBZ O
compounds WO2006019673A3 A NNS O
having WO2006019673A3 A VBG O
formula WO2006019673A3 A NN O
( WO2006019673A3 A ( O
I WO2006019673A3 A PRP O
) WO2006019673A3 A ) O
and WO2006019673A3 A CC O
additionally WO2006019673A3 A RB O
provides WO2006019673A3 A VBZ O
methods WO2006019673A3 A NNS O
for WO2006019673A3 A IN O
the WO2006019673A3 A DT O
synthesis WO2006019673A3 A NN O
thereof WO2006019673A3 A NN O
, WO2006019673A3 A , O
compositions WO2006019673A3 A NNS O
thereof WO2006019673A3 A VBP O
, WO2006019673A3 A , O
and WO2006019673A3 A CC O
methods WO2006019673A3 A NNS O
for WO2006019673A3 A IN O
the WO2006019673A3 A DT O
use WO2006019673A3 A NN O
thereof WO2006019673A3 A NN O
in WO2006019673A3 A IN O
the WO2006019673A3 A DT O
treatment WO2006019673A3 A NN O
of WO2006019673A3 A IN O
neurodegenerative WO2006019673A3 A JJ O
disorders WO2006019673A3 A NNS O
, WO2006019673A3 A , O
wherein WO2006019673A3 A JJ O
R1-R6 WO2006019673A3 A NNP O
, WO2006019673A3 A , O
m WO2006019673A3 A NN O
and WO2006019673A3 A CC O
n WO2006019673A3 A NN O
are WO2006019673A3 A VBP O
as WO2006019673A3 A IN O
defined WO2006019673A3 A JJ O
herein WO2006019673A3 A NN O
. WO2006019673A3 A . O

Bryoanthrathiophenic CN101538262A T JJ O
substance CN101538262A T NN O
and CN101538262A T CC O
synthetic CN101538262A T JJ O
method CN101538262A T NN O
thereof CN101538262A T NN O
. CN101538262A T . O

Hydrogel-forming EP1168934B1 T JJ O
system EP1168934B1 T NN O
with EP1168934B1 T IN O
hydrophobic EP1168934B1 T JJ O
and EP1168934B1 T CC O
hydrophilic EP1168934B1 T JJ O
components EP1168934B1 T NNS O
. EP1168934B1 T . O

3,4-diaryl CN101407500A T JJ O
isoxazole-5-amido CN101407500A T JJ O
derivative CN101407500A T NN O
, CN101407500A T , O
and CN101407500A T CC O
preparation CN101407500A T NN O
and CN101407500A T CC O
use CN101407500A T NN O
thereof CN101407500A T NN O
. CN101407500A T . O

Methods US20110027283 T NNS O
for US20110027283 T IN O
diagnosing US20110027283 T VBG O
and US20110027283 T CC O
treating US20110027283 T VBG O
cancers US20110027283 T NNS O
. US20110027283 T . O

Therapeutic US20110160129 T JJ O
Agent US20110160129 T NNP O
Preparations US20110160129 T NNP O
for US20110160129 T IN O
Delivery US20110160129 T NNP O
Into US20110160129 T NNP O
a US20110160129 T DT O
Lumen US20110160129 T NNP O
of US20110160129 T IN O
the US20110160129 T DT O
Intestinal US20110160129 T NNP O
Tract US20110160129 T NNP O
Using US20110160129 T VBG O
a US20110160129 T DT O
Swallowable US20110160129 T JJ O
Drug US20110160129 T NN O
Delivery US20110160129 T NNP O
Device US20110160129 T NNP O
. US20110160129 T . O

Composition US20090197946 T NN O
and US20090197946 T CC O
method US20090197946 T NN O
for US20090197946 T IN O
treatment US20090197946 T NN O
of US20090197946 T IN O
inflamation US20090197946 T NN O
and US20090197946 T CC O
infections US20090197946 T NNS O
of US20090197946 T IN O
the US20090197946 T DT O
genitalia US20090197946 T NN O
, US20090197946 T , O
contraceptive US20090197946 T NN O
and US20090197946 T CC O
the US20090197946 T DT O
prophylaxis US20090197946 T NN O
of US20090197946 T IN O
sexually US20090197946 T RB O
transmitted US20090197946 T VBN O
diseases US20090197946 T NNS O
. US20090197946 T . O

Treating US7041654 T VBG O
or US7041654 T CC O
preventing US7041654 T VBG O
cancer US7041654 T NN O
by US7041654 T IN O
administering US7041654 T VBG O
to US7041654 T TO O
subject US7041654 T VB O
a US7041654 T DT O
vector US7041654 T NN O
comprising US7041654 T VBG O
a US7041654 T DT O
heterologous US7041654 T JJ O
polynucleotide US7041654 T NN O
operably US7041654 T RB O
linked US7041654 T VBD O
to US7041654 T TO O
one US7041654 T CD O
or US7041654 T CC O
more US7041654 T JJR O
regulatory US7041654 T JJ O
sequences US7041654 T NNS O
derived US7041654 T VBN O
from US7041654 T IN O
an US7041654 T DT O
H19 US7041654 T NNP I-UN
, US7041654 T , O
IGF-1 US7041654 T NNP I-UN
or US7041654 T CC O
IGF-2 US7041654 T NNP I-UN
P4 US7041654 T NNP I-UN
transcriptional US7041654 T JJ O
regulatory US7041654 T JJ O
sequence US7041654 T NN O
. US7041654 T . O

Particularly US7041654 A RB O
preferred US7041654 A JJ O
transcriptional US7041654 A JJ O
regulatory US7041654 A JJ O
sequences US7041654 A NNS O
comprise US7041654 A NN O
H19 US7041654 A NNP I-UN
, US7041654 A , O
IGF-1 US7041654 A NNP I-UN
and US7041654 A CC O
IGF-2 US7041654 A NNP I-UN
P4 US7041654 A NNP I-UN
transcriptional US7041654 A JJ O
regulatory US7041654 A JJ O
sequences US7041654 A NNS O
, US7041654 A , O
and US7041654 A CC O
variants US7041654 A NNS O
thereof US7041654 A NN O
. US7041654 A . O

3-Desoxy-2-Methylene-Vitamin US20130102567 T JJ O
D US20130102567 T NNP O
Analogs US20130102567 T NNP O
and US20130102567 T CC O
Their US20130102567 T NNP O
Uses US20130102567 T NNP O
. US20130102567 T . O

Resorcarenes-polysubstitution CN103483272A T NNP O
pyrimidine CN103483272A T NN O
derivative CN103483272A T NN O
as CN103483272A T RB O
well CN103483272A T RB O
as CN103483272A T IN O
preparation CN103483272A T NN O
method CN103483272A T NN O
and CN103483272A T CC O
application CN103483272A T NN O
of CN103483272A T IN O
derivative CN103483272A T JJ O
. CN103483272A T . O

Crystalline US20100286254 T NNP O
forms US20100286254 T NNS O
of US20100286254 T IN O
dmxaa US20100286254 T JJ O
sodium US20100286254 T NN O
salt US20100286254 T NN O
. US20100286254 T . O

( EP1626973B1 T ( O
1s,5s EP1626973B1 T CD O
) EP1626973B1 T ) O
-3- EP1626973B1 T NN O
( EP1626973B1 T ( O
5,6-dichloro-3-pyridinyl EP1626973B1 T JJ O
) EP1626973B1 T ) O
-3,6-diazabicyclo EP1626973B1 T VBP O
[ EP1626973B1 T $ O
3.2.0 EP1626973B1 T CD O
] EP1626973B1 T NNP O
heptane EP1626973B1 T NN O
is EP1626973B1 T VBZ O
an EP1626973B1 T DT O
effective EP1626973B1 T JJ O
analgesic EP1626973B1 T JJ O
agent EP1626973B1 T NN O
. EP1626973B1 T . O

The EP1626973B1 A DT O
present EP1626973B1 A JJ O
invention EP1626973B1 A NN O
discloses EP1626973B1 A NNS O
( EP1626973B1 A ( O
1S,5S EP1626973B1 A CD O
) EP1626973B1 A ) O
-3- EP1626973B1 A NN O
( EP1626973B1 A ( O
5,6-dichloro-3-pyridinyl EP1626973B1 A JJ O
) EP1626973B1 A ) O
-3,6-diazabicyclo EP1626973B1 A VBP O
[ EP1626973B1 A $ O
3.2.0 EP1626973B1 A CD O
] EP1626973B1 A NNP O
heptane EP1626973B1 A NN O
and EP1626973B1 A CC O
its EP1626973B1 A PRP$ O
use EP1626973B1 A NN O
to EP1626973B1 A TO O
treat EP1626973B1 A VB O
pain EP1626973B1 A NN O
and EP1626973B1 A CC O
other EP1626973B1 A JJ O
disorders EP1626973B1 A NNS O
associated EP1626973B1 A VBN O
with EP1626973B1 A IN O
the EP1626973B1 A DT O
nicotinic EP1626973B1 A JJ I-UN
acetylcholine EP1626973B1 A NN I-UN
receptor EP1626973B1 A NN I-UN
. EP1626973B1 A . O

Use CN103025325A T NNP O
of CN103025325A T IN O
the CN103025325A T DT O
phytocannabinoid CN103025325A T NN O
cannabidivarin CN103025325A T NN O
( CN103025325A T ( O
cbdv CN103025325A T NN O
) CN103025325A T ) O
in CN103025325A T IN O
the CN103025325A T DT O
treatment CN103025325A T NN O
of CN103025325A T IN O
epilepsy CN103025325A T NN O
. CN103025325A T . O

Medicament CN1981765A T JJ O
composition CN1981765A T NN O
of CN1981765A T IN O
cefpodoxime CN1981765A T NN O
proxetil CN1981765A T NN O
and CN1981765A T CC O
cyclodextrin CN1981765A T NN O
and CN1981765A T CC O
preparation CN1981765A T NN O
method CN1981765A T NN O
thereof CN1981765A T NN O
. CN1981765A T . O

Bifunctional US20090082324 T NNP O
Resorcinol US20090082324 T NNP O
, US20090082324 T , O
Thioresorcinol US20090082324 T NNP O
, US20090082324 T , O
and US20090082324 T CC O
Dithioresorcinol US20090082324 T NNP O
Derivative US20090082324 T NNP O
Metal US20090082324 T NNP O
Chelating US20090082324 T NNP O
Conjugates US20090082324 T NNP O
. US20090082324 T . O

The US20090082324 A DT O
present US20090082324 A JJ O
invention US20090082324 A NN O
is US20090082324 A VBZ O
directed US20090082324 A VBN O
to US20090082324 A TO O
metal US20090082324 A VB O
chelating US20090082324 A VBG O
conjugates US20090082324 A NNS O
for US20090082324 A IN O
use US20090082324 A NN O
as US20090082324 A IN O
metallopharmaceutical US20090082324 A JJ O
diagnostic US20090082324 A NN O
or US20090082324 A CC O
therapeutic US20090082324 A JJ O
agents US20090082324 A NNS O
. US20090082324 A . O

Specifically US20090082324 A RB O
, US20090082324 A , O
conjugates US20090082324 A NNS O
of US20090082324 A IN O
the US20090082324 A DT O
present US20090082324 A JJ O
invention US20090082324 A NN O
include US20090082324 A VBP O
one US20090082324 A CD O
or US20090082324 A CC O
more US20090082324 A JJR O
carriers US20090082324 A NNS O
, US20090082324 A , O
a US20090082324 A DT O
linker US20090082324 A NN O
, US20090082324 A , O
and US20090082324 A CC O
metal US20090082324 A NN O
coordinating US20090082324 A VBG O
moiety US20090082324 A NN O
comprising US20090082324 A VBG O
a US20090082324 A DT O
resorcinol US20090082324 A NN O
, US20090082324 A , O
thioresorcinol US20090082324 A NN O
, US20090082324 A , O
or US20090082324 A CC O
dithioresorcinol US20090082324 A NN O
derivative US20090082324 A VBP O
through US20090082324 A IN O
which US20090082324 A WDT O
the US20090082324 A DT O
metal US20090082324 A NN O
coordinating US20090082324 A VBG O
moiety US20090082324 A NN O
is US20090082324 A VBZ O
bonded US20090082324 A VBN O
to US20090082324 A TO O
the US20090082324 A DT O
linker US20090082324 A NN O
. US20090082324 A . O

Stable CN102600068A T JJ O
ready-to-use CN102600068A T NN O
paracetamol CN102600068A T NN O
preparation CN102600068A T NN O
capable CN102600068A T JJ O
of CN102600068A T IN O
being CN102600068A T VBG O
injected CN102600068A T VBN O
. CN102600068A T . O

NELL US8048646 T NNP I-UN
peptide US8048646 T JJ O
expression US8048646 T NN O
systems US8048646 T NNS O
and US8048646 T CC O
bone US8048646 T JJ O
formation US8048646 T NN O
activity US8048646 T NN O
of US8048646 T IN O
NELL US8048646 T NNP I-UN
peptide US8048646 T NN O
. US8048646 T . O

The US8048646 A DT O
invention US8048646 A NN O
generally US8048646 A RB O
relates US8048646 A VBZ O
to US8048646 A TO O
a US8048646 A DT O
bone US8048646 A NN O
growth US8048646 A NN O
factor US8048646 A NN O
, US8048646 A , O
and US8048646 A CC O
more US8048646 A JJR O
particularly US8048646 A RB O
to US8048646 A TO O
compositions US8048646 A NNS O
including US8048646 A VBG O
NELL1 US8048646 A NNP I-UN
, US8048646 A , O
articles US8048646 A NNS O
of US8048646 A IN O
manufacture US8048646 A NN O
including US8048646 A VBG O
NELL1 US8048646 A NNP I-UN
and US8048646 A CC O
methods US8048646 A NNS O
of US8048646 A IN O
using US8048646 A VBG O
NELL1 US8048646 A NNP I-UN
to US8048646 A TO O
induce US8048646 A VB O
bone US8048646 A NN O
formation US8048646 A NN O
. US8048646 A . O

This US8048646 A DT O
invention US8048646 A NN O
also US8048646 A RB O
provides US8048646 A VBZ O
methods US8048646 A NNS O
for US8048646 A IN O
the US8048646 A DT O
expression US8048646 A NN O
and US8048646 A CC O
purification US8048646 A NN O
of US8048646 A IN O
NELL1 US8048646 A NNP I-UN
and US8048646 A CC O
NELL2 US8048646 A NNP I-UN
peptides US8048646 A NNS O
. US8048646 A . O

Imidafenacin CN103054822A T NNP O
tablet CN103054822A T NN O
and CN103054822A T CC O
preparation CN103054822A T NN O
method CN103054822A T NN O
thereof CN103054822A T NN O
. CN103054822A T . O

Recombinant EP2591002A2 T JJ O
antibody EP2591002A2 T NN O
structures EP2591002A2 T VBZ O
binding EP2591002A2 T VBG O
to EP2591002A2 T TO O
and EP2591002A2 T CC O
blocking EP2591002A2 T VBG O
the EP2591002A2 T DT O
activity EP2591002A2 T NN O
of EP2591002A2 T IN O
vascular EP2591002A2 T JJ I-UN
endothelial EP2591002A2 T JJ I-UN
growth EP2591002A2 T NN I-UN
factor EP2591002A2 T NN I-UN
2 EP2591002A2 T CD I-UN
( EP2591002A2 T ( O
vegfr- EP2591002A2 T JJ I-UN
2 EP2591002A2 T CD I-UN
/kdr EP2591002A2 T NN O
) EP2591002A2 T ) O
. EP2591002A2 T . O

Phage EP2591002A2 A NN O
displayed EP2591002A2 A VBD O
recombinant EP2591002A2 A JJ O
antibody EP2591002A2 A NN O
library EP2591002A2 A NN O
was EP2591002A2 A VBD O
developed EP2591002A2 A VBN O
and EP2591002A2 A CC O
the EP2591002A2 A DT O
library EP2591002A2 A NN O
was EP2591002A2 A VBD O
screened EP2591002A2 A VBN O
against EP2591002A2 A IN O
VEGFR-2 EP2591002A2 A NNP I-UN
. EP2591002A2 A . O

After EP2591002A2 A IN O
screening EP2591002A2 A VBG O
and EP2591002A2 A CC O
ELISA EP2591002A2 A NNP O
experiments EP2591002A2 A NNS O
two EP2591002A2 A CD O
recombinant EP2591002A2 A JJ O
antibodies EP2591002A2 A NNS O
showing EP2591002A2 A VBG O
binding EP2591002A2 A VBG O
properties EP2591002A2 A NNS O
to EP2591002A2 A TO O
VEGFR-2 EP2591002A2 A NNP I-UN
was EP2591002A2 A VBD O
obtained EP2591002A2 A VBN O
. EP2591002A2 A . O

Heterobicylic WO2006105063A1 T JJ O
inhibitors WO2006105063A1 T NNS O
of WO2006105063A1 T IN O
tgfbeta WO2006105063A1 T NN I-UN
. WO2006105063A1 T . O

Certain WO2006105063A1 A NNP O
appropriately WO2006105063A1 A RB O
substituted WO2006105063A1 A VBD O
fused WO2006105063A1 A JJ O
bicyclic WO2006105063A1 A JJ O
pyrimidine WO2006105063A1 A NN O
compounds WO2006105063A1 A NNS O
having WO2006105063A1 A VBG O
an WO2006105063A1 A DT O
amide-substituted WO2006105063A1 A JJ O
pyridylamine WO2006105063A1 A NN O
group WO2006105063A1 A NN O
at WO2006105063A1 A IN O
C-4 WO2006105063A1 A NNP O
of WO2006105063A1 A IN O
the WO2006105063A1 A DT O
pyrimidine WO2006105063A1 A NN O
ring WO2006105063A1 A NN O
are WO2006105063A1 A VBP O
useful WO2006105063A1 A JJ O
in WO2006105063A1 A IN O
the WO2006105063A1 A DT O
treatment WO2006105063A1 A NN O
of WO2006105063A1 A IN O
conditions WO2006105063A1 A NNS O
associated WO2006105063A1 A VBN O
with WO2006105063A1 A IN O
excessive WO2006105063A1 A JJ O
TGFβ WO2006105063A1 A NNP I-UN
activity WO2006105063A1 A NN O
and WO2006105063A1 A CC O
certain WO2006105063A1 A JJ O
viral WO2006105063A1 A JJ O
disorders WO2006105063A1 A NNS O
. WO2006105063A1 A . O

Doxycycline CN103083264A T NNP O
tablet CN103083264A T NN O
and CN103083264A T CC O
preparation CN103083264A T NN O
method CN103083264A T NN O
thereof CN103083264A T NN O
. CN103083264A T . O

Biphenyl US6927228 T NNP O
compounds US6927228 T VBZ O
usefuf US6927228 T JJ O
in US6927228 T IN O
treatment US6927228 T NN O
of US6927228 T IN O
human US6927228 T JJ O
and US6927228 T CC O
veterinary US6927228 T JJ O
medicines US6927228 T NNS O
such US6927228 T JJ O
as US6927228 T IN O
dermatology US6927228 T NN O
, US6927228 T , O
cardivovascular US6927228 T JJ O
diseases US6927228 T NNS O
, US6927228 T , O
immune US6927228 T JJ O
diseases US6927228 T NNS O
or US6927228 T CC O
diseases US6927228 T NNS O
associated US6927228 T VBN O
with US6927228 T IN O
lipid US6927228 T JJ O
metabolisms US6927228 T NNS O
, US6927228 T , O
or US6927228 T CC O
in US6927228 T IN O
cosmetic US6927228 T JJ O
formulation US6927228 T NN O
. US6927228 T . O

2-Methyl-3- US20080139589 T JJ O
{ US20080139589 T ( O
4- US20080139589 T JJ O
[ US20080139589 T NN O
3- US20080139589 T JJ O
( US20080139589 T ( O
1-pyrrolidinyl US20080139589 T JJ O
) US20080139589 T ) O
propoxy US20080139589 T NN O
] US20080139589 T NN O
phenyl US20080139589 T NN O
} US20080139589 T ) O
-5-trifluoromethyl-4 US20080139589 T NNP O
( US20080139589 T ( O
3H US20080139589 T CD O
) US20080139589 T ) O
-quinazolinone US20080139589 T NN O
; US20080139589 T : O
sleep US20080139589 T JJ O
, US20080139589 T , O
psychological US20080139589 T JJ O
, US20080139589 T , O
nervous US20080139589 T JJ O
system US20080139589 T NN O
, US20080139589 T , O
and US20080139589 T CC O
attention US20080139589 T NN O
deficit US20080139589 T NN O
disorders US20080139589 T NNS O
; US20080139589 T : O
drug US20080139589 T NN O
abuse US20080139589 T NN O
, US20080139589 T , O
alcoholism US20080139589 T NN O
; US20080139589 T : O
antidiabetic US20080139589 T JJ O
agents US20080139589 T NNS O
, US20080139589 T , O
cognition US20080139589 T NN O
activators US20080139589 T NNS O
; US20080139589 T : O
Alzheimer US20080139589 T NNP O
's US20080139589 T POS O
and US20080139589 T CC O
Parkinson US20080139589 T NNP O
's US20080139589 T POS O
disease US20080139589 T NN O
; US20080139589 T : O
histamine US20080139589 T JJ I-UN
H3 US20080139589 T NNP I-UN
receptor US20080139589 T NN I-UN
antagonists US20080139589 T NNS O
. US20080139589 T . O

A US20080139589 A DT O
substance US20080139589 A NN O
that US20080139589 A WDT O
has US20080139589 A VBZ O
a US20080139589 A DT O
potency US20080139589 A NN O
antagonistic US20080139589 A JJ O
to US20080139589 A TO O
coupling US20080139589 A VBG O
of US20080139589 A IN O
histamine US20080139589 A NN O
with US20080139589 A IN O
histamine US20080139589 A JJ I-UN
H3 US20080139589 A NNP I-UN
receptor US20080139589 A NN I-UN
or US20080139589 A CC O
a US20080139589 A DT O
potency US20080139589 A NN O
of US20080139589 A IN O
inhibiting US20080139589 A VBG O
the US20080139589 A DT O
constant US20080139589 A JJ O
activity US20080139589 A NN O
of US20080139589 A IN O
histamine US20080139589 A NN I-UN
H3 US20080139589 A NNP I-UN
receptor US20080139589 A NN I-UN
. US20080139589 A . O

Administration WO2014134380A1 T NN O
of WO2014134380A1 T IN O
gamma WO2014134380A1 T JJ O
hydroxybutyrate WO2014134380A1 T NN O
with WO2014134380A1 T IN O
monocarboxylate WO2014134380A1 T NN O
transporters WO2014134380A1 T NNS O
. WO2014134380A1 T . O

Substituted CA2777304A1 T VBN O
benzosulphonamides CA2777304A1 T NNS O
. CA2777304A1 T . O

Antiadhesion CN1623561A T NNP O
protective CN1623561A T JJ O
preparation CN1623561A T NN O
and CN1623561A T CC O
its CN1623561A T PRP$ O
application CN1623561A T NN O
. CN1623561A T . O

Nanoparticulate US20110027371 T NNP O
statin US20110027371 T NN O
formulations US20110027371 T NNS O
and US20110027371 T CC O
novel US20110027371 T JJ O
statin US20110027371 T NN O
combinations US20110027371 T NNS O
. US20110027371 T . O

Coenzyme WO2005089740A1 T NNP O
q WO2005089740A1 T POS O
composition WO2005089740A1 T NN O
with WO2005089740A1 T IN O
long-term WO2005089740A1 T JJ O
persistence WO2005089740A1 T NN O
in WO2005089740A1 T IN O
blood WO2005089740A1 T NN O
. WO2005089740A1 T . O

Transdermal CN101357116A T NNP O
and CN101357116A T CC O
transmucosal CN101357116A T VB O
local CN101357116A T JJ O
narcotic CN101357116A T JJ O
analgesic CN101357116A T NN O
and CN101357116A T CC O
preparation CN101357116A T NN O
method CN101357116A T NN O
of CN101357116A T IN O
gel CN101357116A T JJ O
formulation CN101357116A T NN O
thereof CN101357116A T NN O
. CN101357116A T . O

Methods US20110269819 T NNS O
and US20110269819 T CC O
compositions US20110269819 T NNS O
for US20110269819 T IN O
targeting US20110269819 T VBG O
skip US20110269819 T NN I-UN
. US20110269819 T . O

Provided US20110269819 A VBN O
herein US20110269819 A NN O
are US20110269819 A VBP O
methods US20110269819 A NNS O
and US20110269819 A CC O
compositions US20110269819 A NNS O
for US20110269819 A IN O
modulating US20110269819 A VBG O
apoptosis US20110269819 A NN O
by US20110269819 A IN O
targeting US20110269819 A VBG O
SKIP US20110269819 A NNP I-UN
( US20110269819 A ( O
Ski-interacting US20110269819 A NNP I-UN
protein US20110269819 A NN I-UN
) US20110269819 A ) O
activity US20110269819 A NN O
. US20110269819 A . O

Composition CN101091715A T NN O
of CN101091715A T IN O
medication CN101091715A T NN O
for CN101091715A T IN O
treating CN101091715A T VBG O
cardiovascular CN101091715A T JJ O
diseases CN101091715A T NNS O
and CN101091715A T CC O
cerebrovascular CN101091715A T JJ O
diseases CN101091715A T NNS O
. CN101091715A T . O

The CN101091715A A DT O
present CN101091715A A JJ O
invention CN101091715A A NN O
relates CN101091715A A VBZ O
to CN101091715A A TO O
a CN101091715A A DT O
medicine CN101091715A A NN O
composition CN101091715A A NN O
for CN101091715A A IN O
curing CN101091715A A VBG O
angiocardiopathy CN101091715A A JJ O
and CN101091715A A CC O
cerebrovascular CN101091715A A JJ O
disease CN101091715A A NN O
. CN101091715A A . O

Said CN101091715A A NNP O
medicine CN101091715A A NN O
composition CN101091715A A NN O
contains CN101091715A A VBZ O
ginsenoside CN101091715A A JJ O
and CN101091715A A CC O
breviscapine CN101091715A A NN O
. CN101091715A A . O

Preparation CN1869051A T NNP O
method CN1869051A T NN O
of CN1869051A T IN O
trialcohol CN1869051A T NN O
group CN1869051A T NN O
ginseng CN1869051A T NN O
saponine CN1869051A T NN O
and CN1869051A T CC O
dialcohol CN1869051A T NN O
group CN1869051A T NN O
ginseng CN1869051A T NN O
saponine CN1869051A T NN O
. CN1869051A T . O

Quaternised EP1515729B1 T VBN O
ammonium EP1515729B1 T NN O
cyclodextrin EP1515729B1 T NN O
compounds EP1515729B1 T NNS O
. EP1515729B1 T . O

Novel CN101375872A T NNP O
medicament CN101375872A T NN O
prescription CN101375872A T NN O
for CN101375872A T IN O
treating CN101375872A T VBG O
diabetes CN101375872A T NNS O
. CN101375872A T . O

Novel US20120022054 T NNP O
substituted US20120022054 T VBD O
aryl US20120022054 T JJ O
derivatives US20120022054 T NNS O
, US20120022054 T , O
their US20120022054 T PRP$ O
process US20120022054 T NN O
of US20120022054 T IN O
preparation US20120022054 T NN O
and US20120022054 T CC O
their US20120022054 T PRP$ O
therapeutical US20120022054 T JJ O
uses US20120022054 T NNS O
as US20120022054 T IN O
anti-hiv US20120022054 T JJ O
agents US20120022054 T NNS O
. US20120022054 T . O

The US20120022054 A DT O
present US20120022054 A JJ O
invention US20120022054 A NN O
concerns US20120022054 A NNS O
novel US20120022054 A RB O
substituted US20120022054 A VBD O
aryl US20120022054 A JJ O
derivatives US20120022054 A NNS O
, US20120022054 A , O
their US20120022054 A PRP$ O
process US20120022054 A NN O
of US20120022054 A IN O
preparation US20120022054 A NN O
and US20120022054 A CC O
their US20120022054 A PRP$ O
use US20120022054 A NN O
for US20120022054 A IN O
inhibiting US20120022054 A VBG O
virus US20120022054 A JJ O
replication US20120022054 A NN O
and US20120022054 A CC O
for US20120022054 A IN O
treating US20120022054 A VBG O
viral US20120022054 A JJ O
diseases US20120022054 A NNS O
or US20120022054 A CC O
disorders US20120022054 A NNS O
such US20120022054 A JJ O
as US20120022054 A IN O
HIV US20120022054 A NNP O
and/or US20120022054 A VBP O
HCV US20120022054 A NNP O
infection US20120022054 A NN O
. US20120022054 A . O

Chondroitin CN102228466A T NNP O
sulfate CN102228466A T JJ O
glucosamine CN102228466A T NN O
tablets CN102228466A T NNS O
. CN102228466A T . O

New WO2006094662A1 T NNP O
polymorphous WO2006094662A1 T JJ O
forms WO2006094662A1 T NNS O
of WO2006094662A1 T IN O
rifaximin WO2006094662A1 T NN O
, WO2006094662A1 T , O
processes WO2006094662A1 T NNS O
for WO2006094662A1 T IN O
their WO2006094662A1 T PRP$ O
production WO2006094662A1 T NN O
and WO2006094662A1 T CC O
use WO2006094662A1 T NN O
thereof WO2006094662A1 T NN O
in WO2006094662A1 T IN O
the WO2006094662A1 T DT O
medicinal WO2006094662A1 T NN O
. WO2006094662A1 T . O

Crystalline WO2006094662A1 A NNP O
polymorphous WO2006094662A1 A JJ O
forms WO2006094662A1 A NNS O
of WO2006094662A1 A IN O
the WO2006094662A1 A DT O
rifaximin WO2006094662A1 A NN O
( WO2006094662A1 A ( O
INN WO2006094662A1 A NNP O
) WO2006094662A1 A ) O
antibiotic WO2006094662A1 A NN O
named WO2006094662A1 A VBN O
rifaximin WO2006094662A1 A NN O
δ WO2006094662A1 A NN O
and WO2006094662A1 A CC O
rifaximin WO2006094662A1 A NN O
& WO2006094662A1 A CC O
epsiv WO2006094662A1 A NN O
; WO2006094662A1 A : O
useful WO2006094662A1 A JJ O
in WO2006094662A1 A IN O
the WO2006094662A1 A DT O
production WO2006094662A1 A NN O
of WO2006094662A1 A IN O
medicinal WO2006094662A1 A JJ O
preparations WO2006094662A1 A NNS O
containing WO2006094662A1 A VBG O
rifaximin WO2006094662A1 A NN O
for WO2006094662A1 A IN O
oral WO2006094662A1 A JJ O
and WO2006094662A1 A CC O
topical WO2006094662A1 A JJ O
use WO2006094662A1 A NN O
and WO2006094662A1 A CC O
obtained WO2006094662A1 A VBN O
by WO2006094662A1 A IN O
means WO2006094662A1 A NNS O
of WO2006094662A1 A IN O
a WO2006094662A1 A DT O
crystallization WO2006094662A1 A NN O
process WO2006094662A1 A NN O
carried WO2006094662A1 A VBD O
out WO2006094662A1 A RP O
by WO2006094662A1 A IN O
hot-dissolving WO2006094662A1 A VBG O
the WO2006094662A1 A DT O
raw WO2006094662A1 A JJ O
rifaximin WO2006094662A1 A NN O
in WO2006094662A1 A IN O
ethyl WO2006094662A1 A JJ O
alcohol WO2006094662A1 A NN O
and WO2006094662A1 A CC O
by WO2006094662A1 A IN O
causing WO2006094662A1 A VBG O
the WO2006094662A1 A DT O
crystallization WO2006094662A1 A NN O
of WO2006094662A1 A IN O
the WO2006094662A1 A DT O
product WO2006094662A1 A NN O
by WO2006094662A1 A IN O
addition WO2006094662A1 A NN O
of WO2006094662A1 A IN O
water WO2006094662A1 A NN O
at WO2006094662A1 A IN O
a WO2006094662A1 A DT O
determinate WO2006094662A1 A JJ O
temperature WO2006094662A1 A NN O
and WO2006094662A1 A CC O
for WO2006094662A1 A IN O
a WO2006094662A1 A DT O
determinate WO2006094662A1 A JJ O
period WO2006094662A1 A NN O
of WO2006094662A1 A IN O
time WO2006094662A1 A NN O
, WO2006094662A1 A , O
followed WO2006094662A1 A VBN O
by WO2006094662A1 A IN O
a WO2006094662A1 A DT O
drying WO2006094662A1 A NN O
carried WO2006094662A1 A VBN O
out WO2006094662A1 A RP O
under WO2006094662A1 A IN O
controlled WO2006094662A1 A JJ O
conditions WO2006094662A1 A NNS O
until WO2006094662A1 A IN O
reaching WO2006094662A1 A VBG O
a WO2006094662A1 A DT O
settled WO2006094662A1 A JJ O
water WO2006094662A1 A NN O
content WO2006094662A1 A NN O
in WO2006094662A1 A IN O
the WO2006094662A1 A DT O
end WO2006094662A1 A NN O
product WO2006094662A1 A NN O
, WO2006094662A1 A , O
are WO2006094662A1 A VBP O
the WO2006094662A1 A DT O
object WO2006094662A1 A NN O
of WO2006094662A1 A IN O
the WO2006094662A1 A DT O
invention WO2006094662A1 A NN O
. WO2006094662A1 A . O

Salt CN103626700A T NNP O
of CN103626700A T IN O
cyclopropane CN103626700A T NN O
dicarboxamide CN103626700A T NN O
derivative CN103626700A T NN O
. CN103626700A T . O

Use CA2704882A1 T NNP O
of CA2704882A1 T IN O
amorolfine CA2704882A1 T NN O
for CA2704882A1 T IN O
treating CA2704882A1 T VBG O
a CA2704882A1 T DT O
nail CA2704882A1 T JJ O
disease CA2704882A1 T NN O
by CA2704882A1 T IN O
iontophoresis CA2704882A1 T NN O
. CA2704882A1 T . O

L-pantoprazole CN101836985A T JJ O
magnesium-containing CN101836985A T JJ O
pharmaceutical CN101836985A T JJ O
preparation CN101836985A T NN O
and CN101836985A T CC O
preparation CN101836985A T NN O
method CN101836985A T NN O
. CN101836985A T . O

pharmaceutical US20100297221 T JJ O
composition US20100297221 T NN O
of US20100297221 T IN O
tacrolimus US20100297221 T NN O
. US20100297221 T . O

PYRAZOLE WO2010072823A1 T NNP O
[ WO2010072823A1 T VBD O
1,5a WO2010072823A1 T CD O
] WO2010072823A1 T NNP O
PYRIDINE WO2010072823A1 T NNP O
DERIVATIVES WO2010072823A1 T NNP O
. WO2010072823A1 T . O

These WO2010072823A1 A DT O
compounds WO2010072823A1 A NNS O
are WO2010072823A1 A VBP O
useful WO2010072823A1 A JJ O
as WO2010072823A1 A IN O
JAK3 WO2010072823A1 A NNP I-UN
kinase WO2010072823A1 A NN I-UN
inhibitors WO2010072823A1 A NNS O
. WO2010072823A1 A . O

Pyrrolidine CN102766080A T NNP O
derivative CN102766080A T JJ O
, CN102766080A T , O
its CN102766080A T PRP$ O
preparation CN102766080A T NN O
method CN102766080A T NN O
and CN102766080A T CC O
application CN102766080A T NN O
thereof CN102766080A T NN O
. CN102766080A T . O

The CN102766080A A DT O
pyrrolidine CN102766080A A NN O
derivative CN102766080A A JJ O
and CN102766080A A CC O
its CN102766080A A PRP$ O
pharmaceutically CN102766080A A RB O
acceptable CN102766080A A JJ O
salts CN102766080A A NNS O
can CN102766080A A MD O
have CN102766080A A VB O
a CN102766080A A DT O
triple CN102766080A A JJ O
reuptake CN102766080A A NN O
inhibition CN102766080A A NN O
effect CN102766080A A NN O
on CN102766080A A IN O
a CN102766080A A DT O
5-HT/DA/NE CN102766080A A JJ O
transporter CN102766080A A NN I-UN
, CN102766080A A , O
are CN102766080A A VBP O
used CN102766080A A VBN O
to CN102766080A A TO O
prepare CN102766080A A VB O
antidepressant CN102766080A A JJ O
drugs CN102766080A A NNS O
, CN102766080A A , O
can CN102766080A A MD O
be CN102766080A A VB O
used CN102766080A A VBN O
to CN102766080A A TO O
shorten CN102766080A A VB O
the CN102766080A A DT O
onset CN102766080A A NN O
time CN102766080A A NN O
, CN102766080A A , O
enhance CN102766080A A RB O
curative CN102766080A A JJ O
effects CN102766080A A NNS O
and CN102766080A A CC O
minimize CN102766080A A VB O
side CN102766080A A NN O
effect CN102766080A A NN O
, CN102766080A A , O
provide CN102766080A A VB O
a CN102766080A A DT O
novel CN102766080A A JJ O
approach CN102766080A A NN O
for CN102766080A A IN O
preventing CN102766080A A VBG O
and CN102766080A A CC O
treating CN102766080A A VBG O
depression CN102766080A A NN O
, CN102766080A A , O
and CN102766080A A CC O
have CN102766080A A VBP O
a CN102766080A A DT O
better CN102766080A A JJR O
application CN102766080A A NN O
prospect CN102766080A A NN O
. CN102766080A A . O

Use EP1661575A1 T NNP O
of EP1661575A1 T IN O
magnesium EP1661575A1 T NN O
in EP1661575A1 T IN O
the EP1661575A1 T DT O
treatment EP1661575A1 T NN O
of EP1661575A1 T IN O
disorders EP1661575A1 T NNS O
related EP1661575A1 T VBN O
to EP1661575A1 T TO O
hormonal EP1661575A1 T JJ O
variations EP1661575A1 T NNS O
in EP1661575A1 T IN O
women EP1661575A1 T NNS O
. EP1661575A1 T . O

Aryl EP1301475B1 T NNP O
sulfonamides EP1301475B1 T NNS O
as EP1301475B1 T IN O
serotonin EP1301475B1 T JJ O
antagonist EP1301475B1 T NN O
for EP1301475B1 T IN O
the EP1301475B1 T DT O
treatment EP1301475B1 T NN O
of EP1301475B1 T IN O
obesity EP1301475B1 T NN O
. EP1301475B1 T . O

Use US20060148707 T NNP O
of US20060148707 T IN O
ligands US20060148707 T NNS O
to US20060148707 T TO O
GABA US20060148707 T NNP O
beta US20060148707 T NN O
receptors US20060148707 T NNS O
. US20060148707 T . O

Dammarane CN103709223A T NNP O
triterpene CN103709223A T NN O
derivative CN103709223A T NN O
, CN103709223A T , O
pharmaceutical CN103709223A T JJ O
composition CN103709223A T NN O
thereof CN103709223A T NN O
, CN103709223A T , O
and CN103709223A T CC O
applications CN103709223A T NNS O
of CN103709223A T IN O
dammarane CN103709223A T NN O
triterpene CN103709223A T NN O
derivative CN103709223A T JJ O
in CN103709223A T IN O
pharmacy CN103709223A T NN O
. CN103709223A T . O

The CN103709223A A DT O
invention CN103709223A A NN O
discloses CN103709223A A VBZ O
a CN103709223A A DT O
dammarane CN103709223A A NN O
triterpene CN103709223A A NN O
derivative CN103709223A A JJ O
represented CN103709223A A VBN O
by CN103709223A A IN O
formula CN103709223A A NN O
( CN103709223A A ( O
I CN103709223A A PRP O
) CN103709223A A ) O
; CN103709223A A : O
a CN103709223A A DT O
pharmaceutical CN103709223A A JJ O
salt CN103709223A A NN O
thereof CN103709223A A NN O
; CN103709223A A : O
a CN103709223A A DT O
preparation CN103709223A A NN O
method CN103709223A A NN O
of CN103709223A A IN O
the CN103709223A A DT O
dammarane CN103709223A A NN O
triterpene CN103709223A A NN O
derivative CN103709223A A VBP O
; CN103709223A A : O
a CN103709223A A DT O
pharmaceutical CN103709223A A JJ O
composition CN103709223A A NN O
containing CN103709223A A VBG O
the CN103709223A A DT O
dammarane CN103709223A A NN O
triterpene CN103709223A A RB O
derivative CN103709223A A JJ O
as CN103709223A A IN O
an CN103709223A A DT O
active CN103709223A A JJ O
ingredient CN103709223A A NN O
; CN103709223A A : O
applications CN103709223A A NNS O
of CN103709223A A IN O
the CN103709223A A DT O
dammarane CN103709223A A NN O
triterpene CN103709223A A NN O
derivative CN103709223A A JJ O
, CN103709223A A , O
the CN103709223A A DT O
pharmaceutical CN103709223A A JJ O
salt CN103709223A A NN O
, CN103709223A A , O
and CN103709223A A CC O
the CN103709223A A DT O
pharmaceutical CN103709223A A JJ O
composition CN103709223A A NN O
in CN103709223A A IN O
preparation CN103709223A A NN O
of CN103709223A A IN O
medicines CN103709223A A NNS O
used CN103709223A A VBN O
for CN103709223A A IN O
treating CN103709223A A VBG O
or CN103709223A A CC O
preventing CN103709223A A VBG O
obesity CN103709223A A NN O
, CN103709223A A , O
diabetes CN103709223A A VBZ O
, CN103709223A A , O
hypertension CN103709223A A NN O
, CN103709223A A , O
cardiovascular CN103709223A A JJ O
and CN103709223A A CC O
cerebrovascular CN103709223A A JJ O
diseases CN103709223A A NNS O
, CN103709223A A , O
and CN103709223A A CC O
related CN103709223A A JJ O
metabolic CN103709223A A JJ O
diseases CN103709223A A NNS O
; CN103709223A A : O
and CN103709223A A CC O
applications CN103709223A A NNS O
of CN103709223A A IN O
the CN103709223A A DT O
dammarane CN103709223A A NN O
triterpene CN103709223A A NN O
derivative CN103709223A A JJ O
, CN103709223A A , O
the CN103709223A A DT O
pharmaceutical CN103709223A A JJ O
salt CN103709223A A NN O
, CN103709223A A , O
and CN103709223A A CC O
the CN103709223A A DT O
pharmaceutical CN103709223A A JJ O
composition CN103709223A A NN O
in CN103709223A A IN O
preparation CN103709223A A NN O
of CN103709223A A IN O
11 CN103709223A A CD I-UN
< CN103709223A A JJ I-UN
beta CN103709223A A NN I-UN
> CN103709223A A NNP I-UN
-HSD1 CN103709223A A NNP I-UN
inhibitor CN103709223A A NN O
. CN103709223A A . O

Tilmicosin CN101249069B T NNP O
long-acting CN101249069B T JJ O
injection CN101249069B T NN O
and CN101249069B T CC O
method CN101249069B T NN O
of CN101249069B T IN O
preparing CN101249069B T VBG O
the CN101249069B T DT O
same CN101249069B T JJ O
. CN101249069B T . O

Controlled US20050196456 T VBN O
release US20050196456 T NN O
particles US20050196456 T NNS O
. US20050196456 T . O

Fibrate-natural CN103232348A T JJ O
antioxidant CN103232348A T JJ O
twin CN103232348A T JJ O
drug CN103232348A T NN O
used CN103232348A T VBN O
for CN103232348A T IN O
treating CN103232348A T VBG O
hyperlipidemia CN103232348A T NN O
, CN103232348A T , O
and CN103232348A T CC O
preparation CN103232348A T NN O
method CN103232348A T NN O
thereof CN103232348A T NN O
. CN103232348A T . O

Lerivisiticum CN1718578A T NNP O
extract CN1718578A T NN O
, CN1718578A T , O
its CN1718578A T PRP$ O
preparation CN1718578A T NN O
method CN1718578A T NN O
and CN1718578A T CC O
medicine CN1718578A T NN O
containing CN1718578A T NN O
said CN1718578A T VBD O
extract CN1718578A T NN O
. CN1718578A T . O

Medicinal CN102940810A T JJ O
preparation CN102940810A T NN O
for CN102940810A T IN O
treating CN102940810A T VBG O
urinary CN102940810A T JJ O
calculi CN102940810A T NN O
. CN102940810A T . O

Modified WO2006062434A1 T VBN O
5'- WO2006062434A1 T JJ O
phosphonate WO2006062434A1 T JJ O
azidothymidine-potential WO2006062434A1 T JJ O
anti-viral WO2006062434A1 T JJ O
preparations WO2006062434A1 T NNS O
. WO2006062434A1 T . O

The WO2006062434A1 A DT O
invention WO2006062434A1 A NN O
relates WO2006062434A1 A VBZ O
to WO2006062434A1 A TO O
molecular WO2006062434A1 A VB O
biology WO2006062434A1 A NN O
, WO2006062434A1 A , O
virology WO2006062434A1 A NN O
and WO2006062434A1 A CC O
medicine WO2006062434A1 A NN O
, WO2006062434A1 A , O
in WO2006062434A1 A IN O
particular WO2006062434A1 A JJ O
to WO2006062434A1 A TO O
novel WO2006062434A1 A JJ O
3'azido-3'-dezoxythymidine-phosphonates WO2006062434A1 A NNS O
of WO2006062434A1 A IN O
general WO2006062434A1 A JJ O
formula WO2006062434A1 A NN O
( WO2006062434A1 A ( O
I WO2006062434A1 A PRP O
) WO2006062434A1 A ) O
, WO2006062434A1 A , O
wherein WO2006062434A1 A JJ O
R WO2006062434A1 A NNP O
is WO2006062434A1 A VBZ O
alkyl WO2006062434A1 A JJ O
groups WO2006062434A1 A NNS O
including WO2006062434A1 A VBG O
groups WO2006062434A1 A NNS O
containing WO2006062434A1 A VBG O
halogen WO2006062434A1 A NN O
atoms WO2006062434A1 A NNS O
, WO2006062434A1 A , O
carboxy WO2006062434A1 A NN O
, WO2006062434A1 A , O
hydroxy WO2006062434A1 A NN O
, WO2006062434A1 A , O
alkoxy WO2006062434A1 A JJ O
and WO2006062434A1 A CC O
acyloxy- WO2006062434A1 A JJ O
groups WO2006062434A1 A NNS O
and WO2006062434A1 A CC O
substituted WO2006062434A1 A VBN O
aminocarbonyl WO2006062434A1 A NN O
groups WO2006062434A1 A NNS O
. WO2006062434A1 A . O

The WO2006062434A1 A DT O
inventive WO2006062434A1 A JJ O
compounds WO2006062434A1 A NNS O
can WO2006062434A1 A MD O
be WO2006062434A1 A VB O
used WO2006062434A1 A VBN O
in WO2006062434A1 A IN O
the WO2006062434A1 A DT O
form WO2006062434A1 A NN O
of WO2006062434A1 A IN O
anti-viral WO2006062434A1 A JJ O
agents WO2006062434A1 A NNS O
since WO2006062434A1 A IN O
they WO2006062434A1 A PRP O
are WO2006062434A1 A VBP O
low-toxic WO2006062434A1 A JJ O
, WO2006062434A1 A , O
efficiently WO2006062434A1 A RB O
inhibit WO2006062434A1 A VBZ O
the WO2006062434A1 A DT O
reproduction WO2006062434A1 A NN O
of WO2006062434A1 A IN O
a WO2006062434A1 A DT O
type WO2006062434A1 A NN O
1 WO2006062434A1 A CD O
immunodeficiency WO2006062434A1 A NN O
virus WO2006062434A1 A NN O
in WO2006062434A1 A IN O
the WO2006062434A1 A DT O
culture WO2006062434A1 A NN O
of WO2006062434A1 A IN O
MT-4 WO2006062434A1 A NNP O
cells WO2006062434A1 A NNS O
and WO2006062434A1 A CC O
generate WO2006062434A1 A JJ O
azidothymidine WO2006062434A1 A NN O
in WO2006062434A1 A IN O
mammal WO2006062434A1 A JJ O
organisms WO2006062434A1 A NNS O
, WO2006062434A1 A , O
thereby WO2006062434A1 A RB O
ensuring WO2006062434A1 A VBG O
the WO2006062434A1 A DT O
gradual WO2006062434A1 A JJ O
increase WO2006062434A1 A NN O
thereof WO2006062434A1 A NN O
in WO2006062434A1 A IN O
blood WO2006062434A1 A NN O
. WO2006062434A1 A . O

Novel CN103083282A T NNP O
hydrogel CN103083282A T NN O
scar CN103083282A T NN O
patch CN103083282A T NN O
and CN103083282A T CC O
its CN103083282A T PRP$ O
preparation CN103083282A T NN O
process CN103083282A T NN O
. CN103083282A T . O

Pramipexole CN103040781A T NNP O
dihydrochloride CN103040781A T NN O
tablet CN103040781A T NN O
composition CN103040781A T NN O
and CN103040781A T CC O
preparation CN103040781A T NN O
method CN103040781A T NN O
thereof CN103040781A T NN O
. CN103040781A T . O

Identification US20120009190 T NN O
and US20120009190 T CC O
method US20120009190 T NN O
for US20120009190 T IN O
using US20120009190 T VBG O
the US20120009190 T DT O
pre-ligand US20120009190 T NN O
assembly US20120009190 T NN O
domain US20120009190 T NN O
of US20120009190 T IN O
the US20120009190 T DT O
il-17 US20120009190 T JJ I-UN
receptor US20120009190 T NN I-UN
. US20120009190 T . O

The US20120009190 A DT O
invention US20120009190 A NN O
provides US20120009190 A VBZ O
isolated US20120009190 A JJ O
Pre-Ligand US20120009190 A NNP I-UN
Assembly US20120009190 A NNP I-UN
Domain US20120009190 A NNP I-UN
( US20120009190 A ( O
PLAD US20120009190 A NNP I-UN
) US20120009190 A ) O
polypeptides US20120009190 A VBZ O
comprising US20120009190 A VBG O
an US20120009190 A DT O
amino US20120009190 A NN O
acid US20120009190 A JJ O
sequence US20120009190 A NN O
of US20120009190 A IN O
a US20120009190 A DT O
domain US20120009190 A NN O
( US20120009190 A ( O
e.g. US20120009190 A NN O
, US20120009190 A , O
a US20120009190 A DT O
Fibronectin US20120009190 A NNP I-UN
Ill-like US20120009190 A NNP I-UN
domain US20120009190 A NN I-UN
) US20120009190 A ) O
of US20120009190 A IN O
an US20120009190 A DT O
IL-17 US20120009190 A JJ I-UN
Receptor US20120009190 A NNP I-UN
( US20120009190 A ( O
IL-17R US20120009190 A NNP I-UN
) US20120009190 A ) O
family US20120009190 A NN O
member US20120009190 A NN O
, US20120009190 A , O
wherein US20120009190 A VBP O
the US20120009190 A DT O
PLAD US20120009190 A NNP I-UN
polypeptide US20120009190 A NN O
inhibits US20120009190 A VBZ O
multimerization US20120009190 A NN O
of US20120009190 A IN O
a US20120009190 A DT O
receptor US20120009190 A NN O
complex US20120009190 A JJ O
comprising US20120009190 A VBG O
an US20120009190 A DT O
IL-17R US20120009190 A JJ I-UN
family US20120009190 A NN O
member US20120009190 A NN O
. US20120009190 A . O

Also US20120009190 A RB O
provided US20120009190 A VBN O
are US20120009190 A VBP O
isolated US20120009190 A JJ O
PLAD-binding US20120009190 A NNP O
polypeptides US20120009190 A NNS O
, US20120009190 A , O
e.g. US20120009190 A NN O
, US20120009190 A , O
antibodies US20120009190 A NNS O
and US20120009190 A CC O
avimers US20120009190 A NNS O
, US20120009190 A , O
which US20120009190 A WDT O
specifically US20120009190 A RB O
bind US20120009190 A VBP O
to US20120009190 A TO O
a US20120009190 A DT O
PLAD US20120009190 A NNP I-UN
polypeptide US20120009190 A NN O
described US20120009190 A VBD O
herein US20120009190 A NN O
. US20120009190 A . O

Further US20120009190 A RB O
provided US20120009190 A VBN O
are US20120009190 A VBP O
methods US20120009190 A NNS O
of US20120009190 A IN O
treating US20120009190 A VBG O
an US20120009190 A DT O
inflammatory US20120009190 A NN O
or US20120009190 A CC O
autoimmune US20120009190 A JJ O
disease US20120009190 A NN O
, US20120009190 A , O
methods US20120009190 A NNS O
of US20120009190 A IN O
inhibiting US20120009190 A VBG O
IL-17-mediated US20120009190 A JJ O
signal US20120009190 A JJ O
transduction US20120009190 A NN O
, US20120009190 A , O
methods US20120009190 A NNS O
of US20120009190 A IN O
inhibiting US20120009190 A VBG O
IL-17 US20120009190 A NNP I-UN
ligand US20120009190 A NN O
binding US20120009190 A NN O
, US20120009190 A , O
methods US20120009190 A NNS O
of US20120009190 A IN O
inhibiting US20120009190 A VBG O
multimerization US20120009190 A NN O
of US20120009190 A IN O
IL-17R US20120009190 A NNP I-UN
complexes US20120009190 A NNS O
, US20120009190 A , O
and US20120009190 A CC O
methods US20120009190 A NNS O
of US20120009190 A IN O
inhibiting US20120009190 A VBG O
the US20120009190 A DT O
production US20120009190 A NN O
of US20120009190 A IN O
at US20120009190 A IN O
least US20120009190 A JJS O
one US20120009190 A CD O
cytokine US20120009190 A NN I-UN
, US20120009190 A , O
chemokine US20120009190 A NN I-UN
, US20120009190 A , O
matrix US20120009190 A JJ I-UN
metalloproteinase US20120009190 A NN I-UN
, US20120009190 A , O
or US20120009190 A CC O
other US20120009190 A JJ O
molecule US20120009190 A NN O
associated US20120009190 A VBN O
with US20120009190 A IN O
IL-17 US20120009190 A NNP I-UN
signal US20120009190 A JJ O
transduction US20120009190 A NN O
are US20120009190 A VBP O
provided US20120009190 A VBN O
. US20120009190 A . O

Novel WO2008076043A1 T NNP O
2-amino-5,5-diaryl-imidazol-4-ones WO2008076043A1 T NNS O
. WO2008076043A1 T . O

Amino WO2012095281A1 T NNP O
acid WO2012095281A1 T JJ O
composition WO2012095281A1 T NN O
and WO2012095281A1 T CC O
its WO2012095281A1 T PRP$ O
use WO2012095281A1 T NN O
for WO2012095281A1 T IN O
treating WO2012095281A1 T VBG O
intrauterine WO2012095281A1 T JJ O
foetal WO2012095281A1 T JJ O
growth WO2012095281A1 T NN O
restriction WO2012095281A1 T NN O
( WO2012095281A1 T ( O
iugr WO2012095281A1 T NN O
) WO2012095281A1 T ) O
or WO2012095281A1 T CC O
for WO2012095281A1 T IN O
parenteral WO2012095281A1 T JJ O
nutrition WO2012095281A1 T NN O
of WO2012095281A1 T IN O
extremely WO2012095281A1 T RB O
pre-term WO2012095281A1 T JJ O
infants WO2012095281A1 T NNS O
. WO2012095281A1 T . O

Isoflavone CN102964322A T NN O
or CN102964322A T CC O
flavonoid CN102964322A T JJ O
aliphatic CN102964322A T JJ O
ether CN102964322A T NN O
derivates CN102964322A T NNS O
, CN102964322A T , O
preparation CN102964322A T NN O
method CN102964322A T NN O
and CN102964322A T CC O
medical CN102964322A T JJ O
application CN102964322A T NN O
thereof CN102964322A T NN O
. CN102964322A T . O

The CN102964322A A DT O
invention CN102964322A A NN O
relates CN102964322A A VBZ O
to CN102964322A A TO O
the CN102964322A A DT O
field CN102964322A A NN O
of CN102964322A A IN O
medicinal CN102964322A A JJ O
chemistry CN102964322A A NN O
, CN102964322A A , O
specifically CN102964322A A RB O
relates CN102964322A A VBZ O
to CN102964322A A TO O
aliphatic CN102964322A A VB O
ether CN102964322A A RB O
derivates CN102964322A A NNS O
of CN102964322A A IN O
isoflavone CN102964322A A NN O
as CN102964322A A IN O
shown CN102964322A A VBN O
in CN102964322A A IN O
formula CN102964322A A NN O
( CN102964322A A ( O
I CN102964322A A PRP O
) CN102964322A A ) O
or CN102964322A A CC O
flavonoid CN102964322A A VBN O
as CN102964322A A IN O
shown CN102964322A A VBN O
in CN102964322A A IN O
formula CN102964322A A NN O
( CN102964322A A ( O
II CN102964322A A NNP O
) CN102964322A A ) O
, CN102964322A A , O
a CN102964322A A DT O
preparation CN102964322A A NN O
method CN102964322A A NN O
of CN102964322A A IN O
the CN102964322A A DT O
aliphatic CN102964322A A JJ O
ether CN102964322A A NN O
derivates CN102964322A A NNS O
, CN102964322A A , O
medicine CN102964322A A JJ O
composition CN102964322A A NN O
containing CN102964322A A VBG O
the CN102964322A A DT O
aliphatic CN102964322A A JJ O
ether CN102964322A A NN O
derivates CN102964322A A NNS O
, CN102964322A A , O
and CN102964322A A CC O
medical CN102964322A A JJ O
application CN102964322A A NN O
of CN102964322A A IN O
the CN102964322A A DT O
aliphatic CN102964322A A JJ O
ether CN102964322A A NN O
derivates CN102964322A A NNS O
, CN102964322A A , O
and CN102964322A A CC O
in CN102964322A A IN O
particular CN102964322A A JJ O
relates CN102964322A A NNS O
to CN102964322A A TO O
the CN102964322A A DT O
application CN102964322A A NN O
of CN102964322A A IN O
the CN102964322A A DT O
aliphatic CN102964322A A JJ O
ether CN102964322A A NN O
derivates CN102964322A A VBZ O
serving CN102964322A A VBG O
as CN102964322A A IN O
the CN102964322A A DT O
medicine CN102964322A A NN O
for CN102964322A A IN O
preventing CN102964322A A VBG O
or CN102964322A A CC O
treating CN102964322A A VBG O
hyperlipidaemia CN102964322A A NN O
, CN102964322A A , O
obesity CN102964322A A NN O
or CN102964322A A CC O
type CN102964322A A NN O
II CN102964322A A NNP O
diabetes CN102964322A A VBZ O
mellitus CN102964322A A NN O
. CN102964322A A . O

Colored CN101103997A T NNP O
medicinal CN101103997A T JJ O
charcoal CN101103997A T NN O
film CN101103997A T NN O
coated CN101103997A T VBD O
tablet CN101103997A T NN O
preparation CN101103997A T NN O
method CN101103997A T NN O
. CN101103997A T . O

Novel WO2007048918A1 T NNP O
esterified WO2007048918A1 T VBD O
amino WO2007048918A1 T NN O
compounds WO2007048918A1 T NNS O
having WO2007048918A1 T VBG O
a WO2007048918A1 T DT O
hydrocarbon WO2007048918A1 T NN O
ring WO2007048918A1 T VBG O
e WO2007048918A1 T NN O
with WO2007048918A1 T IN O
six WO2007048918A1 T CD O
camptothecin WO2007048918A1 T NNS O
analogue WO2007048918A1 T JJ O
ring WO2007048918A1 T VBG O
members WO2007048918A1 T NNS O
, WO2007048918A1 T , O
preparation WO2007048918A1 T NN O
method WO2007048918A1 T NN O
thereof WO2007048918A1 T NN O
and WO2007048918A1 T CC O
pharmaceutical WO2007048918A1 T JJ O
compositions WO2007048918A1 T NNS O
containing WO2007048918A1 T VBG O
same WO2007048918A1 T JJ O
. WO2007048918A1 T . O

Combination US20120196870 T NNP O
therapy US20120196870 T NN O
and US20120196870 T CC O
cancer US20120196870 T NN O
. US20120196870 T . O

The US20120196870 A DT O
disclosure US20120196870 A NN O
relates US20120196870 A VBZ O
to US20120196870 A TO O
methods US20120196870 A NNS O
of US20120196870 A IN O
treating US20120196870 A VBG O
tuberous US20120196870 A JJ O
sclerosis US20120196870 A NN O
in US20120196870 A IN O
a US20120196870 A DT O
subject US20120196870 A NN O
, US20120196870 A , O
comprising US20120196870 A VBG O
administering US20120196870 A VBG O
a US20120196870 A DT O
composition US20120196870 A NN O
comprising US20120196870 A VBG O
an US20120196870 A DT O
mTOR US20120196870 A NN I-UN
inhibitor US20120196870 A NN O
and US20120196870 A CC O
a US20120196870 A DT O
tyrosine US20120196870 A JJ O
kinase US20120196870 A NN O
inhibitor US20120196870 A NN O
to US20120196870 A TO O
a US20120196870 A DT O
subject US20120196870 A NN O
that US20120196870 A WDT O
is US20120196870 A VBZ O
diagnosed US20120196870 A VBN O
with US20120196870 A IN O
, US20120196870 A , O
suspected US20120196870 A VBN O
of US20120196870 A IN O
, US20120196870 A , O
or US20120196870 A CC O
exhibiting US20120196870 A VBG O
symptoms US20120196870 A NNS O
of US20120196870 A IN O
cancer US20120196870 A NN O
. US20120196870 A . O

In US20120196870 A IN O
some US20120196870 A DT O
embodiments US20120196870 A NNS O
, US20120196870 A , O
the US20120196870 A DT O
mTOR US20120196870 A NN I-UN
inhibitor US20120196870 A NN O
is US20120196870 A VBZ O
sirolimus US20120196870 A JJ O
and US20120196870 A CC O
the US20120196870 A DT O
tyrosine US20120196870 A JJ O
kinase US20120196870 A NN O
inhibitor US20120196870 A NN O
is US20120196870 A VBZ O
imatinib US20120196870 A JJ O
. US20120196870 A . O

In US20120196870 A IN O
some US20120196870 A DT O
embodiments US20120196870 A NNS O
, US20120196870 A , O
the US20120196870 A DT O
disclosure US20120196870 A NN O
relates US20120196870 A VBZ O
to US20120196870 A TO O
a US20120196870 A DT O
composition US20120196870 A NN O
comprising US20120196870 A VBG O
an US20120196870 A DT O
mTOR US20120196870 A NN I-UN
inhibitor US20120196870 A NN O
and US20120196870 A CC O
a US20120196870 A DT O
tyrosine US20120196870 A JJ O
kinase US20120196870 A NN O
inhibitor US20120196870 A NN O
. US20120196870 A . O

Novel CN103130730A T NNP O
quinazoline CN103130730A T NN O
derivative CN103130730A T NN O
, CN103130730A T , O
and CN103130730A T CC O
preparation CN103130730A T NN O
method CN103130730A T NN O
, CN103130730A T , O
anti-HIV CN103130730A T JJ O
activity CN103130730A T NN O
and CN103130730A T CC O
anti-TMV CN103130730A T JJ O
activity CN103130730A T NN O
thereof CN103130730A T NN O
. CN103130730A T . O

Disinfection CN103463140A T NN O
repairing CN103463140A T VBG O
liquid CN103463140A T NN O
. CN103463140A T . O

Combined-ring-containing CN103709093A T JJ O
pleuromutilin CN103709093A T NN O
antibiotics CN103709093A T NNS O
. CN103709093A T . O

Oral US7781408 T JJ O
administration US7781408 T NN O
of US7781408 T IN O
gangliosides US7781408 T NNS O
including US7781408 T VBG O
50 US7781408 T CD O
% US7781408 T NN O
ganglioside US7781408 T JJ O
GD3 US7781408 T NNP O
as US7781408 T IN O
anticholesterol US7781408 T NN O
and US7781408 T CC O
antiinflammatory US7781408 T JJ O
agents US7781408 T NNS O
; US7781408 T : O
decreased US7781408 T VBN O
intestinal US7781408 T JJ O
absorption US7781408 T NN O
of US7781408 T IN O
cholesterol US7781408 T NN O
; US7781408 T : O
mediating US7781408 T VBG O
inflammation US7781408 T NN O
of US7781408 T IN O
the US7781408 T DT O
intestine US7781408 T NN O
, US7781408 T , O
retina US7781408 T NN O
or US7781408 T CC O
neural US7781408 T JJ O
tissues US7781408 T NNS O
; US7781408 T : O
liquid US7781408 T CC O
or US7781408 T CC O
food US7781408 T NN O
suppliment US7781408 T NN O
for US7781408 T IN O
infants US7781408 T NNS O
. US7781408 T . O

Protein CN102949346A T NNP O
medicine-carrying CN102949346A T JJ O
nano CN102949346A T NN O
particle CN102949346A T NN O
synthesis CN102949346A T NN O
method CN102949346A T NN O
. CN102949346A T . O

For US6858620 T IN O
therapy US6858620 T NN O
of US6858620 T IN O
male US6858620 T NN O
erectile US6858620 T JJ O
dysfunction US6858620 T NN O
; US6858620 T : O
female US6858620 T JJ O
arousal US6858620 T NN O
disorder US6858620 T NN O
. US6858620 T . O

2-methylene- WO2010006135A3 T JJ O
( WO2010006135A3 T ( O
17z WO2010006135A3 T CD O
) WO2010006135A3 T ) O
-17 WO2010006135A3 T NN O
( WO2010006135A3 T ( O
20 WO2010006135A3 T CD O
) WO2010006135A3 T ) O
-dehydro-19,21-dinor-vitamin WO2010006135A3 T NN O
d WO2010006135A3 T JJ O
analogs WO2010006135A3 T NNS O
. WO2010006135A3 T . O

Ambroxol CN103536562A T NNP O
hydrochloride CN103536562A T JJ O
composition CN103536562A T NN O
freeze-dried CN103536562A T JJ O
powder CN103536562A T NN O
for CN103536562A T IN O
injection CN103536562A T NN O
. CN103536562A T . O

Preparation CN101167879B T NN O
for CN101167879B T IN O
increasing CN101167879B T VBG O
erection CN101167879B T NN O
rigidity CN101167879B T NN O
and CN101167879B T CC O
prolonging CN101167879B T VBG O
intercourse CN101167879B T JJ O
endurance CN101167879B T NN O
and CN101167879B T CC O
condom CN101167879B T NN O
containing CN101167879B T VBG O
the CN101167879B T DT O
same CN101167879B T JJ O
. CN101167879B T . O

Cefprozil CN101700232A T NNP O
submicron CN101700232A T NN O
emulsion CN101700232A T NN O
solid CN101700232A T JJ O
preparation CN101700232A T NN O
and CN101700232A T CC O
new CN101700232A T JJ O
application CN101700232A T NN O
thereof CN101700232A T NN O
. CN101700232A T . O

Pharmaceutical CN101700256A T NNP O
composite CN101700256A T NN O
for CN101700256A T IN O
reducing CN101700256A T VBG O
blood CN101700256A T NN O
fat CN101700256A T NN O
. CN101700256A T . O

8-beta-substituted US20090029957 T JJ O
estratrienes US20090029957 T NNS O
as US20090029957 T IN O
selectively US20090029957 T RB O
active US20090029957 T JJ O
estrogens US20090029957 T NNS O
. US20090029957 T . O

The US20090029957 A DT O
invention US20090029957 A NN O
refers US20090029957 A NNS O
to US20090029957 A TO O
8β-substituted US20090029957 A JJ O
estra-1,3,5 US20090029957 A JJ O
( US20090029957 A ( O
10 US20090029957 A CD O
) US20090029957 A ) O
-triene US20090029957 A NN O
derivatives US20090029957 A NNS O
of US20090029957 A IN O
general US20090029957 A JJ O
formula US20090029957 A NN O
I US20090029957 A PRP O
their US20090029957 A PRP$ O
use US20090029957 A NN O
as US20090029957 A IN O
pharmaceutical US20090029957 A JJ O
active US20090029957 A JJ O
ingredients US20090029957 A NNS O
, US20090029957 A , O
which US20090029957 A WDT O
have US20090029957 A VBP O
in US20090029957 A IN O
vitro US20090029957 A NN O
a US20090029957 A DT O
higher US20090029957 A JJR O
affinity US20090029957 A NN O
to US20090029957 A TO O
estrogen US20090029957 A VB I-UN
receptor US20090029957 A NN I-UN
preparations US20090029957 A NNS O
from US20090029957 A IN O
rat US20090029957 A NN O
prostates US20090029957 A NNS O
than US20090029957 A IN O
to US20090029957 A TO O
estrogen US20090029957 A VB I-UN
receptor US20090029957 A NN I-UN
preparations US20090029957 A NNS O
from US20090029957 A IN O
rat US20090029957 A NN O
uteri US20090029957 A NN O
and US20090029957 A CC O
in US20090029957 A IN O
vivo US20090029957 A NN O
a US20090029957 A DT O
preferential US20090029957 A JJ O
action US20090029957 A NN O
in US20090029957 A IN O
the US20090029957 A DT O
ovary US20090029957 A JJ O
in US20090029957 A IN O
comparison US20090029957 A NN O
to US20090029957 A TO O
the US20090029957 A DT O
uterus US20090029957 A NN O
, US20090029957 A , O
their US20090029957 A PRP$ O
production US20090029957 A NN O
, US20090029957 A , O
their US20090029957 A PRP$ O
therapeutic US20090029957 A JJ O
use US20090029957 A NN O
and US20090029957 A CC O
pharmaceutical US20090029957 A JJ O
dispensing US20090029957 A NN O
forms US20090029957 A NNS O
that US20090029957 A WDT O
contain US20090029957 A VBP O
the US20090029957 A DT O
new US20090029957 A JJ O
compounds US20090029957 A NNS O
. US20090029957 A . O

surgerical US7829694 T JJ O
insertion US7829694 T NN O
of US7829694 T IN O
catheter US7829694 T NN O
; US7829694 T : O
supplying US7829694 T VBG O
protein US7829694 T NN O
antagonistl US7829694 T VBD O
Alzheimer US7829694 T NNP O
's US7829694 T POS O
disease US7829694 T NN O
; US7829694 T : O
Parkinson US7829694 T NNP O
's US7829694 T POS O
disease US7829694 T NN O
; US7829694 T : O
Huntington US7829694 T NNP O
's US7829694 T POS O
disease US7829694 T NN O
; US7829694 T : O
Spinocerebella US7829694 T NNP O
atropy US7829694 T NN O
. US7829694 T . O

The US7829694 A DT O
present US7829694 A JJ O
invention US7829694 A NN O
provides US7829694 A VBZ O
devices US7829694 A NNS O
, US7829694 A , O
small US7829694 A JJ O
interfering US7829694 A NN O
RNA US7829694 A NNP O
, US7829694 A , O
and US7829694 A CC O
methods US7829694 A NNS O
for US7829694 A IN O
treating US7829694 A VBG O
a US7829694 A DT O
neurodegenerative US7829694 A JJ O
disorder US7829694 A NN O
comprising US7829694 A VBG O
the US7829694 A DT O
steps US7829694 A NNS O
of US7829694 A IN O
surgically US7829694 A RB O
implanting US7829694 A VBG O
a US7829694 A DT O
catheter US7829694 A NN O
so US7829694 A RB O
that US7829694 A IN O
a US7829694 A DT O
discharge US7829694 A NN O
portion US7829694 A NN O
of US7829694 A IN O
the US7829694 A DT O
catheter US7829694 A NN O
lies US7829694 A VBZ O
adjacent US7829694 A JJ O
to US7829694 A TO O
a US7829694 A DT O
predetermined US7829694 A VBN O
infusion US7829694 A NN O
site US7829694 A NN O
in US7829694 A IN O
a US7829694 A DT O
brain US7829694 A NN O
, US7829694 A , O
and US7829694 A CC O
discharging US7829694 A VBG O
through US7829694 A IN O
the US7829694 A DT O
discharge US7829694 A NN O
portion US7829694 A NN O
of US7829694 A IN O
the US7829694 A DT O
catheter US7829694 A NN O
a US7829694 A DT O
predetermined US7829694 A JJ O
dosage US7829694 A NN O
of US7829694 A IN O
at US7829694 A IN O
least US7829694 A JJS O
one US7829694 A CD O
substance US7829694 A NN O
capable US7829694 A JJ O
of US7829694 A IN O
inhibiting US7829694 A VBG O
production US7829694 A NN O
of US7829694 A IN O
at US7829694 A IN O
least US7829694 A JJS O
one US7829694 A CD O
neurodegenerative US7829694 A JJ O
protein US7829694 A NN O
. US7829694 A . O

The US7829694 A DT O
present US7829694 A JJ O
invention US7829694 A NN O
also US7829694 A RB O
provides US7829694 A VBZ O
valuable US7829694 A JJ O
small US7829694 A JJ O
interfering US7829694 A NN O
RNA US7829694 A NNP O
vectors US7829694 A NNS O
, US7829694 A , O
and US7829694 A CC O
methods US7829694 A NNS O
for US7829694 A IN O
treating US7829694 A VBG O
neurodegenerative US7829694 A JJ O
disorders US7829694 A NNS O
such US7829694 A JJ O
as US7829694 A IN O
Alzheimer US7829694 A NNP O
's US7829694 A POS O
disease US7829694 A NN O
, US7829694 A , O
Parkinson US7829694 A NNP O
's US7829694 A POS O
disease US7829694 A NN O
, US7829694 A , O
Huntington US7829694 A NNP O
's US7829694 A POS O
disease US7829694 A NN O
, US7829694 A , O
Spinocerebellar US7829694 A NNP O
Ataxia US7829694 A NNP O
Type US7829694 A NNP O
1 US7829694 A CD O
, US7829694 A , O
Type US7829694 A NNP O
2 US7829694 A CD O
, US7829694 A , O
Type US7829694 A NNP O
3 US7829694 A CD O
, US7829694 A , O
and/or US7829694 A RB O
dentatorubral-pallidoluysian US7829694 A JJ O
atrophy US7829694 A NN O
. US7829694 A . O

Nicotine-containing US20130011461 T JJ O
chewing US20130011461 T VBG O
gum US20130011461 T JJ O
piece US20130011461 T NN O
packed US20130011461 T VBN O
in US20130011461 T IN O
a US20130011461 T DT O
wrapping US20130011461 T NN O
of US20130011461 T IN O
laminate US20130011461 T NN O
. US20130011461 T . O

Deuterium-enriched US20080318904 T JJ O
tenofovir US20080318904 T NN O
. US20080318904 T . O

The US20080318904 A DT O
present US20080318904 A JJ O
application US20080318904 A NN O
describes US20080318904 A VBZ O
deuterium-enriched US20080318904 A JJ O
tenofovir US20080318904 A NN O
, US20080318904 A , O
pharmaceutically US20080318904 A RB O
acceptable US20080318904 A JJ O
salt US20080318904 A NN O
forms US20080318904 A NNS O
thereof US20080318904 A VBP O
, US20080318904 A , O
and US20080318904 A CC O
methods US20080318904 A NNS O
of US20080318904 A IN O
treating US20080318904 A VBG O
using US20080318904 A VBG O
the US20080318904 A DT O
same US20080318904 A JJ O
. US20080318904 A . O

Suspension US20110182997 T NN O
formulations US20110182997 T NNS O
. US20110182997 T . O

Medicine CN103301270A T NNP O
for CN103301270A T IN O
preventing CN103301270A T VBG O
and CN103301270A T CC O
treating CN103301270A T VBG O
coronary CN103301270A T JJ O
heart CN103301270A T NN O
disease CN103301270A T NN O
and CN103301270A T CC O
preparation CN103301270A T NN O
method CN103301270A T NN O
thereof CN103301270A T NN O
. CN103301270A T . O

Thioxoquinazolinone WO2008128982A1 T NN O
derivatives WO2008128982A1 T NNS O
as WO2008128982A1 T IN O
glutaminyl WO2008128982A1 T JJ I-UN
cyclase WO2008128982A1 T NN I-UN
inhibitors WO2008128982A1 T NNS O
. WO2008128982A1 T . O

Novel CA2761068A1 T NNP O
dosage CA2761068A1 T NN O
regimens CA2761068A1 T NNS O
and CA2761068A1 T CC O
methods CA2761068A1 T NNS O
for CA2761068A1 T IN O
treatment CA2761068A1 T NN O
, CA2761068A1 T , O
prevention CA2761068A1 T NN O
, CA2761068A1 T , O
and/or CA2761068A1 T JJ O
management CA2761068A1 T NN O
of CA2761068A1 T IN O
at CA2761068A1 T IN O
least CA2761068A1 T JJS O
one CA2761068A1 T CD O
cns CA2761068A1 T NN O
disorder CA2761068A1 T NN O
. CA2761068A1 T . O

Self CN101066281A T NNP O
first CN101066281A T RB O
aid CN101066281A T VBD O
medicine CN101066281A T NN O
for CN101066281A T IN O
treating CN101066281A T VBG O
injury CN101066281A T NN O
. CN101066281A T . O

Inhibition WO2011109874A1 T NN O
of WO2011109874A1 T IN O
glutathione WO2011109874A1 T NN I-UN
transferase WO2011109874A1 T NN I-UN
zeta WO2011109874A1 T NN I-UN
. WO2011109874A1 T . O

The WO2011109874A1 A DT O
present WO2011109874A1 A JJ O
invention WO2011109874A1 A NN O
relates WO2011109874A1 A VBZ O
to WO2011109874A1 A TO O
a WO2011109874A1 A DT O
method WO2011109874A1 A NN O
for WO2011109874A1 A IN O
treating WO2011109874A1 A VBG O
a WO2011109874A1 A DT O
metabolic WO2011109874A1 A JJ O
condition WO2011109874A1 A NN O
in WO2011109874A1 A IN O
a WO2011109874A1 A DT O
subject WO2011109874A1 A NN O
, WO2011109874A1 A , O
comprising WO2011109874A1 A VBG O
administering WO2011109874A1 A VBG O
a WO2011109874A1 A DT O
compound WO2011109874A1 A NN O
to WO2011109874A1 A TO O
said WO2011109874A1 A VBD O
subject WO2011109874A1 A JJ O
that WO2011109874A1 A IN O
inhibits WO2011109874A1 A VBZ O
the WO2011109874A1 A DT O
expression WO2011109874A1 A NN O
or WO2011109874A1 A CC O
activity WO2011109874A1 A NN O
of WO2011109874A1 A IN O
GSTZ WO2011109874A1 A NNP I-UN
or WO2011109874A1 A CC O
promotes WO2011109874A1 A VBZ O
degradation WO2011109874A1 A NN O
of WO2011109874A1 A IN O
GSTZ WO2011109874A1 A NNP I-UN
. WO2011109874A1 A . O

The WO2011109874A1 A DT O
compound WO2011109874A1 A NN O
may WO2011109874A1 A MD O
inhibit WO2011109874A1 A VB O
or WO2011109874A1 A CC O
disrupt WO2011109874A1 A VB O
an WO2011109874A1 A DT O
interaction WO2011109874A1 A NN O
between WO2011109874A1 A IN O
GSTZ WO2011109874A1 A NNP I-UN
and WO2011109874A1 A CC O
one WO2011109874A1 A CD O
or WO2011109874A1 A CC O
more WO2011109874A1 A JJR O
molecules WO2011109874A1 A NNS O
, WO2011109874A1 A , O
compounds WO2011109874A1 A NNS O
or WO2011109874A1 A CC O
cellular WO2011109874A1 A JJ O
components WO2011109874A1 A NNS O
. WO2011109874A1 A . O

USE EP1684746A1 T NN O
OF EP1684746A1 T IN O
1-AZA-DIBENZO EP1684746A1 T JJ O
[ EP1684746A1 T NNP O
e EP1684746A1 T NN O
, EP1684746A1 T , O
h EP1684746A1 T NN O
] EP1684746A1 T NNP O
|AZULENES EP1684746A1 T NNP O
FOR EP1684746A1 T IN O
THE EP1684746A1 T NNP O
MANUFACTURE EP1684746A1 T NNP O
OF EP1684746A1 T NNP O
PHARMACEUTICAL EP1684746A1 T NNP O
FORMULATIONS EP1684746A1 T NNP O
FOR EP1684746A1 T IN O
THE EP1684746A1 T NNP O
TREATMENT EP1684746A1 T NNP O
AND EP1684746A1 T NNP O
PREVENTION EP1684746A1 T NNP O
OF EP1684746A1 T NNP O
CENTRAL EP1684746A1 T NNP O
NERVOUS EP1684746A1 T NNP O
SYSTEM EP1684746A1 T NNP O
DISEASES EP1684746A1 T NNP O
AND EP1684746A1 T NNP O
DISORDERS EP1684746A1 T NNP O
. EP1684746A1 T . O

Effective WO2010035253A1 T JJ O
nitric WO2010035253A1 T JJ O
oxide WO2010035253A1 T IN O
generating WO2010035253A1 T VBG O
preparations WO2010035253A1 T NNS O
. WO2010035253A1 T . O

Preparation CN101947234A T NNP O
method CN101947234A T NN O
for CN101947234A T IN O
preparation CN101947234A T NN O
containing CN101947234A T VBG O
glucosamine CN101947234A T NN O
and CN101947234A T CC O
application CN101947234A T NN O
thereof CN101947234A T NN O
. CN101947234A T . O

Benzimidazole US20070072853 T NNP O
derivatives US20070072853 T NNS O
compositions US20070072853 T NNS O
containing US20070072853 T VBG O
them US20070072853 T PRP O
, US20070072853 T , O
preparation US20070072853 T NN O
thereof US20070072853 T NN O
and US20070072853 T CC O
uses US20070072853 T VBZ O
thereof US20070072853 T NN O
. US20070072853 T . O

Compounds US20070072853 A NNS O
of US20070072853 A IN O
Formula US20070072853 A NNP O
( US20070072853 A ( O
I US20070072853 A PRP O
) US20070072853 A ) O
or US20070072853 A CC O
pharmaceutically US20070072853 A RB O
acceptable US20070072853 A JJ O
salts US20070072853 A NNS O
thereof US20070072853 A VBP O
; US20070072853 A : O
wherein US20070072853 A CC O
R1 US20070072853 A NNP O
, US20070072853 A , O
R2 US20070072853 A NNP O
, US20070072853 A , O
R3 US20070072853 A NNP O
, US20070072853 A , O
R4 US20070072853 A NNP O
, US20070072853 A , O
n US20070072853 A NN O
and US20070072853 A CC O
Ar US20070072853 A NNP O
are US20070072853 A VBP O
as US20070072853 A IN O
defined US20070072853 A VBN O
in US20070072853 A IN O
the US20070072853 A DT O
specification US20070072853 A NN O
as US20070072853 A RB O
well US20070072853 A RB O
as US20070072853 A IN O
salts US20070072853 A NNS O
and US20070072853 A CC O
pharmaceutical US20070072853 A JJ O
compositions US20070072853 A NNS O
including US20070072853 A VBG O
the US20070072853 A DT O
compounds US20070072853 A NNS O
are US20070072853 A VBP O
prepared US20070072853 A JJ O
. US20070072853 A . O

They US20070072853 A PRP O
are US20070072853 A VBP O
useful US20070072853 A JJ O
in US20070072853 A IN O
therapy US20070072853 A NN O
, US20070072853 A , O
in US20070072853 A IN O
particular US20070072853 A JJ O
in US20070072853 A IN O
the US20070072853 A DT O
management US20070072853 A NN O
of US20070072853 A IN O
pain US20070072853 A NN O
. US20070072853 A . O

Certain EP1224187B1 T NNP O
alkylene EP1224187B1 T JJ O
diamine-substituted EP1224187B1 T JJ O
heterocycles EP1224187B1 T NNS O
. EP1224187B1 T . O

The EP1224187B1 A DT O
present EP1224187B1 A JJ O
invention EP1224187B1 A NN O
also EP1224187B1 A RB O
provides EP1224187B1 A VBZ O
a EP1224187B1 A DT O
general EP1224187B1 A JJ O
method EP1224187B1 A NN O
to EP1224187B1 A TO O
whereby EP1224187B1 A VB O
mono- EP1224187B1 A JJ O
, EP1224187B1 A , O
bi- EP1224187B1 A JJ O
, EP1224187B1 A , O
or EP1224187B1 A CC O
tri-cyclic EP1224187B1 A JJ O
heterocycles EP1224187B1 A NNS O
may EP1224187B1 A MD O
be EP1224187B1 A VB O
modified EP1224187B1 A VBN O
to EP1224187B1 A TO O
obtain EP1224187B1 A VB O
potent EP1224187B1 A JJ O
antagonists EP1224187B1 A NNS O
at EP1224187B1 A IN O
the EP1224187B1 A DT O
NPY1 EP1224187B1 A NNP I-UN
receptor EP1224187B1 A NN I-UN
. EP1224187B1 A . O

The EP1224187B1 A DT O
present EP1224187B1 A JJ O
invention EP1224187B1 A NN O
provides EP1224187B1 A VBZ O
novel EP1224187B1 A JJ O
, EP1224187B1 A , O
potent EP1224187B1 A JJ O
, EP1224187B1 A , O
non-peptidic EP1224187B1 A JJ O
antagonists EP1224187B1 A NNS O
of EP1224187B1 A IN O
NPY EP1224187B1 A NNP I-UN
receptors EP1224187B1 A NNS I-UN
, EP1224187B1 A , O
particularly EP1224187B1 A RB O
, EP1224187B1 A , O
the EP1224187B1 A DT O
NPY1 EP1224187B1 A NNP I-UN
receptors EP1224187B1 A NNS I-UN
, EP1224187B1 A , O
designed EP1224187B1 A VBN O
from EP1224187B1 A IN O
a EP1224187B1 A DT O
selection EP1224187B1 A NN O
of EP1224187B1 A IN O
mono- EP1224187B1 A JJ O
, EP1224187B1 A , O
bi- EP1224187B1 A JJ O
, EP1224187B1 A , O
or EP1224187B1 A CC O
tri-cyclic EP1224187B1 A JJ O
heterocyclic EP1224187B1 A JJ O
cores EP1224187B1 A NNS O
. EP1224187B1 A . O

This EP1224187B1 A DT O
invention EP1224187B1 A NN O
relates EP1224187B1 A VBZ O
to EP1224187B1 A TO O
novel EP1224187B1 A VB O
compounds EP1224187B1 A NNS O
, EP1224187B1 A , O
compositions EP1224187B1 A NNS O
, EP1224187B1 A , O
and EP1224187B1 A CC O
methods EP1224187B1 A NNS O
for EP1224187B1 A IN O
the EP1224187B1 A DT O
treatment EP1224187B1 A NN O
of EP1224187B1 A IN O
physiological EP1224187B1 A JJ O
disorders EP1224187B1 A NNS O
associated EP1224187B1 A VBN O
with EP1224187B1 A IN O
an EP1224187B1 A DT O
excess EP1224187B1 A NN O
of EP1224187B1 A IN O
neuropeptide EP1224187B1 A JJ I-UN
Y EP1224187B1 A NNP I-UN
. EP1224187B1 A . O

Health-caring CN101036722A T JJ O
food CN101036722A T NN O
for CN101036722A T IN O
easing CN101036722A T VBG O
and CN101036722A T CC O
improving CN101036722A T VBG O
climacteric CN101036722A T JJ O
Syndrome CN101036722A T NNP O
of CN101036722A T IN O
men CN101036722A T NNS O
and CN101036722A T CC O
the CN101036722A T DT O
preparation CN101036722A T NN O
thereof CN101036722A T NN O
. CN101036722A T . O

Minocycline CN101288673A T NNP O
hydrochloride CN101288673A T NN O
microballoons CN101288673A T NNS O
and CN101288673A T CC O
preparation CN101288673A T NN O
method CN101288673A T NN O
and CN101288673A T CC O
application CN101288673A T NN O
in CN101288673A T IN O
pharmacy CN101288673A T NN O
thereof CN101288673A T NN O
. CN101288673A T . O

Regimens US20080206310 T NNS O
for US20080206310 T IN O
Controlled US20080206310 T NNP O
Drug US20080206310 T NNP O
Delivery US20080206310 T NNP O
Devices US20080206310 T NNPS O
for US20080206310 T IN O
Contraception US20080206310 T NNP O
. US20080206310 T . O

Acetanilide US8791102 T IN O
sphingosine-1-phosphate US8791102 T JJ I-UN
receptor US8791102 T NN I-UN
antagonists US8791102 T NNS O
. US8791102 T . O

This US8791102 A DT O
disclosure US8791102 A NN O
relates US8791102 A VBZ O
to US8791102 A TO O
sphingosine-1-phosphate US8791102 A VB I-UN
( US8791102 A ( I-UN
S1P US8791102 A NNP I-UN
) US8791102 A ) I-UN
receptor US8791102 A NN I-UN
antagonists US8791102 A NNS O
, US8791102 A , O
compositions US8791102 A NNS O
comprising US8791102 A VBG O
the US8791102 A DT O
S1P US8791102 A NNP I-UN
receptor US8791102 A NN I-UN
antagonists US8791102 A NNS O
and US8791102 A CC O
methods US8791102 A NNS O
for US8791102 A IN O
using US8791102 A VBG O
and US8791102 A CC O
processes US8791102 A NNS O
for US8791102 A IN O
making US8791102 A VBG O
the US8791102 A DT O
S1P US8791102 A NNP I-UN
receptor US8791102 A NN I-UN
antagonists US8791102 A NNS O
. US8791102 A . O

In US8791102 A IN O
particular US8791102 A JJ O
, US8791102 A , O
this US8791102 A DT O
disclosure US8791102 A NN O
relates US8791102 A VBZ O
to US8791102 A TO O
sphingosine-1-phosphate US8791102 A VB I-UN
1 US8791102 A CD I-UN
( US8791102 A ( I-UN
S1P1 US8791102 A NNP I-UN
) US8791102 A ) I-UN
receptor US8791102 A NN I-UN
antagonists US8791102 A NNS O
, US8791102 A , O
compositions US8791102 A NNS O
comprising US8791102 A VBG O
the US8791102 A DT O
S1P1 US8791102 A NNP I-UN
receptor US8791102 A NN I-UN
antagonist US8791102 A NN O
and US8791102 A CC O
methods US8791102 A NNS O
for US8791102 A IN O
using US8791102 A VBG O
the US8791102 A DT O
S1P1 US8791102 A NNP I-UN
receptor US8791102 A NN I-UN
antagonist US8791102 A NN O
, US8791102 A , O
such US8791102 A JJ O
as US8791102 A IN O
in US8791102 A IN O
the US8791102 A DT O
treatment US8791102 A NN O
of US8791102 A IN O
cancer US8791102 A NN O
, US8791102 A , O
and US8791102 A CC O
processes US8791102 A VBZ O
for US8791102 A IN O
making US8791102 A VBG O
the US8791102 A DT O
S1P1 US8791102 A NNP I-UN
receptor US8791102 A NN I-UN
antagonists US8791102 A NNS O
. US8791102 A . O

Reduction WO2013121214A1 T NN O
of WO2013121214A1 T IN O
gastrointestinal WO2013121214A1 T JJ O
tract WO2013121214A1 T NN O
colonisation WO2013121214A1 T NN O
by WO2013121214A1 T IN O
campylobacter WO2013121214A1 T NN O
. WO2013121214A1 T . O

Accordingly WO2013121214A1 A RB O
, WO2013121214A1 A , O
the WO2013121214A1 A DT O
present WO2013121214A1 A JJ O
invention WO2013121214A1 A NN O
provides WO2013121214A1 A VBZ O
a WO2013121214A1 A DT O
method WO2013121214A1 A NN O
for WO2013121214A1 A IN O
disinfection WO2013121214A1 A NN O
of WO2013121214A1 A IN O
an WO2013121214A1 A DT O
animal WO2013121214A1 A JJ O
comprising WO2013121214A1 A NN O
administering WO2013121214A1 A VBG O
to WO2013121214A1 A TO O
said WO2013121214A1 A VBD O
animal WO2013121214A1 A NN O
at WO2013121214A1 A IN O
least WO2013121214A1 A JJS O
one WO2013121214A1 A CD O
compound WO2013121214A1 A NN O
that WO2013121214A1 A WDT O
binds WO2013121214A1 A VBZ O
to WO2013121214A1 A TO O
MOMP WO2013121214A1 A NNP I-UN
or WO2013121214A1 A CC O
FlaA WO2013121214A1 A NNP I-UN
of WO2013121214A1 A IN O
Campylobacter WO2013121214A1 A NNP O
in WO2013121214A1 A IN O
an WO2013121214A1 A DT O
effective WO2013121214A1 A JJ O
amount WO2013121214A1 A NN O
to WO2013121214A1 A TO O
reduce WO2013121214A1 A VB O
the WO2013121214A1 A DT O
number WO2013121214A1 A NN O
of WO2013121214A1 A IN O
Campylobacter WO2013121214A1 A NNP O
present WO2013121214A1 A NN O
in WO2013121214A1 A IN O
the WO2013121214A1 A DT O
gastrointestinal WO2013121214A1 A JJ O
tract WO2013121214A1 A NN O
of WO2013121214A1 A IN O
said WO2013121214A1 A VBD O
animal WO2013121214A1 A NN O
. WO2013121214A1 A . O

Heat US20130171231 T NNP O
Patch US20130171231 T NNP O
For US20130171231 T IN O
Insomnia US20130171231 T NNP O
. US20130171231 T . O

3- US8012991 T JJ O
( US8012991 T ( O
2,4-dimethoxyphenyl US8012991 T JJ O
) US8012991 T ) O
-1,9-dimethyl-2-oxo-2,9-dihydro-1H-pyrido US8012991 T FW O
[ US8012991 T JJ O
2,3-b US8012991 T JJ O
] US8012991 T JJ O
indole-6-carboxylic US8012991 T JJ O
acid US8012991 T NN O
; US8012991 T : O
gamma-aminobutyric US8012991 T JJ O
acid US8012991 T NN O
modulator US8012991 T NN O
; US8012991 T : O
anticarcinogenic US8012991 T JJ O
, US8012991 T , O
antitumor US8012991 T NN O
, US8012991 T , O
antiproliferative US8012991 T JJ O
agent US8012991 T NN O
; US8012991 T : O
amidating US8012991 T VBG O
a US8012991 T DT O
2-aminoindole US8012991 T JJ O
with US8012991 T IN O
an US8012991 T DT O
alpha-substituted-beta-hydroxy-alkyl US8012991 T JJ O
acrylate US8012991 T NN O
. US8012991 T . O

Pharmaceutical WO2013108263A1 T JJ O
formulation WO2013108263A1 T NN O
to WO2013108263A1 T TO O
reduce WO2013108263A1 T VB O
inflammation WO2013108263A1 T NN O
of WO2013108263A1 T IN O
bones WO2013108263A1 T NNS O
and WO2013108263A1 T CC O
joint WO2013108263A1 T JJ O
friction WO2013108263A1 T NN O
with WO2013108263A1 T IN O
improved WO2013108263A1 T JJ O
cartilage WO2013108263A1 T NN O
quality WO2013108263A1 T NN O
. WO2013108263A1 T . O

1,1'- US7067511 T JJ O
( US7067511 T ( O
( US7067511 T ( O
Propane-1,3-diyl US7067511 T NNP O
) US7067511 T ) O
dioxy US7067511 T NN O
) US7067511 T ) O
bis US7067511 T NN O
( US7067511 T ( O
( US7067511 T ( O
11aS US7067511 T CD O
) US7067511 T ) O
-7-methoxy-2 US7067511 T NN O
-methy US7067511 T JJ O
lidene-1,2,3,11-tetrahydro-5H-pyrrolo US7067511 T JJ O
( US7067511 T ( O
2,1-c US7067511 T JJ O
) US7067511 T ) O
( US7067511 T ( O
1,4 US7067511 T CD O
) US7067511 T ) O
benzodiazep US7067511 T IN O
in-5-one US7067511 T NN O
) US7067511 T ) O
derivatives US7067511 T VBZ O
; US7067511 T : O
viricides US7067511 T NNS O
, US7067511 T , O
parasiticide US7067511 T NN O
, US7067511 T , O
bactericides US7067511 T NNS O
, US7067511 T , O
gene US7067511 T NN O
therapy US7067511 T NN O
and US7067511 T CC O
treating US7067511 T VBG O
cisplatin US7067511 T NN O
refractory US7067511 T NN O
disease US7067511 T NN O
. US7067511 T . O

Medicinal CN1990029A T JJ O
composition CN1990029A T NN O
for CN1990029A T IN O
treating CN1990029A T VBG O
hepatic CN1990029A T JJ O
disease CN1990029A T NN O
. CN1990029A T . O

Use US20120270820 T NNP O
of US20120270820 T IN O
albiflorin US20120270820 T NN O
for US20120270820 T IN O
anti-depression US20120270820 T NN O
. US20120270820 T . O

Combinations US20110224239 T NNS O
Comprising US20110224239 T VBG O
a US20110224239 T DT O
S1P US20110224239 T NNP I-UN
Receptor US20110224239 T NNP I-UN
Agonist US20110224239 T NNP O
and US20110224239 T CC O
a US20110224239 T DT O
JAK3 US20110224239 T NNP I-UN
Kinase US20110224239 T NNP I-UN
Inhibitor US20110224239 T NNP O
. US20110224239 T . O

The US20110224239 A DT O
invention US20110224239 A NN O
provides US20110224239 A VBZ O
a US20110224239 A DT O
pharmaceutical US20110224239 A JJ O
combination US20110224239 A NN O
comprising US20110224239 A NN O
: US20110224239 A : O
a US20110224239 A DT O
) US20110224239 A ) O
at US20110224239 A IN O
least US20110224239 A JJS O
one US20110224239 A CD O
S1P US20110224239 A NNP I-UN
receptor US20110224239 A NN I-UN
agonist US20110224239 A NN O
, US20110224239 A , O
and US20110224239 A CC O
b US20110224239 A NN O
) US20110224239 A ) O
at US20110224239 A IN O
least US20110224239 A JJS O
one US20110224239 A CD O
JAK3 US20110224239 A NNP I-UN
kinase US20110224239 A NN I-UN
inhibitor US20110224239 A NN O
and US20110224239 A CC O
a US20110224239 A DT O
method US20110224239 A NN O
for US20110224239 A IN O
treating US20110224239 A VBG O
or US20110224239 A CC O
preventing US20110224239 A VBG O
autoimmune US20110224239 A JJ O
diseases US20110224239 A NNS O
or US20110224239 A CC O
cell US20110224239 A NN O
, US20110224239 A , O
tissue US20110224239 A NN O
or US20110224239 A CC O
organ US20110224239 A NN O
graft US20110224239 A NN O
rejection US20110224239 A NN O
using US20110224239 A VBG O
such US20110224239 A JJ O
a US20110224239 A DT O
combination US20110224239 A NN O
. US20110224239 A . O

Blood CN103566331A T NNP O
matching CN103566331A T VBG O
injection CN103566331A T NN O
of CN103566331A T IN O
Aiaikang CN103566331A T NNP O
capsules CN103566331A T NNS O
and CN103566331A T CC O
activated CN103566331A T JJ O
carbon CN103566331A T NN O
nanoparticles CN103566331A T NNS O
. CN103566331A T . O

Dihydroindolinone WO2009140928A1 T NN O
derivatives WO2009140928A1 T NNS O
. WO2009140928A1 T . O

Medicine CN103623182A T NNP O
for CN103623182A T IN O
treating CN103623182A T VBG O
gynecological CN103623182A T JJ O
inflammations CN103623182A T NNS O
and CN103623182A T CC O
preparation CN103623182A T NN O
method CN103623182A T NN O
thereof CN103623182A T NN O
. CN103623182A T . O

Biomarker US20130012519 T NNP O
Identifying US20130012519 T VBG O
the US20130012519 T DT O
Reactivation US20130012519 T NN O
of US20130012519 T IN O
STAT3 US20130012519 T NNP I-UN
After US20130012519 T IN O
Src US20130012519 T NNP I-UN
Inhibition US20130012519 T NNP O
. US20130012519 T . O

A US20130012519 A DT O
method US20130012519 A NN O
of US20130012519 A IN O
identifying US20130012519 A VBG O
cancer US20130012519 A NN O
or US20130012519 A CC O
an US20130012519 A DT O
associated US20130012519 A JJ O
disorder US20130012519 A NN O
comprising US20130012519 A VBG O
identifying US20130012519 A NN O
and US20130012519 A CC O
quantifying US20130012519 A VBG O
STAT3 US20130012519 A NNP I-UN
occurring US20130012519 A VBG O
in US20130012519 A IN O
a US20130012519 A DT O
biological US20130012519 A JJ O
sample US20130012519 A NN O
taken US20130012519 A VBN O
from US20130012519 A IN O
a US20130012519 A DT O
subject US20130012519 A NN O
after US20130012519 A IN O
administering US20130012519 A VBG O
a US20130012519 A DT O
SFK US20130012519 A NNP I-UN
inhibitor US20130012519 A NN O
to US20130012519 A TO O
said US20130012519 A VBD O
subject US20130012519 A NN O
. US20130012519 A . O

Composition US20110212194 T NN O
for US20110212194 T IN O
Inhibiting US20110212194 T VBG O
Melanogenesis US20110212194 T NNP O
and US20110212194 T CC O
Use US20110212194 T NNP O
Thereof US20110212194 T NNP O
. US20110212194 T . O

The US20110212194 A DT O
present US20110212194 A JJ O
invention US20110212194 A NN O
also US20110212194 A RB O
provides US20110212194 A VBZ O
a US20110212194 A DT O
composition US20110212194 A NN O
for US20110212194 A IN O
inhibiting US20110212194 A VBG O
melanogenesis US20110212194 A NN O
including US20110212194 A VBG O
compounds US20110212194 A NNS O
inhibit US20110212194 A JJ O
tyrosinase US20110212194 A JJ I-UN
activity US20110212194 A NN O
. US20110212194 A . O

Bath CN102973880A T NNP O
powder CN102973880A T NN O
for CN102973880A T IN O
treating CN102973880A T VBG O
neurasthenia CN102973880A T NN O
. CN102973880A T . O

Composition WO2005087224A1 T NN O
for WO2005087224A1 T IN O
stabilizing WO2005087224A1 T VBG O
epigallocatechin WO2005087224A1 T JJ O
gallate WO2005087224A1 T NN O
( WO2005087224A1 T ( O
egcg WO2005087224A1 T NN O
) WO2005087224A1 T ) O
in WO2005087224A1 T IN O
water WO2005087224A1 T NN O
phase WO2005087224A1 T NN O
and WO2005087224A1 T CC O
preparation WO2005087224A1 T NN O
method WO2005087224A1 T NN O
thereof WO2005087224A1 T NN O
. WO2005087224A1 T . O

Compositions US20130052271 T NNS O
and US20130052271 T CC O
Methods US20130052271 T NNS O
for US20130052271 T IN O
Treating US20130052271 T VBG O
Pain US20130052271 T NNP O
. US20130052271 T . O

Phospholipid US7531604 T NNP O
derivative US7531604 T JJ O
containing US7531604 T VBG O
a US7531604 T DT O
polyoxyalkylene US7531604 T NN O
group US7531604 T NN O
comprising US7531604 T VBG O
two US7531604 T CD O
or US7531604 T CC O
more US7531604 T JJR O
kinds US7531604 T NNS O
of US7531604 T IN O
alkylene US7531604 T NN O
oxides US7531604 T NNS O
, US7531604 T , O
as US7531604 T RB O
well US7531604 T RB O
as US7531604 T IN O
a US7531604 T DT O
surfactant US7531604 T NN O
, US7531604 T , O
solubilizer US7531604 T NN O
, US7531604 T , O
dispersing US7531604 T VBG O
agent US7531604 T NN O
; US7531604 T : O
for US7531604 T IN O
cosmetics US7531604 T NNS O
and US7531604 T CC O
lipid US7531604 T JJ O
membrane US7531604 T NN O
structures US7531604 T NNS O
; US7531604 T : O
drug US7531604 T NN O
delivery US7531604 T NN O
of US7531604 T IN O
antitumor US7531604 T NN O
agents US7531604 T NNS O
. US7531604 T . O

Allosteric EP2177510A1 T NNP O
protein EP2177510A1 T NN O
kinase EP2177510A1 T NN I-UN
modulators EP2177510A1 T NNS O
. EP2177510A1 T . O

The EP2177510A1 A DT O
invention EP2177510A1 A NN O
provides EP2177510A1 A VBZ O
specific EP2177510A1 A JJ O
small EP2177510A1 A JJ O
molecule EP2177510A1 A NN O
compounds EP2177510A1 A NNS O
that EP2177510A1 A WDT O
allosterically EP2177510A1 A RB O
regulate EP2177510A1 A VBP O
the EP2177510A1 A DT O
activity EP2177510A1 A NN O
or EP2177510A1 A CC O
modulate EP2177510A1 A VB O
protein-protein EP2177510A1 A JJ O
interactions EP2177510A1 A NNS O
of EP2177510A1 A IN O
AGC EP2177510A1 A NNP I-UN
protein EP2177510A1 A NN I-UN
kinases EP2177510A1 A NNS I-UN
and EP2177510A1 A CC O
the EP2177510A1 A DT O
Aurora EP2177510A1 A NNP I-UN
family EP2177510A1 A NN O
of EP2177510A1 A IN O
protein EP2177510A1 A NN O
kinases EP2177510A1 A NNS I-UN
, EP2177510A1 A , O
methods EP2177510A1 A NNS O
for EP2177510A1 A IN O
their EP2177510A1 A PRP$ O
production EP2177510A1 A NN O
, EP2177510A1 A , O
pharmaceutical EP2177510A1 A JJ O
compositions EP2177510A1 A NNS O
comprising EP2177510A1 A VBG O
same EP2177510A1 A JJ O
, EP2177510A1 A , O
and EP2177510A1 A CC O
their EP2177510A1 A PRP$ O
use EP2177510A1 A NN O
for EP2177510A1 A IN O
preparing EP2177510A1 A VBG O
medicaments EP2177510A1 A NNS O
for EP2177510A1 A IN O
the EP2177510A1 A DT O
treatment EP2177510A1 A NN O
and EP2177510A1 A CC O
prevention EP2177510A1 A NN O
of EP2177510A1 A IN O
diseases EP2177510A1 A NNS O
related EP2177510A1 A VBN O
to EP2177510A1 A TO O
abnormal EP2177510A1 A JJ O
activities EP2177510A1 A NNS O
of EP2177510A1 A IN O
AGC EP2177510A1 A NNP I-UN
protein EP2177510A1 A NN I-UN
kinases EP2177510A1 A VBZ I-UN
or EP2177510A1 A CC O
of EP2177510A1 A IN O
protein EP2177510A1 A JJ O
kinases EP2177510A1 A NNS I-UN
of EP2177510A1 A IN O
the EP2177510A1 A DT O
Aurora EP2177510A1 A NNP I-UN
family EP2177510A1 A NN O
. EP2177510A1 A . O

Treatment EP1071425B1 T NN O
of EP1071425B1 T IN O
depression EP1071425B1 T NN O
and EP1071425B1 T CC O
pharmaceutical EP1071425B1 T JJ O
preparations EP1071425B1 T NNS O
therefor EP1071425B1 T VBP O
. EP1071425B1 T . O

Bath CN1927273A T NNP O
agent CN1927273A T NN O
for CN1927273A T IN O
influenza CN1927273A T JJ O
defervesce CN1927273A T NN O
and CN1927273A T CC O
preparing CN1927273A T VBG O
method CN1927273A T NN O
thereof CN1927273A T NN O
. CN1927273A T . O

The CN1927273A A DT O
invention CN1927273A A NN O
provides CN1927273A A VBZ O
a CN1927273A A DT O
defervesce CN1927273A A JJ O
lotion CN1927273A A NN O
for CN1927273A A IN O
treating CN1927273A A VBG O
common CN1927273A A JJ O
cold CN1927273A A NN O
and CN1927273A A CC O
its CN1927273A A PRP$ O
preparing CN1927273A A NN O
process CN1927273A A NN O
, CN1927273A A , O
wherein CN1927273A A WP O
the CN1927273A A DT O
medicinal CN1927273A A JJ O
raw CN1927273A A JJ O
materials CN1927273A A NNS O
include CN1927273A A VBP O
root CN1927273A A NN O
of CN1927273A A IN O
Dahurain CN1927273A A NNP O
angelica CN1927273A A IN O
6-9 CN1927273A A JJ O
weight CN1927273A A NN O
parts CN1927273A A NNS O
, CN1927273A A , O
ledebouriella CN1927273A A NN O
root CN1927273A A NN O
8-12 CN1927273A A JJ O
weight CN1927273A A NN O
parts CN1927273A A NNS O
, CN1927273A A , O
bupleurum CN1927273A A NN O
root CN1927273A A NN O
12-18 CN1927273A A JJ O
weight CN1927273A A NN O
parts CN1927273A A NNS O
, CN1927273A A , O
kudzuvine CN1927273A A VB O
root CN1927273A A NN O
12-18 CN1927273A A JJ O
weight CN1927273A A NN O
parts CN1927273A A NNS O
, CN1927273A A , O
plaster CN1927273A A NN O
stone CN1927273A A NN O
20-30 CN1927273A A JJ O
weight CN1927273A A NN O
parts CN1927273A A NNS O
, CN1927273A A , O
honeysuckle CN1927273A A VBP O
20-30 CN1927273A A JJ O
weight CN1927273A A NN O
parts CN1927273A A NNS O
, CN1927273A A , O
isatic CN1927273A A JJ O
root CN1927273A A NN O
12-18 CN1927273A A JJ O
weight CN1927273A A NN O
parts CN1927273A A NNS O
, CN1927273A A , O
licorice CN1927273A A JJ O
root CN1927273A A NN O
4-6 CN1927273A A JJ O
weight CN1927273A A NN O
parts CN1927273A A NNS O
and CN1927273A A CC O
capsule CN1927273A A NN O
of CN1927273A A IN O
weeping CN1927273A A VBG O
forsythia CN1927273A A JJ O
10-35 CN1927273A A JJ O
weight CN1927273A A NN O
parts CN1927273A A NNS O
. CN1927273A A . O

Drug CN103070935A T NN O
for CN103070935A T IN O
curing CN103070935A T VBG O
acne CN103070935A T NN O
. CN103070935A T . O

The CN103070935A A DT O
invention CN103070935A A NN O
relates CN103070935A A VBZ O
to CN103070935A A TO O
a CN103070935A A DT O
drug CN103070935A A NN O
for CN103070935A A IN O
curing CN103070935A A VBG O
acne CN103070935A A NN O
, CN103070935A A , O
which CN103070935A A WDT O
is CN103070935A A VBZ O
characterized CN103070935A A VBN O
by CN103070935A A IN O
comprising CN103070935A A VBG O
sulphur CN103070935A A NN O
and CN103070935A A CC O
rheum CN103070935A A NN O
officinale CN103070935A A NN O
, CN103070935A A , O
as CN103070935A A RB O
well CN103070935A A RB O
as CN103070935A A IN O
scutellaria CN103070935A A NNS O
baicalensis CN103070935A A NN O
preferably CN103070935A A RB O
. CN103070935A A . O

The CN103070935A A DT O
drug CN103070935A A NN O
for CN103070935A A IN O
curing CN103070935A A VBG O
acne CN103070935A A NN O
is CN103070935A A VBZ O
pure CN103070935A A JJ O
Chinese CN103070935A A JJ O
materia CN103070935A A NNS O
medica CN103070935A A JJ O
preparation CN103070935A A NN O
, CN103070935A A , O
has CN103070935A A VBZ O
little CN103070935A A JJ O
toxic CN103070935A A JJ O
and CN103070935A A CC O
side CN103070935A A JJ O
effect CN103070935A A NN O
, CN103070935A A , O
is CN103070935A A VBZ O
effective CN103070935A A JJ O
in CN103070935A A IN O
treatment CN103070935A A NN O
, CN103070935A A , O
and CN103070935A A CC O
can CN103070935A A MD O
be CN103070935A A VB O
used CN103070935A A VBN O
for CN103070935A A IN O
effectively CN103070935A A RB O
curing CN103070935A A VBG O
face CN103070935A A NN O
acne CN103070935A A NN O
. CN103070935A A . O

Benzimidazolone WO2014160873A1 T NNP O
derivatives WO2014160873A1 T VBZ O
as WO2014160873A1 T RB O
bromodomain WO2014160873A1 T JJ O
inhibitors WO2014160873A1 T NNS O
. WO2014160873A1 T . O

This WO2014160873A1 A DT O
application WO2014160873A1 A NN O
relates WO2014160873A1 A VBZ O
to WO2014160873A1 A TO O
chemical WO2014160873A1 A VB O
compounds WO2014160873A1 A NNS O
which WO2014160873A1 A WDT O
may WO2014160873A1 A MD O
act WO2014160873A1 A VB O
as WO2014160873A1 A IN O
inhibitors WO2014160873A1 A NNS O
of WO2014160873A1 A IN O
, WO2014160873A1 A , O
or WO2014160873A1 A CC O
which WO2014160873A1 A WDT O
may WO2014160873A1 A MD O
otherwise WO2014160873A1 A VB O
modulate WO2014160873A1 A VB O
the WO2014160873A1 A DT O
activity WO2014160873A1 A NN O
of WO2014160873A1 A IN O
, WO2014160873A1 A , O
a WO2014160873A1 A DT O
bromodomain-containing WO2014160873A1 A JJ O
protein WO2014160873A1 A NN O
, WO2014160873A1 A , O
including WO2014160873A1 A VBG O
bromodomain-containing WO2014160873A1 A JJ I-UN
protein WO2014160873A1 A NN I-UN
4 WO2014160873A1 A CD I-UN
( WO2014160873A1 A ( O
BRD4 WO2014160873A1 A NNP I-UN
) WO2014160873A1 A ) O
, WO2014160873A1 A , O
and WO2014160873A1 A CC O
to WO2014160873A1 A TO O
compositions WO2014160873A1 A NNS O
and WO2014160873A1 A CC O
formulations WO2014160873A1 A NNS O
containing WO2014160873A1 A VBG O
such WO2014160873A1 A JJ O
compounds WO2014160873A1 A NNS O
, WO2014160873A1 A , O
and WO2014160873A1 A CC O
methods WO2014160873A1 A NNS O
of WO2014160873A1 A IN O
using WO2014160873A1 A VBG O
and WO2014160873A1 A CC O
making WO2014160873A1 A VBG O
such WO2014160873A1 A JJ O
compounds WO2014160873A1 A NNS O
. WO2014160873A1 A . O

Ciclesonide CN101007008A T NNP O
medicinal CN101007008A T JJ O
spraying CN101007008A T NN O
agent CN101007008A T NN O
and CN101007008A T CC O
its CN101007008A T PRP$ O
preparation CN101007008A T NN O
method CN101007008A T NN O
. CN101007008A T . O

Administering US7214700 T VBG O
to US7214700 T TO O
a US7214700 T DT O
human US7214700 T JJ O
patient US7214700 T NN O
an US7214700 T DT O
2-oxindole-3-ylidenyl US7214700 T JJ O
) US7214700 T ) O
acetic US7214700 T JJ O
acid US7214700 T NN O
derivatives US7214700 T NNS O
which US7214700 T WDT O
modulate US7214700 T VBP O
the US7214700 T DT O
activity US7214700 T NN O
of US7214700 T IN O
protein US7214700 T NN O
kinases US7214700 T NNS O
and US7214700 T CC O
effective US7214700 T JJ O
to US7214700 T TO O
treat US7214700 T VB O
disorders US7214700 T NNS O
related US7214700 T VBN O
to US7214700 T TO O
abnormal US7214700 T JJ O
protein US7214700 T JJ O
kinase US7214700 T NN O
activity US7214700 T NN O
, US7214700 T , O
such US7214700 T JJ O
as US7214700 T IN O
cancer US7214700 T NN O
. US7214700 T . O

Compound CA2781066C T NNP O
, CA2781066C T , O
certain CA2781066C T JJ O
novel CA2781066C T NN O
forms CA2781066C T NNS O
thereof CA2781066C T VBP O
, CA2781066C T , O
pharmaceutical CA2781066C T JJ O
compositions CA2781066C T NNS O
thereof CA2781066C T NN O
and CA2781066C T CC O
methods CA2781066C T NNS O
for CA2781066C T IN O
preparation CA2781066C T NN O
and CA2781066C T CC O
use CA2781066C T NN O
. CA2781066C T . O

Composition WO2006104154A1 T NN O
for WO2006104154A1 T IN O
enhancing WO2006104154A1 T VBG O
expression WO2006104154A1 T NN O
and WO2006104154A1 T CC O
activity WO2006104154A1 T NN O
of WO2006104154A1 T IN O
protease WO2006104154A1 T NN I-UN
in WO2006104154A1 T IN O
liver WO2006104154A1 T NN O
. WO2006104154A1 T . O

Disclosed WO2006104154A1 A VBN O
is WO2006104154A1 A VBZ O
a WO2006104154A1 A DT O
highly WO2006104154A1 A RB O
safe WO2006104154A1 A JJ O
composition WO2006104154A1 A NN O
for WO2006104154A1 A IN O
enhancing WO2006104154A1 A VBG O
expression WO2006104154A1 A NN O
and WO2006104154A1 A CC O
activity WO2006104154A1 A NN O
of WO2006104154A1 A IN O
a WO2006104154A1 A DT O
protease WO2006104154A1 A NN I-UN
in WO2006104154A1 A IN O
the WO2006104154A1 A DT O
liver WO2006104154A1 A NN O
. WO2006104154A1 A . O

Specifically WO2006104154A1 A RB O
disclosed WO2006104154A1 A VBN O
is WO2006104154A1 A VBZ O
a WO2006104154A1 A DT O
composition WO2006104154A1 A NN O
containing WO2006104154A1 A VBG O
coenzyme WO2006104154A1 A JJ I-UN
Q10 WO2006104154A1 A NNP I-UN
as WO2006104154A1 A IN O
an WO2006104154A1 A DT O
active WO2006104154A1 A JJ O
constituent WO2006104154A1 A NN O
. WO2006104154A1 A . O

This WO2006104154A1 A DT O
composition WO2006104154A1 A NN O
enhances WO2006104154A1 A VBZ O
expression WO2006104154A1 A NN O
and WO2006104154A1 A CC O
activity WO2006104154A1 A NN O
of WO2006104154A1 A IN O
a WO2006104154A1 A DT O
protease WO2006104154A1 A NN I-UN
in WO2006104154A1 A IN O
the WO2006104154A1 A DT O
liver WO2006104154A1 A NN O
. WO2006104154A1 A . O

Amphiphilic US20080213324 T NNP O
or US20080213324 T CC O
lipophilic US20080213324 T JJ O
polar US20080213324 T JJ O
functionalized US20080213324 T VBN O
fullerenes US20080213324 T NNS O
and US20080213324 T CC O
their US20080213324 T PRP$ O
uses US20080213324 T NNS O
. US20080213324 T . O

Benzo US20090192213 T NNP O
[ US20090192213 T NNP O
b US20090192213 T NN O
] US20090192213 T NNP O
furane US20090192213 T NN O
And US20090192213 T CC O
Benzo US20090192213 T NNP O
[ US20090192213 T NNP O
b US20090192213 T NN O
] US20090192213 T NNP O
thiophene US20090192213 T NN O
Derivatives US20090192213 T NNS O
. US20090192213 T . O

NOVEL WO2006101434A1 T NNP O
TETRAHYDRO-1H-PYRIDO WO2006101434A1 T NNP O
[ WO2006101434A1 T NNP O
4,3-b WO2006101434A1 T JJ O
] WO2006101434A1 T NNP O
INDOLE WO2006101434A1 T NNP O
DERIVATIVES WO2006101434A1 T NNP O
AS WO2006101434A1 T NNP O
CB1’ WO2006101434A1 T NNP I-UN
RECEPTOR WO2006101434A1 T NNP I-UN
LIGANDS WO2006101434A1 T NNP O
. WO2006101434A1 T . O

Oligo CN102698285A T NNP O
( CN102698285A T ( O
ethylene CN102698285A T JJ O
glycol CN102698285A T NN O
) CN102698285A T ) O
modified CN102698285A T VBD O
chlorambucil CN102698285A T JJ O
nanomedicine CN102698285A T NN O
and CN102698285A T CC O
preparation CN102698285A T NN O
method CN102698285A T NN O
thereof CN102698285A T NN O
. CN102698285A T . O

Method US20100240763 T NN O
to US20100240763 T TO O
Determine US20100240763 T NNP O
and US20100240763 T CC O
Biomarker US20100240763 T NNP O
for US20100240763 T IN O
Treatment US20100240763 T NNP O
Efficacy US20100240763 T NNP O
With US20100240763 T IN O
Ssri US20100240763 T NNP O
, US20100240763 T , O
Snri US20100240763 T NNP O
, US20100240763 T , O
and US20100240763 T CC O
Sari US20100240763 T NNP O
Antidepressants US20100240763 T NNP O
. US20100240763 T . O

The US20100240763 A DT O
method US20100240763 A NN O
comprises US20100240763 A VBZ O
observing US20100240763 A VBG O
whether US20100240763 A IN O
the US20100240763 A DT O
genome US20100240763 A NN O
of US20100240763 A IN O
the US20100240763 A DT O
patient US20100240763 A NN O
contains US20100240763 A VBZ O
at US20100240763 A IN O
least US20100240763 A JJS O
one US20100240763 A CD O
copy US20100240763 A NN O
of US20100240763 A IN O
the US20100240763 A DT O
BDNF US20100240763 A NNP I-UN
allele US20100240763 A NN I-UN
containing US20100240763 A VBG O
a US20100240763 A DT O
genetic US20100240763 A JJ O
alteration US20100240763 A NN O
, US20100240763 A , O
and US20100240763 A CC O
correlating US20100240763 A VBG O
the US20100240763 A DT O
presence US20100240763 A NN O
of US20100240763 A IN O
the US20100240763 A DT O
allele US20100240763 A NN O
containing US20100240763 A VBG O
the US20100240763 A DT O
genetic US20100240763 A JJ O
alteration US20100240763 A NN O
with US20100240763 A IN O
patients US20100240763 A NNS O
who US20100240763 A WP O
are US20100240763 A VBP O
resistant US20100240763 A JJ O
to US20100240763 A TO O
treatment US20100240763 A NN O
with US20100240763 A IN O
the US20100240763 A DT O
compound US20100240763 A NN O
. US20100240763 A . O

In US20100240763 A IN O
another US20100240763 A DT O
embodiment US20100240763 A NN O
, US20100240763 A , O
the US20100240763 A DT O
method US20100240763 A NN O
comprises US20100240763 A VBZ O
observing US20100240763 A VBG O
whether US20100240763 A IN O
the US20100240763 A DT O
patient US20100240763 A NN O
expresses US20100240763 A VBZ O
a US20100240763 A DT O
BDNF US20100240763 A NNP I-UN
protein US20100240763 A NN O
containing US20100240763 A VBG O
an US20100240763 A DT O
amino US20100240763 A NN O
acid US20100240763 A NN O
alteration US20100240763 A NN O
, US20100240763 A , O
and US20100240763 A CC O
correlating US20100240763 A VBG O
the US20100240763 A DT O
expression US20100240763 A NN O
of US20100240763 A IN O
the US20100240763 A DT O
BDNF US20100240763 A NNP I-UN
protein US20100240763 A NN O
containing US20100240763 A VBG O
the US20100240763 A DT O
amino US20100240763 A NN O
acid US20100240763 A JJ O
alteration US20100240763 A NN O
with US20100240763 A IN O
patients US20100240763 A NNS O
who US20100240763 A WP O
are US20100240763 A VBP O
resistant US20100240763 A JJ O
to US20100240763 A TO O
treatment US20100240763 A NN O
with US20100240763 A IN O
the US20100240763 A DT O
compound US20100240763 A NN O
. US20100240763 A . O

2-aminopropane-1,3-diol USRE39072 T JJ O
compounds USRE39072 T NNS O
, USRE39072 T , O
medicinal USRE39072 T JJ O
use USRE39072 T NN O
thereof USRE39072 T NN O
, USRE39072 T , O
and USRE39072 T CC O
intermediates USRE39072 T NNS O
in USRE39072 T IN O
synthesizing USRE39072 T VBG O
the USRE39072 T DT O
same USRE39072 T JJ O
. USRE39072 T . O

The USRE39072 A DT O
present USRE39072 A JJ O
invention USRE39072 A NN O
relates USRE39072 A VBZ O
to USRE39072 A TO O
a USRE39072 A DT O
compound USRE39072 A NN O
of USRE39072 A IN O
the USRE39072 A DT O
general USRE39072 A JJ O
formula USRE39072 A NN O
wherein USRE39072 A NN O
R1 USRE39072 A NNP O
, USRE39072 A , O
R2 USRE39072 A NNP O
, USRE39072 A , O
R3 USRE39072 A NNP O
and USRE39072 A CC O
R4 USRE39072 A NNP O
are USRE39072 A VBP O
each USRE39072 A DT O
a USRE39072 A DT O
hydrogen USRE39072 A NN O
or USRE39072 A CC O
an USRE39072 A DT O
acyl USRE39072 A NN O
, USRE39072 A , O
a USRE39072 A DT O
pharmaceutically USRE39072 A RB O
acceptable USRE39072 A JJ O
acid USRE39072 A JJ O
addition USRE39072 A NN O
salt USRE39072 A NN O
thereof USRE39072 A NN O
or USRE39072 A CC O
a USRE39072 A DT O
hydrate USRE39072 A JJ O
thereof USRE39072 A NN O
; USRE39072 A : O
a USRE39072 A DT O
pharmaceutical USRE39072 A JJ O
comprising USRE39072 A NN O
this USRE39072 A DT O
compound USRE39072 A NN O
; USRE39072 A : O
a USRE39072 A DT O
pharmaceutical USRE39072 A JJ O
composition USRE39072 A NN O
comprising USRE39072 A VBG O
this USRE39072 A DT O
compound USRE39072 A NN O
and USRE39072 A CC O
a USRE39072 A DT O
pharmaceutically USRE39072 A RB O
acceptable USRE39072 A JJ O
carrier USRE39072 A NN O
; USRE39072 A : O
and USRE39072 A CC O
2-amino-2- USRE39072 A JJ O
( USRE39072 A ( O
2- USRE39072 A JJ O
( USRE39072 A ( O
4- USRE39072 A JJ O
( USRE39072 A ( O
1-hydroxy-5-phenylpentyl USRE39072 A JJ O
) USRE39072 A ) O
phenyl USRE39072 A NN O
) USRE39072 A ) O
ethyl USRE39072 A NN O
) USRE39072 A ) O
propane-1,3-diol USRE39072 A NN O
or USRE39072 A CC O
2-amino-2- USRE39072 A JJ O
( USRE39072 A ( O
2- USRE39072 A JJ O
( USRE39072 A ( O
4-formylphenyl USRE39072 A JJ O
) USRE39072 A ) O
ethyl USRE39072 A NN O
) USRE39072 A ) O
propane-1,3-diol USRE39072 A NN O
, USRE39072 A , O
the USRE39072 A DT O
derivatives USRE39072 A NNS O
of USRE39072 A IN O
the USRE39072 A DT O
two USRE39072 A CD O
compounds USRE39072 A NNS O
whose USRE39072 A WP$ O
amino USRE39072 A NN O
group USRE39072 A NN O
and/or USRE39072 A VBZ O
hydroxy USRE39072 A JJ O
group USRE39072 A NN O
are USRE39072 A VBP O
( USRE39072 A ( O
is USRE39072 A VBZ O
) USRE39072 A ) O
protected USRE39072 A VBD O
or USRE39072 A CC O
a USRE39072 A DT O
salt USRE39072 A JJ O
thereof USRE39072 A NN O
. USRE39072 A . O

The USRE39072 A DT O
compound USRE39072 A NN O
of USRE39072 A IN O
the USRE39072 A DT O
present USRE39072 A JJ O
invention USRE39072 A NN O
shows USRE39072 A VBZ O
superior USRE39072 A JJ O
immunosuppressive USRE39072 A JJ O
action USRE39072 A NN O
with USRE39072 A IN O
less USRE39072 A JJR O
toxicity USRE39072 A NN O
and USRE39072 A CC O
higher USRE39072 A JJR O
safety USRE39072 A NN O
, USRE39072 A , O
and USRE39072 A CC O
is USRE39072 A VBZ O
useful USRE39072 A JJ O
as USRE39072 A IN O
a USRE39072 A DT O
drug USRE39072 A NN O
for USRE39072 A IN O
prevention USRE39072 A NN O
or USRE39072 A CC O
suppression USRE39072 A NN O
of USRE39072 A IN O
rejection USRE39072 A NN O
of USRE39072 A IN O
organs USRE39072 A NNS O
or USRE39072 A CC O
bone USRE39072 A NN O
marrow USRE39072 A NN O
transplantation USRE39072 A NN O
, USRE39072 A , O
or USRE39072 A CC O
as USRE39072 A IN O
a USRE39072 A DT O
drug USRE39072 A NN O
for USRE39072 A IN O
prevention USRE39072 A NN O
or USRE39072 A CC O
treatment USRE39072 A NN O
of USRE39072 A IN O
various USRE39072 A JJ O
autoimmune USRE39072 A JJ O
diseases USRE39072 A NNS O
or USRE39072 A CC O
allergic USRE39072 A JJ O
diseases USRE39072 A NNS O
. USRE39072 A . O

Methods US20080038323 T NNS O
for US20080038323 T IN O
Improving US20080038323 T VBG O
Liver US20080038323 T NNP O
Clearance US20080038323 T NNP O
of US20080038323 T IN O
Xenobiotic US20080038323 T JJ O
Substances US20080038323 T NNS O
in US20080038323 T IN O
an US20080038323 T DT O
Animal US20080038323 T NNP O
. US20080038323 T . O

Glucokinase US20120252814 T NNP I-UN
Activators US20120252814 T NNP O
. US20120252814 T . O

Compounds US20120252814 A NNS O
of US20120252814 A IN O
the US20120252814 A DT O
following US20120252814 A JJ O
formula US20120252814 A NN O
are US20120252814 A VBP O
provided US20120252814 A VBN O
for US20120252814 A IN O
use US20120252814 A NN O
with US20120252814 A IN O
glucokinase US20120252814 A NN I-UN
: US20120252814 A : O
wherein US20120252814 A VB O
the US20120252814 A DT O
variables US20120252814 A NNS O
are US20120252814 A VBP O
as US20120252814 A IN O
defined US20120252814 A JJ O
herein US20120252814 A NN O
. US20120252814 A . O

Hypoglycemics EP1634593A2 T NNS O
comprising EP1634593A2 T VBG O
organic EP1634593A2 T JJ O
zinc EP1634593A2 T NN O
( EP1634593A2 T ( O
II EP1634593A2 T NNP O
) EP1634593A2 T ) O
complexes EP1634593A2 T NNS O
. EP1634593A2 T . O

Compositions WO2009029618A1 T NNS O
and WO2009029618A1 T CC O
methods WO2009029618A1 T NNS O
employing WO2009029618A1 T VBG O
nmda WO2009029618A1 T JJ O
antagonists WO2009029618A1 T NNS O
for WO2009029618A1 T IN O
achieving WO2009029618A1 T VBG O
an WO2009029618A1 T DT O
anesthetic-sparing WO2009029618A1 T JJ O
effect WO2009029618A1 T NN O
. WO2009029618A1 T . O

Antiserotonine US20080108596 T JJ O
agents US20080108596 T NNS O
; US20080108596 T : O
psycholgical US20080108596 T JJ O
disorders US20080108596 T NNS O
; US20080108596 T : O
headaches US20080108596 T NNS O
; US20080108596 T : O
kits US20080108596 T NNS O
. US20080108596 T . O

The US20080108596 A DT O
present US20080108596 A JJ O
invention US20080108596 A NN O
relates US20080108596 A VBZ O
to US20080108596 A TO O
a US20080108596 A DT O
combination US20080108596 A NN O
comprising US20080108596 A VBG O
quetiapine US20080108596 A NN O
or US20080108596 A CC O
a US20080108596 A DT O
pharmaceutically US20080108596 A RB O
acceptable US20080108596 A JJ O
salt US20080108596 A NN O
thereof US20080108596 A NN O
and US20080108596 A CC O
zolmitriptan US20080108596 A NN O
or US20080108596 A CC O
a US20080108596 A DT O
pharmaceutically US20080108596 A RB O
acceptable US20080108596 A JJ O
salt US20080108596 A NN O
thereof US20080108596 A NN O
, US20080108596 A , O
pharmaceutical US20080108596 A JJ O
compositions US20080108596 A NNS O
, US20080108596 A , O
processes US20080108596 A VBZ O
for US20080108596 A IN O
its US20080108596 A PRP$ O
preparation US20080108596 A NN O
, US20080108596 A , O
the US20080108596 A DT O
use US20080108596 A NN O
thereof US20080108596 A NN O
in US20080108596 A IN O
the US20080108596 A DT O
manufacture US20080108596 A NN O
of US20080108596 A IN O
a US20080108596 A DT O
medicament US20080108596 A NN O
and US20080108596 A CC O
a US20080108596 A DT O
method US20080108596 A NN O
of US20080108596 A IN O
treatment US20080108596 A NN O
of US20080108596 A IN O
disease US20080108596 A NN O
and US20080108596 A CC O
more US20080108596 A JJR O
particularly US20080108596 A RB O
to US20080108596 A TO O
a US20080108596 A DT O
method US20080108596 A NN O
of US20080108596 A IN O
treatment US20080108596 A NN O
of US20080108596 A IN O
diseases US20080108596 A NNS O
typically US20080108596 A RB O
treated US20080108596 A VBN O
with US20080108596 A IN O
5-HT1D US20080108596 A JJ I-UN
agonists US20080108596 A NNS O
and/or US20080108596 A VBP O
atypical US20080108596 A JJ O
antipsychotics US20080108596 A NNS O
, US20080108596 A , O
in US20080108596 A IN O
particularly US20080108596 A RB O
, US20080108596 A , O
migraine US20080108596 A NN O
, US20080108596 A , O
related US20080108596 A JJ O
conditions US20080108596 A NNS O
and US20080108596 A CC O
for US20080108596 A IN O
reducing US20080108596 A VBG O
or US20080108596 A CC O
eliminating US20080108596 A VBG O
of US20080108596 A IN O
migraine US20080108596 A JJ O
recurrence US20080108596 A NN O
. US20080108596 A . O

Compositions US20120315223 T NNS O
for US20120315223 T IN O
oral US20120315223 T JJ O
use US20120315223 T NN O
and US20120315223 T CC O
methods US20120315223 T NNS O
for US20120315223 T IN O
treating US20120315223 T VBG O
the US20120315223 T DT O
oral US20120315223 T JJ O
mucosa US20120315223 T NN O
, US20120315223 T , O
lips US20120315223 T NNS O
, US20120315223 T , O
and US20120315223 T CC O
perioral US20120315223 T JJ O
regions US20120315223 T NNS O
. US20120315223 T . O

Method US20120077876 T NNP O
For US20120077876 T IN O
Improved US20120077876 T NNP O
Bioactivation US20120077876 T NNP O
Of US20120077876 T IN O
Pharmaceuticals US20120077876 T NNP O
. US20120077876 T . O

Small US20080015159 T NNP O
Synthetic US20080015159 T NNP O
Rna US20080015159 T NNP O
, US20080015159 T , O
a US20080015159 T DT O
Method US20080015159 T NNP O
of US20080015159 T IN O
Preparing US20080015159 T VBG O
the US20080015159 T DT O
Same US20080015159 T NNP O
and US20080015159 T CC O
Uses US20080015159 T NNP O
Thereof US20080015159 T NNP O
. US20080015159 T . O

Industrial WO2013108921A1 T NNP O
process WO2013108921A1 T NN O
for WO2013108921A1 T IN O
preparation WO2013108921A1 T NN O
of WO2013108921A1 T IN O
1,2-dihydroquinoline WO2013108921A1 T JJ O
derivative WO2013108921A1 T JJ O
or WO2013108921A1 T CC O
a WO2013108921A1 T DT O
salt WO2013108921A1 T NN O
thereof WO2013108921A1 T NN O
, WO2013108921A1 T , O
and WO2013108921A1 T CC O
intermediate WO2013108921A1 T NN O
for WO2013108921A1 T IN O
preparation WO2013108921A1 T NN O
thereof WO2013108921A1 T NN O
. WO2013108921A1 T . O

Atomizing WO2011143843A1 T VBG O
formulation WO2011143843A1 T NN O
comprising WO2011143843A1 T NN O
plant WO2011143843A1 T NN O
extract WO2011143843A1 T NN O
and WO2011143843A1 T CC O
its WO2011143843A1 T PRP$ O
preparation WO2011143843A1 T NN O
method WO2011143843A1 T NN O
. WO2011143843A1 T . O

Pharmaceutical US20050159476 T JJ O
composition US20050159476 T NN O
for US20050159476 T IN O
preventing US20050159476 T VBG O
or US20050159476 T CC O
treating US20050159476 T VBG O
respiratory US20050159476 T JJ O
disease US20050159476 T NN O
. US20050159476 T . O

Stable US20120114752 T JJ O
tablet US20120114752 T NN O
containing US20120114752 T VBG O
4,5-epoxymorphinan US20120114752 T JJ O
derivative US20120114752 T NN O
. US20120114752 T . O

Use WO2010043787A1 T NNP O
of WO2010043787A1 T IN O
4- WO2010043787A1 T JJ O
( WO2010043787A1 T ( O
3- WO2010043787A1 T JJ O
[ WO2010043787A1 T NN O
hexahydrocyclopenta WO2010043787A1 T NN O
[ WO2010043787A1 T NNP O
c WO2010043787A1 T VBZ O
] WO2010043787A1 T JJ O
pyrrol-i WO2010043787A1 T JJ O
( WO2010043787A1 T ( O
1h WO2010043787A1 T CD O
) WO2010043787A1 T ) O
-yl WO2010043787A1 T NN O
] WO2010043787A1 T JJ O
propoxy WO2010043787A1 T NN O
} WO2010043787A1 T ) O
benzamide WO2010043787A1 T NN O
for WO2010043787A1 T IN O
making WO2010043787A1 T VBG O
drugs WO2010043787A1 T NNS O
for WO2010043787A1 T IN O
treating WO2010043787A1 T VBG O
sleep WO2010043787A1 T JJ O
disorders WO2010043787A1 T NNS O
. WO2010043787A1 T . O

Composition WO2012113503A1 T NN O
to WO2012113503A1 T TO O
increase WO2012113503A1 T VB O
joint WO2012113503A1 T JJ O
and/or WO2012113503A1 T JJ O
postural WO2012113503A1 T JJ O
stability WO2012113503A1 T NN O
. WO2012113503A1 T . O

Compositions WO2008062324A3 T NNS O
comprising WO2008062324A3 T VBG O
nicotinamide WO2008062324A3 T RB O
and WO2008062324A3 T CC O
wakame WO2008062324A3 T VB O
extract WO2008062324A3 T JJ O
having WO2008062324A3 T VBG O
skin WO2008062324A3 T JJ O
anti-aging WO2008062324A3 T JJ O
properties WO2008062324A3 T NNS O
. WO2008062324A3 T . O

The WO2008062324A3 A DT O
present WO2008062324A3 A JJ O
invention WO2008062324A3 A NN O
is WO2008062324A3 A VBZ O
directed WO2008062324A3 A VBN O
to WO2008062324A3 A TO O
compositions WO2008062324A3 A NNS O
of WO2008062324A3 A IN O
nicotinamide WO2008062324A3 A JJ O
derivatives WO2008062324A3 A NNS O
combined WO2008062324A3 A VBN O
with WO2008062324A3 A IN O
wakame WO2008062324A3 A NN O
seaweed WO2008062324A3 A NN O
, WO2008062324A3 A , O
wakame WO2008062324A3 A NN O
extracts WO2008062324A3 A NNS O
, WO2008062324A3 A , O
or WO2008062324A3 A CC O
glycosaminoglycans WO2008062324A3 A NNS O
, WO2008062324A3 A , O
and WO2008062324A3 A CC O
their WO2008062324A3 A PRP$ O
use WO2008062324A3 A NN O
in WO2008062324A3 A IN O
treating WO2008062324A3 A VBG O
skin WO2008062324A3 A NN O
diseases WO2008062324A3 A NNS O
and WO2008062324A3 A CC O
disorders WO2008062324A3 A NNS O
. WO2008062324A3 A . O

20-Cyclopropyl US20080318911 T JJ O
, US20080318911 T , O
26,27-Alkyl/Haloalkyl US20080318911 T JJ O
Vitamin US20080318911 T NNP O
D3 US20080318911 T NNP O
Compounds US20080318911 T NNP O
and US20080318911 T CC O
Methods US20080318911 T NNP O
of US20080318911 T IN O
Use US20080318911 T NNP O
Thereof US20080318911 T NNP O
. US20080318911 T . O

Formulation US20090130178 T NN O
for US20090130178 T IN O
decreasing US20090130178 T VBG O
tobacco US20090130178 T NN O
, US20090130178 T , O
alcohol US20090130178 T NN O
, US20090130178 T , O
drug US20090130178 T NN O
or US20090130178 T CC O
food US20090130178 T NN O
consumption US20090130178 T NN O
. US20090130178 T . O

Pharmaceutical US20120208773 T JJ O
compositions US20120208773 T NNS O
with US20120208773 T IN O
tetrabenazine US20120208773 T NN O
. US20120208773 T . O

Novel CN103012429A T NNP O
amoxicillin CN103012429A T NN O
sodium CN103012429A T NN O
compound CN103012429A T NN O
and CN103012429A T CC O
composition CN103012429A T NN O
of CN103012429A T IN O
amoxicillin CN103012429A T JJ O
sodium CN103012429A T NN O
compound CN103012429A T NN O
and CN103012429A T CC O
sulbactam CN103012429A T JJ O
sodium CN103012429A T NN O
compound CN103012429A T NN O
. CN103012429A T . O

Method US20050107411 T NNP O
for US20050107411 T IN O
treating US20050107411 T VBG O
circadian US20050107411 T JJ O
rhythm US20050107411 T NN O
disruptions US20050107411 T NNS O
. US20050107411 T . O

A US20050107411 A DT O
neuropeptide US20050107411 A JJ I-UN
Y US20050107411 A NNP I-UN
Y5 US20050107411 A NNP I-UN
antagonist US20050107411 A NN O
is US20050107411 A VBZ O
useful US20050107411 A JJ O
, US20050107411 A , O
alone US20050107411 A RB O
or US20050107411 A CC O
in US20050107411 A IN O
conjunction US20050107411 A NN O
with US20050107411 A IN O
other US20050107411 A JJ O
agents US20050107411 A NNS O
, US20050107411 A , O
for US20050107411 A IN O
altering US20050107411 A VBG O
circadian US20050107411 A JJ O
rhythmicity US20050107411 A NN O
and US20050107411 A CC O
alleviating US20050107411 A VBG O
circadian US20050107411 A JJ O
rhythm US20050107411 A NN O
disorders US20050107411 A NNS O
and US20050107411 A CC O
for US20050107411 A IN O
enhancing US20050107411 A VBG O
and US20050107411 A CC O
improving US20050107411 A VBG O
the US20050107411 A DT O
quality US20050107411 A NN O
of US20050107411 A IN O
sleep US20050107411 A NN O
. US20050107411 A . O

Composition US20050272694 T NN O
containing US20050272694 T VBG O
beta-glucan US20050272694 T JJ O
and US20050272694 T CC O
constipation-relieving US20050272694 T JJ O
drug US20050272694 T NN O
, US20050272694 T , O
immunopotentiatior US20050272694 T JJ O
, US20050272694 T , O
and US20050272694 T CC O
skin US20050272694 T NN O
moistening US20050272694 T NN O
agent US20050272694 T NN O
using US20050272694 T VBG O
the US20050272694 T DT O
composition US20050272694 T NN O
. US20050272694 T . O

Salinomycin CN101926776A T NNP O
sodium CN101926776A T NN O
suspension CN101926776A T NN O
as CN101926776A T RB O
well CN101926776A T RB O
as CN101926776A T IN O
preparation CN101926776A T NN O
method CN101926776A T NN O
and CN101926776A T CC O
application CN101926776A T NN O
thereof CN101926776A T NN O
. CN101926776A T . O

Lipid US20100074959 T JJ O
growth US20100074959 T NN O
factor US20100074959 T NN O
formulations US20100074959 T NNS O
. US20100074959 T . O

The US20100074959 A DT O
present US20100074959 A JJ O
invention US20100074959 A NN O
is US20100074959 A VBZ O
directed US20100074959 A VBN O
to US20100074959 A TO O
novel US20100074959 A JJ O
formulations US20100074959 A NNS O
and US20100074959 A CC O
methods US20100074959 A NNS O
for US20100074959 A IN O
the US20100074959 A DT O
improved US20100074959 A JJ O
delivery US20100074959 A NN O
and US20100074959 A CC O
administration US20100074959 A NN O
of US20100074959 A IN O
hydrophobic US20100074959 A JJ O
therapeutic US20100074959 A JJ O
compounds US20100074959 A NNS O
that US20100074959 A WDT O
are US20100074959 A VBP O
substantially US20100074959 A RB O
insoluble US20100074959 A JJ O
and/or US20100074959 A NN O
susceptible US20100074959 A JJ O
to US20100074959 A TO O
precipitation US20100074959 A NN O
in US20100074959 A IN O
aqueous US20100074959 A JJ O
solution US20100074959 A NN O
at US20100074959 A IN O
physiological US20100074959 A JJ O
pH US20100074959 A NN O
, US20100074959 A , O
including US20100074959 A VBG O
, US20100074959 A , O
e.g. US20100074959 A NN O
, US20100074959 A , O
growth US20100074959 A NN I-UN
and US20100074959 A CC I-UN
differentiation US20100074959 A NN I-UN
factor-5 US20100074959 A NNS I-UN
and US20100074959 A CC O
related US20100074959 A JJ O
proteins US20100074959 A NNS O
. US20100074959 A . O

Contraceptive WO2006087173A1 T JJ O
pharmaceutical WO2006087173A1 T JJ O
preparation WO2006087173A1 T NN O
. WO2006087173A1 T . O

Composite CN101843630B T NNP O
containing CN101843630B T VBG O
iridoid CN101843630B T JJ O
compound CN101843630B T NN O
and CN101843630B T CC O
application CN101843630B T NN O
thereof CN101843630B T NN O
. CN101843630B T . O

Use US7550475 T NNP O
of US7550475 T IN O
phosphodiesterase US7550475 T NN O
4 US7550475 T CD O
inhibitors US7550475 T NNS O
such US7550475 T JJ O
as US7550475 T IN O
6,7-dimethoxy-1- US7550475 T JJ O
[ US7550475 T JJ O
2- US7550475 T JJ O
( US7550475 T ( O
1,3-dioxocyclohexan-2-yl US7550475 T JJ O
) US7550475 T ) O
pyridin-4-yl US7550475 T NN O
] US7550475 T NN O
-2,3-bis US7550475 T NNP O
( US7550475 T ( O
hydroxymethyl US7550475 T NN O
) US7550475 T ) O
naphthalene US7550475 T NN O
to US7550475 T TO O
treat US7550475 T VB O
asthma US7550475 T NN O
, US7550475 T , O
chronic US7550475 T JJ O
obstructive US7550475 T JJ O
pulmonary US7550475 T JJ O
disease US7550475 T NN O
, US7550475 T , O
atopic US7550475 T NN O
dermatitis US7550475 T NN O
, US7550475 T , O
allergic US7550475 T JJ O
rhinitis US7550475 T NN O
, US7550475 T , O
psoriasis US7550475 T NN O
, US7550475 T , O
rheumatoid US7550475 T JJ O
arthritis US7550475 T NN O
, US7550475 T , O
septic US7550475 T JJ O
shock US7550475 T NN O
, US7550475 T , O
ulcerative US7550475 T JJ O
colitis US7550475 T NN O
. US7550475 T . O

The US7550475 A DT O
present US7550475 A JJ O
invention US7550475 A NN O
provides US7550475 A VBZ O
a US7550475 A DT O
novel US7550475 A NN O
a US7550475 A DT O
condensed US7550475 A VBN O
polycyclic US7550475 A NN O
compound US7550475 A NN O
useful US7550475 A JJ O
as US7550475 A IN O
a US7550475 A DT O
phosphodiesterase US7550475 A NN I-UN
4 US7550475 A CD I-UN
inhibitor US7550475 A NN O
, US7550475 A , O
which US7550475 A WDT O
is US7550475 A VBZ O
shown US7550475 A VBN O
by US7550475 A IN O
the US7550475 A DT O
formula US7550475 A NN O
[ US7550475 A NN O
I US7550475 A PRP O
] US7550475 A VBP O
: US7550475 A : O
or US7550475 A CC O
a US7550475 A DT O
pharmaceutically US7550475 A RB O
acceptable US7550475 A JJ O
salt US7550475 A NN O
thereof US7550475 A NN O
and US7550475 A CC O
a US7550475 A DT O
pharmaceutical US7550475 A JJ O
composition US7550475 A NN O
containing US7550475 A VBG O
the US7550475 A DT O
same US7550475 A JJ O
. US7550475 A . O

Immunosuppression CA2742281A1 T NNP O
compound CA2742281A1 T NN O
and CA2742281A1 T CC O
treatment CA2742281A1 T NN O
method CA2742281A1 T NN O
. CA2742281A1 T . O

The CA2742281A1 A DT O
compound CA2742281A1 A NN O
is CA2742281A1 A VBZ O
an CA2742281A1 A DT O
antisense CA2742281A1 A JJ O
oligonucleotide CA2742281A1 A JJ O
ana-log CA2742281A1 A NN O
compound CA2742281A1 A NN O
having CA2742281A1 A VBG O
a CA2742281A1 A DT O
targeting CA2742281A1 A VBG O
sequence CA2742281A1 A NN O
complementary CA2742281A1 A NN O
to CA2742281A1 A TO O
a CA2742281A1 A DT O
preprocessed CA2742281A1 A VBN O
CTLA CA2742281A1 A NNP I-UN
4 CA2742281A1 A CD I-UN
mRNA CA2742281A1 A NN O
region CA2742281A1 A NN O
identified CA2742281A1 A VBN O
by CA2742281A1 A IN O
SEQ CA2742281A1 A NNP O
ID CA2742281A1 A NNP O
NO CA2742281A1 A NNP O
: CA2742281A1 A : O
22 CA2742281A1 A CD O
in CA2742281A1 A IN O
SEQ CA2742281A1 A NNP O
ID CA2742281A1 A NNP O
NO CA2742281A1 A NNP O
: CA2742281A1 A : O
1 CA2742281A1 A CD O
, CA2742281A1 A , O
spanning CA2742281A1 A VBG O
the CA2742281A1 A DT O
splice CA2742281A1 A NN O
junction CA2742281A1 A NN O
between CA2742281A1 A IN O
intron CA2742281A1 A NN O
1 CA2742281A1 A CD O
and CA2742281A1 A CC O
exon CA2742281A1 A $ O
2 CA2742281A1 A CD O
of CA2742281A1 A IN O
the CA2742281A1 A DT O
preprocessed CA2742281A1 A JJ O
mRNA CA2742281A1 A NN O
of CA2742281A1 A IN O
the CA2742281A1 A DT O
subject CA2742281A1 A NN O
. CA2742281A1 A . O

The CA2742281A1 A DT O
com-pound CA2742281A1 A NN O
is CA2742281A1 A VBZ O
effective CA2742281A1 A JJ O
, CA2742281A1 A , O
when CA2742281A1 A WRB O
administered CA2742281A1 A VBN O
to CA2742281A1 A TO O
a CA2742281A1 A DT O
subject CA2742281A1 A NN O
, CA2742281A1 A , O
to CA2742281A1 A TO O
form CA2742281A1 A VB O
within CA2742281A1 A IN O
host CA2742281A1 A NN O
cells CA2742281A1 A NNS O
, CA2742281A1 A , O
a CA2742281A1 A DT O
heteroduplex CA2742281A1 A JJ O
structure CA2742281A1 A NN O
( CA2742281A1 A ( O
i CA2742281A1 A NN O
) CA2742281A1 A ) O
composed CA2742281A1 A VBD O
of CA2742281A1 A IN O
the CA2742281A1 A DT O
prepro-cessed CA2742281A1 A JJ O
CTLA CA2742281A1 A NNP I-UN
4 CA2742281A1 A CD I-UN
mRNA CA2742281A1 A NN O
and CA2742281A1 A CC O
the CA2742281A1 A DT O
oligonucleotide CA2742281A1 A NN O
compound CA2742281A1 A NN O
, CA2742281A1 A , O
( CA2742281A1 A ( O
ii CA2742281A1 A NN O
) CA2742281A1 A ) O
characterized CA2742281A1 A VBN O
by CA2742281A1 A IN O
a CA2742281A1 A DT O
Tm CA2742281A1 A NNP O
of CA2742281A1 A IN O
dissociation CA2742281A1 A NN O
of CA2742281A1 A IN O
at CA2742281A1 A IN O
least CA2742281A1 A JJS O
45°C CA2742281A1 A CD O
, CA2742281A1 A , O
and CA2742281A1 A CC O
( CA2742281A1 A ( O
iii CA2742281A1 A NN O
) CA2742281A1 A ) O
re-sulting CA2742281A1 A NN O
in CA2742281A1 A IN O
an CA2742281A1 A DT O
increased CA2742281A1 A JJ O
ratio CA2742281A1 A NN O
of CA2742281A1 A IN O
processed CA2742281A1 A VBN O
mRNA CA2742281A1 A NN O
encoding CA2742281A1 A VBG O
ligand CA2742281A1 A NN O
independent CA2742281A1 A JJ O
CTLA CA2742281A1 A NNP I-UN
4 CA2742281A1 A CD O
to CA2742281A1 A TO O
processed CA2742281A1 A VBN O
mRNA CA2742281A1 A NN O
encoding CA2742281A1 A VBG O
full CA2742281A1 A JJ O
length CA2742281A1 A NN O
CTLA CA2742281A1 A NNP I-UN
4 CA2742281A1 A CD O
. CA2742281A1 A . O

Alpha-Hydroxy US20080318976 T JJ O
Amides US20080318976 T NNP O
as US20080318976 T IN O
Bradykinin US20080318976 T NNP I-UN
Antagonists US20080318976 T NNPS O
or US20080318976 T CC O
Inverse US20080318976 T NNP O
Agonists US20080318976 T NNPS O
. US20080318976 T . O

α-Hydroxy US20080318976 A JJ O
amide US20080318976 A JJ O
derivatives US20080318976 A NNS O
of US20080318976 A IN O
the US20080318976 A DT O
general US20080318976 A JJ O
formula US20080318976 A NN O
( US20080318976 A ( O
I US20080318976 A PRP O
) US20080318976 A ) O
are US20080318976 A VBP O
bradykinin US20080318976 A JJ I-UN
B1 US20080318976 A NNP I-UN
antagonists US20080318976 A NNS O
or US20080318976 A CC O
inverse US20080318976 A JJ O
agonists US20080318976 A NNS O
useful US20080318976 A JJ O
in US20080318976 A IN O
the US20080318976 A DT O
treatment US20080318976 A NN O
or US20080318976 A CC O
prevention US20080318976 A NN O
of US20080318976 A IN O
symptoms US20080318976 A NNS O
such US20080318976 A JJ O
as US20080318976 A IN O
pain US20080318976 A NN O
and US20080318976 A CC O
inflammation US20080318976 A NN O
associated US20080318976 A VBN O
with US20080318976 A IN O
the US20080318976 A DT O
bradykinin US20080318976 A NN I-UN
B1 US20080318976 A NNP I-UN
pathway US20080318976 A NN O
. US20080318976 A . O

Series CN101002768A T NNP O
preparation CN101002768A T NN O
of CN101002768A T IN O
swainsonine CN101002768A T NN O
, CN101002768A T , O
preparing CN101002768A T VBG O
method CN101002768A T NN O
and CN101002768A T CC O
use CN101002768A T NN O
thereof CN101002768A T NN O
. CN101002768A T . O

Trisubstituted WO2009115547A8 T VBN O
1 WO2009115547A8 T CD O
, WO2009115547A8 T , O
2 WO2009115547A8 T CD O
, WO2009115547A8 T , O
4 WO2009115547A8 T CD O
-triazoles WO2009115547A8 T NNS O
as WO2009115547A8 T IN O
nicotinic WO2009115547A8 T JJ O
acetylcholine WO2009115547A8 T NN O
receptor WO2009115547A8 T NN O
modulators WO2009115547A8 T NNS O
. WO2009115547A8 T . O

The WO2009115547A8 A DT O
present WO2009115547A8 A JJ O
invention WO2009115547A8 A NN O
relates WO2009115547A8 A VBZ O
to WO2009115547A8 A TO O
l-aryl-3-aniline-5-alkyl-l WO2009115547A8 A JJ O
, WO2009115547A8 A , O
2,4-triazole WO2009115547A8 A JJ O
derivatives WO2009115547A8 A NNS O
and WO2009115547A8 A CC O
analogues WO2009115547A8 A NNS O
or WO2009115547A8 A CC O
pharmaceutically WO2009115547A8 A RB O
acceptable WO2009115547A8 A JJ O
salts WO2009115547A8 A NNS O
thereof WO2009115547A8 A NN O
, WO2009115547A8 A , O
processes WO2009115547A8 A VBZ O
for WO2009115547A8 A IN O
preparing WO2009115547A8 A VBG O
them WO2009115547A8 A PRP O
, WO2009115547A8 A , O
pharmaceutical WO2009115547A8 A JJ O
compositions WO2009115547A8 A NNS O
containing WO2009115547A8 A VBG O
them WO2009115547A8 A PRP O
and WO2009115547A8 A CC O
their WO2009115547A8 A PRP$ O
use WO2009115547A8 A NN O
in WO2009115547A8 A IN O
therapy WO2009115547A8 A NN O
, WO2009115547A8 A , O
according WO2009115547A8 A VBG O
to WO2009115547A8 A TO O
Formula WO2009115547A8 A NNP O
( WO2009115547A8 A ( O
I WO2009115547A8 A PRP O
) WO2009115547A8 A ) O
. WO2009115547A8 A . O

The WO2009115547A8 A DT O
invention WO2009115547A8 A NN O
particularly WO2009115547A8 A RB O
relates WO2009115547A8 A VBZ O
to WO2009115547A8 A TO O
potent WO2009115547A8 A VB O
positive WO2009115547A8 A JJ O
allosteric WO2009115547A8 A JJ O
modulators WO2009115547A8 A NNS O
of WO2009115547A8 A IN O
nicotinic WO2009115547A8 A JJ O
acetylcholine WO2009115547A8 A NN O
receptors WO2009115547A8 A NNS O
, WO2009115547A8 A , O
such WO2009115547A8 A JJ O
positive WO2009115547A8 A JJ O
allosteric WO2009115547A8 A NN O
modulator WO2009115547A8 A NN O
having WO2009115547A8 A VBG O
the WO2009115547A8 A DT O
capability WO2009115547A8 A NN O
to WO2009115547A8 A TO O
increase WO2009115547A8 A VB O
the WO2009115547A8 A DT O
efficacy WO2009115547A8 A NN O
of WO2009115547A8 A IN O
nicotinic WO2009115547A8 A JJ O
receptor WO2009115547A8 A NN O
agonists WO2009115547A8 A NNS O
. WO2009115547A8 A . O

Novel US20100254904 T NNP O
therapeutic US20100254904 T JJ O
delivery US20100254904 T NN O
systems US20100254904 T NNS O
. US20100254904 T . O

Biotin WO2014036427A1 T NNP O
complexes WO2014036427A1 T NNS O
for WO2014036427A1 T IN O
treatment WO2014036427A1 T NN O
and WO2014036427A1 T CC O
diagnosis WO2014036427A1 T NN O
of WO2014036427A1 T IN O
alzheimer WO2014036427A1 T NN O
's WO2014036427A1 T POS O
disease WO2014036427A1 T NN O
. WO2014036427A1 T . O

Described WO2014036427A1 A VBN O
herein WO2014036427A1 A NNS O
are WO2014036427A1 A VBP O
compositions WO2014036427A1 A NNS O
and WO2014036427A1 A CC O
methods WO2014036427A1 A NNS O
for WO2014036427A1 A IN O
treating WO2014036427A1 A VBG O
or WO2014036427A1 A CC O
imaging WO2014036427A1 A VBG O
Alzheimer WO2014036427A1 A NNP O
's WO2014036427A1 A POS O
disease WO2014036427A1 A NN O
( WO2014036427A1 A ( O
AD WO2014036427A1 A NNP O
) WO2014036427A1 A ) O
. WO2014036427A1 A . O

The WO2014036427A1 A DT O
compositions WO2014036427A1 A NNS O
comprise WO2014036427A1 A VBP O
a WO2014036427A1 A DT O
biotin WO2014036427A1 A NN O
moiety WO2014036427A1 A NN O
and WO2014036427A1 A CC O
a WO2014036427A1 A DT O
siRNA WO2014036427A1 A JJ O
moiety WO2014036427A1 A NN O
, WO2014036427A1 A , O
without WO2014036427A1 A IN O
the WO2014036427A1 A DT O
need WO2014036427A1 A NN O
for WO2014036427A1 A IN O
a WO2014036427A1 A DT O
targeting WO2014036427A1 A VBG O
agent WO2014036427A1 A NN O
such WO2014036427A1 A JJ O
as WO2014036427A1 A IN O
an WO2014036427A1 A DT O
antibody WO2014036427A1 A NN O
, WO2014036427A1 A , O
avidin WO2014036427A1 A NN O
, WO2014036427A1 A , O
or WO2014036427A1 A CC O
streptavidin WO2014036427A1 A NN O
. WO2014036427A1 A . O

In WO2014036427A1 A IN O
certain WO2014036427A1 A JJ O
embodiments WO2014036427A1 A NNS O
, WO2014036427A1 A , O
the WO2014036427A1 A DT O
compositions WO2014036427A1 A NNS O
further WO2014036427A1 A RBR O
comprise WO2014036427A1 A VB O
a WO2014036427A1 A DT O
diagnostic WO2014036427A1 A JJ O
agent WO2014036427A1 A NN O
. WO2014036427A1 A . O

Pharmaceutical US20100209519 T JJ O
composition US20100209519 T NN O
for US20100209519 T IN O
inhalation US20100209519 T NN O
delivery US20100209519 T NN O
and US20100209519 T CC O
fabrication US20100209519 T NN O
method US20100209519 T NN O
thereof US20100209519 T NN O
. US20100209519 T . O

GnRH US20060069031 T NNP I-UN
, US20060069031 T , O
for US20060069031 T IN O
preparation US20060069031 T NN O
to US20060069031 T TO O
support US20060069031 T VB O
luteal US20060069031 T JJ O
phase US20060069031 T NN O
during US20060069031 T IN O
infertility US20060069031 T NN O
treatment US20060069031 T NN O
of US20060069031 T IN O
female US20060069031 T JJ O
mammals US20060069031 T NNS O
; US20060069031 T : O
pharmaceutical US20060069031 T JJ O
agent US20060069031 T NN O
supports US20060069031 T NNS O
luteal US20060069031 T NN O
phase US20060069031 T NN O
after US20060069031 T IN O
spontaneous US20060069031 T JJ O
ovulation US20060069031 T NN O
or US20060069031 T CC O
after US20060069031 T IN O
stimulation US20060069031 T NN O
of US20060069031 T IN O
follicular US20060069031 T JJ O
growth US20060069031 T NN O
triggering US20060069031 T VBG O
final US20060069031 T JJ O
follicular US20060069031 T NN O
maturation US20060069031 T NN O
and US20060069031 T CC O
ovulation US20060069031 T NN O
. US20060069031 T . O

Carboxylic US7994156 T JJ O
acid US7994156 T VBZ O
4-phenylazo-phenyl US7994156 T JJ O
ester US7994156 T NN O
derivatives US7994156 T NNS O
and US7994156 T CC O
their US7994156 T PRP$ O
use US7994156 T NN O
as US7994156 T IN O
monoamine US7994156 T JJ O
neurotransmitter US7994156 T IN O
re-uptake US7994156 T JJ O
inhibitors US7994156 T NNS O
. US7994156 T . O

Externally-applied CN101647865B T JJ O
medicine CN101647865B T NN O
for CN101647865B T IN O
treating CN101647865B T VBG O
traumatic CN101647865B T JJ O
injuries CN101647865B T NNS O
. CN101647865B T . O

Bitter WO2011159781A2 T NNP O
taste WO2011159781A2 T NN O
modulators WO2011159781A2 T NNS O
. WO2011159781A2 T . O

The WO2011159781A2 A DT O
present WO2011159781A2 A JJ O
invention WO2011159781A2 A NN O
includes WO2011159781A2 A VBZ O
antagonists WO2011159781A2 A NNS O
of WO2011159781A2 A IN O
human WO2011159781A2 A JJ I-UN
type WO2011159781A2 A NN I-UN
2 WO2011159781A2 A CD I-UN
taste WO2011159781A2 A NN I-UN
receptors WO2011159781A2 A NNS I-UN
( WO2011159781A2 A ( O
hT2Rs WO2011159781A2 A NN I-UN
) WO2011159781A2 A ) O
having WO2011159781A2 A VBG O
structural WO2011159781A2 A JJ O
Formula WO2011159781A2 A NNP O
( WO2011159781A2 A ( O
I WO2011159781A2 A PRP O
) WO2011159781A2 A ) O
. WO2011159781A2 A . O

Dinuceloside WO2013175231A1 T NNP O
polyphosphates WO2013175231A1 T VBZ O
for WO2013175231A1 T IN O
the WO2013175231A1 T DT O
treatment WO2013175231A1 T NN O
of WO2013175231A1 T IN O
pain WO2013175231A1 T NN O
. WO2013175231A1 T . O

The WO2013175231A1 A DT O
invention WO2013175231A1 A NN O
provides WO2013175231A1 A VBZ O
a WO2013175231A1 A DT O
dinucleoside WO2013175231A1 A JJ O
polyphosphate WO2013175231A1 A NN O
analogue WO2013175231A1 A NN O
, WO2013175231A1 A , O
or WO2013175231A1 A CC O
a WO2013175231A1 A DT O
pharmaceutically WO2013175231A1 A RB O
acceptable WO2013175231A1 A JJ O
salt WO2013175231A1 A NN O
thereof WO2013175231A1 A NN O
, WO2013175231A1 A , O
for WO2013175231A1 A IN O
use WO2013175231A1 A NN O
in WO2013175231A1 A IN O
the WO2013175231A1 A DT O
inhibition WO2013175231A1 A NN O
( WO2013175231A1 A ( O
or WO2013175231A1 A CC O
down-regulation WO2013175231A1 A NN O
) WO2013175231A1 A ) O
of WO2013175231A1 A IN O
a WO2013175231A1 A DT O
pain WO2013175231A1 A NN O
, WO2013175231A1 A , O
via WO2013175231A1 A IN O
a WO2013175231A1 A DT O
transducing WO2013175231A1 A VBG O
ATP WO2013175231A1 A NNP O
-gated WO2013175231A1 A VBD O
P2X3 WO2013175231A1 A NNP I-UN
receptor WO2013175231A1 A NN O
, WO2013175231A1 A , O
often WO2013175231A1 A RB O
by WO2013175231A1 A IN O
means WO2013175231A1 A NNS O
of WO2013175231A1 A IN O
high-affinity WO2013175231A1 A NN O
desensitisation WO2013175231A1 A NN O
( WO2013175231A1 A ( O
HAD WO2013175231A1 A NNP O
) WO2013175231A1 A ) O
mechanism WO2013175231A1 A NN O
. WO2013175231A1 A . O

Derivatives WO2012051988A3 T NNS O
of WO2012051988A3 T IN O
steroid WO2012051988A3 T JJ O
benzylamines WO2012051988A3 T NNS O
, WO2012051988A3 T , O
having WO2012051988A3 T VBG O
an WO2012051988A3 T DT O
antiparasitic WO2012051988A3 T JJ O
, WO2012051988A3 T , O
antibacterial WO2012051988A3 T JJ O
, WO2012051988A3 T , O
antimycotic WO2012051988A3 T JJ O
and/or WO2012051988A3 T NN O
antiviral WO2012051988A3 T JJ O
action WO2012051988A3 T NN O
. WO2012051988A3 T . O

Compositions EP1666037A2 T NNS O
for EP1666037A2 T IN O
stimulating EP1666037A2 T VBG O
neurite EP1666037A2 T JJ O
growth EP1666037A2 T NN O
. EP1666037A2 T . O

The EP1666037A2 A DT O
compositions EP1666037A2 A NNS O
comprise EP1666037A2 A VBP O
a EP1666037A2 A DT O
neurotrophic EP1666037A2 A JJ O
amount EP1666037A2 A NN O
of EP1666037A2 A IN O
a EP1666037A2 A DT O
compound EP1666037A2 A NN O
which EP1666037A2 A WDT O
binds EP1666037A2 A VBZ O
to EP1666037A2 A TO O
the EP1666037A2 A DT O
FK-506 EP1666037A2 A NNP I-UN
binding EP1666037A2 A NN I-UN
protein EP1666037A2 A NN I-UN
( EP1666037A2 A ( O
FKBP EP1666037A2 A NNP I-UN
) EP1666037A2 A ) O
and EP1666037A2 A CC O
a EP1666037A2 A DT O
neurotrophic EP1666037A2 A JJ I-UN
factor EP1666037A2 A NN I-UN
, EP1666037A2 A , O
such EP1666037A2 A JJ O
as EP1666037A2 A IN O
nerve EP1666037A2 A NN O
growth EP1666037A2 A NN I-UN
factor EP1666037A2 A NN I-UN
NGF EP1666037A2 A NNP I-UN
. EP1666037A2 A . O

The EP1666037A2 A DT O
methods EP1666037A2 A NNS O
comprise EP1666037A2 A VBP O
treating EP1666037A2 A VBG O
nerve EP1666037A2 A NN O
cells EP1666037A2 A NNS O
with EP1666037A2 A IN O
the EP1666037A2 A DT O
above-described EP1666037A2 A JJ O
compositions EP1666037A2 A NNS O
or EP1666037A2 A CC O
compositions EP1666037A2 A NNS O
comprising EP1666037A2 A VBG O
the EP1666037A2 A DT O
FKBP EP1666037A2 A NNP I-UN
binding EP1666037A2 A NN O
compound EP1666037A2 A NN O
without EP1666037A2 A IN O
a EP1666037A2 A DT O
neurotrophic EP1666037A2 A JJ O
factor EP1666037A2 A NN O
. EP1666037A2 A . O

N- US7642276 T JJ O
[ US7642276 T JJ O
4-methyl-3- US7642276 T JJ O
( US7642276 T ( O
3-piperidin-4-yl-1,2-benzisoxazol-6-yl US7642276 T JJ O
) US7642276 T ) O
phenyl US7642276 T NN O
] US7642276 T NNP O
-2-pyrrolidin-1-ylisonicotinamide US7642276 T NNP O
; US7642276 T : O
rheumatoid US7642276 T JJ O
arthritis US7642276 T NN O
. US7642276 T . O

Nucleic US7683164 T NNP O
acid US7683164 T NN O
derivatives US7683164 T NNS O
. US7683164 T . O

Pillow CN201564118U T NNP O
for CN201564118U T IN O
placing CN201564118U T VBG O
auxiliary CN201564118U T JJ O
substance CN201564118U T NN O
. CN201564118U T . O

Fused EP1771447A1 T VBN O
pyrimidine EP1771447A1 T NN O
derivatives EP1771447A1 T NNS O
and EP1771447A1 T CC O
compositions EP1771447A1 T NNS O
thereof EP1771447A1 T VBP O
as EP1771447A1 T IN O
cxcr3 EP1771447A1 T NN I-UN
receptor EP1771447A1 T NN I-UN
modulators EP1771447A1 T NNS O
, EP1771447A1 T , O
useful EP1771447A1 T JJ O
in EP1771447A1 T IN O
prevention EP1771447A1 T NN O
and EP1771447A1 T CC O
treatment EP1771447A1 T NN O
of EP1771447A1 T IN O
inflammatory EP1771447A1 T NN O
and EP1771447A1 T CC O
immunoregulatory EP1771447A1 T NN O
disorders EP1771447A1 T NNS O
and EP1771447A1 T CC O
diseases EP1771447A1 T NNS O
. EP1771447A1 T . O

Medicinal CN1839867A T JJ O
composition CN1839867A T NN O
with CN1839867A T IN O
heat-clearing CN1839867A T JJ O
, CN1839867A T , O
fire-draining CN1839867A T JJ O
and CN1839867A T CC O
detoxification CN1839867A T NN O
function CN1839867A T NN O
. CN1839867A T . O

Pharmaceutical CN101554377A T JJ O
composition CN101554377A T NN O
containing CN101554377A T VBG O
prasugrel CN101554377A T NN O
and CN101554377A T CC O
carbazochrome CN101554377A T JJ O
sodium CN101554377A T NN O
sulfonate CN101554377A T NN O
. CN101554377A T . O

Anti-insomnia CN103550775A T NNP O
composition CN103550775A T NN O
, CN103550775A T , O
application CN103550775A T NN O
of CN103550775A T IN O
composition CN103550775A T NN O
, CN103550775A T , O
multi-phase CN103550775A T JJ O
pulse CN103550775A T JJ O
immediate-release CN103550775A T JJ O
preparation CN103550775A T NN O
prepared CN103550775A T VBN O
by CN103550775A T IN O
use CN103550775A T NN O
of CN103550775A T IN O
composition CN103550775A T NN O
and CN103550775A T CC O
preparation CN103550775A T NN O
method CN103550775A T NN O
of CN103550775A T IN O
preparation CN103550775A T NN O
. CN103550775A T . O

The CN103550775A A DT O
anti-insomnia CN103550775A A JJ O
composition CN103550775A A NN O
consists CN103550775A A VBZ O
of CN103550775A A IN O
a CN103550775A A DT O
component CN103550775A A NN O
A CN103550775A A NNP O
and CN103550775A A CC O
a CN103550775A A DT O
component CN103550775A A NN O
B CN103550775A A NNP O
, CN103550775A A , O
wherein CN103550775A A VBD O
the CN103550775A A DT O
component CN103550775A A NN O
A CN103550775A A NNP O
is CN103550775A A VBZ O
one CN103550775A A CD O
or CN103550775A A CC O
more CN103550775A A JJR O
of CN103550775A A IN O
melatonin CN103550775A A NN O
, CN103550775A A , O
melatonin CN103550775A A NN O
analogue CN103550775A A NN O
and CN103550775A A CC O
corresponding CN103550775A A NN O
salt CN103550775A A NN O
, CN103550775A A , O
melatonin CN103550775A A NN I-UN
receptor CN103550775A A NN I-UN
stimulant CN103550775A A NN O
, CN103550775A A , O
5-hydroxytryptamine CN103550775A A JJ O
2C CN103550775A A CD O
, CN103550775A A , O
receptor CN103550775A A NN O
antagonist CN103550775A A NN O
and CN103550775A A CC O
5-HTP CN103550775A A JJ O
( CN103550775A A ( O
5-hydroxytryptophan CN103550775A A JJ O
) CN103550775A A ) O
; CN103550775A A : O
the CN103550775A A DT O
component CN103550775A A NN O
B CN103550775A A NNP O
is CN103550775A A VBZ O
one CN103550775A A CD O
or CN103550775A A CC O
more CN103550775A A JJR O
of CN103550775A A IN O
petroselinum CN103550775A A NN O
neapolitanum CN103550775A A NN O
extract CN103550775A A NN O
, CN103550775A A , O
melissa CN103550775A A FW O
extract CN103550775A A NN O
, CN103550775A A , O
tuber CN103550775A A VB O
fleeceflower CN103550775A A JJR O
stem CN103550775A A NN O
extract CN103550775A A NN O
, CN103550775A A , O
chamomile CN103550775A A JJ O
extract CN103550775A A NN O
, CN103550775A A , O
passion CN103550775A A NN O
flower CN103550775A A NN O
extract CN103550775A A NN O
, CN103550775A A , O
radix CN103550775A A VB O
paeoniae CN103550775A A NN O
alba CN103550775A A NN O
extract CN103550775A A NN O
, CN103550775A A , O
manyprickle CN103550775A A FW O
acanthopanax CN103550775A A JJ O
extract CN103550775A A NN O
, CN103550775A A , O
polygala CN103550775A A NN O
tenuifolia CN103550775A A NNS O
extract CN103550775A A NN O
, CN103550775A A , O
hyperforin CN103550775A A NN O
perforatum CN103550775A A NN O
extract CN103550775A A NN O
, CN103550775A A , O
flos CN103550775A A JJ O
albiziae CN103550775A A NN O
extract CN103550775A A NN O
, CN103550775A A , O
lily CN103550775A A RB O
extract CN103550775A A JJ O
and CN103550775A A CC O
prunella CN103550775A A JJ O
vulgaris CN103550775A A NN O
extract CN103550775A A NN O
. CN103550775A A . O

Fluorinated US6867284 T NNP O
oligopeptides US6867284 T NNS O
especially US6867284 T RB O
those US6867284 T DT O
having US6867284 T VBG O
4,4-difluoro- US6867284 T JJ O
2-amino US6867284 T JJ O
butyric US6867284 T JJ O
acid US6867284 T NN O
at US6867284 T IN O
the US6867284 T DT O
C US6867284 T NNP O
terminus US6867284 T NN O
. US6867284 T . O

Fluorinated US6867284 A NNP O
oligopeptides US6867284 A NNS O
, US6867284 A , O
especially US6867284 A RB O
those US6867284 A DT O
having US6867284 A VBG O
4,4-difluoro-2-amino US6867284 A JJ O
butyric US6867284 A JJ O
acid US6867284 A NN O
at US6867284 A IN O
the US6867284 A DT O
C US6867284 A NNP O
terminus US6867284 A NN O
, US6867284 A , O
may US6867284 A MD O
be US6867284 A VB O
effective US6867284 A JJ O
inhibitors US6867284 A NNS O
of US6867284 A IN O
hepatitis US6867284 A NN I-UN
C US6867284 A NNP I-UN
virus US6867284 A NN I-UN
NS3 US6867284 A NNP I-UN
protease US6867284 A NN I-UN
. US6867284 A . O

Embodiments US6867284 A NNS O
of US6867284 A IN O
tripeptides US6867284 A NNS O
of US6867284 A IN O
the US6867284 A DT O
invention US6867284 A NN O
, US6867284 A , O
having US6867284 A VBG O
a US6867284 A DT O
keto-acid US6867284 A JJ O
group US6867284 A NN O
at US6867284 A IN O
the US6867284 A DT O
C-terminus US6867284 A NNP O
are US6867284 A VBP O
, US6867284 A , O
likewise US6867284 A RB O
, US6867284 A , O
potent US6867284 A JJ O
inhibitors US6867284 A NNS O
of US6867284 A IN O
NS3 US6867284 A NNP I-UN
protease US6867284 A NN I-UN
. US6867284 A . O

Indocyanine EP1561425A1 T JJ O
dyes EP1561425A1 T NNS O
. EP1561425A1 T . O

A CN1876077A T DT O
medicament CN1876077A T NN O
for CN1876077A T IN O
treating CN1876077A T VBG O
superficial CN1876077A T JJ O
lymphoid CN1876077A T JJ O
tuberculosis CN1876077A T NN O
. CN1876077A T . O

Extractive CN1903312A T CD O
of CN1903312A T IN O
bulb CN1903312A T NN O
of CN1903312A T IN O
Anhui CN1903312A T NNP O
fritillary CN1903312A T JJ O
, CN1903312A T , O
prepn CN1903312A T NN O
. CN1903312A T . O

method CN1903312A T NN O
and CN1903312A T CC O
use CN1903312A T NN O
thereof CN1903312A T NN O
. CN1903312A T . O

Method US20070203141 T NNP O
for US20070203141 T IN O
administering US20070203141 T VBG O
birb US20070203141 T NN O
796 US20070203141 T CD O
bs US20070203141 T NN O
. US20070203141 T . O

Disclosed US20070203141 A VBN O
are US20070203141 A VBP O
methods US20070203141 A NNS O
of US20070203141 A IN O
administering US20070203141 A VBG O
BIRB US20070203141 A NNP O
796 US20070203141 A CD O
BS US20070203141 A NNP O
, US20070203141 A , O
a US20070203141 A DT O
p38 US20070203141 A NN O
MAPK US20070203141 A NNP O
inhibitor US20070203141 A NN O
, US20070203141 A , O
at US20070203141 A IN O
particular US20070203141 A JJ O
dosages US20070203141 A NNS O
. US20070203141 A . O

Especially US7071195 T RB O
amino- US7071195 T JJ O
or US7071195 T CC O
amido-ethyltetralin US7071195 T JJ O
derivatives US7071195 T NNS O
. US7071195 T . O

Amine US7071195 A NNP O
and US7071195 A CC O
amide US7071195 A JJ O
derivatives US7071195 A NNS O
of US7071195 A IN O
the US7071195 A DT O
formula US7071195 A NN O
: US7071195 A : O
which US7071195 A WDT O
are US7071195 A VBP O
ligands US7071195 A VBZ O
for US7071195 A IN O
the US7071195 A DT O
neuropeptide US7071195 A JJ I-UN
Y US7071195 A NNP I-UN
Y5 US7071195 A NNP I-UN
( US7071195 A ( I-UN
NPY5 US7071195 A NNP I-UN
) US7071195 A ) I-UN
receptor US7071195 A NN I-UN
, US7071195 A , O
methods US7071195 A NNS O
of US7071195 A IN O
preparation US7071195 A NN O
and US7071195 A CC O
pharmaceutical US7071195 A JJ O
compositions US7071195 A NNS O
containing US7071195 A VBG O
amines US7071195 A NNS O
and US7071195 A CC O
amides US7071195 A NNS O
of US7071195 A IN O
formula US7071195 A NN O
A US7071195 A NNP O
as US7071195 A IN O
the US7071195 A DT O
active US7071195 A JJ O
ingredient US7071195 A NN O
are US7071195 A VBP O
described US7071195 A VBN O
. US7071195 A . O

The US7071195 A DT O
amines US7071195 A NNS O
and US7071195 A CC O
amides US7071195 A NNS O
of US7071195 A IN O
formula US7071195 A NN O
A US7071195 A NNP O
are US7071195 A VBP O
useful US7071195 A JJ O
in US7071195 A IN O
the US7071195 A DT O
treatment US7071195 A NN O
of US7071195 A IN O
disorders US7071195 A NNS O
and US7071195 A CC O
diseases US7071195 A NNS O
associated US7071195 A VBN O
with US7071195 A IN O
NPY US7071195 A NNP I-UN
receptor US7071195 A NN I-UN
subtype US7071195 A NN I-UN
Y5 US7071195 A NNP I-UN
. US7071195 A . O

Dihydroindazole WO2008118790A1 T NNP O
compounds WO2008118790A1 T VBZ O
useful WO2008118790A1 T JJ O
in WO2008118790A1 T IN O
treating WO2008118790A1 T VBG O
iron WO2008118790A1 T NN O
disorders WO2008118790A1 T NNS O
. WO2008118790A1 T . O

Carboxamide WO2006105222A3 T NNP O
inhibitors WO2006105222A3 T NNS O
of WO2006105222A3 T IN O
tgfb WO2006105222A3 T NN I-UN
. WO2006105222A3 T . O

Pyrimidine WO2006105222A3 A NNP O
having WO2006105222A3 A VBG O
a WO2006105222A3 A DT O
pyridylamine WO2006105222A3 A NN O
group WO2006105222A3 A NN O
at WO2006105222A3 A IN O
C- WO2006105222A3 A NNP O
4 WO2006105222A3 A CD O
of WO2006105222A3 A IN O
the WO2006105222A3 A DT O
pyrimidine WO2006105222A3 A NN O
and WO2006105222A3 A CC O
an WO2006105222A3 A DT O
amide WO2006105222A3 A JJ O
group WO2006105222A3 A NN O
on WO2006105222A3 A IN O
the WO2006105222A3 A DT O
pyridine WO2006105222A3 A NN O
ring WO2006105222A3 A NN O
( WO2006105222A3 A ( O
compounds WO2006105222A3 A NNS O
of WO2006105222A3 A IN O
formula WO2006105222A3 A NN O
I WO2006105222A3 A PRP O
) WO2006105222A3 A ) O
are WO2006105222A3 A VBP O
useful WO2006105222A3 A JJ O
in WO2006105222A3 A IN O
the WO2006105222A3 A DT O
treatment WO2006105222A3 A NN O
of WO2006105222A3 A IN O
conditions WO2006105222A3 A NNS O
associated WO2006105222A3 A VBN O
with WO2006105222A3 A IN O
excessive WO2006105222A3 A JJ O
TGFB WO2006105222A3 A NNP I-UN
activity WO2006105222A3 A NN O
. WO2006105222A3 A . O

Darifenacin EP1966179A2 T NNP O
hydrobromide EP1966179A2 T NN O
composition EP1966179A2 T NN O
substantially EP1966179A2 T RB O
free EP1966179A2 T JJ O
of EP1966179A2 T IN O
oxidized EP1966179A2 T JJ O
darifenacin EP1966179A2 T NN O
and EP1966179A2 T CC O
salts EP1966179A2 T NNS O
thereof EP1966179A2 T NNS O
and EP1966179A2 T CC O
processes EP1966179A2 T NNS O
for EP1966179A2 T IN O
the EP1966179A2 T DT O
preparation EP1966179A2 T NN O
thereof EP1966179A2 T NN O
. EP1966179A2 T . O

Provided EP1966179A2 A VBN O
are EP1966179A2 A VBP O
darifenacin EP1966179A2 A JJ O
hydrobromide EP1966179A2 A JJ O
free EP1966179A2 A JJ O
of EP1966179A2 A IN O
oxidized EP1966179A2 A JJ O
darifenacin EP1966179A2 A NN O
, EP1966179A2 A , O
and EP1966179A2 A CC O
processes EP1966179A2 A VBZ O
for EP1966179A2 A IN O
the EP1966179A2 A DT O
preparation EP1966179A2 A NN O
thereof EP1966179A2 A NN O
. EP1966179A2 A . O

Intelligent CN102525722A T JJ O
compound CN102525722A T NN O
gestodene CN102525722A T VBD O
vaginal CN102525722A T JJ O
ring CN102525722A T NN O
preparation CN102525722A T NN O
with CN102525722A T IN O
memory CN102525722A T NN O
effect CN102525722A T NN O
and CN102525722A T CC O
application CN102525722A T NN O
of CN102525722A T IN O
intelligent CN102525722A T JJ O
compound CN102525722A T NN O
gestodene CN102525722A T VBD O
vaginal CN102525722A T JJ O
ring CN102525722A T NN O
preparation CN102525722A T NN O
. CN102525722A T . O

Method CN101555210A T NNP O
for CN101555210A T IN O
preparing CN101555210A T VBG O
pregabalin CN101555210A T NN O
. CN101555210A T . O

A CN101555210A A DT O
method CN101555210A A NN O
for CN101555210A A IN O
preparing CN101555210A A VBG O
pregabalin CN101555210A A JJ O
belongs CN101555210A A NNS O
to CN101555210A A TO O
the CN101555210A A DT O
field CN101555210A A NN O
of CN101555210A A IN O
pharmaceutical CN101555210A A JJ O
synthesis CN101555210A A NN O
, CN101555210A A , O
aiming CN101555210A A VBG O
at CN101555210A A IN O
overcoming CN101555210A A VBG O
defects CN101555210A A NNS O
of CN101555210A A IN O
high CN101555210A A JJ O
cost CN101555210A A NN O
, CN101555210A A , O
environment CN101555210A A NN O
pollution CN101555210A A NN O
, CN101555210A A , O
complicate CN101555210A A JJ O
steps CN101555210A A NNS O
and CN101555210A A CC O
the CN101555210A A DT O
like CN101555210A A JJ O
in CN101555210A A IN O
the CN101555210A A DT O
prior CN101555210A A JJ O
art CN101555210A A NN O
for CN101555210A A IN O
synthesizing CN101555210A A VBG O
the CN101555210A A DT O
pregabalin CN101555210A A NN O
. CN101555210A A . O

The CN101555210A A DT O
method CN101555210A A NN O
comprises CN101555210A A VBZ O
the CN101555210A A DT O
steps CN101555210A A NNS O
of CN101555210A A IN O
: CN101555210A A : O
adopting CN101555210A A VBG O
heterogeneous CN101555210A A JJ O
hydrogenation CN101555210A A NN O
catalyst CN101555210A A NN O
for CN101555210A A IN O
carrying CN101555210A A VBG O
out CN101555210A A RP O
catalytic CN101555210A A JJ O
hydrogenation CN101555210A A NN O
on CN101555210A A IN O
3-cyano-group-5-methyl-hexy-3-ethyl CN101555210A A JJ O
gadoleic CN101555210A A NN O
acid CN101555210A A NN O
so CN101555210A A RB O
as CN101555210A A IN O
to CN101555210A A TO O
prepare CN101555210A A VB O
3-amino CN101555210A A JJ O
methyl-5-methylacetic CN101555210A A JJ O
acid CN101555210A A NN O
; CN101555210A A : O
and CN101555210A A CC O
splitting CN101555210A A NN O
( CN101555210A A ( O
S CN101555210A A NNP O
) CN101555210A A ) O
-mandel CN101555210A A NN O
to CN101555210A A TO O
obtain CN101555210A A VB O
( CN101555210A A ( O
S CN101555210A A NNP O
) CN101555210A A ) O
-pregabalin CN101555210A A NN O
. CN101555210A A . O

The CN101555210A A DT O
method CN101555210A A NN O
has CN101555210A A VBZ O
the CN101555210A A DT O
advantages CN101555210A A NNS O
of CN101555210A A IN O
low CN101555210A A JJ O
cost CN101555210A A NN O
, CN101555210A A , O
environment-friendly CN101555210A A RB O
process CN101555210A A NN O
, CN101555210A A , O
easy CN101555210A A JJ O
operation CN101555210A A NN O
, CN101555210A A , O
non-byproduct CN101555210A A NN O
and CN101555210A A CC O
the CN101555210A A DT O
like CN101555210A A JJ O
. CN101555210A A . O

Multi-target CN103214489A T NNP O
kinase CN103214489A T NN I-UN
inhibitors CN103214489A T NNS O
with CN103214489A T IN O
antitumor CN103214489A T NN O
activities CN103214489A T NNS O
, CN103214489A T , O
and CN103214489A T CC O
preparation CN103214489A T NN O
method CN103214489A T NN O
thereof CN103214489A T NN O
. CN103214489A T . O

The CN103214489A A DT O
compounds CN103214489A A NNS O
provided CN103214489A A VBN O
by CN103214489A A IN O
the CN103214489A A DT O
invention CN103214489A A NN O
have CN103214489A A VBP O
substantial CN103214489A A JJ O
tumor CN103214489A A NN O
cytotoxic CN103214489A A NN O
effect CN103214489A A NN O
and CN103214489A A CC O
broad-spectrum CN103214489A A JJ O
kinase CN103214489A A NN I-UN
inhibitory CN103214489A A NN O
activity CN103214489A A NN O
, CN103214489A A , O
and CN103214489A A CC O
can CN103214489A A MD O
be CN103214489A A VB O
used CN103214489A A VBN O
in CN103214489A A IN O
preparing CN103214489A A VBG O
antitumor CN103214489A A NN O
medicines CN103214489A A NNS O
. CN103214489A A . O

A WO2008106731A1 T DT O
target WO2008106731A1 T NN O
for WO2008106731A1 T IN O
breast WO2008106731A1 T NN O
cancer WO2008106731A1 T NN O
therapy WO2008106731A1 T NN O
and/or WO2008106731A1 T JJ O
diagnosis WO2008106731A1 T NN O
. WO2008106731A1 T . O

The WO2008106731A1 A DT O
methods WO2008106731A1 A NNS O
include WO2008106731A1 A VBP O
identifying WO2008106731A1 A VBG O
therapeutic WO2008106731A1 A JJ O
agents WO2008106731A1 A NNS O
which WO2008106731A1 A WDT O
modulate WO2008106731A1 A VBP O
a WO2008106731A1 A DT O
CRAC WO2008106731A1 A NNP I-UN
channel WO2008106731A1 A NN O
and/or WO2008106731A1 A VBZ O
a WO2008106731A1 A DT O
glycoprotein WO2008106731A1 A JJ O
activator WO2008106731A1 A NN O
of WO2008106731A1 A IN O
a WO2008106731A1 A DT O
CRAC WO2008106731A1 A NNP I-UN
channel WO2008106731A1 A NN O
. WO2008106731A1 A . O

Also WO2008106731A1 A RB O
provided WO2008106731A1 A VBN O
are WO2008106731A1 A VBP O
diagnostic WO2008106731A1 A JJ O
methods WO2008106731A1 A NNS O
that WO2008106731A1 A WDT O
ultilise WO2008106731A1 A VBP O
a WO2008106731A1 A DT O
CRAC WO2008106731A1 A NNP I-UN
channel WO2008106731A1 A NN O
and/or WO2008106731A1 A VBZ O
a WO2008106731A1 A DT O
glycoprotein WO2008106731A1 A JJ O
activator WO2008106731A1 A NN O
of WO2008106731A1 A IN O
a WO2008106731A1 A DT O
CRAC WO2008106731A1 A NNP I-UN
channel WO2008106731A1 A NN O
. WO2008106731A1 A . O

3- US20080009483 T JJ O
{ US20080009483 T ( O
[ US20080009483 T JJ O
( US20080009483 T ( O
2,3-dihydro US20080009483 T JJ O
[ US20080009483 T NN O
1,4 US20080009483 T CD O
] US20080009483 T NNP O
dioxino US20080009483 T NN O
[ US20080009483 T NNP O
2,3-c US20080009483 T JJ O
] US20080009483 T NNP O
pyridin-7-ylmethyl US20080009483 T NN O
) US20080009483 T ) O
amino US20080009483 T NN O
] US20080009483 T JJ O
methyl US20080009483 T NN O
} US20080009483 T ) O
-N- US20080009483 T NNP O
[ US20080009483 T NNP O
3-fluoro-6- US20080009483 T NNP O
( US20080009483 T ( O
methyloxy US20080009483 T NN O
) US20080009483 T ) O
-1,5-naphthyridin-4-yl US20080009483 T VBZ O
] US20080009483 T JJ O
-4-hydroxycyclopentanecarboxamide US20080009483 T RB O
; US20080009483 T : O
antibiotic US20080009483 T JJ O
resistance US20080009483 T NN O
; US20080009483 T : O
Staphylococcus US20080009483 T NNP O
aureus US20080009483 T NN O
, US20080009483 T , O
Streptococcus US20080009483 T NNP O
pneumoniae US20080009483 T NN O
and US20080009483 T CC O
pyogenes US20080009483 T NNS O
, US20080009483 T , O
Enterococcus US20080009483 T NNP O
; US20080009483 T : O
Haemophilus US20080009483 T NNP O
influenzae US20080009483 T NN O
, US20080009483 T , O
Moraxella US20080009483 T NNP O
catarrhalis US20080009483 T NN O
, US20080009483 T , O
E-coli US20080009483 T NNP O
. US20080009483 T . O

Compound CN1935186A T NNP O
perillaseed CN1935186A T VBD O
oil CN1935186A T NN O
and CN1935186A T CC O
its CN1935186A T PRP$ O
capsule CN1935186A T NN O
pill CN1935186A T NN O
. CN1935186A T . O

3,4-diaminopyridine US20140080875 T JJ O
tartrate US20140080875 T NN O
and US20140080875 T CC O
phosphate US20140080875 T NN O
, US20140080875 T , O
pharmaceutical US20140080875 T JJ O
compositions US20140080875 T NNS O
and US20140080875 T CC O
uses US20140080875 T VBZ O
thereof US20140080875 T NN O
. US20140080875 T . O

Termitomyces CN102702377A T NNS O
albuminosus CN102702377A T VBP O
polysaccharide CN102702377A T JJ O
separation CN102702377A T NN O
and CN102702377A T CC O
purification CN102702377A T NN O
method CN102702377A T NN O
and CN102702377A T CC O
injection CN102702377A T NN O
thereof CN102702377A T NN O
. CN102702377A T . O

Lin28-mediated EP2688595A2 T JJ O
control EP2688595A2 T NN O
of EP2688595A2 T IN O
let-7 EP2688595A2 T JJ I-UN
biogenesis EP2688595A2 T NN O
. EP2688595A2 T . O

The EP2688595A2 A DT O
present EP2688595A2 A JJ O
embodiments EP2688595A2 A NNS O
provide EP2688595A2 A VBP O
for EP2688595A2 A IN O
compositions EP2688595A2 A NNS O
and EP2688595A2 A CC O
methods EP2688595A2 A NNS O
that EP2688595A2 A WDT O
regulate EP2688595A2 A VBP O
microRNA-binding EP2688595A2 A JJ O
protein-mediated EP2688595A2 A JJ O
miRNA EP2688595A2 A NN O
biogenesis EP2688595A2 A NN O
; EP2688595A2 A : O
for EP2688595A2 A IN O
example EP2688595A2 A NN O
Lin28-mediated EP2688595A2 A JJ O
biogenesis EP2688595A2 A NN O
of EP2688595A2 A IN O
let-7 EP2688595A2 A NN I-UN
; EP2688595A2 A : O
and EP2688595A2 A CC O
in EP2688595A2 A IN O
particular EP2688595A2 A JJ O
Lin28A-recruited EP2688595A2 A JJ O
3 EP2688595A2 A CD I-UN
' EP2688595A2 A POS I-UN
terminal EP2688595A2 A JJ I-UN
uridylyl EP2688595A2 A JJ I-UN
transferase EP2688595A2 A NN I-UN
( EP2688595A2 A ( O
TUTase EP2688595A2 A NNP I-UN
) EP2688595A2 A ) O
uridylation EP2688595A2 A NN O
of EP2688595A2 A IN O
pre-let-7 EP2688595A2 A NN O
. EP2688595A2 A . O

A EP2688595A2 A DT O
particular EP2688595A2 A JJ O
embodiment EP2688595A2 A NN O
provides EP2688595A2 A VBZ O
compositions EP2688595A2 A NNS O
and EP2688595A2 A CC O
methods EP2688595A2 A NNS O
for EP2688595A2 A IN O
screening EP2688595A2 A VBG O
for EP2688595A2 A IN O
agents EP2688595A2 A NNS O
that EP2688595A2 A WDT O
inhibit EP2688595A2 A VBP O
TUTase-dependent EP2688595A2 A JJ O
Lin28A-mediated EP2688595A2 A JJ O
repression EP2688595A2 A NN O
of EP2688595A2 A IN O
let-7 EP2688595A2 A JJ I-UN
miRNA EP2688595A2 A NN O
. EP2688595A2 A . O

Pharmaceutical US20130053446 T JJ O
preparations US20130053446 T NNS O
having US20130053446 T VBG O
individualized US20130053446 T VBN O
dosage US20130053446 T NN O
and US20130053446 T CC O
structure US20130053446 T NN O
. US20130053446 T . O

Platinum EP2759547A1 T NNP O
compound EP2759547A1 T NN O
having EP2759547A1 T VBG O
amino- EP2759547A1 T JJ O
or EP2759547A1 T CC O
alkylamino-containing EP2759547A1 T JJ O
succinic EP2759547A1 T JJ O
acid EP2759547A1 T NN O
derivatives EP2759547A1 T NNS O
as EP2759547A1 T IN O
leaving EP2759547A1 T VBG O
group EP2759547A1 T NN O
, EP2759547A1 T , O
preparation EP2759547A1 T NN O
method EP2759547A1 T NN O
therefor EP2759547A1 T NN O
, EP2759547A1 T , O
and EP2759547A1 T CC O
use EP2759547A1 T NN O
thereof EP2759547A1 T NN O
. EP2759547A1 T . O

Dhea CA2795991A1 T NNP O
bioadhesive CA2795991A1 T NN O
controlled CA2795991A1 T VBD O
release CA2795991A1 T NN O
gel CA2795991A1 T NN O
. CA2795991A1 T . O

Carbazole EP1896035A2 T JJ O
formulations EP1896035A2 T NNS O
for EP1896035A2 T IN O
the EP1896035A2 T DT O
treatment EP1896035A2 T NN O
of EP1896035A2 T IN O
psoriasis EP1896035A2 T NN O
and EP1896035A2 T CC O
angiogenesis EP1896035A2 T NN O
. EP1896035A2 T . O

The EP1896035A2 A DT O
methods EP1896035A2 A NNS O
and EP1896035A2 A CC O
compositions EP1896035A2 A NNS O
disclosed EP1896035A2 A VBD O
herein EP1896035A2 A JJ O
relate EP1896035A2 A NN O
to EP1896035A2 A TO O
using EP1896035A2 A VBG O
carbazole EP1896035A2 A NN O
, EP1896035A2 A , O
and EP1896035A2 A CC O
derivatives EP1896035A2 A NNS O
thereof EP1896035A2 A VBP O
to EP1896035A2 A TO O
modify EP1896035A2 A VB O
a EP1896035A2 A DT O
signaling EP1896035A2 A VBG O
activity EP1896035A2 A NN O
such EP1896035A2 A JJ O
as EP1896035A2 A IN O
epidermal EP1896035A2 A JJ I-UN
growth EP1896035A2 A NN I-UN
factor EP1896035A2 A NN I-UN
receptor EP1896035A2 A NN I-UN
( EP1896035A2 A ( O
EGFR EP1896035A2 A NNP I-UN
) EP1896035A2 A ) O
signalling EP1896035A2 A NN O
, EP1896035A2 A , O
and EP1896035A2 A CC O
angiogenesis EP1896035A2 A NN O
activity EP1896035A2 A NN O
, EP1896035A2 A , O
in EP1896035A2 A IN O
a EP1896035A2 A DT O
cell EP1896035A2 A NN O
. EP1896035A2 A . O

Hepatitis WO2007016476A3 T NNP I-UN
c WO2007016476A3 T VBZ I-UN
serine WO2007016476A3 T JJ I-UN
protease WO2007016476A3 T NN I-UN
inhibitors WO2007016476A3 T NNS O
and WO2007016476A3 T CC O
uses WO2007016476A3 T VBZ O
therefor WO2007016476A3 T NN O
. WO2007016476A3 T . O

The WO2007016476A3 A DT O
present WO2007016476A3 A JJ O
invention WO2007016476A3 A NN O
provides WO2007016476A3 A VBZ O
novel WO2007016476A3 A JJ O
compounds WO2007016476A3 A NNS O
which WO2007016476A3 A WDT O
mimic WO2007016476A3 A VBP O
peptides WO2007016476A3 A NNS O
with WO2007016476A3 A IN O
a WO2007016476A3 A DT O
C-terminal WO2007016476A3 A JJ O
penultimate WO2007016476A3 A NN O
proline WO2007016476A3 A NN O
, WO2007016476A3 A , O
such WO2007016476A3 A JJ O
compounds WO2007016476A3 A NNS O
being WO2007016476A3 A VBG O
useful WO2007016476A3 A JJ O
as WO2007016476A3 A IN O
protease WO2007016476A3 A NN I-UN
inhibitors WO2007016476A3 A NNS O
, WO2007016476A3 A , O
particularly WO2007016476A3 A RB O
as WO2007016476A3 A IN O
inhibitors WO2007016476A3 A NNS O
of WO2007016476A3 A IN O
serine WO2007016476A3 A NN I-UN
proteases WO2007016476A3 A NNS I-UN
, WO2007016476A3 A , O
and WO2007016476A3 A CC O
more WO2007016476A3 A JJR O
particularly WO2007016476A3 A RB O
as WO2007016476A3 A IN O
inhibitors WO2007016476A3 A NNS O
of WO2007016476A3 A IN O
the WO2007016476A3 A DT O
NS3 WO2007016476A3 A NNP I-UN
serine WO2007016476A3 A NN I-UN
protease WO2007016476A3 A NN I-UN
from WO2007016476A3 A IN O
hepatitis WO2007016476A3 A NN O
C. WO2007016476A3 A NNP O
The WO2007016476A3 A DT O
compounds WO2007016476A3 A NNS O
find WO2007016476A3 A VBP O
utility WO2007016476A3 A NN O
as WO2007016476A3 A IN O
antiviral WO2007016476A3 A JJ O
agents WO2007016476A3 A NNS O
directed WO2007016476A3 A VBN O
at WO2007016476A3 A IN O
hepatitis WO2007016476A3 A NN O
C. WO2007016476A3 A NNP O
The WO2007016476A3 A DT O
invention WO2007016476A3 A NN O
further WO2007016476A3 A RB O
provides WO2007016476A3 A VBZ O
methods WO2007016476A3 A NNS O
of WO2007016476A3 A IN O
employing WO2007016476A3 A VBG O
such WO2007016476A3 A JJ O
inhibitors WO2007016476A3 A NNS O
, WO2007016476A3 A , O
alone WO2007016476A3 A RB O
or WO2007016476A3 A CC O
in WO2007016476A3 A IN O
combination WO2007016476A3 A NN O
with WO2007016476A3 A IN O
other WO2007016476A3 A JJ O
therapeutic WO2007016476A3 A JJ O
agents WO2007016476A3 A NNS O
, WO2007016476A3 A , O
to WO2007016476A3 A TO O
treat WO2007016476A3 A VB O
hepatitis WO2007016476A3 A NN O
C WO2007016476A3 A NNP O
infection WO2007016476A3 A NN O
in WO2007016476A3 A IN O
a WO2007016476A3 A DT O
subject WO2007016476A3 A NN O
in WO2007016476A3 A IN O
need WO2007016476A3 A NN O
of WO2007016476A3 A IN O
such WO2007016476A3 A JJ O
treatment WO2007016476A3 A NN O
. WO2007016476A3 A . O

Forming US7025988 T VBG O
dehydration-rehydration US7025988 T NN O
vesicles US7025988 T NNS O
with US7025988 T IN O
lipophilic US7025988 T JJ O
drug US7025988 T NN O
paclitaxel US7025988 T NN O
, US7025988 T , O
dissolving US7025988 T VBG O
sugar US7025988 T NN O
into US7025988 T IN O
the US7025988 T DT O
aqueous US7025988 T JJ O
suspension US7025988 T NN O
; US7025988 T : O
drug US7025988 T NN O
delivery US7025988 T NN O
of US7025988 T IN O
antitumor US7025988 T NN O
treatment US7025988 T NN O
. US7025988 T . O

Food CN101513471A T NNP O
prescription CN101513471A T NN O
for CN101513471A T IN O
treating CN101513471A T VBG O
bacillary CN101513471A T JJ O
dysentery CN101513471A T NN O
. CN101513471A T . O

Notogisennoside CN1785200A T NNP O
composition CN1785200A T NN O
, CN1785200A T , O
prepn CN1785200A T NN O
. CN1785200A T . O

method CN1785200A T NN O
and CN1785200A T CC O
application CN1785200A T NN O
thereof CN1785200A T NN O
. CN1785200A T . O

Supplies CN101390866A T NNS O
for CN101390866A T IN O
removing CN101390866A T VBG O
odor CN101390866A T NN O
. CN101390866A T . O

Zinc-selenium CN102228447A T JJ O
chewable CN102228447A T JJ O
tablet CN102228447A T NN O
. CN102228447A T . O

Water US20080200507 T NNP O
and US20080200507 T CC O
organic US20080200507 T JJ O
solvent US20080200507 T NN O
free US20080200507 T JJ O
crystal US20080200507 T JJ O
lattice US20080200507 T NN O
; US20080200507 T : O
hydrophobic US20080200507 T CC O
, US20080200507 T , O
water US20080200507 T NN O
soluble US20080200507 T JJ O
; US20080200507 T : O
endometriosis US20080200507 T NN O
and/or US20080200507 T NN O
uterine US20080200507 T JJ O
leiomyoma US20080200507 T NN O
; US20080200507 T : O
commercial US20080200507 T JJ O
scale US20080200507 T NN O
; US20080200507 T : O
X US20080200507 T NNP O
ray US20080200507 T VBZ O
diffraction US20080200507 T NN O
pattern US20080200507 T NN O
having US20080200507 T VBG O
peaks US20080200507 T NNS O
at US20080200507 T IN O
13.0 US20080200507 T CD O
, US20080200507 T , O
13.6 US20080200507 T CD O
, US20080200507 T , O
18.6 US20080200507 T CD O
, US20080200507 T , O
19.0 US20080200507 T CD O
, US20080200507 T , O
21.0 US20080200507 T CD O
and US20080200507 T CC O
22.3 US20080200507 T CD O
degrees US20080200507 T NNS O
. US20080200507 T . O

The US20080200507 A DT O
present US20080200507 A JJ O
invention US20080200507 A NN O
relates US20080200507 A VBZ O
to US20080200507 A TO O
the US20080200507 A DT O
mesylate US20080200507 A NN O
salt US20080200507 A NN O
of US20080200507 A IN O
1- US20080200507 A JJ O
( US20080200507 A ( O
4- US20080200507 A JJ O
( US20080200507 A ( O
2-piperidinylethoxy US20080200507 A JJ O
) US20080200507 A ) O
phenoxy US20080200507 A NN O
) US20080200507 A ) O
-2- US20080200507 A NN O
( US20080200507 A ( O
3-hydroxyphenyl US20080200507 A JJ O
) US20080200507 A ) O
-6-hydroxynaphthalene US20080200507 A NN O
. US20080200507 A . O

Kinase US7528116 T NNP I-UN
suppressor US7528116 T NN I-UN
of US7528116 T IN I-UN
Ras US7528116 T NNP I-UN
inactivation US7528116 T NN O
for US7528116 T IN O
therapy US7528116 T NN O
of US7528116 T IN O
Ras US7528116 T NNP I-UN
mediated US7528116 T VBD O
tumorigenesis US7528116 T NN O
. US7528116 T . O

The US7528116 A DT O
present US7528116 A JJ O
invention US7528116 A NN O
relates US7528116 A VBZ O
to US7528116 A TO O
methods US7528116 A NNS O
and US7528116 A CC O
compositions US7528116 A NNS O
for US7528116 A IN O
the US7528116 A DT O
specific US7528116 A JJ O
inhibition US7528116 A NN O
of US7528116 A IN O
kinase US7528116 A NN I-UN
suppressor US7528116 A NN I-UN
of US7528116 A IN I-UN
Ras US7528116 A NNP I-UN
( US7528116 A ( O
KSR US7528116 A NNP I-UN
) US7528116 A ) O
. US7528116 A . O

In US7528116 A IN O
particular US7528116 A JJ O
, US7528116 A , O
the US7528116 A DT O
invention US7528116 A NN O
provides US7528116 A VBZ O
genetic US7528116 A JJ O
approaches US7528116 A NNS O
and US7528116 A CC O
nucleic US7528116 A JJ O
acids US7528116 A NNS O
for US7528116 A IN O
the US7528116 A DT O
specific US7528116 A JJ O
inhibition US7528116 A NN O
of US7528116 A IN O
KSR US7528116 A NNP I-UN
, US7528116 A , O
particularly US7528116 A RB O
of US7528116 A IN O
KSR US7528116 A NNP I-UN
expression US7528116 A NN O
. US7528116 A . O

The US7528116 A DT O
invention US7528116 A NN O
relates US7528116 A VBZ O
to US7528116 A TO O
antisense US7528116 A VB O
oligonucleotides US7528116 A NNS O
and US7528116 A CC O
the US7528116 A DT O
expression US7528116 A NN O
of US7528116 A IN O
nucleic US7528116 A NN O
acid US7528116 A NN O
which US7528116 A WDT O
is US7528116 A VBZ O
substantially US7528116 A RB O
complementary US7528116 A JJ O
to US7528116 A TO O
KSR US7528116 A NNP I-UN
RNA US7528116 A NNP I-UN
. US7528116 A . O

The US7528116 A DT O
invention US7528116 A NN O
provides US7528116 A VBZ O
methods US7528116 A NNS O
to US7528116 A TO O
inhibit US7528116 A VB O
KSR US7528116 A NNP I-UN
, US7528116 A , O
including US7528116 A VBG O
inhibition US7528116 A NN O
of US7528116 A IN O
KSR US7528116 A NNP I-UN
expression US7528116 A NN O
. US7528116 A . O

Methods US7528116 A NNS O
for US7528116 A IN O
blocking US7528116 A VBG O
gf US7528116 A NN O
Ras US7528116 A NNP I-UN
mediated US7528116 A VBD O
tumorigenesis US7528116 A NN O
, US7528116 A , O
metastasis US7528116 A NN O
, US7528116 A , O
and US7528116 A CC O
for US7528116 A IN O
cancer US7528116 A NN O
therapy US7528116 A NN O
are US7528116 A VBP O
provided US7528116 A VBN O
. US7528116 A . O

Substituted US20120071461 T VBN O
Benzamide US20120071461 T NNP O
Compounds US20120071461 T NNP O
. US20120071461 T . O

Substituted US20120071461 A VBN O
benzamide US20120071461 A JJ O
compounds US20120071461 A NNS O
corresponding US20120071461 A VBG O
to US20120071461 A TO O
formula US20120071461 A VB O
( US20120071461 A ( O
I US20120071461 A PRP O
) US20120071461 A ) O
in US20120071461 A IN O
which US20120071461 A WDT O
R5 US20120071461 A NNP O
, US20120071461 A , O
R6 US20120071461 A NNP O
, US20120071461 A , O
R7 US20120071461 A NNP O
, US20120071461 A , O
R8 US20120071461 A NNP O
, US20120071461 A , O
a US20120071461 A DT O
, US20120071461 A , O
b US20120071461 A NN O
, US20120071461 A , O
c US20120071461 A NN O
, US20120071461 A , O
d US20120071461 A NN O
, US20120071461 A , O
t US20120071461 A NN O
, US20120071461 A , O
D US20120071461 A NNP O
and US20120071461 A CC O
X US20120071461 A NNP O
have US20120071461 A VBP O
defined US20120071461 A VBN O
meanings US20120071461 A NNS O
, US20120071461 A , O
a US20120071461 A DT O
process US20120071461 A NN O
for US20120071461 A IN O
their US20120071461 A PRP$ O
preparation US20120071461 A NN O
, US20120071461 A , O
pharmaceutical US20120071461 A JJ O
compositions US20120071461 A NNS O
comprising US20120071461 A VBG O
such US20120071461 A JJ O
compounds US20120071461 A NNS O
, US20120071461 A , O
and US20120071461 A CC O
a US20120071461 A DT O
method US20120071461 A NN O
of US20120071461 A IN O
using US20120071461 A VBG O
such US20120071461 A JJ O
compounds US20120071461 A NNS O
to US20120071461 A TO O
treat US20120071461 A VB O
pain US20120071461 A NN O
and US20120071461 A CC O
other US20120071461 A JJ O
conditions US20120071461 A NNS O
mediated US20120071461 A VBN O
at US20120071461 A IN O
least US20120071461 A JJS O
in US20120071461 A IN O
part US20120071461 A NN O
via US20120071461 A IN O
the US20120071461 A DT O
bradykinin US20120071461 A NN I-UN
1 US20120071461 A CD I-UN
receptor US20120071461 A NN I-UN
. US20120071461 A . O

New CN1724521A T NNP O
quinazoline CN1724521A T NN O
hind CN1724521A T NN O
derivative CN1724521A T JJ O
, CN1724521A T , O
medicinal CN1724521A T JJ O
composition CN1724521A T NN O
containing CN1724521A T VBG O
same CN1724521A T JJ O
and CN1724521A T CC O
their CN1724521A T PRP$ O
use CN1724521A T NN O
. CN1724521A T . O

Aerosol CN101856327A T NNP O
with CN101856327A T IN O
quantitative CN101856327A T JJ O
inhalation CN101856327A T NN O
of CN101856327A T IN O
bencycloquidium CN101856327A T NN O
bromide CN101856327A T NN O
and CN101856327A T CC O
preparation CN101856327A T NN O
method CN101856327A T NN O
thereof CN101856327A T NN O
. CN101856327A T . O

Use US20070015800 T NNP O
of US20070015800 T IN O
a US20070015800 T DT O
compound US20070015800 T NN O
in US20070015800 T IN O
providing US20070015800 T VBG O
refreshedness US20070015800 T NN O
on US20070015800 T IN O
waking US20070015800 T NN O
and US20070015800 T CC O
a US20070015800 T DT O
method US20070015800 T NN O
for US20070015800 T IN O
the US20070015800 T DT O
treatment US20070015800 T NN O
of US20070015800 T IN O
drowsiness US20070015800 T NN O
therewith US20070015800 T NN O
. US20070015800 T . O

Coumarin WO2014046224A1 T NNP O
derivative WO2014046224A1 T NN O
. WO2014046224A1 T . O

Glycine-reuptake CN103254127A T NNP O
inhibitor CN103254127A T NN O
and CN103254127A T CC O
application CN103254127A T NN O
thereof CN103254127A T NN O
. CN103254127A T . O

Use WO2010043550A1 T NNP O
of WO2010043550A1 T IN O
dianhydrohexite WO2010043550A1 T JJ O
mononitrate WO2010043550A1 T NN O
derivatives WO2010043550A1 T NNS O
as WO2010043550A1 T IN O
healing WO2010043550A1 T VBG O
agents WO2010043550A1 T NNS O
. WO2010043550A1 T . O

Flower CN103040102A T NNP O
odor CN103040102A T NN O
type CN103040102A T NN O
snuff CN103040102A T NN O
. CN103040102A T . O

Perfluorinated WO2014134341A1 T VBN O
5,6-dihydro-4h-1,3-oxazin-2-amine WO2014134341A1 T JJ O
compounds WO2014134341A1 T NNS O
as WO2014134341A1 T IN O
beta-secretase WO2014134341A1 T JJ O
inhibitors WO2014134341A1 T NNS O
and WO2014134341A1 T CC O
methods WO2014134341A1 T NNS O
of WO2014134341A1 T IN O
use WO2014134341A1 T NN O
. WO2014134341A1 T . O

Compositions WO2010091241A3 T NNS O
and WO2010091241A3 T CC O
methods WO2010091241A3 T NNS O
for WO2010091241A3 T IN O
promoting WO2010091241A3 T VBG O
the WO2010091241A3 T DT O
generation WO2010091241A3 T NN O
of WO2010091241A3 T IN O
definitive WO2010091241A3 T JJ O
endoderm WO2010091241A3 T NN O
. WO2010091241A3 T . O

Pharmaceutical US8461146 T JJ O
composition US8461146 T NN O
for US8461146 T IN O
the US8461146 T DT O
treatment US8461146 T NN O
of US8461146 T IN O
premature US8461146 T JJ O
ejaculation US8461146 T NN O
. US8461146 T . O

enzyme US7070971 T NN O
inhibitor US7070971 T NN O
for US7070971 T IN O
selectin US7070971 T NN O
mediated US7070971 T VBN O
binding US7070971 T VBG O
events US7070971 T NNS O
and US7070971 T CC O
methods US7070971 T NNS O
of US7070971 T IN O
treating US7070971 T VBG O
disease US7070971 T NN O
conditions US7070971 T NNS O
using US7070971 T VBG O
animal US7070971 T JJ O
models US7070971 T NNS O
; US7070971 T : O
genetic US7070971 T JJ O
engineering US7070971 T NN O
. US7070971 T . O

Novel US7070971 A NN O
glycosylsulfotransferases US7070971 A NNS O
( US7070971 A ( O
GST-4α US7070971 A NNP I-UN
, US7070971 A , O
GST-4β US7070971 A NNP I-UN
, US7070971 A , O
and US7070971 A CC O
GST-6 US7070971 A NNP O
) US7070971 A ) O
and US7070971 A CC O
polypeptides US7070971 A NNS O
related US7070971 A JJ O
thereto US7070971 A NN O
, US7070971 A , O
as US7070971 A RB O
well US7070971 A RB O
as US7070971 A IN O
nucleic US7070971 A JJ O
acid US7070971 A JJ O
compositions US7070971 A NNS O
encoding US7070971 A VBG O
the US7070971 A DT O
same US7070971 A JJ O
, US7070971 A , O
are US7070971 A VBP O
provided US7070971 A VBN O
. US7070971 A . O

Also US7070971 A RB O
provided US7070971 A VBN O
are US7070971 A VBP O
methods US7070971 A NNS O
of US7070971 A IN O
inhibiting US7070971 A VBG O
selectin US7070971 A NN O
mediated US7070971 A VBD O
binding US7070971 A VBG O
events US7070971 A NNS O
and US7070971 A CC O
methods US7070971 A NNS O
of US7070971 A IN O
treating US7070971 A VBG O
disease US7070971 A NN O
conditions US7070971 A NNS O
associated US7070971 A VBN O
therewith US7070971 A RB O
, US7070971 A , O
particularly US7070971 A RB O
by US7070971 A IN O
administering US7070971 A VBG O
an US7070971 A DT O
inhibitor US7070971 A NN O
of US7070971 A IN O
at US7070971 A IN O
least US7070971 A JJS O
one US7070971 A CD O
of US7070971 A IN O
GST-4α US7070971 A NNP I-UN
, US7070971 A , O
GST-4β US7070971 A NNP I-UN
, US7070971 A , O
and US7070971 A CC O
GST-6 US7070971 A NNP O
. US7070971 A . O

Pyrimidine EP1397351B1 T NNP O
, EP1397351B1 T , O
triazine EP1397351B1 T NN O
and EP1397351B1 T CC O
pyrazine EP1397351B1 T NN O
derivatives EP1397351B1 T NNS O
as EP1397351B1 T IN O
glutamate EP1397351B1 T NN I-UN
receptors EP1397351B1 T NNS I-UN
. EP1397351B1 T . O

Compositions US20110117070 T NNS O
and US20110117070 T CC O
methods US20110117070 T NNS O
for US20110117070 T IN O
treating US20110117070 T VBG O
headache US20110117070 T NN O
. US20110117070 T . O

Unc-33 US8377645 T JJ O
like US8377645 T IN O
phosphoprotein US8377645 T NN O
( US8377645 T ( O
ULIP US8377645 T NNP O
) US8377645 T ) O
polypeptide US8377645 T NN O
for US8377645 T IN O
generating US8377645 T VBG O
antibodies US8377645 T NNS O
for US8377645 T IN O
use US8377645 T NN O
in US8377645 T IN O
diagnosis US8377645 T NN O
, US8377645 T , O
preventnion US8377645 T NN O
and US8377645 T CC O
treatment US8377645 T NN O
of US8377645 T IN O
neurodegenerative US8377645 T JJ O
and US8377645 T CC O
neoplastic US8377645 T JJ O
disorders US8377645 T NNS O
. US8377645 T . O

Heterocyclic WO2013164838A1 T NNP O
compounds WO2013164838A1 T NNS O
and WO2013164838A1 T CC O
their WO2013164838A1 T PRP$ O
use WO2013164838A1 T NN O
for WO2013164838A1 T IN O
treatment WO2013164838A1 T NN O
of WO2013164838A1 T IN O
diabetes WO2013164838A1 T NNS O
, WO2013164838A1 T , O
obesity WO2013164838A1 T NN O
or WO2013164838A1 T CC O
related WO2013164838A1 T JJ O
disorders WO2013164838A1 T NNS O
. WO2013164838A1 T . O

Heterocyclic US6939891 T NNP O
ureas US6939891 T NNS O
, US6939891 T , O
their US6939891 T PRP$ O
preparation US6939891 T NN O
and US6939891 T CC O
their US6939891 T PRP$ O
use US6939891 T NN O
as US6939891 T IN O
vanilloid US6939891 T JJ O
receptor US6939891 T NN O
antagonists US6939891 T NNS O
. US6939891 T . O

The US6939891 A DT O
invention US6939891 A NN O
relates US6939891 A VBZ O
to US6939891 A TO O
certain US6939891 A JJ O
novel US6939891 A JJ O
compounds US6939891 A NNS O
having US6939891 A VBG O
Vanilloid US6939891 A NNP O
Receptor US6939891 A NNP O
( US6939891 A ( O
VR1 US6939891 A NNP I-UN
) US6939891 A ) O
antagonist US6939891 A NN O
activity US6939891 A NN O
, US6939891 A , O
processes US6939891 A NNS O
for US6939891 A IN O
their US6939891 A PRP$ O
preparation US6939891 A NN O
, US6939891 A , O
to US6939891 A TO O
compositions US6939891 A NNS O
containing US6939891 A VBG O
them US6939891 A PRP O
and US6939891 A CC O
to US6939891 A TO O
their US6939891 A PRP$ O
use US6939891 A NN O
in US6939891 A IN O
the US6939891 A DT O
treatment US6939891 A NN O
of US6939891 A IN O
various US6939891 A JJ O
disorders US6939891 A NNS O
. US6939891 A . O

Use EP2117552A1 T NNP O
of EP2117552A1 T IN O
condensed EP2117552A1 T JJ O
pyrimidine EP2117552A1 T NN O
derivatives EP2117552A1 T NNS O
for EP2117552A1 T IN O
the EP2117552A1 T DT O
treatment EP2117552A1 T NN O
of EP2117552A1 T IN O
autoimmune EP2117552A1 T NN O
and EP2117552A1 T CC O
inflammatory EP2117552A1 T NN O
diseases EP2117552A1 T NNS O
. EP2117552A1 T . O

Ionophore WO2013147618A1 T NNP O
antibiotic WO2013147618A1 T JJ O
suspension WO2013147618A1 T NN O
. WO2013147618A1 T . O

Use US20050176826 T NNP O
of US20050176826 T IN O
asc-1 US20050176826 T JJ I-UN
inhibitors US20050176826 T NNS O
to US20050176826 T TO O
treat US20050176826 T VB O
neurological US20050176826 T JJ O
and US20050176826 T CC O
psychiatric US20050176826 T JJ O
disorders US20050176826 T NNS O
. US20050176826 T . O

The US20050176826 A DT O
present US20050176826 A JJ O
invention US20050176826 A NN O
relates US20050176826 A VBZ O
to US20050176826 A TO O
the US20050176826 A DT O
identification US20050176826 A NN O
and US20050176826 A CC O
use US20050176826 A NN O
of US20050176826 A IN O
compounds US20050176826 A NNS O
that US20050176826 A WDT O
are US20050176826 A VBP O
inhibitors US20050176826 A NNS O
of US20050176826 A IN O
the US20050176826 A DT O
alanine-serine-cysteine US20050176826 A JJ I-UN
transporter US20050176826 A NN I-UN
1 US20050176826 A CD I-UN
( US20050176826 A ( O
asc-1 US20050176826 A NN I-UN
) US20050176826 A ) O
. US20050176826 A . O

This US20050176826 A DT O
includes US20050176826 A VBZ O
an US20050176826 A DT O
assay US20050176826 A NN O
for US20050176826 A IN O
the US20050176826 A DT O
identification US20050176826 A NN O
of US20050176826 A IN O
compounds US20050176826 A NNS O
that US20050176826 A WDT O
are US20050176826 A VBP O
inhibitors US20050176826 A NNS O
of US20050176826 A IN O
asc-1 US20050176826 A JJ I-UN
, US20050176826 A , O
as US20050176826 A RB O
well US20050176826 A RB O
as US20050176826 A IN O
pharmaceutical US20050176826 A JJ O
compositions US20050176826 A NNS O
comprising US20050176826 A VBG O
these US20050176826 A DT O
compounds US20050176826 A NNS O
. US20050176826 A . O

Method US20120238513 T NNP O
for US20120238513 T IN O
inhibiting US20120238513 T VBG O
activation US20120238513 T NN O
of US20120238513 T IN O
macrophages US20120238513 T NNS O
. US20120238513 T . O

Strategies US20090012130 T NNS O
for US20090012130 T IN O
Designing US20090012130 T VBG O
Drugs US20090012130 T NNP O
that US20090012130 T WDT O
Target US20090012130 T VBP O
the US20090012130 T DT O
Sir2 US20090012130 T NNP O
Family US20090012130 T NNP O
of US20090012130 T IN O
Enzymes US20090012130 T NNP O
. US20090012130 T . O

Ceramide WO2009145299A1 T NNP O
dispersion WO2009145299A1 T NN O
. WO2009145299A1 T . O

2- US7449475 T JJ O
{ US7449475 T ( O
[ US7449475 T NNP O
( US7449475 T ( O
2S US7449475 T CD O
) US7449475 T ) O
-3- US7449475 T NN O
( US7449475 T ( O
5-Chloro-1'H,3H-spiro US7449475 T JJ O
[ US7449475 T NNP O
1-benzofuran-2,4'-piperidin US7449475 T CD O
] US7449475 T NNP O
-1'-yl US7449475 T NNP O
) US7449475 T ) O
-2-hydroxypropyl US7449475 T VBP O
] US7449475 T JJ O
oxy US7449475 T NN O
} US7449475 T ) O
-N-cyclopropylbenzamide US7449475 T NNP O
; US7449475 T : O
macrophage US7449475 T NN I-UN
inflammatory US7449475 T NN I-UN
protein US7449475 T NN I-UN
( US7449475 T ( I-UN
MIP US7449475 T NNP I-UN
) US7449475 T ) I-UN
-1 US7449475 T VBP I-UN
alpha US7449475 T JJ I-UN
chemokine US7449475 T NN I-UN
receptor US7449475 T NN I-UN
modulator US7449475 T NN O
; US7449475 T : O
antiinflammatory US7449475 T NN O
, US7449475 T , O
antiproliferative US7449475 T JJ O
agent US7449475 T NN O
, US7449475 T , O
autoimmune US7449475 T NN O
diseases US7449475 T NNS O
. US7449475 T . O

Agent WO2008093495A1 T NN O
for WO2008093495A1 T IN O
treatment WO2008093495A1 T NN O
of WO2008093495A1 T IN O
multiple WO2008093495A1 T JJ O
sclerosis WO2008093495A1 T NN O
. WO2008093495A1 T . O

Lurasidone CN103130795A T NNP O
HCl CN103130795A T NNP O
crystal CN103130795A T NN O
A CN103130795A T NNP O
and CN103130795A T CC O
purpose CN103130795A T JJ O
thereof CN103130795A T NN O
. CN103130795A T . O

Method WO2013035779A1 T NNP O
of WO2013035779A1 T IN O
analysis WO2013035779A1 T NN O
of WO2013035779A1 T IN O
intercell WO2013035779A1 T NN O
interactions WO2013035779A1 T NNS O
. WO2013035779A1 T . O

The WO2013035779A1 A DT O
purpose WO2013035779A1 A NN O
of WO2013035779A1 A IN O
this WO2013035779A1 A DT O
invention WO2013035779A1 A NN O
is WO2013035779A1 A VBZ O
to WO2013035779A1 A TO O
provide WO2013035779A1 A VB O
an WO2013035779A1 A DT O
analysis WO2013035779A1 A NN O
method WO2013035779A1 A NN O
which WO2013035779A1 A WDT O
, WO2013035779A1 A , O
in WO2013035779A1 A IN O
a WO2013035779A1 A DT O
system WO2013035779A1 A NN O
in WO2013035779A1 A IN O
which WO2013035779A1 A WDT O
cells WO2013035779A1 A NNS O
derived WO2013035779A1 A VBN O
from WO2013035779A1 A IN O
different WO2013035779A1 A JJ O
individuals WO2013035779A1 A NNS O
coexist WO2013035779A1 A NN O
, WO2013035779A1 A , O
comprehensively WO2013035779A1 A RB O
and WO2013035779A1 A CC O
quantitatively WO2013035779A1 A RB O
evaluates WO2013035779A1 A VBZ O
intercell WO2013035779A1 A VBP O
protein WO2013035779A1 A JJ O
interactions WO2013035779A1 A NNS O
and WO2013035779A1 A CC O
identifies WO2013035779A1 A NNS O
significant WO2013035779A1 A JJ O
interactions WO2013035779A1 A NNS O
and WO2013035779A1 A CC O
strongly WO2013035779A1 A RB O
interdependent WO2013035779A1 A JJ O
signals WO2013035779A1 A NNS O
. WO2013035779A1 A . O

This WO2013035779A1 A DT O
method WO2013035779A1 A NN O
of WO2013035779A1 A IN O
analysis WO2013035779A1 A NN O
of WO2013035779A1 A IN O
interactions WO2013035779A1 A NNS O
of WO2013035779A1 A IN O
proteins WO2013035779A1 A NNS O
between WO2013035779A1 A IN O
cells WO2013035779A1 A NNS O
derived WO2013035779A1 A VBN O
from WO2013035779A1 A IN O
two WO2013035779A1 A CD O
or WO2013035779A1 A CC O
more WO2013035779A1 A JJR O
individuals WO2013035779A1 A NNS O
involves WO2013035779A1 A VBZ O
: WO2013035779A1 A : O
a WO2013035779A1 A DT O
step WO2013035779A1 A NN O
for WO2013035779A1 A IN O
obtaining WO2013035779A1 A VBG O
, WO2013035779A1 A , O
and WO2013035779A1 A CC O
grouping WO2013035779A1 A NN O
by WO2013035779A1 A IN O
individual WO2013035779A1 A JJ O
, WO2013035779A1 A , O
the WO2013035779A1 A DT O
expression WO2013035779A1 A NN O
profiles WO2013035779A1 A NNS O
of WO2013035779A1 A IN O
the WO2013035779A1 A DT O
genes WO2013035779A1 A NNS O
in WO2013035779A1 A IN O
the WO2013035779A1 A DT O
micro-environment WO2013035779A1 A NN O
in WO2013035779A1 A IN O
which WO2013035779A1 A WDT O
the WO2013035779A1 A DT O
cells WO2013035779A1 A NNS O
derived WO2013035779A1 A VBN O
from WO2013035779A1 A IN O
two WO2013035779A1 A CD O
or WO2013035779A1 A CC O
more WO2013035779A1 A JJR O
individuals WO2013035779A1 A NNS O
coexist WO2013035779A1 A VBP O
; WO2013035779A1 A : O
a WO2013035779A1 A DT O
step WO2013035779A1 A NN O
for WO2013035779A1 A IN O
selecting WO2013035779A1 A VBG O
combinations WO2013035779A1 A NNS O
of WO2013035779A1 A IN O
two WO2013035779A1 A CD O
proteins WO2013035779A1 A NNS O
that WO2013035779A1 A WDT O
may WO2013035779A1 A MD O
interact WO2013035779A1 A VB O
intercellularly WO2013035779A1 A RB O
; WO2013035779A1 A : O
and WO2013035779A1 A CC O
a WO2013035779A1 A DT O
step WO2013035779A1 A NN O
in WO2013035779A1 A IN O
which WO2013035779A1 A WDT O
, WO2013035779A1 A , O
out WO2013035779A1 A IN O
of WO2013035779A1 A IN O
these WO2013035779A1 A DT O
protein WO2013035779A1 A JJ O
combinations WO2013035779A1 A NNS O
, WO2013035779A1 A , O
if WO2013035779A1 A IN O
, WO2013035779A1 A , O
in WO2013035779A1 A IN O
one WO2013035779A1 A CD O
individual WO2013035779A1 A NN O
of WO2013035779A1 A IN O
the WO2013035779A1 A DT O
two WO2013035779A1 A CD O
or WO2013035779A1 A CC O
more WO2013035779A1 A JJR O
individuals WO2013035779A1 A NNS O
, WO2013035779A1 A , O
the WO2013035779A1 A DT O
expression WO2013035779A1 A NN O
level WO2013035779A1 A NN O
of WO2013035779A1 A IN O
the WO2013035779A1 A DT O
gene WO2013035779A1 A NN O
encoding WO2013035779A1 A VBG O
one WO2013035779A1 A CD O
of WO2013035779A1 A IN O
the WO2013035779A1 A DT O
proteins WO2013035779A1 A NNS O
is WO2013035779A1 A VBZ O
higher WO2013035779A1 A JJR O
than WO2013035779A1 A IN O
in WO2013035779A1 A IN O
other WO2013035779A1 A JJ O
individuals WO2013035779A1 A NNS O
, WO2013035779A1 A , O
and WO2013035779A1 A CC O
if WO2013035779A1 A IN O
, WO2013035779A1 A , O
in WO2013035779A1 A IN O
an WO2013035779A1 A DT O
other WO2013035779A1 A JJ O
individual WO2013035779A1 A NN O
other WO2013035779A1 A JJ O
than WO2013035779A1 A IN O
said WO2013035779A1 A VBD O
one WO2013035779A1 A CD O
individual WO2013035779A1 A NN O
, WO2013035779A1 A , O
the WO2013035779A1 A DT O
expression WO2013035779A1 A NN O
level WO2013035779A1 A NN O
of WO2013035779A1 A IN O
the WO2013035779A1 A DT O
gene WO2013035779A1 A NN O
encoding WO2013035779A1 A VBG O
the WO2013035779A1 A DT O
other WO2013035779A1 A JJ O
of WO2013035779A1 A IN O
the WO2013035779A1 A DT O
proteins WO2013035779A1 A NNS O
is WO2013035779A1 A VBZ O
higher WO2013035779A1 A JJR O
than WO2013035779A1 A IN O
in WO2013035779A1 A IN O
other WO2013035779A1 A JJ O
individuals WO2013035779A1 A NNS O
, WO2013035779A1 A , O
then WO2013035779A1 A RB O
the WO2013035779A1 A DT O
interaction WO2013035779A1 A NN O
resulting WO2013035779A1 A VBG O
from WO2013035779A1 A IN O
said WO2013035779A1 A VBD O
protein WO2013035779A1 A JJ O
combination WO2013035779A1 A NN O
is WO2013035779A1 A VBZ O
estimated WO2013035779A1 A VBN O
, WO2013035779A1 A , O
on WO2013035779A1 A IN O
the WO2013035779A1 A DT O
basis WO2013035779A1 A NN O
of WO2013035779A1 A IN O
the WO2013035779A1 A DT O
expression WO2013035779A1 A NN O
profiles WO2013035779A1 A NNS O
, WO2013035779A1 A , O
to WO2013035779A1 A TO O
be WO2013035779A1 A VB O
a WO2013035779A1 A DT O
more WO2013035779A1 A RBR O
significant WO2013035779A1 A JJ O
interaction WO2013035779A1 A NN O
between WO2013035779A1 A IN O
said WO2013035779A1 A VBD O
cells WO2013035779A1 A NNS O
which WO2013035779A1 A WDT O
are WO2013035779A1 A VBP O
derived WO2013035779A1 A VBN O
from WO2013035779A1 A IN O
the WO2013035779A1 A DT O
two WO2013035779A1 A CD O
or WO2013035779A1 A CC O
more WO2013035779A1 A JJR O
individuals WO2013035779A1 A NNS O
. WO2013035779A1 A . O

Substituted US7462617 T VBN O
acylpiperazine US7462617 T JJ O
derivatives US7462617 T NNS O
. US7462617 T . O

Cannabinoid EP1768667A1 T NNP I-UN
receptor EP1768667A1 T NN I-UN
ligands EP1768667A1 T NNS O
. EP1768667A1 T . O

Flunarizine CN1562028A T NNP O
hydrochoride CN1562028A T NN O
injection CN1562028A T NN O
and CN1562028A T CC O
preparing CN1562028A T VBG O
method CN1562028A T NN O
. CN1562028A T . O

An CN1562028A A DT O
injection CN1562028A A NN O
of CN1562028A A IN O
fluarizine CN1562028A A JJ O
hydrochloride CN1562028A A NN O
as CN1562028A A IN O
a CN1562028A A DT O
Ca CN1562028A A NNP I-UN
channel CN1562028A A NN I-UN
blocker CN1562028A A NN O
for CN1562028A A IN O
preventing CN1562028A A VBG O
cell CN1562028A A NN O
injury CN1562028A A NN O
caused CN1562028A A VBN O
by CN1562028A A IN O
ischemia CN1562028A A NN O
, CN1562028A A , O
relaxing CN1562028A A VBG O
vascular CN1562028A A JJ O
spasm CN1562028A A NN O
, CN1562028A A , O
suppressing CN1562028A A VBG O
vestibule CN1562028A A NN O
, CN1562028A A , O
preventing CN1562028A A VBG O
and CN1562028A A CC O
treating CN1562028A A VBG O
epilepsy CN1562028A A NN O
, CN1562028A A , O
protecting CN1562028A A VBG O
heart CN1562028A A NN O
and CN1562028A A CC O
kidney CN1562028A A NN O
, CN1562028A A , O
etc CN1562028A A FW O
and CN1562028A A CC O
its CN1562028A A PRP$ O
preparing CN1562028A A NN O
process CN1562028A A NN O
are CN1562028A A VBP O
disclosed CN1562028A A VBN O
. CN1562028A A . O

A US20050192236 T DT O
substantially US20050192236 T RB O
crystalline US20050192236 T JJ O
clindamycin US20050192236 T NN O
free US20050192236 T JJ O
base US20050192236 T NN O
of US20050192236 T IN O
three US20050192236 T CD O
polymorphic/pseudopolymorphic US20050192236 T JJ O
forms US20050192236 T NNS O
; US20050192236 T : O
water US20050192236 T NN O
insoluble US20050192236 T JJ O
so US20050192236 T RB O
useful US20050192236 T JJ O
for US20050192236 T IN O
sustained US20050192236 T JJ O
release US20050192236 T NN O
formulations US20050192236 T NNS O
; US20050192236 T : O
storage US20050192236 T NN O
stability US20050192236 T NN O
; US20050192236 T : O
powder US20050192236 T CC O
x-ray US20050192236 T JJ O
diffraction US20050192236 T NN O
; US20050192236 T : O
differential US20050192236 T JJ O
scanning US20050192236 T NN O
calorimetry US20050192236 T NN O
; US20050192236 T : O
bactericides US20050192236 T NNS O
. US20050192236 T . O

Diazaspiroalkane WO2010123018A1 T NNP O
derivative WO2010123018A1 T NN O
. WO2010123018A1 T . O

Disclosed WO2010123018A1 A VBN O
is WO2010123018A1 A VBZ O
a WO2010123018A1 A DT O
diazaspiroalkane WO2010123018A1 A NN O
derivative WO2010123018A1 A NN O
represented WO2010123018A1 A VBN O
by WO2010123018A1 A IN O
general WO2010123018A1 A JJ O
formula WO2010123018A1 A NN O
( WO2010123018A1 A ( O
II WO2010123018A1 A NNP O
) WO2010123018A1 A ) O
[ WO2010123018A1 A VBP O
wherein WO2010123018A1 A JJ O
R11 WO2010123018A1 A NNP O
, WO2010123018A1 A , O
R12 WO2010123018A1 A NNP O
and WO2010123018A1 A CC O
R13 WO2010123018A1 A NNP O
independently WO2010123018A1 A RB O
represent WO2010123018A1 A VBP O
a WO2010123018A1 A DT O
hydrogen WO2010123018A1 A NN O
atom WO2010123018A1 A NN O
, WO2010123018A1 A , O
a WO2010123018A1 A DT O
halogen WO2010123018A1 A NN O
atom WO2010123018A1 A NN O
, WO2010123018A1 A , O
a WO2010123018A1 A DT O
C1-8 WO2010123018A1 A NNP O
alkyl WO2010123018A1 A NN O
group WO2010123018A1 A NN O
, WO2010123018A1 A , O
a WO2010123018A1 A DT O
C1-8 WO2010123018A1 A NNP O
alkoxy WO2010123018A1 A NN O
group WO2010123018A1 A NN O
, WO2010123018A1 A , O
a WO2010123018A1 A DT O
C1-8 WO2010123018A1 A NNP O
alkyl WO2010123018A1 A NN O
group WO2010123018A1 A NN O
which WO2010123018A1 A WDT O
is WO2010123018A1 A VBZ O
substituted WO2010123018A1 A VBN O
by WO2010123018A1 A IN O
1 WO2010123018A1 A CD O
to WO2010123018A1 A TO O
3 WO2010123018A1 A CD O
halogen WO2010123018A1 A NN O
atoms WO2010123018A1 A NNS O
, WO2010123018A1 A , O
a WO2010123018A1 A DT O
C1-8 WO2010123018A1 A NNP O
alkylsulfonyl WO2010123018A1 A NN O
group WO2010123018A1 A NN O
, WO2010123018A1 A , O
or WO2010123018A1 A CC O
the WO2010123018A1 A DT O
like WO2010123018A1 A JJ O
; WO2010123018A1 A : O
T1 WO2010123018A1 A NNP O
, WO2010123018A1 A , O
U1 WO2010123018A1 A NNP O
, WO2010123018A1 A , O
V1 WO2010123018A1 A NNP O
and WO2010123018A1 A CC O
W1 WO2010123018A1 A NNP O
independently WO2010123018A1 A RB O
represent WO2010123018A1 A VBP O
a WO2010123018A1 A DT O
bond WO2010123018A1 A NN O
or WO2010123018A1 A CC O
a WO2010123018A1 A DT O
C1-5 WO2010123018A1 A JJ O
alkylene WO2010123018A1 A NN O
group WO2010123018A1 A NN O
which WO2010123018A1 A WDT O
may WO2010123018A1 A MD O
have WO2010123018A1 A VB O
a WO2010123018A1 A DT O
substituent WO2010123018A1 A NN O
; WO2010123018A1 A : O
B1 WO2010123018A1 A NNP O
represents WO2010123018A1 A VBZ O
C WO2010123018A1 A NNP O
( WO2010123018A1 A ( O
=O WO2010123018A1 A NNP O
) WO2010123018A1 A ) O
, WO2010123018A1 A , O
a WO2010123018A1 A DT O
C1-5 WO2010123018A1 A NNP O
alkylene WO2010123018A1 A NN O
group WO2010123018A1 A NN O
which WO2010123018A1 A WDT O
may WO2010123018A1 A MD O
have WO2010123018A1 A VB O
a WO2010123018A1 A DT O
substituent WO2010123018A1 A NN O
, WO2010123018A1 A , O
or WO2010123018A1 A CC O
the WO2010123018A1 A DT O
like WO2010123018A1 A JJ O
; WO2010123018A1 A : O
Y1 WO2010123018A1 A NNP O
and WO2010123018A1 A CC O
Z1 WO2010123018A1 A NNP O
independently WO2010123018A1 A RB O
represent WO2010123018A1 A VBP O
a WO2010123018A1 A DT O
C1-3 WO2010123018A1 A NNP O
alkylene WO2010123018A1 A NN O
group WO2010123018A1 A NN O
which WO2010123018A1 A WDT O
may WO2010123018A1 A MD O
have WO2010123018A1 A VB O
a WO2010123018A1 A DT O
substituent WO2010123018A1 A NN O
; WO2010123018A1 A : O
and WO2010123018A1 A CC O
R WO2010123018A1 A NNP O
represents WO2010123018A1 A VBZ O
a WO2010123018A1 A DT O
C1-8 WO2010123018A1 A JJ O
alkyl WO2010123018A1 A NN O
group WO2010123018A1 A NN O
, WO2010123018A1 A , O
or WO2010123018A1 A CC O
the WO2010123018A1 A DT O
like WO2010123018A1 A JJ O
] WO2010123018A1 A NNP O
, WO2010123018A1 A , O
which WO2010123018A1 A WDT O
is WO2010123018A1 A VBZ O
a WO2010123018A1 A DT O
GPR119 WO2010123018A1 A NNP I-UN
agonist WO2010123018A1 A NN O
, WO2010123018A1 A , O
or WO2010123018A1 A CC O
a WO2010123018A1 A DT O
pharmaceutically WO2010123018A1 A RB O
acceptable WO2010123018A1 A JJ O
salt WO2010123018A1 A NN O
thereof WO2010123018A1 A NN O
. WO2010123018A1 A . O

Purified US20120142621 T NNP O
Ethyl US20120142621 T NNP O
Ester US20120142621 T NNP O
Sophorolipid US20120142621 T NNP O
for US20120142621 T IN O
the US20120142621 T DT O
Treatment US20120142621 T NNP O
of US20120142621 T IN O
Sepsis US20120142621 T NNP O
. US20120142621 T . O

T US8153610 T NNP O
cell US8153610 T NN O
clones US8153610 T NNS O
; US8153610 T : O
drug US8153610 T NN O
screening US8153610 T NN O
. US8153610 T . O

Arylthioacetamide US20080293721 T NNP O
carboxylate US20080293721 T NN O
derivatives US20080293721 T NNS O
as US20080293721 T IN O
fkbp US20080293721 T JJ I-UN
inhibitors US20080293721 T NNS O
for US20080293721 T IN O
the US20080293721 T DT O
treatment US20080293721 T NN O
of US20080293721 T IN O
neurological US20080293721 T JJ O
diseases US20080293721 T NNS O
. US20080293721 T . O

Use WO2010007034A1 T NNP O
of WO2010007034A1 T IN O
pyrimidylaminobenzamide WO2010007034A1 T NN O
derivatives WO2010007034A1 T NNS O
for WO2010007034A1 T IN O
the WO2010007034A1 T DT O
treatment WO2010007034A1 T NN O
of WO2010007034A1 T IN O
fibrosis WO2010007034A1 T NN O
. WO2010007034A1 T . O

The WO2010007034A1 A DT O
invention WO2010007034A1 A NN O
relates WO2010007034A1 A VBZ O
to WO2010007034A1 A TO O
the WO2010007034A1 A DT O
use WO2010007034A1 A NN O
of WO2010007034A1 A IN O
a WO2010007034A1 A DT O
pyrimidylaminobenzamides WO2010007034A1 A NNS O
of WO2010007034A1 A IN O
formula WO2010007034A1 A NN O
( WO2010007034A1 A ( O
I WO2010007034A1 A PRP O
) WO2010007034A1 A ) O
wherein WO2010007034A1 A VBP O
the WO2010007034A1 A DT O
radicals WO2010007034A1 A NNS O
have WO2010007034A1 A VBP O
the WO2010007034A1 A DT O
meanings WO2010007034A1 A NNS O
as WO2010007034A1 A IN O
defined WO2010007034A1 A JJ O
herein WO2010007034A1 A NN O
, WO2010007034A1 A , O
or WO2010007034A1 A CC O
of WO2010007034A1 A IN O
a WO2010007034A1 A DT O
pharmaceutically WO2010007034A1 A RB O
acceptable WO2010007034A1 A JJ O
salt WO2010007034A1 A NN O
thereof WO2010007034A1 A NN O
for WO2010007034A1 A IN O
the WO2010007034A1 A DT O
manufacture WO2010007034A1 A NN O
of WO2010007034A1 A IN O
pharmaceutical WO2010007034A1 A JJ O
compositions WO2010007034A1 A NNS O
for WO2010007034A1 A IN O
use WO2010007034A1 A NN O
in WO2010007034A1 A IN O
the WO2010007034A1 A DT O
treatment WO2010007034A1 A NN O
of WO2010007034A1 A IN O
fibrosis WO2010007034A1 A NN O
, WO2010007034A1 A , O
to WO2010007034A1 A TO O
the WO2010007034A1 A DT O
use WO2010007034A1 A NN O
of WO2010007034A1 A IN O
a WO2010007034A1 A DT O
pyrimidylaminobenzamides WO2010007034A1 A NNS O
of WO2010007034A1 A IN O
formula WO2010007034A1 A NN O
( WO2010007034A1 A ( O
I WO2010007034A1 A PRP O
) WO2010007034A1 A ) O
or WO2010007034A1 A CC O
pharmaceutically WO2010007034A1 A RB O
acceptable WO2010007034A1 A JJ O
salt WO2010007034A1 A NN O
thereof WO2010007034A1 A NN O
in WO2010007034A1 A IN O
the WO2010007034A1 A DT O
treatment WO2010007034A1 A NN O
of WO2010007034A1 A IN O
fibrosis WO2010007034A1 A NN O
, WO2010007034A1 A , O
to WO2010007034A1 A TO O
a WO2010007034A1 A DT O
method WO2010007034A1 A NN O
of WO2010007034A1 A IN O
treating WO2010007034A1 A VBG O
warm-blooded WO2010007034A1 A JJ O
animals WO2010007034A1 A NNS O
including WO2010007034A1 A VBG O
humans WO2010007034A1 A NNS O
suffering WO2010007034A1 A VBG O
from WO2010007034A1 A IN O
fibrosis WO2010007034A1 A NN O
by WO2010007034A1 A IN O
administering WO2010007034A1 A VBG O
to WO2010007034A1 A TO O
a WO2010007034A1 A DT O
said WO2010007034A1 A VBD O
animal WO2010007034A1 A NN O
in WO2010007034A1 A IN O
need WO2010007034A1 A NN O
of WO2010007034A1 A IN O
such WO2010007034A1 A JJ O
treatment WO2010007034A1 A NN O
an WO2010007034A1 A DT O
effective WO2010007034A1 A JJ O
dose WO2010007034A1 A NN O
of WO2010007034A1 A IN O
a WO2010007034A1 A DT O
pyrimidyl- WO2010007034A1 A JJ O
aminobenzamide WO2010007034A1 A NN O
of WO2010007034A1 A IN O
formula WO2010007034A1 A NN O
I WO2010007034A1 A PRP O
or WO2010007034A1 A CC O
a WO2010007034A1 A DT O
pharmaceutically WO2010007034A1 A RB O
acceptable WO2010007034A1 A JJ O
salt WO2010007034A1 A NN O
thereof WO2010007034A1 A NN O
, WO2010007034A1 A , O
and WO2010007034A1 A CC O
to WO2010007034A1 A TO O
combinationscomprising WO2010007034A1 A VBG O
( WO2010007034A1 A ( O
a WO2010007034A1 A DT O
) WO2010007034A1 A ) O
at WO2010007034A1 A IN O
least WO2010007034A1 A JJS O
one WO2010007034A1 A CD O
pyrimidylaminobenzamides WO2010007034A1 A NNS O
of WO2010007034A1 A IN O
formula WO2010007034A1 A NN O
( WO2010007034A1 A ( O
I WO2010007034A1 A PRP O
) WO2010007034A1 A ) O
as WO2010007034A1 A IN O
and WO2010007034A1 A CC O
( WO2010007034A1 A ( O
b WO2010007034A1 A NN O
) WO2010007034A1 A ) O
at WO2010007034A1 A IN O
least WO2010007034A1 A JJS O
one WO2010007034A1 A CD O
compound WO2010007034A1 A NN O
selected WO2010007034A1 A VBD O
form WO2010007034A1 A JJ O
AT1-receptor WO2010007034A1 A NNP I-UN
antagonists WO2010007034A1 A NNS O
and WO2010007034A1 A CC O
ACE WO2010007034A1 A NNP I-UN
inhibitors WO2010007034A1 A NNS O
and WO2010007034A1 A CC O
the WO2010007034A1 A DT O
use WO2010007034A1 A NN O
of WO2010007034A1 A IN O
such WO2010007034A1 A JJ O
combinations WO2010007034A1 A NNS O
in WO2010007034A1 A IN O
the WO2010007034A1 A DT O
treatment WO2010007034A1 A NN O
of WO2010007034A1 A IN O
fibrosis WO2010007034A1 A NN O
, WO2010007034A1 A , O
in WO2010007034A1 A IN O
particular WO2010007034A1 A JJ O
hepatic WO2010007034A1 A JJ O
fibrosis WO2010007034A1 A NN O
. WO2010007034A1 A . O

Myricitrin WO2005115547A2 T NNP O
compounds WO2005115547A2 T NNS O
for WO2005115547A2 T IN O
sleeping WO2005115547A2 T VBG O
disorders WO2005115547A2 T NNS O
. WO2005115547A2 T . O

Methods US20120289476 T NNS O
for US20120289476 T IN O
treating US20120289476 T VBG O
methylmalonic US20120289476 T JJ O
acidemia US20120289476 T NN O
. US20120289476 T . O

Methods US20120289476 A NNS O
for US20120289476 A IN O
treating US20120289476 A VBG O
methylmalonic US20120289476 A JJ O
acidemia US20120289476 A NN O
in US20120289476 A IN O
which US20120289476 A WDT O
at US20120289476 A IN O
least US20120289476 A JJS O
one US20120289476 A CD O
allele US20120289476 A NN O
of US20120289476 A IN O
a US20120289476 A DT O
gene US20120289476 A NN O
associated US20120289476 A VBN O
with US20120289476 A IN O
MMA US20120289476 A NNP O
( US20120289476 A ( O
e.g. US20120289476 A NN O
, US20120289476 A , O
the US20120289476 A DT O
MUT US20120289476 A NNP I-UN
, US20120289476 A , O
MMAA US20120289476 A NNP I-UN
, US20120289476 A , O
or US20120289476 A CC O
MMAB US20120289476 A NNP I-UN
gene US20120289476 A NN O
) US20120289476 A ) O
contains US20120289476 A VBZ O
a US20120289476 A DT O
mutation US20120289476 A NN O
( US20120289476 A ( O
e.g. US20120289476 A JJ O
, US20120289476 A , O
nonsense US20120289476 A JJ O
mutation US20120289476 A NN O
) US20120289476 A ) O
that US20120289476 A WDT O
results US20120289476 A NNS O
in US20120289476 A IN O
a US20120289476 A DT O
premature US20120289476 A NN O
stop US20120289476 A NN O
codon US20120289476 A NN O
in US20120289476 A IN O
RNA US20120289476 A NNP O
encoded US20120289476 A VBN O
by US20120289476 A IN O
an US20120289476 A DT O
allele US20120289476 A NN O
of US20120289476 A IN O
the US20120289476 A DT O
gene US20120289476 A NN O
associated US20120289476 A VBN O
with US20120289476 A IN O
MMA US20120289476 A NNP O
involving US20120289476 A VBG O
the US20120289476 A DT O
administration US20120289476 A NN O
of US20120289476 A IN O
a US20120289476 A DT O
compound US20120289476 A NN O
that US20120289476 A WDT O
promotes US20120289476 A VBZ O
readthrough US20120289476 A IN O
of US20120289476 A IN O
RNA US20120289476 A NNP O
( US20120289476 A ( O
e.g. US20120289476 A NN O
, US20120289476 A , O
messenger US20120289476 A JJR O
RNA US20120289476 A NNP O
) US20120289476 A ) O
containing US20120289476 A VBG O
a US20120289476 A DT O
premature US20120289476 A NN O
stop US20120289476 A NN O
codon US20120289476 A NN O
encoded US20120289476 A VBN O
by US20120289476 A IN O
an US20120289476 A DT O
allele US20120289476 A NN O
of US20120289476 A IN O
the US20120289476 A DT O
gene US20120289476 A NN O
associated US20120289476 A VBN O
with US20120289476 A IN O
MMA US20120289476 A NNP O
are US20120289476 A VBP O
described US20120289476 A VBN O
. US20120289476 A . O

Use US20120172450 T NNP O
of US20120172450 T IN O
jasmonate US20120172450 T NN O
for US20120172450 T IN O
improving US20120172450 T VBG O
skeletal US20120172450 T JJ O
muscle US20120172450 T NN O
function US20120172450 T NN O
. US20120172450 T . O

Especially US20080275052 T RB O
p38 US20080275052 T JJ O
MAP US20080275052 T NNP O
kinase US20080275052 T NN O
alpha US20080275052 T NN O
and US20080275052 T CC O
beta US20080275052 T NN O
; US20080275052 T : O
2,4-difluorophenyl US20080275052 T JJ O
( US20080275052 T ( O
3- US20080275052 T JJ O
( US20080275052 T ( O
2- US20080275052 T JJ O
( US20080275052 T ( O
trifluoromethyl US20080275052 T NN O
) US20080275052 T ) O
phenyl US20080275052 T NN O
) US20080275052 T ) O
-5,6-dihydroimidazo US20080275052 T VBZ O
[ US20080275052 T JJ O
1,5-a US20080275052 T JJ O
] US20080275052 T NN O
pyrazin-7 US20080275052 T NN O
( US20080275052 T ( O
8H US20080275052 T CD O
) US20080275052 T ) O
-yl US20080275052 T NN O
) US20080275052 T ) O
methanone US20080275052 T NN O
. US20080275052 T . O

Enteric-coated CN103550182A T JJ O
sustained CN103550182A T VBD O
release CN103550182A T NN O
composition CN103550182A T NN O
. CN103550182A T . O

Dihydroquinazolinone WO2014154762A1 T NN O
analogues WO2014154762A1 T NNS O
as WO2014154762A1 T IN O
brd4 WO2014154762A1 T NN I-UN
inhibitors WO2014154762A1 T NNS O
. WO2014154762A1 T . O

Polycyclic US20100009991 T NNP O
acid US20100009991 T VBZ O
compounds US20100009991 T NNS O
useful US20100009991 T JJ O
as US20100009991 T IN O
crth2 US20100009991 T NN I-UN
antagonists US20100009991 T NNS O
and US20100009991 T CC O
antiallergic US20100009991 T JJ O
agents US20100009991 T NNS O
. US20100009991 T . O

The US20100009991 A DT O
present US20100009991 A JJ O
invention US20100009991 A NN O
relates US20100009991 A VBZ O
to US20100009991 A TO O
a US20100009991 A DT O
novel US20100009991 A JJ O
compound US20100009991 A NN O
or US20100009991 A CC O
a US20100009991 A DT O
salt US20100009991 A NN O
thereof US20100009991 A NN O
, US20100009991 A , O
which US20100009991 A WDT O
is US20100009991 A VBZ O
useful US20100009991 A JJ O
as US20100009991 A IN O
a US20100009991 A DT O
CRTH2 US20100009991 A NNP I-UN
antagonist US20100009991 A NN O
, US20100009991 A , O
especially US20100009991 A RB O
as US20100009991 A IN O
a US20100009991 A DT O
medicament US20100009991 A NN O
for US20100009991 A IN O
disorder US20100009991 A NN O
that US20100009991 A WDT O
participates US20100009991 A VBZ O
eosinophil US20100009991 A RB O
, US20100009991 A , O
for US20100009991 A IN O
example US20100009991 A NN O
, US20100009991 A , O
allergic US20100009991 A JJ O
disorder US20100009991 A NN O
such US20100009991 A JJ O
as US20100009991 A IN O
asthma US20100009991 A NN O
, US20100009991 A , O
allergic US20100009991 A JJ O
rhinitis US20100009991 A NN O
, US20100009991 A , O
allergic US20100009991 A JJ O
dermatitis US20100009991 A NN O
, US20100009991 A , O
conjunctival US20100009991 A JJ O
inflammation US20100009991 A NN O
, US20100009991 A , O
hives US20100009991 A NNS O
, US20100009991 A , O
eosinophilic US20100009991 A JJ O
bronchitis US20100009991 A NN O
, US20100009991 A , O
food US20100009991 A NN O
allergy US20100009991 A NN O
, US20100009991 A , O
inflammation US20100009991 A NN O
of US20100009991 A IN O
the US20100009991 A DT O
nasal US20100009991 A NN O
sinuses US20100009991 A VBZ O
, US20100009991 A , O
multiple US20100009991 A JJ O
sclerosis US20100009991 A NN O
, US20100009991 A , O
angiitis US20100009991 A NN O
, US20100009991 A , O
or US20100009991 A CC O
chronic US20100009991 A JJ O
obstructive US20100009991 A JJ O
pulmonary US20100009991 A JJ O
disease US20100009991 A NN O
( US20100009991 A ( O
COPD US20100009991 A NNP O
) US20100009991 A ) O
and US20100009991 A CC O
the US20100009991 A DT O
like US20100009991 A JJ O
. US20100009991 A . O

Medicament CN101297868A T NN O
for CN101297868A T IN O
preventing CN101297868A T VBG O
and CN101297868A T CC O
treating CN101297868A T VBG O
osteoporosis CN101297868A T NN O
and CN101297868A T CC O
preparation CN101297868A T NN O
thereof CN101297868A T NN O
. CN101297868A T . O

Externally CN102151298A T RB O
applied CN102151298A T VBN O
preparation CN102151298A T NN O
for CN102151298A T IN O
relieving CN102151298A T VBG O
pain CN102151298A T NN O
and CN102151298A T CC O
diminishing CN102151298A T VBG O
inflammation CN102151298A T NN O
, CN102151298A T , O
preparation CN102151298A T NN O
method CN102151298A T NN O
and CN102151298A T CC O
detection CN102151298A T NN O
method CN102151298A T NN O
thereof CN102151298A T NN O
. CN102151298A T . O

Medicinal CN101669898A T JJ O
preparation CN101669898A T NN O
for CN101669898A T IN O
injective CN101669898A T JJ O
administration CN101669898A T NN O
and CN101669898A T CC O
preparation CN101669898A T NN O
method CN101669898A T NN O
thereof CN101669898A T NN O
. CN101669898A T . O

The CN101669898A A DT O
invention CN101669898A A NN O
provides CN101669898A A VBZ O
a CN101669898A A DT O
medicinal CN101669898A A JJ O
preparation CN101669898A A NN O
for CN101669898A A IN O
injective CN101669898A A JJ O
administration CN101669898A A NN O
and CN101669898A A CC O
a CN101669898A A DT O
preparation CN101669898A A NN O
method CN101669898A A NN O
thereof CN101669898A A NN O
. CN101669898A A . O

The CN101669898A A DT O
medicinal CN101669898A A JJ O
preparation CN101669898A A NN O
comprises CN101669898A A NNS O
anastrozole CN101669898A A JJ O
and CN101669898A A CC O
solubilizer CN101669898A A NN O
, CN101669898A A , O
and CN101669898A A CC O
has CN101669898A A VBZ O
the CN101669898A A DT O
advantages CN101669898A A NNS O
that CN101669898A A WDT O
: CN101669898A A : O
( CN101669898A A ( O
1 CN101669898A A CD O
) CN101669898A A ) O
the CN101669898A A DT O
preparation CN101669898A A NN O
successfully CN101669898A A RB O
solves CN101669898A A VBZ O
the CN101669898A A DT O
technical CN101669898A A JJ O
problem CN101669898A A NN O
that CN101669898A A IN O
the CN101669898A A DT O
anastrozole CN101669898A A NN O
is CN101669898A A VBZ O
insoluble CN101669898A A JJ O
in CN101669898A A IN O
water CN101669898A A NN O
and CN101669898A A CC O
is CN101669898A A VBZ O
not CN101669898A A RB O
suitable CN101669898A A JJ O
to CN101669898A A TO O
be CN101669898A A VB O
prepared CN101669898A A VBN O
into CN101669898A A IN O
injection CN101669898A A NN O
in CN101669898A A IN O
the CN101669898A A DT O
prior CN101669898A A JJ O
art CN101669898A A NN O
, CN101669898A A , O
and CN101669898A A CC O
greatly CN101669898A A RB O
improves CN101669898A A VBZ O
the CN101669898A A DT O
bioavailability CN101669898A A NN O
of CN101669898A A IN O
the CN101669898A A DT O
anastrozole CN101669898A A NN O
while CN101669898A A IN O
overcoming CN101669898A A VBG O
the CN101669898A A DT O
defect CN101669898A A NN O
that CN101669898A A WDT O
anastrozole CN101669898A A JJ O
tablets CN101669898A A NNS O
irritate CN101669898A A VBP O
gastrointestinal CN101669898A A JJ O
tract CN101669898A A NN O
, CN101669898A A , O
so CN101669898A A IN O
that CN101669898A A IN O
the CN101669898A A DT O
preparation CN101669898A A NN O
is CN101669898A A VBZ O
more CN101669898A A RBR O
effective CN101669898A A JJ O
for CN101669898A A IN O
treating CN101669898A A VBG O
woman CN101669898A A NN O
advanced CN101669898A A VBD O
breastcancer CN101669898A A NN O
; CN101669898A A : O
( CN101669898A A ( O
2 CN101669898A A CD O
) CN101669898A A ) O
the CN101669898A A DT O
medicinal CN101669898A A JJ O
preparation CN101669898A A NN O
has CN101669898A A VBZ O
stable CN101669898A A JJ O
property CN101669898A A NN O
and CN101669898A A CC O
non CN101669898A A JJ O
pollution CN101669898A A NN O
to CN101669898A A TO O
light CN101669898A A NN O
, CN101669898A A , O
heat CN101669898A A NN O
, CN101669898A A , O
oxygen CN101669898A A NN O
, CN101669898A A , O
water CN101669898A A NN O
and CN101669898A A CC O
the CN101669898A A DT O
like CN101669898A A JJ O
, CN101669898A A , O
is CN101669898A A VBZ O
convenient CN101669898A A JJ O
for CN101669898A A IN O
preparation CN101669898A A NN O
, CN101669898A A , O
transportation CN101669898A A NN O
and CN101669898A A CC O
storage CN101669898A A NN O
, CN101669898A A , O
and CN101669898A A CC O
is CN101669898A A VBZ O
suitable CN101669898A A JJ O
for CN101669898A A IN O
mass CN101669898A A NN O
production CN101669898A A NN O
; CN101669898A A : O
( CN101669898A A ( O
3 CN101669898A A CD O
) CN101669898A A ) O
freeze-dried CN101669898A A JJ O
powder CN101669898A A NN O
injection CN101669898A A NN O
solves CN101669898A A VBZ O
the CN101669898A A DT O
problem CN101669898A A NN O
of CN101669898A A IN O
transportation CN101669898A A NN O
and CN101669898A A CC O
storage CN101669898A A NN O
in CN101669898A A IN O
winter CN101669898A A NN O
in CN101669898A A IN O
northern CN101669898A A JJ O
and CN101669898A A CC O
severe CN101669898A A JJ O
cold CN101669898A A JJ O
areas CN101669898A A NNS O
, CN101669898A A , O
reduces CN101669898A A NNS O
volume CN101669898A A NN O
and CN101669898A A CC O
weight CN101669898A A NN O
of CN101669898A A IN O
products CN101669898A A NNS O
with CN101669898A A IN O
the CN101669898A A DT O
same CN101669898A A JJ O
dosage CN101669898A A NN O
and CN101669898A A CC O
greatly CN101669898A A RB O
reduces CN101669898A A NNS O
transportation CN101669898A A NN O
cost CN101669898A A NN O
in CN101669898A A IN O
an CN101669898A A DT O
operating CN101669898A A NN O
process CN101669898A A NN O
; CN101669898A A : O
and CN101669898A A CC O
( CN101669898A A ( O
4 CN101669898A A CD O
) CN101669898A A ) O
the CN101669898A A DT O
injection CN101669898A A NN O
and CN101669898A A CC O
infusion CN101669898A A NN O
can CN101669898A A MD O
effectively CN101669898A A RB O
prevent CN101669898A A VB O
pollution CN101669898A A NN O
in CN101669898A A IN O
a CN101669898A A DT O
dispensing CN101669898A A NN O
process CN101669898A A NN O
. CN101669898A A . O

Compositions US20100286023 T NNS O
and US20100286023 T CC O
Methods US20100286023 T NNS O
for US20100286023 T IN O
Increasing US20100286023 T VBG O
Muscle US20100286023 T NNP O
Mass US20100286023 T NNP O
, US20100286023 T , O
Strength US20100286023 T NNP O
, US20100286023 T , O
and US20100286023 T CC O
Functional US20100286023 T NNP O
Performance US20100286023 T NNP O
in US20100286023 T IN O
the US20100286023 T DT O
Elderly US20100286023 T NNP O
. US20100286023 T . O

Treatment EP1785142A1 T NN O
of EP1785142A1 T IN O
chronic EP1785142A1 T JJ O
kidney EP1785142A1 T NN O
disease EP1785142A1 T NN O
( EP1785142A1 T ( O
CKD EP1785142A1 T NNP O
) EP1785142A1 T ) O
subjects EP1785142A1 T VBZ O
using EP1785142A1 T VBG O
lanthanum EP1785142A1 T JJ O
compounds EP1785142A1 T NNS O
. EP1785142A1 T . O

Once-a-week US8759328 T JJ O
administration US8759328 T NN O
of US8759328 T IN O
25-hydroxy US8759328 T JJ O
vitamin US8759328 T NN O
D3 US8759328 T NNP O
to US8759328 T TO O
sustain US8759328 T VB O
elevated US8759328 T JJ O
steady-state US8759328 T JJ O
pharmacokinetic US8759328 T JJ O
blood US8759328 T NN O
concentration US8759328 T NN O
. US8759328 T . O

Formulation WO2013102234A1 T NN O
and WO2013102234A1 T CC O
method WO2013102234A1 T NN O
for WO2013102234A1 T IN O
treatment WO2013102234A1 T NN O
of WO2013102234A1 T IN O
pain WO2013102234A1 T NN O
and/or WO2013102234A1 T JJ O
inflammation WO2013102234A1 T NN O
associated WO2013102234A1 T VBN O
with WO2013102234A1 T IN O
a WO2013102234A1 T DT O
skin WO2013102234A1 T JJ O
condition WO2013102234A1 T NN O
. WO2013102234A1 T . O

Goose CN103284158A T NNP O
oil CN103284158A T NN O
diacylglycerol CN103284158A T NN O
microcapsules CN103284158A T NNS O
. CN103284158A T . O

Substituted US20080167322 T JJ O
Pyrazoles US20080167322 T NNP O
as US20080167322 T IN O
Modulators US20080167322 T NNP O
of US20080167322 T IN O
Chemokine US20080167322 T NNP I-UN
Receptors US20080167322 T NNP I-UN
. US20080167322 T . O

Substituted US20080167322 A VBN O
pyrazole US20080167322 A JJ O
compounds US20080167322 A NNS O
such US20080167322 A JJ O
compounds US20080167322 A NNS O
represented US20080167322 A VBN O
by US20080167322 A IN O
formula US20080167322 A NN O
I US20080167322 A PRP O
: US20080167322 A : O
which US20080167322 A WDT O
are US20080167322 A VBP O
used US20080167322 A VBN O
to US20080167322 A TO O
modulate US20080167322 A VB O
the US20080167322 A DT O
CCR-2 US20080167322 A NNP I-UN
chemokine US20080167322 A NN I-UN
receptor US20080167322 A NN I-UN
to US20080167322 A TO O
prevent US20080167322 A VB O
or US20080167322 A CC O
treat US20080167322 A VB O
inflammatory US20080167322 A JJ O
and US20080167322 A CC O
immunoregulatory US20080167322 A JJ O
disorders US20080167322 A NNS O
and US20080167322 A CC O
diseases US20080167322 A NNS O
, US20080167322 A , O
allergic US20080167322 A JJ O
diseases US20080167322 A NNS O
, US20080167322 A , O
atopic US20080167322 A NN O
conditions US20080167322 A NNS O
including US20080167322 A VBG O
allergic US20080167322 A JJ O
rhinitis US20080167322 A NN O
, US20080167322 A , O
dermatitis US20080167322 A NN O
, US20080167322 A , O
conjunctivitis US20080167322 A NN O
, US20080167322 A , O
and US20080167322 A CC O
asthma US20080167322 A RB O
, US20080167322 A , O
as US20080167322 A RB O
well US20080167322 A RB O
as US20080167322 A IN O
autoimmune US20080167322 A JJ O
pathologies US20080167322 A NNS O
such US20080167322 A JJ O
as US20080167322 A IN O
rheumatoid US20080167322 A JJ O
arthritis US20080167322 A NN O
and US20080167322 A CC O
atherosclerosis US20080167322 A NN O
; US20080167322 A : O
and US20080167322 A CC O
pharmaceutical US20080167322 A JJ O
compositions US20080167322 A NNS O
comprising US20080167322 A VBG O
these US20080167322 A DT O
compounds US20080167322 A NNS O
and US20080167322 A CC O
the US20080167322 A DT O
use US20080167322 A NN O
of US20080167322 A IN O
these US20080167322 A DT O
compounds US20080167322 A NNS O
and US20080167322 A CC O
compositions US20080167322 A NNS O
. US20080167322 A . O

Cyclohexyl EP1979322A1 T NNP O
sulfonamide EP1979322A1 T NN O
derivatives EP1979322A1 T NNS O
having EP1979322A1 T VBG O
h3 EP1979322A1 T JJ I-UN
receptor EP1979322A1 T NN I-UN
activity EP1979322A1 T NN O
. EP1979322A1 T . O

The EP1979322A1 A DT O
compounds EP1979322A1 A NNS O
are EP1979322A1 A VBP O
useful EP1979322A1 A JJ O
for EP1979322A1 A IN O
the EP1979322A1 A DT O
treatment EP1979322A1 A NN O
and/or EP1979322A1 A JJ O
prevention EP1979322A1 A NN O
of EP1979322A1 A IN O
diseases EP1979322A1 A NNS O
which EP1979322A1 A WDT O
are EP1979322A1 A VBP O
associated EP1979322A1 A VBN O
with EP1979322A1 A IN O
the EP1979322A1 A DT O
modulation EP1979322A1 A NN O
of EP1979322A1 A IN O
H3 EP1979322A1 A NNP I-UN
receptors EP1979322A1 A NNS I-UN
. EP1979322A1 A . O

Compounds CN101224220A T NNS O
for CN101224220A T IN O
strengthening CN101224220A T VBG O
organism CN101224220A T NN O
immunity CN101224220A T NN O
function CN101224220A T NN O
and CN101224220A T CC O
application CN101224220A T NN O
thereof CN101224220A T NN O
. CN101224220A T . O

Preparation CN101987830A T NNP O
method CN101987830A T NN O
and CN101987830A T CC O
preparation CN101987830A T NN O
of CN101987830A T IN O
water-soluble CN101987830A T JJ O
florfenicol CN101987830A T NN O
succinic CN101987830A T JJ O
acid CN101987830A T NN O
ester CN101987830A T NN O
. CN101987830A T . O

Pharmaceutical WO2013170972A1 T JJ O
composition WO2013170972A1 T NN O
comprising WO2013170972A1 T NN O
( WO2013170972A1 T ( O
1r,4r WO2013170972A1 T CD O
) WO2013170972A1 T ) O
-6'-fluoro-n WO2013170972A1 T NN O
, WO2013170972A1 T , O
n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro WO2013170972A1 T JJ O
[ WO2013170972A1 T JJ O
cyclohexane-1,1'-pyrano WO2013170972A1 T NN O
[ WO2013170972A1 T NN O
3,4 WO2013170972A1 T CD O
, WO2013170972A1 T , O
b WO2013170972A1 T NN O
] WO2013170972A1 T NNP O
indol WO2013170972A1 T NN O
] WO2013170972A1 T NNP O
-4-amine WO2013170972A1 T NNP O
and WO2013170972A1 T CC O
an WO2013170972A1 T DT O
anticonvulsant WO2013170972A1 T NN O
. WO2013170972A1 T . O

The WO2013170972A1 A DT O
invention WO2013170972A1 A NN O
relates WO2013170972A1 A VBZ O
to WO2013170972A1 A TO O
a WO2013170972A1 A DT O
pharmaceutical WO2013170972A1 A JJ O
composition WO2013170972A1 A NN O
comprising WO2013170972A1 A VBG O
a WO2013170972A1 A DT O
first WO2013170972A1 A JJ O
pharmacologically WO2013170972A1 A RB O
active WO2013170972A1 A JJ O
ingredient WO2013170972A1 A NN O
selected WO2013170972A1 A VBN O
from WO2013170972A1 A IN O
( WO2013170972A1 A ( O
1r,4r WO2013170972A1 A CD O
) WO2013170972A1 A ) O
-6'-fluoro-N WO2013170972A1 A NN O
, WO2013170972A1 A , O
N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro WO2013170972A1 A NNP O
[ WO2013170972A1 A NNP O
cyclohexane-1,1'-pyrano WO2013170972A1 A NN O
[ WO2013170972A1 A NN O
3,4 WO2013170972A1 A CD O
, WO2013170972A1 A , O
b WO2013170972A1 A NN O
] WO2013170972A1 A NNP O
indol WO2013170972A1 A NN O
] WO2013170972A1 A NNP O
-4-amine WO2013170972A1 A NN O
and WO2013170972A1 A CC O
the WO2013170972A1 A DT O
physiologically WO2013170972A1 A RB O
acceptable WO2013170972A1 A JJ O
salts WO2013170972A1 A NNS O
thereof WO2013170972A1 A NN O
, WO2013170972A1 A , O
and WO2013170972A1 A CC O
a WO2013170972A1 A DT O
second WO2013170972A1 A JJ O
pharmacologically WO2013170972A1 A RB O
active WO2013170972A1 A JJ O
ingredient WO2013170972A1 A NN O
which WO2013170972A1 A WDT O
is WO2013170972A1 A VBZ O
an WO2013170972A1 A DT O
anticonvulsant WO2013170972A1 A JJ O
selected WO2013170972A1 A VBN O
from WO2013170972A1 A IN O
the WO2013170972A1 A DT O
group WO2013170972A1 A NN O
consisting WO2013170972A1 A VBG O
of WO2013170972A1 A IN O
retigabin WO2013170972A1 A NN O
, WO2013170972A1 A , O
lamotrigine WO2013170972A1 A NN O
, WO2013170972A1 A , O
lacosamide WO2013170972A1 A RB O
, WO2013170972A1 A , O
levetiracetam WO2013170972A1 A NN O
, WO2013170972A1 A , O
carbamazepine WO2013170972A1 A NN O
, WO2013170972A1 A , O
sultiame WO2013170972A1 A NN O
, WO2013170972A1 A , O
phenacemide WO2013170972A1 A NN O
, WO2013170972A1 A , O
felbamate WO2013170972A1 A NN O
, WO2013170972A1 A , O
topiramate WO2013170972A1 A NN O
, WO2013170972A1 A , O
pheneturide WO2013170972A1 A NN O
, WO2013170972A1 A , O
brivaracetam WO2013170972A1 A NN O
, WO2013170972A1 A , O
selectracetam WO2013170972A1 A NN O
, WO2013170972A1 A , O
zonisamide WO2013170972A1 A NN O
, WO2013170972A1 A , O
stiripentol WO2013170972A1 A NN O
, WO2013170972A1 A , O
beclamide WO2013170972A1 A NN O
, WO2013170972A1 A , O
mexiletin WO2013170972A1 A NN O
, WO2013170972A1 A , O
ralfinamide WO2013170972A1 A NN O
, WO2013170972A1 A , O
methyl- WO2013170972A1 A JJ O
phenobarbital WO2013170972A1 A NN O
, WO2013170972A1 A , O
phenobarbital WO2013170972A1 A NN O
, WO2013170972A1 A , O
primidone WO2013170972A1 A NN O
, WO2013170972A1 A , O
barbexaclone WO2013170972A1 A NN O
, WO2013170972A1 A , O
metharbital WO2013170972A1 A NN O
, WO2013170972A1 A , O
ethotoin WO2013170972A1 A NN O
, WO2013170972A1 A , O
phenytoin WO2013170972A1 A NN O
, WO2013170972A1 A , O
amino WO2013170972A1 A NN O
( WO2013170972A1 A ( O
diphenylhydantoin WO2013170972A1 A NN O
) WO2013170972A1 A ) O
valeric WO2013170972A1 A NN O
acid WO2013170972A1 A NN O
, WO2013170972A1 A , O
mephenytoin WO2013170972A1 A NN O
, WO2013170972A1 A , O
fosphenytoin WO2013170972A1 A NN O
, WO2013170972A1 A , O
paramethadione WO2013170972A1 A NN O
, WO2013170972A1 A , O
trimethadione WO2013170972A1 A NN O
, WO2013170972A1 A , O
ethadione WO2013170972A1 A NN O
, WO2013170972A1 A , O
ethosuximide WO2013170972A1 A RB O
, WO2013170972A1 A , O
phensuximide WO2013170972A1 A NN O
, WO2013170972A1 A , O
mesuximide WO2013170972A1 A NN O
, WO2013170972A1 A , O
clonazepam WO2013170972A1 A NN O
, WO2013170972A1 A , O
lorazepam WO2013170972A1 A NN O
, WO2013170972A1 A , O
diazepam WO2013170972A1 A NN O
, WO2013170972A1 A , O
clobazam WO2013170972A1 A NN O
, WO2013170972A1 A , O
oxcarbazepine WO2013170972A1 A NN O
, WO2013170972A1 A , O
eslicarbazepine WO2013170972A1 A NN O
, WO2013170972A1 A , O
rufinamide WO2013170972A1 A NN O
, WO2013170972A1 A , O
valproic WO2013170972A1 A JJ O
acid WO2013170972A1 A NN O
, WO2013170972A1 A , O
valpromide WO2013170972A1 A NN O
, WO2013170972A1 A , O
aminobutyric WO2013170972A1 A JJ O
acid WO2013170972A1 A NN O
, WO2013170972A1 A , O
progabide WO2013170972A1 A NN O
, WO2013170972A1 A , O
tiagabine WO2013170972A1 A NN O
, WO2013170972A1 A , O
and WO2013170972A1 A CC O
the WO2013170972A1 A DT O
physiologically WO2013170972A1 A RB O
acceptable WO2013170972A1 A JJ O
salts WO2013170972A1 A NNS O
thereof WO2013170972A1 A NN O
. WO2013170972A1 A . O

Derivatives WO2010091067A3 T NNS O
of WO2010091067A3 T IN O
[ WO2010091067A3 T JJ O
1 WO2010091067A3 T CD O
, WO2010091067A3 T , O
3 WO2010091067A3 T CD O
] WO2010091067A3 T JJ O
oxazin- WO2010091067A3 T JJ O
2-one WO2010091067A3 T JJ O
useful WO2010091067A3 T NN O
for WO2010091067A3 T IN O
the WO2010091067A3 T DT O
treatment WO2010091067A3 T NN O
of WO2010091067A3 T IN O
metabolic WO2010091067A3 T JJ O
diseases WO2010091067A3 T NNS O
such WO2010091067A3 T JJ O
as WO2010091067A3 T IN O
lipid WO2010091067A3 T JJ O
disorders WO2010091067A3 T NNS O
. WO2010091067A3 T . O

This WO2010091067A3 A DT O
invention WO2010091067A3 A NN O
relates WO2010091067A3 A VBZ O
to WO2010091067A3 A TO O
novel WO2010091067A3 A VB O
compounds WO2010091067A3 A NNS O
of WO2010091067A3 A IN O
an WO2010091067A3 A DT O
11 WO2010091067A3 A CD I-UN
β-HSD1 WO2010091067A3 A JJ I-UN
inhibitor WO2010091067A3 A NN O
disclosed WO2010091067A3 A VBD O
herein WO2010091067A3 A NN O
, WO2010091067A3 A , O
pharmaceutically WO2010091067A3 A RB O
acceptable WO2010091067A3 A JJ O
salts WO2010091067A3 A NNS O
thereof WO2010091067A3 A NN O
, WO2010091067A3 A , O
and WO2010091067A3 A CC O
pharmaceutical WO2010091067A3 A JJ O
compositions WO2010091067A3 A NNS O
thereof WO2010091067A3 A NN O
, WO2010091067A3 A , O
which WO2010091067A3 A WDT O
are WO2010091067A3 A VBP O
useful WO2010091067A3 A JJ O
for WO2010091067A3 A IN O
the WO2010091067A3 A DT O
therapeutic WO2010091067A3 A JJ O
treatment WO2010091067A3 A NN O
of WO2010091067A3 A IN O
diseases WO2010091067A3 A NNS O
associated WO2010091067A3 A VBN O
with WO2010091067A3 A IN O
the WO2010091067A3 A DT O
modulation WO2010091067A3 A NN O
or WO2010091067A3 A CC O
inhibition WO2010091067A3 A NN O
of WO2010091067A3 A IN O
11/3-HSD1 WO2010091067A3 A JJ I-UN
in WO2010091067A3 A IN O
mammals WO2010091067A3 A NNS O
. WO2010091067A3 A . O

2-aryl- WO2009120826A1 T JJ O
and WO2009120826A1 T CC O
2-heteroarylthiazolyl WO2009120826A1 T JJ O
compounds WO2009120826A1 T NNS O
, WO2009120826A1 T , O
methods WO2009120826A1 T NNS O
for WO2009120826A1 T IN O
their WO2009120826A1 T PRP$ O
preparation WO2009120826A1 T NN O
and WO2009120826A1 T CC O
use WO2009120826A1 T NN O
thereof WO2009120826A1 T NN O
. WO2009120826A1 T . O

The WO2009120826A1 A DT O
present WO2009120826A1 A JJ O
invention WO2009120826A1 A NN O
discloses WO2009120826A1 A NNS O
fused WO2009120826A1 A VBD O
bicyclic WO2009120826A1 A JJ O
2-aryl- WO2009120826A1 A JJ O
or WO2009120826A1 A CC O
2-heteroarylthiazolyl WO2009120826A1 A JJ O
compounds WO2009120826A1 A NNS O
and WO2009120826A1 A CC O
their WO2009120826A1 A PRP$ O
pharmaceutically WO2009120826A1 A RB O
acceptable WO2009120826A1 A JJ O
salts WO2009120826A1 A NNS O
and WO2009120826A1 A CC O
esters WO2009120826A1 A NNS O
thereof WO2009120826A1 A VBP O
, WO2009120826A1 A , O
which WO2009120826A1 A WDT O
are WO2009120826A1 A VBP O
useful WO2009120826A1 A JJ O
for WO2009120826A1 A IN O
inhibiting WO2009120826A1 A VBG O
the WO2009120826A1 A DT O
growth WO2009120826A1 A NN O
of WO2009120826A1 A IN O
cancerous WO2009120826A1 A JJ O
cells WO2009120826A1 A NNS O
, WO2009120826A1 A , O
inhibiting WO2009120826A1 A VBG O
human WO2009120826A1 A JJ O
breast WO2009120826A1 A NN O
carcinoma WO2009120826A1 A NN O
tumor WO2009120826A1 A NN O
growth WO2009120826A1 A NN O
in WO2009120826A1 A IN O
particular WO2009120826A1 A JJ O
and WO2009120826A1 A CC O
to WO2009120826A1 A TO O
treat WO2009120826A1 A VB O
diseases WO2009120826A1 A NNS O
or WO2009120826A1 A CC O
disorders WO2009120826A1 A NNS O
associated WO2009120826A1 A VBN O
with WO2009120826A1 A IN O
securin WO2009120826A1 A NN O
, WO2009120826A1 A , O
including WO2009120826A1 A VBG O
elevated WO2009120826A1 A VBN O
securin WO2009120826A1 A NN O
levels WO2009120826A1 A NNS O
. WO2009120826A1 A . O

Peritoneal WO2006115067A1 T JJ O
dialysis WO2006115067A1 T NN O
fluid WO2006115067A1 T NN O
. WO2006115067A1 T . O

Oxaliplatin CN103181898A T NNP O
liposome CN103181898A T NN O
and CN103181898A T CC O
application CN103181898A T NN O
thereof CN103181898A T NN O
. CN103181898A T . O

Pyrimidine WO2009013348A3 T NNP O
derivatives WO2009013348A3 T NNS O
useful WO2009013348A3 T JJ O
for WO2009013348A3 T IN O
the WO2009013348A3 T DT O
treatment WO2009013348A3 T NN O
of WO2009013348A3 T IN O
inflammatory WO2009013348A3 T NN O
or WO2009013348A3 T CC O
allergic WO2009013348A3 T JJ O
conditions WO2009013348A3 T NNS O
. WO2009013348A3 T . O

Single US20100285087 T NNP O
phenothiazine US20100285087 T NN O
enantiomers US20100285087 T NNS O
as US20100285087 T IN O
agents US20100285087 T NNS O
for US20100285087 T IN O
the US20100285087 T DT O
prevention US20100285087 T NN O
of US20100285087 T IN O
bone US20100285087 T NN O
loss US20100285087 T NN O
. US20100285087 T . O

Compositions WO2009138198A3 T NNS O
comprising WO2009138198A3 T VBG O
hydroxytyrosol WO2009138198A3 T NN O
for WO2009138198A3 T IN O
the WO2009138198A3 T DT O
preventive WO2009138198A3 T NN O
and WO2009138198A3 T CC O
curative WO2009138198A3 T JJ O
treatment WO2009138198A3 T NN O
of WO2009138198A3 T IN O
intestinal WO2009138198A3 T JJ O
tract WO2009138198A3 T NN O
disorders WO2009138198A3 T NNS O
. WO2009138198A3 T . O

Veterinary CN103271873A T NNP O
tiamulin CN103271873A T NN O
suspension CN103271873A T NN O
injection CN103271873A T NN O
and CN103271873A T CC O
preparation CN103271873A T NN O
method CN103271873A T NN O
thereof CN103271873A T NN O
. CN103271873A T . O

The CN103271873A A DT O
invention CN103271873A A NN O
relates CN103271873A A VBZ O
to CN103271873A A TO O
the CN103271873A A DT O
technical CN103271873A A JJ O
field CN103271873A A NN O
of CN103271873A A IN O
medicine CN103271873A A NN O
, CN103271873A A , O
and CN103271873A A CC O
discloses CN103271873A A VBZ O
a CN103271873A A DT O
veterinary CN103271873A A JJ O
tiamulin CN103271873A A NN O
suspension CN103271873A A NN O
injection CN103271873A A NN O
and CN103271873A A CC O
preparation CN103271873A A NN O
method CN103271873A A NN O
thereof CN103271873A A NN O
. CN103271873A A . O

The CN103271873A A DT O
veterinary CN103271873A A JJ O
tiamulin CN103271873A A NN O
suspension CN103271873A A NN O
injection CN103271873A A NN O
comprises CN103271873A A VBZ O
the CN103271873A A DT O
following CN103271873A A JJ O
compositions CN103271873A A NNS O
in CN103271873A A IN O
percents CN103271873A A NNS O
by CN103271873A A IN O
weight CN103271873A A NN O
: CN103271873A A : O
20 CN103271873A A CD O
% CN103271873A A NN O
of CN103271873A A IN O
tiamulin CN103271873A A NN O
, CN103271873A A , O
6-10 CN103271873A A JJ O
% CN103271873A A NN O
of CN103271873A A IN O
a CN103271873A A DT O
suspending CN103271873A A NN O
agent CN103271873A A NN O
Arabic CN103271873A A NNP O
gum CN103271873A A NN O
, CN103271873A A , O
0.2-1 CN103271873A A CD O
% CN103271873A A NN O
of CN103271873A A IN O
a CN103271873A A DT O
suspending CN103271873A A NN O
agent CN103271873A A NN O
polyvinyl CN103271873A A NN O
pyrrolidone CN103271873A A NN O
, CN103271873A A , O
0.1-0.3 CN103271873A A CD O
% CN103271873A A NN O
of CN103271873A A IN O
a CN103271873A A DT O
surfactant CN103271873A A JJ O
, CN103271873A A , O
0.3-0.9 CN103271873A A JJ O
% CN103271873A A NN O
of CN103271873A A IN O
a CN103271873A A DT O
flocculating CN103271873A A NN O
agent CN103271873A A NN O
, CN103271873A A , O
other CN103271873A A JJ O
auxiliary CN103271873A A JJ O
agent CN103271873A A NN O
and CN103271873A A CC O
the CN103271873A A DT O
balance CN103271873A A NN O
water CN103271873A A NN O
. CN103271873A A . O

The CN103271873A A DT O
veterinary CN103271873A A JJ O
tiamulin CN103271873A A NN O
suspension CN103271873A A NN O
injection CN103271873A A NN O
of CN103271873A A IN O
the CN103271873A A DT O
invention CN103271873A A NN O
is CN103271873A A VBZ O
good CN103271873A A JJ O
in CN103271873A A IN O
stability CN103271873A A NN O
, CN103271873A A , O
rapid CN103271873A A JJ O
in CN103271873A A IN O
absorption CN103271873A A NN O
, CN103271873A A , O
high CN103271873A A JJ O
in CN103271873A A IN O
bioavailability CN103271873A A NN O
and CN103271873A A CC O
substantial CN103271873A A JJ O
in CN103271873A A IN O
effect CN103271873A A NN O
, CN103271873A A , O
and CN103271873A A CC O
helps CN103271873A A VBZ O
to CN103271873A A TO O
provide CN103271873A A VB O
a CN103271873A A DT O
new CN103271873A A JJ O
efficient CN103271873A A JJ O
dosage CN103271873A A NN O
form CN103271873A A NN O
for CN103271873A A IN O
veterinary CN103271873A A JJ O
tiamulin CN103271873A A NN O
. CN103271873A A . O

Deuterium-enriched US20090076153 T JJ O
tigecycline US20090076153 T NN O
. US20090076153 T . O

Gel CN101524365A T NNP O
solution CN101524365A T NN O
for CN101524365A T IN O
treating CN101524365A T VBG O
gastric CN101524365A T JJ O
ulcer CN101524365A T NN O
and CN101524365A T CC O
gastrorrhagia CN101524365A T NN O
. CN101524365A T . O

Novel CN103142565A T NNP O
nimesulide CN103142565A T RB O
sustained-release CN103142565A T JJ O
pharmaceutical CN103142565A T JJ O
composition CN103142565A T NN O
and CN103142565A T CC O
preparation CN103142565A T NN O
method CN103142565A T NN O
thereof CN103142565A T NN O
. CN103142565A T . O

Novel WO2013169397A1 T NNP O
oxysterol WO2013169397A1 T MD O
analogue WO2013169397A1 T VB O
, WO2013169397A1 T , O
oxy149 WO2013169397A1 T PRP O
, WO2013169397A1 T , O
induces WO2013169397A1 T VBZ O
osteogenesis WO2013169397A1 T NN O
and WO2013169397A1 T CC O
hedgehog WO2013169397A1 T NN O
signaling WO2013169397A1 T NN O
and WO2013169397A1 T CC O
inhibits WO2013169397A1 T JJ O
adipogenesis WO2013169397A1 T NN O
. WO2013169397A1 T . O

2 US20080280846 T CD O
' US20080280846 T '' O
, US20080280846 T , O
3'-dideoxynucleoside US20080280846 T JJ O
analogues US20080280846 T NNS O
for US20080280846 T IN O
the US20080280846 T DT O
treatment US20080280846 T NN O
or US20080280846 T CC O
prevention US20080280846 T NN O
of US20080280846 T IN O
flaviviridae US20080280846 T JJ O
infections US20080280846 T NNS O
. US20080280846 T . O

Oxindole EP1105376B1 T JJ O
derivatives EP1105376B1 T NNS O
as EP1105376B1 T IN O
growth EP1105376B1 T NN I-UN
hormone EP1105376B1 T NN I-UN
releasers EP1105376B1 T NNS O
. EP1105376B1 T . O

An EP1105376B1 A DT O
oxindole EP1105376B1 A NN O
of EP1105376B1 A IN O
Formula EP1105376B1 A NNP O
( EP1105376B1 A ( O
1 EP1105376B1 A CD O
) EP1105376B1 A ) O
or EP1105376B1 A CC O
a EP1105376B1 A DT O
prodrug EP1105376B1 A JJ O
thereof EP1105376B1 A NN O
, EP1105376B1 A , O
or EP1105376B1 A CC O
a EP1105376B1 A DT O
pharmaceutically EP1105376B1 A RB O
acceptable EP1105376B1 A JJ O
salt EP1105376B1 A NN O
thereof EP1105376B1 A NN O
is EP1105376B1 A VBZ O
useful EP1105376B1 A JJ O
for EP1105376B1 A IN O
growth EP1105376B1 A NN I-UN
hormone EP1105376B1 A CD I-UN
releaser EP1105376B1 A NN O
wherein EP1105376B1 A NN O
R EP1105376B1 A NNP O
? EP1105376B1 A . O
1 EP1105376B1 A CD O
, EP1105376B1 A , O
R2 EP1105376B1 A NNP O
, EP1105376B1 A , O
R3 EP1105376B1 A NNP O
, EP1105376B1 A , O
and EP1105376B1 A CC O
R4¿ EP1105376B1 A NNP O
are EP1105376B1 A VBP O
independently EP1105376B1 A RB O
hydrogen EP1105376B1 A VBN O
, EP1105376B1 A , O
optionally EP1105376B1 A RB O
substituted EP1105376B1 A VBN O
alkyl EP1105376B1 A NN O
, EP1105376B1 A , O
etc EP1105376B1 A FW O
; EP1105376B1 A : O
R5 EP1105376B1 A NNP O
is EP1105376B1 A VBZ O
optionally EP1105376B1 A RB O
substituted EP1105376B1 A VBN O
aryl EP1105376B1 A NN O
or EP1105376B1 A CC O
optionally EP1105376B1 A RB O
substituted EP1105376B1 A JJ O
heteroaryl EP1105376B1 A NN O
; EP1105376B1 A : O
Z EP1105376B1 A NNP O
is EP1105376B1 A VBZ O
-O- EP1105376B1 A JJ O
or EP1105376B1 A CC O
-NH- EP1105376B1 A NN O
; EP1105376B1 A : O
one EP1105376B1 A CD O
of EP1105376B1 A IN O
W EP1105376B1 A NNP O
? EP1105376B1 A . O
1 EP1105376B1 A CD O
and EP1105376B1 A CC O
W2¿ EP1105376B1 A NNP O
is EP1105376B1 A VBZ O
hydrogen EP1105376B1 A NN O
, EP1105376B1 A , O
alkyl EP1105376B1 A NN O
or EP1105376B1 A CC O
-Y-CON EP1105376B1 A NN O
( EP1105376B1 A ( O
R10 EP1105376B1 A NNP O
) EP1105376B1 A ) O
R11 EP1105376B1 A NNP O
; EP1105376B1 A : O
the EP1105376B1 A DT O
other EP1105376B1 A JJ O
of EP1105376B1 A IN O
W EP1105376B1 A NNP O
? EP1105376B1 A . O
1 EP1105376B1 A CD O
and EP1105376B1 A CC O
W2¿ EP1105376B1 A NNP O
is EP1105376B1 A VBZ O
( EP1105376B1 A ( O
a EP1105376B1 A DT O
) EP1105376B1 A ) O
; EP1105376B1 A : O
n EP1105376B1 A CC O
is EP1105376B1 A VBZ O
1 EP1105376B1 A CD O
, EP1105376B1 A , O
2 EP1105376B1 A CD O
or EP1105376B1 A CC O
3 EP1105376B1 A CD O
; EP1105376B1 A : O
m EP1105376B1 A NN O
is EP1105376B1 A VBZ O
0 EP1105376B1 A CD O
, EP1105376B1 A , O
1 EP1105376B1 A CD O
, EP1105376B1 A , O
2 EP1105376B1 A CD O
or EP1105376B1 A CC O
3 EP1105376B1 A CD O
; EP1105376B1 A : O
Y EP1105376B1 A NNP O
is EP1105376B1 A VBZ O
single EP1105376B1 A JJ O
bond EP1105376B1 A NN O
or EP1105376B1 A CC O
C¿1 EP1105376B1 A NNP O
? EP1105376B1 A . O
-C3 EP1105376B1 A NNP O
alkylene EP1105376B1 A NN O
; EP1105376B1 A : O
R EP1105376B1 A NNP O
? EP1105376B1 A . O
6 EP1105376B1 A CD O
and EP1105376B1 A CC O
R7¿ EP1105376B1 A NNP O
are EP1105376B1 A VBP O
independently EP1105376B1 A RB O
hydrogen EP1105376B1 A VBN O
, EP1105376B1 A , O
optionally EP1105376B1 A RB O
substituted EP1105376B1 A VBN O
alkyl EP1105376B1 A NN O
, EP1105376B1 A , O
etc EP1105376B1 A FW O
; EP1105376B1 A : O
R EP1105376B1 A NNP O
? EP1105376B1 A . O
8 EP1105376B1 A CD O
and EP1105376B1 A CC O
R9¿ EP1105376B1 A NNP O
are EP1105376B1 A VBP O
independently EP1105376B1 A RB O
hydrogen EP1105376B1 A VBN O
, EP1105376B1 A , O
optionally EP1105376B1 A RB O
substituted EP1105376B1 A VBN O
alkyl EP1105376B1 A NN O
, EP1105376B1 A , O
etc EP1105376B1 A FW O
; EP1105376B1 A : O
R EP1105376B1 A NNP O
? EP1105376B1 A . O
10 EP1105376B1 A CD O
and EP1105376B1 A CC O
R11¿ EP1105376B1 A NNP O
are EP1105376B1 A VBP O
independently EP1105376B1 A RB O
hydrogen EP1105376B1 A VBN O
, EP1105376B1 A , O
alkyl EP1105376B1 A JJ O
etc EP1105376B1 A NN O
. EP1105376B1 A . O

Antitumor WO2008092352A1 T NNP O
compounds WO2008092352A1 T NNS O
and WO2008092352A1 T CC O
their WO2008092352A1 T PRP$ O
preparation WO2008092352A1 T NN O
method WO2008092352A1 T NN O
. WO2008092352A1 T . O

The WO2008092352A1 A DT O
compounds WO2008092352A1 A NNS O
provided WO2008092352A1 A VBN O
in WO2008092352A1 A IN O
the WO2008092352A1 A DT O
present WO2008092352A1 A JJ O
invention WO2008092352A1 A NN O
can WO2008092352A1 A MD O
be WO2008092352A1 A VB O
used WO2008092352A1 A VBN O
for WO2008092352A1 A IN O
preparing WO2008092352A1 A VBG O
microtubulin WO2008092352A1 A NN I-UN
protein WO2008092352A1 A NN O
inhibitors WO2008092352A1 A NNS O
and WO2008092352A1 A CC O
have WO2008092352A1 A VBP O
antitumor WO2008092352A1 A VBN O
effect WO2008092352A1 A NN O
, WO2008092352A1 A , O
and WO2008092352A1 A CC O
the WO2008092352A1 A DT O
invention WO2008092352A1 A NN O
also WO2008092352A1 A RB O
provides WO2008092352A1 A VBZ O
antitumor WO2008092352A1 A JJ O
pharmaceutical WO2008092352A1 A JJ O
compositions WO2008092352A1 A NNS O
containing WO2008092352A1 A VBG O
the WO2008092352A1 A DT O
said WO2008092352A1 A VBD O
new WO2008092352A1 A JJ O
compounds WO2008092352A1 A NNS O
as WO2008092352A1 A IN O
active WO2008092352A1 A JJ O
ingredient WO2008092352A1 A NN O
. WO2008092352A1 A . O

Oxadiazole CN101553486A T NNP O
and CN101553486A T CC O
thiadiazole CN101553486A T JJ O
compounds CN101553486A T NNS O
and CN101553486A T CC O
their CN101553486A T PRP$ O
use CN101553486A T NN O
as CN101553486A T IN O
nicotinic CN101553486A T JJ I-UN
acetylcholine CN101553486A T NN I-UN
receptor CN101553486A T NN I-UN
modulators CN101553486A T NNS O
. CN101553486A T . O

This CN101553486A A DT O
invention CN101553486A A NN O
relates CN101553486A A VBZ O
to CN101553486A A TO O
oxadiazolyl CN101553486A A VB O
and CN101553486A A CC O
thiadiazolyl CN101553486A A VB O
derivatives CN101553486A A NNS O
, CN101553486A A , O
which CN101553486A A WDT O
are CN101553486A A VBP O
found CN101553486A A VBN O
to CN101553486A A TO O
be CN101553486A A VB O
modulators CN101553486A A NNS O
of CN101553486A A IN O
the CN101553486A A DT O
nicotinic CN101553486A A JJ I-UN
acetylcholine CN101553486A A NN I-UN
receptors CN101553486A A NNS I-UN
. CN101553486A A . O

Treatment US20080014283 T NN O
methodologies US20080014283 T NNS O
for US20080014283 T IN O
preventing US20080014283 T VBG O
reflux US20080014283 T NN O
induced US20080014283 T VBD O
adenocarcinoma US20080014283 T NN O
of US20080014283 T IN O
the US20080014283 T DT O
esophagus US20080014283 T NN O
. US20080014283 T . O

Intranasal US20100113426 T NNP O
Benzodiazepine US20100113426 T NNP O
Compositions US20100113426 T NNP O
. US20100113426 T . O

Prescription CN101756933A T NN O
, CN101756933A T , O
preparation CN101756933A T NN O
method CN101756933A T NN O
and CN101756933A T CC O
application CN101756933A T NN O
of CN101756933A T IN O
effervescent CN101756933A T JJ O
tablets CN101756933A T NNS O
containing CN101756933A T VBG O
dimemorfan CN101756933A T NN O
. CN101756933A T . O

Compositions US20120071558 T NNS O
of US20120071558 T IN O
very US20120071558 T RB O
long US20120071558 T RB O
chain US20120071558 T NN O
polyunsaturated US20120071558 T VBD O
fatty US20120071558 T JJ O
acids US20120071558 T NNS O
and US20120071558 T CC O
methods US20120071558 T NNS O
of US20120071558 T IN O
use US20120071558 T NN O
. US20120071558 T . O

Simultaneous WO2006030941A1 T JJ O
use WO2006030941A1 T NN O
of WO2006030941A1 T IN O
sulfonamide-containing WO2006030941A1 T JJ O
compound WO2006030941A1 T NN O
and WO2006030941A1 T CC O
angiogenesis WO2006030941A1 T NN O
inhibitor WO2006030941A1 T NN O
. WO2006030941A1 T . O

Topical US20110178177 T JJ O
formulations US20110178177 T NNS O
for US20110178177 T IN O
treatment US20110178177 T NN O
of US20110178177 T IN O
neuropathy US20110178177 T NN O
. US20110178177 T . O

Porcine US7432344 T NNP I-UN
CTLA-4 US7432344 T NNP I-UN
for US7432344 T IN O
xenograft-specific US7432344 T JJ O
immunosuppression US7432344 T NN O
. US7432344 T . O

In US7432344 A IN O
a US7432344 A DT O
first US7432344 A JJ O
aspect US7432344 A NN O
, US7432344 A , O
co-stimulation US7432344 A NN O
is US7432344 A VBZ O
prevented US7432344 A VBN O
by US7432344 A IN O
administration US7432344 A NN O
to US7432344 A TO O
the US7432344 A DT O
organ US7432344 A JJ O
recipient US7432344 A NN O
of US7432344 A IN O
a US7432344 A DT O
soluble US7432344 A JJ O
form US7432344 A NN O
of US7432344 A IN O
CTLA-4 US7432344 A NNP I-UN
from US7432344 A IN O
the US7432344 A DT O
xenogeneic US7432344 A NNP O
donor US7432344 A NN O
organism US7432344 A NN O
. US7432344 A . O

This US7432344 A DT O
preferentially US7432344 A RB O
binds US7432344 A VBZ O
B7 US7432344 A NNP I-UN
on US7432344 A IN O
the US7432344 A DT O
xenograft US7432344 A NN O
and US7432344 A CC O
blocks US7432344 A VBZ O
the US7432344 A DT O
interaction US7432344 A NN O
between US7432344 A IN O
B7 US7432344 A NNP I-UN
on US7432344 A IN O
the US7432344 A DT O
xenogeneic US7432344 A NNP O
donor US7432344 A NN O
cells US7432344 A NNS O
and US7432344 A CC O
CD28 US7432344 A NNP I-UN
on US7432344 A IN O
recipient US7432344 A JJ O
T-cells US7432344 A NNS O
. US7432344 A . O

In US7432344 A IN O
a US7432344 A DT O
second US7432344 A JJ O
aspect US7432344 A NN O
, US7432344 A , O
co-stimulation US7432344 A NN O
is US7432344 A VBZ O
antagonised US7432344 A VBN O
by US7432344 A IN O
expressing US7432344 A VBG O
a US7432344 A DT O
ligand US7432344 A NN O
for US7432344 A IN O
CTLA-4 US7432344 A NNP I-UN
on US7432344 A IN O
the US7432344 A DT O
xenogeneic US7432344 A NNP O
donor US7432344 A NN O
cells US7432344 A NNS O
. US7432344 A . O

This US7432344 A DT O
ligand US7432344 A NN O
binds US7432344 A VBZ O
to US7432344 A TO O
CTLA-4 US7432344 A NNP I-UN
on US7432344 A IN O
activated US7432344 A JJ O
T-cells US7432344 A NNS O
of US7432344 A IN O
the US7432344 A DT O
recipient US7432344 A NN O
and US7432344 A CC O
antagonizes US7432344 A VBZ O
signal US7432344 A JJ O
2 US7432344 A CD O
. US7432344 A . O

If US7432344 A IN O
the US7432344 A DT O
donor US7432344 A NN O
cells US7432344 A NNS O
do US7432344 A VBP O
not US7432344 A RB O
express US7432344 A VB O
B7 US7432344 A NNP I-UN
, US7432344 A , O
or US7432344 A CC O
if US7432344 A IN O
B7 US7432344 A NNP I-UN
is US7432344 A VBZ O
blocked US7432344 A VBN O
, US7432344 A , O
the US7432344 A DT O
xenoreactive US7432344 A JJ O
recipient US7432344 A NN O
T-cell US7432344 A NNP O
becomes US7432344 A VBZ O
anergic US7432344 A JJ O
. US7432344 A . O

Preventive WO2012028340A1 T JJ O
ointment WO2012028340A1 T NN O
for WO2012028340A1 T IN O
diabetic WO2012028340A1 T JJ O
foot WO2012028340A1 T NN O
. WO2012028340A1 T . O

Veterinary CN103301060A T JJ O
amoxicillin-sulbactam CN103301060A T JJ O
suspension CN103301060A T NN O
injection CN103301060A T NN O
and CN103301060A T CC O
preparation CN103301060A T NN O
method CN103301060A T NN O
thereof CN103301060A T NN O
. CN103301060A T . O

Application CN103432139A T NN O
of CN103432139A T IN O
compound CN103432139A T NN O
in CN103432139A T IN O
preparation CN103432139A T NN O
of CN103432139A T IN O
antituberculosis CN103432139A T NN O
medicament CN103432139A T NN O
. CN103432139A T . O

Morphinan EP2506712A1 T NNP O
derivatives EP2506712A1 T NNS O
for EP2506712A1 T IN O
the EP2506712A1 T DT O
treatment EP2506712A1 T NN O
of EP2506712A1 T IN O
drug EP2506712A1 T NN O
overdose EP2506712A1 T NN O
. EP2506712A1 T . O

Compound CN103385928A T NNP O
medical CN103385928A T JJ O
preparation CN103385928A T NN O
for CN103385928A T IN O
curing CN103385928A T VBG O
diarrhea CN103385928A T NN O
of CN103385928A T IN O
young CN103385928A T JJ O
livestock CN103385928A T NN O
and CN103385928A T CC O
applications CN103385928A T NNS O
thereof CN103385928A T VBP O
. CN103385928A T . O

Lonidamine WO2011005759A2 T NNP O
analogues WO2011005759A2 T NNS O
for WO2011005759A2 T IN O
fertility WO2011005759A2 T NN O
management WO2011005759A2 T NN O
. WO2011005759A2 T . O

P2Y4 US7312317 T NNP I-UN
antibodies US7312317 T NNS O
. US7312317 T . O

Deuterated WO2014086284A1 T VBN O
3-cyano WO2014086284A1 T JJ O
quinoline WO2014086284A1 T NN O
compound WO2014086284A1 T NN O
, WO2014086284A1 T , O
pharmaceutical WO2014086284A1 T JJ O
composition WO2014086284A1 T NN O
, WO2014086284A1 T , O
preparation WO2014086284A1 T NN O
method WO2014086284A1 T NN O
and WO2014086284A1 T CC O
use WO2014086284A1 T NN O
thereof WO2014086284A1 T NN O
. WO2014086284A1 T . O

Disclosed WO2014086284A1 A VBN O
in WO2014086284A1 A IN O
the WO2014086284A1 A DT O
invention WO2014086284A1 A NN O
are WO2014086284A1 A VBP O
a WO2014086284A1 A DT O
deuterated WO2014086284A1 A JJ O
3-cyano WO2014086284A1 A JJ O
quinoline WO2014086284A1 A NN O
compound WO2014086284A1 A NN O
or WO2014086284A1 A CC O
pharmaceutically WO2014086284A1 A RB O
acceptable WO2014086284A1 A JJ O
salts WO2014086284A1 A NNS O
, WO2014086284A1 A , O
solvates WO2014086284A1 A NNS O
, WO2014086284A1 A , O
prodrugs WO2014086284A1 A NNS O
, WO2014086284A1 A , O
stereoisomers WO2014086284A1 A NNS O
, WO2014086284A1 A , O
tautomers WO2014086284A1 A NNS O
, WO2014086284A1 A , O
polymorphic WO2014086284A1 A JJ O
substances WO2014086284A1 A NNS O
, WO2014086284A1 A , O
metabolites WO2014086284A1 A NNS O
etc. WO2014086284A1 A VBP O
, WO2014086284A1 A , O
and WO2014086284A1 A CC O
a WO2014086284A1 A DT O
pharmaceutical WO2014086284A1 A JJ O
composition WO2014086284A1 A NN O
containing WO2014086284A1 A VBG O
such WO2014086284A1 A JJ O
compounds WO2014086284A1 A NNS O
, WO2014086284A1 A , O
and WO2014086284A1 A CC O
the WO2014086284A1 A DT O
use WO2014086284A1 A NN O
of WO2014086284A1 A IN O
these WO2014086284A1 A DT O
compounds WO2014086284A1 A NNS O
or WO2014086284A1 A CC O
compositions WO2014086284A1 A NNS O
in WO2014086284A1 A IN O
the WO2014086284A1 A DT O
preparation WO2014086284A1 A NN O
of WO2014086284A1 A IN O
drugs WO2014086284A1 A NNS O
for WO2014086284A1 A IN O
treating WO2014086284A1 A VBG O
or WO2014086284A1 A CC O
preventing WO2014086284A1 A VBG O
tumours WO2014086284A1 A NNS O
, WO2014086284A1 A , O
especially WO2014086284A1 A RB O
drugs WO2014086284A1 A NNS O
such WO2014086284A1 A JJ O
as WO2014086284A1 A IN O
protein WO2014086284A1 A JJ O
kinase WO2014086284A1 A NN O
inhibitors WO2014086284A1 A NNS O
. WO2014086284A1 A . O

Compared WO2014086284A1 A VBN O
with WO2014086284A1 A IN O
the WO2014086284A1 A DT O
prior WO2014086284A1 A JJ O
art WO2014086284A1 A NN O
, WO2014086284A1 A , O
the WO2014086284A1 A DT O
compounds WO2014086284A1 A NNS O
of WO2014086284A1 A IN O
the WO2014086284A1 A DT O
present WO2014086284A1 A JJ O
invention WO2014086284A1 A NN O
have WO2014086284A1 A VBP O
the WO2014086284A1 A DT O
clear WO2014086284A1 A JJ O
advantages WO2014086284A1 A NNS O
of WO2014086284A1 A IN O
properties WO2014086284A1 A NNS O
such WO2014086284A1 A JJ O
as WO2014086284A1 A IN O
plasma WO2014086284A1 A JJ O
drug WO2014086284A1 A NN O
concentration WO2014086284A1 A NN O
, WO2014086284A1 A , O
half-life WO2014086284A1 A JJ O
, WO2014086284A1 A , O
clearance WO2014086284A1 A NN O
, WO2014086284A1 A , O
microsomal WO2014086284A1 A JJ O
stability WO2014086284A1 A NN O
, WO2014086284A1 A , O
bioavailability WO2014086284A1 A NN O
or WO2014086284A1 A CC O
enzyme WO2014086284A1 A JJ O
inhibition WO2014086284A1 A NN O
and WO2014086284A1 A CC O
the WO2014086284A1 A DT O
like WO2014086284A1 A JJ O
, WO2014086284A1 A , O
and WO2014086284A1 A CC O
thus WO2014086284A1 A RB O
can WO2014086284A1 A MD O
more WO2014086284A1 A RBR O
effectively WO2014086284A1 A RB O
inhibit WO2014086284A1 A VB O
the WO2014086284A1 A DT O
activities WO2014086284A1 A NNS O
of WO2014086284A1 A IN O
more WO2014086284A1 A JJR O
than WO2014086284A1 A IN O
one WO2014086284A1 A CD O
protein WO2014086284A1 A NN O
kinase WO2014086284A1 A NN O
and/or WO2014086284A1 A JJ O
inhibit WO2014086284A1 A NN O
the WO2014086284A1 A DT O
growth WO2014086284A1 A NN O
of WO2014086284A1 A IN O
tumuor WO2014086284A1 A NN O
cells WO2014086284A1 A NNS O
. WO2014086284A1 A . O

Crystalline EP1778672A1 T NNP O
form EP1778672A1 T NN O
of EP1778672A1 T IN O
a EP1778672A1 T DT O
biphenyl EP1778672A1 T NN O
compound EP1778672A1 T NN O
. EP1778672A1 T . O

The EP1778672A1 A DT O
invention EP1778672A1 A NN O
provides EP1778672A1 A VBZ O
a EP1778672A1 A DT O
crystalline EP1778672A1 A JJ O
1,2-ethanedisulfonic EP1778672A1 A JJ O
acid EP1778672A1 A NN O
salt EP1778672A1 A NN O
of EP1778672A1 A IN O
biphenyl-2-ylcarbamic EP1778672A1 A JJ O
acid EP1778672A1 A JJ O
1- EP1778672A1 A JJ O
[ EP1778672A1 A NN O
2- EP1778672A1 A JJ O
( EP1778672A1 A ( O
2-chloro-4- EP1778672A1 A JJ O
{ EP1778672A1 A ( O
[ EP1778672A1 A NN O
( EP1778672A1 A ( O
R EP1778672A1 A NNP O
) EP1778672A1 A ) O
-2-hydroxy-2- EP1778672A1 A NN O
( EP1778672A1 A ( O
8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl EP1778672A1 A JJ O
) EP1778672A1 A ) O
ethylamino EP1778672A1 A NN O
] EP1778672A1 A JJ O
methyl EP1778672A1 A NN O
} EP1778672A1 A ) O
-5-methoxyphenylcarbamoyl EP1778672A1 A NNP O
) EP1778672A1 A ) O
ethyl EP1778672A1 A VBP O
] EP1778672A1 A JJ O
piperidin-4-yl EP1778672A1 A JJ O
ester EP1778672A1 A NN O
or EP1778672A1 A CC O
a EP1778672A1 A DT O
solvate EP1778672A1 A JJ O
thereof EP1778672A1 A NN O
. EP1778672A1 A . O

This EP1778672A1 A DT O
invention EP1778672A1 A NN O
also EP1778672A1 A RB O
provides EP1778672A1 A VBZ O
pharmaceutical EP1778672A1 A JJ O
compositions EP1778672A1 A NNS O
comprising EP1778672A1 A VBG O
such EP1778672A1 A JJ O
a EP1778672A1 A DT O
salt EP1778672A1 A NN O
or EP1778672A1 A CC O
prepared EP1778672A1 A JJ O
using EP1778672A1 A VBG O
such EP1778672A1 A JJ O
a EP1778672A1 A DT O
salt EP1778672A1 A NN O
; EP1778672A1 A : O
processes EP1778672A1 A NNS O
and EP1778672A1 A CC O
intermediates EP1778672A1 A NNS O
for EP1778672A1 A IN O
preparing EP1778672A1 A VBG O
such EP1778672A1 A PDT O
a EP1778672A1 A DT O
salt EP1778672A1 A NN O
; EP1778672A1 A : O
and EP1778672A1 A CC O
methods EP1778672A1 A NNS O
of EP1778672A1 A IN O
using EP1778672A1 A VBG O
such EP1778672A1 A JJ O
a EP1778672A1 A DT O
salt EP1778672A1 A NN O
to EP1778672A1 A TO O
treat EP1778672A1 A VB O
a EP1778672A1 A DT O
pulmonary EP1778672A1 A JJ O
disorder EP1778672A1 A NN O
. EP1778672A1 A . O

Cough CN103099936A T NNP O
relieving CN103099936A T NN O
medicine CN103099936A T NN O
. CN103099936A T . O

Quinazolinone WO2013098320A1 T NN O
derivatives WO2013098320A1 T NNS O
as WO2013098320A1 T IN O
hcv WO2013098320A1 T JJ O
inhibitors WO2013098320A1 T NNS O
. WO2013098320A1 T . O

Nanoparticulate US8119163 T NNP O
and US8119163 T CC O
controlled US8119163 T VBD O
release US8119163 T NN O
compositions US8119163 T NNS O
comprising US8119163 T VBG O
cefditoren US8119163 T NN O
. US8119163 T . O

Fast US7867509 T NNP O
dissolving US7867509 T VBG O
orally US7867509 T RB O
consumable US7867509 T JJ O
films US7867509 T NNS O
. US7867509 T . O

Oligonucleotide US20080027019 T NNP O
compositions US20080027019 T NNS O
and US20080027019 T CC O
methods US20080027019 T NNS O
for US20080027019 T IN O
the US20080027019 T DT O
modulation US20080027019 T NN O
of US20080027019 T IN O
the US20080027019 T DT O
expression US20080027019 T NN O
of US20080027019 T IN O
b7 US20080027019 T NN I-UN
protein US20080027019 T NN O
. US20080027019 T . O

Compositions US20080027019 A NNS O
and US20080027019 A CC O
methods US20080027019 A NNS O
for US20080027019 A IN O
the US20080027019 A DT O
treatment US20080027019 A NN O
of US20080027019 A IN O
asthma US20080027019 A NN O
with US20080027019 A IN O
oligonucleotides US20080027019 A NNS O
which US20080027019 A WDT O
specifically US20080027019 A RB O
hybridize US20080027019 A VBP O
with US20080027019 A IN O
nucleic US20080027019 A JJ O
acids US20080027019 A NNS O
encoding US20080027019 A VBG O
B7 US20080027019 A NNP I-UN
proteins US20080027019 A NNS O
. US20080027019 A . O

Method CN101836962A T NNP O
for CN101836962A T IN O
preparing CN101836962A T VBG O
bendamustine CN101836962A T JJ O
hydrochloride CN101836962A T JJ O
freeze-dried CN101836962A T JJ O
powder CN101836962A T NN O
injection CN101836962A T NN O
. CN101836962A T . O

Isosorbide CN103130815A T NNP O
mononitrate CN103130815A T NN O
derivative CN103130815A T NN O
and CN103130815A T CC O
preparation CN103130815A T NN O
method CN103130815A T NN O
and CN103130815A T CC O
application CN103130815A T NN O
thereof CN103130815A T NN O
. CN103130815A T . O

Pyrazole WO2006077419A1 T NNP O
derivatives WO2006077419A1 T NNS O
for WO2006077419A1 T IN O
the WO2006077419A1 T DT O
inhibition WO2006077419A1 T NN O
of WO2006077419A1 T IN O
cdk WO2006077419A1 T NN O
' WO2006077419A1 T POS O
s WO2006077419A1 T NN O
and WO2006077419A1 T CC O
gsk WO2006077419A1 T NN O
' WO2006077419A1 T '' O
s WO2006077419A1 T NN O
. WO2006077419A1 T . O

N CA2396702C T NNP O
, CA2396702C T , O
o-amidomalonate CA2396702C T JJ O
platinum CA2396702C T NN O
complexes CA2396702C T NNS O
. CA2396702C T . O

Polyglycerol US20090068138 T NNP O
anti-microbial US20090068138 T JJ O
agents US20090068138 T NNS O
and US20090068138 T CC O
compositions US20090068138 T NNS O
. US20090068138 T . O

Cosmetics US7169379 T NNS O
. US7169379 T . O

Use US20080279912 T NNP O
of US20080279912 T IN O
Cis-Epoxyeicosatrienoic US20080279912 T NNP O
Acids US20080279912 T NNP O
And US20080279912 T CC O
Inhibitors US20080279912 T NNP O
of US20080279912 T IN O
Soluble US20080279912 T NNP I-UN
Epoxide US20080279912 T NNP I-UN
Hydrolase US20080279912 T NNP I-UN
to US20080279912 T TO O
Alleviate US20080279912 T NNP O
Eye US20080279912 T NNP O
Disorders US20080279912 T NNP O
. US20080279912 T . O

The US20080279912 A DT O
invention US20080279912 A NN O
provides US20080279912 A VBZ O
methods US20080279912 A NNS O
for US20080279912 A IN O
alleviating US20080279912 A VBG O
eye US20080279912 A NN O
disorders US20080279912 A NNS O
due US20080279912 A JJ O
to US20080279912 A TO O
increased US20080279912 A VBN O
intraocular US20080279912 A JJ O
pressure US20080279912 A NN O
( US20080279912 A ( O
“IOP” US20080279912 A JJ O
) US20080279912 A ) O
or US20080279912 A CC O
inflammation US20080279912 A NN O
by US20080279912 A IN O
administering US20080279912 A VBG O
to US20080279912 A TO O
the US20080279912 A DT O
eye US20080279912 A NN O
or US20080279912 A CC O
eyes US20080279912 A NNS O
of US20080279912 A IN O
an US20080279912 A DT O
individual US20080279912 A NN O
in US20080279912 A IN O
need US20080279912 A NN O
thereof US20080279912 A VBP O
a US20080279912 A DT O
cis-epoxyeicosatrienoic US20080279912 A JJ O
acid US20080279912 A NN O
, US20080279912 A , O
an US20080279912 A DT O
inhibitor US20080279912 A NN O
of US20080279912 A IN O
soluble US20080279912 A JJ I-UN
epoxide US20080279912 A JJ I-UN
hydrolase US20080279912 A NN I-UN
( US20080279912 A ( O
sEH US20080279912 A NN I-UN
) US20080279912 A ) O
, US20080279912 A , O
or US20080279912 A CC O
both US20080279912 A DT O
. US20080279912 A . O

The US20080279912 A DT O
invention US20080279912 A NN O
further US20080279912 A RBR O
provides US20080279912 A VBZ O
for US20080279912 A IN O
reducing US20080279912 A VBG O
IOP US20080279912 A NNP O
or US20080279912 A CC O
inflammation US20080279912 A NN O
by US20080279912 A IN O
methods US20080279912 A NNS O
in US20080279912 A IN O
which US20080279912 A WDT O
the US20080279912 A DT O
sEH US20080279912 A NN I-UN
inhibitor US20080279912 A NN O
or US20080279912 A CC O
EETs US20080279912 A NNP O
, US20080279912 A , O
or US20080279912 A CC O
both US20080279912 A DT O
, US20080279912 A , O
are US20080279912 A VBP O
administered US20080279912 A VBN O
systemically US20080279912 A RB O
. US20080279912 A . O

In US20080279912 A IN O
some US20080279912 A DT O
embodiments US20080279912 A NNS O
, US20080279912 A , O
the US20080279912 A DT O
methods US20080279912 A NNS O
comprise US20080279912 A VBP O
administering US20080279912 A VBG O
to US20080279912 A TO O
the US20080279912 A DT O
individual US20080279912 A NN O
a US20080279912 A DT O
nucleic US20080279912 A JJ O
acid US20080279912 A NN O
encoding US20080279912 A VBG O
an US20080279912 A DT O
inhibitor US20080279912 A NN O
of US20080279912 A IN O
sEH US20080279912 A NN I-UN
. US20080279912 A . O

Imaging WO2013066181A1 T VBG O
ligands WO2013066181A1 T NNS O
. WO2013066181A1 T . O

Heterocyclyl-substituted WO2007009690A1 T JJ O
pyrazoline WO2007009690A1 T NN O
compounds WO2007009690A1 T NNS O
, WO2007009690A1 T , O
their WO2007009690A1 T PRP$ O
preparation WO2007009690A1 T NN O
and WO2007009690A1 T CC O
use WO2007009690A1 T NN O
as WO2007009690A1 T IN O
medicaments WO2007009690A1 T NNS O
. WO2007009690A1 T . O

Mitochondrial EP2197890A1 T JJ O
compositions EP2197890A1 T NNS O
and EP2197890A1 T CC O
uses EP2197890A1 T VBZ O
thereof EP2197890A1 T NN O
. EP2197890A1 T . O

Adenine CN102977146A T NNP O
derivative CN102977146A T JJ O
and CN102977146A T CC O
inclusion CN102977146A T NN O
compound CN102977146A T NN O
thereof CN102977146A T NN O
. CN102977146A T . O

Application CN103271913A T NN O
of CN103271913A T IN O
Myriberine CN103271913A T NNP O
A CN103271913A T NNP O
in CN103271913A T IN O
preparing CN103271913A T VBG O
thrombocyte-increasing CN103271913A T JJ O
medicines CN103271913A T NNS O
. CN103271913A T . O

Indole EP1776338A1 T NNP O
, EP1776338A1 T , O
indazole EP1776338A1 T NN O
or EP1776338A1 T CC O
indoline EP1776338A1 T JJ O
derivatives EP1776338A1 T NNS O
. EP1776338A1 T . O

The EP1776338A1 A DT O
compounds EP1776338A1 A NNS O
are EP1776338A1 A VBP O
useful EP1776338A1 A JJ O
for EP1776338A1 A IN O
the EP1776338A1 A DT O
treatment EP1776338A1 A NN O
and/or EP1776338A1 A JJ O
prevention EP1776338A1 A NN O
of EP1776338A1 A IN O
diseases EP1776338A1 A NNS O
which EP1776338A1 A WDT O
are EP1776338A1 A VBP O
mediated EP1776338A1 A VBN O
by EP1776338A1 A IN O
CETP EP1776338A1 A NNP I-UN
inhibitors EP1776338A1 A NNS O
. EP1776338A1 A . O

Combination CN101804059A T NN O
containing CN101804059A T VBG O
ceftriaxone CN101804059A T NN O
sodium CN101804059A T NN O
. CN101804059A T . O

The CN101804059A A DT O
invention CN101804059A A NN O
relates CN101804059A A VBZ O
to CN101804059A A TO O
a CN101804059A A DT O
combination CN101804059A A NN O
containing CN101804059A A VBG O
ceftriaxone CN101804059A A NN O
sodium CN101804059A A NN O
. CN101804059A A . O

In CN101804059A A IN O
the CN101804059A A DT O
combination CN101804059A A NN O
, CN101804059A A , O
the CN101804059A A DT O
weight CN101804059A A NN O
ratio CN101804059A A NN O
of CN101804059A A IN O
the CN101804059A A DT O
ceftriaxone CN101804059A A NN O
sodium CN101804059A A NN O
to CN101804059A A TO O
mezlocillin CN101804059A A VB O
sodium CN101804059A A NN O
is CN101804059A A VBZ O
( CN101804059A A ( O
1-10 CN101804059A A JJ O
) CN101804059A A ) O
:1 CN101804059A A NN O
; CN101804059A A : O
the CN101804059A A DT O
optimum CN101804059A A JJ O
weight CN101804059A A NN O
ratio CN101804059A A NN O
of CN101804059A A IN O
the CN101804059A A DT O
ceftriaxone CN101804059A A NN O
sodium CN101804059A A NN O
to CN101804059A A TO O
the CN101804059A A DT O
mezlocillin CN101804059A A NN O
sodium CN101804059A A NN O
is CN101804059A A VBZ O
5:1 CN101804059A A CD O
; CN101804059A A : O
and CN101804059A A CC O
the CN101804059A A DT O
weight CN101804059A A NN O
ratio CN101804059A A NN O
of CN101804059A A IN O
the CN101804059A A DT O
mixture CN101804059A A NN O
of CN101804059A A IN O
the CN101804059A A DT O
ceftriaxone CN101804059A A NN O
sodium CN101804059A A NN O
and CN101804059A A CC O
the CN101804059A A DT O
mezlocillin CN101804059A A NN O
sodium CN101804059A A NN O
to CN101804059A A TO O
poloxamer CN101804059A A VB O
is CN101804059A A VBZ O
50:1 CN101804059A A CD O
. CN101804059A A . O

The CN101804059A A DT O
invention CN101804059A A NN O
has CN101804059A A VBZ O
the CN101804059A A DT O
advantages CN101804059A A NNS O
of CN101804059A A IN O
good CN101804059A A JJ O
antibacterial CN101804059A A JJ O
activity CN101804059A A NN O
, CN101804059A A , O
wide CN101804059A A JJ O
antimicrobial CN101804059A A JJ O
spectrum CN101804059A A NN O
and CN101804059A A CC O
better CN101804059A A JJR O
drug CN101804059A A NN O
curative CN101804059A A JJ O
effect CN101804059A A NN O
. CN101804059A A . O

three-ring US7098213 T JJ O
saturated US7098213 T VBD O
N-heterocyclic US7098213 T JJ O
compounds US7098213 T NNS O
in US7098213 T IN O
combination US7098213 T NN O
with US7098213 T IN O
one US7098213 T CD O
or US7098213 T CC O
more US7098213 T JJR O
antiviral US7098213 T JJ O
or US7098213 T CC O
other US7098213 T JJ O
agents US7098213 T NNS O
; US7098213 T : O
in US7098213 T IN O
immunotherapy US7098213 T NN O
. US7098213 T . O

Novel EP2100890A1 T NNP O
polynitrogenated EP2100890A1 T VBD O
systems EP2100890A1 T NNS O
as EP2100890A1 T IN O
anti-hiv EP2100890A1 T JJ O
agents EP2100890A1 T NNS O
. EP2100890A1 T . O

The EP2100890A1 A DT O
present EP2100890A1 A JJ O
invention EP2100890A1 A NN O
describes EP2100890A1 A VBZ O
the EP2100890A1 A DT O
synthesis EP2100890A1 A NN O
of EP2100890A1 A IN O
the EP2100890A1 A DT O
compounds EP2100890A1 A NNS O
of EP2100890A1 A IN O
formulae EP2100890A1 A NN O
( EP2100890A1 A ( O
1 EP2100890A1 A CD O
) EP2100890A1 A ) O
, EP2100890A1 A , O
( EP2100890A1 A ( O
2 EP2100890A1 A CD O
) EP2100890A1 A ) O
and EP2100890A1 A CC O
( EP2100890A1 A ( O
3 EP2100890A1 A CD O
) EP2100890A1 A ) O
in EP2100890A1 A IN O
which EP2100890A1 A WDT O
m EP2100890A1 A NN O
and EP2100890A1 A CC O
n EP2100890A1 A NN O
, EP2100890A1 A , O
which EP2100890A1 A WDT O
may EP2100890A1 A MD O
be EP2100890A1 A VB O
identical EP2100890A1 A JJ O
or EP2100890A1 A CC O
different EP2100890A1 A JJ O
, EP2100890A1 A , O
may EP2100890A1 A MD O
have EP2100890A1 A VB O
the EP2100890A1 A DT O
values EP2100890A1 A NNS O
0 EP2100890A1 A CD O
, EP2100890A1 A , O
2 EP2100890A1 A CD O
, EP2100890A1 A , O
3 EP2100890A1 A CD O
, EP2100890A1 A , O
4 EP2100890A1 A CD O
, EP2100890A1 A , O
5 EP2100890A1 A CD O
and EP2100890A1 A CC O
6 EP2100890A1 A CD O
; EP2100890A1 A : O
Z EP2100890A1 A NNP O
and EP2100890A1 A CC O
Y EP2100890A1 A NNP O
, EP2100890A1 A , O
which EP2100890A1 A WDT O
may EP2100890A1 A MD O
be EP2100890A1 A VB O
identical EP2100890A1 A JJ O
or EP2100890A1 A CC O
different EP2100890A1 A JJ O
, EP2100890A1 A , O
represent EP2100890A1 A VB O
a EP2100890A1 A DT O
nitrogenated EP2100890A1 A VBN O
cyclic EP2100890A1 A NN O
system EP2100890A1 A NN O
bonded EP2100890A1 A VBN O
by EP2100890A1 A IN O
nitrogen EP2100890A1 A NN O
or EP2100890A1 A CC O
by EP2100890A1 A IN O
one EP2100890A1 A CD O
of EP2100890A1 A IN O
the EP2100890A1 A DT O
ring EP2100890A1 A NN O
carbons EP2100890A1 A NNS O
or EP2100890A1 A CC O
an EP2100890A1 A DT O
NR1R2 EP2100890A1 A NNP O
system EP2100890A1 A NN O
; EP2100890A1 A : O
and EP2100890A1 A CC O
X EP2100890A1 A NNP O
is EP2100890A1 A VBZ O
selected EP2100890A1 A VBN O
from EP2100890A1 A IN O
the EP2100890A1 A DT O
group EP2100890A1 A NN O
consisting EP2100890A1 A VBG O
of EP2100890A1 A IN O
hydrogen EP2100890A1 A NN O
, EP2100890A1 A , O
C1-C12 EP2100890A1 A NNP O
alkyl EP2100890A1 A NN O
, EP2100890A1 A , O
substituted EP2100890A1 A VBD O
alkyl EP2100890A1 A NN O
, EP2100890A1 A , O
C3-C12 EP2100890A1 A NNP O
aryl EP2100890A1 A NN O
, EP2100890A1 A , O
amino EP2100890A1 A NN O
, EP2100890A1 A , O
alkylamino EP2100890A1 A NN O
, EP2100890A1 A , O
nitro EP2100890A1 A RB O
, EP2100890A1 A , O
hydroxy EP2100890A1 A NN O
, EP2100890A1 A , O
alkoxy EP2100890A1 A NN O
, EP2100890A1 A , O
halogen EP2100890A1 A NN O
, EP2100890A1 A , O
carboxy EP2100890A1 A NN O
or EP2100890A1 A CC O
carboxamido EP2100890A1 A NN O
. EP2100890A1 A . O

The EP2100890A1 A DT O
use EP2100890A1 A NN O
of EP2100890A1 A IN O
the EP2100890A1 A DT O
compounds EP2100890A1 A NNS O
of EP2100890A1 A IN O
formulae EP2100890A1 A NN O
( EP2100890A1 A ( O
1 EP2100890A1 A CD O
) EP2100890A1 A ) O
, EP2100890A1 A , O
( EP2100890A1 A ( O
2 EP2100890A1 A CD O
) EP2100890A1 A ) O
and EP2100890A1 A CC O
( EP2100890A1 A ( O
3 EP2100890A1 A CD O
) EP2100890A1 A ) O
as EP2100890A1 A IN O
anti-HIV EP2100890A1 A JJ O
agents EP2100890A1 A NNS O
in EP2100890A1 A IN O
the EP2100890A1 A DT O
treatment EP2100890A1 A NN O
of EP2100890A1 A IN O
Acquired EP2100890A1 A NNP O
Immune EP2100890A1 A NNP O
Deficiency EP2100890A1 A NNP O
Syndrome EP2100890A1 A NNP O
( EP2100890A1 A ( O
AIDS EP2100890A1 A NNP O
) EP2100890A1 A ) O
is EP2100890A1 A VBZ O
described EP2100890A1 A VBN O
. EP2100890A1 A . O

Novel EP2359852A1 T NNP O
cancer EP2359852A1 T NN O
targeting EP2359852A1 T VBG O
therapy EP2359852A1 T NN O
using EP2359852A1 T VBG O
complex EP2359852A1 T NN O
of EP2359852A1 T IN O
substance EP2359852A1 T NN O
capable EP2359852A1 T JJ O
of EP2359852A1 T IN O
binding EP2359852A1 T VBG O
specifically EP2359852A1 T RB O
to EP2359852A1 T TO O
constituent EP2359852A1 T VB O
factor EP2359852A1 T NN O
of EP2359852A1 T IN O
cancer EP2359852A1 T NN O
stroma EP2359852A1 T NN O
and EP2359852A1 T CC O
anti-tumor EP2359852A1 T JJ O
compound EP2359852A1 T NN O
. EP2359852A1 T . O

Health CN103599137A T NNP O
food CN103599137A T NN O
containing CN103599137A T VBG O
plurality CN103599137A T NN O
of CN103599137A T IN O
trace CN103599137A T NN O
nutrient CN103599137A T JJ O
elements CN103599137A T NNS O
. CN103599137A T . O

Pharmaceutical CN103301134A T JJ O
composition CN103301134A T NN O
for CN103301134A T IN O
treating CN103301134A T VBG O
hyperlipidemia CN103301134A T NN O
as CN103301134A T RB O
well CN103301134A T RB O
as CN103301134A T IN O
preparation CN103301134A T NN O
method CN103301134A T NN O
and CN103301134A T CC O
applications CN103301134A T NNS O
. CN103301134A T . O

Process EP1274686B1 T NN O
for EP1274686B1 T IN O
preparing EP1274686B1 T VBG O
2- EP1274686B1 T JJ O
( EP1274686B1 T ( O
4-chlorobenzolamino EP1274686B1 T JJ O
) EP1274686B1 T ) O
-3- EP1274686B1 T VBZ O
2 EP1274686B1 T CD O
( EP1274686B1 T ( O
1h EP1274686B1 T CD O
) EP1274686B1 T ) O
-quinolinon-4-yl EP1274686B1 T NN O
proprionic EP1274686B1 T JJ O
acid EP1274686B1 T NN O
. EP1274686B1 T . O

P-glycoprotein CN102125522A T NNP O
monoclonal CN102125522A T JJ O
antibody CN102125522A T NN O
modified CN102125522A T VBD O
phenytoin CN102125522A T JJ O
targeting CN102125522A T VBG O
nanopreparation CN102125522A T NN O
and CN102125522A T CC O
preparation CN102125522A T NN O
method CN102125522A T NN O
thereof CN102125522A T NN O
. CN102125522A T . O

Histone WO2004071400A3 T NNP O
deacetylase WO2004071400A3 T NN O
inhibitors WO2004071400A3 T NNS O
of WO2004071400A3 T IN O
novel WO2004071400A3 T JJ O
benzamide WO2004071400A3 T NN O
derivatives WO2004071400A3 T NNS O
with WO2004071400A3 T IN O
potent WO2004071400A3 T JJ O
differentiation WO2004071400A3 T NN O
and WO2004071400A3 T CC O
anti-proliferation WO2004071400A3 T NN O
activity WO2004071400A3 T NN O
. WO2004071400A3 T . O

Method EP1967591A2 T NNP O
of EP1967591A2 T IN O
assessing EP1967591A2 T VBG O
the EP1967591A2 T DT O
usefulness EP1967591A2 T NN O
of EP1967591A2 T IN O
a EP1967591A2 T DT O
test EP1967591A2 T NN O
compound EP1967591A2 T NN O
for EP1967591A2 T IN O
alleviating EP1967591A2 T VBG O
a EP1967591A2 T DT O
pneumococcal EP1967591A2 T JJ O
infection EP1967591A2 T NN O
in EP1967591A2 T IN O
an EP1967591A2 T DT O
animal EP1967591A2 T NN O
. EP1967591A2 T . O

Purine CN102803263A T NNP O
compounds CN102803263A T NNS O
used CN102803263A T VBD O
as CN102803263A T IN O
cb2 CN102803263A T JJ I-UN
agonists CN102803263A T NNS O
. CN102803263A T . O

Quinazoline US20100143295 T JJ O
inhibitors US20100143295 T NNS O
of US20100143295 T IN O
egfr US20100143295 T JJ I-UN
tyrosine US20100143295 T JJ O
kinase US20100143295 T NN O
. US20100143295 T . O

The US20100143295 A DT O
present US20100143295 A JJ O
invention US20100143295 A NN O
relates US20100143295 A VBZ O
to US20100143295 A TO O
new US20100143295 A JJ O
quinazoline US20100143295 A JJ O
inhibitors US20100143295 A NNS O
of US20100143295 A IN O
EGFR US20100143295 A NNP I-UN
tyrosine US20100143295 A NN O
kinase US20100143295 A NN O
, US20100143295 A , O
pharmaceutical US20100143295 A JJ O
compositions US20100143295 A NNS O
thereof US20100143295 A NN O
, US20100143295 A , O
and US20100143295 A CC O
methods US20100143295 A NNS O
of US20100143295 A IN O
use US20100143295 A NN O
thereof US20100143295 A NN O
. US20100143295 A . O

This US20110172274 A DT O
invention US20110172274 A NN O
concerns US20110172274 A NNS O
fluorinated US20110172274 A VBD O
3,4-diaryl-4,5-dihydro-1H-pyrazole-1-carboxamidine US20110172274 A JJ O
derivatives US20110172274 A NNS O
as US20110172274 A IN O
cannabinoid-CB1 US20110172274 A JJ O
receptor US20110172274 A NN I-UN
antagonists US20110172274 A NNS O
, US20110172274 A , O
methods US20110172274 A NNS O
for US20110172274 A IN O
preparing US20110172274 A VBG O
these US20110172274 A DT O
compounds US20110172274 A NNS O
, US20110172274 A , O
novel US20110172274 A JJ O
intermediates US20110172274 A NNS O
useful US20110172274 A JJ O
for US20110172274 A IN O
the US20110172274 A DT O
synthesis US20110172274 A NN O
of US20110172274 A IN O
said US20110172274 A VBD O
compounds US20110172274 A NNS O
, US20110172274 A , O
methods US20110172274 A NNS O
for US20110172274 A IN O
the US20110172274 A DT O
preparation US20110172274 A NN O
of US20110172274 A IN O
these US20110172274 A DT O
intermediates US20110172274 A NNS O
, US20110172274 A , O
pharmaceutical US20110172274 A JJ O
compositions US20110172274 A NNS O
containing US20110172274 A VBG O
one US20110172274 A CD O
or US20110172274 A CC O
more US20110172274 A JJR O
of US20110172274 A IN O
these US20110172274 A DT O
dihydropyrazole US20110172274 A JJ O
derivatives US20110172274 A NNS O
as US20110172274 A IN O
active US20110172274 A JJ O
ingredient US20110172274 A NN O
, US20110172274 A , O
as US20110172274 A RB O
well US20110172274 A RB O
as US20110172274 A IN O
the US20110172274 A DT O
use US20110172274 A NN O
of US20110172274 A IN O
these US20110172274 A DT O
pharmaceutical US20110172274 A JJ O
compositions US20110172274 A NNS O
for US20110172274 A IN O
the US20110172274 A DT O
treatment US20110172274 A NN O
of US20110172274 A IN O
obesity US20110172274 A NN O
and US20110172274 A CC O
obesity-related US20110172274 A JJ O
cardiovascular US20110172274 A NN O
disorders US20110172274 A NNS O
, US20110172274 A , O
drug US20110172274 A NN O
addiction US20110172274 A NN O
, US20110172274 A , O
cognition US20110172274 A NN O
deficits US20110172274 A NNS O
, US20110172274 A , O
liver US20110172274 A JJ O
fibrosis US20110172274 A NN O
and US20110172274 A CC O
inflammatory US20110172274 A NN O
disorders US20110172274 A NNS O
. US20110172274 A . O

Curcumin CN1943566A T NNP O
liposome CN1943566A T NN O
and CN1943566A T CC O
its CN1943566A T PRP$ O
method CN1943566A T NN O
for CN1943566A T IN O
preparing CN1943566A T VBG O
freeze-dried CN1943566A T JJ O
powder CN1943566A T NN O
injection CN1943566A T NN O
. CN1943566A T . O

Pharmaceutically EP2532666A1 T RB O
acceptable EP2532666A1 T JJ O
salts EP2532666A1 T NNS O
of EP2532666A1 T IN O
pyrrolo-nitrogenous EP2532666A1 T JJ O
heterocyclic EP2532666A1 T JJ O
derivatives EP2532666A1 T NNS O
, EP2532666A1 T , O
preparation EP2532666A1 T NN O
method EP2532666A1 T NN O
and EP2532666A1 T CC O
medical EP2532666A1 T JJ O
use EP2532666A1 T NN O
thereof EP2532666A1 T NN O
. EP2532666A1 T . O

Wound CN101991484A T NNP O
pain CN101991484A T NN O
quick CN101991484A T JJ O
recovery CN101991484A T NN O
application CN101991484A T NN O
instrument CN101991484A T NN O
. CN101991484A T . O

The CN101991484A A DT O
invention CN101991484A A NN O
discloses CN101991484A A VBZ O
a CN101991484A A DT O
wound CN101991484A A NN O
pain CN101991484A A NN O
quick CN101991484A A JJ O
recovery CN101991484A A NN O
application CN101991484A A NN O
instrument CN101991484A A NN O
, CN101991484A A , O
which CN101991484A A WDT O
comprises CN101991484A A VBZ O
a CN101991484A A DT O
body CN101991484A A NN O
, CN101991484A A , O
a CN101991484A A DT O
controller CN101991484A A NN O
, CN101991484A A , O
a CN101991484A A DT O
keyboard CN101991484A A NN O
circuit CN101991484A A NN O
, CN101991484A A , O
an CN101991484A A DT O
indicator CN101991484A A NN O
light CN101991484A A NN O
, CN101991484A A , O
a CN101991484A A DT O
display CN101991484A A NN O
screen CN101991484A A NN O
, CN101991484A A , O
and CN101991484A A CC O
three CN101991484A A CD O
current CN101991484A A JJ O
and CN101991484A A CC O
voltage CN101991484A A NN O
regulating CN101991484A A VBG O
circuits CN101991484A A NNS O
, CN101991484A A , O
wherein CN101991484A A VBP O
the CN101991484A A DT O
controller CN101991484A A NN O
is CN101991484A A VBZ O
respectively CN101991484A A RB O
connected CN101991484A A VBN O
with CN101991484A A IN O
the CN101991484A A DT O
keyboard CN101991484A A NN O
circuit CN101991484A A NN O
, CN101991484A A , O
the CN101991484A A DT O
display CN101991484A A NN O
screen CN101991484A A NN O
, CN101991484A A , O
the CN101991484A A DT O
three CN101991484A A CD O
current CN101991484A A JJ O
and CN101991484A A CC O
voltage CN101991484A A NN O
regulating CN101991484A A VBG O
circuits CN101991484A A NNS O
, CN101991484A A , O
a CN101991484A A DT O
timing CN101991484A A NN O
circuit CN101991484A A NN O
and CN101991484A A CC O
the CN101991484A A DT O
indicator CN101991484A A NN O
light CN101991484A A NN O
; CN101991484A A : O
and CN101991484A A CC O
the CN101991484A A DT O
output CN101991484A A NN O
ends CN101991484A A NNS O
of CN101991484A A IN O
the CN101991484A A DT O
three CN101991484A A CD O
current CN101991484A A JJ O
and CN101991484A A CC O
voltage CN101991484A A NN O
regulating CN101991484A A NN O
circuits CN101991484A A NNS O
are CN101991484A A VBP O
respectively CN101991484A A RB O
connected CN101991484A A VBN O
with CN101991484A A IN O
three CN101991484A A CD O
groups CN101991484A A NNS O
of CN101991484A A IN O
positive CN101991484A A JJ O
and CN101991484A A CC O
negative CN101991484A A JJ O
electrodes CN101991484A A NNS O
which CN101991484A A WDT O
are CN101991484A A VBP O
respectively CN101991484A A RB O
connected CN101991484A A VBN O
to CN101991484A A TO O
three CN101991484A A CD O
groups CN101991484A A NNS O
of CN101991484A A IN O
application CN101991484A A NN O
metal CN101991484A A NN O
sheets CN101991484A A NNS O
. CN101991484A A . O

The CN101991484A A DT O
wound CN101991484A A NN O
pain CN101991484A A NN O
quick CN101991484A A JJ O
recovery CN101991484A A NN O
application CN101991484A A NN O
instrument CN101991484A A NN O
has CN101991484A A VBZ O
a CN101991484A A DT O
reasonable CN101991484A A JJ O
structure CN101991484A A NN O
, CN101991484A A , O
is CN101991484A A VBZ O
convenient CN101991484A A JJ O
to CN101991484A A TO O
use CN101991484A A VB O
, CN101991484A A , O
can CN101991484A A MD O
form CN101991484A A VB O
an CN101991484A A DT O
electric CN101991484A A JJ O
field CN101991484A A NN O
on CN101991484A A IN O
the CN101991484A A DT O
wound CN101991484A A NN O
surface CN101991484A A NN O
, CN101991484A A , O
accelerates CN101991484A A VBZ O
the CN101991484A A DT O
quick CN101991484A A JJ O
healing CN101991484A A NN O
of CN101991484A A IN O
the CN101991484A A DT O
wound CN101991484A A NN O
surface CN101991484A A NN O
, CN101991484A A , O
reduces CN101991484A A VBZ O
scar CN101991484A A NN O
tissues CN101991484A A NNS O
, CN101991484A A , O
alleviates CN101991484A A NNS O
pain CN101991484A A VBP O
, CN101991484A A , O
prevents CN101991484A A NNS O
fat CN101991484A A VBP O
liquoring CN101991484A A VBG O
and CN101991484A A CC O
postoperative CN101991484A A JJ O
pulmonary CN101991484A A JJ O
embolism CN101991484A A NN O
, CN101991484A A , O
and CN101991484A A CC O
accelerates CN101991484A A VBZ O
the CN101991484A A DT O
recovery CN101991484A A NN O
of CN101991484A A IN O
myoneural CN101991484A A JJ O
junctions CN101991484A A NNS O
. CN101991484A A . O

Naphthyridin-2 US20120115899 T NNP O
( US20120115899 T ( O
1 US20120115899 T CD O
h US20120115899 T NN O
) US20120115899 T ) O
-one US20120115899 T NN O
compounds US20120115899 T VBZ O
useful US20120115899 T JJ O
as US20120115899 T IN O
antibacterials US20120115899 T NNS O
. US20120115899 T . O

Refreshing CN102038791A T VBG O
liniment CN102038791A T NN O
. CN102038791A T . O

Gynostemma CN1785181A T NNP O
pentaphylla CN1785181A T NN O
tolal CN1785181A T NN O
glucoside CN1785181A T NN O
dripping CN1785181A T VBG O
pills CN1785181A T NNS O
and CN1785181A T CC O
its CN1785181A T PRP$ O
prepn CN1785181A T NN O
. CN1785181A T . O

method CN1785181A T NN O
. CN1785181A T . O

Methods US6942966 T NNS O
for US6942966 T IN O
processing US6942966 T VBG O
chemical US6942966 T NN O
compounds US6942966 T NNS O
having US6942966 T VBG O
reactive US6942966 T JJ O
functional US6942966 T JJ O
groups US6942966 T NNS O
. US6942966 T . O

Lysosomal EP2561069A2 T JJ O
storage EP2561069A2 T NN O
disease EP2561069A2 T NN O
enzyme EP2561069A2 T NN O
. EP2561069A2 T . O

The EP2561069A2 A DT O
present EP2561069A2 A JJ O
invention EP2561069A2 A NN O
provides EP2561069A2 A VBZ O
compositions EP2561069A2 A NNS O
of EP2561069A2 A IN O
recombinant EP2561069A2 A JJ O
human EP2561069A2 A JJ I-UN
lysosomal EP2561069A2 A JJ I-UN
acid EP2561069A2 A NN I-UN
lipase EP2561069A2 A NN I-UN
having EP2561069A2 A VBG O
particular EP2561069A2 A JJ O
glycosylation EP2561069A2 A NN O
patterns EP2561069A2 A NNS O
for EP2561069A2 A IN O
internalization EP2561069A2 A NN O
into EP2561069A2 A IN O
target EP2561069A2 A NN O
cells EP2561069A2 A NNS O
, EP2561069A2 A , O
a EP2561069A2 A DT O
vector EP2561069A2 A NN O
containing EP2561069A2 A VBG O
the EP2561069A2 A DT O
nucleic EP2561069A2 A JJ O
acid EP2561069A2 A NN O
encoding EP2561069A2 A VBG O
human EP2561069A2 A JJ I-UN
lysosomal EP2561069A2 A JJ I-UN
acid EP2561069A2 A NN I-UN
lipase EP2561069A2 A NN I-UN
, EP2561069A2 A , O
a EP2561069A2 A DT O
host EP2561069A2 A NN O
cell EP2561069A2 A NN O
transformed EP2561069A2 A VBN O
with EP2561069A2 A IN O
the EP2561069A2 A DT O
vector EP2561069A2 A NN O
, EP2561069A2 A , O
pharmaceutical EP2561069A2 A JJ O
compositions EP2561069A2 A NNS O
comprising EP2561069A2 A VBG O
the EP2561069A2 A DT O
recombinant EP2561069A2 A JJ O
human EP2561069A2 A JJ I-UN
lysosomal EP2561069A2 A JJ I-UN
acid EP2561069A2 A NN I-UN
lipase EP2561069A2 A NN I-UN
and EP2561069A2 A CC O
method EP2561069A2 A NN O
of EP2561069A2 A IN O
treating EP2561069A2 A VBG O
conditions EP2561069A2 A NNS O
associated EP2561069A2 A VBN O
with EP2561069A2 A IN O
lysosomal EP2561069A2 A JJ I-UN
acid EP2561069A2 A JJ I-UN
lipase EP2561069A2 A NN I-UN
deficiency EP2561069A2 A NN O
. EP2561069A2 A . O

Imidazolidinone WO2009011910A3 T NNP O
compounds WO2009011910A3 T VBZ O
, WO2009011910A3 T , O
methods WO2009011910A3 T NNS O
to WO2009011910A3 T TO O
inhibit WO2009011910A3 T VB O
deubiquitination WO2009011910A3 T NN O
and WO2009011910A3 T CC O
methods WO2009011910A3 T NNS O
of WO2009011910A3 T IN O
treatment WO2009011910A3 T NN O
. WO2009011910A3 T . O

Isoflavone US20090099099 T NNP O
Glycosides US20090099099 T NNP O
as US20090099099 T IN O
Peroxisome US20090099099 T NNP I-UN
Proliferator-Activated US20090099099 T NNP I-UN
Receptor-alpha US20090099099 T NNP I-UN
Modulator US20090099099 T NNP O
. US20090099099 T . O

A US20090099099 A DT O
method US20090099099 A NN O
of US20090099099 A IN O
treating US20090099099 A VBG O
or US20090099099 A CC O
preventing US20090099099 A VBG O
diseases US20090099099 A NNS O
related US20090099099 A VBN O
to US20090099099 A TO O
modulation US20090099099 A NN O
of US20090099099 A IN O
PPAR-α US20090099099 A NNP I-UN
in US20090099099 A IN O
comprising US20090099099 A VBG O
administering US20090099099 A VBG O
to US20090099099 A TO O
a US20090099099 A DT O
human US20090099099 A JJ O
or US20090099099 A CC O
other US20090099099 A JJ O
mammals US20090099099 A NNS O
in US20090099099 A IN O
need US20090099099 A NN O
of US20090099099 A IN O
such US20090099099 A JJ O
treatment US20090099099 A NN O
an US20090099099 A DT O
effective US20090099099 A JJ O
amount US20090099099 A NN O
of US20090099099 A IN O
plant US20090099099 A NN O
material US20090099099 A NN O
derived US20090099099 A VBN O
from US20090099099 A IN O
plants US20090099099 A NNS O
of US20090099099 A IN O
the US20090099099 A DT O
genera US20090099099 A NN O
Puerila US20090099099 A NNP O
Lobata US20090099099 A NNP O
. US20090099099 A . O

Methods US20100015093 T NNS O
and US20100015093 T CC O
compositions US20100015093 T NNS O
of US20100015093 T IN O
treating US20100015093 T VBG O
a US20100015093 T DT O
flaviviridae US20100015093 T JJ O
family US20100015093 T NN O
viral US20100015093 T JJ O
infection US20100015093 T NN O
. US20100015093 T . O

Briefly US20100015093 A NNP O
described US20100015093 A VBD O
, US20100015093 A , O
embodiments US20100015093 A NNS O
of US20100015093 A IN O
this US20100015093 A DT O
disclosure US20100015093 A NN O
include US20100015093 A VBP O
compounds US20100015093 A NNS O
, US20100015093 A , O
pharmaceutical US20100015093 A JJ O
compositions US20100015093 A NNS O
, US20100015093 A , O
methods US20100015093 A NNS O
of US20100015093 A IN O
treating US20100015093 A VBG O
a US20100015093 A DT O
host US20100015093 A NN O
infected US20100015093 A VBN O
with US20100015093 A IN O
a US20100015093 A DT O
virus US20100015093 A NN O
from US20100015093 A IN O
the US20100015093 A DT O
Flaviviridae US20100015093 A NNP O
family US20100015093 A NN O
of US20100015093 A IN O
viruses US20100015093 A NNS O
, US20100015093 A , O
methods US20100015093 A NNS O
of US20100015093 A IN O
inhibiting US20100015093 A VBG O
HCV US20100015093 A NNP O
replication US20100015093 A NN O
in US20100015093 A IN O
a US20100015093 A DT O
host US20100015093 A NN O
, US20100015093 A , O
methods US20100015093 A NNS O
of US20100015093 A IN O
inhibiting US20100015093 A VBG O
the US20100015093 A DT O
binding US20100015093 A NN O
of US20100015093 A IN O
NS4B US20100015093 A NNP I-UN
polypeptide US20100015093 A NN I-UN
to US20100015093 A TO O
the US20100015093 A DT O
3′UTR US20100015093 A CD I-UN
of US20100015093 A IN I-UN
HCV US20100015093 A NNP I-UN
negative US20100015093 A JJ I-UN
strand US20100015093 A NN I-UN
RNA US20100015093 A NNP I-UN
in US20100015093 A IN O
a US20100015093 A DT O
host US20100015093 A NN O
, US20100015093 A , O
methods US20100015093 A NNS O
of US20100015093 A IN O
treating US20100015093 A VBG O
liver US20100015093 A JJ O
fibrosis US20100015093 A NN O
in US20100015093 A IN O
a US20100015093 A DT O
host US20100015093 A NN O
, US20100015093 A , O
and US20100015093 A CC O
the US20100015093 A DT O
like US20100015093 A JJ O
. US20100015093 A . O

Ibuprofen CN101912360A T NNP O
suspension CN101912360A T NN O
and CN101912360A T CC O
preparation CN101912360A T NN O
method CN101912360A T NN O
thereof CN101912360A T NN O
. CN101912360A T . O

Carbazole EP1793819A2 T NNP O
and EP1793819A2 T CC O
cyclopentaindole EP1793819A2 T JJ O
derivatives EP1793819A2 T NNS O
to EP1793819A2 T TO O
treat EP1793819A2 T VB O
infection EP1793819A2 T NN O
with EP1793819A2 T IN O
hepatitis EP1793819A2 T NN O
c EP1793819A2 T NN O
virus EP1793819A2 T NN O
. EP1793819A2 T . O

Substituted US7230103 T VBN O
3,4-dihydropyrido US7230103 T JJ O
[ US7230103 T JJ O
1,2-a US7230103 T JJ O
] US7230103 T NN O
pyrimidines US7230103 T NNS O
. US7230103 T . O

Substituted US20080171786 T VBN O
[ US20080171786 T NN O
( US20080171786 T ( O
Phenylethanoyl US20080171786 T NNP O
) US20080171786 T ) O
Amino US20080171786 T NNP O
] US20080171786 T NNP O
Benzamides US20080171786 T NNP O
. US20080171786 T . O

Kinamycin WO2009027838A3 T NNP O
f WO2009027838A3 T NN O
for WO2009027838A3 T IN O
cancer WO2009027838A3 T NN O
treatment WO2009027838A3 T NN O
. WO2009027838A3 T . O

As WO2009027838A3 A IN O
set WO2009027838A3 A VBN O
forth WO2009027838A3 A NN O
herein WO2009027838A3 A NN O
, WO2009027838A3 A , O
the WO2009027838A3 A DT O
anti-cancer WO2009027838A3 A JJ O
effects WO2009027838A3 A NNS O
of WO2009027838A3 A IN O
kinamycin WO2009027838A3 A NNS O
F WO2009027838A3 A NNP O
may WO2009027838A3 A MD O
be WO2009027838A3 A VB O
attributed WO2009027838A3 A VBN O
to WO2009027838A3 A TO O
, WO2009027838A3 A , O
for WO2009027838A3 A IN O
example WO2009027838A3 A NN O
, WO2009027838A3 A , O
DNA WO2009027838A3 A NNP O
binding WO2009027838A3 A NN O
, WO2009027838A3 A , O
DNA WO2009027838A3 A NNP O
intercalation WO2009027838A3 A NN O
, WO2009027838A3 A , O
topoisomerase WO2009027838A3 A NN I-UN
Ilα WO2009027838A3 A NNP I-UN
decatenation WO2009027838A3 A NN O
activity WO2009027838A3 A NN O
inhibition WO2009027838A3 A NN O
and/or WO2009027838A3 A IN O
production WO2009027838A3 A NN O
of WO2009027838A3 A IN O
radical WO2009027838A3 A JJ O
species WO2009027838A3 A NNS O
by WO2009027838A3 A IN O
kinamycin WO2009027838A3 A NN O
F WO2009027838A3 A NNP O
. WO2009027838A3 A . O

Medicamentous CN101947235A T JJ O
application CN101947235A T NN O
of CN101947235A T IN O
CPE CN101947235A T NNP O
( CN101947235A T ( O
Conjugated CN101947235A T NNP O
Polyelectrolyte CN101947235A T NNP O
) CN101947235A T ) O
. CN101947235A T . O

The CN101947235A A DT O
invention CN101947235A A NN O
relates CN101947235A A VBZ O
to CN101947235A A TO O
application CN101947235A A NN O
of CN101947235A A IN O
a CN101947235A A DT O
CPE CN101947235A A NNP O
( CN101947235A A ( O
Conjugated CN101947235A A NNP O
Polyelectrolyte CN101947235A A NNP O
) CN101947235A A ) O
as CN101947235A A IN O
a CN101947235A A DT O
novel CN101947235A A JJ O
therapeutic CN101947235A A JJ O
agent CN101947235A A NN O
which CN101947235A A WDT O
takes CN101947235A A VBZ O
effect CN101947235A A NN O
by CN101947235A A IN O
interfering CN101947235A A VBG O
the CN101947235A A DT O
formation CN101947235A A NN O
of CN101947235A A IN O
misfolding CN101947235A A NN O
, CN101947235A A , O
pathological CN101947235A A JJ O
or CN101947235A A CC O
rogue CN101947235A A JJ O
proteins CN101947235A A NNS O
or CN101947235A A CC O
capturing CN101947235A A VBG O
the CN101947235A A DT O
misfolding CN101947235A A NN O
, CN101947235A A , O
pathological CN101947235A A JJ O
or CN101947235A A CC O
rogue CN101947235A A JJ O
proteins CN101947235A A NNS O
in CN101947235A A IN O
vivo CN101947235A A NN O
. CN101947235A A . O

Ketoprofen CN101804040A T NNP O
slow-release CN101804040A T NN O
orally CN101804040A T RB O
disintegrating CN101804040A T VBG O
tablets CN101804040A T NNS O
. CN101804040A T . O

Chemical US20120077801 T NNP O
Compounds US20120077801 T NNP O
637 US20120077801 T CD O
. US20120077801 T . O

The US20120077801 A DT O
present US20120077801 A JJ O
invention US20120077801 A NN O
provides US20120077801 A VBZ O
a US20120077801 A DT O
compound US20120077801 A NN O
of US20120077801 A IN O
a US20120077801 A DT O
formula US20120077801 A NN O
( US20120077801 A ( O
I US20120077801 A PRP O
) US20120077801 A ) O
: US20120077801 A : O
wherein US20120077801 A VB O
the US20120077801 A DT O
variables US20120077801 A NNS O
are US20120077801 A VBP O
defined US20120077801 A VBN O
herein US20120077801 A RB O
; US20120077801 A : O
to US20120077801 A TO O
a US20120077801 A DT O
process US20120077801 A NN O
for US20120077801 A IN O
preparing US20120077801 A VBG O
such US20120077801 A PDT O
a US20120077801 A DT O
compound US20120077801 A NN O
; US20120077801 A : O
and US20120077801 A CC O
to US20120077801 A TO O
the US20120077801 A DT O
use US20120077801 A NN O
of US20120077801 A IN O
such US20120077801 A JJ O
a US20120077801 A DT O
compound US20120077801 A NN O
in US20120077801 A IN O
the US20120077801 A DT O
treatment US20120077801 A NN O
of US20120077801 A IN O
a US20120077801 A DT O
PDE4 US20120077801 A NNP I-UN
mediated US20120077801 A VBD O
disease US20120077801 A NN O
state US20120077801 A NN O
. US20120077801 A . O

Pouzolzia CN102362877A T NNP O
extract CN102362877A T NN O
, CN102362877A T , O
preparation CN102362877A T NN O
method CN102362877A T NN O
thereof CN102362877A T NN O
, CN102362877A T , O
and CN102362877A T CC O
application CN102362877A T NN O
thereof CN102362877A T NN O
. CN102362877A T . O

Targeted US20100169995 T VBN O
gene US20100169995 T NN O
disruptions US20100169995 T NNS O
in US20100169995 T IN O
the US20100169995 T DT O
iqgap2 US20100169995 T JJ I-UN
gene US20100169995 T NN O
. US20100169995 T . O

The US20100169995 A DT O
invention US20100169995 A NN O
provides US20100169995 A VBZ O
a US20100169995 A DT O
non-human US20100169995 A JJ O
mammal US20100169995 A NN O
or US20100169995 A CC O
a US20100169995 A DT O
cell US20100169995 A NN O
line US20100169995 A NN O
that US20100169995 A WDT O
has US20100169995 A VBZ O
a US20100169995 A DT O
targeted US20100169995 A VBN O
gene US20100169995 A NN O
disruption US20100169995 A NN O
in US20100169995 A IN O
an US20100169995 A DT O
endogenous US20100169995 A JJ O
Iqgap2 US20100169995 A NNP I-UN
gene US20100169995 A NN O
. US20100169995 A . O

Light-induced WO2013038666A1 T JJ O
seizure WO2013038666A1 T NN O
model WO2013038666A1 T NN O
in WO2013038666A1 T IN O
rat WO2013038666A1 T NN O
brains WO2013038666A1 T NNS O
. WO2013038666A1 T . O

Compositions WO2010005735A3 T NNS O
for WO2010005735A3 T IN O
inducing WO2010005735A3 T VBG O
immune WO2010005735A3 T JJ O
responses WO2010005735A3 T NNS O
specific WO2010005735A3 T JJ O
to WO2010005735A3 T TO O
globo WO2010005735A3 T VB O
h WO2010005735A3 T NN O
and WO2010005735A3 T CC O
ssea3 WO2010005735A3 T NN O
and WO2010005735A3 T CC O
uses WO2010005735A3 T VBZ O
thereof WO2010005735A3 T NN O
in WO2010005735A3 T IN O
cancer WO2010005735A3 T NN O
treatment WO2010005735A3 T NN O
. WO2010005735A3 T . O

Also WO2010005735A3 A RB O
disclosed WO2010005735A3 A VBN O
is WO2010005735A3 A VBZ O
a WO2010005735A3 A DT O
method WO2010005735A3 A NN O
of WO2010005735A3 A IN O
treating WO2010005735A3 A VBG O
cancer WO2010005735A3 A NN O
by WO2010005735A3 A IN O
inhibiting WO2010005735A3 A VBG O
the WO2010005735A3 A DT O
activity WO2010005735A3 A NN O
of WO2010005735A3 A IN O
one WO2010005735A3 A CD O
of WO2010005735A3 A IN O
FUT1 WO2010005735A3 A NNP I-UN
and WO2010005735A3 A CC O
FUT2 WO2010005735A3 A NNP I-UN
, WO2010005735A3 A , O
both WO2010005735A3 A DT O
of WO2010005735A3 A IN O
which WO2010005735A3 A WDT O
involve WO2010005735A3 A VBP O
in WO2010005735A3 A IN O
Globo WO2010005735A3 A NNP O
H WO2010005735A3 A NNP O
biosynthesis WO2010005735A3 A NN O
. WO2010005735A3 A . O

Sodium CN1813674A T NNP O
vitamin CN1813674A T NN O
C CN1813674A T NNP O
formulation CN1813674A T NN O
for CN1813674A T IN O
intravenous CN1813674A T JJ O
administration CN1813674A T NN O
and CN1813674A T CC O
its CN1813674A T PRP$ O
preparing CN1813674A T NN O
method CN1813674A T NN O
. CN1813674A T . O

Antithrombotic US20080108594 T JJ O
Ethers US20080108594 T NNS O
. US20080108594 T . O

Use WO2010079255A1 T NNP O
of WO2010079255A1 T IN O
inverse WO2010079255A1 T JJ O
antagonists WO2010079255A1 T NNS O
and/or WO2010079255A1 T VBP O
agonists WO2010079255A1 T NNS O
of WO2010079255A1 T IN O
cb1 WO2010079255A1 T NN I-UN
receptors WO2010079255A1 T NNS I-UN
for WO2010079255A1 T IN O
preparing WO2010079255A1 T VBG O
drugs WO2010079255A1 T NNS O
to WO2010079255A1 T TO O
increase WO2010079255A1 T VB O
motor WO2010079255A1 T NN O
neurone WO2010079255A1 T JJ O
excitability WO2010079255A1 T NN O
. WO2010079255A1 T . O

Use WO2010079255A1 A NNP O
of WO2010079255A1 A IN O
an WO2010079255A1 A DT O
inverse WO2010079255A1 A JJ O
antagonist WO2010079255A1 A NN O
and/or WO2010079255A1 A JJ O
agonist WO2010079255A1 A NN O
of WO2010079255A1 A IN O
CB1 WO2010079255A1 A NNP I-UN
receptors WO2010079255A1 A NNS I-UN
, WO2010079255A1 A , O
preferably WO2010079255A1 A RB O
rimonabant WO2010079255A1 A NN O
, WO2010079255A1 A , O
for WO2010079255A1 A IN O
preparing WO2010079255A1 A VBG O
drugs WO2010079255A1 A NNS O
that WO2010079255A1 A WDT O
are WO2010079255A1 A VBP O
useful WO2010079255A1 A JJ O
for WO2010079255A1 A IN O
increasing WO2010079255A1 A VBG O
motor WO2010079255A1 A NN O
neurone WO2010079255A1 A NN O
excitability WO2010079255A1 A NN O
at WO2010079255A1 A IN O
the WO2010079255A1 A DT O
level WO2010079255A1 A NN O
of WO2010079255A1 A IN O
the WO2010079255A1 A DT O
cerebral WO2010079255A1 A JJ O
cortex WO2010079255A1 A NN O
and/or WO2010079255A1 A IN O
the WO2010079255A1 A DT O
brainstem WO2010079255A1 A NN O
and/or WO2010079255A1 A NN O
at WO2010079255A1 A IN O
the WO2010079255A1 A DT O
spinal WO2010079255A1 A JJ O
level WO2010079255A1 A NN O
, WO2010079255A1 A , O
and WO2010079255A1 A CC O
also WO2010079255A1 A RB O
a WO2010079255A1 A DT O
method WO2010079255A1 A NN O
for WO2010079255A1 A IN O
increasing WO2010079255A1 A VBG O
motor WO2010079255A1 A NN O
neurone WO2010079255A1 A NN O
excitability WO2010079255A1 A NN O
by WO2010079255A1 A IN O
means WO2010079255A1 A NNS O
of WO2010079255A1 A IN O
the WO2010079255A1 A DT O
administration WO2010079255A1 A NN O
of WO2010079255A1 A IN O
an WO2010079255A1 A DT O
inverse WO2010079255A1 A JJ O
antagonist/agonist WO2010079255A1 A NN O
of WO2010079255A1 A IN O
CB1 WO2010079255A1 A NNP I-UN
receptors WO2010079255A1 A NNS I-UN
, WO2010079255A1 A , O
and WO2010079255A1 A CC O
to WO2010079255A1 A TO O
the WO2010079255A1 A DT O
use WO2010079255A1 A NN O
of WO2010079255A1 A IN O
a WO2010079255A1 A DT O
pharmaceutical WO2010079255A1 A JJ O
composition WO2010079255A1 A NN O
that WO2010079255A1 A WDT O
comprises WO2010079255A1 A VBZ O
an WO2010079255A1 A DT O
inverse WO2010079255A1 A JJ O
antagonist WO2010079255A1 A NN O
and/or WO2010079255A1 A JJ O
agonist WO2010079255A1 A NN O
of WO2010079255A1 A IN O
CB1 WO2010079255A1 A NNP I-UN
receptors WO2010079255A1 A NNS I-UN
, WO2010079255A1 A , O
preferably WO2010079255A1 A RB O
rimonabant WO2010079255A1 A NN O
, WO2010079255A1 A , O
for WO2010079255A1 A IN O
increasing WO2010079255A1 A VBG O
motor WO2010079255A1 A NN O
neurone WO2010079255A1 A NN O
excitability WO2010079255A1 A NN O
at WO2010079255A1 A IN O
the WO2010079255A1 A DT O
level WO2010079255A1 A NN O
of WO2010079255A1 A IN O
the WO2010079255A1 A DT O
cerebral WO2010079255A1 A JJ O
cortex WO2010079255A1 A NN O
and/or WO2010079255A1 A IN O
the WO2010079255A1 A DT O
brainstem WO2010079255A1 A NN O
and/or WO2010079255A1 A NN O
at WO2010079255A1 A IN O
the WO2010079255A1 A DT O
spinal WO2010079255A1 A JJ O
level WO2010079255A1 A NN O
. WO2010079255A1 A . O

CGRP US20080096878 T NNP I-UN
( US20080096878 T ( O
Calcitonin US20080096878 T NNP I-UN
Gene-Related US20080096878 T NNP I-UN
Peptide US20080096878 T NNP I-UN
) US20080096878 T ) O
; US20080096878 T : O
migraine US20080096878 T NN O
and US20080096878 T CC O
cluster US20080096878 T NN O
headaches US20080096878 T NNS O
; US20080096878 T : O
2- US20080096878 T JJ O
( US20080096878 T ( O
5-Bromo-1'1'-dioxido-2-oxo-2',3',5',6'-tetrahydrospiro US20080096878 T JJ O
[ US20080096878 T NNP O
indole-3,4'-thiopyran US20080096878 T NN O
] US20080096878 T NN O
-1 US20080096878 T NNP O
( US20080096878 T ( O
2H US20080096878 T CD O
) US20080096878 T ) O
-yl US20080096878 T NN O
) US20080096878 T ) O
-N- US20080096878 T NN O
( US20080096878 T ( O
2'-oxo-1,1',2',3-tetrahydrospiro US20080096878 T JJ O
[ US20080096878 T NNP O
indene-2,3'-pyrrolo US20080096878 T JJ O
[ US20080096878 T NNP O
2,3-b US20080096878 T JJ O
] US20080096878 T NNP O
pyridin US20080096878 T NN O
] US20080096878 T NNP O
-5-yl US20080096878 T NNP O
) US20080096878 T ) O
acetamide US20080096878 T NN O
for US20080096878 T IN O
example US20080096878 T NN O
; US20080096878 T : O
use US20080096878 T NN O
with US20080096878 T IN O
other US20080096878 T JJ O
drugs US20080096878 T NNS O
. US20080096878 T . O

The US20080096878 A DT O
present US20080096878 A JJ O
invention US20080096878 A NN O
is US20080096878 A VBZ O
directed US20080096878 A VBN O
to US20080096878 A TO O
compounds US20080096878 A NNS O
of US20080096878 A IN O
Formula US20080096878 A NNP O
( US20080096878 A ( O
I US20080096878 A PRP O
) US20080096878 A ) O
: US20080096878 A : O
( US20080096878 A ( O
where US20080096878 A WRB O
variables US20080096878 A NNS O
A1 US20080096878 A NNP O
, US20080096878 A , O
A2 US20080096878 A NNP O
, US20080096878 A , O
B US20080096878 A NNP O
, US20080096878 A , O
J US20080096878 A NNP O
, US20080096878 A , O
K US20080096878 A NNP O
, US20080096878 A , O
m US20080096878 A NN O
, US20080096878 A , O
n US20080096878 A RB O
, US20080096878 A , O
R4 US20080096878 A NNP O
, US20080096878 A , O
R5a US20080096878 A NNP O
, US20080096878 A , O
R5b US20080096878 A NNP O
and US20080096878 A CC O
R5c US20080096878 A NNP O
are US20080096878 A VBP O
as US20080096878 A IN O
defined US20080096878 A JJ O
herein US20080096878 A NN O
) US20080096878 A ) O
useful US20080096878 A JJ O
as US20080096878 A IN O
antagonists US20080096878 A NNS O
of US20080096878 A IN O
CGRP US20080096878 A NNP I-UN
receptors US20080096878 A NNS O
and US20080096878 A CC O
useful US20080096878 A JJ O
in US20080096878 A IN O
the US20080096878 A DT O
treatment US20080096878 A NN O
or US20080096878 A CC O
prevention US20080096878 A NN O
of US20080096878 A IN O
diseases US20080096878 A NNS O
in US20080096878 A IN O
which US20080096878 A WDT O
the US20080096878 A DT O
CGRP US20080096878 A NNP I-UN
is US20080096878 A VBZ O
involved US20080096878 A VBN O
, US20080096878 A , O
such US20080096878 A JJ O
as US20080096878 A IN O
headache US20080096878 A NN O
, US20080096878 A , O
migraine US20080096878 A NN O
and US20080096878 A CC O
cluster US20080096878 A NN O
headache US20080096878 A NN O
. US20080096878 A . O

The US20080096878 A DT O
invention US20080096878 A NN O
is US20080096878 A VBZ O
also US20080096878 A RB O
directed US20080096878 A VBN O
to US20080096878 A TO O
pharmaceutical US20080096878 A JJ O
compositions US20080096878 A NNS O
comprising US20080096878 A VBG O
these US20080096878 A DT O
compounds US20080096878 A NNS O
and US20080096878 A CC O
the US20080096878 A DT O
use US20080096878 A NN O
of US20080096878 A IN O
these US20080096878 A DT O
compounds US20080096878 A NNS O
and US20080096878 A CC O
compositions US20080096878 A NNS O
in US20080096878 A IN O
the US20080096878 A DT O
prevention US20080096878 A NN O
or US20080096878 A CC O
treatment US20080096878 A NN O
of US20080096878 A IN O
such US20080096878 A JJ O
diseases US20080096878 A NNS O
in US20080096878 A IN O
which US20080096878 A WDT O
CGRP US20080096878 A NNP I-UN
is US20080096878 A VBZ O
involved US20080096878 A VBN O
. US20080096878 A . O

Osteogenic US20120219599 T JJ O
promoting US20120219599 T NN O
implants US20120219599 T NNS O
and US20120219599 T CC O
methods US20120219599 T NNS O
of US20120219599 T IN O
inducing US20120219599 T VBG O
bone US20120219599 T NN O
growth US20120219599 T NN O
. US20120219599 T . O

The US20120219599 A DT O
present US20120219599 A JJ O
disclosure US20120219599 A NN O
describes US20120219599 A VBZ O
an US20120219599 A DT O
implant US20120219599 A NN O
for US20120219599 A IN O
improving US20120219599 A VBG O
bone US20120219599 A NN O
growth US20120219599 A NN O
including US20120219599 A VBG O
an US20120219599 A DT O
osteoconductive US20120219599 A JJ O
scaffold US20120219599 A NN O
and US20120219599 A CC O
an US20120219599 A DT O
osteoinductive US20120219599 A JJ O
small US20120219599 A JJ O
molecule US20120219599 A NN O
. US20120219599 A . O

The US20120219599 A DT O
osteoconductive US20120219599 A JJ O
scaffold US20120219599 A NN O
can US20120219599 A MD O
further US20120219599 A RB O
include US20120219599 A VB O
a US20120219599 A DT O
polymeric US20120219599 A JJ O
binder US20120219599 A NN O
. US20120219599 A . O

The US20120219599 A DT O
implant US20120219599 A NN O
can US20120219599 A MD O
also US20120219599 A RB O
include US20120219599 A VB O
an US20120219599 A DT O
osteogenic US20120219599 A JJ O
material US20120219599 A NN O
to US20120219599 A TO O
provide US20120219599 A VB O
a US20120219599 A DT O
viable US20120219599 A JJ O
cell US20120219599 A NN O
population US20120219599 A NN O
to US20120219599 A TO O
assist US20120219599 A VB O
the US20120219599 A DT O
bone US20120219599 A NN O
repair US20120219599 A NN O
and US20120219599 A CC O
remodeling US20120219599 A NN O
. US20120219599 A . O

Also US20120219599 A RB O
disclosed US20120219599 A VBN O
is US20120219599 A VBZ O
a US20120219599 A DT O
system US20120219599 A NN O
for US20120219599 A IN O
forming US20120219599 A VBG O
an US20120219599 A DT O
implant US20120219599 A NN O
for US20120219599 A IN O
improving US20120219599 A VBG O
bone US20120219599 A NN O
growth US20120219599 A NN O
, US20120219599 A , O
as US20120219599 A RB O
well US20120219599 A RB O
as US20120219599 A IN O
methods US20120219599 A NNS O
for US20120219599 A IN O
forming US20120219599 A VBG O
the US20120219599 A DT O
implant US20120219599 A JJ O
according US20120219599 A VBG O
to US20120219599 A TO O
the US20120219599 A DT O
disclosure US20120219599 A NN O
, US20120219599 A , O
in US20120219599 A IN O
addition US20120219599 A NN O
to US20120219599 A TO O
methods US20120219599 A NNS O
of US20120219599 A IN O
therapeutic US20120219599 A JJ O
use US20120219599 A NN O
of US20120219599 A IN O
the US20120219599 A DT O
implant US20120219599 A NN O
. US20120219599 A . O

PYRIDOPYRIMIDINONE WO2007044698A1 T NNP O
INHIBITORS WO2007044698A1 T NNP O
OF WO2007044698A1 T NNP O
PI3Kα WO2007044698A1 T NNP I-UN
. WO2007044698A1 T . O

Agent WO2006126325A1 T NNP O
having WO2006126325A1 T VBG O
antiobesity WO2006126325A1 T NN O
activity WO2006126325A1 T NN O
and WO2006126325A1 T CC O
method WO2006126325A1 T NN O
of WO2006126325A1 T IN O
inhibiting WO2006126325A1 T VBG O
obesity WO2006126325A1 T NN O
. WO2006126325A1 T . O

2-azetidinones CN1870988A T JJ O
as CN1870988A T IN O
anti-hypercholesterolemic CN1870988A T JJ O
agents CN1870988A T NNS O
. CN1870988A T . O

Liquid CN100998603A T NNP O
vitamic CN100998603A T JJ O
C CN100998603A T NNP O
compounded CN100998603A T VBD O
nanometer CN100998603A T RB O
elementary CN100998603A T JJ O
selenium CN100998603A T NN O
its CN100998603A T PRP$ O
preparation CN100998603A T NN O
method CN100998603A T NN O
and CN100998603A T CC O
storage CN100998603A T NN O
method CN100998603A T NN O
. CN100998603A T . O

Directed US20110104120 T VBN O
Evolution US20110104120 T NN O
and US20110104120 T CC O
In US20110104120 T IN O
Vivo US20110104120 T NNP O
Panning US20110104120 T NNP O
of US20110104120 T IN O
Virus US20110104120 T NNP O
Vectors US20110104120 T NNP O
. US20110104120 T . O

Plant CN103055057A T JJ O
weight-losing CN103055057A T NN O
and CN103055057A T CC O
fat-reducing CN103055057A T JJ O
composite CN103055057A T JJ O
compatible CN103055057A T JJ O
to CN103055057A T TO O
L-carnitine CN103055057A T NNP O
. CN103055057A T . O

A CN103055057A A DT O
weight-losing CN103055057A A JJ O
and CN103055057A A CC O
fat-reducing CN103055057A A JJ O
composite CN103055057A A NN O
which CN103055057A A WDT O
has CN103055057A A VBZ O
compatibility CN103055057A A NN O
effect CN103055057A A NN O
with CN103055057A A IN O
L-carnitine CN103055057A A NNP O
is CN103055057A A VBZ O
obtained CN103055057A A VBN O
by CN103055057A A IN O
screening CN103055057A A VBG O
natural CN103055057A A JJ O
products CN103055057A A NNS O
and CN103055057A A CC O
extracts CN103055057A A NNS O
by CN103055057A A IN O
taking CN103055057A A VBG O
a CN103055057A A DT O
triacylglycerol CN103055057A A NN O
enzyme CN103055057A A NN O
, CN103055057A A , O
amylopsin CN103055057A A NN I-UN
, CN103055057A A , O
fatty CN103055057A A JJ I-UN
acid CN103055057A A JJ I-UN
synthetase CN103055057A A NN I-UN
, CN103055057A A , O
an CN103055057A A DT O
auxiliary CN103055057A A JJ O
enzyme CN103055057A A NN O
B CN103055057A A NNP O
as CN103055057A A IN O
target CN103055057A A NN O
spots CN103055057A A NNS O
. CN103055057A A . O

Combination WO2010005851A1 T NNP O
therapy WO2010005851A1 T NN O
for WO2010005851A1 T IN O
treating WO2010005851A1 T VBG O
iron WO2010005851A1 T NN O
disorders WO2010005851A1 T NNS O
. WO2010005851A1 T . O

This WO2010005851A1 A DT O
invention WO2010005851A1 A NN O
is WO2010005851A1 A VBZ O
directed WO2010005851A1 A VBN O
to WO2010005851A1 A TO O
combination WO2010005851A1 A VB O
therapies WO2010005851A1 A NNS O
to WO2010005851A1 A TO O
treat WO2010005851A1 A VB O
iron WO2010005851A1 A NN O
overload WO2010005851A1 A NN O
disorders WO2010005851A1 A NNS O
utilizing WO2010005851A1 A JJ O
inhibitors WO2010005851A1 A NNS O
of WO2010005851A1 A IN O
divalent WO2010005851A1 A JJ I-UN
metal WO2010005851A1 A NN I-UN
transporter-1 WO2010005851A1 A NN I-UN
( WO2010005851A1 A ( O
DMT1 WO2010005851A1 A NNP I-UN
) WO2010005851A1 A ) O
, WO2010005851A1 A , O
proton WO2010005851A1 A JJ O
pump WO2010005851A1 A NN O
inhibitors WO2010005851A1 A NNS O
( WO2010005851A1 A ( O
PPIs WO2010005851A1 A NNP O
) WO2010005851A1 A ) O
, WO2010005851A1 A , O
calcium WO2010005851A1 A JJ O
channel WO2010005851A1 A NN O
blockers WO2010005851A1 A NNS O
and WO2010005851A1 A CC O
iron WO2010005851A1 A NN O
chelators WO2010005851A1 A NNS O
. WO2010005851A1 A . O

Protein CA2547887C T NNP O
modifier CA2547887C T JJR O
production CA2547887C T NN O
inhibitor CA2547887C T NN O
. CA2547887C T . O

Derivatives WO2010149888A1 T NNS O
of WO2010149888A1 T IN O
2-mercaptocyclopentane WO2010149888A1 T JJ O
carboxylic WO2010149888A1 T JJ O
acid WO2010149888A1 T NN O
, WO2010149888A1 T , O
method WO2010149888A1 T NN O
for WO2010149888A1 T IN O
the WO2010149888A1 T DT O
preparation WO2010149888A1 T NN O
thereof WO2010149888A1 T NN O
, WO2010149888A1 T , O
and WO2010149888A1 T CC O
pharmaceutical WO2010149888A1 T JJ O
compositions WO2010149888A1 T NNS O
containing WO2010149888A1 T VBG O
the WO2010149888A1 T DT O
same WO2010149888A1 T JJ O
. WO2010149888A1 T . O

Tetramethylation US20080096946 T NN O
of US20080096946 T IN O
3,5-di US20080096946 T JJ O
( US20080096946 T ( O
cyanomethyl US20080096946 T NN O
) US20080096946 T ) O
toluene US20080096946 T NN O
, US20080096946 T , O
oxidation US20080096946 T NN O
of US20080096946 T IN O
the US20080096946 T DT O
1-methyl US20080096946 T JJ O
group US20080096946 T NN O
to US20080096946 T TO O
form US20080096946 T VB O
an US20080096946 T DT O
aldehyde US20080096946 T NN O
, US20080096946 T , O
conversion US20080096946 T NN O
to US20080096946 T TO O
a US20080096946 T DT O
Boc-protected US20080096946 T JJ O
hydrazone US20080096946 T NN O
, US20080096946 T , O
reduction US20080096946 T NN O
to US20080096946 T TO O
a US20080096946 T DT O
Boc-protected US20080096946 T JJ O
hydrazine US20080096946 T NN O
, US20080096946 T , O
salt US20080096946 T NN O
formation US20080096946 T NN O
, US20080096946 T , O
conversion US20080096946 T NN O
to US20080096946 T TO O
anastrozole US20080096946 T VB O
; US20080096946 T : O
industrial US20080096946 T JJ O
scale US20080096946 T NN O
, US20080096946 T , O
high US20080096946 T JJ O
yield US20080096946 T NN O
and US20080096946 T CC O
purity US20080096946 T NN O
; US20080096946 T : O
anticarcinogenic US20080096946 T JJ O
agent US20080096946 T NN O
; US20080096946 T : O
breast US20080096946 T NN O
cancer US20080096946 T NN O
. US20080096946 T . O

Such US7943639 T JJ O
as US7943639 T IN O
6-benzenesulfonyl-4-piperazin-1-yl-quinoline US7943639 T JJ O
hydrochloride US7943639 T NN O
; US7943639 T : O
for US7943639 T IN O
treatment US7943639 T NN O
of US7943639 T IN O
central US7943639 T JJ O
nervous US7943639 T JJ O
system US7943639 T NN O
and/or US7943639 T JJ O
5- US7943639 T JJ I-UN
HT6 US7943639 T NNP I-UN
receptor US7943639 T NN O
related US7943639 T JJ O
disorders US7943639 T NNS O
; US7943639 T : O
for US7943639 T IN O
weight US7943639 T NN O
gain/loss US7943639 T NN O
. US7943639 T . O

Tissue-specific EP1702983A2 T JJ O
and EP1702983A2 T CC O
pathogen-specific EP1702983A2 T JJ O
toxic EP1702983A2 T NN O
agents EP1702983A2 T NNS O
, EP1702983A2 T , O
ribozymes EP1702983A2 T NNS O
, EP1702983A2 T , O
DNAzymes EP1702983A2 T NNP O
and EP1702983A2 T CC O
antisense EP1702983A2 T JJ O
oligonucleotides EP1702983A2 T NNS O
and EP1702983A2 T CC O
methods EP1702983A2 T NNS O
of EP1702983A2 T IN O
use EP1702983A2 T NN O
thereof EP1702983A2 T NN O
. EP1702983A2 T . O

Use WO2010088071A1 T NNP O
of WO2010088071A1 T IN O
whole WO2010088071A1 T JJ O
grain WO2010088071A1 T NN O
materials WO2010088071A1 T NNS O
with WO2010088071A1 T IN O
high WO2010088071A1 T JJ O
resistant WO2010088071A1 T JJ O
starch WO2010088071A1 T NN O
for WO2010088071A1 T IN O
satiety WO2010088071A1 T NN O
, WO2010088071A1 T , O
reduction WO2010088071A1 T NN O
of WO2010088071A1 T IN O
food WO2010088071A1 T NN O
intake WO2010088071A1 T NN O
and WO2010088071A1 T CC O
weight WO2010088071A1 T JJ O
management WO2010088071A1 T NN O
. WO2010088071A1 T . O

Nicotine-carrier US20090238797 T JJ O
vaccine US20090238797 T NN O
formulation US20090238797 T NN O
. US20090238797 T . O

Kalii CN102657673A T NNP O
dehydrographolidi CN102657673A T VBZ O
succinas CN102657673A T JJ O
freeze-dried CN102657673A T JJ O
powder CN102657673A T NN O
compound CN102657673A T NN O
for CN102657673A T IN O
injection CN102657673A T NN O
and CN102657673A T CC O
preparation CN102657673A T NN O
method CN102657673A T NN O
thereof CN102657673A T NN O
. CN102657673A T . O

Filling CN101366724A T VBG O
liquid CN101366724A T NN O
after CN101366724A T IN O
uterine CN101366724A T JJ O
lumen CN101366724A T NNS O
surgery CN101366724A T NN O
. CN101366724A T . O

Peroxisome USRE40558 T NNP O
proliferator-activated USRE40558 T JJ O
receptors USRE40558 T NNS O
agonists/ USRE40558 T VBP O
antagonists USRE40558 T NNS O
; USRE40558 T : O
2-methyl-6- USRE40558 T JJ O
[ USRE40558 T JJ O
3- USRE40558 T JJ O
( USRE40558 T ( O
quinolin-2-ylmethoxy USRE40558 T JJ O
) USRE40558 T ) O
-propoxymethyl USRE40558 T FW O
] USRE40558 T FW O
-benzoic USRE40558 T NNP O
acid USRE40558 T NN O
; USRE40558 T : O
eating USRE40558 T VBG O
diorders USRE40558 T NNS O
; USRE40558 T : O
physiological USRE40558 T JJ O
detrimental USRE40558 T NN O
blood USRE40558 T NN O
level USRE40558 T NN O
of USRE40558 T IN O
insulin USRE40558 T NN O
, USRE40558 T , O
glucose USRE40558 T NN O
, USRE40558 T , O
free USRE40558 T JJ O
fatty USRE40558 T JJ O
acids USRE40558 T NNS O
, USRE40558 T , O
or USRE40558 T CC O
triglycerides USRE40558 T NNS O
; USRE40558 T : O
hyperlipemia USRE40558 T NN O
; USRE40558 T : O
atherosclerosis USRE40558 T NN O
; USRE40558 T : O
antidiabetic USRE40558 T JJ O
agent USRE40558 T NN O
. USRE40558 T . O

The USRE40558 A DT O
use USRE40558 A NN O
of USRE40558 A IN O
diaryl USRE40558 A NN O
acid USRE40558 A JJ O
derivatives USRE40558 A NNS O
of USRE40558 A IN O
formula USRE40558 A NN O
( USRE40558 A ( O
I USRE40558 A PRP O
) USRE40558 A ) O
or USRE40558 A CC O
pharmaceutically USRE40558 A RB O
acceptable USRE40558 A JJ O
salts USRE40558 A NNS O
, USRE40558 A , O
N-oxides USRE40558 A NNP O
, USRE40558 A , O
hydrates USRE40558 A VBZ O
or USRE40558 A CC O
solvates USRE40558 A VBZ O
thereof USRE40558 A NNS O
, USRE40558 A , O
wherein USRE40558 A VBP O
the USRE40558 A DT O
variables USRE40558 A NNS O
shown USRE40558 A VBN O
are USRE40558 A VBP O
defined USRE40558 A VBN O
in USRE40558 A IN O
the USRE40558 A DT O
disclosure USRE40558 A NN O
, USRE40558 A , O
and USRE40558 A CC O
their USRE40558 A PRP$ O
pharmaceutical USRE40558 A JJ O
compositions USRE40558 A NNS O
as USRE40558 A IN O
PPAR USRE40558 A NNP O
ligand USRE40558 A VBP O
receptor USRE40558 A NN O
binders USRE40558 A NNS O
. USRE40558 A . O

The USRE40558 A DT O
PPAR USRE40558 A NNP O
ligand USRE40558 A NN O
receptor USRE40558 A NN O
binders USRE40558 A NNS O
of USRE40558 A IN O
this USRE40558 A DT O
invention USRE40558 A NN O
are USRE40558 A VBP O
useful USRE40558 A JJ O
as USRE40558 A IN O
agonists USRE40558 A NNS O
or USRE40558 A CC O
antagonists USRE40558 A NNS O
of USRE40558 A IN O
the USRE40558 A DT O
PPAR USRE40558 A NNP O
receptor USRE40558 A NN O
. USRE40558 A . O

4-quinazoline WO2013131424A1 T JJ O
amine WO2013131424A1 T NN O
derivative WO2013131424A1 T NN O
and WO2013131424A1 T CC O
application WO2013131424A1 T NN O
thereof WO2013131424A1 T NN O
. WO2013131424A1 T . O

The WO2013131424A1 A DT O
cancer WO2013131424A1 A NN O
is WO2013131424A1 A VBZ O
a WO2013131424A1 A DT O
drug-resistant WO2013131424A1 A JJ O
cancer WO2013131424A1 A NN O
, WO2013131424A1 A , O
preferably WO2013131424A1 A RB O
a WO2013131424A1 A DT O
cancer WO2013131424A1 A NN O
resisting WO2013131424A1 A VBG O
an WO2013131424A1 A DT O
EGFR WO2013131424A1 A NNP I-UN
reversible WO2013131424A1 A JJ O
inhibitor WO2013131424A1 A NN O
, WO2013131424A1 A , O
and WO2013131424A1 A CC O
more WO2013131424A1 A JJR O
preferably WO2013131424A1 A RB O
, WO2013131424A1 A , O
a WO2013131424A1 A DT O
cancer WO2013131424A1 A NN O
resisting WO2013131424A1 A VBG O
gefitinib WO2013131424A1 A NN O
, WO2013131424A1 A , O
erlotinib WO2013131424A1 A NN O
or WO2013131424A1 A CC O
lapatinib WO2013131424A1 A NN O
; WO2013131424A1 A : O
alternatively WO2013131424A1 A RB O
, WO2013131424A1 A , O
the WO2013131424A1 A DT O
cancer WO2013131424A1 A NN O
carries WO2013131424A1 A VBZ O
EGFR WO2013131424A1 A NNP I-UN
mutation WO2013131424A1 A NN O
. WO2013131424A1 A . O

Human CN101724033A T NNP O
epididymal CN101724033A T JJ O
expression CN101724033A T NN O
sperm CN101724033A T NN O
binding CN101724033A T VBG O
protein CN101724033A T JJ O
HEL-28 CN101724033A T NNP O
as CN101724033A T RB O
well CN101724033A T RB O
as CN101724033A T IN O
encoding CN101724033A T VBG O
gene CN101724033A T NN O
and CN101724033A T CC O
application CN101724033A T NN O
thereof CN101724033A T NN O
. CN101724033A T . O

Physiologically EP1499204A2 T RB O
compatible EP1499204A2 T JJ O
, EP1499204A2 T , O
phospholipid-containing EP1499204A2 T JJ O
, EP1499204A2 T , O
stable EP1499204A2 T JJ O
and EP1499204A2 T CC O
hard EP1499204A2 T JJ O
matrix EP1499204A2 T NN O
. EP1499204A2 T . O

Liyustrazine CN1775762A T NNP O
acyl CN1775762A T NN O
piperazine CN1775762A T NN O
derivative CN1775762A T NN O
, CN1775762A T , O
and CN1775762A T CC O
its CN1775762A T PRP$ O
preparing CN1775762A T NN O
method CN1775762A T NN O
and CN1775762A T CC O
medicinal CN1775762A T JJ O
composition CN1775762A T NN O
and CN1775762A T CC O
use CN1775762A T NN O
. CN1775762A T . O

Methods US20080279844 T NNS O
for US20080279844 T IN O
Treating US20080279844 T VBG O
Cancer US20080279844 T NNP O
Targeting US20080279844 T NNP O
Transglutaminase US20080279844 T NNP I-UN
. US20080279844 T . O

A US20080279844 A DT O
method US20080279844 A NN O
for US20080279844 A IN O
treating US20080279844 A VBG O
cancer US20080279844 A NN O
comprising US20080279844 A VBG O
inhibiting US20080279844 A VBG O
transglutaminase US20080279844 A NN I-UN
activity US20080279844 A NN O
is US20080279844 A VBZ O
provided US20080279844 A VBN O
. US20080279844 A . O

The US20080279844 A DT O
inhibition US20080279844 A NN O
of US20080279844 A IN O
transglutaminase US20080279844 A NN I-UN
activity US20080279844 A NN O
may US20080279844 A MD O
be US20080279844 A VB O
performed US20080279844 A VBN O
by US20080279844 A IN O
one US20080279844 A CD O
or US20080279844 A CC O
more US20080279844 A JJR O
techniques US20080279844 A NNS O
, US20080279844 A , O
including US20080279844 A VBG O
, US20080279844 A , O
but US20080279844 A CC O
not US20080279844 A RB O
limited US20080279844 A JJ O
to US20080279844 A TO O
, US20080279844 A , O
downregulating US20080279844 A VBG O
transglutaminase US20080279844 A NN I-UN
expression US20080279844 A NN O
, US20080279844 A , O
inhibiting US20080279844 A VBG O
TG2 US20080279844 A NNP I-UN
translation US20080279844 A NN O
, US20080279844 A , O
or US20080279844 A CC O
blocking US20080279844 A VBG O
TG2 US20080279844 A NNP I-UN
enzymatic US20080279844 A JJ O
activity US20080279844 A NN O
, US20080279844 A , O
such US20080279844 A JJ O
as US20080279844 A IN O
with US20080279844 A IN O
a US20080279844 A DT O
small US20080279844 A JJ O
molecule US20080279844 A NN O
inhibitor US20080279844 A NN O
or US20080279844 A CC O
intracellular US20080279844 A JJ O
antibody US20080279844 A NN O
( US20080279844 A ( O
intrabody US20080279844 A NN O
) US20080279844 A ) O
. US20080279844 A . O

Methods WO2008139263A3 T NNS O
for WO2008139263A3 T IN O
slowing WO2008139263A3 T VBG O
the WO2008139263A3 T DT O
progression WO2008139263A3 T NN O
of WO2008139263A3 T IN O
multiple WO2008139263A3 T JJ O
sclerosis WO2008139263A3 T NN O
. WO2008139263A3 T . O

Method US8252307 T NNP O
for US8252307 T IN O
treating US8252307 T VBG O
and/or US8252307 T JJ O
preventing US8252307 T VBG O
retinal US8252307 T JJ O
diseases US8252307 T NNS O
with US8252307 T IN O
sustained US8252307 T JJ O
release US8252307 T NN O
corticosteroids US8252307 T NNS O
. US8252307 T . O

Methods US20090098054 T NNS O
and US20090098054 T CC O
compositions US20090098054 T NNS O
relating US20090098054 T VBG O
to US20090098054 T TO O
promoter US20090098054 T VB O
regulation US20090098054 T NN O
by US20090098054 T IN O
muc1 US20090098054 T NN I-UN
and US20090098054 T CC O
klf US20090098054 T NN O
proteins US20090098054 T NNS O
. US20090098054 T . O

The US20090098054 A DT O
invention US20090098054 A NN O
provides US20090098054 A VBZ O
methods US20090098054 A NNS O
of US20090098054 A IN O
, US20090098054 A , O
and US20090098054 A CC O
compositions US20090098054 A NNS O
useful US20090098054 A JJ O
for US20090098054 A IN O
, US20090098054 A , O
inhibiting US20090098054 A VBG O
interactions US20090098054 A NNS O
between US20090098054 A IN O
MUC1 US20090098054 A NNP I-UN
and US20090098054 A CC O
a US20090098054 A DT O
kruppel-like US20090098054 A JJ I-UN
factor US20090098054 A NN I-UN
( US20090098054 A ( O
KLF US20090098054 A NNP I-UN
) US20090098054 A ) O
, US20090098054 A , O
method US20090098054 A NN O
of US20090098054 A IN O
inhibiting US20090098054 A VBG O
interactions US20090098054 A NNS O
between US20090098054 A IN O
a US20090098054 A DT O
KLF US20090098054 A NNP I-UN
protein US20090098054 A NN I-UN
and US20090098054 A CC O
the US20090098054 A DT O
p53 US20090098054 A NN I-UN
promoter US20090098054 A NN O
, US20090098054 A , O
methods US20090098054 A NNS O
of US20090098054 A IN O
inhibiting US20090098054 A VBG O
the US20090098054 A DT O
interaction US20090098054 A NN O
between US20090098054 A IN O
MUC1 US20090098054 A NNP I-UN
and US20090098054 A CC O
the US20090098054 A DT O
p53 US20090098054 A NN I-UN
promoter US20090098054 A NN O
, US20090098054 A , O
methods US20090098054 A NNS O
of US20090098054 A IN O
increasing US20090098054 A VBG O
p53 US20090098054 A NN I-UN
activity US20090098054 A NN O
, US20090098054 A , O
and US20090098054 A CC O
methods US20090098054 A NNS O
of US20090098054 A IN O
increasing US20090098054 A VBG O
histone US20090098054 A NN O
acetylation US20090098054 A NN O
. US20090098054 A . O

Methods WO2011094208A2 T NNS O
and WO2011094208A2 T CC O
pharmaceutical WO2011094208A2 T JJ O
compositions WO2011094208A2 T NNS O
for WO2011094208A2 T IN O
preventing WO2011094208A2 T VBG O
and WO2011094208A2 T CC O
treating WO2011094208A2 T VBG O
renal WO2011094208A2 T JJ O
impairment WO2011094208A2 T NN O
. WO2011094208A2 T . O

The WO2011094208A2 A DT O
present WO2011094208A2 A JJ O
invention WO2011094208A2 A NN O
relates WO2011094208A2 A VBZ O
to WO2011094208A2 A TO O
methods WO2011094208A2 A NNS O
for WO2011094208A2 A IN O
treating WO2011094208A2 A VBG O
and WO2011094208A2 A CC O
preventing WO2011094208A2 A VBG O
renal WO2011094208A2 A JJ O
impairment WO2011094208A2 A NN O
by WO2011094208A2 A IN O
administering WO2011094208A2 A VBG O
to WO2011094208A2 A TO O
a WO2011094208A2 A DT O
subject WO2011094208A2 A NN O
a WO2011094208A2 A DT O
therapeutically WO2011094208A2 A RB O
effective WO2011094208A2 A JJ O
amount WO2011094208A2 A NN O
of WO2011094208A2 A IN O
an WO2011094208A2 A DT O
A1 WO2011094208A2 A NNP I-UN
adenosine WO2011094208A2 A NN I-UN
receptor WO2011094208A2 A NN I-UN
antagonist WO2011094208A2 A VBP O
alone WO2011094208A2 A RB O
or WO2011094208A2 A CC O
in WO2011094208A2 A IN O
combination WO2011094208A2 A NN O
with WO2011094208A2 A IN O
at WO2011094208A2 A IN O
least WO2011094208A2 A JJS O
one WO2011094208A2 A CD O
additional WO2011094208A2 A JJ O
therapeutic WO2011094208A2 A JJ O
agent WO2011094208A2 A NN O
. WO2011094208A2 A . O

The WO2011094208A2 A DT O
invention WO2011094208A2 A NN O
further WO2011094208A2 A JJ O
encompasses WO2011094208A2 A VBZ O
pharmaceutical WO2011094208A2 A JJ O
compositions WO2011094208A2 A NNS O
comprising WO2011094208A2 A VBG O
an WO2011094208A2 A DT O
A1 WO2011094208A2 A NNP I-UN
adenosine WO2011094208A2 A NN I-UN
receptor WO2011094208A2 A NN I-UN
antagonist WO2011094208A2 A VBP O
alone WO2011094208A2 A RB O
or WO2011094208A2 A CC O
with WO2011094208A2 A IN O
, WO2011094208A2 A , O
at WO2011094208A2 A IN O
least WO2011094208A2 A JJS O
, WO2011094208A2 A , O
one WO2011094208A2 A CD O
additional WO2011094208A2 A JJ O
therapeutic WO2011094208A2 A JJ O
agent WO2011094208A2 A NN O
in WO2011094208A2 A IN O
a WO2011094208A2 A DT O
pharmaceutically WO2011094208A2 A RB O
acceptable WO2011094208A2 A JJ O
carrier WO2011094208A2 A NN O
. WO2011094208A2 A . O

( US7989442 T ( O
cis US7989442 T NN O
) US7989442 T ) O
-8-fluorodibenzo US7989442 T NN O
[ US7989442 T NN O
b US7989442 T NN O
, US7989442 T , O
f US7989442 T JJ O
] US7989442 T NNP O
pyrido US7989442 T NN O
[ US7989442 T NNP O
1,2-d US7989442 T JJ O
] US7989442 T NNP O
oxazepine-1-amine US7989442 T JJ O
derivatives US7989442 T NNS O
; US7989442 T : O
contraception US7989442 T NN O
, US7989442 T , O
hormone US7989442 T NN O
replacement US7989442 T NN O
therapy US7989442 T NN O
( US7989442 T ( O
HRT US7989442 T NNP O
) US7989442 T ) O
or US7989442 T CC O
gynaecological US7989442 T JJ O
disorders US7989442 T NNS O
, US7989442 T , O
adjuvant US7989442 T JJ O
therapy US7989442 T NN O
in US7989442 T IN O
cancer US7989442 T NN O
. US7989442 T . O

The US7989442 A DT O
present US7989442 A JJ O
invention US7989442 A NN O
provides US7989442 A VBZ O
new US7989442 A JJ O
progesterone US7989442 A NN I-UN
receptor US7989442 A NN I-UN
modulators US7989442 A NNS O
which US7989442 A WDT O
are US7989442 A VBP O
( US7989442 A ( O
cis US7989442 A NN O
) US7989442 A ) O
-8-fluorodibenzo US7989442 A NN O
[ US7989442 A NN O
b US7989442 A NN O
, US7989442 A , O
f US7989442 A JJ O
] US7989442 A NNP O
pyrido US7989442 A NN O
[ US7989442 A NNP O
1,2-d US7989442 A JJ O
] US7989442 A NNP O
oxazepine-1-amine US7989442 A JJ O
compounds US7989442 A NNS O
and US7989442 A CC O
uses US7989442 A VBZ O
thereof US7989442 A NN O
. US7989442 A . O

Nitrogenated WO2012008564A1 T VBN O
aromatic WO2012008564A1 T JJ O
heterocyclic WO2012008564A1 T JJ O
ring WO2012008564A1 T VBG O
derivative WO2012008564A1 T JJ O
. WO2012008564A1 T . O

A WO2012008564A1 A DT O
nitrogenated WO2012008564A1 A JJ O
aromatic WO2012008564A1 A JJ O
heterocyclic WO2012008564A1 A NN O
ring WO2012008564A1 A VBG O
derivative WO2012008564A1 A JJ O
represented WO2012008564A1 A VBN O
by WO2012008564A1 A IN O
formula WO2012008564A1 A NN O
( WO2012008564A1 A ( O
I WO2012008564A1 A PRP O
) WO2012008564A1 A ) O
[ WO2012008564A1 A VBP O
wherein WO2012008564A1 A JJ O
R1 WO2012008564A1 A NNP O
and WO2012008564A1 A CC O
R2 WO2012008564A1 A NNP O
independently WO2012008564A1 A RB O
represent WO2012008564A1 A VBP O
a WO2012008564A1 A DT O
hydrogen WO2012008564A1 A NN O
atom WO2012008564A1 A NN O
or WO2012008564A1 A CC O
the WO2012008564A1 A DT O
like WO2012008564A1 A JJ O
; WO2012008564A1 A : O
W WO2012008564A1 A NNP O
represents WO2012008564A1 A VBZ O
CR3 WO2012008564A1 A NNP O
( WO2012008564A1 A ( O
wherein WO2012008564A1 A JJ O
R3 WO2012008564A1 A NNP O
represents WO2012008564A1 A VBZ O
a WO2012008564A1 A DT O
hydrogen WO2012008564A1 A NN O
atom WO2012008564A1 A NN O
or WO2012008564A1 A CC O
the WO2012008564A1 A DT O
like WO2012008564A1 A JJ O
) WO2012008564A1 A ) O
or WO2012008564A1 A CC O
the WO2012008564A1 A DT O
like WO2012008564A1 A JJ O
; WO2012008564A1 A : O
R4 WO2012008564A1 A NNP O
and WO2012008564A1 A CC O
R5 WO2012008564A1 A NNP O
independently WO2012008564A1 A RB O
represent WO2012008564A1 A VBP O
a WO2012008564A1 A DT O
hydrogen WO2012008564A1 A NN O
atom WO2012008564A1 A NN O
or WO2012008564A1 A CC O
the WO2012008564A1 A DT O
like WO2012008564A1 A JJ O
; WO2012008564A1 A : O
R9 WO2012008564A1 A NNP O
represents WO2012008564A1 A VBZ O
a WO2012008564A1 A DT O
pyrazolyl WO2012008564A1 A NN O
group WO2012008564A1 A NN O
which WO2012008564A1 A WDT O
may WO2012008564A1 A MD O
have WO2012008564A1 A VB O
a WO2012008564A1 A DT O
substituent WO2012008564A1 A NN O
, WO2012008564A1 A , O
or WO2012008564A1 A CC O
the WO2012008564A1 A DT O
like WO2012008564A1 A JJ O
; WO2012008564A1 A : O
and WO2012008564A1 A CC O
R12 WO2012008564A1 A NNP O
and WO2012008564A1 A CC O
R13 WO2012008564A1 A NNP O
independently WO2012008564A1 A RB O
represent WO2012008564A1 A VBP O
a WO2012008564A1 A DT O
hydrogen WO2012008564A1 A NN O
atom WO2012008564A1 A NN O
or WO2012008564A1 A CC O
the WO2012008564A1 A DT O
like WO2012008564A1 A JJ O
] WO2012008564A1 A NNP O
( WO2012008564A1 A ( O
wherein WO2012008564A1 A JJ O
N- WO2012008564A1 A NNP O
[ WO2012008564A1 A NNP O
2-chloro-4- WO2012008564A1 A JJ O
( WO2012008564A1 A ( O
6,7-dimethoxy-4- WO2012008564A1 A JJ O
quinolyloxy WO2012008564A1 A NN O
) WO2012008564A1 A ) O
phenyl WO2012008564A1 A NN O
] WO2012008564A1 A JJ O
-N'- WO2012008564A1 A NNP O
( WO2012008564A1 A ( O
5-methyl-3-isooxazolyl WO2012008564A1 A JJ O
) WO2012008564A1 A ) O
urea WO2012008564A1 A NN O
is WO2012008564A1 A VBZ O
excluded WO2012008564A1 A VBN O
from WO2012008564A1 A IN O
the WO2012008564A1 A DT O
derivative WO2012008564A1 A JJ O
) WO2012008564A1 A ) O
or WO2012008564A1 A CC O
a WO2012008564A1 A DT O
pharmaceutically WO2012008564A1 A RB O
acceptable WO2012008564A1 A JJ O
salt WO2012008564A1 A NN O
thereof WO2012008564A1 A NN O
; WO2012008564A1 A : O
and WO2012008564A1 A CC O
a WO2012008564A1 A DT O
FGFR WO2012008564A1 A NNP I-UN
inhibitor WO2012008564A1 A NN O
or WO2012008564A1 A CC O
the WO2012008564A1 A DT O
like WO2012008564A1 A JJ O
which WO2012008564A1 A WDT O
comprises WO2012008564A1 A VBZ O
the WO2012008564A1 A DT O
derivative WO2012008564A1 A JJ O
or WO2012008564A1 A CC O
the WO2012008564A1 A DT O
pharmaceutically WO2012008564A1 A RB O
acceptable WO2012008564A1 A JJ O
salt WO2012008564A1 A NN O
as WO2012008564A1 A IN O
an WO2012008564A1 A DT O
active WO2012008564A1 A JJ O
ingredient WO2012008564A1 A NN O
. WO2012008564A1 A . O

Compounds WO2007010514A3 T NNS O
and WO2007010514A3 T CC O
their WO2007010514A3 T PRP$ O
salts WO2007010514A3 T NNS O
specific WO2007010514A3 T JJ O
to WO2007010514A3 T TO O
the WO2007010514A3 T DT O
ppar WO2007010514A3 T NN I-UN
receptors WO2007010514A3 T NNS O
and WO2007010514A3 T CC O
the WO2007010514A3 T DT O
egf WO2007010514A3 T JJ I-UN
receptors WO2007010514A3 T NNS I-UN
and WO2007010514A3 T CC O
their WO2007010514A3 T PRP$ O
use WO2007010514A3 T NN O
in WO2007010514A3 T IN O
the WO2007010514A3 T DT O
medical WO2007010514A3 T JJ O
field WO2007010514A3 T NN O
. WO2007010514A3 T . O

Combined CN103316026A T JJ O
product CN103316026A T NN O
containing CN103316026A T VBG O
phentermine CN103316026A T NN O
and CN103316026A T CC O
topiramate CN103316026A T NN O
, CN103316026A T , O
and CN103316026A T CC O
preparation CN103316026A T NN O
method CN103316026A T NN O
thereof CN103316026A T NN O
. CN103316026A T . O

potent US7435742 T JJ O
antagonists US7435742 T NNS O
of US7435742 T IN O
M3 US7435742 T NNP I-UN
muscarinic US7435742 T JJ I-UN
receptors US7435742 T NNS I-UN
; US7435742 T : O
chronic US7435742 T JJ O
obstructive US7435742 T JJ O
pulmonary US7435742 T JJ O
disease US7435742 T NN O
; US7435742 T : O
bronchitis US7435742 T NN O
, US7435742 T , O
bronchial US7435742 T JJ O
hyperreactivity US7435742 T NN O
, US7435742 T , O
asthma US7435742 T NN O
, US7435742 T , O
cough US7435742 T NN O
and US7435742 T CC O
rhinitis US7435742 T NN O
; US7435742 T : O
gastrointestinal US7435742 T JJ O
disorders US7435742 T NNS O
; US7435742 T : O
incontinenc US7435742 T NN O
; US7435742 T : O
[ US7435742 T CC O
2- US7435742 T JJ O
( US7435742 T ( O
3,4-Dimethoxyphenyl US7435742 T JJ O
) US7435742 T ) O
ethyl US7435742 T NN O
] US7435742 T SYM O
- US7435742 T : O
( US7435742 T ( O
5-methylfuran-2-ylmethyl US7435742 T JJ O
) US7435742 T ) O
carbamic US7435742 T JJ O
acid US7435742 T NN O
( US7435742 T ( O
3R US7435742 T CD O
) US7435742 T ) O
-1 US7435742 T NN O
-azabicyclo US7435742 T NNP O
[ US7435742 T VBZ O
2.2.2 US7435742 T CD O
] US7435742 T JJ O
oct-3-yl US7435742 T JJ O
ester US7435742 T NN O
. US7435742 T . O

Carbamates US7435742 A NNS O
of US7435742 A IN O
formula US7435742 A NN O
( US7435742 A ( O
I US7435742 A PRP O
) US7435742 A ) O
or US7435742 A CC O
pharmaceutically US7435742 A RB O
acceptable US7435742 A JJ O
salts US7435742 A NNS O
thereof US7435742 A NNS O
, US7435742 A , O
including US7435742 A VBG O
quaternary US7435742 A JJ O
ammonium US7435742 A NN O
salts US7435742 A NNS O
of US7435742 A IN O
formula US7435742 A NN O
( US7435742 A ( O
II US7435742 A NNP O
) US7435742 A ) O
are US7435742 A VBP O
disclosed US7435742 A VBN O
; US7435742 A : O
as US7435742 A RB O
well US7435742 A RB O
as US7435742 A IN O
processes US7435742 A NNS O
for US7435742 A IN O
their US7435742 A PRP$ O
preparation US7435742 A NN O
, US7435742 A , O
pharmaceutical US7435742 A JJ O
compositions US7435742 A NNS O
comprising US7435742 A VBG O
them US7435742 A PRP O
and US7435742 A CC O
their US7435742 A PRP$ O
use US7435742 A NN O
in US7435742 A IN O
therapy US7435742 A NN O
as US7435742 A IN O
antagonists US7435742 A NNS O
of US7435742 A IN O
M3 US7435742 A NNP I-UN
muscarinic US7435742 A JJ I-UN
receptors US7435742 A NNS I-UN
. US7435742 A . O

Triterpene WO2014063441A1 T NNP O
derivative WO2014063441A1 T JJ O
and WO2014063441A1 T CC O
its WO2014063441A1 T PRP$ O
anti-influenza WO2014063441A1 T JJ O
use WO2014063441A1 T NN O
. WO2014063441A1 T . O

Treatment US20060089317 T NN O
of US20060089317 T IN O
metastatic US20060089317 T JJ O
breast US20060089317 T NN O
cancer US20060089317 T NN O
with US20060089317 T IN O
anthracyclines US20060089317 T NNS O
, US20060089317 T , O
and US20060089317 T CC O
taxanes US20060089317 T NNS O
. US20060089317 T . O

An US20060089317 A DT O
improved US20060089317 A JJ O
adjuvant US20060089317 A JJ O
treatment US20060089317 A NN O
of US20060089317 A IN O
metastatic US20060089317 A JJ O
breast US20060089317 A NN O
cancer US20060089317 A NN O
in US20060089317 A IN O
which US20060089317 A WDT O
patients US20060089317 A NNS O
are US20060089317 A VBP O
administered US20060089317 A VBN O
an US20060089317 A DT O
anthracycline US20060089317 A NN O
chemotherapeutic US20060089317 A JJ O
agent US20060089317 A NN O
and US20060089317 A CC O
a US20060089317 A DT O
taxane US20060089317 A NN O
chemotherapeutic US20060089317 A JJ O
agent US20060089317 A NN O
is US20060089317 A VBZ O
provided US20060089317 A VBN O
in US20060089317 A IN O
which US20060089317 A WDT O
a US20060089317 A DT O
diphenyl US20060089317 A NN O
compound US20060089317 A NN O
which US20060089317 A WDT O
is US20060089317 A VBZ O
a US20060089317 A DT O
potent US20060089317 A JJ O
antagonist US20060089317 A NN O
of US20060089317 A IN O
histamine US20060089317 A NN O
binding US20060089317 A NN O
at US20060089317 A IN O
the US20060089317 A DT O
intracellular US20060089317 A JJ O
histamine US20060089317 A NN I-UN
receptor US20060089317 A NN I-UN
is US20060089317 A VBZ O
initially US20060089317 A RB O
administered US20060089317 A VBN O
prior US20060089317 A RB O
to US20060089317 A TO O
administration US20060089317 A NN O
of US20060089317 A IN O
the US20060089317 A DT O
chemotherapeutic US20060089317 A JJ O
agents US20060089317 A NNS O
. US20060089317 A . O

Synthesis US8779163 T NN O
of US8779163 T IN O
UDP-Glucose US8779163 T JJ I-UN
: US8779163 T : I-UN
N-acylsphingosine US8779163 T JJ I-UN
glucosyl US8779163 T NN I-UN
transferase US8779163 T NN I-UN
inhibitors US8779163 T NNS O
. US8779163 T . O

Disclosed US8779163 A VBN O
is US8779163 A VBZ O
a US8779163 A DT O
novel US8779163 A JJ O
enantiomeric US8779163 A JJ O
synthesis US8779163 A NN O
ceramide-like US8779163 A JJ O
inhibitors US8779163 A NNS O
of US8779163 A IN O
UDP-glucose US8779163 A JJ I-UN
: US8779163 A : I-UN
N-acylsphingosine US8779163 A JJ I-UN
glucosyltransferase US8779163 A NN I-UN
. US8779163 A . O

Modulators US20050234090 T NNS O
of US20050234090 T IN O
chemokine US20050234090 T JJ I-UN
receptor US20050234090 T NN I-UN
activity US20050234090 T NN O
. US20050234090 T . O

Chemokine US20050234090 A NNP O
receptor US20050234090 A NN O
antagonists US20050234090 A NNS O
, US20050234090 A , O
in US20050234090 A IN O
particular US20050234090 A JJ O
, US20050234090 A , O
bicyclic US20050234090 A JJ O
diamine US20050234090 A NN O
compounds US20050234090 A NNS O
of US20050234090 A IN O
Formula US20050234090 A NNP O
( US20050234090 A ( O
I US20050234090 A PRP O
) US20050234090 A ) O
that US20050234090 A WDT O
act US20050234090 A NN O
as US20050234090 A IN O
antagonists US20050234090 A NNS O
of US20050234090 A IN O
chemokine US20050234090 A NN I-UN
CCR2 US20050234090 A NNP I-UN
and US20050234090 A CC I-UN
CCR3 US20050234090 A NNP I-UN
receptors US20050234090 A NNS I-UN
including US20050234090 A VBG O
pharmaceutical US20050234090 A JJ O
compositions US20050234090 A NNS O
and US20050234090 A CC O
uses US20050234090 A VBZ O
thereof US20050234090 A NN O
to US20050234090 A TO O
treat US20050234090 A VB O
or US20050234090 A CC O
prevent US20050234090 A VB O
diseases US20050234090 A NNS O
associated US20050234090 A VBN O
with US20050234090 A IN O
monocyte US20050234090 A JJ O
accumulation US20050234090 A NN O
, US20050234090 A , O
lymphocyte US20050234090 A JJ O
accumulation US20050234090 A NN O
or US20050234090 A CC O
leucocyte US20050234090 A JJ O
accumulation US20050234090 A NN O
are US20050234090 A VBP O
described US20050234090 A VBN O
herein US20050234090 A NNS O
. US20050234090 A . O

Pharmaceutical CN103494965A T JJ O
composition CN103494965A T NN O
for CN103494965A T IN O
treating CN103494965A T VBG O
radial CN103494965A T JJ O
styloid CN103494965A T NN O
tenosynovitis CN103494965A T NN O
. CN103494965A T . O

Gastric CA2580919A1 T NNP I-UN
inhibitory CA2580919A1 T NN I-UN
polypeptide CA2580919A1 T NN I-UN
( CA2580919A1 T ( O
gip CA2580919A1 T NN I-UN
) CA2580919A1 T ) O
antigen CA2580919A1 T NN O
arrays CA2580919A1 T NNS O
and CA2580919A1 T CC O
uses CA2580919A1 T VBZ O
thereof CA2580919A1 T NN O
. CA2580919A1 T . O

The CA2580919A1 A DT O
present CA2580919A1 A JJ O
invention CA2580919A1 A NN O
provides CA2580919A1 A VBZ O
, CA2580919A1 A , O
inter CA2580919A1 A NN O
alia CA2580919A1 A NN O
, CA2580919A1 A , O
a CA2580919A1 A DT O
composition CA2580919A1 A NN O
comprising CA2580919A1 A VBG O
a CA2580919A1 A DT O
virus-like CA2580919A1 A JJ O
particle CA2580919A1 A NN O
( CA2580919A1 A ( O
VLP CA2580919A1 A NNP O
) CA2580919A1 A ) O
and CA2580919A1 A CC O
at CA2580919A1 A IN O
least CA2580919A1 A JJS O
one CA2580919A1 A CD O
antigen CA2580919A1 A NN O
, CA2580919A1 A , O
wherein CA2580919A1 A NN O
said CA2580919A1 A VBD O
antigen CA2580919A1 A NN O
is CA2580919A1 A VBZ O
a CA2580919A1 A DT O
GIP CA2580919A1 A NNP I-UN
protein CA2580919A1 A NN O
or CA2580919A1 A CC O
a CA2580919A1 A DT O
GIP CA2580919A1 A NNP I-UN
fragment CA2580919A1 A NN O
linked CA2580919A1 A VBD O
to CA2580919A1 A TO O
the CA2580919A1 A DT O
VLP CA2580919A1 A NNP O
respectively CA2580919A1 A RB O
. CA2580919A1 A . O

Fused US8765747 T VBN O
2-aminothiazole US8765747 T JJ O
compounds US8765747 T NNS O
. US8765747 T . O

8-Phenylisoquinolines US20130059882 T NNS O
And US20130059882 T CC O
Pharmaceutical US20130059882 T NNP O
Composition US20130059882 T NNP O
Used US20130059882 T VBD O
In US20130059882 T IN O
Treatment US20130059882 T NNP O
For US20130059882 T IN O
Sepsis US20130059882 T NNP O
. US20130059882 T . O

Vaccins EP1307565B1 T NNS O
against EP1307565B1 T IN O
marek EP1307565B1 T NN O
's EP1307565B1 T POS O
disease EP1307565B1 T NN O
virus EP1307565B1 T NN O
( EP1307565B1 T ( O
mdv EP1307565B1 T NN O
) EP1307565B1 T ) O
and EP1307565B1 T CC O
varicella EP1307565B1 T JJ O
zoster EP1307565B1 T NN O
virus EP1307565B1 T NN O
( EP1307565B1 T ( O
vzv EP1307565B1 T NN O
) EP1307565B1 T ) O
. EP1307565B1 T . O

Antiviral EP2368547B1 T JJ O
compositions EP2368547B1 T NNS O
comprising EP2368547B1 T VBG O
geraniol EP2368547B1 T NN O
and EP2368547B1 T CC O
carvone EP2368547B1 T NN O
. EP2368547B1 T . O

Taste CA2492874C T NN O
masked CA2492874C T VBD O
oral CA2492874C T JJ O
composition CA2492874C T NN O
of CA2492874C T IN O
telithromycin CA2492874C T NN O
. CA2492874C T . O

Talarazole US20120283204 T NNP O
metabolites US20120283204 T NNS O
. US20120283204 T . O

Combination WO2009097670A1 T NN O
of WO2009097670A1 T IN O
immunomodulator WO2009097670A1 T NN O
and WO2009097670A1 T CC O
anti-pathogenic WO2009097670A1 T JJ O
agent WO2009097670A1 T NN O
. WO2009097670A1 T . O

Anthranillic US20120315233 T NNP O
acid US20120315233 T VBZ O
amides US20120315233 T NNS O
and US20120315233 T CC O
derivatives US20120315233 T NNS O
thereof US20120315233 T VBP O
as US20120315233 T IN O
cosmetic US20120315233 T JJ O
and US20120315233 T CC O
pharmaceutical US20120315233 T JJ O
active US20120315233 T JJ O
compounds US20120315233 T NNS O
. US20120315233 T . O

Application CN103127085A T NN O
of CN103127085A T IN O
Eryngiolide CN103127085A T NNP O
A CN103127085A T NNP O
in CN103127085A T IN O
medicines CN103127085A T NNS O
treating CN103127085A T VBG O
chronic CN103127085A T JJ O
obstructive CN103127085A T JJ O
pulmonary CN103127085A T JJ O
disease CN103127085A T NN O
. CN103127085A T . O

Liver-benefiting CN1883671A T JJ O
blood CN1883671A T NN O
circulation-activating CN1883671A T JJ O
eyesight-improving CN1883671A T JJ O
granule CN1883671A T NN O
. CN1883671A T . O

Mammalian EP0740701B1 T JJ I-UN
monocyte EP0740701B1 T NN I-UN
chemoattractant EP0740701B1 T NN I-UN
protein EP0740701B1 T NN I-UN
receptors EP0740701B1 T NNS I-UN
. EP0740701B1 T . O

DNAs EP0740701B1 A NNP O
encoding EP0740701B1 A VBG O
human EP0740701B1 A JJ I-UN
chemokine EP0740701B1 A NN I-UN
receptors EP0740701B1 A NNS I-UN
, EP0740701B1 A , O
MCP-1R EP0740701B1 A NNP I-UN
and EP0740701B1 A CC O
MCP-1RB EP0740701B1 A NNP I-UN
, EP0740701B1 A , O
and EP0740701B1 A CC O
processes EP0740701B1 A VBZ O
for EP0740701B1 A IN O
expressing EP0740701B1 A VBG O
them EP0740701B1 A PRP O
are EP0740701B1 A VBP O
disclosed EP0740701B1 A VBN O
. EP0740701B1 A . O

The EP0740701B1 A DT O
receptor EP0740701B1 A NN O
proteins EP0740701B1 A NNS O
, EP0740701B1 A , O
which EP0740701B1 A WDT O
are EP0740701B1 A VBP O
the EP0740701B1 A DT O
products EP0740701B1 A NNS O
of EP0740701B1 A IN O
alternately EP0740701B1 A RB O
spliced EP0740701B1 A JJ O
versions EP0740701B1 A NNS O
of EP0740701B1 A IN O
the EP0740701B1 A DT O
MCP-1R EP0740701B1 A NNP I-UN
gene EP0740701B1 A NN O
, EP0740701B1 A , O
may EP0740701B1 A MD O
be EP0740701B1 A VB O
used EP0740701B1 A VBN O
in EP0740701B1 A IN O
an EP0740701B1 A DT O
assay EP0740701B1 A NN O
to EP0740701B1 A TO O
identify EP0740701B1 A VB O
antagonists EP0740701B1 A NNS O
of EP0740701B1 A IN O
MCP-1 EP0740701B1 A NNP I-UN
. EP0740701B1 A . O

8-substituted CA2754058A1 T JJ O
quinolines CA2754058A1 T NNS O
and CA2754058A1 T CC O
related CA2754058A1 T JJ O
analogs CA2754058A1 T NNS O
as CA2754058A1 T IN O
sirtuin CA2754058A1 T JJ O
modulators CA2754058A1 T NNS O
. CA2754058A1 T . O

Permeability CN100594024C T NNP O
nose CN100594024C T JJ O
absorption CN100594024C T NN O
type CN100594024C T NN O
medicine CN100594024C T NN O
for CN100594024C T IN O
treating CN100594024C T VBG O
and CN100594024C T CC O
preventing CN100594024C T VBG O
senile CN100594024C T JJ O
dementia CN100594024C T NN O
, CN100594024C T , O
improving CN100594024C T VBG O
learning CN100594024C T VBG O
memory CN100594024C T NN O
faculty CN100594024C T NN O
and CN100594024C T CC O
regulating CN100594024C T VBG O
blood CN100594024C T NN O
brain CN100594024C T NN O
barrier CN100594024C T NN O
. CN100594024C T . O

Stabilized US7309719 T NNP O
pharmaceutical US7309719 T JJ O
preparation US7309719 T NN O
of US7309719 T IN O
gamma-aminobutyric US7309719 T JJ O
acid US7309719 T NN O
derivatives US7309719 T NNS O
and US7309719 T CC O
process US7309719 T NN O
for US7309719 T IN O
preparing US7309719 T VBG O
the US7309719 T DT O
same US7309719 T JJ O
. US7309719 T . O

Triazine CN101511801A T NNP O
derivative CN101511801A T JJ O
compound CN101511801A T NN O
and CN101511801A T CC O
composition CN101511801A T NN O
for CN101511801A T IN O
treating CN101511801A T VBG O
cancer CN101511801A T NN O
containing CN101511801A T VBG O
them CN101511801A T PRP O
. CN101511801A T . O

Neuronal US20120295853 T NNP O
pain US20120295853 T NN O
pathway US20120295853 T NN O
. US20120295853 T . O

Increased US20120295853 A VBN O
cGMP US20120295853 A NN O
results US20120295853 A NNS O
in US20120295853 A IN O
activation US20120295853 A NN O
of US20120295853 A IN O
protein US20120295853 A JJ I-UN
kinase US20120295853 A NN I-UN
G US20120295853 A NNP I-UN
( US20120295853 A ( O
“PKG” US20120295853 A NNP O
) US20120295853 A ) O
, US20120295853 A , O
which US20120295853 A WDT O
then US20120295853 A RB O
is US20120295853 A VBZ O
retrogradely US20120295853 A RB O
transported US20120295853 A VBN O
along US20120295853 A IN O
the US20120295853 A DT O
axon US20120295853 A NN O
to US20120295853 A TO O
the US20120295853 A DT O
neuron US20120295853 A NN O
cell US20120295853 A NN O
body US20120295853 A NN O
, US20120295853 A , O
where US20120295853 A WRB O
it US20120295853 A PRP O
phosphorylates US20120295853 A VBZ O
MAPKerk US20120295853 A NNP O
. US20120295853 A . O

RAF US20100160381 T NNP I-UN
Inhibitors US20100160381 T NNS O
for US20100160381 T IN O
the US20100160381 T DT O
Treatment US20100160381 T NNP O
of US20100160381 T IN O
Thyroid US20100160381 T NNP O
Cancer US20100160381 T NNP O
. US20100160381 T . O

The US20100160381 A DT O
invention US20100160381 A NN O
relates US20100160381 A VBZ O
to US20100160381 A TO O
the US20100160381 A DT O
use US20100160381 A NN O
of US20100160381 A IN O
an US20100160381 A DT O
Raf US20100160381 A NNP I-UN
inhibitor US20100160381 A NN O
for US20100160381 A IN O
the US20100160381 A DT O
manufacture US20100160381 A NN O
of US20100160381 A IN O
pharmaceutical US20100160381 A JJ O
compositions US20100160381 A NNS O
for US20100160381 A IN O
the US20100160381 A DT O
treatment US20100160381 A NN O
of US20100160381 A IN O
thyroid US20100160381 A JJ O
cancer US20100160381 A NN O
, US20100160381 A , O
more US20100160381 A RBR O
specifically US20100160381 A RB O
papillary US20100160381 A JJ O
thyroid US20100160381 A NN O
cancer US20100160381 A NN O
( US20100160381 A ( O
PTC US20100160381 A NNP O
) US20100160381 A ) O
; US20100160381 A : O
the US20100160381 A DT O
use US20100160381 A NN O
of US20100160381 A IN O
a US20100160381 A DT O
Raf US20100160381 A NNP I-UN
inhibitor US20100160381 A NN O
in US20100160381 A IN O
the US20100160381 A DT O
treatment US20100160381 A NN O
of US20100160381 A IN O
thyroid US20100160381 A JJ O
cancer US20100160381 A NN O
, US20100160381 A , O
more US20100160381 A RBR O
specifically US20100160381 A RB O
PTC US20100160381 A NNP O
; US20100160381 A : O
a US20100160381 A DT O
method US20100160381 A NN O
of US20100160381 A IN O
treating US20100160381 A VBG O
warm-blooded US20100160381 A JJ O
animals US20100160381 A NNS O
including US20100160381 A VBG O
mammals US20100160381 A NNS O
, US20100160381 A , O
especially US20100160381 A RB O
humans US20100160381 A NNS O
, US20100160381 A , O
suffering US20100160381 A VBG O
from US20100160381 A IN O
thyroid US20100160381 A JJ O
cancer US20100160381 A NN O
, US20100160381 A , O
more US20100160381 A RBR O
specifically US20100160381 A RB O
PTC US20100160381 A NNP O
, US20100160381 A , O
by US20100160381 A IN O
administering US20100160381 A VBG O
to US20100160381 A TO O
a US20100160381 A DT O
said US20100160381 A VBD O
animal US20100160381 A NN O
in US20100160381 A IN O
need US20100160381 A NN O
of US20100160381 A IN O
such US20100160381 A JJ O
treatment US20100160381 A NN O
a US20100160381 A DT O
dose US20100160381 A JJ O
effective US20100160381 A JJ O
against US20100160381 A IN O
said US20100160381 A VBD O
disease US20100160381 A NN O
of US20100160381 A IN O
an US20100160381 A DT O
Raf US20100160381 A NNP I-UN
inhibitor US20100160381 A NN O
. US20100160381 A . O

The US20100160381 A DT O
invention US20100160381 A NN O
also US20100160381 A RB O
relates US20100160381 A VBZ O
to US20100160381 A TO O
the US20100160381 A DT O
use US20100160381 A NN O
of US20100160381 A IN O
a US20100160381 A DT O
Raf US20100160381 A NNP I-UN
inhibitor US20100160381 A NN O
in US20100160381 A IN O
combination US20100160381 A NN O
with US20100160381 A IN O
a US20100160381 A DT O
platin US20100160381 A NN O
compound US20100160381 A NN O
for US20100160381 A IN O
the US20100160381 A DT O
treatment US20100160381 A NN O
of US20100160381 A IN O
thyroid US20100160381 A JJ O
cancer US20100160381 A NN O
, US20100160381 A , O
more US20100160381 A RBR O
specifically US20100160381 A RB O
papillary US20100160381 A JJ O
thyroid US20100160381 A NN O
cancer US20100160381 A NN O
. US20100160381 A . O

Methods WO2014142780A1 T NNS O
of WO2014142780A1 T IN O
treating WO2014142780A1 T NN O
, WO2014142780A1 T , O
reducing WO2014142780A1 T VBG O
the WO2014142780A1 T DT O
incidence WO2014142780A1 T NN O
of WO2014142780A1 T IN O
, WO2014142780A1 T , O
and/or WO2014142780A1 T IN O
preventing WO2014142780A1 T VBG O
ischemic WO2014142780A1 T JJ O
events WO2014142780A1 T NNS O
. WO2014142780A1 T . O

Amides CA2207804C T NNS O
of CA2207804C T IN O
mono CA2207804C T NN O
and CA2207804C T CC O
bicarboxylic CA2207804C T JJ O
acids CA2207804C T NNS O
with CA2207804C T IN O
amino CA2207804C T JJ O
acids CA2207804C T NNS O
or CA2207804C T CC O
glycosamines CA2207804C T NNS O
, CA2207804C T , O
selectively CA2207804C T RB O
active CA2207804C T JJ O
on CA2207804C T IN O
the CA2207804C T DT O
cannabinoid CA2207804C T JJ O
peripheral CA2207804C T JJ O
receptor CA2207804C T NN O
. CA2207804C T . O

The CA2207804C A DT O
present CA2207804C A JJ O
invention CA2207804C A NN O
relates CA2207804C A VBZ O
to CA2207804C A TO O
amides CA2207804C A NNS O
of CA2207804C A IN O
formula CA2207804C A NN O
( CA2207804C A ( O
I CA2207804C A PRP O
) CA2207804C A ) O
: CA2207804C A : O
wherein CA2207804C A NN O
R1 CA2207804C A NNP O
is CA2207804C A VBZ O
an CA2207804C A DT O
optionally CA2207804C A RB O
substituted CA2207804C A VBN O
linear CA2207804C A JJ O
or CA2207804C A CC O
branched CA2207804C A VBN O
hydrocarbon CA2207804C A NN O
radical CA2207804C A JJ O
, CA2207804C A , O
or CA2207804C A CC O
a CA2207804C A DT O
group CA2207804C A NN O
of CA2207804C A IN O
formula CA2207804C A NN O
( CA2207804C A ( O
II CA2207804C A NNP O
) CA2207804C A ) O
or CA2207804C A CC O
( CA2207804C A ( O
III CA2207804C A NNP O
) CA2207804C A ) O
: CA2207804C A : O
wherein CA2207804C A NN O
R4 CA2207804C A NNP O
is CA2207804C A VBZ O
an CA2207804C A DT O
optionally CA2207804C A RB O
substituted CA2207804C A VBN O
linear CA2207804C A JJ O
hydrocarbon CA2207804C A NN O
radical CA2207804C A JJ O
, CA2207804C A , O
R7 CA2207804C A NNP O
is CA2207804C A VBZ O
H CA2207804C A NNP O
or CA2207804C A CC O
a CA2207804C A DT O
linear CA2207804C A JJ O
or CA2207804C A CC O
branched CA2207804C A VBN O
alkyl CA2207804C A NN O
, CA2207804C A , O
and CA2207804C A CC O
the CA2207804C A DT O
residues CA2207804C A NNS O
are CA2207804C A VBP O
glycosaminic CA2207804C A JJ O
residues CA2207804C A NNS O
; CA2207804C A : O
a CA2207804C A DT O
pharmaceutical CA2207804C A JJ O
composition CA2207804C A NN O
comprising CA2207804C A VBG O
the CA2207804C A DT O
amide CA2207804C A NN O
; CA2207804C A : O
and CA2207804C A CC O
a CA2207804C A DT O
use CA2207804C A NN O
of CA2207804C A IN O
the CA2207804C A DT O
amide CA2207804C A NN O
as CA2207804C A IN O
a CA2207804C A DT O
CB2 CA2207804C A NNP I-UN
receptor CA2207804C A NN I-UN
modulator CA2207804C A NN O
. CA2207804C A . O

injectable US20080269347 T JJ O
pharmaceutical US20080269347 T JJ O
composition US20080269347 T NN O
also US20080269347 T RB O
including US20080269347 T VBG O
EDTA US20080269347 T NNP O
, US20080269347 T , O
antioxidant US20080269347 T NN O
, US20080269347 T , O
selected US20080269347 T VBN O
from US20080269347 T IN O
cysteine US20080269347 T NN O
, US20080269347 T , O
citric US20080269347 T JJ O
acid US20080269347 T NN O
, US20080269347 T , O
thioglycerol US20080269347 T NN O
, US20080269347 T , O
acetylcysteine US20080269347 T NN O
; US20080269347 T : O
treating US20080269347 T VBG O
anaphylaxis US20080269347 T NN O
, US20080269347 T , O
asthma US20080269347 T NN O
, US20080269347 T , O
or US20080269347 T CC O
cardiac US20080269347 T JJ O
arrest US20080269347 T NN O
; US20080269347 T : O
stable US20080269347 T JJ O
in US20080269347 T IN O
light US20080269347 T JJ O
, US20080269347 T , O
oxygen US20080269347 T NN O
, US20080269347 T , O
and/or US20080269347 T JJ O
heat US20080269347 T NN O
conditions US20080269347 T NNS O
without US20080269347 T IN O
a US20080269347 T DT O
stabilizer US20080269347 T NN O
. US20080269347 T . O

Pharmaceutical US20120149739 T JJ O
depot US20120149739 T NN O
for US20120149739 T IN O
n- US20120149739 T JJ O
{ US20120149739 T ( O
5- US20120149739 T JJ O
[ US20120149739 T NN O
( US20120149739 T ( O
cyclopropylamino US20120149739 T NN O
) US20120149739 T ) O
carbonyl US20120149739 T NN O
] US20120149739 T NNP O
-2-methylphenyl US20120149739 T NNP O
) US20120149739 T ) O
-3-fluoro-4- US20120149739 T NN O
( US20120149739 T ( O
pyridin-2-ylmethoxy US20120149739 T JJ O
) US20120149739 T ) O
benzamide US20120149739 T NN O
. US20120149739 T . O

Benzimidazole WO2008000643A1 T NNP O
derivatives WO2008000643A1 T NNS O
, WO2008000643A1 T , O
method WO2008000643A1 T NN O
for WO2008000643A1 T IN O
the WO2008000643A1 T DT O
production WO2008000643A1 T NN O
thereof WO2008000643A1 T NN O
, WO2008000643A1 T , O
their WO2008000643A1 T PRP$ O
use WO2008000643A1 T NN O
as WO2008000643A1 T IN O
fxr WO2008000643A1 T JJ I-UN
agonists WO2008000643A1 T NNS O
and WO2008000643A1 T CC O
pharmaceutical WO2008000643A1 T JJ O
preparations WO2008000643A1 T NNS O
containing WO2008000643A1 T VBG O
the WO2008000643A1 T DT O
same WO2008000643A1 T JJ O
. WO2008000643A1 T . O

These WO2008000643A1 A DT O
compounds WO2008000643A1 A NNS O
bind WO2008000643A1 A VBP O
to WO2008000643A1 A TO O
FXR WO2008000643A1 A NNP I-UN
and WO2008000643A1 A CC O
can WO2008000643A1 A MD O
be WO2008000643A1 A VB O
used WO2008000643A1 A VBN O
as WO2008000643A1 A IN O
medicaments WO2008000643A1 A NNS O
. WO2008000643A1 A . O

Application CN102861067A T NN O
of CN102861067A T IN O
Houttuynoid CN102861067A T NNP O
E CN102861067A T NNP O
in CN102861067A T IN O
anti-helicobacter CN102861067A T JJ O
pylori CN102861067A T NN O
( CN102861067A T ( O
Hp CN102861067A T NNP O
) CN102861067A T ) O
medicine CN102861067A T NN O
. CN102861067A T . O

Biarylrhodanine WO2010024783A1 T NNP O
and WO2010024783A1 T CC O
pyridylrhodanine WO2010024783A1 T VB O
compounds WO2010024783A1 T NNS O
and WO2010024783A1 T CC O
their WO2010024783A1 T PRP$ O
use WO2010024783A1 T NN O
. WO2010024783A1 T . O

The WO2010024783A1 A DT O
present WO2010024783A1 A JJ O
invention WO2010024783A1 A NN O
pertains WO2010024783A1 A VBZ O
generally WO2010024783A1 A RB O
to WO2010024783A1 A TO O
the WO2010024783A1 A DT O
field WO2010024783A1 A NN O
of WO2010024783A1 A IN O
therapeutic WO2010024783A1 A JJ O
compounds WO2010024783A1 A NNS O
, WO2010024783A1 A , O
and WO2010024783A1 A CC O
more WO2010024783A1 A RBR O
specifically WO2010024783A1 A RB O
to WO2010024783A1 A TO O
compounds WO2010024783A1 A NNS O
related WO2010024783A1 A VBN O
to WO2010024783A1 A TO O
rhodanine WO2010024783A1 A VB O
, WO2010024783A1 A , O
which WO2010024783A1 A WDT O
compounds WO2010024783A1 A VBZ O
are WO2010024783A1 A VBP O
inter WO2010024783A1 A JJ O
alia WO2010024783A1 A JJ O
inhibitors WO2010024783A1 A NNS O
and/or WO2010024783A1 A VBP O
binders WO2010024783A1 A NNS O
of WO2010024783A1 A IN O
antiapoptotic/pro-survival WO2010024783A1 A JJ O
Bcl-2 WO2010024783A1 A JJ I-UN
proteins WO2010024783A1 A NNS O
such WO2010024783A1 A JJ O
as WO2010024783A1 A IN O
Bcl-XL WO2010024783A1 A NNP I-UN
and/or WO2010024783A1 A IN O
Mcl-1 WO2010024783A1 A NNP I-UN
. WO2010024783A1 A . O

More WO2010024783A1 A RBR O
specifically WO2010024783A1 A RB O
, WO2010024783A1 A , O
the WO2010024783A1 A DT O
present WO2010024783A1 A JJ O
invention WO2010024783A1 A NN O
is WO2010024783A1 A VBZ O
concerned WO2010024783A1 A VBN O
with WO2010024783A1 A IN O
Rhodanine- WO2010024783A1 A NNP O
based WO2010024783A1 A VBN O
Pan-Bcl-2 WO2010024783A1 A NNP O
inhibitors WO2010024783A1 A NNS O
and WO2010024783A1 A CC O
Mcl-1 WO2010024783A1 A NNP I-UN
-specific WO2010024783A1 A NNP O
inhibitors WO2010024783A1 A NNS O
as WO2010024783A1 A IN O
anti-cancer WO2010024783A1 A JJ O
compounds WO2010024783A1 A NNS O
. WO2010024783A1 A . O

The WO2010024783A1 A DT O
present WO2010024783A1 A JJ O
invention WO2010024783A1 A NN O
also WO2010024783A1 A RB O
pertains WO2010024783A1 A VBZ O
to WO2010024783A1 A TO O
pharmaceutical WO2010024783A1 A JJ O
compositions WO2010024783A1 A NNS O
comprising WO2010024783A1 A VBG O
such WO2010024783A1 A JJ O
compounds WO2010024783A1 A NNS O
, WO2010024783A1 A , O
and WO2010024783A1 A CC O
the WO2010024783A1 A DT O
use WO2010024783A1 A NN O
of WO2010024783A1 A IN O
such WO2010024783A1 A JJ O
compounds WO2010024783A1 A NNS O
and WO2010024783A1 A CC O
compositions WO2010024783A1 A NNS O
, WO2010024783A1 A , O
both WO2010024783A1 A DT O
in WO2010024783A1 A IN O
vitro WO2010024783A1 A NN O
and WO2010024783A1 A CC O
in WO2010024783A1 A IN O
vivo WO2010024783A1 A NN O
, WO2010024783A1 A , O
to WO2010024783A1 A TO O
inhibit WO2010024783A1 A VB O
and/or WO2010024783A1 A JJ O
bind WO2010024783A1 A IN O
Bcl-2 WO2010024783A1 A JJ I-UN
proteins WO2010024783A1 A NNS O
such WO2010024783A1 A JJ O
as WO2010024783A1 A IN O
Bcl-XL WO2010024783A1 A NNP I-UN
and/or WO2010024783A1 A IN O
Mcl-1 WO2010024783A1 A NNP I-UN
, WO2010024783A1 A , O
and WO2010024783A1 A CC O
in WO2010024783A1 A IN O
the WO2010024783A1 A DT O
treatment WO2010024783A1 A NN O
of WO2010024783A1 A IN O
diseases WO2010024783A1 A NNS O
and WO2010024783A1 A CC O
conditions WO2010024783A1 A NNS O
that WO2010024783A1 A WDT O
are WO2010024783A1 A VBP O
mediated WO2010024783A1 A VBN O
by WO2010024783A1 A IN O
Bcl-2 WO2010024783A1 A NNP I-UN
proteins WO2010024783A1 A NNS O
, WO2010024783A1 A , O
that WO2010024783A1 A WDT O
are WO2010024783A1 A VBP O
ameliorated WO2010024783A1 A VBN O
by WO2010024783A1 A IN O
the WO2010024783A1 A DT O
inhibition WO2010024783A1 A NN O
of WO2010024783A1 A IN O
Bcl-2 WO2010024783A1 A NNP I-UN
protein WO2010024783A1 A NN O
function WO2010024783A1 A NN O
( WO2010024783A1 A ( O
such WO2010024783A1 A JJ O
as WO2010024783A1 A IN O
Bcl-XL WO2010024783A1 A NNP I-UN
and/or WO2010024783A1 A IN O
Mcl-1 WO2010024783A1 A NNP I-UN
) WO2010024783A1 A ) O
including WO2010024783A1 A VBG O
proliferative WO2010024783A1 A JJ O
conditions WO2010024783A1 A NNS O
such WO2010024783A1 A JJ O
as WO2010024783A1 A IN O
cancer WO2010024783A1 A NN O
, WO2010024783A1 A , O
optionally WO2010024783A1 A RB O
in WO2010024783A1 A IN O
combination WO2010024783A1 A NN O
with WO2010024783A1 A IN O
another WO2010024783A1 A DT O
agent WO2010024783A1 A NN O
. WO2010024783A1 A . O

Dispensing US20080207756 T VBG O
liquid US20080207756 T NN O
for US20080207756 T IN O
coating US20080207756 T VBG O
interior US20080207756 T JJ O
body US20080207756 T NN O
tissue US20080207756 T NN O
; US20080207756 T : O
prevent US20080207756 T CC O
tissue US20080207756 T VB O
dessciation US20080207756 T NN O
during US20080207756 T IN O
surgery US20080207756 T NN O
. US20080207756 T . O

Pyridazin-3 US7960383 T NNP O
( US7960383 T ( O
2H US7960383 T CD O
) US7960383 T ) O
-one US7960383 T NN O
derivatives US7960383 T NNS O
and US7960383 T CC O
their US7960383 T PRP$ O
use US7960383 T NN O
as US7960383 T IN O
PDE4 US7960383 T NNP I-UN
inhibitors US7960383 T NNS O
. US7960383 T . O

These US7960383 A DT O
compounds US7960383 A NNS O
are US7960383 A VBP O
potent US7960383 A JJ O
and US7960383 A CC O
selective US7960383 A JJ O
inhibitors US7960383 A NNS O
of US7960383 A IN O
phosphodiesterase US7960383 A NN I-UN
4 US7960383 A CD I-UN
( US7960383 A ( O
PDE4 US7960383 A NNP I-UN
) US7960383 A ) O
and US7960383 A CC O
are US7960383 A VBP O
thus US7960383 A RB O
useful US7960383 A JJ O
in US7960383 A IN O
the US7960383 A DT O
treatment US7960383 A NN O
, US7960383 A , O
prevention US7960383 A NN O
or US7960383 A CC O
suppression US7960383 A NN O
of US7960383 A IN O
pathological US7960383 A JJ O
conditions US7960383 A NNS O
, US7960383 A , O
diseases US7960383 A NNS O
and US7960383 A CC O
disorders US7960383 A NNS O
known US7960383 A VBN O
to US7960383 A TO O
be US7960383 A VB O
susceptible US7960383 A JJ O
of US7960383 A IN O
being US7960383 A VBG O
improved US7960383 A VBN O
by US7960383 A IN O
inhibition US7960383 A NN O
of US7960383 A IN O
PDE4 US7960383 A NNP I-UN
such US7960383 A JJ O
as US7960383 A IN O
asthma US7960383 A NN O
, US7960383 A , O
chronic US7960383 A JJ O
obstructive US7960383 A JJ O
pulmonary US7960383 A JJ O
disease US7960383 A NN O
, US7960383 A , O
rheumatoid US7960383 A JJ O
arthritis US7960383 A NN O
, US7960383 A , O
atopic US7960383 A NN O
dermatitis US7960383 A NN O
, US7960383 A , O
psoriasis US7960383 A NN O
or US7960383 A CC O
irritable US7960383 A JJ O
bowel US7960383 A NN O
disease US7960383 A NN O
. US7960383 A . O

Cis-platinum CN102895669A T NNP O
complex CN102895669A T NN O
and CN102895669A T CC O
preparation CN102895669A T NN O
method CN102895669A T NN O
thereof CN102895669A T NN O
. CN102895669A T . O

Non-aminoglycoside US20080139545 T JJ O
antibiotic US20080139545 T JJ O
such US20080139545 T JJ O
as US20080139545 T IN O
a US20080139545 T DT O
quinolone US20080139545 T NN O
antibiotic US20080139545 T JJ O
, US20080139545 T , O
ciprofloxacin US20080139545 T NN O
or US20080139545 T CC O
ofloxacin US20080139545 T NN O
; US20080139545 T : O
antiinflammatory US20080139545 T JJ O
agent US20080139545 T NN O
such US20080139545 T JJ O
as US20080139545 T IN O
dexamethasone US20080139545 T NN O
; US20080139545 T : O
and US20080139545 T CC O
a US20080139545 T DT O
biofilm-dissolving US20080139545 T JJ O
agent US20080139545 T NN O
; US20080139545 T : O
otitis US20080139545 T NN O
; US20080139545 T : O
cleaning US20080139545 T VBG O
contact US20080139545 T NN O
lenses US20080139545 T VBZ O
or US20080139545 T CC O
surgical US20080139545 T JJ O
and US20080139545 T CC O
dental US20080139545 T JJ O
equipment US20080139545 T NN O
. US20080139545 T . O

Katp WO2012150245A1 T NNP O
antagonists WO2012150245A1 T NNS O
( WO2012150245A1 T ( O
glibenglamid WO2012150245A1 T NN O
) WO2012150245A1 T ) O
for WO2012150245A1 T IN O
use WO2012150245A1 T NN O
for WO2012150245A1 T IN O
promoting WO2012150245A1 T VBG O
growth WO2012150245A1 T NN O
and/or WO2012150245A1 T IN O
treating WO2012150245A1 T VBG O
hyperglycaemia WO2012150245A1 T NN O
of WO2012150245A1 T IN O
a WO2012150245A1 T DT O
premature WO2012150245A1 T NN O
infant WO2012150245A1 T NN O
. WO2012150245A1 T . O

Hydrochloric CN101199515B T NNP O
acid CN101199515B T NN O
benzydamine CN101199515B T NN O
and CN101199515B T CC O
preparing CN101199515B T VBG O
method CN101199515B T NN O
thereof CN101199515B T NN O
. CN101199515B T . O

Agent WO2005021038A3 T NN O
for WO2005021038A3 T IN O
treating WO2005021038A3 T VBG O
metabolic WO2005021038A3 T JJ O
syndrome WO2005021038A3 T NN O
. WO2005021038A3 T . O

Aceglutamine CN1868467A T NNP O
prepn CN1868467A T NN O
. CN1868467A T . O

for CN1868467A T IN O
injection CN1868467A T NN O
, CN1868467A T , O
and CN1868467A T CC O
its CN1868467A T PRP$ O
preparing CN1868467A T NN O
method CN1868467A T NN O
. CN1868467A T . O

Use WO2012007632A9 T NNP O
of WO2012007632A9 T IN O
edg2 WO2012007632A9 T NN I-UN
inhibitors WO2012007632A9 T NNS O
for WO2012007632A9 T IN O
treating WO2012007632A9 T VBG O
rheumatoid WO2012007632A9 T JJ O
arthritis WO2012007632A9 T NN O
. WO2012007632A9 T . O

The WO2012007632A9 A DT O
present WO2012007632A9 A JJ O
invention WO2012007632A9 A NN O
relates WO2012007632A9 A VBZ O
to WO2012007632A9 A TO O
the WO2012007632A9 A DT O
novel WO2012007632A9 A NN O
use WO2012007632A9 A NN O
of WO2012007632A9 A IN O
EDG2 WO2012007632A9 A NNP I-UN
inhibitors WO2012007632A9 A NNS O
for WO2012007632A9 A IN O
treating WO2012007632A9 A VBG O
rheumatoid WO2012007632A9 A NN O
arthritis WO2012007632A9 A NN O
, WO2012007632A9 A , O
particularly WO2012007632A9 A RB O
in WO2012007632A9 A IN O
those WO2012007632A9 A DT O
patients WO2012007632A9 A NNS O
exhibiting WO2012007632A9 A VBG O
elevated WO2012007632A9 A JJ O
levels WO2012007632A9 A NNS O
of WO2012007632A9 A IN O
pro-inflammatory WO2012007632A9 A JJ O
molecules WO2012007632A9 A NNS O
despite WO2012007632A9 A IN O
having WO2012007632A9 A VBG O
been WO2012007632A9 A VBN O
treated WO2012007632A9 A VBN O
with WO2012007632A9 A IN O
anti-inflammatories WO2012007632A9 A NNS O
, WO2012007632A9 A , O
i.e WO2012007632A9 A NN O
. WO2012007632A9 A . O

Therapeutic WO2009122748A1 T JJ O
agent WO2009122748A1 T NN O
for WO2009122748A1 T IN O
respiratory WO2009122748A1 T NN O
diseases WO2009122748A1 T NNS O
or WO2009122748A1 T CC O
allergic WO2009122748A1 T JJ O
diseases WO2009122748A1 T NNS O
. WO2009122748A1 T . O

Fungal WO2014120774A1 T NNP O
iron WO2014120774A1 T NN O
acquisition WO2014120774A1 T NN O
inhibitors WO2014120774A1 T NNS O
and WO2014120774A1 T CC O
uses WO2014120774A1 T VBZ O
thereof WO2014120774A1 T NN O
. WO2014120774A1 T . O

Such US7179830 T JJ O
as US7179830 T IN O
2- US7179830 T JJ O
( US7179830 T ( O
4-methyl-3-thienylamino US7179830 T JJ O
) US7179830 T ) O
-1H-thieno US7179830 T FW O
[ US7179830 T JJ O
3,4-d US7179830 T JJ O
] US7179830 T NN O
imidazole US7179830 T NN O
for US7179830 T IN O
treatment US7179830 T NN O
of US7179830 T IN O
repiratory US7179830 T NN O
disorders US7179830 T NNS O
, US7179830 T , O
sleep US7179830 T JJ O
apnea US7179830 T NN O
. US7179830 T . O

Treating US20050031585 T VBG O
individuals US20050031585 T NNS O
having US20050031585 T VBG O
hepatitis US20050031585 T NN O
C US20050031585 T NNP O
virus US20050031585 T NN O
infection US20050031585 T NN O
, US20050031585 T , O
who US20050031585 T WP O
have US20050031585 T VBP O
failed US20050031585 T VBN O
to US20050031585 T TO O
respond US20050031585 T VB O
to US20050031585 T TO O
therapy US20050031585 T VB O
with US20050031585 T IN O
IFN-alpha US20050031585 T NNP I-UN
other US20050031585 T JJ O
than US20050031585 T IN O
consensus US20050031585 T NN O
interferon US20050031585 T NN I-UN
( US20050031585 T ( O
CIFN US20050031585 T NNP O
) US20050031585 T ) O
, US20050031585 T , O
or US20050031585 T CC O
who US20050031585 T WP O
, US20050031585 T , O
following US20050031585 T VBG O
cessation US20050031585 T NN O
of US20050031585 T IN O
therapy US20050031585 T NN O
with US20050031585 T IN O
IFN-alpha US20050031585 T NNP I-UN
other US20050031585 T JJ O
than US20050031585 T IN O
CIFN US20050031585 T NNP O
, US20050031585 T , O
have US20050031585 T VBP O
suffered US20050031585 T VBN O
relapse US20050031585 T NN O
by US20050031585 T IN O
administering US20050031585 T VBG O
first US20050031585 T RB O
, US20050031585 T , O
then US20050031585 T RB O
second US20050031585 T JJ O
dosing US20050031585 T VBG O
CIFN US20050031585 T NNP O
, US20050031585 T , O
and US20050031585 T CC O
ribavirin US20050031585 T NN O
. US20050031585 T . O

The US20050031585 A DT O
present US20050031585 A JJ O
invention US20050031585 A NN O
provides US20050031585 A VBZ O
methods US20050031585 A NNS O
for US20050031585 A IN O
treating US20050031585 A VBG O
individuals US20050031585 A NNS O
having US20050031585 A VBG O
a US20050031585 A DT O
hepatitis US20050031585 A NN O
C US20050031585 A NNP O
virus US20050031585 A NN O
( US20050031585 A ( O
HCV US20050031585 A NNP O
) US20050031585 A ) O
infection US20050031585 A NN O
, US20050031585 A , O
which US20050031585 A WDT O
individuals US20050031585 A NNS O
have US20050031585 A VBP O
failed US20050031585 A VBN O
to US20050031585 A TO O
respond US20050031585 A VB O
to US20050031585 A TO O
therapy US20050031585 A VB O
with US20050031585 A IN O
an US20050031585 A DT O
IFN-α US20050031585 A NNP I-UN
other US20050031585 A JJ O
than US20050031585 A IN O
consensus US20050031585 A NN O
interferon US20050031585 A NN I-UN
( US20050031585 A ( O
CIFN US20050031585 A NNP O
) US20050031585 A ) O
, US20050031585 A , O
or US20050031585 A CC O
who US20050031585 A WP O
, US20050031585 A , O
following US20050031585 A VBG O
cessation US20050031585 A NN O
of US20050031585 A IN O
therapy US20050031585 A NN O
with US20050031585 A IN O
an US20050031585 A DT O
IFN-α US20050031585 A NNP I-UN
other US20050031585 A JJ O
than US20050031585 A IN O
CIFN US20050031585 A NNP O
, US20050031585 A , O
have US20050031585 A VBP O
suffered US20050031585 A VBN O
relapse US20050031585 A NN O
. US20050031585 A . O

Gene US20110218234 T NNP O
vector US20110218234 T NN O
for US20110218234 T IN O
inducing US20110218234 T VBG O
transgene-specific US20110218234 T JJ O
immune US20110218234 T JJ O
tolerance US20110218234 T NN O
. US20110218234 T . O

Substituted US20060189631 T VBN O
imidazopyrimidines US20060189631 T NNS O
for US20060189631 T IN O
the US20060189631 T DT O
prevention US20060189631 T NN O
and US20060189631 T CC O
treatment US20060189631 T NN O
of US20060189631 T IN O
cancer US20060189631 T NN O
. US20060189631 T . O

For US20050059726 T IN O
treating US20050059726 T VBG O
thrombosis US20050059726 T NN O
and US20050059726 T CC O
factor US20050059726 T NN I-UN
xa-related US20050059726 T JJ O
cardiovascular US20050059726 T NN O
and US20050059726 T CC O
neurodegenerative US20050059726 T JJ O
diseases US20050059726 T NNS O
; US20050059726 T : O
6-Chloro-N- US20050059726 T JJ O
{ US20050059726 T ( O
( US20050059726 T ( O
3S US20050059726 T CD O
) US20050059726 T ) O
-1- US20050059726 T NN O
[ US20050059726 T JJ O
3-fluoro-2'- US20050059726 T JJ O
( US20050059726 T ( O
methylsulfonyl US20050059726 T NN O
) US20050059726 T ) O
-1,1'-biphenyl-4-yl US20050059726 T VBZ O
] US20050059726 T JJ O
-2-oxopyrrolidin-3-yl US20050059726 T JJ O
} US20050059726 T ) O
naphthalene-2-sulfonamide US20050059726 T JJ O
for US20050059726 T IN O
example US20050059726 T NN O
. US20050059726 T . O

The US20050059726 A DT O
invention US20050059726 A NN O
also US20050059726 A RB O
relates US20050059726 A VBZ O
to US20050059726 A TO O
processes US20050059726 A VB O
for US20050059726 A IN O
the US20050059726 A DT O
preparation US20050059726 A NN O
of US20050059726 A IN O
the US20050059726 A DT O
compounds US20050059726 A NNS O
, US20050059726 A , O
pharmaceutical US20050059726 A JJ O
compositions US20050059726 A NNS O
containing US20050059726 A VBG O
the US20050059726 A DT O
compounds US20050059726 A NNS O
, US20050059726 A , O
and US20050059726 A CC O
to US20050059726 A TO O
the US20050059726 A DT O
use US20050059726 A NN O
of US20050059726 A IN O
compounds US20050059726 A NNS O
in US20050059726 A IN O
medicine US20050059726 A NN O
, US20050059726 A , O
particularly US20050059726 A RB O
in US20050059726 A IN O
the US20050059726 A DT O
amelioration US20050059726 A NN O
of US20050059726 A IN O
a US20050059726 A DT O
clinical US20050059726 A JJ O
condition US20050059726 A NN O
for US20050059726 A IN O
which US20050059726 A WDT O
a US20050059726 A DT O
Factor US20050059726 A NNP I-UN
Xa US20050059726 A NNP I-UN
inhibitor US20050059726 A NN O
is US20050059726 A VBZ O
indicated US20050059726 A VBN O
. US20050059726 A . O

Novel US20110262511 T JJ O
Uses US20110262511 T NNS O
. US20110262511 T . O

Method WO2006042481A1 T NNP O
of WO2006042481A1 T IN O
obtaining WO2006042481A1 T VBG O
clopidogrel WO2006042481A1 T NN O
. WO2006042481A1 T . O

Derivant CN102690317A T NN O
of CN102690317A T IN O
30-halogenated CN102690317A T JJ O
betulinic CN102690317A T JJ O
acid CN102690317A T NN O
and CN102690317A T CC O
preparation CN102690317A T NN O
method CN102690317A T NN O
and CN102690317A T CC O
application CN102690317A T NN O
thereof CN102690317A T NN O
. CN102690317A T . O

Small US20100144802 T JJ O
Molecule US20100144802 T NNP O
Inhibitors US20100144802 T NNP O
for US20100144802 T IN O
Immune US20100144802 T NNP O
Modulation US20100144802 T NNP O
. US20100144802 T . O

Compound CN102503945A T NNP O
capable CN102503945A T NN O
of CN102503945A T IN O
inhibiting CN102503945A T VBG O
epidermal CN102503945A T JJ I-UN
growth CN102503945A T NN I-UN
factor CN102503945A T NN I-UN
receptor CN102503945A T NN I-UN
and CN102503945A T CC O
application CN102503945A T NN O
thereof CN102503945A T NN O
. CN102503945A T . O

The CN102503945A A DT O
invention CN102503945A A NN O
further CN102503945A A RB O
relates CN102503945A A VBZ O
to CN102503945A A TO O
an CN102503945A A DT O
application CN102503945A A NN O
of CN102503945A A IN O
the CN102503945A A DT O
compound CN102503945A A NN O
in CN102503945A A IN O
the CN102503945A A DT O
aspect CN102503945A A NN O
of CN102503945A A IN O
preventing CN102503945A A VBG O
and CN102503945A A CC O
treating CN102503945A A VBG O
cancers CN102503945A A NNS O
related CN102503945A A VBN O
to CN102503945A A TO O
EGFR CN102503945A A NNP I-UN
( CN102503945A A ( O
epidermal CN102503945A A JJ I-UN
growth CN102503945A A NN I-UN
factor CN102503945A A NN I-UN
receptor CN102503945A A NN I-UN
) CN102503945A A ) O
and CN102503945A A CC O
related CN102503945A A JJ O
diseases CN102503945A A NNS O
thereof CN102503945A A NN O
and CN102503945A A CC O
an CN102503945A A DT O
application CN102503945A A NN O
of CN102503945A A IN O
the CN102503945A A DT O
medicament CN102503945A A JJ O
composition CN102503945A A NN O
in CN102503945A A IN O
the CN102503945A A DT O
aspect CN102503945A A NN O
of CN102503945A A IN O
preventing CN102503945A A VBG O
and CN102503945A A CC O
treating CN102503945A A VBG O
cancers CN102503945A A NNS O
related CN102503945A A VBN O
to CN102503945A A TO O
EGFR CN102503945A A NNP I-UN
and CN102503945A A CC O
related CN102503945A A VBN O
diseases CN102503945A A NNS O
thereof CN102503945A A VBP O
. CN102503945A A . O

Combination CN102596197A T NNP O
therapy CN102596197A T NN O
for CN102596197A T IN O
treating CN102596197A T VBG O
proliferative CN102596197A T JJ O
diseases CN102596197A T NNS O
. CN102596197A T . O

A CN102596197A A DT O
pharmaceutical CN102596197A A JJ O
composition CN102596197A A NN O
of CN102596197A A IN O
a CN102596197A A DT O
tubulin CN102596197A A JJ O
polymerisation CN102596197A A NN O
inhibitor CN102596197A A NN O
and CN102596197A A CC O
an CN102596197A A DT O
mTOR CN102596197A A NN I-UN
inhibitor CN102596197A A NN O
and CN102596197A A CC O
a CN102596197A A DT O
method CN102596197A A NN O
of CN102596197A A IN O
treating CN102596197A A VBG O
proliferative CN102596197A A JJ O
disease CN102596197A A NN O
with CN102596197A A IN O
a CN102596197A A DT O
combination CN102596197A A NN O
of CN102596197A A IN O
a CN102596197A A DT O
tubulin CN102596197A A JJ O
polymerisation CN102596197A A NN O
inhibitor CN102596197A A NN O
and CN102596197A A CC O
an CN102596197A A DT O
mTOR CN102596197A A NN I-UN
inhibitor CN102596197A A NN O

Composition WO2006085562A1 T NN O
for WO2006085562A1 T IN O
preventing WO2006085562A1 T VBG O
and/or WO2006085562A1 T JJ O
treating WO2006085562A1 T VBG O
metabolic WO2006085562A1 T JJ O
syndrome WO2006085562A1 T NN O
and WO2006085562A1 T CC O
insulin WO2006085562A1 T NN I-UN
resistance WO2006085562A1 T NN O
syndrome WO2006085562A1 T NN O
. WO2006085562A1 T . O

It WO2006085562A1 A PRP O
is WO2006085562A1 A VBZ O
intended WO2006085562A1 A VBN O
to WO2006085562A1 A TO O
conveniently WO2006085562A1 A RB O
and WO2006085562A1 A CC O
efficiently WO2006085562A1 A RB O
provide WO2006085562A1 A VB O
a WO2006085562A1 A DT O
specific WO2006085562A1 A JJ O
compound WO2006085562A1 A NN O
originating WO2006085562A1 A NN O
in WO2006085562A1 A IN O
a WO2006085562A1 A DT O
natural WO2006085562A1 A JJ O
material WO2006085562A1 A NN O
and WO2006085562A1 A CC O
a WO2006085562A1 A DT O
composition WO2006085562A1 A NN O
for WO2006085562A1 A IN O
preventing WO2006085562A1 A VBG O
and/or WO2006085562A1 A JJ O
treating WO2006085562A1 A VBG O
metabolic WO2006085562A1 A JJ O
syndrome WO2006085562A1 A NN O
and WO2006085562A1 A CC O
insulin WO2006085562A1 A NN I-UN
resistance WO2006085562A1 A NN O
syndrome WO2006085562A1 A NN O
characterized WO2006085562A1 A VBN O
by WO2006085562A1 A IN O
containing WO2006085562A1 A VBG O
the WO2006085562A1 A DT O
above WO2006085562A1 A JJ O
compound WO2006085562A1 A NN O
as WO2006085562A1 A IN O
the WO2006085562A1 A DT O
active WO2006085562A1 A JJ O
ingredient WO2006085562A1 A NN O
. WO2006085562A1 A . O

Namely WO2006085562A1 A RB O
, WO2006085562A1 A , O
a WO2006085562A1 A DT O
composition WO2006085562A1 A NN O
for WO2006085562A1 A IN O
preventing WO2006085562A1 A VBG O
and/or WO2006085562A1 A JJ O
treating WO2006085562A1 A VBG O
metabolic WO2006085562A1 A JJ O
syndrome WO2006085562A1 A NN O
and WO2006085562A1 A CC O
insulin WO2006085562A1 A NN I-UN
resistance WO2006085562A1 A NN O
syndrome WO2006085562A1 A NN O
which WO2006085562A1 A WDT O
contains WO2006085562A1 A VBZ O
, WO2006085562A1 A , O
as WO2006085562A1 A IN O
the WO2006085562A1 A DT O
active WO2006085562A1 A JJ O
ingredient WO2006085562A1 A NN O
, WO2006085562A1 A , O
at WO2006085562A1 A IN O
least WO2006085562A1 A JJS O
one WO2006085562A1 A CD O
compound WO2006085562A1 A NN O
selected WO2006085562A1 A VBN O
from WO2006085562A1 A IN O
among WO2006085562A1 A IN O
the WO2006085562A1 A DT O
compound WO2006085562A1 A NN O
represented WO2006085562A1 A VBN O
by WO2006085562A1 A IN O
the WO2006085562A1 A DT O
formula WO2006085562A1 A NN O
( WO2006085562A1 A ( O
1 WO2006085562A1 A CD O
) WO2006085562A1 A ) O
, WO2006085562A1 A , O
the WO2006085562A1 A DT O
compound WO2006085562A1 A NN O
represented WO2006085562A1 A VBN O
by WO2006085562A1 A IN O
the WO2006085562A1 A DT O
formula WO2006085562A1 A NN O
( WO2006085562A1 A ( O
4 WO2006085562A1 A CD O
) WO2006085562A1 A ) O
and WO2006085562A1 A CC O
the WO2006085562A1 A DT O
compound WO2006085562A1 A NN O
represented WO2006085562A1 A VBN O
by WO2006085562A1 A IN O
the WO2006085562A1 A DT O
formula WO2006085562A1 A NN O
( WO2006085562A1 A ( O
5 WO2006085562A1 A CD O
) WO2006085562A1 A ) O
or WO2006085562A1 A CC O
a WO2006085562A1 A DT O
salt WO2006085562A1 A NN O
or WO2006085562A1 A CC O
an WO2006085562A1 A DT O
ester WO2006085562A1 A NN O
of WO2006085562A1 A IN O
the WO2006085562A1 A DT O
same WO2006085562A1 A JJ O
. WO2006085562A1 A . O

Method CN101816753A T NNP O
for CN101816753A T IN O
detecting CN101816753A T VBG O
quality CN101816753A T NN O
of CN101816753A T IN O
compound CN101816753A T NN O
preparation CN101816753A T NN O
for CN101816753A T IN O
treating CN101816753A T VBG O
cold CN101816753A T NN O
. CN101816753A T . O

Vaginal CN1732967A T JJ O
tablet CN1732967A T NN O
with CN1732967A T IN O
clindamycin CN1732967A T NN O
and CN1732967A T CC O
metronidazole CN1732967A T NN O
. CN1732967A T . O

Method US20120195911 T NNP O
of US20120195911 T IN O
treatment US20120195911 T NN O
of US20120195911 T IN O
cancer US20120195911 T NN O
patients US20120195911 T NNS O
. US20120195911 T . O

2-aminoquinoline WO2009109493A3 T JJ O
derivatives WO2009109493A3 T NNS O
as WO2009109493A3 T IN O
5-ht WO2009109493A3 T JJ I-UN
( WO2009109493A3 T ( I-UN
5a WO2009109493A3 T CD I-UN
) WO2009109493A3 T ) I-UN
receptor WO2009109493A3 T NN I-UN
antagonists WO2009109493A3 T NNS O
. WO2009109493A3 T . O

The WO2009109493A3 A DT O
present WO2009109493A3 A JJ O
invention WO2009109493A3 A NN O
is WO2009109493A3 A VBZ O
concerned WO2009109493A3 A VBN O
with WO2009109493A3 A IN O
2-Aminoquinoline WO2009109493A3 A JJ O
derivatives WO2009109493A3 A NNS O
as WO2009109493A3 A IN O
5-HT5A WO2009109493A3 A JJ I-UN
receptor WO2009109493A3 A NN O
antagonists WO2009109493A3 A NNS O
, WO2009109493A3 A , O
their WO2009109493A3 A PRP$ O
manufacture WO2009109493A3 A NN O
, WO2009109493A3 A , O
pharmaceutical WO2009109493A3 A JJ O
compositions WO2009109493A3 A NNS O
containing WO2009109493A3 A VBG O
them WO2009109493A3 A PRP O
and WO2009109493A3 A CC O
their WO2009109493A3 A PRP$ O
use WO2009109493A3 A NN O
as WO2009109493A3 A IN O
medicaments WO2009109493A3 A NNS O
. WO2009109493A3 A . O

Novel CA2312990C T NNP O
salts CA2312990C T NNS O
of CA2312990C T IN O
metformin CA2312990C T NN O
and CA2312990C T CC O
method CA2312990C T NN O
. CA2312990C T . O

Novel CA2312990C A NNP O
salts CA2312990C A NNS O
of CA2312990C A IN O
the CA2312990C A DT O
antidiabetic CA2312990C A JJ O
agent CA2312990C A NN O
metformin CA2312990C A NNS O
are CA2312990C A VBP O
provided CA2312990C A VBN O
which CA2312990C A WDT O
are CA2312990C A VBP O
metformin CA2312990C A JJ O
salts CA2312990C A NNS O
of CA2312990C A IN O
dibasic CA2312990C A JJ O
acids CA2312990C A NNS O
( CA2312990C A ( O
2:1 CA2312990C A CD O
molar CA2312990C A RB O
ratio CA2312990C A NN O
) CA2312990C A ) O
, CA2312990C A , O
preferably CA2312990C A RB O
metformin CA2312990C A NN O
( CA2312990C A ( O
2:1 CA2312990C A CD O
) CA2312990C A ) O
fumarate CA2312990C A NN O
and CA2312990C A CC O
metformin CA2312990C A NN O
( CA2312990C A ( O
2:1 CA2312990C A CD O
) CA2312990C A ) O
succinate CA2312990C A NN O
, CA2312990C A , O
which CA2312990C A WDT O
may CA2312990C A MD O
be CA2312990C A VB O
employed CA2312990C A VBN O
alone CA2312990C A RB O
or CA2312990C A CC O
in CA2312990C A IN O
combination CA2312990C A NN O
with CA2312990C A IN O
another CA2312990C A DT O
antihyperglycemic CA2312990C A JJ O
agent CA2312990C A NN O
such CA2312990C A JJ O
as CA2312990C A IN O
glyburide CA2312990C A NN O
, CA2312990C A , O
for CA2312990C A IN O
treating CA2312990C A VBG O
diabetes CA2312990C A NNS O
. CA2312990C A . O

A CA2312990C A DT O
method CA2312990C A NN O
for CA2312990C A IN O
treating CA2312990C A VBG O
diabetes CA2312990C A NNS O
employing CA2312990C A VBG O
the CA2312990C A DT O
novel CA2312990C A JJ O
metformin CA2312990C A NN O
salt CA2312990C A NN O
by CA2312990C A IN O
itself CA2312990C A PRP O
or CA2312990C A CC O
in CA2312990C A IN O
combination CA2312990C A NN O
with CA2312990C A IN O
another CA2312990C A DT O
antidiabetic CA2312990C A JJ O
agent CA2312990C A NN O
is CA2312990C A VBZ O
also CA2312990C A RB O
provided CA2312990C A VBN O
. CA2312990C A . O

Method US20070299032 T NNP O
and US20070299032 T CC O
Composition US20070299032 T NNP O
for US20070299032 T IN O
Thickening US20070299032 T NNP O
Hair US20070299032 T NNP O
. US20070299032 T . O

The US20070299032 A DT O
present US20070299032 A JJ O
invention US20070299032 A NN O
provides US20070299032 A VBZ O
a US20070299032 A DT O
method US20070299032 A NN O
for US20070299032 A IN O
maintaining US20070299032 A VBG O
and US20070299032 A CC O
promoting US20070299032 A VBG O
hair US20070299032 A NN O
thickening US20070299032 A VBG O
by US20070299032 A IN O
increasing US20070299032 A VBG O
the US20070299032 A DT O
expression US20070299032 A NN O
of US20070299032 A IN O
keratinocyte US20070299032 A JJ I-UN
growth US20070299032 A NN I-UN
factor US20070299032 A NN I-UN
( US20070299032 A ( O
FGF-7 US20070299032 A NNP I-UN
) US20070299032 A ) O
in US20070299032 A IN O
hair US20070299032 A NN O
follicle US20070299032 A NN O
cells US20070299032 A NNS O
, US20070299032 A , O
and US20070299032 A CC O
preferably US20070299032 A RB O
dermal US20070299032 A JJ O
papilla US20070299032 A NN O
cells US20070299032 A NNS O
, US20070299032 A , O
a US20070299032 A DT O
composition US20070299032 A NN O
for US20070299032 A IN O
increasing US20070299032 A VBG O
expression US20070299032 A NN O
of US20070299032 A IN O
FGF-7 US20070299032 A NNP I-UN
that US20070299032 A WDT O
contains US20070299032 A VBZ O
adenosine US20070299032 A JJ O
and/or US20070299032 A IN O
a US20070299032 A DT O
derivative US20070299032 A JJ O
thereof US20070299032 A NN O
, US20070299032 A , O
and US20070299032 A CC O
particularly US20070299032 A RB O
, US20070299032 A , O
an US20070299032 A DT O
external US20070299032 A JJ O
scalp US20070299032 A NN O
preparation US20070299032 A NN O
for US20070299032 A IN O
maintaining US20070299032 A VBG O
and US20070299032 A CC O
promoting US20070299032 A VBG O
hair US20070299032 A NN O
thickening US20070299032 A VBG O
. US20070299032 A . O

Inhibitors US20110257100 T NNS O
of US20110257100 T IN O
Protein US20110257100 T NNP I-UN
Tyrosine US20110257100 T NNP I-UN
Kinase US20110257100 T NNP I-UN
Activity US20110257100 T NNP O
. US20110257100 T . O

This US20110257100 A DT O
invention US20110257100 A NN O
relates US20110257100 A VBZ O
to US20110257100 A TO O
compounds US20110257100 A VB O
that US20110257100 A DT O
inhibit US20110257100 A NN O
protein US20110257100 A JJ I-UN
tyrosine US20110257100 A JJ I-UN
kinase US20110257100 A NN I-UN
activity US20110257100 A NN O
. US20110257100 A . O

In US20110257100 A IN O
particular US20110257100 A JJ O
the US20110257100 A DT O
invention US20110257100 A NN O
relates US20110257100 A VBZ O
to US20110257100 A TO O
compounds US20110257100 A VB O
that US20110257100 A DT O
inhibit US20110257100 A VB O
the US20110257100 A DT O
protein US20110257100 A NN I-UN
tyrosine US20110257100 A JJ I-UN
kinase US20110257100 A NN I-UN
activity US20110257100 A NN O
of US20110257100 A IN O
growth US20110257100 A NN I-UN
factor US20110257100 A NN I-UN
receptors US20110257100 A NNS I-UN
, US20110257100 A , O
resulting US20110257100 A VBG O
in US20110257100 A IN O
the US20110257100 A DT O
inhibition US20110257100 A NN O
of US20110257100 A IN O
receptor US20110257100 A NN O
signaling US20110257100 A NN O
, US20110257100 A , O
for US20110257100 A IN O
example US20110257100 A NN O
, US20110257100 A , O
the US20110257100 A DT O
inhibition US20110257100 A NN O
of US20110257100 A IN O
VEGF US20110257100 A NNP I-UN
receptor US20110257100 A NN I-UN
signaling US20110257100 A NN O
. US20110257100 A . O

N- EP1379508B9 T NNP O
( EP1379508B9 T ( O
aryl EP1379508B9 T NN O
) EP1379508B9 T ) O
-2-arylethenesulfonamides EP1379508B9 T NNS O
and EP1379508B9 T CC O
therapeutic EP1379508B9 T JJ O
uses EP1379508B9 T NNS O
thereof EP1379508B9 T NN O
. EP1379508B9 T . O

Compositions EP1719518A1 T NNS O
comprising EP1719518A1 T VBG O
bacillus EP1719518A1 T NN O
coagulans EP1719518A1 T NNS O
for EP1719518A1 T IN O
increasing EP1719518A1 T VBG O
the EP1719518A1 T DT O
solubility EP1719518A1 T NN O
and EP1719518A1 T CC O
bioavailability EP1719518A1 T NN O
of EP1719518A1 T IN O
nutritional EP1719518A1 T JJ O
minerals EP1719518A1 T NNS O
. EP1719518A1 T . O

Novel EP1242437B1 T NNP O
stromelysin EP1242437B1 T NN I-UN
inhibitors EP1242437B1 T NNS O
. EP1242437B1 T . O

The EP1242437B1 A DT O
invention EP1242437B1 A NN O
relates EP1242437B1 A VBZ O
to EP1242437B1 A TO O
compounds EP1242437B1 A NNS O
of EP1242437B1 A IN O
formula EP1242437B1 A NN O
( EP1242437B1 A ( O
I EP1242437B1 A PRP O
) EP1242437B1 A ) O
, EP1242437B1 A , O
which EP1242437B1 A WDT O
are EP1242437B1 A VBP O
suitable EP1242437B1 A JJ O
for EP1242437B1 A IN O
the EP1242437B1 A DT O
production EP1242437B1 A NN O
of EP1242437B1 A IN O
medicaments EP1242437B1 A NNS O
for EP1242437B1 A IN O
the EP1242437B1 A DT O
treatment EP1242437B1 A NN O
and EP1242437B1 A CC O
prophylaxis EP1242437B1 A NN O
of EP1242437B1 A IN O
diseases EP1242437B1 A NNS O
, EP1242437B1 A , O
in EP1242437B1 A IN O
which EP1242437B1 A WDT O
an EP1242437B1 A DT O
increased EP1242437B1 A VBN O
activity EP1242437B1 A NN O
of EP1242437B1 A IN O
matrix-degrading EP1242437B1 A JJ I-UN
enzymes EP1242437B1 A NNS I-UN
, EP1242437B1 A , O
in EP1242437B1 A IN O
particular EP1242437B1 A JJ O
, EP1242437B1 A , O
stromelysin EP1242437B1 A NN I-UN
, EP1242437B1 A , O
are EP1242437B1 A VBP O
implicated EP1242437B1 A VBN O
. EP1242437B1 A . O

Hedgehog US20130012513 T NNP I-UN
inhibitors US20130012513 T NNS O
. US20130012513 T . O

Described US20130012513 A VBN O
herein US20130012513 A NNS O
are US20130012513 A VBP O
compounds US20130012513 A NNS O
, US20130012513 A , O
pharmaceutical US20130012513 A JJ O
compositions US20130012513 A NNS O
and US20130012513 A CC O
methods US20130012513 A NNS O
for US20130012513 A IN O
the US20130012513 A DT O
inhibition US20130012513 A NN O
of US20130012513 A IN O
Hedgehog US20130012513 A NNP I-UN
signaling US20130012513 A VBG O
. US20130012513 A . O

Memory US20100183579 T NN O
enhancing US20100183579 T VBG O
protein US20100183579 T NN O
. US20100183579 T . O

The US20100183579 A DT O
present US20100183579 A JJ O
invention US20100183579 A NN O
provides US20100183579 A VBZ O
methods US20100183579 A NNS O
and US20100183579 A CC O
compositions US20100183579 A NNS O
for US20100183579 A IN O
enhancing US20100183579 A VBG O
memory US20100183579 A NN O
in US20100183579 A IN O
animals US20100183579 A NNS O
, US20100183579 A , O
including US20100183579 A VBG O
humans US20100183579 A NNS O
by US20100183579 A IN O
the US20100183579 A DT O
administration US20100183579 A NN O
of US20100183579 A IN O
an US20100183579 A DT O
effective US20100183579 A JJ O
amount US20100183579 A NN O
of US20100183579 A IN O
an US20100183579 A DT O
atypical US20100183579 A JJ O
form US20100183579 A NN O
of US20100183579 A IN O
protein US20100183579 A JJ O
kinase US20100183579 A NN O
C US20100183579 A NNP O
such US20100183579 A JJ O
as US20100183579 A IN O
protein US20100183579 A JJ I-UN
kinase US20100183579 A NN I-UN
M US20100183579 A NNP I-UN
zeta US20100183579 A NN I-UN
( US20100183579 A ( O
PKMζ US20100183579 A NNP I-UN
) US20100183579 A ) O
or US20100183579 A CC O
protein US20100183579 A JJ I-UN
kinase US20100183579 A NN I-UN
C US20100183579 A NNP I-UN
iota/lambda US20100183579 A NN I-UN
. US20100183579 A . O

Methods WO2013010140A2 T NNS O
of WO2013010140A2 T IN O
diagnosing WO2013010140A2 T VBG O
cancer WO2013010140A2 T NN O
. WO2013010140A2 T . O

Provided WO2013010140A2 A VBN O
are WO2013010140A2 A VBP O
methods WO2013010140A2 A NNS O
of WO2013010140A2 A IN O
predicting WO2013010140A2 A VBG O
or WO2013010140A2 A CC O
assessing WO2013010140A2 A VBG O
the WO2013010140A2 A DT O
level WO2013010140A2 A NN O
of WO2013010140A2 A IN O
severity WO2013010140A2 A NN O
of WO2013010140A2 A IN O
cancer WO2013010140A2 A NN O
or WO2013010140A2 A CC O
cancer WO2013010140A2 A NN O
progression WO2013010140A2 A NN O
in WO2013010140A2 A IN O
a WO2013010140A2 A DT O
patient WO2013010140A2 A NN O
comprising WO2013010140A2 A VBG O
measuring WO2013010140A2 A VBG O
levels WO2013010140A2 A NNS O
of WO2013010140A2 A IN O
SET WO2013010140A2 A NNP I-UN
expression WO2013010140A2 A NN O
in WO2013010140A2 A IN O
a WO2013010140A2 A DT O
biological WO2013010140A2 A JJ O
sample WO2013010140A2 A NN O
from WO2013010140A2 A IN O
a WO2013010140A2 A DT O
patient WO2013010140A2 A NN O
and WO2013010140A2 A CC O
comparing WO2013010140A2 A NN O
levels WO2013010140A2 A NNS O
of WO2013010140A2 A IN O
SET WO2013010140A2 A NNP I-UN
expression WO2013010140A2 A NN O
to WO2013010140A2 A TO O
a WO2013010140A2 A DT O
control WO2013010140A2 A NN O
sample WO2013010140A2 A NN O
or WO2013010140A2 A CC O
standard WO2013010140A2 A JJ O
value WO2013010140A2 A NN O
. WO2013010140A2 A . O

Methods WO2013010140A2 A NNS O
for WO2013010140A2 A IN O
predicting WO2013010140A2 A VBG O
or WO2013010140A2 A CC O
evaluating WO2013010140A2 A VBG O
the WO2013010140A2 A DT O
efficacy WO2013010140A2 A NN O
of WO2013010140A2 A IN O
a WO2013010140A2 A DT O
SET WO2013010140A2 A NNP I-UN
therapeutic WO2013010140A2 A JJ O
and WO2013010140A2 A CC O
kits WO2013010140A2 A VBZ O
comprising WO2013010140A2 A VBG O
at WO2013010140A2 A IN O
least WO2013010140A2 A JJS O
one WO2013010140A2 A CD O
reagent WO2013010140A2 A NN O
for WO2013010140A2 A IN O
measuring WO2013010140A2 A VBG O
SET WO2013010140A2 A NNP I-UN
protein WO2013010140A2 A NN I-UN
expression WO2013010140A2 A NN O
are WO2013010140A2 A VBP O
also WO2013010140A2 A RB O
provided WO2013010140A2 A VBN O
. WO2013010140A2 A . O

Composite CN1939535A T NNP O
collagen CN1939535A T NN I-UN
protein CN1939535A T NN O
liquid CN1939535A T NN O
. CN1939535A T . O

A CN1939535A A DT O
composite CN1939535A A JJ O
collagen CN1939535A A NN I-UN
liquid CN1939535A A NN O
for CN1939535A A IN O
treating CN1939535A A VBG O
skin CN1939535A A NN O
anaphylactin CN1939535A A NN O
contains CN1939535A A VBZ O
proportionally CN1939535A A RB O
the CN1939535A A DT O
collagen CN1939535A A NN I-UN
extracted CN1939535A A VBD O
from CN1939535A A IN O
the CN1939535A A DT O
tendon CN1939535A A NN O
of CN1939535A A IN O
ox CN1939535A A NN O
or CN1939535A A CC O
pig CN1939535A A NN O
, CN1939535A A , O
the CN1939535A A DT O
vitamin CN1939535A A NN O
which CN1939535A A WDT O
is CN1939535A A VBZ O
the CN1939535A A DT O
VC CN1939535A A NNP O
including CN1939535A A VBG O
VC CN1939535A A NNP O
magnesium CN1939535A A NN O
phosphate CN1939535A A NN O
, CN1939535A A , O
levo-VC CN1939535A A JJ O
and CN1939535A A CC O
VC CN1939535A A NNP O
glycoside CN1939535A A NN O
, CN1939535A A , O
and CN1939535A A CC O
purified CN1939535A A JJ O
water CN1939535A A NN O
. CN1939535A A . O

Processes WO2009112954A3 T NNS O
for WO2009112954A3 T IN O
the WO2009112954A3 T DT O
preparation WO2009112954A3 T NN O
of WO2009112954A3 T IN O
bosentan WO2009112954A3 T NN O
and WO2009112954A3 T CC O
related WO2009112954A3 T JJ O
compounds WO2009112954A3 T NNS O
. WO2009112954A3 T . O

Tricyclic WO2013186666A1 T JJ O
compounds WO2013186666A1 T NNS O
as WO2013186666A1 T IN O
kat WO2013186666A1 T NN I-UN
ii WO2013186666A1 T NN I-UN
inhibitors WO2013186666A1 T NNS O
. WO2013186666A1 T . O

Fluoroalkoxy-substituted EP1587474A2 T JJ O
1 EP1587474A2 T CD O
, EP1587474A2 T , O
3-dihydro-isoindolyl EP1587474A2 T JJ O
compounds EP1587474A2 T NNS O
and EP1587474A2 T CC O
their EP1587474A2 T PRP$ O
pharmaceutical EP1587474A2 T JJ O
uses EP1587474A2 T NNS O
. EP1587474A2 T . O

The EP1587474A2 A DT O
invention EP1587474A2 A NN O
encompasses EP1587474A2 A VBZ O
novel EP1587474A2 A JJ O
compounds EP1587474A2 A NNS O
, EP1587474A2 A , O
pharmaceutically EP1587474A2 A RB O
acceptable EP1587474A2 A JJ O
salts EP1587474A2 A NNS O
, EP1587474A2 A , O
hydrates EP1587474A2 A VBZ O
solvates EP1587474A2 A NNS O
, EP1587474A2 A , O
solvates EP1587474A2 A NNS O
, EP1587474A2 A , O
clathrates EP1587474A2 A NNS O
, EP1587474A2 A , O
enantiomers EP1587474A2 A NNS O
, EP1587474A2 A , O
diastereomers EP1587474A2 A NNS O
, EP1587474A2 A , O
racemates EP1587474A2 A NNS O
, EP1587474A2 A , O
or EP1587474A2 A CC O
mixtures EP1587474A2 A NNS O
of EP1587474A2 A IN O
stereoisomers EP1587474A2 A NNS O
thereof EP1587474A2 A VBP O
, EP1587474A2 A , O
pharmaceutical EP1587474A2 A JJ O
compositions EP1587474A2 A NNS O
of EP1587474A2 A IN O
these EP1587474A2 A DT O
compounds EP1587474A2 A NNS O
, EP1587474A2 A , O
and EP1587474A2 A CC O
methods EP1587474A2 A NNS O
of EP1587474A2 A IN O
using EP1587474A2 A VBG O
these EP1587474A2 A DT O
compounds EP1587474A2 A NNS O
in EP1587474A2 A IN O
mammals EP1587474A2 A NNS O
for EP1587474A2 A IN O
treatment EP1587474A2 A NN O
or EP1587474A2 A CC O
prevention EP1587474A2 A NN O
of EP1587474A2 A IN O
diseases EP1587474A2 A NNS O
associated EP1587474A2 A VBN O
with EP1587474A2 A IN O
PDE4 EP1587474A2 A NNP I-UN
. EP1587474A2 A . O

Fatty US7026356 T NNP O
acid US7026356 T NN O
analogues US7026356 T NNS O
for US7026356 T IN O
the US7026356 T DT O
treatment US7026356 T NN O
of US7026356 T IN O
diseases US7026356 T NNS O
caused US7026356 T VBN O
by US7026356 T IN O
the US7026356 T DT O
pathological US7026356 T JJ O
proliferation US7026356 T NN O
of US7026356 T IN O
smooth US7026356 T JJ O
muscle US7026356 T NN O
cells US7026356 T NNS O
. US7026356 T . O

The US7026356 A DT O
present US7026356 A JJ O
invention US7026356 A NN O
relates US7026356 A VBZ O
to US7026356 A TO O
novel US7026356 A VB O
fatty US7026356 A JJ O
acid US7026356 A NN O
analogues US7026356 A NNS O
of US7026356 A IN O
the US7026356 A DT O
general US7026356 A JJ O
formula US7026356 A NN O
( US7026356 A ( O
I US7026356 A PRP O
) US7026356 A ) O
: US7026356 A : O
CH3— US7026356 A NNP O
[ US7026356 A NNP O
CH2 US7026356 A NNP O
] US7026356 A NNP O
m— US7026356 A NN O
[ US7026356 A NNP O
xi—CH2 US7026356 A NNP O
] US7026356 A NNP O
n—COOR US7026356 A NN O
, US7026356 A , O
wherein US7026356 A WP O
n US7026356 A FW O
is US7026356 A VBZ O
an US7026356 A DT O
integer US7026356 A NN O
from US7026356 A IN O
1 US7026356 A CD O
to US7026356 A TO O
12 US7026356 A CD O
, US7026356 A , O
and US7026356 A CC O
wherein US7026356 A JJ O
m US7026356 A NN O
is US7026356 A VBZ O
an US7026356 A DT O
integer US7026356 A NN O
from US7026356 A IN O
0 US7026356 A CD O
to US7026356 A TO O
23 US7026356 A CD O
, US7026356 A , O
and US7026356 A CC O
wherein US7026356 A NN O
i US7026356 A NN O
is US7026356 A VBZ O
an US7026356 A DT O
odd US7026356 A JJ O
number US7026356 A NN O
which US7026356 A WDT O
indicates US7026356 A VBZ O
the US7026356 A DT O
position US7026356 A NN O
relative US7026356 A NN O
to US7026356 A TO O
COOR US7026356 A NNP O
, US7026356 A , O
and US7026356 A CC O
wherein US7026356 A RB O
Xi US7026356 A NNP O
independent US7026356 A JJ O
of US7026356 A IN O
each US7026356 A DT O
other US7026356 A JJ O
are US7026356 A VBP O
selected US7026356 A VBN O
from US7026356 A IN O
the US7026356 A DT O
group US7026356 A NN O
comprising US7026356 A VBG O
O US7026356 A NNP O
, US7026356 A , O
S US7026356 A NNP O
, US7026356 A , O
SO US7026356 A NNP O
, US7026356 A , O
SO2 US7026356 A NNP O
, US7026356 A , O
Se US7026356 A NNP O
and US7026356 A CC O
CH2 US7026356 A NNP O
, US7026356 A , O
and US7026356 A CC O
wherein US7026356 A RB O
R US7026356 A NNP O
represents US7026356 A VBZ O
hydrogen US7026356 A NN O
or US7026356 A CC O
C1–C4 US7026356 A NNP O
alkyl US7026356 A NN O
, US7026356 A , O
with US7026356 A IN O
the US7026356 A DT O
proviso US7026356 A NN O
that US7026356 A WDT O
at US7026356 A IN O
least US7026356 A JJS O
one US7026356 A CD O
of US7026356 A IN O
the US7026356 A DT O
Xi US7026356 A NNP O
is US7026356 A VBZ O
not US7026356 A RB O
CH2 US7026356 A NNP O
, US7026356 A , O
or US7026356 A CC O
a US7026356 A DT O
salt US7026356 A NN O
, US7026356 A , O
prodrug US7026356 A NN O
or US7026356 A CC O
complex US7026356 A JJ O
thereof US7026356 A NN O
, US7026356 A , O
for US7026356 A IN O
the US7026356 A DT O
preparation US7026356 A NN O
of US7026356 A IN O
a US7026356 A DT O
pharmaceutical US7026356 A JJ O
composition US7026356 A NN O
for US7026356 A IN O
the US7026356 A DT O
treatment US7026356 A NN O
and/or US7026356 A JJ O
prevention US7026356 A NN O
of US7026356 A IN O
primary US7026356 A JJ O
and/or US7026356 A JJ O
secondary US7026356 A JJ O
stenosis US7026356 A NN O
. US7026356 A . O

Further US7026356 A RB O
the US7026356 A DT O
present US7026356 A JJ O
invention US7026356 A NN O
relates US7026356 A VBZ O
to US7026356 A TO O
the US7026356 A DT O
use US7026356 A NN O
of US7026356 A IN O
said US7026356 A VBD O
compounds US7026356 A NNS O
for US7026356 A IN O
the US7026356 A DT O
prevention US7026356 A NN O
and/or US7026356 A NN O
treatment US7026356 A NN O
of US7026356 A IN O
a US7026356 A DT O
disease US7026356 A NN O
caused US7026356 A VBN O
by US7026356 A IN O
procedural US7026356 A JJ O
vascular US7026356 A JJ O
trauma US7026356 A NN O
and/or US7026356 A RB O
pathological US7026356 A JJ O
proliferation US7026356 A NN O
of US7026356 A IN O
smooth US7026356 A JJ O
muscle US7026356 A NN O
cells US7026356 A NNS O
, US7026356 A , O
and/or US7026356 A VBP O
an US7026356 A DT O
increased US7026356 A JJ O
level US7026356 A NN O
of US7026356 A IN O
plasma US7026356 A JJ O
homocysteine US7026356 A NN O
. US7026356 A . O

Pharmaceutical CN102366484A T JJ O
composition CN102366484A T NN O
for CN102366484A T IN O
treating CN102366484A T VBG O
herpes CN102366484A T NNS O
zoster CN102366484A T NN O
and CN102366484A T CC O
preparation CN102366484A T NN O
method CN102366484A T NN O
thereof CN102366484A T NN O
. CN102366484A T . O

Manufacture CN1593461B T NNP O
method CN1593461B T NN O
of CN1593461B T IN O
nutrient CN1593461B T JJ O
oral CN1593461B T JJ O
liquor CN1593461B T NN O
of CN1593461B T IN O
ass CN1593461B T NN O
hide CN1593461B T NN O
glue CN1593461B T NN O
flavone CN1593461B T NN O
. CN1593461B T . O

Treatment WO2002053143A3 T NN O
of WO2002053143A3 T IN O
erectile WO2002053143A3 T JJ O
dysfunction WO2002053143A3 T NN O
with WO2002053143A3 T IN O
rho-kinase WO2002053143A3 T JJ I-UN
inhibitors WO2002053143A3 T NNS O
. WO2002053143A3 T . O

In WO2002053143A3 A IN O
one WO2002053143A3 A CD O
aspect WO2002053143A3 A NN O
, WO2002053143A3 A , O
the WO2002053143A3 A DT O
invention WO2002053143A3 A NN O
comprises WO2002053143A3 A VBZ O
methods WO2002053143A3 A NNS O
for WO2002053143A3 A IN O
treating WO2002053143A3 A VBG O
male WO2002053143A3 A NN O
and WO2002053143A3 A CC O
female WO2002053143A3 A JJ O
sexual WO2002053143A3 A JJ O
dysfunction WO2002053143A3 A NN O
which WO2002053143A3 A WDT O
comprises WO2002053143A3 A VBZ O
administering WO2002053143A3 A VBG O
a WO2002053143A3 A DT O
composition WO2002053143A3 A NN O
comprising WO2002053143A3 A VBG O
a WO2002053143A3 A DT O
compound WO2002053143A3 A NN O
which WO2002053143A3 A WDT O
attenuates WO2002053143A3 A VBZ O
RhoA WO2002053143A3 A NNP I-UN
and/or WO2002053143A3 A JJ O
Rho-kinase WO2002053143A3 A NNP I-UN
activity WO2002053143A3 A NN O
in WO2002053143A3 A IN O
an WO2002053143A3 A DT O
organ WO2002053143A3 A JJ O
subject WO2002053143A3 A NN O
to WO2002053143A3 A TO O
sexual WO2002053143A3 A JJ O
stimulation WO2002053143A3 A NN O
in WO2002053143A3 A IN O
a WO2002053143A3 A DT O
pharmaceutically WO2002053143A3 A RB O
acceptable WO2002053143A3 A JJ O
carrier WO2002053143A3 A NN O
to WO2002053143A3 A TO O
an WO2002053143A3 A DT O
individual WO2002053143A3 A NN O
in WO2002053143A3 A IN O
need WO2002053143A3 A NN O
of WO2002053143A3 A IN O
such WO2002053143A3 A JJ O
treatment WO2002053143A3 A NN O
. WO2002053143A3 A . O

In WO2002053143A3 A IN O
one WO2002053143A3 A CD O
embodiment WO2002053143A3 A NN O
, WO2002053143A3 A , O
the WO2002053143A3 A DT O
compound WO2002053143A3 A NN O
comprises WO2002053143A3 A VBZ O
an WO2002053143A3 A DT O
inhibitor WO2002053143A3 A NN O
of WO2002053143A3 A IN O
the WO2002053143A3 A DT O
enzyme WO2002053143A3 A JJ O
Rho-kinase WO2002053143A3 A NNP I-UN
. WO2002053143A3 A . O

Amine-linked EP1853583A1 T JJ O
pyridyl EP1853583A1 T NN O
and EP1853583A1 T CC O
phenyl EP1853583A1 T NN O
substituted EP1853583A1 T VBD O
piperazine-piperidines EP1853583A1 T NNS O
with EP1853583A1 T IN O
cxcr3 EP1853583A1 T JJ I-UN
antagonist EP1853583A1 T NN O
activity EP1853583A1 T NN O
. EP1853583A1 T . O

11,20-cyclic CN101074252B T JJ O
carbonate-azithromycin CN101074252B T JJ O
4-phenproester CN101074252B T JJ O
derivative CN101074252B T NN O
, CN101074252B T , O
its CN101074252B T PRP$ O
production CN101074252B T NN O
and CN101074252B T CC O
medicinal CN101074252B T JJ O
composition CN101074252B T NN O
. CN101074252B T . O

Azido EP2155771A1 T NNP O
purine EP2155771A1 T NN O
nucleosides EP2155771A1 T NNS O
for EP2155771A1 T IN O
treatment EP2155771A1 T NN O
of EP2155771A1 T IN O
viral EP2155771A1 T JJ O
infections EP2155771A1 T NNS O
. EP2155771A1 T . O

In EP2155771A1 A IN O
particular EP2155771A1 A JJ O
, EP2155771A1 A , O
the EP2155771A1 A DT O
compounds EP2155771A1 A NNS O
show EP2155771A1 A VBP O
potent EP2155771A1 A JJ O
antiviral EP2155771A1 A JJ O
activity EP2155771A1 A NN O
against EP2155771A1 A IN O
HIV-1 EP2155771A1 A NNP O
resistance EP2155771A1 A NN O
mutants EP2155771A1 A NNS O
including EP2155771A1 A VBG O
HIV-1K65R EP2155771A1 A NNP O
, EP2155771A1 A , O
HTV-1K70E EP2155771A1 A NNP O
, EP2155771A1 A , O
HIV-1L74V EP2155771A1 A NNP O
, EP2155771A1 A , O
HIV-1M184V EP2155771A1 A NNP O
, EP2155771A1 A , O
HIV-1Q151M EP2155771A1 A NNP O
and EP2155771A1 A CC O
inhibitory EP2155771A1 A JJ O
activity EP2155771A1 A NN O
against EP2155771A1 A IN O
HIV-1 EP2155771A1 A NNP I-UN
RT EP2155771A1 A NNP I-UN
harboring EP2155771A1 A VBG O
TAMS EP2155771A1 A NNP O
or EP2155771A1 A CC O
insertion EP2155771A1 A NN O
mutations EP2155771A1 A NNS O
including EP2155771A1 A VBG O
HIV-1AZT3 EP2155771A1 A NNP O
, EP2155771A1 A , O
HIV-1AZT7 EP2155771A1 A NNP O
, EP2155771A1 A , O
HIV-1AZT9 EP2155771A1 A NNP O
, EP2155771A1 A , O
HIV- EP2155771A1 A NNP O
1Q151M EP2155771A1 A CD O
, EP2155771A1 A , O
or EP2155771A1 A CC O
HIV-169insertion EP2155771A1 A NN O
. EP2155771A1 A . O

Lignans CN101982467A T NNS O
compounds CN101982467A T NNS O
contained CN101982467A T VBN O
in CN101982467A T IN O
Schisandra CN101982467A T NNP O
chinensis CN101982467A T NN O
, CN101982467A T , O
and CN101982467A T CC O
preparation CN101982467A T NN O
method CN101982467A T NN O
and CN101982467A T CC O
application CN101982467A T NN O
thereof CN101982467A T NN O
. CN101982467A T . O

Compositions US20120058086 T NNS O
, US20120058086 T , O
kits US20120058086 T NNS O
, US20120058086 T , O
and US20120058086 T CC O
methods US20120058086 T NNS O
for US20120058086 T IN O
promoting US20120058086 T VBG O
ischemic US20120058086 T JJ O
and US20120058086 T CC O
diabetic US20120058086 T JJ O
wound US20120058086 T NN O
healing US20120058086 T NN O
. US20120058086 T . O

Compositions US20120058086 A NNS O
, US20120058086 A , O
kits US20120058086 A NNS O
and US20120058086 A CC O
methods US20120058086 A NNS O
for US20120058086 A IN O
promoting US20120058086 A VBG O
diabetic US20120058086 A JJ O
wound US20120058086 A IN O
healing US20120058086 A VBG O
are US20120058086 A VBP O
based US20120058086 A VBN O
on US20120058086 A IN O
the US20120058086 A DT O
discovery US20120058086 A NN O
that US20120058086 A IN O
SDF-1α US20120058086 A NNP I-UN
specifically US20120058086 A RB O
upregulates US20120058086 A VBZ O
expression US20120058086 A NN O
of US20120058086 A IN O
E-selectin US20120058086 A NNP I-UN
in US20120058086 A IN O
mature US20120058086 A JJ O
endothelial US20120058086 A JJ O
cells US20120058086 A NNS O
( US20120058086 A ( O
EC US20120058086 A NNP O
) US20120058086 A ) O
, US20120058086 A , O
leading US20120058086 A VBG O
to US20120058086 A TO O
an US20120058086 A DT O
increase US20120058086 A NN O
in US20120058086 A IN O
EC-endothelial US20120058086 A JJ O
progenitor US20120058086 A NN O
cell US20120058086 A NN O
( US20120058086 A ( O
EPC US20120058086 A NNP O
) US20120058086 A ) O
adhesion US20120058086 A NN O
and US20120058086 A CC O
EPC US20120058086 A NNP O
homing US20120058086 A NN O
. US20120058086 A . O

Methods US20120058086 A NNS O
for US20120058086 A IN O
promoting US20120058086 A VBG O
healing US20120058086 A NN O
of US20120058086 A IN O
a US20120058086 A DT O
wound US20120058086 A NN O
in US20120058086 A IN O
a US20120058086 A DT O
diabetic US20120058086 A JJ O
subject US20120058086 A NN O
include US20120058086 A VBP O
providing US20120058086 A VBG O
a US20120058086 A DT O
therapeutically US20120058086 A RB O
effective US20120058086 A JJ O
amount US20120058086 A NN O
of US20120058086 A IN O
a US20120058086 A DT O
composition US20120058086 A NN O
including US20120058086 A VBG O
E-selectin US20120058086 A NNP I-UN
protein US20120058086 A NN O
or US20120058086 A CC O
a US20120058086 A DT O
nucleic US20120058086 A JJ O
acid US20120058086 A NN O
encoding US20120058086 A VBG O
E-selectin US20120058086 A NNP I-UN
protein US20120058086 A NN O
, US20120058086 A , O
and US20120058086 A CC O
optionally US20120058086 A RB O
, US20120058086 A , O
an US20120058086 A DT O
agent US20120058086 A NN O
that US20120058086 A WDT O
specifically US20120058086 A RB O
upregulates US20120058086 A VBZ O
E-selectin US20120058086 A JJ I-UN
expression US20120058086 A NN O
( US20120058086 A ( O
e.g. US20120058086 A JJ O
, US20120058086 A , O
SDF-1α US20120058086 A NNP I-UN
) US20120058086 A ) O
. US20120058086 A . O

Administering US20120058086 A VBG O
the US20120058086 A DT O
composition US20120058086 A NN O
to US20120058086 A TO O
the US20120058086 A DT O
subject US20120058086 A JJ O
results US20120058086 A NNS O
in US20120058086 A IN O
migration US20120058086 A NN O
of US20120058086 A IN O
bone US20120058086 A NN O
marrow-derived US20120058086 A JJ O
progenitor US20120058086 A NN O
cells US20120058086 A NNS O
to US20120058086 A TO O
the US20120058086 A DT O
wound US20120058086 A NN O
, US20120058086 A , O
accelerated US20120058086 A VBN O
wound US20120058086 A IN O
healing US20120058086 A NN O
, US20120058086 A , O
and US20120058086 A CC O
upregulation US20120058086 A NN O
of US20120058086 A IN O
E-selectin US20120058086 A NNP I-UN
expression US20120058086 A NN O
in US20120058086 A IN O
the US20120058086 A DT O
subject US20120058086 A NN O
. US20120058086 A . O

Pharmaceutical EP2094258A1 T JJ O
composition EP2094258A1 T NN O
using EP2094258A1 T VBG O
aliskiren EP2094258A1 T NNS O
and EP2094258A1 T CC O
avosentan EP2094258A1 T NN O
. EP2094258A1 T . O

Thiocarbonyl-substituted WO2007009688A1 T JJ O
pyrazoline WO2007009688A1 T NN O
compounds WO2007009688A1 T NNS O
, WO2007009688A1 T , O
their WO2007009688A1 T PRP$ O
preparation WO2007009688A1 T NN O
and WO2007009688A1 T CC O
use WO2007009688A1 T NN O
as WO2007009688A1 T IN O
cb1 WO2007009688A1 T NN I-UN
modulators WO2007009688A1 T NNS O
. WO2007009688A1 T . O

Piperidinyl-substituted WO2012037393A1 T JJ O
lactams WO2012037393A1 T NNS O
as WO2012037393A1 T IN O
gpr119 WO2012037393A1 T JJ I-UN
modulators WO2012037393A1 T NNS O
. WO2012037393A1 T . O

Compounds WO2012037393A1 A NNS O
of WO2012037393A1 A IN O
Formula WO2012037393A1 A NNP O
( WO2012037393A1 A ( O
I WO2012037393A1 A PRP O
) WO2012037393A1 A ) O
and WO2012037393A1 A CC O
pharmaceutically WO2012037393A1 A RB O
acceptable WO2012037393A1 A JJ O
salts WO2012037393A1 A NNS O
thereof WO2012037393A1 A NN O
in WO2012037393A1 A IN O
which WO2012037393A1 A WDT O
X1 WO2012037393A1 A NNP O
, WO2012037393A1 A , O
X2 WO2012037393A1 A NNP O
, WO2012037393A1 A , O
L WO2012037393A1 A NNP O
, WO2012037393A1 A , O
R3 WO2012037393A1 A NNP O
, WO2012037393A1 A , O
R4 WO2012037393A1 A NNP O
, WO2012037393A1 A , O
R5 WO2012037393A1 A NNP O
, WO2012037393A1 A , O
R7 WO2012037393A1 A NNP O
and WO2012037393A1 A CC O
n WO2012037393A1 A RB O
have WO2012037393A1 A VBP O
the WO2012037393A1 A DT O
meanings WO2012037393A1 A NNS O
given WO2012037393A1 A VBN O
in WO2012037393A1 A IN O
the WO2012037393A1 A DT O
specification WO2012037393A1 A NN O
, WO2012037393A1 A , O
are WO2012037393A1 A VBP O
modulators WO2012037393A1 A NNS O
of WO2012037393A1 A IN O
GPR119 WO2012037393A1 A NNP I-UN
and WO2012037393A1 A CC O
are WO2012037393A1 A VBP O
useful WO2012037393A1 A JJ O
in WO2012037393A1 A IN O
the WO2012037393A1 A DT O
treatment WO2012037393A1 A NN O
or WO2012037393A1 A CC O
prevention WO2012037393A1 A NN O
of WO2012037393A1 A IN O
diseases WO2012037393A1 A NNS O
such WO2012037393A1 A JJ O
as WO2012037393A1 A IN O
such WO2012037393A1 A JJ O
as WO2012037393A1 A IN O
, WO2012037393A1 A , O
but WO2012037393A1 A CC O
not WO2012037393A1 A RB O
limited WO2012037393A1 A JJ O
to WO2012037393A1 A TO O
, WO2012037393A1 A , O
type WO2012037393A1 A VB O
2 WO2012037393A1 A CD O
diabetes WO2012037393A1 A NNS O
, WO2012037393A1 A , O
diabetic WO2012037393A1 A JJ O
complications WO2012037393A1 A NNS O
, WO2012037393A1 A , O
symptoms WO2012037393A1 A NNS O
of WO2012037393A1 A IN O
diabetes WO2012037393A1 A NNS O
, WO2012037393A1 A , O
metabolic WO2012037393A1 A JJ O
syndrome WO2012037393A1 A NN O
, WO2012037393A1 A , O
obesity WO2012037393A1 A NN O
, WO2012037393A1 A , O
dyslipidemia WO2012037393A1 A NN O
, WO2012037393A1 A , O
and WO2012037393A1 A CC O
related WO2012037393A1 A JJ O
conditions WO2012037393A1 A NNS O
. WO2012037393A1 A . O

A WO2010122343A1 T DT O
process WO2010122343A1 T NN O
for WO2010122343A1 T IN O
the WO2010122343A1 T DT O
preparation WO2010122343A1 T NN O
of WO2010122343A1 T IN O
frovatriptan WO2010122343A1 T NN O
and WO2010122343A1 T CC O
frovatriptan WO2010122343A1 T JJ O
succinate WO2010122343A1 T NN O
and WO2010122343A1 T CC O
their WO2010122343A1 T PRP$ O
synthetic WO2010122343A1 T JJ O
intermediates WO2010122343A1 T NNS O
. WO2010122343A1 T . O

2-Phenylthiophene US20080027048 T JJ O
Derivative US20080027048 T NNP O
. US20080027048 T . O

Since US20080027048 A IN O
the US20080027048 A DT O
compound US20080027048 A NN O
of US20080027048 A IN O
the US20080027048 A DT O
invention US20080027048 A NN O
has US20080027048 A VBZ O
good US20080027048 A JJ O
xanthine US20080027048 A NNP I-UN
oxidase-inhibitory US20080027048 A JJ O
action US20080027048 A NN O
and US20080027048 A CC O
uric US20080027048 A JJ O
acid-lowering US20080027048 A JJ O
action US20080027048 A NN O
and US20080027048 A CC O
does US20080027048 A VBZ O
not US20080027048 A RB O
have US20080027048 A VB O
a US20080027048 A DT O
structure US20080027048 A NN O
derived US20080027048 A VBN O
from US20080027048 A IN O
nucleic US20080027048 A JJ O
acid US20080027048 A NN O
, US20080027048 A , O
the US20080027048 A DT O
compound US20080027048 A NN O
has US20080027048 A VBZ O
advantages US20080027048 A NNS O
of US20080027048 A IN O
high US20080027048 A JJ O
safety US20080027048 A NN O
and US20080027048 A CC O
excellent US20080027048 A JJ O
effects US20080027048 A NNS O
as US20080027048 A IN O
compared US20080027048 A VBN O
with US20080027048 A IN O
conventional US20080027048 A JJ O
compounds US20080027048 A NNS O
and US20080027048 A CC O
is US20080027048 A VBZ O
useful US20080027048 A JJ O
as US20080027048 A IN O
a US20080027048 A DT O
therapeutic US20080027048 A JJ O
or US20080027048 A CC O
preventive US20080027048 A JJ O
agent US20080027048 A NN O
for US20080027048 A IN O
hyperuricemia US20080027048 A NN O
, US20080027048 A , O
gout US20080027048 A NN O
, US20080027048 A , O
inflammatory US20080027048 A JJ O
bowel US20080027048 A NN O
diseases US20080027048 A NNS O
, US20080027048 A , O
diabetic US20080027048 A JJ O
kidney US20080027048 A NN O
diseases US20080027048 A NNS O
, US20080027048 A , O
diabetic US20080027048 A JJ O
retinopathy US20080027048 A NN O
, US20080027048 A , O
or US20080027048 A CC O
the US20080027048 A DT O
like US20080027048 A JJ O
. US20080027048 A . O

Compounds US7388020 T NNS O
for US7388020 T IN O
chronic US7388020 T JJ O
obstructive US7388020 T JJ O
pulminary US7388020 T NN O
disorders US7388020 T NNS O
for US7388020 T IN O
breathingand US7388020 T NN O
respiratory US7388020 T NN O
system US7388020 T NN O
diorders US7388020 T NNS O
. US7388020 T . O

Composition WO2009155135A1 T NN O
comprising WO2009155135A1 T VBG O
liposome-entrapped WO2009155135A1 T JJ O
doxorubicin WO2009155135A1 T NN O
and WO2009155135A1 T CC O
methods WO2009155135A1 T NNS O
of WO2009155135A1 T IN O
admnistration WO2009155135A1 T NN O
for WO2009155135A1 T IN O
treatment WO2009155135A1 T NN O
of WO2009155135A1 T IN O
multiple WO2009155135A1 T JJ O
myeloma WO2009155135A1 T NN O
. WO2009155135A1 T . O

Substituted EP2086959A1 T VBN O
2-imidazoles EP2086959A1 T NNS O
as EP2086959A1 T IN O
modulators EP2086959A1 T NNS O
of EP2086959A1 T IN O
the EP2086959A1 T DT O
trace EP2086959A1 T NN O
amine EP2086959A1 T NN O
associated EP2086959A1 T VBN O
receptors EP2086959A1 T NNS O
. EP2086959A1 T . O

It EP2086959A1 A PRP O
has EP2086959A1 A VBZ O
been EP2086959A1 A VBN O
found EP2086959A1 A VBN O
that EP2086959A1 A IN O
the EP2086959A1 A DT O
compounds EP2086959A1 A NNS O
of EP2086959A1 A IN O
formula EP2086959A1 A NN O
( EP2086959A1 A ( O
I EP2086959A1 A PRP O
) EP2086959A1 A ) O
have EP2086959A1 A VBP O
a EP2086959A1 A DT O
good EP2086959A1 A JJ O
affinity EP2086959A1 A NN O
to EP2086959A1 A TO O
the EP2086959A1 A DT O
trace EP2086959A1 A NN I-UN
amine EP2086959A1 A NN I-UN
associated EP2086959A1 A VBN I-UN
receptors EP2086959A1 A NNS I-UN
( EP2086959A1 A ( O
TAARs EP2086959A1 A NNP I-UN
) EP2086959A1 A ) O
, EP2086959A1 A , O
especially EP2086959A1 A RB O
for EP2086959A1 A IN O
TAAR1 EP2086959A1 A NNP I-UN
. EP2086959A1 A . O

Arginine CN101385724A T NNP O
Ibuprofen CN101385724A T NNP O
cream CN101385724A T NN O
and CN101385724A T CC O
preparation CN101385724A T NN O
method CN101385724A T NN O
thereof CN101385724A T NN O
. CN101385724A T . O

Nutraceutical US20080118441 T NNP O
; US20080118441 T : O
omega US20080118441 T JJ O
fatty US20080118441 T JJ O
acids US20080118441 T NNS O
; US20080118441 T : O
mucilaginous US20080118441 T JJ O
fiber US20080118441 T NN O
; US20080118441 T : O
no US20080118441 T DT O
glutamine US20080118441 T NN O
; US20080118441 T : O
gastroesophageal US20080118441 T JJ O
reflux US20080118441 T NN O
disease US20080118441 T NN O
, US20080118441 T , O
heartburn US20080118441 T NN O
, US20080118441 T , O
acid US20080118441 T JJ O
indigestion US20080118441 T NN O
, US20080118441 T , O
constipation US20080118441 T NN O
, US20080118441 T , O
irritable US20080118441 T JJ O
bowel US20080118441 T NN O
syndrome US20080118441 T NN O
. US20080118441 T . O

Bisphosphonate US20100316676 T NNP O
Compounds US20100316676 T NNP O
and US20100316676 T CC O
Methods US20100316676 T NNP O
for US20100316676 T IN O
Bone US20100316676 T NNP O
Resorption US20100316676 T NNP O
Diseases US20100316676 T NNP O
, US20100316676 T , O
Cancer US20100316676 T NNP O
, US20100316676 T , O
Bone US20100316676 T NNP O
Pain US20100316676 T NNP O
, US20100316676 T , O
Immune US20100316676 T NNP O
Disorders US20100316676 T NNP O
, US20100316676 T , O
and US20100316676 T CC O
Infectious US20100316676 T JJ O
Diseases US20100316676 T NNS O
. US20100316676 T . O

The US20100316676 A DT O
activity US20100316676 A NN O
of US20100316676 A IN O
compounds US20100316676 A NNS O
is US20100316676 A VBZ O
disclosed US20100316676 A VBN O
in US20100316676 A IN O
the US20100316676 A DT O
context US20100316676 A NN O
of US20100316676 A IN O
functional US20100316676 A JJ O
assays US20100316676 A NNS O
such US20100316676 A JJ O
as US20100316676 A IN O
Leishmania US20100316676 A NNP I-UN
major US20100316676 A JJ I-UN
farnesyl US20100316676 A NN I-UN
diphosphate US20100316676 A NN I-UN
synthase US20100316676 A NN I-UN
( US20100316676 A ( O
FPPS US20100316676 A NNP I-UN
) US20100316676 A ) O
inhibition US20100316676 A NN O
, US20100316676 A , O
Dictyostelium US20100316676 A NNP O
discoideum US20100316676 A NN O
growth US20100316676 A NN O
inhibition US20100316676 A NN O
, US20100316676 A , O
human US20100316676 A JJ O
gamma US20100316676 A NN O
delta US20100316676 A NN O
T US20100316676 A NNP O
cell US20100316676 A NN O
activation US20100316676 A NN O
, US20100316676 A , O
and US20100316676 A CC O
bone US20100316676 A NN O
resorption US20100316676 A NN O
. US20100316676 A . O

Novel US20120270847 T NNP O
carbamate US20120270847 T NN O
amino US20120270847 T NN O
acid US20120270847 T NN O
and US20120270847 T CC O
peptide US20120270847 T JJ O
prodrugs US20120270847 T NNS O
of US20120270847 T IN O
opiates US20120270847 T NNS O
and US20120270847 T CC O
uses US20120270847 T VBZ O
thereof US20120270847 T NN O
. US20120270847 T . O

Use US8163734 T NNP O
of US8163734 T IN O
a US8163734 T DT O
mast US8163734 T NN O
cell US8163734 T NN O
activation US8163734 T NN O
or US8163734 T CC O
degranulation US8163734 T NN O
blocking US8163734 T VBG O
agent US8163734 T NN O
in US8163734 T IN O
the US8163734 T DT O
manufacture US8163734 T NN O
of US8163734 T IN O
a US8163734 T DT O
medicament US8163734 T NN O
for US8163734 T IN O
the US8163734 T DT O
treatment US8163734 T NN O
of US8163734 T IN O
a US8163734 T DT O
patient US8163734 T NN O
subjected US8163734 T VBN O
to US8163734 T TO O
thrombolyses US8163734 T NNS O
. US8163734 T . O

Fused WO2013033061A1 T VBN O
bicyclic WO2013033061A1 T JJ O
diamine WO2013033061A1 T NN O
derivatives WO2013033061A1 T NNS O
as WO2013033061A1 T IN O
hiv WO2013033061A1 T JJ O
attachment WO2013033061A1 T NN O
inhibitors WO2013033061A1 T NNS O
. WO2013033061A1 T . O

Compounds WO2013033061A1 A NNS O
of WO2013033061A1 A IN O
Formula WO2013033061A1 A NNP O
( WO2013033061A1 A ( O
I WO2013033061A1 A PRP O
) WO2013033061A1 A ) O
, WO2013033061A1 A , O
including WO2013033061A1 A VBG O
pharmaceutically WO2013033061A1 A RB O
acceptable WO2013033061A1 A JJ O
salts WO2013033061A1 A NNS O
thereof WO2013033061A1 A NN O
, WO2013033061A1 A , O
wherein WO2013033061A1 A VB O
A WO2013033061A1 A DT O
is WO2013033061A1 A VBZ O
selected WO2013033061A1 A VBN O
from WO2013033061A1 A IN O
the WO2013033061A1 A DT O
group WO2013033061A1 A NN O
of WO2013033061A1 A IN O
( WO2013033061A1 A ( O
II WO2013033061A1 A NNP O
) WO2013033061A1 A ) O
, WO2013033061A1 A , O
are WO2013033061A1 A VBP O
useful WO2013033061A1 A JJ O
as WO2013033061A1 A IN O
HIV WO2013033061A1 A NNP O
attachment WO2013033061A1 A NN O
inhibitors WO2013033061A1 A NNS O
. WO2013033061A1 A . O

Tiny CN101418293A T JJ O
RNA-21 CN101418293A T JJ O
antisense CN101418293A T NN O
oligonucleotides CN101418293A T NNS O
and CN101418293A T CC O
use CN101418293A T NN O
thereof CN101418293A T NN O
. CN101418293A T . O

Intranasal WO2005063236A1 T NNP O
formulation WO2005063236A1 T NN O
of WO2005063236A1 T IN O
rotigotine WO2005063236A1 T NN O
. WO2005063236A1 T . O

Pharmaceutical EP2578214A2 T JJ O
composition EP2578214A2 T NN O
for EP2578214A2 T IN O
the EP2578214A2 T DT O
prevention EP2578214A2 T NN O
or EP2578214A2 T CC O
treatment EP2578214A2 T NN O
of EP2578214A2 T IN O
inflammatory EP2578214A2 T JJ O
diseases EP2578214A2 T NNS O
or EP2578214A2 T CC O
immune EP2578214A2 T NN O
diseases EP2578214A2 T NNS O
containing EP2578214A2 T VBG O
ramalin EP2578214A2 T NN O
. EP2578214A2 T . O

Candy CN101317619A T NNP O
cigarette CN101317619A T NN O
capable CN101317619A T NN O
of CN101317619A T IN O
relieving CN101317619A T VBG O
a CN101317619A T DT O
craving CN101317619A T NN O
for CN101317619A T IN O
tobacco CN101317619A T NN O
and CN101317619A T CC O
refreshing CN101317619A T VBG O
oneself CN101317619A T PRP O
. CN101317619A T . O

The CN101317619A A DT O
invention CN101317619A A NN O
discloses CN101317619A A VBZ O
a CN101317619A A DT O
candy CN101317619A A NN O
tobacco CN101317619A A NN O
which CN101317619A A WDT O
can CN101317619A A MD O
release CN101317619A A VB O
the CN101317619A A DT O
tobacco CN101317619A A NN O
addiction CN101317619A A NN O
and CN101317619A A CC O
refresh CN101317619A A NN O
, CN101317619A A , O
in CN101317619A A IN O
particular CN101317619A A JJ O
to CN101317619A A TO O
a CN101317619A A DT O
medical CN101317619A A JJ O
candy CN101317619A A NN O
which CN101317619A A WDT O
is CN101317619A A VBZ O
prepared CN101317619A A VBN O
by CN101317619A A IN O
adding CN101317619A A VBG O
nicotine CN101317619A A NN O
, CN101317619A A , O
caffeine CN101317619A A NN O
and CN101317619A A CC O
coca CN101317619A A NN O
extracts CN101317619A A NNS O
with CN101317619A A IN O
safe CN101317619A A JJ O
content CN101317619A A NN O
into CN101317619A A IN O
the CN101317619A A DT O
sugar CN101317619A A NN O
sirup CN101317619A A JJ O
solution CN101317619A A NN O
during CN101317619A A IN O
the CN101317619A A DT O
preparation CN101317619A A NN O
process CN101317619A A NN O
of CN101317619A A IN O
the CN101317619A A DT O
traditional CN101317619A A JJ O
candy CN101317619A A NN O
. CN101317619A A . O

The CN101317619A A DT O
candy CN101317619A A NN O
tobacco CN101317619A A NN O
has CN101317619A A VBZ O
the CN101317619A A DT O
efficacies CN101317619A A NNS O
of CN101317619A A IN O
releasing CN101317619A A VBG O
the CN101317619A A DT O
tobacco CN101317619A A NN O
addiction CN101317619A A NN O
, CN101317619A A , O
refreshing CN101317619A A VBG O
and CN101317619A A CC O
promoting CN101317619A A VBG O
the CN101317619A A DT O
excitation CN101317619A A NN O
as CN101317619A A IN O
the CN101317619A A DT O
candy CN101317619A A NN O
tobacco CN101317619A A NN O
contains CN101317619A A VBZ O
the CN101317619A A DT O
nicotine CN101317619A A NN O
, CN101317619A A , O
caffeine CN101317619A A NN O
and CN101317619A A CC O
coca CN101317619A A NN O
extracts CN101317619A A NNS O
. CN101317619A A . O

When CN101317619A A WRB O
the CN101317619A A DT O
tobacco CN101317619A A NN O
addiction CN101317619A A NN O
comes CN101317619A A VBZ O
, CN101317619A A , O
the CN101317619A A DT O
candy CN101317619A A NN O
tobacco CN101317619A A NN O
product CN101317619A A NN O
can CN101317619A A MD O
be CN101317619A A VB O
held CN101317619A A VBN O
in CN101317619A A IN O
the CN101317619A A DT O
mouth CN101317619A A NN O
so CN101317619A A RB O
as CN101317619A A IN O
to CN101317619A A TO O
replace CN101317619A A VB O
the CN101317619A A DT O
traditional CN101317619A A JJ O
sucking CN101317619A A NN O
tobaccos CN101317619A A NN O
, CN101317619A A , O
thus CN101317619A A RB O
releasing CN101317619A A VBG O
the CN101317619A A DT O
tobacco CN101317619A A NN O
addiction CN101317619A A NN O
, CN101317619A A , O
refreshing CN101317619A A VBG O
and CN101317619A A CC O
promoting CN101317619A A VBG O
the CN101317619A A DT O
excitation CN101317619A A NN O
and CN101317619A A CC O
eliminating CN101317619A A VBG O
the CN101317619A A DT O
harm CN101317619A A NN O
of CN101317619A A IN O
the CN101317619A A DT O
tobacco CN101317619A A NN O
smoke CN101317619A A NN O
on CN101317619A A IN O
the CN101317619A A DT O
environment CN101317619A A NN O
air CN101317619A A NN O
quality CN101317619A A NN O
and CN101317619A A CC O
the CN101317619A A DT O
human CN101317619A A JJ O
body CN101317619A A NN O
; CN101317619A A : O
therefore CN101317619A A RB O
, CN101317619A A , O
the CN101317619A A DT O
candy CN101317619A A NN O
tobacco CN101317619A A NN O
of CN101317619A A IN O
the CN101317619A A DT O
invention CN101317619A A NN O
is CN101317619A A VBZ O
a CN101317619A A DT O
harmless CN101317619A A JJ O
substitute CN101317619A A NN O
for CN101317619A A IN O
traditional CN101317619A A JJ O
tobaccos CN101317619A A NN O
, CN101317619A A , O
which CN101317619A A WDT O
is CN101317619A A VBZ O
worthy CN101317619A A JJ O
of CN101317619A A IN O
generalizing CN101317619A A VBG O
, CN101317619A A , O
thereby CN101317619A A RB O
having CN101317619A A VBG O
wide CN101317619A A JJ O
market CN101317619A A NN O
prospect CN101317619A A NN O
. CN101317619A A . O

Use WO2009002652A3 T NNP O
of WO2009002652A3 T IN O
surfactants WO2009002652A3 T NNS O
for WO2009002652A3 T IN O
treating WO2009002652A3 T VBG O
mycobacterial WO2009002652A3 T JJ O
infections WO2009002652A3 T NNS O
. WO2009002652A3 T . O

Substituted EP1242408B1 T NNP O
bisindolylmaleimides EP1242408B1 T NNS O
for EP1242408B1 T IN O
the EP1242408B1 T DT O
inhibition EP1242408B1 T NN O
of EP1242408B1 T IN O
cell EP1242408B1 T NN O
proliferation EP1242408B1 T NN O
. EP1242408B1 T . O

Modulating US20050176813 T VBG O
the US20050176813 T DT O
potassium US20050176813 T NN O
ion US20050176813 T NN O
channel US20050176813 T NN O
activity US20050176813 T NN O
of US20050176813 T IN O
T-cells US20050176813 T NNP O
; US20050176813 T : O
autoimmune US20050176813 T NN O
and US20050176813 T CC O
inflammatory US20050176813 T JJ O
diseases US20050176813 T NNS O
such US20050176813 T JJ O
as US20050176813 T IN O
multiple US20050176813 T JJ O
sclerosis US20050176813 T NN O
, US20050176813 T , O
rheumatoid US20050176813 T JJ O
arthritis US20050176813 T NN O
or US20050176813 T CC O
transplant US20050176813 T JJ O
rejection US20050176813 T NN O
; US20050176813 T : O
synthesis US20050176813 T NN O
by US20050176813 T IN O
reaction US20050176813 T NN O
of US20050176813 T IN O
an US20050176813 T DT O
acetophenone US20050176813 T NN O
such US20050176813 T JJ O
as US20050176813 T IN O
khellinone US20050176813 T NN O
with US20050176813 T IN O
an US20050176813 T DT O
aryl US20050176813 T JJ O
aldehyde US20050176813 T NN O
. US20050176813 T . O

Application CN103356635A T NN O
of CN103356635A T IN O
Aspeverin CN103356635A T NNP O
in CN103356635A T IN O
preparation CN103356635A T NN O
of CN103356635A T IN O
drug CN103356635A T NN O
used CN103356635A T VBN O
for CN103356635A T IN O
treating CN103356635A T VBG O
lung CN103356635A T NN O
cancer CN103356635A T NN O
. CN103356635A T . O

Colchicines CN101536990A T NNS O
gastric CN101536990A T JJ O
floating CN101536990A T VBG O
sustained-release CN101536990A T JJ O
tablet CN101536990A T NN O
and CN101536990A T CC O
method CN101536990A T NN O
for CN101536990A T IN O
preparing CN101536990A T VBG O
same CN101536990A T JJ O
. CN101536990A T . O

Pharmaceutical US20100144773 T JJ O
compositions US20100144773 T NNS O
for US20100144773 T IN O
intranasal US20100144773 T JJ O
administration US20100144773 T NN O
comprising US20100144773 T VBG O
choline US20100144773 T JJ O
salts US20100144773 T NNS O
of US20100144773 T IN O
succinic US20100144773 T JJ O
acid US20100144773 T NN O
. US20100144773 T . O

Application CN103463056A T NN O
of CN103463056A T IN O
Lycojaponicumin CN103463056A T NNP O
A CN103463056A T NNP O
in CN103463056A T IN O
drugs CN103463056A T NNS O
for CN103463056A T IN O
treating CN103463056A T VBG O
tongue CN103463056A T NN O
cancer CN103463056A T NN O
. CN103463056A T . O

Fishery CN102973586A T NNP O
chitosan CN102973586A T JJ O
immunoenhancer CN102973586A T NN O
. CN102973586A T . O

Nicorandil-containing CN103764146A T JJ O
pharmaceutical CN103764146A T JJ O
composition CN103764146A T NN O
. CN103764146A T . O

Indazole WO2008030584A3 T JJ O
derivatives WO2008030584A3 T NNS O
as WO2008030584A3 T IN O
modulators WO2008030584A3 T NNS O
of WO2008030584A3 T IN O
interleukin- WO2008030584A3 T JJ O
1 WO2008030584A3 T CD O
receptor-associated WO2008030584A3 T JJ O
kinase WO2008030584A3 T NN O
. WO2008030584A3 T . O

The WO2008030584A3 A DT O
present WO2008030584A3 A JJ O
invention WO2008030584A3 A NN O
relates WO2008030584A3 A VBZ O
to WO2008030584A3 A TO O
modulators WO2008030584A3 A NNS O
of WO2008030584A3 A IN O
IRAK WO2008030584A3 A NNP I-UN
kinases WO2008030584A3 A NNS O
of WO2008030584A3 A IN O
formula WO2008030584A3 A NN O
( WO2008030584A3 A ( O
I WO2008030584A3 A PRP O
) WO2008030584A3 A ) O
and WO2008030584A3 A CC O
provides WO2008030584A3 A VBZ O
compositions WO2008030584A3 A NNS O
comprising WO2008030584A3 A VBG O
such WO2008030584A3 A JJ O
modulators WO2008030584A3 A NNS O
, WO2008030584A3 A , O
as WO2008030584A3 A RB O
well WO2008030584A3 A RB O
as WO2008030584A3 A IN O
methods WO2008030584A3 A NNS O
therewith WO2008030584A3 A VBP O
for WO2008030584A3 A IN O
treating WO2008030584A3 A VBG O
IRAK- WO2008030584A3 A NNP O
mediated WO2008030584A3 A VBD O
or WO2008030584A3 A CC O
IRAK WO2008030584A3 A NNP I-UN
-associated WO2008030584A3 A VBD O
conditions WO2008030584A3 A NNS O
or WO2008030584A3 A CC O
diseases WO2008030584A3 A NNS O
. WO2008030584A3 A . O

Novel CN102796080A T NNP O
azole CN102796080A T JJ O
antifungal CN102796080A T NN O
compound CN102796080A T NN O
and CN102796080A T CC O
preparation CN102796080A T NN O
method CN102796080A T NN O
and CN102796080A T CC O
application CN102796080A T NN O
thereof CN102796080A T NN O
. CN102796080A T . O

N-formyl US7148242 T JJ O
hydroxylamine US7148242 T NN O
compounds US7148242 T NNS O
, US7148242 T , O
compositions US7148242 T NNS O
and US7148242 T CC O
methods US7148242 T NNS O
of US7148242 T IN O
use US7148242 T NN O
. US7148242 T . O

Sesquiterpenoid US20080160119 T NNP O
Derivatives US20080160119 T VBZ O
Having US20080160119 T NNP O
Adipocyte US20080160119 T NNP O
Differentiation US20080160119 T NNP O
Inhibitory US20080160119 T NNP O
Effect US20080160119 T NNP O
. US20080160119 T . O

The US20080160119 A DT O
objective US20080160119 A NN O
of US20080160119 A IN O
the US20080160119 A DT O
present US20080160119 A JJ O
invention US20080160119 A NN O
is US20080160119 A VBZ O
to US20080160119 A TO O
identify US20080160119 A VB O
compounds US20080160119 A NNS O
having US20080160119 A VBG O
an US20080160119 A DT O
inhibitory US20080160119 A JJ O
effect US20080160119 A NN O
on US20080160119 A IN O
adipocyte US20080160119 A NN O
differentiation US20080160119 A NN O
, US20080160119 A , O
and US20080160119 A CC O
to US20080160119 A TO O
provide US20080160119 A VB O
pharmaceutical US20080160119 A JJ O
compositions US20080160119 A NNS O
and US20080160119 A CC O
food US20080160119 A NN O
compositions US20080160119 A NNS O
for US20080160119 A IN O
prevention US20080160119 A NN O
, US20080160119 A , O
improvement US20080160119 A NN O
, US20080160119 A , O
or US20080160119 A CC O
treatment US20080160119 A NN O
of US20080160119 A IN O
obesity US20080160119 A NN O
or US20080160119 A CC O
obesity US20080160119 A NN O
related US20080160119 A VBN O
diseases US20080160119 A NNS O
. US20080160119 A . O

By US20080160119 A IN O
enthusiastically US20080160119 A RB O
studying US20080160119 A VBG O
natural US20080160119 A JJ O
products US20080160119 A NNS O
that US20080160119 A WDT O
inhibit US20080160119 A VBP O
the US20080160119 A DT O
differentiation US20080160119 A NN O
induction US20080160119 A NN O
of US20080160119 A IN O
adipocyte US20080160119 A JJ O
precursors US20080160119 A NNS O
into US20080160119 A IN O
adipocytes US20080160119 A NNS O
, US20080160119 A , O
sesquiterpenoid US20080160119 A JJ O
derivatives US20080160119 A NNS O
, US20080160119 A , O
which US20080160119 A WDT O
are US20080160119 A VBP O
extracts US20080160119 A NNS O
from US20080160119 A IN O
a US20080160119 A DT O
Compositae US20080160119 A NNP O
plant US20080160119 A NN O
, US20080160119 A , O
Calea US20080160119 A NNP O
, US20080160119 A , O
growing US20080160119 A VBG O
in US20080160119 A IN O
Central US20080160119 A NNP O
and US20080160119 A CC O
South US20080160119 A NNP O
America US20080160119 A NNP O
, US20080160119 A , O
were US20080160119 A VBD O
demonstrated US20080160119 A VBN O
to US20080160119 A TO O
have US20080160119 A VB O
an US20080160119 A DT O
excellent US20080160119 A JJ O
inhibitory US20080160119 A NN O
effect US20080160119 A NN O
on US20080160119 A IN O
adipocyte US20080160119 A NN O
differentiation US20080160119 A NN O
induction US20080160119 A NN O
. US20080160119 A . O

Calea US20080160119 A NNP O
extract US20080160119 A NN O
or US20080160119 A CC O
the US20080160119 A DT O
sesquiterpenoid US20080160119 A JJ O
derivatives US20080160119 A NNS O
are US20080160119 A VBP O
expected US20080160119 A VBN O
to US20080160119 A TO O
be US20080160119 A VB O
used US20080160119 A VBN O
in US20080160119 A IN O
pharmaceutical US20080160119 A JJ O
compositions US20080160119 A NNS O
and US20080160119 A CC O
food US20080160119 A NN O
compositions US20080160119 A NNS O
for US20080160119 A IN O
prevention US20080160119 A NN O
, US20080160119 A , O
improvement US20080160119 A NN O
, US20080160119 A , O
or US20080160119 A CC O
treatment US20080160119 A NN O
of US20080160119 A IN O
obesity US20080160119 A NN O
or US20080160119 A CC O
obesity US20080160119 A NN O
related US20080160119 A VBN O
diseases US20080160119 A NNS O
. US20080160119 A . O

2-benzo CN101029037A T JJ O
( CN101029037A T ( O
C CN101029037A T NNP O
) CN101029037A T ) O
foroxone CN101029037A T NN O
compound CN101029037A T NN O
, CN101029037A T , O
its CN101029037A T PRP$ O
production CN101029037A T NN O
and CN101029037A T CC O
use CN101029037A T NN O
. CN101029037A T . O

Use US7008947 T NNP O
to US7008947 T TO O
treat US7008947 T VB O
anxiety US7008947 T NN O
, US7008947 T , O
depression US7008947 T NN O
, US7008947 T , O
a US7008947 T DT O
sleep US7008947 T JJ O
disorder US7008947 T NN O
such US7008947 T JJ O
as US7008947 T IN O
primary US7008947 T JJ O
insomnia US7008947 T NN O
, US7008947 T , O
circadian US7008947 T JJ O
rhythm US7008947 T NN O
sleep US7008947 T NN O
disorder US7008947 T NN O
, US7008947 T , O
dyssomnia US7008947 T NN O
NOS US7008947 T NNP I-UN
, US7008947 T , O
nightmare US7008947 T JJ O
disorder US7008947 T NN O
, US7008947 T , O
or US7008947 T CC O
attention US7008947 T NN O
deficit US7008947 T NN O
disorder US7008947 T NN O
. US7008947 T . O

These US7008947 A DT O
compounds US7008947 A NNS O
bind US7008947 A VBP O
to US7008947 A TO O
the US7008947 A DT O
benzodiazepine US7008947 A NN O
site US7008947 A NN O
of US7008947 A IN O
GABAA US7008947 A NNP I-UN
receptors US7008947 A NNS I-UN
are US7008947 A VBP O
provided US7008947 A VBN O
and US7008947 A CC O
, US7008947 A , O
therefore US7008947 A RB O
can US7008947 A MD O
be US7008947 A VB O
used US7008947 A VBN O
to US7008947 A TO O
modulate US7008947 A VB O
ligand US7008947 A NN O
binding US7008947 A VBG O
to US7008947 A TO O
GABAA US7008947 A NNP I-UN
receptors US7008947 A NNS I-UN
in US7008947 A IN O
vivo US7008947 A NN O
or US7008947 A CC O
in US7008947 A IN O
vitro US7008947 A NN O
, US7008947 A , O
and US7008947 A CC O
are US7008947 A VBP O
particularly US7008947 A RB O
useful US7008947 A JJ O
in US7008947 A IN O
the US7008947 A DT O
treatment US7008947 A NN O
of US7008947 A IN O
a US7008947 A DT O
variety US7008947 A NN O
of US7008947 A IN O
central US7008947 A JJ O
nervous US7008947 A JJ O
system US7008947 A NN O
( US7008947 A ( O
CNS US7008947 A NNP O
) US7008947 A ) O
disorders US7008947 A NNS O
in US7008947 A IN O
humans US7008947 A NNS O
, US7008947 A , O
domesticated US7008947 A VBN O
companion US7008947 A NN O
animals US7008947 A NNS O
and US7008947 A CC O
livestock US7008947 A NN O
animals US7008947 A NNS O
. US7008947 A . O

Ulifloxacin CN102784108A T IN O
water-soluble CN102784108A T JJ O
salt CN102784108A T NN O
injection CN102784108A T NN O
. CN102784108A T . O

The CN102784108A A DT O
invention CN102784108A A NN O
discloses CN102784108A A VBZ O
a CN102784108A A DT O
ulifloxacin CN102784108A A JJ O
water-soluble CN102784108A A JJ O
salt CN102784108A A NN O
injection CN102784108A A NN O
and CN102784108A A CC O
a CN102784108A A DT O
preparation CN102784108A A NN O
method CN102784108A A NN O
thereof CN102784108A A NN O
. CN102784108A A . O

The CN102784108A A DT O
pH CN102784108A A JJ O
value CN102784108A A NN O
of CN102784108A A IN O
the CN102784108A A DT O
injection CN102784108A A NN O
is CN102784108A A VBZ O
4.5-7.5 CN102784108A A JJ O
; CN102784108A A : O
1000ml CN102784108A A CD O
of CN102784108A A IN O
the CN102784108A A DT O
injection CN102784108A A NN O
contains CN102784108A A VBZ O
1-30g CN102784108A A CD O
of CN102784108A A IN O
a CN102784108A A DT O
ulifloxacin CN102784108A A JJ O
water-soluble CN102784108A A JJ O
salt CN102784108A A NN O
, CN102784108A A , O
0.1-1.0mol CN102784108A A NN O
of CN102784108A A IN O
a CN102784108A A DT O
cosolvent CN102784108A A NN O
, CN102784108A A , O
and CN102784108A A CC O
0.1-10mmol CN102784108A A NN O
of CN102784108A A IN O
a CN102784108A A DT O
pH CN102784108A A JJ O
adjustment CN102784108A A NN O
agent CN102784108A A NN O
, CN102784108A A , O
and CN102784108A A CC O
the CN102784108A A DT O
preferable CN102784108A A JJ O
content CN102784108A A NN O
of CN102784108A A IN O
the CN102784108A A DT O
ulifloxacin CN102784108A A JJ O
water-soluble CN102784108A A JJ O
salt CN102784108A A NN O
is CN102784108A A VBZ O
1-5g CN102784108A A JJ O
; CN102784108A A : O
and CN102784108A A CC O
the CN102784108A A DT O
ulifloxacin CN102784108A A JJ O
water-soluble CN102784108A A JJ O
salt CN102784108A A NN O
is CN102784108A A VBZ O
a CN102784108A A DT O
compound CN102784108A A NN O
generated CN102784108A A VBN O
by CN102784108A A IN O
reacting CN102784108A A VBG O
ulifloxacin CN102784108A A JJ O
with CN102784108A A IN O
a CN102784108A A DT O
mixture CN102784108A A NN O
containing CN102784108A A VBG O
one CN102784108A A CD O
or CN102784108A A CC O
more CN102784108A A JJR O
than CN102784108A A IN O
two CN102784108A A CD O
of CN102784108A A IN O
inorganic CN102784108A A JJ O
acids CN102784108A A NNS O
, CN102784108A A , O
a CN102784108A A DT O
compound CN102784108A A NN O
generated CN102784108A A VBN O
by CN102784108A A IN O
reacting CN102784108A A VBG O
ulifloxacin CN102784108A A JJ O
with CN102784108A A IN O
a CN102784108A A DT O
mixture CN102784108A A NN O
containing CN102784108A A VBG O
one CN102784108A A CD O
or CN102784108A A CC O
more CN102784108A A JJR O
than CN102784108A A IN O
two CN102784108A A CD O
of CN102784108A A IN O
organic CN102784108A A JJ O
acids CN102784108A A NNS O
, CN102784108A A , O
or CN102784108A A CC O
a CN102784108A A DT O
compound CN102784108A A NN O
generated CN102784108A A VBN O
by CN102784108A A IN O
reacting CN102784108A A VBG O
ulifloxacin CN102784108A A JJ O
with CN102784108A A IN O
a CN102784108A A DT O
mixture CN102784108A A NN O
containing CN102784108A A VBG O
one CN102784108A A CD O
or CN102784108A A CC O
more CN102784108A A JJR O
than CN102784108A A IN O
two CN102784108A A CD O
of CN102784108A A IN O
alkaline CN102784108A A NN O
metal CN102784108A A NN O
and CN102784108A A CC O
alkaline CN102784108A A NN O
earth CN102784108A A NN O
metal CN102784108A A NN O
compounds CN102784108A A NNS O
. CN102784108A A . O

The CN102784108A A DT O
ulifloxacin CN102784108A A JJ O
water-soluble CN102784108A A JJ O
salt CN102784108A A NN O
injection CN102784108A A NN O
prepared CN102784108A A VBN O
in CN102784108A A IN O
the CN102784108A A DT O
invention CN102784108A A NN O
has CN102784108A A VBZ O
a CN102784108A A DT O
better CN102784108A A JJR O
water CN102784108A A NN O
solubility CN102784108A A NN O
than CN102784108A A IN O
ulifloxacin CN102784108A A JJ O
, CN102784108A A , O
overcomes CN102784108A A VBZ O
the CN102784108A A DT O
disadvantages CN102784108A A NNS O
of CN102784108A A IN O
no CN102784108A A DT O
solubility CN102784108A A NN O
in CN102784108A A IN O
water CN102784108A A NN O
and CN102784108A A CC O
low CN102784108A A JJ O
biological CN102784108A A JJ O
availability CN102784108A A NN O
of CN102784108A A IN O
ulifloxacin CN102784108A A JJ O
, CN102784108A A , O
and CN102784108A A CC O
has CN102784108A A VBZ O
a CN102784108A A DT O
stable CN102784108A A JJ O
and CN102784108A A CC O
controllable CN102784108A A JJ O
quality CN102784108A A NN O
. CN102784108A A . O

Crystalline WO2009007441A3 T NNP O
form WO2009007441A3 T NN O
of WO2009007441A3 T IN O
( WO2009007441A3 T ( O
e WO2009007441A3 T NN O
) WO2009007441A3 T ) O
4- WO2009007441A3 T CD O
[ WO2009007441A3 T JJ O
[ WO2009007441A3 T CD O
4- WO2009007441A3 T JJ O
[ WO2009007441A3 T JJ O
[ WO2009007441A3 T JJ O
4- WO2009007441A3 T JJ O
( WO2009007441A3 T ( O
2-cyanoethenyl WO2009007441A3 T JJ O
) WO2009007441A3 T ) O
-2,6-dimethylphenyl WO2009007441A3 T FW O
] WO2009007441A3 T NNP O
amino WO2009007441A3 T NN O
] WO2009007441A3 T NNP O
-2 WO2009007441A3 T NNP O
pyrimidinyl WO2009007441A3 T NN O
] WO2009007441A3 T NNP O
amino WO2009007441A3 T NN O
] WO2009007441A3 T NNP O
benzonitrile WO2009007441A3 T NN O
. WO2009007441A3 T . O

This WO2009007441A3 A DT O
invention WO2009007441A3 A NN O
concerns WO2009007441A3 A VBZ O
polymorph WO2009007441A3 A IN O
I WO2009007441A3 A PRP O
of WO2009007441A3 A IN O
TMC278 WO2009007441A3 A NNP O
, WO2009007441A3 A , O
its WO2009007441A3 A PRP$ O
use WO2009007441A3 A NN O
and WO2009007441A3 A CC O
preparation WO2009007441A3 A NN O
. WO2009007441A3 A . O

It WO2009007441A3 A PRP O
further WO2009007441A3 A JJ O
concerns WO2009007441A3 A NNS O
pharmaceutical WO2009007441A3 A JJ O
formulations WO2009007441A3 A NNS O
comprising WO2009007441A3 A VBG O
this WO2009007441A3 A DT O
polymorph WO2009007441A3 A NN O
. WO2009007441A3 A . O

Method WO2007142139A1 T NNP O
of WO2007142139A1 T IN O
identifying WO2007142139A1 T VBG O
candidate WO2007142139A1 T NN O
for WO2007142139A1 T IN O
remedy WO2007142139A1 T NN O
of WO2007142139A1 T IN O
acute WO2007142139A1 T JJ O
myeloid WO2007142139A1 T NN O
leukemia WO2007142139A1 T NN O
. WO2007142139A1 T . O

It WO2007142139A1 A PRP O
is WO2007142139A1 A VBZ O
intended WO2007142139A1 A VBN O
to WO2007142139A1 A TO O
disclose WO2007142139A1 A VB O
a WO2007142139A1 A DT O
method WO2007142139A1 A NN O
of WO2007142139A1 A IN O
identifying WO2007142139A1 A VBG O
a WO2007142139A1 A DT O
candidate WO2007142139A1 A NN O
for WO2007142139A1 A IN O
a WO2007142139A1 A DT O
remedy WO2007142139A1 A NN O
of WO2007142139A1 A IN O
acute WO2007142139A1 A JJ O
myeloid WO2007142139A1 A NN O
leukemia WO2007142139A1 A NN O
which WO2007142139A1 A WDT O
comprises WO2007142139A1 A VBZ O
contacting WO2007142139A1 A VBG O
activated WO2007142139A1 A VBN O
mutant WO2007142139A1 A JJ O
FLT3 WO2007142139A1 A NNP I-UN
with WO2007142139A1 A IN O
Lyn WO2007142139A1 A NNP I-UN
in WO2007142139A1 A IN O
the WO2007142139A1 A DT O
presence WO2007142139A1 A NN O
of WO2007142139A1 A IN O
a WO2007142139A1 A DT O
test WO2007142139A1 A NN O
substance WO2007142139A1 A NN O
and WO2007142139A1 A CC O
examining WO2007142139A1 A VBG O
whether WO2007142139A1 A IN O
or WO2007142139A1 A CC O
not WO2007142139A1 A RB O
the WO2007142139A1 A DT O
test WO2007142139A1 A NN O
substance WO2007142139A1 A NN O
inhibits WO2007142139A1 A VBZ O
the WO2007142139A1 A DT O
binding WO2007142139A1 A NN O
of WO2007142139A1 A IN O
activated WO2007142139A1 A JJ O
mutant WO2007142139A1 A JJ O
FLT3 WO2007142139A1 A NNP I-UN
to WO2007142139A1 A TO O
Lyn WO2007142139A1 A NNP I-UN
and/or WO2007142139A1 A VB O
whether WO2007142139A1 A IN O
or WO2007142139A1 A CC O
not WO2007142139A1 A RB O
the WO2007142139A1 A DT O
test WO2007142139A1 A NN O
substance WO2007142139A1 A NN O
inhibits WO2007142139A1 A VBZ O
the WO2007142139A1 A DT O
phosphorylation WO2007142139A1 A NN O
of WO2007142139A1 A IN O
Lyn WO2007142139A1 A NNP I-UN
in WO2007142139A1 A IN O
a WO2007142139A1 A DT O
cell WO2007142139A1 A NN O
expressing WO2007142139A1 A VBG O
activated WO2007142139A1 A VBN O
mutant WO2007142139A1 A JJ O
FLT3 WO2007142139A1 A NNP I-UN
. WO2007142139A1 A . O

It WO2007142139A1 A PRP O
is WO2007142139A1 A VBZ O
also WO2007142139A1 A RB O
intended WO2007142139A1 A VBN O
to WO2007142139A1 A TO O
disclose WO2007142139A1 A VB O
a WO2007142139A1 A DT O
method WO2007142139A1 A NN O
of WO2007142139A1 A IN O
identifying WO2007142139A1 A VBG O
a WO2007142139A1 A DT O
candidate WO2007142139A1 A NN O
for WO2007142139A1 A IN O
a WO2007142139A1 A DT O
remedy WO2007142139A1 A NN O
of WO2007142139A1 A IN O
acute WO2007142139A1 A JJ O
myeloid WO2007142139A1 A NN O
leukemia WO2007142139A1 A NN O
which WO2007142139A1 A WDT O
comprises WO2007142139A1 A VBZ O
contacting WO2007142139A1 A VBG O
a WO2007142139A1 A DT O
test WO2007142139A1 A NN O
substance WO2007142139A1 A NN O
with WO2007142139A1 A IN O
a WO2007142139A1 A DT O
cell WO2007142139A1 A NN O
expressing WO2007142139A1 A VBG O
Lyn WO2007142139A1 A NNP I-UN
and WO2007142139A1 A CC O
examining WO2007142139A1 A VBG O
whether WO2007142139A1 A IN O
or WO2007142139A1 A CC O
not WO2007142139A1 A RB O
the WO2007142139A1 A DT O
test WO2007142139A1 A NN O
substance WO2007142139A1 A NN O
inhibits WO2007142139A1 A VBZ O
the WO2007142139A1 A DT O
expression WO2007142139A1 A NN O
or WO2007142139A1 A CC O
Lyn WO2007142139A1 A NNP I-UN
and/or WO2007142139A1 A VBP O
whether WO2007142139A1 A IN O
or WO2007142139A1 A CC O
not WO2007142139A1 A RB O
the WO2007142139A1 A DT O
test WO2007142139A1 A NN O
substance WO2007142139A1 A NN O
inhibits WO2007142139A1 A VBZ O
the WO2007142139A1 A DT O
phosphorylation WO2007142139A1 A NN O
of WO2007142139A1 A IN O
STAT5 WO2007142139A1 A NNP I-UN
by WO2007142139A1 A IN O
Lyn WO2007142139A1 A NNP I-UN
. WO2007142139A1 A . O

Porphyrin US20080280934 T NNP O
ring US20080280934 T VBG O
compound US20080280934 T NN O
containing US20080280934 T VBG O
cyanovinyl US20080280934 T JJ O
group US20080280934 T NN O
; US20080280934 T : O
reacted US20080280934 T VBN O
with US20080280934 T IN O
Vilsmeier US20080280934 T NNP O
reagent US20080280934 T NN O
, US20080280934 T , O
complexed US20080280934 T VBN O
with US20080280934 T IN O
metal US20080280934 T JJ O
ion US20080280934 T NN O
in US20080280934 T IN O
prsence US20080280934 T NN O
of US20080280934 T IN O
an US20080280934 T DT O
acid US20080280934 T NN O
and US20080280934 T CC O
oxidizer US20080280934 T NN O
; US20080280934 T : O
skin US20080280934 T JJ O
disorders US20080280934 T NNS O
; US20080280934 T : O
antiinflammatory US20080280934 T JJ O
agents US20080280934 T NNS O
; US20080280934 T : O
anticancer US20080280934 T NN O
agents US20080280934 T NNS O
; US20080280934 T : O
antitumor US20080280934 T NN O
agents US20080280934 T NNS O
; US20080280934 T : O
vascular US20080280934 T JJ O
disorders US20080280934 T NNS O
, US20080280934 T , O
vision US20080280934 T NN O
defects US20080280934 T NNS O
, US20080280934 T , O
urogenital US20080280934 T JJ O
system US20080280934 T NN O
disorders US20080280934 T NNS O
; US20080280934 T : O
immunology US20080280934 T NN O
. US20080280934 T . O

Piperazine WO2012175715A1 T NNP O
derivatives WO2012175715A1 T NNS O
, WO2012175715A1 T , O
methods WO2012175715A1 T NNS O
for WO2012175715A1 T IN O
preparing WO2012175715A1 T VBG O
same WO2012175715A1 T JJ O
, WO2012175715A1 T , O
and WO2012175715A1 T CC O
uses WO2012175715A1 T VBZ O
thereof WO2012175715A1 T NN O
in WO2012175715A1 T IN O
the WO2012175715A1 T DT O
treatment WO2012175715A1 T NN O
of WO2012175715A1 T IN O
insulin WO2012175715A1 T NN I-UN
resistance WO2012175715A1 T NN O
. WO2012175715A1 T . O

The WO2012175715A1 A DT O
invention WO2012175715A1 A NN O
relates WO2012175715A1 A VBZ O
to WO2012175715A1 A TO O
a WO2012175715A1 A DT O
compound WO2012175715A1 A NN O
of WO2012175715A1 A IN O
formula WO2012175715A1 A NN O
( WO2012175715A1 A ( O
I WO2012175715A1 A PRP O
) WO2012175715A1 A ) O
, WO2012175715A1 A , O
where WO2012175715A1 A WRB O
R1 WO2012175715A1 A NNP O
, WO2012175715A1 A , O
R2 WO2012175715A1 A NNP O
, WO2012175715A1 A , O
R7 WO2012175715A1 A NNP O
, WO2012175715A1 A , O
m WO2012175715A1 A NN O
, WO2012175715A1 A , O
n WO2012175715A1 A NN O
, WO2012175715A1 A , O
and WO2012175715A1 A CC O
L1 WO2012175715A1 A NNP O
are WO2012175715A1 A VBP O
as WO2012175715A1 A IN O
defined WO2012175715A1 A VBN O
in WO2012175715A1 A IN O
claim WO2012175715A1 A NN O
1 WO2012175715A1 A CD O
, WO2012175715A1 A , O
and WO2012175715A1 A CC O
to WO2012175715A1 A TO O
the WO2012175715A1 A DT O
methods WO2012175715A1 A NNS O
for WO2012175715A1 A IN O
preparing WO2012175715A1 A VBG O
same WO2012175715A1 A JJ O
, WO2012175715A1 A , O
to WO2012175715A1 A TO O
the WO2012175715A1 A DT O
pharmaceutical WO2012175715A1 A JJ O
compositions WO2012175715A1 A NNS O
containing WO2012175715A1 A VBG O
same WO2012175715A1 A JJ O
, WO2012175715A1 A , O
and WO2012175715A1 A CC O
to WO2012175715A1 A TO O
the WO2012175715A1 A DT O
uses WO2012175715A1 A NNS O
thereof WO2012175715A1 A VBP O
in WO2012175715A1 A IN O
the WO2012175715A1 A DT O
treatment WO2012175715A1 A NN O
of WO2012175715A1 A IN O
diseases WO2012175715A1 A NNS O
associated WO2012175715A1 A VBN O
with WO2012175715A1 A IN O
insulin WO2012175715A1 A NN I-UN
resistance WO2012175715A1 A NN O
syndrome WO2012175715A1 A NN O
. WO2012175715A1 A . O

4,5-disubstituted-2-aryl CN1976918A T JJ O
pyrimidines CN1976918A T NNS O
. CN1976918A T . O

Such CN1976918A A JJ O
compounds CN1976918A A NNS O
are CN1976918A A VBP O
ligands CN1976918A A NNS O
of CN1976918A A IN O
C5a CN1976918A A NNP I-UN
receptors CN1976918A A NNS I-UN
. CN1976918A A . O

Preferred CN1976918A A NNP O
compounds CN1976918A A NNS O
of CN1976918A A IN O
Formula CN1976918A A NNP O
I CN1976918A A PRP O
and CN1976918A A CC O
II CN1976918A A NNP O
bind CN1976918A A NN O
to CN1976918A A TO O
C5a CN1976918A A NNP I-UN
receptors CN1976918A A NNS I-UN
with CN1976918A A IN O
high CN1976918A A JJ O
affinity CN1976918A A NN O
and CN1976918A A CC O
exhibit CN1976918A A NN O
neutral CN1976918A A JJ O
antagonist CN1976918A A NN O
or CN1976918A A CC O
inverse CN1976918A A JJ O
activity CN1976918A A NN O
at CN1976918A A IN O
C5a CN1976918A A NNP I-UN
receptors CN1976918A A NNS I-UN
. CN1976918A A . O

In CN1976918A A IN O
addition CN1976918A A NN O
, CN1976918A A , O
the CN1976918A A DT O
present CN1976918A A JJ O
invention CN1976918A A NN O
provides CN1976918A A VBZ O
labeled CN1976918A A JJ O
4,5-disubstituted-2-arylpyrimidines CN1976918A A NNS O
, CN1976918A A , O
which CN1976918A A WDT O
are CN1976918A A VBP O
useful CN1976918A A JJ O
as CN1976918A A IN O
probes CN1976918A A NNS O
for CN1976918A A IN O
the CN1976918A A DT O
localization CN1976918A A NN O
of CN1976918A A IN O
C5a CN1976918A A NNP I-UN
receptors CN1976918A A NNS I-UN
. CN1976918A A . O

Therapeutic CA2240494C T JJ O
molecules CA2240494C T NNS O
generated CA2240494C T VBN O
by CA2240494C T IN O
trans-splicing CA2240494C T NN O
. CA2240494C T . O

Isoxazole US20120083496 T NNP O
compound US20120083496 T NN O
for US20120083496 T IN O
the US20120083496 T DT O
treatment US20120083496 T NN O
of US20120083496 T IN O
cancer US20120083496 T NN O
. US20120083496 T . O

Morpholino WO2012160392A1 T NNP O
compounds WO2012160392A1 T NNS O
, WO2012160392A1 T , O
uses WO2012160392A1 T NNS O
and WO2012160392A1 T CC O
methods WO2012160392A1 T NNS O
. WO2012160392A1 T . O

The WO2012160392A1 A DT O
compounds WO2012160392A1 A NNS O
are WO2012160392A1 A VBP O
antagonists WO2012160392A1 A NNS O
, WO2012160392A1 A , O
reverse WO2012160392A1 A JJ O
agonists WO2012160392A1 A NNS O
or WO2012160392A1 A CC O
agonists WO2012160392A1 A NNS O
of WO2012160392A1 A IN O
G-protein WO2012160392A1 A NNP O
coupled WO2012160392A1 A JJ O
receptors WO2012160392A1 A NNS O
, WO2012160392A1 A , O
such WO2012160392A1 A JJ O
as WO2012160392A1 A IN O
dopamine WO2012160392A1 A NN I-UN
D4 WO2012160392A1 A NNP I-UN
and WO2012160392A1 A CC O
5HT1a WO2012160392A1 A CD I-UN
. WO2012160392A1 A . O

Streptococcus US20100143415 T NNP O
Pneumoniae US20100143415 T NNP O
Antigens US20100143415 T NNP O
. US20100143415 T . O

Screen US20110165266 T NN O
for US20110165266 T IN O
inhibitors US20110165266 T NNS O
of US20110165266 T IN O
hiv US20110165266 T JJ O
replication US20110165266 T NN O
. US20110165266 T . O

A US20110165266 A DT O
method US20110165266 A NN O
of US20110165266 A IN O
screening US20110165266 A VBG O
test US20110165266 A NN O
chemicals US20110165266 A NNS O
or US20110165266 A CC O
compounds US20110165266 A NNS O
as US20110165266 A IN O
inhibitors US20110165266 A NNS O
of US20110165266 A IN O
HIV US20110165266 A NNP O
replication US20110165266 A NN O
is US20110165266 A VBZ O
disclosed US20110165266 A VBN O
. US20110165266 A . O

In US20110165266 A IN O
one US20110165266 A CD O
embodiment US20110165266 A NN O
, US20110165266 A , O
the US20110165266 A DT O
method US20110165266 A NN O
comprises US20110165266 A VBZ O
the US20110165266 A DT O
step US20110165266 A NN O
of US20110165266 A IN O
determining US20110165266 A VBG O
whether US20110165266 A IN O
the US20110165266 A DT O
test US20110165266 A NN O
chemical US20110165266 A NN O
or US20110165266 A CC O
compound US20110165266 A NN O
is US20110165266 A VBZ O
a US20110165266 A DT O
sulfonation US20110165266 A NN O
inhibitor US20110165266 A NN O
. US20110165266 A . O

In US20110165266 A IN O
another US20110165266 A DT O
embodiment US20110165266 A NN O
, US20110165266 A , O
the US20110165266 A DT O
invention US20110165266 A NN O
is US20110165266 A VBZ O
a US20110165266 A DT O
method US20110165266 A NN O
of US20110165266 A IN O
treating US20110165266 A VBG O
an US20110165266 A DT O
HIV US20110165266 A NNP O
infected US20110165266 A VBD O
individual US20110165266 A JJ O
to US20110165266 A TO O
reduce US20110165266 A VB O
HIV US20110165266 A NNP O
replication US20110165266 A NN O
comprising US20110165266 A VBG O
the US20110165266 A DT O
step US20110165266 A NN O
of US20110165266 A IN O
treating US20110165266 A VBG O
the US20110165266 A DT O
individual US20110165266 A NN O
with US20110165266 A IN O
an US20110165266 A DT O
effective US20110165266 A JJ O
amount US20110165266 A NN O
of US20110165266 A IN O
sulfonation US20110165266 A NN O
inhibitor US20110165266 A NN O
. US20110165266 A . O

Biological US20080255064 T JJ O
assay US20080255064 T NN O
; US20080255064 T : O
experimental US20080255064 T JJ O
reporter US20080255064 T NN O
expression US20080255064 T NN O
vector US20080255064 T NN O
has US20080255064 T VBZ O
cholecystokinin US20080255064 T VBN I-UN
promoter US20080255064 T NN O
upregulating US20080255064 T VBG O
agent US20080255064 T NN O
operably US20080255064 T RB O
linked US20080255064 T VBD O
to US20080255064 T TO O
experimental US20080255064 T JJ O
Renilla US20080255064 T NNP I-UN
luciferase US20080255064 T NN I-UN
reporter US20080255064 T NN I-UN
gene US20080255064 T NN I-UN
; US20080255064 T : O
separately US20080255064 T RB O
detectable US20080255064 T JJ O
; US20080255064 T : O
co-transform US20080255064 T JJ O
experimental US20080255064 T JJ O
vector US20080255064 T NN O
and US20080255064 T CC O
control US20080255064 T NN O
vector US20080255064 T NN O
in US20080255064 T IN O
pancreatic US20080255064 T JJ O
islet US20080255064 T NN O
host US20080255064 T NN O
cells US20080255064 T NNS O
; US20080255064 T : O
increase US20080255064 T VB O
plasma US20080255064 T JJ O
insulin US20080255064 T NN I-UN
. US20080255064 T . O

The US20080255064 A DT O
invention US20080255064 A NN O
provides US20080255064 A VBZ O
a US20080255064 A DT O
method US20080255064 A NN O
for US20080255064 A IN O
upregulating US20080255064 A VBG O
cholecystokinin US20080255064 A NN I-UN
( US20080255064 A ( O
CCK US20080255064 A NNP I-UN
) US20080255064 A ) O
expression US20080255064 A NN O
in US20080255064 A IN O
mammalian US20080255064 A JJ O
pancreatic US20080255064 A JJ O
islets US20080255064 A NNS O
by US20080255064 A IN O
administrating US20080255064 A VBG O
a US20080255064 A DT O
CCK US20080255064 A NNP I-UN
upregulating US20080255064 A JJ O
agent US20080255064 A NN O
. US20080255064 A . O

The US20080255064 A DT O
increased US20080255064 A VBN O
CCK US20080255064 A NNP I-UN
expression US20080255064 A NN O
activates US20080255064 A VBZ O
islet US20080255064 A VBP O
cell US20080255064 A NN O
proliferation US20080255064 A NN O
triggering US20080255064 A VBG O
an US20080255064 A DT O
increase US20080255064 A NN O
in US20080255064 A IN O
pancreatic US20080255064 A JJ O
β-cell US20080255064 A JJ O
mass US20080255064 A NN O
and US20080255064 A CC O
plasma US20080255064 A JJ O
insulin US20080255064 A NN I-UN
levels US20080255064 A NNS O
. US20080255064 A . O

up-regulating US20050032708 T JJ O
glutathione US20050032708 T NN O
metabolism US20050032708 T NN O
in US20050032708 T IN O
the US20050032708 T DT O
central US20050032708 T JJ O
nervous US20050032708 T JJ O
system US20050032708 T NN O
by US20050032708 T IN O
up-regulating US20050032708 T JJ O
levels US20050032708 T NNS O
of US20050032708 T IN O
glutathione US20050032708 T NN O
precursors US20050032708 T NNS O
( US20050032708 T ( O
N-acetyl US20050032708 T NNP O
cysteine US20050032708 T NN O
) US20050032708 T ) O
; US20050032708 T : O
for US20050032708 T IN O
treating US20050032708 T VBG O
neuropsychiatric US20050032708 T JJ O
disorder US20050032708 T NN O
like US20050032708 T IN O
schizophrenia US20050032708 T NN O
, US20050032708 T , O
psychosis US20050032708 T NN O
, US20050032708 T , O
bipolar US20050032708 T JJ O
disorder US20050032708 T NN O
, US20050032708 T , O
manic US20050032708 T JJ O
depression US20050032708 T NN O
, US20050032708 T , O
affective US20050032708 T JJ O
disorder US20050032708 T NN O
, US20050032708 T , O
drug US20050032708 T NN O
induced US20050032708 T VBD O
psychosis US20050032708 T NN O
, US20050032708 T , O
delirium US20050032708 T NN O
. US20050032708 T . O

The US20050032708 A DT O
present US20050032708 A JJ O
invention US20050032708 A NN O
relates US20050032708 A VBZ O
generally US20050032708 A RB O
to US20050032708 A TO O
a US20050032708 A DT O
method US20050032708 A NN O
of US20050032708 A IN O
modulating US20050032708 A VBG O
glutathione US20050032708 A NN O
metabolism US20050032708 A NN O
in US20050032708 A IN O
the US20050032708 A DT O
central US20050032708 A JJ O
nervous US20050032708 A JJ O
system US20050032708 A NN O
of US20050032708 A IN O
mammals US20050032708 A NNS O
and US20050032708 A CC O
to US20050032708 A TO O
agents US20050032708 A NNS O
for US20050032708 A IN O
use US20050032708 A NN O
therein US20050032708 A NN O
. US20050032708 A . O

More US20050032708 A RBR O
particularly US20050032708 A RB O
, US20050032708 A , O
the US20050032708 A DT O
present US20050032708 A JJ O
invention US20050032708 A NN O
relates US20050032708 A VBZ O
to US20050032708 A TO O
a US20050032708 A DT O
method US20050032708 A NN O
of US20050032708 A IN O
up-regulating US20050032708 A JJ O
glutathione US20050032708 A NN O
metabolism US20050032708 A NN O
in US20050032708 A IN O
the US20050032708 A DT O
central US20050032708 A JJ O
nervous US20050032708 A JJ O
system US20050032708 A NN O
by US20050032708 A IN O
up-regulating US20050032708 A JJ O
levels US20050032708 A NNS O
of US20050032708 A IN O
glutathione US20050032708 A NN O
precursor US20050032708 A NN O
molecules US20050032708 A NNS O
. US20050032708 A . O

The US20050032708 A DT O
method US20050032708 A NN O
of US20050032708 A IN O
the US20050032708 A DT O
present US20050032708 A JJ O
invention US20050032708 A NN O
is US20050032708 A VBZ O
particularly US20050032708 A RB O
useful US20050032708 A JJ O
, US20050032708 A , O
inter US20050032708 A JJ O
alia US20050032708 A NN O
, US20050032708 A , O
in US20050032708 A IN O
the US20050032708 A DT O
treatment US20050032708 A NN O
and/or US20050032708 A JJ O
prophylaxis US20050032708 A NN O
of US20050032708 A IN O
conditions US20050032708 A NNS O
characterised US20050032708 A VBN O
by US20050032708 A IN O
aberrant US20050032708 A NN O
, US20050032708 A , O
unwanted US20050032708 A VBD O
or US20050032708 A CC O
otherwise US20050032708 A RB O
inappropriate US20050032708 A JJ O
central US20050032708 A JJ O
nervous US20050032708 A JJ O
system US20050032708 A NN O
oxidation US20050032708 A NN O
homeostasis US20050032708 A NN O
including US20050032708 A VBG O
, US20050032708 A , O
but US20050032708 A CC O
not US20050032708 A RB O
limited US20050032708 A JJ O
to US20050032708 A TO O
, US20050032708 A , O
schizophrenia US20050032708 A NN O
. US20050032708 A . O

Compositions US20070259014 T NNS O
for US20070259014 T IN O
and US20070259014 T CC O
Methods US20070259014 T NNP O
for US20070259014 T IN O
Treating US20070259014 T NNP O
Hiv US20070259014 T NNP O
. US20070259014 T . O

Use US20120083505 T NNP O
of US20120083505 T IN O
opioid US20120083505 T JJ I-UN
receptor US20120083505 T NN I-UN
antagonists US20120083505 T NNS O
for US20120083505 T IN O
acute US20120083505 T JJ O
treatment US20120083505 T NN O
of US20120083505 T IN O
paraphilic US20120083505 T JJ O
arousal US20120083505 T NN O
states US20120083505 T NNS O
. US20120083505 T . O

The US20120083505 A DT O
present US20120083505 A JJ O
invention US20120083505 A NN O
is US20120083505 A VBZ O
directed US20120083505 A VBN O
to US20120083505 A TO O
an US20120083505 A DT O
opioid US20120083505 A JJ I-UN
receptor US20120083505 A NN I-UN
antagonist US20120083505 A NN O
or US20120083505 A CC O
a US20120083505 A DT O
pharmaceutically US20120083505 A RB O
acceptable US20120083505 A JJ O
salt US20120083505 A NN O
thereof US20120083505 A NN O
for US20120083505 A IN O
use US20120083505 A NN O
in US20120083505 A IN O
a US20120083505 A DT O
method US20120083505 A NN O
of US20120083505 A IN O
acute US20120083505 A JJ O
treatment US20120083505 A NN O
of US20120083505 A IN O
paraphilic US20120083505 A JJ O
sexual US20120083505 A JJ O
arousal US20120083505 A NN O
states US20120083505 A NNS O
in US20120083505 A IN O
patients US20120083505 A NNS O
suffering US20120083505 A VBG O
from US20120083505 A IN O
paraphilia US20120083505 A NN O
. US20120083505 A . O

Alkene WO2014124234A1 T NNP O
derivatives WO2014124234A1 T NNS O
as WO2014124234A1 T IN O
sphingosine WO2014124234A1 T JJ O
1-phosphate WO2014124234A1 T JJ O
( WO2014124234A1 T ( O
s1p WO2014124234A1 T NN O
) WO2014124234A1 T ) O
receptor WO2014124234A1 T NN O
modulators WO2014124234A1 T NNS O
. WO2014124234A1 T . O

Application CN103622992A T NN O
of CN103622992A T IN O
hydrogen CN103622992A T NN O
sulfide CN103622992A T NN O
and CN103622992A T CC O
donor CN103622992A T NN O
thereof CN103622992A T NN O
sodium CN103622992A T NN O
hydrosulfide CN103622992A T NN O
to CN103622992A T TO O
preparation CN103622992A T NN O
of CN103622992A T IN O
medicament CN103622992A T NN O
for CN103622992A T IN O
treating CN103622992A T VBG O
diabetes CN103622992A T NNS O
. CN103622992A T . O

The CN103622992A A DT O
invention CN103622992A A NN O
adopts CN103622992A A VBZ O
the CN103622992A A DT O
exogenous CN103622992A A JJ O
hydrogen CN103622992A A NN O
sulfide CN103622992A A NN O
and CN103622992A A CC O
its CN103622992A A PRP$ O
donor CN103622992A A NN O
sodium CN103622992A A NN O
hydrosulfide CN103622992A A NN O
( CN103622992A A ( O
NaHS CN103622992A A NNP O
) CN103622992A A ) O
for CN103622992A A IN O
insulin CN103622992A A NN I-UN
sensibilization CN103622992A A NN O
and CN103622992A A CC O
tests CN103622992A A NNS O
for CN103622992A A IN O
regulating CN103622992A A VBG O
blood CN103622992A A NN O
sugar CN103622992A A NN O
level CN103622992A A NN O
and CN103622992A A CC O
increasing CN103622992A A VBG O
insulin CN103622992A A NN I-UN
level CN103622992A A NN O
for CN103622992A A IN O
type CN103622992A A NN O
II CN103622992A A NNP O
diabetes CN103622992A A VBZ O
. CN103622992A A . O

Through CN103622992A A IN O
correlation CN103622992A A NN O
test CN103622992A A NN O
of CN103622992A A IN O
skeletal CN103622992A A JJ O
muscle CN103622992A A NN O
and CN103622992A A CC O
adipose CN103622992A A JJ O
cells CN103622992A A NNS O
with CN103622992A A IN O
insulin CN103622992A A NN I-UN
resistance CN103622992A A NN O
, CN103622992A A , O
insulin CN103622992A A NN I-UN
tolerance CN103622992A A NN O
test CN103622992A A NN O
by CN103622992A A IN O
using CN103622992A A VBG O
animal CN103622992A A JJ O
model CN103622992A A NN O
for CN103622992A A IN O
diabetes CN103622992A A NNS O
insulin CN103622992A A JJ I-UN
resistance CN103622992A A NN O
, CN103622992A A , O
glucose CN103622992A A JJ O
consumption CN103622992A A NN O
experiment CN103622992A A NN O
, CN103622992A A , O
animal CN103622992A A JJ O
model CN103622992A A NN O
experiment CN103622992A A NN O
for CN103622992A A IN O
diabetes CN103622992A A NNS O
insulin CN103622992A A JJ I-UN
resistance CN103622992A A NN O
and CN103622992A A CC O
NaHS CN103622992A A NNP O
intervention CN103622992A A NN O
animal CN103622992A A NN O
experiment CN103622992A A NN O
, CN103622992A A , O
the CN103622992A A DT O
results CN103622992A A NNS O
show CN103622992A A VBP O
that CN103622992A A IN O
NaHS CN103622992A A NNP O
can CN103622992A A MD O
promote CN103622992A A VB O
glucose CN103622992A A JJ O
uptake CN103622992A A NN O
in CN103622992A A IN O
the CN103622992A A DT O
presence CN103622992A A NN O
of CN103622992A A IN O
insulin CN103622992A A NN I-UN
, CN103622992A A , O
thus CN103622992A A RB O
indicating CN103622992A A VBG O
insulin CN103622992A A NN I-UN
enhancement CN103622992A A JJ O
effect CN103622992A A NN O
. CN103622992A A . O

The CN103622992A A DT O
invention CN103622992A A NN O
of CN103622992A A IN O
hydrogen CN103622992A A NN O
sulfide CN103622992A A NN O
and CN103622992A A CC O
the CN103622992A A DT O
donor CN103622992A A NN O
thereof CN103622992A A NN O
sodium CN103622992A A NN O
hydrosulfide CN103622992A A NN O
can CN103622992A A MD O
be CN103622992A A VB O
used CN103622992A A VBN O
as CN103622992A A IN O
insulin CN103622992A A NN I-UN
sensitizers CN103622992A A NNS O
and CN103622992A A CC O
medicaments CN103622992A A NNS O
for CN103622992A A IN O
regulating CN103622992A A VBG O
blood CN103622992A A NN O
sugar CN103622992A A NN O
level CN103622992A A NN O
and CN103622992A A CC O
increasing CN103622992A A VBG O
insulin CN103622992A A NN I-UN
level CN103622992A A NN O
for CN103622992A A IN O
type CN103622992A A NN O
II CN103622992A A NNP O
diabetes CN103622992A A VBZ O
. CN103622992A A . O

Pyrazinetin CN101381374B T NNP O
dicarboxylate CN101381374B T NN O
coordination CN101381374B T NN O
compound CN101381374B T NN O
, CN101381374B T , O
preparation CN101381374B T NN O
method CN101381374B T NN O
thereof CN101381374B T NN O
and CN101381374B T CC O
use CN101381374B T NN O
. CN101381374B T . O

Squaric US20080234266 T JJ O
Acid US20080234266 T NNP O
Derivatives US20080234266 T NNP O
II US20080234266 T NNP O
. US20080234266 T . O

Method US20080241251 T NNP O
of US20080241251 T IN O
Producing US20080241251 T NNP O
Microparticles US20080241251 T NNP O
. US20080241251 T . O

A WO2011055247A1 T DT O
synthetic WO2011055247A1 T JJ O
cyclic WO2011055247A1 T NN O
dipeptide WO2011055247A1 T NN O
and WO2011055247A1 T CC O
a WO2011055247A1 T DT O
process WO2011055247A1 T NN O
thereof WO2011055247A1 T NN O
. WO2011055247A1 T . O

The WO2011055247A1 A DT O
disclosure WO2011055247A1 A NN O
relates WO2011055247A1 A VBZ O
to WO2011055247A1 A TO O
preparation WO2011055247A1 A VB O
and WO2011055247A1 A CC O
self-assembly WO2011055247A1 A RB O
of WO2011055247A1 A IN O
aromatic WO2011055247A1 A JJ O
cyclic WO2011055247A1 A JJ O
dipeptide WO2011055247A1 A NN O
into WO2011055247A1 A IN O
one WO2011055247A1 A CD O
and WO2011055247A1 A CC O
two WO2011055247A1 A CD O
dimensional WO2011055247A1 A JJ O
nano WO2011055247A1 A NN O
, WO2011055247A1 A , O
meso WO2011055247A1 A NN O
and WO2011055247A1 A CC O
micro WO2011055247A1 A NN O
structures WO2011055247A1 A NNS O
. WO2011055247A1 A . O

The WO2011055247A1 A DT O
said WO2011055247A1 A VBD O
structures WO2011055247A1 A NNS O
of WO2011055247A1 A IN O
cyclic WO2011055247A1 A JJ O
dipeptide WO2011055247A1 A NN O
can WO2011055247A1 A MD O
be WO2011055247A1 A VB O
electrospinned WO2011055247A1 A VBN O
into WO2011055247A1 A IN O
threads WO2011055247A1 A NNS O
, WO2011055247A1 A , O
fabrics WO2011055247A1 A NNS O
, WO2011055247A1 A , O
suture WO2011055247A1 A NN O
, WO2011055247A1 A , O
bandage WO2011055247A1 A NN O
materials WO2011055247A1 A NNS O
. WO2011055247A1 A . O

They WO2011055247A1 A PRP O
are WO2011055247A1 A VBP O
also WO2011055247A1 A RB O
useful WO2011055247A1 A JJ O
in WO2011055247A1 A IN O
cell WO2011055247A1 A NN O
culturing WO2011055247A1 A NN O
, WO2011055247A1 A , O
tissue WO2011055247A1 A NN O
culturing WO2011055247A1 A NN O
, WO2011055247A1 A , O
drug WO2011055247A1 A NN O
delivery WO2011055247A1 A NN O
system WO2011055247A1 A NN O
, WO2011055247A1 A , O
as WO2011055247A1 A IN O
composite WO2011055247A1 A JJ O
materials WO2011055247A1 A NNS O
, WO2011055247A1 A , O
as WO2011055247A1 A IN O
inhibitors WO2011055247A1 A NNS O
of WO2011055247A1 A IN O
fibrillization WO2011055247A1 A NN O
and WO2011055247A1 A CC O
in WO2011055247A1 A IN O
Biomedical WO2011055247A1 A NNP O
research WO2011055247A1 A NN O
such WO2011055247A1 A JJ O
as WO2011055247A1 A IN O
neurological WO2011055247A1 A JJ O
regeneration WO2011055247A1 A NN O
and WO2011055247A1 A CC O
organ WO2011055247A1 A JJ O
replacement WO2011055247A1 A NN O
studies WO2011055247A1 A NNS O
. WO2011055247A1 A . O

Using US20080254106 T VBG O
antidepressant US20080254106 T JJ O
drug US20080254106 T NN O
2,3,3a,4,5,6-hexahydro-8-methyl-1H-pyrazino US20080254106 T JJ O
[ US20080254106 T NNP O
3,2,1-jk US20080254106 T CD O
] US20080254106 T NNP O
carbazole US20080254106 T NN O
( US20080254106 T ( O
pirlindole US20080254106 T NN O
) US20080254106 T ) O
in US20080254106 T IN O
combination US20080254106 T NN O
with US20080254106 T IN O
other US20080254106 T JJ O
active US20080254106 T JJ O
agents US20080254106 T NNS O
; US20080254106 T : O
topical US20080254106 T JJ O
delivery US20080254106 T NN O
. US20080254106 T . O

Administering US7438934 T VBG O
extractsTribulus US7438934 T JJ O
terrestris US7438934 T NN O
, US7438934 T , O
Epimedium US7438934 T NNP O
koreanum US7438934 T NN O
, US7438934 T , O
Cinnamon US7438934 T NNP O
cassia US7438934 T NN O
. US7438934 T . O

Diagnosing US7122311 T VBG O
respiratory US7122311 T JJ O
disorder US7122311 T NN O
; US7122311 T : O
obtain US7122311 T VB O
cells US7122311 T NNS O
, US7122311 T , O
monitor US7122311 T NN O
expression US7122311 T NN O
of US7122311 T IN O
marker US7122311 T NN O
gene US7122311 T NN O
, US7122311 T , O
determine US7122311 T JJ O
sequence US7122311 T NN O
, US7122311 T , O
compare US7122311 T VB O
to US7122311 T TO O
control US7122311 T VB O
, US7122311 T , O
detect US7122311 T VB O
polymorphism US7122311 T NN O
in US7122311 T IN O
polypeptide US7122311 T NN O
or US7122311 T CC O
nucleotide US7122311 T NN O
, US7122311 T , O
presence US7122311 T NN O
of US7122311 T IN O
polymorphism US7122311 T NN O
indicates US7122311 T VBZ O
respiratory US7122311 T JJ O
disorders US7122311 T NNS O
. US7122311 T . O

The US7122311 A DT O
invention US7122311 A NN O
relates US7122311 A VBZ O
to US7122311 A TO O
the US7122311 A DT O
use US7122311 A NN O
of US7122311 A IN O
an US7122311 A DT O
asthma-associated US7122311 A JJ O
gene US7122311 A NN O
, US7122311 A , O
designated US7122311 A VBN O
AAGA US7122311 A NNP O
, US7122311 A , O
the US7122311 A DT O
protein US7122311 A NN O
molecule US7122311 A NN O
encoded US7122311 A VBN O
by US7122311 A IN O
AAGA US7122311 A NNP O
and US7122311 A CC O
related US7122311 A JJ O
molecules US7122311 A NNS O
in US7122311 A IN O
diagnostic US7122311 A JJ O
and US7122311 A CC O
prognostic US7122311 A JJ O
screening US7122311 A NN O
of US7122311 A IN O
patient US7122311 A JJ O
populations US7122311 A NNS O
, US7122311 A , O
to US7122311 A TO O
polymorphisms US7122311 A VB O
in US7122311 A IN O
AAGA US7122311 A NNP O
, US7122311 A , O
and US7122311 A CC O
to US7122311 A TO O
the US7122311 A DT O
use US7122311 A NN O
of US7122311 A IN O
the US7122311 A DT O
protein US7122311 A NN O
encoded US7122311 A VBN O
by US7122311 A IN O
AAGA US7122311 A NNP O
or US7122311 A CC O
a US7122311 A DT O
variant US7122311 A JJ O
thereof US7122311 A NN O
as US7122311 A IN O
a US7122311 A DT O
therapeutic US7122311 A JJ O
target US7122311 A NN O
. US7122311 A . O

Antineoplastic CN1839865A T JJ O
baicalein CN1839865A T NN O
and CN1839865A T CC O
baicalin CN1839865A T NN O
synergistic CN1839865A T JJ O
pharmaceutical CN1839865A T JJ O
composition CN1839865A T NN O
. CN1839865A T . O

The CN1839865A A DT O
invention CN1839865A A NN O
relates CN1839865A A VBZ O
to CN1839865A A TO O
a CN1839865A A DT O
pharmaceutical CN1839865A A JJ O
composition CN1839865A A NN O
with CN1839865A A IN O
synergic CN1839865A A JJ O
anti-tumor CN1839865A A JJ O
actions CN1839865A A NNS O
, CN1839865A A , O
wherein CN1839865A A VBP O
comprises CN1839865A A VBZ O
Baicalein CN1839865A A NNP O
and CN1839865A A CC O
compound CN1839865A A NN O
having CN1839865A A VBG O
a CN1839865A A DT O
formula CN1839865A A NN O
( CN1839865A A ( O
I CN1839865A A PRP O
) CN1839865A A ) O
by CN1839865A A IN O
a CN1839865A A DT O
molar CN1839865A A JJ O
concentration CN1839865A A NN O
ratio CN1839865A A NN O
of CN1839865A A IN O
1:1 CN1839865A A CD O
to CN1839865A A TO O
1:4 CN1839865A A CD O
, CN1839865A A , O
wherein CN1839865A A NN O
R1 CN1839865A A NNP O
represents CN1839865A A VBZ O
glucuronosyl CN1839865A A NN O
, CN1839865A A , O
R2 CN1839865A A NNP O
represents CN1839865A A VBZ O
hydrogen CN1839865A A NN O
or CN1839865A A CC O
hydroxyl CN1839865A A NN O
. CN1839865A A . O

the CN1839865A A DT O
invention CN1839865A A NN O
also CN1839865A A RB O
provides CN1839865A A VBZ O
the CN1839865A A DT O
method CN1839865A A NN O
for CN1839865A A IN O
preparation CN1839865A A NN O
and CN1839865A A CC O
use CN1839865A A NN O
of CN1839865A A IN O
the CN1839865A A DT O
pharmaceutical CN1839865A A JJ O
composition CN1839865A A NN O
. CN1839865A A . O

Olioodeoxynucleotide US20110313031 T NNP O
and US20110313031 T CC O
its US20110313031 T PRP$ O
use US20110313031 T NN O
to US20110313031 T TO O
induce US20110313031 T VB O
an US20110313031 T DT O
immune US20110313031 T JJ O
response US20110313031 T NN O
. US20110313031 T . O

A US20110313031 A DT O
substantially US20110313031 A RB O
pure US20110313031 A NN O
or US20110313031 A CC O
isolated US20110313031 A JJ O
oligodeoxynucleotide US20110313031 A NN O
of US20110313031 A IN O
at US20110313031 A IN O
least US20110313031 A JJS O
10 US20110313031 A CD O
nucleotides US20110313031 A NNS O
is US20110313031 A VBZ O
disclosed US20110313031 A VBN O
, US20110313031 A , O
wherein US20110313031 A VBZ O
the US20110313031 A DT O
oligodeoxynucleotide US20110313031 A NN O
comprised US20110313031 A VBD O
a US20110313031 A DT O
sequence US20110313031 A NN O
represented US20110313031 A VBN O
by US20110313031 A IN O
either US20110313031 A DT O
formula US20110313031 A NN O
: US20110313031 A : O
5′N1N2N3T-CpG-WN4N5N63′ US20110313031 A JJ O
wherein US20110313031 A IN O
the US20110313031 A DT O
CpG US20110313031 A NNP I-UN
motif US20110313031 A NN I-UN
is US20110313031 A VBZ O
unmethylated US20110313031 A JJ O
, US20110313031 A , O
W US20110313031 A NNP O
is US20110313031 A VBZ O
A US20110313031 A DT O
or US20110313031 A CC O
T US20110313031 A NNP O
, US20110313031 A , O
and US20110313031 A CC O
N1 US20110313031 A NNP O
, US20110313031 A , O
N2 US20110313031 A NNP O
, US20110313031 A , O
N3 US20110313031 A NNP O
, US20110313031 A , O
N4 US20110313031 A NNP O
, US20110313031 A , O
N5 US20110313031 A NNP O
, US20110313031 A , O
and US20110313031 A CC O
N6 US20110313031 A NNP O
are US20110313031 A VBP O
nucleotides US20110313031 A NNS O
, US20110313031 A , O
or US20110313031 A CC O
the US20110313031 A DT O
formula US20110313031 A NN O
: US20110313031 A : O
5′RY—CpG-RY3′ US20110313031 A JJ O
wherein US20110313031 A IN O
the US20110313031 A DT O
central US20110313031 A JJ O
CpG US20110313031 A NNP O
motif US20110313031 A NN O
is US20110313031 A VBZ O
unmethylated US20110313031 A JJ O
, US20110313031 A , O
R US20110313031 A NNP O
is US20110313031 A VBZ O
A US20110313031 A DT O
or US20110313031 A CC O
G US20110313031 A NNP O
, US20110313031 A , O
and US20110313031 A CC O
Y US20110313031 A NNP O
is US20110313031 A VBZ O
C US20110313031 A NNP O
or US20110313031 A CC O
T US20110313031 A NNP O
, US20110313031 A , O
as US20110313031 A RB O
well US20110313031 A RB O
as US20110313031 A IN O
an US20110313031 A DT O
oligodeoxynucleotide US20110313031 A JJ O
delivery US20110313031 A NN O
complex US20110313031 A NN O
and US20110313031 A CC O
a US20110313031 A DT O
pharmacological US20110313031 A JJ O
composition US20110313031 A NN O
comprising US20110313031 A VBG O
the US20110313031 A DT O
present US20110313031 A JJ O
inventive US20110313031 A JJ O
oligodeoxynucleotide US20110313031 A NN O
, US20110313031 A , O
and US20110313031 A CC O
a US20110313031 A DT O
method US20110313031 A NN O
of US20110313031 A IN O
inducing US20110313031 A VBG O
an US20110313031 A DT O
immune US20110313031 A JJ O
response US20110313031 A NN O
by US20110313031 A IN O
administering US20110313031 A VBG O
the US20110313031 A DT O
present US20110313031 A JJ O
inventive US20110313031 A JJ O
oligodeoxynucleotide US20110313031 A NN O
to US20110313031 A TO O
a US20110313031 A DT O
host US20110313031 A NN O
. US20110313031 A . O

Four-membered WO2014129744A1 T JJ O
cyclic WO2014129744A1 T JJ O
nitrogen WO2014129744A1 T NN O
compound WO2014129744A1 T NN O
, WO2014129744A1 T , O
pharmaceutical WO2014129744A1 T JJ O
composition WO2014129744A1 T NN O
for WO2014129744A1 T IN O
preventing WO2014129744A1 T VBG O
or WO2014129744A1 T CC O
treating WO2014129744A1 T VBG O
depression WO2014129744A1 T NN O
, WO2014129744A1 T , O
mental WO2014129744A1 T JJ O
disorders WO2014129744A1 T NNS O
, WO2014129744A1 T , O
premature WO2014129744A1 T JJ O
ejaculation WO2014129744A1 T NN O
or WO2014129744A1 T CC O
neuropathic WO2014129744A1 T JJ O
pain WO2014129744A1 T NN O
, WO2014129744A1 T , O
containing WO2014129744A1 T VBG O
same WO2014129744A1 T JJ O
, WO2014129744A1 T , O
and WO2014129744A1 T CC O
preparation WO2014129744A1 T NN O
containing WO2014129744A1 T VBG O
pharmaceutical WO2014129744A1 T JJ O
composition WO2014129744A1 T NN O
. WO2014129744A1 T . O

Butyric WO2011008054A2 T NNP O
acid WO2011008054A2 T NN O
salt WO2011008054A2 T NN O
of WO2011008054A2 T IN O
n WO2011008054A2 T JJ O
, WO2011008054A2 T , O
n-dimethyl WO2011008054A2 T JJ O
imidocarbon WO2011008054A2 T NN O
imidic WO2011008054A2 T JJ O
diamide WO2011008054A2 T NN O
, WO2011008054A2 T , O
method WO2011008054A2 T NN O
of WO2011008054A2 T IN O
preparing WO2011008054A2 T VBG O
same WO2011008054A2 T JJ O
, WO2011008054A2 T , O
and WO2011008054A2 T CC O
pharmaceutical WO2011008054A2 T JJ O
compositions WO2011008054A2 T NNS O
and WO2011008054A2 T CC O
combinations WO2011008054A2 T NNS O
containing WO2011008054A2 T VBG O
same WO2011008054A2 T JJ O
. WO2011008054A2 T . O

Medicine CN103479785A T NNP O
for CN103479785A T IN O
treating CN103479785A T VBG O
herpes CN103479785A T NNS O
. CN103479785A T . O

The CN103479785A A DT O
invention CN103479785A A NN O
provides CN103479785A A VBZ O
a CN103479785A A DT O
medicine CN103479785A A NN O
for CN103479785A A IN O
treating CN103479785A A VBG O
herpes CN103479785A A NNS O
, CN103479785A A , O
relating CN103479785A A VBG O
to CN103479785A A TO O
medicines CN103479785A A NNS O
for CN103479785A A IN O
treating CN103479785A A VBG O
herpes CN103479785A A NNS O
. CN103479785A A . O

The CN103479785A A DT O
medicine CN103479785A A NN O
is CN103479785A A VBZ O
prepared CN103479785A A VBN O
from CN103479785A A IN O
the CN103479785A A DT O
following CN103479785A A VBG O
selected CN103479785A A VBD O
raw CN103479785A A JJ O
materials CN103479785A A NNS O
by CN103479785A A IN O
weight CN103479785A A NN O
: CN103479785A A : O
12-18g CN103479785A A CD O
of CN103479785A A IN O
dried CN103479785A A VBN O
rehmannia CN103479785A A NN O
root CN103479785A A NN O
, CN103479785A A , O
12-18g CN103479785A A CD O
of CN103479785A A IN O
prepared CN103479785A A JJ O
rehmannia CN103479785A A NN O
root CN103479785A A NN O
, CN103479785A A , O
12-18g CN103479785A A CD O
of CN103479785A A IN O
Chinese CN103479785A A NNP O
angelica CN103479785A A NN O
, CN103479785A A , O
3-7g CN103479785A A CD O
of CN103479785A A IN O
root CN103479785A A NN O
of CN103479785A A IN O
sharpspur CN103479785A A NN O
corydalis CN103479785A A NN O
, CN103479785A A , O
8-12g CN103479785A A CD O
of CN103479785A A IN O
borneol CN103479785A A NN O
, CN103479785A A , O
8-12g CN103479785A A CD O
of CN103479785A A IN O
beewax CN103479785A A NN O
and CN103479785A A CC O
700-800g CN103479785A A CD O
of CN103479785A A IN O
sesame CN103479785A A JJ O
oil CN103479785A A NN O
; CN103479785A A : O
the CN103479785A A DT O
medicine CN103479785A A NN O
is CN103479785A A VBZ O
prepared CN103479785A A VBN O
by CN103479785A A IN O
the CN103479785A A DT O
following CN103479785A A JJ O
steps CN103479785A A NNS O
of CN103479785A A IN O
putting CN103479785A A VBG O
the CN103479785A A DT O
sesame CN103479785A A JJ O
oil CN103479785A A NN O
into CN103479785A A IN O
a CN103479785A A DT O
pot CN103479785A A NN O
, CN103479785A A , O
heating CN103479785A A VBG O
until CN103479785A A IN O
smoke CN103479785A A NN O
appears CN103479785A A VBZ O
, CN103479785A A , O
cutting CN103479785A A VBG O
dried CN103479785A A VBN O
rehmannia CN103479785A A JJ O
root CN103479785A A NN O
, CN103479785A A , O
prepared CN103479785A A VBD O
rehmannia CN103479785A A NN O
root CN103479785A A NN O
, CN103479785A A , O
Chinese CN103479785A A NNP O
angelica CN103479785A A NN O
and CN103479785A A CC O
root CN103479785A A NN O
of CN103479785A A IN O
sharpspur CN103479785A A NN O
corydalis CN103479785A A NN O
into CN103479785A A IN O
pieces CN103479785A A NNS O
or CN103479785A A CC O
strips CN103479785A A NNS O
, CN103479785A A , O
putting CN103479785A A VBG O
into CN103479785A A IN O
the CN103479785A A DT O
sesame CN103479785A A JJ O
oil CN103479785A A NN O
, CN103479785A A , O
frying CN103479785A A VBG O
until CN103479785A A IN O
the CN103479785A A DT O
pieces CN103479785A A NNS O
or CN103479785A A CC O
strips CN103479785A A NNS O
are CN103479785A A VBP O
slightly CN103479785A A RB O
brown CN103479785A A JJ O
, CN103479785A A , O
fishing CN103479785A A VBG O
the CN103479785A A DT O
pieces CN103479785A A NNS O
or CN103479785A A CC O
strips CN103479785A A NNS O
out CN103479785A A RP O
and CN103479785A A CC O
then CN103479785A A RB O
adding CN103479785A A VBG O
borneol CN103479785A A NN O
and CN103479785A A CC O
beewax CN103479785A A NN O
to CN103479785A A TO O
prepare CN103479785A A VB O
paste CN103479785A A NN O
. CN103479785A A . O

The CN103479785A A DT O
medicine CN103479785A A NN O
has CN103479785A A VBZ O
the CN103479785A A DT O
beneficial CN103479785A A JJ O
effects CN103479785A A NNS O
that CN103479785A A IN O
the CN103479785A A DT O
medicine CN103479785A A NN O
is CN103479785A A VBZ O
used CN103479785A A VBN O
externally CN103479785A A RB O
, CN103479785A A , O
takes CN103479785A A VBZ O
effect CN103479785A A NN O
quickly CN103479785A A RB O
, CN103479785A A , O
is CN103479785A A VBZ O
safe CN103479785A A JJ O
and CN103479785A A CC O
reliable CN103479785A A JJ O
and CN103479785A A CC O
has CN103479785A A VBZ O
good CN103479785A A JJ O
curative CN103479785A A JJ O
effects CN103479785A A NNS O
; CN103479785A A : O
47 CN103479785A A CD O
clinical CN103479785A A JJ O
tests CN103479785A A NNS O
show CN103479785A A VBP O
that CN103479785A A IN O
the CN103479785A A DT O
effective CN103479785A A JJ O
rate CN103479785A A NN O
is CN103479785A A VBZ O
100 CN103479785A A CD O
% CN103479785A A NN O
. CN103479785A A . O

Vitamin CN103655500A T NNP O
c CN103655500A T JJ O
tablet CN103655500A T NN O
and CN103655500A T CC O
preparation CN103655500A T NN O
method CN103655500A T NN O
thereof CN103655500A T NN O
. CN103655500A T . O

Anti CN101147803B T NNP O
Toll-like CN101147803B T NNP I-UN
receptor CN101147803B T NN I-UN
2 CN101147803B T CD I-UN
antibody CN101147803B T NN O
inhibiting CN101147803B T VBG O
tumor CN101147803B T NN O
metastasis CN101147803B T NN O
use CN101147803B T NN O
. CN101147803B T . O

Said CN101147803B A NNP O
anti-TLR2 CN101147803B A JJ O
antibody CN101147803B A NN O
not CN101147803B A RB O
only CN101147803B A RB O
can CN101147803B A MD O
block CN101147803B A VB O
TLR2 CN101147803B A NNP I-UN
activity CN101147803B A NN O
, CN101147803B A , O
but CN101147803B A CC O
also CN101147803B A RB O
can CN101147803B A MD O
obviously CN101147803B A RB O
reduce CN101147803B A VB O
number CN101147803B A NN O
of CN101147803B A IN O
metastatic CN101147803B A JJ O
foci CN101147803B A NN O
of CN101147803B A IN O
lung CN101147803B A NN O
. CN101147803B A . O

Isoindoline WO2009145719A1 T NNP O
derivatives WO2009145719A1 T VBZ O
comprising WO2009145719A1 T VBG O
a WO2009145719A1 T DT O
cyano WO2009145719A1 T NN O
group WO2009145719A1 T NN O
and WO2009145719A1 T CC O
their WO2009145719A1 T PRP$ O
use WO2009145719A1 T NN O
in WO2009145719A1 T IN O
the WO2009145719A1 T DT O
treatment WO2009145719A1 T NN O
of WO2009145719A1 T IN O
pain WO2009145719A1 T NN O
disorders WO2009145719A1 T NNS O
. WO2009145719A1 T . O

Montelukast CN103655497A T NNP O
orally CN103655497A T RB O
disintegrating CN103655497A T VBG O
tablet CN103655497A T NN O
and CN103655497A T CC O
preparation CN103655497A T NN O
method CN103655497A T NN O
thereof CN103655497A T NN O
. CN103655497A T . O

Compound CN1751690A T NNP O
injection CN1751690A T NN O
contg CN1751690A T NN O
. CN1751690A T . O

alendronate CN1751690A T JJ O
sodium CN1751690A T NN O
and CN1751690A T CC O
vitamin CN1751690A T NN O
D3 CN1751690A T NNP O
. CN1751690A T . O

Use CA2414774C T NNP O
of CA2414774C T IN O
dopamine CA2414774C T NN I-UN
d2/d3 CA2414774C T NN I-UN
receptor CA2414774C T NN I-UN
agonists CA2414774C T VBZ O
to CA2414774C T TO O
treat CA2414774C T VB O
fibromyalgia CA2414774C T NN O
. CA2414774C T . O

The CA2414774C A DT O
present CA2414774C A JJ O
invention CA2414774C A NN O
is CA2414774C A VBZ O
directed CA2414774C A VBN O
to CA2414774C A TO O
methods CA2414774C A NNS O
for CA2414774C A IN O
the CA2414774C A DT O
treatment CA2414774C A NN O
of CA2414774C A IN O
human CA2414774C A JJ O
patients CA2414774C A NNS O
afflicted CA2414774C A VBN O
with CA2414774C A IN O
fibromyalglia CA2414774C A NNS O
using CA2414774C A VBG O
a CA2414774C A DT O
non-ergot CA2414774C A JJ O
dopamine CA2414774C A NN I-UN
receptor CA2414774C A NN I-UN
D2/D3 CA2414774C A NNP I-UN
agonist CA2414774C A NN O
. CA2414774C A . O

Lansoprazole CN101250182A T NNP O
sodium CN101250182A T NN O
. CN101250182A T . O

Prevention EP1567117B1 T NN O
and EP1567117B1 T CC O
treatment EP1567117B1 T NN O
of EP1567117B1 T IN O
microbe-mediated EP1567117B1 T JJ O
epithelial EP1567117B1 T JJ O
disorders EP1567117B1 T NNS O
. EP1567117B1 T . O

Prodrug WO2010104406A8 T NNP O
forms WO2010104406A8 T NNS O
of WO2010104406A8 T IN O
kinase WO2010104406A8 T NN O
inhibitors WO2010104406A8 T NNS O
and WO2010104406A8 T CC O
their WO2010104406A8 T PRP$ O
use WO2010104406A8 T NN O
in WO2010104406A8 T IN O
therapy WO2010104406A8 T NN O
. WO2010104406A8 T . O

4-pyridyl WO2013086804A1 T JJ O
porphyrin WO2013086804A1 T NN O
bridged WO2013086804A1 T VBD O
crisscross WO2013086804A1 T JJ O
quad-nuclear WO2013086804A1 T JJ O
platinum WO2013086804A1 T NN O
complex WO2013086804A1 T NN O
, WO2013086804A1 T , O
and WO2013086804A1 T CC O
preparation WO2013086804A1 T NN O
method WO2013086804A1 T NN O
and WO2013086804A1 T CC O
anti-tumor WO2013086804A1 T JJ O
activity WO2013086804A1 T NN O
thereof WO2013086804A1 T NN O
. WO2013086804A1 T . O

Activated WO2007027569A1 T VBN O
carbon WO2007027569A1 T NN O
and WO2007027569A1 T CC O
use WO2007027569A1 T NN O
thereof WO2007027569A1 T NN O
for WO2007027569A1 T IN O
reducing WO2007027569A1 T VBG O
or WO2007027569A1 T CC O
maintaining WO2007027569A1 T VBG O
body WO2007027569A1 T NN O
weight WO2007027569A1 T NN O
. WO2007027569A1 T . O

17-deoxycorticosteroid-21-/o/-carboxylic CA2158610C T JJ O
esters CA2158610C T NNS O
, CA2158610C T , O
processes CA2158610C T NNS O
for CA2158610C T IN O
their CA2158610C T PRP$ O
preparation CA2158610C T NN O
and CA2158610C T CC O
pharmaceuticals CA2158610C T NNS O
containing CA2158610C T VBG O
these CA2158610C T DT O
compounds CA2158610C T NNS O
. CA2158610C T . O

17-Deoxycorticoid-21-carboxylic CA2158610C A JJ O
esters CA2158610C A NNS O
of CA2158610C A IN O
the CA2158610C A DT O
formula CA2158610C A NN O
I CA2158610C A PRP O
( CA2158610C A ( O
see CA2158610C A VB O
Formula CA2158610C A NNP O
I CA2158610C A PRP O
) CA2158610C A ) O
are CA2158610C A VBP O
described CA2158610C A VBN O
, CA2158610C A , O
in CA2158610C A IN O
which CA2158610C A WDT O
A CA2158610C A NNP O
is CA2158610C A VBZ O
CHOH CA2158610C A NNP O
and CA2158610C A CC O
CHCl CA2158610C A NNP O
, CA2158610C A , O
CH2 CA2158610C A NNP O
, CA2158610C A , O
C=O CA2158610C A NNP O
or CA2158610C A CC O
9 CA2158610C A CD O
( CA2158610C A ( O
11 CA2158610C A CD O
) CA2158610C A ) O
double CA2158610C A JJ O
bond CA2158610C A NN O
; CA2158610C A : O
Y CA2158610C A NNP O
is CA2158610C A VBZ O
H CA2158610C A NNP O
, CA2158610C A , O
F CA2158610C A NNP O
or CA2158610C A CC O
Cl CA2158610C A NNP O
; CA2158610C A : O
Z CA2158610C A NNP O
is CA2158610C A VBZ O
H CA2158610C A NNP O
, CA2158610C A , O
F CA2158610C A NNP O
or CA2158610C A CC O
CH3 CA2158610C A NNP O
; CA2158610C A : O
R CA2158610C A NNP O
( CA2158610C A ( O
1 CA2158610C A CD O
) CA2158610C A ) O
is CA2158610C A VBZ O
aryl CA2158610C A JJ O
or CA2158610C A CC O
hetaryl CA2158610C A NN O
and CA2158610C A CC O
R CA2158610C A NNP O
( CA2158610C A ( O
2 CA2158610C A CD O
) CA2158610C A ) O
is CA2158610C A VBZ O
H CA2158610C A NNP O
or CA2158610C A CC O
methyl CA2158610C A NN O
. CA2158610C A . O

They CA2158610C A PRP O
are CA2158610C A VBP O
obtained CA2158610C A VBN O
by CA2158610C A IN O
reacting CA2158610C A VBG O
a CA2158610C A DT O
compound CA2158610C A NN O
of CA2158610C A IN O
the CA2158610C A DT O
formula CA2158610C A NN O
II CA2158610C A NNP O
, CA2158610C A , O
( CA2158610C A ( O
see CA2158610C A VB O
formula CA2158610C A RB O
II CA2158610C A NNP O
) CA2158610C A ) O
in CA2158610C A IN O
which CA2158610C A WDT O
R CA2158610C A NNP O
( CA2158610C A ( O
4 CA2158610C A CD O
) CA2158610C A ) O
is CA2158610C A VBZ O
OH CA2158610C A NNP O
, CA2158610C A , O
with CA2158610C A IN O
an CA2158610C A DT O
activated CA2158610C A JJ O
carboxylic CA2158610C A JJ O
acid CA2158610C A NN O
of CA2158610C A IN O
the CA2158610C A DT O
formula CA2158610C A NN O
III CA2158610C A NNP O
, CA2158610C A , O
R CA2158610C A NNP O
( CA2158610C A ( O
5 CA2158610C A CD O
) CA2158610C A ) O
-CO- CA2158610C A NN O
[ CA2158610C A NNP O
( CA2158610C A ( O
C1-C4 CA2158610C A NNP O
) CA2158610C A ) O
-alkyl CA2158610C A VBZ O
] CA2158610C A JJ O
-R CA2158610C A NNP O
( CA2158610C A ( O
1 CA2158610C A CD O
) CA2158610C A ) O
III CA2158610C A NNP O
. CA2158610C A . O

The CA2158610C A DT O
compounds CA2158610C A NNS O
I CA2158610C A PRP O
possess CA2158610C A VBP O
very CA2158610C A RB O
strong CA2158610C A JJ O
local CA2158610C A JJ O
and CA2158610C A CC O
topical CA2158610C A JJ O
antiinflammatory CA2158610C A NN O
activity CA2158610C A NN O
and CA2158610C A CC O
exhibit CA2158610C A NN O
a CA2158610C A DT O
very CA2158610C A RB O
good CA2158610C A JJ O
ratio CA2158610C A NN O
of CA2158610C A IN O
local CA2158610C A JJ O
to CA2158610C A TO O
systemic CA2158610C A VB O
antiinflammatory CA2158610C A JJ O
effect CA2158610C A NN O
, CA2158610C A , O
which CA2158610C A WDT O
ratio CA2158610C A NN O
is CA2158610C A VBZ O
often CA2158610C A RB O
clearly CA2158610C A RB O
superior CA2158610C A JJ O
to CA2158610C A TO O
that CA2158610C A DT O
of CA2158610C A IN O
structurally CA2158610C A RB O
related CA2158610C A VBN O
corticoid CA2158610C A NN O
21-esters CA2158610C A NNS O
which CA2158610C A WDT O
do CA2158610C A VBP O
not CA2158610C A RB O
carry CA2158610C A VB O
any CA2158610C A DT O
aryl CA2158610C A NN O
or CA2158610C A CC O
hetaryl CA2158610C A NN O
group CA2158610C A NN O
in CA2158610C A IN O
the CA2158610C A DT O
21-ester CA2158610C A JJ O
residue CA2158610C A NN O
or CA2158610C A CC O
to CA2158610C A TO O
that CA2158610C A DT O
of CA2158610C A IN O
analogous CA2158610C A JJ O
17-deoxycorticoids CA2158610C A NNS O
having CA2158610C A VBG O
an CA2158610C A DT O
unesterified CA2158610C A JJ O
, CA2158610C A , O
that CA2158610C A WDT O
is CA2158610C A VBZ O
a CA2158610C A DT O
free CA2158610C A JJ O
, CA2158610C A , O
21-hydroxyl CA2158610C A JJ O
group CA2158610C A NN O
. CA2158610C A . O

Methods EP1408950B1 T NNS O
of EP1408950B1 T IN O
treating EP1408950B1 T VBG O
cytokine EP1408950B1 T NN O
mediated EP1408950B1 T VBN O
diseases EP1408950B1 T NNS O
. EP1408950B1 T . O

Glucocorticoid WO2009035067A1 T NNP I-UN
receptor WO2009035067A1 T NN I-UN
agonists WO2009035067A1 T VBZ O
consisting WO2009035067A1 T VBG O
of WO2009035067A1 T IN O
1,3,3-tri- WO2009035067A1 T JJ O
methyl-7-phenyl-3,4-dihydro-1h-quinoxalin-2-one WO2009035067A1 T JJ O
derivatives WO2009035067A1 T NNS O
. WO2009035067A1 T . O

The WO2009035067A1 A DT O
invention WO2009035067A1 A NN O
provides WO2009035067A1 A VBZ O
a WO2009035067A1 A DT O
glucocorticoid WO2009035067A1 A JJ I-UN
receptor WO2009035067A1 A NN I-UN
agonist WO2009035067A1 A NN O
consisting WO2009035067A1 A VBG O
of WO2009035067A1 A IN O
a WO2009035067A1 A DT O
1,3,3-trimethyl-7-phenyl-3,4-dihydro-1H WO2009035067A1 A JJ O
-quinoxalin-2-one WO2009035067A1 A NN O
derivative WO2009035067A1 A NN O
represented WO2009035067A1 A VBN O
by WO2009035067A1 A IN O
the WO2009035067A1 A DT O
general WO2009035067A1 A JJ O
formula WO2009035067A1 A NN O
( WO2009035067A1 A ( O
1 WO2009035067A1 A CD O
) WO2009035067A1 A ) O
or WO2009035067A1 A CC O
a WO2009035067A1 A DT O
salt WO2009035067A1 A JJ O
thereof WO2009035067A1 A NN O
and WO2009035067A1 A CC O
novel WO2009035067A1 A JJ O
pharmacological WO2009035067A1 A JJ O
effects WO2009035067A1 A NNS O
of WO2009035067A1 A IN O
the WO2009035067A1 A DT O
agonist WO2009035067A1 A NN O
: WO2009035067A1 A : O
[ WO2009035067A1 A JJ O
Chemical WO2009035067A1 A NNP O
formula WO2009035067A1 A NN O
1 WO2009035067A1 A CD O
] WO2009035067A1 A NN O
( WO2009035067A1 A ( O
1 WO2009035067A1 A CD O
) WO2009035067A1 A ) O
( WO2009035067A1 A ( O
2a WO2009035067A1 A CD O
) WO2009035067A1 A ) O
( WO2009035067A1 A ( O
4a WO2009035067A1 A CD O
) WO2009035067A1 A ) O
( WO2009035067A1 A ( O
3a WO2009035067A1 A CD O
) WO2009035067A1 A ) O
( WO2009035067A1 A ( O
5a WO2009035067A1 A CD O
) WO2009035067A1 A ) O
wherein WO2009035067A1 A NN O
R1 WO2009035067A1 A NNP O
is WO2009035067A1 A VBZ O
a WO2009035067A1 A DT O
group WO2009035067A1 A NN O
represented WO2009035067A1 A VBN O
by WO2009035067A1 A IN O
the WO2009035067A1 A DT O
general WO2009035067A1 A JJ O
formula WO2009035067A1 A NN O
( WO2009035067A1 A ( O
2a WO2009035067A1 A CD O
) WO2009035067A1 A ) O
, WO2009035067A1 A , O
( WO2009035067A1 A ( O
3a WO2009035067A1 A CD O
) WO2009035067A1 A ) O
, WO2009035067A1 A , O
( WO2009035067A1 A ( O
4a WO2009035067A1 A CD O
) WO2009035067A1 A ) O
or WO2009035067A1 A CC O
( WO2009035067A1 A ( O
5a WO2009035067A1 A CD O
) WO2009035067A1 A ) O
; WO2009035067A1 A : O
R2 WO2009035067A1 A NNP O
and WO2009035067A1 A CC O
R3 WO2009035067A1 A NNP O
may WO2009035067A1 A MD O
be WO2009035067A1 A VB O
the WO2009035067A1 A DT O
same WO2009035067A1 A JJ O
or WO2009035067A1 A CC O
different WO2009035067A1 A JJ O
from WO2009035067A1 A IN O
each WO2009035067A1 A DT O
other WO2009035067A1 A JJ O
and WO2009035067A1 A CC O
are WO2009035067A1 A VBP O
each WO2009035067A1 A DT O
hydrogen WO2009035067A1 A NN O
, WO2009035067A1 A , O
halogeno WO2009035067A1 A NN O
, WO2009035067A1 A , O
lower WO2009035067A1 A JJR O
alkyl WO2009035067A1 A NN O
, WO2009035067A1 A , O
hydroxy WO2009035067A1 A NN O
, WO2009035067A1 A , O
esterified WO2009035067A1 A VBD O
hydroxy WO2009035067A1 A NN O
, WO2009035067A1 A , O
or WO2009035067A1 A CC O
the WO2009035067A1 A DT O
like WO2009035067A1 A JJ O
; WO2009035067A1 A : O
R4 WO2009035067A1 A NNP O
is WO2009035067A1 A VBZ O
lower WO2009035067A1 A JJR O
alkyl WO2009035067A1 A NN O
; WO2009035067A1 A : O
R5 WO2009035067A1 A NNP O
, WO2009035067A1 A , O
R6 WO2009035067A1 A NNP O
, WO2009035067A1 A , O
R7 WO2009035067A1 A NNP O
and WO2009035067A1 A CC O
R8 WO2009035067A1 A NNP O
are WO2009035067A1 A VBP O
each WO2009035067A1 A DT O
halogeno WO2009035067A1 A NN O
, WO2009035067A1 A , O
lower WO2009035067A1 A JJR O
alkyl WO2009035067A1 A NN O
, WO2009035067A1 A , O
hydroxy WO2009035067A1 A NN O
, WO2009035067A1 A , O
lower WO2009035067A1 A JJR O
alkoxy WO2009035067A1 A NN O
, WO2009035067A1 A , O
or WO2009035067A1 A CC O
the WO2009035067A1 A DT O
like WO2009035067A1 A JJ O
; WO2009035067A1 A : O
and WO2009035067A1 A CC O
m WO2009035067A1 A VB O
, WO2009035067A1 A , O
n WO2009035067A1 A FW O
, WO2009035067A1 A , O
p WO2009035067A1 A NN O
and WO2009035067A1 A CC O
q WO2009035067A1 A NN O
are WO2009035067A1 A VBP O
each WO2009035067A1 A DT O
0 WO2009035067A1 A CD O
, WO2009035067A1 A , O
1 WO2009035067A1 A CD O
or WO2009035067A1 A CC O
2 WO2009035067A1 A CD O
. WO2009035067A1 A . O

Bifunctional CN103357022A T NNP O
polyethylene CN103357022A T NN O
glycol CN103357022A T NN O
and CN103357022A T CC O
adriamycin CN103357022A T JJ O
conjugate CN103357022A T NN O
and CN103357022A T CC O
preparation CN103357022A T NN O
method CN103357022A T NN O
thereof CN103357022A T NN O
. CN103357022A T . O

Pyridinylpyrazoles WO2013046041A1 T NNS O
for WO2013046041A1 T IN O
use WO2013046041A1 T NN O
as WO2013046041A1 T IN O
kinase WO2013046041A1 T NN I-UN
modulators WO2013046041A1 T NNS O
for WO2013046041A1 T IN O
the WO2013046041A1 T DT O
treatment WO2013046041A1 T NN O
of WO2013046041A1 T IN O
cancer WO2013046041A1 T NN O
. WO2013046041A1 T . O

A WO2013046041A1 A DT O
method WO2013046041A1 A NN O
of WO2013046041A1 A IN O
treating WO2013046041A1 A VBG O
cancer WO2013046041A1 A NN O
in WO2013046041A1 A IN O
which WO2013046041A1 A WDT O
a WO2013046041A1 A DT O
compound WO2013046041A1 A NN O
that WO2013046041A1 A WDT O
inhibits WO2013046041A1 A VBZ O
the WO2013046041A1 A DT O
activity WO2013046041A1 A NN O
of WO2013046041A1 A IN O
receptor WO2013046041A1 A NN O
kinases WO2013046041A1 A NNS I-UN
is WO2013046041A1 A VBZ O
described WO2013046041A1 A VBN O
. WO2013046041A1 A . O

Medicine CN102302481A T NNP O
composition CN102302481A T NN O
for CN102302481A T IN O
treating CN102302481A T VBG O
fungal CN102302481A T JJ O
keratitis CN102302481A T NN O
. CN102302481A T . O

Pyrazolyl-Pyrimidines US20090036475 T NNS O
as US20090036475 T IN O
Potassium US20090036475 T NNP I-UN
Channel US20090036475 T NNP I-UN
Modulating US20090036475 T VBG O
Agents US20090036475 T NNS O
and US20090036475 T CC O
Their US20090036475 T NNP O
Medical US20090036475 T NNP O
Use US20090036475 T NNP O
. US20090036475 T . O

This US20090036475 A DT O
invention US20090036475 A NN O
relates US20090036475 A VBZ O
to US20090036475 A TO O
novel US20090036475 A VB O
potassium US20090036475 A NN O
channel US20090036475 A NN O
modulating US20090036475 A VBG O
agents US20090036475 A NNS O
, US20090036475 A , O
and US20090036475 A CC O
their US20090036475 A PRP$ O
use US20090036475 A NN O
in US20090036475 A IN O
the US20090036475 A DT O
preparation US20090036475 A NN O
of US20090036475 A IN O
pharmaceutical US20090036475 A JJ O
compositions US20090036475 A NNS O
. US20090036475 A . O

Moreover US20090036475 A RB O
the US20090036475 A DT O
invention US20090036475 A NN O
is US20090036475 A VBZ O
directed US20090036475 A VBN O
to US20090036475 A TO O
pharmaceutical US20090036475 A JJ O
compositions US20090036475 A NNS O
useful US20090036475 A JJ O
for US20090036475 A IN O
the US20090036475 A DT O
treatment US20090036475 A NN O
or US20090036475 A CC O
alleviation US20090036475 A NN O
of US20090036475 A IN O
diseases US20090036475 A NNS O
or US20090036475 A CC O
disorders US20090036475 A NNS O
associated US20090036475 A VBN O
with US20090036475 A IN O
the US20090036475 A DT O
activity US20090036475 A NN O
of US20090036475 A IN O
potassium US20090036475 A NN O
channels US20090036475 A NNS O
, US20090036475 A , O
in US20090036475 A IN O
particular US20090036475 A JJ O
respiratory US20090036475 A NN O
diseases US20090036475 A NNS O
, US20090036475 A , O
epilepsy US20090036475 A NN O
, US20090036475 A , O
convulsions US20090036475 A NNS O
, US20090036475 A , O
vascular US20090036475 A JJ O
spasms US20090036475 A NNS O
, US20090036475 A , O
coronary US20090036475 A JJ O
artery US20090036475 A NN O
spasms US20090036475 A NN O
, US20090036475 A , O
renal US20090036475 A JJ O
disorders US20090036475 A NNS O
, US20090036475 A , O
polycystic US20090036475 A JJ O
kidney US20090036475 A NN O
disease US20090036475 A NN O
, US20090036475 A , O
bladder US20090036475 A NN O
spasms US20090036475 A NNS O
, US20090036475 A , O
urinary US20090036475 A JJ O
incontinence US20090036475 A NN O
, US20090036475 A , O
bladder US20090036475 A NN O
outflow US20090036475 A JJ O
obstruction US20090036475 A NN O
, US20090036475 A , O
irritable US20090036475 A JJ O
bowel US20090036475 A NN O
syndrome US20090036475 A NN O
, US20090036475 A , O
gastrointestinal US20090036475 A JJ O
dysfunction US20090036475 A NN O
, US20090036475 A , O
secretory US20090036475 A JJ O
diarrhoea US20090036475 A NN O
, US20090036475 A , O
ischaemia US20090036475 A NN O
, US20090036475 A , O
cerebral US20090036475 A JJ O
ischaemia US20090036475 A NN O
, US20090036475 A , O
ischaemic US20090036475 A JJ O
heart US20090036475 A NN O
disease US20090036475 A NN O
, US20090036475 A , O
angina US20090036475 A JJ O
pectoris US20090036475 A NN O
, US20090036475 A , O
coronary US20090036475 A JJ O
heart US20090036475 A NN O
disease US20090036475 A NN O
, US20090036475 A , O
traumatic US20090036475 A JJ O
brain US20090036475 A NN O
injury US20090036475 A NN O
, US20090036475 A , O
psychosis US20090036475 A NN O
, US20090036475 A , O
schizophrenia US20090036475 A NN O
, US20090036475 A , O
anxiety US20090036475 A NN O
, US20090036475 A , O
depression US20090036475 A NN O
, US20090036475 A , O
dementia US20090036475 A NN O
, US20090036475 A , O
memory US20090036475 A NN O
and US20090036475 A CC O
attention US20090036475 A NN O
deficits US20090036475 A NNS O
, US20090036475 A , O
Alzheimer US20090036475 A NNP O
's US20090036475 A POS O
disease US20090036475 A NN O
, US20090036475 A , O
dysmenorrhea US20090036475 A NN O
, US20090036475 A , O
narcolepsy US20090036475 A NN O
, US20090036475 A , O
Reynaud US20090036475 A NNP O
's US20090036475 A POS O
disease US20090036475 A NN O
, US20090036475 A , O
intermittent US20090036475 A JJ O
claudication US20090036475 A NN O
, US20090036475 A , O
Sjorgren US20090036475 A NNP O
's US20090036475 A POS O
syndrome US20090036475 A NN O
, US20090036475 A , O
migraine US20090036475 A NN O
, US20090036475 A , O
arrhythmia US20090036475 A NN O
, US20090036475 A , O
hypertension US20090036475 A NN O
, US20090036475 A , O
absence US20090036475 A NN O
seizures US20090036475 A NNS O
, US20090036475 A , O
myotonic US20090036475 A JJ O
muscle US20090036475 A NN O
dystrophia US20090036475 A NN O
, US20090036475 A , O
xerostomi US20090036475 A NNP O
, US20090036475 A , O
diabetes US20090036475 A VBZ O
type US20090036475 A JJ O
II US20090036475 A NNP O
, US20090036475 A , O
hyperinsulinemia US20090036475 A NN O
, US20090036475 A , O
premature US20090036475 A NN O
labour US20090036475 A NN O
, US20090036475 A , O
baldness US20090036475 A NN O
, US20090036475 A , O
cancer US20090036475 A NN O
, US20090036475 A , O
immune US20090036475 A JJ O
suppression US20090036475 A NN O
or US20090036475 A CC O
pain US20090036475 A NN O
. US20090036475 A . O

Application CN1723880A T NN O
of CN1723880A T IN O
total CN1723880A T JJ O
hypone CN1723880A T NN O
of CN1723880A T IN O
radix CN1723880A T NN O
cynanchi CN1723880A T NN O
bungei CN1723880A T NN O
and CN1723880A T CC O
hypnone CN1723880A T NN O
for CN1723880A T IN O
preparing CN1723880A T VBG O
medicine CN1723880A T NN O
for CN1723880A T IN O
treating CN1723880A T VBG O
gastrointestinal CN1723880A T JJ O
tract CN1723880A T NN O
diseases CN1723880A T NNS O
. CN1723880A T . O

Treatment WO2010141427A1 T NN O
of WO2010141427A1 T IN O
ophthalmologic WO2010141427A1 T JJ O
disorders WO2010141427A1 T NNS O
mediated WO2010141427A1 T VBN O
by WO2010141427A1 T IN O
albha-carbonic WO2010141427A1 T JJ I-UN
anhydrase WO2010141427A1 T NN I-UN
isoforms WO2010141427A1 T NNS O
. WO2010141427A1 T . O

The WO2010141427A1 A DT O
present WO2010141427A1 A JJ O
invention WO2010141427A1 A NN O
pertains WO2010141427A1 A NNS O
to WO2010141427A1 A TO O
4- WO2010141427A1 A JJ O
( WO2010141427A1 A ( O
4-methylpiperazin-1-ylmethyl WO2010141427A1 A JJ O
) WO2010141427A1 A ) O
-N- WO2010141427A1 A FW O
[ WO2010141427A1 A JJ O
4-methyl-3- WO2010141427A1 A JJ O
( WO2010141427A1 A ( O
4-pyridin-3-yl WO2010141427A1 A JJ O
) WO2010141427A1 A ) O
pyrimidin-2-ylamino WO2010141427A1 A NN O
) WO2010141427A1 A ) O
phenyl WO2010141427A1 A NN O
] WO2010141427A1 A JJ O
-benzamide WO2010141427A1 A NN O
or WO2010141427A1 A CC O
a WO2010141427A1 A DT O
pharmaceutically WO2010141427A1 A RB O
acceptable WO2010141427A1 A JJ O
salt WO2010141427A1 A NN O
thereof WO2010141427A1 A NN O
, WO2010141427A1 A , O
or WO2010141427A1 A CC O
4-methyl-3- WO2010141427A1 A JJ O
[ WO2010141427A1 A JJ O
[ WO2010141427A1 A JJ O
4- WO2010141427A1 A JJ O
( WO2010141427A1 A ( O
3-pyridinyl WO2010141427A1 A JJ O
) WO2010141427A1 A ) O
-2-pyrimidinyl WO2010141427A1 A FW O
] WO2010141427A1 A NNP O
amino WO2010141427A1 A NN O
] WO2010141427A1 A NNP O
-Λ/- WO2010141427A1 A NNP O
[ WO2010141427A1 A NNP O
5- WO2010141427A1 A JJ O
( WO2010141427A1 A ( O
4-methyl-1 WO2010141427A1 A JJ O
H-imidazol-1-yl WO2010141427A1 A NNP O
) WO2010141427A1 A ) O
-3- WO2010141427A1 A NN O
( WO2010141427A1 A ( O
trifluoro- WO2010141427A1 A JJ O
methyl WO2010141427A1 A NN O
) WO2010141427A1 A ) O
phenyl WO2010141427A1 A NN O
] WO2010141427A1 A JJ O
benzamide WO2010141427A1 A NN O
or WO2010141427A1 A CC O
a WO2010141427A1 A DT O
pharmaceutically WO2010141427A1 A RB O
acceptable WO2010141427A1 A JJ O
salt WO2010141427A1 A NN O
thereof WO2010141427A1 A NN O
, WO2010141427A1 A , O
for WO2010141427A1 A IN O
the WO2010141427A1 A DT O
treatment WO2010141427A1 A NN O
of WO2010141427A1 A IN O
ophthalmologic WO2010141427A1 A JJ O
disorders WO2010141427A1 A NNS O
mediated WO2010141427A1 A VBN O
by WO2010141427A1 A IN O
alpha-carbonic WO2010141427A1 A JJ I-UN
anhydrase WO2010141427A1 A NN I-UN
isoforms WO2010141427A1 A NNS O
. WO2010141427A1 A . O

Raloxifene US7964734 T NNP O
acid US7964734 T JJ O
addition US7964734 T NN O
salts US7964734 T NNS O
and/or US7964734 T VBP O
solvates US7964734 T NNS O
thereof US7964734 T NNS O
, US7964734 T , O
improved US7964734 T VBN O
method US7964734 T NN O
for US7964734 T IN O
purification US7964734 T NN O
of US7964734 T IN O
said US7964734 T VBD O
raloxifene US7964734 T JJ O
acid US7964734 T JJ O
addition US7964734 T NN O
salts US7964734 T NNS O
and/or US7964734 T VBP O
solvates US7964734 T NNS O
thereof US7964734 T NNS O
and US7964734 T CC O
pharmaceutical US7964734 T JJ O
compositions US7964734 T NNS O
comprising US7964734 T VBG O
these US7964734 T DT O
. US7964734 T . O

Crystalline US20100324078 T NNP O
Forms US20100324078 T NNP O
of US20100324078 T IN O
Naltrexone US20100324078 T NNP O
Methobromide US20100324078 T NNP O
. US20100324078 T . O

Water-soluble US6869954 T JJ O
phenylpyridazine US6869954 T NN O
compounds US6869954 T NNS O
and US6869954 T CC O
compositions US6869954 T NNS O
containing US6869954 T VBG O
the US6869954 T DT O
same US6869954 T JJ O
. US6869954 T . O

These US6869954 A DT O
compounds US6869954 A NNS O
have US6869954 A VBP O
inhibitory US6869954 A JJ O
activity US6869954 A NN O
against US6869954 A IN O
IL-1β US6869954 A NNP I-UN
production US6869954 A NN O
, US6869954 A , O
high US6869954 A JJ O
water US6869954 A NN O
solubility US6869954 A NN O
and US6869954 A CC O
good US6869954 A JJ O
oral US6869954 A JJ O
absorbability US6869954 A NN O
. US6869954 A . O

Cell WO2012008908A1 T NNP O
therapy WO2012008908A1 T NN O
. WO2012008908A1 T . O

Indole EP2488514A1 T NNP O
and EP2488514A1 T CC O
azaindole EP2488514A1 T JJ O
modulators EP2488514A1 T NNS O
of EP2488514A1 T IN O
the EP2488514A1 T DT O
alpha EP2488514A1 T NN I-UN
7 EP2488514A1 T CD I-UN
nachr EP2488514A1 T NN I-UN
. EP2488514A1 T . O

This EP2488514A1 A DT O
invention EP2488514A1 A NN O
relates EP2488514A1 A VBZ O
to EP2488514A1 A TO O
modulation EP2488514A1 A NN O
of EP2488514A1 A IN O
the EP2488514A1 A DT O
α7 EP2488514A1 A NNP I-UN
nicotinic EP2488514A1 A JJ I-UN
acetylcholine EP2488514A1 A NN I-UN
receptor EP2488514A1 A NN I-UN
( EP2488514A1 A ( O
nAChR EP2488514A1 A JJ O
) EP2488514A1 A ) O
by EP2488514A1 A IN O
a EP2488514A1 A DT O
compound EP2488514A1 A NN O
of EP2488514A1 A IN O
formula EP2488514A1 A NN O
( EP2488514A1 A ( O
I EP2488514A1 A PRP O
) EP2488514A1 A ) O
or EP2488514A1 A CC O
a EP2488514A1 A DT O
pharmaceutically EP2488514A1 A RB O
acceptable EP2488514A1 A JJ O
salt EP2488514A1 A NN O
thereof EP2488514A1 A NN O
. EP2488514A1 A . O

Cyclopropyl CA2529293A1 T NNP O
group CA2529293A1 T NN O
substituted CA2529293A1 T VBD O
oxazolidinone CA2529293A1 T CD O
antibiotics CA2529293A1 T NNS O
and CA2529293A1 T CC O
derivatives CA2529293A1 T NNS O
thereof CA2529293A1 T VBP O
. CA2529293A1 T . O

Pharmaceutical CA2660939A1 T JJ O
compositions CA2660939A1 T NNS O
for CA2660939A1 T IN O
the CA2660939A1 T DT O
treatment CA2660939A1 T NN O
of CA2660939A1 T IN O
fungal CA2660939A1 T JJ O
infections CA2660939A1 T NNS O
. CA2660939A1 T . O

Synergistic CA2660939A1 A JJ O
combinations CA2660939A1 A NNS O
of CA2660939A1 A IN O
a CA2660939A1 A DT O
squalene CA2660939A1 A JJ O
epoxidase CA2660939A1 A NN O
inhibitor CA2660939A1 A NN O
and CA2660939A1 A CC O
a CA2660939A1 A DT O
leucyl-tRNA CA2660939A1 A JJ I-UN
synthetase CA2660939A1 A NN I-UN
inhibitor CA2660939A1 A NN O
are CA2660939A1 A VBP O
provided CA2660939A1 A VBN O
, CA2660939A1 A , O
which CA2660939A1 A WDT O
are CA2660939A1 A VBP O
useful CA2660939A1 A JJ O
in CA2660939A1 A IN O
particular CA2660939A1 A JJ O
in CA2660939A1 A IN O
the CA2660939A1 A DT O
treatment CA2660939A1 A NN O
of CA2660939A1 A IN O
diseases CA2660939A1 A NNS O
involving CA2660939A1 A VBG O
fungal CA2660939A1 A NN O
or CA2660939A1 A CC O
suspected CA2660939A1 A VBN O
fungal CA2660939A1 A JJ O
infection CA2660939A1 A NN O
, CA2660939A1 A , O
for CA2660939A1 A IN O
immunomodulation CA2660939A1 A NN O
or CA2660939A1 A CC O
immunosuppression CA2660939A1 A NN O
in CA2660939A1 A IN O
conditions CA2660939A1 A NNS O
in CA2660939A1 A IN O
which CA2660939A1 A WDT O
fungal CA2660939A1 A NN O
or CA2660939A1 A CC O
suspected CA2660939A1 A VBN O
fungal CA2660939A1 A JJ O
colonisation CA2660939A1 A NN O
of CA2660939A1 A IN O
e.g CA2660939A1 A NN O
. CA2660939A1 A . O

Long CA2792669A1 T NNP O
- CA2792669A1 T : O
acting CA2792669A1 T VBG O
formulations CA2792669A1 T NNS O
of CA2792669A1 T IN O
insulins CA2792669A1 T NNS I-UN
. CA2792669A1 T . O

The CA2792669A1 A DT O
application CA2792669A1 A NN O
relates CA2792669A1 A VBZ O
to CA2792669A1 A TO O
an CA2792669A1 A DT O
aqueous CA2792669A1 A JJ O
pharmaceutical CA2792669A1 A JJ O
formulation CA2792669A1 A NN O
comprising CA2792669A1 A VBG O
200 CA2792669A1 A CD O
1000 CA2792669A1 A CD O
U/mL CA2792669A1 A NNP O
[ CA2792669A1 A NNP O
equimolar CA2792669A1 A NN O
to CA2792669A1 A TO O
200 CA2792669A1 A CD O
1000 CA2792669A1 A CD O
IU CA2792669A1 A NNP O
human CA2792669A1 A JJ O
insulin CA2792669A1 A NN I-UN
] CA2792669A1 A NN O
of CA2792669A1 A IN O
insulin CA2792669A1 A NN I-UN
glargine CA2792669A1 A NN O
, CA2792669A1 A , O
with CA2792669A1 A IN O
the CA2792669A1 A DT O
proviso CA2792669A1 A NN O
that CA2792669A1 A IN O
the CA2792669A1 A DT O
concentration CA2792669A1 A NN O
of CA2792669A1 A IN O
said CA2792669A1 A VBD O
formulation CA2792669A1 A NN O
is CA2792669A1 A VBZ O
not CA2792669A1 A RB O
684 CA2792669A1 A CD O
U/mL CA2792669A1 A NNP O
of CA2792669A1 A IN O
insulin CA2792669A1 A NN I-UN
glargine CA2792669A1 A NN O
, CA2792669A1 A , O
and CA2792669A1 A CC O
its CA2792669A1 A PRP$ O
use CA2792669A1 A NN O
. CA2792669A1 A . O

Nanometer CN1931130A T NNP O
emulsion CN1931130A T NN O
oral CN1931130A T JJ O
liquid CN1931130A T NN O
of CN1931130A T IN O
andrographolide CN1931130A T NN O
and CN1931130A T CC O
its CN1931130A T PRP$ O
prepn CN1931130A T NN O
process CN1931130A T NN O
. CN1931130A T . O

Slow CN1857244A T NNP O
released CN1857244A T VBD O
pregabalin CN1857244A T JJ O
medicine CN1857244A T JJ O
composition CN1857244A T NN O
. CN1857244A T . O

Controlled US20110212174 T VBN O
release US20110212174 T NN O
arginine US20110212174 T NN O
formulations US20110212174 T NNS O
. US20110212174 T . O

A CN101584798A T DT O
chinese CN101584798A T JJ O
midicine CN101584798A T NN O
for CN101584798A T IN O
curing CN101584798A T VBG O
psoriasis CN101584798A T NN O
completely CN101584798A T RB O
. CN101584798A T . O

Phthalazinone CN102372706A T NNP O
derivative CN102372706A T JJ O
, CN102372706A T , O
its CN102372706A T PRP$ O
preparation CN102372706A T NN O
method CN102372706A T NN O
and CN102372706A T CC O
application CN102372706A T NN O
in CN102372706A T IN O
medicament CN102372706A T NN O
. CN102372706A T . O

The CN102372706A A DT O
invention CN102372706A A NN O
relates CN102372706A A VBZ O
to CN102372706A A TO O
a CN102372706A A DT O
phthalazinone CN102372706A A NN O
derivative CN102372706A A NN O
, CN102372706A A , O
its CN102372706A A PRP$ O
preparation CN102372706A A NN O
method CN102372706A A NN O
and CN102372706A A CC O
application CN102372706A A NN O
in CN102372706A A IN O
medicament CN102372706A A NN O
, CN102372706A A , O
particularly CN102372706A A RB O
relates CN102372706A A VBZ O
to CN102372706A A TO O
a CN102372706A A DT O
novel CN102372706A A JJ O
phthalazinone CN102372706A A NN O
derivative CN102372706A A NN O
of CN102372706A A IN O
formula CN102372706A A NN O
( CN102372706A A ( O
I CN102372706A A PRP O
) CN102372706A A ) O
, CN102372706A A , O
its CN102372706A A PRP$ O
preparation CN102372706A A NN O
method CN102372706A A NN O
, CN102372706A A , O
a CN102372706A A DT O
pharmaceutical CN102372706A A JJ O
composition CN102372706A A NN O
containing CN102372706A A VBG O
the CN102372706A A DT O
phthalazinone CN102372706A A NN O
derivative CN102372706A A NN O
, CN102372706A A , O
and CN102372706A A CC O
an CN102372706A A DT O
application CN102372706A A NN O
of CN102372706A A IN O
the CN102372706A A DT O
phthalazinone CN102372706A A NN O
derivative CN102372706A A JJ O
as CN102372706A A IN O
a CN102372706A A DT O
therapeutic CN102372706A A JJ O
agent CN102372706A A NN O
, CN102372706A A , O
especially CN102372706A A RB O
as CN102372706A A IN O
a CN102372706A A DT O
poly CN102372706A A NN I-UN
( CN102372706A A ( I-UN
ADP-ribose CN102372706A A NNP I-UN
) CN102372706A A ) I-UN
polymerase CN102372706A A NN I-UN
( CN102372706A A ( O
PARP CN102372706A A NNP I-UN
) CN102372706A A ) O
inhibitor CN102372706A A NN O
. CN102372706A A . O

Dextran CN1732972A T NNP O
for CN1732972A T IN O
injection CN1732972A T NN O
and CN1732972A T CC O
method CN1732972A T NN O
for CN1732972A T IN O
preparing CN1732972A T VBG O
the CN1732972A T DT O
same CN1732972A T JJ O
. CN1732972A T . O

Sulpho-glucosan CN101445528B T JJ O
derivative CN101445528B T JJ O
and CN101445528B T CC O
preparation CN101445528B T NN O
method CN101445528B T NN O
and CN101445528B T CC O
application CN101445528B T NN O
thereof CN101445528B T NN O
. CN101445528B T . O

The CN101445528B A DT O
invention CN101445528B A NN O
relates CN101445528B A VBZ O
to CN101445528B A TO O
the CN101445528B A DT O
field CN101445528B A NN O
of CN101445528B A IN O
diabetes CN101445528B A NNS O
related CN101445528B A JJ O
medicine CN101445528B A NN O
, CN101445528B A , O
in CN101445528B A IN O
particular CN101445528B A JJ O
to CN101445528B A TO O
a CN101445528B A DT O
depressor CN101445528B A NN O
for CN101445528B A IN O
a CN101445528B A DT O
Na-glucose CN101445528B A JJ I-UN
transporter CN101445528B A NN I-UN
II CN101445528B A NNP I-UN
containing CN101445528B A VBG O
a CN101445528B A DT O
structure CN101445528B A NN O
of CN101445528B A IN O
sulpho-glucose CN101445528B A JJ O
( CN101445528B A ( O
SGLT2 CN101445528B A NNP I-UN
) CN101445528B A ) O
and CN101445528B A CC O
a CN101445528B A DT O
preparation CN101445528B A NN O
method CN101445528B A NN O
thereof CN101445528B A NN O
, CN101445528B A , O
and CN101445528B A CC O
a CN101445528B A DT O
pharmaceutical CN101445528B A JJ O
composition CN101445528B A NN O
containing CN101445528B A VBG O
SGLT2 CN101445528B A NNP I-UN
and CN101445528B A CC O
an CN101445528B A DT O
application CN101445528B A NN O
thereof CN101445528B A NN O
in CN101445528B A IN O
the CN101445528B A DT O
preparation CN101445528B A NN O
of CN101445528B A IN O
diabetes CN101445528B A NNS O
drugs CN101445528B A NNS O
, CN101445528B A , O
wherein CN101445528B A NN O
, CN101445528B A , O
a CN101445528B A DT O
radical CN101445528B A JJ O
group CN101445528B A NN O
is CN101445528B A VBZ O
defined CN101445528B A VBN O
in CN101445528B A IN O
the CN101445528B A DT O
specification CN101445528B A NN O
. CN101445528B A . O

Modulating WO2011044504A1 T VBG O
levels WO2011044504A1 T NNS O
of WO2011044504A1 T IN O
rna-binding WO2011044504A1 T JJ O
proteins WO2011044504A1 T NNS O
for WO2011044504A1 T IN O
the WO2011044504A1 T DT O
treatment WO2011044504A1 T NN O
of WO2011044504A1 T IN O
breast WO2011044504A1 T NN O
cancer WO2011044504A1 T NN O
. WO2011044504A1 T . O

The WO2011044504A1 A DT O
present WO2011044504A1 A JJ O
invention WO2011044504A1 A NN O
relates WO2011044504A1 A VBZ O
to WO2011044504A1 A TO O
methods WO2011044504A1 A NNS O
of WO2011044504A1 A IN O
using WO2011044504A1 A VBG O
RNA-binding WO2011044504A1 A NNP O
protein WO2011044504A1 A NN O
modulating WO2011044504A1 A VBG O
agents WO2011044504A1 A NNS O
to WO2011044504A1 A TO O
treat WO2011044504A1 A VB O
of WO2011044504A1 A IN O
cancer WO2011044504A1 A NN O
, WO2011044504A1 A , O
particularly WO2011044504A1 A RB O
patients WO2011044504A1 A NNS O
that WO2011044504A1 A WDT O
are WO2011044504A1 A VBP O
susceptible WO2011044504A1 A JJ O
to WO2011044504A1 A TO O
or WO2011044504A1 A CC O
diagnosed WO2011044504A1 A VBN O
with WO2011044504A1 A IN O
estrogen WO2011044504A1 A JJ I-UN
receptor-negative WO2011044504A1 A JJ O
breast WO2011044504A1 A NN O
cancer WO2011044504A1 A NN O
, WO2011044504A1 A , O
such WO2011044504A1 A JJ O
as WO2011044504A1 A IN O
methods WO2011044504A1 A NNS O
of WO2011044504A1 A IN O
inhibiting WO2011044504A1 A VBG O
the WO2011044504A1 A DT O
growth WO2011044504A1 A NN O
or WO2011044504A1 A CC O
metastasis WO2011044504A1 A NN O
of WO2011044504A1 A IN O
cancer WO2011044504A1 A NN O
cells WO2011044504A1 A NNS O
comprising WO2011044504A1 A VBG O
contacting WO2011044504A1 A VBG O
cells WO2011044504A1 A NNS O
with WO2011044504A1 A IN O
a WO2011044504A1 A DT O
therapeutically-effective WO2011044504A1 A JJ O
amount WO2011044504A1 A NN O
of WO2011044504A1 A IN O
an WO2011044504A1 A DT O
HuR-modulating WO2011044504A1 A JJ O
agent WO2011044504A1 A NN O
. WO2011044504A1 A . O

Prescription CN102526118A T NN O
for CN102526118A T IN O
treating CN102526118A T VBG O
fish CN102526118A T JJ O
red CN102526118A T JJ O
skin CN102526118A T NN O
disease CN102526118A T NN O
. CN102526118A T . O

Medicament WO2009036852A1 T NN O
for WO2009036852A1 T IN O
treating WO2009036852A1 T VBG O
or WO2009036852A1 T CC O
preventing WO2009036852A1 T VBG O
proteinuria WO2009036852A1 T NNS O
. WO2009036852A1 T . O

Heterocyclic US7332504 T NNP O
substituted US7332504 T VBD O
aminoazacycles US7332504 T NNS O
useful US7332504 T JJ O
as US7332504 T IN O
central US7332504 T JJ O
nervous US7332504 T JJ O
system US7332504 T NN O
agents US7332504 T NNS O
. US7332504 T . O

Use CN101361752A T NNP O
of CN101361752A T IN O
polystyrol-poly CN101361752A T JJ O
( CN101361752A T ( O
styrene-alternate-sodium CN101361752A T JJ O
maleate CN101361752A T NN O
) CN101361752A T ) O
. CN101361752A T . O

Methods US20100179213 T NNS O
and US20100179213 T CC O
Compositions US20100179213 T NNP O
Involving US20100179213 T NNP O
miRNAs US20100179213 T NN O
In US20100179213 T IN O
Cancer US20100179213 T NNP O
Stem US20100179213 T NNP O
Cells US20100179213 T NNP O
. US20100179213 T . O

Treating WO2008021728A3 T VBG O
infections WO2008021728A3 T NNS O
and WO2008021728A3 T CC O
sequelae WO2008021728A3 T JJ O
thereof WO2008021728A3 T NN O
with WO2008021728A3 T IN O
combined WO2008021728A3 T JJ O
dissociated WO2008021728A3 T VBN O
' WO2008021728A3 T POS O
glucocorticoid WO2008021728A3 T JJ I-UN
receptor WO2008021728A3 T NN I-UN
agonists WO2008021728A3 T NNS O
and WO2008021728A3 T CC O
anti-infective WO2008021728A3 T JJ O
agents WO2008021728A3 T NNS O
. WO2008021728A3 T . O

A WO2008021728A3 A DT O
composition WO2008021728A3 A NN O
for WO2008021728A3 A IN O
treating WO2008021728A3 A VBG O
, WO2008021728A3 A , O
controlling WO2008021728A3 A VBG O
, WO2008021728A3 A , O
reducing WO2008021728A3 A VBG O
, WO2008021728A3 A , O
ameliorating WO2008021728A3 A VBG O
, WO2008021728A3 A , O
or WO2008021728A3 A CC O
alleviating WO2008021728A3 A VBG O
infections WO2008021728A3 A NNS O
and WO2008021728A3 A CC O
their WO2008021728A3 A PRP$ O
inflammatory WO2008021728A3 A JJ O
sequelae WO2008021728A3 A NN O
comprises WO2008021728A3 A VBZ O
a WO2008021728A3 A DT O
dissociated WO2008021728A3 A JJ O
glucocorticoid WO2008021728A3 A NN I-UN
receptor WO2008021728A3 A NN I-UN
agonist WO2008021728A3 A NN O
( WO2008021728A3 A ( O
'DIGRA WO2008021728A3 A NNP O
' WO2008021728A3 A POS O
) WO2008021728A3 A ) O
and WO2008021728A3 A CC O
an WO2008021728A3 A DT O
anti-infective WO2008021728A3 A JJ O
agent WO2008021728A3 A NN O
, WO2008021728A3 A , O
such WO2008021728A3 A JJ O
as WO2008021728A3 A IN O
an WO2008021728A3 A DT O
antibacterial WO2008021728A3 A JJ O
, WO2008021728A3 A , O
antiviral WO2008021728A3 A JJ O
, WO2008021728A3 A , O
antifungal WO2008021728A3 A JJ O
, WO2008021728A3 A , O
antiprotozoal WO2008021728A3 A JJ O
agent WO2008021728A3 A NN O
, WO2008021728A3 A , O
or WO2008021728A3 A CC O
a WO2008021728A3 A DT O
combination WO2008021728A3 A NN O
thereof WO2008021728A3 A NN O
. WO2008021728A3 A . O

Formulations US20060151574 T NNS O
useful US20060151574 T JJ O
against US20060151574 T IN O
hepatitis US20060151574 T NN O
C US20060151574 T NNP O
virus US20060151574 T NN O
infections US20060151574 T NNS O
. US20060151574 T . O

Some WO2009061271A1 T DT O
2-pyrazinone WO2009061271A1 T JJ O
derivatives WO2009061271A1 T NNS O
and WO2009061271A1 T CC O
their WO2009061271A1 T PRP$ O
use WO2009061271A1 T NN O
as WO2009061271A1 T IN O
inhibitors WO2009061271A1 T NNS O
of WO2009061271A1 T IN O
neutrophile WO2009061271A1 T JJ I-UN
elastase WO2009061271A1 T NN I-UN
. WO2009061271A1 T . O

The WO2009061271A1 A DT O
compounds WO2009061271A1 A NNS O
are WO2009061271A1 A VBP O
inhibitord WO2009061271A1 A NN O
of WO2009061271A1 A IN O
human WO2009061271A1 A JJ I-UN
neutrophil WO2009061271A1 A JJ I-UN
elastase WO2009061271A1 A NN I-UN
. WO2009061271A1 A . O

Adenosine CN102525891A T NNP O
cyclophosphate CN102525891A T NN O
injection CN102525891A T NN O
and CN102525891A T CC O
preparation CN102525891A T NN O
method CN102525891A T NN O
thereof CN102525891A T NN O
. CN102525891A T . O

Dioxazole CN1583753A T NNP O
pyrimidine CN1583753A T NN O
nucleotide CN1583753A T NN O
compounds CN1583753A T VBZ O
with CN1583753A T IN O
function CN1583753A T NN O
of CN1583753A T IN O
releasing CN1583753A T VBG O
NO CN1583753A T NNP O
and CN1583753A T CC O
its CN1583753A T PRP$ O
use CN1583753A T NN O
in CN1583753A T IN O
pharmaceutics CN1583753A T NNS O
. CN1583753A T . O

Sterides CN102107007B T NNP O
anti-progestogen CN102107007B T JJ O
composition CN102107007B T NN O
and CN102107007B T CC O
preparation CN102107007B T NN O
method CN102107007B T NN O
thereof CN102107007B T NN O
. CN102107007B T . O

compound US20100137260 T NN O
for US20100137260 T IN O
inhibiting US20100137260 T VBG O
trpv3 US20100137260 T JJ I-UN
function US20100137260 T NN O
and US20100137260 T CC O
use US20100137260 T NN O
thereof US20100137260 T NN O
. US20100137260 T . O

The US20100137260 A DT O
present US20100137260 A JJ O
invention US20100137260 A NN O
relates US20100137260 A VBZ O
to US20100137260 A TO O
a US20100137260 A DT O
TRPV3 US20100137260 A NNP I-UN
( US20100137260 A ( O
transient US20100137260 A JJ I-UN
receptor US20100137260 A NN I-UN
potential US20100137260 A JJ I-UN
vanilloid US20100137260 A NN I-UN
3 US20100137260 A CD I-UN
) US20100137260 A ) O
activity US20100137260 A NN O
inhibitor US20100137260 A NN O
, US20100137260 A , O
more US20100137260 A RBR O
precisely US20100137260 A RB O
to US20100137260 A TO O
a US20100137260 A DT O
method US20100137260 A NN O
for US20100137260 A IN O
inhibiting US20100137260 A VBG O
TRPV3 US20100137260 A NNP I-UN
activity US20100137260 A NN O
including US20100137260 A VBG O
the US20100137260 A DT O
step US20100137260 A NN O
of US20100137260 A IN O
treating US20100137260 A VBG O
isopentenyl US20100137260 A JJ O
pyrophosphate US20100137260 A NN O
and US20100137260 A CC O
a US20100137260 A DT O
method US20100137260 A NN O
for US20100137260 A IN O
treating US20100137260 A VBG O
skin US20100137260 A JJ O
disease US20100137260 A NN O
containing US20100137260 A VBG O
the US20100137260 A DT O
step US20100137260 A NN O
of US20100137260 A IN O
administering US20100137260 A VBG O
isopentenyl US20100137260 A JJ O
pyrophosphate US20100137260 A NN O
to US20100137260 A TO O
a US20100137260 A DT O
subject US20100137260 A NN O
with US20100137260 A IN O
skin US20100137260 A JJ O
disease US20100137260 A NN O
or US20100137260 A CC O
applying US20100137260 A VBG O
the US20100137260 A DT O
same US20100137260 A JJ O
on US20100137260 A IN O
the US20100137260 A DT O
skin US20100137260 A NN O
of US20100137260 A IN O
the US20100137260 A DT O
subject US20100137260 A NN O
. US20100137260 A . O

Isopentenyl US20100137260 A NNP O
pyrophosphate US20100137260 A NN O
of US20100137260 A IN O
the US20100137260 A DT O
present US20100137260 A JJ O
invention US20100137260 A NN O
controls US20100137260 A VBZ O
increase US20100137260 A NN O
of US20100137260 A IN O
sensory US20100137260 A JJ O
cell US20100137260 A NN O
reactivity US20100137260 A NN O
to US20100137260 A TO O
current US20100137260 A JJ O
or US20100137260 A CC O
migration US20100137260 A NN O
and US20100137260 A CC O
proliferation US20100137260 A NN O
of US20100137260 A IN O
skin US20100137260 A NN O
cells US20100137260 A NNS O
induced US20100137260 A VBN O
by US20100137260 A IN O
TRPV3 US20100137260 A NNP I-UN
, US20100137260 A , O
so US20100137260 A IN O
that US20100137260 A IN O
it US20100137260 A PRP O
can US20100137260 A MD O
be US20100137260 A VB O
effectively US20100137260 A RB O
used US20100137260 A VBN O
for US20100137260 A IN O
the US20100137260 A DT O
development US20100137260 A NN O
of US20100137260 A IN O
a US20100137260 A DT O
pain US20100137260 A NN O
reliever US20100137260 A NN O
or US20100137260 A CC O
a US20100137260 A DT O
therapeutic US20100137260 A JJ O
agent US20100137260 A NN O
for US20100137260 A IN O
skin US20100137260 A JJ O
disease US20100137260 A NN O
. US20100137260 A . O

Method US8198300 T NNP O
for US8198300 T IN O
preventing US8198300 T VBG O
tau US8198300 T JJ I-UN
protein US8198300 T NN O
aggregation US8198300 T NN O
and US8198300 T CC O
treating US8198300 T VBG O
Alzheimer US8198300 T NNP O
's US8198300 T POS O
disease US8198300 T NN O
with US8198300 T IN O
a US8198300 T DT O
quinoline US8198300 T JJ O
derivative US8198300 T JJ O
compound US8198300 T NN O
. US8198300 T . O

Method US8198300 A NNP O
for US8198300 A IN O
the US8198300 A DT O
prevention US8198300 A NN O
of US8198300 A IN O
the US8198300 A DT O
tau US8198300 A NN I-UN
protein US8198300 A NN O
aggregation US8198300 A NN O
and US8198300 A CC O
treating US8198300 A VBG O
Alzheimer US8198300 A NNP O
's US8198300 A POS O
disease US8198300 A NN O
by US8198300 A IN O
administering US8198300 A VBG O
a US8198300 A DT O
quinoline US8198300 A JJ O
derivative US8198300 A JJ O
compound US8198300 A NN O
of US8198300 A IN O
formula US8198300 A NN O
wherein US8198300 A NN O
R2 US8198300 A NNP O
is US8198300 A VBZ O
2- US8198300 A JJ O
( US8198300 A ( O
4-aminophenyl US8198300 A JJ O
) US8198300 A ) O
or US8198300 A CC O
2- US8198300 A JJ O
( US8198300 A ( O
4-methylphenyl US8198300 A JJ O
) US8198300 A ) O
and US8198300 A CC O
R6 US8198300 A NNP O
is US8198300 A VBZ O
methyl US8198300 A VBN O
as US8198300 A IN O
an US8198300 A DT O
inhibitor US8198300 A NN O
of US8198300 A IN O
the US8198300 A DT O
tau US8198300 A NN I-UN
protein US8198300 A NN O
aggregation US8198300 A NN O
. US8198300 A . O

An US7297688 T DT O
oral US7297688 T JJ O
contraceptive US7297688 T NN O
starter US7297688 T NN O
kit US7297688 T NN O
comprising US7297688 T VBG O
at US7297688 T IN O
least US7297688 T JJS O
two US7297688 T CD O
cycle US7297688 T NN O
packs US7297688 T NNS O
of US7297688 T IN O
oral US7297688 T JJ O
contraceptives US7297688 T NNS O
containing US7297688 T VBG O
an US7297688 T DT O
estrogen US7297688 T NN O
and US7297688 T CC O
a US7297688 T DT O
progestin US7297688 T NN O
, US7297688 T , O
and US7297688 T CC O
having US7297688 T VBG O
penultimate US7297688 T JJ O
cycle US7297688 T NN O
with US7297688 T IN O
greater US7297688 T JJR O
steroid US7297688 T NN O
dosage US7297688 T NN O
than US7297688 T IN O
last US7297688 T JJ O
cycle US7297688 T NN O
pack US7297688 T NN O
dosage US7297688 T NN O
. US7297688 T . O

Wheat CN1948248A T NNP O
bran CN1948248A T VBD O
total CN1948248A T JJ O
alkyl CN1948248A T JJ O
phenol CN1948248A T NN O
extract CN1948248A T NN O
and CN1948248A T CC O
its CN1948248A T PRP$ O
preparation CN1948248A T NN O
method CN1948248A T NN O
and CN1948248A T CC O
application CN1948248A T NN O
. CN1948248A T . O

Drug US20100098713 T NN O
screening US20100098713 T NN O
; US20100098713 T : O
assay US20100098713 T VB O
for US20100098713 T IN O
aldehyde US20100098713 T JJ O
dehydrogenase US20100098713 T NN O
activity US20100098713 T NN O
; US20100098713 T : O
cancer US20100098713 T NN O
. US20100098713 T . O

Compositions WO2008143637A2 T NNS O
and WO2008143637A2 T CC O
methods WO2008143637A2 T NNS O
for WO2008143637A2 T IN O
making WO2008143637A2 T VBG O
therapies WO2008143637A2 T NNS O
delivered WO2008143637A2 T VBN O
by WO2008143637A2 T IN O
viral WO2008143637A2 T JJ O
vectors WO2008143637A2 T NNS O
reversible WO2008143637A2 T VBP O
for WO2008143637A2 T IN O
safety WO2008143637A2 T NN O
or WO2008143637A2 T CC O
allele-specificity WO2008143637A2 T NN O
. WO2008143637A2 T . O

The WO2008143637A2 A DT O
present WO2008143637A2 A JJ O
invention WO2008143637A2 A NN O
is WO2008143637A2 A VBZ O
directed WO2008143637A2 A VBN O
to WO2008143637A2 A TO O
compositions WO2008143637A2 A NNS O
methods WO2008143637A2 A NNS O
and WO2008143637A2 A CC O
kits WO2008143637A2 A NNS O
for WO2008143637A2 A IN O
regulation WO2008143637A2 A NN O
of WO2008143637A2 A IN O
gene WO2008143637A2 A NN O
therapies WO2008143637A2 A NNS O
, WO2008143637A2 A , O
including WO2008143637A2 A VBG O
, WO2008143637A2 A , O
without WO2008143637A2 A IN O
limitation WO2008143637A2 A NN O
, WO2008143637A2 A , O
reversible WO2008143637A2 A JJ O
gene WO2008143637A2 A NN O
therapies WO2008143637A2 A NNS O
and WO2008143637A2 A CC O
allele- WO2008143637A2 A JJ O
specific WO2008143637A2 A JJ O
therapies WO2008143637A2 A NNS O
. WO2008143637A2 A . O

Ppar EP1539136A2 T NNP I-UN
alpha EP1539136A2 T VBZ I-UN
selective EP1539136A2 T JJ O
compounds EP1539136A2 T NNS O
for EP1539136A2 T IN O
the EP1539136A2 T DT O
treatment EP1539136A2 T NN O
of EP1539136A2 T IN O
dyslipidemia EP1539136A2 T NN O
and EP1539136A2 T CC O
other EP1539136A2 T JJ O
lipid EP1539136A2 T JJ O
disorders EP1539136A2 T NNS O
. EP1539136A2 T . O

Pharmaceutical US20100291160 T JJ O
system US20100291160 T NN O
for US20100291160 T IN O
trans-membrane US20100291160 T JJ O
delivery US20100291160 T NN O
. US20100291160 T . O

Secretory US20100158946 T NNP O
IgA US20100158946 T NNP O
and US20100158946 T CC O
IgG US20100158946 T NNP O
Antibody US20100158946 T NNP O
Inducer US20100158946 T NNP O
. US20100158946 T . O

Combination EP2305228A1 T NNP O
therapy EP2305228A1 T NN O
for EP2305228A1 T IN O
the EP2305228A1 T DT O
treatment EP2305228A1 T NN O
of EP2305228A1 T IN O
hyperlipidemia EP2305228A1 T NN O
. EP2305228A1 T . O

Oxazole EP1519925A1 T NNP O
derivatives EP1519925A1 T NNS O
and EP1519925A1 T CC O
their EP1519925A1 T PRP$ O
use EP1519925A1 T NN O
as EP1519925A1 T IN O
insulin EP1519925A1 T NN I-UN
sensitizers EP1519925A1 T NNS O
. EP1519925A1 T . O

Compound EP1519925A1 A NN O
of EP1519925A1 A IN O
formula EP1519925A1 A NN O
( EP1519925A1 A ( O
I EP1519925A1 A PRP O
) EP1519925A1 A ) O
: EP1519925A1 A : O
and EP1519925A1 A CC O
pharmaceutically EP1519925A1 A RB O
acceptable EP1519925A1 A JJ O
salts EP1519925A1 A NNS O
and EP1519925A1 A CC O
esters EP1519925A1 A NNS O
thereof EP1519925A1 A VBP O
, EP1519925A1 A , O
wherein EP1519925A1 A JJ O
R1 EP1519925A1 A NNP O
is EP1519925A1 A VBZ O
aryl EP1519925A1 A RB O
; EP1519925A1 A : O
R2 EP1519925A1 A NNP O
is EP1519925A1 A VBZ O
hydrogen EP1519925A1 A NN O
, EP1519925A1 A , O
alkyl EP1519925A1 A NN O
or EP1519925A1 A CC O
cycloalkyl EP1519925A1 A NN O
; EP1519925A1 A : O
R3 EP1519925A1 A NNP O
is EP1519925A1 A VBZ O
hydrogen EP1519925A1 A NN O
, EP1519925A1 A , O
alkyl EP1519925A1 A NN O
, EP1519925A1 A , O
aralkyl EP1519925A1 A NN O
, EP1519925A1 A , O
aryl EP1519925A1 A NN O
, EP1519925A1 A , O
alkylcarbonyl EP1519925A1 A NN O
, EP1519925A1 A , O
arylcarbonyl EP1519925A1 A NN O
, EP1519925A1 A , O
alkyl-S EP1519925A1 A JJ O
( EP1519925A1 A ( O
O EP1519925A1 A NNP O
) EP1519925A1 A ) O
2- EP1519925A1 A CD O
or EP1519925A1 A CC O
aryl-S EP1519925A1 A JJ O
( EP1519925A1 A ( O
O EP1519925A1 A NNP O
) EP1519925A1 A ) O
2- EP1519925A1 A CD O
; EP1519925A1 A : O
R4 EP1519925A1 A NNP O
is EP1519925A1 A VBZ O
aralkyl EP1519925A1 A RB O
; EP1519925A1 A : O
R5 EP1519925A1 A NNP O
, EP1519925A1 A , O
R6 EP1519925A1 A NNP O
, EP1519925A1 A , O
R7 EP1519925A1 A NNP O
and EP1519925A1 A CC O
R8 EP1519925A1 A NNP O
are EP1519925A1 A VBP O
independently EP1519925A1 A RB O
selected EP1519925A1 A VBN O
from EP1519925A1 A IN O
hydrogen EP1519925A1 A NN O
, EP1519925A1 A , O
alkyl EP1519925A1 A NN O
or EP1519925A1 A CC O
cycloalkyl EP1519925A1 A NN O
; EP1519925A1 A : O
and EP1519925A1 A CC O
n EP1519925A1 A NN O
is EP1519925A1 A VBZ O
1,2,3,4 EP1519925A1 A CD O
or EP1519925A1 A CC O
5 EP1519925A1 A CD O
, EP1519925A1 A , O
are EP1519925A1 A VBP O
useful EP1519925A1 A JJ O
as EP1519925A1 A IN O
insulin EP1519925A1 A NN I-UN
sensititers EP1519925A1 A NNS O
, EP1519925A1 A , O
particularly EP1519925A1 A RB O
PPAR EP1519925A1 A JJ O
activators EP1519925A1 A NNS O
. EP1519925A1 A . O

Slow CN1857207A T NNP O
released CN1857207A T VBD O
compound CN1857207A T NN O
anticancer CN1857207A T NN O
injection CN1857207A T NN O
containing CN1857207A T VBG O
blood CN1857207A T NN O
vessel CN1857207A T NN O
inhibitor CN1857207A T NN O
. CN1857207A T . O

Medicines CN102188432A T NNS O
for CN102188432A T IN O
preventing CN102188432A T VBG O
and CN102188432A T CC O
treating CN102188432A T VBG O
epilepsia CN102188432A T NN O
. CN102188432A T . O

Derivatives US20120302534 T NNS O
of US20120302534 T IN O
betulin US20120302534 T NN O
. US20120302534 T . O

Method US20050065165 T NNP O
of US20050065165 T IN O
treating US20050065165 T VBG O
certain US20050065165 T JJ O
cancers US20050065165 T NNS O
using US20050065165 T VBG O
an US20050065165 T DT O
estrogen US20050065165 T NN O
agonist/antagonist US20050065165 T NN O
. US20050065165 T . O

for US7214714 T IN O
treatment US7214714 T NN O
of US7214714 T IN O
renal US7214714 T JJ O
diseases US7214714 T NNS O
, US7214714 T , O
cerebrovascular US7214714 T JJ O
diseases US7214714 T NNS O
and US7214714 T CC O
circulatory US7214714 T NN O
diseases US7214714 T NNS O
. US7214714 T . O

Application CN103622968A T NN O
of CN103622968A T IN O
tozasertib CN103622968A T NN O
in CN103622968A T IN O
preparation CN103622968A T NN O
of CN103622968A T IN O
drug CN103622968A T NN O
for CN103622968A T IN O
treating CN103622968A T VBG O
glaucoma CN103622968A T NN O
disease CN103622968A T NN O
. CN103622968A T . O

Methods EP2440201A1 T NNS O
and EP2440201A1 T CC O
compositions EP2440201A1 T NNS O
for EP2440201A1 T IN O
treating EP2440201A1 T VBG O
insulin EP2440201A1 T NN I-UN
resistance EP2440201A1 T NN O
, EP2440201A1 T , O
diabetes EP2440201A1 T VBZ O
mellitus EP2440201A1 T VBP O
type EP2440201A1 T NN O
2 EP2440201A1 T CD O
, EP2440201A1 T , O
metabolic EP2440201A1 T JJ O
syndrome EP2440201A1 T NN O
and EP2440201A1 T CC O
related EP2440201A1 T JJ O
disorders EP2440201A1 T NNS O
. EP2440201A1 T . O

Immune EP1889609A2 T NNP O
response EP1889609A2 T NN O
modifier EP1889609A2 T NN O
foam EP1889609A2 T NN O
formulations EP1889609A2 T NNS O
. EP1889609A2 T . O

Silent WO2009143507A3 T JJ O
desensitizers WO2009143507A3 T NNS O
of WO2009143507A3 T IN O
neuronal WO2009143507A3 T JJ O
nachr WO2009143507A3 T NN I-UN
and WO2009143507A3 T CC O
methods WO2009143507A3 T NNS O
of WO2009143507A3 T IN O
use WO2009143507A3 T NN O
thereof WO2009143507A3 T NN O
. WO2009143507A3 T . O

One WO2009143507A3 A CD O
aspect WO2009143507A3 A NN O
of WO2009143507A3 A IN O
the WO2009143507A3 A DT O
present WO2009143507A3 A JJ O
invention WO2009143507A3 A NN O
relates WO2009143507A3 A VBZ O
to WO2009143507A3 A TO O
heterocyclic WO2009143507A3 A VB O
compounds WO2009143507A3 A NNS O
that WO2009143507A3 A WDT O
are WO2009143507A3 A VBP O
ligands WO2009143507A3 A VBZ O
for WO2009143507A3 A IN O
nicotinic WO2009143507A3 A JJ I-UN
acetylcholine WO2009143507A3 A NN I-UN
receptors WO2009143507A3 A NNS I-UN
. WO2009143507A3 A . O

A WO2009143507A3 A DT O
second WO2009143507A3 A JJ O
aspect WO2009143507A3 A NN O
of WO2009143507A3 A IN O
the WO2009143507A3 A DT O
invention WO2009143507A3 A NN O
relates WO2009143507A3 A VBZ O
to WO2009143507A3 A TO O
the WO2009143507A3 A DT O
use WO2009143507A3 A NN O
of WO2009143507A3 A IN O
a WO2009143507A3 A DT O
compound WO2009143507A3 A NN O
of WO2009143507A3 A IN O
the WO2009143507A3 A DT O
invention WO2009143507A3 A NN O
for WO2009143507A3 A IN O
modulation WO2009143507A3 A NN O
of WO2009143507A3 A IN O
a WO2009143507A3 A DT O
mammalian WO2009143507A3 A JJ I-UN
nicotinic WO2009143507A3 A JJ I-UN
acetylcholine WO2009143507A3 A NN I-UN
receptor WO2009143507A3 A NN I-UN
. WO2009143507A3 A . O

Composition CN103432177A T NN O
for CN103432177A T IN O
preventing CN103432177A T VBG O
and CN103432177A T CC O
treating CN103432177A T VBG O
fatty CN103432177A T JJ O
liver CN103432177A T NN O
and CN103432177A T CC O
preparation CN103432177A T NN O
method CN103432177A T NN O
thereof CN103432177A T NN O
. CN103432177A T . O

Externally-applied CN102119974B T JJ O
medicinal CN102119974B T JJ O
liquor CN102119974B T NN O
. CN102119974B T . O

Tissue-specific EP1561815A2 T JJ O
and EP1561815A2 T CC O
target EP1561815A2 T VB O
rna-specific EP1561815A2 T JJ O
ribozymes EP1561815A2 T NNS O
. EP1561815A2 T . O

Capsule CN103550332A T NN O
and CN103550332A T CC O
preparation CN103550332A T NN O
containing CN103550332A T VBG O
rich CN103550332A T JJ O
hydroxytyrosol CN103550332A T NN O
, CN103550332A T , O
lycium CN103550332A T NN O
barbarum CN103550332A T NN O
polysaccharide CN103550332A T NN O
and CN103550332A T CC O
apple CN103550332A T NN O
polyphenol CN103550332A T NN O
and CN103550332A T CC O
used CN103550332A T VBN O
for CN103550332A T IN O
protecting CN103550332A T VBG O
liver CN103550332A T NN O
. CN103550332A T . O

Method WO2010055022A1 T NNP O
for WO2010055022A1 T IN O
treating WO2010055022A1 T VBG O
or WO2010055022A1 T CC O
preventing WO2010055022A1 T VBG O
thrombosis WO2010055022A1 T NN O
using WO2010055022A1 T VBG O
dabigatran WO2010055022A1 T JJ O
etexilate WO2010055022A1 T NN O
or WO2010055022A1 T CC O
a WO2010055022A1 T DT O
salt WO2010055022A1 T JJ O
thereof WO2010055022A1 T NN O
with WO2010055022A1 T IN O
improved WO2010055022A1 T JJ O
efficacy WO2010055022A1 T NN O
over WO2010055022A1 T IN O
conventional WO2010055022A1 T JJ O
warfarin WO2010055022A1 T JJ O
therapy WO2010055022A1 T NN O
. WO2010055022A1 T . O

Application CN103099804A T NN O
of CN103099804A T IN O
isosteviol CN103099804A T NN O
lactone CN103099804A T NN O
in CN103099804A T IN O
preparation CN103099804A T NN O
of CN103099804A T IN O
antitumor CN103099804A T NN O
medicaments CN103099804A T NNS O
. CN103099804A T . O

Preparation CN103550301A T NN O
for CN103550301A T IN O
treating CN103550301A T VBG O
bromhidrosis CN103550301A T NN O
. CN103550301A T . O

Crystalline US20090036530 T NNP O
acid US20090036530 T NN O
of US20090036530 T IN O
lipoxin US20090036530 T NN O
A4 US20090036530 T NNP O
analogs US20090036530 T NNS O
and US20090036530 T CC O
method US20090036530 T NN O
of US20090036530 T IN O
making US20090036530 T VBG O
. US20090036530 T . O

Combination US20110152328 T NNP O
Therapy US20110152328 T NNP O
For US20110152328 T IN O
Glaucoma US20110152328 T NNP O
. US20110152328 T . O

Disclosed US20110152328 A VBN O
herein US20110152328 A NN O
is US20110152328 A VBZ O
method US20110152328 A CD O
of US20110152328 A IN O
treating US20110152328 A VBG O
glaucoma US20110152328 A NN O
or US20110152328 A CC O
ocular US20110152328 A JJ O
hypertension US20110152328 A NN O
comprising US20110152328 A VBG O
administering US20110152328 A VBG O
a US20110152328 A DT O
prostaglandin US20110152328 A JJ O
agonist US20110152328 A NN O
and US20110152328 A CC O
a US20110152328 A DT O
second US20110152328 A JJ O
therapeutically US20110152328 A RB O
active US20110152328 A JJ O
agent US20110152328 A NN O
to US20110152328 A TO O
a US20110152328 A DT O
mammal US20110152328 A NN O
in US20110152328 A IN O
need US20110152328 A NN O
thereof US20110152328 A NN O
, US20110152328 A , O
wherein US20110152328 A NN O
said US20110152328 A VBD O
second US20110152328 A JJ O
therapeutically US20110152328 A RB O
active US20110152328 A JJ O
agent US20110152328 A NN O
is US20110152328 A VBZ O
selected US20110152328 A VBN O
from US20110152328 A IN O
: US20110152328 A : O
β-Blockers US20110152328 A NNS O
, US20110152328 A , O
Adrenergic US20110152328 A NNP O
Agonists US20110152328 A NNP O
, US20110152328 A , O
non-selective US20110152328 A JJ O
adrenergic US20110152328 A NN O
agonists US20110152328 A NNS O
, US20110152328 A , O
α2-selective US20110152328 A JJ O
adrenergic US20110152328 A NN O
agonists US20110152328 A NNS O
, US20110152328 A , O
Carbonic US20110152328 A NNP O
Anhydrase US20110152328 A NNP O
Inhibitors US20110152328 A NNP O
, US20110152328 A , O
Cholinergic US20110152328 A NNP O
Agonists US20110152328 A NNP O
, US20110152328 A , O
direct US20110152328 A JJ O
acting US20110152328 A VBG O
cholinergic US20110152328 A NN O
agonists US20110152328 A NNS O
, US20110152328 A , O
chlolinesterase US20110152328 A NN O
inhibitors US20110152328 A NNS O
, US20110152328 A , O
Glutamate US20110152328 A NNP O
Antagonists US20110152328 A NNP O
, US20110152328 A , O
Ca2+ US20110152328 A NNP O
channel US20110152328 A NN O
blockers US20110152328 A NNS O
, US20110152328 A , O
Prostamides US20110152328 A NNP O
, US20110152328 A , O
Prostaglandins US20110152328 A NNP O
, US20110152328 A , O
Cannabinoids US20110152328 A NNP O
, US20110152328 A , O
and US20110152328 A CC O
combinations US20110152328 A NNS O
thereof US20110152328 A VBP O
. US20110152328 A . O

Compositions US20110152328 A NNS O
and US20110152328 A CC O
medicaments US20110152328 A NNS O
containing US20110152328 A VBG O
a US20110152328 A DT O
combination US20110152328 A NN O
of US20110152328 A IN O
these US20110152328 A DT O
two US20110152328 A CD O
active US20110152328 A JJ O
agents US20110152328 A NNS O
are US20110152328 A VBP O
also US20110152328 A RB O
disclosed US20110152328 A VBN O
. US20110152328 A . O

Male US20070054882 T JJ O
anti-fertility US20070054882 T NN O
agents US20070054882 T NNS O
. US20070054882 T . O

Compounds US7026318 T NNS O
exhibiting US7026318 T VBG O
X-type US7026318 T JJ I-UN
sPLA2 US7026318 T NN I-UN
inhibiting US7026318 T VBG O
effect US7026318 T NN O
. US7026318 T . O

Pyrazolopyridines WO2013004617A1 T NNS O
useful WO2013004617A1 T JJ O
in WO2013004617A1 T IN O
the WO2013004617A1 T DT O
treatment WO2013004617A1 T NN O
of WO2013004617A1 T IN O
disorders WO2013004617A1 T NNS O
of WO2013004617A1 T IN O
the WO2013004617A1 T DT O
central WO2013004617A1 T JJ O
nervous WO2013004617A1 T JJ O
system WO2013004617A1 T NN O
. WO2013004617A1 T . O

The WO2013004617A1 A DT O
compounds WO2013004617A1 A NNS O
referred WO2013004617A1 A VBN O
to WO2013004617A1 A TO O
are WO2013004617A1 A VBP O
positive WO2013004617A1 A JJ O
allosteric WO2013004617A1 A JJ O
modulators WO2013004617A1 A NNS O
( WO2013004617A1 A ( O
PAMs WO2013004617A1 A NNP O
) WO2013004617A1 A ) O
of WO2013004617A1 A IN O
the WO2013004617A1 A DT O
nicotinic WO2013004617A1 A JJ I-UN
acetylcholine WO2013004617A1 A NN I-UN
α7 WO2013004617A1 A NNP I-UN
receptor WO2013004617A1 A NN I-UN
. WO2013004617A1 A . O

Enzyme USRE39682 T NNP O
inhibitors USRE39682 T NNS O
, USRE39682 T , O
for USRE39682 T IN O
cancer USRE39682 T NN O
therapy USRE39682 T NN O
. USRE39682 T . O

Novel USRE39682 A NNP O
farnesyl USRE39682 A NN O
derivatives USRE39682 A NNS O
which USRE39682 A WDT O
are USRE39682 A VBP O
inhibitors USRE39682 A NNS O
of USRE39682 A IN O
the USRE39682 A DT O
prenylated USRE39682 A JJ O
protein USRE39682 A NN O
methyltransferase USRE39682 A NN I-UN
enzyme USRE39682 A NN O
, USRE39682 A , O
and USRE39682 A CC O
useful USRE39682 A JJ O
as USRE39682 A IN O
anti-cancer USRE39682 A JJ O
drugs USRE39682 A NNS O
, USRE39682 A , O
have USRE39682 A VBP O
the USRE39682 A DT O
following USRE39682 A JJ O
formula USRE39682 A NN O
: USRE39682 A : O
wherein USRE39682 A NN O
R1represents USRE39682 A NNS O
farnesyl USRE39682 A VBP O
, USRE39682 A , O
geranyl USRE39682 A JJ O
or USRE39682 A CC O
geranyl-geranyl USRE39682 A JJ O
; USRE39682 A : O
Z USRE39682 A NNP O
represents USRE39682 A VBZ O
C—R6 USRE39682 A NNP O
or USRE39682 A CC O
N USRE39682 A NNP O
; USRE39682 A : O
R2 USRE39682 A NNP O
represents USRE39682 A VBZ O
H USRE39682 A NNP O
, USRE39682 A , O
CN USRE39682 A NNP O
, USRE39682 A , O
the USRE39682 A DT O
groups USRE39682 A NNS O
COOR7 USRE39682 A NNP O
, USRE39682 A , O
SO3R7 USRE39682 A NNP O
, USRE39682 A , O
CONR7R8 USRE39682 A NNP O
and USRE39682 A CC O
SO2NR7R7 USRE39682 A NNP O
, USRE39682 A , O
wherein USRE39682 A NN O
R7 USRE39682 A NNP O
and USRE39682 A CC O
R8 USRE39682 A NNP O
are USRE39682 A VBP O
each USRE39682 A DT O
independently USRE39682 A RB O
hydrogen USRE39682 A NN O
, USRE39682 A , O
alkyl USRE39682 A NN O
, USRE39682 A , O
alkenyl USRE39682 A NN O
, USRE39682 A , O
and USRE39682 A CC O
the USRE39682 A DT O
groups USRE39682 A NNS O
COOM USRE39682 A NNP O
and USRE39682 A CC O
SO3M USRE39682 A NNP O
, USRE39682 A , O
wherein USRE39682 A NN O
M USRE39682 A NNP O
is USRE39682 A VBZ O
a USRE39682 A DT O
cation USRE39682 A NN O
; USRE39682 A : O
R3 USRE39682 A NNP O
, USRE39682 A , O
R4 USRE39682 A NNP O
, USRE39682 A , O
R5 USRE39682 A NNP O
and USRE39682 A CC O
R6 USRE39682 A NNP O
are USRE39682 A VBP O
each USRE39682 A DT O
independently USRE39682 A RB O
hydrogen USRE39682 A NN O
, USRE39682 A , O
carboxyl USRE39682 A NN O
, USRE39682 A , O
alkyl USRE39682 A NN O
, USRE39682 A , O
alkenyl USRE39682 A NN O
, USRE39682 A , O
aminoalkyl USRE39682 A NN O
, USRE39682 A , O
nitroalkyl USRE39682 A RB O
, USRE39682 A , O
nitro USRE39682 A RB O
, USRE39682 A , O
halo USRE39682 A NN O
, USRE39682 A , O
amino USRE39682 A NN O
, USRE39682 A , O
mono- USRE39682 A JJ O
or USRE39682 A CC O
di-alkylamino USRE39682 A NN O
, USRE39682 A , O
mercapto USRE39682 A NN O
, USRE39682 A , O
mercaptoalkyl USRE39682 A NN O
, USRE39682 A , O
azido USRE39682 A NN O
, USRE39682 A , O
or USRE39682 A CC O
thiocyanato USRE39682 A NN O
; USRE39682 A : O
X USRE39682 A CC O
represents USRE39682 A VBZ O
O USRE39682 A NNP O
, USRE39682 A , O
S USRE39682 A NNP O
, USRE39682 A , O
SO USRE39682 A NNP O
, USRE39682 A , O
SO2 USRE39682 A NNP O
, USRE39682 A , O
NH USRE39682 A NNP O
or USRE39682 A CC O
Se USRE39682 A NNP O
; USRE39682 A : O
and USRE39682 A CC O
the USRE39682 A DT O
quaternary USRE39682 A JJ O
ammonium USRE39682 A NN O
salts USRE39682 A NNS O
and USRE39682 A CC O
N-oxides USRE39682 A NNS O
of USRE39682 A IN O
the USRE39682 A DT O
compounds USRE39682 A NNS O
of USRE39682 A IN O
formula USRE39682 A NN O
I USRE39682 A PRP O
wherein USRE39682 A VBP O
Z USRE39682 A NNP O
is USRE39682 A VBZ O
N USRE39682 A NNP O
. USRE39682 A . O

Immediate-release US20090053307 T NNP O
therapeutic US20090053307 T JJ O
systems US20090053307 T NNS O
for US20090053307 T IN O
improved US20090053307 T JJ O
oral US20090053307 T JJ O
absorption US20090053307 T NN O
of US20090053307 T IN O
7- US20090053307 T JJ O
[ US20090053307 T NNP O
( US20090053307 T ( O
e US20090053307 T NN O
) US20090053307 T ) O
] US20090053307 T VBZ O
-t-buty-loxyminomethyl US20090053307 T JJ O
] US20090053307 T NNP O
camptothecin US20090053307 T NN O
. US20090053307 T . O

Hypoglycemic CN101658537B T NNP O
ferment CN101658537B T NN O
compound CN101658537B T NN O
and CN101658537B T CC O
its CN101658537B T PRP$ O
preparation CN101658537B T NN O
method CN101658537B T NN O
. CN101658537B T . O

Pharmaceutical CN101920015A T JJ O
composition CN101920015A T NN O
for CN101920015A T IN O
cancer CN101920015A T NN O
treatment CN101920015A T NN O
. CN101920015A T . O

The CN101920015A A DT O
invention CN101920015A A NN O
relates CN101920015A A VBZ O
to CN101920015A A TO O
the CN101920015A A DT O
field CN101920015A A NN O
of CN101920015A A IN O
medical CN101920015A A JJ O
technology CN101920015A A NN O
, CN101920015A A , O
in CN101920015A A IN O
particular CN101920015A A JJ O
to CN101920015A A TO O
a CN101920015A A DT O
pharmaceutical CN101920015A A JJ O
composition CN101920015A A NN O
for CN101920015A A IN O
cancer CN101920015A A NN O
treatment CN101920015A A NN O
, CN101920015A A , O
which CN101920015A A WDT O
consists CN101920015A A VBZ O
of CN101920015A A IN O
anti-angiogenesis CN101920015A A JJ O
drug CN101920015A A NN O
Avastin CN101920015A A NNP O
and CN101920015A A CC O
autophagy CN101920015A A JJ O
inhibitor CN101920015A A NN O
chloroquine CN101920015A A NN O
. CN101920015A A . O

When CN101920015A A WRB O
in CN101920015A A IN O
use CN101920015A A NN O
, CN101920015A A , O
Avastin CN101920015A A NNP O
and CN101920015A A CC O
chloroquine CN101920015A A NN O
are CN101920015A A VBP O
mixed CN101920015A A JJ O
according CN101920015A A VBG O
to CN101920015A A TO O
respective CN101920015A A JJ O
dose CN101920015A A NN O
, CN101920015A A , O
wherein CN101920015A A VBD O
the CN101920015A A DT O
doses CN101920015A A NNS O
of CN101920015A A IN O
Avastin CN101920015A A NNP O
and CN101920015A A CC O
chloroquine CN101920015A A NN O
are CN101920015A A VBP O
respectively CN101920015A A RB O
7.6mg/kg CN101920015A A CD O
and CN101920015A A CC O
60mg/kg CN101920015A A CD O
calculated CN101920015A A VBD O
according CN101920015A A VBG O
to CN101920015A A TO O
weight CN101920015A A NN O
. CN101920015A A . O

Animal CN101920015A A NNP O
experimental CN101920015A A JJ O
results CN101920015A A NNS O
show CN101920015A A VBP O
that CN101920015A A IN O
the CN101920015A A DT O
pharmaceutical CN101920015A A JJ O
composition CN101920015A A NN O
can CN101920015A A MD O
obviously CN101920015A A RB O
inhibit CN101920015A A VB O
the CN101920015A A DT O
growth CN101920015A A NN O
of CN101920015A A IN O
skin CN101920015A A NN O
cancer CN101920015A A NN O
and CN101920015A A CC O
liver CN101920015A A NN O
cancer CN101920015A A NN O
cells CN101920015A A NNS O
in CN101920015A A IN O
mice CN101920015A A NN O
, CN101920015A A , O
and CN101920015A A CC O
the CN101920015A A DT O
effect CN101920015A A NN O
of CN101920015A A IN O
inhabiting CN101920015A A VBG O
tumors CN101920015A A NNS O
is CN101920015A A VBZ O
obviously CN101920015A A RB O
higher CN101920015A A JJR O
than CN101920015A A IN O
that CN101920015A A DT O
of CN101920015A A IN O
solely CN101920015A A RB O
using CN101920015A A VBG O
Avastin CN101920015A A NNP O
or CN101920015A A CC O
chloroquine CN101920015A A NN O
, CN101920015A A , O
thus CN101920015A A RB O
illustrating CN101920015A A VBG O
that CN101920015A A IN O
the CN101920015A A DT O
Avastin CN101920015A A NNP O
and CN101920015A A CC O
the CN101920015A A DT O
chloroquine CN101920015A A NN O
have CN101920015A A VBP O
the CN101920015A A DT O
function CN101920015A A NN O
of CN101920015A A IN O
synergistic CN101920015A A JJ O
inhibition CN101920015A A NN O
on CN101920015A A IN O
tumor CN101920015A A NN O
growth CN101920015A A NN O
, CN101920015A A , O
therefore CN101920015A A RB O
, CN101920015A A , O
the CN101920015A A DT O
pharmaceutical CN101920015A A JJ O
composition CN101920015A A NN O
can CN101920015A A MD O
be CN101920015A A VB O
used CN101920015A A VBN O
for CN101920015A A IN O
treating CN101920015A A VBG O
tumors CN101920015A A NNS O
. CN101920015A A . O

Amorphous WO2008040816A1 T JJ O
asenapine WO2008040816A1 T NN O
and WO2008040816A1 T CC O
processes WO2008040816A1 T NNS O
for WO2008040816A1 T IN O
preparing WO2008040816A1 T VBG O
same WO2008040816A1 T JJ O
. WO2008040816A1 T . O

A WO2008067781B1 T DT O
method WO2008067781B1 T NN O
of WO2008067781B1 T IN O
purification WO2008067781B1 T NN O
of WO2008067781B1 T IN O
( WO2008067781B1 T ( O
s WO2008067781B1 T NN O
) WO2008067781B1 T ) O
-n-methyl-3- WO2008067781B1 T NN O
( WO2008067781B1 T ( O
1-naphtyloxy WO2008067781B1 T JJ O
) WO2008067781B1 T ) O
-3- WO2008067781B1 T NN O
( WO2008067781B1 T ( O
2-thienyl WO2008067781B1 T JJ O
) WO2008067781B1 T ) O
propylamine WO2008067781B1 T NN O
hydrochloride WO2008067781B1 T NN O
( WO2008067781B1 T ( O
duloxetine WO2008067781B1 T NN O
) WO2008067781B1 T ) O
. WO2008067781B1 T . O

Aminopyridine WO2014106612A1 T NNP O
derived WO2014106612A1 T VBD O
compounds WO2014106612A1 T NNS O
as WO2014106612A1 T IN O
lrrk2 WO2014106612A1 T JJ I-UN
inhibitors WO2014106612A1 T NNS O
. WO2014106612A1 T . O

The WO2014106612A1 A DT O
compounds WO2014106612A1 A NNS O
are WO2014106612A1 A VBP O
considered WO2014106612A1 A VBN O
useful WO2014106612A1 A JJ O
for WO2014106612A1 A IN O
the WO2014106612A1 A DT O
treatment WO2014106612A1 A NN O
of WO2014106612A1 A IN O
diseases WO2014106612A1 A NNS O
associated WO2014106612A1 A VBN O
with WO2014106612A1 A IN O
LRRK2 WO2014106612A1 A NNP I-UN
such WO2014106612A1 A PDT O
a WO2014106612A1 A DT O
Lewy WO2014106612A1 A NNP O
body WO2014106612A1 A NN O
dementia WO2014106612A1 A NN O
, WO2014106612A1 A , O
Parkinson WO2014106612A1 A NNP O
's WO2014106612A1 A POS O
disease WO2014106612A1 A NN O
or WO2014106612A1 A CC O
cancer WO2014106612A1 A NN O
. WO2014106612A1 A . O

Sweet US20110117175 T NNP O
analgesic US20110117175 T NN O
for US20110117175 T IN O
use US20110117175 T NN O
in US20110117175 T IN O
medical US20110117175 T JJ O
procedures US20110117175 T NNS O
or US20110117175 T CC O
treatments US20110117175 T NNS O
. US20110117175 T . O

Pyrrolone-phenyl-oxazolidinone CN103450173A T JJ O
compounds CN103450173A T NNS O
as CN103450173A T RB O
well CN103450173A T RB O
as CN103450173A T IN O
preparation CN103450173A T NN O
methods CN103450173A T NNS O
and CN103450173A T CC O
applications CN103450173A T NNS O
thereof CN103450173A T VBP O
. CN103450173A T . O

Nitrogen US6936617 T NNP O
compounds US6936617 T NNS O
such US6936617 T JJ O
as US6936617 T IN O
6-chloro-3-ethyl-2- US6936617 T JJ O
( US6936617 T ( O
2-thiazol-2-yl US6936617 T JJ O
-imidazol-1-ylmethyl US6936617 T NN O
) US6936617 T ) O
-imidazo US6936617 T NN O
( US6936617 T ( O
1,2-b US6936617 T JJ O
) US6936617 T ) O
pyridazine US6936617 T NN O
used US6936617 T VBN O
for US6936617 T IN O
prophylaxis US6936617 T NN O
of US6936617 T IN O
nervous US6936617 T JJ O
system US6936617 T NN O
disorders US6936617 T NNS O
. US6936617 T . O

This US6936617 A DT O
invention US6936617 A NN O
relates US6936617 A VBZ O
to US6936617 A TO O
heteroaryl US6936617 A VB O
substituted US6936617 A VBN O
fused US6936617 A JJ O
bicyclic US6936617 A JJ O
heteroaryl US6936617 A NN O
compounds US6936617 A NNS O
, US6936617 A , O
such US6936617 A JJ O
as US6936617 A IN O
heteroaryl US6936617 A NN O
substituted US6936617 A VBN O
imidazopyridines US6936617 A NNS O
, US6936617 A , O
imidazopyrazines US6936617 A NNS O
, US6936617 A , O
imidazopyridizines US6936617 A NNS O
, US6936617 A , O
imidazopyrimidines US6936617 A NNS O
, US6936617 A , O
and US6936617 A CC O
imidazothiazoles US6936617 A NNS O
, US6936617 A , O
which US6936617 A WDT O
may US6936617 A MD O
be US6936617 A VB O
described US6936617 A VBN O
by US6936617 A IN O
Formula US6936617 A NNP O
I US6936617 A PRP O
or US6936617 A CC O
Formula US6936617 A NNP O
II US6936617 A NNP O
: US6936617 A : O
The US6936617 A DT O
invention US6936617 A NN O
is US6936617 A VBZ O
particularly US6936617 A RB O
related US6936617 A VBN O
to US6936617 A TO O
such US6936617 A JJ O
compounds US6936617 A NNS O
that US6936617 A WDT O
bind US6936617 A VBP O
with US6936617 A IN O
high US6936617 A JJ O
selectivity US6936617 A NN O
and US6936617 A CC O
high US6936617 A JJ O
affinity US6936617 A NN O
to US6936617 A TO O
the US6936617 A DT O
benzodiazepine US6936617 A NN O
site US6936617 A NN O
of US6936617 A IN O
GABAA US6936617 A NNP I-UN
receptors US6936617 A NNS I-UN
. US6936617 A . O

Additionally US6936617 A RB O
this US6936617 A DT O
invention US6936617 A NN O
relates US6936617 A VBZ O
to US6936617 A TO O
the US6936617 A DT O
use US6936617 A NN O
such US6936617 A JJ O
compounds US6936617 A NNS O
as US6936617 A IN O
probes US6936617 A NNS O
for US6936617 A IN O
the US6936617 A DT O
localization US6936617 A NN O
of US6936617 A IN O
GABAA US6936617 A NNP I-UN
receptors US6936617 A NNS I-UN
in US6936617 A IN O
tissue US6936617 A NN O
sections US6936617 A NNS O
. US6936617 A . O

Scald CN101744922A T NNP O
cream CN101744922A T NN O
and CN101744922A T CC O
preparation CN101744922A T NN O
method CN101744922A T NN O
thereof CN101744922A T NN O
. CN101744922A T . O

Cosmetic WO2013068966A2 T JJ O
composition WO2013068966A2 T NN O
comprising WO2013068966A2 T VBG O
an WO2013068966A2 T DT O
urea WO2013068966A2 T JJ O
or WO2013068966A2 T CC O
amide WO2013068966A2 T JJ O
based WO2013068966A2 T VBN O
alpha-alkoxysilane WO2013068966A2 T NN O
. WO2013068966A2 T . O

Short CN101210037A T JJ O
interference CN101210037A T NN O
ribonucleic CN101210037A T NN O
acid CN101210037A T RB O
pointed CN101210037A T VBD O
to CN101210037A T TO O
human CN101210037A T JJ O
OPN CN101210037A T NNP I-UN
gene CN101210037A T NN O
for CN101210037A T IN O
treating CN101210037A T VBG O
tumor CN101210037A T NN O
gene CN101210037A T NN O
. CN101210037A T . O

The CN101210037A A DT O
invention CN101210037A A NN O
discloses CN101210037A A VBZ O
a CN101210037A A DT O
short CN101210037A A JJ O
interfering CN101210037A A NN O
RNA CN101210037A A NNP O
( CN101210037A A ( O
short CN101210037A A JJ O
interfering CN101210037A A NN O
RNA CN101210037A A NNP O
, CN101210037A A , O
siRNA CN101210037A A NN O
) CN101210037A A ) O
used CN101210037A A VBN O
in CN101210037A A IN O
curing CN101210037A A VBG O
oncogene CN101210037A A JJ O
aiming CN101210037A A VBG O
at CN101210037A A IN O
the CN101210037A A DT O
OPN CN101210037A A NNP I-UN
genes CN101210037A A NNS O
of CN101210037A A IN O
human CN101210037A A JJ O
beings CN101210037A A NNS O
. CN101210037A A . O

The CN101210037A A DT O
OPN CN101210037A A NNP I-UN
genes CN101210037A A NNS O
express CN101210037A A VBD O
a CN101210037A A DT O
multi-functional CN101210037A A JJ O
protein CN101210037A A NN O
, CN101210037A A , O
which CN101210037A A WDT O
attends CN101210037A A VBZ O
the CN101210037A A DT O
production CN101210037A A NN O
and CN101210037A A CC O
diversion CN101210037A A NN O
of CN101210037A A IN O
tumours CN101210037A A NNS O
of CN101210037A A IN O
human CN101210037A A JJ O
beings CN101210037A A NNS O
. CN101210037A A . O

Being CN101210037A A VBG O
proved CN101210037A A VBN O
by CN101210037A A IN O
the CN101210037A A DT O
experiment CN101210037A A NN O
, CN101210037A A , O
the CN101210037A A DT O
growth CN101210037A A NN O
of CN101210037A A IN O
tumour CN101210037A A NN O
cells CN101210037A A NNS O
is CN101210037A A VBZ O
obviously CN101210037A A RB O
restricted CN101210037A A VBN O
after CN101210037A A IN O
the CN101210037A A DT O
expression CN101210037A A NN O
of CN101210037A A IN O
the CN101210037A A DT O
OPN CN101210037A A NNP I-UN
genes CN101210037A A NNS O
is CN101210037A A VBZ O
controlled CN101210037A A VBN O
. CN101210037A A . O

Sovaprevir WO2014144087A1 T NNP O
polymorphs WO2014144087A1 T NN O
and WO2014144087A1 T CC O
methods WO2014144087A1 T NNS O
of WO2014144087A1 T IN O
manufacture WO2014144087A1 T NN O
thereof WO2014144087A1 T NN O
. WO2014144087A1 T . O

Amorphous WO2006127941A9 T JJ O
cinacalcet WO2006127941A9 T NN O
hydrochloride WO2006127941A9 T NN O
and WO2006127941A9 T CC O
preparation WO2006127941A9 T NN O
thereof WO2006127941A9 T NN O
. WO2006127941A9 T . O

( CN103113202A T ( O
2E CN103113202A T CD O
, CN103113202A T , O
5E CN103113202A T CD O
) CN103113202A T ) O
-2 CN103113202A T NN O
, CN103113202A T , O
5-benzal CN103113202A T JJ O
cyclopentanone CN103113202A T NN O
analogue CN103113202A T NN O
and CN103113202A T CC O
preparation CN103113202A T NN O
method CN103113202A T NN O
and CN103113202A T CC O
application CN103113202A T NN O
thereof CN103113202A T NN O
. CN103113202A T . O

In CN103113202A A IN O
addition CN103113202A A NN O
, CN103113202A A , O
the CN103113202A A DT O
invention CN103113202A A NN O
further CN103113202A A RB O
provides CN103113202A A VBZ O
a CN103113202A A DT O
preparation CN103113202A A NN O
method CN103113202A A NN O
of CN103113202A A IN O
the CN103113202A A DT O
compounds CN103113202A A NNS O
and CN103113202A A CC O
an CN103113202A A DT O
application CN103113202A A NN O
thereof CN103113202A A NN O
as CN103113202A A IN O
a CN103113202A A DT O
11beta-hydroxyoxysterooid CN103113202A A JJ I-UN
dehydrogenase CN103113202A A NN I-UN
type CN103113202A A NN I-UN
I CN103113202A A PRP I-UN
, CN103113202A A , O
11b-HSD1 CN103113202A A JJ I-UN
inhibitor CN103113202A A NN O
for CN103113202A A IN O
preventing CN103113202A A VBG O
and CN103113202A A CC O
treating CN103113202A A VBG O
human CN103113202A A JJ O
diabetes CN103113202A A NNS O
. CN103113202A A . O

Stabilization WO2009066138A2 T NN O
of WO2009066138A2 T IN O
vitamin WO2009066138A2 T NN O
b WO2009066138A2 T NN O
complex WO2009066138A2 T NN O
and WO2009066138A2 T CC O
lidocaine WO2009066138A2 T NN O
hydrochloride WO2009066138A2 T NN O
injection WO2009066138A2 T NN O
. WO2009066138A2 T . O

Hepatitis EP2659885A1 T NNP O
C EP2659885A1 T NNP O
Antiviral EP2659885A1 T NNP O
Compositions EP2659885A1 T NNP O
and EP2659885A1 T CC O
Methods EP2659885A1 T NNP O
. EP2659885A1 T . O

Anticancer WO2009151762A2 T NNP O
methods WO2009151762A2 T NNS O
using WO2009151762A2 T VBG O
extracts WO2009151762A2 T NNS O
of WO2009151762A2 T IN O
anemarrhena WO2009151762A2 T NN O
asphodeloides WO2009151762A2 T NNS O
bunge WO2009151762A2 T NN O
. WO2009151762A2 T . O

Heat CN101804093A T NNP O
clearing CN101804093A T VBG O
antidote CN101804093A T NN O
. CN101804093A T . O

Azaindoles EP1490365B1 T NNS O
as EP1490365B1 T IN O
inhibitors EP1490365B1 T NNS O
of EP1490365B1 T IN O
c-jun EP1490365B1 T JJ O
n-terminal EP1490365B1 T JJ O
kinases EP1490365B1 T NNS O
. EP1490365B1 T . O

Method US20090311346 T NNP O
for US20090311346 T IN O
treating US20090311346 T VBG O
acne US20090311346 T NN O
. US20090311346 T . O

Pharmaceutical CN101513409B T JJ O
composition CN101513409B T NN O
of CN101513409B T IN O
cephalexin CN101513409B T NN O
. CN101513409B T . O

Novel US20080227786 T NNP O
Crystalline US20080227786 T NNP O
Salts US20080227786 T NNP O
of US20080227786 T IN O
a US20080227786 T DT O
Dipeptidyl US20080227786 T NNP I-UN
Peptidase-IV US20080227786 T NNP I-UN
Inhibitor US20080227786 T NNP O
. US20080227786 T . O

Novel US20080227786 A NNP O
crystalline US20080227786 A NN O
salts US20080227786 A NNS O
of US20080227786 A IN O
( US20080227786 A ( O
2R US20080227786 A CD O
) US20080227786 A ) O
-4-oxo-4- US20080227786 A NN O
[ US20080227786 A JJ O
3- US20080227786 A JJ O
( US20080227786 A ( O
trifluoromethyl US20080227786 A NN O
) US20080227786 A ) O
-5,6-dihydro US20080227786 A VBZ O
[ US20080227786 A $ O
1,2,4 US20080227786 A CD O
] US20080227786 A NNP O
triazolo US20080227786 A NN O
[ US20080227786 A NNP O
4,3-a US20080227786 A JJ O
] US20080227786 A NNP O
pyrazin-7 US20080227786 A NN O
( US20080227786 A ( O
8H US20080227786 A CD O
) US20080227786 A ) O
-yl US20080227786 A NN O
] US20080227786 A JJ O
-1- US20080227786 A NNP O
( US20080227786 A ( O
2,4,5-trifluorophenyl US20080227786 A JJ O
) US20080227786 A ) O
butan-2- US20080227786 A NN O
& US20080227786 A CC O
agr US20080227786 A NN O
; US20080227786 A : O
amine US20080227786 A CC O
are US20080227786 A VBP O
potent US20080227786 A JJ O
inhibitors US20080227786 A NNS O
of US20080227786 A IN O
dipeptidyl US20080227786 A JJ I-UN
peptidase-IV US20080227786 A NN I-UN
and US20080227786 A CC O
are US20080227786 A VBP O
useful US20080227786 A JJ O
for US20080227786 A IN O
the US20080227786 A DT O
treatment US20080227786 A NN O
of US20080227786 A IN O
non-insulin US20080227786 A JJ O
dependent US20080227786 A NN O
( US20080227786 A ( O
Type US20080227786 A NNP O
2 US20080227786 A CD O
) US20080227786 A ) O
diabetes US20080227786 A VBZ O
mellitus US20080227786 A NN O
. US20080227786 A . O

4'-fluoro WO2014099941A1 T JJ O
nucleosides WO2014099941A1 T NNS O
for WO2014099941A1 T IN O
the WO2014099941A1 T DT O
treatment WO2014099941A1 T NN O
of WO2014099941A1 T IN O
hcv WO2014099941A1 T NN O
. WO2014099941A1 T . O

Use US20100086556 T NNP O
of US20100086556 T IN O
hemagglutinin US20100086556 T NN O
of US20100086556 T IN O
the US20100086556 T DT O
african US20100086556 T JJ O
swine US20100086556 T NN O
fever US20100086556 T NN O
virus US20100086556 T NN O
as US20100086556 T IN O
an US20100086556 T DT O
adjuvant US20100086556 T NN O
. US20100086556 T . O

Compositions EP1059930B1 T NNS O
comprising EP1059930B1 T VBG O
isovaleramide EP1059930B1 T NN O
and EP1059930B1 T CC O
ibuprofen EP1059930B1 T NN O
. EP1059930B1 T . O

Gemcitabine US20100016254 T NNP O
prodrugs US20100016254 T NN O
, US20100016254 T , O
pharmaceutical US20100016254 T JJ O
compositions US20100016254 T NNS O
and US20100016254 T CC O
uses US20100016254 T VBZ O
thereof US20100016254 T NN O
. US20100016254 T . O

Treatment WO2008040967A1 T NN O
of WO2008040967A1 T IN O
fibrosis WO2008040967A1 T NN O
. WO2008040967A1 T . O

Application CN102872084A T NN O
of CN102872084A T IN O
Houttuynoid CN102872084A T NNP O
B CN102872084A T NNP O
in CN102872084A T IN O
medicines CN102872084A T NNS O
for CN102872084A T IN O
inhibiting CN102872084A T VBG O
pulmonary CN102872084A T JJ O
metastasis CN102872084A T NN O
. CN102872084A T . O

New WO2011080266A1 T NNP O
secondary WO2011080266A1 T JJ O
8-hydroxyquinoline-7-carboxamide WO2011080266A1 T JJ O
derivatives.. WO2011080266A1 T NN O

Heterodimers US20080193381 T NNS O
of US20080193381 T IN O
glutamic US20080193381 T JJ O
acid US20080193381 T NN O
. US20080193381 T . O

Compounds US20080193381 A NNS O
of US20080193381 A IN O
Formula US20080193381 A NNP O
( US20080193381 A ( O
Ia US20080193381 A NNP O
) US20080193381 A ) O
wherein US20080193381 A NN O
R US20080193381 A NNP O
is US20080193381 A VBZ O
a US20080193381 A DT O
C6-C12 US20080193381 A JJ O
substituted US20080193381 A JJ O
or US20080193381 A CC O
unsubstituted US20080193381 A JJ O
aryl US20080193381 A NN O
, US20080193381 A , O
a US20080193381 A DT O
C6-C12 US20080193381 A NNP O
substituted US20080193381 A VBD O
or US20080193381 A CC O
unsubstituted US20080193381 A JJ O
heteroaryl US20080193381 A NN O
, US20080193381 A , O
a US20080193381 A DT O
C1-C6 US20080193381 A NNP O
substituted US20080193381 A VBD O
or US20080193381 A CC O
unsubstituted US20080193381 A JJ O
alkyl US20080193381 A NN O
or US20080193381 A CC O
—NR′R′ US20080193381 A NN O
, US20080193381 A , O
Q US20080193381 A NNP O
is US20080193381 A VBZ O
C US20080193381 A NNP O
( US20080193381 A ( O
O US20080193381 A NNP O
) US20080193381 A ) O
, US20080193381 A , O
O US20080193381 A NNP O
, US20080193381 A , O
NR′ US20080193381 A NNP O
, US20080193381 A , O
S US20080193381 A NNP O
, US20080193381 A , O
S US20080193381 A NNP O
( US20080193381 A ( O
O US20080193381 A NNP O
) US20080193381 A ) O
2 US20080193381 A CD O
, US20080193381 A , O
C US20080193381 A NNP O
( US20080193381 A ( O
O US20080193381 A NNP O
) US20080193381 A ) O
2 US20080193381 A CD O
( US20080193381 A ( O
CH2 US20080193381 A NNP O
) US20080193381 A ) O
p US20080193381 A NN O
Y US20080193381 A NNP O
is US20080193381 A VBZ O
C US20080193381 A NNP O
( US20080193381 A ( O
O US20080193381 A NNP O
) US20080193381 A ) O
, US20080193381 A , O
O US20080193381 A NNP O
, US20080193381 A , O
NR′ US20080193381 A NNP O
, US20080193381 A , O
S US20080193381 A NNP O
, US20080193381 A , O
S US20080193381 A NNP O
( US20080193381 A ( O
O US20080193381 A NNP O
) US20080193381 A ) O
2 US20080193381 A CD O
, US20080193381 A , O
C US20080193381 A NNP O
( US20080193381 A ( O
O US20080193381 A NNP O
) US20080193381 A ) O
2 US20080193381 A CD O
( US20080193381 A ( O
CH2 US20080193381 A NNP O
) US20080193381 A ) O
p US20080193381 A NN O
Z US20080193381 A NNP O
is US20080193381 A VBZ O
H US20080193381 A NNP O
or US20080193381 A CC O
C1-C4 US20080193381 A NNP O
alkyl US20080193381 A NN O
, US20080193381 A , O
R′ US20080193381 A NNP O
is US20080193381 A VBZ O
H US20080193381 A NNP O
, US20080193381 A , O
C US20080193381 A NNP O
( US20080193381 A ( O
O US20080193381 A NNP O
) US20080193381 A ) O
, US20080193381 A , O
S US20080193381 A NNP O
( US20080193381 A ( O
O US20080193381 A NNP O
) US20080193381 A ) O
2 US20080193381 A CD O
, US20080193381 A , O
C US20080193381 A NNP O
( US20080193381 A ( O
O US20080193381 A NNP O
) US20080193381 A ) O
2 US20080193381 A CD O
, US20080193381 A , O
a US20080193381 A DT O
C6-C12 US20080193381 A NNP O
substituted US20080193381 A VBD O
or US20080193381 A CC O
unsubstituted US20080193381 A JJ O
aryl US20080193381 A NN O
, US20080193381 A , O
a US20080193381 A DT O
C6-C12 US20080193381 A NNP O
substituted US20080193381 A VBD O
or US20080193381 A CC O
unsubstituted US20080193381 A JJ O
heteroaryl US20080193381 A NN O
or US20080193381 A CC O
a US20080193381 A DT O
C1-C6 US20080193381 A JJ O
substituted US20080193381 A JJ O
or US20080193381 A CC O
unsubstituted US20080193381 A JJ O
alkyl US20080193381 A NN O
, US20080193381 A , O
when US20080193381 A WRB O
substituted US20080193381 A VBN O
, US20080193381 A , O
aryl US20080193381 A RB O
, US20080193381 A , O
heteroaryl US20080193381 A NN O
and US20080193381 A CC O
alkyl US20080193381 A NN O
are US20080193381 A VBP O
substituted US20080193381 A VBN O
with US20080193381 A IN O
halogen US20080193381 A NN O
, US20080193381 A , O
C6-C12 US20080193381 A NNP O
heteroaryl US20080193381 A NN O
, US20080193381 A , O
—NR′R′ US20080193381 A '' O
or US20080193381 A CC O
COOZ US20080193381 A NNP O
, US20080193381 A , O
which US20080193381 A WDT O
have US20080193381 A VBP O
diagnostic US20080193381 A JJ O
and US20080193381 A CC O
therapeutic US20080193381 A JJ O
properties US20080193381 A NNS O
, US20080193381 A , O
such US20080193381 A JJ O
as US20080193381 A IN O
the US20080193381 A DT O
treatment US20080193381 A NN O
and US20080193381 A CC O
management US20080193381 A NN O
of US20080193381 A IN O
prostate US20080193381 A NN O
cancer US20080193381 A NN O
and US20080193381 A CC O
other US20080193381 A JJ O
diseases US20080193381 A NNS O
related US20080193381 A VBN O
to US20080193381 A TO O
NAALADase US20080193381 A NNP I-UN
inhibition US20080193381 A NN O
. US20080193381 A . O

Pyridazine WO2013019938A1 T NNP O
derivatives WO2013019938A1 T NNS O
as WO2013019938A1 T IN O
eaat2 WO2013019938A1 T JJ I-UN
activators WO2013019938A1 T NNS O
. WO2013019938A1 T . O

Pyridazine WO2013019938A1 A NNP O
derivatives WO2013019938A1 A VBZ O
that WO2013019938A1 A WDT O
activate WO2013019938A1 A VBP O
the WO2013019938A1 A DT O
excitatory WO2013019938A1 A NN I-UN
amino WO2013019938A1 A NN I-UN
acid WO2013019938A1 A VBP I-UN
transporter WO2013019938A1 A NN I-UN
2 WO2013019938A1 A CD I-UN
( WO2013019938A1 A ( O
EAAT2 WO2013019938A1 A NNP I-UN
) WO2013019938A1 A ) O
, WO2013019938A1 A , O
and WO2013019938A1 A CC O
methods WO2013019938A1 A NNS O
of WO2013019938A1 A IN O
use WO2013019938A1 A NN O
thereof WO2013019938A1 A NN O
for WO2013019938A1 A IN O
treating WO2013019938A1 A VBG O
or WO2013019938A1 A CC O
preventing WO2013019938A1 A VBG O
diseases WO2013019938A1 A NNS O
, WO2013019938A1 A , O
disorders WO2013019938A1 A NNS O
, WO2013019938A1 A , O
and WO2013019938A1 A CC O
conditions WO2013019938A1 A NNS O
associated WO2013019938A1 A VBN O
with WO2013019938A1 A IN O
glutamate WO2013019938A1 A JJ O
excitotoxicity WO2013019938A1 A NN O
. WO2013019938A1 A . O

Nitrogen-containing WO2005061492A1 T JJ O
heterocyclic WO2005061492A1 T JJ O
compounds WO2005061492A1 T NNS O
and WO2005061492A1 T CC O
drugs WO2005061492A1 T NNS O
comprising WO2005061492A1 T VBG O
the WO2005061492A1 T DT O
same WO2005061492A1 T JJ O
as WO2005061492A1 T IN O
the WO2005061492A1 T DT O
active WO2005061492A1 T JJ O
ingredient WO2005061492A1 T NN O
. WO2005061492A1 T . O

Because WO2005061492A1 A IN O
of WO2005061492A1 A IN O
having WO2005061492A1 A VBG O
a WO2005061492A1 A DT O
potent WO2005061492A1 A JJ O
agonism WO2005061492A1 A NN O
to WO2005061492A1 A TO O
EP2 WO2005061492A1 A NNP I-UN
and WO2005061492A1 A CC O
a WO2005061492A1 A DT O
potent WO2005061492A1 A JJ O
effect WO2005061492A1 A NN O
of WO2005061492A1 A IN O
lowering WO2005061492A1 A VBG O
ocular WO2005061492A1 A JJ O
tension WO2005061492A1 A NN O
while WO2005061492A1 A IN O
little WO2005061492A1 A JJ O
irritating WO2005061492A1 A VBG O
the WO2005061492A1 A DT O
eye WO2005061492A1 A NN O
, WO2005061492A1 A , O
these WO2005061492A1 A DT O
compounds WO2005061492A1 A NNS O
are WO2005061492A1 A VBP O
useful WO2005061492A1 A JJ O
in WO2005061492A1 A IN O
treating WO2005061492A1 A VBG O
eye WO2005061492A1 A NN O
diseases WO2005061492A1 A NNS O
such WO2005061492A1 A JJ O
as WO2005061492A1 A IN O
glaucoma WO2005061492A1 A NN O
, WO2005061492A1 A , O
ocular WO2005061492A1 A JJ O
hypertension WO2005061492A1 A NN O
, WO2005061492A1 A , O
macular WO2005061492A1 A JJ O
edema WO2005061492A1 A NN O
, WO2005061492A1 A , O
macular WO2005061492A1 A JJ O
degeneration WO2005061492A1 A NN O
, WO2005061492A1 A , O
blood WO2005061492A1 A NN O
flow WO2005061492A1 A NN O
loss WO2005061492A1 A NN O
in WO2005061492A1 A IN O
retinal WO2005061492A1 A JJ O
and WO2005061492A1 A CC O
optic WO2005061492A1 A JJ O
nerve WO2005061492A1 A NN O
papillae WO2005061492A1 A NN O
, WO2005061492A1 A , O
retinal WO2005061492A1 A JJ O
and WO2005061492A1 A CC O
optic WO2005061492A1 A JJ O
nerve WO2005061492A1 A NN O
hypertension WO2005061492A1 A NN O
, WO2005061492A1 A , O
myopia WO2005061492A1 A NN O
, WO2005061492A1 A , O
hyperopia WO2005061492A1 A NN O
, WO2005061492A1 A , O
astigma WO2005061492A1 A NN O
, WO2005061492A1 A , O
dry WO2005061492A1 A JJ O
eye WO2005061492A1 A NN O
, WO2005061492A1 A , O
retinal WO2005061492A1 A JJ O
detachment WO2005061492A1 A NN O
, WO2005061492A1 A , O
cataract WO2005061492A1 A NN O
and WO2005061492A1 A CC O
so WO2005061492A1 A RB O
on WO2005061492A1 A IN O
. WO2005061492A1 A . O

Treatment EP1971230A2 T NN O
of EP1971230A2 T IN O
stressed EP1971230A2 T JJ O
patients EP1971230A2 T NNS O
. EP1971230A2 T . O

Use WO2012061931A1 T NNP O
of WO2012061931A1 T IN O
geniposide WO2012061931A1 T NN O
in WO2012061931A1 T IN O
diabetes WO2012061931A1 T NNS O
prevention WO2012061931A1 T NN O
. WO2012061931A1 T . O

Heterocyclic CA2644356A1 T NNP O
organic CA2644356A1 T JJ O
compounds CA2644356A1 T NNS O
for CA2644356A1 T IN O
the CA2644356A1 T DT O
treatment CA2644356A1 T NN O
of CA2644356A1 T IN O
in CA2644356A1 T IN O
particular CA2644356A1 T JJ O
melanoma CA2644356A1 T NN O
. CA2644356A1 T . O

The CA2644356A1 A DT O
present CA2644356A1 A JJ O
invention CA2644356A1 A NN O
relates CA2644356A1 A VBZ O
to CA2644356A1 A TO O
the CA2644356A1 A DT O
discovery CA2644356A1 A NN O
that CA2644356A1 A WDT O
certain CA2644356A1 A JJ O
compounds CA2644356A1 A NNS O
inhibit CA2644356A1 A NN O
, CA2644356A1 A , O
regulate CA2644356A1 A VB O
and/or CA2644356A1 A JJ O
modulate CA2644356A1 A NN O
tyrosine CA2644356A1 A NN O
and CA2644356A1 A CC O
serine/threonine CA2644356A1 A JJ O
kinase CA2644356A1 A NN O
and CA2644356A1 A CC O
kinase-like CA2644356A1 A JJ O
proteins CA2644356A1 A NNS O
, CA2644356A1 A , O
such CA2644356A1 A JJ O
as CA2644356A1 A IN O
RAF CA2644356A1 A NNP I-UN
kinase CA2644356A1 A NN O
, CA2644356A1 A , O
a CA2644356A1 A DT O
serine/threonine CA2644356A1 A JJ O
kinase CA2644356A1 A NN O
that CA2644356A1 A WDT O
functions CA2644356A1 A NNS O
in CA2644356A1 A IN O
the CA2644356A1 A DT O
MAP CA2644356A1 A NNP O
kinase CA2644356A1 A NN O
signaling CA2644356A1 A VBG O
pathway CA2644356A1 A NN O
, CA2644356A1 A , O
and CA2644356A1 A CC O
is CA2644356A1 A VBZ O
concerned CA2644356A1 A VBN O
with CA2644356A1 A IN O
compositions CA2644356A1 A NNS O
which CA2644356A1 A WDT O
contain CA2644356A1 A VBP O
these CA2644356A1 A DT O
compounds CA2644356A1 A NNS O
, CA2644356A1 A , O
and CA2644356A1 A CC O
methods CA2644356A1 A NNS O
of CA2644356A1 A IN O
using CA2644356A1 A VBG O
them CA2644356A1 A PRP O
to CA2644356A1 A TO O
treat CA2644356A1 A VB O
tyrosine CA2644356A1 A NN O
and CA2644356A1 A CC O
serine/threonine CA2644356A1 A JJ O
kinase CA2644356A1 A NN O
and CA2644356A1 A CC O
kinase-like CA2644356A1 A JJ O
dependent CA2644356A1 A NN O
diseases CA2644356A1 A NNS O
, CA2644356A1 A , O
such CA2644356A1 A JJ O
as CA2644356A1 A IN O
angiogenesis CA2644356A1 A NN O
, CA2644356A1 A , O
cancer CA2644356A1 A NN O
and CA2644356A1 A CC O
cardiac CA2644356A1 A JJ O
hypertrophy CA2644356A1 A NN O
. CA2644356A1 A . O

Methods US20100113374 T NNS O
and US20100113374 T CC O
related US20100113374 T JJ O
compositions US20100113374 T NNS O
using US20100113374 T VBG O
specific US20100113374 T JJ O
flavonoids US20100113374 T NNS O
and US20100113374 T CC O
indanes US20100113374 T NNS O
to US20100113374 T TO O
reduce US20100113374 T VB O
weight US20100113374 T NN O
and US20100113374 T CC O
inhibit US20100113374 T NN O
lipase US20100113374 T NN I-UN
, US20100113374 T , O
alpha-amylase US20100113374 T JJ I-UN
and US20100113374 T CC O
alpha-glucosidase US20100113374 T JJ I-UN
activity US20100113374 T NN O
in US20100113374 T IN O
mammals US20100113374 T NNS O
. US20100113374 T . O

The US20100113374 A DT O
present US20100113374 A JJ O
invention US20100113374 A NN O
relates US20100113374 A VBZ O
generally US20100113374 A RB O
to US20100113374 A TO O
methods US20100113374 A NNS O
and US20100113374 A CC O
related US20100113374 A JJ O
compositions US20100113374 A NNS O
using US20100113374 A VBG O
flavonoids US20100113374 A NNS O
and/or US20100113374 A JJ O
indanes US20100113374 A NNS O
extracted US20100113374 A VBN O
from US20100113374 A IN O
the US20100113374 A DT O
stems US20100113374 A NNS O
and US20100113374 A CC O
leaves US20100113374 A NNS O
of US20100113374 A IN O
C. US20100113374 A NNP O
quadrangularis US20100113374 A NN O
to US20100113374 A TO O
reduce US20100113374 A VB O
weight US20100113374 A NN O
and US20100113374 A CC O
inhibit US20100113374 A NN O
lipase US20100113374 A NN I-UN
, US20100113374 A , O
α-amylase US20100113374 A JJ I-UN
and US20100113374 A CC O
α-glucosidase US20100113374 A JJ I-UN
activity US20100113374 A NN O
in US20100113374 A IN O
mammals US20100113374 A NNS O
. US20100113374 A . O

By US20100113374 A IN O
example US20100113374 A NN O
and US20100113374 A CC O
not US20100113374 A RB O
by US20100113374 A IN O
way US20100113374 A NN O
of US20100113374 A IN O
limitation US20100113374 A NN O
, US20100113374 A , O
embodiments US20100113374 A NNS O
of US20100113374 A IN O
the US20100113374 A DT O
present US20100113374 A JJ O
disclosure US20100113374 A NN O
, US20100113374 A , O
a US20100113374 A DT O
composition US20100113374 A NN O
and US20100113374 A CC O
related US20100113374 A JJ O
methods US20100113374 A NNS O
for US20100113374 A IN O
reducing US20100113374 A VBG O
body US20100113374 A NN O
weight US20100113374 A VBD O
and/or US20100113374 A JJ O
inhibiting US20100113374 A VBG O
any US20100113374 A DT O
combination US20100113374 A NN O
of US20100113374 A IN O
lipase US20100113374 A NN I-UN
, US20100113374 A , O
α-amylase US20100113374 A JJ I-UN
and US20100113374 A CC O
α-glucosidase US20100113374 A JJ I-UN
is US20100113374 A VBZ O
provided US20100113374 A VBN O
. US20100113374 A . O

Bicyclic US20110054040 T NNP O
Triterpenoid US20110054040 T NNP O
Iripallidal US20110054040 T NNP O
as US20110054040 T IN O
a US20110054040 T DT O
Novel US20110054040 T NNP O
Anti-Glioma US20110054040 T NNP O
and US20110054040 T CC O
Anti-Neoplastic US20110054040 T JJ O
Therapy US20110054040 T NNP O
. US20110054040 T . O

This US20110054040 A DT O
invention US20110054040 A NN O
relates US20110054040 A VBZ O
to US20110054040 A TO O
a US20110054040 A DT O
Bicyclic US20110054040 A NNP O
triterpenoid US20110054040 A NN O
Iripallidal US20110054040 A NNP O
as US20110054040 A IN O
a US20110054040 A DT O
novel US20110054040 A JJ O
anti-glioma US20110054040 A NN O
and US20110054040 A CC O
anti US20110054040 A JJ O
neoplastic US20110054040 A JJ O
agent US20110054040 A NN O
, US20110054040 A , O
having US20110054040 A VBG O
the US20110054040 A DT O
composition US20110054040 A NN O
[ US20110054040 A NNP O
( US20110054040 A ( O
− US20110054040 A NNP O
) US20110054040 A ) O
( US20110054040 A ( O
6R,10S,11S,18R,22S US20110054040 A CD O
) US20110054040 A ) O
-26 US20110054040 A CD O
Hydroxy-22-α US20110054040 A JJ O
methylcyloirid-16-enal US20110054040 A JJ O
NSC US20110054040 A NNP O
631939 US20110054040 A CD O
] US20110054040 A NNP O
, US20110054040 A , O
wherein US20110054040 A VBD O
it US20110054040 A PRP O
binds US20110054040 A VBZ O
to US20110054040 A TO O
Ras US20110054040 A NNP I-UN
GRP3 US20110054040 A NNP I-UN
, US20110054040 A , O
a US20110054040 A DT O
phorbol US20110054040 A NN O
ester US20110054040 A NN O
receptor US20110054040 A NN O
that US20110054040 A WDT O
links US20110054040 A VBZ O
DAG/phorbolester US20110054040 A NNP O
signaling US20110054040 A VBG O
with US20110054040 A IN O
Ras US20110054040 A NNP I-UN
activation US20110054040 A NN O
and US20110054040 A CC O
induces US20110054040 A NNS O
phosphorylation US20110054040 A NN O
of US20110054040 A IN O
ER US20110054040 A NNP I-UN
K1/2 US20110054040 A NNP I-UN
in US20110054040 A IN O
a US20110054040 A DT I-UN
Ras US20110054040 A NNP I-UN
dependent US20110054040 A JJ O
manner US20110054040 A NN O
, US20110054040 A , O
reducing US20110054040 A VBG O
proliferation US20110054040 A NN O
of US20110054040 A IN O
cancer US20110054040 A NN O
cell US20110054040 A NN O
lines US20110054040 A NNS O
to US20110054040 A TO O
the US20110054040 A DT O
extent US20110054040 A NN O
of US20110054040 A IN O
50-70 US20110054040 A JJ O
% US20110054040 A NN O
. US20110054040 A . O

Compounds EP2094673A1 T NNS O
and EP2094673A1 T CC O
methods EP2094673A1 T NNS O
for EP2094673A1 T IN O
inhibiting EP2094673A1 T VBG O
the EP2094673A1 T DT O
interaction EP2094673A1 T NN O
of EP2094673A1 T IN O
bcl EP2094673A1 T NN O
proteins EP2094673A1 T NNS O
with EP2094673A1 T IN O
binding EP2094673A1 T VBG O
partners EP2094673A1 T NNS O
. EP2094673A1 T . O

Mglur5 WO2007130821A3 T NNP I-UN
modulators WO2007130821A3 T NNS O
ii WO2007130821A3 T VBP O
. WO2007130821A3 T . O

Coated US20100316589 T NNP O
Pharmaceutical US20100316589 T NNP O
Compositions US20100316589 T NNP O
. US20100316589 T . O

Amorphous US20070259857 T JJ O
form US20070259857 T NN O
of US20070259857 T IN O
Olanzapine US20070259857 T NNP O
. US20070259857 T . O

Pyrimidine EP2142516A1 T NNP O
hydrazide EP2142516A1 T NN O
compounds EP2142516A1 T VBZ O
as EP2142516A1 T IN O
pgds EP2142516A1 T NN I-UN
inhibitors EP2142516A1 T NNS O
. EP2142516A1 T . O

Pyrrolidine WO2010123006A1 T NNP O
compound WO2010123006A1 T NN O
. WO2010123006A1 T . O

Quinolinone US20120115885 T CD O
PDE2 US20120115885 T NNP I-UN
Inhibitors US20120115885 T NNPS O
. US20120115885 T . O

The US20120115885 A DT O
present US20120115885 A JJ O
invention US20120115885 A NN O
is US20120115885 A VBZ O
directed US20120115885 A VBN O
to US20120115885 A TO O
quinolinone US20120115885 A VB O
compounds US20120115885 A NNS O
which US20120115885 A WDT O
are US20120115885 A VBP O
useful US20120115885 A JJ O
as US20120115885 A IN O
therapeutic US20120115885 A JJ O
agents US20120115885 A NNS O
for US20120115885 A IN O
the US20120115885 A DT O
treatment US20120115885 A NN O
of US20120115885 A IN O
central US20120115885 A JJ O
nervous US20120115885 A JJ O
system US20120115885 A NN O
disorders US20120115885 A NNS O
associated US20120115885 A VBN O
with US20120115885 A IN O
phosphodiesterase US20120115885 A NN I-UN
2 US20120115885 A CD I-UN
( US20120115885 A ( O
PDE2 US20120115885 A NNP I-UN
) US20120115885 A ) O
. US20120115885 A . O

Oral WO2006072878A1 T JJ O
dosage WO2006072878A1 T NN O
forms WO2006072878A1 T NNS O
of WO2006072878A1 T IN O
sertraline WO2006072878A1 T NN O
having WO2006072878A1 T VBG O
controlled WO2006072878A1 T VBN O
particle WO2006072878A1 T NN O
size WO2006072878A1 T NN O
and WO2006072878A1 T CC O
processes WO2006072878A1 T NNS O
for WO2006072878A1 T IN O
their WO2006072878A1 T PRP$ O
preparation WO2006072878A1 T NN O
. WO2006072878A1 T . O

Mushroom CN101732256A T NNP O
polysaccharide CN101732256A T NN O
chitosan CN101732256A T NN O
nanoparticle CN101732256A T NN O
and CN101732256A T CC O
preparation CN101732256A T NN O
method CN101732256A T NN O
thereof CN101732256A T NN O
. CN101732256A T . O

Method CN103054972A T NNP O
of CN103054972A T IN O
extracting CN103054972A T VBG O
oleanolic CN103054972A T JJ O
acid CN103054972A T NN O
and CN103054972A T CC O
ursolic CN103054972A T JJ O
acid CN103054972A T NN O
from CN103054972A T IN O
pawpaw CN103054972A T NN O
. CN103054972A T . O

Oxidative CA2834341A1 T JJ O
retinal CA2834341A1 T JJ O
diseases CA2834341A1 T NNS O
. CA2834341A1 T . O

Treatment WO2009035534A3 T NN O
of WO2009035534A3 T IN O
ischemic WO2009035534A3 T JJ O
eye WO2009035534A3 T NN O
disease WO2009035534A3 T NN O
by WO2009035534A3 T IN O
the WO2009035534A3 T DT O
systematic WO2009035534A3 T JJ O
pharmaceutical WO2009035534A3 T JJ O
activation WO2009035534A3 T NN O
of WO2009035534A3 T IN O
hypoxia WO2009035534A3 T NN O
inducible WO2009035534A3 T JJ O
factor WO2009035534A3 T NN O
( WO2009035534A3 T ( O
hif WO2009035534A3 T NN O
) WO2009035534A3 T ) O
. WO2009035534A3 T . O

The WO2009035534A3 A DT O
present WO2009035534A3 A JJ O
invention WO2009035534A3 A NN O
consists WO2009035534A3 A VBZ O
of WO2009035534A3 A IN O
a WO2009035534A3 A DT O
method WO2009035534A3 A NN O
of WO2009035534A3 A IN O
treating WO2009035534A3 A VBG O
a WO2009035534A3 A DT O
subject WO2009035534A3 A NN O
with WO2009035534A3 A IN O
an WO2009035534A3 A DT O
ischemic WO2009035534A3 A JJ O
eye WO2009035534A3 A NN O
disease WO2009035534A3 A NN O
associated WO2009035534A3 A VBN O
with WO2009035534A3 A IN O
the WO2009035534A3 A DT O
down-regulation WO2009035534A3 A NN O
of WO2009035534A3 A IN O
HIF WO2009035534A3 A NNP O
comprising WO2009035534A3 A VBG O
administering WO2009035534A3 A VBG O
to WO2009035534A3 A TO O
the WO2009035534A3 A DT O
subject WO2009035534A3 A NN O
an WO2009035534A3 A DT O
effective WO2009035534A3 A JJ O
amount WO2009035534A3 A NN O
of WO2009035534A3 A IN O
a WO2009035534A3 A DT O
compound WO2009035534A3 A NN O
that WO2009035534A3 A WDT O
induces WO2009035534A3 A VBZ O
HIF WO2009035534A3 A NNP O
activity WO2009035534A3 A NN O
and/or WO2009035534A3 A NN O
induces WO2009035534A3 A NNS O
EPO WO2009035534A3 A NNP I-UN
activity WO2009035534A3 A NN O
to WO2009035534A3 A TO O
induce WO2009035534A3 A VB O
and WO2009035534A3 A CC O
maintain WO2009035534A3 A VB O
growth WO2009035534A3 A NN O
or WO2009035534A3 A CC O
normal WO2009035534A3 A JJ O
retinal WO2009035534A3 A JJ O
blood WO2009035534A3 A NN O
vessels WO2009035534A3 A NNS O
in WO2009035534A3 A IN O
the WO2009035534A3 A DT O
early WO2009035534A3 A JJ O
stage WO2009035534A3 A NN O
of WO2009035534A3 A IN O
the WO2009035534A3 A DT O
disease WO2009035534A3 A NN O
. WO2009035534A3 A . O

Skin CN101084868A T NNP O
beauty CN101084868A T NN O
water CN101084868A T NN O
. CN101084868A T . O

Combinations WO2009067607A2 T NNS O
of WO2009067607A2 T IN O
pde4 WO2009067607A2 T NN O
inhibitors WO2009067607A2 T NNS O
and WO2009067607A2 T CC O
antipsychotics WO2009067607A2 T NNS O
for WO2009067607A2 T IN O
the WO2009067607A2 T DT O
treatment WO2009067607A2 T NN O
of WO2009067607A2 T IN O
psychotic WO2009067607A2 T JJ O
disorders WO2009067607A2 T NNS O
. WO2009067607A2 T . O

The WO2009067607A2 A DT O
invention WO2009067607A2 A NN O
relates WO2009067607A2 A VBZ O
to WO2009067607A2 A TO O
methods WO2009067607A2 A NNS O
and WO2009067607A2 A CC O
compositions WO2009067607A2 A NNS O
for WO2009067607A2 A IN O
treating WO2009067607A2 A VBG O
a WO2009067607A2 A DT O
psychotic WO2009067607A2 A JJ O
disorder WO2009067607A2 A NN O
or WO2009067607A2 A CC O
condition WO2009067607A2 A NN O
, WO2009067607A2 A , O
associated WO2009067607A2 A VBN O
with WO2009067607A2 A IN O
cognitive WO2009067607A2 A JJ O
impairment WO2009067607A2 A NN O
. WO2009067607A2 A . O

The WO2009067607A2 A DT O
pharmaceutical WO2009067607A2 A JJ O
composition WO2009067607A2 A NN O
comprises WO2009067607A2 A NNS O
: WO2009067607A2 A : O
( WO2009067607A2 A ( O
a WO2009067607A2 A DT O
) WO2009067607A2 A ) O
an WO2009067607A2 A DT O
amount WO2009067607A2 A NN O
of WO2009067607A2 A IN O
an WO2009067607A2 A DT O
antipsychotic WO2009067607A2 A JJ O
agent WO2009067607A2 A NN O
and WO2009067607A2 A CC O
( WO2009067607A2 A ( O
b WO2009067607A2 A NN O
) WO2009067607A2 A ) O
an WO2009067607A2 A DT O
amount WO2009067607A2 A NN O
of WO2009067607A2 A IN O
a WO2009067607A2 A DT O
PDE4 WO2009067607A2 A NNP O
inhibitor WO2009067607A2 A NN O
compound WO2009067607A2 A NN O
, WO2009067607A2 A , O
wherein WO2009067607A2 A VBP O
the WO2009067607A2 A DT O
amounts WO2009067607A2 A NNS O
of WO2009067607A2 A IN O
( WO2009067607A2 A ( O
a WO2009067607A2 A DT O
) WO2009067607A2 A ) O
and WO2009067607A2 A CC O
( WO2009067607A2 A ( O
b WO2009067607A2 A NN O
) WO2009067607A2 A ) O
are WO2009067607A2 A VBP O
together WO2009067607A2 A RB O
effective WO2009067607A2 A JJ O
in WO2009067607A2 A IN O
treating WO2009067607A2 A VBG O
the WO2009067607A2 A DT O
cognitive WO2009067607A2 A JJ O
impairment WO2009067607A2 A NN O
or WO2009067607A2 A CC O
psychotic WO2009067607A2 A JJ O
disorder WO2009067607A2 A NN O
such WO2009067607A2 A JJ O
as WO2009067607A2 A IN O
schizophrenia WO2009067607A2 A NN O
. WO2009067607A2 A . O

The WO2009067607A2 A DT O
method WO2009067607A2 A NN O
of WO2009067607A2 A IN O
treatment WO2009067607A2 A NN O
comprises WO2009067607A2 A NNS O
administering WO2009067607A2 A VBG O
to WO2009067607A2 A TO O
a WO2009067607A2 A DT O
patient WO2009067607A2 A NN O
( WO2009067607A2 A ( O
a WO2009067607A2 A DT O
) WO2009067607A2 A ) O
an WO2009067607A2 A DT O
amount WO2009067607A2 A NN O
of WO2009067607A2 A IN O
a WO2009067607A2 A DT O
antipsychotic WO2009067607A2 A JJ O
agent WO2009067607A2 A NN O
and WO2009067607A2 A CC O
( WO2009067607A2 A ( O
b WO2009067607A2 A NN O
) WO2009067607A2 A ) O
an WO2009067607A2 A DT O
amount WO2009067607A2 A NN O
of WO2009067607A2 A IN O
a WO2009067607A2 A DT O
PDE4 WO2009067607A2 A NNP O
inhibitor WO2009067607A2 A NN O
compound WO2009067607A2 A NN O
, WO2009067607A2 A , O
wherein WO2009067607A2 A VBP O
the WO2009067607A2 A DT O
amounts WO2009067607A2 A NNS O
of WO2009067607A2 A IN O
( WO2009067607A2 A ( O
a WO2009067607A2 A DT O
) WO2009067607A2 A ) O
and WO2009067607A2 A CC O
( WO2009067607A2 A ( O
b WO2009067607A2 A NN O
) WO2009067607A2 A ) O
are WO2009067607A2 A VBP O
together WO2009067607A2 A RB O
effective WO2009067607A2 A JJ O
in WO2009067607A2 A IN O
treating WO2009067607A2 A VBG O
the WO2009067607A2 A DT O
psychotic WO2009067607A2 A JJ O
disorder WO2009067607A2 A NN O
such WO2009067607A2 A JJ O
as WO2009067607A2 A IN O
schizophrenia WO2009067607A2 A NN O
. WO2009067607A2 A . O

Ibuprofen CN102824340A T NNP O
composition CN102824340A T NN O
injection CN102824340A T NN O
and CN102824340A T CC O
preparation CN102824340A T NN O
method CN102824340A T NN O
thereof CN102824340A T NN O
. CN102824340A T . O

Oral CN1726908A T JJ O
emulsion CN1726908A T NN O
combination CN1726908A T NN O
of CN1726908A T IN O
'Chuanhuning CN1726908A T VBG O
' CN1726908A T POS O
. CN1726908A T . O

Blueberry CN101040893A T NNP O
capsule CN101040893A T NN O
for CN101040893A T IN O
protecting CN101040893A T VBG O
vision CN101040893A T NN O
and CN101040893A T CC O
the CN101040893A T DT O
preparing CN101040893A T NN O
method CN101040893A T NN O
. CN101040893A T . O

Levofloxacin CN103520124A T NNP O
hydrochloride CN103520124A T JJ O
tablet CN103520124A T NN O
and CN103520124A T CC O
preparation CN103520124A T NN O
method CN103520124A T NN O
thereof CN103520124A T NN O
. CN103520124A T . O

Using US7763601 T VBG O
O- US7763601 T NNP O
( US7763601 T ( O
3-piperidino-2-hydroxypropyl US7763601 T CD O
) US7763601 T ) O
-nicotinic US7763601 T NN O
amidoxime US7763601 T NN O
( US7763601 T ( O
BGP-15 US7763601 T NNP O
) US7763601 T ) O
; US7763601 T : O
weight US7763601 T JJ O
loss US7763601 T NN O
. US7763601 T . O

Manipulation US20100191040 T NN O
of US20100191040 T IN O
ovarian US20100191040 T JJ O
primordial US20100191040 T JJ O
follicles US20100191040 T NNS O
. US20100191040 T . O

Methods US20100191040 A NNS O
are US20100191040 A VBP O
provided US20100191040 A VBN O
for US20100191040 A IN O
activating US20100191040 A VBG O
dormant US20100191040 A JJ O
ovarian US20100191040 A JJ O
primordial US20100191040 A NN O
follicles US20100191040 A NNS O
in US20100191040 A IN O
a US20100191040 A DT O
mammal US20100191040 A JJ O
to US20100191040 A TO O
promote US20100191040 A VB O
development US20100191040 A NN O
to US20100191040 A TO O
preovulatory US20100191040 A NN O
follicles US20100191040 A NNS O
. US20100191040 A . O

Application CN103446079A T NN O
of CN103446079A T IN O
Bostrycin CN103446079A T NNP O
to CN103446079A T TO O
preparation CN103446079A T NN O
of CN103446079A T IN O
protein CN103446079A T JJ O
tyrodine CN103446079A T JJ O
phosphatase CN103446079A T NN O
( CN103446079A T ( O
PTP CN103446079A T NNP O
) CN103446079A T ) O
bonding CN103446079A T VBG O
agents CN103446079A T NNS O
or CN103446079A T CC O
inhibitors CN103446079A T NNS O
. CN103446079A T . O

Fluoroquinolone-oxazolidone CN1948306A T CD O
derivative CN1948306A T JJ O
, CN1948306A T , O
its CN1948306A T PRP$ O
preparation CN1948306A T NN O
method CN1948306A T NN O
and CN1948306A T CC O
application CN1948306A T NN O
. CN1948306A T . O

Biomarkers US20110182822 T NNS O
for US20110182822 T IN O
Painful US20110182822 T NNP O
Intervertebral US20110182822 T NNP O
Discs US20110182822 T NNP O
and US20110182822 T CC O
Methods US20110182822 T NNP O
of US20110182822 T IN O
Use US20110182822 T NNP O
Thereof US20110182822 T NNP O
. US20110182822 T . O

Useful US7217844 T JJ O
for US7217844 T IN O
inhibiting US7217844 T VBG O
the US7217844 T DT O
growth US7217844 T NN O
of US7217844 T IN O
a US7217844 T DT O
cancer US7217844 T NN O
cell US7217844 T NN O
or US7217844 T CC O
neoplastic US7217844 T JJ O
cell US7217844 T NN O
, US7217844 T , O
or US7217844 T CC O
for US7217844 T IN O
inducing US7217844 T VBG O
apoptosis US7217844 T NN O
in US7217844 T IN O
a US7217844 T DT O
cancer US7217844 T NN O
or US7217844 T CC O
neoplastic US7217844 T JJ O
cell US7217844 T NN O
; US7217844 T : O
reduced US7217844 T VBN O
side US7217844 T NN O
effects US7217844 T NNS O
. US7217844 T . O

Stable CN102357085A T JJ O
method CN102357085A T NN O
for CN102357085A T IN O
preparing CN102357085A T VBG O
repaglinide CN102357085A T NN O
compressed CN102357085A T VBD O
tablets CN102357085A T NNS O
. CN102357085A T . O

2-carbamo WO2013159224A1 T JJ O
( WO2013159224A1 T ( O
thio WO2013159224A1 T NN O
) WO2013159224A1 T ) O
yl-1,3- WO2013159224A1 T NN O
dioxopropyl WO2013159224A1 T NN O
derivatives WO2013159224A1 T NNS O
in WO2013159224A1 T IN O
cancer WO2013159224A1 T NN O
therapy WO2013159224A1 T NN O
. WO2013159224A1 T . O

Certain WO2013159224A1 A VB O
2-carbamo WO2013159224A1 A JJ O
( WO2013159224A1 A ( O
thio WO2013159224A1 A NN O
) WO2013159224A1 A ) O
yl-1,3-dioxopropyl WO2013159224A1 A NN O
derivatives WO2013159224A1 A NNS O
, WO2013159224A1 A , O
or WO2013159224A1 A CC O
the WO2013159224A1 A DT O
tautomers WO2013159224A1 A NNS O
and WO2013159224A1 A CC O
pharmacologically WO2013159224A1 A RB O
acceptable WO2013159224A1 A JJ O
addition WO2013159224A1 A NN O
salts WO2013159224A1 A NNS O
thereof WO2013159224A1 A NNS O
are WO2013159224A1 A VBP O
found WO2013159224A1 A VBN O
to WO2013159224A1 A TO O
be WO2013159224A1 A VB O
toxic WO2013159224A1 A JJ O
to WO2013159224A1 A TO O
cancer WO2013159224A1 A NN O
cells WO2013159224A1 A NNS O
, WO2013159224A1 A , O
in WO2013159224A1 A IN O
part WO2013159224A1 A NN O
, WO2013159224A1 A , O
by WO2013159224A1 A IN O
inhibiting WO2013159224A1 A VBG O
DNA WO2013159224A1 A NNP I-UN
topoisomerase WO2013159224A1 A NN I-UN
II WO2013159224A1 A NNP I-UN
enzyme WO2013159224A1 A NN O
making WO2013159224A1 A VBG O
them WO2013159224A1 A PRP O
candidates WO2013159224A1 A NNS O
for WO2013159224A1 A IN O
pharmaceutical WO2013159224A1 A JJ O
use WO2013159224A1 A NN O
as WO2013159224A1 A IN O
anticancer WO2013159224A1 A NN O
agents WO2013159224A1 A NNS O
. WO2013159224A1 A . O

Alcohol EP2247286A2 T NNP O
antimicrobial EP2247286A2 T JJ O
skin EP2247286A2 T NN O
sanitizing EP2247286A2 T VBG O
compositions EP2247286A2 T NNS O
including EP2247286A2 T VBG O
cationic EP2247286A2 T JJ O
compatible EP2247286A2 T JJ O
thickeners EP2247286A2 T NNS O
. EP2247286A2 T . O

Dimer US20140018333 T NNP O
diol US20140018333 T NN O
compositions US20140018333 T NNS O
as US20140018333 T IN O
substitutes US20140018333 T NNS O
of US20140018333 T IN O
body US20140018333 T NN O
fluids US20140018333 T NNS O
. US20140018333 T . O

Orally US20110268798 T RB O
disntegrating US20110268798 T VBG O
tablets US20110268798 T NNS O
for US20110268798 T IN O
the US20110268798 T DT O
treatment US20110268798 T NN O
of US20110268798 T IN O
pain US20110268798 T NN O
. US20110268798 T . O

Compounds CA2803880A1 T NNS O
for CA2803880A1 T IN O
the CA2803880A1 T DT O
inhibition CA2803880A1 T NN O
of CA2803880A1 T IN O
cellular CA2803880A1 T JJ O
proliferation CA2803880A1 T NN O
. CA2803880A1 T . O

Propylene CN103099797A T NNP O
glycol CN103099797A T NN O
mannate CN103099797A T NN O
sulfate CN103099797A T NN O
capsule CN103099797A T NN O
and CN103099797A T CC O
its CN103099797A T PRP$ O
preparation CN103099797A T NN O
method CN103099797A T NN O
. CN103099797A T . O

Application CN103356573A T NN O
of CN103356573A T IN O
Sarcaboside CN103356573A T NNP O
A CN103356573A T NNP O
in CN103356573A T IN O
anti-hypoxia CN103356573A T JJ O
medicine CN103356573A T NN O
. CN103356573A T . O

Pan-selectin WO2009126556A1 T JJ O
inhibitor WO2009126556A1 T NN O
with WO2009126556A1 T IN O
enhanced WO2009126556A1 T JJ O
pharmacokinetic WO2009126556A1 T JJ O
activity WO2009126556A1 T NN O
. WO2009126556A1 T . O

Devices EP1592447B1 T NNS O
and EP1592447B1 T CC O
compositions EP1592447B1 T NNS O
containing EP1592447B1 T VBG O
boron EP1592447B1 T NN O
and EP1592447B1 T CC O
silicon EP1592447B1 T NN O
for EP1592447B1 T IN O
use EP1592447B1 T NN O
in EP1592447B1 T IN O
neutron EP1592447B1 T JJ O
capture EP1592447B1 T NN O
therapy EP1592447B1 T NN O
. EP1592447B1 T . O

Novel CN103483487A T JJ O
structure CN103483487A T NN O
product CN103483487A T NN O
, CN103483487A T , O
preparation CN103483487A T NN O
method CN103483487A T NN O
and CN103483487A T CC O
use CN103483487A T NN O
of CN103483487A T IN O
styrenic CN103483487A T JJ O
resin CN103483487A T NN O
. CN103483487A T . O

Tumor WO2005083074A1 T NNP O
antigen WO2005083074A1 T NN O
peptides WO2005083074A1 T NNS O
. WO2005083074A1 T . O

Health CN103417764A T NNP O
care CN103417764A T NN O
product CN103417764A T NN O
containing CN103417764A T VBG O
L-carnitine CN103417764A T NNP O
. CN103417764A T . O

Treatment CN102131508A T NN O
of CN102131508A T IN O
anxiety CN102131508A T NN O
disorders CN102131508A T NNS O
. CN102131508A T . O

Antidiabetic WO2007043606A1 T JJ O
agent WO2007043606A1 T NN O
comprising WO2007043606A1 T VBG O
anionic WO2007043606A1 T JJ O
polyamino WO2007043606A1 T NN O
acid-metal WO2007043606A1 T JJ O
complex WO2007043606A1 T NN O
. WO2007043606A1 T . O

More WO2007043606A1 A RBR O
particularly WO2007043606A1 A RB O
, WO2007043606A1 A , O
the WO2007043606A1 A DT O
invention WO2007043606A1 A NN O
relates WO2007043606A1 A VBZ O
to WO2007043606A1 A TO O
the WO2007043606A1 A DT O
pharmaceutical WO2007043606A1 A JJ O
composition WO2007043606A1 A NN O
for WO2007043606A1 A IN O
treating WO2007043606A1 A VBG O
or WO2007043606A1 A CC O
preventing WO2007043606A1 A VBG O
diabetes WO2007043606A1 A NNS O
comprising WO2007043606A1 A VBG O
an WO2007043606A1 A DT O
anionic WO2007043606A1 A JJ O
polyamino WO2007043606A1 A NN O
acid WO2007043606A1 A NN O
, WO2007043606A1 A , O
preferably WO2007043606A1 A RB O
a WO2007043606A1 A DT O
metal-polyamino WO2007043606A1 A JJ O
acid WO2007043606A1 A NN O
complex WO2007043606A1 A NN O
which WO2007043606A1 A WDT O
can WO2007043606A1 A MD O
be WO2007043606A1 A VB O
produced WO2007043606A1 A VBN O
from WO2007043606A1 A IN O
poly-gamma-glutamic WO2007043606A1 A JJ O
acid WO2007043606A1 A NN O
and WO2007043606A1 A CC O
a WO2007043606A1 A DT O
metal WO2007043606A1 A NN O
compound WO2007043606A1 A NN O
and WO2007043606A1 A CC O
having WO2007043606A1 A VBG O
at WO2007043606A1 A IN O
least WO2007043606A1 A JJS O
one WO2007043606A1 A CD O
action WO2007043606A1 A NN O
of WO2007043606A1 A IN O
a WO2007043606A1 A DT O
hypoglycemic WO2007043606A1 A JJ O
action WO2007043606A1 A NN O
, WO2007043606A1 A , O
a WO2007043606A1 A DT O
glucose WO2007043606A1 A JJ O
tolerance WO2007043606A1 A NN O
improving WO2007043606A1 A VBG O
action WO2007043606A1 A NN O
, WO2007043606A1 A , O
a WO2007043606A1 A DT O
blood WO2007043606A1 A NN O
pressure-lowering WO2007043606A1 A JJ O
action WO2007043606A1 A NN O
and WO2007043606A1 A CC O
an WO2007043606A1 A DT O
insulin WO2007043606A1 A NN I-UN
resistance WO2007043606A1 A NN O
improving WO2007043606A1 A VBG O
action WO2007043606A1 A NN O
. WO2007043606A1 A . O

Pharmaceutical US20080287417 T JJ O
compositions US20080287417 T NNS O
comprising US20080287417 T VBG O
a US20080287417 T DT O
poorly US20080287417 T JJ O
water-soluble US20080287417 T JJ O
active US20080287417 T JJ O
ingredient US20080287417 T NN O
, US20080287417 T , O
a US20080287417 T DT O
surfactant US20080287417 T NN O
and US20080287417 T CC O
a US20080287417 T DT O
water-soluble US20080287417 T JJ O
polymer US20080287417 T NN O
. US20080287417 T . O

Compounds CA2377309C T NNS O
for CA2377309C T IN O
the CA2377309C T DT O
modulation CA2377309C T NN O
of CA2377309C T IN O
ppar.gamma CA2377309C T NN I-UN
. CA2377309C T . O

Modulators CA2377309C A NNS O
of CA2377309C A IN O
PPAR.gamma CA2377309C A NNP I-UN
. CA2377309C A . O

Azetidine WO2007116230A1 T NNP O
derivatives WO2007116230A1 T NNS O
as WO2007116230A1 T IN O
g-protein WO2007116230A1 T NN O
coupled WO2007116230A1 T VBN O
receptor WO2007116230A1 T NN O
( WO2007116230A1 T ( O
gpr119 WO2007116230A1 T NN I-UN
) WO2007116230A1 T ) O
agonists WO2007116230A1 T VBZ O
. WO2007116230A1 T . O

Compounds WO2007116230A1 A NNS O
of WO2007116230A1 A IN O
formula WO2007116230A1 A NN O
( WO2007116230A1 A ( O
I WO2007116230A1 A PRP O
) WO2007116230A1 A ) O
or WO2007116230A1 A CC O
pharmaceutically WO2007116230A1 A RB O
acceptable WO2007116230A1 A JJ O
salts WO2007116230A1 A NNS O
thereof WO2007116230A1 A NN O
, WO2007116230A1 A , O
are WO2007116230A1 A VBP O
agonists WO2007116230A1 A NNS O
of WO2007116230A1 A IN O
GPR119 WO2007116230A1 A NNP I-UN
and WO2007116230A1 A CC O
are WO2007116230A1 A VBP O
useful WO2007116230A1 A JJ O
for WO2007116230A1 A IN O
the WO2007116230A1 A DT O
treatment WO2007116230A1 A NN O
of WO2007116230A1 A IN O
diabetes WO2007116230A1 A NNS O
and WO2007116230A1 A CC O
as WO2007116230A1 A IN O
peripheral WO2007116230A1 A JJ O
regulators WO2007116230A1 A NNS O
of WO2007116230A1 A IN O
satiety WO2007116230A1 A NN O
, WO2007116230A1 A , O
e.g WO2007116230A1 A NN O
. WO2007116230A1 A . O

Bioactive WO2010073642A1 T JJ O
agent WO2010073642A1 T NN O
, WO2010073642A1 T , O
pharmaceutical WO2010073642A1 T JJ O
product WO2010073642A1 T NN O
, WO2010073642A1 T , O
cosmetic WO2010073642A1 T JJ O
product WO2010073642A1 T NN O
, WO2010073642A1 T , O
freshness WO2010073642A1 T JJ O
keeping WO2010073642A1 T VBG O
agent WO2010073642A1 T NN O
, WO2010073642A1 T , O
and WO2010073642A1 T CC O
plant WO2010073642A1 T NN O
and WO2010073642A1 T CC O
animal WO2010073642A1 T JJ O
growth WO2010073642A1 T NN O
promoting WO2010073642A1 T VBG O
agent WO2010073642A1 T NN O
. WO2010073642A1 T . O

Directional US20100108059 T NNP O
use US20100108059 T NN O
. US20100108059 T . O

Novel WO2011152071A1 T NNP O
hyaluronic WO2011152071A1 T JJ O
acid WO2011152071A1 T NN O
decomposition-promoting WO2011152071A1 T JJ O
factor WO2011152071A1 T NN O
and WO2011152071A1 T CC O
inhibitor WO2011152071A1 T NN O
thereof WO2011152071A1 T NN O
. WO2011152071A1 T . O

Disclosed WO2011152071A1 A VBN O
is WO2011152071A1 A VBZ O
a WO2011152071A1 A DT O
novel WO2011152071A1 A JJ O
factor WO2011152071A1 A NN O
KIAA1199 WO2011152071A1 A NNP I-UN
that WO2011152071A1 A WDT O
participates WO2011152071A1 A VBZ O
in WO2011152071A1 A IN O
the WO2011152071A1 A DT O
decomposition WO2011152071A1 A NN O
of WO2011152071A1 A IN O
hyaluronic WO2011152071A1 A JJ O
acid WO2011152071A1 A NN O
, WO2011152071A1 A , O
and WO2011152071A1 A CC O
also WO2011152071A1 A RB O
disclosed WO2011152071A1 A VBN O
is WO2011152071A1 A VBZ O
the WO2011152071A1 A DT O
use WO2011152071A1 A NN O
thereof WO2011152071A1 A NN O
. WO2011152071A1 A . O

Specifically WO2011152071A1 A RB O
disclosed WO2011152071A1 A VBN O
are WO2011152071A1 A VBP O
: WO2011152071A1 A : O
a WO2011152071A1 A DT O
hyaluronic WO2011152071A1 A JJ O
acid WO2011152071A1 A NN O
decomposition WO2011152071A1 A NN O
promoter WO2011152071A1 A NN O
comprising WO2011152071A1 A VBG O
the WO2011152071A1 A DT O
KIAA1199 WO2011152071A1 A NNP I-UN
gene WO2011152071A1 A NN O
and WO2011152071A1 A CC O
protein WO2011152071A1 A JJ O
thereof WO2011152071A1 A NN O
; WO2011152071A1 A : O
a WO2011152071A1 A DT O
hyaluronic WO2011152071A1 A JJ O
acid WO2011152071A1 A NN O
decomposition WO2011152071A1 A NN O
inhibitor WO2011152071A1 A NN O
( WO2011152071A1 A ( O
comprising WO2011152071A1 A VBG O
siRNA WO2011152071A1 A NN O
or WO2011152071A1 A CC O
monoclonal WO2011152071A1 A JJ O
antibody WO2011152071A1 A NN O
) WO2011152071A1 A ) O
that WO2011152071A1 A WDT O
inhibits WO2011152071A1 A VBZ O
the WO2011152071A1 A DT O
activity WO2011152071A1 A NN O
or WO2011152071A1 A CC O
expression WO2011152071A1 A NN O
of WO2011152071A1 A IN O
the WO2011152071A1 A DT O
hyaluronic WO2011152071A1 A JJ O
acid WO2011152071A1 A NN O
decomposition WO2011152071A1 A NN O
promoter WO2011152071A1 A NN O
; WO2011152071A1 A : O
and WO2011152071A1 A CC O
a WO2011152071A1 A DT O
method WO2011152071A1 A NN O
for WO2011152071A1 A IN O
screening WO2011152071A1 A VBG O
for WO2011152071A1 A IN O
a WO2011152071A1 A DT O
novel WO2011152071A1 A JJ O
hyaluronic WO2011152071A1 A JJ O
acid WO2011152071A1 A NN O
decomposition WO2011152071A1 A NN O
inhibitor WO2011152071A1 A NN O
using WO2011152071A1 A VBG O
KIAA1199 WO2011152071A1 A NNP I-UN
expression WO2011152071A1 A NN O
as WO2011152071A1 A IN O
the WO2011152071A1 A DT O
indicator WO2011152071A1 A NN O
. WO2011152071A1 A . O

4-substituted CN102625807A T JJ O
pyridin-3-yl-carboxamide CN102625807A T JJ O
compounds CN102625807A T NNS O
and CN102625807A T CC O
methods CN102625807A T NNS O
of CN102625807A T IN O
use CN102625807A T NN O
. CN102625807A T . O

The CN102625807A A DT O
invention CN102625807A A NN O
relates CN102625807A A VBZ O
to CN102625807A A TO O
compounds CN102625807A A NNS O
of CN102625807A A IN O
Formula CN102625807A A NNP O
( CN102625807A A ( O
I CN102625807A A PRP O
) CN102625807A A ) O
which CN102625807A A WDT O
are CN102625807A A VBP O
useful CN102625807A A JJ O
as CN102625807A A IN O
kinase CN102625807A A NN I-UN
inhibitors CN102625807A A NNS O
, CN102625807A A , O
more CN102625807A A RBR O
specifically CN102625807A A RB O
useful CN102625807A A JJ O
as CN102625807A A IN O
PIM CN102625807A A NNP I-UN
kinase CN102625807A A NN I-UN
inhibitors CN102625807A A NNS O
, CN102625807A A , O
thus CN102625807A A RB O
useful CN102625807A A JJ O
as CN102625807A A IN O
cancer CN102625807A A NN O
therapeutics CN102625807A A NNS O
. CN102625807A A . O

Antifungal EP1224168B1 T NNP O
enediynes EP1224168B1 T NNS O
. EP1224168B1 T . O

Application CN102526087A T NN O
of CN102526087A T IN O
nucleoside CN102526087A T JJ O
compound CN102526087A T NN O
to CN102526087A T TO O
preparation CN102526087A T NN O
of CN102526087A T IN O
medicament CN102526087A T NN O
for CN102526087A T IN O
treating CN102526087A T VBG O
enterovirus CN102526087A T NN O
71 CN102526087A T CD O
( CN102526087A T ( O
EV71 CN102526087A T NNP O
) CN102526087A T ) O
infectious CN102526087A T JJ O
disease CN102526087A T NN O
. CN102526087A T . O

Cannabinoids WO2014057067A1 T NNS O
for WO2014057067A1 T IN O
the WO2014057067A1 T DT O
treatment WO2014057067A1 T NN O
of WO2014057067A1 T IN O
cancers WO2014057067A1 T NNS O
dependent WO2014057067A1 T VBP O
on WO2014057067A1 T IN O
hedgehog WO2014057067A1 T NN O
mechanisms WO2014057067A1 T NNS O
. WO2014057067A1 T . O

Method US20110257074 T NNP O
for US20110257074 T IN O
the US20110257074 T DT O
purification US20110257074 T NN O
of US20110257074 T IN O
substituted US20110257074 T JJ O
cyclopent-2-en-1-one US20110257074 T NN O
congeners US20110257074 T NNS O
and US20110257074 T CC O
substituted US20110257074 T VBD O
1,3-cyclopentadione US20110257074 T CD O
congeners US20110257074 T NNS O
from US20110257074 T IN O
a US20110257074 T DT O
complex US20110257074 T JJ O
mixture US20110257074 T NN O
using US20110257074 T VBG O
countercurrent US20110257074 T JJ O
separation US20110257074 T NN O
. US20110257074 T . O

Respiratory US7390811 T NNP O
syncytial US7390811 T JJ O
virus US7390811 T NN O
replication US7390811 T NN O
inhibitors US7390811 T NNS O
. US7390811 T . O

Clindamycin CN101401814B T NNP O
phosphate CN101401814B T JJ O
oral CN101401814B T JJ O
patches CN101401814B T NNS O
. CN101401814B T . O

Compositions US7452556 T NNS O
for US7452556 T IN O
the US7452556 T DT O
treatment US7452556 T NN O
of US7452556 T IN O
pilosebaceous US7452556 T JJ O
gland US7452556 T NN O
inflammations US7452556 T NNS O
comprising US7452556 T VBG O
aluminum US7452556 T NN O
fluoride US7452556 T NN O
. US7452556 T . O

Imidazole WO2007122401A1 T NNP O
derivatives WO2007122401A1 T NNS O
for WO2007122401A1 T IN O
use WO2007122401A1 T NN O
as WO2007122401A1 T IN O
edg-1 WO2007122401A1 T JJ I-UN
antagonists WO2007122401A1 T NNS O
. WO2007122401A1 T . O

The WO2007122401A1 A DT O
invention WO2007122401A1 A NN O
relates WO2007122401A1 A VBZ O
to WO2007122401A1 A TO O
chemical WO2007122401A1 A VB O
compounds WO2007122401A1 A NNS O
of WO2007122401A1 A IN O
formula WO2007122401A1 A NN O
( WO2007122401A1 A ( O
I WO2007122401A1 A PRP O
) WO2007122401A1 A ) O
: WO2007122401A1 A : O
or WO2007122401A1 A CC O
pharmaceutically WO2007122401A1 A RB O
acceptable WO2007122401A1 A JJ O
salts WO2007122401A1 A NNS O
thereof WO2007122401A1 A NN O
, WO2007122401A1 A , O
which WO2007122401A1 A WDT O
possess WO2007122401A1 A VBP O
Edg-1 WO2007122401A1 A NNP I-UN
antagonistic WO2007122401A1 A JJ O
activity WO2007122401A1 A NN O
and WO2007122401A1 A CC O
are WO2007122401A1 A VBP O
accordingly WO2007122401A1 A RB O
useful WO2007122401A1 A JJ O
for WO2007122401A1 A IN O
their WO2007122401A1 A PRP$ O
anti WO2007122401A1 A JJ O
cancer WO2007122401A1 A NN O
activity WO2007122401A1 A NN O
and WO2007122401A1 A CC O
thus WO2007122401A1 A RB O
in WO2007122401A1 A IN O
methods WO2007122401A1 A NNS O
of WO2007122401A1 A IN O
treatment WO2007122401A1 A NN O
of WO2007122401A1 A IN O
the WO2007122401A1 A DT O
human WO2007122401A1 A NN O
or WO2007122401A1 A CC O
animal WO2007122401A1 A NN O
body WO2007122401A1 A NN O
. WO2007122401A1 A . O

Preparation CN102895494A T NNP O
method CN102895494A T NN O
of CN102895494A T IN O
blended CN102895494A T JJ O
medicine CN102895494A T NN O
for CN102895494A T IN O
respiratory CN102895494A T NN O
diseases CN102895494A T NNS O
of CN102895494A T IN O
chicken CN102895494A T NN O
. CN102895494A T . O

Application CN102000046B T NN O
of CN102000046B T IN O
antrodia CN102000046B T NN O
camphorata CN102000046B T NN O
cyclohexenone CN102000046B T NN O
compound CN102000046B T NN O
in CN102000046B T IN O
preparing CN102000046B T VBG O
medicine CN102000046B T NN O
for CN102000046B T IN O
inhibiting CN102000046B T VBG O
growth CN102000046B T NN O
of CN102000046B T IN O
pancreatic CN102000046B T JJ O
cancer CN102000046B T NN O
tumor CN102000046B T NN O
cells CN102000046B T NNS O
. CN102000046B T . O

Such US6995184 T JJ O
as US6995184 T IN O
( US6995184 T ( O
7-chloro-2-methyl-1- US6995184 T JJ O
( US6995184 T ( O
3- US6995184 T JJ O
( US6995184 T ( O
methylsulphanyl US6995184 T NN O
) US6995184 T ) O
propyl US6995184 T NN O
) US6995184 T ) O
-1H-indol-3-yl US6995184 T NN O
) US6995184 T ) O
( US6995184 T ( O
2,3-dichloro-phenyl US6995184 T JJ O
) US6995184 T ) O
methanone US6995184 T NN O
; US6995184 T : O
cannabinoid US6995184 T JJ O
receptors US6995184 T NNS O
( US6995184 T ( O
cb2 US6995184 T NN I-UN
) US6995184 T ) O
; US6995184 T : O
G US6995184 T NNP O
proteins US6995184 T VBZ O
coupled US6995184 T VBN O
receptors US6995184 T NNS O
. US6995184 T . O

These US6995184 A DT O
compounds US6995184 A NNS O
are US6995184 A VBP O
agonists US6995184 A NNS O
for US6995184 A IN O
CB2 US6995184 A NNP I-UN
cannabinoid US6995184 A NN I-UN
receptors US6995184 A NNS I-UN
. US6995184 A . O

Caffeic CN101585770B T NNP O
acid CN101585770B T VBP O
diester CN101585770B T NN O
compounds CN101585770B T NNS O
and CN101585770B T CC O
preparation CN101585770B T NN O
method CN101585770B T NN O
thereof CN101585770B T NN O
, CN101585770B T , O
and CN101585770B T CC O
application CN101585770B T NN O
thereof CN101585770B T NN O
in CN101585770B T IN O
preparing CN101585770B T VBG O
medicine CN101585770B T NN O
for CN101585770B T IN O
curing CN101585770B T VBG O
thrombus CN101585770B T NN O
. CN101585770B T . O

The CN101585770B A DT O
invention CN101585770B A NN O
discloses CN101585770B A VBZ O
caffeic CN101585770B A JJ O
acid CN101585770B A JJ O
diester CN101585770B A NN O
compounds CN101585770B A NNS O
of CN101585770B A IN O
formula CN101585770B A NN O
( CN101585770B A ( O
I CN101585770B A PRP O
) CN101585770B A ) O
and CN101585770B A CC O
prepartion CN101585770B A NN O
method CN101585770B A NN O
thereof CN101585770B A NN O
, CN101585770B A , O
and CN101585770B A CC O
application CN101585770B A NN O
of CN101585770B A IN O
preparing CN101585770B A VBG O
medicine CN101585770B A NN O
for CN101585770B A IN O
curing CN101585770B A VBG O
thrombus CN101585770B A NN O
, CN101585770B A , O
experments CN101585770B A VBZ O
show CN101585770B A VBP O
that CN101585770B A IN O
the CN101585770B A DT O
invention CN101585770B A NN O
synthesized CN101585770B A VBD O
caffeic CN101585770B A JJ O
acid CN101585770B A NN O
diester CN101585770B A NN O
compounds CN101585770B A VBZ O
has CN101585770B A VBZ O
strong CN101585770B A JJ O
inhibition CN101585770B A NN O
function CN101585770B A NN O
to CN101585770B A TO O
platelet CN101585770B A VB O
aggregation CN101585770B A NN O
induced CN101585770B A VBN O
by CN101585770B A IN O
ADP CN101585770B A NNP O
, CN101585770B A , O
comparison CN101585770B A NN O
of CN101585770B A IN O
50 CN101585770B A CD O
% CN101585770B A NN O
aggregation CN101585770B A NN O
inhibition CN101585770B A NN O
concentration CN101585770B A NN O
shows CN101585770B A VBZ O
that CN101585770B A IN O
, CN101585770B A , O
the CN101585770B A DT O
invention CN101585770B A NN O
provided CN101585770B A VBD O
caffeic CN101585770B A JJ O
acid CN101585770B A JJ O
diester CN101585770B A NN O
compounds CN101585770B A NNS O
has CN101585770B A VBZ O
better CN101585770B A JJR O
inhibition CN101585770B A NN O
function CN101585770B A NN O
to CN101585770B A TO O
platelet CN101585770B A VB O
aggregation CN101585770B A NN O
than CN101585770B A IN O
caffeic CN101585770B A JJ O
acid CN101585770B A NN O
and CN101585770B A CC O
acetylsalicylic CN101585770B A JJ O
acid CN101585770B A NN O
, CN101585770B A , O
the CN101585770B A DT O
caffeic CN101585770B A NN O
acid CN101585770B A NN O
diester CN101585770B A NN O
compounds CN101585770B A NNS O
obtained CN101585770B A VBN O
by CN101585770B A IN O
condensation CN101585770B A NN O
of CN101585770B A IN O
caffeicacid CN101585770B A NN O
and CN101585770B A CC O
acetylsalicylic CN101585770B A JJ O
acid CN101585770B A NN O
has CN101585770B A VBZ O
synergistic CN101585770B A JJ O
function CN101585770B A NN O
with CN101585770B A IN O
less CN101585770B A JJR O
clinical CN101585770B A JJ O
dosage CN101585770B A NN O
, CN101585770B A , O
reduced CN101585770B A VBN O
untoward CN101585770B A JJ O
effect CN101585770B A NN O
. CN101585770B A . O

The CN101585770B A DT O
invention CN101585770B A NN O
provided CN101585770B A VBD O
method CN101585770B A NN O
for CN101585770B A IN O
preparing CN101585770B A VBG O
caffeic CN101585770B A JJ O
acid CN101585770B A JJ O
diester CN101585770B A NN O
compounds CN101585770B A VBZ O
uses CN101585770B A NNS O
microwave CN101585770B A VBP O
reaction CN101585770B A NN O
that CN101585770B A WDT O
reduces CN101585770B A VBZ O
reaction CN101585770B A NN O
time CN101585770B A NN O
and CN101585770B A CC O
improves CN101585770B A VBZ O
reaction CN101585770B A NN O
efficiency CN101585770B A NN O
, CN101585770B A , O
and CN101585770B A CC O
the CN101585770B A DT O
cost CN101585770B A NN O
is CN101585770B A VBZ O
reduced CN101585770B A VBN O
, CN101585770B A , O
the CN101585770B A DT O
invention CN101585770B A NN O
also CN101585770B A RB O
has CN101585770B A VBZ O
excellent CN101585770B A JJ O
operability CN101585770B A NN O
and CN101585770B A CC O
certain CN101585770B A JJ O
protection CN101585770B A NN O
function CN101585770B A NN O
to CN101585770B A TO O
environment CN101585770B A NN O
. CN101585770B A . O

Pharmaceutical US8716251 T JJ O
formulations US8716251 T NNS O
containing US8716251 T VBG O
an US8716251 T DT O
SGLT2 US8716251 T NNP I-UN
inhibitor US8716251 T NN O
. US8716251 T . O

Iron-enriched WO2009084122A1 T JJ O
composition WO2009084122A1 T NN O
. WO2009084122A1 T . O

6- CN103304486A T JJ O
( CN103304486A T ( O
4-arylpiperazine-1-yl CN103304486A T JJ O
) CN103304486A T ) O
pyridazine-3 CN103304486A T NN O
( CN103304486A T ( O
2H CN103304486A T CD O
) CN103304486A T ) O
-ketone CN103304486A T NN O
and CN103304486A T CC O
application CN103304486A T NN O
thereof CN103304486A T NN O
. CN103304486A T . O

The CN103304486A A DT O
6- CN103304486A A JJ O
( CN103304486A A ( O
4-arylpiperazine-1-yl CN103304486A A JJ O
) CN103304486A A ) O
pyridazine-3 CN103304486A A NN O
( CN103304486A A ( O
2H CN103304486A A CD O
) CN103304486A A ) O
-ketone CN103304486A A NN O
disclosed CN103304486A A VBN O
by CN103304486A A IN O
the CN103304486A A DT O
invention CN103304486A A NN O
is CN103304486A A VBZ O
remarkable CN103304486A A JJ O
in CN103304486A A IN O
effect CN103304486A A NN O
of CN103304486A A IN O
suppressing CN103304486A A VBG O
an CN103304486A A DT O
alpha CN103304486A A JJ I-UN
1-adrenergic CN103304486A A JJ I-UN
receptor CN103304486A A NN I-UN
. CN103304486A A . O

Application CN101019843A T NN O
of CN101019843A T IN O
hypericin CN101019843A T NN O
in CN101019843A T IN O
preventing CN101019843A T VBG O
and CN101019843A T CC O
treating CN101019843A T VBG O
swine CN101019843A T JJ O
PC CN101019843A T NN O
and CN101019843A T CC O
PRRS CN101019843A T NNP O
. CN101019843A T . O

Pyrimidone EP2464632A1 T NN O
derivatives EP2464632A1 T NNS O
used EP2464632A1 T VBN O
as EP2464632A1 T IN O
tau EP2464632A1 T JJ I-UN
protein EP2464632A1 T NN I-UN
kinase EP2464632A1 T VBD I-UN
1 EP2464632A1 T CD I-UN
inhibitors EP2464632A1 T NNS O
. EP2464632A1 T . O

A EP2464632A1 A DT O
compound EP2464632A1 A NN O
represented EP2464632A1 A VBN O
by EP2464632A1 A IN O
the EP2464632A1 A DT O
formula EP2464632A1 A NN O
( EP2464632A1 A ( O
I EP2464632A1 A PRP O
) EP2464632A1 A ) O
or EP2464632A1 A CC O
a EP2464632A1 A DT O
pharmaceutically EP2464632A1 A RB O
acceptable EP2464632A1 A JJ O
salt EP2464632A1 A NN O
thereof EP2464632A1 A NN O
: EP2464632A1 A : O
wherein EP2464632A1 A NN O
Z EP2464632A1 A NNP O
represents EP2464632A1 A VBZ O
nitrogen EP2464632A1 A JJ O
atom EP2464632A1 A NN O
or EP2464632A1 A CC O
C-X EP2464632A1 A NNP O
; EP2464632A1 A : O
X EP2464632A1 A CD O
represents EP2464632A1 A VBZ O
hydrogen EP2464632A1 A NN O
atom EP2464632A1 A NN O
or EP2464632A1 A CC O
fluorine EP2464632A1 A JJ O
atom EP2464632A1 A NN O
; EP2464632A1 A : O
R1 EP2464632A1 A NNP O
is EP2464632A1 A VBZ O
hydrogen EP2464632A1 A JJ O
atom EP2464632A1 A NN O
or EP2464632A1 A CC O
a EP2464632A1 A DT O
C1-C3 EP2464632A1 A JJ O
alkyl EP2464632A1 A NN O
group EP2464632A1 A NN O
; EP2464632A1 A : O
L EP2464632A1 A NNP O
represents EP2464632A1 A VBZ O
single EP2464632A1 A JJ O
bond EP2464632A1 A NN O
or EP2464632A1 A CC O
a EP2464632A1 A DT O
C1-C6 EP2464632A1 A JJ O
alkylene EP2464632A1 A NN O
group EP2464632A1 A NN O
which EP2464632A1 A WDT O
may EP2464632A1 A MD O
be EP2464632A1 A VB O
substituted EP2464632A1 A VBN O
; EP2464632A1 A : O
Y EP2464632A1 A NNP O
represents EP2464632A1 A VBZ O
single EP2464632A1 A JJ O
bond EP2464632A1 A NN O
, EP2464632A1 A , O
sulfur EP2464632A1 A NN O
atom EP2464632A1 A NN O
, EP2464632A1 A , O
oxygen EP2464632A1 A NN O
atom EP2464632A1 A NN O
, EP2464632A1 A , O
NH EP2464632A1 A NNP O
, EP2464632A1 A , O
or EP2464632A1 A CC O
the EP2464632A1 A DT O
like EP2464632A1 A JJ O
; EP2464632A1 A : O
R2 EP2464632A1 A NNP O
represents EP2464632A1 A VBZ O
hydrogen EP2464632A1 A NN O
atom EP2464632A1 A NN O
or EP2464632A1 A CC O
a EP2464632A1 A DT O
cyclic EP2464632A1 A JJ O
group EP2464632A1 A NN O
which EP2464632A1 A WDT O
may EP2464632A1 A MD O
be EP2464632A1 A VB O
substituted EP2464632A1 A VBN O
, EP2464632A1 A , O
which EP2464632A1 A WDT O
is EP2464632A1 A VBZ O
used EP2464632A1 A VBN O
for EP2464632A1 A IN O
preventive EP2464632A1 A JJ O
and/or EP2464632A1 A JJ O
therapeutic EP2464632A1 A JJ O
treatment EP2464632A1 A NN O
of EP2464632A1 A IN O
a EP2464632A1 A DT O
disease EP2464632A1 A NN O
caused EP2464632A1 A VBN O
by EP2464632A1 A IN O
abnormal EP2464632A1 A JJ O
activity EP2464632A1 A NN O
of EP2464632A1 A IN O
tau EP2464632A1 A NN I-UN
protein EP2464632A1 A NN I-UN
kinase EP2464632A1 A VBD I-UN
1 EP2464632A1 A CD I-UN
such EP2464632A1 A JJ O
as EP2464632A1 A IN O
a EP2464632A1 A DT O
neurodegenerative EP2464632A1 A JJ O
diseases EP2464632A1 A NNS O
( EP2464632A1 A ( O
e.g EP2464632A1 A NN O
. EP2464632A1 A . O

6-substituted WO2005108398A1 T JJ O
pyridoindolone WO2005108398A1 T NN O
derivatives WO2005108398A1 T NNS O
production WO2005108398A1 T NN O
and WO2005108398A1 T CC O
therapeutic WO2005108398A1 T JJ O
use WO2005108398A1 T NN O
thereof WO2005108398A1 T NN O
. WO2005108398A1 T . O

FKBP-binding EP1778637B1 T JJ O
composition EP1778637B1 T NN O
and EP1778637B1 T CC O
pharmaceutical EP1778637B1 T JJ O
use EP1778637B1 T NN O
thereof EP1778637B1 T NN O
. EP1778637B1 T . O

Ointment CN103417750A T NN O
for CN103417750A T IN O
treating CN103417750A T VBG O
rhagadia CN103417750A T NN O
and CN103417750A T CC O
preparation CN103417750A T NN O
method CN103417750A T NN O
of CN103417750A T IN O
same CN103417750A T JJ O
. CN103417750A T . O

Prevent US6987105 T NNP O
apoptosis US6987105 T NN O
; US6987105 T : O
vision US6987105 T NN O
defects US6987105 T NNS O
; US6987105 T : O
central US6987105 T JJ O
nervous US6987105 T JJ O
system US6987105 T NN O
disorders US6987105 T NNS O
; US6987105 T : O
antiischemic US6987105 T JJ O
agents US6987105 T NNS O
; US6987105 T : O
stroke US6987105 T VBD O
therapy US6987105 T NN O
. US6987105 T . O

Methods WO2007124308A3 T NNS O
and WO2007124308A3 T CC O
compositions WO2007124308A3 T NNS O
for WO2007124308A3 T IN O
modulation WO2007124308A3 T NN O
of WO2007124308A3 T IN O
blood-neural WO2007124308A3 T JJ O
barrier WO2007124308A3 T NN O
. WO2007124308A3 T . O

The WO2007124308A3 A DT O
present WO2007124308A3 A JJ O
invention WO2007124308A3 A NN O
further WO2007124308A3 A RBR O
relates WO2007124308A3 A VBZ O
to WO2007124308A3 A TO O
improved WO2007124308A3 A VB O
tPA WO2007124308A3 A JJ I-UN
treatment WO2007124308A3 A NN O
of WO2007124308A3 A IN O
ischemic WO2007124308A3 A JJ O
cerebrovascular WO2007124308A3 A NN O
and WO2007124308A3 A CC O
related WO2007124308A3 A JJ O
diseases WO2007124308A3 A NNS O
in WO2007124308A3 A IN O
combination WO2007124308A3 A NN O
with WO2007124308A3 A IN O
antagonism WO2007124308A3 A NN O
of WO2007124308A3 A IN O
the WO2007124308A3 A DT O
PDGF WO2007124308A3 A NNP I-UN
signaling WO2007124308A3 A VBG I-UN
pathway WO2007124308A3 A RB O
. WO2007124308A3 A . O

The WO2007124308A3 A DT O
inventive WO2007124308A3 A JJ O
method WO2007124308A3 A NN O
and WO2007124308A3 A CC O
composition WO2007124308A3 A NN O
is WO2007124308A3 A VBZ O
particularly WO2007124308A3 A RB O
suitable WO2007124308A3 A JJ O
for WO2007124308A3 A IN O
conjunctive WO2007124308A3 A JJ O
therapy WO2007124308A3 A NN O
of WO2007124308A3 A IN O
ischemic WO2007124308A3 A JJ O
stroke WO2007124308A3 A NN O
using WO2007124308A3 A VBG O
tPA WO2007124308A3 A NN I-UN
and WO2007124308A3 A CC O
an WO2007124308A3 A DT O
anti-PDGF-C WO2007124308A3 A JJ O
antagonist WO2007124308A3 A NN O
or WO2007124308A3 A CC O
an WO2007124308A3 A DT O
anti-PDGFR-α WO2007124308A3 A JJ O
antagonist WO2007124308A3 A NN O
. WO2007124308A3 A . O

Compounds WO2010054307A1 T NNS O
and WO2010054307A1 T CC O
methods WO2010054307A1 T NNS O
of WO2010054307A1 T IN O
promoting WO2010054307A1 T VBG O
oligodendrocyte WO2010054307A1 T NN O
precursor WO2010054307A1 T NN O
differentiation WO2010054307A1 T NN O
. WO2010054307A1 T . O

Novel WO2012090221A1 T NNP O
salts WO2012090221A1 T NNS O
of WO2012090221A1 T IN O
imatinib WO2012090221A1 T NN O
. WO2012090221A1 T . O

Compounds US20110263610 T NNS O
and US20110263610 T CC O
compositions US20110263610 T NNS O
as US20110263610 T IN O
itpkb US20110263610 T JJ O
inhibitors US20110263610 T NNS O
. US20110263610 T . O

The US20110263610 A DT O
invention US20110263610 A NN O
provides US20110263610 A VBZ O
a US20110263610 A DT O
novel US20110263610 A JJ O
class US20110263610 A NN O
of US20110263610 A IN O
compounds US20110263610 A NNS O
, US20110263610 A , O
pharmaceutical US20110263610 A JJ O
compositions US20110263610 A NNS O
comprising US20110263610 A VBG O
such US20110263610 A JJ O
compounds US20110263610 A NNS O
and US20110263610 A CC O
methods US20110263610 A NNS O
of US20110263610 A IN O
using US20110263610 A VBG O
such US20110263610 A JJ O
compounds US20110263610 A NNS O
to US20110263610 A TO O
treat US20110263610 A VB O
or US20110263610 A CC O
prevent US20110263610 A VB O
diseases US20110263610 A NNS O
or US20110263610 A CC O
disorders US20110263610 A NNS O
associated US20110263610 A VBN O
with US20110263610 A IN O
abnormal US20110263610 A JJ O
or US20110263610 A CC O
deregulated US20110263610 A VBN O
B US20110263610 A NNP O
cell US20110263610 A NN O
activities US20110263610 A NNS O
, US20110263610 A , O
particularly US20110263610 A RB O
diseases US20110263610 A VBZ O
or US20110263610 A CC O
disorders US20110263610 A NNS O
that US20110263610 A WDT O
involve US20110263610 A VBP O
aberrant US20110263610 A JJ O
activation US20110263610 A NN O
of US20110263610 A IN O
inositol US20110263610 A JJ I-UN
1,4,5-trisphosphate US20110263610 A JJ I-UN
3-kinase US20110263610 A JJ I-UN
B US20110263610 A NNP I-UN
( US20110263610 A ( O
ITPKb US20110263610 A NNP I-UN
) US20110263610 A ) O
. US20110263610 A . O

Slow CN1857218A T NNP O
released CN1857218A T VBD O
medicine CN1857218A T NN O
containing CN1857218A T VBG O
antituberculotic CN1857218A T JJ O
. CN1857218A T . O

The CN1857218A A DT O
slow CN1857218A A JJ O
released CN1857218A A VBN O
implanting CN1857218A A NN O
agent CN1857218A A NN O
and CN1857218A A CC O
injection CN1857218A A NN O
containing CN1857218A A NN O
antituberculotic CN1857218A A JJ O
are CN1857218A A VBP O
set CN1857218A A VBN O
or CN1857218A A CC O
injected CN1857218A A VBN O
to CN1857218A A TO O
local CN1857218A A JJ O
tuberculosis CN1857218A A NN O
focus CN1857218A A NN O
for CN1857218A A IN O
maintaining CN1857218A A VBG O
the CN1857218A A DT O
local CN1857218A A JJ O
effective CN1857218A A JJ O
medicine CN1857218A A NN O
concentration CN1857218A A NN O
while CN1857218A A IN O
lowing CN1857218A A VBG O
the CN1857218A A DT O
systemic CN1857218A A JJ O
toxicity CN1857218A A NN O
. CN1857218A A . O

The CN1857218A A DT O
slow CN1857218A A JJ O
released CN1857218A A VBN O
injection CN1857218A A NN O
consists CN1857218A A VBZ O
of CN1857218A A IN O
slow CN1857218A A JJ O
released CN1857218A A VBN O
microsphere CN1857218A A RB O
and CN1857218A A CC O
solvent CN1857218A A NN O
. CN1857218A A . O

The CN1857218A A DT O
slow CN1857218A A JJ O
released CN1857218A A VBN O
microsphere CN1857218A A RB O
includes CN1857218A A VBZ O
antituberculotic CN1857218A A JJ O
selected CN1857218A A VBN O
from CN1857218A A IN O
Cycloserine CN1857218A A NNP O
, CN1857218A A , O
Ofloxacin CN1857218A A NNP O
, CN1857218A A , O
Ciprofloxacin CN1857218A A NNP O
and CN1857218A A CC O
Sparfloxacin CN1857218A A NNP O
and CN1857218A A CC O
slow CN1857218A A VB O
releasing CN1857218A A VBG O
supplementary CN1857218A A JJ O
material CN1857218A A NN O
, CN1857218A A , O
and CN1857218A A CC O
the CN1857218A A DT O
solvent CN1857218A A NN O
is CN1857218A A VBZ O
special CN1857218A A JJ O
solvent CN1857218A A JJ O
containing CN1857218A A VBG O
suspending CN1857218A A VBG O
agent CN1857218A A NN O
. CN1857218A A . O

The CN1857218A A DT O
suspending CN1857218A A NN O
agent CN1857218A A NN O
is CN1857218A A VBZ O
carboxymethyl CN1857218A A JJ O
cellulose CN1857218A A JJ O
sodium CN1857218A A NN O
, CN1857218A A , O
etc CN1857218A A FW O
. CN1857218A A . O

and CN1857218A A CC O
has CN1857218A A VBZ O
viscosity CN1857218A A NN O
of CN1857218A A IN O
100-3000 CN1857218A A CD O
cp CN1857218A A NNS O
at CN1857218A A IN O
20-30 CN1857218A A JJ O
deg.c CN1857218A A NN O
. CN1857218A A . O

The CN1857218A A DT O
slow CN1857218A A JJ O
releasing CN1857218A A NN O
supplementary CN1857218A A JJ O
material CN1857218A A NN O
is CN1857218A A VBZ O
selected CN1857218A A VBN O
from CN1857218A A IN O
EVAc CN1857218A A NNP O
, CN1857218A A , O
PLA CN1857218A A NNP O
, CN1857218A A , O
PLGA CN1857218A A NNP O
, CN1857218A A , O
etc CN1857218A A NN O
. CN1857218A A . O

The CN1857218A A DT O
slow CN1857218A A JJ O
released CN1857218A A VBN O
implanting CN1857218A A VBG O
agent CN1857218A A NN O
may CN1857218A A MD O
be CN1857218A A VB O
prepared CN1857218A A VBN O
with CN1857218A A IN O
slow CN1857218A A JJ O
released CN1857218A A VBN O
microsphere CN1857218A A RB O
. CN1857218A A . O

The CN1857218A A DT O
present CN1857218A A JJ O
invention CN1857218A A NN O
has CN1857218A A VBZ O
obvious CN1857218A A JJ O
and CN1857218A A CC O
unique CN1857218A A JJ O
treating CN1857218A A VBG O
effect CN1857218A A NN O
on CN1857218A A IN O
various CN1857218A A JJ O
kinds CN1857218A A NNS O
of CN1857218A A IN O
intractable CN1857218A A JJ O
tuberculosis CN1857218A A NN O
. CN1857218A A . O

Heterocyclic WO2008153947A2 T NNP O
compounds WO2008153947A2 T VBZ O
as WO2008153947A2 T IN O
raf WO2008153947A2 T NN O
kinase WO2008153947A2 T NN O
modulators WO2008153947A2 T NNS O
. WO2008153947A2 T . O

Sodium CN102614144A T NNP O
rabeprazole CN102614144A T VBP O
medicinal CN102614144A T JJ O
composite CN102614144A T NN O
and CN102614144A T CC O
method CN102614144A T NN O
for CN102614144A T IN O
preparing CN102614144A T VBG O
same CN102614144A T JJ O
. CN102614144A T . O

Composition US20050181042 T NN O
for US20050181042 T IN O
oral US20050181042 T JJ O
or US20050181042 T CC O
rectal US20050181042 T JJ O
administration US20050181042 T NN O
. US20050181042 T . O

Methocarbamol CN103130828A T NNP O
diammonium CN103130828A T NN O
phosphate CN103130828A T NN O
, CN103130828A T , O
and CN103130828A T CC O
polymorphism CN103130828A T NN O
and CN103130828A T CC O
preparation CN103130828A T NN O
method CN103130828A T NN O
thereof CN103130828A T NN O
. CN103130828A T . O

Topical US20110245345 T JJ O
Treatment US20110245345 T NNP O
Formulation US20110245345 T NNP O
of US20110245345 T IN O
Natural US20110245345 T NNP O
Ingredients US20110245345 T NNP O
for US20110245345 T IN O
Enhancing US20110245345 T VBG O
Sexual US20110245345 T JJ O
Response US20110245345 T NNP O
. US20110245345 T . O

Helquat WO2014111069A1 T NNP O
derivatives WO2014111069A1 T NNS O
, WO2014111069A1 T , O
preparation WO2014111069A1 T NN O
thereof WO2014111069A1 T NN O
, WO2014111069A1 T , O
and WO2014111069A1 T CC O
use WO2014111069A1 T RB O
thereof WO2014111069A1 T JJ O
as WO2014111069A1 T IN O
medicaments WO2014111069A1 T NNS O
. WO2014111069A1 T . O

Solid CN1947701A T JJ O
self-micro CN1947701A T JJ O
emulsion CN1947701A T NN O
contg CN1947701A T NN O
. CN1947701A T . O

jervic CN1947701A T NN O
alcohol CN1947701A T NN O
for CN1947701A T IN O
antineoplastic CN1947701A T JJ O
medicine CN1947701A T NN O
and CN1947701A T CC O
its CN1947701A T PRP$ O
prepn CN1947701A T NN O
. CN1947701A T . O

method CN1947701A T NN O
. CN1947701A T . O

Catechin EP1501497A2 T JJ O
multimers EP1501497A2 T NNS O
as EP1501497A2 T IN O
therapeutic EP1501497A2 T JJ O
drug EP1501497A2 T NN O
delivery EP1501497A2 T NN O
agents EP1501497A2 T NNS O
. EP1501497A2 T . O

Ambroxol CN103211789A T NNP O
hydrochloride CN103211789A T JJ O
film-controlled CN103211789A T JJ O
slow-release CN103211789A T JJ O
pellet CN103211789A T NN O
capsule CN103211789A T NN O
. CN103211789A T . O

METHODS US20090163577 T NNP O
AND US20090163577 T CC O
COMPOSITIONS US20090163577 T NNP O
FOR US20090163577 T NNP O
ANTAGONIZING US20090163577 T NNP O
ANTI-APOPTOTIC US20090163577 T NNP O
Bcl-2-FAMILY US20090163577 T NNP I-UN
PROTEINS US20090163577 T NNP O
. US20090163577 T . O

The US20090163577 A DT O
cytotoxic US20090163577 A JJ O
natural US20090163577 A JJ O
product US20090163577 A NN O
gambogic US20090163577 A NN O
acid US20090163577 A NN O
( US20090163577 A ( O
GA US20090163577 A NNP O
) US20090163577 A ) O
competes US20090163577 A VBZ O
for US20090163577 A IN O
BH3 US20090163577 A NNP O
peptide US20090163577 A NN O
binding US20090163577 A VBG O
sites US20090163577 A NNS O
on US20090163577 A IN O
several US20090163577 A JJ O
anti-apoptotic US20090163577 A JJ O
members US20090163577 A NNS O
of US20090163577 A IN O
the US20090163577 A DT O
Bcl-2 US20090163577 A NNP I-UN
family US20090163577 A NN I-UN
of US20090163577 A IN O
proteins US20090163577 A NNS O
and US20090163577 A CC O
neutralizes US20090163577 A VBZ O
the US20090163577 A DT O
ability US20090163577 A NN O
of US20090163577 A IN O
these US20090163577 A DT O
proteins US20090163577 A NNS O
to US20090163577 A TO O
suppress US20090163577 A VB O
release US20090163577 A NN O
of US20090163577 A IN O
apoptogenic US20090163577 A JJ O
proteins US20090163577 A NNS O
from US20090163577 A IN O
isolated US20090163577 A JJ O
mitochondria US20090163577 A NNS O
. US20090163577 A . O

Compositions US20090163577 A NNS O
and US20090163577 A CC O
methods US20090163577 A NNS O
are US20090163577 A VBP O
provided US20090163577 A VBN O
for US20090163577 A IN O
using US20090163577 A VBG O
GA US20090163577 A NNP O
and US20090163577 A CC O
its US20090163577 A PRP$ O
derivatives US20090163577 A NNS O
for US20090163577 A IN O
treating US20090163577 A VBG O
cancer US20090163577 A NN O
and US20090163577 A CC O
for US20090163577 A IN O
discovering US20090163577 A VBG O
other US20090163577 A JJ O
compounds US20090163577 A NNS O
that US20090163577 A WDT O
are US20090163577 A VBP O
useful US20090163577 A JJ O
for US20090163577 A IN O
treating US20090163577 A VBG O
cancer US20090163577 A NN O
through US20090163577 A IN O
their US20090163577 A PRP$ O
interaction US20090163577 A NN O
with US20090163577 A IN O
Bcl-2-family US20090163577 A NNP I-UN
proteins US20090163577 A NNS O
. US20090163577 A . O

Tubulysin WO2014160360A1 T NNP O
compounds WO2014160360A1 T NNS O
and WO2014160360A1 T CC O
conjugates WO2014160360A1 T NNS O
thereof WO2014160360A1 T VBP O
. WO2014160360A1 T . O

Multiple US20120184494 T JJ O
myeloma US20120184494 T NN O
prognosis US20120184494 T NN O
and US20120184494 T CC O
treatment US20120184494 T NN O
. US20120184494 T . O

The US20120184494 A DT O
methods US20120184494 A NNS O
involve US20120184494 A VBP O
the US20120184494 A DT O
detection US20120184494 A NN O
of US20120184494 A IN O
PTHR1 US20120184494 A NNP I-UN
gene US20120184494 A NN O
expression US20120184494 A NN O
alone US20120184494 A RB O
or US20120184494 A CC O
in US20120184494 A IN O
combination US20120184494 A NN O
with US20120184494 A IN O
other US20120184494 A JJ O
clinical US20120184494 A JJ O
factors US20120184494 A NNS O
. US20120184494 A . O

The US20120184494 A DT O
disclosure US20120184494 A NN O
also US20120184494 A RB O
relates US20120184494 A VBZ O
to US20120184494 A TO O
proteasome US20120184494 A VB O
inhibitors US20120184494 A NNS O
and US20120184494 A CC O
other US20120184494 A JJ O
activators US20120184494 A NNS O
of US20120184494 A IN O
PTHR1 US20120184494 A NNP I-UN
, US20120184494 A , O
for US20120184494 A IN O
the US20120184494 A DT O
treatment US20120184494 A NN O
of US20120184494 A IN O
multiple US20120184494 A JJ O
myeloma US20120184494 A NN O
. US20120184494 A . O

Inhibitors US20100311711 T NNS O
of US20100311711 T IN O
NAAA US20100311711 T NNP I-UN
and US20100311711 T CC O
Methods US20100311711 T NNP O
Thereof US20100311711 T NNP O
. US20100311711 T . O

Compounds US20100311711 A NNS O
and US20100311711 A CC O
pharmaceutical US20100311711 A JJ O
compositions US20100311711 A NNS O
are US20100311711 A VBP O
contemplated US20100311711 A VBN O
that US20100311711 A IN O
inhibit US20100311711 A NN O
N-acyl-ethanolamine-hydrolyzing US20100311711 A JJ I-UN
acid US20100311711 A NN I-UN
amidase US20100311711 A NN I-UN
( US20100311711 A ( O
NAAA US20100311711 A NNP I-UN
) US20100311711 A ) O
to US20100311711 A TO O
so US20100311711 A RB O
increase US20100311711 A VB O
the US20100311711 A DT O
concentration US20100311711 A NN O
of US20100311711 A IN O
the US20100311711 A DT O
substrate US20100311711 A NN O
of US20100311711 A IN O
NAAA US20100311711 A NNP I-UN
, US20100311711 A , O
palmitoylethanolamide US20100311711 A NN O
( US20100311711 A ( O
PEA US20100311711 A NNP O
) US20100311711 A ) O
. US20100311711 A . O

NAAA US20100311711 A NNP I-UN
inhibition US20100311711 A NN O
is US20100311711 A VBZ O
contemplated US20100311711 A VBN O
to US20100311711 A TO O
be US20100311711 A VB O
effective US20100311711 A JJ O
to US20100311711 A TO O
alleviate US20100311711 A VB O
conditions US20100311711 A NNS O
associated US20100311711 A VBN O
with US20100311711 A IN O
a US20100311711 A DT O
reduced US20100311711 A JJ O
concentration US20100311711 A NN O
of US20100311711 A IN O
PEA US20100311711 A NNP O
. US20100311711 A . O

Among US20100311711 A IN O
other US20100311711 A JJ O
uses US20100311711 A NNS O
, US20100311711 A , O
various US20100311711 A JJ O
NAAA US20100311711 A NNP I-UN
inhibitors US20100311711 A NNS O
are US20100311711 A VBP O
especially US20100311711 A RB O
contemplated US20100311711 A VBN O
as US20100311711 A IN O
therapeutic US20100311711 A JJ O
agents US20100311711 A NNS O
in US20100311711 A IN O
the US20100311711 A DT O
treatment US20100311711 A NN O
of US20100311711 A IN O
inflammatory US20100311711 A JJ O
diseases US20100311711 A NNS O
. US20100311711 A . O

Application CN103156827A T NN O
of CN103156827A T IN O
stilbene CN103156827A T JJ O
compounds CN103156827A T NNS O
in CN103156827A T IN O
treating CN103156827A T VBG O
and CN103156827A T CC O
preventing CN103156827A T VBG O
AIDS CN103156827A T NNP O
. CN103156827A T . O

In CN103156827A A IN O
the CN103156827A A DT O
compounds CN103156827A A NNS O
represented CN103156827A A VBN O
by CN103156827A A IN O
the CN103156827A A DT O
general CN103156827A A JJ O
formula CN103156827A A NN O
( CN103156827A A ( O
I CN103156827A A PRP O
) CN103156827A A ) O
, CN103156827A A , O
the CN103156827A A DT O
inhibition CN103156827A A NN O
activity CN103156827A A NN O
IC50 CN103156827A A NNP O
of CN103156827A A IN O
a CN103156827A A DT O
stilbene CN103156827A A NN O
compound CN103156827A A NN O
piceatannol CN103156827A A NN O
against CN103156827A A IN O
HIV-1 CN103156827A A NNP I-UN
protease CN103156827A A NN I-UN
reaches CN103156827A A VBZ O
59mum CN103156827A A CD O
. CN103156827A A . O

Taste CN101632642B T NN O
and CN101632642B T CC O
stability CN101632642B T NN O
improved CN101632642B T VBN O
formula CN101632642B T NN O
. CN101632642B T . O

The CN101632642B A DT O
present CN101632642B A JJ O
invention CN101632642B A NN O
relates CN101632642B A VBZ O
to CN101632642B A TO O
pharmaceutical CN101632642B A JJ O
compositions CN101632642B A NNS O
for CN101632642B A IN O
oral CN101632642B A JJ O
administration CN101632642B A NN O
of CN101632642B A IN O
active CN101632642B A JJ O
compounds CN101632642B A NNS O
. CN101632642B A . O

Polyphosphazene EP1578441A2 T NNP O
immunocstimulants EP1578441A2 T NNS O
. EP1578441A2 T . O

System EP0989863B1 T NN O
for EP0989863B1 T IN O
the EP0989863B1 T DT O
in EP0989863B1 T IN O
vivo EP0989863B1 T JJ O
delivery EP0989863B1 T NN O
and EP0989863B1 T CC O
expression EP0989863B1 T NN O
of EP0989863B1 T IN O
heterologous EP0989863B1 T JJ O
genes EP0989863B1 T NNS O
in EP0989863B1 T IN O
the EP0989863B1 T DT O
bone EP0989863B1 T NN O
marrow EP0989863B1 T NN O
. EP0989863B1 T . O

Compositions CA2073500C T NNS O
and CA2073500C T CC O
methods CA2073500C T NNS O
for CA2073500C T IN O
detecting CA2073500C T VBG O
and CA2073500C T CC O
modulating CA2073500C T VBG O
rna CA2073500C T NN O
activity CA2073500C T NN O
and CA2073500C T CC O
gene CA2073500C T NN O
expression CA2073500C T NN O
. CA2073500C T . O

viricides US7189718 T NNS O
; US7189718 T : O
polymerase US7189718 T NN O
inhibitor US7189718 T NN O
; US7189718 T : O
therapy US7189718 T NN O
for US7189718 T IN O
genetic US7189718 T JJ O
engineered US7189718 T JJ O
viruses US7189718 T NNS O
. US7189718 T . O

This US7189718 A DT O
invention US7189718 A NN O
relates US7189718 A VBZ O
to US7189718 A TO O
novel US7189718 A VB O
pyridazinone US7189718 A NN O
derivatives US7189718 A NNS O
of US7189718 A IN O
formula US7189718 A NN O
I US7189718 A PRP O
wherein US7189718 A VBP O
R1–R4 US7189718 A NNP O
, US7189718 A , O
R7 US7189718 A NNP O
, US7189718 A , O
R8 US7189718 A NNP O
and US7189718 A CC O
X1 US7189718 A NNP O
are US7189718 A VBP O
as US7189718 A IN O
defined US7189718 A VBN O
in US7189718 A IN O
the US7189718 A DT O
summary US7189718 A JJ O
and US7189718 A CC O
pharmaceutically US7189718 A RB O
acceptable US7189718 A JJ O
salts US7189718 A NNS O
and US7189718 A CC O
solvates US7189718 A NNS O
thereof US7189718 A VBP O
, US7189718 A , O
methods US7189718 A NNS O
to US7189718 A TO O
inhibit US7189718 A VB O
or US7189718 A CC O
modulate US7189718 A VB O
Human US7189718 A NNP I-UN
Immunodeficiency US7189718 A NNP I-UN
Virus US7189718 A NNP I-UN
( US7189718 A ( I-UN
HIV US7189718 A NNP I-UN
) US7189718 A ) I-UN
reverse US7189718 A NN I-UN
transcriptase US7189718 A NN I-UN
with US7189718 A IN O
compounds US7189718 A NNS O
of US7189718 A IN O
formula US7189718 A NN O
I US7189718 A PRP O
, US7189718 A , O
pharmaceutical US7189718 A JJ O
compositions US7189718 A NNS O
containing US7189718 A VBG O
of US7189718 A IN O
formula US7189718 A NN O
I US7189718 A PRP O
admixed US7189718 A VBP O
with US7189718 A IN O
at US7189718 A IN O
least US7189718 A JJS O
one US7189718 A CD O
solvent US7189718 A NN O
, US7189718 A , O
carrier US7189718 A NN O
or US7189718 A CC O
excipient US7189718 A NN O
and US7189718 A CC O
processes US7189718 A VBZ O
to US7189718 A TO O
prepare US7189718 A VB O
compounds US7189718 A NNS O
of US7189718 A IN O
formula US7189718 A NN O
I US7189718 A PRP O
. US7189718 A . O

Oral CN1559435A T JJ O
liqid-supplement CN1559435A T JJ O
salt CN1559435A T NN O
effervesce CN1559435A T JJ O
tablets CN1559435A T NNS O
, CN1559435A T , O
and CN1559435A T CC O
prepn CN1559435A T NN O
. CN1559435A T . O

method CN1559435A T NN O
therefor CN1559435A T NN O
. CN1559435A T . O

serotonin US20080200470 T JJ I-UN
5-HT1A US20080200470 T JJ I-UN
receptor US20080200470 T NN I-UN
agonists US20080200470 T NNS O
; US20080200470 T : O
N-heterocyclclediones US20080200470 T NNP O
substituted US20080200470 T VBD O
with US20080200470 T IN O
a US20080200470 T DT O
chroman-2-yl US20080200470 T JJ O
, US20080200470 T , O
2-quinolyl US20080200470 T JJ O
, US20080200470 T , O
or US20080200470 T CC O
phenoxy US20080200470 T JJ O
group US20080200470 T NN O
; US20080200470 T : O
2- US20080200470 T JJ O
[ US20080200470 T NNP O
4- US20080200470 T JJ O
[ US20080200470 T NNP O
( US20080200470 T ( O
Chroman-2-yl US20080200470 T NNP O
) US20080200470 T ) O
methylamino US20080200470 T NN O
] US20080200470 T JJ O
butyl US20080200470 T NN O
] US20080200470 T NNP O
-1,3-dioxoperhydroimidazo US20080200470 T NNP O
[ US20080200470 T NNP O
1,5-a US20080200470 T JJ O
] US20080200470 T NNP O
pyridine US20080200470 T NN O
; US20080200470 T : O
Parkinson US20080200470 T NNP O
's US20080200470 T POS O
, US20080200470 T , O
cerebral US20080200470 T JJ O
damage US20080200470 T NN O
by US20080200470 T IN O
thromboembolitic US20080200470 T JJ O
ictus US20080200470 T NN O
, US20080200470 T , O
depression US20080200470 T NN O
, US20080200470 T , O
migraine US20080200470 T NN O
, US20080200470 T , O
psychosis US20080200470 T NN O
, US20080200470 T , O
urinary US20080200470 T JJ O
disorde US20080200470 T NN O
. US20080200470 T . O

The US20080200470 A DT O
present US20080200470 A JJ O
invention US20080200470 A NN O
relates US20080200470 A VBZ O
to US20080200470 A TO O
certain US20080200470 A JJ O
derivatives US20080200470 A NNS O
of US20080200470 A IN O
cycloalkanediones US20080200470 A NNS O
invariably US20080200470 A RB O
substituted US20080200470 A VBD O
with US20080200470 A IN O
a US20080200470 A DT O
chroman-2-yl US20080200470 A JJ O
, US20080200470 A , O
2-quinolyl US20080200470 A JJ O
or US20080200470 A CC O
—O-phenyl US20080200470 A JJ O
residue US20080200470 A NN O
which US20080200470 A WDT O
are US20080200470 A VBP O
serotonin US20080200470 A JJ O
( US20080200470 A ( O
5-hydroxytryptamine US20080200470 A JJ O
, US20080200470 A , O
5-HT US20080200470 A JJ O
) US20080200470 A ) O
5-HT1A US20080200470 A JJ I-UN
receptor US20080200470 A NN I-UN
subtype US20080200470 A NN O
agonists US20080200470 A VBZ O
modulators US20080200470 A NNS O
, US20080200470 A , O
to US20080200470 A TO O
their US20080200470 A PRP$ O
stereochemical US20080200470 A JJ O
isomers US20080200470 A NNS O
and US20080200470 A CC O
to US20080200470 A TO O
their US20080200470 A PRP$ O
use US20080200470 A NN O
in US20080200470 A IN O
the US20080200470 A DT O
preparation US20080200470 A NN O
of US20080200470 A IN O
a US20080200470 A DT O
medicament US20080200470 A NN O
for US20080200470 A IN O
the US20080200470 A DT O
treatment US20080200470 A NN O
of US20080200470 A IN O
pathological US20080200470 A JJ O
states US20080200470 A NNS O
for US20080200470 A IN O
which US20080200470 A WDT O
an US20080200470 A DT O
agonist US20080200470 A NN O
a US20080200470 A DT O
modulator US20080200470 A NN O
of US20080200470 A IN O
these US20080200470 A DT O
receptors US20080200470 A NNS O
is US20080200470 A VBZ O
indicated US20080200470 A VBN O
. US20080200470 A . O

contacting US7872140 T NN O
( US7872140 T ( O
S US7872140 T NNP O
) US7872140 T ) O
-omeprazole US7872140 T VBP O
freebase US7872140 T NN O
or US7872140 T CC O
its US7872140 T PRP$ O
sodium/potassium US7872140 T NN O
salt US7872140 T NN O
with US7872140 T IN O
inorganic US7872140 T JJ O
or US7872140 T CC O
organic US7872140 T JJ O
acid US7872140 T NN O
salt US7872140 T NN O
of US7872140 T IN O
the US7872140 T DT O
barium US7872140 T NN O
( US7872140 T ( O
barium US7872140 T JJ O
chloride US7872140 T NN O
, US7872140 T , O
barium US7872140 T NN O
sulfate US7872140 T NN O
, US7872140 T , O
barium US7872140 T NN O
oxalate US7872140 T NN O
, US7872140 T , O
barium US7872140 T NN O
acetate US7872140 T NN O
) US7872140 T ) O
in US7872140 T IN O
a US7872140 T DT O
suitable US7872140 T JJ O
solvent US7872140 T NN O
( US7872140 T ( O
methanol US7872140 T NN O
) US7872140 T ) O
in US7872140 T IN O
presence US7872140 T NN O
of US7872140 T IN O
a US7872140 T DT O
base US7872140 T NN O
( US7872140 T ( O
NaOH US7872140 T NNP O
) US7872140 T ) O
to US7872140 T TO O
form US7872140 T VB O
( US7872140 T ( O
S US7872140 T NNP O
) US7872140 T ) O
-omeprazole US7872140 T NNP O
barium US7872140 T NN O
; US7872140 T : O
helicobacter US7872140 T NN O
infections US7872140 T NNS O
. US7872140 T . O

Combination US20080058345 T NNP O
Therapy US20080058345 T NNP O
with US20080058345 T IN O
Mecamylamine US20080058345 T NNP O
for US20080058345 T IN O
the US20080058345 T DT O
Treatment US20080058345 T NNP O
of US20080058345 T IN O
Mood US20080058345 T NNP O
Disorders US20080058345 T NNP O
. US20080058345 T . O

Treating US7122187 T VBG O
autoimmune US7122187 T NN O
diseases US7122187 T NNS O
with US7122187 T IN O
humanized US7122187 T JJ O
anti-CD40L US7122187 T JJ O
antibody US7122187 T NN O
. US7122187 T . O

The US7122187 A DT O
present US7122187 A JJ O
invention US7122187 A NN O
is US7122187 A VBZ O
directed US7122187 A VBN O
to US7122187 A TO O
humanized US7122187 A VB O
antibodies US7122187 A NNS O
which US7122187 A WDT O
bind US7122187 A VBP O
human US7122187 A JJ O
gp39 US7122187 A NN O
and US7122187 A CC O
their US7122187 A PRP$ O
use US7122187 A NN O
as US7122187 A IN O
therapeutic US7122187 A JJ O
agents US7122187 A NNS O
. US7122187 A . O

These US7122187 A DT O
humanized US7122187 A VBN O
antibodies US7122187 A NNS O
are US7122187 A VBP O
especially US7122187 A RB O
useful US7122187 A JJ O
for US7122187 A IN O
treatment US7122187 A NN O
of US7122187 A IN O
autoimmune US7122187 A JJ O
diseases US7122187 A NNS O
; US7122187 A : O
and US7122187 A CC O
an US7122187 A DT O
immunosuppressant US7122187 A NN O
during US7122187 A IN O
transplantation US7122187 A NN O
of US7122187 A IN O
heterologous US7122187 A JJ O
cells US7122187 A NNS O
, US7122187 A , O
tissues US7122187 A NNS O
or US7122187 A CC O
organs US7122187 A NNS O
, US7122187 A , O
cell US7122187 A NN O
therapy US7122187 A NN O
, US7122187 A , O
and US7122187 A CC O
gene US7122187 A NN O
therapy US7122187 A NN O
. US7122187 A . O

Thiadiazole CN101378757B T NNP O
derivatives CN101378757B T NNS O
for CN101378757B T IN O
the CN101378757B T DT O
treatment CN101378757B T NN O
of CN101378757B T IN O
neuro CN101378757B T JJ O
degenerative CN101378757B T JJ O
diseases CN101378757B T NNS O
. CN101378757B T . O

Method WO2008092465A1 T NNP O
and WO2008092465A1 T CC O
device WO2008092465A1 T NN O
for WO2008092465A1 T IN O
obtaining WO2008092465A1 T VBG O
a WO2008092465A1 T DT O
salt WO2008092465A1 T NN O
aerosol WO2008092465A1 T NN O
of WO2008092465A1 T IN O
adjustable WO2008092465A1 T JJ O
concentration WO2008092465A1 T NN O
and WO2008092465A1 T CC O
personal WO2008092465A1 T JJ O
halotheraphy WO2008092465A1 T NN O
assembly WO2008092465A1 T NN O
. WO2008092465A1 T . O

Sulfonylurea WO2013086980A1 T NNP O
guanidine WO2013086980A1 T NN O
, WO2013086980A1 T , O
preparation WO2013086980A1 T NN O
method WO2013086980A1 T NN O
and WO2013086980A1 T CC O
use WO2013086980A1 T NN O
thereof WO2013086980A1 T NN O
. WO2013086980A1 T . O

Compared WO2013086980A1 A VBN O
to WO2013086980A1 A TO O
prior WO2013086980A1 A VB O
art WO2013086980A1 A NN O
, WO2013086980A1 A , O
the WO2013086980A1 A DT O
compound WO2013086980A1 A NN O
of WO2013086980A1 A IN O
the WO2013086980A1 A DT O
present WO2013086980A1 A JJ O
invention WO2013086980A1 A NN O
has WO2013086980A1 A VBZ O
a WO2013086980A1 A DT O
dual WO2013086980A1 A JJ O
structure WO2013086980A1 A NN O
of WO2013086980A1 A IN O
sulfonylurea WO2013086980A1 A NN O
and WO2013086980A1 A CC O
aminoguanidine WO2013086980A1 A NN O
; WO2013086980A1 A : O
the WO2013086980A1 A DT O
sulfonylurea WO2013086980A1 A NN O
can WO2013086980A1 A MD O
reduce WO2013086980A1 A VB O
blood WO2013086980A1 A NN O
sugar WO2013086980A1 A NN O
level WO2013086980A1 A NN O
by WO2013086980A1 A IN O
enhancing WO2013086980A1 A VBG O
the WO2013086980A1 A DT O
secretion WO2013086980A1 A NN O
of WO2013086980A1 A IN O
endogenous WO2013086980A1 A JJ O
insulin WO2013086980A1 A NN I-UN
, WO2013086980A1 A , O
and WO2013086980A1 A CC O
the WO2013086980A1 A DT O
aminoguanidine WO2013086980A1 A NN O
structure WO2013086980A1 A NN O
has WO2013086980A1 A VBZ O
significant WO2013086980A1 A JJ O
prevention WO2013086980A1 A NN O
and WO2013086980A1 A CC O
treatment WO2013086980A1 A NN O
effects WO2013086980A1 A NNS O
for WO2013086980A1 A IN O
various WO2013086980A1 A JJ O
complications WO2013086980A1 A NNS O
of WO2013086980A1 A IN O
diabetic WO2013086980A1 A JJ O
patients WO2013086980A1 A NNS O
. WO2013086980A1 A . O

N-acetyl-l-cysteine US20120238627 T NN O
for US20120238627 T IN O
the US20120238627 T DT O
treatment US20120238627 T NN O
of US20120238627 T IN O
endometriosis US20120238627 T NN O
. US20120238627 T . O

Sulfur-containing CN1951923A T JJ O
quinoxaline CN1951923A T NN O
dioxide CN1951923A T NN O
, CN1951923A T , O
method CN1951923A T NN O
for CN1951923A T IN O
producing CN1951923A T VBG O
same CN1951923A T JJ O
and CN1951923A T CC O
their CN1951923A T PRP$ O
application CN1951923A T NN O
. CN1951923A T . O

The CN1951923A A DT O
invention CN1951923A A NN O
discloses CN1951923A A VBZ O
a CN1951923A A DT O
quinoxaline CN1951923A A NN O
dioxide CN1951923A A NN O
with CN1951923A A IN O
sulphur CN1951923A A NN O
, CN1951923A A , O
which CN1951923A A WDT O
possesses CN1951923A A VBZ O
structural CN1951923A A JJ O
formula CN1951923A A NN O
as CN1951923A A IN O
follows CN1951923A A VBZ O
: CN1951923A A : O
R1=CH3 CN1951923A A NNP O
, CN1951923A A , O
OCH3 CN1951923A A NNP O
, CN1951923A A , O
Cl CN1951923A A NNP O
, CN1951923A A , O
H CN1951923A A NNP O
; CN1951923A A : O
R2=CH3 CN1951923A A NNP O
, CN1951923A A , O
F CN1951923A A NNP O
, CN1951923A A , O
Cl CN1951923A A NNP O
, CN1951923A A , O
Br CN1951923A A NNP O
, CN1951923A A , O
OCH3 CN1951923A A NNP O
, CN1951923A A , O
H CN1951923A A NNP O
; CN1951923A A : O
R3=CH2CH3 CN1951923A A NNP O
, CN1951923A A , O
C6H6 CN1951923A A NNP O
. CN1951923A A . O

The CN1951923A A DT O
preparing CN1951923A A NN O
method CN1951923A A NN O
comprises CN1951923A A VBZ O
the CN1951923A A DT O
following CN1951923A A JJ O
steps CN1951923A A NNS O
: CN1951923A A : O
adopting CN1951923A A VBG O
quinoxaline CN1951923A A JJ O
dioxide CN1951923A A RB O
ZM-81853 CN1951923A A NNP O
as CN1951923A A IN O
lead CN1951923A A NN O
; CN1951923A A : O
modifying CN1951923A A VBG O
benzene CN1951923A A NN O
ring CN1951923A A NN O
and CN1951923A A CC O
3-amino CN1951923A A JJ O
; CN1951923A A : O
synthesizing CN1951923A A VBG O
2-substituted CN1951923A A JJ O
benzene-3-thioalkylation CN1951923A A NN O
or CN1951923A A CC O
thioaryl-quinoxaline-1 CN1951923A A NN O
, CN1951923A A , O
4-dioxide CN1951923A A JJ O
; CN1951923A A : O
possessing CN1951923A A VBG O
tumour-resistance CN1951923A A NN O
activity CN1951923A A NN O
and CN1951923A A CC O
low-oxygen CN1951923A A JJ O
selectivity CN1951923A A NN O
corresponding CN1951923A A VBG O
to CN1951923A A TO O
ZM-81853 CN1951923A A NNP O
. CN1951923A A . O

Nebivolol US20090181975 T NNP O
in US20090181975 T IN O
the US20090181975 T DT O
treatment US20090181975 T NN O
of US20090181975 T IN O
sexual US20090181975 T JJ O
dysfunction US20090181975 T NN O
. US20090181975 T . O

a US20090181975 A DT O
PDE-5 US20090181975 A NNP I-UN
inhibitor US20090181975 A NN O
, US20090181975 A , O
such US20090181975 A JJ O
as US20090181975 A IN O
sildenafil US20090181975 A JJ O
citrate US20090181975 A NN O
. US20090181975 A . O

Novel US20110319423 T NNP O
dopamine US20110319423 T NN I-UN
d3 US20110319423 T NN I-UN
receptor US20110319423 T NN I-UN
ligands US20110319423 T NNS O
and US20110319423 T CC O
preparation US20110319423 T NN O
and US20110319423 T CC O
medical US20110319423 T JJ O
uses US20110319423 T NNS O
of US20110319423 T IN O
the US20110319423 T DT O
same US20110319423 T JJ O
. US20110319423 T . O

The US20110319423 A DT O
present US20110319423 A JJ O
invention US20110319423 A NN O
relates US20110319423 A VBZ O
to US20110319423 A TO O
a US20110319423 A DT O
novel US20110319423 A JJ O
piperazine US20110319423 A NN O
derivative US20110319423 A NN O
represented US20110319423 A VBN O
by US20110319423 A IN O
Formula US20110319423 A NNP O
I US20110319423 A PRP O
having US20110319423 A VBG O
an US20110319423 A DT O
activity US20110319423 A NN O
for US20110319423 A IN O
regulating US20110319423 A VBG O
dopamine US20110319423 A NN I-UN
D3 US20110319423 A NNP I-UN
receptor US20110319423 A NN I-UN
, US20110319423 A , O
stereoisomers US20110319423 A NNS O
thereof US20110319423 A VBP O
, US20110319423 A , O
pharmaceutically US20110319423 A RB O
acceptable US20110319423 A JJ O
salts US20110319423 A NNS O
or US20110319423 A CC O
solvates US20110319423 A NNS O
, US20110319423 A , O
and US20110319423 A CC O
a US20110319423 A DT O
pharmaceutical US20110319423 A JJ O
composition US20110319423 A NN O
comprising US20110319423 A VBG O
the US20110319423 A DT O
compound US20110319423 A NN O
, US20110319423 A , O
a US20110319423 A DT O
process US20110319423 A NN O
for US20110319423 A IN O
preparing US20110319423 A VBG O
the US20110319423 A DT O
same US20110319423 A JJ O
, US20110319423 A , O
and US20110319423 A CC O
use US20110319423 A VB O
thereof US20110319423 A NN O
in US20110319423 A IN O
the US20110319423 A DT O
prevention US20110319423 A NN O
or US20110319423 A CC O
treatment US20110319423 A NN O
of US20110319423 A IN O
a US20110319423 A DT O
disease US20110319423 A NN O
associated US20110319423 A VBN O
with US20110319423 A IN O
central US20110319423 A JJ O
nervous US20110319423 A JJ O
system US20110319423 A NN O
dysfunction US20110319423 A NN O
, US20110319423 A , O
such US20110319423 A JJ O
as US20110319423 A IN O
Parkinson US20110319423 A NNP O
's US20110319423 A POS O
disease US20110319423 A NN O
, US20110319423 A , O
schizophrenia US20110319423 A NN O
, US20110319423 A , O
drug US20110319423 A NN O
addiction US20110319423 A NN O
and US20110319423 A CC O
relapse US20110319423 A NN O
, US20110319423 A , O
as US20110319423 A RB O
well US20110319423 A RB O
as US20110319423 A IN O
kidney US20110319423 A NN O
protection US20110319423 A NN O
and US20110319423 A CC O
immunoregulation US20110319423 A NN O
, US20110319423 A , O
or US20110319423 A CC O
as US20110319423 A IN O
a US20110319423 A DT O
tool US20110319423 A NN O
for US20110319423 A IN O
researching US20110319423 A VBG O
D3R US20110319423 A NNP I-UN
function US20110319423 A NN O
or US20110319423 A CC O
diseases US20110319423 A NNS O
associated US20110319423 A VBN O
with US20110319423 A IN O
D3R US20110319423 A NNP I-UN
dysfunction US20110319423 A NN O
. US20110319423 A . O

Nitrogen CN102875564A T NNP O
substitution CN102875564A T NN O
podophyllum CN102875564A T NN O
type CN102875564A T NN O
derivatives CN102875564A T NNS O
with CN102875564A T IN O
antitumor CN102875564A T NN O
activity CN102875564A T NN O
and CN102875564A T CC O
preparation CN102875564A T NN O
method CN102875564A T NN O
and CN102875564A T CC O
application CN102875564A T NN O
thereof CN102875564A T NN O
. CN102875564A T . O

Thiophene-2-carboxamide US20110183960 T JJ O
derivatives US20110183960 T NNS O
, US20110183960 T , O
preparation US20110183960 T NN O
thereof US20110183960 T NN O
and US20110183960 T CC O
therapeutic US20110183960 T JJ O
use US20110183960 T NN O
thereof US20110183960 T NN O
. US20110183960 T . O

Foodstuff CN102813112A T NNP O
for CN102813112A T IN O
diabetic CN102813112A T JJ O
nephropathy CN102813112A T NN O
. CN102813112A T . O

The CN102813112A A DT O
invention CN102813112A A NN O
provides CN102813112A A VBZ O
a CN102813112A A DT O
foodstuff CN102813112A A NN O
for CN102813112A A IN O
diabetic CN102813112A A JJ O
nephropathy CN102813112A A NN O
. CN102813112A A . O

The CN102813112A A DT O
foodstuff CN102813112A A NN O
is CN102813112A A VBZ O
prepared CN102813112A A VBN O
from CN102813112A A IN O
the CN102813112A A DT O
following CN102813112A A JJ O
raw CN102813112A A JJ O
materials CN102813112A A NNS O
expressed CN102813112A A VBN O
in CN102813112A A IN O
weight CN102813112A A NN O
parts CN102813112A A NNS O
: CN102813112A A : O
20 CN102813112A A CD O
to CN102813112A A TO O
50 CN102813112A A CD O
parts CN102813112A A NNS O
of CN102813112A A IN O
total CN102813112A A JJ O
polysaccharide CN102813112A A NN O
of CN102813112A A IN O
Radix CN102813112A A NNP O
Astragali CN102813112A A NNP O
, CN102813112A A , O
15 CN102813112A A CD O
to CN102813112A A TO O
60 CN102813112A A CD O
parts CN102813112A A NNS O
of CN102813112A A IN O
polysaccharide CN102813112A A NN O
of CN102813112A A IN O
rehmannia CN102813112A A NN O
, CN102813112A A , O
1 CN102813112A A CD O
to CN102813112A A TO O
4 CN102813112A A CD O
parts CN102813112A A NNS O
of CN102813112A A IN O
total CN102813112A A JJ O
glycoside CN102813112A A NN O
of CN102813112A A IN O
rhizome CN102813112A A JJ O
alismatis CN102813112A A NN O
, CN102813112A A , O
2 CN102813112A A CD O
to CN102813112A A TO O
4 CN102813112A A CD O
parts CN102813112A A NNS O
of CN102813112A A IN O
paeoniflorin CN102813112A A NN O
, CN102813112A A , O
15 CN102813112A A CD O
to CN102813112A A TO O
36 CN102813112A A CD O
parts CN102813112A A NNS O
of CN102813112A A IN O
polysaccharide CN102813112A A NN O
of CN102813112A A IN O
plantain CN102813112A A NN O
seeds CN102813112A A NNS O
, CN102813112A A , O
1 CN102813112A A CD O
to CN102813112A A TO O
3 CN102813112A A CD O
parts CN102813112A A NNS O
of CN102813112A A IN O
methionine CN102813112A A NN O
, CN102813112A A , O
2 CN102813112A A CD O
to CN102813112A A TO O
6 CN102813112A A CD O
parts CN102813112A A NNS O
of CN102813112A A IN O
taurine CN102813112A A NN O
, CN102813112A A , O
1 CN102813112A A CD O
to CN102813112A A TO O
3 CN102813112A A CD O
parts CN102813112A A NNS O
of CN102813112A A IN O
choline CN102813112A A NN O
, CN102813112A A , O
1 CN102813112A A CD O
to CN102813112A A TO O
3 CN102813112A A CD O
parts CN102813112A A NNS O
of CN102813112A A IN O
inositol CN102813112A A NN O
and CN102813112A A CC O
400 CN102813112A A CD O
to CN102813112A A TO O
1000 CN102813112A A CD O
parts CN102813112A A NNS O
of CN102813112A A IN O
a CN102813112A A DT O
water CN102813112A A NN O
extract CN102813112A A NN O
of CN102813112A A IN O
corn CN102813112A A NN O
silk CN102813112A A NN O
. CN102813112A A . O

Process US20100210716 T NN O
for US20100210716 T IN O
Preparing US20100210716 T VBG O
an US20100210716 T DT O
Alpha-Lipoic US20100210716 T JJ O
Acid/Cyclodextrin US20100210716 T NNP O
Complex US20100210716 T NNP O
and US20100210716 T CC O
Product US20100210716 T NNP O
Prepared US20100210716 T NNP O
. US20100210716 T . O

Amino WO2011121068A1 T NNP O
derivatives WO2011121068A1 T NNS O
of WO2011121068A1 T IN O
cyclohex-2-enone WO2011121068A1 T NN O
, WO2011121068A1 T , O
their WO2011121068A1 T PRP$ O
preparation WO2011121068A1 T NN O
and WO2011121068A1 T CC O
use WO2011121068A1 T NN O
as WO2011121068A1 T IN O
antioxidants WO2011121068A1 T NNS O
. WO2011121068A1 T . O

Preparation CN102633849A T NNP O
method CN102633849A T NN O
and CN102633849A T CC O
anticancer CN102633849A T NN O
use CN102633849A T NN O
of CN102633849A T IN O
iridoid CN102633849A T JJ O
catalpa CN102633849A T NN O
glycosides CN102633849A T NNS O
. CN102633849A T . O

Method US20090060983 T NNP O
And US20090060983 T CC O
Composition US20090060983 T NNP O
For US20090060983 T IN O
Making US20090060983 T VBG O
An US20090060983 T DT O
Orally US20090060983 T NNP O
Disintegrating US20090060983 T NNP O
Dosage US20090060983 T NNP O
Form US20090060983 T NNP O
. US20090060983 T . O

Aerosol US20050129621 T NNP O
formulations US20050129621 T NNS O
for US20050129621 T IN O
pulmonary US20050129621 T JJ O
administration US20050129621 T NN O
of US20050129621 T IN O
medicaments US20050129621 T NNS O
to US20050129621 T TO O
produce US20050129621 T VB O
a US20050129621 T DT O
systemic US20050129621 T JJ O
effect US20050129621 T NN O
. US20050129621 T . O

Scce EP1367886B1 T NNP I-UN
transgenic EP1367886B1 T JJ O
mice EP1367886B1 T NN O
and EP1367886B1 T CC O
their EP1367886B1 T PRP$ O
use EP1367886B1 T NN O
as EP1367886B1 T IN O
models EP1367886B1 T NNS O
of EP1367886B1 T IN O
human EP1367886B1 T JJ O
disease EP1367886B1 T NN O
. EP1367886B1 T . O

The EP1367886B1 A DT O
serine EP1367886B1 A JJ O
protease EP1367886B1 A NN O
SCCE EP1367886B1 A NNP I-UN
is EP1367886B1 A VBZ O
preferentially EP1367886B1 A RB O
expressed EP1367886B1 A VBN O
in EP1367886B1 A IN O
cornifying EP1367886B1 A VBG O
epithelia EP1367886B1 A NN O
. EP1367886B1 A . O

Increased EP1367886B1 A VBN O
expression EP1367886B1 A NN O
of EP1367886B1 A IN O
SCCE EP1367886B1 A NNP I-UN
in EP1367886B1 A IN O
psoriasis EP1367886B1 A NN O
has EP1367886B1 A VBZ O
previously EP1367886B1 A RB O
been EP1367886B1 A VBN O
reported EP1367886B1 A VBN O
. EP1367886B1 A . O

Increased EP1367886B1 A VBN O
SCCE EP1367886B1 A NNP I-UN
expression EP1367886B1 A NN O
also EP1367886B1 A RB O
in EP1367886B1 A IN O
chronic EP1367886B1 A JJ O
lesions EP1367886B1 A NNS O
of EP1367886B1 A IN O
atopic EP1367886B1 A NN O
dermatitis EP1367886B1 A NN O
is EP1367886B1 A VBZ O
described EP1367886B1 A VBN O
herein EP1367886B1 A NNS O
. EP1367886B1 A . O

Transgenic EP1367886B1 A NNP O
mice EP1367886B1 A NN O
expressing EP1367886B1 A VBG O
human EP1367886B1 A JJ I-UN
SCCE EP1367886B1 A NNP I-UN
in EP1367886B1 A IN O
suprabasal EP1367886B1 A NN O
epidermal EP1367886B1 A JJ O
keratinocytes EP1367886B1 A NNS O
were EP1367886B1 A VBD O
found EP1367886B1 A VBN O
to EP1367886B1 A TO O
develop EP1367886B1 A VB O
pathological EP1367886B1 A JJ O
skin EP1367886B1 A NN O
changes EP1367886B1 A NNS O
with EP1367886B1 A IN O
increased EP1367886B1 A JJ O
epidermal EP1367886B1 A JJ O
thickness EP1367886B1 A NN O
, EP1367886B1 A , O
hyperkeratosis EP1367886B1 A NN O
, EP1367886B1 A , O
dermal EP1367886B1 A JJ O
inflammation EP1367886B1 A NN O
, EP1367886B1 A , O
and EP1367886B1 A CC O
severe EP1367886B1 A JJ O
pruritus EP1367886B1 A NN O
. EP1367886B1 A . O

The EP1367886B1 A DT O
results EP1367886B1 A NNS O
strengthen EP1367886B1 A VBP O
the EP1367886B1 A DT O
idea EP1367886B1 A NN O
that EP1367886B1 A IN O
SCCE EP1367886B1 A NNP I-UN
may EP1367886B1 A MD O
be EP1367886B1 A VB O
involved EP1367886B1 A VBN O
in EP1367886B1 A IN O
the EP1367886B1 A DT O
pathogenesis EP1367886B1 A NN O
of EP1367886B1 A IN O
inflammatory EP1367886B1 A JJ O
skin EP1367886B1 A NN O
diseases EP1367886B1 A NNS O
, EP1367886B1 A , O
and EP1367886B1 A CC O
may EP1367886B1 A MD O
offer EP1367886B1 A VB O
a EP1367886B1 A DT O
new EP1367886B1 A JJ O
therapeutic EP1367886B1 A JJ O
target EP1367886B1 A NN O
. EP1367886B1 A . O

α-arylethylpiperazine US6916797 T JJ O
derivatives US6916797 T NNS O
as US6916797 T IN O
neurokinin US6916797 T JJ O
antagonists US6916797 T NNS O
. US6916797 T . O

Application WO2008040153A1 T NN O
of WO2008040153A1 T IN O
a WO2008040153A1 T DT O
coumarin WO2008040153A1 T NN O
compound WO2008040153A1 T NN O
in WO2008040153A1 T IN O
preparation WO2008040153A1 T NN O
of WO2008040153A1 T IN O
medicament WO2008040153A1 T NN O
for WO2008040153A1 T IN O
inducing WO2008040153A1 T VBG O
nerve WO2008040153A1 T JJ O
stem WO2008040153A1 T NN O
cell WO2008040153A1 T NN O
orienting WO2008040153A1 T VBG O
differentiation WO2008040153A1 T NN O
. WO2008040153A1 T . O

Epherin WO2013106824A1 T NNP O
receptor WO2013106824A1 T NN O
targeting WO2013106824A1 T VBG O
agents WO2013106824A1 T NNS O
. WO2013106824A1 T . O

In WO2013106824A1 A IN O
particular WO2013106824A1 A JJ O
, WO2013106824A1 A , O
the WO2013106824A1 A DT O
agents WO2013106824A1 A NNS O
can WO2013106824A1 A MD O
be WO2013106824A1 A VB O
used WO2013106824A1 A VBN O
for WO2013106824A1 A IN O
targeting WO2013106824A1 A VBG O
cells WO2013106824A1 A NNS O
expressing WO2013106824A1 A VBG O
EphB4 WO2013106824A1 A NNP I-UN
and/or WO2013106824A1 A NN O
EphA2 WO2013106824A1 A NNP I-UN
receptors WO2013106824A1 A NNS O
. WO2013106824A1 A . O

Composite CN101757624A T NNP O
for CN101757624A T IN O
preventing CN101757624A T VBG O
and CN101757624A T CC O
curing CN101757624A T VBG O
senile CN101757624A T JJ O
dementia CN101757624A T NN O
. CN101757624A T . O

The CN101757624A A DT O
invention CN101757624A A NN O
provides CN101757624A A VBZ O
a CN101757624A A DT O
composite CN101757624A A JJ O
for CN101757624A A IN O
preventing CN101757624A A VBG O
and CN101757624A A CC O
curing CN101757624A A VBG O
senile CN101757624A A JJ O
dementia CN101757624A A NN O
, CN101757624A A , O
particularly CN101757624A A RB O
, CN101757624A A , O
the CN101757624A A DT O
invention CN101757624A A NN O
provides CN101757624A A VBZ O
a CN101757624A A DT O
composite CN101757624A A NN O
for CN101757624A A IN O
improving CN101757624A A VBG O
the CN101757624A A DT O
ability CN101757624A A NN O
of CN101757624A A IN O
memory CN101757624A A NN O
and CN101757624A A CC O
cognition CN101757624A A NN O
, CN101757624A A , O
which CN101757624A A WDT O
comprises CN101757624A A VBZ O
: CN101757624A A : O
( CN101757624A A ( O
a CN101757624A A DT O
) CN101757624A A ) O
PQQ CN101757624A A NNP O
( CN101757624A A ( O
pyrro-quinoline CN101757624A A JJ O
quinone CN101757624A A NN O
) CN101757624A A ) O
, CN101757624A A , O
salt CN101757624A A JJ O
and/or CN101757624A A NN O
ester CN101757624A A NN O
which CN101757624A A WDT O
are CN101757624A A VBP O
( CN101757624A A ( O
is CN101757624A A VBZ O
) CN101757624A A ) O
pharmaceutically CN101757624A A RB O
or CN101757624A A CC O
physiologically CN101757624A A RB O
acceptable CN101757624A A JJ O
; CN101757624A A : O
( CN101757624A A ( O
b CN101757624A A NN O
) CN101757624A A ) O
acetylcholinesterase CN101757624A A NN I-UN
inhibitor CN101757624A A NN O
; CN101757624A A : O
and CN101757624A A CC O
( CN101757624A A ( O
c CN101757624A A NN O
) CN101757624A A ) O
carrier CN101757624A A NN O
which CN101757624A A WDT O
can CN101757624A A MD O
be CN101757624A A VB O
pharmaceutically CN101757624A A RB O
or CN101757624A A CC O
physiologically CN101757624A A RB O
acceptable CN101757624A A JJ O
, CN101757624A A , O
wherein CN101757624A A WP O
the CN101757624A A DT O
molar CN101757624A A JJ O
ratio CN101757624A A NN O
of CN101757624A A IN O
the CN101757624A A DT O
group CN101757624A A NN O
( CN101757624A A ( O
a CN101757624A A DT O
) CN101757624A A ) O
and CN101757624A A CC O
the CN101757624A A DT O
group CN101757624A A NN O
( CN101757624A A ( O
b CN101757624A A NN O
) CN101757624A A ) O
is CN101757624A A VBZ O
1:100-100:1 CN101757624A A JJ O
. CN101757624A A . O

Process WO2014041558A3 T NN O
for WO2014041558A3 T IN O
preparation WO2014041558A3 T NN O
of WO2014041558A3 T IN O
crystalline WO2014041558A3 T NN O
etoricoxib WO2014041558A3 T NN O
. WO2014041558A3 T . O

Iminosugar WO2008134265A2 T NNP O
for WO2008134265A2 T IN O
treatment WO2008134265A2 T NN O
of WO2008134265A2 T IN O
tumors WO2008134265A2 T NNS O
. WO2008134265A2 T . O

Also WO2008134265A2 A RB O
a WO2008134265A2 A DT O
secretion WO2008134265A2 A NN O
of WO2008134265A2 A IN O
a WO2008134265A2 A DT O
matrix WO2008134265A2 A JJ I-UN
metalloproteinase WO2008134265A2 A NN I-UN
( WO2008134265A2 A ( O
MMP WO2008134265A2 A NNP I-UN
) WO2008134265A2 A ) O
enzyme WO2008134265A2 A NN O
by WO2008134265A2 A IN O
cells WO2008134265A2 A NNS O
can WO2008134265A2 A MD O
be WO2008134265A2 A VB O
reduced WO2008134265A2 A VBN O
by WO2008134265A2 A IN O
contacting WO2008134265A2 A VBG O
the WO2008134265A2 A DT O
cells WO2008134265A2 A NNS O
with WO2008134265A2 A IN O
the WO2008134265A2 A DT O
compound WO2008134265A2 A NN O
having WO2008134265A2 A VBG O
formula WO2008134265A2 A NN O
( WO2008134265A2 A ( O
I WO2008134265A2 A PRP O
) WO2008134265A2 A ) O
. WO2008134265A2 A . O

Accordingly WO2008134265A2 A RB O
, WO2008134265A2 A , O
compounds WO2008134265A2 A NNS O
of WO2008134265A2 A IN O
formula WO2008134265A2 A NN O
( WO2008134265A2 A ( O
I WO2008134265A2 A PRP O
) WO2008134265A2 A ) O
can WO2008134265A2 A MD O
be WO2008134265A2 A VB O
used WO2008134265A2 A VBN O
for WO2008134265A2 A IN O
treatment WO2008134265A2 A NN O
physiological WO2008134265A2 A JJ O
conditions WO2008134265A2 A NNS O
associated WO2008134265A2 A VBN O
with WO2008134265A2 A IN O
an WO2008134265A2 A DT O
elevated WO2008134265A2 A JJ O
MMP WO2008134265A2 A NNP I-UN
level WO2008134265A2 A NN O
, WO2008134265A2 A , O
such WO2008134265A2 A JJ O
as WO2008134265A2 A IN O
tumors WO2008134265A2 A NNS O
. WO2008134265A2 A . O

Treating US6916793 T VBG O
tumor US6916793 T NN O
cells US6916793 T NNS O
with US6916793 T IN O
a US6916793 T DT O
selenium US6916793 T NN O
prodrug US6916793 T NN O
lyase US6916793 T NN O
and US6916793 T CC O
a US6916793 T DT O
selenium-containing US6916793 T JJ O
prodrug US6916793 T NN O
such US6916793 T JJ O
as US6916793 T IN O
selenocysteine US6916793 T NN O
, US6916793 T , O
selenohomocysteine US6916793 T NN O
, US6916793 T , O
selenomethionine US6916793 T NN O
or US6916793 T CC O
selenoethionine.. US6916793 T NN O

Methods US6916793 A NNS O
for US6916793 A IN O
inhibiting US6916793 A VBG O
the US6916793 A DT O
growth US6916793 A NN O
of US6916793 A IN O
tumor US6916793 A NN O
cells US6916793 A NNS O
by US6916793 A IN O
combination US6916793 A NN O
treatment US6916793 A NN O
with US6916793 A IN O
a US6916793 A DT O
selenium-containing US6916793 A JJ O
prodrug US6916793 A NN O
and US6916793 A CC O
an US6916793 A DT O
enzyme US6916793 A NN O
for US6916793 A IN O
which US6916793 A WDT O
it US6916793 A PRP O
is US6916793 A VBZ O
a US6916793 A DT O
substrate US6916793 A NN O
are US6916793 A VBP O
described US6916793 A VBN O
. US6916793 A . O

The US6916793 A DT O
treatment US6916793 A NN O
also US6916793 A RB O
enhances US6916793 A VBZ O
the US6916793 A DT O
effect US6916793 A NN O
of US6916793 A IN O
anti-tumor US6916793 A JJ O
agents US6916793 A NNS O
. US6916793 A . O

Antibacterial US20060116389 T JJ O
oxazolidinones US20060116389 T NNS O
. US20060116389 T . O

N-methylpurine US20110245309 T JJ I-UN
dna US20110245309 T NN I-UN
glycosylase US20110245309 T NN I-UN
and US20110245309 T CC O
polymerase US20110245309 T NN I-UN
beta US20110245309 T NN I-UN
as US20110245309 T IN O
biomarkers US20110245309 T NNS O
for US20110245309 T IN O
alkylator US20110245309 T NN O
chemotherapy US20110245309 T NN O
potentiation US20110245309 T NN O
. US20110245309 T . O

Described US20110245309 A NNP O
herein US20110245309 A NN O
is US20110245309 A VBZ O
the US20110245309 A DT O
finding US20110245309 A NN O
that US20110245309 A WDT O
polymerase US20110245309 A NN I-UN
β US20110245309 A NNP I-UN
( US20110245309 A ( O
Polβ US20110245309 A NNP I-UN
) US20110245309 A ) O
and US20110245309 A CC O
N-methylpurine US20110245309 A JJ I-UN
DNA US20110245309 A NNP I-UN
glycosylase US20110245309 A NN I-UN
( US20110245309 A ( O
MPG US20110245309 A NNP I-UN
) US20110245309 A ) O
can US20110245309 A MD O
be US20110245309 A VB O
used US20110245309 A VBN O
as US20110245309 A IN O
biomarkers US20110245309 A NNS O
to US20110245309 A TO O
evaluate US20110245309 A VB O
the US20110245309 A DT O
sensitivity US20110245309 A NN O
of US20110245309 A IN O
a US20110245309 A DT O
subject US20110245309 A NN O
to US20110245309 A TO O
combination US20110245309 A NN O
therapy US20110245309 A NN O
that US20110245309 A WDT O
includes US20110245309 A VBZ O
treatment US20110245309 A NN O
with US20110245309 A IN O
either US20110245309 A DT O
temozolomide US20110245309 A NN O
( US20110245309 A ( O
TMZ US20110245309 A NNP O
) US20110245309 A ) O
and US20110245309 A CC O
methoxyamine US20110245309 A NN O
, US20110245309 A , O
or US20110245309 A CC O
TMZ US20110245309 A NNP O
and US20110245309 A CC O
a US20110245309 A DT I-UN
poly US20110245309 A NN I-UN
( US20110245309 A ( I-UN
ADP-ribose US20110245309 A NNP I-UN
) US20110245309 A ) I-UN
polymerase US20110245309 A NN I-UN
( US20110245309 A ( O
PARP US20110245309 A NNP I-UN
) US20110245309 A ) O
inhibitor US20110245309 A NN O
. US20110245309 A . O

Thus US20110245309 A RB O
, US20110245309 A , O
provided US20110245309 A VBN O
herein US20110245309 A NN O
is US20110245309 A VBZ O
a US20110245309 A DT O
method US20110245309 A NN O
of US20110245309 A IN O
determining US20110245309 A VBG O
if US20110245309 A IN O
a US20110245309 A DT O
subject US20110245309 A NN O
will US20110245309 A MD O
be US20110245309 A VB O
sensitive US20110245309 A JJ O
to US20110245309 A TO O
TMZ US20110245309 A NNP O
and US20110245309 A CC O
methoxyamine US20110245309 A NN O
, US20110245309 A , O
or US20110245309 A CC O
TMZ US20110245309 A NNP O
and US20110245309 A CC O
a US20110245309 A DT O
PARP US20110245309 A NNP I-UN
inhibitor US20110245309 A NN O
by US20110245309 A IN O
measuring US20110245309 A VBG O
expression US20110245309 A NN O
of US20110245309 A IN O
Polβ US20110245309 A NNP I-UN
and US20110245309 A CC O
MPG US20110245309 A NNP I-UN
in US20110245309 A IN O
a US20110245309 A DT O
sample US20110245309 A NN O
from US20110245309 A IN O
the US20110245309 A DT O
subject US20110245309 A NN O
and US20110245309 A CC O
comparing US20110245309 A VBG O
expression US20110245309 A NN O
of US20110245309 A IN O
Polβ US20110245309 A NNP I-UN
and US20110245309 A CC O
MPG US20110245309 A NNP I-UN
in US20110245309 A IN O
the US20110245309 A DT O
sample US20110245309 A NN O
to US20110245309 A TO O
a US20110245309 A DT O
control US20110245309 A NN O
. US20110245309 A . O

A US20110245309 A DT O
decrease US20110245309 A NN O
in US20110245309 A IN O
expression US20110245309 A NN O
of US20110245309 A IN O
Polβ US20110245309 A NNP I-UN
and US20110245309 A CC O
an US20110245309 A DT O
increase US20110245309 A NN O
in US20110245309 A IN O
expression US20110245309 A NN O
of US20110245309 A IN O
MPG US20110245309 A NNP I-UN
relative US20110245309 A NN O
to US20110245309 A TO O
the US20110245309 A DT O
control US20110245309 A NN O
indicates US20110245309 A VBZ O
the US20110245309 A DT O
subject US20110245309 A NN O
is US20110245309 A VBZ O
sensitive US20110245309 A JJ O
to US20110245309 A TO O
TMZ US20110245309 A NNP O
and US20110245309 A CC O
methoxyamine US20110245309 A NN O
, US20110245309 A , O
or US20110245309 A CC O
sensitive US20110245309 A JJ O
to US20110245309 A TO O
TMZ US20110245309 A NNP O
and US20110245309 A CC O
the US20110245309 A DT O
PARP US20110245309 A NNP I-UN
inhibitor US20110245309 A NN O
. US20110245309 A . O

Methods US20100311678 T NNS O
and US20100311678 T CC O
compositions US20100311678 T NNS O
for US20100311678 T IN O
treating US20100311678 T VBG O
cancer US20100311678 T NN O
and US20100311678 T CC O
modulating US20100311678 T VBG O
signal US20100311678 T JJ O
transduction US20100311678 T NN O
and US20100311678 T CC O
metabolism US20100311678 T NN O
pathways US20100311678 T NNS O
. US20100311678 T . O

Pharmaceutical CN103393633A T JJ O
composition CN103393633A T NN O
of CN103393633A T IN O
paclitaxel CN103393633A T NN O
and CN103393633A T CC O
ranitidine CN103393633A T NN O
hydrochloride CN103393633A T NN O
. CN103393633A T . O

Amino CN102190589A T NNP O
acid CN102190589A T VBZ O
ionic CN102190589A T JJ O
liquid CN102190589A T NN O
for CN102190589A T IN O
foodstuffs CN102190589A T NNS O
and CN102190589A T CC O
medical CN102190589A T JJ O
treatments CN102190589A T NNS O
. CN102190589A T . O

RNA WO2013162363A1 T NNP O
modulating WO2013162363A1 T VBG O
oligonucleotides WO2013162363A1 T NNS O
with WO2013162363A1 T IN O
improved WO2013162363A1 T JJ O
characteristics WO2013162363A1 T NNS O
for WO2013162363A1 T IN O
the WO2013162363A1 T DT O
treatment WO2013162363A1 T NN O
of WO2013162363A1 T IN O
neuromuscular WO2013162363A1 T JJ O
disorders WO2013162363A1 T NNS O
. WO2013162363A1 T . O

Use EP2699218A1 T NNP O
of EP2699218A1 T IN O
a EP2699218A1 T DT O
combination EP2699218A1 T NN O
of EP2699218A1 T IN O
carotenoid EP2699218A1 T NN O
, EP2699218A1 T , O
phytoestrogen EP2699218A1 T NN O
and EP2699218A1 T CC O
vitamin EP2699218A1 T NN O
c EP2699218A1 T NN O
for EP2699218A1 T IN O
the EP2699218A1 T DT O
prevention EP2699218A1 T NN O
and/or EP2699218A1 T NN O
treatment EP2699218A1 T NN O
of EP2699218A1 T IN O
pigmentation EP2699218A1 T NN O
disorders EP2699218A1 T NNS O
. EP2699218A1 T . O

Oligodeoxyribonucleotides CA2320288C T IN O
comprising CA2320288C T VBG O
o6-benzylguanine CA2320288C T JJ O
and CA2320288C T CC O
their CA2320288C T PRP$ O
use CA2320288C T NN O
. CA2320288C T . O

The CA2320288C A DT O
present CA2320288C A JJ O
invention CA2320288C A NN O
provides CA2320288C A VBZ O
a CA2320288C A DT O
single-stranded CA2320288C A JJ O
oligodeoxyribonucleotide CA2320288C A NN O
, CA2320288C A , O
which CA2320288C A WDT O
( CA2320288C A ( O
i CA2320288C A NN O
) CA2320288C A ) O
comprises CA2320288C A VBZ O
from CA2320288C A IN O
about CA2320288C A RB O
5 CA2320288C A CD O
to CA2320288C A TO O
11 CA2320288C A CD O
bases CA2320288C A NNS O
, CA2320288C A , O
at CA2320288C A IN O
least CA2320288C A JJS O
one CA2320288C A CD O
of CA2320288C A IN O
which CA2320288C A WDT O
is CA2320288C A VBZ O
a CA2320288C A DT O
substituted CA2320288C A JJ O
or CA2320288C A CC O
an CA2320288C A DT O
unsubstituted CA2320288C A JJ O
O6-benzylguanine CA2320288C A NN O
, CA2320288C A , O
and CA2320288C A CC O
( CA2320288C A ( O
ii CA2320288C A NN O
) CA2320288C A ) O
inactivates CA2320288C A VBZ O
human CA2320288C A JJ I-UN
AGT CA2320288C A NNP I-UN
. CA2320288C A . O

The CA2320288C A DT O
present CA2320288C A JJ O
invention CA2320288C A NN O
also CA2320288C A RB O
provides CA2320288C A VBZ O
a CA2320288C A DT O
single-stranded CA2320288C A JJ O
oligodeoxyribonucleotide CA2320288C A NN O
, CA2320288C A , O
which CA2320288C A WDT O
can CA2320288C A MD O
inactivate CA2320288C A VB O
a CA2320288C A DT O
mutant CA2320288C A JJ O
human CA2320288C A JJ I-UN
AGT CA2320288C A NNP I-UN
, CA2320288C A , O
which CA2320288C A WDT O
either CA2320288C A DT O
is CA2320288C A VBZ O
not CA2320288C A RB O
inactivated CA2320288C A VBN O
by CA2320288C A IN O
O6-benzylguanine CA2320288C A NNP O
or CA2320288C A CC O
is CA2320288C A VBZ O
less CA2320288C A RBR O
inactivated CA2320288C A VBN O
by CA2320288C A IN O
O6-benzylguanine CA2320288C A NNP O
than CA2320288C A IN O
by CA2320288C A IN O
said CA2320288C A VBD O
single-stranded CA2320288C A JJ O
oligodeoxyribonucleotide CA2320288C A NN O
. CA2320288C A . O

Phthiobuzonum/diclothane CN101342174A T NNP O
compound CN101342174A T NN O
topical CN101342174A T JJ O
formulation CN101342174A T NN O
. CN101342174A T . O

The CN101342174A A DT O
invention CN101342174A A NN O
discloses CN101342174A A VBZ O
a CN101342174A A DT O
compound CN101342174A A NN O
topical CN101342174A A JJ O
preparation CN101342174A A NN O
of CN101342174A A IN O
fitbamzone CN101342174A A NN O
dyclonine CN101342174A A NN O
used CN101342174A A VBN O
for CN101342174A A IN O
curing CN101342174A A VBG O
viral CN101342174A A JJ O
skin CN101342174A A NN O
diseases CN101342174A A NNS O
, CN101342174A A , O
such CN101342174A A JJ O
as CN101342174A A IN O
herpes CN101342174A A NNS O
zoster CN101342174A A NN O
, CN101342174A A , O
etc CN101342174A A FW O
. CN101342174A A . O

The CN101342174A A DT O
topical CN101342174A A JJ O
preparation CN101342174A A NN O
of CN101342174A A IN O
fitbamzone CN101342174A A JJ O
dyclonine CN101342174A A NN O
complex CN101342174A A JJ O
prescription CN101342174A A NN O
consists CN101342174A A VBZ O
of CN101342174A A IN O
following CN101342174A A VBG O
components CN101342174A A NNS O
by CN101342174A A IN O
percentage CN101342174A A NN O
composition CN101342174A A NN O
: CN101342174A A : O
( CN101342174A A ( O
1 CN101342174A A CD O
) CN101342174A A ) O
0.1 CN101342174A A CD O
to CN101342174A A TO O
10 CN101342174A A CD O
weight CN101342174A A JJ O
percent CN101342174A A NN O
of CN101342174A A IN O
the CN101342174A A DT O
fitbamzone CN101342174A A NN O
, CN101342174A A , O
( CN101342174A A ( O
2 CN101342174A A CD O
) CN101342174A A ) O
0.1 CN101342174A A CD O
to CN101342174A A TO O
10 CN101342174A A CD O
weight CN101342174A A JJ O
percent CN101342174A A NN O
of CN101342174A A IN O
the CN101342174A A DT O
dyclonine CN101342174A A NN O
, CN101342174A A , O
and CN101342174A A CC O
( CN101342174A A ( O
3 CN101342174A A CD O
) CN101342174A A ) O
excipient CN101342174A A NN O
acceptable CN101342174A A JJ O
to CN101342174A A TO O
pharmacy CN101342174A A NN O
. CN101342174A A . O

The CN101342174A A DT O
compound CN101342174A A NN O
topical CN101342174A A JJ O
preparation CN101342174A A NN O
used CN101342174A A VBN O
for CN101342174A A IN O
curing CN101342174A A VBG O
the CN101342174A A DT O
herpes CN101342174A A NNS O
zoster CN101342174A A NN O
can CN101342174A A MD O
stop CN101342174A A VB O
pain CN101342174A A NN O
, CN101342174A A , O
immediately CN101342174A A RB O
relieve CN101342174A A VBP O
the CN101342174A A DT O
suffering CN101342174A A NN O
of CN101342174A A IN O
a CN101342174A A DT O
patient CN101342174A A NN O
to CN101342174A A TO O
the CN101342174A A DT O
maximum CN101342174A A NN O
, CN101342174A A , O
improve CN101342174A A VB O
the CN101342174A A DT O
life CN101342174A A NN O
quality CN101342174A A NN O
of CN101342174A A IN O
the CN101342174A A DT O
patient CN101342174A A NN O
and CN101342174A A CC O
contribute CN101342174A A NN O
to CN101342174A A TO O
improve CN101342174A A VB O
the CN101342174A A DT O
clinical CN101342174A A JJ O
compliance CN101342174A A NN O
of CN101342174A A IN O
the CN101342174A A DT O
patient CN101342174A A NN O
based CN101342174A A VBN O
on CN101342174A A IN O
ensuring CN101342174A A VBG O
the CN101342174A A DT O
curative CN101342174A A JJ O
effect CN101342174A A NN O
of CN101342174A A IN O
anti-virus CN101342174A A NN O
and CN101342174A A CC O
achieving CN101342174A A VBG O
the CN101342174A A DT O
purpose CN101342174A A NN O
of CN101342174A A IN O
treatment CN101342174A A NN O
. CN101342174A A . O

The CN101342174A A DT O
compound CN101342174A A NN O
topical CN101342174A A JJ O
preparation CN101342174A A NN O
has CN101342174A A VBZ O
the CN101342174A A DT O
advantages CN101342174A A NNS O
of CN101342174A A IN O
having CN101342174A A VBG O
an CN101342174A A DT O
evident CN101342174A A JJ O
curative CN101342174A A JJ O
effect CN101342174A A NN O
on CN101342174A A IN O
the CN101342174A A DT O
herpes CN101342174A A NNS O
zoster CN101342174A A NN O
, CN101342174A A , O
a CN101342174A A DT O
good CN101342174A A JJ O
analgesic CN101342174A A JJ O
effect CN101342174A A NN O
, CN101342174A A , O
stable CN101342174A A JJ O
preparation CN101342174A A NN O
performance CN101342174A A NN O
, CN101342174A A , O
controllable CN101342174A A JJ O
quality CN101342174A A NN O
, CN101342174A A , O
a CN101342174A A DT O
good CN101342174A A JJ O
curative CN101342174A A NN O
effect CN101342174A A NN O
, CN101342174A A , O
and CN101342174A A CC O
nonirritant CN101342174A A JJ O
to CN101342174A A TO O
skin CN101342174A A VB O
without CN101342174A A IN O
causing CN101342174A A VBG O
allergic CN101342174A A JJ O
reaction CN101342174A A NN O
. CN101342174A A . O

Preparation WO2006035142A1 T NN O
of WO2006035142A1 T IN O
phenol-amide WO2006035142A1 T JJ O
compounds WO2006035142A1 T NNS O
with WO2006035142A1 T IN O
antioxidant WO2006035142A1 T JJ O
properties WO2006035142A1 T NNS O
. WO2006035142A1 T . O

The WO2006035142A1 A DT O
invention WO2006035142A1 A NN O
relates WO2006035142A1 A VBZ O
to WO2006035142A1 A TO O
the WO2006035142A1 A DT O
preparation WO2006035142A1 A NN O
of WO2006035142A1 A IN O
compounds WO2006035142A1 A NNS O
comprising WO2006035142A1 A VBG O
at WO2006035142A1 A IN O
least WO2006035142A1 A JJS O
one WO2006035142A1 A CD O
phenol WO2006035142A1 A NN O
function WO2006035142A1 A NN O
and WO2006035142A1 A CC O
one WO2006035142A1 A CD O
amide WO2006035142A1 A NN O
function WO2006035142A1 A NN O
derived WO2006035142A1 A VBN O
from WO2006035142A1 A IN O
amino-2 WO2006035142A1 A JJ O
alkanol-1 WO2006035142A1 A JJ O
having WO2006035142A1 A VBG O
formula WO2006035142A1 A NN O
( WO2006035142A1 A ( O
I WO2006035142A1 A PRP O
) WO2006035142A1 A ) O
and WO2006035142A1 A CC O
( WO2006035142A1 A ( O
II WO2006035142A1 A NNP O
) WO2006035142A1 A ) O
, WO2006035142A1 A , O
which WO2006035142A1 A WDT O
have WO2006035142A1 A VBP O
antioxidant WO2006035142A1 A NN O
and WO2006035142A1 A CC O
antiradical WO2006035142A1 A JJ O
properties WO2006035142A1 A NNS O
and WO2006035142A1 A CC O
which WO2006035142A1 A WDT O
are WO2006035142A1 A VBP O
soluble WO2006035142A1 A JJ O
in WO2006035142A1 A IN O
lipid WO2006035142A1 A JJ O
media WO2006035142A1 A NNS O
. WO2006035142A1 A . O

The WO2006035142A1 A DT O
inventive WO2006035142A1 A JJ O
compounds WO2006035142A1 A NNS O
can WO2006035142A1 A MD O
be WO2006035142A1 A VB O
used WO2006035142A1 A VBN O
as WO2006035142A1 A IN O
cosmetic WO2006035142A1 A JJ O
or WO2006035142A1 A CC O
pharmaceutical WO2006035142A1 A JJ O
preparations WO2006035142A1 A NNS O
for WO2006035142A1 A IN O
the WO2006035142A1 A DT O
prevention WO2006035142A1 A NN O
of WO2006035142A1 A IN O
biological WO2006035142A1 A JJ O
degradation WO2006035142A1 A NN O
caused WO2006035142A1 A VBN O
by WO2006035142A1 A IN O
free WO2006035142A1 A JJ O
radicals WO2006035142A1 A NNS O
. WO2006035142A1 A . O

Methods US20090197893 T NNS O
of US20090197893 T IN O
Identifying US20090197893 T NNP O
and US20090197893 T CC O
Treating US20090197893 T NNP O
Individuals US20090197893 T NNP O
Exhibiting US20090197893 T NNP O
Complex US20090197893 T NNP O
Karyotypes US20090197893 T NNP O
. US20090197893 T . O

Method US6890911 T NNP O
for US6890911 T IN O
the US6890911 T DT O
treatment US6890911 T NN O
of US6890911 T IN O
inflammation US6890911 T NN O
. US6890911 T . O

Novel CN103599081A T NNP O
niacin CN103599081A T MD O
compound CN103599081A T VB O
slow-release CN103599081A T JJ O
preparation CN103599081A T NN O
for CN103599081A T IN O
treating CN103599081A T VBG O
hyperlipoidemia CN103599081A T NN O
. CN103599081A T . O

Anti-angiogenic EP2594268A1 T JJ O
composition EP2594268A1 T NN O
containing EP2594268A1 T VBG O
macrolactin EP2594268A1 T NN O
a EP2594268A1 T DT O
and EP2594268A1 T CC O
a EP2594268A1 T DT O
derivative EP2594268A1 T JJ O
thereof EP2594268A1 T NN O
as EP2594268A1 T IN O
active EP2594268A1 T JJ O
ingredients EP2594268A1 T NNS O
. EP2594268A1 T . O

Anti-inflammation CN101194940A T NNP O
medicament CN101194940A T NN O
for CN101194940A T IN O
treating CN101194940A T VBG O
toothache CN101194940A T NN O
and CN101194940A T CC O
preparation CN101194940A T NN O
method CN101194940A T NN O
thereof CN101194940A T NN O
. CN101194940A T . O

Radioprotectors EP2044938A2 T NNS O
. EP2044938A2 T . O

Momestasone CN102000023B T NN O
furoate CN102000023B T NN O
cream CN102000023B T NN O
and CN102000023B T CC O
preparation CN102000023B T NN O
method CN102000023B T NN O
thereof CN102000023B T NN O
. CN102000023B T . O

Cannabinoid-2-receptor WO2013041859A1 T JJ I-UN
agonists WO2013041859A1 T NNS O
. WO2013041859A1 T . O

The WO2013041859A1 A DT O
present WO2013041859A1 A JJ O
invention WO2013041859A1 A NN O
relates WO2013041859A1 A VBZ O
to WO2013041859A1 A TO O
cannabinnoid-2-receptor WO2013041859A1 A NN I-UN
( WO2013041859A1 A ( O
CB2R WO2013041859A1 A NNP I-UN
) WO2013041859A1 A ) O
agonist WO2013041859A1 A NN O
compounds WO2013041859A1 A NNS O
. WO2013041859A1 A . O

The WO2013041859A1 A DT O
present WO2013041859A1 A JJ O
invention WO2013041859A1 A NN O
also WO2013041859A1 A RB O
relates WO2013041859A1 A VBZ O
to WO2013041859A1 A TO O
processes WO2013041859A1 A VB O
for WO2013041859A1 A IN O
the WO2013041859A1 A DT O
preparation WO2013041859A1 A NN O
of WO2013041859A1 A IN O
these WO2013041859A1 A DT O
compounds WO2013041859A1 A NNS O
, WO2013041859A1 A , O
to WO2013041859A1 A TO O
pharmaceutical WO2013041859A1 A JJ O
compositions WO2013041859A1 A NNS O
comprising WO2013041859A1 A VBG O
them WO2013041859A1 A PRP O
and WO2013041859A1 A CC O
to WO2013041859A1 A TO O
their WO2013041859A1 A PRP$ O
use WO2013041859A1 A NN O
as WO2013041859A1 A IN O
therapeutic WO2013041859A1 A JJ O
agents WO2013041859A1 A NNS O
for WO2013041859A1 A IN O
the WO2013041859A1 A DT O
treatment WO2013041859A1 A NN O
and/or WO2013041859A1 A JJ O
prevention WO2013041859A1 A NN O
of WO2013041859A1 A IN O
diseases WO2013041859A1 A NNS O
or WO2013041859A1 A CC O
conditions WO2013041859A1 A NNS O
in WO2013041859A1 A IN O
which WO2013041859A1 A WDT O
CB2R WO2013041859A1 A NNP I-UN
stimulation WO2013041859A1 A NN O
is WO2013041859A1 A VBZ O
beneficial WO2013041859A1 A JJ O
( WO2013041859A1 A ( O
especially WO2013041859A1 A RB O
inflammatory WO2013041859A1 A JJ O
conditions WO2013041859A1 A NNS O
) WO2013041859A1 A ) O
. WO2013041859A1 A . O

Method WO2005040045A3 T NNP O
for WO2005040045A3 T IN O
the WO2005040045A3 T DT O
production WO2005040045A3 T NN O
of WO2005040045A3 T IN O
trans- WO2005040045A3 T JJ O
or WO2005040045A3 T CC O
cis-diammoniumdichlorodihydroxoplatinum WO2005040045A3 T NN O
( WO2005040045A3 T ( O
iv WO2005040045A3 T NN O
) WO2005040045A3 T ) O
and WO2005040045A3 T CC O
use WO2005040045A3 T VBP O
thereof WO2005040045A3 T NN O
for WO2005040045A3 T IN O
the WO2005040045A3 T DT O
production WO2005040045A3 T NN O
of WO2005040045A3 T IN O
pharmaceutical WO2005040045A3 T JJ O
agent WO2005040045A3 T NN O
. WO2005040045A3 T . O

Alka-eeze US20100092550 T NN O
. US20100092550 T . O

Fatty WO2008061399A1 T NNP I-UN
acid WO2008061399A1 T JJ I-UN
synthase WO2008061399A1 T NN I-UN
inhibitor WO2008061399A1 T NN O
and WO2008061399A1 T CC O
its WO2008061399A1 T PRP$ O
use WO2008061399A1 T NN O
. WO2008061399A1 T . O

Administering US7342125 T VBG O
derivatives US7342125 T NNS O
of US7342125 T IN O
Kauranoic US7342125 T NNP O
acid US7342125 T NN O
; US7342125 T : O
cachexia US7342125 T NN O
, US7342125 T , O
analgesics US7342125 T NNS O
, US7342125 T , O
in US7342125 T IN O
treating US7342125 T VBG O
immune US7342125 T NN O
disorders US7342125 T NNS O
, US7342125 T , O
as US7342125 T IN O
anti-cancer US7342125 T JJ O
and US7342125 T CC O
anti-tumor US7342125 T JJ O
agents US7342125 T NNS O
, US7342125 T , O
otitis US7342125 T NN O
media US7342125 T NNS O
, US7342125 T , O
sinusitis US7342125 T NN O
, US7342125 T , O
antidiabetic US7342125 T JJ O
agent US7342125 T NN O
. US7342125 T . O

Novel US7342125 A NNP O
compounds US7342125 A NNS O
are US7342125 A VBP O
disclosed US7342125 A VBN O
that US7342125 A WDT O
have US7342125 A VBP O
the US7342125 A DT O
chemical US7342125 A NN O
structure US7342125 A NN O
of US7342125 A IN O
Formula US7342125 A NNP O
( US7342125 A ( O
II US7342125 A NNP O
) US7342125 A ) O
, US7342125 A , O
and US7342125 A CC O
its US7342125 A PRP$ O
prodrug US7342125 A NN O
esters US7342125 A NNS O
and US7342125 A CC O
acid-addition US7342125 A NN O
salts US7342125 A NNS O
, US7342125 A , O
and US7342125 A CC O
that US7342125 A DT O
are US7342125 A VBP O
useful US7342125 A JJ O
as US7342125 A IN O
Interleukin-1 US7342125 A NNP O
and US7342125 A CC O
Tumor US7342125 A NNP I-UN
Necrosis US7342125 A NNP I-UN
Factor-α US7342125 A NNP I-UN
modulators US7342125 A NNS O
, US7342125 A , O
and US7342125 A CC O
thus US7342125 A RB O
are US7342125 A VBP O
useful US7342125 A JJ O
in US7342125 A IN O
the US7342125 A DT O
treatment US7342125 A NN O
of US7342125 A IN O
various US7342125 A JJ O
listed US7342125 A VBN O
diseases US7342125 A NNS O
. US7342125 A . O

Pharmaceutical US20110098315 T JJ O
compositions US20110098315 T NNS O
of US20110098315 T IN O
rosuvastatin US20110098315 T NN O
calcium US20110098315 T NN O
. US20110098315 T . O

Method CN103505737A T NNP O
for CN103505737A T IN O
preparing CN103505737A T VBG O
docetaxel/beta-cyclodextrin CN103505737A T JJ O
clathrates CN103505737A T NNS O
. CN103505737A T . O

comprises US7090874 T NNS O
curcumin US7090874 T VBP O
for US7090874 T IN O
preventing US7090874 T VBG O
and/or US7090874 T JJ O
improving US7090874 T VBG O
Insulin US7090874 T NNP I-UN
Resistance US7090874 T NNP O
Syndrome US7090874 T NNP O
, US7090874 T , O
diabetes US7090874 T VBZ O
mellitus US7090874 T NN O
, US7090874 T , O
obesity US7090874 T NN O
or US7090874 T CC O
visceral US7090874 T JJ O
fat US7090874 T JJ O
obesity US7090874 T NN O
, US7090874 T , O
hypertension US7090874 T NN O
or US7090874 T CC O
arterosclerotic US7090874 T JJ O
cardiovascular US7090874 T JJ O
disorders US7090874 T NNS O
. US7090874 T . O

The US7090874 A DT O
object US7090874 A NN O
of US7090874 A IN O
the US7090874 A DT O
present US7090874 A JJ O
invention US7090874 A NN O
is US7090874 A VBZ O
to US7090874 A TO O
provide US7090874 A VB O
PPARγ US7090874 A NNP I-UN
ligand US7090874 A NN O
derived US7090874 A VBD O
from US7090874 A IN O
naturally US7090874 A RB O
occurring US7090874 A VBG O
sources US7090874 A NNS O
and US7090874 A CC O
a US7090874 A DT O
composition US7090874 A NN O
for US7090874 A IN O
preventing US7090874 A VBG O
and/or US7090874 A JJ O
improving US7090874 A VBG O
Insulin US7090874 A NNP I-UN
Resistance US7090874 A NNP O
Syndrome US7090874 A NNP O
, US7090874 A , O
diabetes US7090874 A VBZ O
mellitus US7090874 A NN O
, US7090874 A , O
obesity US7090874 A NN O
or US7090874 A CC O
visceral US7090874 A JJ O
fat US7090874 A JJ O
obesity US7090874 A NN O
comprising US7090874 A VBG O
the US7090874 A DT O
PPARγ US7090874 A NNP I-UN
ligand US7090874 A NN O
as US7090874 A IN O
an US7090874 A DT O
active US7090874 A JJ O
agent US7090874 A NN O
. US7090874 A . O

The US7090874 A DT O
present US7090874 A JJ O
invention US7090874 A NN O
relates US7090874 A VBZ O
to US7090874 A TO O
a US7090874 A DT O
ligand US7090874 A NN O
for US7090874 A IN O
peroxisome US7090874 A JJ I-UN
proliferator-activated US7090874 A JJ I-UN
receptor US7090874 A NN I-UN
which US7090874 A WDT O
comprises US7090874 A VBZ O
curcumin US7090874 A NN O
or US7090874 A CC O
its US7090874 A PRP$ O
derivatives US7090874 A NNS O
. US7090874 A . O

The US7090874 A DT O
composition US7090874 A NN O
according US7090874 A VBG O
to US7090874 A TO O
the US7090874 A DT O
present US7090874 A JJ O
invention US7090874 A NN O
, US7090874 A , O
which US7090874 A WDT O
comprises US7090874 A VBZ O
the US7090874 A DT O
PPARγ US7090874 A NNP I-UN
ligand US7090874 A NN O
as US7090874 A IN O
an US7090874 A DT O
active US7090874 A JJ O
agent US7090874 A NN O
is US7090874 A VBZ O
useful US7090874 A JJ O
for US7090874 A IN O
preventing US7090874 A VBG O
and/or US7090874 A JJ O
improving US7090874 A VBG O
Insulin US7090874 A NNP I-UN
Resistance US7090874 A NNP O
Syndrome US7090874 A NNP O
, US7090874 A , O
diabetes US7090874 A VBZ O
mellitus US7090874 A NN O
, US7090874 A , O
obesity US7090874 A NN O
or US7090874 A CC O
visceral US7090874 A JJ O
fat US7090874 A JJ O
obesity US7090874 A NN O
. US7090874 A . O

Monosaccharide-based WO2012097052A3 T JJ O
compounds WO2012097052A3 T NNS O
for WO2012097052A3 T IN O
the WO2012097052A3 T DT O
treatment WO2012097052A3 T NN O
of WO2012097052A3 T IN O
proliferative WO2012097052A3 T JJ O
and WO2012097052A3 T CC O
inflammatory WO2012097052A3 T JJ O
dermatological WO2012097052A3 T JJ O
diseases WO2012097052A3 T NNS O
. WO2012097052A3 T . O

The WO2012097052A3 A DT O
present WO2012097052A3 A JJ O
invention WO2012097052A3 A NN O
relates WO2012097052A3 A VBZ O
to WO2012097052A3 A TO O
compounds WO2012097052A3 A NNS O
and WO2012097052A3 A CC O
methods WO2012097052A3 A NNS O
which WO2012097052A3 A WDT O
may WO2012097052A3 A MD O
be WO2012097052A3 A VB O
useful WO2012097052A3 A JJ O
as WO2012097052A3 A IN O
inhibitors WO2012097052A3 A NNS O
of WO2012097052A3 A IN O
glycolysis WO2012097052A3 A NN O
, WO2012097052A3 A , O
inhibitors WO2012097052A3 A NNS O
of WO2012097052A3 A IN O
protein WO2012097052A3 A NN O
glycosylation WO2012097052A3 A NN O
, WO2012097052A3 A , O
anti-virals WO2012097052A3 A NNS O
, WO2012097052A3 A , O
and WO2012097052A3 A CC O
down-regulators WO2012097052A3 A NNS O
of WO2012097052A3 A IN O
insulin WO2012097052A3 A NN I-UN
receptor WO2012097052A3 A NN I-UN
and WO2012097052A3 A CC O
IGF- WO2012097052A3 A JJ I-UN
1 WO2012097052A3 A CD I-UN
receptor WO2012097052A3 A NN I-UN
for WO2012097052A3 A IN O
the WO2012097052A3 A DT O
treatment WO2012097052A3 A NN O
or WO2012097052A3 A CC O
prevention WO2012097052A3 A NN O
of WO2012097052A3 A IN O
inflammatory WO2012097052A3 A JJ O
dermatological WO2012097052A3 A JJ O
diseases WO2012097052A3 A NNS O
or WO2012097052A3 A CC O
proliferative WO2012097052A3 A JJ O
dermatological WO2012097052A3 A JJ O
diseases WO2012097052A3 A NNS O
. WO2012097052A3 A . O

Biomarkers US20100292331 T NNS O
for US20100292331 T IN O
Prostate US20100292331 T NNP O
Cancer US20100292331 T NNP O
and US20100292331 T CC O
Methods US20100292331 T NNP O
Using US20100292331 T NNP O
the US20100292331 T DT O
Same US20100292331 T NNP O
. US20100292331 T . O

N-substituted EP2164850A2 T JJ O
azaindoles EP2164850A2 T NNS O
and EP2164850A2 T CC O
methods EP2164850A2 T NNS O
of EP2164850A2 T IN O
use EP2164850A2 T NN O
. EP2164850A2 T . O

Inhibition EP1951318A1 T NN O
of EP1951318A1 T IN O
autophagy EP1951318A1 T JJ O
genes EP1951318A1 T NNS O
in EP1951318A1 T IN O
cancer EP1951318A1 T NN O
chemotherapy EP1951318A1 T NN O
. EP1951318A1 T . O

Heterocyclic CN101239979A T NNP O
compound CN101239979A T NN O
capable CN101239979A T NN O
of CN101239979A T IN O
inversing CN101239979A T VBG O
tumor CN101239979A T NN O
cell CN101239979A T NN O
drug CN101239979A T NN O
tolerance CN101239979A T NN O
, CN101239979A T , O
preparation CN101239979A T NN O
method CN101239979A T NN O
and CN101239979A T CC O
application CN101239979A T NN O
thereof CN101239979A T NN O
. CN101239979A T . O

Novel US20130136798 T NNP O
parenteral US20130136798 T NN O
controlled US20130136798 T VBD O
release US20130136798 T NN O
formulations US20130136798 T NNS O
of US20130136798 T IN O
nsaid US20130136798 T NN O
's US20130136798 T POS O
. US20130136798 T . O

Acrylamide WO2010114181A1 T NNP O
compounds WO2010114181A1 T NNS O
and WO2010114181A1 T CC O
the WO2010114181A1 T DT O
use WO2010114181A1 T NN O
thereof WO2010114181A1 T NN O
. WO2010114181A1 T . O

Depolymerized WO2011063595A1 T VBN O
glycosaminoglycan WO2011063595A1 T JJ O
from WO2011063595A1 T IN O
thelenota WO2011063595A1 T JJ O
ananas WO2011063595A1 T NNS O
and WO2011063595A1 T CC O
preparation WO2011063595A1 T NN O
method WO2011063595A1 T NN O
thereof WO2011063595A1 T NN O
. WO2011063595A1 T . O

Immunological US20120308593 T JJ O
Compositions US20120308593 T NNS O
for US20120308593 T IN O
HIV US20120308593 T NNP O
. US20120308593 T . O

Phenylalanyl CN101337920A T NNP O
pyrrolidine CN101337920A T NN O
derivates CN101337920A T NNS O
, CN101337920A T , O
preparation CN101337920A T NN O
method CN101337920A T NN O
and CN101337920A T CC O
application CN101337920A T NN O
thereof CN101337920A T NN O
. CN101337920A T . O

The CN101337920A A DT O
invention CN101337920A A NN O
discloses CN101337920A A VBZ O
a CN101337920A A DT O
2-pyrrolidine CN101337920A A JJ O
substitution-hydrocinnamoyl CN101337920A A JJ O
pyrrolidine CN101337920A A NN O
derivant CN101337920A A NN O
which CN101337920A A WDT O
is CN101337920A A VBZ O
the CN101337920A A DT O
compound CN101337920A A NN O
in CN101337920A A IN O
formula CN101337920A A JJ O
1 CN101337920A A CD O
or CN101337920A A CC O
an CN101337920A A DT O
acceptable CN101337920A A JJ O
salt CN101337920A A NN O
thereof CN101337920A A NN O
in CN101337920A A IN O
pharmacy CN101337920A A NN O
, CN101337920A A , O
wherein CN101337920A A NN O
, CN101337920A A , O
R1 CN101337920A A NNP O
or CN101337920A A CC O
R2 CN101337920A A NNP O
is CN101337920A A VBZ O
respectively CN101337920A A RB O
hydrogen CN101337920A A JJ O
, CN101337920A A , O
cyano-group CN101337920A A JJ O
, CN101337920A A , O
acidic CN101337920A A JJ O
group CN101337920A A NN O
, CN101337920A A , O
ester CN101337920A A NN O
group CN101337920A A NN O
, CN101337920A A , O
acyl CN101337920A A NN O
group CN101337920A A NN O
, CN101337920A A , O
amide CN101337920A A RB O
group CN101337920A A NN O
or CN101337920A A CC O
substitution CN101337920A A NN O
amide CN101337920A A IN O
group CN101337920A A NN O
independently CN101337920A A RB O
; CN101337920A A : O
the CN101337920A A DT O
hexagram CN101337920A A NN O
symbol CN101337920A A NN O
stands CN101337920A A VBZ O
for CN101337920A A IN O
a CN101337920A A DT O
chiral CN101337920A A JJ O
centre CN101337920A A NN O
. CN101337920A A . O

The CN101337920A A DT O
invention CN101337920A A NN O
further CN101337920A A JJ O
discloses CN101337920A A VBZ O
a CN101337920A A DT O
method CN101337920A A NN O
for CN101337920A A IN O
preparing CN101337920A A VBG O
the CN101337920A A DT O
compound CN101337920A A NN O
and CN101337920A A CC O
the CN101337920A A DT O
application CN101337920A A NN O
thereof CN101337920A A NN O
for CN101337920A A IN O
preparing CN101337920A A VBG O
or CN101337920A A CC O
preventing CN101337920A A VBG O
noninsulin-dependent CN101337920A A JJ O
diabetes CN101337920A A NNS O
mellitus CN101337920A A NN O
, CN101337920A A , O
adiposis CN101337920A A NN O
, CN101337920A A , O
arthritis CN101337920A A NN O
or CN101337920A A CC O
other CN101337920A A JJ O
glucose CN101337920A A JJ O
tolerance CN101337920A A NN O
abnormality CN101337920A A NN O
diseases CN101337920A A NNS O
. CN101337920A A . O

Shiga US20110243914 T NNP O
toxin US20110243914 T NN O
b-subunit US20110243914 T NN O
as US20110243914 T IN O
a US20110243914 T DT O
vector US20110243914 T NN O
for US20110243914 T IN O
tumor US20110243914 T NN O
diagnosis US20110243914 T NN O
and US20110243914 T CC O
drug US20110243914 T NN O
delivery US20110243914 T NN O
to US20110243914 T TO O
gb3 US20110243914 T VB O
expressing US20110243914 T VBG O
tumors US20110243914 T NNS O
. US20110243914 T . O

The US20110243914 A DT O
invention US20110243914 A NN O
relates US20110243914 A VBZ O
to US20110243914 A TO O
new US20110243914 A JJ O
compounds US20110243914 A NNS O
for US20110243914 A IN O
cancer US20110243914 A NN O
therapy US20110243914 A NN O
or US20110243914 A CC O
diagnosis US20110243914 A NN O
and US20110243914 A CC O
more US20110243914 A RBR O
specifically US20110243914 A RB O
to US20110243914 A TO O
the US20110243914 A DT O
use US20110243914 A NN O
of US20110243914 A IN O
a US20110243914 A DT O
non-toxic US20110243914 A JJ O
B US20110243914 A NNP O
subunit US20110243914 A NN O
of US20110243914 A IN O
Shiga US20110243914 A NNP O
toxin US20110243914 A NN O
mutant US20110243914 A NN O
as US20110243914 A IN O
a US20110243914 A DT O
vector US20110243914 A NN O
for US20110243914 A IN O
diagnostic US20110243914 A JJ O
products US20110243914 A NNS O
or US20110243914 A CC O
drugs US20110243914 A NNS O
in US20110243914 A IN O
over-expressing US20110243914 A JJ O
Gb3 US20110243914 A NNP I-UN
receptor US20110243914 A NN I-UN
cells US20110243914 A NNS O
, US20110243914 A , O
such US20110243914 A JJ O
compounds US20110243914 A NNS O
having US20110243914 A VBG O
the US20110243914 A DT O
following US20110243914 A JJ O
formula US20110243914 A NN O
: US20110243914 A : O
STxB-Z US20110243914 A JJ O
( US20110243914 A ( O
n US20110243914 A JJ O
) US20110243914 A ) O
-Cys-Y US20110243914 A NN O
( US20110243914 A ( O
m US20110243914 A NN O
) US20110243914 A ) O
-T US20110243914 A VBZ O
wherein US20110243914 A JJ O
STxB US20110243914 A NNP I-UN
is US20110243914 A VBZ O
the US20110243914 A DT O
Shiga US20110243914 A NNP I-UN
Toxin US20110243914 A NNP I-UN
B US20110243914 A NNP I-UN
subunit US20110243914 A NN I-UN
or US20110243914 A CC O
a US20110243914 A DT O
functional US20110243914 A JJ O
equivalent US20110243914 A NN O
thereof US20110243914 A NN O
, US20110243914 A , O
Z US20110243914 A NNP O
( US20110243914 A ( O
n US20110243914 A NN O
) US20110243914 A ) O
whrein US20110243914 A NN O
n US20110243914 A NN O
is US20110243914 A VBZ O
0 US20110243914 A CD O
or US20110243914 A CC O
1 US20110243914 A CD O
and US20110243914 A CC O
when US20110243914 A WRB O
n US20110243914 A NN O
is US20110243914 A VBZ O
1 US20110243914 A CD O
, US20110243914 A , O
Z US20110243914 A NNP O
is US20110243914 A VBZ O
an US20110243914 A DT O
amino-acid US20110243914 A JJ O
residue US20110243914 A JJ O
devoidof US20110243914 A NN O
sulfydryl US20110243914 A NN O
group US20110243914 A NN O
, US20110243914 A , O
or US20110243914 A CC O
is US20110243914 A VBZ O
a US20110243914 A DT O
polypeptide US20110243914 A NN O
, US20110243914 A , O
Cys US20110243914 A NNP O
is US20110243914 A VBZ O
the US20110243914 A DT O
amino-acid US20110243914 A JJ O
residue US20110243914 A NN O
for US20110243914 A IN O
Cysteine US20110243914 A NNP O
, US20110243914 A , O
T US20110243914 A NNP O
is US20110243914 A VBZ O
a US20110243914 A DT O
molecule US20110243914 A NN O
linked US20110243914 A VBN O
by US20110243914 A IN O
a US20110243914 A DT O
covalent US20110243914 A NN O
bound US20110243914 A NN O
to US20110243914 A TO O
the US20110243914 A DT O
S US20110243914 A NNP O
part US20110243914 A NN O
of US20110243914 A IN O
Cys US20110243914 A NNP O
, US20110243914 A , O
selected US20110243914 A VBN O
in US20110243914 A IN O
a US20110243914 A DT O
group US20110243914 A NN O
comprising US20110243914 A NN O
: US20110243914 A : O
agents US20110243914 A NNS O
for US20110243914 A IN O
in US20110243914 A IN O
vivo US20110243914 A JJ O
diagnosis US20110243914 A NN O
, US20110243914 A , O
cytotoxic US20110243914 A NN O
agents US20110243914 A NNS O
, US20110243914 A , O
prodrugs US20110243914 A NNS O
, US20110243914 A , O
or US20110243914 A CC O
enzymes US20110243914 A NNS O
for US20110243914 A IN O
the US20110243914 A DT O
conversion US20110243914 A NN O
of US20110243914 A IN O
a US20110243914 A DT O
prodrug US20110243914 A NN O
to US20110243914 A TO O
a US20110243914 A DT O
drug US20110243914 A NN O
, US20110243914 A , O
Y US20110243914 A NNP O
( US20110243914 A ( O
m US20110243914 A NN O
) US20110243914 A ) O
wherein US20110243914 A NN O
m US20110243914 A NN O
is US20110243914 A VBZ O
0 US20110243914 A CD O
or US20110243914 A CC O
1 US20110243914 A CD O
and US20110243914 A CC O
when US20110243914 A WRB O
m US20110243914 A NN O
is US20110243914 A VBZ O
1 US20110243914 A CD O
, US20110243914 A , O
Y US20110243914 A NNP O
is US20110243914 A VBZ O
a US20110243914 A DT O
linker US20110243914 A NN O
between US20110243914 A IN O
T US20110243914 A NNP O
and US20110243914 A CC O
Cys US20110243914 A NNP O
, US20110243914 A , O
said US20110243914 A VBD O
linker US20110243914 A NN O
being US20110243914 A VBG O
either US20110243914 A CC O
cleavable US20110243914 A JJ O
or US20110243914 A CC O
not US20110243914 A RB O
cleavable US20110243914 A JJ O
for US20110243914 A IN O
the US20110243914 A DT O
release US20110243914 A NN O
of US20110243914 A IN O
T US20110243914 A NNP O
after US20110243914 A IN O
the US20110243914 A DT O
internalization US20110243914 A NN O
of US20110243914 A IN O
the US20110243914 A DT O
hybrid US20110243914 A JJ O
compound US20110243914 A NN O
into US20110243914 A IN O
said US20110243914 A VBD O
cells US20110243914 A NNS O
. US20110243914 A . O

A CN101117349B T DT O
macrocyclic CN101117349B T JJ O
oxidation CN101117349B T NN O
substituted CN101117349B T VBD O
pentacyclic CN101117349B T JJ O
triterpanoids CN101117349B T NNS O
derivative CN101117349B T JJ O
and CN101117349B T CC O
preparation CN101117349B T NN O
method CN101117349B T NN O
and CN101117349B T CC O
use CN101117349B T NN O
thereof CN101117349B T NN O
. CN101117349B T . O

Method CN101234092A T NNP O
for CN101234092A T IN O
preparing CN101234092A T VBG O
metronidazole CN101234092A T JJ O
furanzolidon CN101234092A T JJ O
vaginal CN101234092A T JJ O
tablet CN101234092A T NN O
and CN101234092A T CC O
quality CN101234092A T NN O
control CN101234092A T NN O
method CN101234092A T NN O
. CN101234092A T . O

Composition WO2009101698A1 T NN O
and WO2009101698A1 T CC O
method WO2009101698A1 T NN O
for WO2009101698A1 T IN O
suppressing WO2009101698A1 T VBG O
fat WO2009101698A1 T JJ O
accumulation WO2009101698A1 T NN O
. WO2009101698A1 T . O

Benzyloxy-substituted CN1817861A T JJ O
tryptophan CN1817861A T NN O
derivative CN1817861A T NN O
, CN1817861A T , O
its CN1817861A T PRP$ O
analogs CN1817861A T NNS O
, CN1817861A T , O
production CN1817861A T NN O
and CN1817861A T CC O
use CN1817861A T NN O
thereof CN1817861A T NN O
. CN1817861A T . O

It CN1817861A A PRP O
can CN1817861A A MD O
be CN1817861A A VB O
used CN1817861A A VBN O
for CN1817861A A IN O
PPAR CN1817861A A NNP I-UN
gamma CN1817861A A JJ I-UN
agonist CN1817861A A NN O
and CN1817861A A CC O
medicine CN1817861A A NN O
treating CN1817861A A VBG O
II-type CN1817861A A JJ O
diabetes CN1817861A A NNS O
. CN1817861A A . O

Pharmaceutical WO2008136374A1 T JJ O
composition WO2008136374A1 T NN O
for WO2008136374A1 T IN O
inhibiting WO2008136374A1 T VBG O
peripheral WO2008136374A1 T JJ O
neuropathy WO2008136374A1 T NNS O
caused WO2008136374A1 T VBN O
by WO2008136374A1 T IN O
the WO2008136374A1 T DT O
administration WO2008136374A1 T NN O
of WO2008136374A1 T IN O
anticancer WO2008136374A1 T JJ O
agent WO2008136374A1 T NN O
. WO2008136374A1 T . O

Pharmaceuticals US20100204320 T NNS O
for US20100204320 T IN O
xerosis US20100204320 T NN O
. US20100204320 T . O

Salts CN103360401A T NNS O
of CN103360401A T IN O
methoxyl CN103360401A T JJ O
dictamnine CN103360401A T NN O
derivatives CN103360401A T NNS O
. CN103360401A T . O

Tiotropium CN103110584A T NNP O
bromide CN103110584A T NN O
powder CN103110584A T NN O
inhalation CN103110584A T NN O
and CN103110584A T CC O
preparation CN103110584A T NN O
method CN103110584A T NN O
thereof CN103110584A T NN O
. CN103110584A T . O

Farnesoid WO2008051942A2 T NNP I-UN
x WO2008051942A2 T NNP I-UN
receptor WO2008051942A2 T NN I-UN
agonists WO2008051942A2 T NNS O
. WO2008051942A2 T . O

Novel CN101970430A T NNP O
pyrimidine CN101970430A T NN O
derivatives CN101970430A T NNS O
. CN101970430A T . O

Method US20110142797 T NNP O
For US20110142797 T IN O
Prophylaxis US20110142797 T NNP O
or US20110142797 T CC O
Treatment US20110142797 T NNP O
of US20110142797 T IN O
Feline US20110142797 T NNP O
Infectious US20110142797 T NNP O
Peritonitis US20110142797 T NNP O
. US20110142797 T . O

The US20110142797 A DT O
cysteine US20110142797 A NN O
protease US20110142797 A NN O
inhibitor US20110142797 A NN O
can US20110142797 A MD O
be US20110142797 A VB O
a US20110142797 A DT O
selective US20110142797 A JJ O
cathepsin US20110142797 A NN I-UN
B US20110142797 A NNP I-UN
inhibitor US20110142797 A NN O
. US20110142797 A . O

Chiral CN103193668A T JJ O
indan CN103193668A T NN O
derivant CN103193668A T NN O
and CN103193668A T CC O
preparation CN103193668A T NN O
method CN103193668A T NN O
and CN103193668A T CC O
application CN103193668A T NN O
thereof CN103193668A T NN O
. CN103193668A T . O

The CN103193668A A DT O
compound CN103193668A A NN O
is CN103193668A A VBZ O
high CN103193668A A JJ O
in CN103193668A A IN O
melatonin CN103193668A A JJ O
acceptors CN103193668A A NNS O
MT1 CN103193668A A NNP I-UN
and CN103193668A A CC O
MT2 CN103193668A A NNP I-UN
which CN103193668A A WDT O
are CN103193668A A VBP O
used CN103193668A A VBN O
for CN103193668A A IN O
exciting CN103193668A A VBG O
the CN103193668A A DT O
activity CN103193668A A NN O
, CN103193668A A , O
can CN103193668A A MD O
be CN103193668A A VB O
applied CN103193668A A VBN O
to CN103193668A A TO O
preparation CN103193668A A NN O
of CN103193668A A IN O
medicines CN103193668A A NNS O
for CN103193668A A IN O
resisting CN103193668A A VBG O
insomnia CN103193668A A NN O
and CN103193668A A CC O
depression CN103193668A A NN O
, CN103193668A A , O
and CN103193668A A CC O
can CN103193668A A MD O
be CN103193668A A VB O
clinically CN103193668A A RB O
used CN103193668A A VBN O
in CN103193668A A IN O
modes CN103193668A A NNS O
of CN103193668A A IN O
oral CN103193668A A JJ O
administration CN103193668A A NN O
, CN103193668A A , O
intravenous CN103193668A A JJ O
injection CN103193668A A NN O
, CN103193668A A , O
intramuscular CN103193668A A JJ O
injection CN103193668A A NN O
and CN103193668A A CC O
the CN103193668A A DT O
like CN103193668A A JJ O
. CN103193668A A . O

Corticosteroid WO2010132743A1 T NNP O
beta-agonist WO2010132743A1 T JJ O
compounds WO2010132743A1 T NNS O
for WO2010132743A1 T IN O
use WO2010132743A1 T NN O
in WO2010132743A1 T IN O
therapy WO2010132743A1 T NN O
. WO2010132743A1 T . O

Antiseptic CN102908362A T JJ O
compositions CN102908362A T NNS O
and CN102908362A T CC O
methods CN102908362A T NNS O
of CN102908362A T IN O
use CN102908362A T NN O
. CN102908362A T . O

Pyrazolo US7662826 T NNP O
[ US7662826 T NNP O
1,5-a US7662826 T JJ O
] US7662826 T NNP O
pyrimidine US7662826 T NN O
derivative US7662826 T NN O
and US7662826 T CC O
nad US7662826 T NN O
( US7662826 T ( O
p US7662826 T NN O
) US7662826 T ) O
h US7662826 T NN O
oxidase US7662826 T JJ O
inhibitor US7662826 T NN O
containing US7662826 T VBG O
the US7662826 T DT O
same US7662826 T JJ O
. US7662826 T . O

Pyrrolotriazine WO2014082230A1 T NNP O
derivative WO2014082230A1 T NN O
, WO2014082230A1 T , O
preparation WO2014082230A1 T NN O
method WO2014082230A1 T NN O
thereof WO2014082230A1 T NN O
and WO2014082230A1 T CC O
application WO2014082230A1 T NN O
thereof WO2014082230A1 T NN O
in WO2014082230A1 T IN O
medicine WO2014082230A1 T NN O
. WO2014082230A1 T . O

The WO2014082230A1 A DT O
present WO2014082230A1 A JJ O
invention WO2014082230A1 A NN O
relates WO2014082230A1 A VBZ O
to WO2014082230A1 A TO O
a WO2014082230A1 A DT O
pyrrolotriazine WO2014082230A1 A NN O
derivative WO2014082230A1 A NN O
, WO2014082230A1 A , O
a WO2014082230A1 A DT O
preparation WO2014082230A1 A NN O
method WO2014082230A1 A NN O
thereof WO2014082230A1 A NN O
and WO2014082230A1 A CC O
an WO2014082230A1 A DT O
application WO2014082230A1 A NN O
thereof WO2014082230A1 A NN O
in WO2014082230A1 A IN O
medicine WO2014082230A1 A NN O
. WO2014082230A1 A . O

Specifically WO2014082230A1 A RB O
, WO2014082230A1 A , O
disclosed WO2014082230A1 A VBN O
is WO2014082230A1 A VBZ O
a WO2014082230A1 A DT O
pyrrolotriazine WO2014082230A1 A JJ O
derivative WO2014082230A1 A NN O
that WO2014082230A1 A WDT O
has WO2014082230A1 A VBZ O
remarkable WO2014082230A1 A JJ O
inhibition WO2014082230A1 A NN O
activity WO2014082230A1 A NN O
to WO2014082230A1 A TO O
tyrosine WO2014082230A1 A VB O
kinase WO2014082230A1 A NN O
and WO2014082230A1 A CC O
is WO2014082230A1 A VBZ O
an WO2014082230A1 A DT O
effective WO2014082230A1 A JJ O
tyrosine WO2014082230A1 A NN O
kinase WO2014082230A1 A NN O
inhibitor WO2014082230A1 A NN O
. WO2014082230A1 A . O

The WO2014082230A1 A DT O
pyrrolotriazine WO2014082230A1 A JJ O
derivative WO2014082230A1 A JJ O
provides WO2014082230A1 A VBZ O
a WO2014082230A1 A DT O
new WO2014082230A1 A JJ O
research WO2014082230A1 A NN O
direction WO2014082230A1 A NN O
and WO2014082230A1 A CC O
path WO2014082230A1 A NN O
for WO2014082230A1 A IN O
developing WO2014082230A1 A VBG O
new WO2014082230A1 A JJ O
tyrosine WO2014082230A1 A NN O
kinase WO2014082230A1 A NN O
inhibiting WO2014082230A1 A VBG O
medicine WO2014082230A1 A NN O
that WO2014082230A1 A WDT O
has WO2014082230A1 A VBZ O
low WO2014082230A1 A JJ O
drug WO2014082230A1 A NN O
resistance WO2014082230A1 A NN O
or WO2014082230A1 A CC O
can WO2014082230A1 A MD O
relieve WO2014082230A1 A VB O
early WO2014082230A1 A JJ O
inhibitor WO2014082230A1 A NN O
drug WO2014082230A1 A NN O
resistance WO2014082230A1 A NN O
, WO2014082230A1 A , O
and WO2014082230A1 A CC O
has WO2014082230A1 A VBZ O
a WO2014082230A1 A DT O
wide WO2014082230A1 A JJ O
application WO2014082230A1 A NN O
prospect WO2014082230A1 A NN O
and WO2014082230A1 A CC O
a WO2014082230A1 A DT O
high WO2014082230A1 A JJ O
medicinal WO2014082230A1 A JJ O
value WO2014082230A1 A NN O
. WO2014082230A1 A . O

AChE EP2599489A1 T NNP I-UN
antisense EP2599489A1 T JJ O
deoxyoligonucleotide EP2599489A1 T NN O
as EP2599489A1 T IN O
an EP2599489A1 T DT O
anti-inflammatory EP2599489A1 T JJ O
agent EP2599489A1 T NN O
. EP2599489A1 T . O

The EP2599489A1 A DT O
present EP2599489A1 A JJ O
invention EP2599489A1 A NN O
provides EP2599489A1 A VBZ O
a EP2599489A1 A DT O
novel EP2599489A1 A NN O
use EP2599489A1 A NN O
for EP2599489A1 A IN O
AChE EP2599489A1 A NNP I-UN
antisense EP2599489A1 A NN O
oligonucleotides EP2599489A1 A NNS O
as EP2599489A1 A IN O
anti-inflammatory EP2599489A1 A JJ O
agents EP2599489A1 A NNS O
, EP2599489A1 A , O
wherein EP2599489A1 A NN O
said EP2599489A1 A VBD O
oligonucleotides EP2599489A1 A NNS O
are EP2599489A1 A VBP O
preferably EP2599489A1 A RB O
as EP2599489A1 A IN O
denoted EP2599489A1 A VBN O
by EP2599489A1 A IN O
SEQ EP2599489A1 A NNP O
. EP2599489A1 A . O

Described EP2599489A1 A VBN O
are EP2599489A1 A VBP O
pharmaceutical EP2599489A1 A JJ O
compositions EP2599489A1 A NNS O
for EP2599489A1 A IN O
the EP2599489A1 A DT O
treatment EP2599489A1 A NN O
of EP2599489A1 A IN O
inflammatory EP2599489A1 A JJ O
conditions EP2599489A1 A NNS O
comprising EP2599489A1 A VBG O
as EP2599489A1 A IN O
active EP2599489A1 A JJ O
agent EP2599489A1 A NN O
said EP2599489A1 A VBD O
AChE EP2599489A1 A NNP I-UN
antisense EP2599489A1 A NN O
oligonucleotides EP2599489A1 A NNS O
. EP2599489A1 A . O

Pyrrolo-and CN103497184A T NNP O
thiazolo-pyridine CN103497184A T JJ O
compounds CN103497184A T NNS O
as CN103497184A T IN O
HIF CN103497184A T NNP O
modulators CN103497184A T NNS O
. CN103497184A T . O

Formulations WO2008156349A3 T NNS O
that WO2008156349A3 T WDT O
contain WO2008156349A3 T VBP O
combination WO2008156349A3 T NN O
of WO2008156349A3 T IN O
zink WO2008156349A3 T NN O
sulphate WO2008156349A3 T NN O
and WO2008156349A3 T CC O
eteric WO2008156349A3 T JJ O
oil WO2008156349A3 T NN O
of WO2008156349A3 T IN O
achilea WO2008156349A3 T NN O
millefolium WO2008156349A3 T NN O
for WO2008156349A3 T IN O
treatment WO2008156349A3 T NN O
of WO2008156349A3 T IN O
the WO2008156349A3 T DT O
herpes WO2008156349A3 T NNS O
simplex WO2008156349A3 T JJ O
virus WO2008156349A3 T NN O
. WO2008156349A3 T . O

Formulations WO2008156349A3 A NNS O
that WO2008156349A3 A WDT O
contain WO2008156349A3 A VBP O
a WO2008156349A3 A DT O
specially WO2008156349A3 A RB O
adjusted WO2008156349A3 A VBN O
combination WO2008156349A3 A NN O
of WO2008156349A3 A IN O
zinc WO2008156349A3 A NN O
sulphate WO2008156349A3 A NN O
and WO2008156349A3 A CC O
eteric WO2008156349A3 A JJ O
oil WO2008156349A3 A NN O
of WO2008156349A3 A IN O
achilea WO2008156349A3 A NN O
millefolium WO2008156349A3 A NN O
. WO2008156349A3 A . O

The WO2008156349A3 A DT O
usage WO2008156349A3 A NN O
of WO2008156349A3 A IN O
such WO2008156349A3 A JJ O
formulations WO2008156349A3 A NNS O
in WO2008156349A3 A IN O
treatment WO2008156349A3 A NN O
of WO2008156349A3 A IN O
viral WO2008156349A3 A JJ O
infections WO2008156349A3 A NNS O
herpes WO2008156349A3 A NNS O
simplex WO2008156349A3 A VBP O
type WO2008156349A3 A JJ O
1 WO2008156349A3 A CD O
or WO2008156349A3 A CC O
type WO2008156349A3 A VB O
2 WO2008156349A3 A CD O
is WO2008156349A3 A VBZ O
shown WO2008156349A3 A VBN O
. WO2008156349A3 A . O

The WO2008156349A3 A DT O
zinc WO2008156349A3 A NN O
i.e WO2008156349A3 A NN O
. WO2008156349A3 A . O

zinc WO2008156349A3 A NN O
sulphate WO2008156349A3 A NN O
has WO2008156349A3 A VBZ O
an WO2008156349A3 A DT O
antiviral WO2008156349A3 A JJ O
activity WO2008156349A3 A NN O
i.e WO2008156349A3 A NN O
. WO2008156349A3 A . O

take WO2008156349A3 A VB O
significant WO2008156349A3 A JJ O
part WO2008156349A3 A NN O
in WO2008156349A3 A IN O
polynucleotide WO2008156349A3 A JJ O
transcription WO2008156349A3 A NN O
and WO2008156349A3 A CC O
translation WO2008156349A3 A NN O
and WO2008156349A3 A CC O
with WO2008156349A3 A IN O
that WO2008156349A3 A DT O
in WO2008156349A3 A IN O
genetically WO2008156349A3 A RB O
expression WO2008156349A3 A NN O
. WO2008156349A3 A . O

Whereas WO2008156349A3 A NNP O
achilea WO2008156349A3 A NN O
millefolium WO2008156349A3 A NN O
aetheroleum WO2008156349A3 A NN O
has WO2008156349A3 A VBZ O
anti- WO2008156349A3 A JJ O
inflammatory WO2008156349A3 A NN O
and WO2008156349A3 A CC O
astringently WO2008156349A3 A RB O
activity WO2008156349A3 A NN O
and WO2008156349A3 A CC O
intensify WO2008156349A3 A VB O
the WO2008156349A3 A DT O
activity WO2008156349A3 A NN O
of WO2008156349A3 A IN O
zinc WO2008156349A3 A NN O
sulphate WO2008156349A3 A NN O
. WO2008156349A3 A . O

Use WO2008156349A3 A NNP O
of WO2008156349A3 A IN O
the WO2008156349A3 A DT O
combination WO2008156349A3 A NN O
of WO2008156349A3 A IN O
extract WO2008156349A3 A NN O
of WO2008156349A3 A IN O
yarrow WO2008156349A3 A NN O
with WO2008156349A3 A IN O
zinc WO2008156349A3 A NN O
sulphate WO2008156349A3 A NN O
with WO2008156349A3 A IN O
an WO2008156349A3 A DT O
antiviral WO2008156349A3 A JJ O
activity WO2008156349A3 A NN O
with WO2008156349A3 A IN O
adding WO2008156349A3 A VBG O
in WO2008156349A3 A IN O
all WO2008156349A3 A DT O
pharmaceutical WO2008156349A3 A JJ O
forms WO2008156349A3 A NNS O
, WO2008156349A3 A , O
whereupon WO2008156349A3 A JJ O
pharmaceutical WO2008156349A3 A JJ O
forms WO2008156349A3 A NNS O
can WO2008156349A3 A MD O
be WO2008156349A3 A VB O
in WO2008156349A3 A IN O
liquid WO2008156349A3 A NN O
and WO2008156349A3 A CC O
semisolid WO2008156349A3 A JJ O
form WO2008156349A3 A NN O
. WO2008156349A3 A . O

Prostaglandin EP1605948A1 T NNP O
compositions EP1605948A1 T NNS O
for EP1605948A1 T IN O
the EP1605948A1 T DT O
treatment EP1605948A1 T NN O
of EP1605948A1 T IN O
erectile EP1605948A1 T JJ O
dysfunction EP1605948A1 T NN O
. EP1605948A1 T . O

Methods US20120232102 T NNS O
Of US20120232102 T IN O
Administration US20120232102 T NNP O
And US20120232102 T CC O
Treatment US20120232102 T NNP O
. US20120232102 T . O

2,3-diaryl CN102766109A T JJ O
thiazolidine-4-one/-thioketone CN102766109A T NN O
compounds CN102766109A T NNS O
, CN102766109A T , O
oxides CN102766109A T NNS O
thereof CN102766109A T VBP O
and CN102766109A T CC O
use CN102766109A T VBP O
thereof CN102766109A T NN O
. CN102766109A T . O

Combination WO2014090875A1 T NN O
of WO2014090875A1 T IN O
ethambutol WO2014090875A1 T NN O
with WO2014090875A1 T IN O
at WO2014090875A1 T IN O
least WO2014090875A1 T JJS O
one WO2014090875A1 T CD O
additional WO2014090875A1 T JJ O
anti-bacterial WO2014090875A1 T JJ O
agent WO2014090875A1 T NN O
for WO2014090875A1 T IN O
use WO2014090875A1 T NN O
in WO2014090875A1 T IN O
the WO2014090875A1 T DT O
treatment WO2014090875A1 T NN O
of WO2014090875A1 T IN O
bacterial WO2014090875A1 T JJ O
infections WO2014090875A1 T NNS O
. WO2014090875A1 T . O

Anticancer CN101130556A T NNP O
diaminocyclohexane CN101130556A T VBZ O
metallic CN101130556A T JJ O
complex CN101130556A T NN O
. CN101130556A T . O

The CN101130556A A DT O
invention CN101130556A A NN O
discloses CN101130556A A VBZ O
a CN101130556A A DT O
medicinal CN101130556A A JJ O
molecule CN101130556A A NN O
with CN101130556A A IN O
selective CN101130556A A JJ O
anticancer CN101130556A A NN O
activity CN101130556A A NN O
with CN101130556A A IN O
structure CN101130556A A NN O
as CN101130556A A IN O
general CN101130556A A JJ O
formula CN101130556A A NN O
( CN101130556A A ( O
I CN101130556A A PRP O
) CN101130556A A ) O
, CN101130556A A , O
which CN101130556A A WDT O
uses CN101130556A A VBZ O
chiral CN101130556A A JJ O
cyclohexamethylene CN101130556A A NN O
diamine CN101130556A A NN O
derivative CN101130556A A JJ O
and CN101130556A A CC O
metal CN101130556A A JJ O
ion CN101130556A A NN O
to CN101130556A A TO O
form CN101130556A A VB O
metal CN101130556A A NN O
complex CN101130556A A NN O
after CN101130556A A IN O
coordinating CN101130556A A VBG O
and CN101130556A A CC O
provides CN101130556A A VBZ O
the CN101130556A A DT O
making CN101130556A A VBG O
method CN101130556A A NN O
of CN101130556A A IN O
the CN101130556A A DT O
typical CN101130556A A JJ O
compound CN101130556A A NN O
and CN101130556A A CC O
inhibition CN101130556A A NN O
and CN101130556A A CC O
mechanism CN101130556A A NN O
of CN101130556A A IN O
the CN101130556A A DT O
growth CN101130556A A NN O
of CN101130556A A IN O
human CN101130556A A JJ O
breast CN101130556A A NN O
cancer CN101130556A A NN O
and CN101130556A A CC O
lung CN101130556A A NN O
cancer CN101130556A A NN O
, CN101130556A A , O
wherein CN101130556A A VBP O
R1 CN101130556A A NNP O
and CN101130556A A CC O
R2 CN101130556A A NNP O
contains CN101130556A A VBZ O
random CN101130556A A VB O
one CN101130556A A CD O
meaning CN101130556A A NN O
organic CN101130556A A JJ O
group CN101130556A A NN O
or CN101130556A A CC O
hydrogen CN101130556A A NN O
atom CN101130556A A NN O
; CN101130556A A : O
A1 CN101130556A A NNP O
and CN101130556A A CC O
A2 CN101130556A A NNP O
can CN101130556A A MD O
be CN101130556A A VB O
individually CN101130556A A RB O
selected CN101130556A A VBN O
from CN101130556A A IN O
random CN101130556A A JJ O
organic CN101130556A A JJ O
group CN101130556A A NN O
; CN101130556A A : O
M CN101130556A A NNP O
is CN101130556A A VBZ O
random CN101130556A A JJ O
one CN101130556A A CD O
transition CN101130556A A NN O
system CN101130556A A NN O
, CN101130556A A , O
expensive CN101130556A A JJ O
metal CN101130556A A NN O
or CN101130556A A CC O
rare CN101130556A A JJ O
earth CN101130556A A NN O
metal CN101130556A A JJ O
ion CN101130556A A NN O
or CN101130556A A CC O
radioactive CN101130556A A JJ O
isotope CN101130556A A NN O
; CN101130556A A : O
B1 CN101130556A A NNP O
, CN101130556A A , O
B2 CN101130556A A NNP O
, CN101130556A A , O
C1 CN101130556A A NNP O
and CN101130556A A CC O
C2 CN101130556A A NNP O
represent CN101130556A A VBP O
random CN101130556A A JJ O
one CN101130556A A CD O
complex CN101130556A A JJ O
ion CN101130556A A NN O
, CN101130556A A , O
molecular CN101130556A A JJ O
or CN101130556A A CC O
vacant CN101130556A A JJ O
site CN101130556A A NN O
individually CN101130556A A RB O
; CN101130556A A : O
B1 CN101130556A A NNP O
and CN101130556A A CC O
B2 CN101130556A A NNP O
can CN101130556A A MD O
represent CN101130556A A VB O
a CN101130556A A DT O
couple CN101130556A A NN O
of CN101130556A A IN O
tooth CN101130556A A NN O
complex CN101130556A A JJ O
together CN101130556A A RB O
; CN101130556A A : O
R1 CN101130556A A NNP O
, CN101130556A A , O
R2 CN101130556A A NNP O
, CN101130556A A , O
A1 CN101130556A A NNP O
, CN101130556A A , O
A2 CN101130556A A NNP O
, CN101130556A A , O
B1 CN101130556A A NNP O
, CN101130556A A , O
B2 CN101130556A A NNP O
, CN101130556A A , O
C1 CN101130556A A NNP O
and CN101130556A A CC O
C2 CN101130556A A NNP O
can CN101130556A A MD O
link CN101130556A A VB O
biological CN101130556A A JJ O
molecule CN101130556A A NN O
. CN101130556A A . O

Phenoxyacetic WO2007062678A1 T JJ O
acid WO2007062678A1 T NN O
derivatives WO2007062678A1 T NNS O
as WO2007062678A1 T IN O
crth2 WO2007062678A1 T NN I-UN
receptor WO2007062678A1 T NN O
ligands WO2007062678A1 T VBZ O
. WO2007062678A1 T . O

4-Bromo-2- WO2007062678A1 A JJ O
[ WO2007062678A1 A JJ O
1- WO2007062678A1 A JJ O
( WO2007062678A1 A ( O
3,5-dichloropyridin-2-yl WO2007062678A1 A JJ O
) WO2007062678A1 A ) O
-1H-pyrazole-4-carbonyl WO2007062678A1 A FW O
] WO2007062678A1 A NNP O
-phenoxyacetic WO2007062678A1 A JJ O
acid WO2007062678A1 A NN O
, WO2007062678A1 A , O
4-bromo­2- WO2007062678A1 A JJ O
[ WO2007062678A1 A JJ O
1- WO2007062678A1 A JJ O
( WO2007062678A1 A ( O
3,5-dichloro-1-oxypyridin-4-yl WO2007062678A1 A JJ O
) WO2007062678A1 A ) O
-1 WO2007062678A1 A VBZ O
H-pyrazole-4-carbonyl WO2007062678A1 A NNP O
] WO2007062678A1 A NNP O
-phenoxyacetic WO2007062678A1 A JJ O
acid WO2007062678A1 A NN O
, WO2007062678A1 A , O
4-bromo-2­ WO2007062678A1 A JJ O
[ WO2007062678A1 A NN O
1 WO2007062678A1 A CD O
- WO2007062678A1 A : O
( WO2007062678A1 A ( O
3,5-dichloro-2-hydroxypyridin-4-yl WO2007062678A1 A JJ O
) WO2007062678A1 A ) O
-1 WO2007062678A1 A VBZ O
H-pyrazole-4-carbonyl WO2007062678A1 A NNP O
] WO2007062678A1 A NNP O
-phenoxyacetic WO2007062678A1 A JJ O
acid WO2007062678A1 A NN O
, WO2007062678A1 A , O
and WO2007062678A1 A CC O
{ WO2007062678A1 A ( O
4­cyclopropyl-2- WO2007062678A1 A JJ O
[ WO2007062678A1 A NN O
1- WO2007062678A1 A JJ O
( WO2007062678A1 A ( O
2,6-dichloro-phenyl WO2007062678A1 A JJ O
) WO2007062678A1 A ) O
-1 WO2007062678A1 A VBZ O
H-pyrazole-4-carbonyl WO2007062678A1 A NNP O
] WO2007062678A1 A NNP O
-phenoxy WO2007062678A1 A NNP O
} WO2007062678A1 A ) O
-acetic WO2007062678A1 A JJ O
acid WO2007062678A1 A NN O
and WO2007062678A1 A CC O
salts WO2007062678A1 A NNS O
, WO2007062678A1 A , O
hydrates WO2007062678A1 A NNS O
and WO2007062678A1 A CC O
solvates WO2007062678A1 A NNS O
thereof WO2007062678A1 A NNS O
are WO2007062678A1 A VBP O
ligands WO2007062678A1 A NNS O
of WO2007062678A1 A IN O
the WO2007062678A1 A DT O
CRTH2 WO2007062678A1 A NNP I-UN
receptor WO2007062678A1 A NN O
, WO2007062678A1 A , O
and WO2007062678A1 A CC O
of WO2007062678A1 A IN O
value WO2007062678A1 A NN O
for WO2007062678A1 A IN O
the WO2007062678A1 A DT O
treatment WO2007062678A1 A NN O
of WO2007062678A1 A IN O
, WO2007062678A1 A , O
inter WO2007062678A1 A NN O
alia WO2007062678A1 A NN O
, WO2007062678A1 A , O
asthma WO2007062678A1 A NN O
, WO2007062678A1 A , O
rhinitis WO2007062678A1 A NN O
, WO2007062678A1 A , O
allergic WO2007062678A1 A JJ O
airway WO2007062678A1 A RB O
syndrome WO2007062678A1 A JJ O
, WO2007062678A1 A , O
or WO2007062678A1 A CC O
allergic WO2007062678A1 A JJ O
rhinobronchitis WO2007062678A1 A NN O
. WO2007062678A1 A . O

Methods US20120149775 T NNS O
for US20120149775 T IN O
preventing US20120149775 T VBG O
and US20120149775 T CC O
improving US20120149775 T VBG O
skin US20120149775 T JJ O
elastic US20120149775 T JJ O
property US20120149775 T NN O
loss US20120149775 T NN O
. US20120149775 T . O

Glucocorticoid EP1809648A2 T JJ O
16alpha,17.alpha.-isoxazolidines EP1809648A2 T NNS O
as EP1809648A2 T IN O
anti-inflammatory EP1809648A2 T JJ O
agents EP1809648A2 T NNS O
. EP1809648A2 T . O

Inhibiting US20110021507 T VBG O
antipsychotic-induced US20110021507 T JJ O
weight US20110021507 T NN O
gain US20110021507 T NN O
. US20110021507 T . O

Combinations EP1485090B1 T NNS O
comprising EP1485090B1 T VBG O
an EP1485090B1 T DT O
epothilone EP1485090B1 T NN O
derivative EP1485090B1 T NN O
and EP1485090B1 T CC O
an EP1485090B1 T DT O
imidazotetrazinone EP1485090B1 T NN O
. EP1485090B1 T . O

Use EP1879572B1 T NNP O
of EP1879572B1 T IN O
antagonists EP1879572B1 T NNS O
of EP1879572B1 T IN O
oxytocin EP1879572B1 T JJ O
and/or EP1879572B1 T NN O
vasopressin EP1879572B1 T NN O
in EP1879572B1 T IN O
assisted EP1879572B1 T JJ O
reproduction EP1879572B1 T NN O
. EP1879572B1 T . O

New CN102697771A T NNP O
application CN102697771A T NN O
of CN102697771A T IN O
alpinetin CN102697771A T NN O
. CN102697771A T . O

Method US20100047362 T NNP O
and US20100047362 T CC O
Pharmaceutical US20100047362 T NNP O
Composition US20100047362 T NNP O
for US20100047362 T IN O
Improvement US20100047362 T NNP O
of US20100047362 T IN O
Wound US20100047362 T NNP O
Healing US20100047362 T NNP O
. US20100047362 T . O

Memantine EP2218450A1 T NNP O
for EP2218450A1 T IN O
treating EP2218450A1 T VBG O
bipolar EP2218450A1 T JJ O
mood EP2218450A1 T NN O
disorders EP2218450A1 T NNS O
resistant EP2218450A1 T VBP O
to EP2218450A1 T TO O
conventional EP2218450A1 T JJ O
treatments EP2218450A1 T NNS O
. EP2218450A1 T . O

N-piperidin-4-ylmethyl-amide US20100204275 T JJ O
derivatives US20100204275 T NNS O
and US20100204275 T CC O
their US20100204275 T PRP$ O
use US20100204275 T NN O
as US20100204275 T IN O
monoamine US20100204275 T JJ O
neurotransmitter US20100204275 T IN O
re-uptake US20100204275 T JJ O
inhibitors US20100204275 T NNS O
. US20100204275 T . O

This US20100204275 A DT O
invention US20100204275 A NN O
relates US20100204275 A VBZ O
to US20100204275 A TO O
novel US20100204275 A VB O
N-piperidin-4-ylmethyl US20100204275 A NNP O
amide US20100204275 A NN O
derivatives US20100204275 A NNS O
useful US20100204275 A JJ O
as US20100204275 A IN O
monoamine US20100204275 A JJ O
neurotransmitter US20100204275 A IN O
re-uptake US20100204275 A JJ O
inhibitors US20100204275 A NNS O
. US20100204275 A . O

In US20100204275 A IN O
other US20100204275 A JJ O
aspects US20100204275 A NNS O
the US20100204275 A DT O
invention US20100204275 A NN O
relates US20100204275 A VBZ O
to US20100204275 A TO O
the US20100204275 A DT O
use US20100204275 A NN O
of US20100204275 A IN O
these US20100204275 A DT O
compounds US20100204275 A NNS O
in US20100204275 A IN O
a US20100204275 A DT O
method US20100204275 A NN O
for US20100204275 A IN O
therapy US20100204275 A NN O
, US20100204275 A , O
and US20100204275 A CC O
to US20100204275 A TO O
pharmaceutical US20100204275 A JJ O
compositions US20100204275 A NNS O
comprising US20100204275 A VBG O
the US20100204275 A DT O
compounds US20100204275 A NNS O
of US20100204275 A IN O
the US20100204275 A DT O
invention US20100204275 A NN O
. US20100204275 A . O

Therapeutic WO2009131201A1 T JJ O
agent WO2009131201A1 T NN O
for WO2009131201A1 T IN O
intermittent WO2009131201A1 T JJ O
claudication WO2009131201A1 T NN O
. WO2009131201A1 T . O

Tramadol CN101780039A T NNP O
multivesicular CN101780039A T JJ O
liposome CN101780039A T NN O
and CN101780039A T CC O
preparation CN101780039A T NN O
method CN101780039A T NN O
thereof CN101780039A T NN O
. CN101780039A T . O

Serially US20100168685 T RB O
Dispensable US20100168685 T NNP O
Antiseptic US20100168685 T NNP O
Wet US20100168685 T NNP O
Wipes US20100168685 T NNP O
Moistened US20100168685 T VBD O
with US20100168685 T IN O
Tincture US20100168685 T NNP O
of US20100168685 T IN O
Green US20100168685 T NNP O
Soap US20100168685 T NNP O
. US20100168685 T . O

Stable CN103505437A T JJ O
pitavastatin CN103505437A T NN O
calcium CN103505437A T NN O
capsules CN103505437A T NNS O
. CN103505437A T . O

Using WO2007131154A3 T VBG O
naltrexone WO2007131154A3 T NN O
as WO2007131154A3 T IN O
a WO2007131154A3 T DT O
multi-purpose WO2007131154A3 T JJ O
health WO2007131154A3 T NN O
supplement WO2007131154A3 T NN O
to WO2007131154A3 T TO O
improve WO2007131154A3 T VB O
the WO2007131154A3 T DT O
human WO2007131154A3 T JJ O
condition WO2007131154A3 T NN O
and WO2007131154A3 T CC O
preventing WO2007131154A3 T VBG O
multiple WO2007131154A3 T JJ O
diseases WO2007131154A3 T NNS O
and WO2007131154A3 T CC O
infirmities WO2007131154A3 T NNS O
by WO2007131154A3 T IN O
stimulating WO2007131154A3 T VBG O
immune WO2007131154A3 T JJ O
system WO2007131154A3 T NN O
vitality WO2007131154A3 T NN O
and WO2007131154A3 T CC O
robustness WO2007131154A3 T NN O
. WO2007131154A3 T . O

Bicyclic EP2690102A1 T NNP O
aza-amides EP2690102A1 T NNS O
for EP2690102A1 T IN O
treatment EP2690102A1 T NN O
of EP2690102A1 T IN O
psychiatric EP2690102A1 T JJ O
disorders EP2690102A1 T NNS O
. EP2690102A1 T . O

Medicament CN101199523B T JJ O
composition CN101199523B T NN O
containing CN101199523B T VBG O
levorotatory CN101199523B T JJ O
ammonia CN101199523B T JJ O
chlorine CN101199523B T NN O
horizon CN101199523B T NN O
and CN101199523B T CC O
atorvastatin CN101199523B T NN O
and CN101199523B T CC O
preparing CN101199523B T VBG O
method CN101199523B T NN O
thereof CN101199523B T NN O
. CN101199523B T . O

Therapeutic WO2012115182A1 T JJ O
agent WO2012115182A1 T NN O
for WO2012115182A1 T IN O
corneal WO2012115182A1 T JJ O
sensory WO2012115182A1 T JJ O
nerve WO2012115182A1 T NN O
damage WO2012115182A1 T NN O
containing WO2012115182A1 T VBG O
semaphorin WO2012115182A1 T JJ O
inhibitor WO2012115182A1 T NN O
as WO2012115182A1 T IN O
active WO2012115182A1 T JJ O
ingredient WO2012115182A1 T NN O
. WO2012115182A1 T . O

Niacin US20120077808 T NNP O
Mimetics US20120077808 T NNP O
, US20120077808 T , O
and US20120077808 T CC O
Methods US20120077808 T NNS O
of US20120077808 T IN O
Use US20120077808 T NNP O
Thereof US20120077808 T NNP O
. US20120077808 T . O

Drug US20090010992 T NN O
formulations US20090010992 T NNS O
for US20090010992 T IN O
oral US20090010992 T JJ O
transmucosal US20090010992 T NN O
delivery US20090010992 T NN O
to US20090010992 T TO O
pediatric US20090010992 T JJ O
patients US20090010992 T NNS O
. US20090010992 T . O

Method WO2006117220A3 T NNP O
of WO2006117220A3 T IN O
administering WO2006117220A3 T VBG O
a WO2006117220A3 T DT O
cationic WO2006117220A3 T JJ O
liposomal WO2006117220A3 T JJ O
preparation WO2006117220A3 T NN O
comprising WO2006117220A3 T VBG O
paclitaxel WO2006117220A3 T NN O
. WO2006117220A3 T . O

Benzisoselenazolone CN101921303A T NNP O
difluorocytidine CN101921303A T NN O
compound CN101921303A T NN O
as CN101921303A T RB O
well CN101921303A T RB O
as CN101921303A T IN O
preparation CN101921303A T NN O
method CN101921303A T NN O
and CN101921303A T CC O
application CN101921303A T NN O
thereof CN101921303A T NN O
. CN101921303A T . O

The CN101921303A A DT O
invention CN101921303A A NN O
discloses CN101921303A A VBZ O
a CN101921303A A DT O
novel CN101921303A A JJ O
antitumor CN101921303A A NN O
medicament CN101921303A A NN O
, CN101921303A A , O
in CN101921303A A IN O
particular CN101921303A A JJ O
a CN101921303A A DT O
benzisoselenazolone CN101921303A A NN O
difluorocytidine CN101921303A A NN O
compound CN101921303A A NN O
or CN101921303A A CC O
a CN101921303A A DT O
pharmaceutically CN101921303A A RB O
acceptable CN101921303A A JJ O
salt CN101921303A A NN O
or CN101921303A A CC O
ester CN101921303A A NN O
thereof CN101921303A A NN O
as CN101921303A A RB O
well CN101921303A A RB O
as CN101921303A A IN O
a CN101921303A A DT O
preparation CN101921303A A NN O
method CN101921303A A NN O
and CN101921303A A CC O
application CN101921303A A NN O
thereof CN101921303A A NN O
, CN101921303A A , O
wherein CN101921303A A VBP O
a CN101921303A A DT O
benzisoselenazolone CN101921303A A NN O
structure CN101921303A A NN O
can CN101921303A A MD O
identify CN101921303A A VB O
selenocysteine CN101921303A A JJ O
residues CN101921303A A NNS O
in CN101921303A A IN O
the CN101921303A A DT O
activity CN101921303A A NN O
center CN101921303A A NN O
of CN101921303A A IN O
thioredoxin CN101921303A A NN I-UN
reductase CN101921303A A NN I-UN
to CN101921303A A TO O
generate CN101921303A A VB O
the CN101921303A A DT O
action CN101921303A A NN O
of CN101921303A A IN O
reversibly CN101921303A A RB O
competitive CN101921303A A JJ O
inhibition CN101921303A A NN O
and CN101921303A A CC O
reserves CN101921303A A NNS O
the CN101921303A A DT O
activity CN101921303A A NN O
structure CN101921303A A NN O
of CN101921303A A IN O
2'-deoxidization-2'2'-difluorocytidine CN101921303A A JJ O
. CN101921303A A . O

Pharmaceutically US20110071115 T RB O
useful US20110071115 T JJ O
heterocycle-substituted US20110071115 T JJ O
lactams US20110071115 T NNS O
. US20110071115 T . O

The US20110071115 A DT O
invention US20110071115 A NN O
provides US20110071115 A VBZ O
compounds US20110071115 A NNS O
that US20110071115 A IN O
inhibit US20110071115 A NN O
CK2 US20110071115 A NNP I-UN
and/or US20110071115 A NN O
Pim US20110071115 A NNP I-UN
kinases US20110071115 A NNS I-UN
and US20110071115 A CC O
compositions US20110071115 A NNS O
containing US20110071115 A VBG O
such US20110071115 A JJ O
compounds US20110071115 A NNS O
. US20110071115 A . O

1,2,5-Oxadiazoles US20120058079 T NNS O
as US20120058079 T IN O
Inhibitors US20120058079 T NNS O
of US20120058079 T IN O
Indoleamine US20120058079 T NNP I-UN
2,3-Dioxygenase US20120058079 T JJ I-UN
. US20120058079 T . O

The US20120058079 A DT O
present US20120058079 A JJ O
invention US20120058079 A NN O
is US20120058079 A VBZ O
directed US20120058079 A VBN O
to US20120058079 A TO O
1,2,5-oxadiazole US20120058079 A JJ O
derivatives US20120058079 A NNS O
, US20120058079 A , O
and US20120058079 A CC O
compositions US20120058079 A NNS O
of US20120058079 A IN O
the US20120058079 A DT O
same US20120058079 A JJ O
, US20120058079 A , O
which US20120058079 A WDT O
are US20120058079 A VBP O
inhibitors US20120058079 A NNS O
of US20120058079 A IN O
indoleamine US20120058079 A JJ I-UN
2,3-dioxygenase US20120058079 A JJ I-UN
and US20120058079 A CC O
are US20120058079 A VBP O
useful US20120058079 A JJ O
in US20120058079 A IN O
the US20120058079 A DT O
treatment US20120058079 A NN O
of US20120058079 A IN O
cancer US20120058079 A NN O
and US20120058079 A CC O
other US20120058079 A JJ O
disorders US20120058079 A NNS O
, US20120058079 A , O
and US20120058079 A CC O
to US20120058079 A TO O
the US20120058079 A DT O
processes US20120058079 A NNS O
and US20120058079 A CC O
intermediates US20120058079 A NNS O
for US20120058079 A IN O
making US20120058079 A VBG O
such US20120058079 A JJ O
1,2,5-oxadiazole US20120058079 A JJ O
derivatives US20120058079 A NNS O
. US20120058079 A . O

Application CN103520010A T NN O
of CN103520010A T IN O
tetrahydropalmatine CN103520010A T NN O
and CN103520010A T CC O
naringin CN103520010A T NN O
in CN103520010A T IN O
preparing CN103520010A T VBG O
oral CN103520010A T JJ O
care CN103520010A T NN O
products CN103520010A T NNS O
. CN103520010A T . O

Preparation CN1840052A T NNP O
method CN1840052A T NN O
of CN1840052A T IN O
notoginseng-containing CN1840052A T JJ O
tablet CN1840052A T NN O
for CN1840052A T IN O
treating CN1840052A T VBG O
traumatic CN1840052A T JJ O
injury CN1840052A T NN O
. CN1840052A T . O

Vasoconstrictive CA2168021C T NNP O
dihydrobenzopyran CA2168021C T NN O
derivatives CA2168021C T NNS O
. CA2168021C T . O

Diketopiperidine WO2009158396A1 T NNP O
derivatives WO2009158396A1 T NNS O
as WO2009158396A1 T IN O
hiv WO2009158396A1 T JJ O
attachment WO2009158396A1 T NN O
inhibitors WO2009158396A1 T NNS O
. WO2009158396A1 T . O

Medicament CN1879737A T NN O
for CN1879737A T IN O
treating CN1879737A T VBG O
poultry CN1879737A T NN O
infectious CN1879737A T JJ O
laryngotracheitis CN1879737A T NN O
. CN1879737A T . O

Heterocyclic EP1495016A2 T NNP O
compounds EP1495016A2 T NNS O
and EP1495016A2 T CC O
their EP1495016A2 T PRP$ O
use EP1495016A2 T NN O
as EP1495016A2 T IN O
modulators EP1495016A2 T NNS O
of EP1495016A2 T IN O
p38 EP1495016A2 T NN I-UN
map EP1495016A2 T NN I-UN
kinase EP1495016A2 T NN I-UN
. EP1495016A2 T . O

The EP1495016A2 A DT O
invention EP1495016A2 A NN O
provides EP1495016A2 A VBZ O
a EP1495016A2 A DT O
compound EP1495016A2 A NN O
for EP1495016A2 A IN O
use EP1495016A2 A NN O
in EP1495016A2 A IN O
the EP1495016A2 A DT O
prophylaxis EP1495016A2 A NN O
or EP1495016A2 A CC O
treatment EP1495016A2 A NN O
of EP1495016A2 A IN O
a EP1495016A2 A DT O
disease EP1495016A2 A NN O
state EP1495016A2 A NN O
or EP1495016A2 A CC O
condition EP1495016A2 A NN O
mediated EP1495016A2 A VBN O
by EP1495016A2 A IN O
a EP1495016A2 A DT O
p38 EP1495016A2 A NN I-UN
MAP EP1495016A2 A NNP I-UN
kinase EP1495016A2 A NN I-UN
such EP1495016A2 A JJ O
as EP1495016A2 A IN O
rheumatoid EP1495016A2 A JJ O
arthritis EP1495016A2 A NN O
and EP1495016A2 A CC O
osteoarthritis EP1495016A2 A NN O
; EP1495016A2 A : O
the EP1495016A2 A DT O
compound EP1495016A2 A NN O
being EP1495016A2 A VBG O
of EP1495016A2 A IN O
the EP1495016A2 A DT O
general EP1495016A2 A JJ O
formula EP1495016A2 A NN O
( EP1495016A2 A ( O
I EP1495016A2 A PRP O
) EP1495016A2 A ) O
: EP1495016A2 A : O
wherein EP1495016A2 A NN O
U EP1495016A2 A NNP O
, EP1495016A2 A , O
T EP1495016A2 A NNP O
, EP1495016A2 A , O
V EP1495016A2 A NNP O
and EP1495016A2 A CC O
W EP1495016A2 A NNP O
are EP1495016A2 A VBP O
each EP1495016A2 A DT O
a EP1495016A2 A DT O
nitrogen EP1495016A2 A JJ O
atom EP1495016A2 A NN O
or EP1495016A2 A CC O
a EP1495016A2 A DT O
group EP1495016A2 A NN O
CR4 EP1495016A2 A NNP O
provided EP1495016A2 A VBD O
that EP1495016A2 A IN O
no EP1495016A2 A DT O
more EP1495016A2 A JJR O
than EP1495016A2 A IN O
three EP1495016A2 A CD O
of EP1495016A2 A IN O
U EP1495016A2 A NNP O
, EP1495016A2 A , O
T EP1495016A2 A NNP O
, EP1495016A2 A , O
V EP1495016A2 A NNP O
and EP1495016A2 A CC O
W EP1495016A2 A NNP O
are EP1495016A2 A VBP O
nitrogen EP1495016A2 A JJ O
atoms EP1495016A2 A NNS O
; EP1495016A2 A : O
R0 EP1495016A2 A NNP O
is EP1495016A2 A VBZ O
hydrogen EP1495016A2 A JJ O
, EP1495016A2 A , O
C1-4 EP1495016A2 A NNP O
hydrocarbyl EP1495016A2 A NN O
, EP1495016A2 A , O
halogen EP1495016A2 A NN O
or EP1495016A2 A CC O
a EP1495016A2 A DT O
group EP1495016A2 A NN O
-A-R3 EP1495016A2 A NNP O
; EP1495016A2 A : O
R1 EP1495016A2 A NNP O
is EP1495016A2 A VBZ O
hydrogen EP1495016A2 A JJ O
, EP1495016A2 A , O
C1-4 EP1495016A2 A JJ O
hydrocarbyl EP1495016A2 A NN O
or EP1495016A2 A CC O
a EP1495016A2 A DT O
group EP1495016A2 A NN O
-A-R3 EP1495016A2 A NNP O
; EP1495016A2 A : O
provided EP1495016A2 A VBD O
that EP1495016A2 A IN O
only EP1495016A2 A RB O
one EP1495016A2 A CD O
of EP1495016A2 A IN O
R0 EP1495016A2 A NNP O
and EP1495016A2 A CC O
R1 EP1495016A2 A NNP O
is EP1495016A2 A VBZ O
a EP1495016A2 A DT O
group EP1495016A2 A NN O
-A-R3 EP1495016A2 A NNP O
; EP1495016A2 A : O
R2 EP1495016A2 A NNP O
is EP1495016A2 A VBZ O
hydrogen EP1495016A2 A JJ O
, EP1495016A2 A , O
C1-4 EP1495016A2 A JJ O
hydrocarbyl EP1495016A2 A NN O
or EP1495016A2 A CC O
halogen EP1495016A2 A NN O
; EP1495016A2 A : O
A EP1495016A2 A NNP O
is EP1495016A2 A VBZ O
a EP1495016A2 A DT O
carbon- EP1495016A2 A JJ O
or EP1495016A2 A CC O
heteroatom-containing EP1495016A2 A JJ O
linker EP1495016A2 A NN O
group EP1495016A2 A NN O
having EP1495016A2 A VBG O
a EP1495016A2 A DT O
linking EP1495016A2 A VBG O
chain EP1495016A2 A NN O
length EP1495016A2 A NN O
of EP1495016A2 A IN O
one EP1495016A2 A CD O
or EP1495016A2 A CC O
two EP1495016A2 A CD O
atoms EP1495016A2 A NNS O
; EP1495016A2 A : O
R3 EP1495016A2 A NNP O
is EP1495016A2 A VBZ O
a EP1495016A2 A DT O
monocyclic EP1495016A2 A JJ O
or EP1495016A2 A CC O
bicyclic EP1495016A2 A JJ O
heteroaryl EP1495016A2 A NN O
group EP1495016A2 A NN O
containing EP1495016A2 A VBG O
from EP1495016A2 A IN O
five EP1495016A2 A CD O
to EP1495016A2 A TO O
twelve EP1495016A2 A VB O
ring EP1495016A2 A VBG O
members EP1495016A2 A NNS O
; EP1495016A2 A : O
each EP1495016A2 A DT O
group EP1495016A2 A NN O
R4 EP1495016A2 A NNP O
is EP1495016A2 A VBZ O
independently EP1495016A2 A RB O
selected EP1495016A2 A VBN O
from EP1495016A2 A IN O
hydrogen EP1495016A2 A NN O
, EP1495016A2 A , O
hydroxy EP1495016A2 A NN O
, EP1495016A2 A , O
halogen EP1495016A2 A NN O
, EP1495016A2 A , O
nitro EP1495016A2 A RB O
, EP1495016A2 A , O
cyano EP1495016A2 A NN O
, EP1495016A2 A , O
a EP1495016A2 A DT O
monocyclic EP1495016A2 A JJ O
heterocyclic EP1495016A2 A NN O
group EP1495016A2 A NN O
having EP1495016A2 A VBG O
up EP1495016A2 A RP O
to EP1495016A2 A TO O
seven EP1495016A2 A CD O
ring EP1495016A2 A VBG O
members EP1495016A2 A NNS O
, EP1495016A2 A , O
a EP1495016A2 A DT O
group EP1495016A2 A NN O
N EP1495016A2 A NNP O
( EP1495016A2 A ( O
R5 EP1495016A2 A NNP O
) EP1495016A2 A ) O
2 EP1495016A2 A CD O
, EP1495016A2 A , O
a EP1495016A2 A DT O
group EP1495016A2 A NN O
C EP1495016A2 A NNP O
( EP1495016A2 A ( O
O EP1495016A2 A NNP O
) EP1495016A2 A ) O
N EP1495016A2 A NNP O
( EP1495016A2 A ( O
R6 EP1495016A2 A NNP O
) EP1495016A2 A ) O
2 EP1495016A2 A CD O
, EP1495016A2 A , O
a EP1495016A2 A DT O
group EP1495016A2 A NN O
S02N EP1495016A2 A NNP O
( EP1495016A2 A ( O
R6 EP1495016A2 A NNP O
) EP1495016A2 A ) O
2 EP1495016A2 A CD O
, EP1495016A2 A , O
a EP1495016A2 A DT O
group EP1495016A2 A NN O
Ra-Rb EP1495016A2 A NNP O
and EP1495016A2 A CC O
a EP1495016A2 A DT O
group EP1495016A2 A NN O
Y EP1495016A2 A NNP O
; EP1495016A2 A : O
provided EP1495016A2 A VBD O
that EP1495016A2 A IN O
no EP1495016A2 A DT O
more EP1495016A2 A JJR O
than EP1495016A2 A IN O
one EP1495016A2 A CD O
group EP1495016A2 A NN O
Y EP1495016A2 A NNP O
is EP1495016A2 A VBZ O
present EP1495016A2 A JJ O
; EP1495016A2 A : O

Medical US20120083523 T JJ O
devices US20120083523 T NNS O
having US20120083523 T VBG O
polymeric US20120083523 T JJ O
regions US20120083523 T NNS O
with US20120083523 T IN O
copolymers US20120083523 T NNS O
containing US20120083523 T VBG O
hydrocarbon US20120083523 T NN O
and US20120083523 T CC O
heteroatom-containing US20120083523 T JJ O
monomeric US20120083523 T JJ O
species US20120083523 T NNS O
. US20120083523 T . O

HM74 US8394808 T NNP I-UN
receptor US8394808 T NN O
agonists US8394808 T NNS O
: US8394808 T : O
xanthine US8394808 T NN O
derivatives US8394808 T NNS O
, US8394808 T , O
corresponding US8394808 T VBG O
pharmaceutical US8394808 T JJ O
compositions US8394808 T NNS O
, US8394808 T , O
treatment US8394808 T NN O
methods US8394808 T NNS O
and US8394808 T CC O
processes US8394808 T NNS O
. US8394808 T . O

The US8394808 A DT O
present US8394808 A JJ O
invention US8394808 A NN O
relates US8394808 A VBZ O
to US8394808 A TO O
therapeutically US8394808 A RB O
active US8394808 A JJ O
xanthine US8394808 A NNP O
derivative US8394808 A JJ O
compounds US8394808 A NNS O
of US8394808 A IN O
Formula US8394808 A NNP O
( US8394808 A ( O
I US8394808 A PRP O
) US8394808 A ) O
: US8394808 A : O
corresponding US8394808 A NN O
processes US8394808 A VBZ O
for US8394808 A IN O
manufacture US8394808 A NN O
of US8394808 A IN O
said US8394808 A VBD O
derivatives US8394808 A NNS O
, US8394808 A , O
pharmaceutical US8394808 A JJ O
formulations US8394808 A NNS O
containing US8394808 A VBG O
and US8394808 A CC O
uses US8394808 A NNS O
of US8394808 A IN O
such US8394808 A JJ O
compounds US8394808 A NNS O
in US8394808 A IN O
therapy US8394808 A NN O
, US8394808 A , O
particularly US8394808 A RB O
in US8394808 A IN O
treatment US8394808 A NN O
of US8394808 A IN O
diseases US8394808 A NNS O
where US8394808 A WRB O
under-activation US8394808 A NN O
of US8394808 A IN O
the US8394808 A DT O
HM74A US8394808 A NNP I-UN
receptor US8394808 A NN O
contributes US8394808 A VBZ O
to US8394808 A TO O
the US8394808 A DT O
disease US8394808 A NN O
or US8394808 A CC O
where US8394808 A WRB O
activation US8394808 A NN O
of US8394808 A IN O
the US8394808 A DT O
receptor US8394808 A NN O
will US8394808 A MD O
be US8394808 A VB O
beneficial US8394808 A JJ O
. US8394808 A . O

Liposomal EP1855669A1 T JJ O
compositions EP1855669A1 T NNS O
for EP1855669A1 T IN O
parenteral EP1855669A1 T JJ O
delivery EP1855669A1 T NN O
of EP1855669A1 T IN O
agents EP1855669A1 T NNS O
. EP1855669A1 T . O

Ortho EP2475648A1 T NNP O
substituted EP2475648A1 T VBD O
pyrimidine EP2475648A1 T JJ O
compounds EP2475648A1 T NNS O
as EP2475648A1 T IN O
jak EP2475648A1 T NN I-UN
inhibitors EP2475648A1 T NNS O
. EP2475648A1 T . O

Said EP2475648A1 A NNP O
compounds EP2475648A1 A NNS O
are EP2475648A1 A VBP O
useful EP2475648A1 A JJ O
as EP2475648A1 A IN O
JAK EP2475648A1 A NNP I-UN
inhibitors EP2475648A1 A NNS O
for EP2475648A1 A IN O
the EP2475648A1 A DT O
treatment EP2475648A1 A NN O
or EP2475648A1 A CC O
prophylaxis EP2475648A1 A NN O
of EP2475648A1 A IN O
immunological EP2475648A1 A JJ O
, EP2475648A1 A , O
inflammatory EP2475648A1 A JJ O
, EP2475648A1 A , O
autoimmune EP2475648A1 A JJ O
, EP2475648A1 A , O
allergic EP2475648A1 A JJ O
disorders EP2475648A1 A NNS O
, EP2475648A1 A , O
and EP2475648A1 A CC O
immunologically-mediated EP2475648A1 A JJ O
diseases EP2475648A1 A NNS O
. EP2475648A1 A . O

Method US20100080851 T NNP O
of US20100080851 T IN O
preparing US20100080851 T VBG O
a US20100080851 T DT O
microcapsule US20100080851 T NN O
containing US20100080851 T VBG O
unsaturated US20100080851 T JJ O
fatty US20100080851 T JJ O
acids US20100080851 T NNS O
, US20100080851 T , O
the US20100080851 T DT O
microcapsule US20100080851 T NN O
prepared US20100080851 T VBN O
by US20100080851 T IN O
the US20100080851 T DT O
method US20100080851 T NN O
, US20100080851 T , O
and US20100080851 T CC O
articles US20100080851 T NNS O
containing US20100080851 T VBG O
the US20100080851 T DT O
microcapsule US20100080851 T NN O
. US20100080851 T . O

The US20100080851 A DT O
present US20100080851 A JJ O
invention US20100080851 A NN O
provides US20100080851 A VBZ O
a US20100080851 A DT O
preparing US20100080851 A VBG O
method US20100080851 A NN O
of US20100080851 A IN O
microcapsule US20100080851 A NN O
containing US20100080851 A VBG O
unsaturated US20100080851 A JJ O
fatty US20100080851 A JJ O
acid US20100080851 A NN O
comprising US20100080851 A VBG O
the US20100080851 A DT O
steps US20100080851 A NNS O
of US20100080851 A IN O
( US20100080851 A ( O
a US20100080851 A DT O
) US20100080851 A ) O
preparing US20100080851 A VBG O
a US20100080851 A DT O
first US20100080851 A JJ O
coating US20100080851 A VBG O
material US20100080851 A NN O
by US20100080851 A IN O
mixing US20100080851 A VBG O
and US20100080851 A CC O
gelatinating US20100080851 A VBG O
one US20100080851 A CD O
or US20100080851 A CC O
more US20100080851 A JJR O
gums US20100080851 A NNS O
selected US20100080851 A VBN O
from US20100080851 A IN O
the US20100080851 A DT O
group US20100080851 A NN O
consisting US20100080851 A VBG O
of US20100080851 A IN O
xanthan US20100080851 A NNP O
gum US20100080851 A NN O
, US20100080851 A , O
guar US20100080851 A NN O
gum US20100080851 A NN O
, US20100080851 A , O
and US20100080851 A CC O
locusbean US20100080851 A JJ O
gum US20100080851 A NN O
, US20100080851 A , O
with US20100080851 A IN O
poly US20100080851 A JJ O
glycerin US20100080851 A NN O
esters US20100080851 A NNS O
of US20100080851 A IN O
fatty US20100080851 A JJ O
acid US20100080851 A NN O
in US20100080851 A IN O
sterilized US20100080851 A JJ O
water US20100080851 A NN O
, US20100080851 A , O
adding US20100080851 A VBG O
unsaturated US20100080851 A JJ O
fatty US20100080851 A JJ O
acid US20100080851 A NN O
to US20100080851 A TO O
the US20100080851 A DT O
solution US20100080851 A NN O
, US20100080851 A , O
and US20100080851 A CC O
homogenizing US20100080851 A VBG O
the US20100080851 A DT O
solution US20100080851 A NN O
; US20100080851 A : O
( US20100080851 A ( O
b US20100080851 A NN O
) US20100080851 A ) O
preparing US20100080851 A VBG O
a US20100080851 A DT O
second US20100080851 A JJ O
coating US20100080851 A NN O
material US20100080851 A NN O
by US20100080851 A IN O
mixing US20100080851 A VBG O
and US20100080851 A CC O
gelatinating US20100080851 A VBG O
starch US20100080851 A NN O
or US20100080851 A CC O
modified US20100080851 A VBN O
starch US20100080851 A NN O
, US20100080851 A , O
gelatin US20100080851 A NN I-UN
or US20100080851 A CC O
casein US20100080851 A NN I-UN
, US20100080851 A , O
and US20100080851 A CC O
poly US20100080851 A JJ O
glycerin US20100080851 A NN O
esters US20100080851 A NNS O
of US20100080851 A IN O
fatty US20100080851 A JJ O
acid US20100080851 A NN O
in US20100080851 A IN O
sterilized US20100080851 A JJ O
water US20100080851 A NN O
, US20100080851 A , O
adding US20100080851 A VBG O
the US20100080851 A DT O
first US20100080851 A JJ O
coating US20100080851 A VBG O
material US20100080851 A NN O
prepared US20100080851 A VBN O
in US20100080851 A IN O
( US20100080851 A ( O
a US20100080851 A DT O
) US20100080851 A ) O
to US20100080851 A TO O
the US20100080851 A DT O
solution US20100080851 A NN O
, US20100080851 A , O
and US20100080851 A CC O
homogenizing US20100080851 A VBG O
the US20100080851 A DT O
solution US20100080851 A NN O
; US20100080851 A : O
and US20100080851 A CC O
( US20100080851 A ( O
c US20100080851 A NN O
) US20100080851 A ) O
spraying US20100080851 A VBG O
the US20100080851 A DT O
second US20100080851 A JJ O
coating US20100080851 A NN O
material US20100080851 A NN O
prepared US20100080851 A VBN O
in US20100080851 A IN O
( US20100080851 A ( O
b US20100080851 A NN O
) US20100080851 A ) O
in US20100080851 A IN O
cold US20100080851 A JJ O
sterilized US20100080851 A JJ O
water US20100080851 A NN O
; US20100080851 A : O
a US20100080851 A DT O
microcapsule US20100080851 A NN O
prepared US20100080851 A VBN O
by US20100080851 A IN O
the US20100080851 A DT O
method US20100080851 A NN O
; US20100080851 A : O
and US20100080851 A CC O
articles US20100080851 A NNS O
containing US20100080851 A VBG O
the US20100080851 A DT O
microcapsule US20100080851 A NN O
. US20100080851 A . O

Method US20100256057 T NNP O
of US20100256057 T IN O
preventing US20100256057 T VBG O
or US20100256057 T CC O
treating US20100256057 T VBG O
body US20100256057 T NN O
weight US20100256057 T NN O
disorders US20100256057 T NNS O
by US20100256057 T IN O
employing US20100256057 T VBG O
clusterin US20100256057 T NN I-UN
. US20100256057 T . O

Clusterin US20100256057 A NNP I-UN
possesses US20100256057 A VBZ O
an US20100256057 A DT O
excellent US20100256057 A JJ O
anorexigenic US20100256057 A JJ O
effect US20100256057 A NN O
and US20100256057 A CC O
, US20100256057 A , O
accordingly US20100256057 A RB O
, US20100256057 A , O
is US20100256057 A VBZ O
useful US20100256057 A JJ O
for US20100256057 A IN O
treating US20100256057 A VBG O
or US20100256057 A CC O
preventing US20100256057 A VBG O
obesity US20100256057 A NN O
or US20100256057 A CC O
an US20100256057 A DT O
obesity-related US20100256057 A JJ O
disorder US20100256057 A NN O
. US20100256057 A . O

Co-administration US20100256057 A NN O
of US20100256057 A IN O
sub-clinical US20100256057 A JJ O
dose US20100256057 A NN O
of US20100256057 A IN O
clustrin US20100256057 A NN I-UN
potentiates US20100256057 A VBZ O
the US20100256057 A DT O
anorexigenic US20100256057 A JJ O
effect US20100256057 A NN O
of US20100256057 A IN O
leptin US20100256057 A NN I-UN
. US20100256057 A . O

Use US20110152294 T NNP O
of US20110152294 T IN O
osmolytes US20110152294 T NNS O
obtained US20110152294 T VBN O
from US20110152294 T IN O
extremophilic US20110152294 T JJ O
bacteria US20110152294 T NNS O
for US20110152294 T IN O
the US20110152294 T DT O
production US20110152294 T NN O
of US20110152294 T IN O
inhalable US20110152294 T JJ O
medicaments US20110152294 T NNS O
for US20110152294 T IN O
the US20110152294 T DT O
prophylaxis US20110152294 T NN O
and US20110152294 T CC O
treatment US20110152294 T NN O
of US20110152294 T IN O
pulmonary US20110152294 T JJ O
and US20110152294 T CC O
cardiovascular US20110152294 T JJ O
diseases US20110152294 T NNS O
and US20110152294 T CC O
an US20110152294 T DT O
inhalation US20110152294 T NN O
device US20110152294 T NN O
comprising US20110152294 T VBG O
osmolyte US20110152294 T NN O
as US20110152294 T IN O
active US20110152294 T JJ O
agent US20110152294 T NN O
component US20110152294 T NN O
. US20110152294 T . O

Use EP2306996A1 T NNP O
of EP2306996A1 T IN O
hdac EP2306996A1 T NN O
inhibitors EP2306996A1 T NNS O
for EP2306996A1 T IN O
the EP2306996A1 T DT O
treatment EP2306996A1 T NN O
of EP2306996A1 T IN O
hodgkin EP2306996A1 T NN O
's EP2306996A1 T POS O
disease EP2306996A1 T NN O
. EP2306996A1 T . O

Rafamycin WO2014082286A1 T NNP O
analogs WO2014082286A1 T NNS O
and WO2014082286A1 T CC O
methods WO2014082286A1 T NNS O
for WO2014082286A1 T IN O
making WO2014082286A1 T VBG O
same WO2014082286A1 T JJ O
. WO2014082286A1 T . O

A WO2014082286A1 A DT O
semi-synthetic WO2014082286A1 A JJ O
rapamycin WO2014082286A1 A NN O
analog WO2014082286A1 A NN O
with WO2014082286A1 A IN O
a WO2014082286A1 A DT O
triazole WO2014082286A1 A JJ O
moiety WO2014082286A1 A NN O
or WO2014082286A1 A CC O
a WO2014082286A1 A DT O
pharmaceutically WO2014082286A1 A RB O
acceptable WO2014082286A1 A JJ O
salt WO2014082286A1 A NN O
or WO2014082286A1 A CC O
prodrug WO2014082286A1 A NN O
thereof WO2014082286A1 A NN O
, WO2014082286A1 A , O
is WO2014082286A1 A VBZ O
a WO2014082286A1 A DT O
broad-spectrum WO2014082286A1 A JJ O
cytostatic WO2014082286A1 A JJ O
agent WO2014082286A1 A NN O
and WO2014082286A1 A CC O
a WO2014082286A1 A DT O
m WO2014082286A1 A NN I-UN
TOR WO2014082286A1 A NNP I-UN
inhibitor WO2014082286A1 A NN O
, WO2014082286A1 A , O
and WO2014082286A1 A CC O
is WO2014082286A1 A VBZ O
useful WO2014082286A1 A JJ O
in WO2014082286A1 A IN O
the WO2014082286A1 A DT O
treatment WO2014082286A1 A NN O
of WO2014082286A1 A IN O
various WO2014082286A1 A JJ O
cancers WO2014082286A1 A NNS O
, WO2014082286A1 A , O
or WO2014082286A1 A CC O
tumors WO2014082286A1 A NNS O
in WO2014082286A1 A IN O
organs WO2014082286A1 A NNS O
such WO2014082286A1 A JJ O
as WO2014082286A1 A IN O
kidney WO2014082286A1 A NN O
, WO2014082286A1 A , O
liver WO2014082286A1 A NN O
, WO2014082286A1 A , O
breast WO2014082286A1 A NN O
, WO2014082286A1 A , O
head WO2014082286A1 A NN O
and WO2014082286A1 A CC O
neck WO2014082286A1 A NN O
, WO2014082286A1 A , O
lung WO2014082286A1 A NN O
, WO2014082286A1 A , O
prostate WO2014082286A1 A NN O
, WO2014082286A1 A , O
and WO2014082286A1 A CC O
restenosis WO2014082286A1 A NN O
in WO2014082286A1 A IN O
coronary WO2014082286A1 A JJ O
arteries WO2014082286A1 A NNS O
, WO2014082286A1 A , O
peripheral WO2014082286A1 A JJ O
arteries WO2014082286A1 A NNS O
, WO2014082286A1 A , O
and WO2014082286A1 A CC O
arteries WO2014082286A1 A NNS O
in WO2014082286A1 A IN O
the WO2014082286A1 A DT O
brain WO2014082286A1 A NN O
, WO2014082286A1 A , O
immune WO2014082286A1 A JJ O
and WO2014082286A1 A CC O
autoimmune WO2014082286A1 A JJ O
diseases WO2014082286A1 A NNS O
. WO2014082286A1 A . O

Therapy EP1951303B1 T NN O
with EP1951303B1 T IN O
anti-cd4 EP1951303B1 T JJ O
antibodies EP1951303B1 T NNS O
and EP1951303B1 T CC O
radiation EP1951303B1 T NN O
. EP1951303B1 T . O

The EP1951303B1 A DT O
present EP1951303B1 A JJ O
invention EP1951303B1 A NN O
relates EP1951303B1 A VBZ O
to EP1951303B1 A TO O
a EP1951303B1 A DT O
peptide EP1951303B1 A NN O
, EP1951303B1 A , O
such EP1951303B1 A JJ O
as EP1951303B1 A IN O
an EP1951303B1 A DT O
antibody EP1951303B1 A NN O
, EP1951303B1 A , O
capable EP1951303B1 A JJ O
of EP1951303B1 A IN O
binding EP1951303B1 A VBG O
to EP1951303B1 A TO O
CD4 EP1951303B1 A NNP I-UN
and EP1951303B1 A CC O
use EP1951303B1 A VB O
thereof EP1951303B1 A NN O
for EP1951303B1 A IN O
the EP1951303B1 A DT O
mediation EP1951303B1 A NN O
of EP1951303B1 A IN O
radiation EP1951303B1 A NN O
treatment EP1951303B1 A NN O
of EP1951303B1 A IN O
a EP1951303B1 A DT O
clinical EP1951303B1 A JJ O
condition EP1951303B1 A NN O
. EP1951303B1 A . O

minoxidil US20110189114 T NN O
composition US20110189114 T NN O
and US20110189114 T CC O
non-aerosol US20110189114 T JJ O
, US20110189114 T , O
non-spray US20110189114 T JJ O
foam US20110189114 T NN O
method US20110189114 T NN O
of US20110189114 T IN O
delivery US20110189114 T NN O
therefor US20110189114 T NN O
. US20110189114 T . O

Antiviral WO2013173492A1 T JJ O
compounds WO2013173492A1 T NNS O
with WO2013173492A1 T IN O
an WO2013173492A1 T DT O
imidazole WO2013173492A1 T JJ O
- WO2013173492A1 T : O
biphenyl WO2013173492A1 T NN O
- WO2013173492A1 T : O
imidazole WO2013173492A1 T NN O
core WO2013173492A1 T NN O
. WO2013173492A1 T . O

External CN101007040B T NNP O
applied CN101007040B T VBD O
medicine CN101007040B T NN O
for CN101007040B T IN O
treating CN101007040B T VBG O
bone CN101007040B T NN O
fractures CN101007040B T NNS O
. CN101007040B T . O

The CN101007040B A DT O
invention CN101007040B A NN O
discloses CN101007040B A VBZ O
an CN101007040B A DT O
externally-used CN101007040B A JJ O
medicament CN101007040B A NN O
for CN101007040B A IN O
treating CN101007040B A VBG O
bone CN101007040B A NN O
fracture CN101007040B A NN O
, CN101007040B A , O
which CN101007040B A WDT O
is CN101007040B A VBZ O
prepared CN101007040B A VBN O
from CN101007040B A IN O
the CN101007040B A DT O
raw CN101007040B A JJ O
materials CN101007040B A NNS O
of CN101007040B A IN O
drynaria CN101007040B A NN O
, CN101007040B A , O
native CN101007040B A JJ O
copper CN101007040B A NN O
, CN101007040B A , O
wood CN101007040B A NN O
louse CN101007040B A NN O
, CN101007040B A , O
leopard CN101007040B A RB O
bone CN101007040B A NN O
, CN101007040B A , O
hairy CN101007040B A JJ O
deerhorn CN101007040B A NN O
, CN101007040B A , O
safflower CN101007040B A JJR O
, CN101007040B A , O
cortex CN101007040B A JJ O
acanthopanacis CN101007040B A NN O
, CN101007040B A , O
dipsacus CN101007040B A NN O
root CN101007040B A NN O
, CN101007040B A , O
frankincense CN101007040B A NN O
, CN101007040B A , O
myrrh CN101007040B A NN O
and CN101007040B A CC O
musk CN101007040B A NN O
through CN101007040B A IN O
grinding CN101007040B A VBG O
into CN101007040B A IN O
micro-powders CN101007040B A NNS O
. CN101007040B A . O

Sulfonylaminocarboxylic US7160903 T JJ O
acids US7160903 T NNS O
. US7160903 T . O

Compounds US7160903 A NNS O
of US7160903 A IN O
formula US7160903 A NN O
( US7160903 A ( O
I US7160903 A PRP O
) US7160903 A ) O
are US7160903 A VBP O
suitable US7160903 A JJ O
for US7160903 A IN O
the US7160903 A DT O
production US7160903 A NN O
of US7160903 A IN O
pharmaceuticals US7160903 A NNS O
for US7160903 A IN O
the US7160903 A DT O
prophylaxis US7160903 A NN O
and US7160903 A CC O
therapy US7160903 A NN O
of US7160903 A IN O
disorders US7160903 A NNS O
in US7160903 A IN O
the US7160903 A DT O
course US7160903 A NN O
of US7160903 A IN O
which US7160903 A WDT O
an US7160903 A DT O
increased US7160903 A VBN O
activity US7160903 A NN O
of US7160903 A IN O
matrix-degrading US7160903 A JJ O
metalloproteinases US7160903 A NNS O
is US7160903 A VBZ O
involved US7160903 A VBN O
. US7160903 A . O

Preparation CN103622910A T NNP O
method CN103622910A T NN O
for CN103622910A T IN O
betulinic CN103622910A T JJ O
acid CN103622910A T NN O
liposomes CN103622910A T NNS O
. CN103622910A T . O

Tetrahydrobenzoisoxazole WO2008080455A1 T NNP O
- WO2008080455A1 T : O
and WO2008080455A1 T CC O
tetrahydroindazole WO2008080455A1 T JJ O
derivatives WO2008080455A1 T NNS O
as WO2008080455A1 T IN O
modulators WO2008080455A1 T NNS O
of WO2008080455A1 T IN O
the WO2008080455A1 T DT O
mitotic WO2008080455A1 T JJ O
motor WO2008080455A1 T NN O
protein WO2008080455A1 T NN O
. WO2008080455A1 T . O

Quaternary WO2010126025A1 T JJ O
ammonium WO2010126025A1 T NN O
salt WO2010126025A1 T NN O
compound WO2010126025A1 T NN O
. WO2010126025A1 T . O

A WO2010126025A1 A DT O
compound WO2010126025A1 A NN O
represented WO2010126025A1 A VBN O
by WO2010126025A1 A IN O
formula WO2010126025A1 A NN O
( WO2010126025A1 A ( O
I WO2010126025A1 A PRP O
) WO2010126025A1 A ) O
or WO2010126025A1 A CC O
a WO2010126025A1 A DT O
salt WO2010126025A1 A NN O
thereof WO2010126025A1 A NN O
, WO2010126025A1 A , O
which WO2010126025A1 A WDT O
has WO2010126025A1 A VBZ O
a WO2010126025A1 A DT O
β2 WO2010126025A1 A JJ I-UN
adrenergic WO2010126025A1 A JJ I-UN
receptor WO2010126025A1 A NN I-UN
agonist WO2010126025A1 A NN O
activity WO2010126025A1 A NN O
and WO2010126025A1 A CC O
a WO2010126025A1 A DT O
muscarin WO2010126025A1 A NN I-UN
receptor WO2010126025A1 A NN I-UN
antagonist WO2010126025A1 A NN O
activity WO2010126025A1 A NN O
. WO2010126025A1 A . O

3- WO2014038623A1 T JJ O
( WO2014038623A1 T ( O
4-piperidyl WO2014038623A1 T JJ O
) WO2014038623A1 T ) O
-indazole WO2014038623A1 T JJ O
derivative WO2014038623A1 T NN O
. WO2014038623A1 T . O

Provided WO2014038623A1 A VBN O
is WO2014038623A1 A VBZ O
a WO2014038623A1 A DT O
therapeutic WO2014038623A1 A JJ O
agent WO2014038623A1 A NN O
for WO2014038623A1 A IN O
diseases WO2014038623A1 A NNS O
associated WO2014038623A1 A VBN O
with WO2014038623A1 A IN O
central WO2014038623A1 A JJ O
nervous WO2014038623A1 A JJ O
system WO2014038623A1 A NN O
( WO2014038623A1 A ( O
CNS WO2014038623A1 A NNP O
) WO2014038623A1 A ) O
and/or WO2014038623A1 A VBP O
peripheral WO2014038623A1 A JJ O
nervous WO2014038623A1 A JJ O
system WO2014038623A1 A NN O
( WO2014038623A1 A ( O
PNS WO2014038623A1 A NNP O
) WO2014038623A1 A ) O
cholinergicity WO2014038623A1 A NN O
, WO2014038623A1 A , O
diseases WO2014038623A1 A NNS O
associated WO2014038623A1 A VBN O
with WO2014038623A1 A IN O
smooth WO2014038623A1 A JJ O
muscle WO2014038623A1 A NN O
contraction WO2014038623A1 A NN O
, WO2014038623A1 A , O
endocrine WO2014038623A1 A NN O
diseases WO2014038623A1 A NNS O
, WO2014038623A1 A , O
diseases WO2014038623A1 A NNS O
associated WO2014038623A1 A VBN O
with WO2014038623A1 A IN O
neurodegeneration WO2014038623A1 A NN O
, WO2014038623A1 A , O
and WO2014038623A1 A CC O
the WO2014038623A1 A DT O
like WO2014038623A1 A JJ O
, WO2014038623A1 A , O
said WO2014038623A1 A VBD O
therapeutic WO2014038623A1 A JJ O
agent WO2014038623A1 A NN O
comprising WO2014038623A1 A VBG O
a WO2014038623A1 A DT O
compound WO2014038623A1 A NN O
represented WO2014038623A1 A VBN O
by WO2014038623A1 A IN O
formula WO2014038623A1 A NN O
( WO2014038623A1 A ( O
I WO2014038623A1 A PRP O
) WO2014038623A1 A ) O
[ WO2014038623A1 A VBP O
wherein WO2014038623A1 A JJ O
R1A WO2014038623A1 A NNP O
to WO2014038623A1 A TO O
R1D WO2014038623A1 A NNP O
are WO2014038623A1 A VBP O
the WO2014038623A1 A DT O
same WO2014038623A1 A JJ O
as WO2014038623A1 A IN O
or WO2014038623A1 A CC O
different WO2014038623A1 A JJ O
from WO2014038623A1 A IN O
one WO2014038623A1 A CD O
another WO2014038623A1 A DT O
and WO2014038623A1 A CC O
independently WO2014038623A1 A RB O
represent WO2014038623A1 A VBP O
an WO2014038623A1 A DT O
optionally WO2014038623A1 A RB O
substituted WO2014038623A1 A VBN O
C1-6 WO2014038623A1 A NNP O
alkyl WO2014038623A1 A JJ O
group WO2014038623A1 A NN O
or WO2014038623A1 A CC O
the WO2014038623A1 A DT O
like WO2014038623A1 A JJ O
; WO2014038623A1 A : O
R2 WO2014038623A1 A NNP O
represents WO2014038623A1 A VBZ O
a WO2014038623A1 A DT O
hydrogen WO2014038623A1 A NN O
atom WO2014038623A1 A NN O
or WO2014038623A1 A CC O
the WO2014038623A1 A DT O
like WO2014038623A1 A JJ O
; WO2014038623A1 A : O
R3A WO2014038623A1 A NNP O
to WO2014038623A1 A TO O
R3E WO2014038623A1 A NNP O
are WO2014038623A1 A VBP O
the WO2014038623A1 A DT O
same WO2014038623A1 A JJ O
as WO2014038623A1 A IN O
or WO2014038623A1 A CC O
different WO2014038623A1 A JJ O
from WO2014038623A1 A IN O
one WO2014038623A1 A CD O
another WO2014038623A1 A DT O
and WO2014038623A1 A CC O
independently WO2014038623A1 A RB O
represent WO2014038623A1 A VB O
a WO2014038623A1 A DT O
hydrogen WO2014038623A1 A NN O
atom WO2014038623A1 A NN O
or WO2014038623A1 A CC O
the WO2014038623A1 A DT O
like WO2014038623A1 A JJ O
; WO2014038623A1 A : O
R4 WO2014038623A1 A NNP O
represents WO2014038623A1 A VBZ O
an WO2014038623A1 A DT O
optionally WO2014038623A1 A RB O
substituted WO2014038623A1 A VBN O
C1-10 WO2014038623A1 A NNP O
alkyl WO2014038623A1 A JJ O
group WO2014038623A1 A NN O
or WO2014038623A1 A CC O
the WO2014038623A1 A DT O
like WO2014038623A1 A JJ O
; WO2014038623A1 A : O
and WO2014038623A1 A CC O
n WO2014038623A1 A JJ O
represents WO2014038623A1 A VBZ O
1 WO2014038623A1 A CD O
or WO2014038623A1 A CC O
2 WO2014038623A1 A CD O
] WO2014038623A1 A NNS O
or WO2014038623A1 A CC O
a WO2014038623A1 A DT O
pharmaceutically WO2014038623A1 A RB O
acceptable WO2014038623A1 A JJ O
salt WO2014038623A1 A NN O
thereof WO2014038623A1 A NN O
and WO2014038623A1 A CC O
having WO2014038623A1 A VBG O
a WO2014038623A1 A DT O
potent WO2014038623A1 A JJ O
action WO2014038623A1 A NN O
of WO2014038623A1 A IN O
regulating WO2014038623A1 A VBG O
an WO2014038623A1 A DT O
α7 WO2014038623A1 A NN I-UN
nicotinic WO2014038623A1 A JJ I-UN
acetylcholine WO2014038623A1 A NN I-UN
receptor WO2014038623A1 A NN I-UN
( WO2014038623A1 A ( O
α7 WO2014038623A1 A NNP I-UN
nAChR WO2014038623A1 A RB I-UN
) WO2014038623A1 A ) O
. WO2014038623A1 A . O

Compounds CN101381320B T NNS O
with CN101381320B T IN O
mannich CN101381320B T JJ O
base CN101381320B T NN O
structure CN101381320B T NN O
and CN101381320B T CC O
application CN101381320B T NN O
thereof CN101381320B T NN O
in CN101381320B T IN O
preparation CN101381320B T NN O
of CN101381320B T IN O
medicament CN101381320B T NN O
treating CN101381320B T VBG O
and/or CN101381320B T JJ O
preventing CN101381320B T VBG O
leukemia CN101381320B T NN O
. CN101381320B T . O

Percutaneously US20090209632 T RB O
Absorptive US20090209632 T JJ O
Ophthalmic US20090209632 T NNP O
Preparation US20090209632 T NNP O
Comprising US20090209632 T NNP O
Olopatadine US20090209632 T NNP O
. US20090209632 T . O

Shortened US20110136894 T VBN O
Alk1 US20110136894 T NNP I-UN
Regulatory US20110136894 T NNP O
Fragment US20110136894 T NNP O
. US20110136894 T . O

Regulatory US20110136894 A JJ O
elements US20110136894 A NNS O
for US20110136894 A IN O
controlling US20110136894 A VBG O
expression US20110136894 A NN O
of US20110136894 A IN O
transgenes US20110136894 A NNS O
in US20110136894 A IN O
angiogenic US20110136894 A JJ O
tissue US20110136894 A NN O
are US20110136894 A VBP O
provided US20110136894 A VBN O
. US20110136894 A . O

One US20110136894 A CD O
embodiment US20110136894 A NN O
provides US20110136894 A VBZ O
an US20110136894 A DT O
isolated US20110136894 A JJ O
nucleic US20110136894 A NN O
acid US20110136894 A NN O
having US20110136894 A VBG O
at US20110136894 A IN O
least US20110136894 A JJS O
80 US20110136894 A CD O
% US20110136894 A NN O
, US20110136894 A , O
85 US20110136894 A CD O
% US20110136894 A NN O
, US20110136894 A , O
90 US20110136894 A CD O
% US20110136894 A NN O
, US20110136894 A , O
95 US20110136894 A CD O
% US20110136894 A NN O
, US20110136894 A , O
97 US20110136894 A CD O
% US20110136894 A NN O
, US20110136894 A , O
99 US20110136894 A CD O
% US20110136894 A NN O
or US20110136894 A CC O
100 US20110136894 A CD O
% US20110136894 A NN O
sequence US20110136894 A NN O
identity US20110136894 A NN O
to US20110136894 A TO O
SEQ US20110136894 A NNP O
ID US20110136894 A NNP O
NO:1 US20110136894 A NNP O
, US20110136894 A , O
or US20110136894 A CC O
a US20110136894 A DT O
fragment US20110136894 A JJ O
thereof US20110136894 A NN O
that US20110136894 A WDT O
causes US20110136894 A VBZ O
expression US20110136894 A NN O
of US20110136894 A IN O
a US20110136894 A DT O
transgene US20110136894 A NN O
in US20110136894 A IN O
angiogenic US20110136894 A JJ O
tissue US20110136894 A NN O
. US20110136894 A . O

Vectors US20110136894 A NNS O
containing US20110136894 A VBG O
SEQ US20110136894 A NNP O
ID US20110136894 A NNP O
NO:1 US20110136894 A NNP O
and US20110136894 A CC O
one US20110136894 A CD O
or US20110136894 A CC O
more US20110136894 A JJR O
transgenes US20110136894 A NNS O
are US20110136894 A VBP O
also US20110136894 A RB O
provided US20110136894 A VBN O
. US20110136894 A . O

A US20110136894 A DT O
preferred US20110136894 A JJ O
vector US20110136894 A NN O
is US20110136894 A VBZ O
an US20110136894 A DT O
adenovirus US20110136894 A JJ O
vector US20110136894 A NN O
. US20110136894 A . O

The US20110136894 A DT O
transgene US20110136894 A NN O
can US20110136894 A MD O
encode US20110136894 A VB O
a US20110136894 A DT O
cytotoxin US20110136894 A NN O
, US20110136894 A , O
pro-apoptotic US20110136894 A JJ O
polypeptide US20110136894 A NN O
, US20110136894 A , O
or US20110136894 A CC O
a US20110136894 A DT O
therapeutic US20110136894 A JJ O
polypeptide US20110136894 A NN O
. US20110136894 A . O

SEQ US20110136894 A NNP O
ID US20110136894 A NNP O
NO:1 US20110136894 A NNP O
regulates US20110136894 A VBZ O
the US20110136894 A DT O
expression US20110136894 A NN O
of US20110136894 A IN O
the US20110136894 A DT O
transgene US20110136894 A NN O
such US20110136894 A JJ O
that US20110136894 A IN O
the US20110136894 A DT O
transgene US20110136894 A NN O
is US20110136894 A VBZ O
only US20110136894 A RB O
expressed US20110136894 A VBN O
in US20110136894 A IN O
angiogenic US20110136894 A JJ O
tissue US20110136894 A NN O
including US20110136894 A VBG O
, US20110136894 A , O
but US20110136894 A CC O
not US20110136894 A RB O
limited US20110136894 A JJ O
to US20110136894 A TO O
arteries US20110136894 A NNS O
feeding US20110136894 A VBG O
ischemic US20110136894 A JJ O
tissues US20110136894 A NNS O
. US20110136894 A . O

Methods US20110136894 A NNS O
of US20110136894 A IN O
using US20110136894 A VBG O
vectors US20110136894 A NNS O
containing US20110136894 A VBG O
SEQ US20110136894 A NNP O
ID US20110136894 A NNP O
NO:1 US20110136894 A NNP O
are US20110136894 A VBP O
also US20110136894 A RB O
provided US20110136894 A VBN O
. US20110136894 A . O

Antibacterial CN102920237A T JJ O
health-care CN102920237A T NN O
pillow CN102920237A T NN O
. CN102920237A T . O

Method US20070275887 T NNP O
of US20070275887 T IN O
Inhibiting US20070275887 T NNP O
Secretase US20070275887 T NNP I-UN
Activity US20070275887 T NNP O
. US20070275887 T . O

The US20070275887 A DT O
present US20070275887 A JJ O
invention US20070275887 A NN O
provides US20070275887 A VBZ O
a US20070275887 A DT O
method US20070275887 A NN O
for US20070275887 A IN O
inhibiting US20070275887 A VBG O
secretase US20070275887 A NN I-UN
activity US20070275887 A NN O
. US20070275887 A . O

A US20070275887 A DT O
method US20070275887 A NN O
for US20070275887 A IN O
promoting US20070275887 A VBG O
the US20070275887 A DT O
sensitivity US20070275887 A NN O
of US20070275887 A IN O
a US20070275887 A DT O
secretase US20070275887 A NN I-UN
inhibitor US20070275887 A NN O
, US20070275887 A , O
a US20070275887 A DT O
method US20070275887 A NN O
for US20070275887 A IN O
binding US20070275887 A VBG O
synoviolin US20070275887 A NN I-UN
to US20070275887 A TO O
Herp US20070275887 A NNP I-UN
( US20070275887 A ( O
homocysteine-inducible US20070275887 A JJ I-UN
endoplasmic US20070275887 A JJ I-UN
reticulum US20070275887 A NN I-UN
stress-inducible US20070275887 A JJ I-UN
ubiquitin-like US20070275887 A JJ I-UN
domain US20070275887 A NN I-UN
member US20070275887 A NN I-UN
1 US20070275887 A CD I-UN
) US20070275887 A ) O
, US20070275887 A , O
or US20070275887 A CC O
the US20070275887 A DT O
like US20070275887 A JJ O
is US20070275887 A VBZ O
employed US20070275887 A VBN O
to US20070275887 A TO O
inhibit US20070275887 A VB O
secretase US20070275887 A JJ I-UN
activity US20070275887 A NN O
. US20070275887 A . O

Agent WO2013176054A1 T NNP O
containing WO2013176054A1 T VBG O
ascorbic WO2013176054A1 T JJ O
acid WO2013176054A1 T JJ O
derivative WO2013176054A1 T NN O
, WO2013176054A1 T , O
and WO2013176054A1 T CC O
use WO2013176054A1 T NN O
for WO2013176054A1 T IN O
said WO2013176054A1 T VBD O
agent WO2013176054A1 T NN O
. WO2013176054A1 T . O

Ointment CN102846991A T NN O
for CN102846991A T IN O
treating CN102846991A T VBG O
burn CN102846991A T NN O
or CN102846991A T CC O
scald CN102846991A T NN O
. CN102846991A T . O

Preparation US20080057133 T NN O
of US20080057133 T IN O
Aqueous US20080057133 T JJ O
Clear US20080057133 T JJ O
Solution US20080057133 T NNP O
Dosage US20080057133 T NNP O
Forms US20080057133 T NNP O
with US20080057133 T IN O
Bile US20080057133 T NNP O
Acids US20080057133 T NNP O
. US20080057133 T . O

Composite CN103656098A T JJ O
fish CN103656098A T JJ O
oil CN103656098A T NN O
soft CN103656098A T JJ O
capsule CN103656098A T NN O
and CN103656098A T CC O
preparation CN103656098A T NN O
method CN103656098A T NN O
thereof CN103656098A T NN O
. CN103656098A T . O

Vaccine EP1939295A1 T NNP O
compostions EP1939295A1 T NNS O
and EP1939295A1 T CC O
methods EP1939295A1 T NNS O
useful EP1939295A1 T JJ O
in EP1939295A1 T IN O
inducing EP1939295A1 T VBG O
immune EP1939295A1 T JJ O
protection EP1939295A1 T NN O
against EP1939295A1 T IN O
arthritogenic EP1939295A1 T JJ O
peptides EP1939295A1 T NNS O
involved EP1939295A1 T VBN O
in EP1939295A1 T IN O
the EP1939295A1 T DT O
pathogenesis EP1939295A1 T NN O
of EP1939295A1 T IN O
rheumatoid EP1939295A1 T JJ O
arthritis EP1939295A1 T NN O
. EP1939295A1 T . O

Nutritious CN101683344A T JJ O
mixture CN101683344A T NN O
of CN101683344A T IN O
amino CN101683344A T NN O
acid CN101683344A T NN O
and CN101683344A T CC O
vitamin CN101683344A T NN O
for CN101683344A T IN O
preventing CN101683344A T VBG O
hair CN101683344A T NN O
losing CN101683344A T VBG O
and CN101683344A T CC O
improving CN101683344A T VBG O
hair CN101683344A T NN O
growing CN101683344A T VBG O
. CN101683344A T . O

The CN101683344A A DT O
hair CN101683344A A NN O
keratin CN101683344A A NN I-UN
of CN101683344A A IN O
human CN101683344A A JJ O
body CN101683344A A NN O
is CN101683344A A VBZ O
composed CN101683344A A VBN O
of CN101683344A A IN O
more CN101683344A A JJR O
than CN101683344A A IN O
twenty CN101683344A A NN O
amino CN101683344A A NN O
acids CN101683344A A NNS O
, CN101683344A A , O
and CN101683344A A CC O
sufficient CN101683344A A JJ O
supplement CN101683344A A NN O
of CN101683344A A IN O
these CN101683344A A DT O
amino CN101683344A A JJ O
acid CN101683344A A NN O
substances CN101683344A A NNS O
can CN101683344A A MD O
synthesize CN101683344A A VB O
and CN101683344A A CC O
repair CN101683344A A VB O
the CN101683344A A DT O
hair CN101683344A A NN O
keratin CN101683344A A NN I-UN
of CN101683344A A IN O
human CN101683344A A JJ O
body CN101683344A A NN O
effectively CN101683344A A RB O
, CN101683344A A , O
and CN101683344A A CC O
has CN101683344A A VBZ O
special CN101683344A A JJ O
effect CN101683344A A NN O
for CN101683344A A IN O
preventing CN101683344A A VBG O
alopecia CN101683344A A NN O
and CN101683344A A CC O
promoting CN101683344A A VBG O
hair CN101683344A A NN O
growing CN101683344A A VBG O
. CN101683344A A . O

Considering CN101683344A A VBG O
that CN101683344A A DT O
most CN101683344A A JJS O
of CN101683344A A IN O
the CN101683344A A DT O
amino CN101683344A A NN O
acid CN101683344A A NN O
substances CN101683344A A NNS O
can CN101683344A A MD O
be CN101683344A A VB O
obtained CN101683344A A VBN O
in CN101683344A A IN O
daily CN101683344A A JJ O
diet CN101683344A A NN O
, CN101683344A A , O
so CN101683344A A RB O
in CN101683344A A IN O
the CN101683344A A DT O
invention CN101683344A A NN O
, CN101683344A A , O
kind CN101683344A A NN O
and CN101683344A A CC O
content CN101683344A A NN O
of CN101683344A A IN O
four CN101683344A A CD O
main CN101683344A A JJ O
amino CN101683344A A NN O
acid CN101683344A A NN O
substances CN101683344A A NNS O
for CN101683344A A IN O
composing CN101683344A A VBG O
hair CN101683344A A NN O
keratin CN101683344A A NN I-UN
is CN101683344A A VBZ O
provided CN101683344A A VBN O
, CN101683344A A , O
which CN101683344A A WDT O
are CN101683344A A VBP O
cystine CN101683344A A NN O
, CN101683344A A , O
arginine CN101683344A A NN O
, CN101683344A A , O
leucine CN101683344A A NN O
, CN101683344A A , O
threonine CN101683344A A NN O
in CN101683344A A IN O
sequence CN101683344A A NN O
of CN101683344A A IN O
content CN101683344A A NN O
. CN101683344A A . O

Omeprazole CN103127003A T NNP O
enteric CN103127003A T JJ O
micropelets CN103127003A T NNS O
and CN103127003A T CC O
capsule CN103127003A T NN O
as CN103127003A T RB O
well CN103127003A T RB O
as CN103127003A T IN O
preparation CN103127003A T NN O
method CN103127003A T NN O
thereof CN103127003A T NN O
. CN103127003A T . O

Ligand EP1674575A2 T NNP O
for EP1674575A2 T IN O
herpes EP1674575A2 T NNS O
simplex EP1674575A2 T JJ O
virus EP1674575A2 T NN O
entry EP1674575A2 T NN O
mediator EP1674575A2 T NN O
and EP1674575A2 T CC O
methods EP1674575A2 T NNS O
of EP1674575A2 T IN O
use EP1674575A2 T NN O
. EP1674575A2 T . O

Product US20070167402 T NN O
of US20070167402 T IN O
coprecipitation US20070167402 T NN O
of US20070167402 T IN O
sparingly US20070167402 T RB O
soluble US20070167402 T JJ O
substance US20070167402 T NN O
and US20070167402 T CC O
water-soluble US20070167402 T JJ O
polymer US20070167402 T NN O
and US20070167402 T CC O
process US20070167402 T NN O
for US20070167402 T IN O
producing US20070167402 T VBG O
the US20070167402 T DT O
same US20070167402 T JJ O
. US20070167402 T . O

( CN102180870A T ( O
4- CN102180870A T JJ O
[ CN102180870A T NN O
2- CN102180870A T JJ O
( CN102180870A T ( O
aryl-methyl CN102180870A T JJ O
amine CN102180870A T NN O
) CN102180870A T ) O
-4-methyl-thiazole-5 CN102180870A T VBZ O
] CN102180870A T JJ O
-pyrimidine-2 CN102180870A T NNP O
) CN102180870A T ) O
-arylamine CN102180870A T VBP O
derivative CN102180870A T JJ O
and CN102180870A T CC O
preparation CN102180870A T NN O
method CN102180870A T NN O
and CN102180870A T CC O
pharmaceutical CN102180870A T JJ O
application CN102180870A T NN O
thereof CN102180870A T NN O
. CN102180870A T . O

Crystalline CN102206195A T NNP O
quetiapine CN102206195A T NN O
fumarate CN102206195A T NN O
and CN102206195A T CC O
pharmaceutical CN102206195A T JJ O
compositions CN102206195A T NNS O
thereof CN102206195A T NN O
. CN102206195A T . O

Cabazitaxel CN103044364A T NNP O
amorphous CN103044364A T JJ O
crystal CN103044364A T NN O
and CN103044364A T CC O
preparation CN103044364A T NN O
method CN103044364A T NN O
thereof CN103044364A T NN O
. CN103044364A T . O

3-pyrrole CN103420890A T JJ O
carboxylic CN103420890A T JJ O
acid CN103420890A T NN O
derivatives CN103420890A T NNS O
, CN103420890A T , O
and CN103420890A T CC O
preparing CN103420890A T VBG O
method CN103420890A T NN O
and CN103420890A T CC O
application CN103420890A T NN O
thereof CN103420890A T NN O
. CN103420890A T . O

The CN103420890A A DT O
invention CN103420890A A NN O
relates CN103420890A A VBZ O
to CN103420890A A TO O
3-pyrrole CN103420890A A JJ O
carboxylic CN103420890A A JJ O
acid CN103420890A A NN O
derivatives CN103420890A A NNS O
, CN103420890A A , O
and CN103420890A A CC O
a CN103420890A A DT O
preparing CN103420890A A NN O
method CN103420890A A NN O
and CN103420890A A CC O
an CN103420890A A DT O
application CN103420890A A NN O
thereof CN103420890A A NN O
, CN103420890A A , O
and CN103420890A A CC O
particularly CN103420890A A RB O
relates CN103420890A A NNS O
to CN103420890A A TO O
the CN103420890A A DT O
3-pyrrole CN103420890A A JJ O
carboxylic CN103420890A A JJ O
acid CN103420890A A NN O
derivatives CN103420890A A NNS O
having CN103420890A A VBG O
a CN103420890A A DT O
structure CN103420890A A NN O
represented CN103420890A A VBN O
by CN103420890A A IN O
formula CN103420890A A NN O
I CN103420890A A PRP O
and CN103420890A A CC O
pharmaceutically CN103420890A A RB O
acceptable CN103420890A A JJ O
salts CN103420890A A NNS O
thereof CN103420890A A NN O
and CN103420890A A CC O
the CN103420890A A DT O
preparing CN103420890A A VBG O
method CN103420890A A NN O
of CN103420890A A IN O
the CN103420890A A DT O
derivatives CN103420890A A NNS O
, CN103420890A A , O
pharmaceutical CN103420890A A JJ O
compositions CN103420890A A NNS O
with CN103420890A A IN O
the CN103420890A A DT O
3-pyrrole CN103420890A A JJ O
carboxylic CN103420890A A JJ O
acid CN103420890A A NN O
derivatives CN103420890A A NNS O
having CN103420890A A VBG O
the CN103420890A A DT O
structure CN103420890A A NN O
represented CN103420890A A VBN O
by CN103420890A A IN O
the CN103420890A A DT O
formula CN103420890A A NN O
I CN103420890A A PRP O
and CN103420890A A CC O
the CN103420890A A DT O
pharmaceutically CN103420890A A RB O
acceptable CN103420890A A JJ O
salts CN103420890A A NNS O
of CN103420890A A IN O
the CN103420890A A DT O
3-pyrrole CN103420890A A JJ O
carboxylic CN103420890A A JJ O
acid CN103420890A A NN O
derivatives CN103420890A A NNS O
as CN103420890A A IN O
active CN103420890A A JJ O
ingredients CN103420890A A NNS O
, CN103420890A A , O
and CN103420890A A CC O
applications CN103420890A A NNS O
of CN103420890A A IN O
the CN103420890A A DT O
pharmaceutical CN103420890A A JJ O
compositions CN103420890A A NNS O
in CN103420890A A IN O
prevention CN103420890A A NN O
or CN103420890A A CC O
treatment CN103420890A A NN O
of CN103420890A A IN O
diseases CN103420890A A NNS O
related CN103420890A A VBN O
with CN103420890A A IN O
an CN103420890A A DT O
arginine CN103420890A A NN I-UN
vasopressin CN103420890A A NN I-UN
V1a CN103420890A A NNP I-UN
receptor CN103420890A A NN I-UN
, CN103420890A A , O
an CN103420890A A DT O
arginine CN103420890A A NN I-UN
vasopressin CN103420890A A NN I-UN
V1b CN103420890A A NNP I-UN
receptor CN103420890A A NN I-UN
, CN103420890A A , O
an CN103420890A A DT O
arginine CN103420890A A NN I-UN
vasopressin CN103420890A A NN I-UN
V2 CN103420890A A NNP I-UN
receptor CN103420890A A NN I-UN
, CN103420890A A , O
a CN103420890A A DT O
sympathetic CN103420890A A JJ O
nervous CN103420890A A JJ O
system CN103420890A A NN O
or CN103420890A A CC O
a CN103420890A A DT O
renin-angiotensin-aldosterone CN103420890A A JJ O
system CN103420890A A NN O
. CN103420890A A . O

Carboxylic EP1001755B1 T JJ O
acids EP1001755B1 T NNS O
and EP1001755B1 T CC O
derivatives EP1001755B1 T NNS O
thereof EP1001755B1 T VBP O
and EP1001755B1 T CC O
pharmaceutical EP1001755B1 T JJ O
compositions EP1001755B1 T NNS O
containing EP1001755B1 T VBG O
them EP1001755B1 T PRP O
. EP1001755B1 T . O

Agent WO2007094071A1 T NN O
for WO2007094071A1 T IN O
improvement WO2007094071A1 T NN O
of WO2007094071A1 T IN O
hepatic WO2007094071A1 T JJ O
function WO2007094071A1 T NN O
. WO2007094071A1 T . O

Helminthic CN101683352A T NNP O
for CN101683352A T IN O
aquaculture CN101683352A T NN O
of CN101683352A T IN O
aquatic CN101683352A T JJ O
animal CN101683352A T NN O
and CN101683352A T CC O
preparation CN101683352A T NN O
method CN101683352A T NN O
thereof CN101683352A T NN O
. CN101683352A T . O

Lyophilized US20080004310 T VBN O
pharmaceutical US20080004310 T JJ O
composition US20080004310 T NN O
. US20080004310 T . O

Manganoporphyrin-lonidamine CN102000070A T JJ O
combined CN102000070A T VBN O
drug CN102000070A T NN O
for CN102000070A T IN O
treating CN102000070A T VBG O
tumor CN102000070A T NN O
. CN102000070A T . O

Nicotinic EP1370264B1 T NNP O
receptor EP1370264B1 T NN O
agonists EP1370264B1 T NNS O
for EP1370264B1 T IN O
the EP1370264B1 T DT O
treatment EP1370264B1 T NN O
of EP1370264B1 T IN O
pulmonary EP1370264B1 T JJ O
inflammatory EP1370264B1 T NN O
diseases EP1370264B1 T NNS O
. EP1370264B1 T . O

Medicine CN101224216A T NNP O
compounds CN101224216A T VBZ O
for CN101224216A T IN O
anti-tumor CN101224216A T NN O
. CN101224216A T . O

The CN101224216A A DT O
invention CN101224216A A NN O
pertains CN101224216A A VBZ O
to CN101224216A A TO O
the CN101224216A A DT O
bio-pharmaceutical CN101224216A A JJ O
field CN101224216A A NN O
and CN101224216A A CC O
relates CN101224216A A VBZ O
to CN101224216A A TO O
a CN101224216A A DT O
medicine CN101224216A A NN O
combination CN101224216A A NN O
for CN101224216A A IN O
treating CN101224216A A VBG O
tumor CN101224216A A NN O
. CN101224216A A . O

The CN101224216A A DT O
tumor CN101224216A A NN O
is CN101224216A A VBZ O
the CN101224216A A DT O
worldwide CN101224216A A JJ O
No CN101224216A A NNP O
. CN101224216A A . O

2 CN101224216A A CD O
killer CN101224216A A NN O
of CN101224216A A IN O
human CN101224216A A JJ O
being CN101224216A A VBG O
and CN101224216A A CC O
the CN101224216A A DT O
drug CN101224216A A NN O
resistance CN101224216A A NN O
is CN101224216A A VBZ O
one CN101224216A A CD O
of CN101224216A A IN O
the CN101224216A A DT O
difficulties CN101224216A A NNS O
in CN101224216A A IN O
the CN101224216A A DT O
treatment CN101224216A A NN O
of CN101224216A A IN O
the CN101224216A A DT O
tumor CN101224216A A NN O
diseases CN101224216A A NNS O
. CN101224216A A . O

Therefore CN101224216A A RB O
, CN101224216A A , O
to CN101224216A A TO O
find CN101224216A A VB O
a CN101224216A A DT O
chemical CN101224216A A NN O
compound CN101224216A A NN O
which CN101224216A A WDT O
can CN101224216A A MD O
reduce CN101224216A A VB O
drug CN101224216A A NN O
resistance CN101224216A A NN O
is CN101224216A A VBZ O
one CN101224216A A CD O
of CN101224216A A IN O
the CN101224216A A DT O
hot CN101224216A A JJ O
topics CN101224216A A NNS O
in CN101224216A A IN O
the CN101224216A A DT O
study CN101224216A A NN O
field CN101224216A A NN O
of CN101224216A A IN O
tumor CN101224216A A NN O
disease CN101224216A A NN O
. CN101224216A A . O

The CN101224216A A DT O
invention CN101224216A A NN O
provides CN101224216A A VBZ O
the CN101224216A A DT O
medicine CN101224216A A NN O
combination CN101224216A A NN O
for CN101224216A A IN O
treating CN101224216A A VBG O
tumor CN101224216A A NN O
and CN101224216A A CC O
the CN101224216A A DT O
medicine CN101224216A A NN O
combination CN101224216A A NN O
comprises CN101224216A A VBZ O
nucleic CN101224216A A JJ O
acid CN101224216A A NN O
with CN101224216A A IN O
a CN101224216A A DT O
gene CN101224216A A NN O
sequence CN101224216A A NN O
of CN101224216A A IN O
5'-GCCAGUGGAGGCUUCCAGG-3 CN101224216A A JJ O
' CN101224216A A '' O
or CN101224216A A CC O
5'-GCCAGTGGAGGCTTCCAGG-3 CN101224216A A JJ O
' CN101224216A A '' O
and CN101224216A A CC O
daunomycin CN101224216A A NNS O
. CN101224216A A . O

The CN101224216A A DT O
application CN101224216A A NN O
of CN101224216A A IN O
the CN101224216A A DT O
nucleic CN101224216A A JJ O
acid CN101224216A A NN O
and CN101224216A A CC O
the CN101224216A A DT O
daunomycin CN101224216A A NN O
can CN101224216A A MD O
dramatically CN101224216A A RB O
reduce CN101224216A A VB O
the CN101224216A A DT O
drug CN101224216A A NN O
resistance CN101224216A A NN O
of CN101224216A A IN O
tumor CN101224216A A NN O
cells CN101224216A A NNS O
. CN101224216A A . O

Compositions US20100068162 T NNS O
Having US20100068162 T VBG O
Silicone US20100068162 T NNP O
Properties US20100068162 T NNPS O
. US20100068162 T . O

Novel WO2013188813A3 T NNP O
therapeutics WO2013188813A3 T NNS O
for WO2013188813A3 T IN O
brain WO2013188813A3 T NN O
cancer WO2013188813A3 T NN O
. WO2013188813A3 T . O

Provided WO2013188813A3 A VBN O
herein WO2013188813A3 A NN O
are WO2013188813A3 A VBP O
novel WO2013188813A3 A JJ O
compositions WO2013188813A3 A NNS O
and WO2013188813A3 A CC O
methods WO2013188813A3 A NNS O
to WO2013188813A3 A TO O
inhibit WO2013188813A3 A VB O
Olig2 WO2013188813A3 A NNP I-UN
activity WO2013188813A3 A NN O
. WO2013188813A3 A . O

The WO2013188813A3 A DT O
Olig2 WO2013188813A3 A NNP I-UN
inhibitors WO2013188813A3 A NNS O
and WO2013188813A3 A CC O
methods WO2013188813A3 A NNS O
of WO2013188813A3 A IN O
using WO2013188813A3 A VBG O
the WO2013188813A3 A DT O
same WO2013188813A3 A JJ O
are WO2013188813A3 A VBP O
useful WO2013188813A3 A JJ O
, WO2013188813A3 A , O
inter WO2013188813A3 A JJ O
alia WO2013188813A3 A NN O
, WO2013188813A3 A , O
for WO2013188813A3 A IN O
treating WO2013188813A3 A VBG O
cancer WO2013188813A3 A NN O
. WO2013188813A3 A . O

In WO2013188813A3 A IN O
particular WO2013188813A3 A JJ O
the WO2013188813A3 A DT O
Olig2 WO2013188813A3 A NNP I-UN
inhibitors WO2013188813A3 A NNS O
may WO2013188813A3 A MD O
be WO2013188813A3 A VB O
used WO2013188813A3 A VBN O
to WO2013188813A3 A TO O
treat WO2013188813A3 A VB O
glioblastoma WO2013188813A3 A NN O
. WO2013188813A3 A . O

Further WO2013188813A3 A RB O
, WO2013188813A3 A , O
provided WO2013188813A3 A VBN O
are WO2013188813A3 A VBP O
peptide WO2013188813A3 A JJ O
compositions WO2013188813A3 A NNS O
capable WO2013188813A3 A JJ O
of WO2013188813A3 A IN O
inhibiting WO2013188813A3 A VBG O
Olig WO2013188813A3 A NNP I-UN
2 WO2013188813A3 A CD I-UN
. WO2013188813A3 A . O

2-indolinone US20090182029 T JJ O
derivatives US20090182029 T NNS O
as US20090182029 T IN O
selective US20090182029 T JJ O
histone US20090182029 T NN O
deacetylase US20090182029 T NN O
inhibitors US20090182029 T NNS O
. US20090182029 T . O

Oral WO2005115344A1 T JJ O
delivery WO2005115344A1 T NN O
system WO2005115344A1 T NN O
. WO2005115344A1 T . O

Sulfonamido EP2486006A1 T NNP O
pyrrolidine EP2486006A1 T NN O
compounds EP2486006A1 T NNS O
which EP2486006A1 T WDT O
inhibit EP2486006A1 T VBP O
beta-secretase EP2486006A1 T JJ O
activity EP2486006A1 T NN O
and EP2486006A1 T CC O
methods EP2486006A1 T NNS O
of EP2486006A1 T IN O
use EP2486006A1 T NN O
thereof EP2486006A1 T NN O
. EP2486006A1 T . O

Novel CN102670635A T NNP O
application CN102670635A T NN O
of CN102670635A T IN O
icariin CN102670635A T NN O
to CN102670635A T TO O
resisting CN102670635A T NN O
of CN102670635A T IN O
oxygen CN102670635A T NN O
deficiency CN102670635A T NN O
. CN102670635A T . O

11β-HYDROXYSTEROID WO2007115935A1 T JJ I-UN
DEHYDROGENASE WO2007115935A1 T NNP I-UN
TYPE WO2007115935A1 T NNP I-UN
1 WO2007115935A1 T CD O
ACTIVE WO2007115935A1 T NNP O
COMPOUNDS WO2007115935A1 T NNP O
. WO2007115935A1 T . O

The WO2007115935A1 A DT O
present WO2007115935A1 A JJ O
compounds WO2007115935A1 A NNS O
modulate WO2007115935A1 A VBP O
the WO2007115935A1 A DT O
activity WO2007115935A1 A NN O
of WO2007115935A1 A IN O
11β-hydroxy-steroid WO2007115935A1 A JJ I-UN
dehydrogenase WO2007115935A1 A NN I-UN
type WO2007115935A1 A NN I-UN
1 WO2007115935A1 A CD O
( WO2007115935A1 A ( O
11βHSD1 WO2007115935A1 A CD I-UN
) WO2007115935A1 A ) O
and WO2007115935A1 A CC O
are WO2007115935A1 A VBP O
accordingly WO2007115935A1 A RB O
useful WO2007115935A1 A JJ O
in WO2007115935A1 A IN O
the WO2007115935A1 A DT O
treatment WO2007115935A1 A NN O
of WO2007115935A1 A IN O
diseases WO2007115935A1 A NNS O
in WO2007115935A1 A IN O
which WO2007115935A1 A WDT O
such WO2007115935A1 A PDT O
a WO2007115935A1 A DT O
modulation WO2007115935A1 A NN O
is WO2007115935A1 A VBZ O
beneficial WO2007115935A1 A JJ O
, WO2007115935A1 A , O
e.g WO2007115935A1 A NN O
. WO2007115935A1 A . O

Clusianon US20050090693 T NNP O
derivatives US20050090693 T NNS O
; US20050090693 T : O
anticarcinogenic US20050090693 T JJ O
, US20050090693 T , O
antitumor US20050090693 T NN O
and US20050090693 T CC O
viricidal US20050090693 T JJ O
agents US20050090693 T NNS O
; US20050090693 T : O
mixture US20050090693 T NN O
with US20050090693 T IN O
mitogen-activated US20050090693 T JJ O
protein US20050090693 T NN O
( US20050090693 T ( O
MAP US20050090693 T NNP O
) US20050090693 T ) O
kinase US20050090693 T NN O
inhibitors US20050090693 T NNS O
. US20050090693 T . O

They US20050090693 A PRP O
are US20050090693 A VBP O
especially US20050090693 A RB O
used US20050090693 A VBN O
as US20050090693 A IN O
inhibitors US20050090693 A NNS O
of US20050090693 A IN O
topoisomerases US20050090693 A NNS O
and US20050090693 A CC O
telomerases US20050090693 A NNS I-UN
and US20050090693 A CC O
as US20050090693 A IN O
regulators US20050090693 A NNS O
during US20050090693 A IN O
the US20050090693 A DT O
MAP US20050090693 A NNP O
kinase US20050090693 A NNP O
signal US20050090693 A JJ O
transduction US20050090693 A NN O
and US20050090693 A CC O
can US20050090693 A MD O
thus US20050090693 A RB O
intervene US20050090693 A VB O
on US20050090693 A IN O
a US20050090693 A DT O
cellular US20050090693 A JJ O
scale US20050090693 A NN O
in US20050090693 A IN O
the US20050090693 A DT O
mechanism US20050090693 A NN O
for US20050090693 A IN O
multiplication US20050090693 A NN O
of US20050090693 A IN O
tumour US20050090693 A NN O
or US20050090693 A CC O
cancer US20050090693 A NN O
cells US20050090693 A NNS O
and US20050090693 A CC O
viruses US20050090693 A NNS O
. US20050090693 A . O

Krypton-based WO2011154630A1 T JJ O
inhalable WO2011154630A1 T JJ O
gaseous WO2011154630A1 T JJ O
medicinal WO2011154630A1 T JJ O
product WO2011154630A1 T NN O
for WO2011154630A1 T IN O
combatting WO2011154630A1 T VBG O
deficiencies WO2011154630A1 T NNS O
or WO2011154630A1 T CC O
failure WO2011154630A1 T NN O
of WO2011154630A1 T IN O
peripheral WO2011154630A1 T JJ O
organs WO2011154630A1 T NNS O
. WO2011154630A1 T . O

Composition WO2012157921A3 T NN O
for WO2012157921A3 T IN O
transdermal WO2012157921A3 T JJ O
administration WO2012157921A3 T NN O
, WO2012157921A3 T , O
containing WO2012157921A3 T VBG O
rivastigmine WO2012157921A3 T NN O
or WO2012157921A3 T CC O
salt WO2012157921A3 T NN O
thereof WO2012157921A3 T NN O
. WO2012157921A3 T . O

Omeprazole CN101396348A T JJ O
enteric-coated CN101396348A T JJ O
micro-pill CN101396348A T NN O
. CN101396348A T . O

Halofuginone US20110263532 T NNP O
analogs US20110263532 T NNS O
for US20110263532 T IN O
inhibition US20110263532 T NN O
of US20110263532 T IN O
trna US20110263532 T NN O
synthetases US20110263532 T NNS O
and US20110263532 T CC O
uses US20110263532 T VBZ O
thereof US20110263532 T NN O
. US20110263532 T . O

Aminotriazole WO2009077990A1 T NNP O
derivatives WO2009077990A1 T NNS O
as WO2009077990A1 T IN O
alx WO2009077990A1 T JJ I-UN
agonists WO2009077990A1 T NNS O
. WO2009077990A1 T . O

The WO2009077990A1 A DT O
compounds WO2009077990A1 A NNS O
are WO2009077990A1 A VBP O
useful WO2009077990A1 A JJ O
for WO2009077990A1 A IN O
the WO2009077990A1 A DT O
prevention WO2009077990A1 A NN O
or WO2009077990A1 A CC O
treatment WO2009077990A1 A NN O
of WO2009077990A1 A IN O
diseases WO2009077990A1 A NNS O
, WO2009077990A1 A , O
which WO2009077990A1 A WDT O
respond WO2009077990A1 A VBP O
to WO2009077990A1 A TO O
the WO2009077990A1 A DT O
modulation WO2009077990A1 A NN O
of WO2009077990A1 A IN O
the WO2009077990A1 A DT O
ALX WO2009077990A1 A NNP I-UN
receptor WO2009077990A1 A NN I-UN
such WO2009077990A1 A JJ O
as WO2009077990A1 A IN O
inflammatory WO2009077990A1 A JJ O
diseases WO2009077990A1 A NNS O
. WO2009077990A1 A . O

Polymorphs WO2012038785A1 T NNP O
of WO2012038785A1 T IN O
rosuvastatin WO2012038785A1 T NN O
acetonide WO2012038785A1 T IN O
calcium WO2012038785A1 T NN O
( WO2012038785A1 T ( O
( WO2012038785A1 T ( O
3r,5s,6e WO2012038785A1 T CD O
) WO2012038785A1 T ) O
-7- WO2012038785A1 T NN O
[ WO2012038785A1 T JJ O
4- WO2012038785A1 T JJ O
( WO2012038785A1 T ( O
4- WO2012038785A1 T JJ O
fluorophenyl WO2012038785A1 T NN O
) WO2012038785A1 T ) O
-6-isopropyl-2- WO2012038785A1 T NN O
( WO2012038785A1 T ( O
methanesulfonyl-methyl-amino WO2012038785A1 T NN O
) WO2012038785A1 T ) O
-pyrimn WO2012038785A1 T NN O
) WO2012038785A1 T ) O
in-5- WO2012038785A1 T NN O
yl WO2012038785A1 T NN O
) WO2012038785A1 T ) O
vinyl WO2012038785A1 T NN O
) WO2012038785A1 T ) O
-2,2-dimethyl-l,3-dioxan-4-yl WO2012038785A1 T NN O
) WO2012038785A1 T ) O
acetic WO2012038785A1 T JJ O
acid WO2012038785A1 T NN O
calcium WO2012038785A1 T NN O
salt WO2012038785A1 T NN O
. WO2012038785A1 T . O

Isoflavonoid US20100160268 T NNP O
Analogs US20100160268 T NNP O
and US20100160268 T CC O
their US20100160268 T PRP$ O
Metal US20100160268 T NN O
Conjugates US20100160268 T NNPS O
as US20100160268 T IN O
Anti-Cancer US20100160268 T NNP O
Agents US20100160268 T NNP O
. US20100160268 T . O

Method CN102146014A T NNP O
for CN102146014A T IN O
extracting CN102146014A T VBG O
squalene CN102146014A T NN O
by CN102146014A T IN O
using CN102146014A T VBG O
camellia CN102146014A T JJ O
oleosa CN102146014A T JJ O
seeds CN102146014A T NNS O
as CN102146014A T IN O
raw CN102146014A T JJ O
materials CN102146014A T NNS O
and CN102146014A T CC O
tea CN102146014A T JJ O
oil CN102146014A T NN O
and CN102146014A T CC O
squalene CN102146014A T NN O
soft CN102146014A T JJ O
capsules CN102146014A T NNS O
. CN102146014A T . O

Use US6943181 T NNP O
of US6943181 T IN O
substituted US6943181 T JJ O
gamma-lactone US6943181 T JJ O
compounds US6943181 T NNS O
as US6943181 T IN O
pharmaceutical US6943181 T JJ O
preparations US6943181 T NNS O
. US6943181 T . O

Drug CN101862337B T NNP O
composite CN101862337B T JJ O
containing CN101862337B T NN O
limaprost CN101862337B T NN O
and CN101862337B T CC O
preparation CN101862337B T NN O
method CN101862337B T NN O
thereof CN101862337B T NN O
. CN101862337B T . O

Nimodipine CN103315948A T NNP O
polymer CN103315948A T NN O
blending CN103315948A T VBG O
micelle CN103315948A T JJ O
preparation CN103315948A T NN O
and CN103315948A T CC O
preparation CN103315948A T NN O
method CN103315948A T NN O
thereof CN103315948A T NN O
. CN103315948A T . O

The CN103315948A A DT O
invention CN103315948A A NN O
relates CN103315948A A VBZ O
to CN103315948A A TO O
the CN103315948A A DT O
technical CN103315948A A JJ O
field CN103315948A A NN O
of CN103315948A A IN O
medicine CN103315948A A JJ O
preparation CN103315948A A NN O
, CN103315948A A , O
and CN103315948A A CC O
discloses CN103315948A A VBZ O
a CN103315948A A DT O
nimodipine CN103315948A A JJ O
polymer CN103315948A A NN O
blending CN103315948A A VBG O
micelle CN103315948A A JJ O
preparation CN103315948A A NN O
and CN103315948A A CC O
a CN103315948A A DT O
preparation CN103315948A A NN O
method CN103315948A A NN O
thereof CN103315948A A NN O
. CN103315948A A . O

The CN103315948A A DT O
nimodipine CN103315948A A JJ O
polymer CN103315948A A NN O
blending CN103315948A A VBG O
micelle CN103315948A A JJ O
preparation CN103315948A A NN O
is CN103315948A A VBZ O
formed CN103315948A A VBN O
by CN103315948A A IN O
embedding CN103315948A A VBG O
nimodipine CN103315948A A NN O
in CN103315948A A IN O
polyethylene CN103315948A A JJ O
glycol-polylactic CN103315948A A JJ O
acid CN103315948A A NN O
( CN103315948A A ( O
PEG-PLA CN103315948A A NNP O
) CN103315948A A ) O
and CN103315948A A CC O
D-alpha-Tocopheryl CN103315948A A NNP O
polyethylene CN103315948A A NN O
glycol CN103315948A A NN O
1000 CN103315948A A CD O
succinate CN103315948A A NN O
( CN103315948A A ( O
TPGS CN103315948A A NNP O
) CN103315948A A ) O
, CN103315948A A , O
wherein CN103315948A A VBD O
the CN103315948A A DT O
mass CN103315948A A NN O
ratio CN103315948A A NN O
of CN103315948A A IN O
nimodipine CN103315948A A NN O
, CN103315948A A , O
PEG-PLA CN103315948A A NNP O
and CN103315948A A CC O
TPGS CN103315948A A NNP O
is CN103315948A A VBZ O
2-10:20:5-30 CN103315948A A JJ O
. CN103315948A A . O

The CN103315948A A DT O
weight CN103315948A A JJ O
average CN103315948A A JJ O
molecular CN103315948A A JJ O
weight CN103315948A A NN O
of CN103315948A A IN O
PEG-PLA CN103315948A A NNP O
is CN103315948A A VBZ O
7000-45000 CN103315948A A CD O
, CN103315948A A , O
wherein CN103315948A A VBZ O
the CN103315948A A DT O
molecular CN103315948A A JJ O
weight CN103315948A A NN O
of CN103315948A A IN O
PEG CN103315948A A NNP O
is CN103315948A A VBZ O
2000-15000 CN103315948A A CD O
, CN103315948A A , O
and CN103315948A A CC O
the CN103315948A A DT O
molecular CN103315948A A JJ O
weight CN103315948A A NN O
of CN103315948A A IN O
PLA CN103315948A A NNP O
is CN103315948A A VBZ O
5000-30000 CN103315948A A CD O
. CN103315948A A . O

The CN103315948A A DT O
nimodipine CN103315948A A JJ O
polymer CN103315948A A NN O
blending CN103315948A A VBG O
micelle CN103315948A A JJ O
preparation CN103315948A A NN O
is CN103315948A A VBZ O
prepared CN103315948A A VBN O
by CN103315948A A IN O
employing CN103315948A A VBG O
solvent CN103315948A A JJ O
evaporation CN103315948A A NN O
method CN103315948A A NN O
with CN103315948A A IN O
optimized CN103315948A A JJ O
technology CN103315948A A NN O
conditions CN103315948A A NNS O
, CN103315948A A , O
wherein CN103315948A A VBP O
the CN103315948A A DT O
ratios CN103315948A A NNS O
of CN103315948A A IN O
an CN103315948A A DT O
organic CN103315948A A JJ O
phase CN103315948A A NN O
to CN103315948A A TO O
a CN103315948A A DT O
water CN103315948A A NN O
phase CN103315948A A NN O
and CN103315948A A CC O
PEG-PLA CN103315948A A NNP O
to CN103315948A A TO O
TPGS CN103315948A A NNP O
, CN103315948A A , O
dosage CN103315948A A NN O
and CN103315948A A CC O
the CN103315948A A DT O
like CN103315948A A JJ O
are CN103315948A A VBP O
all CN103315948A A DT O
best CN103315948A A JJS O
defined CN103315948A A VBN O
, CN103315948A A , O
and CN103315948A A CC O
the CN103315948A A DT O
obtained CN103315948A A JJ O
preparation CN103315948A A NN O
can CN103315948A A MD O
help CN103315948A A VB O
to CN103315948A A TO O
prolong CN103315948A A VB O
drug CN103315948A A NN O
release CN103315948A A NN O
time CN103315948A A NN O
by CN103315948A A IN O
experiments CN103315948A A NNS O
in CN103315948A A IN O
vitro CN103315948A A NN O
. CN103315948A A . O

Composition CN103006718A T NNP O
capable CN103006718A T NN O
of CN103006718A T IN O
effectively CN103006718A T RB O
degrading CN103006718A T VBG O
blood CN103006718A T NN O
lipid CN103006718A T NN O
. CN103006718A T . O

Capsule CN101966166A T NNP O
containing CN101966166A T VBG O
cefixime CN101966166A T JJ O
liposome CN101966166A T NN O
and CN101966166A T CC O
preparation CN101966166A T NN O
method CN101966166A T NN O
thereof CN101966166A T NN O
. CN101966166A T . O

A EP2709674A1 T DT O
process EP2709674A1 T NN O
for EP2709674A1 T IN O
delivering EP2709674A1 T VBG O
encapsulated EP2709674A1 T JJ O
neutral EP2709674A1 T JJ O
bioimaging EP2709674A1 T NN O
molecules EP2709674A1 T NNS O
, EP2709674A1 T , O
complex EP2709674A1 T JJ O
, EP2709674A1 T , O
and EP2709674A1 T CC O
process EP2709674A1 T NN O
thereof EP2709674A1 T NN O
. EP2709674A1 T . O

Retroviral EP1534847A1 T JJ O
vector EP1534847A1 T NN O
and EP1534847A1 T CC O
stable EP1534847A1 T JJ O
packaging EP1534847A1 T NN O
cell EP1534847A1 T NN O
lines EP1534847A1 T NNS O
. EP1534847A1 T . O

Gel CN103610688A T NNP O
reagent CN103610688A T JJ O
pharmaceutical CN103610688A T JJ O
composition CN103610688A T NN O
and CN103610688A T CC O
preparation CN103610688A T NN O
method CN103610688A T NN O
thereof CN103610688A T NN O
. CN103610688A T . O

Pharmaceutical EP2151237A1 T JJ O
composition EP2151237A1 T NN O
combining EP2151237A1 T VBG O
a EP2151237A1 T DT O
non-steroidal EP2151237A1 T JJ O
anti-inflammatory EP2151237A1 T JJ O
agent EP2151237A1 T NN O
and EP2151237A1 T CC O
an EP2151237A1 T DT O
anticonvulsant EP2151237A1 T JJ O
agent EP2151237A1 T NN O
. EP2151237A1 T . O

Penetrating CN101926823A T VBG O
agent CN101926823A T NN O
used CN101926823A T VBN O
for CN101926823A T IN O
peritoneal CN101926823A T JJ O
dialysate CN101926823A T NN O
and CN101926823A T CC O
dialysate CN101926823A T NN O
thereof CN101926823A T NN O
. CN101926823A T . O

A US20120316225 A DT O
modification US20120316225 A NN O
of US20120316225 A IN O
the US20120316225 A DT O
existing US20120316225 A VBG O
INSM1 US20120316225 A NNP I-UN
promoter US20120316225 A NN O
region US20120316225 A NN O
has US20120316225 A VBZ O
been US20120316225 A VBN O
discovered US20120316225 A VBN O
that US20120316225 A IN O
incorporated US20120316225 A JJ O
DNA US20120316225 A NNP O
elements US20120316225 A NNS O
that US20120316225 A WDT O
silence US20120316225 A VBP O
expression US20120316225 A NN O
of US20120316225 A IN O
neuronal US20120316225 A JJ O
genes US20120316225 A NNS O
in US20120316225 A IN O
non-neuronal US20120316225 A JJ O
cells US20120316225 A NNS O
and US20120316225 A CC O
that US20120316225 A DT O
has US20120316225 A VBZ O
increased US20120316225 A VBN O
the US20120316225 A DT O
effectiveness US20120316225 A NN O
and US20120316225 A CC O
safety US20120316225 A NN O
of US20120316225 A IN O
using US20120316225 A VBG O
the US20120316225 A DT O
INSM1 US20120316225 A NNP I-UN
promoter US20120316225 A NN O
for US20120316225 A IN O
tumor US20120316225 A NN O
treatment US20120316225 A NN O
. US20120316225 A . O

These US20120316225 A DT O
NRSEs US20120316225 A NNP O
were US20120316225 A VBD O
placed US20120316225 A VBN O
in US20120316225 A IN O
the US20120316225 A DT O
expression US20120316225 A NN O
construct US20120316225 A NN O
either US20120316225 A CC O
directly US20120316225 A RB O
upstream US20120316225 A JJ O
or US20120316225 A CC O
downstream US20120316225 A NN O
of US20120316225 A IN O
the US20120316225 A DT O
INSM1 US20120316225 A NNP I-UN
promoter US20120316225 A NN O
sequence US20120316225 A NN O
. US20120316225 A . O

The US20120316225 A DT O
most US20120316225 A RBS O
effective US20120316225 A JJ O
expression US20120316225 A NN O
construct US20120316225 A NN O
was US20120316225 A VBD O
the US20120316225 A DT O
nAChR US20120316225 A JJ O
NRSE US20120316225 A NNP O
element US20120316225 A NN O
positioned US20120316225 A VBD O
downstream US20120316225 A NN O
of US20120316225 A IN O
the US20120316225 A DT O
INSM1 US20120316225 A NNP I-UN
promoter US20120316225 A NN O
. US20120316225 A . O

This US20120316225 A DT O
expression US20120316225 A NN O
construct US20120316225 A NN O
increased US20120316225 A VBD O
the US20120316225 A DT O
tissue US20120316225 A NN O
specificity US20120316225 A NN O
of US20120316225 A IN O
the US20120316225 A DT O
INSM1 US20120316225 A NNP I-UN
promoter US20120316225 A NN O
without US20120316225 A IN O
a US20120316225 A DT O
significant US20120316225 A JJ O
decrease US20120316225 A NN O
in US20120316225 A IN O
its US20120316225 A PRP$ O
activity US20120316225 A NN O
. US20120316225 A . O

In US20120316225 A IN O
addition US20120316225 A NN O
, US20120316225 A , O
the US20120316225 A DT O
modified US20120316225 A JJ O
INSM1 US20120316225 A NNP I-UN
promoter US20120316225 A NN O
was US20120316225 A VBD O
placed US20120316225 A VBN O
into US20120316225 A IN O
a US20120316225 A DT O
viral US20120316225 A JJ O
vector US20120316225 A NN O
, US20120316225 A , O
adenovirus US20120316225 A RB O
5 US20120316225 A CD O
. US20120316225 A . O

Constructs US20120316225 A NNS O
with US20120316225 A IN O
an US20120316225 A DT O
insulator US20120316225 A NN O
element US20120316225 A NN O
, US20120316225 A , O
the US20120316225 A DT O
chicken US20120316225 A NN O
HS4 US20120316225 A NNP O
β-globin US20120316225 A JJ O
insulator US20120316225 A NN O
element US20120316225 A NN O
, US20120316225 A , O
with US20120316225 A IN O
the US20120316225 A DT O
INSM1 US20120316225 A NNP I-UN
promoter US20120316225 A NN O
was US20120316225 A VBD O
shown US20120316225 A VBN O
to US20120316225 A TO O
decrease US20120316225 A VB O
the US20120316225 A DT O
interference US20120316225 A NN O
of US20120316225 A IN O
the US20120316225 A DT O
viral US20120316225 A JJ O
genome US20120316225 A NN O
on US20120316225 A IN O
its US20120316225 A PRP$ O
expression US20120316225 A NN O
. US20120316225 A . O

Constructs US20120316225 A NNS O
have US20120316225 A VBP O
been US20120316225 A VBN O
made US20120316225 A VBN O
that US20120316225 A WDT O
do US20120316225 A VBP O
not US20120316225 A RB O
decrease US20120316225 A VB O
the US20120316225 A DT O
INSM1 US20120316225 A NNP I-UN
promoter US20120316225 A NN O
activity US20120316225 A NN O
but US20120316225 A CC O
significantly US20120316225 A RB O
augment US20120316225 A VBD O
the US20120316225 A DT O
tumor US20120316225 A NN O
specificity US20120316225 A NN O
of US20120316225 A IN O
the US20120316225 A DT O
promoter US20120316225 A NN O
. US20120316225 A . O

Isoliquirtigenin CN101152167B T NNP O
pessary CN101152167B T NN O
for CN101152167B T IN O
treating CN101152167B T VBG O
chronic CN101152167B T JJ O
cervicitis CN101152167B T NN O
and CN101152167B T CC O
method CN101152167B T NN O
of CN101152167B T IN O
preparing CN101152167B T VBG O
the CN101152167B T DT O
same CN101152167B T JJ O
. CN101152167B T . O

Method US20120094965 T NNP O
and US20120094965 T CC O
Formulation US20120094965 T NNP O
for US20120094965 T IN O
Chemical US20120094965 T NNP O
Peeling US20120094965 T NNP O
. US20120094965 T . O

Fluoro-acrylamide CN102675311A T JJ O
derivative CN102675311A T NN O
. CN102675311A T . O

The CN102675311A A DT O
invention CN102675311A A NN O
relates CN102675311A A VBZ O
to CN102675311A A TO O
a CN102675311A A DT O
new CN102675311A A JJ O
compound CN102675311A A NN O
with CN102675311A A IN O
remarkable CN102675311A A JJ O
antibacterial CN102675311A A JJ O
and CN102675311A A CC O
antineoplastic CN102675311A A JJ O
activity CN102675311A A NN O
, CN102675311A A , O
which CN102675311A A WDT O
has CN102675311A A VBZ O
the CN102675311A A DT O
following CN102675311A A JJ O
structure CN102675311A A NN O
( CN102675311A A ( O
shown CN102675311A A VBN O
in CN102675311A A IN O
formula CN102675311A A NN O
I CN102675311A A PRP O
) CN102675311A A ) O
, CN102675311A A , O
and CN102675311A A CC O
has CN102675311A A VBZ O
good CN102675311A A JJ O
antibacterial CN102675311A A JJ O
function CN102675311A A NN O
for CN102675311A A IN O
methicillin-resistant CN102675311A A JJ O
staphylococcus CN102675311A A NN O
aureus CN102675311A A NN O
( CN102675311A A ( O
MRSA CN102675311A A NNP O
) CN102675311A A ) O
and CN102675311A A CC O
methicillin CN102675311A A $ O
sensitive CN102675311A A JJ O
staphylococcus CN102675311A A NN O
aureus CN102675311A A NN O
( CN102675311A A ( O
MSSA CN102675311A A NNP O
) CN102675311A A ) O
as CN102675311A A RB O
well CN102675311A A RB O
as CN102675311A A IN O
good CN102675311A A JJ O
antineoplastic CN102675311A A JJ O
function CN102675311A A NN O
for CN102675311A A IN O
human CN102675311A A JJ O
cervical CN102675311A A JJ O
cancer CN102675311A A NN O
Hela CN102675311A A NNP O
cells CN102675311A A NNS O
, CN102675311A A , O
human CN102675311A A JJ O
liver CN102675311A A NN O
cancer CN102675311A A NN O
BEL-7402 CN102675311A A NNP O
cells CN102675311A A NNS O
, CN102675311A A , O
human CN102675311A A JJ O
mucinous CN102675311A A JJ O
epidermoid CN102675311A A NN O
lung CN102675311A A NN O
cancer CN102675311A A NN O
A549 CN102675311A A NNP O
cells CN102675311A A NNS O
, CN102675311A A , O
human CN102675311A A JJ O
breast CN102675311A A NN O
cancer CN102675311A A NN O
MCF-7/ CN102675311A A NNP O
s CN102675311A A NN O
cells CN102675311A A NNS O
and CN102675311A A CC O
human CN102675311A A JJ O
glioma CN102675311A A NN O
U251 CN102675311A A NNP O
cells CN102675311A A NNS O
. CN102675311A A . O

( CN102675311A A ( O
In CN102675311A A IN O
the CN102675311A A DT O
formula CN102675311A A NN O
I CN102675311A A PRP O
, CN102675311A A , O
) CN102675311A A ) O
R=-CH3 CN102675311A A NNP O
or CN102675311A A CC O
CF3 CN102675311A A NNP O
, CN102675311A A , O
X=O CN102675311A A NNP O
, CN102675311A A , O
S CN102675311A A NNP O
or CN102675311A A CC O
N CN102675311A A NNP O
, CN102675311A A , O
and CN102675311A A CC O
R1=-Cl CN102675311A A NNP O
, CN102675311A A , O
-F CN102675311A A NNP O
, CN102675311A A , O
-CH3 CN102675311A A NNP O
, CN102675311A A , O
-CF3 CN102675311A A NNP O
, CN102675311A A , O
-OCH3 CN102675311A A NNP O
and CN102675311A A CC O
-OCF3 CN102675311A A NNP O
. CN102675311A A . O

Thiadiazole CN102199134A T NNP O
histone CN102199134A T NN O
deacetylase CN102199134A T NN O
inhibitors CN102199134A T NNS O
and CN102199134A T CC O
application CN102199134A T NN O
thereof CN102199134A T NN O
. CN102199134A T . O

The CN102199134A A DT O
invention CN102199134A A NN O
relates CN102199134A A VBZ O
to CN102199134A A TO O
a CN102199134A A DT O
method CN102199134A A NN O
for CN102199134A A IN O
preparing CN102199134A A VBG O
a CN102199134A A DT O
series CN102199134A A NN O
of CN102199134A A IN O
thiadiazole CN102199134A A JJ O
histone CN102199134A A NN O
deacetylase CN102199134A A NN O
inhibitors CN102199134A A NNS O
and CN102199134A A CC O
an CN102199134A A DT O
application CN102199134A A NN O
thereof CN102199134A A NN O
. CN102199134A A . O

The CN102199134A A DT O
series CN102199134A A NN O
of CN102199134A A IN O
compounds CN102199134A A NNS O
have CN102199134A A VBP O
the CN102199134A A DT O
structure CN102199134A A NN O
in CN102199134A A IN O
a CN102199134A A DT O
general CN102199134A A JJ O
formula CN102199134A A NN O
I CN102199134A A PRP O
, CN102199134A A , O
has CN102199134A A VBZ O
the CN102199134A A DT O
inhibitory CN102199134A A NN O
activity CN102199134A A NN O
on CN102199134A A IN O
histone CN102199134A A NN O
deacetylase CN102199134A A NN O
and CN102199134A A CC O
proliferation CN102199134A A NN O
of CN102199134A A IN O
multiple CN102199134A A JJ O
kinds CN102199134A A NNS O
of CN102199134A A IN O
tumor CN102199134A A NN O
cells CN102199134A A NNS O
as CN102199134A A IN O
is CN102199134A A VBZ O
shown CN102199134A A VBN O
in CN102199134A A IN O
an CN102199134A A DT O
activity CN102199134A A NN O
screening CN102199134A A VBG O
experiment CN102199134A A NN O
, CN102199134A A , O
and CN102199134A A CC O
can CN102199134A A MD O
be CN102199134A A VB O
possibly CN102199134A A RB O
used CN102199134A A VBN O
for CN102199134A A IN O
treating CN102199134A A VBG O
diseases CN102199134A A NNS O
caused CN102199134A A VBN O
by CN102199134A A IN O
disorder CN102199134A A NN O
of CN102199134A A IN O
activity CN102199134A A NN O
of CN102199134A A IN O
the CN102199134A A DT O
histone CN102199134A A NN O
deacetylase CN102199134A A NN O
. CN102199134A A . O

The CN102199134A A DT O
invention CN102199134A A NN O
further CN102199134A A RB O
relates CN102199134A A VBZ O
to CN102199134A A TO O
a CN102199134A A DT O
pharmaceutical CN102199134A A JJ O
application CN102199134A A NN O
of CN102199134A A IN O
a CN102199134A A DT O
composition CN102199134A A NN O
of CN102199134A A IN O
the CN102199134A A DT O
compounds CN102199134A A NNS O
with CN102199134A A IN O
the CN102199134A A DT O
general CN102199134A A JJ O
formula CN102199134A A NN O
I CN102199134A A PRP O
. CN102199134A A . O

Pharmaceutical US20080050430 T JJ O
compositions US20080050430 T NNS O
and US20080050430 T CC O
methods US20080050430 T NNS O
for US20080050430 T IN O
improved US20080050430 T JJ O
bacterial US20080050430 T JJ O
eradication US20080050430 T NN O
. US20080050430 T . O

External CN102552402A T JJ O
medicine CN102552402A T NN O
for CN102552402A T IN O
treating CN102552402A T VBG O
rheumatic CN102552402A T JJ O
diseases CN102552402A T NNS O
. CN102552402A T . O

Methods WO2014039960A1 T NNS O
for WO2014039960A1 T IN O
the WO2014039960A1 T DT O
treatment WO2014039960A1 T NN O
of WO2014039960A1 T IN O
locally WO2014039960A1 T RB O
advanced WO2014039960A1 T JJ O
breast WO2014039960A1 T NN O
cancer WO2014039960A1 T NN O
. WO2014039960A1 T . O

Benzoimidazole US20090247508 T NNP O
Compounds US20090247508 T NNP O
. US20090247508 T . O

Benzoimidazole US20090247508 A NNP O
compounds US20090247508 A NNS O
, US20090247508 A , O
compositions US20090247508 A NNS O
, US20090247508 A , O
and US20090247508 A CC O
methods US20090247508 A NNS O
of US20090247508 A IN O
using US20090247508 A VBG O
them US20090247508 A PRP O
in US20090247508 A IN O
leukocyte US20090247508 A JJ O
recruitment US20090247508 A NN O
inhibition US20090247508 A NN O
, US20090247508 A , O
in US20090247508 A IN O
modulating US20090247508 A VBG O
H4 US20090247508 A NNP I-UN
receptor US20090247508 A NN I-UN
, US20090247508 A , O
and US20090247508 A CC O
in US20090247508 A IN O
treating US20090247508 A VBG O
conditions US20090247508 A NNS O
such US20090247508 A JJ O
as US20090247508 A IN O
inflammation US20090247508 A NN O
, US20090247508 A , O
H4 US20090247508 A NNP I-UN
receptor-mediated US20090247508 A JJ O
conditions US20090247508 A NNS O
, US20090247508 A , O
and US20090247508 A CC O
related US20090247508 A JJ O
conditions US20090247508 A NNS O
. US20090247508 A . O

Pharmaceutical WO2010021247A1 T JJ O
preparation WO2010021247A1 T NN O
, WO2010021247A1 T , O
food WO2010021247A1 T NN O
or WO2010021247A1 T CC O
beverage WO2010021247A1 T NN O
having WO2010021247A1 T VBG O
inhibitory WO2010021247A1 T JJ O
activity WO2010021247A1 T NN O
on WO2010021247A1 T IN O
serotonin WO2010021247A1 T NN I-UN
transporter WO2010021247A1 T NN I-UN
. WO2010021247A1 T . O

Methods US20120115939 T NNS O
for US20120115939 T IN O
using US20120115939 T VBG O
lipoic US20120115939 T JJ O
acid US20120115939 T NN O
. US20120115939 T . O

New US20090149503 T NNP O
5-aryl US20090149503 T JJ O
pyridines US20090149503 T NNS O
as US20090149503 T IN O
11-beta US20090149503 T JJ O
inhibitors US20090149503 T NNS O
for US20090149503 T IN O
the US20090149503 T DT O
treatment US20090149503 T NN O
of US20090149503 T IN O
diabetes US20090149503 T NNS O
. US20090149503 T . O

Fully-modified WO2009074157A1 T JJ O
phenyl WO2009074157A1 T NN O
pyrrole WO2009074157A1 T NN O
aminoguanidines WO2009074157A1 T NNS O
. WO2009074157A1 T . O

The WO2009074157A1 A DT O
invention WO2009074157A1 A NN O
further WO2009074157A1 A RB O
relates WO2009074157A1 A VBZ O
to WO2009074157A1 A TO O
the WO2009074157A1 A DT O
use WO2009074157A1 A NN O
of WO2009074157A1 A IN O
such WO2009074157A1 A JJ O
modified WO2009074157A1 A VBN O
phenyl WO2009074157A1 A JJ O
pyrrole WO2009074157A1 A NN O
aminoguanidines WO2009074157A1 A NNS O
for WO2009074157A1 A IN O
the WO2009074157A1 A DT O
treatment WO2009074157A1 A NN O
of WO2009074157A1 A IN O
diseases WO2009074157A1 A NNS O
associated WO2009074157A1 A VBN O
with WO2009074157A1 A IN O
the WO2009074157A1 A DT O
melanocortin WO2009074157A1 A NN I-UN
receptors WO2009074157A1 A NNS I-UN
or WO2009074157A1 A CC O
related WO2009074157A1 A JJ O
systems WO2009074157A1 A NNS O
, WO2009074157A1 A , O
e.g WO2009074157A1 A NN O
. WO2009074157A1 A . O

Hydroxypyridinone WO2006028523A3 T NN O
, WO2006028523A3 T , O
hydroxypyridinethione WO2006028523A3 T NN O
, WO2006028523A3 T , O
pyrone WO2006028523A3 T NN O
, WO2006028523A3 T , O
and WO2006028523A3 T CC O
thiopyrone WO2006028523A3 T NN O
metalloprotein WO2006028523A3 T NN O
inhibitors WO2006028523A3 T NNS O
. WO2006028523A3 T . O

Cosmetic WO2014037903A3 T JJ O
compositions WO2014037903A3 T NNS O
comprising WO2014037903A3 T VBG O
eicosapentaeninic WO2014037903A3 T JJ O
free WO2014037903A3 T JJ O
acid WO2014037903A3 T NN O
and WO2014037903A3 T CC O
gamma-linopenic WO2014037903A3 T JJ O
free WO2014037903A3 T JJ O
acid WO2014037903A3 T NN O
and WO2014037903A3 T CC O
methods WO2014037903A3 T NNS O
of WO2014037903A3 T IN O
making WO2014037903A3 T VBG O
and WO2014037903A3 T CC O
using WO2014037903A3 T VBG O
same WO2014037903A3 T JJ O
. WO2014037903A3 T . O

Substituted WO2013049174A1 T VBN O
octahydropyrrolo WO2013049174A1 T JJ O
[ WO2013049174A1 T JJ O
1,2-a WO2013049174A1 T JJ O
] WO2013049174A1 T NNP O
pyrazine WO2013049174A1 T NN O
sulfonamides WO2013049174A1 T NNS O
as WO2013049174A1 T IN O
calcium WO2013049174A1 T NN O
channel WO2013049174A1 T NN O
blockers WO2013049174A1 T NNS O
. WO2013049174A1 T . O

Composition CN102988960A T NN O
which CN102988960A T WDT O
promotes CN102988960A T VBZ O
wound CN102988960A T IN O
healing CN102988960A T VBG O
. CN102988960A T . O

The CN102988960A A DT O
invention CN102988960A A NN O
discloses CN102988960A A VBZ O
a CN102988960A A DT O
composition CN102988960A A NN O
which CN102988960A A WDT O
promotes CN102988960A A VBZ O
wound CN102988960A A IN O
healing CN102988960A A VBG O
, CN102988960A A , O
comprising CN102988960A A VBG O
the CN102988960A A DT O
components CN102988960A A NNS O
of CN102988960A A IN O
0.5-2.5 CN102988960A A CD O
% CN102988960A A NN O
of CN102988960A A IN O
chlorhexidine CN102988960A A NN O
acetate CN102988960A A NN O
, CN102988960A A , O
1-3.5 CN102988960A A CD O
% CN102988960A A NN O
of CN102988960A A IN O
prednisolone CN102988960A A NN O
acetate CN102988960A A NN O
, CN102988960A A , O
2-5 CN102988960A A CD O
% CN102988960A A NN O
of CN102988960A A IN O
dodecyl CN102988960A A NN O
dimethyl CN102988960A A NN O
benzyl CN102988960A A NN O
ammonium CN102988960A A NN O
chloride CN102988960A A NN O
, CN102988960A A , O
0.05-0.3 CN102988960A A CD O
% CN102988960A A NN O
of CN102988960A A IN O
vascular CN102988960A A JJ I-UN
endothelial CN102988960A A JJ I-UN
growth CN102988960A A NN I-UN
factor CN102988960A A NN I-UN
, CN102988960A A , O
5-15 CN102988960A A JJ O
% CN102988960A A NN O
of CN102988960A A IN O
sterile CN102988960A A JJ O
water CN102988960A A NN O
and CN102988960A A CC O
the CN102988960A A DT O
balance CN102988960A A NN O
of CN102988960A A IN O
ointment CN102988960A A JJ O
matrix CN102988960A A NN O
by CN102988960A A IN O
weight CN102988960A A JJ O
percentage CN102988960A A NN O
. CN102988960A A . O

New CN102992997A T NNP O
medical CN102992997A T JJ O
salt CN102992997A T NN O
of CN102992997A T IN O
dexibuprofen CN102992997A T NN O
. CN102992997A T . O

Hydroxybutyrate EP2020869A1 T NNP O
and EP2020869A1 T CC O
poly-hydroxybutyrate EP2020869A1 T NN O
as EP2020869A1 T IN O
components EP2020869A1 T NNS O
of EP2020869A1 T IN O
animal EP2020869A1 T JJ O
feed EP2020869A1 T NN O
or EP2020869A1 T CC O
feed EP2020869A1 T NN O
additives EP2020869A1 T NNS O
. EP2020869A1 T . O

Nociceptin US20080287478 T NNP I-UN
Analogues US20080287478 T NNP O
and US20080287478 T CC O
Uses US20080287478 T NNP O
Thereof US20080287478 T NNP O
. US20080287478 T . O

The US20080287478 A DT O
present US20080287478 A JJ O
invention US20080287478 A NN O
relates US20080287478 A VBZ O
to US20080287478 A TO O
nociceptin US20080287478 A VB I-UN
analogues US20080287478 A NNS O
and US20080287478 A CC O
uses US20080287478 A VBZ O
thereof US20080287478 A NN O
to US20080287478 A TO O
modulate US20080287478 A VB O
biological US20080287478 A JJ O
functions US20080287478 A NNS O
. US20080287478 A . O

( US6852714 T ( O
Benzodioxan US6852714 T NNP O
, US6852714 T , O
benzofuran US6852714 T VBD O
or US6852714 T CC O
benzopyran US6852714 T NN O
) US6852714 T ) O
derivatives US6852714 T VBZ O
having US6852714 T VBG O
fundic US6852714 T JJ O
relaxation US6852714 T NN O
properties US6852714 T NNS O
. US6852714 T . O

Mono WO2007125293A1 T NNP O
and WO2007125293A1 T CC O
combination WO2007125293A1 T NN O
therapy WO2007125293A1 T NN O
with WO2007125293A1 T IN O
a WO2007125293A1 T DT O
m1/m4 WO2007125293A1 T NN O
muscarinic WO2007125293A1 T JJ O
agonist WO2007125293A1 T NN O
( WO2007125293A1 T ( O
sabcomeline WO2007125293A1 T NN O
) WO2007125293A1 T ) O
for WO2007125293A1 T IN O
treatment WO2007125293A1 T NN O
of WO2007125293A1 T IN O
cognitive WO2007125293A1 T JJ O
disorders WO2007125293A1 T NNS O
in WO2007125293A1 T IN O
schizophrenia WO2007125293A1 T NN O
. WO2007125293A1 T . O

The WO2007125293A1 A DT O
invention WO2007125293A1 A NN O
relates WO2007125293A1 A VBZ O
to WO2007125293A1 A TO O
the WO2007125293A1 A DT O
use WO2007125293A1 A NN O
of WO2007125293A1 A IN O
a WO2007125293A1 A DT O
functional WO2007125293A1 A JJ O
muscarinic WO2007125293A1 A NN I-UN
M1/M4 WO2007125293A1 A NNP I-UN
receptor WO2007125293A1 A NN I-UN
agonist WO2007125293A1 A NN O
such WO2007125293A1 A JJ O
as WO2007125293A1 A IN O
the WO2007125293A1 A DT O
functional WO2007125293A1 A JJ O
muscarinic WO2007125293A1 A NN I-UN
M1/M4 WO2007125293A1 A NNP I-UN
receptor WO2007125293A1 A NN I-UN
agonist WO2007125293A1 A NN O
or WO2007125293A1 A CC O
a WO2007125293A1 A DT O
pharmaceutically WO2007125293A1 A RB O
acceptable WO2007125293A1 A JJ O
salt WO2007125293A1 A NN O
thereof WO2007125293A1 A NN O
, WO2007125293A1 A , O
in WO2007125293A1 A IN O
particular WO2007125293A1 A JJ O
sabcomeline WO2007125293A1 A NN O
or WO2007125293A1 A CC O
a WO2007125293A1 A DT O
pharmaceutically WO2007125293A1 A RB O
acceptable WO2007125293A1 A JJ O
salt WO2007125293A1 A NN O
thereof WO2007125293A1 A NN O
in WO2007125293A1 A IN O
for WO2007125293A1 A IN O
the WO2007125293A1 A DT O
treatment WO2007125293A1 A NN O
of WO2007125293A1 A IN O
cognitive WO2007125293A1 A JJ O
impairment WO2007125293A1 A NN O
in WO2007125293A1 A IN O
schizophrenia WO2007125293A1 A NN O
and WO2007125293A1 A CC O
to WO2007125293A1 A TO O
combination WO2007125293A1 A NN O
therapies WO2007125293A1 A NNS O
for WO2007125293A1 A IN O
the WO2007125293A1 A DT O
treatment WO2007125293A1 A NN O
of WO2007125293A1 A IN O
cognitive WO2007125293A1 A JJ O
impairment WO2007125293A1 A NN O
in WO2007125293A1 A IN O
schizophrenia WO2007125293A1 A NN O
which WO2007125293A1 A WDT O
the WO2007125293A1 A DT O
functional WO2007125293A1 A NN O
muscarinic WO2007125293A1 A JJ I-UN
M1/M4 WO2007125293A1 A NNP I-UN
receptor WO2007125293A1 A NN I-UN
agonist WO2007125293A1 A NN O
or WO2007125293A1 A CC O
a WO2007125293A1 A DT O
pharmaceutically WO2007125293A1 A RB O
acceptable WO2007125293A1 A JJ O
salt WO2007125293A1 A NN O
thereof WO2007125293A1 A NN O
, WO2007125293A1 A , O
in WO2007125293A1 A IN O
particular WO2007125293A1 A JJ O
sabcomeline WO2007125293A1 A NN O
or WO2007125293A1 A CC O
a WO2007125293A1 A DT O
pharmaceutically WO2007125293A1 A RB O
acceptable WO2007125293A1 A JJ O
salt WO2007125293A1 A NN O
thereof WO2007125293A1 A NN O
and WO2007125293A1 A CC O
at WO2007125293A1 A IN O
least WO2007125293A1 A JJS O
one WO2007125293A1 A CD O
other WO2007125293A1 A JJ O
neuroprotective WO2007125293A1 A JJ O
agent WO2007125293A1 A NN O
and/or WO2007125293A1 A RB O
neuroleptic WO2007125293A1 A JJ O
and/or WO2007125293A1 A RB O
atypical WO2007125293A1 A JJ O
antipsyhcotic WO2007125293A1 A JJ O
agent WO2007125293A1 A NN O
are WO2007125293A1 A VBP O
administered WO2007125293A1 A VBN O
adjunctively WO2007125293A1 A RB O
or WO2007125293A1 A CC O
simultaneously WO2007125293A1 A RB O
. WO2007125293A1 A . O

Environment-friendly CN103493847A T RB O
immersing CN103493847A T NN O
and CN103493847A T CC O
spraying CN103493847A T VBG O
liquid CN103493847A T NN O
and CN103493847A T CC O
preparation CN103493847A T NN O
method CN103493847A T NN O
thereof CN103493847A T NN O
. CN103493847A T . O

Proteasome WO2010005534A3 T NNP O
inhibitors WO2010005534A3 T NNS O
for WO2010005534A3 T IN O
selectively WO2010005534A3 T RB O
inducing WO2010005534A3 T VBG O
apoptosis WO2010005534A3 T NN O
in WO2010005534A3 T IN O
cancer WO2010005534A3 T NN O
cells WO2010005534A3 T NNS O
. WO2010005534A3 T . O

Application CN101536997B T NN O
of CN101536997B T IN O
ginseng CN101536997B T NN O
alkynol CN101536997B T NN O
in CN101536997B T IN O
pharmacy CN101536997B T NN O
. CN101536997B T . O

Water-soluble CN101007809A T JJ O
camptothecine CN101007809A T NN O
derivative CN101007809A T NN O
and CN101007809A T CC O
its CN101007809A T PRP$ O
preparation CN101007809A T NN O
process CN101007809A T NN O
and CN101007809A T CC O
application CN101007809A T NN O
thereof CN101007809A T NN O
. CN101007809A T . O

Pyrazolo- WO2010049731A1 T NNP O
and WO2010049731A1 T CC O
imidazopyridinylpyrimidineamines WO2010049731A1 T NNS O
as WO2010049731A1 T IN O
igf-1r WO2010049731A1 T JJ I-UN
tyrosine WO2010049731A1 T NN I-UN
kinase WO2010049731A1 T NN I-UN
inhibitors WO2010049731A1 T NNS O
. WO2010049731A1 T . O

Novel CN101352445A T NNP O
use CN101352445A T NN O
of CN101352445A T IN O
chuanbeinone CN101352445A T NN O
compounds CN101352445A T NNS O
. CN101352445A T . O

Application CN103462989A T NN O
of CN103462989A T IN O
Lycojaponicumin CN103462989A T NNP O
B CN103462989A T NNP O
in CN103462989A T IN O
preparation CN103462989A T NN O
of CN103462989A T IN O
medicines CN103462989A T NNS O
for CN103462989A T IN O
resisting CN103462989A T VBG O
human CN103462989A T JJ O
body CN103462989A T NN O
fungi CN103462989A T NNS O
. CN103462989A T . O

The CN103462989A A DT O
invention CN103462989A A NN O
relates CN103462989A A VBZ O
to CN103462989A A TO O
an CN103462989A A DT O
application CN103462989A A NN O
of CN103462989A A IN O
Lycojaponicumin CN103462989A A NNP O
B CN103462989A A NNP O
in CN103462989A A IN O
the CN103462989A A DT O
preparation CN103462989A A NN O
of CN103462989A A IN O
medicines CN103462989A A NNS O
for CN103462989A A IN O
resisting CN103462989A A VBG O
human CN103462989A A JJ O
body CN103462989A A NN O
fungi CN103462989A A NNS O
, CN103462989A A , O
belonging CN103462989A A VBG O
to CN103462989A A TO O
the CN103462989A A DT O
field CN103462989A A NN O
of CN103462989A A IN O
medicines CN103462989A A NNS O
. CN103462989A A . O

The CN103462989A A DT O
Lycojaponicumin CN103462989A A NNP O
B CN103462989A A NNP O
has CN103462989A A VBZ O
very CN103462989A A RB O
strong CN103462989A A JJ O
inhibitory CN103462989A A NN O
effect CN103462989A A NN O
on CN103462989A A IN O
trichophyton CN103462989A A NN O
rubrum CN103462989A A NN O
, CN103462989A A , O
microsporum CN103462989A A NN O
lanosum CN103462989A A NN O
or CN103462989A A CC O
trichophyton CN103462989A A NN O
tonsurans CN103462989A A NNS O
. CN103462989A A . O

Therefore CN103462989A A RB O
, CN103462989A A , O
the CN103462989A A DT O
Lycojaponicumin CN103462989A A NNP O
B CN103462989A A NNP O
can CN103462989A A MD O
serve CN103462989A A VB O
as CN103462989A A IN O
a CN103462989A A DT O
compound CN103462989A A NN O
capable CN103462989A A JJ O
of CN103462989A A IN O
resisting CN103462989A A VBG O
human CN103462989A A JJ O
body CN103462989A A NN O
fungi CN103462989A A NNS O
and CN103462989A A CC O
is CN103462989A A VBZ O
expected CN103462989A A VBN O
to CN103462989A A TO O
be CN103462989A A VB O
applied CN103462989A A VBN O
in CN103462989A A IN O
the CN103462989A A DT O
preparation CN103462989A A NN O
of CN103462989A A IN O
related CN103462989A A JJ O
medicines CN103462989A A NNS O
. CN103462989A A . O

The CN103462989A A DT O
application CN103462989A A NN O
of CN103462989A A IN O
the CN103462989A A DT O
Lycojaponicumin CN103462989A A NNP O
B CN103462989A A NNP O
in CN103462989A A IN O
the CN103462989A A DT O
preparation CN103462989A A NN O
of CN103462989A A IN O
the CN103462989A A DT O
medicines CN103462989A A NNS O
for CN103462989A A IN O
resisting CN103462989A A VBG O
human CN103462989A A JJ O
body CN103462989A A NN O
fungi CN103462989A A NN O
is CN103462989A A VBZ O
disclosed CN103462989A A VBN O
for CN103462989A A IN O
the CN103462989A A DT O
first CN103462989A A JJ O
time CN103462989A A NN O
. CN103462989A A . O

As CN103462989A A IN O
the CN103462989A A DT O
skeleton CN103462989A A NN O
type CN103462989A A NN O
of CN103462989A A IN O
the CN103462989A A DT O
Lycojaponicumin CN103462989A A NNP O
B CN103462989A A NNP O
belongs CN103462989A A VBZ O
to CN103462989A A TO O
a CN103462989A A DT O
brand-new CN103462989A A JJ O
skeleton CN103462989A A NN O
type CN103462989A A NN O
, CN103462989A A , O
the CN103462989A A DT O
Lycojaponicumin CN103462989A A NNP O
B CN103462989A A NNP O
has CN103462989A A VBZ O
unexpected CN103462989A A VBN O
strong CN103462989A A JJ O
inhibitory CN103462989A A NN O
activity CN103462989A A NN O
on CN103462989A A IN O
human CN103462989A A JJ O
body CN103462989A A NN O
fungi CN103462989A A NNS O
, CN103462989A A , O
and CN103462989A A CC O
the CN103462989A A DT O
possibility CN103462989A A NN O
that CN103462989A A IN O
other CN103462989A A JJ O
compounds CN103462989A A NNS O
provide CN103462989A A VBP O
revelation CN103462989A A NN O
does CN103462989A A VBZ O
not CN103462989A A RB O
exist CN103462989A A VB O
. CN103462989A A . O

The CN103462989A A DT O
Lycojaponicumin CN103462989A A NNP O
B CN103462989A A NNP O
has CN103462989A A VBZ O
prominently CN103462989A A RB O
substantial CN103462989A A JJ O
characteristics CN103462989A A NNS O
and CN103462989A A CC O
meanwhile CN103462989A A NN O
has CN103462989A A VBZ O
remarkably CN103462989A A RB O
progressive CN103462989A A JJ O
significance CN103462989A A NN O
when CN103462989A A WRB O
being CN103462989A A VBG O
used CN103462989A A VBN O
for CN103462989A A IN O
preventing CN103462989A A VBG O
and CN103462989A A CC O
treating CN103462989A A VBG O
human CN103462989A A JJ O
body CN103462989A A NN O
fungi CN103462989A A JJ O
infection CN103462989A A NN O
. CN103462989A A . O

Insulin-mimetics CA2857487A1 T NNS O
as CA2857487A1 T IN O
therapeutic CA2857487A1 T JJ O
adjuncts CA2857487A1 T NNS O
for CA2857487A1 T IN O
bone CA2857487A1 T NN O
regeneration CA2857487A1 T NN O
. CA2857487A1 T . O

Methods CA2857487A1 A NNS O
of CA2857487A1 A IN O
promoting CA2857487A1 A VBG O
bone CA2857487A1 A NN O
healing CA2857487A1 A NN O
or CA2857487A1 A CC O
regeneration CA2857487A1 A NN O
by CA2857487A1 A IN O
locally CA2857487A1 A RB O
administering CA2857487A1 A VBG O
insulin CA2857487A1 A NN I-UN
mimetic CA2857487A1 A JJ O
agents CA2857487A1 A NNS O
to CA2857487A1 A TO O
patients CA2857487A1 A NNS O
in CA2857487A1 A IN O
need CA2857487A1 A NN O
thereof CA2857487A1 A NNS O
and CA2857487A1 A CC O
new CA2857487A1 A JJ O
uses CA2857487A1 A NNS O
of CA2857487A1 A IN O
insulin-mimetic CA2857487A1 A JJ O
compounds CA2857487A1 A NNS O
for CA2857487A1 A IN O
accelerating CA2857487A1 A VBG O
bone-healing CA2857487A1 A JJ O
processes CA2857487A1 A NNS O
are CA2857487A1 A VBP O
disclosed CA2857487A1 A VBN O
. CA2857487A1 A . O

Process WO2010113183A3 T NN O
for WO2010113183A3 T IN O
the WO2010113183A3 T DT O
preparation WO2010113183A3 T NN O
of WO2010113183A3 T IN O
1- WO2010113183A3 T JJ O
[ WO2010113183A3 T NNP O
[ WO2010113183A3 T NNP O
[ WO2010113183A3 T NNP O
3- WO2010113183A3 T JJ O
[ WO2010113183A3 T NNP O
2- WO2010113183A3 T CD O
( WO2010113183A3 T ( O
dimethylamino WO2010113183A3 T NN O
) WO2010113183A3 T ) O
ethyl WO2010113183A3 T NN O
] WO2010113183A3 T NNP O
-1h-indol-5-yl WO2010113183A3 T NNP O
] WO2010113183A3 T NNP O
methyl WO2010113183A3 T NN O
] WO2010113183A3 T NNP O
sulfonyl WO2010113183A3 T NN O
] WO2010113183A3 T NNP O
pyrrolidine WO2010113183A3 T NN O
and WO2010113183A3 T CC O
its WO2010113183A3 T PRP$ O
pharmaceutically WO2010113183A3 T RB O
acceptable WO2010113183A3 T JJ O
salts WO2010113183A3 T NNS O
. WO2010113183A3 T . O

Rasagiline/folic CN103127121A T JJ O
acid CN103127121A T NN O
compound CN103127121A T NN O
medicine CN103127121A T NN O
combination CN103127121A T NN O
and CN103127121A T CC O
purpose CN103127121A T JJ O
thereof CN103127121A T NN O
. CN103127121A T . O

Drug US20120141591 T NN O
Delivery US20120141591 T NNP O
Nanocarriers US20120141591 T NNP O
Targeted US20120141591 T VBN O
by US20120141591 T IN O
Landscape US20120141591 T NNP O
Phage US20120141591 T NNP O
. US20120141591 T . O

Arylmethylidene US20090275538 T NNP O
heterocycles US20090275538 T NNS O
as US20090275538 T IN O
novel US20090275538 T JJ O
analgesics US20090275538 T NNS O
. US20090275538 T . O

Use US20120295858 T NNP O
of US20120295858 T IN O
danshensu US20120295858 T NN O
, US20120295858 T , O
notoginsenoside US20120295858 T JJ O
r1 US20120295858 T NN O
or US20120295858 T CC O
their US20120295858 T PRP$ O
combination US20120295858 T NN O
in US20120295858 T IN O
preparation US20120295858 T NN O
of US20120295858 T IN O
medicaments US20120295858 T NNS O
for US20120295858 T IN O
preventing US20120295858 T VBG O
and US20120295858 T CC O
treating US20120295858 T VBG O
diseases US20120295858 T NNS O
caused US20120295858 T VBN O
by US20120295858 T IN O
microcirculation US20120295858 T NN O
disorder US20120295858 T NN O
. US20120295858 T . O

Antagonists US20080076805 T NNS O
and/or US20080076805 T VBP O
inverse US20080076805 T JJ O
agonists US20080076805 T NNS O
of US20080076805 T IN O
CB1 US20080076805 T NNP I-UN
; US20080076805 T : O
N'- US20080076805 T JJ O
[ US20080076805 T JJ O
1- US20080076805 T JJ O
( US20080076805 T ( O
3-chlorophenyl US20080076805 T JJ O
) US20080076805 T ) O
-2- US20080076805 T NN O
( US20080076805 T ( O
4-chlorophenyl US20080076805 T JJ O
) US20080076805 T ) O
ethyl US20080076805 T FW O
] US20080076805 T FW O
-N'-methyl-N- US20080076805 T FW O
( US20080076805 T ( O
2-methyl-2- US20080076805 T JJ O
[ US20080076805 T NN O
5- US20080076805 T JJ O
( US20080076805 T ( O
trifluoromethylpyridin-2-yl US20080076805 T JJ O
) US20080076805 T ) O
oxy US20080076805 T MD O
] US20080076805 T VB O
propanoyl US20080076805 T NN O
) US20080076805 T ) O
hydrazide US20080076805 T NN O
for US20080076805 T IN O
example US20080076805 T NN O
; US20080076805 T : O
obesity US20080076805 T NN O
, US20080076805 T , O
psychological US20080076805 T JJ O
disorders US20080076805 T NNS O
, US20080076805 T , O
analgesics US20080076805 T NNS O
, US20080076805 T , O
drug US20080076805 T NN O
abuse US20080076805 T NN O
, US20080076805 T , O
constipation US20080076805 T NN O
, US20080076805 T , O
asthma US20080076805 T NN O
, US20080076805 T , O
cirrhosis US20080076805 T NN O
. US20080076805 T . O

The US20080076805 A DT O
acyclic US20080076805 A JJ O
hydrazides US20080076805 A NNS O
of US20080076805 A IN O
the US20080076805 A DT O
invention US20080076805 A NN O
are US20080076805 A VBP O
antagonists US20080076805 A VBZ O
and/or US20080076805 A JJ O
inverse US20080076805 A JJ O
agonists US20080076805 A NNS O
of US20080076805 A IN O
the US20080076805 A DT O
Cannabinoid-1 US20080076805 A NNP I-UN
( US20080076805 A ( I-UN
CB1 US20080076805 A NNP I-UN
) US20080076805 A ) I-UN
receptor US20080076805 A NN I-UN
and US20080076805 A CC O
are US20080076805 A VBP O
useful US20080076805 A JJ O
in US20080076805 A IN O
the US20080076805 A DT O
treatment US20080076805 A NN O
, US20080076805 A , O
prevention US20080076805 A NN O
and US20080076805 A CC O
suppression US20080076805 A NN O
of US20080076805 A IN O
diseases US20080076805 A NNS O
mediated US20080076805 A VBN O
by US20080076805 A IN O
the US20080076805 A DT O
CB1 US20080076805 A NNP I-UN
receptor US20080076805 A NN O
. US20080076805 A . O

Stomatocase CN1931329A T NNP O
treating CN1931329A T VBG O
medicine CN1931329A T NN O
. CN1931329A T . O

Use WO2013030512A1 T NNP O
of WO2013030512A1 T IN O
compositions WO2013030512A1 T NNS O
having WO2013030512A1 T VBG O
a WO2013030512A1 T DT O
low WO2013030512A1 T JJ O
polyamine WO2013030512A1 T NN O
content WO2013030512A1 T NN O
in WO2013030512A1 T IN O
the WO2013030512A1 T DT O
prevention WO2013030512A1 T NN O
or WO2013030512A1 T CC O
treatment WO2013030512A1 T NN O
of WO2013030512A1 T IN O
adverse WO2013030512A1 T JJ O
effects WO2013030512A1 T NNS O
linked WO2013030512A1 T VBN O
to WO2013030512A1 T TO O
cancer WO2013030512A1 T NN O
treatment WO2013030512A1 T NN O
. WO2013030512A1 T . O

Heterocyclic US20090221603 T NNP O
amide US20090221603 T VBP O
derivatives US20090221603 T NNS O
as US20090221603 T IN O
calcium US20090221603 T NN I-UN
channel US20090221603 T NN I-UN
blockers US20090221603 T NNS O
. US20090221603 T . O

Methods US20090221603 A NNS O
and US20090221603 A CC O
compounds US20090221603 A NNS O
effective US20090221603 A JJ O
in US20090221603 A IN O
ameliorating US20090221603 A VBG O
conditions US20090221603 A NNS O
characterized US20090221603 A VBN O
by US20090221603 A IN O
unwanted US20090221603 A JJ O
calcium US20090221603 A NN O
channel US20090221603 A NN O
activity US20090221603 A NN O
, US20090221603 A , O
particularly US20090221603 A RB O
unwanted US20090221603 A JJ O
N-type US20090221603 A JJ I-UN
or US20090221603 A CC I-UN
T-type US20090221603 A JJ I-UN
calcium US20090221603 A NN I-UN
channel US20090221603 A NN I-UN
activity US20090221603 A NN O
are US20090221603 A VBP O
disclosed US20090221603 A VBN O
. US20090221603 A . O

Anti-Retroviral US20110008429 T JJ O
Combination US20110008429 T NNP O
. US20110008429 T . O

Materials US8691799 T NNS O
and US8691799 T CC O
methods US8691799 T NNS O
for US8691799 T IN O
treatment US8691799 T NN O
of US8691799 T IN O
cancer US8691799 T NN O
and US8691799 T CC O
identification US8691799 T NN O
of US8691799 T IN O
anti-cancer US8691799 T JJ O
compounds US8691799 T NNS O
. US8691799 T . O

The US8691799 A DT O
present US8691799 A JJ O
invention US8691799 A NN O
further US8691799 A RBR O
pertains US8691799 A NNS O
to US8691799 A TO O
methods US8691799 A NNS O
of US8691799 A IN O
moderating US8691799 A VBG O
the US8691799 A DT O
JAK US8691799 A NNP O
and/or US8691799 A NN O
STAT3 US8691799 A NNP I-UN
signaling US8691799 A VBG O
pathways US8691799 A NNS O
in US8691799 A IN O
vitro US8691799 A NN O
or US8691799 A CC O
in US8691799 A IN O
vivo US8691799 A JJ O
using US8691799 A VBG O
cucurbitacin US8691799 A NN O
I US8691799 A PRP O
, US8691799 A , O
or US8691799 A CC O
a US8691799 A DT O
pharmaceutically US8691799 A RB O
acceptable US8691799 A JJ O
salt US8691799 A NN O
or US8691799 A CC O
analog US8691799 A NN O
thereof US8691799 A NNS O
. US8691799 A . O

Another US8691799 A DT O
aspect US8691799 A NN O
of US8691799 A IN O
the US8691799 A DT O
present US8691799 A JJ O
invention US8691799 A NN O
concerns US8691799 A NNS O
a US8691799 A DT O
method US8691799 A NN O
for US8691799 A IN O
screening US8691799 A VBG O
candidate US8691799 A NN O
compounds US8691799 A NNS O
for US8691799 A IN O
JAK US8691799 A NNP O
and/or US8691799 A NN O
STAT3 US8691799 A NNP I-UN
inhibition US8691799 A NN O
and US8691799 A CC O
anti-tumor US8691799 A JJ O
activity US8691799 A NN O
. US8691799 A . O

High US20110182984 T JJ O
Content US20110182984 T NNP O
Sodium US20110182984 T NNP O
Ibuprofen US20110182984 T NNP O
Granules US20110182984 T NNP O
, US20110182984 T , O
Their US20110182984 T NNP O
Preparation US20110182984 T NNP O
And US20110182984 T CC O
Their US20110182984 T NNP O
Use US20110182984 T NNP O
In US20110182984 T IN O
Preparing US20110182984 T VBG O
Non-Effervescent US20110182984 T JJ O
Solid US20110182984 T NNP O
Dosage US20110182984 T NN O
Forms US20110182984 T NNP O
. US20110182984 T . O

Silybin CN101961319A T NNP O
meglumine CN101961319A T NN O
enteric CN101961319A T JJ O
agent CN101961319A T NN O
with CN101961319A T IN O
high CN101961319A T JJ O
bioavailability CN101961319A T NN O
and CN101961319A T CC O
preparation CN101961319A T NN O
method CN101961319A T NN O
thereof CN101961319A T NN O
. CN101961319A T . O

Use US20110166207 T NNP O
of US20110166207 T IN O
aav US20110166207 T JJ O
integration US20110166207 T NN O
efficiency US20110166207 T NN O
element US20110166207 T NN O
for US20110166207 T IN O
mediating US20110166207 T VBG O
site-specific US20110166207 T JJ O
integration US20110166207 T NN O
of US20110166207 T IN O
a US20110166207 T DT O
transcription US20110166207 T NN O
unit US20110166207 T NN O
. US20110166207 T . O

Such US20110166207 A JJ O
an US20110166207 A DT O
expression US20110166207 A NN O
construct US20110166207 A NN O
site-specifically US20110166207 A RB O
integrates US20110166207 A VBZ O
into US20110166207 A IN O
a US20110166207 A DT O
host US20110166207 A NN O
cell US20110166207 A NN O
chromosome US20110166207 A NN O
when US20110166207 A WRB O
provided US20110166207 A VBN O
to US20110166207 A TO O
a US20110166207 A DT O
host US20110166207 A NN O
cell US20110166207 A NN O
in US20110166207 A IN O
conjunction US20110166207 A NN O
with US20110166207 A IN O
an US20110166207 A DT O
AAV US20110166207 A NNP I-UN
Rep US20110166207 A NNP I-UN
protein US20110166207 A NN O
. US20110166207 A . O

Solution CN101978978A T NN O
with CN101978978A T IN O
effect CN101978978A T NN O
of CN101978978A T IN O
repairing CN101978978A T VBG O
exercise-induced CN101978978A T JJ O
skeletal CN101978978A T JJ O
muscle CN101978978A T NN O
microdamage CN101978978A T NN O
. CN101978978A T . O

Nanoparticles WO2013087920A1 T NNS O
comprising WO2013087920A1 T VBG O
metallic WO2013087920A1 T NN O
and WO2013087920A1 T CC O
hafnium WO2013087920A1 T NN O
oxide WO2013087920A1 T NN O
materials WO2013087920A1 T NNS O
, WO2013087920A1 T , O
preparation WO2013087920A1 T NN O
and WO2013087920A1 T CC O
uses WO2013087920A1 T VBZ O
thereof WO2013087920A1 T NN O
. WO2013087920A1 T . O

The WO2013087920A1 A DT O
present WO2013087920A1 A JJ O
invention WO2013087920A1 A NN O
relates WO2013087920A1 A VBZ O
to WO2013087920A1 A TO O
novel WO2013087920A1 A VB O
nanoparticles WO2013087920A1 A NNS O
which WO2013087920A1 A WDT O
can WO2013087920A1 A MD O
be WO2013087920A1 A VB O
advantageously WO2013087920A1 A RB O
used WO2013087920A1 A VBN O
in WO2013087920A1 A IN O
the WO2013087920A1 A DT O
health WO2013087920A1 A NN O
sector WO2013087920A1 A NN O
as WO2013087920A1 A IN O
diagnostic WO2013087920A1 A JJ O
and/or WO2013087920A1 A NN O
therapeutic WO2013087920A1 A JJ O
agents WO2013087920A1 A NNS O
. WO2013087920A1 A . O

Nanoparticles WO2013087920A1 A NNS O
of WO2013087920A1 A IN O
the WO2013087920A1 A DT O
invention WO2013087920A1 A NN O
comprise WO2013087920A1 A NN O
a WO2013087920A1 A DT O
metallic WO2013087920A1 A JJ O
material WO2013087920A1 A NN O
at WO2013087920A1 A IN O
least WO2013087920A1 A JJS O
partly WO2013087920A1 A RB O
covered WO2013087920A1 A VBN O
withan WO2013087920A1 A JJ O
hafnium WO2013087920A1 A NN O
oxide WO2013087920A1 A IN O
material WO2013087920A1 A NN O
or WO2013087920A1 A CC O
embedded WO2013087920A1 A VBN O
therein WO2013087920A1 A NN O
. WO2013087920A1 A . O

When WO2013087920A1 A WRB O
compared WO2013087920A1 A VBN O
to WO2013087920A1 A TO O
existing WO2013087920A1 A VBG O
products WO2013087920A1 A NNS O
, WO2013087920A1 A , O
these WO2013087920A1 A DT O
nanoparticles WO2013087920A1 A NNS O
offer WO2013087920A1 A VBP O
a WO2013087920A1 A DT O
remarkable WO2013087920A1 A JJ O
benefit WO2013087920A1 A NN O
over WO2013087920A1 A IN O
risk WO2013087920A1 A NN O
ratio WO2013087920A1 A NN O
. WO2013087920A1 A . O

Specifically WO2013087920A1 A RB O
, WO2013087920A1 A , O
these WO2013087920A1 A DT O
nanoparticles WO2013087920A1 A NNS O
potentiate WO2013087920A1 A VBP O
the WO2013087920A1 A DT O
efficiency WO2013087920A1 A NN O
of WO2013087920A1 A IN O
known WO2013087920A1 A VBN O
metallic WO2013087920A1 A JJ O
nanoparticles WO2013087920A1 A NNS O
. WO2013087920A1 A . O

Indeed WO2013087920A1 A RB O
, WO2013087920A1 A , O
they WO2013087920A1 A PRP O
retain WO2013087920A1 A VBP O
the WO2013087920A1 A DT O
metal WO2013087920A1 A NN O
intrinsic WO2013087920A1 A JJ O
properties WO2013087920A1 A NNS O
and WO2013087920A1 A CC O
are WO2013087920A1 A VBP O
now WO2013087920A1 A RB O
in WO2013087920A1 A IN O
addition WO2013087920A1 A NN O
safely WO2013087920A1 A RB O
usable WO2013087920A1 A JJ O
in WO2013087920A1 A IN O
a WO2013087920A1 A DT O
mammal WO2013087920A1 A NN O
, WO2013087920A1 A , O
in WO2013087920A1 A IN O
particular WO2013087920A1 A JJ O
in WO2013087920A1 A IN O
a WO2013087920A1 A DT O
human WO2013087920A1 A JJ O
being WO2013087920A1 A VBG O
. WO2013087920A1 A . O

The WO2013087920A1 A DT O
invention WO2013087920A1 A NN O
also WO2013087920A1 A RB O
relates WO2013087920A1 A VBZ O
to WO2013087920A1 A TO O
methods WO2013087920A1 A NNS O
for WO2013087920A1 A IN O
producing WO2013087920A1 A VBG O
said WO2013087920A1 A VBD O
nanoparticles WO2013087920A1 A NNS O
, WO2013087920A1 A , O
to WO2013087920A1 A TO O
compositions WO2013087920A1 A NNS O
containing WO2013087920A1 A VBG O
same WO2013087920A1 A JJ O
, WO2013087920A1 A , O
and WO2013087920A1 A CC O
to WO2013087920A1 A TO O
uses WO2013087920A1 A NNS O
thereof WO2013087920A1 A NN O
. WO2013087920A1 A . O

Administering US7282599 T VBG O
dithiocarbamate US7282599 T NN O
compound US7282599 T NN O
having US7282599 T VBG O
the US7282599 T DT O
structural US7282599 T JJ O
formula US7282599 T NN O
R1R2NCS2H US7282599 T NNP O
for US7282599 T IN O
therapy US7282599 T NN O
of US7282599 T IN O
infection US7282599 T NN O
by US7282599 T IN O
an US7282599 T DT O
RNA US7282599 T NNP O
virus US7282599 T NN O
which US7282599 T WDT O
attacks US7282599 T VBZ O
the US7282599 T DT O
respiratory US7282599 T NN O
tract US7282599 T NN O
and US7282599 T CC O
causes US7282599 T VBZ O
disease US7282599 T NN O
selected US7282599 T VBN O
from US7282599 T IN O
picornavirus US7282599 T NN O
, US7282599 T , O
ortho-myxovirus US7282599 T JJ O
, US7282599 T , O
rhinovirus US7282599 T NN O
, US7282599 T , O
enterovirus US7282599 T NN O
, US7282599 T , O
coxsackie US7282599 T NN O
virus US7282599 T NN O
, US7282599 T , O
aphthovirus US7282599 T NN O
, US7282599 T , O
or US7282599 T CC O
paramyxovirus US7282599 T NN O
. US7282599 T . O

Compound CN102872173A T NNP O
acetaminophen CN102872173A T VBZ O
orally CN102872173A T RB O
disintegrating CN102872173A T JJ O
tablet CN102872173A T NN O
for CN102872173A T IN O
beasts CN102872173A T NNS O
and CN102872173A T CC O
birds CN102872173A T NNS O
and CN102872173A T CC O
preparation CN102872173A T NN O
method CN102872173A T NN O
for CN102872173A T IN O
compound CN102872173A T NN O
acetaminophen CN102872173A T NN O
orally CN102872173A T RB O
disintegrating CN102872173A T VBG O
tablet CN102872173A T NN O
. CN102872173A T . O

Fused WO2009133127A1 T VBN O
bicyclic WO2009133127A1 T JJ O
compounds WO2009133127A1 T NNS O
and WO2009133127A1 T CC O
use WO2009133127A1 T VB O
thereof WO2009133127A1 T NN O
as WO2009133127A1 T IN O
pi3k WO2009133127A1 T JJ I-UN
inhibitors WO2009133127A1 T NNS O
. WO2009133127A1 T . O

The WO2009133127A1 A DT O
invention WO2009133127A1 A NN O
relates WO2009133127A1 A VBZ O
to WO2009133127A1 A TO O
compounds WO2009133127A1 A NNS O
of WO2009133127A1 A IN O
formula WO2009133127A1 A NN O
( WO2009133127A1 A ( O
I WO2009133127A1 A PRP O
) WO2009133127A1 A ) O
, WO2009133127A1 A , O
for WO2009133127A1 A IN O
the WO2009133127A1 A DT O
regulation WO2009133127A1 A NN O
of WO2009133127A1 A IN O
phosphoinositides WO2009133127A1 A NNS I-UN
3-kinases WO2009133127A1 A JJ I-UN
activity WO2009133127A1 A NN O
and WO2009133127A1 A CC O
related WO2009133127A1 A JJ O
diseases WO2009133127A1 A NNS O
. WO2009133127A1 A . O

method US20080146502 T NN O
for US20080146502 T IN O
modulating US20080146502 T VBG O
the US20080146502 T DT O
sensation US20080146502 T NN O
of US20080146502 T IN O
satiety US20080146502 T NN O
perception US20080146502 T NN O
and US20080146502 T CC O
to US20080146502 T TO O
agents US20080146502 T NNS O
useful US20080146502 T JJ O
for US20080146502 T IN O
same US20080146502 T JJ O
. US20080146502 T . O

Such US20080146502 T JJ O
agents US20080146502 T NNS O
are US20080146502 T VBP O
useful US20080146502 T JJ O
in US20080146502 T IN O
modulating US20080146502 T NN O
, US20080146502 T , O
controlling US20080146502 T VBG O
or US20080146502 T CC O
otherwise US20080146502 T RB O
affecting US20080146502 T JJ O
inter US20080146502 T NN O
alia US20080146502 T NN O
obesity US20080146502 T NN O
, US20080146502 T , O
anorexia US20080146502 T NN O
, US20080146502 T , O
weight US20080146502 T JJ O
maintenance US20080146502 T NN O
, US20080146502 T , O
metabolic US20080146502 T JJ O
energy US20080146502 T NN O
levels US20080146502 T NNS O
and/or US20080146502 T VBP O
inflammatory US20080146502 T JJ O
conditions US20080146502 T NNS O
in US20080146502 T IN O
a US20080146502 T DT O
subject US20080146502 T NN O
. US20080146502 T . O

Polypeptide US20120108493 T NNP O
Fragments US20120108493 T NNP O
Comprising US20120108493 T NNP O
Endonuclease US20120108493 T NNP I-UN
Activity US20120108493 T NNP O
and US20120108493 T CC O
Their US20120108493 T NNP O
Use US20120108493 T NNP O
. US20120108493 T . O

The US20120108493 A DT O
present US20120108493 A JJ O
invention US20120108493 A NN O
relates US20120108493 A VBZ O
to US20120108493 A TO O
polypeptide US20120108493 A VB O
fragments US20120108493 A NNS O
comprising US20120108493 A VBG O
an US20120108493 A DT O
amino-terminal US20120108493 A JJ O
fragment US20120108493 A NN O
of US20120108493 A IN O
the US20120108493 A DT O
PA US20120108493 A NNP O
subunit US20120108493 A NN O
of US20120108493 A IN O
a US20120108493 A DT O
viral US20120108493 A JJ O
RNA-dependent US20120108493 A JJ I-UN
RNA US20120108493 A NNP I-UN
polymerase US20120108493 A NN I-UN
or US20120108493 A CC O
variants US20120108493 A NNS O
thereof US20120108493 A IN O
possessing US20120108493 A VBG O
endonuclease US20120108493 A NN I-UN
activity US20120108493 A NN O
, US20120108493 A , O
wherein US20120108493 A NN O
said US20120108493 A VBD O
PA US20120108493 A NNP O
subunit US20120108493 A NN O
is US20120108493 A VBZ O
from US20120108493 A IN O
a US20120108493 A DT O
virus US20120108493 A NN O
belonging US20120108493 A NN O
to US20120108493 A TO O
the US20120108493 A DT O
Orthomyxoviridae US20120108493 A NNP O
family US20120108493 A NN O
. US20120108493 A . O

In US20120108493 A IN O
addition US20120108493 A NN O
, US20120108493 A , O
this US20120108493 A DT O
invention US20120108493 A NN O
relates US20120108493 A VBZ O
to US20120108493 A TO O
methods US20120108493 A VB O
identifying US20120108493 A VBG O
compounds US20120108493 A NNS O
that US20120108493 A WDT O
bind US20120108493 A VBP O
to US20120108493 A TO O
the US20120108493 A DT O
PA US20120108493 A NNP O
polypeptide US20120108493 A NN O
fragments US20120108493 A NNS O
possessing US20120108493 A VBG O
endonuclease US20120108493 A NN I-UN
activity US20120108493 A NN O
and US20120108493 A CC O
preferably US20120108493 A RB O
inhibit US20120108493 A NN O
said US20120108493 A VBD O
endonucleolytic US20120108493 A JJ O
activity US20120108493 A NN O
, US20120108493 A , O
preferably US20120108493 A RB O
in US20120108493 A IN O
a US20120108493 A DT O
high US20120108493 A JJ O
throughput US20120108493 A NN O
setting US20120108493 A NN O
. US20120108493 A . O

Selective WO2008122618A1 T JJ O
inhibitors WO2008122618A1 T NNS O
of WO2008122618A1 T IN O
cb2 WO2008122618A1 T NN I-UN
receptor WO2008122618A1 T NN O
expression WO2008122618A1 T NN O
and/or WO2008122618A1 T NN O
activity WO2008122618A1 T NN O
for WO2008122618A1 T IN O
the WO2008122618A1 T DT O
treatment WO2008122618A1 T NN O
of WO2008122618A1 T IN O
obesity WO2008122618A1 T NN O
and WO2008122618A1 T CC O
obesity-related WO2008122618A1 T JJ O
disorders WO2008122618A1 T NNS O
. WO2008122618A1 T . O

The WO2008122618A1 A DT O
invention WO2008122618A1 A NN O
relates WO2008122618A1 A VBZ O
to WO2008122618A1 A TO O
the WO2008122618A1 A DT O
use WO2008122618A1 A NN O
of WO2008122618A1 A IN O
a WO2008122618A1 A DT O
selective WO2008122618A1 A JJ O
inhibitor WO2008122618A1 A NN O
of WO2008122618A1 A IN O
CB2 WO2008122618A1 A NNP I-UN
receptor WO2008122618A1 A NN O
expression WO2008122618A1 A NN O
and/or WO2008122618A1 A NN O
for WO2008122618A1 A IN O
the WO2008122618A1 A DT O
manufacture WO2008122618A1 A NN O
of WO2008122618A1 A IN O
a WO2008122618A1 A DT O
medicament WO2008122618A1 A NN O
indented WO2008122618A1 A VBN O
for WO2008122618A1 A IN O
the WO2008122618A1 A DT O
treatment WO2008122618A1 A NN O
and/or WO2008122618A1 A VBZ O
the WO2008122618A1 A DT O
prevention WO2008122618A1 A NN O
of WO2008122618A1 A IN O
obesity WO2008122618A1 A NN O
and WO2008122618A1 A CC O
obesity-related WO2008122618A1 A JJ O
disorders WO2008122618A1 A NNS O
. WO2008122618A1 A . O

Novel US20090192153 T NNP O
adenine US20090192153 T NN O
compound US20090192153 T NN O
. US20090192153 T . O

Methods US20110086802 T NNS O
to US20110086802 T TO O
increase US20110086802 T VB O
permeability US20110086802 T NN O
of US20110086802 T IN O
corneal US20110086802 T JJ O
epithelium US20110086802 T NN O
and US20110086802 T CC O
destabilize US20110086802 T VB O
stromal US20110086802 T JJ O
collagen US20110086802 T NN O
fibril US20110086802 T NN O
network US20110086802 T NN O
. US20110086802 T . O

Use EP1513525B1 T NNP O
of EP1513525B1 T IN O
mglur5 EP1513525B1 T NN I-UN
antagonists EP1513525B1 T NNS O
for EP1513525B1 T IN O
the EP1513525B1 T DT O
treatment EP1513525B1 T NN O
of EP1513525B1 T IN O
gerd EP1513525B1 T NN O
. EP1513525B1 T . O

The EP1513525B1 A DT O
present EP1513525B1 A JJ O
invention EP1513525B1 A NN O
relates EP1513525B1 A VBZ O
to EP1513525B1 A TO O
the EP1513525B1 A DT O
use EP1513525B1 A NN O
of EP1513525B1 A IN O
metabotropic EP1513525B1 A NN I-UN
glutamate EP1513525B1 A NN I-UN
receptor EP1513525B1 A NN I-UN
5 EP1513525B1 A CD I-UN
antagonists EP1513525B1 A NNS O
for EP1513525B1 A IN O
the EP1513525B1 A DT O
inhibition EP1513525B1 A NN O
of EP1513525B1 A IN O
transient EP1513525B1 A NN O
lower EP1513525B1 A JJR O
esophageal EP1513525B1 A NN O
sphincter EP1513525B1 A NN O
relaxations EP1513525B1 A NNS O
. EP1513525B1 A . O

A EP1513525B1 A DT O
further EP1513525B1 A JJ O
aspects EP1513525B1 A NNS O
of EP1513525B1 A IN O
the EP1513525B1 A DT O
invention EP1513525B1 A NN O
is EP1513525B1 A VBZ O
directed EP1513525B1 A VBN O
to EP1513525B1 A TO O
the EP1513525B1 A DT O
use EP1513525B1 A NN O
of EP1513525B1 A IN O
metabotropic EP1513525B1 A NN I-UN
glutamate EP1513525B1 A NN I-UN
receptor EP1513525B1 A NN I-UN
5 EP1513525B1 A CD I-UN
antagonists EP1513525B1 A NNS O
for EP1513525B1 A IN O
the EP1513525B1 A DT O
treatment EP1513525B1 A NN O
of EP1513525B1 A IN O
gastro EP1513525B1 A NN O
, EP1513525B1 A , O
esophageal EP1513525B1 A JJ O
reflux EP1513525B1 A NN O
disease EP1513525B1 A NN O
, EP1513525B1 A , O
as EP1513525B1 A RB O
well EP1513525B1 A RB O
as EP1513525B1 A IN O
for EP1513525B1 A IN O
the EP1513525B1 A DT O
treatment EP1513525B1 A NN O
of EP1513525B1 A IN O
regurgitation EP1513525B1 A NN O
and EP1513525B1 A CC O
asthma EP1513525B1 A NN O
. EP1513525B1 A . O

The EP2494965A2 A DT O
invention EP2494965A2 A NN O
provides EP2494965A2 A VBZ O
methods EP2494965A2 A NNS O
and EP2494965A2 A CC O
compositions EP2494965A2 A NNS O
for EP2494965A2 A IN O
treating EP2494965A2 A VBG O
and EP2494965A2 A CC O
preventing EP2494965A2 A VBG O
a EP2494965A2 A DT O
skin EP2494965A2 A JJ O
rash EP2494965A2 A NN O
secondary EP2494965A2 A JJ O
to EP2494965A2 A TO O
anti-epidermal EP2494965A2 A JJ O
growth EP2494965A2 A NN I-UN
factor EP2494965A2 A NN I-UN
receptor EP2494965A2 A NN I-UN
( EP2494965A2 A ( O
EGFR EP2494965A2 A NNP I-UN
) EP2494965A2 A ) O
therapy EP2494965A2 A NN O
, EP2494965A2 A , O
where EP2494965A2 A WRB O
the EP2494965A2 A DT O
method EP2494965A2 A NN O
comprises EP2494965A2 A VBZ O
applying EP2494965A2 A VBG O
a EP2494965A2 A DT O
vitamin EP2494965A2 A NN O
K EP2494965A2 A NNP O
analog EP2494965A2 A NN O
or EP2494965A2 A CC O
a EP2494965A2 A DT O
phosphatase EP2494965A2 A NN I-UN
inhibitor EP2494965A2 A NN O
to EP2494965A2 A TO O
the EP2494965A2 A DT O
skin EP2494965A2 A NN O
. EP2494965A2 A . O

Protection CN103501789A T NN O
of CN103501789A T IN O
renal CN103501789A T JJ O
tissues CN103501789A T NNS O
from CN103501789A T IN O
ischemia CN103501789A T NN O
through CN103501789A T IN O
inhibition CN103501789A T NN O
of CN103501789A T IN O
the CN103501789A T DT O
proliferative CN103501789A T JJ O
kinases CN103501789A T NNS I-UN
CDK4 CN103501789A T NNP I-UN
and CN103501789A T CC O
CDK6 CN103501789A T NNP I-UN
. CN103501789A T . O

In CN103501789A A IN O
particular CN103501789A A JJ O
, CN103501789A A , O
the CN103501789A A DT O
presently CN103501789A A RB O
disclosed CN103501789A A VBN O
subject CN103501789A A JJ O
matter CN103501789A A NN O
relates CN103501789A A VBZ O
to CN103501789A A TO O
the CN103501789A A DT O
protective CN103501789A A JJ O
action CN103501789A A NN O
of CN103501789A A IN O
cyclin CN103501789A A NN I-UN
dependent CN103501789A A JJ I-UN
kinase CN103501789A A NN I-UN
4/6 CN103501789A A CD I-UN
( CN103501789A A ( O
CDK4/6 CN103501789A A NNP I-UN
) CN103501789A A ) O
inhibitors CN103501789A A NNS O
administered CN103501789A A VBD O
to CN103501789A A TO O
subjects CN103501789A A NNS O
that CN103501789A A WDT O
have CN103501789A A VBP O
been CN103501789A A VBN O
exposed CN103501789A A VBN O
to CN103501789A A TO O
, CN103501789A A , O
or CN103501789A A CC O
that CN103501789A A DT O
are CN103501789A A VBP O
at CN103501789A A IN O
risk CN103501789A A NN O
of CN103501789A A IN O
, CN103501789A A , O
ischemia CN103501789A A NN O
. CN103501789A A . O

Synergistic WO2008077234A1 T JJ O
effects WO2008077234A1 T NNS O
of WO2008077234A1 T IN O
c3 WO2008077234A1 T NN I-UN
, WO2008077234A1 T , O
cyclic WO2008077234A1 T JJ O
amp WO2008077234A1 T NN O
and WO2008077234A1 T CC O
ciliary WO2008077234A1 T JJ I-UN
neurotrophic WO2008077234A1 T JJ I-UN
factor WO2008077234A1 T NN I-UN
on WO2008077234A1 T IN O
neuronal WO2008077234A1 T JJ O
survival WO2008077234A1 T NN O
and WO2008077234A1 T CC O
axonal WO2008077234A1 T JJ O
regeneration WO2008077234A1 T NN O
. WO2008077234A1 T . O

The WO2008077234A1 A DT O
present WO2008077234A1 A JJ O
invention WO2008077234A1 A NN O
relates WO2008077234A1 A VBZ O
to WO2008077234A1 A TO O
the WO2008077234A1 A DT O
synergistic WO2008077234A1 A JJ O
effects WO2008077234A1 A NNS O
of WO2008077234A1 A IN O
a WO2008077234A1 A DT O
combined WO2008077234A1 A JJ O
administration WO2008077234A1 A NN O
of WO2008077234A1 A IN O
a WO2008077234A1 A DT O
Rho WO2008077234A1 A NNP I-UN
antagonist WO2008077234A1 A NN O
, WO2008077234A1 A , O
e.g WO2008077234A1 A NN O
. WO2008077234A1 A . O

a WO2008077234A1 A DT O
C3 WO2008077234A1 A NNP I-UN
fusion WO2008077234A1 A NN I-UN
protein WO2008077234A1 A NN I-UN
, WO2008077234A1 A , O
with WO2008077234A1 A IN O
a WO2008077234A1 A DT O
growth WO2008077234A1 A NN O
factor WO2008077234A1 A NN O
, WO2008077234A1 A , O
e.g WO2008077234A1 A NN O
. WO2008077234A1 A . O

CNTF WO2008077234A1 A NNP I-UN
, WO2008077234A1 A , O
and WO2008077234A1 A CC O
cAMP WO2008077234A1 A NN O
or WO2008077234A1 A CC O
analogues WO2008077234A1 A NNS O
or WO2008077234A1 A CC O
modulators WO2008077234A1 A NNS O
thereof WO2008077234A1 A VBP O
, WO2008077234A1 A , O
which WO2008077234A1 A WDT O
have WO2008077234A1 A VBP O
synergistic WO2008077234A1 A JJ O
effects WO2008077234A1 A NNS O
on WO2008077234A1 A IN O
promoting WO2008077234A1 A VBG O
neuronal WO2008077234A1 A JJ O
, WO2008077234A1 A , O
e.g WO2008077234A1 A NN O
. WO2008077234A1 A . O

Exemplary WO2008077234A1 A JJ O
compositions WO2008077234A1 A NNS O
of WO2008077234A1 A IN O
the WO2008077234A1 A DT O
invention WO2008077234A1 A NN O
comprise WO2008077234A1 A NN O
Rho WO2008077234A1 A NNP I-UN
antagonists WO2008077234A1 A NNS O
, WO2008077234A1 A , O
e.g WO2008077234A1 A NN O
. WO2008077234A1 A . O

C3 WO2008077234A1 A NNP I-UN
proteins WO2008077234A1 A VBZ I-UN
or WO2008077234A1 A CC O
C3-like WO2008077234A1 A JJ I-UN
proteins WO2008077234A1 A NNS I-UN
, WO2008077234A1 A , O
growth WO2008077234A1 A NN O
factors WO2008077234A1 A NNS O
such WO2008077234A1 A JJ O
as WO2008077234A1 A IN O
CNTF WO2008077234A1 A NNP I-UN
, WO2008077234A1 A , O
and WO2008077234A1 A CC O
CAMP WO2008077234A1 A NNP O
, WO2008077234A1 A , O
or WO2008077234A1 A CC O
analogues WO2008077234A1 A NNS O
or WO2008077234A1 A CC O
modulators WO2008077234A1 A NNS O
thereof WO2008077234A1 A VBP O
. WO2008077234A1 A . O

It WO2008077234A1 A PRP O
is WO2008077234A1 A VBZ O
also WO2008077234A1 A RB O
provided WO2008077234A1 A VBN O
that WO2008077234A1 A IN O
the WO2008077234A1 A DT O
effects WO2008077234A1 A NNS O
of WO2008077234A1 A IN O
administering WO2008077234A1 A VBG O
SEQ WO2008077234A1 A NNP O
ID WO2008077234A1 A NNP O
NO WO2008077234A1 A NNP O
: WO2008077234A1 A : O
4 WO2008077234A1 A CD O
, WO2008077234A1 A , O
CNTF WO2008077234A1 A NNP I-UN
and WO2008077234A1 A CC O
cAMP WO2008077234A1 A NN O
or WO2008077234A1 A CC O
CPT-CAMP WO2008077234A1 A NN O
are WO2008077234A1 A VBP O
synergistic WO2008077234A1 A JJ O
, WO2008077234A1 A , O
increasing WO2008077234A1 A VBG O
both WO2008077234A1 A PDT O
the WO2008077234A1 A DT O
number WO2008077234A1 A NN O
of WO2008077234A1 A IN O
surviving WO2008077234A1 A VBG O
RGCs WO2008077234A1 A NNP O
and WO2008077234A1 A CC O
the WO2008077234A1 A DT O
proportion WO2008077234A1 A NN O
of WO2008077234A1 A IN O
viable WO2008077234A1 A JJ O
RGCs WO2008077234A1 A NNP O
that WO2008077234A1 A WDT O
regenerate WO2008077234A1 A VBP O
an WO2008077234A1 A DT O
axon WO2008077234A1 A NN O
. WO2008077234A1 A . O

Non-insulin US20080153766 T JJ O
dependent US20080153766 T NN O
diabetes US20080153766 T VBZ O
mellitus US20080153766 T RB O
; US20080153766 T : O
lowers US20080153766 T NNS O
hepatic US20080153766 T JJ O
fatty US20080153766 T JJ O
degeneration US20080153766 T NN O
; US20080153766 T : O
improving US20080153766 T VBG O
liver US20080153766 T NN O
function US20080153766 T NN O
by US20080153766 T IN O
reducing US20080153766 T VBG O
alanine US20080153766 T JJ I-UN
transaminase US20080153766 T NN I-UN
and US20080153766 T CC O
aspartate US20080153766 T JJ I-UN
transaminase US20080153766 T NN I-UN
levels US20080153766 T NNS O
. US20080153766 T . O

Antisense US20080153766 A NNP O
compounds US20080153766 A NNS O
, US20080153766 A , O
compositions US20080153766 A NNS O
and US20080153766 A CC O
methods US20080153766 A NNS O
are US20080153766 A VBP O
provided US20080153766 A VBN O
for US20080153766 A IN O
modulating US20080153766 A VBG O
the US20080153766 A DT O
expression US20080153766 A NN O
of US20080153766 A IN O
stearoyl-CoA US20080153766 A JJ I-UN
desaturase US20080153766 A NN I-UN
. US20080153766 A . O

The US20080153766 A DT O
compositions US20080153766 A NNS O
comprise US20080153766 A VBP O
antisense US20080153766 A JJ O
compounds US20080153766 A NNS O
, US20080153766 A , O
particularly US20080153766 A RB O
antisense US20080153766 A JJ O
oligonucleotides US20080153766 A NNS O
, US20080153766 A , O
targeted US20080153766 A VBN O
to US20080153766 A TO O
nucleic US20080153766 A JJ O
acids US20080153766 A NNS O
encoding US20080153766 A VBG O
stearoyl-CoA US20080153766 A JJ I-UN
desaturase US20080153766 A NN I-UN
. US20080153766 A . O

Methods US20080153766 A NNS O
of US20080153766 A IN O
using US20080153766 A VBG O
these US20080153766 A DT O
compounds US20080153766 A NNS O
for US20080153766 A IN O
modulation US20080153766 A NN O
of US20080153766 A IN O
stearoyl-CoA US20080153766 A JJ I-UN
desaturase US20080153766 A NN I-UN
expression US20080153766 A NN O
and US20080153766 A CC O
for US20080153766 A IN O
treatment US20080153766 A NN O
of US20080153766 A IN O
diseases US20080153766 A NNS O
associated US20080153766 A VBN O
with US20080153766 A IN O
expression US20080153766 A NN O
of US20080153766 A IN O
stearoyl-CoA US20080153766 A JJ I-UN
desaturase US20080153766 A NN I-UN
are US20080153766 A VBP O
provided US20080153766 A VBN O
. US20080153766 A . O

Zidovudine CN102617676A T NNP O
quinoline CN102617676A T NN O
conjugated CN102617676A T VBN O
compound CN102617676A T NN O
, CN102617676A T , O
preparation CN102617676A T NN O
method CN102617676A T NN O
thereof CN102617676A T NN O
and CN102617676A T CC O
application CN102617676A T NN O
for CN102617676A T IN O
liver CN102617676A T NN O
cancer CN102617676A T NN O
resistance CN102617676A T NN O
. CN102617676A T . O

Medicine CN103127393A T NNP O
for CN103127393A T IN O
treating CN103127393A T VBG O
oyster CN103127393A T NN O
larval CN103127393A T JJ O
bacterial CN103127393A T JJ O
canker CN103127393A T NN O
. CN103127393A T . O

Multi-targets US20120232126 T NNS O
interfering US20120232126 T VBG O
rna US20120232126 T NN O
molecules US20120232126 T NNS O
and US20120232126 T CC O
their US20120232126 T PRP$ O
applications US20120232126 T NNS O
. US20120232126 T . O

Trisubstituted EP1979341B1 T VBN O
amine EP1979341B1 T JJ O
compound EP1979341B1 T NN O
. EP1979341B1 T . O

The EP1979341B1 A DT O
present EP1979341B1 A JJ O
invention EP1979341B1 A NN O
relates EP1979341B1 A VBZ O
to EP1979341B1 A TO O
a EP1979341B1 A DT O
compound EP1979341B1 A NN O
of EP1979341B1 A IN O
the EP1979341B1 A DT O
general EP1979341B1 A JJ O
formula EP1979341B1 A NN O
( EP1979341B1 A ( O
1 EP1979341B1 A CD O
) EP1979341B1 A ) O
: EP1979341B1 A : O
wherein EP1979341B1 A NN O
, EP1979341B1 A , O
Y EP1979341B1 A NNP O
is EP1979341B1 A VBZ O
a EP1979341B1 A DT O
methylene EP1979341B1 A NN O
group EP1979341B1 A NN O
, EP1979341B1 A , O
and EP1979341B1 A CC O
the EP1979341B1 A DT O
like EP1979341B1 A JJ O
; EP1979341B1 A : O
A EP1979341B1 A NNP O
is EP1979341B1 A VBZ O
an EP1979341B1 A DT O
optionally EP1979341B1 A RB O
substituted EP1979341B1 A VBN O
heterocyclic EP1979341B1 A JJ O
group EP1979341B1 A NN O
, EP1979341B1 A , O
and EP1979341B1 A CC O
the EP1979341B1 A DT O
like EP1979341B1 A JJ O
; EP1979341B1 A : O
B EP1979341B1 A NNP O
is EP1979341B1 A VBZ O
an EP1979341B1 A DT O
optionally EP1979341B1 A RB O
substituted EP1979341B1 A VBN O
heterocyclic EP1979341B1 A JJ O
group EP1979341B1 A NN O
, EP1979341B1 A , O
and EP1979341B1 A CC O
the EP1979341B1 A DT O
like EP1979341B1 A JJ O
; EP1979341B1 A : O
R1 EP1979341B1 A NNP O
is EP1979341B1 A VBZ O
an EP1979341B1 A DT O
optionally EP1979341B1 A RB O
substituted EP1979341B1 A JJ O
alkyl EP1979341B1 A NN O
group EP1979341B1 A NN O
, EP1979341B1 A , O
wherein EP1979341B1 A VBZ O
the EP1979341B1 A DT O
alkyl EP1979341B1 A NN O
group EP1979341B1 A NN O
further EP1979341B1 A RBR O
may EP1979341B1 A MD O
optionally EP1979341B1 A RB O
be EP1979341B1 A VB O
substituted EP1979341B1 A VBN O
by EP1979341B1 A IN O
an EP1979341B1 A DT O
optionally EP1979341B1 A RB O
substituted EP1979341B1 A VBN O
homocyclic EP1979341B1 A JJ O
group EP1979341B1 A NN O
, EP1979341B1 A , O
and EP1979341B1 A CC O
the EP1979341B1 A DT O
like EP1979341B1 A JJ O
; EP1979341B1 A : O
and EP1979341B1 A CC O
R2 EP1979341B1 A NNP O
is EP1979341B1 A VBZ O
an EP1979341B1 A DT O
optionally EP1979341B1 A RB O
substituted EP1979341B1 A VBN O
amino EP1979341B1 A NN O
group EP1979341B1 A NN O
, EP1979341B1 A , O
and EP1979341B1 A CC O
the EP1979341B1 A DT O
like EP1979341B1 A JJ O
; EP1979341B1 A : O
or EP1979341B1 A CC O
a EP1979341B1 A DT O
pharmaceutically EP1979341B1 A RB O
acceptable EP1979341B1 A JJ O
derivative EP1979341B1 A JJ O
thereof EP1979341B1 A NN O
, EP1979341B1 A , O
which EP1979341B1 A WDT O
has EP1979341B1 A VBZ O
an EP1979341B1 A DT O
inhibitory EP1979341B1 A JJ O
activity EP1979341B1 A NN O
against EP1979341B1 A IN O
cholesteryl EP1979341B1 A NN I-UN
ester EP1979341B1 A NN I-UN
transfer EP1979341B1 A NN I-UN
protein EP1979341B1 A NN I-UN
( EP1979341B1 A ( O
CETP EP1979341B1 A NNP I-UN
) EP1979341B1 A ) O
, EP1979341B1 A , O
thereby EP1979341B1 A RB O
being EP1979341B1 A VBG O
useful EP1979341B1 A JJ O
for EP1979341B1 A IN O
prophylaxis EP1979341B1 A JJ O
and/or EP1979341B1 A JJ O
treatment EP1979341B1 A NN O
of EP1979341B1 A IN O
arteriosclerotic EP1979341B1 A JJ O
diseases EP1979341B1 A NNS O
, EP1979341B1 A , O
hyperlipemia EP1979341B1 A NN O
or EP1979341B1 A CC O
dyslipidemia EP1979341B1 A NN O
, EP1979341B1 A , O
and EP1979341B1 A CC O
the EP1979341B1 A DT O
like EP1979341B1 A JJ O
. EP1979341B1 A . O

Stable CN101716159B T JJ O
lansoprazole CN101716159B T JJ O
tablet CN101716159B T NN O
and CN101716159B T CC O
preparation CN101716159B T NN O
method CN101716159B T NN O
thereof CN101716159B T NN O
. CN101716159B T . O

Medicinal CN101006986A T JJ O
composition CN101006986A T NN O
containing CN101006986A T VBG O
mycophonolate CN101006986A T NN O
mofetil CN101006986A T NN O
and CN101006986A T CC O
its CN101006986A T PRP$ O
preparation CN101006986A T NN O
method CN101006986A T NN O
. CN101006986A T . O

Crystalline US20120142693 T NNP O
compound US20120142693 T NN O
of US20120142693 T IN O
7- US20120142693 T JJ O
[ US20120142693 T NNP O
( US20120142693 T ( O
3r US20120142693 T CD O
) US20120142693 T ) O
-3-amino-1-oxo-4- US20120142693 T NN O
( US20120142693 T ( O
2 US20120142693 T CD O
, US20120142693 T , O
4 US20120142693 T CD O
, US20120142693 T , O
5-trifluorphenyl US20120142693 T JJ O
) US20120142693 T ) O
butyl US20120142693 T NN O
] US20120142693 T NNP O
-5 US20120142693 T NNP O
, US20120142693 T , O
6 US20120142693 T CD O
, US20120142693 T , O
7 US20120142693 T CD O
, US20120142693 T , O
8-tetrahydro-3- US20120142693 T JJ O
( US20120142693 T ( O
tri US20120142693 T JJ O
fluormethyl US20120142693 T NN O
) US20120142693 T ) O
-1 US20120142693 T NN O
, US20120142693 T , O
2 US20120142693 T CD O
, US20120142693 T , O
4 US20120142693 T CD O
-triazolo US20120142693 T JJ O
[ US20120142693 T JJ O
4,3-a US20120142693 T JJ O
] US20120142693 T NN O
pyrazin US20120142693 T NN O
. US20120142693 T . O

Materials US20080167264 T NNS O
and US20080167264 T CC O
methods US20080167264 T NNS O
to US20080167264 T TO O
inhibit US20080167264 T VB O
hodgkin US20080167264 T JJ O
and US20080167264 T CC O
reed US20080167264 T VB O
sternberg US20080167264 T NN O
cell US20080167264 T NN O
growth US20080167264 T NN O
. US20080167264 T . O

Materials US20080167264 A NNS O
and US20080167264 A CC O
methods US20080167264 A NNS O
are US20080167264 A VBP O
disclosed US20080167264 A VBN O
for US20080167264 A IN O
modulating US20080167264 A VBG O
proliferation US20080167264 A NN O
of US20080167264 A IN O
cell US20080167264 A NN O
types US20080167264 A NNS O
associated US20080167264 A VBN O
with US20080167264 A IN O
Hodgkin US20080167264 A NNP O
's US20080167264 A POS O
disease US20080167264 A NN O
through US20080167264 A IN O
inhibition US20080167264 A NN O
of US20080167264 A IN O
IL-13 US20080167264 A NNP I-UN
and US20080167264 A CC O
components US20080167264 A NNS O
in US20080167264 A IN O
IL-13 US20080167264 A NNP I-UN
associated US20080167264 A VBD O
signal US20080167264 A JJ O
transduction US20080167264 A NN O
pathways US20080167264 A NNS O
. US20080167264 A . O

Novel US20120214803 T NNP O
Sulfonaminoquinoline US20120214803 T NNP O
Hepcidin US20120214803 T NNP I-UN
Antagonists US20120214803 T NNP O
. US20120214803 T . O

The US20120214803 A DT O
present US20120214803 A JJ O
invention US20120214803 A NN O
relates US20120214803 A VBZ O
to US20120214803 A TO O
novel US20120214803 A VB O
hepcidin US20120214803 A JJ I-UN
antagonists US20120214803 A NNS O
, US20120214803 A , O
pharmaceutical US20120214803 A JJ O
compositions US20120214803 A NNS O
comprising US20120214803 A VBG O
them US20120214803 A PRP O
and US20120214803 A CC O
the US20120214803 A DT O
use US20120214803 A NN O
thereof US20120214803 A NN O
as US20120214803 A IN O
medicaments US20120214803 A NNS O
for US20120214803 A IN O
the US20120214803 A DT O
use US20120214803 A NN O
in US20120214803 A IN O
the US20120214803 A DT O
treatment US20120214803 A NN O
of US20120214803 A IN O
iron US20120214803 A NN O
metabolism US20120214803 A NN O
disorders US20120214803 A NNS O
, US20120214803 A , O
such US20120214803 A JJ O
as US20120214803 A IN O
, US20120214803 A , O
in US20120214803 A IN O
particular US20120214803 A JJ O
, US20120214803 A , O
iron US20120214803 A JJ O
deficiency US20120214803 A NN O
diseases US20120214803 A NNS O
and US20120214803 A CC O
anemias US20120214803 A NNS O
, US20120214803 A , O
in US20120214803 A IN O
particular US20120214803 A JJ O
anemias US20120214803 A NNS O
in US20120214803 A IN O
connection US20120214803 A NN O
with US20120214803 A IN O
chronic US20120214803 A JJ O
inflammatory US20120214803 A NN O
diseases US20120214803 A NNS O
. US20120214803 A . O

Method US20100196358 T NNP O
and US20100196358 T CC O
kit US20100196358 T VB O
to US20100196358 T TO O
profile US20100196358 T VB O
tumors US20100196358 T NNS O
by US20100196358 T IN O
biomarker US20100196358 T NN O
analyses US20100196358 T NNS O
including US20100196358 T VBG O
transcriptional US20100196358 T JJ O
factor US20100196358 T NN O
assays US20100196358 T NNS O
. US20100196358 T . O

The US20100196358 A DT O
present US20100196358 A JJ O
invention US20100196358 A NN O
is US20100196358 A VBZ O
related US20100196358 A VBN O
to US20100196358 A TO O
a US20100196358 A DT O
method US20100196358 A NN O
and US20100196358 A CC O
kit US20100196358 A NN O
( US20100196358 A ( O
or US20100196358 A CC O
device US20100196358 A NN O
) US20100196358 A ) O
for US20100196358 A IN O
the US20100196358 A DT O
detection US20100196358 A NN O
and/or US20100196358 A IN O
the US20100196358 A DT O
quantification US20100196358 A NN O
of US20100196358 A IN O
biomarkers US20100196358 A NNS O
related US20100196358 A VBN O
to US20100196358 A TO O
tumorigenesis US20100196358 A NN O
. US20100196358 A . O

Said US20100196358 A NNP O
method US20100196358 A NN O
is US20100196358 A VBZ O
advantageously US20100196358 A RB O
used US20100196358 A VBN O
to US20100196358 A TO O
propose US20100196358 A VB O
or US20100196358 A CC O
adapt US20100196358 A VB O
an US20100196358 A DT O
anti-tumoral US20100196358 A JJ O
therapeutic US20100196358 A JJ O
protocol US20100196358 A NN O
to US20100196358 A TO O
be US20100196358 A VB O
administered US20100196358 A VBN O
to US20100196358 A TO O
a US20100196358 A DT O
subject US20100196358 A NN O
. US20100196358 A . O

Furthermore US20100196358 A RB O
, US20100196358 A , O
said US20100196358 A VBD O
method US20100196358 A NN O
and US20100196358 A CC O
kit US20100196358 A NN O
( US20100196358 A ( O
or US20100196358 A CC O
device US20100196358 A NN O
) US20100196358 A ) O
are US20100196358 A VBP O
a US20100196358 A DT O
technical US20100196358 A JJ O
platform US20100196358 A NN O
for US20100196358 A IN O
the US20100196358 A DT O
identification US20100196358 A NN O
of US20100196358 A IN O
new US20100196358 A JJ O
compounds US20100196358 A NNS O
, US20100196358 A , O
which US20100196358 A WDT O
are US20100196358 A VBP O
preferably US20100196358 A RB O
used US20100196358 A VBN O
at US20100196358 A IN O
( US20100196358 A ( O
a US20100196358 A DT O
) US20100196358 A ) O
specific US20100196358 A JJ O
step US20100196358 A NN O
( US20100196358 A ( O
s US20100196358 A PRP O
) US20100196358 A ) O
of US20100196358 A IN O
an US20100196358 A DT O
anti-tumoral US20100196358 A JJ O
therapeutic US20100196358 A JJ O
protocol US20100196358 A NN O
. US20100196358 A . O

Butylammonium WO2010056672A2 T NNP O
modulators WO2010056672A2 T NNS O
of WO2010056672A2 T IN O
fatty WO2010056672A2 T JJ O
acid WO2010056672A2 T JJ O
transport WO2010056672A2 T NN O
. WO2010056672A2 T . O

Propranolol CN103385859A T NNP O
hydrochloride CN103385859A T JJ O
oral CN103385859A T JJ O
disintegrating CN103385859A T VBG O
tablet CN103385859A T NN O
used CN103385859A T VBN O
for CN103385859A T IN O
treating CN103385859A T VBG O
post-traumatic CN103385859A T JJ O
stress CN103385859A T NN O
disorder CN103385859A T NN O
, CN103385859A T , O
and CN103385859A T CC O
preparation CN103385859A T NN O
method CN103385859A T NN O
thereof CN103385859A T NN O
. CN103385859A T . O

Ustilipides EP1049707B1 T NNS O
, EP1049707B1 T , O
method EP1049707B1 T NN O
for EP1049707B1 T IN O
the EP1049707B1 T DT O
production EP1049707B1 T NN O
and EP1049707B1 T CC O
the EP1049707B1 T DT O
use EP1049707B1 T NN O
thereof EP1049707B1 T NN O
. EP1049707B1 T . O

Bone US20110104278 T NNP O
tissue US20110104278 T NN O
substitute US20110104278 T NN O
, US20110104278 T , O
a US20110104278 T DT O
solidifiable US20110104278 T JJ O
bone US20110104278 T NN O
precursor US20110104278 T NN O
and US20110104278 T CC O
method US20110104278 T NN O
of US20110104278 T IN O
making US20110104278 T VBG O
same US20110104278 T JJ O
. US20110104278 T . O

Composition WO2007102703A1 T NN O
for WO2007102703A1 T IN O
prevention WO2007102703A1 T NN O
or WO2007102703A1 T CC O
treatment WO2007102703A1 T NN O
of WO2007102703A1 T IN O
diseases WO2007102703A1 T NNS O
in WO2007102703A1 T IN O
central WO2007102703A1 T JJ O
nervous WO2007102703A1 T JJ O
system WO2007102703A1 T NN O
comprising WO2007102703A1 T VBG O
extract WO2007102703A1 T NN O
of WO2007102703A1 T IN O
cimicifuga WO2007102703A1 T NN O
heracleifolia WO2007102703A1 T NN O
komarow WO2007102703A1 T NN O
. WO2007102703A1 T . O

Esomeprazole CN102824316A T NNP O
medicated CN102824316A T VBD O
pellet CN102824316A T NN O
and CN102824316A T CC O
preparing CN102824316A T VBG O
method CN102824316A T NN O
thereof CN102824316A T NN O
. CN102824316A T . O

Pharmaceutical US20110135722 T JJ O
formulation US20110135722 T NN O
comprising US20110135722 T VBG O
a US20110135722 T DT O
proton US20110135722 T NN O
pump US20110135722 T NN O
inhibitor US20110135722 T NN O
and US20110135722 T CC O
antacids US20110135722 T NNS O
. US20110135722 T . O

Asarone CN102133211A T NNP O
medical CN102133211A T JJ O
composition CN102133211A T NN O
as CN102133211A T RB O
well CN102133211A T RB O
as CN102133211A T IN O
preparation CN102133211A T NN O
method CN102133211A T NN O
and CN102133211A T CC O
preparation CN102133211A T NN O
thereof CN102133211A T NN O
. CN102133211A T . O

Eutectic CN102702092A T NNP O
of CN102702092A T IN O
two CN102702092A T CD O
curcumin CN102702092A T NN O
organic CN102702092A T JJ O
medicaments CN102702092A T NNS O
and CN102702092A T CC O
preparation CN102702092A T NN O
method CN102702092A T NN O
thereof CN102702092A T NN O
. CN102702092A T . O

Glycogen US20100305207 T NNP O
phosphorylase US20100305207 T NN O
inhibitor US20100305207 T NN O
compound US20100305207 T NN O
and US20100305207 T CC O
pharmaceutical US20100305207 T JJ O
composition US20100305207 T NN O
thereof US20100305207 T NN O
. US20100305207 T . O

Application CN103083342A T NN O
of CN103083342A T IN O
flavan CN103083342A T NN O
compound CN103083342A T NN O
in CN103083342A T IN O
preparing CN103083342A T VBG O
anti-complement CN103083342A T JJ O
medicines CN103083342A T NNS O
. CN103083342A T . O

Ampa CN101189221B T NNP I-UN
receptor CN101189221B T NN I-UN
potentiators CN101189221B T NNS O
. CN101189221B T . O

Polydeoxyribonucleotides WO2012011063A1 T NNS O
( WO2012011063A1 T ( O
pdrns WO2012011063A1 T NNS O
) WO2012011063A1 T ) O
for WO2012011063A1 T IN O
use WO2012011063A1 T NN O
in WO2012011063A1 T IN O
the WO2012011063A1 T DT O
treatment WO2012011063A1 T NN O
of WO2012011063A1 T IN O
metabolic WO2012011063A1 T JJ O
and/or WO2012011063A1 T JJ O
lactic WO2012011063A1 T JJ O
acidosis WO2012011063A1 T NN O
and WO2012011063A1 T CC O
polydeoxyribonucleotide-based WO2012011063A1 T JJ O
compositions WO2012011063A1 T NNS O
for WO2012011063A1 T IN O
the WO2012011063A1 T DT O
aforesaid WO2012011063A1 T NN O
use WO2012011063A1 T NN O
. WO2012011063A1 T . O

Galactosyl CN101307078A T NNP O
thiourea CN101307078A T VBZ O
heterocyclic CN101307078A T JJ O
compounds CN101307078A T NNS O
, CN101307078A T , O
synthetic CN101307078A T JJ O
method CN101307078A T NN O
thereof CN101307078A T NN O
and CN101307078A T CC O
antineoplastic CN101307078A T JJ O
applications CN101307078A T NNS O
. CN101307078A T . O

A WO2006081739A1 T DT O
composition WO2006081739A1 T NN O
for WO2006081739A1 T IN O
treating WO2006081739A1 T VBG O
or WO2006081739A1 T CC O
preventing WO2006081739A1 T VBG O
hyperlipemia WO2006081739A1 T NN O
, WO2006081739A1 T , O
hypertension WO2006081739A1 T NN O
and WO2006081739A1 T CC O
hepatic WO2006081739A1 T JJ O
adipose WO2006081739A1 T JJ O
infiltration WO2006081739A1 T NN O
. WO2006081739A1 T . O

Fe EP2714030A1 T NNP O
( EP2714030A1 T ( O
iii EP2714030A1 T NN O
) EP2714030A1 T ) O
2,4-dioxo-1-carbonyl EP2714030A1 T CD O
complexes EP2714030A1 T NNS O
for EP2714030A1 T IN O
treatment EP2714030A1 T NN O
and EP2714030A1 T CC O
prophylaxis EP2714030A1 T NN O
of EP2714030A1 T IN O
iron EP2714030A1 T NN O
deficiency EP2714030A1 T NN O
symptoms EP2714030A1 T NNS O
and EP2714030A1 T CC O
iron EP2714030A1 T NN O
deficiency EP2714030A1 T NN O
anaemias EP2714030A1 T NN O
. EP2714030A1 T . O

Combinations WO2014114627A1 T NNS O
with WO2014114627A1 T IN O
2-aminoethanesulfonic WO2014114627A1 T JJ O
acid WO2014114627A1 T NN O
. WO2014114627A1 T . O

Composition CA2311128C T NN O
with CA2311128C T IN O
azelaic CA2311128C T JJ O
acid CA2311128C T NN O
. CA2311128C T . O

Dropping CN101011386A T VBG O
pill CN101011386A T NN O
of CN101011386A T IN O
coumarin CN101011386A T NN O
derivative CN101011386A T JJ O
and CN101011386A T CC O
its CN101011386A T PRP$ O
preparation CN101011386A T NN O
and CN101011386A T CC O
application CN101011386A T NN O
. CN101011386A T . O

Disclosed CN101011386A A VBN O
is CN101011386A A VBZ O
a CN101011386A A DT O
dripping CN101011386A A VBG O
pill CN101011386A A NN O
medicament CN101011386A A NN O
containing CN101011386A A VBG O
6 CN101011386A A CD O
, CN101011386A A , O
7-dimethoxycoumarin CN101011386A A JJ O
and/or CN101011386A A NN O
6-hydroxy-7-methylcoumarin CN101011386A A CD O
, CN101011386A A , O
the CN101011386A A DT O
process CN101011386A A NN O
for CN101011386A A IN O
preparation CN101011386A A NN O
and CN101011386A A CC O
its CN101011386A A PRP$ O
use CN101011386A A NN O
in CN101011386A A IN O
preparing CN101011386A A VBG O
liver-protection CN101011386A A NN O
pharmaceuticals CN101011386A A NNS O
. CN101011386A A . O

Treatment US20120157424 T NN O
of US20120157424 T IN O
menopause-associated US20120157424 T JJ O
symptoms US20120157424 T NNS O
. US20120157424 T . O

Drug WO2014072967A1 T NNP O
combination WO2014072967A1 T NN O
comprising WO2014072967A1 T VBG O
a WO2014072967A1 T DT O
glycolysis WO2014072967A1 T NN O
inhibitor WO2014072967A1 T NN O
and WO2014072967A1 T CC O
a WO2014072967A1 T DT O
tyrosine WO2014072967A1 T JJ O
kinase WO2014072967A1 T NN O
inhibitor WO2014072967A1 T NN O
. WO2014072967A1 T . O

The WO2014072967A1 A DT O
inhibitor WO2014072967A1 A NN O
of WO2014072967A1 A IN O
tyrosine WO2014072967A1 A JJ O
kinase WO2014072967A1 A NN O
may WO2014072967A1 A MD O
be WO2014072967A1 A VB O
an WO2014072967A1 A DT O
inhibitor WO2014072967A1 A NN O
of WO2014072967A1 A IN O
at WO2014072967A1 A IN O
least WO2014072967A1 A JJS O
one WO2014072967A1 A CD O
of WO2014072967A1 A IN O
the WO2014072967A1 A DT O
tyrosine WO2014072967A1 A NN O
kinases WO2014072967A1 A VBZ O
Fer WO2014072967A1 A NNP I-UN
and WO2014072967A1 A CC O
FerT WO2014072967A1 A NNP I-UN
. WO2014072967A1 A . I-UN

Bicycloheteroaryl US20090298825 T NNP O
Compounds US20090298825 T NNP O
as US20090298825 T IN O
P2x7 US20090298825 T NNP I-UN
Modulators US20090298825 T NNPS O
and US20090298825 T CC O
Uses US20090298825 T VBZ O
Thereof US20090298825 T NNP O
. US20090298825 T . O

4-amino-thieno CN101263145A T JJ O
[ CN101263145A T NNP O
3,2-C CN101263145A T JJ O
] CN101263145A T NNP O
pyridine-7-carboxylic CN101263145A T JJ O
acid CN101263145A T NN O
derivatives CN101263145A T NNS O
. CN101263145A T . O

The CN101263145A A DT O
compounds CN101263145A A NNS O
exhibit CN101263145A A VBP O
activity CN101263145A A NN O
as CN101263145A A IN O
Raf CN101263145A A NNP I-UN
kinase CN101263145A A NN I-UN
inhibitors CN101263145A A NNS O
and CN101263145A A CC O
therefore CN101263145A A NN O
may CN101263145A A MD O
be CN101263145A A VB O
useful CN101263145A A JJ O
for CN101263145A A IN O
the CN101263145A A DT O
treatment CN101263145A A NN O
of CN101263145A A IN O
diseases CN101263145A A NNS O
mediated CN101263145A A VBN O
by CN101263145A A IN O
said CN101263145A A VBD O
kinases CN101263145A A NNS O
, CN101263145A A , O
especially CN101263145A A RB O
as CN101263145A A IN O
anticancer CN101263145A A JJ O
agents CN101263145A A NNS O
. CN101263145A A . O

Diaryl WO2009041567A1 T NNP O
ketimine WO2009041567A1 T NN O
derivative WO2009041567A1 T JJ O
having WO2009041567A1 T VBG O
antagonistic WO2009041567A1 T JJ O
activity WO2009041567A1 T NN O
on WO2009041567A1 T IN O
melanin-concentrating WO2009041567A1 T NN O
hormone WO2009041567A1 T NN O
receptor WO2009041567A1 T NN O
. WO2009041567A1 T . O

Preparation CN103655465A T NNP O
method CN103655465A T NN O
for CN103655465A T IN O
improving CN103655465A T VBG O
stability CN103655465A T NN O
of CN103655465A T IN O
doxofylline CN103655465A T JJ O
injection CN103655465A T NN O
. CN103655465A T . O

Nucleoside US20100305060 T NNP O
Prodrugs US20100305060 T NNP O
and US20100305060 T CC O
Uses US20100305060 T NNP O
Thereof US20100305060 T NNP O
. US20100305060 T . O

N-substitutedbenzenepropanamide WO2009109850A3 T JJ O
or WO2009109850A3 T CC O
benzenepropenamide WO2009109850A3 T JJ O
derivatives WO2009109850A3 T NNS O
for WO2009109850A3 T IN O
use WO2009109850A3 T NN O
in WO2009109850A3 T IN O
the WO2009109850A3 T DT O
treatment WO2009109850A3 T NN O
of WO2009109850A3 T IN O
pain WO2009109850A3 T NN O
and WO2009109850A3 T CC O
inflammation WO2009109850A3 T NN O
. WO2009109850A3 T . O

Novel CN103083370A T NNP O
application CN103083370A T NN O
of CN103083370A T IN O
total CN103083370A T JJ O
flavones CN103083370A T NNS O
of CN103083370A T IN O
hippophae CN103083370A T NN O
rhamnoides CN103083370A T NNS O
. CN103083370A T . O

Pharmaceutical WO2007077158A1 T JJ O
compositions WO2007077158A1 T NNS O
for WO2007077158A1 T IN O
the WO2007077158A1 T DT O
eradication WO2007077158A1 T NN O
of WO2007077158A1 T IN O
helicobacter WO2007077158A1 T NN O
pylori WO2007077158A1 T NN O
. WO2007077158A1 T . O

Pyrazole WO2012052459A1 T NNP O
compounds WO2012052459A1 T VBZ O
acting WO2012052459A1 T VBG O
against WO2012052459A1 T IN O
allergic WO2012052459A1 T NN O
, WO2012052459A1 T , O
inflammatory WO2012052459A1 T NN O
and WO2012052459A1 T CC O
immune WO2012052459A1 T JJ O
disorders WO2012052459A1 T NNS O
. WO2012052459A1 T . O

Hyperosteogeny CN102188512A T NNP O
plaster CN102188512A T NN O
. CN102188512A T . O

Long-circulation CN101219144A T JJ O
nano-grain CN101219144A T NN O
of CN101219144A T IN O
hydroxycamptothecin CN101219144A T NN O
and CN101219144A T CC O
method CN101219144A T NN O
for CN101219144A T IN O
preparing CN101219144A T VBG O
the CN101219144A T DT O
same CN101219144A T JJ O
. CN101219144A T . O

Glaucocalyxin CN103601641A T NNP O
derivatives CN103601641A T NNS O
and CN103601641A T CC O
application CN103601641A T NN O
thereof CN103601641A T NN O
in CN103601641A T IN O
preparation CN103601641A T NN O
of CN103601641A T IN O
antitumor CN103601641A T NN O
drugs CN103601641A T NNS O
. CN103601641A T . O

Alkanoic US7259175 T NNP O
acids US7259175 T NNS O
substituted US7259175 T VBD O
with US7259175 T IN O
a US7259175 T DT O
group US7259175 T NN O
containing US7259175 T VBG O
pyridinyl- US7259175 T JJ O
, US7259175 T , O
pyrimidinyl- US7259175 T JJ O
or US7259175 T CC O
pyrazinyl-phenyl US7259175 T JJ O
linked US7259175 T VBN O
through US7259175 T IN O
a US7259175 T DT O
thiazolyl- US7259175 T JJ O
or US7259175 T CC O
oxazolyl- US7259175 T JJ O
phenyl US7259175 T NN O
group US7259175 T NN O
; US7259175 T : O
e.g. US7259175 T CC O
, US7259175 T , O
3- US7259175 T JJ O
[ US7259175 T JJ O
4- US7259175 T JJ O
( US7259175 T ( O
2- US7259175 T JJ O
{ US7259175 T ( O
2- US7259175 T JJ O
[ US7259175 T NN O
6- US7259175 T JJ O
( US7259175 T ( O
2-Fluoro-phenyl US7259175 T JJ O
) US7259175 T ) O
-pyridin-3-yl US7259175 T FW O
] US7259175 T FW O
-5-methyl-thiazol-4-yl US7259175 T FW O
} US7259175 T ) O
-ethoxy US7259175 T NNP O
) US7259175 T ) O
-2-methyl-phenyl US7259175 T VBP O
] US7259175 T JJ O
-propionic US7259175 T JJ O
acid US7259175 T NN O
; US7259175 T : O
treating US7259175 T VBG O
diabetes US7259175 T NNS O
and US7259175 T CC O
atherosclerosis US7259175 T NN O
. US7259175 T . O

Pharmaceutical WO2011009039A2 T NNP O
for WO2011009039A2 T IN O
oral WO2011009039A2 T JJ O
delivery WO2011009039A2 T NN O
comprising WO2011009039A2 T VBG O
mgbg WO2011009039A2 T NN O
and WO2011009039A2 T CC O
methods WO2011009039A2 T NNS O
of WO2011009039A2 T IN O
treating WO2011009039A2 T VBG O
disease WO2011009039A2 T NN O
. WO2011009039A2 T . O

Disclosed WO2011009039A2 A VBN O
herein WO2011009039A2 A NNS O
are WO2011009039A2 A VBP O
new WO2011009039A2 A JJ O
oral WO2011009039A2 A JJ O
pharmaceutical WO2011009039A2 A JJ O
compositions WO2011009039A2 A NNS O
of WO2011009039A2 A IN O
MGBG WO2011009039A2 A NNP O
and WO2011009039A2 A CC O
related WO2011009039A2 A VBN O
polyamine WO2011009039A2 A JJ O
analogs WO2011009039A2 A NNS O
, WO2011009039A2 A , O
polyamine WO2011009039A2 A JJ O
biosynthesis WO2011009039A2 A NN O
inhibitors WO2011009039A2 A NNS O
, WO2011009039A2 A , O
polyamine WO2011009039A2 A JJ O
inhibitors WO2011009039A2 A NNS O
of WO2011009039A2 A IN O
AMD-I WO2011009039A2 A NNP I-UN
and WO2011009039A2 A CC O
regulators WO2011009039A2 A NNS O
of WO2011009039A2 A IN O
osteopontin WO2011009039A2 A NN O
, WO2011009039A2 A , O
and WO2011009039A2 A CC O
their WO2011009039A2 A PRP$ O
application WO2011009039A2 A NN O
for WO2011009039A2 A IN O
the WO2011009039A2 A DT O
treatment WO2011009039A2 A NN O
of WO2011009039A2 A IN O
disease WO2011009039A2 A NN O
. WO2011009039A2 A . O

Topical US7892574 T JJ O
administration US7892574 T NN O
of US7892574 T IN O
oxazolidinones US7892574 T NNS O
for US7892574 T IN O
transdermal US7892574 T JJ O
delivery US7892574 T NN O
. US7892574 T . O

Pronephrium CN102793830A T NNP O
triphyllum-rheum CN102793830A T JJ O
officinale CN102793830A T NN O
gel CN102793830A T NN O
and CN102793830A T CC O
preparation CN102793830A T NN O
method CN102793830A T NN O
thereof CN102793830A T NN O
. CN102793830A T . O

Process US6933386 T NN O
for US6933386 T IN O
preparing US6933386 T VBG O
certain US6933386 T JJ O
pyrrolotriazine US6933386 T JJ O
compounds US6933386 T NNS O
. US6933386 T . O

The US6933386 A DT O
formula US6933386 A NN O
I US6933386 A PRP O
compounds US6933386 A VBP O
inhibit US6933386 A VB O
the US6933386 A DT O
tyrosine US6933386 A JJ O
kinase US6933386 A NN O
activity US6933386 A NN O
of US6933386 A IN O
growth US6933386 A NN O
factor US6933386 A NN O
receptors US6933386 A NNS O
such US6933386 A JJ O
as US6933386 A IN O
VEGFR-2 US6933386 A NNP I-UN
and US6933386 A CC O
FGFR-1 US6933386 A NNP I-UN
, US6933386 A , O
thereby US6933386 A RB O
making US6933386 A VBG O
them US6933386 A PRP O
useful US6933386 A JJ O
as US6933386 A IN O
anti-cancer US6933386 A JJ O
agents US6933386 A NNS O
. US6933386 A . O

Preparation CN1629159A T NN O
of CN1629159A T IN O
13-hexyl CN1629159A T JJ O
fibrauretine CN1629159A T NN O
and CN1629159A T CC O
its CN1629159A T PRP$ O
anti-virus CN1629159A T NN O
and CN1629159A T CC O
antibacterial CN1629159A T JJ O
action CN1629159A T NN O
. CN1629159A T . O

Biomaterials US7838510 T NNS O
based US7838510 T VBN O
on US7838510 T IN O
hyaluronic US7838510 T JJ O
acid US7838510 T NN O
for US7838510 T IN O
the US7838510 T DT O
anti-angiogenic US7838510 T JJ O
therapy US7838510 T NN O
in US7838510 T IN O
the US7838510 T DT O
treatment US7838510 T NN O
of US7838510 T IN O
tumors US7838510 T NNS O
. US7838510 T . O

Substituted EP1968958A1 T VBN O
thiazoles EP1968958A1 T NNS O
and EP1968958A1 T CC O
their EP1968958A1 T PRP$ O
use EP1968958A1 T NN O
for EP1968958A1 T IN O
producing EP1968958A1 T VBG O
drugs EP1968958A1 T NNS O
. EP1968958A1 T . O

Compounds CN103648588A T NNS O
for CN103648588A T IN O
the CN103648588A T DT O
treatment CN103648588A T NN O
of CN103648588A T IN O
cancers CN103648588A T NNS O
associated CN103648588A T VBN O
with CN103648588A T IN O
human CN103648588A T JJ O
papillomavirus CN103648588A T NN O
. CN103648588A T . O

Stabilized WO2006011159A3 T NNP O
pharmaceutical WO2006011159A3 T JJ O
composition WO2006011159A3 T NN O
containing WO2006011159A3 T VBG O
rabeprazole WO2006011159A3 T JJ O
sodium WO2006011159A3 T NN O
with WO2006011159A3 T IN O
improved WO2006011159A3 T JJ O
bioavailability WO2006011159A3 T NN O
. WO2006011159A3 T . O

Process WO2006035296A1 T NN O
for WO2006035296A1 T IN O
the WO2006035296A1 T DT O
preparation WO2006035296A1 T NN O
of WO2006035296A1 T IN O
an WO2006035296A1 T DT O
orlistat WO2006035296A1 T JJ O
derivative WO2006035296A1 T JJ O
useful WO2006035296A1 T JJ O
as WO2006035296A1 T IN O
reference WO2006035296A1 T NN O
standard WO2006035296A1 T NN O
in WO2006035296A1 T IN O
the WO2006035296A1 T DT O
determination WO2006035296A1 T NN O
of WO2006035296A1 T IN O
the WO2006035296A1 T DT O
purity WO2006035296A1 T NN O
of WO2006035296A1 T IN O
orlistat WO2006035296A1 T NN O
and WO2006035296A1 T CC O
process WO2006035296A1 T NN O
for WO2006035296A1 T IN O
the WO2006035296A1 T DT O
preparation WO2006035296A1 T NN O
of WO2006035296A1 T IN O
orlistat WO2006035296A1 T NN O
. WO2006035296A1 T . O

Method EP0876612B1 T NNP O
for EP0876612B1 T IN O
identifying EP0876612B1 T VBG O
sex EP0876612B1 T NN O
specific EP0876612B1 T JJ O
and EP0876612B1 T CC O
species EP0876612B1 T NNS O
specific EP0876612B1 T JJ O
molecules EP0876612B1 T NNS O
, EP0876612B1 T , O
molecules EP0876612B1 T NNS O
identified EP0876612B1 T VBD O
using EP0876612B1 T VBG O
the EP0876612B1 T DT O
method EP0876612B1 T NN O
, EP0876612B1 T , O
and EP0876612B1 T CC O
uses EP0876612B1 T NNS O
of EP0876612B1 T IN O
the EP0876612B1 T DT O
molecules EP0876612B1 T NNS O
. EP0876612B1 T . O

Stable WO2014078581A1 T JJ O
thermolysin WO2014078581A1 T NN O
hydrogel WO2014078581A1 T NN O
. WO2014078581A1 T . O

A WO2012128582A3 T DT O
COMPOUND WO2012128582A3 T NNP O
FOR WO2012128582A3 T NNP O
INHIBITING WO2012128582A3 T NNP O
HUMAN WO2012128582A3 T NNP I-UN
11-β-HYDROXY WO2012128582A3 T JJ I-UN
STEROID WO2012128582A3 T NNP I-UN
DEHYDROGENASE WO2012128582A3 T NNP I-UN
TYPE WO2012128582A3 T NNP I-UN
1 WO2012128582A3 T CD O
, WO2012128582A3 T , O
AND WO2012128582A3 T CC O
A WO2012128582A3 T NNP O
PHARMACEUTICAL WO2012128582A3 T NNP O
COMPOSITION WO2012128582A3 T NNP O
COMPRISING WO2012128582A3 T NNP O
THE WO2012128582A3 T NNP O
SAME WO2012128582A3 T NNP O
. WO2012128582A3 T . O

The WO2012128582A3 A DT O
present WO2012128582A3 A JJ O
invention WO2012128582A3 A NN O
relates WO2012128582A3 A VBZ O
to WO2012128582A3 A TO O
a WO2012128582A3 A DT O
novel WO2012128582A3 A JJ O
compound WO2012128582A3 A NN O
, WO2012128582A3 A , O
or WO2012128582A3 A CC O
a WO2012128582A3 A DT O
stereoisomer WO2012128582A3 A NN O
, WO2012128582A3 A , O
or WO2012128582A3 A CC O
a WO2012128582A3 A DT O
pharmaceutically WO2012128582A3 A RB O
acceptable WO2012128582A3 A JJ O
salt WO2012128582A3 A NN O
thereof WO2012128582A3 A NN O
, WO2012128582A3 A , O
and WO2012128582A3 A CC O
a WO2012128582A3 A DT O
pharmaceutical WO2012128582A3 A JJ O
composition WO2012128582A3 A NN O
for WO2012128582A3 A IN O
human-11-beta-hydroxysteroid WO2012128582A3 A JJ I-UN
dehydrogenase WO2012128582A3 A NN I-UN
type WO2012128582A3 A NN I-UN
1 WO2012128582A3 A CD I-UN
( WO2012128582A3 A ( O
11β-HSD1 WO2012128582A3 A JJ I-UN
) WO2012128582A3 A ) O
comprising WO2012128582A3 A VBG O
the WO2012128582A3 A DT O
same WO2012128582A3 A JJ O
. WO2012128582A3 A . O

The WO2012128582A3 A DT O
invention WO2012128582A3 A NN O
provides WO2012128582A3 A VBZ O
a WO2012128582A3 A DT O
compound WO2012128582A3 A NN O
, WO2012128582A3 A , O
which WO2012128582A3 A WDT O
has WO2012128582A3 A VBZ O
excellent WO2012128582A3 A JJ O
activity WO2012128582A3 A NN O
and WO2012128582A3 A CC O
solubility WO2012128582A3 A NN O
and WO2012128582A3 A CC O
is WO2012128582A3 A VBZ O
more WO2012128582A3 A RBR O
efficiently WO2012128582A3 A RB O
formulated WO2012128582A3 A VBN O
and WO2012128582A3 A CC O
delivered WO2012128582A3 A VBN O
, WO2012128582A3 A , O
and WO2012128582A3 A CC O
a WO2012128582A3 A DT O
pharmaceutical WO2012128582A3 A JJ O
composition WO2012128582A3 A NN O
for WO2012128582A3 A IN O
human-11-beta-hydroxysteroid WO2012128582A3 A JJ I-UN
dehydrogenase WO2012128582A3 A NN I-UN
type WO2012128582A3 A NN I-UN
1 WO2012128582A3 A CD O
comprising WO2012128582A3 A VBG O
the WO2012128582A3 A DT O
same WO2012128582A3 A JJ O
. WO2012128582A3 A . O

Anti-inflammatory WO2014162313A1 T JJ O
synergistic WO2014162313A1 T JJ O
combinations WO2014162313A1 T NNS O
comprising WO2014162313A1 T VBG O
omega-3 WO2014162313A1 T JJ O
fatty WO2014162313A1 T JJ O
acid WO2014162313A1 T NN O
and WO2014162313A1 T CC O
tomato WO2014162313A1 T JJ O
lycopene WO2014162313A1 T NN O
. WO2014162313A1 T . O

Topical WO2013067591A1 T JJ O
formulations WO2013067591A1 T NNS O
for WO2013067591A1 T IN O
pain WO2013067591A1 T NN O
management WO2013067591A1 T NN O
. WO2013067591A1 T . O

The WO2013067591A1 A DT O
present WO2013067591A1 A JJ O
disclosure WO2013067591A1 A NN O
relates WO2013067591A1 A VBZ O
generally WO2013067591A1 A RB O
to WO2013067591A1 A TO O
the WO2013067591A1 A DT O
field WO2013067591A1 A NN O
of WO2013067591A1 A IN O
pain WO2013067591A1 A NN O
management WO2013067591A1 A NN O
, WO2013067591A1 A , O
including WO2013067591A1 A VBG O
methods WO2013067591A1 A NNS O
and WO2013067591A1 A CC O
formulations WO2013067591A1 A NNS O
for WO2013067591A1 A IN O
the WO2013067591A1 A DT O
topical WO2013067591A1 A JJ O
management WO2013067591A1 A NN O
of WO2013067591A1 A IN O
pain WO2013067591A1 A NN O
, WO2013067591A1 A , O
such WO2013067591A1 A JJ O
as WO2013067591A1 A IN O
localized WO2013067591A1 A JJ O
pain WO2013067591A1 A NN O
. WO2013067591A1 A . O

The WO2013067591A1 A DT O
present WO2013067591A1 A JJ O
disclosure WO2013067591A1 A NN O
further WO2013067591A1 A RBR O
teaches WO2013067591A1 A NNS O
combination WO2013067591A1 A NN O
therapy WO2013067591A1 A NN O
to WO2013067591A1 A TO O
topically WO2013067591A1 A RB O
ameliorate WO2013067591A1 A VB O
more WO2013067591A1 A JJR O
intense WO2013067591A1 A JJ O
levels WO2013067591A1 A NNS O
of WO2013067591A1 A IN O
pain WO2013067591A1 A NN O
. WO2013067591A1 A . O

Methods WO2007051119A1 T NNS O
and WO2007051119A1 T CC O
compositions WO2007051119A1 T NNS O
of WO2007051119A1 T IN O
parp WO2007051119A1 T JJ I-UN
inhibitors WO2007051119A1 T NNS O
as WO2007051119A1 T IN O
potentiators WO2007051119A1 T NNS O
in WO2007051119A1 T IN O
cancer WO2007051119A1 T NN O
therapy WO2007051119A1 T NN O
. WO2007051119A1 T . O

The WO2007051119A1 A DT O
present WO2007051119A1 A JJ O
disclosure WO2007051119A1 A NN O
relates WO2007051119A1 A VBZ O
generally WO2007051119A1 A RB O
to WO2007051119A1 A TO O
a WO2007051119A1 A DT O
series WO2007051119A1 A NN O
of WO2007051119A1 A IN O
compounds WO2007051119A1 A NNS O
which WO2007051119A1 A WDT O
are WO2007051119A1 A VBP O
derivatives WO2007051119A1 A NNS O
of WO2007051119A1 A IN O
tricyclic WO2007051119A1 A JJ O
compounds WO2007051119A1 A NNS O
which WO2007051119A1 A WDT O
inhibit WO2007051119A1 A VBP O
poly WO2007051119A1 A JJ I-UN
( WO2007051119A1 A ( I-UN
ADP-ribose WO2007051119A1 A NNP I-UN
) WO2007051119A1 A ) I-UN
polymerase WO2007051119A1 A NN I-UN
( WO2007051119A1 A ( O
PARP WO2007051119A1 A NNP I-UN
) WO2007051119A1 A ) O
and WO2007051119A1 A CC O
their WO2007051119A1 A PRP$ O
use WO2007051119A1 A NN O
in WO2007051119A1 A IN O
the WO2007051119A1 A DT O
potentiation WO2007051119A1 A NN O
of WO2007051119A1 A IN O
cancer WO2007051119A1 A NN O
therapies WO2007051119A1 A NNS O
. WO2007051119A1 A . O

Burn CN103479906A T NNP O
ointment CN103479906A T NN O
for CN103479906A T IN O
treating CN103479906A T VBG O
burn CN103479906A T NN O
and CN103479906A T CC O
preparation CN103479906A T NN O
method CN103479906A T NN O
thereof CN103479906A T NN O
. CN103479906A T . O

Cocrystals WO2010069561A1 T NNS O
of WO2010069561A1 T IN O
tramadol WO2010069561A1 T NN O
and WO2010069561A1 T CC O
paracetamol WO2010069561A1 T NN O
. WO2010069561A1 T . O

Medicine CN102671081A T NNP O
for CN102671081A T IN O
treating CN102671081A T VBG O
pimples CN102671081A T NNS O
. CN102671081A T . O

Hypoxia WO2006075642A1 T NNP O
response WO2006075642A1 T NN O
enhancing WO2006075642A1 T VBG O
agent WO2006075642A1 T NN O
. WO2006075642A1 T . O

This WO2006075642A1 A DT O
hypoxia WO2006075642A1 A NN O
response WO2006075642A1 A NN O
enhancing WO2006075642A1 A VBG O
agent WO2006075642A1 A NN O
can WO2006075642A1 A MD O
enhance WO2006075642A1 A VB O
the WO2006075642A1 A DT O
activity WO2006075642A1 A NN O
of WO2006075642A1 A IN O
HIF-1 WO2006075642A1 A NNP I-UN
being WO2006075642A1 A VBG O
a WO2006075642A1 A DT O
hypoxia WO2006075642A1 A NN O
inducing WO2006075642A1 A VBG O
factor WO2006075642A1 A NN O
, WO2006075642A1 A , O
thereby WO2006075642A1 A RB O
realizing WO2006075642A1 A VBG O
an WO2006075642A1 A DT O
enhancement WO2006075642A1 A NN O
of WO2006075642A1 A IN O
hypoxia WO2006075642A1 A JJ O
response WO2006075642A1 A NN O
. WO2006075642A1 A . O

Metformin CN103110600A T NNP O
hydrochloride CN103110600A T NN O
gastric CN103110600A T NN O
floating CN103110600A T VBG O
tablet CN103110600A T NN O
and CN103110600A T CC O
preparation CN103110600A T NN O
method CN103110600A T NN O
thereof CN103110600A T NN O
. CN103110600A T . O

Isoindole WO2007139464A1 T NNP O
derivatives WO2007139464A1 T NNS O
useful WO2007139464A1 T JJ O
for WO2007139464A1 T IN O
treating WO2007139464A1 T VBG O
pain WO2007139464A1 T NN O
, WO2007139464A1 T , O
gastrointestinal WO2007139464A1 T JJ O
diseases WO2007139464A1 T NNS O
and WO2007139464A1 T CC O
cancer WO2007139464A1 T NN O
. WO2007139464A1 T . O

Method CN101955459A T NNP O
for CN101955459A T IN O
preparing CN101955459A T VBG O
blonanserin CN101955459A T NN O
. CN101955459A T . O

The CN101955459A A DT O
invention CN101955459A A NN O
relates CN101955459A A VBZ O
to CN101955459A A TO O
a CN101955459A A DT O
method CN101955459A A NN O
for CN101955459A A IN O
preparing CN101955459A A VBG O
a CN101955459A A DT O
compound CN101955459A A NN O
blonanserin CN101955459A A NN O
in CN101955459A A IN O
a CN101955459A A DT O
formula CN101955459A A NN O
( CN101955459A A ( O
I CN101955459A A PRP O
) CN101955459A A ) O
, CN101955459A A , O
which CN101955459A A WDT O
comprises CN101955459A A VBZ O
a CN101955459A A DT O
step CN101955459A A NN O
of CN101955459A A IN O
transforming CN101955459A A VBG O
a CN101955459A A DT O
compound CN101955459A A NN O
in CN101955459A A IN O
a CN101955459A A DT O
formula CN101955459A A NN O
( CN101955459A A ( O
II CN101955459A A NNP O
) CN101955459A A ) O
and CN101955459A A CC O
N-ethylpiperazine CN101955459A A JJ O
under CN101955459A A IN O
the CN101955459A A DT O
catalysis CN101955459A A NN O
of CN101955459A A IN O
base CN101955459A A NN O
into CN101955459A A IN O
the CN101955459A A DT O
compound CN101955459A A NN O
blonanserin CN101955459A A NN O
in CN101955459A A IN O
the CN101955459A A DT O
formula CN101955459A A NN O
( CN101955459A A ( O
I CN101955459A A PRP O
) CN101955459A A ) O
. CN101955459A A . O

The CN101955459A A DT O
blonanserin CN101955459A A NN O
has CN101955459A A VBZ O
extremely CN101955459A A RB O
valuable CN101955459A A JJ O
pharmacodynamic CN101955459A A JJ O
and CN101955459A A CC O
treatment CN101955459A A NN O
properties CN101955459A A NNS O
in CN101955459A A IN O
the CN101955459A A DT O
aspect CN101955459A A NN O
of CN101955459A A IN O
treating CN101955459A A VBG O
schizophrenia CN101955459A A NN O
. CN101955459A A . O

Metronidazole CN101152176B T NNP O
effervescence CN101152176B T NN O
patch CN101152176B T NN O
and CN101152176B T CC O
technique CN101152176B T NN O
of CN101152176B T IN O
preparing CN101152176B T VBG O
the CN101152176B T DT O
same CN101152176B T JJ O
. CN101152176B T . O

Paramagnetic CN101845033A T NNP O
iron CN101845033A T NN O
and CN101845033A T CC O
selenium CN101845033A T NN O
quercetin CN101845033A T NN O
complex CN101845033A T NN O
and CN101845033A T CC O
preparation CN101845033A T NN O
method CN101845033A T NN O
as CN101845033A T RB O
well CN101845033A T RB O
as CN101845033A T IN O
application CN101845033A T NN O
thereof CN101845033A T NN O
. CN101845033A T . O

Use DE102004008375A1 T NNP O
of DE102004008375A1 T IN O
synergistic DE102004008375A1 T JJ O
combination DE102004008375A1 T NN O
of DE102004008375A1 T IN O
ascorbate DE102004008375A1 T NN O
and DE102004008375A1 T CC O
a DE102004008375A1 T DT O
sympathomimetic DE102004008375A1 T JJ O
for DE102004008375A1 T IN O
topical DE102004008375A1 T JJ O
treatment DE102004008375A1 T NN O
of DE102004008375A1 T IN O
inflammation DE102004008375A1 T NN O
of DE102004008375A1 T IN O
respiratory DE102004008375A1 T NN O
mucosa DE102004008375A1 T NN O
, DE102004008375A1 T , O
particularly DE102004008375A1 T RB O
where DE102004008375A1 T WRB O
caused DE102004008375A1 T VBN O
by DE102004008375A1 T IN O
viral DE102004008375A1 T JJ O
infection DE102004008375A1 T NN O
. DE102004008375A1 T . O

Uses WO2012138003A1 T NNS O
of WO2012138003A1 T IN O
a WO2012138003A1 T DT O
desulfated WO2012138003A1 T JJ O
heparin-bile WO2012138003A1 T JJ O
acid WO2012138003A1 T NN O
derivative WO2012138003A1 T NN O
for WO2012138003A1 T IN O
the WO2012138003A1 T DT O
prevention WO2012138003A1 T NN O
and WO2012138003A1 T CC O
treatment WO2012138003A1 T NN O
of WO2012138003A1 T IN O
inflammatory WO2012138003A1 T JJ O
diseases WO2012138003A1 T NNS O
. WO2012138003A1 T . O

External CN103285049A T JJ O
drug CN103285049A T NN O
for CN103285049A T IN O
treating CN103285049A T VBG O
bums CN103285049A T NNS O
or CN103285049A T CC O
scalds CN103285049A T NNS O
and CN103285049A T CC O
preparation CN103285049A T NN O
method CN103285049A T NN O
thereof CN103285049A T NN O
. CN103285049A T . O

Use EP0800829B2 T NNP O
of EP0800829B2 T IN O
a EP0800829B2 T DT O
pm-1 EP0800829B2 T JJ O
antibody EP0800829B2 T NN O
or EP0800829B2 T CC O
of EP0800829B2 T IN O
a EP0800829B2 T DT O
mh EP0800829B2 T NN O
166 EP0800829B2 T CD O
antibody EP0800829B2 T NN O
for EP0800829B2 T IN O
enhancing EP0800829B2 T VBG O
the EP0800829B2 T DT O
anti-tumor EP0800829B2 T JJ O
effect EP0800829B2 T NN O
of EP0800829B2 T IN O
cisplatin EP0800829B2 T NN O
or EP0800829B2 T CC O
carboplatin EP0800829B2 T NN O
. EP0800829B2 T . O

A EP0800829B2 A DT O
potentiator EP0800829B2 A NN O
for EP0800829B2 A IN O
antitumor EP0800829B2 A NN O
agents EP0800829B2 A NNS O
, EP0800829B2 A , O
for EP0800829B2 A IN O
example EP0800829B2 A NN O
, EP0800829B2 A , O
platinum EP0800829B2 A VB O
compounds EP0800829B2 A NNS O
such EP0800829B2 A JJ O
as EP0800829B2 A IN O
cisplatin EP0800829B2 A NN O
and EP0800829B2 A CC O
carboplatin EP0800829B2 A NN O
, EP0800829B2 A , O
mitomycin EP0800829B2 A FW O
C EP0800829B2 A NNP O
, EP0800829B2 A , O
etc. EP0800829B2 A NN O
, EP0800829B2 A , O
which EP0800829B2 A WDT O
comprises EP0800829B2 A VBZ O
an EP0800829B2 A DT O
interleukin-6 EP0800829B2 A JJ I-UN
( EP0800829B2 A ( O
IL-6 EP0800829B2 A NNP I-UN
) EP0800829B2 A ) O
antagonist EP0800829B2 A NN O
such EP0800829B2 A JJ O
as EP0800829B2 A IN O
an EP0800829B2 A DT O
antibody EP0800829B2 A NN O
against EP0800829B2 A IN O
IL-6 EP0800829B2 A NNP I-UN
, EP0800829B2 A , O
an EP0800829B2 A DT O
antibody EP0800829B2 A NN O
against EP0800829B2 A IN O
IL-6 EP0800829B2 A NNP I-UN
receptor EP0800829B2 A NN I-UN
, EP0800829B2 A , O
an EP0800829B2 A DT O
antibody EP0800829B2 A NN O
against EP0800829B2 A IN O
protein EP0800829B2 A NN O
gp130 EP0800829B2 A NN I-UN
, EP0800829B2 A , O
etc EP0800829B2 A FW O
. EP0800829B2 A . O

Aspartic US7132420 T JJ I-UN
protease US7132420 T NN I-UN
inhibitors US7132420 T NNS O
. US7132420 T . O

The US7132420 A DT O
present US7132420 A JJ O
invention US7132420 A NN O
provides US7132420 A VBZ O
an US7132420 A DT O
aspartic US7132420 A JJ O
proteinase-inhibiting US7132420 A NN O
compound US7132420 A NN O
of US7132420 A IN O
the US7132420 A DT O
formula US7132420 A NN O
: US7132420 A : O
wherein US7132420 A NN O
a US7132420 A DT O
, US7132420 A , O
b US7132420 A NN O
, US7132420 A , O
c US7132420 A NN O
, US7132420 A , O
d US7132420 A NN O
, US7132420 A , O
and US7132420 A CC O
e US7132420 A RB O
, US7132420 A , O
can US7132420 A MD O
be US7132420 A VB O
the US7132420 A DT O
same US7132420 A JJ O
or US7132420 A CC O
different US7132420 A JJ O
and US7132420 A CC O
each US7132420 A DT O
are US7132420 A VBP O
R7 US7132420 A NNP O
, US7132420 A , O
OR7 US7132420 A NNP O
, US7132420 A , O
SR7 US7132420 A NNP O
, US7132420 A , O
NR7R8 US7132420 A NNP O
, US7132420 A , O
NHCOR7 US7132420 A NNP O
, US7132420 A , O
CO2R7 US7132420 A NNP O
, US7132420 A , O
CN US7132420 A NNP O
, US7132420 A , O
NO2 US7132420 A NNP O
, US7132420 A , O
NH2 US7132420 A NNP O
, US7132420 A , O
N3 US7132420 A NNP O
, US7132420 A , O
or US7132420 A CC O
a US7132420 A DT O
halogen US7132420 A NN O
, US7132420 A , O
wherein US7132420 A NN O
R7 US7132420 A NNP O
and US7132420 A CC O
R8 US7132420 A NNP O
are US7132420 A VBP O
independently US7132420 A RB O
H US7132420 A NNP O
or US7132420 A CC O
an US7132420 A DT O
alkyl US7132420 A NN O
. US7132420 A . O

Substituents US7132420 A NNS O
R1 US7132420 A NNP O
or US7132420 A CC O
R2 US7132420 A NNP O
are US7132420 A VBP O
each US7132420 A DT O
H US7132420 A NNP O
or US7132420 A CC O
an US7132420 A DT O
alkyl US7132420 A NN O
. US7132420 A . O

Substituent US7132420 A NNP O
R3 US7132420 A NNP O
is US7132420 A VBZ O
a US7132420 A DT O
straight US7132420 A JJ O
chain US7132420 A NN O
or US7132420 A CC O
branched US7132420 A VBN O
alkyl US7132420 A NN O
, US7132420 A , O
alkenyl US7132420 A NN O
, US7132420 A , O
or US7132420 A CC O
alkynyl US7132420 A JJ O
substituent US7132420 A NN O
, US7132420 A , O
or US7132420 A CC O
is US7132420 A VBZ O
a US7132420 A DT O
cycloalkyl US7132420 A NN O
. US7132420 A . O

Substituent US7132420 A NN O
A US7132420 A DT O
is US7132420 A VBZ O
OH US7132420 A NNP O
, US7132420 A , O
NH2 US7132420 A NNP O
, US7132420 A , O
or US7132420 A CC O
SH US7132420 A NNP O
. US7132420 A . O

Further US7132420 A RB O
provided US7132420 A VBN O
are US7132420 A VBP O
pharmaceutical US7132420 A JJ O
compositions US7132420 A NNS O
, US7132420 A , O
which US7132420 A WDT O
include US7132420 A VBP O
a US7132420 A DT O
therapeutically US7132420 A RB O
effective US7132420 A JJ O
amount US7132420 A NN O
of US7132420 A IN O
at US7132420 A IN O
least US7132420 A JJS O
one US7132420 A CD O
of US7132420 A IN O
the US7132420 A DT O
foregoing US7132420 A NN O
compounds US7132420 A NNS O
, US7132420 A , O
and US7132420 A CC O
therapeutic US7132420 A JJ O
methods US7132420 A NNS O
of US7132420 A IN O
using US7132420 A VBG O
the US7132420 A DT O
foregoing US7132420 A NN O
compounds US7132420 A NNS O
. US7132420 A . O

Therapeutic US20060235045 T JJ O
agent US20060235045 T NN O
for US20060235045 T IN O
chronic US20060235045 T JJ O
obstructive US20060235045 T JJ O
pulmonary US20060235045 T JJ O
disease US20060235045 T NN O
and US20060235045 T CC O
method US20060235045 T NN O
for US20060235045 T IN O
treatment US20060235045 T NN O
for US20060235045 T IN O
chronic US20060235045 T JJ O
obstructive US20060235045 T JJ O
pulmonary US20060235045 T JJ O
disease US20060235045 T NN O
with US20060235045 T IN O
the US20060235045 T DT O
same US20060235045 T JJ O
. US20060235045 T . O

Compositions WO2012096887A2 T NNS O
comprising WO2012096887A2 T VBG O
enzyme-cleavable WO2012096887A2 T JJ O
oxycodone WO2012096887A2 T NN O
prodrug WO2012096887A2 T NN O
. WO2012096887A2 T . O

Such WO2012096887A2 A JJ O
compositions WO2012096887A2 A NNS O
can WO2012096887A2 A MD O
optionally WO2012096887A2 A RB O
provide WO2012096887A2 A VB O
a WO2012096887A2 A DT O
trypsin WO2012096887A2 A NN I-UN
inhibitor WO2012096887A2 A NN O
that WO2012096887A2 A WDT O
interacts WO2012096887A2 A VBZ O
with WO2012096887A2 A IN O
the WO2012096887A2 A DT O
enzyme WO2012096887A2 A NN O
that WO2012096887A2 A WDT O
mediates WO2012096887A2 A VBZ O
the WO2012096887A2 A DT O
controlled WO2012096887A2 A JJ O
release WO2012096887A2 A NN O
of WO2012096887A2 A IN O
oxycodone WO2012096887A2 A NN O
from WO2012096887A2 A IN O
the WO2012096887A2 A DT O
prodrug WO2012096887A2 A NN O
so WO2012096887A2 A RB O
as WO2012096887A2 A IN O
to WO2012096887A2 A TO O
attenuate WO2012096887A2 A VB O
enzymatic WO2012096887A2 A JJ O
cleavage WO2012096887A2 A NN O
of WO2012096887A2 A IN O
the WO2012096887A2 A DT O
prodrug WO2012096887A2 A NN O
. WO2012096887A2 A . O

Tumor US20130011422 T NN O
Antigens US20130011422 T NNP O
for US20130011422 T IN O
the US20130011422 T DT O
Prevention US20130011422 T NNP O
and/or US20130011422 T FW O
Treatment US20130011422 T NNP O
of US20130011422 T IN O
Cancer US20130011422 T NNP O
. US20130011422 T . O

Benzthiazoles EP1263757B1 T NNS O
as EP1263757B1 T IN O
tnf EP1263757B1 T NN I-UN
and EP1263757B1 T CC O
pde-iv EP1263757B1 T JJ I-UN
inhibitors EP1263757B1 T NNS O
. EP1263757B1 T . O

Compounds EP1263757B1 A NNS O
that EP1263757B1 A WDT O
are EP1263757B1 A VBP O
inhibitors EP1263757B1 A NNS O
of EP1263757B1 A IN O
phosphodiesterase EP1263757B1 A NN I-UN
and EP1263757B1 A CC O
have EP1263757B1 A VBP O
therapeutic EP1263757B1 A JJ O
utility EP1263757B1 A NN O
, EP1263757B1 A , O
are EP1263757B1 A VBP O
of EP1263757B1 A IN O
formula EP1263757B1 A NN O
( EP1263757B1 A ( O
i EP1263757B1 A NN O
) EP1263757B1 A ) O
wherein EP1263757B1 A NN O
R1 EP1263757B1 A NNP O
is EP1263757B1 A VBZ O
C3-6 EP1263757B1 A NNP O
cycloalkyl EP1263757B1 A NN O
, EP1263757B1 A , O
or EP1263757B1 A CC O
C1-3 EP1263757B1 A NNP O
alkyl EP1263757B1 A VBP O
optionally EP1263757B1 A RB O
substituted EP1263757B1 A VBN O
with EP1263757B1 A IN O
one EP1263757B1 A CD O
or EP1263757B1 A CC O
more EP1263757B1 A JJR O
fluorine EP1263757B1 A JJ O
atoms EP1263757B1 A NNS O
; EP1263757B1 A : O
R2 EP1263757B1 A NNP O
is EP1263757B1 A VBZ O
C1-6 EP1263757B1 A NNP O
alkyl EP1263757B1 A NN O
, EP1263757B1 A , O
C3-6 EP1263757B1 A NNP O
cycloalkyl EP1263757B1 A NN O
, EP1263757B1 A , O
CF3 EP1263757B1 A NNP O
, EP1263757B1 A , O
CH2CF3 EP1263757B1 A NNP O
, EP1263757B1 A , O
C2F5 EP1263757B1 A NNP O
or EP1263757B1 A CC O
NR4R5 EP1263757B1 A NNP O
; EP1263757B1 A : O
R3 EP1263757B1 A NNP O
is EP1263757B1 A VBZ O
pyrazole EP1263757B1 A JJ O
, EP1263757B1 A , O
imidazole EP1263757B1 A JJ O
or EP1263757B1 A CC O
isoxazole EP1263757B1 A JJ O
group EP1263757B1 A NN O
of EP1263757B1 A IN O
partial EP1263757B1 A JJ O
formula EP1263757B1 A NN O
( EP1263757B1 A ( O
A EP1263757B1 A DT O
) EP1263757B1 A ) O
, EP1263757B1 A , O
( EP1263757B1 A ( O
B EP1263757B1 A NNP O
) EP1263757B1 A ) O
or EP1263757B1 A CC O
( EP1263757B1 A ( O
C EP1263757B1 A NNP O
) EP1263757B1 A ) O
NR4R5 EP1263757B1 A NNP O
is EP1263757B1 A VBZ O
a EP1263757B1 A DT O
nitrogen-containing EP1263757B1 A JJ O
heterocyclic EP1263757B1 A JJ O
ring EP1263757B1 A NN O
; EP1263757B1 A : O
R6 EP1263757B1 A NNP O
is EP1263757B1 A VBZ O
C1-3 EP1263757B1 A NNP O
alkyl EP1263757B1 A NN O
; EP1263757B1 A : O
and EP1263757B1 A CC O
R7 EP1263757B1 A NNP O
and EP1263757B1 A CC O
R8 EP1263757B1 A NNP O
, EP1263757B1 A , O
which EP1263757B1 A WDT O
are EP1263757B1 A VBP O
the EP1263757B1 A DT O
same EP1263757B1 A JJ O
or EP1263757B1 A CC O
different EP1263757B1 A JJ O
, EP1263757B1 A , O
are EP1263757B1 A VBP O
each EP1263757B1 A DT O
H EP1263757B1 A NNP O
, EP1263757B1 A , O
C1-3 EP1263757B1 A NNP O
alkyl EP1263757B1 A NN O
, EP1263757B1 A , O
halogen EP1263757B1 A NN O
, EP1263757B1 A , O
CF3 EP1263757B1 A NNP O
or EP1263757B1 A CC O
CN EP1263757B1 A NNP O
, EP1263757B1 A , O
provided EP1263757B1 A VBD O
that EP1263757B1 A IN O
both EP1263757B1 A DT O
are EP1263757B1 A VBP O
not EP1263757B1 A RB O
H EP1263757B1 A NNP O
; EP1263757B1 A : O
or EP1263757B1 A CC O
a EP1263757B1 A DT O
pharmaceutically-acceptable EP1263757B1 A JJ O
salt EP1263757B1 A NN O
thereof EP1263757B1 A NN O
. EP1263757B1 A . O

Medicament CN101584705B T JJ O
composition CN101584705B T NN O
for CN101584705B T IN O
treating CN101584705B T VBG O
diabetes CN101584705B T NNS O
and CN101584705B T CC O
complications CN101584705B T NNS O
of CN101584705B T IN O
diabetes CN101584705B T NNS O
. CN101584705B T . O

Agents EP0865446B1 T NNS O
for EP0865446B1 T IN O
promoting EP0865446B1 T VBG O
bone EP0865446B1 T NN O
formation EP0865446B1 T NN O
. EP0865446B1 T . O

Oxadiazole WO2008050200A1 T NNP O
compounds WO2008050200A1 T VBZ O
as WO2008050200A1 T IN O
calcium WO2008050200A1 T NN O
channel WO2008050200A1 T NN O
antagonists WO2008050200A1 T NNS O
. WO2008050200A1 T . O

Use US20080292681 T NNP O
of US20080292681 T IN O
Dha US20080292681 T NNP O
, US20080292681 T , O
Epa US20080292681 T NNP O
or US20080292681 T CC O
Dha-Derived US20080292681 T NNP O
Epa US20080292681 T NNP O
for US20080292681 T IN O
Treating US20080292681 T VBG O
a US20080292681 T DT O
Pathology US20080292681 T NNP O
Associated US20080292681 T NNP O
with US20080292681 T IN O
Cellular US20080292681 T NNP O
Oxidative US20080292681 T NNP O
Damage US20080292681 T NNP O
. US20080292681 T . O

Preventives/remedies EP1077069B1 T NNS O
for EP1077069B1 T IN O
hepatic EP1077069B1 T JJ O
cirrhosis EP1077069B1 T NN O
. EP1077069B1 T . O

Novel EP1077069B1 A NNP O
preventives/remedies EP1077069B1 A NNS O
for EP1077069B1 A IN O
hepatic EP1077069B1 A JJ O
cirrhosis EP1077069B1 A NN O
or EP1077069B1 A CC O
bile EP1077069B1 A JJ O
duct EP1077069B1 A NN O
disappearance EP1077069B1 A NN O
syndrome EP1077069B1 A NN O
which EP1077069B1 A WDT O
contain EP1077069B1 A NN O
as EP1077069B1 A IN O
the EP1077069B1 A DT O
active EP1077069B1 A JJ O
ingredient EP1077069B1 A NN O
a EP1077069B1 A DT O
Fas EP1077069B1 A NNP I-UN
antagonist EP1077069B1 A NN O
; EP1077069B1 A : O
and EP1077069B1 A CC O
a EP1077069B1 A DT O
preventive/therapeutic EP1077069B1 A JJ O
method EP1077069B1 A NN O
. EP1077069B1 A . O

Composition CN103393783A T NN O
containing CN103393783A T VBG O
resveratrol CN103393783A T NN O
and CN103393783A T CC O
application CN103393783A T NN O
. CN103393783A T . O

Diazocine US6924305 T NNP O
derivatives US6924305 T NNS O
and US6924305 T CC O
their US6924305 T PRP$ O
use US6924305 T NN O
as US6924305 T IN O
tryptase US6924305 T NN I-UN
inhibitors US6924305 T NNS O
. US6924305 T . O

Compounds US6924305 A NNS O
of US6924305 A IN O
the US6924305 A DT O
formula US6924305 A NN O
I US6924305 A PRP O
, US6924305 A , O
in US6924305 A IN O
which US6924305 A WDT O
B1 US6924305 A NNP O
, US6924305 A , O
B2 US6924305 A NNP O
, US6924305 A , O
R1 US6924305 A NNP O
, US6924305 A , O
R2 US6924305 A NNP O
, US6924305 A , O
R6 US6924305 A NNP O
, US6924305 A , O
R7 US6924305 A NNP O
, US6924305 A , O
K1 US6924305 A NNP O
and US6924305 A CC O
K2 US6924305 A NNP O
are US6924305 A VBP O
as US6924305 A IN O
defined US6924305 A VBN O
in US6924305 A IN O
the US6924305 A DT O
description US6924305 A NN O
are US6924305 A VBP O
novel US6924305 A JJ O
effective US6924305 A JJ O
tryp-tase US6924305 A NN I-UN
inhibitors US6924305 A NNS O
. US6924305 A . O

Novel US20110301233 T NNP O
Polyisoprenylated US20110301233 T VBD O
Benzophenone US20110301233 T NNP O
Derivatives US20110301233 T NNS O
from US20110301233 T IN O
Garcinia US20110301233 T NNP O
paucinervis US20110301233 T NN O
. US20110301233 T . O

These US20110301233 A DT O
compounds US20110301233 A VBZ O
a US20110301233 A DT O
potent US20110301233 A JJ O
ability US20110301233 A NN O
to US20110301233 A TO O
activate US20110301233 A VB O
caspase-3 US20110301233 A NN I-UN
in US20110301233 A IN O
HeLa-C3 US20110301233 A NNP O
cells US20110301233 A NNS O
within US20110301233 A IN O
72 US20110301233 A CD O
hours US20110301233 A NNS O
at US20110301233 A IN O
a US20110301233 A DT O
low US20110301233 A JJ O
concentration US20110301233 A NN O
and US20110301233 A CC O
significant US20110301233 A JJ O
cytotoxicity US20110301233 A NN O
against US20110301233 A IN O
HeLa-C3 US20110301233 A NNP O
cells US20110301233 A NNS O
. US20110301233 A . O

Novel EP1861371A1 T NNP O
compounds EP1861371A1 T VBZ O
ii EP1861371A1 T JJ O
2-pyridine EP1861371A1 T JJ O
derivatives EP1861371A1 T NNS O
as EP1861371A1 T IN O
inhibitors EP1861371A1 T NNS O
of EP1861371A1 T IN O
neutrophile EP1861371A1 T JJ I-UN
elastase.. EP1861371A1 T NN O

The EP1861371A1 A DT O
compounds EP1861371A1 A NNS O
are EP1861371A1 A VBP O
inhibitors EP1861371A1 A NNS O
of EP1861371A1 A IN O
human EP1861371A1 A JJ O
neutrophil EP1861371A1 A JJ I-UN
elastase EP1861371A1 A NN I-UN
. EP1861371A1 A . O

Use EP1613329A1 T NNP O
of EP1613329A1 T IN O
10-hydroxy-10,11-dihydrocarbamazepine EP1613329A1 T JJ O
derivatives EP1613329A1 T NNS O
for EP1613329A1 T IN O
the EP1613329A1 T DT O
treatment EP1613329A1 T NN O
of EP1613329A1 T IN O
affective EP1613329A1 T JJ O
disorders EP1613329A1 T NNS O
. EP1613329A1 T . O

Methods US20120010178 T NNS O
and US20120010178 T CC O
compounds US20120010178 T NNS O
for US20120010178 T IN O
treatment US20120010178 T NN O
of US20120010178 T IN O
neurodegenerative US20120010178 T JJ O
disorders US20120010178 T NNS O
. US20120010178 T . O

Application CN103690547A T NN O
of CN103690547A T IN O
polydatin CN103690547A T NN O
to CN103690547A T TO O
preparation CN103690547A T NN O
of CN103690547A T IN O
medicament CN103690547A T NN O
for CN103690547A T IN O
treating CN103690547A T VBG O
chronic CN103690547A T JJ O
alcoholism CN103690547A T NN O
cerebral CN103690547A T JJ O
injury CN103690547A T NN O
. CN103690547A T . O

The CN103690547A A DT O
polydatin CN103690547A A NN O
has CN103690547A A VBZ O
the CN103690547A A DT O
effect CN103690547A A NN O
of CN103690547A A IN O
protecting CN103690547A A VBG O
nerves CN103690547A A NNS O
, CN103690547A A , O
and CN103690547A A CC O
can CN103690547A A MD O
remarkably CN103690547A A VB O
improve CN103690547A A VB O
the CN103690547A A DT O
nerve CN103690547A A JJ O
injury CN103690547A A NN O
of CN103690547A A IN O
a CN103690547A A DT O
chronic CN103690547A A JJ O
alcoholism CN103690547A A NN O
model CN103690547A A NN O
rat CN103690547A A NN O
and CN103690547A A CC O
reduce CN103690547A A VB O
the CN103690547A A DT O
expression CN103690547A A NN O
of CN103690547A A IN O
the CN103690547A A DT O
hippocampus CN103690547A A NN O
Cdk5 CN103690547A A NNP I-UN
of CN103690547A A IN O
the CN103690547A A DT O
chronic CN103690547A A JJ O
alcoholism CN103690547A A NN O
model CN103690547A A NN O
rat CN103690547A A NN O
. CN103690547A A . O

Application CN103356678A T NN O
of CN103356678A T IN O
Houttuynoid CN103356678A T NNP O
C CN103356678A T NNP O
in CN103356678A T IN O
anti-platelet CN103356678A T JJ O
aggregation CN103356678A T NN O
medicines CN103356678A T NNS O
. CN103356678A T . O

Homocysteine CA2725425A1 T NNP I-UN
synthase CA2725425A1 T NN I-UN
inhibitor CA2725425A1 T NN O
. CA2725425A1 T . O

The CA2725425A1 A DT O
present CA2725425A1 A JJ O
invention CA2725425A1 A NN O
aims CA2725425A1 A NNS O
to CA2725425A1 A TO O
provide CA2725425A1 A VB O
a CA2725425A1 A DT O
homocysteine CA2725425A1 A JJ I-UN
synthase CA2725425A1 A NN I-UN
inhibitor CA2725425A1 A NN O
useful CA2725425A1 A JJ O
for CA2725425A1 A IN O
the CA2725425A1 A DT O
prophylaxis CA2725425A1 A NN O
or CA2725425A1 A CC O
treatment CA2725425A1 A NN O
of CA2725425A1 A IN O
diseases CA2725425A1 A NNS O
involving CA2725425A1 A VBG O
, CA2725425A1 A , O
homocysteine CA2725425A1 A JJ I-UN
synthase CA2725425A1 A NN I-UN
. CA2725425A1 A . O

The CA2725425A1 A DT O
present CA2725425A1 A JJ O
invention CA2725425A1 A NN O
relates CA2725425A1 A VBZ O
to CA2725425A1 A TO O
use CA2725425A1 A VB O
of CA2725425A1 A IN O
a CA2725425A1 A DT O
compound CA2725425A1 A NN O
represented CA2725425A1 A VBN O
by CA2725425A1 A IN O
the CA2725425A1 A DT O
following CA2725425A1 A JJ O
formula CA2725425A1 A NN O
( CA2725425A1 A ( O
I CA2725425A1 A PRP O
) CA2725425A1 A ) O
( CA2725425A1 A ( O
see CA2725425A1 A VB O
formula CA2725425A1 A RB O
I CA2725425A1 A PRP O
) CA2725425A1 A ) O
wherein CA2725425A1 A VBP O
each CA2725425A1 A DT O
symbol CA2725425A1 A NN O
is CA2725425A1 A VBZ O
as CA2725425A1 A RB O
defined CA2725425A1 A VBN O
in CA2725425A1 A IN O
the CA2725425A1 A DT O
DESCRIPTION CA2725425A1 A NNP O
, CA2725425A1 A , O
or CA2725425A1 A CC O
a CA2725425A1 A DT O
pharmacologically CA2725425A1 A RB O
acceptable CA2725425A1 A JJ O
salt CA2725425A1 A NN O
thereof CA2725425A1 A NN O
, CA2725425A1 A , O
or CA2725425A1 A CC O
a CA2725425A1 A DT O
solvate CA2725425A1 A JJ O
thereof CA2725425A1 A NN O
as CA2725425A1 A IN O
a CA2725425A1 A DT O
homocysteine CA2725425A1 A NN I-UN
synthase CA2725425A1 A NN I-UN
inhibitor CA2725425A1 A NN O
. CA2725425A1 A . O

Phosphoric US20050101593 T NNP O
acid US20050101593 T NN O
salt US20050101593 T NN O
of US20050101593 T IN O
an US20050101593 T DT O
integrin US20050101593 T JJ I-UN
receptor US20050101593 T NN I-UN
antagonist US20050101593 T NN O
. US20050101593 T . O

The US20050101593 A DT O
phosphoric US20050101593 A JJ O
acid US20050101593 A NN O
salt US20050101593 A NN O
of US20050101593 A IN O
3- US20050101593 A JJ O
( US20050101593 A ( O
2-methoxy-pyrimidin-5-yl US20050101593 A JJ O
) US20050101593 A ) O
-5-oxo-9- US20050101593 A NN O
( US20050101593 A ( O
6,7,8,9-tetrahydro-5H-pyrido US20050101593 A JJ O
[ US20050101593 A NNP O
2,3-b US20050101593 A JJ O
] US20050101593 A NNP O
azepin-2-yl US20050101593 A NN O
) US20050101593 A ) O
-nonanoic US20050101593 A NN O
acid US20050101593 A NN O
is US20050101593 A VBZ O
a US20050101593 A DT O
potent US20050101593 A JJ O
antagonist US20050101593 A NN O
of US20050101593 A IN O
the US20050101593 A DT O
integrin US20050101593 A NN I-UN
αvβ3 US20050101593 A NNP I-UN
receptor US20050101593 A NN I-UN
and US20050101593 A CC O
is US20050101593 A VBZ O
useful US20050101593 A JJ O
for US20050101593 A IN O
the US20050101593 A DT O
prevention US20050101593 A NN O
and/or US20050101593 A NN O
treatment US20050101593 A NN O
of US20050101593 A IN O
osteoporosis US20050101593 A NN O
and US20050101593 A CC O
vascular US20050101593 A JJ O
restenosis US20050101593 A NN O
, US20050101593 A , O
as US20050101593 A RB O
well US20050101593 A RB O
as US20050101593 A IN O
conditions US20050101593 A NNS O
associated US20050101593 A VBN O
with US20050101593 A IN O
excessive US20050101593 A JJ O
angiogenesis US20050101593 A NN O
, US20050101593 A , O
such US20050101593 A JJ O
as US20050101593 A IN O
macular US20050101593 A JJ O
degeneration US20050101593 A NN O
, US20050101593 A , O
diabetic US20050101593 A JJ O
retinopathy US20050101593 A NN O
, US20050101593 A , O
atherosclerosis US20050101593 A NN O
, US20050101593 A , O
inflammatory US20050101593 A JJ O
arthritis US20050101593 A NN O
, US20050101593 A , O
cancer US20050101593 A NN O
, US20050101593 A , O
and US20050101593 A CC O
metastatic US20050101593 A JJ O
tumor US20050101593 A NN O
growth US20050101593 A NN O
. US20050101593 A . O

Hexahydrobenzisoxazole CN103319427A T NNP O
compounds CN103319427A T NNS O
and CN103319427A T CC O
application CN103319427A T NN O
thereof CN103319427A T NN O
. CN103319427A T . O

The CN103319427A A DT O
invention CN103319427A A NN O
also CN103319427A A RB O
provides CN103319427A A VBZ O
a CN103319427A A DT O
synthesis CN103319427A A NN O
method CN103319427A A NN O
of CN103319427A A IN O
the CN103319427A A DT O
hexahydrobenzisoxazole CN103319427A A JJ O
compounds CN103319427A A NNS O
and CN103319427A A CC O
an CN103319427A A DT O
application CN103319427A A NN O
of CN103319427A A IN O
the CN103319427A A DT O
hexahydrobenzisoxazole CN103319427A A JJ O
compounds CN103319427A A NNS O
in CN103319427A A IN O
the CN103319427A A DT O
activation CN103319427A A NN O
of CN103319427A A IN O
a CN103319427A A DT O
PPAR-gamma CN103319427A A JJ I-UN
channel CN103319427A A NN I-UN
. CN103319427A A . O

Wound CN102415988B T IN O
healing CN102415988B T VBG O
gel CN102415988B T NN O
and CN102415988B T CC O
preparation CN102415988B T NN O
process CN102415988B T NN O
thereof CN102415988B T NN O
. CN102415988B T . O

Application CN103040853A T NN O
of CN103040853A T IN O
gardenia CN103040853A T NN O
sesou CN103040853A T NN O
as CN103040853A T IN O
vision CN103040853A T NN O
care CN103040853A T NN O
drug CN103040853A T NN O
ingredient CN103040853A T NN O
. CN103040853A T . O

The CN103040853A A DT O
invention CN103040853A A NN O
provides CN103040853A A VBZ O
an CN103040853A A DT O
application CN103040853A A NN O
of CN103040853A A IN O
a CN103040853A A DT O
new CN103040853A A JJ O
ingredient-gardenia CN103040853A A JJ O
sesou CN103040853A A NN O
as CN103040853A A IN O
a CN103040853A A DT O
vision CN103040853A A NN O
care CN103040853A A NN O
drug CN103040853A A NN O
ingredient CN103040853A A NN O
. CN103040853A A . O

The CN103040853A A DT O
drug CN103040853A A NN O
can CN103040853A A MD O
improve CN103040853A A VB O
the CN103040853A A DT O
blood CN103040853A A NN O
circulation CN103040853A A NN O
of CN103040853A A IN O
eyes CN103040853A A NNS O
, CN103040853A A , O
protect CN103040853A A VBP O
the CN103040853A A DT O
retina CN103040853A A NN O
against CN103040853A A IN O
the CN103040853A A DT O
harm CN103040853A A NN O
of CN103040853A A IN O
ultraviolet CN103040853A A JJ O
visible CN103040853A A JJ O
light CN103040853A A NN O
, CN103040853A A , O
effectively CN103040853A A RB O
protect CN103040853A A VBP O
the CN103040853A A DT O
eyes CN103040853A A NNS O
, CN103040853A A , O
and CN103040853A A CC O
prevent CN103040853A A NN O
and CN103040853A A CC O
reduce CN103040853A A VB O
the CN103040853A A DT O
possibility CN103040853A A NN O
of CN103040853A A IN O
myopia CN103040853A A NN O
, CN103040853A A , O
hyperopia CN103040853A A NN O
and CN103040853A A CC O
amblyopia CN103040853A A NN O
, CN103040853A A , O
and CN103040853A A CC O
the CN103040853A A DT O
preparation CN103040853A A NN O
is CN103040853A A VBZ O
simple CN103040853A A JJ O
. CN103040853A A . O

The CN103040853A A DT O
gardenia CN103040853A A NN O
sesou CN103040853A A NN O
is CN103040853A A VBZ O
a CN103040853A A DT O
new-structural CN103040853A A JJ O
compound CN103040853A A NN O
which CN103040853A A WDT O
is CN103040853A A VBZ O
extracted CN103040853A A VBN O
and CN103040853A A CC O
separated CN103040853A A VBN O
from CN103040853A A IN O
gardenia CN103040853A A NN O
, CN103040853A A , O
and CN103040853A A CC O
the CN103040853A A DT O
molecular CN103040853A A JJ O
formula CN103040853A A NN O
of CN103040853A A IN O
the CN103040853A A DT O
gardenia CN103040853A A NN O
sesou CN103040853A A NN O
is CN103040853A A VBZ O
C42H60O14 CN103040853A A NNP O
. CN103040853A A . O

The CN103040853A A DT O
gardenia CN103040853A A NN O
sesou CN103040853A A NN O
can CN103040853A A MD O
be CN103040853A A VB O
applied CN103040853A A VBN O
to CN103040853A A TO O
the CN103040853A A DT O
field CN103040853A A NN O
of CN103040853A A IN O
vision CN103040853A A NN O
care CN103040853A A NN O
. CN103040853A A . O

Controlled US20120035259 T JJ O
Release US20120035259 T NNP O
of US20120035259 T IN O
Nitric US20120035259 T NNP O
Oxide US20120035259 T NNP O
And US20120035259 T CC O
Drugs US20120035259 T NNP O
From US20120035259 T NNP O
Functionalized US20120035259 T NNP O
Macromers US20120035259 T NNP O
And US20120035259 T CC O
Oligomers US20120035259 T NNP O
. US20120035259 T . O

DERIVATIVE US20130109752 T NNP O
OF US20130109752 T NNP O
18beta-GLYCYRRHETINIC US20130109752 T JJ O
ACID US20130109752 T NNP O
APT US20130109752 T NNP O
TO US20130109752 T NNP O
SUPPRESS US20130109752 T NNP O
CANCER US20130109752 T NNP O
CELLS US20130109752 T NNP O
. US20130109752 T . O

Nutrient US20080241101 T NNP O
broth US20080241101 T CC O
comprising US20080241101 T VBG O
serine US20080241101 T JJ I-UN
protease US20080241101 T NN I-UN
inhibitors US20080241101 T NNS O
and US20080241101 T CC O
cytokine US20080241101 T NN I-UN
for US20080241101 T IN O
use US20080241101 T NN O
propgation US20080241101 T NN O
of US20080241101 T IN O
skin US20080241101 T JJ O
basement US20080241101 T NN O
membrane US20080241101 T NN O
tissues US20080241101 T NNS O
; US20080241101 T : O
regenerative US20080241101 T JJ O
medicine US20080241101 T NN O
; US20080241101 T : O
tissue US20080241101 T NN O
repair US20080241101 T NN O
. US20080241101 T . O

The US20080241101 A DT O
invention US20080241101 A NN O
provides US20080241101 A VBZ O
an US20080241101 A DT O
epidermal US20080241101 A JJ O
basement US20080241101 A NN O
membrane US20080241101 A NN O
structure US20080241101 A NN O
formation US20080241101 A NN O
accelerating US20080241101 A VBG O
preparation US20080241101 A NN O
and US20080241101 A CC O
a US20080241101 A DT O
skin US20080241101 A JJ O
external US20080241101 A JJ O
preparation US20080241101 A NN O
comprising US20080241101 A VBG O
a US20080241101 A DT O
serine US20080241101 A JJ I-UN
protease US20080241101 A NN I-UN
inhibitor US20080241101 A NN O
, US20080241101 A , O
and US20080241101 A CC O
optionally US20080241101 A RB O
an US20080241101 A DT O
accelerator US20080241101 A NN O
of US20080241101 A IN O
production US20080241101 A NN O
of US20080241101 A IN O
extracellular US20080241101 A JJ I-UN
matrix US20080241101 A NN I-UN
protein US20080241101 A NN I-UN
components US20080241101 A NNS O
of US20080241101 A IN O
the US20080241101 A DT O
epidermal US20080241101 A JJ O
basement US20080241101 A NN O
membrane US20080241101 A NN O
. US20080241101 A . O

It US20080241101 A PRP O
also US20080241101 A RB O
provides US20080241101 A VBZ O
, US20080241101 A , O
as US20080241101 A IN O
a US20080241101 A DT O
means US20080241101 A NN O
for US20080241101 A IN O
producing US20080241101 A VBG O
artificial US20080241101 A JJ O
skin US20080241101 A NN O
having US20080241101 A VBG O
an US20080241101 A DT O
adequately US20080241101 A RB O
formed US20080241101 A VBN O
basement US20080241101 A NN O
membrane US20080241101 A NN O
, US20080241101 A , O
an US20080241101 A DT O
artificial US20080241101 A JJ O
skin-forming US20080241101 A NN O
medium US20080241101 A NN O
which US20080241101 A WDT O
comprises US20080241101 A VBZ O
a US20080241101 A DT O
serine US20080241101 A JJ I-UN
protease US20080241101 A NN I-UN
inhibitor US20080241101 A NN O
, US20080241101 A , O
and US20080241101 A CC O
optionally US20080241101 A RB O
an US20080241101 A DT O
accelerator US20080241101 A NN O
of US20080241101 A IN O
production US20080241101 A NN O
of US20080241101 A IN O
extracellular US20080241101 A JJ I-UN
matrix US20080241101 A NN I-UN
protein US20080241101 A NN I-UN
components US20080241101 A NNS O
of US20080241101 A IN O
the US20080241101 A DT O
epidermal US20080241101 A JJ O
basement US20080241101 A NN O
membrane US20080241101 A NN O
and US20080241101 A CC O
a US20080241101 A DT O
matrix US20080241101 A JJ I-UN
metalloprotease US20080241101 A NN I-UN
inhibitor US20080241101 A NN O
, US20080241101 A , O
as US20080241101 A RB O
well US20080241101 A RB O
as US20080241101 A IN O
a US20080241101 A DT O
method US20080241101 A NN O
for US20080241101 A IN O
producing US20080241101 A VBG O
the US20080241101 A DT O
same US20080241101 A JJ O
. US20080241101 A . O

Liver CN103191102A T RB O
protecting CN103191102A T VBG O
application CN103191102A T NN O
of CN103191102A T IN O
piperic CN103191102A T JJ O
acid CN103191102A T NN O
. CN103191102A T . O

The CN103191102A A DT O
invention CN103191102A A NN O
discloses CN103191102A A VBZ O
liver CN103191102A A RB O
protecting CN103191102A A JJ O
application CN103191102A A NN O
of CN103191102A A IN O
a CN103191102A A DT O
piperic CN103191102A A JJ O
acid CN103191102A A NN O
and CN103191102A A CC O
application CN103191102A A NN O
of CN103191102A A IN O
the CN103191102A A DT O
piperic CN103191102A A JJ O
acid CN103191102A A NN O
in CN103191102A A IN O
medicaments CN103191102A A NNS O
or CN103191102A A CC O
health-care CN103191102A A NN O
products CN103191102A A NNS O
for CN103191102A A IN O
reducing CN103191102A A VBG O
alanine CN103191102A A JJ I-UN
transaminase CN103191102A A NN I-UN
( CN103191102A A ( O
ALT CN103191102A A NNP I-UN
) CN103191102A A ) O
and CN103191102A A CC O
aspartate CN103191102A A JJ I-UN
aminotransferase CN103191102A A NN I-UN
( CN103191102A A ( O
AST CN103191102A A NNP I-UN
) CN103191102A A ) O
. CN103191102A A . O

Compositions WO2007148308A3 T NNS O
and WO2007148308A3 T CC O
kits WO2007148308A3 T NNS O
comprising WO2007148308A3 T VBG O
a WO2007148308A3 T DT O
melatonin WO2007148308A3 T NN O
component WO2007148308A3 T NN O
and WO2007148308A3 T CC O
an WO2007148308A3 T DT O
omega-3-fatty WO2007148308A3 T JJ O
acid WO2007148308A3 T NN O
component WO2007148308A3 T NN O
. WO2007148308A3 T . O

Acid WO2006133498A1 T NNP O
addition WO2006133498A1 T NN O
salts WO2006133498A1 T NNS O
of WO2006133498A1 T IN O
n-ethyi-n'- WO2006133498A1 T JJ O
[ WO2006133498A1 T JJ O
2-methoxy-4- WO2006133498A1 T JJ O
( WO2006133498A1 T ( O
5-methyi-4- WO2006133498A1 T JJ O
{ WO2006133498A1 T ( O
[ WO2006133498A1 T NNP O
( WO2006133498A1 T ( O
1s WO2006133498A1 T CD O
) WO2006133498A1 T ) O
-1-pyridin-3-ylbutyi WO2006133498A1 T NN O
] WO2006133498A1 T NNP O
amino WO2006133498A1 T NN O
} WO2006133498A1 T ) O
pyrimidin- WO2006133498A1 T JJ O
2-yl WO2006133498A1 T JJ O
) WO2006133498A1 T ) O
phenyl WO2006133498A1 T NN O
] WO2006133498A1 T NNP O
urea WO2006133498A1 T NN O
and WO2006133498A1 T CC O
uses WO2006133498A1 T VBZ O
thereof WO2006133498A1 T NN O
. WO2006133498A1 T . O

including US20080019915 T VBG O
cystic US20080019915 T JJ I-UN
fibrosis US20080019915 T NN I-UN
transmembrane US20080019915 T NN I-UN
conductance US20080019915 T NN I-UN
regulator US20080019915 T NN I-UN
( US20080019915 T ( O
`` US20080019915 T `` O
CFTR US20080019915 T NNP I-UN
'' US20080019915 T '' O
) US20080019915 T ) O
; US20080019915 T : O
N US20080019915 T NNP O
[ US20080019915 T VBZ O
6- US20080019915 T JJ O
( US20080019915 T ( O
2-hydroxymethylphenyl-1yl US20080019915 T JJ O
) US20080019915 T ) O
-5-methylpyrimidine US20080019915 T NN O
] US20080019915 T NN O
[ US20080019915 T NNP O
( US20080019915 T ( O
4-methoxophenyl-1-yl US20080019915 T JJ O
) US20080019915 T ) O
cyclopopyl US20080019915 T NN O
] US20080019915 T NNP O
-amide US20080019915 T NNP O
; US20080019915 T : O
genetic US20080019915 T JJ O
disorders US20080019915 T NNS O
; US20080019915 T : O
respiratory US20080019915 T NN O
system US20080019915 T NN O
disorders US20080019915 T NNS O
, US20080019915 T , O
cystic US20080019915 T JJ O
fibrosis US20080019915 T NN O
, US20080019915 T , O
hereditary US20080019915 T JJ O
emphysema US20080019915 T NN O
and US20080019915 T CC O
hemochromatosis US20080019915 T NN O
, US20080019915 T , O
coagulation-fibrinolysis US20080019915 T NN O
. US20080019915 T . O

Compounds US20080019915 A NNS O
of US20080019915 A IN O
the US20080019915 A DT O
present US20080019915 A JJ O
invention US20080019915 A NN O
, US20080019915 A , O
and US20080019915 A CC O
pharmaceutically US20080019915 A RB O
acceptable US20080019915 A JJ O
compositions US20080019915 A NNS O
thereof US20080019915 A NN O
, US20080019915 A , O
are US20080019915 A VBP O
useful US20080019915 A JJ O
as US20080019915 A IN O
modulators US20080019915 A NNS O
of US20080019915 A IN O
ATP-Binding US20080019915 A NNP I-UN
Cassette US20080019915 A NNP I-UN
( US20080019915 A ( I-UN
“ABC” US20080019915 A NNP I-UN
) US20080019915 A ) I-UN
transporters US20080019915 A NNS I-UN
or US20080019915 A CC O
fragments US20080019915 A NNS O
thereof US20080019915 A NNS O
, US20080019915 A , O
including US20080019915 A VBG O
Cystic US20080019915 A JJ I-UN
Fibrosis US20080019915 A NNP I-UN
Transmembrane US20080019915 A NNP I-UN
Conductance US20080019915 A NNP I-UN
Regulator US20080019915 A NNP I-UN
( US20080019915 A ( O
“CFTR” US20080019915 A NNP O
) US20080019915 A ) O
. US20080019915 A . O

The US20080019915 A DT O
present US20080019915 A JJ O
invention US20080019915 A NN O
also US20080019915 A RB O
relates US20080019915 A VBZ O
to US20080019915 A TO O
methods US20080019915 A NNS O
of US20080019915 A IN O
treating US20080019915 A VBG O
ABC US20080019915 A NNP I-UN
transporter US20080019915 A NN I-UN
mediated US20080019915 A VBD O
diseases US20080019915 A NNS O
using US20080019915 A VBG O
compounds US20080019915 A NNS O
of US20080019915 A IN O
the US20080019915 A DT O
present US20080019915 A JJ O
invention US20080019915 A NN O
. US20080019915 A . O

Triblock WO2013111801A1 T NNP O
copolymer WO2013111801A1 T NN O
and WO2013111801A1 T CC O
use WO2013111801A1 T NN O
thereof WO2013111801A1 T NN O
. WO2013111801A1 T . O

Disinfecting CN102657676A T VBG O
, CN102657676A T , O
vein-expanding CN102657676A T JJ O
and CN102657676A T CC O
pain-relieving CN102657676A T JJ O
patch CN102657676A T NN O
for CN102657676A T IN O
skin CN102657676A T NN O
. CN102657676A T . O

Transmucosal US20090208425 T NNP O
administration US20090208425 T NN O
of US20090208425 T IN O
2,3-dimethoxy-5-methyl-6- US20090208425 T JJ O
( US20090208425 T ( O
10-hydroxydecyl US20090208425 T JJ O
) US20090208425 T ) O
-1,4-benzoquinone US20090208425 T NN O
. US20090208425 T . O

Combinations CN101304747A T NNS O
comprising CN101304747A T VBG O
a CN101304747A T DT O
VEGF CN101304747A T NNP I-UN
receptor CN101304747A T NN I-UN
inhibitor CN101304747A T NN O
and CN101304747A T CC O
a CN101304747A T DT O
penetration CN101304747A T NN O
enhancer CN101304747A T NN O
. CN101304747A T . O

The CN101304747A A DT O
present CN101304747A A JJ O
invention CN101304747A A NN O
relates CN101304747A A VBZ O
to CN101304747A A TO O
a CN101304747A A DT O
composition CN101304747A A NN O
comprising CN101304747A A VBG O
a CN101304747A A DT O
VEGF CN101304747A A NNP I-UN
receptor CN101304747A A NN I-UN
inhibitor CN101304747A A NN O
and CN101304747A A CC O
a CN101304747A A DT O
penetration CN101304747A A NN O
enhancer CN101304747A A NN O
and CN101304747A A CC O
uses CN101304747A A VBZ O
thereof CN101304747A A NN O
, CN101304747A A , O
for CN101304747A A IN O
the CN101304747A A DT O
treatment CN101304747A A NN O
of CN101304747A A IN O
dermatological CN101304747A A JJ O
diseases CN101304747A A NNS O
selected CN101304747A A VBN O
from CN101304747A A IN O
psoriasis CN101304747A A NN O
, CN101304747A A , O
atopic CN101304747A A NN O
dermatitis CN101304747A A NN O
and CN101304747A A CC O
acne CN101304747A A NN O
. CN101304747A A . O

Novel WO2013179309A1 T NNP O
compounds WO2013179309A1 T VBZ O
as WO2013179309A1 T IN O
memory WO2013179309A1 T NN O
enhancers WO2013179309A1 T NNS O
. WO2013179309A1 T . O

The WO2013179309A1 A DT O
present WO2013179309A1 A JJ O
invention WO2013179309A1 A NN O
relates WO2013179309A1 A VBZ O
to WO2013179309A1 A TO O
a WO2013179309A1 A DT O
new WO2013179309A1 A JJ O
series WO2013179309A1 A NN O
of WO2013179309A1 A IN O
chemical WO2013179309A1 A JJ O
compounds WO2013179309A1 A NNS O
with WO2013179309A1 A IN O
a WO2013179309A1 A DT O
novel WO2013179309A1 A JJ O
norneolignan WO2013179309A1 A JJ O
skeleton WO2013179309A1 A NN O
( WO2013179309A1 A ( O
chemical WO2013179309A1 A JJ O
formula WO2013179309A1 A NN O
I WO2013179309A1 A PRP O
) WO2013179309A1 A ) O
possessing WO2013179309A1 A VBG O
a WO2013179309A1 A DT O
biological WO2013179309A1 A JJ O
activity WO2013179309A1 A NN O
on WO2013179309A1 A IN O
the WO2013179309A1 A DT O
central WO2013179309A1 A JJ O
nervous WO2013179309A1 A JJ O
system WO2013179309A1 A NN O
( WO2013179309A1 A ( O
CNS WO2013179309A1 A NNP O
) WO2013179309A1 A ) O
, WO2013179309A1 A , O
especially WO2013179309A1 A RB O
memory-enhancing WO2013179309A1 A JJ O
and WO2013179309A1 A CC O
acetylcholinesterase WO2013179309A1 A JJ I-UN
inhibitory WO2013179309A1 A NN O
activity WO2013179309A1 A NN O
, WO2013179309A1 A , O
individually WO2013179309A1 A RB O
, WO2013179309A1 A , O
or WO2013179309A1 A CC O
in WO2013179309A1 A IN O
combination WO2013179309A1 A NN O
thereof WO2013179309A1 A NN O
. WO2013179309A1 A . O

Pharmaceutical CN101129388B T JJ O
composition CN101129388B T NN O
of CN101129388B T IN O
compound CN101129388B T NN O
fat-soluble CN101129388B T JJ O
vitamin CN101129388B T NN O
and CN101129388B T CC O
method CN101129388B T NN O
of CN101129388B T IN O
preparing CN101129388B T VBG O
the CN101129388B T DT O
same CN101129388B T JJ O
. CN101129388B T . O

ORAL US20110159088 T NNP O
PHARMACEUTICAL US20110159088 T NNP O
FOR US20110159088 T NNP O
BASED US20110159088 T NNP O
ON US20110159088 T NNP O
AT US20110159088 T NNP O
LEAST US20110159088 T NNP O
ONE US20110159088 T NNP O
ACTIVE US20110159088 T NNP O
PRINCIPLE US20110159088 T NNP O
WHOSE US20110159088 T NNP O
SOLUBILITY US20110159088 T NNP O
VARIES US20110159088 T NNP O
AS US20110159088 T IN O
A US20110159088 T NNP O
FUNCTION US20110159088 T NNP O
OF US20110159088 T IN O
THE US20110159088 T NNP O
GASTRIC US20110159088 T NNP O
pH US20110159088 T NN O
CONDITIONS US20110159088 T NNP O
. US20110159088 T . O

N- WO2014140065A1 T NNP O
( WO2014140065A1 T ( O
4- WO2014140065A1 T JJ O
( WO2014140065A1 T ( O
azaindazol-6-yl WO2014140065A1 T JJ O
) WO2014140065A1 T ) O
-phenyl WO2014140065A1 T NN O
) WO2014140065A1 T ) O
-sulfonamides WO2014140065A1 T NNS O
and WO2014140065A1 T CC O
their WO2014140065A1 T PRP$ O
use WO2014140065A1 T NN O
as WO2014140065A1 T IN O
pharmaceuticals WO2014140065A1 T NNS O
. WO2014140065A1 T . O

The WO2014140065A1 A DT O
compounds WO2014140065A1 A NNS O
of WO2014140065A1 A IN O
the WO2014140065A1 A DT O
formula WO2014140065A1 A NN O
I WO2014140065A1 A PRP O
are WO2014140065A1 A VBP O
valuable WO2014140065A1 A JJ O
pharmacologically WO2014140065A1 A RB O
active WO2014140065A1 A JJ O
compounds WO2014140065A1 A NNS O
which WO2014140065A1 A WDT O
modulate WO2014140065A1 A VBP O
protein WO2014140065A1 A JJ O
kinase WO2014140065A1 A NN O
activity WO2014140065A1 A NN O
, WO2014140065A1 A , O
specifically WO2014140065A1 A RB O
the WO2014140065A1 A DT O
activity WO2014140065A1 A NN O
of WO2014140065A1 A IN O
serum WO2014140065A1 A NN O
and WO2014140065A1 A CC O
glucocorticoid WO2014140065A1 A NN O
regulated WO2014140065A1 A VBN O
kinase WO2014140065A1 A NN O
( WO2014140065A1 A ( O
SGK WO2014140065A1 A NNP O
) WO2014140065A1 A ) O
, WO2014140065A1 A , O
in WO2014140065A1 A IN O
particular WO2014140065A1 A JJ O
of WO2014140065A1 A IN O
serum WO2014140065A1 A NN I-UN
and WO2014140065A1 A CC I-UN
glucocorticoid WO2014140065A1 A NN I-UN
regulated WO2014140065A1 A VBD I-UN
kinase WO2014140065A1 A NN I-UN
isoform WO2014140065A1 A NN I-UN
1 WO2014140065A1 A CD I-UN
( WO2014140065A1 A ( O
SGK-1 WO2014140065A1 A NNP I-UN
, WO2014140065A1 A , O
SGK1 WO2014140065A1 A NNP I-UN
) WO2014140065A1 A ) O
, WO2014140065A1 A , O
and WO2014140065A1 A CC O
are WO2014140065A1 A VBP O
suitable WO2014140065A1 A JJ O
for WO2014140065A1 A IN O
the WO2014140065A1 A DT O
treatment WO2014140065A1 A NN O
of WO2014140065A1 A IN O
diseases WO2014140065A1 A NNS O
in WO2014140065A1 A IN O
which WO2014140065A1 A WDT O
SGK WO2014140065A1 A NNP O
activity WO2014140065A1 A NN O
is WO2014140065A1 A VBZ O
inappropriate WO2014140065A1 A JJ O
, WO2014140065A1 A , O
for WO2014140065A1 A IN O
example WO2014140065A1 A NN O
degenerative WO2014140065A1 A JJ O
joint WO2014140065A1 A NN O
disorders WO2014140065A1 A NNS O
or WO2014140065A1 A CC O
inflammatory WO2014140065A1 A JJ O
processes WO2014140065A1 A NNS O
such WO2014140065A1 A JJ O
as WO2014140065A1 A IN O
osteoarthritis WO2014140065A1 A NN O
or WO2014140065A1 A CC O
rheumatism WO2014140065A1 A NN O
. WO2014140065A1 A . O

Compound CN1682737B T NNP O
dimethylbiguanide/glipizide CN1682737B T NN O
control CN1682737B T NN O
release CN1682737B T NN O
tablet CN1682737B T NN O
and CN1682737B T CC O
preparing CN1682737B T VBG O
method CN1682737B T NN O
. CN1682737B T . O

Composition CA2251840C T NN O
, CA2251840C T , O
barrier CA2251840C T NN O
film CA2251840C T NN O
, CA2251840C T , O
and CA2251840C T CC O
method CA2251840C T NN O
for CA2251840C T IN O
preventing CA2251840C T VBG O
contact CA2251840C T NN O
dermatitis CA2251840C T NN O
. CA2251840C T . O

The CA2251840C A DT O
present CA2251840C A JJ O
invention CA2251840C A NN O
relates CA2251840C A VBZ O
to CA2251840C A TO O
a CA2251840C A DT O
composition CA2251840C A NN O
, CA2251840C A , O
and CA2251840C A CC O
a CA2251840C A DT O
method CA2251840C A NN O
for CA2251840C A IN O
preventing CA2251840C A VBG O
or CA2251840C A CC O
reducing CA2251840C A VBG O
contact CA2251840C A JJ O
dermatitis CA2251840C A NN O
. CA2251840C A . O

The CA2251840C A DT O
composition CA2251840C A NN O
contains CA2251840C A VBZ O
a CA2251840C A DT O
polysaccharide CA2251840C A NN O
; CA2251840C A : O
a CA2251840C A DT O
low CA2251840C A JJ O
molecular CA2251840C A JJ O
weight CA2251840C A NN O
, CA2251840C A , O
synergistic CA2251840C A JJ O
saccharide CA2251840C A NN O
; CA2251840C A : O
a CA2251840C A DT O
solvent CA2251840C A NN O
; CA2251840C A : O
and CA2251840C A CC O
optionally CA2251840C A RB O
an CA2251840C A DT O
additive CA2251840C A JJ O
material CA2251840C A NN O
. CA2251840C A . O

The CA2251840C A DT O
present CA2251840C A JJ O
invention CA2251840C A NN O
is CA2251840C A VBZ O
further CA2251840C A RBR O
a CA2251840C A DT O
dermatologically-compatible CA2251840C A JJ O
barrier CA2251840C A NN O
film CA2251840C A NN O
for CA2251840C A IN O
preventing CA2251840C A VBG O
and CA2251840C A CC O
reducing CA2251840C A VBG O
contact CA2251840C A NN O
dermatitis CA2251840C A NN O
which CA2251840C A WDT O
contains CA2251840C A VBZ O
a CA2251840C A DT O
polysaccharide CA2251840C A NN O
; CA2251840C A : O
a CA2251840C A DT O
low CA2251840C A JJ O
molecular CA2251840C A JJ O
weight CA2251840C A NN O
, CA2251840C A , O
synergistic CA2251840C A JJ O
saccharide CA2251840C A NN O
; CA2251840C A : O
and CA2251840C A CC O
optionally CA2251840C A RB O
one CA2251840C A CD O
or CA2251840C A CC O
more CA2251840C A JJR O
additives CA2251840C A NNS O
. CA2251840C A . O

The CA2251840C A DT O
dermatologically-compatible CA2251840C A JJ O
barrier CA2251840C A NN O
film CA2251840C A NN O
is CA2251840C A VBZ O
formed CA2251840C A VBN O
of CA2251840C A IN O
a CA2251840C A DT O
composition CA2251840C A NN O
containing CA2251840C A VBG O
a CA2251840C A DT O
polysaccharide CA2251840C A NN O
; CA2251840C A : O
a CA2251840C A DT O
low CA2251840C A JJ O
molecular CA2251840C A JJ O
weight CA2251840C A NN O
, CA2251840C A , O
synergistic CA2251840C A JJ O
saccharide CA2251840C A NN O
; CA2251840C A : O
a CA2251840C A DT O
solvent CA2251840C A NN O
; CA2251840C A : O
and CA2251840C A CC O
optionally CA2251840C A RB O
an CA2251840C A DT O
additive CA2251840C A JJ O
material.The CA2251840C A NN O
composition CA2251840C A NN O
is CA2251840C A VBZ O
a CA2251840C A DT O
skin CA2251840C A JJ O
care CA2251840C A NN O
product CA2251840C A NN O
in CA2251840C A IN O
a CA2251840C A DT O
form CA2251840C A NN O
of CA2251840C A IN O
a CA2251840C A DT O
lotion CA2251840C A NN O
, CA2251840C A , O
a CA2251840C A DT O
gel CA2251840C A NN O
or CA2251840C A CC O
a CA2251840C A DT O
cream CA2251840C A NN O
that CA2251840C A WDT O
is CA2251840C A VBZ O
applied CA2251840C A VBN O
to CA2251840C A TO O
skin CA2251840C A VB O
of CA2251840C A IN O
mammals CA2251840C A NNS O
. CA2251840C A . O

Once CA2251840C A RB O
applied CA2251840C A VBN O
, CA2251840C A , O
the CA2251840C A DT O
solvent CA2251840C A NN O
in CA2251840C A IN O
the CA2251840C A DT O
composition CA2251840C A NN O
evaporates CA2251840C A VBZ O
, CA2251840C A , O
and CA2251840C A CC O
thereby CA2251840C A RB O
leaves CA2251840C A VBZ O
behind CA2251840C A IN O
a CA2251840C A DT O
dermatologically-compatible CA2251840C A JJ O
barrier CA2251840C A NN O
film CA2251840C A NN O
containing CA2251840C A VBG O
a CA2251840C A DT O
polysaccharide CA2251840C A NN O
; CA2251840C A : O
a CA2251840C A DT O
low CA2251840C A JJ O
molecular CA2251840C A JJ O
weight CA2251840C A NN O
, CA2251840C A , O
synergistic CA2251840C A JJ O
saccharide CA2251840C A NN O
; CA2251840C A : O
and CA2251840C A CC O
optionally CA2251840C A RB O
an CA2251840C A DT O
additive CA2251840C A JJ O
material CA2251840C A NN O
. CA2251840C A . O

Compound CN101375947A T NNP O
Macleaya CN101375947A T NNP O
cordata CN101375947A T POS O
injection CN101375947A T NN O
and CN101375947A T CC O
preparation CN101375947A T NN O
method CN101375947A T NN O
. CN101375947A T . O

Novel US20120064092 T NNP O
Target US20120064092 T NNP O
for US20120064092 T IN O
Regulating US20120064092 T VBG O
Multiple US20120064092 T JJ O
Sclerosis US20120064092 T NNP O
. US20120064092 T . O

Methods US20120064092 A NNS O
are US20120064092 A VBP O
provided US20120064092 A VBN O
for US20120064092 A IN O
decreasing US20120064092 A VBG O
demyelinating US20120064092 A VBG O
inflammatory US20120064092 A JJ O
disease US20120064092 A NN O
in US20120064092 A IN O
a US20120064092 A DT O
subject US20120064092 A NN O
by US20120064092 A IN O
inhibiting US20120064092 A VBG O
the US20120064092 A DT O
activity US20120064092 A NN O
of US20120064092 A IN O
chemokine-like US20120064092 A JJ I-UN
receptor US20120064092 A NN I-UN
1 US20120064092 A CD I-UN
( US20120064092 A ( O
CMKLR1 US20120064092 A NNP I-UN
) US20120064092 A ) O
. US20120064092 A . O

Brominated CN102038677A T VBN O
dihydroartemisinin CN102038677A T JJ O
compound CN102038677A T NN O
double-releasing CN102038677A T JJ O
preparation CN102038677A T NN O
. CN102038677A T . O

Applicator US20090036541 T NN O
and US20090036541 T CC O
chemical US20090036541 T NN O
combination US20090036541 T NN O
for US20090036541 T IN O
better US20090036541 T JJR O
topical US20090036541 T JJ O
anesthesia US20090036541 T NN O
. US20090036541 T . O

Liposome CN1883454A T NNP O
administration CN1883454A T NN O
system CN1883454A T NN O
with CN1883454A T IN O
tumor CN1883454A T NN O
necrosis CN1883454A T NN O
targeted CN1883454A T VBD O
antibody CN1883454A T NN O
for CN1883454A T IN O
preposition CN1883454A T NN O
and CN1883454A T CC O
application CN1883454A T NN O
thereof CN1883454A T NN O
. CN1883454A T . O

Self-assembling US20100285111 T JJ O
micelle-like US20100285111 T JJ O
nanoparticles US20100285111 T NNS O
for US20100285111 T IN O
systemic US20100285111 T JJ O
gene US20100285111 T NN O
delivery US20100285111 T NN O
. US20100285111 T . O

Nanoparticles US20100285111 A NNS O
containing US20100285111 A VBG O
nucleic US20100285111 A JJ O
acid US20100285111 A NN O
and US20100285111 A CC O
suitable US20100285111 A JJ O
for US20100285111 A IN O
use US20100285111 A NN O
as US20100285111 A IN O
in US20100285111 A IN O
vivo US20100285111 A JJ O
delivery US20100285111 A NN O
agents US20100285111 A NNS O
for US20100285111 A IN O
nucleic US20100285111 A JJ O
acids US20100285111 A NNS O
are US20100285111 A VBP O
provided US20100285111 A VBN O
. US20100285111 A . O

The US20100285111 A DT O
nanoparticles US20100285111 A NNS O
use US20100285111 A VBP O
a US20100285111 A DT O
covalent US20100285111 A NN O
conjugate US20100285111 A NN O
of US20100285111 A IN O
a US20100285111 A DT O
polycation US20100285111 A NN O
such US20100285111 A JJ O
as US20100285111 A IN O
polyethylenimine US20100285111 A NN O
and US20100285111 A CC O
phospholipids US20100285111 A NNS O
. US20100285111 A . O

The US20100285111 A DT O
final US20100285111 A JJ O
DNA-containing US20100285111 A NN O
nanoparticle US20100285111 A NN O
has US20100285111 A VBZ O
a US20100285111 A DT O
vesicular US20100285111 A JJ O
structure US20100285111 A NN O
with US20100285111 A IN O
a US20100285111 A DT O
polyplex US20100285111 A JJ O
core US20100285111 A NN O
surrounded US20100285111 A VBN O
by US20100285111 A IN O
a US20100285111 A DT O
mixed US20100285111 A JJ O
lipid/PEG-lipid US20100285111 A JJ O
monolayer US20100285111 A NN O
envelope US20100285111 A NN O
and US20100285111 A CC O
offers US20100285111 A VBZ O
simple US20100285111 A JJ O
preparation US20100285111 A NN O
, US20100285111 A , O
high US20100285111 A JJ O
loading US20100285111 A NN O
capacity US20100285111 A NN O
, US20100285111 A , O
and US20100285111 A CC O
in US20100285111 A IN O
vivo US20100285111 A JJ O
stability US20100285111 A NN O
. US20100285111 A . O

The US20100285111 A DT O
nanoparticles US20100285111 A NNS O
have US20100285111 A VBP O
good US20100285111 A VBN O
in US20100285111 A IN O
vivo US20100285111 A JJ O
stability US20100285111 A NN O
and US20100285111 A CC O
a US20100285111 A DT O
prolonged US20100285111 A JJ O
blood US20100285111 A NN O
circulation US20100285111 A NN O
time US20100285111 A NN O
and US20100285111 A CC O
can US20100285111 A MD O
effectively US20100285111 A RB O
deliver US20100285111 A VB O
a US20100285111 A DT O
gene US20100285111 A NN O
to US20100285111 A TO O
a US20100285111 A DT O
biological US20100285111 A JJ O
target US20100285111 A NN O
such US20100285111 A JJ O
as US20100285111 A IN O
a US20100285111 A DT O
tumor US20100285111 A NN O
. US20100285111 A . O

Compositions WO2010122456A1 T NNS O
of WO2010122456A1 T IN O
sulopenem WO2010122456A1 T NN O
and WO2010122456A1 T CC O
use WO2010122456A1 T NN O
for WO2010122456A1 T IN O
treating WO2010122456A1 T VBG O
tuberculosis WO2010122456A1 T NN O
. WO2010122456A1 T . O

Bacteria WO2012045124A1 T NNP I-UN
topoisomerase WO2012045124A1 T NN I-UN
ii WO2012045124A1 T NN I-UN
inhibiting WO2012045124A1 T VBG O
2-ethylcarbamoylamino-1 WO2012045124A1 T JJ O
, WO2012045124A1 T , O
3-benzothiazol-5-yls WO2012045124A1 T JJ O
. WO2012045124A1 T . O

Pyrrolotriazolopyrimidinone US7060824 T NN O
derivatives US7060824 T NNS O
. US7060824 T . O

Application CN101513407A T NN O
of CN101513407A T IN O
naloxone CN101513407A T NN O
and CN101513407A T CC O
composition CN101513407A T NN O
thereof CN101513407A T NN O
in CN101513407A T IN O
preparing CN101513407A T VBG O
drug CN101513407A T NN O
for CN101513407A T IN O
treating CN101513407A T VBG O
cancer CN101513407A T NN O
. CN101513407A T . O

Anti-tubercular US20090192173 T JJ O
drugs US20090192173 T NNS O
: US20090192173 T : O
compositions US20090192173 T NNS O
and US20090192173 T CC O
methods US20090192173 T NNS O
. US20090192173 T . O

Medicine CN102038872A T NNP O
for CN102038872A T IN O
treating CN102038872A T VBG O
rheumatic CN102038872A T JJ O
fever CN102038872A T NN O
. CN102038872A T . O

Transcription US20110009476 T NNP O
factor US20110009476 T NN O
decoys US20110009476 T NN O
, US20110009476 T , O
compositions US20110009476 T NNS O
and US20110009476 T CC O
methods US20110009476 T NNS O
. US20110009476 T . O

Compositions US20100266581 T NNS O
and US20100266581 T CC O
methods US20100266581 T NNS O
for US20100266581 T IN O
modulating US20100266581 T VBG O
s-nitrosogluthione US20100266581 T JJ I-UN
reductase US20100266581 T NN I-UN
. US20100266581 T . O

Disclosed US20100266581 A VBN O
herein US20100266581 A NNS O
are US20100266581 A VBP O
methods US20100266581 A NNS O
and US20100266581 A CC O
compositions US20100266581 A NNS O
for US20100266581 A IN O
modulating US20100266581 A VBG O
the US20100266581 A DT O
levels US20100266581 A NNS O
and/or US20100266581 A VBP O
activity US20100266581 A NN O
of US20100266581 A IN O
S-nitrosoglutathione US20100266581 A JJ I-UN
reductase US20100266581 A NN I-UN
( US20100266581 A ( O
GSNOR US20100266581 A NNP I-UN
) US20100266581 A ) O
in US20100266581 A IN O
vivo US20100266581 A NN O
or US20100266581 A CC O
in US20100266581 A IN O
vitro US20100266581 A NN O
. US20100266581 A . O

Specifically US20100266581 A RB O
disclosed US20100266581 A VBN O
are US20100266581 A VBP O
GSNOR US20100266581 A NNP I-UN
deletion US20100266581 A NN O
constructs US20100266581 A NNS O
, US20100266581 A , O
host US20100266581 A NN O
cells US20100266581 A NNS O
and US20100266581 A CC O
non-human US20100266581 A JJ O
mammals US20100266581 A NNS O
comprising US20100266581 A VBG O
GSNOR US20100266581 A NNP I-UN
deletions US20100266581 A NNS O
, US20100266581 A , O
and US20100266581 A CC O
methods US20100266581 A NNS O
of US20100266581 A IN O
screening US20100266581 A VBG O
employing US20100266581 A VBG O
GSNOR US20100266581 A NNP I-UN
deletion US20100266581 A NN O
mutants US20100266581 A NNS O
. US20100266581 A . O

Also US20100266581 A RB O
specifically US20100266581 A RB O
disclosed US20100266581 A VBN O
are US20100266581 A VBP O
reagents US20100266581 A NNS O
and US20100266581 A CC O
procedures US20100266581 A NNS O
for US20100266581 A IN O
measuring US20100266581 A VBG O
, US20100266581 A , O
monitoring US20100266581 A NN O
, US20100266581 A , O
or US20100266581 A CC O
altering US20100266581 A VBG O
GSNOR US20100266581 A NNP I-UN
levels US20100266581 A NNS O
or US20100266581 A CC O
activity US20100266581 A NN O
( US20100266581 A ( O
as US20100266581 A RB O
well US20100266581 A RB O
as US20100266581 A IN O
nitric US20100266581 A JJ O
oxide US20100266581 A NN O
and US20100266581 A CC O
S-nitrosothiol US20100266581 A NNP O
levels US20100266581 A NNS O
) US20100266581 A ) O
in US20100266581 A IN O
connection US20100266581 A NN O
with US20100266581 A IN O
various US20100266581 A JJ O
medical US20100266581 A JJ O
conditions US20100266581 A NNS O
. US20100266581 A . O

Anti-inflammatory CA2372384C T JJ O
bioactive CA2372384C T JJ O
glass CA2372384C T NN O
particulates CA2372384C T NNS O
. CA2372384C T . O

Compositions CA2372384C A NNS O
and CA2372384C A CC O
methods CA2372384C A NNS O
for CA2372384C A IN O
systemically CA2372384C A RB O
minimizing CA2372384C A VBG O
the CA2372384C A DT O
inflammatory CA2372384C A JJ O
effects CA2372384C A NNS O
of CA2372384C A IN O
TNF-.alpha CA2372384C A NNP I-UN
. CA2372384C A . O

When CA2372384C A WRB O
administered CA2372384C A VBN O
to CA2372384C A TO O
a CA2372384C A DT O
patient CA2372384C A NN O
, CA2372384C A , O
the CA2372384C A DT O
particles CA2372384C A NNS O
bring CA2372384C A VBP O
about CA2372384C A IN O
elevated CA2372384C A JJ O
levels CA2372384C A NNS O
of CA2372384C A IN O
IL-6 CA2372384C A NNP I-UN
and CA2372384C A CC O
do CA2372384C A VB O
not CA2372384C A RB O
cause CA2372384C A VB O
elevated CA2372384C A JJ O
levels CA2372384C A NNS O
of CA2372384C A IN O
TNF-.alpha.. CA2372384C A NNP O

Dry CN101836969B T NNP O
ice CN101836969B T NN O
defatting CN101836969B T VBG O
pill CN101836969B T NN O
. CN101836969B T . O

Pharmaceutical WO2013176567A1 T JJ O
composition WO2013176567A1 T NN O
for WO2013176567A1 T IN O
the WO2013176567A1 T DT O
prophylaxis WO2013176567A1 T NN O
and WO2013176567A1 T CC O
treatment WO2013176567A1 T NN O
of WO2013176567A1 T IN O
psychological WO2013176567A1 T JJ O
, WO2013176567A1 T , O
behavioral WO2013176567A1 T JJ O
and WO2013176567A1 T CC O
cognitive WO2013176567A1 T JJ O
disorders WO2013176567A1 T NNS O
. WO2013176567A1 T . O

The WO2013176567A1 A DT O
invention WO2013176567A1 A NN O
may WO2013176567A1 A MD O
be WO2013176567A1 A VB O
realized WO2013176567A1 A VBN O
through WO2013176567A1 A IN O
the WO2013176567A1 A DT O
preparation WO2013176567A1 A NN O
of WO2013176567A1 A IN O
a WO2013176567A1 A DT O
finished WO2013176567A1 A JJ O
pharmaceutical WO2013176567A1 A JJ O
product WO2013176567A1 A NN O
such WO2013176567A1 A JJ O
as WO2013176567A1 A IN O
capsules WO2013176567A1 A NNS O
, WO2013176567A1 A , O
preferably WO2013176567A1 A RB O
hard WO2013176567A1 A JJ O
gelatin WO2013176567A1 A NN I-UN
capsules WO2013176567A1 A NNS O
. WO2013176567A1 A . O

Method US20080064758 T NNP O
of US20080064758 T IN O
treatment US20080064758 T NN O
or US20080064758 T CC O
prophylaxis US20080064758 T NN O
of US20080064758 T IN O
depression US20080064758 T NN O
. US20080064758 T . O

The US20080064758 A DT O
invention US20080064758 A NN O
concerns US20080064758 A VBZ O
a US20080064758 A DT O
method US20080064758 A NN O
of US20080064758 A IN O
treatment US20080064758 A NN O
or US20080064758 A CC O
prophylaxis US20080064758 A NN O
of US20080064758 A IN O
depression US20080064758 A NN O
by US20080064758 A IN O
administering US20080064758 A VBG O
a US20080064758 A DT O
phenylethanolaminocyclohexylphenyl US20080064758 A NN O
compound US20080064758 A NN O
of US20080064758 A IN O
a US20080064758 A DT O
general US20080064758 A JJ O
formula US20080064758 A NN O
( US20080064758 A ( O
I US20080064758 A PRP O
) US20080064758 A ) O
in US20080064758 A IN O
which US20080064758 A WDT O
R1 US20080064758 A NNP O
represents US20080064758 A VBZ O
hydrogen US20080064758 A NN O
or US20080064758 A CC O
halogen US20080064758 A NN O
; US20080064758 A : O
R2 US20080064758 A NNP O
represents US20080064758 A VBZ O
hydrogen US20080064758 A NN O
, US20080064758 A , O
hydroxy US20080064758 A NN O
, US20080064758 A , O
lower US20080064758 A JJR O
alkoxy US20080064758 A NN O
, US20080064758 A , O
lower US20080064758 A JJR O
alkoxy US20080064758 A NN O
substituted US20080064758 A VBD O
with US20080064758 A IN O
one US20080064758 A CD O
or US20080064758 A CC O
two US20080064758 A CD O
lower US20080064758 A JJR O
alkoxycarbonyl US20080064758 A NN O
or US20080064758 A CC O
carboxy US20080064758 A NN O
groups US20080064758 A NNS O
, US20080064758 A , O
lower US20080064758 A JJR O
alkoxy US20080064758 A NN O
substituted US20080064758 A VBN O
with US20080064758 A IN O
lower US20080064758 A JJR O
alkylaminocarbonyl US20080064758 A NN O
which US20080064758 A WDT O
may US20080064758 A MD O
be US20080064758 A VB O
substituted US20080064758 A VBN O
with US20080064758 A IN O
lower US20080064758 A JJR O
alkoxy US20080064758 A NN O
, US20080064758 A , O
lower US20080064758 A JJR O
alkoxy US20080064758 A NN O
substituted US20080064758 A VBN O
with US20080064758 A IN O
cyclic US20080064758 A JJ O
aminocarbonyl US20080064758 A NN O
of US20080064758 A IN O
4 US20080064758 A CD O
to US20080064758 A TO O
6 US20080064758 A CD O
carbon US20080064758 A NN O
atoms US20080064758 A NNS O
, US20080064758 A , O
lower US20080064758 A JJR O
alkoxycarbonyl US20080064758 A NN O
or US20080064758 A CC O
carboxy US20080064758 A NN O
; US20080064758 A : O
R3 US20080064758 A NNP O
represents US20080064758 A VBZ O
hydrogen US20080064758 A NN O
, US20080064758 A , O
hydroxy US20080064758 A NN O
, US20080064758 A , O
lower US20080064758 A JJR O
alkoxy US20080064758 A NN O
or US20080064758 A CC O
lower US20080064758 A JJR O
alkoxy US20080064758 A NN O
substituted US20080064758 A VBD O
with US20080064758 A IN O
one US20080064758 A CD O
or US20080064758 A CC O
two US20080064758 A CD O
lower US20080064758 A JJR O
alkoxycarbonyl US20080064758 A NN O
or US20080064758 A CC O
carboxy US20080064758 A JJ O
groups US20080064758 A NNS O
; US20080064758 A : O
R2 US20080064758 A NNP O
and US20080064758 A CC O
R3 US20080064758 A NNP O
may US20080064758 A MD O
be US20080064758 A VB O
bonded US20080064758 A VBN O
to US20080064758 A TO O
each US20080064758 A DT O
other US20080064758 A JJ O
to US20080064758 A TO O
form US20080064758 A VB O
methylenedioxy US20080064758 A NN O
substituted US20080064758 A VBN O
with US20080064758 A IN O
carboxy US20080064758 A NN O
or US20080064758 A CC O
lower US20080064758 A JJR O
alkoxycarbonyl US20080064758 A NN O
; US20080064758 A : O
and US20080064758 A CC O
m US20080064758 A VB O
and US20080064758 A CC O
n US20080064758 A NNS O
are US20080064758 A VBP O
0 US20080064758 A CD O
or US20080064758 A CC O
1 US20080064758 A CD O
, US20080064758 A , O
and US20080064758 A CC O
their US20080064758 A PRP$ O
pharmacologically US20080064758 A RB O
acceptable US20080064758 A JJ O
metabolites US20080064758 A NNS O
or US20080064758 A CC O
salts US20080064758 A NNS O
, US20080064758 A , O
which US20080064758 A WDT O
have US20080064758 A VBP O
selective US20080064758 A JJ O
stimulating US20080064758 A NN O
activity US20080064758 A NN O
and US20080064758 A CC O
binding US20080064758 A NN O
affinity US20080064758 A NN O
for US20080064758 A IN O
β3 US20080064758 A NNP I-UN
adrenergic US20080064758 A JJ I-UN
receptors US20080064758 A NNS I-UN
. US20080064758 A . O

Oligonucleotidic US20110213015 T JJ O
sequences US20110213015 T NNS O
able US20110213015 T JJ O
to US20110213015 T TO O
silence US20110213015 T VB O
the US20110213015 T DT O
expression US20110213015 T NN O
of US20110213015 T IN O
the US20110213015 T DT O
cyclin US20110213015 T NN I-UN
d1-trop2 US20110213015 T JJ O
chimera US20110213015 T NN O
and US20110213015 T CC O
uses US20110213015 T VBZ O
thereof US20110213015 T NN O
in US20110213015 T IN O
medical US20110213015 T JJ O
field US20110213015 T NN O
. US20110213015 T . O

The US20110213015 A DT O
invention US20110213015 A NN O
concerns US20110213015 A NNS O
RNA US20110213015 A NNP O
oligonucleotide US20110213015 A NN O
sequences US20110213015 A NNS O
or US20110213015 A CC O
sequences US20110213015 A NNS O
that US20110213015 A WDT O
are US20110213015 A VBP O
transcribed US20110213015 A VBN O
into US20110213015 A IN O
RNA US20110213015 A NNP O
or US20110213015 A CC O
analogous US20110213015 A JJ O
molecules US20110213015 A NNS O
able US20110213015 A JJ O
to US20110213015 A TO O
silence US20110213015 A VB O
the US20110213015 A DT O
expression US20110213015 A NN O
of US20110213015 A IN O
the US20110213015 A DT O
CYCLIN US20110213015 A NNP I-UN
D1/TROP2 US20110213015 A NNP O
chimeric US20110213015 A JJ O
mRNA US20110213015 A NN O
and US20110213015 A CC O
their US20110213015 A PRP$ O
use US20110213015 A NN O
in US20110213015 A IN O
the US20110213015 A DT O
treatment US20110213015 A NN O
and US20110213015 A CC O
the US20110213015 A DT O
prevention US20110213015 A NN O
of US20110213015 A IN O
tumors US20110213015 A NNS O
. US20110213015 A . O

Benzobinaphthoquinone CN1951896A T NNP O
derivative CN1951896A T JJ O
with CN1951896A T IN O
anticancer CN1951896A T JJ O
activity CN1951896A T NN O
. CN1951896A T . O

Use WO2007054451A1 T NNP O
of WO2007054451A1 T IN O
combinations WO2007054451A1 T NNS O
of WO2007054451A1 T IN O
nitric WO2007054451A1 T JJ O
oxide-releasing WO2007054451A1 T JJ O
aspirin WO2007054451A1 T NN O
and WO2007054451A1 T CC O
aspirin WO2007054451A1 T NN O
for WO2007054451A1 T IN O
the WO2007054451A1 T DT O
treatment WO2007054451A1 T NN O
of WO2007054451A1 T IN O
cardiovascular WO2007054451A1 T JJ O
diseases WO2007054451A1 T NNS O
. WO2007054451A1 T . O

Growth US20070243192 T NNP I-UN
hormone US20070243192 T NN I-UN
receptor US20070243192 T NN I-UN
antagonist US20070243192 T JJ O
cancer US20070243192 T NN O
treatment US20070243192 T NN O
. US20070243192 T . O

The US20070243192 A DT O
present US20070243192 A JJ O
invention US20070243192 A NN O
provides US20070243192 A VBZ O
methods US20070243192 A NNS O
and US20070243192 A CC O
compositions US20070243192 A NNS O
for US20070243192 A IN O
treating US20070243192 A VBG O
tumorigenic US20070243192 A JJ O
cells US20070243192 A NNS O
( US20070243192 A ( O
e.g. US20070243192 A NN O
, US20070243192 A , O
mammary US20070243192 A JJ O
progenitor US20070243192 A NN O
cancer US20070243192 A NN O
cells US20070243192 A NNS O
) US20070243192 A ) O
, US20070243192 A , O
with US20070243192 A IN O
growth US20070243192 A NN I-UN
hormone US20070243192 A NN I-UN
receptor US20070243192 A NN I-UN
antagonists US20070243192 A NNS O
( US20070243192 A ( O
e.g. US20070243192 A NN O
, US20070243192 A , O
Pegvisomant US20070243192 A NNP O
) US20070243192 A ) O
, US20070243192 A , O
as US20070243192 A RB O
well US20070243192 A RB O
as US20070243192 A IN O
methods US20070243192 A NNS O
and US20070243192 A CC O
compositions US20070243192 A NNS O
for US20070243192 A IN O
screening US20070243192 A VBG O
growth US20070243192 A NN I-UN
hormone US20070243192 A NN I-UN
receptor US20070243192 A NN I-UN
antagonists US20070243192 A NNS O
for US20070243192 A IN O
their US20070243192 A PRP$ O
ability US20070243192 A NN O
serve US20070243192 A VBP O
as US20070243192 A IN O
anti-neoplastic US20070243192 A JJ O
agents US20070243192 A NNS O
capable US20070243192 A JJ O
of US20070243192 A IN O
killing US20070243192 A VBG O
tumorigenic US20070243192 A JJ O
cells US20070243192 A NNS O
. US20070243192 A . O

isolated US20080306139 T VBN O
from US20080306139 T IN O
a US20080306139 T DT O
fermentation US20080306139 T NN O
broth US20080306139 T NN O
of US20080306139 T IN O
eubacterium US20080306139 T NN O
Streptomyces US20080306139 T NNP O
sp US20080306139 T NN O
. US20080306139 T . O

cultures US20080306139 T NNS O
; US20080306139 T : O
effective US20080306139 T JJ O
in US20080306139 T IN O
the US20080306139 T DT O
treatment US20080306139 T NN O
of US20080306139 T IN O
bacterial US20080306139 T JJ O
infections US20080306139 T NNS O
. US20080306139 T . O

tert-butyl US7541378 T JJ O
3-amino-1H-thieno US7541378 T JJ O
[ US7541378 T JJ O
2,3-c US7541378 T JJ O
] US7541378 T JJ O
pyrazole-5-carboxylate US7541378 T NN O
; US7541378 T : O
N-benzyl-3- US7541378 T NNP O
[ US7541378 T NNP O
( US7541378 T ( O
4-fluorobenzoyl US7541378 T JJ O
) US7541378 T ) O
amino US7541378 T NN O
] US7541378 T JJ O
-1H-thieno US7541378 T NNP O
[ US7541378 T NNP O
2,3-c US7541378 T JJ O
] US7541378 T NNP O
pyrazole-5-carboxamide US7541378 T NN O
; US7541378 T : O
treats US7541378 T VBZ O
a US7541378 T DT O
disease US7541378 T NN O
caused US7541378 T VBN O
associated US7541378 T VBN O
with US7541378 T IN O
an US7541378 T DT O
altered US7541378 T VBN O
( US7541378 T ( O
disregulated US7541378 T VBN O
) US7541378 T ) O
protein US7541378 T NN O
kinase US7541378 T NN O
activity US7541378 T NN O
e.g US7541378 T NN O
cancer US7541378 T NN O
, US7541378 T , O
cell US7541378 T VBP O
proliferative US7541378 T JJ O
disorders US7541378 T NNS O
, US7541378 T , O
Alzheimer US7541378 T NNP O
's US7541378 T POS O
disease US7541378 T NN O
, US7541378 T , O
viral US7541378 T JJ O
infections US7541378 T NNS O
. US7541378 T . O

Unnatural US20100035929 T JJ O
dispyrin US20100035929 T NN O
analogues US20100035929 T NNS O
, US20100035929 T , O
preparation US20100035929 T NN O
and US20100035929 T CC O
uses US20100035929 T VBZ O
thereof US20100035929 T NN O
. US20100035929 T . O

Disclosed US20100035929 A VBN O
are US20100035929 A VBP O
dispyrin US20100035929 A JJ O
analogue US20100035929 A JJ O
compounds US20100035929 A NNS O
useful US20100035929 A JJ O
as US20100035929 A IN O
H3 US20100035929 A NNP I-UN
receptor US20100035929 A NN I-UN
activity US20100035929 A NN O
modulators US20100035929 A NNS O
, US20100035929 A , O
methods US20100035929 A NNS O
of US20100035929 A IN O
making US20100035929 A VBG O
same US20100035929 A JJ O
, US20100035929 A , O
pharmaceutical US20100035929 A JJ O
compositions US20100035929 A NNS O
comprising US20100035929 A VBG O
same US20100035929 A JJ O
, US20100035929 A , O
and US20100035929 A CC O
methods US20100035929 A NNS O
of US20100035929 A IN O
treating US20100035929 A VBG O
neurological US20100035929 A JJ O
and US20100035929 A CC O
psychiatric US20100035929 A JJ O
disorders US20100035929 A NNS O
associated US20100035929 A VBN O
with US20100035929 A IN O
histamine US20100035929 A NN I-UN
H3 US20100035929 A NNP I-UN
receptor US20100035929 A NN I-UN
activity US20100035929 A NN O
using US20100035929 A VBG O
same US20100035929 A JJ O
. US20100035929 A . O

Monocyclic US6951872 T NNP O
or US6951872 T CC O
bicyclic US6951872 T JJ O
carbocycles US6951872 T NNS O
and US6951872 T CC O
heterocycles US6951872 T NNS O
as US6951872 T IN O
factor US6951872 T NN I-UN
Xa US6951872 T NN I-UN
inhibitors US6951872 T NNS O
. US6951872 T . O

The US6951872 A DT O
present US6951872 A JJ O
application US6951872 A NN O
describes US6951872 A VBZ O
monocyclic US6951872 A JJ O
or US6951872 A CC O
bicyclic US6951872 A JJ O
carbocycles US6951872 A NNS O
and US6951872 A CC O
heterocycles US6951872 A NNS O
and US6951872 A CC O
derivatives US6951872 A NNS O
thereof US6951872 A NNS O
of US6951872 A IN O
Formula US6951872 A NNP O
I US6951872 A PRP O
: US6951872 A : O
or US6951872 A CC O
pharmaceutically US6951872 A RB O
acceptable US6951872 A JJ O
salt US6951872 A NN O
forms US6951872 A NNS O
thereof US6951872 A NN O
, US6951872 A , O
which US6951872 A WDT O
are US6951872 A VBP O
useful US6951872 A JJ O
as US6951872 A IN O
inhibitors US6951872 A NNS O
of US6951872 A IN O
factor US6951872 A NN I-UN
Xa US6951872 A NNP I-UN
. US6951872 A . O

Antitumoral US20110034549 T JJ O
Compounds US20110034549 T NNP O
. US20110034549 T . O

Risperidone-containing WO2010098261A1 T JJ O
transdermal WO2010098261A1 T JJ O
preparation WO2010098261A1 T NN O
and WO2010098261A1 T CC O
adhesive WO2010098261A1 T JJ O
patch WO2010098261A1 T NN O
using WO2010098261A1 T VBG O
same WO2010098261A1 T JJ O
. WO2010098261A1 T . O

Indole US20120184574 T NNP O
derivatives US20120184574 T NNS O
and US20120184574 T CC O
methods US20120184574 T NNS O
for US20120184574 T IN O
antiviral US20120184574 T JJ O
treatment US20120184574 T NN O
. US20120184574 T . O

The US20120184574 A DT O
present US20120184574 A JJ O
invention US20120184574 A NN O
is US20120184574 A VBZ O
directed US20120184574 A VBN O
to US20120184574 A TO O
compounds US20120184574 A NNS O
and US20120184574 A CC O
forms US20120184574 A NNS O
and US20120184574 A CC O
pharmaceutical US20120184574 A JJ O
compositions US20120184574 A NNS O
thereof US20120184574 A VBP O
useful US20120184574 A JJ O
for US20120184574 A IN O
treating US20120184574 A VBG O
a US20120184574 A DT O
viral US20120184574 A JJ O
infection US20120184574 A NN O
, US20120184574 A , O
or US20120184574 A CC O
for US20120184574 A IN O
affecting US20120184574 A VBG O
viral US20120184574 A JJ O
activity US20120184574 A NN O
by US20120184574 A IN O
modulating US20120184574 A VBG O
viral US20120184574 A JJ O
replication US20120184574 A NN O
. US20120184574 A . O

Synthesis CA2615112A1 T NN O
and CA2615112A1 T CC O
complete CA2615112A1 T JJ O
stereochemical CA2615112A1 T JJ O
assignment CA2615112A1 T NN O
of CA2615112A1 T IN O
psymberin/irciniastatin CA2615112A1 T NN O
for CA2615112A1 T IN O
anti-tumor CA2615112A1 T NN O
use CA2615112A1 T NN O
. CA2615112A1 T . O

Vitamin CN103239414A T NNP O
C CN103239414A T NNP O
freeze-dried CN103239414A T JJ O
powder CN103239414A T NN O
for CN103239414A T IN O
injection CN103239414A T NN O
and CN103239414A T CC O
preparation CN103239414A T NN O
method CN103239414A T NN O
thereof CN103239414A T NN O
. CN103239414A T . O

Application CN102652758A T NNP O
of CN102652758A T IN O
health CN102652758A T NN O
care CN102652758A T NN O
drinking CN102652758A T VBG O
liquid CN102652758A T JJ O
containing CN102652758A T VBG O
deep CN102652758A T JJ O
seawater CN102652758A T NN O
in CN102652758A T IN O
preparation CN102652758A T NN O
of CN102652758A T IN O
medicaments CN102652758A T NNS O
or CN102652758A T CC O
health CN102652758A T NN O
care CN102652758A T NN O
products CN102652758A T NNS O
for CN102652758A T IN O
preventing CN102652758A T VBG O
or CN102652758A T CC O
treating CN102652758A T VBG O
hyperlipidemia CN102652758A T NN O
. CN102652758A T . O

The CN102652758A A DT O
health CN102652758A A NN O
care CN102652758A A NN O
drinking CN102652758A A VBG O
liquid CN102652758A A NN O
is CN102652758A A VBZ O
given CN102652758A A VBN O
to CN102652758A A TO O
a CN102652758A A DT O
rat CN102652758A A NN O
with CN102652758A A IN O
the CN102652758A A DT O
hyperlipoidemia CN102652758A A NN O
, CN102652758A A , O
which CN102652758A A WDT O
is CN102652758A A VBZ O
subjected CN102652758A A VBN O
to CN102652758A A TO O
modeling CN102652758A A VBG O
by CN102652758A A IN O
a CN102652758A A DT O
high-fat CN102652758A A JJ O
emulsion CN102652758A A NN O
, CN102652758A A , O
in CN102652758A A IN O
a CN102652758A A DT O
free CN102652758A A JJ O
drinking CN102652758A A NN O
way CN102652758A A NN O
, CN102652758A A , O
after CN102652758A A IN O
the CN102652758A A DT O
medicament CN102652758A A NN O
is CN102652758A A VBZ O
administrated CN102652758A A VBN O
for CN102652758A A IN O
28 CN102652758A A CD O
days CN102652758A A NNS O
, CN102652758A A , O
the CN102652758A A DT O
blood CN102652758A A NN O
lipid CN102652758A A JJ O
level CN102652758A A NN O
of CN102652758A A IN O
the CN102652758A A DT O
rat CN102652758A A NN O
with CN102652758A A IN O
the CN102652758A A DT O
hyperlipoidemia CN102652758A A NN O
can CN102652758A A MD O
be CN102652758A A VB O
significantly CN102652758A A RB O
reduced CN102652758A A VBN O
, CN102652758A A , O
lipid CN102652758A A JJ O
peroxidation CN102652758A A NN O
can CN102652758A A MD O
be CN102652758A A VB O
inhibited CN102652758A A VBN O
, CN102652758A A , O
the CN102652758A A DT O
activity CN102652758A A NN O
of CN102652758A A IN O
lipoprotein CN102652758A A NN O
metabolic CN102652758A A JJ O
enzymes CN102652758A A NNS O
, CN102652758A A , O
namely CN102652758A A RB O
LCAT CN102652758A A NNP I-UN
( CN102652758A A ( O
lecithin-cholesterol CN102652758A A JJ I-UN
acetyltransferase CN102652758A A NN I-UN
) CN102652758A A ) O
, CN102652758A A , O
LPL CN102652758A A NNP I-UN
( CN102652758A A ( O
lipoprotein CN102652758A A JJ I-UN
lipase CN102652758A A NN I-UN
) CN102652758A A ) O
and CN102652758A A CC O
HL CN102652758A A NNP I-UN
( CN102652758A A ( O
hepatic CN102652758A A JJ I-UN
lipase CN102652758A A NN I-UN
) CN102652758A A ) O
, CN102652758A A , O
can CN102652758A A MD O
be CN102652758A A VB O
significantly CN102652758A A RB O
improved CN102652758A A VBN O
, CN102652758A A , O
and CN102652758A A CC O
the CN102652758A A DT O
state CN102652758A A NN O
of CN102652758A A IN O
lipid CN102652758A A JJ O
metabolism CN102652758A A NN O
disorder CN102652758A A NN O
in CN102652758A A IN O
the CN102652758A A DT O
rat CN102652758A A NN O
with CN102652758A A IN O
the CN102652758A A DT O
hyperlipoidemia CN102652758A A NN O
, CN102652758A A , O
as CN102652758A A RB O
well CN102652758A A RB O
as CN102652758A A IN O
concurrent CN102652758A A NN O
fatty CN102652758A A NN O
liver CN102652758A A NN O
and CN102652758A A CC O
diabetes CN102652758A A VBZ O
thereof CN102652758A A NNS O
, CN102652758A A , O
can CN102652758A A MD O
be CN102652758A A VB O
further CN102652758A A RB O
improved CN102652758A A VBN O
. CN102652758A A . O

Gastrodin CN103126980A T NNP O
injection CN103126980A T NN O
preparation CN103126980A T NN O
and CN103126980A T CC O
preparation CN103126980A T NN O
method CN103126980A T NN O
. CN103126980A T . O

Tooth WO2010113801A1 T DT O
calcification WO2010113801A1 T NN O
agent WO2010113801A1 T NN O
and WO2010113801A1 T CC O
method WO2010113801A1 T NN O
for WO2010113801A1 T IN O
producing WO2010113801A1 T VBG O
same WO2010113801A1 T JJ O
. WO2010113801A1 T . O

Esters WO2013003114A8 T NNS O
for WO2013003114A8 T IN O
treatment WO2013003114A8 T NN O
of WO2013003114A8 T IN O
ocular WO2013003114A8 T JJ O
inflammatory WO2013003114A8 T JJ O
conditions WO2013003114A8 T NNS O
. WO2013003114A8 T . O

Enhanced US20110319489 T NNP O
stability US20110319489 T NN O
peracid US20110319489 T NN O
compositions US20110319489 T NNS O
. US20110319489 T . O

2,4-substituted EP1337523B1 T JJ O
pyridine EP1337523B1 T NN O
derivatives EP1337523B1 T NNS O
. EP1337523B1 T . O

These EP1337523B1 A DT O
compounds EP1337523B1 A NNS O
are EP1337523B1 A VBP O
agonists EP1337523B1 A NNS O
, EP1337523B1 A , O
antagonists EP1337523B1 A NNS O
or EP1337523B1 A CC O
inverse EP1337523B1 A JJ O
agonists EP1337523B1 A NNS O
for EP1337523B1 A IN O
GABAA EP1337523B1 A NNP O
brain EP1337523B1 A NN O
receptors EP1337523B1 A NNS O
or EP1337523B1 A CC O
prodrugs EP1337523B1 A NNS O
of EP1337523B1 A IN O
agonists EP1337523B1 A NNS O
, EP1337523B1 A , O
antagonists EP1337523B1 A NNS O
or EP1337523B1 A CC O
inverse EP1337523B1 A JJ O
agonists EP1337523B1 A NNS O
for EP1337523B1 A IN O
GABAA EP1337523B1 A NNP I-UN
brain EP1337523B1 A NN I-UN
receptors EP1337523B1 A NNS I-UN
and EP1337523B1 A CC O
are EP1337523B1 A VBP O
therefore EP1337523B1 A RB O
useful EP1337523B1 A JJ O
in EP1337523B1 A IN O
the EP1337523B1 A DT O
diagnosis EP1337523B1 A NN O
and EP1337523B1 A CC O
treatment EP1337523B1 A NN O
of EP1337523B1 A IN O
anxiety EP1337523B1 A NN O
, EP1337523B1 A , O
depression EP1337523B1 A NN O
, EP1337523B1 A , O
down EP1337523B1 A RB O
Syndrome EP1337523B1 A NNP O
, EP1337523B1 A , O
sleep EP1337523B1 A NN O
and EP1337523B1 A CC O
seizure EP1337523B1 A NN O
disorders EP1337523B1 A NNS O
, EP1337523B1 A , O
overdose EP1337523B1 A RB O
with EP1337523B1 A IN O
benzodiazepine EP1337523B1 A NN O
drugs EP1337523B1 A NNS O
and EP1337523B1 A CC O
for EP1337523B1 A IN O
enhancement EP1337523B1 A NN O
of EP1337523B1 A IN O
memory EP1337523B1 A NN O
. EP1337523B1 A . O

Compounds EP1337523B1 A NNS O
of EP1337523B1 A IN O
the EP1337523B1 A DT O
invention EP1337523B1 A NN O
are EP1337523B1 A VBP O
also EP1337523B1 A RB O
useful EP1337523B1 A JJ O
as EP1337523B1 A IN O
probes EP1337523B1 A NNS O
for EP1337523B1 A IN O
the EP1337523B1 A DT O
localization EP1337523B1 A NN O
of EP1337523B1 A IN O
GABAA EP1337523B1 A NNP I-UN
receptors EP1337523B1 A NNS I-UN
in EP1337523B1 A IN O
tissue EP1337523B1 A NN O
samples EP1337523B1 A NNS O
. EP1337523B1 A . O

Pilocarpine US20080254101 T NNP O
compositions US20080254101 T NNS O
and US20080254101 T CC O
methods US20080254101 T NNS O
of US20080254101 T IN O
use US20080254101 T NN O
thereof US20080254101 T NN O
. US20080254101 T . O

Antibiotic EP2301626A2 T NNP O
for EP2301626A2 T IN O
use EP2301626A2 T NN O
in EP2301626A2 T IN O
local EP2301626A2 T JJ O
infection EP2301626A2 T NN O
. EP2301626A2 T . O

Inhibitors US20110275673 T NNS O
of US20110275673 T IN O
sphingosine US20110275673 T JJ I-UN
kinase US20110275673 T NN I-UN
1 US20110275673 T CD I-UN
. US20110275673 T . O

Compounds US20110275673 A NNS O
of US20110275673 A IN O
the US20110275673 A DT O
present US20110275673 A JJ O
invention US20110275673 A NN O
are US20110275673 A VBP O
inhibitors US20110275673 A NNS O
of US20110275673 A IN O
sphingosine US20110275673 A JJ I-UN
kinase US20110275673 A NN I-UN
3 US20110275673 A CD I-UN
, US20110275673 A , O
and US20110275673 A CC O
are US20110275673 A VBP O
useful US20110275673 A JJ O
in US20110275673 A IN O
the US20110275673 A DT O
treatment US20110275673 A NN O
of US20110275673 A IN O
various US20110275673 A JJ O
disorders US20110275673 A NNS O
and US20110275673 A CC O
conditions US20110275673 A NNS O
, US20110275673 A , O
such US20110275673 A JJ O
as US20110275673 A IN O
inflammatory US20110275673 A JJ O
disorders US20110275673 A NNS O
. US20110275673 A . O

Methods WO2014081675A1 T NNS O
and WO2014081675A1 T CC O
compositions WO2014081675A1 T NNS O
for WO2014081675A1 T IN O
treating WO2014081675A1 T VBG O
neurodegenerative WO2014081675A1 T JJ O
diseases WO2014081675A1 T NNS O
. WO2014081675A1 T . O

Substituted WO2007104560A1 T VBN O
4-amino-quinazoline WO2007104560A1 T JJ O
derivatives WO2007104560A1 T NNS O
as WO2007104560A1 T IN O
regulators WO2007104560A1 T NNS O
of WO2007104560A1 T IN O
metabotropic WO2007104560A1 T NN I-UN
glutamate WO2007104560A1 T NN I-UN
receptors WO2007104560A1 T NNS I-UN
and WO2007104560A1 T CC O
their WO2007104560A1 T PRP$ O
use WO2007104560A1 T NN O
for WO2007104560A1 T IN O
producing WO2007104560A1 T VBG O
drugs WO2007104560A1 T NNS O
. WO2007104560A1 T . O

Application CN103735537A T NN O
of CN103735537A T IN O
xanthohumol CN103735537A T NN O
in CN103735537A T IN O
preparation CN103735537A T NN O
of CN103735537A T IN O
drug CN103735537A T NN O
or CN103735537A T CC O
health-care CN103735537A T JJ O
product CN103735537A T NN O
for CN103735537A T IN O
inhibiting CN103735537A T VBG O
alpha-glucosaccharase CN103735537A T JJ I-UN
activity CN103735537A T NN O
. CN103735537A T . O

The CN103735537A A DT O
invention CN103735537A A NN O
discloses CN103735537A A VBZ O
application CN103735537A A NN O
of CN103735537A A IN O
xanthohumol CN103735537A A NN O
in CN103735537A A IN O
preparation CN103735537A A NN O
of CN103735537A A IN O
a CN103735537A A DT O
drug CN103735537A A NN O
or CN103735537A A CC O
a CN103735537A A DT O
health-care CN103735537A A JJ O
product CN103735537A A NN O
for CN103735537A A IN O
inhibiting CN103735537A A VBG O
alpha-glucosaccharase CN103735537A A JJ I-UN
activity CN103735537A A NN O
. CN103735537A A . O

An CN103735537A A DT O
experiment CN103735537A A JJ O
proves CN103735537A A NNS O
that CN103735537A A IN O
the CN103735537A A DT O
xanthohumol CN103735537A A NN O
has CN103735537A A VBZ O
strong CN103735537A A JJ O
inhibitory CN103735537A A NN O
activity CN103735537A A NN O
on CN103735537A A IN O
the CN103735537A A DT O
alpha-glucosaccharase CN103735537A A JJ I-UN
under CN103735537A A IN O
a CN103735537A A DT O
low-concentration CN103735537A A JJ O
condition CN103735537A A NN O
, CN103735537A A , O
IC50 CN103735537A A NNP O
for CN103735537A A IN O
in CN103735537A A IN O
vitro CN103735537A A JJ O
inhibition CN103735537A A NN O
of CN103735537A A IN O
the CN103735537A A DT O
alpha-glucosaccharase CN103735537A A NN I-UN
is CN103735537A A VBZ O
8.8mu CN103735537A A CD O
M CN103735537A A NNP O
, CN103735537A A , O
the CN103735537A A DT O
inhibition CN103735537A A NN O
type CN103735537A A NN O
is CN103735537A A VBZ O
noncompetitive CN103735537A A JJ O
inhibition CN103735537A A NN O
, CN103735537A A , O
the CN103735537A A DT O
alpha-glucosaccharase CN103735537A A JJ I-UN
activity CN103735537A A NN O
can CN103735537A A MD O
be CN103735537A A VB O
effectively CN103735537A A RB O
inhibited CN103735537A A VBN O
, CN103735537A A , O
the CN103735537A A DT O
xanthohumol CN103735537A A NN O
has CN103735537A A VBZ O
reversibility CN103735537A A NN O
on CN103735537A A IN O
the CN103735537A A DT O
activity CN103735537A A NN O
of CN103735537A A IN O
the CN103735537A A DT O
alpha-glucosaccharase CN103735537A A NN I-UN
, CN103735537A A , O
and CN103735537A A CC O
a CN103735537A A DT O
potential CN103735537A A JJ O
side CN103735537A A NN O
effect CN103735537A A NN O
of CN103735537A A IN O
an CN103735537A A DT O
irreversible CN103735537A A JJ O
inhibitor CN103735537A A NN O
can CN103735537A A MD O
be CN103735537A A VB O
effectively CN103735537A A RB O
avoided CN103735537A A VBN O
. CN103735537A A . O

Wound US20120121687 T IN O
healing US20120121687 T VBG O
material US20120121687 T NN O
and US20120121687 T CC O
method US20120121687 T NN O
for US20120121687 T IN O
fabricating US20120121687 T VBG O
the US20120121687 T DT O
same US20120121687 T JJ O
. US20120121687 T . O

6-Methoxy-8- US20070299083 T JJ O
[ US20070299083 T JJ O
4- US20070299083 T JJ O
( US20070299083 T ( O
1- US20070299083 T JJ O
( US20070299083 T ( O
5-fluoro US20070299083 T JJ O
) US20070299083 T ) O
-quinolin-8-yl-piperidin-4-yl US20070299083 T NN O
) US20070299083 T ) O
-piperazin-1-yl US20070299083 T VBZ O
] US20070299083 T JJ O
-quinoline US20070299083 T NNP O
hydrochloric US20070299083 T NN O
acid US20070299083 T NN O
salts US20070299083 T NNS O
. US20070299083 T . O

The US20070299083 A DT O
present US20070299083 A JJ O
invention US20070299083 A NN O
relates US20070299083 A VBZ O
to US20070299083 A TO O
hydrochloric US20070299083 A VB O
acid US20070299083 A JJ O
salt US20070299083 A NN O
and US20070299083 A CC O
crystalline US20070299083 A NN O
forms US20070299083 A NNS O
of US20070299083 A IN O
the US20070299083 A DT O
5-HT1A US20070299083 A JJ I-UN
binding US20070299083 A NN O
agent US20070299083 A NN O
6-methoxy-8- US20070299083 A JJ O
[ US20070299083 A JJ O
4- US20070299083 A JJ O
( US20070299083 A ( O
1- US20070299083 A JJ O
( US20070299083 A ( O
5-fluoro US20070299083 A JJ O
) US20070299083 A ) O
-quinolin-8-yl-piperidin-4-yl US20070299083 A NN O
) US20070299083 A ) O
-piperazin-1-yl US20070299083 A VBZ O
] US20070299083 A JJ O
-quinoline US20070299083 A NN O
, US20070299083 A , O
as US20070299083 A RB O
well US20070299083 A RB O
as US20070299083 A IN O
pharmaceutical US20070299083 A JJ O
compositions US20070299083 A NNS O
thereof US20070299083 A NN O
, US20070299083 A , O
and US20070299083 A CC O
methods US20070299083 A NNS O
of US20070299083 A IN O
use US20070299083 A NN O
thereof US20070299083 A NN O
. US20070299083 A . O

Clenbuterol CN101244049A T NNP O
hydrochloride CN101244049A T JJ O
double-layer CN101244049A T NN O
sustained CN101244049A T VBD O
release CN101244049A T NN O
tablets CN101244049A T NNS O
and CN101244049A T CC O
preparation CN101244049A T NN O
thereof CN101244049A T NN O
. CN101244049A T . O

The CN101244049A A DT O
invention CN101244049A A NN O
discloses CN101244049A A VBZ O
a CN101244049A A DT O
clenbuterol CN101244049A A NN O
hydrochloride CN101244049A A JJ O
two-layer CN101244049A A JJ O
slow CN101244049A A JJ O
release CN101244049A A NN O
tablet CN101244049A A NN O
used CN101244049A A VBN O
for CN101244049A A IN O
easing CN101244049A A VBG O
asthma CN101244049A A NN O
, CN101244049A A , O
which CN101244049A A WDT O
comprises CN101244049A A VBZ O
two CN101244049A A CD O
layers CN101244049A A NNS O
, CN101244049A A , O
namely CN101244049A A RB O
, CN101244049A A , O
a CN101244049A A DT O
quick CN101244049A A JJ O
release CN101244049A A NN O
layer CN101244049A A NN O
and CN101244049A A CC O
a CN101244049A A DT O
slow CN101244049A A JJ O
release CN101244049A A NN O
layer CN101244049A A NN O
; CN101244049A A : O
wherein CN101244049A A CC O
, CN101244049A A , O
the CN101244049A A DT O
quick CN101244049A A JJ O
release CN101244049A A NN O
layer CN101244049A A NN O
comprises CN101244049A A VBZ O
0.02 CN101244049A A CD O
to CN101244049A A TO O
0.1 CN101244049A A CD O
% CN101244049A A NN O
clenbuterol CN101244049A A NN O
hydrochloride CN101244049A A NN O
, CN101244049A A , O
0.1 CN101244049A A CD O
to CN101244049A A TO O
15 CN101244049A A CD O
% CN101244049A A NN O
disintegrating CN101244049A A NN O
agent CN101244049A A NN O
and CN101244049A A CC O
10 CN101244049A A CD O
to CN101244049A A TO O
25 CN101244049A A CD O
filler CN101244049A A NN O
( CN101244049A A ( O
the CN101244049A A DT O
percentages CN101244049A A NNS O
are CN101244049A A VBP O
all CN101244049A A DT O
calculated CN101244049A A VBN O
against CN101244049A A IN O
the CN101244049A A DT O
overall CN101244049A A JJ O
weight CN101244049A A NN O
of CN101244049A A IN O
the CN101244049A A DT O
two-layer CN101244049A A JJ O
tablet CN101244049A A NN O
) CN101244049A A ) O
. CN101244049A A . O

The CN101244049A A DT O
slow CN101244049A A JJ O
release CN101244049A A NN O
layer CN101244049A A NN O
comprises CN101244049A A VBZ O
0.03 CN101244049A A CD O
to CN101244049A A TO O
0.15 CN101244049A A CD O
clenbuterol CN101244049A A NN O
hydrochloride CN101244049A A NN O
, CN101244049A A , O
40 CN101244049A A CD O
to CN101244049A A TO O
70 CN101244049A A CD O
% CN101244049A A NN O
slow CN101244049A A JJ O
release CN101244049A A NN O
material CN101244049A A NN O
and CN101244049A A CC O
2 CN101244049A A CD O
to CN101244049A A TO O
25 CN101244049A A CD O
% CN101244049A A NN O
filler CN101244049A A NN O
, CN101244049A A , O
where CN101244049A A WRB O
all CN101244049A A PDT O
the CN101244049A A DT O
percentages CN101244049A A NNS O
are CN101244049A A VBP O
also CN101244049A A RB O
calculated CN101244049A A VBN O
against CN101244049A A IN O
the CN101244049A A DT O
overall CN101244049A A JJ O
weight CN101244049A A NN O
of CN101244049A A IN O
the CN101244049A A DT O
two-layer CN101244049A A JJ O
tablet CN101244049A A NN O
. CN101244049A A . O

In CN101244049A A IN O
the CN101244049A A DT O
clenbuterol CN101244049A A NN O
hydrochloride CN101244049A A JJ O
two-layer CN101244049A A JJ O
slow CN101244049A A JJ O
release CN101244049A A NN O
tablet CN101244049A A NN O
, CN101244049A A , O
the CN101244049A A DT O
quick CN101244049A A JJ O
release CN101244049A A NN O
layer CN101244049A A NN O
has CN101244049A A VBZ O
the CN101244049A A DT O
advantages CN101244049A A NNS O
of CN101244049A A IN O
quickly CN101244049A A RB O
releasing CN101244049A A VBG O
the CN101244049A A DT O
drug CN101244049A A NN O
, CN101244049A A , O
generating CN101244049A A VBG O
instant CN101244049A A JJ O
effects CN101244049A A NNS O
, CN101244049A A , O
and CN101244049A A CC O
alleviating CN101244049A A VBG O
the CN101244049A A DT O
symptoms CN101244049A A NNS O
rapidly CN101244049A A RB O
; CN101244049A A : O
while CN101244049A A IN O
the CN101244049A A DT O
slow CN101244049A A JJ O
release CN101244049A A NN O
layer CN101244049A A NN O
has CN101244049A A VBZ O
the CN101244049A A DT O
advantages CN101244049A A NNS O
of CN101244049A A IN O
slowly CN101244049A A RB O
releasing CN101244049A A VBG O
the CN101244049A A DT O
drug CN101244049A A NN O
, CN101244049A A , O
stabilizing CN101244049A A VBG O
the CN101244049A A DT O
blood CN101244049A A NN O
drug CN101244049A A NN O
level CN101244049A A NN O
, CN101244049A A , O
reducing CN101244049A A VBG O
the CN101244049A A DT O
side CN101244049A A NN O
effects CN101244049A A NNS O
, CN101244049A A , O
lowering CN101244049A A VBG O
the CN101244049A A DT O
use CN101244049A A NN O
times CN101244049A A NNS O
, CN101244049A A , O
and CN101244049A A CC O
improving CN101244049A A VBG O
the CN101244049A A DT O
compliance CN101244049A A NN O
of CN101244049A A IN O
the CN101244049A A DT O
patients CN101244049A A NNS O
when CN101244049A A WRB O
using CN101244049A A VBG O
the CN101244049A A DT O
drug CN101244049A A NN O
. CN101244049A A . O

Compositions US20100272818 T NNS O
and US20100272818 T CC O
methods US20100272818 T NNS O
comprising US20100272818 T VBG O
terpenes US20100272818 T NNS O
or US20100272818 T CC O
terpene US20100272818 T NN O
mixtures US20100272818 T NNS O
selected US20100272818 T VBN O
from US20100272818 T IN O
thymol US20100272818 T NN O
, US20100272818 T , O
eugenol US20100272818 T NN O
, US20100272818 T , O
geraniol US20100272818 T NN O
, US20100272818 T , O
citral US20100272818 T JJ O
, US20100272818 T , O
and US20100272818 T CC O
l-carvone US20100272818 T NN O
. US20100272818 T . O

The US20100272818 A DT O
present US20100272818 A JJ O
invention US20100272818 A NN O
relates US20100272818 A VBZ O
to US20100272818 A TO O
compositions US20100272818 A NNS O
comprising US20100272818 A VBG O
terpenes US20100272818 A NNS O
which US20100272818 A WDT O
are US20100272818 A VBP O
particularly US20100272818 A RB O
suitable US20100272818 A JJ O
for US20100272818 A IN O
treating US20100272818 A VBG O
plant US20100272818 A NN O
infections US20100272818 A NNS O
, US20100272818 A , O
to US20100272818 A TO O
methods US20100272818 A NNS O
of US20100272818 A IN O
making US20100272818 A VBG O
such US20100272818 A JJ O
compositions US20100272818 A NNS O
, US20100272818 A , O
and US20100272818 A CC O
to US20100272818 A TO O
methods US20100272818 A NNS O
of US20100272818 A IN O
using US20100272818 A VBG O
them US20100272818 A PRP O
. US20100272818 A . O

The US20100272818 A DT O
present US20100272818 A JJ O
invention US20100272818 A NN O
also US20100272818 A RB O
relates US20100272818 A VBZ O
to US20100272818 A TO O
compositions US20100272818 A NNS O
comprising US20100272818 A VBG O
terpenes US20100272818 A NNS O
and US20100272818 A CC O
hollow US20100272818 A JJ O
glucan US20100272818 A JJ O
particles US20100272818 A NNS O
or US20100272818 A CC O
cell US20100272818 A NN O
wall US20100272818 A NN O
particles US20100272818 A NNS O
and US20100272818 A CC O
methods US20100272818 A NNS O
for US20100272818 A IN O
preparing US20100272818 A VBG O
such US20100272818 A JJ O
compositions US20100272818 A NNS O
; US20100272818 A : O
such US20100272818 A JJ O
compositions US20100272818 A NNS O
increase US20100272818 A VBP O
terpene US20100272818 A JJ O
stability US20100272818 A NN O
and US20100272818 A CC O
activity US20100272818 A NN O
and US20100272818 A CC O
provide US20100272818 A VB O
a US20100272818 A DT O
suitable US20100272818 A JJ O
carrier US20100272818 A NN O
for US20100272818 A IN O
the US20100272818 A DT O
terpenes US20100272818 A NNS O
. US20100272818 A . O

The US20100272818 A DT O
invention US20100272818 A NN O
also US20100272818 A RB O
relates US20100272818 A VBZ O
to US20100272818 A TO O
methods US20100272818 A NNS O
of US20100272818 A IN O
using US20100272818 A VBG O
such US20100272818 A JJ O
compositions US20100272818 A NNS O
in US20100272818 A IN O
the US20100272818 A DT O
medical US20100272818 A JJ O
, US20100272818 A , O
veterinary US20100272818 A JJ O
and US20100272818 A CC O
agricultural US20100272818 A JJ O
fields US20100272818 A NNS O
. US20100272818 A . O

In US20100272818 A IN O
particular US20100272818 A JJ O
, US20100272818 A , O
the US20100272818 A DT O
terpenes US20100272818 A NNS O
disclosed US20100272818 A VBN O
are US20100272818 A VBP O
thymol US20100272818 A JJ O
, US20100272818 A , O
eugenol US20100272818 A JJ O
, US20100272818 A , O
geraniol US20100272818 A NN O
, US20100272818 A , O
citral US20100272818 A JJ O
and US20100272818 A CC O
L-carvone US20100272818 A NNP O
. US20100272818 A . O

Combination US8835450 T NN O
of US8835450 T IN O
inhibitor US8835450 T NN O
of US8835450 T IN O
B-Raf US8835450 T NNP I-UN
and US8835450 T CC O
an US8835450 T DT O
inhibitor US8835450 T NN O
of US8835450 T IN O
Akt US8835450 T NNP I-UN
in US8835450 T IN O
the US8835450 T DT O
treatment US8835450 T NN O
of US8835450 T IN O
cancer US8835450 T NN O
. US8835450 T . O

Pyrazole-amide WO2014142290A1 T JJ O
compound WO2014142290A1 T NN O
and WO2014142290A1 T CC O
medicinal WO2014142290A1 T JJ O
uses WO2014142290A1 T NNS O
therefor WO2014142290A1 T VBP O
. WO2014142290A1 T . O

Pseudo CN1651455A T NNP O
portulaca CN1651455A T NN O
oleracea CN1651455A T NN O
saponin CN1651455A T NN O
compound CN1651455A T NN O
, CN1651455A T , O
total CN1651455A T JJ O
sapon CN1651455A T NN O
in CN1651455A T IN O
and CN1651455A T CC O
its CN1651455A T PRP$ O
application CN1651455A T NN O
in CN1651455A T IN O
medicine CN1651455A T NN O
. CN1651455A T . O

Sh2 WO2011034919A2 T NNP I-UN
domain WO2011034919A2 T NN I-UN
profiling WO2011034919A2 T VBG O
to WO2011034919A2 T TO O
characterize WO2011034919A2 T VB O
tyrosine WO2011034919A2 T JJ O
phosphorylation WO2011034919A2 T NN O
signaling WO2011034919A2 T VBG O
in WO2011034919A2 T IN O
cancer WO2011034919A2 T NN O
. WO2011034919A2 T . O

A WO2011034919A2 A DT O
phosphoproteomic WO2011034919A2 A JJ O
method WO2011034919A2 A NN O
termed WO2011034919A2 A VBD O
SH2 WO2011034919A2 A NNP I-UN
profiling WO2011034919A2 A VBG O
to WO2011034919A2 A TO O
characterize WO2011034919A2 A VB O
phosphotyrosine WO2011034919A2 A NN O
( WO2011034919A2 A ( O
pTyr WO2011034919A2 A NN O
) WO2011034919A2 A ) O
signaling WO2011034919A2 A NN O
in WO2011034919A2 A IN O
lung WO2011034919A2 A NN O
cancer WO2011034919A2 A NN O
. WO2011034919A2 A . O

This WO2011034919A2 A DT O
method WO2011034919A2 A NN O
provides WO2011034919A2 A VBZ O
quantitative WO2011034919A2 A JJ O
values WO2011034919A2 A NNS O
for WO2011034919A2 A IN O
the WO2011034919A2 A DT O
phosphorylated WO2011034919A2 A JJ O
binding WO2011034919A2 A NN O
sites WO2011034919A2 A NNS O
for WO2011034919A2 A IN O
Src WO2011034919A2 A NNP I-UN
Homology WO2011034919A2 A NNP I-UN
2 WO2011034919A2 A CD I-UN
( WO2011034919A2 A ( I-UN
SH2 WO2011034919A2 A NNP I-UN
) WO2011034919A2 A ) I-UN
domains WO2011034919A2 A NNS I-UN
, WO2011034919A2 A , O
which WO2011034919A2 A WDT O
the WO2011034919A2 A DT O
cell WO2011034919A2 A NN O
uses WO2011034919A2 A VBZ O
to WO2011034919A2 A TO O
relay WO2011034919A2 A VB O
signals WO2011034919A2 A NNS O
from WO2011034919A2 A IN O
tyrosine WO2011034919A2 A NN I-UN
kinases WO2011034919A2 A NNS I-UN
. WO2011034919A2 A . O

Lung WO2011034919A2 A NNP O
cancer WO2011034919A2 A NN O
cell WO2011034919A2 A NN O
lines WO2011034919A2 A NNS O
with WO2011034919A2 A IN O
known WO2011034919A2 A VBN O
mutational WO2011034919A2 A JJ O
status WO2011034919A2 A NN O
of WO2011034919A2 A IN O
the WO2011034919A2 A DT O
epidermal WO2011034919A2 A JJ I-UN
growth WO2011034919A2 A NN I-UN
factor WO2011034919A2 A NN I-UN
receptor WO2011034919A2 A NN I-UN
( WO2011034919A2 A ( O
EGFR WO2011034919A2 A NNP I-UN
) WO2011034919A2 A ) O
and WO2011034919A2 A CC O
Ras WO2011034919A2 A NNP I-UN
were WO2011034919A2 A VBD O
profiled WO2011034919A2 A VBN O
. WO2011034919A2 A . O

Changes WO2011034919A2 A NNS O
in WO2011034919A2 A IN O
SH2 WO2011034919A2 A NNP I-UN
domain WO2011034919A2 A NN I-UN
binding WO2011034919A2 A NN O
were WO2011034919A2 A VBD O
characterized WO2011034919A2 A VBN O
in WO2011034919A2 A IN O
response WO2011034919A2 A NN O
to WO2011034919A2 A TO O
the WO2011034919A2 A DT O
EGFR WO2011034919A2 A NNP I-UN
inhibitor WO2011034919A2 A NN O
erlotinib WO2011034919A2 A NN O
, WO2011034919A2 A , O
and WO2011034919A2 A CC O
the WO2011034919A2 A DT O
SRC/multi-kinase WO2011034919A2 A NNP I-UN
inhibitor WO2011034919A2 A NN O
dasatinib WO2011034919A2 A NN O
. WO2011034919A2 A . O

Cell WO2011034919A2 A NNP O
lines WO2011034919A2 A NNS O
grouped WO2011034919A2 A VBD O
based WO2011034919A2 A VBN O
on WO2011034919A2 A IN O
SH2 WO2011034919A2 A NNP I-UN
binding WO2011034919A2 A VBG O
patterns WO2011034919A2 A NNS O
. WO2011034919A2 A . O

Clusters WO2011034919A2 A NNS O
correlated WO2011034919A2 A VBD O
with WO2011034919A2 A IN O
EGFR WO2011034919A2 A NNP I-UN
mutation WO2011034919A2 A NN O
status WO2011034919A2 A NN O
or WO2011034919A2 A CC O
MET WO2011034919A2 A NNP I-UN
activation WO2011034919A2 A NN O
. WO2011034919A2 A . O

Binding WO2011034919A2 A NN O
of WO2011034919A2 A IN O
specific WO2011034919A2 A JJ O
SH2 WO2011034919A2 A NNP I-UN
domains WO2011034919A2 A NNS I-UN
correlated WO2011034919A2 A VBD O
with WO2011034919A2 A IN O
EGFR WO2011034919A2 A NNP I-UN
mutation WO2011034919A2 A NN O
and WO2011034919A2 A CC O
erlotinib WO2011034919A2 A JJ O
sensitivity WO2011034919A2 A NN O
. WO2011034919A2 A . O

SH2 WO2011034919A2 A NNP I-UN
domain WO2011034919A2 A NN I-UN
profiling WO2011034919A2 A VBG O
identifies WO2011034919A2 A NNS O
subsets WO2011034919A2 A NNS O
of WO2011034919A2 A IN O
lung WO2011034919A2 A NN O
cancer WO2011034919A2 A NN O
cells WO2011034919A2 A NNS O
with WO2011034919A2 A IN O
distinct WO2011034919A2 A JJ O
patterns WO2011034919A2 A NNS O
of WO2011034919A2 A IN O
pTyr WO2011034919A2 A NN O
signaling WO2011034919A2 A NN O
and WO2011034919A2 A CC O
provides WO2011034919A2 A VBZ O
a WO2011034919A2 A DT O
powerful WO2011034919A2 A JJ O
molecular WO2011034919A2 A JJ O
diagnostic WO2011034919A2 A JJ O
tool WO2011034919A2 A NN O
for WO2011034919A2 A IN O
classification WO2011034919A2 A NN O
and WO2011034919A2 A CC O
biomarker WO2011034919A2 A NN O
identification WO2011034919A2 A NN O
. WO2011034919A2 A . O

This WO2011034919A2 A DT O
analysis WO2011034919A2 A NN O
has WO2011034919A2 A VBZ O
therapeutic WO2011034919A2 A JJ O
importance WO2011034919A2 A NN O
for WO2011034919A2 A IN O
personalized WO2011034919A2 A VBN O
use WO2011034919A2 A NN O
of WO2011034919A2 A IN O
tyrosine WO2011034919A2 A JJ I-UN
kinase WO2011034919A2 A NN I-UN
inhibitors WO2011034919A2 A NNS O
in WO2011034919A2 A IN O
cancer WO2011034919A2 A NN O
. WO2011034919A2 A . O

Opthalmic US20060078626 T NNP O
and US20060078626 T CC O
contact US20060078626 T NN O
lens US20060078626 T NNS O
solutions US20060078626 T NNS O
with US20060078626 T IN O
a US20060078626 T DT O
peroxide US20060078626 T NN O
source US20060078626 T NN O
and US20060078626 T CC O
a US20060078626 T DT O
cationic US20060078626 T JJ O
polymeric US20060078626 T JJ O
preservative US20060078626 T NN O
. US20060078626 T . O

Fused US20090221611 T VBN O
Triazole US20090221611 T NNP O
Tachykinin US20090221611 T NNP I-UN
Receptor US20090221611 T NNP I-UN
Antagonists US20090221611 T NNP O
. US20090221611 T . O

The US20090221611 A DT O
present US20090221611 A JJ O
invention US20090221611 A NN O
is US20090221611 A VBZ O
directed US20090221611 A VBN O
to US20090221611 A TO O
certain US20090221611 A JJ O
fused US20090221611 A JJ O
triazole US20090221611 A NN O
compounds US20090221611 A NNS O
which US20090221611 A WDT O
are US20090221611 A VBP O
useful US20090221611 A JJ O
as US20090221611 A IN O
neurokinin-1 US20090221611 A JJ I-UN
( US20090221611 A ( I-UN
NK-I US20090221611 A NNP I-UN
) US20090221611 A ) I-UN
receptor US20090221611 A NN I-UN
antagonists US20090221611 A NNS O
, US20090221611 A , O
and US20090221611 A CC O
inhibitors US20090221611 A NNS O
of US20090221611 A IN O
tachykinin US20090221611 A NN I-UN
and US20090221611 A CC O
in US20090221611 A IN O
particular US20090221611 A JJ O
substance US20090221611 A NN O
P- US20090221611 A NNP O
The US20090221611 A DT O
invention US20090221611 A NN O
is US20090221611 A VBZ O
also US20090221611 A RB O
concerned US20090221611 A VBN O
with US20090221611 A IN O
pharmaceutical US20090221611 A JJ O
formulations US20090221611 A NNS O
comprising US20090221611 A VBG O
these US20090221611 A DT O
compounds US20090221611 A NNS O
as US20090221611 A IN O
active US20090221611 A JJ O
ingredients US20090221611 A NNS O
and US20090221611 A CC O
the US20090221611 A DT O
use US20090221611 A NN O
of US20090221611 A IN O
the US20090221611 A DT O
compounds US20090221611 A NNS O
and US20090221611 A CC O
their US20090221611 A PRP$ O
formulations US20090221611 A NNS O
in US20090221611 A IN O
the US20090221611 A DT O
treatment US20090221611 A NN O
of US20090221611 A IN O
certain US20090221611 A JJ O
disorders US20090221611 A NNS O
, US20090221611 A , O
including US20090221611 A VBG O
emesis US20090221611 A NN O
, US20090221611 A , O
urinary US20090221611 A JJ O
incontinence US20090221611 A NN O
, US20090221611 A , O
depression US20090221611 A NN O
, US20090221611 A , O
and US20090221611 A CC O
anxiety US20090221611 A NN O
. US20090221611 A . O

Pharmaceutical WO2009044930A1 T JJ O
composition WO2009044930A1 T NN O
for WO2009044930A1 T IN O
inhibiting WO2009044930A1 T VBG O
the WO2009044930A1 T DT O
accumulation WO2009044930A1 T NN O
of WO2009044930A1 T IN O
amyloid-β WO2009044930A1 T JJ I-UN
protein WO2009044930A1 T NN I-UN
. WO2009044930A1 T . O

Disclosed WO2009044930A1 A VBN O
are WO2009044930A1 A VBP O
: WO2009044930A1 A : O
a WO2009044930A1 A DT O
pharmaceutical WO2009044930A1 A JJ O
composition WO2009044930A1 A NN O
for WO2009044930A1 A IN O
inhibiting WO2009044930A1 A VBG O
the WO2009044930A1 A DT O
accumulation WO2009044930A1 A NN O
of WO2009044930A1 A IN O
amyloid-β WO2009044930A1 A JJ I-UN
protein WO2009044930A1 A NN I-UN
, WO2009044930A1 A , O
which WO2009044930A1 A WDT O
comprises WO2009044930A1 A VBZ O
a WO2009044930A1 A DT O
compound WO2009044930A1 A NN O
represented WO2009044930A1 A VBN O
by WO2009044930A1 A IN O
the WO2009044930A1 A DT O
formula WO2009044930A1 A NN O
( WO2009044930A1 A ( O
I WO2009044930A1 A PRP O
) WO2009044930A1 A ) O
or WO2009044930A1 A CC O
a WO2009044930A1 A DT O
pharmaceutically WO2009044930A1 A RB O
acceptable WO2009044930A1 A JJ O
salt WO2009044930A1 A NN O
thereof WO2009044930A1 A NN O
; WO2009044930A1 A : O
a WO2009044930A1 A DT O
method WO2009044930A1 A NN O
for WO2009044930A1 A IN O
inhibiting WO2009044930A1 A VBG O
the WO2009044930A1 A DT O
accumulation WO2009044930A1 A NN O
of WO2009044930A1 A IN O
amyloid-β WO2009044930A1 A JJ I-UN
protein WO2009044930A1 A NN I-UN
, WO2009044930A1 A , O
which WO2009044930A1 A WDT O
comprises WO2009044930A1 A VBZ O
the WO2009044930A1 A DT O
step WO2009044930A1 A NN O
of WO2009044930A1 A IN O
administering WO2009044930A1 A VBG O
an WO2009044930A1 A DT O
effective WO2009044930A1 A JJ O
amount WO2009044930A1 A NN O
of WO2009044930A1 A IN O
a WO2009044930A1 A DT O
compound WO2009044930A1 A NN O
represented WO2009044930A1 A VBN O
by WO2009044930A1 A IN O
the WO2009044930A1 A DT O
formula WO2009044930A1 A NN O
( WO2009044930A1 A ( O
I WO2009044930A1 A PRP O
) WO2009044930A1 A ) O
or WO2009044930A1 A CC O
a WO2009044930A1 A DT O
pharmaceutically WO2009044930A1 A RB O
acceptable WO2009044930A1 A JJ O
salt WO2009044930A1 A NN O
thereof WO2009044930A1 A NN O
to WO2009044930A1 A TO O
a WO2009044930A1 A DT O
mammal WO2009044930A1 A NN O
which WO2009044930A1 A WDT O
is WO2009044930A1 A VBZ O
suspected WO2009044930A1 A VBN O
to WO2009044930A1 A TO O
be WO2009044930A1 A VB O
diagnosed WO2009044930A1 A VBN O
as WO2009044930A1 A IN O
being WO2009044930A1 A VBG O
affected WO2009044930A1 A VBN O
by WO2009044930A1 A IN O
a WO2009044930A1 A DT O
disease WO2009044930A1 A NN O
associated WO2009044930A1 A VBN O
with WO2009044930A1 A IN O
amyloid-β WO2009044930A1 A JJ I-UN
protein WO2009044930A1 A NN I-UN
; WO2009044930A1 A : O
and WO2009044930A1 A CC O
others WO2009044930A1 A NNS O
. WO2009044930A1 A . O

Methods US7531175 T NNS O
for US7531175 T IN O
modulation US7531175 T NN O
of US7531175 T IN O
immune US7531175 T JJ O
responses US7531175 T NNS O
using US7531175 T VBG O
humanized US7531175 T JJ O
immunoglobulins US7531175 T NNS O
reactive US7531175 T JJ O
with US7531175 T IN O
B7-1 US7531175 T NNP O
molecules US7531175 T NNS O
. US7531175 T . O

Method US20060111235 T NNP O
of US20060111235 T IN O
manufacturing US20060111235 T VBG O
ferromagnetic US20060111235 T JJ O
particle US20060111235 T NN O
exothermic US20060111235 T JJ O
elements US20060111235 T NNS O
. US20060111235 T . O

Application CN102204900A T NN O
of CN102204900A T IN O
sodium CN102204900A T NN O
oxamate CN102204900A T NN O
in CN102204900A T IN O
preparing CN102204900A T VBG O
drugs CN102204900A T NNS O
for CN102204900A T IN O
radiotherapy CN102204900A T NN O
sensitization CN102204900A T NN O
. CN102204900A T . O

Application CN103462982A T NN O
of CN103462982A T IN O
spirooliganones CN103462982A T NNS O
B CN103462982A T NNP O
in CN103462982A T IN O
preparation CN103462982A T NN O
of CN103462982A T IN O
medicine CN103462982A T NN O
inhibiting CN103462982A T VBG O
bacteria CN103462982A T NNS O
. CN103462982A T . O

Pharmaceutical CN102046152A T JJ O
composition CN102046152A T NN O
with CN102046152A T IN O
bisphosphonate CN102046152A T NN O
. CN102046152A T . O

Amino-5- US20100168194 T JJ O
[ US20100168194 T JJ O
4- US20100168194 T JJ O
( US20100168194 T ( O
difluoromethoxy US20100168194 T JJ O
) US20100168194 T ) O
phenyl US20100168194 T NN O
] US20100168194 T NNP O
-5-phenylimidazolone US20100168194 T NNP O
Compounds US20100168194 T NNP O
For US20100168194 T IN O
The US20100168194 T DT O
Inhibition US20100168194 T NNP O
Of US20100168194 T IN O
Beta-secretase US20100168194 T NNP I-UN
. US20100168194 T . O

The US20100168194 A DT O
present US20100168194 A JJ O
invention US20100168194 A NN O
provides US20100168194 A VBZ O
compounds US20100168194 A NNS O
and US20100168194 A CC O
methods US20100168194 A NNS O
for US20100168194 A IN O
the US20100168194 A DT O
use US20100168194 A NN O
thereof US20100168194 A NN O
to US20100168194 A TO O
inhibit US20100168194 A VB O
β-secretase US20100168194 A JJ I-UN
( US20100168194 A ( O
BACE US20100168194 A NNP I-UN
) US20100168194 A ) O
and US20100168194 A CC O
treat US20100168194 A JJ O
β-amyloid US20100168194 A JJ O
deposits US20100168194 A NNS O
and US20100168194 A CC O
neurofibrillary US20100168194 A JJ O
tangles US20100168194 A NNS O
. US20100168194 A . O

Flash-melt CA2311734C T JJ O
oral CA2311734C T JJ O
dosage CA2311734C T NN O
formulation CA2311734C T NN O
. CA2311734C T . O

Tetrahydroisoquinoline EP1280777B1 T NNP O
analogs EP1280777B1 T NNS O
useful EP1280777B1 T JJ O
as EP1280777B1 T IN O
growth EP1280777B1 T NN I-UN
hormone EP1280777B1 T NN I-UN
secretagogues EP1280777B1 T NNS O
. EP1280777B1 T . O

Tetrahydroisoquinoline EP1280777B1 A NNP O
analogs EP1280777B1 A NNS O
are EP1280777B1 A VBP O
provided EP1280777B1 A VBN O
which EP1280777B1 A WDT O
are EP1280777B1 A VBP O
useful EP1280777B1 A JJ O
in EP1280777B1 A IN O
stimulating EP1280777B1 A VBG O
endogenous EP1280777B1 A JJ O
production EP1280777B1 A NN O
or EP1280777B1 A CC O
release EP1280777B1 A NN O
of EP1280777B1 A IN O
growth EP1280777B1 A NN I-UN
hormone EP1280777B1 A NN I-UN
and EP1280777B1 A CC O
in EP1280777B1 A IN O
treating EP1280777B1 A VBG O
obesity EP1280777B1 A NN O
, EP1280777B1 A , O
osteoporosis EP1280777B1 A NN O
( EP1280777B1 A ( O
improving EP1280777B1 A VBG O
bone EP1280777B1 A NN O
density EP1280777B1 A NN O
) EP1280777B1 A ) O
and EP1280777B1 A CC O
in EP1280777B1 A IN O
improving EP1280777B1 A VBG O
muscle EP1280777B1 A NN O
mass EP1280777B1 A NN O
and EP1280777B1 A CC O
muscle EP1280777B1 A NN O
strength EP1280777B1 A NN O
. EP1280777B1 A . O

Oral CN102085370A T JJ O
spray CN102085370A T NN O
for CN102085370A T IN O
inflammatory CN102085370A T JJ O
diseases CN102085370A T NNS O
of CN102085370A T IN O
oral CN102085370A T JJ O
cavity CN102085370A T NN O
and CN102085370A T CC O
preparation CN102085370A T NN O
method CN102085370A T NN O
thereof CN102085370A T NN O
. CN102085370A T . O

The CN102085370A A DT O
invention CN102085370A A NN O
relates CN102085370A A VBZ O
to CN102085370A A TO O
an CN102085370A A DT O
oral CN102085370A A JJ O
spray CN102085370A A NN O
for CN102085370A A IN O
inflammatory CN102085370A A JJ O
diseases CN102085370A A NNS O
of CN102085370A A IN O
the CN102085370A A DT O
oral CN102085370A A JJ O
cavity CN102085370A A NN O
and CN102085370A A CC O
a CN102085370A A DT O
preparation CN102085370A A NN O
method CN102085370A A NN O
thereof CN102085370A A NN O
. CN102085370A A . O

The CN102085370A A DT O
oral CN102085370A A JJ O
spray CN102085370A A NN O
comprises CN102085370A A VBZ O
the CN102085370A A DT O
following CN102085370A A JJ O
components CN102085370A A NNS O
: CN102085370A A : O
0.1-5 CN102085370A A CD O
% CN102085370A A NN O
of CN102085370A A IN O
water-soluble CN102085370A A JJ O
chitosan CN102085370A A NN O
, CN102085370A A , O
0.5-5 CN102085370A A CD O
% CN102085370A A NN O
of CN102085370A A IN O
propolis CN102085370A A NN O
extract CN102085370A A NN O
, CN102085370A A , O
0.1-1 CN102085370A A CD O
% CN102085370A A NN O
of CN102085370A A IN O
lactoferrin CN102085370A A NN O
, CN102085370A A , O
0.01-0.5 CN102085370A A CD O
% CN102085370A A NN O
of CN102085370A A IN O
lactoperoxidase CN102085370A A NN O
, CN102085370A A , O
0.1-0.5 CN102085370A A CD O
% CN102085370A A NN O
of CN102085370A A IN O
lysozyme CN102085370A A NN O
, CN102085370A A , O
0.01-0.1 CN102085370A A CD O
% CN102085370A A NN O
of CN102085370A A IN O
immunoglobulin CN102085370A A NN O
, CN102085370A A , O
1-10 CN102085370A A JJ O
% CN102085370A A NN O
of CN102085370A A IN O
bovine CN102085370A A NN O
colostrum CN102085370A A NN O
extract CN102085370A A NN O
, CN102085370A A , O
1-10 CN102085370A A JJ O
% CN102085370A A NN O
of CN102085370A A IN O
anti-caries CN102085370A A JJ O
sweetener CN102085370A A NN O
, CN102085370A A , O
0.8-1.2 CN102085370A A CD O
% CN102085370A A NN O
of CN102085370A A IN O
cold CN102085370A A JJ O
aromatic CN102085370A A JJ O
, CN102085370A A , O
0.1-1 CN102085370A A JJ O
% CN102085370A A NN O
of CN102085370A A IN O
preservative CN102085370A A JJ O
and CN102085370A A CC O
the CN102085370A A DT O
balance CN102085370A A NN O
of CN102085370A A IN O
water CN102085370A A NN O
for CN102085370A A IN O
injections CN102085370A A NNS O
. CN102085370A A . O

The CN102085370A A DT O
preparation CN102085370A A NN O
method CN102085370A A NN O
is CN102085370A A VBZ O
characterized CN102085370A A VBN O
by CN102085370A A IN O
mixing CN102085370A A VBG O
the CN102085370A A DT O
components CN102085370A A NNS O
, CN102085370A A , O
stirring CN102085370A A VBG O
uniformly CN102085370A A RB O
, CN102085370A A , O
filling CN102085370A A VBG O
into CN102085370A A IN O
an CN102085370A A DT O
oral CN102085370A A JJ O
sprayer CN102085370A A NN O
, CN102085370A A , O
and CN102085370A A CC O
sterilizing CN102085370A A VBG O
at CN102085370A A IN O
85 CN102085370A A CD O
DEG CN102085370A A NNP O
C CN102085370A A NNP O
for CN102085370A A IN O
15 CN102085370A A CD O
minutes CN102085370A A NNS O
to CN102085370A A TO O
obtain CN102085370A A VB O
the CN102085370A A DT O
finished CN102085370A A JJ O
product CN102085370A A NN O
. CN102085370A A . O

The CN102085370A A DT O
oral CN102085370A A JJ O
spray CN102085370A A NN O
has CN102085370A A VBZ O
the CN102085370A A DT O
effect CN102085370A A NN O
of CN102085370A A IN O
immediately CN102085370A A RB O
and CN102085370A A CC O
rapidly CN102085370A A RB O
treating CN102085370A A VBG O
inflammatory CN102085370A A NN O
diseases CN102085370A A NNS O
of CN102085370A A IN O
the CN102085370A A DT O
oral CN102085370A A JJ O
cavity CN102085370A A NN O
and CN102085370A A CC O
the CN102085370A A DT O
functions CN102085370A A NNS O
of CN102085370A A IN O
resisting CN102085370A A VBG O
bacteria CN102085370A A NNS O
and CN102085370A A CC O
viruses CN102085370A A NNS O
, CN102085370A A , O
relieving CN102085370A A VBG O
pains CN102085370A A NNS O
, CN102085370A A , O
reducing CN102085370A A VBG O
gum CN102085370A A JJ O
inflammation CN102085370A A NN O
and CN102085370A A CC O
blooding CN102085370A A NN O
, CN102085370A A , O
promoting CN102085370A A VBG O
the CN102085370A A DT O
healing CN102085370A A NN O
of CN102085370A A IN O
oral CN102085370A A JJ O
ulcer CN102085370A A JJ O
wounds CN102085370A A NNS O
, CN102085370A A , O
treating CN102085370A A VBG O
acute CN102085370A A NN O
and CN102085370A A CC O
chronic CN102085370A A JJ O
pharyngitis CN102085370A A NN O
, CN102085370A A , O
moistening CN102085370A A VBG O
and CN102085370A A CC O
freshening CN102085370A A VBG O
the CN102085370A A DT O
oral CN102085370A A JJ O
cavity CN102085370A A NN O
and CN102085370A A CC O
removing CN102085370A A VBG O
halitosis CN102085370A A NN O
. CN102085370A A . O

The CN102085370A A DT O
oral CN102085370A A JJ O
spray CN102085370A A NN O
has CN102085370A A VBZ O
the CN102085370A A DT O
advantages CN102085370A A NNS O
of CN102085370A A IN O
simple CN102085370A A JJ O
and CN102085370A A CC O
convenient CN102085370A A JJ O
large-scale CN102085370A A JJ O
production CN102085370A A NN O
process CN102085370A A NN O
and CN102085370A A CC O
no CN102085370A A DT O
environmental CN102085370A A JJ O
pollution CN102085370A A NN O
in CN102085370A A IN O
the CN102085370A A DT O
production CN102085370A A NN O
process CN102085370A A NN O
. CN102085370A A . O

TRANSCRIPTIONAL EP1813269A1 T NNP O
FACTOR EP1813269A1 T NNP O
Nrf2 EP1813269A1 T NNP I-UN
ACTIVATOR EP1813269A1 T NNP O
AND EP1813269A1 T NNP O
FOOD EP1813269A1 T NNP O
HAVING EP1813269A1 T NNP O
THE EP1813269A1 T NNP O
FUNCTION EP1813269A1 T NNP O
OF EP1813269A1 T IN O
THE EP1813269A1 T NNP O
SAME EP1813269A1 T NNP O
IMPARTED EP1813269A1 T NNP O
THERETO EP1813269A1 T NNP O
. EP1813269A1 T . O

A EP1813269A1 A DT O
composition EP1813269A1 A NN O
, EP1813269A1 A , O
an EP1813269A1 A DT O
Nrf2 EP1813269A1 A NNP I-UN
activating EP1813269A1 A NN O
agent EP1813269A1 A NN O
, EP1813269A1 A , O
and EP1813269A1 A CC O
a EP1813269A1 A DT O
food EP1813269A1 A NN O
according EP1813269A1 A VBG O
to EP1813269A1 A TO O
the EP1813269A1 A DT O
present EP1813269A1 A JJ O
invention EP1813269A1 A NN O
comprise EP1813269A1 A NN O
isohumulones EP1813269A1 A NNS O
or EP1813269A1 A CC O
isomerized EP1813269A1 A VBN O
hop EP1813269A1 A NN O
extract EP1813269A1 A NN O
as EP1813269A1 A IN O
an EP1813269A1 A DT O
active EP1813269A1 A JJ O
ingredient EP1813269A1 A NN O
. EP1813269A1 A . O

They EP1813269A1 A PRP O
are EP1813269A1 A VBP O
useful EP1813269A1 A JJ O
in EP1813269A1 A IN O
treating EP1813269A1 A VBG O
, EP1813269A1 A , O
preventing EP1813269A1 A VBG O
, EP1813269A1 A , O
or EP1813269A1 A CC O
ameliorating EP1813269A1 A VBG O
a EP1813269A1 A DT O
disease EP1813269A1 A NN O
of EP1813269A1 A IN O
condition EP1813269A1 A NN O
which EP1813269A1 A WDT O
is EP1813269A1 A VBZ O
treatable EP1813269A1 A JJ O
, EP1813269A1 A , O
preventable EP1813269A1 A JJ O
, EP1813269A1 A , O
or EP1813269A1 A CC O
ameliorable EP1813269A1 A JJ O
by EP1813269A1 A IN O
the EP1813269A1 A DT O
activation EP1813269A1 A NN O
of EP1813269A1 A IN O
transcription EP1813269A1 A NN O
factor EP1813269A1 A NN O
Nrf2 EP1813269A1 A NNP I-UN
. EP1813269A1 A . O

More EP1813269A1 A RBR O
specifically EP1813269A1 A RB O
, EP1813269A1 A , O
the EP1813269A1 A DT O
composition EP1813269A1 A NN O
, EP1813269A1 A , O
the EP1813269A1 A DT O
Nrf2 EP1813269A1 A NNP I-UN
activating EP1813269A1 A NN O
agent EP1813269A1 A NN O
and EP1813269A1 A CC O
the EP1813269A1 A DT O
food EP1813269A1 A NN O
according EP1813269A1 A VBG O
to EP1813269A1 A TO O
the EP1813269A1 A DT O
present EP1813269A1 A JJ O
invention EP1813269A1 A NN O
are EP1813269A1 A VBP O
useful EP1813269A1 A JJ O
in EP1813269A1 A IN O
treating EP1813269A1 A VBG O
, EP1813269A1 A , O
preventing EP1813269A1 A VBG O
, EP1813269A1 A , O
ameliorating EP1813269A1 A VBG O
, EP1813269A1 A , O
or EP1813269A1 A CC O
alleviating EP1813269A1 A VBG O
chronic EP1813269A1 A JJ O
diseases EP1813269A1 A NNS O
which EP1813269A1 A WDT O
are EP1813269A1 A VBP O
believed EP1813269A1 A VBN O
to EP1813269A1 A TO O
be EP1813269A1 A VB O
caused EP1813269A1 A VBN O
or EP1813269A1 A CC O
exacerbated EP1813269A1 A VBN O
by EP1813269A1 A IN O
cellular EP1813269A1 A JJ O
damages EP1813269A1 A NNS O
due EP1813269A1 A JJ O
to EP1813269A1 A TO O
oxidative EP1813269A1 A JJ O
stress EP1813269A1 A NN O
in EP1813269A1 A IN O
the EP1813269A1 A DT O
body EP1813269A1 A NN O
or EP1813269A1 A CC O
environmental EP1813269A1 A JJ O
substances EP1813269A1 A NNS O
( EP1813269A1 A ( O
for EP1813269A1 A IN O
example EP1813269A1 A NN O
, EP1813269A1 A , O
arteriosclerosis EP1813269A1 A NN O
, EP1813269A1 A , O
hypertension EP1813269A1 A NN O
, EP1813269A1 A , O
diabetes EP1813269A1 A VBZ O
, EP1813269A1 A , O
cerebral EP1813269A1 A JJ O
nerve EP1813269A1 A NN O
degenerative EP1813269A1 A JJ O
diseases EP1813269A1 A NNS O
, EP1813269A1 A , O
skin EP1813269A1 A NN O
diseases EP1813269A1 A NNS O
, EP1813269A1 A , O
eye EP1813269A1 A NN O
diseases EP1813269A1 A NNS O
, EP1813269A1 A , O
asthma EP1813269A1 A NN O
, EP1813269A1 A , O
and EP1813269A1 A CC O
cancer EP1813269A1 A NN O
) EP1813269A1 A ) O
or EP1813269A1 A CC O
delaying EP1813269A1 A VBG O
progress EP1813269A1 A NN O
of EP1813269A1 A IN O
these EP1813269A1 A DT O
diseases EP1813269A1 A NNS O
, EP1813269A1 A , O
or EP1813269A1 A CC O
in EP1813269A1 A IN O
detoxificating EP1813269A1 A VBG O
xenobiotic EP1813269A1 A JJ O
substances EP1813269A1 A NNS O
. EP1813269A1 A . O

Cycloalkyloxybiaryl WO2012165398A1 T NNP O
compound WO2012165398A1 T NN O
. WO2012165398A1 T . O

Use CA2350713C T NNP O
of CA2350713C T IN O
biochemical CA2350713C T JJ O
substances CA2350713C T NNS O
for CA2350713C T IN O
a CA2350713C T DT O
composition CA2350713C T NN O
for CA2350713C T IN O
the CA2350713C T DT O
prevention CA2350713C T NN O
and CA2350713C T CC O
treatment CA2350713C T NN O
of CA2350713C T IN O
health CA2350713C T NN O
conditions CA2350713C T NNS O
caused CA2350713C T VBN O
by CA2350713C T IN O
constriction CA2350713C T NN O
of CA2350713C T IN O
smooth CA2350713C T JJ O
muscle CA2350713C T NN O
cells CA2350713C T NNS O
in CA2350713C T IN O
organs CA2350713C T NNS O
of CA2350713C T IN O
the CA2350713C T DT O
human CA2350713C T JJ O
body CA2350713C T NN O
. CA2350713C T . O

Taste-masked US20120093738 T JJ O
oral US20120093738 T JJ O
formulations US20120093738 T NNS O
of US20120093738 T IN O
influenza US20120093738 T JJ O
antivirals US20120093738 T NNS O
. US20120093738 T . O

Use CN101011380A T NNP O
of CN101011380A T IN O
taspine CN101011380A T NN O
for CN101011380A T IN O
preparing CN101011380A T VBG O
medicament CN101011380A T NN O
for CN101011380A T IN O
inhibiting CN101011380A T VBG O
tumor CN101011380A T NN O
angiogenesis CN101011380A T NN O
. CN101011380A T . O

The CN101011380A A DT O
invention CN101011380A A NN O
uses CN101011380A A VBZ O
said CN101011380A A VBD O
test CN101011380A A NN O
model CN101011380A A NN O
, CN101011380A A , O
ELISA CN101011380A A NNP O
, CN101011380A A , O
immunity CN101011380A A NN O
protein CN101011380A A NN O
label CN101011380A A NN O
, CN101011380A A , O
and CN101011380A A CC O
Real CN101011380A A JJ O
Time CN101011380A A NNP O
RCR CN101011380A A NNP O
test CN101011380A A NN O
method CN101011380A A NN O
to CN101011380A A TO O
research CN101011380A A NN O
the CN101011380A A DT O
effects CN101011380A A NNS O
of CN101011380A A IN O
tasepi CN101011380A A NN O
alkali CN101011380A A NN O
on CN101011380A A IN O
the CN101011380A A DT O
CAM CN101011380A A NNP O
vessel CN101011380A A NN O
structure CN101011380A A NN O
, CN101011380A A , O
the CN101011380A A DT O
growth CN101011380A A NN O
of CN101011380A A IN O
tumor CN101011380A A NN O
, CN101011380A A , O
the CN101011380A A DT O
shape CN101011380A A NN O
change CN101011380A A NN O
and CN101011380A A CC O
the CN101011380A A DT O
fresh CN101011380A A JJ O
vessel CN101011380A A NN O
distribution CN101011380A A NN O
of CN101011380A A IN O
tumor CN101011380A A NN O
, CN101011380A A , O
the CN101011380A A DT O
protein CN101011380A A JJ O
expression CN101011380A A NN O
of CN101011380A A IN O
VEGF CN101011380A A NNP O
and CN101011380A A CC O
bFGF CN101011380A A NN I-UN
, CN101011380A A , O
the CN101011380A A DT O
gene CN101011380A A NN O
expressions CN101011380A A NNS O
of CN101011380A A IN O
VEGF CN101011380A A NNP O
acceptors CN101011380A A NNS O
as CN101011380A A IN O
flt-1 CN101011380A A JJ I-UN
and CN101011380A A CC O
flk-1/KDR CN101011380A A JJ O
, CN101011380A A , O
the CN101011380A A DT O
protein CN101011380A A JJ O
expressions CN101011380A A NNS O
of CN101011380A A IN O
AKT CN101011380A A NNP I-UN
and CN101011380A A CC O
Erk1/2 CN101011380A A NNP O
, CN101011380A A , O
and CN101011380A A CC O
the CN101011380A A DT O
phosphorylation CN101011380A A NN O
level CN101011380A A NN O
, CN101011380A A , O
to CN101011380A A TO O
prove CN101011380A A VB O
the CN101011380A A DT O
function CN101011380A A NN O
of CN101011380A A IN O
tasepi CN101011380A A NN O
alkali CN101011380A A NN O
for CN101011380A A IN O
restraining CN101011380A A VBG O
the CN101011380A A DT O
growth CN101011380A A NN O
of CN101011380A A IN O
tumor CN101011380A A NN O
vessel CN101011380A A NN O
. CN101011380A A . O

Formulations WO2013016501A1 T NNS O
of WO2013016501A1 T IN O
thiophene WO2013016501A1 T JJ O
compounds WO2013016501A1 T NNS O
. WO2013016501A1 T . O

Hyperhidrosis US20100317731 T NNP O
treatment US20100317731 T NN O
. US20100317731 T . O

Cucurbitane WO2009079921A1 T NNP O
triterpenoid WO2009079921A1 T NN O
saponins WO2009079921A1 T NNS O
, WO2009079921A1 T , O
pharmaceutical WO2009079921A1 T JJ O
composition WO2009079921A1 T NN O
thereof WO2009079921A1 T NN O
, WO2009079921A1 T , O
preparation WO2009079921A1 T NN O
and WO2009079921A1 T CC O
use WO2009079921A1 T NN O
thereof WO2009079921A1 T NN O
. WO2009079921A1 T . O

Growth CN102688322A T NNP O
promoting CN102688322A T VBG O
agent CN102688322A T NN O
for CN102688322A T IN O
blackone CN102688322A T NN O
chicken CN102688322A T NN O
and CN102688322A T CC O
preparation CN102688322A T NN O
method CN102688322A T NN O
thereof CN102688322A T NN O
. CN102688322A T . O

NOVEL WO2006003013B1 T JJ O
2-SUBSTITUTED WO2006003013B1 T JJ O
ESTRA-1,3,5 WO2006003013B1 T NNP O
( WO2006003013B1 T ( O
10 WO2006003013B1 T CD O
) WO2006003013B1 T ) O
-TRIEN-17-ONES WO2006003013B1 T NN O
USED WO2006003013B1 T VBN O
IN WO2006003013B1 T NNP O
THE WO2006003013B1 T NNP O
FORM WO2006003013B1 T NNP O
OF WO2006003013B1 T NNP O
INHIBITORS WO2006003013B1 T NNP O
OF WO2006003013B1 T NNP O
17β-HYDROXYSTEROIDDEHYDROGENASE WO2006003013B1 T CD I-UN
OF WO2006003013B1 T NNP I-UN
TYPE WO2006003013B1 T NNP I-UN
1 WO2006003013B1 T CD O
. WO2006003013B1 T . O

Pharmaceutically WO2006003013B1 A RB O
acceptable WO2006003013B1 A JJ O
salts WO2006003013B1 A NNS O
of WO2006003013B1 A IN O
said WO2006003013B1 A VBD O
compounds WO2006003013B1 A NNS O
, WO2006003013B1 A , O
the WO2006003013B1 A DT O
production WO2006003013B1 A NN O
and WO2006003013B1 A CC O
use WO2006003013B1 A NN O
thereof WO2006003013B1 A NN O
in WO2006003013B1 A IN O
the WO2006003013B1 A DT O
form WO2006003013B1 A NN O
of WO2006003013B1 A IN O
drags WO2006003013B1 A NNS O
which WO2006003013B1 A WDT O
are WO2006003013B1 A VBP O
usable WO2006003013B1 A JJ O
for WO2006003013B1 A IN O
preventing WO2006003013B1 A VBG O
and WO2006003013B1 A CC O
treating WO2006003013B1 A VBG O
estrogen-dependent WO2006003013B1 A JJ O
diseases WO2006003013B1 A NNS O
and WO2006003013B1 A CC O
are WO2006003013B1 A VBP O
influenced WO2006003013B1 A VBN O
by WO2006003013B1 A IN O
inhibiting WO2006003013B1 A VBG O
17ß-hydroxysteroiddehydrogenase WO2006003013B1 A CD I-UN
of WO2006003013B1 A IN I-UN
type WO2006003013B1 A NN I-UN
1 WO2006003013B1 A CD O
are WO2006003013B1 A VBP O
also WO2006003013B1 A RB O
disclosed WO2006003013B1 A VBN O
. WO2006003013B1 A . O

Medicinal-composition CN101703506B T NNP O
suspension CN101703506B T NN O
powder CN101703506B T NN O
injection CN101703506B T NN O
with CN101703506B T IN O
mezlocillin CN101703506B T JJ O
sodium CN101703506B T NN O
and CN101703506B T CC O
sulbactam CN101703506B T JJ O
sodium CN101703506B T NN O
, CN101703506B T , O
and CN101703506B T CC O
novel CN101703506B T JJ O
application CN101703506B T NN O
thereof CN101703506B T NN O
. CN101703506B T . O

Preparation CN102895424A T NNP O
method CN102895424A T NN O
of CN102895424A T IN O
drug CN102895424A T NN O
, CN102895424A T , O
calculus-removing CN102895424A T JJ O
powder CN102895424A T NN O
, CN102895424A T , O
for CN102895424A T IN O
treating CN102895424A T VBG O
urolithiasis CN102895424A T NN O
. CN102895424A T . O

Dispersive CN1672686A T NNP O
asiaticoside CN1672686A T NN O
tablet CN1672686A T NN O
and CN1672686A T CC O
its CN1672686A T PRP$ O
prepn CN1672686A T NN O
process CN1672686A T NN O
. CN1672686A T . O

Cladribine US20100203017 T NNP O
Regimen US20100203017 T NNP O
for US20100203017 T IN O
Treating US20100203017 T VBG O
Multiple US20100203017 T JJ O
Sclerosis US20100203017 T NNP O
. US20100203017 T . O

Aryl-Quinolyl US20110053946 T JJ O
Compounds US20110053946 T NNS O
and US20110053946 T CC O
Their US20110053946 T NNP O
Use US20110053946 T NNP O
. US20110053946 T . O

The US20110053946 A DT O
present US20110053946 A JJ O
invention US20110053946 A NN O
pertains US20110053946 A VBZ O
generally US20110053946 A RB O
to US20110053946 A TO O
the US20110053946 A DT O
field US20110053946 A NN O
of US20110053946 A IN O
therapeutic US20110053946 A JJ O
compounds US20110053946 A NNS O
for US20110053946 A IN O
treating US20110053946 A VBG O
proliferative US20110053946 A JJ O
disorders US20110053946 A NNS O
, US20110053946 A , O
cancer US20110053946 A NN O
, US20110053946 A , O
etc. US20110053946 A FW O
, US20110053946 A , O
and US20110053946 A CC O
more US20110053946 A RBR O
specifically US20110053946 A RB O
to US20110053946 A TO O
certain US20110053946 A JJ O
aryl-quinolyl US20110053946 A JJ O
compounds US20110053946 A NNS O
, US20110053946 A , O
as US20110053946 A IN O
described US20110053946 A VBN O
herein US20110053946 A NN O
, US20110053946 A , O
which US20110053946 A WDT O
, US20110053946 A , O
inter US20110053946 A NN O
alia US20110053946 A NN O
, US20110053946 A , O
inhibit US20110053946 A NN O
RAF US20110053946 A NNP I-UN
( US20110053946 A ( O
e.g. US20110053946 A JJ O
, US20110053946 A , O
B-RAF US20110053946 A NNP I-UN
) US20110053946 A ) O
activity US20110053946 A NN O
. US20110053946 A . O

The US20110053946 A DT O
present US20110053946 A JJ O
invention US20110053946 A NN O
also US20110053946 A RB O
pertains US20110053946 A VBZ O
to US20110053946 A TO O
pharmaceutical US20110053946 A JJ O
compositions US20110053946 A NNS O
comprising US20110053946 A VBG O
such US20110053946 A JJ O
compounds US20110053946 A NNS O
, US20110053946 A , O
and US20110053946 A CC O
the US20110053946 A DT O
use US20110053946 A NN O
of US20110053946 A IN O
such US20110053946 A JJ O
compounds US20110053946 A NNS O
and US20110053946 A CC O
compositions US20110053946 A NNS O
, US20110053946 A , O
both US20110053946 A DT O
in US20110053946 A IN O
vitro US20110053946 A NN O
and US20110053946 A CC O
in US20110053946 A IN O
vivo US20110053946 A NN O
, US20110053946 A , O
to US20110053946 A TO O
inhibit US20110053946 A VB O
RAF US20110053946 A NNP I-UN
( US20110053946 A ( O
e.g. US20110053946 A NN O
, US20110053946 A , O
BRAF US20110053946 A NNP I-UN
) US20110053946 A ) O
activity US20110053946 A NN O
, US20110053946 A , O
to US20110053946 A TO O
inhibit US20110053946 A VB O
receptor US20110053946 A JJ I-UN
tyrosine US20110053946 A JJ I-UN
kinase US20110053946 A NN I-UN
( US20110053946 A ( O
RTK US20110053946 A NNP I-UN
) US20110053946 A ) O
activity US20110053946 A NN O
, US20110053946 A , O
to US20110053946 A TO O
inhibit US20110053946 A VB O
cell US20110053946 A NN O
proliferation US20110053946 A NN O
, US20110053946 A , O
and US20110053946 A CC O
in US20110053946 A IN O
the US20110053946 A DT O
treatment US20110053946 A NN O
of US20110053946 A IN O
diseases US20110053946 A NNS O
and US20110053946 A CC O
disorders US20110053946 A NNS O
that US20110053946 A WDT O
are US20110053946 A VBP O
ameliorated US20110053946 A VBN O
by US20110053946 A IN O
the US20110053946 A DT O
inhibition US20110053946 A NN O
of US20110053946 A IN O
RAF US20110053946 A NNP I-UN
, US20110053946 A , O
RTK US20110053946 A NNP I-UN
, US20110053946 A , O
etc. US20110053946 A NN O
, US20110053946 A , O
proliferative US20110053946 A JJ O
disorders US20110053946 A NNS O
such US20110053946 A JJ O
as US20110053946 A IN O
cancer US20110053946 A NN O
( US20110053946 A ( O
e.g. US20110053946 A UH O
, US20110053946 A , O
colorectal US20110053946 A JJ O
cancer US20110053946 A NN O
, US20110053946 A , O
melanoma US20110053946 A NN O
) US20110053946 A ) O
, US20110053946 A , O
etc US20110053946 A FW O
. US20110053946 A . O

Benzofuran US7638540 T NNP O
compound US7638540 T NN O
and US7638540 T CC O
medicinal US7638540 T JJ O
composition US7638540 T NN O
containing US7638540 T VBG O
the US7638540 T DT O
same US7638540 T JJ O
. US7638540 T . O

The US7638540 A DT O
compound US7638540 A NN O
of US7638540 A IN O
the US7638540 A DT O
present US7638540 A JJ O
invention US7638540 A NN O
has US7638540 A VBZ O
superior US7638540 A JJ O
leukotriene US7638540 A JJ O
inhibitory US7638540 A JJ O
action US7638540 A NN O
, US7638540 A , O
BLT2 US7638540 A NNP I-UN
competitive US7638540 A JJ O
inhibitory US7638540 A NN O
action US7638540 A NN O
, US7638540 A , O
BLT2 US7638540 A NNP I-UN
blocking US7638540 A VBG O
action US7638540 A NN O
, US7638540 A , O
action US7638540 A NN O
for US7638540 A IN O
the US7638540 A DT O
prophylaxis US7638540 A NN O
or US7638540 A CC O
treatment US7638540 A NN O
of US7638540 A IN O
allergy US7638540 A NN O
, US7638540 A , O
action US7638540 A NN O
for US7638540 A IN O
the US7638540 A DT O
prophylaxis US7638540 A NN O
or US7638540 A CC O
treatment US7638540 A NN O
of US7638540 A IN O
asthma US7638540 A NN O
and US7638540 A CC O
action US7638540 A NN O
for US7638540 A IN O
the US7638540 A DT O
prophylaxis US7638540 A NN O
or US7638540 A CC O
treatment US7638540 A NN O
of US7638540 A IN O
inflammation US7638540 A NN O
, US7638540 A , O
and US7638540 A CC O
is US7638540 A VBZ O
useful US7638540 A JJ O
as US7638540 A IN O
an US7638540 A DT O
agent US7638540 A NN O
for US7638540 A IN O
the US7638540 A DT O
prophylaxis US7638540 A NN O
or US7638540 A CC O
treatment US7638540 A NN O
of US7638540 A IN O
diseases US7638540 A NNS O
such US7638540 A JJ O
as US7638540 A IN O
allergic US7638540 A JJ O
disease US7638540 A NN O
, US7638540 A , O
asthma US7638540 A NN O
, US7638540 A , O
inflammation US7638540 A NN O
and US7638540 A CC O
the US7638540 A DT O
like US7638540 A JJ O
, US7638540 A , O
and US7638540 A CC O
other US7638540 A JJ O
diseases US7638540 A NNS O
. US7638540 A . O

Use EP1382336B1 T NNP O
of EP1382336B1 T IN O
the EP1382336B1 T DT O
abc EP1382336B1 T JJ I-UN
expression EP1382336B1 T NN O
promotor EP1382336B1 T NN O
pioglitazone EP1382336B1 T NN O
for EP1382336B1 T IN O
the EP1382336B1 T DT O
treatment EP1382336B1 T NN O
of EP1382336B1 T IN O
arteriosclerosis EP1382336B1 T NN O
obliterans EP1382336B1 T NNS O
. EP1382336B1 T . O

ABC-A1 EP1382336B1 A JJ I-UN
mRNA EP1382336B1 A NN I-UN
expression EP1382336B1 A NN O
promoters EP1382336B1 A NNS O
, EP1382336B1 A , O
LXRα EP1382336B1 A NNP I-UN
mRNA EP1382336B1 A POS I-UN
expression EP1382336B1 A NN O
promoters EP1382336B1 A NNS O
, EP1382336B1 A , O
ABC-G1 EP1382336B1 A NNP I-UN
mRNA EP1382336B1 A NN I-UN
expression EP1382336B1 A NN O
promoters EP1382336B1 A NNS O
, EP1382336B1 A , O
cholesterol EP1382336B1 A NN O
transport EP1382336B1 A NN O
promoters EP1382336B1 A NNS O
and EP1382336B1 A CC O
cholesteryl EP1382336B1 A JJ O
ester EP1382336B1 A NN O
accumulation EP1382336B1 A NN O
inhibitors EP1382336B1 A NNS O
containing EP1382336B1 A VBG O
PPARδ EP1382336B1 A NNP I-UN
modulators EP1382336B1 A NNS O
such EP1382336B1 A JJ O
as EP1382336B1 A IN O
pioglitazone EP1382336B1 A NN O
; EP1382336B1 A : O
ABC-G1 EP1382336B1 A NNP I-UN
mRNA EP1382336B1 A NN I-UN
expression EP1382336B1 A NN O
promoters EP1382336B1 A NNS O
containing EP1382336B1 A VBG O
PPARδ EP1382336B1 A NNP I-UN
modulators EP1382336B1 A NNS O
; EP1382336B1 A : O
or EP1382336B1 A CC O
ACAT-1 EP1382336B1 A NNP I-UN
mRNA EP1382336B1 A JJ I-UN
expression EP1382336B1 A NN O
promoters EP1382336B1 A NNS O
and EP1382336B1 A CC O
CEH EP1382336B1 A NNP I-UN
mRNA EP1382336B1 A NNP I-UN
expression EP1382336B1 A NN O
promoters EP1382336B1 A NNS O
containing EP1382336B1 A VBG O
PPARδ EP1382336B1 A NNP I-UN
modulators EP1382336B1 A NNS O
such EP1382336B1 A JJ O
as EP1382336B1 A IN O
pioglitazone EP1382336B1 A NN O
. EP1382336B1 A . O

Combination WO2014152514A1 T NN O
of WO2014152514A1 T IN O
two WO2014152514A1 T CD O
antivirals WO2014152514A1 T NNS O
for WO2014152514A1 T IN O
treating WO2014152514A1 T VBG O
hepatitis WO2014152514A1 T NN O
c WO2014152514A1 T NN O
. WO2014152514A1 T . O

Nitrendipine CN103083265A T NNP O
tablet CN103083265A T NN O
and CN103083265A T CC O
preparation CN103083265A T NN O
method CN103083265A T NN O
thereof CN103083265A T NN O
. CN103083265A T . O

The CN103083265A A DT O
invention CN103083265A A NN O
relates CN103083265A A VBZ O
to CN103083265A A TO O
a CN103083265A A DT O
nitrendipine CN103083265A A JJ O
tablet CN103083265A A NN O
and CN103083265A A CC O
a CN103083265A A DT O
preparation CN103083265A A NN O
method CN103083265A A NN O
thereof CN103083265A A NN O
. CN103083265A A . O

The CN103083265A A DT O
nitrendipine CN103083265A A JJ O
tablet CN103083265A A NN O
comprises CN103083265A A NNS O
, CN103083265A A , O
by CN103083265A A IN O
weight CN103083265A A NN O
, CN103083265A A , O
1 CN103083265A A CD O
part CN103083265A A NN O
of CN103083265A A IN O
nitrendipine CN103083265A A NN O
, CN103083265A A , O
1.0 CN103083265A A CD O
to CN103083265A A TO O
5.0 CN103083265A A CD O
parts CN103083265A A NNS O
of CN103083265A A IN O
polyvinylpyrrolidone CN103083265A A NN O
, CN103083265A A , O
0.05 CN103083265A A CD O
to CN103083265A A TO O
0.25 CN103083265A A CD O
parts CN103083265A A NNS O
of CN103083265A A IN O
polyethylene CN103083265A A NN O
glycol CN103083265A A NN O
, CN103083265A A , O
0.05 CN103083265A A CD O
to CN103083265A A TO O
0.4 CN103083265A A CD O
parts CN103083265A A NNS O
of CN103083265A A IN O
hydroxypropyl CN103083265A A NN O
methyl CN103083265A A NN O
cellulose CN103083265A A NN O
, CN103083265A A , O
and CN103083265A A CC O
0.5 CN103083265A A CD O
to CN103083265A A TO O
2.0 CN103083265A A CD O
parts CN103083265A A NNS O
of CN103083265A A IN O
polysaccharide CN103083265A A NN O
. CN103083265A A . O

The CN103083265A A DT O
preparation CN103083265A A NN O
method CN103083265A A NN O
comprises CN103083265A A VBZ O
the CN103083265A A DT O
following CN103083265A A JJ O
steps CN103083265A A NNS O
of CN103083265A A IN O
dissolving CN103083265A A VBG O
nitrendipine CN103083265A A NN O
in CN103083265A A IN O
a CN103083265A A DT O
solvent CN103083265A A NN O
, CN103083265A A , O
adding CN103083265A A VBG O
a CN103083265A A DT O
part CN103083265A A NN O
of CN103083265A A IN O
auxiliary CN103083265A A JJ O
materials CN103083265A A NNS O
into CN103083265A A IN O
the CN103083265A A DT O
solution CN103083265A A NN O
, CN103083265A A , O
fully CN103083265A A RB O
mixing CN103083265A A VBG O
to CN103083265A A TO O
obtain CN103083265A A VB O
a CN103083265A A DT O
homogeneous CN103083265A A JJ O
system CN103083265A A NN O
, CN103083265A A , O
wherein CN103083265A A JJ O
nitrendipine CN103083265A A NN O
is CN103083265A A VBZ O
distributed CN103083265A A VBN O
in CN103083265A A IN O
a CN103083265A A DT O
molecular CN103083265A A JJ O
state CN103083265A A NN O
or CN103083265A A CC O
an CN103083265A A DT O
amorphous CN103083265A A JJ O
state CN103083265A A NN O
, CN103083265A A , O
and CN103083265A A CC O
adding CN103083265A A VBG O
the CN103083265A A DT O
rest CN103083265A A NN O
of CN103083265A A IN O
the CN103083265A A DT O
auxiliary CN103083265A A JJ O
materials CN103083265A A NNS O
into CN103083265A A IN O
the CN103083265A A DT O
mixture CN103083265A A NN O
to CN103083265A A TO O
obtain CN103083265A A VB O
the CN103083265A A DT O
nitrendipine CN103083265A A JJ O
tablet CN103083265A A NN O
. CN103083265A A . O

The CN103083265A A DT O
nitrendipine CN103083265A A JJ O
tablet CN103083265A A NN O
has CN103083265A A VBZ O
high CN103083265A A JJ O
bioavailability CN103083265A A NN O
and CN103083265A A CC O
can CN103083265A A MD O
be CN103083265A A VB O
fully CN103083265A A RB O
and CN103083265A A CC O
easily CN103083265A A RB O
absorbed CN103083265A A VBN O
by CN103083265A A IN O
organisms CN103083265A A NNS O
after CN103083265A A IN O
oral CN103083265A A JJ O
administration CN103083265A A NN O
. CN103083265A A . O

Antidepressant US6906087 T NNP O
; US6906087 T : O
storage US6906087 T NN O
stability US6906087 T NN O
. US6906087 T . O

Anti-sense WO2006008649A1 T JJ O
polynucleotide WO2006008649A1 T NN O
therapy WO2006008649A1 T NN O
for WO2006008649A1 T IN O
gastrin-promoted WO2006008649A1 T JJ O
tumors WO2006008649A1 T NNS O
. WO2006008649A1 T . O

Tnf CA2113023C T NNP O
receptor CA2113023C T NN O
promoter CA2113023C T NN O
. CA2113023C T . O

A CA2113023C A DT O
promoter CA2113023C A NN O
sequence CA2113023C A NN O
of CA2113023C A IN O
the CA2113023C A DT O
human CA2113023C A JJ I-UN
p55 CA2113023C A NN I-UN
TNF-R CA2113023C A NNP O
gene CA2113023C A NN O
is CA2113023C A VBZ O
provided CA2113023C A VBN O
. CA2113023C A . O

Methods CA2113023C A NNS O
for CA2113023C A IN O
preparing CA2113023C A VBG O
these CA2113023C A DT O
motifs CA2113023C A NNS O
or CA2113023C A CC O
motif CA2113023C A JJ O
regions CA2113023C A NNS O
and CA2113023C A CC O
their CA2113023C A PRP$ O
use CA2113023C A NN O
in CA2113023C A IN O
the CA2113023C A DT O
modulation CA2113023C A NN O
of CA2113023C A IN O
TNF CA2113023C A NNP I-UN
function CA2113023C A NN O
are CA2113023C A VBP O
also CA2113023C A RB O
provided CA2113023C A VBN O
. CA2113023C A . O

Misprostol WO2014016394A1 T NNP O
composition WO2014016394A1 T NN O
. WO2014016394A1 T . O

Compound CN101007164A T NNP O
ofloxacin CN101007164A T MD O
injection CN101007164A T VB O
and CN101007164A T CC O
its CN101007164A T PRP$ O
preparation CN101007164A T NN O
method CN101007164A T NN O
. CN101007164A T . O

Ofloxacin CN101007164A A NNP O
has CN101007164A A VBZ O
the CN101007164A A DT O
antibacterial CN101007164A A JJ O
activity CN101007164A A NN O
of CN101007164A A IN O
the CN101007164A A DT O
third CN101007164A A JJ O
generation CN101007164A A NN O
quinolones CN101007164A A NNS O
which CN101007164A A WDT O
can CN101007164A A MD O
inhibit CN101007164A A VB O
the CN101007164A A DT O
bacteria CN101007164A A NNS I-UN
prokaryotic CN101007164A A JJ I-UN
cell CN101007164A A NN I-UN
DNA CN101007164A A NNP I-UN
gyrase CN101007164A A NN I-UN
and CN101007164A A CC O
DNA CN101007164A A NNP O
replication CN101007164A A NN O
. CN101007164A A . O

Oral CN1939264A T JJ O
preparation CN1939264A T NN O
containing CN1939264A T VBG O
ceftazidime CN1939264A T NN O
and CN1939264A T CC O
its CN1939264A T PRP$ O
making CN1939264A T NN O
method CN1939264A T NN O
. CN1939264A T . O

Process US20100113479 T NN O
for US20100113479 T IN O
the US20100113479 T DT O
preparation US20100113479 T NN O
of US20100113479 T IN O
tri-substituted US20100113479 T JJ O
pyridine US20100113479 T NN O
and US20100113479 T CC O
tri-substituted US20100113479 T JJ O
pyrimidine US20100113479 T NN O
derivatives US20100113479 T NNS O
useful US20100113479 T JJ O
as US20100113479 T IN O
gdir US20100113479 T JJ I-UN
agonists US20100113479 T NNS O
. US20100113479 T . O

The US20100113479 A DT O
present US20100113479 A JJ O
invention US20100113479 A NN O
is US20100113479 A VBZ O
directed US20100113479 A VBN O
to US20100113479 A TO O
novel US20100113479 A JJ O
processes US20100113479 A NNS O
for US20100113479 A IN O
the US20100113479 A DT O
preparation US20100113479 A NN O
of US20100113479 A IN O
tri-substituted US20100113479 A JJ O
pyridine US20100113479 A NN O
and US20100113479 A CC O
tri-substituted US20100113479 A JJ O
pyrimidine US20100113479 A NN O
derivatives US20100113479 A NNS O
, US20100113479 A , O
useful US20100113479 A JJ O
as US20100113479 A IN O
glucose US20100113479 A JJ I-UN
dependent US20100113479 A JJ I-UN
insulinotropic US20100113479 A NN I-UN
receptor US20100113479 A NN I-UN
agonist US20100113479 A NN O
, US20100113479 A , O
for US20100113479 A IN O
the US20100113479 A DT O
treatment US20100113479 A NN O
of US20100113479 A IN O
metabolic-related US20100113479 A JJ O
disorders US20100113479 A NNS O
and US20100113479 A CC O
complications US20100113479 A NNS O
thereof US20100113479 A VBP O
, US20100113479 A , O
such US20100113479 A JJ O
as US20100113479 A IN O
, US20100113479 A , O
diabetes US20100113479 A NNS O
and US20100113479 A CC O
obesity US20100113479 A NN O
. US20100113479 A . O

Grafts US20110076315 T NNS O
and US20110076315 T CC O
Stents US20110076315 T NNS O
Having US20110076315 T VBG O
Inorganic US20110076315 T NNP O
Bio-Compatible US20110076315 T JJ O
Calcium US20110076315 T NNP O
Salt US20110076315 T NNP O
. US20110076315 T . O

Composition CA2389650C T NN O
for CA2389650C T IN O
treatment CA2389650C T NN O
of CA2389650C T IN O
constipation CA2389650C T NN O
and CA2389650C T CC O
irritable CA2389650C T JJ O
bowel CA2389650C T NN O
syndrome CA2389650C T NN O
. CA2389650C T . O

Anticancer US20050014769 T NNP O
agents US20050014769 T NNS O
; US20050014769 T : O
controlling US20050014769 T VBG O
apoptosis US20050014769 T NN O
. US20050014769 T . O

19-nor-vitamin WO2010006121A3 T JJ O
d WO2010006121A3 T NN O
analogs WO2010006121A3 T NNS O
with WO2010006121A3 T IN O
3,2-dihydrofuran WO2010006121A3 T JJ O
ring WO2010006121A3 T NN O
. WO2010006121A3 T . O

pyrimidine WO2006044524A1 T NN O
compounds WO2006044524A1 T NNS O
as WO2006044524A1 T IN O
inhibitors WO2006044524A1 T NNS O
of WO2006044524A1 T IN O
tyrosine WO2006044524A1 T JJ O
kinase WO2006044524A1 T NN O
activities WO2006044524A1 T NNS O
of WO2006044524A1 T IN O
the WO2006044524A1 T DT O
epidermal WO2006044524A1 T JJ I-UN
growth WO2006044524A1 T NN I-UN
factor WO2006044524A1 T NN I-UN
receptors WO2006044524A1 T NNS I-UN
( WO2006044524A1 T ( O
egfrs WO2006044524A1 T NN I-UN
) WO2006044524A1 T ) O
for WO2006044524A1 T IN O
the WO2006044524A1 T DT O
treatment WO2006044524A1 T NN O
of WO2006044524A1 T IN O
hyperproliferative WO2006044524A1 T JJ O
diseases WO2006044524A1 T NNS O
. WO2006044524A1 T . O

FUSED WO2007149557A1 T NNP O
[ WO2007149557A1 T NNP O
d WO2007149557A1 T NN O
] WO2007149557A1 T NNP O
PYRIDAZIN-7-ONES WO2007149557A1 T NNP O
. WO2007149557A1 T . O

In WO2007149557A1 A IN O
particular WO2007149557A1 A JJ O
, WO2007149557A1 A , O
the WO2007149557A1 A DT O
compounds WO2007149557A1 A NNS O
of WO2007149557A1 A IN O
the WO2007149557A1 A DT O
present WO2007149557A1 A JJ O
invention WO2007149557A1 A NN O
may WO2007149557A1 A MD O
he WO2007149557A1 A PRP O
effective WO2007149557A1 A JJ O
in WO2007149557A1 A IN O
the WO2007149557A1 A DT O
treatment WO2007149557A1 A NN O
of WO2007149557A1 A IN O
diseases WO2007149557A1 A NNS O
or WO2007149557A1 A CC O
disease WO2007149557A1 A VB O
states WO2007149557A1 A NNS O
related WO2007149557A1 A VBN O
to WO2007149557A1 A TO O
the WO2007149557A1 A DT O
activity WO2007149557A1 A NN O
of WO2007149557A1 A IN O
VEGFR2 WO2007149557A1 A NNP I-UN
, WO2007149557A1 A , O
MLKl WO2007149557A1 A NNP I-UN
and WO2007149557A1 A CC O
CDK5 WO2007149557A1 A NNP I-UN
enzymes WO2007149557A1 A NNS O
, WO2007149557A1 A , O
including WO2007149557A1 A VBG O
, WO2007149557A1 A , O
for WO2007149557A1 A IN O
example WO2007149557A1 A NN O
, WO2007149557A1 A , O
angiogenic WO2007149557A1 A JJ O
disorders WO2007149557A1 A NNS O
and WO2007149557A1 A CC O
neurodegenerative WO2007149557A1 A JJ O
diseases WO2007149557A1 A NNS O
. WO2007149557A1 A . O

Compositions WO2014130894A1 T NNS O
for WO2014130894A1 T IN O
the WO2014130894A1 T DT O
treatment WO2014130894A1 T NN O
of WO2014130894A1 T IN O
inflammatory WO2014130894A1 T JJ O
diseases WO2014130894A1 T NNS O
. WO2014130894A1 T . O

Regulator WO2007049642A1 T NN O
of WO2007049642A1 T IN O
capsaicin WO2007049642A1 T JJ I-UN
receptor WO2007049642A1 T NN I-UN
activity WO2007049642A1 T NN O
and WO2007049642A1 T CC O
pharmaceutical WO2007049642A1 T JJ O
composition WO2007049642A1 T NN O
using WO2007049642A1 T VBG O
the WO2007049642A1 T DT O
same WO2007049642A1 T JJ O
. WO2007049642A1 T . O

The WO2007049642A1 A DT O
object WO2007049642A1 A NN O
is WO2007049642A1 A VBZ O
to WO2007049642A1 A TO O
analyze WO2007049642A1 A VB O
a WO2007049642A1 A DT O
TRPV1-binding WO2007049642A1 A JJ O
protein WO2007049642A1 A NN O
for WO2007049642A1 A IN O
the WO2007049642A1 A DT O
purpose WO2007049642A1 A NN O
of WO2007049642A1 A IN O
controlling WO2007049642A1 A VBG O
a WO2007049642A1 A DT O
pain WO2007049642A1 A NN O
or WO2007049642A1 A CC O
the WO2007049642A1 A DT O
protection WO2007049642A1 A NN O
activity WO2007049642A1 A NN O
of WO2007049642A1 A IN O
a WO2007049642A1 A DT O
gastric WO2007049642A1 A JJ O
mucosa WO2007049642A1 A NN O
induced WO2007049642A1 A VBN O
by WO2007049642A1 A IN O
TRPV1 WO2007049642A1 A NNP I-UN
and WO2007049642A1 A CC O
to WO2007049642A1 A TO O
achieve WO2007049642A1 A VB O
the WO2007049642A1 A DT O
regulation WO2007049642A1 A NN O
of WO2007049642A1 A IN O
the WO2007049642A1 A DT O
action WO2007049642A1 A NN O
of WO2007049642A1 A IN O
TRPV1 WO2007049642A1 A NNP I-UN
. WO2007049642A1 A . O

Disclosed WO2007049642A1 A VBN O
are WO2007049642A1 A VBP O
: WO2007049642A1 A : O
a WO2007049642A1 A DT O
mutant WO2007049642A1 A NN O
EHD4 WO2007049642A1 A NNP I-UN
which WO2007049642A1 A WDT O
has WO2007049642A1 A VBZ O
a WO2007049642A1 A DT O
mutation WO2007049642A1 A NN O
in WO2007049642A1 A IN O
at WO2007049642A1 A IN O
least WO2007049642A1 A JJS O
one WO2007049642A1 A CD O
amino WO2007049642A1 A NN O
acid WO2007049642A1 A NN O
residue WO2007049642A1 A JJ O
selected WO2007049642A1 A VBN O
from WO2007049642A1 A IN O
amino WO2007049642A1 A JJ O
acid WO2007049642A1 A NN O
residues WO2007049642A1 A NNS O
corresponding WO2007049642A1 A VBG O
to WO2007049642A1 A TO O
position-66 WO2007049642A1 A JJ O
, WO2007049642A1 A , O
position-184 WO2007049642A1 A JJ O
and WO2007049642A1 A CC O
position-225 WO2007049642A1 A JJ O
in WO2007049642A1 A IN O
the WO2007049642A1 A DT O
amino WO2007049642A1 A NN O
acid WO2007049642A1 A JJ O
sequence WO2007049642A1 A NN O
of WO2007049642A1 A IN O
a WO2007049642A1 A DT O
normal WO2007049642A1 A JJ O
murine WO2007049642A1 A NN I-UN
EHD4 WO2007049642A1 A NNP I-UN
; WO2007049642A1 A : O
and WO2007049642A1 A CC O
a WO2007049642A1 A DT O
gene WO2007049642A1 A NN O
encoding WO2007049642A1 A VBG O
the WO2007049642A1 A DT O
mutant WO2007049642A1 A JJ O
protein WO2007049642A1 A NN O
; WO2007049642A1 A : O
a WO2007049642A1 A DT O
regulator WO2007049642A1 A NN O
of WO2007049642A1 A IN O
the WO2007049642A1 A DT O
activity WO2007049642A1 A NN O
of WO2007049642A1 A IN O
TRPV1 WO2007049642A1 A NNP I-UN
, WO2007049642A1 A , O
which WO2007049642A1 A WDT O
comprises WO2007049642A1 A VBZ O
the WO2007049642A1 A DT O
mutant WO2007049642A1 A JJ O
protein WO2007049642A1 A NN O
; WO2007049642A1 A : O
and WO2007049642A1 A CC O
a WO2007049642A1 A DT O
pharmaceutical WO2007049642A1 A JJ O
composition WO2007049642A1 A NN O
comprising WO2007049642A1 A VBG O
EHD4 WO2007049642A1 A NNP I-UN
, WO2007049642A1 A , O
a WO2007049642A1 A DT O
substance WO2007049642A1 A NN O
capable WO2007049642A1 A JJ O
of WO2007049642A1 A IN O
increasing WO2007049642A1 A VBG O
the WO2007049642A1 A DT O
activity WO2007049642A1 A NN O
of WO2007049642A1 A IN O
EHD4 WO2007049642A1 A NNP I-UN
or WO2007049642A1 A CC O
a WO2007049642A1 A DT O
substance WO2007049642A1 A NN O
capable WO2007049642A1 A JJ O
of WO2007049642A1 A IN O
inhibiting WO2007049642A1 A VBG O
the WO2007049642A1 A DT O
activity WO2007049642A1 A NN O
of WO2007049642A1 A IN O
EHD4 WO2007049642A1 A NNP I-UN
and WO2007049642A1 A CC O
a WO2007049642A1 A DT O
pharmaceutically WO2007049642A1 A RB O
acceptable WO2007049642A1 A JJ O
carrier WO2007049642A1 A NN O
. WO2007049642A1 A . O

Cyanopyridine CN101166732A T NNP O
derivative CN101166732A T NN O
and CN101166732A T CC O
use CN101166732A T NN O
thereof CN101166732A T NN O
as CN101166732A T IN O
medicine CN101166732A T NN O
. CN101166732A T . O

Externally CN101342277A T RB O
used CN101342277A T VBN O
antimicrobial CN101342277A T JJ O
spray CN101342277A T NN O
for CN101342277A T IN O
treating CN101342277A T VBG O
snore CN101342277A T NN O
and CN101342277A T CC O
preparation CN101342277A T NN O
method CN101342277A T NN O
thereof CN101342277A T NN O
. CN101342277A T . O

Dimeric US20110152289 T NNP O
derivatives US20110152289 T NNS O
of US20110152289 T IN O
artemisinin US20110152289 T NN O
and US20110152289 T CC O
application US20110152289 T NN O
in US20110152289 T IN O
anti-cancer US20110152289 T JJ O
therapy US20110152289 T NN O
. US20110152289 T . O

The US20110152289 A DT O
present US20110152289 A JJ O
invention US20110152289 A NN O
relates US20110152289 A VBZ O
to US20110152289 A TO O
dimeric US20110152289 A VB O
derivatives US20110152289 A NNS O
of US20110152289 A IN O
10-trifluoromethylated US20110152289 A JJ O
artemisinin US20110152289 A NN O
of US20110152289 A IN O
formula US20110152289 A NN O
( US20110152289 A ( O
I US20110152289 A PRP O
) US20110152289 A ) O
below US20110152289 A IN O
: US20110152289 A : O
Formula US20110152289 A NNP O
( US20110152289 A ( O
I US20110152289 A PRP O
) US20110152289 A ) O
and US20110152289 A CC O
the US20110152289 A DT O
pharmaceutically US20110152289 A RB O
acceptable US20110152289 A JJ O
salts US20110152289 A NNS O
thereof US20110152289 A NN O
, US20110152289 A , O
and US20110152289 A CC O
also US20110152289 A RB O
to US20110152289 A TO O
the US20110152289 A DT O
preparation US20110152289 A NN O
method US20110152289 A NN O
thereof US20110152289 A NN O
and US20110152289 A CC O
to US20110152289 A TO O
the US20110152289 A DT O
uses US20110152289 A NNS O
thereof US20110152289 A VBP O
, US20110152289 A , O
especially US20110152289 A RB O
in US20110152289 A IN O
the US20110152289 A DT O
treatment US20110152289 A NN O
of US20110152289 A IN O
cancer US20110152289 A NN O
. US20110152289 A . O

Multifunctional CN201542233U T JJ O
shape-protecting CN201542233U T NN O
health CN201542233U T NN O
care CN201542233U T NN O
medical CN201542233U T JJ O
pillow CN201542233U T NN O
for CN201542233U T IN O
babies CN201542233U T NNS O
. CN201542233U T . O

Inhalation US20090042843 T NNP O
Device US20090042843 T NNP O
Containing US20090042843 T NNP O
Plural US20090042843 T NNP O
Doses US20090042843 T NNP O
of US20090042843 T IN O
a US20090042843 T DT O
Pharmaceutical US20090042843 T JJ O
Composition US20090042843 T NN O
. US20090042843 T . O

Geldanamycin CN103450083A T NNP O
derivatives CN103450083A T NNS O
and CN103450083A T CC O
preparation CN103450083A T NN O
method CN103450083A T NN O
and CN103450083A T CC O
applications CN103450083A T NNS O
thereof CN103450083A T VBP O
. CN103450083A T . O

Isolation US20120117672 T NN O
and US20120117672 T CC O
growth US20120117672 T NN O
of US20120117672 T IN O
stem US20120117672 T NN O
cells US20120117672 T NNS O
from US20120117672 T IN O
hemangiomas US20120117672 T NN O
. US20120117672 T . O

Youlikang CN102178976A T NN O
. CN102178976A T . O

ABCA-1 US6919339 T JJ I-UN
elevating US6919339 T VBG O
compounds US6919339 T NNS O
. US6919339 T . O

The US6919339 A DT O
present US6919339 A JJ O
invention US6919339 A NN O
provides US6919339 A VBZ O
compounds US6919339 A NNS O
that US6919339 A IN O
elevate US6919339 A VBP O
cellular US6919339 A JJ O
expression US6919339 A NN O
of US6919339 A IN O
the US6919339 A DT O
ABCA-1 US6919339 A NNP I-UN
gene US6919339 A NN O
, US6919339 A , O
promoting US6919339 A VBG O
cholesterol US6919339 A NN O
efflux US6919339 A NN O
from US6919339 A IN O
cells US6919339 A NNS O
and US6919339 A CC O
increasing US6919339 A VBG O
HDL US6919339 A NNP O
levels US6919339 A NNS O
in US6919339 A IN O
the US6919339 A DT O
plasma US6919339 A NN O
of US6919339 A IN O
a US6919339 A DT O
mammal US6919339 A NN O
, US6919339 A , O
in US6919339 A IN O
particular US6919339 A JJ O
humans US6919339 A NNS O
. US6919339 A . O

Fused WO2007028638A1 T VBN O
and WO2007028638A1 T CC O
spirocycle WO2007028638A1 T VB O
compounds WO2007028638A1 T NNS O
and WO2007028638A1 T CC O
the WO2007028638A1 T DT O
use WO2007028638A1 T NN O
thereof WO2007028638A1 T NN O
. WO2007028638A1 T . O

The WO2007028638A1 A DT O
invention WO2007028638A1 A NN O
relates WO2007028638A1 A VBZ O
to WO2007028638A1 A TO O
fused WO2007028638A1 A VBN O
and WO2007028638A1 A CC O
spirocycle WO2007028638A1 A JJ O
compounds WO2007028638A1 A NNS O
of WO2007028638A1 A IN O
Formula WO2007028638A1 A NNP O
( WO2007028638A1 A ( O
I WO2007028638A1 A PRP O
) WO2007028638A1 A ) O
, WO2007028638A1 A , O
or WO2007028638A1 A CC O
a WO2007028638A1 A DT O
pharmaceutically WO2007028638A1 A RB O
acceptable WO2007028638A1 A JJ O
salt WO2007028638A1 A NN O
, WO2007028638A1 A , O
prodrug WO2007028638A1 A NN O
, WO2007028638A1 A , O
or WO2007028638A1 A CC O
solvate WO2007028638A1 A VB O
thereof WO2007028638A1 A NN O
, WO2007028638A1 A , O
wherein WO2007028638A1 A NN O
R1 WO2007028638A1 A NNP O
, WO2007028638A1 A , O
R2 WO2007028638A1 A NNP O
, WO2007028638A1 A , O
Q1-Q3 WO2007028638A1 A NNP O
, WO2007028638A1 A , O
and WO2007028638A1 A CC O
Z WO2007028638A1 A NNP O
are WO2007028638A1 A VBP O
defined WO2007028638A1 A VBN O
as WO2007028638A1 A IN O
set WO2007028638A1 A NN O
forth WO2007028638A1 A NN O
in WO2007028638A1 A IN O
the WO2007028638A1 A DT O
specification WO2007028638A1 A NN O
. WO2007028638A1 A . O

The WO2007028638A1 A DT O
invention WO2007028638A1 A NN O
is WO2007028638A1 A VBZ O
also WO2007028638A1 A RB O
directed WO2007028638A1 A VBN O
to WO2007028638A1 A TO O
the WO2007028638A1 A DT O
use WO2007028638A1 A NN O
of WO2007028638A1 A IN O
compounds WO2007028638A1 A NNS O
of WO2007028638A1 A IN O
Formula WO2007028638A1 A NNP O
( WO2007028638A1 A ( O
I WO2007028638A1 A PRP O
) WO2007028638A1 A ) O
to WO2007028638A1 A TO O
treat WO2007028638A1 A VB O
, WO2007028638A1 A , O
prevent WO2007028638A1 A NN O
or WO2007028638A1 A CC O
ameliorate WO2007028638A1 A VB O
a WO2007028638A1 A DT O
disorder WO2007028638A1 A NN O
responsive WO2007028638A1 A NN O
to WO2007028638A1 A TO O
the WO2007028638A1 A DT O
blockade WO2007028638A1 A NN O
of WO2007028638A1 A IN O
calcium WO2007028638A1 A NN O
channels WO2007028638A1 A NNS O
, WO2007028638A1 A , O
and WO2007028638A1 A CC O
particularly WO2007028638A1 A RB O
N-type WO2007028638A1 A JJ O
calcium WO2007028638A1 A NN O
channels WO2007028638A1 A NNS O
. WO2007028638A1 A . O

Compounds WO2007028638A1 A NNS O
of WO2007028638A1 A IN O
the WO2007028638A1 A DT O
present WO2007028638A1 A JJ O
invention WO2007028638A1 A NN O
are WO2007028638A1 A VBP O
especially WO2007028638A1 A RB O
useful WO2007028638A1 A JJ O
for WO2007028638A1 A IN O
treating WO2007028638A1 A VBG O
pain WO2007028638A1 A NN O
. WO2007028638A1 A . O

1,2,3-triazole US20100297054 T JJ O
derivatives US20100297054 T NNS O
for US20100297054 T IN O
use US20100297054 T NN O
as US20100297054 T IN O
stearoyl-coa US20100297054 T JJ O
desaturase US20100297054 T NN O
inhibitors US20100297054 T NNS O
. US20100297054 T . O

Compositions US20100069464 T NNS O
and US20100069464 T CC O
methods US20100069464 T NNS O
for US20100069464 T IN O
modulating US20100069464 T VBG O
activity US20100069464 T NN O
of US20100069464 T IN O
capped US20100069464 T VBN O
small US20100069464 T JJ O
rnas US20100069464 T NNS O
. US20100069464 T . O

Use CN101134029A T NNP O
of CN101134029A T IN O
alvianolic CN101134029A T JJ O
acid CN101134029A T NN O
B CN101134029A T NNP O
salt CN101134029A T NN O
as CN101134029A T IN O
Na+/K+-ATP CN101134029A T NNP I-UN
enzyme CN101134029A T NN I-UN
inhibitor CN101134029A T NN O
. CN101134029A T . O

The CN101134029A A DT O
present CN101134029A A JJ O
invention CN101134029A A NN O
is CN101134029A A VBZ O
the CN101134029A A DT O
use CN101134029A A NN O
of CN101134029A A IN O
one CN101134029A A CD O
kind CN101134029A A NN O
of CN101134029A A IN O
salvianolate CN101134029A A NN O
B CN101134029A A NNP O
salt CN101134029A A NN O
or CN101134029A A CC O
its CN101134029A A PRP$ O
isomer CN101134029A A NN O
, CN101134029A A , O
precursor CN101134029A A NN O
, CN101134029A A , O
derivative CN101134029A A JJ O
, CN101134029A A , O
pharmaceutically CN101134029A A RB O
acceptable CN101134029A A JJ O
salt CN101134029A A NN O
and CN101134029A A CC O
composition CN101134029A A NN O
as CN101134029A A IN O
Na+/K+-ATP CN101134029A A NNP I-UN
enzyme CN101134029A A NN I-UN
inhibitor CN101134029A A NN O
. CN101134029A A . O

The CN101134029A A DT O
Na+/K+-ATP CN101134029A A NNP I-UN
enzyme CN101134029A A NN I-UN
activity CN101134029A A NN O
test CN101134029A A NN O
on CN101134029A A IN O
magnesium CN101134029A A NN O
salvianolate CN101134029A A NN O
B CN101134029A A NNP O
as CN101134029A A IN O
one CN101134029A A CD O
common CN101134029A A JJ O
salvianolate CN101134029A A NN O
B CN101134029A A NNP O
salt CN101134029A A NN O
proves CN101134029A A VBZ O
that CN101134029A A IN O
magnesium CN101134029A A NN O
salvianolate CN101134029A A NN O
B CN101134029A A NNP O
has CN101134029A A VBZ O
suck CN101134029A A VBN O
structure CN101134029A A NN O
as CN101134029A A IN O
to CN101134029A A TO O
be CN101134029A A VB O
capable CN101134029A A JJ O
of CN101134029A A IN O
substituting CN101134029A A VBG O
cyclopentahydrophenanathrene CN101134029A A NN O
, CN101134029A A , O
as CN101134029A A IN O
one CN101134029A A CD O
kind CN101134029A A NN O
of CN101134029A A IN O
cardio-glucoside CN101134029A A JJ O
steroid CN101134029A A JJ O
medicine CN101134029A A NN O
. CN101134029A A . O

All CN101134029A A PDT O
the CN101134029A A DT O
said CN101134029A A VBD O
functions CN101134029A A NNS O
come CN101134029A A VBP O
from CN101134029A A IN O
that CN101134029A A DT O
salvianolate CN101134029A A NN O
B CN101134029A A NNP O
salt CN101134029A A NN O
can CN101134029A A MD O
inhibit CN101134029A A VB O
the CN101134029A A DT O
hydrolysis CN101134029A A NN O
of CN101134029A A IN O
Na+/K+-ATP CN101134029A A NNP I-UN
enzyme CN101134029A A NN I-UN
actively CN101134029A A RB O
transported CN101134029A A VBN O
phosphate CN101134029A A JJ O
radical CN101134029A A JJ O
to CN101134029A A TO O
reduce CN101134029A A VB O
the CN101134029A A DT O
Na+/K+ CN101134029A A NNP O
exchange CN101134029A A NN O
of CN101134029A A IN O
cell CN101134029A A NN O
and CN101134029A A CC O
increase CN101134029A A VB O
calcium CN101134029A A NN O
ions CN101134029A A NNS O
inside CN101134029A A IN O
cell CN101134029A A NN O
. CN101134029A A . O

Amplification WO2009072625A1 T NNP O
method WO2009072625A1 T NN O
for WO2009072625A1 T IN O
hematopoietic WO2009072625A1 T JJ O
stem WO2009072625A1 T NN O
cells WO2009072625A1 T NNS O
with WO2009072625A1 T IN O
heterocyclic WO2009072625A1 T JJ O
compound WO2009072625A1 T NN O
. WO2009072625A1 T . O

Derives US20100331398 T VBZ O
du US20100331398 T JJ O
gossypol US20100331398 T JJ O
et US20100331398 T FW O
de US20100331398 T FW O
l'apogossypol US20100331398 T FW O
, US20100331398 T , O
leurs US20100331398 T FW O
preparations US20100331398 T NNS O
et US20100331398 T VBP O
leurs US20100331398 T JJ O
applictions US20100331398 T NNS O
. US20100331398 T . O

N-acetyl-DL-leucine CN103079550A T NNP O
, CN103079550A T , O
neuroprotective CN103079550A T JJ O
and CN103079550A T CC O
retinoprotective CN103079550A T JJ O
medicament CN103079550A T NN O
. CN103079550A T . O

Oxazolidinones WO2007023507A2 T NNS O
bearing WO2007023507A2 T VBG O
antimicrobial WO2007023507A2 T JJ O
activity WO2007023507A2 T NN O
composition WO2007023507A2 T NN O
and WO2007023507A2 T CC O
methods WO2007023507A2 T NNS O
of WO2007023507A2 T IN O
preparation WO2007023507A2 T NN O
. WO2007023507A2 T . O

3 CN101564537A T CD O
, CN101564537A T , O
5-dihydroxy-4-isopropyl CN101564537A T JJ O
diphenyl CN101564537A T JJ O
ethylene-ethyl CN101564537A T JJ O
bromoacetate-polyoxyethylene CN101564537A T NN O
compound CN101564537A T NN O
and CN101564537A T CC O
synthetic CN101564537A T JJ O
method CN101564537A T NN O
thereof CN101564537A T NN O
. CN101564537A T . O

Therapeutic EP0784429B1 T JJ O
combinations EP0784429B1 T NNS O
of EP0784429B1 T IN O
venous EP0784429B1 T JJ O
dilators EP0784429B1 T NNS O
and EP0784429B1 T CC O
arterial EP0784429B1 T JJ O
dilators EP0784429B1 T NNS O
. EP0784429B1 T . O

A EP0784429B1 A DT O
therapeutic EP0784429B1 A JJ O
mixture EP0784429B1 A NN O
comprising EP0784429B1 A VBG O
a EP0784429B1 A DT O
mixture EP0784429B1 A NN O
of EP0784429B1 A IN O
L-arginine EP0784429B1 A NNP O
and EP0784429B1 A CC O
an EP0784429B1 A DT O
agonist EP0784429B1 A NN O
of EP0784429B1 A IN O
nitric EP0784429B1 A JJ I-UN
oxide EP0784429B1 A JJ I-UN
synthase EP0784429B1 A NN I-UN
, EP0784429B1 A , O
namely EP0784429B1 A RB O
nitroglycerin EP0784429B1 A JJ O
, EP0784429B1 A , O
is EP0784429B1 A VBZ O
disclosed EP0784429B1 A VBN O
for EP0784429B1 A IN O
the EP0784429B1 A DT O
treatment EP0784429B1 A NN O
of EP0784429B1 A IN O
diseases EP0784429B1 A NNS O
related EP0784429B1 A VBN O
to EP0784429B1 A TO O
vasoconstriction EP0784429B1 A NN O
, EP0784429B1 A , O
wherein EP0784429B1 A VBP O
the EP0784429B1 A DT O
vasoconstriction EP0784429B1 A NN O
is EP0784429B1 A VBZ O
relieved EP0784429B1 A VBN O
by EP0784429B1 A IN O
stimulating EP0784429B1 A VBG O
the EP0784429B1 A DT O
constitutive EP0784429B1 A JJ I-UN
form EP0784429B1 A NN I-UN
of EP0784429B1 A IN I-UN
nitric EP0784429B1 A JJ I-UN
oxide EP0784429B1 A JJ I-UN
synthase EP0784429B1 A NN I-UN
( EP0784429B1 A ( O
cNOS EP0784429B1 A NN I-UN
) EP0784429B1 A ) O
to EP0784429B1 A TO O
produce EP0784429B1 A VB O
native EP0784429B1 A JJ O
nitric EP0784429B1 A JJ O
oxide EP0784429B1 A NN O
( EP0784429B1 A ( O
NO EP0784429B1 A NNP O
) EP0784429B1 A ) O
. EP0784429B1 A . O

Formulation US20110212170 T NN O
For US20110212170 T IN O
Retinoid-Containing US20110212170 T NNP O
Soft US20110212170 T NNP O
Gelatin US20110212170 T NNP O
Capsules US20110212170 T NNP O
. US20110212170 T . O

Adiponectin US20070059357 T NNP I-UN
production US20070059357 T NN O
enhancer US20070059357 T NN O
. US20070059357 T . O

The US20070059357 A DT O
present US20070059357 A JJ O
invention US20070059357 A NN O
provides US20070059357 A VBZ O
a US20070059357 A DT O
pharmaceutical US20070059357 A JJ O
composition US20070059357 A NN O
for US20070059357 A IN O
enhancement US20070059357 A NN O
of US20070059357 A IN O
adiponectin US20070059357 A JJ I-UN
production US20070059357 A NN O
, US20070059357 A , O
treatment US20070059357 A NN O
or US20070059357 A CC O
prevention US20070059357 A NN O
of US20070059357 A IN O
hypoadiponectinemia US20070059357 A NN O
, US20070059357 A , O
and US20070059357 A CC O
the US20070059357 A DT O
like US20070059357 A JJ O
, US20070059357 A , O
comprising US20070059357 A VBG O
as US20070059357 A IN O
an US20070059357 A DT O
active US20070059357 A JJ O
ingredient US20070059357 A NN O
an US20070059357 A DT O
HMG-CoA US20070059357 A JJ I-UN
reductase US20070059357 A NN I-UN
inhibitor US20070059357 A NN O
. US20070059357 A . O

Tissue CN102988341A T NNP O
specificity CN102988341A T NN O
proteasome CN102988341A T NN I-UN
inhibitor CN102988341A T NN O
and CN102988341A T CC O
application CN102988341A T NN O
thereof CN102988341A T NN O
. CN102988341A T . O

The CN102988341A A DT O
invention CN102988341A A NN O
discloses CN102988341A A VBZ O
a CN102988341A A DT O
tissue CN102988341A A NN O
specificity CN102988341A A NN O
proteasome CN102988341A A NN I-UN
inhibitor CN102988341A A NN O
, CN102988341A A , O
and CN102988341A A CC O
application CN102988341A A NN O
of CN102988341A A IN O
the CN102988341A A DT O
tissue CN102988341A A NN O
specificity CN102988341A A NN O
proteasome CN102988341A A NN I-UN
inhibitor CN102988341A A NN O
in CN102988341A A IN O
preparation CN102988341A A NN O
of CN102988341A A IN O
a CN102988341A A DT O
medicament CN102988341A A NN O
for CN102988341A A IN O
inhibiting CN102988341A A VBG O
tumor CN102988341A A NN O
proteasome CN102988341A A NN I-UN
. CN102988341A A . O

The CN102988341A A DT O
tissue CN102988341A A NN O
specificity CN102988341A A NN O
proteasome CN102988341A A NN I-UN
inhibitor CN102988341A A NN O
is CN102988341A A VBZ O
gambogic CN102988341A A JJ O
acid CN102988341A A RB O
and/or CN102988341A A VBP O
a CN102988341A A DT O
metabolite CN102988341A A JJ O
MT1 CN102988341A A NNP O
of CN102988341A A IN O
the CN102988341A A DT O
tissue CN102988341A A NN O
specificity CN102988341A A NN O
proteasome CN102988341A A NN I-UN
inhibitor CN102988341A A NN O
. CN102988341A A . O

Imidazopyridine US7495009 T NNP O
derivatives US7495009 T NNS O
as US7495009 T IN O
melancortin US7495009 T NN O
receptor US7495009 T NN O
agonists US7495009 T NNS O
. US7495009 T . O

Derivatives US7495009 A NNS O
of US7495009 A IN O
imidazopyridine US7495009 A NN O
which US7495009 A WDT O
have US7495009 A VBP O
a US7495009 A DT O
good US7495009 A JJ O
affinity US7495009 A NN O
for US7495009 A IN O
certain US7495009 A JJ O
sub-types US7495009 A NNS O
of US7495009 A IN O
melanocortin US7495009 A NN O
receptors US7495009 A NNS O
, US7495009 A , O
in US7495009 A IN O
particular US7495009 A JJ O
MC4 US7495009 A NNP I-UN
receptors US7495009 A NNS O
and US7495009 A CC O
are US7495009 A VBP O
useful US7495009 A JJ O
for US7495009 A IN O
treating US7495009 A VBG O
pathological US7495009 A JJ O
states US7495009 A NNS O
and US7495009 A CC O
diseases US7495009 A NNS O
in US7495009 A IN O
which US7495009 A WDT O
one US7495009 A CD O
or US7495009 A CC O
more US7495009 A JJR O
melanocortin US7495009 A JJ O
receptors US7495009 A NNS O
are US7495009 A VBP O
involved US7495009 A VBN O
and US7495009 A CC O
pharmaceutical US7495009 A JJ O
compositions US7495009 A NNS O
containing US7495009 A VBG O
said US7495009 A VBD O
products US7495009 A NNS O
. US7495009 A . O

Composition CN1568978B T NN O
for CN1568978B T IN O
preventing CN1568978B T VBG O
and CN1568978B T CC O
treating CN1568978B T VBG O
whelk CN1568978B T NN O
. CN1568978B T . O

Synthesis CN1733704A T NN O
and CN1733704A T CC O
biological CN1733704A T JJ O
and CN1733704A T CC O
pharmacological CN1733704A T JJ O
action CN1733704A T NN O
of CN1733704A T IN O
betaine CN1733704A T NN O
salicylate CN1733704A T NN O
. CN1733704A T . O

Synthesis US20060223990 T NN O
, US20060223990 T , O
deprotection US20060223990 T NN O
, US20060223990 T , O
analysis US20060223990 T NN O
& US20060223990 T CC O
purification US20060223990 T NN O
of US20060223990 T IN O
RNA US20060223990 T NNP O
& US20060223990 T CC O
ribozymes US20060223990 T NNS O
. US20060223990 T . O

Medicinal CN103566325A T JJ O
liquor CN103566325A T NN O
good CN103566325A T NN O
for CN103566325A T IN O
throat CN103566325A T NN O
. CN103566325A T . O

Use EP1699452A2 T NNP O
of EP1699452A2 T IN O
statins EP1699452A2 T NNS O
for EP1699452A2 T IN O
the EP1699452A2 T DT O
treatment EP1699452A2 T NN O
of EP1699452A2 T IN O
metabolic EP1699452A2 T JJ O
syndrome EP1699452A2 T NN O
. EP1699452A2 T . O

The EP1699452A2 A DT O
present EP1699452A2 A JJ O
invention EP1699452A2 A NN O
relates EP1699452A2 A VBZ O
to EP1699452A2 A TO O
the EP1699452A2 A DT O
use EP1699452A2 A NN O
of EP1699452A2 A IN O
a EP1699452A2 A DT O
pharmaceutical EP1699452A2 A JJ O
composition EP1699452A2 A NN O
consisting EP1699452A2 A NN O
of EP1699452A2 A IN O
a EP1699452A2 A DT O
statin EP1699452A2 A NN O
( EP1699452A2 A ( O
especially EP1699452A2 A RB O
fluvastatin EP1699452A2 A VBZ O
or EP1699452A2 A CC O
pitavastatin EP1699452A2 A NN O
) EP1699452A2 A ) O
or EP1699452A2 A CC O
a EP1699452A2 A DT O
pharmaceutically EP1699452A2 A RB O
acceptable EP1699452A2 A JJ O
salt EP1699452A2 A NN O
thereof EP1699452A2 A NN O
and EP1699452A2 A CC O
a EP1699452A2 A DT O
pharmaceutically EP1699452A2 A RB O
acceptable EP1699452A2 A JJ O
carrier EP1699452A2 A NN O
for EP1699452A2 A IN O
the EP1699452A2 A DT O
preparation EP1699452A2 A NN O
of EP1699452A2 A IN O
a EP1699452A2 A DT O
medicament EP1699452A2 A NN O
for EP1699452A2 A IN O
the EP1699452A2 A DT O
prevention EP1699452A2 A NN O
or EP1699452A2 A CC O
treatment EP1699452A2 A NN O
of EP1699452A2 A IN O
metabolic EP1699452A2 A JJ O
syndrome EP1699452A2 A NN O
( EP1699452A2 A ( O
or EP1699452A2 A CC O
syndrome EP1699452A2 A VB O
X EP1699452A2 A NN O
) EP1699452A2 A ) O
. EP1699452A2 A . O

Medicinal CN102198272A T JJ O
composition CN102198272A T NN O
for CN102198272A T IN O
promoting CN102198272A T VBG O
fracture CN102198272A T NN O
union CN102198272A T NN O
and CN102198272A T CC O
repairing CN102198272A T VBG O
injured CN102198272A T JJ O
nerves CN102198272A T NNS O
. CN102198272A T . O

Theanine US20080009505 T NNP O
derivatives US20080009505 T NNS O
, US20080009505 T , O
uses US20080009505 T VBZ O
thereof US20080009505 T NN O
and US20080009505 T CC O
processes US20080009505 T NNS O
for US20080009505 T IN O
the US20080009505 T DT O
manufacture US20080009505 T NN O
thereof US20080009505 T NN O
. US20080009505 T . O

Colon CN101069695A T NNP O
target-positioning CN101069695A T JJ O
preparation CN101069695A T NN O
for CN101069695A T IN O
treating CN101069695A T VBG O
colonitis CN101069695A T NN O
and CN101069695A T CC O
preparing CN101069695A T VBG O
method CN101069695A T NN O
. CN101069695A T . O

The CN101069695A A DT O
present CN101069695A A JJ O
invention CN101069695A A NN O
provides CN101069695A A VBZ O
a CN101069695A A DT O
kind CN101069695A A NN O
of CN101069695A A IN O
colon CN101069695A A NN O
target CN101069695A A NN O
orientation CN101069695A A NN O
preparation CN101069695A A NN O
for CN101069695A A IN O
curing CN101069695A A VBG O
colitis CN101069695A A NN O
and CN101069695A A CC O
its CN101069695A A PRP$ O
preparation CN101069695A A NN O
method CN101069695A A NN O
. CN101069695A A . O

Said CN101069695A A NNP O
preparation CN101069695A A NN O
is CN101069695A A VBZ O
formed CN101069695A A VBN O
from CN101069695A A IN O
250-500g CN101069695A A CD O
of CN101069695A A IN O
montmorillonite CN101069695A A NN O
, CN101069695A A , O
3-15g CN101069695A A CD O
of CN101069695A A IN O
binding CN101069695A A VBG O
agent CN101069695A A NN O
and CN101069695A A CC O
0.20-3.0g CN101069695A A NN O
of CN101069695A A IN O
lubricating CN101069695A A VBG O
agent CN101069695A A NN O
. CN101069695A A . O

Said CN101069695A A NNP O
colon CN101069695A A NN O
target CN101069695A A NN O
orientation CN101069695A A NN O
preparation CN101069695A A NN O
can CN101069695A A MD O
be CN101069695A A VB O
made CN101069695A A VBN O
into CN101069695A A IN O
oral CN101069695A A JJ O
enteric CN101069695A A JJ O
soluble CN101069695A A JJ O
tablet CN101069695A A NN O
or CN101069695A A CC O
oral CN101069695A A JJ O
enteric CN101069695A A JJ O
soluble CN101069695A A JJ O
capsule CN101069695A A NN O
. CN101069695A A . O

Besides CN101069695A A IN O
, CN101069695A A , O
said CN101069695A A VBD O
invention CN101069695A A NN O
also CN101069695A A RB O
provides CN101069695A A VBZ O
the CN101069695A A DT O
concrete CN101069695A A JJ O
steps CN101069695A A NNS O
of CN101069695A A IN O
its CN101069695A A PRP$ O
preparation CN101069695A A NN O
method CN101069695A A NN O
. CN101069695A A . O

drug US7807355 T NN O
screening US7807355 T NN O
; US7807355 T : O
identifying US7807355 T VBG O
a US7807355 T DT O
therapeutic US7807355 T JJ O
for US7807355 T IN O
decreasing US7807355 T VBG O
intraocular US7807355 T JJ O
pressure US7807355 T NN O
raised US7807355 T VBN O
due US7807355 T JJ O
to US7807355 T TO O
frizzled US7807355 T VB I-UN
related US7807355 T JJ I-UN
protein US7807355 T NN I-UN
( US7807355 T ( O
FRP US7807355 T NNP I-UN
) US7807355 T ) O
overexpression US7807355 T NN O
; US7807355 T : O
contacting US7807355 T VBG O
a US7807355 T DT O
trabecular US7807355 T JJ O
meshwork US7807355 T NN O
cell US7807355 T NN O
expressing US7807355 T VBG O
a US7807355 T DT O
Wnt US7807355 T NNP O
pathway US7807355 T NN O
component US7807355 T NN O
or US7807355 T CC O
a US7807355 T DT O
frizzled US7807355 T VBN I-UN
related US7807355 T JJ I-UN
protein US7807355 T NN I-UN
gene US7807355 T NN O
product US7807355 T NN O
with US7807355 T IN O
a US7807355 T DT O
test US7807355 T NN O
compound US7807355 T NN O
. US7807355 T . O

New WO2004110344A3 T NNP O
azetidine WO2004110344A3 T JJ O
compounds WO2004110344A3 T NNS O
. WO2004110344A3 T . O

Novel US20120094944 T NNP O
imidazopyridine US20120094944 T NN O
compound US20120094944 T NN O
. US20120094944 T . O

For US20120094944 A IN O
the US20120094944 A DT O
prevention US20120094944 A NN O
and/or US20120094944 A NN O
treatment US20120094944 A NN O
of US20120094944 A IN O
chymase-mediated US20120094944 A JJ O
diseases US20120094944 A NNS O
such US20120094944 A JJ O
as US20120094944 A IN O
skin US20120094944 A NN O
diseases US20120094944 A NNS O
, US20120094944 A , O
circulatory US20120094944 A NN O
diseases US20120094944 A NNS O
, US20120094944 A , O
digestive US20120094944 A JJ O
system US20120094944 A NN O
diseases US20120094944 A NNS O
, US20120094944 A , O
respiratory US20120094944 A NN O
diseases US20120094944 A NNS O
, US20120094944 A , O
liver US20120094944 A NN O
diseases US20120094944 A NNS O
, US20120094944 A , O
ocular US20120094944 A JJ O
diseases US20120094944 A NNS O
or US20120094944 A CC O
the US20120094944 A DT O
like US20120094944 A JJ O
, US20120094944 A , O
a US20120094944 A DT O
drug US20120094944 A NN O
is US20120094944 A VBZ O
provided US20120094944 A VBN O
having US20120094944 A VBG O
as US20120094944 A IN O
an US20120094944 A DT O
active US20120094944 A JJ O
ingredient US20120094944 A NN O
a US20120094944 A DT O
compound US20120094944 A NN O
having US20120094944 A VBG O
extremely US20120094944 A RB O
strong US20120094944 A JJ O
chymase US20120094944 A NN I-UN
inhibitory US20120094944 A NN O
activity US20120094944 A NN O
, US20120094944 A , O
high US20120094944 A JJ O
safety US20120094944 A NN O
, US20120094944 A , O
and US20120094944 A CC O
high US20120094944 A JJ O
metabolic US20120094944 A JJ O
stability US20120094944 A NN O
. US20120094944 A . O

The US20120094944 A DT O
compound US20120094944 A NN O
represented US20120094944 A VBN O
by US20120094944 A IN O
the US20120094944 A DT O
formula US20120094944 A NN O
( US20120094944 A ( O
I US20120094944 A PRP O
) US20120094944 A ) O
: US20120094944 A : O
wherein US20120094944 A NN O
all US20120094944 A DT O
symbols US20120094944 A NNS O
have US20120094944 A VBP O
the US20120094944 A DT O
same US20120094944 A JJ O
meanings US20120094944 A NNS O
as US20120094944 A IN O
in US20120094944 A IN O
the US20120094944 A DT O
description US20120094944 A NN O
, US20120094944 A , O
a US20120094944 A DT O
salt US20120094944 A NN O
thereof US20120094944 A NN O
, US20120094944 A , O
an US20120094944 A DT O
N-oxide US20120094944 A JJ O
thereof US20120094944 A NN O
or US20120094944 A CC O
a US20120094944 A DT O
solvate US20120094944 A JJ O
thereof US20120094944 A NN O
, US20120094944 A , O
or US20120094944 A CC O
a US20120094944 A DT O
prodrug US20120094944 A JJ O
thereof US20120094944 A NN O
, US20120094944 A , O
is US20120094944 A VBZ O
useful US20120094944 A JJ O
as US20120094944 A IN O
a US20120094944 A DT O
pharmaceutical US20120094944 A JJ O
ingredient US20120094944 A NN O
having US20120094944 A VBG O
chymase US20120094944 A JJ I-UN
inhibitory US20120094944 A JJ O
activity US20120094944 A NN O
for US20120094944 A IN O
preventing US20120094944 A VBG O
and/or US20120094944 A JJ O
treating US20120094944 A NN O
of US20120094944 A IN O
chymase-mediated US20120094944 A JJ O
disease US20120094944 A NN O
, US20120094944 A , O
such US20120094944 A JJ O
as US20120094944 A IN O
skin US20120094944 A NN O
diseases US20120094944 A NNS O
, US20120094944 A , O
circulatory US20120094944 A NN O
diseases US20120094944 A NNS O
, US20120094944 A , O
digestive US20120094944 A JJ O
system US20120094944 A NN O
diseases US20120094944 A NNS O
, US20120094944 A , O
respiratory US20120094944 A NN O
diseases US20120094944 A NNS O
, US20120094944 A , O
liver US20120094944 A NN O
diseases US20120094944 A NNS O
, US20120094944 A , O
ocular US20120094944 A JJ O
diseases US20120094944 A NNS O
or US20120094944 A CC O
the US20120094944 A DT O
like US20120094944 A JJ O
. US20120094944 A . O

G US7253190 T NNP I-UN
protein-coupled US7253190 T JJ I-UN
receptors US7253190 T NNS I-UN
activators US7253190 T NNS O
such US7253190 T JJ O
as US7253190 T IN O
2- US7253190 T JJ O
[ US7253190 T JJ O
2- US7253190 T JJ O
( US7253190 T ( O
3-chlorophenyl US7253190 T JJ O
) US7253190 T ) O
-2H-tetrazol-5-yl US7253190 T FW O
] US7253190 T FW O
pyridine US7253190 T NN O
, US7253190 T , O
used US7253190 T VBD O
as US7253190 T IN O
analgesics US7253190 T NNS O
, US7253190 T , O
anxiolytic US7253190 T JJ O
, US7253190 T , O
antidepressants US7253190 T NNS O
, US7253190 T , O
and US7253190 T CC O
for US7253190 T IN O
prophylaxis US7253190 T NN O
of US7253190 T IN O
psychological US7253190 T JJ O
disorders US7253190 T NNS O
. US7253190 T . O

Tetrazole US7253190 A NNP O
compounds US7253190 A NNS O
substituted US7253190 A VBD O
directly US7253190 A RB O
, US7253190 A , O
or US7253190 A CC O
by US7253190 A IN O
a US7253190 A DT O
bridge US7253190 A NN O
, US7253190 A , O
with US7253190 A IN O
a US7253190 A DT O
heteroaryl US7253190 A NN O
moiety US7253190 A NN O
containing US7253190 A VBG O
N US7253190 A NNP O
adjacent US7253190 A NN O
to US7253190 A TO O
the US7253190 A DT O
point US7253190 A NN O
of US7253190 A IN O
connection US7253190 A NN O
of US7253190 A IN O
the US7253190 A DT O
heteroaryl US7253190 A NN O
, US7253190 A , O
are US7253190 A VBP O
mGluR5 US7253190 A JJ I-UN
modulators US7253190 A NNS O
useful US7253190 A JJ O
in US7253190 A IN O
the US7253190 A DT O
treatment US7253190 A NN O
of US7253190 A IN O
psychiatric US7253190 A JJ O
and US7253190 A CC O
mood US7253190 A NN O
disorders US7253190 A NNS O
such US7253190 A JJ O
as US7253190 A IN O
, US7253190 A , O
for US7253190 A IN O
example US7253190 A NN O
, US7253190 A , O
schizophrenia US7253190 A NN O
, US7253190 A , O
anxiety US7253190 A NN O
, US7253190 A , O
depression US7253190 A NN O
, US7253190 A , O
and US7253190 A CC O
panic US7253190 A NN O
, US7253190 A , O
as US7253190 A RB O
well US7253190 A RB O
as US7253190 A IN O
in US7253190 A IN O
the US7253190 A DT O
treatment US7253190 A NN O
of US7253190 A IN O
pain US7253190 A NN O
and US7253190 A CC O
other US7253190 A JJ O
diseases US7253190 A NNS O
. US7253190 A . O

Levonorgestrel CN101288660B T NNP O
drop CN101288660B T NN O
pills CN101288660B T NNS O
preparation CN101288660B T NN O
method CN101288660B T NN O
. CN101288660B T . O

Application CN103494798A T NN O
of CN103494798A T IN O
Incarviatone CN103494798A T NNP O
A CN103494798A T NNP O
in CN103494798A T IN O
influenza CN103494798A T NN O
A CN103494798A T NNP O
virus CN103494798A T NN O
drugs CN103494798A T NNS O
. CN103494798A T . O

Pyrrolidine WO2014049515A1 T NNP O
substituted WO2014049515A1 T VBD O
flavones WO2014049515A1 T NNS O
for WO2014049515A1 T IN O
treatment WO2014049515A1 T NN O
of WO2014049515A1 T IN O
renal WO2014049515A1 T JJ O
cystic WO2014049515A1 T JJ O
diseases WO2014049515A1 T NNS O
. WO2014049515A1 T . O

Aporphine US20090318489 T NNP O
compounds US20090318489 T NNS O
and US20090318489 T CC O
pharmaceutical US20090318489 T JJ O
use US20090318489 T NN O
thereof US20090318489 T NN O
. US20090318489 T . O

Novel WO2008078762A1 T JJ O
n- WO2008078762A1 T JJ O
( WO2008078762A1 T ( O
2-aminophenyl WO2008078762A1 T JJ O
) WO2008078762A1 T ) O
benzamide WO2008078762A1 T RB O
derivative WO2008078762A1 T JJ O
having WO2008078762A1 T VBG O
an WO2008078762A1 T DT O
urea WO2008078762A1 T JJ O
structure WO2008078762A1 T NN O
. WO2008078762A1 T . O

Melphalan CN102038652A T NNP O
multi-targeted CN102038652A T JJ O
drug CN102038652A T NN O
carrying CN102038652A T VBG O
system CN102038652A T NN O
, CN102038652A T , O
and CN102038652A T CC O
preparation CN102038652A T NN O
method CN102038652A T NN O
and CN102038652A T CC O
application CN102038652A T NN O
thereof CN102038652A T NN O
. CN102038652A T . O

Methods US20080153818 T NNS O
for US20080153818 T IN O
preventing US20080153818 T VBG O
inflammation US20080153818 T NN O
during US20080153818 T IN O
surgery US20080153818 T NN O
. US20080153818 T . O

The US20080153818 A DT O
present US20080153818 A JJ O
invention US20080153818 A NN O
provides US20080153818 A VBZ O
compositions US20080153818 A NNS O
and US20080153818 A CC O
methods US20080153818 A NNS O
for US20080153818 A IN O
preventing US20080153818 A VBG O
inflammation US20080153818 A NN O
and US20080153818 A CC O
retinal US20080153818 A JJ O
edema US20080153818 A NN O
resulting US20080153818 A VBG O
from US20080153818 A IN O
an US20080153818 A DT O
ocular US20080153818 A JJ O
surgical US20080153818 A JJ O
procedure US20080153818 A NN O
by US20080153818 A IN O
administering US20080153818 A VBG O
to US20080153818 A TO O
a US20080153818 A DT O
patient US20080153818 A NN O
undergoing US20080153818 A VBG O
surgery US20080153818 A NN O
a US20080153818 A DT O
therapeutically US20080153818 A RB O
effective US20080153818 A JJ O
amount US20080153818 A NN O
of US20080153818 A IN O
a US20080153818 A DT O
composition US20080153818 A NN O
comprising US20080153818 A VBG O
an US20080153818 A DT O
active US20080153818 A JJ O
agent US20080153818 A NN O
selected US20080153818 A VBN O
from US20080153818 A IN O
the US20080153818 A DT O
group US20080153818 A NN O
consisting US20080153818 A VBG O
of US20080153818 A IN O
RTK US20080153818 A NNP O
inhibitors US20080153818 A NNS O
and US20080153818 A CC O
anti-VEGF US20080153818 A JJ O
compounds US20080153818 A NNS O
, US20080153818 A , O
and US20080153818 A CC O
a US20080153818 A DT O
pharmaceutically US20080153818 A RB O
acceptable US20080153818 A JJ O
carrier US20080153818 A NN O
, US20080153818 A , O
wherein US20080153818 A VBP O
the US20080153818 A DT O
RTK US20080153818 A NNP O
inhibitor US20080153818 A NN O
blocks US20080153818 A NNS O
tyrosine US20080153818 A VBP O
autophosphorylation US20080153818 A NN O
of US20080153818 A IN O
VEGFR-1 US20080153818 A NNP I-UN
, US20080153818 A , O
VEGFR-2 US20080153818 A NNP I-UN
, US20080153818 A , O
VEGFR-3 US20080153818 A NNP I-UN
, US20080153818 A , O
Tie-2 US20080153818 A NNP I-UN
, US20080153818 A , O
PDGFR US20080153818 A NNP I-UN
, US20080153818 A , O
c-KIT US20080153818 A JJ I-UN
, US20080153818 A , O
Flt-3 US20080153818 A NNP I-UN
, US20080153818 A , O
and US20080153818 A CC O
CSF-1R US20080153818 A NNP I-UN
. US20080153818 A . O

Prepn CN1772025A T NNP O
of CN1772025A T IN O
antiphlogistic CN1772025A T JJ O
tinea CN1772025A T NN O
and CN1772025A T CC O
eczema CN1772025A T NN O
treating CN1772025A T VBG O
ointment CN1772025A T NN O
. CN1772025A T . O

Solid EP1189614B1 T JJ O
preparations EP1189614B1 T NNS O
containing EP1189614B1 T VBG O
paroxetine EP1189614B1 T NN O
. EP1189614B1 T . O

Pilocarpine CN1919183A T NNP O
nitrate CN1919183A T NN O
dispersible CN1919183A T JJ O
tablet CN1919183A T NN O
and CN1919183A T CC O
preparation CN1919183A T NN O
method CN1919183A T NN O
thereof CN1919183A T NN O
. CN1919183A T . O

The CN1919183A A DT O
invention CN1919183A A NN O
relates CN1919183A A VBZ O
to CN1919183A A TO O
a CN1919183A A DT O
pilocarpine CN1919183A A NN O
nitrate CN1919183A A NN O
dispersible CN1919183A A JJ O
tablet CN1919183A A NN O
and CN1919183A A CC O
method CN1919183A A NN O
for CN1919183A A IN O
preparation CN1919183A A NN O
, CN1919183A A , O
wherein CN1919183A A VBP O
the CN1919183A A DT O
dispersible CN1919183A A JJ O
tablet CN1919183A A NN O
comprises CN1919183A A VBZ O
the CN1919183A A DT O
following CN1919183A A JJ O
constituents CN1919183A A NNS O
( CN1919183A A ( O
by CN1919183A A IN O
weight CN1919183A A NN O
ratio CN1919183A A NN O
) CN1919183A A ) O
: CN1919183A A : O
pilocarpine CN1919183A A JJ O
nitrate CN1919183A A JJ O
0.5-5 CN1919183A A JJ O
parts CN1919183A A NNS O
, CN1919183A A , O
filling CN1919183A A VBG O
agent CN1919183A A JJ O
50-185 CN1919183A A JJ O
parts CN1919183A A NNS O
, CN1919183A A , O
crumbling CN1919183A A VBG O
agent CN1919183A A JJ O
20-140 CN1919183A A JJ O
parts CN1919183A A NNS O
, CN1919183A A , O
lubricant CN1919183A A JJ O
0.2-5 CN1919183A A JJ O
parts CN1919183A A NNS O
. CN1919183A A . O

Granulation CN102755349A T NNP O
promoting CN102755349A T VBG O
powder CN102755349A T NN O
for CN102755349A T IN O
treating CN102755349A T VBG O
recurrent CN102755349A T NN O
aphthous CN102755349A T JJ O
ulcer CN102755349A T NN O
and CN102755349A T CC O
preparation CN102755349A T NN O
method CN102755349A T NN O
thereof CN102755349A T NN O
. CN102755349A T . O

Benz WO2012123563A1 T NNP O
imidazole WO2012123563A1 T JJ O
derivatives WO2012123563A1 T NNS O
as WO2012123563A1 T IN O
inhibitors WO2012123563A1 T NNS O
of WO2012123563A1 T IN O
glutaminyl WO2012123563A1 T JJ I-UN
cyclase WO2012123563A1 T NN I-UN
. WO2012123563A1 T . O

The WO2012123563A1 A DT O
invention WO2012123563A1 A NN O
relates WO2012123563A1 A VBZ O
to WO2012123563A1 A TO O
novel WO2012123563A1 A VB O
heterocyclic WO2012123563A1 A JJ O
derivatives WO2012123563A1 A NNS O
of WO2012123563A1 A IN O
formula WO2012123563A1 A NN O
( WO2012123563A1 A ( O
I WO2012123563A1 A PRP O
) WO2012123563A1 A ) O
: WO2012123563A1 A : O
or WO2012123563A1 A CC O
a WO2012123563A1 A DT O
pharmaceutically WO2012123563A1 A RB O
acceptable WO2012123563A1 A JJ O
salt WO2012123563A1 A NN O
, WO2012123563A1 A , O
solvate WO2012123563A1 A NN O
or WO2012123563A1 A CC O
polymorph WO2012123563A1 A NN O
thereof WO2012123563A1 A NNS O
, WO2012123563A1 A , O
including WO2012123563A1 A VBG O
all WO2012123563A1 A DT O
tautomers WO2012123563A1 A NNS O
and WO2012123563A1 A CC O
stereoisomers WO2012123563A1 A NNS O
thereof WO2012123563A1 A VBP O
, WO2012123563A1 A , O
wherein WO2012123563A1 A JJ O
Ra WO2012123563A1 A NNP O
, WO2012123563A1 A , O
n WO2012123563A1 A RB O
, WO2012123563A1 A , O
R1 WO2012123563A1 A NNP O
and WO2012123563A1 A CC O
R2 WO2012123563A1 A NNP O
are WO2012123563A1 A VBP O
as WO2012123563A1 A IN O
defined WO2012123563A1 A JJ O
herein WO2012123563A1 A NN O
, WO2012123563A1 A , O
as WO2012123563A1 A IN O
inhibitors WO2012123563A1 A NNS O
of WO2012123563A1 A IN O
glutaminyl WO2012123563A1 A JJ I-UN
cyclase WO2012123563A1 A NN I-UN
( WO2012123563A1 A ( O
QC WO2012123563A1 A NNP O
, WO2012123563A1 A , O
EC WO2012123563A1 A NNP O
2.3.2.5 WO2012123563A1 A CD O
) WO2012123563A1 A ) O
. WO2012123563A1 A . O

Method US20090110749 T NNP O
and US20090110749 T CC O
apparatus US20090110749 T NN O
for US20090110749 T IN O
producing US20090110749 T VBG O
a US20090110749 T DT O
stabilized US20090110749 T JJ O
antimicrobial US20090110749 T JJ O
non-toxic US20090110749 T JJ O
electrolyzed US20090110749 T VBN O
saline US20090110749 T JJ O
solution US20090110749 T NN O
exhibiting US20090110749 T VBG O
potential US20090110749 T JJ O
as US20090110749 T IN O
a US20090110749 T DT O
therapeutic US20090110749 T JJ O
. US20090110749 T . O

Paroxetine CA2210022C T NNP O
hydrochloride CA2210022C T NN O
solvates CA2210022C T NNS O
. CA2210022C T . O

For US7157582 T IN O
example US7157582 T NN O
, US7157582 T , O
3S,4aR,6S,8aR US7157582 T CD O
Ethyl US7157582 T NNP O
6- US7157582 T JJ O
( US7157582 T ( O
( US7157582 T ( O
( US7157582 T ( O
5S US7157582 T CD O
) US7157582 T ) O
-5- US7157582 T NN O
( US7157582 T ( O
Ethoxycarbonyl US7157582 T NNP O
) US7157582 T ) O
-3-oxopyrrolidinyl US7157582 T NN O
) US7157582 T ) O
methyl US7157582 T NN O
) US7157582 T ) O
-2-methoxycarbonyl-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylate US7157582 T NN O
; US7157582 T : O
for US7157582 T IN O
treating US7157582 T VBG O
or US7157582 T CC O
preventing US7157582 T VBG O
migraine US7157582 T NN O
. US7157582 T . O

The US7157582 A DT O
present US7157582 A JJ O
invention US7157582 A NN O
provides US7157582 A VBZ O
a US7157582 A DT O
method US7157582 A NN O
of US7157582 A IN O
treating US7157582 A VBG O
or US7157582 A CC O
preventing US7157582 A VBG O
migraine US7157582 A JJ O
comprising US7157582 A VBG O
administering US7157582 A VBG O
to US7157582 A TO O
a US7157582 A DT O
patient US7157582 A NN O
in US7157582 A IN O
need US7157582 A NN O
thereof US7157582 A VBP O
an US7157582 A DT O
effective US7157582 A JJ O
amount US7157582 A NN O
of US7157582 A IN O
a US7157582 A DT O
selective US7157582 A JJ O
iGluR5 US7157582 A NN I-UN
receptor US7157582 A NN O
antagonist US7157582 A NN O
. US7157582 A . O

The US7157582 A DT O
present US7157582 A JJ O
invention US7157582 A NN O
further US7157582 A RBR O
provides US7157582 A VBZ O
novel US7157582 A JJ O
compounds US7157582 A NNS O
functional US7157582 A JJ O
as US7157582 A IN O
selective US7157582 A JJ O
iGluR5 US7157582 A NN I-UN
receptor US7157582 A NN O
antagonists US7157582 A VBZ O
as US7157582 A RB O
well US7157582 A RB O
as US7157582 A IN O
compositions US7157582 A NNS O
and US7157582 A CC O
formulations US7157582 A NNS O
comprising US7157582 A VBG O
said US7157582 A VBD O
selective US7157582 A JJ O
iGluR5 US7157582 A NN I-UN
receptor US7157582 A NN O
antagonists US7157582 A NNS O
. US7157582 A . O

Gastric US20110104272 T NNP O
retentive US20110104272 T JJ O
extended-release US20110104272 T JJ O
dosage US20110104272 T NN O
forms US20110104272 T NNS O
comprising US20110104272 T VBG O
combinations US20110104272 T NNS O
of US20110104272 T IN O
acetaminophen US20110104272 T NN O
and US20110104272 T CC O
phenylephrine US20110104272 T NN O
. US20110104272 T . O

Methods US20100081705 T NNS O
for US20100081705 T IN O
slowing US20100081705 T VBG O
familial US20100081705 T JJ O
als US20100081705 T NNS O
disease US20100081705 T JJ O
progression US20100081705 T NN O
. US20100081705 T . O

These US20100081705 A DT O
methods US20100081705 A NNS O
employ US20100081705 A VBP O
antisense US20100081705 A JJ O
oligonucleotides US20100081705 A NNS O
targeted US20100081705 A VBN O
to US20100081705 A TO O
SOD1 US20100081705 A NNP I-UN
, US20100081705 A , O
for US20100081705 A IN O
use US20100081705 A NN O
in US20100081705 A IN O
inhibiting US20100081705 A VBG O
the US20100081705 A DT O
expression US20100081705 A NN O
of US20100081705 A IN O
SOD1 US20100081705 A NNP I-UN
in US20100081705 A IN O
the US20100081705 A DT O
central US20100081705 A JJ O
nervous US20100081705 A JJ O
system US20100081705 A NN O
of US20100081705 A IN O
an US20100081705 A DT O
individual US20100081705 A JJ O
suffering US20100081705 A NN O
from US20100081705 A IN O
familial US20100081705 A JJ O
ALS US20100081705 A NNP O
. US20100081705 A . O

Abnormal WO2006007227A2 T NNP O
cannabidiols WO2006007227A2 T NNS O
for WO2006007227A2 T IN O
lowering WO2006007227A2 T VBG O
intraocular WO2006007227A2 T JJ O
pressure WO2006007227A2 T NN O
. WO2006007227A2 T . O

Method CN101323649B T NNP O
for CN101323649B T IN O
extracting CN101323649B T VBG O
mushroom CN101323649B T NN O
polysaccharide CN101323649B T NN O
by CN101323649B T IN O
using CN101323649B T VBG O
ultra-high CN101323649B T JJ O
pressure CN101323649B T NN O
. CN101323649B T . O

Utilization CA2362515C T NN O
of CA2362515C T IN O
material CA2362515C T NN O
containing CA2362515C T VBG O
docosapentaenoic CA2362515C T JJ O
acid CA2362515C T NN O
. CA2362515C T . O

2- EP1718645A1 T JJ O
( EP1718645A1 T ( O
pyridin-3-ylamino EP1718645A1 T NN O
) EP1718645A1 T ) O
-pyrido EP1718645A1 T VBZ O
2,3-d EP1718645A1 T JJ O
pyrimidin-7-ones EP1718645A1 T NNS O
. EP1718645A1 T . O

Ocular US20080171072 T JJ O
inserts US20080171072 T NNS O
containing US20080171072 T VBG O
apomorphine US20080171072 T NN O
. US20080171072 T . O

Anti-diabetic US20110275579 T JJ O
extract US20110275579 T NN O
of US20110275579 T IN O
rooibos US20110275579 T NN O
. US20110275579 T . O

Simvastatin CN103230376A T NNP O
tablet CN103230376A T NN O
preparation CN103230376A T NN O
method CN103230376A T NN O
. CN103230376A T . O

Substituted US8080565 T VBN O
4-amino-benzylpiperidine US8080565 T JJ O
compounds US8080565 T NNS O
. US8080565 T . O

Biologically WO2007062468A1 T RB O
active WO2007062468A1 T JJ O
compounds WO2007062468A1 T NNS O
. WO2007062468A1 T . O

Formula CN102302587A T NNP O
for CN102302587A T IN O
treating CN102302587A T VBG O
flat CN102302587A T JJ O
wart CN102302587A T NN O
. CN102302587A T . O

siRNA CN101113158A T NN O
disturbing CN101113158A T VBG O
RdRp CN101113158A T NNP I-UN
gene CN101113158A T NN O
function CN101113158A T NN O
of CN101113158A T IN O
SARS CN101113158A T NNP O
virus CN101113158A T NN O
. CN101113158A T . O

Medicinal CN101850087A T JJ O
composition CN101850087A T NN O
used CN101850087A T VBN O
for CN101850087A T IN O
alleviating CN101850087A T VBG O
pains CN101850087A T NNS O
and CN101850087A T CC O
preparation CN101850087A T NN O
method CN101850087A T NN O
and CN101850087A T CC O
application CN101850087A T NN O
thereof CN101850087A T NN O
. CN101850087A T . O

Agent DE102006012873A1 T NN O
, DE102006012873A1 T , O
useful DE102006012873A1 T JJ O
e.g DE102006012873A1 T NN O
. DE102006012873A1 T . O

for DE102006012873A1 T IN O
the DE102006012873A1 T DT O
effective DE102006012873A1 T JJ O
lowering DE102006012873A1 T NN O
of DE102006012873A1 T IN O
increased DE102006012873A1 T VBN O
cholesterol DE102006012873A1 T NN O
levels DE102006012873A1 T NNS O
in DE102006012873A1 T IN O
the DE102006012873A1 T DT O
blood DE102006012873A1 T NN O
, DE102006012873A1 T , O
comprises DE102006012873A1 T VBZ O
long-chain DE102006012873A1 T JJ O
carboxylic DE102006012873A1 T NN O
acid DE102006012873A1 T NNS O
based DE102006012873A1 T VBN O
on DE102006012873A1 T IN O
montana DE102006012873A1 T NNS O
wax DE102006012873A1 T NNS O
and DE102006012873A1 T CC O
their DE102006012873A1 T PRP$ O
derivative DE102006012873A1 T JJ O
and/or DE102006012873A1 T NN O
guerbet DE102006012873A1 T NN O
wax DE102006012873A1 T NN O
or DE102006012873A1 T CC O
the DE102006012873A1 T DT O
corresponding DE102006012873A1 T JJ O
components DE102006012873A1 T NNS O
of DE102006012873A1 T IN O
carnauba DE102006012873A1 T JJ O
wax DE102006012873A1 T NN O
. DE102006012873A1 T . O

Combination WO2006124684A3 T NNP O
therapy WO2006124684A3 T NN O
comprising WO2006124684A3 T VBG O
a WO2006124684A3 T DT O
taxane WO2006124684A3 T NN O
and WO2006124684A3 T CC O
a WO2006124684A3 T DT O
thymidylate WO2006124684A3 T JJ I-UN
synthase WO2006124684A3 T NN I-UN
inhibitor WO2006124684A3 T NN O
. WO2006124684A3 T . O

This WO2006124684A3 A DT O
invention WO2006124684A3 A NN O
relates WO2006124684A3 A VBZ O
to WO2006124684A3 A TO O
a WO2006124684A3 A DT O
combination WO2006124684A3 A NN O
of WO2006124684A3 A IN O
anti-cancer WO2006124684A3 A NN O
compounds WO2006124684A3 A NNS O
which WO2006124684A3 A WDT O
comprises WO2006124684A3 A VBZ O
a WO2006124684A3 A DT O
) WO2006124684A3 A ) O
an WO2006124684A3 A DT O
orally WO2006124684A3 A RB O
effective WO2006124684A3 A JJ O
taxane WO2006124684A3 A NN O
, WO2006124684A3 A , O
and WO2006124684A3 A CC O
b WO2006124684A3 A NN O
) WO2006124684A3 A ) O
a WO2006124684A3 A DT O
thymidylate WO2006124684A3 A JJ I-UN
synthase WO2006124684A3 A NN I-UN
inhibitor WO2006124684A3 A NN O
, WO2006124684A3 A , O
and WO2006124684A3 A CC O
optionally WO2006124684A3 A RB O
at WO2006124684A3 A IN O
least WO2006124684A3 A JJS O
one WO2006124684A3 A CD O
pharmaceutically WO2006124684A3 A RB O
acceptable WO2006124684A3 A JJ O
carrier WO2006124684A3 A NN O
for WO2006124684A3 A IN O
simultaneous WO2006124684A3 A JJ O
, WO2006124684A3 A , O
separate WO2006124684A3 A JJ O
or WO2006124684A3 A CC O
sequential WO2006124684A3 A JJ O
use WO2006124684A3 A NN O
. WO2006124684A3 A . O

Once EP1615622B1 T RB O
daily EP1615622B1 T JJ O
formulations EP1615622B1 T NNS O
of EP1615622B1 T IN O
doxycyclines EP1615622B1 T NNS O
. EP1615622B1 T . O

Application CN101703500A T NN O
of CN101703500A T IN O
isofraxidin CN101703500A T NN O
in CN101703500A T IN O
preparing CN101703500A T VBG O
medicament CN101703500A T NN O
for CN101703500A T IN O
treating CN101703500A T VBG O
osteoporosis CN101703500A T NN O
. CN101703500A T . O

Novel US20100152189 T NNP O
polymorphous US20100152189 T JJ O
form US20100152189 T NN O
and US20100152189 T CC O
the US20100152189 T DT O
amorphous US20100152189 T JJ O
form US20100152189 T NN O
of US20100152189 T IN O
5-chloro-n- US20100152189 T JJ O
( US20100152189 T ( O
{ US20100152189 T ( O
( US20100152189 T ( O
5s US20100152189 T CD O
) US20100152189 T ) O
-2-oxo-3 US20100152189 T NN O
[ US20100152189 T JJ O
4- US20100152189 T JJ O
( US20100152189 T ( O
3-oxo-4-morpholinyl US20100152189 T JJ O
( US20100152189 T ( O
-phenyl US20100152189 T JJ O
] US20100152189 T NNP O
-1,3-oxazolidine-5-yl US20100152189 T NNP O
} US20100152189 T ) O
-methyl US20100152189 T NNP O
) US20100152189 T ) O
-2-thiophene US20100152189 T NNP O
carboxamide US20100152189 T NN O
. US20100152189 T . O

Prodrugs WO2010109008A1 T NNS O
of WO2010109008A1 T IN O
substituted WO2010109008A1 T VBN O
3- WO2010109008A1 T JJ O
( WO2010109008A1 T ( O
4-hydroxyphenyl WO2010109008A1 T JJ O
) WO2010109008A1 T ) O
-indolin-2-ones WO2010109008A1 T NNS O
. WO2010109008A1 T . O

Pharmaceutical EP1231894B1 T JJ O
formulations EP1231894B1 T NNS O
of EP1231894B1 T IN O
salmeterol EP1231894B1 T NN O
. EP1231894B1 T . O

Methods CA2172392C T NNS O
of CA2172392C T IN O
inhibiting CA2172392C T VBG O
phagocytosis CA2172392C T NN O
. CA2172392C T . O

The CA2172392C A DT O
present CA2172392C A JJ O
invention CA2172392C A NN O
relates CA2172392C A NNS O
, CA2172392C A , O
in CA2172392C A IN O
general CA2172392C A JJ O
, CA2172392C A , O
to CA2172392C A TO O
methods CA2172392C A NNS O
of CA2172392C A IN O
treating CA2172392C A VBG O
diseases CA2172392C A NNS O
resulting CA2172392C A VBG O
from CA2172392C A IN O
interactions CA2172392C A NNS O
between CA2172392C A IN O
immune CA2172392C A NN O
complexes CA2172392C A NNS O
and CA2172392C A CC O
Fc CA2172392C A NNP I-UN
receptors CA2172392C A NNS I-UN
. CA2172392C A . O

In CA2172392C A IN O
particular CA2172392C A JJ O
, CA2172392C A , O
the CA2172392C A DT O
present CA2172392C A JJ O
invention CA2172392C A NN O
relates CA2172392C A VBZ O
to CA2172392C A TO O
methods CA2172392C A NNS O
of CA2172392C A IN O
modulating CA2172392C A VBG O
the CA2172392C A DT O
clearance CA2172392C A NN O
of CA2172392C A IN O
antibody-coated CA2172392C A JJ O
cells CA2172392C A NNS O
from CA2172392C A IN O
the CA2172392C A DT O
circulation CA2172392C A NN O
by CA2172392C A IN O
inhibiting CA2172392C A VBG O
phagocytosis CA2172392C A NN O
and CA2172392C A CC O
to CA2172392C A TO O
methods CA2172392C A NNS O
of CA2172392C A IN O
modulating CA2172392C A VBG O
the CA2172392C A DT O
interaction CA2172392C A NN O
of CA2172392C A IN O
immune CA2172392C A NN O
complexes CA2172392C A NNS O
with CA2172392C A IN O
tissue CA2172392C A NN O
Fc CA2172392C A NNP I-UN
receptors CA2172392C A NNS I-UN
. CA2172392C A . O

Further CA2172392C A RB O
, CA2172392C A , O
the CA2172392C A DT O
invention CA2172392C A NN O
relates CA2172392C A VBZ O
to CA2172392C A TO O
methods CA2172392C A NNS O
of CA2172392C A IN O
modulating CA2172392C A VBG O
the CA2172392C A DT O
activation CA2172392C A NN O
of CA2172392C A IN O
immunological CA2172392C A JJ O
processes CA2172392C A NNS O
mediated CA2172392C A VBN O
by CA2172392C A IN O
Fc CA2172392C A NNP I-UN
receptor CA2172392C A NN I-UN
activation CA2172392C A NN O
resulting CA2172392C A VBG O
from CA2172392C A IN O
antibody-antigen/receptor CA2172392C A JJ O
interaction CA2172392C A NN O
. CA2172392C A . O

Methods WO2012109673A1 T NNS O
of WO2012109673A1 T IN O
treating WO2012109673A1 T VBG O
macular WO2012109673A1 T JJ O
edema WO2012109673A1 T NN O
using WO2012109673A1 T VBG O
antiedema WO2012109673A1 T JJ O
therapeutics WO2012109673A1 T NNS O
. WO2012109673A1 T . O

Drug CN101590053A T NNP O
combination CN101590053A T NN O
containing CN101590053A T VBG O
nicotinic CN101590053A T JJ O
acid CN101590053A T NN O
, CN101590053A T , O
statins CN101590053A T VBZ O
compound CN101590053A T NN O
and CN101590053A T CC O
TZD CN101590053A T NNP O
compound CN101590053A T NN O
. CN101590053A T . O

The CN101590053A A DT O
invention CN101590053A A NN O
relates CN101590053A A VBZ O
to CN101590053A A TO O
a CN101590053A A DT O
drug CN101590053A A NN O
combination CN101590053A A NN O
containing CN101590053A A VBG O
nicotinic CN101590053A A JJ O
acid CN101590053A A NN O
, CN101590053A A , O
HMG-CoA CN101590053A A NNP I-UN
reductase CN101590053A A NN I-UN
inhibitor CN101590053A A NN O
and CN101590053A A CC O
TZD CN101590053A A NNP O
medicines CN101590053A A NNS O
and CN101590053A A CC O
carrier CN101590053A A NN O
which CN101590053A A WDT O
can CN101590053A A MD O
be CN101590053A A VB O
accepted CN101590053A A VBN O
by CN101590053A A IN O
pharmaceutics CN101590053A A NNS O
and CN101590053A A CC O
an CN101590053A A DT O
application CN101590053A A NN O
of CN101590053A A IN O
the CN101590053A A DT O
combination CN101590053A A NN O
for CN101590053A A IN O
preparing CN101590053A A VBG O
medicines CN101590053A A NNS O
for CN101590053A A IN O
preventing CN101590053A A VBG O
or CN101590053A A CC O
treating CN101590053A A VBG O
diabetes CN101590053A A NNS O
and CN101590053A A CC O
diabetes-related CN101590053A A JJ O
complications CN101590053A A NNS O
. CN101590053A A . O

Accelerated US20120122795 T JJ O
extension US20120122795 T NN O
of US20120122795 T IN O
axons US20120122795 T NNS O
. US20120122795 T . O

Mikanolide US6887869 T NNP O
derivatives US6887869 T NNS O
, US6887869 T , O
their US6887869 T PRP$ O
preparation US6887869 T NN O
and US6887869 T CC O
therapeutic US6887869 T JJ O
uses US6887869 T NNS O
. US6887869 T . O

The US6887869 A DT O
invention US6887869 A NN O
concerns US6887869 A NNS O
novel US6887869 A JJ O
mikanolide US6887869 A NN O
derivatives US6887869 A NNS O
, US6887869 A , O
their US6887869 A PRP$ O
preparation US6887869 A NN O
method US6887869 A NN O
and US6887869 A CC O
their US6887869 A PRP$ O
therapeutic US6887869 A JJ O
uses US6887869 A NNS O
, US6887869 A , O
in US6887869 A IN O
particular US6887869 A JJ O
as US6887869 A IN O
anti-cancer US6887869 A JJ O
and US6887869 A CC O
anti-viral US6887869 A JJ O
agents US6887869 A NNS O
. US6887869 A . O

The US6887869 A DT O
compounds US6887869 A NNS O
correspond US6887869 A NN O
to US6887869 A TO O
general US6887869 A JJ O
formula US6887869 A NN O
( US6887869 A ( O
1 US6887869 A CD O
) US6887869 A ) O
corresponding US6887869 A NN O
to US6887869 A TO O
general US6887869 A JJ O
sub-formulae US6887869 A NN O
( US6887869 A ( O
I US6887869 A PRP O
) US6887869 A ) O
1 US6887869 A CD O
and US6887869 A CC O
( US6887869 A ( O
I US6887869 A PRP O
) US6887869 A ) O
2 US6887869 A CD O
, US6887869 A , O
wherein US6887869 A NN O
: US6887869 A : O
R1 US6887869 A JJ O
represents US6887869 A VBZ O
H US6887869 A NNP O
, US6887869 A , O
SR4 US6887869 A NNP O
or US6887869 A CC O
NR4R5 US6887869 A NNP O
; US6887869 A : O
R2 US6887869 A NNP O
represents US6887869 A VBZ O
SR6 US6887869 A NNP O
or US6887869 A CC O
NR6R7 US6887869 A NNP O
; US6887869 A : O
R3 US6887869 A NNP O
represents US6887869 A VBZ O
OH US6887869 A NNP O
, US6887869 A , O
O US6887869 A NNP O
( US6887869 A ( O
CO US6887869 A NNP O
) US6887869 A ) O
R14 US6887869 A NNP O
, US6887869 A , O
OSiR15R16R17 US6887869 A NNP O
, US6887869 A , O
O US6887869 A NNP O
( US6887869 A ( O
CO US6887869 A NNP O
) US6887869 A ) O
OR18 US6887869 A NNP O
or US6887869 A CC O
O US6887869 A NNP O
( US6887869 A ( O
CO US6887869 A NNP O
) US6887869 A ) O
NHR18 US6887869 A NNP O
, US6887869 A , O
each US6887869 A DT O
of US6887869 A IN O
the US6887869 A DT O
radicals US6887869 A NNS O
R4 US6887869 A NNP O
, US6887869 A , O
R6 US6887869 A NNP O
, US6887869 A , O
R15 US6887869 A NNP O
, US6887869 A , O
R16 US6887869 A NNP O
and US6887869 A CC O
R17 US6887869 A NNP O
representing US6887869 A VBG O
independently US6887869 A RB O
( US6887869 A ( O
in US6887869 A IN O
particular US6887869 A NN O
) US6887869 A ) O
an US6887869 A DT O
alkyl US6887869 A JJ O
radical US6887869 A NN O
, US6887869 A , O
the US6887869 A DT O
radicals US6887869 A NNS O
R5 US6887869 A NNP O
and US6887869 A CC O
R7 US6887869 A NNP O
representing US6887869 A VBG O
( US6887869 A ( O
in US6887869 A IN O
particular US6887869 A NN O
) US6887869 A ) O
radicals US6887869 A NNS O
selected US6887869 A VBN O
independently US6887869 A RB O
among US6887869 A IN O
a US6887869 A DT O
hydrogen US6887869 A NN O
atom US6887869 A NN O
and US6887869 A CC O
an US6887869 A DT O
alkyl US6887869 A JJ O
radical US6887869 A NN O
, US6887869 A , O
and US6887869 A CC O
each US6887869 A DT O
of US6887869 A IN O
the US6887869 A DT O
radicals US6887869 A NNS O
R14 US6887869 A NNP O
and US6887869 A CC O
R18 US6887869 A NNP O
representing US6887869 A VBG O
independently US6887869 A RB O
( US6887869 A ( O
in US6887869 A IN O
particular US6887869 A NN O
) US6887869 A ) O
an US6887869 A DT O
alkyl US6887869 A NN O
or US6887869 A CC O
cycloalkyl US6887869 A VB O
radical US6887869 A JJ O
, US6887869 A , O
or US6887869 A CC O
one US6887869 A CD O
among US6887869 A IN O
aryl US6887869 A NN O
, US6887869 A , O
heteroaryl US6887869 A NN O
, US6887869 A , O
aralkyl US6887869 A NN O
or US6887869 A CC O
heteroalkyl US6887869 A NN O
radicals US6887869 A NNS O
optionally US6887869 A RB O
substituted US6887869 A VBD O
; US6887869 A : O
provided US6887869 A VBN O
that US6887869 A IN O
when US6887869 A WRB O
the US6887869 A DT O
compounds US6887869 A NNS O
correspond US6887869 A NN O
to US6887869 A TO O
the US6887869 A DT O
general US6887869 A JJ O
sub-formula US6887869 A NN O
( US6887869 A ( O
I US6887869 A PRP O
) US6887869 A ) O
2 US6887869 A CD O
, US6887869 A , O
then US6887869 A RB O
R1 US6887869 A NNP O
does US6887869 A VBZ O
not US6887869 A RB O
represent US6887869 A VB O
a US6887869 A DT O
hydrogen US6887869 A NN O
atom US6887869 A NN O

Isatine US7595336 T NNP O
derivatives US7595336 T NNS O
with US7595336 T IN O
neurotrophic US7595336 T JJ O
activity US7595336 T NN O
. US7595336 T . O

Homeopathic US20120195970 T JJ O
Formulations US20120195970 T NNS O
For US20120195970 T IN O
Treatment US20120195970 T NNP O
Of US20120195970 T IN O
Herpes US20120195970 T NNP O
Virus US20120195970 T NNP O
Symptoms US20120195970 T NNP O
. US20120195970 T . O

Methods US8309355 T NNS O
of US8309355 T IN O
treating US8309355 T VBG O
Parkinson US8309355 T NNP O
's US8309355 T POS O
disease US8309355 T NN O
using US8309355 T VBG O
viral US8309355 T JJ O
vectors US8309355 T NNS O
. US8309355 T . O

The US8309355 A DT O
methods US8309355 A NNS O
entail US8309355 A VBP O
providing US8309355 A VBG O
rAAV US8309355 A NN O
virions US8309355 A NNS O
that US8309355 A WDT O
comprise US8309355 A VBP O
a US8309355 A DT O
transgene US8309355 A NN O
encoding US8309355 A VBG O
aromatic US8309355 A JJ I-UN
amino US8309355 A NN I-UN
acid US8309355 A NN I-UN
decarboxylase US8309355 A NN I-UN
( US8309355 A ( O
AADC US8309355 A NNP I-UN
) US8309355 A ) O
and US8309355 A CC O
administering US8309355 A VBG O
the US8309355 A DT O
virions US8309355 A NNS O
to US8309355 A TO O
the US8309355 A DT O
brain US8309355 A NN O
of US8309355 A IN O
a US8309355 A DT O
mammal US8309355 A JJ O
using US8309355 A VBG O
a US8309355 A DT O
non-manual US8309355 A JJ O
pump US8309355 A NN O
. US8309355 A . O

Klf5 WO2008078785A1 T NNP I-UN
suppressor WO2008078785A1 T NN O
and WO2008078785A1 T CC O
method WO2008078785A1 T NN O
for WO2008078785A1 T IN O
selecting WO2008078785A1 T VBG O
active WO2008078785A1 T JJ O
ingredient WO2008078785A1 T NN O
of WO2008078785A1 T IN O
the WO2008078785A1 T DT O
medicament WO2008078785A1 T NN O
. WO2008078785A1 T . O

It WO2008078785A1 A PRP O
is WO2008078785A1 A VBZ O
intended WO2008078785A1 A VBN O
to WO2008078785A1 A TO O
discover WO2008078785A1 A VB O
a WO2008078785A1 A DT O
new WO2008078785A1 A JJ O
medicament WO2008078785A1 A NN O
capable WO2008078785A1 A JJ O
of WO2008078785A1 A IN O
suppressing WO2008078785A1 A VBG O
the WO2008078785A1 A DT O
action WO2008078785A1 A NN O
of WO2008078785A1 A IN O
KLF5 WO2008078785A1 A NNP I-UN
which WO2008078785A1 A WDT O
is WO2008078785A1 A VBZ O
present WO2008078785A1 A JJ O
as WO2008078785A1 A IN O
a WO2008078785A1 A DT O
transcription WO2008078785A1 A NN O
factor WO2008078785A1 A NN O
and WO2008078785A1 A CC O
is WO2008078785A1 A VBZ O
associated WO2008078785A1 A VBN O
with WO2008078785A1 A IN O
the WO2008078785A1 A DT O
onset WO2008078785A1 A NN O
, WO2008078785A1 A , O
progression WO2008078785A1 A NN O
or WO2008078785A1 A CC O
the WO2008078785A1 A DT O
like WO2008078785A1 A IN O
of WO2008078785A1 A IN O
various WO2008078785A1 A JJ O
diseases WO2008078785A1 A NNS O
, WO2008078785A1 A , O
and WO2008078785A1 A CC O
to WO2008078785A1 A TO O
provide WO2008078785A1 A VB O
new WO2008078785A1 A JJ O
means WO2008078785A1 A NNS O
for WO2008078785A1 A IN O
prevention WO2008078785A1 A NN O
or WO2008078785A1 A CC O
treatment WO2008078785A1 A NN O
of WO2008078785A1 A IN O
the WO2008078785A1 A DT O
diseases WO2008078785A1 A NNS O
. WO2008078785A1 A . O

More WO2008078785A1 A RBR O
specifically WO2008078785A1 A RB O
, WO2008078785A1 A , O
it WO2008078785A1 A PRP O
was WO2008078785A1 A VBD O
found WO2008078785A1 A VBN O
that WO2008078785A1 A IN O
the WO2008078785A1 A DT O
abundance WO2008078785A1 A NN O
of WO2008078785A1 A IN O
the WO2008078785A1 A DT O
KLF5 WO2008078785A1 A NNP I-UN
was WO2008078785A1 A VBD O
suppressed WO2008078785A1 A VBN O
by WO2008078785A1 A IN O
a WO2008078785A1 A DT O
proteolytic WO2008078785A1 A JJ O
action WO2008078785A1 A NN O
through WO2008078785A1 A IN O
a WO2008078785A1 A DT O
nuclear WO2008078785A1 A JJ O
receptor WO2008078785A1 A NN O
, WO2008078785A1 A , O
and WO2008078785A1 A CC O
that WO2008078785A1 A IN O
the WO2008078785A1 A DT O
above WO2008078785A1 A IN O
object WO2008078785A1 A NN O
can WO2008078785A1 A MD O
be WO2008078785A1 A VB O
achieved WO2008078785A1 A VBN O
by WO2008078785A1 A IN O
providing WO2008078785A1 A VBG O
a WO2008078785A1 A DT O
medicament WO2008078785A1 A NN O
containing WO2008078785A1 A VBG O
a WO2008078785A1 A DT O
substance WO2008078785A1 A NN O
binding WO2008078785A1 A NN O
to WO2008078785A1 A TO O
a WO2008078785A1 A DT O
nuclear WO2008078785A1 A JJ O
receptor WO2008078785A1 A NN O
which WO2008078785A1 A WDT O
has WO2008078785A1 A VBZ O
an WO2008078785A1 A DT O
action WO2008078785A1 A NN O
of WO2008078785A1 A IN O
suppressing WO2008078785A1 A VBG O
the WO2008078785A1 A DT O
amount WO2008078785A1 A NN O
of WO2008078785A1 A IN O
KLF5 WO2008078785A1 A NNP I-UN
protein WO2008078785A1 A NN O
as WO2008078785A1 A IN O
an WO2008078785A1 A DT O
active WO2008078785A1 A JJ O
ingredient WO2008078785A1 A NN O
. WO2008078785A1 A . O

Further WO2008078785A1 A RB O
, WO2008078785A1 A , O
the WO2008078785A1 A DT O
invention WO2008078785A1 A NN O
provides WO2008078785A1 A VBZ O
a WO2008078785A1 A DT O
method WO2008078785A1 A NN O
for WO2008078785A1 A IN O
selecting WO2008078785A1 A VBG O
the WO2008078785A1 A DT O
active WO2008078785A1 A JJ O
ingredient WO2008078785A1 A NN O
of WO2008078785A1 A IN O
the WO2008078785A1 A DT O
medicament WO2008078785A1 A NN O
suitable WO2008078785A1 A NN O
for WO2008078785A1 A IN O
the WO2008078785A1 A DT O
mechanism WO2008078785A1 A NN O
of WO2008078785A1 A IN O
degradation WO2008078785A1 A NN O
of WO2008078785A1 A IN O
the WO2008078785A1 A DT O
KLF5 WO2008078785A1 A NNP I-UN
. WO2008078785A1 A . O

Repaglinide CN102525968A T NNP O
orally CN102525968A T RB O
disintegrating CN102525968A T VBG O
tablet CN102525968A T NN O
and CN102525968A T CC O
preparation CN102525968A T NN O
method CN102525968A T NN O
thereof CN102525968A T NN O
. CN102525968A T . O

Synthesis WO2009152584A1 T NN O
of WO2009152584A1 T IN O
ageladine WO2009152584A1 T NN O
a WO2009152584A1 T DT O
and WO2009152584A1 T CC O
analogs WO2009152584A1 T JJ O
thereof WO2009152584A1 T NN O
. WO2009152584A1 T . O

Pregnancy WO2010015372A1 T NNP O
prevention WO2010015372A1 T NN O
using WO2010015372A1 T VBG O
gestagens WO2010015372A1 T NNS O
. WO2010015372A1 T . O

Complex US20050070595 T NNP O
of US20050070595 T IN O
trioxane US20050070595 T NN O
with US20050070595 T IN O
iron US20050070595 T NN O
compound US20050070595 T NN O
. US20050070595 T . O

Process CA2347981C T NN O
for CA2347981C T IN O
the CA2347981C T DT O
manufacturing CA2347981C T NN O
of CA2347981C T IN O
alkaline CA2347981C T NN O
salts CA2347981C T NNS O
of CA2347981C T IN O
substituted CA2347981C T JJ O
sulphinyl CA2347981C T NN O
compounds CA2347981C T NNS O
and CA2347981C T CC O
products CA2347981C T NNS O
prepared CA2347981C T VBN O
thereby CA2347981C T RB O
. CA2347981C T . O

Process CA2347981C A NN O
for CA2347981C A IN O
the CA2347981C A DT O
manufacturing CA2347981C A NN O
of CA2347981C A IN O
slightly CA2347981C A RB O
soluble CA2347981C A JJ O
or CA2347981C A CC O
less CA2347981C A RBR O
soluble CA2347981C A JJ O
alkaline CA2347981C A NN O
salts CA2347981C A NNS O
of CA2347981C A IN O
substituted CA2347981C A JJ O
sulphinyl CA2347981C A NN O
heterocycles CA2347981C A NNS O
containing CA2347981C A VBG O
an CA2347981C A DT O
imidazole CA2347981C A JJ O
moiety CA2347981C A NN O
with CA2347981C A IN O
formula CA2347981C A NN O
( CA2347981C A ( O
I CA2347981C A PRP O
) CA2347981C A ) O
, CA2347981C A , O
preferably CA2347981C A RB O
alkaline CA2347981C A JJ O
salts CA2347981C A NNS O
of CA2347981C A IN O
a CA2347981C A DT O
proton CA2347981C A NN I-UN
pump CA2347981C A NN I-UN
inhibitor CA2347981C A NN O
compound CA2347981C A NN O
, CA2347981C A , O
wherein CA2347981C A VBP O
the CA2347981C A DT O
process CA2347981C A NN O
comprises CA2347981C A VBZ O
the CA2347981C A DT O
step CA2347981C A NN O
of CA2347981C A IN O
reacting CA2347981C A VBG O
the CA2347981C A DT O
substituted CA2347981C A VBN O
sulphinyl CA2347981C A NN O
heterocycle CA2347981C A NN O
of CA2347981C A IN O
formula CA2347981C A NN O
( CA2347981C A ( O
I CA2347981C A PRP O
) CA2347981C A ) O
with CA2347981C A IN O
a CA2347981C A DT O
source CA2347981C A NN O
of CA2347981C A IN O
the CA2347981C A DT O
cation CA2347981C A NN O
in CA2347981C A IN O
the CA2347981C A DT O
presence CA2347981C A NN O
of CA2347981C A IN O
a CA2347981C A DT O
base CA2347981C A NN O
, CA2347981C A , O
characterized CA2347981C A VBN O
by CA2347981C A IN O
a CA2347981C A DT O
washing CA2347981C A JJ O
step CA2347981C A NN O
in CA2347981C A IN O
which CA2347981C A WDT O
the CA2347981C A DT O
prepared CA2347981C A JJ O
alkaline CA2347981C A NN O
salt CA2347981C A NN O
of CA2347981C A IN O
the CA2347981C A DT O
substituted CA2347981C A JJ O
sulphinyl CA2347981C A NN O
compound CA2347981C A NN O
is CA2347981C A VBZ O
washed CA2347981C A VBN O
with CA2347981C A IN O
a CA2347981C A DT O
basic CA2347981C A JJ O
aqueous CA2347981C A JJ O
solvent CA2347981C A JJ O
mixture CA2347981C A NN O
. CA2347981C A . O

Isoforms US20120003252 T NNS O
of US20120003252 T IN O
human US20120003252 T JJ I-UN
somatostatin US20120003252 T NN I-UN
receptor US20120003252 T NN I-UN
type US20120003252 T NN I-UN
5 US20120003252 T CD I-UN
produced US20120003252 T VBN O
by US20120003252 T IN O
alternative US20120003252 T JJ O
processing US20120003252 T NN O
and US20120003252 T CC O
oligo-nucleotide US20120003252 T JJ O
pairs US20120003252 T NNS O
for US20120003252 T IN O
detection US20120003252 T NN O
thereof US20120003252 T NN O
by US20120003252 T IN O
pcr US20120003252 T NN O
. US20120003252 T . O

The US20120003252 A DT O
present US20120003252 A JJ O
invention US20120003252 A NN O
concerns US20120003252 A NNS O
two US20120003252 A CD O
human US20120003252 A JJ O
nucleic US20120003252 A JJ O
acids US20120003252 A NNS O
comprising US20120003252 A VBG O
sequences US20120003252 A NNS O
which US20120003252 A WDT O
code US20120003252 A VBP O
two US20120003252 A CD O
novel US20120003252 A JJ O
isoforms US20120003252 A NNS O
of US20120003252 A IN O
human US20120003252 A JJ I-UN
somatostatin US20120003252 A NN I-UN
receptor US20120003252 A NN I-UN
type US20120003252 A NN I-UN
5 US20120003252 A CD I-UN
produced US20120003252 A VBN O
by US20120003252 A IN O
alternative US20120003252 A JJ O
adjustment US20120003252 A NN O
, US20120003252 A , O
called US20120003252 A VBN O
sst5B US20120003252 A NN I-UN
and US20120003252 A CC O
sst5C US20120003252 A NN I-UN
and US20120003252 A CC O
with US20120003252 A IN O
possible US20120003252 A JJ O
uses US20120003252 A NNS O
in US20120003252 A IN O
tumoral US20120003252 A JJ O
processes US20120003252 A NNS O
. US20120003252 A . O

Methods WO2012174229A3 T NNS O
for WO2012174229A3 T IN O
the WO2012174229A3 T DT O
synthesis WO2012174229A3 T NN O
and WO2012174229A3 T CC O
purification WO2012174229A3 T NN O
of WO2012174229A3 T IN O
deoxycholic WO2012174229A3 T JJ O
acid WO2012174229A3 T NN O
. WO2012174229A3 T . O

Triazole US20100062972 T NNP O
compounds US20100062972 T NNS O
and US20100062972 T CC O
uses US20100062972 T NNS O
related US20100062972 T JJ O
thereto US20100062972 T NN O
. US20100062972 T . O

The US20100062972 A DT O
above-mentioned US20100062972 A JJ O
triazole US20100062972 A NN O
compound US20100062972 A NN O
has US20100062972 A VBZ O
superior US20100062972 A JJ O
HSD1 US20100062972 A NNP I-UN
inhibitory US20100062972 A NN O
activity US20100062972 A NN O
, US20100062972 A , O
and US20100062972 A CC O
is US20100062972 A VBZ O
useful US20100062972 A JJ O
as US20100062972 A IN O
an US20100062972 A DT O
HSD1 US20100062972 A NNP I-UN
inhibitor US20100062972 A NN O
, US20100062972 A , O
a US20100062972 A DT O
therapeutic US20100062972 A JJ O
drug US20100062972 A NN O
of US20100062972 A IN O
diabetes US20100062972 A NNS O
or US20100062972 A CC O
a US20100062972 A DT O
therapeutic US20100062972 A JJ O
drug US20100062972 A NN O
of US20100062972 A IN O
obesity US20100062972 A NN O
or US20100062972 A CC O
a US20100062972 A DT O
therapeutic US20100062972 A JJ O
drug US20100062972 A NN O
of US20100062972 A IN O
metabolic US20100062972 A JJ O
syndrome US20100062972 A NN O
. US20100062972 A . O

Preparation CN102775389A T NNP O
method CN102775389A T NN O
of CN102775389A T IN O
N-substituted-4- CN102775389A T NNP O
( CN102775389A T ( O
7-chloro-quinoline CN102775389A T JJ O
-4-amino CN102775389A T NN O
) CN102775389A T ) O
-benzamide CN102775389A T NN O
derivatives CN102775389A T NNS O
, CN102775389A T , O
and CN102775389A T CC O
application CN102775389A T NN O
thereof CN102775389A T NN O
. CN102775389A T . O

Thermogelling EP1320359B1 T VBG O
biodegradable EP1320359B1 T JJ O
aqueous EP1320359B1 T JJ O
polymer EP1320359B1 T NN O
solution EP1320359B1 T NN O
. EP1320359B1 T . O

Stable CN102861015A T JJ O
amoxicillin CN102861015A T NN O
and CN102861015A T CC O
clavulanate CN102861015A T NN O
potassium CN102861015A T NN O
sustained CN102861015A T VBD O
release CN102861015A T NN O
preparation CN102861015A T NN O
and CN102861015A T CC O
preparation CN102861015A T NN O
technology CN102861015A T NN O
. CN102861015A T . O

Trimetazidine CN103735528A T NNP O
hydrochloride CN103735528A T JJ O
bi-layer CN103735528A T JJ O
osmotic CN103735528A T JJ O
pump CN103735528A T NN O
controlled CN103735528A T VBD O
release CN103735528A T NN O
tablet CN103735528A T NN O
and CN103735528A T CC O
preparation CN103735528A T NN O
method CN103735528A T NN O
thereof CN103735528A T NN O
. CN103735528A T . O

Erk WO2012160130A1 T NNP I-UN
inhibitors WO2012160130A1 T NNS O
for WO2012160130A1 T IN O
use WO2012160130A1 T NN O
in WO2012160130A1 T IN O
treating WO2012160130A1 T VBG O
spinal WO2012160130A1 T JJ O
muscular WO2012160130A1 T JJ O
atrophy WO2012160130A1 T NN O
. WO2012160130A1 T . O

The WO2012160130A1 A DT O
present WO2012160130A1 A JJ O
invention WO2012160130A1 A NN O
relates WO2012160130A1 A VBZ O
to WO2012160130A1 A TO O
a WO2012160130A1 A DT O
method WO2012160130A1 A NN O
for WO2012160130A1 A IN O
treating WO2012160130A1 A VBG O
spinal WO2012160130A1 A JJ O
muscular WO2012160130A1 A JJ O
atrophy WO2012160130A1 A NN O
and WO2012160130A1 A CC O
other WO2012160130A1 A JJ O
related WO2012160130A1 A JJ O
neuromuscular WO2012160130A1 A JJ O
disorders WO2012160130A1 A NNS O
in WO2012160130A1 A IN O
a WO2012160130A1 A DT O
subject WO2012160130A1 A NN O
in WO2012160130A1 A IN O
need WO2012160130A1 A NN O
thereof WO2012160130A1 A NN O
, WO2012160130A1 A , O
said WO2012160130A1 A VBD O
method WO2012160130A1 A NN O
comprising WO2012160130A1 A VBG O
administering WO2012160130A1 A VBG O
a WO2012160130A1 A DT O
therapeutically WO2012160130A1 A RB O
effective WO2012160130A1 A JJ O
amount WO2012160130A1 A NN O
of WO2012160130A1 A IN O
an WO2012160130A1 A DT O
ERK WO2012160130A1 A NNP I-UN
inhibitor WO2012160130A1 A NN O
, WO2012160130A1 A , O
such WO2012160130A1 A JJ O
as WO2012160130A1 A IN O
Selumetinib WO2012160130A1 A NNP O
to WO2012160130A1 A TO O
said WO2012160130A1 A VBD O
subject WO2012160130A1 A NN O
. WO2012160130A1 A . O

HUMAN EP0934412B1 T NNP I-UN
THYMOSIN EP0934412B1 T NNP I-UN
beta EP0934412B1 T VBD I-UN
15 EP0934412B1 T CD I-UN
GENE EP0934412B1 T NNP O
, EP0934412B1 T , O
PROTEIN EP0934412B1 T NNP O
AND EP0934412B1 T NNP O
USES EP0934412B1 T NNP O
THEREOF EP0934412B1 T NNP O
. EP0934412B1 T . O

This EP0934412B1 A DT O
novel EP0934412B1 A JJ O
protein EP0934412B1 A NN O
, EP0934412B1 A , O
herein EP0934412B1 A RB O
referred EP0934412B1 A VBD O
to EP0934412B1 A TO O
as EP0934412B1 A IN O
thymosin EP0934412B1 A NN I-UN
beta EP0934412B1 A NN I-UN
15 EP0934412B1 A CD I-UN
, EP0934412B1 A , O
has EP0934412B1 A VBZ O
the EP0934412B1 A DT O
ability EP0934412B1 A NN O
to EP0934412B1 A TO O
bind EP0934412B1 A VB O
and EP0934412B1 A CC O
sequester EP0934412B1 A JJR O
G-actin EP0934412B1 A NNP I-UN
, EP0934412B1 A , O
like EP0934412B1 A IN O
other EP0934412B1 A JJ O
members EP0934412B1 A NNS O
of EP0934412B1 A IN O
the EP0934412B1 A DT O
thymosin EP0934412B1 A NN I-UN
beta EP0934412B1 A NN I-UN
family EP0934412B1 A NN O
, EP0934412B1 A , O
but EP0934412B1 A CC O
unlike EP0934412B1 A IN O
what EP0934412B1 A WP O
is EP0934412B1 A VBZ O
known EP0934412B1 A VBN O
about EP0934412B1 A IN O
other EP0934412B1 A JJ O
members EP0934412B1 A NNS O
it EP0934412B1 A PRP O
also EP0934412B1 A RB O
directly EP0934412B1 A RB O
regulates EP0934412B1 A VBZ O
cell EP0934412B1 A NN O
motility EP0934412B1 A NN O
in EP0934412B1 A IN O
prostatic EP0934412B1 A JJ O
carcinoma EP0934412B1 A NN O
cells EP0934412B1 A NNS O
. EP0934412B1 A . O

The EP0934412B1 A DT O
present EP0934412B1 A JJ O
invention EP0934412B1 A NN O
is EP0934412B1 A VBZ O
directed EP0934412B1 A VBN O
to EP0934412B1 A TO O
an EP0934412B1 A DT O
isolated EP0934412B1 A JJ O
cDNA EP0934412B1 A NN O
encoding EP0934412B1 A VBG O
the EP0934412B1 A DT O
human EP0934412B1 A JJ I-UN
thymosin EP0934412B1 A NN I-UN
beta EP0934412B1 A NN I-UN
15 EP0934412B1 A CD I-UN
gene EP0934412B1 A NN O
( EP0934412B1 A ( O
SEQ EP0934412B1 A NNP O
ID EP0934412B1 A NNP O
NO EP0934412B1 A NNP O
: EP0934412B1 A : O
1 EP0934412B1 A CD O
) EP0934412B1 A ) O
and EP0934412B1 A CC O
have EP0934412B1 A VBP O
deduced EP0934412B1 A VBN O
the EP0934412B1 A DT O
amino EP0934412B1 A NN O
acid EP0934412B1 A NN O
sequence EP0934412B1 A NN O
( EP0934412B1 A ( O
SEQ EP0934412B1 A NNP O
ID EP0934412B1 A NNP O
NO EP0934412B1 A NNP O
: EP0934412B1 A : O
2 EP0934412B1 A CD O
) EP0934412B1 A ) O
. EP0934412B1 A . O

Pharmaceutical WO2013132208A1 T JJ O
antiretroviral WO2013132208A1 T JJ O
combinations WO2013132208A1 T NNS O
comprising WO2013132208A1 T VBG O
lamivudine WO2013132208A1 T NN O
, WO2013132208A1 T , O
festinavir WO2013132208A1 T NN O
and WO2013132208A1 T CC O
nevirapine WO2013132208A1 T NN O
. WO2013132208A1 T . O

3-tetrazolyl WO2007128454A1 T JJ O
indazoles WO2007128454A1 T NNS O
, WO2007128454A1 T , O
3-tetrazolyl WO2007128454A1 T JJ O
pyrazolopyridines WO2007128454A1 T NNS O
, WO2007128454A1 T , O
and WO2007128454A1 T CC O
use WO2007128454A1 T NN O
thereof WO2007128454A1 T NN O
. WO2007128454A1 T . O

Trihydroxy-substituted CN102070699A T JJ O
pentacyclic CN102070699A T JJ O
triterpene CN102070699A T NN O
compounds CN102070699A T NNS O
and CN102070699A T CC O
preparation CN102070699A T NN O
method CN102070699A T NN O
and CN102070699A T CC O
application CN102070699A T NN O
thereof CN102070699A T NN O
. CN102070699A T . O

Application CN101966195A T NN O
of CN101966195A T IN O
quercetin CN101966195A T NN O
in CN101966195A T IN O
preparing CN101966195A T VBG O
medicaments CN101966195A T NNS O
for CN101966195A T IN O
treating CN101966195A T VBG O
organ CN101966195A T JJ O
transplant CN101966195A T JJ O
rejection CN101966195A T NN O
reactions CN101966195A T NNS O
. CN101966195A T . O

Method CN1802950A T NNP O
for CN1802950A T IN O
preparing CN1802950A T VBG O
bowel-lubricating CN1802950A T JJ O
, CN1802950A T , O
face-beautifying CN1802950A T JJ O
soybean CN1802950A T NN O
milk CN1802950A T NN O
with CN1802950A T IN O
micron CN1802950A T JJ O
pine CN1802950A T NN O
pollen CN1802950A T NN O
, CN1802950A T , O
cactus CN1802950A T NN O
powder CN1802950A T NN O
, CN1802950A T , O
glossy CN1802950A T JJ O
ganoderma CN1802950A T NN O
powder CN1802950A T NN O
and CN1802950A T CC O
medlar CN1802950A T NN O
. CN1802950A T . O

Compositions US20110293526 T NNS O
and US20110293526 T CC O
methods US20110293526 T NNS O
to US20110293526 T TO O
modulate US20110293526 T VB O
hair US20110293526 T NN O
growth US20110293526 T NN O
. US20110293526 T . O

The US20110293526 A DT O
invention US20110293526 A NN O
provides US20110293526 A VBZ O
compositions US20110293526 A NNS O
and US20110293526 A CC O
methods US20110293526 A NNS O
to US20110293526 A TO O
modulate US20110293526 A VB O
hair US20110293526 A NN O
growth US20110293526 A NN O
in US20110293526 A IN O
a US20110293526 A DT O
tissue US20110293526 A NN O
comprising US20110293526 A VBG O
administering US20110293526 A VBG O
to US20110293526 A TO O
the US20110293526 A DT O
tissue US20110293526 A NN O
an US20110293526 A DT O
effective US20110293526 A JJ O
amount US20110293526 A NN O
of US20110293526 A IN O
an US20110293526 A DT O
agent US20110293526 A NN O
that US20110293526 A WDT O
inhibits US20110293526 A VBZ O
or US20110293526 A CC O
augments US20110293526 A NNS O
Bone US20110293526 A NNP I-UN
Morphogenic US20110293526 A NNP I-UN
Protein US20110293526 A NNP I-UN
( US20110293526 A ( O
BMP US20110293526 A NNP I-UN
) US20110293526 A ) O
signaling US20110293526 A VBG O
in US20110293526 A IN O
the US20110293526 A DT O
tissue US20110293526 A NN O
, US20110293526 A , O
thereby US20110293526 A RB O
facilitating US20110293526 A VBG O
or US20110293526 A CC O
inhibiting US20110293526 A VBG O
hair US20110293526 A JJ O
growth US20110293526 A NN O
. US20110293526 A . O

Thiazole CN1993358A T JJ O
derivatives CN1993358A T NNS O
as CN1993358A T IN O
chemokine CN1993358A T NN O
receptor CN1993358A T NN O
antagonists CN1993358A T NNS O
. CN1993358A T . O

Use EP1768661A1 T NNP O
of EP1768661A1 T IN O
targeted EP1768661A1 T JJ O
oxidative EP1768661A1 T JJ O
therapeutic EP1768661A1 T JJ O
formulation EP1768661A1 T NN O
in EP1768661A1 T IN O
treatment EP1768661A1 T NN O
of EP1768661A1 T IN O
burns EP1768661A1 T NNS O
. EP1768661A1 T . O

Via US7612050 T NNP O
bisphosphonate US7612050 T JJ O
drug US7612050 T NN O
; US7612050 T : O
for US7612050 T IN O
prophylaxis US7612050 T NN O
of US7612050 T IN O
cartilage US7612050 T NN O
destruction US7612050 T NN O
or US7612050 T CC O
chondrolysis US7612050 T NN O
associated US7612050 T VBN O
with US7612050 T IN O
osteonecrosis US7612050 T NN O
and/or US7612050 T NN O
osteochondritis US7612050 T NN O
dissecans US7612050 T NNS O
. US7612050 T . O

Sublingual EP2442650A1 T JJ O
apomorphine EP2442650A1 T NN O
. EP2442650A1 T . O

The EP2442650A1 A DT O
invention EP2442650A1 A NN O
features EP2442650A1 A VBZ O
sublingual EP2442650A1 A JJ O
formulations EP2442650A1 A NNS O
of EP2442650A1 A IN O
apomorphine EP2442650A1 A NN O
and EP2442650A1 A CC O
apomorphine EP2442650A1 A NN O
prodrugs EP2442650A1 A NNS O
, EP2442650A1 A , O
and EP2442650A1 A CC O
methods EP2442650A1 A NNS O
of EP2442650A1 A IN O
treating EP2442650A1 A VBG O
Parkinson EP2442650A1 A NNP O
's EP2442650A1 A POS O
disease EP2442650A1 A NN O
, EP2442650A1 A , O
sexual EP2442650A1 A JJ O
dysfunction EP2442650A1 A NN O
, EP2442650A1 A , O
and EP2442650A1 A CC O
depressive EP2442650A1 A JJ O
disorders EP2442650A1 A NNS O
therewith EP2442650A1 A VBP O
. EP2442650A1 A . O

Aqueous CN101528229B T JJ O
pharmaceutical CN101528229B T JJ O
suspensions CN101528229B T NNS O
containing CN101528229B T VBG O
rebamipide CN101528229B T NN O
and CN101528229B T CC O
manufacturing CN101528229B T NN O
process CN101528229B T NN O
thereof CN101528229B T NN O
. CN101528229B T . O

2-alkylidene-19-nor-vitamin WO2005027927A1 T JJ O
d WO2005027927A1 T NN O
derivatives WO2005027927A1 T NNS O
for WO2005027927A1 T IN O
enhancement WO2005027927A1 T NN O
of WO2005027927A1 T IN O
peak WO2005027927A1 T NN O
bone WO2005027927A1 T NN O
mass WO2005027927A1 T NN O
in WO2005027927A1 T IN O
adolescence WO2005027927A1 T NN O
. WO2005027927A1 T . O

Purine EP0735888B1 T NNP O
compositions EP0735888B1 T NNS O
. EP0735888B1 T . O

Radio-opaque US20120148646 T JJ O
bioactive US20120148646 T JJ O
glass US20120148646 T NN O
materials US20120148646 T NNS O
. US20120148646 T . O

Vinorelbine CN101134026A T NNP O
soft CN101134026A T JJ O
capsule CN101134026A T NN O
and CN101134026A T CC O
method CN101134026A T NN O
for CN101134026A T IN O
preparation CN101134026A T NN O
and CN101134026A T CC O
application CN101134026A T NN O
thereof CN101134026A T NN O
. CN101134026A T . O

25-hydroxy CN1850849A T JJ O
dioscin CN1850849A T NN O
ketone CN1850849A T NN O
, CN1850849A T , O
and CN1850849A T CC O
its CN1850849A T PRP$ O
preparing CN1850849A T NN O
method CN1850849A T NN O
and CN1850849A T CC O
use CN1850849A T NN O
. CN1850849A T . O

7-Amino US20050101588 T JJ O
alkylidenyl-heterocyclic US20050101588 T JJ O
quinolones US20050101588 T NNS O
and US20050101588 T CC O
naphthyridones US20050101588 T NNS O
. US20050101588 T . O

Casein US20090311329 T NNP I-UN
micelles US20090311329 T NNS O
for US20090311329 T IN O
nanoencapsulation US20090311329 T NN O
of US20090311329 T IN O
hydrophobic US20090311329 T JJ O
compounds US20090311329 T NNS O
. US20090311329 T . O

Psychological US7265110 T JJ O
disorders US7265110 T NNS O
; US7265110 T : O
antidepressants US7265110 T NNS O
; US7265110 T : O
anxiolytic US7265110 T JJ O
agents US7265110 T NNS O
; US7265110 T : O
analgesics US7265110 T NNS O
; US7265110 T : O
antiinflammatory US7265110 T JJ O
agents US7265110 T NNS O
; US7265110 T : O
central US7265110 T JJ O
nervous US7265110 T JJ O
system US7265110 T NN O
disorders US7265110 T NNS O
. US7265110 T . O

A EP1389466B1 T DT O
dispersion EP1389466B1 T NN O
on EP1389466B1 T IN O
the EP1389466B1 T DT O
basis EP1389466B1 T NN O
of EP1389466B1 T IN O
beta-glucan EP1389466B1 T JJ O
containing EP1389466B1 T VBG O
superfine EP1389466B1 T NN O
particles EP1389466B1 T NNS O
, EP1389466B1 T , O
a EP1389466B1 T DT O
corresponding EP1389466B1 T JJ O
process EP1389466B1 T NN O
of EP1389466B1 T IN O
manufacturing EP1389466B1 T NN O
and EP1389466B1 T CC O
the EP1389466B1 T DT O
use EP1389466B1 T NN O
of EP1389466B1 T IN O
said EP1389466B1 T VBD O
dispersion EP1389466B1 T NN O
. EP1389466B1 T . O

Aerosol WO2008023005A1 T NNP O
formulation WO2008023005A1 T NN O
for WO2008023005A1 T IN O
the WO2008023005A1 T DT O
inhalation WO2008023005A1 T NN O
of WO2008023005A1 T IN O
beta-agonists WO2008023005A1 T NNS O
. WO2008023005A1 T . O

The WO2008023005A1 A DT O
present WO2008023005A1 A JJ O
invention WO2008023005A1 A NN O
relates WO2008023005A1 A VBZ O
to WO2008023005A1 A TO O
a WO2008023005A1 A DT O
propellant-gas-free WO2008023005A1 A JJ O
aerosol WO2008023005A1 A NN O
formulation WO2008023005A1 A NN O
which WO2008023005A1 A WDT O
comprises WO2008023005A1 A VBZ O
one WO2008023005A1 A CD O
or WO2008023005A1 A CC O
more WO2008023005A1 A JJR O
compounds WO2008023005A1 A NNS O
of WO2008023005A1 A IN O
the WO2008023005A1 A DT O
general WO2008023005A1 A JJ O
formula WO2008023005A1 A NN O
( WO2008023005A1 A ( O
1 WO2008023005A1 A CD O
) WO2008023005A1 A ) O
in WO2008023005A1 A IN O
which WO2008023005A1 A WDT O
the WO2008023005A1 A DT O
radicals WO2008023005A1 A NNS O
R1 WO2008023005A1 A NNP O
, WO2008023005A1 A , O
R2 WO2008023005A1 A NNP O
, WO2008023005A1 A , O
R3 WO2008023005A1 A NNP O
and WO2008023005A1 A CC O
X WO2008023005A1 A NNP O
' WO2008023005A1 A POS O
can WO2008023005A1 A MD O
have WO2008023005A1 A VB O
the WO2008023005A1 A DT O
meanings WO2008023005A1 A NNS O
given WO2008023005A1 A VBN O
in WO2008023005A1 A IN O
the WO2008023005A1 A DT O
claims WO2008023005A1 A NNS O
and WO2008023005A1 A CC O
in WO2008023005A1 A IN O
the WO2008023005A1 A DT O
description WO2008023005A1 A NN O
for WO2008023005A1 A IN O
inhalation WO2008023005A1 A NN O
. WO2008023005A1 A . O

Topical US20100029765 T NNP O
aqueous US20100029765 T JJ O
composition US20100029765 T NN O
comprising US20100029765 T VBG O
tretinoin US20100029765 T NN O
. US20100029765 T . O

Active CN102626424A T JJ O
bacteriostasis CN102626424A T NN O
capsule CN102626424A T NN O
. CN102626424A T . O

Nootropic US6987106 T NNP O
agents US6987106 T NNS O
; US6987106 T : O
Alzheimer US6987106 T NNP O
's US6987106 T POS O
Disease US6987106 T NNP O
, US6987106 T , O
Schizophrenia US6987106 T NNP O
; US6987106 T : O
ligands US6987106 T VBZ O
for US6987106 T IN O
the US6987106 T DT O
a7 US6987106 T JJ I-UN
subunits US6987106 T NNS I-UN
of US6987106 T IN I-UN
the US6987106 T DT I-UN
nicotinic US6987106 T JJ I-UN
receptor US6987106 T NN I-UN
; US6987106 T : O
4-Bromophenyl-1,4-diazabicyclo US6987106 T JJ O
[ US6987106 T NN O
3.2.2 US6987106 T CD O
] US6987106 T JJ O
nonane-4-carboxylate US6987106 T NN O
. US6987106 T . O

Ibuprofen CN102697718A T NNP O
liquid CN102697718A T NN O
injection CN102697718A T NN O
composition CN102697718A T NN O
and CN102697718A T CC O
preparation CN102697718A T NN O
method CN102697718A T NN O
thereof CN102697718A T NN O
. CN102697718A T . O

Medicinal CN102648936A T JJ O
composition CN102648936A T NN O
for CN102648936A T IN O
treating CN102648936A T VBG O
wound CN102648936A T NN O
surface CN102648936A T NN O
and CN102648936A T CC O
preparation CN102648936A T NN O
method CN102648936A T NN O
and CN102648936A T CC O
application CN102648936A T NN O
thereof CN102648936A T NN O
. CN102648936A T . O

Novel US20110020430 T NNP O
mRNA US20110020430 T NN O
splice US20110020430 T NN O
variant US20110020430 T NN O
of US20110020430 T IN O
the US20110020430 T DT O
doublecortin-like US20110020430 T JJ I-UN
kinase US20110020430 T NN I-UN
gene US20110020430 T NN I-UN
and US20110020430 T CC O
its US20110020430 T PRP$ O
use US20110020430 T NN O
in US20110020430 T IN O
cancer US20110020430 T NN O
diagnosis US20110020430 T NN O
and US20110020430 T CC O
therapy US20110020430 T NN O
. US20110020430 T . O

The US20110020430 A DT O
methods US20110020430 A NNS O
include US20110020430 A VBP O
administering US20110020430 A VBG O
to US20110020430 A TO O
the US20110020430 A DT O
subject US20110020430 A NN O
nucleic US20110020430 A JJ O
acid US20110020430 A NN O
that US20110020430 A WDT O
is US20110020430 A VBZ O
capable US20110020430 A JJ O
of US20110020430 A IN O
causing US20110020430 A VBG O
a US20110020430 A DT O
significant US20110020430 A JJ O
reduction US20110020430 A NN O
of US20110020430 A IN O
the US20110020430 A DT O
amount US20110020430 A NN O
of US20110020430 A IN O
doublecortin US20110020430 A NN I-UN
like US20110020430 A IN I-UN
protein US20110020430 A NN I-UN
( US20110020430 A ( O
DCL US20110020430 A NNP I-UN
) US20110020430 A ) O
in US20110020430 A IN O
the US20110020430 A DT O
subject US20110020430 A NN O
. US20110020430 A . O

Pharmaceutical WO2007123186A1 T JJ O
product WO2007123186A1 T NN O
. WO2007123186A1 T . O

A WO2007123186A1 A DT O
TLR WO2007123186A1 A NNP I-UN
signaling WO2007123186A1 A VBG O
inhibitor WO2007123186A1 A NN O
, WO2007123186A1 A , O
preferably WO2007123186A1 A RB O
an WO2007123186A1 A DT O
inhibitor WO2007123186A1 A NN O
of WO2007123186A1 A IN O
the WO2007123186A1 A DT O
production WO2007123186A1 A NN O
of WO2007123186A1 A IN O
various WO2007123186A1 A JJ O
cytokines WO2007123186A1 A NNS O
such WO2007123186A1 A JJ O
as WO2007123186A1 A IN O
IL-8 WO2007123186A1 A NNP I-UN
or WO2007123186A1 A CC O
an WO2007123186A1 A DT O
inflammatory WO2007123186A1 A JJ O
mediator WO2007123186A1 A NN O
, WO2007123186A1 A , O
an WO2007123186A1 A DT O
inhibitor WO2007123186A1 A NN O
of WO2007123186A1 A IN O
the WO2007123186A1 A DT O
expression WO2007123186A1 A NN O
of WO2007123186A1 A IN O
COX-II WO2007123186A1 A NNP I-UN
or WO2007123186A1 A CC O
the WO2007123186A1 A DT O
like WO2007123186A1 A JJ O
or WO2007123186A1 A CC O
an WO2007123186A1 A DT O
inhibitor WO2007123186A1 A NN O
of WO2007123186A1 A IN O
various WO2007123186A1 A JJ O
kinases WO2007123186A1 A NNS O
such WO2007123186A1 A JJ O
as WO2007123186A1 A IN O
ATF2 WO2007123186A1 A NNP I-UN
containing WO2007123186A1 A VBG O
a WO2007123186A1 A DT O
compound WO2007123186A1 A NN O
represented WO2007123186A1 A VBN O
by WO2007123186A1 A IN O
the WO2007123186A1 A DT O
formula WO2007123186A1 A NN O
( WO2007123186A1 A ( O
I WO2007123186A1 A PRP O
) WO2007123186A1 A ) O
or WO2007123186A1 A CC O
the WO2007123186A1 A DT O
formula WO2007123186A1 A NN O
( WO2007123186A1 A ( O
II WO2007123186A1 A NNP O
) WO2007123186A1 A ) O
: WO2007123186A1 A : O
( WO2007123186A1 A ( O
I WO2007123186A1 A PRP O
) WO2007123186A1 A ) O
( WO2007123186A1 A ( O
II WO2007123186A1 A NNP O
) WO2007123186A1 A ) O
( WO2007123186A1 A ( O
wherein WO2007123186A1 A IN O
the WO2007123186A1 A DT O
definition WO2007123186A1 A NN O
of WO2007123186A1 A IN O
each WO2007123186A1 A DT O
symbol WO2007123186A1 A NN O
is WO2007123186A1 A VBZ O
as WO2007123186A1 A RB O
described WO2007123186A1 A VBN O
in WO2007123186A1 A IN O
the WO2007123186A1 A DT O
description WO2007123186A1 A NN O
) WO2007123186A1 A ) O
, WO2007123186A1 A , O
a WO2007123186A1 A DT O
salt WO2007123186A1 A NN O
thereof WO2007123186A1 A NN O
or WO2007123186A1 A CC O
a WO2007123186A1 A DT O
prodrug WO2007123186A1 A JJ O
thereof WO2007123186A1 A NN O
. WO2007123186A1 A . O

Monomethylamine WO2009134725A3 T NNP O
progesteron WO2009134725A3 T NN O
antagonists WO2009134725A3 T NNS O
such WO2009134725A3 T JJ O
as WO2009134725A3 T IN O
cdb-4453 WO2009134725A3 T NN O
in WO2009134725A3 T IN O
the WO2009134725A3 T DT O
treatment WO2009134725A3 T NN O
of WO2009134725A3 T IN O
endometriosis WO2009134725A3 T NN O
, WO2009134725A3 T , O
uterine WO2009134725A3 T JJ O
fibroids WO2009134725A3 T NNS O
, WO2009134725A3 T , O
dysmenorrhea WO2009134725A3 T NN O
, WO2009134725A3 T , O
breast WO2009134725A3 T NN O
cancer WO2009134725A3 T NN O
etc WO2009134725A3 T NN O
. WO2009134725A3 T . O

Compositions WO2009134725A3 A NNS O
for WO2009134725A3 A IN O
practicing WO2009134725A3 A VBG O
the WO2009134725A3 A DT O
methods WO2009134725A3 A NNS O
, WO2009134725A3 A , O
comprising WO2009134725A3 A VBG O
one WO2009134725A3 A CD O
or WO2009134725A3 A CC O
more WO2009134725A3 A JJR O
19-norsteroid WO2009134725A3 A JJ I-UN
progesterone WO2009134725A3 A NN I-UN
receptor WO2009134725A3 A NN I-UN
modulators WO2009134725A3 A NNS O
having WO2009134725A3 A VBG O
a WO2009134725A3 A DT O
monomethylamine-substituted WO2009134725A3 A JJ O
phenyl WO2009134725A3 A NN O
ring WO2009134725A3 A NN O
at WO2009134725A3 A IN O
the WO2009134725A3 A DT O
11 WO2009134725A3 A CD O
β-position WO2009134725A3 A NN O
of WO2009134725A3 A IN O
carbon WO2009134725A3 A NN O
11 WO2009134725A3 A CD O
and WO2009134725A3 A CC O
exhibiting WO2009134725A3 A VBG O
low WO2009134725A3 A JJ O
antiglucocorticoid WO2009134725A3 A NN O
activity WO2009134725A3 A NN O
, WO2009134725A3 A , O
are WO2009134725A3 A VBP O
also WO2009134725A3 A RB O
disclosed WO2009134725A3 A VBN O
. WO2009134725A3 A . O

Application CN101961329A T NN O
of CN101961329A T IN O
Silibinin CN101961329A T NNP O
in CN101961329A T IN O
preparing CN101961329A T VBG O
anti-male CN101961329A T JJ O
hormone CN101961329A T NN O
medicaments CN101961329A T NNS O
. CN101961329A T . O

Wound WO2008041031A1 T IN O
healing WO2008041031A1 T VBG O
compositions WO2008041031A1 T NNS O
. WO2008041031A1 T . O

Combination WO2011027344A2 T NN O
of WO2011027344A2 T IN O
vitamin WO2011027344A2 T NN O
e WO2011027344A2 T NN O
and WO2011027344A2 T CC O
beta-glycosphingolipids WO2011027344A2 T NNS O
in WO2011027344A2 T IN O
compositions WO2011027344A2 T NNS O
and WO2011027344A2 T CC O
methods WO2011027344A2 T NNS O
for WO2011027344A2 T IN O
preventing WO2011027344A2 T VBG O
and WO2011027344A2 T CC O
treating WO2011027344A2 T VBG O
hepatic WO2011027344A2 T JJ O
disorders WO2011027344A2 T NNS O
. WO2011027344A2 T . O

Gastroretentive US20110171275 T JJ O
drug US20110171275 T NN O
delivery US20110171275 T NN O
system US20110171275 T NN O
, US20110171275 T , O
preparation US20110171275 T NN O
method US20110171275 T NN O
and US20110171275 T CC O
use US20110171275 T NN O
thereof US20110171275 T NN O
. US20110171275 T . O

Diagnosis US20110092592 T NN O
and US20110092592 T CC O
treatment US20110092592 T NN O
of US20110092592 T IN O
hepatic US20110092592 T JJ O
disorder US20110092592 T NN O
. US20110092592 T . O

Tamsulosin CN102670546A T NNP O
hydrochloride CN102670546A T PRP O
osmotic CN102670546A T JJ O
pump CN102670546A T NN O
controlled-release CN102670546A T JJ O
tablet CN102670546A T NN O
. CN102670546A T . O

Disubstituted WO2011076744A1 T VBN O
heteroaryl-fused WO2011076744A1 T JJ O
pyridines WO2011076744A1 T NNS O
. WO2011076744A1 T . O

Nuclear CA2404688C T JJ I-UN
factor CA2404688C T NN I-UN
.kappa.b CA2404688C T IN I-UN
inducing CA2404688C T VBG O
factor CA2404688C T NN O
. CA2404688C T . O

The CA2404688C A DT O
present CA2404688C A JJ O
invention CA2404688C A NN O
is CA2404688C A VBZ O
directed CA2404688C A VBN O
to CA2404688C A TO O
nuclear CA2404688C A JJ O
factor CA2404688C A NN O
kB CA2404688C A NN O
( CA2404688C A ( O
NFkB CA2404688C A NNP I-UN
) CA2404688C A ) O
-inducing CA2404688C A VBG O
factor CA2404688C A NN O
polypeptides CA2404688C A NNS O
( CA2404688C A ( O
NFIF CA2404688C A NNP O
polypeptides CA2404688C A NNS O
) CA2404688C A ) O
which CA2404688C A WDT O
are CA2404688C A VBP O
capable CA2404688C A JJ O
of CA2404688C A IN O
inducing CA2404688C A VBG O
NKkB CA2404688C A NNP I-UN
. CA2404688C A . O

Also CA2404688C A RB O
included CA2404688C A VBN O
are CA2404688C A VBP O
methods CA2404688C A NNS O
and CA2404688C A CC O
compositions CA2404688C A NNS O
for CA2404688C A IN O
increasing CA2404688C A VBG O
NFkB CA2404688C A NNP I-UN
induction CA2404688C A NN O
in CA2404688C A IN O
a CA2404688C A DT O
patient CA2404688C A NN O
, CA2404688C A , O
methods CA2404688C A NNS O
and CA2404688C A CC O
compositions CA2404688C A NNS O
for CA2404688C A IN O
lowering CA2404688C A VBG O
NFkB CA2404688C A NNP I-UN
induction CA2404688C A NN O
in CA2404688C A IN O
a CA2404688C A DT O
patient CA2404688C A NN O
, CA2404688C A , O
methods CA2404688C A NNS O
for CA2404688C A IN O
inhibiting CA2404688C A VBG O
inflammation CA2404688C A NN O
, CA2404688C A , O
and CA2404688C A CC O
methods CA2404688C A NNS O
for CA2404688C A IN O
manufacture CA2404688C A NN O
of CA2404688C A IN O
a CA2404688C A DT O
medicament CA2404688C A NN O
intended CA2404688C A VBN O
for CA2404688C A IN O
the CA2404688C A DT O
treament CA2404688C A NN O
and/or CA2404688C A JJ O
prevention CA2404688C A NN O
of CA2404688C A IN O
an CA2404688C A DT O
NFkB-regulated CA2404688C A JJ O
inflammatory CA2404688C A NN O
response CA2404688C A NN O
. CA2404688C A . O

Application CN103446179A T NN O
of CN103446179A T IN O
amphiphilic CN103446179A T JJ O
poly-fullerene CN103446179A T JJ O
tree-based CN103446179A T JJ O
cross-linked CN103446179A T JJ O
poly-cation CN103446179A T NN O
gel CN103446179A T NN O
as CN103446179A T IN O
chelating CN103446179A T VBG O
agent CN103446179A T NN O
for CN103446179A T IN O
binding CN103446179A T VBG O
phosphate CN103446179A T NN O
, CN103446179A T , O
fatty CN103446179A T JJ O
acid CN103446179A T NN O
and CN103446179A T CC O
bile CN103446179A T JJ O
acid CN103446179A T NN O
. CN103446179A T . O

According CN103446179A A VBG O
to CN103446179A A TO O
the CN103446179A A DT O
application CN103446179A A NN O
, CN103446179A A , O
the CN103446179A A DT O
gel CN103446179A A NN O
has CN103446179A A VBZ O
effects CN103446179A A NNS O
of CN103446179A A IN O
resisting CN103446179A A VBG O
obesity CN103446179A A NN O
and CN103446179A A CC O
reducing CN103446179A A VBG O
low-density CN103446179A A NN I-UN
lipoprotein CN103446179A A NN I-UN
( CN103446179A A ( O
LDL CN103446179A A NNP I-UN
) CN103446179A A ) O
in CN103446179A A IN O
the CN103446179A A DT O
fields CN103446179A A NNS O
of CN103446179A A IN O
prevention CN103446179A A NN O
and CN103446179A A CC O
healthcare CN103446179A A NN O
. CN103446179A A . O

Phenyl CN101501023A T NNP O
substituted CN101501023A T VBD O
heteroaryl-derivatives CN101501023A T NNS O
and CN101501023A T CC O
use CN101501023A T VB O
thereof CN101501023A T NN O
as CN101501023A T IN O
anti-tumor CN101501023A T JJ O
agents CN101501023A T NNS O
. CN101501023A T . O

Substituted US7947706 T VBN O
pyrrolopyridines US7947706 T NNS O
, US7947706 T , O
compositions US7947706 T NNS O
containing US7947706 T VBG O
them US7947706 T PRP O
, US7947706 T , O
manufacturing US7947706 T VBG O
process US7947706 T NN O
therefor US7947706 T NN O
and US7947706 T CC O
use US7947706 T NN O
thereof US7947706 T NN O
. US7947706 T . O

Glucan-adriamycin CN103656670A T JJ O
conjugate CN103656670A T JJ O
drug CN103656670A T NN O
and CN103656670A T CC O
preparation CN103656670A T NN O
method CN103656670A T NN O
thereof CN103656670A T NN O
. CN103656670A T . O

Anti-cancer WO2013025064A2 T JJ O
composition WO2013025064A2 T NN O
comprising WO2013025064A2 T VBG O
wnt WO2013025064A2 T JJ I-UN
decoy WO2013025064A2 T JJ O
receptors WO2013025064A2 T NNS O
. WO2013025064A2 T . O

The WO2013025064A2 A DT O
present WO2013025064A2 A JJ O
invention WO2013025064A2 A NN O
relates WO2013025064A2 A VBZ O
to WO2013025064A2 A TO O
a WO2013025064A2 A DT O
composition WO2013025064A2 A NN O
for WO2013025064A2 A IN O
preventing WO2013025064A2 A VBG O
or WO2013025064A2 A CC O
treating WO2013025064A2 A VBG O
cancer WO2013025064A2 A NN O
, WO2013025064A2 A , O
comprising WO2013025064A2 A VBG O
Wnt WO2013025064A2 A NNP I-UN
decoy WO2013025064A2 A NN O
receptors WO2013025064A2 A NNS O
as WO2013025064A2 A IN O
active WO2013025064A2 A JJ O
ingredients WO2013025064A2 A NNS O
. WO2013025064A2 A . O

The WO2013025064A2 A DT O
composition WO2013025064A2 A NN O
or WO2013025064A2 A CC O
expression WO2013025064A2 A NN O
products WO2013025064A2 A NNS O
thereof WO2013025064A2 A VBP O
according WO2013025064A2 A VBG O
to WO2013025064A2 A TO O
the WO2013025064A2 A DT O
present WO2013025064A2 A JJ O
invention WO2013025064A2 A NN O
are WO2013025064A2 A VBP O
bound WO2013025064A2 A VBN O
to WO2013025064A2 A TO O
Wnt WO2013025064A2 A NNP I-UN
ligands WO2013025064A2 A VBZ O
to WO2013025064A2 A TO O
block WO2013025064A2 A VB O
ligand-receptor WO2013025064A2 A JJ O
interactions WO2013025064A2 A NNS O
, WO2013025064A2 A , O
thereby WO2013025064A2 A RB O
inhibiting WO2013025064A2 A VBG O
carcinogenesis WO2013025064A2 A NN O
and WO2013025064A2 A CC O
the WO2013025064A2 A DT O
growth WO2013025064A2 A NN O
, WO2013025064A2 A , O
proliferation WO2013025064A2 A NN O
, WO2013025064A2 A , O
and WO2013025064A2 A CC O
metastasis WO2013025064A2 A NN O
of WO2013025064A2 A IN O
cancer WO2013025064A2 A NN O
and WO2013025064A2 A CC O
inducing WO2013025064A2 A VBG O
apoptosis WO2013025064A2 A NN O
in WO2013025064A2 A IN O
cancer WO2013025064A2 A NN O
cells WO2013025064A2 A NNS O
, WO2013025064A2 A , O
and WO2013025064A2 A CC O
thus WO2013025064A2 A RB O
may WO2013025064A2 A MD O
be WO2013025064A2 A VB O
valuably WO2013025064A2 A RB O
used WO2013025064A2 A VBN O
as WO2013025064A2 A IN O
an WO2013025064A2 A DT O
efficient WO2013025064A2 A JJ O
anti-cancer WO2013025064A2 A JJ O
composition WO2013025064A2 A NN O
. WO2013025064A2 A . O

Skin US20100272763 T NNP O
external US20100272763 T JJ O
preparation US20100272763 T NN O
and US20100272763 T CC O
method US20100272763 T NN O
of US20100272763 T IN O
producing US20100272763 T VBG O
the US20100272763 T DT O
same US20100272763 T JJ O
. US20100272763 T . O

N-2 WO2006024627A2 T JJ O
adamantanyl-2-phenoxy-acetamide WO2006024627A2 T JJ O
derivatives WO2006024627A2 T NNS O
as WO2006024627A2 T IN O
11-beta WO2006024627A2 T JJ I-UN
hydroxysteroid WO2006024627A2 T NN I-UN
dehydrogenase WO2006024627A2 T NN I-UN
inhibitors WO2006024627A2 T NNS O
. WO2006024627A2 T . O

Substituted US7838528 T VBN O
bicyclic US7838528 T JJ O
8-pyrrolidinoxanthines US7838528 T NNS O
, US7838528 T , O
methods US7838528 T NNS O
for US7838528 T IN O
their US7838528 T PRP$ O
production US7838528 T NN O
, US7838528 T , O
pharmaceutical US7838528 T JJ O
formulations US7838528 T NNS O
and US7838528 T CC O
their US7838528 T PRP$ O
use US7838528 T NN O
. US7838528 T . O

Particular US7838528 A JJ O
blood US7838528 A NN O
glucose US7838528 A NN O
disorders US7838528 A NNS O
treatable US7838528 A JJ O
thereby US7838528 A RB O
include US7838528 A VBP O
type-2 US7838528 A JJ O
diabetes US7838528 A NNS O
, US7838528 A , O
insulin US7838528 A NN I-UN
resistance US7838528 A NN O
, US7838528 A , O
hyperglycemia US7838528 A NN O
, US7838528 A , O
arteriosclerotic US7838528 A JJ O
diseases US7838528 A NNS O
and US7838528 A CC O
the US7838528 A DT O
like US7838528 A JJ O
. US7838528 A . O

Pleuromutilin CN103265487A T NNP O
expansion CN103265487A T NN O
ring CN103265487A T VBG O
derivative CN103265487A T JJ O
, CN103265487A T , O
and CN103265487A T CC O
preparation CN103265487A T NN O
method CN103265487A T NN O
and CN103265487A T CC O
application CN103265487A T NN O
thereof CN103265487A T NN O
. CN103265487A T . O

Heterocyclic US6925388 T NNP O
nonnucleoside US6925388 T JJ O
inhibitors US6925388 T NNS O
of US6925388 T IN O
reverse US6925388 T JJ I-UN
transcriptase US6925388 T NN I-UN
. US6925388 T . O

Novel US6925388 A NNP O
compounds US6925388 A VBZ O
that US6925388 A WDT O
are US6925388 A VBP O
potent US6925388 A JJ O
inhibitors US6925388 A NNS O
of US6925388 A IN O
HIV US6925388 A NNP I-UN
reverse US6925388 A NN I-UN
transcriptase US6925388 A NN I-UN
( US6925388 A ( O
RT US6925388 A NNP I-UN
) US6925388 A ) O
are US6925388 A VBP O
described US6925388 A VBN O
in US6925388 A IN O
the US6925388 A DT O
invention US6925388 A NN O
. US6925388 A . O

The US6925388 A DT O
invention US6925388 A NN O
additionally US6925388 A RB O
provides US6925388 A VBZ O
a US6925388 A DT O
composite US6925388 A JJ O
HIV US6925388 A NNP I-UN
reverse-transcriptase US6925388 A NN I-UN
( US6925388 A ( O
RT US6925388 A NNP I-UN
) US6925388 A ) O
nonnucleoside US6925388 A RB O
inhibitor US6925388 A NN O
( US6925388 A ( O
NNI US6925388 A NNP O
) US6925388 A ) O
binding US6925388 A VBG O
pocket US6925388 A NN O
constructed US6925388 A VBN O
from US6925388 A IN O
a US6925388 A DT O
composite US6925388 A NN O
of US6925388 A IN O
multiple US6925388 A JJ O
NNI-RT US6925388 A NNP O
complexes US6925388 A NN O
. US6925388 A . O

The US6925388 A DT O
composite US6925388 A JJ O
RT-NNI US6925388 A JJ O
binding US6925388 A NN O
pocket US6925388 A NN O
provides US6925388 A VBZ O
a US6925388 A DT O
unique US6925388 A JJ O
and US6925388 A CC O
useful US6925388 A JJ O
tool US6925388 A NN O
for US6925388 A IN O
designing US6925388 A VBG O
and US6925388 A CC O
identifying US6925388 A VBG O
novel US6925388 A NN O
, US6925388 A , O
potent US6925388 A JJ O
inhibitors US6925388 A NNS O
of US6925388 A IN O
reverse US6925388 A JJ I-UN
transcriptase US6925388 A NN I-UN
. US6925388 A . O

RNAi US20120252872 T NNP O
Modulation US20120252872 T NNP O
of US20120252872 T IN O
APOB US20120252872 T NNP I-UN
and US20120252872 T CC O
Uses US20120252872 T NNP O
Thereof US20120252872 T NNP O
. US20120252872 T . O

The US20120252872 A DT O
invention US20120252872 A NN O
relates US20120252872 A VBZ O
to US20120252872 A TO O
compositions US20120252872 A NNS O
and US20120252872 A CC O
methods US20120252872 A NNS O
for US20120252872 A IN O
modulating US20120252872 A VBG O
the US20120252872 A DT O
expression US20120252872 A NN O
of US20120252872 A IN O
apolipoprotein US20120252872 A NN I-UN
B US20120252872 A NNP I-UN
, US20120252872 A , O
and US20120252872 A CC O
more US20120252872 A JJR O
particularly US20120252872 A RB O
to US20120252872 A TO O
the US20120252872 A DT O
downregulation US20120252872 A NN O
of US20120252872 A IN O
apolipoprotein US20120252872 A NN I-UN
B US20120252872 A NNP I-UN
by US20120252872 A IN O
chemically US20120252872 A RB O
modified US20120252872 A VBN O
oligonucleotides US20120252872 A NNS O
. US20120252872 A . O

Feed EP2397147A1 T NN O
for EP2397147A1 T IN O
preventing EP2397147A1 T VBG O
and/or EP2397147A1 T JJ O
treating EP2397147A1 T NN O
diseases EP2397147A1 T NNS O
due EP2397147A1 T JJ O
to EP2397147A1 T TO O
clostridium EP2397147A1 T VB O
sp EP2397147A1 T NN O
. EP2397147A1 T . O

bacteria EP2397147A1 T NNS O
in EP2397147A1 T IN O
livestock EP2397147A1 T NN O
, EP2397147A1 T , O
and EP2397147A1 T CC O
anti-clostridium EP2397147A1 T JJ O
agent EP2397147A1 T NN O
. EP2397147A1 T . O

Hydrogenated EP2066322A2 T VBN O
pyrido EP2066322A2 T JJ O
[ EP2066322A2 T JJ O
4,3-b EP2066322A2 T JJ O
] EP2066322A2 T NN O
indoles EP2066322A2 T NNS O
such EP2066322A2 T JJ O
as EP2066322A2 T IN O
dimebon EP2066322A2 T NN O
for EP2066322A2 T IN O
treating EP2066322A2 T VBG O
canine EP2066322A2 T NN O
cognitive EP2066322A2 T JJ O
dysfunction EP2066322A2 T NN O
syndrome EP2066322A2 T NN O
. EP2066322A2 T . O

Nursing CN102552392A T VBG O
product CN102552392A T NN O
for CN102552392A T IN O
protecting CN102552392A T VBG O
fingers CN102552392A T NNS O
of CN102552392A T IN O
diabetics CN102552392A T NNS O
. CN102552392A T . O

Vaginal US20060002966 T JJ O
delivery US20060002966 T NN O
of US20060002966 T IN O
chemotherapeutic US20060002966 T JJ O
agents US20060002966 T NNS O
and US20060002966 T CC O
inhibitors US20060002966 T NNS O
of US20060002966 T IN O
membrane US20060002966 T NN O
efflux US20060002966 T NN O
systems US20060002966 T NNS O
for US20060002966 T IN O
cancer US20060002966 T NN O
therapy US20060002966 T NN O
. US20060002966 T . O

Novel CN101054403A T NNP O
antibiotic CN101054403A T JJ O
Chemomycin CN101054403A T NNP O
A CN101054403A T NNP O
, CN101054403A T , O
B CN101054403A T NNP O
, CN101054403A T , O
C CN101054403A T NNP O
, CN101054403A T , O
D CN101054403A T NNP O
and CN101054403A T CC O
preparation CN101054403A T NN O
method CN101054403A T NN O
thereof CN101054403A T NN O
. CN101054403A T . O

2-arylthiazole CN101928259A T JJ O
derivative CN101928259A T JJ O
and CN101928259A T CC O
medicament CN101928259A T JJ O
composition CN101928259A T NN O
thereof CN101928259A T NN O
. CN101928259A T . O

The CN101928259A A DT O
invention CN101928259A A NN O
designs CN101928259A A NNS O
and CN101928259A A CC O
combines CN101928259A A NNS O
a CN101928259A A DT O
2-arylthiazole CN101928259A A JJ O
derivative CN101928259A A NN O
with CN101928259A A IN O
an CN101928259A A DT O
xanthine CN101928259A A JJ I-UN
oxidase CN101928259A A NN I-UN
inhibition CN101928259A A NN O
activity CN101928259A A NN O
, CN101928259A A , O
which CN101928259A A WDT O
has CN101928259A A VBZ O
a CN101928259A A DT O
chemical CN101928259A A NN O
structure CN101928259A A NN O
shown CN101928259A A VBN O
as CN101928259A A IN O
( CN101928259A A ( O
I CN101928259A A PRP O
) CN101928259A A ) O
, CN101928259A A , O
wherein CN101928259A A JJ O
Y CN101928259A A NNP O
represents CN101928259A A VBZ O
O CN101928259A A NNP O
, CN101928259A A , O
S CN101928259A A NNP O
and CN101928259A A CC O
NH CN101928259A A NNP O
; CN101928259A A : O
R1 CN101928259A A NNP O
represents CN101928259A A VBZ O
H CN101928259A A NNP O
, CN101928259A A , O
C1-C4 CN101928259A A NNP O
alkane CN101928259A A NN O
; CN101928259A A : O
R2 CN101928259A A NNP O
represents CN101928259A A VBZ O
formacyl CN101928259A A NN O
, CN101928259A A , O
- CN101928259A A : O
( CN101928259A A ( O
CH2 CN101928259A A NNP O
) CN101928259A A ) O
nCO2H CN101928259A A NN O
or CN101928259A A CC O
- CN101928259A A : O
( CN101928259A A ( O
CH2 CN101928259A A NNP O
) CN101928259A A ) O
nCOR5 CN101928259A A NN O
, CN101928259A A , O
wherein CN101928259A A JJ O
n=0-4 CN101928259A A JJ O
, CN101928259A A , O
R5 CN101928259A A NNP O
is CN101928259A A VBZ O
C1-C4 CN101928259A A JJ O
alkoxy CN101928259A A NN O
or CN101928259A A CC O
an CN101928259A A DT O
amino CN101928259A A JJ O
acid CN101928259A A NN O
; CN101928259A A : O
R3 CN101928259A A NNP O
represents CN101928259A A VBZ O
formacyl CN101928259A A NN O
, CN101928259A A , O
cyano CN101928259A A NN O
, CN101928259A A , O
nitro CN101928259A A RB O
, CN101928259A A , O
amino CN101928259A A NN O
or CN101928259A A CC O
hydroxamino CN101928259A A NN O
; CN101928259A A : O
and CN101928259A A CC O
R4 CN101928259A A NNP O
represents CN101928259A A VBZ O
linear CN101928259A A JJ O
or CN101928259A A CC O
branched CN101928259A A VBN O
C2-C8 CN101928259A A JJ O
alkenyl CN101928259A A NN O
or CN101928259A A CC O
conjugated CN101928259A A VBN O
or CN101928259A A CC O
non-conjugated CN101928259A A JJ O
multi-alkenyl CN101928259A A NN O
, CN101928259A A , O
linear CN101928259A A JJ O
or CN101928259A A CC O
branched CN101928259A A VBN O
C2-C8 CN101928259A A JJ O
alkynyl CN101928259A A NN O
or CN101928259A A CC O
linear CN101928259A A JJ O
or CN101928259A A CC O
branched CN101928259A A VBN O
and CN101928259A A CC O
conjugated CN101928259A A VBN O
or CN101928259A A CC O
non-conjugated CN101928259A A JJ O
C2-C8 CN101928259A A JJ O
alkenylalkynyl CN101928259A A NN O
and CN101928259A A CC O
pyridyl CN101928259A A NN O
. CN101928259A A . O

The CN101928259A A DT O
2-arylthiazole CN101928259A A JJ O
derivative CN101928259A A NN O
has CN101928259A A VBZ O
the CN101928259A A DT O
activity CN101928259A A NN O
of CN101928259A A IN O
inhibiting CN101928259A A VBG O
xanthine CN101928259A A JJ I-UN
oxidase CN101928259A A NN I-UN
, CN101928259A A , O
can CN101928259A A MD O
be CN101928259A A VB O
used CN101928259A A VBN O
for CN101928259A A IN O
preparing CN101928259A A VBG O
a CN101928259A A DT O
medicament CN101928259A A NN O
for CN101928259A A IN O
preventing CN101928259A A VBG O
and CN101928259A A CC O
treating CN101928259A A VBG O
diseases CN101928259A A NNS O
, CN101928259A A , O
such CN101928259A A JJ O
as CN101928259A A IN O
hyperuricemia CN101928259A A NN O
, CN101928259A A , O
gout CN101928259A A NN O
, CN101928259A A , O
and CN101928259A A CC O
the CN101928259A A DT O
like CN101928259A A JJ O
and CN101928259A A CC O
has CN101928259A A VBZ O
wide CN101928259A A JJ O
application CN101928259A A NN O
in CN101928259A A IN O
medicine CN101928259A A NN O
. CN101928259A A . O

Amidine WO2006031556A3 T NNP O
substituted WO2006031556A3 T VBD O
aryl WO2006031556A3 T JJ O
aniline WO2006031556A3 T JJ O
compounds WO2006031556A3 T NNS O
. WO2006031556A3 T . O

The WO2006031556A3 A DT O
invention WO2006031556A3 A NN O
provides WO2006031556A3 A VBZ O
novel WO2006031556A3 A JJ O
ß2 WO2006031556A3 A NNP I-UN
adrenergic WO2006031556A3 A NN I-UN
receptor WO2006031556A3 A NN I-UN
agonist WO2006031556A3 A JJ O
compounds WO2006031556A3 A NNS O
. WO2006031556A3 A . O

The WO2006031556A3 A DT O
invention WO2006031556A3 A NN O
also WO2006031556A3 A RB O
provides WO2006031556A3 A VBZ O
pharmaceutical WO2006031556A3 A JJ O
compositions WO2006031556A3 A NNS O
comprising WO2006031556A3 A VBG O
such WO2006031556A3 A JJ O
compounds WO2006031556A3 A NNS O
, WO2006031556A3 A , O
methods WO2006031556A3 A NNS O
of WO2006031556A3 A IN O
using WO2006031556A3 A VBG O
such WO2006031556A3 A JJ O
compounds WO2006031556A3 A NNS O
to WO2006031556A3 A TO O
treat WO2006031556A3 A VB O
diseases WO2006031556A3 A NNS O
associated WO2006031556A3 A VBN O
with WO2006031556A3 A IN O
ß2adrenergic WO2006031556A3 A JJ I-UN
receptor WO2006031556A3 A NN I-UN
activity WO2006031556A3 A NN O
, WO2006031556A3 A , O
and WO2006031556A3 A CC O
processes WO2006031556A3 A NNS O
and WO2006031556A3 A CC O
intermediates WO2006031556A3 A NNS O
useful WO2006031556A3 A JJ O
for WO2006031556A3 A IN O
preparing WO2006031556A3 A VBG O
such WO2006031556A3 A JJ O
compounds WO2006031556A3 A NNS O
. WO2006031556A3 A . O

Polypeptide US6939541 T NNP O
for US6939541 T IN O
use US6939541 T NN O
in US6939541 T IN O
the US6939541 T DT O
treatment US6939541 T NN O
of US6939541 T IN O
viral US6939541 T JJ O
diseases US6939541 T NNS O
and US6939541 T CC O
cancer US6939541 T NN O
. US6939541 T . O

Histidine US6939541 A NNP I-UN
ammonia US6939541 A NN I-UN
lyase US6939541 A NN I-UN
( US6939541 A ( O
HAL US6939541 A NNP I-UN
) US6939541 A ) O
isolated US6939541 A VBD O
from US6939541 A IN O
Corynebacteriaceae US6939541 A NNP O
can US6939541 A MD O
decrease US6939541 A VB O
serum US6939541 A JJ O
histidine US6939541 A NN O
levels US6939541 A NNS O
, US6939541 A , O
induce US6939541 A VB O
accumulation US6939541 A NN O
of US6939541 A IN O
urocanic US6939541 A JJ O
acid US6939541 A NN O
, US6939541 A , O
and US6939541 A CC O
is US6939541 A VBZ O
not US6939541 A RB O
inhibited US6939541 A VBN O
by US6939541 A IN O
L-histidinol US6939541 A NNP O
. US6939541 A . O

Pharmaceutical CN102949408A T JJ O
composition CN102949408A T NN O
capable CN102949408A T NN O
of CN102949408A T IN O
strengthening CN102949408A T VBG O
immunity CN102949408A T NN O
of CN102949408A T IN O
poultry CN102949408A T NN O
and CN102949408A T CC O
method CN102949408A T NN O
for CN102949408A T IN O
preparing CN102949408A T VBG O
pharmaceutical CN102949408A T JJ O
composition CN102949408A T NN O
. CN102949408A T . O

Imidazo EP2419428A1 T NNP O
[ EP2419428A1 T NNP O
1,2-a EP2419428A1 T JJ O
] EP2419428A1 T NNP O
pyridine EP2419428A1 T NN O
derivatives EP2419428A1 T NNS O
as EP2419428A1 T IN O
fgfr EP2419428A1 T JJ I-UN
kinase EP2419428A1 T NN I-UN
inhibitors EP2419428A1 T NNS O
for EP2419428A1 T IN O
use EP2419428A1 T NN O
in EP2419428A1 T IN O
therapy EP2419428A1 T NN O
. EP2419428A1 T . O

Tigecycline WO2012142958A1 T NNP O
crystalline WO2012142958A1 T NN O
hydrate WO2012142958A1 T NN O
and WO2012142958A1 T CC O
preparation WO2012142958A1 T NN O
method WO2012142958A1 T NN O
therefor WO2012142958A1 T NN O
and WO2012142958A1 T CC O
use WO2012142958A1 T NN O
thereof WO2012142958A1 T NN O
. WO2012142958A1 T . O

Provided WO2012142958A1 A VBN O
are WO2012142958A1 A VBP O
a WO2012142958A1 A DT O
Tigecycline WO2012142958A1 A NNP O
crystalline WO2012142958A1 A NN O
hydrate WO2012142958A1 A NN O
, WO2012142958A1 A , O
and WO2012142958A1 A CC O
a WO2012142958A1 A DT O
preparation WO2012142958A1 A NN O
method WO2012142958A1 A NN O
therefor WO2012142958A1 A NN O
and WO2012142958A1 A CC O
use WO2012142958A1 A NN O
thereof WO2012142958A1 A NN O
. WO2012142958A1 A . O

The WO2012142958A1 A DT O
crystalline WO2012142958A1 A NN O
hydrate WO2012142958A1 A NN O
has WO2012142958A1 A VBZ O
high WO2012142958A1 A JJ O
stability WO2012142958A1 A NN O
for WO2012142958A1 A IN O
storage WO2012142958A1 A NN O
, WO2012142958A1 A , O
and WO2012142958A1 A CC O
is WO2012142958A1 A VBZ O
applicable WO2012142958A1 A JJ O
to WO2012142958A1 A TO O
the WO2012142958A1 A DT O
preparation WO2012142958A1 A NN O
of WO2012142958A1 A IN O
medicaments WO2012142958A1 A NNS O
for WO2012142958A1 A IN O
treating WO2012142958A1 A VBG O
or WO2012142958A1 A CC O
preventing WO2012142958A1 A VBG O
Gram-positive WO2012142958A1 A JJ O
or WO2012142958A1 A CC O
negative WO2012142958A1 A JJ O
bacterium WO2012142958A1 A NN O
sensitive WO2012142958A1 A JJ O
bacterium WO2012142958A1 A NN O
or WO2012142958A1 A CC O
diseases WO2012142958A1 A NNS O
in WO2012142958A1 A IN O
human WO2012142958A1 A NN O
or WO2012142958A1 A CC O
animal WO2012142958A1 A NN O
caused WO2012142958A1 A VBN O
by WO2012142958A1 A IN O
Gram-positive WO2012142958A1 A JJ O
or WO2012142958A1 A CC O
negative WO2012142958A1 A JJ O
bacterium WO2012142958A1 A NN O
sensitive WO2012142958A1 A JJ O
bacterium WO2012142958A1 A NN O
, WO2012142958A1 A , O
such WO2012142958A1 A JJ O
as WO2012142958A1 A IN O
infection WO2012142958A1 A NN O
of WO2012142958A1 A IN O
respiratory WO2012142958A1 A NN O
system WO2012142958A1 A NN O
, WO2012142958A1 A , O
liver WO2012142958A1 A RB O
and WO2012142958A1 A CC O
gall WO2012142958A1 A JJ O
system WO2012142958A1 A NN O
, WO2012142958A1 A , O
five WO2012142958A1 A CD O
sense WO2012142958A1 A NN O
organs WO2012142958A1 A NNS O
and WO2012142958A1 A CC O
urogenital WO2012142958A1 A JJ O
system WO2012142958A1 A NN O
, WO2012142958A1 A , O
bone WO2012142958A1 A NN O
and WO2012142958A1 A CC O
joint WO2012142958A1 A JJ O
infection WO2012142958A1 A NN O
, WO2012142958A1 A , O
skin WO2012142958A1 A FW O
soft WO2012142958A1 A JJ O
tissue WO2012142958A1 A NN O
infection WO2012142958A1 A NN O
and WO2012142958A1 A CC O
endocarditis WO2012142958A1 A NN O
, WO2012142958A1 A , O
septicemia WO2012142958A1 A NN O
, WO2012142958A1 A , O
meningitis WO2012142958A1 A NN O
. WO2012142958A1 A . O

Magnesium EP1753742A2 T NNP O
complexes EP1753742A2 T NNS O
of EP1753742A2 T IN O
s-omeprazole EP1753742A2 T NN O
. EP1753742A2 T . O

Methods CA2749947A1 T NNS O
for CA2749947A1 T IN O
treating CA2749947A1 T VBG O
estrogen CA2749947A1 T NN I-UN
receptor CA2749947A1 T NN I-UN
positive CA2749947A1 T JJ O
cancer CA2749947A1 T NN O
by CA2749947A1 T IN O
x-box CA2749947A1 T JJ I-UN
binding CA2749947A1 T NN I-UN
protein CA2749947A1 T NN I-UN
1 CA2749947A1 T CD I-UN
inhibition CA2749947A1 T NN O
. CA2749947A1 T . O

Provided CA2749947A1 A VBN O
is CA2749947A1 A VBZ O
a CA2749947A1 A DT O
method CA2749947A1 A NN O
of CA2749947A1 A IN O
inhibiting CA2749947A1 A VBG O
proliferation CA2749947A1 A NN O
of CA2749947A1 A IN O
estrogen CA2749947A1 A NN O
receptor CA2749947A1 A NN O
alpha CA2749947A1 A VBP O
positive CA2749947A1 A JJ O
tumor CA2749947A1 A NN O
cells CA2749947A1 A NNS O
comprising CA2749947A1 A VBG O
the CA2749947A1 A DT O
inhibition CA2749947A1 A NN O
of CA2749947A1 A IN O
X-box CA2749947A1 A JJ I-UN
binding CA2749947A1 A VBG I-UN
protein-1 CA2749947A1 A NN I-UN
( CA2749947A1 A ( O
Xbp1 CA2749947A1 A NNP I-UN
) CA2749947A1 A ) O
, CA2749947A1 A , O
including CA2749947A1 A VBG O
inhibiting CA2749947A1 A VBG O
estrogen-induced CA2749947A1 A JJ O
proliferation CA2749947A1 A NN O
. CA2749947A1 A . O

3-amino-pyrazolo WO2006063805A1 T JJ O
[ WO2006063805A1 T NN O
3,4b WO2006063805A1 T CD O
] WO2006063805A1 T NN O
pyridines WO2006063805A1 T NNS O
used WO2006063805A1 T VBN O
as WO2006063805A1 T IN O
inhibitors WO2006063805A1 T NNS O
of WO2006063805A1 T IN O
protein WO2006063805A1 T NN O
tyrosine WO2006063805A1 T NN O
kinases WO2006063805A1 T NNS I-UN
for WO2006063805A1 T IN O
treating WO2006063805A1 T VBG O
angiogenic WO2006063805A1 T JJ O
, WO2006063805A1 T , O
hyperproliferative WO2006063805A1 T JJ O
or WO2006063805A1 T CC O
neurodegenerative WO2006063805A1 T JJ O
diseases WO2006063805A1 T NNS O
. WO2006063805A1 T . O

The WO2006063805A1 A DT O
invention WO2006063805A1 A NN O
relates WO2006063805A1 A VBZ O
to WO2006063805A1 A TO O
compounds WO2006063805A1 A NNS O
of WO2006063805A1 A IN O
general WO2006063805A1 A JJ O
formula WO2006063805A1 A NN O
( WO2006063805A1 A ( O
I WO2006063805A1 A PRP O
) WO2006063805A1 A ) O
, WO2006063805A1 A , O
in WO2006063805A1 A IN O
which WO2006063805A1 A WDT O
R1 WO2006063805A1 A NNP O
and WO2006063805A1 A CC O
R2 WO2006063805A1 A NNP O
are WO2006063805A1 A VBP O
described WO2006063805A1 A VBN O
in WO2006063805A1 A IN O
the WO2006063805A1 A DT O
application WO2006063805A1 A NN O
, WO2006063805A1 A , O
to WO2006063805A1 A TO O
the WO2006063805A1 A DT O
use WO2006063805A1 A NN O
of WO2006063805A1 A IN O
the WO2006063805A1 A DT O
compounds WO2006063805A1 A NNS O
of WO2006063805A1 A IN O
general WO2006063805A1 A JJ O
formula WO2006063805A1 A NN O
( WO2006063805A1 A ( O
I WO2006063805A1 A PRP O
) WO2006063805A1 A ) O
as WO2006063805A1 A IN O
inhibitors WO2006063805A1 A NNS O
of WO2006063805A1 A IN O
protein WO2006063805A1 A NN O
tyrosine WO2006063805A1 A NN O
kinases WO2006063805A1 A NNS I-UN
for WO2006063805A1 A IN O
treating WO2006063805A1 A VBG O
various WO2006063805A1 A JJ O
diseases WO2006063805A1 A NNS O
, WO2006063805A1 A , O
and WO2006063805A1 A CC O
to WO2006063805A1 A TO O
the WO2006063805A1 A DT O
compounds WO2006063805A1 A NNS O
of WO2006063805A1 A IN O
general WO2006063805A1 A JJ O
formulas WO2006063805A1 A NNS O
( WO2006063805A1 A ( O
II WO2006063805A1 A NNP O
) WO2006063805A1 A ) O
and WO2006063805A1 A CC O
( WO2006063805A1 A ( O
III WO2006063805A1 A NNP O
) WO2006063805A1 A ) O
as WO2006063805A1 A IN O
intermediate WO2006063805A1 A JJ O
compounds WO2006063805A1 A NNS O
for WO2006063805A1 A IN O
producing WO2006063805A1 A VBG O
compounds WO2006063805A1 A NNS O
of WO2006063805A1 A IN O
general WO2006063805A1 A JJ O
formula WO2006063805A1 A NN O
( WO2006063805A1 A ( O
I WO2006063805A1 A PRP O
) WO2006063805A1 A ) O
, WO2006063805A1 A , O
in WO2006063805A1 A IN O
which WO2006063805A1 A WDT O
X WO2006063805A1 A NNP O
, WO2006063805A1 A , O
R1a WO2006063805A1 A NNP O
and WO2006063805A1 A CC O
R2a WO2006063805A1 A NNP O
have WO2006063805A1 A VBP O
the WO2006063805A1 A DT O
meanings WO2006063805A1 A NNS O
as WO2006063805A1 A IN O
described WO2006063805A1 A VBN O
in WO2006063805A1 A IN O
general WO2006063805A1 A JJ O
formulas WO2006063805A1 A NN O
( WO2006063805A1 A ( O
II WO2006063805A1 A NNP O
) WO2006063805A1 A ) O
and WO2006063805A1 A CC O
( WO2006063805A1 A ( O
III WO2006063805A1 A NNP O
) WO2006063805A1 A ) O
. WO2006063805A1 A . O

Compositions CA2077637C T NNS O
comprising CA2077637C T VBG O
a CA2077637C T DT O
tramadol CA2077637C T JJ O
material CA2077637C T NN O
and CA2077637C T CC O
any CA2077637C T DT O
of CA2077637C T IN O
codeine CA2077637C T NN O
, CA2077637C T , O
oxycodone CA2077637C T NN O
or CA2077637C T CC O
hydrocodone CA2077637C T NN O
and CA2077637C T CC O
their CA2077637C T PRP$ O
use CA2077637C T NN O
. CA2077637C T . O

This CA2077637C A DT O
invention CA2077637C A NN O
relates CA2077637C A VBZ O
to CA2077637C A TO O
compositions CA2077637C A NNS O
comprising CA2077637C A VBG O
a CA2077637C A DT O
tramadol CA2077637C A JJ O
material CA2077637C A NN O
and CA2077637C A CC O
any CA2077637C A DT O
of CA2077637C A IN O
codeine CA2077637C A NN O
, CA2077637C A , O
oxycodone CA2077637C A NN O
or CA2077637C A CC O
hydrocodone CA2077637C A NN O
, CA2077637C A , O
and CA2077637C A CC O
their CA2077637C A PRP$ O
use CA2077637C A NN O
. CA2077637C A . O

The CA2077637C A DT O
compositions CA2077637C A NNS O
are CA2077637C A VBP O
pharmacologically CA2077637C A RB O
useful CA2077637C A JJ O
in CA2077637C A IN O
treating CA2077637C A VBG O
pain CA2077637C A NN O
, CA2077637C A , O
diarrhea CA2077637C A NN O
and CA2077637C A CC O
tussive CA2077637C A JJ O
conditions CA2077637C A NNS O
. CA2077637C A . O

The CA2077637C A DT O
compositions CA2077637C A NNS O
are CA2077637C A VBP O
also CA2077637C A RB O
subject CA2077637C A JJ O
to CA2077637C A TO O
less CA2077637C A JJR O
side-effects CA2077637C A NNS O
as CA2077637C A IN O
compared CA2077637C A VBN O
to CA2077637C A TO O
pure CA2077637C A VB O
opiate CA2077637C A NN O
based CA2077637C A VBN O
compositions CA2077637C A NNS O
, CA2077637C A , O
such CA2077637C A JJ O
as CA2077637C A IN O
abuse CA2077637C A NN O
liability CA2077637C A NN O
, CA2077637C A , O
tolerance CA2077637C A NN O
, CA2077637C A , O
constipation CA2077637C A NN O
and CA2077637C A CC O
respiratory CA2077637C A JJ O
depression CA2077637C A NN O
. CA2077637C A . O

Furthermore CA2077637C A RB O
, CA2077637C A , O
where CA2077637C A WRB O
the CA2077637C A DT O
components CA2077637C A NNS O
, CA2077637C A , O
i.e. CA2077637C A FW O
, CA2077637C A , O
a CA2077637C A DT O
tramadol CA2077637C A JJ O
material CA2077637C A NN O
and CA2077637C A CC O
any CA2077637C A DT O
of CA2077637C A IN O
codeine CA2077637C A NN O
, CA2077637C A , O
oxycodone CA2077637C A NN O
or CA2077637C A CC O
hydrocodone CA2077637C A NN O
, CA2077637C A , O
of CA2077637C A IN O
the CA2077637C A DT O
compositions CA2077637C A NNS O
are CA2077637C A VBP O
within CA2077637C A IN O
certain CA2077637C A JJ O
ratios CA2077637C A NNS O
the CA2077637C A DT O
pharmacological CA2077637C A JJ O
effects CA2077637C A NNS O
of CA2077637C A IN O
the CA2077637C A DT O
compositions CA2077637C A NNS O
are CA2077637C A VBP O
superadditive CA2077637C A JJ O
( CA2077637C A ( O
synergistic CA2077637C A JJ O
) CA2077637C A ) O
. CA2077637C A . O

An CN1736393A T DT O
anit-AIDS CN1736393A T JJ O
material CN1736393A T NN O
drug CN1736393A T NN O
, CN1736393A T , O
formulation CN1736393A T NN O
and CN1736393A T CC O
preparation CN1736393A T NN O
process CN1736393A T NN O
thereof CN1736393A T NN O
. CN1736393A T . O

The CN1736393A A DT O
invention CN1736393A A NN O
relates CN1736393A A VBZ O
to CN1736393A A TO O
a CN1736393A A DT O
raw CN1736393A A JJ O
material CN1736393A A NN O
medicament CN1736393A A NN O
, CN1736393A A , O
tablets CN1736393A A NNS O
, CN1736393A A , O
capsules CN1736393A A NNS O
and CN1736393A A CC O
oral CN1736393A A JJ O
liquids CN1736393A A NNS O
having CN1736393A A VBG O
substantial CN1736393A A JJ O
effect CN1736393A A NN O
for CN1736393A A IN O
treating CN1736393A A VBG O
AIDS CN1736393A A NNP O
, CN1736393A A , O
wherein CN1736393A A VBD O
the CN1736393A A DT O
preparing CN1736393A A NN O
process CN1736393A A NN O
comprises CN1736393A A VBZ O
cantharis CN1736393A A JJ O
selection CN1736393A A NN O
, CN1736393A A , O
disintegrating CN1736393A A VBG O
, CN1736393A A , O
cantharidin CN1736393A A JJ O
extraction CN1736393A A NN O
, CN1736393A A , O
cantharidin CN1736393A A NN O
degreasing CN1736393A A NN O
, CN1736393A A , O
methylcantharidinimide CN1736393A A RB O
synthesizing CN1736393A A VBG O
, CN1736393A A , O
methylcantharidinimide CN1736393A A NN O
refining CN1736393A A NN O
, CN1736393A A , O
a CN1736393A A DT O
series CN1736393A A NN O
of CN1736393A A IN O
technical CN1736393A A JJ O
procedures CN1736393A A NNS O
of CN1736393A A IN O
formulation CN1736393A A NN O
combination CN1736393A A NN O
, CN1736393A A , O
tabletting CN1736393A A VBG O
, CN1736393A A , O
loading CN1736393A A VBG O
and CN1736393A A CC O
packaging CN1736393A A NN O
. CN1736393A A . O

Medium DE102007002073A1 T NN O
for DE102007002073A1 T IN O
use DE102007002073A1 T NN O
during DE102007002073A1 T IN O
care DE102007002073A1 T NN O
and DE102007002073A1 T CC O
antimicrobial DE102007002073A1 T JJ O
treatment DE102007002073A1 T NN O
of DE102007002073A1 T IN O
skin DE102007002073A1 T NN O
, DE102007002073A1 T , O
for DE102007002073A1 T IN O
topical DE102007002073A1 T JJ O
dermatological DE102007002073A1 T JJ O
application DE102007002073A1 T NN O
, DE102007002073A1 T , O
and DE102007002073A1 T CC O
for DE102007002073A1 T IN O
therapeutic DE102007002073A1 T JJ O
skin DE102007002073A1 T NN O
and DE102007002073A1 T CC O
sore DE102007002073A1 T NN O
treatment DE102007002073A1 T NN O
, DE102007002073A1 T , O
comprises DE102007002073A1 T VBZ O
benzalkonium DE102007002073A1 T NN O
chloride DE102007002073A1 T NN O
, DE102007002073A1 T , O
which DE102007002073A1 T WDT O
is DE102007002073A1 T VBZ O
basically DE102007002073A1 T RB O
exclusive DE102007002073A1 T JJ O
pharmaceutically DE102007002073A1 T RB O
active DE102007002073A1 T JJ O
. DE102007002073A1 T . O

Strychnos CN101574394A T NNP O
alkaloid CN101574394A T JJ O
vesicle CN101574394A T NN O
and CN101574394A T CC O
preparation CN101574394A T NN O
method CN101574394A T NN O
thereof CN101574394A T NN O
. CN101574394A T . O

Calcitonin US7842686 T NNP I-UN
gene-related US7842686 T JJ I-UN
peptide US7842686 T NN I-UN
( US7842686 T ( I-UN
CGRP US7842686 T NNP I-UN
) US7842686 T ) I-UN
receptor US7842686 T NN I-UN
antagonists US7842686 T NNS O
, US7842686 T , O
such US7842686 T JJ O
as US7842686 T IN O
2- US7842686 T JJ O
( US7842686 T ( O
2-Butyl-3-oxo-2H-benzo US7842686 T JJ O
[ US7842686 T NN O
b US7842686 T NN O
] US7842686 T NNP O
[ US7842686 T VBZ O
1,4 US7842686 T CD O
] US7842686 T JJ O
thiazin-4 US7842686 T NN O
( US7842686 T ( O
3H US7842686 T CD O
) US7842686 T ) O
-yl US7842686 T NN O
) US7842686 T ) O
-N- US7842686 T NN O
( US7842686 T ( O
2,5-dioxo-1',3'-dihydrospiro US7842686 T JJ O
[ US7842686 T NNP O
imidazolidine-4,2'-indene US7842686 T NN O
] US7842686 T NNP O
-5'-yl US7842686 T NNP O
) US7842686 T ) O
acetamide US7842686 T NN O
, US7842686 T , O
used US7842686 T VBD O
as US7842686 T IN O
analgesics US7842686 T NNS O
. US7842686 T . O

The US7842686 A DT O
present US7842686 A JJ O
invention US7842686 A NN O
relates US7842686 A VBZ O
to US7842686 A TO O
CGRP US7842686 A NNP I-UN
receptor US7842686 A NN I-UN
antagonists US7842686 A NNS O
, US7842686 A , O
pharmaceutical US7842686 A JJ O
compositions US7842686 A NNS O
thereof US7842686 A NN O
, US7842686 A , O
and US7842686 A CC O
methods US7842686 A NNS O
therewith US7842686 A NN O
for US7842686 A IN O
treating US7842686 A VBG O
CGRP US7842686 A NNP I-UN
receptor-mediated US7842686 A JJ O
diseases US7842686 A NNS O
and US7842686 A CC O
conditions US7842686 A NNS O
. US7842686 A . O

Upregulating WO2008036282A1 T VBG O
activity WO2008036282A1 T NN O
or WO2008036282A1 T CC O
expression WO2008036282A1 T NN O
of WO2008036282A1 T IN O
bdnf WO2008036282A1 T NN I-UN
to WO2008036282A1 T TO O
mitigate WO2008036282A1 T VB O
cognitive WO2008036282A1 T JJ O
impairment WO2008036282A1 T NN O
in WO2008036282A1 T IN O
asymptomatic WO2008036282A1 T JJ O
huntington WO2008036282A1 T NN O
's WO2008036282A1 T POS O
subjects WO2008036282A1 T NNS O
. WO2008036282A1 T . O

This WO2008036282A1 A DT O
invention WO2008036282A1 A NN O
provides WO2008036282A1 A VBZ O
novel WO2008036282A1 A JJ O
methods WO2008036282A1 A NNS O
of WO2008036282A1 A IN O
treatment WO2008036282A1 A NN O
to WO2008036282A1 A TO O
ameliorate WO2008036282A1 A VB O
or WO2008036282A1 A CC O
prevent WO2008036282A1 A VB O
cognitive WO2008036282A1 A JJ O
disorder/dysfunction WO2008036282A1 A NN O
in WO2008036282A1 A IN O
pre- WO2008036282A1 A NN O
or WO2008036282A1 A CC O
asymptomatic WO2008036282A1 A JJ O
subject WO2008036282A1 A NN O
having WO2008036282A1 A VBG O
one WO2008036282A1 A CD O
or WO2008036282A1 A CC O
more WO2008036282A1 A JJR O
mutations WO2008036282A1 A NNS O
in WO2008036282A1 A IN O
the WO2008036282A1 A DT O
Huntington WO2008036282A1 A NNP I-UN
gene WO2008036282A1 A NN O
. WO2008036282A1 A . O

Cyanoacrylate EP1807064B1 T NNP O
monomer EP1807064B1 T NN O
formulation EP1807064B1 T NN O
containing EP1807064B1 T VBG O
diiodomethyl-p-tolylsulfone EP1807064B1 T NN O
and EP1807064B1 T CC O
hydroxydiphenyl EP1807064B1 T NN O
ether EP1807064B1 T NN O
. EP1807064B1 T . O

Nucleic WO2011111715A1 T NNP O
acid WO2011111715A1 T VBZ O
capable WO2011111715A1 T JJ O
of WO2011111715A1 T IN O
regulating WO2011111715A1 T VBG O
cell WO2011111715A1 T NN O
cycle WO2011111715A1 T NN O
. WO2011111715A1 T . O

Arachidonic WO2012016314A9 T JJ O
acid-derived WO2012016314A9 T JJ O
coxib WO2012016314A9 T NN O
analogue-substituted WO2012016314A9 T JJ O
compounds WO2012016314A9 T NNS O
for WO2012016314A9 T IN O
use WO2012016314A9 T NN O
in WO2012016314A9 T IN O
treating WO2012016314A9 T VBG O
pain WO2012016314A9 T NN O
. WO2012016314A9 T . O

Antineoplastic CN101225070A T JJ O
medicament CN101225070A T NN O
. CN101225070A T . O

Furan-flavone CN102675330A T CD O
compound CN102675330A T NN O
in CN102675330A T IN O
arundina CN102675330A T JJ O
graminifolia CN102675330A T NN O
, CN102675330A T , O
preparation CN102675330A T NN O
method CN102675330A T NN O
and CN102675330A T CC O
application CN102675330A T NN O
. CN102675330A T . O

Use CN102988366A T NNP O
and CN102988366A T CC O
nasal CN102988366A T JJ O
administration CN102988366A T NN O
medicine CN102988366A T NN O
of CN102988366A T IN O
hydroxycamptothecine CN102988366A T NN O
. CN102988366A T . O

High US7560131 T JJ O
solubility US7560131 T NN O
composition US7560131 T NN O
with US7560131 T IN O
high US7560131 T JJ O
isoflavone US7560131 T NN O
concentration US7560131 T NN O
and US7560131 T CC O
process US7560131 T NN O
of US7560131 T IN O
producing US7560131 T VBG O
same US7560131 T JJ O
. US7560131 T . O

Preparation CN103012231A T NNP O
method CN103012231A T NN O
and CN103012231A T CC O
application CN103012231A T NN O
of CN103012231A T IN O
glycopyrronium CN103012231A T NN O
bromide CN103012231A T IN O
chiral CN103012231A T JJ O
antipode CN103012231A T NN O
. CN103012231A T . O

Process US20090163590 T NN O
for US20090163590 T IN O
producing US20090163590 T VBG O
refined US20090163590 T JJ O
avocado US20090163590 T JJ O
oil US20090163590 T NN O
rich US20090163590 T NN O
in US20090163590 T IN O
triglycerides US20090163590 T NNS O
, US20090163590 T , O
and US20090163590 T CC O
oil US20090163590 T NN O
obtainable US20090163590 T JJ O
by US20090163590 T IN O
said US20090163590 T VBD O
process US20090163590 T NN O
. US20090163590 T . O

Prevention US20060013801 T NN O
of US20060013801 T IN O
and US20060013801 T CC O
therapy US20060013801 T NN O
for US20060013801 T IN O
radiation US20060013801 T NN O
toxicity US20060013801 T NN O
of US20060013801 T IN O
normal US20060013801 T JJ O
tissues US20060013801 T NNS O
using US20060013801 T VBG O
drugs US20060013801 T NNS O
which US20060013801 T WDT O
block US20060013801 T VBP O
il-1 US20060013801 T JJ I-UN
activity US20060013801 T NN O
. US20060013801 T . O

More US20060013801 A RBR O
particularly US20060013801 A RB O
, US20060013801 A , O
we US20060013801 A PRP O
have US20060013801 A VBP O
discovered US20060013801 A VBN O
a US20060013801 A DT O
method US20060013801 A NN O
for US20060013801 A IN O
prophylactically US20060013801 A RB O
treating US20060013801 A VBG O
radiation US20060013801 A NN O
toxicity US20060013801 A NN O
in US20060013801 A IN O
normal US20060013801 A JJ O
tissue US20060013801 A NN O
of US20060013801 A IN O
subject US20060013801 A JJ O
comprising US20060013801 A VBG O
administering US20060013801 A VBG O
an US20060013801 A DT O
anti-radiation US20060013801 A JJ O
toxicity US20060013801 A NN O
effective US20060013801 A JJ O
amount US20060013801 A NN O
of US20060013801 A IN O
a US20060013801 A DT O
cytokine US20060013801 A NN I-UN
blocking US20060013801 A NN O
agent US20060013801 A NN O
through US20060013801 A IN O
the US20060013801 A DT O
subject US20060013801 A NN O
. US20060013801 A . O

More US20060013801 A RBR O
specifically US20060013801 A RB O
, US20060013801 A , O
we US20060013801 A PRP O
have US20060013801 A VBP O
discovered US20060013801 A VBN O
a US20060013801 A DT O
method US20060013801 A NN O
for US20060013801 A IN O
prophylactically US20060013801 A RB O
treating US20060013801 A VBG O
radiation US20060013801 A NN O
pneumonitis US20060013801 A NN O
, US20060013801 A , O
dermatitis US20060013801 A NN O
, US20060013801 A , O
soft US20060013801 A JJ O
tissue US20060013801 A NN O
fibrosis US20060013801 A NN O
or US20060013801 A CC O
central US20060013801 A JJ O
nervous US20060013801 A JJ O
system US20060013801 A NN O
toxicity US20060013801 A NN O
in US20060013801 A IN O
a US20060013801 A DT O
subject US20060013801 A JJ O
comprising US20060013801 A NN O
administering US20060013801 A VBG O
an US20060013801 A DT O
anti-radiation US20060013801 A NN O
pneumonitis US20060013801 A NN O
, US20060013801 A , O
dermatitis US20060013801 A NN O
, US20060013801 A , O
soft US20060013801 A JJ O
tissue US20060013801 A NN O
fibrosis US20060013801 A NN O
or US20060013801 A CC O
central US20060013801 A JJ O
nervous US20060013801 A JJ O
system US20060013801 A NN O
toxicity US20060013801 A NN O
effective US20060013801 A JJ O
amount US20060013801 A NN O
of US20060013801 A IN O
a US20060013801 A DT O
cytokine US20060013801 A NN I-UN
blocking US20060013801 A VBG O
agent US20060013801 A NN O
to US20060013801 A TO O
the US20060013801 A DT O
subject US20060013801 A NN O
. US20060013801 A . O

Therapy US20120202848 T NN O
of US20120202848 T IN O
autoimmune US20120202848 T NN O
colitis US20120202848 T NN O
using US20120202848 T VBG O
a US20120202848 T DT O
tip60 US20120202848 T NN I-UN
inhibitor US20120202848 T NN O
. US20120202848 T . O

More US20120202848 A RBR O
particularly US20120202848 A RB O
it US20120202848 A PRP O
concerns US20120202848 A VBZ O
methods US20120202848 A NNS O
of US20120202848 A IN O
treating US20120202848 A VBG O
patients US20120202848 A NNS O
with US20120202848 A IN O
compounds US20120202848 A NNS O
which US20120202848 A WDT O
are US20120202848 A VBP O
useful US20120202848 A JJ O
agents US20120202848 A NNS O
for US20120202848 A IN O
inhibiting US20120202848 A VBG O
the US20120202848 A DT O
functions US20120202848 A NNS O
of US20120202848 A IN O
TIP60 US20120202848 A NNP I-UN
in US20120202848 A IN O
the US20120202848 A DT O
treatment US20120202848 A NN O
of US20120202848 A IN O
an US20120202848 A DT O
individual US20120202848 A JJ O
suffering US20120202848 A NN O
, US20120202848 A , O
for US20120202848 A IN O
example US20120202848 A NN O
, US20120202848 A , O
from US20120202848 A IN O
ulcerative US20120202848 A JJ O
colitis US20120202848 A NN O
and US20120202848 A CC O
other US20120202848 A JJ O
irritable US20120202848 A JJ O
bowel US20120202848 A NN O
diseases US20120202848 A NNS O
. US20120202848 A . O

For US20080089884 T IN O
treating US20080089884 T VBG O
and/or US20080089884 T NN O
preventing US20080089884 T VBG O
bladder US20080089884 T NN O
disorders US20080089884 T NNS O
; US20080089884 T : O
for US20080089884 T IN O
decreasing US20080089884 T VBG O
the US20080089884 T DT O
expression US20080089884 T NN O
, US20080089884 T , O
release US20080089884 T NN O
or US20080089884 T CC O
biological US20080089884 T JJ O
activity US20080089884 T NN O
of US20080089884 T IN O
macrophage US20080089884 T NN O
migration US20080089884 T NN O
inhibition US20080089884 T NN O
factor US20080089884 T NN O
. US20080089884 T . O

In US20080089884 A IN O
certain US20080089884 A JJ O
embodiments US20080089884 A NNS O
the US20080089884 A DT O
invention US20080089884 A NN O
comprises US20080089884 A VBZ O
methods US20080089884 A NNS O
for US20080089884 A IN O
the US20080089884 A DT O
treatment US20080089884 A NN O
and/or US20080089884 A JJ O
prevention US20080089884 A NN O
of US20080089884 A IN O
a US20080089884 A DT O
bladder US20080089884 A NN O
disorder US20080089884 A NN O
comprising US20080089884 A VBG O
administering US20080089884 A VBG O
an US20080089884 A DT O
effective US20080089884 A JJ O
amount US20080089884 A NN O
of US20080089884 A IN O
a US20080089884 A DT O
therapeutic US20080089884 A JJ O
agent US20080089884 A NN O
that US20080089884 A WDT O
decreases US20080089884 A VBZ O
the US20080089884 A DT O
expression US20080089884 A NN O
, US20080089884 A , O
release US20080089884 A NN O
or US20080089884 A CC O
biological US20080089884 A JJ O
activity US20080089884 A NN O
of US20080089884 A IN O
macrophage US20080089884 A NN I-UN
migration US20080089884 A NN I-UN
inhibition US20080089884 A NN I-UN
factor US20080089884 A NN I-UN
( US20080089884 A ( O
MIF US20080089884 A NNP I-UN
) US20080089884 A ) O
to US20080089884 A TO O
a US20080089884 A DT O
subject US20080089884 A NN O
in US20080089884 A IN O
need US20080089884 A NN O
thereof US20080089884 A NN O
. US20080089884 A . O

In US20080089884 A IN O
other US20080089884 A JJ O
aspects US20080089884 A NNS O
the US20080089884 A DT O
invention US20080089884 A NN O
relates US20080089884 A VBZ O
to US20080089884 A TO O
a US20080089884 A DT O
method US20080089884 A NN O
for US20080089884 A IN O
diagnosing US20080089884 A VBG O
bladder US20080089884 A NN O
disease US20080089884 A NN O
and/or US20080089884 A NN O
bladder US20080089884 A NN O
disease US20080089884 A NN O
severity US20080089884 A NN O
comprising US20080089884 A VBG O
screening US20080089884 A VBG O
for US20080089884 A IN O
a US20080089884 A DT O
MIF US20080089884 A NNP I-UN
gene US20080089884 A NN O
or US20080089884 A CC O
MIF US20080089884 A NNP I-UN
receptor US20080089884 A NN I-UN
gene US20080089884 A NN O
polymorphism US20080089884 A NN O
or US20080089884 A CC O
expression US20080089884 A NN O
level US20080089884 A NN O
. US20080089884 A . O

Mollugin CN102875517A T NN O
and CN102875517A T CC O
preparation CN102875517A T NN O
method CN102875517A T NN O
and CN102875517A T CC O
application CN102875517A T NN O
thereof CN102875517A T NN O
. CN102875517A T . O

Experiments CN102875517A A NNS O
show CN102875517A A VBP O
that CN102875517A A IN O
the CN102875517A A DT O
mollugin CN102875517A A NN O
can CN102875517A A MD O
effectively CN102875517A A RB O
reduce CN102875517A A VB O
blood CN102875517A A NN O
sugar CN102875517A A NN O
, CN102875517A A , O
TC CN102875517A A NNP O
( CN102875517A A ( O
total CN102875517A A JJ O
cholesterol CN102875517A A NN O
) CN102875517A A ) O
, CN102875517A A , O
TG CN102875517A A NNP O
( CN102875517A A ( O
total CN102875517A A JJ O
glycerin CN102875517A A NN O
) CN102875517A A ) O
and CN102875517A A CC O
MDA CN102875517A A NNP O
( CN102875517A A ( O
methylene CN102875517A A JJ O
dioxyamphetamine CN102875517A A NN O
) CN102875517A A ) O
content CN102875517A A NN O
of CN102875517A A IN O
mice CN102875517A A NN O
with CN102875517A A IN O
high CN102875517A A JJ O
blood CN102875517A A NN O
sugar CN102875517A A NN O
caused CN102875517A A VBN O
by CN102875517A A IN O
alloxan CN102875517A A NN O
, CN102875517A A , O
and CN102875517A A CC O
can CN102875517A A MD O
evidently CN102875517A A RB O
increase CN102875517A A VB O
SOD CN102875517A A NNP I-UN
( CN102875517A A ( O
superoxide CN102875517A A JJ I-UN
dismutase CN102875517A A NN I-UN
) CN102875517A A ) O
activity CN102875517A A NN O
and CN102875517A A CC O
hepatic CN102875517A A JJ O
glycogen CN102875517A A NN O
content CN102875517A A NN O
of CN102875517A A IN O
the CN102875517A A DT O
mice CN102875517A A NN O
. CN102875517A A . O

Hydroxy US20120189569 T NNP O
Acid US20120189569 T NNP O
Complexes US20120189569 T NNP O
for US20120189569 T IN O
Skin US20120189569 T NNP O
Renovation US20120189569 T NNP O
and US20120189569 T CC O
Clarity US20120189569 T NNP O
. US20120189569 T . O

New WO2008150231A1 T NNP O
heterocyclic WO2008150231A1 T JJ O
compounds WO2008150231A1 T NNS O
for WO2008150231A1 T IN O
treatment WO2008150231A1 T NN O
of WO2008150231A1 T IN O
respiratory WO2008150231A1 T NN O
, WO2008150231A1 T , O
airway WO2008150231A1 T RB O
or WO2008150231A1 T CC O
inflammatory WO2008150231A1 T JJ O
disorders WO2008150231A1 T NNS O
. WO2008150231A1 T . O

Inhibitors WO2009033284A1 T NNS O
of WO2009033284A1 T IN O
collagen WO2009033284A1 T NN O
biosynthesis WO2009033284A1 T NN O
as WO2009033284A1 T IN O
anti-tumor WO2009033284A1 T JJ O
agents WO2009033284A1 T NNS O
. WO2009033284A1 T . O

Amidoalkylpiperazinyl WO2013001498A1 T NNP O
derivatives WO2013001498A1 T NNS O
for WO2013001498A1 T IN O
the WO2013001498A1 T DT O
treatment WO2013001498A1 T NN O
of WO2013001498A1 T IN O
central WO2013001498A1 T JJ O
nervous WO2013001498A1 T JJ O
system WO2013001498A1 T NN O
diseases WO2013001498A1 T NNS O
. WO2013001498A1 T . O

Potassium CN103536623A T NNP O
magnesium CN103536623A T NN O
aspartate CN103536623A T NN O
composition CN103536623A T NN O
freeze-dried CN103536623A T JJ O
powder CN103536623A T NN O
for CN103536623A T IN O
injection CN103536623A T NN O
. CN103536623A T . O

Penetration CN101862311A T NN O
promoting CN101862311A T NN O
and CN101862311A T CC O
eyesight CN101862311A T JJ O
improving CN101862311A T VBG O
eye CN101862311A T NN O
drop CN101862311A T NN O
. CN101862311A T . O

From US7297789 T IN O
4-amino-2-methyl-10H-thieno US7297789 T JJ O
( US7297789 T ( O
2,3-b US7297789 T JJ O
) US7297789 T ) O
( US7297789 T ( O
1,5 US7297789 T CD O
) US7297789 T ) O
benzodiazpine US7297789 T NN O
HCl US7297789 T NNP O
and US7297789 T CC O
1-methylpiperazine US7297789 T JJ O
in US7297789 T IN O
an US7297789 T DT O
aprotic US7297789 T JJ O
high US7297789 T JJ O
boiling US7297789 T NN O
solvent US7297789 T NN O
; US7297789 T : O
purifying US7297789 T VBG O
in US7297789 T IN O
an US7297789 T DT O
acid US7297789 T JJ O
medium US7297789 T NN O
; US7297789 T : O
basifying US7297789 T VBG O
to US7297789 T TO O
pH US7297789 T VB O
of US7297789 T IN O
7.5-9 US7297789 T JJ O
; US7297789 T : O
and US7297789 T CC O
extracting US7297789 T VBG O
with US7297789 T IN O
a US7297789 T DT O
low US7297789 T JJ O
boiling US7297789 T NN O
organic US7297789 T JJ O
solvent US7297789 T NN O
. US7297789 T . O

A US7297789 A DT O
process US7297789 A NN O
for US7297789 A IN O
the US7297789 A DT O
preparation US7297789 A NN O
of US7297789 A IN O
polymorph US7297789 A JJ O
Form US7297789 A NNP O
I US7297789 A PRP O
of US7297789 A IN O
2-methyl-4- US7297789 A JJ O
( US7297789 A ( O
4-methyl-1-piperazinyl US7297789 A JJ O
) US7297789 A ) O
-10H-thieno US7297789 A FW O
[ US7297789 A JJ O
2,3-b US7297789 A JJ O
] US7297789 A NN O
[ US7297789 A $ O
1,5 US7297789 A CD O
] US7297789 A NNP O
benzodiazepine US7297789 A NN O
, US7297789 A , O
or US7297789 A CC O
olanzapine US7297789 A NN O
. US7297789 A . O

Diarrhea-treating CN1876014A T JJ O
medicine CN1876014A T NN O
for CN1876014A T IN O
birds CN1876014A T NNS O
and CN1876014A T CC O
preparation CN1876014A T NN O
method CN1876014A T NN O
thereof CN1876014A T NN O
. CN1876014A T . O

Azetidin US20100137280 T NNP O
compounds US20100137280 T VBZ O
suitable US20100137280 T JJ O
for US20100137280 T IN O
treating US20100137280 T VBG O
disorders US20100137280 T NNS O
that US20100137280 T WDT O
respond US20100137280 T VBP O
to US20100137280 T TO O
modulation US20100137280 T NN O
of US20100137280 T IN O
the US20100137280 T DT O
serotonin US20100137280 T JJ O
5-ht6 US20100137280 T JJ I-UN
receptor US20100137280 T NN O
. US20100137280 T . O

The US20100137280 A DT O
present US20100137280 A JJ O
invention US20100137280 A NN O
relates US20100137280 A VBZ O
to US20100137280 A TO O
compounds US20100137280 A NNS O
of US20100137280 A IN O
formula US20100137280 A NN O
( US20100137280 A ( O
I US20100137280 A PRP O
) US20100137280 A ) O
wherein US20100137280 A VBP O
A US20100137280 A DT O
is US20100137280 A VBZ O
C1-C6-alkyl US20100137280 A JJ O
, US20100137280 A , O
C1-C6-haloalkyl US20100137280 A NNP O
, US20100137280 A , O
C1-C6-hydroxyalkyl US20100137280 A NNP O
, US20100137280 A , O
C2-C6-alkenyl US20100137280 A NNP O
, US20100137280 A , O
C2-C6-halo-alkenyl US20100137280 A NNP O
, US20100137280 A , O
C3-C6-cycloalkyl US20100137280 A NNP O
, US20100137280 A , O
aryl-C1-C4-alkyl US20100137280 A JJ O
, US20100137280 A , O
aryl-C2-C4-alkenyl US20100137280 A JJ O
, US20100137280 A , O
aryl US20100137280 A JJ O
or US20100137280 A CC O
hetaryl US20100137280 A NN O
, US20100137280 A , O
is US20100137280 A VBZ O
a US20100137280 A DT O
single US20100137280 A JJ O
or US20100137280 A CC O
double US20100137280 A JJ O
bond US20100137280 A NN O
; US20100137280 A : O
X1 US20100137280 A NNP O
and US20100137280 A CC O
X2 US20100137280 A NNP O
are US20100137280 A VBP O
N US20100137280 A NNP O
, US20100137280 A , O
CRx1 US20100137280 A NNP O
, US20100137280 A , O
NRx2 US20100137280 A NNP O
, US20100137280 A , O
or US20100137280 A CC O
CRx3Rx4 US20100137280 A NNP O
; US20100137280 A : O
Rx1 US20100137280 A NNP O
, US20100137280 A , O
Rx3 US20100137280 A NNP O
and US20100137280 A CC O
Rx4 US20100137280 A NNP O
are US20100137280 A VBP O
H US20100137280 A NNP O
, US20100137280 A , O
halogen US20100137280 A NN O
, US20100137280 A , O
CN US20100137280 A NNP O
, US20100137280 A , O
NO2 US20100137280 A NNP O
, US20100137280 A , O
C1-C6-alkyl US20100137280 A NNP O
, US20100137280 A , O
C1-C6-alkoxy US20100137280 A NNP O
, US20100137280 A , O
C1-C6-alkylcarbonyl US20100137280 A NNP O
, US20100137280 A , O
etc US20100137280 A NN O
. US20100137280 A . O

or US20100137280 A CC O
two US20100137280 A CD O
geminal US20100137280 A JJ O
radicals US20100137280 A NNS O
Rx3 US20100137280 A NNP O
and US20100137280 A CC O
Rx4 US20100137280 A NNP O
together US20100137280 A RB O
with US20100137280 A IN O
the US20100137280 A DT O
carbon US20100137280 A NN O
atom US20100137280 A NN O
to US20100137280 A TO O
which US20100137280 A WDT O
they US20100137280 A PRP O
are US20100137280 A VBP O
bound US20100137280 A VBN O
may US20100137280 A MD O
form US20100137280 A VB O
a US20100137280 A DT O
carbonyl US20100137280 A NN O
group US20100137280 A NN O
or US20100137280 A CC O
a US20100137280 A DT O
3- US20100137280 A JJ O
to US20100137280 A TO O
6-membered US20100137280 A JJ O
carbocyclic US20100137280 A NN O
or US20100137280 A CC O
heterocyclic US20100137280 A JJ O
spiro-annulated US20100137280 A JJ O
ring US20100137280 A NN O
; US20100137280 A : O
Rx2 US20100137280 A NNP O
is US20100137280 A VBZ O
hydrogen US20100137280 A JJ O
, US20100137280 A , O
C1-C6-alkyl US20100137280 A NNP O
, US20100137280 A , O
C1-C6-alkylcarbonyl US20100137280 A NNP O
, US20100137280 A , O
C1-C6-haloalkyl US20100137280 A NNP O
, US20100137280 A , O
etc US20100137280 A NN O
. US20100137280 A . O

; US20100137280 A : O
or US20100137280 A CC O
two US20100137280 A CD O
vicinal US20100137280 A JJ O
radicals US20100137280 A NNS O
Rx1 US20100137280 A NNP O
, US20100137280 A , O
Rx2 US20100137280 A NNP O
, US20100137280 A , O
Rx3 US20100137280 A NNP O
or US20100137280 A CC O
Rx4 US20100137280 A NNP O
together US20100137280 A RB O
with US20100137280 A IN O
X1 US20100137280 A NNP O
and US20100137280 A CC O
X2 US20100137280 A NNP O
form US20100137280 A VB O
a US20100137280 A DT O
five- US20100137280 A JJ O
or US20100137280 A CC O
six-membered US20100137280 A JJ O
carbocyclic US20100137280 A NN O
or US20100137280 A CC O
heterocyclic US20100137280 A NN O
fused US20100137280 A VBN O
ring US20100137280 A NN O
; US20100137280 A : O
Y1 US20100137280 A NNP O
, US20100137280 A , O
Y2 US20100137280 A NNP O
and US20100137280 A CC O
Y3 US20100137280 A NNP O
are US20100137280 A VBP O
N US20100137280 A NNP O
or US20100137280 A CC O
CRy US20100137280 A NNP O
; US20100137280 A : O
Ry US20100137280 A NNP O
is US20100137280 A VBZ O
H US20100137280 A NNP O
, US20100137280 A , O
halogen US20100137280 A NN O
, US20100137280 A , O
CN US20100137280 A NNP O
, US20100137280 A , O
NO2 US20100137280 A NNP O
, US20100137280 A , O
C1-C6-alkyl US20100137280 A NNP O
, US20100137280 A , O
C1-C6-alkoxy US20100137280 A NNP O
, US20100137280 A , O
C1-C6-alkylcarbonyl US20100137280 A NNP O
, US20100137280 A , O
C1-C6-haloalkyl US20100137280 A NNP O
, US20100137280 A , O
etc US20100137280 A NN O
. US20100137280 A . O

; US20100137280 A : O
wherein US20100137280 A VB O
a US20100137280 A DT O
maximum US20100137280 A NN O
of US20100137280 A IN O
3 US20100137280 A CD O
of US20100137280 A IN O
the US20100137280 A DT O
radicals US20100137280 A NNS O
X1 US20100137280 A NNP O
, US20100137280 A , O
X2 US20100137280 A NNP O
, US20100137280 A , O
Y1 US20100137280 A NNP O
, US20100137280 A , O
Y2 US20100137280 A NNP O
and US20100137280 A CC O
Y3 US20100137280 A NNP O
are US20100137280 A VBP O
selected US20100137280 A VBN O
from US20100137280 A IN O
NRx1 US20100137280 A NNP O
and US20100137280 A CC O
N US20100137280 A NNP O
; US20100137280 A : O
R1 US20100137280 A NNP O
is US20100137280 A VBZ O
hydrogen US20100137280 A JJ O
, US20100137280 A , O
C1-C6-alkyl US20100137280 A NNP O
, US20100137280 A , O
C1-C6-hydroxyalkyl US20100137280 A NNP O
, US20100137280 A , O
C1-C6-haloalkyl US20100137280 A NNP O
, US20100137280 A , O
etc US20100137280 A NN O
. US20100137280 A . O

; US20100137280 A : O
R2 US20100137280 A NNP O
is US20100137280 A VBZ O
C1-C4-alkyl US20100137280 A JJ O
or US20100137280 A CC O
C1-C4-haloalkyl US20100137280 A JJ O
; US20100137280 A : O
n US20100137280 A CC O
is US20100137280 A VBZ O
0 US20100137280 A CD O
, US20100137280 A , O
1 US20100137280 A CD O
or US20100137280 A CC O
2 US20100137280 A CD O
; US20100137280 A : O
physiologically US20100137280 A RB O
tolerated US20100137280 A VBD O
acid US20100137280 A JJ O
addition US20100137280 A NN O
salts US20100137280 A NNS O
and US20100137280 A CC O
the US20100137280 A DT O
N-oxides US20100137280 A NNP O
thereof US20100137280 A NN O
, US20100137280 A , O
pharmaceutical US20100137280 A JJ O
composition US20100137280 A NN O
comprising US20100137280 A VBG O
them US20100137280 A PRP O
, US20100137280 A , O
a US20100137280 A DT O
method US20100137280 A NN O
for US20100137280 A IN O
treating US20100137280 A VBG O
medical US20100137280 A JJ O
disorders US20100137280 A NNS O
selected US20100137280 A VBN O
from US20100137280 A IN O
diseases US20100137280 A NNS O
of US20100137280 A IN O
the US20100137280 A DT O
central US20100137280 A JJ O
nervous US20100137280 A JJ O
system US20100137280 A NN O
, US20100137280 A , O
addiction US20100137280 A NN O
diseases US20100137280 A NNS O
or US20100137280 A CC O
obesity US20100137280 A NN O
, US20100137280 A , O
said US20100137280 A VBD O
method US20100137280 A NN O
comprising US20100137280 A VBG O
administering US20100137280 A VBG O
an US20100137280 A DT O
effective US20100137280 A JJ O
amount US20100137280 A NN O
of US20100137280 A IN O
such US20100137280 A JJ O
compounds US20100137280 A NNS O
to US20100137280 A TO O
a US20100137280 A DT O
subject US20100137280 A NN O
in US20100137280 A IN O
need US20100137280 A NN O
and US20100137280 A CC O
the US20100137280 A DT O
use US20100137280 A NN O
of US20100137280 A IN O
such US20100137280 A JJ O
a US20100137280 A DT O
compound US20100137280 A NN O
for US20100137280 A IN O
preparing US20100137280 A VBG O
a US20100137280 A DT O
pharmaceutical US20100137280 A JJ O
compositions US20100137280 A NNS O
. US20100137280 A . O

Silybin CN101632638B T NNP O
nanostructured CN101632638B T VBD O
lipid CN101632638B T JJ O
carrier CN101632638B T NN O
and CN101632638B T CC O
preparation CN101632638B T NN O
method CN101632638B T NN O
thereof CN101632638B T NN O
. CN101632638B T . O

Antisense US20090036355 T NNP O
Modulation US20090036355 T NNP O
of US20090036355 T IN O
PTP1B US20090036355 T NNP I-UN
Expression US20090036355 T NNP O
. US20090036355 T . O

Compositions US20090036355 A NNS O
and US20090036355 A CC O
methods US20090036355 A NNS O
are US20090036355 A VBP O
provided US20090036355 A VBN O
for US20090036355 A IN O
decreasing US20090036355 A VBG O
blood US20090036355 A NN O
glucose US20090036355 A NN O
levels US20090036355 A NNS O
in US20090036355 A IN O
an US20090036355 A DT O
animal US20090036355 A NN O
or US20090036355 A CC O
for US20090036355 A IN O
preventing US20090036355 A VBG O
or US20090036355 A CC O
de-laying US20090036355 A VBG O
the US20090036355 A DT O
onset US20090036355 A NN O
of US20090036355 A IN O
a US20090036355 A DT O
rise US20090036355 A NN O
in US20090036355 A IN O
blood US20090036355 A NN O
glucose US20090036355 A NN O
levels US20090036355 A NNS O
in US20090036355 A IN O
an US20090036355 A DT O
animal US20090036355 A NN O
, US20090036355 A , O
comprising US20090036355 A VBG O
administering US20090036355 A VBG O
to US20090036355 A TO O
said US20090036355 A VBD O
animal US20090036355 A RP O
an US20090036355 A DT O
antisense US20090036355 A JJ O
inhibitor US20090036355 A NN O
of US20090036355 A IN O
PTP1B US20090036355 A NNP I-UN
expression US20090036355 A NN O
in US20090036355 A IN O
combination US20090036355 A NN O
with US20090036355 A IN O
at US20090036355 A IN O
least US20090036355 A JJS O
one US20090036355 A CD O
glucose-lowering US20090036355 A JJ O
drug US20090036355 A NN O
. US20090036355 A . O

The US20090036355 A DT O
present US20090036355 A JJ O
invention US20090036355 A NN O
is US20090036355 A VBZ O
also US20090036355 A RB O
directed US20090036355 A VBN O
to US20090036355 A TO O
compositions US20090036355 A NNS O
and US20090036355 A CC O
methods US20090036355 A NNS O
for US20090036355 A IN O
improving US20090036355 A VBG O
insulin US20090036355 A JJ I-UN
sensitivity US20090036355 A NN O
in US20090036355 A IN O
an US20090036355 A DT O
animal US20090036355 A NN O
or US20090036355 A CC O
for US20090036355 A IN O
preventing US20090036355 A VBG O
or US20090036355 A CC O
delaying US20090036355 A VBG O
the US20090036355 A DT O
onset US20090036355 A NN O
of US20090036355 A IN O
insulin US20090036355 A NN I-UN
resistance US20090036355 A NN O
in US20090036355 A IN O
an US20090036355 A DT O
animal US20090036355 A NN O
. US20090036355 A . O

Sulfonamide CN101273013A T NNP O
derivative CN101273013A T JJ O
having CN101273013A T VBG O
PGD2 CN101273013A T NNP I-UN
receptor CN101273013A T NN I-UN
antagonistic CN101273013A T JJ O
activity CN101273013A T NN O
. CN101273013A T . O

The CN101273013A A DT O
invention CN101273013A A NN O
provides CN101273013A A VBZ O
a CN101273013A A DT O
sulfonamide CN101273013A A NN O
derivative CN101273013A A JJ O
having CN101273013A A VBG O
DP CN101273013A A NNP I-UN
receptor CN101273013A A NN I-UN
antagonistic CN101273013A A JJ O
activity CN101273013A A NN O
; CN101273013A A : O
and CN101273013A A CC O
a CN101273013A A DT O
medicinal CN101273013A A JJ O
composition CN101273013A A NN O
and CN101273013A A CC O
a CN101273013A A DT O
therapeutic CN101273013A A JJ O
agent CN101273013A A NN O
for CN101273013A A IN O
allergic CN101273013A A NN O
diseases CN101273013A A NNS O
which CN101273013A A WDT O
each CN101273013A A DT O
contains CN101273013A A VBZ O
the CN101273013A A DT O
compound CN101273013A A NN O
as CN101273013A A IN O
an CN101273013A A DT O
active CN101273013A A JJ O
ingredient CN101273013A A NN O
. CN101273013A A . O

Mimics EP1497247A2 T NNS O
of EP1497247A2 T IN O
acyl EP1497247A2 T JJ O
coenzyme-a EP1497247A2 T NN O
, EP1497247A2 T , O
compositions EP1497247A2 T NNS O
thereof EP1497247A2 T VBP O
, EP1497247A2 T , O
and EP1497247A2 T CC O
methods EP1497247A2 T NNS O
of EP1497247A2 T IN O
cholesterol EP1497247A2 T NN O
management EP1497247A2 T NN O
and EP1497247A2 T CC O
related EP1497247A2 T JJ O
uses EP1497247A2 T NNS O
. EP1497247A2 T . O

Pain CN102423466A T NN O
relief CN102423466A T NN O
tincture CN102423466A T NN O
. CN102423466A T . O

Nux CN1718190A T NN O
vomica CN1718190A T NN O
alkaloid CN1718190A T JJ O
liposome CN1718190A T NN O
, CN1718190A T , O
and CN1718190A T CC O
its CN1718190A T PRP$ O
prepn CN1718190A T NN O
. CN1718190A T . O

method CN1718190A T NN O
. CN1718190A T . O

A WO2014040087A1 T DT O
virucidal WO2014040087A1 T NN O
small WO2014040087A1 T JJ O
molecule WO2014040087A1 T NN O
and WO2014040087A1 T CC O
uses WO2014040087A1 T VBZ O
thereof WO2014040087A1 T NN O
. WO2014040087A1 T . O

Process EP1854799A1 T NN O
for EP1854799A1 T IN O
the EP1854799A1 T DT O
preparation EP1854799A1 T NN O
of EP1854799A1 T IN O
a EP1854799A1 T DT O
taxane EP1854799A1 T NN O
derivative EP1854799A1 T NN O
. EP1854799A1 T . O

End-Modified US20080242626 T JJ O
Poly US20080242626 T NNP O
( US20080242626 T ( O
beta-amino US20080242626 T JJ O
esters US20080242626 T NNS O
) US20080242626 T ) O
and US20080242626 T CC O
Uses US20080242626 T VBZ O
Thereof US20080242626 T NNP O
. US20080242626 T . O

Compound CN101040712A T NNP O
containing CN101040712A T VBG O
DAG CN101040712A T NNP O
and CN101040712A T CC O
the CN101040712A T DT O
method CN101040712A T NN O
for CN101040712A T IN O
preparing CN101040712A T VBG O
the CN101040712A T DT O
same CN101040712A T JJ O
. CN101040712A T . O

Inhibiting US7432389 T VBG O
beta-secretase US7432389 T JJ O
enzyme US7432389 T NN O
activity US7432389 T NN O
and US7432389 T CC O
A US7432389 T DT I-UN
beta US7432389 T NN I-UN
peptide US7432389 T NN I-UN
production US7432389 T NN O
, US7432389 T , O
to US7432389 T TO O
reduce US7432389 T VB O
amyloid US7432389 T JJ I-UN
beta US7432389 T NN I-UN
deposits US7432389 T NNS O
or US7432389 T CC O
plaques US7432389 T NNS O
. US7432389 T . O

Use CN101785773A T NNP O
of CN101785773A T IN O
metal CN101785773A T NN O
supermolecular CN101785773A T JJ O
compound CN101785773A T NN O
in CN101785773A T IN O
preparation CN101785773A T NN O
of CN101785773A T IN O
medicament CN101785773A T NN O
for CN101785773A T IN O
treating CN101785773A T VBG O
alzheimer CN101785773A T NN O
's CN101785773A T POS O
disease CN101785773A T NN O
. CN101785773A T . O

Delivery EP2744483A1 T NN O
system EP2744483A1 T NN O
for EP2744483A1 T IN O
specifically EP2744483A1 T RB O
targeting EP2744483A1 T VBG O
cancer EP2744483A1 T NN O
cells EP2744483A1 T NNS O
and EP2744483A1 T CC O
method EP2744483A1 T NN O
of EP2744483A1 T IN O
use EP2744483A1 T NN O
thereof EP2744483A1 T NN O
. EP2744483A1 T . O

Methods EP2744483A1 A NNS O
for EP2744483A1 A IN O
prevention EP2744483A1 A NN O
, EP2744483A1 A , O
treatment EP2744483A1 A NN O
or EP2744483A1 A CC O
inhibition EP2744483A1 A NN O
of EP2744483A1 A IN O
the EP2744483A1 A DT O
growth EP2744483A1 A NN O
or EP2744483A1 A CC O
metastasis EP2744483A1 A NN O
of EP2744483A1 A IN O
cancer EP2744483A1 A NN O
cells EP2744483A1 A NNS O
in EP2744483A1 A IN O
a EP2744483A1 A DT O
subject EP2744483A1 A NN O
are EP2744483A1 A VBP O
disclosed EP2744483A1 A VBN O
. EP2744483A1 A . O

One EP2744483A1 A CD O
method EP2744483A1 A NN O
comprises EP2744483A1 A VBZ O
the EP2744483A1 A DT O
step EP2744483A1 A NN O
of EP2744483A1 A IN O
administering EP2744483A1 A VBG O
to EP2744483A1 A TO O
the EP2744483A1 A DT O
subject EP2744483A1 A NN O
a EP2744483A1 A DT O
therapeutically EP2744483A1 A RB O
effective EP2744483A1 A JJ O
amount EP2744483A1 A NN O
of EP2744483A1 A IN O
tumor EP2744483A1 A NN O
associated EP2744483A1 A VBN O
antigen EP2744483A1 A IN O
binding EP2744483A1 A VBG O
ligand-coated EP2744483A1 A JJ O
planetary EP2744483A1 A JJ O
ball EP2744483A1 A NN O
milled EP2744483A1 A VBD O
( EP2744483A1 A ( O
PBM EP2744483A1 A NNP O
) EP2744483A1 A ) O
nanoparticles EP2744483A1 A VBZ O
containing EP2744483A1 A VBG O
a EP2744483A1 A DT O
cytotoxic EP2744483A1 A NN O
agent EP2744483A1 A NN O
. EP2744483A1 A . O

Tacrolimus CN103239391A T NNP O
ointment CN103239391A T NN O
. CN103239391A T . O

Crystalline US20120022093 T NNP O
forms US20120022093 T NNS O
of US20120022093 T IN O
oxymorphone US20120022093 T NN O
hydrochloride US20120022093 T NN O
. US20120022093 T . O

The US20120022093 A DT O
present US20120022093 A JJ O
invention US20120022093 A NN O
is US20120022093 A VBZ O
directed US20120022093 A VBN O
to US20120022093 A TO O
crystalline US20120022093 A VB O
forms US20120022093 A NNS O
of US20120022093 A IN O
oxymorphone US20120022093 A NN O
hydrochloride US20120022093 A NN O
. US20120022093 A . O

Indolines CN101417971B T NNS O
compounds CN101417971B T NNS O
, CN101417971B T , O
preparation CN101417971B T NN O
method CN101417971B T NN O
and CN101417971B T CC O
pharmaceutical CN101417971B T JJ O
application CN101417971B T NN O
thereof CN101417971B T NN O
. CN101417971B T . O

The CN101417971B A DT O
invention CN101417971B A NN O
relates CN101417971B A VBZ O
to CN101417971B A TO O
the CN101417971B A DT O
field CN101417971B A NN O
of CN101417971B A IN O
pharmaceutical CN101417971B A JJ O
chemistry CN101417971B A NN O
, CN101417971B A , O
in CN101417971B A IN O
particular CN101417971B A JJ O
to CN101417971B A TO O
an CN101417971B A DT O
alpha CN101417971B A JJ I-UN
1-AR CN101417971B A JJ I-UN
antagonist CN101417971B A NN O
indoline CN101417971B A NN O
compound CN101417971B A NN O
( CN101417971B A ( O
I CN101417971B A PRP O
) CN101417971B A ) O
, CN101417971B A , O
wherein CN101417971B A VBD O
the CN101417971B A DT O
definitions CN101417971B A NNS O
of CN101417971B A IN O
R1 CN101417971B A NNP O
, CN101417971B A , O
R2 CN101417971B A NNP O
, CN101417971B A , O
R3 CN101417971B A NNP O
and CN101417971B A CC O
m CN101417971B A VB O
see CN101417971B A VBP O
the CN101417971B A DT O
instruction CN101417971B A NN O
. CN101417971B A . O

Exterior-applied CN101129522A T JJ O
medicine CN101129522A T NN O
for CN101129522A T IN O
treating CN101129522A T VBG O
dermatopathy CN101129522A T NN O
. CN101129522A T . O

Novel EP1521576A1 T NNP O
pharmaceutical EP1521576A1 T JJ O
compositions EP1521576A1 T NNS O
comprising EP1521576A1 T VBG O
novel EP1521576A1 T JJ O
anticholinergic EP1521576A1 T JJ O
agents EP1521576A1 T NNS O
and EP1521576A1 T CC O
pde-iv EP1521576A1 T JJ O
inhibitors EP1521576A1 T NNS O
. EP1521576A1 T . O

Treating US20050101632 T VBG O
inflammation US20050101632 T NN O
of US20050101632 T IN O
the US20050101632 T DT O
skin US20050101632 T NN O
or US20050101632 T CC O
mucous US20050101632 T JJ O
membrane US20050101632 T NN O
by US20050101632 T IN O
topical US20050101632 T JJ O
administration US20050101632 T NN O
of US20050101632 T IN O
an US20050101632 T DT O
anti-inflammatory US20050101632 T JJ O
amount US20050101632 T NN O
of US20050101632 T IN O
dimethicone US20050101632 T NN O
in US20050101632 T IN O
the US20050101632 T DT O
absence US20050101632 T NN O
of US20050101632 T IN O
any US20050101632 T DT O
other US20050101632 T JJ O
anti-inflammatory US20050101632 T JJ O
agent US20050101632 T NN O
. US20050101632 T . O

Compounds WO2014036595A1 T NNS O
and WO2014036595A1 T CC O
methods WO2014036595A1 T NNS O
for WO2014036595A1 T IN O
treating WO2014036595A1 T VBG O
diseases WO2014036595A1 T NNS O
or WO2014036595A1 T CC O
conditions WO2014036595A1 T NNS O
associated WO2014036595A1 T VBN O
with WO2014036595A1 T IN O
the WO2014036595A1 T DT O
central WO2014036595A1 T JJ O
nervous WO2014036595A1 T JJ O
system WO2014036595A1 T NN O
and/or WO2014036595A1 T JJ O
neurite WO2014036595A1 T JJ O
outgrowth WO2014036595A1 T NN O
. WO2014036595A1 T . O

Methods US7789610 T NNS O
for US7789610 T IN O
preventing/treating US7789610 T VBG O
damage US7789610 T NN O
to US7789610 T TO O
sensory US7789610 T JJ O
hair US7789610 T NN O
cells US7789610 T NNS O
and US7789610 T CC O
cochlear US7789610 T JJ O
neurons US7789610 T NNS O
. US7789610 T . O

Aqueous US20090163532 T JJ O
Gel US20090163532 T NNP O
Formulations US20090163532 T NNP O
Containing US20090163532 T NNP O
Immune US20090163532 T NNP O
Response US20090163532 T NNP O
Modifiers US20090163532 T NNP O
. US20090163532 T . O

Coumarone CN103333163A T NNP O
derivative CN103333163A T JJ O
, CN103333163A T , O
and CN103333163A T CC O
preparation CN103333163A T NN O
method CN103333163A T NN O
and CN103333163A T CC O
applications CN103333163A T NNS O
thereof CN103333163A T VBP O
. CN103333163A T . O

The CN103333163A A DT O
coumarone CN103333163A A NN O
derivative CN103333163A A NN O
can CN103333163A A MD O
be CN103333163A A VB O
used CN103333163A A VBN O
for CN103333163A A IN O
preparation CN103333163A A NN O
of CN103333163A A IN O
an CN103333163A A DT O
inhibitor CN103333163A A NN O
for CN103333163A A IN O
aggregation CN103333163A A NN O
of CN103333163A A IN O
acetylcholinesterase CN103333163A A NN I-UN
and CN103333163A A CC O
amyloid CN103333163A A JJ I-UN
protein CN103333163A A NN I-UN
. CN103333163A A . O

Treatment EP2101806A2 T NN O
of EP2101806A2 T IN O
disease EP2101806A2 T NN O
or EP2101806A2 T CC O
injury EP2101806A2 T NN O
of EP2101806A2 T IN O
the EP2101806A2 T DT O
nervous EP2101806A2 T JJ O
system EP2101806A2 T NN O
using EP2101806A2 T VBG O
agents EP2101806A2 T NNS O
that EP2101806A2 T WDT O
decrease EP2101806A2 T VBP O
the EP2101806A2 T DT O
activity EP2101806A2 T NN O
of EP2101806A2 T IN O
the EP2101806A2 T DT O
melanocortin EP2101806A2 T NN I-UN
4 EP2101806A2 T CD I-UN
receptor EP2101806A2 T NN I-UN
. EP2101806A2 T . O

Novel EP2101806A2 A NNP O
methods EP2101806A2 A NNS O
are EP2101806A2 A VBP O
provided EP2101806A2 A VBN O
for EP2101806A2 A IN O
modulating EP2101806A2 A VBG O
CNS EP2101806A2 A NNP O
cell EP2101806A2 A NN O
neogenesis EP2101806A2 A NN O
in EP2101806A2 A IN O
the EP2101806A2 A DT O
CNS EP2101806A2 A NNP O
cells EP2101806A2 A NNS O
in EP2101806A2 A IN O
vitro EP2101806A2 A NN O
or EP2101806A2 A CC O
in EP2101806A2 A IN O
vivo EP2101806A2 A NN O
, EP2101806A2 A , O
involving EP2101806A2 A VBG O
the EP2101806A2 A DT O
use EP2101806A2 A NN O
of EP2101806A2 A IN O
agents EP2101806A2 A NNS O
that EP2101806A2 A WDT O
decrease EP2101806A2 A VBP O
the EP2101806A2 A DT O
activity EP2101806A2 A NN O
of EP2101806A2 A IN O
the EP2101806A2 A DT O
melanocortin EP2101806A2 A NN I-UN
4 EP2101806A2 A CD I-UN
receptor EP2101806A2 A NN I-UN
( EP2101806A2 A ( O
MC4R EP2101806A2 A NNP I-UN
) EP2101806A2 A ) O
. EP2101806A2 A . O

Methods WO2013122778A1 T NNS O
of WO2013122778A1 T IN O
treating WO2013122778A1 T VBG O
and WO2013122778A1 T CC O
preventing WO2013122778A1 T VBG O
diseases WO2013122778A1 T NNS O
and WO2013122778A1 T CC O
disorders WO2013122778A1 T NNS O
of WO2013122778A1 T IN O
the WO2013122778A1 T DT O
central WO2013122778A1 T JJ O
nervous WO2013122778A1 T JJ O
system WO2013122778A1 T NN O
. WO2013122778A1 T . O

Examples WO2013122778A1 A NNS O
of WO2013122778A1 A IN O
the WO2013122778A1 A DT O
anti-inflammatory WO2013122778A1 A JJ O
agent WO2013122778A1 A NN O
include WO2013122778A1 A VBP O
glutathione WO2013122778A1 A NN O
and WO2013122778A1 A CC O
inhibitors WO2013122778A1 A NNS O
of WO2013122778A1 A IN O
purinergic WO2013122778A1 A JJ O
receptors WO2013122778A1 A NNS O
such WO2013122778A1 A JJ O
as WO2013122778A1 A IN O
P2X4 WO2013122778A1 A NNP I-UN
, WO2013122778A1 A , O
P2X7 WO2013122778A1 A NNP I-UN
, WO2013122778A1 A , O
P2Y6 WO2013122778A1 A NNP I-UN
, WO2013122778A1 A , O
and WO2013122778A1 A CC O
P2Y12receptors WO2013122778A1 A NNS I-UN
. WO2013122778A1 A . O

Use CN101433550A T NNP O
of CN101433550A T IN O
sulfur CN101433550A T NN O
and CN101433550A T CC O
ferric CN101433550A T JJ O
oxide CN101433550A T NN O
for CN101433550A T IN O
preparing CN101433550A T VBG O
medicament CN101433550A T NN O
for CN101433550A T IN O
treating CN101433550A T VBG O
epilepsy CN101433550A T NN O
. CN101433550A T . O

Quinoline EP0971587B1 T NNP O
leukotriene EP0971587B1 T NN O
antagonists EP0971587B1 T NNS O
. EP0971587B1 T . O

2,4-Diaminoquinazolines EP2615086A1 T NNS O
for EP2615086A1 T IN O
the EP2615086A1 T DT O
treatment EP2615086A1 T NN O
of EP2615086A1 T IN O
spinal EP2615086A1 T JJ O
muscular EP2615086A1 T JJ O
atrophy EP2615086A1 T NN O
. EP2615086A1 T . O

The US20080160060 A DT O
present US20080160060 A JJ O
invention US20080160060 A NN O
provides US20080160060 A VBZ O
a US20080160060 A DT O
method US20080160060 A NN O
of US20080160060 A IN O
promoting US20080160060 A VBG O
local US20080160060 A JJ O
bone US20080160060 A NN O
growth US20080160060 A NN O
by US20080160060 A IN O
administering US20080160060 A VBG O
a US20080160060 A DT O
therapeutic US20080160060 A JJ O
amount US20080160060 A NN O
of US20080160060 A IN O
a US20080160060 A DT O
Sost US20080160060 A NNP I-UN
antagonist US20080160060 A NN O
to US20080160060 A TO O
a US20080160060 A DT O
mammalian US20080160060 A JJ O
patient US20080160060 A NN O
in US20080160060 A IN O
need US20080160060 A NN O
thereof US20080160060 A NN O
. US20080160060 A . O

Preferably US20080160060 A RB O
, US20080160060 A , O
the US20080160060 A DT O
Sost US20080160060 A NNP I-UN
antagonist US20080160060 A NN O
is US20080160060 A VBZ O
an US20080160060 A DT O
antibody US20080160060 A NN O
or US20080160060 A CC O
FAB US20080160060 A NNP O
fragment US20080160060 A NN O
selectively US20080160060 A RB O
recognizing US20080160060 A VBG O
any US20080160060 A DT O
one US20080160060 A CD O
of US20080160060 A IN O
SEQ US20080160060 A NNP O
ID US20080160060 A NNP O
NOS US20080160060 A NNP O
: US20080160060 A : O
1-23 US20080160060 A JJ O
. US20080160060 A . O

The US20080160060 A DT O
Sost US20080160060 A NNP I-UN
antagonist US20080160060 A NN O
may US20080160060 A MD O
be US20080160060 A VB O
coadministered US20080160060 A VBN O
together US20080160060 A RB O
or US20080160060 A CC O
sequentially US20080160060 A RB O
with US20080160060 A IN O
a US20080160060 A DT O
matrix US20080160060 A NN O
conducive US20080160060 A NN O
to US20080160060 A TO O
anchoring US20080160060 A VBG O
new US20080160060 A JJ O
bone US20080160060 A NN O
growth US20080160060 A NN O
. US20080160060 A . O

Orthopedic US20080160060 A NNP O
and US20080160060 A CC O
Periodontal US20080160060 A NNP O
devices US20080160060 A NNS O
comprising US20080160060 A VBG O
an US20080160060 A DT O
implantable US20080160060 A JJ O
portion US20080160060 A NN O
adapted US20080160060 A VBD O
to US20080160060 A TO O
be US20080160060 A VB O
permanently US20080160060 A RB O
implanted US20080160060 A VBN O
within US20080160060 A IN O
a US20080160060 A DT O
mammalian US20080160060 A JJ O
body US20080160060 A NN O
and US20080160060 A CC O
bearing US20080160060 A VBG O
an US20080160060 A DT O
external US20080160060 A JJ O
coating US20080160060 A NN O
of US20080160060 A IN O
a US20080160060 A DT O
Sost US20080160060 A NNP I-UN
antagonist US20080160060 A NN O
are US20080160060 A VBP O
also US20080160060 A RB O
disclosed US20080160060 A VBN O
, US20080160060 A , O
as US20080160060 A IN O
it US20080160060 A PRP O
a US20080160060 A DT O
method US20080160060 A NN O
of US20080160060 A IN O
increasing US20080160060 A VBG O
bone US20080160060 A NN O
density US20080160060 A NN O
by US20080160060 A IN O
administering US20080160060 A VBG O
to US20080160060 A TO O
a US20080160060 A DT O
mammalian US20080160060 A JJ O
patient US20080160060 A NN O
a US20080160060 A DT O
therapeutic US20080160060 A JJ O
amount US20080160060 A NN O
of US20080160060 A IN O
a US20080160060 A DT O
Sost US20080160060 A NNP I-UN
antagonist US20080160060 A NN O
together US20080160060 A RB O
with US20080160060 A IN O
an US20080160060 A DT O
antiresorptive US20080160060 A JJ O
drug US20080160060 A NN O
. US20080160060 A . O

Application CN102872106A T NN O
of CN102872106A T IN O
Houttuynoid CN102872106A T NNP O
B CN102872106A T NNP O
in CN102872106A T IN O
medicine CN102872106A T NN O
for CN102872106A T IN O
preventing CN102872106A T VBG O
and CN102872106A T CC O
treating CN102872106A T VBG O
liver CN102872106A T JJ O
injury CN102872106A T NN O
. CN102872106A T . O

Compositions US20090035250 T NNS O
and US20090035250 T CC O
methods US20090035250 T NNS O
for US20090035250 T IN O
treating US20090035250 T VBG O
cavity US20090035250 T NN O
conditions US20090035250 T NNS O
. US20090035250 T . O

Mammalian WO2007054623A3 T JJ O
hedgehog WO2007054623A3 T NN I-UN
signaling WO2007054623A3 T VBG O
inhiabitors WO2007054623A3 T NNS O
. WO2007054623A3 T . O

( WO2007054623A3 A ( O
The WO2007054623A3 A DT O
disclosure WO2007054623A3 A NN O
relates WO2007054623A3 A VBZ O
to WO2007054623A3 A TO O
compositions WO2007054623A3 A NNS O
for WO2007054623A3 A IN O
and WO2007054623A3 A CC O
methods WO2007054623A3 A NNS O
of WO2007054623A3 A IN O
inhibiting WO2007054623A3 A VBG O
the WO2007054623A3 A DT O
mammalian WO2007054623A3 A JJ O
Hedgehog WO2007054623A3 A NNP I-UN
signaling WO2007054623A3 A VBG O
pathway WO2007054623A3 A RB O
. WO2007054623A3 A . O

Ginger CN202761909U T NNP O
medicine CN202761909U T NN O
hot CN202761909U T JJ O
push CN202761909U T NN O
capsule CN202761909U T NN O
. CN202761909U T . O

Specific CN103193781A T JJ O
inhibition CN103193781A T NN O
compound CN103193781A T NN O
of CN103193781A T IN O
SAHN CN103193781A T NNP I-UN
enzyme CN103193781A T FW O
protein CN103193781A T NN O
and CN103193781A T CC O
synthetic CN103193781A T JJ O
method CN103193781A T NN O
of CN103193781A T IN O
specific CN103193781A T JJ O
inhibition CN103193781A T NN O
compound CN103193781A T NN O
. CN103193781A T . O

The CN103193781A A DT O
invention CN103193781A A NN O
relates CN103193781A A VBZ O
to CN103193781A A TO O
the CN103193781A A DT O
technical CN103193781A A JJ O
field CN103193781A A NN O
of CN103193781A A IN O
polymer CN103193781A A JJ O
synthesis CN103193781A A NN O
and CN103193781A A CC O
in CN103193781A A IN O
particular CN103193781A A JJ O
relates CN103193781A A NNS O
to CN103193781A A TO O
a CN103193781A A DT O
specific CN103193781A A JJ O
inhibition CN103193781A A NN O
compound CN103193781A A NN O
of CN103193781A A IN O
an CN103193781A A DT O
SAHN CN103193781A A NNP I-UN
enzyme CN103193781A A NN O
protein CN103193781A A NN O
and CN103193781A A CC O
a CN103193781A A DT O
synthetic CN103193781A A JJ O
method CN103193781A A NN O
of CN103193781A A IN O
the CN103193781A A DT O
specific CN103193781A A JJ O
inhibition CN103193781A A NN O
compound CN103193781A A NN O
. CN103193781A A . O

The CN103193781A A DT O
specific CN103193781A A JJ O
inhibition CN103193781A A NN O
compound CN103193781A A NN O
of CN103193781A A IN O
escherichia CN103193781A A JJ I-UN
coli CN103193781A A NNS I-UN
SAHN CN103193781A A NNP I-UN
enzyme CN103193781A A NN O
protein CN103193781A A NN O
is CN103193781A A VBZ O
obtained CN103193781A A VBN O
in CN103193781A A IN O
a CN103193781A A DT O
targeted CN103193781A A JJ O
manner CN103193781A A NN O
by CN103193781A A IN O
virtue CN103193781A A NN O
of CN103193781A A IN O
an CN103193781A A DT O
organic CN103193781A A JJ O
synthetic CN103193781A A JJ O
method CN103193781A A NN O
, CN103193781A A , O
so CN103193781A A IN O
that CN103193781A A IN O
a CN103193781A A DT O
novel CN103193781A A JJ O
anti-infective CN103193781A A JJ O
drug CN103193781A A NN O
pilot CN103193781A A NN O
compound CN103193781A A NN O
is CN103193781A A VBZ O
developed CN103193781A A VBN O
. CN103193781A A . O

Synthetic CN101538191A T JJ O
method CN101538191A T NN O
of CN101538191A T IN O
high-purity CN101538191A T NN O
propofol CN101538191A T NN O
. CN101538191A T . O

Natural CN101138567A T NNP O
glycosides CN101138567A T NNS O
component CN101138567A T NN O
having CN101138567A T VBG O
good CN101138567A T JJ O
effect CN101138567A T NN O
of CN101138567A T IN O
reducing CN101138567A T VBG O
blood CN101138567A T NN O
sugar CN101138567A T NN O
. CN101138567A T . O

Novel CN103417519A T NNP O
purpose CN103417519A T NN O
of CN103417519A T IN O
cinnamyl CN103417519A T NN O
aldehyde CN103417519A T NN O
. CN103417519A T . O

The CN103417519A A DT O
cinnamyl CN103417519A A NN O
aldehyde CN103417519A A NN O
is CN103417519A A VBZ O
used CN103417519A A VBN O
for CN103417519A A IN O
activating CN103417519A A VBG O
a CN103417519A A DT O
TRPA1 CN103417519A A NNP I-UN
receptor CN103417519A A NN O
in CN103417519A A IN O
a CN103417519A A DT O
TRP CN103417519A A NNP O
protein CN103417519A A NN O
family CN103417519A A NN O
as CN103417519A A IN O
the CN103417519A A DT O
cough CN103417519A A JJ O
agonist CN103417519A A NN O
. CN103417519A A . O

Indoles US20120029016 T NNS O
Useful US20120029016 T NNP O
in US20120029016 T IN O
the US20120029016 T DT O
Treatment US20120029016 T NNP O
of US20120029016 T IN O
Inflammation US20120029016 T NNP O
. US20120029016 T . O

There US20120029016 A EX O
is US20120029016 A VBZ O
provided US20120029016 A JJ O
compounds US20120029016 A NNS O
of US20120029016 A IN O
formula US20120029016 A NN O
I US20120029016 A PRP O
, US20120029016 A , O
wherein US20120029016 A VBD O
ring US20120029016 A VBG O
R1a US20120029016 A NNP O
to US20120029016 A TO O
R1c US20120029016 A NNP O
, US20120029016 A , O
R2a US20120029016 A NNP O
to US20120029016 A TO O
R2e US20120029016 A NNP O
, US20120029016 A , O
and US20120029016 A CC O
X US20120029016 A NNP O
have US20120029016 A VBP O
meanings US20120029016 A NNS O
given US20120029016 A VBN O
in US20120029016 A IN O
the US20120029016 A DT O
description US20120029016 A NN O
, US20120029016 A , O
and US20120029016 A CC O
pharmaceutically-acceptable US20120029016 A JJ O
salts US20120029016 A NNS O
thereof US20120029016 A NN O
, US20120029016 A , O
which US20120029016 A WDT O
compounds US20120029016 A VBZ O
are US20120029016 A VBP O
useful US20120029016 A JJ O
in US20120029016 A IN O
the US20120029016 A DT O
treatment US20120029016 A NN O
of US20120029016 A IN O
diseases US20120029016 A NNS O
in US20120029016 A IN O
which US20120029016 A WDT O
inhibition US20120029016 A NN O
of US20120029016 A IN O
leukotriene US20120029016 A JJ I-UN
C4 US20120029016 A NNP I-UN
synthase US20120029016 A NN I-UN
is US20120029016 A VBZ O
desired US20120029016 A VBN O
and/or US20120029016 A RB O
required US20120029016 A VBN O
, US20120029016 A , O
and US20120029016 A CC O
particularly US20120029016 A RB O
in US20120029016 A IN O
the US20120029016 A DT O
treatment US20120029016 A NN O
of US20120029016 A IN O
a US20120029016 A DT O
respiratory US20120029016 A NN O
disorder US20120029016 A NN O
and/or US20120029016 A NN O
inflammation US20120029016 A NN O
. US20120029016 A . O

treatment US20050033051 T NN O
of US20050033051 T IN O
RNA US20050033051 T NNP O
viral US20050033051 T JJ O
infections US20050033051 T NNS O
such US20050033051 T JJ O
as US20050033051 T IN O
HCV US20050033051 T NNP O
, US20050033051 T , O
HBV US20050033051 T NNP O
, US20050033051 T , O
small US20050033051 T JJ O
pox US20050033051 T NN O
, US20050033051 T , O
Ebola US20050033051 T NNP O
, US20050033051 T , O
polio US20050033051 T NN O
, US20050033051 T , O
West US20050033051 T NNP O
Nile US20050033051 T NNP O
, US20050033051 T , O
Coxsackie US20050033051 T NNP O
A US20050033051 T NNP O
and US20050033051 T CC O
B US20050033051 T NNP O
, US20050033051 T , O
Rhino US20050033051 T NNP O
, US20050033051 T , O
and US20050033051 T CC O
Echo US20050033051 T NNP O
viral US20050033051 T JJ O
infection US20050033051 T NN O
using US20050033051 T VBG O
modified US20050033051 T JJ O
nucleotides US20050033051 T NNS O
; US20050033051 T : O
viricides US20050033051 T NNS O
. US20050033051 T . O

Compounds US20050033051 A NNS O
represented US20050033051 A VBN O
by US20050033051 A IN O
the US20050033051 A DT O
formula US20050033051 A NN O
( US20050033051 A ( O
I US20050033051 A PRP O
) US20050033051 A ) O
R US20050033051 A NN O
is US20050033051 A VBZ O
H US20050033051 A NNP O
, US20050033051 A , O
OH US20050033051 A NNP O
, US20050033051 A , O
alkyl US20050033051 A NN O
, US20050033051 A , O
O-alkyl US20050033051 A NNP O
, US20050033051 A , O
CH2—O-alkyl US20050033051 A NNP O
, US20050033051 A , O
( US20050033051 A ( O
CH2 US20050033051 A NNP O
) US20050033051 A ) O
nOH US20050033051 A NN O
, US20050033051 A , O
( US20050033051 A ( O
CH2 US20050033051 A NNP O
) US20050033051 A ) O
nNH2 US20050033051 A NN O
, US20050033051 A , O
( US20050033051 A ( O
CH2 US20050033051 A NNP O
) US20050033051 A ) O
nCONH2 US20050033051 A NN O
, US20050033051 A , O
( US20050033051 A ( O
CH2 US20050033051 A NNP O
) US20050033051 A ) O
nOOOH US20050033051 A NN O
; US20050033051 A : O
R1 US20050033051 A NNP O
is US20050033051 A VBZ O
H US20050033051 A NNP O
, US20050033051 A , O
OH US20050033051 A NNP O
, US20050033051 A , O
alkyl US20050033051 A NN O
, US20050033051 A , O
O-alkyl US20050033051 A NNP O
, US20050033051 A , O
CH2—O-alkyl US20050033051 A NNP O
, US20050033051 A , O
C6H11 US20050033051 A NNP O
, US20050033051 A , O
CH2OH US20050033051 A NNP O
; US20050033051 A : O
R2 US20050033051 A NNP O
is US20050033051 A VBZ O
H US20050033051 A NNP O
, US20050033051 A , O
alkyl US20050033051 A NN O
, US20050033051 A , O
OH US20050033051 A NNP O
, US20050033051 A , O
CH2OH US20050033051 A NNP O
, US20050033051 A , O
CH2—O-alkyl US20050033051 A NNP O
, US20050033051 A , O
CH US20050033051 A NNP O
( US20050033051 A ( O
OH US20050033051 A NNP O
) US20050033051 A ) O
-alkyl US20050033051 A NN O
, US20050033051 A , O
CH US20050033051 A NNP O
( US20050033051 A ( O
OH US20050033051 A NNP O
) US20050033051 A ) O
CH2OH US20050033051 A NNP O
, US20050033051 A , O
CH2-halogen US20050033051 A NNP O
; US20050033051 A : O
R3 US20050033051 A NNP O
and US20050033051 A CC O
R4 US20050033051 A NNP O
independently US20050033051 A RB O
is US20050033051 A VBZ O
H US20050033051 A NNP O
, US20050033051 A , O
OH US20050033051 A NNP O
, US20050033051 A , O
alkyl US20050033051 A NN O
; US20050033051 A : O
Z US20050033051 A NNP O
is US20050033051 A VBZ O
OR5 US20050033051 A NNP O
, US20050033051 A , O
OR6 US20050033051 A NNP O
, US20050033051 A , O
or US20050033051 A CC O
aminoacids US20050033051 A NNS O
and US20050033051 A CC O
esters US20050033051 A NNS O
thereof US20050033051 A VBP O
R5 US20050033051 A NNP O
and US20050033051 A CC O
R6 US20050033051 A NNP O
independently US20050033051 A RB O
is US20050033051 A VBZ O
H US20050033051 A NNP O
, US20050033051 A , O
alkyl US20050033051 A NN O
, US20050033051 A , O
aryl US20050033051 A NN O
, US20050033051 A , O
pivaloyloxymethyl US20050033051 A NN O
, US20050033051 A , O
C US20050033051 A NNP O
( US20050033051 A ( O
R7 US20050033051 A NNP O
) US20050033051 A ) O
2OC US20050033051 A CD O
( US20050033051 A ( O
O US20050033051 A NNP O
) US20050033051 A ) O
X US20050033051 A NNP O
( US20050033051 A ( O
R8 US20050033051 A NNP O
) US20050033051 A ) O
a US20050033051 A DT O
formula US20050033051 A NN O
( US20050033051 A ( O
II US20050033051 A NNP O
) US20050033051 A ) O
, US20050033051 A , O
R7 US20050033051 A NNP O
independently US20050033051 A RB O
is US20050033051 A VBZ O
—H US20050033051 A JJ O
, US20050033051 A , O
C1-C12 US20050033051 A NNP O
alkyl US20050033051 A NN O
, US20050033051 A , O
C5-C12 US20050033051 A NNP O
aryl US20050033051 A NN O
, US20050033051 A , O
C2-C12 US20050033051 A NNP O
alkenyl US20050033051 A NN O
, US20050033051 A , O
C2-C12 US20050033051 A NNP O
alkynyl US20050033051 A NN O
, US20050033051 A , O
C7-C12 US20050033051 A NNP O
alkenylaryl US20050033051 A NN O
, US20050033051 A , O
C7-C12 US20050033051 A NNP O
alkynylaryl US20050033051 A NN O
, US20050033051 A , O
or US20050033051 A CC O
C6-C12 US20050033051 A NNP O
alkaryl US20050033051 A NN O
, US20050033051 A , O
any US20050033051 A DT O
of US20050033051 A IN O
which US20050033051 A WDT O
is US20050033051 A VBZ O
unsubstituted US20050033051 A JJ O
or US20050033051 A CC O
is US20050033051 A VBZ O
substituted US20050033051 A VBN O
with US20050033051 A IN O
1 US20050033051 A CD O
or US20050033051 A CC O
2 US20050033051 A CD O
halo US20050033051 A NN O
, US20050033051 A , O
cyano US20050033051 A NN O
, US20050033051 A , O
azido US20050033051 A NN O
, US20050033051 A , O
nitro US20050033051 A RB O
, US20050033051 A , O
or US20050033051 A CC O
—OR9 US20050033051 A NN O
; US20050033051 A : O
R9 US20050033051 A NNP O
is US20050033051 A VBZ O
C1-C12 US20050033051 A NNP O
alkyl US20050033051 A NN O
, US20050033051 A , O
C2-C12 US20050033051 A NNP O
alkenyl US20050033051 A NN O
, US20050033051 A , O
C2-C12 US20050033051 A NNP O
alkynyl US20050033051 A NN O
or US20050033051 A CC O
C5-C12 US20050033051 A NNP O
aryl US20050033051 A NN O
; US20050033051 A : O
provided US20050033051 A VBD O
that US20050033051 A IN O
at US20050033051 A IN O
least US20050033051 A JJS O
one US20050033051 A CD O
R8 US20050033051 A NNP O
is US20050033051 A VBZ O
not US20050033051 A RB O
H US20050033051 A NNP O
; US20050033051 A : O
and US20050033051 A CC O
a US20050033051 A DT O
is US20050033051 A VBZ O
1 US20050033051 A CD O
when US20050033051 A WRB O
X US20050033051 A NN O
is US20050033051 A VBZ O
CH2 US20050033051 A NNP O
, US20050033051 A , O
or US20050033051 A CC O
direct US20050033051 A JJ O
bond US20050033051 A NN O
, US20050033051 A , O
or US20050033051 A CC O
1 US20050033051 A CD O
or US20050033051 A CC O
2 US20050033051 A CD O
when US20050033051 A WRB O
X US20050033051 A NN O
is US20050033051 A VBZ O
N US20050033051 A NNP O
with US20050033051 A IN O
the US20050033051 A DT O
proviso US20050033051 A NN O
that US20050033051 A IN O
when US20050033051 A WRB O
a US20050033051 A DT O
is US20050033051 A VBZ O
2 US20050033051 A CD O
and US20050033051 A CC O
X US20050033051 A NNP O
is US20050033051 A VBZ O
N US20050033051 A NNP O
, US20050033051 A , O
( US20050033051 A ( O
a US20050033051 A DT O
) US20050033051 A ) O
two US20050033051 A CD O
N-linked US20050033051 A JJ O
R US20050033051 A NNP O
groups US20050033051 A NNS O
can US20050033051 A MD O
be US20050033051 A VB O
taken US20050033051 A VBN O
together US20050033051 A RB O
to US20050033051 A TO O
form US20050033051 A VB O
a US20050033051 A DT O
carbocyclic US20050033051 A NN O
or US20050033051 A CC O
oxygen US20050033051 A NN O
containing US20050033051 A VBG O
heterocycle US20050033051 A NN O
, US20050033051 A , O
( US20050033051 A ( O
b US20050033051 A NN O
) US20050033051 A ) O
one US20050033051 A CD O
N-linked US20050033051 A JJ O
R8 US20050033051 A NNP O
additionally US20050033051 A RB O
can US20050033051 A MD O
be US20050033051 A VB O
—OR9 US20050033051 A VBN O
or US20050033051 A CC O
( US20050033051 A ( O
c US20050033051 A NN O
) US20050033051 A ) O
both US20050033051 A DT O
N-linked US20050033051 A JJ O
R8 US20050033051 A NNP O
groups US20050033051 A NNS O
can US20050033051 A MD O
be US20050033051 A VB O
—H US20050033051 A VBN O
; US20050033051 A : O
R10 US20050033051 A NNP O
is US20050033051 A VBZ O
H US20050033051 A NNP O
or US20050033051 A CC O
C1-C8 US20050033051 A NNP O
alkyl US20050033051 A NN O
; US20050033051 A : O
R11 US20050033051 A NNP O
is US20050033051 A VBZ O
selected US20050033051 A VBN O
from US20050033051 A IN O
H US20050033051 A NNP O
, US20050033051 A , O
alkyl US20050033051 A NN O
, US20050033051 A , O
alkenyl US20050033051 A NN O
, US20050033051 A , O
alkynyl US20050033051 A NN O
, US20050033051 A , O
aryl US20050033051 A NN O
, US20050033051 A , O
acyloxyalkyl US20050033051 A NN O
, US20050033051 A , O
and US20050033051 A CC O
pivaloyloxyalkyl US20050033051 A NN O
n US20050033051 A NN O
is US20050033051 A VBZ O
1-5 US20050033051 A JJ O
m US20050033051 A NN O
is US20050033051 A VBZ O
0 US20050033051 A CD O
to US20050033051 A TO O
5 US20050033051 A CD O
X US20050033051 A NN O
is US20050033051 A VBZ O
S US20050033051 A NNP O
, US20050033051 A , O
N US20050033051 A NNP O
( US20050033051 A ( O
R8 US20050033051 A NNP O
) US20050033051 A ) O
or US20050033051 A CC O
direct US20050033051 A JJ O
bond US20050033051 A NN O
Y US20050033051 A NNP O
is US20050033051 A VBZ O
O US20050033051 A NNP O
, US20050033051 A , O
S US20050033051 A NNP O
, US20050033051 A , O
N US20050033051 A NNP O
( US20050033051 A ( O
R8 US20050033051 A NNP O
) US20050033051 A ) O
, US20050033051 A , O
and US20050033051 A CC O
CHR1 US20050033051 A NNP O
B US20050033051 A NNP O
is US20050033051 A VBZ O
selected US20050033051 A VBN O
from US20050033051 A IN O
the US20050033051 A DT O
group US20050033051 A NN O
consisting US20050033051 A VBG O
of US20050033051 A IN O
adenine US20050033051 A NN O
, US20050033051 A , O
guanine US20050033051 A NN O
, US20050033051 A , O
cytosine US20050033051 A NN O
, US20050033051 A , O
uracil US20050033051 A NN O
, US20050033051 A , O
thymine US20050033051 A NN O
, US20050033051 A , O
modified US20050033051 A VBN O
purines US20050033051 A NNS O
and US20050033051 A CC O
pyrimidines US20050033051 A NNS O
such US20050033051 A JJ O
as US20050033051 A IN O
inosin-9-yl US20050033051 A JJ O
, US20050033051 A , O
2-amino-purin-9-yl US20050033051 A JJ O
, US20050033051 A , O
2amino-6-chloro-purin-9-yl US20050033051 A JJ O
, US20050033051 A , O
2-6-diamino-purin-9-yl US20050033051 A JJ O
, US20050033051 A , O
3-carboxamido-1 US20050033051 A JJ O
, US20050033051 A , O
2 US20050033051 A CD O
, US20050033051 A , O
4-triazol-1-yl US20050033051 A JJ O
, US20050033051 A , O
3-deaza-adenin-9-yl US20050033051 A JJ O
, US20050033051 A , O
3-deaza-guanin-9-yl US20050033051 A JJ O
, US20050033051 A , O
3-deaza-inosin-9-yl US20050033051 A JJ O
, US20050033051 A , O
3-deaza-2-amino-purin-9-yl US20050033051 A JJ O
, US20050033051 A , O
3-deaza-2-amino-6-chloro-purin-9-yl US20050033051 A JJ O
, US20050033051 A , O
3-deaza-2 US20050033051 A JJ O
, US20050033051 A , O
6-diamino-purin-9-yl US20050033051 A JJ O
, US20050033051 A , O
7-deaza-adenin-9-yl US20050033051 A JJ O
, US20050033051 A , O
7-deaza-guanin-9-yl US20050033051 A JJ O
, US20050033051 A , O
7-deaza-inosin-9-yl US20050033051 A JJ O
, US20050033051 A , O
7-deaza-2-amino-purin-9-yl US20050033051 A JJ O
, US20050033051 A , O
7-deaza-2-amino-6-chloro-purin-9-yl US20050033051 A JJ O
, US20050033051 A , O
7-deaza-2-6-diamino-purin-9-yl US20050033051 A JJ O
, US20050033051 A , O
7-deaza-8-aza-adenin-9-yl US20050033051 A JJ O
, US20050033051 A , O
7-deaza-8-aza-guanin-9-yl US20050033051 A JJ O
, US20050033051 A , O
7-deaza-8-aza-inosnin-9-yl US20050033051 A JJ O
, US20050033051 A , O
7-deaza-8-aza-2-amino-purin-9-yl US20050033051 A JJ O
, US20050033051 A , O
7-deaza-8-aza-2-amino-6-chloro-purin-9-yl US20050033051 A JJ O
, US20050033051 A , O
7-deaza-8-aza-2-6-diamino-purin-9-yl US20050033051 A JJ O
, US20050033051 A , O
-8-aza-adenin-9-yl US20050033051 A NNP O
, US20050033051 A , O
-8-aza-guanin-9-yl US20050033051 A NNP O
, US20050033051 A , O
-8-aza-inosnin-9-yl US20050033051 A NNP O
, US20050033051 A , O
-8-aza-2-amino-purin-9-yl US20050033051 A NNP O
, US20050033051 A , O
-8-aza-2-amino-6-chloro-purin-9-yl US20050033051 A NNP O
, US20050033051 A , O
-8-aza-2-6-diamino-purin-9-yl US20050033051 A NNP O
, US20050033051 A , O
5-aza-thymin-1-yl US20050033051 A JJ O
, US20050033051 A , O
5-aza-cytosin-1-yl US20050033051 A JJ O
, US20050033051 A , O
5-aza-uracil-1-yl US20050033051 A JJ O
, US20050033051 A , O
6-aza-thymin-1-yl US20050033051 A JJ O
, US20050033051 A , O
6-aza-cytosin-1-yl US20050033051 A JJ O
, US20050033051 A , O
6-aza-uracil-1-yl US20050033051 A JJ O
, US20050033051 A , O
2-thiouracil-1-yl US20050033051 A JJ O
, US20050033051 A , O
4-thiouracil-1-yl US20050033051 A JJ O
, US20050033051 A , O
2 US20050033051 A CD O
thiocytosine-1-yl US20050033051 A NN O
, US20050033051 A , O
uracil-5-yl US20050033051 A JJ O
, US20050033051 A , O
2-thiouracil-5-yl US20050033051 A JJ O
, US20050033051 A , O
4-thiouracil-5-yl US20050033051 A JJ O
, US20050033051 A , O
substituted US20050033051 A JJ O
pyridine US20050033051 A NN O
derivatives US20050033051 A NNS O
such US20050033051 A JJ O
as US20050033051 A IN O
6-azauracil US20050033051 A JJ O
, US20050033051 A , O
and US20050033051 A CC O
azacyzosine US20050033051 A NN O
. US20050033051 A . O

In US20050033051 A IN O
general US20050033051 A JJ O
, US20050033051 A , O
attachment US20050033051 A NN O
may US20050033051 A MD O
be US20050033051 A VB O
at US20050033051 A IN O
different US20050033051 A JJ O
positions US20050033051 A NNS O
in US20050033051 A IN O
the US20050033051 A DT O
ring US20050033051 A NN O
at US20050033051 A IN O
nitrogen US20050033051 A NN O
or US20050033051 A CC O
carbon US20050033051 A NN O
. US20050033051 A . O

These US20050033051 A DT O
B US20050033051 A NNP O
ring US20050033051 A VBG O
systems US20050033051 A NNS O
may US20050033051 A MD O
be US20050033051 A VB O
substituted US20050033051 A VBN O
with US20050033051 A IN O
halo US20050033051 A NN O
, US20050033051 A , O
alkyl US20050033051 A NN O
, US20050033051 A , O
substituted US20050033051 A VBN O
alkyl US20050033051 A NN O
( US20050033051 A ( O
F US20050033051 A NNP O
, US20050033051 A , O
Cl US20050033051 A NNP O
, US20050033051 A , O
Br US20050033051 A NNP O
, US20050033051 A , O
I US20050033051 A PRP O
, US20050033051 A , O
OH US20050033051 A NNP O
) US20050033051 A ) O
, US20050033051 A , O
NH2 US20050033051 A NNP O
, US20050033051 A , O
N3 US20050033051 A NNP O
, US20050033051 A , O
aryl US20050033051 A NN O
, US20050033051 A , O
substituted US20050033051 A VBN O
aryl US20050033051 A NN O
( US20050033051 A ( O
F US20050033051 A NNP O
, US20050033051 A , O
Cl US20050033051 A NNP O
, US20050033051 A , O
Br US20050033051 A NNP O
, US20050033051 A , O
I US20050033051 A PRP O
, US20050033051 A , O
OH US20050033051 A NNP O
, US20050033051 A , O
NH2 US20050033051 A NNP O
) US20050033051 A ) O
, US20050033051 A , O
aralkyl US20050033051 A RB O
; US20050033051 A : O
and US20050033051 A CC O
pharmaceutically US20050033051 A RB O
acceptable US20050033051 A JJ O
salts US20050033051 A NNS O
thereof US20050033051 A NN O
and US20050033051 A CC O
prodrugs US20050033051 A NNS O
thereof US20050033051 A NNS O
are US20050033051 A VBP O
provided US20050033051 A VBN O
. US20050033051 A . O

Amino US20110313042 T NNP O
Acid US20110313042 T NNP O
Compositions US20110313042 T NNP O
. US20110313042 T . O

Polymer-based US20100104618 T JJ O
surgically US20100104618 T RB O
implantable US20100104618 T JJ O
haloperidol US20100104618 T JJ O
delivery US20100104618 T NN O
systems US20100104618 T NNS O
and US20100104618 T CC O
methods US20100104618 T NNS O
for US20100104618 T IN O
their US20100104618 T PRP$ O
production US20100104618 T NN O
and US20100104618 T CC O
use US20100104618 T NN O
. US20100104618 T . O

Unsaturated CA2144312C T VBN O
aliphatic CA2144312C T JJ O
dicarboxylic CA2144312C T JJ O
acids CA2144312C T NNS O
. CA2144312C T . O

Disclosed CA2144312C A VBN O
are CA2144312C A VBP O
certain CA2144312C A JJ O
novel CA2144312C A JJ O
polyunsaturated CA2144312C A VBN O
dioic CA2144312C A NN O
acids CA2144312C A NNS O
having CA2144312C A VBG O
between CA2144312C A IN O
8 CA2144312C A CD O
and CA2144312C A CC O
16 CA2144312C A CD O
carbon CA2144312C A NN O
atoms CA2144312C A NNS O
( CA2144312C A ( O
inclusive CA2144312C A JJ O
) CA2144312C A ) O
, CA2144312C A , O
excluding CA2144312C A VBG O
those CA2144312C A DT O
compounds CA2144312C A NNS O
in CA2144312C A IN O
the CA2144312C A DT O
group CA2144312C A NN O
consisting CA2144312C A VBG O
of CA2144312C A IN O
: CA2144312C A : O
2,5 CA2144312C A CD O
octadienedioic CA2144312C A JJ O
acid CA2144312C A NN O
; CA2144312C A : O
1,7 CA2144312C A CD O
octadienedioic CA2144312C A IN O
acid CA2144312C A NN O
; CA2144312C A : O
2,4,6 CA2144312C A CD O
octatrienedioic CA2144312C A IN O
acid CA2144312C A NN O
; CA2144312C A : O
and CA2144312C A CC O
1,3,5,7 CA2144312C A CD O
nonatetraenedioic CA2144312C A JJ O
acid CA2144312C A NN O
; CA2144312C A : O
2,5,8 CA2144312C A CD O
decatrienedioic CA2144312C A NN O
acid CA2144312C A NN O
; CA2144312C A : O
3,6 CA2144312C A CD O
dodecadienedioic CA2144312C A NN O
acid CA2144312C A NN O
; CA2144312C A : O
3,13 CA2144312C A CD O
hexadecadienedioic CA2144312C A NN O
acid CA2144312C A NN O
. CA2144312C A . O

Also CA2144312C A RB O
disclosed CA2144312C A VBN O
are CA2144312C A VBP O
pharmaceutical CA2144312C A JJ O
or CA2144312C A CC O
cosmetic CA2144312C A JJ O
compositions CA2144312C A NNS O
comprising CA2144312C A VBG O
unsaturated CA2144312C A JJ O
dioic CA2144312C A JJ O
acids CA2144312C A NNS O
and CA2144312C A CC O
certain CA2144312C A JJ O
of CA2144312C A IN O
their CA2144312C A PRP$ O
derivatives CA2144312C A NNS O
. CA2144312C A . O

Also CA2144312C A RB O
disclosed CA2144312C A VBN O
are CA2144312C A VBP O
methods CA2144312C A NNS O
of CA2144312C A IN O
treating CA2144312C A VBG O
human CA2144312C A JJ O
skin CA2144312C A NN O
and CA2144312C A CC O
a CA2144312C A DT O
method CA2144312C A NN O
of CA2144312C A IN O
preparing CA2144312C A VBG O
unsaturated CA2144312C A JJ O
dioic CA2144312C A JJ O
acids CA2144312C A NNS O
. CA2144312C A . O

Micronutrient US20110305775 T NNP O
Supplement US20110305775 T NNP O
Dispensing US20110305775 T NNP O
Package US20110305775 T NNP O
. US20110305775 T . O

Medical US20110230561 T JJ O
adhesive US20110230561 T JJ O
compositions US20110230561 T NNS O
. US20110230561 T . O

Acetanilide CN101040972A T NNP O
for CN101040972A T IN O
treating CN101040972A T VBG O
rheumatism CN101040972A T NN O
disease CN101040972A T NN O
and CN101040972A T CC O
the CN101040972A T DT O
preparing CN101040972A T NN O
method CN101040972A T NN O
. CN101040972A T . O

Chlorite US8501244 T NNP O
formulations US8501244 T NNS O
and US8501244 T CC O
methods US8501244 T NNS O
of US8501244 T IN O
preparation US8501244 T NN O
and US8501244 T CC O
use US8501244 T NN O
thereof US8501244 T NN O
. US8501244 T . O

Collagen CN101152129A T NN O
produced CN101152129A T VBD O
accelerant CN101152129A T JJ O
, CN101152129A T , O
dressing CN101152129A T VBG O
material CN101152129A T NN O
, CN101152129A T , O
and CN101152129A T CC O
method CN101152129A T NN O
for CN101152129A T IN O
producing CN101152129A T VBG O
collagen CN101152129A T NN O
. CN101152129A T . O

Compositions US7049322 T NNS O
and US7049322 T CC O
formulations US7049322 T NNS O
of US7049322 T IN O
9-nitrocamptothecin US7049322 T JJ O
polymorphs US7049322 T NN O
and US7049322 T CC O
methods US7049322 T NNS O
of US7049322 T IN O
use US7049322 T NN O
therefor US7049322 T NN O
. US7049322 T . O

Diphenyl US20090197883 T NNP O
Substituted US20090197883 T NNP O
Cycloalkanes US20090197883 T NNP O
, US20090197883 T , O
Compositions US20090197883 T NNP O
Containing US20090197883 T NNP O
Such US20090197883 T JJ O
Compounds US20090197883 T NNS O
and US20090197883 T CC O
Methods US20090197883 T NNS O
Of US20090197883 T IN O
Use US20090197883 T NNP O
. US20090197883 T . O

Identification US20080193454 T NN O
of US20080193454 T IN O
Surface-Associated US20080193454 T JJ O
Antigens US20080193454 T NNP O
for US20080193454 T IN O
Tumor US20080193454 T NNP O
Diagnosis US20080193454 T NNP O
and US20080193454 T CC O
Therapy US20080193454 T NNP O
. US20080193454 T . O

Magnetic CN101732583A T JJ O
therapeutic CN101732583A T JJ O
plaster CN101732583A T NN O
for CN101732583A T IN O
activating CN101732583A T VBG O
blood CN101732583A T NN O
circulation CN101732583A T NN O
, CN101732583A T , O
removing CN101732583A T VBG O
blood CN101732583A T NN O
stasis CN101732583A T NN O
and CN101732583A T CC O
inducing CN101732583A T VBG O
menstruation CN101732583A T NN O
to CN101732583A T TO O
relieve CN101732583A T VB O
menalgia CN101732583A T NN O
and CN101732583A T CC O
preparation CN101732583A T NN O
method CN101732583A T NN O
. CN101732583A T . O

Application CN102743401A T NN O
of CN102743401A T IN O
panaxadiol CN102743401A T NN O
saponins CN102743401A T NNS O
fraction CN102743401A T NN O
in CN102743401A T IN O
preparing CN102743401A T VBG O
medicine CN102743401A T NN O
for CN102743401A T IN O
preventing CN102743401A T VBG O
epilepsia CN102743401A T NN O
. CN102743401A T . O

Drug-delivery US20130035754 T NNP O
endovascular US20130035754 T JJ O
stent US20130035754 T NN O
and US20130035754 T CC O
method US20130035754 T NN O
of US20130035754 T IN O
forming US20130035754 T VBG O
the US20130035754 T DT O
same US20130035754 T JJ O
. US20130035754 T . O

Organic CN101007811A T JJ O
amine CN101007811A T NN O
salt CN101007811A T NN O
of CN101007811A T IN O
cephalosporin CN101007811A T NN O
compound CN101007811A T NN O
and CN101007811A T CC O
its CN101007811A T PRP$ O
preparation CN101007811A T NN O
method CN101007811A T NN O
. CN101007811A T . O

Medicine CN103223172A T NNP O
used CN103223172A T VBD O
for CN103223172A T IN O
preventing CN103223172A T VBG O
and CN103223172A T CC O
treating CN103223172A T VBG O
postmenopausal CN103223172A T JJ O
osteoporosis CN103223172A T NN O
. CN103223172A T . O

Dnai WO2008103431A2 T NNP O
- WO2008103431A2 T : O
liposomes WO2008103431A2 T NNS O
. WO2008103431A2 T . O

Preparation CN1562004A T NN O
containing CN1562004A T VBG O
methimazole CN1562004A T NN O
and CN1562004A T CC O
its CN1562004A T PRP$ O
preparing CN1562004A T NN O
method CN1562004A T NN O
. CN1562004A T . O

Topical WO2013083910A3 T JJ O
emulsions WO2013083910A3 T NNS O
based WO2013083910A3 T VBN O
on WO2013083910A3 T IN O
mixtures WO2013083910A3 T NNS O
of WO2013083910A3 T IN O
local WO2013083910A3 T JJ O
eutectic WO2013083910A3 T JJ O
anaesthetics WO2013083910A3 T NNS O
and WO2013083910A3 T CC O
fatty WO2013083910A3 T JJ O
acids WO2013083910A3 T NNS O
as WO2013083910A3 T IN O
analgesics WO2013083910A3 T NNS O
, WO2013083910A3 T , O
antalgics WO2013083910A3 T NNS O
, WO2013083910A3 T , O
or WO2013083910A3 T CC O
as WO2013083910A3 T IN O
sexual WO2013083910A3 T JJ O
retardants WO2013083910A3 T NNS O
. WO2013083910A3 T . O

The WO2013083910A3 A DT O
invention WO2013083910A3 A NN O
relates WO2013083910A3 A VBZ O
to WO2013083910A3 A TO O
novel WO2013083910A3 A VB O
formulations WO2013083910A3 A NNS O
for WO2013083910A3 A IN O
topical WO2013083910A3 A JJ O
local WO2013083910A3 A JJ O
anaesthesia WO2013083910A3 A NN O
and WO2013083910A3 A CC O
for WO2013083910A3 A IN O
the WO2013083910A3 A DT O
use WO2013083910A3 A NN O
thereof WO2013083910A3 A NN O
as WO2013083910A3 A IN O
analgesics WO2013083910A3 A NNS O
, WO2013083910A3 A , O
antalgics WO2013083910A3 A NNS O
, WO2013083910A3 A , O
or WO2013083910A3 A CC O
as WO2013083910A3 A IN O
sexual WO2013083910A3 A JJ O
retardants WO2013083910A3 A NNS O
. WO2013083910A3 A . O

Imidazolyl US7244746 T NNP O
derivatives US7244746 T NNS O
as US7244746 T IN O
corticotropin US7244746 T NN I-UN
releasing US7244746 T VBG I-UN
factor US7244746 T NN I-UN
inhibitors US7244746 T NNS O
. US7244746 T . O

The US7244746 A DT O
present US7244746 A JJ O
invention US7244746 A NN O
relates US7244746 A VBZ O
to US7244746 A TO O
novel US7244746 A VB O
heterocyclic US7244746 A JJ O
antagonists US7244746 A NNS O
of US7244746 A IN O
Formula US7244746 A NNP O
( US7244746 A ( O
I US7244746 A PRP O
) US7244746 A ) O
and US7244746 A CC O
pharmaceutical US7244746 A JJ O
compositions US7244746 A NNS O
comprising US7244746 A VBG O
said US7244746 A VBD O
antagonists US7244746 A NNS O
of US7244746 A IN O
the US7244746 A DT O
corticotropin US7244746 A NN I-UN
releasing US7244746 A VBG I-UN
factor US7244746 A NN I-UN
receptor US7244746 A NN I-UN
( US7244746 A ( O
“CRF US7244746 A NNP O
receptor” US7244746 A NN O
) US7244746 A ) O
useful US7244746 A NN O
for US7244746 A IN O
the US7244746 A DT O
treatment US7244746 A NN O
of US7244746 A IN O
depression US7244746 A NN O
, US7244746 A , O
anxiety US7244746 A NN O
, US7244746 A , O
affective US7244746 A JJ O
disorders US7244746 A NNS O
, US7244746 A , O
feeding US7244746 A VBG O
disorders US7244746 A NNS O
, US7244746 A , O
post-traumatic US7244746 A JJ O
stress US7244746 A NN O
disorder US7244746 A NN O
, US7244746 A , O
headache US7244746 A NN O
, US7244746 A , O
drug US7244746 A NN O
addiction US7244746 A NN O
, US7244746 A , O
inflammatory US7244746 A NN O
disorders US7244746 A NNS O
, US7244746 A , O
drug US7244746 A NN O
or US7244746 A CC O
alcohol US7244746 A NN O
withdrawal US7244746 A NN O
symptoms US7244746 A NNS O
and US7244746 A CC O
other US7244746 A JJ O
conditions US7244746 A NNS O
the US7244746 A DT O
treatment US7244746 A NN O
of US7244746 A IN O
which US7244746 A WDT O
can US7244746 A MD O
be US7244746 A VB O
effected US7244746 A VBN O
by US7244746 A IN O
the US7244746 A DT O
antagonism US7244746 A NN O
of US7244746 A IN O
the US7244746 A DT O
CRF-1 US7244746 A NNP I-UN
receptor US7244746 A NN I-UN
. US7244746 A . O

Spiroindene EP1385514B1 T NNP O
and EP1385514B1 T CC O
spiroindane EP1385514B1 T JJ O
compounds EP1385514B1 T NNS O
. EP1385514B1 T . O

A EP1385514B1 A DT O
compound EP1385514B1 A NN O
of EP1385514B1 A IN O
the EP1385514B1 A DT O
formula EP1385514B1 A NN O
( EP1385514B1 A ( O
I EP1385514B1 A PRP O
) EP1385514B1 A ) O
: EP1385514B1 A : O
( EP1385514B1 A ( O
I EP1385514B1 A PRP O
) EP1385514B1 A ) O
wherein EP1385514B1 A VBP O
Z EP1385514B1 A NNP O
, EP1385514B1 A , O
A EP1385514B1 A NNP O
, EP1385514B1 A , O
B EP1385514B1 A NNP O
, EP1385514B1 A , O
C EP1385514B1 A NNP O
, EP1385514B1 A , O
R1 EP1385514B1 A NNP O
, EP1385514B1 A , O
R2 EP1385514B1 A NNP O
, EP1385514B1 A , O
X1 EP1385514B1 A NNP O
, EP1385514B1 A , O
X2 EP1385514B1 A NNP O
, EP1385514B1 A , O
Q EP1385514B1 A NNP O
and EP1385514B1 A CC O
n EP1385514B1 A RB O
are EP1385514B1 A VBP O
as EP1385514B1 A IN O
disclosed EP1385514B1 A JJ O
herein EP1385514B1 A NN O
. EP1385514B1 A . O

Medicine CN1861082A T NNP O
prepn CN1861082A T NN O
. CN1861082A T . O

of CN1861082A T IN O
compounding CN1861082A T VBG O
deoxypregnene CN1861082A T NN O
contg CN1861082A T NN O
. CN1861082A T . O

non-ionic CN1861082A T JJ O
surfactant CN1861082A T NN O
. CN1861082A T . O

Morpholino US20110034454 T NNP O
pyrimidine US20110034454 T NN O
derivatives US20110034454 T NNS O
and US20110034454 T CC O
their US20110034454 T PRP$ O
use US20110034454 T NN O
in US20110034454 T IN O
therapy US20110034454 T NN O
. US20110034454 T . O

A US20110034454 A DT O
compound US20110034454 A NN O
of US20110034454 A IN O
formula US20110034454 A NN O
( US20110034454 A ( O
I US20110034454 A PRP O
) US20110034454 A ) O
or US20110034454 A CC O
a US20110034454 A DT O
salt US20110034454 A NN O
, US20110034454 A , O
ester US20110034454 A NN O
or US20110034454 A CC O
prodrug US20110034454 A NN O
thereof US20110034454 A NN O
, US20110034454 A , O
processes US20110034454 A NNS O
for US20110034454 A IN O
their US20110034454 A PRP$ O
preparation US20110034454 A NN O
, US20110034454 A , O
pharmaceutical US20110034454 A JJ O
compositions US20110034454 A NNS O
containing US20110034454 A VBG O
them US20110034454 A PRP O
and US20110034454 A CC O
their US20110034454 A PRP$ O
use US20110034454 A NN O
in US20110034454 A IN O
therapy US20110034454 A NN O
, US20110034454 A , O
for US20110034454 A IN O
example US20110034454 A NN O
in US20110034454 A IN O
the US20110034454 A DT O
treatment US20110034454 A NN O
of US20110034454 A IN O
proliferative US20110034454 A JJ O
disease US20110034454 A NN O
such US20110034454 A JJ O
as US20110034454 A IN O
cancer US20110034454 A NN O
and US20110034454 A CC O
particularly US20110034454 A RB O
in US20110034454 A IN O
disease US20110034454 A NN O
mediated US20110034454 A VBN O
by US20110034454 A IN O
an US20110034454 A DT O
mTOR US20110034454 A NN I-UN
kinase US20110034454 A NN I-UN
and/or US20110034454 A VBZ O
one US20110034454 A CD O
or US20110034454 A CC O
more US20110034454 A JJR O
PI3K US20110034454 A NNP I-UN
enzyme US20110034454 A NN O
. US20110034454 A . O

Compositions WO2009032972A1 T NNS O
and WO2009032972A1 T CC O
methods WO2009032972A1 T NNS O
for WO2009032972A1 T IN O
treating WO2009032972A1 T VBG O
immunological WO2009032972A1 T JJ O
and WO2009032972A1 T CC O
inflammatory WO2009032972A1 T JJ O
diseases WO2009032972A1 T NNS O
and WO2009032972A1 T CC O
disorders WO2009032972A1 T NNS O
. WO2009032972A1 T . O

Particular WO2009032972A1 A JJ O
methods WO2009032972A1 A NNS O
and WO2009032972A1 A CC O
compositions WO2009032972A1 A NNS O
comprise WO2009032972A1 A VBP O
the WO2009032972A1 A DT O
administration WO2009032972A1 A NN O
of WO2009032972A1 A IN O
an WO2009032972A1 A DT O
agent WO2009032972A1 A NN O
that WO2009032972A1 A IN O
inhibits WO2009032972A1 A VBZ O
S1P WO2009032972A1 A NNP I-UN
lyase WO2009032972A1 A NN I-UN
activity WO2009032972A1 A NN O
and WO2009032972A1 A CC O
at WO2009032972A1 A IN O
least WO2009032972A1 A JJS O
one WO2009032972A1 A CD O
additional WO2009032972A1 A JJ O
immunosuppressive WO2009032972A1 A JJ O
and/or WO2009032972A1 A NN O
anti-inflammatory WO2009032972A1 A JJ O
agent WO2009032972A1 A NN O
. WO2009032972A1 A . O

1- EP2024354B1 T JJ O
[ EP2024354B1 T NNP O
( EP2024354B1 T ( O
4- EP2024354B1 T JJ O
[ EP2024354B1 T NN O
benzoyl EP2024354B1 T NN O
( EP2024354B1 T ( O
methyl EP2024354B1 T NN O
) EP2024354B1 T ) O
amino EP2024354B1 T NN O
] EP2024354B1 T JJ O
-3- EP2024354B1 T NNP O
( EP2024354B1 T ( O
phenyl EP2024354B1 T NN O
) EP2024354B1 T ) O
butyl EP2024354B1 T NN O
] EP2024354B1 T JJ O
azetidine EP2024354B1 T NN O
derivatives EP2024354B1 T NNS O
for EP2024354B1 T IN O
the EP2024354B1 T DT O
treatment EP2024354B1 T NN O
of EP2024354B1 T IN O
gastrointestinal EP2024354B1 T JJ O
disorders EP2024354B1 T NNS O
1 EP2024354B1 T CD O
. EP2024354B1 T . O

The EP2024354B1 A DT O
compounds EP2024354B1 A NNS O
are EP2024354B1 A VBP O
neurokinin EP2024354B1 A JJ I-UN
( EP2024354B1 A ( I-UN
NK EP2024354B1 A NNP I-UN
) EP2024354B1 A ) I-UN
receptor EP2024354B1 A NN I-UN
antagonists EP2024354B1 A NNS O
. EP2024354B1 A . O

Low-molecular WO2010087207A1 T JJ O
polysulfated WO2010087207A1 T VBD O
hyaluronic WO2010087207A1 T JJ O
acid WO2010087207A1 T NN O
derivative WO2010087207A1 T JJ O
and WO2010087207A1 T CC O
medicine WO2010087207A1 T JJ O
containing WO2010087207A1 T NN O
same WO2010087207A1 T JJ O
. WO2010087207A1 T . O

17Beta-Hydroxysteroid US20100204234 T JJ I-UN
Dehydrogenase US20100204234 T NNP I-UN
Type US20100204234 T NNP I-UN
1 US20100204234 T CD I-UN
Inhibitors US20100204234 T NNS O
for US20100204234 T IN O
the US20100204234 T DT O
Treatment US20100204234 T NNP O
of US20100204234 T IN O
Hormone-Related US20100204234 T NNP O
Diseases US20100204234 T NNP O
. US20100204234 T . O

The US20100204234 A DT O
invention US20100204234 A NN O
relates US20100204234 A VBZ O
to US20100204234 A TO O
the US20100204234 A DT O
use US20100204234 A NN O
of US20100204234 A IN O
non-steroidal US20100204234 A JJ O
17beta-hydroxysteroid US20100204234 A JJ I-UN
dehydrogenase US20100204234 A NN I-UN
type US20100204234 A NN I-UN
1 US20100204234 A CD I-UN
inhibitors US20100204234 A NNS O
for US20100204234 A IN O
the US20100204234 A DT O
treatment US20100204234 A NN O
and US20100204234 A CC O
prophylaxis US20100204234 A NN O
of US20100204234 A IN O
hormone-dependent US20100204234 A JJ O
, US20100204234 A , O
particularly US20100204234 A RB O
estrogen-dependent US20100204234 A JJ O
, US20100204234 A , O
diseases US20100204234 A NNS O
. US20100204234 A . O

Injection CN1943589A T NN O
for CN1943589A T IN O
positioning CN1943589A T VBG O
and CN1943589A T CC O
promoting CN1943589A T VBG O
fat CN1943589A T JJ O
growth CN1943589A T NN O
and CN1943589A T CC O
its CN1943589A T PRP$ O
preparing CN1943589A T NN O
method CN1943589A T NN O
. CN1943589A T . O

Use WO2008086739A1 T NNP O
of WO2008086739A1 T IN O
ursolic WO2008086739A1 T JJ O
acid WO2008086739A1 T NN O
saponin WO2008086739A1 T NN O
, WO2008086739A1 T , O
oleanolic WO2008086739A1 T JJ O
acid WO2008086739A1 T NN O
saponin WO2008086739A1 T NN O
in WO2008086739A1 T IN O
preparation WO2008086739A1 T NN O
of WO2008086739A1 T IN O
increasing WO2008086739A1 T VBG O
leucocyte WO2008086739A1 T JJ O
and/or WO2008086739A1 T NN O
platelet WO2008086739A1 T NN O
medicine WO2008086739A1 T NN O
. WO2008086739A1 T . O

Multiple US20110135732 T JJ O
phase US20110135732 T NN O
cross-linked US20110135732 T JJ O
compositions US20110135732 T NNS O
and US20110135732 T CC O
uses US20110135732 T VBZ O
thereof US20110135732 T NN O
. US20110135732 T . O

Slow CN1857219A T NNP O
released CN1857219A T VBD O
medicine CN1857219A T NN O
prepn CN1857219A T NN O
containing CN1857219A T VBG O
antituberculotic CN1857219A T JJ O
. CN1857219A T . O

Application CN1846698A T NN O
of CN1846698A T IN O
cimetidine CN1846698A T NN O
in CN1846698A T IN O
treating CN1846698A T VBG O
cough-treating CN1846698A T JJ O
medicine CN1846698A T NN O
. CN1846698A T . O

Invisible EP1603499A2 T JJ O
patch EP1603499A2 T NN O
for EP1603499A2 T IN O
the EP1603499A2 T DT O
controlled EP1603499A2 T JJ O
delivery EP1603499A2 T NN O
of EP1603499A2 T IN O
cosmetic EP1603499A2 T JJ O
, EP1603499A2 T , O
dermatological EP1603499A2 T JJ O
, EP1603499A2 T , O
and EP1603499A2 T CC O
pharmaceutical EP1603499A2 T JJ O
active EP1603499A2 T JJ O
ingredients EP1603499A2 T NNS O
onto EP1603499A2 T IN O
the EP1603499A2 T DT O
skin EP1603499A2 T NN O
. EP1603499A2 T . O

Crystal WO2009026790A1 T NNP O
entecavir WO2009026790A1 T CC O
fomulation WO2009026790A1 T NN O
and WO2009026790A1 T CC O
the WO2009026790A1 T DT O
preparation WO2009026790A1 T NN O
method WO2009026790A1 T NN O
thereof WO2009026790A1 T NN O
. WO2009026790A1 T . O

Application CN103006675A T NN O
of CN103006675A T IN O
doxycycline CN103006675A T NN O
in CN103006675A T IN O
preparing CN103006675A T VBG O
medicament CN103006675A T NN O
for CN103006675A T IN O
treating CN103006675A T VBG O
epithelial CN103006675A T JJ O
ovarian CN103006675A T JJ O
cancer CN103006675A T NN O
. CN103006675A T . O

The CN103006675A A DT O
invention CN103006675A A NN O
relates CN103006675A A VBZ O
to CN103006675A A TO O
the CN103006675A A DT O
technical CN103006675A A JJ O
field CN103006675A A NN O
of CN103006675A A IN O
medicines CN103006675A A NNS O
, CN103006675A A , O
and CN103006675A A CC O
in CN103006675A A IN O
particular CN103006675A A JJ O
relates CN103006675A A NNS O
to CN103006675A A TO O
a CN103006675A A DT O
novel CN103006675A A JJ O
application CN103006675A A NN O
of CN103006675A A IN O
doxycycline CN103006675A A NN O
in CN103006675A A IN O
preparing CN103006675A A VBG O
a CN103006675A A DT O
medicament CN103006675A A NN O
for CN103006675A A IN O
treating CN103006675A A VBG O
epithelial CN103006675A A JJ O
ovarian CN103006675A A JJ O
cancer CN103006675A A NN O
. CN103006675A A . O

Animal CN103006675A A JJ O
experiments CN103006675A A NNS O
and CN103006675A A CC O
in-vitro CN103006675A A JJ O
cell CN103006675A A NN O
experiments CN103006675A A NNS O
prove CN103006675A A VBP O
that CN103006675A A IN O
doxycycline CN103006675A A NN O
can CN103006675A A MD O
inhibit CN103006675A A VB O
multiplication CN103006675A A NN O
and CN103006675A A CC O
invasion CN103006675A A NN O
of CN103006675A A IN O
ovarian CN103006675A A JJ O
cancer CN103006675A A NN O
cells CN103006675A A NNS O
, CN103006675A A , O
can CN103006675A A MD O
prevent CN103006675A A VB O
epithelial CN103006675A A JJ O
ovarian CN103006675A A JJ O
cancer CN103006675A A NN O
cells CN103006675A A NNS O
from CN103006675A A IN O
transferring CN103006675A A VBG O
, CN103006675A A , O
can CN103006675A A MD O
promote CN103006675A A VB O
apoptosis CN103006675A A NN O
of CN103006675A A IN O
epithelial CN103006675A A JJ O
ovarian CN103006675A A JJ O
cancer CN103006675A A NN O
cells CN103006675A A NNS O
, CN103006675A A , O
has CN103006675A A VBZ O
a CN103006675A A DT O
remarkable CN103006675A A JJ O
inhibition CN103006675A A NN O
effect CN103006675A A NN O
to CN103006675A A TO O
ovarian CN103006675A A JJ O
cancer CN103006675A A NN O
cells CN103006675A A NNS O
, CN103006675A A , O
in CN103006675A A IN O
particular CN103006675A A JJ O
platinum-based CN103006675A A JJ O
drug-resistance CN103006675A A NN O
ovarian CN103006675A A JJ O
cancer CN103006675A A NN O
cells CN103006675A A NNS O
, CN103006675A A , O
and CN103006675A A CC O
can CN103006675A A MD O
inhibit CN103006675A A VB O
growth CN103006675A A NN O
of CN103006675A A IN O
ovarian CN103006675A A JJ O
cancer CN103006675A A NN O
tissues CN103006675A A NNS O
and CN103006675A A CC O
formation CN103006675A A NN O
of CN103006675A A IN O
ascites CN103006675A A NNS O
, CN103006675A A , O
so CN103006675A A IN O
that CN103006675A A DT O
doxycycline CN103006675A A NN O
can CN103006675A A MD O
be CN103006675A A VB O
used CN103006675A A VBN O
for CN103006675A A IN O
preparing CN103006675A A VBG O
a CN103006675A A DT O
medicament CN103006675A A NN O
for CN103006675A A IN O
treating CN103006675A A VBG O
epithelial CN103006675A A JJ O
ovarian CN103006675A A JJ O
cancer CN103006675A A NN O
. CN103006675A A . O

The CN103006675A A DT O
invention CN103006675A A NN O
provides CN103006675A A VBZ O
a CN103006675A A DT O
novel CN103006675A A JJ O
application CN103006675A A NN O
to CN103006675A A TO O
doxycycline CN103006675A A VB O
, CN103006675A A , O
and CN103006675A A CC O
compared CN103006675A A VBN O
with CN103006675A A IN O
other CN103006675A A JJ O
chemotherapeutic CN103006675A A JJ O
drugs CN103006675A A NNS O
, CN103006675A A , O
doxycycline CN103006675A A NN O
has CN103006675A A VBZ O
the CN103006675A A DT O
advantages CN103006675A A NNS O
of CN103006675A A IN O
convenient CN103006675A A JJ O
administration CN103006675A A NN O
and CN103006675A A CC O
small CN103006675A A JJ O
side CN103006675A A NN O
effect CN103006675A A NN O
in CN103006675A A IN O
the CN103006675A A DT O
field CN103006675A A NN O
of CN103006675A A IN O
treating CN103006675A A VBG O
epithelial CN103006675A A JJ O
ovarian CN103006675A A JJ O
cancer CN103006675A A NN O
. CN103006675A A . O

Fistula CN102058620A T NNP O
affused CN102058620A T VBD O
liquid CN102058620A T JJ O
medicine CN102058620A T NN O
for CN102058620A T IN O
anal CN102058620A T JJ O
fistula CN102058620A T NN O
. CN102058620A T . O

Candesartan CN102885810A T NNP O
cilexetil CN102885810A T VBD O
double-release CN102885810A T JJ O
capsule CN102885810A T NN O
and CN102885810A T CC O
preparation CN102885810A T NN O
method CN102885810A T NN O
thereof CN102885810A T NN O
. CN102885810A T . O

Piperazine WO2014146747A1 T NNP O
derivatives WO2014146747A1 T NNS O
as WO2014146747A1 T IN O
fasn WO2014146747A1 T JJ I-UN
inhibitors WO2014146747A1 T NNS O
. WO2014146747A1 T . O

Compounds WO2014146747A1 A NNS O
of WO2014146747A1 A IN O
the WO2014146747A1 A DT O
formula WO2014146747A1 A NN O
( WO2014146747A1 A ( O
I WO2014146747A1 A PRP O
) WO2014146747A1 A ) O
, WO2014146747A1 A , O
in WO2014146747A1 A IN O
which WO2014146747A1 A WDT O
R WO2014146747A1 A NNP O
, WO2014146747A1 A , O
X1 WO2014146747A1 A NNP O
, WO2014146747A1 A , O
X2 WO2014146747A1 A NNP O
, WO2014146747A1 A , O
X3 WO2014146747A1 A NNP O
, WO2014146747A1 A , O
X4 WO2014146747A1 A NNP O
, WO2014146747A1 A , O
R1 WO2014146747A1 A NNP O
, WO2014146747A1 A , O
R2 WO2014146747A1 A NNP O
and WO2014146747A1 A CC O
q WO2014146747A1 A RB O
have WO2014146747A1 A VBP O
the WO2014146747A1 A DT O
meanings WO2014146747A1 A NNS O
indicated WO2014146747A1 A VBD O
in WO2014146747A1 A IN O
Claim WO2014146747A1 A NNP O
1 WO2014146747A1 A CD O
, WO2014146747A1 A , O
are WO2014146747A1 A VBP O
inhibitors WO2014146747A1 A NNS O
of WO2014146747A1 A IN O
fatty WO2014146747A1 A JJ I-UN
acid WO2014146747A1 A JJ I-UN
synthase WO2014146747A1 A NN I-UN
, WO2014146747A1 A , O
and WO2014146747A1 A CC O
can WO2014146747A1 A MD O
be WO2014146747A1 A VB O
employed WO2014146747A1 A VBN O
, WO2014146747A1 A , O
inter WO2014146747A1 A NN O
alia WO2014146747A1 A NNS O
, WO2014146747A1 A , O
for WO2014146747A1 A IN O
the WO2014146747A1 A DT O
treatment WO2014146747A1 A NN O
of WO2014146747A1 A IN O
diseases WO2014146747A1 A NNS O
such WO2014146747A1 A JJ O
as WO2014146747A1 A IN O
cancer WO2014146747A1 A NN O
, WO2014146747A1 A , O
cardiovascular WO2014146747A1 A JJ O
diseases WO2014146747A1 A NNS O
, WO2014146747A1 A , O
central WO2014146747A1 A JJ O
nervous WO2014146747A1 A JJ O
system WO2014146747A1 A NN O
injury WO2014146747A1 A NN O
and WO2014146747A1 A CC O
different WO2014146747A1 A JJ O
forms WO2014146747A1 A NNS O
of WO2014146747A1 A IN O
inflammation WO2014146747A1 A NN O
. WO2014146747A1 A . O

Application CN103655592A T NN O
of CN103655592A T IN O
astragaloside CN103655592A T JJ O
IV CN103655592A T NNP O
in CN103655592A T IN O
preparing CN103655592A T VBG O
medicine CN103655592A T NN O
for CN103655592A T IN O
treating CN103655592A T VBG O
HAAF CN103655592A T NNP O
( CN103655592A T ( O
hypoglycemia CN103655592A T NN O
associated CN103655592A T VBN O
autonomic CN103655592A T JJ O
failure CN103655592A T NN O
) CN103655592A T ) O
diabetic CN103655592A T JJ O
complications CN103655592A T NNS O
. CN103655592A T . O

Treatment CA2776971A1 T NN O
with CA2776971A1 T IN O
cholinergic CA2776971A1 T JJ O
agonists CA2776971A1 T NNS O
. CA2776971A1 T . O

Methods CA2776971A1 A NNS O
of CA2776971A1 A IN O
treating CA2776971A1 A VBG O
disorders CA2776971A1 A NNS O
with CA2776971A1 A IN O
cholinergic CA2776971A1 A JJ O
agonists CA2776971A1 A NNS O
for CA2776971A1 A IN O
example CA2776971A1 A NN O
, CA2776971A1 A , O
muscarinic CA2776971A1 A JJ O
receptor CA2776971A1 A NN O
agonists CA2776971A1 A NNS O
such CA2776971A1 A JJ O
as CA2776971A1 A IN O
pilocarpine CA2776971A1 A NN O
and CA2776971A1 A CC O
cevimeline CA2776971A1 A NN O
are CA2776971A1 A VBP O
provided CA2776971A1 A VBN O
. CA2776971A1 A . O

In CA2776971A1 A IN O
particular CA2776971A1 A JJ O
, CA2776971A1 A , O
methods CA2776971A1 A NNS O
of CA2776971A1 A IN O
treating CA2776971A1 A VBG O
and/or CA2776971A1 A JJ O
preventing CA2776971A1 A VBG O
interstitial CA2776971A1 A JJ O
cystitis CA2776971A1 A NN O
, CA2776971A1 A , O
yeast CA2776971A1 A JJ O
infections CA2776971A1 A NNS O
, CA2776971A1 A , O
urinary CA2776971A1 A JJ O
tract CA2776971A1 A NN O
infections CA2776971A1 A NNS O
, CA2776971A1 A , O
atrophic CA2776971A1 A JJ O
vaginitis CA2776971A1 A NN O
, CA2776971A1 A , O
vaginal CA2776971A1 A JJ O
dryness CA2776971A1 A NN O
, CA2776971A1 A , O
and CA2776971A1 A CC O
sexual CA2776971A1 A JJ O
dysfunction CA2776971A1 A NN O
associated CA2776971A1 A VBN O
with CA2776971A1 A IN O
vaginal CA2776971A1 A JJ O
dryness CA2776971A1 A NN O
by CA2776971A1 A IN O
administering CA2776971A1 A VBG O
a CA2776971A1 A DT O
cholinergic CA2776971A1 A JJ O
agonist CA2776971A1 A NN O
to CA2776971A1 A TO O
the CA2776971A1 A DT O
subject CA2776971A1 A NN O
suffering CA2776971A1 A VBG O
from CA2776971A1 A IN O
the CA2776971A1 A DT O
disorders CA2776971A1 A NNS O
are CA2776971A1 A VBP O
provided CA2776971A1 A VBN O
. CA2776971A1 A . O

In CA2776971A1 A IN O
addition CA2776971A1 A NN O
, CA2776971A1 A , O
intra- CA2776971A1 A JJ O
vaginal CA2776971A1 A JJ O
administration CA2776971A1 A NN O
of CA2776971A1 A IN O
cholinergic CA2776971A1 A JJ O
agonists CA2776971A1 A NNS O
such CA2776971A1 A JJ O
as CA2776971A1 A IN O
muscarinic CA2776971A1 A JJ O
receptor CA2776971A1 A NN O
agonists CA2776971A1 A NNS O
to CA2776971A1 A TO O
patients CA2776971A1 A NNS O
suffering CA2776971A1 A VBG O
from CA2776971A1 A IN O
interstitial CA2776971A1 A JJ O
cystitis CA2776971A1 A NN O
, CA2776971A1 A , O
vaginal CA2776971A1 A JJ O
dryness CA2776971A1 A NN O
, CA2776971A1 A , O
and CA2776971A1 A CC O
sexual CA2776971A1 A JJ O
dysfunction CA2776971A1 A NN O
associated CA2776971A1 A VBN O
with CA2776971A1 A IN O
vaginal CA2776971A1 A JJ O
dryness CA2776971A1 A NN O
is CA2776971A1 A VBZ O
also CA2776971A1 A RB O
provided CA2776971A1 A VBN O
. CA2776971A1 A . O

Non-steroidal CN101011374A T JJ O
analgesic-antipyretic CN101011374A T JJ O
medicament CN101011374A T NN O
paracetamol CN101011374A T NN O
containing CN101011374A T VBG O
carboxyl CN101011374A T NN O
group CN101011374A T NN O
. CN101011374A T . O

Bioresorbable US20090074837 T JJ O
Calcium-Deficient US20090074837 T JJ O
Hydroxyapatite US20090074837 T NNP O
Hydrogel US20090074837 T NNP O
Composite US20090074837 T NNP O
. US20090074837 T . O

Chinese CN101401852A T JJ O
and CN101401852A T CC O
western CN101401852A T JJ O
combined CN101401852A T VBN O
externally CN101401852A T RB O
applied CN101401852A T JJ O
formulation CN101401852A T NN O
for CN101401852A T IN O
treating CN101401852A T VBG O
empyrosis CN101401852A T NN O
. CN101401852A T . O

A EP2347757A1 T DT O
natural EP2347757A1 T JJ O
allicin EP2347757A1 T NN O
tablet EP2347757A1 T NN O
and EP2347757A1 T CC O
preparation EP2347757A1 T NN O
method EP2347757A1 T NN O
thereof EP2347757A1 T NN O
. EP2347757A1 T . O

5-HT4 US20060094702 T JJ O
receptor US20060094702 T NN O
antagonists US20060094702 T NNS O
. US20060094702 T . O

Peptide WO2006131303A3 T NNP O
deformylase WO2006131303A3 T NN O
( WO2006131303A3 T ( O
pdf WO2006131303A3 T NN O
) WO2006131303A3 T ) O
inhibitors WO2006131303A3 T VBZ O
4 WO2006131303A3 T CD O
. WO2006131303A3 T . O

Norcantharidin CN1927169A T NNP O
magnetic CN1927169A T JJ O
nano CN1927169A T NN O
microsphere CN1927169A T RB O
and CN1927169A T CC O
its CN1927169A T PRP$ O
preparing CN1927169A T NN O
process CN1927169A T NN O
. CN1927169A T . O

The CN1927169A A DT O
invention CN1927169A A NN O
belongs CN1927169A A VBZ O
to CN1927169A A TO O
the CN1927169A A DT O
field CN1927169A A NN O
of CN1927169A A IN O
composite CN1927169A A JJ O
materials CN1927169A A NNS O
and CN1927169A A CC O
biomedical CN1927169A A JJ O
technology CN1927169A A NN O
, CN1927169A A , O
specifically CN1927169A A RB O
involves CN1927169A A VBZ O
Norcantharidin-magnetic CN1927169A A JJ O
nanoparticles CN1927169A A NNS O
and CN1927169A A CC O
their CN1927169A A PRP$ O
preparation CN1927169A A NN O
methods CN1927169A A NNS O
. CN1927169A A . O

The CN1927169A A DT O
invention CN1927169A A NN O
take CN1927169A A VB O
the CN1927169A A DT O
biodegradable CN1927169A A JJ O
polymers CN1927169A A NNS O
as CN1927169A A IN O
carriers CN1927169A A NNS O
, CN1927169A A , O
nanometer CN1927169A A RB O
Fe304 CN1927169A A NNP O
as CN1927169A A IN O
magnetic CN1927169A A JJ O
seeds CN1927169A A NNS O
, CN1927169A A , O
use CN1927169A A VBP O
hybrid CN1927169A A JJ O
emulsion CN1927169A A NN O
-solvent CN1927169A A NN O
volatilixation CN1927169A A NN O
method CN1927169A A NN O
( CN1927169A A ( O
water-oil-water CN1927169A A NN O
) CN1927169A A ) O
to CN1927169A A TO O
preparation CN1927169A A VB O
packing CN1927169A A VBG O
parcels CN1927169A A NNS O
Norcantharidin CN1927169A A NNP O
magnetic CN1927169A A JJ O
nanoparticles CN1927169A A NNS O
. CN1927169A A . O

The CN1927169A A DT O
main CN1927169A A JJ O
technological CN1927169A A JJ O
process CN1927169A A NN O
includes CN1927169A A VBZ O
the CN1927169A A DT O
preparation CN1927169A A NN O
, CN1927169A A , O
admixture CN1927169A A NN O
and CN1927169A A CC O
re- CN1927169A A JJ O
emulsification CN1927169A A NN O
of CN1927169A A IN O
two CN1927169A A CD O
colostric CN1927169A A JJ O
fluid CN1927169A A NN O
, CN1927169A A , O
solvent CN1927169A A JJ O
removal CN1927169A A NN O
, CN1927169A A , O
removal CN1927169A A NN O
of CN1927169A A IN O
non-encapsulationed CN1927169A A JJ O
drug CN1927169A A NN O
and CN1927169A A CC O
free CN1927169A A JJ O
magnetic CN1927169A A JJ O
particles CN1927169A A NNS O
, CN1927169A A , O
magnetic CN1927169A A JJ O
microspheres CN1927169A A NNS O
washing CN1927169A A VBG O
cryodesiccation CN1927169A A NN O
and CN1927169A A CC O
so CN1927169A A RB O
on CN1927169A A IN O
. CN1927169A A . O

The CN1927169A A DT O
Microspheres CN1927169A A NNS O
have CN1927169A A VBP O
smooth CN1927169A A VBN O
roundness CN1927169A A JJ O
surface CN1927169A A NN O
, CN1927169A A , O
no CN1927169A A DT O
adhesion CN1927169A A NN O
, CN1927169A A , O
diameter CN1927169A A NN O
below CN1927169A A IN O
400 CN1927169A A CD O
nm CN1927169A A NNS O
, CN1927169A A , O
6-9 CN1927169A A JJ O
% CN1927169A A NN O
Fe3O4 CN1927169A A NNP O
content CN1927169A A NN O
, CN1927169A A , O
8-15 CN1927169A A CD O
% CN1927169A A NN O
drug CN1927169A A NN O
encapsulation CN1927169A A NN O
, CN1927169A A , O
and CN1927169A A CC O
has CN1927169A A VBZ O
a CN1927169A A DT O
good CN1927169A A JJ O
biodegradable CN1927169A A JJ O
character CN1927169A A NN O
. CN1927169A A . O

The CN1927169A A DT O
magnetic CN1927169A A JJ O
microspheres CN1927169A A NNS O
have CN1927169A A VBP O
a CN1927169A A DT O
broad CN1927169A A JJ O
prospect CN1927169A A NN O
in CN1927169A A IN O
experimental CN1927169A A JJ O
research CN1927169A A NN O
and CN1927169A A CC O
future CN1927169A A JJ O
clinical CN1927169A A JJ O
cancer CN1927169A A NN O
therapy CN1927169A A NN O
. CN1927169A A . O

The CN1927169A A DT O
invention CN1927169A A NN O
is CN1927169A A VBZ O
characterized CN1927169A A VBN O
in CN1927169A A IN O
simple CN1927169A A JJ O
process CN1927169A A NN O
, CN1927169A A , O
good CN1927169A A JJ O
reproducibility CN1927169A A NN O
, CN1927169A A , O
and CN1927169A A CC O
low CN1927169A A JJ O
cost CN1927169A A NN O
. CN1927169A A . O

Medical CN101069741A T JJ O
radiation-ray CN101069741A T JJ O
preventive CN101069741A T NN O
spray CN101069741A T NN O
agent CN101069741A T NN O
. CN101069741A T . O

The CN101069741A A DT O
present CN101069741A A JJ O
invention CN101069741A A NN O
discloses CN101069741A A VBZ O
a CN101069741A A DT O
medical CN101069741A A JJ O
ray CN101069741A A NN O
protection CN101069741A A NN O
spray CN101069741A A NN O
capable CN101069741A A JJ O
of CN101069741A A IN O
protecting CN101069741A A VBG O
human CN101069741A A JJ O
body CN101069741A A NN O
against CN101069741A A IN O
injury CN101069741A A NN O
due CN101069741A A JJ O
to CN101069741A A TO O
radiation CN101069741A A VB O
ray CN101069741A A VB O
The CN101069741A A DT O
effective CN101069741A A JJ O
components CN101069741A A NNS O
of CN101069741A A IN O
said CN101069741A A VBD O
spray CN101069741A A NN O
include CN101069741A A NN O
( CN101069741A A ( O
by CN101069741A A IN O
wt CN101069741A A NN O
% CN101069741A A NN O
) CN101069741A A ) O
0.002-0.3 CN101069741A A CD O
% CN101069741A A NN O
of CN101069741A A IN O
superoxide CN101069741A A JJ I-UN
dismutase CN101069741A A NN I-UN
, CN101069741A A , O
0.01 CN101069741A A CD O
% CN101069741A A NN O
of CN101069741A A IN O
pentose CN101069741A A NN O
, CN101069741A A , O
0.1 CN101069741A A CD O
% CN101069741A A NN O
of CN101069741A A IN O
polyethylene CN101069741A A NN O
glycol CN101069741A A NN O
6000 CN101069741A A CD O
, CN101069741A A , O
0.1 CN101069741A A CD O
% CN101069741A A NN O
of CN101069741A A IN O
witamin CN101069741A A JJ O
C CN101069741A A NNP O
0.1 CN101069741A A CD O
% CN101069741A A NN O
of CN101069741A A IN O
potassium CN101069741A A NN O
sorbate CN101069741A A NN O
and CN101069741A A CC O
the CN101069741A A DT O
rest CN101069741A A NN O
is CN101069741A A VBZ O
distilled CN101069741A A JJ O
water CN101069741A A NN O
. CN101069741A A . O

Medicament CN101322747A T NN O
for CN101322747A T IN O
treating CN101322747A T VBG O
mammitis CN101322747A T NN O
. CN101322747A T . O

Use EP1467762B1 T NNP O
of EP1467762B1 T IN O
a EP1467762B1 T DT O
h1 EP1467762B1 T JJ I-UN
antagonist EP1467762B1 T NN O
and EP1467762B1 T CC O
rimexolone EP1467762B1 T NN O
as EP1467762B1 T IN O
a EP1467762B1 T DT O
safe EP1467762B1 T JJ O
steroid EP1467762B1 T NN O
to EP1467762B1 T TO O
treat EP1467762B1 T VB O
rhinitis EP1467762B1 T NN O
. EP1467762B1 T . O

Compositions EP1467762B1 A NNS O
and EP1467762B1 A CC O
methods EP1467762B1 A NNS O
for EP1467762B1 A IN O
treating EP1467762B1 A VBG O
rhinitis EP1467762B1 A NN O
with EP1467762B1 A IN O
H1 EP1467762B1 A NNP I-UN
antagonists/antiallergics EP1467762B1 A NNS O
and EP1467762B1 A CC O
safe EP1467762B1 A JJ O
steroids EP1467762B1 A NNS O
are EP1467762B1 A VBP O
disclosed EP1467762B1 A VBN O
. EP1467762B1 A . O

the US7371407 T DT O
oil US7371407 T NN O
is US7371407 T VBZ O
used US7371407 T VBN O
as US7371407 T IN O
a US7371407 T DT O
carrying US7371407 T NN O
agent US7371407 T NN O
for US7371407 T IN O
anti-microbial US7371407 T JJ O
formulations US7371407 T NNS O
; US7371407 T : O
comprises US7371407 T VBZ O
terbinafine US7371407 T NN O
and US7371407 T CC O
other US7371407 T JJ O
antibiotics US7371407 T NNS O
; US7371407 T : O
for US7371407 T IN O
topical US7371407 T JJ O
application US7371407 T NN O
to US7371407 T TO O
the US7371407 T DT O
skin US7371407 T NN O
or US7371407 T CC O
mucosal US7371407 T NN O
membranes US7371407 T NNS O
of US7371407 T IN O
a US7371407 T DT O
mammal US7371407 T NN O
. US7371407 T . O

Lemon CN101429201A T NNP O
acid CN101429201A T VBZ O
berbamine CN101429201A T NN O
salt CN101429201A T NN O
, CN101429201A T , O
preparation CN101429201A T NN O
method CN101429201A T NN O
and CN101429201A T CC O
application CN101429201A T NN O
thereof CN101429201A T NN O
. CN101429201A T . O

Substituted CA2318184C T VBN O
5- CA2318184C T JJ O
( CA2318184C T ( O
2,2-difluoro-1,3-benzodioxol-5-yl CA2318184C T JJ O
) CA2318184C T ) O
cyclopentenopyridine CA2318184C T NN O
derivative CA2318184C T JJ O
as CA2318184C T IN O
selective CA2318184C T JJ O
endothelin CA2318184C T NN I-UN
antagonists CA2318184C T NNS O
. CA2318184C T . O

The CA2318184C A DT O
present CA2318184C A JJ O
invention CA2318184C A NN O
relates CA2318184C A VBZ O
to CA2318184C A TO O
a CA2318184C A DT O
cyclopentenopyridine CA2318184C A NN O
derivative CA2318184C A NN O
represented CA2318184C A VBN O
by CA2318184C A IN O
general CA2318184C A JJ O
formula CA2318184C A NN O
[ CA2318184C A NN O
I CA2318184C A PRP O
] CA2318184C A VBP O
or CA2318184C A CC O
a CA2318184C A DT O
pharmaceutically CA2318184C A RB O
acceptable CA2318184C A JJ O
salt CA2318184C A NN O
thereof CA2318184C A NN O
: CA2318184C A : O
( CA2318184C A ( O
see CA2318184C A VB O
formula CA2318184C A RB O
I CA2318184C A PRP O
) CA2318184C A ) O
wherein CA2318184C A NN O
Ar CA2318184C A NNP O
is CA2318184C A VBZ O
a CA2318184C A DT O
phenyl CA2318184C A JJ O
group CA2318184C A NN O
or CA2318184C A CC O
the CA2318184C A DT O
like CA2318184C A JJ O
, CA2318184C A , O
R1 CA2318184C A NNP O
is CA2318184C A VBZ O
a CA2318184C A DT O
mono-or CA2318184C A JJ O
di-C1-C6 CA2318184C A JJ O
alkylamino CA2318184C A NN O
group CA2318184C A NN O
or CA2318184C A CC O
the CA2318184C A DT O
like CA2318184C A JJ O
, CA2318184C A , O
and CA2318184C A CC O
R2 CA2318184C A NNP O
is CA2318184C A VBZ O
a CA2318184C A DT O
hydroxyl CA2318184C A JJ O
group CA2318184C A NN O
or CA2318184C A CC O
the CA2318184C A DT O
like CA2318184C A JJ O
, CA2318184C A , O
a CA2318184C A DT O
process CA2318184C A NN O
for CA2318184C A IN O
its CA2318184C A PRP$ O
production CA2318184C A NN O
and CA2318184C A CC O
its CA2318184C A PRP$ O
use CA2318184C A NN O
as CA2318184C A IN O
endothelin CA2318184C A JJ I-UN
antagonist CA2318184C A NN O
. CA2318184C A . O

Novel CN102429870A T NNP O
tumor-targeting CN102429870A T JJ O
arboraceous CN102429870A T JJ O
polymer CN102429870A T NN O
nano CN102429870A T NN O
carrier CN102429870A T NN O
of CN102429870A T IN O
camptothecin CN102429870A T JJ O
drug CN102429870A T NN O
. CN102429870A T . O

Application CN101829081A T NN O
of CN101829081A T IN O
chromane CN101829081A T NN O
compound CN101829081A T NN O
HEF-05 CN101829081A T NNP O
in CN101829081A T IN O
relaxing CN101829081A T VBG O
smooth CN101829081A T JJ O
muscle CN101829081A T NN O
of CN101829081A T IN O
blood CN101829081A T NN O
vessel CN101829081A T NN O
. CN101829081A T . O

The CN101829081A A DT O
invention CN101829081A A NN O
relates CN101829081A A VBZ O
to CN101829081A A TO O
the CN101829081A A DT O
technical CN101829081A A JJ O
field CN101829081A A NN O
of CN101829081A A IN O
medicament CN101829081A A NN O
, CN101829081A A , O
and CN101829081A A CC O
mainly CN101829081A A RB O
relates CN101829081A A VBZ O
to CN101829081A A TO O
application CN101829081A A NN O
of CN101829081A A IN O
chromane CN101829081A A NN O
compound CN101829081A A NN O
HEF-05 CN101829081A A NNP O
in CN101829081A A IN O
preparing CN101829081A A VBG O
a CN101829081A A DT O
vasodilator CN101829081A A NN O
, CN101829081A A , O
a CN101829081A A DT O
potassium CN101829081A A NN I-UN
channel CN101829081A A NN I-UN
opener CN101829081A A NN O
, CN101829081A A , O
a CN101829081A A DT O
calcium CN101829081A A NN I-UN
channel CN101829081A A NN I-UN
blocker CN101829081A A NN O
and CN101829081A A CC O
an CN101829081A A DT O
endothelium CN101829081A A NN O
relaxing CN101829081A A VBG O
factor CN101829081A A NN O
releasing CN101829081A A VBG O
agent CN101829081A A NN O
. CN101829081A A . O

In CN101829081A A IN O
addition CN101829081A A NN O
, CN101829081A A , O
in CN101829081A A IN O
a CN101829081A A DT O
pilot CN101829081A A NN O
study CN101829081A A NN O
of CN101829081A A IN O
a CN101829081A A DT O
relaxing CN101829081A A NN O
mechanism CN101829081A A NN O
, CN101829081A A , O
the CN101829081A A DT O
relaxation CN101829081A A NN O
function CN101829081A A NN O
of CN101829081A A IN O
the CN101829081A A DT O
HEF-05 CN101829081A A NNP O
is CN101829081A A VBZ O
inhibited CN101829081A A VBN O
after CN101829081A A IN O
the CN101829081A A DT O
smooth CN101829081A A JJ O
muscle CN101829081A A NN O
of CN101829081A A IN O
the CN101829081A A DT O
blood CN101829081A A NN O
vessel CN101829081A A NN O
is CN101829081A A VBZ O
incubated CN101829081A A VBN O
by CN101829081A A IN O
the CN101829081A A DT O
ATP-sensitive CN101829081A A JJ I-UN
potassium CN101829081A A NN I-UN
channel CN101829081A A NN I-UN
blocker CN101829081A A NN O
glibenclamide CN101829081A A NN O
. CN101829081A A . O

Therefore CN101829081A A RB O
, CN101829081A A , O
the CN101829081A A DT O
HEF-05 CN101829081A A NNP O
can CN101829081A A MD O
be CN101829081A A VB O
used CN101829081A A VBN O
for CN101829081A A IN O
preparing CN101829081A A VBG O
a CN101829081A A DT O
preparation CN101829081A A NN O
for CN101829081A A IN O
relaxing CN101829081A A VBG O
the CN101829081A A DT O
smooth CN101829081A A JJ O
muscle CN101829081A A NN O
of CN101829081A A IN O
the CN101829081A A DT O
blood CN101829081A A NN O
vessel CN101829081A A NN O
and CN101829081A A CC O
can CN101829081A A MD O
be CN101829081A A VB O
used CN101829081A A VBN O
as CN101829081A A IN O
the CN101829081A A DT O
potassium CN101829081A A NN I-UN
channel CN101829081A A NN I-UN
opener CN101829081A A NN O
, CN101829081A A , O
the CN101829081A A DT O
calcium CN101829081A A NN I-UN
channel CN101829081A A NN I-UN
blocker CN101829081A A NN O
and CN101829081A A CC O
the CN101829081A A DT O
endothelium CN101829081A A NN O
relaxing CN101829081A A VBG O
factor CN101829081A A NN O
releasing CN101829081A A VBG O
agent CN101829081A A NN O
. CN101829081A A . O

Peptide CN102757386A T NNP O
derivative CN102757386A T JJ O
and CN102757386A T CC O
pharmaceutical CN102757386A T JJ O
composition CN102757386A T NN O
and CN102757386A T CC O
application CN102757386A T NN O
thereof CN102757386A T NN O
. CN102757386A T . O

Compounds US20110207736 T NNS O
that US20110207736 T WDT O
modulate US20110207736 T VBP O
egfr US20110207736 T JJ I-UN
activity US20110207736 T NN O
and US20110207736 T CC O
methods US20110207736 T NNS O
for US20110207736 T IN O
treating US20110207736 T VBG O
or US20110207736 T CC O
preventing US20110207736 T VBG O
conditions US20110207736 T NNS O
therewith US20110207736 T NN O
. US20110207736 T . O

Novel US20090118263 T NNP O
Adenine US20090118263 T NNP O
Compound US20090118263 T NNP O
. US20090118263 T . O

Nucleic CN101302510A T NNP O
acid CN101302510A T NN O
molecule CN101302510A T NN O
and CN101302510A T CC O
use CN101302510A T NN O
thereof CN101302510A T NN O
in CN101302510A T IN O
anti-cancer CN101302510A T JJ O
medicine CN101302510A T NN O
preparation CN101302510A T NN O
. CN101302510A T . O

Benzimidazo WO2008016288A1 T NNP O
[ WO2008016288A1 T NNP O
1,2-c WO2008016288A1 T JJ O
] WO2008016288A1 T NNP O
[ WO2008016288A1 T NNP O
1,2,3 WO2008016288A1 T CD O
] WO2008016288A1 T NNP O
thiadiazol-7-sulfonamides WO2008016288A1 T NNS O
as WO2008016288A1 T IN O
inhibitors WO2008016288A1 T NNS O
of WO2008016288A1 T IN O
carbonic WO2008016288A1 T JJ I-UN
anhydrase WO2008016288A1 T NN I-UN
and WO2008016288A1 T CC O
the WO2008016288A1 T DT O
intermediates WO2008016288A1 T NNS O
for WO2008016288A1 T IN O
production WO2008016288A1 T NN O
thereof WO2008016288A1 T NN O
. WO2008016288A1 T . O

The WO2008016288A1 A DT O
compounds WO2008016288A1 A NNS O
of WO2008016288A1 A IN O
formula WO2008016288A1 A NN O
( WO2008016288A1 A ( O
I WO2008016288A1 A PRP O
) WO2008016288A1 A ) O
inhibits WO2008016288A1 A VBZ O
enzymes WO2008016288A1 A NNS O
such WO2008016288A1 A JJ O
as WO2008016288A1 A IN O
carbonic WO2008016288A1 A JJ I-UN
anhydrases WO2008016288A1 A NNS I-UN
and WO2008016288A1 A CC O
metallo WO2008016288A1 A NN I-UN
proteinases WO2008016288A1 A NNS I-UN
. WO2008016288A1 A . O

Process CN1561991A T NN O
for CN1561991A T IN O
producing CN1561991A T VBG O
medicine CN1561991A T NN O
grade CN1561991A T JJ O
natural CN1561991A T JJ O
vitamin CN1561991A T NN O
E CN1561991A T NNP O
raw CN1561991A T JJ O
oil CN1561991A T NN O
. CN1561991A T . O

Treating US20050009902 T VBG O
any US20050009902 T DT O
types US20050009902 T NNS O
of US20050009902 T IN O
pruritus US20050009902 T NN O
such US20050009902 T JJ O
as US20050009902 T IN O
ocular US20050009902 T JJ O
pruritus US20050009902 T NN O
, US20050009902 T , O
skin US20050009902 T NN O
pruritus US20050009902 T NN O
and US20050009902 T CC O
systemic US20050009902 T JJ O
pruritus US20050009902 T NN O
with US20050009902 T IN O
a US20050009902 T DT O
cannabinoid US20050009902 T JJ O
agonist US20050009902 T NN O
such US20050009902 T JJ O
as US20050009902 T IN O
palmidrol US20050009902 T NN O
and US20050009902 T CC O
anandamide US20050009902 T NN O
or US20050009902 T CC O
a US20050009902 T DT O
derivative US20050009902 T JJ O
. US20050009902 T . O

Substituted US20090069376 T VBN O
N US20090069376 T NNP O
[ US20090069376 T NNP O
N- US20090069376 T NNP O
( US20090069376 T ( O
sulphonylphenyl US20090069376 T NN O
) US20090069376 T ) O
sulfonyl-prolyl US20090069376 T NN O
] US20090069376 T JJ O
-phenylalanine US20090069376 T NN O
derivatives US20090069376 T NNS O
are US20090069376 T VBP O
antagonists US20090069376 T NNS O
of US20090069376 T IN O
the US20090069376 T DT O
very US20090069376 T RB I-UN
late US20090069376 T JJ I-UN
antigen-4 US20090069376 T JJ I-UN
integrin US20090069376 T NN I-UN
; US20090069376 T : O
ulcerative US20090069376 T JJ O
colitis US20090069376 T NN O
, US20090069376 T , O
Crohn US20090069376 T NNP O
's US20090069376 T POS O
disease US20090069376 T NN O
, US20090069376 T , O
asthma US20090069376 T NN O
, US20090069376 T , O
multiple US20090069376 T JJ O
sclerosis US20090069376 T NN O
, US20090069376 T , O
rheumatoid US20090069376 T JJ O
arthritis US20090069376 T NN O
. US20090069376 T . O

Substituted US20090069376 A VBN O
N— US20090069376 A NNP O
[ US20090069376 A NNP O
N- US20090069376 A NNP O
( US20090069376 A ( O
sulphonylphenyl US20090069376 A NN O
) US20090069376 A ) O
sulfonyl-prolyl US20090069376 A NN O
] US20090069376 A JJ O
-phenylalanine US20090069376 A NNP O
derivatives US20090069376 A NNS O
of US20090069376 A IN O
the US20090069376 A DT O
present US20090069376 A JJ O
invention US20090069376 A NN O
are US20090069376 A VBP O
antagonists US20090069376 A NNS O
of US20090069376 A IN O
the US20090069376 A DT O
VLA-4 US20090069376 A NNP I-UN
integrin US20090069376 A NN I-UN
and US20090069376 A CC O
are US20090069376 A VBP O
useful US20090069376 A JJ O
in US20090069376 A IN O
the US20090069376 A DT O
treatment US20090069376 A NN O
, US20090069376 A , O
prevention US20090069376 A NN O
and US20090069376 A CC O
suppression US20090069376 A NN O
of US20090069376 A IN O
diseases US20090069376 A NNS O
mediated US20090069376 A VBN O
by US20090069376 A IN O
VLA-4-binding US20090069376 A NNP O
and US20090069376 A CC O
cell US20090069376 A NN O
adhesion US20090069376 A NN O
and US20090069376 A CC O
activation US20090069376 A NN O
. US20090069376 A . O

Moreover US20090069376 A RB O
, US20090069376 A , O
the US20090069376 A DT O
compounds US20090069376 A NNS O
of US20090069376 A IN O
the US20090069376 A DT O
present US20090069376 A JJ O
invention US20090069376 A NN O
demonstrate US20090069376 A NN O
significant US20090069376 A JJ O
receptor US20090069376 A NN O
occupancy US20090069376 A NN O
of US20090069376 A IN O
VLA-4 US20090069376 A NNP I-UN
bearing US20090069376 A NN O
cells US20090069376 A NNS O
after US20090069376 A IN O
oral US20090069376 A JJ O
administration US20090069376 A NN O
and US20090069376 A CC O
are US20090069376 A VBP O
suitable US20090069376 A JJ O
for US20090069376 A IN O
once- US20090069376 A JJ O
, US20090069376 A , O
twice- US20090069376 A JJ O
, US20090069376 A , O
or US20090069376 A CC O
thrice-a-day US20090069376 A JJ O
oral US20090069376 A JJ O
administration US20090069376 A NN O
. US20090069376 A . O

Medicine CN103417766A T NNP O
for CN103417766A T IN O
treating CN103417766A T VBG O
juvenile CN103417766A T NN O
parotitis CN103417766A T NN O
. CN103417766A T . O

Hydrogel US20120035129 T NNP O
tissue US20120035129 T NN O
adhesive US20120035129 T NN O
having US20120035129 T VBG O
reduced US20120035129 T VBN O
degradation US20120035129 T NN O
time US20120035129 T NN O
. US20120035129 T . O

Small US8633198 T JJ O
molecule US8633198 T NN O
inhibitors US8633198 T NNS O
of US8633198 T IN O
influenza US8633198 T NN I-UN
A US8633198 T DT I-UN
RNA-dependent US8633198 T JJ I-UN
RNA US8633198 T NNP I-UN
polymerase US8633198 T NN I-UN
. US8633198 T . O

Also US8633198 A RB O
presented US8633198 A VBN O
are US8633198 A VBP O
cellular US8633198 A JJ O
assays US8633198 A NNS O
to US8633198 A TO O
identify US8633198 A VB O
small US8633198 A JJ O
molecule US8633198 A NN O
compounds US8633198 A NNS O
having US8633198 A VBG O
antiviral US8633198 A JJ O
properties US8633198 A NNS O
, US8633198 A , O
particularly US8633198 A RB O
as US8633198 A IN O
it US8633198 A PRP O
relates US8633198 A VBZ O
to US8633198 A TO O
detection US8633198 A NN O
of US8633198 A IN O
influenza US8633198 A NN I-UN
A US8633198 A DT I-UN
RNA-dependent US8633198 A JJ I-UN
RNA US8633198 A NNP I-UN
polymerase US8633198 A NN I-UN
activity US8633198 A NN O
in US8633198 A IN O
a US8633198 A DT O
mammalian US8633198 A JJ O
cell US8633198 A NN O
independent US8633198 A JJ O
of US8633198 A IN O
other US8633198 A JJ O
influenza US8633198 A NN O
A US8633198 A DT O
components US8633198 A NNS O
. US8633198 A . O

Scraping CN103479775A T VBG O
liniment CN103479775A T NN O
and CN103479775A T CC O
preparation CN103479775A T NN O
method CN103479775A T NN O
thereof CN103479775A T NN O
. CN103479775A T . O

The CN103479775A A DT O
invention CN103479775A A NN O
belongs CN103479775A A VBZ O
to CN103479775A A TO O
the CN103479775A A DT O
technical CN103479775A A JJ O
field CN103479775A A NN O
of CN103479775A A IN O
health CN103479775A A NN O
care CN103479775A A NN O
products CN103479775A A NNS O
, CN103479775A A , O
in CN103479775A A IN O
particular CN103479775A A JJ O
to CN103479775A A TO O
a CN103479775A A DT O
scraping CN103479775A A JJ O
liniment CN103479775A A NN O
and CN103479775A A CC O
a CN103479775A A DT O
preparation CN103479775A A NN O
method CN103479775A A NN O
thereof CN103479775A A NN O
. CN103479775A A . O

The CN103479775A A DT O
scraping CN103479775A A VBG O
liniment CN103479775A A NN O
comprises CN103479775A A VBZ O
the CN103479775A A DT O
following CN103479775A A JJ O
ingredients CN103479775A A NNS O
in CN103479775A A IN O
percentage CN103479775A A NN O
by CN103479775A A IN O
weight CN103479775A A NN O
: CN103479775A A : O
50 CN103479775A A CD O
% CN103479775A A NN O
-70 CN103479775A A CD O
% CN103479775A A NN O
of CN103479775A A IN O
olive CN103479775A A JJ O
oil CN103479775A A NN O
, CN103479775A A , O
20 CN103479775A A CD O
% CN103479775A A NN O
-30 CN103479775A A CD O
% CN103479775A A NN O
of CN103479775A A IN O
sweet CN103479775A A JJ O
almond CN103479775A A JJ O
oil CN103479775A A NN O
, CN103479775A A , O
0.5 CN103479775A A CD O
% CN103479775A A NN O
-2 CN103479775A A CD O
% CN103479775A A NN O
of CN103479775A A IN O
angelica CN103479775A A JJ O
oil CN103479775A A NN O
, CN103479775A A , O
1 CN103479775A A CD O
% CN103479775A A NN O
-3 CN103479775A A CD O
% CN103479775A A NN O
of CN103479775A A IN O
vitamin CN103479775A A NN O
E CN103479775A A NNP O
, CN103479775A A , O
1 CN103479775A A CD O
% CN103479775A A NN O
-3 CN103479775A A CD O
% CN103479775A A NN O
of CN103479775A A IN O
safflower CN103479775A A JJR O
oil CN103479775A A NN O
, CN103479775A A , O
1 CN103479775A A CD O
% CN103479775A A NN O
-3 CN103479775A A CD O
% CN103479775A A NN O
of CN103479775A A IN O
ligusticum CN103479775A A JJ O
wallichii CN103479775A A JJ O
oil CN103479775A A NN O
, CN103479775A A , O
1 CN103479775A A CD O
% CN103479775A A NN O
-3 CN103479775A A CD O
% CN103479775A A NN O
of CN103479775A A IN O
peppermint CN103479775A A NN O
, CN103479775A A , O
1 CN103479775A A CD O
% CN103479775A A NN O
-3 CN103479775A A CD O
% CN103479775A A NN O
of CN103479775A A IN O
artemisia CN103479775A A JJ O
vulgaris CN103479775A A JJ O
oil CN103479775A A NN O
, CN103479775A A , O
and CN103479775A A CC O
1 CN103479775A A CD O
% CN103479775A A NN O
-3 CN103479775A A CD O
% CN103479775A A NN O
of CN103479775A A IN O
pepper CN103479775A A JJ O
essential CN103479775A A JJ O
oil CN103479775A A NN O
. CN103479775A A . O

The CN103479775A A DT O
scraping CN103479775A A VBG O
liniment CN103479775A A NN O
provided CN103479775A A VBN O
by CN103479775A A IN O
the CN103479775A A DT O
invention CN103479775A A NN O
has CN103479775A A VBZ O
efficacies CN103479775A A NNS O
of CN103479775A A IN O
activating CN103479775A A VBG O
blood CN103479775A A NN O
and CN103479775A A CC O
dissolving CN103479775A A VBG O
stasis CN103479775A A NN O
, CN103479775A A , O
and CN103479775A A CC O
eliminating CN103479775A A VBG O
cold CN103479775A A JJ O
and CN103479775A A CC O
stopping CN103479775A A VBG O
pain CN103479775A A NN O
, CN103479775A A , O
and CN103479775A A CC O
has CN103479775A A VBZ O
an CN103479775A A DT O
excellent CN103479775A A JJ O
assistant CN103479775A A NN O
treatment CN103479775A A NN O
effect CN103479775A A NN O
on CN103479775A A IN O
pain CN103479775A A NN O
caused CN103479775A A VBN O
by CN103479775A A IN O
cervical CN103479775A A JJ O
spondylosis CN103479775A A NN O
, CN103479775A A , O
scapulohumeral CN103479775A A JJ O
periarthritis CN103479775A A NN O
or CN103479775A A CC O
catching CN103479775A A VBG O
cold CN103479775A A JJ O
. CN103479775A A . O

Curing EP1647272A1 T VBG O
and EP1647272A1 T CC O
prophylactic EP1647272A1 T JJ O
agent EP1647272A1 T NN O
applied EP1647272A1 T VBN O
during EP1647272A1 T IN O
the EP1647272A1 T DT O
use EP1647272A1 T NN O
of EP1647272A1 T IN O
alcohol EP1647272A1 T NN O
and EP1647272A1 T CC O
psychoactive EP1647272A1 T JJ O
substances EP1647272A1 T NNS O
. EP1647272A1 T . O

Modulation US20110034532 T NN O
of US20110034532 T IN O
T US20110034532 T NNP O
Cell US20110034532 T NNP O
Signaling US20110034532 T NNP O
Threshold US20110034532 T NNP O
and US20110034532 T CC O
T US20110034532 T NNP O
Cell US20110034532 T NNP O
Sensitivity US20110034532 T NNP O
to US20110034532 T TO O
Antigens US20110034532 T NNP O
. US20110034532 T . O

Increased US20110034532 A VBN O
miR-181a US20110034532 A JJ I-UN
expression US20110034532 A NN O
in US20110034532 A IN O
mature US20110034532 A NN O
T US20110034532 A NNP O
cells US20110034532 A NNS O
is US20110034532 A VBZ O
shown US20110034532 A VBN O
to US20110034532 A TO O
cause US20110034532 A VB O
a US20110034532 A DT O
marked US20110034532 A JJ O
increase US20110034532 A NN O
in US20110034532 A IN O
T US20110034532 A NNP O
cell US20110034532 A NN O
activation US20110034532 A NN O
and US20110034532 A CC O
augments US20110034532 A NNS O
T US20110034532 A NNP O
cell US20110034532 A NN O
sensitivity US20110034532 A NN O
to US20110034532 A TO O
peptide US20110034532 A VB O
antigens US20110034532 A NNS O
. US20110034532 A . O

Moreover US20110034532 A RB O
, US20110034532 A , O
T US20110034532 A NNP O
cell US20110034532 A NN O
blasts US20110034532 A NNS O
with US20110034532 A IN O
higher US20110034532 A JJR O
miR-181a US20110034532 A NN I-UN
expression US20110034532 A NN O
become US20110034532 A VB O
reactive US20110034532 A JJ O
to US20110034532 A TO O
antagonists US20110034532 A NNS O
. US20110034532 A . O

The US20110034532 A DT O
effects US20110034532 A NNS O
of US20110034532 A IN O
miR-181a US20110034532 A NN I-UN
on US20110034532 A IN O
antigen US20110034532 A NN O
discrimination US20110034532 A NN O
are US20110034532 A VBP O
in US20110034532 A IN O
part US20110034532 A NN O
achieved US20110034532 A VBN O
by US20110034532 A IN O
dampening US20110034532 A VBG O
the US20110034532 A DT O
expression US20110034532 A NN O
of US20110034532 A IN O
multiple US20110034532 A JJ O
negative US20110034532 A JJ O
regulators US20110034532 A NNS O
in US20110034532 A IN O
the US20110034532 A DT O
T US20110034532 A NNP O
cell US20110034532 A NN O
receptor US20110034532 A NN O
( US20110034532 A ( O
TCR US20110034532 A NNP O
) US20110034532 A ) O
signaling US20110034532 A VBG O
pathway US20110034532 A NN O
, US20110034532 A , O
including US20110034532 A VBG O
PTPN22 US20110034532 A NNP I-UN
and US20110034532 A CC O
the US20110034532 A DT O
dual US20110034532 A JJ O
specificity US20110034532 A NN O
phosphatases US20110034532 A NNS O
DUSP5 US20110034532 A NNP I-UN
and US20110034532 A CC O
DUSP6 US20110034532 A NNP I-UN
. US20110034532 A . O

Phenylphthalimide US20100247659 T NNP O
analogs US20100247659 T NNS O
for US20100247659 T IN O
treating US20100247659 T VBG O
diabetic US20100247659 T JJ O
macular US20100247659 T JJ O
edema US20100247659 T NN O
. US20100247659 T . O

Novel US20100247659 A NNP O
methods US20100247659 A NNS O
are US20100247659 A VBP O
provided US20100247659 A VBN O
to US20100247659 A TO O
prevent US20100247659 A VB O
blindness US20100247659 A NN O
associated US20100247659 A VBN O
with US20100247659 A IN O
diabetic US20100247659 A JJ O
macular US20100247659 A NN O
edema US20100247659 A NN O
by US20100247659 A IN O
administration US20100247659 A NN O
of US20100247659 A IN O
a US20100247659 A DT O
phenylphthalimide US20100247659 A JJ O
analog US20100247659 A NN O
. US20100247659 A . O

Additionally US20100247659 A RB O
, US20100247659 A , O
sustainability US20100247659 A NN O
of US20100247659 A IN O
the US20100247659 A DT O
effect US20100247659 A NN O
of US20100247659 A IN O
administration US20100247659 A NN O
of US20100247659 A IN O
the US20100247659 A DT O
phenylphthalimide US20100247659 A NN O
analog US20100247659 A NN O
is US20100247659 A VBZ O
improved US20100247659 A VBN O
via US20100247659 A IN O
encapsulation US20100247659 A NN O
with US20100247659 A IN O
poly US20100247659 A NN O
( US20100247659 A ( O
lactic-co-glycolic US20100247659 A JJ O
acid US20100247659 A NN O
) US20100247659 A ) O
nanoparticles US20100247659 A NNS O
. US20100247659 A . O

Finally US20100247659 A RB O
, US20100247659 A , O
a US20100247659 A DT O
novel US20100247659 A JJ O
method US20100247659 A NN O
for US20100247659 A IN O
synthesizing US20100247659 A VBG O
( US20100247659 A ( O
2,6-diisopropylphenyl US20100247659 A JJ O
) US20100247659 A ) O
-5-amino-1H-isoindole-1,3-dione US20100247659 A NN O
is US20100247659 A VBZ O
disclosed US20100247659 A VBN O
. US20100247659 A . O

Selenium-enriched CN101773463A T JJ O
nano CN101773463A T NN O
pearl CN101773463A T NN O
powder CN101773463A T NN O
formula CN101773463A T NN O
and CN101773463A T CC O
production CN101773463A T NN O
method CN101773463A T NN O
thereof CN101773463A T NN O
. CN101773463A T . O

Granular CN1943613A T JJ O
agent CN1943613A T NN O
with CN1943613A T IN O
brain CN1943613A T NN O
strengthening CN1943613A T VBG O
function CN1943613A T NN O
. CN1943613A T . O

Isoindoline EP2358697A1 T NNP O
compounds EP2358697A1 T NNS O
for EP2358697A1 T IN O
use EP2358697A1 T NN O
in EP2358697A1 T IN O
the EP2358697A1 T DT O
treatment EP2358697A1 T NN O
of EP2358697A1 T IN O
cancer EP2358697A1 T NN O
. EP2358697A1 T . O

Octahydro-indolizine US20090263322 T JJ O
and US20090263322 T CC O
quinolizine US20090263322 T JJ O
and US20090263322 T CC O
hexahydro-pyrrolizines US20090263322 T NNS O
. US20090263322 T . O

The CN1739571A A DT O
dietotherapeutic CN1739571A A JJ O
nutrient CN1739571A A NN O
is CN1739571A A VBZ O
used CN1739571A A VBN O
as CN1739571A A IN O
main CN1739571A A JJ O
material CN1739571A A NN O
or CN1739571A A CC O
additive CN1739571A A NN O
for CN1739571A A IN O
food CN1739571A A NN O
products CN1739571A A NNS O
and CN1739571A A CC O
medicines CN1739571A A NNS O
for CN1739571A A IN O
preventing CN1739571A A VBG O
and CN1739571A A CC O
treating CN1739571A A VBG O
diabetes CN1739571A A NNS O
through CN1739571A A IN O
balancing CN1739571A A VBG O
insulin CN1739571A A NN I-UN
and CN1739571A A CC O
hyperglycemic CN1739571A A JJ O
hormone CN1739571A A NN O
, CN1739571A A , O
repairing CN1739571A A VBG O
the CN1739571A A DT O
functions CN1739571A A NNS O
of CN1739571A A IN O
pancreatic CN1739571A A JJ O
island CN1739571A A NN O
and CN1739571A A CC O
kidney CN1739571A A NN O
, CN1739571A A , O
preventing CN1739571A A VBG O
and CN1739571A A CC O
treating CN1739571A A VBG O
complication CN1739571A A NN O
and CN1739571A A CC O
restoring CN1739571A A VBG O
normal CN1739571A A JJ O
synthesis CN1739571A A NN O
and CN1739571A A CC O
metabolism CN1739571A A NN O
. CN1739571A A . O

Isoquercitrin CN101301477A T NNP O
clathrate CN101301477A T NN O
and CN101301477A T CC O
preparation CN101301477A T NN O
thereof CN101301477A T NN O
. CN101301477A T . O

Plaster CA2306214C T NN O
for CA2306214C T IN O
topical CA2306214C T JJ O
use CA2306214C T NN O
containing CA2306214C T VBG O
heparin CA2306214C T NN O
and CA2306214C T CC O
diclofenac CA2306214C T NN O
. CA2306214C T . O

Combinations US20120270849 T NNS O
of US20120270849 T IN O
niacin US20120270849 T NN O
, US20120270849 T , O
omega-3 US20120270849 T JJ O
and US20120270849 T CC O
plant US20120270849 T NN O
sterols/stanols US20120270849 T NNS O
for US20120270849 T IN O
prevention US20120270849 T NN O
cholesterol US20120270849 T NN O
treatment US20120270849 T NN O
. US20120270849 T . O

Method CN1682763A T NNP O
for CN1682763A T IN O
extracting CN1682763A T VBG O
bone CN1682763A T NN O
calcium CN1682763A T NN O
from CN1682763A T IN O
animal CN1682763A T JJ O
bone CN1682763A T NN O
powder CN1682763A T NN O
. CN1682763A T . O

Epidemic CN103750606A T JJ O
disease CN103750606A T NN O
wind CN103750606A T NN O
expelling CN103750606A T NN O
, CN103750606A T , O
preventing CN103750606A T VBG O
and CN103750606A T CC O
treating CN103750606A T VBG O
perfume CN103750606A T NN O
satchel CN103750606A T NN O
. CN103750606A T . O

Process US20080248124 T NN O
for US20080248124 T IN O
producing US20080248124 T VBG O
pharmaceutical US20080248124 T JJ O
composition US20080248124 T NN O
. US20080248124 T . O

Intedanib WO2012068441A3 T NNP O
salts WO2012068441A3 T NNS O
and WO2012068441A3 T CC O
solid WO2012068441A3 T JJ O
state WO2012068441A3 T NN O
forms WO2012068441A3 T NNS O
thereof WO2012068441A3 T NN O
. WO2012068441A3 T . O

Compound CN101234195A T NNP O
gargle CN101234195A T NN O
for CN101234195A T IN O
preventing CN101234195A T VBG O
and CN101234195A T CC O
controlling CN101234195A T VBG O
stomatitis CN101234195A T NN O
and CN101234195A T CC O
confecting CN101234195A T VBG O
method CN101234195A T NN O
thereof CN101234195A T NN O
. CN101234195A T . O

A CN1961868A T DT O
rapidly CN1961868A T RB O
disintegrating CN1961868A T VBG O
tablet CN1961868A T NN O
of CN1961868A T IN O
acid CN1961868A T JJ O
sensitive CN1961868A T JJ O
drug CN1961868A T NN O
. CN1961868A T . O

The CN1961868A A DT O
invention CN1961868A A NN O
relates CN1961868A A VBZ O
to CN1961868A A TO O
a CN1961868A A DT O
drug CN1961868A A NN O
compound CN1961868A A NN O
, CN1961868A A , O
as CN1961868A A IN O
one CN1961868A A CD O
quick CN1961868A A NN O
release CN1961868A A NN O
tablet CN1961868A A NN O
with CN1961868A A IN O
acid CN1961868A A JJ O
sensitive CN1961868A A JJ O
active CN1961868A A JJ O
component CN1961868A A NN O
as CN1961868A A IN O
acid CN1961868A A JJ O
sensitive CN1961868A A JJ O
proton CN1961868A A NN I-UN
pump CN1961868A A NN I-UN
restrain CN1961868A A NN O
agent CN1961868A A NN O
, CN1961868A A , O
wherein CN1961868A A NN O
said CN1961868A A VBD O
tablet CN1961868A A NN O
can CN1961868A A MD O
protect CN1961868A A VB O
the CN1961868A A DT O
active CN1961868A A JJ O
component CN1961868A A NN O
in CN1961868A A IN O
pH CN1961868A A JJ O
condition CN1961868A A NN O
of CN1961868A A IN O
mouth CN1961868A A NN O
, CN1961868A A , O
and CN1961868A A CC O
it CN1961868A A PRP O
uses CN1961868A A VBZ O
fluid CN1961868A A JJ O
bed CN1961868A A NN O
method CN1961868A A NN O
to CN1961868A A TO O
pack CN1961868A A VB O
the CN1961868A A DT O
active CN1961868A A JJ O
component CN1961868A A NN O
to CN1961868A A TO O
obtain CN1961868A A VB O
the CN1961868A A DT O
packed CN1961868A A JJ O
particles CN1961868A A NNS O
; CN1961868A A : O
then CN1961868A A RB O
adds CN1961868A A VBZ O
acid CN1961868A A RP O
pH CN1961868A A NNS O
adjuster CN1961868A A NN O
which CN1961868A A WDT O
can CN1961868A A MD O
neutralize CN1961868A A VB O
the CN1961868A A DT O
pH CN1961868A A JJ O
condition CN1961868A A NN O
of CN1961868A A IN O
mouth CN1961868A A NN O
, CN1961868A A , O
to CN1961868A A TO O
avoid CN1961868A A VB O
pack CN1961868A A NN O
player CN1961868A A NN O
being CN1961868A A VBG O
dissolved CN1961868A A VBN O
in CN1961868A A IN O
mouth CN1961868A A NN O
. CN1961868A A . O

Treating US20070238640 T VBG O
an US20070238640 T DT O
inflammatory US20070238640 T JJ O
condition US20070238640 T NN O
in US20070238640 T IN O
an US20070238640 T DT O
individual US20070238640 T NN O
by US20070238640 T IN O
administering US20070238640 T VBG O
an US20070238640 T DT O
agent US20070238640 T NN O
which US20070238640 T WDT O
inhibits US20070238640 T VBZ O
the US20070238640 T DT O
interaction US20070238640 T NN O
between US20070238640 T IN O
a US20070238640 T DT O
Toll-like US20070238640 T NNP I-UN
receptor US20070238640 T NN I-UN
2 US20070238640 T CD I-UN
and US20070238640 T CC O
a US20070238640 T DT O
high US20070238640 T JJ I-UN
mobility US20070238640 T NN I-UN
group US20070238640 T NN I-UN
B US20070238640 T NNP I-UN
polypeptide US20070238640 T NN I-UN
; US20070238640 T : O
treating US20070238640 T VBG O
Crohn US20070238640 T NNP O
's US20070238640 T POS O
disease US20070238640 T NN O
, US20070238640 T , O
sepsis US20070238640 T NN O
, US20070238640 T , O
rheumatoid US20070238640 T JJ O
arthritis US20070238640 T NN O
, US20070238640 T , O
systemic US20070238640 T JJ O
lupus US20070238640 T NN O
erythematosus US20070238640 T NN O
, US20070238640 T , O
endotoxic US20070238640 T NN O
shock US20070238640 T NN O
, US20070238640 T , O
allograft US20070238640 T NN O
rejection US20070238640 T NN O
. US20070238640 T . O

The US20070238640 A DT O
invention US20070238640 A NN O
features US20070238640 A VBZ O
a US20070238640 A DT O
method US20070238640 A NN O
of US20070238640 A IN O
treating US20070238640 A VBG O
an US20070238640 A DT O
inflammatory US20070238640 A JJ O
condition US20070238640 A NN O
in US20070238640 A IN O
an US20070238640 A DT O
individual US20070238640 A NN O
, US20070238640 A , O
comprising US20070238640 A VBG O
administering US20070238640 A VBG O
an US20070238640 A DT O
agent US20070238640 A NN O
inhibits US20070238640 A VBZ O
the US20070238640 A DT O
interaction US20070238640 A NN O
between US20070238640 A IN O
a US20070238640 A DT O
Toll-like US20070238640 A NNP I-UN
receptor US20070238640 A NN I-UN
2 US20070238640 A CD I-UN
( US20070238640 A ( O
TLR2 US20070238640 A NNP I-UN
) US20070238640 A ) O
and US20070238640 A CC O
a US20070238640 A DT O
high US20070238640 A JJ I-UN
mobility US20070238640 A NN I-UN
group US20070238640 A NN I-UN
B US20070238640 A NNP I-UN
( US20070238640 A ( O
HMGB US20070238640 A NNP I-UN
) US20070238640 A ) O
polypeptide US20070238640 A NN O
to US20070238640 A TO O
the US20070238640 A DT O
individual US20070238640 A NN O
. US20070238640 A . O

The US20070238640 A DT O
invention US20070238640 A NN O
also US20070238640 A RB O
features US20070238640 A VBZ O
methods US20070238640 A NNS O
for US20070238640 A IN O
identifying US20070238640 A VBG O
agents US20070238640 A NNS O
that US20070238640 A WDT O
inhibit US20070238640 A VBP O
the US20070238640 A DT O
interaction US20070238640 A NN O
between US20070238640 A IN O
TLR2 US20070238640 A NNP I-UN
and US20070238640 A CC O
HMGB US20070238640 A NNP I-UN
. US20070238640 A . O

S100 WO2011092505A1 T NNP I-UN
protein WO2011092505A1 T NN O
binding WO2011092505A1 T VBG O
interaction WO2011092505A1 T NN O
inhibitors WO2011092505A1 T NNS O
. WO2011092505A1 T . O

This WO2011092505A1 A DT O
invention WO2011092505A1 A NN O
relates WO2011092505A1 A VBZ O
to WO2011092505A1 A TO O
compounds WO2011092505A1 A VB O
that WO2011092505A1 A DT O
are WO2011092505A1 A VBP O
inhibitors WO2011092505A1 A NNS O
of WO2011092505A1 A IN O
S100 WO2011092505A1 A NNP I-UN
protein WO2011092505A1 A NN O
binding WO2011092505A1 A VBG O
interactions WO2011092505A1 A NNS O
, WO2011092505A1 A , O
such WO2011092505A1 A JJ O
as WO2011092505A1 A IN O
, WO2011092505A1 A , O
for WO2011092505A1 A IN O
example WO2011092505A1 A NN O
, WO2011092505A1 A , O
the WO2011092505A1 A DT O
annexin WO2011092505A1 A NN O
A2-S100A10 WO2011092505A1 A NNP O
protein WO2011092505A1 A NN O
binding WO2011092505A1 A VBG O
interaction WO2011092505A1 A NN O
. WO2011092505A1 A . O

More WO2011092505A1 A RBR O
specifically WO2011092505A1 A RB O
, WO2011092505A1 A , O
the WO2011092505A1 A DT O
present WO2011092505A1 A JJ O
invention WO2011092505A1 A NN O
concerns WO2011092505A1 A NNS O
certain WO2011092505A1 A JJ O
substituted WO2011092505A1 A JJ O
pyrrole WO2011092505A1 A NN O
derivatives WO2011092505A1 A NNS O
of WO2011092505A1 A IN O
the WO2011092505A1 A DT O
general WO2011092505A1 A JJ O
formula WO2011092505A1 A NN O
I WO2011092505A1 A PRP O
or WO2011092505A1 A CC O
II WO2011092505A1 A NNP O
as WO2011092505A1 A IN O
defined WO2011092505A1 A JJ O
herein WO2011092505A1 A NN O
, WO2011092505A1 A , O
as WO2011092505A1 A RB O
well WO2011092505A1 A RB O
as WO2011092505A1 A IN O
processes WO2011092505A1 A NNS O
for WO2011092505A1 A IN O
preparing WO2011092505A1 A VBG O
these WO2011092505A1 A DT O
derivatives WO2011092505A1 A NNS O
, WO2011092505A1 A , O
pharmaceutical WO2011092505A1 A JJ O
compositions WO2011092505A1 A NNS O
comprising WO2011092505A1 A VBG O
these WO2011092505A1 A DT O
derivatives WO2011092505A1 A NNS O
and WO2011092505A1 A CC O
their WO2011092505A1 A PRP$ O
use WO2011092505A1 A NN O
in WO2011092505A1 A IN O
the WO2011092505A1 A DT O
treatment WO2011092505A1 A NN O
, WO2011092505A1 A , O
prevention WO2011092505A1 A NN O
or WO2011092505A1 A CC O
delay WO2011092505A1 A NN O
of WO2011092505A1 A IN O
progression WO2011092505A1 A NN O
of WO2011092505A1 A IN O
diseases WO2011092505A1 A NNS O
in WO2011092505A1 A IN O
which WO2011092505A1 A WDT O
S100 WO2011092505A1 A NNP I-UN
protein WO2011092505A1 A NN O
binding WO2011092505A1 A NN O
interactions WO2011092505A1 A NNS O
are WO2011092505A1 A VBP O
implicated WO2011092505A1 A VBN O
( WO2011092505A1 A ( O
such WO2011092505A1 A JJ O
as WO2011092505A1 A IN O
cancer WO2011092505A1 A NN O
) WO2011092505A1 A ) O
. WO2011092505A1 A . O

Freeze CN1729978A T NNP O
dry CN1729978A T NN O
powdered CN1729978A T VBD O
injection CN1729978A T NN O
of CN1729978A T IN O
moxlfloxacin CN1729978A T NN O
or CN1729978A T CC O
its CN1729978A T PRP$ O
salts CN1729978A T NNS O
and CN1729978A T CC O
preparation CN1729978A T NN O
process CN1729978A T NN O
thereof CN1729978A T NN O
. CN1729978A T . O

3- US20080103136 T JJ O
[ US20080103136 T JJ O
1- US20080103136 T JJ O
( US20080103136 T ( O
2-chlorophenyl US20080103136 T JJ O
) US20080103136 T ) O
ethoxy US20080103136 T FW O
] US20080103136 T FW O
-5-imidazo US20080103136 T FW O
[ US20080103136 T FW O
1,2-a US20080103136 T JJ O
] US20080103136 T JJ O
pyridin-3-ylthiophene-2-carboxyamide US20080103136 T NN O
; US20080103136 T : O
polo US20080103136 T CC I-UN
like US20080103136 T IN I-UN
kinase US20080103136 T NNP I-UN
inhibitor US20080103136 T NN O
; US20080103136 T : O
antitumor US20080103136 T NN O
and US20080103136 T CC O
anticarcinogenic US20080103136 T JJ O
agent US20080103136 T NN O
; US20080103136 T : O
mitotic US20080103136 T JJ O
phase US20080103136 T NN O
( US20080103136 T ( O
M US20080103136 T NNP O
phase US20080103136 T NN O
) US20080103136 T ) O
of US20080103136 T IN O
the US20080103136 T DT O
cell US20080103136 T NN O
cycle US20080103136 T NN O
. US20080103136 T . O

Peptide US20100331247 T NNP O
therapy US20100331247 T NN O
for US20100331247 T IN O
hyperglycemia US20100331247 T NN O
. US20100331247 T . O

Methods US20100331247 A NNS O
of US20100331247 A IN O
modulating US20100331247 A VBG O
blood US20100331247 A NN O
glucose US20100331247 A NN O
levels US20100331247 A NNS O
treating US20100331247 A VBG O
hyperglycemia US20100331247 A NN O
and US20100331247 A CC O
related US20100331247 A JJ O
complications US20100331247 A NNS O
and US20100331247 A CC O
conditions US20100331247 A NNS O
by US20100331247 A IN O
administration US20100331247 A NN O
of US20100331247 A IN O
a US20100331247 A DT O
VGF US20100331247 A NNP I-UN
biomolecule US20100331247 A NN O
to US20100331247 A TO O
a US20100331247 A DT O
patient US20100331247 A NN O
in US20100331247 A IN O
need US20100331247 A NN O
of US20100331247 A IN O
such US20100331247 A JJ O
treatment US20100331247 A NN O
are US20100331247 A VBP O
provided US20100331247 A VBN O
. US20100331247 A . O

Methods US20100331247 A NNS O
of US20100331247 A IN O
enhancing US20100331247 A VBG O
insulin US20100331247 A JJ I-UN
secretion US20100331247 A NN O
from US20100331247 A IN O
islet US20100331247 A NN O
beta US20100331247 A NN O
cells US20100331247 A NNS O
in US20100331247 A IN O
a US20100331247 A DT O
mammal US20100331247 A JJ O
exhibiting US20100331247 A NN O
reduced US20100331247 A VBN O
insulin US20100331247 A JJ I-UN
secretion US20100331247 A NN O
by US20100331247 A IN O
administration US20100331247 A NN O
of US20100331247 A IN O
a US20100331247 A DT O
therapeutically US20100331247 A RB O
effective US20100331247 A JJ O
amount US20100331247 A NN O
of US20100331247 A IN O
a US20100331247 A DT O
VGF US20100331247 A NNP I-UN
biomolecule US20100331247 A NN O
are US20100331247 A VBP O
also US20100331247 A RB O
provided US20100331247 A VBN O
. US20100331247 A . O

Substituted WO2008120003A1 T VBN O
piperidines WO2008120003A1 T NNS O
for WO2008120003A1 T IN O
use WO2008120003A1 T NN O
in WO2008120003A1 T IN O
the WO2008120003A1 T DT O
treatment WO2008120003A1 T NN O
of WO2008120003A1 T IN O
bacterial WO2008120003A1 T JJ O
infections WO2008120003A1 T NNS O
. WO2008120003A1 T . O

Novel CA2180660C T NNP O
piperidine CA2180660C T NN O
derivatives CA2180660C T NNS O
with CA2180660C T IN O
paf CA2180660C T JJ I-UN
antagonist CA2180660C T NN O
activity CA2180660C T NN O
. CA2180660C T . O

Compounds CA2180660C A NNS O
of CA2180660C A IN O
general CA2180660C A JJ O
formula CA2180660C A NN O
( CA2180660C A ( O
I CA2180660C A PRP O
) CA2180660C A ) O
and CA2180660C A CC O
their CA2180660C A PRP$ O
salts CA2180660C A NNS O
and CA2180660C A CC O
solvates CA2180660C A NNS O
are CA2180660C A VBP O
PAF CA2180660C A NNP I-UN
antagonists CA2180660C A NNS O
and CA2180660C A CC O
as CA2180660C A IN O
such CA2180660C A JJ O
are CA2180660C A VBP O
useful CA2180660C A JJ O
in CA2180660C A IN O
the CA2180660C A DT O
treatment CA2180660C A NN O
of CA2180660C A IN O
various CA2180660C A JJ O
diseases CA2180660C A NNS O
or CA2180660C A CC O
disorders CA2180660C A NNS O
mediated CA2180660C A VBN O
by CA2180660C A IN O
PAF CA2180660C A NNP I-UN
. CA2180660C A . O

Ezetimibe US20110130378 T NNP O
process US20110130378 T NN O
and US20110130378 T CC O
composition US20110130378 T NN O
. US20110130378 T . O

Acid-sensitive CN101880265A T JJ O
polymeric CN101880265A T JJ O
micelle CN101880265A T NN O
pharmaceutical CN101880265A T JJ O
composition CN101880265A T NN O
and CN101880265A T CC O
preparation CN101880265A T NN O
method CN101880265A T NN O
thereof CN101880265A T NN O
. CN101880265A T . O

Injectable US20100203163 T JJ O
polymer-lipid US20100203163 T JJ O
blend US20100203163 T NN O
for US20100203163 T IN O
localized US20100203163 T JJ O
drug US20100203163 T NN O
delivery US20100203163 T NN O
. US20100203163 T . O

Pharmaceutical CA2559634A1 T JJ O
preparations CA2559634A1 T NNS O
for CA2559634A1 T IN O
the CA2559634A1 T DT O
treatment CA2559634A1 T NN O
of CA2559634A1 T IN O
arthritis CA2559634A1 T NN O
. CA2559634A1 T . O

The CA2559634A1 A DT O
pharmaceutical CA2559634A1 A JJ O
composition CA2559634A1 A NN O
for CA2559634A1 A IN O
treating CA2559634A1 A VBG O
arthritis CA2559634A1 A NN O
comprises CA2559634A1 A NNS O
glucosamine CA2559634A1 A VBP O
or CA2559634A1 A CC O
a CA2559634A1 A DT O
salt CA2559634A1 A NN O
thereof CA2559634A1 A NN O
, CA2559634A1 A , O
plant CA2559634A1 A NN O
materials CA2559634A1 A NNS O
or CA2559634A1 A CC O
extracts CA2559634A1 A NNS O
, CA2559634A1 A , O
collagen CA2559634A1 A NN I-UN
, CA2559634A1 A , O
pantothenic CA2559634A1 A JJ O
acid CA2559634A1 A NN O
and CA2559634A1 A CC O
minerals CA2559634A1 A NNS O
. CA2559634A1 A . O

Diarylamine-substituted WO2009029617A1 T JJ O
quinolones WO2009029617A1 T NNS O
useful WO2009029617A1 T JJ O
as WO2009029617A1 T IN O
inducible WO2009029617A1 T JJ I-UN
nitric WO2009029617A1 T JJ I-UN
oxide WO2009029617A1 T IN I-UN
synthase WO2009029617A1 T NN I-UN
inhibitors WO2009029617A1 T NNS O
. WO2009029617A1 T . O

Novel WO2009029617A1 A NNP O
diarylamine-substituted WO2009029617A1 A JJ O
quinolone WO2009029617A1 A NN O
compounds WO2009029617A1 A NNS O
and WO2009029617A1 A CC O
pharmaceutical WO2009029617A1 A JJ O
compositions WO2009029617A1 A NNS O
, WO2009029617A1 A , O
certain WO2009029617A1 A JJ O
of WO2009029617A1 A IN O
which WO2009029617A1 A WDT O
have WO2009029617A1 A VBP O
been WO2009029617A1 A VBN O
found WO2009029617A1 A VBN O
to WO2009029617A1 A TO O
inhibit WO2009029617A1 A VB O
inducible WO2009029617A1 A JJ I-UN
NOS WO2009029617A1 A NNP I-UN
synthase WO2009029617A1 A NN I-UN
have WO2009029617A1 A VBP O
been WO2009029617A1 A VBN O
discovered WO2009029617A1 A VBN O
, WO2009029617A1 A , O
together WO2009029617A1 A RB O
with WO2009029617A1 A IN O
methods WO2009029617A1 A NNS O
of WO2009029617A1 A IN O
synthesizing WO2009029617A1 A NN O
and WO2009029617A1 A CC O
using WO2009029617A1 A VBG O
the WO2009029617A1 A DT O
compounds WO2009029617A1 A NNS O
including WO2009029617A1 A VBG O
methods WO2009029617A1 A NNS O
for WO2009029617A1 A IN O
the WO2009029617A1 A DT O
treatment WO2009029617A1 A NN O
of WO2009029617A1 A IN O
iNOS-mediated WO2009029617A1 A JJ O
diseases WO2009029617A1 A NNS O
in WO2009029617A1 A IN O
a WO2009029617A1 A DT O
patient WO2009029617A1 A NN O
by WO2009029617A1 A IN O
administering WO2009029617A1 A VBG O
the WO2009029617A1 A DT O
compounds WO2009029617A1 A NNS O
. WO2009029617A1 A . O

Levofloxacin CN102048704A T NNP O
lactate CN102048704A T NN O
dispersible CN102048704A T JJ O
tablet CN102048704A T NN O
and CN102048704A T CC O
preparation CN102048704A T NN O
method CN102048704A T NN O
thereof CN102048704A T NN O
. CN102048704A T . O

Novel CN102485222A T NNP O
purpose CN102485222A T NN O
of CN102485222A T IN O
3-methyl-1-phenyl-2-pyrazoline-5-ketone CN102485222A T CD O
. CN102485222A T . O

Compositions US20080085324 T NNS O
and US20080085324 T CC O
methods US20080085324 T NNS O
for US20080085324 T IN O
detecting US20080085324 T VBG O
and US20080085324 T CC O
treating US20080085324 T VBG O
renal US20080085324 T JJ O
injury US20080085324 T NN O
and US20080085324 T CC O
inflammation US20080085324 T NN O
. US20080085324 T . O

Renal US20080085324 A JJ O
injury US20080085324 A NN O
and US20080085324 A CC O
inflammation US20080085324 A NN O
is US20080085324 A VBZ O
diagnosed US20080085324 A VBN O
by US20080085324 A IN O
detecting US20080085324 A VBG O
an US20080085324 A DT O
elevation US20080085324 A NN O
in US20080085324 A IN O
GSK3b US20080085324 A NNP I-UN
level US20080085324 A NN O
or US20080085324 A CC O
activity US20080085324 A NN O
. US20080085324 A . O

Inflammation US20080085324 A NN O
of US20080085324 A IN O
bodily US20080085324 A RB O
tissues US20080085324 A NNS O
such US20080085324 A JJ O
as US20080085324 A IN O
renal US20080085324 A JJ O
tissue US20080085324 A NN O
is US20080085324 A VBZ O
inhibited US20080085324 A VBN O
by US20080085324 A IN O
administration US20080085324 A NN O
of US20080085324 A IN O
GSK3b US20080085324 A NNP I-UN
inhibitory US20080085324 A JJ O
compositions US20080085324 A NNS O
. US20080085324 A . O

Black CN101028265A T NNP O
and CN101028265A T CC O
white CN101028265A T JJ O
medicinal CN101028265A T JJ O
composition CN101028265A T NN O
for CN101028265A T IN O
improving CN101028265A T VBG O
sleep CN101028265A T NN O
and CN101028265A T CC O
adjusting CN101028265A T VBG O
sleep-rhythm CN101028265A T JJ O
functions CN101028265A T NNS O
. CN101028265A T . O

Instantaneous WO2014163031A1 T JJ O
intestinal WO2014163031A1 T JJ O
regulator WO2014163031A1 T NN O
. WO2014163031A1 T . O

Tryptamine-derived WO2011060976A1 T JJ O
compounds WO2011060976A1 T NNS O
as WO2011060976A1 T IN O
antibacterial WO2011060976A1 T JJ O
agents WO2011060976A1 T NNS O
. WO2011060976A1 T . O

Prevent US7425319 T NN O
, US7425319 T , O
maintenance US7425319 T NN O
of US7425319 T IN O
Dna US7425319 T NNP O
damage US7425319 T NN O
; US7425319 T : O
administering US7425319 T VBG O
compound US7425319 T NN O
which US7425319 T WDT O
forms US7425319 T VBZ O
nicotinamide-adenine US7425319 T JJ O
dinucleotide US7425319 T NN O
. US7425319 T . O

Slow-released CN1846685A T JJ O
injection CN1846685A T NN O
containing CN1846685A T VBG O
bendamustine CN1846685A T NN O
and CN1846685A T CC O
its CN1846685A T PRP$ O
synergist CN1846685A T NN O
. CN1846685A T . O

The CN1846685A A DT O
effective CN1846685A A JJ O
anticancer CN1846685A A NN O
component CN1846685A A NN O
is CN1846685A A VBZ O
bendamustine CN1846685A A JJ O
and/or CN1846685A A JJ O
bendamustine CN1846685A A NN O
synergist CN1846685A A NN O
of CN1846685A A IN O
topoisomerase CN1846685A A NN I-UN
inhibitor CN1846685A A NN O
, CN1846685A A , O
guanine CN1846685A A NN O
analogue CN1846685A A NN O
, CN1846685A A , O
tetrazine CN1846685A A NN O
compound CN1846685A A NN O
and/or CN1846685A A IN O
platinum CN1846685A A NN O
compound CN1846685A A NN O
; CN1846685A A : O
the CN1846685A A DT O
slow CN1846685A A JJ O
releasing CN1846685A A NN O
supplementary CN1846685A A JJ O
material CN1846685A A NN O
is CN1846685A A VBZ O
PLA CN1846685A A NNP O
, CN1846685A A , O
PLGA CN1846685A A NNP O
, CN1846685A A , O
EVAc CN1846685A A NNP O
, CN1846685A A , O
etc CN1846685A A FW O
or CN1846685A A CC O
their CN1846685A A PRP$ O
composition CN1846685A A NN O
; CN1846685A A : O
and CN1846685A A CC O
the CN1846685A A DT O
suspending CN1846685A A NN O
agent CN1846685A A NN O
is CN1846685A A VBZ O
sodium CN1846685A A JJ O
carboxymethyl CN1846685A A NN O
cellulose CN1846685A A NN O
, CN1846685A A , O
etc CN1846685A A NN O
of CN1846685A A IN O
viscosity CN1846685A A NN O
of CN1846685A A IN O
100-3000 CN1846685A A CD O
cp CN1846685A A NN O
( CN1846685A A ( O
at CN1846685A A IN O
20-30 CN1846685A A JJ O
deg.c CN1846685A A NN O
) CN1846685A A ) O
. CN1846685A A . O

Medicinal CN102579472A T JJ O
composition CN102579472A T NN O
capable CN102579472A T JJ O
of CN102579472A T IN O
expanding CN102579472A T VBG O
tracheal CN102579472A T NN O
smooth CN102579472A T JJ O
muscles CN102579472A T NNS O
and CN102579472A T CC O
application CN102579472A T NN O
thereof CN102579472A T NN O
. CN102579472A T . O

2-phenyl-4-cyclopropyl-pyrimidine US20110028484 T JJ O
derivatives US20110028484 T NNS O
. US20110028484 T . O

The US20110028484 A DT O
present US20110028484 A JJ O
invention US20110028484 A NN O
relates US20110028484 A VBZ O
to US20110028484 A TO O
2-phenyl-4-cyclopropyl-pyrimidine US20110028484 A JJ O
derivatives US20110028484 A NNS O
and US20110028484 A CC O
their US20110028484 A PRP$ O
use US20110028484 A NN O
as US20110028484 A IN O
P2Y12 US20110028484 A NNP I-UN
receptor US20110028484 A NN O
antagonists US20110028484 A NNS O
in US20110028484 A IN O
the US20110028484 A DT O
treatment US20110028484 A NN O
and/or US20110028484 A JJ O
prevention US20110028484 A NN O
of US20110028484 A IN O
peripheral US20110028484 A JJ O
vascular US20110028484 A NN O
, US20110028484 A , O
of US20110028484 A IN O
visceral- US20110028484 A JJ O
, US20110028484 A , O
hepatic- US20110028484 A JJ O
and US20110028484 A CC O
renal-vascular US20110028484 A JJ O
, US20110028484 A , O
of US20110028484 A IN O
cardiovascular US20110028484 A JJ O
and US20110028484 A CC O
of US20110028484 A IN O
cerebrovascular US20110028484 A JJ O
diseases US20110028484 A NNS O
or US20110028484 A CC O
conditions US20110028484 A NNS O
associated US20110028484 A VBN O
with US20110028484 A IN O
platelet US20110028484 A NN O
aggregation US20110028484 A NN O
, US20110028484 A , O
including US20110028484 A VBG O
thrombosis US20110028484 A NN O
in US20110028484 A IN O
humans US20110028484 A NNS O
and US20110028484 A CC O
other US20110028484 A JJ O
mammals US20110028484 A NNS O
. US20110028484 A . O

Formable US20100178278 T JJ O
bioceramics US20100178278 T NNS O
. US20100178278 T . O

Selected WO2014102315A1 T VBN O
macrolides WO2014102315A1 T NNS O
with WO2014102315A1 T IN O
pde4-inhibiting WO2014102315A1 T JJ O
activity WO2014102315A1 T NN O
. WO2014102315A1 T . O

Combined WO2011110087A1 T VBN O
use WO2011110087A1 T NN O
of WO2011110087A1 T IN O
ribonuclease WO2011110087A1 T NN I-UN
and WO2011110087A1 T CC O
artemisinsin WO2011110087A1 T NN O
. WO2011110087A1 T . O

It WO2011110087A1 A PRP O
comprises WO2011110087A1 A VBZ O
an WO2011110087A1 A DT O
agent WO2011110087A1 A NN O
comprising WO2011110087A1 A VBG O
an WO2011110087A1 A DT O
artemisinin WO2011110087A1 A NN O
or WO2011110087A1 A CC O
an WO2011110087A1 A DT O
artemisinin WO2011110087A1 A JJ O
derivative WO2011110087A1 A NN O
; WO2011110087A1 A : O
an WO2011110087A1 A DT O
agent WO2011110087A1 A NN O
comprising WO2011110087A1 A VBG O
a WO2011110087A1 A DT O
ribonuclease WO2011110087A1 A NN I-UN
; WO2011110087A1 A : O
and WO2011110087A1 A CC O
a WO2011110087A1 A DT O
description WO2011110087A1 A NN O
. WO2011110087A1 A . O

Methods EP0879281B1 T NNS O
for EP0879281B1 T IN O
transforming EP0879281B1 T VBG O
dendritic EP0879281B1 T JJ O
cells EP0879281B1 T NNS O
and EP0879281B1 T CC O
activating EP0879281B1 T VBG O
t EP0879281B1 T JJ O
cells EP0879281B1 T NNS O
. EP0879281B1 T . O

The EP0879281B1 A DT O
resulting EP0879281B1 A VBG O
dendritic EP0879281B1 A JJ O
cell EP0879281B1 A NN O
is EP0879281B1 A VBZ O
an EP0879281B1 A DT O
antigen EP0879281B1 A NN O
presenting EP0879281B1 A NN O
cell EP0879281B1 A NN O
which EP0879281B1 A WDT O
activates EP0879281B1 A VBZ O
T EP0879281B1 A NNP O
cells EP0879281B1 A NNS O
against EP0879281B1 A IN O
MHC EP0879281B1 A NNP I-UN
class EP0879281B1 A NN I-UN
I-antigen EP0879281B1 A NNP O
targets EP0879281B1 A NNS O
. EP0879281B1 A . O

Poly US20130004455 T NNP O
( US20130004455 T ( O
organophosphazene US20130004455 T NN O
) US20130004455 T ) O
composition US20130004455 T NN O
for US20130004455 T IN O
biomaterials US20130004455 T NNS O
. US20130004455 T . O

Assessing US20050180982 T VBG O
metastatic US20050180982 T JJ O
potential US20050180982 T NN O
of US20050180982 T IN O
carcinoma US20050180982 T NN O
cells US20050180982 T NNS O
by US20050180982 T IN O
contacting US20050180982 T VBG O
cells US20050180982 T NNS O
in US20050180982 T IN O
tissue US20050180982 T NN O
sample US20050180982 T NN O
suspected US20050180982 T VBD O
of US20050180982 T IN O
containing US20050180982 T VBG O
carcinoma US20050180982 T NN O
with US20050180982 T IN O
detectable US20050180982 T JJ O
indicator US20050180982 T NN O
capable US20050180982 T JJ O
of US20050180982 T IN O
binding US20050180982 T VBG O
to US20050180982 T TO O
cad-11 US20050180982 T NN I-UN
or US20050180982 T CC O
cad-11 US20050180982 T NN I-UN
mRNA US20050180982 T NN I-UN
and US20050180982 T CC O
determining US20050180982 T VBG O
presence US20050180982 T NN O
or US20050180982 T CC O
absence US20050180982 T NN O
of US20050180982 T IN O
cad-11 US20050180982 T JJ I-UN
expression US20050180982 T NN O
in US20050180982 T IN O
tissue US20050180982 T NN O
; US20050180982 T : O
method US20050180982 T NN O
of US20050180982 T IN O
preventing US20050180982 T VBG O
or US20050180982 T CC O
terminating US20050180982 T VBG O
pregnancy US20050180982 T NN O
. US20050180982 T . O

A US20050180982 A DT O
method US20050180982 A NN O
of US20050180982 A IN O
modulating US20050180982 A VBG O
differentiation US20050180982 A NN O
or US20050180982 A CC O
neoplastic US20050180982 A JJ O
transformation US20050180982 A NN O
of US20050180982 A IN O
cells US20050180982 A NNS O
is US20050180982 A VBZ O
provided US20050180982 A VBN O
in US20050180982 A IN O
which US20050180982 A WDT O
the US20050180982 A DT O
cells US20050180982 A NNS O
are US20050180982 A VBP O
caused US20050180982 A VBN O
to US20050180982 A TO O
increase US20050180982 A VB O
or US20050180982 A CC O
decrease US20050180982 A VB O
cad-11 US20050180982 A JJ I-UN
expression US20050180982 A NN O
or US20050180982 A CC O
function US20050180982 A NN O
. US20050180982 A . O

Such US20050180982 A JJ O
method US20050180982 A NN O
has US20050180982 A VBZ O
application US20050180982 A NN O
in US20050180982 A IN O
affecting US20050180982 A VBG O
differentiation US20050180982 A NN O
or US20050180982 A CC O
neoplastic US20050180982 A JJ O
transformation US20050180982 A NN O
of US20050180982 A IN O
cells US20050180982 A NNS O
, US20050180982 A , O
preventing US20050180982 A VBG O
or US20050180982 A CC O
terminating US20050180982 A VBG O
pregnancy US20050180982 A NN O
by US20050180982 A IN O
altering US20050180982 A VBG O
cad-11 US20050180982 A JJ I-UN
function US20050180982 A NN O
or US20050180982 A CC O
expression US20050180982 A NN O
in US20050180982 A IN O
trophoblast US20050180982 A NN O
cells US20050180982 A NNS O
, US20050180982 A , O
or US20050180982 A CC O
for US20050180982 A IN O
reducing US20050180982 A VBG O
the US20050180982 A DT O
viability US20050180982 A NN O
of US20050180982 A IN O
carcinoma US20050180982 A NN O
cells US20050180982 A NNS O
having US20050180982 A VBG O
a US20050180982 A DT O
low US20050180982 A JJ O
to US20050180982 A TO O
moderate US20050180982 A VB O
metastatic US20050180982 A JJ O
potential US20050180982 A NN O
. US20050180982 A . O

The US20050180982 A DT O
use US20050180982 A NN O
of US20050180982 A IN O
agents US20050180982 A NNS O
which US20050180982 A WDT O
increase US20050180982 A VBP O
or US20050180982 A CC O
decrease US20050180982 A VB O
cad-11 US20050180982 A JJ I-UN
expression US20050180982 A NN O
or US20050180982 A CC O
function US20050180982 A NN O
is US20050180982 A VBZ O
also US20050180982 A RB O
provided US20050180982 A VBN O
, US20050180982 A , O
including US20050180982 A VBG O
such US20050180982 A JJ O
use US20050180982 A NN O
for US20050180982 A IN O
preparation US20050180982 A NN O
of US20050180982 A IN O
medicaments US20050180982 A NNS O
for US20050180982 A IN O
modulating US20050180982 A VBG O
differentiation US20050180982 A NN O
or US20050180982 A CC O
neoplastic US20050180982 A JJ O
transformation US20050180982 A NN O
of US20050180982 A IN O
cells US20050180982 A NNS O
. US20050180982 A . O

Promotion US20080153796 T NN O
of US20080153796 T IN O
wound US20080153796 T NN O
contraction US20080153796 T NN O
. US20080153796 T . O

Corticosteroid-beta-agonist-muscarinic WO2011081937A1 T JJ O
antagonist WO2011081937A1 T NN O
compounds WO2011081937A1 T NNS O
for WO2011081937A1 T IN O
use WO2011081937A1 T NN O
in WO2011081937A1 T IN O
therapy WO2011081937A1 T NN O
. WO2011081937A1 T . O

The WO2011081937A1 A DT O
instant WO2011081937A1 A JJ O
invention WO2011081937A1 A NN O
relates WO2011081937A1 A VBZ O
to WO2011081937A1 A TO O
new WO2011081937A1 A JJ O
chemical WO2011081937A1 A NN O
entities WO2011081937A1 A NNS O
which WO2011081937A1 A WDT O
comprise WO2011081937A1 A VBP O
corticosteroids WO2011081937A1 A NNS O
, WO2011081937A1 A , O
phosphorylated WO2011081937A1 A VBD O
β-agonists WO2011081937A1 A NNS O
and WO2011081937A1 A CC O
muscarinic WO2011081937A1 A NN I-UN
( WO2011081937A1 A ( I-UN
M3 WO2011081937A1 A NNP I-UN
) WO2011081937A1 A ) O
antagonists WO2011081937A1 A VBZ O
for WO2011081937A1 A IN O
use WO2011081937A1 A NN O
in WO2011081937A1 A IN O
therapy WO2011081937A1 A NN O
and WO2011081937A1 A CC O
compositions WO2011081937A1 A NNS O
comprising WO2011081937A1 A VBG O
and WO2011081937A1 A CC O
processes WO2011081937A1 A NNS O
for WO2011081937A1 A IN O
preparing WO2011081937A1 A VBG O
the WO2011081937A1 A DT O
same WO2011081937A1 A JJ O
. WO2011081937A1 A . O

Adhesion-Promoting US20120134950 T NNP O
thin US20120134950 T JJ O
Film US20120134950 T NNP O
and US20120134950 T CC O
Moisture US20120134950 T NNP O
Resistant US20120134950 T NNP O
Skin US20120134950 T NNP O
Barrier US20120134950 T NNP O
Compositions US20120134950 T NNP O
. US20120134950 T . O

Application CN102784135A T NN O
of CN102784135A T IN O
equol-based CN102784135A T JJ O
BKCa CN102784135A T NNP I-UN
channel CN102784135A T NN I-UN
activation CN102784135A T NN O
. CN102784135A T . O

The CN102784135A A DT O
invention CN102784135A A NN O
discloses CN102784135A A VBZ O
an CN102784135A A DT O
application CN102784135A A NN O
of CN102784135A A IN O
equol-based CN102784135A A JJ O
BKCa CN102784135A A NNP I-UN
channel CN102784135A A NN I-UN
activation CN102784135A A NN O
. CN102784135A A . O

Pharmaceutical CN102784135A A JJ O
activity CN102784135A A NN O
of CN102784135A A IN O
equol CN102784135A A NN O
is CN102784135A A VBZ O
detected CN102784135A A VBN O
on CN102784135A A IN O
the CN102784135A A DT O
basis CN102784135A A NN O
of CN102784135A A IN O
applying CN102784135A A VBG O
a CN102784135A A DT O
rat CN102784135A A NN O
focal CN102784135A A JJ O
cerebral CN102784135A A JJ O
ischemia CN102784135A A NN O
reperfusion CN102784135A A NN O
model CN102784135A A NN O
, CN102784135A A , O
a CN102784135A A DT O
tail-cuff CN102784135A A JJ O
method CN102784135A A NN O
to CN102784135A A TO O
measure CN102784135A A VB O
rat CN102784135A A VB O
blood CN102784135A A NN O
pressure CN102784135A A NN O
, CN102784135A A , O
a CN102784135A A DT O
Laser CN102784135A A NNP O
Doppler CN102784135A A NNP O
Flowmetry CN102784135A A NNP O
to CN102784135A A TO O
observe CN102784135A A VB O
brain CN102784135A A NN O
parenchyma CN102784135A A NN O
and CN102784135A A CC O
pia CN102784135A A NN O
mater CN102784135A A NN O
blood CN102784135A A NN O
flow CN102784135A A NN O
, CN102784135A A , O
an CN102784135A A DT O
in-vitro CN102784135A A JJ O
vascular CN102784135A A JJ O
muscle CN102784135A A NN O
tension CN102784135A A NN O
tracing CN102784135A A NN O
and CN102784135A A CC O
a CN102784135A A DT O
patch CN102784135A A NN O
clamp CN102784135A A NN O
technology CN102784135A A NN O
, CN102784135A A , O
and CN102784135A A CC O
results CN102784135A A NNS O
show CN102784135A A VBP O
that CN102784135A A IN O
the CN102784135A A DT O
equol CN102784135A A NN O
, CN102784135A A , O
through CN102784135A A IN O
activating CN102784135A A VBG O
beta1 CN102784135A A JJ O
subunit CN102784135A A NN O
of CN102784135A A IN O
BKCa CN102784135A A NNP I-UN
channel CN102784135A A NN I-UN
, CN102784135A A , O
can CN102784135A A MD O
dilate CN102784135A A VB O
blood CN102784135A A NN O
vessels CN102784135A A NNS O
, CN102784135A A , O
increase CN102784135A A VB O
cerebral CN102784135A A JJ O
blood CN102784135A A NN O
flow CN102784135A A NN O
and CN102784135A A CC O
protect CN102784135A A JJ O
ischemic CN102784135A A JJ O
reperfusion CN102784135A A NN O
brain CN102784135A A NN O
tissue CN102784135A A NN O
, CN102784135A A , O
is CN102784135A A VBZ O
beneficial CN102784135A A JJ O
for CN102784135A A IN O
prevention CN102784135A A NN O
and CN102784135A A CC O
treatment CN102784135A A NN O
of CN102784135A A IN O
ischemia CN102784135A A NN O
brain CN102784135A A NN O
stroke CN102784135A A NN O
, CN102784135A A , O
and CN102784135A A CC O
can CN102784135A A MD O
be CN102784135A A VB O
used CN102784135A A VBN O
for CN102784135A A IN O
preparation CN102784135A A NN O
of CN102784135A A IN O
related CN102784135A A JJ O
medicaments CN102784135A A NNS O
. CN102784135A A . O

Compound CN101785761A T NNP O
hemostasis CN101785761A T NN O
medicine CN101785761A T NN O
and CN101785761A T CC O
preparation CN101785761A T NN O
method CN101785761A T NN O
thereof CN101785761A T NN O
. CN101785761A T . O

Freezing-drying CN1559413A T JJ O
powder-injection CN1559413A T NN O
contg CN1559413A T NN O
. CN1559413A T . O

dexamethasone CN1559413A T NN O
sodium CN1559413A T NN O
phosphate CN1559413A T NN O
, CN1559413A T , O
and CN1559413A T CC O
its CN1559413A T PRP$ O
prepn CN1559413A T NN O
. CN1559413A T . O

method CN1559413A T NN O
. CN1559413A T . O

CREATINE WO2011019348A1 T JJ O
β-ALANINATE WO2011019348A1 T NN O
: WO2011019348A1 T : O
A WO2011019348A1 T DT O
NOVEL WO2011019348A1 T NNP O
SALT WO2011019348A1 T NNP O
FOR WO2011019348A1 T NNP O
INCREASING WO2011019348A1 T NNP O
ATHLETIC WO2011019348A1 T NNP O
PERFORMANCE WO2011019348A1 T NNP O
. WO2011019348A1 T . O

Buccal CN101152144A T JJ O
preparation CN101152144A T NN O
containing CN101152144A T VBG O
levorotation CN101152144A T NN O
ofloxacin CN101152144A T NN O
and CN101152144A T CC O
method CN101152144A T NN O
for CN101152144A T IN O
preparing CN101152144A T VBG O
the CN101152144A T DT O
same CN101152144A T JJ O
. CN101152144A T . O

Therapeutic WO2008020491A1 T JJ O
agent WO2008020491A1 T NN O
for WO2008020491A1 T IN O
pigmented WO2008020491A1 T JJ O
skin WO2008020491A1 T JJ O
lesion WO2008020491A1 T NN O
. WO2008020491A1 T . O

Hydrochloride US20070191435 T NNP O
salt US20070191435 T NN O
of US20070191435 T IN O
5- US20070191435 T JJ O
[ US20070191435 T JJ O
4- US20070191435 T JJ O
[ US20070191435 T NN O
2- US20070191435 T JJ O
( US20070191435 T ( O
n-methyl-n- US20070191435 T JJ O
( US20070191435 T ( O
2-pyridyl US20070191435 T JJ O
) US20070191435 T ) O
amino US20070191435 T NN O
) US20070191435 T ) O
ethoxy US20070191435 T NN O
] US20070191435 T NNP O
benzyl US20070191435 T NN O
] US20070191435 T NNP O
thiazolidine-2,4-dione US20070191435 T NN O
. US20070191435 T . O

A US20070191435 A DT O
novel US20070191435 A JJ O
pharmaceutical US20070191435 A JJ O
compound US20070191435 A NN O
5- US20070191435 A JJ O
[ US20070191435 A JJ O
4- US20070191435 A JJ O
[ US20070191435 A NN O
2- US20070191435 A JJ O
( US20070191435 A ( O
N-methyl-N- US20070191435 A NNP O
( US20070191435 A ( O
2-pyridyl US20070191435 A JJ O
) US20070191435 A ) O
amino US20070191435 A NN O
) US20070191435 A ) O
ethoxy US20070191435 A NN O
] US20070191435 A NNP O
benzyl US20070191435 A NN O
] US20070191435 A NNP O
thiazolidine-2,4-dione US20070191435 A NN O
hydrochloride US20070191435 A NN O
, US20070191435 A , O
a US20070191435 A DT O
process US20070191435 A NN O
for US20070191435 A IN O
preparing US20070191435 A VBG O
such US20070191435 A PDT O
a US20070191435 A DT O
compound US20070191435 A NN O
, US20070191435 A , O
a US20070191435 A DT O
pharmaceutical US20070191435 A JJ O
composition US20070191435 A NN O
comprising US20070191435 A VBG O
such US20070191435 A JJ O
a US20070191435 A DT O
compound US20070191435 A NN O
and US20070191435 A CC O
the US20070191435 A DT O
use US20070191435 A NN O
of US20070191435 A IN O
such US20070191435 A JJ O
a US20070191435 A DT O
compound US20070191435 A NN O
in US20070191435 A IN O
medicine US20070191435 A NN O

Fused US20120316154 T VBN O
tricyclic US20120316154 T JJ O
compounds US20120316154 T NNS O
for US20120316154 T IN O
the US20120316154 T DT O
treatment US20120316154 T NN O
of US20120316154 T IN O
inflammatory US20120316154 T NN O
disorders US20120316154 T NNS O
. US20120316154 T . O

Bifunctional US20070270357 T NNP O
Macrolide US20070270357 T NNP O
Heterocyclic US20070270357 T NNP O
Compounds US20070270357 T NNP O
and US20070270357 T CC O
Methods US20070270357 T NNP O
of US20070270357 T IN O
Making US20070270357 T NNP O
and US20070270357 T CC O
Using US20070270357 T VBG O
the US20070270357 T DT O
Same US20070270357 T NNP O
. US20070270357 T . O

Pregnenolone US20120122830 T NN O
sulfate US20120122830 T NN O
for US20120122830 T IN O
the US20120122830 T DT O
treatment US20120122830 T NN O
of US20120122830 T IN O
neurologic US20120122830 T JJ O
disorders US20120122830 T NNS O
. US20120122830 T . O

The US20120122830 A DT O
disclosure US20120122830 A NN O
relates US20120122830 A VBZ O
, US20120122830 A , O
in US20120122830 A IN O
part US20120122830 A NN O
, US20120122830 A , O
to US20120122830 A TO O
methods US20120122830 A NNS O
of US20120122830 A IN O
using US20120122830 A VBG O
pregnenolone US20120122830 A NN O
sulfate US20120122830 A NN O
( US20120122830 A ( O
PREGS US20120122830 A NNP O
) US20120122830 A ) O
to US20120122830 A TO O
protect US20120122830 A VB O
against US20120122830 A IN O
the US20120122830 A DT O
neurotoxicity US20120122830 A NN O
of US20120122830 A IN O
the US20120122830 A DT O
β-amyloid US20120122830 A JJ I-UN
peptide US20120122830 A JJ O
Aβ1-42 US20120122830 A NNP I-UN
. US20120122830 A . O

Compounds EP2268141A1 T NNS O
and EP2268141A1 T CC O
method EP2268141A1 T NN O
for EP2268141A1 T IN O
reducing EP2268141A1 T VBG O
uric EP2268141A1 T JJ O
acid EP2268141A1 T NN O
. EP2268141A1 T . O

Drospirenone US20080160004 T NN O
, US20080160004 T , O
ethinylestradiol US20080160004 T NN O
; US20080160004 T : O
oral US20080160004 T JJ O
contraceptives US20080160004 T NNS O
; US20080160004 T : O
kits US20080160004 T NNS O
. US20080160004 T . O

Encapsulated US20080118562 T VBN O
by US20080118562 T IN O
a US20080118562 T DT O
biocompatible US20080118562 T JJ O
polymer US20080118562 T NN O
shell US20080118562 T NN O
; US20080118562 T : O
decreased US20080118562 T VBN O
toxicity US20080118562 T NN O
of US20080118562 T IN O
anticarcinogenic US20080118562 T JJ O
agents US20080118562 T NNS O
; US20080118562 T : O
side US20080118562 T VB O
effect US20080118562 T NN O
reduction US20080118562 T NN O
. US20080118562 T . O

Aminoglycoside CN102558255A T NNP O
compound CN102558255A T NN O
and CN102558255A T CC O
extracting CN102558255A T NN O
and CN102558255A T CC O
separating CN102558255A T VBG O
method CN102558255A T NN O
thereof CN102558255A T NN O
. CN102558255A T . O

Antioxidant CN102356874A T NNP O
health CN102356874A T NN O
food CN102356874A T NN O
composition CN102356874A T NN O
, CN102356874A T , O
and CN102356874A T CC O
its CN102356874A T PRP$ O
preparation CN102356874A T NN O
method CN102356874A T NN O
and CN102356874A T CC O
application CN102356874A T NN O
. CN102356874A T . O

Duloxetine CN101412707A T NNP O
derivative CN101412707A T JJ O
and CN101412707A T CC O
preparation CN101412707A T NN O
thereof CN101412707A T NN O
. CN101412707A T . O

Treatment US20120269802 T NN O
And US20120269802 T CC O
Prognosis US20120269802 T NN O
With US20120269802 T IN O
Thalidomide US20120269802 T NNP O
In US20120269802 T IN O
Multiple US20120269802 T NNP O
Myeloma US20120269802 T NNP O
Based US20120269802 T VBD O
on US20120269802 T IN O
Karyotyping US20120269802 T NNP O
And US20120269802 T CC O
Gene US20120269802 T NNP O
Expression US20120269802 T NNP O
Profiling US20120269802 T NNP O
. US20120269802 T . O

The US20120269802 A DT O
present US20120269802 A JJ O
invention US20120269802 A NN O
provides US20120269802 A VBZ O
a US20120269802 A DT O
method US20120269802 A NN O
treating US20120269802 A VBG O
a US20120269802 A DT O
myeloma US20120269802 A NN O
patient US20120269802 A NN O
by US20120269802 A IN O
administering US20120269802 A VBG O
one US20120269802 A CD O
or US20120269802 A CC O
more US20120269802 A JJR O
of US20120269802 A IN O
thalidomide US20120269802 A NN O
, US20120269802 A , O
a US20120269802 A DT O
Total US20120269802 A JJ O
Therapy US20120269802 A NNP O
2 US20120269802 A CD O
regimen US20120269802 A NNS O
, US20120269802 A , O
an US20120269802 A DT O
interleukin-6 US20120269802 A JJ I-UN
signaling US20120269802 A NN O
suppressor US20120269802 A NN O
, US20120269802 A , O
an US20120269802 A DT O
interleukin-6R US20120269802 A JJ O
signaling US20120269802 A NN O
suppressor US20120269802 A NN O
, US20120269802 A , O
an US20120269802 A DT O
IGF1 US20120269802 A NNP I-UN
signaling US20120269802 A NN O
suppressor US20120269802 A NN O
, US20120269802 A , O
an US20120269802 A DT O
IGF1 US20120269802 A NNP I-UN
R US20120269802 A NNP I-UN
signaling US20120269802 A VBG O
suppressor US20120269802 A NN O
, US20120269802 A , O
shRNA US20120269802 A NN O
or US20120269802 A CC O
other US20120269802 A JJ O
modulators US20120269802 A NNS O
of US20120269802 A IN O
gene US20120269802 A NN O
expression US20120269802 A NN O
. US20120269802 A . O

Also US20120269802 A RB O
, US20120269802 A , O
provided US20120269802 A VBN O
are US20120269802 A VBP O
methods US20120269802 A NNS O
for US20120269802 A IN O
predicting US20120269802 A VBG O
outcome US20120269802 A NN O
of US20120269802 A IN O
a US20120269802 A DT O
treatment US20120269802 A NN O
for US20120269802 A IN O
an US20120269802 A DT O
individual US20120269802 A JJ O
having US20120269802 A VBG O
a US20120269802 A DT O
cancer US20120269802 A NN O
, US20120269802 A , O
e.g. US20120269802 A NN O
, US20120269802 A , O
myeloma US20120269802 A NN O
, US20120269802 A , O
by US20120269802 A IN O
performing US20120269802 A VBG O
one US20120269802 A CD O
or US20120269802 A CC O
more US20120269802 A JJR O
of US20120269802 A IN O
karyotyping US20120269802 A NN O
or US20120269802 A CC O
expression US20120269802 A NN O
profiling US20120269802 A NN O
of US20120269802 A IN O
chromosomes US20120269802 A NNS O
1 US20120269802 A CD O
and US20120269802 A CC O
13 US20120269802 A CD O
or US20120269802 A CC O
expression US20120269802 A NN O
level US20120269802 A NN O
measurement US20120269802 A NN O
of US20120269802 A IN O
IL-6R US20120269802 A NNP I-UN
. US20120269802 A . O

Medicinal CN101933945A T JJ O
composition CN101933945A T NN O
taking CN101933945A T VBG O
salidroside CN101933945A T JJ O
, CN101933945A T , O
D-ribose CN101933945A T JJ O
and CN101933945A T CC O
honey CN101933945A T NN O
as CN101933945A T IN O
raw CN101933945A T JJ O
materials CN101933945A T NNS O
. CN101933945A T . O

Using US20050042655 T VBG O
hematopoietoic US20050042655 T JJ O
regulatory US20050042655 T JJ O
related US20050042655 T VBN O
polypeptide US20050042655 T NN O
( US20050042655 T ( O
HEMA US20050042655 T NNP O
) US20050042655 T ) O
for US20050042655 T IN O
use US20050042655 T NN O
in US20050042655 T IN O
diagnosis US20050042655 T NN O
, US20050042655 T , O
treatment US20050042655 T NN O
and US20050042655 T CC O
prevention US20050042655 T NN O
of US20050042655 T IN O
hematopoietic US20050042655 T JJ O
disorders US20050042655 T NNS O
. US20050042655 T . O

Inhibitors US20120136023 T NNS O
of US20120136023 T IN O
HIV US20120136023 T NNP O
Replication US20120136023 T NNP O
. US20120136023 T . O

Combination EP2311818A1 T NN O
of EP2311818A1 T IN O
a EP2311818A1 T DT O
5-phenylthiazole EP2311818A1 T JJ O
compound EP2311818A1 T NN O
as EP2311818A1 T IN O
PI3 EP2311818A1 T NNP O
kinase EP2311818A1 T NNP O
inhibitor EP2311818A1 T NN O
with EP2311818A1 T IN O
an EP2311818A1 T DT O
antiinflammatory EP2311818A1 T NN O
, EP2311818A1 T , O
bronchodilatory EP2311818A1 T NN O
or EP2311818A1 T CC O
antihistamine EP2311818A1 T JJ O
drug EP2311818A1 T NN O
. EP2311818A1 T . O

Crlf2 US20120282258 T NNP I-UN
in US20120282258 T IN O
precursor US20120282258 T NN O
b-cell US20120282258 T NN O
acute US20120282258 T JJ O
lymphoblastic US20120282258 T JJ O
leukemia US20120282258 T NN O
. US20120282258 T . O

The US20120282258 A DT O
invention US20120282258 A NN O
relates US20120282258 A VBZ O
to US20120282258 A TO O
cytokine US20120282258 A VB I-UN
receptor-like US20120282258 A JJ I-UN
factor US20120282258 A NN I-UN
2 US20120282258 A CD I-UN
( US20120282258 A ( O
CRLF2 US20120282258 A NNP I-UN
) US20120282258 A ) O
, US20120282258 A , O
and US20120282258 A CC O
particularly US20120282258 A RB O
certain US20120282258 A JJ O
mutant US20120282258 A JJ O
forms US20120282258 A NNS O
of US20120282258 A IN O
CRLF2 US20120282258 A NNP I-UN
, US20120282258 A , O
as US20120282258 A IN O
prognostic US20120282258 A JJ O
and US20120282258 A CC O
therapeutic US20120282258 A JJ O
targets US20120282258 A NNS O
in US20120282258 A IN O
precursor US20120282258 A JJ O
B-cell US20120282258 A NNP O
acute US20120282258 A NN O
lymphoblastic US20120282258 A JJ O
leukemia US20120282258 A NN O
( US20120282258 A ( O
B-ALL US20120282258 A NNP O
) US20120282258 A ) O
. US20120282258 A . O

Mutant US20120282258 A JJ O
CRLF2 US20120282258 A NNP I-UN
with US20120282258 A IN O
a US20120282258 A DT O
Phe232-Cys US20120282258 A NNP O
( US20120282258 A ( O
F232C US20120282258 A NNP O
) US20120282258 A ) O
mutation US20120282258 A NN O
is US20120282258 A VBZ O
overexpressed US20120282258 A VBN O
and US20120282258 A CC O
constitutively US20120282258 A RB O
activates US20120282258 A VBZ O
STAT5 US20120282258 A NNP I-UN
in US20120282258 A IN O
a US20120282258 A DT O
subset US20120282258 A NN O
of US20120282258 A IN O
B-ALL US20120282258 A NNP O
patients US20120282258 A NNS O
with US20120282258 A IN O
particularly US20120282258 A RB O
poor US20120282258 A JJ O
prognosis US20120282258 A NN O
. US20120282258 A . O

Methods US20120282258 A NNS O
and US20120282258 A CC O
compositions US20120282258 A NNS O
useful US20120282258 A JJ O
for US20120282258 A IN O
identifying US20120282258 A VBG O
, US20120282258 A , O
inhibiting US20120282258 A VBG O
expression US20120282258 A NN O
, US20120282258 A , O
and US20120282258 A CC O
inhibiting US20120282258 A VBG O
activity US20120282258 A NN O
of US20120282258 A IN O
the US20120282258 A DT O
mutant US20120282258 A JJ O
CRLF2 US20120282258 A NNP I-UN
are US20120282258 A VBP O
provided US20120282258 A VBN O
. US20120282258 A . O

Stabilized US20100234313 T VBN O
micronised US20100234313 T JJ O
particles US20100234313 T NNS O
. US20100234313 T . O

The US20100234313 A DT O
present US20100234313 A JJ O
invention US20100234313 A NN O
relates US20100234313 A VBZ O
to US20100234313 A TO O
a US20100234313 A DT O
method US20100234313 A NN O
for US20100234313 A IN O
preparing US20100234313 A VBG O
a US20100234313 A DT O
suspension US20100234313 A NN O
of US20100234313 A IN O
micronised US20100234313 A JJ O
particles US20100234313 A NNS O
of US20100234313 A IN O
a US20100234313 A DT O
solid US20100234313 A JJ O
organic US20100234313 A JJ O
compound US20100234313 A NN O
, US20100234313 A , O
which US20100234313 A WDT O
method US20100234313 A VBP O
comprises US20100234313 A NNS O
subjecting US20100234313 A VBG O
the US20100234313 A DT O
solid US20100234313 A JJ O
organic US20100234313 A JJ O
compound US20100234313 A NN O
to US20100234313 A TO O
size US20100234313 A NN O
reduction US20100234313 A NN O
by US20100234313 A IN O
wet US20100234313 A JJ O
grinding US20100234313 A VBG O
under US20100234313 A IN O
pH US20100234313 A JJ O
conditions US20100234313 A NNS O
wherein US20100234313 A VBP O
the US20100234313 A DT O
intrinsic US20100234313 A JJ O
surface US20100234313 A NN O
charge US20100234313 A NN O
of US20100234313 A IN O
the US20100234313 A DT O
size-reduced US20100234313 A JJ O
organic US20100234313 A JJ O
compound US20100234313 A NN O
is US20100234313 A VBZ O
sufficient US20100234313 A JJ O
to US20100234313 A TO O
keep US20100234313 A VB O
the US20100234313 A DT O
suspension US20100234313 A NN O
stable US20100234313 A NN O
. US20100234313 A . O

Antibodies US8388971 T NNS O
that US8388971 T WDT O
bind US8388971 T VBP O
CD40 US8388971 T NNP I-UN
and US8388971 T CC O
methods US8388971 T NNS O
of US8388971 T IN O
treating US8388971 T VBG O
cancer US8388971 T NN O
and US8388971 T CC O
enhancing US8388971 T VBG O
immune US8388971 T JJ O
responses US8388971 T NNS O
. US8388971 T . O

The US8388971 A DT O
present US8388971 A JJ O
invention US8388971 A NN O
relates US8388971 A VBZ O
to US8388971 A TO O
antibodies US8388971 A NNS O
and US8388971 A CC O
antigen-binding US8388971 A JJ O
portions US8388971 A NNS O
thereof US8388971 A VBP O
that US8388971 A IN O
specifically US8388971 A RB O
bind US8388971 A VB O
to US8388971 A TO O
CD40 US8388971 A NNP I-UN
, US8388971 A , O
preferably US8388971 A RB O
human US8388971 A JJ I-UN
CD40 US8388971 A NNP I-UN
, US8388971 A , O
and US8388971 A CC O
that US8388971 A DT O
function US8388971 A NN O
as US8388971 A IN O
CD40 US8388971 A NNP I-UN
agonists US8388971 A NNS O
. US8388971 A . O

One-step EP2382213A1 T JJ O
process EP2382213A1 T NN O
for EP2382213A1 T IN O
preparing EP2382213A1 T VBG O
paliperidone EP2382213A1 T NN O
and EP2382213A1 T CC O
its EP2382213A1 T PRP$ O
oxalate EP2382213A1 T NN O
salt EP2382213A1 T NN O
. EP2382213A1 T . O

New DE102010051391A1 T NNP O
lisuride DE102010051391A1 T NN O
, DE102010051391A1 T , O
terguride DE102010051391A1 T NN O
or DE102010051391A1 T CC O
1,1-diethyl-3- DE102010051391A1 T JJ O
( DE102010051391A1 T ( O
R DE102010051391A1 T NNP O
) DE102010051391A1 T ) O
-4,6,6a,7,8,9,10,10a-octa DE102010051391A1 T VBZ O
hydro-indolo DE102010051391A1 T JJ O
( DE102010051391A1 T ( O
4,3-fg DE102010051391A1 T JJ O
) DE102010051391A1 T ) O
quinolin-9-yl-urea DE102010051391A1 T JJ O
derivative DE102010051391A1 T JJ O
, DE102010051391A1 T , O
is DE102010051391A1 T VBZ O
5-hydroxytryptamine DE102010051391A1 T JJ I-UN
2A DE102010051391A1 T CD I-UN
receptor DE102010051391A1 T NN I-UN
antagonist DE102010051391A1 T NN O
, DE102010051391A1 T , O
useful DE102010051391A1 T JJ O
to DE102010051391A1 T TO O
treat DE102010051391A1 T VB O
and/or DE102010051391A1 T JJ O
prevent DE102010051391A1 T NN O
pulmonary DE102010051391A1 T JJ O
arterial DE102010051391A1 T JJ O
hypertension DE102010051391A1 T NN O
. DE102010051391A1 T . O

- DE102010051391A1 A : O
MECHANISM DE102010051391A1 A NN O
OF DE102010051391A1 A IN O
ACTION DE102010051391A1 A NNP O
: DE102010051391A1 A : O
5-Hydroxytryptamine DE102010051391A1 A JJ I-UN
2A DE102010051391A1 A CD I-UN
receptor DE102010051391A1 A NN I-UN
antagonist DE102010051391A1 A NN O
; DE102010051391A1 A : O
5-Hydroxytryptamine DE102010051391A1 A JJ I-UN
2B DE102010051391A1 A CD I-UN
receptor DE102010051391A1 A NN I-UN
antagonist DE102010051391A1 A NN O
. DE102010051391A1 A . O

The DE102010051391A1 A DT O
5-hydroxytryptamine DE102010051391A1 A JJ I-UN
2A DE102010051391A1 A CD I-UN
receptor DE102010051391A1 A NN I-UN
antagonistic DE102010051391A1 A JJ O
activity DE102010051391A1 A NN O
of DE102010051391A1 A IN O
( DE102010051391A1 A ( O
I DE102010051391A1 A PRP O
) DE102010051391A1 A ) O
was DE102010051391A1 A VBD O
tested DE102010051391A1 A VBN O
. DE102010051391A1 A . O

Electric WO2005020967A1 T NNP O
drug WO2005020967A1 T NN O
transport WO2005020967A1 T NN O
preparation WO2005020967A1 T NN O
. WO2005020967A1 T . O

Pharmaceutical US20090306026 T JJ O
Formulations US20090306026 T NNS O
and US20090306026 T CC O
Uses US20090306026 T VBZ O
Thereof US20090306026 T NNP O
in US20090306026 T IN O
the US20090306026 T DT O
Treatment US20090306026 T NNP O
of US20090306026 T IN O
Female US20090306026 T NNP O
Sexual US20090306026 T NNP O
Dysfunction US20090306026 T NNP O
. US20090306026 T . O

Method US7074574 T NNP O
of US7074574 T IN O
detecting US7074574 T VBG O
growth US7074574 T NN I-UN
differentiation US7074574 T NN I-UN
factor-7 US7074574 T NN I-UN
( US7074574 T ( O
GDF-7 US7074574 T NNP I-UN
) US7074574 T ) O
using US7074574 T VBG O
GDF-7 US7074574 T JJ I-UN
antibodies US7074574 T NNS O
. US7074574 T . O

The US7074574 A DT O
present US7074574 A JJ O
invention US7074574 A NN O
provides US7074574 A VBZ O
methods US7074574 A NNS O
of US7074574 A IN O
using US7074574 A VBG O
antibodies US7074574 A NNS O
that US7074574 A WDT O
bind US7074574 A VBP O
to US7074574 A TO O
the US7074574 A DT O
growth US7074574 A NN I-UN
differentiation US7074574 A NN I-UN
factor-7 US7074574 A NN I-UN
to US7074574 A TO O
identify US7074574 A VB O
GDF-7 US7074574 A NNP I-UN
in US7074574 A IN O
a US7074574 A DT O
sample US7074574 A NN O
. US7074574 A . O

Medicaments CN101259222B T NNS O
for CN101259222B T IN O
treating CN101259222B T VBG O
bone CN101259222B T NN O
fracture CN101259222B T NN O
bone CN101259222B T NN O
fracture CN101259222B T NN O
disease CN101259222B T NN O
. CN101259222B T . O

Disinfectant US20100256576 T JJ O
Compositions US20100256576 T NNP O
, US20100256576 T , O
Methods US20100256576 T NNP O
and US20100256576 T CC O
Systems US20100256576 T NNPS O
. US20100256576 T . O

Mannitol CN102526099A T NNP O
sodium CN102526099A T NN O
chloride CN102526099A T NN O
injection CN102526099A T NN O
and CN102526099A T CC O
preparation CN102526099A T NN O
method CN102526099A T NN O
thereof CN102526099A T NN O
. CN102526099A T . O

The CN102526099A A DT O
invention CN102526099A A NN O
discloses CN102526099A A VBZ O
a CN102526099A A DT O
mannitol CN102526099A A JJ O
sodium CN102526099A A NN O
chloride CN102526099A A NN O
injection CN102526099A A NN O
and CN102526099A A CC O
a CN102526099A A DT O
preparation CN102526099A A NN O
method CN102526099A A NN O
thereof CN102526099A A NN O
. CN102526099A A . O

The CN102526099A A DT O
mannitol CN102526099A A NN O
sodium CN102526099A A NN O
chloride CN102526099A A NN O
injection CN102526099A A NN O
comprises CN102526099A A VBZ O
the CN102526099A A DT O
following CN102526099A A JJ O
components CN102526099A A NNS O
in CN102526099A A IN O
percentage CN102526099A A NN O
by CN102526099A A IN O
weight CN102526099A A NN O
: CN102526099A A : O
5-10 CN102526099A A JJ O
percent CN102526099A A NN O
of CN102526099A A IN O
glycerol CN102526099A A NN O
, CN102526099A A , O
5-10 CN102526099A A JJ O
percent CN102526099A A NN O
of CN102526099A A IN O
fructose CN102526099A A NN O
, CN102526099A A , O
0.9 CN102526099A A CD O
percent CN102526099A A NN O
of CN102526099A A IN O
sodium CN102526099A A NN O
chloride CN102526099A A NN O
and CN102526099A A CC O
0.01-0.05 CN102526099A A JJ O
percent CN102526099A A NN O
of CN102526099A A IN O
an CN102526099A A DT O
antioxidant CN102526099A A NN O
. CN102526099A A . O

The CN102526099A A DT O
mannitol CN102526099A A NN O
sodium CN102526099A A NN O
chloride CN102526099A A NN O
injection CN102526099A A NN O
provided CN102526099A A VBN O
by CN102526099A A IN O
the CN102526099A A DT O
invention CN102526099A A NN O
has CN102526099A A VBZ O
high CN102526099A A JJ O
quality CN102526099A A NN O
stability CN102526099A A NN O
, CN102526099A A , O
the CN102526099A A DT O
general CN102526099A A JJ O
problem CN102526099A A NN O
of CN102526099A A IN O
quick CN102526099A A JJ O
rising CN102526099A A NN O
of CN102526099A A IN O
5-hydroxymethylfurfural CN102526099A A JJ O
existing CN102526099A A VBG O
in CN102526099A A IN O
a CN102526099A A DT O
mannitol CN102526099A A NN O
sodium CN102526099A A NN O
chloride CN102526099A A NN O
injection CN102526099A A NN O
product CN102526099A A NN O
is CN102526099A A VBZ O
solved CN102526099A A VBN O
, CN102526099A A , O
and CN102526099A A CC O
safe CN102526099A A JJ O
clinical CN102526099A A JJ O
use CN102526099A A NN O
is CN102526099A A VBZ O
ensured CN102526099A A VBN O
effectively CN102526099A A RB O
. CN102526099A A . O

Moreover CN102526099A A RB O
, CN102526099A A , O
the CN102526099A A DT O
preparation CN102526099A A NN O
method CN102526099A A NN O
provided CN102526099A A VBN O
by CN102526099A A IN O
the CN102526099A A DT O
invention CN102526099A A NN O
is CN102526099A A VBZ O
simple CN102526099A A JJ O
and CN102526099A A CC O
convenient CN102526099A A JJ O
and CN102526099A A CC O
is CN102526099A A VBZ O
convenient CN102526099A A JJ O
for CN102526099A A IN O
clinical CN102526099A A JJ O
use CN102526099A A NN O
, CN102526099A A , O
and CN102526099A A CC O
the CN102526099A A DT O
product CN102526099A A NN O
quality CN102526099A A NN O
is CN102526099A A VBZ O
stable CN102526099A A JJ O
and CN102526099A A CC O
reliable CN102526099A A JJ O
. CN102526099A A . O

Dispersible CN103110599A T JJ O
tablet CN103110599A T NN O
of CN103110599A T IN O
prulifloxacin CN103110599A T NN O
and CN103110599A T CC O
preparation CN103110599A T NN O
method CN103110599A T NN O
thereof CN103110599A T NN O
. CN103110599A T . O

Ilex CN102838485A T NNP O
latifolia CN102838485A T VBZ O
thunb CN102838485A T JJ O
extract CN102838485A T NN O
. CN102838485A T . O

Oxazolidinon-3-ylphenyl US7217726 T JJ O
-piperazine US7217726 T NN O
, US7217726 T , O
-imidazolidine US7217726 T NN O
, US7217726 T , O
and US7217726 T CC O
-diazepine US7217726 T JJ O
derivatives US7217726 T NNS O
, US7217726 T , O
e.g. US7217726 T NN O
, US7217726 T , O
S US7217726 T NNP O
) US7217726 T ) O
-N- US7217726 T VBP O
[ US7217726 T JJ O
3- US7217726 T JJ O
[ US7217726 T JJ O
3-Fluoro-4- US7217726 T JJ O
[ US7217726 T NN O
4- US7217726 T JJ O
( US7217726 T ( O
5-nitrofuran-2-ylthiocarbonyl US7217726 T JJ O
) US7217726 T ) O
piperazin-1-yl US7217726 T NN O
] US7217726 T NNP O
phenyl US7217726 T NN O
] US7217726 T NNP O
-2-oxooxazolidin-5-ylmethyl US7217726 T NNP O
] US7217726 T NNP O
thioacetamide US7217726 T NN O
; US7217726 T : O
treating US7217726 T VBG O
bacterial US7217726 T JJ O
infections US7217726 T NNS O
, US7217726 T , O
particularly US7217726 T RB O
those US7217726 T DT O
that US7217726 T WDT O
are US7217726 T VBP O
antibiotic US7217726 T JJ O
resistant US7217726 T NN O
. US7217726 T . O

The US7217726 A DT O
present US7217726 A JJ O
invention US7217726 A NN O
provides US7217726 A VBZ O
novel US7217726 A JJ O
compounds US7217726 A NNS O
of US7217726 A IN O
the US7217726 A DT O
general US7217726 A JJ O
formula US7217726 A NN O
( US7217726 A ( O
I US7217726 A PRP O
) US7217726 A ) O
, US7217726 A , O
their US7217726 A PRP$ O
derivatives US7217726 A NNS O
, US7217726 A , O
their US7217726 A PRP$ O
analogs US7217726 A NNS O
, US7217726 A , O
their US7217726 A PRP$ O
tautomeric US7217726 A JJ O
forms US7217726 A NNS O
, US7217726 A , O
their US7217726 A PRP$ O
stereoisomers US7217726 A NNS O
, US7217726 A , O
their US7217726 A PRP$ O
polymorphs US7217726 A NN O
, US7217726 A , O
their US7217726 A PRP$ O
hydrates US7217726 A NNS O
, US7217726 A , O
their US7217726 A PRP$ O
solvates US7217726 A NNS O
, US7217726 A , O
their US7217726 A PRP$ O
pharmaceutically US7217726 A RB O
acceptable US7217726 A JJ O
salts US7217726 A NNS O
and US7217726 A CC O
pharmaceutically US7217726 A RB O
acceptable US7217726 A JJ O
compositions US7217726 A NNS O
containing US7217726 A VBG O
them US7217726 A PRP O
. US7217726 A . O

The US7217726 A DT O
present US7217726 A JJ O
invention US7217726 A NN O
more US7217726 A RBR O
particularly US7217726 A RB O
provides US7217726 A VBZ O
novel US7217726 A JJ O
oxazolidinone US7217726 A NN O
derivatives US7217726 A NNS O
of US7217726 A IN O
the US7217726 A DT O
general US7217726 A JJ O
formula US7217726 A NN O
( US7217726 A ( O
I US7217726 A PRP O
) US7217726 A ) O

Modulators US20050124537 T NNS O
of US20050124537 T IN O
receptors US20050124537 T NNS I-UN
for US20050124537 T IN I-UN
parathyroid US20050124537 T NN I-UN
hormone US20050124537 T NN I-UN
and US20050124537 T CC I-UN
parathyroid US20050124537 T JJ I-UN
hormone-related US20050124537 T JJ I-UN
protein US20050124537 T NN I-UN
. US20050124537 T . O

The US20050124537 A DT O
present US20050124537 A JJ O
invention US20050124537 A NN O
concerns US20050124537 A NNS O
therapeutic US20050124537 A JJ O
agents US20050124537 A NNS O
that US20050124537 A WDT O
modulate US20050124537 A VBP O
the US20050124537 A DT O
activity US20050124537 A NN O
of US20050124537 A IN O
PTH US20050124537 A NNP I-UN
and US20050124537 A CC O
PTHrP US20050124537 A NNP I-UN
. US20050124537 A . O

In US20050124537 A IN O
accordance US20050124537 A NN O
with US20050124537 A IN O
the US20050124537 A DT O
present US20050124537 A JJ O
invention US20050124537 A NN O
, US20050124537 A , O
modulators US20050124537 A NNS O
of US20050124537 A IN O
PTH US20050124537 A NNP I-UN
and US20050124537 A CC O
PTHrP US20050124537 A NNP I-UN
comprise US20050124537 A NN O
: US20050124537 A : O
( US20050124537 A ( O
a US20050124537 A DT O
) US20050124537 A ) O
a US20050124537 A DT O
PTH/PTHrP US20050124537 A NNP O
modulating US20050124537 A NN O
domain US20050124537 A NN O
; US20050124537 A : O
and US20050124537 A CC O
( US20050124537 A ( O
b US20050124537 A NN O
) US20050124537 A ) O
a US20050124537 A DT O
vehicle US20050124537 A NN O
, US20050124537 A , O
such US20050124537 A JJ O
as US20050124537 A IN O
a US20050124537 A DT O
polymer US20050124537 A NN O
( US20050124537 A ( O
e.g. US20050124537 A JJ O
, US20050124537 A , O
PEG US20050124537 A NNP O
or US20050124537 A CC O
dextran US20050124537 A NN O
) US20050124537 A ) O
or US20050124537 A CC O
an US20050124537 A DT O
Fc US20050124537 A NNP O
domain US20050124537 A NN O
, US20050124537 A , O
which US20050124537 A WDT O
is US20050124537 A VBZ O
preferred US20050124537 A VBN O
; US20050124537 A : O
wherein US20050124537 A VBZ O
the US20050124537 A DT O
vehicle US20050124537 A NN O
is US20050124537 A VBZ O
covalently US20050124537 A RB O
attached US20050124537 A VBN O
to US20050124537 A TO O
the US20050124537 A DT O
C-terminus US20050124537 A NNP O
of US20050124537 A IN O
the US20050124537 A DT O
PTH/PTHrP US20050124537 A NNP O
modulating US20050124537 A NN O
domain US20050124537 A NN O
or US20050124537 A CC O
through US20050124537 A IN O
a US20050124537 A DT O
sidechain US20050124537 A NN O
at US20050124537 A IN O
any US20050124537 A DT O
residue US20050124537 A JJ O
from US20050124537 A IN O
residue US20050124537 A JJ O
14 US20050124537 A CD O
through US20050124537 A IN O
the US20050124537 A DT O
C-terminal US20050124537 A JJ O
residue US20050124537 A NN O
. US20050124537 A . O

Preferred US20050124537 A NNP O
PTH/PTHrP US20050124537 A NNP O
modulating US20050124537 A NN O
domains US20050124537 A NNS O
comprise US20050124537 A VBP O
the US20050124537 A DT O
PTH US20050124537 A NNP I-UN
and US20050124537 A CC O
PTHrP-derived US20050124537 A NNP O
amino US20050124537 A NN O
acid US20050124537 A NN O
sequences US20050124537 A NNS O
described US20050124537 A VBD O
hereinafter US20050124537 A NN O
. US20050124537 A . O

Such US20050124537 A JJ O
peptides US20050124537 A NNS O
typically US20050124537 A RB O
will US20050124537 A MD O
be US20050124537 A VB O
modulators US20050124537 A NNS O
of US20050124537 A IN O
both US20050124537 A DT O
PTH US20050124537 A NNP I-UN
activity US20050124537 A NN O
and US20050124537 A CC O
PTHrP US20050124537 A NNP I-UN
activity US20050124537 A NN O
, US20050124537 A , O
although US20050124537 A IN O
such US20050124537 A JJ O
techniques US20050124537 A NNS O
can US20050124537 A MD O
be US20050124537 A VB O
used US20050124537 A VBN O
to US20050124537 A TO O
generate US20050124537 A VB O
peptide US20050124537 A NN O
sequences US20050124537 A NNS O
that US20050124537 A WDT O
serve US20050124537 A VBP O
as US20050124537 A IN O
selective US20050124537 A JJ O
modulators US20050124537 A NNS O
( US20050124537 A ( O
e.g. US20050124537 A NN O
, US20050124537 A , O
agonists US20050124537 A NNS O
of US20050124537 A IN O
PTH US20050124537 A NNP I-UN
activity US20050124537 A NN O
but US20050124537 A CC O
not US20050124537 A RB O
PTHrP US20050124537 A NNP I-UN
activity US20050124537 A NN O
) US20050124537 A ) O
. US20050124537 A . O

Paclitaxel CN103599548A T NNP O
polymer CN103599548A T NN O
bonding CN103599548A T VBG O
drug CN103599548A T NN O
and CN103599548A T CC O
preparation CN103599548A T NN O
method CN103599548A T NN O
thereof CN103599548A T NN O
. CN103599548A T . O

Coordination US20090082438 T NNP O
Compound US20090082438 T NNP O
Composed US20090082438 T VBD O
of US20090082438 T IN O
Diaminocyclohexane US20090082438 T NNP O
Platinum US20090082438 T NNP O
( US20090082438 T ( O
II US20090082438 T NNP O
) US20090082438 T ) O
and US20090082438 T CC O
Block US20090082438 T NNP O
Copolymer US20090082438 T NNP O
and US20090082438 T CC O
Anti-Cancer US20090082438 T NNP O
Agent US20090082438 T NNP O
Comprising US20090082438 T VBG O
the US20090082438 T DT O
Same US20090082438 T NNP O
. US20090082438 T . O

The US20090082438 A DT O
invention US20090082438 A NN O
discloses US20090082438 A VBZ O
a US20090082438 A DT O
coordination US20090082438 A NN O
compound US20090082438 A NN O
comprising US20090082438 A NN O
( US20090082438 A ( O
1,2-diaminocyclohexane US20090082438 A JJ O
) US20090082438 A ) O
platinum US20090082438 A NN O
( US20090082438 A ( O
II US20090082438 A NNP O
) US20090082438 A ) O
moiety US20090082438 A NN O
and US20090082438 A CC O
poly US20090082438 A NN O
( US20090082438 A ( O
ethylene US20090082438 A JJ O
glycol US20090082438 A NN O
) US20090082438 A ) O
-block-poly US20090082438 A NN O
( US20090082438 A ( O
glutamic US20090082438 A JJ O
acid US20090082438 A NN O
) US20090082438 A ) O
copolymer US20090082438 A NN O
moiety US20090082438 A NN O
; US20090082438 A : O
and US20090082438 A CC O
its US20090082438 A PRP$ O
use US20090082438 A NN O
as US20090082438 A IN O
an US20090082438 A DT O
anti-cancer US20090082438 A JJ O
agent US20090082438 A NN O
. US20090082438 A . O

The US20090082438 A DT O
characteristic US20090082438 A JJ O
feature US20090082438 A NN O
lies US20090082438 A VBZ O
in US20090082438 A IN O
the US20090082438 A DT O
use US20090082438 A NN O
of US20090082438 A IN O
a US20090082438 A DT O
copolymer US20090082438 A NN O
whose US20090082438 A WP$ O
poly US20090082438 A NN O
( US20090082438 A ( O
glutamic US20090082438 A JJ O
acid US20090082438 A NN O
) US20090082438 A ) O
segment US20090082438 A NN O
has US20090082438 A VBZ O
a US20090082438 A DT O
chain US20090082438 A NN O
length US20090082438 A NN O
consisting US20090082438 A NN O
of US20090082438 A IN O
, US20090082438 A , O
on US20090082438 A IN O
an US20090082438 A DT O
average US20090082438 A NN O
, US20090082438 A , O
less US20090082438 A JJR O
than US20090082438 A IN O
35 US20090082438 A CD O
repeating US20090082438 A VBG O
units US20090082438 A NNS O
. US20090082438 A . O

Infusion EP2298281A1 T NN O
and EP2298281A1 T CC O
injection EP2298281A1 T NN O
solution EP2298281A1 T NN O
of EP2298281A1 T IN O
Levodopa EP2298281A1 T NNP O
. EP2298281A1 T . O

Bicyclic WO2009152087A1 T NNP O
heteroaryl WO2009152087A1 T NN O
compounds WO2009152087A1 T NNS O
and WO2009152087A1 T CC O
methods WO2009152087A1 T NNS O
for WO2009152087A1 T IN O
kinase WO2009152087A1 T NN O
modulation WO2009152087A1 T NN O
, WO2009152087A1 T , O
and WO2009152087A1 T CC O
indications WO2009152087A1 T NNS O
therefor WO2009152087A1 T VBP O
. WO2009152087A1 T . O

In WO2009152087A1 A IN O
certain WO2009152087A1 A JJ O
aspects WO2009152087A1 A NNS O
and WO2009152087A1 A CC O
embodiments WO2009152087A1 A NNS O
, WO2009152087A1 A , O
the WO2009152087A1 A DT O
described WO2009152087A1 A JJ O
compounds WO2009152087A1 A NNS O
or WO2009152087A1 A CC O
salts WO2009152087A1 A NNS O
thereof WO2009152087A1 A NNS O
, WO2009152087A1 A , O
formulations WO2009152087A1 A NNS O
thereof WO2009152087A1 A VBP O
, WO2009152087A1 A , O
conjugates WO2009152087A1 A VBZ O
thereof WO2009152087A1 A NNS O
, WO2009152087A1 A , O
derivatives WO2009152087A1 A NNS O
thereof WO2009152087A1 A VBP O
, WO2009152087A1 A , O
forms WO2009152087A1 A NNS O
thereof WO2009152087A1 A VBP O
are WO2009152087A1 A VBP O
active WO2009152087A1 A JJ O
on WO2009152087A1 A IN O
at WO2009152087A1 A IN O
least WO2009152087A1 A JJS O
one WO2009152087A1 A CD O
Raf WO2009152087A1 A NNP I-UN
protein WO2009152087A1 A NN O
kinase WO2009152087A1 A NN O
. WO2009152087A1 A . O

Also WO2009152087A1 A RB O
described WO2009152087A1 A VBN O
are WO2009152087A1 A VBP O
methods WO2009152087A1 A NNS O
of WO2009152087A1 A IN O
use WO2009152087A1 A NN O
thereof WO2009152087A1 A NN O
to WO2009152087A1 A TO O
treat WO2009152087A1 A VB O
diseases WO2009152087A1 A NNS O
and WO2009152087A1 A CC O
conditions WO2009152087A1 A NNS O
, WO2009152087A1 A , O
including WO2009152087A1 A VBG O
diseases WO2009152087A1 A NNS O
and WO2009152087A1 A CC O
conditions WO2009152087A1 A NNS O
associated WO2009152087A1 A VBN O
with WO2009152087A1 A IN O
activity WO2009152087A1 A NN O
of WO2009152087A1 A IN O
Raf WO2009152087A1 A NNP I-UN
protein WO2009152087A1 A NN O
kinases WO2009152087A1 A NNS O
, WO2009152087A1 A , O
including WO2009152087A1 A VBG O
melanoma WO2009152087A1 A NN O
, WO2009152087A1 A , O
colorectal WO2009152087A1 A JJ O
cancer WO2009152087A1 A NN O
, WO2009152087A1 A , O
thyroid WO2009152087A1 A JJ O
cancer WO2009152087A1 A NN O
, WO2009152087A1 A , O
ovarian WO2009152087A1 A JJ O
cancer WO2009152087A1 A NN O
, WO2009152087A1 A , O
cholangiocarcinoma WO2009152087A1 A NN O
, WO2009152087A1 A , O
pain WO2009152087A1 A NN O
or WO2009152087A1 A CC O
polycystic WO2009152087A1 A JJ O
kidney WO2009152087A1 A NN O
disease WO2009152087A1 A NN O
. WO2009152087A1 A . O

Ocular US20130302420 T JJ O
biodegradable US20130302420 T JJ O
drug US20130302420 T NN O
implant US20130302420 T NN O
and US20130302420 T CC O
method US20130302420 T NN O
of US20130302420 T IN O
its US20130302420 T PRP$ O
use US20130302420 T NN O
. US20130302420 T . O

Method US20100076002 T NNP O
of US20100076002 T IN O
Treating US20100076002 T NNP O
Atherosclerosis US20100076002 T NNP O
, US20100076002 T , O
Dyslipidemias US20100076002 T NNP O
and US20100076002 T CC O
Related US20100076002 T VBN O
Conditions US20100076002 T NNS O
and US20100076002 T CC O
Pharmaceutical US20100076002 T NNP O
Compositions US20100076002 T NNP O
. US20100076002 T . O

Polymorph WO2014143630A1 T NNP O
forms WO2014143630A1 T NNS O
of WO2014143630A1 T IN O
desazadesferrithiocin WO2014143630A1 T JJ O
analogs WO2014143630A1 T NNS O
. WO2014143630A1 T . O

Vitamin CN201586232U T NNP O
C CN201586232U T NNP O
fructus CN201586232U T NN O
forsythiae CN201586232U T NN O
soft CN201586232U T JJ O
capsule CN201586232U T NN O
. CN201586232U T . O

The CN201586232U A DT O
utility CN201586232U A NN O
model CN201586232U A NN O
relates CN201586232U A VBZ O
to CN201586232U A TO O
a CN201586232U A DT O
vitamin CN201586232U A NN O
C CN201586232U A NNP O
fructus CN201586232U A NN O
forsythiae CN201586232U A NN O
soft CN201586232U A JJ O
capsule CN201586232U A NN O
, CN201586232U A , O
which CN201586232U A WDT O
comprises CN201586232U A VBZ O
medicaments CN201586232U A NNS O
in CN201586232U A IN O
liquid CN201586232U A JJ O
form CN201586232U A NN O
or CN201586232U A CC O
suspension CN201586232U A NN O
liquid CN201586232U A JJ O
form CN201586232U A NN O
or CN201586232U A CC O
paste CN201586232U A NN O
form CN201586232U A NN O
. CN201586232U A . O

The CN201586232U A DT O
medicaments CN201586232U A NNS O
are CN201586232U A VBP O
closely CN201586232U A RB O
disposed CN201586232U A JJ O
inside CN201586232U A IN O
a CN201586232U A DT O
capsule CN201586232U A NN O
outer CN201586232U A NN O
casing CN201586232U A VBG O
in CN201586232U A IN O
shape CN201586232U A NN O
of CN201586232U A IN O
an CN201586232U A DT O
ellipse CN201586232U A NN O
or CN201586232U A CC O
ball CN201586232U A NN O
or CN201586232U A CC O
rugby CN201586232U A NN O
or CN201586232U A CC O
water CN201586232U A NN O
drop CN201586232U A NN O
. CN201586232U A . O

Thickness CN201586232U A NN O
of CN201586232U A IN O
the CN201586232U A DT O
capsule CN201586232U A NN O
outer CN201586232U A NN O
casing CN201586232U A NN O
is CN201586232U A VBZ O
0.7-0.8mm CN201586232U A JJ O
. CN201586232U A . O

The CN201586232U A DT O
vitamin CN201586232U A NN O
C CN201586232U A NNP O
fructus CN201586232U A NN O
forsythiae CN201586232U A NN O
soft CN201586232U A JJ O
capsule CN201586232U A NN O
has CN201586232U A VBZ O
high CN201586232U A JJ O
bioavailability CN201586232U A NN O
, CN201586232U A , O
good CN201586232U A JJ O
tightness CN201586232U A NN O
, CN201586232U A , O
fine CN201586232U A JJ O
uniformity CN201586232U A NN O
, CN201586232U A , O
stable CN201586232U A JJ O
content CN201586232U A NN O
, CN201586232U A , O
beautiful CN201586232U A JJ O
appearance CN201586232U A NN O
and CN201586232U A CC O
the CN201586232U A DT O
like CN201586232U A JJ O
. CN201586232U A . O

Iron US20130344113 T NNP O
Fortified US20130344113 T NNP O
Food US20130344113 T NNP O
Product US20130344113 T NNP O
and US20130344113 T CC O
Additive US20130344113 T NNP O
. US20130344113 T . O

Immune WO2006035939A1 T NNP O
stimulating WO2006035939A1 T VBG O
oligonucleotide WO2006035939A1 T RB O
and WO2006035939A1 T CC O
use WO2006035939A1 T VB O
thereof WO2006035939A1 T NN O
in WO2006035939A1 T IN O
pharmaceutical WO2006035939A1 T JJ O
. WO2006035939A1 T . O

A WO2006035939A1 A DT O
novel WO2006035939A1 A JJ O
immune WO2006035939A1 A NN O
stimulating WO2006035939A1 A VBG O
oligonucleotide WO2006035939A1 A IN O
having WO2006035939A1 A VBG O
the WO2006035939A1 A DT O
activity WO2006035939A1 A NN O
of WO2006035939A1 A IN O
inducing WO2006035939A1 A VBG O
strong WO2006035939A1 A JJ O
immune WO2006035939A1 A JJ O
responses WO2006035939A1 A NNS O
; WO2006035939A1 A : O
a WO2006035939A1 A DT O
pharmaceutical WO2006035939A1 A JJ O
product WO2006035939A1 A NN O
comprising WO2006035939A1 A VBG O
this WO2006035939A1 A DT O
immune WO2006035939A1 A JJ O
stimulating WO2006035939A1 A JJ O
oligonucleotide WO2006035939A1 A NN O
; WO2006035939A1 A : O
and WO2006035939A1 A CC O
use WO2006035939A1 A VB O
thereof WO2006035939A1 A NN O
. WO2006035939A1 A . O

This WO2006035939A1 A DT O
immune WO2006035939A1 A JJ O
stimulating WO2006035939A1 A NN O
oligonucleotide WO2006035939A1 A NN O
, WO2006035939A1 A , O
for WO2006035939A1 A IN O
example WO2006035939A1 A NN O
, WO2006035939A1 A , O
consists WO2006035939A1 A VBZ O
of WO2006035939A1 A IN O
an WO2006035939A1 A DT O
oligonucleotide WO2006035939A1 A NN O
having WO2006035939A1 A VBG O
the WO2006035939A1 A DT O
sequence WO2006035939A1 A NN O
of WO2006035939A1 A IN O
ggtgccgatcggcagggggg WO2006035939A1 A NN O
. WO2006035939A1 A . O

This WO2006035939A1 A DT O
oligonucleotide WO2006035939A1 A NN O
can WO2006035939A1 A MD O
be WO2006035939A1 A VB O
used WO2006035939A1 A VBN O
as WO2006035939A1 A IN O
an WO2006035939A1 A DT O
active WO2006035939A1 A JJ O
ingredient WO2006035939A1 A NN O
of WO2006035939A1 A IN O
pharmaceuticals WO2006035939A1 A NNS O
, WO2006035939A1 A , O
such WO2006035939A1 A JJ O
as WO2006035939A1 A IN O
a WO2006035939A1 A DT O
preventive WO2006035939A1 A NN O
or WO2006035939A1 A CC O
therapeutic WO2006035939A1 A JJ O
agent WO2006035939A1 A NN O
for WO2006035939A1 A IN O
allergoses WO2006035939A1 A NNS O
. WO2006035939A1 A . O

As WO2006035939A1 A IN O
this WO2006035939A1 A DT O
immune WO2006035939A1 A JJ O
stimulating WO2006035939A1 A NN O
oligonucleotide WO2006035939A1 A NN O
has WO2006035939A1 A VBZ O
a WO2006035939A1 A DT O
strong WO2006035939A1 A JJ O
immune WO2006035939A1 A JJ O
stimulating WO2006035939A1 A NN O
activity WO2006035939A1 A NN O
, WO2006035939A1 A , O
the WO2006035939A1 A DT O
use WO2006035939A1 A NN O
thereof WO2006035939A1 A NN O
renders WO2006035939A1 A NNS O
it WO2006035939A1 A PRP O
promising WO2006035939A1 A VBG O
to WO2006035939A1 A TO O
attain WO2006035939A1 A VB O
enhanced WO2006035939A1 A JJ O
treating WO2006035939A1 A NN O
, WO2006035939A1 A , O
preventive WO2006035939A1 A JJ O
and WO2006035939A1 A CC O
remedial WO2006035939A1 A JJ O
effects WO2006035939A1 A NNS O
and WO2006035939A1 A CC O
to WO2006035939A1 A TO O
through WO2006035939A1 A IN O
reduction WO2006035939A1 A NN O
of WO2006035939A1 A IN O
administration WO2006035939A1 A NN O
frequency WO2006035939A1 A NN O
, WO2006035939A1 A , O
attain WO2006035939A1 A JJ O
side WO2006035939A1 A NN O
effect WO2006035939A1 A NN O
suppression WO2006035939A1 A NN O
and WO2006035939A1 A CC O
QOL WO2006035939A1 A NNP O
remedy WO2006035939A1 A NN O
. WO2006035939A1 A . O

Pentacyclic CN102552279A T NNP O
triterpenoid CN102552279A T NN O
compound CN102552279A T NN O
and CN102552279A T CC O
application CN102552279A T NN O
of CN102552279A T IN O
plant CN102552279A T NN O
extract CN102552279A T NN O
containing CN102552279A T VBG O
same CN102552279A T JJ O
. CN102552279A T . O

Alkynyl US20110086834 T NNP O
alcohols US20110086834 T VBZ O
as US20110086834 T IN O
kinase US20110086834 T NN O
inhibitors US20110086834 T NNS O
. US20110086834 T . O

Methods US20080254017 T NNS O
and US20080254017 T CC O
compositions US20080254017 T NNS O
for US20080254017 T IN O
treating US20080254017 T VBG O
symptomes US20080254017 T NNS O
of US20080254017 T IN O
diseases US20080254017 T NNS O
related US20080254017 T VBN O
to US20080254017 T TO O
imbalance US20080254017 T NN O
of US20080254017 T IN O
essential US20080254017 T JJ O
fatty US20080254017 T JJ O
acids US20080254017 T NNS O
. US20080254017 T . O

Such US7199148 T JJ O
as US7199148 T IN O
( US7199148 T ( O
1-Benzyl-2-hydroxy-3- US7199148 T JJ O
{ US7199148 T ( O
isobutyl- US7199148 T JJ O
[ US7199148 T NN O
2-oxo-3- US7199148 T JJ O
( US7199148 T ( O
1H-pyrrol-2-ylmethylene US7199148 T JJ O
) US7199148 T ) O
-2,3-dihydro-1H-indole-5-sulfonyl US7199148 T FW O
] US7199148 T $ O
-amino US7199148 T NN O
} US7199148 T ) O
-propyl US7199148 T NNP O
) US7199148 T ) O
-carbamic US7199148 T JJ O
acid US7199148 T JJ O
hexahydro-furo US7199148 T JJ O
[ US7199148 T JJ O
2,3-b US7199148 T JJ O
] US7199148 T JJ O
furan-3-yl US7199148 T JJ O
ester US7199148 T NN O
; US7199148 T : O
multi-drug US7199148 T JJ O
resistant US7199148 T JJ O
HIV US7199148 T NNP O
infections US7199148 T NNS O
. US7199148 T . O

Tumor-Specific US20080221058 T JJ O
Vector US20080221058 T NNP O
for US20080221058 T IN O
Gene US20080221058 T NNP O
Therapy US20080221058 T NNP O
. US20080221058 T . O

The US20080221058 A DT O
gene US20080221058 A NN O
is US20080221058 A VBZ O
controlled US20080221058 A VBN O
by US20080221058 A IN O
the US20080221058 A DT O
promoter US20080221058 A NN O
for US20080221058 A IN O
the US20080221058 A DT O
catalytic US20080221058 A JJ O
subunit US20080221058 A NN O
of US20080221058 A IN O
the US20080221058 A DT O
telomerase US20080221058 A NN I-UN
or US20080221058 A CC O
by US20080221058 A IN O
the US20080221058 A DT O
promoter US20080221058 A NN O
for US20080221058 A IN O
cyclin US20080221058 A NN O
A US20080221058 A NNP O
. US20080221058 A . O

Modulation WO2005115367A3 T NN O
of WO2005115367A3 T IN O
neurotransmitter WO2005115367A3 T NN O
activity WO2005115367A3 T NN O
in WO2005115367A3 T IN O
neurons WO2005115367A3 T NNS O
. WO2005115367A3 T . O

The WO2005115367A3 A DT O
present WO2005115367A3 A JJ O
invention WO2005115367A3 A NN O
relates WO2005115367A3 A VBZ O
generally WO2005115367A3 A RB O
to WO2005115367A3 A TO O
methods WO2005115367A3 A NNS O
, WO2005115367A3 A , O
devices WO2005115367A3 A NNS O
and WO2005115367A3 A CC O
compositions WO2005115367A3 A NNS O
for WO2005115367A3 A IN O
treating WO2005115367A3 A VBG O
mental WO2005115367A3 A JJ O
, WO2005115367A3 A , O
neurological WO2005115367A3 A JJ O
, WO2005115367A3 A , O
and WO2005115367A3 A CC O
cognitive WO2005115367A3 A JJ O
diseases WO2005115367A3 A NNS O
related WO2005115367A3 A VBN O
to WO2005115367A3 A TO O
deficiencies WO2005115367A3 A NNS O
in WO2005115367A3 A IN O
the WO2005115367A3 A DT O
biosynthesis WO2005115367A3 A NN O
and/or WO2005115367A3 A JJ O
metabolism WO2005115367A3 A NN O
of WO2005115367A3 A IN O
neurotransmitters WO2005115367A3 A NNS O
, WO2005115367A3 A , O
wherein WO2005115367A3 A VBP O
the WO2005115367A3 A DT O
neurotransmitter WO2005115367A3 A NN O
is WO2005115367A3 A VBZ O
acetylcholine WO2005115367A3 A JJ O
, WO2005115367A3 A , O
nitric WO2005115367A3 A JJ O
oxide WO2005115367A3 A NN O
, WO2005115367A3 A , O
histamine WO2005115367A3 A NN O
, WO2005115367A3 A , O
norepinephrine WO2005115367A3 A NN O
, WO2005115367A3 A , O
a WO2005115367A3 A DT O
bioactive WO2005115367A3 A JJ O
amine WO2005115367A3 A NN O
, WO2005115367A3 A , O
an WO2005115367A3 A DT O
amino WO2005115367A3 A NN O
acid WO2005115367A3 A NN O
or WO2005115367A3 A CC O
a WO2005115367A3 A DT O
neuropeptide WO2005115367A3 A JJ O
, WO2005115367A3 A , O
veratridine WO2005115367A3 A NN O
, WO2005115367A3 A , O
curare WO2005115367A3 A NN O
, WO2005115367A3 A , O
tetrodotoxin WO2005115367A3 A NN O
, WO2005115367A3 A , O
f WO2005115367A3 A JJ O
lunarizine WO2005115367A3 A NN O
, WO2005115367A3 A , O
calσicludine WO2005115367A3 A NN O
, WO2005115367A3 A , O
and WO2005115367A3 A CC O
omega WO2005115367A3 A FW O
-cono WO2005115367A3 A NNP O
toxin WO2005115367A3 A NN O
; WO2005115367A3 A : O
wherein WO2005115367A3 A CC O
the WO2005115367A3 A DT O
bioactive WO2005115367A3 A JJ O
amine WO2005115367A3 A NN O
is WO2005115367A3 A VBZ O
selected WO2005115367A3 A VBN O
from WO2005115367A3 A IN O
the WO2005115367A3 A DT O
group WO2005115367A3 A NN O
consisting WO2005115367A3 A VBG O
of WO2005115367A3 A IN O
dopamine WO2005115367A3 A NN O
, WO2005115367A3 A , O
epinephrine WO2005115367A3 A NN O
, WO2005115367A3 A , O
norepinephrine WO2005115367A3 A NN O
, WO2005115367A3 A , O
serotonin WO2005115367A3 A NN O
; WO2005115367A3 A : O
wherein WO2005115367A3 A CC O
the WO2005115367A3 A DT O
amino WO2005115367A3 A NN O
acid WO2005115367A3 A NN O
is WO2005115367A3 A VBZ O
selected WO2005115367A3 A VBN O
from WO2005115367A3 A IN O
the WO2005115367A3 A DT O
group WO2005115367A3 A NN O
consisting WO2005115367A3 A VBG O
of WO2005115367A3 A IN O
glutamate WO2005115367A3 A NN O
, WO2005115367A3 A , O
glycine WO2005115367A3 A NN O
and WO2005115367A3 A CC O
gamma- WO2005115367A3 A JJ O
aminobutyric WO2005115367A3 A JJ O
acid WO2005115367A3 A NN O
( WO2005115367A3 A ( O
GABA WO2005115367A3 A NNP O
) WO2005115367A3 A ) O
; WO2005115367A3 A : O
the WO2005115367A3 A DT O
neuropeptide WO2005115367A3 A NN O
is WO2005115367A3 A VBZ O
selected WO2005115367A3 A VBN O
from WO2005115367A3 A IN O
the WO2005115367A3 A DT O
group WO2005115367A3 A NN O
consisting WO2005115367A3 A VBG O
of WO2005115367A3 A IN O
enkephalins WO2005115367A3 A NNS O
, WO2005115367A3 A , O
dynorphins WO2005115367A3 A NNS O
and WO2005115367A3 A CC O
substance WO2005115367A3 A NN O
P WO2005115367A3 A NNP O
and WO2005115367A3 A CC O
the WO2005115367A3 A DT O
psychological WO2005115367A3 A JJ O
disorder WO2005115367A3 A NN O
is WO2005115367A3 A VBZ O
selected WO2005115367A3 A VBN O
from WO2005115367A3 A IN O
the WO2005115367A3 A DT O
group WO2005115367A3 A NN O
consisting WO2005115367A3 A VBG O
of WO2005115367A3 A IN O
addiction WO2005115367A3 A NN O
, WO2005115367A3 A , O
substance WO2005115367A3 A NN O
abuse WO2005115367A3 A NN O
, WO2005115367A3 A , O
autism WO2005115367A3 A NN O
, WO2005115367A3 A , O
dyslexia WO2005115367A3 A NN O
, WO2005115367A3 A , O
obsessive- WO2005115367A3 A JJ O
compulsive WO2005115367A3 A JJ O
disorder WO2005115367A3 A NN O
, WO2005115367A3 A , O
generalized WO2005115367A3 A VBN O
anxiety WO2005115367A3 A NN O
disorder WO2005115367A3 A NN O
, WO2005115367A3 A , O
post- WO2005115367A3 A JJ O
traumatic WO2005115367A3 A JJ O
stress WO2005115367A3 A NN O
disorder WO2005115367A3 A NN O
, WO2005115367A3 A , O
panic WO2005115367A3 A JJ O
attacks WO2005115367A3 A NNS O
, WO2005115367A3 A , O
social WO2005115367A3 A JJ O
phobia WO2005115367A3 A NN O
, WO2005115367A3 A , O
major WO2005115367A3 A JJ O
depression WO2005115367A3 A NN O
, WO2005115367A3 A , O
bipolar WO2005115367A3 A JJ O
disorder WO2005115367A3 A NN O
and WO2005115367A3 A CC O
schizophrenia WO2005115367A3 A NN O
, WO2005115367A3 A , O
tardive WO2005115367A3 A JJ O
dyskinesia WO2005115367A3 A NN O
, WO2005115367A3 A , O
Huntington WO2005115367A3 A NNP O
's WO2005115367A3 A POS O
disease WO2005115367A3 A NN O
, WO2005115367A3 A , O
and WO2005115367A3 A CC O
Parkinson WO2005115367A3 A NNP O
's WO2005115367A3 A POS O
disease WO2005115367A3 A NN O
. WO2005115367A3 A . O

Novel EP1511487A1 T NNP O
formulation EP1511487A1 T NN O
for EP1511487A1 T IN O
the EP1511487A1 T DT O
parenteral EP1511487A1 T JJ O
application EP1511487A1 T NN O
of EP1511487A1 T IN O
crobenetine EP1511487A1 T NN O
. EP1511487A1 T . O

3,3-diphenylpropylamines USRE40851 T NNS O
, USRE40851 T , O
their USRE40851 T PRP$ O
use USRE40851 T NN O
and USRE40851 T CC O
preparation USRE40851 T NN O
. USRE40851 T . O

The USRE40851 A DT O
invention USRE40851 A NN O
relates USRE40851 A VBZ O
to USRE40851 A TO O
3,3-diphenylpropylamines USRE40851 A NNS O
of USRE40851 A IN O
formula USRE40851 A NN O
( USRE40851 A ( O
I USRE40851 A PRP O
) USRE40851 A ) O
, USRE40851 A , O
wherein USRE40851 A JJ O
R1 USRE40851 A NNP O
signifies USRE40851 A NNS O
hydrogen USRE40851 A NN O
or USRE40851 A CC O
methyl USRE40851 A NN O
, USRE40851 A , O
R2 USRE40851 A NNP O
and USRE40851 A CC O
R3 USRE40851 A NNP O
independently USRE40851 A RB O
signify USRE40851 A VBZ O
hydrogen USRE40851 A NN O
, USRE40851 A , O
methyl USRE40851 A NN O
, USRE40851 A , O
methoxy USRE40851 A NN O
, USRE40851 A , O
hydroxy USRE40851 A NN O
, USRE40851 A , O
carbamoyl USRE40851 A NN O
, USRE40851 A , O
sulphamoyl USRE40851 A NN O
or USRE40851 A CC O
halogen USRE40851 A NN O
, USRE40851 A , O
and USRE40851 A CC O
X USRE40851 A NNP O
represents USRE40851 A VBZ O
a USRE40851 A DT O
tertiary USRE40851 A JJ O
amino USRE40851 A NN O
group USRE40851 A NN O
of USRE40851 A IN O
formula USRE40851 A NN O
( USRE40851 A ( O
II USRE40851 A NNP O
) USRE40851 A ) O
, USRE40851 A , O
wherein USRE40851 A JJ O
R4 USRE40851 A NNP O
and USRE40851 A CC O
R5 USRE40851 A NNP O
signify USRE40851 A VB O
non-aromatic USRE40851 A JJ O
hydrocarbyl USRE40851 A NN O
groups USRE40851 A NNS O
, USRE40851 A , O
which USRE40851 A WDT O
may USRE40851 A MD O
be USRE40851 A VB O
the USRE40851 A DT O
same USRE40851 A JJ O
or USRE40851 A CC O
different USRE40851 A JJ O
and USRE40851 A CC O
which USRE40851 A WDT O
together USRE40851 A RB O
contain USRE40851 A VBP O
at USRE40851 A IN O
least USRE40851 A JJS O
three USRE40851 A CD O
carbon USRE40851 A NN O
atoms USRE40851 A NNS O
, USRE40851 A , O
and USRE40851 A CC O
wherein USRE40851 A NN O
R4 USRE40851 A NNP O
and USRE40851 A CC O
R5 USRE40851 A NNP O
may USRE40851 A MD O
form USRE40851 A VB O
a USRE40851 A DT O
ring USRE40851 A NN O
together USRE40851 A RB O
with USRE40851 A IN O
the USRE40851 A DT O
amine USRE40851 A NN O
nitrogen USRE40851 A NN O
, USRE40851 A , O
their USRE40851 A PRP$ O
salts USRE40851 A NNS O
with USRE40851 A IN O
physiologically USRE40851 A RB O
acceptable USRE40851 A JJ O
acids USRE40851 A NNS O
and USRE40851 A CC O
, USRE40851 A , O
when USRE40851 A WRB O
the USRE40851 A DT O
compounds USRE40851 A NNS O
can USRE40851 A MD O
be USRE40851 A VB O
in USRE40851 A IN O
the USRE40851 A DT O
form USRE40851 A NN O
of USRE40851 A IN O
optical USRE40851 A JJ O
isomers USRE40851 A NNS O
, USRE40851 A , O
the USRE40851 A DT O
racemic USRE40851 A JJ O
mixture USRE40851 A NN O
and USRE40851 A CC O
the USRE40851 A DT O
individual USRE40851 A JJ O
enantiomers USRE40851 A NNS O
. USRE40851 A . O

The USRE40851 A DT O
invention USRE40851 A NN O
also USRE40851 A RB O
relates USRE40851 A VBZ O
to USRE40851 A TO O
methods USRE40851 A NNS O
for USRE40851 A IN O
their USRE40851 A PRP$ O
preparation USRE40851 A NN O
, USRE40851 A , O
pharmaceutical USRE40851 A JJ O
compositions USRE40851 A NNS O
containing USRE40851 A VBG O
the USRE40851 A DT O
novel USRE40851 A JJ O
compounds USRE40851 A NNS O
, USRE40851 A , O
and USRE40851 A CC O
the USRE40851 A DT O
use USRE40851 A NN O
of USRE40851 A IN O
the USRE40851 A DT O
compounds USRE40851 A NNS O
for USRE40851 A IN O
preparing USRE40851 A VBG O
drugs USRE40851 A NNS O

Compositions WO2011057269A2 T NNS O
for WO2011057269A2 T IN O
enhancing WO2011057269A2 T VBG O
hair WO2011057269A2 T NN O
growth WO2011057269A2 T NN O
. WO2011057269A2 T . O

Methods WO2011057269A2 A NNS O
and WO2011057269A2 A CC O
compositions WO2011057269A2 A NNS O
for WO2011057269A2 A IN O
stimulating WO2011057269A2 A VBG O
the WO2011057269A2 A DT O
growth WO2011057269A2 A NN O
of WO2011057269A2 A IN O
hair WO2011057269A2 A NN O
are WO2011057269A2 A VBP O
disclosed WO2011057269A2 A VBN O
wherein WO2011057269A2 A JJ O
emulsions WO2011057269A2 A NNS O
include WO2011057269A2 A VBP O
a WO2011057269A2 A DT O
cyclopentane WO2011057269A2 A NN O
heptanoic WO2011057269A2 A NN O
acid WO2011057269A2 A NN O
, WO2011057269A2 A , O
2-cycloalkyl WO2011057269A2 A JJ O
or WO2011057269A2 A CC O
arylalkyl WO2011057269A2 A JJ O
compound WO2011057269A2 A NN O
represented WO2011057269A2 A VBN O
by WO2011057269A2 A IN O
the WO2011057269A2 A DT O
formula WO2011057269A2 A NN O
I WO2011057269A2 A PRP O
wherein WO2011057269A2 A VBP O
the WO2011057269A2 A DT O
dashed WO2011057269A2 A JJ O
bonds WO2011057269A2 A NNS O
represent WO2011057269A2 A VBP O
a WO2011057269A2 A DT O
single WO2011057269A2 A JJ O
or WO2011057269A2 A CC O
double WO2011057269A2 A JJ O
bond WO2011057269A2 A NN O
which WO2011057269A2 A WDT O
can WO2011057269A2 A MD O
be WO2011057269A2 A VB O
in WO2011057269A2 A IN O
the WO2011057269A2 A DT O
cis WO2011057269A2 A NN O
or WO2011057269A2 A CC O
trans WO2011057269A2 A NNS O
configuration WO2011057269A2 A NN O
, WO2011057269A2 A , O
A WO2011057269A2 A NNP O
, WO2011057269A2 A , O
B WO2011057269A2 A NNP O
, WO2011057269A2 A , O
Z WO2011057269A2 A NNP O
, WO2011057269A2 A , O
X WO2011057269A2 A NNP O
, WO2011057269A2 A , O
R1 WO2011057269A2 A NNP O
and WO2011057269A2 A CC O
R2 WO2011057269A2 A NNP O
are WO2011057269A2 A VBP O
as WO2011057269A2 A IN O
defined WO2011057269A2 A VBN O
in WO2011057269A2 A IN O
the WO2011057269A2 A DT O
specification WO2011057269A2 A NN O
. WO2011057269A2 A . O

Such WO2011057269A2 A JJ O
compositions WO2011057269A2 A NNS O
are WO2011057269A2 A VBP O
used WO2011057269A2 A VBN O
in WO2011057269A2 A IN O
treating WO2011057269A2 A VBG O
the WO2011057269A2 A DT O
skin WO2011057269A2 A NN O
or WO2011057269A2 A CC O
scalp WO2011057269A2 A NN O
of WO2011057269A2 A IN O
a WO2011057269A2 A DT O
human WO2011057269A2 A JJ O
or WO2011057269A2 A CC O
non-human WO2011057269A2 A JJ O
animal WO2011057269A2 A NN O
. WO2011057269A2 A . O

Medication EP1970059A1 T NN O
with EP1970059A1 T IN O
Dobesilat-Calcium EP1970059A1 T NNP O
for EP1970059A1 T IN O
treatment EP1970059A1 T NN O
and EP1970059A1 T CC O
prophylaxis EP1970059A1 T NN O
of EP1970059A1 T IN O
tendon EP1970059A1 T JJ O
disease EP1970059A1 T NN O
. EP1970059A1 T . O

The US20110212108 A DT O
present US20110212108 A JJ O
invention US20110212108 A NN O
resides US20110212108 A NNS O
in US20110212108 A IN O
the US20110212108 A DT O
discovery US20110212108 A NN O
that US20110212108 A IN O
the US20110212108 A DT O
specific US20110212108 A JJ O
interaction US20110212108 A NN O
between US20110212108 A IN O
neuregulin US20110212108 A $ I-UN
1 US20110212108 A CD I-UN
( US20110212108 A ( O
NRG1 US20110212108 A NNP I-UN
) US20110212108 A ) O
and US20110212108 A CC O
integrin US20110212108 A NN O
is US20110212108 A VBZ O
important US20110212108 A JJ O
for US20110212108 A IN O
ErbB US20110212108 A NNP I-UN
signaling US20110212108 A NN O
, US20110212108 A , O
which US20110212108 A WDT O
in US20110212108 A IN O
turn US20110212108 A NN O
plays US20110212108 A NNS O
an US20110212108 A DT O
important US20110212108 A JJ O
role US20110212108 A NN O
in US20110212108 A IN O
cellular US20110212108 A JJ O
signaling US20110212108 A NN O
in US20110212108 A IN O
various US20110212108 A JJ O
physiological US20110212108 A JJ O
processes US20110212108 A NNS O
such US20110212108 A JJ O
as US20110212108 A IN O
cell US20110212108 A NN O
proliferation US20110212108 A NN O
, US20110212108 A , O
especially US20110212108 A RB O
in US20110212108 A IN O
cancer US20110212108 A NN O
cells US20110212108 A NNS O
overexpressing US20110212108 A VBG O
ErbB US20110212108 A NNP I-UN
family US20110212108 A NN O
members US20110212108 A NNS O
. US20110212108 A . O

Thus US20110212108 A RB O
, US20110212108 A , O
this US20110212108 A DT O
invention US20110212108 A NN O
provides US20110212108 A VBZ O
for US20110212108 A IN O
a US20110212108 A DT O
novel US20110212108 A JJ O
method US20110212108 A NN O
for US20110212108 A IN O
inhibiting US20110212108 A VBG O
ErbB US20110212108 A NNP I-UN
signaling US20110212108 A NN O
by US20110212108 A IN O
using US20110212108 A VBG O
an US20110212108 A DT O
inhibitor US20110212108 A NN O
of US20110212108 A IN O
NRG1-integrin US20110212108 A NNP O
binding US20110212108 A NN O
. US20110212108 A . O

Further US20110212108 A RB O
disclosed US20110212108 A VBN O
are US20110212108 A VBP O
polypeptides US20110212108 A NNS O
, US20110212108 A , O
nucleic US20110212108 A JJ O
acids US20110212108 A NNS O
, US20110212108 A , O
and US20110212108 A CC O
corresponding US20110212108 A VBG O
compositions US20110212108 A NNS O
for US20110212108 A IN O
inhibiting US20110212108 A VBG O
ErbB US20110212108 A NNP I-UN
signaling US20110212108 A NN O
. US20110212108 A . O

A US20050036949 T DT O
pharmaceutical US20050036949 T JJ O
dispenser US20050036949 T NN O
; US20050036949 T : O
a US20050036949 T DT O
liquid US20050036949 T JJ O
formulation US20050036949 T NN O
comprising US20050036949 T VBG O
nitric US20050036949 T JJ O
oxide US20050036949 T NN O
; US20050036949 T : O
respiratory US20050036949 T NN O
system US20050036949 T NN O
diseases US20050036949 T VBZ O
; US20050036949 T : O
atomizing US20050036949 T VBG O
. US20050036949 T . O

A WO2012123889A1 T DT O
synergistic WO2012123889A1 T JJ O
pharmaceutical WO2012123889A1 T JJ O
combination WO2012123889A1 T NN O
for WO2012123889A1 T IN O
the WO2012123889A1 T DT O
treatment WO2012123889A1 T NN O
of WO2012123889A1 T IN O
pancreatic WO2012123889A1 T JJ O
cancer WO2012123889A1 T NN O
. WO2012123889A1 T . O

In WO2012123889A1 A IN O
accordance WO2012123889A1 A NN O
with WO2012123889A1 A IN O
the WO2012123889A1 A DT O
present WO2012123889A1 A JJ O
invention WO2012123889A1 A NN O
there WO2012123889A1 A EX O
is WO2012123889A1 A VBZ O
provided WO2012123889A1 A VBN O
a WO2012123889A1 A DT O
pharmaceutical WO2012123889A1 A JJ O
combination WO2012123889A1 A NN O
useful WO2012123889A1 A JJ O
for WO2012123889A1 A IN O
the WO2012123889A1 A DT O
treatment WO2012123889A1 A NN O
of WO2012123889A1 A IN O
pancreatic WO2012123889A1 A JJ O
cancer WO2012123889A1 A NN O
comprising WO2012123889A1 A VBG O
a WO2012123889A1 A DT O
CDK WO2012123889A1 A NNP I-UN
inhibitor WO2012123889A1 A NN O
selected WO2012123889A1 A VBD O
from WO2012123889A1 A IN O
the WO2012123889A1 A DT O
compounds WO2012123889A1 A NNS O
of WO2012123889A1 A IN O
Formula WO2012123889A1 A NNP O
( WO2012123889A1 A ( O
I WO2012123889A1 A PRP O
) WO2012123889A1 A ) O
; WO2012123889A1 A : O
and WO2012123889A1 A CC O
a WO2012123889A1 A DT O
compound WO2012123889A1 A NN O
capable WO2012123889A1 A JJ O
of WO2012123889A1 A IN O
inhibiting WO2012123889A1 A VBG O
epidermal WO2012123889A1 A JJ I-UN
growth WO2012123889A1 A NN I-UN
factor WO2012123889A1 A NN I-UN
receptor WO2012123889A1 A NN I-UN
( WO2012123889A1 A ( O
EGFR WO2012123889A1 A NNP I-UN
) WO2012123889A1 A ) O
kinase WO2012123889A1 A NN O
activity WO2012123889A1 A NN O
. WO2012123889A1 A . O

Use EP1670481A1 T NNP O
of EP1670481A1 T IN O
ciclesonide EP1670481A1 T NN O
for EP1670481A1 T IN O
the EP1670481A1 T DT O
treatment EP1670481A1 T NN O
of EP1670481A1 T IN O
inflammatory EP1670481A1 T JJ O
bowel EP1670481A1 T NN O
diseases EP1670481A1 T NNS O
. EP1670481A1 T . O

Use US20090011978 T NNP O
of US20090011978 T IN O
Surfactant US20090011978 T NNP O
Preparations US20090011978 T NNP O
for US20090011978 T IN O
the US20090011978 T DT O
Treatment US20090011978 T NNP O
of US20090011978 T IN O
Surgical US20090011978 T NNP O
Adhesions US20090011978 T NNP O
. US20090011978 T . O

Combinations WO2011009193A8 T NNS O
of WO2011009193A8 T IN O
curcuminoids WO2011009193A8 T NNS O
and WO2011009193A8 T CC O
mtor WO2011009193A8 T NN I-UN
inhibitors WO2011009193A8 T NNS O
for WO2011009193A8 T IN O
the WO2011009193A8 T DT O
treatment WO2011009193A8 T NN O
of WO2011009193A8 T IN O
tauopathies WO2011009193A8 T NNS O
. WO2011009193A8 T . O

Methods WO2011009193A8 A NNS O
, WO2011009193A8 A , O
uses WO2011009193A8 A NNS O
, WO2011009193A8 A , O
compositions WO2011009193A8 A NNS O
, WO2011009193A8 A , O
combinations WO2011009193A8 A NNS O
and WO2011009193A8 A CC O
kits WO2011009193A8 A NNS O
relating WO2011009193A8 A VBG O
to WO2011009193A8 A TO O
the WO2011009193A8 A DT O
decrease WO2011009193A8 A NN O
of WO2011009193A8 A IN O
Tau WO2011009193A8 A NNP I-UN
protein WO2011009193A8 A NN I-UN
levels WO2011009193A8 A NNS O
, WO2011009193A8 A , O
and WO2011009193A8 A CC O
prevention WO2011009193A8 A NN O
and/or WO2011009193A8 A VBP O
treatment WO2011009193A8 A NN O
of WO2011009193A8 A IN O
diseases WO2011009193A8 A NNS O
or WO2011009193A8 A CC O
disorders WO2011009193A8 A NNS O
associated WO2011009193A8 A VBN O
with WO2011009193A8 A IN O
Tau WO2011009193A8 A NNP I-UN
protein WO2011009193A8 A NN I-UN
( WO2011009193A8 A ( O
Tauophathies WO2011009193A8 A NNPS O
) WO2011009193A8 A ) O
, WO2011009193A8 A , O
such WO2011009193A8 A JJ O
as WO2011009193A8 A IN O
Alzheimer WO2011009193A8 A NNP O
's WO2011009193A8 A POS O
disease WO2011009193A8 A NN O
, WO2011009193A8 A , O
using WO2011009193A8 A VBG O
a WO2011009193A8 A DT O
curcuminoid WO2011009193A8 A NN O
and WO2011009193A8 A CC O
a WO2011009193A8 A DT O
mammalian WO2011009193A8 A JJ O
target WO2011009193A8 A NN O
of WO2011009193A8 A IN O
rapamycin WO2011009193A8 A NN I-UN
( WO2011009193A8 A ( O
mTOR WO2011009193A8 A NN I-UN
) WO2011009193A8 A ) O
inhibitor WO2011009193A8 A NN O
, WO2011009193A8 A , O
are WO2011009193A8 A VBP O
described WO2011009193A8 A VBN O
. WO2011009193A8 A . O

Pathogenic WO2007140588A1 T JJ O
attenuation WO2007140588A1 T NN O
via WO2007140588A1 T IN O
the WO2007140588A1 T DT O
administration WO2007140588A1 T NN O
of WO2007140588A1 T IN O
an WO2007140588A1 T DT O
equilibiotic WO2007140588A1 T JJ O
compound WO2007140588A1 T NN O
. WO2007140588A1 T . O

A WO2007140588A1 A DT O
pharmaceutical WO2007140588A1 A JJ O
preparation WO2007140588A1 A NN O
comprising WO2007140588A1 A NN O
as WO2007140588A1 A IN O
an WO2007140588A1 A DT O
active WO2007140588A1 A JJ O
ingredient WO2007140588A1 A NN O
micron-sized WO2007140588A1 A JJ O
sulphur WO2007140588A1 A NN O
particles WO2007140588A1 A NNS O
[ WO2007140588A1 A VBP O
- WO2007140588A1 A : O
( WO2007140588A1 A ( O
300 WO2007140588A1 A CD O
microns WO2007140588A1 A NNS O
] WO2007140588A1 A VBP O
. WO2007140588A1 A . O

The WO2007140588A1 A DT O
pharmaceutical WO2007140588A1 A JJ O
preparation WO2007140588A1 A NN O
further WO2007140588A1 A RBR O
comprises WO2007140588A1 A VBZ O
an WO2007140588A1 A DT O
excipient WO2007140588A1 A NN O
, WO2007140588A1 A , O
i.e WO2007140588A1 A NN O
. WO2007140588A1 A . O

a WO2007140588A1 A DT O
sodium WO2007140588A1 A NN O
lignin WO2007140588A1 A NN O
sulphate WO2007140588A1 A NN O
or WO2007140588A1 A CC O
other WO2007140588A1 A JJ O
suitable WO2007140588A1 A JJ O
agents WO2007140588A1 A NNS O
. WO2007140588A1 A . O

The WO2007140588A1 A DT O
preparation WO2007140588A1 A NN O
is WO2007140588A1 A VBZ O
used WO2007140588A1 A VBN O
for WO2007140588A1 A IN O
the WO2007140588A1 A DT O
prevention WO2007140588A1 A NN O
and WO2007140588A1 A CC O
treatment WO2007140588A1 A NN O
of WO2007140588A1 A IN O
pathogenic WO2007140588A1 A JJ O
disorders WO2007140588A1 A NNS O
in WO2007140588A1 A IN O
humans WO2007140588A1 A NNS O
and WO2007140588A1 A CC O
animals WO2007140588A1 A NNS O
, WO2007140588A1 A , O
in WO2007140588A1 A IN O
a WO2007140588A1 A DT O
nutritional WO2007140588A1 A JJ O
and/or WO2007140588A1 A NN O
supplemental WO2007140588A1 A JJ O
regime WO2007140588A1 A NN O
, WO2007140588A1 A , O
as WO2007140588A1 A RB O
well WO2007140588A1 A RB O
as WO2007140588A1 A IN O
, WO2007140588A1 A , O
to WO2007140588A1 A TO O
improve WO2007140588A1 A VB O
feed WO2007140588A1 A NN O
and WO2007140588A1 A CC O
reproductive WO2007140588A1 A JJ O
performance WO2007140588A1 A NN O
. WO2007140588A1 A . O

A WO2007140588A1 A DT O
variety WO2007140588A1 A NN O
of WO2007140588A1 A IN O
conditions WO2007140588A1 A NNS O
were WO2007140588A1 A VBD O
treated WO2007140588A1 A VBN O
including WO2007140588A1 A VBG O
: WO2007140588A1 A : O
pneumonia WO2007140588A1 A NN O
, WO2007140588A1 A , O
arthritis WO2007140588A1 A NN O
, WO2007140588A1 A , O
ulcers WO2007140588A1 A NNS O
, WO2007140588A1 A , O
diabetes WO2007140588A1 A VBZ O
mellitus WO2007140588A1 A NN O
, WO2007140588A1 A , O
GI WO2007140588A1 A NNP O
cancer WO2007140588A1 A NN O
, WO2007140588A1 A , O
lupus WO2007140588A1 A NN O
, WO2007140588A1 A , O
herpes WO2007140588A1 A NNS O
, WO2007140588A1 A , O
psoriasis WO2007140588A1 A NN O
and WO2007140588A1 A CC O
early WO2007140588A1 A JJ O
menopause WO2007140588A1 A NN O
. WO2007140588A1 A . O

nucleosides US7816333 T NNS O
such US7816333 T JJ O
as US7816333 T IN O
3',5'-di-O-Benzyl-2'-O,4'-C-ethylene-4-N-benzoylcytidine US7816333 T JJ O
for US7816333 T IN O
treatment US7816333 T NN O
of US7816333 T IN O
pain US7816333 T NN O
, US7816333 T , O
psoriasis US7816333 T NN O
, US7816333 T , O
inflammatory US7816333 T NN O
disorders US7816333 T NNS O
, US7816333 T , O
infectious US7816333 T JJ O
skin US7816333 T NN O
disease US7816333 T NN O
, US7816333 T , O
skin US7816333 T JJ O
cancer US7816333 T NN O
, US7816333 T , O
Lyme US7816333 T NNP O
disease US7816333 T NN O
, US7816333 T , O
influenza US7816333 T JJ O
virus US7816333 T NN O
, US7816333 T , O
cytomegalovirus US7816333 T NN O
, US7816333 T , O
herpes US7816333 T VBZ O
virus US7816333 T NN O
, US7816333 T , O
herpes US7816333 T VBZ O
simplex US7816333 T JJ O
virus US7816333 T NN O
, US7816333 T , O
papilloma US7816333 T NN O
virus US7816333 T NN O
, US7816333 T , O
Epstein US7816333 T NNP O
Barr US7816333 T NNP O
virus US7816333 T NN O
or US7816333 T CC O
HIV US7816333 T NNP O
. US7816333 T . O

Pyrrolo-pyridine WO2008060907A3 T JJ I-UN
kinase WO2008060907A3 T NN I-UN
inhibitors WO2008060907A3 T NNS O
. WO2008060907A3 T . O

The WO2008060907A3 A DT O
Formula WO2008060907A3 A NNP O
( WO2008060907A3 A ( O
I WO2008060907A3 A PRP O
) WO2008060907A3 A ) O
compounds WO2008060907A3 A VBZ O
inhibit WO2008060907A3 A VBP O
the WO2008060907A3 A DT O
tyrosine WO2008060907A3 A JJ I-UN
kinase WO2008060907A3 A NN I-UN
activity WO2008060907A3 A NN O
of WO2008060907A3 A IN O
growth WO2008060907A3 A NN O
factor WO2008060907A3 A NN O
receptors WO2008060907A3 A NNS O
such WO2008060907A3 A JJ O
as WO2008060907A3 A IN O
VEGFR-2 WO2008060907A3 A NNP I-UN
, WO2008060907A3 A , O
FGFR-1 WO2008060907A3 A NNP I-UN
and WO2008060907A3 A CC O
IGFR-1 WO2008060907A3 A NNP I-UN
, WO2008060907A3 A , O
thereby WO2008060907A3 A RB O
making WO2008060907A3 A VBG O
them WO2008060907A3 A PRP O
useful WO2008060907A3 A JJ O
as WO2008060907A3 A IN O
anti-cancer WO2008060907A3 A JJ O
agents WO2008060907A3 A NNS O
. WO2008060907A3 A . O

Phosphinic EP1685142B1 T NNP O
acid EP1685142B1 T NN O
derivatives EP1685142B1 T NNS O
, EP1685142B1 T , O
beta-secretase EP1685142B1 T JJ O
inhibitors EP1685142B1 T NNS O
for EP1685142B1 T IN O
the EP1685142B1 T DT O
treatment EP1685142B1 T NN O
of EP1685142B1 T IN O
alzheimer EP1685142B1 T NN O
's EP1685142B1 T POS O
disease EP1685142B1 T NN O
. EP1685142B1 T . O

Gossypol CN101810577B T NNP O
intravenous CN101810577B T JJ O
injection CN101810577B T NN O
fatty CN101810577B T JJ O
emulsion CN101810577B T NN O
for CN101810577B T IN O
curing CN101810577B T VBG O
tumors CN101810577B T NNS O
. CN101810577B T . O

Artemisinin-Based US20140011829 T JJ O
Combination US20140011829 T NNP O
Therapy US20140011829 T NNP O
For US20140011829 T IN O
Treating US20140011829 T NNP O
Viral US20140011829 T NNP O
Mediated US20140011829 T NNP O
Disease US20140011829 T NNP O
. US20140011829 T . O

The US20140011829 A DT O
present US20140011829 A JJ O
invention US20140011829 A NN O
describes US20140011829 A VBZ O
a US20140011829 A DT O
method US20140011829 A NN O
of US20140011829 A IN O
treating US20140011829 A VBG O
individuals US20140011829 A NNS O
suffering US20140011829 A VBG O
from US20140011829 A IN O
microbial US20140011829 A JJ O
infections US20140011829 A NNS O
, US20140011829 A , O
including US20140011829 A VBG O
a US20140011829 A DT O
viral US20140011829 A JJ O
infection US20140011829 A NN O
such US20140011829 A JJ O
as US20140011829 A IN O
Dengue US20140011829 A NNP O
Fever US20140011829 A NNP O
, US20140011829 A , O
using US20140011829 A VBG O
an US20140011829 A DT O
improved US20140011829 A JJ O
Artemisinin US20140011829 A NNP O
Combination US20140011829 A NNP O
Therapy US20140011829 A NNP O
( US20140011829 A ( O
ACT US20140011829 A NNP O
) US20140011829 A ) O
, US20140011829 A , O
known US20140011829 A VBN O
as US20140011829 A IN O
Tri-ACT US20140011829 A NNP O
. US20140011829 A . O

The US20140011829 A DT O
improved US20140011829 A VBN O
ACT US20140011829 A NNP O
therapy US20140011829 A NN O
includes US20140011829 A VBZ O
administering US20140011829 A VBG O
a US20140011829 A DT O
combination US20140011829 A NN O
of US20140011829 A IN O
three US20140011829 A CD O
drugs US20140011829 A NNS O
. US20140011829 A . O

In US20140011829 A IN O
one US20140011829 A CD O
embodiment US20140011829 A NN O
of US20140011829 A IN O
the US20140011829 A DT O
present US20140011829 A JJ O
invention US20140011829 A NN O
, US20140011829 A , O
the US20140011829 A DT O
method US20140011829 A NN O
includes US20140011829 A VBZ O
administering US20140011829 A VBG O
to US20140011829 A TO O
an US20140011829 A DT O
individual US20140011829 A NN O
a US20140011829 A DT O
first US20140011829 A JJ O
composition US20140011829 A NN O
comprising US20140011829 A VBG O
a US20140011829 A DT O
therapeutically US20140011829 A RB O
effective US20140011829 A JJ O
amount US20140011829 A NN O
of US20140011829 A IN O
an US20140011829 A DT O
artemether US20140011829 A NN O
spray US20140011829 A NN O
sublingually US20140011829 A RB O
. US20140011829 A . O

The US20140011829 A DT O
individual US20140011829 A NN O
is US20140011829 A VBZ O
then US20140011829 A RB O
administered US20140011829 A VBN O
a US20140011829 A DT O
second US20140011829 A JJ O
composition US20140011829 A NN O
, US20140011829 A , O
a US20140011829 A DT O
therapeutically US20140011829 A RB O
effective US20140011829 A JJ O
amount US20140011829 A NN O
of US20140011829 A IN O
artesunate US20140011829 A NN O
. US20140011829 A . O

A US20140011829 A DT O
third US20140011829 A JJ O
composition US20140011829 A NN O
, US20140011829 A , O
an US20140011829 A DT O
effective US20140011829 A JJ O
amount US20140011829 A NN O
of US20140011829 A IN O
berberine US20140011829 A NN O
, US20140011829 A , O
or US20140011829 A CC O
its US20140011829 A PRP$ O
pharmaceutically US20140011829 A RB O
acceptable US20140011829 A JJ O
derivatives US20140011829 A NNS O
or US20140011829 A CC O
salts US20140011829 A NNS O
is US20140011829 A VBZ O
then US20140011829 A RB O
administered US20140011829 A VBN O
to US20140011829 A TO O
the US20140011829 A DT O
individual US20140011829 A NN O
. US20140011829 A . O

Functional WO2005115377A1 T NNP O
foods WO2005115377A1 T NNS O
comprising WO2005115377A1 T VBG O
flavonoids WO2005115377A1 T NNS O
and WO2005115377A1 T CC O
tocotrienols WO2005115377A1 T NNS O
and WO2005115377A1 T CC O
methods WO2005115377A1 T NNS O
thereof WO2005115377A1 T NN O
. WO2005115377A1 T . O

Use US20080213234 T NNP O
of US20080213234 T IN O
osteopontin US20080213234 T NN I-UN
for US20080213234 T IN O
the US20080213234 T DT O
treatment US20080213234 T NN O
and/or US20080213234 T JJ O
prevention US20080213234 T NN O
of US20080213234 T IN O
neurologic US20080213234 T JJ O
diseases US20080213234 T NNS O
. US20080213234 T . O

The US20080213234 A DT O
invention US20080213234 A NN O
relates US20080213234 A VBZ O
to US20080213234 A TO O
the US20080213234 A DT O
use US20080213234 A NN O
of US20080213234 A IN O
osteopontin US20080213234 A NN I-UN
, US20080213234 A , O
or US20080213234 A CC O
of US20080213234 A IN O
an US20080213234 A DT O
agonist US20080213234 A NN O
of US20080213234 A IN O
osteopontin US20080213234 A NN I-UN
activity US20080213234 A NN O
, US20080213234 A , O
for US20080213234 A IN O
treatment US20080213234 A NN O
or US20080213234 A CC O
prevention US20080213234 A NN O
of US20080213234 A IN O
a US20080213234 A DT O
neurologic US20080213234 A JJ O
diseases US20080213234 A NNS O
. US20080213234 A . O

Protopanaxadiol CN1850098A T NNP O
liposome CN1850098A T NN O
and CN1850098A T CC O
its CN1850098A T PRP$ O
preparing CN1850098A T NN O
method CN1850098A T NN O
. CN1850098A T . O

Pharmaceutical WO2004105775A8 T JJ O
composition WO2004105775A8 T NN O
comprising WO2004105775A8 T VBG O
glucan WO2004105775A8 T JJ O
derived WO2004105775A8 T VBN O
from WO2004105775A8 T IN O
microalgae WO2004105775A8 T NN O
. WO2004105775A8 T . O

Treatment WO2003053360A3 T NN O
of WO2003053360A3 T IN O
ebv WO2003053360A3 T NN O
and WO2003053360A3 T CC O
khsv WO2003053360A3 T VB O
infection WO2003053360A3 T NN O
and WO2003053360A3 T CC O
associated WO2003053360A3 T VBN O
abnormal WO2003053360A3 T JJ O
cellular WO2003053360A3 T JJ O
proliferation WO2003053360A3 T NN O
. WO2003053360A3 T . O

Photo-Activated US20080214530 T JJ O
Disinfection US20080214530 T NNP O
. US20080214530 T . O

The US20080214530 A DT O
present US20080214530 A JJ O
invention US20080214530 A NN O
relates US20080214530 A VBZ O
to US20080214530 A TO O
photo-activated US20080214530 A JJ O
disinfection US20080214530 A NN O
. US20080214530 A . O

In US20080214530 A IN O
particular US20080214530 A JJ O
, US20080214530 A , O
the US20080214530 A DT O
present US20080214530 A JJ O
invention US20080214530 A NN O
relates US20080214530 A VBZ O
to US20080214530 A TO O
photo-activated US20080214530 A JJ O
disinfection US20080214530 A NN O
in US20080214530 A IN O
the US20080214530 A DT O
oral US20080214530 A JJ O
cavity US20080214530 A NN O
. US20080214530 A . O

We US20080214530 A PRP O
describe US20080214530 A VBP O
a US20080214530 A DT O
dental US20080214530 A JJ O
apparatus US20080214530 A NN O
comprising US20080214530 A VBG O
a US20080214530 A DT O
light US20080214530 A JJ O
source US20080214530 A NN O
producing US20080214530 A VBG O
light US20080214530 A NN O
at US20080214530 A IN O
a US20080214530 A DT O
predetermined US20080214530 A JJ O
wavelength US20080214530 A NN O
and US20080214530 A CC O
power US20080214530 A NN O
, US20080214530 A , O
and US20080214530 A CC O
optical US20080214530 A JJ O
transmission US20080214530 A NN O
means US20080214530 A VBZ O
to US20080214530 A TO O
train US20080214530 A VB O
the US20080214530 A DT O
light US20080214530 A NN O
from US20080214530 A IN O
the US20080214530 A DT O
light US20080214530 A JJ O
source US20080214530 A NN O
onto US20080214530 A NN O
at US20080214530 A IN O
least US20080214530 A JJS O
one US20080214530 A CD O
external US20080214530 A JJ O
side US20080214530 A NN O
of US20080214530 A IN O
a US20080214530 A DT O
tooth US20080214530 A NN O
. US20080214530 A . O

Preferably US20080214530 A RB O
, US20080214530 A , O
the US20080214530 A DT O
optical US20080214530 A JJ O
transmission US20080214530 A NN O
means US20080214530 A VBZ O
comprises US20080214530 A NNS O
at US20080214530 A IN O
least US20080214530 A JJS O
one US20080214530 A CD O
optical US20080214530 A JJ O
guide US20080214530 A NN O
. US20080214530 A . O

In US20080214530 A IN O
a US20080214530 A DT O
preferred US20080214530 A JJ O
embodiment US20080214530 A NN O
, US20080214530 A , O
the US20080214530 A DT O
optical US20080214530 A JJ O
transmission US20080214530 A NN O
means US20080214530 A VBZ O
comprises US20080214530 A VBZ O
a US20080214530 A DT O
pair US20080214530 A NN O
of US20080214530 A IN O
substantially US20080214530 A RB O
parallel US20080214530 A JJ O
elongate US20080214530 A NN O
light US20080214530 A JJ O
guides US20080214530 A NNS O
each US20080214530 A DT O
light US20080214530 A NN O
guide US20080214530 A RB O
having US20080214530 A VBG O
a US20080214530 A DT O
distal US20080214530 A JJ O
end US20080214530 A NN O
provided US20080214530 A VBD O
with US20080214530 A IN O
a US20080214530 A DT O
reflective US20080214530 A JJ O
surface US20080214530 A NN O
inclined US20080214530 A VBN O
at US20080214530 A IN O
45° US20080214530 A CD O
to US20080214530 A TO O
the US20080214530 A DT O
direction US20080214530 A NN O
of US20080214530 A IN O
light US20080214530 A JJ O
transmission US20080214530 A NN O
along US20080214530 A IN O
the US20080214530 A DT O
light US20080214530 A JJ O
guides US20080214530 A NNS O
, US20080214530 A , O
the US20080214530 A DT O
reflective US20080214530 A JJ O
surfaces US20080214530 A NNS O
of US20080214530 A IN O
the US20080214530 A DT O
light US20080214530 A JJ O
guides US20080214530 A NNS O
being US20080214530 A VBG O
opposed US20080214530 A VBD O
such US20080214530 A JJ O
that US20080214530 A IN O
light US20080214530 A JJ O
emitted US20080214530 A VBN O
from US20080214530 A IN O
each US20080214530 A DT O
light US20080214530 A JJ O
guide US20080214530 A NN O
is US20080214530 A VBZ O
parallel US20080214530 A JJ O
but US20080214530 A CC O
opposite US20080214530 A JJ O
in US20080214530 A IN O
direction US20080214530 A NN O
. US20080214530 A . O

Preferably US20080214530 A RB O
, US20080214530 A , O
the US20080214530 A DT O
light US20080214530 A JJ O
source US20080214530 A NN O
is US20080214530 A VBZ O
a US20080214530 A DT O
light US20080214530 A JJ O
emitting US20080214530 A VBG O
diode US20080214530 A NN O
or US20080214530 A CC O
array US20080214530 A NN O
of US20080214530 A IN O
light US20080214530 A JJ O
emitting US20080214530 A VBG O
diodes US20080214530 A NNS O
and US20080214530 A CC O
the US20080214530 A DT O
has US20080214530 A VBZ O
a US20080214530 A DT O
wavelength US20080214530 A NN O
of US20080214530 A IN O
from US20080214530 A IN O
550 US20080214530 A CD O
to US20080214530 A TO O
690 US20080214530 A CD O
nm US20080214530 A NNS O
, US20080214530 A , O
more US20080214530 A JJR O
preferably US20080214530 A RB O
from US20080214530 A IN O
600 US20080214530 A CD O
nm US20080214530 A NNS O
to US20080214530 A TO O
680 US20080214530 A CD O
nm US20080214530 A NNS O
, US20080214530 A , O
even US20080214530 A RB O
more US20080214530 A RBR O
preferably US20080214530 A RB O
from US20080214530 A IN O
625 US20080214530 A CD O
to US20080214530 A TO O
660 US20080214530 A CD O
nm US20080214530 A NNS O
. US20080214530 A . O

Mif WO2007142923A1 T NNP I-UN
inhibitors WO2007142923A1 T NNS O
for WO2007142923A1 T IN O
treating WO2007142923A1 T VBG O
neuropathic WO2007142923A1 T JJ O
pain WO2007142923A1 T NN O
and WO2007142923A1 T CC O
associated WO2007142923A1 T VBN O
syndromes WO2007142923A1 T NNS O
. WO2007142923A1 T . O

Methods WO2007142923A1 A NNS O
of WO2007142923A1 A IN O
using WO2007142923A1 A VBG O
MIF WO2007142923A1 A NNP I-UN
inhibitors WO2007142923A1 A NNS O
such WO2007142923A1 A JJ O
as WO2007142923A1 A IN O
those WO2007142923A1 A DT O
characterized WO2007142923A1 A VBN O
by WO2007142923A1 A IN O
structure WO2007142923A1 A NN O
I WO2007142923A1 A PRP O
are WO2007142923A1 A VBP O
disclosed WO2007142923A1 A VBN O
. WO2007142923A1 A . O

The WO2007142923A1 A DT O
MIF WO2007142923A1 A NNP I-UN
inhibitors WO2007142923A1 A NNS O
can WO2007142923A1 A MD O
be WO2007142923A1 A VB O
used WO2007142923A1 A VBN O
for WO2007142923A1 A IN O
treating WO2007142923A1 A VBG O
conditions WO2007142923A1 A NNS O
such WO2007142923A1 A JJ O
as WO2007142923A1 A IN O
neuropathic WO2007142923A1 A JJ O
pain WO2007142923A1 A NN O
and WO2007142923A1 A CC O
its WO2007142923A1 A PRP$ O
associated WO2007142923A1 A VBN O
symptoms WO2007142923A1 A NNS O
, WO2007142923A1 A , O
as WO2007142923A1 A RB O
well WO2007142923A1 A RB O
as WO2007142923A1 A IN O
for WO2007142923A1 A IN O
treating WO2007142923A1 A VBG O
drug WO2007142923A1 A NN O
and WO2007142923A1 A CC O
behavioral WO2007142923A1 A JJ O
addictions WO2007142923A1 A NNS O
, WO2007142923A1 A , O
such WO2007142923A1 A JJ O
as WO2007142923A1 A IN O
opiate WO2007142923A1 A JJ O
dependence WO2007142923A1 A NN O
. WO2007142923A1 A . O

Additionally WO2007142923A1 A RB O
, WO2007142923A1 A , O
MIF WO2007142923A1 A NNP I-UN
inhibitor WO2007142923A1 A NN O
compounds WO2007142923A1 A NNS O
can WO2007142923A1 A MD O
be WO2007142923A1 A VB O
used WO2007142923A1 A VBN O
for WO2007142923A1 A IN O
treating WO2007142923A1 A VBG O
withdrawal WO2007142923A1 A NN O
syndromes WO2007142923A1 A NNS O
after WO2007142923A1 A IN O
discontinuance WO2007142923A1 A NN O
of WO2007142923A1 A IN O
addictive WO2007142923A1 A JJ O
drug WO2007142923A1 A NN O
use WO2007142923A1 A NN O
or WO2007142923A1 A CC O
behavior WO2007142923A1 A NN O
. WO2007142923A1 A . O

Treatment US6897212 T NN O
of US6897212 T IN O
oppositional US6897212 T JJ O
defiant US6897212 T JJ O
disorder US6897212 T NN O
and US6897212 T CC O
conduct US6897212 T NN O
disorder US6897212 T NN O
with US6897212 T IN O
5-aminoalkyl-4,5,6,7-tetrahydro-4-oxyindolones US6897212 T NNS O
. US6897212 T . O

Inhibitors US20130040906 T NNS O
of US20130040906 T IN O
Human US20130040906 T NNP O
EZH2 US20130040906 T NNP I-UN
, US20130040906 T , O
and US20130040906 T CC O
Methods US20130040906 T NNS O
of US20130040906 T IN O
Use US20130040906 T NNP O
Thereof US20130040906 T NNP O
. US20130040906 T . O

The US20130040906 A DT O
invention US20130040906 A NN O
relates US20130040906 A VBZ O
to US20130040906 A TO O
inhibition US20130040906 A NN O
of US20130040906 A IN O
wild-type US20130040906 A JJ O
and US20130040906 A CC O
certain US20130040906 A JJ O
mutant US20130040906 A JJ O
forms US20130040906 A NNS O
of US20130040906 A IN O
human US20130040906 A JJ I-UN
histone US20130040906 A NN I-UN
methyltransferase US20130040906 A NN I-UN
EZH2 US20130040906 A NNP I-UN
, US20130040906 A , O
the US20130040906 A DT O
catalytic US20130040906 A JJ O
subunit US20130040906 A NN O
of US20130040906 A IN O
the US20130040906 A DT O
PRC2 US20130040906 A NNP O
complex US20130040906 A NN O
which US20130040906 A WDT O
catalyzes US20130040906 A VBZ O
the US20130040906 A DT O
mono- US20130040906 A JJ O
through US20130040906 A IN O
tri-methylation US20130040906 A NN O
of US20130040906 A IN O
lysine US20130040906 A JJ I-UN
27 US20130040906 A CD I-UN
on US20130040906 A IN I-UN
histone US20130040906 A NN I-UN
H3 US20130040906 A NNP I-UN
( US20130040906 A ( O
H3-K27 US20130040906 A NNP I-UN
) US20130040906 A ) O
. US20130040906 A . O

In US20130040906 A IN O
one US20130040906 A CD O
embodiment US20130040906 A NN O
the US20130040906 A DT O
inhibition US20130040906 A NN O
is US20130040906 A VBZ O
selective US20130040906 A JJ O
for US20130040906 A IN O
the US20130040906 A DT O
mutant US20130040906 A JJ O
form US20130040906 A NN O
of US20130040906 A IN O
the US20130040906 A DT O
EZH2 US20130040906 A NNP I-UN
, US20130040906 A , O
such US20130040906 A JJ O
that US20130040906 A IN O
trimethylation US20130040906 A NN O
of US20130040906 A IN O
H3-K27 US20130040906 A NNP I-UN
, US20130040906 A , O
which US20130040906 A WDT O
is US20130040906 A VBZ O
associated US20130040906 A VBN O
with US20130040906 A IN O
certain US20130040906 A JJ O
cancers US20130040906 A NNS O
, US20130040906 A , O
is US20130040906 A VBZ O
inhibited US20130040906 A VBN O
. US20130040906 A . O

Also US20130040906 A RB O
provided US20130040906 A VBN O
are US20130040906 A VBP O
methods US20130040906 A NNS O
for US20130040906 A IN O
identifying US20130040906 A VBG O
small US20130040906 A JJ O
molecule US20130040906 A NN O
selective US20130040906 A JJ O
inhibitors US20130040906 A NNS O
of US20130040906 A IN O
the US20130040906 A DT O
mutant US20130040906 A JJ O
forms US20130040906 A NNS O
of US20130040906 A IN O
EZH2 US20130040906 A NNP I-UN
and US20130040906 A CC O
also US20130040906 A RB O
methods US20130040906 A NNS O
for US20130040906 A IN O
determining US20130040906 A VBG O
responsiveness US20130040906 A NN O
to US20130040906 A TO O
an US20130040906 A DT O
EZH2 US20130040906 A NNP I-UN
inhibitor US20130040906 A NN O
in US20130040906 A IN O
a US20130040906 A DT O
subject US20130040906 A NN O
. US20130040906 A . O

Externally-applied CN103623007A T JJ O
ointment CN103623007A T NN O
for CN103623007A T IN O
treating CN103623007A T VBG O
ringworm CN103623007A T NN O
of CN103623007A T IN O
scalp CN103623007A T NN O
and CN103623007A T CC O
preparation CN103623007A T NN O
and CN103623007A T CC O
application CN103623007A T NN O
methods CN103623007A T NNS O
thereof CN103623007A T NN O
. CN103623007A T . O

Application CN103462996A T NN O
of CN103462996A T IN O
Neonectrolide CN103462996A T NNP O
A CN103462996A T NNP O
in CN103462996A T IN O
preparing CN103462996A T VBG O
medicament CN103462996A T NN O
for CN103462996A T IN O
treating CN103462996A T VBG O
acute CN103462996A T JJ O
renal CN103462996A T JJ O
failure CN103462996A T NN O
. CN103462996A T . O

Medicament CN102068487A T NN O
for CN102068487A T IN O
treating CN102068487A T VBG O
empyrosis CN102068487A T NN O
and CN102068487A T CC O
scalding CN102068487A T NN O
. CN102068487A T . O

6-benzyl-2,3,4,7-tetrahydro-indolo WO2010015585A1 T JJ O
[ WO2010015585A1 T NNP O
2,3-c WO2010015585A1 T JJ O
] WO2010015585A1 T NNP O
quinoline WO2010015585A1 T NN O
compounds WO2010015585A1 T NNS O
. WO2010015585A1 T . O

The WO2010015585A1 A DT O
present WO2010015585A1 A JJ O
invention WO2010015585A1 A NN O
pertains WO2010015585A1 A NNS O
to WO2010015585A1 A TO O
6-benzyl-2,3,4,7-tetrahydro-indolo WO2010015585A1 A JJ O
[ WO2010015585A1 A JJ O
2,3-c WO2010015585A1 A JJ O
] WO2010015585A1 A NNP O
quinoline WO2010015585A1 A NN O
compounds WO2010015585A1 A NNS O
of WO2010015585A1 A IN O
formula WO2010015585A1 A NN O
( WO2010015585A1 A ( O
I WO2010015585A1 A PRP O
) WO2010015585A1 A ) O
, WO2010015585A1 A , O
as WO2010015585A1 A RB O
well WO2010015585A1 A RB O
as WO2010015585A1 A IN O
the WO2010015585A1 A DT O
resulting WO2010015585A1 A VBG O
pharmaceutical WO2010015585A1 A JJ O
compositions WO2010015585A1 A NNS O
, WO2010015585A1 A , O
and WO2010015585A1 A CC O
their WO2010015585A1 A PRP$ O
use WO2010015585A1 A NN O
in WO2010015585A1 A IN O
the WO2010015585A1 A DT O
treatment WO2010015585A1 A NN O
or WO2010015585A1 A CC O
prophylaxis WO2010015585A1 A NN O
of WO2010015585A1 A IN O
diseases WO2010015585A1 A NNS O
alleviated WO2010015585A1 A VBN O
by WO2010015585A1 A IN O
inhibition WO2010015585A1 A NN O
of WO2010015585A1 A IN O
type WO2010015585A1 A NN I-UN
5 WO2010015585A1 A CD I-UN
phosphodiesterases WO2010015585A1 A NNS I-UN
. WO2010015585A1 A . O

1- WO2010135976A1 T JJ O
( WO2010135976A1 T ( O
substituted WO2010135976A1 T JJ O
benzyl WO2010135976A1 T NN O
) WO2010135976A1 T ) O
-5-trifluoromethyl-2- WO2010135976A1 T NN O
( WO2010135976A1 T ( O
1h WO2010135976A1 T CD O
) WO2010135976A1 T ) O
pyridone WO2010135976A1 T NN O
compounds WO2010135976A1 T NNS O
and WO2010135976A1 T CC O
their WO2010135976A1 T PRP$ O
salts WO2010135976A1 T NNS O
, WO2010135976A1 T , O
their WO2010135976A1 T PRP$ O
preparation WO2010135976A1 T NN O
methods WO2010135976A1 T NNS O
and WO2010135976A1 T CC O
use WO2010135976A1 T NN O
thereof WO2010135976A1 T NN O
. WO2010135976A1 T . O

Methods WO2012177746A1 T NNS O
of WO2012177746A1 T IN O
preventing WO2012177746A1 T VBG O
or WO2012177746A1 T CC O
treating WO2012177746A1 T VBG O
disease WO2012177746A1 T NN O
states WO2012177746A1 T NNS O
related WO2012177746A1 T VBN O
to WO2012177746A1 T TO O
certain WO2012177746A1 T JJ O
metabolic WO2012177746A1 T JJ O
abnormalities WO2012177746A1 T NNS O
. WO2012177746A1 T . O

Caffeine WO2012091372A2 T NNP O
tape WO2012091372A2 T NN O
for WO2012091372A2 T IN O
body WO2012091372A2 T NN O
slimming WO2012091372A2 T NN O
. WO2012091372A2 T . O

Inhibition WO2012013821A1 T NN O
of WO2012013821A1 T IN O
dicer WO2012013821A1 T NN O
function WO2012013821A1 T NN O
for WO2012013821A1 T IN O
treatment WO2012013821A1 T NN O
of WO2012013821A1 T IN O
cancer WO2012013821A1 T NN O
. WO2012013821A1 T . O

The WO2012013821A1 A DT O
present WO2012013821A1 A JJ O
application WO2012013821A1 A NN O
relates WO2012013821A1 A VBZ O
to WO2012013821A1 A TO O
the WO2012013821A1 A DT O
field WO2012013821A1 A NN O
of WO2012013821A1 A IN O
cancer WO2012013821A1 A NN O
, WO2012013821A1 A , O
particularly WO2012013821A1 A RB O
cancers WO2012013821A1 A NNS O
wherein WO2012013821A1 A VBP O
p53 WO2012013821A1 A VB I-UN
tumour WO2012013821A1 A JJ O
suppression WO2012013821A1 A NN O
function WO2012013821A1 A NN O
is WO2012013821A1 A VBZ O
lost WO2012013821A1 A VBN O
or WO2012013821A1 A CC O
impaired WO2012013821A1 A VBN O
. WO2012013821A1 A . O

It WO2012013821A1 A PRP O
is WO2012013821A1 A VBZ O
shown WO2012013821A1 A VBN O
herein WO2012013821A1 A NNS O
that WO2012013821A1 A IN O
Dicer WO2012013821A1 A NNP O
is WO2012013821A1 A VBZ O
a WO2012013821A1 A DT O
synthetic WO2012013821A1 A JJ O
lethal WO2012013821A1 A JJ O
partner WO2012013821A1 A NN O
of WO2012013821A1 A IN O
p53 WO2012013821A1 A NN I-UN
, WO2012013821A1 A , O
allowing WO2012013821A1 A VBG O
the WO2012013821A1 A DT O
selective WO2012013821A1 A JJ O
targeting WO2012013821A1 A NN O
and WO2012013821A1 A CC O
killing WO2012013821A1 A NN O
of WO2012013821A1 A IN O
cancer WO2012013821A1 A NN O
cells WO2012013821A1 A NNS O
. WO2012013821A1 A . O

New CN101613382B T NNP O
geranium CN101613382B T NN O
extract CN101613382B T NN O
. CN101613382B T . O

An CN101006984B T DT O
injection CN101006984B T NN O
preparation CN101006984B T NN O
containing CN101006984B T VBG O
salvianolic CN101006984B T JJ O
acid CN101006984B T NN O
A CN101006984B T NNP O
and CN101006984B T CC O
extract CN101006984B T NN O
of CN101006984B T IN O
panax CN101006984B T NN O
natoginseng CN101006984B T NN O
, CN101006984B T , O
and CN101006984B T CC O
its CN101006984B T PRP$ O
preparation CN101006984B T NN O
method CN101006984B T NN O
and CN101006984B T CC O
application CN101006984B T NN O
. CN101006984B T . O

Perospirone CN103393614A T NNP O
hydrochloride CN103393614A T NN O
sustained CN103393614A T VBD O
release CN103393614A T NN O
preparation CN103393614A T NN O
and CN103393614A T CC O
preparation CN103393614A T NN O
method CN103393614A T NN O
thereof CN103393614A T NN O
. CN103393614A T . O

Synthesis WO2006027705A3 T NN O
of WO2006027705A3 T IN O
triethylenetetramines WO2006027705A3 T NNS O
. WO2006027705A3 T . O

Infusion CN101077344A T NNP O
preparation CN101077344A T NN O
of CN101077344A T IN O
ibuprofen CN101077344A T NN O
and CN101077344A T CC O
preparation CN101077344A T NN O
method CN101077344A T NN O
thereof CN101077344A T NN O
. CN101077344A T . O

Agent WO2008050698A2 T NN O
for WO2008050698A2 T IN O
prophylaxis WO2008050698A2 T NN O
or WO2008050698A2 T CC O
treatment WO2008050698A2 T NN O
of WO2008050698A2 T IN O
alcohol WO2008050698A2 T NN O
dependence WO2008050698A2 T NN O
or WO2008050698A2 T CC O
drug WO2008050698A2 T NN O
dependence WO2008050698A2 T NN O
. WO2008050698A2 T . O

Application CN103751169A T NN O
of CN103751169A T IN O
3'-methoxy CN103751169A T JJ O
benzyl-3,5-dimethoxy-4- CN103751169A T JJ O
( CN103751169A T ( O
3'-methoxy CN103751169A T JJ O
benzyloxy CN103751169A T NN O
) CN103751169A T ) O
benzoate CN103751169A T NN O
in CN103751169A T IN O
preparation CN103751169A T NN O
of CN103751169A T IN O
drugs CN103751169A T NNS O
for CN103751169A T IN O
treating CN103751169A T VBG O
or CN103751169A T CC O
preventing CN103751169A T VBG O
rheumatoid CN103751169A T JJ O
arthritis CN103751169A T NN O
. CN103751169A T . O

Ice CN103316353A T NNP O
laser CN103316353A T NN O
treatment CN103316353A T NN O
device CN103316353A T NN O
carrier CN103316353A T NN O
liquid CN103316353A T NN O
and CN103316353A T CC O
preparation CN103316353A T NN O
method CN103316353A T NN O
thereof CN103316353A T NN O
. CN103316353A T . O

Pyrazole-containing CN103232394A T VBG O
compound CN103232394A T NN O
as CN103232394A T RB O
well CN103232394A T RB O
as CN103232394A T IN O
preparation CN103232394A T NN O
method CN103232394A T NN O
and CN103232394A T CC O
use CN103232394A T NN O
thereof CN103232394A T NN O
. CN103232394A T . O

AQUEOUS WO2012108297A1 T NNP O
SOLUTION WO2012108297A1 T NNP O
CONTAINING WO2012108297A1 T NNP O
PARTIAL WO2012108297A1 T NNP O
RaS WO2012108297A1 T NNP O
POLYPEPTIDE WO2012108297A1 T NNP O
AND WO2012108297A1 T NNP O
METHOD WO2012108297A1 T NNP O
FOR WO2012108297A1 T NNP O
SCREENING WO2012108297A1 T NNP O
INHIBITOR WO2012108297A1 T NNP O
OF WO2012108297A1 T NNP O
RaS WO2012108297A1 T NNP O
FUNCTION WO2012108297A1 T NNP O
. WO2012108297A1 T . O

Coumarone CN102351852A T NNP O
compound CN102351852A T NN O
, CN102351852A T , O
its CN102351852A T PRP$ O
preparation CN102351852A T NN O
method CN102351852A T NN O
and CN102351852A T CC O
its CN102351852A T PRP$ O
application CN102351852A T NN O
. CN102351852A T . O

Compounds WO2006012504A3 T NNS O
and WO2006012504A3 T CC O
methods WO2006012504A3 T NNS O
for WO2006012504A3 T IN O
treatment WO2006012504A3 T NN O
of WO2006012504A3 T IN O
thrombosis WO2006012504A3 T NN O
. WO2006012504A3 T . O

Formulation CA2321523C T NN O
of CA2321523C T IN O
fast-dissolving CA2321523C T JJ O
efavirenz CA2321523C T JJ O
capsules CA2321523C T NNS O
or CA2321523C T CC O
tablets CA2321523C T NNS O
using CA2321523C T VBG O
super-disintegrants CA2321523C T NNS O
. CA2321523C T . O

Composition US20090012141 T NN O
and US20090012141 T CC O
Method US20090012141 T NNP O
for US20090012141 T IN O
Making US20090012141 T VBG O
Oligo-Benzamide US20090012141 T JJ O
Compounds US20090012141 T NNP O
. US20090012141 T . O

Prophylactic WO2010110923A2 T JJ O
and WO2010110923A2 T CC O
therapeutic WO2010110923A2 T JJ O
treatment WO2010110923A2 T NN O
of WO2010110923A2 T IN O
alzheimer WO2010110923A2 T NN O
's WO2010110923A2 T POS O
disease WO2010110923A2 T NN O
. WO2010110923A2 T . O

A WO2010110923A2 A DT O
composition WO2010110923A2 A NN O
and WO2010110923A2 A CC O
method WO2010110923A2 A NN O
for WO2010110923A2 A IN O
the WO2010110923A2 A DT O
treatment WO2010110923A2 A NN O
of WO2010110923A2 A IN O
Alzheimer WO2010110923A2 A NNP O
's WO2010110923A2 A POS O
disease WO2010110923A2 A NN O
and WO2010110923A2 A CC O
related WO2010110923A2 A JJ O
amyloid WO2010110923A2 A NN O
plaque WO2010110923A2 A NN O
development WO2010110923A2 A NN O
and WO2010110923A2 A CC O
reduction WO2010110923A2 A NN O
of WO2010110923A2 A IN O
amyloid WO2010110923A2 A JJ O
plaque WO2010110923A2 A NN O
, WO2010110923A2 A , O
amyloidosis WO2010110923A2 A NN O
and WO2010110923A2 A CC O
amyotrophic WO2010110923A2 A JJ O
lateral WO2010110923A2 A JJ O
sclerosis WO2010110923A2 A NN O
, WO2010110923A2 A , O
includes WO2010110923A2 A VBZ O
an WO2010110923A2 A DT O
effective WO2010110923A2 A JJ O
amount WO2010110923A2 A NN O
of WO2010110923A2 A IN O
a WO2010110923A2 A DT O
compound WO2010110923A2 A NN O
selected WO2010110923A2 A VBN O
from WO2010110923A2 A IN O
the WO2010110923A2 A DT O
group WO2010110923A2 A NN O
consisting WO2010110923A2 A VBG O
of WO2010110923A2 A IN O
phytic WO2010110923A2 A JJ O
acid WO2010110923A2 A NN O
, WO2010110923A2 A , O
a WO2010110923A2 A DT O
phytate WO2010110923A2 A NN O
salt WO2010110923A2 A NN O
, WO2010110923A2 A , O
an WO2010110923A2 A DT O
isomer WO2010110923A2 A NN O
or WO2010110923A2 A CC O
hydrolysate WO2010110923A2 A NN O
of WO2010110923A2 A IN O
phytic WO2010110923A2 A JJ O
acid WO2010110923A2 A NN O
or WO2010110923A2 A CC O
a WO2010110923A2 A DT O
phytate WO2010110923A2 A JJ O
salt WO2010110923A2 A NN O
, WO2010110923A2 A , O
or WO2010110923A2 A CC O
a WO2010110923A2 A DT O
mixture WO2010110923A2 A NN O
of WO2010110923A2 A IN O
any WO2010110923A2 A DT O
combination WO2010110923A2 A NN O
thereof WO2010110923A2 A NN O
, WO2010110923A2 A , O
being WO2010110923A2 A VBG O
administered WO2010110923A2 A VBN O
to WO2010110923A2 A TO O
a WO2010110923A2 A DT O
person WO2010110923A2 A NN O
in WO2010110923A2 A IN O
an WO2010110923A2 A DT O
amount WO2010110923A2 A NN O
from WO2010110923A2 A IN O
about WO2010110923A2 A IN O
0.5 WO2010110923A2 A CD O
grams WO2010110923A2 A NNS O
to WO2010110923A2 A TO O
about WO2010110923A2 A IN O
18.75 WO2010110923A2 A CD O
grams WO2010110923A2 A NNS O
per WO2010110923A2 A IN O
day WO2010110923A2 A NN O
. WO2010110923A2 A . O

Pyrrolopyridine EP2560971A1 T NNP O
inhibitors EP2560971A1 T NNS O
of EP2560971A1 T IN O
kinases EP2560971A1 T NNS I-UN
. EP2560971A1 T . O

The EP2560971A1 A DT O
present EP2560971A1 A JJ O
invention EP2560971A1 A NN O
relates EP2560971A1 A VBZ O
also EP2560971A1 A RB O
to EP2560971A1 A TO O
compositions EP2560971A1 A NNS O
containing EP2560971A1 A VBG O
said EP2560971A1 A VBD O
compounds EP2560971A1 A NNS O
which EP2560971A1 A WDT O
are EP2560971A1 A VBP O
useful EP2560971A1 A JJ O
for EP2560971A1 A IN O
inhibiting EP2560971A1 A VBG O
kinases EP2560971A1 A NNS I-UN
such EP2560971A1 A JJ O
as EP2560971A1 A IN O
Cdc7 EP2560971A1 A NNP I-UN
and EP2560971A1 A CC O
methods EP2560971A1 A NNS O
of EP2560971A1 A IN O
treating EP2560971A1 A VBG O
diseases EP2560971A1 A NNS O
such EP2560971A1 A JJ O
as EP2560971A1 A IN O
cancer EP2560971A1 A NN O
. EP2560971A1 A . O

Benzothiazepine US7192945 T NNP O
derivatives US7192945 T NNS O
. US7192945 T . O

The US7192945 A DT O
present US7192945 A JJ O
invention US7192945 A NN O
relates US7192945 A VBZ O
to US7192945 A TO O
compounds US7192945 A NNS O
of US7192945 A IN O
the US7192945 A DT O
formula US7192945 A NN O
( US7192945 A ( O
I US7192945 A PRP O
) US7192945 A ) O
: US7192945 A : O
( US7192945 A ( O
wherein US7192945 A WRB O
variable US7192945 A JJ O
groups US7192945 A NNS O
are US7192945 A VBP O
as US7192945 A IN O
defined US7192945 A VBN O
within US7192945 A IN O
) US7192945 A ) O
pharmaceutically US7192945 A RB O
acceptable US7192945 A JJ O
salts US7192945 A NNS O
, US7192945 A , O
solvates US7192945 A NNS O
, US7192945 A , O
solvates US7192945 A NNS O
of US7192945 A IN O
such US7192945 A JJ O
salts US7192945 A NNS O
and US7192945 A CC O
prodrugs US7192945 A NNS O
thereof US7192945 A NNS O
and US7192945 A CC O
their US7192945 A PRP$ O
use US7192945 A NN O
as US7192945 A IN O
ileal US7192945 A NN I-UN
bile US7192945 A IN I-UN
acid US7192945 A JJ I-UN
transport US7192945 A NN I-UN
( US7192945 A ( O
IBAT US7192945 A NNP I-UN
) US7192945 A ) O
inhibitors US7192945 A NNS O
for US7192945 A IN O
the US7192945 A DT O
treatment US7192945 A NN O
of US7192945 A IN O
hyperlipidaemia US7192945 A NN O
. US7192945 A . O

7-phenyl CN102040591A T JJ O
quinolone CN102040591A T NN O
compounds CN102040591A T NNS O
. CN102040591A T . O

Methods EP2595636A2 T NNS O
of EP2595636A2 T IN O
treating EP2595636A2 T VBG O
or EP2595636A2 T CC O
ameliorating EP2595636A2 T VBG O
diseases EP2595636A2 T NNS O
and EP2595636A2 T CC O
enhancing EP2595636A2 T VBG O
performance EP2595636A2 T NN O
comprising EP2595636A2 T VBG O
the EP2595636A2 T DT O
use EP2595636A2 T NN O
of EP2595636A2 T IN O
a EP2595636A2 T DT O
magnetic EP2595636A2 T JJ O
dipole EP2595636A2 T NN O
stabilized EP2595636A2 T VBN O
solution EP2595636A2 T NN O
. EP2595636A2 T . O

Rusco CN1596900A T NNP O
saponin CN1596900A T NN O
element CN1596900A T NN O
and CN1596900A T CC O
application CN1596900A T NN O
of CN1596900A T IN O
its CN1596900A T PRP$ O
saponin CN1596900A T NN O
in CN1596900A T IN O
preparation CN1596900A T NN O
of CN1596900A T IN O
medicine CN1596900A T NN O
preventing CN1596900A T NN O
and CN1596900A T CC O
treating CN1596900A T VBG O
embolus CN1596900A T JJ O
disease CN1596900A T NN O
. CN1596900A T . O

Novel CN101371840B T NNP O
use CN101371840B T NN O
of CN101371840B T IN O
vinetine CN101371840B T NN O
and CN101371840B T CC O
analogue CN101371840B T NN O
thereof CN101371840B T NN O
in CN101371840B T IN O
preparing CN101371840B T VBG O
medicine CN101371840B T NN O
for CN101371840B T IN O
preventing CN101371840B T VBG O
and/or CN101371840B T JJ O
treating CN101371840B T VBG O
leukemia CN101371840B T NN O
. CN101371840B T . O

Oxyacanthineexpressed CN101371840B A VBN O
by CN101371840B A IN O
formula CN101371840B A NN O
( CN101371840B A ( O
I CN101371840B A PRP O
) CN101371840B A ) O
and CN101371840B A CC O
oxyacanthine CN101371840B A JJ O
analogue CN101371840B A NN O
or CN101371840B A CC O
the CN101371840B A DT O
pharmaceutically CN101371840B A RB O
acceptable CN101371840B A JJ O
salt CN101371840B A NN O
thereof CN101371840B A NN O
can CN101371840B A MD O
combine CN101371840B A VB O
with CN101371840B A IN O
G-quadruplex CN101371840B A NNP O
DNA CN101371840B A NNP O
to CN101371840B A TO O
increase CN101371840B A VB O
the CN101371840B A DT O
stability CN101371840B A NN O
of CN101371840B A IN O
G-quadruplex CN101371840B A NNP O
DNA CN101371840B A NNP O
, CN101371840B A , O
so CN101371840B A RB O
as CN101371840B A IN O
to CN101371840B A TO O
competitively CN101371840B A RB O
inhibit CN101371840B A VB O
the CN101371840B A DT O
combination CN101371840B A NN O
of CN101371840B A IN O
a CN101371840B A DT O
telomerase CN101371840B A NN I-UN
and CN101371840B A CC O
a CN101371840B A DT O
telomere CN101371840B A RB O
, CN101371840B A , O
restrain CN101371840B A VB O
the CN101371840B A DT O
activity CN101371840B A NN O
of CN101371840B A IN O
the CN101371840B A DT O
telomerase CN101371840B A NN I-UN
, CN101371840B A , O
weaken CN101371840B A VBP O
the CN101371840B A DT O
proliferation CN101371840B A NN O
capability CN101371840B A NN O
of CN101371840B A IN O
cells CN101371840B A NNS O
of CN101371840B A IN O
the CN101371840B A DT O
telomerase CN101371840B A NN I-UN
, CN101371840B A , O
control CN101371840B A VB O
the CN101371840B A DT O
extension CN101371840B A NN O
of CN101371840B A IN O
the CN101371840B A DT O
telomere CN101371840B A NN O
and CN101371840B A CC O
accelerate CN101371840B A VB O
the CN101371840B A DT O
apoptosis CN101371840B A NN O
of CN101371840B A IN O
telomere CN101371840B A JJ O
cells CN101371840B A NNS O
. CN101371840B A . O

ARYL EP1594976A2 T NNP O
PHOSPHATE EP1594976A2 T NNP O
DERIVATIVES EP1594976A2 T NNP O
OF EP1594976A2 T NNP O
d4T EP1594976A2 T NN O
HAVING EP1594976A2 T NNP O
ACTIVITY EP1594976A2 T NNP O
AGAINST EP1594976A2 T NNP O
RESISTANT EP1594976A2 T NNP O
HIV EP1594976A2 T NNP O
STRAINS EP1594976A2 T NNP O
. EP1594976A2 T . O

Personal US20080193489 T JJ O
Lubricant US20080193489 T NNP O
Compositions US20080193489 T NNP O
That US20080193489 T WDT O
Are US20080193489 T NNP O
Free US20080193489 T NNP O
Of US20080193489 T IN O
Glycerin US20080193489 T NNP O
and US20080193489 T CC O
Parabens US20080193489 T NNP O
. US20080193489 T . O

Inhibitors US20050261333 T NNS O
of US20050261333 T IN O
the US20050261333 T DT O
kinase US20050261333 T NN O
Itk US20050261333 T NNP I-UN
; US20050261333 T : O
2-aryl-substituted US20050261333 T JJ O
derivatives US20050261333 T NNS O
of US20050261333 T IN O
6-substituted-3H-imidazo US20050261333 T JJ O
[ US20050261333 T JJ O
4,5-b US20050261333 T JJ O
] US20050261333 T NNP O
pyridines US20050261333 T NNS O
; US20050261333 T : O
to US20050261333 T TO O
treat US20050261333 T VB O
allergic US20050261333 T JJ O
, US20050261333 T , O
autoimmune US20050261333 T JJ O
, US20050261333 T , O
inflammatory US20050261333 T JJ O
, US20050261333 T , O
proliferative US20050261333 T JJ O
and US20050261333 T CC O
hyperproliferative US20050261333 T JJ O
diseases US20050261333 T NNS O
and US20050261333 T CC O
immune-mediated US20050261333 T JJ O
diseases US20050261333 T NNS O
; US20050261333 T : O
6,7-dichloro-2- US20050261333 T JJ O
[ US20050261333 T JJ O
4- US20050261333 T JJ O
( US20050261333 T ( O
2-morpholin-4-ylethoxy US20050261333 T JJ O
) US20050261333 T ) O
phenyl US20050261333 T NN O
] US20050261333 T NNP O
-3H-imidazo US20050261333 T NNP O
[ US20050261333 T NNP O
4,5-b US20050261333 T JJ O
] US20050261333 T NNP O
pyridine US20050261333 T NN O
. US20050261333 T . O

The US20050261333 A DT O
use US20050261333 A NN O
of US20050261333 A IN O
compounds US20050261333 A NNS O
of US20050261333 A IN O
formula US20050261333 A NN O
( US20050261333 A ( O
I US20050261333 A PRP O
) US20050261333 A ) O
wherein US20050261333 A NN O
R1 US20050261333 A NNP O
, US20050261333 A , O
R3 US20050261333 A NNP O
, US20050261333 A , O
R10 US20050261333 A NNP O
, US20050261333 A , O
m US20050261333 A NN O
and US20050261333 A CC O
Ar US20050261333 A NNP O
are US20050261333 A VBP O
as US20050261333 A IN O
defined US20050261333 A VBN O
in US20050261333 A IN O
the US20050261333 A DT O
Specification US20050261333 A NNP O
and US20050261333 A CC O
pharmaceutically US20050261333 A RB O
acceptable US20050261333 A JJ O
salts US20050261333 A NNS O
thereof US20050261333 A NN O
in US20050261333 A IN O
the US20050261333 A DT O
manufacture US20050261333 A NN O
of US20050261333 A IN O
a US20050261333 A DT O
medicament US20050261333 A NN O
for US20050261333 A IN O
the US20050261333 A DT O
treatment US20050261333 A NN O
or US20050261333 A CC O
prophylaxis US20050261333 A NN O
of US20050261333 A IN O
diseases US20050261333 A NNS O
or US20050261333 A CC O
conditions US20050261333 A NNS O
in US20050261333 A IN O
which US20050261333 A WDT O
inhibition US20050261333 A NN O
of US20050261333 A IN O
kinase US20050261333 A NN O
Itk US20050261333 A NNP I-UN
activity US20050261333 A NN O
is US20050261333 A VBZ O
beneficial US20050261333 A JJ O
is US20050261333 A VBZ O
disclosed US20050261333 A VBN O
. US20050261333 A . O

Compound CN101439021A T NNP O
diclofenac CN101439021A T NN O
sodium CN101439021A T NN O
, CN101439021A T , O
methopterin CN101439021A T NN O
flexible CN101439021A T JJ O
lipidosome CN101439021A T NN O
and CN101439021A T CC O
preparation CN101439021A T NN O
method CN101439021A T NN O
thereof CN101439021A T NN O
. CN101439021A T . O

Lansoprazole CN103655454A T JJ O
drug CN103655454A T NN O
composition CN103655454A T NN O
. CN103655454A T . O

Medicament CN101278933A T JJ O
composition CN101278933A T NN O
containing CN101278933A T VBG O
dimemorfan CN101278933A T NN O
and CN101278933A T CC O
method CN101278933A T NN O
of CN101278933A T IN O
preparing CN101278933A T VBG O
the CN101278933A T DT O
same CN101278933A T JJ O
. CN101278933A T . O

Medicament CN101502611B T NN O
for CN101502611B T IN O
treating CN101502611B T VBG O
cancer CN101502611B T NN O
and CN101502611B T CC O
preparation CN101502611B T NN O
method CN101502611B T NN O
thereof CN101502611B T NN O
. CN101502611B T . O

Method CN101084879A T NNP O
for CN101084879A T IN O
preparing CN101084879A T VBG O
fotemustine CN101084879A T JJ O
freezing-dried CN101084879A T JJ O
powder CN101084879A T NN O
injection CN101084879A T NN O
for CN101084879A T IN O
injection CN101084879A T NN O
. CN101084879A T . O

A WO2009063476A1 T DT O
crystalline WO2009063476A1 T JJ O
form WO2009063476A1 T NN O
of WO2009063476A1 T IN O
atorvastatin WO2009063476A1 T JJ O
hemi WO2009063476A1 T JJ O
magnesium WO2009063476A1 T NN O
salt WO2009063476A1 T NN O
and WO2009063476A1 T CC O
a WO2009063476A1 T DT O
process WO2009063476A1 T NN O
thereof WO2009063476A1 T NN O
. WO2009063476A1 T . O

Application CN102302504A T NN O
of CN102302504A T IN O
high-purity CN102302504A T NN O
baicalin CN102302504A T NN O
or CN102302504A T CC O
baicalein CN102302504A T NN O
to CN102302504A T TO O
preparation CN102302504A T NN O
of CN102302504A T IN O
inhaled CN102302504A T JJ O
asthma CN102302504A T NN O
relieving CN102302504A T VBG O
medicament CN102302504A T NN O
. CN102302504A T . O

Novel CN201182672Y T NNP O
nano CN201182672Y T JJ O
memory CN201182672Y T NN O
alloy CN201182672Y T NN O
intrauterine CN201182672Y T JJ O
device CN201182672Y T NN O
. CN201182672Y T . O

1,4-disulfide-7-azaspiro CN102010425A T JJ O
[ CN102010425A T NN O
4,4 CN102010425A T CD O
] CN102010425A T JJ O
nonane-8-carboxylic CN102010425A T JJ O
acid CN102010425A T NN O
derivative CN102010425A T JJ O
histone CN102010425A T NN O
deacetylase CN102010425A T NN O
inhibitor CN102010425A T NN O
and CN102010425A T CC O
application CN102010425A T NN O
thereof CN102010425A T NN O
. CN102010425A T . O

Preparation WO2010119741A1 T NN O
for WO2010119741A1 T IN O
external WO2010119741A1 T JJ O
use WO2010119741A1 T NN O
. WO2010119741A1 T . O

2- CA2548922A1 T JJ O
( CA2548922A1 T ( O
( CA2548922A1 T ( O
2 CA2548922A1 T CD O
, CA2548922A1 T , O
3-dihydroxypropyl CA2548922A1 T JJ O
) CA2548922A1 T ) O
aminomethyl CA2548922A1 T NN O
) CA2548922A1 T ) O
chromane CA2548922A1 T NN O
derivatives CA2548922A1 T NNS O
for CA2548922A1 T IN O
use CA2548922A1 T NN O
as CA2548922A1 T IN O
beta-3 CA2548922A1 T JJ I-UN
adrenoreceptor CA2548922A1 T NN I-UN
agonists CA2548922A1 T NNS O
in CA2548922A1 T IN O
the CA2548922A1 T DT O
treatment CA2548922A1 T NN O
of CA2548922A1 T IN O
urological CA2548922A1 T JJ O
and CA2548922A1 T CC O
inflammatory CA2548922A1 T JJ O
disorders CA2548922A1 T NNS O
. CA2548922A1 T . O

The CA2548922A1 A DT O
chroman CA2548922A1 A JJ O
derivatives CA2548922A1 A NNS O
of CA2548922A1 A IN O
the CA2548922A1 A DT O
present CA2548922A1 A JJ O
invention CA2548922A1 A NN O
have CA2548922A1 A VBP O
an CA2548922A1 A DT O
excellent CA2548922A1 A JJ O
activity CA2548922A1 A NN O
as CA2548922A1 A IN O
BETA CA2548922A1 A NNP I-UN
3 CA2548922A1 A CD I-UN
antagonists CA2548922A1 A NNS O
and CA2548922A1 A CC O
are CA2548922A1 A VBP O
useful CA2548922A1 A JJ O
for CA2548922A1 A IN O
the CA2548922A1 A DT O
prophylaxis CA2548922A1 A NN O
and CA2548922A1 A CC O
treatment CA2548922A1 A NN O
of CA2548922A1 A IN O
diseases CA2548922A1 A NNS O
associated CA2548922A1 A VBN O
with CA2548922A1 A IN O
BETA CA2548922A1 A NNP I-UN
3 CA2548922A1 A CD I-UN
activity CA2548922A1 A NN O
, CA2548922A1 A , O
in CA2548922A1 A IN O
particular CA2548922A1 A JJ O
for CA2548922A1 A IN O
the CA2548922A1 A DT O
treatment CA2548922A1 A NN O
of CA2548922A1 A IN O
urological CA2548922A1 A JJ O
disorder CA2548922A1 A NN O
or CA2548922A1 A CC O
disease CA2548922A1 A NN O
, CA2548922A1 A , O
such CA2548922A1 A JJ O
as CA2548922A1 A IN O
detrusor CA2548922A1 A NN O
overactivity CA2548922A1 A NN O
( CA2548922A1 A ( O
overactive CA2548922A1 A JJ O
bladder CA2548922A1 A NN O
) CA2548922A1 A ) O
, CA2548922A1 A , O
urinary CA2548922A1 A JJ O
incontinence CA2548922A1 A NN O
, CA2548922A1 A , O
neurogenic CA2548922A1 A JJ O
detrusor CA2548922A1 A NN O
overactivity CA2548922A1 A NN O
( CA2548922A1 A ( O
detrusor CA2548922A1 A JJ O
hyperflexia CA2548922A1 A NN O
) CA2548922A1 A ) O
, CA2548922A1 A , O
idiopathic CA2548922A1 A JJ O
detrusor CA2548922A1 A NN O
overactivity CA2548922A1 A NN O
( CA2548922A1 A ( O
detrusor CA2548922A1 A JJ O
instability CA2548922A1 A NN O
) CA2548922A1 A ) O
, CA2548922A1 A , O
benign CA2548922A1 A JJ O
prostatic CA2548922A1 A JJ O
hyperplasia CA2548922A1 A NN O
, CA2548922A1 A , O
and CA2548922A1 A CC O
lower CA2548922A1 A JJR O
urinary CA2548922A1 A JJ O
tract CA2548922A1 A NN O
symptoms CA2548922A1 A NNS O
; CA2548922A1 A : O
and CA2548922A1 A CC O
inflammatory CA2548922A1 A JJ O
disorders CA2548922A1 A NNS O
, CA2548922A1 A , O
such CA2548922A1 A JJ O
as CA2548922A1 A IN O
asthma CA2548922A1 A NN O
and CA2548922A1 A CC O
COPD CA2548922A1 A NNP O
. CA2548922A1 A . O

Water-Soluble US20110092593 T JJ O
Colonoscopy US20110092593 T NNP O
Lubricant US20110092593 T NNP O
. US20110092593 T . O

Codrugs CA2182228C T NNP O
as CA2182228C T IN O
a CA2182228C T DT O
method CA2182228C T NN O
of CA2182228C T IN O
controlled CA2182228C T JJ O
drug CA2182228C T NN O
delivery CA2182228C T NN O
. CA2182228C T . O

Deuterium-enriched US20090076080 T JJ O
fexofenadine US20090076080 T NN O
. US20090076080 T . O

2,3,4,5-tetrasubstituted CN101050179A T JJ O
derivatives CN101050179A T NNS O
of CN101050179A T IN O
benzyl CN101050179A T JJ O
ethylene CN101050179A T JJ O
class CN101050179A T NN O
, CN101050179A T , O
preparation CN101050179A T NN O
method CN101050179A T NN O
and CN101050179A T CC O
application CN101050179A T NN O
. CN101050179A T . O

Macrocycles US7115651 T NNS O
and US7115651 T CC O
uses US7115651 T VBZ O
thereof US7115651 T NN O
. US7115651 T . O

Combinations WO2009007680A3 T NNS O
comprising WO2009007680A3 T VBG O
a WO2009007680A3 T DT O
mast WO2009007680A3 T NN O
cell WO2009007680A3 T NN O
inhibitor WO2009007680A3 T NN O
and WO2009007680A3 T CC O
a WO2009007680A3 T DT O
statin WO2009007680A3 T NN O
for WO2009007680A3 T IN O
use WO2009007680A3 T NN O
in WO2009007680A3 T IN O
the WO2009007680A3 T DT O
treatment WO2009007680A3 T NN O
of WO2009007680A3 T IN O
inflammatory WO2009007680A3 T NN O
disorders WO2009007680A3 T NNS O
. WO2009007680A3 T . O

Anln US20110269797 T NNP I-UN
protein US20110269797 T NN O
as US20110269797 T IN O
an US20110269797 T DT O
endocrine US20110269797 T NN O
treatment US20110269797 T NN O
predictive US20110269797 T JJ O
factor US20110269797 T NN O
. US20110269797 T . O

Provided US20110269797 A VBN O
methods US20110269797 A NNS O
comprises US20110269797 A VBZ O
the US20110269797 A DT O
steps US20110269797 A NNS O
of US20110269797 A IN O
: US20110269797 A : O
providing US20110269797 A VBG O
a US20110269797 A DT O
sample US20110269797 A NN O
earlier US20110269797 A RBR O
obtained US20110269797 A VBN O
from US20110269797 A IN O
a US20110269797 A DT O
breast US20110269797 A NN O
cancer US20110269797 A NN O
subject US20110269797 A NN O
; US20110269797 A : O
evaluating US20110269797 A VBG O
the US20110269797 A DT O
amount US20110269797 A NN O
of US20110269797 A IN O
ANLN US20110269797 A NNP I-UN
protein US20110269797 A FW O
present US20110269797 A NN O
in US20110269797 A IN O
at US20110269797 A IN O
least US20110269797 A JJS O
part US20110269797 A NN O
of US20110269797 A IN O
said US20110269797 A VBD O
sample US20110269797 A NN O
, US20110269797 A , O
and US20110269797 A CC O
determining US20110269797 A VBG O
a US20110269797 A DT O
sample US20110269797 A JJ O
value US20110269797 A NN O
corresponding US20110269797 A VBG O
to US20110269797 A TO O
said US20110269797 A VBD O
amount US20110269797 A NN O
; US20110269797 A : O
comparing US20110269797 A VBG O
the US20110269797 A DT O
sample US20110269797 A NN O
value US20110269797 A NN O
with US20110269797 A IN O
a US20110269797 A DT O
reference US20110269797 A NN O
value US20110269797 A NN O
; US20110269797 A : O
and US20110269797 A CC O
, US20110269797 A , O
if US20110269797 A IN O
said US20110269797 A VBD O
sample US20110269797 A NN O
value US20110269797 A NN O
is US20110269797 A VBZ O
higher US20110269797 A JJR O
than US20110269797 A IN O
said US20110269797 A VBD O
reference US20110269797 A NN O
value US20110269797 A NN O
, US20110269797 A , O
concluding US20110269797 A VBG O
that US20110269797 A IN O
the US20110269797 A DT O
subject US20110269797 A NN O
is US20110269797 A VBZ O
not US20110269797 A RB O
likely US20110269797 A JJ O
to US20110269797 A TO O
benefit US20110269797 A VB O
from US20110269797 A IN O
an US20110269797 A DT O
endocrine US20110269797 A JJ O
treatment US20110269797 A NN O
or US20110269797 A CC O
that US20110269797 A IN O
a US20110269797 A DT O
prognosis US20110269797 A NN O
for US20110269797 A IN O
said US20110269797 A VBD O
subject US20110269797 A NN O
is US20110269797 A VBZ O
worse US20110269797 A JJR O
than US20110269797 A IN O
a US20110269797 A DT O
reference US20110269797 A NN O
prognosis US20110269797 A NN O
associated US20110269797 A VBN O
with US20110269797 A IN O
the US20110269797 A DT O
reference US20110269797 A NN O
value US20110269797 A NN O
. US20110269797 A . O

Medicinal CN102861039A T JJ O
formulation CN102861039A T NN O
for CN102861039A T IN O
treating CN102861039A T VBG O
beriberi CN102861039A T NN O
. CN102861039A T . O

Bivalent US20120263675 T NNP O
diazo US20120263675 T VBZ O
bicyclic US20120263675 T JJ O
smac US20120263675 T NN O
. US20120263675 T . O

Bivalent US20120263675 A NNP O
diazo US20120263675 A VBZ O
bicyclic US20120263675 A JJ O
Smac US20120263675 A NNP O
mimetics US20120263675 A NNS O
function US20120263675 A NN O
as US20120263675 A IN O
inhibitors US20120263675 A NNS O
of US20120263675 A IN O
Inhibitor US20120263675 A NNP I-UN
of US20120263675 A IN I-UN
Apoptosis US20120263675 A NNP I-UN
Proteins US20120263675 A NNP I-UN
( US20120263675 A ( O
IAPs US20120263675 A NNP I-UN
) US20120263675 A ) O
. US20120263675 A . O

Aqueous US20080207675 T JJ O
Gel US20080207675 T NNP O
Formulations US20080207675 T NNP O
Containing US20080207675 T NNP O
1- US20080207675 T JJ O
( US20080207675 T ( O
2-Methylpropyl US20080207675 T JJ O
) US20080207675 T ) O
-1H-Imidazo US20080207675 T FW O
[ US20080207675 T JJ O
4,5-C US20080207675 T JJ O
] US20080207675 T NN O
[ US20080207675 T $ O
1,5 US20080207675 T CD O
] US20080207675 T JJ O
Naphthyridin-4-Amine US20080207675 T NNP O
. US20080207675 T . O

Methods WO2014020608A1 T NNS O
of WO2014020608A1 T IN O
diagnosing WO2014020608A1 T VBG O
and WO2014020608A1 T CC O
treating WO2014020608A1 T VBG O
motor WO2014020608A1 T NN O
neuron WO2014020608A1 T NN O
diseases WO2014020608A1 T NNS O
. WO2014020608A1 T . O

Preparation CN1857356A T NN O
and CN1857356A T CC O
application CN1857356A T NN O
of CN1857356A T IN O
total CN1857356A T JJ O
seabuckthorn CN1857356A T JJ O
flavone CN1857356A T NN O
composition CN1857356A T NN O
. CN1857356A T . O

Ointment CN1911306A T NN O
for CN1911306A T IN O
treating CN1911306A T VBG O
beri-beri CN1911306A T NN O
. CN1911306A T . O

Alkylene CN101790553B T NNP O
oxide CN101790553B T MD O
derivative CN101790553B T VB O
and CN101790553B T CC O
skin CN101790553B T VB O
external CN101790553B T JJ O
preparation CN101790553B T NN O
containing CN101790553B T VBG O
the CN101790553B T DT O
same CN101790553B T JJ O
. CN101790553B T . O

Novel CN101790553B A NNP O
compounds CN101790553B A VBZ O
as CN101790553B A IN O
a CN101790553B A DT O
component CN101790553B A NN O
that CN101790553B A WDT O
has CN101790553B A VBZ O
rough CN101790553B A VBN O
skin CN101790553B A JJ O
remedying CN101790553B A NN O
effects CN101790553B A NNS O
, CN101790553B A , O
ensuring CN101790553B A VBG O
safety CN101790553B A NN O
, CN101790553B A , O
application CN101790553B A NN O
feeling CN101790553B A NN O
especially CN101790553B A RB O
free CN101790553B A JJ O
of CN101790553B A IN O
sensation CN101790553B A NN O
of CN101790553B A IN O
stickiness CN101790553B A NN O
and CN101790553B A CC O
favorable CN101790553B A JJ O
freshness CN101790553B A NN O
and CN101790553B A CC O
that CN101790553B A DT O
is CN101790553B A VBZ O
capable CN101790553B A JJ O
of CN101790553B A IN O
enhancing CN101790553B A VBG O
a CN101790553B A DT O
base CN101790553B A NN O
agent CN101790553B A NN O
stability CN101790553B A NN O
. CN101790553B A . O

There CN101790553B A EX O
are CN101790553B A VBP O
disclosed CN101790553B A VBN O
alkylene CN101790553B A JJ O
oxide CN101790553B A JJ O
derivatives CN101790553B A NNS O
characterized CN101790553B A VBN O
by CN101790553B A IN O
being CN101790553B A VBG O
represented CN101790553B A VBN O
by CN101790553B A IN O
the CN101790553B A DT O
general CN101790553B A JJ O
formula CN101790553B A NN O
: CN101790553B A : O
Z- CN101790553B A JJ O
{ CN101790553B A ( O
O- CN101790553B A JJ O
[ CN101790553B A NN O
( CN101790553B A ( O
AO CN101790553B A NNP O
) CN101790553B A ) O
a- CN101790553B A NN O
( CN101790553B A ( O
EO CN101790553B A NNP O
) CN101790553B A ) O
b CN101790553B A NN O
] CN101790553B A NN O
-R CN101790553B A NN O
} CN101790553B A ) O
2 CN101790553B A CD O
( CN101790553B A ( O
I CN101790553B A PRP O
) CN101790553B A ) O
( CN101790553B A ( O
in CN101790553B A IN O
the CN101790553B A DT O
formula CN101790553B A NN O
, CN101790553B A , O
Z CN101790553B A NNP O
is CN101790553B A VBZ O
a CN101790553B A DT O
residue CN101790553B A NN O
of CN101790553B A IN O
dimer CN101790553B A NN O
diol CN101790553B A NN O
devoid CN101790553B A NN O
of CN101790553B A IN O
hydroxyls CN101790553B A NN O
; CN101790553B A : O
EO CN101790553B A NNP O
is CN101790553B A VBZ O
an CN101790553B A DT O
oxyethylene CN101790553B A JJ O
group CN101790553B A NN O
; CN101790553B A : O
AO CN101790553B A NNP O
is CN101790553B A VBZ O
a CN101790553B A DT O
C3-C4 CN101790553B A JJ O
oxyalkylene CN101790553B A NN O
group CN101790553B A NN O
; CN101790553B A : O
the CN101790553B A DT O
mode CN101790553B A NN O
of CN101790553B A IN O
addition CN101790553B A NN O
of CN101790553B A IN O
these CN101790553B A DT O
groups CN101790553B A NNS O
is CN101790553B A VBZ O
a CN101790553B A DT O
block CN101790553B A NN O
; CN101790553B A : O
a CN101790553B A DT O
and CN101790553B A CC O
b CN101790553B A NN O
are CN101790553B A VBP O
the CN101790553B A DT O
average CN101790553B A JJ O
addition CN101790553B A NN O
molar CN101790553B A JJ O
quantities CN101790553B A NNS O
of CN101790553B A IN O
the CN101790553B A DT O
oxyalkylene CN101790553B A NN O
group CN101790553B A NN O
and CN101790553B A CC O
oxyethylene CN101790553B A NN O
group CN101790553B A NN O
, CN101790553B A , O
respectively CN101790553B A RB O
; CN101790553B A : O
1=2xa=150 CN101790553B A CD O
and CN101790553B A CC O
1=2xb=150 CN101790553B A CD O
; CN101790553B A : O
the CN101790553B A DT O
ratio CN101790553B A NN O
of CN101790553B A IN O
oxyethylene CN101790553B A NN O
group CN101790553B A NN O
to CN101790553B A TO O
the CN101790553B A DT O
sum CN101790553B A NN O
of CN101790553B A IN O
C3-C4 CN101790553B A NNP O
oxyalkylene CN101790553B A NNP O
group CN101790553B A NN O
and CN101790553B A CC O
oxyethylene CN101790553B A NN O
group CN101790553B A NN O
is CN101790553B A VBZ O
in CN101790553B A IN O
the CN101790553B A DT O
range CN101790553B A NN O
of CN101790553B A IN O
10 CN101790553B A CD O
to CN101790553B A TO O
99 CN101790553B A CD O
mass CN101790553B A NN O
% CN101790553B A NN O
; CN101790553B A : O
and CN101790553B A CC O
each CN101790553B A DT O
of CN101790553B A IN O
Rs CN101790553B A NNP O
independently CN101790553B A RB O
is CN101790553B A VBZ O
a CN101790553B A DT O
C1-C4 CN101790553B A JJ O
hydrocarbon CN101790553B A NN O
group CN101790553B A NN O
) CN101790553B A ) O
. CN101790553B A . O

Dressing US20130131621 T VBG O
device US20130131621 T NN O
. US20130131621 T . O

The US20130131621 A DT O
invention US20130131621 A NN O
relates US20130131621 A VBZ O
to US20130131621 A TO O
a US20130131621 A DT O
transparent US20130131621 A NN O
, US20130131621 A , O
absorbent US20130131621 A JJ O
device US20130131621 A NN O
for US20130131621 A IN O
the US20130131621 A DT O
dressing US20130131621 A NN O
of US20130131621 A IN O
wounds US20130131621 A NNS O
and US20130131621 A CC O
insertion US20130131621 A NN O
sites US20130131621 A NNS O
of US20130131621 A IN O
percutaneous US20130131621 A JJ O
and US20130131621 A CC O
drug US20130131621 A NN O
delivery US20130131621 A NN O
devices US20130131621 A NNS O
. US20130131621 A . O

The US20130131621 A DT O
device US20130131621 A NN O
provides US20130131621 A VBZ O
360 US20130131621 A CD O
degree US20130131621 A NN O
or US20130131621 A CC O
complete US20130131621 A JJ O
circumferential US20130131621 A JJ O
protection US20130131621 A NN O
of US20130131621 A IN O
a US20130131621 A DT O
wound US20130131621 A NN O
or US20130131621 A CC O
insertion US20130131621 A NN O
site US20130131621 A NN O
of US20130131621 A IN O
a US20130131621 A DT O
percutaneous US20130131621 A JJ O
or US20130131621 A CC O
drug US20130131621 A NN O
delivery US20130131621 A NN O
device US20130131621 A NN O
and US20130131621 A CC O
comprises US20130131621 A VBZ O
a US20130131621 A DT O
hydrogel US20130131621 A NN O
center US20130131621 A NN O
and US20130131621 A CC O
at US20130131621 A IN O
least US20130131621 A JJS O
one US20130131621 A CD O
absorbent US20130131621 A JJ O
material US20130131621 A NN O
. US20130131621 A . O

The US20130131621 A DT O
hydrogel US20130131621 A NN O
center US20130131621 A NN O
can US20130131621 A MD O
optionally US20130131621 A RB O
comprise US20130131621 A VB O
a US20130131621 A DT O
bioactive US20130131621 A JJ O
agent US20130131621 A NN O
( US20130131621 A ( O
s US20130131621 A NN O
) US20130131621 A ) O
. US20130131621 A . O

Composition WO2007071876A1 T NN O
of WO2007071876A1 T IN O
inverse WO2007071876A1 T JJ O
emulsion WO2007071876A1 T NN O
type WO2007071876A1 T NN O
comprising WO2007071876A1 T VBG O
ivermectin WO2007071876A1 T NN O
, WO2007071876A1 T , O
and WO2007071876A1 T CC O
uses WO2007071876A1 T VBZ O
thereof WO2007071876A1 T NN O
in WO2007071876A1 T IN O
cosmetics WO2007071876A1 T NNS O
and WO2007071876A1 T CC O
dermatology WO2007071876A1 T NN O
. WO2007071876A1 T . O

Application CN101862323A T NN O
of CN101862323A T IN O
1,2-O-stearyl CN101862323A T JJ O
glyceraldehyde CN101862323A T NN O
in CN101862323A T IN O
preparing CN101862323A T VBG O
antibacterial CN101862323A T JJ O
agents CN101862323A T NNS O
. CN101862323A T . O

Administering US7851507 T VBG O
to US7851507 T TO O
a US7851507 T DT O
lung US7851507 T NN O
cancer US7851507 T NN O
patient US7851507 T JJ O
2-hydroxyoleic US7851507 T JJ O
acid US7851507 T NN O
in US7851507 T IN O
an US7851507 T DT O
amount US7851507 T NN O
effective US7851507 T JJ O
to US7851507 T TO O
inhabit US7851507 T VB O
proliferation US7851507 T NN O
of US7851507 T IN O
the US7851507 T DT O
cancer US7851507 T NN O
; US7851507 T : O
leukemia US7851507 T CC O
, US7851507 T , O
brain US7851507 T NN O
metastasis US7851507 T NN O
. US7851507 T . O

Describes US7851507 A NNP O
the US7851507 A DT O
use US7851507 A NN O
of US7851507 A IN O
hydroxyoleic US7851507 A NN O
acid US7851507 A NN O
and US7851507 A CC O
its US7851507 A PRP$ O
analogs US7851507 A NNS O
of US7851507 A IN O
general US7851507 A JJ O
formula US7851507 A NN O
I US7851507 A PRP O
: US7851507 A : O
COOH—CHR— US7851507 A NNP O
( US7851507 A ( O
CH2 US7851507 A NNP O
) US7851507 A ) O
m—CH═CH— US7851507 A NN O
( US7851507 A ( O
CH2 US7851507 A NNP O
) US7851507 A ) O
n—CH3 US7851507 A NN O
, US7851507 A , O
in US7851507 A IN O
which US7851507 A WDT O
m US7851507 A NN O
and US7851507 A CC O
n US7851507 A NNS O
have US7851507 A VBP O
, US7851507 A , O
independently US7851507 A RB O
, US7851507 A , O
a US7851507 A DT O
value US7851507 A NN O
of US7851507 A IN O
0-15 US7851507 A NNP O
and US7851507 A CC O
R US7851507 A NNP O
can US7851507 A MD O
be US7851507 A VB O
any US7851507 A DT O
residue US7851507 A JJ O
with US7851507 A IN O
molecular US7851507 A JJ O
weight US7851507 A NN O
below US7851507 A IN O
200 US7851507 A CD O
Da US7851507 A NNP O
, US7851507 A , O
in US7851507 A IN O
the US7851507 A DT O
manufacture US7851507 A NN O
of US7851507 A IN O
drugs US7851507 A NNS O
that US7851507 A WDT O
can US7851507 A MD O
be US7851507 A VB O
used US7851507 A VBN O
in US7851507 A IN O
the US7851507 A DT O
treatment US7851507 A NN O
of US7851507 A IN O
cancer US7851507 A NN O
, US7851507 A , O
hypertension US7851507 A NN O
, US7851507 A , O
obesity US7851507 A NN O
or US7851507 A CC O
diseases US7851507 A NNS O
mediated US7851507 A VBN O
by US7851507 A IN O
alteration US7851507 A NN O
of US7851507 A IN O
the US7851507 A DT O
membrane US7851507 A NN O
structure US7851507 A NN O
and US7851507 A CC O
the US7851507 A DT O
consequent US7851507 A JJ O
regulation US7851507 A NN O
of US7851507 A IN O
G-proteins US7851507 A NNP I-UN
or US7851507 A CC O
of US7851507 A IN O
the US7851507 A DT O
receptors US7851507 A NNS O
coupled US7851507 A VBD O
to US7851507 A TO O
them US7851507 A PRP O
. US7851507 A . O

Methods CN101222850B T NNS O
for CN101222850B T IN O
treating CN101222850B T VBG O
drug CN101222850B T NN O
resistant CN101222850B T JJ O
cancer CN101222850B T NN O
. CN101222850B T . O

A CN101222850B A DT O
method CN101222850B A NN O
for CN101222850B A IN O
treating CN101222850B A VBG O
drug-resistant CN101222850B A JJ O
cancer CN101222850B A NN O
, CN101222850B A , O
includes CN101222850B A VBZ O
: CN101222850B A : O
administering CN101222850B A NN O
to CN101222850B A TO O
a CN101222850B A DT O
patient CN101222850B A NN O
in CN101222850B A IN O
need CN101222850B A NN O
thereof CN101222850B A NN O
, CN101222850B A , O
a CN101222850B A DT O
compound CN101222850B A NN O
of CN101222850B A IN O
formula CN101222850B A NN O
I CN101222850B A PRP O
, CN101222850B A , O
a CN101222850B A DT O
tautomer CN101222850B A NN O
of CN101222850B A IN O
the CN101222850B A DT O
compound CN101222850B A NN O
, CN101222850B A , O
a CN101222850B A DT O
salt CN101222850B A NN O
of CN101222850B A IN O
the CN101222850B A DT O
compound CN101222850B A NN O
, CN101222850B A , O
a CN101222850B A DT O
salt CN101222850B A NN O
of CN101222850B A IN O
the CN101222850B A DT O
tautomer CN101222850B A NN O
, CN101222850B A , O
a CN101222850B A DT O
mixture CN101222850B A NN O
thereof CN101222850B A NN O
, CN101222850B A , O
or CN101222850B A CC O
a CN101222850B A DT O
pharmaceutical CN101222850B A JJ O
composition CN101222850B A NN O
comprising CN101222850B A VBG O
the CN101222850B A DT O
compound CN101222850B A NN O
, CN101222850B A , O
the CN101222850B A DT O
tautomer CN101222850B A NN O
, CN101222850B A , O
the CN101222850B A DT O
salt CN101222850B A NN O
of CN101222850B A IN O
the CN101222850B A DT O
compound CN101222850B A NN O
, CN101222850B A , O
the CN101222850B A DT O
salt CN101222850B A NN O
of CN101222850B A IN O
the CN101222850B A DT O
tautomer CN101222850B A NN O
, CN101222850B A , O
or CN101222850B A CC O
the CN101222850B A DT O
mixture CN101222850B A NN O
, CN101222850B A , O
wherein CN101222850B A VBP O
the CN101222850B A DT O
patient CN101222850B A NN O
is CN101222850B A VBZ O
a CN101222850B A DT O
cancer CN101222850B A NN O
patient CN101222850B A NN O
with CN101222850B A IN O
drug-resistant CN101222850B A JJ O
cancer CN101222850B A NN O
, CN101222850B A , O
wherein CN101222850B A VBP O
the CN101222850B A DT O
compound CN101222850B A NN O
of CN101222850B A IN O
Formula CN101222850B A NNP O
I CN101222850B A PRP O
is CN101222850B A VBZ O
as CN101222850B A RB O
defined CN101222850B A VBN O
in CN101222850B A IN O
the CN101222850B A DT O
application CN101222850B A NN O
. CN101222850B A . O

Composition CA2305799C T NN O
for CA2305799C T IN O
the CA2305799C T DT O
treatment CA2305799C T NN O
of CA2305799C T IN O
nicotine CA2305799C T JJ O
addiction CA2305799C T NN O
containing CA2305799C T VBG O
a CA2305799C T DT O
nicotine CA2305799C T JJ I-UN
receptor CA2305799C T NN I-UN
antagonist CA2305799C T NN O
and CA2305799C T CC O
an CA2305799C T DT O
anti-depressant CA2305799C T JJ O
or CA2305799C T CC O
anti-anxiety CA2305799C T JJ O
drug CA2305799C T NN O
. CA2305799C T . O

The CA2305799C A DT O
invention CA2305799C A NN O
also CA2305799C A RB O
includes CA2305799C A VBZ O
related CA2305799C A JJ O
pharmaceutical CA2305799C A JJ O
compositions CA2305799C A NNS O
comprising CA2305799C A VBG O
nicotine CA2305799C A JJ I-UN
receptor CA2305799C A NN I-UN
antagonists CA2305799C A NNS O
and CA2305799C A CC O
either CA2305799C A DT O
an CA2305799C A DT O
anti-depressant CA2305799C A JJ O
or CA2305799C A CC O
an CA2305799C A DT O
anti-anxiety CA2305799C A JJ O
drug CA2305799C A NN O
. CA2305799C A . O

Xanthophyll US20110065805 T JJ O
composition US20110065805 T NN O
containing US20110065805 T VBG O
macular US20110065805 T JJ O
pigments US20110065805 T NNS O
and US20110065805 T CC O
a US20110065805 T DT O
process US20110065805 T NN O
for US20110065805 T IN O
its US20110065805 T PRP$ O
preparation US20110065805 T NN O
. US20110065805 T . O

Method US20090042909 T NNP O
of US20090042909 T IN O
treating US20090042909 T VBG O
dermatological US20090042909 T JJ O
disorders US20090042909 T NNS O
. US20090042909 T . O

A US20090042909 A DT O
method US20090042909 A NN O
of US20090042909 A IN O
treating US20090042909 A VBG O
a US20090042909 A DT O
dermatological US20090042909 A JJ O
disorder US20090042909 A NN O
in US20090042909 A IN O
a US20090042909 A DT O
subject US20090042909 A NN O
includes US20090042909 A VBZ O
the US20090042909 A DT O
step US20090042909 A NN O
of US20090042909 A IN O
administering US20090042909 A VBG O
a US20090042909 A DT O
therapeutically US20090042909 A RB O
effective US20090042909 A JJ O
amount US20090042909 A NN O
of US20090042909 A IN O
at US20090042909 A IN O
least US20090042909 A JJS O
one US20090042909 A CD O
PPARγ US20090042909 A NNP I-UN
agonist US20090042909 A NN O
or US20090042909 A CC O
derivative US20090042909 A JJ O
thereof US20090042909 A NN O
to US20090042909 A TO O
the US20090042909 A DT O
subject US20090042909 A NN O
. US20090042909 A . O

Increase US20050020519 T NNP O
concentration US20050020519 T NN O
of US20050020519 T IN O
peptide US20050020519 T NN O
; US20050020519 T : O
controlling US20050020519 T VBG O
glucose US20050020519 T JJ O
uptake US20050020519 T JJ O
into US20050020519 T IN O
cells US20050020519 T NNS O
; US20050020519 T : O
adjust US20050020519 T JJ O
metabolism US20050020519 T NN O
; US20050020519 T : O
stimulate US20050020519 T CC O
cell US20050020519 T NN O
proliferation US20050020519 T NN O
; US20050020519 T : O
reduce US20050020519 T VB O
apoptosis US20050020519 T NN O
; US20050020519 T : O
moderate US20050020519 T JJ O
gene US20050020519 T NN O
expression US20050020519 T NN O
' US20050020519 T POS O
. US20050020519 T . O

The US20050020519 A DT O
invention US20050020519 A NN O
relates US20050020519 A VBZ O
to US20050020519 A TO O
modulators US20050020519 A NNS O
of US20050020519 A IN O
insulin-regulated US20050020519 A JJ I-UN
aminopeptidase US20050020519 A NN I-UN
( US20050020519 A ( O
IRAP US20050020519 A NNP I-UN
) US20050020519 A ) O
/Angiotensin US20050020519 A VBP O
IV US20050020519 A NNP I-UN
receptor US20050020519 A NN I-UN
( US20050020519 A ( O
AT4 US20050020519 A NNP I-UN
) US20050020519 A ) O
activity US20050020519 A NN O
, US20050020519 A , O
which US20050020519 A WDT O
have US20050020519 A VBP O
the US20050020519 A DT O
ability US20050020519 A NN O
to US20050020519 A TO O
( US20050020519 A ( O
a US20050020519 A DT O
) US20050020519 A ) O
increase US20050020519 A NN O
local US20050020519 A JJ O
concentration US20050020519 A NN O
of US20050020519 A IN O
a US20050020519 A DT O
wide US20050020519 A JJ O
range US20050020519 A NN O
of US20050020519 A IN O
peptides US20050020519 A NNS O
, US20050020519 A , O
thereby US20050020519 A RB O
enhancing US20050020519 A VBG O
the US20050020519 A DT O
activity US20050020519 A NN O
of US20050020519 A IN O
these US20050020519 A DT O
peptides US20050020519 A NNS O
; US20050020519 A : O
( US20050020519 A ( O
b US20050020519 A NN O
) US20050020519 A ) O
regulate US20050020519 A NN O
glucose US20050020519 A JJ O
uptake US20050020519 A NN O
into US20050020519 A IN O
cells US20050020519 A NNS O
and US20050020519 A CC O
tissues US20050020519 A NNS O
, US20050020519 A , O
thereby US20050020519 A RB O
altering US20050020519 A VBG O
the US20050020519 A DT O
metabolic US20050020519 A NN O
or US20050020519 A CC O
energy US20050020519 A NN O
status US20050020519 A NN O
of US20050020519 A IN O
the US20050020519 A DT O
cells US20050020519 A NNS O
or US20050020519 A CC O
tissues US20050020519 A NNS O
; US20050020519 A : O
( US20050020519 A ( O
c US20050020519 A NN O
) US20050020519 A ) O
trigger US20050020519 A NN O
second US20050020519 A JJ O
messenger US20050020519 A NN O
or US20050020519 A CC O
signalling US20050020519 A VBG O
pathways US20050020519 A NNS O
associated US20050020519 A VBN O
with US20050020519 A IN O
IRAP/AT4 US20050020519 A NNP O
function US20050020519 A NN O
; US20050020519 A : O
and/or US20050020519 A CC O
( US20050020519 A ( O
d US20050020519 A NN O
) US20050020519 A ) O
increase US20050020519 A NN O
cell US20050020519 A NN O
surface US20050020519 A JJ O
expression US20050020519 A NN O
of US20050020519 A IN O
IRAP/AT4 US20050020519 A NNP O
. US20050020519 A . O

Substituted WO2005016255A3 T VBN O
tetrahydroquinolines WO2005016255A3 T NNS O
, WO2005016255A3 T , O
phenylacetic WO2005016255A3 T JJ O
acids WO2005016255A3 T NNS O
and WO2005016255A3 T CC O
benzoic WO2005016255A3 T JJ O
acids WO2005016255A3 T NNS O
as WO2005016255A3 T IN O
hepatocyte WO2005016255A3 T JJ I-UN
nuclear WO2005016255A3 T JJ I-UN
factor WO2005016255A3 T NN I-UN
4 WO2005016255A3 T CD I-UN
( WO2005016255A3 T ( O
hnf-4 WO2005016255A3 T NN I-UN
) WO2005016255A3 T ) O
modulator WO2005016255A3 T NN O
compounds WO2005016255A3 T NNS O
. WO2005016255A3 T . O

This WO2005016255A3 A DT O
invention WO2005016255A3 A NN O
relates WO2005016255A3 A VBZ O
to WO2005016255A3 A TO O
substituted WO2005016255A3 A VB O
tetrahydroquinoline WO2005016255A3 A JJ O
phenylacetic WO2005016255A3 A JJ O
acids WO2005016255A3 A NNS O
and WO2005016255A3 A CC O
benzoic WO2005016255A3 A JJ O
acids WO2005016255A3 A NNS O
that WO2005016255A3 A WDT O
bind WO2005016255A3 A VBP O
to WO2005016255A3 A TO O
and/or WO2005016255A3 A VB O
modulate WO2005016255A3 A NN O
hepatocyte WO2005016255A3 A NN I-UN
factor WO2005016255A3 A NN I-UN
4α WO2005016255A3 A CD I-UN
receptors WO2005016255A3 A NNS O
and WO2005016255A3 A CC O
to WO2005016255A3 A TO O
methods WO2005016255A3 A NNS O
for WO2005016255A3 A IN O
making WO2005016255A3 A VBG O
and WO2005016255A3 A CC O
using WO2005016255A3 A VBG O
such WO2005016255A3 A JJ O
compounds WO2005016255A3 A NNS O
. WO2005016255A3 A . O

Antiviral US8383164 T JJ O
composition US8383164 T NN O
and US8383164 T CC O
method US8383164 T NN O
for US8383164 T IN O
using US8383164 T VBG O
the US8383164 T DT O
same US8383164 T JJ O
. US8383164 T . O

Solid WO2014054969A1 T JJ O
dosage WO2014054969A1 T NN O
form WO2014054969A1 T NN O
having WO2014054969A1 T VBG O
a WO2014054969A1 T DT O
choleretic WO2014054969A1 T JJ O
effect WO2014054969A1 T NN O
( WO2014054969A1 T ( O
variants WO2014054969A1 T NNS O
) WO2014054969A1 T ) O
. WO2014054969A1 T . O

External CN1911312A T JJ O
application CN1911312A T NN O
medicine CN1911312A T NN O
for CN1911312A T IN O
treating CN1911312A T VBG O
beri-beri CN1911312A T NN O
. CN1911312A T . O

Dermal US20060018956 T NNP O
application US20060018956 T NN O
system US20060018956 T NN O
for US20060018956 T IN O
aminolevulinic US20060018956 T JJ O
acid-derivatives US20060018956 T NNS O
. US20060018956 T . O

Pharmaceutical US20120295968 T JJ O
Composition US20120295968 T NNP O
Comprising US20120295968 T NNP O
Cannabinoids US20120295968 T NNP O
. US20120295968 T . O

The US20120295968 A DT O
present US20120295968 A JJ O
invention US20120295968 A NN O
is US20120295968 A VBZ O
further US20120295968 A RB O
directed US20120295968 A VBN O
to US20120295968 A TO O
methods US20120295968 A NNS O
of US20120295968 A IN O
treating US20120295968 A VBG O
one US20120295968 A CD O
or US20120295968 A CC O
more US20120295968 A JJR O
disease US20120295968 A NN O
( US20120295968 A ( O
s US20120295968 A JJ O
) US20120295968 A ) O
or US20120295968 A CC O
disorder US20120295968 A NN O
( US20120295968 A ( O
s US20120295968 A PRP O
) US20120295968 A ) O
modulated US20120295968 A VBN O
by US20120295968 A IN O
the US20120295968 A DT O
activation US20120295968 A NN O
of US20120295968 A IN O
the US20120295968 A DT O
Cannabinoid US20120295968 A NNP I-UN
CB1 US20120295968 A NNP I-UN
and/or US20120295968 A VBZ O
CB2 US20120295968 A NNP I-UN
receptors US20120295968 A NNS I-UN
, US20120295968 A , O
by US20120295968 A IN O
administering US20120295968 A VBG O
a US20120295968 A DT O
therapeutically US20120295968 A RB O
effective US20120295968 A JJ O
amount US20120295968 A NN O
of US20120295968 A IN O
the US20120295968 A DT O
composition US20120295968 A NN O
of US20120295968 A IN O
the US20120295968 A DT O
present US20120295968 A JJ O
invention US20120295968 A NN O
to US20120295968 A TO O
a US20120295968 A DT O
subject US20120295968 A NN O
in US20120295968 A IN O
need US20120295968 A NN O
thereof US20120295968 A NN O
. US20120295968 A . O

Article US20100179184 T NN O
of US20100179184 T IN O
manufacture US20100179184 T NN O
for US20100179184 T IN O
prasugrel US20100179184 T NN O
. US20100179184 T . O

Extended US20110052687 T VBN O
release US20110052687 T NN O
pharmaceutical US20110052687 T JJ O
composition US20110052687 T NN O
of US20110052687 T IN O
paliperidone US20110052687 T NN O
. US20110052687 T . O

Substituted EP2683697A1 T VBN O
morpholines EP2683697A1 T NNS O
as EP2683697A1 T IN O
modulators EP2683697A1 T NNS O
for EP2683697A1 T IN O
the EP2683697A1 T DT O
calcium EP2683697A1 T NN I-UN
sensing EP2683697A1 T VBG I-UN
receptor EP2683697A1 T NN I-UN
. EP2683697A1 T . O

Compounds EP2683697A1 A NNS O
of EP2683697A1 A IN O
Formula EP2683697A1 A NNP O
( EP2683697A1 A ( O
I EP2683697A1 A PRP O
) EP2683697A1 A ) O
along EP2683697A1 A IN O
with EP2683697A1 A IN O
processes EP2683697A1 A NNS O
for EP2683697A1 A IN O
their EP2683697A1 A PRP$ O
preparation EP2683697A1 A NN O
that EP2683697A1 A WDT O
are EP2683697A1 A VBP O
useful EP2683697A1 A JJ O
for EP2683697A1 A IN O
treating EP2683697A1 A VBG O
, EP2683697A1 A , O
managing EP2683697A1 A VBG O
and/or EP2683697A1 A NN O
lessening EP2683697A1 A VBG O
the EP2683697A1 A DT O
diseases EP2683697A1 A NNS O
, EP2683697A1 A , O
disorders EP2683697A1 A NNS O
, EP2683697A1 A , O
syndromes EP2683697A1 A NNS O
or EP2683697A1 A CC O
conditions EP2683697A1 A NNS O
associated EP2683697A1 A VBN O
with EP2683697A1 A IN O
the EP2683697A1 A DT O
modulation EP2683697A1 A NN O
of EP2683697A1 A IN O
calcium EP2683697A1 A NN I-UN
sensing EP2683697A1 A NN I-UN
( EP2683697A1 A ( I-UN
Ca EP2683697A1 A NNP I-UN
SR EP2683697A1 A NNP I-UN
) EP2683697A1 A ) I-UN
receptors EP2683697A1 A NNS I-UN
. EP2683697A1 A . O

Methods EP2683697A1 A NNS O
of EP2683697A1 A IN O
treating EP2683697A1 A NN O
, EP2683697A1 A , O
managing EP2683697A1 A VBG O
and/or EP2683697A1 A NN O
lessening EP2683697A1 A VBG O
the EP2683697A1 A DT O
diseases EP2683697A1 A NNS O
, EP2683697A1 A , O
disorders EP2683697A1 A NNS O
, EP2683697A1 A , O
syndromes EP2683697A1 A NNS O
or EP2683697A1 A CC O
conditions EP2683697A1 A NNS O
associated EP2683697A1 A VBN O
with EP2683697A1 A IN O
the EP2683697A1 A DT O
modulation EP2683697A1 A NN O
of EP2683697A1 A IN O
calcium EP2683697A1 A NN I-UN
sensing EP2683697A1 A NN I-UN
( EP2683697A1 A ( I-UN
Ca EP2683697A1 A NNP I-UN
SR EP2683697A1 A NNP I-UN
) EP2683697A1 A ) I-UN
receptors EP2683697A1 A NNS I-UN
of EP2683697A1 A IN O
Formula EP2683697A1 A NNP O
( EP2683697A1 A ( O
I EP2683697A1 A PRP O
) EP2683697A1 A ) O
. EP2683697A1 A . O

Chiral WO2010132873A3 T JJ O
pyrrolidine WO2010132873A3 T NN O
core WO2010132873A3 T NN O
compounds WO2010132873A3 T NNS O
en WO2010132873A3 T IN O
route WO2010132873A3 T NN O
to WO2010132873A3 T TO O
inhibitors WO2010132873A3 T NNS O
of WO2010132873A3 T IN O
nitric WO2010132873A3 T JJ I-UN
oxide WO2010132873A3 T JJ I-UN
synthase WO2010132873A3 T NN I-UN
. WO2010132873A3 T . O

Diastereomeric WO2010132873A3 A NNP O
pyrrolidine WO2010132873A3 A NN O
compounds WO2010132873A3 A NNS O
and WO2010132873A3 A CC O
methods WO2010132873A3 A NNS O
of WO2010132873A3 A IN O
preparation WO2010132873A3 A NN O
, WO2010132873A3 A , O
as WO2010132873A3 A IN O
can WO2010132873A3 A MD O
be WO2010132873A3 A VB O
used WO2010132873A3 A VBN O
en WO2010132873A3 A IN O
route WO2010132873A3 A NN O
to WO2010132873A3 A TO O
the WO2010132873A3 A DT O
preparation WO2010132873A3 A NN O
of WO2010132873A3 A IN O
a WO2010132873A3 A DT O
range WO2010132873A3 A NN O
of WO2010132873A3 A IN O
nitric WO2010132873A3 A JJ I-UN
oxide WO2010132873A3 A JJ I-UN
synthase WO2010132873A3 A NN I-UN
inhibitors WO2010132873A3 A NNS O
. WO2010132873A3 A . O

Recombinant CA2239072C T JJ O
live CA2239072C T JJ O
vaccine CA2239072C T NN O
containing CA2239072C T VBG O
feline CA2239072C T JJ O
herpes CA2239072C T NNS O
virus CA2239072C T VBP O
type CA2239072C T JJ O
1 CA2239072C T CD O
, CA2239072C T , O
particularly CA2239072C T RB O
for CA2239072C T IN O
treating CA2239072C T VBG O
feline CA2239072C T NN O
infectious CA2239072C T JJ O
peritonitis CA2239072C T NN O
. CA2239072C T . O

A CA2239072C A DT O
recombinant CA2239072C A JJ O
live CA2239072C A JJ O
vaccine CA2239072C A NN O
including CA2239072C A VBG O
, CA2239072C A , O
as CA2239072C A IN O
the CA2239072C A DT O
vector CA2239072C A NN O
, CA2239072C A , O
a CA2239072C A DT O
feline CA2239072C A JJ O
herpes CA2239072C A NNS O
virus CA2239072C A VBP O
that CA2239072C A DT O
includes CA2239072C A VBZ O
and CA2239072C A CC O
expresses CA2239072C A VBZ O
at CA2239072C A IN O
least CA2239072C A JJS O
one CA2239072C A CD O
nucleotide CA2239072C A JJ O
sequence CA2239072C A NN O
coding CA2239072C A VBG O
for CA2239072C A IN O
a CA2239072C A DT O
polypeptide CA2239072C A NN O
, CA2239072C A , O
said CA2239072C A VBD O
sequence CA2239072C A NN O
being CA2239072C A VBG O
inserted CA2239072C A VBN O
in CA2239072C A IN O
sites CA2239072C A NNS O
ORF5 CA2239072C A NNP O
and/or CA2239072C A NN O
ORF2 CA2239072C A NNP O
, CA2239072C A , O
is CA2239072C A VBZ O
disclosed CA2239072C A VBN O
. CA2239072C A . O

A CA2239072C A DT O
multivalent CA2239072C A JJ O
vaccine CA2239072C A NN O
formula CA2239072C A NN O
and CA2239072C A CC O
feline CA2239072C A JJ O
herpes CA2239072C A NNS O
virus CA2239072C A VBP O
DNA CA2239072C A NN O
fragments CA2239072C A NNS O
are CA2239072C A VBP O
also CA2239072C A RB O
disclosed CA2239072C A VBN O
. CA2239072C A . O

Use WO2008071869A3 T NNP O
of WO2008071869A3 T IN O
agomelatine WO2008071869A3 T NN O
in WO2008071869A3 T IN O
order WO2008071869A3 T NN O
to WO2008071869A3 T TO O
obtain WO2008071869A3 T VB O
drugs WO2008071869A3 T NNS O
intended WO2008071869A3 T VBN O
for WO2008071869A3 T IN O
the WO2008071869A3 T DT O
treatment WO2008071869A3 T NN O
of WO2008071869A3 T IN O
periventricular WO2008071869A3 T JJ O
leukomalacia WO2008071869A3 T NN O
. WO2008071869A3 T . O

Piperazinyl-alkyl-benzoimidazol-2-one WO2011032903A1 T JJ O
derivatives WO2011032903A1 T NNS O
and WO2011032903A1 T CC O
their WO2011032903A1 T PRP$ O
use WO2011032903A1 T NN O
as WO2011032903A1 T IN O
monoamine WO2011032903A1 T JJ O
neurotransmitter WO2011032903A1 T IN O
re-uptake WO2011032903A1 T JJ O
inhibitors WO2011032903A1 T NNS O
. WO2011032903A1 T . O

Pyrimidine WO2010061903A1 T NNP O
derivative WO2010061903A1 T JJ O
and WO2010061903A1 T CC O
pyridine WO2010061903A1 T JJ O
derivative WO2010061903A1 T JJ O
both WO2010061903A1 T DT O
having WO2010061903A1 T VBG O
pi3k WO2010061903A1 T JJ I-UN
inhibitory WO2010061903A1 T JJ O
activity WO2010061903A1 T NN O
. WO2010061903A1 T . O

A WO2010061903A1 A DT O
pyrimidine WO2010061903A1 A JJ O
derivative WO2010061903A1 A NN O
or WO2010061903A1 A CC O
a WO2010061903A1 A DT O
pyridine WO2010061903A1 A JJ O
derivative WO2010061903A1 A NN O
represented WO2010061903A1 A VBN O
by WO2010061903A1 A IN O
formula WO2010061903A1 A NN O
( WO2010061903A1 A ( O
I WO2010061903A1 A PRP O
) WO2010061903A1 A ) O
or WO2010061903A1 A CC O
a WO2010061903A1 A DT O
pharmaceutically WO2010061903A1 A RB O
acceptable WO2010061903A1 A JJ O
salt WO2010061903A1 A NN O
of WO2010061903A1 A IN O
the WO2010061903A1 A DT O
pyrimidine WO2010061903A1 A NN O
derivative WO2010061903A1 A NN O
or WO2010061903A1 A CC O
the WO2010061903A1 A DT O
pyridine WO2010061903A1 A JJ O
derivative WO2010061903A1 A NN O
, WO2010061903A1 A , O
which WO2010061903A1 A WDT O
can WO2010061903A1 A MD O
inhibit WO2010061903A1 A VB O
the WO2010061903A1 A DT O
activity WO2010061903A1 A NN O
of WO2010061903A1 A IN O
PI3K WO2010061903A1 A NNP I-UN
to WO2010061903A1 A TO O
control WO2010061903A1 A VB O
many WO2010061903A1 A JJ O
biological WO2010061903A1 A JJ O
processes WO2010061903A1 A NNS O
including WO2010061903A1 A VBG O
growth WO2010061903A1 A NN O
, WO2010061903A1 A , O
differentiation WO2010061903A1 A NN O
, WO2010061903A1 A , O
survival WO2010061903A1 A NN O
, WO2010061903A1 A , O
proliferation WO2010061903A1 A NN O
, WO2010061903A1 A , O
migration WO2010061903A1 A NN O
and WO2010061903A1 A CC O
metabolism WO2010061903A1 A NN O
of WO2010061903A1 A IN O
cells WO2010061903A1 A NNS O
and WO2010061903A1 A CC O
is WO2010061903A1 A VBZ O
therefore WO2010061903A1 A RB O
useful WO2010061903A1 A JJ O
for WO2010061903A1 A IN O
the WO2010061903A1 A DT O
prevention/treatment WO2010061903A1 A NN O
of WO2010061903A1 A IN O
diseases WO2010061903A1 A NNS O
including WO2010061903A1 A VBG O
inflammatory WO2010061903A1 A NN O
diseases WO2010061903A1 A NNS O
, WO2010061903A1 A , O
arteriosclerosis WO2010061903A1 A NN O
, WO2010061903A1 A , O
vascular/cardiovascular WO2010061903A1 A JJ O
diseases WO2010061903A1 A NNS O
, WO2010061903A1 A , O
cancer/tumors WO2010061903A1 A NNS O
, WO2010061903A1 A , O
immune WO2010061903A1 A JJ O
diseases WO2010061903A1 A NNS O
, WO2010061903A1 A , O
cell WO2010061903A1 A NN O
proliferative WO2010061903A1 A JJ O
diseases WO2010061903A1 A NNS O
and WO2010061903A1 A CC O
infectious WO2010061903A1 A JJ O
diseases WO2010061903A1 A NNS O
. WO2010061903A1 A . O

Cycloalkylfused CA2597616A1 T JJ O
indole CA2597616A1 T NN O
, CA2597616A1 T , O
benzothiophene CA2597616A1 T NN O
, CA2597616A1 T , O
benzofuran CA2597616A1 T NN O
and CA2597616A1 T CC O
indene CA2597616A1 T JJ O
derivatives CA2597616A1 T NNS O
. CA2597616A1 T . O

The CA2597616A1 A DT O
present CA2597616A1 A JJ O
invention CA2597616A1 A NN O
provides CA2597616A1 A VBZ O
cycloalkylfused CA2597616A1 A JJ O
indole CA2597616A1 A NN O
, CA2597616A1 A , O
benzothiophene CA2597616A1 A NN O
, CA2597616A1 A , O
benzofuran CA2597616A1 A NN O
, CA2597616A1 A , O
and CA2597616A1 A CC O
indene CA2597616A1 A JJ O
derivatives CA2597616A1 A NNS O
, CA2597616A1 A , O
and CA2597616A1 A CC O
methods CA2597616A1 A NNS O
for CA2597616A1 A IN O
using CA2597616A1 A VBG O
them CA2597616A1 A PRP O
to CA2597616A1 A TO O
, CA2597616A1 A , O
for CA2597616A1 A IN O
example CA2597616A1 A NN O
, CA2597616A1 A , O
treat CA2597616A1 A NN O
, CA2597616A1 A , O
prevent CA2597616A1 A NN O
and/or CA2597616A1 A NN O
ameliorate CA2597616A1 A JJ O
central CA2597616A1 A JJ O
nervous CA2597616A1 A JJ O
system CA2597616A1 A NN O
diseases CA2597616A1 A NNS O
by CA2597616A1 A IN O
antagonizing CA2597616A1 A VBG O
5-HT1A CA2597616A1 A JJ I-UN
receptors CA2597616A1 A NNS O
and CA2597616A1 A CC O
modulating CA2597616A1 A VBG O
serotonin CA2597616A1 A NN O
levels CA2597616A1 A NNS O
. CA2597616A1 A . O

Novel WO2010007794A1 T NNP O
spiro WO2010007794A1 T NN O
compound WO2010007794A1 T NN O
, WO2010007794A1 T , O
and WO2010007794A1 T CC O
pharmaceutical WO2010007794A1 T JJ O
preparation WO2010007794A1 T NN O
comprising WO2010007794A1 T VBG O
the WO2010007794A1 T DT O
same WO2010007794A1 T JJ O
. WO2010007794A1 T . O

Physalin CN103214497A T NNP O
A CN103214497A T NNP O
extracting CN103214497A T VBG O
process CN103214497A T NN O
and CN103214497A T CC O
medical CN103214497A T JJ O
application CN103214497A T NN O
thereof CN103214497A T NN O
. CN103214497A T . O

The CN103214497A A DT O
mechanism CN103214497A A NN O
is CN103214497A A VBZ O
that CN103214497A A IN O
the CN103214497A A DT O
downstream CN103214497A A NN O
caspase CN103214497A A NN I-UN
family-associated CN103214497A A JJ O
protein CN103214497A A NN O
is CN103214497A A VBZ O
activated CN103214497A A VBN O
by CN103214497A A IN O
activating CN103214497A A VBG O
Fas CN103214497A A NNP I-UN
death CN103214497A A NN I-UN
receptors CN103214497A A NNS I-UN
, CN103214497A A , O
so CN103214497A A IN O
that CN103214497A A IN O
the CN103214497A A DT O
tumor CN103214497A A NN O
cells CN103214497A A NNS O
are CN103214497A A VBP O
induced CN103214497A A VBN O
to CN103214497A A TO O
generate CN103214497A A VB O
apoptosis CN103214497A A NN O
. CN103214497A A . O

Meanwhile CN103214497A A RB O
, CN103214497A A , O
the CN103214497A A DT O
physalin CN103214497A A NN O
A CN103214497A A NNP O
can CN103214497A A MD O
be CN103214497A A VB O
used CN103214497A A VBN O
for CN103214497A A IN O
inducing CN103214497A A VBG O
the CN103214497A A DT O
tumor CN103214497A A NN O
cells CN103214497A A NNS O
to CN103214497A A TO O
generate CN103214497A A VB O
autophagy CN103214497A A NN O
for CN103214497A A IN O
achieving CN103214497A A VBG O
autophagy CN103214497A A JJ O
antagonism CN103214497A A NN O
apoptosis CN103214497A A NN O
in CN103214497A A IN O
the CN103214497A A DT O
HT1080 CN103214497A A NNP O
and CN103214497A A CC O
the CN103214497A A DT O
A375-S2 CN103214497A A NNP O
cells CN103214497A A NNS O
; CN103214497A A : O
and CN103214497A A CC O
the CN103214497A A DT O
p53 CN103214497A A NN I-UN
protein CN103214497A A NN O
and CN103214497A A CC O
the CN103214497A A DT O
MAPK CN103214497A A NNP I-UN
( CN103214497A A ( O
Mitogen-Activated CN103214497A A JJ I-UN
Protein CN103214497A A NNP I-UN
Kinase CN103214497A A NNP I-UN
) CN103214497A A ) O
-familty CN103214497A A NN O
p38 CN103214497A A NN I-UN
protein CN103214497A A NN O
have CN103214497A A VBP O
a CN103214497A A DT O
key CN103214497A A JJ O
regulation CN103214497A A NN O
effect CN103214497A A NN O
. CN103214497A A . O

Synthesizing CN101475484B T VBG O
method CN101475484B T NN O
and CN101475484B T CC O
use CN101475484B T NN O
of CN101475484B T IN O
bone-targeted CN101475484B T JJ O
antiphlogistic CN101475484B T JJ O
medicament CN101475484B T NN O
. CN101475484B T . O

Intravenous CN102846663A T JJ O
drip CN102846663A T NN O
type CN102846663A T NN O
body CN102846663A T NN O
fluid CN102846663A T NN O
replenisher CN102846663A T NN O
. CN102846663A T . O

Pharmaceutical EP1313489B1 T JJ O
compositions EP1313489B1 T NNS O
for EP1313489B1 T IN O
the EP1313489B1 T DT O
treatment EP1313489B1 T NN O
of EP1313489B1 T IN O
mucositis EP1313489B1 T NN O
, EP1313489B1 T , O
stomatitis EP1313489B1 T NN O
and EP1313489B1 T CC O
behcet EP1313489B1 T NN O
's EP1313489B1 T POS O
syndrome EP1313489B1 T NN O
. EP1313489B1 T . O

Medication CN1660126A T NN O
of CN1660126A T IN O
combination CN1660126A T NN O
of CN1660126A T IN O
sodium CN1660126A T NN O
cytidine CN1660126A T NN O
triphosphate CN1660126A T NN O
and CN1660126A T CC O
ebselen CN1660126A T NN O
. CN1660126A T . O

Oral CN102100660A T NNP O
solid CN102100660A T JJ O
preparation CN102100660A T NN O
containing CN102100660A T VBG O
venlafaxine CN102100660A T JJ O
hydrochloride CN102100660A T NN O
and CN102100660A T CC O
preparation CN102100660A T NN O
method CN102100660A T NN O
thereof CN102100660A T NN O
. CN102100660A T . O

Preparation CN103432209A T NNP O
method CN103432209A T NN O
of CN103432209A T IN O
rhizoma CN103432209A T NN O
corydalis CN103432209A T NNS O
crude CN103432209A T VBP O
drug CN103432209A T NN O
. CN103432209A T . O

Substituted WO2012014221A1 T VBN O
4- WO2012014221A1 T JJ O
( WO2012014221A1 T ( O
4-fluoro-3- WO2012014221A1 T JJ O
( WO2012014221A1 T ( O
piperazine-1- WO2012014221A1 T JJ O
carbonyl WO2012014221A1 T NN O
) WO2012014221A1 T ) O
benzyl WO2012014221A1 T NN O
) WO2012014221A1 T ) O
phthalazin-1 WO2012014221A1 T NN O
( WO2012014221A1 T ( O
2h WO2012014221A1 T CD O
) WO2012014221A1 T ) O
-one WO2012014221A1 T NN O
derivatives WO2012014221A1 T NNS O
as WO2012014221A1 T IN O
poly WO2012014221A1 T NN I-UN
( WO2012014221A1 T ( I-UN
adp-ribose WO2012014221A1 T JJ I-UN
) WO2012014221A1 T ) I-UN
polymerase- WO2012014221A1 T JJ I-UN
1 WO2012014221A1 T CD I-UN
inhibitors WO2012014221A1 T NNS O
. WO2012014221A1 T . O

These WO2012014221A1 A DT O
compounds WO2012014221A1 A NNS O
are WO2012014221A1 A VBP O
suitable WO2012014221A1 A JJ O
as WO2012014221A1 A IN O
Poly WO2012014221A1 A NNP I-UN
( WO2012014221A1 A ( I-UN
ADP-ribose WO2012014221A1 A NNP I-UN
) WO2012014221A1 A ) I-UN
polymerase- WO2012014221A1 A NN I-UN
1 WO2012014221A1 A CD I-UN
inhibitors WO2012014221A1 A NNS O
( WO2012014221A1 A ( O
PARP-1 WO2012014221A1 A NNP I-UN
inhibitors WO2012014221A1 A NNS O
) WO2012014221A1 A ) O
. WO2012014221A1 A . O

Salinosporamide EP2276765A1 T NNP O
derivatives EP2276765A1 T VBZ O
as EP2276765A1 T IN O
proteasome EP2276765A1 T JJ I-UN
inhibitors EP2276765A1 T NNS O
. EP2276765A1 T . O

Disclosed EP2276765A1 A VBN O
herein EP2276765A1 A NNS O
are EP2276765A1 A VBP O
6-oxa-2-azabicyclo EP2276765A1 A JJ O
[ EP2276765A1 A JJ O
3.2.0 EP2276765A1 A CD O
] EP2276765A1 A JJ O
heptane-3,7-dione EP2276765A1 A NN O
or EP2276765A1 A CC O
heterobicyclic EP2276765A1 A JJ O
γ-lactam-β-lactone EP2276765A1 A JJ O
derivatives EP2276765A1 A NNS O
of EP2276765A1 A IN O
formula EP2276765A1 A NN O
( EP2276765A1 A ( O
I EP2276765A1 A PRP O
) EP2276765A1 A ) O
that EP2276765A1 A WDT O
include EP2276765A1 A VBP O
a EP2276765A1 A DT O
sulfonate EP2276765A1 A JJ O
ester EP2276765A1 A NN O
, EP2276765A1 A , O
ester EP2276765A1 A NN O
or EP2276765A1 A CC O
ether EP2276765A1 A NN O
group EP2276765A1 A NN O
in EP2276765A1 A IN O
the EP2276765A1 A DT O
substituent EP2276765A1 A NN O
at EP2276765A1 A IN O
the EP2276765A1 A DT O
4-position EP2276765A1 A NN O
as EP2276765A1 A IN O
proteasome EP2276765A1 A JJ I-UN
inhibitors EP2276765A1 A NNS O
. EP2276765A1 A . O

Hydroxymethylfurfural WO2013094676A1 T NNP O
derivative WO2013094676A1 T NN O
. WO2013094676A1 T . O

Application CN101721405A T NN O
of CN101721405A T IN O
diacetylbaicalein CN101721405A T NN O
in CN101721405A T IN O
preparation CN101721405A T NN O
of CN101721405A T IN O
drugs CN101721405A T NNS O
used CN101721405A T VBN O
for CN101721405A T IN O
curing CN101721405A T VBG O
or CN101721405A T CC O
preventing CN101721405A T VBG O
liver CN101721405A T JJ O
diseases CN101721405A T NNS O
. CN101721405A T . O

6-deoxy-6-thioether-amino EP2644624A1 T JJ O
acid EP2644624A1 T NN O
cyclodextrin EP2644624A1 T NN O
derivatives EP2644624A1 T NNS O
and EP2644624A1 T CC O
preparation EP2644624A1 T NN O
method EP2644624A1 T NN O
thereof EP2644624A1 T NN O
. EP2644624A1 T . O

Therapeutic US20120071483 T JJ O
approaches US20120071483 T NNS O
for US20120071483 T IN O
treating US20120071483 T VBG O
alzheimer US20120071483 T JJ O
disease US20120071483 T NN O
and US20120071483 T CC O
related US20120071483 T JJ O
disorders US20120071483 T NNS O
through US20120071483 T IN O
a US20120071483 T DT O
modulation US20120071483 T NN O
of US20120071483 T IN O
cell US20120071483 T NN O
stress US20120071483 T NN O
response US20120071483 T NN O
. US20120071483 T . O

Having US20060217349 T VBG O
antiinflammatory US20060217349 T NN O
, US20060217349 T , O
anti-pyretic US20060217349 T JJ O
and US20060217349 T CC O
anti-diarrheal US20060217349 T JJ O
properties US20060217349 T NNS O
. US20060217349 T . O

Famotidine CN101380313A T NNP O
high CN101380313A T JJ O
density CN101380313A T NN O
type CN101380313A T NN O
gastric CN101380313A T JJ O
retention CN101380313A T NN O
osmotic CN101380313A T JJ O
pump CN101380313A T NN O
controlled CN101380313A T VBD O
release CN101380313A T NN O
preparation CN101380313A T NN O
and CN101380313A T CC O
preparation CN101380313A T NN O
method CN101380313A T NN O
thereof CN101380313A T NN O
. CN101380313A T . O

Method US20080279786 T NNP O
for US20080279786 T IN O
Extending US20080279786 T NNP O
Lifespan US20080279786 T NNP O
Delaying US20080279786 T VBG O
the US20080279786 T DT O
Onset US20080279786 T NNP O
of US20080279786 T IN O
Age-Related US20080279786 T NNP O
Disease US20080279786 T NNP O
. US20080279786 T . O

A US20080279786 A DT O
method US20080279786 A NN O
and US20080279786 A CC O
composition US20080279786 A NN O
for US20080279786 A IN O
extending US20080279786 A VBG O
the US20080279786 A DT O
lifespan US20080279786 A NN O
of US20080279786 A IN O
an US20080279786 A DT O
individual US20080279786 A JJ O
and US20080279786 A CC O
delaying US20080279786 A VBG O
the US20080279786 A DT O
onset US20080279786 A NN O
of US20080279786 A IN O
age-related US20080279786 A JJ O
disease US20080279786 A NN O
is US20080279786 A VBZ O
provided US20080279786 A VBN O
. US20080279786 A . O

The US20080279786 A DT O
method US20080279786 A NN O
includes US20080279786 A VBZ O
the US20080279786 A DT O
administration US20080279786 A NN O
of US20080279786 A IN O
an US20080279786 A DT O
effective US20080279786 A JJ O
dose US20080279786 A NN O
of US20080279786 A IN O
oxaloacetate US20080279786 A NN O
, US20080279786 A , O
wherein US20080279786 A VBP O
the US20080279786 A DT O
oxaloacetate US20080279786 A NN O
acts US20080279786 A VBZ O
to US20080279786 A TO O
mimic US20080279786 A VB O
the US20080279786 A DT O
cellular US20080279786 A JJ O
conditions US20080279786 A NNS O
obtained US20080279786 A VBN O
under US20080279786 A IN O
caloric US20080279786 A JJ O
restriction US20080279786 A NN O
to US20080279786 A TO O
provide US20080279786 A VB O
similar US20080279786 A JJ O
benefits US20080279786 A NNS O
. US20080279786 A . O

The US20080279786 A DT O
invention US20080279786 A NN O
further US20080279786 A RB O
includes US20080279786 A VBZ O
methods US20080279786 A NNS O
and US20080279786 A CC O
compositions US20080279786 A NNS O
for US20080279786 A IN O
reducing US20080279786 A VBG O
the US20080279786 A DT O
incidence US20080279786 A NN O
or US20080279786 A CC O
treatment US20080279786 A NN O
of US20080279786 A IN O
cancer US20080279786 A NN O
. US20080279786 A . O

Compositions US20080279786 A NNS O
and US20080279786 A CC O
methods US20080279786 A NNS O
for US20080279786 A IN O
reducing US20080279786 A VBG O
body US20080279786 A NN O
fat US20080279786 A JJ O
by US20080279786 A IN O
administering US20080279786 A VBG O
an US20080279786 A DT O
effective US20080279786 A JJ O
amount US20080279786 A NN O
of US20080279786 A IN O
oxaloacetate US20080279786 A NN O
are US20080279786 A VBP O
likewise US20080279786 A RB O
provided US20080279786 A VBN O
. US20080279786 A . O

Compositions US20080279786 A NNS O
for US20080279786 A IN O
DNA US20080279786 A NNP O
repair US20080279786 A NN O
in US20080279786 A IN O
UV US20080279786 A NNP O
damaged US20080279786 A VBD O
cells US20080279786 A NNS O
is US20080279786 A VBZ O
provided US20080279786 A VBN O
are US20080279786 A VBP O
also US20080279786 A RB O
provided US20080279786 A VBN O
. US20080279786 A . O

Similarly US20080279786 A RB O
, US20080279786 A , O
a US20080279786 A DT O
method US20080279786 A NN O
for US20080279786 A IN O
treating US20080279786 A VBG O
a US20080279786 A DT O
hang-over US20080279786 A JJ O
comprising US20080279786 A NN O
administering US20080279786 A VBG O
an US20080279786 A DT O
effective US20080279786 A JJ O
amount US20080279786 A NN O
of US20080279786 A IN O
oxaloacetate US20080279786 A NN O
is US20080279786 A VBZ O
disclosed US20080279786 A VBN O
. US20080279786 A . O

Esomeprazole CN103509001A T NNP O
magnesium CN103509001A T NN O
trihydrate CN103509001A T NN O
and CN103509001A T CC O
preparation CN103509001A T NN O
method CN103509001A T NN O
thereof CN103509001A T NN O
. CN103509001A T . O

Therapeutic WO2007149382A3 T JJ O
compositions WO2007149382A3 T NNS O
and WO2007149382A3 T CC O
methods WO2007149382A3 T NNS O
useful WO2007149382A3 T JJ O
in WO2007149382A3 T IN O
treating WO2007149382A3 T VBG O
hepatitis WO2007149382A3 T NN O
. WO2007149382A3 T . O

Combination EP2437747A1 T NN O
preparations EP2437747A1 T NNS O
comprising EP2437747A1 T VBG O
exosomes EP2437747A1 T NNS O
and EP2437747A1 T CC O
corticosteroid EP2437747A1 T NN O
. EP2437747A1 T . O

The EP2437747A1 A DT O
invention EP2437747A1 A NN O
relates EP2437747A1 A VBZ O
to EP2437747A1 A TO O
pharmaceutical EP2437747A1 A JJ O
compositions EP2437747A1 A NNS O
for EP2437747A1 A IN O
combination EP2437747A1 A NN O
therapy EP2437747A1 A NN O
, EP2437747A1 A , O
comprising EP2437747A1 A VBG O
a EP2437747A1 A DT O
corticosteroid EP2437747A1 A NN O
and EP2437747A1 A CC O
exosomes EP2437747A1 A NNS O
. EP2437747A1 A . O

Said EP2437747A1 A NNP O
combination EP2437747A1 A NN O
therapy EP2437747A1 A NN O
allows EP2437747A1 A VBZ O
diseases EP2437747A1 A NNS O
such EP2437747A1 A JJ O
as EP2437747A1 A IN O
osteoarthritis EP2437747A1 A NN O
, EP2437747A1 A , O
rheumatoid EP2437747A1 A JJ O
arthritis EP2437747A1 A NN O
, EP2437747A1 A , O
and/or EP2437747A1 A RB O
degenerative EP2437747A1 A JJ O
diseases EP2437747A1 A NNS O
of EP2437747A1 A IN O
the EP2437747A1 A DT O
spine EP2437747A1 A NN O
to EP2437747A1 A TO O
be EP2437747A1 A VB O
treated EP2437747A1 A VBN O
. EP2437747A1 A . O

Liquid WO2012098562A3 T NNP O
oral WO2012098562A3 T JJ O
compositions WO2012098562A3 T NNS O
of WO2012098562A3 T IN O
lanthanum WO2012098562A3 T NN O
salts WO2012098562A3 T NNS O
. WO2012098562A3 T . O

Novel CN103405387A T NNP O
cefixime CN103405387A T NN O
dry CN103405387A T JJ O
suspension CN103405387A T NN O
and CN103405387A T CC O
preparation CN103405387A T NN O
method CN103405387A T NN O
thereof CN103405387A T NN O
. CN103405387A T . O

Compounds WO2010075636A1 T NNS O
and WO2010075636A1 T CC O
methods WO2010075636A1 T NNS O
for WO2010075636A1 T IN O
treatment WO2010075636A1 T NN O
of WO2010075636A1 T IN O
influenza WO2010075636A1 T NN O
. WO2010075636A1 T . O

Methylprednisolone CN103371979A T NNP O
sodium CN103371979A T NN O
succinate CN103371979A T NN O
freeze-dried CN103371979A T JJ O
powder CN103371979A T NN O
injection CN103371979A T NN O
. CN103371979A T . O

Coumarin CN103387582A T NNP O
natural CN103387582A T JJ O
product CN103387582A T NN O
, CN103387582A T , O
and CN103387582A T CC O
preparation CN103387582A T NN O
method CN103387582A T NN O
and CN103387582A T CC O
application CN103387582A T NN O
thereof CN103387582A T NN O
. CN103387582A T . O

The CN103387582A A DT O
invention CN103387582A A NN O
belongs CN103387582A A VBZ O
to CN103387582A A TO O
the CN103387582A A DT O
pharmaceutical CN103387582A A JJ O
field CN103387582A A NN O
, CN103387582A A , O
relates CN103387582A A VBZ O
to CN103387582A A TO O
an CN103387582A A DT O
application CN103387582A A NN O
of CN103387582A A IN O
a CN103387582A A DT O
furocoumarin CN103387582A A JJ O
compound CN103387582A A NN O
in CN103387582A A IN O
inhibiting CN103387582A A VBG O
a CN103387582A A DT O
resistant CN103387582A A JJ O
staphylococcus CN103387582A A NN O
aureus CN103387582A A NN O
, CN103387582A A , O
and CN103387582A A CC O
a CN103387582A A DT O
preparation CN103387582A A NN O
method CN103387582A A NN O
for CN103387582A A IN O
the CN103387582A A DT O
furocoumarin CN103387582A A NN O
compound CN103387582A A NN O
, CN103387582A A , O
and CN103387582A A CC O
particularly CN103387582A A RB O
relates CN103387582A A NNS O
to CN103387582A A TO O
an CN103387582A A DT O
application CN103387582A A NN O
of CN103387582A A IN O
the CN103387582A A DT O
furocoumarin CN103387582A A NN O
compound CN103387582A A NN O
in CN103387582A A IN O
preparing CN103387582A A VBG O
a CN103387582A A DT O
TetK CN103387582A A NNP I-UN
tetracycline-containing CN103387582A A JJ O
outer CN103387582A A NN O
pump CN103387582A A NN O
protein CN103387582A A NN O
and CN103387582A A CC O
a CN103387582A A DT O
methicillin-resistant CN103387582A A JJ O
staphylococcus CN103387582A A NN O
epidermidis CN103387582A A NN O
staphylococcus CN103387582A A NN O
aureus CN103387582A A JJ O
drug CN103387582A A NN O
. CN103387582A A . O

The CN103387582A A DT O
pharmacological CN103387582A A JJ O
activity CN103387582A A NN O
results CN103387582A A NNS O
of CN103387582A A IN O
the CN103387582A A DT O
compound CN103387582A A NN O
show CN103387582A A NN O
that CN103387582A A IN O
the CN103387582A A DT O
furocoumarin CN103387582A A NN O
compound CN103387582A A NN O
presents CN103387582A A NNS O
specific CN103387582A A JJ O
inhibition CN103387582A A NN O
activity CN103387582A A NN O
for CN103387582A A IN O
the CN103387582A A DT O
TetK CN103387582A A NNP I-UN
tetracycline-containing CN103387582A A JJ O
outer CN103387582A A NN O
pump CN103387582A A NN O
protein CN103387582A A NN O
drug-resistant CN103387582A A JJ O
staphylococcus CN103387582A A NN O
aureus CN103387582A A NN O
strain CN103387582A A NN O
XU212 CN103387582A A NNP O
and CN103387582A A CC O
mecA CN103387582A A JJ O
gene-containing CN103387582A A JJ O
methicillin-resistant CN103387582A A JJ O
staphylococcus CN103387582A A NN O
epidermidis CN103387582A A NN O
staphylococcus CN103387582A A NN O
aureus CN103387582A A NN O
strain CN103387582A A VBP O
EMRSA-16 CN103387582A A NNP O
; CN103387582A A : O
and CN103387582A A CC O
the CN103387582A A DT O
inhibition CN103387582A A NN O
activity CN103387582A A NN O
is CN103387582A A VBZ O
obviously CN103387582A A RB O
stronger CN103387582A A JJR O
than CN103387582A A IN O
that CN103387582A A DT O
of CN103387582A A IN O
contrast CN103387582A A NN O
drugs CN103387582A A NNS O
of CN103387582A A IN O
tetracycline CN103387582A A NN O
and CN103387582A A CC O
oxacillin CN103387582A A NN O
. CN103387582A A . O

Smooth CN203436580U T NNP O
slimming CN203436580U T VBG O
capsule CN203436580U T NN O
structure CN203436580U T NN O
capable CN203436580U T JJ O
of CN203436580U T IN O
preventing CN203436580U T VBG O
and CN203436580U T CC O
treating CN203436580U T VBG O
obesity CN203436580U T NN O
and CN203436580U T CC O
promoting CN203436580U T VBG O
micro-lipid CN203436580U T JJ O
metabolism CN203436580U T NN O
. CN203436580U T . O

Medicinal CN103751207A T JJ O
composition CN103751207A T NN O
for CN103751207A T IN O
treating CN103751207A T VBG O
Alzheimer CN103751207A T NNP O
's CN103751207A T POS O
disease CN103751207A T NN O
and CN103751207A T CC O
application CN103751207A T NN O
thereof CN103751207A T NN O
. CN103751207A T . O

Composition CN101978961A T NN O
for CN101978961A T IN O
treating CN101978961A T VBG O
gingivitis CN101978961A T NN O
or CN101978961A T CC O
peridentitis CN101978961A T NN O
and CN101978961A T CC O
application CN101978961A T NN O
thereof CN101978961A T NN O
. CN101978961A T . O

Burn CN103239600A T NNP O
and CN103239600A T CC O
scald CN103239600A T JJ O
plaster CN103239600A T NN O
and CN103239600A T CC O
preparation CN103239600A T NN O
method CN103239600A T NN O
thereof CN103239600A T NN O
. CN103239600A T . O

Compounds EP2268647A2 T NNS O
and EP2268647A2 T CC O
compositions EP2268647A2 T NNS O
for EP2268647A2 T IN O
the EP2268647A2 T DT O
detection EP2268647A2 T NN O
and EP2268647A2 T CC O
treatment EP2268647A2 T NN O
of EP2268647A2 T IN O
alzheimer EP2268647A2 T NN O
's EP2268647A2 T POS O
disease EP2268647A2 T NN O
and EP2268647A2 T CC O
related EP2268647A2 T JJ O
disorders EP2268647A2 T NNS O
. EP2268647A2 T . O

New CA2270952C T NNP O
use CA2270952C T NN O
for CA2270952C T IN O
1,3-propanediol CA2270952C T JJ O
derivatives CA2270952C T NNS O
. CA2270952C T . O

Tenofovir CN103224530A T NNP O
disoproxil CN103224530A T NN O
compounds CN103224530A T NNS O
, CN103224530A T , O
and CN103224530A T CC O
preparation CN103224530A T NN O
method CN103224530A T NN O
and CN103224530A T CC O
application CN103224530A T NN O
thereof CN103224530A T NN O
in CN103224530A T IN O
anti-virus CN103224530A T JJ O
aspects CN103224530A T NNS O
. CN103224530A T . O

Slow-releasing CN1579396A T JJ O
medicine CN1579396A T NN O
inplanted CN1579396A T VBN O
in CN1579396A T IN O
eye CN1579396A T NN O
and CN1579396A T CC O
use CN1579396A T NN O
thereof CN1579396A T NN O
. CN1579396A T . O

polysaccharide US7196073 T RB O
binding US7196073 T VBG O
to US7196073 T TO O
surface US7196073 T VB O
receptor US7196073 T NN O
on US7196073 T IN O
antigen US7196073 T NN O
presenting US7196073 T VBG O
cells US7196073 T NNS O
. US7196073 T . O

Process CN102988287A T NN O
for CN102988287A T IN O
preparing CN102988287A T VBG O
racanisodamine CN102988287A T NN O
hydrochloride CN102988287A T NN O
used CN102988287A T VBN O
for CN102988287A T IN O
injection CN102988287A T NN O
. CN102988287A T . O

ApoE EP2279743A2 T NNP I-UN
mimetic EP2279743A2 T JJ O
agents EP2279743A2 T NNS O
. EP2279743A2 T . O

Solid CN102008440A T JJ O
preparation CN102008440A T NN O
of CN102008440A T IN O
atorvastatin CN102008440A T JJ O
calcium CN102008440A T NN O
liposome CN102008440A T NN O
. CN102008440A T . O

Medicine CN101912584A T NNP O
for CN101912584A T IN O
treating CN101912584A T VBG O
melancholia CN101912584A T NN O
and CN101912584A T CC O
preparation CN101912584A T NN O
method CN101912584A T NN O
thereof CN101912584A T NN O
. CN101912584A T . O

Particles WO2014140203A1 T NNS O
comprising WO2014140203A1 T VBG O
luminescent WO2014140203A1 T JJ O
lanthanide WO2014140203A1 T NN O
complexes WO2014140203A1 T NNS O
. WO2014140203A1 T . O

Povidone-iodine WO2011085356A2 T NN O
and WO2011085356A2 T CC O
sucrose WO2011085356A2 T VB O
wound WO2011085356A2 T NN O
healing WO2011085356A2 T VBG O
dressing WO2011085356A2 T NN O
. WO2011085356A2 T . O

The WO2011085356A2 A DT O
present WO2011085356A2 A JJ O
invention WO2011085356A2 A NN O
relates WO2011085356A2 A VBZ O
to WO2011085356A2 A TO O
a WO2011085356A2 A DT O
composition WO2011085356A2 A NN O
and WO2011085356A2 A CC O
wound WO2011085356A2 A NN O
dressing WO2011085356A2 A NN O
for WO2011085356A2 A IN O
delivering WO2011085356A2 A VBG O
a WO2011085356A2 A DT O
composition WO2011085356A2 A NN O
comprising WO2011085356A2 A VBG O
povidone-iodine WO2011085356A2 A JJ O
and WO2011085356A2 A CC O
sucrose WO2011085356A2 A JJ O
mixture WO2011085356A2 A NN O
. WO2011085356A2 A . O

The WO2011085356A2 A DT O
composition WO2011085356A2 A NN O
is WO2011085356A2 A VBZ O
gelled WO2011085356A2 A VBN O
and WO2011085356A2 A CC O
, WO2011085356A2 A , O
in WO2011085356A2 A IN O
one WO2011085356A2 A CD O
embodiment WO2011085356A2 A NN O
, WO2011085356A2 A , O
is WO2011085356A2 A VBZ O
impregnated WO2011085356A2 A VBN O
on WO2011085356A2 A IN O
a WO2011085356A2 A DT O
gauze WO2011085356A2 A NN O
or WO2011085356A2 A CC O
other WO2011085356A2 A JJ O
like WO2011085356A2 A IN O
material WO2011085356A2 A NN O
for WO2011085356A2 A IN O
application WO2011085356A2 A NN O
to WO2011085356A2 A TO O
an WO2011085356A2 A DT O
exuding WO2011085356A2 A NN O
or WO2011085356A2 A CC O
non-exuding WO2011085356A2 A JJ O
wound WO2011085356A2 A NN O
. WO2011085356A2 A . O

Diamino-propanol-compounds EP1098642B1 T NNS O
for EP1098642B1 T IN O
treating EP1098642B1 T VBG O
ischemia EP1098642B1 T NN O
. EP1098642B1 T . O

Pharmaceutical WO2007042811A1 T JJ O
compositions WO2007042811A1 T NNS O
for WO2007042811A1 T IN O
the WO2007042811A1 T DT O
treatment WO2007042811A1 T NN O
of WO2007042811A1 T IN O
chronic WO2007042811A1 T JJ O
obstructive WO2007042811A1 T JJ O
pulmonary WO2007042811A1 T JJ O
disease WO2007042811A1 T NN O
. WO2007042811A1 T . O

Calcitriol CN103142534A T NNP O
controlled-release CN103142534A T JJ O
tablet CN103142534A T NN O
and CN103142534A T CC O
preparation CN103142534A T NN O
method CN103142534A T NN O
thereof CN103142534A T NN O
. CN103142534A T . O

Application CN103655596A T NN O
of CN103655596A T IN O
CpG-ODN CN103655596A T NNP O
7909 CN103655596A T CD O
sequence CN103655596A T NN O
to CN103655596A T TO O
preparation CN103655596A T NN O
of CN103655596A T IN O
drug CN103655596A T NN O
for CN103655596A T IN O
relieving CN103655596A T VBG O
tumor CN103655596A T NN O
cell CN103655596A T NN O
radiation CN103655596A T NN O
tolerance CN103655596A T NN O
. CN103655596A T . O

Selected US7230026 T VBN O
fused US7230026 T JJ O
pyrrolocarbazoles US7230026 T NNS O
. US7230026 T . O

Preparation CN101884612A T NNP O
method CN101884612A T NN O
of CN101884612A T IN O
large CN101884612A T JJ O
volume CN101884612A T NN O
ribavirin CN101884612A T NN O
injection CN101884612A T NN O
. CN101884612A T . O

Kappa US20060178426 T NNP I-UN
agonists US20060178426 T NNS O
, US20060178426 T , O
especialy US20060178426 T NN O
for US20060178426 T IN O
the US20060178426 T DT O
treatment US20060178426 T NN O
and/or US20060178426 T JJ O
prophylaxis US20060178426 T NN O
of US20060178426 T IN O
irritable US20060178426 T JJ O
bowel US20060178426 T NN O
syndrome US20060178426 T NN O
. US20060178426 T . O

Isoalpha US20080051466 T NNP O
acid US20080051466 T NN O
based US20080051466 T VBN O
protein US20080051466 T JJ O
kinase US20080051466 T JJ I-UN
modulation US20080051466 T NN O
cancer US20080051466 T NN O
treatment US20080051466 T NN O
. US20080051466 T . O

Compounds US20080051466 A NNS O
and US20080051466 A CC O
methods US20080051466 A NNS O
for US20080051466 A IN O
protein US20080051466 A JJ O
kinase US20080051466 A NN I-UN
modulation US20080051466 A NN O
for US20080051466 A IN O
cancer US20080051466 A NN O
treatment US20080051466 A NN O
are US20080051466 A VBP O
disclosed US20080051466 A VBN O
. US20080051466 A . O

( US7425580 T ( O
Diaryl-methyl US7425580 T NNP O
) US7425580 T ) O
-malononitriles US7425580 T NNS O
and US7425580 T CC O
their US7425580 T PRP$ O
use US7425580 T NN O
as US7425580 T IN O
estrogen US7425580 T NN I-UN
receptor US7425580 T NN I-UN
ligands US7425580 T VBZ O
. US7425580 T . O

Reducing US7169809 T VBG O
risk US7169809 T NN O
of US7169809 T IN O
thrombotic US7169809 T JJ O
cardiovascular US7169809 T JJ O
events US7169809 T NNS O
such US7169809 T JJ O
as US7169809 T IN O
stroke US7169809 T NN O
, US7169809 T , O
myocardial US7169809 T JJ O
ischemia US7169809 T NN O
, US7169809 T , O
myocardial US7169809 T JJ O
infarction US7169809 T NN O
, US7169809 T , O
angina US7169809 T JJ O
pectoris US7169809 T NN O
, US7169809 T , O
and US7169809 T CC O
transient US7169809 T JJ O
ischemic US7169809 T JJ O
attack US7169809 T NN O
; US7169809 T : O
side US7169809 T CC O
effect US7169809 T NN O
reduction US7169809 T NN O
. US7169809 T . O

The US7169809 A DT O
invention US7169809 A NN O
encompasses US7169809 A VBZ O
novel US7169809 A JJ O
compounds US7169809 A NNS O
of US7169809 A IN O
Formula US7169809 A NNP O
I US7169809 A PRP O
, US7169809 A , O
which US7169809 A WDT O
are US7169809 A VBP O
nitric US7169809 A JJ O
oxide-releasing US7169809 A JJ O
prodrugs US7169809 A NNS O
of US7169809 A IN O
diaryl-2- US7169809 A NN O
( US7169809 A ( O
5H US7169809 A CD O
) US7169809 A ) O
furanones US7169809 A NNS O
useful US7169809 A JJ O
in US7169809 A IN O
the US7169809 A DT O
treatment US7169809 A NN O
of US7169809 A IN O
cyclooxygenase-2 US7169809 A NN I-UN
mediated US7169809 A VBN O
diseases US7169809 A NNS O
. US7169809 A . O

The US7169809 A DT O
invention US7169809 A NN O
also US7169809 A RB O
encompasses US7169809 A VBZ O
certain US7169809 A JJ O
pharmaceutical US7169809 A JJ O
compositions US7169809 A NNS O
and US7169809 A CC O
methods US7169809 A NNS O
for US7169809 A IN O
treating US7169809 A VBG O
cyclooxygenase-2 US7169809 A JJ I-UN
mediated US7169809 A JJ O
diseases US7169809 A NNS O
comprising US7169809 A VBG O
the US7169809 A DT O
use US7169809 A NN O
of US7169809 A IN O
compounds US7169809 A NNS O
of US7169809 A IN O
Formula US7169809 A NNP O
I US7169809 A PRP O
. US7169809 A . O

The US7169809 A DT O
above US7169809 A JJ O
compounds US7169809 A NNS O
may US7169809 A MD O
be US7169809 A VB O
used US7169809 A VBN O
as US7169809 A IN O
a US7169809 A DT O
combination US7169809 A NN O
therapy US7169809 A NN O
with US7169809 A IN O
low-dose US7169809 A JJ O
aspirin US7169809 A NN O
to US7169809 A TO O
treat US7169809 A VB O
chronic US7169809 A JJ O
cyclooxygenase-2 US7169809 A NN I-UN
mediated US7169809 A VBN O
diseases US7169809 A NNS O
or US7169809 A CC O
conditions US7169809 A NNS O
while US7169809 A IN O
also US7169809 A RB O
reducing US7169809 A VBG O
the US7169809 A DT O
risk US7169809 A NN O
of US7169809 A IN O
thrombotic US7169809 A JJ O
cardiovascular US7169809 A JJ O
events US7169809 A NNS O
. US7169809 A . O

Efficient CN1706371B T JJ O
sword-like CN1706371B T JJ O
iris CN1706371B T NN O
seed CN1706371B T NN O
preparation CN1706371B T NN O
and CN1706371B T CC O
its CN1706371B T PRP$ O
preparation CN1706371B T NN O
process CN1706371B T NN O
. CN1706371B T . O

Vitamin CN103520102A T NNP O
D CN103520102A T NNP O
nano-emulsion CN103520102A T NN O
and CN103520102A T CC O
preparation CN103520102A T NN O
method CN103520102A T NN O
thereof CN103520102A T NN O
. CN103520102A T . O

The CN103520102A A DT O
invention CN103520102A A NN O
provides CN103520102A A VBZ O
a CN103520102A A DT O
vitamin CN103520102A A JJ O
D CN103520102A A NNP O
nano-emulsion CN103520102A A NN O
and CN103520102A A CC O
a CN103520102A A DT O
preparation CN103520102A A NN O
method CN103520102A A NN O
thereof CN103520102A A NN O
. CN103520102A A . O

The CN103520102A A DT O
vitamin CN103520102A A NN O
D CN103520102A A NNP O
nano-emulsion CN103520102A A NN O
comprises CN103520102A A NNS O
vitamin CN103520102A A VBP O
D CN103520102A A NNP O
and CN103520102A A CC O
tween-80 CN103520102A A NN O
in CN103520102A A IN O
a CN103520102A A DT O
mass CN103520102A A NN O
ratio CN103520102A A NN O
of CN103520102A A IN O
1 CN103520102A A CD O
: CN103520102A A : O
( CN103520102A A ( O
1-6 CN103520102A A JJ O
) CN103520102A A ) O
, CN103520102A A , O
and CN103520102A A CC O
water CN103520102A A NN O
of CN103520102A A IN O
which CN103520102A A WDT O
the CN103520102A A DT O
mass CN103520102A A NN O
is CN103520102A A VBZ O
0.8-4.5 CN103520102A A JJ O
times CN103520102A A NNS O
of CN103520102A A IN O
the CN103520102A A DT O
total CN103520102A A JJ O
mass CN103520102A A NN O
of CN103520102A A IN O
vitamin CN103520102A A NN O
D CN103520102A A NNP O
and CN103520102A A CC O
tween-80 CN103520102A A NN O
. CN103520102A A . O

The CN103520102A A DT O
method CN103520102A A NN O
comprises CN103520102A A VBZ O
the CN103520102A A DT O
following CN103520102A A JJ O
steps CN103520102A A NNS O
: CN103520102A A : O
adding CN103520102A A VBG O
vitamin CN103520102A A NN O
D CN103520102A A NNP O
and CN103520102A A CC O
tween-80 CN103520102A A NN O
into CN103520102A A IN O
a CN103520102A A DT O
container CN103520102A A NN O
, CN103520102A A , O
uniformly CN103520102A A RB O
mixing CN103520102A A VBG O
, CN103520102A A , O
and CN103520102A A CC O
adding CN103520102A A VBG O
water CN103520102A A NN O
to CN103520102A A TO O
obtain CN103520102A A VB O
a CN103520102A A DT O
mixed CN103520102A A JJ O
solution CN103520102A A NN O
; CN103520102A A : O
performing CN103520102A A VBG O
ultrasonic CN103520102A A JJ O
treatment CN103520102A A NN O
on CN103520102A A IN O
the CN103520102A A DT O
mixed CN103520102A A JJ O
solution CN103520102A A NN O
until CN103520102A A IN O
the CN103520102A A DT O
mixed CN103520102A A JJ O
solution CN103520102A A NN O
is CN103520102A A VBZ O
clear CN103520102A A JJ O
and CN103520102A A CC O
transparent CN103520102A A JJ O
to CN103520102A A TO O
obtain CN103520102A A VB O
the CN103520102A A DT O
vitamin CN103520102A A NN O
D CN103520102A A NNP O
nano-emulsion CN103520102A A NN O
. CN103520102A A . O

The CN103520102A A DT O
method CN103520102A A NN O
is CN103520102A A VBZ O
used CN103520102A A VBN O
for CN103520102A A IN O
preparing CN103520102A A VBG O
the CN103520102A A DT O
vitamin CN103520102A A NN O
D CN103520102A A NNP O
nano-emulsion CN103520102A A NN O
by CN103520102A A IN O
adopting CN103520102A A VBG O
an CN103520102A A DT O
ultrasonic CN103520102A A JJ O
emulsification CN103520102A A NN O
method CN103520102A A NN O
, CN103520102A A , O
is CN103520102A A VBZ O
simple CN103520102A A JJ O
in CN103520102A A IN O
production CN103520102A A NN O
process CN103520102A A NN O
, CN103520102A A , O
mild CN103520102A A NN O
in CN103520102A A IN O
condition CN103520102A A NN O
, CN103520102A A , O
short CN103520102A A JJ O
in CN103520102A A IN O
preparation CN103520102A A NN O
time CN103520102A A NN O
and CN103520102A A CC O
low CN103520102A A JJ O
in CN103520102A A IN O
equipment CN103520102A A NN O
requirement CN103520102A A NN O
. CN103520102A A . O

The CN103520102A A DT O
prepared CN103520102A A JJ O
vitamin CN103520102A A NN O
D CN103520102A A NNP O
nano-emulsion CN103520102A A NN O
is CN103520102A A VBZ O
of CN103520102A A IN O
an CN103520102A A DT O
oil-in-water CN103520102A A JJ O
mode CN103520102A A NN O
, CN103520102A A , O
is CN103520102A A VBZ O
clear CN103520102A A JJ O
and CN103520102A A CC O
transparent CN103520102A A JJ O
, CN103520102A A , O
good CN103520102A A JJ O
in CN103520102A A IN O
water CN103520102A A NN O
solution CN103520102A A NN O
and CN103520102A A CC O
good CN103520102A A JJ O
in CN103520102A A IN O
stability CN103520102A A NN O
, CN103520102A A , O
has CN103520102A A VBZ O
a CN103520102A A DT O
grain CN103520102A A NN O
distribution CN103520102A A NN O
range CN103520102A A NN O
of CN103520102A A IN O
28-66nm CN103520102A A JJ O
and CN103520102A A CC O
average CN103520102A A JJ O
grain CN103520102A A NN O
diameter CN103520102A A NN O
of CN103520102A A IN O
41nm CN103520102A A CD O
, CN103520102A A , O
and CN103520102A A CC O
accords CN103520102A A NNS O
with CN103520102A A IN O
the CN103520102A A DT O
basic CN103520102A A JJ O
characteristics CN103520102A A NNS O
of CN103520102A A IN O
a CN103520102A A DT O
nano-grade CN103520102A A JJ O
material CN103520102A A NN O
. CN103520102A A . O

Preparation CN101804032A T NNP O
method CN101804032A T NN O
of CN101804032A T IN O
5-fluorouracil-wrapped CN101804032A T JJ O
biodegradable CN101804032A T JJ O
polylactic CN101804032A T JJ O
acid/nano-hydroxyapatite CN101804032A T JJ O
compound CN101804032A T NN O
microspheres CN101804032A T NNS O
. CN101804032A T . O

Compositions US20100210605 T NNS O
Comprising US20100210605 T VBG O
5-Amino-2-Hydroxybenzoic US20100210605 T JJ O
Acid US20100210605 T NNP O
and US20100210605 T CC O
a US20100210605 T DT O
Reducing US20100210605 T NNP O
Sugar US20100210605 T NNP O
. US20100210605 T . O

Compositions US20100210605 A NNS O
comprising US20100210605 A VBG O
5-amino-2-hydroxybenzoic US20100210605 A JJ O
acid US20100210605 A NN O
( US20100210605 A ( O
5-amino US20100210605 A JJ O
salicylic US20100210605 A NN O
acid US20100210605 A NN O
, US20100210605 A , O
mesalamine US20100210605 A NN O
) US20100210605 A ) O
and US20100210605 A CC O
a US20100210605 A DT O
reducing US20100210605 A NN O
sugar US20100210605 A NN O
, US20100210605 A , O
e.g. US20100210605 A NN O
, US20100210605 A , O
lactose US20100210605 A RB O
, US20100210605 A , O
undergo US20100210605 A IN O
the US20100210605 A DT O
Maillard US20100210605 A NNP O
and US20100210605 A CC O
other US20100210605 A JJ O
chemical US20100210605 A JJ O
reactions US20100210605 A NNS O
and US20100210605 A CC O
produce US20100210605 A VB O
, US20100210605 A , O
in US20100210605 A IN O
the US20100210605 A DT O
case US20100210605 A NN O
of US20100210605 A IN O
lactose US20100210605 A NN O
, US20100210605 A , O
a US20100210605 A DT O
degradant US20100210605 A JJ O
5- US20100210605 A JJ O
[ US20100210605 A NN O
2-formyl-5- US20100210605 A JJ O
( US20100210605 A ( O
hydroxymethyl US20100210605 A NN O
) US20100210605 A ) O
-1H-pyrrol-1-yl US20100210605 A VBZ O
] US20100210605 A JJ O
-2-hydroxybenzoic US20100210605 A NNP O
acid US20100210605 A NN O
. US20100210605 A . O

Inventors US20100210605 A NNS O
have US20100210605 A VBP O
developed US20100210605 A VBN O
means US20100210605 A NNS O
to US20100210605 A TO O
contain US20100210605 A VB O
and/or US20100210605 A JJ O
reduce US20100210605 A VB O
the US20100210605 A DT O
formation US20100210605 A NN O
of US20100210605 A IN O
degradants US20100210605 A NNS O
of US20100210605 A IN O
5-amino-2-hydroxybenzoic US20100210605 A JJ O
acid US20100210605 A NN O
. US20100210605 A . O

Transdermal US20080008745 T JJ O
delivery US20080008745 T NN O
of US20080008745 T IN O
naltrexone US20080008745 T NN O
hydrochloride US20080008745 T NN O
, US20080008745 T , O
naltrexol US20080008745 T JJ O
hydrochloride US20080008745 T NN O
, US20080008745 T , O
and US20080008745 T CC O
bis US20080008745 T NN O
( US20080008745 T ( O
hydroxy-methyl US20080008745 T JJ O
) US20080008745 T ) O
propionyl-3-0 US20080008745 T JJ O
ester US20080008745 T NN O
naltrexone US20080008745 T NN O
using US20080008745 T VBG O
microneedles US20080008745 T NNS O
. US20080008745 T . O

New CN101596245A T NNP O
wart CN101596245A T NN O
eliminating CN101596245A T VBG O
medicine CN101596245A T NN O
and CN101596245A T CC O
preparation CN101596245A T NN O
method CN101596245A T NN O
thereof CN101596245A T NN O
. CN101596245A T . O

The CN101596245A A DT O
invention CN101596245A A NN O
discloses CN101596245A A VBZ O
a CN101596245A A DT O
new CN101596245A A JJ O
wart CN101596245A A NN O
eliminating CN101596245A A VBG O
medicine CN101596245A A NN O
and CN101596245A A CC O
preparation CN101596245A A NN O
method CN101596245A A NN O
thereof CN101596245A A NN O
. CN101596245A A . O

The CN101596245A A DT O
raw CN101596245A A JJ O
materials CN101596245A A NNS O
thereof CN101596245A A EX O
are CN101596245A A VBP O
khosam CN101596245A A NNS O
, CN101596245A A , O
smoked CN101596245A A VBD O
plum CN101596245A A NN O
and CN101596245A A CC O
white CN101596245A A JJ O
vinegar CN101596245A A NN O
. CN101596245A A . O

The CN101596245A A DT O
preparation CN101596245A A NN O
method CN101596245A A NN O
thereof CN101596245A A NN O
includes CN101596245A A VBZ O
that CN101596245A A IN O
the CN101596245A A DT O
raw CN101596245A A JJ O
materials CN101596245A A NNS O
are CN101596245A A VBP O
prepared CN101596245A A JJ O
into CN101596245A A IN O
ointment CN101596245A A JJ O
by CN101596245A A IN O
weight CN101596245A A NN O
parts CN101596245A A NNS O
. CN101596245A A . O

For US7109338 T IN O
use US7109338 T NN O
in US7109338 T IN O
the US7109338 T DT O
prophylaxis US7109338 T NN O
and US7109338 T CC O
the US7109338 T DT O
treatment US7109338 T NN O
of US7109338 T IN O
Picornavirus US7109338 T NNP O
and US7109338 T CC O
human US7109338 T JJ O
rotavirus US7109338 T NN O
infections.. US7109338 T NN O

Treatment US8076319 T NN O
of US8076319 T IN O
conditions US8076319 T NNS O
relating US8076319 T VBG O
to US8076319 T TO O
hormone US8076319 T VB O
deficiencies US8076319 T NNS O
by US8076319 T IN O
administration US8076319 T NN O
of US8076319 T IN O
progestins US8076319 T NNS O
. US8076319 T . O

Preparation CN101921238A T NN O
of CN101921238A T IN O
substituted CN101921238A T JJ O
nitrogen-containing CN101921238A T JJ O
benzoheterocycle CN101921238A T NN O
derivatives CN101921238A T NNS O
and CN101921238A T CC O
pharmacological CN101921238A T JJ O
application CN101921238A T NN O
thereof CN101921238A T NN O
. CN101921238A T . O

Preparation EP2034991B1 T NN O
for EP2034991B1 T IN O
preventing EP2034991B1 T VBG O
ageing EP2034991B1 T VBG O
symptoms EP2034991B1 T NNS O
containing EP2034991B1 T VBG O
phytoestrogens EP2034991B1 T NNS O
and EP2034991B1 T CC O
melatonin EP2034991B1 T NN O
. EP2034991B1 T . O

Pyrimidine WO2013164337A9 T NNP O
derivatives WO2013164337A9 T NNS O
for WO2013164337A9 T IN O
the WO2013164337A9 T DT O
treatment WO2013164337A9 T NN O
of WO2013164337A9 T IN O
bacterial WO2013164337A9 T JJ O
diseases WO2013164337A9 T NNS O
. WO2013164337A9 T . O

2-imin0is0thiaz0le WO2008130953A2 T JJ O
derivatives WO2008130953A2 T NNS O
as WO2008130953A2 T IN O
cannabinoid WO2008130953A2 T JJ I-UN
receptor WO2008130953A2 T NN I-UN
ligands WO2008130953A2 T NNS O
. WO2008130953A2 T . O

Flavone CN103087024A T CD O
alkylamine CN103087024A T JJ O
compounds CN103087024A T NNS O
as CN103087024A T RB O
well CN103087024A T RB O
as CN103087024A T IN O
preparation CN103087024A T NN O
method CN103087024A T NN O
and CN103087024A T CC O
application CN103087024A T NN O
thereof CN103087024A T NN O
. CN103087024A T . O

Application CN1559419A T NN O
of CN1559419A T IN O
saponin CN1559419A T NN O
of CN1559419A T IN O
Bolbostemma CN1559419A T NNP O
paniculatum CN1559419A T NN O
Franquet CN1559419A T NNP O
for CN1559419A T IN O
preparing CN1559419A T VBG O
medicine CN1559419A T NN O
for CN1559419A T IN O
treating CN1559419A T VBG O
malignant CN1559419A T JJ O
tumour CN1559419A T NN O
. CN1559419A T . O

An CN1559419A A DT O
application CN1559419A A NN O
of CN1559419A A IN O
bolbostemma CN1559419A A NN O
saponin CN1559419A A NN O
C CN1559419A A NNP O
in CN1559419A A IN O
preparing CN1559419A A VBG O
the CN1559419A A DT O
medicines CN1559419A A NNS O
for CN1559419A A IN O
treating CN1559419A A VBG O
cancers CN1559419A A NNS O
is CN1559419A A VBZ O
disclosed CN1559419A A VBN O
. CN1559419A A . O

Its CN1559419A A PRP$ O
advantages CN1559419A A NNS O
are CN1559419A A VBP O
broad CN1559419A A JJ O
spectrum CN1559419A A NN O
, CN1559419A A , O
and CN1559419A A CC O
high CN1559419A A JJ O
anticancer CN1559419A A NN O
activity CN1559419A A NN O
. CN1559419A A . O

Immunotherapy CA2243235C T NNP O
using CA2243235C T VBG O
cytotoxic CA2243235C T JJ O
t CA2243235C T NN O
lymphocytes CA2243235C T NNS O
( CA2243235C T ( O
ctl CA2243235C T NN O
) CA2243235C T ) O
. CA2243235C T . O

Antipruritic US20090170888 T JJ O
Agent US20090170888 T NNP O
for US20090170888 T IN O
Pruritus US20090170888 T NNP O
Caused US20090170888 T VBN O
by US20090170888 T IN O
Multiple US20090170888 T JJ O
Sclerosis US20090170888 T NNP O
. US20090170888 T . O

The US20090170888 A DT O
antipruritic US20090170888 A JJ O
comprises US20090170888 A NNS O
as US20090170888 A IN O
an US20090170888 A DT O
effective US20090170888 A JJ O
ingredient US20090170888 A NN O
an US20090170888 A DT O
κ US20090170888 A JJ I-UN
opioid US20090170888 A NN I-UN
receptor US20090170888 A NN I-UN
agonist US20090170888 A NN O
compound US20090170888 A NN O
having US20090170888 A VBG O
a US20090170888 A DT O
4,5-epoxymorphinan US20090170888 A JJ O
skeleton US20090170888 A NN O
and US20090170888 A CC O
having US20090170888 A VBG O
a US20090170888 A DT O
specific US20090170888 A JJ O
chemical US20090170888 A NN O
structure US20090170888 A NN O
, US20090170888 A , O
such US20090170888 A JJ O
as US20090170888 A IN O
Compound US20090170888 A NNP O
1 US20090170888 A CD O
having US20090170888 A VBG O
the US20090170888 A DT O
following US20090170888 A JJ O
structure US20090170888 A NN O
: US20090170888 A : O

Chimeric US20070259826 T NNP O
( US20070259826 T ( O
Double US20070259826 T NNP O
) US20070259826 T ) O
Decoy US20070259826 T NNP O
. US20070259826 T . O

Application CN103432111A T NN O
of CN103432111A T IN O
compound CN103432111A T NN O
to CN103432111A T TO O
preparation CN103432111A T NN O
of CN103432111A T IN O
drug CN103432111A T NN O
for CN103432111A T IN O
treating CN103432111A T VBG O
rectal CN103432111A T JJ O
cancer CN103432111A T NN O
. CN103432111A T . O

Bismuth-thiols WO2010091124A2 T NNP O
as WO2010091124A2 T IN O
antiseptics WO2010091124A2 T NNS O
for WO2010091124A2 T IN O
epithelial WO2010091124A2 T JJ O
tissues WO2010091124A2 T NNS O
, WO2010091124A2 T , O
acute WO2010091124A2 T NN O
and WO2010091124A2 T CC O
chronic WO2010091124A2 T JJ O
wounds WO2010091124A2 T NNS O
, WO2010091124A2 T , O
bacterial WO2010091124A2 T JJ O
biofilms WO2010091124A2 T NN O
and WO2010091124A2 T CC O
other WO2010091124A2 T JJ O
indications WO2010091124A2 T NNS O
. WO2010091124A2 T . O

Physiologically US7501431 T RB O
active US7501431 T JJ O
substances US7501431 T NNS O
PF1270A US7501431 T NNP O
, US7501431 T , O
B US7501431 T NNP O
and US7501431 T CC O
C US7501431 T NNP O
substances US7501431 T NNS O
. US7501431 T . O

Ppar-gamma WO2006044961A1 T JJ I-UN
modulatores WO2006044961A1 T NNS O
. WO2006044961A1 T . O

The WO2006044961A1 A DT O
present WO2006044961A1 A JJ O
invention WO2006044961A1 A NN O
relates WO2006044961A1 A VBZ O
to WO2006044961A1 A TO O
modulators WO2006044961A1 A NNS O
of WO2006044961A1 A IN O
PPAR-gamma WO2006044961A1 A NNP I-UN
of WO2006044961A1 A IN O
formula WO2006044961A1 A NN O
( WO2006044961A1 A ( O
I WO2006044961A1 A PRP O
) WO2006044961A1 A ) O
, WO2006044961A1 A , O
and WO2006044961A1 A CC O
to WO2006044961A1 A TO O
processes WO2006044961A1 A NNS O
for WO2006044961A1 A IN O
the WO2006044961A1 A DT O
preparation WO2006044961A1 A NN O
and WO2006044961A1 A CC O
use WO2006044961A1 A NN O
of WO2006044961A1 A IN O
the WO2006044961A1 A DT O
same WO2006044961A1 A JJ O
. WO2006044961A1 A . O

Such WO2006044961A1 A JJ O
PPAR-gamma WO2006044961A1 A JJ I-UN
modulators WO2006044961A1 A NNS O
are WO2006044961A1 A VBP O
useful WO2006044961A1 A JJ O
in WO2006044961A1 A IN O
the WO2006044961A1 A DT O
treatment WO2006044961A1 A NN O
of WO2006044961A1 A IN O
metabolic WO2006044961A1 A JJ O
diseases WO2006044961A1 A NNS O
and WO2006044961A1 A CC O
disorders WO2006044961A1 A NNS O
. WO2006044961A1 A . O

Fatty WO2008042892A3 T NNP I-UN
acid WO2008042892A3 T JJ I-UN
amide WO2008042892A3 T RB I-UN
hydrolase WO2008042892A3 T NN I-UN
inhibitors WO2008042892A3 T NNS O
for WO2008042892A3 T IN O
energy WO2008042892A3 T NN O
metabolism WO2008042892A3 T NN O
disorders WO2008042892A3 T NNS O
. WO2008042892A3 T . O

Disclosed WO2008042892A3 A VBN O
herein WO2008042892A3 A NNS O
are WO2008042892A3 A VBP O
methods WO2008042892A3 A NNS O
for WO2008042892A3 A IN O
treating WO2008042892A3 A VBG O
energy WO2008042892A3 A NN O
metabolism WO2008042892A3 A NN O
disorders WO2008042892A3 A NNS O
by WO2008042892A3 A IN O
administering WO2008042892A3 A VBG O
a WO2008042892A3 A DT O
composition WO2008042892A3 A NN O
containing WO2008042892A3 A VBG O
a WO2008042892A3 A DT O
therapeutically WO2008042892A3 A RB O
effective WO2008042892A3 A JJ O
amount WO2008042892A3 A NN O
of WO2008042892A3 A IN O
a WO2008042892A3 A DT O
fatty WO2008042892A3 A JJ I-UN
acid WO2008042892A3 A NN I-UN
amide WO2008042892A3 A IN I-UN
hydrolase WO2008042892A3 A NN I-UN
inhibitor WO2008042892A3 A NN O
. WO2008042892A3 A . O

Methods US20100113610 T NNS O
for US20100113610 T IN O
controlling US20100113610 T VBG O
inflammatory US20100113610 T NN O
and US20100113610 T CC O
immunological US20100113610 T JJ O
diseases US20100113610 T NNS O
. US20100113610 T . O

Additional US20100113610 A JJ O
methods US20100113610 A NNS O
are US20100113610 A VBP O
also US20100113610 A RB O
provided US20100113610 A VBN O
for US20100113610 A IN O
boosting US20100113610 A VBG O
the US20100113610 A DT O
immune US20100113610 A JJ O
system US20100113610 A NN O
of US20100113610 A IN O
a US20100113610 A DT O
mammal US20100113610 A JJ O
by US20100113610 A IN O
inhibiting US20100113610 A VBG O
the US20100113610 A DT O
generation US20100113610 A NN O
of US20100113610 A IN O
immunosuppressive US20100113610 A JJ O
T-cells US20100113610 A NNS O
by US20100113610 A IN O
administering US20100113610 A VBG O
a US20100113610 A DT O
therapeutically US20100113610 A RB O
effective US20100113610 A JJ O
dose US20100113610 A NN O
of US20100113610 A IN O
a US20100113610 A DT O
retinoid US20100113610 A JJ I-UN
receptor US20100113610 A NN I-UN
antagonist US20100113610 A NN O
to US20100113610 A TO O
the US20100113610 A DT O
mammal US20100113610 A NN O
. US20100113610 A . O

Advanced US20110263920 T NNP O
methods US20110263920 T NNS O
and US20110263920 T CC O
systems US20110263920 T NNS O
for US20110263920 T IN O
treating US20110263920 T VBG O
cell US20110263920 T NN O
proliferation US20110263920 T NN O
disorders US20110263920 T NNS O
. US20110263920 T . O

Medicament CN101869634B T NN O
for CN101869634B T IN O
treating CN101869634B T VBG O
acute CN101869634B T JJ O
appendicitis CN101869634B T NN O
. CN101869634B T . O

The CN101869634B A DT O
invention CN101869634B A NN O
relates CN101869634B A VBZ O
to CN101869634B A TO O
a CN101869634B A DT O
medicament CN101869634B A NN O
for CN101869634B A IN O
treating CN101869634B A VBG O
acute CN101869634B A JJ O
appendicitis CN101869634B A NN O
, CN101869634B A , O
which CN101869634B A WDT O
consists CN101869634B A VBZ O
of CN101869634B A IN O
rhubarb CN101869634B A NN O
, CN101869634B A , O
honeysuckle CN101869634B A NN O
, CN101869634B A , O
mirabilite CN101869634B A NN O
, CN101869634B A , O
common CN101869634B A JJ O
selfheal CN101869634B A NN O
fruit-spike CN101869634B A JJ O
, CN101869634B A , O
bunge CN101869634B A NN O
corydalis CN101869634B A NN O
herb CN101869634B A NN O
, CN101869634B A , O
european CN101869634B A JJ O
verbena CN101869634B A NN O
and CN101869634B A CC O
honey CN101869634B A NN O
. CN101869634B A . O

A CN101869634B A DT O
method CN101869634B A NN O
for CN101869634B A IN O
preparing CN101869634B A VBG O
the CN101869634B A DT O
medicament CN101869634B A NN O
comprises CN101869634B A VBZ O
the CN101869634B A DT O
steps CN101869634B A NNS O
of CN101869634B A IN O
drying CN101869634B A VBG O
and CN101869634B A CC O
pulverizing CN101869634B A VBG O
raw CN101869634B A JJ O
medicaments CN101869634B A NNS O
and CN101869634B A CC O
sieving CN101869634B A VBG O
the CN101869634B A DT O
powder CN101869634B A NN O
with CN101869634B A IN O
a CN101869634B A DT O
100-mesh CN101869634B A JJ O
screen CN101869634B A NN O
; CN101869634B A : O
blending CN101869634B A VBG O
the CN101869634B A DT O
powder CN101869634B A NN O
by CN101869634B A IN O
using CN101869634B A VBG O
the CN101869634B A DT O
honey CN101869634B A NN O
to CN101869634B A TO O
prepare CN101869634B A VB O
ointment CN101869634B A NN O
; CN101869634B A : O
and CN101869634B A CC O
bottling CN101869634B A VBG O
and CN101869634B A CC O
sealing CN101869634B A VBG O
. CN101869634B A . O

The CN101869634B A DT O
medicament CN101869634B A NN O
is CN101869634B A VBZ O
used CN101869634B A VBN O
for CN101869634B A IN O
treating CN101869634B A VBG O
the CN101869634B A DT O
acute CN101869634B A NN O
appendicitis CN101869634B A NN O
, CN101869634B A , O
and CN101869634B A CC O
has CN101869634B A VBZ O
the CN101869634B A DT O
advantages CN101869634B A NNS O
of CN101869634B A IN O
simple CN101869634B A JJ O
use CN101869634B A NN O
( CN101869634B A ( O
direct CN101869634B A JJ O
external CN101869634B A JJ O
application CN101869634B A NN O
) CN101869634B A ) O
and CN101869634B A CC O
100 CN101869634B A CD O
percent CN101869634B A NN O
of CN101869634B A IN O
cure CN101869634B A NN O
rate CN101869634B A NN O
. CN101869634B A . O

Application CN101524362A T NN O
of CN101524362A T IN O
nucleic CN101524362A T JJ O
acid CN101524362A T NN O
with CN101524362A T IN O
CpG CN101524362A T NNP O
motif CN101524362A T NN O
for CN101524362A T IN O
preparing CN101524362A T VBG O
anti-fibrotic CN101524362A T JJ O
drug CN101524362A T NN O
. CN101524362A T . O

Reduced WO2012176842A1 T VBN O
coenzyme WO2012176842A1 T JJ O
q10 WO2012176842A1 T NN O
crystal WO2012176842A1 T NN O
having WO2012176842A1 T VBG O
excellent WO2012176842A1 T JJ O
stability WO2012176842A1 T NN O
. WO2012176842A1 T . O

Imines US6995155 T NNS O
such US6995155 T JJ O
as US6995155 T IN O
4- US6995155 T JJ O
( US6995155 T ( O
3- US6995155 T JJ O
( US6995155 T ( O
( US6995155 T ( O
3- US6995155 T CD O
( US6995155 T ( O
2,4-dichlorophenyl US6995155 T CD O
) US6995155 T ) O
propanoyl US6995155 T NN O
) US6995155 T ) O
amino US6995155 T NN O
) US6995155 T ) O
-1- US6995155 T NN O
( US6995155 T ( O
3- US6995155 T JJ O
( US6995155 T ( O
morpholin-4-yl US6995155 T JJ O
) US6995155 T ) O
propyl US6995155 T NN O
) US6995155 T ) O
-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-5-yl US6995155 T NN O
) US6995155 T ) O
benzamide US6995155 T NN O
, US6995155 T , O
administered US6995155 T VBN O
for US6995155 T IN O
prophylaxis US6995155 T NN O
of US6995155 T IN O
Alzheimer US6995155 T NNP O
's US6995155 T POS O
disease US6995155 T NN O
. US6995155 T . O

The US6995155 A DT O
compounds US6995155 A NNS O
inhibit US6995155 A VBP O
the US6995155 A DT O
action US6995155 A NN O
of US6995155 A IN O
gamma US6995155 A NN I-UN
secretase US6995155 A NN I-UN
, US6995155 A , O
and US6995155 A CC O
hence US6995155 A RB O
find US6995155 A VB O
use US6995155 A NN O
in US6995155 A IN O
the US6995155 A DT O
treatment US6995155 A NN O
and US6995155 A CC O
prevention US6995155 A NN O
of US6995155 A IN O
Alzheimer US6995155 A NNP O
's US6995155 A POS O
disease US6995155 A NN O
. US6995155 A . O

Metformin CN102357088A T NNP O
hydrochloride CN102357088A T JJ O
enteric-coated CN102357088A T JJ O
tablet CN102357088A T NN O
. CN102357088A T . O

Imidazolidine EP1077994B1 T NNP O
derivatives EP1077994B1 T NNS O
, EP1077994B1 T , O
the EP1077994B1 T DT O
production EP1077994B1 T NN O
thereof EP1077994B1 T NN O
, EP1077994B1 T , O
their EP1077994B1 T PRP$ O
use EP1077994B1 T NN O
and EP1077994B1 T CC O
pharmaceutical EP1077994B1 T JJ O
preparations EP1077994B1 T NNS O
containing EP1077994B1 T VBG O
the EP1077994B1 T DT O
same EP1077994B1 T JJ O
. EP1077994B1 T . O

The EP1077994B1 A DT O
compounds EP1077994B1 A NNS O
of EP1077994B1 A IN O
formula EP1077994B1 A NN O
( EP1077994B1 A ( O
I EP1077994B1 A PRP O
) EP1077994B1 A ) O
are EP1077994B1 A VBP O
inhibitors EP1077994B1 A NNS O
of EP1077994B1 A IN O
adhesion EP1077994B1 A NN O
and EP1077994B1 A CC O
migration EP1077994B1 A NN O
of EP1077994B1 A IN O
leukocytes EP1077994B1 A NNS O
and/or EP1077994B1 A JJ O
antagonists EP1077994B1 A NNS O
of EP1077994B1 A IN O
the EP1077994B1 A DT O
adhesion EP1077994B1 A NN O
receptor EP1077994B1 A NN O
VLA-4 EP1077994B1 A NNP I-UN
which EP1077994B1 A WDT O
belong EP1077994B1 A VBP O
to EP1077994B1 A TO O
the EP1077994B1 A DT O
group EP1077994B1 A NN O
of EP1077994B1 A IN O
integrins EP1077994B1 A NNS O
. EP1077994B1 A . O

Said EP1077994B1 A NNP O
interactions EP1077994B1 A NNS O
are EP1077994B1 A VBP O
based EP1077994B1 A VBN O
on EP1077994B1 A IN O
interactions EP1077994B1 A NNS O
of EP1077994B1 A IN O
VLA-4 EP1077994B1 A NNP I-UN
receptors EP1077994B1 A NNS O
with EP1077994B1 A IN O
the EP1077994B1 A DT O
ligands EP1077994B1 A NNS O
thereof EP1077994B1 A NN O
. EP1077994B1 A . O

Gel EP2210583A1 T NNP O
sheet EP2210583A1 T NN O
and EP2210583A1 T CC O
cosmetic EP2210583A1 T JJ O
preparation EP2210583A1 T NN O
in EP2210583A1 T IN O
sheet EP2210583A1 T NN O
form EP2210583A1 T NN O
using EP2210583A1 T VBG O
the EP2210583A1 T DT O
same EP2210583A1 T JJ O
. EP2210583A1 T . O

Crosslinking CN101112363A T VBG O
wrapped CN101112363A T VBD O
core CN101112363A T NN O
slice CN101112363A T NN O
in CN101112363A T IN O
vivo CN101112363A T NN O
for CN101112363A T IN O
. CN101112363A T . O

Zap-70 US20100331391 T NNP I-UN
as US20100331391 T IN O
predictor US20100331391 T NN O
and US20100331391 T CC O
modulator US20100331391 T NN O
of US20100331391 T IN O
effector US20100331391 T NN O
function US20100331391 T NN O
of US20100331391 T IN O
t US20100331391 T NN O
cells US20100331391 T NNS O
. US20100331391 T . O

In US20100331391 A IN O
this US20100331391 A DT O
application US20100331391 A NN O
is US20100331391 A VBZ O
described US20100331391 A VBN O
a US20100331391 A DT O
novel US20100331391 A NN O
, US20100331391 A , O
multiparameter US20100331391 A JJR O
analysis US20100331391 A NN O
of US20100331391 A IN O
TCR-coupled US20100331391 A JJ O
signaling US20100331391 A NN O
and US20100331391 A CC O
function US20100331391 A NN O
in US20100331391 A IN O
resting US20100331391 A VBG O
and US20100331391 A CC O
activated US20100331391 A VBN O
naive US20100331391 A JJ O
and US20100331391 A CC O
memory US20100331391 A NN O
CD4 US20100331391 A NNP I-UN
T US20100331391 A NNP O
cells US20100331391 A NNS O
, US20100331391 A , O
revealing US20100331391 A VBG O
a US20100331391 A DT O
biochemical US20100331391 A JJ O
basis US20100331391 A NN O
for US20100331391 A IN O
immunological US20100331391 A JJ O
recall US20100331391 A NN O
. US20100331391 A . O

Results US20100331391 A NNS O
reveal US20100331391 A VBP O
a US20100331391 A DT O
novel US20100331391 A JJ O
biochemical US20100331391 A JJ O
signature US20100331391 A NN O
imparted US20100331391 A VBN O
to US20100331391 A TO O
memory US20100331391 A VB O
CD4 US20100331391 A NNP I-UN
T US20100331391 A NNP O
cells US20100331391 A NNS O
enabling US20100331391 A VBG O
efficacious US20100331391 A JJ O
responses US20100331391 A NNS O
through US20100331391 A IN O
increased US20100331391 A VBN O
ZAP-70 US20100331391 A NNP I-UN
expression US20100331391 A NN O
and US20100331391 A CC O
reduced US20100331391 A JJ O
accumulation US20100331391 A NN O
of US20100331391 A IN O
downstream US20100331391 A NN O
signaling US20100331391 A VBG O
events US20100331391 A NNS O
. US20100331391 A . O

Orally WO2013051680A1 T RB O
administered WO2013051680A1 T VBN O
adsorbent WO2013051680A1 T NN O
. WO2013051680A1 T . O

The WO2013051680A1 A DT O
purpose WO2013051680A1 A NN O
of WO2013051680A1 A IN O
the WO2013051680A1 A DT O
present WO2013051680A1 A JJ O
invention WO2013051680A1 A NN O
is WO2013051680A1 A VBZ O
to WO2013051680A1 A TO O
provide WO2013051680A1 A VB O
an WO2013051680A1 A DT O
orally WO2013051680A1 A RB O
administered WO2013051680A1 A VBN O
adsorbent WO2013051680A1 A NN O
comprising WO2013051680A1 A VBG O
activated WO2013051680A1 A VBN O
carbon WO2013051680A1 A NN O
fiber WO2013051680A1 A NN O
having WO2013051680A1 A VBG O
high WO2013051680A1 A JJ O
adsorption WO2013051680A1 A NN O
performance WO2013051680A1 A NN O
or WO2013051680A1 A CC O
removal WO2013051680A1 A JJ O
performance WO2013051680A1 A NN O
, WO2013051680A1 A , O
whereby WO2013051680A1 A WRB O
a WO2013051680A1 A DT O
toxic WO2013051680A1 A NN O
substance WO2013051680A1 A NN O
inside WO2013051680A1 A IN O
the WO2013051680A1 A DT O
body WO2013051680A1 A NN O
can WO2013051680A1 A MD O
be WO2013051680A1 A VB O
adsorbed WO2013051680A1 A VBN O
or WO2013051680A1 A CC O
removed WO2013051680A1 A VBN O
rapidly WO2013051680A1 A RB O
and WO2013051680A1 A CC O
in WO2013051680A1 A IN O
large WO2013051680A1 A JJ O
quantity WO2013051680A1 A NN O
. WO2013051680A1 A . O

The WO2013051680A1 A DT O
present WO2013051680A1 A JJ O
invention WO2013051680A1 A NN O
is WO2013051680A1 A VBZ O
an WO2013051680A1 A DT O
orally WO2013051680A1 A RB O
administered WO2013051680A1 A VBN O
adsorbent WO2013051680A1 A NN O
comprising WO2013051680A1 A VBG O
activated WO2013051680A1 A VBN O
carbon WO2013051680A1 A NN O
fiber WO2013051680A1 A NN O
, WO2013051680A1 A , O
wherein WO2013051680A1 A VBP O
the WO2013051680A1 A DT O
orally WO2013051680A1 A RB O
administered WO2013051680A1 A VBN O
adsorbent WO2013051680A1 A NN O
is WO2013051680A1 A VBZ O
a WO2013051680A1 A DT O
drug WO2013051680A1 A NN O
for WO2013051680A1 A IN O
treating WO2013051680A1 A VBG O
or WO2013051680A1 A CC O
preventing WO2013051680A1 A VBG O
kidney WO2013051680A1 A NN O
disease WO2013051680A1 A NN O
, WO2013051680A1 A , O
or WO2013051680A1 A CC O
a WO2013051680A1 A DT O
drug WO2013051680A1 A NN O
for WO2013051680A1 A IN O
treating WO2013051680A1 A VBG O
or WO2013051680A1 A CC O
preventing WO2013051680A1 A VBG O
dialysis WO2013051680A1 A NN O
complications WO2013051680A1 A NNS O
. WO2013051680A1 A . O

Cyclodextrin CN101810611A T NNP O
inclusion CN101810611A T NN O
compound CN101810611A T NN O
of CN101810611A T IN O
prasugrel CN101810611A T NN O
and CN101810611A T CC O
acid CN101810611A T JJ O
addition CN101810611A T NN O
salt CN101810611A T NN O
thereof CN101810611A T NN O
and CN101810611A T CC O
preparation CN101810611A T NN O
method CN101810611A T NN O
thereof CN101810611A T NN O
. CN101810611A T . O

water US20080181852 T NN O
soluble US20080181852 T JJ O
polyglutamnylglutamine US20080181852 T NN O
conjugated US20080181852 T VBN O
to US20080181852 T TO O
drugs US20080181852 T NNS O
, US20080181852 T , O
polydentate US20080181852 T NN O
ligands US20080181852 T NNS O
, US20080181852 T , O
targeting US20080181852 T VBG O
, US20080181852 T , O
optical US20080181852 T JJ O
imaging US20080181852 T NN O
, US20080181852 T , O
magnetic US20080181852 T JJ O
resonance US20080181852 T NN O
imaging US20080181852 T NN O
or US20080181852 T CC O
stabilizing US20080181852 T VBG O
agents US20080181852 T NNS O
, US20080181852 T , O
having US20080181852 T VBG O
improved US20080181852 T VBN O
bioavailability US20080181852 T NN O
. US20080181852 T . O

Dihydromyricetin CN101327209A T NNP O
injection CN101327209A T NN O
, CN101327209A T , O
powder CN101327209A T NN O
injection CN101327209A T NN O
and CN101327209A T CC O
preparation CN101327209A T NN O
method CN101327209A T NN O
thereof CN101327209A T NN O
. CN101327209A T . O

Nutrient US20120237596 T JJ O
delivery US20120237596 T NN O
drug US20120237596 T NN O
composition US20120237596 T NN O
. US20120237596 T . O

Sitagliptin WO2010131025A1 T NNP O
synthesis WO2010131025A1 T NN O
. WO2010131025A1 T . O

Substituted EP1603912A1 T VBN O
piperidine EP1603912A1 T NN O
and EP1603912A1 T CC O
piperazine EP1603912A1 T NN O
derivatives EP1603912A1 T NNS O
as EP1603912A1 T IN O
melanocortin-4 EP1603912A1 T JJ I-UN
receptor EP1603912A1 T NN I-UN
modulators EP1603912A1 T NNS O
. EP1603912A1 T . O

The EP1603912A1 A DT O
present EP1603912A1 A JJ O
invention EP1603912A1 A NN O
relates EP1603912A1 A VBZ O
to EP1603912A1 A TO O
novel EP1603912A1 A VB O
substituted EP1603912A1 A JJ O
piperidine EP1603912A1 A NN O
and EP1603912A1 A CC O
piperazine EP1603912A1 A NN O
derivatives EP1603912A1 A NNS O
as EP1603912A1 A IN O
melanocortin-4 EP1603912A1 A JJ I-UN
receptor EP1603912A1 A NN I-UN
( EP1603912A1 A ( O
MC-4R EP1603912A1 A NNP I-UN
) EP1603912A1 A ) O
modulators EP1603912A1 A NNS O
. EP1603912A1 A . O

MC-4R EP1603912A1 A JJ I-UN
agonists EP1603912A1 A NNS O
of EP1603912A1 A IN O
the EP1603912A1 A DT O
invention EP1603912A1 A NN O
can EP1603912A1 A MD O
be EP1603912A1 A VB O
used EP1603912A1 A VBN O
for EP1603912A1 A IN O
the EP1603912A1 A DT O
treatment EP1603912A1 A NN O
of EP1603912A1 A IN O
disorders EP1603912A1 A NNS O
and EP1603912A1 A CC O
diseases EP1603912A1 A NNS O
such EP1603912A1 A JJ O
as EP1603912A1 A IN O
obesity EP1603912A1 A NN O
, EP1603912A1 A , O
diabetes EP1603912A1 A VBZ O
, EP1603912A1 A , O
and EP1603912A1 A CC O
sexual EP1603912A1 A JJ O
dysfunction EP1603912A1 A NN O
, EP1603912A1 A , O
whereas EP1603912A1 A IN O
the EP1603912A1 A DT O
MC-4R EP1603912A1 A JJ I-UN
antagonists EP1603912A1 A NNS O
are EP1603912A1 A VBP O
useful EP1603912A1 A JJ O
for EP1603912A1 A IN O
the EP1603912A1 A DT O
treatment EP1603912A1 A NN O
of EP1603912A1 A IN O
disorders EP1603912A1 A NNS O
and EP1603912A1 A CC O
diseases EP1603912A1 A NNS O
such EP1603912A1 A JJ O
as EP1603912A1 A IN O
cancer EP1603912A1 A NN O
cachexia EP1603912A1 A NN O
, EP1603912A1 A , O
muscle EP1603912A1 A NN O
wasting EP1603912A1 A NN O
, EP1603912A1 A , O
anorexia EP1603912A1 A NN O
, EP1603912A1 A , O
anxiety EP1603912A1 A NN O
and EP1603912A1 A CC O
depression EP1603912A1 A NN O
. EP1603912A1 A . O

All EP1603912A1 A DT O
diseases EP1603912A1 A NNS O
and EP1603912A1 A CC O
disorders EP1603912A1 A NNS O
where EP1603912A1 A WRB O
the EP1603912A1 A DT O
regulation EP1603912A1 A NN O
of EP1603912A1 A IN O
the EP1603912A1 A DT O
MC-4R EP1603912A1 A NNP I-UN
is EP1603912A1 A VBZ O
involved EP1603912A1 A VBN O
can EP1603912A1 A MD O
be EP1603912A1 A VB O
treated EP1603912A1 A VBN O
with EP1603912A1 A IN O
the EP1603912A1 A DT O
compounds EP1603912A1 A NNS O
of EP1603912A1 A IN O
the EP1603912A1 A DT O
invention EP1603912A1 A NN O
. EP1603912A1 A . O

Multi-Functional US20080221132 T JJ O
Small US20080221132 T NNP O
Molecules US20080221132 T NNP O
as US20080221132 T IN O
Anti-Proliferative US20080221132 T JJ O
Agents US20080221132 T NNS O
. US20080221132 T . O

More US20080221132 A RBR O
specifically US20080221132 A RB O
, US20080221132 A , O
the US20080221132 A DT O
present US20080221132 A JJ O
invention US20080221132 A NN O
relates US20080221132 A VBZ O
to US20080221132 A TO O
multi-functional US20080221132 A JJ O
small US20080221132 A JJ O
molecules US20080221132 A NNS O
wherein US20080221132 A VBP O
one US20080221132 A CD O
functionality US20080221132 A NN O
is US20080221132 A VBZ O
capable US20080221132 A JJ O
of US20080221132 A IN O
inhibiting US20080221132 A VBG O
histone US20080221132 A NN I-UN
deacetylases US20080221132 A NNS I-UN
( US20080221132 A ( O
HDAC US20080221132 A NNP I-UN
) US20080221132 A ) O
and US20080221132 A CC O
the US20080221132 A DT O
other US20080221132 A JJ O
functionality US20080221132 A NN O
is US20080221132 A VBZ O
capable US20080221132 A JJ O
of US20080221132 A IN O
inhibiting US20080221132 A VBG O
a US20080221132 A DT O
different US20080221132 A JJ O
cellular US20080221132 A NN O
or US20080221132 A CC O
molecular US20080221132 A JJ O
pathway US20080221132 A NN O
involved US20080221132 A VBN O
in US20080221132 A IN O
aberrant US20080221132 A JJ O
cell US20080221132 A NN O
proliferation US20080221132 A NN O
, US20080221132 A , O
differentiation US20080221132 A NN O
or US20080221132 A CC O
survival US20080221132 A NN O
. US20080221132 A . O

Injection CN102940636A T NN O
of CN102940636A T IN O
piperacillin-sulbactum CN102940636A T JJ O
sodium CN102940636A T NN O
medicine CN102940636A T NN O
composition CN102940636A T NN O
and CN102940636A T CC O
preparation CN102940636A T NN O
method CN102940636A T NN O
thereof CN102940636A T NN O
. CN102940636A T . O

The CN102940636A A DT O
invention CN102940636A A NN O
discloses CN102940636A A VBZ O
an CN102940636A A DT O
injection CN102940636A A NN O
of CN102940636A A IN O
a CN102940636A A DT O
piperacillin-sulbactum CN102940636A A JJ O
sodium CN102940636A A NN O
medicine CN102940636A A NN O
composition CN102940636A A NN O
and CN102940636A A CC O
a CN102940636A A DT O
preparation CN102940636A A NN O
method CN102940636A A NN O
thereof CN102940636A A NN O
. CN102940636A A . O

The CN102940636A A DT O
injection CN102940636A A NN O
disclosed CN102940636A A VBD O
herein CN102940636A A JJ O
comprises CN102940636A A NNS O
10-15 CN102940636A A JJ O
weight CN102940636A A NN O
parts CN102940636A A NNS O
of CN102940636A A IN O
piperacillin CN102940636A A NN O
, CN102940636A A , O
2.5 CN102940636A A CD O
weight CN102940636A A NN O
parts CN102940636A A NNS O
of CN102940636A A IN O
sulbactam CN102940636A A NN O
sodium CN102940636A A NN O
, CN102940636A A , O
2-5 CN102940636A A JJ O
weight CN102940636A A NN O
parts CN102940636A A NNS O
of CN102940636A A IN O
lactose CN102940636A A NN O
, CN102940636A A , O
1 CN102940636A A CD O
weight CN102940636A A JJ O
part CN102940636A A NN O
of CN102940636A A IN O
sodium CN102940636A A NN O
chloride CN102940636A A NN O
, CN102940636A A , O
and CN102940636A A CC O
0.1-0.5 CN102940636A A JJ O
weight CN102940636A A NN O
parts CN102940636A A NNS O
of CN102940636A A IN O
sodium CN102940636A A NN O
citrate CN102940636A A NN O
. CN102940636A A . O

The CN102940636A A DT O
preparation CN102940636A A NN O
method CN102940636A A NN O
comprises CN102940636A A VBZ O
the CN102940636A A DT O
following CN102940636A A JJ O
steps CN102940636A A NNS O
: CN102940636A A : O
weighing CN102940636A A VBG O
piperacillin CN102940636A A NN O
, CN102940636A A , O
sulbactam CN102940636A A JJ O
sodium CN102940636A A NN O
, CN102940636A A , O
lactose CN102940636A A NN O
, CN102940636A A , O
and CN102940636A A CC O
sodium CN102940636A A NN O
chloride CN102940636A A NN O
based CN102940636A A VBN O
on CN102940636A A IN O
the CN102940636A A DT O
weight CN102940636A A NN O
parts CN102940636A A NNS O
, CN102940636A A , O
using CN102940636A A VBG O
water CN102940636A A NN O
for CN102940636A A IN O
injection CN102940636A A NN O
to CN102940636A A TO O
dissolve CN102940636A A VB O
, CN102940636A A , O
preparing CN102940636A A VBG O
sodium CN102940636A A NN O
citrate CN102940636A A NN O
into CN102940636A A IN O
a CN102940636A A DT O
0.1mol/L CN102940636A A CD O
solution CN102940636A A NN O
by CN102940636A A IN O
using CN102940636A A VBG O
water CN102940636A A NN O
for CN102940636A A IN O
injection CN102940636A A NN O
, CN102940636A A , O
adding CN102940636A A VBG O
the CN102940636A A DT O
0.1mol/L CN102940636A A CD O
solution CN102940636A A NN O
dropwisely CN102940636A A RB O
to CN102940636A A TO O
the CN102940636A A DT O
solution CN102940636A A NN O
obtained CN102940636A A VBN O
by CN102940636A A IN O
dissolving CN102940636A A VBG O
and CN102940636A A CC O
stopping CN102940636A A VBG O
adding CN102940636A A VBG O
dropwisely CN102940636A A RB O
when CN102940636A A WRB O
the CN102940636A A DT O
pH CN102940636A A NN O
value CN102940636A A NN O
is CN102940636A A VBZ O
6.8 CN102940636A A CD O
, CN102940636A A , O
and CN102940636A A CC O
then CN102940636A A RB O
dilute CN102940636A A VB O
with CN102940636A A IN O
water CN102940636A A NN O
for CN102940636A A IN O
injection CN102940636A A NN O
to CN102940636A A TO O
make CN102940636A A VB O
5000mL CN102940636A A CD O
to CN102940636A A TO O
obtain CN102940636A A VB O
a CN102940636A A DT O
colorless CN102940636A A NN O
and CN102940636A A CC O
transparent CN102940636A A JJ O
medicine CN102940636A A NN O
solution CN102940636A A NN O
; CN102940636A A : O
filtering CN102940636A A VBG O
the CN102940636A A DT O
medicine CN102940636A A NN O
solution CN102940636A A NN O
by CN102940636A A IN O
a CN102940636A A DT O
filtering CN102940636A A NN O
membrane CN102940636A A NN O
, CN102940636A A , O
drying CN102940636A A VBG O
, CN102940636A A , O
conducting CN102940636A A VBG O
sterile CN102940636A A JJ O
crushing CN102940636A A NN O
, CN102940636A A , O
and CN102940636A A CC O
filling CN102940636A A VBG O
to CN102940636A A TO O
obtain CN102940636A A VB O
the CN102940636A A DT O
injection CN102940636A A NN O
. CN102940636A A . O

According CN102940636A A VBG O
to CN102940636A A TO O
the CN102940636A A DT O
invention CN102940636A A NN O
, CN102940636A A , O
the CN102940636A A DT O
injection CN102940636A A NN O
has CN102940636A A VBZ O
the CN102940636A A DT O
advantages CN102940636A A NNS O
of CN102940636A A IN O
good CN102940636A A JJ O
stability CN102940636A A NN O
, CN102940636A A , O
fast CN102940636A A RB O
dissolving CN102940636A A VBG O
speed CN102940636A A NN O
, CN102940636A A , O
etc CN102940636A A FW O
. CN102940636A A . O

; CN102940636A A : O
and CN102940636A A CC O
the CN102940636A A DT O
preparation CN102940636A A NN O
method CN102940636A A NN O
has CN102940636A A VBZ O
simple CN102940636A A JJ O
operation CN102940636A A NN O
, CN102940636A A , O
reduces CN102940636A A VBZ O
production CN102940636A A NN O
cost CN102940636A A NN O
, CN102940636A A , O
and CN102940636A A CC O
is CN102940636A A VBZ O
suitable CN102940636A A JJ O
for CN102940636A A IN O
large-scale CN102940636A A JJ O
production CN102940636A A NN O
. CN102940636A A . O

Compounds WO2011085544A1 T NNS O
which WO2011085544A1 T WDT O
effecttively WO2011085544A1 T RB O
remove WO2011085544A1 T VBP O
tumor WO2011085544A1 T NN O
or WO2011085544A1 T CC O
cancer WO2011085544A1 T NN O
cell WO2011085544A1 T NN O
. WO2011085544A1 T . O

Application CN102872093A T NN O
of CN102872093A T IN O
Houttuynoid CN102872093A T NNP O
E CN102872093A T NNP O
in CN102872093A T IN O
medicine CN102872093A T NN O
for CN102872093A T IN O
treating CN102872093A T VBG O
pancreatic CN102872093A T JJ O
cancer CN102872093A T NN O
. CN102872093A T . O

The CN102872093A A DT O
invention CN102872093A A NN O
discloses CN102872093A A VBZ O
application CN102872093A A NN O
of CN102872093A A IN O
Houttuynoid CN102872093A A NNP O
E CN102872093A A NNP O
in CN102872093A A IN O
preparing CN102872093A A VBG O
a CN102872093A A DT O
medicine CN102872093A A NN O
for CN102872093A A IN O
treating CN102872093A A VBG O
pancreatic CN102872093A A JJ O
cancer CN102872093A A NN O
, CN102872093A A , O
belonging CN102872093A A VBG O
to CN102872093A A TO O
the CN102872093A A DT O
technical CN102872093A A JJ O
field CN102872093A A NN O
of CN102872093A A IN O
new CN102872093A A JJ O
application CN102872093A A NN O
of CN102872093A A IN O
a CN102872093A A DT O
medicine CN102872093A A NN O
. CN102872093A A . O

According CN102872093A A VBG O
to CN102872093A A TO O
the CN102872093A A DT O
invention CN102872093A A NN O
, CN102872093A A , O
the CN102872093A A DT O
in-vitro CN102872093A A JJ O
MTT CN102872093A A NNP O
anti-tumor CN102872093A A NN O
activity CN102872093A A NN O
evaluation CN102872093A A NN O
discovers CN102872093A A NNS O
that CN102872093A A IN O
the CN102872093A A DT O
Houttuynoid CN102872093A A NNP O
E CN102872093A A NNP O
also CN102872093A A RB O
has CN102872093A A VBZ O
an CN102872093A A DT O
obvious CN102872093A A JJ O
effect CN102872093A A NN O
on CN102872093A A IN O
suppressing CN102872093A A VBG O
the CN102872093A A DT O
growth CN102872093A A NN O
of CN102872093A A IN O
the CN102872093A A DT O
human CN102872093A A JJ O
pancreatic CN102872093A A JJ O
cancer CN102872093A A NN O
cell CN102872093A A NN O
strains CN102872093A A VBZ O
PANC-1 CN102872093A A NNP O
and CN102872093A A CC O
BXPC-3 CN102872093A A NNP O
. CN102872093A A . O

Thus CN102872093A A RB O
, CN102872093A A , O
the CN102872093A A DT O
Houttuynoid CN102872093A A NNP O
E CN102872093A A NNP O
can CN102872093A A MD O
be CN102872093A A VB O
used CN102872093A A VBN O
for CN102872093A A IN O
preparing CN102872093A A VBG O
an CN102872093A A DT O
anti-pancreatic CN102872093A A JJ O
cancer CN102872093A A NN O
medicine CN102872093A A NN O
and CN102872093A A CC O
has CN102872093A A VBZ O
good CN102872093A A JJ O
prospects CN102872093A A NNS O
in CN102872093A A IN O
development CN102872093A A NN O
and CN102872093A A CC O
application CN102872093A A NN O
. CN102872093A A . O

The CN102872093A A DT O
application CN102872093A A NN O
of CN102872093A A IN O
Houttuynoid CN102872093A A NNP O
E CN102872093A A NNP O
in CN102872093A A IN O
preparing CN102872093A A VBG O
a CN102872093A A DT O
medicine CN102872093A A NN O
for CN102872093A A IN O
treating CN102872093A A VBG O
pancreatic CN102872093A A JJ O
cancer CN102872093A A NN O
is CN102872093A A VBZ O
disclosed CN102872093A A VBN O
for CN102872093A A IN O
the CN102872093A A DT O
first CN102872093A A JJ O
time CN102872093A A NN O
; CN102872093A A : O
and CN102872093A A CC O
the CN102872093A A DT O
skeleton CN102872093A A NN O
type CN102872093A A NN O
is CN102872093A A VBZ O
a CN102872093A A DT O
brand CN102872093A A NN O
new CN102872093A A JJ O
one CN102872093A A CD O
, CN102872093A A , O
and CN102872093A A CC O
the CN102872093A A DT O
activity CN102872093A A NN O
in CN102872093A A IN O
suppressing CN102872093A A VBG O
pancreatic CN102872093A A JJ O
cancer CN102872093A A NN O
cells CN102872093A A NNS O
is CN102872093A A VBZ O
unexpectedly CN102872093A A RB O
strong CN102872093A A JJ O
. CN102872093A A . O

Allele-specific US20080176812 T JJ O
silencing US20080176812 T NN O
of US20080176812 T IN O
disease US20080176812 T NN O
genes US20080176812 T NNS O
. US20080176812 T . O

Pharmaceutical CA2323536C T JJ O
formulation CA2323536C T NN O
comprising CA2323536C T VBG O
a CA2323536C T DT O
2- CA2323536C T JJ O
[ CA2323536C T NN O
[ CA2323536C T NNP O
( CA2323536C T ( O
2-pyridinyl CA2323536C T JJ O
) CA2323536C T ) O
methyl CA2323536C T NN O
] CA2323536C T NNP O
sulfinyl CA2323536C T NN O
] CA2323536C T NNP O
benzimidazole CA2323536C T NN O
having CA2323536C T VBG O
anti-ulcer CA2323536C T JJ O
activity CA2323536C T NN O
and CA2323536C T CC O
a CA2323536C T DT O
process CA2323536C T NN O
for CA2323536C T IN O
the CA2323536C T DT O
preparation CA2323536C T NN O
of CA2323536C T IN O
such CA2323536C T JJ O
formulation CA2323536C T NN O
. CA2323536C T . O

Targeting US20060128750 T VBG O
chemokine US20060128750 T NN O
receptors US20060128750 T NNS O
and US20060128750 T CC O
interfere US20060128750 T VB O
with US20060128750 T IN O
the US20060128750 T DT O
binding US20060128750 T NN O
of US20060128750 T IN O
the US20060128750 T DT O
natural US20060128750 T JJ O
ligand US20060128750 T NN O
thereto US20060128750 T NN O
; US20060128750 T : O
antagonists US20060128750 T NNS O
or US20060128750 T CC O
agonists US20060128750 T NNS O
; US20060128750 T : O
protecting US20060128750 T VBG O
target US20060128750 T NN O
cells US20060128750 T NNS O
from US20060128750 T IN O
HIV US20060128750 T NNP O
infection US20060128750 T NN O
; US20060128750 T : O
treating US20060128750 T VBG O
HIV US20060128750 T NNP O
or US20060128750 T CC O
FIV US20060128750 T NNP O
infected US20060128750 T JJ O
patients US20060128750 T NNS O
. US20060128750 T . O

Tertiary US20060128750 A JJ O
amine US20060128750 A NN O
compounds US20060128750 A VBZ O
that US20060128750 A IN O
bind US20060128750 A NN O
chemokine US20060128750 A NN O
receptors US20060128750 A NNS O
such US20060128750 A JJ O
as US20060128750 A IN O
CXCR4 US20060128750 A NNP I-UN
and US20060128750 A CC O
CCR5 US20060128750 A NNP I-UN
are US20060128750 A VBP O
disclosed US20060128750 A VBN O
. US20060128750 A . O

Method WO2010123008A1 T NNP O
for WO2010123008A1 T IN O
evaluating WO2010123008A1 T VBG O
skin WO2010123008A1 T JJ O
barrier WO2010123008A1 T NN O
function WO2010123008A1 T NN O
recovery-accelerator WO2010123008A1 T NN O
using WO2010123008A1 T VBG O
work WO2010123008A1 T NN O
function WO2010123008A1 T NN O
as WO2010123008A1 T IN O
indication WO2010123008A1 T NN O
. WO2010123008A1 T . O

Cathepsin-d US20110064721 T JJ I-UN
neuroprotection US20110064721 T NN O
. US20110064721 T . O

Provided US20110064721 A VBN O
herein US20110064721 A NN O
are US20110064721 A VBP O
methods US20110064721 A NNS O
and US20110064721 A CC O
compositions US20110064721 A NNS O
for US20110064721 A IN O
promoting US20110064721 A VBG O
neuroprotection US20110064721 A NN O
in US20110064721 A IN O
a US20110064721 A DT O
subject US20110064721 A NN O
and US20110064721 A CC O
for US20110064721 A IN O
treating US20110064721 A VBG O
a US20110064721 A DT O
neural US20110064721 A JJ O
disorder US20110064721 A NN O
associated US20110064721 A VBN O
with US20110064721 A IN O
protein US20110064721 A JJ O
aggregation US20110064721 A NN O
comprising US20110064721 A VBG O
administering US20110064721 A VBG O
to US20110064721 A TO O
the US20110064721 A DT O
subject US20110064721 A NN O
an US20110064721 A DT O
agent US20110064721 A NN O
that US20110064721 A WDT O
increases US20110064721 A VBZ O
expression US20110064721 A NN O
or US20110064721 A CC O
activity US20110064721 A NN O
of US20110064721 A IN O
cathepsin-D. US20110064721 A NN O
Also US20110064721 A RB O
provided US20110064721 A VBN O
are US20110064721 A VBP O
methods US20110064721 A NNS O
of US20110064721 A IN O
screening US20110064721 A VBG O
for US20110064721 A IN O
agents US20110064721 A NNS O
that US20110064721 A WDT O
increase US20110064721 A VBP O
expression US20110064721 A NN O
or US20110064721 A CC O
activity US20110064721 A NN O
of US20110064721 A IN O
cathepsin-D US20110064721 A NN I-UN
and US20110064721 A CC O
methods US20110064721 A NNS O
of US20110064721 A IN O
screening US20110064721 A VBG O
for US20110064721 A IN O
neuroprotective US20110064721 A JJ O
agents US20110064721 A NNS O
. US20110064721 A . O

Bicyclic WO2007060821A1 T NNP O
cinnamide WO2007060821A1 T NN O
compound WO2007060821A1 T NN O
. WO2007060821A1 T . O

A WO2007060821A1 A DT O
bicyclic WO2007060821A1 A JJ O
cinnamide WO2007060821A1 A NN O
compound WO2007060821A1 A NN O
represented WO2007060821A1 A VBN O
by WO2007060821A1 A IN O
the WO2007060821A1 A DT O
formula WO2007060821A1 A NN O
( WO2007060821A1 A ( O
I WO2007060821A1 A PRP O
) WO2007060821A1 A ) O
[ WO2007060821A1 A VBP O
wherein WO2007060821A1 A NN O
( WO2007060821A1 A ( O
II WO2007060821A1 A NNP O
) WO2007060821A1 A ) O
indicates WO2007060821A1 A VBZ O
a WO2007060821A1 A DT O
single WO2007060821A1 A JJ O
bond WO2007060821A1 A NN O
or WO2007060821A1 A CC O
double WO2007060821A1 A JJ O
bond WO2007060821A1 A NN O
; WO2007060821A1 A : O
Ar1 WO2007060821A1 A NNP O
represents WO2007060821A1 A VBZ O
phenyl WO2007060821A1 A NN O
or WO2007060821A1 A CC O
pyridinyl WO2007060821A1 A VB O
optionally WO2007060821A1 A RB O
substituted WO2007060821A1 A VBN O
by WO2007060821A1 A IN O
one WO2007060821A1 A CD O
to WO2007060821A1 A TO O
three WO2007060821A1 A CD O
substituents WO2007060821A1 A NNS O
; WO2007060821A1 A : O
R1 WO2007060821A1 A NNP O
and WO2007060821A1 A CC O
R2 WO2007060821A1 A NNP O
each WO2007060821A1 A DT O
represents WO2007060821A1 A VBZ O
C1-6 WO2007060821A1 A JJ O
alkyl WO2007060821A1 A NN O
, WO2007060821A1 A , O
hydroxy WO2007060821A1 A NN O
, WO2007060821A1 A , O
etc WO2007060821A1 A FW O
. WO2007060821A1 A . O

; WO2007060821A1 A : O
Z1 WO2007060821A1 A NNP O
represents WO2007060821A1 A VBZ O
optionally WO2007060821A1 A RB O
substituted WO2007060821A1 A VBN O
methylene WO2007060821A1 A NN O
or WO2007060821A1 A CC O
vinylene WO2007060821A1 A NN O
, WO2007060821A1 A , O
oxygen WO2007060821A1 A NN O
, WO2007060821A1 A , O
or WO2007060821A1 A CC O
imino WO2007060821A1 A NN O
optionally WO2007060821A1 A RB O
substituted WO2007060821A1 A VBN O
by WO2007060821A1 A IN O
C1-6 WO2007060821A1 A NNP O
alkyl WO2007060821A1 A NN O
or WO2007060821A1 A CC O
C1-6 WO2007060821A1 A NNP O
acyl WO2007060821A1 A NN O
; WO2007060821A1 A : O
and WO2007060821A1 A CC O
p WO2007060821A1 A VB O
, WO2007060821A1 A , O
q WO2007060821A1 A NN O
, WO2007060821A1 A , O
and WO2007060821A1 A CC O
r WO2007060821A1 A VB O
each WO2007060821A1 A DT O
is WO2007060821A1 A VBZ O
an WO2007060821A1 A DT O
integer WO2007060821A1 A NN O
of WO2007060821A1 A IN O
0-2 WO2007060821A1 A JJ O
] WO2007060821A1 A NN O
. WO2007060821A1 A . O

It WO2007060821A1 A PRP O
functions WO2007060821A1 A VBZ O
to WO2007060821A1 A TO O
reduce WO2007060821A1 A VB O
the WO2007060821A1 A DT O
production WO2007060821A1 A NN O
of WO2007060821A1 A IN O
Aβ40 WO2007060821A1 A NNP O
and WO2007060821A1 A CC O
Aβ42 WO2007060821A1 A NNP O
. WO2007060821A1 A . O

It WO2007060821A1 A PRP O
is WO2007060821A1 A VBZ O
hence WO2007060821A1 A RB O
useful WO2007060821A1 A JJ O
especially WO2007060821A1 A RB O
as WO2007060821A1 A IN O
a WO2007060821A1 A DT O
preventive WO2007060821A1 A NN O
or WO2007060821A1 A CC O
remedy WO2007060821A1 A NN O
for WO2007060821A1 A IN O
neurodegenerative WO2007060821A1 A JJ O
diseases WO2007060821A1 A NNS O
of WO2007060821A1 A IN O
which WO2007060821A1 A WDT O
Aβ WO2007060821A1 A NNP O
is WO2007060821A1 A VBZ O
causative WO2007060821A1 A JJ O
, WO2007060821A1 A , O
such WO2007060821A1 A JJ O
as WO2007060821A1 A IN O
Alzheimer WO2007060821A1 A NNP O
's WO2007060821A1 A POS O
disease WO2007060821A1 A NN O
and WO2007060821A1 A CC O
Down WO2007060821A1 A NNP O
's WO2007060821A1 A POS O
syndrome WO2007060821A1 A NN O
. WO2007060821A1 A . O

Microemulsion WO2014160079A1 T NNP O
topical WO2014160079A1 T JJ O
delivery WO2014160079A1 T NN O
platform WO2014160079A1 T NN O
. WO2014160079A1 T . O

Provided WO2014160079A1 A VBN O
are WO2014160079A1 A VBP O
pharmaceutical WO2014160079A1 A JJ O
carriers WO2014160079A1 A NNS O
suitable WO2014160079A1 A JJ O
based WO2014160079A1 A VBN O
on WO2014160079A1 A IN O
oil-in- WO2014160079A1 A JJ O
water WO2014160079A1 A NN O
microemulsions WO2014160079A1 A NNS O
and WO2014160079A1 A CC O
methods WO2014160079A1 A NNS O
of WO2014160079A1 A IN O
making WO2014160079A1 A VBG O
same WO2014160079A1 A JJ O
. WO2014160079A1 A . O

Also WO2014160079A1 A RB O
provided WO2014160079A1 A VBN O
are WO2014160079A1 A VBP O
pharmaceutical WO2014160079A1 A JJ O
compositions WO2014160079A1 A NNS O
comprising WO2014160079A1 A VBG O
a WO2014160079A1 A DT O
carrier WO2014160079A1 A NN O
of WO2014160079A1 A IN O
the WO2014160079A1 A DT O
invention WO2014160079A1 A NN O
and WO2014160079A1 A CC O
a WO2014160079A1 A DT O
lipophilic WO2014160079A1 A JJ O
active WO2014160079A1 A JJ O
pharmaceutical WO2014160079A1 A JJ O
ingredient WO2014160079A1 A NN O
( WO2014160079A1 A ( O
API WO2014160079A1 A NNP O
) WO2014160079A1 A ) O
, WO2014160079A1 A , O
as WO2014160079A1 A RB O
well WO2014160079A1 A RB O
as WO2014160079A1 A IN O
methods WO2014160079A1 A NNS O
for WO2014160079A1 A IN O
making WO2014160079A1 A VBG O
same WO2014160079A1 A JJ O
. WO2014160079A1 A . O

The WO2014160079A1 A DT O
pharmaceutical WO2014160079A1 A JJ O
compositions WO2014160079A1 A NNS O
are WO2014160079A1 A VBP O
particularly WO2014160079A1 A RB O
suitable WO2014160079A1 A JJ O
for WO2014160079A1 A IN O
use WO2014160079A1 A NN O
in WO2014160079A1 A IN O
formulating WO2014160079A1 A VBG O
lipophilic WO2014160079A1 A JJ O
APIs WO2014160079A1 A NNP O
for WO2014160079A1 A IN O
topical WO2014160079A1 A JJ O
administration WO2014160079A1 A NN O
to WO2014160079A1 A TO O
the WO2014160079A1 A DT O
eye WO2014160079A1 A NN O
. WO2014160079A1 A . O

Specifically WO2014160079A1 A RB O
included WO2014160079A1 A VBN O
are WO2014160079A1 A VBP O
pharmaceutical WO2014160079A1 A JJ O
compositions WO2014160079A1 A NNS O
comprising WO2014160079A1 A VBG O
fenofibrate WO2014160079A1 A NN O
or WO2014160079A1 A CC O
fenofibric WO2014160079A1 A JJ O
acid WO2014160079A1 A NN O
as WO2014160079A1 A IN O
API WO2014160079A1 A NNP O
. WO2014160079A1 A . O

Also WO2014160079A1 A RB O
provided WO2014160079A1 A VBN O
is WO2014160079A1 A VBZ O
a WO2014160079A1 A DT O
method WO2014160079A1 A NN O
of WO2014160079A1 A IN O
treating WO2014160079A1 A VBG O
a WO2014160079A1 A DT O
disease WO2014160079A1 A NN O
of WO2014160079A1 A IN O
the WO2014160079A1 A DT O
posterior WO2014160079A1 A JJ O
segment WO2014160079A1 A NN O
of WO2014160079A1 A IN O
the WO2014160079A1 A DT O
eye WO2014160079A1 A NN O
. WO2014160079A1 A . O

Also WO2014160079A1 A RB O
provided WO2014160079A1 A VBN O
is WO2014160079A1 A VBZ O
a WO2014160079A1 A DT O
pharmaceutical WO2014160079A1 A JJ O
composition WO2014160079A1 A NN O
comprising WO2014160079A1 A VBG O
a WO2014160079A1 A DT O
compound WO2014160079A1 A NN O
represented WO2014160079A1 A VBN O
by WO2014160079A1 A IN O
( WO2014160079A1 A ( O
Formula WO2014160079A1 A NNP O
I WO2014160079A1 A PRP O
) WO2014160079A1 A ) O
formulated WO2014160079A1 A VBD O
for WO2014160079A1 A IN O
topical WO2014160079A1 A JJ O
administration WO2014160079A1 A NN O
to WO2014160079A1 A TO O
the WO2014160079A1 A DT O
eye WO2014160079A1 A NN O
. WO2014160079A1 A . O

Hsp90 US20120264770 T NNP I-UN
inhibitors US20120264770 T NNS O
. US20120264770 T . O

The US20120264770 A DT O
invention US20120264770 A NN O
relates US20120264770 A VBZ O
to US20120264770 A TO O
HSP90 US20120264770 A NNP I-UN
inhibiting US20120264770 A VBG O
compounds US20120264770 A NNS O
consisting US20120264770 A VBG O
of US20120264770 A IN O
the US20120264770 A DT O
formula US20120264770 A NN O
: US20120264770 A : O
wherein US20120264770 A VB O
the US20120264770 A DT O
variables US20120264770 A NNS O
are US20120264770 A VBP O
as US20120264770 A IN O
defined US20120264770 A JJ O
herein US20120264770 A NN O
. US20120264770 A . O

Treatment CN102106994A T NNP O
formula CN102106994A T NN O
for CN102106994A T IN O
epilepsies CN102106994A T NNS O
and CN102106994A T CC O
manufacturing CN102106994A T VBG O
method CN102106994A T NN O
thereof CN102106994A T NN O
. CN102106994A T . O

Substituted WO2012076966A1 T VBN O
thieno WO2012076966A1 T JJ O
[ WO2012076966A1 T JJ O
3,4-b WO2012076966A1 T JJ O
] WO2012076966A1 T NNP O
pyrazine WO2012076966A1 T NN O
compounds WO2012076966A1 T NNS O
. WO2012076966A1 T . O

The WO2012076966A1 A DT O
invention WO2012076966A1 A NN O
also WO2012076966A1 A RB O
relates WO2012076966A1 A VBZ O
to WO2012076966A1 A TO O
methods WO2012076966A1 A NNS O
for WO2012076966A1 A IN O
treating WO2012076966A1 A VBG O
, WO2012076966A1 A , O
preventing WO2012076966A1 A VBG O
and/or WO2012076966A1 A RP O
managing WO2012076966A1 A VBG O
diseases WO2012076966A1 A NNS O
, WO2012076966A1 A , O
disorders WO2012076966A1 A NNS O
, WO2012076966A1 A , O
syndromes WO2012076966A1 A NNS O
or WO2012076966A1 A CC O
conditions WO2012076966A1 A NNS O
associated WO2012076966A1 A VBN O
with WO2012076966A1 A IN O
inadequate WO2012076966A1 A JJ O
insulin WO2012076966A1 A NN I-UN
secretion WO2012076966A1 A NN O
such WO2012076966A1 A JJ O
as WO2012076966A1 A IN O
diabetes WO2012076966A1 A NNS O
, WO2012076966A1 A , O
related WO2012076966A1 A JJ O
disorders WO2012076966A1 A NNS O
and WO2012076966A1 A CC O
metabolic WO2012076966A1 A JJ O
syndrome WO2012076966A1 A NN O
. WO2012076966A1 A . O

The WO2012076966A1 A DT O
invention WO2012076966A1 A NN O
also WO2012076966A1 A RB O
relates WO2012076966A1 A VBZ O
to WO2012076966A1 A TO O
methods WO2012076966A1 A NNS O
for WO2012076966A1 A IN O
treating WO2012076966A1 A VBG O
, WO2012076966A1 A , O
preventing WO2012076966A1 A VBG O
and/or WO2012076966A1 A RP O
managing WO2012076966A1 A VBG O
diseases WO2012076966A1 A NNS O
, WO2012076966A1 A , O
disorders WO2012076966A1 A NNS O
, WO2012076966A1 A , O
syndromes WO2012076966A1 A NNS O
or WO2012076966A1 A CC O
conditions WO2012076966A1 A NNS O
which WO2012076966A1 A WDT O
are WO2012076966A1 A VBP O
affected WO2012076966A1 A VBN O
or WO2012076966A1 A CC O
facilitated WO2012076966A1 A VBN O
by WO2012076966A1 A IN O
the WO2012076966A1 A DT O
modulation WO2012076966A1 A NN O
of WO2012076966A1 A IN O
GLP-1 WO2012076966A1 A NNP I-UN
receptor WO2012076966A1 A NN I-UN
. WO2012076966A1 A . O

Timolol CN101401791A T NNP O
liposome CN101401791A T NN O
and CN101401791A T CC O
preparation CN101401791A T NN O
method CN101401791A T NN O
thereof CN101401791A T NN O
. CN101401791A T . O

Preparation US20110257253 T NNP O
method US20110257253 T NN O
of US20110257253 T IN O
polymeric US20110257253 T JJ O
micellar US20110257253 T JJ O
nanoparticles US20110257253 T NNS O
composition US20110257253 T NN O
containing US20110257253 T VBG O
a US20110257253 T DT O
poorly US20110257253 T JJ O
water-soluble US20110257253 T JJ O
drug US20110257253 T NN O
. US20110257253 T . O

Method CN102079700A T NNP O
for CN102079700A T IN O
synthesizing CN102079700A T VBG O
novel CN102079700A T JJ O
tetracyclic CN102079700A T JJ O
diterpene CN102079700A T NN O
compound CN102079700A T NN O
from CN102079700A T IN O
stevioside CN102079700A T NN O
. CN102079700A T . O

administering US7041652 T VBG O
ascorbic US7041652 T JJ O
acid US7041652 T NN O
, US7041652 T , O
ascorbate US7041652 T NN O
or US7041652 T CC O
a US7041652 T DT O
derivative US7041652 T JJ O
thereof US7041652 T NN O
in US7041652 T IN O
combination US7041652 T NN O
with US7041652 T IN O
quercetin-3-O-glucoside US7041652 T JJ O
( US7041652 T ( O
isoquercetin US7041652 T NN O
) US7041652 T ) O
, US7041652 T , O
quercetin-4'-glucoside US7041652 T JJ O
, US7041652 T , O
quercetin-3'-glucoside US7041652 T JJ O
, US7041652 T , O
or US7041652 T CC O
quercetin-7-glucoside US7041652 T JJ O
to US7041652 T TO O
increase US7041652 T VB O
bioavailability US7041652 T NN O
. US7041652 T . O

2-phenyl-5-heterocyclyl-tetrahydro-2h-pyran-3-amine WO2014061031A1 T JJ O
compounds WO2014061031A1 T NNS O
for WO2014061031A1 T IN O
use WO2014061031A1 T NN O
in WO2014061031A1 T IN O
the WO2014061031A1 T DT O
treatment WO2014061031A1 T NN O
of WO2014061031A1 T IN O
diabetes WO2014061031A1 T NNS O
and WO2014061031A1 T CC O
its WO2014061031A1 T PRP$ O
associated WO2014061031A1 T JJ O
disorders WO2014061031A1 T NNS O
. WO2014061031A1 T . O

Medicine CN1628653A T NNP O
for CN1628653A T IN O
trichomonas CN1628653A T NN O
vaginalis CN1628653A T NN O
disease CN1628653A T NN O
. CN1628653A T . O

Nmda EP1347760B1 T NNP I-UN
receptor EP1347760B1 T NN I-UN
agonist EP1347760B1 T NN O
pharmaceutical EP1347760B1 T JJ O
compositions EP1347760B1 T NNS O
. EP1347760B1 T . O

This EP1347760B1 A DT O
invention EP1347760B1 A NN O
relates EP1347760B1 A VBZ O
to EP1347760B1 A TO O
stable EP1347760B1 A VB O
pharmaceutical EP1347760B1 A JJ O
compositions EP1347760B1 A NNS O
of EP1347760B1 A IN O
the EP1347760B1 A DT O
NMDA EP1347760B1 A NNP I-UN
receptor EP1347760B1 A NN I-UN
agonist EP1347760B1 A NN O
, EP1347760B1 A , O
( EP1347760B1 A ( O
1S EP1347760B1 A CD O
, EP1347760B1 A , O
2S EP1347760B1 A CD O
) EP1347760B1 A ) O
-1- EP1347760B1 A NN O
( EP1347760B1 A ( O
4-hydroxyphenyl EP1347760B1 A JJ O
) EP1347760B1 A ) O
-2- EP1347760B1 A NN O
( EP1347760B1 A ( O
4-hydroxy-4-phenylpiperidin-1-yl EP1347760B1 A JJ O
) EP1347760B1 A ) O
-1-propanol EP1347760B1 A FW O
] EP1347760B1 A NN O
, EP1347760B1 A , O
methods EP1347760B1 A NNS O
of EP1347760B1 A IN O
preparing EP1347760B1 A VBG O
such EP1347760B1 A JJ O
pharmaceutical EP1347760B1 A JJ O
compositions EP1347760B1 A NNS O
and EP1347760B1 A CC O
methods EP1347760B1 A NNS O
of EP1347760B1 A IN O
treating EP1347760B1 A VBG O
stroke EP1347760B1 A NN O
, EP1347760B1 A , O
spinal EP1347760B1 A JJ O
cord EP1347760B1 A NN O
trauma EP1347760B1 A NN O
, EP1347760B1 A , O
traumatic EP1347760B1 A JJ O
brain EP1347760B1 A NN O
injury EP1347760B1 A NN O
, EP1347760B1 A , O
multiinfarct EP1347760B1 A NN O
dementia EP1347760B1 A NN O
, EP1347760B1 A , O
CNS EP1347760B1 A NNP O
degenerative EP1347760B1 A JJ O
diseases EP1347760B1 A NNS O
such EP1347760B1 A JJ O
as EP1347760B1 A IN O
Alzheimer EP1347760B1 A NNP O
's EP1347760B1 A POS O
disease EP1347760B1 A NN O
, EP1347760B1 A , O
senile EP1347760B1 A JJ O
dementia EP1347760B1 A NN O
of EP1347760B1 A IN O
the EP1347760B1 A DT O
Alzheimer EP1347760B1 A NNP O
's EP1347760B1 A POS O
type EP1347760B1 A NN O
, EP1347760B1 A , O
Huntington EP1347760B1 A NNP O
's EP1347760B1 A POS O
disease EP1347760B1 A NN O
, EP1347760B1 A , O
Parkinson EP1347760B1 A NNP O
's EP1347760B1 A POS O
disease EP1347760B1 A NN O
, EP1347760B1 A , O
epilepsy EP1347760B1 A NN O
, EP1347760B1 A , O
amyotrophic EP1347760B1 A JJ O
lateral EP1347760B1 A JJ O
sclerosis EP1347760B1 A NN O
, EP1347760B1 A , O
pain EP1347760B1 A NN O
, EP1347760B1 A , O
AIDS EP1347760B1 A NNP O
dementia EP1347760B1 A NN O
, EP1347760B1 A , O
psychotic EP1347760B1 A JJ O
conditions EP1347760B1 A NNS O
, EP1347760B1 A , O
drug EP1347760B1 A NN O
addictions EP1347760B1 A NNS O
, EP1347760B1 A , O
migraine EP1347760B1 A NN O
, EP1347760B1 A , O
hypoglycemia EP1347760B1 A NN O
, EP1347760B1 A , O
anxiolytic EP1347760B1 A JJ O
conditions EP1347760B1 A NNS O
, EP1347760B1 A , O
urinary EP1347760B1 A JJ O
incontinence EP1347760B1 A NN O
and EP1347760B1 A CC O
an EP1347760B1 A DT O
ischemic EP1347760B1 A JJ O
event EP1347760B1 A NN O
arising EP1347760B1 A VBG O
from EP1347760B1 A IN O
CNS EP1347760B1 A NNP O
surgery EP1347760B1 A NN O
, EP1347760B1 A , O
open EP1347760B1 A JJ O
heart EP1347760B1 A NN O
surgery EP1347760B1 A NN O
or EP1347760B1 A CC O
any EP1347760B1 A DT O
procedure EP1347760B1 A NN O
during EP1347760B1 A IN O
which EP1347760B1 A WDT O
the EP1347760B1 A DT O
function EP1347760B1 A NN O
of EP1347760B1 A IN O
the EP1347760B1 A DT O
cardiovascular EP1347760B1 A JJ O
system EP1347760B1 A NN O
is EP1347760B1 A VBZ O
compromised EP1347760B1 A VBN O
using EP1347760B1 A VBG O
the EP1347760B1 A DT O
pharmaceutical EP1347760B1 A JJ O
compositions EP1347760B1 A NNS O
. EP1347760B1 A . O

Veterinary CN102784145A T JJ O
compound CN102784145A T NN O
florfenicol CN102784145A T NN O
injection CN102784145A T NN O
. CN102784145A T . O

A CN1875965A T DT O
micro-emulsion CN1875965A T NN O
containing CN1875965A T VBG O
Vitamin CN1875965A T NNP O
C CN1875965A T NNP O
and CN1875965A T CC O
Vitamin CN1875965A T NNP O
E CN1875965A T NNP O
and CN1875965A T CC O
preparation CN1875965A T NN O
method CN1875965A T NN O
thereof CN1875965A T NN O
. CN1875965A T . O

The CN1875965A A DT O
invention CN1875965A A NN O
discloses CN1875965A A VBZ O
a CN1875965A A DT O
microemulsion CN1875965A A NN O
containing CN1875965A A VBG O
vitamin CN1875965A A JJ O
C CN1875965A A NNP O
and CN1875965A A CC O
vitamin CN1875965A A NNP O
E CN1875965A A NNP O
, CN1875965A A , O
wherein CN1875965A A VBD O
the CN1875965A A DT O
continuous CN1875965A A JJ O
phase CN1875965A A NN O
of CN1875965A A IN O
the CN1875965A A DT O
microemulsion CN1875965A A NN O
comprises CN1875965A A VBZ O
vitamin CN1875965A A JJ O
C CN1875965A A NNP O
0.1-25.0 CN1875965A A CD O
% CN1875965A A NN O
, CN1875965A A , O
vitamin CN1875965A A JJ O
E CN1875965A A NNP O
0.1-2.0 CN1875965A A CD O
% CN1875965A A NN O
, CN1875965A A , O
and CN1875965A A CC O
the CN1875965A A DT O
matrix CN1875965A A NN O
of CN1875965A A IN O
the CN1875965A A DT O
microemulsion CN1875965A A NN O
comprises CN1875965A A VBZ O
surface CN1875965A A VBP O
active CN1875965A A JJ O
agent CN1875965A A JJ O
9.0-48.0 CN1875965A A CD O
% CN1875965A A NN O
, CN1875965A A , O
oil CN1875965A A NN O
1.0-20.0 CN1875965A A CD O
% CN1875965A A NN O
, CN1875965A A , O
and CN1875965A A CC O
water CN1875965A A NN O
40.0-89.0 CN1875965A A CD O
% CN1875965A A NN O
. CN1875965A A . O

Treatment US7119074 T NN O
of US7119074 T IN O
cancers US7119074 T NNS O
, US7119074 T , O
tumors US7119074 T NNS O
and US7119074 T CC O
malignancies US7119074 T NNS O
using US7119074 T VBG O
amphiphilic US7119074 T JJ O
prodrugs US7119074 T NNS O
. US7119074 T . O

Compound CN102614184A T NNP O
cefquinome CN102614184A T NN O
sulfate CN102614184A T NN O
suspension CN102614184A T NN O
for CN102614184A T IN O
domestic CN102614184A T JJ O
animals CN102614184A T NNS O
, CN102614184A T , O
and CN102614184A T CC O
preparation CN102614184A T NN O
method CN102614184A T NN O
thereof CN102614184A T NN O
. CN102614184A T . O

Benzothiophene- EP1730133A1 T NNP O
and EP1730133A1 T CC O
thiochromene EP1730133A1 T NN O
containing EP1730133A1 T VBG O
phenethanolamine EP1730133A1 T NN O
derivatives EP1730133A1 T NNS O
for EP1730133A1 T IN O
the EP1730133A1 T DT O
treatment EP1730133A1 T NN O
of EP1730133A1 T IN O
respiratory EP1730133A1 T NN O
disorders EP1730133A1 T NNS O
. EP1730133A1 T . O

Compounds EP1730133A1 A NNS O
of EP1730133A1 A IN O
formula EP1730133A1 A NN O
( EP1730133A1 A ( O
I EP1730133A1 A PRP O
) EP1730133A1 A ) O
and EP1730133A1 A CC O
salts EP1730133A1 A NNS O
, EP1730133A1 A , O
solvates EP1730133A1 A NNS O
, EP1730133A1 A , O
and EP1730133A1 A CC O
physiologically EP1730133A1 A RB O
functional EP1730133A1 A JJ O
derivatives EP1730133A1 A NNS O
thereof EP1730133A1 A VBP O
, EP1730133A1 A , O
useful EP1730133A1 A JJ O
for EP1730133A1 A IN O
the EP1730133A1 A DT O
prophylaxis EP1730133A1 A NN O
or EP1730133A1 A CC O
treatment EP1730133A1 A NN O
of EP1730133A1 A IN O
a EP1730133A1 A DT O
clinical EP1730133A1 A JJ O
condition EP1730133A1 A NN O
for EP1730133A1 A IN O
which EP1730133A1 A WDT O
a EP1730133A1 A DT O
selective EP1730133A1 A JJ O
β2-adrenoreceptor EP1730133A1 A JJ I-UN
agonist EP1730133A1 A NN O
is EP1730133A1 A VBZ O
indicated EP1730133A1 A VBN O
, EP1730133A1 A , O
for EP1730133A1 A IN O
example EP1730133A1 A NN O
asthma EP1730133A1 A NN O
or EP1730133A1 A CC O
chronic EP1730133A1 A JJ O
obstructive EP1730133A1 A JJ O
pulmonary EP1730133A1 A JJ O
disease EP1730133A1 A NN O
( EP1730133A1 A ( O
COPD EP1730133A1 A NNP O
) EP1730133A1 A ) O
. EP1730133A1 A . O

Atr WO2007046426A1 T NNP I-UN
inhibitor WO2007046426A1 T NN O
. WO2007046426A1 T . O

It WO2007046426A1 A PRP O
is WO2007046426A1 A VBZ O
intended WO2007046426A1 A VBN O
to WO2007046426A1 A TO O
provide WO2007046426A1 A VB O
an WO2007046426A1 A DT O
ATR WO2007046426A1 A NNP I-UN
inhibitor WO2007046426A1 A NN O
containing WO2007046426A1 A NN O
, WO2007046426A1 A , O
as WO2007046426A1 A IN O
the WO2007046426A1 A DT O
active WO2007046426A1 A JJ O
ingredient WO2007046426A1 A NN O
, WO2007046426A1 A , O
a WO2007046426A1 A DT O
tricyclic WO2007046426A1 A JJ O
compound WO2007046426A1 A NN O
selected WO2007046426A1 A VBN O
from WO2007046426A1 A IN O
among WO2007046426A1 A IN O
various WO2007046426A1 A JJ O
schizandrins WO2007046426A1 A NNS O
, WO2007046426A1 A , O
gomisins WO2007046426A1 A NNS O
and WO2007046426A1 A CC O
so WO2007046426A1 A RB O
on WO2007046426A1 A IN O
which WO2007046426A1 A WDT O
are WO2007046426A1 A VBP O
useful WO2007046426A1 A JJ O
as WO2007046426A1 A IN O
ATR WO2007046426A1 A NNP I-UN
protein WO2007046426A1 A NN O
kinase WO2007046426A1 A NN O
inhibitors WO2007046426A1 A NNS O
. WO2007046426A1 A . O

Slow CN1985958A T NNP O
released CN1985958A T VBD O
capsule CN1985958A T NN O
of CN1985958A T IN O
netilmicin CN1985958A T JJ O
sulfate CN1985958A T NN O
and CN1985958A T CC O
bletilla CN1985958A T NN O
tuber CN1985958A T VBP O
glue CN1985958A T NN O
for CN1985958A T IN O
animal CN1985958A T NN O
and CN1985958A T CC O
birds CN1985958A T NNS O
. CN1985958A T . O

Pharmaceutical EP2529728A1 T JJ O
compositions EP2529728A1 T NNS O
for EP2529728A1 T IN O
the EP2529728A1 T DT O
treatment EP2529728A1 T NN O
of EP2529728A1 T IN O
bacterial EP2529728A1 T JJ O
infections EP2529728A1 T NNS O
. EP2529728A1 T . O

Treatment US20060148810 T NN O
of US20060148810 T IN O
amm US20060148810 T NN O
. US20060148810 T . O

Spiro CN102796083A T NNP O
heterocyclic CN102796083A T JJ O
ketone CN102796083A T CD O
N-phenyl CN102796083A T JJ O
indole CN102796083A T NN O
compound CN102796083A T NN O
, CN102796083A T , O
its CN102796083A T PRP$ O
preparation CN102796083A T NN O
method CN102796083A T NN O
and CN102796083A T CC O
application CN102796083A T NN O
in CN102796083A T IN O
controlling CN102796083A T VBG O
cardiovascular CN102796083A T JJ O
diseases CN102796083A T NNS O
and CN102796083A T CC O
other CN102796083A T JJ O
medicine CN102796083A T NN O
fields CN102796083A T NNS O
. CN102796083A T . O

The CN102796083A A DT O
compound CN102796083A A NN O
is CN102796083A A VBZ O
formed CN102796083A A VBN O
by CN102796083A A IN O
organically CN102796083A A RB O
connecting CN102796083A A VBG O
spiro CN102796083A A JJ O
heterocycle CN102796083A A NN O
, CN102796083A A , O
indole CN102796083A A NN O
, CN102796083A A , O
phenyl CN102796083A A NN O
ring CN102796083A A NN O
and CN102796083A A CC O
tetrazole CN102796083A A NN O
, CN102796083A A , O
is CN102796083A A VBZ O
an CN102796083A A DT O
AT1 CN102796083A A NNP I-UN
type CN102796083A A NN O
acceptor CN102796083A A NN O
retarding CN102796083A A VBG O
agent CN102796083A A NN O
of CN102796083A A IN O
angiotensin CN102796083A A NN I-UN
II CN102796083A A NNP I-UN
, CN102796083A A , O
and CN102796083A A CC O
can CN102796083A A MD O
be CN102796083A A VB O
used CN102796083A A VBN O
for CN102796083A A IN O
preventing CN102796083A A VBG O
or CN102796083A A CC O
treating CN102796083A A VBG O
hypertension CN102796083A A NN O
, CN102796083A A , O
coronary CN102796083A A JJ O
heart CN102796083A A NN O
disease CN102796083A A NN O
, CN102796083A A , O
disease CN102796083A A NN O
in CN102796083A A IN O
blood CN102796083A A NN O
vessels CN102796083A A NNS O
of CN102796083A A IN O
heart CN102796083A A NN O
, CN102796083A A , O
brain CN102796083A A NN O
and CN102796083A A CC O
kidney CN102796083A A NN O
, CN102796083A A , O
hemicrania CN102796083A A NN O
, CN102796083A A , O
pulmonary CN102796083A A JJ O
hypertension CN102796083A A NN O
and CN102796083A A CC O
other CN102796083A A JJ O
diseases CN102796083A A NNS O
. CN102796083A A . O

Novel WO2006062094A1 T NNP O
cancer WO2006062094A1 T NN O
antigen WO2006062094A1 T NN O
peptide WO2006062094A1 T NN O
and WO2006062094A1 T CC O
the WO2006062094A1 T DT O
use WO2006062094A1 T NN O
thereof WO2006062094A1 T NN O
. WO2006062094A1 T . O

Medicine CN1887295A T NNP O
for CN1887295A T IN O
promoting CN1887295A T VBG O
healing CN1887295A T NN O
of CN1887295A T IN O
wound CN1887295A T NN O
. CN1887295A T . O

Boronic WO2013053372A1 T NNP O
acid WO2013053372A1 T NN O
inhibitors WO2013053372A1 T NNS O
of WO2013053372A1 T IN O
beta-lactamases WO2013053372A1 T NNS O
. WO2013053372A1 T . O

Administering US6884819 T VBG O
to US6884819 T TO O
a US6884819 T DT O
Alzheimer US6884819 T NNP O
's US6884819 T POS O
patient US6884819 T NN O
an US6884819 T DT O
effective US6884819 T JJ O
amount US6884819 T NN O
of US6884819 T IN O
a US6884819 T DT O
( US6884819 T ( O
15R US6884819 T CD O
) US6884819 T ) O
-isocarbacycline US6884819 T NN O
compound US6884819 T NN O
to US6884819 T TO O
treat US6884819 T VB O
the US6884819 T DT O
disease US6884819 T NN O
. US6884819 T . O

selenium US6992094 T NN O
nicotinic US6992094 T JJ O
acid US6992094 T NN O
tetrahyronaphthaline US6992094 T NN O
compounds US6992094 T VBZ O
; US6992094 T : O
treating US6992094 T VBG O
skin US6992094 T NN O
disorders US6992094 T NNS O
. US6992094 T . O

The US6992094 A DT O
invention US6992094 A NN O
concerns US6992094 A NNS O
novel US6992094 A JJ O
diarylselenide US6992094 A JJ O
compounds US6992094 A NNS O
corresponding US6992094 A VBG O
to US6992094 A TO O
the US6992094 A DT O
general US6992094 A JJ O
formula US6992094 A NN O
( US6992094 A ( O
I US6992094 A PRP O
) US6992094 A ) O
and US6992094 A CC O
the US6992094 A DT O
use US6992094 A NN O
thereof US6992094 A NN O
in US6992094 A IN O
pharmaceutical US6992094 A JJ O
compositions US6992094 A NNS O
in US6992094 A IN O
human US6992094 A JJ O
or US6992094 A CC O
veterinary US6992094 A JJ O
medicine US6992094 A NN O
( US6992094 A ( O
in US6992094 A IN O
the US6992094 A DT O
treatment US6992094 A NN O
of US6992094 A IN O
dermatological US6992094 A JJ O
, US6992094 A , O
rheumatic US6992094 A JJ O
, US6992094 A , O
cardiovascular US6992094 A JJ O
and US6992094 A CC O
ophthalmologic US6992094 A JJ O
pathologies US6992094 A NNS O
in US6992094 A IN O
particular US6992094 A JJ O
) US6992094 A ) O
, US6992094 A , O
or US6992094 A CC O
in US6992094 A IN O
cosmetic US6992094 A JJ O
compositions US6992094 A NNS O
. US6992094 A . O

Application CN101732310A T NN O
of CN101732310A T IN O
epothilone CN101732310A T NN O
B CN101732310A T NNP O
. CN101732310A T . O

Methods WO2014036608A1 T NNS O
and WO2014036608A1 T CC O
products WO2014036608A1 T NNS O
for WO2014036608A1 T IN O
preventing WO2014036608A1 T VBG O
and/or WO2014036608A1 T JJ O
treating WO2014036608A1 T VBG O
metastatic WO2014036608A1 T JJ O
cancer WO2014036608A1 T NN O
. WO2014036608A1 T . O

The WO2014036608A1 A DT O
method WO2014036608A1 A NN O
comprises WO2014036608A1 A VBZ O
administering WO2014036608A1 A VBG O
to WO2014036608A1 A TO O
the WO2014036608A1 A DT O
subject WO2014036608A1 A NN O
a WO2014036608A1 A DT O
therapeutically WO2014036608A1 A RB O
effective WO2014036608A1 A JJ O
amount WO2014036608A1 A NN O
of WO2014036608A1 A IN O
an WO2014036608A1 A DT O
inhibitor WO2014036608A1 A NN O
of WO2014036608A1 A IN O
a WO2014036608A1 A DT O
chemokine WO2014036608A1 A JJ I-UN
receptor WO2014036608A1 A NN I-UN
CCX-CKR WO2014036608A1 A NNP I-UN
. WO2014036608A1 A . O

Urapidil CN101721360A T NNP O
fructose CN101721360A T JJ O
injection CN101721360A T NN O
and CN101721360A T CC O
preparation CN101721360A T NN O
method CN101721360A T NN O
thereof CN101721360A T NN O
. CN101721360A T . O

The CN101721360A A DT O
invention CN101721360A A NN O
relates CN101721360A A VBZ O
to CN101721360A A TO O
an CN101721360A A DT O
urapidil CN101721360A A JJ O
fructose CN101721360A A JJ O
injection CN101721360A A NN O
and CN101721360A A CC O
a CN101721360A A DT O
preparation CN101721360A A NN O
method CN101721360A A NN O
thereof CN101721360A A NN O
. CN101721360A A . O

The CN101721360A A DT O
injection CN101721360A A NN O
consists CN101721360A A VBZ O
of CN101721360A A IN O
urapidil CN101721360A A JJ O
, CN101721360A A , O
fructose CN101721360A A JJ O
, CN101721360A A , O
water CN101721360A A NN O
for CN101721360A A IN O
injection CN101721360A A NN O
and CN101721360A A CC O
an CN101721360A A DT O
acidity CN101721360A A NN O
and CN101721360A A CC O
alkalinity CN101721360A A NN O
regulator CN101721360A A NN O
, CN101721360A A , O
wherein CN101721360A A VBP O
the CN101721360A A DT O
mass CN101721360A A NN O
and CN101721360A A CC O
volume CN101721360A A NN O
concentration CN101721360A A NN O
of CN101721360A A IN O
urapidil CN101721360A A JJ O
is CN101721360A A VBZ O
0.01-0.05 CN101721360A A JJ O
% CN101721360A A NN O
, CN101721360A A , O
the CN101721360A A DT O
mass CN101721360A A NN O
and CN101721360A A CC O
volume CN101721360A A NN O
concentration CN101721360A A NN O
of CN101721360A A IN O
fructose CN101721360A A JJ O
is CN101721360A A VBZ O
5-10 CN101721360A A JJ O
% CN101721360A A NN O
and CN101721360A A CC O
the CN101721360A A DT O
pH CN101721360A A NN O
value CN101721360A A NN O
is CN101721360A A VBZ O
3.1-6.1 CN101721360A A JJ O
. CN101721360A A . O

Compared CN101721360A A VBN O
with CN101721360A A IN O
the CN101721360A A DT O
traditional CN101721360A A JJ O
urapidil CN101721360A A JJ O
injection CN101721360A A NN O
, CN101721360A A , O
the CN101721360A A DT O
invention CN101721360A A NN O
has CN101721360A A VBZ O
the CN101721360A A DT O
advantages CN101721360A A NNS O
that CN101721360A A IN O
the CN101721360A A DT O
amount CN101721360A A NN O
of CN101721360A A IN O
insulin CN101721360A A NN O
in CN101721360A A IN O
vivo CN101721360A A NN O
of CN101721360A A IN O
a CN101721360A A DT O
patient CN101721360A A NN O
is CN101721360A A VBZ O
not CN101721360A A RB O
needed CN101721360A A VBN O
to CN101721360A A TO O
consider CN101721360A A VB O
when CN101721360A A WRB O
the CN101721360A A DT O
urapidil CN101721360A A JJ O
injection CN101721360A A NN O
is CN101721360A A VBZ O
applied CN101721360A A VBN O
, CN101721360A A , O
wherein CN101721360A A VBZ O
the CN101721360A A DT O
urapidil CN101721360A A JJ O
injection CN101721360A A NN O
is CN101721360A A VBZ O
particularly CN101721360A A RB O
suitable CN101721360A A JJ O
for CN101721360A A IN O
the CN101721360A A DT O
hypertension CN101721360A A NN O
patient CN101721360A A NN O
suffering CN101721360A A VBG O
from CN101721360A A IN O
diabetes CN101721360A A NNS O
and CN101721360A A CC O
the CN101721360A A DT O
hypertension CN101721360A A NN O
patient CN101721360A A NN O
in CN101721360A A IN O
a CN101721360A A DT O
perioperative CN101721360A A JJ O
period CN101721360A A NN O
; CN101721360A A : O
infection CN101721360A A NN O
and CN101721360A A CC O
pollution CN101721360A A NN O
in CN101721360A A IN O
the CN101721360A A DT O
intermediate CN101721360A A JJ O
link CN101721360A A NN O
in CN101721360A A IN O
the CN101721360A A DT O
use CN101721360A A NN O
process CN101721360A A NN O
of CN101721360A A IN O
the CN101721360A A DT O
traditional CN101721360A A JJ O
product CN101721360A A NN O
can CN101721360A A MD O
be CN101721360A A VB O
avoided CN101721360A A VBN O
in CN101721360A A IN O
the CN101721360A A DT O
process CN101721360A A NN O
of CN101721360A A IN O
applying CN101721360A A VBG O
the CN101721360A A DT O
urapidil CN101721360A A JJ O
injection CN101721360A A NN O
, CN101721360A A , O
thereby CN101721360A A RB O
the CN101721360A A DT O
urapidil CN101721360A A JJ O
injection CN101721360A A NN O
is CN101721360A A VBZ O
safer CN101721360A A JJR O
, CN101721360A A , O
faster CN101721360A A JJR O
and CN101721360A A CC O
more CN101721360A A RBR O
convenient CN101721360A A NN O
. CN101721360A A . O

The CN101721360A A DT O
preparation CN101721360A A NN O
method CN101721360A A NN O
of CN101721360A A IN O
the CN101721360A A DT O
urapidil CN101721360A A JJ O
fructose CN101721360A A JJ O
injection CN101721360A A NN O
has CN101721360A A VBZ O
simple CN101721360A A JJ O
operation CN101721360A A NN O
and CN101721360A A CC O
is CN101721360A A VBZ O
suitable CN101721360A A JJ O
for CN101721360A A IN O
industrial CN101721360A A JJ O
production CN101721360A A NN O
in CN101721360A A IN O
large CN101721360A A JJ O
scale CN101721360A A NN O
. CN101721360A A . O

Methods EP2180890A1 T NNS O
of EP2180890A1 T IN O
inhibiting EP2180890A1 T VBG O
or EP2180890A1 T CC O
suppressing EP2180890A1 T VBG O
cellular EP2180890A1 T JJ O
proliferation EP2180890A1 T NN O
. EP2180890A1 T . O

Compound CN102579626A T NNP O
aged-vinegar CN102579626A T JJ O
dropping CN102579626A T NN O
pill CN102579626A T NN O
and CN102579626A T CC O
preparation CN102579626A T NN O
method CN102579626A T NN O
thereof CN102579626A T NN O
. CN102579626A T . O

4- US7696208 T JJ O
( US7696208 T ( O
2-Pyridyl US7696208 T JJ O
) US7696208 T ) O
-1-amino US7696208 T NN O
( US7696208 T ( O
thio US7696208 T NN O
) US7696208 T ) O
carbonylpiperazine US7696208 T NN O
derivatives US7696208 T NNS O
are US7696208 T VBP O
inhibitors US7696208 T NNS O
of US7696208 T IN O
VR1 US7696208 T NNP I-UN
expression US7696208 T NN O
in US7696208 T IN O
a US7696208 T DT O
cell US7696208 T NN O
. US7696208 T . O

Method WO2006121968A3 T NNP O
for WO2006121968A3 T IN O
treatment WO2006121968A3 T NN O
of WO2006121968A3 T IN O
uterine WO2006121968A3 T JJ O
fibroid WO2006121968A3 T JJ O
tumors WO2006121968A3 T NNS O
. WO2006121968A3 T . O

Various WO2006121968A3 A JJ O
injectable WO2006121968A3 A JJ O
or WO2006121968A3 A CC O
insertable WO2006121968A3 A JJ O
uterine WO2006121968A3 A JJ O
fibroid WO2006121968A3 A NN O
treatment WO2006121968A3 A NN O
formulations WO2006121968A3 A NNS O
are WO2006121968A3 A VBP O
provided WO2006121968A3 A VBN O
, WO2006121968A3 A , O
which WO2006121968A3 A WDT O
comprise WO2006121968A3 A VBP O
a WO2006121968A3 A DT O
uterine WO2006121968A3 A JJ O
fibroid WO2006121968A3 A NN O
treatment WO2006121968A3 A NN O
agent WO2006121968A3 A NN O
in WO2006121968A3 A IN O
an WO2006121968A3 A DT O
amount WO2006121968A3 A NN O
effective WO2006121968A3 A JJ O
to WO2006121968A3 A TO O
cause WO2006121968A3 A VB O
shrinkage WO2006121968A3 A NN O
or WO2006121968A3 A CC O
elimination WO2006121968A3 A NN O
of WO2006121968A3 A IN O
uterine WO2006121968A3 A JJ O
fibroids WO2006121968A3 A NNS O
. WO2006121968A3 A . O

The WO2006121968A3 A DT O
injectable WO2006121968A3 A JJ O
or WO2006121968A3 A CC O
insertable WO2006121968A3 A JJ O
formulations WO2006121968A3 A NNS O
are WO2006121968A3 A VBP O
typically WO2006121968A3 A RB O
solids WO2006121968A3 A NNS O
, WO2006121968A3 A , O
semi-solids WO2006121968A3 A NNS O
or WO2006121968A3 A CC O
high-viscosity WO2006121968A3 A NN O
fluids WO2006121968A3 A NNS O
. WO2006121968A3 A . O

Other WO2006121968A3 A JJ O
aspects WO2006121968A3 A NNS O
of WO2006121968A3 A IN O
the WO2006121968A3 A DT O
invention WO2006121968A3 A NN O
are WO2006121968A3 A VBP O
directed WO2006121968A3 A VBN O
to WO2006121968A3 A TO O
systems WO2006121968A3 A NNS O
and WO2006121968A3 A CC O
methods WO2006121968A3 A NNS O
for WO2006121968A3 A IN O
treatment WO2006121968A3 A NN O
of WO2006121968A3 A IN O
uterine WO2006121968A3 A JJ O
fibroids WO2006121968A3 A NNS O
. WO2006121968A3 A . O

Esomeprazole CN103446065A T JJ O
sodium CN103446065A T NN O
freeze-dried CN103446065A T JJ O
powder CN103446065A T NN O
injection CN103446065A T NN O
for CN103446065A T IN O
injection CN103446065A T NN O
and CN103446065A T CC O
preparation CN103446065A T NN O
method CN103446065A T NN O
thereof CN103446065A T NN O
. CN103446065A T . O

Dipeptidyl WO2005095381A1 T NNP I-UN
peptidase WO2005095381A1 T NN I-UN
inhibitors WO2005095381A1 T NNS O
. WO2005095381A1 T . O

Compounds WO2005095381A1 A NNS O
, WO2005095381A1 A , O
pharmaceuticals WO2005095381A1 A NNS O
, WO2005095381A1 A , O
kits WO2005095381A1 A NNS O
and WO2005095381A1 A CC O
methods WO2005095381A1 A NNS O
are WO2005095381A1 A VBP O
provided WO2005095381A1 A VBN O
for WO2005095381A1 A IN O
use WO2005095381A1 A NN O
with WO2005095381A1 A IN O
DPP-IV WO2005095381A1 A NNP I-UN
and WO2005095381A1 A CC O
other WO2005095381A1 A JJ O
S9 WO2005095381A1 A NNP O
proteases WO2005095381A1 A NNS O
that WO2005095381A1 A WDT O
comprise WO2005095381A1 A VBP O
a WO2005095381A1 A DT O
compound WO2005095381A1 A NN O
comprising WO2005095381A1 A VBG O
Formula WO2005095381A1 A NNP O
( WO2005095381A1 A ( O
I WO2005095381A1 A PRP O
) WO2005095381A1 A ) O
: WO2005095381A1 A : O
& WO2005095381A1 A CC O
num WO2005095381A1 A NN O
; WO2005095381A1 A : O
& WO2005095381A1 A CC O
num WO2005095381A1 A NN O
; WO2005095381A1 A : O
STR1 WO2005095381A1 A NNP O
& WO2005095381A1 A CC O
num WO2005095381A1 A NN O
; WO2005095381A1 A : O
& WO2005095381A1 A CC O
num WO2005095381A1 A NN O
; WO2005095381A1 A : O
wherein WO2005095381A1 A CC O
M WO2005095381A1 A NNP O
is WO2005095381A1 A VBZ O
N WO2005095381A1 A NNP O
or WO2005095381A1 A CC O
CR4 WO2005095381A1 A NNP O
; WO2005095381A1 A : O
Q1 WO2005095381A1 A NNP O
and WO2005095381A1 A CC O
Q2 WO2005095381A1 A NNP O
are WO2005095381A1 A VBP O
each WO2005095381A1 A DT O
independently WO2005095381A1 A RB O
selected WO2005095381A1 A VBN O
from WO2005095381A1 A IN O
the WO2005095381A1 A DT O
group WO2005095381A1 A NN O
consisting WO2005095381A1 A VBG O
of WO2005095381A1 A IN O
CO WO2005095381A1 A NNP O
, WO2005095381A1 A , O
SO WO2005095381A1 A NNP O
, WO2005095381A1 A , O
SO2 WO2005095381A1 A NNP O
, WO2005095381A1 A , O
and WO2005095381A1 A CC O
C=NR9 WO2005095381A1 A NNP O
; WO2005095381A1 A : O
and WO2005095381A1 A CC O
each WO2005095381A1 A DT O
R1 WO2005095381A1 A NNP O
, WO2005095381A1 A , O
R2 WO2005095381A1 A NNP O
, WO2005095381A1 A , O
R3 WO2005095381A1 A NNP O
, WO2005095381A1 A , O
R4 WO2005095381A1 A NNP O
and WO2005095381A1 A CC O
R9 WO2005095381A1 A NNP O
are WO2005095381A1 A VBP O
as WO2005095381A1 A IN O
defined WO2005095381A1 A JJ O
herein WO2005095381A1 A NN O
. WO2005095381A1 A . O

Analgesic CN1990003A T JJ O
applying CN1990003A T VBG O
agent CN1990003A T NN O
special CN1990003A T JJ O
for CN1990003A T IN O
athlete CN1990003A T NN O
. CN1990003A T . O

The CN1990003A A DT O
invention CN1990003A A NN O
relates CN1990003A A VBZ O
to CN1990003A A TO O
a CN1990003A A DT O
liniment CN1990003A A NN O
for CN1990003A A IN O
athletes CN1990003A A NNS O
, CN1990003A A , O
wherein CN1990003A A VBP O
the CN1990003A A DT O
main CN1990003A A JJ O
constituents CN1990003A A NNS O
include CN1990003A A VBP O
olive CN1990003A A JJ O
oil CN1990003A A NN O
, CN1990003A A , O
isopropanol CN1990003A A NN O
, CN1990003A A , O
mustard CN1990003A A RB O
seed CN1990003A A NN O
oil CN1990003A A NN O
, CN1990003A A , O
camphor CN1990003A A NN O
and CN1990003A A CC O
menthanol CN1990003A A NN O
, CN1990003A A , O
and CN1990003A A CC O
the CN1990003A A DT O
medicament CN1990003A A NN O
is CN1990003A A VBZ O
prepared CN1990003A A VBN O
through CN1990003A A IN O
specific CN1990003A A JJ O
processes CN1990003A A NNS O
. CN1990003A A . O

Antifungal WO2013002439A1 T NNP O
composition WO2013002439A1 T NN O
comprising WO2013002439A1 T VBG O
cis-cyclo WO2013002439A1 T JJ O
( WO2013002439A1 T ( O
l-phe-l-pro WO2013002439A1 T JJ O
) WO2013002439A1 T ) O
having WO2013002439A1 T VBG O
genus WO2013002439A1 T VBN O
ganoderma WO2013002439A1 T JJ O
fungus-specific WO2013002439A1 T JJ O
antifungal WO2013002439A1 T JJ O
activity WO2013002439A1 T NN O
. WO2013002439A1 T . O

Novel WO2009066009A1 T NNP O
4,5-dihydroisoxazoles WO2009066009A1 T NNS O
with WO2009066009A1 T IN O
estrogenic WO2009066009A1 T JJ O
activity WO2009066009A1 T NN O
. WO2009066009A1 T . O

This WO2009066009A1 A DT O
invention WO2009066009A1 A NN O
relates WO2009066009A1 A VBZ O
to WO2009066009A1 A TO O
novel WO2009066009A1 A VB O
4,5-dihydroisoxazoles WO2009066009A1 A NNS O
of WO2009066009A1 A IN O
formula WO2009066009A1 A NN O
( WO2009066009A1 A ( O
I WO2009066009A1 A PRP O
) WO2009066009A1 A ) O
, WO2009066009A1 A , O
to WO2009066009A1 A TO O
their WO2009066009A1 A PRP$ O
use WO2009066009A1 A NN O
as WO2009066009A1 A IN O
estrogen WO2009066009A1 A NN I-UN
receptor WO2009066009A1 A NN I-UN
modulators WO2009066009A1 A NNS O
, WO2009066009A1 A , O
and WO2009066009A1 A CC O
to WO2009066009A1 A TO O
methods WO2009066009A1 A NNS O
of WO2009066009A1 A IN O
their WO2009066009A1 A PRP$ O
preparation WO2009066009A1 A NN O
. WO2009066009A1 A . O

Fluorinated US20100209345 T VBN O
Ligands US20100209345 T NNS O
for US20100209345 T IN O
Targeting US20100209345 T VBG O
Peripheral US20100209345 T NNP I-UN
Benzodiazepine US20100209345 T NNP I-UN
Receptors US20100209345 T NNP I-UN
. US20100209345 T . O

The US20100209345 A DT O
invention US20100209345 A NN O
provides US20100209345 A VBZ O
fluorinated US20100209345 A JJ O
compounds US20100209345 A NNS O
of US20100209345 A IN O
formula US20100209345 A NN O
( US20100209345 A ( O
I US20100209345 A PRP O
) US20100209345 A ) O
: US20100209345 A : O
The US20100209345 A DT O
compounds US20100209345 A NNS O
may US20100209345 A MD O
be US20100209345 A VB O
used US20100209345 A VBN O
in US20100209345 A IN O
diagnosis US20100209345 A NN O
or US20100209345 A CC O
treatment US20100209345 A NN O
of US20100209345 A IN O
a US20100209345 A DT O
disorder US20100209345 A NN O
in US20100209345 A IN O
a US20100209345 A DT O
mammal US20100209345 A NN O
characterised US20100209345 A VBN O
by US20100209345 A IN O
an US20100209345 A DT O
abnormal US20100209345 A JJ O
density US20100209345 A NN O
of US20100209345 A IN O
peripheral US20100209345 A JJ I-UN
benzodiazepine US20100209345 A NN I-UN
receptors US20100209345 A NNS I-UN
. US20100209345 A . O

Composition CN101810616A T NN O
containing CN101810616A T VBG O
potassium CN101810616A T NN O
sodium CN101810616A T NN O
dehydroandroan CN101810616A T NN O
drographolide CN101810616A T NN O
succinate CN101810616A T NN O
. CN101810616A T . O

Composition CN101698016B T NN O
for CN101698016B T IN O
treating CN101698016B T VBG O
cattle CN101698016B T NNS O
omasum CN101698016B T JJ O
obstruction CN101698016B T NN O
and CN101698016B T CC O
preparation CN101698016B T NN O
method CN101698016B T NN O
thereof CN101698016B T NN O
. CN101698016B T . O

Aspirin CN2798942Y T NNP O
dipyridamole CN2798942Y T JJ O
slow-release CN2798942Y T JJ O
tablet CN2798942Y T NN O
. CN2798942Y T . O

Methods US20110015249 T NNS O
and US20110015249 T CC O
compositions US20110015249 T NNS O
for US20110015249 T IN O
treatment US20110015249 T NN O
of US20110015249 T IN O
cancer US20110015249 T NN O
and US20110015249 T CC O
other US20110015249 T JJ O
angiogenesis-related US20110015249 T JJ O
diseases US20110015249 T NNS O
. US20110015249 T . O

Triterpenoid CN102614195A T NNP O
composition CN102614195A T NN O
of CN102614195A T IN O
antrodia CN102614195A T NN O
cinnamomea CN102614195A T NN O
, CN102614195A T , O
preparation CN102614195A T NN O
and CN102614195A T CC O
analysis CN102614195A T NN O
method CN102614195A T NN O
thereof CN102614195A T NN O
. CN102614195A T . O

Heterocyclic WO2014125444A1 T NNP O
amides WO2014125444A1 T VBZ O
as WO2014125444A1 T IN O
kinase WO2014125444A1 T NN I-UN
inhibitors WO2014125444A1 T NNS O
. WO2014125444A1 T . O

Mirna WO2012096573A1 T NNP O
for WO2012096573A1 T IN O
treating WO2012096573A1 T VBG O
diseases WO2012096573A1 T NNS O
and WO2012096573A1 T CC O
conditions WO2012096573A1 T NNS O
associated WO2012096573A1 T VBN O
with WO2012096573A1 T IN O
neo-angiogenesis WO2012096573A1 T NN O
. WO2012096573A1 T . O

Inclusion CN1977975A T NNP O
puerarin/cyclodextrin CN1977975A T POS O
composition CN1977975A T NN O
and CN1977975A T CC O
its CN1977975A T PRP$ O
preparing CN1977975A T NN O
method CN1977975A T NN O
. CN1977975A T . O

( WO2005100363A8 T ( O
poly WO2005100363A8 T NN O
) WO2005100363A8 T ) O
aminoacetamide WO2005100363A8 T IN O
derivatives WO2005100363A8 T NNS O
of WO2005100363A8 T IN O
epipodophyllotoxin WO2005100363A8 T VBP O
their WO2005100363A8 T PRP$ O
process WO2005100363A8 T NN O
of WO2005100363A8 T IN O
preparation WO2005100363A8 T NN O
and WO2005100363A8 T CC O
their WO2005100363A8 T PRP$ O
applications WO2005100363A8 T NNS O
in WO2005100363A8 T IN O
therapeutics WO2005100363A8 T NNS O
as WO2005100363A8 T IN O
anticancer WO2005100363A8 T NN O
agents WO2005100363A8 T NNS O
. WO2005100363A8 T . O

Anion WO2008001442A1 T NNP O
adsorbent WO2008001442A1 T NN O
, WO2008001442A1 T , O
water WO2008001442A1 T NN O
or WO2008001442A1 T CC O
soil WO2008001442A1 T NN O
cleanup WO2008001442A1 T NN O
agent WO2008001442A1 T NN O
and WO2008001442A1 T CC O
process WO2008001442A1 T NN O
for WO2008001442A1 T IN O
producing WO2008001442A1 T VBG O
the WO2008001442A1 T DT O
same WO2008001442A1 T JJ O
. WO2008001442A1 T . O

AMINO-IMIDAZOLONES WO2006076284A3 T NNP O
FOR WO2006076284A3 T NNP O
THE WO2006076284A3 T NNP O
INHIBITION WO2006076284A3 T NNP O
OF WO2006076284A3 T IN O
ß-SECRETASE WO2006076284A3 T NNP I-UN
. WO2006076284A3 T . O

Also WO2006076284A3 A RB O
provided WO2006076284A3 A VBN O
are WO2006076284A3 A VBP O
compositions WO2006076284A3 A NNS O
and WO2006076284A3 A CC O
methods WO2006076284A3 A NNS O
for WO2006076284A3 A IN O
the WO2006076284A3 A DT O
use WO2006076284A3 A NN O
thereof WO2006076284A3 A NN O
to WO2006076284A3 A TO O
inhibit WO2006076284A3 A VB O
β-secretase WO2006076284A3 A JJ I-UN
( WO2006076284A3 A ( O
BACE WO2006076284A3 A NNP I-UN
) WO2006076284A3 A ) O
and WO2006076284A3 A CC O
treat WO2006076284A3 A JJ O
β-amyloid WO2006076284A3 A JJ I-UN
deposits WO2006076284A3 A NNS O
and WO2006076284A3 A CC O
neurofibrillary WO2006076284A3 A JJ O
tangles WO2006076284A3 A NNS O
. WO2006076284A3 A . O

Eutectic CN102898438A T NNP O
of CN102898438A T IN O
Piperacillin CN102898438A T NNP O
sodium CN102898438A T NN O
and CN102898438A T CC O
Sulbactam CN102898438A T NNP O
sodium CN102898438A T NN O
, CN102898438A T , O
preparation CN102898438A T NN O
method CN102898438A T NN O
thereof CN102898438A T NN O
, CN102898438A T , O
pharmaceutical CN102898438A T JJ O
composition CN102898438A T NN O
containing CN102898438A T VBG O
eutectic CN102898438A T JJ O
and CN102898438A T CC O
application CN102898438A T NN O
of CN102898438A T IN O
pharmaceutical CN102898438A T JJ O
composition CN102898438A T NN O
. CN102898438A T . O

Medicine CN101019905A T NNP O
composition CN101019905A T NN O
containing CN101019905A T VBG O
tribulus CN101019905A T CC O
fruit CN101019905A T JJ O
furostanol CN101019905A T NN O
saponin CN101019905A T NN O
and CN101019905A T CC O
its CN101019905A T PRP$ O
application CN101019905A T NN O
. CN101019905A T . O

Polycyclic WO2005121126A1 T NNP O
pyrazines WO2005121126A1 T NNS O
as WO2005121126A1 T IN O
potassium WO2005121126A1 T NN I-UN
ion WO2005121126A1 T NN I-UN
channel WO2005121126A1 T NN I-UN
modulators WO2005121126A1 T NNS O
. WO2005121126A1 T . O

The WO2005121126A1 A DT O
present WO2005121126A1 A JJ O
invention WO2005121126A1 A NN O
provides WO2005121126A1 A VBZ O
a WO2005121126A1 A DT O
genus WO2005121126A1 A NN O
of WO2005121126A1 A IN O
polycyclic WO2005121126A1 A JJ O
pyrazines WO2005121126A1 A NNS O
of WO2005121126A1 A IN O
formula WO2005121126A1 A NN O
I WO2005121126A1 A PRP O
( WO2005121126A1 A ( O
I WO2005121126A1 A PRP O
) WO2005121126A1 A ) O
that WO2005121126A1 A WDT O
are WO2005121126A1 A VBP O
useful WO2005121126A1 A JJ O
as WO2005121126A1 A IN O
modulators WO2005121126A1 A NNS O
of WO2005121126A1 A IN O
potassium WO2005121126A1 A NN I-UN
ion WO2005121126A1 A NN I-UN
channels WO2005121126A1 A NNS O
. WO2005121126A1 A . O

Intraesophageal WO2012068081A1 T NNP O
administration WO2012068081A1 T NN O
of WO2012068081A1 T IN O
targeted WO2012068081A1 T JJ O
nitroxide WO2012068081A1 T JJ O
agents WO2012068081A1 T NNS O
for WO2012068081A1 T IN O
protection WO2012068081A1 T NN O
against WO2012068081A1 T IN O
ionizing WO2012068081A1 T VBG O
irradiation-induced WO2012068081A1 T JJ O
esophagatis WO2012068081A1 T NN O
. WO2012068081A1 T . O

Anti-april EP1255558B1 T JJ O
antibodies EP1255558B1 T NNS O
and EP1255558B1 T CC O
hybridoma EP1255558B1 T NN O
cells EP1255558B1 T NNS O
. EP1255558B1 T . O

Methods EP1255558B1 A NNS O
of EP1255558B1 A IN O
using EP1255558B1 A VBG O
one EP1255558B1 A CD O
or EP1255558B1 A CC O
more EP1255558B1 A JJR O
agonists EP1255558B1 A NNS O
or EP1255558B1 A CC O
antagonists EP1255558B1 A NNS O
to EP1255558B1 A TO O
modulate EP1255558B1 A VB O
activity EP1255558B1 A NN O
of EP1255558B1 A IN O
the EP1255558B1 A DT O
members EP1255558B1 A NNS O
of EP1255558B1 A IN O
the EP1255558B1 A DT O
TNF EP1255558B1 A NNP I-UN
and EP1255558B1 A CC O
TNFR EP1255558B1 A NNP O
families EP1255558B1 A NNS O
referred EP1255558B1 A VBD O
to EP1255558B1 A TO O
as EP1255558B1 A IN O
TALL-1 EP1255558B1 A NNP I-UN
, EP1255558B1 A , O
APRIL EP1255558B1 A NNP I-UN
, EP1255558B1 A , O
TACI EP1255558B1 A NNP I-UN
, EP1255558B1 A , O
and EP1255558B1 A CC O
BCMA EP1255558B1 A NNP I-UN
are EP1255558B1 A VBP O
provided EP1255558B1 A VBN O
. EP1255558B1 A . O

The EP1255558B1 A DT O
methods EP1255558B1 A NNS O
include EP1255558B1 A VBP O
in EP1255558B1 A IN O
vitro EP1255558B1 A NN O
, EP1255558B1 A , O
in EP1255558B1 A IN O
situ EP1255558B1 A NN O
, EP1255558B1 A , O
and/or EP1255558B1 A NN O
in EP1255558B1 A IN O
vivo EP1255558B1 A JJ O
diagnosis EP1255558B1 A NN O
and/or EP1255558B1 A NN O
treatment EP1255558B1 A NN O
of EP1255558B1 A IN O
mammalian EP1255558B1 A JJ O
cells EP1255558B1 A NNS O
or EP1255558B1 A CC O
pathological EP1255558B1 A JJ O
conditions EP1255558B1 A NNS O
associated EP1255558B1 A VBN O
with EP1255558B1 A IN O
TALL-1 EP1255558B1 A NNP I-UN
, EP1255558B1 A , O
APRIL EP1255558B1 A NNP I-UN
, EP1255558B1 A , O
TACI EP1255558B1 A NNP I-UN
, EP1255558B1 A , O
or EP1255558B1 A CC O
BCMA EP1255558B1 A NNP I-UN
, EP1255558B1 A , O
using EP1255558B1 A VBG O
one EP1255558B1 A CD O
or EP1255558B1 A CC O
more EP1255558B1 A JJR O
agonist EP1255558B1 A NN O
or EP1255558B1 A CC O
antagonist EP1255558B1 A NN O
molecules EP1255558B1 A NNS O
. EP1255558B1 A . O

Pro-drugs US20110172193 T NNS O
of US20110172193 T IN O
( US20110172193 T ( O
e US20110172193 T NN O
) US20110172193 T ) O
-7- US20110172193 T NN O
( US20110172193 T ( O
3- US20110172193 T JJ O
( US20110172193 T ( O
2-amino-1-fluoroethylidene US20110172193 T JJ O
) US20110172193 T ) O
piperidin-1-yl US20110172193 T NN O
) US20110172193 T ) O
-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic US20110172193 T JJ O
acid US20110172193 T NN O
. US20110172193 T . O

Pyrrolidinium CN101087777B T NN O
derivatives CN101087777B T NNS O
as CN101087777B T IN O
M3 CN101087777B T NNP I-UN
muscarinic CN101087777B T JJ I-UN
receptors CN101087777B T NNS I-UN
. CN101087777B T . O

Compounds CN101087777B A NNS O
of CN101087777B A IN O
formula CN101087777B A NN O
( CN101087777B A ( O
I CN101087777B A PRP O
) CN101087777B A ) O
in CN101087777B A IN O
salt CN101087777B A NN O
or CN101087777B A CC O
zwitterionic CN101087777B A JJ O
form CN101087777B A NN O
, CN101087777B A , O
wherein CN101087777B A WP O
R CN101087777B A NNP O
< CN101087777B A VBD O
1 CN101087777B A CD O
> CN101087777B A NN O
, CN101087777B A , O
R CN101087777B A NNP O
< CN101087777B A VBZ O
2 CN101087777B A CD O
> CN101087777B A NN O
, CN101087777B A , O
R CN101087777B A NNP O
< CN101087777B A VBZ O
3 CN101087777B A CD O
> CN101087777B A NN O
, CN101087777B A , O
R CN101087777B A NNP O
< CN101087777B A VBZ O
4 CN101087777B A CD O
> CN101087777B A NN O
and CN101087777B A CC O
R CN101087777B A NNP O
< CN101087777B A NNP O
5 CN101087777B A CD O
> CN101087777B A NNS O
have CN101087777B A VBP O
the CN101087777B A DT O
meanings CN101087777B A NNS O
as CN101087777B A IN O
indicated CN101087777B A VBN O
in CN101087777B A IN O
the CN101087777B A DT O
specification CN101087777B A NN O
, CN101087777B A , O
are CN101087777B A VBP O
useful CN101087777B A JJ O
for CN101087777B A IN O
treating CN101087777B A VBG O
conditions CN101087777B A NNS O
that CN101087777B A WDT O
are CN101087777B A VBP O
mediated CN101087777B A VBN O
by CN101087777B A IN O
the CN101087777B A DT O
muscarinic CN101087777B A JJ I-UN
M3 CN101087777B A NNP I-UN
receptor CN101087777B A NN I-UN
. CN101087777B A . O

Tricyclic WO2012085176A1 T NNP O
pyrazinone WO2012085176A1 T NN O
compounds WO2012085176A1 T NNS O
, WO2012085176A1 T , O
compositions WO2012085176A1 T NNS O
and WO2012085176A1 T CC O
methods WO2012085176A1 T NNS O
of WO2012085176A1 T IN O
use WO2012085176A1 T NN O
thereof WO2012085176A1 T NN O
as WO2012085176A1 T IN O
janus WO2012085176A1 T NN O
kinase WO2012085176A1 T NN O
inhibitors WO2012085176A1 T NNS O
. WO2012085176A1 T . O

The WO2012085176A1 A DT O
invention WO2012085176A1 A NN O
provides WO2012085176A1 A VBZ O
novel WO2012085176A1 A JJ O
compounds WO2012085176A1 A NNS O
of WO2012085176A1 A IN O
formula WO2012085176A1 A NN O
I WO2012085176A1 A PRP O
having WO2012085176A1 A VBG O
the WO2012085176A1 A DT O
general WO2012085176A1 A JJ O
formula WO2012085176A1 A NN O
( WO2012085176A1 A ( O
I WO2012085176A1 A PRP O
) WO2012085176A1 A ) O
wherein WO2012085176A1 A NN O
X WO2012085176A1 A NNP O
, WO2012085176A1 A , O
R1 WO2012085176A1 A NNP O
, WO2012085176A1 A , O
R2 WO2012085176A1 A NNP O
, WO2012085176A1 A , O
R3 WO2012085176A1 A NNP O
and WO2012085176A1 A CC O
R5 WO2012085176A1 A NNP O
are WO2012085176A1 A VBP O
as WO2012085176A1 A IN O
described WO2012085176A1 A JJ O
herein WO2012085176A1 A NN O
. WO2012085176A1 A . O

Accordingly WO2012085176A1 A RB O
, WO2012085176A1 A , O
the WO2012085176A1 A DT O
compounds WO2012085176A1 A NNS O
may WO2012085176A1 A MD O
be WO2012085176A1 A VB O
provided WO2012085176A1 A VBN O
in WO2012085176A1 A IN O
pharmaceutically WO2012085176A1 A RB O
acceptable WO2012085176A1 A JJ O
compositions WO2012085176A1 A NNS O
and WO2012085176A1 A CC O
used WO2012085176A1 A VBN O
for WO2012085176A1 A IN O
the WO2012085176A1 A DT O
treatment WO2012085176A1 A NN O
of WO2012085176A1 A IN O
immunological WO2012085176A1 A JJ O
or WO2012085176A1 A CC O
hyperproliferative WO2012085176A1 A JJ O
disorders WO2012085176A1 A NNS O
. WO2012085176A1 A . O

New EP2141164A1 T NNP O
1,2,4-triazine EP2141164A1 T JJ O
derivatives EP2141164A1 T NNS O
and EP2141164A1 T CC O
biological EP2141164A1 T JJ O
applications EP2141164A1 T NNS O
thereof EP2141164A1 T NN O
. EP2141164A1 T . O

Rxr-ppargamma WO2010070379A1 T JJ O
agonist/growth WO2010070379A1 T NN O
factor WO2010070379A1 T NN I-UN
inhibitor WO2010070379A1 T NN O
combination WO2010070379A1 T NN O
therapy WO2010070379A1 T NN O
for WO2010070379A1 T IN O
inducing WO2010070379A1 T VBG O
apoptosis WO2010070379A1 T NN O
and WO2010070379A1 T CC O
the WO2010070379A1 T DT O
treatment WO2010070379A1 T NN O
of WO2010070379A1 T IN O
cancer WO2010070379A1 T NN O
. WO2010070379A1 T . O

The WO2010070379A1 A DT O
present WO2010070379A1 A JJ O
invention WO2010070379A1 A NN O
relates WO2010070379A1 A VBZ O
to WO2010070379A1 A TO O
novel WO2010070379A1 A VB O
anti-cancer WO2010070379A1 A JJ O
treatments WO2010070379A1 A NNS O
and WO2010070379A1 A CC O
compositions WO2010070379A1 A NNS O
using WO2010070379A1 A VBG O
combinations WO2010070379A1 A NNS O
of WO2010070379A1 A IN O
at WO2010070379A1 A IN O
least WO2010070379A1 A JJS O
one WO2010070379A1 A CD O
agonist WO2010070379A1 A NN O
of WO2010070379A1 A IN O
the WO2010070379A1 A DT O
RXR-PPARγ WO2010070379A1 A JJ O
heterodimer WO2010070379A1 A NN O
complex WO2010070379A1 A NN O
selected WO2010070379A1 A VBN O
in WO2010070379A1 A IN O
the WO2010070379A1 A DT O
group WO2010070379A1 A NN O
consisting WO2010070379A1 A VBG O
of WO2010070379A1 A IN O
a WO2010070379A1 A DT O
RXRα WO2010070379A1 A NNP I-UN
agonist WO2010070379A1 A NN O
, WO2010070379A1 A , O
a WO2010070379A1 A DT O
RXRβ WO2010070379A1 A NNP I-UN
agonist WO2010070379A1 A NN O
, WO2010070379A1 A , O
a WO2010070379A1 A DT O
RXRγ WO2010070379A1 A NNP I-UN
agonist WO2010070379A1 A NN O
, WO2010070379A1 A , O
a WO2010070379A1 A DT O
PPARγ WO2010070379A1 A NNP I-UN
agonist WO2010070379A1 A NN O
or WO2010070379A1 A CC O
a WO2010070379A1 A DT O
RXR-PPARγ WO2010070379A1 A JJ O
heterodimer WO2010070379A1 A NN O
agonist WO2010070379A1 A NN O
and WO2010070379A1 A CC O
a WO2010070379A1 A DT O
growth WO2010070379A1 A NN O
factor WO2010070379A1 A NN O
inhibitor WO2010070379A1 A NN O
. WO2010070379A1 A . O

Diniconazole-1,2,3-triazole CN103058943A T NNP O
compound CN103058943A T NN O
having CN103058943A T VBG O
antibacterial CN103058943A T JJ O
activity CN103058943A T NN O
, CN103058943A T , O
and CN103058943A T CC O
its CN103058943A T PRP$ O
preparation CN103058943A T NN O
method CN103058943A T NN O
. CN103058943A T . O

Process US20100286089 T NN O
for US20100286089 T IN O
the US20100286089 T DT O
Preparation US20100286089 T NNP O
of US20100286089 T IN O
Entecavir US20100286089 T NNP O
and US20100286089 T CC O
Novel US20100286089 T NNP O
Intermediates US20100286089 T NNP O
Thereof US20100286089 T NNP O
Via US20100286089 T NNP O
Carbon-Silicon US20100286089 T NNP O
Oxidation US20100286089 T NNP O
. US20100286089 T . O

Diclofenac US7166641 T NNP O
salt US7166641 T NN O
of US7166641 T IN O
lidocaine US7166641 T NN O
. US7166641 T . O

The US7166641 A DT O
present US7166641 A JJ O
invention US7166641 A NN O
provides US7166641 A VBZ O
pharmaceutically US7166641 A RB O
acceptable US7166641 A JJ O
salts US7166641 A NNS O
having US7166641 A VBG O
local US7166641 A JJ O
anesthetic US7166641 A JJ O
and US7166641 A CC O
anti-inflammatory US7166641 A JJ O
activities US7166641 A NNS O
. US7166641 A . O

The US7166641 A DT O
preferred US7166641 A JJ O
pharmaceutically US7166641 A RB O
acceptable US7166641 A JJ O
salt US7166641 A NN O
is US7166641 A VBZ O
a US7166641 A DT O
diclofenac US7166641 A JJ O
salt US7166641 A NN O
of US7166641 A IN O
lidocaine US7166641 A NN O
. US7166641 A . O

Diclofenac US7166641 A NNP O
is US7166641 A VBZ O
a US7166641 A DT O
non-steroidal US7166641 A JJ O
anti-inflammatory US7166641 A JJ O
drug US7166641 A NN O
( US7166641 A ( O
“NSAID” US7166641 A NNP O
) US7166641 A ) O
. US7166641 A . O

Lidocaine US7166641 A NNP O
is US7166641 A VBZ O
a US7166641 A DT O
local US7166641 A JJ O
anesthetic US7166641 A NN O
. US7166641 A . O

Other US7166641 A JJ O
NSAID US7166641 A NNP O
( US7166641 A ( O
except US7166641 A IN O
the US7166641 A DT O
salicylic US7166641 A JJ O
acid US7166641 A NN O
derivatives US7166641 A NNS O
of US7166641 A IN O
NSAID US7166641 A NNP O
) US7166641 A ) O
can US7166641 A MD O
be US7166641 A VB O
used US7166641 A VBN O
to US7166641 A TO O
replace US7166641 A VB O
diclofenac US7166641 A JJ O
and/or US7166641 A IN O
other US7166641 A JJ O
local US7166641 A JJ O
anesthetics US7166641 A NNS O
can US7166641 A MD O
be US7166641 A VB O
used US7166641 A VBN O
to US7166641 A TO O
replace US7166641 A VB O
lidocaine US7166641 A NN O
. US7166641 A . O

The US7166641 A DT O
pharmaceutically US7166641 A RB O
acceptable US7166641 A JJ O
salts US7166641 A NNS O
are US7166641 A VBP O
crystalline US7166641 A JJ O
compounds US7166641 A NNS O
, US7166641 A , O
which US7166641 A WDT O
are US7166641 A VBP O
distinctively US7166641 A RB O
different US7166641 A JJ O
from US7166641 A IN O
either US7166641 A CC O
the US7166641 A DT O
NSAID US7166641 A NNP O
alone US7166641 A RB O
or US7166641 A CC O
the US7166641 A DT O
local US7166641 A JJ O
anesthetic US7166641 A JJ O
alone US7166641 A RB O
, US7166641 A , O
as US7166641 A IN O
indicated US7166641 A VBN O
by US7166641 A IN O
differential US7166641 A JJ O
scanning US7166641 A VBG O
calorimetry US7166641 A NN O
( US7166641 A ( O
DSC US7166641 A NNP O
) US7166641 A ) O
, US7166641 A , O
thermogravimetric US7166641 A JJ O
analysis US7166641 A NN O
( US7166641 A ( O
TGA US7166641 A NNP O
) US7166641 A ) O
, US7166641 A , O
High US7166641 A JJ O
Performance US7166641 A NNP O
Liquid US7166641 A NNP O
Chromatography US7166641 A NNP O
( US7166641 A ( O
HPLC US7166641 A NNP O
) US7166641 A ) O
and US7166641 A CC O
Fourier-Transformed US7166641 A NNP O
Infrared US7166641 A NNP O
Spectroscopy US7166641 A NNP O
( US7166641 A ( O
FTIR US7166641 A NNP O
) US7166641 A ) O
analyses US7166641 A VBZ O
. US7166641 A . O

These US7166641 A DT O
pharmaceutically US7166641 A RB O
acceptable US7166641 A JJ O
salts US7166641 A NNS O
are US7166641 A VBP O
suitable US7166641 A JJ O
for US7166641 A IN O
use US7166641 A NN O
in US7166641 A IN O
topical US7166641 A JJ O
treatment US7166641 A NN O
or US7166641 A CC O
parenteral US7166641 A JJ O
injection US7166641 A NN O
to US7166641 A TO O
treat US7166641 A VB O
patients US7166641 A NNS O
with US7166641 A IN O
localized US7166641 A JJ O
pain US7166641 A NN O
, US7166641 A , O
including US7166641 A VBG O
muscle US7166641 A NN O
pain US7166641 A NN O
, US7166641 A , O
joint US7166641 A JJ O
pain US7166641 A NN O
, US7166641 A , O
pain US7166641 A NN O
associated US7166641 A VBN O
with US7166641 A IN O
herpes US7166641 A NNS O
infection US7166641 A NN O
, US7166641 A , O
and US7166641 A CC O
wound US7166641 A NN O
pain US7166641 A NN O
( US7166641 A ( O
such US7166641 A JJ O
as US7166641 A IN O
surgical US7166641 A JJ O
wound US7166641 A NN O
, US7166641 A , O
burn US7166641 A VBP O
wound US7166641 A JJ O
etc US7166641 A NN O
. US7166641 A . O

) US7166641 A ) O
. US7166641 A . O

New CA2765919A1 T NNP O
antiviral CA2765919A1 T JJ O
compounds CA2765919A1 T NNS O
useful CA2765919A1 T JJ O
for CA2765919A1 T IN O
the CA2765919A1 T DT O
treatment CA2765919A1 T NN O
or CA2765919A1 T CC O
the CA2765919A1 T DT O
prevention CA2765919A1 T NN O
of CA2765919A1 T IN O
epidemic CA2765919A1 T JJ O
keratoconjonctivitis CA2765919A1 T NN O
. CA2765919A1 T . O

Polymorphic US20120022035 T NNP O
and US20120022035 T CC O
Amorphous US20120022035 T NNP O
Salt US20120022035 T NNP O
Forms US20120022035 T NNP O
of US20120022035 T IN O
Squalamine US20120022035 T NNP O
Dilactate US20120022035 T NNP O
. US20120022035 T . O

Compound CN102631385A T NNP O
anti-aging CN102631385A T JJ O
quercetin CN102631385A T JJ O
nanoemulsion CN102631385A T NN O
health CN102631385A T NN O
care CN102631385A T NN O
product CN102631385A T NN O
. CN102631385A T . O

Nose CN1634062A T NNP O
cavity CN1634062A T NN O
administering CN1634062A T VBG O
formulation CN1634062A T NN O
of CN1634062A T IN O
nalmefene CN1634062A T NN O
. CN1634062A T . O

N- US7427627 T NNP O
( US7427627 T ( O
4- US7427627 T JJ O
( US7427627 T ( O
4-methylthiazol-5-yl US7427627 T JJ O
) US7427627 T ) O
pyrimidin-2-yl US7427627 T NN O
) US7427627 T ) O
-N-phenylamines US7427627 T VBZ O
as US7427627 T IN O
antiproliferative US7427627 T JJ O
compounds US7427627 T NNS O
. US7427627 T . O

The US7427627 A DT O
present US7427627 A JJ O
invention US7427627 A NN O
relates US7427627 A VBZ O
to US7427627 A TO O
2-substituted US7427627 A JJ O
4-heteroaryl-pyrimidines US7427627 A NNS O
, US7427627 A , O
their US7427627 A PRP$ O
preparation US7427627 A NN O
, US7427627 A , O
pharmaceutical US7427627 A JJ O
compositions US7427627 A NNS O
containing US7427627 A VBG O
them US7427627 A PRP O
and US7427627 A CC O
their US7427627 A PRP$ O
use US7427627 A NN O
as US7427627 A IN O
inhibitors US7427627 A NNS O
of US7427627 A IN O
cyclin-dependent US7427627 A JJ I-UN
kinases US7427627 A NNS I-UN
( US7427627 A ( O
CDKs US7427627 A NNP I-UN
) US7427627 A ) O
and US7427627 A CC O
hence US7427627 A RB O
their US7427627 A PRP$ O
use US7427627 A NN O
in US7427627 A IN O
the US7427627 A DT O
treatment US7427627 A NN O
of US7427627 A IN O
proliferative US7427627 A JJ O
disorders US7427627 A NNS O
such US7427627 A JJ O
as US7427627 A IN O
cancer US7427627 A NN O
, US7427627 A , O
leukaemia US7427627 A NN O
, US7427627 A , O
psoriasis US7427627 A NN O
and US7427627 A CC O
the US7427627 A DT O
like US7427627 A JJ O
. US7427627 A . O

Indolo US20100286163 T NNP O
[ US20100286163 T NNP O
3,2-c US20100286163 T JJ O
] US20100286163 T NNP O
quinoline US20100286163 T NN O
compounds US20100286163 T NNS O
. US20100286163 T . O

These US20100286163 A DT O
compounds US20100286163 A NNS O
can US20100286163 A MD O
be US20100286163 A VB O
used US20100286163 A VBN O
to US20100286163 A TO O
inhibit US20100286163 A VB O
both US20100286163 A DT O
growth US20100286163 A NN O
of US20100286163 A IN O
cancer US20100286163 A NN O
cells US20100286163 A NNS O
and US20100286163 A CC O
activity US20100286163 A NN O
of US20100286163 A IN O
telomerase US20100286163 A NN I-UN
. US20100286163 A . O

inhibitors US20090215736 T NNS O
of US20090215736 T IN O
apoptosis US20090215736 T NN O
and US20090215736 T CC O
IL-1 US20090215736 T NNP I-UN
beta US20090215736 T NN I-UN
secretion US20090215736 T NN O
; US20090215736 T : O
mediate US20090215736 T NN O
cell US20090215736 T NN O
apoptosis US20090215736 T NN O
and US20090215736 T CC O
inflammation US20090215736 T NN O
; US20090215736 T : O
good US20090215736 T JJ O
cell US20090215736 T NN O
penetration US20090215736 T NN O
and US20090215736 T CC O
pharmacokinetic US20090215736 T JJ O
properties US20090215736 T NNS O
; US20090215736 T : O
[ US20090215736 T CC O
3S/R US20090215736 T CD O
( US20090215736 T ( O
2S US20090215736 T CD O
) US20090215736 T ) O
] US20090215736 T CD O
3- US20090215736 T JJ O
[ US20090215736 T JJ O
2- US20090215736 T JJ O
( US20090215736 T ( O
Carbazol-9-yl-2-oxo-ethyl US20090215736 T NNP O
) US20090215736 T ) O
-pentanoylamino US20090215736 T NN O
] US20090215736 T JJ O
-5-fluoro-4-oxo-pentanoic US20090215736 T NNP O
acid US20090215736 T NN O
. US20090215736 T . O

This US20090215736 A DT O
invention US20090215736 A NN O
provides US20090215736 A VBZ O
caspase US20090215736 A JJ I-UN
inhibitors US20090215736 A NNS O
of US20090215736 A IN O
formula US20090215736 A NN O
I US20090215736 A PRP O
: US20090215736 A : O
wherein US20090215736 A NN O
Z US20090215736 A NNP O
is US20090215736 A VBZ O
oxygen US20090215736 A JJ O
or US20090215736 A CC O
sulfur US20090215736 A NN O
; US20090215736 A : O
R1 US20090215736 A NNP O
is US20090215736 A VBZ O
hydrogen US20090215736 A NN O
, US20090215736 A , O
—CHN2 US20090215736 A NNP O
, US20090215736 A , O
R US20090215736 A NNP O
, US20090215736 A , O
CH2OR US20090215736 A NNP O
, US20090215736 A , O
CH2SR US20090215736 A NNP O
, US20090215736 A , O
or US20090215736 A CC O
—CH2Y US20090215736 A NN O
; US20090215736 A : O
between US20090215736 A IN O
R3 US20090215736 A NNP O
and US20090215736 A CC O
R4 US20090215736 A NNP O
represents US20090215736 A VBZ O
a US20090215736 A DT O
single US20090215736 A JJ O
or US20090215736 A CC O
double US20090215736 A JJ O
bond US20090215736 A NN O
; US20090215736 A : O
Y US20090215736 A NNP O
is US20090215736 A VBZ O
an US20090215736 A DT O
electronegative US20090215736 A JJ O
leaving US20090215736 A NN O
group US20090215736 A NN O
; US20090215736 A : O
R2 US20090215736 A NNP O
is US20090215736 A VBZ O
CO2H US20090215736 A NNP O
, US20090215736 A , O
CH2CO2H US20090215736 A NNP O
, US20090215736 A , O
or US20090215736 A CC O
esters US20090215736 A NNS O
, US20090215736 A , O
amides US20090215736 A NNS O
or US20090215736 A CC O
isosteres US20090215736 A NNS O
thereof US20090215736 A VBP O
; US20090215736 A : O
R3 US20090215736 A NNP O
is US20090215736 A VBZ O
a US20090215736 A DT O
group US20090215736 A NN O
capable US20090215736 A JJ O
of US20090215736 A IN O
fitting US20090215736 A VBG O
into US20090215736 A IN O
the US20090215736 A DT O
S2 US20090215736 A NNP O
subsite US20090215736 A NN O
of US20090215736 A IN O
a US20090215736 A DT I-UN
caspase US20090215736 A NN I-UN
enzyme US20090215736 A NN O
; US20090215736 A : O
R4 US20090215736 A NNP O
is US20090215736 A VBZ O
a US20090215736 A DT O
hydrogen US20090215736 A NN O
or US20090215736 A CC O
C1-6 US20090215736 A JJ O
alkyl US20090215736 A NN O
or US20090215736 A CC O
R3 US20090215736 A NNP O
and US20090215736 A CC O
R4 US20090215736 A NNP O
taken US20090215736 A VBN O
together US20090215736 A RB O
form US20090215736 A VB O
a US20090215736 A DT O
ring US20090215736 A NN O
; US20090215736 A : O
Ring US20090215736 A VBG O
A US20090215736 A DT O
and US20090215736 A CC O
Ring US20090215736 A NNP O
B US20090215736 A NNP O
are US20090215736 A VBP O
each US20090215736 A DT O
heterocyclic US20090215736 A JJ O
rings US20090215736 A NNS O
, US20090215736 A , O
and US20090215736 A CC O
R US20090215736 A NNP O
and US20090215736 A CC O
R5 US20090215736 A NNP O
are US20090215736 A VBP O
as US20090215736 A IN O
described US20090215736 A VBN O
in US20090215736 A IN O
the US20090215736 A DT O
specification US20090215736 A NN O
. US20090215736 A . O

The US20090215736 A DT O
compounds US20090215736 A NNS O
are US20090215736 A VBP O
effective US20090215736 A JJ O
inhibitors US20090215736 A NNS O
of US20090215736 A IN O
apoptosis US20090215736 A NN O
and US20090215736 A CC O
IL-1β US20090215736 A JJ I-UN
secretion US20090215736 A NN O
. US20090215736 A . O

Crystalline WO2014088315A1 T NNP O
doripenem WO2014088315A1 T NN O
monohydrate WO2014088315A1 T NN O
, WO2014088315A1 T , O
and WO2014088315A1 T CC O
method WO2014088315A1 T NN O
for WO2014088315A1 T IN O
preparing WO2014088315A1 T VBG O
same WO2014088315A1 T JJ O
. WO2014088315A1 T . O

The WO2014088315A1 A DT O
present WO2014088315A1 A JJ O
invention WO2014088315A1 A NN O
relates WO2014088315A1 A VBZ O
to WO2014088315A1 A TO O
a WO2014088315A1 A DT O
method WO2014088315A1 A NN O
for WO2014088315A1 A IN O
preparing WO2014088315A1 A VBG O
doripenem WO2014088315A1 A JJ O
monohydrate WO2014088315A1 A NN O
, WO2014088315A1 A , O
and WO2014088315A1 A CC O
more WO2014088315A1 A JJR O
particularly WO2014088315A1 A RB O
, WO2014088315A1 A , O
to WO2014088315A1 A TO O
a WO2014088315A1 A DT O
method WO2014088315A1 A NN O
for WO2014088315A1 A IN O
preparing WO2014088315A1 A VBG O
doripenem WO2014088315A1 A JJ O
monohydrate WO2014088315A1 A NN O
produced WO2014088315A1 A VBN O
through WO2014088315A1 A IN O
the WO2014088315A1 A DT O
steps WO2014088315A1 A NNS O
of WO2014088315A1 A IN O
: WO2014088315A1 A : O
conducting WO2014088315A1 A VBG O
a WO2014088315A1 A DT O
deprotecting WO2014088315A1 A VBG O
reaction WO2014088315A1 A NN O
by WO2014088315A1 A IN O
reacting WO2014088315A1 A VBG O
doripenem-PNB WO2014088315A1 A NN O
with WO2014088315A1 A IN O
a WO2014088315A1 A DT O
zinc WO2014088315A1 A NN O
powder WO2014088315A1 A NN O
in WO2014088315A1 A IN O
a WO2014088315A1 A DT O
mixture WO2014088315A1 A NN O
solution WO2014088315A1 A NN O
including WO2014088315A1 A VBG O
an WO2014088315A1 A DT O
organic WO2014088315A1 A JJ O
solvent WO2014088315A1 A NN O
and WO2014088315A1 A CC O
an WO2014088315A1 A DT O
aqueous WO2014088315A1 A JJ O
phosphate WO2014088315A1 A NN O
solution WO2014088315A1 A NN O
( WO2014088315A1 A ( O
step WO2014088315A1 A VB O
1 WO2014088315A1 A CD O
) WO2014088315A1 A ) O
; WO2014088315A1 A : O
removing WO2014088315A1 A VBG O
phosphate WO2014088315A1 A NN O
from WO2014088315A1 A IN O
the WO2014088315A1 A DT O
product WO2014088315A1 A NN O
of WO2014088315A1 A IN O
step WO2014088315A1 A NN O
1 WO2014088315A1 A CD O
( WO2014088315A1 A ( O
step WO2014088315A1 A VB O
2 WO2014088315A1 A CD O
) WO2014088315A1 A ) O
; WO2014088315A1 A : O
and WO2014088315A1 A CC O
crystallizing WO2014088315A1 A VBG O
the WO2014088315A1 A DT O
product WO2014088315A1 A NN O
of WO2014088315A1 A IN O
step WO2014088315A1 A NN O
2 WO2014088315A1 A CD O
using WO2014088315A1 A VBG O
a WO2014088315A1 A DT O
solvent WO2014088315A1 A NN O
for WO2014088315A1 A IN O
crystallization WO2014088315A1 A NN O
to WO2014088315A1 A TO O
crystallize WO2014088315A1 A VB O
the WO2014088315A1 A DT O
doripenem WO2014088315A1 A NN O
monohydrate WO2014088315A1 A NN O
( WO2014088315A1 A ( O
step WO2014088315A1 A VB O
3 WO2014088315A1 A CD O
) WO2014088315A1 A ) O
. WO2014088315A1 A . O

According WO2014088315A1 A VBG O
to WO2014088315A1 A TO O
the WO2014088315A1 A DT O
method WO2014088315A1 A NN O
for WO2014088315A1 A IN O
preparing WO2014088315A1 A VBG O
the WO2014088315A1 A DT O
doripenem WO2014088315A1 A NN O
monohydrate WO2014088315A1 A NN O
, WO2014088315A1 A , O
the WO2014088315A1 A DT O
method WO2014088315A1 A NN O
can WO2014088315A1 A MD O
be WO2014088315A1 A VB O
conducted WO2014088315A1 A VBN O
at WO2014088315A1 A IN O
room WO2014088315A1 A NN O
temperature WO2014088315A1 A NN O
and WO2014088315A1 A CC O
at WO2014088315A1 A IN O
a WO2014088315A1 A DT O
moderate WO2014088315A1 A JJ O
atmospheric WO2014088315A1 A JJ O
pressure WO2014088315A1 A NN O
without WO2014088315A1 A IN O
using WO2014088315A1 A VBG O
an WO2014088315A1 A DT O
expensive WO2014088315A1 A JJ O
metal WO2014088315A1 A NN O
catalyst WO2014088315A1 A NN O
and WO2014088315A1 A CC O
special WO2014088315A1 A JJ O
equipment WO2014088315A1 A NN O
. WO2014088315A1 A . O

Thus WO2014088315A1 A RB O
, WO2014088315A1 A , O
the WO2014088315A1 A DT O
method WO2014088315A1 A NN O
is WO2014088315A1 A VBZ O
economical WO2014088315A1 A JJ O
and WO2014088315A1 A CC O
safe WO2014088315A1 A JJ O
, WO2014088315A1 A , O
and WO2014088315A1 A CC O
the WO2014088315A1 A DT O
doripenem WO2014088315A1 A NN O
monohydrate WO2014088315A1 A NN O
can WO2014088315A1 A MD O
be WO2014088315A1 A VB O
obtained WO2014088315A1 A VBN O
at WO2014088315A1 A IN O
a WO2014088315A1 A DT O
high WO2014088315A1 A JJ O
yield WO2014088315A1 A NN O
. WO2014088315A1 A . O

Accordingly WO2014088315A1 A RB O
, WO2014088315A1 A , O
the WO2014088315A1 A DT O
preparation WO2014088315A1 A NN O
method WO2014088315A1 A NN O
of WO2014088315A1 A IN O
the WO2014088315A1 A DT O
present WO2014088315A1 A JJ O
invention WO2014088315A1 A NN O
can WO2014088315A1 A MD O
be WO2014088315A1 A VB O
usefully WO2014088315A1 A RB O
applied WO2014088315A1 A VBN O
in WO2014088315A1 A IN O
an WO2014088315A1 A DT O
industrial WO2014088315A1 A JJ O
field WO2014088315A1 A NN O
related WO2014088315A1 A VBN O
to WO2014088315A1 A TO O
doripenem WO2014088315A1 A VB O
monohydrate WO2014088315A1 A NN O
. WO2014088315A1 A . O

In US8828358 T IN O
situ US8828358 T JJ O
formation US8828358 T NN O
of US8828358 T IN O
an US8828358 T DT O
artificial US8828358 T JJ O
blockage US8828358 T NN O
to US8828358 T TO O
control US8828358 T VB O
bleeding US8828358 T NN O
by US8828358 T IN O
polymer US8828358 T JJ O
expansion US8828358 T NN O
with US8828358 T IN O
hydrogen US8828358 T NN O
peroxide US8828358 T NN O
. US8828358 T . O

The US8828358 A DT O
decomposing US8828358 A NN O
agent US8828358 A NN O
includes US8828358 A VBZ O
exogenous US8828358 A JJ O
or US8828358 A CC O
endogenous US8828358 A JJ O
catalase US8828358 A NN I-UN
, US8828358 A , O
or US8828358 A CC O
both US8828358 A DT O
. US8828358 A . O

Novel WO2010055164A2 T NNP O
inhibitors WO2010055164A2 T NNS O
of WO2010055164A2 T IN O
flavivirus WO2010055164A2 T JJ O
replication WO2010055164A2 T NN O
. WO2010055164A2 T . O

Macrolide CN103360447A T NNP O
solid-state CN103360447A T JJ O
forms CN103360447A T NNS O
. CN103360447A T . O

Aryloxypropanolamines WO2008090140A1 T NNS O
, WO2008090140A1 T , O
methods WO2008090140A1 T NNS O
of WO2008090140A1 T IN O
preparation WO2008090140A1 T NN O
thereof WO2008090140A1 T NN O
and WO2008090140A1 T CC O
use WO2008090140A1 T NN O
of WO2008090140A1 T IN O
aryloxypropanolamines WO2008090140A1 T NNS O
as WO2008090140A1 T IN O
medicaments WO2008090140A1 T NNS O
. WO2008090140A1 T . O

Said WO2008090140A1 A NNP O
compounds WO2008090140A1 A NNS O
have WO2008090140A1 A VBP O
agonistic WO2008090140A1 A JJ O
activity WO2008090140A1 A NN O
at WO2008090140A1 A IN O
β3 WO2008090140A1 A NNP I-UN
adrenergic WO2008090140A1 A JJ I-UN
receptors WO2008090140A1 A NNS I-UN
and WO2008090140A1 A CC O
are WO2008090140A1 A VBP O
useful WO2008090140A1 A JJ O
for WO2008090140A1 A IN O
treatment WO2008090140A1 A NN O
of WO2008090140A1 A IN O
ailments WO2008090140A1 A NNS O
influenced WO2008090140A1 A VBN O
by WO2008090140A1 A IN O
activation WO2008090140A1 A NN O
of WO2008090140A1 A IN O
β3 WO2008090140A1 A NNP I-UN
adrenergic WO2008090140A1 A JJ I-UN
receptors WO2008090140A1 A NNS I-UN
. WO2008090140A1 A . O

Hepatitis US20100324117 T NNP O
c US20100324117 T VBZ O
dsrna US20100324117 T JJ O
effector US20100324117 T NN O
molecules US20100324117 T NNS O
, US20100324117 T , O
expression US20100324117 T NN O
constructs US20100324117 T NNS O
, US20100324117 T , O
compositions US20100324117 T NNS O
, US20100324117 T , O
and US20100324117 T CC O
methods US20100324117 T NNS O
of US20100324117 T IN O
use US20100324117 T NN O
. US20100324117 T . O

DNA US7459528 T NN O
sequences US7459528 T NNS O
encoding US7459528 T VBG O
tumor US7459528 T NN O
necrosis US7459528 T NN O
factor US7459528 T NN O
receptors US7459528 T NNS O
; US7459528 T : O
recombinant US7459528 T JJ O
expression US7459528 T NN O
vectors US7459528 T NNS O
. US7459528 T . O

Medicament CN103202855A T JJ O
composition CN103202855A T NN O
for CN103202855A T IN O
preventing CN103202855A T VBG O
and CN103202855A T CC O
curing CN103202855A T VBG O
newly-born CN103202855A T JJ O
piglet CN103202855A T NN O
diarrhea CN103202855A T NN O
syndrome CN103202855A T NN O
. CN103202855A T . O

Dry WO2014137877A1 T NNP O
pharmaceutical WO2014137877A1 T JJ O
compositions WO2014137877A1 T NNS O
comprising WO2014137877A1 T VBG O
active WO2014137877A1 T JJ O
agent WO2014137877A1 T NN O
nanoparticles WO2014137877A1 T NNS O
bound WO2014137877A1 T IN O
to WO2014137877A1 T TO O
carrier WO2014137877A1 T NN O
particles WO2014137877A1 T NNS O
. WO2014137877A1 T . O

Methods CN101955976A T NNS O
and CN101955976A T CC O
immune CN101955976A T JJ O
modulatory CN101955976A T NN O
nucleic CN101955976A T JJ O
acid CN101955976A T JJ O
compositions CN101955976A T NNS O
for CN101955976A T IN O
preventing CN101955976A T VBG O
and CN101955976A T CC O
treating CN101955976A T VBG O
disease CN101955976A T NN O
. CN101955976A T . O

Dietary EP2004187A1 T JJ O
supplement EP2004187A1 T NN O
for EP2004187A1 T IN O
healing EP2004187A1 T VBG O
or EP2004187A1 T CC O
regressing EP2004187A1 T VBG O
symptoms EP2004187A1 T NNS O
of EP2004187A1 T IN O
gastroesophageal EP2004187A1 T JJ O
reflux EP2004187A1 T JJ O
disease EP2004187A1 T NN O
, EP2004187A1 T , O
gastritis EP2004187A1 T NN O
and EP2004187A1 T CC O
ulcers EP2004187A1 T NNS O
. EP2004187A1 T . O

Deuterium-enriched US20090062331 T JJ O
maraviroc US20090062331 T NN O
. US20090062331 T . O

such US7763641 T JJ O
as US7763641 T IN O
[ US7763641 T NNP O
( US7763641 T ( O
1S,2R US7763641 T CD O
) US7763641 T ) O
-2-hydroxy-3- US7763641 T NN O
[ US7763641 T JJ O
N- US7763641 T JJ O
[ US7763641 T NN O
4- US7763641 T JJ O
( US7763641 T ( O
2-methylaminothiazol-4-yl US7763641 T JJ O
) US7763641 T ) O
phenylsulfonyl US7763641 T NN O
] US7763641 T JJ O
-N- US7763641 T NNP O
( US7763641 T ( O
2-methylpropyl US7763641 T JJ O
) US7763641 T ) O
amino US7763641 T NN O
] US7763641 T JJ O
-1- US7763641 T NNP O
( US7763641 T ( O
phenylmethyl US7763641 T NN O
) US7763641 T ) O
propyl US7763641 T NN O
] US7763641 T JJ O
carbamic US7763641 T JJ O
acid US7763641 T NN O
, US7763641 T , O
[ US7763641 T NNP O
( US7763641 T ( O
3R,3aS,6aR US7763641 T CD O
) US7763641 T ) O
-hexahydrofuro US7763641 T NN O
[ US7763641 T JJ O
2,3-b US7763641 T JJ O
] US7763641 T JJ O
furan-3-yl US7763641 T JJ O
] US7763641 T NN O
ester US7763641 T NN O
, US7763641 T , O
used US7763641 T VBN O
for US7763641 T IN O
treating US7763641 T VBG O
human US7763641 T JJ O
immunodeficiency US7763641 T NN O
virus US7763641 T NN O
infections US7763641 T NNS O
. US7763641 T . O

Pharmaceutical EP1700597A1 T JJ O
composition EP1700597A1 T NN O
containing EP1700597A1 T VBG O
in EP1700597A1 T IN O
association EP1700597A1 T NN O
ubidecarenone EP1700597A1 T NN O
, EP1700597A1 T , O
dexpanthenol EP1700597A1 T NN O
and EP1700597A1 T CC O
chlorhexidine EP1700597A1 T NN O
or EP1700597A1 T CC O
a EP1700597A1 T DT O
pharmaceutically EP1700597A1 T RB O
acceptable EP1700597A1 T JJ O
salt EP1700597A1 T NN O
thereof EP1700597A1 T NN O
for EP1700597A1 T IN O
cutaneous EP1700597A1 T JJ O
application EP1700597A1 T NN O
. EP1700597A1 T . O

Application CN103709015A T NN O
of CN103709015A T IN O
ginkgol CN103709015A T NN O
C17:1 CN103709015A T NNP O
in CN103709015A T IN O
treatment CN103709015A T NN O
of CN103709015A T IN O
liver CN103709015A T NN O
cancer CN103709015A T NN O
. CN103709015A T . O

Useful WO2011158931A1 T JJ O
salts WO2011158931A1 T NNS O
of WO2011158931A1 T IN O
indazole WO2011158931A1 T JJ O
derivative WO2011158931A1 T NN O
. WO2011158931A1 T . O

Application CN101513423A T NN O
of CN101513423A T IN O
oleanane-28-acid-2,9 CN101513423A T JJ O
( CN101513423A T ( O
11 CN101513423A T CD O
) CN101513423A T ) O
,12-triene CN101513423A T NN O
in CN101513423A T IN O
preparing CN101513423A T VBG O
medicament CN101513423A T NN O
for CN101513423A T IN O
treating CN101513423A T VBG O
skin CN101513423A T NN O
diseases CN101513423A T NNS O
. CN101513423A T . O

comprising US7871635 T VBG O
a US7871635 T DT O
cosmetically US7871635 T RB O
acceptable US7871635 T JJ O
medium US7871635 T NN O
and US7871635 T CC O
a US7871635 T DT O
compound US7871635 T NN O
N- US7871635 T NNP O
( US7871635 T ( O
omega US7871635 T JJ O
-undecylenoyl US7871635 T NN O
) US7871635 T ) O
phenylalanine US7871635 T NN O
; US7871635 T : O
inactivates US7871635 T VBZ O
adenylate US7871635 T JJ O
cyclase US7871635 T NN O
and US7871635 T CC O
has US7871635 T VBZ O
an US7871635 T DT O
affinity US7871635 T NN O
for US7871635 T IN O
the US7871635 T DT O
melocytic US7871635 T JJ O
specific US7871635 T JJ O
hormone US7871635 T NN O
( US7871635 T ( O
alpha US7871635 T JJ O
-MSH US7871635 T NN O
) US7871635 T ) O
. US7871635 T . O

Organometallic WO2012138988A3 T JJ O
anti-cancer WO2012138988A3 T NN O
complexes WO2012138988A3 T NNS O
. WO2012138988A3 T . O

Small CN1751691A T JJ O
volume CN1751691A T NN O
intravenous CN1751691A T JJ O
injection CN1751691A T NN O
of CN1751691A T IN O
gastrodine CN1751691A T NN O
and CN1751691A T CC O
its CN1751691A T PRP$ O
prepn CN1751691A T NN O
. CN1751691A T . O

method CN1751691A T NN O
. CN1751691A T . O

Adonis WO2013100585A3 T NNP O
amurensis WO2013100585A3 T NN O
extract WO2013100585A3 T NN O
or WO2013100585A3 T CC O
anti-cancer WO2013100585A3 T JJ O
composition WO2013100585A3 T NN O
using WO2013100585A3 T VBG O
same WO2013100585A3 T JJ O
as WO2013100585A3 T IN O
an WO2013100585A3 T DT O
active WO2013100585A3 T JJ O
ingredient WO2013100585A3 T NN O
. WO2013100585A3 T . O

The WO2013100585A3 A DT O
present WO2013100585A3 A JJ O
invention WO2013100585A3 A NN O
relates WO2013100585A3 A VBZ O
to WO2013100585A3 A TO O
an WO2013100585A3 A DT O
Adonis WO2013100585A3 A NNP O
amurensis WO2013100585A3 A NN O
extract WO2013100585A3 A NN O
showing WO2013100585A3 A VBG O
anti-cancer WO2013100585A3 A JJ O
activity WO2013100585A3 A NN O
in WO2013100585A3 A IN O
cell WO2013100585A3 A NN O
and WO2013100585A3 A CC O
animal WO2013100585A3 A NN O
experiments WO2013100585A3 A NNS O
, WO2013100585A3 A , O
and WO2013100585A3 A CC O
an WO2013100585A3 A DT O
anti-cancer WO2013100585A3 A JJ O
composition WO2013100585A3 A NN O
using WO2013100585A3 A VBG O
the WO2013100585A3 A DT O
same WO2013100585A3 A JJ O
as WO2013100585A3 A IN O
an WO2013100585A3 A DT O
active WO2013100585A3 A JJ O
material WO2013100585A3 A NN O
. WO2013100585A3 A . O

Use WO2004096195A3 T NNP O
of WO2004096195A3 T IN O
ppar-gamma WO2004096195A3 T JJ O
agonists WO2004096195A3 T NNS O
as WO2004096195A3 T IN O
anti-infective WO2004096195A3 T JJ O
agents WO2004096195A3 T NNS O
. WO2004096195A3 T . O

The WO2004096195A3 A DT O
invention WO2004096195A3 A NN O
relates WO2004096195A3 A VBZ O
to WO2004096195A3 A TO O
a WO2004096195A3 A DT O
method WO2004096195A3 A NN O
of WO2004096195A3 A IN O
producing WO2004096195A3 A VBG O
a WO2004096195A3 A DT O
therapeutic WO2004096195A3 A JJ O
composition WO2004096195A3 A NN O
that WO2004096195A3 A WDT O
stimulates WO2004096195A3 A VBZ O
the WO2004096195A3 A DT O
innate WO2004096195A3 A NN O
immune WO2004096195A3 A JJ O
response WO2004096195A3 A NN O
by WO2004096195A3 A IN O
induction WO2004096195A3 A NN O
and/or WO2004096195A3 A JJ O
amplification WO2004096195A3 A NN O
of WO2004096195A3 A IN O
the WO2004096195A3 A DT O
expression WO2004096195A3 A NN O
of WO2004096195A3 A IN O
macrophage WO2004096195A3 A NN O
mannose WO2004096195A3 A JJ O
receptors WO2004096195A3 A NNS O
. WO2004096195A3 A . O

Advantageously WO2004096195A3 A RB O
, WO2004096195A3 A , O
the WO2004096195A3 A DT O
invention WO2004096195A3 A NN O
is WO2004096195A3 A VBZ O
applicable WO2004096195A3 A JJ O
for WO2004096195A3 A IN O
preventive WO2004096195A3 A JJ O
or WO2004096195A3 A CC O
curative WO2004096195A3 A JJ O
treatments WO2004096195A3 A NNS O
for WO2004096195A3 A IN O
infectious WO2004096195A3 A JJ O
diseases WO2004096195A3 A NNS O
of WO2004096195A3 A IN O
bacterial WO2004096195A3 A NN O
, WO2004096195A3 A , O
fungal WO2004096195A3 A NN O
, WO2004096195A3 A , O
protozoan WO2004096195A3 A NN O
, WO2004096195A3 A , O
etc WO2004096195A3 A FW O
. WO2004096195A3 A . O

origin WO2004096195A3 A NN O
and WO2004096195A3 A CC O
is WO2004096195A3 A VBZ O
of WO2004096195A3 A IN O
particular WO2004096195A3 A JJ O
interest WO2004096195A3 A NN O
in WO2004096195A3 A IN O
the WO2004096195A3 A DT O
treatment WO2004096195A3 A NN O
of WO2004096195A3 A IN O
immunodepressed WO2004096195A3 A JJ O
patients WO2004096195A3 A NNS O
. WO2004096195A3 A . O

According WO2004096195A3 A VBG O
to WO2004096195A3 A TO O
the WO2004096195A3 A DT O
invention WO2004096195A3 A NN O
, WO2004096195A3 A , O
in WO2004096195A3 A IN O
order WO2004096195A3 A NN O
to WO2004096195A3 A TO O
induce WO2004096195A3 A VB O
and/or WO2004096195A3 A JJ O
amplify WO2004096195A3 A VB O
the WO2004096195A3 A DT O
expression WO2004096195A3 A NN O
of WO2004096195A3 A IN O
the WO2004096195A3 A DT O
macrophage WO2004096195A3 A NN O
mannose WO2004096195A3 A JJ O
receptor WO2004096195A3 A NN O
, WO2004096195A3 A , O
the WO2004096195A3 A DT O
aforementioned WO2004096195A3 A JJ O
macrophages WO2004096195A3 A NNS O
are WO2004096195A3 A VBP O
brought WO2004096195A3 A VBN O
into WO2004096195A3 A IN O
contact WO2004096195A3 A NN O
with WO2004096195A3 A IN O
an WO2004096195A3 A DT O
effective WO2004096195A3 A JJ O
quantity WO2004096195A3 A NN O
of WO2004096195A3 A IN O
at WO2004096195A3 A IN O
least WO2004096195A3 A JJS O
one WO2004096195A3 A CD O
agonist WO2004096195A3 A JJ O
ligand WO2004096195A3 A NN O
of WO2004096195A3 A IN O
the WO2004096195A3 A DT O
PPARϜ WO2004096195A3 A NNP O
nuclear WO2004096195A3 A JJ O
receptor WO2004096195A3 A NN O
. WO2004096195A3 A . O

Substituted CN102206180A T VBN O
6-cyclohexylalkyl CN102206180A T JJ O
substituted CN102206180A T VBN O
2-quinolinones CN102206180A T JJ O
and CN102206180A T CC O
2-quinoxalinones CN102206180A T JJ O
as CN102206180A T IN O
poly CN102206180A T NN I-UN
( CN102206180A T ( I-UN
ADP-ribose CN102206180A T NNP I-UN
) CN102206180A T ) I-UN
polymerase CN102206180A T NN I-UN
inhibitors CN102206180A T NNS O
. CN102206180A T . O

The CN102206180A A DT O
present CN102206180A A JJ O
invention CN102206180A A NN O
provides CN102206180A A VBZ O
compounds CN102206180A A NNS O
of CN102206180A A IN O
formula CN102206180A A NN O
( CN102206180A A ( O
I CN102206180A A PRP O
) CN102206180A A ) O
, CN102206180A A , O
their CN102206180A A PRP$ O
use CN102206180A A NN O
as CN102206180A A IN O
PARP CN102206180A A NNP I-UN
inhibitors CN102206180A A NNS O
as CN102206180A A RB O
well CN102206180A A RB O
as CN102206180A A IN O
pharmaceutical CN102206180A A JJ O
compositions CN102206180A A NNS O
comprising CN102206180A A VBG O
said CN102206180A A VBD O
compounds CN102206180A A NNS O
of CN102206180A A IN O
formula CN102206180A A NN O
( CN102206180A A ( O
I CN102206180A A PRP O
) CN102206180A A ) O
wherein CN102206180A A NN O
n CN102206180A A NN O
, CN102206180A A , O
s CN102206180A A NN O
, CN102206180A A , O
R CN102206180A A NNP O
< CN102206180A A VBZ O
1 CN102206180A A CD O
> CN102206180A A NN O
, CN102206180A A , O
R CN102206180A A NNP O
< CN102206180A A VBZ O
2 CN102206180A A CD O
> CN102206180A A NN O
, CN102206180A A , O
R CN102206180A A NNP O
< CN102206180A A VBZ O
3 CN102206180A A CD O
> CN102206180A A NN O
, CN102206180A A , O
Q CN102206180A A NNP O
, CN102206180A A , O
X CN102206180A A NNP O
and CN102206180A A CC O
Y CN102206180A A NNP O
have CN102206180A A VBP O
defined CN102206180A A VBN O
meanings CN102206180A A NNS O
. CN102206180A A . O

Inhibitors EP1175399B1 T NNS O
of EP1175399B1 T IN O
c-jun EP1175399B1 T JJ I-UN
n-terminal EP1175399B1 T JJ I-UN
kinases EP1175399B1 T NNS I-UN
( EP1175399B1 T ( O
jnk EP1175399B1 T NN I-UN
) EP1175399B1 T ) O
. EP1175399B1 T . O

The EP1175399B1 A DT O
present EP1175399B1 A JJ O
invention EP1175399B1 A NN O
relates EP1175399B1 A VBZ O
to EP1175399B1 A TO O
compounds EP1175399B1 A NNS O
of EP1175399B1 A IN O
formula EP1175399B1 A NN O
( EP1175399B1 A ( O
I EP1175399B1 A PRP O
) EP1175399B1 A ) O
or EP1175399B1 A CC O
( EP1175399B1 A ( O
II EP1175399B1 A NNP O
) EP1175399B1 A ) O
, EP1175399B1 A , O
or EP1175399B1 A CC O
a EP1175399B1 A DT O
pharmaceutically EP1175399B1 A RB O
acceptable EP1175399B1 A JJ O
derivative EP1175399B1 A JJ O
or EP1175399B1 A CC O
prodrug EP1175399B1 A JJ O
thereof EP1175399B1 A NN O
; EP1175399B1 A : O
wherein EP1175399B1 A CC O
Y EP1175399B1 A NNP O
is EP1175399B1 A VBZ O
selected EP1175399B1 A VBN O
from EP1175399B1 A IN O
- EP1175399B1 A : O
( EP1175399B1 A ( O
CH2 EP1175399B1 A NNP O
) EP1175399B1 A ) O
-Q1 EP1175399B1 A NN O
; EP1175399B1 A : O
- EP1175399B1 A : O
( EP1175399B1 A ( O
CO EP1175399B1 A NNP O
) EP1175399B1 A ) O
-Q1 EP1175399B1 A NN O
; EP1175399B1 A : O
- EP1175399B1 A : O
( EP1175399B1 A ( O
CO EP1175399B1 A NNP O
) EP1175399B1 A ) O
NH-Q1 EP1175399B1 A NN O
; EP1175399B1 A : O
- EP1175399B1 A : O
( EP1175399B1 A ( O
CO EP1175399B1 A NNP O
) EP1175399B1 A ) O
-O-Q1 EP1175399B1 A NN O
; EP1175399B1 A : O
- EP1175399B1 A : O
( EP1175399B1 A ( O
SO2 EP1175399B1 A NNP O
) EP1175399B1 A ) O
-Q1 EP1175399B1 A NN O
or EP1175399B1 A CC O
- EP1175399B1 A : O
( EP1175399B1 A ( O
SO2 EP1175399B1 A NNP O
) EP1175399B1 A ) O
NH-Q1 EP1175399B1 A NNP O
; EP1175399B1 A : O
Q1 EP1175399B1 A NNP O
is EP1175399B1 A VBZ O
a EP1175399B1 A DT O
C1-C6 EP1175399B1 A JJ O
straight EP1175399B1 A NN O
chain EP1175399B1 A NN O
or EP1175399B1 A CC O
branched EP1175399B1 A VBN O
alkyl EP1175399B1 A NN O
or EP1175399B1 A CC O
alkenyl EP1175399B1 A JJ O
group EP1175399B1 A NN O
; EP1175399B1 A : O
a EP1175399B1 A DT O
5-7 EP1175399B1 A JJ O
membered EP1175399B1 A JJ O
aromatic EP1175399B1 A JJ O
or EP1175399B1 A CC O
non-aromatic EP1175399B1 A JJ O
carbocyclic EP1175399B1 A NN O
or EP1175399B1 A CC O
heterocyclic EP1175399B1 A JJ O
ring EP1175399B1 A NN O
; EP1175399B1 A : O
or EP1175399B1 A CC O
a EP1175399B1 A DT O
9-14 EP1175399B1 A CD O
membered EP1175399B1 A JJ O
bicyclic EP1175399B1 A NN O
or EP1175399B1 A CC O
tricyclic EP1175399B1 A JJ O
aromatic EP1175399B1 A JJ O
or EP1175399B1 A CC O
non-aromatic EP1175399B1 A JJ O
carbocyclic EP1175399B1 A NN O
or EP1175399B1 A CC O
heterocyclic EP1175399B1 A JJ O
ring EP1175399B1 A NN O
system EP1175399B1 A NN O
, EP1175399B1 A , O
W EP1175399B1 A NNP O
is EP1175399B1 A VBZ O
N EP1175399B1 A NNP O
or EP1175399B1 A CC O
C EP1175399B1 A NNP O
; EP1175399B1 A : O
Z EP1175399B1 A NNP O
is EP1175399B1 A VBZ O
CH EP1175399B1 A NNP O
or EP1175399B1 A CC O
N EP1175399B1 A NNP O
, EP1175399B1 A , O
which EP1175399B1 A WDT O
are EP1175399B1 A VBP O
inhibitors EP1175399B1 A NNS O
of EP1175399B1 A IN O
JNK EP1175399B1 A NNP I-UN
, EP1175399B1 A , O
a EP1175399B1 A DT O
mammalian EP1175399B1 A JJ O
protein EP1175399B1 A NN O
kinase EP1175399B1 A NN I-UN
involved EP1175399B1 A VBN O
cell EP1175399B1 A NN O
proliferation EP1175399B1 A NN O
, EP1175399B1 A , O
cell EP1175399B1 A NN O
death EP1175399B1 A NN O
and EP1175399B1 A CC O
response EP1175399B1 A NN O
to EP1175399B1 A TO O
extracellular EP1175399B1 A JJ O
stimuli EP1175399B1 A NNS O
. EP1175399B1 A . O

Prophylactic US20110009376 T JJ O
or US20110009376 T CC O
therapeutic US20110009376 T JJ O
agent US20110009376 T NN O
for US20110009376 T IN O
eye US20110009376 T NN O
disease US20110009376 T NN O
accompanied US20110009376 T VBN O
by US20110009376 T IN O
optic US20110009376 T JJ O
nerve US20110009376 T NN O
disorder US20110009376 T NN O
. US20110009376 T . O

Biphenyl CN101792401B T NNP O
compound CN101792401B T NN O
with CN101792401B T IN O
anti-tumor CN101792401B T JJ O
activity CN101792401B T NN O
and CN101792401B T CC O
preparation CN101792401B T NN O
method CN101792401B T NN O
thereof CN101792401B T NN O
. CN101792401B T . O

Piperazine WO2013087806A1 T NNP O
derivatives WO2013087806A1 T NNS O
and WO2013087806A1 T CC O
their WO2013087806A1 T PRP$ O
use WO2013087806A1 T NN O
as WO2013087806A1 T IN O
positive WO2013087806A1 T JJ O
allosteric WO2013087806A1 T JJ O
modulators WO2013087806A1 T NNS O
of WO2013087806A1 T IN O
mglu5 WO2013087806A1 T NN I-UN
receptors WO2013087806A1 T NNS I-UN
. WO2013087806A1 T . O

This WO2013087806A1 A DT O
invention WO2013087806A1 A NN O
relates WO2013087806A1 A VBZ O
to WO2013087806A1 A TO O
compounds WO2013087806A1 A NNS O
of WO2013087806A1 A IN O
formula WO2013087806A1 A NN O
I WO2013087806A1 A PRP O
their WO2013087806A1 A PRP$ O
use WO2013087806A1 A NN O
as WO2013087806A1 A IN O
positive WO2013087806A1 A JJ O
allosteric WO2013087806A1 A JJ O
modulators WO2013087806A1 A NNS O
of WO2013087806A1 A IN O
mGlu5 WO2013087806A1 A JJ I-UN
receptor WO2013087806A1 A NN I-UN
activity WO2013087806A1 A NN O
, WO2013087806A1 A , O
pharmaceutical WO2013087806A1 A JJ O
compositions WO2013087806A1 A NNS O
containing WO2013087806A1 A VBG O
the WO2013087806A1 A DT O
same WO2013087806A1 A JJ O
, WO2013087806A1 A , O
and WO2013087806A1 A CC O
methods WO2013087806A1 A NNS O
of WO2013087806A1 A IN O
using WO2013087806A1 A VBG O
the WO2013087806A1 A DT O
same WO2013087806A1 A JJ O
as WO2013087806A1 A IN O
agents WO2013087806A1 A NNS O
for WO2013087806A1 A IN O
treatment WO2013087806A1 A NN O
and/or WO2013087806A1 A JJ O
prevention WO2013087806A1 A NN O
of WO2013087806A1 A IN O
neurological WO2013087806A1 A JJ O
and WO2013087806A1 A CC O
psychiatric WO2013087806A1 A JJ O
disorders WO2013087806A1 A NNS O
associated WO2013087806A1 A VBN O
with WO2013087806A1 A IN O
glutamate WO2013087806A1 A JJ O
dysfunction WO2013087806A1 A NN O
such WO2013087806A1 A JJ O
as WO2013087806A1 A IN O
schizophrenia WO2013087806A1 A NN O
or WO2013087806A1 A CC O
cognitive WO2013087806A1 A JJ O
decline WO2013087806A1 A NN O
such WO2013087806A1 A JJ O
as WO2013087806A1 A IN O
dementia WO2013087806A1 A NN O
or WO2013087806A1 A CC O
cognitive WO2013087806A1 A JJ O
impairment WO2013087806A1 A NN O
. WO2013087806A1 A . O

Preparation CN1730075A T NNP O
method CN1730075A T NN O
of CN1730075A T IN O
blood CN1730075A T NN O
enriching CN1730075A T VBG O
tablet CN1730075A T NN O
. CN1730075A T . O

Purkinje WO2007105744A1 T NNP O
cell-tropic WO2007105744A1 T JJ O
viral WO2007105744A1 T JJ O
vector WO2007105744A1 T NN O
. WO2007105744A1 T . O

Preparation US20050228043 T NN O
of US20050228043 T IN O
trans-fused US20050228043 T JJ O
3,3a,8,12b-tetrahydro-2H-dibenzo US20050228043 T JJ O
[ US20050228043 T NN O
3,4:6,7 US20050228043 T CD O
] US20050228043 T NN O
cyclohepta US20050228043 T NN O
[ US20050228043 T NNP O
1,2-b US20050228043 T JJ O
] US20050228043 T NNP O
furan US20050228043 T NN O
derivatives US20050228043 T NNS O
. US20050228043 T . O

Preparation US8481075 T NN O
and US8481075 T CC O
application US8481075 T NN O
of US8481075 T IN O
biodegradable-material-made US8481075 T NN O
microsphere US8481075 T FW O
vascular US8481075 T JJ O
embolus US8481075 T NN O
containing US8481075 T VBG O
liposome-encapsulated US8481075 T JJ O
cytokines US8481075 T NNS O
. US8481075 T . O

The US8481075 A DT O
present US8481075 A JJ O
invention US8481075 A NN O
is US8481075 A VBZ O
technologically US8481075 A RB O
characterized US8481075 A VBN O
by US8481075 A IN O
encapsulation US8481075 A NN O
of US8481075 A IN O
liposome-wrapped US8481075 A JJ O
immunocytokines US8481075 A NNS O
such US8481075 A JJ O
as US8481075 A IN O
IL-2 US8481075 A NNP I-UN
, US8481075 A , O
TNF US8481075 A NNP I-UN
and US8481075 A CC O
interferon US8481075 A NN O
by US8481075 A IN O
sodium US8481075 A NN O
polysaccharide US8481075 A NN O
or US8481075 A CC O
gelatin US8481075 A NN O
, US8481075 A , O
which US8481075 A WDT O
is US8481075 A VBZ O
extracted US8481075 A VBN O
from US8481075 A IN O
natural US8481075 A JJ O
alga US8481075 A NN O
and US8481075 A CC O
is US8481075 A VBZ O
good US8481075 A JJ O
at US8481075 A IN O
biodegradability US8481075 A NN O
and US8481075 A CC O
biocompatibility US8481075 A NN O
. US8481075 A . O

Arctigenin CN102836140A T NNP O
micro-emulsion CN102836140A T NN O
enteric CN102836140A T JJ O
soft CN102836140A T JJ O
capsule CN102836140A T NN O
preparation CN102836140A T NN O
. CN102836140A T . O

TREATMENT US20070282007 T NNP O
OF US20070282007 T NNP O
PAIN US20070282007 T NNP O
DISORDERS US20070282007 T NNP O
WITH US20070282007 T NNP O
trans US20070282007 T VBZ O
4- US20070282007 T JJ O
( US20070282007 T ( O
3,4-DICHLOROPHENYL US20070282007 T JJ O
) US20070282007 T ) O
-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE US20070282007 T NN O
AND US20070282007 T CC O
ITS US20070282007 T NNP O
FORMAMIDE US20070282007 T NNP O
. US20070282007 T . O

Substituted WO2012143399A1 T VBN O
4-aryl-n-phenyl-1,3,5-triazin-2-amines WO2012143399A1 T NNS O
. WO2012143399A1 T . O

Amino CN102649773A T NNP O
aromatic CN102649773A T JJ O
hydrocarbon CN102649773A T NN O
compound CN102649773A T NN O
and CN102649773A T CC O
application CN102649773A T NN O
thereof CN102649773A T NN O
to CN102649773A T TO O
preparation CN102649773A T NN O
of CN102649773A T IN O
medicine CN102649773A T NN O
for CN102649773A T IN O
resisting CN102649773A T VBG O
malignant CN102649773A T JJ O
tumor CN102649773A T NN O
. CN102649773A T . O

The CN102649773A A DT O
invention CN102649773A A NN O
relates CN102649773A A VBZ O
to CN102649773A A TO O
an CN102649773A A DT O
amino CN102649773A A NN O
aromatic CN102649773A A JJ O
hydrocarbon CN102649773A A NN O
compound CN102649773A A NN O
capable CN102649773A A JJ O
of CN102649773A A IN O
serving CN102649773A A VBG O
as CN102649773A A IN O
an CN102649773A A DT O
active-mitogen-activated CN102649773A A JJ O
protein CN102649773A A NN I-UN
kinase/extracellular CN102649773A A JJ O
signal CN102649773A A NN I-UN
regulated CN102649773A A VBN I-UN
kinase CN102649773A A NN I-UN
( CN102649773A A ( I-UN
ERK CN102649773A A NNP I-UN
) CN102649773A A ) I-UN
1/2 CN102649773A A CD I-UN
inhibitor CN102649773A A NN O
and CN102649773A A CC O
application CN102649773A A NN O
of CN102649773A A IN O
the CN102649773A A DT O
amino CN102649773A A NN O
aromatic CN102649773A A JJ O
hydrocarbon CN102649773A A NN O
compound CN102649773A A NN O
to CN102649773A A TO O
preparation CN102649773A A NN O
of CN102649773A A IN O
a CN102649773A A DT O
medicine CN102649773A A NN O
for CN102649773A A IN O
resisting CN102649773A A VBG O
malignant CN102649773A A JJ O
tumor CN102649773A A NN O
. CN102649773A A . O

The CN102649773A A DT O
amino CN102649773A A NN O
aromatic CN102649773A A JJ O
hydrocarbon CN102649773A A NN O
compound CN102649773A A NN O
is CN102649773A A VBZ O
a CN102649773A A DT O
selective CN102649773A A JJ O
active-mitogen-activated CN102649773A A JJ O
protein CN102649773A A NN I-UN
kinase/ERK CN102649773A A VBD O
1/2 CN102649773A A CD I-UN
inhibitor CN102649773A A NN O
and CN102649773A A CC O
can CN102649773A A MD O
be CN102649773A A VB O
used CN102649773A A VBN O
for CN102649773A A IN O
preventing CN102649773A A VBG O
or CN102649773A A CC O
treating CN102649773A A VBG O
malignant CN102649773A A JJ O
tumor CN102649773A A NN O
, CN102649773A A , O
in CN102649773A A IN O
particular CN102649773A A JJ O
for CN102649773A A IN O
treating CN102649773A A VBG O
melanoma CN102649773A A NN O
, CN102649773A A , O
colorectal CN102649773A A JJ O
cancer CN102649773A A NN O
, CN102649773A A , O
breast CN102649773A A NN O
cancer CN102649773A A NN O
, CN102649773A A , O
pancreatic CN102649773A A JJ O
cancer CN102649773A A NN O
, CN102649773A A , O
epidermoid CN102649773A A JJ O
tumor CN102649773A A NN O
, CN102649773A A , O
brain CN102649773A A NN O
tumor CN102649773A A NN O
and CN102649773A A CC O
liver CN102649773A A NN O
cancer CN102649773A A NN O
. CN102649773A A . O

Methods US20090105240 T NNS O
for US20090105240 T IN O
treating US20090105240 T VBG O
leukemia US20090105240 T NN O
and US20090105240 T CC O
myelodysplastic US20090105240 T JJ O
syndrome US20090105240 T NN O
, US20090105240 T , O
and US20090105240 T CC O
methods US20090105240 T NNS O
for US20090105240 T IN O
identifying US20090105240 T VBG O
agents US20090105240 T NNS O
for US20090105240 T IN O
treating US20090105240 T VBG O
same US20090105240 T JJ O
. US20090105240 T . O

The US20090105240 A DT O
present US20090105240 A JJ O
disclosure US20090105240 A NN O
relates US20090105240 A VBZ O
to US20090105240 A TO O
methods US20090105240 A NNS O
for US20090105240 A IN O
treating US20090105240 A VBG O
leukemia US20090105240 A NN O
, US20090105240 A , O
pre-leukemic US20090105240 A JJ O
conditions US20090105240 A NNS O
, US20090105240 A , O
as US20090105240 A RB O
well US20090105240 A RB O
as US20090105240 A IN O
myelodysplastic US20090105240 A JJ O
syndrome US20090105240 A NN O
and US20090105240 A CC O
acute US20090105240 A NN O
myelogenous US20090105240 A JJ O
leukemia US20090105240 A NN O
. US20090105240 A . O

The US20090105240 A DT O
present US20090105240 A JJ O
disclosure US20090105240 A NN O
further US20090105240 A RBR O
relates US20090105240 A VBZ O
to US20090105240 A TO O
compounds US20090105240 A NNS O
that US20090105240 A WDT O
can US20090105240 A MD O
be US20090105240 A VB O
used US20090105240 A VBN O
for US20090105240 A IN O
treating US20090105240 A VBG O
leukemia US20090105240 A NN O
, US20090105240 A , O
pre-leukemic US20090105240 A JJ O
conditions US20090105240 A NNS O
, US20090105240 A , O
as US20090105240 A RB O
well US20090105240 A RB O
as US20090105240 A IN O
myelodysplastic US20090105240 A JJ O
syndrome US20090105240 A NN O
and US20090105240 A CC O
acute US20090105240 A NN O
myelogenous US20090105240 A JJ O
leukemia US20090105240 A NN O
. US20090105240 A . O

The US20090105240 A DT O
present US20090105240 A JJ O
disclosure US20090105240 A NN O
also US20090105240 A RB O
relates US20090105240 A VBZ O
to US20090105240 A TO O
methods US20090105240 A NNS O
for US20090105240 A IN O
identifying US20090105240 A VBG O
compounds US20090105240 A NNS O
that US20090105240 A WDT O
can US20090105240 A MD O
be US20090105240 A VB O
used US20090105240 A VBN O
for US20090105240 A IN O
treating US20090105240 A VBG O
leukemia US20090105240 A NN O
, US20090105240 A , O
pre-leukemic US20090105240 A JJ O
conditions US20090105240 A NNS O
, US20090105240 A , O
as US20090105240 A RB O
well US20090105240 A RB O
as US20090105240 A IN O
myelodysplastic US20090105240 A JJ O
syndrome US20090105240 A NN O
. US20090105240 A . O

Darifenacin CN102048706A T NNP O
hydrobromide CN102048706A T JJ O
sustained-release CN102048706A T JJ O
tablet CN102048706A T NN O
and CN102048706A T CC O
preparation CN102048706A T NN O
method CN102048706A T NN O
. CN102048706A T . O

Administration EP1525882A1 T NNP O
form EP1525882A1 T NN O
comprising EP1525882A1 T VBG O
an EP1525882A1 T DT O
acid-labile EP1525882A1 T JJ O
active EP1525882A1 T JJ O
compound EP1525882A1 T NN O
. EP1525882A1 T . O

Novel US20120214769 T JJ O
Antagonists US20120214769 T NNS O
of US20120214769 T IN O
the US20120214769 T DT O
Glucagon US20120214769 T NNP I-UN
Receptor US20120214769 T NNP I-UN
. US20120214769 T . O

The US20120214769 A DT O
present US20120214769 A JJ O
invention US20120214769 A NN O
provides US20120214769 A VBZ O
for US20120214769 A IN O
novel US20120214769 A JJ O
compounds US20120214769 A NNS O
of US20120214769 A IN O
Formula US20120214769 A NNP O
( US20120214769 A ( O
I US20120214769 A PRP O
) US20120214769 A ) O
and US20120214769 A CC O
pharmaceutically US20120214769 A RB O
acceptable US20120214769 A JJ O
salts US20120214769 A NNS O
and US20120214769 A CC O
co-crystals US20120214769 A NNS O
thereof US20120214769 A NN O
which US20120214769 A WDT O
have US20120214769 A VBP O
glucagon US20120214769 A VBN I-UN
receptor US20120214769 A NN I-UN
antagonist US20120214769 A NN O
or US20120214769 A CC O
inverse US20120214769 A JJ O
agonist US20120214769 A NN O
activity US20120214769 A NN O
. US20120214769 A . O

The US20120214769 A DT O
present US20120214769 A JJ O
invention US20120214769 A NN O
further US20120214769 A RBR O
provides US20120214769 A VBZ O
for US20120214769 A IN O
pharmaceutical US20120214769 A JJ O
compositions US20120214769 A NNS O
comprising US20120214769 A VBG O
the US20120214769 A DT O
same US20120214769 A JJ O
as US20120214769 A RB O
well US20120214769 A RB O
as US20120214769 A IN O
methods US20120214769 A NNS O
of US20120214769 A IN O
treating US20120214769 A NN O
, US20120214769 A , O
preventing US20120214769 A VBG O
, US20120214769 A , O
delaying US20120214769 A VBG O
the US20120214769 A DT O
time US20120214769 A NN O
to US20120214769 A TO O
onset US20120214769 A VB O
or US20120214769 A CC O
reducing US20120214769 A VBG O
the US20120214769 A DT O
risk US20120214769 A NN O
for US20120214769 A IN O
the US20120214769 A DT O
development US20120214769 A NN O
or US20120214769 A CC O
progression US20120214769 A NN O
of US20120214769 A IN O
a US20120214769 A DT O
disease US20120214769 A NN O
or US20120214769 A CC O
condition US20120214769 A NN O
for US20120214769 A IN O
which US20120214769 A WDT O
one US20120214769 A CD O
or US20120214769 A CC O
more US20120214769 A JJR O
glucagon US20120214769 A NNS I-UN
receptor US20120214769 A NN I-UN
antagonist US20120214769 A NN O
is US20120214769 A VBZ O
indicated US20120214769 A VBN O
, US20120214769 A , O
including US20120214769 A VBG O
Type US20120214769 A NN O
I US20120214769 A PRP O
and US20120214769 A CC O
II US20120214769 A NNP O
diabetes US20120214769 A NNS O
, US20120214769 A , O
insulin US20120214769 A NN I-UN
resistance US20120214769 A NN O
and US20120214769 A CC O
hyperglycemia US20120214769 A NN O
. US20120214769 A . O

Process US20120251626 T NN O
for US20120251626 T IN O
manufacturing US20120251626 T VBG O
biocompatible US20120251626 T JJ O
material US20120251626 T NN O
. US20120251626 T . O

A US20120251626 A DT O
process US20120251626 A NN O
for US20120251626 A IN O
producing US20120251626 A VBG O
a US20120251626 A DT O
biocompatible US20120251626 A JJ O
material US20120251626 A NN O
includes US20120251626 A VBZ O
the US20120251626 A DT O
steps US20120251626 A NNS O
of US20120251626 A IN O
mixing US20120251626 A VBG O
an US20120251626 A DT O
extract US20120251626 A NN O
of US20120251626 A IN O
a US20120251626 A DT O
fish US20120251626 A JJ O
scale-derived US20120251626 A JJ O
hydroxyapatite US20120251626 A NN O
( US20120251626 A ( O
with US20120251626 A IN O
water US20120251626 A NN O
content US20120251626 A NN O
of US20120251626 A IN O
70 US20120251626 A CD O
to US20120251626 A TO O
75 US20120251626 A CD O
% US20120251626 A NN O
by US20120251626 A IN O
weight US20120251626 A NN O
) US20120251626 A ) O
and US20120251626 A CC O
of US20120251626 A IN O
a US20120251626 A DT O
fish US20120251626 A JJ O
scale-derived US20120251626 A JJ O
collagen US20120251626 A NN I-UN
( US20120251626 A ( O
with US20120251626 A IN O
water US20120251626 A NN O
content US20120251626 A NN O
of US20120251626 A IN O
40 US20120251626 A CD O
to US20120251626 A TO O
60 US20120251626 A CD O
% US20120251626 A NN O
by US20120251626 A IN O
weight US20120251626 A NN O
) US20120251626 A ) O
in US20120251626 A IN O
the US20120251626 A DT O
weight US20120251626 A NN O
percent US20120251626 A NN O
ratio US20120251626 A NN O
of US20120251626 A IN O
about US20120251626 A RB O
8:2 US20120251626 A CD O
, US20120251626 A , O
stirring US20120251626 A VBG O
the US20120251626 A DT O
mixture US20120251626 A NN O
and US20120251626 A CC O
drying US20120251626 A VBG O
the US20120251626 A DT O
mixture US20120251626 A NN O
by US20120251626 A IN O
a US20120251626 A DT O
hot US20120251626 A JJ O
blast US20120251626 A NN O
in US20120251626 A IN O
order US20120251626 A NN O
to US20120251626 A TO O
obtain US20120251626 A VB O
a US20120251626 A DT O
composite US20120251626 A NN O
. US20120251626 A . O

Water WO2005095369A1 T NNP O
soluble WO2005095369A1 T JJ O
esters WO2005095369A1 T NNS O
of WO2005095369A1 T IN O
[ WO2005095369A1 T JJ O
n- WO2005095369A1 T JJ O
( WO2005095369A1 T ( O
4-amino-2-butynyl WO2005095369A1 T JJ O
) WO2005095369A1 T ) O
] WO2005095369A1 T NN O
with WO2005095369A1 T IN O
anticancer WO2005095369A1 T NN O
activity WO2005095369A1 T NN O
. WO2005095369A1 T . O

The WO2005095369A1 A DT O
present WO2005095369A1 A JJ O
invention WO2005095369A1 A NN O
relates WO2005095369A1 A VBZ O
to WO2005095369A1 A TO O
water WO2005095369A1 A NN O
soluble WO2005095369A1 A JJ O
esters WO2005095369A1 A NNS O
of WO2005095369A1 A IN O
[ WO2005095369A1 A JJ O
N- WO2005095369A1 A NNP O
( WO2005095369A1 A ( O
4-amino-2-butynyl WO2005095369A1 A JJ O
) WO2005095369A1 A ) O
] WO2005095369A1 A CD O
or WO2005095369A1 A CC O
4- WO2005095369A1 A JJ O
( WO2005095369A1 A ( O
N-substituted WO2005095369A1 A NNP O
amino WO2005095369A1 A NN O
) WO2005095369A1 A ) O
-2-butynyl-1-esters WO2005095369A1 A NNS O
and WO2005095369A1 A CC O
methods WO2005095369A1 A NNS O
for WO2005095369A1 A IN O
production WO2005095369A1 A NN O
of WO2005095369A1 A IN O
said WO2005095369A1 A VBD O
esters WO2005095369A1 A NNS O
and WO2005095369A1 A CC O
the WO2005095369A1 A DT O
use WO2005095369A1 A NN O
of WO2005095369A1 A IN O
the WO2005095369A1 A DT O
esters WO2005095369A1 A NNS O
for WO2005095369A1 A IN O
treatment WO2005095369A1 A NN O
of WO2005095369A1 A IN O
cancer WO2005095369A1 A NN O
. WO2005095369A1 A . O

Method US7504500 T NNP O
for US7504500 T IN O
the US7504500 T DT O
production US7504500 T NN O
of US7504500 T IN O
pyrrolidine-1,2-dicarboxylic US7504500 T JJ O
acid-1- US7504500 T JJ O
( US7504500 T ( O
phenyl US7504500 T NN O
( US7504500 T ( O
-amide US7504500 T NNP O
) US7504500 T ) O
) US7504500 T ) O
-2 US7504500 T FW O
( US7504500 T ( O
phenyl US7504500 T NN O
( US7504500 T ( O
-amide US7504500 T NNP O
) US7504500 T ) O
) US7504500 T ) O
derivatives US7504500 T NNS O
and US7504500 T CC O
1- US7504500 T JJ O
( US7504500 T ( O
phenylcarbamoyl US7504500 T NN O
) US7504500 T ) O
-pyrrolidine-2-carboxylic US7504500 T JJ O
acid US7504500 T JJ O
derivatives US7504500 T NNS O
as US7504500 T IN O
intermediate US7504500 T JJ O
products US7504500 T NNS O
. US7504500 T . O

Drug WO2006051818A1 T NN O
for WO2006051818A1 T IN O
external WO2006051818A1 T JJ O
use WO2006051818A1 T NN O
and WO2006051818A1 T CC O
adhesive WO2006051818A1 T JJ O
patch WO2006051818A1 T NN O
. WO2006051818A1 T . O

Pharmaceutical WO2011086577A3 T JJ O
composition WO2011086577A3 T NN O
of WO2011086577A3 T IN O
moxifloxacin WO2011086577A3 T NN O
and WO2011086577A3 T CC O
its WO2011086577A3 T PRP$ O
pharmaceutically WO2011086577A3 T RB O
acceptable WO2011086577A3 T JJ O
salts WO2011086577A3 T NNS O
. WO2011086577A3 T . O

Pure WO2007075838A2 T NN O
and WO2007075838A2 T CC O
stable WO2007075838A2 T JJ O
tiotropium WO2007075838A2 T NN O
bromide WO2007075838A2 T NN O
. WO2007075838A2 T . O

Compound CN1850094A T NNP O
Tara CN1850094A T NNP O
vagina-anus-cleaning CN1850094A T JJ O
liquid CN1850094A T NN O
and CN1850094A T CC O
its CN1850094A T PRP$ O
preparing CN1850094A T NN O
method CN1850094A T NN O
. CN1850094A T . O

Pharmaceutical EP2646434A1 T JJ O
compositions EP2646434A1 T NNS O
, EP2646434A1 T , O
dosage EP2646434A1 T NN O
forms EP2646434A1 T NNS O
and EP2646434A1 T CC O
new EP2646434A1 T JJ O
forms EP2646434A1 T NNS O
of EP2646434A1 T IN O
the EP2646434A1 T DT O
compound EP2646434A1 T NN O
of EP2646434A1 T IN O
formula EP2646434A1 T NN O
( EP2646434A1 T ( O
i EP2646434A1 T NN O
) EP2646434A1 T ) O
, EP2646434A1 T , O
and EP2646434A1 T CC O
methods EP2646434A1 T NNS O
of EP2646434A1 T IN O
use EP2646434A1 T NN O
thereof EP2646434A1 T NN O
. EP2646434A1 T . O

The EP2646434A1 A DT O
present EP2646434A1 A JJ O
invention EP2646434A1 A NN O
relates EP2646434A1 A VBZ O
to EP2646434A1 A TO O
a EP2646434A1 A DT O
novel EP2646434A1 A JJ O
crystalline EP2646434A1 A NN O
anhydrous EP2646434A1 A JJ O
form EP2646434A1 A NN O
of EP2646434A1 A IN O
[ EP2646434A1 A NNP O
( EP2646434A1 A ( O
5-chlorothiophene-2- EP2646434A1 A JJ O
ylsulfonylcarbamoyl EP2646434A1 A NN O
) EP2646434A1 A ) O
- EP2646434A1 A : O
( EP2646434A1 A ( O
4- EP2646434A1 A JJ O
( EP2646434A1 A ( O
6-fluoro-7- EP2646434A1 A JJ O
( EP2646434A1 A ( O
methylamino EP2646434A1 A NN O
) EP2646434A1 A ) O
-2,4-dioxo-1,2-dihydroquinazolin-3 EP2646434A1 A NN O
( EP2646434A1 A ( O
4H EP2646434A1 A CD O
) EP2646434A1 A ) O
- EP2646434A1 A : O
yl EP2646434A1 A NN O
) EP2646434A1 A ) O
phenyl EP2646434A1 A NN O
) EP2646434A1 A ) O
amide EP2646434A1 A NN O
, EP2646434A1 A , O
potassium EP2646434A1 A NN O
salt EP2646434A1 A NN O
, EP2646434A1 A , O
and EP2646434A1 A CC O
its EP2646434A1 A PRP$ O
use EP2646434A1 A NN O
in EP2646434A1 A IN O
the EP2646434A1 A DT O
treatment EP2646434A1 A NN O
or EP2646434A1 A CC O
prevention EP2646434A1 A NN O
of EP2646434A1 A IN O
a EP2646434A1 A DT O
condition EP2646434A1 A NN O
or EP2646434A1 A CC O
a EP2646434A1 A DT O
disorder EP2646434A1 A NN O
with EP2646434A1 A IN O
platelet EP2646434A1 A NN O
ADP EP2646434A1 A NNP O
receptor EP2646434A1 A NN O
inhibition EP2646434A1 A NN O
, EP2646434A1 A , O
in EP2646434A1 A IN O
particular EP2646434A1 A JJ O
, EP2646434A1 A , O
P2Y12 EP2646434A1 A NNP I-UN
inhibition EP2646434A1 A NN O
, EP2646434A1 A , O
in EP2646434A1 A IN O
animals EP2646434A1 A NNS O
, EP2646434A1 A , O
particularly EP2646434A1 A RB O
humans EP2646434A1 A NNS O
. EP2646434A1 A . O

Navel-warming CN102008695B T JJ O
plaster CN102008695B T NN O
for CN102008695B T IN O
treating CN102008695B T VBG O
poor CN102008695B T JJ O
alimentary CN102008695B T JJ O
system CN102008695B T NN O
caused CN102008695B T VBN O
by CN102008695B T IN O
catching CN102008695B T VBG O
cold CN102008695B T NN O
. CN102008695B T . O

Rare CN101817817A T NNP O
earth CN101817817A T NN O
metal CN101817817A T NN O
complexes CN101817817A T NNS O
using CN101817817A T VBG O
orbifloxacin CN101817817A T NN O
as CN101817817A T IN O
ligand CN101817817A T NN O
, CN101817817A T , O
method CN101817817A T NN O
for CN101817817A T IN O
synthesizing CN101817817A T VBG O
same CN101817817A T JJ O
and CN101817817A T CC O
application CN101817817A T NN O
thereof CN101817817A T NN O
. CN101817817A T . O

Wound-healing US20120196801 T JJ O
, US20120196801 T , O
anti-ambustial US20120196801 T JJ O
, US20120196801 T , O
regenerating US20120196801 T NN O
, US20120196801 T , O
and US20120196801 T CC O
anti-viral US20120196801 T JJ O
pharmaceutical US20120196801 T JJ O
formula US20120196801 T NN O
for US20120196801 T IN O
local US20120196801 T JJ O
administration US20120196801 T NN O
. US20120196801 T . O

Metallo-oxidoreductase WO2008064311A2 T JJ I-UN
inhibitors WO2008064311A2 T NNS O
using WO2008064311A2 T VBG O
metal WO2008064311A2 T NN O
binding WO2008064311A2 T VBG O
moieties WO2008064311A2 T NNS O
in WO2008064311A2 T IN O
combination WO2008064311A2 T NN O
with WO2008064311A2 T IN O
targeting WO2008064311A2 T VBG O
moieties WO2008064311A2 T NNS O
. WO2008064311A2 T . O

The WO2008064311A2 A DT O
presently WO2008064311A2 A RB O
disclosed WO2008064311A2 A VBN O
subject WO2008064311A2 A JJ O
matter WO2008064311A2 A NN O
is WO2008064311A2 A VBZ O
directed WO2008064311A2 A VBN O
to WO2008064311A2 A TO O
metallo-oxidoreductase WO2008064311A2 A JJ I-UN
inhibitors WO2008064311A2 A NNS O
having WO2008064311A2 A VBG O
metal WO2008064311A2 A NN O
binding WO2008064311A2 A VBG O
moities WO2008064311A2 A NNS O
linked WO2008064311A2 A VBN O
to WO2008064311A2 A TO O
a WO2008064311A2 A DT O
targeting WO2008064311A2 A VBG O
moiety WO2008064311A2 A NN O
through WO2008064311A2 A IN O
a WO2008064311A2 A DT O
linking WO2008064311A2 A VBG O
group WO2008064311A2 A NN O
or WO2008064311A2 A CC O
a WO2008064311A2 A DT O
direct WO2008064311A2 A JJ O
bond WO2008064311A2 A NN O
, WO2008064311A2 A , O
methods WO2008064311A2 A NNS O
for WO2008064311A2 A IN O
screening WO2008064311A2 A VBG O
for WO2008064311A2 A IN O
metallo-oxidoreductase WO2008064311A2 A JJ I-UN
inhibitors WO2008064311A2 A NNS O
, WO2008064311A2 A , O
and WO2008064311A2 A CC O
methods WO2008064311A2 A NNS O
of WO2008064311A2 A IN O
treating WO2008064311A2 A VBG O
an WO2008064311A2 A DT O
oxidoreductase WO2008064311A2 A NN I-UN
related WO2008064311A2 A VBN O
disorder WO2008064311A2 A NN O
by WO2008064311A2 A IN O
administering WO2008064311A2 A VBG O
a WO2008064311A2 A DT O
metallo- WO2008064311A2 A JJ I-UN
oxidoreductase WO2008064311A2 A NN I-UN
inhibitor WO2008064311A2 A NN O
to WO2008064311A2 A TO O
a WO2008064311A2 A DT O
subject WO2008064311A2 A NN O
in WO2008064311A2 A IN O
need WO2008064311A2 A NN O
of WO2008064311A2 A IN O
treatment WO2008064311A2 A NN O
thereof WO2008064311A2 A NN O
. WO2008064311A2 A . O

Compositions US20110152350 T NNS O
and US20110152350 T CC O
Methods US20110152350 T NNS O
for US20110152350 T IN O
Inhibiting US20110152350 T VBG O
Expression US20110152350 T NNP O
of US20110152350 T IN O
XBP-1 US20110152350 T NNP I-UN
Gene US20110152350 T NNP O
. US20110152350 T . O

The US20110152350 A DT O
invention US20110152350 A NN O
relates US20110152350 A VBZ O
to US20110152350 A TO O
a US20110152350 A DT O
double-stranded US20110152350 A JJ O
ribonucleic US20110152350 A NN O
acid US20110152350 A NN O
( US20110152350 A ( O
dsRNA US20110152350 A NN O
) US20110152350 A ) O
targeting US20110152350 A VBG O
X-Box US20110152350 A JJ I-UN
Protein US20110152350 A NNP I-UN
1 US20110152350 A CD I-UN
( US20110152350 A ( O
XBP-1 US20110152350 A NN I-UN
) US20110152350 A ) O
, US20110152350 A , O
and US20110152350 A CC O
methods US20110152350 A NNS O
of US20110152350 A IN O
using US20110152350 A VBG O
the US20110152350 A DT O
dsRNA US20110152350 A NN O
to US20110152350 A TO O
inhibit US20110152350 A VB O
expression US20110152350 A NN O
of US20110152350 A IN O
XBP-1 US20110152350 A NNP I-UN
. US20110152350 A . O

Application CN102719521A T NN O
of CN102719521A T IN O
cystine/glutamic CN102719521A T JJ I-UN
acid CN102719521A T JJ I-UN
reverse CN102719521A T NN I-UN
transporter CN102719521A T NN I-UN
xCT CN102719521A T NNP I-UN
inhibitor CN102719521A T NN O
in CN102719521A T IN O
treating CN102719521A T VBG O
liver CN102719521A T NN O
cancer CN102719521A T NN O
. CN102719521A T . O

The CN102719521A A DT O
invention CN102719521A A NN O
provides CN102719521A A VBZ O
an CN102719521A A DT O
application CN102719521A A NN O
of CN102719521A A IN O
a CN102719521A A DT O
cystine/glutamic CN102719521A A JJ I-UN
acid CN102719521A A NN I-UN
reverse CN102719521A A NN I-UN
transporter CN102719521A A NN I-UN
xCT CN102719521A A NNP I-UN
inhibitor CN102719521A A NN O
in CN102719521A A IN O
treating CN102719521A A VBG O
liver CN102719521A A NN O
cancer CN102719521A A NN O
, CN102719521A A , O
particularly CN102719521A A RB O
provides CN102719521A A VBZ O
a CN102719521A A DT O
highly CN102719521A A RB O
expressed CN102719521A A VBN O
marker CN102719521A A NN O
xCT CN102719521A A NN I-UN
in CN102719521A A IN O
live CN102719521A A JJ O
cancer CN102719521A A NN O
. CN102719521A A . O

In CN102719521A A IN O
addition CN102719521A A NN O
, CN102719521A A , O
the CN102719521A A DT O
expression CN102719521A A NN O
or CN102719521A A CC O
activity CN102719521A A NN O
of CN102719521A A IN O
the CN102719521A A DT O
xCT CN102719521A A NNP I-UN
is CN102719521A A VBZ O
related CN102719521A A VBN O
to CN102719521A A TO O
prognosis CN102719521A A NN O
of CN102719521A A IN O
patients CN102719521A A NNS O
, CN102719521A A , O
thus CN102719521A A RB O
the CN102719521A A DT O
expression CN102719521A A NN O
of CN102719521A A IN O
the CN102719521A A DT O
xCT CN102719521A A NN I-UN
in CN102719521A A IN O
liver CN102719521A A NN O
cancer CN102719521A A NN O
cells CN102719521A A NNS O
or CN102719521A A CC O
tissues CN102719521A A NNS O
can CN102719521A A MD O
be CN102719521A A VB O
used CN102719521A A VBN O
for CN102719521A A IN O
auxiliarily CN102719521A A RB O
diagnosing CN102719521A A VBG O
or CN102719521A A CC O
determining CN102719521A A VBG O
the CN102719521A A DT O
probability CN102719521A A NN O
of CN102719521A A IN O
cancer CN102719521A A NN O
occurrence CN102719521A A NN O
in CN102719521A A IN O
subjects CN102719521A A NNS O
and CN102719521A A CC O
used CN102719521A A VBN O
for CN102719521A A IN O
prognosis CN102719521A A NN O
of CN102719521A A IN O
liver CN102719521A A NN O
cancer CN102719521A A NN O
patients CN102719521A A NNS O
. CN102719521A A . O

Botanical WO2005112965A2 T JJ O
anti-inflammatory WO2005112965A2 T JJ O
compositions WO2005112965A2 T NNS O
and WO2005112965A2 T CC O
methods WO2005112965A2 T NNS O
. WO2005112965A2 T . O

Recipe CN1772288A T NNP O
of CN1772288A T IN O
skin CN1772288A T NN O
repairing CN1772288A T VBG O
composition CN1772288A T NN O
. CN1772288A T . O

The CN1772288A A DT O
recipe CN1772288A A NN O
of CN1772288A A IN O
skin CN1772288A A NN O
repairing CN1772288A A VBG O
composition CN1772288A A NN O
includes CN1772288A A VBZ O
: CN1772288A A : O
EDTA-2Na CN1772288A A JJ O
, CN1772288A A , O
glycerin CN1772288A A NN O
, CN1772288A A , O
1 CN1772288A A CD O
, CN1772288A A , O
3-butanediol CN1772288A A CD O
, CN1772288A A , O
metallothionein CN1772288A A FW O
zinc CN1772288A A NN O
, CN1772288A A , O
heparin CN1772288A A JJ O
sodium CN1772288A A NN O
, CN1772288A A , O
recombinant CN1772288A A JJ O
human CN1772288A A JJ I-UN
epidermal CN1772288A A JJ I-UN
growth CN1772288A A NN I-UN
factor CN1772288A A NN I-UN
, CN1772288A A , O
liposoluble CN1772288A A JJ O
preservative CN1772288A A NN O
, CN1772288A A , O
recombinant CN1772288A A JJ O
human CN1772288A A JJ O
stem CN1772288A A NN O
cell CN1772288A A NN O
factor CN1772288A A NN O
, CN1772288A A , O
and CN1772288A A CC O
buffering CN1772288A A VBG O
solution CN1772288A A NN O
. CN1772288A A . O

The CN1772288A A DT O
addition CN1772288A A NN O
of CN1772288A A IN O
the CN1772288A A DT O
epidermal CN1772288A A JJ I-UN
growth CN1772288A A NN I-UN
factor CN1772288A A NN I-UN
can CN1772288A A MD O
induce CN1772288A A VB O
the CN1772288A A DT O
fast CN1772288A A JJ O
proliferation CN1772288A A NN O
of CN1772288A A IN O
the CN1772288A A DT O
transient CN1772288A A NN O
proliferating CN1772288A A VBG O
cells CN1772288A A NNS O
and CN1772288A A CC O
improve CN1772288A A VB O
intercellular CN1772288A A JJ O
substance CN1772288A A NN O
circumstance CN1772288A A NN O
to CN1772288A A TO O
regulate CN1772288A A VB O
the CN1772288A A DT O
growth CN1772288A A NN O
of CN1772288A A IN O
skin CN1772288A A NN O
cell CN1772288A A NN O
. CN1772288A A . O

The CN1772288A A DT O
metallothionein CN1772288A A NN O
can CN1772288A A MD O
eliminate CN1772288A A VB O
free CN1772288A A JJ O
radical CN1772288A A NN O
and CN1772288A A CC O
other CN1772288A A JJ O
cell CN1772288A A NN O
metabolism CN1772288A A NN O
products CN1772288A A NNS O
during CN1772288A A IN O
cell CN1772288A A NN O
growth CN1772288A A NN O
specifically CN1772288A A RB O
, CN1772288A A , O
so CN1772288A A RB O
as CN1772288A A IN O
to CN1772288A A TO O
create CN1772288A A VB O
clean CN1772288A A JJ O
circumstance CN1772288A A NN O
for CN1772288A A IN O
sustained CN1772288A A JJ O
effective CN1772288A A JJ O
action CN1772288A A NN O
of CN1772288A A IN O
stem CN1772288A A NN O
cell CN1772288A A NN O
factor CN1772288A A NN O
and CN1772288A A CC O
epidermal CN1772288A A JJ I-UN
growth CN1772288A A NN I-UN
factor CN1772288A A NN I-UN
on CN1772288A A IN O
the CN1772288A A DT O
cells CN1772288A A NNS O
. CN1772288A A . O

hexoses US7186544 T NNS O
or US7186544 T CC O
their US7186544 T PRP$ O
non-toxic US7186544 T JJ O
salts US7186544 T NNS O
or US7186544 T CC O
their US7186544 T PRP$ O
intramolecular US7186544 T JJ O
esterification US7186544 T NN O
products US7186544 T NNS O
, US7186544 T , O
particularly US7186544 T RB O
sodium US7186544 T JJ O
gluconate US7186544 T NN O
, US7186544 T , O
calcium US7186544 T NN O
gluconate US7186544 T NN O
or US7186544 T CC O
glucono US7186544 T NN O
delta US7186544 T NN O
lactone US7186544 T NN O
; US7186544 T : O
promoting US7186544 T VBG O
the US7186544 T DT O
growth US7186544 T NN O
of US7186544 T IN O
enterobacteria US7186544 T NNS O
that US7186544 T IN O
short-chain US7186544 T JJ O
fatty US7186544 T JJ O
acids US7186544 T NNS O
. US7186544 T . O

Enzyme US7291624 T JJ O
inhibitors US7291624 T NNS O
as US7291624 T IN O
drugs US7291624 T NNS O
for US7291624 T IN O
cardiovascular US7291624 T NN O
disorders US7291624 T NNS O
, US7291624 T , O
aids US7291624 T NNS O
, US7291624 T , O
alzheimers US7291624 T NNS O
disease US7291624 T VBP O
or US7291624 T CC O
urogenital US7291624 T JJ O
disorders US7291624 T NNS O
. US7291624 T . O

This US7291624 A DT O
invention US7291624 A NN O
relates US7291624 A VBZ O
to US7291624 A TO O
pyrimidine US7291624 A VB O
derivatives US7291624 A NNS O
of US7291624 A IN O
general US7291624 A JJ O
formula US7291624 A NN O
I US7291624 A PRP O
in US7291624 A IN O
which US7291624 A WDT O
R1 US7291624 A NNP O
, US7291624 A , O
R2 US7291624 A NNP O
, US7291624 A , O
X US7291624 A NNP O
, US7291624 A , O
A US7291624 A NNP O
and US7291624 A CC O
B US7291624 A NNP O
have US7291624 A VBP O
the US7291624 A DT O
meanings US7291624 A NNS O
that US7291624 A WDT O
are US7291624 A VBP O
contained US7291624 A VBN O
in US7291624 A IN O
the US7291624 A DT O
description US7291624 A NN O
, US7291624 A , O
as US7291624 A IN O
inhibitors US7291624 A NNS O
of US7291624 A IN O
the US7291624 A DT O
cyclin-dependent US7291624 A JJ I-UN
kinases US7291624 A NNS I-UN
, US7291624 A , O
their US7291624 A PRP$ O
production US7291624 A NN O
as US7291624 A RB O
well US7291624 A RB O
as US7291624 A IN O
their US7291624 A PRP$ O
use US7291624 A NN O
as US7291624 A IN O
medications US7291624 A NNS O
for US7291624 A IN O
treating US7291624 A VBG O
various US7291624 A JJ O
diseases US7291624 A NNS O
. US7291624 A . O

Apoe CA2555367A1 T NNP I-UN
genetic CA2555367A1 T JJ O
markers CA2555367A1 T NNS O
associated CA2555367A1 T VBN O
with CA2555367A1 T IN O
age CA2555367A1 T NN O
of CA2555367A1 T IN O
onset CA2555367A1 T NN O
of CA2555367A1 T IN O
alzheimer CA2555367A1 T NN O
's CA2555367A1 T POS O
disease CA2555367A1 T NN O
. CA2555367A1 T . O

Haplotypes CA2555367A1 A NNS O
in CA2555367A1 A IN O
the CA2555367A1 A DT O
APOE CA2555367A1 A NNP I-UN
gene CA2555367A1 A NN O
associated CA2555367A1 A VBN O
with CA2555367A1 A IN O
age CA2555367A1 A NN O
of CA2555367A1 A IN O
onset CA2555367A1 A NN O
of CA2555367A1 A IN O
Alzheimer~s CA2555367A1 A NNP O
Disease CA2555367A1 A NNP O
are CA2555367A1 A VBP O
disclosed CA2555367A1 A VBN O
. CA2555367A1 A . O

Compositions CA2555367A1 A NNS O
and CA2555367A1 A CC O
methods CA2555367A1 A NNS O
for CA2555367A1 A IN O
detecting CA2555367A1 A VBG O
and CA2555367A1 A CC O
using CA2555367A1 A VBG O
these CA2555367A1 A DT O
APOE CA2555367A1 A NNP I-UN
haplotypes CA2555367A1 A NNS O
in CA2555367A1 A IN O
a CA2555367A1 A DT O
variety CA2555367A1 A NN O
of CA2555367A1 A IN O
clinical CA2555367A1 A JJ O
applications CA2555367A1 A NNS O
are CA2555367A1 A VBP O
disclosed CA2555367A1 A VBN O
. CA2555367A1 A . O

Such CA2555367A1 A JJ O
applications CA2555367A1 A NNS O
include CA2555367A1 A VBP O
articles CA2555367A1 A NNS O
of CA2555367A1 A IN O
manufacture CA2555367A1 A NN O
comprising CA2555367A1 A VBG O
compounds CA2555367A1 A NNS O
effective CA2555367A1 A JJ O
in CA2555367A1 A IN O
delaying CA2555367A1 A VBG O
the CA2555367A1 A DT O
age CA2555367A1 A NN O
of CA2555367A1 A IN O
onset CA2555367A1 A NN O
of CA2555367A1 A IN O
AD CA2555367A1 A NNP O
in CA2555367A1 A IN O
individuals CA2555367A1 A NNS O
at CA2555367A1 A IN O
risk CA2555367A1 A NN O
for CA2555367A1 A IN O
developing CA2555367A1 A VBG O
AD CA2555367A1 A NNP O
and CA2555367A1 A CC O
having CA2555367A1 A VBG O
one CA2555367A1 A CD O
of CA2555367A1 A IN O
these CA2555367A1 A DT O
APOE CA2555367A1 A NNP I-UN
haplotypes CA2555367A1 A NNS O
, CA2555367A1 A , O
methods CA2555367A1 A NNS O
and CA2555367A1 A CC O
kits CA2555367A1 A NNS O
for CA2555367A1 A IN O
predicting CA2555367A1 A VBG O
the CA2555367A1 A DT O
age CA2555367A1 A NN O
of CA2555367A1 A IN O
onset CA2555367A1 A NN O
of CA2555367A1 A IN O
AD CA2555367A1 A NNP O
in CA2555367A1 A IN O
an CA2555367A1 A DT O
individual CA2555367A1 A NN O
at CA2555367A1 A IN O
risk CA2555367A1 A NN O
for CA2555367A1 A IN O
developing CA2555367A1 A VBG O
AD CA2555367A1 A NNP O
based CA2555367A1 A VBN O
upon CA2555367A1 A IN O
his/her CA2555367A1 A JJR O
haplotype CA2555367A1 A NN O
profile CA2555367A1 A NN O
, CA2555367A1 A , O
and CA2555367A1 A CC O
methods CA2555367A1 A NNS O
for CA2555367A1 A IN O
delaying CA2555367A1 A VBG O
the CA2555367A1 A DT O
age CA2555367A1 A NN O
of CA2555367A1 A IN O
onset CA2555367A1 A NN O
of CA2555367A1 A IN O
AD CA2555367A1 A NNP O
in CA2555367A1 A IN O
individuals CA2555367A1 A NNS O
at CA2555367A1 A IN O
risk CA2555367A1 A NN O
for CA2555367A1 A IN O
developing CA2555367A1 A VBG O
AD CA2555367A1 A NNP O
based CA2555367A1 A VBN O
upon CA2555367A1 A IN O
their CA2555367A1 A PRP$ O
haplotype CA2555367A1 A NN O
profile CA2555367A1 A NN O
. CA2555367A1 A . O

Angiogenesis US20070066633 T NNP O
inhibitor US20070066633 T NN O
; US20070066633 T : O
anticancer US20070066633 T CC O
agents US20070066633 T NNS O
; US20070066633 T : O
antiarthritic US20070066633 T JJ O
agents US20070066633 T NNS O
; US20070066633 T : O
psoriasis US20070066633 T NN O
. US20070066633 T . O

The US20070066633 A DT O
invention US20070066633 A NN O
concerns US20070066633 A NNS O
compounds US20070066633 A NNS O
of US20070066633 A IN O
the US20070066633 A DT O
formula US20070066633 A NN O
( US20070066633 A ( O
I US20070066633 A PRP O
) US20070066633 A ) O
: US20070066633 A : O
wherein US20070066633 A NN O
ring US20070066633 A VBG O
A US20070066633 A NNP O
is US20070066633 A VBZ O
phenyl US20070066633 A JJ O
or US20070066633 A CC O
a US20070066633 A DT O
5- US20070066633 A JJ O
or US20070066633 A CC O
6-membered US20070066633 A JJ O
heterocyclic US20070066633 A JJ O
ring US20070066633 A NN O
as US20070066633 A IN O
defined US20070066633 A JJ O
herein US20070066633 A NN O
; US20070066633 A : O
Z US20070066633 A NNP O
is US20070066633 A VBZ O
—O— US20070066633 A NNP O
, US20070066633 A , O
—NH— US20070066633 A NNP O
or US20070066633 A CC O
—S— US20070066633 A NNP O
; US20070066633 A : O
m US20070066633 A NN O
is US20070066633 A VBZ O
an US20070066633 A DT O
integer US20070066633 A NN O
from US20070066633 A IN O
0 US20070066633 A CD O
to US20070066633 A TO O
5 US20070066633 A CD O
inclusive US20070066633 A NN O
; US20070066633 A : O
R1 US20070066633 A NNP O
is US20070066633 A VBZ O
hydrogen US20070066633 A NN O
, US20070066633 A , O
hydroxy US20070066633 A NN O
, US20070066633 A , O
halogeno US20070066633 A NN O
, US20070066633 A , O
nitro US20070066633 A RB O
, US20070066633 A , O
trifluoromethyl US20070066633 A NN O
, US20070066633 A , O
cyano US20070066633 A NN O
, US20070066633 A , O
C1-3alkyl US20070066633 A NNP O
, US20070066633 A , O
C1-3alkoxy US20070066633 A NNP O
, US20070066633 A , O
C1-3alkylthio US20070066633 A NNP O
, US20070066633 A , O
or US20070066633 A CC O
—NR5R6 US20070066633 A NNP O
( US20070066633 A ( O
wherein US20070066633 A JJ O
R5 US20070066633 A NNP O
and US20070066633 A CC O
R6 US20070066633 A NNP O
, US20070066633 A , O
which US20070066633 A WDT O
may US20070066633 A MD O
be US20070066633 A VB O
the US20070066633 A DT O
same US20070066633 A JJ O
or US20070066633 A CC O
different US20070066633 A JJ O
, US20070066633 A , O
are US20070066633 A VBP O
hydrogen US20070066633 A JJ O
or US20070066633 A CC O
C1-3alkyl US20070066633 A JJ O
) US20070066633 A ) O
; US20070066633 A : O
R2 US20070066633 A NNP O
is US20070066633 A VBZ O
hydrogen US20070066633 A NN O
, US20070066633 A , O
hydroxy US20070066633 A NN O
, US20070066633 A , O
halogeno US20070066633 A NN O
, US20070066633 A , O
C1-3alkyl US20070066633 A NNP O
, US20070066633 A , O
C1-3alkoxy US20070066633 A NNP O
, US20070066633 A , O
trifluoromethyl US20070066633 A NN O
, US20070066633 A , O
amino US20070066633 A NN O
or US20070066633 A CC O
nitro US20070066633 A NN O
; US20070066633 A : O
R3 US20070066633 A NNP O
is US20070066633 A VBZ O
hydroxy US20070066633 A JJ O
, US20070066633 A , O
halogeno US20070066633 A JJ O
, US20070066633 A , O
C1-3alkyl US20070066633 A NNP O
, US20070066633 A , O
C1-3alkoxy US20070066633 A NNP O
, US20070066633 A , O
C1-3alkanoyloxy US20070066633 A NNP O
, US20070066633 A , O
trifluoromethyl US20070066633 A NN O
, US20070066633 A , O
cyano US20070066633 A NN O
, US20070066633 A , O
amino US20070066633 A NN O
or US20070066633 A CC O
nitro US20070066633 A NN O
; US20070066633 A : O
provided US20070066633 A VBN O
that US20070066633 A IN O
when US20070066633 A WRB O
ring US20070066633 A VBG O
A US20070066633 A DT O
is US20070066633 A VBZ O
a US20070066633 A DT O
5- US20070066633 A JJ O
or US20070066633 A CC O
6-membered US20070066633 A JJ O
heterocyclic US20070066633 A JJ O
ring US20070066633 A NN O
, US20070066633 A , O
at US20070066633 A IN O
least US20070066633 A JJS O
one US20070066633 A CD O
R3 US20070066633 A NNP O
is US20070066633 A VBZ O
either US20070066633 A DT O
hydroxy US20070066633 A NN O
or US20070066633 A CC O
halogeno US20070066633 A NN O
; US20070066633 A : O
X1 US20070066633 A NNP O
is US20070066633 A VBZ O
—O— US20070066633 A NNP O
, US20070066633 A , O
—CH2— US20070066633 A NNP O
, US20070066633 A , O
—S— US20070066633 A NNP O
, US20070066633 A , O
—SO— US20070066633 A NNP O
, US20070066633 A , O
—SO2— US20070066633 A NNP O
, US20070066633 A , O
—NR7— US20070066633 A NNP O
, US20070066633 A , O
—NR7CO— US20070066633 A NNP O
, US20070066633 A , O
—CONR7— US20070066633 A NNP O
, US20070066633 A , O
—SO2NR7— US20070066633 A NNP O
or US20070066633 A CC O
—NR7SO2— US20070066633 A NNP O
, US20070066633 A , O
( US20070066633 A ( O
wherein US20070066633 A JJ O
R7 US20070066633 A NNP O
is US20070066633 A VBZ O
hydrogen US20070066633 A JJ O
, US20070066633 A , O
C1-3alkyl US20070066633 A JJ O
or US20070066633 A CC O
C1-3alkoxyC2-3alkyl US20070066633 A JJ O
) US20070066633 A ) O
; US20070066633 A : O
and US20070066633 A CC O
R4 US20070066633 A NNP O
is US20070066633 A VBZ O
selected US20070066633 A VBN O
from US20070066633 A IN O
a US20070066633 A DT O
number US20070066633 A NN O
of US20070066633 A IN O
groups US20070066633 A NNS O
defined US20070066633 A VBN O
herein US20070066633 A RB O
comprising US20070066633 A VBG O
an US20070066633 A DT O
C2-5alkylene US20070066633 A JJ O
, US20070066633 A , O
C3-5alkenylene US20070066633 A NNP O
or US20070066633 A CC O
C3-5alkynylene US20070066633 A NNP O
chain US20070066633 A NN O
wherein US20070066633 A VBD O
each US20070066633 A DT O
methylene US20070066633 A NN O
group US20070066633 A NN O
( US20070066633 A ( O
other US20070066633 A JJ O
than US20070066633 A IN O
that US20070066633 A DT O
of US20070066633 A IN O
the US20070066633 A DT O
α-carbon US20070066633 A NN O
) US20070066633 A ) O
is US20070066633 A VBZ O
optionally US20070066633 A RB O
substituted US20070066633 A VBN O
by US20070066633 A IN O
1 US20070066633 A CD O
substituent US20070066633 A NN O
independently US20070066633 A RB O
selected US20070066633 A VBN O
from US20070066633 A IN O
hydroxy US20070066633 A NN O
, US20070066633 A , O
halogeno US20070066633 A NN O
, US20070066633 A , O
amino US20070066633 A NN O
and US20070066633 A CC O
C1-4alkanoyloxy US20070066633 A NNP O
; US20070066633 A : O
provisos US20070066633 A NNS O
are US20070066633 A VBP O
as US20070066633 A IN O
defined US20070066633 A JJ O
herein US20070066633 A NN O
. US20070066633 A . O

The US20070066633 A DT O
invention US20070066633 A NN O
also US20070066633 A RB O
relates US20070066633 A VBZ O
to US20070066633 A TO O
pharmaceutical US20070066633 A JJ O
compositions US20070066633 A NNS O
comprising US20070066633 A VBG O
a US20070066633 A DT O
compound US20070066633 A NN O
of US20070066633 A IN O
formula US20070066633 A NN O
( US20070066633 A ( O
I US20070066633 A PRP O
) US20070066633 A ) O
, US20070066633 A , O
to US20070066633 A TO O
the US20070066633 A DT O
use US20070066633 A NN O
of US20070066633 A IN O
a US20070066633 A DT O
compound US20070066633 A NN O
of US20070066633 A IN O
formula US20070066633 A NN O
( US20070066633 A ( O
I US20070066633 A PRP O
) US20070066633 A ) O
in US20070066633 A IN O
the US20070066633 A DT O
manufacture US20070066633 A NN O
of US20070066633 A IN O
a US20070066633 A DT O
medicament US20070066633 A NN O
for US20070066633 A IN O
use US20070066633 A NN O
in US20070066633 A IN O
the US20070066633 A DT O
production US20070066633 A NN O
of US20070066633 A IN O
an US20070066633 A DT O
antiangiogenic US20070066633 A JJ O
and/or US20070066633 A NN O
vascular US20070066633 A JJ O
permeability US20070066633 A NN O
reducing US20070066633 A VBG O
effect US20070066633 A NN O
in US20070066633 A IN O
a US20070066633 A DT O
warm-blooded US20070066633 A JJ O
animal US20070066633 A NN O
and US20070066633 A CC O
to US20070066633 A TO O
a US20070066633 A DT O
method US20070066633 A NN O
for US20070066633 A IN O
producing US20070066633 A VBG O
an US20070066633 A DT O
antiangiogenic US20070066633 A JJ O
and/or US20070066633 A NN O
vascular US20070066633 A JJ O
permeability US20070066633 A NN O
reducing US20070066633 A VBG O
effect US20070066633 A NN O
in US20070066633 A IN O
a US20070066633 A DT O
warm-blooded US20070066633 A JJ O
animal US20070066633 A NN O
in US20070066633 A IN O
need US20070066633 A NN O
of US20070066633 A IN O
such US20070066633 A JJ O
treatment US20070066633 A NN O
. US20070066633 A . O

The US20070066633 A DT O
compounds US20070066633 A NNS O
are US20070066633 A VBP O
useful US20070066633 A JJ O
in US20070066633 A IN O
disease US20070066633 A NN O
states US20070066633 A NNS O
such US20070066633 A JJ O
as US20070066633 A IN O
cancer US20070066633 A NN O
, US20070066633 A , O
rheumatoid US20070066633 A VB O
arthritis US20070066633 A NN O
and US20070066633 A CC O
psoriasis US20070066633 A NN O
. US20070066633 A . O

Recipe CN1757409A T NNP O
of CN1757409A T IN O
Wanshou CN1757409A T NNP O
capsule CN1757409A T NN O
, CN1757409A T , O
and CN1757409A T CC O
health-care CN1757409A T JJ O
function CN1757409A T NN O
. CN1757409A T . O

Compositions US20090181110 T NNS O
from US20090181110 T IN O
Garcinia US20090181110 T NNP O
as US20090181110 T IN O
Aromatase US20090181110 T NNP I-UN
Inhibitors US20090181110 T NNP O
for US20090181110 T IN O
Breast US20090181110 T NNP O
Cancer US20090181110 T NNP O
Chemoprevention US20090181110 T NNP O
and US20090181110 T CC O
Chemotherapy US20090181110 T NNP O
. US20090181110 T . O

Aromatase US20090181110 A NNP I-UN
inhibitors US20090181110 A NNS O
( US20090181110 A ( O
AIs US20090181110 A NNP O
) US20090181110 A ) O
are US20090181110 A VBP O
disclosed US20090181110 A VBN O
which US20090181110 A WDT O
are US20090181110 A VBP O
useful US20090181110 A JJ O
in US20090181110 A IN O
the US20090181110 A DT O
treatment US20090181110 A NN O
and US20090181110 A CC O
prevention US20090181110 A NN O
of US20090181110 A IN O
post-menopausal US20090181110 A JJ O
breast US20090181110 A NN O
cancer US20090181110 A NN O
. US20090181110 A . O

Several US20090181110 A JJ O
pure US20090181110 A NN O
compounds US20090181110 A NNS O
demonstrated US20090181110 A VBD O
AI US20090181110 A NNP O
activity US20090181110 A NN O
using US20090181110 A VBG O
a US20090181110 A DT O
noncellular US20090181110 A JJ O
, US20090181110 A , O
enzyme-based US20090181110 A JJ O
microsomal US20090181110 A NN O
and US20090181110 A CC O
a US20090181110 A DT O
cell-based US20090181110 A JJ O
aromatase US20090181110 A NN I-UN
assay US20090181110 A NN O
. US20090181110 A . O

Correlations US20090181110 A NNS O
are US20090181110 A VBP O
made US20090181110 A VBN O
between US20090181110 A IN O
structural US20090181110 A JJ O
classes US20090181110 A NNS O
with US20090181110 A IN O
levels US20090181110 A NNS O
of US20090181110 A IN O
aromatase US20090181110 A NN I-UN
inhibition US20090181110 A NN O
. US20090181110 A . O

The US20090181110 A DT O
disclosure US20090181110 A NN O
may US20090181110 A MD O
be US20090181110 A VB O
utilized US20090181110 A VBN O
to US20090181110 A TO O
direct US20090181110 A VB O
synthetic US20090181110 A JJ O
modification US20090181110 A NN O
of US20090181110 A IN O
natural US20090181110 A JJ O
product US20090181110 A NN O
scaffolds US20090181110 A NNS O
to US20090181110 A TO O
enhance US20090181110 A VB O
aromatase US20090181110 A JJ I-UN
inhibition US20090181110 A NN O
or US20090181110 A CC O
to US20090181110 A TO O
standardize US20090181110 A VB O
botanical US20090181110 A JJ O
dietary US20090181110 A JJ O
supplements US20090181110 A NNS O
for US20090181110 A IN O
increased US20090181110 A JJ O
aromatase US20090181110 A JJ I-UN
inhibition US20090181110 A NN O
activity US20090181110 A NN O
. US20090181110 A . O

Azole CN103265538A T NNP O
antifungal CN103265538A T JJ O
compound CN103265538A T NN O
and CN103265538A T CC O
preparation CN103265538A T NN O
method CN103265538A T NN O
and CN103265538A T CC O
application CN103265538A T NN O
thereof CN103265538A T NN O
. CN103265538A T . O

Corossolone CN101812040A T NNP O
derivative CN101812040A T JJ O
, CN101812040A T , O
preparation CN101812040A T NN O
method CN101812040A T NN O
and CN101812040A T CC O
application CN101812040A T NN O
thereof CN101812040A T NN O
. CN101812040A T . O

Pharmaceutical US6919370 T JJ O
formulations US6919370 T NNS O
comprising US6919370 T VBG O
paclitaxel US6919370 T NN O
, US6919370 T , O
derivatives US6919370 T NNS O
, US6919370 T , O
and US6919370 T CC O
pharmaceutically US6919370 T RB O
acceptable US6919370 T JJ O
salts US6919370 T NNS O
thereof US6919370 T NN O
. US6919370 T . O

Agent WO2011161964A1 T NN O
for WO2011161964A1 T IN O
improving WO2011161964A1 T VBG O
insulin WO2011161964A1 T NN I-UN
resistance WO2011161964A1 T NN O
with WO2011161964A1 T IN O
acat WO2011161964A1 T JJ I-UN
inhibitor WO2011161964A1 T NN O
as WO2011161964A1 T IN O
active WO2011161964A1 T JJ O
component WO2011161964A1 T NN O
. WO2011161964A1 T . O

The WO2011161964A1 A DT O
present WO2011161964A1 A JJ O
invention WO2011161964A1 A NN O
relates WO2011161964A1 A VBZ O
to WO2011161964A1 A TO O
a WO2011161964A1 A DT O
prophylactic WO2011161964A1 A JJ O
or WO2011161964A1 A CC O
therapeutic WO2011161964A1 A JJ O
agent WO2011161964A1 A NN O
for WO2011161964A1 A IN O
diabetes WO2011161964A1 A NNS O
, WO2011161964A1 A , O
and WO2011161964A1 A CC O
insulin WO2011161964A1 A NN I-UN
resistance WO2011161964A1 A NN O
in WO2011161964A1 A IN O
particular WO2011161964A1 A JJ O
, WO2011161964A1 A , O
having WO2011161964A1 A VBG O
an WO2011161964A1 A DT O
ACAT WO2011161964A1 A NNP I-UN
inhibitor WO2011161964A1 A NN O
as WO2011161964A1 A IN O
an WO2011161964A1 A DT O
active WO2011161964A1 A JJ O
component WO2011161964A1 A NN O
thereof WO2011161964A1 A NN O
. WO2011161964A1 A . O

Antagonists WO2014074700A1 T NNS O
of WO2014074700A1 T IN O
gpr119 WO2014074700A1 T NN I-UN
receptor WO2014074700A1 T NN O
and WO2014074700A1 T CC O
the WO2014074700A1 T DT O
treatment WO2014074700A1 T NN O
of WO2014074700A1 T IN O
disorders WO2014074700A1 T NNS O
related WO2014074700A1 T JJ O
thereto WO2014074700A1 T NN O
. WO2014074700A1 T . O

The WO2014074700A1 A DT O
present WO2014074700A1 A JJ O
invention WO2014074700A1 A NN O
relates WO2014074700A1 A VBZ O
to WO2014074700A1 A TO O
compounds WO2014074700A1 A NNS O
of WO2014074700A1 A IN O
Formula WO2014074700A1 A NNP O
I WO2014074700A1 A PRP O
and WO2014074700A1 A CC O
pharmaceutically WO2014074700A1 A RB O
acceptable WO2014074700A1 A JJ O
salts WO2014074700A1 A NNS O
, WO2014074700A1 A , O
solvates WO2014074700A1 A NNS O
, WO2014074700A1 A , O
and WO2014074700A1 A CC O
hydrates WO2014074700A1 A VBZ O
thereof WO2014074700A1 A NNS O
, WO2014074700A1 A , O
that WO2014074700A1 A WDT O
are WO2014074700A1 A VBP O
antagonists WO2014074700A1 A NNS O
of WO2014074700A1 A IN O
GPR119 WO2014074700A1 A NNP I-UN
useful WO2014074700A1 A JJ O
in WO2014074700A1 A IN O
the WO2014074700A1 A DT O
treatment WO2014074700A1 A NN O
of WO2014074700A1 A IN O
, WO2014074700A1 A , O
for WO2014074700A1 A IN O
example WO2014074700A1 A NN O
, WO2014074700A1 A , O
a WO2014074700A1 A DT O
disorder WO2014074700A1 A NN O
selected WO2014074700A1 A VBN O
from WO2014074700A1 A IN O
: WO2014074700A1 A : O
obesity WO2014074700A1 A NN O
and WO2014074700A1 A CC O
diseases/conditions WO2014074700A1 A NNS O
related WO2014074700A1 A VBN O
to WO2014074700A1 A TO O
obesity WO2014074700A1 A NN O
such WO2014074700A1 A JJ O
as WO2014074700A1 A IN O
congestive WO2014074700A1 A JJ O
heart WO2014074700A1 A NN O
failure WO2014074700A1 A NN O
, WO2014074700A1 A , O
polycystic WO2014074700A1 A JJ O
ovarian WO2014074700A1 A JJ O
syndrome WO2014074700A1 A NN O
, WO2014074700A1 A , O
infertility WO2014074700A1 A NN O
, WO2014074700A1 A , O
gastroesophageal WO2014074700A1 A JJ O
reflux WO2014074700A1 A NN O
disease WO2014074700A1 A NN O
, WO2014074700A1 A , O
cholelithiasis WO2014074700A1 A NN O
( WO2014074700A1 A ( O
gall WO2014074700A1 A JJ O
stones WO2014074700A1 A NNS O
) WO2014074700A1 A ) O
, WO2014074700A1 A , O
hernia WO2014074700A1 A UH O
, WO2014074700A1 A , O
erectile WO2014074700A1 A JJ O
dysfunction WO2014074700A1 A NN O
, WO2014074700A1 A , O
urinary WO2014074700A1 A JJ O
incontinence WO2014074700A1 A NN O
, WO2014074700A1 A , O
chronic WO2014074700A1 A JJ O
renal WO2014074700A1 A JJ O
failure WO2014074700A1 A NN O
, WO2014074700A1 A , O
lymphedema WO2014074700A1 A NN O
, WO2014074700A1 A , O
osteoarthritis WO2014074700A1 A NN O
, WO2014074700A1 A , O
hyperuricemia WO2014074700A1 A NN O
, WO2014074700A1 A , O
lower WO2014074700A1 A JJR O
back WO2014074700A1 A RB O
pain WO2014074700A1 A NN O
, WO2014074700A1 A , O
stroke WO2014074700A1 A NN O
, WO2014074700A1 A , O
headache WO2014074700A1 A NN O
, WO2014074700A1 A , O
asthma WO2014074700A1 A NN O
, WO2014074700A1 A , O
and WO2014074700A1 A CC O
immobility WO2014074700A1 A NN O
. WO2014074700A1 A . O

In WO2014074700A1 A IN O
addition WO2014074700A1 A NN O
, WO2014074700A1 A , O
the WO2014074700A1 A DT O
present WO2014074700A1 A JJ O
antagonists WO2014074700A1 A NNS O
of WO2014074700A1 A IN O
GPR119 WO2014074700A1 A NNP I-UN
are WO2014074700A1 A VBP O
useful WO2014074700A1 A JJ O
for WO2014074700A1 A IN O
treating WO2014074700A1 A VBG O
non-alcoholic WO2014074700A1 A JJ O
fatty WO2014074700A1 A JJ O
liver WO2014074700A1 A NN O
disease WO2014074700A1 A NN O
, WO2014074700A1 A , O
food-dependent WO2014074700A1 A JJ O
Cushing WO2014074700A1 A NNP O
's WO2014074700A1 A POS O
syndrome WO2014074700A1 A NN O
, WO2014074700A1 A , O
and WO2014074700A1 A CC O
cancer WO2014074700A1 A NN O
( WO2014074700A1 A ( O
e.g. WO2014074700A1 A UH O
, WO2014074700A1 A , O
cancers WO2014074700A1 A NNS O
of WO2014074700A1 A IN O
the WO2014074700A1 A DT O
esophagus WO2014074700A1 A NN O
, WO2014074700A1 A , O
uterine WO2014074700A1 A JJ O
lining WO2014074700A1 A NN O
, WO2014074700A1 A , O
ovary WO2014074700A1 A JJ O
, WO2014074700A1 A , O
kidney WO2014074700A1 A NN O
, WO2014074700A1 A , O
pancreas WO2014074700A1 A NNS O
, WO2014074700A1 A , O
and WO2014074700A1 A CC O
breast WO2014074700A1 A NN O
; WO2014074700A1 A : O
leukemia WO2014074700A1 A CC O
, WO2014074700A1 A , O
multiple WO2014074700A1 A JJ O
myeloma WO2014074700A1 A NN O
, WO2014074700A1 A , O
non-Hodgkin WO2014074700A1 A JJ O
's WO2014074700A1 A POS O
lymphoma WO2014074700A1 A NN O
, WO2014074700A1 A , O
and WO2014074700A1 A CC O
colorectal WO2014074700A1 A JJ O
cancer WO2014074700A1 A NN O
) WO2014074700A1 A ) O
. WO2014074700A1 A . O

Application CN103356542A T NN O
of CN103356542A T IN O
Sarcaboside CN103356542A T NNP O
B CN103356542A T NNP O
in CN103356542A T IN O
preparation CN103356542A T NN O
of CN103356542A T IN O
medicines CN103356542A T NNS O
for CN103356542A T IN O
treating CN103356542A T VBG O
lung CN103356542A T NN O
cancer CN103356542A T NN O
. CN103356542A T . O

By US7364751 T IN O
adding US7364751 T VBG O
an US7364751 T DT O
antioxidant US7364751 T JJ O
and/or US7364751 T NN O
a US7364751 T DT O
chelating US7364751 T NN O
agent US7364751 T NN O
in US7364751 T IN O
the US7364751 T DT O
same US7364751 T JJ O
aqueous US7364751 T JJ O
solution US7364751 T NN O
; US7364751 T : O
reduced US7364751 T VBN O
coenzyme US7364751 T NN O
Q10 US7364751 T NNP O
, US7364751 T , O
vitamin US7364751 T NN O
C US7364751 T NNP O
and US7364751 T CC O
ethylenediaminetetracetic US7364751 T JJ O
acid US7364751 T NN O
for US7364751 T IN O
example US7364751 T NN O
. US7364751 T . O

Slow CN1857280A T NNP O
released CN1857280A T VBD O
compound CN1857280A T NN O
antituberculotic CN1857280A T JJ O
preparation CN1857280A T NN O
. CN1857280A T . O

and US7098203 T CC O
selective US7098203 T JJ O
serotonin US7098203 T NN O
reuptake US7098203 T NN O
inhibitors US7098203 T NNS O
; US7098203 T : O
4-benzyloxymethyl-4-phenylazepanes US7098203 T NNS O
; US7098203 T : O
antidepressants US7098203 T NNS O
; US7098203 T : O
anxiety US7098203 T NN O
. US7098203 T . O

In US7098203 A IN O
a US7098203 A DT O
specific US7098203 A JJ O
embodiment US7098203 A NN O
, US7098203 A , O
compounds US7098203 A NNS O
of US7098203 A IN O
Formula US7098203 A NNP O
( US7098203 A ( O
I US7098203 A PRP O
) US7098203 A ) O
or US7098203 A CC O
an US7098203 A DT O
isomer US7098203 A NN O
, US7098203 A , O
a US7098203 A DT O
pharmaceutically US7098203 A RB O
acceptable US7098203 A JJ O
salt US7098203 A NN O
or US7098203 A CC O
solvate US7098203 A VB O
thereof US7098203 A NN O
or US7098203 A CC O
a US7098203 A DT O
pharmaceutically US7098203 A RB O
acceptable US7098203 A JJ O
formulation US7098203 A NN O
comprising US7098203 A NN O
said US7098203 A VBD O
compounds US7098203 A NNS O
useful US7098203 A JJ O
for US7098203 A IN O
the US7098203 A DT O
treatment US7098203 A NN O
or US7098203 A CC O
prevention US7098203 A NN O
of US7098203 A IN O
conditions US7098203 A NNS O
mediated US7098203 A VBN O
by US7098203 A IN O
tachykinins US7098203 A NNS I-UN
and/or US7098203 A JJ O
selective US7098203 A JJ O
inhibition US7098203 A NN O
of US7098203 A IN O
serotonin US7098203 A JJ O
reuptake US7098203 A NN O
transporter US7098203 A NN O
protein US7098203 A NN O
. US7098203 A . O

The US7098203 A DT O
compounds US7098203 A NNS O
act US7098203 A NN O
as US7098203 A IN O
dual US7098203 A JJ O
NK-1 US7098203 A NNP I-UN
antagonists US7098203 A NNS O
and US7098203 A CC O
selective US7098203 A JJ O
serotonin US7098203 A NN O
reuptake US7098203 A NN O
inhibitors US7098203 A NNS O
. US7098203 A . O

C-glycosylflavones CN102670634A T JJ O
composition CN102670634A T NN O
, CN102670634A T , O
preparation CN102670634A T NN O
method CN102670634A T NN O
and CN102670634A T CC O
application CN102670634A T NN O
thereof CN102670634A T NN O
. CN102670634A T . O

Bicyclic WO2006130588A1 T JJ O
6-alkylidene-penems WO2006130588A1 T JJ O
as WO2006130588A1 T IN O
class-d WO2006130588A1 T JJ O
beta-lactamases WO2006130588A1 T NNS O
inhibitors WO2006130588A1 T NNS O
. WO2006130588A1 T . O

for US7074392 T IN O
high US7074392 T JJ O
penetration US7074392 T NN O
into US7074392 T IN O
fingernails US7074392 T NNS O
and US7074392 T CC O
toenails US7074392 T NNS O
; US7074392 T : O
contains US7074392 T VBZ O
humectant US7074392 T NN O
for US7074392 T IN O
trapping US7074392 T VBG O
water US7074392 T NN O
and US7074392 T CC O
liquid US7074392 T NN O
nail US7074392 T NN O
lacquer US7074392 T NN O
containing US7074392 T VBG O
film US7074392 T NN O
forming US7074392 T VBG O
agent US7074392 T NN O
. US7074392 T . O

A US7074392 A DT O
topical US7074392 A JJ O
sustained US7074392 A JJ O
release US7074392 A NN O
delivery US7074392 A NN O
system US7074392 A NN O
for US7074392 A IN O
delivery US7074392 A NN O
of US7074392 A IN O
antifungal US7074392 A JJ O
agents US7074392 A NNS O
to US7074392 A TO O
the US7074392 A DT O
finger US7074392 A NN O
or US7074392 A CC O
toenails US7074392 A NNS O
achieving US7074392 A VBG O
high US7074392 A JJ O
penetration US7074392 A NN O
through US7074392 A IN O
the US7074392 A DT O
nails US7074392 A NNS O
by US7074392 A IN O
combining US7074392 A VBG O
the US7074392 A DT O
antifingal US7074392 A JJ O
agent US7074392 A NN O
with US7074392 A IN O
a US7074392 A DT O
keratolytic US7074392 A JJ O
agent US7074392 A NN O
and US7074392 A CC O
a US7074392 A DT O
humectant US7074392 A NN O
. US7074392 A . O

The US7074392 A DT O
pharmaceutical US7074392 A JJ O
sustained US7074392 A VBD O
release US7074392 A NN O
topical US7074392 A JJ O
preparation US7074392 A NN O
is US7074392 A VBZ O
provided US7074392 A VBN O
in US7074392 A IN O
a US7074392 A DT O
varnish US7074392 A JJ O
or US7074392 A CC O
spray US7074392 A JJ O
form US7074392 A NN O
for US7074392 A IN O
treating US7074392 A VBG O
the US7074392 A DT O
nail US7074392 A NN O
and US7074392 A CC O
surrounding US7074392 A VBG O
tissues US7074392 A NNS O
, US7074392 A , O
where US7074392 A WRB O
the US7074392 A DT O
active US7074392 A JJ O
ingredient US7074392 A NN O
is US7074392 A VBZ O
an US7074392 A DT O
antifungal US7074392 A JJ O
agent US7074392 A NN O
, US7074392 A , O
a US7074392 A DT O
keratolytic US7074392 A JJ O
agent US7074392 A NN O
, US7074392 A , O
or US7074392 A CC O
preferably US7074392 A RB O
a US7074392 A DT O
combination US7074392 A NN O
of US7074392 A IN O
an US7074392 A DT O
antifuingal US7074392 A NN O
and US7074392 A CC O
a US7074392 A DT O
keratolytic US7074392 A JJ O
agent US7074392 A NN O
. US7074392 A . O

The US7074392 A DT O
composition US7074392 A NN O
may US7074392 A MD O
further US7074392 A RB O
comprise US7074392 A VB O
an US7074392 A DT O
antibacterial US7074392 A NN O
, US7074392 A , O
an US7074392 A DT O
antiviral US7074392 A JJ O
, US7074392 A , O
an US7074392 A DT O
antipsoriatic US7074392 A JJ O
agents US7074392 A NNS O
, US7074392 A , O
or US7074392 A CC O
combinations US7074392 A NNS O
thereof US7074392 A VBP O
. US7074392 A . O

Carrier US20120189688 T NNP O
component US20120189688 T NN O
and US20120189688 T CC O
fabrication US20120189688 T NN O
method US20120189688 T NN O
thereof US20120189688 T NN O
. US20120189688 T . O

Dosage EP1539129A1 T NN O
forms EP1539129A1 T NNS O
and EP1539129A1 T CC O
related EP1539129A1 T JJ O
therapies EP1539129A1 T NNS O
. EP1539129A1 T . O

Expression CA2685270C T NN O
vectors CA2685270C T NNS O
for CA2685270C T IN O
stimulating CA2685270C T VBG O
an CA2685270C T DT O
immune CA2685270C T JJ O
response CA2685270C T NN O
and CA2685270C T CC O
methods CA2685270C T NNS O
of CA2685270C T IN O
using CA2685270C T VBG O
the CA2685270C T DT O
same CA2685270C T JJ O
. CA2685270C T . O

Utilizing US20050171214 T VBG O
astaxanthin US20050171214 T JJ O
and/or US20050171214 T RB O
ester US20050171214 T RB O
as US20050171214 T IN O
food US20050171214 T NN O
and/or US20050171214 T NN O
drink US20050171214 T VBP O
nutritional US20050171214 T JJ O
supplement US20050171214 T NN O
; US20050171214 T : O
supporting US20050171214 T VBG O
and US20050171214 T CC O
restoring US20050171214 T VBG O
human US20050171214 T JJ O
eyes US20050171214 T NNS O
automatic US20050171214 T JJ O
focusing US20050171214 T VBG O
ability US20050171214 T NN O
. US20050171214 T . O

Transdermal WO2008006226A1 T JJ O
formulations WO2008006226A1 T NNS O
of WO2008006226A1 T IN O
synthetic WO2008006226A1 T JJ O
cannabinoids WO2008006226A1 T NNS O
and WO2008006226A1 T CC O
nano WO2008006226A1 T JJ O
colloidal WO2008006226A1 T NN O
silica WO2008006226A1 T NN O
. WO2008006226A1 T . O

Preparation CN102727459A T NN O
with CN102727459A T IN O
first CN102727459A T JJ O
active CN102727459A T JJ O
medicament CN102727459A T NN O
and CN102727459A T CC O
second CN102727459A T JJ O
active CN102727459A T JJ O
medicament CN102727459A T NN O
. CN102727459A T . O

Externally-applied CN102198119A T JJ O
medicinal CN102198119A T JJ O
patch CN102198119A T NN O
. CN102198119A T . O

Bicyclic CN102134243A T NNP O
amino CN102134243A T NN O
pyrazole CN102134243A T NN O
derivatives CN102134243A T NNS O
with CN102134243A T IN O
anti-tumor CN102134243A T JJ O
activity CN102134243A T NN O
. CN102134243A T . O

Treatment WO2013160222A1 T NNP O
method WO2013160222A1 T NN O
for WO2013160222A1 T IN O
steroid WO2013160222A1 T JJ O
responsive WO2013160222A1 T JJ O
dermatoses WO2013160222A1 T NNS O
. WO2013160222A1 T . O

Compositions WO2012125413A2 T NNS O
for WO2012125413A2 T IN O
ameliorating WO2012125413A2 T VBG O
systemic WO2012125413A2 T JJ O
inflammation WO2012125413A2 T NN O
and WO2012125413A2 T CC O
methods WO2012125413A2 T NNS O
for WO2012125413A2 T IN O
making WO2012125413A2 T VBG O
and WO2012125413A2 T CC O
using WO2012125413A2 T VBG O
them WO2012125413A2 T PRP O
. WO2012125413A2 T . O

Nucleic WO2009148137A1 T NNP O
acid WO2009148137A1 T VBZ O
capable WO2009148137A1 T JJ O
of WO2009148137A1 T IN O
controlling WO2009148137A1 T VBG O
degranulation WO2009148137A1 T NN O
of WO2009148137A1 T IN O
mast WO2009148137A1 T NN O
cell WO2009148137A1 T NN O
. WO2009148137A1 T . O

Modulation WO2009040512A3 T NN O
of WO2009040512A3 T IN O
rsk WO2009040512A3 T NN O
. WO2009040512A3 T . O

The WO2009040512A3 A DT O
present WO2009040512A3 A JJ O
invention WO2009040512A3 A NN O
relates WO2009040512A3 A VBZ O
to WO2009040512A3 A TO O
specific WO2009040512A3 A VB O
compounds WO2009040512A3 A NNS O
for WO2009040512A3 A IN O
use WO2009040512A3 A NN O
in WO2009040512A3 A IN O
controlling WO2009040512A3 A VBG O
inflammatory WO2009040512A3 A NN O
cell WO2009040512A3 A NN O
function WO2009040512A3 A NN O
and WO2009040512A3 A CC O
their WO2009040512A3 A PRP$ O
potential WO2009040512A3 A JJ O
use WO2009040512A3 A NN O
in WO2009040512A3 A IN O
modulating WO2009040512A3 A VBG O
an WO2009040512A3 A DT O
immune WO2009040512A3 A JJ O
response WO2009040512A3 A NN O
or WO2009040512A3 A CC O
inflammation WO2009040512A3 A NN O
. WO2009040512A3 A . O

The WO2009040512A3 A DT O
present WO2009040512A3 A JJ O
invention WO2009040512A3 A NN O
also WO2009040512A3 A RB O
relates WO2009040512A3 A VBZ O
to WO2009040512A3 A TO O
the WO2009040512A3 A DT O
identification WO2009040512A3 A NN O
of WO2009040512A3 A IN O
an WO2009040512A3 A DT O
alternative WO2009040512A3 A JJ O
RSK WO2009040512A3 A NNP O
pathway WO2009040512A3 A NN O
in WO2009040512A3 A IN O
, WO2009040512A3 A , O
for WO2009040512A3 A IN O
example WO2009040512A3 A NN O
, WO2009040512A3 A , O
dendritic WO2009040512A3 A JJ O
cells WO2009040512A3 A NNS O
and WO2009040512A3 A CC O
the WO2009040512A3 A DT O
development WO2009040512A3 A NN O
of WO2009040512A3 A IN O
assays WO2009040512A3 A NNS O
for WO2009040512A3 A IN O
the WO2009040512A3 A DT O
identification WO2009040512A3 A NN O
of WO2009040512A3 A IN O
compounds WO2009040512A3 A NNS O
capable WO2009040512A3 A JJ O
of WO2009040512A3 A IN O
modulating WO2009040512A3 A VBG O
the WO2009040512A3 A DT O
alternative WO2009040512A3 A JJ O
RSK WO2009040512A3 A NNP O
associated WO2009040512A3 A VBD O
pathway WO2009040512A3 A RB O
in WO2009040512A3 A IN O
dendritic WO2009040512A3 A JJ O
cells/macrophage WO2009040512A3 A NN O
cells WO2009040512A3 A NNS O
and WO2009040512A3 A CC O
their WO2009040512A3 A PRP$ O
potential WO2009040512A3 A JJ O
use WO2009040512A3 A NN O
in WO2009040512A3 A IN O
enhancing WO2009040512A3 A VBG O
, WO2009040512A3 A , O
or WO2009040512A3 A CC O
controlling WO2009040512A3 A VBG O
an WO2009040512A3 A DT O
immune WO2009040512A3 A JJ O
response WO2009040512A3 A NN O
or WO2009040512A3 A CC O
in WO2009040512A3 A IN O
treating WO2009040512A3 A VBG O
inflammation WO2009040512A3 A NN O
. WO2009040512A3 A . O

rheumatoid US7683061 T NN O
arthritis US7683061 T NN O
, US7683061 T , O
systemic US7683061 T JJ O
lupus US7683061 T NN O
erythematosus US7683061 T NN O
( US7683061 T ( O
SLE US7683061 T NNP O
) US7683061 T ) O
, US7683061 T , O
idiopathic US7683061 T JJ O
( US7683061 T ( O
immune US7683061 T JJ O
) US7683061 T ) O
thrombocytopenia US7683061 T NN O
( US7683061 T ( O
ITP US7683061 T NNP O
) US7683061 T ) O
, US7683061 T , O
glomerulonephritis US7683061 T NN O
and US7683061 T CC O
vasculitis US7683061 T NN O
; US7683061 T : O
reduced US7683061 T VBN O
drug US7683061 T NN O
toxicity US7683061 T NN O
. US7683061 T . O

Medicament CN102885891A T NN O
for CN102885891A T IN O
treating CN102885891A T VBG O
dental CN102885891A T JJ O
ulcer CN102885891A T NN O
. CN102885891A T . O

Drop CN1872045B T NNP O
pills CN1872045B T NNS O
of CN1872045B T IN O
lysionotin CN1872045B T NN O
, CN1872045B T , O
and CN1872045B T CC O
preparation CN1872045B T NN O
method CN1872045B T NN O
. CN1872045B T . O

Compound CN103110631A T NNP O
phenol CN103110631A T NN O
caplets CN103110631A T NNS O
sustained CN103110631A T VBD O
release CN103110631A T NN O
preparation CN103110631A T NN O
and CN103110631A T CC O
preparation CN103110631A T NN O
method CN103110631A T NN O
thereof CN103110631A T NN O
. CN103110631A T . O

Aryl US20110245221 T NNP O
isoxazole US20110245221 T JJ O
compounds US20110245221 T NNS O
with US20110245221 T IN O
antitumoural US20110245221 T JJ O
activities US20110245221 T NNS O
. US20110245221 T . O

The US20110245221 A DT O
present US20110245221 A JJ O
invention US20110245221 A NN O
relates US20110245221 A VBZ O
to US20110245221 A TO O
formula US20110245221 A VB O
I US20110245221 A PRP O
compounds US20110245221 A NNS O
having US20110245221 A VBG O
antitumoural US20110245221 A JJ O
activities US20110245221 A NNS O
through US20110245221 A RB O
, US20110245221 A , O
as US20110245221 A IN O
one US20110245221 A CD O
possible US20110245221 A JJ O
biological US20110245221 A JJ O
target US20110245221 A NN O
, US20110245221 A , O
the US20110245221 A DT O
molecular US20110245221 A JJ O
chaperone US20110245221 A NN O
heat US20110245221 A NN I-UN
shock US20110245221 A NN I-UN
protein US20110245221 A NN I-UN
90 US20110245221 A CD I-UN
( US20110245221 A ( O
Hsp90 US20110245221 A NNP I-UN
) US20110245221 A ) O
inhibition US20110245221 A NN O
. US20110245221 A . O

The US20110245221 A DT O
invention US20110245221 A NN O
includes US20110245221 A VBZ O
the US20110245221 A DT O
use US20110245221 A NN O
of US20110245221 A IN O
such US20110245221 A JJ O
compounds US20110245221 A NNS O
in US20110245221 A IN O
medicine US20110245221 A NN O
, US20110245221 A , O
in US20110245221 A IN O
relation US20110245221 A NN O
to US20110245221 A TO O
cancer US20110245221 A NN O
disease US20110245221 A NN O
as US20110245221 A RB O
well US20110245221 A RB O
as US20110245221 A IN O
other US20110245221 A JJ O
diseases US20110245221 A NNS O
where US20110245221 A WRB O
an US20110245221 A DT O
inhibition US20110245221 A NN O
of US20110245221 A IN O
Hsp90 US20110245221 A NNP I-UN
is US20110245221 A VBZ O
responsive US20110245221 A JJ O
, US20110245221 A , O
and US20110245221 A CC O
the US20110245221 A DT O
pharmaceutical US20110245221 A JJ O
compositions US20110245221 A NNS O
containing US20110245221 A VBG O
such US20110245221 A JJ O
compounds US20110245221 A NNS O
. US20110245221 A . O

Pyrrole US20110136857 T NNP O
[ US20110136857 T NNP O
2,3-b US20110136857 T JJ O
] US20110136857 T NNP O
pyridine US20110136857 T NN O
derivatives US20110136857 T NNS O
active US20110136857 T JJ O
as US20110136857 T IN O
kinase US20110136857 T NN O
inhibitors US20110136857 T NNS O
. US20110136857 T . O

Pharmaceutical CA2137764C T JJ O
compositions CA2137764C T NNS O
comprising CA2137764C T VBG O
solutions CA2137764C T NNS O
or CA2137764C T CC O
dispersions CA2137764C T NNS O
of CA2137764C T IN O
a CA2137764C T DT O
staurosporine CA2137764C T JJ O
active CA2137764C T JJ O
ingredient CA2137764C T NN O
in CA2137764C T IN O
a CA2137764C T DT O
saturated CA2137764C T JJ O
polyalkylene CA2137764C T NN O
glycol CA2137764C T NN O
glyceride CA2137764C T NN O
. CA2137764C T . O

A CA2137764C A DT O
pharmaceutical CA2137764C A JJ O
composition CA2137764C A NN O
comprising CA2137764C A VBG O
a CA2137764C A DT O
solution CA2137764C A NN O
or CA2137764C A CC O
dispersion CA2137764C A NN O
of CA2137764C A IN O
a CA2137764C A DT O
staurosporine CA2137764C A JJ O
active CA2137764C A JJ O
ingredient CA2137764C A NN O
in CA2137764C A IN O
a CA2137764C A DT O
saturated CA2137764C A JJ O
polyalkylene CA2137764C A NN O
glycol CA2137764C A NN O
glyceride CA2137764C A NN O
such CA2137764C A JJ O
as CA2137764C A IN O
a CA2137764C A DT O
mixture CA2137764C A NN O
of CA2137764C A IN O
esters CA2137764C A NNS O
of CA2137764C A IN O
C8-C18 CA2137764C A NNP O
saturated CA2137764C A VBD O
fatty CA2137764C A JJ O
acids CA2137764C A NNS O
with CA2137764C A IN O
glycerol CA2137764C A NN O
and CA2137764C A CC O
polyethylene CA2137764C A NN O
glycol CA2137764C A NN O
. CA2137764C A . O

The CA2137764C A DT O
composition CA2137764C A NN O
may CA2137764C A MD O
be CA2137764C A VB O
administered CA2137764C A VBN O
in CA2137764C A IN O
capsules CA2137764C A NNS O
or CA2137764C A CC O
as CA2137764C A IN O
a CA2137764C A DT O
dispersion CA2137764C A NN O
in CA2137764C A IN O
an CA2137764C A DT O
aqueous CA2137764C A JJ O
medium CA2137764C A NN O
. CA2137764C A . O

The CA2137764C A DT O
pharmaceutical CA2137764C A JJ O
composition CA2137764C A NN O
may CA2137764C A MD O
be CA2137764C A VB O
used CA2137764C A VBN O
as CA2137764C A IN O
an CA2137764C A DT O
orally CA2137764C A RB O
administrable CA2137764C A JJ O
form CA2137764C A NN O
of CA2137764C A IN O
a CA2137764C A DT O
staurosporine CA2137764C A JJ O
active CA2137764C A JJ O
ingredient CA2137764C A NN O
. CA2137764C A . O

Over-coated US20100104620 T JJ O
product US20100104620 T NN O
including US20100104620 T VBG O
tableted US20100104620 T VBN O
center US20100104620 T NN O
and US20100104620 T CC O
medicament US20100104620 T NN O
. US20100104620 T . O

Compositions EP2170335A1 T NNS O
comprising EP2170335A1 T VBG O
tryptophan EP2170335A1 T JJ I-UN
hydroxylase EP2170335A1 T NN I-UN
inhibitors EP2170335A1 T NNS O
. EP2170335A1 T . O

Methods EP2170335A1 A NNS O
and EP2170335A1 A CC O
compositions EP2170335A1 A NNS O
comprising EP2170335A1 A VBG O
tryptophan EP2170335A1 A JJ I-UN
hydroxylase EP2170335A1 A NN I-UN
inhibitors EP2170335A1 A NNS O
are EP2170335A1 A VBP O
disclosed EP2170335A1 A VBN O
. EP2170335A1 A . O

Gel CN101530386A T NNP O
with CN101530386A T IN O
the CN101530386A T DT O
active CN101530386A T JJ O
component CN101530386A T NN O
being CN101530386A T VBG O
11-hydroxy-oleanane-28-carboxylic CN101530386A T JJ O
acid CN101530386A T NN O
methyl CN101530386A T NN O
ester-2,12-diene CN101530386A T NN O
. CN101530386A T . O

Preparation CN103463644A T NNP O
method CN103463644A T NN O
of CN103463644A T IN O
allyl CN103463644A T JJ O
isothiocyanate-beta-cyclodextrin CN103463644A T JJ O
clathrate CN103463644A T NN O
compound CN103463644A T NN O
. CN103463644A T . O

Combinations EP2226072A1 T NNS O
of EP2226072A1 T IN O
suberoylanilide EP2226072A1 T JJ O
hydroxamic EP2226072A1 T JJ O
acid EP2226072A1 T NN O
and EP2226072A1 T CC O
antimetbolic EP2226072A1 T JJ O
agents EP2226072A1 T NNS O
for EP2226072A1 T IN O
treating EP2226072A1 T VBG O
cancer EP2226072A1 T NN O
. EP2226072A1 T . O

The EP2226072A1 A DT O
present EP2226072A1 A JJ O
invention EP2226072A1 A NN O
relates EP2226072A1 A VBZ O
to EP2226072A1 A TO O
a EP2226072A1 A DT O
method EP2226072A1 A NN O
of EP2226072A1 A IN O
treating EP2226072A1 A VBG O
cancer EP2226072A1 A NN O
in EP2226072A1 A IN O
a EP2226072A1 A DT O
subject EP2226072A1 A NN O
in EP2226072A1 A IN O
need EP2226072A1 A NN O
thereof EP2226072A1 A NNS O
, EP2226072A1 A , O
by EP2226072A1 A IN O
administering EP2226072A1 A VBG O
to EP2226072A1 A TO O
a EP2226072A1 A DT O
subject EP2226072A1 A NN O
in EP2226072A1 A IN O
need EP2226072A1 A NN O
thereof EP2226072A1 A VBP O
a EP2226072A1 A DT O
first EP2226072A1 A JJ O
amount EP2226072A1 A NN O
of EP2226072A1 A IN O
a EP2226072A1 A DT O
histone EP2226072A1 A NN I-UN
deacetylase EP2226072A1 A NN I-UN
( EP2226072A1 A ( O
HDAC EP2226072A1 A NNP I-UN
) EP2226072A1 A ) O
inhibitor EP2226072A1 A NN O
or EP2226072A1 A CC O
a EP2226072A1 A DT O
pharmaceutically EP2226072A1 A RB O
acceptable EP2226072A1 A JJ O
salt EP2226072A1 A NN O
or EP2226072A1 A CC O
hydrate EP2226072A1 A NN O
thereof EP2226072A1 A NN O
, EP2226072A1 A , O
in EP2226072A1 A IN O
a EP2226072A1 A DT O
first EP2226072A1 A JJ O
treatment EP2226072A1 A NN O
procedure EP2226072A1 A NN O
, EP2226072A1 A , O
and EP2226072A1 A CC O
a EP2226072A1 A DT O
second EP2226072A1 A JJ O
amount EP2226072A1 A NN O
of EP2226072A1 A IN O
an EP2226072A1 A DT O
anti-cancer EP2226072A1 A JJ O
agent EP2226072A1 A NN O
in EP2226072A1 A IN O
a EP2226072A1 A DT O
second EP2226072A1 A JJ O
treatment EP2226072A1 A NN O
procedure EP2226072A1 A NN O
. EP2226072A1 A . O

The EP2226072A1 A DT O
effect EP2226072A1 A NN O
of EP2226072A1 A IN O
the EP2226072A1 A DT O
HDAC EP2226072A1 A NNP I-UN
inhibitor EP2226072A1 A NN O
and EP2226072A1 A CC O
the EP2226072A1 A DT O
anti-cancer EP2226072A1 A JJ O
agent EP2226072A1 A NN O
may EP2226072A1 A MD O
be EP2226072A1 A VB O
additive EP2226072A1 A JJ O
or EP2226072A1 A CC O
synergistic EP2226072A1 A JJ O
. EP2226072A1 A . O

9-fluoro-6,7 US20080108646 T CD O
, US20080108646 T , O
-dihydro-8- US20080108646 T NNP O
( US20080108646 T ( O
4-hydroxypiperidin-1-yl US20080108646 T JJ O
) US20080108646 T ) O
-5-methyl-1-oxo-1H,5H-benzo US20080108646 T FW O
[ US20080108646 T NN O
i US20080108646 T NN O
, US20080108646 T , O
j US20080108646 T NN O
] US20080108646 T NNP O
quinolizine-2-carboxylic US20080108646 T JJ O
acid US20080108646 T NN O
; US20080108646 T : O
optically US20080108646 T RB O
pure US20080108646 T VBP O
isomers US20080108646 T NNS O
of US20080108646 T IN O
Nadifloxacin US20080108646 T NNP O
; US20080108646 T : O
bactericide US20080108646 T NN O
; US20080108646 T : O
systemic US20080108646 T CC O
or US20080108646 T CC O
topical US20080108646 T JJ O
Gram-positive US20080108646 T JJ O
, US20080108646 T , O
Gram-negative US20080108646 T JJ O
bacterial US20080108646 T NN O
, US20080108646 T , O
mycobacterial US20080108646 T JJ O
and US20080108646 T CC O
nosocomlal US20080108646 T JJ O
pathogen US20080108646 T NN O
infections US20080108646 T NNS O
. US20080108646 T . O

Therapeutic US7511075 T JJ O
malonic US7511075 T JJ O
acid/acetic US7511075 T JJ O
acid US7511075 T NN O
C60 US7511075 T NNP O
tri-adducts US7511075 T NNS O
of US7511075 T IN O
buckminsterfullerene US7511075 T NN O
and US7511075 T CC O
methods US7511075 T NNS O
related US7511075 T VBN O
thereto US7511075 T NN O
. US7511075 T . O

Pyrrolobenzodiazepine US20080090812 T NNP O
Therapeutic US20080090812 T NNP O
Agents US20080090812 T NNP O
Useful US20080090812 T NNP O
in US20080090812 T IN O
the US20080090812 T DT O
Treatment US20080090812 T NNP O
of US20080090812 T IN O
Leukemias US20080090812 T NNP O
. US20080090812 T . O

Gambogic CN102871983A T NNP O
acid CN102871983A T VBD O
colon-specific CN102871983A T NN O
controlled CN102871983A T VBN O
release CN102871983A T NN O
tablet CN102871983A T NN O
and CN102871983A T CC O
preparation CN102871983A T NN O
method CN102871983A T NN O
thereof CN102871983A T NN O
. CN102871983A T . O

Combination US20070149476 T NN O
Comprising US20070149476 T NNP O
Combretastatin US20070149476 T NNP O
and US20070149476 T CC O
Anticancer US20070149476 T NNP O
Agents US20070149476 T NNP O
. US20070149476 T . O

negative US20080090909 T JJ O
regulator US20080090909 T NN O
of US20080090909 T IN O
cell US20080090909 T NN O
growth US20080090909 T NN O
factor US20080090909 T NN O
receptor US20080090909 T NN O
; US20080090909 T : O
pelorol US20080090909 T NN O
( US20080090909 T ( O
benzo US20080090909 T NN O
( US20080090909 T ( O
a US20080090909 T DT O
) US20080090909 T ) O
fluorene US20080090909 T NN O
) US20080090909 T ) O
related US20080090909 T VBD O
compounds US20080090909 T NNS O
from US20080090909 T IN O
marine US20080090909 T JJ O
sponge US20080090909 T NN O
species US20080090909 T NNS O
; US20080090909 T : O
antiinflammatory US20080090909 T NN O
, US20080090909 T , O
antitumor US20080090909 T NN O
agent US20080090909 T NN O
, US20080090909 T , O
immunostimulant US20080090909 T JJ O
; US20080090909 T : O
control US20080090909 T VB O
gene US20080090909 T NN O
expression US20080090909 T NN O
, US20080090909 T , O
differentiation US20080090909 T NN O
, US20080090909 T , O
metabolism US20080090909 T NN O
, US20080090909 T , O
phospholipid US20080090909 T JJ O
signaling US20080090909 T VBG O
pathway US20080090909 T NN O
, US20080090909 T , O
signal US20080090909 T JJ O
tansduction US20080090909 T NN O
. US20080090909 T . O

The US20080090909 A DT O
present US20080090909 A JJ O
invention US20080090909 A NN O
includes US20080090909 A VBZ O
the US20080090909 A DT O
use US20080090909 A NN O
of US20080090909 A IN O
pelorol US20080090909 A NN O
, US20080090909 A , O
related US20080090909 A JJ O
compounds US20080090909 A NNS O
and US20080090909 A CC O
pharmaceutical US20080090909 A JJ O
compositions US20080090909 A NNS O
thereof US20080090909 A VBP O
as US20080090909 A IN O
modulators US20080090909 A NNS O
of US20080090909 A IN O
SHIP US20080090909 A NNP I-UN
1 US20080090909 A CD I-UN
activity US20080090909 A NN O
. US20080090909 A . O

This US20080090909 A DT O
invention US20080090909 A NN O
also US20080090909 A RB O
provides US20080090909 A VBZ O
novel US20080090909 A JJ O
terpene US20080090909 A NN O
compounds US20080090909 A NNS O
capable US20080090909 A JJ O
of US20080090909 A IN O
modulating US20080090909 A VBG O
SHIP US20080090909 A NNP I-UN
1 US20080090909 A CD I-UN
activity US20080090909 A NN O
and US20080090909 A CC O
methods US20080090909 A NNS O
of US20080090909 A IN O
synthesis US20080090909 A NN O
thereof US20080090909 A NN O
. US20080090909 A . O

Somatostatin EP1549309A2 T NNP I-UN
analogue EP1549309A2 T NN O
compounds EP1549309A2 T NNS O
. EP1549309A2 T . O

Use WO2007010337A8 T NNP O
of WO2007010337A8 T IN O
phosphodiesterase WO2007010337A8 T NN I-UN
type WO2007010337A8 T NN I-UN
5 WO2007010337A8 T CD I-UN
inhibitors WO2007010337A8 T NNS O
for WO2007010337A8 T IN O
the WO2007010337A8 T DT O
prevention WO2007010337A8 T NN O
and WO2007010337A8 T CC O
treatment WO2007010337A8 T NN O
of WO2007010337A8 T IN O
diseases WO2007010337A8 T NNS O
or WO2007010337A8 T CC O
health WO2007010337A8 T NN O
disorders WO2007010337A8 T NNS O
and WO2007010337A8 T CC O
dispensing WO2007010337A8 T VBG O
system WO2007010337A8 T NN O
for WO2007010337A8 T IN O
said WO2007010337A8 T VBD O
inhibitors WO2007010337A8 T NNS O
. WO2007010337A8 T . O

The WO2007010337A8 A DT O
invention WO2007010337A8 A NN O
relates WO2007010337A8 A VBZ O
to WO2007010337A8 A TO O
the WO2007010337A8 A DT O
use WO2007010337A8 A NN O
of WO2007010337A8 A IN O
phosphodiesterase WO2007010337A8 A NN I-UN
( WO2007010337A8 A ( I-UN
PDE WO2007010337A8 A NNP I-UN
) WO2007010337A8 A ) I-UN
type WO2007010337A8 A VBD I-UN
5 WO2007010337A8 A CD I-UN
inhibitors WO2007010337A8 A NNS O
or WO2007010337A8 A CC O
their WO2007010337A8 A PRP$ O
pharmaceutically WO2007010337A8 A RB O
compatible WO2007010337A8 A JJ O
salts WO2007010337A8 A NNS O
for WO2007010337A8 A IN O
producing WO2007010337A8 A VBG O
a WO2007010337A8 A DT O
medicament WO2007010337A8 A NN O
for WO2007010337A8 A IN O
preventing WO2007010337A8 A VBG O
and/or WO2007010337A8 A JJ O
treating WO2007010337A8 A NN O
diseases WO2007010337A8 A NNS O
or WO2007010337A8 A CC O
health WO2007010337A8 A NN O
disorders WO2007010337A8 A NNS O
, WO2007010337A8 A , O
which WO2007010337A8 A WDT O
are WO2007010337A8 A VBP O
associated WO2007010337A8 A VBN O
with WO2007010337A8 A IN O
an WO2007010337A8 A DT O
excessive WO2007010337A8 A JJ O
proliferation WO2007010337A8 A NN O
of WO2007010337A8 A IN O
adipose WO2007010337A8 A JJ O
tissue WO2007010337A8 A NN O
in WO2007010337A8 A IN O
the WO2007010337A8 A DT O
body WO2007010337A8 A NN O
. WO2007010337A8 A . O

In WO2007010337A8 A IN O
particular WO2007010337A8 A JJ O
, WO2007010337A8 A , O
the WO2007010337A8 A DT O
invention WO2007010337A8 A NN O
relates WO2007010337A8 A VBZ O
to WO2007010337A8 A TO O
the WO2007010337A8 A DT O
use WO2007010337A8 A NN O
of WO2007010337A8 A IN O
phosphodiesterase WO2007010337A8 A NN I-UN
type WO2007010337A8 A NN I-UN
5 WO2007010337A8 A CD I-UN
inhibitors WO2007010337A8 A NNS O
for WO2007010337A8 A IN O
preventing WO2007010337A8 A VBG O
and WO2007010337A8 A CC O
treating WO2007010337A8 A VBG O
adiposity WO2007010337A8 A NN O
. WO2007010337A8 A . O

In WO2007010337A8 A IN O
addition WO2007010337A8 A NN O
, WO2007010337A8 A , O
the WO2007010337A8 A DT O
invention WO2007010337A8 A NN O
relates WO2007010337A8 A VBZ O
to WO2007010337A8 A TO O
special WO2007010337A8 A JJ O
dispensing WO2007010337A8 A VBG O
systems WO2007010337A8 A NNS O
for WO2007010337A8 A IN O
the WO2007010337A8 A DT O
vaginal WO2007010337A8 A JJ O
and WO2007010337A8 A CC O
sub-cutaneous WO2007010337A8 A JJ O
administration WO2007010337A8 A NN O
of WO2007010337A8 A IN O
PDE5 WO2007010337A8 A NNP I-UN
inhibitors WO2007010337A8 A NNS O
. WO2007010337A8 A . O

Imidazolidinedione WO2013087004A1 T NNP O
compounds WO2013087004A1 T NNS O
and WO2013087004A1 T CC O
their WO2013087004A1 T PRP$ O
uses WO2013087004A1 T NNS O
. WO2013087004A1 T . O

Said WO2013087004A1 A NNP O
imidazolidinedione WO2013087004A1 A NN O
compounds WO2013087004A1 A VBZ O
possess WO2013087004A1 A JJ O
androgen WO2013087004A1 A NN I-UN
receptor WO2013087004A1 A NN I-UN
antagonist WO2013087004A1 A NN O
activity WO2013087004A1 A NN O
and WO2013087004A1 A CC O
can WO2013087004A1 A MD O
be WO2013087004A1 A VB O
used WO2013087004A1 A VBN O
for WO2013087004A1 A IN O
preventing WO2013087004A1 A VBG O
and WO2013087004A1 A CC O
treating WO2013087004A1 A VBG O
diseases WO2013087004A1 A NNS O
and WO2013087004A1 A CC O
disorders WO2013087004A1 A NNS O
related WO2013087004A1 A VBN O
to WO2013087004A1 A TO O
androgen WO2013087004A1 A VB I-UN
receptor WO2013087004A1 A NN I-UN
, WO2013087004A1 A , O
such WO2013087004A1 A JJ O
as WO2013087004A1 A IN O
prostate WO2013087004A1 A NN O
cancer WO2013087004A1 A NN O
, WO2013087004A1 A , O
alopecia WO2013087004A1 A NN O
, WO2013087004A1 A , O
hair WO2013087004A1 A NN O
regeneration WO2013087004A1 A NN O
, WO2013087004A1 A , O
acne WO2013087004A1 A NN O
and WO2013087004A1 A CC O
adolescent WO2013087004A1 A JJ O
acne WO2013087004A1 A NN O
. WO2013087004A1 A . O

Zinc CN1634013A T NNP O
gluconate CN1634013A T JJ O
oral CN1634013A T JJ O
disintegrating CN1634013A T VBG O
tablet CN1634013A T NN O
and CN1634013A T CC O
its CN1634013A T PRP$ O
preparation CN1634013A T NN O
process CN1634013A T NN O
. CN1634013A T . O

Cefdinir CN103301081A T NNP O
dispersible CN103301081A T JJ O
tablet CN103301081A T NN O
and CN103301081A T CC O
preparation CN103301081A T NN O
method CN103301081A T NN O
thereof CN103301081A T NN O
. CN103301081A T . O

Biodegradable CN101053553B T JJ O
fluorourcacil CN101053553B T NN O
polyester CN101053553B T NN O
medicine-carried CN101053553B T JJ O
nanospheres CN101053553B T NNS O
and CN101053553B T CC O
its CN101053553B T PRP$ O
preparation CN101053553B T NN O
method CN101053553B T NN O
. CN101053553B T . O

The CN101053553B A DT O
invention CN101053553B A NN O
relates CN101053553B A VBZ O
to CN101053553B A TO O
biodegradable CN101053553B A VB O
fluorouracil CN101053553B A NN O
( CN101053553B A ( O
Fu CN101053553B A NNP O
) CN101053553B A ) O
polyester CN101053553B A NN O
drug-bearing CN101053553B A JJ O
manoparticles CN101053553B A NNS O
with CN101053553B A IN O
a CN101053553B A DT O
coating CN101053553B A VBG O
material CN101053553B A NN O
of CN101053553B A IN O
polylactic CN101053553B A JJ O
acid CN101053553B A NN O
, CN101053553B A , O
polylactic CN101053553B A JJ O
acid-glycolic CN101053553B A JJ O
acid CN101053553B A NN O
, CN101053553B A , O
polylactic CN101053553B A JJ O
acid-polyethylene CN101053553B A JJ O
glycol CN101053553B A NN O
block CN101053553B A NN O
copolymer CN101053553B A NN O
or CN101053553B A CC O
polylactic CN101053553B A JJ O
acid-glycolic CN101053553B A JJ O
acid-polyethylene CN101053553B A JJ O
glycol CN101053553B A NN O
block CN101053553B A NN O
copolymer CN101053553B A NN O
and CN101053553B A CC O
the CN101053553B A DT O
producing CN101053553B A VBG O
method CN101053553B A NN O
including CN101053553B A VBG O
: CN101053553B A : O
firstly CN101053553B A RB O
, CN101053553B A , O
fully CN101053553B A RB O
dissolving CN101053553B A VBG O
the CN101053553B A DT O
copolymer CN101053553B A NN O
in CN101053553B A IN O
the CN101053553B A DT O
dichloromethane CN101053553B A NN O
, CN101053553B A , O
under CN101053553B A IN O
the CN101053553B A DT O
ultrasonic CN101053553B A JJ O
shock CN101053553B A NN O
, CN101053553B A , O
injecting CN101053553B A VBG O
the CN101053553B A DT O
fluorouracil CN101053553B A NN O
NaOH CN101053553B A NNP O
solution CN101053553B A NN O
in CN101053553B A IN O
the CN101053553B A DT O
dichloromethane CN101053553B A NN O
solution CN101053553B A NN O
, CN101053553B A , O
dispersing CN101053553B A VBG O
uniformly CN101053553B A RB O
, CN101053553B A , O
forming CN101053553B A VBG O
W/O CN101053553B A NNP O
primary CN101053553B A JJ O
latex CN101053553B A NN O
, CN101053553B A , O
and CN101053553B A CC O
beating CN101053553B A VBG O
up CN101053553B A RP O
the CN101053553B A DT O
primary CN101053553B A JJ O
latex CN101053553B A NN O
and CN101053553B A CC O
injecting CN101053553B A VBG O
into CN101053553B A IN O
the CN101053553B A DT O
fluorouracil CN101053553B A NN O
saturated CN101053553B A VBD O
water CN101053553B A NN O
solution CN101053553B A NN O
containing CN101053553B A VBG O
5 CN101053553B A CD O
wt CN101053553B A JJ O
% CN101053553B A NN O
of CN101053553B A IN O
polyvinylalcohol CN101053553B A NN O
( CN101053553B A ( O
PVA CN101053553B A NNP O
) CN101053553B A ) O
, CN101053553B A , O
and CN101053553B A CC O
storing CN101053553B A VBG O
in CN101053553B A IN O
the CN101053553B A DT O
refrigeratory CN101053553B A NN O
after CN101053553B A IN O
freeze-dry CN101053553B A JJ O
. CN101053553B A . O

The CN101053553B A DT O
drug-bearing CN101053553B A JJ O
manoparticle CN101053553B A NN O
has CN101053553B A VBZ O
a CN101053553B A DT O
drug CN101053553B A NN O
content CN101053553B A NN O
which CN101053553B A WDT O
is CN101053553B A VBZ O
10-25 CN101053553B A CD O
% CN101053553B A NN O
of CN101053553B A IN O
the CN101053553B A DT O
microparticle CN101053553B A NN O
mass CN101053553B A NN O
, CN101053553B A , O
and CN101053553B A CC O
has CN101053553B A VBZ O
a CN101053553B A DT O
smooth CN101053553B A JJ O
surface CN101053553B A NN O
, CN101053553B A , O
an CN101053553B A DT O
even CN101053553B A RB O
diameter CN101053553B A JJR O
distribution CN101053553B A NN O
, CN101053553B A , O
a CN101053553B A DT O
remarkable CN101053553B A JJ O
slow CN101053553B A JJ O
release CN101053553B A NN O
function CN101053553B A NN O
and CN101053553B A CC O
not CN101053553B A RB O
adhesive CN101053553B A JJ O
. CN101053553B A . O

The CN101053553B A DT O
micropartical CN101053553B A JJ O
size CN101053553B A NN O
is CN101053553B A VBZ O
100-1000nm CN101053553B A JJ O
. CN101053553B A . O

Citrulline-containing CN101868156A T JJ O
drink CN101868156A T NN O
. CN101868156A T . O

nucleic US20080183123 T JJ O
acid US20080183123 T NN O
composition US20080183123 T NN O
for US20080183123 T IN O
injection US20080183123 T NN O
; US20080183123 T : O
ciliary US20080183123 T JJ O
body US20080183123 T NN O
tissue US20080183123 T NN O
( US20080183123 T ( O
s US20080183123 T NN O
) US20080183123 T ) O
or US20080183123 T CC O
cells US20080183123 T NNS O
and/or US20080183123 T VBP O
to US20080183123 T TO O
the US20080183123 T DT O
extra-ocular US20080183123 T JJ O
muscle US20080183123 T NN O
tissue US20080183123 T NN O
or US20080183123 T CC O
cells US20080183123 T NNS O
; US20080183123 T : O
antiproliferative US20080183123 T JJ O
, US20080183123 T , O
antiinflammatory US20080183123 T JJ O
, US20080183123 T , O
antiischemic US20080183123 T JJ O
agent US20080183123 T NN O
; US20080183123 T : O
neurodegenerative US20080183123 T JJ O
diseases US20080183123 T NNS O
; US20080183123 T : O
ocular US20080183123 T JJ O
disease US20080183123 T NN O
, US20080183123 T , O
vision US20080183123 T NN O
deffects US20080183123 T NNS O
. US20080183123 T . O

Application CN103494875A T NN O
of CN103494875A T IN O
cyclocarya CN103494875A T NN O
paliurus CN103494875A T NN O
extract CN103494875A T NN O
in CN103494875A T IN O
preparation CN103494875A T NN O
of CN103494875A T IN O
medicament CN103494875A T NN O
for CN103494875A T IN O
preventing CN103494875A T VBG O
and CN103494875A T CC O
treating CN103494875A T VBG O
leukemia CN103494875A T NN O
. CN103494875A T . O

Preparation CN102603396A T NN O
of CN102603396A T IN O
chitosamine-selenium CN102603396A T JJ O
nanometer CN102603396A T JJ O
trace-element CN102603396A T JJ O
nutrition CN102603396A T NN O
regulator CN102603396A T NN O
. CN102603396A T . O

Use US7632808 T NNP O
of US7632808 T IN O
MP52 US7632808 T NNP I-UN
or US7632808 T CC I-UN
MP121 US7632808 T NNP I-UN
for US7632808 T IN O
the US7632808 T DT O
treatment US7632808 T NN O
and US7632808 T CC O
prevention US7632808 T NN O
of US7632808 T IN O
diseases US7632808 T NNS O
of US7632808 T IN O
the US7632808 T DT O
nervous US7632808 T JJ O
system US7632808 T NN O
. US7632808 T . O

The US7632808 A DT O
present US7632808 A JJ O
invention US7632808 A NN O
concerns US7632808 A NNS O
the US7632808 A DT O
use US7632808 A NN O
of US7632808 A IN O
biologically US7632808 A RB O
active US7632808 A JJ O
MP52 US7632808 A NNP I-UN
or/and US7632808 A NN I-UN
MP121 US7632808 A NNP I-UN
for US7632808 A IN O
the US7632808 A DT O
treatment US7632808 A NN O
and US7632808 A CC O
prevention US7632808 A NN O
of US7632808 A IN O
diseases US7632808 A NNS O
of US7632808 A IN O
the US7632808 A DT O
nervous US7632808 A JJ O
system US7632808 A NN O
or/and US7632808 A NN O
for US7632808 A IN O
the US7632808 A DT O
treatment US7632808 A NN O
of US7632808 A IN O
neuropathological US7632808 A JJ O
situations US7632808 A NNS O
which US7632808 A WDT O
are US7632808 A VBP O
caused US7632808 A VBN O
by US7632808 A IN O
ageing US7632808 A VBG O
of US7632808 A IN O
the US7632808 A DT O
nervous US7632808 A JJ O
system US7632808 A NN O
. US7632808 A . O

A US7632808 A DT O
pharmaceutical US7632808 A JJ O
agent US7632808 A NN O
according US7632808 A VBG O
to US7632808 A TO O
the US7632808 A DT O
invention US7632808 A NN O
for US7632808 A IN O
the US7632808 A DT O
treatment US7632808 A NN O
and US7632808 A CC O
prevention US7632808 A NN O
of US7632808 A IN O
diseases US7632808 A NNS O
of US7632808 A IN O
the US7632808 A DT O
nervous US7632808 A JJ O
system US7632808 A NN O
or/and US7632808 A NN O
for US7632808 A IN O
treating US7632808 A VBG O
neuropathological US7632808 A JJ O
situations US7632808 A NNS O
which US7632808 A WDT O
are US7632808 A VBP O
caused US7632808 A VBN O
by US7632808 A IN O
ageing US7632808 A VBG O
of US7632808 A IN O
the US7632808 A DT O
nervous US7632808 A JJ O
system US7632808 A NN O
therefore US7632808 A NN O
contains US7632808 A VBZ O
biologically US7632808 A RB O
active US7632808 A JJ O
MP52 US7632808 A NNP I-UN
or/and US7632808 A NN I-UN
MP121 US7632808 A NNP I-UN
as US7632808 A IN O
the US7632808 A DT O
active US7632808 A JJ O
substance US7632808 A NN O
. US7632808 A . O

Combination CA2444821C T NNP O
therapy CA2444821C T NN O
using CA2444821C T VBG O
anti-angiogenic CA2444821C T JJ O
agents CA2444821C T NNS O
and CA2444821C T CC O
tnfa CA2444821C T NN I-UN
. CA2444821C T . O

The CA2444821C A DT O
invention CA2444821C A NN O
relates CA2444821C A VBZ O
to CA2444821C A TO O
a CA2444821C A DT O
combination CA2444821C A NN O
therapy CA2444821C A NN O
for CA2444821C A IN O
the CA2444821C A DT O
treatment CA2444821C A NN O
of CA2444821C A IN O
tumors CA2444821C A NNS O
metastases CA2444821C A NNS O
comprising CA2444821C A VBG O
administration CA2444821C A NN O
of CA2444821C A IN O
anti-angiogenic CA2444821C A JJ O
agents CA2444821C A NNS O
and CA2444821C A CC O
tumor CA2444821C A NN I-UN
necrosis CA2444821C A NN I-UN
factor CA2444821C A NN I-UN
alpha CA2444821C A NN I-UN
( CA2444821C A ( O
TNF.alpha CA2444821C A NNP I-UN
. CA2444821C A . O
) CA2444821C A ) O

optionally CA2444821C A RB O
together CA2444821C A RB O
with CA2444821C A IN O
other CA2444821C A JJ O
cytotoxic CA2444821C A NN O
agents CA2444821C A NNS O
, CA2444821C A , O
such CA2444821C A JJ O
as CA2444821C A IN O
interferon CA2444821C A NN I-UN
gamma CA2444821C A NN I-UN
( CA2444821C A ( O
IFNy CA2444821C A NNP I-UN
) CA2444821C A ) O
orchemotherapeutic CA2444821C A JJ O
agents CA2444821C A NNS O
such CA2444821C A JJ O
as CA2444821C A IN O
anti-EGFR CA2444821C A JJ O
antibodies CA2444821C A NNS O
. CA2444821C A . O

Ophthalmic US7321000 T NNP O
composition US7321000 T NN O
containing US7321000 T VBG O
N-acetyl-cysteine US7321000 T NNP O
for US7321000 T IN O
the US7321000 T DT O
treatment US7321000 T NN O
of US7321000 T IN O
dry-eye US7321000 T JJ O
syndrome US7321000 T NN O
. US7321000 T . O

Spray CN101810604A T NN O
taking CN101810604A T VBG O
salbutamol CN101810604A T NN O
and CN101810604A T CC O
ambroxol CN101810604A T NN O
as CN101810604A T IN O
active CN101810604A T JJ O
ingredients CN101810604A T NNS O
. CN101810604A T . O

Substances WO2011074881A2 T NNS O
for WO2011074881A2 T IN O
inhibiting WO2011074881A2 T VBG O
expression WO2011074881A2 T NN O
of WO2011074881A2 T IN O
genes WO2011074881A2 T NNS O
for WO2011074881A2 T IN O
sensitivity WO2011074881A2 T NN O
to WO2011074881A2 T TO O
allergic WO2011074881A2 T VB O
disorders WO2011074881A2 T NNS O
. WO2011074881A2 T . O

Method CN101229190A T NNP O
for CN101229190A T IN O
preparing CN101229190A T VBG O
highly CN101229190A T RB O
water-soluble CN101229190A T JJ O
cydiodine CN101229190A T NN O
. CN101229190A T . O

Amino US20070112040 T NNP O
nicotinate US20070112040 T JJ O
derivatives US20070112040 T NNS O
as US20070112040 T IN O
glucokinase US20070112040 T NN I-UN
( US20070112040 T ( O
GLK US20070112040 T NNP I-UN
) US20070112040 T ) O
modulators US20070112040 T NNS O
. US20070112040 T . O

The US20070112040 A DT O
invention US20070112040 A NN O
is US20070112040 A VBZ O
related US20070112040 A VBN O
to US20070112040 A TO O
novel US20070112040 A JJ O
compounds US20070112040 A NNS O
of US20070112040 A IN O
Formula US20070112040 A NNP O
( US20070112040 A ( O
I US20070112040 A PRP O
) US20070112040 A ) O
or US20070112040 A CC O
a US20070112040 A DT O
salt US20070112040 A NN O
, US20070112040 A , O
solvate US20070112040 A NN O
or US20070112040 A CC O
prodrug US20070112040 A NN O
thereof US20070112040 A NN O
, US20070112040 A , O
wherein US20070112040 A NN O
R1 US20070112040 A NNP O
, US20070112040 A , O
R2 US20070112040 A NNP O
, US20070112040 A , O
R3 US20070112040 A NNP O
, US20070112040 A , O
n US20070112040 A NN O
and US20070112040 A CC O
m US20070112040 A NN O
are US20070112040 A VBP O
as US20070112040 A IN O
described US20070112040 A VBN O
in US20070112040 A IN O
the US20070112040 A DT O
specification US20070112040 A NN O
, US20070112040 A , O
useful US20070112040 A JJ O
in US20070112040 A IN O
the US20070112040 A DT O
treatment US20070112040 A NN O
of US20070112040 A IN O
a US20070112040 A DT O
disease US20070112040 A NN O
or US20070112040 A CC O
condition US20070112040 A NN O
mediated US20070112040 A VBN O
through US20070112040 A IN O
glucokinase US20070112040 A NN I-UN
( US20070112040 A ( O
GLK US20070112040 A NNP I-UN
) US20070112040 A ) O
, US20070112040 A , O
such US20070112040 A JJ O
as US20070112040 A IN O
type US20070112040 A NN O
2 US20070112040 A CD O
diabetes US20070112040 A NNS O
. US20070112040 A . O

The US20070112040 A DT O
invention US20070112040 A NN O
also US20070112040 A RB O
relates US20070112040 A VBZ O
to US20070112040 A TO O
methods US20070112040 A NNS O
for US20070112040 A IN O
preparing US20070112040 A VBG O
compounds US20070112040 A NNS O
of US20070112040 A IN O
Formula US20070112040 A NNP O
( US20070112040 A ( O
I US20070112040 A PRP O
) US20070112040 A ) O
and US20070112040 A CC O
their US20070112040 A PRP$ O
use US20070112040 A NN O
as US20070112040 A IN O
medicaments US20070112040 A NNS O
in US20070112040 A IN O
the US20070112040 A DT O
treatment US20070112040 A NN O
of US20070112040 A IN O
diseases US20070112040 A NNS O
mediated US20070112040 A VBN O
by US20070112040 A IN O
glucokinase US20070112040 A NN I-UN
. US20070112040 A . O

Formulations CA2304704C T NNS O
and CA2304704C T CC O
methods CA2304704C T NNS O
for CA2304704C T IN O
reducing CA2304704C T VBG O
toxicity CA2304704C T NN O
of CA2304704C T IN O
antineoplastic CA2304704C T JJ O
agents CA2304704C T NNS O
. CA2304704C T . O

This CA2304704C A DT O
invention CA2304704C A NN O
provides CA2304704C A VBZ O
for CA2304704C A IN O
pharmaceutical CA2304704C A JJ O
formulations CA2304704C A NNS O
of CA2304704C A IN O
compounds CA2304704C A NNS O
which CA2304704C A WDT O
are CA2304704C A VBP O
useful CA2304704C A JJ O
as CA2304704C A IN O
protective CA2304704C A JJ O
agents CA2304704C A NNS O
when CA2304704C A WRB O
administered CA2304704C A VBN O
to CA2304704C A TO O
patients CA2304704C A NNS O
also CA2304704C A RB O
receiving CA2304704C A VBG O
antineoplastic CA2304704C A JJ O
drugs CA2304704C A NNS O
. CA2304704C A . O

The CA2304704C A DT O
invention CA2304704C A NN O
also CA2304704C A RB O
includes CA2304704C A VBZ O
methods CA2304704C A NNS O
of CA2304704C A IN O
reducing CA2304704C A VBG O
the CA2304704C A DT O
toxicity CA2304704C A NN O
of CA2304704C A IN O
various CA2304704C A JJ O
antineoplastic CA2304704C A JJ O
agents CA2304704C A NNS O
by CA2304704C A IN O
administering CA2304704C A VBG O
an CA2304704C A DT O
effective CA2304704C A JJ O
amount CA2304704C A NN O
of CA2304704C A IN O
the CA2304704C A DT O
protective CA2304704C A JJ O
agent CA2304704C A NN O
to CA2304704C A TO O
a CA2304704C A DT O
patient CA2304704C A NN O
receiving CA2304704C A VBG O
one CA2304704C A CD O
or CA2304704C A CC O
more CA2304704C A JJR O
antineoplastic CA2304704C A JJ O
agents CA2304704C A NNS O
. CA2304704C A . O

The CA2304704C A DT O
compounds CA2304704C A NNS O
useful CA2304704C A JJ O
as CA2304704C A IN O
protective CA2304704C A JJ O
agents CA2304704C A NNS O
have CA2304704C A VBP O
either CA2304704C A CC O
a CA2304704C A DT O
sulfhydryl CA2304704C A JJ O
moiety CA2304704C A NN O
or CA2304704C A CC O
are CA2304704C A VBP O
reducible CA2304704C A JJ O
disulfides CA2304704C A NNS O
. CA2304704C A . O

Use EP1047422B1 T NNP O
of EP1047422B1 T IN O
histamine EP1047422B1 T NN O
for EP1047422B1 T IN O
elevating EP1047422B1 T VBG O
blood EP1047422B1 T NN O
histamine EP1047422B1 T NN O
levels EP1047422B1 T NNS O
. EP1047422B1 T . O

N3- US20060052417 T NNP O
( US20060052417 T ( O
( US20060052417 T ( O
1- US20060052417 T CD O
( US20060052417 T ( O
2-Oxo-2- US20060052417 T CD O
( US20060052417 T ( O
phenylamino US20060052417 T NN O
) US20060052417 T ) O
ethyl US20060052417 T NN O
) US20060052417 T ) O
-4-piperidyl US20060052417 T NN O
) US20060052417 T ) O
methyl US20060052417 T NN O
) US20060052417 T ) O
- US20060052417 T : O
1- US20060052417 T JJ O
( US20060052417 T ( O
1-methylethyl US20060052417 T JJ O
) US20060052417 T ) O
-1H-indazole-3-carboxamide US20060052417 T NN O
; US20060052417 T : O
antiarthritic US20060052417 T JJ O
agents US20060052417 T NNS O
; US20060052417 T : O
rheumatic US20060052417 T JJ O
diseases US20060052417 T NNS O
; US20060052417 T : O
osteoarthritis US20060052417 T NN O
; US20060052417 T : O
fibromyaleia US20060052417 T CC O
; US20060052417 T : O
anticarcinogenic US20060052417 T JJ O
agents US20060052417 T NNS O
, US20060052417 T , O
pain US20060052417 T NN O
; US20060052417 T : O
neuropathic US20060052417 T JJ O
pain US20060052417 T NN O
; US20060052417 T : O
immunoincompetance US20060052417 T NN O
; US20060052417 T : O
trauma US20060052417 T CC O
; US20060052417 T : O
antiischemic US20060052417 T JJ O
agents US20060052417 T NNS O
; US20060052417 T : O
multiple US20060052417 T JJ O
sclerosis US20060052417 T NN O
. US20060052417 T . O

Therapeutic WO2010005725A2 T JJ O
polymeric WO2010005725A2 T NN O
nanoparticles WO2010005725A2 T NNS O
comprising WO2010005725A2 T VBG O
vinca WO2010005725A2 T JJ O
alkaloids WO2010005725A2 T NNS O
and WO2010005725A2 T CC O
methods WO2010005725A2 T NNS O
of WO2010005725A2 T IN O
making WO2010005725A2 T VBG O
and WO2010005725A2 T CC O
using WO2010005725A2 T VBG O
same WO2010005725A2 T JJ O
. WO2010005725A2 T . O

Treating US20080167277 T VBG O
plaque US20080167277 T JJ O
psoriasis US20080167277 T NN O
or US20080167277 T CC O
inverse US20080167277 T JJ O
psoriasis US20080167277 T NN O
by US20080167277 T IN O
topically US20080167277 T RB O
administering US20080167277 T VBG O
phenethyl US20080167277 T NN O
or US20080167277 T CC O
benzyl US20080167277 T VB O
3,4-dihydroxycinnamate US20080167277 T JJ O
to US20080167277 T TO O
inhibit US20080167277 T VB O
a US20080167277 T DT O
Signal US20080167277 T NNP O
Transducers US20080167277 T NNP O
and US20080167277 T CC O
Activators US20080167277 T NNP O
of US20080167277 T IN O
Transcription US20080167277 T NNP O
3 US20080167277 T CD O
signaling US20080167277 T VBG O
pathway US20080167277 T RB O
; US20080167277 T : O
may US20080167277 T MD O
also US20080167277 T RB O
include US20080167277 T VB O
a US20080167277 T DT O
petroleum US20080167277 T NN O
jelly US20080167277 T RB O
or US20080167277 T CC O
dimethyl US20080167277 T VB O
sulfoxide US20080167277 T JJ O
solubilizer US20080167277 T NN O
and US20080167277 T CC O
a US20080167277 T DT O
cell US20080167277 T NN O
differentiation US20080167277 T NN O
agent US20080167277 T NN O
. US20080167277 T . O

Methods US20080167277 A NNS O
of US20080167277 A IN O
treating US20080167277 A VBG O
skin US20080167277 A JJ O
diseases US20080167277 A NNS O
such US20080167277 A JJ O
as US20080167277 A IN O
plaque US20080167277 A JJ O
psoriasis US20080167277 A NN O
and US20080167277 A CC O
inverse US20080167277 A JJ O
psoriasis US20080167277 A NN O
include US20080167277 A VBP O
topical US20080167277 A JJ O
application US20080167277 A NN O
of US20080167277 A IN O
one US20080167277 A CD O
or US20080167277 A CC O
a US20080167277 A DT O
combination US20080167277 A NN O
of US20080167277 A IN O
caffeic US20080167277 A JJ O
acid US20080167277 A NN O
phenethyl US20080167277 A NN O
ester US20080167277 A NN O
, US20080167277 A , O
caffeic US20080167277 A JJ O
acid US20080167277 A NN O
benzyl US20080167277 A NN O
ester US20080167277 A NN O
, US20080167277 A , O
and US20080167277 A CC O
analogs US20080167277 A NNS O
thereof US20080167277 A RP O
as US20080167277 A IN O
an US20080167277 A DT O
active US20080167277 A JJ O
agent US20080167277 A NN O
. US20080167277 A . O

A US20080167277 A DT O
pharmaceutical US20080167277 A JJ O
composition US20080167277 A NN O
containing US20080167277 A VBG O
the US20080167277 A DT O
active US20080167277 A JJ O
agent US20080167277 A NN O
may US20080167277 A MD O
further US20080167277 A RB O
include US20080167277 A VB O
a US20080167277 A DT O
cell US20080167277 A NN O
differentiating US20080167277 A VBG O
agent US20080167277 A NN O
such US20080167277 A JJ O
as US20080167277 A IN O
a US20080167277 A DT O
retinoid US20080167277 A NN O
, US20080167277 A , O
and/or US20080167277 A JJ O
vitamin US20080167277 A NN O
D US20080167277 A NNP O
or US20080167277 A CC O
analogs US20080167277 A NNS O
thereof US20080167277 A NNS O
. US20080167277 A . O

The US20080167277 A DT O
method US20080167277 A NN O
enables US20080167277 A VBZ O
treatment US20080167277 A NN O
of US20080167277 A IN O
a US20080167277 A DT O
lesion US20080167277 A NN O
with US20080167277 A IN O
active US20080167277 A JJ O
agent US20080167277 A NN O
dosages US20080167277 A NNS O
of US20080167277 A IN O
ten US20080167277 A JJ O
percent US20080167277 A NN O
by US20080167277 A IN O
weight US20080167277 A NN O
, US20080167277 A , O
for US20080167277 A IN O
example US20080167277 A NN O
. US20080167277 A . O

3- EP2343291A1 T JJ O
( EP2343291A1 T ( O
Indolyl EP2343291A1 T NNP O
) EP2343291A1 T ) O
- EP2343291A1 T : O
or EP2343291A1 T CC O
3- EP2343291A1 T JJ O
( EP2343291A1 T ( O
Azaindolyl EP2343291A1 T NNP O
) EP2343291A1 T ) O
-4-arylmaleimide EP2343291A1 T VBP O
compounds EP2343291A1 T NNS O
and EP2343291A1 T CC O
their EP2343291A1 T PRP$ O
use EP2343291A1 T NN O
in EP2343291A1 T IN O
tumor EP2343291A1 T NN O
treatment EP2343291A1 T NN O
. EP2343291A1 T . O

Eye CN1965857A T NNP O
drop CN1965857A T NN O
of CN1965857A T IN O
povidone CN1965857A T NN O
iodine CN1965857A T NN O
and CN1965857A T CC O
preparation CN1965857A T NN O
process CN1965857A T NN O
thereof CN1965857A T NN O
. CN1965857A T . O

The CN1965857A A DT O
invention CN1965857A A NN O
relates CN1965857A A VBZ O
to CN1965857A A TO O
a CN1965857A A DT O
polyketone CN1965857A A NN O
iodine CN1965857A A NN O
eyedrops CN1965857A A NNS O
, CN1965857A A , O
and CN1965857A A CC O
relative CN1965857A A JJ O
production CN1965857A A NN O
, CN1965857A A , O
wherein CN1965857A A WP O
it CN1965857A A PRP O
adds CN1965857A A VBZ O
polyketone CN1965857A A JJ O
iodine CN1965857A A NN O
into CN1965857A A IN O
osmotic CN1965857A A JJ O
pressure CN1965857A A NN O
adjuster CN1965857A A NN O
, CN1965857A A , O
stabilizer CN1965857A A NN O
, CN1965857A A , O
and CN1965857A A CC O
pH CN1965857A A RB O
adjuster CN1965857A A NN O
to CN1965857A A TO O
be CN1965857A A VB O
dissolved CN1965857A A VBN O
, CN1965857A A , O
and CN1965857A A CC O
using CN1965857A A VBG O
pH CN1965857A A JJ O
adjuster CN1965857A A NN O
to CN1965857A A TO O
realize CN1965857A A VB O
constant CN1965857A A JJ O
volume CN1965857A A NN O
; CN1965857A A : O
pH CN1965857A A CC O
adjuster CN1965857A A NN O
at CN1965857A A IN O
100 CN1965857A A CD O
volume CN1965857A A NN O
units CN1965857A A NNS O
contain CN1965857A A VBP O
0.1-0.5 CN1965857A A JJ O
units CN1965857A A NNS O
of CN1965857A A IN O
polyketone CN1965857A A NN O
iodine CN1965857A A NN O
, CN1965857A A , O
0.35-0.65 CN1965857A A JJ O
osmotic CN1965857A A JJ O
pressure CN1965857A A NN O
adjuster CN1965857A A NN O
mass CN1965857A A NN O
units CN1965857A A NNS O
, CN1965857A A , O
stabilizer CN1965857A A NN O
at CN1965857A A IN O
0.05 CN1965857A A CD O
mass CN1965857A A NN O
units CN1965857A A NNS O
; CN1965857A A : O
the CN1965857A A DT O
pH CN1965857A A NN O
of CN1965857A A IN O
osmotic CN1965857A A JJ O
pressure CN1965857A A NN O
adjuster CN1965857A A NN O
is CN1965857A A VBZ O
6.0-6.8 CN1965857A A JJ O
. CN1965857A A . O

The CN1965857A A DT O
invention CN1965857A A NN O
can CN1965857A A MD O
treat CN1965857A A VB O
kinds CN1965857A A NNS O
of CN1965857A A IN O
ceratitis CN1965857A A NN O
, CN1965857A A , O
with CN1965857A A IN O
high CN1965857A A JJ O
safety CN1965857A A NN O
but CN1965857A A CC O
no CN1965857A A DT O
side CN1965857A A NN O
effect CN1965857A A NN O
. CN1965857A A . O

Phytoestrogenic US20120164122 T JJ O
formulations US20120164122 T NNS O
for US20120164122 T IN O
alleviation US20120164122 T NN O
or US20120164122 T CC O
prevention US20120164122 T NN O
of US20120164122 T IN O
neurodegenerative US20120164122 T JJ O
diseases US20120164122 T NNS O
. US20120164122 T . O

These US20120164122 A DT O
select US20120164122 A JJ O
phytoestrogen US20120164122 A NN O
formulations US20120164122 A NNS O
are US20120164122 A VBP O
composed US20120164122 A VBN O
of US20120164122 A IN O
a US20120164122 A DT O
number US20120164122 A NN O
of US20120164122 A IN O
plant-derived US20120164122 A JJ O
estrogenic US20120164122 A JJ O
molecules US20120164122 A NNS O
and/or US20120164122 A VBP O
their US20120164122 A PRP$ O
structural US20120164122 A JJ O
analogues US20120164122 A NNS O
and US20120164122 A CC O
exhibit US20120164122 A NN O
binding US20120164122 A VBG O
preference US20120164122 A NN O
to US20120164122 A TO O
ERβ US20120164122 A NNP I-UN
over US20120164122 A IN O
ERα US20120164122 A NNP I-UN
and US20120164122 A CC O
agonist US20120164122 A JJ O
activity US20120164122 A NN O
in US20120164122 A IN O
the US20120164122 A DT O
brain US20120164122 A NN O
. US20120164122 A . O

Pharmaceutical CN103735552A T JJ O
composition CN103735552A T NN O
of CN103735552A T IN O
ticagrelor CN103735552A T NN O
and CN103735552A T CC O
cilostazol CN103735552A T NN O
as CN103735552A T RB O
well CN103735552A T RB O
as CN103735552A T IN O
preparation CN103735552A T NN O
method CN103735552A T NN O
and CN103735552A T CC O
application CN103735552A T NN O
of CN103735552A T IN O
pharmaceutical CN103735552A T JJ O
composition CN103735552A T NN O
. CN103735552A T . O

The CN103735552A A DT O
invention CN103735552A A NN O
relates CN103735552A A VBZ O
to CN103735552A A TO O
a CN103735552A A DT O
pharmaceutical CN103735552A A JJ O
composition CN103735552A A NN O
of CN103735552A A IN O
ticagrelor CN103735552A A NN O
and CN103735552A A CC O
cilostazol CN103735552A A NN O
, CN103735552A A , O
a CN103735552A A DT O
preparation CN103735552A A NN O
method CN103735552A A NN O
of CN103735552A A IN O
the CN103735552A A DT O
pharmaceutical CN103735552A A JJ O
composition CN103735552A A NN O
, CN103735552A A , O
and CN103735552A A CC O
application CN103735552A A NN O
of CN103735552A A IN O
the CN103735552A A DT O
pharmaceutical CN103735552A A JJ O
composition CN103735552A A NN O
in CN103735552A A IN O
medicines CN103735552A A NNS O
. CN103735552A A . O

The CN103735552A A DT O
pharmaceutical CN103735552A A JJ O
composition CN103735552A A NN O
has CN103735552A A VBZ O
the CN103735552A A DT O
effect CN103735552A A NN O
of CN103735552A A IN O
inhibiting CN103735552A A VBG O
or CN103735552A A CC O
reversing CN103735552A A VBG O
atherosclerosis CN103735552A A NN O
lipid CN103735552A A JJ O
plaques CN103735552A A NNS O
of CN103735552A A IN O
artery CN103735552A A NN O
blood CN103735552A A NN O
vessel CN103735552A A NN O
, CN103735552A A , O
in CN103735552A A IN O
particular CN103735552A A JJ O
the CN103735552A A DT O
effect CN103735552A A NN O
of CN103735552A A IN O
inhibiting CN103735552A A VBG O
or CN103735552A A CC O
reversing CN103735552A A VBG O
atherosclerosis CN103735552A A NN O
lipid CN103735552A A JJ O
plaques CN103735552A A NNS O
of CN103735552A A IN O
coronary CN103735552A A JJ O
artery CN103735552A A NN O
or CN103735552A A CC O
carotid CN103735552A A NN O
artery CN103735552A A NN O
. CN103735552A A . O

The CN103735552A A DT O
composition CN103735552A A NN O
is CN103735552A A VBZ O
able CN103735552A A JJ O
to CN103735552A A TO O
effectively CN103735552A A RB O
solve CN103735552A A VB O
the CN103735552A A DT O
problem CN103735552A A NN O
due CN103735552A A JJ O
to CN103735552A A TO O
interregnum CN103735552A A VB O
of CN103735552A A IN O
pharmaceutical CN103735552A A JJ O
function CN103735552A A NN O
caused CN103735552A A VBN O
by CN103735552A A IN O
occasionally CN103735552A A RB O
missing CN103735552A A VBG O
ticagrelor CN103735552A A NN O
, CN103735552A A , O
as CN103735552A A RB O
well CN103735552A A RB O
as CN103735552A A IN O
reduce CN103735552A A VB O
the CN103735552A A DT O
possible CN103735552A A JJ O
cardiovascular CN103735552A A NN O
and CN103735552A A CC O
cerebrovascular CN103735552A A JJ O
diseases CN103735552A A NNS O
; CN103735552A A : O
in CN103735552A A IN O
addition CN103735552A A NN O
, CN103735552A A , O
the CN103735552A A DT O
gastrointestinal CN103735552A A JJ O
bleeding CN103735552A A NN O
can CN103735552A A MD O
be CN103735552A A VB O
greatly CN103735552A A RB O
reduced CN103735552A A VBN O
, CN103735552A A , O
and CN103735552A A CC O
the CN103735552A A DT O
effect CN103735552A A NN O
is CN103735552A A VBZ O
far CN103735552A A RB O
more CN103735552A A JJR O
than CN103735552A A IN O
the CN103735552A A DT O
effect CN103735552A A NN O
of CN103735552A A IN O
the CN103735552A A DT O
composition CN103735552A A NN O
of CN103735552A A IN O
ticagrelor CN103735552A A NN O
and CN103735552A A CC O
aspirin CN103735552A A NN O
. CN103735552A A . O

Niacin US20110028462 T NNP I-UN
Receptor US20110028462 T NNP I-UN
Agonists US20110028462 T NNP O
, US20110028462 T , O
compositions US20110028462 T NNS O
Containing US20110028462 T VBG O
Such US20110028462 T JJ O
Compounds US20110028462 T NNS O
and US20110028462 T CC O
Methods US20110028462 T NNS O
of US20110028462 T IN O
Treatment US20110028462 T NNP O
. US20110028462 T . O

The US20110028462 A DT O
compounds US20110028462 A NNS O
are US20110028462 A VBP O
useful US20110028462 A JJ O
for US20110028462 A IN O
treating US20110028462 A VBG O
dyslipidemias US20110028462 A NN O
, US20110028462 A , O
and US20110028462 A CC O
in US20110028462 A IN O
particular US20110028462 A JJ O
, US20110028462 A , O
reducing US20110028462 A VBG O
serum US20110028462 A NN O
LDL US20110028462 A NNP I-UN
, US20110028462 A , O
VLDL US20110028462 A NNP I-UN
and US20110028462 A CC O
triglycerides US20110028462 A NNS O
, US20110028462 A , O
and US20110028462 A CC O
raising US20110028462 A VBG O
HDL US20110028462 A NNP I-UN
levels US20110028462 A NNS O
. US20110028462 A . O

Compositions WO2014118677A1 T NNS O
and WO2014118677A1 T CC O
methods WO2014118677A1 T NNS O
for WO2014118677A1 T IN O
counteracting WO2014118677A1 T VBG O
factor WO2014118677A1 T NN O
xa WO2014118677A1 T JJ O
inhibition WO2014118677A1 T NN O
. WO2014118677A1 T . O

Light-stable US20100062063 T JJ O
solid US20100062063 T JJ O
pharmaceutical US20100062063 T JJ O
composition US20100062063 T NN O
of US20100062063 T IN O
ramosetron US20100062063 T NN O
. US20100062063 T . O

Method US20050202101 T NNP O
and US20050202101 T CC O
composition US20050202101 T NN O
for US20050202101 T IN O
preventing US20050202101 T VBG O
or US20050202101 T CC O
reducing US20050202101 T VBG O
the US20050202101 T DT O
symptoms US20050202101 T NNS O
of US20050202101 T IN O
insulin US20050202101 T NN I-UN
resistance US20050202101 T NN O
syndrome US20050202101 T NN O
. US20050202101 T . O

A US20050202101 A DT O
method US20050202101 A NN O
for US20050202101 A IN O
preventing US20050202101 A VBG O
and US20050202101 A CC O
or US20050202101 A CC O
reducing US20050202101 A VBG O
the US20050202101 A DT O
symptoms US20050202101 A NNS O
of US20050202101 A IN O
insulin US20050202101 A NN I-UN
resistance US20050202101 A NN O
and US20050202101 A CC O
a US20050202101 A DT O
related US20050202101 A JJ O
syndrome US20050202101 A NN O
in US20050202101 A IN O
persons US20050202101 A NNS O
comprises US20050202101 A NNS O
identifying US20050202101 A VBG O
persons US20050202101 A NNS O
having US20050202101 A VBG O
or US20050202101 A CC O
at US20050202101 A IN O
risk US20050202101 A NN O
for US20050202101 A IN O
having US20050202101 A VBG O
such US20050202101 A JJ O
symptoms US20050202101 A NNS O
, US20050202101 A , O
and US20050202101 A CC O
administering US20050202101 A VBG O
to US20050202101 A TO O
them US20050202101 A PRP O
an US20050202101 A DT O
effective US20050202101 A JJ O
amount US20050202101 A NN O
of US20050202101 A IN O
a US20050202101 A DT O
composition US20050202101 A NN O
comprising US20050202101 A VBG O
chromium US20050202101 A NN O
bound US20050202101 A NN O
niacin US20050202101 A IN O
that US20050202101 A DT O
prevents US20050202101 A NNS O
or US20050202101 A CC O
reduces US20050202101 A VBZ O
the US20050202101 A DT O
symptoms US20050202101 A NNS O
. US20050202101 A . O

Benzisothiazole-3-ketone-2-amide CN103172587A T JJ O
compound CN103172587A T NN O
with CN103172587A T IN O
Caspase-3 CN103172587A T NNP I-UN
inhibiting CN103172587A T VBG O
activity CN103172587A T NN O
. CN103172587A T . O

The CN103172587A A DT O
invention CN103172587A A NN O
relates CN103172587A A VBZ O
to CN103172587A A TO O
a CN103172587A A DT O
benzisothiazole-3-ketone-2-amide CN103172587A A JJ O
compound CN103172587A A NN O
with CN103172587A A IN O
Caspase-3 CN103172587A A NNP I-UN
inhibiting CN103172587A A VBG O
activity CN103172587A A NN O
. CN103172587A A . O

The CN103172587A A DT O
benzisothiazole-3-ketone-2-amide CN103172587A A JJ O
compound CN103172587A A NN O
has CN103172587A A VBZ O
the CN103172587A A DT O
Caspase-3 CN103172587A A NNP I-UN
inhibiting CN103172587A A NN O
activity CN103172587A A NN O
, CN103172587A A , O
can CN103172587A A MD O
be CN103172587A A VB O
used CN103172587A A VBN O
for CN103172587A A IN O
treating CN103172587A A VBG O
diseases CN103172587A A NNS O
mediated CN103172587A A VBN O
by CN103172587A A IN O
Caspase-3 CN103172587A A NNP I-UN
, CN103172587A A , O
belongs CN103172587A A VBZ O
to CN103172587A A TO O
the CN103172587A A DT O
field CN103172587A A NN O
of CN103172587A A IN O
pharmaceutical CN103172587A A JJ O
chemistry CN103172587A A NN O
, CN103172587A A , O
and CN103172587A A CC O
has CN103172587A A VBZ O
a CN103172587A A DT O
structural CN103172587A A JJ O
formula CN103172587A A NN O
( CN103172587A A ( O
I CN103172587A A PRP O
) CN103172587A A ) O
as CN103172587A A IN O
shown CN103172587A A VBN O
in CN103172587A A IN O
the CN103172587A A DT O
specification CN103172587A A NN O
. CN103172587A A . O

Meropenem CN103570720A T NNP O
raw CN103570720A T JJ O
medicine CN103570720A T NN O
, CN103570720A T , O
preparation CN103570720A T NN O
method CN103570720A T NN O
thereof CN103570720A T NN O
and CN103570720A T CC O
pharmaceutical CN103570720A T JJ O
composition CN103570720A T NN O
containing CN103570720A T VBG O
same CN103570720A T JJ O
. CN103570720A T . O

Vidarabine CN103202804A T NNP O
monophosphate CN103202804A T NN O
injection CN103202804A T NN O
and CN103202804A T CC O
preparation CN103202804A T NN O
method CN103202804A T NN O
thereof CN103202804A T NN O
. CN103202804A T . O

Bicycle US20070082908 T NNP O
pyrazole US20070082908 T JJ O
derivative US20070082908 T NN O
. US20070082908 T . O

These US20070082908 A DT O
are US20070082908 A VBP O
compounds US20070082908 A NNS O
having US20070082908 A VBG O
high US20070082908 A JJ O
DPP-IV US20070082908 A JJ I-UN
inhibitory US20070082908 A NN O
activity US20070082908 A NN O
and US20070082908 A CC O
improved US20070082908 A VBN O
in US20070082908 A IN O
safety US20070082908 A NN O
, US20070082908 A , O
nontoxicity US20070082908 A NN O
, US20070082908 A , O
etc US20070082908 A FW O
. US20070082908 A . O

Azithromycin CN1634112A T NNP O
gel CN1634112A T NN O
formulation CN1634112A T NN O
and CN1634112A T CC O
its CN1634112A T PRP$ O
preparing CN1634112A T NN O
process CN1634112A T NN O
. CN1634112A T . O

The CN1634112A A DT O
invention CN1634112A A NN O
relates CN1634112A A VBZ O
to CN1634112A A TO O
an CN1634112A A DT O
Azithromycin CN1634112A A NNP O
gel CN1634112A A NN O
formulation CN1634112A A NN O
and CN1634112A A CC O
its CN1634112A A PRP$ O
preparing CN1634112A A NN O
process CN1634112A A NN O
, CN1634112A A , O
which CN1634112A A WDT O
is CN1634112A A VBZ O
a CN1634112A A DT O
gel CN1634112A A JJ O
form CN1634112A A NN O
oral CN1634112A A JJ O
administration CN1634112A A NN O
preparation CN1634112A A NN O
prepared CN1634112A A VBD O
through CN1634112A A IN O
using CN1634112A A VBG O
Azithromycin CN1634112A A NNP O
and CN1634112A A CC O
right CN1634112A A JJ O
amount CN1634112A A NN O
of CN1634112A A IN O
base CN1634112A A NN O
material CN1634112A A NN O
as CN1634112A A IN O
gel CN1634112A A NN O
or CN1634112A A CC O
paste CN1634112A A NN O
, CN1634112A A , O
the CN1634112A A DT O
aged CN1634112A A JJ O
people CN1634112A A NNS O
and CN1634112A A CC O
children CN1634112A A NNS O
are CN1634112A A VBP O
willing CN1634112A A JJ O
to CN1634112A A TO O
take CN1634112A A VB O
the CN1634112A A DT O
preparation CN1634112A A NN O
. CN1634112A A . O

The CN1634112A A DT O
preparation CN1634112A A NN O
can CN1634112A A MD O
be CN1634112A A VB O
used CN1634112A A VBN O
for CN1634112A A IN O
treating CN1634112A A VBG O
respiratory CN1634112A A NN O
tract CN1634112A A NN O
, CN1634112A A , O
skin CN1634112A A NN O
and CN1634112A A CC O
soft CN1634112A A JJ O
tissue CN1634112A A NN O
affection CN1634112A A NN O
diseases CN1634112A A NNS O
caused CN1634112A A VBN O
by CN1634112A A IN O
responsive CN1634112A A JJ O
microorganisms CN1634112A A NNS O
. CN1634112A A . O

The CN1634112A A DT O
invention CN1634112A A NN O
also CN1634112A A RB O
provides CN1634112A A VBZ O
the CN1634112A A DT O
process CN1634112A A NN O
for CN1634112A A IN O
preparing CN1634112A A VBG O
the CN1634112A A DT O
preparation CN1634112A A NN O
. CN1634112A A . O

1-Substituted- US7713939 T JJ O
[ US7713939 T NNP O
1H-indene-6,1'-cyclopropane US7713939 T CD O
] US7713939 T NNP O
-4-one US7713939 T CD O
derivatives US7713939 T NNS O
: US7713939 T : O
solid US7713939 T JJ O
tumors US7713939 T NNS O
and US7713939 T CC O
multi-drug US7713939 T JJ O
resistant US7713939 T JJ O
tumors US7713939 T NNS O
; US7713939 T : O
-cell US7713939 T NNP O
leukemia US7713939 T NN O
, US7713939 T , O
B-cell US7713939 T NNP O
lymphoma US7713939 T NN O
, US7713939 T , O
myeloma US7713939 T NN O
, US7713939 T , O
T-cell US7713939 T NNP O
leukemia US7713939 T NN O
, US7713939 T , O
T-cell US7713939 T NNP O
lymphoma US7713939 T NN O
, US7713939 T , O
small US7713939 T JJ O
leukemia US7713939 T NN O
, US7713939 T , O
and US7713939 T CC O
small US7713939 T JJ O
cell US7713939 T NN O
lymphoma US7713939 T NN O
. US7713939 T . O

Methods CN101918036A T NNS O
for CN101918036A T IN O
inhibiting CN101918036A T VBG O
fascin CN101918036A T NN I-UN
. CN101918036A T . O

The CN101918036A A DT O
invention CN101918036A A NN O
relates CN101918036A A VBZ O
to CN101918036A A TO O
compositions CN101918036A A NNS O
and CN101918036A A CC O
methods CN101918036A A NNS O
useful CN101918036A A JJ O
for CN101918036A A IN O
inhibiting CN101918036A A VBG O
fascin CN101918036A A NN I-UN
. CN101918036A A . O

For CN101918036A A IN O
example CN101918036A A NN O
, CN101918036A A , O
according CN101918036A A VBG O
to CN101918036A A TO O
the CN101918036A A DT O
invention CN101918036A A NN O
inhibition CN101918036A A NN O
of CN101918036A A IN O
fascin CN101918036A A JJ I-UN
inhibits CN101918036A A NNS O
metastasis CN101918036A A NN O
of CN101918036A A IN O
tumor CN101918036A A NN O
cells CN101918036A A NNS O
in CN101918036A A IN O
mammals CN101918036A A NNS O
. CN101918036A A . O

Novel WO2005053679A1 T NNP O
use WO2005053679A1 T NN O
of WO2005053679A1 T IN O
silymarin WO2005053679A1 T NN O
and WO2005053679A1 T CC O
the WO2005053679A1 T DT O
composition WO2005053679A1 T NN O
comprising WO2005053679A1 T VBG O
the WO2005053679A1 T DT O
same WO2005053679A1 T JJ O
. WO2005053679A1 T . O

Silymarin WO2005053679A1 A NNP O
showed WO2005053679A1 A VBD O
potent WO2005053679A1 A JJ O
inhibiting WO2005053679A1 A VBG O
effect WO2005053679A1 A NN O
on WO2005053679A1 A IN O
NO WO2005053679A1 A NNP O
( WO2005053679A1 A ( O
Nitric WO2005053679A1 A NNP O
Oxide WO2005053679A1 A NNP O
) WO2005053679A1 A ) O
, WO2005053679A1 A , O
TNF WO2005053679A1 A NNP I-UN
( WO2005053679A1 A ( I-UN
Tumor WO2005053679A1 A NNP I-UN
Necrosis WO2005053679A1 A NNP I-UN
Factor WO2005053679A1 A NNP I-UN
) WO2005053679A1 A ) I-UN
- WO2005053679A1 A : I-UN
alpha WO2005053679A1 A NN I-UN
, WO2005053679A1 A , O
Interleukin-1 WO2005053679A1 A NNP I-UN
beta WO2005053679A1 A NN I-UN
( WO2005053679A1 A ( O
IL-1 WO2005053679A1 A NNP I-UN
beta WO2005053679A1 A NN I-UN
) WO2005053679A1 A ) O
and WO2005053679A1 A CC O
prostaglandin WO2005053679A1 A JJ O
E2 WO2005053679A1 A NNP O
( WO2005053679A1 A ( O
PGE2 WO2005053679A1 A NNP O
) WO2005053679A1 A ) O
, WO2005053679A1 A , O
NF- WO2005053679A1 A NNP I-UN
kappa WO2005053679A1 A NN I-UN
B WO2005053679A1 A NNP I-UN
and WO2005053679A1 A CC O
the WO2005053679A1 A DT O
activity WO2005053679A1 A NN O
of WO2005053679A1 A IN O
sepsis WO2005053679A1 A NN O
, WO2005053679A1 A , O
therefore WO2005053679A1 A IN O
it WO2005053679A1 A PRP O
can WO2005053679A1 A MD O
be WO2005053679A1 A VB O
useful WO2005053679A1 A JJ O
in WO2005053679A1 A IN O
treating WO2005053679A1 A VBG O
or WO2005053679A1 A CC O
preventing WO2005053679A1 A VBG O
sepsis WO2005053679A1 A NN O
or WO2005053679A1 A CC O
inflammation WO2005053679A1 A NN O
mediated WO2005053679A1 A VBN O
disease WO2005053679A1 A NN O
such WO2005053679A1 A JJ O
as WO2005053679A1 A IN O
bronchitis WO2005053679A1 A NN O
, WO2005053679A1 A , O
gastritis WO2005053679A1 A NN O
, WO2005053679A1 A , O
colitis WO2005053679A1 A NN O
, WO2005053679A1 A , O
arthritis WO2005053679A1 A NN O
, WO2005053679A1 A , O
nephritis WO2005053679A1 A NN O
, WO2005053679A1 A , O
hepatitis WO2005053679A1 A NN O
, WO2005053679A1 A , O
cancer WO2005053679A1 A NN O
or WO2005053679A1 A CC O
generative WO2005053679A1 A JJ O
diseases WO2005053679A1 A NNS O
as WO2005053679A1 A IN O
a WO2005053679A1 A DT O
medicament WO2005053679A1 A NN O
or WO2005053679A1 A CC O
functional WO2005053679A1 A JJ O
health WO2005053679A1 A NN O
food WO2005053679A1 A NN O
. WO2005053679A1 A . O

Preparing CN1927208A T VBG O
technique CN1927208A T NN O
for CN1927208A T IN O
stomatocace CN1927208A T NN O
film CN1927208A T NN O
. CN1927208A T . O

Use US20100087547 T NNP O
of US20100087547 T IN O
a US20100087547 T DT O
Blood-Flow US20100087547 T JJ O
Decrease US20100087547 T NNP O
Preventing US20100087547 T NNP O
Agent US20100087547 T NNP O
in US20100087547 T IN O
Conjunction US20100087547 T NNP O
With US20100087547 T IN O
Insufflating US20100087547 T NNP O
Gas US20100087547 T NNP O
. US20100087547 T . O

Methods WO2006123246A3 T NNS O
for WO2006123246A3 T IN O
identifying WO2006123246A3 T VBG O
chemotherapeutic WO2006123246A3 T JJ O
resistance WO2006123246A3 T NN O
in WO2006123246A3 T IN O
non-hematopoietic WO2006123246A3 T JJ O
tumors WO2006123246A3 T NNS O
. WO2006123246A3 T . O

The WO2006123246A3 A DT O
methods WO2006123246A3 A NNS O
include WO2006123246A3 A VBP O
detecting WO2006123246A3 A VBG O
a WO2006123246A3 A DT O
level WO2006123246A3 A NN O
of WO2006123246A3 A IN O
pl6 WO2006123246A3 A JJ I-UN
expression WO2006123246A3 A NN O
in WO2006123246A3 A IN O
the WO2006123246A3 A DT O
test WO2006123246A3 A NN O
neoplastic WO2006123246A3 A JJ O
cell WO2006123246A3 A NN O
of WO2006123246A3 A IN O
a WO2006123246A3 A DT O
given WO2006123246A3 A VBN O
origin WO2006123246A3 A NN O
or WO2006123246A3 A CC O
cell WO2006123246A3 A NN O
type WO2006123246A3 A NN O
, WO2006123246A3 A , O
and WO2006123246A3 A CC O
comparing WO2006123246A3 A VBG O
the WO2006123246A3 A DT O
level WO2006123246A3 A NN O
of WO2006123246A3 A IN O
pl6 WO2006123246A3 A JJ I-UN
expression WO2006123246A3 A NN O
detected WO2006123246A3 A VBN O
in WO2006123246A3 A IN O
the WO2006123246A3 A DT O
test WO2006123246A3 A NN O
neoplastic WO2006123246A3 A JJ O
cell WO2006123246A3 A NN O
to WO2006123246A3 A TO O
the WO2006123246A3 A DT O
level WO2006123246A3 A NN O
of WO2006123246A3 A IN O
pl6 WO2006123246A3 A JJ I-UN
expression WO2006123246A3 A NN O
in WO2006123246A3 A IN O
a WO2006123246A3 A DT O
nonresistant WO2006123246A3 A JJ O
neoplastic WO2006123246A3 A JJ O
cell WO2006123246A3 A NN O
of WO2006123246A3 A IN O
the WO2006123246A3 A DT O
same WO2006123246A3 A JJ O
origin WO2006123246A3 A NN O
or WO2006123246A3 A CC O
cell WO2006123246A3 A NN O
type WO2006123246A3 A NN O
, WO2006123246A3 A , O
wherein WO2006123246A3 A VBP O
the WO2006123246A3 A DT O
test WO2006123246A3 A NN O
neoplastic WO2006123246A3 A JJ O
cell WO2006123246A3 A NN O
is WO2006123246A3 A VBZ O
adriamycin WO2006123246A3 A JJ O
resistant WO2006123246A3 A JJ O
if WO2006123246A3 A IN O
the WO2006123246A3 A DT O
level WO2006123246A3 A NN O
of WO2006123246A3 A IN O
pl6 WO2006123246A3 A JJ I-UN
expression WO2006123246A3 A NN O
is WO2006123246A3 A VBZ O
greater WO2006123246A3 A JJR O
than WO2006123246A3 A IN O
the WO2006123246A3 A DT O
level WO2006123246A3 A NN O
of WO2006123246A3 A IN O
pl6 WO2006123246A3 A JJ I-UN
expression WO2006123246A3 A NN O
in WO2006123246A3 A IN O
the WO2006123246A3 A DT O
nonresistant WO2006123246A3 A JJ O
neoplastic WO2006123246A3 A JJ O
cell WO2006123246A3 A NN O
of WO2006123246A3 A IN O
the WO2006123246A3 A DT O
same WO2006123246A3 A JJ O
origin WO2006123246A3 A NN O
or WO2006123246A3 A CC O
cell WO2006123246A3 A NN O
type WO2006123246A3 A NN O
. WO2006123246A3 A . O

Also WO2006123246A3 A RB O
disclosed WO2006123246A3 A VBN O
are WO2006123246A3 A VBP O
therapeutic WO2006123246A3 A JJ O
compositions WO2006123246A3 A NNS O
comprising WO2006123246A3 A VBG O
an WO2006123246A3 A DT O
agent WO2006123246A3 A NN O
that WO2006123246A3 A IN O
inhibits WO2006123246A3 A VBZ O
pl6 WO2006123246A3 A NN I-UN
and WO2006123246A3 A CC O
a WO2006123246A3 A DT O
pharmaceutically WO2006123246A3 A RB O
acceptable WO2006123246A3 A JJ O
carrier WO2006123246A3 A NN O
. WO2006123246A3 A . O

Solid CN101040843A T JJ O
tumor CN101040843A T NN O
resisting CN101040843A T VBG O
release CN101040843A T NN O
agent CN101040843A T NN O
including CN101040843A T VBG O
nimustine CN101040843A T NN O
and CN101040843A T CC O
the CN101040843A T DT O
intensifier CN101040843A T NN O
. CN101040843A T . O

Application CN103463106A T NN O
of CN103463106A T IN O
Phyllanthoid CN103463106A T NNP O
A CN103463106A T NNP O
in CN103463106A T IN O
preparing CN103463106A T VBG O
medicament CN103463106A T NN O
for CN103463106A T IN O
treating CN103463106A T VBG O
rheumatoid CN103463106A T JJ O
arthritis CN103463106A T NN O
. CN103463106A T . O

The CN103463106A A DT O
invention CN103463106A A NN O
provides CN103463106A A VBZ O
Phyllanthoid CN103463106A A NNP O
A CN103463106A A NNP O
for CN103463106A A IN O
treating CN103463106A A VBG O
immune CN103463106A A JJ O
inflammation CN103463106A A NN O
, CN103463106A A , O
which CN103463106A A WDT O
is CN103463106A A VBZ O
a CN103463106A A DT O
medicament CN103463106A A NN O
for CN103463106A A IN O
treating CN103463106A A VBG O
rheumatoid CN103463106A A JJ O
arthritis CN103463106A A NN O
. CN103463106A A . O

By CN103463106A A IN O
adopting CN103463106A A VBG O
terfenatine CN103463106A A NN O
and CN103463106A A CC O
diclofenac CN103463106A A JJ O
sodium CN103463106A A NN O
as CN103463106A A IN O
controls CN103463106A A NNS O
, CN103463106A A , O
Phyllanthoid CN103463106A A NNP O
A CN103463106A A NNP O
has CN103463106A A VBZ O
an CN103463106A A DT O
exact CN103463106A A JJ O
curative CN103463106A A JJ O
effect CN103463106A A NN O
, CN103463106A A , O
and CN103463106A A CC O
is CN103463106A A VBZ O
disclosed CN103463106A A VBN O
for CN103463106A A IN O
the CN103463106A A DT O
first CN103463106A A JJ O
time CN103463106A A NN O
. CN103463106A A . O

The CN103463106A A DT O
frame CN103463106A A NN O
model CN103463106A A NN O
is CN103463106A A VBZ O
a CN103463106A A DT O
brand-new CN103463106A A JJ O
frame CN103463106A A NN O
model CN103463106A A NN O
, CN103463106A A , O
and CN103463106A A CC O
Phyllanthoid CN103463106A A NNP O
A CN103463106A A NNP O
has CN103463106A A VBZ O
a CN103463106A A DT O
strong CN103463106A A JJ O
activity CN103463106A A NN O
in CN103463106A A IN O
treating CN103463106A A VBG O
rheumatoid CN103463106A A NN O
arthritis CN103463106A A NN O
, CN103463106A A , O
has CN103463106A A VBZ O
a CN103463106A A DT O
highlighted CN103463106A A VBN O
substantial CN103463106A A JJ O
characteristic CN103463106A A JJ O
, CN103463106A A , O
and CN103463106A A CC O
is CN103463106A A VBZ O
remarkably CN103463106A A RB O
progressed CN103463106A A VBN O
when CN103463106A A WRB O
being CN103463106A A VBG O
used CN103463106A A VBN O
for CN103463106A A IN O
preventing CN103463106A A VBG O
and CN103463106A A CC O
treating CN103463106A A VBG O
rheumatoid CN103463106A A JJ O
arthritis CN103463106A A NN O
. CN103463106A A . O

Novel WO2013070116A3 T NNP O
antithrombotic WO2013070116A3 T JJ O
and WO2013070116A3 T CC O
antiatherosclerotic WO2013070116A3 T JJ O
agent WO2013070116A3 T NN O
and WO2013070116A3 T CC O
method WO2013070116A3 T NN O
for WO2013070116A3 T IN O
producing WO2013070116A3 T VBG O
same WO2013070116A3 T JJ O
( WO2013070116A3 T ( O
variants WO2013070116A3 T NNS O
) WO2013070116A3 T ) O
. WO2013070116A3 T . O

A WO2013070116A3 A DT O
novel WO2013070116A3 A JJ O
compound WO2013070116A3 A NN O
of WO2013070116A3 A IN O
formula WO2013070116A3 A NN O
I WO2013070116A3 A PRP O
is WO2013070116A3 A VBZ O
proposed WO2013070116A3 A VBN O
which WO2013070116A3 A WDT O
exhibits WO2013070116A3 A VBZ O
the WO2013070116A3 A DT O
properties WO2013070116A3 A NNS O
of WO2013070116A3 A IN O
an WO2013070116A3 A DT O
exogenous WO2013070116A3 A JJ O
nitric WO2013070116A3 A JJ O
oxide WO2013070116A3 A NN O
donor WO2013070116A3 A NN O
and WO2013070116A3 A CC O
thus WO2013070116A3 A RB O
a WO2013070116A3 A DT O
thrombocyte WO2013070116A3 A JJ O
aggregation WO2013070116A3 A NN O
inhibitor WO2013070116A3 A NN O
, WO2013070116A3 A , O
as WO2013070116A3 A RB O
well WO2013070116A3 A RB O
as WO2013070116A3 A IN O
displaying WO2013070116A3 A VBG O
antihypertensive WO2013070116A3 A JJ O
activity WO2013070116A3 A NN O
and WO2013070116A3 A CC O
activating WO2013070116A3 A VBG O
activity WO2013070116A3 A NN O
towards WO2013070116A3 A IN O
the WO2013070116A3 A DT O
enzyme WO2013070116A3 A NN O
soluble WO2013070116A3 A JJ I-UN
guanylyl WO2013070116A3 A JJ I-UN
cyclase WO2013070116A3 A NN I-UN
. WO2013070116A3 A . O

Novel WO2010114471A1 T NNP O
amide WO2010114471A1 T JJ O
derivatives WO2010114471A1 T NNS O
of WO2010114471A1 T IN O
steroidal WO2010114471A1 T JJ O
[ WO2010114471A1 T NNP O
3,2-c WO2010114471A1 T JJ O
] WO2010114471A1 T NNP O
pyrazole WO2010114471A1 T NN O
compounds WO2010114471A1 T NNS O
with WO2010114471A1 T IN O
glucocorticoid WO2010114471A1 T JJ I-UN
activity WO2010114471A1 T NN O
. WO2010114471A1 T . O

Methods US20110076258 T NNS O
of US20110076258 T IN O
modulating US20110076258 T VBG O
t US20110076258 T JJ O
cell- US20110076258 T JJ O
dependent US20110076258 T NN O
immune US20110076258 T NN O
responses US20110076258 T NNS O
. US20110076258 T . O

Novel WO2014117948A1 T NNP O
substituted WO2014117948A1 T VBD O
condensed WO2014117948A1 T JJ O
pyrimidine WO2014117948A1 T NN O
compounds WO2014117948A1 T NNS O
. WO2014117948A1 T . O

e.g US7776868 T NN O
. US7776868 T . O

6- US7776868 T JJ O
[ US7776868 T NNP O
( US7776868 T ( O
1E US7776868 T CD O
) US7776868 T ) O
-2- US7776868 T NN O
( US7776868 T ( O
3,4-dimethoxyphenyl US7776868 T JJ O
) US7776868 T ) O
vinyl US7776868 T FW O
] US7776868 T FW O
-3-ethyl-1,5-dimethyl-1,3-dihydrothiopheno US7776868 T FW O
[ US7776868 T FW O
2,3-d US7776868 T JJ O
] US7776868 T JJ O
pyrimidine-2,4-dione US7776868 T NN O
; US7776868 T : O
neurodegenerative US7776868 T JJ O
disorders US7776868 T NNS O
, US7776868 T , O
antiischemic US7776868 T JJ O
agent US7776868 T NN O
, US7776868 T , O
antidepressant US7776868 T NN O
, US7776868 T , O
attention US7776868 T NN O
deficit US7776868 T NN O
disorder US7776868 T NN O
, US7776868 T , O
hepatic US7776868 T JJ O
fibrosis US7776868 T NN O
, US7776868 T , O
cirrhosis US7776868 T NN O
of US7776868 T IN O
the US7776868 T DT O
liver US7776868 T NN O
, US7776868 T , O
and US7776868 T CC O
drug US7776868 T NN O
addiction US7776868 T NN O
. US7776868 T . O

An US20080145410 T DT O
iron-containing US20080145410 T JJ O
complex US20080145410 T NN O
to US20080145410 T TO O
treat US20080145410 T VB O
hyperphosphatemia US20080145410 T NN O
by US20080145410 T IN O
adsorbing US20080145410 T VBG O
excess US20080145410 T JJ O
phosphates US20080145410 T NNS O
in US20080145410 T IN O
the US20080145410 T DT O
blood US20080145410 T NN O
; US20080145410 T : O
capacity US20080145410 T NN O
of US20080145410 T IN O
> US20080145410 T $ O
140 US20080145410 T CD O
mg US20080145410 T NN O
adsorbed US20080145410 T VBN O
phosphate US20080145410 T NN O
by US20080145410 T IN O
1 US20080145410 T CD O
g US20080145410 T NN O
complex US20080145410 T NN O
of US20080145410 T IN O
an US20080145410 T DT O
insoluble US20080145410 T JJ O
carbohydrate US20080145410 T NN O
( US20080145410 T ( O
starch US20080145410 T NN O
) US20080145410 T ) O
, US20080145410 T , O
polynuclear US20080145410 T JJ O
iron US20080145410 T NN O
oxide/hydroxide US20080145410 T NN O
and US20080145410 T CC O
a US20080145410 T DT O
soluble US20080145410 T JJ O
glucose US20080145410 T NN O
; US20080145410 T : O
stability US20080145410 T NN O
; US20080145410 T : O
packaging US20080145410 T NN O
; US20080145410 T : O
industrial US20080145410 T JJ O
scale US20080145410 T NN O
. US20080145410 T . O

The US20080145410 A DT O
present US20080145410 A JJ O
invention US20080145410 A NN O
relates US20080145410 A VBZ O
to US20080145410 A TO O
a US20080145410 A DT O
new US20080145410 A JJ O
iron US20080145410 A NN O
containing US20080145410 A VBG O
phosphate US20080145410 A JJ O
adsorbent US20080145410 A NN O
and US20080145410 A CC O
its US20080145410 A PRP$ O
use US20080145410 A NN O
e.g US20080145410 A NN O
. US20080145410 A . O

for US20080145410 A IN O
treating US20080145410 A VBG O
hyperphosphataemia US20080145410 A NN O
. US20080145410 A . O

Use WO2009060073A1 T NNP O
of WO2009060073A1 T IN O
oligosaccharides WO2009060073A1 T NNS O
containing WO2009060073A1 T VBG O
n-acetyllactosamine WO2009060073A1 T NN O
for WO2009060073A1 T IN O
maturation WO2009060073A1 T NN O
of WO2009060073A1 T IN O
immune WO2009060073A1 T JJ O
responses WO2009060073A1 T NNS O
in WO2009060073A1 T IN O
neonates WO2009060073A1 T NNS O
. WO2009060073A1 T . O

Salicylic CN102093261A T JJ O
acid CN102093261A T NN O
metformin CN102093261A T NN O
salt CN102093261A T NN O
and CN102093261A T CC O
preparation CN102093261A T NN O
method CN102093261A T NN O
and CN102093261A T CC O
medical CN102093261A T JJ O
application CN102093261A T NN O
thereof CN102093261A T NN O
. CN102093261A T . O

S-Nitrosothiols US20100062059 T JJ O
Containing US20100062059 T NNP O
Composition US20100062059 T NNP O
for US20100062059 T IN O
the US20100062059 T DT O
Treatment US20100062059 T NNP O
of US20100062059 T IN O
Fatty US20100062059 T NNP O
Liver US20100062059 T NNP O
Diseases US20100062059 T NNP O
, US20100062059 T , O
Obesity US20100062059 T NNP O
and US20100062059 T CC O
Other US20100062059 T JJ O
Diseases US20100062059 T NNS O
Associated US20100062059 T VBN O
with US20100062059 T IN O
the US20100062059 T DT O
Metabolic US20100062059 T NNP O
Syndrome US20100062059 T NNP O
and US20100062059 T CC O
the US20100062059 T DT O
Use US20100062059 T NNP O
of US20100062059 T IN O
Such US20100062059 T JJ O
Compositions US20100062059 T NNS O
. US20100062059 T . O

2-Aryl-Propionic US20110207785 T JJ O
Acids US20110207785 T NNP O
and US20110207785 T CC O
Derivatives US20110207785 T NNP O
and US20110207785 T CC O
Pharmaceutical US20110207785 T NNP O
Compositions US20110207785 T NNP O
Containing US20110207785 T NNP O
Them US20110207785 T NNP O
. US20110207785 T . O

substituted US7563784 T VBN O
1,1,4-1l6-trioxo US7563784 T JJ O
[ US7563784 T NN O
1,2 US7563784 T CD O
] US7563784 T JJ O
thiazepan-4-ylamide-derived US7563784 T JJ O
protease US7563784 T NN O
inhibitors US7563784 T NNS O
which US7563784 T WDT O
inhibit US7563784 T VBP O
the US7563784 T DT O
likes US7563784 T NNS O
of US7563784 T IN O
cathepsin US7563784 T NN I-UN
K US7563784 T NNP I-UN
; US7563784 T : O
treating US7563784 T VBG O
osteoporosis US7563784 T NN O
, US7563784 T , O
osteo- US7563784 T JJ O
and US7563784 T CC O
rheumatoid US7563784 T JJ O
arthritis US7563784 T NN O
and US7563784 T CC O
periodontal US7563784 T JJ O
disease US7563784 T NN O
; US7563784 T : O
inhibiting US7563784 T VBG O
excessive US7563784 T JJ O
cartilage US7563784 T NN O
or US7563784 T CC O
matrix US7563784 T JJ O
degradation US7563784 T NN O
. US7563784 T . O

The US7563784 A DT O
present US7563784 A JJ O
invention US7563784 A NN O
provides US7563784 A VBZ O
C1-6alkyl-4-amino-azepan-3-one US7563784 A JJ O
protease US7563784 A NN O
inhibitors US7563784 A NNS O
and US7563784 A CC O
pharmaceutically US7563784 A RB O
acceptable US7563784 A JJ O
salts US7563784 A NNS O
, US7563784 A , O
hydrates US7563784 A NNS O
and US7563784 A CC O
solvates US7563784 A NNS O
thereof US7563784 A VBP O
which US7563784 A WDT O
inhibit US7563784 A NN O
proteases US7563784 A NNS O
, US7563784 A , O
including US7563784 A VBG O
cathepsin US7563784 A NN I-UN
K US7563784 A NNP I-UN
, US7563784 A , O
pharmaceutical US7563784 A JJ O
compositions US7563784 A NNS O
of US7563784 A IN O
such US7563784 A JJ O
compounds US7563784 A NNS O
, US7563784 A , O
novel US7563784 A JJ O
intermediates US7563784 A NNS O
of US7563784 A IN O
such US7563784 A JJ O
compounds US7563784 A NNS O
, US7563784 A , O
and US7563784 A CC O
methods US7563784 A NNS O
for US7563784 A IN O
treating US7563784 A VBG O
diseases US7563784 A NNS O
of US7563784 A IN O
excessive US7563784 A JJ O
bone US7563784 A NN O
loss US7563784 A NN O
or US7563784 A CC O
cartilage US7563784 A NN O
or US7563784 A CC O
matrix US7563784 A NN O
degradation US7563784 A NN O
, US7563784 A , O
including US7563784 A VBG O
osteoporosis US7563784 A NN O
; US7563784 A : O
gingival US7563784 A JJ O
disease US7563784 A NN O
including US7563784 A VBG O
gingivitis US7563784 A NN O
and US7563784 A CC O
periodontitis US7563784 A NN O
; US7563784 A : O
arthritis US7563784 A NN O
, US7563784 A , O
more US7563784 A RBR O
specifically US7563784 A RB O
, US7563784 A , O
osteoarthritis US7563784 A NN O
and US7563784 A CC O
rheumatoid US7563784 A JJ O
arthritis US7563784 A NN O
; US7563784 A : O
Paget US7563784 A NNP O
's US7563784 A POS O
disease US7563784 A NN O
; US7563784 A : O
hypercalcemia US7563784 A NN O
of US7563784 A IN O
malignancy US7563784 A NN O
; US7563784 A : O
and US7563784 A CC O
metabolic US7563784 A VB O
bone US7563784 A NN O
disease US7563784 A NN O
; US7563784 A : O
and US7563784 A CC O
parasitic US7563784 A JJ O
diseases US7563784 A NNS O
, US7563784 A , O
including US7563784 A VBG O
malaria US7563784 A NNS O
, US7563784 A , O
by US7563784 A IN O
administering US7563784 A VBG O
to US7563784 A TO O
a US7563784 A DT O
patient US7563784 A NN O
in US7563784 A IN O
need US7563784 A NN O
thereof US7563784 A VBP O
one US7563784 A CD O
or US7563784 A CC O
more US7563784 A JJR O
compounds US7563784 A NNS O
of US7563784 A IN O
the US7563784 A DT O
present US7563784 A JJ O
invention US7563784 A NN O
. US7563784 A . O

Preparation CN101940796A T NN O
of CN101940796A T IN O
gene CN101940796A T NN O
immunization CN101940796A T NN O
treating CN101940796A T VBG O
tumor CN101940796A T NN O
used CN101940796A T VBN O
for CN101940796A T IN O
vein CN101940796A T NN O
. CN101940796A T . O

The CN101940796A A DT O
invention CN101940796A A NN O
discloses CN101940796A A VBZ O
a CN101940796A A DT O
preparation CN101940796A A NN O
of CN101940796A A IN O
gene CN101940796A A NN O
immunization CN101940796A A NN O
treating CN101940796A A VBG O
tumor CN101940796A A NN O
used CN101940796A A VBN O
for CN101940796A A IN O
veins CN101940796A A NNS O
, CN101940796A A , O
which CN101940796A A WDT O
is CN101940796A A VBZ O
composed CN101940796A A VBN O
of CN101940796A A IN O
replication CN101940796A A NN O
deficient CN101940796A A NN O
adenovirus CN101940796A A NN O
loading CN101940796A A VBG O
human CN101940796A A JJ I-UN
telomerase CN101940796A A NN I-UN
reverse CN101940796A A NN I-UN
transcriptase CN101940796A A NN I-UN
C-terminal CN101940796A A NNP I-UN
polypeptide CN101940796A A NN I-UN
hTERTC27 CN101940796A A NN I-UN
and CN101940796A A CC O
an CN101940796A A DT O
acceptable CN101940796A A JJ O
pharmaceutic CN101940796A A JJ O
adjuvant CN101940796A A NN O
. CN101940796A A . O

The CN101940796A A DT O
anti-tumor CN101940796A A JJ O
gene CN101940796A A NN O
preparation CN101940796A A NN O
of CN101940796A A IN O
the CN101940796A A DT O
invention CN101940796A A NN O
can CN101940796A A MD O
effectively CN101940796A A RB O
lead CN101940796A A VB O
the CN101940796A A DT O
peptides CN101940796A A NNS O
transfection CN101940796A A NN O
to CN101940796A A TO O
enter CN101940796A A VB O
into CN101940796A A IN O
the CN101940796A A DT O
dendritic CN101940796A A JJ O
cell CN101940796A A NN O
DCs CN101940796A A NNP O
, CN101940796A A , O
so CN101940796A A RB O
as CN101940796A A IN O
to CN101940796A A TO O
activate CN101940796A A VB O
the CN101940796A A DT O
DCs CN101940796A A NNP O
, CN101940796A A , O
secrete CN101940796A A JJ O
IFN-gamma CN101940796A A NNP I-UN
, CN101940796A A , O
IL-2 CN101940796A A NNP I-UN
, CN101940796A A , O
increase CN101940796A A NN O
and CN101940796A A CC O
further CN101940796A A JJ O
stimulate CN101940796A A NN O
T CN101940796A A NNP O
lymphopoiesis CN101940796A A NN O
, CN101940796A A , O
promote CN101940796A A VBP O
the CN101940796A A DT O
T CN101940796A A NNP O
lymphocyte CN101940796A A NN O
to CN101940796A A TO O
generate CN101940796A A VB O
the CN101940796A A DT O
special CN101940796A A JJ O
killing CN101940796A A VBG O
effect CN101940796A A NN O
CTL CN101940796A A NNP O
corresponding CN101940796A A NN O
to CN101940796A A TO O
the CN101940796A A DT O
tumor CN101940796A A NN O
cell CN101940796A A NN O
, CN101940796A A , O
and CN101940796A A CC O
immunoregulation CN101940796A A NN O
is CN101940796A A VBZ O
carried CN101940796A A VBN O
out CN101940796A A IN O
on CN101940796A A IN O
the CN101940796A A DT O
tumor CN101940796A A NN O
. CN101940796A A . O

Hair CN1843373A T NNP O
growth CN1843373A T NN O
promoting CN1843373A T VBG O
liquid CN1843373A T NN O
. CN1843373A T . O

Application CN102579441A T NN O
of CN102579441A T IN O
mycoepoxydiene CN102579441A T NN O
nicotinic CN102579441A T JJ O
acids CN102579441A T NNS O
derivatives CN102579441A T NNS O
in CN102579441A T IN O
preparation CN102579441A T NN O
process CN102579441A T NN O
of CN102579441A T IN O
pro-inflammatory CN102579441A T JJ O
mediator CN102579441A T NN O
inhibitors CN102579441A T NNS O
. CN102579441A T . O

Pharmacology CN102579441A A NN O
experiments CN102579441A A NNS O
prove CN102579441A A VBP O
that CN102579441A A IN O
the CN102579441A A DT O
mycoepoxydiene CN102579441A A NN O
nicotinic CN102579441A A JJ O
acids CN102579441A A NNS O
derivatives CN102579441A A NNS O
can CN102579441A A MD O
effectively CN102579441A A RB O
inhibit CN102579441A A VB O
the CN102579441A A DT O
expression CN102579441A A NN O
of CN102579441A A IN O
the CN102579441A A DT O
inflammatory CN102579441A A JJ O
factors CN102579441A A NNS O
such CN102579441A A JJ O
as CN102579441A A IN O
tumor CN102579441A A NN I-UN
necrosis CN102579441A A NN I-UN
factor CN102579441A A NN I-UN
( CN102579441A A ( O
TNF-Alpha CN102579441A A NNP I-UN
) CN102579441A A ) O
, CN102579441A A , O
interleukin CN102579441A A JJ I-UN
6 CN102579441A A CD I-UN
( CN102579441A A ( O
IL-6 CN102579441A A NNP I-UN
) CN102579441A A ) O
and CN102579441A A CC O
nitric CN102579441A A JJ O
monoxide CN102579441A A NN O
( CN102579441A A ( O
NO CN102579441A A NNP O
) CN102579441A A ) O
. CN102579441A A . O

Marker CN103261413A T NNP O
for CN103261413A T IN O
determination CN103261413A T NN O
of CN103261413A T IN O
sensitivity CN103261413A T NN O
to CN103261413A T TO O
triplet CN103261413A T VB O
combination CN103261413A T NN O
anti-cancer CN103261413A T JJ O
agent CN103261413A T NN O
. CN103261413A T . O

A CN103261413A A DT O
marker CN103261413A A NN O
for CN103261413A A IN O
determining CN103261413A A VBG O
the CN103261413A A DT O
sensitivity CN103261413A A NN O
to CN103261413A A TO O
an CN103261413A A DT O
anti-cancer CN103261413A A JJ O
agent CN103261413A A NN O
, CN103261413A A , O
which CN103261413A A WDT O
comprises CN103261413A A VBZ O
at CN103261413A A IN O
least CN103261413A A JJS O
one CN103261413A A CD O
gene CN103261413A A NN O
selected CN103261413A A VBN O
from CN103261413A A IN O
ALAD CN103261413A A NNP I-UN
gene CN103261413A A NN O
, CN103261413A A , O
C20orf43 CN103261413A A NNP I-UN
gene CN103261413A A NN O
, CN103261413A A , O
CABLES1 CN103261413A A NNP I-UN
gene CN103261413A A NN O
, CN103261413A A , O
CDC14B CN103261413A A NNP I-UN
gene CN103261413A A NN O
, CN103261413A A , O
GDA CN103261413A A NNP I-UN
gene CN103261413A A NN O
, CN103261413A A , O
HOXB6 CN103261413A A NNP I-UN
gene CN103261413A A NN O
, CN103261413A A , O
RPL7AP27 CN103261413A A NNP I-UN
gene CN103261413A A NN O
, CN103261413A A , O
TMEM18 CN103261413A A NNP I-UN
gene CN103261413A A NN O
and CN103261413A A CC O
UGT2B10 CN103261413A A NNP I-UN
gene CN103261413A A NN O
and CN103261413A A CC O
contains CN103261413A A VBZ O
oxaliplatin CN103261413A A NN O
or CN103261413A A CC O
a CN103261413A A DT O
salt CN103261413A A NN O
thereof CN103261413A A NN O
, CN103261413A A , O
fluorouracil CN103261413A A NN O
or CN103261413A A CC O
a CN103261413A A DT O
salt CN103261413A A JJ O
thereof CN103261413A A NN O
and CN103261413A A CC O
levofolinate CN103261413A A NN O
or CN103261413A A CC O
a CN103261413A A DT O
salt CN103261413A A JJ O
thereof CN103261413A A NN O
. CN103261413A A . O

Indoleacetic CN102146081B T JJ O
acid CN102146081B T NN O
derivatives CN102146081B T NNS O
and CN102146081B T CC O
preparation CN102146081B T NN O
method CN102146081B T NN O
and CN102146081B T CC O
application CN102146081B T NN O
thereof CN102146081B T NN O
. CN102146081B T . O

The CN102146081B A DT O
invention CN102146081B A NN O
discloses CN102146081B A VBZ O
indole-3-acetic CN102146081B A JJ O
acid CN102146081B A NN O
derivatives CN102146081B A NNS O
shown CN102146081B A VBN O
as CN102146081B A IN O
a CN102146081B A DT O
general CN102146081B A JJ O
formula CN102146081B A NN O
I CN102146081B A PRP O
and CN102146081B A CC O
a CN102146081B A DT O
synthesis CN102146081B A NN O
method CN102146081B A NN O
thereof CN102146081B A NN O
, CN102146081B A , O
also CN102146081B A RB O
discloses CN102146081B A VBZ O
the CN102146081B A DT O
in-vitro CN102146081B A JJ O
activity CN102146081B A NN O
thereof CN102146081B A NN O
which CN102146081B A WDT O
is CN102146081B A VBZ O
derived CN102146081B A VBN O
from CN102146081B A IN O
the CN102146081B A DT O
interaction CN102146081B A NN O
of CN102146081B A IN O
the CN102146081B A DT O
derivatives CN102146081B A NNS O
with CN102146081B A IN O
DNA CN102146081B A NNP O
of CN102146081B A IN O
tumor CN102146081B A NN O
cells CN102146081B A NNS O
to CN102146081B A TO O
inhibit CN102146081B A VB O
the CN102146081B A DT O
multiplication CN102146081B A NN O
of CN102146081B A IN O
tumor CN102146081B A NN O
cells CN102146081B A NNS O
, CN102146081B A , O
and CN102146081B A CC O
further CN102146081B A JJ O
discloses CN102146081B A VBZ O
the CN102146081B A DT O
antitumor CN102146081B A JJ O
effect CN102146081B A NN O
of CN102146081B A IN O
the CN102146081B A DT O
derivatives CN102146081B A NNS O
on CN102146081B A IN O
a CN102146081B A DT O
mouse CN102146081B A NN O
transplanted CN102146081B A VBN O
tumor CN102146081B A NN O
model CN102146081B A NN O
. CN102146081B A . O

Therefore CN102146081B A RB O
, CN102146081B A , O
the CN102146081B A DT O
invention CN102146081B A NN O
illustrates CN102146081B A VBZ O
the CN102146081B A DT O
clinical CN102146081B A JJ O
application CN102146081B A NN O
prospect CN102146081B A NN O
of CN102146081B A IN O
indole-3-acetic CN102146081B A JJ O
acid CN102146081B A NN O
derivatives CN102146081B A NNS O
as CN102146081B A IN O
antitumor CN102146081B A NN O
agents CN102146081B A NNS O
. CN102146081B A . O

The CN102146081B A DT O
formula CN102146081B A NN O
I CN102146081B A PRP O
is CN102146081B A VBZ O
shown CN102146081B A VBN O
in CN102146081B A IN O
the CN102146081B A DT O
specification CN102146081B A NN O
. CN102146081B A . O

Preparation CN103417481A T NNP O
methods CN103417481A T NNS O
for CN103417481A T IN O
multiple CN103417481A T JJ O
breviscapinum CN103417481A T NN O
lipid CN103417481A T JJ O
carriers CN103417481A T NNS O
and CN103417481A T CC O
gels CN103417481A T NNS O
thereof CN103417481A T NN O
. CN103417481A T . O

Application CN103751174A T NN O
of CN103751174A T IN O
schisandra CN103751174A T JJ O
chinensis CN103751174A T NN O
monomer CN103751174A T NN O
compound CN103751174A T NN O
in CN103751174A T IN O
preparation CN103751174A T NN O
of CN103751174A T IN O
drugs CN103751174A T NNS O
for CN103751174A T IN O
prevention CN103751174A T NN O
and CN103751174A T CC O
treatment CN103751174A T NN O
of CN103751174A T IN O
hepatotoxicity CN103751174A T NN O
caused CN103751174A T VBN O
by CN103751174A T IN O
acetaminophen CN103751174A T NN O
. CN103751174A T . O

Experiment CN103751174A A JJ O
results CN103751174A A NNS O
show CN103751174A A VBP O
that CN103751174A A IN O
: CN103751174A A : O
with CN103751174A A IN O
the CN103751174A A DT O
schisandra CN103751174A A JJ O
chinensis CN103751174A A NN O
monomer CN103751174A A NN O
compound CN103751174A A NN O
, CN103751174A A , O
the CN103751174A A DT O
ALT CN103751174A A NNP I-UN
content CN103751174A A NN O
and CN103751174A A CC O
the CN103751174A A DT O
AST CN103751174A A NNP I-UN
content CN103751174A A NN O
in CN103751174A A IN O
the CN103751174A A DT O
APAP-induced CN103751174A A NNP O
liver CN103751174A A NN O
injury CN103751174A A NN O
animal CN103751174A A JJ O
model CN103751174A A NN O
can CN103751174A A MD O
be CN103751174A A VB O
significantly CN103751174A A RB O
reduced CN103751174A A VBN O
, CN103751174A A , O
consumption CN103751174A A NN O
of CN103751174A A IN O
glutathione CN103751174A A NN O
in CN103751174A A IN O
liver CN103751174A A NN O
cells CN103751174A A NNS O
can CN103751174A A MD O
be CN103751174A A VB O
inhibited CN103751174A A VBN O
, CN103751174A A , O
the CN103751174A A DT O
liver CN103751174A A NN O
cell CN103751174A A NN O
necrosis CN103751174A A IN O
degree CN103751174A A NN O
can CN103751174A A MD O
be CN103751174A A VB O
effectively CN103751174A A RB O
improved CN103751174A A VBN O
, CN103751174A A , O
and CN103751174A A CC O
the CN103751174A A DT O
schisandra CN103751174A A JJ O
chinensis CN103751174A A NN O
monomer CN103751174A A NN O
compound CN103751174A A NN O
provides CN103751174A A VBZ O
significant CN103751174A A JJ O
treatment CN103751174A A NN O
and CN103751174A A CC O
protection CN103751174A A NN O
effects CN103751174A A NNS O
for CN103751174A A IN O
hepatotoxicity CN103751174A A NN O
symptoms CN103751174A A NNS O
caused CN103751174A A VBN O
by CN103751174A A IN O
APAP CN103751174A A NNP O
. CN103751174A A . O

4-piperazinylthieno WO2006103544A3 T JJ O
[ WO2006103544A3 T NN O
2 WO2006103544A3 T CD O
, WO2006103544A3 T , O
3-d WO2006103544A3 T JJ O
] WO2006103544A3 T NNP O
pyrimidine WO2006103544A3 T NN O
compounds WO2006103544A3 T NNS O
as WO2006103544A3 T IN O
platelet WO2006103544A3 T NN O
aggregation WO2006103544A3 T NN O
inhibitors WO2006103544A3 T NNS O
. WO2006103544A3 T . O

Use CA2601705A1 T NNP O
of CA2601705A1 T IN O
wnv CA2601705A1 T NN O
dna CA2601705A1 T NN O
vaccine CA2601705A1 T NN O
in CA2601705A1 T IN O
combination CA2601705A1 T NN O
with CA2601705A1 T IN O
a CA2601705A1 T DT O
conventional CA2601705A1 T JJ O
vaccine CA2601705A1 T NN O
to CA2601705A1 T TO O
overcome CA2601705A1 T VB O
immunogen CA2601705A1 T NN O
interference CA2601705A1 T NN O
. CA2601705A1 T . O

Application CN103372002A T NN O
of CN103372002A T IN O
Chukrasone CN103372002A T NNP O
B CN103372002A T NNP O
in CN103372002A T IN O
preparation CN103372002A T NN O
of CN103372002A T IN O
medicines CN103372002A T NNS O
for CN103372002A T IN O
increasing CN103372002A T VBG O
red CN103372002A T JJ O
blood CN103372002A T NN O
cells CN103372002A T NNS O
. CN103372002A T . O

Natural US20120027878 T JJ O
lycopene US20120027878 T NN O
concentrate US20120027878 T NN O
and US20120027878 T CC O
method US20120027878 T NN O
for US20120027878 T IN O
production US20120027878 T NN O
thereof US20120027878 T NN O
. US20120027878 T . O

The WO2012158517A1 T DT O
use WO2012158517A1 T NN O
of WO2012158517A1 T IN O
purified WO2012158517A1 T JJ O
2'-fucosyllactose WO2012158517A1 T JJ O
, WO2012158517A1 T , O
3-fucosyllactose WO2012158517A1 T JJ O
and WO2012158517A1 T CC O
lactodifucotetraose WO2012158517A1 T JJ O
as WO2012158517A1 T IN O
prebiotics WO2012158517A1 T NNS O
. WO2012158517A1 T . O

Medicine WO2005094813A1 T NNP O
for WO2005094813A1 T IN O
kidney WO2005094813A1 T NN O
disorder WO2005094813A1 T NN O
. WO2005094813A1 T . O

C-2 EP1181299B1 T NNP O
modified EP1181299B1 T VBD O
erythromycin EP1181299B1 T JJ O
derivatives EP1181299B1 T NNS O
. EP1181299B1 T . O

Crystalline US20110262369 T NNP O
, US20110262369 T , O
enantiomerically US20110262369 T RB O
pure US20110262369 T JJ O
salt US20110262369 T JJ O
form US20110262369 T NN O
of US20110262369 T IN O
a US20110262369 T DT O
beta-agonist US20110262369 T NN O
, US20110262369 T , O
and US20110262369 T CC O
the US20110262369 T DT O
use US20110262369 T NN O
thereof US20110262369 T NN O
as US20110262369 T IN O
a US20110262369 T DT O
drug US20110262369 T NN O
. US20110262369 T . O

Pharmaceutical EP1280555B1 T JJ O
composition EP1280555B1 T NN O
comprising EP1280555B1 T VBG O
furosemide EP1280555B1 T NN O
and EP1280555B1 T CC O
conivaptan EP1280555B1 T NN O
for EP1280555B1 T IN O
the EP1280555B1 T DT O
treatment EP1280555B1 T NN O
of EP1280555B1 T IN O
congestive EP1280555B1 T JJ O
heart EP1280555B1 T NN O
failure EP1280555B1 T NN O
. EP1280555B1 T . O

Compound WO2013081118A1 T NNP O
having WO2013081118A1 T VBG O
read-through WO2013081118A1 T JJ O
activity WO2013081118A1 T NN O
. WO2013081118A1 T . O

( WO2013081118A1 A ( O
Problem WO2013081118A1 A NNP O
) WO2013081118A1 A ) O
To WO2013081118A1 A TO O
provide WO2013081118A1 A VB O
a WO2013081118A1 A DT O
novel WO2013081118A1 A NN O
compound WO2013081118A1 A NN O
having WO2013081118A1 A VBG O
read-through WO2013081118A1 A JJ O
activity WO2013081118A1 A NN O
, WO2013081118A1 A , O
and WO2013081118A1 A CC O
a WO2013081118A1 A DT O
therapeutic WO2013081118A1 A JJ O
agent WO2013081118A1 A NN O
for WO2013081118A1 A IN O
nonsense WO2013081118A1 A JJ O
mutation WO2013081118A1 A NN O
diseases WO2013081118A1 A NNS O
containing WO2013081118A1 A VBG O
the WO2013081118A1 A DT O
compound WO2013081118A1 A NN O
. WO2013081118A1 A . O

( WO2013081118A1 A ( O
Solution WO2013081118A1 A NN O
) WO2013081118A1 A ) O
A WO2013081118A1 A DT O
compound WO2013081118A1 A NN O
represented WO2013081118A1 A VBN O
by WO2013081118A1 A IN O
the WO2013081118A1 A DT O
general WO2013081118A1 A JJ O
formula WO2013081118A1 A NN O
( WO2013081118A1 A ( O
1 WO2013081118A1 A CD O
) WO2013081118A1 A ) O
, WO2013081118A1 A , O
and WO2013081118A1 A CC O
a WO2013081118A1 A DT O
pharmaceutical WO2013081118A1 A JJ O
composition WO2013081118A1 A NN O
containing WO2013081118A1 A VBG O
the WO2013081118A1 A DT O
compound WO2013081118A1 A NN O
. WO2013081118A1 A . O

Inhibitors WO2007096251A1 T NNS O
of WO2007096251A1 T IN O
cpt WO2007096251A1 T NN I-UN
in WO2007096251A1 T IN O
the WO2007096251A1 T DT O
central WO2007096251A1 T JJ O
nervous WO2007096251A1 T JJ O
system WO2007096251A1 T NN O
as WO2007096251A1 T IN O
antidiabetic WO2007096251A1 T JJ O
and/or WO2007096251A1 T IN O
anti-obesity WO2007096251A1 T NN O
drugs WO2007096251A1 T NNS O
. WO2007096251A1 T . O

The WO2007096251A1 A DT O
invention WO2007096251A1 A NN O
relates WO2007096251A1 A VBZ O
to WO2007096251A1 A TO O
a WO2007096251A1 A DT O
new WO2007096251A1 A JJ O
class WO2007096251A1 A NN O
of WO2007096251A1 A IN O
compounds WO2007096251A1 A NNS O
with WO2007096251A1 A IN O
inhibitory WO2007096251A1 A JJ O
action WO2007096251A1 A NN O
on WO2007096251A1 A IN O
carnitine WO2007096251A1 A NN I-UN
palmitoyl WO2007096251A1 A NN I-UN
transferase WO2007096251A1 A NN I-UN
( WO2007096251A1 A ( O
CPT WO2007096251A1 A NNP I-UN
) WO2007096251A1 A ) O
in WO2007096251A1 A IN O
the WO2007096251A1 A DT O
central WO2007096251A1 A JJ O
nervous WO2007096251A1 A JJ O
system WO2007096251A1 A NN O
( WO2007096251A1 A ( O
SNC WO2007096251A1 A NNP O
) WO2007096251A1 A ) O
, WO2007096251A1 A , O
derived WO2007096251A1 A VBN O
from WO2007096251A1 A IN O
trimetazidine WO2007096251A1 A NN O
and WO2007096251A1 A CC O
perhexiline WO2007096251A1 A NN O
, WO2007096251A1 A , O
preferentially WO2007096251A1 A RB O
selective WO2007096251A1 A JJ O
for WO2007096251A1 A IN O
the WO2007096251A1 A DT O
hepatic WO2007096251A1 A JJ O
form WO2007096251A1 A NN O
of WO2007096251A1 A IN O
CPT1 WO2007096251A1 A NNP I-UN
( WO2007096251A1 A ( O
CPT1L WO2007096251A1 A NNP I-UN
) WO2007096251A1 A ) O
, WO2007096251A1 A , O
pharmaceutical WO2007096251A1 A JJ O
compounds WO2007096251A1 A NNS O
which WO2007096251A1 A WDT O
contain WO2007096251A1 A VBP O
at WO2007096251A1 A IN O
least WO2007096251A1 A JJS O
one WO2007096251A1 A CD O
new WO2007096251A1 A JJ O
compound WO2007096251A1 A NN O
according WO2007096251A1 A VBG O
to WO2007096251A1 A TO O
the WO2007096251A1 A DT O
invention WO2007096251A1 A NN O
, WO2007096251A1 A , O
and WO2007096251A1 A CC O
their WO2007096251A1 A PRP$ O
therapeutic WO2007096251A1 A JJ O
use WO2007096251A1 A NN O
in WO2007096251A1 A IN O
the WO2007096251A1 A DT O
treatment WO2007096251A1 A NN O
and/or WO2007096251A1 A NN O
in WO2007096251A1 A IN O
the WO2007096251A1 A DT O
prevention WO2007096251A1 A NN O
of WO2007096251A1 A IN O
obesity WO2007096251A1 A NN O
, WO2007096251A1 A , O
hyperglycaemia WO2007096251A1 A NN O
, WO2007096251A1 A , O
diabetes WO2007096251A1 A NNS O
and WO2007096251A1 A CC O
disorders WO2007096251A1 A NNS O
associated WO2007096251A1 A VBN O
with WO2007096251A1 A IN O
them WO2007096251A1 A PRP O
, WO2007096251A1 A , O
such WO2007096251A1 A JJ O
as WO2007096251A1 A IN O
, WO2007096251A1 A , O
for WO2007096251A1 A IN O
example WO2007096251A1 A NN O
, WO2007096251A1 A , O
diabetic WO2007096251A1 A JJ O
retinopathy WO2007096251A1 A NN O
, WO2007096251A1 A , O
diabetic WO2007096251A1 A JJ O
neuropathy WO2007096251A1 A NN O
and WO2007096251A1 A CC O
cardiovascular WO2007096251A1 A JJ O
disorders WO2007096251A1 A NNS O
. WO2007096251A1 A . O

Intralymphatic US20120100218 T JJ O
Chemotherapy US20120100218 T NNP O
Drug US20120100218 T NNP O
Carriers US20120100218 T NNP O
. US20120100218 T . O

Pyrimidines WO2009145814A3 T NNS O
and WO2009145814A3 T CC O
pyridines WO2009145814A3 T NNS O
useful WO2009145814A3 T JJ O
as WO2009145814A3 T IN O
inhibitors WO2009145814A3 T NNS O
of WO2009145814A3 T IN O
protein WO2009145814A3 T NN O
kinases WO2009145814A3 T NNS I-UN
. WO2009145814A3 T . O

The WO2009145814A3 A DT O
present WO2009145814A3 A JJ O
invention WO2009145814A3 A NN O
relates WO2009145814A3 A VBZ O
to WO2009145814A3 A TO O
compounds WO2009145814A3 A VB O
useful WO2009145814A3 A JJ O
as WO2009145814A3 A IN O
inhibitors WO2009145814A3 A NNS O
of WO2009145814A3 A IN O
protein WO2009145814A3 A NN O
kinases WO2009145814A3 A NNS I-UN
, WO2009145814A3 A , O
such WO2009145814A3 A JJ O
as WO2009145814A3 A IN O
inhibitors WO2009145814A3 A NNS O
of WO2009145814A3 A IN O
GSK-3 WO2009145814A3 A NNP I-UN
. WO2009145814A3 A . O

Compound CN102503987A T NN O
with CN102503987A T IN O
anti-tumor CN102503987A T JJ O
activity CN102503987A T NN O
as CN102503987A T RB O
well CN102503987A T RB O
as CN102503987A T IN O
preparation CN102503987A T NN O
method CN102503987A T NN O
and CN102503987A T CC O
purpose CN102503987A T JJ O
thereof CN102503987A T NN O
. CN102503987A T . O

The CN102503987A A DT O
invention CN102503987A A NN O
discloses CN102503987A A VBZ O
a CN102503987A A DT O
compound CN102503987A A NN O
with CN102503987A A IN O
anti-tumor CN102503987A A JJ O
activity CN102503987A A NN O
as CN102503987A A RB O
well CN102503987A A RB O
as CN102503987A A IN O
a CN102503987A A DT O
preparation CN102503987A A NN O
method CN102503987A A NN O
and CN102503987A A CC O
a CN102503987A A DT O
purpose CN102503987A A NN O
of CN102503987A A IN O
the CN102503987A A DT O
compound CN102503987A A NN O
. CN102503987A A . O

The CN102503987A A DT O
compound CN102503987A A NN O
is CN102503987A A VBZ O
a CN102503987A A DT O
metallic CN102503987A A JJ O
ruthenium CN102503987A A NN O
compound CN102503987A A NN O
with CN102503987A A IN O
the CN102503987A A DT O
chemical CN102503987A A NN O
name CN102503987A A NN O
of CN102503987A A IN O
monochloro CN102503987A A NN O
benzaldehyde CN102503987A A NN O
thiosemicarbazone CN102503987A A NN O
monomethyl CN102503987A A NN O
isopropylbenzene CN102503987A A NN O
ruthenium CN102503987A A NN O
( CN102503987A A ( O
II CN102503987A A NNP O
) CN102503987A A ) O
, CN102503987A A , O
and CN102503987A A CC O
a CN102503987A A DT O
structural CN102503987A A JJ O
formula CN102503987A A NN O
is CN102503987A A VBZ O
shown CN102503987A A VBN O
as CN102503987A A IN O
the CN102503987A A DT O
accompanying CN102503987A A VBG O
drawing CN102503987A A NN O
. CN102503987A A . O

The CN102503987A A DT O
preparation CN102503987A A NN O
method CN102503987A A NN O
comprises CN102503987A A VBZ O
the CN102503987A A DT O
following CN102503987A A JJ O
steps CN102503987A A NNS O
that CN102503987A A WDT O
: CN102503987A A : O
1 CN102503987A A CD O
) CN102503987A A ) O
products CN102503987A A NNS O
A CN102503987A A DT O
are CN102503987A A VBP O
prepared CN102503987A A JJ O
; CN102503987A A : O
2 CN102503987A A CD O
) CN102503987A A ) O
benzaldehyde CN102503987A A NN O
thiosemicarbazone CN102503987A A NN O
is CN102503987A A VBZ O
prepared CN102503987A A VBN O
; CN102503987A A : O
and CN102503987A A CC O
3 CN102503987A A CD O
) CN102503987A A ) O
the CN102503987A A DT O
benzaldehyde CN102503987A A NN O
thiosemicarbazone CN102503987A A NN O
and CN102503987A A CC O
the CN102503987A A DT O
products CN102503987A A NNS O
A CN102503987A A DT O
are CN102503987A A VBP O
dissolved CN102503987A A VBN O
in CN102503987A A IN O
acetone CN102503987A A NN O
, CN102503987A A , O
heating CN102503987A A NN O
and CN102503987A A CC O
stirring CN102503987A A NN O
backflow CN102503987A A NN O
are CN102503987A A VBP O
carried CN102503987A A VBN O
out CN102503987A A IN O
, CN102503987A A , O
orange CN102503987A A NN O
red CN102503987A A JJ O
solid CN102503987A A NN O
is CN102503987A A VBZ O
separated CN102503987A A VBN O
out CN102503987A A RP O
, CN102503987A A , O
and CN102503987A A CC O
the CN102503987A A DT O
benzaldehyde CN102503987A A NN O
thiosemicarbazone CN102503987A A NN O
ruthenium CN102503987A A NN O
compound CN102503987A A NN O
products CN102503987A A NNS O
are CN102503987A A VBP O
obtained CN102503987A A VBN O
. CN102503987A A . O

In-vitro CN102503987A A JJ O
anti-tumor CN102503987A A JJ O
experiments CN102503987A A NNS O
show CN102503987A A VBP O
that CN102503987A A IN O
the CN102503987A A DT O
benzaldehyde CN102503987A A NN O
thiosemicarbazone CN102503987A A NN O
ruthenium CN102503987A A NN O
compound CN102503987A A NN O
has CN102503987A A VBZ O
high CN102503987A A JJ O
anti-tumor CN102503987A A JJ O
activity CN102503987A A NN O
. CN102503987A A . O

S.japonica CN1565466A T NNP O
( CN1565466A T ( O
Sw. CN1565466A T NNP O
) CN1565466A T ) O
Ohwi CN1565466A T NNP O
flavone CN1565466A T NN O
glucoside CN1565466A T NN O
injection CN1565466A T NN O
and CN1565466A T CC O
its CN1565466A T PRP$ O
preparing CN1565466A T NN O
process CN1565466A T NN O
. CN1565466A T . O

Chewing CN103690619A T VBG O
tablet CN103690619A T NN O
for CN103690619A T IN O
treating CN103690619A T VBG O
coronary CN103690619A T JJ O
heart CN103690619A T NN O
disease CN103690619A T NN O
. CN103690619A T . O

Facial US20090270881 T JJ O
blemish US20090270881 T NN O
removing US20090270881 T VBG O
device US20090270881 T NN O
. US20090270881 T . O

Composition CN103355665A T NN O
for CN103355665A T IN O
regulation CN103355665A T NN O
of CN103355665A T IN O
blood CN103355665A T NN O
sugar CN103355665A T NN O
level CN103355665A T NN O
and CN103355665A T CC O
adjunctive CN103355665A T JJ O
treatment CN103355665A T NN O
of CN103355665A T IN O
diabetes CN103355665A T NNS O
mellitus CN103355665A T NNS O
. CN103355665A T . O

According CN103355665A A VBG O
to CN103355665A A TO O
the CN103355665A A DT O
composition CN103355665A A NN O
, CN103355665A A , O
in CN103355665A A IN O
the CN103355665A A DT O
active CN103355665A A JJ O
ingredients CN103355665A A NNS O
, CN103355665A A , O
the CN103355665A A DT O
resveratrol CN103355665A A NN O
has CN103355665A A VBZ O
the CN103355665A A DT O
effects CN103355665A A NNS O
of CN103355665A A IN O
regulating CN103355665A A VBG O
the CN103355665A A DT O
blood CN103355665A A NN O
sugar CN103355665A A NN O
level CN103355665A A NN O
and CN103355665A A CC O
preventing CN103355665A A VBG O
oxidative CN103355665A A JJ O
stress CN103355665A A NN O
of CN103355665A A IN O
a CN103355665A A DT O
body CN103355665A A NN O
caused CN103355665A A VBN O
by CN103355665A A IN O
the CN103355665A A DT O
diabetes CN103355665A A NNS O
mellitus CN103355665A A VBP O
; CN103355665A A : O
the CN103355665A A DT O
bioavailability CN103355665A A NN O
of CN103355665A A IN O
the CN103355665A A DT O
resveratrol CN103355665A A NN O
can CN103355665A A MD O
be CN103355665A A VB O
improved CN103355665A A VBN O
by CN103355665A A IN O
the CN103355665A A DT O
piperine CN103355665A A NN O
; CN103355665A A : O
pancreas CN103355665A A CC O
cell CN103355665A A NN O
apoptosis CN103355665A A NN O
is CN103355665A A VBZ O
prevented CN103355665A A VBN O
and CN103355665A A CC O
beta-cell CN103355665A A JJ O
palingenesis CN103355665A A NN O
is CN103355665A A VBZ O
facilitated CN103355665A A VBN O
by CN103355665A A IN O
the CN103355665A A DT O
gamma-aminobutyric CN103355665A A JJ O
acid CN103355665A A NN O
; CN103355665A A : O
and CN103355665A A CC O
the CN103355665A A DT O
antioxidant CN103355665A A JJ O
ability CN103355665A A NN O
of CN103355665A A IN O
the CN103355665A A DT O
body CN103355665A A NN O
and CN103355665A A CC O
glucose CN103355665A A JJ O
utilization CN103355665A A NN O
are CN103355665A A VBP O
indirectly CN103355665A A RB O
improved CN103355665A A VBN O
by CN103355665A A IN O
the CN103355665A A DT O
organic CN103355665A A JJ O
selenium CN103355665A A NN O
participating CN103355665A A VBG O
into CN103355665A A IN O
in CN103355665A A IN O
vivo CN103355665A A JJ O
synthesis CN103355665A A NN O
of CN103355665A A IN O
glutathion CN103355665A A NN I-UN
peroxidase CN103355665A A NN I-UN
and CN103355665A A CC I-UN
deiodinase CN103355665A A NN I-UN
. CN103355665A A . O

A WO2011086575A8 T DT O
pharmaceutical WO2011086575A8 T JJ O
composition WO2011086575A8 T NN O
for WO2011086575A8 T IN O
treatment WO2011086575A8 T NN O
of WO2011086575A8 T IN O
respiratory WO2011086575A8 T NN O
tract WO2011086575A8 T JJ O
infections WO2011086575A8 T NNS O
. WO2011086575A8 T . O

Dopamine US20060223869 T NNP I-UN
D1 US20060223869 T NNP I-UN
, US20060223869 T , O
D2 US20060223869 T NNP O
, US20060223869 T , O
D3 US20060223869 T NNP O
, US20060223869 T , O
and US20060223869 T CC O
D4 US20060223869 T NNP O
receptor US20060223869 T VBP O
agonist US20060223869 T NN O
such US20060223869 T JJ O
as US20060223869 T IN O
pramipexole US20060223869 T NN O
in US20060223869 T IN O
combination US20060223869 T NN O
with US20060223869 T IN O
a US20060223869 T DT O
second US20060223869 T JJ O
active US20060223869 T JJ O
substance US20060223869 T NN O
selected US20060223869 T VBN O
from US20060223869 T IN O
D1 US20060223869 T NNP I-UN
, US20060223869 T , I-UN
D2 US20060223869 T NNP I-UN
, US20060223869 T , I-UN
D3 US20060223869 T NNP I-UN
, US20060223869 T , I-UN
and US20060223869 T CC I-UN
D4 US20060223869 T NNP I-UN
receptor US20060223869 T NN O
agonists US20060223869 T NNS O
, US20060223869 T , O
anorectics US20060223869 T NNS O
, US20060223869 T , O
lipase US20060223869 T NN I-UN
inhibitors US20060223869 T NNS O
and US20060223869 T CC O
sympathomimetics US20060223869 T NNS O
; US20060223869 T : O
for US20060223869 T IN O
treating US20060223869 T VBG O
overweight US20060223869 T NN O
or US20060223869 T CC O
obesity US20060223869 T NN O
or US20060223869 T CC O
type US20060223869 T NN O
2 US20060223869 T CD O
diabetes US20060223869 T NNS O
. US20060223869 T . O

The US20060223869 A DT O
invention US20060223869 A NN O
relates US20060223869 A VBZ O
to US20060223869 A TO O
the US20060223869 A DT O
use US20060223869 A NN O
of US20060223869 A IN O
dopamine US20060223869 A NN I-UN
receptor US20060223869 A NN I-UN
agonists US20060223869 A NNS O
for US20060223869 A IN O
preparing US20060223869 A VBG O
a US20060223869 A DT O
pharmaceutical US20060223869 A JJ O
composition US20060223869 A NN O
for US20060223869 A IN O
the US20060223869 A DT O
reduction US20060223869 A NN O
of US20060223869 A IN O
excessive US20060223869 A JJ O
food US20060223869 A NN O
intake US20060223869 A NN O
. US20060223869 A . O

Modified US20120282337 T NNP O
Release US20120282337 T NNP O
Formulation US20120282337 T NNP O
. US20120282337 T . O

Hla-a* US20100292160 T JJ O
3303-restricted US20100292160 T JJ O
wt1 US20100292160 T NN I-UN
peptide US20100292160 T NN O
and US20100292160 T CC O
pharmaceutical US20100292160 T JJ O
composition US20100292160 T NN O
comprising US20100292160 T VBG O
the US20100292160 T DT O
same US20100292160 T JJ O
. US20100292160 T . O

Disclosed US20100292160 A VBN O
are US20100292160 A VBP O
: US20100292160 A : O
a US20100292160 A DT O
peptide US20100292160 A NN O
comprising US20100292160 A VBG O
an US20100292160 A DT O
amino US20100292160 A NN O
acid US20100292160 A NN O
sequence US20100292160 A NN O
composed US20100292160 A VBD O
of US20100292160 A IN O
contiguous US20100292160 A JJ O
nine US20100292160 A CD O
amino US20100292160 A NN O
acid US20100292160 A NN O
residues US20100292160 A NNS O
derived US20100292160 A VBN O
from US20100292160 A IN O
a US20100292160 A DT O
WT1 US20100292160 A NNP I-UN
protein US20100292160 A NN O
, US20100292160 A , O
wherein US20100292160 A VBP O
an US20100292160 A DT O
amino US20100292160 A NN O
acid US20100292160 A NN O
residue US20100292160 A NN O
at US20100292160 A IN O
position US20100292160 A NN O
2 US20100292160 A CD O
in US20100292160 A IN O
the US20100292160 A DT O
amino US20100292160 A NN O
acid US20100292160 A NN O
sequence US20100292160 A NN O
is US20100292160 A VBZ O
selected US20100292160 A VBN O
from US20100292160 A IN O
the US20100292160 A DT O
group US20100292160 A NN O
consisting US20100292160 A VBG O
of US20100292160 A IN O
Ala US20100292160 A NNP O
, US20100292160 A , O
Ile US20100292160 A NNP O
, US20100292160 A , O
Leu US20100292160 A NNP O
, US20100292160 A , O
Val US20100292160 A NNP O
, US20100292160 A , O
Phe US20100292160 A NNP O
, US20100292160 A , O
Tyr US20100292160 A NNP O
, US20100292160 A , O
Ser US20100292160 A NNP O
and US20100292160 A CC O
Asp US20100292160 A NNP O
and US20100292160 A CC O
an US20100292160 A DT O
amino US20100292160 A NN O
acid US20100292160 A NN O
residue US20100292160 A NN O
at US20100292160 A IN O
position US20100292160 A NN O
9 US20100292160 A CD O
in US20100292160 A IN O
the US20100292160 A DT O
amino US20100292160 A NN O
acid US20100292160 A NN O
sequence US20100292160 A NN O
is US20100292160 A VBZ O
Arg US20100292160 A NNP O
; US20100292160 A : O
a US20100292160 A DT O
polynucleotide US20100292160 A NN O
encoding US20100292160 A VBG O
the US20100292160 A DT O
peptide US20100292160 A NN O
; US20100292160 A : O
a US20100292160 A DT O
pharmaceutical US20100292160 A JJ O
composition US20100292160 A NN O
comprising US20100292160 A VBG O
the US20100292160 A DT O
peptide US20100292160 A NN O
; US20100292160 A : O
and US20100292160 A CC O
others US20100292160 A NNS O
. US20100292160 A . O

Venlafaxine CN102935071A T NNP O
hydrochloride CN102935071A T JJ O
controlled-release CN102935071A T JJ O
pellet CN102935071A T NN O
and CN102935071A T CC O
preparation CN102935071A T NN O
method CN102935071A T NN O
thereof CN102935071A T NN O
. CN102935071A T . O

Amine EP1727820B1 T NNP O
derivatives EP1727820B1 T NNS O
with EP1727820B1 T IN O
tyrosinkinase EP1727820B1 T JJ I-UN
inhibiting EP1727820B1 T VBG O
activity EP1727820B1 T NN O
. EP1727820B1 T . O

Compounds EP1727820B1 A NNS O
of EP1727820B1 A IN O
formula EP1727820B1 A NN O
( EP1727820B1 A ( O
I EP1727820B1 A PRP O
) EP1727820B1 A ) O
, EP1727820B1 A , O
wherein EP1727820B1 A JJ O
R1 EP1727820B1 A NNP O
, EP1727820B1 A , O
R2 EP1727820B1 A NNP O
, EP1727820B1 A , O
R3 EP1727820B1 A NNP O
, EP1727820B1 A , O
R4 EP1727820B1 A NNP O
, EP1727820B1 A , O
R5 EP1727820B1 A NNP O
, EP1727820B1 A , O
B EP1727820B1 A NNP O
and EP1727820B1 A CC O
X EP1727820B1 A NNP O
have EP1727820B1 A VBP O
the EP1727820B1 A DT O
meanings EP1727820B1 A NNS O
cited EP1727820B1 A VBD O
in EP1727820B1 A IN O
Claim EP1727820B1 A NNP O
1 EP1727820B1 A CD O
, EP1727820B1 A , O
are EP1727820B1 A VBP O
inhibitors EP1727820B1 A NNS O
of EP1727820B1 A IN O
tyrosine EP1727820B1 A NN I-UN
kinases EP1727820B1 A NNS I-UN
, EP1727820B1 A , O
particularly EP1727820B1 A RB O
TIE-2 EP1727820B1 A NNP I-UN
, EP1727820B1 A , O
and EP1727820B1 A CC O
Raf EP1727820B1 A NNP I-UN
kinases EP1727820B1 A NNS O
and EP1727820B1 A CC O
can EP1727820B1 A MD O
be EP1727820B1 A VB O
used EP1727820B1 A VBN O
inter EP1727820B1 A JJ O
alia EP1727820B1 A NN O
in EP1727820B1 A IN O
the EP1727820B1 A DT O
treatment EP1727820B1 A NN O
of EP1727820B1 A IN O
tumors EP1727820B1 A NNS O
. EP1727820B1 A . O

Bagged CN102048876A T NNP O
external CN102048876A T JJ O
washing CN102048876A T NN O
ointment CN102048876A T NN O
for CN102048876A T IN O
assisting CN102048876A T VBG O
treatment CN102048876A T NN O
of CN102048876A T IN O
gynecologic CN102048876A T JJ O
inflammation CN102048876A T NN O
and CN102048876A T CC O
itchiness CN102048876A T NN O
and CN102048876A T CC O
preparation CN102048876A T NN O
method CN102048876A T NN O
thereof CN102048876A T NN O
. CN102048876A T . O

The CN102048876A A DT O
invention CN102048876A A NN O
provides CN102048876A A VBZ O
a CN102048876A A DT O
bagged CN102048876A A JJ O
external CN102048876A A JJ O
washing CN102048876A A NN O
ointment CN102048876A A NN O
for CN102048876A A IN O
assisting CN102048876A A VBG O
treatment CN102048876A A NN O
of CN102048876A A IN O
gynecologic CN102048876A A JJ O
inflammation CN102048876A A NN O
and CN102048876A A CC O
itchiness CN102048876A A NN O
. CN102048876A A . O

The CN102048876A A DT O
ointment CN102048876A A NN O
is CN102048876A A VBZ O
characterized CN102048876A A VBN O
in CN102048876A A IN O
that CN102048876A A DT O
the CN102048876A A DT O
formula CN102048876A A NN O
comprises CN102048876A A VBZ O
the CN102048876A A DT O
following CN102048876A A JJ O
raw CN102048876A A JJ O
materials CN102048876A A NNS O
according CN102048876A A VBG O
to CN102048876A A TO O
weight CN102048876A A JJ O
percentage CN102048876A A NN O
: CN102048876A A : O
15-35 CN102048876A A JJ O
percent CN102048876A A NN O
of CN102048876A A IN O
dandelion CN102048876A A NN O
, CN102048876A A , O
10-25 CN102048876A A JJ O
percent CN102048876A A NN O
of CN102048876A A IN O
sophora CN102048876A A NN O
flavescens CN102048876A A NNS O
ait CN102048876A A VBP O
, CN102048876A A , O
5-25 CN102048876A A JJ O
percent CN102048876A A NN O
of CN102048876A A IN O
common CN102048876A A JJ O
cnidium CN102048876A A NN O
fruit CN102048876A A NN O
, CN102048876A A , O
5-25 CN102048876A A JJ O
percent CN102048876A A NN O
of CN102048876A A IN O
cortex CN102048876A A NN O
phellodendri CN102048876A A NN O
, CN102048876A A , O
15-35 CN102048876A A JJ O
percent CN102048876A A NN O
of CN102048876A A IN O
honeysuckle CN102048876A A NN O
and CN102048876A A CC O
3-10 CN102048876A A JJ O
percent CN102048876A A NN O
of CN102048876A A IN O
calcined CN102048876A A JJ O
alum CN102048876A A NN O
. CN102048876A A . O

The CN102048876A A DT O
preparation CN102048876A A NN O
method CN102048876A A NN O
comprises CN102048876A A VBZ O
the CN102048876A A DT O
following CN102048876A A JJ O
steps CN102048876A A NNS O
of CN102048876A A IN O
removing CN102048876A A VBG O
foreign CN102048876A A JJ O
impurities CN102048876A A NNS O
, CN102048876A A , O
cleaning CN102048876A A NN O
, CN102048876A A , O
drying CN102048876A A VBG O
, CN102048876A A , O
grinding CN102048876A A VBG O
, CN102048876A A , O
sieving CN102048876A A VBG O
and CN102048876A A CC O
bagging CN102048876A A NN O
. CN102048876A A . O

The CN102048876A A DT O
ointment CN102048876A A NN O
has CN102048876A A VBZ O
the CN102048876A A DT O
effects CN102048876A A NNS O
of CN102048876A A IN O
clearing CN102048876A A VBG O
away CN102048876A A RB O
heat CN102048876A A NN O
and CN102048876A A CC O
toxic CN102048876A A JJ O
material CN102048876A A NN O
, CN102048876A A , O
diminishing CN102048876A A VBG O
inflammation CN102048876A A NN O
, CN102048876A A , O
treating CN102048876A A VBG O
urinary CN102048876A A JJ O
tract CN102048876A A NN O
infection CN102048876A A NN O
, CN102048876A A , O
treating CN102048876A A VBG O
toxic CN102048876A A NN O
heat CN102048876A A NN O
, CN102048876A A , O
curing CN102048876A A VBG O
leprosy CN102048876A A JJ O
and CN102048876A A CC O
sore CN102048876A A NN O
, CN102048876A A , O
removing CN102048876A A VBG O
erosion CN102048876A A NN O
and CN102048876A A CC O
itchiness CN102048876A A NN O
of CN102048876A A IN O
vulva CN102048876A A NN O
, CN102048876A A , O
curing CN102048876A A VBG O
trichomonas CN102048876A A NNS O
vaginitis CN102048876A A NN O
, CN102048876A A , O
eliminating CN102048876A A VBG O
pustules CN102048876A A NNS O
, CN102048876A A , O
reducing CN102048876A A VBG O
swelling CN102048876A A VBG O
, CN102048876A A , O
curing CN102048876A A VBG O
phlegm CN102048876A A NN O
and CN102048876A A CC O
persistent CN102048876A A JJ O
pain CN102048876A A NN O
, CN102048876A A , O
relieving CN102048876A A VBG O
itching CN102048876A A NN O
, CN102048876A A , O
curing CN102048876A A VBG O
trauma CN102048876A A JJ O
infection CN102048876A A NN O
, CN102048876A A , O
relieving CN102048876A A VBG O
prickly CN102048876A A RB O
heat CN102048876A A NN O
, CN102048876A A , O
astringing CN102048876A A VBG O
, CN102048876A A , O
stopping CN102048876A A VBG O
bleeding CN102048876A A NN O
, CN102048876A A , O
growing CN102048876A A VBG O
flesh CN102048876A A JJ O
and CN102048876A A CC O
the CN102048876A A DT O
like CN102048876A A JJ O
. CN102048876A A . O

Cyclopropane CN103153963A T NNP O
compound CN103153963A T NN O
. CN103153963A T . O

Nano CN101450041B T NNP O
lycorine CN101450041B T NN O
chloride CN101450041B T NN O
microcapsule CN101450041B T NN O
latex CN101450041B T NN O
and CN101450041B T CC O
preparation CN101450041B T NN O
method CN101450041B T NN O
thereof CN101450041B T NN O
. CN101450041B T . O

Methods WO2013013003A1 T NNS O
for WO2013013003A1 T IN O
treating WO2013013003A1 T VBG O
inflamatory WO2013013003A1 T JJ O
conditions WO2013013003A1 T NNS O
and WO2013013003A1 T CC O
states WO2013013003A1 T NNS O
, WO2013013003A1 T , O
and WO2013013003A1 T CC O
cancers WO2013013003A1 T NNS O
by WO2013013003A1 T IN O
antagonizing WO2013013003A1 T VBG O
nf-kb WO2013013003A1 T JJ I-UN
activation WO2013013003A1 T NN O
. WO2013013003A1 T . O

The WO2013013003A1 A DT O
disclosure WO2013013003A1 A NN O
is WO2013013003A1 A VBZ O
directed WO2013013003A1 A VBN O
to WO2013013003A1 A TO O
methods WO2013013003A1 A NNS O
for WO2013013003A1 A IN O
treating WO2013013003A1 A VBG O
inflammatory WO2013013003A1 A JJ O
conditions WO2013013003A1 A NNS O
and WO2013013003A1 A CC O
cancers WO2013013003A1 A NNS O
that WO2013013003A1 A WDT O
have WO2013013003A1 A VBP O
misregulated WO2013013003A1 A VBN O
NF-κB WO2013013003A1 A NNP I-UN
. WO2013013003A1 A . O

Medicinal WO2013051672A1 T JJ O
agent WO2013051672A1 T NN O
comprising WO2013051672A1 T VBG O
thiazolidine WO2013051672A1 T JJ O
derivative WO2013051672A1 T JJ O
or WO2013051672A1 T CC O
salt WO2013051672A1 T JJ O
thereof WO2013051672A1 T NN O
as WO2013051672A1 T IN O
active WO2013051672A1 T JJ O
ingredient WO2013051672A1 T NN O
. WO2013051672A1 T . O

Provided WO2013051672A1 A VBN O
is WO2013051672A1 A VBZ O
a WO2013051672A1 A DT O
compound WO2013051672A1 A NN O
having WO2013051672A1 A VBG O
an WO2013051672A1 A DT O
excellent WO2013051672A1 A JJ O
Pim WO2013051672A1 A NNP I-UN
inhibition WO2013051672A1 A NN O
activity WO2013051672A1 A NN O
and WO2013051672A1 A CC O
useful WO2013051672A1 A JJ O
as WO2013051672A1 A IN O
a WO2013051672A1 A DT O
medicinal WO2013051672A1 A JJ O
agent WO2013051672A1 A NN O
. WO2013051672A1 A . O

Fused WO2014017803A1 T VBN O
ring WO2014017803A1 T VBG O
compound WO2014017803A1 T NN O
containing WO2014017803A1 T VBG O
furan WO2014017803A1 T NN O
or WO2014017803A1 T CC O
salt WO2014017803A1 T NN O
thereof WO2014017803A1 T NN O
and WO2014017803A1 T CC O
pharmaceutical WO2014017803A1 T JJ O
composition WO2014017803A1 T NN O
comprising WO2014017803A1 T VBG O
same WO2014017803A1 T JJ O
. WO2014017803A1 T . O

Pteridine US20050054653 T NNP O
derivatives US20050054653 T NNS O
, US20050054653 T , O
method US20050054653 T NN O
of US20050054653 T IN O
producing US20050054653 T VBG O
them US20050054653 T PRP O
and US20050054653 T CC O
their US20050054653 T PRP$ O
application US20050054653 T NN O
. US20050054653 T . O

These US20050054653 A DT O
pteridine US20050054653 A JJ O
derivatives US20050054653 A NNS O
are US20050054653 A VBP O
suitable US20050054653 A JJ O
for US20050054653 A IN O
the US20050054653 A DT O
inhibition US20050054653 A NN O
of US20050054653 A IN O
phosphodiesterases US20050054653 A NNS I-UN
and US20050054653 A CC O
therefore US20050054653 A RB O
for US20050054653 A IN O
the US20050054653 A DT O
prophylaxis US20050054653 A NN O
and/or US20050054653 A JJ O
treatment US20050054653 A NN O
of US20050054653 A IN O
thrombo-embolic US20050054653 A JJ O
, US20050054653 A , O
neurodegenerative US20050054653 A JJ O
diseases US20050054653 A NNS O
, US20050054653 A , O
inflammatory US20050054653 A NN O
diseases US20050054653 A NNS O
, US20050054653 A , O
asthmatic US20050054653 A JJ O
diseases US20050054653 A NNS O
as US20050054653 A RB O
well US20050054653 A RB O
as US20050054653 A IN O
hemato-oncological US20050054653 A JJ O
diseases US20050054653 A NNS O
. US20050054653 A . O

Tricyclic US20120202791 T NNP O
and US20120202791 T CC O
Tetracyclic US20120202791 T NNP O
Systems US20120202791 T NNPS O
with US20120202791 T IN O
Activity US20120202791 T NNP O
on US20120202791 T IN O
the US20120202791 T DT O
Central US20120202791 T NNP O
Nervous US20120202791 T NNP O
and US20120202791 T CC O
Vascular US20120202791 T NNP O
Systems US20120202791 T NNPS O
. US20120202791 T . O

The WO2007106862A3 T DT O
use WO2007106862A3 T NN O
of WO2007106862A3 T IN O
statins WO2007106862A3 T NNS O
to WO2007106862A3 T TO O
stimulate WO2007106862A3 T VB O
neurogenesis WO2007106862A3 T NN O
. WO2007106862A3 T . O

Dbait US20100022622 T NNP O
and US20100022622 T CC O
its US20100022622 T PRP$ O
Standalone US20100022622 T NNP O
Uses US20100022622 T NNP O
Thereof US20100022622 T NNP O
. US20100022622 T . O

Compositions US20100152125 T NNS O
And US20100152125 T CC O
Methods US20100152125 T NNS O
For US20100152125 T IN O
The US20100152125 T DT O
Diagnosis US20100152125 T NNP O
, US20100152125 T , O
Treatment US20100152125 T NNP O
, US20100152125 T , O
And US20100152125 T CC O
Prevention US20100152125 T NNP O
Of US20100152125 T IN O
Amyotrophic US20100152125 T NNP O
Lateral US20100152125 T NNP O
Sclerosis US20100152125 T NNP O
And US20100152125 T CC O
Related US20100152125 T NNP O
Neurological US20100152125 T NNP O
Diseases US20100152125 T NNP O
. US20100152125 T . O

Yet US20100152125 A RB O
another US20100152125 A DT O
aspect US20100152125 A NN O
of US20100152125 A IN O
the US20100152125 A DT O
invention US20100152125 A NN O
relates US20100152125 A VBZ O
to US20100152125 A TO O
molecules US20100152125 A NNS O
, US20100152125 A , O
and US20100152125 A CC O
methods US20100152125 A NNS O
of US20100152125 A IN O
use US20100152125 A NN O
thereof US20100152125 A NN O
, US20100152125 A , O
which US20100152125 A WDT O
bind US20100152125 A VBP O
at US20100152125 A IN O
or US20100152125 A CC O
adjacent US20100152125 A JJ O
to US20100152125 A TO O
SOD-I US20100152125 A NNP I-UN
Trp32 US20100152125 A NNP O
, US20100152125 A , O
including US20100152125 A VBG O
molecules US20100152125 A NNS O
that US20100152125 A WDT O
bind US20100152125 A VBP O
in US20100152125 A IN O
a US20100152125 A DT O
site US20100152125 A NN O
adjacent US20100152125 A JJ O
to US20100152125 A TO O
SOD-I US20100152125 A NNP I-UN
Trp32 US20100152125 A NNP O
whether US20100152125 A IN O
or US20100152125 A CC O
not US20100152125 A RB O
it US20100152125 A PRP O
is US20100152125 A VBZ O
oxidized US20100152125 A VBN O
, US20100152125 A , O
for US20100152125 A IN O
treating US20100152125 A VBG O
or US20100152125 A CC O
preventing US20100152125 A VBG O
neurodegenerative US20100152125 A JJ O
disease US20100152125 A NN O
. US20100152125 A . O

Substituted WO2006100082A3 T VBN O
oxindol WO2006100082A3 T JJ O
derivatives WO2006100082A3 T NNS O
, WO2006100082A3 T , O
drugs WO2006100082A3 T NNS O
containing WO2006100082A3 T VBG O
said WO2006100082A3 T VBD O
derivatives WO2006100082A3 T NNS O
and WO2006100082A3 T CC O
the WO2006100082A3 T DT O
use WO2006100082A3 T NN O
thereof WO2006100082A3 T NN O
. WO2006100082A3 T . O

Formulations EP1763370A1 T NNS O
comprising EP1763370A1 T VBG O
a EP1763370A1 T DT O
capsaicinoid EP1763370A1 T NN O
, EP1763370A1 T , O
a EP1763370A1 T DT O
local EP1763370A1 T JJ O
anesthetic EP1763370A1 T JJ O
and/or EP1763370A1 T NN O
an EP1763370A1 T DT O
antipruritic EP1763370A1 T JJ O
agent EP1763370A1 T NN O
for EP1763370A1 T IN O
the EP1763370A1 T DT O
treatment EP1763370A1 T NN O
of EP1763370A1 T IN O
pain EP1763370A1 T NN O
. EP1763370A1 T . O

Formulations EP1763370A1 A NNS O
and EP1763370A1 A CC O
methods EP1763370A1 A NNS O
are EP1763370A1 A VBP O
provided EP1763370A1 A VBN O
for EP1763370A1 A IN O
the EP1763370A1 A DT O
treatment EP1763370A1 A NN O
of EP1763370A1 A IN O
pain EP1763370A1 A NN O
, EP1763370A1 A , O
and EP1763370A1 A CC O
neuropathic EP1763370A1 A JJ O
pain EP1763370A1 A NN O
in EP1763370A1 A IN O
particular EP1763370A1 A JJ O
. EP1763370A1 A . O

The EP1763370A1 A DT O
formulations EP1763370A1 A NNS O
are EP1763370A1 A VBP O
eutectic EP1763370A1 A JJ O
mixtures EP1763370A1 A NNS O
of EP1763370A1 A IN O
a EP1763370A1 A DT O
capsaicinoid EP1763370A1 A NN O
and EP1763370A1 A CC O
a EP1763370A1 A DT O
local EP1763370A1 A JJ O
anesthetic EP1763370A1 A JJ O
agent EP1763370A1 A NN O
and/or EP1763370A1 A IN O
anti-pruritic EP1763370A1 A JJ O
agent EP1763370A1 A NN O
. EP1763370A1 A . O

Intrathecal WO2013168131A1 T JJ O
administration WO2013168131A1 T NN O
of WO2013168131A1 T IN O
mtor WO2013168131A1 T NN O
inhibitors WO2013168131A1 T NNS O
for WO2013168131A1 T IN O
the WO2013168131A1 T DT O
therapy WO2013168131A1 T NN O
of WO2013168131A1 T IN O
neurodegenerative WO2013168131A1 T JJ O
, WO2013168131A1 T , O
neuroinflammatory WO2013168131A1 T JJ O
and WO2013168131A1 T CC O
neurooncologic WO2013168131A1 T JJ O
diseases WO2013168131A1 T NNS O
. WO2013168131A1 T . O

The WO2013168131A1 A DT O
invention WO2013168131A1 A NN O
relates WO2013168131A1 A VBZ O
to WO2013168131A1 A TO O
the WO2013168131A1 A DT O
use WO2013168131A1 A NN O
of WO2013168131A1 A IN O
inhibitors WO2013168131A1 A NNS O
of WO2013168131A1 A IN O
the WO2013168131A1 A DT O
enzyme WO2013168131A1 A NN O
mTOR WO2013168131A1 A NN I-UN
kinase WO2013168131A1 A NN I-UN
( WO2013168131A1 A ( O
mammalian WO2013168131A1 A JJ I-UN
target WO2013168131A1 A NN I-UN
of WO2013168131A1 A IN I-UN
rapamycin WO2013168131A1 A NN I-UN
) WO2013168131A1 A ) O
in WO2013168131A1 A IN O
the WO2013168131A1 A DT O
treatment WO2013168131A1 A NN O
of WO2013168131A1 A IN O
neuro-oncologic WO2013168131A1 A JJ O
diseases WO2013168131A1 A NNS O
, WO2013168131A1 A , O
in WO2013168131A1 A IN O
particular WO2013168131A1 A JJ O
tuberous WO2013168131A1 A JJ O
sclerosis WO2013168131A1 A NN O
, WO2013168131A1 A , O
neurodegenerative WO2013168131A1 A JJ O
diseases WO2013168131A1 A NNS O
, WO2013168131A1 A , O
in WO2013168131A1 A IN O
particular WO2013168131A1 A JJ O
Alzheimer WO2013168131A1 A NNP O
's WO2013168131A1 A POS O
disease WO2013168131A1 A NN O
, WO2013168131A1 A , O
and WO2013168131A1 A CC O
neuroinflammatory WO2013168131A1 A JJ O
diseases WO2013168131A1 A NNS O
, WO2013168131A1 A , O
in WO2013168131A1 A IN O
particular WO2013168131A1 A JJ O
multiple WO2013168131A1 A JJ O
sclerosis WO2013168131A1 A NN O
and WO2013168131A1 A CC O
primary WO2013168131A1 A JJ O
progressive WO2013168131A1 A JJ O
aphasia WO2013168131A1 A NN O
, WO2013168131A1 A , O
via WO2013168131A1 A IN O
intrathecal WO2013168131A1 A JJ O
, WO2013168131A1 A , O
or WO2013168131A1 A CC O
preferably WO2013168131A1 A RB O
intraventricular WO2013168131A1 A JJ O
, WO2013168131A1 A , O
administration WO2013168131A1 A NN O
of WO2013168131A1 A IN O
said WO2013168131A1 A VBD O
inhibitors WO2013168131A1 A NNS O
. WO2013168131A1 A . O

Modified WO2013119794A1 T NNP O
release WO2013119794A1 T NN O
formulations WO2013119794A1 T NNS O
of WO2013119794A1 T IN O
viloxazine WO2013119794A1 T NN O
. WO2013119794A1 T . O

Modified WO2013119794A1 A NNP O
release WO2013119794A1 A NN O
formulations WO2013119794A1 A NNS O
of WO2013119794A1 A IN O
viloxazine WO2013119794A1 A NN O
and WO2013119794A1 A CC O
methods WO2013119794A1 A NNS O
of WO2013119794A1 A IN O
administering WO2013119794A1 A VBG O
the WO2013119794A1 A DT O
same WO2013119794A1 A JJ O
are WO2013119794A1 A VBP O
disclosed WO2013119794A1 A VBN O
. WO2013119794A1 A . O

High- WO2013119794A1 A JJ O
drug WO2013119794A1 A NN O
load WO2013119794A1 A NN O
formulations WO2013119794A1 A NNS O
of WO2013119794A1 A IN O
viloxazine WO2013119794A1 A NN O
are WO2013119794A1 A VBP O
further WO2013119794A1 A RB O
disclosed WO2013119794A1 A VBN O
. WO2013119794A1 A . O

Compound CN1628667A T NNP O
dried CN1628667A T VBD O
suspension CN1628667A T NN O
of CN1628667A T IN O
dextromethorphan CN1628667A T NN O
and CN1628667A T CC O
gualfenesin CN1628667A T NN O
and CN1628667A T CC O
preparation CN1628667A T NN O
method CN1628667A T NN O
thereof CN1628667A T NN O
. CN1628667A T . O

The CN1628667A A DT O
invention CN1628667A A NN O
relates CN1628667A A VBZ O
to CN1628667A A TO O
a CN1628667A A DT O
compound CN1628667A A NN O
dried CN1628667A A VBD O
suspension CN1628667A A NN O
of CN1628667A A IN O
dextromethorphan CN1628667A A NN O
and CN1628667A A CC O
gualfenesin CN1628667A A NN O
and CN1628667A A CC O
preparation CN1628667A A NN O
method CN1628667A A NN O
, CN1628667A A , O
wherein CN1628667A A WP O
each CN1628667A A DT O
bag CN1628667A A NN O
of CN1628667A A IN O
suspension CN1628667A A NN O
comprises CN1628667A A NNS O
dextromethorphan CN1628667A A VBP O
2.5-32.5mg CN1628667A A CD O
, CN1628667A A , O
preferably CN1628667A A RB O
5-30mg CN1628667A A JJ O
, CN1628667A A , O
guaifenesin CN1628667A A JJ O
20-400mg CN1628667A A CD O
, CN1628667A A , O
preferably CN1628667A A RB O
50-300mg CN1628667A A JJ O
, CN1628667A A , O
thickening CN1628667A A VBG O
agent CN1628667A A NN O
and CN1628667A A CC O
suspending CN1628667A A VBG O
agent CN1628667A A NN O
whose CN1628667A A WP$ O
total CN1628667A A JJ O
amount CN1628667A A NN O
is CN1628667A A VBZ O
0.5-7 CN1628667A A JJ O
% CN1628667A A NN O
of CN1628667A A IN O
prescription CN1628667A A NN O
amount CN1628667A A NN O
, CN1628667A A , O
preferably CN1628667A A RB O
1-5 CN1628667A A CD O
% CN1628667A A NN O
, CN1628667A A , O
0.5-2 CN1628667A A CD O
% CN1628667A A NN O
, CN1628667A A , O
preferably CN1628667A A RB O
1-1.5 CN1628667A A CD O
% CN1628667A A NN O
of CN1628667A A IN O
stabilizing CN1628667A A VBG O
agent CN1628667A A NN O
, CN1628667A A , O
0.1-2 CN1628667A A CD O
% CN1628667A A NN O
, CN1628667A A , O
preferably CN1628667A A RB O
0.5-1.5 CN1628667A A CD O
% CN1628667A A NN O
of CN1628667A A IN O
surface-active CN1628667A A JJ O
agent CN1628667A A NN O
, CN1628667A A , O
75-97 CN1628667A A CD O
% CN1628667A A NN O
, CN1628667A A , O
preferably CN1628667A A RB O
80-95 CN1628667A A CD O
% CN1628667A A NN O
of CN1628667A A IN O
fragrant CN1628667A A JJ O
taste CN1628667A A NN O
correction CN1628667A A NN O
agent CN1628667A A NN O
, CN1628667A A , O
the CN1628667A A DT O
preparation CN1628667A A NN O
has CN1628667A A VBZ O
the CN1628667A A DT O
advantages CN1628667A A NNS O
of CN1628667A A IN O
good CN1628667A A JJ O
taste CN1628667A A NN O
, CN1628667A A , O
high CN1628667A A JJ O
medicament CN1628667A A NN O
dissolving CN1628667A A VBG O
degree CN1628667A A NN O
, CN1628667A A , O
and CN1628667A A CC O
fitting CN1628667A A VBG O
for CN1628667A A IN O
children CN1628667A A NNS O
. CN1628667A A . O

Combinations CA2691943A1 T NNS O
of CA2691943A1 T IN O
vasoactive CA2691943A1 T JJ O
substances CA2691943A1 T NNS O
with CA2691943A1 T IN O
estrogens CA2691943A1 T NNS O
and CA2691943A1 T CC O
their CA2691943A1 T PRP$ O
use CA2691943A1 T NN O
in CA2691943A1 T IN O
the CA2691943A1 T DT O
treatment CA2691943A1 T NN O
of CA2691943A1 T IN O
female CA2691943A1 T JJ O
sexual CA2691943A1 T JJ O
dysfunctions CA2691943A1 T NNS O
. CA2691943A1 T . O

Lysine CN1754534A T NNP O
hydrochlorate CN1754534A T NN O
for CN1754534A T IN O
injection CN1754534A T NN O
and CN1754534A T CC O
its CN1754534A T PRP$ O
preparation CN1754534A T NN O
method CN1754534A T NN O
. CN1754534A T . O

Modified EP2402356A2 T VBN O
2',3'-dideoxynucleosides EP2402356A2 T JJ O
for EP2402356A2 T IN O
treatment EP2402356A2 T NN O
infections EP2402356A2 T NNS O
caused EP2402356A2 T VBN O
by EP2402356A2 T IN O
human EP2402356A2 T JJ O
immunodeficiency EP2402356A2 T NN O
virus EP2402356A2 T NN O
( EP2402356A2 T ( O
HIV EP2402356A2 T NNP O
) EP2402356A2 T ) O
multidrug EP2402356A2 T NN O
resistant EP2402356A2 T JJ O
strains EP2402356A2 T NNS O
, EP2402356A2 T , O
method EP2402356A2 T NN O
of EP2402356A2 T IN O
their EP2402356A2 T PRP$ O
synthesis EP2402356A2 T NN O
and EP2402356A2 T CC O
the EP2402356A2 T DT O
pharmaceutical EP2402356A2 T JJ O
agent EP2402356A2 T NN O
containing EP2402356A2 T VBG O
these EP2402356A2 T DT O
nucleosides EP2402356A2 T NNS O
. EP2402356A2 T . O

Compositions EP1613316A1 T NNS O
comprising EP1613316A1 T VBG O
macrolide EP1613316A1 T JJ O
t-cell EP1613316A1 T JJ O
immunomodulators EP1613316A1 T NNS O
or EP1613316A1 T CC O
immunosuppressants EP1613316A1 T NNS O
in EP1613316A1 T IN O
combination EP1613316A1 T NN O
with EP1613316A1 T IN O
antibacterials EP1613316A1 T NNS O
. EP1613316A1 T . O

Ligand CA2676146A1 T NNP O
modified CA2676146A1 T VBD O
poly CA2676146A1 T JJ O
oxo-hydroxy CA2676146A1 T JJ O
metal CA2676146A1 T NN O
ion CA2676146A1 T NN O
materials CA2676146A1 T NNS O
, CA2676146A1 T , O
their CA2676146A1 T PRP$ O
uses CA2676146A1 T NNS O
and CA2676146A1 T CC O
processes CA2676146A1 T NNS O
for CA2676146A1 T IN O
their CA2676146A1 T PRP$ O
preparation CA2676146A1 T NN O
. CA2676146A1 T . O

An US7312209 T DT O
immunosuppressants US7312209 T NNS O
for US7312209 T IN O
treating US7312209 T VBG O
allograft US7312209 T NN O
rejection US7312209 T NN O
, US7312209 T , O
transplant US7312209 T JJ O
rejection US7312209 T NN O
, US7312209 T , O
psoriasis US7312209 T NN O
, US7312209 T , O
and US7312209 T CC O
rheumatoid US7312209 T JJ O
arthritis US7312209 T NN O
, US7312209 T , O
a US7312209 T DT O
9,10-dihydro-9-oxo-acridine-3-yl- US7312209 T JJ O
derivatives US7312209 T NNS O
. US7312209 T . O

Covalently CA2288983C T RB O
linked CA2288983C T VBN O
n CA2288983C T JJ O
, CA2288983C T , O
o-carboxymethylchitosan CA2288983C T JJ O
and CA2288983C T CC O
uses CA2288983C T VBZ O
thereof CA2288983C T NN O
. CA2288983C T . O

3 WO2010122151A1 T CD O
-azabicyclo WO2010122151A1 T JJ O
[ WO2010122151A1 T $ O
4.1.0 WO2010122151A1 T CD O
] WO2010122151A1 T NNP O
heptanes WO2010122151A1 T NNS O
used WO2010122151A1 T VBD O
as WO2010122151A1 T IN O
orexin WO2010122151A1 T JJ I-UN
antagonists WO2010122151A1 T NNS O
. WO2010122151A1 T . O

This WO2010122151A1 A DT O
invention WO2010122151A1 A NN O
relates WO2010122151A1 A VBZ O
to WO2010122151A1 A TO O
3-azabicyclo WO2010122151A1 A JJ O
[ WO2010122151A1 A JJ O
4.1.0 WO2010122151A1 A CD O
] WO2010122151A1 A JJ O
heptane WO2010122151A1 A NN O
derivatives WO2010122151A1 A NNS O
( WO2010122151A1 A ( O
I WO2010122151A1 A PRP O
) WO2010122151A1 A ) O
and WO2010122151A1 A CC O
their WO2010122151A1 A PRP$ O
use WO2010122151A1 A NN O
as WO2010122151A1 A IN O
orexin WO2010122151A1 A NN I-UN
receptor WO2010122151A1 A NN O
antagonists WO2010122151A1 A NNS O
. WO2010122151A1 A . O

5 CN102949338A T CD O
% CN102949338A T NN O
povidone-iodine CN102949338A T JJ O
solution CN102949338A T NN O
for CN102949338A T IN O
dairy CN102949338A T NN O
cattle CN102949338A T NNS O
with CN102949338A T IN O
strong CN102949338A T JJ O
stability CN102949338A T NN O
and CN102949338A T CC O
preparation CN102949338A T NN O
process CN102949338A T NN O
thereof CN102949338A T NN O
. CN102949338A T . O

A WO2006135621A2 A DT O
method WO2006135621A2 A NN O
of WO2006135621A2 A IN O
increasing WO2006135621A2 A VBG O
the WO2006135621A2 A DT O
activity WO2006135621A2 A NN O
of WO2006135621A2 A IN O
angiotensin WO2006135621A2 A NN I-UN
converting WO2006135621A2 A VBG I-UN
enzyme WO2006135621A2 A JJ I-UN
comprising WO2006135621A2 A VBG O
incubation WO2006135621A2 A NN O
with WO2006135621A2 A IN O
hemoglobin WO2006135621A2 A NN O
or WO2006135621A2 A CC O
hemoglobin WO2006135621A2 A NN O
and WO2006135621A2 A CC O
peroxide WO2006135621A2 A NN O
. WO2006135621A2 A . O

A WO2006135621A2 A DT O
method WO2006135621A2 A NN O
according WO2006135621A2 A VBG O
of WO2006135621A2 A IN O
activating WO2006135621A2 A VBG O
the WO2006135621A2 A DT O
renin-angiotensin-aldosterone WO2006135621A2 A NN O
system WO2006135621A2 A NN O
comprising WO2006135621A2 A VBG O
contacting WO2006135621A2 A VBG O
in WO2006135621A2 A IN O
vivo WO2006135621A2 A NN O
a WO2006135621A2 A DT O
free WO2006135621A2 A JJ O
hemoglobin WO2006135621A2 A NN O
based WO2006135621A2 A VBN O
blood WO2006135621A2 A NN O
substitute WO2006135621A2 A NN O
with WO2006135621A2 A IN O
a WO2006135621A2 A DT O
peroxide WO2006135621A2 A NN O
wherein WO2006135621A2 A IN O
the WO2006135621A2 A DT O
product WO2006135621A2 A NN O
induces WO2006135621A2 A VBZ O
the WO2006135621A2 A DT O
production WO2006135621A2 A NN O
of WO2006135621A2 A IN O
angiotensin WO2006135621A2 A NN I-UN
I WO2006135621A2 A PRP I-UN
metabolites WO2006135621A2 A VBZ O
which WO2006135621A2 A WDT O
comprise WO2006135621A2 A NN O
metabolites WO2006135621A2 A VBZ O
capable WO2006135621A2 A JJ O
of WO2006135621A2 A IN O
affecting WO2006135621A2 A VBG O
the WO2006135621A2 A DT O
vascular WO2006135621A2 A JJ O
tone WO2006135621A2 A NN O
and/or WO2006135621A2 A NN O
stimulating WO2006135621A2 A VBG O
aldosterone WO2006135621A2 A JJ O
production WO2006135621A2 A NN O
. WO2006135621A2 A . O

Quercetin CN103467426A T NNP O
hydrocarbylation CN103467426A T NN O
derivative CN103467426A T NN O
and CN103467426A T CC O
preparation CN103467426A T NN O
method CN103467426A T NN O
and CN103467426A T CC O
application CN103467426A T NN O
thereof CN103467426A T NN O
. CN103467426A T . O

Multimeric US20110003858 T NNP O
heterocyclic US20110003858 T JJ O
compounds US20110003858 T NNS O
useful US20110003858 T JJ O
as US20110003858 T IN O
neutrophil US20110003858 T JJ I-UN
elastase US20110003858 T NN I-UN
inhibitors US20110003858 T NNS O
. US20110003858 T . O

The US20110003858 A DT O
compounds US20110003858 A NNS O
are US20110003858 A VBP O
inhibitors US20110003858 A NNS O
of US20110003858 A IN O
human US20110003858 A JJ I-UN
neutrophil US20110003858 A JJ I-UN
elastase US20110003858 A NN I-UN
. US20110003858 A . O

Application CN102961383A T NN O
of CN102961383A T IN O
tanshinone CN102961383A T NN O
IIA CN102961383A T NNP O
or CN102961383A T CC O
pharmaceutically CN102961383A T RB O
acceptable CN102961383A T JJ O
salt CN102961383A T NN O
thereof CN102961383A T NN O
in CN102961383A T IN O
improving CN102961383A T VBG O
exercise CN102961383A T NN O
tolerance CN102961383A T NN O
of CN102961383A T IN O
pulmonary CN102961383A T JJ O
vascular CN102961383A T JJ O
disease CN102961383A T NN O
patients CN102961383A T NNS O
. CN102961383A T . O

Clopidogrel CN102512415A T NNP O
bisulfate CN102512415A T NN O
medicine CN102512415A T NN O
composition CN102512415A T NN O
and CN102512415A T CC O
preparation CN102512415A T NN O
method CN102512415A T NN O
. CN102512415A T . O

Pharmaceutical CN101522198B T JJ O
formulation CN101522198B T NN O
for CN101522198B T IN O
the CN101522198B T DT O
treatment CN101522198B T NN O
of CN101522198B T IN O
complaints CN101522198B T NNS O
. CN101522198B T . O

Rotundic CN102140126B T JJ O
acid CN102140126B T NN O
derivative CN102140126B T JJ O
and CN102140126B T CC O
synthesis CN102140126B T NN O
method CN102140126B T NN O
thereof CN102140126B T NN O
as CN102140126B T RB O
well CN102140126B T RB O
as CN102140126B T IN O
application CN102140126B T NN O
of CN102140126B T IN O
rotundic CN102140126B T JJ O
acid CN102140126B T JJ O
derivative CN102140126B T NN O
in CN102140126B T IN O
preparing CN102140126B T VBG O
medicament CN102140126B T NN O
for CN102140126B T IN O
preventing CN102140126B T VBG O
and CN102140126B T CC O
curing CN102140126B T VBG O
cardiovascular CN102140126B T JJ O
disease CN102140126B T NN O
. CN102140126B T . O

The CN102140126B A DT O
invention CN102140126B A NN O
discloses CN102140126B A VBZ O
a CN102140126B A DT O
succinic CN102140126B A JJ O
acid CN102140126B A NN O
base CN102140126B A NN O
rotundic CN102140126B A JJ O
acid CN102140126B A JJ O
derivative CN102140126B A NN O
and CN102140126B A CC O
a CN102140126B A DT O
correspondingly CN102140126B A RB O
pharmaceutically CN102140126B A RB O
acceptable CN102140126B A JJ O
salt CN102140126B A NN O
thereof CN102140126B A NN O
. CN102140126B A . O

The CN102140126B A DT O
succinic CN102140126B A JJ O
acid CN102140126B A NN O
base CN102140126B A NN O
rotundic CN102140126B A JJ O
acid CN102140126B A JJ O
derivative CN102140126B A NN O
and CN102140126B A CC O
the CN102140126B A DT O
correspondingly CN102140126B A RB O
pharmaceutically CN102140126B A RB O
acceptable CN102140126B A JJ O
salt CN102140126B A NN O
thereof CN102140126B A NNS O
are CN102140126B A VBP O
prepared CN102140126B A JJ O
and CN102140126B A CC O
synthesized CN102140126B A VBN O
by CN102140126B A IN O
using CN102140126B A VBG O
rotundic CN102140126B A JJ O
acid CN102140126B A NN O
as CN102140126B A IN O
a CN102140126B A DT O
lead CN102140126B A NN O
compound CN102140126B A NN O
and CN102140126B A CC O
taking CN102140126B A VBG O
succinic CN102140126B A JJ O
anhydride CN102140126B A NN O
as CN102140126B A IN O
a CN102140126B A DT O
raw CN102140126B A JJ O
material CN102140126B A NN O
in CN102140126B A IN O
an CN102140126B A DT O
acidic CN102140126B A JJ O
medium CN102140126B A NN O
. CN102140126B A . O

Compared CN102140126B A VBN O
with CN102140126B A IN O
the CN102140126B A DT O
rotundic CN102140126B A JJ O
acid CN102140126B A NN O
mother CN102140126B A NN O
nucleus CN102140126B A NN O
, CN102140126B A , O
the CN102140126B A DT O
solubility CN102140126B A NN O
of CN102140126B A IN O
the CN102140126B A DT O
derivative CN102140126B A JJ O
is CN102140126B A VBZ O
obviously CN102140126B A RB O
improved CN102140126B A VBN O
, CN102140126B A , O
and CN102140126B A CC O
the CN102140126B A DT O
outdegree CN102140126B A NN O
of CN102140126B A IN O
the CN102140126B A DT O
medicament CN102140126B A NN O
is CN102140126B A VBZ O
improved CN102140126B A VBN O
. CN102140126B A . O

The CN102140126B A DT O
derivative CN102140126B A NN O
has CN102140126B A VBZ O
the CN102140126B A DT O
effects CN102140126B A NNS O
of CN102140126B A IN O
obviously CN102140126B A RB O
increasing CN102140126B A VBG O
coronary CN102140126B A JJ O
blood CN102140126B A NN O
flow CN102140126B A NN O
and CN102140126B A CC O
reducing CN102140126B A VBG O
blood CN102140126B A NN O
fat CN102140126B A NN O
, CN102140126B A , O
thus CN102140126B A RB O
the CN102140126B A DT O
derivative CN102140126B A NN O
has CN102140126B A VBZ O
novel CN102140126B A VBN O
applications CN102140126B A NNS O
in CN102140126B A IN O
the CN102140126B A DT O
aspects CN102140126B A NNS O
of CN102140126B A IN O
medicaments CN102140126B A NNS O
for CN102140126B A IN O
preventing CN102140126B A VBG O
and CN102140126B A CC O
curing CN102140126B A VBG O
cardiovascular CN102140126B A JJ O
disease CN102140126B A NN O
and CN102140126B A CC O
regulating CN102140126B A VBG O
blood CN102140126B A NN O
fat CN102140126B A NN O
. CN102140126B A . O

Novel CN102344442A T NNP O
crystal CN102344442A T JJ O
form CN102344442A T NN O
of CN102344442A T IN O
tandospirone CN102344442A T NN O
citrate CN102344442A T NN O
and CN102344442A T CC O
preparation CN102344442A T NN O
method CN102344442A T NN O
and CN102344442A T CC O
application CN102344442A T NN O
thereof CN102344442A T NN O
. CN102344442A T . O

Method CN100579977C T NNP O
for CN100579977C T IN O
producing CN100579977C T VBG O
antifungal CN100579977C T JJ O
drug CN100579977C T NN O
in CN100579977C T IN O
triazole CN100579977C T JJ O
class CN100579977C T NN O
. CN100579977C T . O

Famciclovir CN102920663A T NNP O
sustained-release CN102920663A T JJ O
pellet CN102920663A T NN O
, CN102920663A T , O
preparation CN102920663A T NN O
method CN102920663A T NN O
and CN102920663A T CC O
application CN102920663A T NN O
thereof CN102920663A T NN O
. CN102920663A T . O

Pyrazolopyridine CN102898426A T NNP O
derivatives CN102898426A T NNS O
for CN102898426A T IN O
inhibiting CN102898426A T VBG O
activity CN102898426A T NN O
of CN102898426A T IN O
insulin-like CN102898426A T JJ I-UN
growth CN102898426A T NN I-UN
factor-1 CN102898426A T JJ I-UN
receptor CN102898426A T NN I-UN
( CN102898426A T ( O
IGF-1R CN102898426A T NNP I-UN
) CN102898426A T ) O
tyrosine CN102898426A T NN O
kinase CN102898426A T NN O
. CN102898426A T . O

Application CN102198121B T NN O
of CN102198121B T IN O
2 CN102198121B T CD O
, CN102198121B T , O
2 CN102198121B T CD O
, CN102198121B T , O
3 CN102198121B T CD O
, CN102198121B T , O
3- CN102198121B T JJ O
tetramethyl CN102198121B T NN O
cyclopropyl CN102198121B T NN O
carbonyl CN102198121B T NN O
thiourea CN102198121B T NN O
in CN102198121B T IN O
the CN102198121B T DT O
process CN102198121B T NN O
for CN102198121B T IN O
preparing CN102198121B T VBG O
antitumor CN102198121B T JJ O
medicine CN102198121B T NN O
. CN102198121B T . O

The CN102198121B A DT O
antitumor CN102198121B A NN O
medicine CN102198121B A NN O
comprises CN102198121B A VBZ O
an CN102198121B A DT O
up-regulating CN102198121B A JJ O
tumor CN102198121B A NN O
suppressor CN102198121B A NN O
gene CN102198121B A NN O
p21 CN102198121B A NN I-UN
< CN102198121B A NNP O
WAF1/CIP1 CN102198121B A NNP O
> CN102198121B A NNP O
medicine CN102198121B A NN O
, CN102198121B A , O
a CN102198121B A DT O
down-regulating CN102198121B A JJ O
cyclin CN102198121B A NN O
D1 CN102198121B A NNP O
medicine CN102198121B A NN O
or CN102198121B A CC O
a CN102198121B A DT O
down-regulating CN102198121B A JJ O
HDAC3 CN102198121B A NNP I-UN
and CN102198121B A CC O
HDAC4 CN102198121B A NNP I-UN
expression CN102198121B A NN O
medicine CN102198121B A NN O
. CN102198121B A . O

The CN102198121B A DT O
invention CN102198121B A NN O
confirms CN102198121B A VBZ O
that CN102198121B A IN O
2 CN102198121B A CD O
, CN102198121B A , O
2 CN102198121B A CD O
, CN102198121B A , O
3 CN102198121B A CD O
, CN102198121B A , O
3-tetramethyl CN102198121B A JJ O
cyclopropyl CN102198121B A NN O
carbonyl CN102198121B A NN O
thiourea CN102198121B A NN O
( CN102198121B A ( O
TCCT CN102198121B A NNP O
for CN102198121B A IN O
short CN102198121B A JJ O
) CN102198121B A ) O
possesses CN102198121B A VBZ O
inhibitory CN102198121B A JJ O
effect CN102198121B A NN O
on CN102198121B A IN O
the CN102198121B A DT O
growth CN102198121B A NN O
of CN102198121B A IN O
U251 CN102198121B A NNP O
human CN102198121B A JJ O
glioma CN102198121B A NN O
cells CN102198121B A NNS O
by CN102198121B A IN O
using CN102198121B A VBG O
a CN102198121B A DT O
molecular CN102198121B A JJ O
biology CN102198121B A NN O
method CN102198121B A NN O
, CN102198121B A , O
the CN102198121B A DT O
2 CN102198121B A CD O
, CN102198121B A , O
2 CN102198121B A CD O
, CN102198121B A , O
3 CN102198121B A CD O
, CN102198121B A , O
3-tetramethyl CN102198121B A JJ O
cyclopropyl CN102198121B A NN O
carbonyl CN102198121B A NN O
thiourea CN102198121B A NN O
provided CN102198121B A VBN O
in CN102198121B A IN O
the CN102198121B A DT O
invention CN102198121B A NN O
interferes CN102198121B A VBZ O
the CN102198121B A DT O
cell CN102198121B A NN O
cycle CN102198121B A NN O
through CN102198121B A IN O
the CN102198121B A DT O
effect CN102198121B A NN O
of CN102198121B A IN O
p21 CN102198121B A NN I-UN
< CN102198121B A NNP O
WAF1/CIP1 CN102198121B A NNP O
> CN102198121B A NNP O
and CN102198121B A CC O
CyclinD1 CN102198121B A NNP I-UN
expression CN102198121B A NN O
, CN102198121B A , O
so CN102198121B A RB O
as CN102198121B A IN O
to CN102198121B A TO O
exert CN102198121B A VB O
the CN102198121B A DT O
effect CN102198121B A NN O
of CN102198121B A IN O
inhibition CN102198121B A NN O
, CN102198121B A , O
whichhas CN102198121B A VBP O
the CN102198121B A DT O
obvious CN102198121B A JJ O
effect CN102198121B A NN O
. CN102198121B A . O

Antiprotozoa US7109331 T NNP O
agents US7109331 T NNS O
; US7109331 T : O
4-pyrrolidine US7109331 T JJ O
pyrrolo US7109331 T NN O
( US7109331 T ( O
3,2-d US7109331 T JJ O
) US7109331 T ) O
pyrimidine US7109331 T NN O
and US7109331 T CC O
4-pyrrolidine US7109331 T JJ O
pyrazolo US7109331 T NN O
( US7109331 T ( O
4,3-d US7109331 T JJ O
) US7109331 T ) O
pyrimidine US7109331 T NN O
derivatives US7109331 T NNS O
. US7109331 T . O

Pyrazole WO2009010560A1 T NNP O
derivatives WO2009010560A1 T NNS O
and WO2009010560A1 T CC O
use WO2009010560A1 T VB O
thereof WO2009010560A1 T NN O
as WO2009010560A1 T IN O
inhibitors WO2009010560A1 T NNS O
of WO2009010560A1 T IN O
stearoyl-coa WO2009010560A1 T JJ I-UN
desaturase WO2009010560A1 T NN I-UN
. WO2009010560A1 T . O

In WO2009010560A1 A IN O
particular WO2009010560A1 A JJ O
, WO2009010560A1 A , O
the WO2009010560A1 A DT O
invention WO2009010560A1 A NN O
relates WO2009010560A1 A VBZ O
to WO2009010560A1 A TO O
compounds WO2009010560A1 A NNS O
of WO2009010560A1 A IN O
formula WO2009010560A1 A NN O
( WO2009010560A1 A ( O
I WO2009010560A1 A PRP O
) WO2009010560A1 A ) O
for WO2009010560A1 A IN O
inhibiting WO2009010560A1 A VBG O
stearoyl-CoA WO2009010560A1 A JJ I-UN
desaturase WO2009010560A1 A NN I-UN
( WO2009010560A1 A ( O
SCD WO2009010560A1 A NNP I-UN
) WO2009010560A1 A ) O
activity WO2009010560A1 A NN O
. WO2009010560A1 A . O

Clindamycin CN101032469A T NNP O
phosphate CN101032469A T NN O
bubble CN101032469A T JJ O
agent CN101032469A T NN O
and CN101032469A T CC O
preparing CN101032469A T VBG O
method CN101032469A T NN O
. CN101032469A T . O

Use US20060063711 T NNP O
of US20060063711 T IN O
sglt US20060063711 T NN I-UN
homolog US20060063711 T NN O
. US20060063711 T . O

The US20060063711 A DT O
present US20060063711 A JJ O
invention US20060063711 A NN O
provides US20060063711 A VBZ O
an US20060063711 A DT O
agent US20060063711 A NN O
that US20060063711 A WDT O
inhibits US20060063711 A VBZ O
or US20060063711 A CC O
promotes US20060063711 A NNS O
glucose US20060063711 A VBP O
uptake US20060063711 A JJ O
in US20060063711 A IN O
the US20060063711 A DT O
small US20060063711 A JJ O
intestine US20060063711 A NN O
, US20060063711 A , O
etc. US20060063711 A FW O
, US20060063711 A , O
comprising US20060063711 A VBG O
a US20060063711 A DT O
compound US20060063711 A NN O
that US20060063711 A IN O
inhibits US20060063711 A VBZ O
or US20060063711 A CC O
promotes US20060063711 A VBZ O
the US20060063711 A DT O
activity US20060063711 A NN O
of US20060063711 A IN O
Na+/glucose US20060063711 A NNP I-UN
transporter US20060063711 A NN I-UN
( US20060063711 A ( O
SGLT US20060063711 A NNP I-UN
) US20060063711 A ) O
homologs US20060063711 A NNS O
. US20060063711 A . O

Medicine CN101537019A T NNP O
for CN101537019A T IN O
curing CN101537019A T VBG O
tympanitis CN101537019A T NN O
. CN101537019A T . O

Novel WO2009148004A1 T NNP O
compound WO2009148004A1 T NN O
and WO2009148004A1 T CC O
pharmaceutical WO2009148004A1 T JJ O
application WO2009148004A1 T NN O
of WO2009148004A1 T IN O
same WO2009148004A1 T JJ O
. WO2009148004A1 T . O

Provided WO2009148004A1 A VBN O
is WO2009148004A1 A VBZ O
a WO2009148004A1 A DT O
compound WO2009148004A1 A NN O
represented WO2009148004A1 A VBN O
by WO2009148004A1 A IN O
general WO2009148004A1 A JJ O
formula WO2009148004A1 A NN O
( WO2009148004A1 A ( O
I WO2009148004A1 A PRP O
) WO2009148004A1 A ) O
, WO2009148004A1 A , O
or WO2009148004A1 A CC O
a WO2009148004A1 A DT O
pharmaceutically WO2009148004A1 A RB O
acceptable WO2009148004A1 A JJ O
salt WO2009148004A1 A NN O
thereof WO2009148004A1 A NN O
, WO2009148004A1 A , O
which WO2009148004A1 A WDT O
can WO2009148004A1 A MD O
be WO2009148004A1 A VB O
used WO2009148004A1 A VBN O
in WO2009148004A1 A IN O
pharmaceutical WO2009148004A1 A JJ O
applications WO2009148004A1 A NNS O
, WO2009148004A1 A , O
and WO2009148004A1 A CC O
an WO2009148004A1 A DT O
agent WO2009148004A1 A NN O
for WO2009148004A1 A IN O
blocking WO2009148004A1 A VBG O
GIP WO2009148004A1 A NNP I-UN
receptor WO2009148004A1 A NN I-UN
binding WO2009148004A1 A VBG O
for WO2009148004A1 A IN O
preventing WO2009148004A1 A VBG O
or WO2009148004A1 A CC O
ameliorating WO2009148004A1 A VBG O
obesity WO2009148004A1 A NN O
, WO2009148004A1 A , O
insulin WO2009148004A1 A NN I-UN
resistance WO2009148004A1 A NN O
or WO2009148004A1 A CC O
the WO2009148004A1 A DT O
accumulation WO2009148004A1 A NN O
of WO2009148004A1 A IN O
lipid WO2009148004A1 A NN O
in WO2009148004A1 A IN O
the WO2009148004A1 A DT O
liver WO2009148004A1 A NN O
, WO2009148004A1 A , O
based WO2009148004A1 A VBN O
on WO2009148004A1 A IN O
blocking WO2009148004A1 A VBG O
GIP WO2009148004A1 A NNP I-UN
function WO2009148004A1 A NN O
and WO2009148004A1 A CC O
more WO2009148004A1 A RBR O
precisely WO2009148004A1 A RB O
based WO2009148004A1 A VBN O
on WO2009148004A1 A IN O
blocking WO2009148004A1 A VBG O
GIP WO2009148004A1 A NNP I-UN
receptor WO2009148004A1 A NN I-UN
binding WO2009148004A1 A NN O
, WO2009148004A1 A , O
wherein WO2009148004A1 A NN O
said WO2009148004A1 A VBD O
compound WO2009148004A1 A NN O
forms WO2009148004A1 A VBZ O
the WO2009148004A1 A DT O
effective WO2009148004A1 A JJ O
component WO2009148004A1 A NN O
. WO2009148004A1 A . O

Compositions US20100286241 T NNS O
comprising US20100286241 T VBG O
k-ras US20100286241 T JJ I-UN
sirna US20100286241 T NN O
and US20100286241 T CC O
methods US20100286241 T NNS O
of US20100286241 T IN O
use US20100286241 T NN O
. US20100286241 T . O

The US20100286241 A DT O
present US20100286241 A JJ O
invention US20100286241 A NN O
provides US20100286241 A VBZ O
nucleic US20100286241 A JJ O
acid US20100286241 A NN O
molecules US20100286241 A NNS O
that US20100286241 A WDT O
inhibit US20100286241 A VBP O
K-ras US20100286241 A JJ I-UN
expression US20100286241 A NN O
. US20100286241 A . O

Helianthus CN102924622A T NNP O
annuus CN102924622A T NN O
polysaccharide CN102924622A T NN O
and CN102924622A T CC O
preparation CN102924622A T NN O
method CN102924622A T NN O
thereof CN102924622A T NN O
. CN102924622A T . O

Medicament CN103239666A T NN O
for CN103239666A T IN O
treating CN103239666A T VBG O
arthritis CN103239666A T NN O
bone CN103239666A T NN O
disease CN103239666A T NN O
. CN103239666A T . O

Expression US20080254035 T NNP O
vector US20080254035 T NN O
comprising US20080254035 T VBG O
lipocalin US20080254035 T JJ I-UN
gene US20080254035 T NN I-UN
sequences US20080254035 T NNS O
for US20080254035 T IN O
use US20080254035 T NN O
in US20080254035 T IN O
prevention US20080254035 T NN O
and US20080254035 T CC O
treatment US20080254035 T NN O
of US20080254035 T IN O
cell US20080254035 T NN O
proliferative US20080254035 T NN O
, US20080254035 T , O
inflammatory US20080254035 T NN O
, US20080254035 T , O
autoimmune US20080254035 T NN O
and US20080254035 T CC O
cardiovascular US20080254035 T JJ O
disorders US20080254035 T NNS O
. US20080254035 T . O

The US20080254035 A DT O
invention US20080254035 A NN O
is US20080254035 A VBZ O
based US20080254035 A VBN O
on US20080254035 A IN O
the US20080254035 A DT O
discovery US20080254035 A NN O
that US20080254035 A IN O
the US20080254035 A DT O
human US20080254035 A JJ O
protein US20080254035 A NN O
referred US20080254035 A VBD O
to US20080254035 A TO O
herein US20080254035 A VB O
as US20080254035 A IN O
INSP181 US20080254035 A NNP I-UN
protein US20080254035 A NN O
is US20080254035 A VBZ O
a US20080254035 A DT O
lipocalin US20080254035 A NN I-UN
. US20080254035 A . O

5-nonyloxytrptamine WO2013063216A1 T JJ O
and WO2013063216A1 T CC O
related WO2013063216A1 T JJ O
intracellular WO2013063216A1 T JJ O
ph WO2013063216A1 T NN O
acidifiers WO2013063216A1 T NNS O
for WO2013063216A1 T IN O
the WO2013063216A1 T DT O
treatment WO2013063216A1 T NN O
and WO2013063216A1 T CC O
prevention WO2013063216A1 T NN O
of WO2013063216A1 T IN O
cancer WO2013063216A1 T NN O
. WO2013063216A1 T . O

Application CN102319272B T NN O
of CN102319272B T IN O
ginkgolic CN102319272B T JJ O
acid CN102319272B T NN O
in CN102319272B T IN O
preparation CN102319272B T NN O
of CN102319272B T IN O
external CN102319272B T JJ O
preparation CN102319272B T NN O
for CN102319272B T IN O
treating CN102319272B T VBG O
dermatopathy CN102319272B T NN O
. CN102319272B T . O

Swelling-diminishing CN103251716A T JJ O
pain-erasing CN103251716A T JJ O
ointment CN103251716A T NN O
and CN103251716A T CC O
preparation CN103251716A T NN O
method CN103251716A T NN O
thereof CN103251716A T NN O
. CN103251716A T . O

The CN103251716A A DT O
invention CN103251716A A NN O
belongs CN103251716A A VBZ O
to CN103251716A A TO O
the CN103251716A A DT O
medical CN103251716A A JJ O
field CN103251716A A NN O
, CN103251716A A , O
in CN103251716A A IN O
particular CN103251716A A JJ O
relates CN103251716A A NNS O
to CN103251716A A TO O
swelling-diminishing CN103251716A A JJ O
pain-erasing CN103251716A A JJ O
ointment CN103251716A A NN O
and CN103251716A A CC O
a CN103251716A A DT O
preparation CN103251716A A NN O
method CN103251716A A NN O
thereof CN103251716A A NN O
, CN103251716A A , O
and CN103251716A A CC O
aims CN103251716A A VBZ O
at CN103251716A A IN O
lowering CN103251716A A VBG O
the CN103251716A A DT O
production CN103251716A A NN O
period CN103251716A A NN O
of CN103251716A A IN O
the CN103251716A A DT O
swelling-diminishing CN103251716A A JJ O
pain-erasing CN103251716A A JJ O
ointment CN103251716A A NN O
. CN103251716A A . O

The CN103251716A A DT O
swelling-diminishing CN103251716A A JJ O
pain-erasing CN103251716A A JJ O
ointment CN103251716A A NN O
comprises CN103251716A A VBZ O
the CN103251716A A DT O
following CN103251716A A JJ O
bulk CN103251716A A NN O
pharmaceutical CN103251716A A JJ O
chemicals CN103251716A A NNS O
: CN103251716A A : O
ligusticum CN103251716A A NN O
wallichii CN103251716A A NN O
, CN103251716A A , O
Chinese CN103251716A A NNP O
angelica CN103251716A A NN O
, CN103251716A A , O
madder CN103251716A A NN O
, CN103251716A A , O
green CN103251716A A JJ O
tangerine CN103251716A A NN O
peel CN103251716A A NN O
, CN103251716A A , O
red CN103251716A A JJ O
flower CN103251716A A NN O
, CN103251716A A , O
ephedra CN103251716A A NN O
and CN103251716A A CC O
borneol CN103251716A A NN O
. CN103251716A A . O

The CN103251716A A DT O
swelling-diminishing CN103251716A A JJ O
pain-erasing CN103251716A A JJ O
ointment CN103251716A A NN O
is CN103251716A A VBZ O
prepared CN103251716A A VBN O
by CN103251716A A IN O
the CN103251716A A DT O
following CN103251716A A JJ O
method CN103251716A A NN O
: CN103251716A A : O
A CN103251716A A DT O
, CN103251716A A , O
crushing CN103251716A A VBG O
the CN103251716A A DT O
drugs CN103251716A A NNS O
into CN103251716A A IN O
crude CN103251716A A NN O
powder CN103251716A A NN O
except CN103251716A A IN O
borneol CN103251716A A NN O
, CN103251716A A , O
extracting CN103251716A A VBG O
by CN103251716A A IN O
using CN103251716A A VBG O
60 CN103251716A A CD O
% CN103251716A A NN O
-80 CN103251716A A CD O
% CN103251716A A NN O
of CN103251716A A IN O
alcohol CN103251716A A NN O
, CN103251716A A , O
and CN103251716A A CC O
filtering CN103251716A A VBG O
to CN103251716A A TO O
obtain CN103251716A A VB O
filtrate CN103251716A A NN O
; CN103251716A A : O
B CN103251716A A NNP O
, CN103251716A A , O
recycling CN103251716A A VBG O
the CN103251716A A DT O
alcohol CN103251716A A NN O
and CN103251716A A CC O
concentrating CN103251716A A VBG O
the CN103251716A A DT O
recycled CN103251716A A JJ O
alcohol CN103251716A A NN O
to CN103251716A A TO O
obtain CN103251716A A VB O
thick CN103251716A A JJ O
ointment CN103251716A A NN O
with CN103251716A A IN O
relative CN103251716A A JJ O
density CN103251716A A NN O
of CN103251716A A IN O
1.3-1.34 CN103251716A A JJ O
( CN103251716A A ( O
at CN103251716A A IN O
80 CN103251716A A CD O
DEG CN103251716A A NNP O
C CN103251716A A NNP O
) CN103251716A A ) O
; CN103251716A A : O
C CN103251716A A NNP O
, CN103251716A A , O
taking CN103251716A A VBG O
and CN103251716A A CC O
uniformly CN103251716A A JJ O
mixing CN103251716A A VBG O
BC-1 CN103251716A A NNP O
medical CN103251716A A JJ O
pressure CN103251716A A NN O
sensitive CN103251716A A JJ O
adhesive CN103251716A A NN O
with CN103251716A A IN O
trichloromethane CN103251716A A NN O
in CN103251716A A IN O
a CN103251716A A DT O
weight CN103251716A A NN O
ratio CN103251716A A NN O
of CN103251716A A IN O
1:1 CN103251716A A CD O
to CN103251716A A TO O
form CN103251716A A VB O
substrate CN103251716A A NN O
; CN103251716A A : O
and CN103251716A A CC O
D CN103251716A A NNP O
, CN103251716A A , O
uniformly CN103251716A A RB O
stirring CN103251716A A VBG O
the CN103251716A A DT O
thick CN103251716A A JJ O
ointment CN103251716A A NN O
with CN103251716A A IN O
the CN103251716A A DT O
substrate CN103251716A A NN O
in CN103251716A A IN O
the CN103251716A A DT O
weight CN103251716A A NN O
ratio CN103251716A A NN O
of CN103251716A A IN O
1:2 CN103251716A A CD O
, CN103251716A A , O
adding CN103251716A A VBG O
borneol CN103251716A A NN O
for CN103251716A A IN O
uniformly CN103251716A A JJ O
mixing CN103251716A A NN O
, CN103251716A A , O
filtering CN103251716A A VBG O
to CN103251716A A TO O
obtain CN103251716A A VB O
paint CN103251716A A NN O
, CN103251716A A , O
coating CN103251716A A VBG O
the CN103251716A A DT O
ointment CN103251716A A NN O
, CN103251716A A , O
drying CN103251716A A VBG O
, CN103251716A A , O
slitting CN103251716A A VBG O
, CN103251716A A , O
bushing CN103251716A A VBG O
and CN103251716A A CC O
slicing CN103251716A A VBG O
to CN103251716A A TO O
obtain CN103251716A A VB O
the CN103251716A A DT O
swelling-diminishing CN103251716A A JJ O
pain-erasing CN103251716A A JJ O
ointment CN103251716A A NN O
. CN103251716A A . O

According CN103251716A A VBG O
to CN103251716A A TO O
the CN103251716A A DT O
swelling-diminishing CN103251716A A JJ O
pain-erasing CN103251716A A JJ O
ointment CN103251716A A NN O
and CN103251716A A CC O
the CN103251716A A DT O
preparation CN103251716A A NN O
method CN103251716A A NN O
thereof CN103251716A A NN O
, CN103251716A A , O
trichloromethane CN103251716A A NN O
is CN103251716A A VBZ O
used CN103251716A A VBN O
for CN103251716A A IN O
dissolving CN103251716A A VBG O
the CN103251716A A DT O
BC-1 CN103251716A A NNP O
medical CN103251716A A JJ O
pressure CN103251716A A NN O
sensitive CN103251716A A JJ O
adhesive CN103251716A A NN O
, CN103251716A A , O
so CN103251716A A IN O
that CN103251716A A IN O
the CN103251716A A DT O
production CN103251716A A NN O
period CN103251716A A NN O
can CN103251716A A MD O
be CN103251716A A VB O
remarkably CN103251716A A RB O
shortened CN103251716A A VBN O
, CN103251716A A , O
and CN103251716A A CC O
therefore CN103251716A A RB O
, CN103251716A A , O
the CN103251716A A DT O
ointment CN103251716A A JJ O
surface CN103251716A A NN O
appearance CN103251716A A NN O
is CN103251716A A VBZ O
more CN103251716A A RBR O
beautiful CN103251716A A JJ O
, CN103251716A A , O
the CN103251716A A DT O
viscosity CN103251716A A NN O
is CN103251716A A VBZ O
properly CN103251716A A RB O
lowered CN103251716A A VBN O
, CN103251716A A , O
and CN103251716A A CC O
a CN103251716A A DT O
patient CN103251716A A NN O
can CN103251716A A MD O
use CN103251716A A VB O
the CN103251716A A DT O
ointment CN103251716A A NN O
more CN103251716A A JJR O
comfortably CN103251716A A RB O
. CN103251716A A . O

Derivatives WO2008115259A3 T NNS O
of WO2008115259A3 T IN O
benzoxadiazole WO2008115259A3 T NN O
suitable WO2008115259A3 T NN O
for WO2008115259A3 T IN O
the WO2008115259A3 T DT O
treatment WO2008115259A3 T NN O
of WO2008115259A3 T IN O
cell WO2008115259A3 T NN O
proliferative WO2008115259A3 T JJ O
diseases WO2008115259A3 T NNS O
. WO2008115259A3 T . O

This WO2008115259A3 A DT O
invention WO2008115259A3 A NN O
describes WO2008115259A3 A VBZ O
compounds WO2008115259A3 A NNS O
and WO2008115259A3 A CC O
pharmaceutical WO2008115259A3 A JJ O
compositions WO2008115259A3 A NNS O
useful WO2008115259A3 A JJ O
as WO2008115259A3 A IN O
ubiquitin WO2008115259A3 A JJ I-UN
agent WO2008115259A3 A NN O
inhibitors WO2008115259A3 A NNS O
, WO2008115259A3 A , O
particularly WO2008115259A3 A RB O
ubiquitin WO2008115259A3 A JJ I-UN
ligase WO2008115259A3 A NN I-UN
inhibitors WO2008115259A3 A NNS O
. WO2008115259A3 A . O

Particularly WO2008115259A3 A RB O
, WO2008115259A3 A , O
the WO2008115259A3 A DT O
compounds WO2008115259A3 A NNS O
and WO2008115259A3 A CC O
pharmaceutical WO2008115259A3 A JJ O
compositions WO2008115259A3 A NNS O
are WO2008115259A3 A VBP O
useful WO2008115259A3 A JJ O
to WO2008115259A3 A TO O
inhibit WO2008115259A3 A VB O
the WO2008115259A3 A DT O
ubiquitin WO2008115259A3 A JJ I-UN
ligase WO2008115259A3 A NN O
activity WO2008115259A3 A NN O
of WO2008115259A3 A IN O
TRAF6 WO2008115259A3 A NNP I-UN
. WO2008115259A3 A . O

Use US20120129877 T NNP O
of US20120129877 T IN O
quinazoline US20120129877 T NN O
derivatives US20120129877 T NNS O
for US20120129877 T IN O
neurodegenerative US20120129877 T JJ O
diseases US20120129877 T NNS O
. US20120129877 T . O

RNAi US20110003882 T NNP O
Modulation US20110003882 T NNP O
of US20110003882 T IN O
AHA US20110003882 T NNP O
and US20110003882 T CC O
Therapeutic US20110003882 T NNP O
Uses US20110003882 T NNP O
Thereof US20110003882 T NNP O
. US20110003882 T . O

The US20110003882 A DT O
invention US20110003882 A NN O
relates US20110003882 A VBZ O
to US20110003882 A TO O
a US20110003882 A DT O
double-stranded US20110003882 A JJ O
ribonucleic US20110003882 A NN O
acid US20110003882 A NN O
( US20110003882 A ( O
dsRNA US20110003882 A NN O
) US20110003882 A ) O
for US20110003882 A IN O
inhibiting US20110003882 A VBG O
the US20110003882 A DT O
expression US20110003882 A NN O
of US20110003882 A IN O
an US20110003882 A DT O
Aha US20110003882 A NNP I-UN
gene US20110003882 A NN O
( US20110003882 A ( O
Aha1 US20110003882 A NNP I-UN
gene US20110003882 A NN O
) US20110003882 A ) O
, US20110003882 A , O
comprising US20110003882 A VBG O
an US20110003882 A DT O
antisense US20110003882 A NN O
strand US20110003882 A NN O
having US20110003882 A VBG O
a US20110003882 A DT O
nucleotide US20110003882 A JJ O
sequence US20110003882 A NN O
which US20110003882 A WDT O
is US20110003882 A VBZ O
less US20110003882 A JJR O
that US20110003882 A IN O
30 US20110003882 A CD O
nucleotides US20110003882 A NNS O
in US20110003882 A IN O
length US20110003882 A NN O
, US20110003882 A , O
generally US20110003882 A RB O
19-25 US20110003882 A JJ O
nucleotides US20110003882 A NNS O
in US20110003882 A IN O
length US20110003882 A NN O
, US20110003882 A , O
and US20110003882 A CC O
which US20110003882 A WDT O
is US20110003882 A VBZ O
substantially US20110003882 A RB O
complementary US20110003882 A JJ O
to US20110003882 A TO O
at US20110003882 A IN O
least US20110003882 A JJS O
a US20110003882 A DT O
part US20110003882 A NN O
of US20110003882 A IN O
an US20110003882 A DT O
Aha US20110003882 A NNP I-UN
gene US20110003882 A NN O
. US20110003882 A . O

The US20110003882 A DT O
invention US20110003882 A NN O
also US20110003882 A RB O
relates US20110003882 A VBZ O
to US20110003882 A TO O
a US20110003882 A DT O
pharmaceutical US20110003882 A JJ O
composition US20110003882 A NN O
comprising US20110003882 A VBG O
the US20110003882 A DT O
dsRNA US20110003882 A NN O
together US20110003882 A RB O
with US20110003882 A IN O
a US20110003882 A DT O
pharmaceutically US20110003882 A RB O
acceptable US20110003882 A JJ O
carrier US20110003882 A NN O
; US20110003882 A : O
methods US20110003882 A NNS O
for US20110003882 A IN O
treating US20110003882 A VBG O
diseases US20110003882 A NNS O
caused US20110003882 A VBN O
by US20110003882 A IN O
Aha1 US20110003882 A NNP I-UN
expression US20110003882 A NN O
and US20110003882 A CC O
the US20110003882 A DT O
expression US20110003882 A NN O
of US20110003882 A IN O
an US20110003882 A DT O
Aha US20110003882 A NNP I-UN
gene US20110003882 A NN O
using US20110003882 A VBG O
the US20110003882 A DT O
pharmaceutical US20110003882 A JJ O
composition US20110003882 A NN O
; US20110003882 A : O
and US20110003882 A CC O
methods US20110003882 A NNS O
for US20110003882 A IN O
inhibiting US20110003882 A VBG O
the US20110003882 A DT O
expression US20110003882 A NN O
of US20110003882 A IN O
an US20110003882 A DT O
Aha US20110003882 A NNP I-UN
gene US20110003882 A NN O
in US20110003882 A IN O
a US20110003882 A DT O
cell US20110003882 A NN O
. US20110003882 A . O

Modulators CN103497192A T NNS O
of CN103497192A T IN O
TOLL-like CN103497192A T JJ O
receptors CN103497192A T NNS O
. CN103497192A T . O

Compound CN101991591A T NNP O
apramycin CN101991591A T NN O
sulfate CN101991591A T NN O
injection CN101991591A T NN O
and CN101991591A T CC O
preparation CN101991591A T NN O
method CN101991591A T NN O
thereof CN101991591A T NN O
. CN101991591A T . O

Anti-cancer CN101926503A T NNP O
macrobiotic CN101926503A T JJ O
cigarette CN101926503A T NN O
rich CN101926503A T JJ O
in CN101926503A T IN O
trace CN101926503A T NN O
elements CN101926503A T NNS O
selenium CN101926503A T NN O
and CN101926503A T CC O
germanium CN101926503A T NN O
and CN101926503A T CC O
having CN101926503A T VBG O
function CN101926503A T NN O
of CN101926503A T IN O
powerfully CN101926503A T RB O
eliminating CN101926503A T VBG O
toxicity CN101926503A T NN O
of CN101926503A T IN O
tar CN101926503A T NN O
smoke CN101926503A T NN O
. CN101926503A T . O

Topical DE102007054985A1 T JJ O
product DE102007054985A1 T NN O
, DE102007054985A1 T , O
useful DE102007054985A1 T JJ O
e.g DE102007054985A1 T NN O
. DE102007054985A1 T . O

to DE102007054985A1 T TO O
prevent/treat DE102007054985A1 T VB O
relapses DE102007054985A1 T NNS O
by DE102007054985A1 T IN O
herpes DE102007054985A1 T NNS O
simplex DE102007054985A1 T JJ O
I DE102007054985A1 T PRP O
, DE102007054985A1 T , O
comprises DE102007054985A1 T VBZ O
histone DE102007054985A1 T NN O
deacetylase DE102007054985A1 T NN O
activator DE102007054985A1 T NN O
comprising DE102007054985A1 T VBG O
resveratrol DE102007054985A1 T NN O
, DE102007054985A1 T , O
quercetin DE102007054985A1 T NN O
and/or DE102007054985A1 T NN O
luteolin DE102007054985A1 T NN O
, DE102007054985A1 T , O
and DE102007054985A1 T CC O
additionally DE102007054985A1 T RB O
vitamin DE102007054985A1 T JJ O
B12 DE102007054985A1 T NNP O
, DE102007054985A1 T , O
vitamin DE102007054985A1 T NN O
B6 DE102007054985A1 T NNP O
, DE102007054985A1 T , O
folic DE102007054985A1 T JJ O
acid DE102007054985A1 T NN O
and DE102007054985A1 T CC O
betaine DE102007054985A1 T NN O
. DE102007054985A1 T . O

Topical DE102007054985A1 A JJ O
product DE102007054985A1 A NN O
( DE102007054985A1 A ( O
I DE102007054985A1 A PRP O
) DE102007054985A1 A ) O
for DE102007054985A1 A IN O
the DE102007054985A1 A DT O
prevention DE102007054985A1 A NN O
and DE102007054985A1 A CC O
treatment DE102007054985A1 A NN O
of DE102007054985A1 A IN O
relapses DE102007054985A1 A NNS O
by DE102007054985A1 A IN O
herpes DE102007054985A1 A NNS O
simplex DE102007054985A1 A JJ O
I DE102007054985A1 A PRP O
, DE102007054985A1 A , O
comprises DE102007054985A1 A VBZ O
histone DE102007054985A1 A NN O
deacetylase DE102007054985A1 A NN O
activator DE102007054985A1 A NN O
comprising DE102007054985A1 A VBG O
resveratrol DE102007054985A1 A NN O
, DE102007054985A1 A , O
quercetin DE102007054985A1 A NN O
and/or DE102007054985A1 A NN O
luteolin DE102007054985A1 A NN O
, DE102007054985A1 A , O
where DE102007054985A1 A WRB O
( DE102007054985A1 A ( O
I DE102007054985A1 A PRP O
) DE102007054985A1 A ) O
further DE102007054985A1 A RBR O
comprises DE102007054985A1 A NNS O
vitamin DE102007054985A1 A VBP O
B12 DE102007054985A1 A NNP O
, DE102007054985A1 A , O
vitamin DE102007054985A1 A NN O
B6 DE102007054985A1 A NNP O
, DE102007054985A1 A , O
folic DE102007054985A1 A JJ O
acid DE102007054985A1 A NN O
and DE102007054985A1 A CC O
betaine DE102007054985A1 A NN O
. DE102007054985A1 A . O

- DE102007054985A1 A : O
ACTIVITY DE102007054985A1 A NN O
: DE102007054985A1 A : O
Virucide DE102007054985A1 A NN O
; DE102007054985A1 A : O
Analgesic DE102007054985A1 A NNP O
; DE102007054985A1 A : O
Antiinflammatory DE102007054985A1 A NNP O
; DE102007054985A1 A : O
Antimicrobial DE102007054985A1 A NNP O
. DE102007054985A1 A . O

- DE102007054985A1 A : O
MECHANISM DE102007054985A1 A NN O
OF DE102007054985A1 A IN O
ACTION DE102007054985A1 A NNP O
: DE102007054985A1 A : O
Histone DE102007054985A1 A CD O
deacetylase DE102007054985A1 A NN O
activator DE102007054985A1 A NN O
. DE102007054985A1 A . O

No DE102007054985A1 A DT O
biological DE102007054985A1 A JJ O
data DE102007054985A1 A NNS O
given DE102007054985A1 A VBN O
. DE102007054985A1 A . O

Targeted WO2013101983A3 T VBN O
self-assembly WO2013101983A3 T RB O
0f WO2013101983A3 T CD O
functionalized WO2013101983A3 T JJ O
carbon WO2013101983A3 T NN O
nanotubes WO2013101983A3 T NNS O
on WO2013101983A3 T IN O
tumors WO2013101983A3 T NNS O
. WO2013101983A3 T . O

Sphingomyelin US20080096845 T NNP O
therapy US20080096845 T NN O
of US20080096845 T IN O
autoimmune US20080096845 T JJ O
disease US20080096845 T NN O
. US20080096845 T . O

The US20080096845 A DT O
combination US20080096845 A NN O
most US20080096845 A RBS O
likely US20080096845 A JJ O
enhances US20080096845 A NNS O
an US20080096845 A DT O
autoimmune US20080096845 A JJ O
disease US20080096845 A NN O
cell US20080096845 A NN O
's US20080096845 A POS O
ability US20080096845 A NN O
to US20080096845 A TO O
undergo US20080096845 A VB O
ceramide-induced US20080096845 A JJ O
apoptosis US20080096845 A NN O
by US20080096845 A IN O
increasing US20080096845 A VBG O
the US20080096845 A DT O
levels US20080096845 A NNS O
of US20080096845 A IN O
sphingomyelin US20080096845 A NN O
in US20080096845 A IN O
all US20080096845 A DT O
cellular US20080096845 A JJ O
compartments US20080096845 A NNS O
, US20080096845 A , O
thereby US20080096845 A RB O
providing US20080096845 A VBG O
sufficient US20080096845 A JJ O
substrate US20080096845 A NN O
for US20080096845 A IN O
activated US20080096845 A JJ O
sphingomyelinase US20080096845 A NN I-UN
. US20080096845 A . O

Acrochordon EP1365781A4 T DT O
alleviation EP1365781A4 T NN O
. EP1365781A4 T . O

Novel US20110257144 T NNP O
dermaceutical US20110257144 T JJ O
cream US20110257144 T NN O
made US20110257144 T VBD O
using US20110257144 T VBG O
sodium US20110257144 T JJ O
fusidate US20110257144 T NN O
. US20110257144 T . O

Cefprozil CN103524533A T NNP O
compound CN103524533A T NN O
, CN103524533A T , O
and CN103524533A T CC O
dispersible CN103524533A T JJ O
tablets CN103524533A T NNS O
, CN103524533A T , O
dry CN103524533A T JJ O
suspension CN103524533A T NN O
and CN103524533A T CC O
preparation CN103524533A T NN O
method CN103524533A T NN O
thereof CN103524533A T NN O
. CN103524533A T . O

Nontoxic US7101908 T NNP O
treatment US7101908 T NN O
for US7101908 T IN O
infections US7101908 T NNS O
from US7101908 T IN O
cytomegalovirus US7101908 T NN O
. US7101908 T . O

Indazole WO2014047662A3 T NNP O
derivatives WO2014047662A3 T NNS O
and WO2014047662A3 T CC O
uses WO2014047662A3 T VBZ O
thereof WO2014047662A3 T NN O
. WO2014047662A3 T . O

The WO2014047662A3 A DT O
compounds WO2014047662A3 A NNS O
of WO2014047662A3 A IN O
the WO2014047662A3 A DT O
invention WO2014047662A3 A NN O
may WO2014047662A3 A MD O
inhibit WO2014047662A3 A VB O
the WO2014047662A3 A DT O
activity WO2014047662A3 A NN O
of WO2014047662A3 A IN O
fungal WO2014047662A3 A NN O
or WO2014047662A3 A CC O
protozoan WO2014047662A3 A NN O
cytochrome WO2014047662A3 A NN O
b WO2014047662A3 A NN O
and/or WO2014047662A3 A JJ O
fungal WO2014047662A3 A NN O
or WO2014047662A3 A CC O
protozoan WO2014047662A3 A NN O
Hsp90 WO2014047662A3 A NNP I-UN
. WO2014047662A3 A . O

Novel CN101234203B T NNP O
medical CN101234203B T JJ O
photosensitive CN101234203B T NN O
agent CN101234203B T NN O
for CN101234203B T IN O
anti-tumor CN101234203B T JJ O
treatment CN101234203B T NN O
and CN101234203B T CC O
preparation CN101234203B T NN O
thereof CN101234203B T NN O
. CN101234203B T . O

Application CN103446094A T NN O
of CN103446094A T IN O
Incarviatone CN103446094A T NNP O
A CN103446094A T NNP O
in CN103446094A T IN O
anti-respiratory CN103446094A T JJ O
syncytial CN103446094A T JJ O
virus CN103446094A T NN O
drug CN103446094A T NN O
. CN103446094A T . O

Combinations US20080027140 T NNS O
of US20080027140 T IN O
Serotonin US20080027140 T NNP O
Reuptake US20080027140 T NNP O
Inhibitors US20080027140 T NNP O
and US20080027140 T CC O
Imidazoline US20080027140 T NNP O
I US20080027140 T PRP O
2 US20080027140 T CD O
Agonists US20080027140 T NNS O
. US20080027140 T . O

N- WO2011135464A3 T NNP O
( WO2011135464A3 T ( O
aminoacyl WO2011135464A3 T NN O
) WO2011135464A3 T ) O
-amino WO2011135464A3 T NN O
compound WO2011135464A3 T NN O
. WO2011135464A3 T . O

The WO2011135464A3 A DT O
invention WO2011135464A3 A NN O
relates WO2011135464A3 A VBZ O
to WO2011135464A3 A TO O
an WO2011135464A3 A DT O
N- WO2011135464A3 A NNP O
( WO2011135464A3 A ( O
aminoacyl WO2011135464A3 A NN O
) WO2011135464A3 A ) O
-amino WO2011135464A3 A NN O
compound WO2011135464A3 A NN O
or WO2011135464A3 A CC O
N- WO2011135464A3 A NNP O
( WO2011135464A3 A ( O
aminoacyl WO2011135464A3 A NN O
) WO2011135464A3 A ) O
-amino WO2011135464A3 A NN O
salt WO2011135464A3 A NN O
, WO2011135464A3 A , O
of WO2011135464A3 A IN O
the WO2011135464A3 A DT O
following WO2011135464A3 A JJ O
formula WO2011135464A3 A NN O
( WO2011135464A3 A ( O
I WO2011135464A3 A PRP O
) WO2011135464A3 A ) O
, WO2011135464A3 A , O
where WO2011135464A3 A WRB O
R1 WO2011135464A3 A NNP O
is WO2011135464A3 A VBZ O
hydrogen WO2011135464A3 A NN O
, WO2011135464A3 A , O
lower WO2011135464A3 A JJR O
alkyl WO2011135464A3 A NN O
or WO2011135464A3 A CC O
carbonyl WO2011135464A3 A NN O
and WO2011135464A3 A CC O
N1 WO2011135464A3 A NNP O
is WO2011135464A3 A VBZ O
a WO2011135464A3 A DT O
NH WO2011135464A3 A NNP O
group WO2011135464A3 A NN O
and WO2011135464A3 A CC O
R2 WO2011135464A3 A NNP O
is WO2011135464A3 A VBZ O
hydrogen WO2011135464A3 A NN O
or WO2011135464A3 A CC O
lower WO2011135464A3 A JJR O
alkyl-phenyl WO2011135464A3 A NN O
or WO2011135464A3 A CC O
aralkyl WO2011135464A3 A NN O
or WO2011135464A3 A CC O
imidazolyl WO2011135464A3 A VB O
alkyl WO2011135464A3 A NN O
or WO2011135464A3 A CC O
indolyl WO2011135464A3 A NN O
alkyl WO2011135464A3 A NN O
, WO2011135464A3 A , O
which WO2011135464A3 A WDT O
may WO2011135464A3 A MD O
be WO2011135464A3 A VB O
substituted WO2011135464A3 A VBN O
by WO2011135464A3 A IN O
lower WO2011135464A3 A JJR O
alkyl WO2011135464A3 A NN O
or WO2011135464A3 A CC O
hydroxy WO2011135464A3 A NN O
or WO2011135464A3 A CC O
alkylhydroxy WO2011135464A3 A NN O
or WO2011135464A3 A CC O
methylene WO2011135464A3 A NN O
dioxy WO2011135464A3 A NN O
or WO2011135464A3 A CC O
mercapto WO2011135464A3 A NN O
or WO2011135464A3 A CC O
alkylmercapto WO2011135464A3 A NN O
or WO2011135464A3 A CC O
amino WO2011135464A3 A NN O
or WO2011135464A3 A CC O
guanidino WO2011135464A3 A NN O
or WO2011135464A3 A CC O
carboxa WO2011135464A3 A NN O
and WO2011135464A3 A CC O
R1 WO2011135464A3 A NNP O
and WO2011135464A3 A CC O
R2 WO2011135464A3 A NNP O
together WO2011135464A3 A RB O
can WO2011135464A3 A MD O
complete WO2011135464A3 A VB O
a WO2011135464A3 A DT O
pyrrolidine WO2011135464A3 A NN O
or WO2011135464A3 A CC O
piperidine WO2011135464A3 A NN O
or WO2011135464A3 A CC O
thiazolidine WO2011135464A3 A NN O
ring WO2011135464A3 A NN O
, WO2011135464A3 A , O
and WO2011135464A3 A CC O
each WO2011135464A3 A DT O
ring WO2011135464A3 A NN O
may WO2011135464A3 A MD O
be WO2011135464A3 A VB O
substituted WO2011135464A3 A VBN O
by WO2011135464A3 A IN O
a WO2011135464A3 A DT O
lower WO2011135464A3 A JJR O
alkyl WO2011135464A3 A NN O
or WO2011135464A3 A CC O
aralkyl WO2011135464A3 A NN O
or WO2011135464A3 A CC O
phenyl WO2011135464A3 A NN O
or WO2011135464A3 A CC O
furyl WO2011135464A3 A NN O
or WO2011135464A3 A CC O
thienyl WO2011135464A3 A NN O
or WO2011135464A3 A CC O
pyridyl WO2011135464A3 A NN O
or WO2011135464A3 A CC O
naphthyl WO2011135464A3 A NN O
, WO2011135464A3 A , O
which WO2011135464A3 A WDT O
in WO2011135464A3 A IN O
turn WO2011135464A3 A NN O
may WO2011135464A3 A MD O
be WO2011135464A3 A VB O
substituted WO2011135464A3 A VBN O
by WO2011135464A3 A IN O
a WO2011135464A3 A DT O
lower WO2011135464A3 A JJR O
alkyl WO2011135464A3 A NN O
or WO2011135464A3 A CC O
hydroxy WO2011135464A3 A VB O
lower WO2011135464A3 A JJR O
alkyl WO2011135464A3 A NN O
or WO2011135464A3 A CC O
mercapto WO2011135464A3 A VB O
lower WO2011135464A3 A JJR O
alkyl WO2011135464A3 A NN O
or WO2011135464A3 A CC O
hydroxy WO2011135464A3 A NN O
or WO2011135464A3 A CC O
lower WO2011135464A3 A JJR O
alkoxy WO2011135464A3 A NN O
or WO2011135464A3 A CC O
alkylene WO2011135464A3 A JJ O
dioxy WO2011135464A3 A NN O
or WO2011135464A3 A CC O
halogen WO2011135464A3 A NN O
or WO2011135464A3 A CC O
nitro WO2011135464A3 A NN O
or WO2011135464A3 A CC O
amino WO2011135464A3 A NN O
or WO2011135464A3 A CC O
lower WO2011135464A3 A JJR O
alkylamino WO2011135464A3 A NN O
or WO2011135464A3 A CC O
acylamino WO2011135464A3 A NN O
, WO2011135464A3 A , O
and WO2011135464A3 A CC O
R3 WO2011135464A3 A NNP O
is WO2011135464A3 A VBZ O
hydrogen WO2011135464A3 A NN O
or WO2011135464A3 A CC O
methyl WO2011135464A3 A NN O
or WO2011135464A3 A CC O
lower WO2011135464A3 A JJR O
alkyl WO2011135464A3 A NN O
and WO2011135464A3 A CC O
R4 WO2011135464A3 A NNP O
is WO2011135464A3 A VBZ O
hydrogen WO2011135464A3 A NN O
or WO2011135464A3 A CC O
alkyl WO2011135464A3 A NN O
or WO2011135464A3 A CC O
is WO2011135464A3 A VBZ O
the WO2011135464A3 A DT O
group WO2011135464A3 A NN O
remaining WO2011135464A3 A VBG O
upon WO2011135464A3 A IN O
exclusion WO2011135464A3 A NN O
of WO2011135464A3 A IN O
R4 WO2011135464A3 A NNP O
from WO2011135464A3 A IN O
the WO2011135464A3 A DT O
formula WO2011135464A3 A NN O
and WO2011135464A3 A CC O
Z WO2011135464A3 A NNP O
is WO2011135464A3 A VBZ O
a WO2011135464A3 A DT O
straight-chain WO2011135464A3 A JJ O
or WO2011135464A3 A CC O
branched WO2011135464A3 A VBN O
alkylene WO2011135464A3 A IN O
that WO2011135464A3 A DT O
can WO2011135464A3 A MD O
contain WO2011135464A3 A VB O
up WO2011135464A3 A RB O
to WO2011135464A3 A TO O
3 WO2011135464A3 A CD O
carbon WO2011135464A3 A NN O
atoms WO2011135464A3 A NNS O
and WO2011135464A3 A CC O
R5 WO2011135464A3 A NNP O
is WO2011135464A3 A VBZ O
nitrogen WO2011135464A3 A JJ O
or WO2011135464A3 A CC O
sulphur WO2011135464A3 A NN O
or WO2011135464A3 A CC O
oxygen WO2011135464A3 A NN O
or WO2011135464A3 A CC O
salts WO2011135464A3 A NNS O
and WO2011135464A3 A CC O
ester WO2011135464A3 A NN O
compounds WO2011135464A3 A NNS O
thereof WO2011135464A3 A NN O
, WO2011135464A3 A , O
where WO2011135464A3 A WRB O
A WO2011135464A3 A NNP O
is WO2011135464A3 A VBZ O
an WO2011135464A3 A DT O
ester WO2011135464A3 A NN O
or WO2011135464A3 A CC O
A WO2011135464A3 A NNP O
is WO2011135464A3 A VBZ O
a WO2011135464A3 A DT O
sodium WO2011135464A3 A NN O
or WO2011135464A3 A CC O
potassium WO2011135464A3 A NN O
salt WO2011135464A3 A NN O
of WO2011135464A3 A IN O
arginate WO2011135464A3 A JJ O
and/or WO2011135464A3 A NN O
of WO2011135464A3 A IN O
ornitrate WO2011135464A3 A JJ O
and/or WO2011135464A3 A NN O
of WO2011135464A3 A IN O
asparaginate WO2011135464A3 A NN O
, WO2011135464A3 A , O
that WO2011135464A3 A WDT O
is WO2011135464A3 A VBZ O
, WO2011135464A3 A , O
a WO2011135464A3 A DT O
sodium WO2011135464A3 A NN O
arginate WO2011135464A3 A NN O
and/or WO2011135464A3 A VBZ O
a WO2011135464A3 A DT O
potassium WO2011135464A3 A NN O
arginate WO2011135464A3 A NN O
and/or WO2011135464A3 A VBZ O
a WO2011135464A3 A DT O
sodium WO2011135464A3 A NN O
ornitrate WO2011135464A3 A NN O
and/or WO2011135464A3 A VBZ O
a WO2011135464A3 A DT O
potassium WO2011135464A3 A NN O
ornitrate WO2011135464A3 A NN O
and/or WO2011135464A3 A VBZ O
a WO2011135464A3 A DT O
sodium WO2011135464A3 A NN O
asparaginate WO2011135464A3 A NN O
and/or WO2011135464A3 A VBZ O
a WO2011135464A3 A DT O
potassium WO2011135464A3 A NN O
asparaginate WO2011135464A3 A NN O
or WO2011135464A3 A CC O
A WO2011135464A3 A NNP O
is WO2011135464A3 A VBZ O
an WO2011135464A3 A DT O
amino WO2011135464A3 A JJ O
acid WO2011135464A3 A NN O
. WO2011135464A3 A . O

Application CN102349888A T NN O
of CN102349888A T IN O
atractylodin CN102349888A T JJ O
alcohol CN102349888A T NN O
in CN102349888A T IN O
medicament CN102349888A T JJ O
preparation CN102349888A T NN O
. CN102349888A T . O

The CN102349888A A DT O
CZSC CN102349888A A NNP O
has CN102349888A A VBZ O
remarkable CN102349888A A JJ O
effects CN102349888A A NNS O
of CN102349888A A IN O
regulating CN102349888A A VBG O
nucleoprotein CN102349888A A JJ I-UN
gene CN102349888A A NN O
expression CN102349888A A NN O
of CN102349888A A IN O
the CN102349888A A DT O
PRRSV CN102349888A A NNP O
down CN102349888A A RB O
and CN102349888A A CC O
inhibiting CN102349888A A VBG O
virus CN102349888A A JJ O
proliferation CN102349888A A NN O
; CN102349888A A : O
and CN102349888A A CC O
in CN102349888A A IN O
vitro CN102349888A A JJ O
cellular CN102349888A A JJ O
pharmacological CN102349888A A JJ O
tests CN102349888A A NNS O
shows CN102349888A A VBZ O
that CN102349888A A IN O
the CN102349888A A DT O
CZSC CN102349888A A NNP O
has CN102349888A A VBZ O
definite CN102349888A A VBN O
anti-virus CN102349888A A JJ O
effect CN102349888A A NN O
. CN102349888A A . O

Ointment CN102512462A T NN O
for CN102512462A T IN O
treating CN102512462A T VBG O
rhinitis CN102512462A T NN O
. CN102512462A T . O

Non-peptidic WO2007117398B1 T JJ O
molecules WO2007117398B1 T NNS O
for WO2007117398B1 T IN O
detecting WO2007117398B1 T VBG O
and WO2007117398B1 T CC O
treating WO2007117398B1 T VBG O
tumors WO2007117398B1 T NNS O
. WO2007117398B1 T . O

One WO2007117398B1 A CD O
of WO2007117398B1 A IN O
the WO2007117398B1 A DT O
most WO2007117398B1 A RBS O
universal WO2007117398B1 A JJ O
characteristics WO2007117398B1 A NNS O
of WO2007117398B1 A IN O
malignant WO2007117398B1 A JJ O
tumors WO2007117398B1 A NNS O
is WO2007117398B1 A VBZ O
their WO2007117398B1 A PRP$ O
acidity WO2007117398B1 A NN O
. WO2007117398B1 A . O

Onco-tools WO2007117398B1 A NNS O
are WO2007117398B1 A VBP O
small WO2007117398B1 A JJ O
non-peptide WO2007117398B1 A JJ O
synthetic WO2007117398B1 A JJ O
molecules WO2007117398B1 A NNS O
designed WO2007117398B1 A VBN O
to WO2007117398B1 A TO O
exploit WO2007117398B1 A VB O
this WO2007117398B1 A DT O
acidity WO2007117398B1 A NN O
for WO2007117398B1 A IN O
early WO2007117398B1 A JJ O
detection WO2007117398B1 A NN O
and WO2007117398B1 A CC O
destruction WO2007117398B1 A NN O
of WO2007117398B1 A IN O
tumors WO2007117398B1 A NNS O
. WO2007117398B1 A . O

Each WO2007117398B1 A DT O
onco-tool WO2007117398B1 A NN O
has WO2007117398B1 A VBZ O
a WO2007117398B1 A DT O
structure WO2007117398B1 A NN O
which WO2007117398B1 A WDT O
is WO2007117398B1 A VBZ O
anionic WO2007117398B1 A JJ O
and WO2007117398B1 A CC O
hydrophilic WO2007117398B1 A JJ O
at WO2007117398B1 A IN O
pH WO2007117398B1 A JJ O
7.4 WO2007117398B1 A CD O
and WO2007117398B1 A CC O
so WO2007117398B1 A RB O
repels WO2007117398B1 A NNS O
from WO2007117398B1 A IN O
the WO2007117398B1 A DT O
negatively-charged WO2007117398B1 A JJ O
surfaces WO2007117398B1 A NNS O
of WO2007117398B1 A IN O
cells WO2007117398B1 A NNS O
in WO2007117398B1 A IN O
normal WO2007117398B1 A JJ O
tissues WO2007117398B1 A NNS O
. WO2007117398B1 A . O

When WO2007117398B1 A WRB O
an WO2007117398B1 A DT O
onco-tool WO2007117398B1 A JJ O
enters WO2007117398B1 A NNS O
an WO2007117398B1 A DT O
acidic WO2007117398B1 A JJ O
environment WO2007117398B1 A NN O
, WO2007117398B1 A , O
such WO2007117398B1 A JJ O
as WO2007117398B1 A IN O
in WO2007117398B1 A IN O
a WO2007117398B1 A DT O
tumor WO2007117398B1 A NN O
, WO2007117398B1 A , O
a WO2007117398B1 A DT O
portion WO2007117398B1 A NN O
of WO2007117398B1 A IN O
the WO2007117398B1 A DT O
onco-tool WO2007117398B1 A JJ O
molecules WO2007117398B1 A NNS O
switch WO2007117398B1 A VBP O
to WO2007117398B1 A TO O
their WO2007117398B1 A PRP$ O
non-ionic WO2007117398B1 A JJ O
lipophilic WO2007117398B1 A JJ O
form WO2007117398B1 A NN O
which WO2007117398B1 A WDT O
is WO2007117398B1 A VBZ O
designed WO2007117398B1 A VBN O
to WO2007117398B1 A TO O
enter WO2007117398B1 A VB O
cells WO2007117398B1 A NNS O
, WO2007117398B1 A , O
such WO2007117398B1 A JJ O
as WO2007117398B1 A IN O
cells WO2007117398B1 A NNS O
in WO2007117398B1 A IN O
acidic WO2007117398B1 A JJ O
areas WO2007117398B1 A NNS O
of WO2007117398B1 A IN O
tumors WO2007117398B1 A NNS O
. WO2007117398B1 A . O

Prior WO2007117398B1 A RB O
to WO2007117398B1 A TO O
use WO2007117398B1 A VB O
of WO2007117398B1 A IN O
an WO2007117398B1 A DT O
onco-tool WO2007117398B1 A JJ O
, WO2007117398B1 A , O
a WO2007117398B1 A DT O
selected WO2007117398B1 A VBN O
radioisotope WO2007117398B1 A NN O
is WO2007117398B1 A VBZ O
linked WO2007117398B1 A VBN O
to WO2007117398B1 A TO O
the WO2007117398B1 A DT O
onco-tool WO2007117398B1 A NN O
. WO2007117398B1 A . O

If WO2007117398B1 A IN O
that WO2007117398B1 A DT O
radioisotope WO2007117398B1 A VBP O
emits WO2007117398B1 A NNS O
radiation WO2007117398B1 A NN O
which WO2007117398B1 A WDT O
can WO2007117398B1 A MD O
be WO2007117398B1 A VB O
detected WO2007117398B1 A VBN O
outside WO2007117398B1 A IN O
the WO2007117398B1 A DT O
body WO2007117398B1 A NN O
, WO2007117398B1 A , O
then WO2007117398B1 A RB O
the WO2007117398B1 A DT O
onco-tool WO2007117398B1 A NN O
can WO2007117398B1 A MD O
serve WO2007117398B1 A VB O
for WO2007117398B1 A IN O
detecting WO2007117398B1 A VBG O
tumors WO2007117398B1 A NNS O
. WO2007117398B1 A . O

If WO2007117398B1 A IN O
that WO2007117398B1 A DT O
radioisotope WO2007117398B1 A VBP O
emits WO2007117398B1 A VBZ O
radiation WO2007117398B1 A NN O
effective WO2007117398B1 A JJ O
to WO2007117398B1 A TO O
kill WO2007117398B1 A VB O
cells WO2007117398B1 A NNS O
, WO2007117398B1 A , O
then WO2007117398B1 A RB O
the WO2007117398B1 A DT O
onco-tool WO2007117398B1 A NN O
can WO2007117398B1 A MD O
serve WO2007117398B1 A VB O
for WO2007117398B1 A IN O
treating WO2007117398B1 A VBG O
tumors WO2007117398B1 A NNS O
. WO2007117398B1 A . O

Nasal CA2799881A1 T NNP O
wash CA2799881A1 T JJ O
solution CA2799881A1 T NN O
. CA2799881A1 T . O

Synthetic US20100222432 T JJ O
Carbon US20100222432 T NNP O
Nanotubes US20100222432 T NNP O
. US20100222432 T . O

Tyrosine WO2014063631A1 T NNP I-UN
kinase WO2014063631A1 T NN I-UN
irreversible WO2014063631A1 T JJ O
inhibitor WO2014063631A1 T NN O
and WO2014063631A1 T CC O
preparation WO2014063631A1 T NN O
method WO2014063631A1 T NN O
and WO2014063631A1 T CC O
applications WO2014063631A1 T NNS O
thereof WO2014063631A1 T VBP O
. WO2014063631A1 T . O

The WO2014063631A1 A DT O
present WO2014063631A1 A JJ O
invention WO2014063631A1 A NN O
provides WO2014063631A1 A VBZ O
a WO2014063631A1 A DT O
tyrosine WO2014063631A1 A JJ I-UN
kinase WO2014063631A1 A NN I-UN
irreversible WO2014063631A1 A JJ O
inhibitor WO2014063631A1 A NN O
shown WO2014063631A1 A VBN O
in WO2014063631A1 A IN O
formula WO2014063631A1 A NN O
I WO2014063631A1 A PRP O
or WO2014063631A1 A CC O
a WO2014063631A1 A DT O
pharmaceutically WO2014063631A1 A RB O
acceptable WO2014063631A1 A JJ O
salt WO2014063631A1 A NN O
thereof WO2014063631A1 A NN O
, WO2014063631A1 A , O
a WO2014063631A1 A DT O
preparation WO2014063631A1 A NN O
method WO2014063631A1 A NN O
for WO2014063631A1 A IN O
the WO2014063631A1 A DT O
tyrosine WO2014063631A1 A JJ I-UN
kinase WO2014063631A1 A NN I-UN
irreversible WO2014063631A1 A JJ O
inhibitor WO2014063631A1 A NN O
and WO2014063631A1 A CC O
applications WO2014063631A1 A NNS O
of WO2014063631A1 A IN O
the WO2014063631A1 A DT O
tyrosine WO2014063631A1 A JJ I-UN
kinase WO2014063631A1 A NN I-UN
irreversible WO2014063631A1 A JJ O
inhibitor WO2014063631A1 A NN O
. WO2014063631A1 A . O

The WO2014063631A1 A DT O
tyrosine WO2014063631A1 A NN I-UN
kinase WO2014063631A1 A NN I-UN
irreversible WO2014063631A1 A JJ O
inhibitor WO2014063631A1 A NN O
or WO2014063631A1 A CC O
the WO2014063631A1 A DT O
pharmaceutically WO2014063631A1 A RB O
acceptable WO2014063631A1 A JJ O
salt WO2014063631A1 A NN O
thereof WO2014063631A1 A NN O
is WO2014063631A1 A VBZ O
very WO2014063631A1 A RB O
high WO2014063631A1 A JJ O
in WO2014063631A1 A IN O
activity WO2014063631A1 A NN O
of WO2014063631A1 A IN O
inhibiting WO2014063631A1 A VBG O
growth WO2014063631A1 A NN O
of WO2014063631A1 A IN O
cancer WO2014063631A1 A NN O
cells WO2014063631A1 A NNS O
, WO2014063631A1 A , O
and WO2014063631A1 A CC O
is WO2014063631A1 A VBZ O
especially WO2014063631A1 A RB O
remarkable WO2014063631A1 A JJ O
in WO2014063631A1 A IN O
effect WO2014063631A1 A NN O
of WO2014063631A1 A IN O
inhibiting WO2014063631A1 A VBG O
the WO2014063631A1 A DT O
growth WO2014063631A1 A NN O
of WO2014063631A1 A IN O
cancer WO2014063631A1 A NN O
cells WO2014063631A1 A NNS O
with WO2014063631A1 A IN O
high WO2014063631A1 A JJ O
expression WO2014063631A1 A NN O
of WO2014063631A1 A IN O
EGFR WO2014063631A1 A NNP I-UN
and WO2014063631A1 A CC O
HER2 WO2014063631A1 A NNP I-UN
. WO2014063631A1 A . O

Cyclizine CN1562026A T NNP O
hydrochloride CN1562026A T NN O
dripping CN1562026A T VBG O
pill CN1562026A T NN O
and CN1562026A T CC O
its CN1562026A T PRP$ O
preparing CN1562026A T NN O
method CN1562026A T NN O
. CN1562026A T . O

Compositions US20100273858 T NNS O
comprising US20100273858 T VBG O
stat5 US20100273858 T NN I-UN
sirna US20100273858 T NN O
and US20100273858 T CC O
methods US20100273858 T NNS O
of US20100273858 T IN O
use US20100273858 T NN O
thereof US20100273858 T NN O
. US20100273858 T . O

The US20100273858 A DT O
present US20100273858 A JJ O
invention US20100273858 A NN O
provides US20100273858 A VBZ O
nucleic US20100273858 A JJ O
acid US20100273858 A NN O
molecules US20100273858 A NNS O
that US20100273858 A WDT O
inhibit US20100273858 A VBP O
STAT5 US20100273858 A JJ I-UN
expression US20100273858 A NN O
. US20100273858 A . O

Composition WO2014020031A1 T NN O
comprising WO2014020031A1 T VBG O
a WO2014020031A1 T DT O
sucrose WO2014020031A1 T JJ O
octasulphate WO2014020031A1 T NN O
and WO2014020031A1 T CC O
a WO2014020031A1 T DT O
specific WO2014020031A1 T JJ O
emollient WO2014020031A1 T NN O
. WO2014020031A1 T . O

Chemical US20080312206 T NNP O
Compounds-149 US20080312206 T NNP O
. US20080312206 T . O

The US20080312206 A DT O
invention US20080312206 A NN O
relates US20080312206 A VBZ O
to US20080312206 A TO O
chemical US20080312206 A VB O
compounds US20080312206 A NNS O
, US20080312206 A , O
or US20080312206 A CC O
pharmaceutically US20080312206 A RB O
acceptable US20080312206 A JJ O
salts US20080312206 A NNS O
thereof US20080312206 A NN O
of US20080312206 A IN O
the US20080312206 A DT O
formula US20080312206 A NN O
which US20080312206 A WDT O
possess US20080312206 A NN O
CSF US20080312206 A NNP I-UN
1R US20080312206 A CD I-UN
kinase US20080312206 A NN O
inhibitory US20080312206 A NN O
activity US20080312206 A NN O
and US20080312206 A CC O
are US20080312206 A VBP O
accordingly US20080312206 A RB O
useful US20080312206 A JJ O
for US20080312206 A IN O
their US20080312206 A PRP$ O
anti US20080312206 A JJ O
cancer US20080312206 A NN O
activity US20080312206 A NN O
and US20080312206 A CC O
thus US20080312206 A RB O
in US20080312206 A IN O
methods US20080312206 A NNS O
of US20080312206 A IN O
treatment US20080312206 A NN O
of US20080312206 A IN O
the US20080312206 A DT O
human US20080312206 A NN O
or US20080312206 A CC O
animal US20080312206 A NN O
body US20080312206 A NN O
. US20080312206 A . O

SOLUBLE WO2005012352A1 T NNP O
HUMAN WO2005012352A1 T NNP O
INTERLEUKIN WO2005012352A1 T NNP O
18 WO2005012352A1 T CD O
RECEPTOR-α WO2005012352A1 T NNP O
, WO2005012352A1 T , O
METHOD WO2005012352A1 T NNP O
OF WO2005012352A1 T NNP O
ASSAYING WO2005012352A1 T NNP O
THE WO2005012352A1 T NNP O
SAME WO2005012352A1 T NNP O
, WO2005012352A1 T , O
ASSAY WO2005012352A1 T NNP O
KIT WO2005012352A1 T NNP O
AND WO2005012352A1 T NNP O
MEDICINAL WO2005012352A1 T NNP O
COMPOSITION WO2005012352A1 T NNP O
. WO2005012352A1 T . O

Application CN103356651A T NN O
of CN103356651A T IN O
Chukrasone CN103356651A T NNP O
A CN103356651A T NNP O
in CN103356651A T IN O
preparing CN103356651A T VBG O
medicines CN103356651A T NNS O
for CN103356651A T IN O
treating CN103356651A T VBG O
yellow CN103356651A T JJ O
fever CN103356651A T NN O
virus CN103356651A T NN O
infection CN103356651A T NN O
. CN103356651A T . O

The CN103356651A A DT O
invention CN103356651A A NN O
discloses CN103356651A A VBZ O
an CN103356651A A DT O
application CN103356651A A NN O
of CN103356651A A IN O
Chukrasone CN103356651A A NNP O
A CN103356651A A NNP O
in CN103356651A A IN O
preparing CN103356651A A VBG O
medicines CN103356651A A NNS O
for CN103356651A A IN O
treating CN103356651A A VBG O
or CN103356651A A CC O
preventing CN103356651A A VBG O
yellow CN103356651A A JJ O
fever CN103356651A A NN O
virus CN103356651A A NN O
infection CN103356651A A NN O
. CN103356651A A . O

The CN103356651A A DT O
Chukrasone CN103356651A A NNP O
A CN103356651A A NNP O
can CN103356651A A MD O
effectively CN103356651A A RB O
inhibit CN103356651A A VB O
proliferation CN103356651A A NN O
of CN103356651A A IN O
yellow CN103356651A A JJ O
fever CN103356651A A NN O
virus CN103356651A A NN O
but CN103356651A A CC O
is CN103356651A A VBZ O
small CN103356651A A JJ O
in CN103356651A A IN O
cytotoxicity CN103356651A A NN O
, CN103356651A A , O
so CN103356651A A IN O
that CN103356651A A IN O
the CN103356651A A DT O
Chukrasone CN103356651A A NNP O
A CN103356651A A NNP O
can CN103356651A A MD O
be CN103356651A A VB O
further CN103356651A A RB O
developed CN103356651A A VBN O
to CN103356651A A TO O
medicines CN103356651A A NNS O
for CN103356651A A IN O
treating CN103356651A A VBG O
diseases CN103356651A A NNS O
caused CN103356651A A VBN O
by CN103356651A A IN O
the CN103356651A A DT O
virus CN103356651A A NN O
infection CN103356651A A NN O
, CN103356651A A , O
and CN103356651A A CC O
has CN103356651A A VBZ O
a CN103356651A A DT O
wide CN103356651A A JJ O
application CN103356651A A NN O
prospect CN103356651A A NN O
. CN103356651A A . O

The CN103356651A A DT O
use CN103356651A A NN O
of CN103356651A A IN O
the CN103356651A A DT O
Chukrasone CN103356651A A NNP O
A CN103356651A A NNP O
for CN103356651A A IN O
preparing CN103356651A A VBG O
medicines CN103356651A A NNS O
for CN103356651A A IN O
treating CN103356651A A VBG O
yellow CN103356651A A JJ O
fever CN103356651A A NN O
virus CN103356651A A NN O
infection CN103356651A A NN O
provided CN103356651A A VBN O
by CN103356651A A IN O
the CN103356651A A DT O
invention CN103356651A A NN O
is CN103356651A A VBZ O
disclosed CN103356651A A VBN O
for CN103356651A A IN O
the CN103356651A A DT O
first CN103356651A A JJ O
time CN103356651A A NN O
. CN103356651A A . O

As CN103356651A A IN O
the CN103356651A A DT O
framework CN103356651A A NN O
type CN103356651A A NN O
belongs CN103356651A A VBZ O
to CN103356651A A TO O
a CN103356651A A DT O
brand-new CN103356651A A JJ O
framework CN103356651A A NN O
type CN103356651A A NN O
, CN103356651A A , O
and CN103356651A A CC O
the CN103356651A A DT O
inhibitory CN103356651A A JJ O
activity CN103356651A A NN O
of CN103356651A A IN O
the CN103356651A A DT O
Chukrasone CN103356651A A NNP O
A CN103356651A A NNP O
to CN103356651A A TO O
yellow CN103356651A A VB O
fever CN103356651A A RB O
virus CN103356651A A JJ O
infection CN103356651A A NN O
is CN103356651A A VBZ O
unimaginably CN103356651A A RB O
strong CN103356651A A JJ O
, CN103356651A A , O
the CN103356651A A DT O
probability CN103356651A A NN O
of CN103356651A A IN O
giving CN103356651A A VBG O
any CN103356651A A DT O
enlightenment CN103356651A A NN O
by CN103356651A A IN O
other CN103356651A A JJ O
compounds CN103356651A A NNS O
does CN103356651A A VBZ O
not CN103356651A A RB O
exist CN103356651A A VB O
. CN103356651A A . O

The CN103356651A A DT O
Chukrasone CN103356651A A NNP O
A CN103356651A A NNP O
has CN103356651A A VBZ O
remarkable CN103356651A A JJ O
substantial CN103356651A A JJ O
characteristics CN103356651A A NNS O
and CN103356651A A CC O
meanwhile CN103356651A A NN O
has CN103356651A A VBZ O
remarkable CN103356651A A JJ O
progress CN103356651A A NN O
for CN103356651A A IN O
preventing CN103356651A A VBG O
and CN103356651A A CC O
treating CN103356651A A VBG O
yellow CN103356651A A JJ O
fever CN103356651A A NN O
virus CN103356651A A NN O
infection CN103356651A A NN O
. CN103356651A A . O

Conjugate CA2410526C T NNP O
addition CA2410526C T NN O
reactions CA2410526C T NNS O
for CA2410526C T IN O
the CA2410526C T DT O
controlled CA2410526C T JJ O
delivery CA2410526C T NN O
of CA2410526C T IN O
pharmaceutically CA2410526C T RB O
active CA2410526C T JJ O
compounds CA2410526C T NNS O
. CA2410526C T . O

Hydroxyphenyl-piperazinyl-methyl-benzamide EP1278740B1 T JJ O
derivatives EP1278740B1 T NNS O
for EP1278740B1 T IN O
the EP1278740B1 T DT O
treatment EP1278740B1 T NN O
of EP1278740B1 T IN O
pain EP1278740B1 T NN O
. EP1278740B1 T . O

Breast CN101579347A T NNP O
perfusion CN101579347A T NN O
preparation CN101579347A T NN O
for CN101579347A T IN O
treating CN101579347A T VBG O
mammitis CN101579347A T NN O
of CN101579347A T IN O
milk CN101579347A T NN O
cow CN101579347A T NN O
in CN101579347A T IN O
lactation CN101579347A T NN O
period CN101579347A T NN O
and CN101579347A T CC O
preparation CN101579347A T NN O
method CN101579347A T NN O
thereof CN101579347A T NN O
. CN101579347A T . O

Sustained US20100120887 T VBN O
release US20100120887 T NN O
formulation US20100120887 T NN O
of US20100120887 T IN O
melatonin US20100120887 T NN O
. US20100120887 T . O

The US20100120887 A DT O
present US20100120887 A JJ O
invention US20100120887 A NN O
relates US20100120887 A VBZ O
to US20100120887 A TO O
low-dose US20100120887 A JJ O
formulations US20100120887 A NNS O
of US20100120887 A IN O
melatonin US20100120887 A NN O
, US20100120887 A , O
and US20100120887 A CC O
methods US20100120887 A NNS O
of US20100120887 A IN O
use US20100120887 A NN O
thereof US20100120887 A NN O
, US20100120887 A , O
which US20100120887 A WDT O
provide US20100120887 A VBP O
a US20100120887 A DT O
sustained US20100120887 A JJ O
release US20100120887 A NN O
of US20100120887 A IN O
melatonin US20100120887 A NN O
so US20100120887 A RB O
as US20100120887 A IN O
to US20100120887 A TO O
rapidly US20100120887 A RB O
increase US20100120887 A VB O
plasma US20100120887 A NN O
levels US20100120887 A NNS O
of US20100120887 A IN O
melatonin US20100120887 A NN O
, US20100120887 A , O
maintain US20100120887 A VBP O
a US20100120887 A DT O
relatively US20100120887 A RB O
high US20100120887 A JJ O
level US20100120887 A NN O
( US20100120887 A ( O
which US20100120887 A WDT O
mimics US20100120887 A VBZ O
the US20100120887 A DT O
endogenous US20100120887 A JJ O
level US20100120887 A NN O
of US20100120887 A IN O
a US20100120887 A DT O
young US20100120887 A JJ O
subject US20100120887 A NN O
) US20100120887 A ) O
for US20100120887 A IN O
approximately US20100120887 A RB O
5-6 US20100120887 A JJ O
hours US20100120887 A NNS O
, US20100120887 A , O
and US20100120887 A CC O
then US20100120887 A RB O
decrease US20100120887 A VB O
so US20100120887 A RB O
as US20100120887 A IN O
to US20100120887 A TO O
achieve US20100120887 A VB O
low US20100120887 A JJ O
levels US20100120887 A NNS O
by US20100120887 A IN O
early US20100120887 A JJ O
morning US20100120887 A NN O
( US20100120887 A ( O
rapid US20100120887 A JJ O
washout US20100120887 A NN O
) US20100120887 A ) O
, US20100120887 A , O
thereby US20100120887 A RB O
avoiding US20100120887 A VBG O
a US20100120887 A DT O
“hangover US20100120887 A NN O
effect” US20100120887 A NN O
. US20100120887 A . O

The US20100120887 A DT O
sustained US20100120887 A JJ O
release US20100120887 A NN O
formulations US20100120887 A NNS O
of US20100120887 A IN O
the US20100120887 A DT O
invention US20100120887 A NN O
may US20100120887 A MD O
be US20100120887 A VB O
used US20100120887 A VBN O
to US20100120887 A TO O
treat US20100120887 A VB O
a US20100120887 A DT O
variety US20100120887 A NN O
of US20100120887 A IN O
sleep-related US20100120887 A JJ O
disorders US20100120887 A NNS O
, US20100120887 A , O
including US20100120887 A VBG O
, US20100120887 A , O
but US20100120887 A CC O
not US20100120887 A RB O
limited US20100120887 A JJ O
to US20100120887 A TO O
, US20100120887 A , O
delayed US20100120887 A VBN O
onset US20100120887 A NN O
and US20100120887 A CC O
maintenance US20100120887 A NN O
forms US20100120887 A NNS O
of US20100120887 A IN O
insomnia US20100120887 A NN O
. US20100120887 A . O

Pharmaceutical WO2013085352A1 T JJ O
composition WO2013085352A1 T NN O
comprising WO2013085352A1 T VBG O
diaminodiphenylsulfone WO2013085352A1 T NN O
or WO2013085352A1 T CC O
the WO2013085352A1 T DT O
pharmaceutically WO2013085352A1 T RB O
acceptable WO2013085352A1 T JJ O
salts WO2013085352A1 T NNS O
thereof WO2013085352A1 T NN O
for WO2013085352A1 T IN O
preventing WO2013085352A1 T VBG O
or WO2013085352A1 T CC O
treating WO2013085352A1 T VBG O
diseases WO2013085352A1 T NNS O
associated WO2013085352A1 T VBN O
with WO2013085352A1 T IN O
decrease WO2013085352A1 T NN O
in WO2013085352A1 T IN O
bone WO2013085352A1 T NN O
mass WO2013085352A1 T NN O
. WO2013085352A1 T . O

Methods US20120052062 T NNS O
for US20120052062 T IN O
Treatment US20120052062 T NNP O
of US20120052062 T IN O
Non-Small US20120052062 T NNP O
Cell US20120052062 T NNP O
Lung US20120052062 T NNP O
Cancer US20120052062 T NNP O
. US20120052062 T . O

The US20120052062 A DT O
present US20120052062 A JJ O
invention US20120052062 A NN O
provides US20120052062 A VBZ O
methods US20120052062 A NNS O
of US20120052062 A IN O
treating US20120052062 A VBG O
non-small US20120052062 A JJ O
cell US20120052062 A NN O
lung US20120052062 A NN O
cancer US20120052062 A NN O
by US20120052062 A IN O
administering US20120052062 A VBG O
to US20120052062 A TO O
a US20120052062 A DT O
subject US20120052062 A NN O
in US20120052062 A IN O
need US20120052062 A NN O
thereof US20120052062 A VBP O
a US20120052062 A DT O
therapeutically US20120052062 A RB O
effective US20120052062 A JJ O
amount US20120052062 A NN O
of US20120052062 A IN O
a US20120052062 A DT O
pyrroloquinolinyl-pyrrole-2,5-dione US20120052062 A JJ O
compound US20120052062 A NN O
in US20120052062 A IN O
combination US20120052062 A NN O
with US20120052062 A IN O
a US20120052062 A DT O
therapeutically US20120052062 A RB O
effective US20120052062 A JJ O
amount US20120052062 A NN O
of US20120052062 A IN O
an US20120052062 A DT O
epidermal US20120052062 A JJ I-UN
growth US20120052062 A NN I-UN
factor US20120052062 A NN I-UN
tyrosine US20120052062 A JJ I-UN
kinase US20120052062 A NN I-UN
inhibitor US20120052062 A NN O

Methods US20090074754 T NNS O
and US20090074754 T CC O
compositions US20090074754 T NNS O
useful US20090074754 T JJ O
in US20090074754 T IN O
the US20090074754 T DT O
treatment US20090074754 T NN O
of US20090074754 T IN O
mucositis US20090074754 T NN O
. US20090074754 T . O

Method CN101538299A T NNP O
for CN101538299A T IN O
synthesizing CN101538299A T VBG O
5,6,4'-trihydroxyflavone-7-O-D-glucuronic CN101538299A T JJ O
acid CN101538299A T NN O
. CN101538299A T . O

Composition EP1411986B1 T NN O
comprising EP1411986B1 T VBG O
epigallocatechin EP1411986B1 T JJ O
gallate EP1411986B1 T NN O
. EP1411986B1 T . O

Pharmaceutical WO2014132215A1 T JJ O
compositions WO2014132215A1 T NNS O
of WO2014132215A1 T IN O
donepezil WO2014132215A1 T NN O
having WO2014132215A1 T VBG O
specific WO2014132215A1 T JJ O
in WO2014132215A1 T IN O
vitro WO2014132215A1 T JJ O
dissolution WO2014132215A1 T NN O
profile WO2014132215A1 T NN O
or WO2014132215A1 T CC O
pharmacokinetics WO2014132215A1 T NNS O
parameters WO2014132215A1 T NNS O
. WO2014132215A1 T . O

Taste-masked WO2013143688A1 T JJ O
ibuprofen WO2013143688A1 T NN O
granules WO2013143688A1 T NNS O
. WO2013143688A1 T . O

Application CN101214233A T NN O
of CN101214233A T IN O
sodium CN101214233A T NN O
iodoacetate CN101214233A T NN O
in CN101214233A T IN O
preparing CN101214233A T VBG O
medicament CN101214233A T NN O
for CN101214233A T IN O
treating CN101214233A T VBG O
malignant CN101214233A T JJ O
tumor CN101214233A T NN O
. CN101214233A T . O

Topical EP2301525A1 T JJ O
ibuprofen EP2301525A1 T NN O
formulation EP2301525A1 T NN O
. EP2301525A1 T . O

Novel CN101890150A T NNP O
and CN101890150A T CC O
special CN101890150A T JJ O
Likexiao CN101890150A T NNP O
. CN101890150A T . O

Methods US20100016253 T NNS O
and US20100016253 T CC O
compositions US20100016253 T NNS O
related US20100016253 T VBN O
to US20100016253 T TO O
heightened US20100016253 T VBN O
apobec-1 US20100016253 T RB I-UN
related US20100016253 T JJ O
protein US20100016253 T NN O
( US20100016253 T ( O
arp US20100016253 T JJ O
) US20100016253 T ) O
expression US20100016253 T NN O
. US20100016253 T . O

Complex CN101157689A T NNP O
salt CN101157689A T NN O
of CN101157689A T IN O
Silybin CN101157689A T NNP O
and CN101157689A T CC O
oxymatrine CN101157689A T NN O
or CN101157689A T CC O
matrine CN101157689A T NN O
and CN101157689A T CC O
uses CN101157689A T VBZ O
thereof CN101157689A T NN O
. CN101157689A T . O

Treatment US6943192 T JJ O
regimen US6943192 T NNS O
for US6943192 T IN O
administration US6943192 T NN O
of US6943192 T IN O
phenylacetylglutamine US6943192 T NN O
, US6943192 T , O
phenylacetylisoglutamine US6943192 T NN O
, US6943192 T , O
and/or US6943192 T JJ O
phenylacetate US6943192 T NN O
. US6943192 T . O

Administrating US7745455 T VBG O
a US7745455 T DT O
first US7745455 T JJ O
cytidine US7745455 T NN O
analogue US7745455 T NN O
reverse US7745455 T NN I-UN
transcriptase US7745455 T NN I-UN
inhibitor US7745455 T NN O
concurrently US7745455 T RB O
with US7745455 T IN O
deoxycytidine US7745455 T NN O
; US7745455 T : O
increasing US7745455 T VBG O
the US7745455 T DT O
antiretroviral US7745455 T JJ O
activity US7745455 T NN O
of US7745455 T IN O
the US7745455 T DT O
first US7745455 T JJ O
analogue US7745455 T NN O
; US7745455 T : O
HIV US7745455 T NNP O
treatment US7745455 T NN O
. US7745455 T . O

Boosted US7745455 A VBN O
cytidine US7745455 A NN O
analogue US7745455 A NN O
reverse US7745455 A NN O
transcriptase US7745455 A NN O
inhibitor US7745455 A NN O
antiretroviral US7745455 A JJ O
compound US7745455 A NN O
is US7745455 A VBZ O
a US7745455 A DT O
new US7745455 A JJ O
therapeutic US7745455 A JJ O
anti US7745455 A NN O
HIV US7745455 A NNP O
option US7745455 A NN O
, US7745455 A , O
in US7745455 A IN O
combination US7745455 A NN O
with US7745455 A IN O
another US7745455 A DT O
drug US7745455 A NN O
such US7745455 A JJ O
as US7745455 A IN O
a US7745455 A DT O
NRTI US7745455 A NNP O
or US7745455 A CC O
a US7745455 A DT O
protease US7745455 A NN I-UN
inhibitor US7745455 A NN O
. US7745455 A . O

Boosted US7745455 A VBN O
cytidine US7745455 A NN O
analogue US7745455 A NN O
reverse US7745455 A NN I-UN
transcriptase US7745455 A NN I-UN
inhibitor US7745455 A NN O
antiretroviral US7745455 A JJ O
compound US7745455 A NN O
could US7745455 A MD O
also US7745455 A RB O
be US7745455 A VB O
formulated US7745455 A VBN O
in US7745455 A IN O
combination US7745455 A NN O
with US7745455 A IN O
another US7745455 A DT O
drug US7745455 A NN O
such US7745455 A JJ O
as US7745455 A IN O
another US7745455 A DT O
NRTI US7745455 A NNP O
( US7745455 A ( O
e.g US7745455 A NN O
. US7745455 A . O

abacavir US7745455 A NN O
) US7745455 A ) O
or US7745455 A CC O
any US7745455 A DT O
protease US7745455 A JJ I-UN
inhibitor US7745455 A NN O
in US7745455 A IN O
the US7745455 A DT O
same US7745455 A JJ O
capsule US7745455 A NN O
or US7745455 A CC O
tablet US7745455 A NN O
. US7745455 A . O

This US7745455 A DT O
new US7745455 A JJ O
formulation US7745455 A NN O
is US7745455 A VBZ O
convenient US7745455 A JJ O
and US7745455 A CC O
well US7745455 A RB O
tolerated US7745455 A VBN O
with US7745455 A IN O
no US7745455 A DT O
additional US7745455 A JJ O
toxicity US7745455 A NN O
than US7745455 A IN O
that US7745455 A DT O
of US7745455 A IN O
the US7745455 A DT O
combining US7745455 A VBG O
drug US7745455 A NN O
( US7745455 A ( O
NRTI US7745455 A NNP O
or US7745455 A CC O
protease US7745455 A VB I-UN
inhibitor US7745455 A NN O
) US7745455 A ) O
and US7745455 A CC O
3TC US7745455 A CD O
. US7745455 A . O

Composition CN103585159A T NN O
with CN103585159A T IN O
hypoglycemic CN103585159A T JJ O
effect CN103585159A T NN O
, CN103585159A T , O
and CN103585159A T CC O
preparation CN103585159A T NN O
and CN103585159A T CC O
drug CN103585159A T NN O
thereof CN103585159A T NN O
. CN103585159A T . O

4-alkyl-6-aryl-5-acetyl-1 CN102070565A T JJ O
, CN102070565A T , O
3-thiazine CN102070565A T JJ O
, CN102070565A T , O
and CN102070565A T CC O
preparation CN102070565A T NN O
method CN102070565A T NN O
and CN102070565A T CC O
application CN102070565A T NN O
thereof CN102070565A T NN O
. CN102070565A T . O

Application CN101036669A T NN O
of CN101036669A T IN O
Li2WO4 CN101036669A T NNP O
in CN101036669A T IN O
preparing CN101036669A T VBG O
medicine CN101036669A T NN O
. CN101036669A T . O

By CN101036669A A IN O
inhibiting CN101036669A A VBG O
activity CN101036669A A NN O
of CN101036669A A IN O
a CN101036669A A DT O
GSK-3 CN101036669A A NNP I-UN
alpha CN101036669A A NN I-UN
, CN101036669A A , O
generation CN101036669A A NN O
of CN101036669A A IN O
the CN101036669A A DT O
A CN101036669A A NNP I-UN
beta CN101036669A A NN I-UN
is CN101036669A A VBZ O
reduced CN101036669A A VBN O
to CN101036669A A TO O
decrease CN101036669A A VB O
SP CN101036669A A NNP O
; CN101036669A A : O
by CN101036669A A IN O
inhibiting CN101036669A A VBG O
activity CN101036669A A NN O
of CN101036669A A IN O
a CN101036669A A DT O
GSK-3 CN101036669A A NNP I-UN
beta CN101036669A A NN I-UN
, CN101036669A A , O
hyperphosphorylation CN101036669A A NN O
of CN101036669A A IN O
tau CN101036669A A NN I-UN
protein CN101036669A A NN I-UN
is CN101036669A A VBZ O
inhibitted CN101036669A A VBN O
to CN101036669A A TO O
reduce CN101036669A A VB O
NFT CN101036669A A NNP O
. CN101036669A A . O

Thereby CN101036669A A RB O
, CN101036669A A , O
survival CN101036669A A NN O
and CN101036669A A CC O
wound CN101036669A A NN O
repair CN101036669A A NN O
of CN101036669A A IN O
neurocyte CN101036669A A NN O
are CN101036669A A VBP O
promoted CN101036669A A VBN O
even CN101036669A A RB O
in CN101036669A A IN O
a CN101036669A A DT O
state CN101036669A A NN O
of CN101036669A A IN O
ischemia CN101036669A A NN O
and CN101036669A A CC O
anoxia CN101036669A A NN O
to CN101036669A A TO O
improve CN101036669A A VB O
learning CN101036669A A NN O
and CN101036669A A CC O
memory CN101036669A A NN O
dysfunction CN101036669A A NN O
by CN101036669A A IN O
increasing CN101036669A A VBG O
content CN101036669A A NN O
of CN101036669A A IN O
BDNF CN101036669A A NNP I-UN
in CN101036669A A IN O
cortical CN101036669A A JJ O
neurons CN101036669A A NNS O
. CN101036669A A . O

Polymorphic WO2006040643A2 T JJ O
forms WO2006040643A2 T NNS O
of WO2006040643A2 T IN O
efavirenz WO2006040643A2 T NN O
and WO2006040643A2 T CC O
processes WO2006040643A2 T NNS O
for WO2006040643A2 T IN O
their WO2006040643A2 T PRP$ O
preparation WO2006040643A2 T NN O
. WO2006040643A2 T . O

2-undecyl-3-methyl-hydroxyl-quinoline CN103664777A T JJ O
compound CN103664777A T NN O
as CN103664777A T RB O
well CN103664777A T RB O
as CN103664777A T IN O
preparation CN103664777A T NN O
method CN103664777A T NN O
, CN103664777A T , O
pharmaceutical CN103664777A T JJ O
composition CN103664777A T NN O
and CN103664777A T CC O
use CN103664777A T NN O
thereof CN103664777A T NN O
. CN103664777A T . O

Azabicyclic US6894042 T NNP O
compounds US6894042 T VBZ O
for US6894042 T IN O
the US6894042 T DT O
treatment US6894042 T NN O
of US6894042 T IN O
disease US6894042 T NN O
. US6894042 T . O

The US6894042 A DT O
invention US6894042 A NN O
provides US6894042 A VBZ O
compounds US6894042 A NNS O
of US6894042 A IN O
Formula US6894042 A NNP O
I US6894042 A PRP O
: US6894042 A : O
wherein US6894042 A NN O
Azabicyclo US6894042 A NNP O
is US6894042 A VBZ O
These US6894042 A DT O
compounds US6894042 A NNS O
may US6894042 A MD O
be US6894042 A VB O
in US6894042 A IN O
the US6894042 A DT O
form US6894042 A NN O
of US6894042 A IN O
pharmaceutical US6894042 A JJ O
salts US6894042 A NNS O
or US6894042 A CC O
compositions US6894042 A NNS O
, US6894042 A , O
may US6894042 A MD O
be US6894042 A VB O
in US6894042 A IN O
pure US6894042 A JJ O
enantiomeric US6894042 A JJ O
form US6894042 A NN O
or US6894042 A CC O
racemic US6894042 A JJ O
mixtures US6894042 A NNS O
, US6894042 A , O
and US6894042 A CC O
are US6894042 A VBP O
useful US6894042 A JJ O
in US6894042 A IN O
pharmaceuticals US6894042 A NNS O
in US6894042 A IN O
which US6894042 A WDT O
α7 US6894042 A NNP I-UN
is US6894042 A VBZ O
known US6894042 A VBN O
to US6894042 A TO O
be US6894042 A VB O
involved US6894042 A VBN O
. US6894042 A . O

Imidazoles WO2007042910A1 T NNS O
and WO2007042910A1 T CC O
their WO2007042910A1 T PRP$ O
use WO2007042910A1 T NN O
as WO2007042910A1 T IN O
hmg-coa WO2007042910A1 T JJ I-UN
reductase WO2007042910A1 T NN I-UN
inhibitors WO2007042910A1 T NNS O
. WO2007042910A1 T . O

A WO2012159593A2 T DT O
combined WO2012159593A2 T JJ O
oral WO2012159593A2 T JJ O
formulation WO2012159593A2 T NN O
with WO2012159593A2 T IN O
controlled WO2012159593A2 T JJ O
release WO2012159593A2 T NN O
of WO2012159593A2 T IN O
acetylsalicylic WO2012159593A2 T JJ O
acid WO2012159593A2 T NN O
and WO2012159593A2 T CC O
a WO2012159593A2 T DT O
method WO2012159593A2 T NN O
for WO2012159593A2 T IN O
the WO2012159593A2 T DT O
preparation WO2012159593A2 T NN O
. WO2012159593A2 T . O

Anticancer US7759371 T NNP O
, US7759371 T , O
antitumor US7759371 T NN O
agents US7759371 T NNS O
, US7759371 T , O
using US7759371 T VBG O
2-amino-5-phenyl- US7759371 T JJ O
( US7759371 T ( O
1,3,4 US7759371 T CD O
) US7759371 T ) O
thiadiazoline US7759371 T NN O
compounds US7759371 T NNS O
. US7759371 T . O

4-dimethylaminobutyric CN101952243A T JJ O
acid CN101952243A T NN O
derivatives CN101952243A T NNS O
. CN101952243A T . O

These CN101952243A A DT O
compounds CN101952243A A NNS O
inhibit CN101952243A A VBP O
carnitine CN101952243A A JJ I-UN
palmitoyl CN101952243A A NN I-UN
transferase CN101952243A A NN I-UN
( CN101952243A A ( O
CPT CN101952243A A NNP I-UN
) CN101952243A A ) O
activity CN101952243A A NN O
, CN101952243A A , O
in CN101952243A A IN O
particular CN101952243A A JJ O
CPT2 CN101952243A A NNP I-UN
activity CN101952243A A NN O
, CN101952243A A , O
and CN101952243A A CC O
can CN101952243A A MD O
be CN101952243A A VB O
used CN101952243A A VBN O
as CN101952243A A IN O
medicaments CN101952243A A NNS O
. CN101952243A A . O

Diffractive-ring CN101693034A T NNP O
mangiferin CN101693034A T NN O
A CN101693034A T NNP O
in CN101693034A T IN O
mango CN101693034A T NN O
leaves CN101693034A T NNS O
and CN101693034A T CC O
new CN101693034A T JJ O
application CN101693034A T NN O
of CN101693034A T IN O
mango CN101693034A T NN O
leaf CN101693034A T NN O
extractives CN101693034A T VBZ O
containing CN101693034A T VBG O
diffractive-ring CN101693034A T JJ O
mangiferin CN101693034A T NN O
A CN101693034A T NNP O
. CN101693034A T . O

Prulifloxacin CN101711763A T NNP O
composition CN101711763A T NN O
and CN101711763A T CC O
preparation CN101711763A T NN O
method CN101711763A T NN O
thereof CN101711763A T NN O
, CN101711763A T , O
and CN101711763A T CC O
synthesis CN101711763A T NN O
method CN101711763A T NN O
of CN101711763A T IN O
raw CN101711763A T JJ O
material CN101711763A T NN O
drugs CN101711763A T NNS O
. CN101711763A T . O

Methods EP2442818A1 T NNS O
of EP2442818A1 T IN O
treating EP2442818A1 T VBG O
outer EP2442818A1 T NN O
eye EP2442818A1 T NN O
disorders EP2442818A1 T NNS O
using EP2442818A1 T VBG O
high EP2442818A1 T JJ O
orp EP2442818A1 T NN O
acid EP2442818A1 T NN O
water EP2442818A1 T NN O
and EP2442818A1 T CC O
compositions EP2442818A1 T NNS O
thereof EP2442818A1 T VBP O
. EP2442818A1 T . O

Aza CN1129942B T NNP O
spiro-compounds CN1129942B T NNS O
acting CN1129942B T VBG O
on CN1129942B T IN O
the CN1129942B T DT O
cholinergic CN1129942B T NN O
system CN1129942B T NN O
with CN1129942B T IN O
muscarinic CN1129942B T JJ O
agonist CN1129942B T NN O
activity CN1129942B T NN O
. CN1129942B T . O

Submicron CN1857222B T NNP O
docetaxel CN1857222B T NN O
emulsion CN1857222B T NN O
for CN1857222B T IN O
intravenous CN1857222B T JJ O
injection CN1857222B T NN O
and CN1857222B T CC O
its CN1857222B T PRP$ O
preparing CN1857222B T NN O
process CN1857222B T NN O
. CN1857222B T . O

1,7-diaryl-1,6-trans-diene-3,5-diketone CN102807566A T CD O
as CN102807566A T RB O
well CN102807566A T RB O
as CN102807566A T IN O
preparation CN102807566A T NN O
method CN102807566A T NN O
and CN102807566A T CC O
application CN102807566A T NN O
thereof CN102807566A T NN O
. CN102807566A T . O

The CN102807566A A DT O
invention CN102807566A A NN O
discloses CN102807566A A VBZ O
a CN102807566A A DT O
1,7-diaryl-1,6-trans-diene-3,5-diketone CN102807566A A JJ O
compound CN102807566A A NN O
, CN102807566A A , O
namely CN102807566A A RB O
a CN102807566A A DT O
compound CN102807566A A NN O
6 CN102807566A A CD O
( CN102807566A A ( O
a-i CN102807566A A NN O
) CN102807566A A ) O
represented CN102807566A A VBN O
by CN102807566A A IN O
a CN102807566A A DT O
general CN102807566A A JJ O
formula CN102807566A A NN O
I CN102807566A A PRP O
as CN102807566A A RB O
well CN102807566A A RB O
as CN102807566A A IN O
a CN102807566A A DT O
preparation CN102807566A A NN O
method CN102807566A A NN O
of CN102807566A A IN O
the CN102807566A A DT O
1,7-diaryl-1,6-trans-diene-3,5-diketone CN102807566A A JJ O
compound CN102807566A A NN O
and CN102807566A A CC O
an CN102807566A A DT O
application CN102807566A A NN O
of CN102807566A A IN O
the CN102807566A A DT O
1,7-diaryl-1,6-trans-diene-3,5-diketone CN102807566A A JJ O
compound CN102807566A A NN O
to CN102807566A A TO O
preparation CN102807566A A NN O
of CN102807566A A IN O
a CN102807566A A DT O
medicament CN102807566A A NN O
for CN102807566A A IN O
treating CN102807566A A VBG O
tumor CN102807566A A NN O
. CN102807566A A . O

The CN102807566A A DT O
tumor CN102807566A A NN O
resistant CN102807566A A JJ O
activity CN102807566A A NN O
of CN102807566A A IN O
the CN102807566A A DT O
1,7-diaryl-1,6-trans-diene-3,5-diketone CN102807566A A JJ O
compound CN102807566A A NN O
is CN102807566A A VBZ O
evaluated CN102807566A A VBN O
on CN102807566A A IN O
a CN102807566A A DT O
mouse CN102807566A A NN O
S180 CN102807566A A NNP O
model CN102807566A A NN O
; CN102807566A A : O
and CN102807566A A CC O
the CN102807566A A DT O
experiment CN102807566A A NN O
result CN102807566A A NN O
shows CN102807566A A VBZ O
that CN102807566A A IN O
the CN102807566A A DT O
compound CN102807566A A NN O
6 CN102807566A A CD O
( CN102807566A A ( O
a-i CN102807566A A NN O
) CN102807566A A ) O
has CN102807566A A VBZ O
an CN102807566A A DT O
excellent CN102807566A A JJ O
tumor CN102807566A A NN O
resisting CN102807566A A VBG O
action CN102807566A A NN O
and CN102807566A A CC O
can CN102807566A A MD O
be CN102807566A A VB O
applied CN102807566A A VBN O
to CN102807566A A TO O
production CN102807566A A NN O
of CN102807566A A IN O
preparing CN102807566A A VBG O
a CN102807566A A DT O
tumor-resistant CN102807566A A JJ O
medicament CN102807566A A NN O
. CN102807566A A . O

Nitrogen—containing US8044206 T VBG O
heterocyclic US8044206 T JJ O
derivatives US8044206 T NNS O
having US8044206 T VBG O
2,6-disubstituted US8044206 T JJ O
styryl US8044206 T NN O
. US8044206 T . O

The US8044206 A DT O
invention US8044206 A NN O
provides US8044206 A VBZ O
a US8044206 A DT O
novel US8044206 A JJ O
nitrogen-containing US8044206 A JJ O
heterocyclic US8044206 A NN O
derivative US8044206 A JJ O
having US8044206 A VBG O
2,6-disubstituted US8044206 A JJ O
styryl US8044206 A NN O
and US8044206 A CC O
a US8044206 A DT O
pharmaceutically US8044206 A RB O
acceptable US8044206 A JJ O
salt US8044206 A NN O
thereof US8044206 A NN O
, US8044206 A , O
and US8044206 A CC O
a US8044206 A DT O
pharmaceutical US8044206 A JJ O
composition US8044206 A NN O
comprising US8044206 A VBG O
the US8044206 A DT O
nitrogen-containing US8044206 A JJ O
heterocyclic US8044206 A JJ O
derivative US8044206 A NN O
and US8044206 A CC O
a US8044206 A DT O
pharmaceutically US8044206 A RB O
acceptable US8044206 A JJ O
salt US8044206 A NN O
thereof US8044206 A NN O
, US8044206 A , O
in US8044206 A IN O
particular US8044206 A JJ O
, US8044206 A , O
a US8044206 A DT O
pharmaceutical US8044206 A JJ O
composition US8044206 A NN O
effective US8044206 A JJ O
as US8044206 A IN O
a US8044206 A DT O
sodium US8044206 A NN I-UN
channel US8044206 A NN I-UN
inhibitor US8044206 A NN O
, US8044206 A , O
having US8044206 A VBG O
an US8044206 A DT O
excellent US8044206 A JJ O
analgesic US8044206 A JJ O
action US8044206 A NN O
especially US8044206 A RB O
on US8044206 A IN O
neuropathic US8044206 A JJ O
pain US8044206 A NN O
with US8044206 A IN O
minimized US8044206 A JJ O
side US8044206 A NN O
effects US8044206 A NNS O
. US8044206 A . O

Antibodies CA2242750C T NNS O
with CA2242750C T IN O
reduced CA2242750C T JJ O
net CA2242750C T JJ O
positive CA2242750C T JJ O
charge CA2242750C T NN O
. CA2242750C T . O

Inhibitors WO2009085226A2 T NNS O
of WO2009085226A2 T IN O
cdc2-like WO2009085226A2 T JJ I-UN
kinases WO2009085226A2 T NNS I-UN
( WO2009085226A2 T ( O
clks WO2009085226A2 T NNS I-UN
) WO2009085226A2 T ) O
and WO2009085226A2 T CC O
methods WO2009085226A2 T NNS O
of WO2009085226A2 T IN O
use WO2009085226A2 T NN O
thereof WO2009085226A2 T NN O
. WO2009085226A2 T . O

Provided WO2009085226A2 A VBN O
herein WO2009085226A2 A NN O
are WO2009085226A2 A VBP O
compounds WO2009085226A2 A NNS O
which WO2009085226A2 A WDT O
are WO2009085226A2 A VBP O
CDC2-Like WO2009085226A2 A JJ I-UN
Kinase WO2009085226A2 A NNP I-UN
( WO2009085226A2 A ( O
CLK WO2009085226A2 A NNP I-UN
) WO2009085226A2 A ) O
inhibiting WO2009085226A2 A VBG O
compounds WO2009085226A2 A NNS O
and WO2009085226A2 A CC O
methods WO2009085226A2 A NNS O
of WO2009085226A2 A IN O
use WO2009085226A2 A NN O
thereof WO2009085226A2 A NN O
. WO2009085226A2 A . O

Heat-reversible US20050180965 T JJ O
composition US20050180965 T NN O
treating US20050180965 T VBG O
hyposalia US20050180965 T NNS O
and US20050180965 T CC O
asialia US20050180965 T NNS O
. US20050180965 T . O

Compounds US20090017112 T NNS O
for US20090017112 T IN O
Inhibiting US20090017112 T VBG O
Beta-Amyloid US20090017112 T JJ I-UN
Production US20090017112 T NN O
. US20090017112 T . O

Also US20090017112 A RB O
provided US20090017112 A VBN O
are US20090017112 A VBP O
methods US20090017112 A NNS O
of US20090017112 A IN O
treating US20090017112 A VBG O
or US20090017112 A CC O
reducing US20090017112 A VBG O
the US20090017112 A DT O
risk US20090017112 A NN O
of US20090017112 A IN O
developing US20090017112 A VBG O
β-amyloid US20090017112 A JJ I-UN
production US20090017112 A NN O
, US20090017112 A , O
β-amyloid US20090017112 A JJ I-UN
deposition US20090017112 A NN O
, US20090017112 A , O
β-amyloid US20090017112 A JJ I-UN
neurotoxicity US20090017112 A NN O
( US20090017112 A ( O
including US20090017112 A VBG O
abnormal US20090017112 A JJ O
hyperphosphorylation US20090017112 A NN O
of US20090017112 A IN O
tau US20090017112 A NN I-UN
) US20090017112 A ) O
and US20090017112 A CC O
microgliosis US20090017112 A NN O
associated US20090017112 A VBN O
with US20090017112 A IN O
cerebral US20090017112 A JJ O
accumulation US20090017112 A NN O
of US20090017112 A IN O
Alzheimer US20090017112 A NNP O
's US20090017112 A POS O
amyloid US20090017112 A NN O
by US20090017112 A IN O
administering US20090017112 A VBG O
therapeutically US20090017112 A RB O
effective US20090017112 A JJ O
amounts US20090017112 A NNS O
of US20090017112 A IN O
the US20090017112 A DT O
compounds US20090017112 A NNS O
. US20090017112 A . O

Prevention EP2060257A1 T NN O
and EP2060257A1 T CC O
treatment EP2060257A1 T NN O
of EP2060257A1 T IN O
secondary EP2060257A1 T JJ O
infections EP2060257A1 T NNS O
following EP2060257A1 T VBG O
viral EP2060257A1 T JJ O
infection EP2060257A1 T NN O
. EP2060257A1 T . O

Compound US20120115851 T NN O
inhibiting US20120115851 T NN O
in US20120115851 T IN O
vivo US20120115851 T NN O
phosphorus US20120115851 T NN O
transport US20120115851 T NN O
and US20120115851 T CC O
medicine US20120115851 T NN O
containing US20120115851 T VBG O
the US20120115851 T DT O
same US20120115851 T JJ O
. US20120115851 T . O

Tricyclic US8163752 T NNP O
anilide US8163752 T VBZ O
heterocyclic US8163752 T JJ O
CGRP US8163752 T NNP I-UN
receptor US8163752 T NN I-UN
antagonists US8163752 T NNS O
. US8163752 T . O

Compounds US8163752 A NNS O
of US8163752 A IN O
formula US8163752 A NN O
I US8163752 A PRP O
: US8163752 A : O
wherein US8163752 A NN O
variables US8163752 A NNS O
A1 US8163752 A NNP O
, US8163752 A , O
A2 US8163752 A NNP O
, US8163752 A , O
B US8163752 A NNP O
, US8163752 A , O
m US8163752 A NN O
, US8163752 A , O
n US8163752 A RB O
, US8163752 A , O
J US8163752 A NNP O
, US8163752 A , O
R4 US8163752 A NNP O
, US8163752 A , O
G1 US8163752 A NNP O
, US8163752 A , O
G2 US8163752 A NNP O
, US8163752 A , O
G3 US8163752 A NNP O
and US8163752 A CC O
Y US8163752 A NNP O
are US8163752 A VBP O
as US8163752 A IN O
described US8163752 A JJ O
herein US8163752 A NN O
, US8163752 A , O
which US8163752 A WDT O
are US8163752 A VBP O
antagonists US8163752 A NNS O
of US8163752 A IN O
CGRP US8163752 A NNP I-UN
receptors US8163752 A NNS I-UN
and US8163752 A CC O
which US8163752 A WDT O
are US8163752 A VBP O
useful US8163752 A JJ O
in US8163752 A IN O
the US8163752 A DT O
treatment US8163752 A NN O
or US8163752 A CC O
prevention US8163752 A NN O
of US8163752 A IN O
diseases US8163752 A NNS O
in US8163752 A IN O
which US8163752 A WDT O
the US8163752 A DT O
CGRP US8163752 A NNP I-UN
is US8163752 A VBZ O
involved US8163752 A VBN O
, US8163752 A , O
such US8163752 A JJ O
as US8163752 A IN O
migraine US8163752 A NN O
. US8163752 A . O

The US8163752 A DT O
invention US8163752 A NN O
is US8163752 A VBZ O
also US8163752 A RB O
directed US8163752 A VBN O
to US8163752 A TO O
pharmaceutical US8163752 A JJ O
compositions US8163752 A NNS O
comprising US8163752 A VBG O
these US8163752 A DT O
compounds US8163752 A NNS O
and US8163752 A CC O
the US8163752 A DT O
use US8163752 A NN O
of US8163752 A IN O
these US8163752 A DT O
compounds US8163752 A NNS O
and US8163752 A CC O
compositions US8163752 A NNS O
in US8163752 A IN O
the US8163752 A DT O
prevention US8163752 A NN O
or US8163752 A CC O
treatment US8163752 A NN O
of US8163752 A IN O
such US8163752 A JJ O
diseases US8163752 A NNS O
in US8163752 A IN O
which US8163752 A WDT O
CGRP US8163752 A NNP I-UN
is US8163752 A VBZ O
involved US8163752 A VBN O
. US8163752 A . O

Leukotriene EP0979817B1 T NNP O
a4 EP0979817B1 T NN O
hydrolaze EP0979817B1 T NN O
inhibitors EP0979817B1 T NNS O
. EP0979817B1 T . O

Transdermal CN102218074A T NNP O
patch CN102218074A T NN O
containing CN102218074A T VBG O
paeoniflorin CN102218074A T NN O
and CN102218074A T CC O
glycyrrhetinic CN102218074A T JJ O
acid CN102218074A T NN O
and CN102218074A T CC O
method CN102218074A T NN O
for CN102218074A T IN O
preparing CN102218074A T VBG O
same CN102218074A T JJ O
. CN102218074A T . O

Pharmaceutical US6884795 T JJ O
compositions US6884795 T NNS O
and US6884795 T CC O
uses US6884795 T NNS O
for US6884795 T IN O
androst-5-ene-3β US6884795 T JJ O
, US6884795 T , O
17β-diol US6884795 T JJ O
. US6884795 T . O

Androst-5-ene-3β,17β US6884795 A JJ O
diol US6884795 A NN O
is US6884795 A VBZ O
used US6884795 A VBN O
to US6884795 A TO O
treat US6884795 A VB O
or US6884795 A CC O
reduce US6884795 A VB O
the US6884795 A DT O
likelihood US6884795 A NN O
of US6884795 A IN O
acquiring US6884795 A VBG O
osteoporosis US6884795 A NN O
or US6884795 A CC O
menopausal US6884795 A NN O
symptoms US6884795 A NNS O
, US6884795 A , O
or US6884795 A CC O
other US6884795 A JJ O
diseases US6884795 A NNS O
affected US6884795 A VBN O
by US6884795 A IN O
estrogen US6884795 A JJ I-UN
receptor US6884795 A NN I-UN
activity US6884795 A NN O
, US6884795 A , O
and US6884795 A CC O
for US6884795 A IN O
conditions US6884795 A NNS O
which US6884795 A WDT O
respond US6884795 A VBP O
well US6884795 A RB O
to US6884795 A TO O
DHEA US6884795 A NNP O
treatment US6884795 A NN O
, US6884795 A , O
but US6884795 A CC O
where US6884795 A WRB O
a US6884795 A DT O
higher US6884795 A JJR O
ratio US6884795 A NN O
of US6884795 A IN O
estrogenic US6884795 A JJ O
to US6884795 A TO O
androgenic US6884795 A JJ O
effects US6884795 A NNS O
is US6884795 A VBZ O
desired US6884795 A VBN O
. US6884795 A . O

Omeprazole CN101780104A T NNP O
sodium CN101780104A T NN O
bicarbonate CN101780104A T NN O
and CN101780104A T CC O
magnesium CN101780104A T NN O
hydroxide CN101780104A T NN O
medicine CN101780104A T NN O
composition CN101780104A T NN O
chewable CN101780104A T JJ O
tablet CN101780104A T NN O
. CN101780104A T . O

Combination WO2013139423A1 T NN O
of WO2013139423A1 T IN O
a WO2013139423A1 T DT O
6-oxo-1,6-dihydro-pyridazine WO2013139423A1 T JJ O
derivative WO2013139423A1 T JJ O
having WO2013139423A1 T VBG O
anti-cancer WO2013139423A1 T JJ O
activity WO2013139423A1 T NN O
with WO2013139423A1 T IN O
other WO2013139423A1 T JJ O
anti-tumor WO2013139423A1 T JJ O
compounds WO2013139423A1 T NNS O
. WO2013139423A1 T . O

Inhibition US7049303 T NN O
of US7049303 T IN O
viruses US7049303 T NNS O
. US7049303 T . O

Piperazinotriazines WO2011135520A1 T NNS O
as WO2011135520A1 T IN O
pi3k WO2011135520A1 T NN O
inhibitors WO2011135520A1 T NNS O
for WO2011135520A1 T IN O
use WO2011135520A1 T NN O
in WO2011135520A1 T IN O
the WO2011135520A1 T DT O
treatment WO2011135520A1 T NN O
antiproliferative WO2011135520A1 T JJ O
disorders WO2011135520A1 T NNS O
. WO2011135520A1 T . O

These WO2011135520A1 A DT O
compounds WO2011135520A1 A NNS O
are WO2011135520A1 A VBP O
effective WO2011135520A1 A JJ O
in WO2011135520A1 A IN O
preventing WO2011135520A1 A VBG O
or WO2011135520A1 A CC O
treating WO2011135520A1 A VBG O
a WO2011135520A1 A DT O
disease WO2011135520A1 A NN O
or WO2011135520A1 A CC O
disorder WO2011135520A1 A NN O
modulated WO2011135520A1 A VBN O
by WO2011135520A1 A IN O
PI3 WO2011135520A1 A NNP O
kinases WO2011135520A1 A NNS O
and/or WO2011135520A1 A VBP O
mTOR WO2011135520A1 A NN I-UN
, WO2011135520A1 A , O
in WO2011135520A1 A IN O
particular WO2011135520A1 A JJ O
treating WO2011135520A1 A VBG O
a WO2011135520A1 A DT O
hyperproliferative WO2011135520A1 A JJ O
disorder WO2011135520A1 A NN O
. WO2011135520A1 A . O

Application CN1973848A T NN O
of CN1973848A T IN O
Wushan CN1973848A T NNP O
epimedium CN1973848A T NN O
fotal CN1973848A T JJ O
phenolic CN1973848A T JJ O
acid CN1973848A T NN O
in CN1973848A T IN O
medicine CN1973848A T NN O
and CN1973848A T CC O
health CN1973848A T NN O
food CN1973848A T NN O
. CN1973848A T . O

The CN1973848A A DT O
present CN1973848A A JJ O
invention CN1973848A A NN O
discloses CN1973848A A VBZ O
the CN1973848A A DT O
extraction CN1973848A A NN O
process CN1973848A A NN O
and CN1973848A A CC O
application CN1973848A A NN O
in CN1973848A A IN O
preparing CN1973848A A VBG O
medicine CN1973848A A NN O
and CN1973848A A CC O
health CN1973848A A NN O
food CN1973848A A NN O
for CN1973848A A IN O
resisting CN1973848A A VBG O
oxidation CN1973848A A NN O
, CN1973848A A , O
antisepsis CN1973848A A NN O
and CN1973848A A CC O
strengthening CN1973848A A VBG O
immunity CN1973848A A NN O
of CN1973848A A IN O
Wushan CN1973848A A NNP O
epimedium CN1973848A A NN O
total CN1973848A A JJ O
phenolic CN1973848A A JJ O
acid CN1973848A A NN O
. CN1973848A A . O

The CN1973848A A DT O
preparation CN1973848A A NN O
process CN1973848A A NN O
of CN1973848A A IN O
Wushan CN1973848A A NNP O
epimedium CN1973848A A NN O
total CN1973848A A JJ O
phenolic CN1973848A A JJ O
acid CN1973848A A NN O
includes CN1973848A A VBZ O
the CN1973848A A DT O
following CN1973848A A JJ O
steps CN1973848A A NNS O
: CN1973848A A : O
decocting CN1973848A A VBG O
Wushan CN1973848A A NNP O
epimedium CN1973848A A NN O
for CN1973848A A IN O
three CN1973848A A CD O
times CN1973848A A NNS O
and CN1973848A A CC O
merging CN1973848A A NN O
and CN1973848A A CC O
centrifuging CN1973848A A VBG O
the CN1973848A A DT O
decoction CN1973848A A NN O
to CN1973848A A TO O
obtain CN1973848A A VB O
the CN1973848A A DT O
supernatant CN1973848A A NN O
; CN1973848A A : O
eluting CN1973848A A VBG O
the CN1973848A A DT O
supernatant CN1973848A A NN O
in CN1973848A A IN O
AB-8 CN1973848A A NNP O
macroporous CN1973848A A JJ O
resin CN1973848A A NN O
first CN1973848A A RB O
with CN1973848A A IN O
2-5 CN1973848A A JJ O
times CN1973848A A NNS O
water CN1973848A A NN O
, CN1973848A A , O
then CN1973848A A RB O
with CN1973848A A IN O
2-3 CN1973848A A JJ O
times CN1973848A A NNS O
30 CN1973848A A CD O
% CN1973848A A NN O
concentration CN1973848A A NN O
alcohol CN1973848A A NN O
solution CN1973848A A NN O
and CN1973848A A CC O
finally CN1973848A A RB O
with CN1973848A A IN O
3-8 CN1973848A A JJ O
times CN1973848A A NNS O
70 CN1973848A A CD O
% CN1973848A A NN O
concentration CN1973848A A NN O
alcohol CN1973848A A NN O
solution CN1973848A A NN O
; CN1973848A A : O
decompression CN1973848A A NN O
drying CN1973848A A VBG O
the CN1973848A A DT O
final CN1973848A A JJ O
alcohol CN1973848A A NN O
eluted CN1973848A A VBD O
liquid CN1973848A A NN O
while CN1973848A A IN O
recovering CN1973848A A VBG O
alcohol CN1973848A A NN O
to CN1973848A A TO O
obtain CN1973848A A VB O
the CN1973848A A DT O
residue CN1973848A A NN O
as CN1973848A A IN O
the CN1973848A A DT O
Wushan CN1973848A A NNP O
epimedium CN1973848A A NN O
total CN1973848A A JJ O
phenolic CN1973848A A JJ O
acid CN1973848A A NN O
. CN1973848A A . O

Transdermal CN101843603A T JJ O
delivery CN101843603A T NN O
of CN101843603A T IN O
hormones CN101843603A T NNS O
without CN101843603A T IN O
the CN101843603A T DT O
need CN101843603A T NN O
of CN101843603A T IN O
penetration CN101843603A T NN O
enhancers CN101843603A T NNS O
. CN101843603A T . O

6-Phenylpyrimidinones US20100135954 T NNS O
as US20100135954 T IN O
PIM US20100135954 T NNP I-UN
Modulators US20100135954 T NNPS O
. US20100135954 T . O

Triazolopyridines EP1370559B1 T NNS O
as EP1370559B1 T IN O
anti-inflammatory EP1370559B1 T JJ O
agents EP1370559B1 T NNS O
. EP1370559B1 T . O

The EP1370559B1 A DT O
present EP1370559B1 A JJ O
invention EP1370559B1 A NN O
relates EP1370559B1 A VBZ O
to EP1370559B1 A TO O
novel EP1370559B1 A VB O
triazolo-pyridines EP1370559B1 A NNS O
of EP1370559B1 A IN O
the EP1370559B1 A DT O
formula EP1370559B1 A NN O
I EP1370559B1 A PRP O
wherein EP1370559B1 A VBP O
Het EP1370559B1 A NNP O
is EP1370559B1 A VBZ O
an EP1370559B1 A DT O
optionally EP1370559B1 A RB O
substituted EP1370559B1 A VBN O
5-membered EP1370559B1 A JJ O
heterocycle EP1370559B1 A NN O
containing EP1370559B1 A VBG O
one EP1370559B1 A CD O
to EP1370559B1 A TO O
two EP1370559B1 A CD O
heteroatoms EP1370559B1 A NNS O
selected EP1370559B1 A VBN O
from EP1370559B1 A IN O
nitrogen EP1370559B1 A NN O
, EP1370559B1 A , O
sulfur EP1370559B1 A NN O
and EP1370559B1 A CC O
oxygen EP1370559B1 A NN O
wherein EP1370559B1 A NN O
at EP1370559B1 A IN O
least EP1370559B1 A JJS O
one EP1370559B1 A CD O
of EP1370559B1 A IN O
said EP1370559B1 A VBD O
heteroatoms EP1370559B1 A NNS O
atoms EP1370559B1 A NNS O
must EP1370559B1 A MD O
be EP1370559B1 A VB O
nitrogen EP1370559B1 A RB O
; EP1370559B1 A : O
R2 EP1370559B1 A NNP O
is EP1370559B1 A VBZ O
selected EP1370559B1 A VBN O
from EP1370559B1 A IN O
the EP1370559B1 A DT O
group EP1370559B1 A NN O
consisting EP1370559B1 A VBG O
of EP1370559B1 A IN O
hydrogen EP1370559B1 A NN O
, EP1370559B1 A , O
( EP1370559B1 A ( O
C¿1 EP1370559B1 A NNP O
? EP1370559B1 A . O
-C6 EP1370559B1 A NN O
) EP1370559B1 A ) O
alkyl EP1370559B1 A NN O
or EP1370559B1 A CC O
other EP1370559B1 A JJ O
suitable EP1370559B1 A JJ O
substituents EP1370559B1 A NNS O
; EP1370559B1 A : O
R EP1370559B1 A NNP O
? EP1370559B1 A . O
3¿ EP1370559B1 A CD O
is EP1370559B1 A VBZ O
selected EP1370559B1 A VBN O
from EP1370559B1 A IN O
the EP1370559B1 A DT O
group EP1370559B1 A NN O
consisting EP1370559B1 A VBG O
of EP1370559B1 A IN O
hydrogen EP1370559B1 A NN O
, EP1370559B1 A , O
( EP1370559B1 A ( O
C¿1 EP1370559B1 A NNP O
? EP1370559B1 A . O
-C6 EP1370559B1 A NN O
) EP1370559B1 A ) O
alkyl EP1370559B1 A NN O
or EP1370559B1 A CC O
other EP1370559B1 A JJ O
suitable EP1370559B1 A JJ O
substituents EP1370559B1 A NNS O
; EP1370559B1 A : O
s EP1370559B1 A NN O
is EP1370559B1 A VBZ O
an EP1370559B1 A DT O
integer EP1370559B1 A NN O
from EP1370559B1 A IN O
0-5 EP1370559B1 A JJ O
; EP1370559B1 A : O
to EP1370559B1 A TO O
intermediates EP1370559B1 A NNS O
for EP1370559B1 A IN O
their EP1370559B1 A PRP$ O
preparation EP1370559B1 A NN O
, EP1370559B1 A , O
to EP1370559B1 A TO O
pharmaceutical EP1370559B1 A JJ O
compositions EP1370559B1 A NNS O
containing EP1370559B1 A VBG O
them EP1370559B1 A PRP O
and EP1370559B1 A CC O
to EP1370559B1 A TO O
their EP1370559B1 A PRP$ O
medicinal EP1370559B1 A JJ O
use EP1370559B1 A NN O
. EP1370559B1 A . O

The EP1370559B1 A DT O
compounds EP1370559B1 A NNS O
of EP1370559B1 A IN O
the EP1370559B1 A DT O
present EP1370559B1 A JJ O
invention EP1370559B1 A NN O
are EP1370559B1 A VBP O
potent EP1370559B1 A JJ O
inhibitors EP1370559B1 A NNS O
of EP1370559B1 A IN O
MAP EP1370559B1 A NNP O
kinases EP1370559B1 A NNS O
, EP1370559B1 A , O
preferably EP1370559B1 A RB O
p38 EP1370559B1 A JJ O
kinase EP1370559B1 A NN O
. EP1370559B1 A . O

They EP1370559B1 A PRP O
are EP1370559B1 A VBP O
useful EP1370559B1 A JJ O
in EP1370559B1 A IN O
the EP1370559B1 A DT O
treatment EP1370559B1 A NN O
of EP1370559B1 A IN O
inflammation EP1370559B1 A NN O
, EP1370559B1 A , O
osteoarthritis EP1370559B1 A NN O
, EP1370559B1 A , O
rheumatoid EP1370559B1 A JJ O
arthritis EP1370559B1 A NN O
, EP1370559B1 A , O
cancer EP1370559B1 A NN O
, EP1370559B1 A , O
repurfusion EP1370559B1 A NN O
or EP1370559B1 A CC O
ischemia EP1370559B1 A NN O
in EP1370559B1 A IN O
stroke EP1370559B1 A NN O
or EP1370559B1 A CC O
heart EP1370559B1 A NN O
attack EP1370559B1 A NN O
, EP1370559B1 A , O
autoimmune EP1370559B1 A NN O
diseases EP1370559B1 A NNS O
and EP1370559B1 A CC O
other EP1370559B1 A JJ O
disorders EP1370559B1 A NNS O
. EP1370559B1 A . O

Heterocyclic-substitued WO2013034047A1 T NNP O
benzofuran WO2013034047A1 T NN O
derivatives WO2013034047A1 T NNS O
and WO2013034047A1 T CC O
methods WO2013034047A1 T NNS O
of WO2013034047A1 T IN O
use WO2013034047A1 T NN O
thereof WO2013034047A1 T NN O
for WO2013034047A1 T IN O
the WO2013034047A1 T DT O
treatment WO2013034047A1 T NN O
of WO2013034047A1 T IN O
viral WO2013034047A1 T JJ O
diseases WO2013034047A1 T NNS O
. WO2013034047A1 T . O

The WO2013034047A1 A DT O
present WO2013034047A1 A JJ O
invention WO2013034047A1 A NN O
relates WO2013034047A1 A VBZ O
to WO2013034047A1 A TO O
compounds WO2013034047A1 A NNS O
of WO2013034047A1 A IN O
formula WO2013034047A1 A NN O
( WO2013034047A1 A ( O
I WO2013034047A1 A PRP O
) WO2013034047A1 A ) O
that WO2013034047A1 A WDT O
are WO2013034047A1 A VBP O
useful WO2013034047A1 A JJ O
as WO2013034047A1 A IN O
hepatitis WO2013034047A1 A NN I-UN
C WO2013034047A1 A NNP I-UN
virus WO2013034047A1 A NN I-UN
( WO2013034047A1 A ( I-UN
HCV WO2013034047A1 A NNP I-UN
) WO2013034047A1 A ) I-UN
NS5B WO2013034047A1 A NNP I-UN
polymerase WO2013034047A1 A NN I-UN
inhibitors WO2013034047A1 A NNS O
, WO2013034047A1 A , O
the WO2013034047A1 A DT O
synthesis WO2013034047A1 A NN O
of WO2013034047A1 A IN O
such WO2013034047A1 A JJ O
compounds WO2013034047A1 A NNS O
, WO2013034047A1 A , O
and WO2013034047A1 A CC O
the WO2013034047A1 A DT O
use WO2013034047A1 A NN O
of WO2013034047A1 A IN O
such WO2013034047A1 A JJ O
compounds WO2013034047A1 A NNS O
for WO2013034047A1 A IN O
inhibiting WO2013034047A1 A VBG O
HCV WO2013034047A1 A NNP I-UN
NS5B WO2013034047A1 A NNP I-UN
polymerase WO2013034047A1 A NN I-UN
activity WO2013034047A1 A NN O
, WO2013034047A1 A , O
for WO2013034047A1 A IN O
treating WO2013034047A1 A VBG O
or WO2013034047A1 A CC O
preventing WO2013034047A1 A VBG O
HCV WO2013034047A1 A NNP O
infections WO2013034047A1 A NNS O
and WO2013034047A1 A CC O
for WO2013034047A1 A IN O
inhibiting WO2013034047A1 A VBG O
HCV WO2013034047A1 A NNP O
viral WO2013034047A1 A JJ O
replication WO2013034047A1 A NN O
and/or WO2013034047A1 A IN O
viral WO2013034047A1 A JJ O
production WO2013034047A1 A NN O
in WO2013034047A1 A IN O
a WO2013034047A1 A DT O
cell-based WO2013034047A1 A JJ O
system WO2013034047A1 A NN O
. WO2013034047A1 A . O

Salacia WO2009002977A1 T NNP O
cuspidata WO2009002977A1 T NN O
extract WO2009002977A1 T NN O
and WO2009002977A1 T CC O
methods WO2009002977A1 T NNS O
of WO2009002977A1 T IN O
extracting WO2009002977A1 T VBG O
and WO2009002977A1 T CC O
using WO2009002977A1 T VBG O
such WO2009002977A1 T JJ O
extract WO2009002977A1 T NN O
. WO2009002977A1 T . O

A WO2009002977A1 A DT O
method WO2009002977A1 A NN O
of WO2009002977A1 A IN O
inhibiting WO2009002977A1 A VBG O
COX-2 WO2009002977A1 A NNP I-UN
, WO2009002977A1 A , O
inhibiting WO2009002977A1 A VBG O
NF-Kappa WO2009002977A1 A NNP I-UN
B WO2009002977A1 A NNP I-UN
activation WO2009002977A1 A NN O
, WO2009002977A1 A , O
treating WO2009002977A1 A VBG O
inflammation WO2009002977A1 A NN O
, WO2009002977A1 A , O
or WO2009002977A1 A CC O
treating WO2009002977A1 A VBG O
cancer WO2009002977A1 A NN O
may WO2009002977A1 A MD O
comprise WO2009002977A1 A VB O
administering WO2009002977A1 A VBG O
a WO2009002977A1 A DT O
therapeutically WO2009002977A1 A RB O
effective WO2009002977A1 A JJ O
amount WO2009002977A1 A NN O
of WO2009002977A1 A IN O
an WO2009002977A1 A DT O
extract WO2009002977A1 A NN O
of WO2009002977A1 A IN O
Salacia WO2009002977A1 A NNP O
cuspidata WO2009002977A1 A NN O
to WO2009002977A1 A TO O
a WO2009002977A1 A DT O
patient WO2009002977A1 A NN O
. WO2009002977A1 A . O

Antitumour WO2013018018A1 T NNP O
combination WO2013018018A1 T NN O
comprising WO2013018018A1 T VBG O
ombrabulin WO2013018018A1 T NN O
and WO2013018018A1 T CC O
cetuximab WO2013018018A1 T NN O
, WO2013018018A1 T , O
associated WO2013018018A1 T VBN O
with WO2013018018A1 T IN O
radiotherapy WO2013018018A1 T NN O
. WO2013018018A1 T . O

Epothilone CN1988904A T NN O
combinations CN1988904A T NNS O
. CN1988904A T . O

Use WO2007141764A1 T NN O
of WO2007141764A1 T IN O
at WO2007141764A1 T IN O
least WO2007141764A1 T JJS O
one WO2007141764A1 T CD O
polyphenol WO2007141764A1 T NN O
for WO2007141764A1 T IN O
promoting WO2007141764A1 T VBG O
eye WO2007141764A1 T NN O
health WO2007141764A1 T NN O
. WO2007141764A1 T . O

Spermicidal US20070116745 T NNP O
preparations US20070116745 T NNS O
and US20070116745 T CC O
uses US20070116745 T VBZ O
thereof US20070116745 T NN O
. US20070116745 T . O

Using US20080269210 T VBG O
1- US20080269210 T JJ O
( US20080269210 T ( O
4- US20080269210 T JJ O
( US20080269210 T ( O
( US20080269210 T ( O
2- US20080269210 T CD O
( US20080269210 T ( O
2-aminopyrimidin-5-yl US20080269210 T CD O
) US20080269210 T ) O
-4-morpholinothieno US20080269210 T NN O
( US20080269210 T ( O
3,2-d US20080269210 T JJ O
) US20080269210 T ) O
pyrimifin-6-yl US20080269210 T NN O
) US20080269210 T ) O
methyl US20080269210 T NN O
) US20080269210 T ) O
piperazin-1-yl US20080269210 T NN O
) US20080269210 T ) O
-2- US20080269210 T NN O
( US20080269210 T ( O
methylsulfony US20080269210 T NN O
) US20080269210 T ) O
ethanone US20080269210 T NN O
; US20080269210 T : O
lipid US20080269210 T JJ I-UN
kinase US20080269210 T NN I-UN
inhibitor US20080269210 T NN O
; US20080269210 T : O
anticancer US20080269210 T NN O
agents US20080269210 T NNS O
. US20080269210 T . O

Compounds US20080269210 A NNS O
of US20080269210 A IN O
Formulas US20080269210 A NNP O
Ia-d US20080269210 A NNP O
where US20080269210 A WRB O
X US20080269210 A NNP O
is US20080269210 A VBZ O
S US20080269210 A NNP O
or US20080269210 A CC O
O US20080269210 A NNP O
, US20080269210 A , O
mor US20080269210 A NN O
is US20080269210 A VBZ O
a US20080269210 A DT O
morpholine US20080269210 A NN O
group US20080269210 A NN O
, US20080269210 A , O
and US20080269210 A CC O
R3 US20080269210 A NNP O
is US20080269210 A VBZ O
a US20080269210 A DT O
monocyclic US20080269210 A JJ O
heteroaryl US20080269210 A NN O
group US20080269210 A NN O
, US20080269210 A , O
and US20080269210 A CC O
including US20080269210 A VBG O
stereoisomers US20080269210 A NNS O
, US20080269210 A , O
geometric US20080269210 A JJ O
isomers US20080269210 A NNS O
, US20080269210 A , O
tautomers US20080269210 A NNS O
, US20080269210 A , O
solvates US20080269210 A NNS O
, US20080269210 A , O
metabolites US20080269210 A NNS O
and US20080269210 A CC O
pharmaceutically US20080269210 A RB O
acceptable US20080269210 A JJ O
salts US20080269210 A NNS O
thereof US20080269210 A NN O
, US20080269210 A , O
are US20080269210 A VBP O
useful US20080269210 A JJ O
for US20080269210 A IN O
modulating US20080269210 A VBG O
the US20080269210 A DT O
activity US20080269210 A NN O
of US20080269210 A IN O
lipid US20080269210 A JJ I-UN
kinases US20080269210 A NNS I-UN
including US20080269210 A VBG O
PI3K US20080269210 A NNP I-UN
, US20080269210 A , O
and US20080269210 A CC O
for US20080269210 A IN O
treating US20080269210 A VBG O
disorders US20080269210 A NNS O
such US20080269210 A JJ O
as US20080269210 A IN O
cancer US20080269210 A NN O
mediated US20080269210 A VBN O
by US20080269210 A IN O
lipid US20080269210 A JJ I-UN
kinases US20080269210 A NNS I-UN
. US20080269210 A . O

Pharmaceutical US20090042988 T JJ O
compositions US20090042988 T NNS O
containing US20090042988 T VBG O
a US20090042988 T DT O
meglitinide US20090042988 T NN O
compound US20090042988 T NN O
for US20090042988 T IN O
preventing US20090042988 T VBG O
hepatic US20090042988 T JJ O
fibrosis US20090042988 T NN O
. US20090042988 T . O

The US20090042988 A DT O
present US20090042988 A JJ O
invention US20090042988 A NN O
discloses US20090042988 A VBZ O
pharmaceutical US20090042988 A JJ O
compositions US20090042988 A NNS O
for US20090042988 A IN O
preventing US20090042988 A VBG O
, US20090042988 A , O
improving US20090042988 A VBG O
or US20090042988 A CC O
treating US20090042988 A VBG O
hepatic US20090042988 A JJ O
fibrosis US20090042988 A NN O
, US20090042988 A , O
hepatocellular US20090042988 A JJ O
degeneration US20090042988 A NN O
or US20090042988 A CC O
cirrhosis US20090042988 A NN O
, US20090042988 A , O
which US20090042988 A WDT O
contain US20090042988 A VBP O
a US20090042988 A DT O
meglitinide US20090042988 A NN O
compound US20090042988 A NN O
such US20090042988 A JJ O
as US20090042988 A IN O
nateglinide US20090042988 A NN O
. US20090042988 A . O

Heterocyclic WO2005035534A1 T NNP O
bicyclo WO2005035534A1 T NN O
ring WO2005035534A1 T NN O
and WO2005035534A1 T CC O
heterocyclic WO2005035534A1 T JJ O
tricyclo WO2005035534A1 T NN O
ring WO2005035534A1 T VBG O
compounds WO2005035534A1 T NNS O
and WO2005035534A1 T CC O
drugs WO2005035534A1 T NNS O
comprising WO2005035534A1 T VBG O
the WO2005035534A1 T DT O
same WO2005035534A1 T JJ O
. WO2005035534A1 T . O

Among WO2005035534A1 A IN O
compounds WO2005035534A1 A NNS O
represented WO2005035534A1 A VBN O
by WO2005035534A1 A IN O
the WO2005035534A1 A DT O
following WO2005035534A1 A JJ O
general WO2005035534A1 A JJ O
formula WO2005035534A1 A NN O
: WO2005035534A1 A : O
[ WO2005035534A1 A JJ O
Chemical WO2005035534A1 A NNP O
formula WO2005035534A1 A NN O
1 WO2005035534A1 A CD O
] WO2005035534A1 A NN O
( WO2005035534A1 A ( O
I WO2005035534A1 A PRP O
) WO2005035534A1 A ) O
compounds WO2005035534A1 A VBZ O
having WO2005035534A1 A VBG O
antagonism WO2005035534A1 A NN O
to WO2005035534A1 A TO O
CXCR3 WO2005035534A1 A NNP I-UN
are WO2005035534A1 A VBP O
useful WO2005035534A1 A JJ O
in WO2005035534A1 A IN O
preventing WO2005035534A1 A VBG O
and/or WO2005035534A1 A JJ O
treating WO2005035534A1 A VBG O
CXCR3-mediated WO2005035534A1 A JJ O
diseases WO2005035534A1 A NNS O
such WO2005035534A1 A JJ O
as WO2005035534A1 A IN O
inflammatory WO2005035534A1 A NN O
or WO2005035534A1 A CC O
allergic WO2005035534A1 A JJ O
diseases WO2005035534A1 A NNS O
, WO2005035534A1 A , O
metabolic WO2005035534A1 A NN O
or WO2005035534A1 A CC O
endocrine WO2005035534A1 A NN O
diseases WO2005035534A1 A NNS O
, WO2005035534A1 A , O
cancer WO2005035534A1 A NN O
, WO2005035534A1 A , O
infectious WO2005035534A1 A JJ O
diseases WO2005035534A1 A NNS O
or WO2005035534A1 A CC O
diseases WO2005035534A1 A NNS O
accompanying WO2005035534A1 A VBG O
infection WO2005035534A1 A NN O
; WO2005035534A1 A : O
and WO2005035534A1 A CC O
compounds WO2005035534A1 A VBZ O
having WO2005035534A1 A VBG O
11β-HSD1 WO2005035534A1 A JJ I-UN
inhibitory WO2005035534A1 A JJ O
effect WO2005035534A1 A NN O
are WO2005035534A1 A VBP O
useful WO2005035534A1 A JJ O
in WO2005035534A1 A IN O
preventing WO2005035534A1 A VBG O
and/or WO2005035534A1 A JJ O
treating WO2005035534A1 A NN O
diseases WO2005035534A1 A NNS O
caused WO2005035534A1 A VBN O
by WO2005035534A1 A IN O
the WO2005035534A1 A DT O
production WO2005035534A1 A NN O
of WO2005035534A1 A IN O
cortisol WO2005035534A1 A NN O
such WO2005035534A1 A JJ O
as WO2005035534A1 A IN O
type WO2005035534A1 A NN O
II WO2005035534A1 A NNP O
diabetes WO2005035534A1 A VBZ O
, WO2005035534A1 A , O
impaired WO2005035534A1 A VBD O
glucose WO2005035534A1 A JJ O
tolerance WO2005035534A1 A NN O
, WO2005035534A1 A , O
hyperglycemia WO2005035534A1 A NN O
, WO2005035534A1 A , O
insulin WO2005035534A1 A NN I-UN
resistance WO2005035534A1 A NN O
, WO2005035534A1 A , O
lipid WO2005035534A1 A JJ O
metabolic WO2005035534A1 A JJ O
error WO2005035534A1 A NN O
, WO2005035534A1 A , O
lipemia WO2005035534A1 A NN O
, WO2005035534A1 A , O
hyperlipidemia WO2005035534A1 A NN O
, WO2005035534A1 A , O
hypertriglyceridemia WO2005035534A1 A NN O
, WO2005035534A1 A , O
obesity WO2005035534A1 A NN O
, WO2005035534A1 A , O
athelomatous WO2005035534A1 A JJ O
arteriosclerosis WO2005035534A1 A NN O
, WO2005035534A1 A , O
syndrome WO2005035534A1 A JJ O
X WO2005035534A1 A NNP O
, WO2005035534A1 A , O
Cushing’s WO2005035534A1 A NNP O
syndrome WO2005035534A1 A NN O
, WO2005035534A1 A , O
hypertension WO2005035534A1 A NN O
, WO2005035534A1 A , O
cognitive WO2005035534A1 A JJ O
impairment WO2005035534A1 A NN O
, WO2005035534A1 A , O
memory WO2005035534A1 A NN O
impairment WO2005035534A1 A NN O
, WO2005035534A1 A , O
depression WO2005035534A1 A NN O
, WO2005035534A1 A , O
anxiety WO2005035534A1 A NN O
, WO2005035534A1 A , O
dementia WO2005035534A1 A NN O
, WO2005035534A1 A , O
Alzheimer’s WO2005035534A1 A NNP O
disease WO2005035534A1 A NN O
, WO2005035534A1 A , O
osteoporosis WO2005035534A1 A NN O
, WO2005035534A1 A , O
glaucoma WO2005035534A1 A NN O
or WO2005035534A1 A CC O
immune WO2005035534A1 A JJ O
diseases WO2005035534A1 A NNS O
. WO2005035534A1 A . O

Azulene US7169761 T NNP O
derivatives US7169761 T NNS O
and US7169761 T CC O
salts US7169761 T NNS O
thereof US7169761 T NN O
. US7169761 T . O

The US7169761 A DT O
present US7169761 A JJ O
invention US7169761 A NN O
provides US7169761 A VBZ O
an US7169761 A DT O
azulene US7169761 A JJ O
derivative US7169761 A NN O
and US7169761 A CC O
a US7169761 A DT O
salt US7169761 A NN O
thereof US7169761 A NN O
, US7169761 A , O
wherein US7169761 A VBP O
an US7169761 A DT O
azulene US7169761 A NN O
ring US7169761 A NN O
is US7169761 A VBZ O
bonded US7169761 A VBN O
to US7169761 A TO O
a US7169761 A DT O
benzene US7169761 A NN O
ring US7169761 A VBG O
directly US7169761 A RB O
or US7169761 A CC O
via US7169761 A IN O
a US7169761 A DT O
lower US7169761 A JJR O
alkylene US7169761 A NN O
which US7169761 A WDT O
may US7169761 A MD O
be US7169761 A VB O
substituted US7169761 A VBN O
with US7169761 A IN O
a US7169761 A DT O
halogen US7169761 A NN O
atom US7169761 A NN O
and US7169761 A CC O
the US7169761 A DT O
benzene US7169761 A NN O
ring US7169761 A NN O
is US7169761 A VBZ O
directly US7169761 A RB O
bonded US7169761 A VBN O
to US7169761 A TO O
the US7169761 A DT O
glucose US7169761 A NN O
residue US7169761 A NN O
, US7169761 A , O
and US7169761 A CC O
it US7169761 A PRP O
is US7169761 A VBZ O
usable US7169761 A JJ O
as US7169761 A IN O
a US7169761 A DT O
Na+-glucose US7169761 A JJ I-UN
cotransporter US7169761 A NN I-UN
inhibitor US7169761 A NN O
, US7169761 A , O
especially US7169761 A RB O
for US7169761 A IN O
a US7169761 A DT O
therapeutic US7169761 A JJ O
and/or US7169761 A NN O
preventive US7169761 A JJ O
agent US7169761 A NN O
for US7169761 A IN O
diabetes US7169761 A NNS O
such US7169761 A JJ O
as US7169761 A IN O
insulin-dependent US7169761 A JJ O
diabetes US7169761 A NNS O
( US7169761 A ( O
type US7169761 A JJ O
1 US7169761 A CD O
diabetes US7169761 A NNS O
) US7169761 A ) O
and US7169761 A CC O
insulin-independent US7169761 A JJ O
diabetes US7169761 A NNS O
( US7169761 A ( O
type US7169761 A JJ O
2 US7169761 A CD O
diabetes US7169761 A NNS O
) US7169761 A ) O
, US7169761 A , O
as US7169761 A RB O
well US7169761 A RB O
as US7169761 A IN O
diabetes-related US7169761 A JJ O
diseases US7169761 A NNS O
such US7169761 A JJ O
as US7169761 A IN O
insulin-resistant US7169761 A JJ O
diseases US7169761 A NNS O
and US7169761 A CC O
obesity US7169761 A NN O
. US7169761 A . O

Crystal CN103360276A T JJ O
form CN103360276A T NN O
, CN103360276A T , O
preparation CN103360276A T NN O
method CN103360276A T NN O
and CN103360276A T CC O
application CN103360276A T NN O
of CN103360276A T IN O
agomelatine CN103360276A T NN O
, CN103360276A T , O
as CN103360276A T RB O
well CN103360276A T RB O
as CN103360276A T IN O
medicine CN103360276A T JJ O
composition CN103360276A T NN O
. CN103360276A T . O

Transplanting US7067496 T VBG O
into US7067496 T IN O
dermis US7067496 T NN O
, US7067496 T , O
least US7067496 T JJS O
one US7067496 T CD O
hair US7067496 T NN O
follicle US7067496 T NN O
that US7067496 T WDT O
has US7067496 T VBZ O
been US7067496 T VBN O
modified US7067496 T VBN O
ex US7067496 T JJ O
vivo US7067496 T NN O
to US7067496 T TO O
contain US7067496 T VB O
nucleic US7067496 T JJ O
acid US7067496 T NN O
molecule US7067496 T NN O
to US7067496 T TO O
introduce US7067496 T VB O
nucleic US7067496 T JJ O
acid US7067496 T NN O
molecule US7067496 T NN O
into US7067496 T IN O
mammal US7067496 T NN O
. US7067496 T . O

Modification US7067496 A NN O
is US7067496 A VBZ O
assisted US7067496 A VBN O
by US7067496 A IN O
treating US7067496 A VBG O
the US7067496 A DT O
histoculture US7067496 A NN O
with US7067496 A IN O
collagenase US7067496 A NN I-UN
prior US7067496 A RB O
to US7067496 A TO O
contacting US7067496 A VBG O
the US7067496 A DT O
histoculture US7067496 A NN O
with US7067496 A IN O
the US7067496 A DT O
delivery US7067496 A NN O
vehicle US7067496 A NN O
for US7067496 A IN O
the US7067496 A DT O
desired US7067496 A JJ O
gene US7067496 A NN O
. US7067496 A . O

Method CA2336628C T NNP O
for CA2336628C T IN O
reducing CA2336628C T VBG O
the CA2336628C T DT O
damaging CA2336628C T JJ O
effects CA2336628C T NNS O
of CA2336628C T IN O
radiation CA2336628C T NN O
therapy CA2336628C T NN O
on CA2336628C T IN O
animal CA2336628C T NN O
skin CA2336628C T NN O
and CA2336628C T CC O
mucosa CA2336628C T NN O
. CA2336628C T . O

Medicine CN101032517A T NNP O
for CN101032517A T IN O
curing CN101032517A T VBG O
dermatophytosis CN101032517A T NN O
. CN101032517A T . O

Acyclic US20100179224 T NNP O
Sulfamide US20100179224 T NNP O
Derivatives US20100179224 T NNP O
. US20100179224 T . O

Glycoside CA2832958A1 T NNP O
derivatives CA2832958A1 T NNS O
and CA2832958A1 T CC O
their CA2832958A1 T PRP$ O
use CA2832958A1 T NN O
for CA2832958A1 T IN O
the CA2832958A1 T DT O
treatment CA2832958A1 T NN O
of CA2832958A1 T IN O
diabetes CA2832958A1 T NNS O
. CA2832958A1 T . O

The CA2832958A1 A DT O
present CA2832958A1 A JJ O
invention CA2832958A1 A NN O
provides CA2832958A1 A VBZ O
a CA2832958A1 A DT O
compound CA2832958A1 A NN O
of CA2832958A1 A IN O
formula CA2832958A1 A NN O
I CA2832958A1 A PRP O
; CA2832958A1 A : O
( CA2832958A1 A ( O
I CA2832958A1 A PRP O
) CA2832958A1 A ) O
a CA2832958A1 A DT O
method CA2832958A1 A NN O
for CA2832958A1 A IN O
manufacturing CA2832958A1 A VBG O
the CA2832958A1 A DT O
compounds CA2832958A1 A NNS O
of CA2832958A1 A IN O
the CA2832958A1 A DT O
invention CA2832958A1 A NN O
, CA2832958A1 A , O
and CA2832958A1 A CC O
its CA2832958A1 A PRP$ O
therapeutic CA2832958A1 A JJ O
uses CA2832958A1 A NNS O
. CA2832958A1 A . O

The CA2832958A1 A DT O
present CA2832958A1 A JJ O
invention CA2832958A1 A NN O
further CA2832958A1 A RBR O
provides CA2832958A1 A VBZ O
a CA2832958A1 A DT O
combination CA2832958A1 A NN O
of CA2832958A1 A IN O
pharmacologically CA2832958A1 A RB O
active CA2832958A1 A JJ O
agents CA2832958A1 A NNS O
and CA2832958A1 A CC O
a CA2832958A1 A DT O
pharmaceutical CA2832958A1 A JJ O
composition CA2832958A1 A NN O
. CA2832958A1 A . O

Hormone CN101797257A T CD O
preparation CN101797257A T NN O
for CN101797257A T IN O
sow CN101797257A T JJ O
aphrodisiac CN101797257A T NN O
. CN101797257A T . O

Compositions US8518919 T NNS O
comprising US8518919 T VBG O
azelastine US8518919 T NN O
and US8518919 T CC O
methods US8518919 T NNS O
of US8518919 T IN O
use US8518919 T NN O
thereof US8518919 T NN O
. US8518919 T . O

COMBINATION US20120128628 T NNP O
OF US20120128628 T IN O
A US20120128628 T NNP O
NUCLEOSIDE US20120128628 T NNP I-UN
POLYMERASE US20120128628 T NNP I-UN
INHIBITOR US20120128628 T NNP O
WITH US20120128628 T NNP O
A US20120128628 T NNP O
MACROCYCLIC US20120128628 T NNP O
PROTEASE US20120128628 T NNP I-UN
INHIBITOR US20120128628 T NNP O
AND US20120128628 T NNP O
USE US20120128628 T NNP O
THEREOF US20120128628 T NNP O
IN US20120128628 T NNP O
THE US20120128628 T NNP O
TREATMENT US20120128628 T NNP O
OF US20120128628 T NNP O
HEPATITIS US20120128628 T NNP O
C US20120128628 T NNP O
, US20120128628 T , O
LIVER US20120128628 T NNP O
FIBROSIS US20120128628 T NNP O
AND US20120128628 T NNP O
IMPAIRED US20120128628 T NNP O
LIVER US20120128628 T NNP O
FUNCTION US20120128628 T NNP O
( US20120128628 T ( O
as US20120128628 T IN O
amended US20120128628 T VBN O
) US20120128628 T ) O
. US20120128628 T . O

Embodiments US20120128628 A NNS O
disclosed US20120128628 A VBN O
in US20120128628 A IN O
the US20120128628 A DT O
present US20120128628 A JJ O
application US20120128628 A NN O
relate US20120128628 A NN O
to US20120128628 A TO O
a US20120128628 A DT O
composition US20120128628 A NN O
that US20120128628 A WDT O
can US20120128628 A MD O
include US20120128628 A VB O
a US20120128628 A DT O
hepatitis US20120128628 A NN I-UN
C US20120128628 A NNP I-UN
viral US20120128628 A JJ I-UN
polymerase US20120128628 A NN I-UN
inhibitor US20120128628 A NN O
, US20120128628 A , O
or US20120128628 A CC O
pharmaceutically US20120128628 A RB O
acceptable US20120128628 A JJ O
salt US20120128628 A NN O
or US20120128628 A CC O
prodrug US20120128628 A NN O
thereof US20120128628 A NN O
and US20120128628 A CC O
a US20120128628 A DT O
hepatitis US20120128628 A NN I-UN
C US20120128628 A NNP I-UN
viral US20120128628 A JJ I-UN
protease US20120128628 A NN I-UN
inhibitor US20120128628 A NN O
, US20120128628 A , O
or US20120128628 A CC O
pharmaceutically US20120128628 A RB O
acceptable US20120128628 A JJ O
salt US20120128628 A NN O
or US20120128628 A CC O
prodrug US20120128628 A JJ O
thereof US20120128628 A NN O
. US20120128628 A . O

Additional US20120128628 A JJ O
embodiments US20120128628 A NNS O
disclosed US20120128628 A VBD O
relate US20120128628 A NN O
to US20120128628 A TO O
methods US20120128628 A NNS O
for US20120128628 A IN O
treating US20120128628 A VBG O
a US20120128628 A DT O
disease US20120128628 A NN O
condition US20120128628 A NN O
such US20120128628 A JJ O
as US20120128628 A IN O
a US20120128628 A DT O
hepatitis US20120128628 A NN O
C US20120128628 A NNP O
virus US20120128628 A NN O
infection US20120128628 A NN O
, US20120128628 A , O
liver US20120128628 A JJ O
fibrosis US20120128628 A NN O
and/or US20120128628 A NN O
impaired US20120128628 A VBD O
liver US20120128628 A JJ O
function US20120128628 A NN O
with US20120128628 A IN O
a US20120128628 A DT O
hepatitis US20120128628 A NN I-UN
C US20120128628 A NNP I-UN
viral US20120128628 A JJ I-UN
polymerase US20120128628 A NN I-UN
inhibitor US20120128628 A NN O
, US20120128628 A , O
or US20120128628 A CC O
pharmaceutically US20120128628 A RB O
acceptable US20120128628 A JJ O
salt US20120128628 A NN O
or US20120128628 A CC O
prodrug US20120128628 A NN O
thereof US20120128628 A NN O
and US20120128628 A CC O
a US20120128628 A DT O
hepatitis US20120128628 A NN O
C US20120128628 A NNP O
viral US20120128628 A JJ O
protease US20120128628 A NN O
inhibitor US20120128628 A NN O
, US20120128628 A , O
or US20120128628 A CC O
pharmaceutically US20120128628 A RB O
acceptable US20120128628 A JJ O
salt US20120128628 A NN O
or US20120128628 A CC O
prodrug US20120128628 A JJ O
thereof US20120128628 A NN O
. US20120128628 A . O

Steroid WO2008065428A2 T JJ I-UN
sulphatase WO2008065428A2 T NN I-UN
inhibitors WO2008065428A2 T NNS O
for WO2008065428A2 T IN O
treating WO2008065428A2 T VBG O
hormone WO2008065428A2 T NN O
dependent WO2008065428A2 T JJ O
cancer WO2008065428A2 T NN O
. WO2008065428A2 T . O

There WO2008065428A2 A EX O
is WO2008065428A2 A VBZ O
provided WO2008065428A2 A VBN O
use WO2008065428A2 A NN O
of WO2008065428A2 A IN O
a WO2008065428A2 A DT O
compound WO2008065428A2 A NN O
capable WO2008065428A2 A JJ O
of WO2008065428A2 A IN O
inhibiting WO2008065428A2 A VBG O
a WO2008065428A2 A DT O
steroid WO2008065428A2 A JJ I-UN
sulphatase WO2008065428A2 A NN I-UN
enzyme WO2008065428A2 A NN O
( WO2008065428A2 A ( O
E.C.3.1.6.2 WO2008065428A2 A NNP O
) WO2008065428A2 A ) O
in WO2008065428A2 A IN O
the WO2008065428A2 A DT O
manufacture WO2008065428A2 A NN O
of WO2008065428A2 A IN O
a WO2008065428A2 A DT O
medicament WO2008065428A2 A NN O
for WO2008065428A2 A IN O
the WO2008065428A2 A DT O
treatment WO2008065428A2 A NN O
of WO2008065428A2 A IN O
cancer WO2008065428A2 A NN O
, WO2008065428A2 A , O
wherein WO2008065428A2 A VBP O
the WO2008065428A2 A DT O
cancer WO2008065428A2 A NN O
is WO2008065428A2 A VBZ O
of WO2008065428A2 A IN O
a WO2008065428A2 A DT O
type WO2008065428A2 A NN O
in WO2008065428A2 A IN O
which WO2008065428A2 A WDT O
the WO2008065428A2 A DT O
cancer WO2008065428A2 A NN O
cells WO2008065428A2 A NNS O
overexpress WO2008065428A2 A JJ O
aromatase WO2008065428A2 A NN I-UN
enzyme WO2008065428A2 A NN O
. WO2008065428A2 A . O

Chondrocyte-like CN102257133A T NNP O
cell CN102257133A T NN O
, CN102257133A T , O
and CN102257133A T CC O
method CN102257133A T NN O
for CN102257133A T IN O
producing CN102257133A T VBG O
same CN102257133A T JJ O
. CN102257133A T . O

A CN102257133A A DT O
chondrocyte-like CN102257133A A NN O
cell CN102257133A A NN O
which CN102257133A A WDT O
has CN102257133A A VBZ O
the CN102257133A A DT O
same CN102257133A A JJ O
properties CN102257133A A NNS O
as CN102257133A A IN O
those CN102257133A A DT O
of CN102257133A A IN O
a CN102257133A A DT O
chondrocyte CN102257133A A NN O
and CN102257133A A CC O
can CN102257133A A MD O
proliferate CN102257133A A VB O
can CN102257133A A MD O
be CN102257133A A VB O
produced CN102257133A A VBN O
by CN102257133A A IN O
selecting CN102257133A A VBG O
a CN102257133A A DT O
combination CN102257133A A NN O
of CN102257133A A IN O
an CN102257133A A DT O
Myc CN102257133A A NNP I-UN
family CN102257133A A NN O
gene CN102257133A A NN O
and/or CN102257133A A VBP O
a CN102257133A A DT O
Klf CN102257133A A NNP I-UN
family CN102257133A A NN O
gene CN102257133A A NN O
and CN102257133A A CC O
a CN102257133A A DT O
SOX9 CN102257133A A NNP I-UN
gene CN102257133A A NN I-UN
and CN102257133A A CC O
introducing CN102257133A A VBG O
the CN102257133A A DT O
combination CN102257133A A NN O
into CN102257133A A IN O
a CN102257133A A DT O
somatic CN102257133A A JJ O
cell CN102257133A A NN O
. CN102257133A A . O

Hyaluronic WO2007064543A1 T NNP O
acid WO2007064543A1 T NN O
and WO2007064543A1 T CC O
hyaluronidase WO2007064543A1 T NN O
in WO2007064543A1 T IN O
the WO2007064543A1 T DT O
enhancement WO2007064543A1 T NN O
of WO2007064543A1 T IN O
lens WO2007064543A1 T JJ O
regeneration WO2007064543A1 T NN O
. WO2007064543A1 T . O

Pyrazolospiroketone WO2009144555A8 T CD O
acetyl-coa WO2009144555A8 T JJ O
carboxylase WO2009144555A8 T NN O
inhibitors WO2009144555A8 T NNS O
. WO2009144555A8 T . O

Pharmaceutical WO2006045865A1 T JJ O
formulation WO2006045865A1 T NN O
comprising WO2006045865A1 T VBG O
microcapusles WO2006045865A1 T NNS O
of WO2006045865A1 T IN O
statins WO2006045865A1 T NNS O
suspended WO2006045865A1 T VBN O
in WO2006045865A1 T IN O
alkyl WO2006045865A1 T JJ O
esters WO2006045865A1 T NNS O
of WO2006045865A1 T IN O
polyunsaturated WO2006045865A1 T JJ O
fatty WO2006045865A1 T JJ O
acids WO2006045865A1 T NNS O
( WO2006045865A1 T ( O
pufa WO2006045865A1 T NN O
) WO2006045865A1 T ) O
. WO2006045865A1 T . O

Method EP2194780A1 T NNP O
of EP2194780A1 T IN O
treating EP2194780A1 T VBG O
glaucoma EP2194780A1 T NN O
using EP2194780A1 T VBG O
rasagiline EP2194780A1 T NN O
. EP2194780A1 T . O

Medicine CN101062182A T NNP O
made CN101062182A T VBD O
from CN101062182A T IN O
root CN101062182A T NN O
of CN101062182A T IN O
dahuriae CN101062182A T NN O
angelica CN101062182A T NN O
, CN101062182A T , O
atractylodes CN101062182A T NNS O
and CN101062182A T CC O
so CN101062182A T RB O
on CN101062182A T IN O
for CN101062182A T IN O
treating CN101062182A T VBG O
snakebite CN101062182A T NN O
. CN101062182A T . O

Selected CA2256633C T VBN O
derivatives CA2256633C T NNS O
of CA2256633C T IN O
k-252a CA2256633C T NN O
. CA2256633C T . O

They CA2256633C A PRP O
inhibit CA2256633C A VBP O
interleukin-2 CA2256633C A JJ I-UN
production CA2256633C A NN O
and CA2256633C A CC O
have CA2256633C A VBP O
immunosuppressive CA2256633C A JJ O
activity CA2256633C A NN O
. CA2256633C A . O

Preparation CN101693012A T NN O
and CN101693012A T CC O
application CN101693012A T NN O
of CN101693012A T IN O
florfenicol CN101693012A T JJ O
slowly-releasing CN101693012A T JJ O
micropill CN101693012A T NN O
for CN101693012A T IN O
treating CN101693012A T VBG O
animal CN101693012A T JJ O
digestive CN101693012A T JJ O
canal CN101693012A T JJ O
infection CN101693012A T NN O
. CN101693012A T . O

Medicine CN103638422A T NNP O
for CN103638422A T IN O
treating CN103638422A T VBG O
urinary CN103638422A T JJ O
retention CN103638422A T NN O
and CN103638422A T CC O
preparation CN103638422A T NN O
method CN103638422A T NN O
of CN103638422A T IN O
medicine CN103638422A T NN O
. CN103638422A T . O

Method CN101333236A T NNP O
for CN101333236A T IN O
preparing CN101333236A T VBG O
clitocine CN101333236A T NN O
and CN101333236A T CC O
applications CN101333236A T NNS O
in CN101333236A T IN O
antineoplastic CN101333236A T JJ O
medicaments CN101333236A T NNS O
. CN101333236A T . O

Using US20090131353 T VBG O
cyclic US20090131353 T JJ O
nucleotide US20090131353 T JJ O
phosphodiesterase US20090131353 T NN O
profiles US20090131353 T NNS O
as US20090131353 T IN O
tool US20090131353 T NN O
in US20090131353 T IN O
detection US20090131353 T NN O
of US20090131353 T IN O
cell US20090131353 T NN O
proliferative US20090131353 T JJ O
disorders US20090131353 T NNS O
. US20090131353 T . O

The US20090131353 A DT O
present US20090131353 A JJ O
invention US20090131353 A NN O
provides US20090131353 A VBZ O
diagnostic US20090131353 A JJ O
methods US20090131353 A NNS O
and US20090131353 A CC O
kits US20090131353 A NNS O
for US20090131353 A IN O
diagnosis US20090131353 A NN O
of US20090131353 A IN O
chronic US20090131353 A JJ O
lymphocytic US20090131353 A JJ O
leukemia US20090131353 A NN O
( US20090131353 A ( O
CLL US20090131353 A NNP O
) US20090131353 A ) O
by US20090131353 A IN O
determining US20090131353 A VBG O
expression US20090131353 A NN O
levels US20090131353 A NNS O
of US20090131353 A IN O
isoforms US20090131353 A NNS O
of US20090131353 A IN O
cyclic US20090131353 A JJ O
nucleotide US20090131353 A JJ O
phosphodiesterases US20090131353 A NNS I-UN
( US20090131353 A ( O
PDEs US20090131353 A NNP I-UN
) US20090131353 A ) O
associated US20090131353 A VBN O
with US20090131353 A IN O
CLL US20090131353 A NNP O
particularly US20090131353 A RB O
, US20090131353 A , O
PDE7B US20090131353 A NNP I-UN
and/or US20090131353 A VBZ O
PDE3B US20090131353 A NNP I-UN
, US20090131353 A , O
and US20090131353 A CC O
a US20090131353 A DT O
ratio US20090131353 A NN O
of US20090131353 A IN O
mRNA US20090131353 A JJ O
expression US20090131353 A NN O
of US20090131353 A IN O
PDE7B US20090131353 A NNP I-UN
to US20090131353 A TO O
PDE3B US20090131353 A NNP I-UN
. US20090131353 A . O

The US20090131353 A DT O
present US20090131353 A JJ O
invention US20090131353 A NN O
provides US20090131353 A VBZ O
that US20090131353 A IN O
CLL US20090131353 A NNP O
lymphocytes US20090131353 A VBZ O
uniformly US20090131353 A RB O
expressed US20090131353 A VBN O
high US20090131353 A JJ O
levels US20090131353 A NNS O
of US20090131353 A IN O
PDE7B US20090131353 A NNP I-UN
and US20090131353 A CC O
low US20090131353 A JJ O
levels US20090131353 A NNS O
of US20090131353 A IN O
PDE3B US20090131353 A NNP I-UN
relative US20090131353 A JJ O
to US20090131353 A TO O
those US20090131353 A DT O
of US20090131353 A IN O
normal US20090131353 A JJ O
lymphocytes US20090131353 A NNS O
. US20090131353 A . O

A US20090131353 A DT O
method US20090131353 A NN O
of US20090131353 A IN O
treatment US20090131353 A NN O
and US20090131353 A CC O
a US20090131353 A DT O
pharmaceutical US20090131353 A JJ O
composition US20090131353 A NN O
for US20090131353 A IN O
CLL US20090131353 A NNP O
comprising US20090131353 A VBG O
one US20090131353 A CD O
or US20090131353 A CC O
more US20090131353 A JJR O
therapeutic US20090131353 A JJ O
agents US20090131353 A NNS O
capable US20090131353 A JJ O
of US20090131353 A IN O
modulating US20090131353 A VBG O
expression US20090131353 A NN O
or US20090131353 A CC O
activity US20090131353 A NN O
levels US20090131353 A NNS O
of US20090131353 A IN O
isoforms US20090131353 A NNS O
of US20090131353 A IN O
PDEs US20090131353 A NNP I-UN
associated US20090131353 A VBD O
with US20090131353 A IN O
CLL US20090131353 A NNP O
, US20090131353 A , O
and/or US20090131353 A RB O
reversing US20090131353 A VBG O
the US20090131353 A DT O
ratio US20090131353 A NN O
of US20090131353 A IN O
PDE7B/PDE3B US20090131353 A NNP O
mRNA US20090131353 A FW O
expression US20090131353 A NN O
levels US20090131353 A NNS O
are US20090131353 A VBP O
also US20090131353 A RB O
provided US20090131353 A VBN O
. US20090131353 A . O

Micro-powder CN1850079A T JJ O
dom CN1850079A T NN O
peridone CN1850079A T NN O
maleate CN1850079A T NN O
medicinal CN1850079A T JJ O
composition CN1850079A T NN O
and CN1850079A T CC O
its CN1850079A T PRP$ O
preparing CN1850079A T NN O
method CN1850079A T NN O
. CN1850079A T . O

Use EP2113251A1 T NNP O
of EP2113251A1 T IN O
compounds EP2113251A1 T NNS O
as EP2113251A1 T IN O
inhibitors EP2113251A1 T NNS O
for EP2113251A1 T IN O
helicobacter EP2113251A1 T NN O
flavodoxin EP2113251A1 T NN I-UN
. EP2113251A1 T . O

Aminoglycoside CN103665069A T NNP O
compound CN103665069A T NN O
and CN103665069A T CC O
extraction CN103665069A T NN O
separation CN103665069A T NN O
method CN103665069A T NN O
thereof CN103665069A T NN O
. CN103665069A T . O

Tricyclic WO2009059047A3 T NNP O
compounds WO2009059047A3 T NNS O
and WO2009059047A3 T CC O
methods WO2009059047A3 T NNS O
for WO2009059047A3 T IN O
using WO2009059047A3 T VBG O
the WO2009059047A3 T DT O
same WO2009059047A3 T JJ O
. WO2009059047A3 T . O

The WO2009059047A3 A DT O
invention WO2009059047A3 A NN O
provides WO2009059047A3 A VBZ O
tricyclic WO2009059047A3 A JJ O
compounds WO2009059047A3 A NNS O
of WO2009059047A3 A IN O
the WO2009059047A3 A DT O
formula WO2009059047A3 A NN O
: WO2009059047A3 A : O
or WO2009059047A3 A CC O
a WO2009059047A3 A DT O
pharmaceutically WO2009059047A3 A RB O
acceptable WO2009059047A3 A JJ O
salt WO2009059047A3 A NN O
or WO2009059047A3 A CC O
a WO2009059047A3 A DT O
pro-drug WO2009059047A3 A JJ O
thereof WO2009059047A3 A NN O
, WO2009059047A3 A , O
where WO2009059047A3 A WRB O
R1 WO2009059047A3 A NNP O
, WO2009059047A3 A , O
R2 WO2009059047A3 A NNP O
, WO2009059047A3 A , O
X WO2009059047A3 A NNP O
, WO2009059047A3 A , O
Y WO2009059047A3 A NNP O
, WO2009059047A3 A , O
n WO2009059047A3 A RB O
, WO2009059047A3 A , O
A WO2009059047A3 A NNP O
, WO2009059047A3 A , O
and WO2009059047A3 A CC O
B WO2009059047A3 A NNP O
are WO2009059047A3 A VBP O
those WO2009059047A3 A DT O
defined WO2009059047A3 A JJ O
herein WO2009059047A3 A NN O
. WO2009059047A3 A . O

The WO2009059047A3 A DT O
invention WO2009059047A3 A NN O
also WO2009059047A3 A RB O
provides WO2009059047A3 A VBZ O
compositions WO2009059047A3 A NNS O
comprising WO2009059047A3 A VBG O
the WO2009059047A3 A DT O
same WO2009059047A3 A JJ O
, WO2009059047A3 A , O
and WO2009059047A3 A CC O
methods WO2009059047A3 A NNS O
for WO2009059047A3 A IN O
using WO2009059047A3 A VBG O
the WO2009059047A3 A DT O
same WO2009059047A3 A JJ O
. WO2009059047A3 A . O

Preparation CN103536926A T NNP O
method CN103536926A T NN O
of CN103536926A T IN O
chitosan CN103536926A T JJ O
oligosaccharide CN103536926A T JJ O
nanoparticle CN103536926A T NN O
. CN103536926A T . O

3-azabicyclo US7049335 T JJ O
[ US7049335 T NN O
3.1.0 US7049335 T CD O
] US7049335 T NNP O
hexane US7049335 T NN O
derivatives US7049335 T NNS O
. US7049335 T . O

Compounds US7049335 A NNS O
of US7049335 A IN O
formula US7049335 A NN O
I US7049335 A PRP O
have US7049335 A VBP O
activity US7049335 A NN O
as US7049335 A IN O
opioid US7049335 A JJ I-UN
receptor US7049335 A NN I-UN
antagonists US7049335 A NNS O
. US7049335 A . O

Controlled EP1490029A4 T VBN O
release EP1490029A4 T JJ O
drug EP1490029A4 T NN O
delivery EP1490029A4 T NN O
system EP1490029A4 T NN O
of EP1490029A4 T IN O
pravastatin EP1490029A4 T NN O
. EP1490029A4 T . O

Pharmaceutical WO2013142202A1 T JJ O
compositions WO2013142202A1 T NNS O
comprising WO2013142202A1 T VBG O
glycerol WO2013142202A1 T NN O
esters WO2013142202A1 T NNS O
. WO2013142202A1 T . O

Medicament CN102119951A T NN O
for CN102119951A T IN O
treating CN102119951A T VBG O
plugged CN102119951A T JJ O
duct CN102119951A T NN O
of CN102119951A T IN O
breast CN102119951A T NN O
and CN102119951A T CC O
preparation CN102119951A T NN O
method CN102119951A T NN O
thereof CN102119951A T NN O
. CN102119951A T . O

Oxazolo US7148232 T NNP O
, US7148232 T , O
thiazolo US7148232 T NN O
and US7148232 T CC O
selenazolo US7148232 T JJ O
[ US7148232 T NNP O
4,5-c US7148232 T JJ O
] US7148232 T NNP O
-quinolin-4-amines US7148232 T NNS O
and US7148232 T CC O
analogs US7148232 T NNS O
thereof US7148232 T NN O
. US7148232 T . O

Preparation WO2013186138A1 T NN O
comprising WO2013186138A1 T VBG O
insulin WO2013186138A1 T NN I-UN
, WO2013186138A1 T , O
nicotinamide WO2013186138A1 T RB O
and WO2013186138A1 T CC O
arginine WO2013186138A1 T VB O
. WO2013186138A1 T . O

Insulin WO2013186138A1 A NNP I-UN
preparations WO2013186138A1 A NNS O
comprising WO2013186138A1 A VBG O
an WO2013186138A1 A DT O
insulin WO2013186138A1 A NN I-UN
compound WO2013186138A1 A NN O
or WO2013186138A1 A CC O
a WO2013186138A1 A DT O
mixture WO2013186138A1 A NN O
of WO2013186138A1 A IN O
two WO2013186138A1 A CD O
or WO2013186138A1 A CC O
more WO2013186138A1 A JJR O
insulin WO2013186138A1 A JJ I-UN
compounds WO2013186138A1 A NNS O
, WO2013186138A1 A , O
a WO2013186138A1 A DT O
nicotinic WO2013186138A1 A JJ O
compound WO2013186138A1 A NN O
and WO2013186138A1 A CC O
arginine WO2013186138A1 A NN O
. WO2013186138A1 A . O

Dry US20120107406 T NNP O
Powder US20120107406 T NNP O
Formulations US20120107406 T NNP O
. US20120107406 T . O

Biomaterials US20100144666 T NNS O
In US20100144666 T IN O
the US20100144666 T DT O
Form US20100144666 T NNP O
of US20100144666 T IN O
Fibres US20100144666 T NNP O
for US20100144666 T IN O
Use US20100144666 T NNP O
as US20100144666 T IN O
Medical US20100144666 T NNP O
Devices US20100144666 T NNPS O
In US20100144666 T IN O
the US20100144666 T DT O
Treatment US20100144666 T NNP O
of US20100144666 T IN O
Wounds US20100144666 T NNP O
, US20100144666 T , O
and US20100144666 T CC O
Their US20100144666 T PRP$ O
Production US20100144666 T NN O
Process US20100144666 T NN O
. US20100144666 T . O

The US20100144666 A DT O
present US20100144666 A JJ O
invention US20100144666 A NN O
relates US20100144666 A VBZ O
to US20100144666 A TO O
new US20100144666 A JJ O
biomaterials US20100144666 A NNS O
in US20100144666 A IN O
the US20100144666 A DT O
form US20100144666 A NN O
of US20100144666 A IN O
fibres US20100144666 A NNS O
, US20100144666 A , O
essentially US20100144666 A RB O
consisting US20100144666 A VBG O
of US20100144666 A IN O
a US20100144666 A DT O
mixture US20100144666 A NN O
of US20100144666 A IN O
gellan US20100144666 A NN O
and US20100144666 A CC O
hyaluronic US20100144666 A JJ O
acid US20100144666 A NN O
derivatives US20100144666 A NNS O
, US20100144666 A , O
for US20100144666 A IN O
use US20100144666 A NN O
in US20100144666 A IN O
surgery US20100144666 A NN O
, US20100144666 A , O
especially US20100144666 A RB O
in US20100144666 A IN O
the US20100144666 A DT O
treatment US20100144666 A NN O
of US20100144666 A IN O
wounds US20100144666 A NNS O
and US20100144666 A CC O
mild US20100144666 A JJ O
burns US20100144666 A NNS O
. US20100144666 A . O

The US20100144666 A DT O
present US20100144666 A JJ O
invention US20100144666 A NN O
also US20100144666 A RB O
relates US20100144666 A VBZ O
to US20100144666 A TO O
the US20100144666 A DT O
process US20100144666 A NN O
for US20100144666 A IN O
the US20100144666 A DT O
preparation US20100144666 A NN O
of US20100144666 A IN O
said US20100144666 A VBD O
biomaterials US20100144666 A NNS O
. US20100144666 A . O

Use CN101214247A T NNP O
of CN101214247A T IN O
tetramethylpyrazine CN101214247A T NN O
and CN101214247A T CC O
its CN101214247A T PRP$ O
salt CN101214247A T NN O
. CN101214247A T . O

Use WO2005013691A1 T NNP O
of WO2005013691A1 T IN O
boranocarbonates WO2005013691A1 T NNS O
for WO2005013691A1 T IN O
the WO2005013691A1 T DT O
therapeutic WO2005013691A1 T JJ O
delivery WO2005013691A1 T NN O
of WO2005013691A1 T IN O
carbon WO2005013691A1 T NN O
monoxide WO2005013691A1 T NN O
. WO2005013691A1 T . O

1-aza-bicyclo WO2009153536A1 T JJ O
[ WO2009153536A1 T NN O
2.2.2 WO2009153536A1 T CD O
] WO2009153536A1 T NNP O
octane WO2009153536A1 T NN O
derivatives WO2009153536A1 T NNS O
useful WO2009153536A1 T JJ O
as WO2009153536A1 T IN O
muscarinic WO2009153536A1 T JJ I-UN
receptor WO2009153536A1 T NN I-UN
antagonists WO2009153536A1 T NNS O
. WO2009153536A1 T . O

Hepatitis US20090215869 T NNP O
c US20090215869 T VBZ O
virus US20090215869 T JJ O
non-structural US20090215869 T JJ O
ns3/4a US20090215869 T JJ I-UN
fusion US20090215869 T NN O
gene US20090215869 T NN O
. US20090215869 T . O

Aspects US20090215869 A NNS O
of US20090215869 A IN O
the US20090215869 A DT O
present US20090215869 A JJ O
invention US20090215869 A NN O
relate US20090215869 A NN O
to US20090215869 A TO O
the US20090215869 A DT O
creation US20090215869 A NN O
of US20090215869 A IN O
mutant US20090215869 A JJ O
hepatitis US20090215869 A NN O
C US20090215869 A NNP O
virus US20090215869 A NN O
( US20090215869 A ( O
HCV US20090215869 A NNP O
) US20090215869 A ) O
NS3/4A US20090215869 A NNP I-UN
genes US20090215869 A NNS O
encoding US20090215869 A VBG O
proteins US20090215869 A NNS O
with US20090215869 A IN O
altered US20090215869 A JJ O
protease US20090215869 A NN I-UN
activity US20090215869 A NN O
. US20090215869 A . O

Embodiments US20090215869 A NNS O
include US20090215869 A VBP O
said US20090215869 A VBD O
NS3/4A US20090215869 A NNP I-UN
genes US20090215869 A NNS O
, US20090215869 A , O
HCV US20090215869 A NNP O
peptides US20090215869 A NNS O
encoded US20090215869 A VBN O
by US20090215869 A IN O
said US20090215869 A VBD O
nucleic US20090215869 A JJ O
acids US20090215869 A NNS O
, US20090215869 A , O
nucleic US20090215869 A JJ O
acids US20090215869 A NNS O
encoding US20090215869 A VBG O
said US20090215869 A VBD O
HCV US20090215869 A NNP O
peptides US20090215869 A NNS O
, US20090215869 A , O
antibodies US20090215869 A NNS O
directed US20090215869 A VBD O
to US20090215869 A TO O
said US20090215869 A VBD O
peptides US20090215869 A NNS O
, US20090215869 A , O
compositions US20090215869 A NNS O
containing US20090215869 A VBG O
said US20090215869 A VBD O
nucleic US20090215869 A JJ O
acids US20090215869 A NNS O
and US20090215869 A CC O
peptides US20090215869 A NNS O
, US20090215869 A , O
as US20090215869 A RB O
well US20090215869 A RB O
as US20090215869 A IN O
methods US20090215869 A NNS O
of US20090215869 A IN O
making US20090215869 A VBG O
and US20090215869 A CC O
using US20090215869 A VBG O
the US20090215869 A DT O
aforementioned US20090215869 A JJ O
compositions US20090215869 A NNS O
including US20090215869 A VBG O
, US20090215869 A , O
but US20090215869 A CC O
not US20090215869 A RB O
limited US20090215869 A JJ O
to US20090215869 A TO O
, US20090215869 A , O
diagnostics US20090215869 A NNS O
and US20090215869 A CC O
medicaments US20090215869 A NNS O
for US20090215869 A IN O
the US20090215869 A DT O
treatment US20090215869 A NN O
and US20090215869 A CC O
prevention US20090215869 A NN O
of US20090215869 A IN O
HCV US20090215869 A NNP O
infection US20090215869 A NN O
. US20090215869 A . O

Dermal US20130045290 T JJ O
rejuvenation US20130045290 T NN O
compositions US20130045290 T NNS O
and US20130045290 T CC O
methods US20130045290 T NNS O
. US20130045290 T . O

Anti-anoxia CN1682715A T JJ O
medicinal CN1682715A T JJ O
composition CN1682715A T NN O
. CN1682715A T . O

Application CN103405426A T NN O
of CN103405426A T IN O
compound CN103405426A T NN O
in CN103405426A T IN O
preparation CN103405426A T NN O
of CN103405426A T IN O
medicines CN103405426A T NNS O
for CN103405426A T IN O
treating CN103405426A T VBG O
acute CN103405426A T NN O
gout CN103405426A T NN O
. CN103405426A T . O

Experimental CN103405426A A JJ O
research CN103405426A A NN O
results CN103405426A A NNS O
show CN103405426A A VBP O
that CN103405426A A IN O
the CN103405426A A DT O
Aphanamgrandiol CN103405426A A NNP O
A CN103405426A A NNP O
has CN103405426A A VBZ O
the CN103405426A A DT O
protective CN103405426A A JJ O
effect CN103405426A A NN O
on CN103405426A A IN O
an CN103405426A A DT O
acute CN103405426A A NN O
gout CN103405426A A NN O
model CN103405426A A NN O
of CN103405426A A IN O
urate-caused CN103405426A A JJ O
injury CN103405426A A NN O
of CN103405426A A IN O
human CN103405426A A JJ O
vascular CN103405426A A JJ O
endothelial CN103405426A A NN O
cells CN103405426A A NNS O
and CN103405426A A CC O
inhibits CN103405426A A NNS O
expression CN103405426A A NN O
of CN103405426A A IN O
ICAM-1 CN103405426A A NNP I-UN
( CN103405426A A ( O
Intercellular CN103405426A A NNP I-UN
Adhesion CN103405426A A NNP I-UN
Molecule CN103405426A A NNP I-UN
1 CN103405426A A CD I-UN
) CN103405426A A ) O
, CN103405426A A , O
so CN103405426A A RB O
that CN103405426A A IN O
the CN103405426A A DT O
Aphanamgrandiol CN103405426A A NNP O
A CN103405426A A NNP O
can CN103405426A A MD O
be CN103405426A A VB O
used CN103405426A A VBN O
to CN103405426A A TO O
prepare CN103405426A A VB O
medicines CN103405426A A NNS O
for CN103405426A A IN O
treating CN103405426A A VBG O
acute CN103405426A A JJ O
gouty CN103405426A A NN O
inflammation CN103405426A A NN O
. CN103405426A A . O

Targeted EP2440250A1 T VBN O
liposomes EP2440250A1 T NNS O
comprising EP2440250A1 T VBG O
n-containing EP2440250A1 T JJ O
bisphosphonates EP2440250A1 T NNS O
and EP2440250A1 T CC O
uses EP2440250A1 T VBZ O
thereof EP2440250A1 T NN O
. EP2440250A1 T . O

Preparation CN102988444A T NNP O
method CN102988444A T NN O
of CN102988444A T IN O
blood CN102988444A T NN O
circulation CN102988444A T NN O
promoting CN102988444A T NN O
and CN102988444A T CC O
meridian CN102988444A T JJ O
obstruction CN102988444A T NN O
removing CN102988444A T VBG O
pill CN102988444A T NN O
for CN102988444A T IN O
preventing CN102988444A T VBG O
and CN102988444A T CC O
treating CN102988444A T VBG O
osteoporosis CN102988444A T NN O
. CN102988444A T . O

4,6-dl- WO2008009078A2 T JJ O
and WO2008009078A2 T CC O
2,4,6-trisubstituted WO2008009078A2 T JJ O
quinazoline WO2008009078A2 T NN O
derivatives WO2008009078A2 T NNS O
useful WO2008009078A2 T JJ O
for WO2008009078A2 T IN O
treating WO2008009078A2 T VBG O
viral WO2008009078A2 T JJ O
infections WO2008009078A2 T NNS O
. WO2008009078A2 T . O

This WO2008009078A2 A DT O
invention WO2008009078A2 A NN O
provides WO2008009078A2 A VBZ O
quinazoline WO2008009078A2 A JJ O
derivatives WO2008009078A2 A NNS O
represented WO2008009078A2 A VBN O
by WO2008009078A2 A IN O
the WO2008009078A2 A DT O
structural WO2008009078A2 A JJ O
formula WO2008009078A2 A NN O
: WO2008009078A2 A : O
( WO2008009078A2 A ( O
I WO2008009078A2 A PRP O
) WO2008009078A2 A ) O
; WO2008009078A2 A : O
wherein WO2008009078A2 A NN O
: WO2008009078A2 A : O
R2 WO2008009078A2 A NNP O
is WO2008009078A2 A VBZ O
hydrogen WO2008009078A2 A NN O
, WO2008009078A2 A , O
NR'R WO2008009078A2 A NNP O
' WO2008009078A2 A POS O
, WO2008009078A2 A , O
C1-7 WO2008009078A2 A NNP O
alkyl WO2008009078A2 A NN O
, WO2008009078A2 A , O
arylC1-7 WO2008009078A2 A JJ O
alkyl WO2008009078A2 A NN O
or WO2008009078A2 A CC O
C3-10 WO2008009078A2 A NNP O
cycloalkyl WO2008009078A2 A NN O
; WO2008009078A2 A : O
R4 WO2008009078A2 A NNP O
is WO2008009078A2 A VBZ O
amino WO2008009078A2 A JJ O
, WO2008009078A2 A , O
C1-7 WO2008009078A2 A NNP O
alkyl WO2008009078A2 A NN O
, WO2008009078A2 A , O
C2-7 WO2008009078A2 A NNP O
alkenyl WO2008009078A2 A NN O
, WO2008009078A2 A , O
C3-10 WO2008009078A2 A NNP O
cycloalkyl WO2008009078A2 A NN O
, WO2008009078A2 A , O
C3-10 WO2008009078A2 A NNP O
cycloalkenyl WO2008009078A2 A NN O
, WO2008009078A2 A , O
aryl WO2008009078A2 A NN O
, WO2008009078A2 A , O
heterocyclic WO2008009078A2 A NN O
, WO2008009078A2 A , O
arylalkyl WO2008009078A2 A NN O
, WO2008009078A2 A , O
heterocyclic-substituted WO2008009078A2 A JJ O
C1-7 WO2008009078A2 A NNP O
alkyl WO2008009078A2 A NN O
or WO2008009078A2 A CC O
C3-10 WO2008009078A2 A JJ O
cycloalkyl-C1-7 WO2008009078A2 A JJ O
alkyl WO2008009078A2 A NN O
; WO2008009078A2 A : O
R5 WO2008009078A2 A NNP O
is WO2008009078A2 A VBZ O
hydrogen WO2008009078A2 A JJ O
or WO2008009078A2 A CC O
C1-7 WO2008009078A2 A JJ O
alkyl WO2008009078A2 A NN O
, WO2008009078A2 A , O
or WO2008009078A2 A CC O
R5 WO2008009078A2 A NNP O
and WO2008009078A2 A CC O
R4 WO2008009078A2 A NNP O
together WO2008009078A2 A RB O
with WO2008009078A2 A IN O
the WO2008009078A2 A DT O
nitrogen WO2008009078A2 A NN O
atom WO2008009078A2 A NN O
to WO2008009078A2 A TO O
which WO2008009078A2 A WDT O
they WO2008009078A2 A PRP O
are WO2008009078A2 A VBP O
attached WO2008009078A2 A VBN O
form WO2008009078A2 A IN O
a WO2008009078A2 A DT O
heterocyclic WO2008009078A2 A JJ O
ring WO2008009078A2 A NN O
; WO2008009078A2 A : O
Y WO2008009078A2 A NNP O
is WO2008009078A2 A VBZ O
a WO2008009078A2 A DT O
single WO2008009078A2 A JJ O
bond WO2008009078A2 A NN O
, WO2008009078A2 A , O
C1-7alkylene WO2008009078A2 A NNP O
, WO2008009078A2 A , O
C2-7 WO2008009078A2 A NNP O
alkenylene WO2008009078A2 A NN O
or WO2008009078A2 A CC O
C2-7 WO2008009078A2 A JJ O
alkynylene WO2008009078A2 A NN O
; WO2008009078A2 A : O
R6 WO2008009078A2 A NNP O
is WO2008009078A2 A VBZ O
halogen WO2008009078A2 A NN O
, WO2008009078A2 A , O
heteroaryl WO2008009078A2 A NN O
or WO2008009078A2 A CC O
aryl WO2008009078A2 A NN O
; WO2008009078A2 A : O
R WO2008009078A2 A NNP O
' WO2008009078A2 A POS O
and WO2008009078A2 A CC O
R WO2008009078A2 A NNP O
' WO2008009078A2 A '' O
are WO2008009078A2 A VBP O
each WO2008009078A2 A DT O
independently WO2008009078A2 A RB O
hydrogen WO2008009078A2 A NN O
, WO2008009078A2 A , O
C1-7 WO2008009078A2 A JJ O
alkyl-carbonyl WO2008009078A2 A JJ O
or WO2008009078A2 A CC O
C1-7 WO2008009078A2 A JJ O
alkyl WO2008009078A2 A NN O
; WO2008009078A2 A : O
provided WO2008009078A2 A VBD O
that WO2008009078A2 A IN O
R4 WO2008009078A2 A NNP O
is WO2008009078A2 A VBZ O
not WO2008009078A2 A RB O
phenyl WO2008009078A2 A JJ O
substituted WO2008009078A2 A VBN O
with WO2008009078A2 A IN O
morpholino WO2008009078A2 A NN O
when WO2008009078A2 A WRB O
R2 WO2008009078A2 A NNP O
is WO2008009078A2 A VBZ O
H WO2008009078A2 A NNP O
and WO2008009078A2 A CC O
R5 WO2008009078A2 A NNP O
is WO2008009078A2 A VBZ O
H WO2008009078A2 A NNP O
, WO2008009078A2 A , O
and WO2008009078A2 A CC O
provided WO2008009078A2 A VBD O
that WO2008009078A2 A IN O
when WO2008009078A2 A WRB O
NR4R5 WO2008009078A2 A NNP O
is WO2008009078A2 A VBZ O
piperazinyl WO2008009078A2 A JJ O
, WO2008009078A2 A , O
said WO2008009078A2 A VBD O
NR4R5 WO2008009078A2 A NNP O
is WO2008009078A2 A VBZ O
either WO2008009078A2 A DT O
non-substituted WO2008009078A2 A JJ O
or WO2008009078A2 A CC O
substituted WO2008009078A2 A VBN O
with WO2008009078A2 A IN O
methyl WO2008009078A2 A NN O
or WO2008009078A2 A CC O
acetyl WO2008009078A2 A NN O
; WO2008009078A2 A : O
a WO2008009078A2 A DT O
pharmaceutically WO2008009078A2 A RB O
acceptable WO2008009078A2 A JJ O
addition WO2008009078A2 A NN O
salt WO2008009078A2 A NN O
, WO2008009078A2 A , O
a WO2008009078A2 A DT O
stereoisomer WO2008009078A2 A NN O
, WO2008009078A2 A , O
a WO2008009078A2 A DT O
mono- WO2008009078A2 A NN O
or WO2008009078A2 A CC O
a WO2008009078A2 A DT O
di-N-oxide WO2008009078A2 A JJ O
, WO2008009078A2 A , O
a WO2008009078A2 A DT O
solvate WO2008009078A2 A NN O
or WO2008009078A2 A CC O
a WO2008009078A2 A DT O
pro-drug WO2008009078A2 A JJ O
thereof WO2008009078A2 A NN O
, WO2008009078A2 A , O
for WO2008009078A2 A IN O
the WO2008009078A2 A DT O
treatment WO2008009078A2 A NN O
of WO2008009078A2 A IN O
viral WO2008009078A2 A JJ O
infections WO2008009078A2 A NNS O
. WO2008009078A2 A . O

Siv-based EP1183383B1 T JJ O
packaging-deficient EP1183383B1 T JJ O
vectors EP1183383B1 T NNS O
. EP1183383B1 T . O

Methods US20090048302 T NNS O
and US20090048302 T CC O
compositions US20090048302 T NNS O
for US20090048302 T IN O
the US20090048302 T DT O
treatment US20090048302 T NN O
of US20090048302 T IN O
conditions US20090048302 T NNS O
related US20090048302 T VBN O
to US20090048302 T TO O
gastric US20090048302 T JJ O
acid US20090048302 T JJ O
secretion US20090048302 T NN O
. US20090048302 T . O

A US20090048302 A DT O
method US20090048302 A NN O
comprising US20090048302 A VBG O
orally US20090048302 A RB O
administering US20090048302 A VBG O
to US20090048302 A TO O
a US20090048302 A DT O
mammal US20090048302 A NN O
a US20090048302 A DT O
proton US20090048302 A NN O
pump US20090048302 A NN O
inhibitor US20090048302 A NN O
, US20090048302 A , O
or US20090048302 A CC O
a US20090048302 A DT O
pharmaceutically US20090048302 A RB O
acceptable US20090048302 A JJ O
prodrug US20090048302 A NN O
thereof US20090048302 A NN O
, US20090048302 A , O
and US20090048302 A CC O
a US20090048302 A DT O
compound US20090048302 A NN O
which US20090048302 A WDT O
modulates US20090048302 A VBZ O
the US20090048302 A DT O
activity US20090048302 A NN O
of US20090048302 A IN O
the US20090048302 A DT O
MRP2 US20090048302 A NNP I-UN
or US20090048302 A CC O
other US20090048302 A JJ O
transporter US20090048302 A NN O
proteins US20090048302 A NNS O
involved US20090048302 A VBN O
in US20090048302 A IN O
efflux US20090048302 A NN O
of US20090048302 A IN O
a US20090048302 A DT O
proton US20090048302 A NN I-UN
pump US20090048302 A NN I-UN
inhibitor US20090048302 A NN O
or US20090048302 A CC O
a US20090048302 A DT O
prodrug US20090048302 A NN O
, US20090048302 A , O
is US20090048302 A VBZ O
disclosed US20090048302 A VBN O
herein US20090048302 A NN O
, US20090048302 A , O
said US20090048302 A VBD O
method US20090048302 A NN O
being US20090048302 A VBG O
effective US20090048302 A JJ O
for US20090048302 A IN O
the US20090048302 A DT O
prevention US20090048302 A NN O
or US20090048302 A CC O
treatment US20090048302 A NN O
of US20090048302 A IN O
a US20090048302 A DT O
disease US20090048302 A NN O
or US20090048302 A CC O
condition US20090048302 A NN O
related US20090048302 A VBN O
to US20090048302 A TO O
gastric US20090048302 A JJ O
acid US20090048302 A JJ O
secretion US20090048302 A NN O
. US20090048302 A . O

This US20090048302 A DT O
method US20090048302 A NN O
applied US20090048302 A VBD O
to US20090048302 A TO O
compounds US20090048302 A NNS O
which US20090048302 A WDT O
both US20090048302 A DT O
inhibit US20090048302 A NN O
and US20090048302 A CC O
stimulate US20090048302 A JJ O
MRP2 US20090048302 A NNP I-UN
activity US20090048302 A NN O
or US20090048302 A CC O
activity US20090048302 A NN O
of US20090048302 A IN O
other US20090048302 A JJ O
transporter US20090048302 A NN O
proteins US20090048302 A NNS O
involved US20090048302 A VBN O
in US20090048302 A IN O
efflux US20090048302 A NN O
of US20090048302 A IN O
a US20090048302 A DT O
proton US20090048302 A NN I-UN
pump US20090048302 A NN I-UN
inhibitor US20090048302 A NN O
or US20090048302 A CC O
a US20090048302 A DT O
prodrug US20090048302 A NN O
. US20090048302 A . O

Use US20110092599 T NNP O
of US20110092599 T IN O
Treprostinil US20110092599 T NNP O
to US20110092599 T TO O
treat US20110092599 T VB O
neuropathic US20110092599 T JJ O
diabetic US20110092599 T JJ O
foot US20110092599 T NN O
ulcers US20110092599 T NNS O
. US20110092599 T . O

Disease CN101760389A T NNP O
and CN101760389A T CC O
phytophthora-resistant CN101760389A T JJ O
yellow CN101760389A T JJ O
wine CN101760389A T NN O
and CN101760389A T CC O
production CN101760389A T NN O
method CN101760389A T NN O
. CN101760389A T . O

Ethyl EP2719382A1 T NNP O
Eicosapentanoate EP2719382A1 T NNP O
and EP2719382A1 T CC O
Pharmaceutical EP2719382A1 T NNP O
Compositions EP2719382A1 T NNP O
Comprising EP2719382A1 T NNP O
Ethyl EP2719382A1 T NNP O
Eicosapentanoate EP2719382A1 T NNP O
as EP2719382A1 T IN O
an EP2719382A1 T DT O
Active EP2719382A1 T JJ O
Ingredient EP2719382A1 T NN O
for EP2719382A1 T IN O
Use EP2719382A1 T NNP O
in EP2719382A1 T IN O
the EP2719382A1 T DT O
Treatment EP2719382A1 T NNP O
of EP2719382A1 T IN O
Non-Alcoholic EP2719382A1 T NNP O
Steatohepatitis EP2719382A1 T NNP O
. EP2719382A1 T . O

Sulfonylamino-derivatives US8163733 T NNS O
as US8163733 T IN O
novel US8163733 T JJ O
inhibitors US8163733 T NNS O
of US8163733 T IN O
histone US8163733 T NN I-UN
deacetylase US8163733 T NN I-UN
. US8163733 T . O

This US8163733 A DT O
invention US8163733 A NN O
comprises US8163733 A VBZ O
the US8163733 A DT O
novel US8163733 A JJ O
compounds US8163733 A NNS O
of US8163733 A IN O
formula US8163733 A NN O
( US8163733 A ( O
I US8163733 A PRP O
) US8163733 A ) O
wherein US8163733 A NN O
n US8163733 A NN O
, US8163733 A , O
m US8163733 A NN O
, US8163733 A , O
t US8163733 A NN O
, US8163733 A , O
R1 US8163733 A NNP O
, US8163733 A , O
R2 US8163733 A NNP O
, US8163733 A , O
R3 US8163733 A NNP O
, US8163733 A , O
R4 US8163733 A NNP O
, US8163733 A , O
R5 US8163733 A NNP O
, US8163733 A , O
L US8163733 A NNP O
, US8163733 A , O
Q US8163733 A NNP O
, US8163733 A , O
X US8163733 A NNP O
, US8163733 A , O
Y US8163733 A NNP O
, US8163733 A , O
Z US8163733 A NNP O
and US8163733 A CC O
have US8163733 A VBP O
defined US8163733 A VBN O
meanings US8163733 A NNS O
, US8163733 A , O
having US8163733 A VBG O
histone US8163733 A NN I-UN
deacetylase US8163733 A NN I-UN
inhibiting US8163733 A VBG O
enzymatic US8163733 A JJ O
activity US8163733 A NN O
; US8163733 A : O
their US8163733 A PRP$ O
preparation US8163733 A NN O
, US8163733 A , O
compositions US8163733 A NNS O
containing US8163733 A VBG O
them US8163733 A PRP O
and US8163733 A CC O
their US8163733 A PRP$ O
use US8163733 A NN O
as US8163733 A IN O
a US8163733 A DT O
medicine US8163733 A NN O
. US8163733 A . O

Methods US20110158980 T NNS O
to US20110158980 T TO O
treat US20110158980 T VB O
and US20110158980 T CC O
screen US20110158980 T VB O
for US20110158980 T IN O
agents US20110158980 T NNS O
to US20110158980 T TO O
treat US20110158980 T VB O
obesity US20110158980 T NN O
. US20110158980 T . O

Acetylcysteine CN103191080A T NNP O
effervescent CN103191080A T JJ O
tablet CN103191080A T NN O
. CN103191080A T . O

Carbapenem CN102250095A T NNP O
derivative CN102250095A T JJ O
or CN102250095A T CC O
hydrate CN102250095A T JJ O
crystal CN102250095A T NN O
and CN102250095A T CC O
preparation CN102250095A T NN O
method CN102250095A T NN O
thereof CN102250095A T NN O
. CN102250095A T . O

Houttuynoid CN103304609A T NNP O
and CN103304609A T CC O
preparation CN103304609A T NN O
method CN103304609A T NN O
and CN103304609A T CC O
application CN103304609A T NN O
thereof CN103304609A T NN O
. CN103304609A T . O

Compounds EP2563785A1 T NNS O
as EP2563785A1 T IN O
agonists EP2563785A1 T NNS O
of EP2563785A1 T IN O
s1p1 EP2563785A1 T JJ I-UN
receptors EP2563785A1 T NNS O
. EP2563785A1 T . O

Compounds EP2563785A1 A NNS O
of EP2563785A1 A IN O
formula EP2563785A1 A NN O
( EP2563785A1 A ( O
I EP2563785A1 A PRP O
) EP2563785A1 A ) O
, EP2563785A1 A , O
processes EP2563785A1 A VBZ O
for EP2563785A1 A IN O
their EP2563785A1 A PRP$ O
preparation EP2563785A1 A NN O
, EP2563785A1 A , O
pharmaceutical EP2563785A1 A JJ O
compositions EP2563785A1 A NNS O
containing EP2563785A1 A VBG O
them EP2563785A1 A PRP O
and EP2563785A1 A CC O
their EP2563785A1 A PRP$ O
use EP2563785A1 A NN O
in EP2563785A1 A IN O
the EP2563785A1 A DT O
treatment EP2563785A1 A NN O
of EP2563785A1 A IN O
diseases EP2563785A1 A NNS O
mediated EP2563785A1 A VBN O
by EP2563785A1 A IN O
S1P1 EP2563785A1 A NNP I-UN
receptors EP2563785A1 A NNS O
. EP2563785A1 A . O

Application CN101897699A T NN O
in CN101897699A T IN O
preparation CN101897699A T NN O
of CN101897699A T IN O
medicament CN101897699A T NN O
for CN101897699A T IN O
preventing CN101897699A T VBG O
and CN101897699A T CC O
controlling CN101897699A T VBG O
lipopolysaccharide-induced CN101897699A T JJ O
acute CN101897699A T NN O
liver CN101897699A T NN O
damage CN101897699A T NN O
. CN101897699A T . O

A CN101897699A A DT O
protein CN101897699A A NN I-UN
kinase CN101897699A A NN I-UN
D CN101897699A A NNP I-UN
( CN101897699A A ( O
PKD CN101897699A A NNP I-UN
) CN101897699A A ) O
inhibitor CN101897699A A NN O
has CN101897699A A VBZ O
the CN101897699A A DT O
advantages CN101897699A A NNS O
of CN101897699A A IN O
preventing CN101897699A A VBG O
LPS-induced CN101897699A A NNP O
mice CN101897699A A NN O
acute CN101897699A A NN O
liver CN101897699A A NN O
damage CN101897699A A NN O
, CN101897699A A , O
remarkably CN101897699A A RB O
reducing CN101897699A A VBG O
the CN101897699A A DT O
phosphorylation CN101897699A A NN O
level CN101897699A A NN O
of CN101897699A A IN O
LPS-induced CN101897699A A NNP O
PKD CN101897699A A NNP I-UN
, CN101897699A A , O
lowering CN101897699A A VBG O
death CN101897699A A NN O
rate CN101897699A A NN O
and CN101897699A A CC O
levels CN101897699A A NNS O
of CN101897699A A IN O
alanine CN101897699A A NN I-UN
aminotransferase CN101897699A A NN I-UN
( CN101897699A A ( O
ALT CN101897699A A NNP I-UN
) CN101897699A A ) O
and CN101897699A A CC O
aspartate CN101897699A A JJ I-UN
transaminase CN101897699A A NN I-UN
( CN101897699A A ( O
AST CN101897699A A NNP I-UN
) CN101897699A A ) O
, CN101897699A A , O
improving CN101897699A A VBG O
inflammatory CN101897699A A JJ O
reaction CN101897699A A NN O
, CN101897699A A , O
restraining CN101897699A A VBG O
the CN101897699A A DT O
signal CN101897699A A JJ O
channel CN101897699A A NN O
of CN101897699A A IN O
LPS CN101897699A A NNP O
activated CN101897699A A VBD O
p38 CN101897699A A JJ I-UN
mitogen-activated CN101897699A A JJ I-UN
protein CN101897699A A NN I-UN
kinase CN101897699A A NN I-UN
( CN101897699A A ( O
p38MAPK CN101897699A A NN I-UN
) CN101897699A A ) O
, CN101897699A A , O
lowering CN101897699A A VBG O
the CN101897699A A DT O
level CN101897699A A NN O
of CN101897699A A IN O
LPS-induced CN101897699A A NNP O
tumor CN101897699A A NN I-UN
necrosis CN101897699A A NN I-UN
factor-alpha CN101897699A A JJ I-UN
( CN101897699A A ( O
TNK-alpha CN101897699A A NNP I-UN
) CN101897699A A ) O
, CN101897699A A , O
reducing CN101897699A A VBG O
the CN101897699A A DT O
apoptosis CN101897699A A NN O
number CN101897699A A NN O
of CN101897699A A IN O
hepatic CN101897699A A JJ O
cells CN101897699A A NNS O
, CN101897699A A , O
the CN101897699A A DT O
activation CN101897699A A NN O
of CN101897699A A IN O
caspases CN101897699A A NNS O
and CN101897699A A CC O
the CN101897699A A DT O
expression CN101897699A A NN O
level CN101897699A A NN O
of CN101897699A A IN O
hepatic CN101897699A A JJ O
tissue CN101897699A A NN O
adhesion CN101897699A A NN O
molecules CN101897699A A NNS O
and CN101897699A A CC O
lowering CN101897699A A VBG O
the CN101897699A A DT O
activation CN101897699A A NN O
level CN101897699A A NN O
of CN101897699A A IN O
myeloperoxidase CN101897699A A NN I-UN
( CN101897699A A ( O
MPO CN101897699A A NNP I-UN
) CN101897699A A ) O
. CN101897699A A . O

Manufacture WO2014008295A1 T NN O
of WO2014008295A1 T IN O
2- WO2014008295A1 T JJ O
( WO2014008295A1 T ( O
5- WO2014008295A1 T JJ O
bromo-4 WO2014008295A1 T NN O
( WO2014008295A1 T ( O
-cyclopropylnaphthalen-1-yl WO2014008295A1 T NNP O
) WO2014008295A1 T ) O
-4h-1,2,4-triazol-3-ylthio WO2014008295A1 T NN O
) WO2014008295A1 T ) O
acetic WO2014008295A1 T JJ O
acid WO2014008295A1 T NN O
. WO2014008295A1 T . O

5-amino-1,2,4-thiadiazole WO2012050484A3 T JJ O
derivatives WO2012050484A3 T NNS O
. WO2012050484A3 T . O

Topical US7195787 T JJ O
cosmetic US7195787 T NN O
. US7195787 T . O

By US7078521 T IN O
reaction US7078521 T NN O
of US7078521 T IN O
pyrrolobenzothiazepin-9-one US7078521 T NN O
with US7078521 T IN O
amine US7078521 T NN O
to US7078521 T TO O
give US7078521 T VB O
the US7078521 T DT O
corresponding US7078521 T JJ O
enamine US7078521 T NN O
, US7078521 T , O
which US7078521 T WDT O
is US7078521 T VBZ O
subsequently US7078521 T RB O
transformed US7078521 T VBN O
into US7078521 T IN O
the US7078521 T DT O
final US7078521 T JJ O
compound US7078521 T NN O
. US7078521 T . O

Therapeutic US20080317759 T JJ O
uses US20080317759 T NNS O
of US20080317759 T IN O
factors US20080317759 T NNS O
which US20080317759 T WDT O
inhibit US20080317759 T VBP O
or US20080317759 T CC O
neutralize US20080317759 T JJ O
MIF US20080317759 T NNP O
activity US20080317759 T NN O
. US20080317759 T . O

Benzo WO2005020911A3 T NNP O
[ WO2005020911A3 T NNP O
1 WO2005020911A3 T CD O
, WO2005020911A3 T , O
3 WO2005020911A3 T CD O
] WO2005020911A3 T JJ O
dioxole WO2005020911A3 T NN O
compounds WO2005020911A3 T NNS O
, WO2005020911A3 T , O
pharmaceutical WO2005020911A3 T JJ O
compositions WO2005020911A3 T NNS O
thereof WO2005020911A3 T NN O
, WO2005020911A3 T , O
and WO2005020911A3 T CC O
processes WO2005020911A3 T NNS O
of WO2005020911A3 T IN O
making WO2005020911A3 T VBG O
and WO2005020911A3 T CC O
using WO2005020911A3 T VBG O
the WO2005020911A3 T DT O
same WO2005020911A3 T JJ O
. WO2005020911A3 T . O

Method US6867236 T NNP O
of US6867236 T IN O
preventing US6867236 T VBG O
of US6867236 T IN O
delaying US6867236 T VBG O
the US6867236 T DT O
onset US6867236 T NN O
and US6867236 T CC O
progression US6867236 T NN O
of US6867236 T IN O
Alzheimer US6867236 T NNP O
's US6867236 T POS O
disease US6867236 T NN O
and US6867236 T CC O
related US6867236 T JJ O
disorders US6867236 T NNS O
. US6867236 T . O

The US6867236 A DT O
methods US6867236 A NNS O
involve US6867236 A VBP O
the US6867236 A DT O
administration US6867236 A NN O
of US6867236 A IN O
a US6867236 A DT O
non-steroidal US6867236 A JJ O
anti-inflammatory US6867236 A JJ O
agent US6867236 A NN O
and/or US6867236 A VBZ O
a US6867236 A DT O
histamine US6867236 A NN I-UN
H2 US6867236 A NNP I-UN
receptor US6867236 A NN I-UN
blocking US6867236 A VBG O
agent US6867236 A NN O
. US6867236 A . O

Process US7214805 T NN O
for US7214805 T IN O
the US7214805 T DT O
industrial US7214805 T JJ O
synthesis US7214805 T NN O
of US7214805 T IN O
strontium US7214805 T NN O
ranelate US7214805 T NN O
and US7214805 T CC O
its US7214805 T PRP$ O
hydrates US7214805 T NNS O
. US7214805 T . O

Nitroimidazole CN101016264A T NNP O
derivative CN101016264A T NN O
for CN101016264A T IN O
treatment CN101016264A T NN O
, CN101016264A T , O
preparing CN101016264A T VBG O
method CN101016264A T NN O
and CN101016264A T CC O
use CN101016264A T NN O
. CN101016264A T . O

Ingenol-3-acylates EP2655323A1 T NNS O
iii EP2655323A1 T NN O
and EP2655323A1 T CC O
ingenol-3-carbamates EP2655323A1 T NNS O
. EP2655323A1 T . O

The EP2655323A1 A DT O
invention EP2655323A1 A NN O
relates EP2655323A1 A VBZ O
to EP2655323A1 A TO O
compounds EP2655323A1 A NNS O
of EP2655323A1 A IN O
general EP2655323A1 A JJ O
formula EP2655323A1 A NN O
I EP2655323A1 A PRP O
wherein EP2655323A1 A VBP O
R EP2655323A1 A NNP O
is EP2655323A1 A VBZ O
heteroaryl EP2655323A1 A VBN O
optionally EP2655323A1 A RB O
substituted EP2655323A1 A VBN O
by EP2655323A1 A IN O
R7 EP2655323A1 A NNP O
; EP2655323A1 A : O
or EP2655323A1 A CC O
R EP2655323A1 A NNP O
is EP2655323A1 A VBZ O
heterocycloalkyl EP2655323A1 A JJ O
or EP2655323A1 A CC O
heterocycloalkenyl EP2655323A1 A NN O
, EP2655323A1 A , O
optionally EP2655323A1 A RB O
substituted EP2655323A1 A VBN O
by EP2655323A1 A IN O
R8 EP2655323A1 A NNP O
; EP2655323A1 A : O
or EP2655323A1 A CC O
R EP2655323A1 A NNP O
is EP2655323A1 A VBZ O
X EP2655323A1 A NNP O
wherein EP2655323A1 A NN O
X EP2655323A1 A NNP O
is EP2655323A1 A VBZ O
-NR11R12 EP2655323A1 A JJ O
; EP2655323A1 A : O
and EP2655323A1 A CC O
pharmaceutically EP2655323A1 A RB O
acceptable EP2655323A1 A JJ O
salts EP2655323A1 A NNS O
, EP2655323A1 A , O
hydrates EP2655323A1 A NNS O
, EP2655323A1 A , O
or EP2655323A1 A CC O
solvates EP2655323A1 A VBZ O
thereof EP2655323A1 A NNS O
, EP2655323A1 A , O
for EP2655323A1 A IN O
use EP2655323A1 A NN O
-alone EP2655323A1 A CD O
or EP2655323A1 A CC O
in EP2655323A1 A IN O
combination EP2655323A1 A NN O
with EP2655323A1 A IN O
one EP2655323A1 A CD O
or EP2655323A1 A CC O
more EP2655323A1 A JJR O
other EP2655323A1 A JJ O
pharmaceutically EP2655323A1 A RB O
active EP2655323A1 A JJ O
compounds- EP2655323A1 A NN O
in EP2655323A1 A IN O
therapy EP2655323A1 A NN O
, EP2655323A1 A , O
for EP2655323A1 A IN O
preventing EP2655323A1 A VBG O
, EP2655323A1 A , O
treating EP2655323A1 A VBG O
or EP2655323A1 A CC O
ameliorating EP2655323A1 A VBG O
diseases EP2655323A1 A NNS O
or EP2655323A1 A CC O
conditions EP2655323A1 A NNS O
responsive EP2655323A1 A VBP O
to EP2655323A1 A TO O
stimulation EP2655323A1 A NN O
of EP2655323A1 A IN O
neutrophil EP2655323A1 A JJ O
oxidative EP2655323A1 A JJ O
burst EP2655323A1 A NN O
, EP2655323A1 A , O
responsive EP2655323A1 A NN O
to EP2655323A1 A TO O
stimulation EP2655323A1 A NN O
of EP2655323A1 A IN O
keratinocyte EP2655323A1 A JJ O
IL-8 EP2655323A1 A NNP I-UN
release EP2655323A1 A NN O
or EP2655323A1 A CC O
responsive EP2655323A1 A NN O
to EP2655323A1 A TO O
induction EP2655323A1 A NN O
of EP2655323A1 A IN O
necrosis EP2655323A1 A NN O
. EP2655323A1 A . O

Glycine-substituted US7375109 T JJ O
thieno US7375109 T NN O
[ US7375109 T NNP O
2,3-d US7375109 T JJ O
] US7375109 T NNP O
pyrimidines US7375109 T NNS O
with US7375109 T IN O
combined US7375109 T JJ O
LH US7375109 T NNP I-UN
and US7375109 T CC O
FSH US7375109 T NNP I-UN
agonistic US7375109 T JJ O
activity US7375109 T NN O
. US7375109 T . O

The US7375109 A DT O
compounds US7375109 A NNS O
of US7375109 A IN O
the US7375109 A DT O
invention US7375109 A NN O
have US7375109 A VBP O
LH US7375109 A VBN I-UN
as US7375109 A RB O
well US7375109 A RB O
as US7375109 A IN O
FSH US7375109 A NNP I-UN
receptor US7375109 A NN I-UN
activating US7375109 A VBG O
activity US7375109 A NN O
and US7375109 A CC O
can US7375109 A MD O
be US7375109 A VB O
used US7375109 A VBN O
in US7375109 A IN O
fertility US7375109 A NN O
regulating US7375109 A NN O
therapies US7375109 A NNS O
. US7375109 A . O

Glutathione US20080234283 T NNP O
peroxidase US20080234283 T NN O
mimetics US20080234283 T NNS O
for US20080234283 T IN O
treatment US20080234283 T NN O
of US20080234283 T IN O
neurodegenerative US20080234283 T JJ O
, US20080234283 T , O
pulmonary US20080234283 T JJ O
and US20080234283 T CC O
inflammatory US20080234283 T JJ O
diseases US20080234283 T NNS O
. US20080234283 T . O

Compound CN101606945A T NNP O
sodium CN101606945A T NN O
sulfadimidine CN101606945A T NN O
injection CN101606945A T NN O
liquid CN101606945A T NN O
for CN101606945A T IN O
pig CN101606945A T NN O
and CN101606945A T CC O
preparation CN101606945A T NN O
method CN101606945A T NN O
thereof CN101606945A T NN O
. CN101606945A T . O

Pyrazole EP1847531A1 T NNP O
compound EP1847531A1 T NN O
. EP1847531A1 T . O

The EP1847531A1 A DT O
present EP1847531A1 A JJ O
invention EP1847531A1 A NN O
provides EP1847531A1 A VBZ O
a EP1847531A1 A DT O
pyrazole EP1847531A1 A JJ O
compound EP1847531A1 A NN O
represented EP1847531A1 A VBN O
by EP1847531A1 A IN O
the EP1847531A1 A DT O
formula EP1847531A1 A NN O
( EP1847531A1 A ( O
I EP1847531A1 A PRP O
) EP1847531A1 A ) O
: EP1847531A1 A : O
wherein EP1847531A1 A NN O
ring EP1847531A1 A VBG O
A0 EP1847531A1 A NNP O
is EP1847531A1 A VBZ O
a EP1847531A1 A DT O
pyrazole EP1847531A1 A JJ O
ring EP1847531A1 A NN O
optionally EP1847531A1 A RB O
further EP1847531A1 A RB O
having EP1847531A1 A VBG O
1 EP1847531A1 A CD O
or EP1847531A1 A CC O
2 EP1847531A1 A CD O
substituents EP1847531A1 A NNS O
; EP1847531A1 A : O
Ra EP1847531A1 A NNP O
is EP1847531A1 A VBZ O
a EP1847531A1 A DT O
substituted EP1847531A1 A JJ O
carbamoyl EP1847531A1 A NN O
group EP1847531A1 A NN O
; EP1847531A1 A : O
and EP1847531A1 A CC O
Rb EP1847531A1 A NNP O
is EP1847531A1 A VBZ O
an EP1847531A1 A DT O
optionally EP1847531A1 A RB O
substituted EP1847531A1 A VBN O
acylamino EP1847531A1 A NN O
group EP1847531A1 A NN O
, EP1847531A1 A , O
or EP1847531A1 A CC O
a EP1847531A1 A DT O
salt EP1847531A1 A JJ O
thereof EP1847531A1 A NN O
or EP1847531A1 A CC O
a EP1847531A1 A DT O
prodrug EP1847531A1 A JJ O
thereof EP1847531A1 A NN O
, EP1847531A1 A , O
which EP1847531A1 A WDT O
is EP1847531A1 A VBZ O
useful EP1847531A1 A JJ O
as EP1847531A1 A IN O
an EP1847531A1 A DT O
agent EP1847531A1 A NN O
for EP1847531A1 A IN O
the EP1847531A1 A DT O
prophylaxis EP1847531A1 A NN O
or EP1847531A1 A CC O
treatment EP1847531A1 A NN O
of EP1847531A1 A IN O
GSK-3β EP1847531A1 A NNP I-UN
related EP1847531A1 A JJ O
pathology EP1847531A1 A NN O
or EP1847531A1 A CC O
disease EP1847531A1 A NN O
, EP1847531A1 A , O
and EP1847531A1 A CC O
a EP1847531A1 A DT O
GSK-3β EP1847531A1 A NNP I-UN
inhibitor EP1847531A1 A NN O
including EP1847531A1 A VBG O
same EP1847531A1 A JJ O
. EP1847531A1 A . O

Enhanced US20110021583 T NNP O
transmucosal US20110021583 T NN O
composition US20110021583 T NN O
and US20110021583 T CC O
dosage US20110021583 T NN O
form US20110021583 T NN O
. US20110021583 T . O

Compositions US7468359 T NNS O
comprising US7468359 T VBG O
oxophosphonate-based US7468359 T JJ O
metalloproteinase US7468359 T NN O
inhibitors US7468359 T NNS O
. US7468359 T . O

Method EP1801231B1 T NNP O
of EP1801231B1 T IN O
screening EP1801231B1 T VBG O
baff EP1801231B1 T NN I-UN
suppressor EP1801231B1 T NN O
or EP1801231B1 T CC O
inhibitor EP1801231B1 T NN O
. EP1801231B1 T . O

A EP1801231B1 A DT O
method EP1801231B1 A NN O
of EP1801231B1 A IN O
screening EP1801231B1 A VBG O
a EP1801231B1 A DT O
novel EP1801231B1 A JJ O
BAFF EP1801231B1 A NNP I-UN
suppressor EP1801231B1 A NN O
or EP1801231B1 A CC O
inhibitor EP1801231B1 A NN O
. EP1801231B1 A . O

More EP1801231B1 A RBR O
specifically EP1801231B1 A RB O
speaking EP1801231B1 A VBG O
, EP1801231B1 A , O
a EP1801231B1 A DT O
method EP1801231B1 A NN O
which EP1801231B1 A WDT O
comprises EP1801231B1 A VBZ O
adding EP1801231B1 A VBG O
a EP1801231B1 A DT O
combination EP1801231B1 A NN O
of EP1801231B1 A IN O
TPA EP1801231B1 A NNP O
with EP1801231B1 A IN O
ionomycin EP1801231B1 A JJ O
and/or EP1801231B1 A VBP O
an EP1801231B1 A DT O
anti-CD3 EP1801231B1 A JJ O
antibody EP1801231B1 A NN O
to EP1801231B1 A TO O
a EP1801231B1 A DT O
cultured EP1801231B1 A JJ O
human EP1801231B1 A NN O
cell EP1801231B1 A NN O
to EP1801231B1 A TO O
thereby EP1801231B1 A RB O
induce EP1801231B1 A VB O
the EP1801231B1 A DT O
production EP1801231B1 A NN O
of EP1801231B1 A IN O
BAFF EP1801231B1 A NNP I-UN
by EP1801231B1 A IN O
the EP1801231B1 A DT O
cell EP1801231B1 A NN O
; EP1801231B1 A : O
a EP1801231B1 A DT O
method EP1801231B1 A NN O
of EP1801231B1 A IN O
screening EP1801231B1 A VBG O
a EP1801231B1 A DT O
substance EP1801231B1 A NN O
capable EP1801231B1 A JJ O
of EP1801231B1 A IN O
suppressing EP1801231B1 A VBG O
the EP1801231B1 A DT O
expression EP1801231B1 A NN O
or EP1801231B1 A CC O
activity EP1801231B1 A NN O
of EP1801231B1 A IN O
BAFF EP1801231B1 A NNP I-UN
which EP1801231B1 A WDT O
comprises EP1801231B1 A VBZ O
adding EP1801231B1 A VBG O
a EP1801231B1 A DT O
test EP1801231B1 A NN O
substance EP1801231B1 A NN O
to EP1801231B1 A TO O
a EP1801231B1 A DT O
BAFF-production EP1801231B1 A NNP O
system EP1801231B1 A NN O
prepared EP1801231B1 A VBN O
by EP1801231B1 A IN O
adding EP1801231B1 A VBG O
a EP1801231B1 A DT O
combination EP1801231B1 A NN O
of EP1801231B1 A IN O
TPA EP1801231B1 A NNP O
with EP1801231B1 A IN O
ionomycin EP1801231B1 A JJ O
and/or EP1801231B1 A VBP O
an EP1801231B1 A DT O
anti-CD3 EP1801231B1 A JJ O
antibody EP1801231B1 A NN O
to EP1801231B1 A TO O
a EP1801231B1 A DT O
cultured EP1801231B1 A JJ O
human EP1801231B1 A NN O
cell EP1801231B1 A NN O
and EP1801231B1 A CC O
measuring EP1801231B1 A VBG O
the EP1801231B1 A DT O
expression EP1801231B1 A NN O
amount EP1801231B1 A NN O
and/or EP1801231B1 A VBD O
the EP1801231B1 A DT O
activity EP1801231B1 A NN O
of EP1801231B1 A IN O
BAFF EP1801231B1 A NNP I-UN
in EP1801231B1 A IN O
the EP1801231B1 A DT O
BAFF-production EP1801231B1 A NNP O
system EP1801231B1 A NN O
; EP1801231B1 A : O
and EP1801231B1 A CC O
a EP1801231B1 A DT O
BAFF EP1801231B1 A NNP I-UN
production EP1801231B1 A NN O
inducer EP1801231B1 A NN O
for EP1801231B1 A IN O
a EP1801231B1 A DT O
BAFF-producing EP1801231B1 A NNP O
cell EP1801231B1 A NN O
which EP1801231B1 A WDT O
contains EP1801231B1 A VBZ O
a EP1801231B1 A DT O
combination EP1801231B1 A NN O
of EP1801231B1 A IN O
TPA EP1801231B1 A NNP O
with EP1801231B1 A IN O
ionomycin EP1801231B1 A JJ O
and/or EP1801231B1 A VBP O
an EP1801231B1 A DT O
anti-CD3 EP1801231B1 A JJ O
antibody EP1801231B1 A NN O
. EP1801231B1 A . O

Alpha-carbolines CA2610347A1 T NNS O
as CA2610347A1 T IN O
cdk-1 CA2610347A1 T JJ I-UN
inhibitors CA2610347A1 T NNS O
. CA2610347A1 T . O

Use US20080300213 T NNP O
of US20080300213 T IN O
A3 US20080300213 T NNP O
Adenosine US20080300213 T NNP O
Receptor US20080300213 T NNP O
Agonist US20080300213 T NNP O
in US20080300213 T IN O
Osteoarthritis US20080300213 T NNP O
Treatment US20080300213 T NNP O
. US20080300213 T . O

The US20080300213 A DT O
present US20080300213 A JJ O
invention US20080300213 A NN O
provides US20080300213 A VBZ O
the US20080300213 A DT O
use US20080300213 A NN O
of US20080300213 A IN O
an US20080300213 A DT O
A3 US20080300213 A NNP O
adenosine US20080300213 A NN O
receptor US20080300213 A NN O
agonist US20080300213 A NN O
( US20080300213 A ( O
A3AR US20080300213 A NNP O
agonist US20080300213 A NN O
) US20080300213 A ) O
for US20080300213 A IN O
the US20080300213 A DT O
preparation US20080300213 A NN O
of US20080300213 A IN O
a US20080300213 A DT O
pharmaceutical US20080300213 A JJ O
composition US20080300213 A NN O
for US20080300213 A IN O
the US20080300213 A DT O
treatment US20080300213 A NN O
of US20080300213 A IN O
a US20080300213 A DT O
mammal US20080300213 A NN O
subject US20080300213 A JJ O
having US20080300213 A VBG O
osteoarthritis US20080300213 A NN O
( US20080300213 A ( O
OA US20080300213 A NNP O
) US20080300213 A ) O
, US20080300213 A , O
as US20080300213 A RB O
well US20080300213 A RB O
as US20080300213 A IN O
to US20080300213 A TO O
a US20080300213 A DT O
method US20080300213 A NN O
for US20080300213 A IN O
the US20080300213 A DT O
treatment US20080300213 A NN O
of US20080300213 A IN O
OA US20080300213 A NNP O
in US20080300213 A IN O
a US20080300213 A DT O
mammal US20080300213 A JJ O
subject US20080300213 A NN O
, US20080300213 A , O
the US20080300213 A DT O
method US20080300213 A NN O
comprises US20080300213 A VBZ O
administering US20080300213 A VBG O
to US20080300213 A TO O
said US20080300213 A VBD O
subject US20080300213 A NN O
in US20080300213 A IN O
need US20080300213 A NN O
of US20080300213 A IN O
said US20080300213 A VBD O
treatment US20080300213 A NN O
an US20080300213 A DT O
amount US20080300213 A NN O
of US20080300213 A IN O
an US20080300213 A DT O
A3AR US20080300213 A NNP O
agonist US20080300213 A NN O
, US20080300213 A , O
the US20080300213 A DT O
amount US20080300213 A NN O
being US20080300213 A VBG O
effective US20080300213 A JJ O
to US20080300213 A TO O
treat US20080300213 A VB O
or US20080300213 A CC O
prevent US20080300213 A VB O
the US20080300213 A DT O
development US20080300213 A NN O
of US20080300213 A IN O
OA US20080300213 A NNP O
. US20080300213 A . O

Preferred US20080300213 A VBN O
but US20080300213 A CC O
not US20080300213 A RB O
exclusive US20080300213 A JJ O
A3AR US20080300213 A NNP O
agonists US20080300213 A NNS O
in US20080300213 A IN O
accordance US20080300213 A NN O
with US20080300213 A IN O
the US20080300213 A DT O
invention US20080300213 A NN O
are US20080300213 A VBP O
IB-MECA US20080300213 A NNP O
and US20080300213 A CC O
Cl—IB-MECA US20080300213 A NNP O
. US20080300213 A . O

The US20080300213 A DT O
A3AR US20080300213 A NNP O
agonist US20080300213 A NN O
may US20080300213 A MD O
be US20080300213 A VB O
administered US20080300213 A VBN O
in US20080300213 A IN O
combination US20080300213 A NN O
with US20080300213 A IN O
another US20080300213 A DT O
drug US20080300213 A NN O
, US20080300213 A , O
such US20080300213 A JJ O
as US20080300213 A IN O
, US20080300213 A , O
Methotrexate US20080300213 A NNP O
( US20080300213 A ( O
MTX US20080300213 A NNP O
) US20080300213 A ) O
. US20080300213 A . O

The US20080300213 A DT O
invention US20080300213 A NN O
also US20080300213 A RB O
provides US20080300213 A VBZ O
pharmaceutical US20080300213 A JJ O
compositions US20080300213 A NNS O
for US20080300213 A IN O
treatment US20080300213 A NN O
of US20080300213 A IN O
osteoarthritis US20080300213 A NN O
comprising US20080300213 A VBG O
an US20080300213 A DT O
amount US20080300213 A NN O
of US20080300213 A IN O
an US20080300213 A DT O
A3AR US20080300213 A NNP O
agonist US20080300213 A NN O
. US20080300213 A . O

Oral WO2012016707A2 T JJ O
dosage WO2012016707A2 T NN O
form WO2012016707A2 T NN O
for WO2012016707A2 T IN O
the WO2012016707A2 T DT O
modified WO2012016707A2 T JJ O
release WO2012016707A2 T NN O
of WO2012016707A2 T IN O
dimebolin WO2012016707A2 T NN O
. WO2012016707A2 T . O

Fused WO2013152269A1 T VBN O
cyclopentyl WO2013152269A1 T JJ O
antagonists WO2013152269A1 T NNS O
of WO2013152269A1 T IN O
ccr2 WO2013152269A1 T NN I-UN
. WO2013152269A1 T . O

The WO2013152269A1 A DT O
invention WO2013152269A1 A NN O
also WO2013152269A1 A RB O
comprises WO2013152269A1 A VBZ O
a WO2013152269A1 A DT O
method WO2013152269A1 A NN O
of WO2013152269A1 A IN O
inhibiting WO2013152269A1 A VBG O
CCR2 WO2013152269A1 A NNP I-UN
activity WO2013152269A1 A NN O
in WO2013152269A1 A IN O
a WO2013152269A1 A DT O
mammal WO2013152269A1 A JJ O
by WO2013152269A1 A IN O
administration WO2013152269A1 A NN O
of WO2013152269A1 A IN O
a WO2013152269A1 A DT O
therapeutically WO2013152269A1 A RB O
effective WO2013152269A1 A JJ O
amount WO2013152269A1 A NN O
of WO2013152269A1 A IN O
at WO2013152269A1 A IN O
least WO2013152269A1 A JJS O
one WO2013152269A1 A CD O
compound WO2013152269A1 A NN O
of WO2013152269A1 A IN O
Formula WO2013152269A1 A NNP O
( WO2013152269A1 A ( O
I WO2013152269A1 A PRP O
) WO2013152269A1 A ) O
. WO2013152269A1 A . O

Tricyclic WO2012006760A1 T JJ O
compounds WO2012006760A1 T NNS O
as WO2012006760A1 T IN O
allosteric WO2012006760A1 T JJ O
modulators WO2012006760A1 T NNS O
of WO2012006760A1 T IN O
metabotropic WO2012006760A1 T NN I-UN
glutamate WO2012006760A1 T NN I-UN
receptors WO2012006760A1 T NNS I-UN
. WO2012006760A1 T . O

Tape CN1839796A T NN O
preparation CN1839796A T NN O
. CN1839796A T . O

Classes WO2006081616A1 T NNS O
of WO2006081616A1 T IN O
compounds WO2006081616A1 T NNS O
that WO2006081616A1 T WDT O
interact WO2006081616A1 T VBP O
with WO2006081616A1 T IN O
integrins WO2006081616A1 T NNS I-UN
. WO2006081616A1 T . O

consisting US20050215579 T VBG O
of US20050215579 T IN O
lung US20050215579 T NN O
, US20050215579 T , O
renal US20050215579 T JJ O
, US20050215579 T , O
prostate US20050215579 T NN O
, US20050215579 T , O
uterine US20050215579 T JJ O
, US20050215579 T , O
melanoma US20050215579 T NN O
and US20050215579 T CC O
breast US20050215579 T NN O
tumors US20050215579 T NNS O
; US20050215579 T : O
cyclodextrin US20050215579 T VB O
inclusion US20050215579 T NN O
compounds US20050215579 T NNS O
aid US20050215579 T JJ O
solubility US20050215579 T NN O
. US20050215579 T . O

Camphene EP2760439A2 T NNP O
reduces EP2760439A2 T VBZ O
plasma EP2760439A2 T NN O
cholesterol EP2760439A2 T NN O
and EP2760439A2 T CC O
triglycerides EP2760439A2 T NNS O
. EP2760439A2 T . O

Denibulin US20130041002 T NNP O
di-hydrochloride US20130041002 T NN O
. US20130041002 T . O

For US7153968 T IN O
therapy US7153968 T NN O
of US7153968 T IN O
asthma US7153968 T NN O
, US7153968 T , O
chronic US7153968 T JJ O
bronchitis US7153968 T NN O
, US7153968 T , O
chronic US7153968 T JJ O
obstructive US7153968 T JJ O
pulmonary US7153968 T JJ O
disease US7153968 T NN O
, US7153968 T , O
eosinophilic US7153968 T JJ O
granuloma US7153968 T NN O
, US7153968 T , O
psoriasis US7153968 T NN O
and US7153968 T CC O
other US7153968 T JJ O
benign US7153968 T NN O
or US7153968 T CC O
malignant US7153968 T JJ O
proliferative US7153968 T JJ O
skin US7153968 T NN O
diseases US7153968 T NNS O
, US7153968 T , O
endotoxic US7153968 T NN O
shock US7153968 T NN O
, US7153968 T , O
laminitis US7153968 T NN O
in US7153968 T IN O
horses US7153968 T NNS O
, US7153968 T , O
colic US7153968 T NN O
in US7153968 T IN O
horses US7153968 T NNS O
, US7153968 T , O
septic US7153968 T JJ O
shock US7153968 T NN O
, US7153968 T , O
ulcerative US7153968 T JJ O
colitis US7153968 T NN O
, US7153968 T , O
Crohn US7153968 T NNP O
's US7153968 T POS O
disease US7153968 T NN O
, US7153968 T , O
reperfusion US7153968 T NN O
injury US7153968 T NN O
. US7153968 T . O

Application CN102871991A T NN O
of CN102871991A T IN O
dimethyldiguanide CN102871991A T NN O
in CN102871991A T IN O
drugs CN102871991A T NNS O
taking CN102871991A T VBG O
protective CN102871991A T JJ O
effect CN102871991A T NN O
on CN102871991A T IN O
chemoradiotherapy CN102871991A T NN O
injury CN102871991A T NN O
. CN102871991A T . O

Novel US20120214869 T NNP O
ligand US20120214869 T NN O
activators US20120214869 T NNS O
of US20120214869 T IN O
the US20120214869 T DT O
rar US20120214869 T NN O
receptors US20120214869 T NNS O
and US20120214869 T CC O
pharmaceutical/cosmetic US20120214869 T JJ O
applications US20120214869 T NNS O
thereof US20120214869 T NN O
. US20120214869 T . O

Anti-computer CN101744910A T JJ O
radiation CN101744910A T NN O
liniment CN101744910A T NN O
for CN101744910A T IN O
external CN101744910A T JJ O
application CN101744910A T NN O
. CN101744910A T . O

Instant CN103689748A T JJ O
drink CN103689748A T NN O
capable CN103689748A T JJ O
of CN103689748A T IN O
regulating CN103689748A T VBG O
gastrointestinal CN103689748A T JJ O
function CN103689748A T NN O
and CN103689748A T CC O
preventing CN103689748A T VBG O
constipation CN103689748A T NN O
. CN103689748A T . O

Combination WO2007016679A3 T NN O
immediate WO2007016679A3 T JJ O
release WO2007016679A3 T NN O
controlled WO2007016679A3 T VBD O
release WO2007016679A3 T NN O
levodopa WO2007016679A3 T NN O
and WO2007016679A3 T CC O
carbidopa WO2007016679A3 T JJ O
dosage WO2007016679A3 T NN O
forms WO2007016679A3 T NNS O
. WO2007016679A3 T . O

A WO2013076646A1 T DT O
new WO2013076646A1 T JJ O
diaza-benzofluoranthene WO2013076646A1 T JJ O
derivative WO2013076646A1 T JJ O
as WO2013076646A1 T IN O
drug WO2013076646A1 T NN O
. WO2013076646A1 T . O

A EP1648453A1 T DT O
synergistic EP1648453A1 T JJ O
pharmaceutical EP1648453A1 T JJ O
combination EP1648453A1 T NN O
comprising EP1648453A1 T VBG O
cicletanine EP1648453A1 T NN O
for EP1648453A1 T IN O
the EP1648453A1 T DT O
prevention EP1648453A1 T NN O
or EP1648453A1 T CC O
treatment EP1648453A1 T NN O
of EP1648453A1 T IN O
diabetes EP1648453A1 T NNS O
. EP1648453A1 T . O

Immunological US20080187536 T JJ O
modulation US20080187536 T NN O
of US20080187536 T IN O
insulin-like US20080187536 T JJ I-UN
growth US20080187536 T NN I-UN
factor US20080187536 T NN I-UN
1 US20080187536 T CD I-UN
for US20080187536 T IN O
cancer US20080187536 T NN O
prevention/treatment US20080187536 T NN O
and US20080187536 T CC O
prolonging US20080187536 T VBG O
longevity US20080187536 T NN O
. US20080187536 T . O

Provided US20080187536 A VBN O
is US20080187536 A VBZ O
a US20080187536 A DT O
simple US20080187536 A JJ O
and US20080187536 A CC O
safe US20080187536 A JJ O
immunization US20080187536 A NN O
procedure US20080187536 A NN O
to US20080187536 A TO O
reduce US20080187536 A VB O
cancer US20080187536 A NN O
incidence US20080187536 A NN O
and US20080187536 A CC O
increase US20080187536 A VB O
longevity US20080187536 A NN O
by US20080187536 A IN O
modulating US20080187536 A VBG O
IGF-1 US20080187536 A JJ I-UN
levels US20080187536 A NNS O
in US20080187536 A IN O
the US20080187536 A DT O
body US20080187536 A NN O
. US20080187536 A . O

Described US20080187536 A VBN O
are US20080187536 A VBP O
cancer US20080187536 A NN O
preventive US20080187536 A JJ O
vaccines US20080187536 A NNS O
and US20080187536 A CC O
methods US20080187536 A NNS O
that US20080187536 A WDT O
elicit US20080187536 A VBP O
circulating US20080187536 A VBG O
antibodies US20080187536 A NNS O
specific US20080187536 A JJ O
to US20080187536 A TO O
insulin-like US20080187536 A JJ I-UN
growth US20080187536 A NN I-UN
factor US20080187536 A NN I-UN
1 US20080187536 A CD I-UN
( US20080187536 A ( O
IGF-1 US20080187536 A NNP I-UN
) US20080187536 A ) O
in US20080187536 A IN O
the US20080187536 A DT O
body US20080187536 A NN O
. US20080187536 A . O

Many US20080187536 A JJ O
cancers US20080187536 A NNS O
will US20080187536 A MD O
be US20080187536 A VB O
less US20080187536 A RBR O
likely US20080187536 A JJ O
to US20080187536 A TO O
occur US20080187536 A VB O
and US20080187536 A CC O
spread US20080187536 A VB O
in US20080187536 A IN O
the US20080187536 A DT O
absence US20080187536 A NN O
or US20080187536 A CC O
reduced US20080187536 A JJ O
levels US20080187536 A NNS O
of US20080187536 A IN O
the US20080187536 A DT O
stimulatory US20080187536 A NN O
signals US20080187536 A NNS O
provided US20080187536 A VBN O
by US20080187536 A IN O
IGF-1 US20080187536 A NNP I-UN
. US20080187536 A . O

Longevity US20080187536 A NNP O
also US20080187536 A RB O
can US20080187536 A MD O
be US20080187536 A VB O
extended US20080187536 A VBN O
by US20080187536 A IN O
immunologically US20080187536 A RB O
lowering US20080187536 A VBG O
the US20080187536 A DT O
level US20080187536 A NN O
of US20080187536 A IN O
bioavailable US20080187536 A JJ O
IGF-1 US20080187536 A NNP I-UN
in US20080187536 A IN O
adult US20080187536 A NN O
animals US20080187536 A NNS O
. US20080187536 A . O

This US20080187536 A DT O
prolongation US20080187536 A NN O
of US20080187536 A IN O
lifespan US20080187536 A JJ O
resulting US20080187536 A VBG O
from US20080187536 A IN O
lower US20080187536 A JJR O
IGF-1 US20080187536 A NN I-UN
levels US20080187536 A NNS O
is US20080187536 A VBZ O
produced US20080187536 A VBN O
independently US20080187536 A RB O
of US20080187536 A IN O
the US20080187536 A DT O
inhibitory US20080187536 A JJ O
effects US20080187536 A NNS O
on US20080187536 A IN O
carcinogenesis US20080187536 A NN O
. US20080187536 A . O

Methods US20080187536 A NNS O
of US20080187536 A IN O
active US20080187536 A JJ O
and US20080187536 A CC O
passive US20080187536 A JJ O
immunization US20080187536 A NN O
to US20080187536 A TO O
suppress US20080187536 A VB O
IGF-1 US20080187536 A NNP I-UN
activity US20080187536 A NN O
are US20080187536 A VBP O
included US20080187536 A VBN O
. US20080187536 A . O

Also US20080187536 A RB O
described US20080187536 A VBN O
are US20080187536 A VBP O
methods US20080187536 A NNS O
for US20080187536 A IN O
increasing US20080187536 A VBG O
longevity US20080187536 A NN O
or US20080187536 A CC O
reducing US20080187536 A VBG O
one US20080187536 A CD O
or US20080187536 A CC O
more US20080187536 A JJR O
symptoms US20080187536 A NNS O
of US20080187536 A IN O
aging US20080187536 A VBG O
in US20080187536 A IN O
a US20080187536 A DT O
warm-blooded US20080187536 A JJ O
animal US20080187536 A NN O
comprising US20080187536 A VBG O
administering US20080187536 A VBG O
anti-IGF-1 US20080187536 A JJ O
antibodies US20080187536 A NNS O
such US20080187536 A JJ O
that US20080187536 A IN O
IGF-1 US20080187536 A NNP I-UN
is US20080187536 A VBZ O
inactivated US20080187536 A VBN O
or US20080187536 A CC O
suppressed US20080187536 A VBN O
or US20080187536 A CC O
administering US20080187536 A VBG O
IGF-1 US20080187536 A JJ I-UN
antigen US20080187536 A NN O
such US20080187536 A JJ O
that US20080187536 A IN O
the US20080187536 A DT O
animal US20080187536 A JJ O
produces US20080187536 A VBZ O
endogenous US20080187536 A JJ O
antibodies US20080187536 A NNS O
to US20080187536 A TO O
IGF-1 US20080187536 A NNP I-UN
. US20080187536 A . O

Application CN102058609A T NN O
of CN102058609A T IN O
polydatin CN102058609A T NN O
to CN102058609A T TO O
preparing CN102058609A T VBG O
antineoplastic CN102058609A T JJ O
drug CN102058609A T NN O
. CN102058609A T . O

Antiarrhythmia US7582654 T NNP O
agents US7582654 T NNS O
, US7582654 T , O
treating US7582654 T VBG O
gastrointensinal US7582654 T JJ O
disorder US7582654 T NN O
, US7582654 T , O
gastroesophageal US7582654 T NN O
reflux US7582654 T NN O
, US7582654 T , O
chronic US7582654 T JJ O
obstructive US7582654 T JJ O
pulmonary US7582654 T JJ O
disease US7582654 T NN O
, US7582654 T , O
diabetes US7582654 T VBZ O
; US7582654 T : O
N-cotnaining US7582654 T NNP O
heterocyclic US7582654 T NN O
compound US7582654 T NN O
with US7582654 T IN O
carbamate US7582654 T NN O
or US7582654 T CC O
amide US7582654 T NN O
groups US7582654 T NNS O
and US7582654 T CC O
indazole US7582654 T JJ O
ring US7582654 T NN O
. US7582654 T . O

Novel US7582654 A NNP O
heterocyclo US7582654 A NN O
compounds US7582654 A VBZ O
useful US7582654 A JJ O
as US7582654 A IN O
inhibitors US7582654 A NNS O
of US7582654 A IN O
potassium US7582654 A NN I-UN
channel US7582654 A NN I-UN
function US7582654 A NN O
( US7582654 A ( O
especially US7582654 A RB O
inhibitors US7582654 A NNS O
of US7582654 A IN O
the US7582654 A DT O
Kv1 US7582654 A NNP I-UN
subfamily US7582654 A NN O
of US7582654 A IN O
voltage US7582654 A NN I-UN
gated US7582654 A VBN I-UN
K+ US7582654 A NNP I-UN
channels US7582654 A NNS I-UN
, US7582654 A , O
especially US7582654 A RB O
inhibitors US7582654 A NNS O
Kv1.5 US7582654 A NNP I-UN
which US7582654 A WDT O
has US7582654 A VBZ O
been US7582654 A VBN O
linked US7582654 A VBN O
to US7582654 A TO O
the US7582654 A DT O
ultra-rapidly US7582654 A JJ O
activating US7582654 A NN O
delayed US7582654 A VBN O
rectifier US7582654 A RBR O
K+ US7582654 A NNP O
current US7582654 A JJ O
IKur US7582654 A NNP O
) US7582654 A ) O
, US7582654 A , O
methods US7582654 A NNS O
of US7582654 A IN O
using US7582654 A VBG O
such US7582654 A JJ O
compounds US7582654 A NNS O
in US7582654 A IN O
the US7582654 A DT O
prevention US7582654 A NN O
and US7582654 A CC O
treatment US7582654 A NN O
of US7582654 A IN O
arrhythmia US7582654 A NN O
and US7582654 A CC O
IKur-associated US7582654 A JJ O
conditions US7582654 A NNS O
, US7582654 A , O
and US7582654 A CC O
pharmaceutical US7582654 A JJ O
compositions US7582654 A NNS O
containing US7582654 A VBG O
such US7582654 A JJ O
compounds US7582654 A NNS O
. US7582654 A . O

Interleukin WO2008008981A1 T NNP I-UN
21 WO2008008981A1 T CD I-UN
and WO2008008981A1 T CC O
tyrosine WO2008008981A1 T JJ I-UN
kinase WO2008008981A1 T NN I-UN
inhibitor WO2008008981A1 T NN O
combination WO2008008981A1 T NN O
therapy WO2008008981A1 T NN O
. WO2008008981A1 T . O

The WO2008008981A1 A DT O
present WO2008008981A1 A JJ O
invention WO2008008981A1 A NN O
provides WO2008008981A1 A VBZ O
methods WO2008008981A1 A NNS O
for WO2008008981A1 A IN O
use WO2008008981A1 A NN O
of WO2008008981A1 A IN O
IL-21 WO2008008981A1 A NNP I-UN
in WO2008008981A1 A IN O
combination WO2008008981A1 A NN O
with WO2008008981A1 A IN O
a WO2008008981A1 A DT O
tyrosine WO2008008981A1 A JJ I-UN
kinase WO2008008981A1 A NN I-UN
inhibitor WO2008008981A1 A NN O
( WO2008008981A1 A ( O
TKI WO2008008981A1 A NNP O
) WO2008008981A1 A ) O
in WO2008008981A1 A IN O
treatment WO2008008981A1 A NN O
of WO2008008981A1 A IN O
diseases WO2008008981A1 A NNS O
in WO2008008981A1 A IN O
which WO2008008981A1 A WDT O
inhibition WO2008008981A1 A NN O
of WO2008008981A1 A IN O
phosphorylation WO2008008981A1 A NN O
via WO2008008981A1 A IN O
TK WO2008008981A1 A NNP I-UN
inhibition WO2008008981A1 A NN O
and WO2008008981A1 A CC O
modulation WO2008008981A1 A NN O
of WO2008008981A1 A IN O
immune WO2008008981A1 A JJ O
function WO2008008981A1 A NN O
play WO2008008981A1 A VB O
a WO2008008981A1 A DT O
clinically WO2008008981A1 A RB O
beneficial WO2008008981A1 A JJ O
role WO2008008981A1 A NN O
. WO2008008981A1 A . O

Hair WO2014092007A1 T NNP O
growing WO2014092007A1 T VBG O
agent WO2014092007A1 T NN O
. WO2014092007A1 T . O

Use WO2008144665A1 T NNP O
of WO2008144665A1 T IN O
pimavanserin WO2008144665A1 T NN O
in WO2008144665A1 T IN O
the WO2008144665A1 T DT O
treatment WO2008144665A1 T NN O
of WO2008144665A1 T IN O
parkinson WO2008144665A1 T NN O
and WO2008144665A1 T CC O
symptoms WO2008144665A1 T NNS O
thereof WO2008144665A1 T NN O
. WO2008144665A1 T . O

Combination DE102010014427A1 T NN O
, DE102010014427A1 T , O
to DE102010014427A1 T TO O
treat DE102010014427A1 T VB O
e.g DE102010014427A1 T NN O
. DE102010014427A1 T . O

tumors DE102010014427A1 T NNS O
e.g DE102010014427A1 T VBP O
. DE102010014427A1 T . O

breast DE102010014427A1 T NN O
cancer DE102010014427A1 T NN O
, DE102010014427A1 T , O
and DE102010014427A1 T CC O
psoriasis DE102010014427A1 T NN O
comprises DE102010014427A1 T NNS O
substituted DE102010014427A1 T VBD O
N- DE102010014427A1 T NNP O
( DE102010014427A1 T ( O
4-hydrosulfonimidoylphenyl DE102010014427A1 T JJ O
) DE102010014427A1 T ) O
-5- DE102010014427A1 T NN O
( DE102010014427A1 T ( O
trifluorometh DE102010014427A1 T JJ O
yl DE102010014427A1 T NN O
) DE102010014427A1 T ) O
pyrimidin-2-amine DE102010014427A1 T NN O
compounds DE102010014427A1 T NNS O
and DE102010014427A1 T CC O
antihyperproliferative DE102010014427A1 T JJ O
, DE102010014427A1 T , O
cytostatic DE102010014427A1 T JJ O
or DE102010014427A1 T CC O
cytotoxic DE102010014427A1 T JJ O
substances DE102010014427A1 T NNS O
. DE102010014427A1 T . O

- DE102010014427A1 A : O
MECHANISM DE102010014427A1 A NN O
OF DE102010014427A1 A IN O
ACTION DE102010014427A1 A NNP O
: DE102010014427A1 A : O
Pan-cyclin DE102010014427A1 A JJ I-UN
dependent DE102010014427A1 A JJ I-UN
kinase DE102010014427A1 A NN I-UN
( DE102010014427A1 A ( O
CDK DE102010014427A1 A NNP I-UN
) DE102010014427A1 A ) O
inhibitor DE102010014427A1 A NN O
. DE102010014427A1 A . O

Zoledronic CN101259133A T JJ O
acid CN101259133A T NN O
for CN101259133A T IN O
preparing CN101259133A T VBG O
medicaments CN101259133A T NNS O
for CN101259133A T IN O
preventing CN101259133A T VBG O
and CN101259133A T CC O
treating CN101259133A T VBG O
osteoporosis CN101259133A T NN O
. CN101259133A T . O

Means US20130012471 T NNS O
and US20130012471 T CC O
methods US20130012471 T NNS O
for US20130012471 T IN O
producing US20130012471 T VBG O
artificial US20130012471 T JJ O
capsular US20130012471 T JJ O
polysaccharides US20130012471 T NNS O
of US20130012471 T IN O
neisseria US20130012471 T JJ O
meningitidis US20130012471 T NN O
. US20130012471 T . O

Novel US20050256178 T NNP O
nutraceutical US20050256178 T JJ O
compositions US20050256178 T NNS O
comprising US20050256178 T VBG O
boitin US20050256178 T NN O
. US20050256178 T . O

Acylbenzene EP2628733A1 T NNP O
derivative EP2628733A1 T NN O
. EP2628733A1 T . O

Composition CA2602555A1 T NN O
and CA2602555A1 T CC O
method CA2602555A1 T NN O
for CA2602555A1 T IN O
reducing CA2602555A1 T VBG O
inflammation CA2602555A1 T NN O
. CA2602555A1 T . O

The CA2602555A1 A DT O
present CA2602555A1 A JJ O
invention CA2602555A1 A NN O
relates CA2602555A1 A VBZ O
to CA2602555A1 A TO O
a CA2602555A1 A DT O
composition CA2602555A1 A NN O
and CA2602555A1 A CC O
method CA2602555A1 A NN O
for CA2602555A1 A IN O
the CA2602555A1 A DT O
simultaneous CA2602555A1 A JJ O
alleviation CA2602555A1 A NN O
of CA2602555A1 A IN O
the CA2602555A1 A DT O
symptoms CA2602555A1 A NNS O
of CA2602555A1 A IN O
inflammation CA2602555A1 A NN O
brought CA2602555A1 A VBN O
about CA2602555A1 A IN O
by CA2602555A1 A IN O
innate CA2602555A1 A NN O
immune CA2602555A1 A NN O
responses CA2602555A1 A NNS O
wherein CA2602555A1 A VBP O
said CA2602555A1 A VBD O
composition CA2602555A1 A NN O
acts CA2602555A1 A NNS O
by CA2602555A1 A IN O
inhibiting CA2602555A1 A VBG O
leukotrienes CA2602555A1 A NNS O
, CA2602555A1 A , O
chemotactic CA2602555A1 A JJ O
cytokines CA2602555A1 A NNS I-UN
and CA2602555A1 A CC O
cyclooxygenases CA2602555A1 A NNS I-UN
. CA2602555A1 A . O

Sex CA2124932C T NN O
steroid CA2124932C T NN O
activity CA2124932C T NN O
inhibitors CA2124932C T NNS O
. CA2124932C T . O

Methods US7442719 T NNS O
using US7442719 T VBG O
phenethanolamine US7442719 T JJ O
derivatives US7442719 T NNS O
for US7442719 T IN O
treatment US7442719 T NN O
of US7442719 T IN O
respiratory US7442719 T NN O
diseases US7442719 T NNS O
. US7442719 T . O

Human CN1935133A T NNP I-UN
leucocyte CN1935133A T VBZ I-UN
antigen CN1935133A T NN I-UN
DR4 CN1935133A T NNP I-UN
subtype CN1935133A T NN I-UN
protein CN1935133A T NN I-UN
agonist CN1935133A T NN O
. CN1935133A T . O

The CN1935133A A DT O
present CN1935133A A JJ O
invention CN1935133A A NN O
discloses CN1935133A A VBZ O
an CN1935133A A DT O
antagonist CN1935133A A NN O
of CN1935133A A IN O
human CN1935133A A JJ I-UN
leukocyte CN1935133A A NN I-UN
antigen CN1935133A A NN I-UN
DR4 CN1935133A A NNP I-UN
subtype CN1935133A A NN I-UN
protein CN1935133A A NN I-UN
. CN1935133A A . O

17-hydroxy-17-pentafluorethyl-estra-4,9 WO2011009533A3 T JJ O
( WO2011009533A3 T ( O
10 WO2011009533A3 T CD O
) WO2011009533A3 T ) O
-dien-11-ethinylphenyl WO2011009533A3 T NN O
derivatives WO2011009533A3 T NNS O
, WO2011009533A3 T , O
methods WO2011009533A3 T NNS O
for WO2011009533A3 T IN O
the WO2011009533A3 T DT O
production WO2011009533A3 T NN O
thereof WO2011009533A3 T NN O
and WO2011009533A3 T CC O
use WO2011009533A3 T NN O
thereof WO2011009533A3 T NN O
for WO2011009533A3 T IN O
treating WO2011009533A3 T VBG O
diseases WO2011009533A3 T NNS O
. WO2011009533A3 T . O

Pharmaceutical CN101658646B T JJ O
composition CN101658646B T NN O
for CN101658646B T IN O
curing CN101658646B T VBG O
summer-heat CN101658646B T JJ O
cold CN101658646B T NN O
and CN101658646B T CC O
preparation CN101658646B T NN O
method CN101658646B T NN O
thereof CN101658646B T NN O
. CN101658646B T . O

Application CN1864697A T NN O
of CN1864697A T IN O
non-adenine CN1864697A T JJ O
in CN1864697A T IN O
preparation CN1864697A T NN O
of CN1864697A T IN O
drug CN1864697A T NN O
for CN1864697A T IN O
promoting CN1864697A T VBG O
wound CN1864697A T NN O
healing CN1864697A T NN O
. CN1864697A T . O

Diamine EP1614684B1 T NNP O
derivative EP1614684B1 T NN O
, EP1614684B1 T , O
production EP1614684B1 T NN O
process EP1614684B1 T NN O
, EP1614684B1 T , O
and EP1614684B1 T CC O
antioxidizing EP1614684B1 T VBG O
drug EP1614684B1 T NN O
. EP1614684B1 T . O

Application CN103356522A T NN O
of CN103356522A T IN O
Sarcaboside CN103356522A T NNP O
B CN103356522A T NNP O
in CN103356522A T IN O
preparation CN103356522A T NN O
of CN103356522A T IN O
medicines CN103356522A T NNS O
for CN103356522A T IN O
treating CN103356522A T VBG O
alzheimer CN103356522A T JJ O
disease CN103356522A T NN O
. CN103356522A T . O

The CN103356522A A DT O
Sarcaboside CN103356522A A NNP O
B CN103356522A A NNP O
has CN103356522A A VBZ O
inhibitory CN103356522A A JJ O
activity CN103356522A A NN O
on CN103356522A A IN O
acetylcholin CN103356522A A NN I-UN
esterase CN103356522A A NN I-UN
and CN103356522A A CC O
a CN103356522A A DT O
nerve CN103356522A A NN O
cell CN103356522A A NN O
protection CN103356522A A NN O
effect CN103356522A A NN O
. CN103356522A A . O

As CN103356522A A IN O
the CN103356522A A DT O
skeleton CN103356522A A NN O
type CN103356522A A NN O
of CN103356522A A IN O
the CN103356522A A DT O
Sarcaboside CN103356522A A NNP O
B CN103356522A A NNP O
belongs CN103356522A A VBZ O
to CN103356522A A TO O
a CN103356522A A DT O
brand-new CN103356522A A JJ O
skeleton CN103356522A A NN O
type CN103356522A A NN O
, CN103356522A A , O
the CN103356522A A DT O
Sarcaboside CN103356522A A NNP O
B CN103356522A A NNP O
has CN103356522A A VBZ O
unexpected CN103356522A A VBN O
strong CN103356522A A JJ O
inhibitory CN103356522A A NN O
activity CN103356522A A NN O
on CN103356522A A IN O
the CN103356522A A DT O
acetylcholin CN103356522A A NN I-UN
esterase CN103356522A A NN I-UN
, CN103356522A A , O
and CN103356522A A CC O
the CN103356522A A DT O
possibility CN103356522A A NN O
that CN103356522A A IN O
other CN103356522A A JJ O
compounds CN103356522A A NNS O
provide CN103356522A A VBP O
revelation CN103356522A A NN O
does CN103356522A A VBZ O
not CN103356522A A RB O
exist CN103356522A A VB O
. CN103356522A A . O

Pyrido US6897222 T NNP O
[ US6897222 T NNP O
2,1-a US6897222 T JJ O
] US6897222 T NNP O
isoquinoline US6897222 T NN O
derivatives US6897222 T NNS O
. US6897222 T . O

The US6897222 A DT O
compounds US6897222 A NNS O
are US6897222 A VBP O
useful US6897222 A JJ O
for US6897222 A IN O
the US6897222 A DT O
treatment US6897222 A NN O
and/or US6897222 A JJ O
prophylaxis US6897222 A NN O
of US6897222 A IN O
diseases US6897222 A NNS O
which US6897222 A WDT O
are US6897222 A VBP O
associated US6897222 A VBN O
with US6897222 A IN O
DPP-IV US6897222 A NNP I-UN
, US6897222 A , O
such US6897222 A JJ O
as US6897222 A IN O
diabetes US6897222 A NNS O
, US6897222 A , O
particularly US6897222 A RB O
non-insulin US6897222 A JJ O
dependent US6897222 A NN O
diabetes US6897222 A VBZ O
mellitus US6897222 A RBS O
, US6897222 A , O
and US6897222 A CC O
impaired US6897222 A VBD O
glucose US6897222 A JJ O
tolerance US6897222 A NN O
. US6897222 A . O

Derivatives EP2185523A2 T NNS O
of EP2185523A2 T IN O
1-oxo-1,2-dihydroisoquinoline-5-carboxamides EP2185523A2 T NNS O
and EP2185523A2 T CC O
of EP2185523A2 T IN O
4-oxo-3,4-dihydroquinazoline-8-carboxamides EP2185523A2 T NNS O
, EP2185523A2 T , O
preparation EP2185523A2 T NN O
thereof EP2185523A2 T NN O
and EP2185523A2 T CC O
application EP2185523A2 T NN O
thereof EP2185523A2 T NN O
in EP2185523A2 T IN O
therapeutics EP2185523A2 T NNS O
. EP2185523A2 T . O

The EP2185523A2 A DT O
invention EP2185523A2 A NN O
also EP2185523A2 A RB O
relates EP2185523A2 A VBZ O
to EP2185523A2 A TO O
the EP2185523A2 A DT O
method EP2185523A2 A NN O
of EP2185523A2 A IN O
producing EP2185523A2 A VBG O
said EP2185523A2 A VBD O
derivatives EP2185523A2 A NNS O
and EP2185523A2 A CC O
the EP2185523A2 A DT O
application EP2185523A2 A NN O
thereof EP2185523A2 A NN O
in EP2185523A2 A IN O
therapeutics EP2185523A2 A NNS O
as EP2185523A2 A IN O
β-secretase EP2185523A2 A NN I-UN
for EP2185523A2 A IN O
treating EP2185523A2 A VBG O
neurodegenerative EP2185523A2 A JJ O
disorders EP2185523A2 A NNS O
such EP2185523A2 A JJ O
as EP2185523A2 A IN O
Alzheimer EP2185523A2 A NNP O
's EP2185523A2 A POS O
disease EP2185523A2 A NN O
. EP2185523A2 A . O

Maintenance US20110144003 T NNP O
therapy US20110144003 T NN O
regime/regimen US20110144003 T NNS O
for US20110144003 T IN O
the US20110144003 T DT O
treatment US20110144003 T NN O
of US20110144003 T IN O
acne US20110144003 T NN O
. US20110144003 T . O

Molecular US20120214829 T JJ O
Predictors US20120214829 T NNS O
of US20120214829 T IN O
Therapeutic US20120214829 T JJ O
Response US20120214829 T NNP O
to US20120214829 T TO O
Specific US20120214829 T NNP O
Anti-Cancer US20120214829 T NNP O
Agents US20120214829 T NNP O
. US20120214829 T . O

Hypoxia US20080226622 T NNP O
inducible US20080226622 T JJ O
factor US20080226622 T NN O
( US20080226622 T ( O
Hif US20080226622 T NNP O
) US20080226622 T ) O
; US20080226622 T : O
for US20080226622 T IN O
modulating US20080226622 T VBG O
mRNA US20080226622 T JJ O
translation US20080226622 T NN O
within US20080226622 T IN O
cells US20080226622 T NNS O
; US20080226622 T : O
prevents US20080226622 T NNS O
excessive US20080226622 T JJ O
vascularization US20080226622 T NN O
. US20080226622 T . O

HIF-1 US20080226622 A JJ I-UN
inhibitors US20080226622 A NNS O
and US20080226622 A CC O
methods US20080226622 A NNS O
of US20080226622 A IN O
use US20080226622 A NN O
thereof US20080226622 A NN O
are US20080226622 A VBP O
provided US20080226622 A VBN O
. US20080226622 A . O

Intestinal EP1986670A2 T JJ I-UN
alpha-glucosidase EP1986670A2 T JJ I-UN
inhibitors EP1986670A2 T NNS O
and EP1986670A2 T CC O
a EP1986670A2 T DT O
process EP1986670A2 T NN O
for EP1986670A2 T IN O
the EP1986670A2 T DT O
isolation EP1986670A2 T NN O
and EP1986670A2 T CC O
use EP1986670A2 T NN O
thereof EP1986670A2 T NN O
. EP1986670A2 T . O

This EP1986670A2 A DT O
invention EP1986670A2 A NN O
provides EP1986670A2 A VBZ O
α-glucosidase EP1986670A2 A JJ I-UN
inhibitors EP1986670A2 A NNS O
isolated EP1986670A2 A VBD O
from EP1986670A2 A IN O
Oroxylum EP1986670A2 A NNP O
indicum EP1986670A2 A VBP O
an EP1986670A2 A DT O
Indian EP1986670A2 A JJ O
medicinal EP1986670A2 A NN O
plant EP1986670A2 A NN O
. EP1986670A2 A . O

Particularly EP1986670A2 A RB O
, EP1986670A2 A , O
this EP1986670A2 A DT O
invention EP1986670A2 A NN O
provides EP1986670A2 A VBZ O
hexane EP1986670A2 A NN O
and EP1986670A2 A CC O
acetone EP1986670A2 A JJ O
fraction EP1986670A2 A NN O
of EP1986670A2 A IN O
Oroxylum EP1986670A2 A NNP O
indicum EP1986670A2 A NN O
wherein EP1986670A2 A VBD O
the EP1986670A2 A DT O
hexane EP1986670A2 A NN O
fraction EP1986670A2 A NN O
comprises EP1986670A2 A VBZ O
α-glucosidase EP1986670A2 A JJ I-UN
active EP1986670A2 A JJ O
compounds EP1986670A2 A NNS O
of EP1986670A2 A IN O
oroxylin EP1986670A2 A NN O
A EP1986670A2 A NNP O
, EP1986670A2 A , O
chrysin EP1986670A2 A NN O
and EP1986670A2 A CC O
baicalain EP1986670A2 A NN O
and EP1986670A2 A CC O
acetone EP1986670A2 A NN O
fraction EP1986670A2 A NN O
comprises EP1986670A2 A VBZ O
the EP1986670A2 A DT O
compounds EP1986670A2 A NNS O
of EP1986670A2 A IN O
oroxylin EP1986670A2 A NN O
A EP1986670A2 A NNP O
, EP1986670A2 A , O
chrysin EP1986670A2 A NN O
, EP1986670A2 A , O
baicalain EP1986670A2 A NN O
, EP1986670A2 A , O
methoxy EP1986670A2 A JJ O
chrysin EP1986670A2 A NN O
and EP1986670A2 A CC O
oroxyloside EP1986670A2 A JJ O
methyl EP1986670A2 A NN O
ester EP1986670A2 A NN O
. EP1986670A2 A . O

This EP1986670A2 A DT O
invention EP1986670A2 A NN O
also EP1986670A2 A RB O
relates EP1986670A2 A VBZ O
to EP1986670A2 A TO O
a EP1986670A2 A DT O
process EP1986670A2 A NN O
for EP1986670A2 A IN O
the EP1986670A2 A DT O
isolation EP1986670A2 A NN O
of EP1986670A2 A IN O
α-glucosidase EP1986670A2 A JJ I-UN
inhibitory EP1986670A2 A NN O
active EP1986670A2 A JJ O
compounds EP1986670A2 A NNS O
from EP1986670A2 A IN O
the EP1986670A2 A DT O
above EP1986670A2 A NN O
said EP1986670A2 A VBD O
hexane EP1986670A2 A NN O
and EP1986670A2 A CC O
acetone EP1986670A2 A JJ O
fraction EP1986670A2 A NN O
of EP1986670A2 A IN O
Oroxylum EP1986670A2 A NNP O
indicum EP1986670A2 A NN O
. EP1986670A2 A . O

This EP1986670A2 A DT O
invention EP1986670A2 A NN O
also EP1986670A2 A RB O
provides EP1986670A2 A VBZ O
the EP1986670A2 A DT O
use EP1986670A2 A NN O
of EP1986670A2 A IN O
potent EP1986670A2 A JJ O
intestinal EP1986670A2 A JJ I-UN
α-glucosidase EP1986670A2 A JJ I-UN
inhibitors EP1986670A2 A NNS O
as EP1986670A2 A IN O
active EP1986670A2 A JJ O
ingredients EP1986670A2 A NNS O
that EP1986670A2 A WDT O
can EP1986670A2 A MD O
be EP1986670A2 A VB O
used EP1986670A2 A VBN O
in EP1986670A2 A IN O
pharmaceuticals EP1986670A2 A NNS O
, EP1986670A2 A , O
food EP1986670A2 A NN O
products EP1986670A2 A NNS O
, EP1986670A2 A , O
health EP1986670A2 A NN O
foods EP1986670A2 A NNS O
and EP1986670A2 A CC O
specialized EP1986670A2 A JJ O
health EP1986670A2 A NN O
care EP1986670A2 A NN O
foods EP1986670A2 A NNS O
as EP1986670A2 A IN O
anti EP1986670A2 A JJ O
hyperglycemic EP1986670A2 A JJ O
agent EP1986670A2 A NN O
for EP1986670A2 A IN O
prevention EP1986670A2 A NN O
and EP1986670A2 A CC O
treatment EP1986670A2 A NN O
of EP1986670A2 A IN O
post EP1986670A2 A NN O
prandial EP1986670A2 A JJ O
hyperglycemia EP1986670A2 A NN O
, EP1986670A2 A , O
hyperglycemia EP1986670A2 A NN O
and EP1986670A2 A CC O
related EP1986670A2 A JJ O
conditions EP1986670A2 A NNS O
in EP1986670A2 A IN O
diabetes EP1986670A2 A NNS O
mellitus EP1986670A2 A NNS O
, EP1986670A2 A , O
obesity EP1986670A2 A NN O
and EP1986670A2 A CC O
disease EP1986670A2 A NN O
conditions EP1986670A2 A NNS O
requiring EP1986670A2 A VBG O
hyperglycemic EP1986670A2 A JJ O
control EP1986670A2 A NN O
as EP1986670A2 A RB O
well EP1986670A2 A RB O
as EP1986670A2 A IN O
inhibition EP1986670A2 A NN O
of EP1986670A2 A IN O
α-glucosidase EP1986670A2 A JJ I-UN
activity EP1986670A2 A NN O
. EP1986670A2 A . O

Increasing US20050004171 T VBG O
blood US20050004171 T NN O
absorption US20050004171 T NN O
of US20050004171 T IN O
proton US20050004171 T NN I-UN
pump US20050004171 T NN I-UN
inhibitor US20050004171 T NN O
; US20050004171 T : O
adjusting US20050004171 T VBG O
stomach US20050004171 T NN O
gastric US20050004171 T JJ O
fluid US20050004171 T NN O
pH US20050004171 T NN O
with US20050004171 T IN O
buffering US20050004171 T VBG O
agent US20050004171 T NN O
to US20050004171 T TO O
inhibit US20050004171 T VB O
acid US20050004171 T JJ O
degradation US20050004171 T NN O
. US20050004171 T . O

Disclosed US20050004171 A VBN O
herein US20050004171 A NNS O
are US20050004171 A VBP O
methods US20050004171 A NNS O
, US20050004171 A , O
kits US20050004171 A NNS O
, US20050004171 A , O
combinations US20050004171 A NNS O
, US20050004171 A , O
and US20050004171 A CC O
compositions US20050004171 A NNS O
for US20050004171 A IN O
treating US20050004171 A VBG O
gastric US20050004171 A JJ O
acid US20050004171 A NN O
disorders US20050004171 A NNS O
employing US20050004171 A VBG O
pharmaceutical US20050004171 A JJ O
compositions US20050004171 A NNS O
comprising US20050004171 A VBG O
a US20050004171 A DT O
proton US20050004171 A NN I-UN
pump US20050004171 A NN I-UN
inhibiting US20050004171 A VBG O
agent US20050004171 A NN O
( US20050004171 A ( O
PPI US20050004171 A NNP O
) US20050004171 A ) O
and US20050004171 A CC O
a US20050004171 A DT O
buffering US20050004171 A NN O
agent US20050004171 A NN O
in US20050004171 A IN O
a US20050004171 A DT O
pharmaceutically US20050004171 A RB O
acceptable US20050004171 A JJ O
carrier US20050004171 A NN O
. US20050004171 A . O

Matrine CN1593407A T NNP O
pellicle CN1593407A T NN O
and CN1593407A T CC O
its CN1593407A T PRP$ O
preparation CN1593407A T NN O
process CN1593407A T NN O
. CN1593407A T . O

C US20090318543 T NNP O
( US20090318543 T ( O
10 US20090318543 T CD O
) US20090318543 T ) O
ethyl US20090318543 T NN O
ester US20090318543 T NN O
and US20090318543 T CC O
c US20090318543 T NN O
( US20090318543 T ( O
10 US20090318543 T CD O
) US20090318543 T ) O
cyclopropyl US20090318543 T NN O
ester US20090318543 T NN O
substituted US20090318543 T VBD O
taxanes US20090318543 T NNS O
. US20090318543 T . O

Substituted US20130064794 T VBN O
Carbonyloxymethylphosphoramidate US20130064794 T NNP O
Compounds US20130064794 T NNP O
and US20130064794 T CC O
Pharmaceutical US20130064794 T NNP O
Compositions US20130064794 T NNP O
for US20130064794 T IN O
the US20130064794 T DT O
Treatment US20130064794 T NNP O
of US20130064794 T IN O
Viral US20130064794 T NNP O
Infections US20130064794 T NNP O
. US20130064794 T . O

TRIM33 US20110301110 T NNP I-UN
( US20110301110 T ( O
TIF1gamma US20110301110 T NNP I-UN
) US20110301110 T ) O
AS US20110301110 T IN O
A US20110301110 T DT O
NEW US20110301110 T NNP O
DIAGNOSTIC US20110301110 T NNP O
MARKER US20110301110 T NNP O
OF US20110301110 T NNP O
CHRONIC US20110301110 T NNP O
MYELOMONOCYTIC US20110301110 T NNP O
LEUKEMIA US20110301110 T NNP O
( US20110301110 T ( O
CMML US20110301110 T NNP O
) US20110301110 T ) O
. US20110301110 T . O

A US20110301110 A DT O
method US20110301110 A NN O
for US20110301110 A IN O
diagnosing US20110301110 A VBG O
a US20110301110 A DT O
chronic US20110301110 A JJ O
myelomonocytic US20110301110 A JJ O
leukemia US20110301110 A NN O
( US20110301110 A ( O
CMML US20110301110 A NNP O
) US20110301110 A ) O
in US20110301110 A IN O
a US20110301110 A DT O
subject US20110301110 A NN O
includes US20110301110 A VBZ O
the US20110301110 A DT O
steps US20110301110 A NNS O
of US20110301110 A IN O
( US20110301110 A ( O
i US20110301110 A NN O
) US20110301110 A ) O
determining US20110301110 A VBG O
the US20110301110 A DT O
level US20110301110 A NN O
of US20110301110 A IN O
expression US20110301110 A NN O
of US20110301110 A IN O
the US20110301110 A DT O
Trim33 US20110301110 A NNP I-UN
( US20110301110 A ( O
tripartite US20110301110 A JJ I-UN
motif-containing US20110301110 A NN I-UN
33 US20110301110 A CD I-UN
) US20110301110 A ) O
gene US20110301110 A NN O
in US20110301110 A IN O
a US20110301110 A DT O
biological US20110301110 A JJ O
sample US20110301110 A NN O
from US20110301110 A IN O
the US20110301110 A DT O
subject US20110301110 A NN O
, US20110301110 A , O
and US20110301110 A CC O
( US20110301110 A ( O
ii US20110301110 A NN O
) US20110301110 A ) O
comparing US20110301110 A VBG O
the US20110301110 A DT O
level US20110301110 A NN O
of US20110301110 A IN O
expression US20110301110 A NN O
of US20110301110 A IN O
the US20110301110 A DT O
Trim33 US20110301110 A NNP I-UN
gene US20110301110 A NN I-UN
in US20110301110 A IN O
the US20110301110 A DT O
biological US20110301110 A JJ O
sample US20110301110 A NN O
with US20110301110 A IN O
its US20110301110 A PRP$ O
normal US20110301110 A JJ O
level US20110301110 A NN O
of US20110301110 A IN O
expression US20110301110 A NN O
; US20110301110 A : O
wherein US20110301110 A CC O
an US20110301110 A DT O
under-expression US20110301110 A NN O
of US20110301110 A IN O
the US20110301110 A DT O
Trim33 US20110301110 A NNP I-UN
gene US20110301110 A NN I-UN
is US20110301110 A VBZ O
associated US20110301110 A VBN O
with US20110301110 A IN O
CMML US20110301110 A NNP O
, US20110301110 A , O
and US20110301110 A CC O
to US20110301110 A TO O
a US20110301110 A DT O
kit US20110301110 A NN O
for US20110301110 A IN O
diagnosing US20110301110 A VBG O
CMML US20110301110 A NNP O
in US20110301110 A IN O
a US20110301110 A DT O
subject US20110301110 A JJ O
including US20110301110 A VBG O
at US20110301110 A IN O
least US20110301110 A JJS O
one US20110301110 A CD O
nucleic US20110301110 A JJ O
acid US20110301110 A NN O
probe US20110301110 A NN O
or US20110301110 A CC O
oligonucleotide US20110301110 A NN O
or US20110301110 A CC O
at US20110301110 A IN O
least US20110301110 A JJS O
one US20110301110 A CD O
antibody US20110301110 A NN O
, US20110301110 A , O
which US20110301110 A WDT O
can US20110301110 A MD O
be US20110301110 A VB O
used US20110301110 A VBN O
in US20110301110 A IN O
a US20110301110 A DT O
such US20110301110 A JJ O
a US20110301110 A DT O
method US20110301110 A NN O
. US20110301110 A . O

Glyco-substituted CN103096887A T JJ O
dihydroxy-chlorins CN103096887A T NNS O
and CN103096887A T CC O
b-functionalized CN103096887A T JJ O
chlorins CN103096887A T NNS O
for CN103096887A T IN O
anti-microbial CN103096887A T JJ O
photodynamic CN103096887A T JJ O
therapy CN103096887A T NN O
. CN103096887A T . O

Prophylactic US20110293595 T JJ O
and US20110293595 T CC O
therapeutic US20110293595 T JJ O
treatment US20110293595 T NN O
of US20110293595 T IN O
Alzheimer US20110293595 T NNP O
's US20110293595 T POS O
Disease US20110293595 T NNP O
, US20110293595 T , O
neuro-degenerative US20110293595 T JJ O
diseases US20110293595 T NNS O
, US20110293595 T , O
protein US20110293595 T NN O
aggregation US20110293595 T NN O
diseases US20110293595 T NNS O
, US20110293595 T , O
Parkinson US20110293595 T NNP O
's US20110293595 T POS O
Disease US20110293595 T NNP O
and US20110293595 T CC O
amyloid US20110293595 T JJ O
diseases US20110293595 T NNS O
, US20110293595 T , O
using US20110293595 T VBG O
phytic US20110293595 T JJ O
acid US20110293595 T NN O
and US20110293595 T CC O
phytate US20110293595 T NN O
. US20110293595 T . O

5-cyano-1h-indole US20050100902 T JJ O
derivatives US20050100902 T NNS O
as US20050100902 T IN O
antagonist US20050100902 T NN O
of US20050100902 T IN O
the US20050100902 T DT O
inerleukine-8 US20050100902 T JJ O
receptors US20050100902 T NNS O
. US20050100902 T . O

Pharmaceutical US20050100902 A JJ O
compositions US20050100902 A NNS O
containing US20050100902 A VBG O
them US20050100902 A PRP O
, US20050100902 A , O
as US20050100902 A RB O
well US20050100902 A RB O
as US20050100902 A IN O
their US20050100902 A PRP$ O
use US20050100902 A NN O
for US20050100902 A IN O
the US20050100902 A DT O
preparation US20050100902 A NN O
of US20050100902 A IN O
medicaments US20050100902 A NNS O
intended US20050100902 A VBN O
for US20050100902 A IN O
the US20050100902 A DT O
preventative US20050100902 A NN O
or US20050100902 A CC O
curative US20050100902 A JJ O
treatment US20050100902 A NN O
of US20050100902 A IN O
illnesses US20050100902 A NNS O
which US20050100902 A WDT O
are US20050100902 A VBP O
dependent US20050100902 A JJ O
upon US20050100902 A IN O
the US20050100902 A DT O
activation US20050100902 A NN O
of US20050100902 A IN O
the US20050100902 A DT O
interleukin US20050100902 A JJ I-UN
CXCR2 US20050100902 A NNP I-UN
receptor US20050100902 A NN O
and US20050100902 A CC O
of US20050100902 A IN O
the US20050100902 A DT O
chemokines US20050100902 A NNS O
of US20050100902 A IN O
the US20050100902 A DT O
same US20050100902 A JJ O
family US20050100902 A NN O
, US20050100902 A , O
are US20050100902 A VBP O
also US20050100902 A RB O
subjects US20050100902 A NNS O
of US20050100902 A IN O
the US20050100902 A DT O
invention US20050100902 A NN O
. US20050100902 A . O

Azithromycin CN103054813A T NNP O
oral CN103054813A T JJ O
sustained-release CN103054813A T NN O
dry CN103054813A T JJ O
suspension CN103054813A T NN O
and CN103054813A T CC O
preparation CN103054813A T NN O
method CN103054813A T NN O
thereof CN103054813A T NN O
. CN103054813A T . O

Prodrug US7037907 T NNP O
of US7037907 T IN O
an US7037907 T DT O
estradiol US7037907 T NN O
conjugated US7037907 T VBD O
to US7037907 T TO O
a US7037907 T DT O
glucuronide US7037907 T NN O
sugar US7037907 T NN O
; US7037907 T : O
6-oxo-2-methoxyestradiol US7037907 T JJ O
; US7037907 T : O
3-acetyl-6-oxo-2-methoxyestradiol US7037907 T JJ O
; US7037907 T : O
and US7037907 T CC O
2-methoxyestradiol-6-hydrazone US7037907 T CD O
; US7037907 T : O
angiogenesis US7037907 T NN O
inhibitor US7037907 T NN O
; US7037907 T : O
antiinflammatory US7037907 T NN O
for US7037907 T IN O
asthma US7037907 T NN O
or US7037907 T CC O
rheumatoid US7037907 T NN O
arthritis US7037907 T NN O
. US7037907 T . O

Oxadiazolyl-biphenylcarboxamides US20050065195 T NNS O
and US20050065195 T CC O
their US20050065195 T PRP$ O
use US20050065195 T NN O
as US20050065195 T IN O
p38 US20050065195 T JJ I-UN
kinase US20050065195 T NN I-UN
inhibitors US20050065195 T NNS O
. US20050065195 T . O

Compounds US20050065195 A NNS O
of US20050065195 A IN O
formula US20050065195 A NN O
( US20050065195 A ( O
I US20050065195 A PRP O
) US20050065195 A ) O
, US20050065195 A , O
wherein US20050065195 A JJ O
R3 US20050065195 A NNP O
is US20050065195 A VBZ O
the US20050065195 A DT O
group US20050065195 A NN O
; US20050065195 A : O
or US20050065195 A CC O
pharmaceutically US20050065195 A RB O
acceptable US20050065195 A JJ O
salts US20050065195 A NNS O
or US20050065195 A CC O
solvates US20050065195 A NNS O
thereof US20050065195 A VBP O
, US20050065195 A , O
and US20050065195 A CC O
their US20050065195 A PRP$ O
use US20050065195 A NN O
as US20050065195 A IN O
pharmaceuticals US20050065195 A NNS O
, US20050065195 A , O
particularly US20050065195 A RB O
as US20050065195 A IN O
p38 US20050065195 A JJ I-UN
kinase US20050065195 A NN I-UN
inhibitors US20050065195 A NNS O
. US20050065195 A . O

Deuterium-enriched US20090075953 T JJ O
ed-71 US20090075953 T NN O
. US20090075953 T . O

Preparation CN101322689A T NN O
of CN101322689A T IN O
docetaxel CN101322689A T JJ O
long-circulating CN101322689A T JJ O
liposome CN101322689A T NN O
and CN101322689A T CC O
freeze-dried CN101322689A T JJ O
powder CN101322689A T NN O
injection CN101322689A T NN O
thereof CN101322689A T NN O
. CN101322689A T . O

New US20080004228 T NNP O
Expression US20080004228 T NNP O
Tools US20080004228 T NNP O
for US20080004228 T IN O
Multiprotein US20080004228 T NNP O
Applications US20080004228 T NNP O
. US20080004228 T . O

Application CN101116664B T NN O
of CN101116664B T IN O
compound CN101116664B T NN O
1- CN101116664B T JJ O
( CN101116664B T ( O
4-chloroaniline CN101116664B T JJ O
) CN101116664B T ) O
-4- CN101116664B T NN O
( CN101116664B T ( O
4-picoline CN101116664B T JJ O
) CN101116664B T ) O
-2 CN101116664B T NN O
, CN101116664B T , O
3-naphthyridine CN101116664B T JJ O
. CN101116664B T . O

Halogenated EP2523691A1 T VBN O
ether EP2523691A1 T DT O
complex EP2523691A1 T NN O
. EP2523691A1 T . O

Sensitization US20060052319 T NN O
of US20060052319 T IN O
cells US20060052319 T NNS O
to US20060052319 T TO O
cytotoxic US20060052319 T VB O
agents US20060052319 T NNS O
using US20060052319 T VBG O
oligonucleotides US20060052319 T NNS O
directed US20060052319 T VBD O
to US20060052319 T TO O
nucleotide US20060052319 T VB O
excision US20060052319 T NN O
repair US20060052319 T NN O
or US20060052319 T CC O
transcritpion US20060052319 T NN O
coupled US20060052319 T VBN O
repair US20060052319 T NN O
genes US20060052319 T NNS O
. US20060052319 T . O

Pyrazinooxazepine US20100317651 T NNP O
derivatives US20100317651 T NNS O
. US20100317651 T . O

Macrocyclics WO2010028116A1 T NNS O
pyrimidines WO2010028116A1 T NNS O
as WO2010028116A1 T IN O
aurora WO2010028116A1 T JJ I-UN
kinase WO2010028116A1 T NN I-UN
inhibitors WO2010028116A1 T NNS O
. WO2010028116A1 T . O

Macrocyclic WO2010028116A1 A NNP O
derivative WO2010028116A1 A JJ O
compounds WO2010028116A1 A NNS O
that WO2010028116A1 A WDT O
inhibit WO2010028116A1 A VBP O
protein WO2010028116A1 A JJ I-UN
kinase WO2010028116A1 A NN I-UN
enzymes WO2010028116A1 A NNS O
are WO2010028116A1 A VBP O
disclosed WO2010028116A1 A VBN O
along WO2010028116A1 A IN O
with WO2010028116A1 A IN O
pharmaceutical WO2010028116A1 A JJ O
compositions WO2010028116A1 A NNS O
comprising WO2010028116A1 A VBG O
these WO2010028116A1 A DT O
compounds WO2010028116A1 A NNS O
and WO2010028116A1 A CC O
methods WO2010028116A1 A NNS O
for WO2010028116A1 A IN O
synthesizing WO2010028116A1 A VBG O
the WO2010028116A1 A DT O
same WO2010028116A1 A JJ O
. WO2010028116A1 A . O

Such WO2010028116A1 A JJ O
compounds WO2010028116A1 A NNS O
have WO2010028116A1 A VBP O
utility WO2010028116A1 A NN O
in WO2010028116A1 A IN O
the WO2010028116A1 A DT O
treatment WO2010028116A1 A NN O
of WO2010028116A1 A IN O
proliferative WO2010028116A1 A JJ O
diseases WO2010028116A1 A NNS O
resulting WO2010028116A1 A VBG O
from WO2010028116A1 A IN O
unregulated WO2010028116A1 A JJ O
and/or WO2010028116A1 A NN O
disturbed WO2010028116A1 A VBD O
kinase WO2010028116A1 A JJ I-UN
activity WO2010028116A1 A NN O
such WO2010028116A1 A JJ O
as WO2010028116A1 A IN O
cancers WO2010028116A1 A NNS O
, WO2010028116A1 A , O
psoriasis WO2010028116A1 A NN O
, WO2010028116A1 A , O
viral WO2010028116A1 A JJ O
and WO2010028116A1 A CC O
bacterial WO2010028116A1 A JJ O
infections WO2010028116A1 A NNS O
, WO2010028116A1 A , O
inflammatory WO2010028116A1 A NN O
and WO2010028116A1 A CC O
autoimmune WO2010028116A1 A NN O
diseases WO2010028116A1 A NNS O
. WO2010028116A1 A . O

A CN101007087A T DT O
medicinal CN101007087A T JJ O
ointment CN101007087A T NN O
for CN101007087A T IN O
treating CN101007087A T VBG O
burn CN101007087A T NN O
and CN101007087A T CC O
its CN101007087A T PRP$ O
preparation CN101007087A T NN O
method CN101007087A T NN O
. CN101007087A T . O

Benzoic WO2013041468A1 T NNP O
acid WO2013041468A1 T NN O
derivatives WO2013041468A1 T NNS O
as WO2013041468A1 T IN O
eif4e WO2013041468A1 T JJ I-UN
inhibitors WO2013041468A1 T NNS O
. WO2013041468A1 T . O

Disclosed WO2013041468A1 A VBN O
are WO2013041468A1 A VBP O
compounds WO2013041468A1 A NNS O
with WO2013041468A1 A IN O
the WO2013041468A1 A DT O
formula WO2013041468A1 A NN O
( WO2013041468A1 A ( O
I WO2013041468A1 A PRP O
) WO2013041468A1 A ) O
, WO2013041468A1 A , O
where WO2013041468A1 A WRB O
R1 WO2013041468A1 A NNP O
and WO2013041468A1 A CC O
R2 WO2013041468A1 A NNP O
are WO2013041468A1 A VBP O
as WO2013041468A1 A IN O
disclosed WO2013041468A1 A JJ O
herein WO2013041468A1 A NN O
, WO2013041468A1 A , O
which WO2013041468A1 A WDT O
are WO2013041468A1 A VBP O
eIF4E WO2013041468A1 A JJ I-UN
inhibitors WO2013041468A1 A NNS O
useful WO2013041468A1 A JJ O
in WO2013041468A1 A IN O
the WO2013041468A1 A DT O
treatment WO2013041468A1 A NN O
of WO2013041468A1 A IN O
cancers WO2013041468A1 A NNS O
. WO2013041468A1 A . O

New CN101352550A T NNP O
use CN101352550A T NN O
of CN101352550A T IN O
compound CN101352550A T NN O
medicament CN101352550A T NN O
composition CN101352550A T NN O
. CN101352550A T . O

Pyrazole EP1075467B1 T NNP O
derivatives EP1075467B1 T NNS O
as EP1075467B1 T IN O
p-38 EP1075467B1 T JJ O
map EP1075467B1 T NN O
kinase EP1075467B1 T NN O
inhibitors EP1075467B1 T NNS O
. EP1075467B1 T . O

The EP1075467B1 A DT O
present EP1075467B1 A JJ O
invention EP1075467B1 A NN O
relates EP1075467B1 A VBZ O
to EP1075467B1 A TO O
certain EP1075467B1 A JJ O
pyrazole EP1075467B1 A JJ O
derivatives EP1075467B1 A NNS O
of EP1075467B1 A IN O
Formula EP1075467B1 A NNP O
( EP1075467B1 A ( O
I EP1075467B1 A PRP O
) EP1075467B1 A ) O
that EP1075467B1 A WDT O
are EP1075467B1 A VBP O
p-38 EP1075467B1 A JJ O
MAP EP1075467B1 A NNP O
kinase EP1075467B1 A NN O
inhibitors EP1075467B1 A NNS O
, EP1075467B1 A , O
pharmaceutical EP1075467B1 A JJ O
compositions EP1075467B1 A NNS O
containing EP1075467B1 A VBG O
them EP1075467B1 A PRP O
, EP1075467B1 A , O
methods EP1075467B1 A NNS O
for EP1075467B1 A IN O
their EP1075467B1 A PRP$ O
use EP1075467B1 A NN O
, EP1075467B1 A , O
and EP1075467B1 A CC O
methods EP1075467B1 A NNS O
for EP1075467B1 A IN O
preparing EP1075467B1 A VBG O
these EP1075467B1 A DT O
compounds EP1075467B1 A NNS O
. EP1075467B1 A . O

Methods WO2006043966A3 T NNS O
for WO2006043966A3 T IN O
inducing WO2006043966A3 T VBG O
apoptosis WO2006043966A3 T NN O
in WO2006043966A3 T IN O
adipocytes WO2006043966A3 T NNS O
. WO2006043966A3 T . O

The WO2006043966A3 A DT O
subject WO2006043966A3 A JJ O
invention WO2006043966A3 A NN O
provides WO2006043966A3 A VBZ O
for WO2006043966A3 A IN O
materials WO2006043966A3 A NNS O
and WO2006043966A3 A CC O
methods WO2006043966A3 A NNS O
of WO2006043966A3 A IN O
using WO2006043966A3 A VBG O
dietary WO2006043966A3 A JJ O
calcium WO2006043966A3 A NN O
, WO2006043966A3 A , O
calcium-containing WO2006043966A3 A JJ O
products WO2006043966A3 A NNS O
, WO2006043966A3 A , O
dairy WO2006043966A3 A NN O
and WO2006043966A3 A CC O
antagonists WO2006043966A3 A NNS O
of WO2006043966A3 A IN O
calcitrophic WO2006043966A3 A JJ O
hormone WO2006043966A3 A NN O
activity WO2006043966A3 A NN O
for WO2006043966A3 A IN O
inducing WO2006043966A3 A VBG O
apoptosis WO2006043966A3 A NN O
in WO2006043966A3 A IN O
adipocytes WO2006043966A3 A NNS O
in WO2006043966A3 A IN O
order WO2006043966A3 A NN O
to WO2006043966A3 A TO O
reduce WO2006043966A3 A VB O
the WO2006043966A3 A DT O
number WO2006043966A3 A NN O
of WO2006043966A3 A IN O
adipocytes WO2006043966A3 A NNS O
in WO2006043966A3 A IN O
an WO2006043966A3 A DT O
individual WO2006043966A3 A JJ O
regulating WO2006043966A3 A NN O
body WO2006043966A3 A NN O
weight WO2006043966A3 A NN O
. WO2006043966A3 A . O

Non-pathogenic EP0754223B1 T JJ O
strains EP0754223B1 T NNS O
of EP0754223B1 T IN O
hiv-1 EP0754223B1 T NN O
. EP0754223B1 T . O

A WO2009140078A1 A DT O
method WO2009140078A1 A NN O
is WO2009140078A1 A VBZ O
disclosed WO2009140078A1 A VBN O
utilizing WO2009140078A1 A VBG O
a WO2009140078A1 A DT O
cannabinoid WO2009140078A1 A JJ I-UN
receptor WO2009140078A1 A NN I-UN
type WO2009140078A1 A NN I-UN
2-receptor-selective WO2009140078A1 A JJ O
agonist WO2009140078A1 A NN O
for WO2009140078A1 A IN O
treating WO2009140078A1 A VBG O
or WO2009140078A1 A CC O
preventing WO2009140078A1 A VBG O
lower WO2009140078A1 A JJR O
urinary WO2009140078A1 A JJ O
tract WO2009140078A1 A NN O
dysfunction WO2009140078A1 A NN O
, WO2009140078A1 A , O
including WO2009140078A1 A VBG O
overactive WO2009140078A1 A JJ O
bladder WO2009140078A1 A NN O
, WO2009140078A1 A , O
lower WO2009140078A1 A JJR O
urinary WO2009140078A1 A JJ O
tract WO2009140078A1 A NN O
symptoms WO2009140078A1 A NNS O
and WO2009140078A1 A CC O
detrusor WO2009140078A1 A NN O
overactivity WO2009140078A1 A NN O
. WO2009140078A1 A . O

Novel US20110200665 T NNP O
Thermosensitive US20110200665 T NNP O
Liposomes US20110200665 T NNP O
Containing US20110200665 T NNP O
Therapeutic US20110200665 T NNP O
Agents US20110200665 T NNP O
. US20110200665 T . O

Inhibition US20090191194 T NN O
of US20090191194 T IN O
protein US20090191194 T JJ I-UN
kinase US20090191194 T NN I-UN
c US20090191194 T NN I-UN
alpha US20090191194 T NN I-UN
for US20090191194 T IN O
the US20090191194 T DT O
treatment US20090191194 T NN O
of US20090191194 T IN O
cardiovascular US20090191194 T JJ O
diseases US20090191194 T NNS O
. US20090191194 T . O

The US20090191194 A DT O
invention US20090191194 A NN O
relates US20090191194 A VBZ O
to US20090191194 A TO O
the US20090191194 A DT O
use US20090191194 A NN O
of US20090191194 A IN O
agents US20090191194 A NNS O
impeding US20090191194 A VBG O
the US20090191194 A DT O
expression US20090191194 A NN O
and/or US20090191194 A NN O
activity US20090191194 A NN O
of US20090191194 A IN O
protein US20090191194 A JJ I-UN
kinase US20090191194 A NN I-UN
C-alpha US20090191194 A NNP I-UN
( US20090191194 A ( O
PKC-α US20090191194 A NNP I-UN
) US20090191194 A ) O
, US20090191194 A , O
especially US20090191194 A RB O
for US20090191194 A IN O
treatment US20090191194 A NN O
of US20090191194 A IN O
patients US20090191194 A NNS O
with US20090191194 A IN O
diabetes US20090191194 A NNS O
and US20090191194 A CC O
complications US20090191194 A NNS O
such US20090191194 A JJ O
as US20090191194 A IN O
diabetic US20090191194 A JJ O
nephropathy US20090191194 A NN O
, US20090191194 A , O
retinopathy US20090191194 A NN O
or US20090191194 A CC O
neuropathy US20090191194 A NN O
. US20090191194 A . O

Quinazoline WO2010054968A1 T JJ O
derivatives WO2010054968A1 T NNS O
as WO2010054968A1 T IN O
nk3 WO2010054968A1 T JJ I-UN
receptor WO2010054968A1 T NN I-UN
antagonists WO2010054968A1 T NNS O
. WO2010054968A1 T . O

It WO2010054968A1 A PRP O
has WO2010054968A1 A VBZ O
been WO2010054968A1 A VBN O
found WO2010054968A1 A VBN O
that WO2010054968A1 A IN O
the WO2010054968A1 A DT O
present WO2010054968A1 A JJ O
compounds WO2010054968A1 A NNS O
are WO2010054968A1 A VBP O
high WO2010054968A1 A JJ O
potential WO2010054968A1 A JJ O
NK-3 WO2010054968A1 A NNP I-UN
receptor WO2010054968A1 A NN I-UN
antagonists WO2010054968A1 A NNS O
for WO2010054968A1 A IN O
the WO2010054968A1 A DT O
treatment WO2010054968A1 A NN O
of WO2010054968A1 A IN O
depression WO2010054968A1 A NN O
, WO2010054968A1 A , O
pain WO2010054968A1 A NN O
, WO2010054968A1 A , O
psychosis WO2010054968A1 A NN O
, WO2010054968A1 A , O
Parkinson WO2010054968A1 A NNP O
's WO2010054968A1 A POS O
disease WO2010054968A1 A NN O
, WO2010054968A1 A , O
schizophrenia WO2010054968A1 A NN O
, WO2010054968A1 A , O
anxiety WO2010054968A1 A NN O
and WO2010054968A1 A CC O
attention WO2010054968A1 A NN O
deficit WO2010054968A1 A NN O
hyperactivity WO2010054968A1 A NN O
disorder WO2010054968A1 A NN O
( WO2010054968A1 A ( O
ADHD WO2010054968A1 A NNP O
) WO2010054968A1 A ) O
. WO2010054968A1 A . O

Anti-inflammatory WO2010086349A1 T JJ O
macrolide WO2010086349A1 T NN O
. WO2010086349A1 T . O

Medicinal CN1977855A T JJ O
composition CN1977855A T NN O
containing CN1977855A T VBG O
mangiferin CN1977855A T NN O
and CN1977855A T CC O
its CN1977855A T PRP$ O
preparing CN1977855A T NN O
method CN1977855A T NN O
. CN1977855A T . O

Anti-connexin US20120093768 T JJ O
compounds US20120093768 T NNS O
targeted US20120093768 T VBN O
to US20120093768 T TO O
connexins US20120093768 T NNS O
and US20120093768 T CC O
methods US20120093768 T NNS O
of US20120093768 T IN O
use US20120093768 T NN O
thereof US20120093768 T NN O
. US20120093768 T . O

Methods US20120142675 T NNS O
for US20120142675 T IN O
Treating US20120142675 T VBG O
Diseases US20120142675 T NNP O
of US20120142675 T IN O
the US20120142675 T DT O
Retina US20120142675 T NNP O
. US20120142675 T . O

Cyclic WO2014020405A1 T JJ O
urea- WO2014020405A1 T JJ O
or WO2014020405A1 T CC O
lactam-substituted WO2014020405A1 T JJ O
quinoxaline-type WO2014020405A1 T JJ O
piperidine WO2014020405A1 T NN O
compounds WO2014020405A1 T NNS O
and WO2014020405A1 T CC O
the WO2014020405A1 T DT O
uses WO2014020405A1 T NNS O
thereof WO2014020405A1 T NN O
. WO2014020405A1 T . O

Naloxone CN1615867A T CD O
hydrchloride CN1615867A T JJ O
freeze-dried CN1615867A T JJ O
powder CN1615867A T NN O
preparation CN1615867A T NN O
for CN1615867A T IN O
injection CN1615867A T NN O
. CN1615867A T . O

Electrically US20060241133 T RB O
variable US20060241133 T JJ O
pneumatic US20060241133 T JJ O
structural US20060241133 T JJ O
element US20060241133 T NN O
. US20060241133 T . O

Methods EP2405755A1 T NNS O
and EP2405755A1 T CC O
compositions EP2405755A1 T NNS O
for EP2405755A1 T IN O
the EP2405755A1 T DT O
treatment EP2405755A1 T NN O
of EP2405755A1 T IN O
metabolic EP2405755A1 T NN O
and EP2405755A1 T CC O
cardiovascular EP2405755A1 T JJ O
disorders EP2405755A1 T NNS O
. EP2405755A1 T . O

Methods EP2405755A1 A NNS O
and EP2405755A1 A CC O
compositions EP2405755A1 A NNS O
containing EP2405755A1 A VBG O
a EP2405755A1 A DT O
berberine EP2405755A1 A NN O
related EP2405755A1 A VBN O
compound EP2405755A1 A NN O
are EP2405755A1 A VBP O
provided EP2405755A1 A VBN O
for EP2405755A1 A IN O
the EP2405755A1 A DT O
prevention EP2405755A1 A NN O
and EP2405755A1 A CC O
treatment EP2405755A1 A NN O
of EP2405755A1 A IN O
metabolic EP2405755A1 A NN O
and EP2405755A1 A CC O
cardiovascular EP2405755A1 A JJ O
disorders EP2405755A1 A NNS O
including EP2405755A1 A VBG O
metabolic EP2405755A1 A JJ O
syndrome EP2405755A1 A NN O
, EP2405755A1 A , O
hyperlipidemia EP2405755A1 A NN O
, EP2405755A1 A , O
obesity EP2405755A1 A NN O
, EP2405755A1 A , O
diabetes EP2405755A1 A VBZ O
, EP2405755A1 A , O
insulin EP2405755A1 A NN I-UN
resistance EP2405755A1 A NN O
, EP2405755A1 A , O
hyperglycemia EP2405755A1 A NN O
, EP2405755A1 A , O
hypertension EP2405755A1 A NN O
and EP2405755A1 A CC O
elevated EP2405755A1 A VBN O
cholesterol EP2405755A1 A NN O
in EP2405755A1 A IN O
mammalian EP2405755A1 A JJ O
subjects EP2405755A1 A NNS O
. EP2405755A1 A . O

The EP2405755A1 A DT O
methods EP2405755A1 A NNS O
and EP2405755A1 A CC O
compositions EP2405755A1 A NNS O
of EP2405755A1 A IN O
the EP2405755A1 A DT O
invention EP2405755A1 A NN O
are EP2405755A1 A VBP O
effective EP2405755A1 A JJ O
for EP2405755A1 A IN O
prevention EP2405755A1 A NN O
and EP2405755A1 A CC O
treatment EP2405755A1 A NN O
of EP2405755A1 A IN O
metabolic EP2405755A1 A JJ O
syndrome EP2405755A1 A NN O
, EP2405755A1 A , O
hyperlipidemia EP2405755A1 A NN O
, EP2405755A1 A , O
obesity EP2405755A1 A NN O
, EP2405755A1 A , O
diabetes EP2405755A1 A VBZ O
, EP2405755A1 A , O
insulin EP2405755A1 A NN I-UN
resistance EP2405755A1 A NN O
, EP2405755A1 A , O
hyperglycemia EP2405755A1 A NN O
, EP2405755A1 A , O
hypertension EP2405755A1 A NN O
and EP2405755A1 A CC O
elevated EP2405755A1 A VBN O
cholesterol EP2405755A1 A NN O
. EP2405755A1 A . O

New CN102028696A T NNP O
application CN102028696A T NN O
of CN102028696A T IN O
prostaglandin CN102028696A T JJ O
compounds CN102028696A T NNS O
. CN102028696A T . O

Methods US20100074897 T NNS O
and US20100074897 T CC O
Compositions US20100074897 T NNP O
related US20100074897 T VBD O
to US20100074897 T TO O
HIF-1 US20100074897 T NNP I-UN
alpha US20100074897 T NN I-UN
. US20100074897 T . O

Disclosed US20100074897 A VBN O
are US20100074897 A VBP O
compositions US20100074897 A NNS O
and US20100074897 A CC O
methods US20100074897 A NNS O
related US20100074897 A VBN O
to US20100074897 A TO O
HIF-1α US20100074897 A NNP I-UN
. US20100074897 A . O

Ganciclovir CN1640404A T NNP O
injection CN1640404A T NN O
liquid CN1640404A T NN O
and CN1640404A T CC O
its CN1640404A T PRP$ O
production CN1640404A T NN O
method CN1640404A T NN O
. CN1640404A T . O

Receptors US20120263730 T NNS O
of US20120263730 T IN O
rspo2 US20120263730 T NN I-UN
and US20120263730 T CC O
rspo3 US20120263730 T NN I-UN
. US20120263730 T . O

The US20120263730 A DT O
present US20120263730 A JJ O
invention US20120263730 A NN O
relates US20120263730 A VBZ O
to US20120263730 A TO O
the US20120263730 A DT O
finding US20120263730 A NN O
that US20120263730 A WDT O
Syndecans US20120263730 A NNP I-UN
( US20120263730 A ( O
Sdc US20120263730 A NNP I-UN
) US20120263730 A ) O
are US20120263730 A VBP O
receptors US20120263730 A NNS O
of US20120263730 A IN O
Rspondin-2 US20120263730 A NNP I-UN
( US20120263730 A ( O
Rspo2 US20120263730 A NNP I-UN
) US20120263730 A ) O
and US20120263730 A CC O
Rspondin-3 US20120263730 A NNP O
( US20120263730 A ( O
Rspo3 US20120263730 A NNP I-UN
) US20120263730 A ) O
. US20120263730 A . O

Thus US20120263730 A RB O
, US20120263730 A , O
the US20120263730 A DT O
present US20120263730 A JJ O
invention US20120263730 A NN O
relates US20120263730 A VBZ O
to US20120263730 A TO O
the US20120263730 A DT O
identification US20120263730 A NN O
of US20120263730 A IN O
Rspo2 US20120263730 A NNP I-UN
, US20120263730 A , O
Rspo3 US20120263730 A NNP I-UN
and/or US20120263730 A VBZ O
Sdc US20120263730 A NNP I-UN
activity US20120263730 A NN O
modulators US20120263730 A NNS O
by US20120263730 A IN O
determining US20120263730 A VBG O
if US20120263730 A IN O
a US20120263730 A DT O
test US20120263730 A NN O
compound US20120263730 A NN O
has US20120263730 A VBZ O
the US20120263730 A DT O
ability US20120263730 A NN O
to US20120263730 A TO O
modulate US20120263730 A VB O
the US20120263730 A DT O
binding US20120263730 A NN O
of US20120263730 A IN O
an US20120263730 A DT O
Rspo2 US20120263730 A NNP I-UN
and/or US20120263730 A NN O
Rspo3 US20120263730 A NNP I-UN
polypeptide US20120263730 A NN O
to US20120263730 A TO O
an US20120263730 A DT O
Sdc US20120263730 A NNP I-UN
polypeptide US20120263730 A NN O
. US20120263730 A . O

Further US20120263730 A RB O
, US20120263730 A , O
the US20120263730 A DT O
invention US20120263730 A NN O
refers US20120263730 A NNS O
to US20120263730 A TO O
novel US20120263730 A JJ O
uses US20120263730 A NNS O
for US20120263730 A IN O
antagonists US20120263730 A NNS O
of US20120263730 A IN O
Rspo2 US20120263730 A NNP I-UN
and/or US20120263730 A NN O
Rspo3 US20120263730 A NNP I-UN
in US20120263730 A IN O
the US20120263730 A DT O
treatment US20120263730 A NN O
of US20120263730 A IN O
Sdc-associated US20120263730 A JJ O
disorders US20120263730 A NNS O
and US20120263730 A CC O
for US20120263730 A IN O
Sdc US20120263730 A NNP I-UN
antagonists US20120263730 A NNS O
in US20120263730 A IN O
the US20120263730 A DT O
treatment US20120263730 A NN O
of US20120263730 A IN O
Rspo2- US20120263730 A NNP O
and/or US20120263730 A JJ O
Rspo3-associated US20120263730 A JJ O
disorders US20120263730 A NNS O
. US20120263730 A . O

An CN101254170A T DT O
anticancer CN101254170A T NN O
sustained CN101254170A T VBD O
release CN101254170A T NN O
injection CN101254170A T NN O
carrying CN101254170A T VBG O
clorfarabine CN101254170A T NN O
and CN101254170A T CC O
its CN101254170A T PRP$ O
synergist CN101254170A T NN O
. CN101254170A T . O

Therapeutic WO2011001954A1 T JJ O
agent WO2011001954A1 T NN O
for WO2011001954A1 T IN O
abnormal WO2011001954A1 T JJ O
defecation WO2011001954A1 T NN O
in WO2011001954A1 T IN O
inflammatory WO2011001954A1 T JJ O
bowel WO2011001954A1 T NN O
disease WO2011001954A1 T NN O
patient WO2011001954A1 T NN O
who WO2011001954A1 T WP O
is WO2011001954A1 T VBZ O
in WO2011001954A1 T IN O
remission WO2011001954A1 T NN O
phase WO2011001954A1 T NN O
. WO2011001954A1 T . O

Entecavir CN101703489B T NNP O
soft CN101703489B T JJ O
capsule CN101703489B T NN O
. CN101703489B T . O

The CN101703489B A DT O
invention CN101703489B A NN O
relates CN101703489B A VBZ O
to CN101703489B A TO O
a CN101703489B A DT O
soft CN101703489B A JJ O
capsule CN101703489B A NN O
with CN101703489B A IN O
an CN101703489B A DT O
active CN101703489B A JJ O
component CN101703489B A NN O
inhibiting CN101703489B A VBG O
hepatitis CN101703489B A NN O
virus CN101703489B A NN O
, CN101703489B A , O
in CN101703489B A IN O
particular CN101703489B A JJ O
to CN101703489B A TO O
an CN101703489B A DT O
Entecavir CN101703489B A NNP O
soft CN101703489B A JJ O
capsule CN101703489B A NN O
with CN101703489B A IN O
high CN101703489B A JJ O
dissolubility CN101703489B A NN O
, CN101703489B A , O
low CN101703489B A JJ O
penetration CN101703489B A NN O
rate CN101703489B A NN O
and CN101703489B A CC O
stable CN101703489B A JJ O
property CN101703489B A NN O
. CN101703489B A . O

The CN101703489B A DT O
Entecavir CN101703489B A NNP O
soft CN101703489B A JJ O
capsule CN101703489B A NN O
comprises CN101703489B A VBZ O
a CN101703489B A DT O
soft CN101703489B A JJ O
capsule CN101703489B A NN O
shell CN101703489B A NN O
and CN101703489B A CC O
a CN101703489B A DT O
content CN101703489B A JJ O
composition CN101703489B A NN O
, CN101703489B A , O
wherein CN101703489B A VBP O
the CN101703489B A DT O
content CN101703489B A JJ O
composition CN101703489B A NN O
comprises CN101703489B A VBZ O
the CN101703489B A DT O
following CN101703489B A JJ O
components CN101703489B A NNS O
by CN101703489B A IN O
100 CN101703489B A CD O
percent CN101703489B A NN O
of CN101703489B A IN O
total CN101703489B A JJ O
weight CN101703489B A NN O
of CN101703489B A IN O
the CN101703489B A DT O
composition CN101703489B A NN O
: CN101703489B A : O
0.05-1.0 CN101703489B A JJ O
percent CN101703489B A NN O
of CN101703489B A IN O
Entecavir CN101703489B A NNP O
, CN101703489B A , O
80-99.85 CN101703489B A JJ O
percent CN101703489B A NN O
of CN101703489B A IN O
filling CN101703489B A VBG O
solvent CN101703489B A JJ O
and CN101703489B A CC O
0.10-5.0 CN101703489B A JJ O
percent CN101703489B A NN O
of CN101703489B A IN O
povidone CN101703489B A NN O
; CN101703489B A : O
and CN101703489B A CC O
the CN101703489B A DT O
total CN101703489B A JJ O
weight CN101703489B A NN O
of CN101703489B A IN O
all CN101703489B A DT O
components CN101703489B A NNS O
in CN101703489B A IN O
the CN101703489B A DT O
composition CN101703489B A NN O
is CN101703489B A VBZ O
100 CN101703489B A CD O
percent CN101703489B A NN O
. CN101703489B A . O

The CN101703489B A DT O
invention CN101703489B A NN O
improves CN101703489B A VBZ O
the CN101703489B A DT O
dissolubility CN101703489B A NN O
and CN101703489B A CC O
stability CN101703489B A NN O
of CN101703489B A IN O
the CN101703489B A DT O
Entecavir CN101703489B A NNP O
and CN101703489B A CC O
can CN101703489B A MD O
maintain CN101703489B A VB O
a CN101703489B A DT O
stable CN101703489B A JJ O
composition CN101703489B A NN O
system CN101703489B A NN O
under CN101703489B A IN O
various CN101703489B A JJ O
conditions CN101703489B A NNS O
without CN101703489B A IN O
precipitation CN101703489B A NN O
; CN101703489B A : O
the CN101703489B A DT O
Entecavir CN101703489B A NNP O
active CN101703489B A JJ O
component CN101703489B A NN O
can CN101703489B A MD O
not CN101703489B A RB O
be CN101703489B A VB O
changed CN101703489B A VBN O
along CN101703489B A IN O
with CN101703489B A IN O
the CN101703489B A DT O
change CN101703489B A NN O
of CN101703489B A IN O
time CN101703489B A NN O
and CN101703489B A CC O
has CN101703489B A VBZ O
uniform CN101703489B A NN O
and CN101703489B A CC O
consistent CN101703489B A JJ O
content CN101703489B A NN O
and CN101703489B A CC O
high CN101703489B A JJ O
storage CN101703489B A NN O
stability CN101703489B A NN O
, CN101703489B A , O
and CN101703489B A CC O
impurities CN101703489B A NNS O
of CN101703489B A IN O
the CN101703489B A DT O
Entecavir CN101703489B A NNP O
active CN101703489B A JJ O
component CN101703489B A NN O
can CN101703489B A MD O
not CN101703489B A RB O
increase CN101703489B A VB O
by CN101703489B A IN O
long-time CN101703489B A JJ O
storage CN101703489B A NN O
. CN101703489B A . O

Compared CN101703489B A VBN O
with CN101703489B A IN O
propylene CN101703489B A NN O
glycol CN101703489B A NN O
, CN101703489B A , O
the CN101703489B A DT O
Entecavir CN101703489B A NNP O
soft CN101703489B A JJ O
capsule CN101703489B A NN O
has CN101703489B A VBZ O
low CN101703489B A JJ O
penetration CN101703489B A NN O
rate CN101703489B A NN O
and CN101703489B A CC O
more CN101703489B A RBR O
stable CN101703489B A JJ O
composition CN101703489B A NN O
system CN101703489B A NN O
without CN101703489B A IN O
sediment CN101703489B A JJ O
precipitation CN101703489B A NN O
of CN101703489B A IN O
the CN101703489B A DT O
active CN101703489B A JJ O
component CN101703489B A NN O
for CN101703489B A IN O
long-time CN101703489B A JJ O
storage CN101703489B A NN O
under CN101703489B A IN O
a CN101703489B A DT O
certain CN101703489B A JJ O
condition CN101703489B A NN O
. CN101703489B A . O

Plaster CN101352503A T NN O
for CN101352503A T IN O
treating CN101352503A T VBG O
joint CN101352503A T JJ O
ache CN101352503A T NN O
and CN101352503A T CC O
preparation CN101352503A T NN O
method CN101352503A T NN O
thereof CN101352503A T NN O
. CN101352503A T . O

Benzamide US7223774 T IN O
2-hydroxy-3-diaminoalkanes US7223774 T NNS O
. US7223774 T . O

These US7223774 A DT O
compounds US7223774 A NNS O
include US7223774 A VBP O
inhibitors US7223774 A NNS O
of US7223774 A IN O
the US7223774 A DT O
beta-secretase US7223774 A JJ O
enzyme US7223774 A NN O
that US7223774 A WDT O
are US7223774 A VBP O
useful US7223774 A JJ O
in US7223774 A IN O
the US7223774 A DT O
treatment US7223774 A NN O
of US7223774 A IN O
Alzheimer US7223774 A NNP O
's US7223774 A POS O
disease US7223774 A NN O
and US7223774 A CC O
other US7223774 A JJ O
diseases US7223774 A NNS O
characterized US7223774 A VBN O
by US7223774 A IN O
deposition US7223774 A NN O
of US7223774 A IN O
A US7223774 A NNP I-UN
beta US7223774 A NN I-UN
peptide US7223774 A NN I-UN
in US7223774 A IN O
a US7223774 A DT O
mammal US7223774 A NN O
. US7223774 A . O

The US7223774 A DT O
compounds US7223774 A NNS O
of US7223774 A IN O
the US7223774 A DT O
invention US7223774 A NN O
are US7223774 A VBP O
also US7223774 A RB O
useful US7223774 A JJ O
in US7223774 A IN O
pharmaceutical US7223774 A JJ O
compositions US7223774 A NNS O
and US7223774 A CC O
methods US7223774 A NNS O
of US7223774 A IN O
treatment US7223774 A NN O
to US7223774 A TO O
reduce US7223774 A VB O
A US7223774 A NNP I-UN
beta US7223774 A NN I-UN
peptide US7223774 A NN I-UN
formation US7223774 A NN O
. US7223774 A . O

Pharmaceutical EP1666034A1 T JJ O
combination EP1666034A1 T NN O
comprising EP1666034A1 T VBG O
a EP1666034A1 T DT O
biguanide EP1666034A1 T NN O
. EP1666034A1 T . O

Combination US7501405 T NNP O
therapy US7501405 T NN O
using US7501405 T VBG O
an US7501405 T DT O
11β-hydroxysteroid US7501405 T JJ I-UN
dehydrogenase US7501405 T NN I-UN
type US7501405 T NN I-UN
1 US7501405 T CD O
inhibitor US7501405 T NN O
and US7501405 T CC O
an US7501405 T DT O
antihypertensive US7501405 T JJ O
agent US7501405 T NN O
for US7501405 T IN O
the US7501405 T DT O
treatment US7501405 T NN O
of US7501405 T IN O
metabolic US7501405 T JJ O
syndrome US7501405 T NN O
and US7501405 T CC O
related US7501405 T JJ O
diseases US7501405 T NNS O
and US7501405 T CC O
disorders US7501405 T NNS O
. US7501405 T . O

Combination US7501405 A NNP O
therapy US7501405 A NN O
comprising US7501405 A VBG O
the US7501405 A DT O
administration US7501405 A NN O
of US7501405 A IN O
an US7501405 A DT O
11β-hydroxysteroid US7501405 A JJ I-UN
dehydrogenase US7501405 A NN I-UN
type US7501405 A NN I-UN
1 US7501405 A CD O
inhibitor US7501405 A NN O
and US7501405 A CC O
an US7501405 A DT O
antihypertensive US7501405 A JJ O
agent US7501405 A NN O
useful US7501405 A JJ O
for US7501405 A IN O
treating US7501405 A VBG O
, US7501405 A , O
preventing US7501405 A VBG O
and US7501405 A CC O
reducing US7501405 A VBG O
the US7501405 A DT O
risk US7501405 A NN O
of US7501405 A IN O
developing US7501405 A VBG O
insulin US7501405 A NN I-UN
resistance US7501405 A NN O
, US7501405 A , O
dyslipidemia US7501405 A NN O
, US7501405 A , O
obesity US7501405 A NN O
, US7501405 A , O
hypertension US7501405 A NN O
and US7501405 A CC O
other US7501405 A JJ O
related US7501405 A JJ O
diseases US7501405 A NNS O
and US7501405 A CC O
disorders US7501405 A NNS O
. US7501405 A . O

Novel WO2012150520A1 T NNP O
cephalosporins WO2012150520A1 T VBZ O
useful WO2012150520A1 T JJ O
as WO2012150520A1 T IN O
antibacterial WO2012150520A1 T JJ O
agents WO2012150520A1 T NNS O
. WO2012150520A1 T . O

Indoles CN103086943A T NNS O
derivative CN103086943A T JJ O
functioning CN103086943A T NN O
as CN103086943A T IN O
CRTH2 CN103086943A T NNP I-UN
receptor CN103086943A T NN I-UN
antagonist CN103086943A T NN O
. CN103086943A T . O

The CN103086943A A DT O
invention CN103086943A A NN O
belongs CN103086943A A VBZ O
to CN103086943A A TO O
the CN103086943A A DT O
technical CN103086943A A JJ O
field CN103086943A A NN O
of CN103086943A A IN O
medicine CN103086943A A NN O
, CN103086943A A , O
and CN103086943A A CC O
in CN103086943A A IN O
particular CN103086943A A JJ O
relates CN103086943A A NNS O
to CN103086943A A TO O
indoles CN103086943A A VB O
derivatives CN103086943A A NNS O
shown CN103086943A A VBN O
in CN103086943A A IN O
general CN103086943A A JJ O
formula CN103086943A A NN O
( CN103086943A A ( O
I CN103086943A A PRP O
) CN103086943A A ) O
and CN103086943A A CC O
functioning CN103086943A A VBG O
as CN103086943A A IN O
a CN103086943A A DT O
CRTH2 CN103086943A A NNP I-UN
receptor CN103086943A A NN I-UN
antagonist CN103086943A A NN O
, CN103086943A A , O
and CN103086943A A CC O
pharmaceutically CN103086943A A RB O
acceptable CN103086943A A JJ O
salts CN103086943A A NNS O
and CN103086943A A CC O
stereoisomerides CN103086943A A NNS O
of CN103086943A A IN O
the CN103086943A A DT O
indoles CN103086943A A NNS O
derivatives CN103086943A A NNS O
, CN103086943A A , O
wherein CN103086943A A NN O
X1 CN103086943A A NNP O
, CN103086943A A , O
X2 CN103086943A A NNP O
, CN103086943A A , O
X3 CN103086943A A NNP O
, CN103086943A A , O
X4 CN103086943A A NNP O
, CN103086943A A , O
R1 CN103086943A A NNP O
, CN103086943A A , O
R2 CN103086943A A NNP O
, CN103086943A A , O
R3 CN103086943A A NNP O
, CN103086943A A , O
Z CN103086943A A NNP O
, CN103086943A A , O
Y CN103086943A A NNP O
, CN103086943A A , O
A CN103086943A A NNP O
, CN103086943A A , O
and CN103086943A A CC O
B CN103086943A A NNP O
are CN103086943A A VBP O
defined CN103086943A A VBN O
in CN103086943A A IN O
specifications CN103086943A A NNS O
, CN103086943A A , O
and CN103086943A A CC O
the CN103086943A A DT O
invention CN103086943A A NN O
also CN103086943A A RB O
relates CN103086943A A VBZ O
to CN103086943A A TO O
a CN103086943A A DT O
preparation CN103086943A A NN O
method CN103086943A A NN O
of CN103086943A A IN O
the CN103086943A A DT O
compounds CN103086943A A NNS O
, CN103086943A A , O
medicine CN103086943A A JJ O
preparations CN103086943A A NNS O
and CN103086943A A CC O
medicine CN103086943A A JJ O
compositions CN103086943A A NNS O
containing CN103086943A A VBG O
the CN103086943A A DT O
compounds CN103086943A A NNS O
, CN103086943A A , O
and CN103086943A A CC O
an CN103086943A A DT O
application CN103086943A A NN O
of CN103086943A A IN O
the CN103086943A A DT O
compounds CN103086943A A NNS O
in CN103086943A A IN O
the CN103086943A A DT O
preparation CN103086943A A NN O
of CN103086943A A IN O
medicines CN103086943A A NNS O
for CN103086943A A IN O
treating CN103086943A A VBG O
and/or CN103086943A A JJ O
preventing CN103086943A A VBG O
CRTH2 CN103086943A A NNP I-UN
activity CN103086943A A NN O
relevant CN103086943A A NN O
diseases CN103086943A A NNS O
. CN103086943A A . O

Pharmaceutical CN101273973B T JJ O
combination CN101273973B T NN O
containing CN101273973B T VBG O
Mosapride CN101273973B T NNP O
citrate CN101273973B T NN O
. CN101273973B T . O

The CN101273973B A DT O
invention CN101273973B A NN O
relates CN101273973B A VBZ O
to CN101273973B A TO O
a CN101273973B A DT O
pharmaceutical CN101273973B A JJ O
composition CN101273973B A NN O
containing CN101273973B A VBG O
mosapride CN101273973B A NN O
citrate CN101273973B A NN O
which CN101273973B A WDT O
is CN101273973B A VBZ O
applicable CN101273973B A JJ O
to CN101273973B A TO O
the CN101273973B A DT O
usage CN101273973B A NN O
of CN101273973B A IN O
direct CN101273973B A JJ O
powder CN101273973B A NN O
compression CN101273973B A NN O
for CN101273973B A IN O
preparation CN101273973B A NN O
and CN101273973B A CC O
a CN101273973B A DT O
preparation CN101273973B A NN O
method CN101273973B A NN O
thereof CN101273973B A NN O
. CN101273973B A . O

The CN101273973B A DT O
pharmaceutical CN101273973B A JJ O
composition CN101273973B A NN O
further CN101273973B A RBR O
contains CN101273973B A VBZ O
a CN101273973B A DT O
disintegrant CN101273973B A NN O
, CN101273973B A , O
a CN101273973B A DT O
thinner CN101273973B A NN O
, CN101273973B A , O
a CN101273973B A DT O
lubricant CN101273973B A NN O
, CN101273973B A , O
a CN101273973B A DT O
glidant CN101273973B A NN O
and CN101273973B A CC O
an CN101273973B A DT O
adhesive CN101273973B A JJ O
in CN101273973B A IN O
addition CN101273973B A NN O
to CN101273973B A TO O
the CN101273973B A DT O
active CN101273973B A JJ O
component CN101273973B A NN O
of CN101273973B A IN O
the CN101273973B A DT O
mosapride CN101273973B A NN O
citrate CN101273973B A NN O
. CN101273973B A . O

The CN101273973B A DT O
pharmaceutical CN101273973B A JJ O
composition CN101273973B A NN O
is CN101273973B A VBZ O
applicable CN101273973B A JJ O
to CN101273973B A TO O
the CN101273973B A DT O
preparation CN101273973B A NN O
of CN101273973B A IN O
dispersible CN101273973B A JJ O
tablets CN101273973B A NNS O
which CN101273973B A WDT O
can CN101273973B A MD O
be CN101273973B A VB O
fully CN101273973B A RB O
disintegrated CN101273973B A VBN O
in CN101273973B A IN O
2 CN101273973B A CD O
minutes CN101273973B A NNS O
in CN101273973B A IN O
water CN101273973B A NN O
under CN101273973B A IN O
the CN101273973B A DT O
temperature CN101273973B A NN O
of CN101273973B A IN O
19 CN101273973B A CD O
DEG CN101273973B A NNP O
C CN101273973B A NNP O
to CN101273973B A TO O
21 CN101273973B A CD O
DEG CN101273973B A NNP O
C CN101273973B A NNP O
and CN101273973B A CC O
pass CN101273973B A VBP O
through CN101273973B A IN O
a CN101273973B A DT O
No CN101273973B A NNP O
. CN101273973B A . O

2 CN101273973B A CD O
screen CN101273973B A NN O
, CN101273973B A , O
the CN101273973B A DT O
hardness CN101273973B A NN O
is CN101273973B A VBZ O
8 CN101273973B A CD O
to CN101273973B A TO O
11Kg CN101273973B A CD O
, CN101273973B A , O
and CN101273973B A CC O
the CN101273973B A DT O
dissolution CN101273973B A NN O
rate CN101273973B A NN O
is CN101273973B A VBZ O
in CN101273973B A IN O
line CN101273973B A NN O
with CN101273973B A IN O
the CN101273973B A DT O
relevant CN101273973B A JJ O
provisions CN101273973B A NNS O
, CN101273973B A , O
thus CN101273973B A RB O
solving CN101273973B A VBG O
the CN101273973B A DT O
problems CN101273973B A NNS O
of CN101273973B A IN O
higher CN101273973B A JJR O
relevant CN101273973B A NN O
substances CN101273973B A NNS O
, CN101273973B A , O
instable CN101273973B A JJ O
quality CN101273973B A NN O
and CN101273973B A CC O
difficult CN101273973B A JJ O
packaging CN101273973B A NN O
of CN101273973B A IN O
the CN101273973B A DT O
mosapridecitrate CN101273973B A NN O
dispersible CN101273973B A JJ O
tablets CN101273973B A NNS O
prepared CN101273973B A VBN O
by CN101273973B A IN O
wet CN101273973B A JJ O
granulation CN101273973B A NN O
. CN101273973B A . O

Aivlosin CN102119921A T NNP O
injection CN102119921A T NN O
for CN102119921A T IN O
swine CN102119921A T NN O
and CN102119921A T CC O
preparation CN102119921A T NN O
method CN102119921A T NN O
thereof CN102119921A T NN O
. CN102119921A T . O

Application CN102716122A T NN O
of CN102716122A T IN O
15-benzal-14-deoxy-11 CN102716122A T JJ O
, CN102716122A T , O
12-dehydro-andrographolide CN102716122A T JJ O
derivatives CN102716122A T NNS O
in CN102716122A T IN O
preparing CN102716122A T VBG O
medicines CN102716122A T NNS O
for CN102716122A T IN O
treating CN102716122A T VBG O
diabetes CN102716122A T NNS O
mellitus CN102716122A T NN O
. CN102716122A T . O

Aryl-substituted EP1824832A1 T JJ O
benzimidazole EP1824832A1 T NN O
and EP1824832A1 T CC O
imidazopyridine EP1824832A1 T JJ O
ethers EP1824832A1 T NNS O
as EP1824832A1 T IN O
anti-cancer EP1824832A1 T JJ O
agents EP1824832A1 T NNS O
. EP1824832A1 T . O

Aryl EP1824832A1 A NNP O
substituted EP1824832A1 A VBD O
benzimidazole EP1824832A1 A NN O
and EP1824832A1 A CC O
imidazo EP1824832A1 A NN O
[ EP1824832A1 A VBP O
4,5 EP1824832A1 A CD O
] EP1824832A1 A JJ O
Aryl EP1824832A1 A NNP O
substituted EP1824832A1 A VBD O
benzimidazole EP1824832A1 A NN O
and EP1824832A1 A CC O
imidazo EP1824832A1 A NN O
[ EP1824832A1 A VBP O
4,5 EP1824832A1 A CD O
] EP1824832A1 A JJ O
Aryl EP1824832A1 A NNP O
substituted EP1824832A1 A VBD O
benzimidazole EP1824832A1 A NN O
and EP1824832A1 A CC O
imidazo EP1824832A1 A NN O
[ EP1824832A1 A VBP O
4,5 EP1824832A1 A CD O
] EP1824832A1 A JJ O
pyridine EP1824832A1 A NN O
ethers EP1824832A1 A NNS O
are EP1824832A1 A VBP O
described EP1824832A1 A VBN O
as EP1824832A1 A IN O
inhibitors EP1824832A1 A NNS O
of EP1824832A1 A IN O
Cds1 EP1824832A1 A NNP I-UN
and EP1824832A1 A CC O
useful EP1824832A1 A JJ O
as EP1824832A1 A IN O
adjuvants EP1824832A1 A NNS O
to EP1824832A1 A TO O
chemotherapy EP1824832A1 A VB O
or EP1824832A1 A CC O
radiation EP1824832A1 A VB O
therapy EP1824832A1 A NN O
in EP1824832A1 A IN O
the EP1824832A1 A DT O
treatment EP1824832A1 A NN O
of EP1824832A1 A IN O
cancer EP1824832A1 A NN O
. EP1824832A1 A . O

Thiazolidine CN102558167A T NNP O
derivant CN102558167A T NN O
with CN102558167A T IN O
GK CN102558167A T NNP I-UN
and CN102558167A T CC O
PPAR CN102558167A T NNP I-UN
double CN102558167A T JJ O
excitation CN102558167A T NN O
activity CN102558167A T NN O
. CN102558167A T . O

The CN102558167A A DT O
invention CN102558167A A NN O
discloses CN102558167A A VBZ O
a CN102558167A A DT O
novel CN102558167A A JJ O
thiazolidine CN102558167A A NN O
derivant CN102558167A A NN O
and CN102558167A A CC O
a CN102558167A A DT O
preparation CN102558167A A NN O
method CN102558167A A NN O
, CN102558167A A , O
a CN102558167A A DT O
medicine CN102558167A A NN O
combination CN102558167A A NN O
and CN102558167A A CC O
a CN102558167A A DT O
purpose CN102558167A A JJ O
thereof CN102558167A A NN O
, CN102558167A A , O
which CN102558167A A WDT O
specifically CN102558167A A RB O
relate CN102558167A A VBP O
to CN102558167A A TO O
the CN102558167A A DT O
thiazolidine CN102558167A A NN O
derivant CN102558167A A JJ O
shown CN102558167A A VBN O
as CN102558167A A IN O
the CN102558167A A DT O
formula CN102558167A A NN O
I CN102558167A A PRP O
and CN102558167A A CC O
the CN102558167A A DT O
formula CN102558167A A NN O
II CN102558167A A NNP O
, CN102558167A A , O
officinal CN102558167A A JJ O
salt CN102558167A A NN O
of CN102558167A A IN O
the CN102558167A A DT O
derivant CN102558167A A NN O
, CN102558167A A , O
a CN102558167A A DT O
precursor CN102558167A A NN O
or CN102558167A A CC O
a CN102558167A A DT O
derivant CN102558167A A NN O
with CN102558167A A IN O
the CN102558167A A DT O
same CN102558167A A JJ O
biological CN102558167A A JJ O
function CN102558167A A NN O
with CN102558167A A IN O
the CN102558167A A DT O
thiazolidine CN102558167A A NN O
derivant CN102558167A A NN O
, CN102558167A A , O
the CN102558167A A DT O
preparation CN102558167A A NN O
method CN102558167A A NN O
of CN102558167A A IN O
the CN102558167A A DT O
thiazolidine CN102558167A A NN O
derivant CN102558167A A NN O
, CN102558167A A , O
the CN102558167A A DT O
combination CN102558167A A NN O
of CN102558167A A IN O
one CN102558167A A CD O
or CN102558167A A CC O
a CN102558167A A DT O
plurality CN102558167A A NN O
of CN102558167A A IN O
thiazolidine CN102558167A A JJ O
derivants CN102558167A A NNS O
and CN102558167A A CC O
the CN102558167A A DT O
purpose CN102558167A A NN O
of CN102558167A A IN O
the CN102558167A A DT O
compound CN102558167A A NN O
in CN102558167A A IN O
treatment CN102558167A A NN O
on CN102558167A A IN O
diseases CN102558167A A NNS O
related CN102558167A A VBN O
with CN102558167A A IN O
glucokinase CN102558167A A NN I-UN
and CN102558167A A CC O
a CN102558167A A DT O
peroxisome CN102558167A A JJ I-UN
proliferators CN102558167A A NNS I-UN
activated CN102558167A A VBD I-UN
receptor CN102558167A A NN I-UN
, CN102558167A A , O
such CN102558167A A JJ O
as CN102558167A A IN O
diabetes CN102558167A A NNS O
mellitus CN102558167A A NNS O
and CN102558167A A CC O
obesity CN102558167A A NN O
. CN102558167A A . O

Application CN1823788A T NN O
of CN1823788A T IN O
lucid CN1823788A T JJ O
ganoderma CN1823788A T JJ O
acid CN1823788A T NN O
in CN1823788A T IN O
treating CN1823788A T VBG O
cancer CN1823788A T NN O
as CN1823788A T IN O
synergistic CN1823788A T JJ O
agent CN1823788A T NN O
and CN1823788A T CC O
inhibitor CN1823788A T NN O
. CN1823788A T . O

An CN1823788A A DT O
application CN1823788A A NN O
of CN1823788A A IN O
the CN1823788A A DT O
ganoderic CN1823788A A JJ O
acid CN1823788A A NN O
T CN1823788A A NNP O
and CN1823788A A CC O
ganoderic CN1823788A A JJ O
acid CN1823788A A NN O
Me CN1823788A A NNP O
in CN1823788A A IN O
preparing CN1823788A A VBG O
the CN1823788A A DT O
depressant CN1823788A A NN O
, CN1823788A A , O
sensitizer CN1823788A A NN O
and CN1823788A A CC O
synergist CN1823788A A NN O
for CN1823788A A IN O
suppressing CN1823788A A VBG O
the CN1823788A A DT O
growth CN1823788A A NN O
and CN1823788A A CC O
reproduction CN1823788A A NN O
of CN1823788A A IN O
the CN1823788A A DT O
cancer CN1823788A A NN O
cells CN1823788A A NNS O
resistant CN1823788A A VBP O
to CN1823788A A TO O
multiple CN1823788A A VB O
medicines CN1823788A A NNS O
and CN1823788A A CC O
improving CN1823788A A VBG O
the CN1823788A A DT O
sensitivity CN1823788A A NN O
of CN1823788A A IN O
said CN1823788A A VBD O
cancer CN1823788A A NN O
cells CN1823788A A NNS O
to CN1823788A A TO O
anticancer CN1823788A A VB O
medicines CN1823788A A NNS O
is CN1823788A A VBZ O
disclosed CN1823788A A VBN O
. CN1823788A A . O

Administering US7244414 T VBG O
fine US7244414 T JJ O
powder US7244414 T NN O
of US7244414 T IN O
active US7244414 T JJ O
material US7244414 T NN O
; US7244414 T : O
measured US7244414 T VBN O
aerosol US7244414 T NN O
. US7244414 T . O

GEP US20120230942 T NNP I-UN
, US20120230942 T , O
a US20120230942 T DT O
novel US20120230942 T JJ O
chondrogenic US20120230942 T JJ O
growth US20120230942 T NN O
factor US20120230942 T NN O
and US20120230942 T CC O
target US20120230942 T NN O
in US20120230942 T IN O
cartilage US20120230942 T NN O
disorders US20120230942 T NNS O
. US20120230942 T . O

The US20120230942 A DT O
present US20120230942 A JJ O
invention US20120230942 A NN O
relates US20120230942 A VBZ O
to US20120230942 A TO O
the US20120230942 A DT O
expression US20120230942 A NN O
and US20120230942 A CC O
regulating US20120230942 A NN O
growth US20120230942 A NN O
factors US20120230942 A NNS O
in US20120230942 A IN O
chrondrocytes US20120230942 A NNS O
and US20120230942 A CC O
developing US20120230942 A VBG O
cartilage US20120230942 A NN O
, US20120230942 A , O
particularly US20120230942 A RB O
granulin-epithelin US20120230942 A NN I-UN
precursor US20120230942 A NN I-UN
( US20120230942 A ( O
GEP US20120230942 A NNP I-UN
) US20120230942 A ) O
. US20120230942 A . O

The US20120230942 A DT O
invention US20120230942 A NN O
relates US20120230942 A VBZ O
to US20120230942 A TO O
the US20120230942 A DT O
modulation US20120230942 A NN O
and US20120230942 A CC O
manipulation US20120230942 A NN O
of US20120230942 A IN O
these US20120230942 A DT O
growth US20120230942 A NN O
factors US20120230942 A NNS O
, US20120230942 A , O
GEP US20120230942 A NNP I-UN
, US20120230942 A , O
and/or US20120230942 A VBZ O
the US20120230942 A DT O
molecules US20120230942 A NNS O
they US20120230942 A PRP O
interact US20120230942 A VBP O
with US20120230942 A IN O
, US20120230942 A , O
for US20120230942 A IN O
instance US20120230942 A NN O
COMP US20120230942 A NNP I-UN
, US20120230942 A , O
in US20120230942 A IN O
cartilage US20120230942 A NN O
disorders US20120230942 A NNS O
, US20120230942 A , O
including US20120230942 A VBG O
arthritis US20120230942 A NN O
. US20120230942 A . O

Assays US20120230942 A NNS O
and US20120230942 A CC O
screening US20120230942 A VBG O
methods US20120230942 A NNS O
for US20120230942 A IN O
the US20120230942 A DT O
determination US20120230942 A NN O
of US20120230942 A IN O
the US20120230942 A DT O
expression US20120230942 A NN O
and US20120230942 A CC O
activity US20120230942 A NN O
of US20120230942 A IN O
GEP US20120230942 A NNP I-UN
, US20120230942 A , O
or US20120230942 A CC O
of US20120230942 A IN O
GEP-COMP US20120230942 A NNP O
, US20120230942 A , O
are US20120230942 A VBP O
provided US20120230942 A VBN O
, US20120230942 A , O
including US20120230942 A VBG O
for US20120230942 A IN O
screening US20120230942 A VBG O
for US20120230942 A IN O
the US20120230942 A DT O
presence US20120230942 A NN O
or US20120230942 A CC O
extent US20120230942 A NN O
of US20120230942 A IN O
cartilage US20120230942 A NN O
or US20120230942 A CC O
arthritic US20120230942 A JJ O
disease US20120230942 A NN O
and US20120230942 A CC O
for US20120230942 A IN O
identifying US20120230942 A VBG O
modulators US20120230942 A NNS O
or US20120230942 A CC O
compounds/agents US20120230942 A NNS O
for US20120230942 A IN O
treatment US20120230942 A NN O
or US20120230942 A CC O
prevention US20120230942 A NN O
of US20120230942 A IN O
cartilage US20120230942 A NN O
or US20120230942 A CC O
arthritic US20120230942 A JJ O
diseases US20120230942 A NNS O
. US20120230942 A . O

Drug US7101995 T NN O
delivery US7101995 T NN O
to US7101995 T TO O
inhibit US7101995 T VB O
abnormal US7101995 T JJ O
gene US7101995 T NN O
expression US7101995 T NN O
in US7101995 T IN O
mammalian US7101995 T JJ O
cells US7101995 T NNS O
; US7101995 T : O
small US7101995 T JJ O
interfering US7101995 T NN O
RNAs US7101995 T NNP O
( US7101995 T ( O
siRNA US7101995 T NN O
) US7101995 T ) O
. US7101995 T . O

Described US7101995 A NNP O
is US7101995 A VBZ O
a US7101995 A DT O
deliverable US7101995 A JJ O
composition US7101995 A NN O
with US7101995 A IN O
low US7101995 A JJ O
toxicity US7101995 A NN O
comprising US7101995 A VBG O
an US7101995 A DT O
amphipathic US7101995 A JJ O
compound US7101995 A NN O
, US7101995 A , O
a US7101995 A DT O
polycation US7101995 A NN O
, US7101995 A , O
and US7101995 A CC O
a US7101995 A DT O
siRNA US7101995 A NN O
. US7101995 A . O

The US7101995 A DT O
composition US7101995 A NN O
may US7101995 A MD O
be US7101995 A VB O
used US7101995 A VBN O
in US7101995 A IN O
the US7101995 A DT O
process US7101995 A NN O
of US7101995 A IN O
delivering US7101995 A VBG O
a US7101995 A DT O
siRNA US7101995 A NN O
to US7101995 A TO O
an US7101995 A DT O
animal US7101995 A NN O
cell US7101995 A NN O
or US7101995 A CC O
more US7101995 A JJR O
particularly US7101995 A RB O
, US7101995 A , O
a US7101995 A DT O
mammal US7101995 A JJ O
cell US7101995 A NN O
. US7101995 A . O

Policresulen CN101095658A T NNP O
gelling CN101095658A T VBG O
agent CN101095658A T NN O
, CN101095658A T , O
method CN101095658A T NN O
for CN101095658A T IN O
preparation CN101095658A T NN O
the CN101095658A T DT O
same CN101095658A T JJ O
and CN101095658A T CC O
the CN101095658A T DT O
pharmaceutical CN101095658A T JJ O
use CN101095658A T NN O
thereof CN101095658A T NN O
. CN101095658A T . O

Method US20120288553 T NN O
for US20120288553 T IN O
controlling US20120288553 T VBG O
toxicity US20120288553 T NN O
of US20120288553 T IN O
metallic US20120288553 T JJ O
particle US20120288553 T NN O
and US20120288553 T CC O
low-toxicity US20120288553 T JJ O
composite US20120288553 T NN O
of US20120288553 T IN O
metallic US20120288553 T JJ O
nanoparticle US20120288553 T NN O
and US20120288553 T CC O
inorganic US20120288553 T JJ O
clay US20120288553 T NN O
. US20120288553 T . O

Oral CN1939259A T JJ O
preparation CN1939259A T NN O
containing CN1939259A T VBG O
penicillin CN1939259A T NN O
G CN1939259A T NNP O
and CN1939259A T CC O
its CN1939259A T PRP$ O
making CN1939259A T NN O
method CN1939259A T NN O
. CN1939259A T . O

Bioerodible EP1521572B1 T JJ O
film EP1521572B1 T NN O
for EP1521572B1 T IN O
ophthalmic EP1521572B1 T JJ O
drug EP1521572B1 T NN O
delivery EP1521572B1 T NN O
. EP1521572B1 T . O

Novel US20110257215 T NNP O
co-crystal US20110257215 T NN O
of US20110257215 T IN O
tiotropium US20110257215 T NN O
bromide US20110257215 T NN O
. US20110257215 T . O

Synergistic US20080153891 T JJ O
anti-cancer US20080153891 T JJ O
compositions US20080153891 T NNS O
. US20080153891 T . O

Application CN102861079A T NN O
of CN102861079A T IN O
Houttuynoid CN102861079A T NNP O
B CN102861079A T NNP O
in CN102861079A T IN O
medicine CN102861079A T NN O
for CN102861079A T IN O
treating CN102861079A T VBG O
skin CN102861079A T JJ O
cancer CN102861079A T NN O
. CN102861079A T . O

Cefquinome CN101347407A T NNP O
sulfate CN101347407A T NN O
injection CN101347407A T NN O
and CN101347407A T CC O
process CN101347407A T NN O
for CN101347407A T IN O
producing CN101347407A T VBG O
the CN101347407A T DT O
same CN101347407A T JJ O
. CN101347407A T . O

The CN101347407A A DT O
product CN101347407A A NN O
prepared CN101347407A A VBN O
has CN101347407A A VBZ O
wider CN101347407A A VBN O
antimicrobial CN101347407A A JJ O
spectrum CN101347407A A NN O
, CN101347407A A , O
stronger CN101347407A A JJR O
antibacterial CN101347407A A JJ O
activity CN101347407A A NN O
and CN101347407A A CC O
more CN101347407A A RBR O
stable CN101347407A A JJ O
Beta-lactamase CN101347407A A NNP I-UN
for CN101347407A A IN O
bacteria CN101347407A A NNS O
compared CN101347407A A VBN O
with CN101347407A A IN O
the CN101347407A A DT O
third CN101347407A A JJ O
generation CN101347407A A NN O
cephalosporin CN101347407A A NN O
, CN101347407A A , O
fills CN101347407A A VBZ O
up CN101347407A A RP O
the CN101347407A A DT O
gap CN101347407A A NN O
of CN101347407A A IN O
no CN101347407A A DT O
domestic CN101347407A A JJ O
fourth CN101347407A A JJ O
generation CN101347407A A NN O
cefamandole CN101347407A A VBD O
antibiotic CN101347407A A JJ O
preparation CN101347407A A NN O
which CN101347407A A WDT O
is CN101347407A A VBZ O
special CN101347407A A JJ O
for CN101347407A A IN O
animals CN101347407A A NNS O
, CN101347407A A , O
and CN101347407A A CC O
the CN101347407A A DT O
whole CN101347407A A JJ O
preparation CN101347407A A NN O
process CN101347407A A NN O
is CN101347407A A VBZ O
simple CN101347407A A JJ O
and CN101347407A A CC O
practicable CN101347407A A JJ O
. CN101347407A A . O

Compound CN101850119B T NNP O
preparation CN101850119B T NN O
used CN101850119B T VBN O
for CN101850119B T IN O
treating CN101850119B T VBG O
melancholia CN101850119B T NN O
and CN101850119B T CC O
senile CN101850119B T JJ O
dementia CN101850119B T NN O
. CN101850119B T . O

Sterilizing CN1989983A T VBG O
therapeutic CN1989983A T JJ O
agent CN1989983A T NN O
for CN1989983A T IN O
burn CN1989983A T NN O
and CN1989983A T CC O
scald CN1989983A T NN O
. CN1989983A T . O

Binding US7425623 T VBG O
to US7425623 T TO O
surface US7425623 T NN O
of US7425623 T IN O
tumor US7425623 T NN O
cell US7425623 T NN O
; US7425623 T : O
bacteriophage US7425623 T NN O
separation US7425623 T NN O
; US7425623 T : O
in US7425623 T IN O
situ US7425623 T JJ O
diagnosis US7425623 T NN O
. US7425623 T . O

Tumor CN102961785A T NNP O
cavity CN102961785A T NN O
filler CN102961785A T NN O
for CN102961785A T IN O
treating CN102961785A T VBG O
giant CN102961785A T NN O
cell CN102961785A T NN O
tumor CN102961785A T NN O
of CN102961785A T IN O
bone CN102961785A T NN O
and CN102961785A T CC O
preparation CN102961785A T NN O
method CN102961785A T NN O
thereof CN102961785A T NN O
. CN102961785A T . O

Bottled CN203075251U T VBN O
soda CN203075251U T JJ O
water CN203075251U T NN O
capable CN203075251U T JJ O
of CN203075251U T IN O
alleviating CN203075251U T VBG O
mosquito CN203075251U T NN O
biting CN203075251U T VBG O
reaction CN203075251U T NN O
. CN203075251U T . O

A CN1876015A T DT O
medicament CN1876015A T NN O
for CN1876015A T IN O
treating CN1876015A T VBG O
rheumatism CN1876015A T NN O
. CN1876015A T . O

Isoxazole US20080114044 T NNP O
compounds US20080114044 T VBZ O
as US20080114044 T IN O
Peroxisome US20080114044 T NNP I-UN
Proliferator-Activated US20080114044 T NNP I-UN
Receptor US20080114044 T NNP I-UN
( US20080114044 T ( I-UN
PPAR US20080114044 T NNP I-UN
) US20080114044 T ) I-UN
delta US20080114044 T NN I-UN
modulators US20080114044 T NNS O
; US20080114044 T : O
( US20080114044 T ( O
5- US20080114044 T JJ O
{ US20080114044 T ( O
4- US20080114044 T JJ O
[ US20080114044 T NN O
2- US20080114044 T JJ O
( US20080114044 T ( O
2,4-Dichloro-phenoxy US20080114044 T JJ O
) US20080114044 T ) O
-ethyl-carbamoyl US20080114044 T FW O
] US20080114044 T FW O
-5-phenyl-isoxazol-3-yl US20080114044 T FW O
} US20080114044 T ) O
-phenyl US20080114044 T NNP O
) US20080114044 T ) O
-acetic US20080114044 T JJ O
acid US20080114044 T NN O
; US20080114044 T : O
diabetes US20080114044 T NNS O
, US20080114044 T , O
cardiovascular US20080114044 T JJ O
disorders US20080114044 T NNS O
, US20080114044 T , O
dyslipidemias US20080114044 T NN O
, US20080114044 T , O
irritable US20080114044 T JJ O
bowel US20080114044 T NN O
disease US20080114044 T NN O
, US20080114044 T , O
cancer US20080114044 T NN O
, US20080114044 T , O
skin US20080114044 T NN O
disorders US20080114044 T NNS O
, US20080114044 T , O
eye US20080114044 T NN O
disorders US20080114044 T NNS O
. US20080114044 T . O

Method US20070160545 T NNP O
for US20070160545 T IN O
reducing US20070160545 T VBG O
ultraviolet US20070160545 T JJ O
light US20070160545 T NN O
induced US20070160545 T VBN O
apoptosis US20070160545 T NN O
. US20070160545 T . O

The US20070160545 A DT O
present US20070160545 A JJ O
invention US20070160545 A NN O
provides US20070160545 A VBZ O
a US20070160545 A DT O
method US20070160545 A NN O
for US20070160545 A IN O
enhancing US20070160545 A VBG O
resistance US20070160545 A NN O
to US20070160545 A TO O
the US20070160545 A DT O
onset US20070160545 A NN O
of US20070160545 A IN O
skin US20070160545 A JJ O
damage US20070160545 A NN O
caused US20070160545 A VBN O
by US20070160545 A IN O
irradiation US20070160545 A NN O
of US20070160545 A IN O
the US20070160545 A DT O
skin US20070160545 A NN O
with US20070160545 A IN O
ultraviolet US20070160545 A JJ O
light US20070160545 A NN O
by US20070160545 A IN O
inhibiting US20070160545 A VBG O
ultraviolet US20070160545 A JJ O
irradiation-induced US20070160545 A JJ O
apoptosis US20070160545 A NN O
of US20070160545 A IN O
epidermal US20070160545 A JJ O
cells US20070160545 A NNS O
as US20070160545 A IN O
a US20070160545 A DT O
result US20070160545 A NN O
of US20070160545 A IN O
increasing US20070160545 A VBG O
expression US20070160545 A NN O
of US20070160545 A IN O
SCCA-1 US20070160545 A NNP I-UN
and/or US20070160545 A JJ O
SCCA-2 US20070160545 A NNP I-UN
in US20070160545 A IN O
epidermal US20070160545 A JJ O
cells US20070160545 A NNS O
. US20070160545 A . O

Moreover US20070160545 A RB O
, US20070160545 A , O
the US20070160545 A DT O
present US20070160545 A JJ O
invention US20070160545 A NN O
provides US20070160545 A VBZ O
a US20070160545 A DT O
skin US20070160545 A JJ O
testing US20070160545 A NN O
method US20070160545 A NN O
for US20070160545 A IN O
evaluating US20070160545 A VBG O
resistance US20070160545 A NN O
of US20070160545 A IN O
the US20070160545 A DT O
skin US20070160545 A NN O
to US20070160545 A TO O
skin US20070160545 A VB O
damage US20070160545 A NN O
caused US20070160545 A VBN O
by US20070160545 A IN O
ultraviolet US20070160545 A JJ O
irradiation US20070160545 A NN O
by US20070160545 A IN O
measuring US20070160545 A VBG O
the US20070160545 A DT O
expression US20070160545 A NN O
of US20070160545 A IN O
SCCA-1 US20070160545 A NNP I-UN
and/or US20070160545 A JJ O
SCCA-2 US20070160545 A NNP I-UN
in US20070160545 A IN O
epidermal US20070160545 A JJ O
cells US20070160545 A NNS O
, US20070160545 A , O
and US20070160545 A CC O
judging US20070160545 A VBG O
UV US20070160545 A NNP O
resistance US20070160545 A NN O
of US20070160545 A IN O
the US20070160545 A DT O
epidermis US20070160545 A NN O
to US20070160545 A TO O
be US20070160545 A VB O
weak US20070160545 A JJ O
in US20070160545 A IN O
the US20070160545 A DT O
case US20070160545 A NN O
expression US20070160545 A NN O
is US20070160545 A VBZ O
decreased US20070160545 A VBN O
as US20070160545 A IN O
compared US20070160545 A VBN O
with US20070160545 A IN O
expression US20070160545 A NN O
in US20070160545 A IN O
epidermal US20070160545 A JJ O
cells US20070160545 A NNS O
. US20070160545 A . O

Moreover US20070160545 A RB O
, US20070160545 A , O
the US20070160545 A DT O
present US20070160545 A JJ O
invention US20070160545 A NN O
provides US20070160545 A VBZ O
a US20070160545 A DT O
method US20070160545 A NN O
for US20070160545 A IN O
screening US20070160545 A VBG O
drugs US20070160545 A NNS O
which US20070160545 A WDT O
enhance US20070160545 A VBP O
resistance US20070160545 A NN O
of US20070160545 A IN O
the US20070160545 A DT O
skin US20070160545 A NN O
to US20070160545 A TO O
skin US20070160545 A VB O
damage US20070160545 A NN O
by US20070160545 A IN O
ultraviolet US20070160545 A JJ O
irradiation US20070160545 A NN O
by US20070160545 A IN O
selecting US20070160545 A VBG O
a US20070160545 A DT O
drug US20070160545 A NN O
that US20070160545 A WDT O
increases US20070160545 A VBZ O
expression US20070160545 A NN O
of US20070160545 A IN O
SCCA-1 US20070160545 A NNP I-UN
and/or US20070160545 A JJ O
SCCA-2 US20070160545 A NNP I-UN
as US20070160545 A IN O
a US20070160545 A DT O
UV US20070160545 A NNP O
resistance US20070160545 A NN O
enhancer US20070160545 A NN O
. US20070160545 A . O

Use EP2090309A1 T NNP O
of EP2090309A1 T IN O
thiazole EP2090309A1 T JJ O
inhibitors EP2090309A1 T NNS O
of EP2090309A1 T IN O
fatty EP2090309A1 T JJ O
acid EP2090309A1 T JJ O
oxidation EP2090309A1 T NN O
of EP2090309A1 T IN O
formula EP2090309A1 T NN O
( EP2090309A1 T ( O
I EP2090309A1 T PRP O
) EP2090309A1 T ) O
for EP2090309A1 T IN O
the EP2090309A1 T DT O
treatment EP2090309A1 T NN O
of EP2090309A1 T IN O
Alzheimer EP2090309A1 T NNP O
's EP2090309A1 T POS O
disease EP2090309A1 T NN O
and EP2090309A1 T CC O
other EP2090309A1 T JJ O
neurological EP2090309A1 T JJ O
conditions EP2090309A1 T NNS O
. EP2090309A1 T . O

Methods EP2090309A1 A NNS O
for EP2090309A1 A IN O
inhibiting EP2090309A1 A VBG O
and/or EP2090309A1 A JJ O
reversing EP2090309A1 A VBG O
tau EP2090309A1 A JJ I-UN
filament EP2090309A1 A JJ O
formation EP2090309A1 A NN O
or EP2090309A1 A CC O
polymerization EP2090309A1 A NN O
are EP2090309A1 A VBP O
provided EP2090309A1 A VBN O
. EP2090309A1 A . O

These EP2090309A1 A DT O
methods EP2090309A1 A NNS O
can EP2090309A1 A MD O
be EP2090309A1 A VB O
used EP2090309A1 A VBN O
for EP2090309A1 A IN O
treating EP2090309A1 A VBG O
certain EP2090309A1 A JJ O
neurological EP2090309A1 A JJ O
disorders EP2090309A1 A NNS O
in EP2090309A1 A IN O
vivo EP2090309A1 A NN O
by EP2090309A1 A IN O
administering EP2090309A1 A VBG O
pharmaceutical EP2090309A1 A JJ O
compositions EP2090309A1 A NNS O
which EP2090309A1 A WDT O
inhibit EP2090309A1 A VBP O
and/or EP2090309A1 A JJ O
reverse EP2090309A1 A NN O
tau EP2090309A1 A NN I-UN
filament EP2090309A1 A JJ O
formation EP2090309A1 A NN O
or EP2090309A1 A CC O
polymerization EP2090309A1 A NN O
. EP2090309A1 A . O

Phenyl US20080119549 T NNP O
esters US20080119549 T NNS O
of US20080119549 T IN O
alkylcarbamic US20080119549 T JJ O
acids US20080119549 T NNS O
; US20080119549 T : O
analgesics US20080119549 T NNS O
. US20080119549 T . O

4- CN101362718A T JJ O
( CN101362718A T ( O
4-benzamido CN101362718A T JJ O
phenoxy CN101362718A T NN O
) CN101362718A T ) O
-2- CN101362718A T NN O
( CN101362718A T ( O
methylcarbamoyl CN101362718A T NN O
) CN101362718A T ) O
pyridine CN101362718A T NN O
derivatives CN101362718A T NNS O
, CN101362718A T , O
preparation CN101362718A T NN O
method CN101362718A T NN O
and CN101362718A T CC O
application CN101362718A T NN O
thereof CN101362718A T NN O
. CN101362718A T . O

The CN101362718A A DT O
invention CN101362718A A NN O
relates CN101362718A A VBZ O
to CN101362718A A TO O
a CN101362718A A DT O
derivative CN101362718A A JJ O
of CN101362718A A IN O
4- CN101362718A A JJ O
( CN101362718A A ( O
4-benzoyl CN101362718A A JJ O
amino-phenoxy CN101362718A A NN O
) CN101362718A A ) O
-2- CN101362718A A NN O
( CN101362718A A ( O
methyl CN101362718A A JJ O
ammonia CN101362718A A NN O
formyl CN101362718A A NN O
) CN101362718A A ) O
pyridine CN101362718A A NN O
and CN101362718A A CC O
a CN101362718A A DT O
preparation CN101362718A A NN O
method CN101362718A A NN O
and CN101362718A A CC O
purposes CN101362718A A NNS O
thereof CN101362718A A VBP O
, CN101362718A A , O
belonging CN101362718A A VBG O
to CN101362718A A TO O
the CN101362718A A DT O
chemical CN101362718A A JJ O
medicine CN101362718A A NN O
field CN101362718A A NN O
. CN101362718A A . O

The CN101362718A A DT O
structure CN101362718A A NN O
of CN101362718A A IN O
the CN101362718A A DT O
derivative CN101362718A A NN O
is CN101362718A A VBZ O
shown CN101362718A A VBN O
as CN101362718A A IN O
Formula CN101362718A A NNP O
I CN101362718A A PRP O
: CN101362718A A : O
R1 CN101362718A A NN O
is CN101362718A A VBZ O
hydrogen CN101362718A A JJ O
, CN101362718A A , O
halogenated CN101362718A A JJ O
base CN101362718A A NN O
, CN101362718A A , O
trifluoromethyl CN101362718A A NN O
, CN101362718A A , O
nitro CN101362718A A RB O
, CN101362718A A , O
alkoxy CN101362718A A JJ O
, CN101362718A A , O
dimethoxy CN101362718A A JJ O
or CN101362718A A CC O
amino CN101362718A A NN O
; CN101362718A A : O
R2 CN101362718A A NNP O
is CN101362718A A VBZ O
hydrogen CN101362718A A NN O
, CN101362718A A , O
halogenated CN101362718A A VBD O
base CN101362718A A NN O
, CN101362718A A , O
trifluoromethyl CN101362718A A NN O
, CN101362718A A , O
nitro CN101362718A A RB O
, CN101362718A A , O
alkoxy CN101362718A A JJ O
, CN101362718A A , O
dimethoxy CN101362718A A JJ O
or CN101362718A A CC O
amino CN101362718A A NN O
; CN101362718A A : O
R3 CN101362718A A NNP O
is CN101362718A A VBZ O
hydrogen CN101362718A A NN O
, CN101362718A A , O
halogenated CN101362718A A VBD O
base CN101362718A A NN O
, CN101362718A A , O
trifluoromethyl CN101362718A A NN O
, CN101362718A A , O
nitro CN101362718A A RB O
, CN101362718A A , O
alkoxy CN101362718A A JJ O
, CN101362718A A , O
dimethoxy CN101362718A A JJ O
or CN101362718A A CC O
amino CN101362718A A NN O
. CN101362718A A . O

The CN101362718A A DT O
derivative CN101362718A A JJ O
can CN101362718A A MD O
be CN101362718A A VB O
used CN101362718A A VBN O
for CN101362718A A IN O
preparing CN101362718A A VBG O
anti-tumor CN101362718A A JJ O
medicines CN101362718A A NNS O
. CN101362718A A . O

Crystals US20110009434 T NNS O
of US20110009434 T IN O
isopropyl US20110009434 T JJ O
ester US20110009434 T NN O
of US20110009434 T IN O
n- US20110009434 T JJ O
( US20110009434 T ( O
2,6-dichlorobenzoyl US20110009434 T JJ O
) US20110009434 T ) O
-4- US20110009434 T FW O
[ US20110009434 T JJ O
6- US20110009434 T JJ O
( US20110009434 T ( O
methylamino US20110009434 T NN O
) US20110009434 T ) O
methyl US20110009434 T NN O
-1-methyl-2,4-dioxo-1,4-dihydroquinazoline-3 US20110009434 T NNP O
( US20110009434 T ( O
2h US20110009434 T CD O
) US20110009434 T ) O
-yl US20110009434 T NN O
] US20110009434 T NNP O
-l- US20110009434 T NNP O
phenylalanine US20110009434 T NN O
hydrochloride US20110009434 T NN O
, US20110009434 T , O
production US20110009434 T NN O
method US20110009434 T NN O
thereof US20110009434 T NN O
and US20110009434 T CC O
use US20110009434 T NN O
thereof US20110009434 T NN O
. US20110009434 T . O

Crystals US20110009434 A NNS O
of US20110009434 A IN O
isopropyl US20110009434 A JJ O
ester US20110009434 A NN O
of US20110009434 A IN O
N- US20110009434 A NNP O
( US20110009434 A ( O
2,6-dichlorobenzoyl US20110009434 A JJ O
) US20110009434 A ) O
-4- US20110009434 A FW O
[ US20110009434 A JJ O
6- US20110009434 A JJ O
( US20110009434 A ( O
methylamino US20110009434 A NN O
) US20110009434 A ) O
methyl-1-methyl-2,4-dioxo-1,4-dihydroquinazoline-3 US20110009434 A NN O
( US20110009434 A ( O
2H US20110009434 A CD O
) US20110009434 A ) O
-yl US20110009434 A NN O
] US20110009434 A JJ O
-L-phenylalanine US20110009434 A NNP O
hydrochloride US20110009434 A NN O
are US20110009434 A VBP O
useful US20110009434 A JJ O
as US20110009434 A IN O
α4 US20110009434 A JJ I-UN
integrin US20110009434 A NN I-UN
inhibitors US20110009434 A NNS O
. US20110009434 A . O

Pharmaceutical CN101444614B T JJ O
composition CN101444614B T NN O
with CN101444614B T IN O
fat CN101444614B T JJ O
burning CN101444614B T NN O
and CN101444614B T CC O
firming CN101444614B T JJ O
effect CN101444614B T NN O
and CN101444614B T CC O
preparation CN101444614B T NN O
method CN101444614B T NN O
thereof CN101444614B T NN O
. CN101444614B T . O

Use CN101396561A T NNP O
of CN101396561A T IN O
composition CN101396561A T NN O
containing CN101396561A T VBG O
ACEI CN101396561A T NNP O
in CN101396561A T IN O
preparing CN101396561A T VBG O
medicine CN101396561A T NN O
for CN101396561A T IN O
treating CN101396561A T VBG O
hyperhomocysteinemia CN101396561A T JJ O
injury CN101396561A T NN O
and CN101396561A T CC O
related CN101396561A T JJ O
diseases CN101396561A T NNS O
thereof CN101396561A T VBP O
. CN101396561A T . O

The CN101396561A A DT O
invention CN101396561A A NN O
relates CN101396561A A VBZ O
to CN101396561A A TO O
a CN101396561A A DT O
use CN101396561A A NN O
of CN101396561A A IN O
a CN101396561A A DT O
pharmaceutical CN101396561A A JJ O
composition CN101396561A A NN O
containing CN101396561A A VBG O
an CN101396561A A DT O
angiotensin CN101396561A A NN I-UN
converting CN101396561A A VBG I-UN
enzyme CN101396561A A JJ I-UN
inhibitor CN101396561A A NN O
and CN101396561A A CC O
a CN101396561A A DT O
vitamin CN101396561A A NN O
in CN101396561A A IN O
vitamin CN101396561A A NN O
B CN101396561A A NNP O
family CN101396561A A NN O
in CN101396561A A IN O
the CN101396561A A DT O
preparation CN101396561A A NN O
of CN101396561A A IN O
drugs CN101396561A A NNS O
for CN101396561A A IN O
treating CN101396561A A VBG O
body CN101396561A A NN O
injuries CN101396561A A NNS O
and CN101396561A A CC O
the CN101396561A A DT O
related CN101396561A A JJ O
diseases CN101396561A A NNS O
caused CN101396561A A VBN O
by CN101396561A A IN O
hyperhomocysteinemia CN101396561A A NN O
( CN101396561A A ( O
brain CN101396561A A NN O
stroke CN101396561A A NN O
, CN101396561A A , O
ischemic CN101396561A A JJ O
heart CN101396561A A NN O
disease CN101396561A A NN O
, CN101396561A A , O
deep CN101396561A A JJ O
vein CN101396561A A NN O
thrombosis CN101396561A A NN O
, CN101396561A A , O
and CN101396561A A CC O
the CN101396561A A DT O
like CN101396561A A JJ O
) CN101396561A A ) O
, CN101396561A A , O
in CN101396561A A IN O
particular CN101396561A A JJ O
to CN101396561A A TO O
the CN101396561A A DT O
drugs CN101396561A A NNS O
for CN101396561A A IN O
treating CN101396561A A VBG O
the CN101396561A A DT O
brain CN101396561A A NN O
stroke CN101396561A A NN O
. CN101396561A A . O

The CN101396561A A DT O
combined CN101396561A A VBN O
use CN101396561A A NN O
of CN101396561A A IN O
the CN101396561A A DT O
angiotensin CN101396561A A NN O
converting CN101396561A A VBG O
enzyme CN101396561A A JJ O
inhibitor CN101396561A A NN O
and CN101396561A A CC O
the CN101396561A A DT O
vitamin CN101396561A A NN O
in CN101396561A A IN O
the CN101396561A A DT O
vitamin CN101396561A A NN O
B CN101396561A A NNP O
family CN101396561A A NN O
can CN101396561A A MD O
further CN101396561A A RB O
inhibit CN101396561A A VB O
the CN101396561A A DT O
proliferation CN101396561A A NN O
of CN101396561A A IN O
VSMC CN101396561A A NNP O
, CN101396561A A , O
improve CN101396561A A VB O
the CN101396561A A DT O
symptoms CN101396561A A NNS O
of CN101396561A A IN O
cerebral CN101396561A A JJ O
ischemia CN101396561A A NN O
and CN101396561A A CC O
be CN101396561A A VB O
better CN101396561A A JJR O
than CN101396561A A IN O
the CN101396561A A DT O
single CN101396561A A JJ O
use CN101396561A A NN O
of CN101396561A A IN O
the CN101396561A A DT O
drug CN101396561A A NN O
, CN101396561A A , O
thereby CN101396561A A RB O
showing CN101396561A A VBG O
that CN101396561A A IN O
the CN101396561A A DT O
combined CN101396561A A VBN O
use CN101396561A A NN O
of CN101396561A A IN O
the CN101396561A A DT O
angiotensin CN101396561A A NN I-UN
converting CN101396561A A VBG I-UN
enzyme CN101396561A A JJ I-UN
inhibitor CN101396561A A NN O
and CN101396561A A CC O
the CN101396561A A DT O
vitamin CN101396561A A NN O
in CN101396561A A IN O
the CN101396561A A DT O
vitamin CN101396561A A NN O
B CN101396561A A NNP O
can CN101396561A A MD O
be CN101396561A A VB O
acted CN101396561A A VBN O
on CN101396561A A IN O
the CN101396561A A DT O
different CN101396561A A JJ O
routes CN101396561A A NNS O
and CN101396561A A CC O
the CN101396561A A DT O
links CN101396561A A NNS O
for CN101396561A A IN O
delaying/treating CN101396561A A VBG O
the CN101396561A A DT O
body CN101396561A A NN O
injuries CN101396561A A NNS O
and CN101396561A A CC O
the CN101396561A A DT O
related CN101396561A A JJ O
diseases CN101396561A A NNS O
caused CN101396561A A VBN O
by CN101396561A A IN O
Hcy CN101396561A A NNP O
and CN101396561A A CC O
further CN101396561A A RB O
having CN101396561A A VBG O
the CN101396561A A DT O
overlapping CN101396561A A VBG O
effect CN101396561A A NN O
or CN101396561A A CC O
the CN101396561A A DT O
synergy CN101396561A A NN O
. CN101396561A A . O

copolymer US7014845 T NN O
of US7014845 T IN O
a US7014845 T DT O
polysaccharide US7014845 T NN O
and US7014845 T CC O
a US7014845 T DT O
vinyl US7014845 T NN O
or US7014845 T CC O
acrylic US7014845 T JJ O
polymer US7014845 T NN O
crosslinked US7014845 T VBN O
with US7014845 T IN O
a US7014845 T DT O
diamine US7014845 T NN O
, US7014845 T , O
amino US7014845 T JJ O
acid US7014845 T NN O
or US7014845 T CC O
polypeptide US7014845 T NN O
; US7014845 T : O
sustained US7014845 T VBN O
release US7014845 T NN O
; US7014845 T : O
as US7014845 T IN O
the US7014845 T DT O
polysaccharide US7014845 T NN O
is US7014845 T VBZ O
degraded US7014845 T VBN O
by US7014845 T IN O
intestinal US7014845 T JJ O
bacteria US7014845 T NNS O
, US7014845 T , O
an US7014845 T DT O
active US7014845 T JJ O
steroidal US7014845 T NN O
or US7014845 T CC O
nonsteroidal US7014845 T JJ O
drug US7014845 T NN O
is US7014845 T VBZ O
released US7014845 T VBN O
for US7014845 T IN O
effective US7014845 T JJ O
absorption US7014845 T NN O
. US7014845 T . O

Application CN102872124A T NN O
of CN102872124A T IN O
Houttuynoid CN102872124A T NNP O
A CN102872124A T NNP O
in CN102872124A T IN O
medicament CN102872124A T NN O
for CN102872124A T IN O
preventing CN102872124A T VBG O
or CN102872124A T CC O
treating CN102872124A T VBG O
pancreatic CN102872124A T JJ O
fibrosis CN102872124A T NN O
. CN102872124A T . O

Compounds WO2013024028A1 T NNS O
and WO2013024028A1 T CC O
compositions WO2013024028A1 T NNS O
for WO2013024028A1 T IN O
treating WO2013024028A1 T VBG O
proteinopathies WO2013024028A1 T NNS O
. WO2013024028A1 T . O

Methods WO2003062392A3 T NNS O
of WO2003062392A3 T IN O
treating WO2003062392A3 T VBG O
conditions WO2003062392A3 T NNS O
associated WO2003062392A3 T VBN O
with WO2003062392A3 T IN O
an WO2003062392A3 T DT O
edg WO2003062392A3 T JJ O
receptor WO2003062392A3 T NN O
. WO2003062392A3 T . O

The WO2003062392A3 A DT O
present WO2003062392A3 A JJ O
invention WO2003062392A3 A NN O
provides WO2003062392A3 A VBZ O
a WO2003062392A3 A DT O
method WO2003062392A3 A NN O
of WO2003062392A3 A IN O
modulating WO2003062392A3 A VBG O
an WO2003062392A3 A DT O
Edg-2 WO2003062392A3 A JJ I-UN
, WO2003062392A3 A , O
Edg-3 WO2003062392A3 A JJ I-UN
, WO2003062392A3 A , O
Ed-4 WO2003062392A3 A NNP I-UN
or WO2003062392A3 A CC O
Edg7 WO2003062392A3 A NNP I-UN
receptor WO2003062392A3 A NN I-UN
mediated WO2003062392A3 A VBD O
biological WO2003062392A3 A JJ O
activity WO2003062392A3 A NN O
in WO2003062392A3 A IN O
a WO2003062392A3 A DT O
cell WO2003062392A3 A NN O
. WO2003062392A3 A . O

A WO2003062392A3 A DT O
cell WO2003062392A3 A NN O
expressing WO2003062392A3 A VBG O
the WO2003062392A3 A DT O
Edg-2 WO2003062392A3 A NNP I-UN
, WO2003062392A3 A , O
Edg-3 WO2003062392A3 A NNP I-UN
, WO2003062392A3 A , O
Edg-4 WO2003062392A3 A NNP I-UN
or WO2003062392A3 A CC O
Edg WO2003062392A3 A NNP I-UN
7 WO2003062392A3 A CD I-UN
receptor WO2003062392A3 A NN I-UN
is WO2003062392A3 A VBZ O
contacted WO2003062392A3 A VBN O
with WO2003062392A3 A IN O
a WO2003062392A3 A DT O
modulator WO2003062392A3 A NN O
of WO2003062392A3 A IN O
the WO2003062392A3 A DT O
Edg-2 WO2003062392A3 A NNP I-UN
, WO2003062392A3 A , O
Edg-3 WO2003062392A3 A NNP I-UN
, WO2003062392A3 A , O
Ed-4 WO2003062392A3 A NNP I-UN
or WO2003062392A3 A CC O
Edg WO2003062392A3 A NNP I-UN
7 WO2003062392A3 A CD I-UN
receptor WO2003062392A3 A NN I-UN
sufficient WO2003062392A3 A NN O
to WO2003062392A3 A TO O
modulate WO2003062392A3 A VB O
receptor WO2003062392A3 A NN O
mediated WO2003062392A3 A JJ O
biological WO2003062392A3 A JJ O
activity WO2003062392A3 A NN O
. WO2003062392A3 A . O

In WO2003062392A3 A IN O
another WO2003062392A3 A DT O
aspect WO2003062392A3 A NN O
, WO2003062392A3 A , O
the WO2003062392A3 A DT O
present WO2003062392A3 A JJ O
invention WO2003062392A3 A NN O
provides WO2003062392A3 A VBZ O
a WO2003062392A3 A DT O
method WO2003062392A3 A NN O
for WO2003062392A3 A IN O
modulating WO2003062392A3 A VBG O
an WO2003062392A3 A DT O
Edg-2 WO2003062392A3 A JJ I-UN
, WO2003062392A3 A , O
Edg-3 WO2003062392A3 A JJ I-UN
, WO2003062392A3 A , O
Ed-4 WO2003062392A3 A JJ I-UN
or WO2003062392A3 A CC O
Edg-7 WO2003062392A3 A JJ I-UN
receptor WO2003062392A3 A NN I-UN
mediated WO2003062392A3 A VBD O
biological WO2003062392A3 A JJ O
in WO2003062392A3 A IN O
a WO2003062392A3 A DT O
subject WO2003062392A3 A NN O
. WO2003062392A3 A . O

A WO2003062392A3 A DT O
therapeutically WO2003062392A3 A RB O
effective WO2003062392A3 A JJ O
amount WO2003062392A3 A NN O
of WO2003062392A3 A IN O
a WO2003062392A3 A DT O
modulator WO2003062392A3 A NN O
of WO2003062392A3 A IN O
the WO2003062392A3 A DT O
Edg-2 WO2003062392A3 A NNP I-UN
, WO2003062392A3 A , O
Edg-3 WO2003062392A3 A NNP I-UN
, WO2003062392A3 A , O
Ed-4 WO2003062392A3 A NNP I-UN
or WO2003062392A3 A CC O
Edg7 WO2003062392A3 A NNP I-UN
receptor WO2003062392A3 A NN I-UN
is WO2003062392A3 A VBZ O
administered WO2003062392A3 A VBN O
to WO2003062392A3 A TO O
the WO2003062392A3 A DT O
subject WO2003062392A3 A NN O
. WO2003062392A3 A . O

Method EP1828149A1 T NNP O
for EP1828149A1 T IN O
the EP1828149A1 T DT O
production EP1828149A1 T NN O
of EP1828149A1 T IN O
oxazoles EP1828149A1 T NNS O
by EP1828149A1 T IN O
condensing EP1828149A1 T VBG O
aromatic EP1828149A1 T JJ O
aldehydes EP1828149A1 T NNS O
with EP1828149A1 T IN O
a-ketoximes EP1828149A1 T NNS O
to EP1828149A1 T TO O
n-oxides EP1828149A1 T NNS O
and EP1828149A1 T CC O
then EP1828149A1 T RB O
reacting EP1828149A1 T VBG O
the EP1828149A1 T DT O
same EP1828149A1 T JJ O
with EP1828149A1 T IN O
activated EP1828149A1 T JJ O
acid EP1828149A1 T NN O
derivatives EP1828149A1 T NNS O
. EP1828149A1 T . O

Composition CN103690543A T NN O
and CN103690543A T CC O
method CN103690543A T NN O
for CN103690543A T IN O
killing CN103690543A T VBG O
aspergillus CN103690543A T JJ O
fumigatus CN103690543A T NN O
. CN103690543A T . O

Se-garlic CN200939251Y T JJ O
capsules CN200939251Y T NNS O
. CN200939251Y T . O

Novel CN103243147A T NNP O
high-throughput CN103243147A T JJ O
yeast CN103243147A T NN O
cell-based CN103243147A T JJ O
screening CN103243147A T NN O
platform CN103243147A T NN O
for CN103243147A T IN O
identifying CN103243147A T VBG O
HMG-CoA CN103243147A T NNP I-UN
reductase CN103243147A T NN I-UN
inhibitors CN103243147A T NNS O
and CN103243147A T CC O
uses CN103243147A T NNS O
of CN103243147A T IN O
such CN103243147A T JJ O
inhibitors CN103243147A T NNS O
. CN103243147A T . O

Methods CN103243147A A NNS O
of CN103243147A A IN O
screening CN103243147A A NN O
, CN103243147A A , O
identifying CN103243147A A VBG O
and CN103243147A A CC O
isolating CN103243147A A VBG O
HMG-CoAR CN103243147A A JJ I-UN
inhibitors CN103243147A A NNS O
are CN103243147A A VBP O
disclosed CN103243147A A VBN O
herein CN103243147A A NN O
. CN103243147A A . O

The CN103243147A A DT O
present CN103243147A A JJ O
invention CN103243147A A NN O
also CN103243147A A RB O
provides CN103243147A A VBZ O
potent CN103243147A A JJ O
HMG-CoAR CN103243147A A JJ I-UN
inhibitors CN103243147A A NNS O
for CN103243147A A IN O
treatment CN103243147A A NN O
and CN103243147A A CC O
prevention CN103243147A A NN O
of CN103243147A A IN O
diseases CN103243147A A NNS O
and CN103243147A A CC O
conditions CN103243147A A NNS O
associated CN103243147A A VBN O
with CN103243147A A IN O
elevated CN103243147A A VBN O
cholesterol CN103243147A A NN O
and/or CN103243147A A NN O
blood CN103243147A A NN O
lipid CN103243147A A JJ O
levels CN103243147A A NNS O
. CN103243147A A . O

Digestive CN1792380A T NNP O
tract CN1792380A T NN O
stent CN1792380A T NN O
with CN1792380A T IN O
anti-cancer CN1792380A T JJ O
medicinal CN1792380A T JJ O
particles CN1792380A T NNS O
. CN1792380A T . O

Application CN102861055A T NN O
of CN102861055A T IN O
Houttuynoid CN102861055A T NNP O
A CN102861055A T NNP O
in CN102861055A T IN O
helicobacter CN102861055A T NN O
pylori CN102861055A T NN O
resisting CN102861055A T VBG O
medicine CN102861055A T NN O
. CN102861055A T . O

Use WO2006021660A8 T NN O
of WO2006021660A8 T IN O
at WO2006021660A8 T IN O
least WO2006021660A8 T JJS O
one WO2006021660A8 T CD O
conjugated WO2006021660A8 T VBN O
triene-containing WO2006021660A8 T JJ O
fatty WO2006021660A8 T JJ O
acid WO2006021660A8 T NN O
for WO2006021660A8 T IN O
preparing WO2006021660A8 T VBG O
a WO2006021660A8 T DT O
medicine WO2006021660A8 T NN O
for WO2006021660A8 T IN O
treating WO2006021660A8 T VBG O
inflammation WO2006021660A8 T NN O
. WO2006021660A8 T . O

Antibacterial EP1140965B1 T NNP O
protonated EP1140965B1 T VBD O
oligonucleotides EP1140965B1 T NNS O
. EP1140965B1 T . O

Cosmetic/dermatological DE20321277U1 T JJ O
preparation DE20321277U1 T NN O
in DE20321277U1 T IN O
form DE20321277U1 T NN O
of DE20321277U1 T IN O
oil-in DE20321277U1 T JJ O
water DE20321277U1 T NN O
emulsion DE20321277U1 T NN O
, DE20321277U1 T , O
useful DE20321277U1 T JJ O
for DE20321277U1 T IN O
treating DE20321277U1 T VBG O
e.g DE20321277U1 T NN O
. DE20321277U1 T . O

neurodermatitis DE20321277U1 T NN O
and DE20321277U1 T CC O
skin DE20321277U1 T NN O
aging DE20321277U1 T NN O
, DE20321277U1 T , O
comprises DE20321277U1 T VBZ O
phytosterol DE20321277U1 T NN O
groups DE20321277U1 T NNS O
, DE20321277U1 T , O
oil DE20321277U1 T NN O
components DE20321277U1 T NNS O
and DE20321277U1 T CC O
additional DE20321277U1 T JJ O
materials DE20321277U1 T NNS O
. DE20321277U1 T . O

Medical US7402318 T JJ O
devices US7402318 T NNS O
having US7402318 T VBG O
antimicrobial US7402318 T JJ O
coatings US7402318 T NNS O
thereon US7402318 T NN O
. US7402318 T . O

Treatment EP1119361A4 T NN O
of EP1119361A4 T IN O
carcinomas EP1119361A4 T NN O
using EP1119361A4 T VBG O
squalamine EP1119361A4 T NN O
in EP1119361A4 T IN O
combination EP1119361A4 T NN O
with EP1119361A4 T IN O
other EP1119361A4 T JJ O
anti-cancer EP1119361A4 T JJ O
agents EP1119361A4 T NNS O
or EP1119361A4 T CC O
modalities EP1119361A4 T NNS O
. EP1119361A4 T . O

As EP1119361A4 A IN O
examples EP1119361A4 A NNS O
, EP1119361A4 A , O
the EP1119361A4 A DT O
anti-hormonal EP1119361A4 A JJ O
agents EP1119361A4 A NNS O
may EP1119361A4 A MD O
be EP1119361A4 A VB O
a EP1119361A4 A DT O
LHRH EP1119361A4 A NNP I-UN
( EP1119361A4 A ( O
luteinizing EP1119361A4 A VBG I-UN
hormone EP1119361A4 A NN I-UN
releasing EP1119361A4 A VBG I-UN
hormone EP1119361A4 A NN I-UN
) EP1119361A4 A ) O
agonist EP1119361A4 A NN O
or EP1119361A4 A CC O
an EP1119361A4 A DT O
anti-androgen EP1119361A4 A JJ O
such EP1119361A4 A JJ O
as EP1119361A4 A IN O
flutamide EP1119361A4 A NN O
, EP1119361A4 A , O
biclutamide EP1119361A4 A NN O
, EP1119361A4 A , O
nilutamide EP1119361A4 A RB O
, EP1119361A4 A , O
and EP1119361A4 A CC O
luprolide EP1119361A4 A RB O
. EP1119361A4 A . O

Ceratamines US20080255090 T NNS O
A US20080255090 T NNP O
and US20080255090 T CC O
B US20080255090 T NNP O
, US20080255090 T , O
and US20080255090 T CC O
Analogues US20080255090 T NNP O
, US20080255090 T , O
Syntheses US20080255090 T NNP O
and US20080255090 T CC O
Pharmaceutical US20080255090 T NNP O
Compositions US20080255090 T NNP O
Thereof US20080255090 T NNP O
. US20080255090 T . O

Method US20090291150 T NNP O
and US20090291150 T CC O
compositions US20090291150 T NNS O
for US20090291150 T IN O
treating US20090291150 T VBG O
and US20090291150 T CC O
preventing US20090291150 T VBG O
seizures US20090291150 T NNS O
by US20090291150 T IN O
modulating US20090291150 T VBG O
acid-sensing US20090291150 T JJ O
ion US20090291150 T NN O
channel US20090291150 T NN O
activity US20090291150 T NN O
. US20090291150 T . O

Diamino-pyridine US20110092474 T NNP O
, US20110092474 T , O
pyrimidine US20110092474 T NN O
, US20110092474 T , O
and US20110092474 T CC O
pyrazine US20110092474 T JJ O
modulators US20110092474 T NNS O
of US20110092474 T IN O
the US20110092474 T DT O
histamine US20110092474 T NN I-UN
H4 US20110092474 T NNP I-UN
receptor US20110092474 T NN I-UN
. US20110092474 T . O

Diamino-pyridine US20110092474 A NNP O
, US20110092474 A , O
pyrimidine US20110092474 A NN O
and US20110092474 A CC O
pyridazine US20110092474 A NN O
compounds US20110092474 A NNS O
which US20110092474 A WDT O
may US20110092474 A MD O
be US20110092474 A VB O
used US20110092474 A VBN O
as US20110092474 A IN O
H4 US20110092474 A NNP I-UN
receptor US20110092474 A NN I-UN
modulators US20110092474 A NNS O
, US20110092474 A , O
and US20110092474 A CC O
in US20110092474 A IN O
pharmaceutical US20110092474 A JJ O
compositions US20110092474 A NNS O
and US20110092474 A CC O
methods US20110092474 A NNS O
for US20110092474 A IN O
the US20110092474 A DT O
treatment US20110092474 A NN O
of US20110092474 A IN O
disease US20110092474 A NN O
states US20110092474 A NNS O
, US20110092474 A , O
disorders US20110092474 A NNS O
, US20110092474 A , O
and US20110092474 A CC O
conditions US20110092474 A NNS O
mediated US20110092474 A VBN O
by US20110092474 A IN O
H4 US20110092474 A NNP I-UN
receptor US20110092474 A NN I-UN
activity US20110092474 A NN O
, US20110092474 A , O
such US20110092474 A JJ O
as US20110092474 A IN O
allergy US20110092474 A NN O
, US20110092474 A , O
asthma US20110092474 A NN O
, US20110092474 A , O
autoimmune US20110092474 A NN O
diseases US20110092474 A NNS O
, US20110092474 A , O
and US20110092474 A CC O
pruritis US20110092474 A NN O
. US20110092474 A . O

Trans-Clomiphene US20120022167 T NNP O
for US20120022167 T IN O
Metabolic US20120022167 T NNP O
Syndrome US20120022167 T NNP O
. US20120022167 T . O

The US20120022167 A DT O
present US20120022167 A JJ O
invention US20120022167 A NN O
relates US20120022167 A VBZ O
to US20120022167 A TO O
the US20120022167 A DT O
administration US20120022167 A NN O
of US20120022167 A IN O
compositions US20120022167 A NNS O
comprising US20120022167 A VBG O
an US20120022167 A DT O
antiestrogen US20120022167 A NN O
, US20120022167 A , O
preferably US20120022167 A RB O
trans-clomiphene US20120022167 A NN O
, US20120022167 A , O
for US20120022167 A IN O
treating US20120022167 A VBG O
metabolic US20120022167 A JJ O
syndrome US20120022167 A NN O
in US20120022167 A IN O
a US20120022167 A DT O
subject US20120022167 A NN O
. US20120022167 A . O

The US20120022167 A DT O
invention US20120022167 A NN O
is US20120022167 A VBZ O
also US20120022167 A RB O
directed US20120022167 A VBN O
to US20120022167 A TO O
methods US20120022167 A NNS O
for US20120022167 A IN O
reducing US20120022167 A VBG O
fasting US20120022167 A VBG O
glucose US20120022167 A JJ O
levels US20120022167 A NNS O
in US20120022167 A IN O
a US20120022167 A DT O
subject US20120022167 A NN O
by US20120022167 A IN O
administering US20120022167 A VBG O
a US20120022167 A DT O
composition US20120022167 A NN O
comprising US20120022167 A VBG O
an US20120022167 A DT O
antiestrogen US20120022167 A NN O
, US20120022167 A , O
preferably US20120022167 A RB O
trans-clomiphene US20120022167 A NN O
. US20120022167 A . O

A CN101007165A T DT O
compound CN101007165A T NN O
preparation CN101007165A T NN O
for CN101007165A T IN O
treating CN101007165A T VBG O
respiratory CN101007165A T NN O
tract CN101007165A T JJ O
infection CN101007165A T NN O
and CN101007165A T CC O
its CN101007165A T PRP$ O
preparation CN101007165A T NN O
method CN101007165A T NN O
. CN101007165A T . O

Method US8383100 T NNP O
to US8383100 T TO O
treat US8383100 T VB O
and US8383100 T CC O
prevent US8383100 T VB O
skin US8383100 T NN O
diseases US8383100 T NNS O
with US8383100 T IN O
Porifera-based US8383100 T JJ O
therapeutic US8383100 T JJ O
compositions US8383100 T NNS O
treating US8383100 T VBG O
and US8383100 T CC O
preventing US8383100 T VBG O
skin US8383100 T NN O
diseases US8383100 T NNS O
. US8383100 T . O

Methods WO2013181322A1 T NNS O
of WO2013181322A1 T IN O
administering WO2013181322A1 T VBG O
nitric WO2013181322A1 T JJ O
oxide WO2013181322A1 T NN O
to WO2013181322A1 T TO O
arterial WO2013181322A1 T JJ O
or WO2013181322A1 T CC O
arterialized WO2013181322A1 T JJ O
blood WO2013181322A1 T NN O
. WO2013181322A1 T . O

Compound CN102949406A T NNP O
elvucitabine CN102949406A T NN O
medicine CN102949406A T NN O
composition CN102949406A T NN O
as CN102949406A T RB O
well CN102949406A T RB O
as CN102949406A T IN O
preparation CN102949406A T NN O
method CN102949406A T NN O
and CN102949406A T CC O
use CN102949406A T NN O
for CN102949406A T IN O
same CN102949406A T JJ O
. CN102949406A T . O

1,3,4-oxadiazole WO2010070343A1 T JJ O
derivatives WO2010070343A1 T NNS O
and WO2010070343A1 T CC O
their WO2010070343A1 T PRP$ O
uses WO2010070343A1 T NNS O
to WO2010070343A1 T TO O
treat WO2010070343A1 T VB O
diabetes WO2010070343A1 T NNS O
. WO2010070343A1 T . O

DGAT-1 WO2010070343A1 A NNP I-UN
inhibitor WO2010070343A1 A NN O
compounds WO2010070343A1 A NNS O
of WO2010070343A1 A IN O
formula WO2010070343A1 A NN O
( WO2010070343A1 A ( O
I WO2010070343A1 A PRP O
) WO2010070343A1 A ) O
and WO2010070343A1 A CC O
pharmaceutically-acceptable WO2010070343A1 A JJ O
salts WO2010070343A1 A NNS O
thereof WO2010070343A1 A NNS O
are WO2010070343A1 A VBP O
described WO2010070343A1 A VBN O
, WO2010070343A1 A , O
together WO2010070343A1 A RB O
with WO2010070343A1 A IN O
pharmaceutical WO2010070343A1 A JJ O
compositions WO2010070343A1 A NNS O
, WO2010070343A1 A , O
processes WO2010070343A1 A NNS O
for WO2010070343A1 A IN O
making WO2010070343A1 A VBG O
them WO2010070343A1 A PRP O
and WO2010070343A1 A CC O
their WO2010070343A1 A PRP$ O
use WO2010070343A1 A NN O
in WO2010070343A1 A IN O
treating WO2010070343A1 A NN O
, WO2010070343A1 A , O
for WO2010070343A1 A IN O
example WO2010070343A1 A NN O
, WO2010070343A1 A , O
obesity WO2010070343A1 A NN O
( WO2010070343A1 A ( O
I WO2010070343A1 A PRP O
) WO2010070343A1 A ) O
wherein WO2010070343A1 A NN O
n WO2010070343A1 A NN O
is WO2010070343A1 A VBZ O
0 WO2010070343A1 A CD O
, WO2010070343A1 A , O
1 WO2010070343A1 A CD O
, WO2010070343A1 A , O
2 WO2010070343A1 A CD O
or WO2010070343A1 A CC O
3 WO2010070343A1 A CD O
, WO2010070343A1 A , O
R WO2010070343A1 A NNP O
is WO2010070343A1 A VBZ O
independently WO2010070343A1 A RB O
selected WO2010070343A1 A VBN O
from WO2010070343A1 A IN O
fluoro WO2010070343A1 A NN O
, WO2010070343A1 A , O
chloro WO2010070343A1 A NN O
, WO2010070343A1 A , O
bromo WO2010070343A1 A NN O
, WO2010070343A1 A , O
trifluoromethyl WO2010070343A1 A NN O
, WO2010070343A1 A , O
methoxy WO2010070343A1 A NN O
, WO2010070343A1 A , O
difluoromethoxy WO2010070343A1 A NN O
and WO2010070343A1 A CC O
trifluoromethoxy WO2010070343A1 A NN O
and WO2010070343A1 A CC O
Z WO2010070343A1 A NNP O
is WO2010070343A1 A VBZ O
carboxy WO2010070343A1 A JJ O
or WO2010070343A1 A CC O
a WO2010070343A1 A DT O
mimic WO2010070343A1 A JJ O
or WO2010070343A1 A CC O
bioisostere WO2010070343A1 A JJ O
thereof WO2010070343A1 A NN O
, WO2010070343A1 A , O
hydroxyl WO2010070343A1 A NN O
, WO2010070343A1 A , O
hydroxymethyl WO2010070343A1 A NN O
, WO2010070343A1 A , O
or WO2010070343A1 A CC O
−CONRbRc WO2010070343A1 A VB O
wherein WO2010070343A1 A JJ O
Rb WO2010070343A1 A NNP O
and WO2010070343A1 A CC O
Rc WO2010070343A1 A NNP O
are WO2010070343A1 A VBP O
independently WO2010070343A1 A RB O
selected WO2010070343A1 A VBN O
from WO2010070343A1 A IN O
hydrogen WO2010070343A1 A NN O
and WO2010070343A1 A CC O
( WO2010070343A1 A ( O
1-4C WO2010070343A1 A JJ O
) WO2010070343A1 A ) O
alkyl WO2010070343A1 A NN O
, WO2010070343A1 A , O
which WO2010070343A1 A WDT O
( WO2010070343A1 A ( O
1-4C WO2010070343A1 A CD O
) WO2010070343A1 A ) O
alkyl WO2010070343A1 A NN O
group WO2010070343A1 A NN O
may WO2010070343A1 A MD O
be WO2010070343A1 A VB O
optionally WO2010070343A1 A RB O
substituted WO2010070343A1 A VBN O
by WO2010070343A1 A IN O
carboxy WO2010070343A1 A NN O
or WO2010070343A1 A CC O
a WO2010070343A1 A DT O
mimic WO2010070343A1 A JJ O
or WO2010070343A1 A CC O
bioisostere WO2010070343A1 A JJ O
thereof WO2010070343A1 A NN O
. WO2010070343A1 A . O

The CA2281918C A DT O
compounds CA2281918C A NNS O
of CA2281918C A IN O
formula CA2281918C A NN O
( CA2281918C A ( O
I CA2281918C A PRP O
) CA2281918C A ) O
act CA2281918C A NN O
as CA2281918C A IN O
5-HT2A CA2281918C A JJ I-UN
antagonists CA2281918C A NNS O
having CA2281918C A VBG O
a CA2281918C A DT O
reuptake-inhibiting CA2281918C A NN O
, CA2281918C A , O
antidepressant CA2281918C A NN O
or CA2281918C A CC O
anxiolytic CA2281918C A JJ O
effect CA2281918C A NN O
and CA2281918C A CC O
can CA2281918C A MD O
be CA2281918C A VB O
used CA2281918C A VBN O
in CA2281918C A IN O
the CA2281918C A DT O
production CA2281918C A NN O
of CA2281918C A IN O
medicaments CA2281918C A NNS O
. CA2281918C A . O

A2b WO2009088518A1 T NNP O
adenosine WO2009088518A1 T NN O
receptor WO2009088518A1 T NN O
antagonists WO2009088518A1 T NNS O
for WO2009088518A1 T IN O
the WO2009088518A1 T DT O
treatment WO2009088518A1 T NN O
of WO2009088518A1 T IN O
cancer WO2009088518A1 T NN O
. WO2009088518A1 T . O

Multi-azole CN102850337A T JJ O
linked CN102850337A T VBD O
spirorenone CN102850337A T NN O
compound CN102850337A T NN O
and CN102850337A T CC O
preparation CN102850337A T NN O
method CN102850337A T NN O
and CN102850337A T CC O
application CN102850337A T NN O
thereof CN102850337A T NN O
. CN102850337A T . O

Combination US20110281935 T NNP O
Therapy US20110281935 T NNP O
Based US20110281935 T VBD O
on US20110281935 T IN O
SRC US20110281935 T NNP I-UN
and US20110281935 T CC O
Aurora US20110281935 T NNP O
Kinase US20110281935 T NNP O
Inhibition US20110281935 T NNP O
for US20110281935 T IN O
the US20110281935 T DT O
Treatment US20110281935 T NNP O
of US20110281935 T IN O
Cancer US20110281935 T NNP O
. US20110281935 T . O

Neurodegenerative US20090170814 T JJ O
disorders US20090170814 T NNS O
; US20090170814 T : O
antiinflammatory US20090170814 T JJ O
agents US20090170814 T NNS O
; US20090170814 T : O
antiischemic US20090170814 T JJ O
agents US20090170814 T NNS O
; US20090170814 T : O
neuropathic US20090170814 T JJ O
pain US20090170814 T NN O
; US20090170814 T : O
antiepileptic US20090170814 T JJ O
agents US20090170814 T NNS O
; US20090170814 T : O
Parkinson US20090170814 T NNP O
's US20090170814 T POS O
disease US20090170814 T NN O
; US20090170814 T : O
Alzheimer US20090170814 T NNP O
's US20090170814 T POS O
disease US20090170814 T NN O
; US20090170814 T : O
antidiabetic US20090170814 T JJ O
agents US20090170814 T NNS O
; US20090170814 T : O
3- US20090170814 T JJ O
( US20090170814 T ( O
6-Hydroxy-2-methyl-3,4,7,8,9,10-hexahydro-7,10-methano-2H US20090170814 T JJ O
-benzo US20090170814 T NNP O
[ US20090170814 T NNP O
h US20090170814 T VBD O
] US20090170814 T NNP O
chromen-2-yl US20090170814 T NN O
) US20090170814 T ) O
-propionic US20090170814 T JJ O
acid US20090170814 T NN O
methyl US20090170814 T NN O
ester US20090170814 T NN O
. US20090170814 T . O

Application CN102488678A T NN O
of CN102488678A T IN O
embelin CN102488678A T NN O
to CN102488678A T TO O
preparation CN102488678A T NN O
of CN102488678A T IN O
medicament CN102488678A T NN O
for CN102488678A T IN O
treating CN102488678A T VBG O
autoimmune CN102488678A T JJ O
disease CN102488678A T NN O
. CN102488678A T . O

The US20080132460 A DT O
application US20080132460 A NN O
discloses US20080132460 A VBZ O
a US20080132460 A DT O
role US20080132460 A NN O
of US20080132460 A IN O
p62 US20080132460 A NN I-UN
in US20080132460 A IN O
aging-related US20080132460 A JJ O
disease US20080132460 A NN O
, US20080132460 A , O
such US20080132460 A JJ O
as US20080132460 A IN O
development US20080132460 A NN O
of US20080132460 A IN O
obesity US20080132460 A NN O
, US20080132460 A , O
type US20080132460 A NN O
2 US20080132460 A CD O
diabetes US20080132460 A NNS O
mellitus US20080132460 A RB O
, US20080132460 A , O
non-alcoholic US20080132460 A JJ O
fatty US20080132460 A NN O
liver US20080132460 A NN O
, US20080132460 A , O
various US20080132460 A JJ O
tumors US20080132460 A NNS O
, US20080132460 A , O
increased US20080132460 A VBD O
male US20080132460 A JJ O
mortality US20080132460 A NN O
, US20080132460 A , O
intracellular US20080132460 A JJ O
inclusion US20080132460 A NN O
named US20080132460 A VBN O
sequestosome US20080132460 A NN O
, US20080132460 A , O
and US20080132460 A CC O
redox US20080132460 A JJ O
regulation US20080132460 A NN O
. US20080132460 A . O

Further US20080132460 A RB O
, US20080132460 A , O
transgenic US20080132460 A JJ O
mice US20080132460 A NN O
containing US20080132460 A VBG O
a US20080132460 A DT O
mutation US20080132460 A NN O
in US20080132460 A IN O
the US20080132460 A DT O
p62 US20080132460 A NN I-UN
gene US20080132460 A NN O
and US20080132460 A CC O
having US20080132460 A VBG O
a US20080132460 A DT O
functionally US20080132460 A RB O
disrupted US20080132460 A VBN O
p62 US20080132460 A JJ I-UN
gene US20080132460 A NN O
locus US20080132460 A NN O
are US20080132460 A VBP O
also US20080132460 A RB O
disclosed US20080132460 A VBN O
. US20080132460 A . O

Polymorph WO2011005645A1 T NNP O
of WO2011005645A1 T IN O
[ WO2011005645A1 T NNP O
4,6-bis WO2011005645A1 T JJ O
( WO2011005645A1 T ( O
dimethylamino WO2011005645A1 T NN O
) WO2011005645A1 T ) O
-2- WO2011005645A1 T NN O
( WO2011005645A1 T ( O
4- WO2011005645A1 T JJ O
{ WO2011005645A1 T ( O
[ WO2011005645A1 T JJ O
4- WO2011005645A1 T JJ O
( WO2011005645A1 T ( O
trifluoromethyl WO2011005645A1 T NN O
) WO2011005645A1 T ) O
benzoyl WO2011005645A1 T NN O
] WO2011005645A1 T NNP O
amino WO2011005645A1 T NN O
} WO2011005645A1 T ) O
benzyl WO2011005645A1 T NN O
) WO2011005645A1 T ) O
pyrimidin-5-yl WO2011005645A1 T NN O
] WO2011005645A1 T NN O
. WO2011005645A1 T . O

Compositions US20090274766 T NNS O
and US20090274766 T CC O
Methods US20090274766 T NNS O
For US20090274766 T IN O
Inhibiting US20090274766 T VBG O
Gastric US20090274766 T NNP O
Acide US20090274766 T NNP O
Secretion US20090274766 T NNP O
Using US20090274766 T NNP O
Derivatives US20090274766 T NNP O
of US20090274766 T IN O
Small US20090274766 T NNP O
Dicarboxylic US20090274766 T NNP O
Acids US20090274766 T NNP O
in US20090274766 T IN O
Combination US20090274766 T NNP O
with US20090274766 T IN O
PPI US20090274766 T NNP O
. US20090274766 T . O

Ointment CN101028381A T NN O
for CN101028381A T IN O
treating CN101028381A T VBG O
burn CN101028381A T NN O
and CN101028381A T CC O
scald CN101028381A T NN O
. CN101028381A T . O

An CN101028381A A DT O
ointment CN101028381A A NN O
for CN101028381A A IN O
treating CN101028381A A VBG O
burn CN101028381A A NN O
and CN101028381A A CC O
scald CN101028381A A NN O
is CN101028381A A VBZ O
prepared CN101028381A A VBN O
from CN101028381A A IN O
calcite CN101028381A A NN O
( CN101028381A A ( O
90-95 CN101028381A A JJ O
Wt CN101028381A A NNP O
. CN101028381A A . O

Portions CN101028381A A NNS O
) CN101028381A A ) O
, CN101028381A A , O
borneol CN101028381A A FW O
( CN101028381A A ( O
2.5-5 CN101028381A A JJ O
) CN101028381A A ) O
and CN101028381A A CC O
tea CN101028381A A JJ O
oil CN101028381A A NN O
( CN101028381A A ( O
2.5-5 CN101028381A A JJ O
) CN101028381A A ) O
. CN101028381A A . O

Application CN103239465A T NN O
of CN103239465A T IN O
quercetin-3-O-alpha-L-rhamnose-3'-alpha-L-rhamnoside CN103239465A T NN O
in CN103239465A T IN O
preparation CN103239465A T NN O
of CN103239465A T IN O
medicine CN103239465A T NN O
for CN103239465A T IN O
treating CN103239465A T VBG O
cardiovascular CN103239465A T JJ O
and CN103239465A T CC O
cerebrovascular CN103239465A T JJ O
diseases CN103239465A T NNS O
. CN103239465A T . O

Pet CA2767335C T NNP O
food CA2767335C T NN O
compositions CA2767335C T NNS O
including CA2767335C T VBG O
a CA2767335C T DT O
sustained-release CA2767335C T JJ O
lipoic CA2767335C T NN O
acid CA2767335C T NN O
and CA2767335C T CC O
methods CA2767335C T NNS O
of CA2767335C T IN O
manufacture CA2767335C T NN O
and CA2767335C T CC O
use CA2767335C T NN O
thereof CA2767335C T NN O
. CA2767335C T . O

Anti-wssv WO2012006946A1 T JJ O
and/or WO2012006946A1 T NN O
tsv WO2012006946A1 T NN O
nucleic WO2012006946A1 T JJ O
acid WO2012006946A1 T JJ O
drug WO2012006946A1 T NN O
. WO2012006946A1 T . O

Treatment EP1068328B1 T NN O
and EP1068328B1 T CC O
diagnosis EP1068328B1 T NN O
of EP1068328B1 T IN O
staphylococcal EP1068328B1 T JJ O
infections EP1068328B1 T NNS O
. EP1068328B1 T . O

The EP1068328B1 A DT O
present EP1068328B1 A JJ O
invention EP1068328B1 A NN O
concerns EP1068328B1 A VBZ O
the EP1068328B1 A DT O
treatment EP1068328B1 A NN O
and EP1068328B1 A CC O
diagnosis EP1068328B1 A NN O
of EP1068328B1 A IN O
Staphylococcal EP1068328B1 A JJ O
infections EP1068328B1 A NNS O
, EP1068328B1 A , O
particularly EP1068328B1 A RB O
those EP1068328B1 A DT O
of EP1068328B1 A IN O
Staphylococcus EP1068328B1 A NNP O
aureus EP1068328B1 A NN O
, EP1068328B1 A , O
and EP1068328B1 A CC O
provides EP1068328B1 A VBZ O
a EP1068328B1 A DT O
protein EP1068328B1 A NN O
, EP1068328B1 A , O
epitopes EP1068328B1 A NNS O
of EP1068328B1 A IN O
same EP1068328B1 A JJ O
, EP1068328B1 A , O
and EP1068328B1 A CC O
antibodies EP1068328B1 A NNS O
and EP1068328B1 A CC O
other EP1068328B1 A JJ O
binding EP1068328B1 A NN O
and EP1068328B1 A CC O
neutralising EP1068328B1 A VBG O
agents EP1068328B1 A NNS O
specific EP1068328B1 A JJ O
against EP1068328B1 A IN O
same EP1068328B1 A JJ O
. EP1068328B1 A . O

Suspension CN103301075A T NN O
granules CN103301075A T NNS O
for CN103301075A T IN O
cefixime CN103301075A T JJ O
composition CN103301075A T NN O
and CN103301075A T CC O
preparation CN103301075A T NN O
method CN103301075A T NN O
thereof CN103301075A T NN O
. CN103301075A T . O

Topical US20060210553 T JJ O
use US20060210553 T NN O
of US20060210553 T IN O
tyrosine US20060210553 T JJ O
kinase US20060210553 T NN O
inhibitors US20060210553 T NNS O
of US20060210553 T IN O
microbial US20060210553 T JJ O
origin US20060210553 T NN O
to US20060210553 T TO O
prevent US20060210553 T VB O
and US20060210553 T CC O
treat US20060210553 T VB O
skin US20060210553 T JJ O
disorders US20060210553 T NNS O
characterised US20060210553 T VBN O
by US20060210553 T IN O
excesssive US20060210553 T JJ O
cell US20060210553 T NN O
proliferation US20060210553 T NN O
. US20060210553 T . O

Compounds CN103665004A T NNS O
for CN103665004A T IN O
treating CN103665004A T VBG O
narrow CN103665004A T JJ O
chamber CN103665004A T NN O
angle CN103665004A T NN O
and CN103665004A T CC O
application CN103665004A T NN O
thereof CN103665004A T NN O
. CN103665004A T . O

Febuxostat CN102988326A T NNP O
tablets CN102988326A T NNS O
and CN102988326A T CC O
preparation CN102988326A T NN O
method CN102988326A T NN O
and CN102988326A T CC O
detection CN102988326A T NN O
method CN102988326A T NN O
thereof CN102988326A T NN O
. CN102988326A T . O

Tetrahydro-isoalpha US20110136917 T JJ O
acid US20110136917 T NN O
compositions US20110136917 T NNS O
and US20110136917 T CC O
methods US20110136917 T NNS O
for US20110136917 T IN O
weight US20110136917 T JJ O
management US20110136917 T NN O
. US20110136917 T . O

Benzocycloheptane US20110046139 T NNP O
and US20110046139 T CC O
benzoxepine US20110046139 T JJ O
derivatives US20110046139 T NNS O
. US20110046139 T . O

The US20110046139 A DT O
claimed US20110046139 A JJ O
compounds US20110046139 A NNS O
are US20110046139 A VBP O
useful US20110046139 A JJ O
for US20110046139 A IN O
the US20110046139 A DT O
treatment US20110046139 A NN O
of US20110046139 A IN O
a US20110046139 A DT O
disease US20110046139 A NN O
, US20110046139 A , O
the US20110046139 A DT O
treatment US20110046139 A NN O
of US20110046139 A IN O
which US20110046139 A WDT O
is US20110046139 A VBZ O
affected US20110046139 A VBN O
, US20110046139 A , O
mediated US20110046139 A VBD O
or US20110046139 A CC O
facilitated US20110046139 A VBN O
by US20110046139 A IN O
activating US20110046139 A VBG O
the US20110046139 A DT O
GHS1A-r US20110046139 A NNP I-UN
receptor US20110046139 A NN O
. US20110046139 A . O

treating US7825158 T VBG O
amphetamine US7825158 T NN O
or US7825158 T CC O
methamphetamine US7825158 T NN O
dependence US7825158 T NN O
by US7825158 T IN O
administering US7825158 T VBG O
an US7825158 T DT O
effective US7825158 T JJ O
amount US7825158 T NN O
of US7825158 T IN O
( US7825158 T ( O
- US7825158 T : O
) US7825158 T ) O
1- US7825158 T CD O
( US7825158 T ( O
benzofuran-2-yl US7825158 T NN O
) US7825158 T ) O
-2-propylaminopentane US7825158 T NN O
, US7825158 T , O
or US7825158 T CC O
a US7825158 T DT O
pharmaceutical US7825158 T JJ O
acceptable US7825158 T JJ O
acid US7825158 T NN O
salt US7825158 T NN O
thereof US7825158 T NN O
, US7825158 T , O
to US7825158 T TO O
an US7825158 T DT O
amphetamine US7825158 T NN O
or US7825158 T CC O
methamphetamine-dependent US7825158 T JJ O
patient US7825158 T NN O
. US7825158 T . O

Bioresorbable US20120148667 T JJ O
fillers US20120148667 T NNS O
constituted US20120148667 T VBN O
by US20120148667 T IN O
phospholipid US20120148667 T JJ O
liposomes US20120148667 T NNS O
and US20120148667 T CC O
hyaluronic US20120148667 T JJ O
acid US20120148667 T NN O
and/or US20120148667 T IN O
the US20120148667 T DT O
derivatives US20120148667 T NNS O
thereof US20120148667 T VBP O
. US20120148667 T . O

High-permeability CN103284942A T NNP O
emulsifiable CN103284942A T JJ O
paste CN103284942A T NN O
for CN103284942A T IN O
diminishing CN103284942A T VBG O
inflammation CN103284942A T NN O
and CN103284942A T CC O
easing CN103284942A T VBG O
pain CN103284942A T NN O
. CN103284942A T . O

valacyclovir US20090124639 T JJ O
formulations US20090124639 T NNS O
. US20090124639 T . O

Methods WO2014063189A1 T NNS O
and WO2014063189A1 T CC O
products WO2014063189A1 T NNS O
for WO2014063189A1 T IN O
preventing WO2014063189A1 T VBG O
and/or WO2014063189A1 T JJ O
treating WO2014063189A1 T VBG O
a WO2014063189A1 T DT O
stress WO2014063189A1 T NN O
induced WO2014063189A1 T VBN O
cardiomyopathy WO2014063189A1 T NN O
. WO2014063189A1 T . O

Use CN103054850A T NNP O
of CN103054850A T IN O
pinocembrin CN103054850A T NN O
in CN103054850A T IN O
preparation CN103054850A T NN O
of CN103054850A T IN O
medicines CN103054850A T NNS O
for CN103054850A T IN O
treating CN103054850A T VBG O
neurodegenerative CN103054850A T JJ O
diseases CN103054850A T NNS O
. CN103054850A T . O

Concrete CN103054850A A NNP O
researches CN103054850A A NNS O
prove CN103054850A A VBP O
that CN103054850A A IN O
pinocembrin CN103054850A A NN O
has CN103054850A A VBZ O
the CN103054850A A DT O
nerve CN103054850A A NN O
protection CN103054850A A NN O
effect CN103054850A A NN O
on CN103054850A A IN O
Alzheimer CN103054850A A NNP O
disease CN103054850A A NN O
beta-amyloid CN103054850A A JJ I-UN
protein CN103054850A A NN I-UN
( CN103054850A A ( O
Abeta CN103054850A A NNP I-UN
) CN103054850A A ) O
and CN103054850A A CC O
1-methyl-4-phenylpyridine CN103054850A A JJ O
( CN103054850A A ( O
MPP CN103054850A A NNP O
< CN103054850A A NNP O
+ CN103054850A A NNP O
> CN103054850A A NNP O
) CN103054850A A ) O
induced CN103054850A A VBD O
Parkinson CN103054850A A NNP O
's CN103054850A A POS O
disease CN103054850A A NN O
models CN103054850A A NNS O
, CN103054850A A , O
so CN103054850A A IN O
pinocembrin CN103054850A A JJ O
can CN103054850A A MD O
be CN103054850A A VB O
used CN103054850A A VBN O
for CN103054850A A IN O
preparing CN103054850A A VBG O
medicines CN103054850A A NNS O
for CN103054850A A IN O
preventing CN103054850A A VBG O
and CN103054850A A CC O
treating CN103054850A A VBG O
the CN103054850A A DT O
neurodegenerative CN103054850A A JJ O
diseases CN103054850A A NNS O
. CN103054850A A . O

Regenerating WO2009139876A2 T VBG O
and WO2009139876A2 T CC O
enhancing WO2009139876A2 T VBG O
development WO2009139876A2 T NN O
of WO2009139876A2 T IN O
muscle WO2009139876A2 T NN O
tissue WO2009139876A2 T NN O
. WO2009139876A2 T . O

The WO2009139876A2 A DT O
present WO2009139876A2 A JJ O
invention WO2009139876A2 A NN O
pertains WO2009139876A2 A NNS O
to WO2009139876A2 A TO O
cdk9-55 WO2009139876A2 A JJ I-UN
and WO2009139876A2 A CC O
its WO2009139876A2 A PRP$ O
ability WO2009139876A2 A NN O
to WO2009139876A2 A TO O
regenerate WO2009139876A2 A VB O
muscle WO2009139876A2 A NN O
tissue WO2009139876A2 A NN O
and WO2009139876A2 A CC O
enhance WO2009139876A2 A NN O
development WO2009139876A2 A NN O
. WO2009139876A2 A . O

Cdk9-55 WO2009139876A2 A NNP I-UN
is WO2009139876A2 A VBZ O
specifically WO2009139876A2 A RB O
induced WO2009139876A2 A JJ O
upon WO2009139876A2 A IN O
satellite WO2009139876A2 A NN O
cell WO2009139876A2 A NN O
differentiation WO2009139876A2 A NN O
and WO2009139876A2 A CC O
is WO2009139876A2 A VBZ O
necessary WO2009139876A2 A JJ O
for WO2009139876A2 A IN O
the WO2009139876A2 A DT O
gene WO2009139876A2 A NN O
expression WO2009139876A2 A NN O
reprogramming WO2009139876A2 A VBG O
required WO2009139876A2 A VBN O
to WO2009139876A2 A TO O
complete WO2009139876A2 A VB O
the WO2009139876A2 A DT O
regeneration WO2009139876A2 A NN O
process WO2009139876A2 A NN O
. WO2009139876A2 A . O

Inhibitors WO2010118309A3 T NNS O
of WO2010118309A3 T IN O
stat3 WO2010118309A3 T NN I-UN
and WO2010118309A3 T CC O
uses WO2010118309A3 T VBZ O
thereof WO2010118309A3 T NN O
. WO2010118309A3 T . O

Compounds WO2010118309A3 A NNS O
which WO2010118309A3 A WDT O
inhibit WO2010118309A3 A VBP O
the WO2010118309A3 A DT O
activity WO2010118309A3 A NN O
of WO2010118309A3 A IN O
signal WO2010118309A3 A JJ I-UN
transducer WO2010118309A3 A NN I-UN
and WO2010118309A3 A CC I-UN
activator WO2010118309A3 A NN I-UN
of WO2010118309A3 A IN I-UN
transcription WO2010118309A3 A NN I-UN
3 WO2010118309A3 A CD I-UN
( WO2010118309A3 A ( O
STAT3 WO2010118309A3 A NNP I-UN
) WO2010118309A3 A ) O
are WO2010118309A3 A VBP O
provided WO2010118309A3 A VBN O
together WO2010118309A3 A RB O
with WO2010118309A3 A IN O
methods WO2010118309A3 A NNS O
of WO2010118309A3 A IN O
making WO2010118309A3 A VBG O
and WO2010118309A3 A CC O
using WO2010118309A3 A VBG O
the WO2010118309A3 A DT O
same WO2010118309A3 A JJ O
. WO2010118309A3 A . O

The WO2010118309A3 A DT O
compounds WO2010118309A3 A NNS O
are WO2010118309A3 A VBP O
designed WO2010118309A3 A VBN O
to WO2010118309A3 A TO O
bind WO2010118309A3 A VB O
to WO2010118309A3 A TO O
the WO2010118309A3 A DT O
SH2 WO2010118309A3 A NNP O
domain WO2010118309A3 A NN O
of WO2010118309A3 A IN O
STAT3 WO2010118309A3 A NNP I-UN
, WO2010118309A3 A , O
preventing WO2010118309A3 A VBG O
STAT3 WO2010118309A3 A NNP I-UN
from WO2010118309A3 A IN O
binding WO2010118309A3 A VBG O
to WO2010118309A3 A TO O
receptors WO2010118309A3 A NNS O
for WO2010118309A3 A IN O
interleukin-6 WO2010118309A3 A JJ I-UN
family WO2010118309A3 A NN O
cytokines WO2010118309A3 A NNS O
, WO2010118309A3 A , O
growth WO2010118309A3 A NN O
factors WO2010118309A3 A NNS O
such WO2010118309A3 A JJ O
as WO2010118309A3 A IN O
the WO2010118309A3 A DT O
platelet-derived WO2010118309A3 A JJ O
growth WO2010118309A3 A NN O
factor WO2010118309A3 A NN O
, WO2010118309A3 A , O
the WO2010118309A3 A DT O
epidermal WO2010118309A3 A JJ I-UN
growth WO2010118309A3 A NN I-UN
factor WO2010118309A3 A NN I-UN
, WO2010118309A3 A , O
vascular WO2010118309A3 A JJ O
endothelial WO2010118309A3 A JJ O
growth WO2010118309A3 A NN O
factor WO2010118309A3 A NN O
, WO2010118309A3 A , O
and WO2010118309A3 A CC O
other WO2010118309A3 A JJ O
signaling WO2010118309A3 A VBG O
molecules WO2010118309A3 A NNS O
such WO2010118309A3 A JJ O
as WO2010118309A3 A IN O
leptin WO2010118309A3 A NN O
. WO2010118309A3 A . O

Blocking WO2010118309A3 A VBG O
these WO2010118309A3 A DT O
interactions WO2010118309A3 A NNS O
prevents WO2010118309A3 A NNS O
STAT3 WO2010118309A3 A VBP I-UN
from WO2010118309A3 A IN O
being WO2010118309A3 A VBG O
phosphorylated WO2010118309A3 A VBN O
on WO2010118309A3 A IN O
Tyr705 WO2010118309A3 A NNP O
, WO2010118309A3 A , O
which WO2010118309A3 A WDT O
is WO2010118309A3 A VBZ O
required WO2010118309A3 A VBN O
for WO2010118309A3 A IN O
the WO2010118309A3 A DT O
dimerization WO2010118309A3 A NN O
of WO2010118309A3 A IN O
STAT3 WO2010118309A3 A NNP I-UN
, WO2010118309A3 A , O
translocation WO2010118309A3 A NN O
to WO2010118309A3 A TO O
the WO2010118309A3 A DT O
nucleus WO2010118309A3 A NN O
, WO2010118309A3 A , O
binding WO2010118309A3 A VBG O
to WO2010118309A3 A TO O
STAT3 WO2010118309A3 A NNP I-UN
response WO2010118309A3 A NN O
elements WO2010118309A3 A NNS O
on WO2010118309A3 A IN O
promotors WO2010118309A3 A NNS O
, WO2010118309A3 A , O
and WO2010118309A3 A CC O
transcription WO2010118309A3 A NN O
of WO2010118309A3 A IN O
genes WO2010118309A3 A NNS O
. WO2010118309A3 A . O

In WO2010118309A3 A IN O
addition WO2010118309A3 A NN O
to WO2010118309A3 A TO O
these WO2010118309A3 A DT O
activities WO2010118309A3 A NNS O
, WO2010118309A3 A , O
binding WO2010118309A3 A VBG O
to WO2010118309A3 A TO O
the WO2010118309A3 A DT O
SH2 WO2010118309A3 A NNP O
domain WO2010118309A3 A NN O
of WO2010118309A3 A IN O
STAT3 WO2010118309A3 A NNP I-UN
breaks WO2010118309A3 A VBZ O
up WO2010118309A3 A RP O
pre-formed WO2010118309A3 A JJ O
dimmers WO2010118309A3 A NNS O
, WO2010118309A3 A , O
thereby WO2010118309A3 A RB O
preventing WO2010118309A3 A VBG O
the WO2010118309A3 A DT O
transcriptional WO2010118309A3 A JJ O
activity WO2010118309A3 A NN O
of WO2010118309A3 A IN O
the WO2010118309A3 A DT O
inhibitor WO2010118309A3 A NN O
. WO2010118309A3 A . O

Methods US20110189199 T NNS O
for US20110189199 T IN O
p2ry5 US20110189199 T NN I-UN
mediated US20110189199 T VBN O
regulation US20110189199 T NN O
of US20110189199 T IN O
hair US20110189199 T NN O
growth US20110189199 T NN O
and US20110189199 T CC O
mutants US20110189199 T NNS O
thereof US20110189199 T NN O
. US20110189199 T . O

The US20110189199 A DT O
invention US20110189199 A NN O
provides US20110189199 A VBZ O
for US20110189199 A IN O
a US20110189199 A DT O
method US20110189199 A NN O
for US20110189199 A IN O
screening US20110189199 A VBG O
compounds US20110189199 A NNS O
that US20110189199 A WDT O
bind US20110189199 A VBP O
to US20110189199 A TO O
and US20110189199 A CC O
modulate US20110189199 A VB O
the US20110189199 A DT O
hair-specific US20110189199 A JJ O
G-protein US20110189199 A NNP O
coupled US20110189199 A VBD O
receptor US20110189199 A NN O
, US20110189199 A , O
P2RY5 US20110189199 A NNP I-UN
. US20110189199 A . O

The US20110189199 A DT O
invention US20110189199 A NN O
further US20110189199 A RBR O
provides US20110189199 A VBZ O
for US20110189199 A IN O
methods US20110189199 A NNS O
for US20110189199 A IN O
controlling US20110189199 A VBG O
hair US20110189199 A NN O
growth US20110189199 A NN O
by US20110189199 A IN O
administering US20110189199 A VBG O
a US20110189199 A DT O
P2RY5 US20110189199 A NNP I-UN
modulating US20110189199 A VBG O
compound US20110189199 A NN O
to US20110189199 A TO O
a US20110189199 A DT O
subject US20110189199 A NN O
. US20110189199 A . O

Modulators WO2012021647A2 T NNS O
of WO2012021647A2 T IN O
nod1 WO2012021647A2 T NN I-UN
and WO2012021647A2 T CC O
nod2 WO2012021647A2 T JJ I-UN
signaling WO2012021647A2 T NN O
, WO2012021647A2 T , O
methods WO2012021647A2 T NNS O
of WO2012021647A2 T IN O
identifying WO2012021647A2 T VBG O
modulators WO2012021647A2 T NNS O
of WO2012021647A2 T IN O
nod1 WO2012021647A2 T NN I-UN
and WO2012021647A2 T CC O
nod2 WO2012021647A2 T JJ I-UN
signaling WO2012021647A2 T NN O
, WO2012021647A2 T , O
and WO2012021647A2 T CC O
uses WO2012021647A2 T VBZ O
thereof WO2012021647A2 T NN O
. WO2012021647A2 T . O

Disclosed WO2012021647A2 A VBN O
herein WO2012021647A2 A NNS O
are WO2012021647A2 A VBP O
compositions WO2012021647A2 A NNS O
and WO2012021647A2 A CC O
methods WO2012021647A2 A NNS O
relating WO2012021647A2 A VBG O
to WO2012021647A2 A TO O
modulators WO2012021647A2 A NNS O
of WO2012021647A2 A IN O
Nod-like WO2012021647A2 A JJ O
Receptors WO2012021647A2 A NNS O
NOD1 WO2012021647A2 A NNP I-UN
( WO2012021647A2 A ( O
NLRC1 WO2012021647A2 A NNP I-UN
) WO2012021647A2 A ) O
and WO2012021647A2 A CC O
NOD2 WO2012021647A2 A NNP I-UN
( WO2012021647A2 A ( O
NLRC2 WO2012021647A2 A NNP I-UN
) WO2012021647A2 A ) O
signaling WO2012021647A2 A NN O
. WO2012021647A2 A . O

Further WO2012021647A2 A RB O
provided WO2012021647A2 A VBN O
are WO2012021647A2 A VBP O
methods WO2012021647A2 A NNS O
of WO2012021647A2 A IN O
identifying WO2012021647A2 A VBG O
modulators WO2012021647A2 A NNS O
of WO2012021647A2 A IN O
Nod-like WO2012021647A2 A JJ O
Receptors WO2012021647A2 A NNPS O
NOD1 WO2012021647A2 A NNP I-UN
and WO2012021647A2 A CC O
NOD2 WO2012021647A2 A NNP I-UN
activity WO2012021647A2 A NN O
. WO2012021647A2 A . O

Enteric-coated CN101006994A T JJ O
capsules CN101006994A T NNS O
of CN101006994A T IN O
allimin CN101006994A T NN O
and CN101006994A T CC O
its CN101006994A T PRP$ O
preparation CN101006994A T NN O
method CN101006994A T NN O
. CN101006994A T . O

The CN101006994A A DT O
invention CN101006994A A NN O
relates CN101006994A A VBZ O
to CN101006994A A TO O
a CN101006994A A DT O
kind CN101006994A A NN O
of CN101006994A A IN O
allicin CN101006994A A JJ O
capsulate CN101006994A A NN O
enterosolubilis CN101006994A A NN O
as CN101006994A A RB O
well CN101006994A A RB O
as CN101006994A A IN O
its CN101006994A A PRP$ O
preparing CN101006994A A NN O
method CN101006994A A NN O
. CN101006994A A . O

The CN101006994A A DT O
invention CN101006994A A NN O
is CN101006994A A VBZ O
composed CN101006994A A VBN O
by CN101006994A A IN O
garlic CN101006994A A JJ O
oil CN101006994A A NN O
, CN101006994A A , O
beta-schardinger CN101006994A A NN O
dextrin CN101006994A A NN O
and CN101006994A A CC O
starches CN101006994A A NNS O
. CN101006994A A . O

The CN101006994A A DT O
preparing CN101006994A A JJ O
procedure CN101006994A A NN O
includes CN101006994A A VBZ O
the CN101006994A A DT O
following CN101006994A A JJ O
steps CN101006994A A NNS O
: CN101006994A A : O
putting CN101006994A A VBG O
purified CN101006994A A JJ O
water CN101006994A A NN O
and CN101006994A A CC O
beta-schardinger CN101006994A A NN O
into CN101006994A A IN O
the CN101006994A A DT O
castration CN101006994A A NN O
jar CN101006994A A NN O
in CN101006994A A IN O
turns CN101006994A A NNS O
and CN101006994A A CC O
heating CN101006994A A VBG O
them CN101006994A A PRP O
; CN101006994A A : O
stirring CN101006994A A VBG O
to CN101006994A A TO O
get CN101006994A A VB O
the CN101006994A A DT O
emulsified CN101006994A A JJ O
suspension CN101006994A A NN O
; CN101006994A A : O
putting CN101006994A A VBG O
garlic CN101006994A A JJ O
oil CN101006994A A NN O
into CN101006994A A IN O
the CN101006994A A DT O
jar CN101006994A A NN O
and CN101006994A A CC O
keeping CN101006994A A VBG O
stirring CN101006994A A VBG O
at CN101006994A A IN O
a CN101006994A A DT O
certain CN101006994A A JJ O
temperature CN101006994A A NN O
for CN101006994A A IN O
several CN101006994A A JJ O
hours CN101006994A A NNS O
; CN101006994A A : O
pumping CN101006994A A VBG O
the CN101006994A A DT O
mentioned CN101006994A A JJ O
materials CN101006994A A NNS O
into CN101006994A A IN O
the CN101006994A A DT O
storage CN101006994A A NN O
tank CN101006994A A NN O
, CN101006994A A , O
stetting CN101006994A A VBG O
at CN101006994A A IN O
low CN101006994A A JJ O
temperature CN101006994A A NN O
; CN101006994A A : O
removing CN101006994A A VBG O
water CN101006994A A NN O
through CN101006994A A IN O
filtering CN101006994A A NN O
; CN101006994A A : O
after CN101006994A A IN O
heating CN101006994A A NN O
, CN101006994A A , O
airblast CN101006994A A IN O
drying CN101006994A A NN O
, CN101006994A A , O
pulverizing CN101006994A A VBG O
and CN101006994A A CC O
sieving CN101006994A A VBG O
the CN101006994A A DT O
materials CN101006994A A NNS O
, CN101006994A A , O
mixing CN101006994A A VBG O
them CN101006994A A PRP O
with CN101006994A A IN O
starches CN101006994A A NNS O
; CN101006994A A : O
getting CN101006994A A VBG O
the CN101006994A A DT O
particles CN101006994A A NNS O
or CN101006994A A CC O
micro CN101006994A A JJ O
pallets CN101006994A A NNS O
with CN101006994A A IN O
75 CN101006994A A CD O
% CN101006994A A NN O
as CN101006994A A IN O
the CN101006994A A DT O
demulcent CN101006994A A NN O
; CN101006994A A : O
cryodrying CN101006994A A VBG O
; CN101006994A A : O
polishing CN101006994A A VBG O
; CN101006994A A : O
loading CN101006994A A VBG O
the CN101006994A A DT O
materials CN101006994A A NNS O
into CN101006994A A IN O
the CN101006994A A DT O
No CN101006994A A NNP O
. CN101006994A A . O

1 CN101006994A A CD O
capsulae CN101006994A A NN O
enterosolubilis CN101006994A A NN O
; CN101006994A A : O
packaging CN101006994A A NN O
. CN101006994A A . O

The CN101006994A A DT O
invention CN101006994A A NN O
belongs CN101006994A A VBZ O
to CN101006994A A TO O
hard CN101006994A A VB O
capsule CN101006994A A NN O
dosage CN101006994A A NN O
form CN101006994A A NN O
; CN101006994A A : O
it CN101006994A A PRP O
's CN101006994A A VBZ O
capsulae CN101006994A A JJ O
enterosolubilis CN101006994A A NN O
( CN101006994A A ( O
white CN101006994A A JJ O
or CN101006994A A CC O
off-white CN101006994A A JJ O
color CN101006994A A NN O
particles CN101006994A A NNS O
) CN101006994A A ) O
; CN101006994A A : O
its CN101006994A A PRP$ O
specification CN101006994A A NN O
is CN101006994A A VBZ O
20mg/grain CN101006994A A CD O
. CN101006994A A . O

The CN101006994A A DT O
advantages CN101006994A A NNS O
of CN101006994A A IN O
the CN101006994A A DT O
invention CN101006994A A NN O
includes CN101006994A A VBZ O
: CN101006994A A : O
up-to-date CN101006994A A JJ O
idea CN101006994A A NN O
, CN101006994A A , O
proper CN101006994A A JJ O
design CN101006994A A NN O
, CN101006994A A , O
standard CN101006994A A JJ O
technology CN101006994A A NN O
, CN101006994A A , O
simple CN101006994A A JJ O
preparing CN101006994A A VBG O
method CN101006994A A NN O
, CN101006994A A , O
easily CN101006994A A RB O
available CN101006994A A JJ O
medicine CN101006994A A NN O
, CN101006994A A , O
low CN101006994A A JJ O
cost CN101006994A A NN O
, CN101006994A A , O
convenient CN101006994A A NN O
to CN101006994A A TO O
take CN101006994A A VB O
with CN101006994A A IN O
, CN101006994A A , O
easy CN101006994A A JJ O
absorption CN101006994A A NN O
by CN101006994A A IN O
intestinal CN101006994A A JJ O
tract CN101006994A A NN O
, CN101006994A A , O
no CN101006994A A DT O
gastric CN101006994A A JJ O
irritation CN101006994A A NN O
, CN101006994A A , O
excellent CN101006994A A JJ O
curative CN101006994A A JJ O
effect CN101006994A A NN O
, CN101006994A A , O
good CN101006994A A JJ O
acceptability CN101006994A A NN O
, CN101006994A A , O
no CN101006994A A DT O
pollution CN101006994A A NN O
and CN101006994A A CC O
it CN101006994A A PRP O
's CN101006994A A VBZ O
easy CN101006994A A JJ O
to CN101006994A A TO O
realize CN101006994A A VB O
production CN101006994A A NN O
in CN101006994A A IN O
quantity CN101006994A A NN O
. CN101006994A A . O

The CN101006994A A DT O
product CN101006994A A NN O
is CN101006994A A VBZ O
applicable CN101006994A A JJ O
to CN101006994A A TO O
prevent CN101006994A A VB O
and CN101006994A A CC O
treat CN101006994A A VB O
deep CN101006994A A JJ O
part CN101006994A A NN O
fungus CN101006994A A JJ O
infection CN101006994A A NN O
such CN101006994A A JJ O
as CN101006994A A IN O
bellows CN101006994A A NNS O
and CN101006994A A CC O
alimentary CN101006994A A JJ O
canal CN101006994A A NN O
fungus CN101006994A A JJ O
infection CN101006994A A NN O
; CN101006994A A : O
blastomyces CN101006994A A NNS O
alb CN101006994A A VBP O
cans CN101006994A A NNS O
bacteria CN101006994A A NNS O
, CN101006994A A , O
chronic CN101006994A A JJ O
and CN101006994A A CC O
acute CN101006994A A JJ O
enteritis CN101006994A A NN O
, CN101006994A A , O
whooping CN101006994A A JJ O
cough CN101006994A A NN O
and CN101006994A A CC O
so CN101006994A A RB O
on CN101006994A A IN O
. CN101006994A A . O

Bicalutamide WO2006090129A3 T NNP O
for WO2006090129A3 T IN O
delivering WO2006090129A3 T VBG O
increasing WO2006090129A3 T VBG O
steady WO2006090129A3 T JJ O
state WO2006090129A3 T NN O
plasma WO2006090129A3 T NN O
levels WO2006090129A3 T NNS O
. WO2006090129A3 T . O

Small US20100215635 T JJ O
molecules US20100215635 T NNS O
to US20100215635 T TO O
induce US20100215635 T VB O
weight US20100215635 T JJ O
loss US20100215635 T NN O
or US20100215635 T CC O
to US20100215635 T TO O
reduce US20100215635 T VB O
weight US20100215635 T NN O
gain US20100215635 T NN O
. US20100215635 T . O

Embodiments US20100215635 A NNS O
of US20100215635 A IN O
the US20100215635 A DT O
present US20100215635 A JJ O
invention US20100215635 A NN O
include US20100215635 A VBP O
the US20100215635 A DT O
use US20100215635 A NN O
of US20100215635 A IN O
heterocyclic US20100215635 A JJ O
trialkyl US20100215635 A JJ O
ammonium-containing US20100215635 A JJ O
compounds US20100215635 A NNS O
alone US20100215635 A RB O
or US20100215635 A CC O
in US20100215635 A IN O
combination US20100215635 A NN O
with US20100215635 A IN O
alkaline US20100215635 A JJ I-UN
phosphatase US20100215635 A NN I-UN
or US20100215635 A CC O
other US20100215635 A JJ O
weight US20100215635 A JJ O
loss-inducing US20100215635 A JJ O
drugs US20100215635 A NNS O
or US20100215635 A CC O
methods US20100215635 A NNS O
to US20100215635 A TO O
reduce US20100215635 A VB O
or US20100215635 A CC O
reverse US20100215635 A VB O
excess US20100215635 A JJ O
weight US20100215635 A JJ O
gain US20100215635 A NN O
and US20100215635 A CC O
obesity US20100215635 A NN O
as US20100215635 A RB O
well US20100215635 A RB O
as US20100215635 A IN O
reduce US20100215635 A VB O
the US20100215635 A DT O
risk US20100215635 A NN O
of US20100215635 A IN O
development US20100215635 A NN O
and US20100215635 A CC O
help US20100215635 A NN O
treatment US20100215635 A NN O
of US20100215635 A IN O
diseases US20100215635 A NNS O
and US20100215635 A CC O
unhealthy US20100215635 A JJ O
conditions US20100215635 A NNS O
related US20100215635 A VBN O
to US20100215635 A TO O
overweight US20100215635 A CD O
and US20100215635 A CC O
obesity US20100215635 A NN O
. US20100215635 A . O

Therapeutic US20050113370 T JJ O
substituted US20050113370 T VBD O
indazole US20050113370 T JJ O
derivatives US20050113370 T NNS O
. US20050113370 T . O

Enhancers US6881731 T NNS O
for US6881731 T IN O
microbiological US6881731 T JJ O
disinfection US6881731 T NN O
. US6881731 T . O

Preparation CN102440956A T NNP O
method CN102440956A T NN O
of CN102440956A T IN O
self-emulsified CN102440956A T JJ O
sumatriptan CN102440956A T NN O
and CN102440956A T CC O
salt CN102440956A T NN O
preparation CN102440956A T NN O
thereof CN102440956A T NN O
. CN102440956A T . O

Hydrophillia CN100998579A T NNP O
Babu CN100998579A T NNP O
agent CN100998579A T NN O
for CN100998579A T IN O
treating CN100998579A T VBG O
depression CN100998579A T NN O
. CN100998579A T . O

Arginine CN101390844B T NNP O
ibuprofen CN101390844B T NN O
tablet CN101390844B T NN O
and CN101390844B T CC O
preparation CN101390844B T NN O
method CN101390844B T NN O
thereof CN101390844B T NN O
. CN101390844B T . O

Agent US20090118224 T NNP O
against US20090118224 T IN O
psychosocial US20090118224 T JJ O
stresses US20090118224 T NNS O
. US20090118224 T . O

Rifaximin US20090312357 T NNP O
. US20090312357 T . O

Gene US20080096840 T NNP O
expression US20080096840 T NN O
inhibition US20080096840 T NN O
by US20080096840 T IN O
contacting US20080096840 T VBG O
cells US20080096840 T NNS O
which US20080096840 T WDT O
express US20080096840 T VBP O
kinase US20080096840 T NN I-UN
suppressor US20080096840 T NN I-UN
of US20080096840 T IN I-UN
Ras US20080096840 T NNP I-UN
( US20080096840 T ( O
KSR US20080096840 T NNP I-UN
) US20080096840 T ) O
with US20080096840 T IN O
a US20080096840 T DT O
nucleic US20080096840 T NN O
acid US20080096840 T NN O
which US20080096840 T WDT O
is US20080096840 T VBZ O
complementary US20080096840 T JJ O
to US20080096840 T TO O
a US20080096840 T DT O
portion US20080096840 T NN O
of US20080096840 T IN O
the US20080096840 T DT O
mRNA US20080096840 T NN O
encoding US20080096840 T VBG O
KSR US20080096840 T NNP I-UN
; US20080096840 T : O
antitumor US20080096840 T NN O
, US20080096840 T , O
anticarcinogenic US20080096840 T JJ O
, US20080096840 T , O
antimetastasis US20080096840 T NN O
and US20080096840 T CC O
antiproliferative US20080096840 T JJ O
agents US20080096840 T NNS O
. US20080096840 T . O

The US20080096840 A DT O
present US20080096840 A JJ O
invention US20080096840 A NN O
relates US20080096840 A VBZ O
to US20080096840 A TO O
methods US20080096840 A NNS O
and US20080096840 A CC O
compositions US20080096840 A NNS O
for US20080096840 A IN O
the US20080096840 A DT O
specific US20080096840 A JJ O
inhibition US20080096840 A NN O
of US20080096840 A IN O
kinase US20080096840 A NN I-UN
suppressor US20080096840 A NN I-UN
of US20080096840 A IN I-UN
Ras US20080096840 A NNP I-UN
( US20080096840 A ( O
KSR US20080096840 A NNP I-UN
) US20080096840 A ) O
. US20080096840 A . O

In US20080096840 A IN O
particular US20080096840 A JJ O
, US20080096840 A , O
the US20080096840 A DT O
invention US20080096840 A NN O
provides US20080096840 A VBZ O
genetic US20080096840 A JJ O
approaches US20080096840 A NNS O
and US20080096840 A CC O
nucleic US20080096840 A JJ O
acids US20080096840 A NNS O
for US20080096840 A IN O
the US20080096840 A DT O
specific US20080096840 A JJ O
inhibition US20080096840 A NN O
of US20080096840 A IN O
KSR US20080096840 A NNP I-UN
, US20080096840 A , O
particularly US20080096840 A RB O
of US20080096840 A IN O
KSR US20080096840 A NNP I-UN
expression US20080096840 A NN O
. US20080096840 A . O

The US20080096840 A DT O
invention US20080096840 A NN O
relates US20080096840 A VBZ O
to US20080096840 A TO O
antisense US20080096840 A VB O
oligonucleotides US20080096840 A NNS O
and US20080096840 A CC O
the US20080096840 A DT O
expression US20080096840 A NN O
of US20080096840 A IN O
nucleic US20080096840 A NN O
acid US20080096840 A NN O
which US20080096840 A WDT O
is US20080096840 A VBZ O
substantially US20080096840 A RB O
complementary US20080096840 A JJ O
to US20080096840 A TO O
KSR US20080096840 A NNP I-UN
RNA US20080096840 A NNP O
. US20080096840 A . O

The US20080096840 A DT O
invention US20080096840 A NN O
provides US20080096840 A VBZ O
methods US20080096840 A NNS O
to US20080096840 A TO O
inhibit US20080096840 A VB O
KSR US20080096840 A NNP I-UN
, US20080096840 A , O
including US20080096840 A VBG O
inhibition US20080096840 A NN O
of US20080096840 A IN O
KSR US20080096840 A NNP I-UN
expression US20080096840 A NN O
. US20080096840 A . O

Geodate US20120195932 T NNP O
delivery US20120195932 T NN O
vehicles US20120195932 T NNS O
. US20120195932 T . O

Hydroxypropylamines US7244755 T NNS O
. US7244755 T . O

These US7244755 A DT O
compounds US7244755 A NNS O
include US7244755 A VBP O
inhibitors US7244755 A NNS O
of US7244755 A IN O
the US7244755 A DT O
beta-secretase US7244755 A JJ I-UN
enzyme US7244755 A NN O
that US7244755 A WDT O
are US7244755 A VBP O
useful US7244755 A JJ O
in US7244755 A IN O
the US7244755 A DT O
treatment US7244755 A NN O
of US7244755 A IN O
Alzheimer US7244755 A NNP O
's US7244755 A POS O
disease US7244755 A NN O
and US7244755 A CC O
other US7244755 A JJ O
diseases US7244755 A NNS O
characterized US7244755 A VBN O
by US7244755 A IN O
deposition US7244755 A NN O
of US7244755 A IN O
A US7244755 A NNP O
beta US7244755 A NN O
peptide US7244755 A NN O
in US7244755 A IN O
a US7244755 A DT O
mammal US7244755 A NN O
. US7244755 A . O

Combined CN101244065A T VBN O
sustained-release CN101244065A T JJ O
agent CN101244065A T NN O
for CN101244065A T IN O
preventing CN101244065A T VBG O
and CN101244065A T CC O
controlling CN101244065A T VBG O
livestock CN101244065A T NN O
coccidiosis CN101244065A T NN O
and CN101244065A T CC O
bacillary CN101244065A T JJ O
dysentery CN101244065A T NN O
, CN101244065A T , O
and CN101244065A T CC O
preparation CN101244065A T NN O
thereof CN101244065A T NN O
. CN101244065A T . O

Pheophorbide CN103224499A T NNP O
curcumin CN103224499A T NN O
ester CN103224499A T NN O
with CN103224499A T IN O
photosensitive CN103224499A T JJ O
activity CN103224499A T NN O
and CN103224499A T CC O
preparation CN103224499A T NN O
method CN103224499A T NN O
and CN103224499A T CC O
application CN103224499A T NN O
thereof CN103224499A T NN O
. CN103224499A T . O

Substituted WO2006122800A1 T VBN O
benzo WO2006122800A1 T NN O
( WO2006122800A1 T ( O
d WO2006122800A1 T NN O
) WO2006122800A1 T ) O
isoxazol-3-yl WO2006122800A1 T JJ O
amine WO2006122800A1 T JJ O
compounds WO2006122800A1 T NNS O
as WO2006122800A1 T IN O
analgesics WO2006122800A1 T NNS O
. WO2006122800A1 T . O

Disclosed WO2006122800A1 A VBN O
are WO2006122800A1 A VBP O
substituted WO2006122800A1 A VBN O
benzo WO2006122800A1 A JJ O
[ WO2006122800A1 A NNP O
d WO2006122800A1 A NN O
] WO2006122800A1 A NNP O
isoxazol-3-yl WO2006122800A1 A JJ O
amine WO2006122800A1 A NN O
compounds WO2006122800A1 A NNS O
of WO2006122800A1 A IN O
general WO2006122800A1 A JJ O
formula WO2006122800A1 A NN O
( WO2006122800A1 A ( O
I WO2006122800A1 A PRP O
) WO2006122800A1 A ) O
, WO2006122800A1 A , O
which WO2006122800A1 A WDT O
are WO2006122800A1 A VBP O
suitable WO2006122800A1 A JJ O
for WO2006122800A1 A IN O
the WO2006122800A1 A DT O
treatment WO2006122800A1 A NN O
of WO2006122800A1 A IN O
pain WO2006122800A1 A NN O
while WO2006122800A1 A IN O
being WO2006122800A1 A VBG O
provided WO2006122800A1 A VBN O
with WO2006122800A1 A IN O
an WO2006122800A1 A DT O
excellent WO2006122800A1 A JJ O
affinity WO2006122800A1 A NN O
to WO2006122800A1 A TO O
the WO2006122800A1 A DT O
KCNQ2/3 WO2006122800A1 A NNP I-UN
K+ WO2006122800A1 A NNP I-UN
channel WO2006122800A1 A NN I-UN
and WO2006122800A1 A CC O
thus WO2006122800A1 A RB O
being WO2006122800A1 A VBG O
suitable WO2006122800A1 A JJ O
for WO2006122800A1 A IN O
the WO2006122800A1 A DT O
treatment WO2006122800A1 A NN O
of WO2006122800A1 A IN O
disorders WO2006122800A1 A NNS O
or WO2006122800A1 A CC O
diseases WO2006122800A1 A NNS O
that WO2006122800A1 A WDT O
are WO2006122800A1 A VBP O
transmitted WO2006122800A1 A VBN O
at WO2006122800A1 A IN O
least WO2006122800A1 A JJS O
in WO2006122800A1 A IN O
part WO2006122800A1 A NN O
through WO2006122800A1 A IN O
KCNQ2/3 WO2006122800A1 A NNP I-UN
K+ WO2006122800A1 A NNP I-UN
channels WO2006122800A1 A NNS I-UN
. WO2006122800A1 A . O

Celecoxib CN103263385A T NNP O
long-acting CN103263385A T JJ O
nano CN103263385A T NN O
injection CN103263385A T NN O
and CN103263385A T CC O
preparation CN103263385A T NN O
method CN103263385A T NN O
thereof CN103263385A T NN O
. CN103263385A T . O

Drug WO2007079391A3 T NN O
delivery WO2007079391A3 T NN O
system WO2007079391A3 T NN O
for WO2007079391A3 T IN O
bioadhesion WO2007079391A3 T NN O
to WO2007079391A3 T TO O
a WO2007079391A3 T DT O
vulvovaginal WO2007079391A3 T JJ O
surface WO2007079391A3 T NN O
. WO2007079391A3 T . O

Stable CN102579455A T JJ O
cefaclor CN102579455A T NN O
chewing CN102579455A T VBG O
composition CN102579455A T NN O
. CN102579455A T . O

Metformin CN101278919B T NNP O
hydrochloride CN101278919B T NN O
and CN101278919B T CC O
Glipizide CN101278919B T NNP O
sustained-release CN101278919B T JJ O
pellet CN101278919B T NN O
and CN101278919B T CC O
method CN101278919B T NN O
of CN101278919B T IN O
preparing CN101278919B T VBG O
the CN101278919B T DT O
same CN101278919B T JJ O
. CN101278919B T . O

Substituted US20090005399 T VBN O
Imidazo US20090005399 T NNP O
[ US20090005399 T NNP O
2,1-b US20090005399 T JJ O
] US20090005399 T NNP O
thiazole US20090005399 T NN O
Compounds US20090005399 T NNP O
and US20090005399 T CC O
Uses US20090005399 T NNP O
Thereof US20090005399 T NNP O
. US20090005399 T . O

Substituted US20090005399 A VBN O
imidazo US20090005399 A JJ O
[ US20090005399 A JJ O
2,1-b US20090005399 A JJ O
] US20090005399 A NN O
thiazole US20090005399 A NN O
compounds US20090005399 A VBZ O
corresponding US20090005399 A VBG O
to US20090005399 A TO O
formula US20090005399 A VB O
I US20090005399 A PRP O
, US20090005399 A , O
a US20090005399 A DT O
method US20090005399 A NN O
for US20090005399 A IN O
producing US20090005399 A VBG O
them US20090005399 A PRP O
, US20090005399 A , O
pharmaceutical US20090005399 A JJ O
compositions US20090005399 A NNS O
containing US20090005399 A VBG O
them US20090005399 A PRP O
, US20090005399 A , O
and US20090005399 A CC O
the US20090005399 A DT O
use US20090005399 A NN O
thereof US20090005399 A NN O
for US20090005399 A IN O
regularing US20090005399 A VBG O
mGluR5 US20090005399 A JJ I-UN
receptors US20090005399 A NNS O
, US20090005399 A , O
or US20090005399 A CC O
for US20090005399 A IN O
treating US20090005399 A VBG O
or US20090005399 A CC O
inhibiting US20090005399 A VBG O
disorders US20090005399 A NNS O
or US20090005399 A CC O
disease US20090005399 A VB O
states US20090005399 A NNS O
at US20090005399 A IN O
least US20090005399 A JJS O
partially US20090005399 A RB O
mediated US20090005399 A VBN O
by US20090005399 A IN O
mGluR5 US20090005399 A JJ I-UN
receptor US20090005399 A NN O
such US20090005399 A JJ O
as US20090005399 A IN O
pain US20090005399 A NN O
, US20090005399 A , O
anxiety US20090005399 A NN O
attacks US20090005399 A NNS O
, US20090005399 A , O
drug US20090005399 A NN O
or US20090005399 A CC O
alcohol US20090005399 A NN O
dependency US20090005399 A NN O
, US20090005399 A , O
and US20090005399 A CC O
others US20090005399 A NNS O
. US20090005399 A . O

Nucleotide CN102558261A T NNP O
analogue CN102558261A T NN O
and CN102558261A T CC O
synthesis CN102558261A T NN O
and CN102558261A T CC O
application CN102558261A T NN O
thereof CN102558261A T NN O
. CN102558261A T . O

The CN102558261A A DT O
nucleotide CN102558261A A JJ O
analogue CN102558261A A NN O
can CN102558261A A MD O
restrain CN102558261A A VB O
the CN102558261A A DT O
growth CN102558261A A NN O
of CN102558261A A IN O
microorganism CN102558261A A NN O
such CN102558261A A JJ O
as CN102558261A A IN O
escherichia CN102558261A A JJ O
coli CN102558261A A NN O
, CN102558261A A , O
and CN102558261A A CC O
can CN102558261A A MD O
be CN102558261A A VB O
used CN102558261A A VBN O
as CN102558261A A IN O
an CN102558261A A DT O
inhibitor CN102558261A A NN O
of CN102558261A A IN O
dehydrogenase CN102558261A A NN O
such CN102558261A A JJ O
as CN102558261A A IN O
malate CN102558261A A JJ I-UN
dehydrogenase CN102558261A A NN I-UN
. CN102558261A A . O

Cefpiramide CN101822680A T NNP O
drug CN101822680A T NN O
combination CN101822680A T NN O
. CN101822680A T . O

Diaminopyrimidines CN101300235A T NNS O
as CN101300235A T IN O
P2X3 CN101300235A T NNP I-UN
and CN101300235A T CC O
P2X2/3 CN101300235A T NNP I-UN
modulators CN101300235A T NNS O
. CN101300235A T . O

Compounds CN101300235A A NNS O
and CN101300235A A CC O
methods CN101300235A A NNS O
for CN101300235A A IN O
treating CN101300235A A VBG O
diseases CN101300235A A NNS O
mediated CN101300235A A VBN O
by CN101300235A A IN O
a CN101300235A A DT O
P2X3 CN101300235A A NNP I-UN
and/or CN101300235A A NN O
a CN101300235A A DT O
P2X2/3 CN101300235A A NNP I-UN
receptor CN101300235A A NN I-UN
antagonist CN101300235A A NN O
, CN101300235A A , O
the CN101300235A A DT O
compounds CN101300235A A NNS O
being CN101300235A A VBG O
of CN101300235A A IN O
formula CN101300235A A NN O
( CN101300235A A ( O
I CN101300235A A PRP O
) CN101300235A A ) O
wherein CN101300235A A NN O
D CN101300235A A NNP O
, CN101300235A A , O
X CN101300235A A NNP O
, CN101300235A A , O
R CN101300235A A NNP O
< CN101300235A A VBZ O
1 CN101300235A A CD O
> CN101300235A A NN O
, CN101300235A A , O
R CN101300235A A NNP O
< CN101300235A A VBZ O
2 CN101300235A A CD O
> CN101300235A A NN O
, CN101300235A A , O
R CN101300235A A NNP O
< CN101300235A A VBZ O
3 CN101300235A A CD O
> CN101300235A A NN O
, CN101300235A A , O
R CN101300235A A NNP O
< CN101300235A A VBZ O
4 CN101300235A A CD O
> CN101300235A A NN O
, CN101300235A A , O
R CN101300235A A NNP O
< CN101300235A A VBZ O
5 CN101300235A A CD O
> CN101300235A A NN O
, CN101300235A A , O
R CN101300235A A NNP O
< CN101300235A A VBZ O
6 CN101300235A A CD O
> CN101300235A A NN O
, CN101300235A A , O
R CN101300235A A NNP O
< CN101300235A A VBZ O
7 CN101300235A A CD O
> CN101300235A A NN O
and CN101300235A A CC O
R CN101300235A A NNP O
< CN101300235A A NNP O
8 CN101300235A A CD O
> CN101300235A A NN O
are CN101300235A A VBP O
as CN101300235A A IN O
defined CN101300235A A JJ O
herein CN101300235A A NN O
. CN101300235A A . O

Rasagiline WO2011121607A2 T NNP O
and WO2011121607A2 T CC O
its WO2011121607A2 T PRP$ O
pharmaceutically WO2011121607A2 T RB O
acceptable WO2011121607A2 T JJ O
salts WO2011121607A2 T NNS O
. WO2011121607A2 T . O

Transcobalamin US7531162 T NNP I-UN
receptor US7531162 T NN I-UN
binding US7531162 T VBG O
conjugates US7531162 T NNS O
useful US7531162 T JJ O
for US7531162 T IN O
treating US7531162 T VBG O
abnormal US7531162 T JJ O
cellular US7531162 T JJ O
proliferation US7531162 T NN O
. US7531162 T . O

Methods US20100098678 T NNS O
of US20100098678 T IN O
Treatment US20100098678 T NNP O
of US20100098678 T IN O
Mitochondrial US20100098678 T NNP O
Disorders US20100098678 T NNP O
. US20100098678 T . O

Novel EP1254904B1 T NNP O
piperidine EP1254904B1 T NN O
compounds EP1254904B1 T NNS O
and EP1254904B1 T CC O
drugs EP1254904B1 T NNS O
containing EP1254904B1 T VBG O
the EP1254904B1 T DT O
same EP1254904B1 T JJ O
. EP1254904B1 T . O

Substituted US20110105578 T VBN O
Imidazole US20110105578 T NNP O
Derivatives US20110105578 T NNPS O
And US20110105578 T CC O
Methods US20110105578 T NNP O
Of US20110105578 T IN O
Use US20110105578 T NNP O
Thereof US20110105578 T NNP O
. US20110105578 T . O

Application CN1954818B T NN O
of CN1954818B T IN O
phillyrin CN1954818B T NN O
in CN1954818B T IN O
preparation CN1954818B T NN O
for CN1954818B T IN O
treating CN1954818B T VBG O
endotoxemia CN1954818B T NN O
. CN1954818B T . O

Tonsillitis-clearing CN103505556A T JJ O
decoction CN103505556A T NN O
for CN103505556A T IN O
treating CN103505556A T VBG O
infantile CN103505556A T JJ O
acute CN103505556A T NN O
tonsillitis CN103505556A T NN O
and CN103505556A T CC O
preparation CN103505556A T NN O
method CN103505556A T NN O
thereof CN103505556A T NN O
. CN103505556A T . O

Has US6911442 T VBZ O
no US6911442 T DT O
toxicological US6911442 T JJ O
effects US6911442 T NNS O
; US6911442 T : O
adapted US6911442 T VBN O
for US6911442 T IN O
oral US6911442 T JJ O
, US6911442 T , O
topical US6911442 T JJ O
or US6911442 T CC O
parenteral US6911442 T JJ O
use US6911442 T NN O
and US6911442 T CC O
may US6911442 T MD O
be US6911442 T VB O
used US6911442 T VBN O
for US6911442 T IN O
the US6911442 T DT O
treatment US6911442 T NN O
of US6911442 T IN O
bacterial US6911442 T JJ O
infection US6911442 T NN O
in US6911442 T IN O
mammals US6911442 T NNS O
. US6911442 T . O

N-benzylamino US20080255218 T NNP O
cyclic US20080255218 T JJ O
thioureas US20080255218 T NNS O
; US20080255218 T : O
obesity US20080255218 T NN O
and US20080255218 T CC O
related US20080255218 T JJ O
disorders US20080255218 T NNS O
; US20080255218 T : O
( US20080255218 T ( O
N- US20080255218 T NNP O
( US20080255218 T ( O
3- US20080255218 T JJ O
{ US20080255218 T ( O
( US20080255218 T ( O
4S US20080255218 T CD O
) US20080255218 T ) O
-1- US20080255218 T NN O
[ US20080255218 T NNP O
( US20080255218 T ( O
1S US20080255218 T CD O
) US20080255218 T ) O
-2- US20080255218 T NN O
( US20080255218 T ( O
benzylamino US20080255218 T NN O
) US20080255218 T ) O
-1-methylethyl US20080255218 T VBZ O
] US20080255218 T JJ O
-3- US20080255218 T NNP O
[ US20080255218 T NNP O
2- US20080255218 T JJ O
( US20080255218 T ( O
3-fluorophenyl US20080255218 T JJ O
) US20080255218 T ) O
ethyl US20080255218 T FW O
] US20080255218 T FW O
-2-thioxoimidazolidin-4-yl US20080255218 T FW O
} US20080255218 T ) O
propyl US20080255218 T NN O
) US20080255218 T ) O
guanidine US20080255218 T NN O
. US20080255218 T . O

This US20080255218 A DT O
invention US20080255218 A NN O
relates US20080255218 A VBZ O
generally US20080255218 A RB O
to US20080255218 A TO O
N-benzylamino US20080255218 A NNP O
cyclic US20080255218 A JJ O
thioureas US20080255218 A NNS O
, US20080255218 A , O
pharmaceutical US20080255218 A JJ O
compositions US20080255218 A NNS O
containing US20080255218 A VBG O
them US20080255218 A PRP O
, US20080255218 A , O
and US20080255218 A CC O
their US20080255218 A PRP$ O
use US20080255218 A NN O
as US20080255218 A IN O
antagonists US20080255218 A NNS O
of US20080255218 A IN O
melanin-concentrating US20080255218 A JJ I-UN
hormone US20080255218 A NN I-UN
receptor US20080255218 A NN I-UN
( US20080255218 A ( O
MCH US20080255218 A NNP I-UN
receptor US20080255218 A NN I-UN
) US20080255218 A ) O
. US20080255218 A . O

Antimicrobial WO2007144057A3 T JJ O
carbon WO2007144057A3 T NN O
. WO2007144057A3 T . O

Skin WO2011093600A3 T NNP O
wound WO2011093600A3 T NN O
healing WO2011093600A3 T VBG O
agent WO2011093600A3 T NN O
containing WO2011093600A3 T VBG O
decursin WO2011093600A3 T NN O
and WO2011093600A3 T CC O
decursinol WO2011093600A3 T NN O
angelate WO2011093600A3 T NN O
. WO2011093600A3 T . O

New CN102793695A T NNP O
pharmaceutical CN102793695A T JJ O
application CN102793695A T NN O
of CN102793695A T IN O
3-hydroxy CN102793695A T JJ O
fatty CN102793695A T JJ O
acid CN102793695A T NN O
methyl CN102793695A T NN O
ester CN102793695A T NN O
and CN102793695A T CC O
analogs CN102793695A T NNS O
thereof CN102793695A T NN O
. CN102793695A T . O

Methods US7202280 T NNS O
for US7202280 T IN O
the US7202280 T DT O
treatment US7202280 T NN O
and US7202280 T CC O
prevention US7202280 T NN O
of US7202280 T IN O
pancreatitis US7202280 T NN O
and US7202280 T CC O
for US7202280 T IN O
induction US7202280 T NN O
of US7202280 T IN O
liver US7202280 T JJ O
regeneration US7202280 T NN O
. US7202280 T . O

Retinol US20100113352 T NNP O
formulations US20100113352 T NNS O
and US20100113352 T CC O
methods US20100113352 T NNS O
for US20100113352 T IN O
their US20100113352 T PRP$ O
use US20100113352 T NN O
. US20100113352 T . O

The US20100113352 A DT O
composition US20100113352 A NN O
may US20100113352 A MD O
further US20100113352 A RB O
include US20100113352 A VB O
at US20100113352 A IN O
least US20100113352 A JJS O
one US20100113352 A CD O
protein US20100113352 A NN O
species US20100113352 A NNS O
, US20100113352 A , O
and US20100113352 A CC O
some US20100113352 A DT O
proteins US20100113352 A NNS O
used US20100113352 A VBN O
in US20100113352 A IN O
the US20100113352 A DT O
composition US20100113352 A NN O
include US20100113352 A VBP O
collagen US20100113352 A NN I-UN
and US20100113352 A CC O
elastin US20100113352 A NN I-UN
. US20100113352 A . O

Application CN103356521A T NN O
of CN103356521A T IN O
butylphthalide CN103356521A T NN O
or CN103356521A T CC O
derivatives CN103356521A T NNS O
thereof CN103356521A T VBP O
in CN103356521A T IN O
preparation CN103356521A T NN O
of CN103356521A T IN O
medicaments CN103356521A T NNS O
for CN103356521A T IN O
treating CN103356521A T VBG O
or CN103356521A T CC O
preventing CN103356521A T VBG O
radiation CN103356521A T NN O
brain CN103356521A T NN O
damage CN103356521A T NN O
. CN103356521A T . O

The CN103356521A A DT O
mechanism CN103356521A A NN O
of CN103356521A A IN O
action CN103356521A A NN O
for CN103356521A A IN O
treating CN103356521A A VBG O
the CN103356521A A DT O
radiation CN103356521A A NN O
brain CN103356521A A NN O
damage CN103356521A A NN O
by CN103356521A A IN O
using CN103356521A A VBG O
the CN103356521A A DT O
butylphthalide CN103356521A A NN O
is CN103356521A A VBZ O
that CN103356521A A IN O
oxygen CN103356521A A NN O
free CN103356521A A JJ O
radical CN103356521A A JJ O
balance CN103356521A A NN O
in CN103356521A A IN O
brain CN103356521A A NN O
tissues CN103356521A A NNS O
subjected CN103356521A A VBN O
to CN103356521A A TO O
radiation CN103356521A A VB O
damage CN103356521A A NN O
can CN103356521A A MD O
be CN103356521A A VB O
improved CN103356521A A VBN O
and CN103356521A A CC O
the CN103356521A A DT O
damage CN103356521A A NN O
effect CN103356521A A NN O
of CN103356521A A IN O
oxygen CN103356521A A NN O
free CN103356521A A JJ O
radicals CN103356521A A NNS O
can CN103356521A A MD O
be CN103356521A A VB O
relieved CN103356521A A VBN O
by CN103356521A A IN O
the CN103356521A A DT O
butylphthalide CN103356521A A NN O
; CN103356521A A : O
the CN103356521A A DT O
permeability CN103356521A A NN O
of CN103356521A A IN O
blood-brain CN103356521A A JJ O
barrier CN103356521A A NN O
of CN103356521A A IN O
a CN103356521A A DT O
rat CN103356521A A NN O
with CN103356521A A IN O
radioactive CN103356521A A JJ O
brain CN103356521A A NN O
damage CN103356521A A NN O
can CN103356521A A MD O
be CN103356521A A VB O
reduced CN103356521A A VBN O
by CN103356521A A IN O
reducing CN103356521A A VBG O
the CN103356521A A DT O
number CN103356521A A NN O
of CN103356521A A IN O
circulating CN103356521A A VBG O
endothelial CN103356521A A JJ O
cells CN103356521A A NNS O
of CN103356521A A IN O
the CN103356521A A DT O
rat CN103356521A A NN O
after CN103356521A A IN O
whole CN103356521A A JJ O
brain CN103356521A A NN O
irradiation CN103356521A A NN O
, CN103356521A A , O
and CN103356521A A CC O
the CN103356521A A DT O
radioactive CN103356521A A JJ O
brain CN103356521A A NN O
damage CN103356521A A NN O
is CN103356521A A VBZ O
protected CN103356521A A VBN O
, CN103356521A A , O
i.e. CN103356521A A FW O
, CN103356521A A , O
acting CN103356521A A VBG O
target CN103356521A A NN O
cells CN103356521A A NNS O
of CN103356521A A IN O
the CN103356521A A DT O
butylphthalide CN103356521A A NN O
are CN103356521A A VBP O
mainly CN103356521A A RB O
vascular CN103356521A A JJ O
endothelial CN103356521A A JJ O
cells CN103356521A A NNS O
; CN103356521A A : O
and CN103356521A A CC O
the CN103356521A A DT O
AQP4 CN103356521A A NNP I-UN
( CN103356521A A ( O
Aquaporin CN103356521A A NNP I-UN
4 CN103356521A A CD I-UN
) CN103356521A A ) O
effect CN103356521A A NN O
can CN103356521A A MD O
be CN103356521A A VB O
adjusted CN103356521A A VBN O
so CN103356521A A RB O
as CN103356521A A IN O
to CN103356521A A TO O
protect CN103356521A A VB O
the CN103356521A A DT O
blood-brain CN103356521A A JJ O
barrier CN103356521A A NN O
. CN103356521A A . O

non-nucleoside US20080096832 T JJ O
HIV-1 US20080096832 T NNP I-UN
reverse US20080096832 T NN I-UN
transcriptase US20080096832 T NN I-UN
inhibitor US20080096832 T NN O
( US20080096832 T ( O
NNRTI US20080096832 T NNP O
) US20080096832 T ) O
; US20080096832 T : O
co-administering US20080096832 T JJ O
cytochrome US20080096832 T NN I-UN
P450 US20080096832 T NNP I-UN
inhibitor US20080096832 T NN O
such US20080096832 T JJ O
as US20080096832 T IN O
ritonavir US20080096832 T NN O
to US20080096832 T TO O
reduce US20080096832 T VB O
metabolism US20080096832 T NN O
of US20080096832 T IN O
the US20080096832 T DT O
NNRTI US20080096832 T NNP O
5,11-Dihydro-11-ethyl-5-methyl-8- US20080096832 T JJ O
{ US20080096832 T ( O
2- US20080096832 T JJ O
{ US20080096832 T ( O
( US20080096832 T ( O
1-oxido-4-quinolinyl US20080096832 T CD O
) US20080096832 T ) O
oxy US20080096832 T NN O
} US20080096832 T ) O
ethyl US20080096832 T NN O
} US20080096832 T ) O
-6H-dipyrido US20080096832 T NNP O
[ US20080096832 T NNP O
3,2-b:2',3'-e US20080096832 T JJ O
] US20080096832 T NNP O
[ US20080096832 T NNP O
1,4 US20080096832 T CD O
] US20080096832 T NNP O
diazepin-6-one US20080096832 T NN O
, US20080096832 T , O
( US20080096832 T ( O
BILR US20080096832 T NNP O
355 US20080096832 T CD O
) US20080096832 T ) O
by US20080096832 T IN O
half US20080096832 T NN O
. US20080096832 T . O

An US20080096832 A DT O
improved US20080096832 A JJ O
method US20080096832 A NN O
for US20080096832 A IN O
using US20080096832 A VBG O
a US20080096832 A DT O
NNRTI US20080096832 A NNP O
in US20080096832 A IN O
the US20080096832 A DT O
treatment US20080096832 A NN O
of US20080096832 A IN O
HIV-1 US20080096832 A NNP O
infection US20080096832 A NN O
, US20080096832 A , O
comprising US20080096832 A VBG O
administering US20080096832 A VBG O
to US20080096832 A TO O
a US20080096832 A DT O
human US20080096832 A JJ O
, US20080096832 A , O
needing US20080096832 A JJ O
treatment US20080096832 A NN O
for US20080096832 A IN O
HIV-1 US20080096832 A NNP O
infection US20080096832 A NN O
, US20080096832 A , O
a US20080096832 A DT O
therapeutically US20080096832 A RB O
effective US20080096832 A JJ O
amount US20080096832 A NN O
of US20080096832 A IN O
said US20080096832 A VBD O
NNRTI US20080096832 A NNP O
or US20080096832 A CC O
a US20080096832 A DT O
pharmaceutically US20080096832 A RB O
acceptable US20080096832 A JJ O
salt US20080096832 A NN O
thereof US20080096832 A NN O
, US20080096832 A , O
and US20080096832 A CC O
an US20080096832 A DT O
amount US20080096832 A NN O
of US20080096832 A IN O
an US20080096832 A DT O
inhibitor US20080096832 A NN O
of US20080096832 A IN O
the US20080096832 A DT O
cytochromes US20080096832 A NNS I-UN
P450 US20080096832 A NNP I-UN
that US20080096832 A WDT O
is US20080096832 A VBZ O
sufficient US20080096832 A JJ O
to US20080096832 A TO O
elevate US20080096832 A VB O
, US20080096832 A , O
enhance US20080096832 A VB O
, US20080096832 A , O
or US20080096832 A CC O
extend US20080096832 A VB O
plasma US20080096832 A JJ O
concentrations US20080096832 A NNS O
of US20080096832 A IN O
said US20080096832 A VBD O
NNRTI US20080096832 A NNP O
. US20080096832 A . O

Compositions WO2014028025A1 T NNS O
and WO2014028025A1 T CC O
methods WO2014028025A1 T NNS O
for WO2014028025A1 T IN O
treating WO2014028025A1 T VBG O
myotonic WO2014028025A1 T JJ O
dystrophy WO2014028025A1 T NN O
type WO2014028025A1 T NN O
1 WO2014028025A1 T CD O
. WO2014028025A1 T . O

Carbamate CN103739642A T NNP O
derivates CN103739642A T NNS O
of CN103739642A T IN O
scutellarin CN103739642A T NN O
and CN103739642A T CC O
seutellarein CN103739642A T NN O
, CN103739642A T , O
and CN103739642A T CC O
application CN103739642A T NN O
thereof CN103739642A T NN O
. CN103739642A T . O

Nitrogen-containing WO2008054454A3 T JJ O
heterocycle WO2008054454A3 T NN O
derivatives WO2008054454A3 T NNS O
, WO2008054454A3 T , O
pharmaceutical WO2008054454A3 T JJ O
compositions WO2008054454A3 T NNS O
, WO2008054454A3 T , O
and WO2008054454A3 T CC O
methods WO2008054454A3 T NNS O
of WO2008054454A3 T IN O
use WO2008054454A3 T NN O
thereof WO2008054454A3 T NN O
as WO2008054454A3 T IN O
antiviral WO2008054454A3 T JJ O
agents WO2008054454A3 T NNS O
. WO2008054454A3 T . O

POLYMORPHS WO2008058278A2 T NNP O
OF WO2008058278A2 T NNP O
N2- WO2008058278A2 T NNP O
( WO2008058278A2 T ( O
1 WO2008058278A2 T CD O
, WO2008058278A2 T , O
1 WO2008058278A2 T CD O
' WO2008058278A2 T POS O
- WO2008058278A2 T : O
BIPHENYL WO2008058278A2 T NNP O
- WO2008058278A2 T : O
4 WO2008058278A2 T CD O
- WO2008058278A2 T : O
YLCARBONYL WO2008058278A2 T NN O
) WO2008058278A2 T ) O
- WO2008058278A2 T : O
N1- WO2008058278A2 T JJ O
[ WO2008058278A2 T JJ O
2- WO2008058278A2 T JJ O
( WO2008058278A2 T ( O
4 WO2008058278A2 T CD O
- WO2008058278A2 T : O
FLUOROPHENYL WO2008058278A2 T NN O
) WO2008058278A2 T ) O
-1 WO2008058278A2 T NN O
, WO2008058278A2 T , O
1 WO2008058278A2 T CD O
- WO2008058278A2 T : O
DIMETHYLETHYL WO2008058278A2 T NNP O
] WO2008058278A2 T NNP O
- WO2008058278A2 T : O
L WO2008058278A2 T NNP O
- WO2008058278A2 T : O
α WO2008058278A2 T NN O
-GLUTAMINE WO2008058278A2 T NN O
. WO2008058278A2 T . O

Crystalline WO2008050871A1 T NNP O
carbapenem WO2008050871A1 T NN O
compounds WO2008050871A1 T NNS O
. WO2008050871A1 T . O

Inhibitors WO2007124322A1 T NNS O
of WO2007124322A1 T IN O
c-fms WO2007124322A1 T JJ I-UN
kinase WO2007124322A1 T NN I-UN
. WO2007124322A1 T . O

The WO2007124322A1 A DT O
invention WO2007124322A1 A NN O
is WO2007124322A1 A VBZ O
directed WO2007124322A1 A VBN O
to WO2007124322A1 A TO O
compounds WO2007124322A1 A NNS O
of WO2007124322A1 A IN O
Formula WO2007124322A1 A NNP O
( WO2007124322A1 A ( O
I WO2007124322A1 A PRP O
) WO2007124322A1 A ) O
: WO2007124322A1 A : O
wherein WO2007124322A1 A NN O
Z WO2007124322A1 A NNP O
, WO2007124322A1 A , O
X WO2007124322A1 A NNP O
, WO2007124322A1 A , O
J WO2007124322A1 A NNP O
, WO2007124322A1 A , O
R2 WO2007124322A1 A NNP O
and WO2007124322A1 A CC O
W WO2007124322A1 A NNP O
are WO2007124322A1 A VBP O
set WO2007124322A1 A VBN O
forth WO2007124322A1 A NN O
in WO2007124322A1 A IN O
the WO2007124322A1 A DT O
specification WO2007124322A1 A NN O
, WO2007124322A1 A , O
as WO2007124322A1 A RB O
well WO2007124322A1 A RB O
as WO2007124322A1 A IN O
solvates WO2007124322A1 A NNS O
, WO2007124322A1 A , O
hydrates WO2007124322A1 A NNS O
, WO2007124322A1 A , O
tautomers WO2007124322A1 A NNS O
and WO2007124322A1 A CC O
pharmaceutically WO2007124322A1 A RB O
acceptable WO2007124322A1 A JJ O
salts WO2007124322A1 A NNS O
thereof WO2007124322A1 A NN O
, WO2007124322A1 A , O
that WO2007124322A1 A WDT O
inhibit WO2007124322A1 A VBP O
protein WO2007124322A1 A JJ O
tyrosine WO2007124322A1 A NN I-UN
kinases WO2007124322A1 A NNS I-UN
, WO2007124322A1 A , O
especially WO2007124322A1 A RB O
c-fms WO2007124322A1 A JJ I-UN
kinase WO2007124322A1 A NN I-UN
. WO2007124322A1 A . O

Rubescensine CN101703462A T NNP O
B CN101703462A T NNP O
high CN101703462A T JJ O
dispersion CN101703462A T NN O
preparation CN101703462A T NN O
. CN101703462A T . O

Compositions WO2004047727A3 T NNS O
and WO2004047727A3 T CC O
methods WO2004047727A3 T NNS O
for WO2004047727A3 T IN O
diagnosing WO2004047727A3 T VBG O
and WO2004047727A3 T CC O
treating WO2004047727A3 T VBG O
mood WO2004047727A3 T NN O
disorders WO2004047727A3 T NNS O
. WO2004047727A3 T . O

Method US20120202875 T NNP O
Of US20120202875 T IN O
Treatment US20120202875 T NNP O
. US20120202875 T . O

The US20120202875 A DT O
present US20120202875 A JJ O
invention US20120202875 A NN O
relates US20120202875 A VBZ O
to US20120202875 A TO O
methods US20120202875 A NNS O
for US20120202875 A IN O
treatment US20120202875 A NN O
or US20120202875 A CC O
prevention US20120202875 A NN O
of US20120202875 A IN O
autoimmune US20120202875 A NN O
and US20120202875 A CC O
inflammatory US20120202875 A NN O
diseases US20120202875 A NNS O
and US20120202875 A CC O
conditions US20120202875 A NNS O
by US20120202875 A IN O
inhibiting US20120202875 A VBG O
or US20120202875 A CC O
modifying US20120202875 A VBG O
histone US20120202875 A JJ I-UN
demethylation US20120202875 A NN O
. US20120202875 A . O

The US20120202875 A DT O
invention US20120202875 A NN O
particularly US20120202875 A RB O
describes US20120202875 A VBZ O
the US20120202875 A DT O
role US20120202875 A NN O
of US20120202875 A IN O
certain US20120202875 A JJ O
histone US20120202875 A NN I-UN
demethylase US20120202875 A NN I-UN
enzymes US20120202875 A VBZ O
in US20120202875 A IN O
these US20120202875 A DT O
diseases US20120202875 A NNS O
and US20120202875 A CC O
conditions US20120202875 A NNS O
and US20120202875 A CC O
their US20120202875 A PRP$ O
use US20120202875 A NN O
as US20120202875 A IN O
therapeutic US20120202875 A JJ O
and US20120202875 A CC O
screening US20120202875 A VBG O
targets US20120202875 A NNS O
. US20120202875 A . O

Use US20090011040 T NNP O
of US20090011040 T IN O
compacted US20090011040 T JJ O
nucleic US20090011040 T JJ O
acid US20090011040 T NN O
nanoparticles US20090011040 T NNS O
in US20090011040 T IN O
non-viral US20090011040 T JJ O
treatments US20090011040 T NNS O
of US20090011040 T IN O
ocular US20090011040 T JJ O
diseases US20090011040 T NNS O
. US20090011040 T . O

New EP2582660A1 T NNP O
cathepsin EP2582660A1 T NN O
s EP2582660A1 T NN O
protease EP2582660A1 T NN O
inhibitors EP2582660A1 T NNS O
, EP2582660A1 T , O
useful EP2582660A1 T JJ O
in EP2582660A1 T IN O
the EP2582660A1 T DT O
treatment EP2582660A1 T NN O
of EP2582660A1 T IN O
e.g EP2582660A1 T NN O
. EP2582660A1 T . O

autoimmune EP2582660A1 T NN O
disorders EP2582660A1 T NNS O
, EP2582660A1 T , O
allergy EP2582660A1 T NN O
and EP2582660A1 T CC O
chronic EP2582660A1 T JJ O
pain EP2582660A1 T NN O
conditions EP2582660A1 T NNS O
. EP2582660A1 T . O

Composition US20120070401 T NN O
and US20120070401 T CC O
Method US20120070401 T NNP O
for US20120070401 T IN O
Promoting US20120070401 T VBG O
Wound US20120070401 T NNP O
Healing US20120070401 T NNP O
. US20120070401 T . O

Use US20120184607 T NNP O
of US20120184607 T IN O
piperphentonamine US20120184607 T NN O
or US20120184607 T CC O
salts US20120184607 T NNS O
thereof US20120184607 T VBP O
in US20120184607 T IN O
manufacture US20120184607 T NN O
of US20120184607 T IN O
madicaments US20120184607 T NNS O
for US20120184607 T IN O
prevention/treating US20120184607 T VBG O
brain US20120184607 T NN O
diseases US20120184607 T NNS O
. US20120184607 T . O

Pteridine US20090075992 T NNP O
Derivatives US20090075992 T NNP O
as US20090075992 T IN O
Nitric US20090075992 T NNP O
Oxide US20090075992 T NNP O
Synthase US20090075992 T NNP O
Activators US20090075992 T NNP O
. US20090075992 T . O

Substituted US20090005371 T VBN O
Fused US20090005371 T VBD O
[ US20090005371 T JJ O
1,2 US20090005371 T CD O
] US20090005371 T JJ O
Imidazo US20090005371 T NNP O
[ US20090005371 T NNP O
4,5-C US20090005371 T JJ O
] US20090005371 T NNP O
Ring US20090005371 T NNP O
Compounds US20090005371 T NNP O
and US20090005371 T CC O
Methods US20090005371 T NNP O
. US20090005371 T . O

Fused US20090005371 A VBN O
[ US20090005371 A $ O
1,2 US20090005371 A CD O
] US20090005371 A NNP O
imidazo US20090005371 A JJ O
[ US20090005371 A NNP O
4,5-c US20090005371 A JJ O
] US20090005371 A NNP O
ring US20090005371 A NN O
compounds US20090005371 A NNS O
, US20090005371 A , O
e.g. US20090005371 A NN O
, US20090005371 A , O
fused US20090005371 A VBD O
[ US20090005371 A JJ O
1,2 US20090005371 A CD O
] US20090005371 A JJ O
imidazo US20090005371 A JJ O
[ US20090005371 A JJ O
4,5-c US20090005371 A JJ O
] US20090005371 A NN O
quinolines US20090005371 A NNS O
and US20090005371 A CC O
[ US20090005371 A $ O
1,2 US20090005371 A CD O
] US20090005371 A NNP O
imidazo US20090005371 A JJ O
[ US20090005371 A NNP O
4,5-c US20090005371 A JJ O
] US20090005371 A NNP O
naphthyridines US20090005371 A NNS O
, US20090005371 A , O
with US20090005371 A IN O
a US20090005371 A DT O
substituent US20090005371 A NN O
, US20090005371 A , O
e.g. US20090005371 A NN O
, US20090005371 A , O
a US20090005371 A DT O
substituted US20090005371 A JJ O
alkoxy US20090005371 A JJ O
substituent US20090005371 A NN O
, US20090005371 A , O
at US20090005371 A IN O
the US20090005371 A DT O
6 US20090005371 A CD O
, US20090005371 A , O
7 US20090005371 A CD O
, US20090005371 A , O
8 US20090005371 A CD O
, US20090005371 A , O
or US20090005371 A CC O
9-position US20090005371 A NN O
, US20090005371 A , O
pharmaceutical US20090005371 A JJ O
compositions US20090005371 A NNS O
containing US20090005371 A VBG O
the US20090005371 A DT O
compounds US20090005371 A NNS O
, US20090005371 A , O
intermediates US20090005371 A NNS O
, US20090005371 A , O
methods US20090005371 A NNS O
of US20090005371 A IN O
making US20090005371 A VBG O
and US20090005371 A CC O
methods US20090005371 A NNS O
of US20090005371 A IN O
use US20090005371 A NN O
of US20090005371 A IN O
these US20090005371 A DT O
compounds US20090005371 A NNS O
as US20090005371 A IN O
immunomodulators US20090005371 A NNS O
, US20090005371 A , O
for US20090005371 A IN O
inducing US20090005371 A VBG O
cytokine US20090005371 A JJ O
biosynthesis US20090005371 A NN O
in US20090005371 A IN O
animals US20090005371 A NNS O
and US20090005371 A CC O
in US20090005371 A IN O
the US20090005371 A DT O
treatment US20090005371 A NN O
of US20090005371 A IN O
diseases US20090005371 A NNS O
including US20090005371 A VBG O
viral US20090005371 A JJ O
and US20090005371 A CC O
neoplastic US20090005371 A JJ O
diseases US20090005371 A NNS O
are US20090005371 A VBP O
disclosed US20090005371 A VBN O
. US20090005371 A . O

The WO2012174327A1 A DT O
invention WO2012174327A1 A NN O
provides WO2012174327A1 A VBZ O
a WO2012174327A1 A DT O
method WO2012174327A1 A NN O
for WO2012174327A1 A IN O
treating WO2012174327A1 A VBG O
cancers WO2012174327A1 A NNS O
including WO2012174327A1 A VBG O
hematologic WO2012174327A1 A JJ O
malignancies WO2012174327A1 A NNS O
comprising WO2012174327A1 A VBG O
administering WO2012174327A1 A VBG O
a WO2012174327A1 A DT O
compound WO2012174327A1 A NN O
of WO2012174327A1 A IN O
Formula WO2012174327A1 A NNP O
( WO2012174327A1 A ( O
I WO2012174327A1 A PRP O
) WO2012174327A1 A ) O
: WO2012174327A1 A : O
in WO2012174327A1 A IN O
combination WO2012174327A1 A NN O
with WO2012174327A1 A IN O
one WO2012174327A1 A CD O
or WO2012174327A1 A CC O
both WO2012174327A1 A DT O
of WO2012174327A1 A IN O
bendamustine WO2012174327A1 A NN O
and WO2012174327A1 A CC O
rituximab WO2012174327A1 A NN O
. WO2012174327A1 A . O

Imidazolidinone WO2008119657A1 T NN O
derivatives WO2008119657A1 T NNS O
. WO2008119657A1 T . O

These WO2008119657A1 A DT O
compounds WO2008119657A1 A NNS O
bind WO2008119657A1 A VBP O
to WO2008119657A1 A TO O
LXR WO2008119657A1 A NNP I-UN
alpha WO2008119657A1 A NN I-UN
and WO2008119657A1 A CC O
LXR WO2008119657A1 A NNP I-UN
beta WO2008119657A1 A NN I-UN
and WO2008119657A1 A CC O
can WO2008119657A1 A MD O
be WO2008119657A1 A VB O
used WO2008119657A1 A VBN O
as WO2008119657A1 A IN O
medicaments WO2008119657A1 A NNS O
. WO2008119657A1 A . O

External-use CN101347596A T NNP O
plaster CN101347596A T NN O
for CN101347596A T IN O
treating CN101347596A T VBG O
beriberi CN101347596A T NN O
. CN101347596A T . O

Method CN102274203B T NNP O
for CN102274203B T IN O
improving CN102274203B T VBG O
moisture CN102274203B T NN O
resistance CN102274203B T NN O
of CN102274203B T IN O
L-carnitine CN102274203B T NNP O
tea CN102274203B T NN O
polyphenol CN102274203B T NN O
capsule CN102274203B T NN O
inclusion CN102274203B T NN O
. CN102274203B T . O

Agomelatine CN102670514A T NNP O
solid CN102670514A T JJ O
preparation CN102670514A T NN O
. CN102670514A T . O

Novel CN102924322A T NNP O
crystal CN102924322A T JJ O
form CN102924322A T NN O
of CN102924322A T IN O
tigecycline CN102924322A T NN O
and CN102924322A T CC O
preparation CN102924322A T NN O
method CN102924322A T NN O
thereof CN102924322A T NN O
. CN102924322A T . O

Method EP2554170A1 T NNP O
for EP2554170A1 T IN O
treatment EP2554170A1 T NN O
of EP2554170A1 T IN O
diseases EP2554170A1 T NNS O
. EP2554170A1 T . O

The EP2554170A1 A DT O
present EP2554170A1 A JJ O
invention EP2554170A1 A NN O
relates EP2554170A1 A VBZ O
to EP2554170A1 A TO O
a EP2554170A1 A DT O
vascular-hyperpermeability-inhibiting EP2554170A1 A JJ O
amount EP2554170A1 A NN O
of EP2554170A1 A IN O
a EP2554170A1 A DT O
compound EP2554170A1 A NN O
selected EP2554170A1 A VBN O
from EP2554170A1 A IN O
danazol EP2554170A1 A NN O
and EP2554170A1 A CC O
pharmaceutically EP2554170A1 A RB O
acceptable EP2554170A1 A JJ O
salts EP2554170A1 A NNS O
of EP2554170A1 A IN O
danazol EP2554170A1 A NN O
, EP2554170A1 A , O
for EP2554170A1 A IN O
use EP2554170A1 A NN O
in EP2554170A1 A IN O
inhibiting EP2554170A1 A VBG O
vascular EP2554170A1 A JJ O
hyperpermeability EP2554170A1 A NN O
in EP2554170A1 A IN O
an EP2554170A1 A DT O
animal EP2554170A1 A NN O
in EP2554170A1 A IN O
need EP2554170A1 A NN O
thereof EP2554170A1 A NN O
, EP2554170A1 A , O
wherein EP2554170A1 A VBP O
the EP2554170A1 A DT O
vascular EP2554170A1 A JJ O
hyperpermeability EP2554170A1 A NN O
is EP2554170A1 A VBZ O
vascular EP2554170A1 A JJ O
hyperpermeability EP2554170A1 A NN O
of EP2554170A1 A IN O
a EP2554170A1 A DT O
continuous EP2554170A1 A JJ O
endothelium EP2554170A1 A NN O
or EP2554170A1 A CC O
a EP2554170A1 A DT O
fenestrated EP2554170A1 A JJ O
endothelium EP2554170A1 A NN O
. EP2554170A1 A . O

serotonin US20080004347 T NN I-UN
( US20080004347 T ( I-UN
5-HT2C US20080004347 T JJ I-UN
) US20080004347 T ) I-UN
receptor US20080004347 T NN I-UN
antagonist US20080004347 T NN O
; US20080004347 T : O
antidepressant US20080004347 T JJ O
, US20080004347 T , O
anxiolytic US20080004347 T JJ O
agent US20080004347 T NN O
; US20080004347 T : O
seasonal US20080004347 T JJ O
affective US20080004347 T JJ O
disorders US20080004347 T NNS O
, US20080004347 T , O
sleep US20080004347 T NN O
disorders US20080004347 T NNS O
, US20080004347 T , O
cardiovascular US20080004347 T JJ O
pathologies US20080004347 T NNS O
, US20080004347 T , O
pathologies US20080004347 T NNS O
of US20080004347 T IN O
the US20080004347 T DT O
digestive US20080004347 T JJ O
system US20080004347 T NN O
, US20080004347 T , O
insomnia US20080004347 T NN O
and US20080004347 T CC O
fatigue US20080004347 T NN O
resulting US20080004347 T VBG O
from US20080004347 T IN O
jetlag US20080004347 T NN O
, US20080004347 T , O
appetite US20080004347 T JJ O
disorders US20080004347 T NNS O
and US20080004347 T CC O
obesity US20080004347 T NN O
. US20080004347 T . O

16 WO2009108118A9 T CD O
alpha WO2009108118A9 T NN O
, WO2009108118A9 T , O
17 WO2009108118A9 T CD O
alpha-acetal WO2009108118A9 T JJ O
glucocorticosteroidal WO2009108118A9 T NN O
derivatives WO2009108118A9 T NNS O
and WO2009108118A9 T CC O
their WO2009108118A9 T PRP$ O
use WO2009108118A9 T NN O
. WO2009108118A9 T . O

Applications CN103381162A T NNS O
of CN103381162A T IN O
Chukrasone CN103381162A T NNP O
A CN103381162A T NNP O
in CN103381162A T IN O
medicines CN103381162A T NNS O
used CN103381162A T VBN O
for CN103381162A T IN O
treating CN103381162A T VBG O
dengue CN103381162A T NN O
virus CN103381162A T NN O
infection CN103381162A T NN O
. CN103381162A T . O

The CN103381162A A DT O
invention CN103381162A A NN O
discloses CN103381162A A VBZ O
applications CN103381162A A NNS O
of CN103381162A A IN O
Chukrasone CN103381162A A NNP O
A CN103381162A A NNP O
in CN103381162A A IN O
medicines CN103381162A A NNS O
used CN103381162A A VBN O
for CN103381162A A IN O
treating CN103381162A A VBG O
dengue CN103381162A A NN O
virus CN103381162A A NN O
infection CN103381162A A NN O
. CN103381162A A . O

Chukrasone CN103381162A A NN O
A CN103381162A A DT O
is CN103381162A A VBZ O
capable CN103381162A A JJ O
of CN103381162A A IN O
inhibiting CN103381162A A VBG O
dengue CN103381162A A NN O
virus CN103381162A A NN O
multiplication CN103381162A A NN O
effectively CN103381162A A RB O
, CN103381162A A , O
and CN103381162A A CC O
possesses CN103381162A A VBZ O
little CN103381162A A JJ O
toxicity CN103381162A A NN O
on CN103381162A A IN O
cells CN103381162A A NNS O
, CN103381162A A , O
so CN103381162A A IN O
that CN103381162A A IN O
Chukrasone CN103381162A A NNP O
A CN103381162A A NNP O
can CN103381162A A MD O
be CN103381162A A VB O
further CN103381162A A RB O
used CN103381162A A VBN O
for CN103381162A A IN O
preparation CN103381162A A NN O
of CN103381162A A IN O
medicines CN103381162A A NNS O
used CN103381162A A VBN O
for CN103381162A A IN O
treating CN103381162A A VBG O
diseases CN103381162A A NNS O
caused CN103381162A A VBN O
by CN103381162A A IN O
dengue CN103381162A A NN O
virus CN103381162A A NN O
infection CN103381162A A NN O
, CN103381162A A , O
and CN103381162A A CC O
the CN103381162A A DT O
application CN103381162A A NN O
prospect CN103381162A A NN O
is CN103381162A A VBZ O
promising CN103381162A A VBG O
. CN103381162A A . O

The CN103381162A A DT O
applications CN103381162A A NNS O
of CN103381162A A IN O
Chukrasone CN103381162A A NNP O
A CN103381162A A NNP O
in CN103381162A A IN O
preparation CN103381162A A NN O
of CN103381162A A IN O
medicines CN103381162A A NNS O
used CN103381162A A VBN O
for CN103381162A A IN O
treating CN103381162A A VBG O
or CN103381162A A CC O
preventing CN103381162A A VBG O
dengue CN103381162A A JJ O
virus CN103381162A A NN O
infection CN103381162A A NN O
are CN103381162A A VBP O
disclosed CN103381162A A VBN O
for CN103381162A A IN O
the CN103381162A A DT O
first CN103381162A A JJ O
time CN103381162A A NN O
. CN103381162A A . O

The CN103381162A A DT O
molecular CN103381162A A JJ O
skeleton CN103381162A A NN O
is CN103381162A A VBZ O
novel CN103381162A A JJ O
, CN103381162A A , O
so CN103381162A A IN O
that CN103381162A A DT O
inhibitory CN103381162A A NN O
activity CN103381162A A NN O
on CN103381162A A IN O
dengue CN103381162A A NN O
virus CN103381162A A NN O
is CN103381162A A VBZ O
surprisingly CN103381162A A RB O
strong CN103381162A A JJ O
, CN103381162A A , O
and CN103381162A A CC O
it CN103381162A A PRP O
is CN103381162A A VBZ O
impossible CN103381162A A JJ O
to CN103381162A A TO O
estimate CN103381162A A VB O
the CN103381162A A DT O
inhibitory CN103381162A A NN O
activity CN103381162A A NN O
according CN103381162A A VBG O
to CN103381162A A TO O
the CN103381162A A DT O
activities CN103381162A A NNS O
of CN103381162A A IN O
other CN103381162A A JJ O
compounds CN103381162A A NNS O
. CN103381162A A . O

Chukrasone CN103381162A A NN O
A CN103381162A A DT O
possesses CN103381162A A NNS O
outstanding CN103381162A A JJ O
substantiality CN103381162A A NN O
, CN103381162A A , O
and CN103381162A A CC O
the CN103381162A A DT O
applications CN103381162A A NNS O
of CN103381162A A IN O
Chukrasone CN103381162A A NNP O
A CN103381162A A NNP O
in CN103381162A A IN O
treatment CN103381162A A NN O
and CN103381162A A CC O
prevention CN103381162A A NN O
of CN103381162A A IN O
dengue CN103381162A A NN O
virus CN103381162A A NN O
infection CN103381162A A NN O
possess CN103381162A A NN O
significant CN103381162A A JJ O
advantages CN103381162A A NNS O
. CN103381162A A . O

Phenyl WO2007009635A1 T NNP O
substituted WO2007009635A1 T VBD O
piperazine-derivatives WO2007009635A1 T NNS O
as WO2007009635A1 T IN O
inhibitors WO2007009635A1 T NNS O
of WO2007009635A1 T IN O
plaminogenic WO2007009635A1 T JJ O
activator WO2007009635A1 T NN O
inhibitors-i WO2007009635A1 T JJ O
( WO2007009635A1 T ( O
pai-i WO2007009635A1 T JJ O
) WO2007009635A1 T ) O
. WO2007009635A1 T . O

Novel CN101397330A T NNP O
nitrogen-containing CN101397330A T JJ O
medicament CN101397330A T NN O
with CN101397330A T IN O
anti-inflammatory CN101397330A T JJ O
activity CN101397330A T NN O
. CN101397330A T . O

The CN101397330A A DT O
invention CN101397330A A NN O
relates CN101397330A A VBZ O
to CN101397330A A TO O
an CN101397330A A DT O
androstane CN101397330A A NN O
azotic CN101397330A A JJ O
glucocorticoid CN101397330A A NN I-UN
receptor CN101397330A A NN I-UN
stimulant CN101397330A A NN O
compound CN101397330A A NN O
and CN101397330A A CC O
a CN101397330A A DT O
preparation CN101397330A A NN O
method CN101397330A A NN O
thereof CN101397330A A NN O
. CN101397330A A . O

Acesodyne CN101559100A T NNP O
capsule CN101559100A T NN O
for CN101559100A T IN O
heart CN101559100A T NN O
and CN101559100A T CC O
stomach CN101559100A T NN O
. CN101559100A T . O

Paclitaxel CN101439032A T NNP O
lipid CN101439032A T NN O
complexes CN101439032A T NNS O
and CN101439032A T CC O
micelle CN101439032A T JJ O
composition CN101439032A T NN O
thereof CN101439032A T NN O
for CN101439032A T IN O
injection CN101439032A T NN O
. CN101439032A T . O

Applying US20080214506 T VBG O
to US20080214506 T TO O
patient US20080214506 T VB O
a US20080214506 T DT O
medicament US20080214506 T NN O
for US20080214506 T IN O
transdermal US20080214506 T JJ O
, US20080214506 T , O
oral US20080214506 T JJ O
, US20080214506 T , O
or US20080214506 T CC O
ophthalmological US20080214506 T JJ O
administration US20080214506 T NN O
comprising US20080214506 T VBG O
ethanol US20080214506 T NNS O
, US20080214506 T , O
vitamin US20080214506 T FW O
B6 US20080214506 T NNP O
or US20080214506 T CC O
analog US20080214506 T NN O
thereof US20080214506 T NN O
, US20080214506 T , O
and US20080214506 T CC O
an US20080214506 T DT O
ion US20080214506 T NN O
channel US20080214506 T NN O
affinity US20080214506 T NN O
component US20080214506 T NN O
; US20080214506 T : O
providing US20080214506 T VBG O
transport US20080214506 T NN O
vehicle US20080214506 T NN O
of US20080214506 T IN O
meperidine US20080214506 T NN O
, US20080214506 T , O
lecithin US20080214506 T NN O
, US20080214506 T , O
or US20080214506 T CC O
DMSO US20080214506 T NNP O
for US20080214506 T IN O
transfer US20080214506 T NN O
of US20080214506 T IN O
vitamin US20080214506 T JJ O
B6 US20080214506 T NNP O
or US20080214506 T CC O
analog US20080214506 T VBN O
through US20080214506 T IN O
cell US20080214506 T NN O
membrane US20080214506 T NN O
. US20080214506 T . O

Cembrane CN102675252A T NNP O
type CN102675252A T NN O
diterpenoids CN102675252A T NNS O
with CN102675252A T IN O
anti-tumor CN102675252A T JJ O
activities CN102675252A T NNS O
and CN102675252A T CC O
application CN102675252A T NN O
thereof CN102675252A T NN O
. CN102675252A T . O

Asymmetric WO2006047228A1 T JJ O
synthesis WO2006047228A1 T NN O
of WO2006047228A1 T IN O
substituted WO2006047228A1 T JJ O
dihydrobenzofurans WO2006047228A1 T NNS O
. WO2006047228A1 T . O

Bicyclo-pyrazoles US8273765 T NNS O
and US8273765 T CC O
pharmaceutical US8273765 T JJ O
compositions US8273765 T NNS O
comprising US8273765 T VBG O
them US8273765 T PRP O
. US8273765 T . O

Bicyclo-pyrazole US8273765 A JJ O
compounds US8273765 A NNS O
of US8273765 A IN O
formula US8273765 A NN O
( US8273765 A ( O
I US8273765 A PRP O
) US8273765 A ) O
, US8273765 A , O
as US8273765 A IN O
herein US8273765 A NN O
defined US8273765 A VBN O
, US8273765 A , O
are US8273765 A VBP O
useful US8273765 A JJ O
for US8273765 A IN O
treating US8273765 A VBG O
diseases US8273765 A NNS O
linked US8273765 A VBN O
to US8273765 A TO O
disregulated US8273765 A VBN O
protein US8273765 A NN O
kinases US8273765 A NNS I-UN
. US8273765 A . O

Refreshing CN102335296A T NNP O
, CN102335296A T , O
inflammation CN102335296A T NN O
eliminating CN102335296A T NN O
and CN102335296A T CC O
pain CN102335296A T NN O
relieving CN102335296A T NN O
ointment CN102335296A T NN O
. CN102335296A T . O

10-acetyl-dithranol CN101380293A T JJ O
hydrogel CN101380293A T NN O
and CN101380293A T CC O
preparation CN101380293A T NN O
method CN101380293A T NN O
thereof CN101380293A T NN O
. CN101380293A T . O

Rapidly CN103040780A T RB O
disintegrating CN103040780A T VBG O
pramipexole CN103040780A T JJ O
tablet CN103040780A T JJ O
drug CN103040780A T NN O
composition CN103040780A T NN O
and CN103040780A T CC O
preparation CN103040780A T NN O
method CN103040780A T NN O
thereof CN103040780A T NN O
. CN103040780A T . O

Derivatives US20100331345 T NNS O
of US20100331345 T IN O
substituted US20100331345 T JJ O
tartaric US20100331345 T JJ O
acid US20100331345 T NN O
and US20100331345 T CC O
usage US20100331345 T NN O
for US20100331345 T IN O
preparing US20100331345 T VBG O
beta-secretase US20100331345 T JJ O
inhibitors US20100331345 T NNS O
. US20100331345 T . O

C-type US8022174 T JJ O
lectin US8022174 T NN O
transmembrane US8022174 T NN O
antigen US8022174 T NN O
expressed US8022174 T VBN O
in US8022174 T IN O
human US8022174 T JJ O
prostate US8022174 T NN O
cancer US8022174 T NN O
and US8022174 T CC O
uses US8022174 T VBZ O
therof US8022174 T NN O
. US8022174 T . O

Inhibitors US20070293548 T NNS O
of US20070293548 T IN O
semicarbazide-sensitive US20070293548 T JJ I-UN
amine US20070293548 T JJ I-UN
oxidase US20070293548 T NN I-UN
( US20070293548 T ( O
SSAO US20070293548 T NNP I-UN
) US20070293548 T ) O
and US20070293548 T CC O
VAP-1 US20070293548 T NNP I-UN
mediated US20070293548 T VBD O
adhesion US20070293548 T NN O
useful US20070293548 T JJ O
for US20070293548 T IN O
treatment US20070293548 T NN O
and US20070293548 T CC O
prevention US20070293548 T NN O
of US20070293548 T IN O
diseases US20070293548 T NNS O
. US20070293548 T . O

Allylamino US20070293548 A NNP O
compounds US20070293548 A NNS O
are US20070293548 A VBP O
disclosed US20070293548 A VBN O
which US20070293548 A WDT O
are US20070293548 A VBP O
inhibitors US20070293548 A NNS O
of US20070293548 A IN O
semicarbazide-sensitive US20070293548 A JJ I-UN
amine US20070293548 A JJ I-UN
oxidase US20070293548 A NN I-UN
( US20070293548 A ( O
SSAO US20070293548 A NNP I-UN
) US20070293548 A ) O
and/or US20070293548 A VBP O
vascular US20070293548 A JJ I-UN
adhesion US20070293548 A NN I-UN
protein US20070293548 A NN I-UN
1 US20070293548 A CD I-UN
( US20070293548 A ( O
VAP-1 US20070293548 A NNP I-UN
) US20070293548 A ) O
. US20070293548 A . O

Preparation DE102008034739A1 T NN O
, DE102008034739A1 T , O
useful DE102008034739A1 T JJ O
for DE102008034739A1 T IN O
the DE102008034739A1 T DT O
treatment DE102008034739A1 T NN O
of DE102008034739A1 T IN O
equine DE102008034739A1 T NN O
Cushing DE102008034739A1 T NNP O
's DE102008034739A1 T POS O
syndrome DE102008034739A1 T NN O
, DE102008034739A1 T , O
comprises DE102008034739A1 T VBZ O
allopurinol DE102008034739A1 T NN O
. DE102008034739A1 T . O

New EP1511489A1 T NNP O
pharmaceutical EP1511489A1 T JJ O
compositions EP1511489A1 T NNS O
containing EP1511489A1 T VBG O
flibanserin EP1511489A1 T NN O
polymorph EP1511489A1 T NN O
a EP1511489A1 T DT O
. EP1511489A1 T . O

Polymeric US20090047368 T NNP O
polyphenol US20090047368 T NN O
extracted US20090047368 T VBD O
from US20090047368 T IN O
fermented US20090047368 T VBN O
tea US20090047368 T NN O
, US20090047368 T , O
therapeutic US20090047368 T JJ O
agent US20090047368 T NN O
for US20090047368 T IN O
mitochondrial US20090047368 T JJ O
disease US20090047368 T NN O
, US20090047368 T , O
preventive/therapeutic US20090047368 T JJ O
agent US20090047368 T NN O
for US20090047368 T IN O
diabetes US20090047368 T NNS O
mellitus US20090047368 T NNS O
, US20090047368 T , O
and US20090047368 T CC O
food US20090047368 T NN O
or US20090047368 T CC O
beverage US20090047368 T NN O
. US20090047368 T . O

Antibody EP1505075B1 T NN O
to EP1505075B1 T TO O
human EP1505075B1 T JJ I-UN
insulin-like EP1505075B1 T JJ I-UN
growth EP1505075B1 T NN I-UN
factor EP1505075B1 T NN I-UN
. EP1505075B1 T . O

To EP1505075B1 A TO O
efficiently EP1505075B1 A RB O
treat EP1505075B1 A VB O
diseases EP1505075B1 A NNS O
such EP1505075B1 A JJ O
as EP1505075B1 A IN O
cancer EP1505075B1 A NN O
in EP1505075B1 A IN O
which EP1505075B1 A WDT O
hIGF EP1505075B1 A NN I-UN
participates EP1505075B1 A NNS O
, EP1505075B1 A , O
there EP1505075B1 A EX O
have EP1505075B1 A VBP O
been EP1505075B1 A VBN O
required EP1505075B1 A VBN O
antibodies EP1505075B1 A NNS O
which EP1505075B1 A WDT O
strongly EP1505075B1 A RB O
bind EP1505075B1 A VBZ O
to EP1505075B1 A TO O
both EP1505075B1 A DT O
of EP1505075B1 A IN O
hIGF-I EP1505075B1 A NN I-UN
and EP1505075B1 A CC O
hIGF-II EP1505075B1 A NN I-UN
and EP1505075B1 A CC O
inhibit EP1505075B1 A VB O
their EP1505075B1 A PRP$ O
functions EP1505075B1 A NNS O
and EP1505075B1 A CC O
fragments EP1505075B1 A NNS O
of EP1505075B1 A IN O
these EP1505075B1 A DT O
antibodies EP1505075B1 A NNS O
. EP1505075B1 A . O

It EP1505075B1 A PRP O
is EP1505075B1 A VBZ O
intended EP1505075B1 A VBN O
to EP1505075B1 A TO O
provide EP1505075B1 A VB O
antibodies EP1505075B1 A NNS O
which EP1505075B1 A WDT O
can EP1505075B1 A MD O
specifically EP1505075B1 A RB O
bind EP1505075B1 A VB O
respectively EP1505075B1 A RB O
to EP1505075B1 A TO O
human EP1505075B1 A JJ I-UN
IGF-I EP1505075B1 A NNP I-UN
and EP1505075B1 A CC O
human EP1505075B1 A JJ I-UN
IGF-II EP1505075B1 A NNP I-UN
to EP1505075B1 A TO O
thereby EP1505075B1 A VB O
inhibit EP1505075B1 A VB O
the EP1505075B1 A DT O
functions EP1505075B1 A NNS O
of EP1505075B1 A IN O
human EP1505075B1 A JJ I-UN
IGF-I EP1505075B1 A NNP I-UN
and EP1505075B1 A CC O
human EP1505075B1 A JJ I-UN
IGF-II EP1505075B1 A NNP I-UN
and EP1505075B1 A CC O
have EP1505075B1 A VBP O
binding EP1505075B1 A VBG O
activity EP1505075B1 A NN O
with EP1505075B1 A IN O
a EP1505075B1 A DT O
binding EP1505075B1 A VBG O
constant EP1505075B1 A NN O
of EP1505075B1 A IN O
5x10 EP1505075B1 A CD O
< EP1505075B1 A JJ O
9 EP1505075B1 A CD O
> EP1505075B1 A JJ O
M EP1505075B1 A NNP O
< EP1505075B1 A NNP O
-1 EP1505075B1 A NNP O
> EP1505075B1 A NNP O
or EP1505075B1 A CC O
more EP1505075B1 A JJR O
measured EP1505075B1 A VBN O
with EP1505075B1 A IN O
a EP1505075B1 A DT O
biosensor EP1505075B1 A NN O
BIACORE EP1505075B1 A NNP O
. EP1505075B1 A . O

It EP1505075B1 A PRP O
is EP1505075B1 A VBZ O
also EP1505075B1 A RB O
intended EP1505075B1 A VBN O
to EP1505075B1 A TO O
provide EP1505075B1 A VB O
diagnostics EP1505075B1 A NNS O
, EP1505075B1 A , O
preventives EP1505075B1 A NNS O
and EP1505075B1 A CC O
remedies EP1505075B1 A NNS O
comprising EP1505075B1 A VBG O
the EP1505075B1 A DT O
above EP1505075B1 A JJ O
antibodies EP1505075B1 A NNS O
for EP1505075B1 A IN O
an EP1505075B1 A DT O
hIGF-mediated EP1505075B1 A JJ O
disease EP1505075B1 A NN O
and EP1505075B1 A CC O
a EP1505075B1 A DT O
disease EP1505075B1 A NN O
showing EP1505075B1 A VBG O
pathological EP1505075B1 A JJ O
progressing EP1505075B1 A NN O
due EP1505075B1 A JJ O
to EP1505075B1 A TO O
abnormally EP1505075B1 A RB O
accelerated EP1505075B1 A JJ O
hIGF EP1505075B1 A NN I-UN
production EP1505075B1 A NN O
. EP1505075B1 A . O

Scutellarin CN1850097A T NNP O
injection CN1850097A T NN O
preparation CN1850097A T NN O
and CN1850097A T CC O
its CN1850097A T PRP$ O
preparing CN1850097A T NN O
method CN1850097A T NN O
. CN1850097A T . O

Composite CN101654499B T NNP O
of CN101654499B T IN O
natural CN101654499B T JJ O
macromolecule CN101654499B T NN O
or CN101654499B T CC O
amphiphilic CN101654499B T JJ O
grafting CN101654499B T VBG O
copolymer CN101654499B T NN O
of CN101654499B T IN O
water-soluble CN101654499B T JJ O
derivant CN101654499B T NN O
and CN101654499B T CC O
nanometer CN101654499B T JJ O
iodine CN101654499B T NN O
and CN101654499B T CC O
preparation CN101654499B T NN O
method CN101654499B T NN O
thereof CN101654499B T NN O
. CN101654499B T . O

Cadmium CN103356719A T NNP O
displacement CN103356719A T NN O
agent CN103356719A T NN O
. CN103356719A T . O

Benzoxazepin-4- WO2010118208A1 T NNP O
( WO2010118208A1 T ( O
5h WO2010118208A1 T CD O
) WO2010118208A1 T ) O
-yl WO2010118208A1 T NN O
derivatives WO2010118208A1 T NNS O
and WO2010118208A1 T CC O
their WO2010118208A1 T PRP$ O
use WO2010118208A1 T NN O
to WO2010118208A1 T TO O
treat WO2010118208A1 T VB O
cancer WO2010118208A1 T NN O
. WO2010118208A1 T . O

Preparation CN102988595A T NNP O
method CN102988595A T NN O
of CN102988595A T IN O
medicinal CN102988595A T JJ O
Radix CN102988595A T NNP O
Sanguisorbae CN102988595A T NNP O
and CN102988595A T CC O
Akebia CN102988595A T NNP O
Stem CN102988595A T NNP O
powder CN102988595A T NN O
for CN102988595A T IN O
treating CN102988595A T VBG O
scalds CN102988595A T NNS O
. CN102988595A T . O

Compositions CA2149408C T NNS O
for CA2149408C T IN O
curing CA2149408C T VBG O
affected CA2149408C T JJ O
abnormal CA2149408C T JJ O
tissues CA2149408C T NNS O
, CA2149408C T , O
method CA2149408C T NN O
for CA2149408C T IN O
the CA2149408C T DT O
preparation CA2149408C T NN O
thereof CA2149408C T NN O
, CA2149408C T , O
and CA2149408C T CC O
usage CA2149408C T JJ O
thereof CA2149408C T NN O
. CA2149408C T . O

Method CN1723913A T NNP O
for CN1723913A T IN O
preparing CN1723913A T VBG O
coenzyme-A CN1723913A T JJ O
sublingual CN1723913A T JJ O
lozenge CN1723913A T NN O
. CN1723913A T . O

Intrauterine CN200942144Y T NNP O
device CN200942144Y T NN O
. CN200942144Y T . O

Heterocyclic EP1783128A1 T NNP O
compounds EP1783128A1 T NNS O
and EP1783128A1 T CC O
their EP1783128A1 T PRP$ O
use EP1783128A1 T NN O
as EP1783128A1 T IN O
antifouling EP1783128A1 T VBG O
agents EP1783128A1 T NNS O
. EP1783128A1 T . O

Human WO2006084758A1 T NNP O
monoclonal WO2006084758A1 T JJ O
antibody WO2006084758A1 T NN O
specific WO2006084758A1 T JJ O
for WO2006084758A1 T IN O
lipopolysaccharides WO2006084758A1 T NNS O
( WO2006084758A1 T ( O
lps WO2006084758A1 T NN O
) WO2006084758A1 T ) O
of WO2006084758A1 T IN O
the WO2006084758A1 T DT O
pseudomonas WO2006084758A1 T NN O
aeruginosa WO2006084758A1 T NN O
iats WO2006084758A1 T NNS O
o11 WO2006084758A1 T VBP O
serotype WO2006084758A1 T NN O
. WO2006084758A1 T . O

Composition CN1883481A T NN O
of CN1883481A T IN O
leukotrienes CN1883481A T NNS O
antagonist CN1883481A T JJ O
oral CN1883481A T JJ O
liquid CN1883481A T NN O
. CN1883481A T . O

Use WO2008070169A2 T NNP O
of WO2008070169A2 T IN O
carboxyamidotriazole WO2008070169A2 T NN O
( WO2008070169A2 T ( O
cai WO2008070169A2 T NN O
) WO2008070169A2 T ) O
orotate WO2008070169A2 T NN O
in WO2008070169A2 T IN O
macular WO2008070169A2 T JJ O
degeneration WO2008070169A2 T NN O
. WO2008070169A2 T . O

Biodegradable CN101862628A T JJ O
microencapsulated CN101862628A T VBN O
capsaicine CN101862628A T NN O
and CN101862628A T CC O
preparation CN101862628A T NN O
method CN101862628A T NN O
thereof CN101862628A T NN O
. CN101862628A T . O

Use WO2013175047A1 T NNP O
of WO2013175047A1 T IN O
a WO2013175047A1 T DT O
compound WO2013175047A1 T NN O
of WO2013175047A1 T IN O
formula WO2013175047A1 T NN O
( WO2013175047A1 T ( O
i WO2013175047A1 T NN O
) WO2013175047A1 T ) O
to WO2013175047A1 T TO O
manufacture WO2013175047A1 T VB O
a WO2013175047A1 T DT O
medicament WO2013175047A1 T NN O
for WO2013175047A1 T IN O
treating WO2013175047A1 T VBG O
gaucher WO2013175047A1 T NN O
's WO2013175047A1 T POS O
disease WO2013175047A1 T NN O
, WO2013175047A1 T , O
pharmaceutical WO2013175047A1 T JJ O
composition WO2013175047A1 T NN O
, WO2013175047A1 T , O
a WO2013175047A1 T DT O
compound WO2013175047A1 T NN O
of WO2013175047A1 T IN O
formula WO2013175047A1 T NN O
( WO2013175047A1 T ( O
ib WO2013175047A1 T NN O
) WO2013175047A1 T ) O
and WO2013175047A1 T CC O
method WO2013175047A1 T NN O
for WO2013175047A1 T IN O
obtaining WO2013175047A1 T VBG O
said WO2013175047A1 T VBD O
compound WO2013175047A1 T NN O
. WO2013175047A1 T . O

Immunomodulating EP1409485B1 T VBG O
compounds EP1409485B1 T NNS O
. EP1409485B1 T . O

More EP1409485B1 A RBR O
particularly EP1409485B1 A RB O
the EP1409485B1 A DT O
present EP1409485B1 A JJ O
invention EP1409485B1 A NN O
relates EP1409485B1 A VBZ O
to EP1409485B1 A TO O
novel EP1409485B1 A VB O
heterocyclic EP1409485B1 A JJ O
compounds EP1409485B1 A NNS O
, EP1409485B1 A , O
which EP1409485B1 A WDT O
are EP1409485B1 A VBP O
CD80 EP1409485B1 A NNP I-UN
antagonists EP1409485B1 A NNS O
capable EP1409485B1 A JJ O
of EP1409485B1 A IN O
inhibiting EP1409485B1 A VBG O
the EP1409485B1 A DT O
interactions EP1409485B1 A NNS O
between EP1409485B1 A IN O
CD80 EP1409485B1 A NNP I-UN
and EP1409485B1 A CC O
CD28 EP1409485B1 A NNP I-UN
. EP1409485B1 A . O

Morin-7-sodium CN102302482A T JJ O
sulfate CN102302482A T NN O
for CN102302482A T IN O
inhibiting CN102302482A T VBG O
enzymatic CN102302482A T JJ O
activity CN102302482A T NN O
of CN102302482A T IN O
PRL-3 CN102302482A T NNP I-UN
( CN102302482A T ( O
phosphatase CN102302482A T NN I-UN
of CN102302482A T IN I-UN
regenerating CN102302482A T VBG I-UN
liver-3 CN102302482A T NN I-UN
) CN102302482A T ) O
and CN102302482A T CC O
application CN102302482A T NN O
of CN102302482A T IN O
morin-7- CN102302482A T JJ O
sodium CN102302482A T NN O
sulfate CN102302482A T NN O
in CN102302482A T IN O
medicines CN102302482A T NNS O
for CN102302482A T IN O
resisting CN102302482A T VBG O
tumor CN102302482A T NN O
metastasis CN102302482A T NN O
. CN102302482A T . O

The CN102302482A A DT O
invention CN102302482A A NN O
relates CN102302482A A VBZ O
to CN102302482A A TO O
morin-7-sodium CN102302482A A JJ O
sulfate CN102302482A A NN O
for CN102302482A A IN O
inhibiting CN102302482A A VBG O
enzymatic CN102302482A A JJ O
activity CN102302482A A NN O
of CN102302482A A IN O
PRL-3 CN102302482A A NNP I-UN
( CN102302482A A ( O
phosphatase CN102302482A A NN I-UN
of CN102302482A A IN I-UN
regenerating CN102302482A A VBG I-UN
liver-3 CN102302482A A NN I-UN
) CN102302482A A ) O
and CN102302482A A CC O
application CN102302482A A NN O
of CN102302482A A IN O
the CN102302482A A DT O
morin-7- CN102302482A A JJ O
sodium CN102302482A A NN O
sulfate CN102302482A A NN O
in CN102302482A A IN O
medicines CN102302482A A NNS O
for CN102302482A A IN O
resisting CN102302482A A VBG O
tumor CN102302482A A NN O
metastasis CN102302482A A NN O
. CN102302482A A . O

Human CN102302482A A JJ O
PRL-3 CN102302482A A NNP I-UN
protein CN102302482A A NN O
with CN102302482A A IN O
enzymatic CN102302482A A JJ O
activity CN102302482A A NN O
is CN102302482A A VBZ O
obtained CN102302482A A VBN O
through CN102302482A A IN O
a CN102302482A A DT O
gene CN102302482A A NN O
engineering CN102302482A A NN O
technology CN102302482A A NN O
, CN102302482A A , O
the CN102302482A A DT O
water-soluble CN102302482A A JJ O
morin-7-sodium CN102302482A A NN O
sulfate CN102302482A A NN O
obtained CN102302482A A VBN O
through CN102302482A A IN O
screening CN102302482A A NN O
has CN102302482A A VBZ O
an CN102302482A A DT O
obvious CN102302482A A JJ O
inhibiting CN102302482A A NN O
effect CN102302482A A NN O
for CN102302482A A IN O
the CN102302482A A DT O
enzymatic CN102302482A A JJ O
activity CN102302482A A NN O
of CN102302482A A IN O
the CN102302482A A DT O
PRL-3 CN102302482A A NNP I-UN
, CN102302482A A , O
the CN102302482A A DT O
inhibiting CN102302482A A VBG O
effect CN102302482A A NN O
of CN102302482A A IN O
the CN102302482A A DT O
morin-7-sodium CN102302482A A JJ O
sulfate CN102302482A A NN O
is CN102302482A A VBZ O
stronger CN102302482A A JJR O
than CN102302482A A IN O
that CN102302482A A DT O
of CN102302482A A IN O
parent CN102302482A A NN O
morin CN102302482A A NN O
of CN102302482A A IN O
the CN102302482A A DT O
morin-7-sodium CN102302482A A JJ O
sulfate CN102302482A A NN O
and CN102302482A A CC O
is CN102302482A A VBZ O
also CN102302482A A RB O
superior CN102302482A A JJ O
to CN102302482A A TO O
the CN102302482A A DT O
inhibiting CN102302482A A JJ O
effects CN102302482A A NNS O
of CN102302482A A IN O
other CN102302482A A JJ O
compounds CN102302482A A NNS O
or CN102302482A A CC O
natural CN102302482A A JJ O
products CN102302482A A NNS O
, CN102302482A A , O
a CN102302482A A DT O
Transwell CN102302482A A NNP O
measurement CN102302482A A NN O
result CN102302482A A NN O
shows CN102302482A A VBZ O
that CN102302482A A IN O
the CN102302482A A DT O
compound CN102302482A A NN O
can CN102302482A A MD O
obviously CN102302482A A RB O
inhibit CN102302482A A VB O
the CN102302482A A DT O
invitro CN102302482A A JJ O
invasive CN102302482A A JJ O
capability CN102302482A A NN O
and CN102302482A A CC O
the CN102302482A A DT O
motility CN102302482A A NN O
of CN102302482A A IN O
a CN102302482A A DT O
tumour CN102302482A A NN O
cell CN102302482A A NN O
, CN102302482A A , O
and CN102302482A A CC O
a CN102302482A A DT O
Western CN102302482A A JJ O
blot CN102302482A A NN O
and CN102302482A A CC O
fluorescence CN102302482A A NN O
quantitative CN102302482A A JJ O
PCR CN102302482A A NNP O
( CN102302482A A ( O
polymerase CN102302482A A NN O
chain CN102302482A A NN O
reaction CN102302482A A NN O
) CN102302482A A ) O
result CN102302482A A NN O
shows CN102302482A A VBZ O
that CN102302482A A IN O
the CN102302482A A DT O
compound CN102302482A A NN O
can CN102302482A A MD O
specifically CN102302482A A RB O
inhibit CN102302482A A VB O
the CN102302482A A DT O
PRL-3 CN102302482A A NNP I-UN
protein CN102302482A A NN O
and CN102302482A A CC O
mRNA CN102302482A A NN O
( CN102302482A A ( O
Messenger CN102302482A A NNP O
RNA CN102302482A A NNP O
) CN102302482A A ) O
expression CN102302482A A NN O
rather CN102302482A A RB O
than CN102302482A A IN O
PRL-1 CN102302482A A NNP I-UN
protein CN102302482A A NN O
and CN102302482A A CC O
PRL-2 CN102302482A A NNP I-UN
protein CN102302482A A NN O
( CN102302482A A ( O
same CN102302482A A JJ O
species CN102302482A A NNS O
as CN102302482A A IN O
the CN102302482A A DT O
PRL-3 CN102302482A A NNP I-UN
protein CN102302482A A NN O
) CN102302482A A ) O
and CN102302482A A CC O
mRNA CN102302482A A JJ O
expression CN102302482A A NN O
. CN102302482A A . O

The CN102302482A A DT O
compound CN102302482A A NN O
provided CN102302482A A VBN O
by CN102302482A A IN O
the CN102302482A A DT O
invention CN102302482A A NN O
has CN102302482A A VBZ O
higher CN102302482A A JJR O
application CN102302482A A NN O
value CN102302482A A NN O
in CN102302482A A IN O
researching CN102302482A A VBG O
the CN102302482A A DT O
effect CN102302482A A NN O
of CN102302482A A IN O
the CN102302482A A DT O
PRL-3 CN102302482A A NNP I-UN
in CN102302482A A IN O
the CN102302482A A DT O
tumor CN102302482A A NN O
metastasis CN102302482A A NN O
and CN102302482A A CC O
designing CN102302482A A NN O
, CN102302482A A , O
researching CN102302482A A VBG O
and CN102302482A A CC O
developing CN102302482A A VBG O
the CN102302482A A DT O
medicines CN102302482A A NNS O
for CN102302482A A IN O
resisting CN102302482A A VBG O
the CN102302482A A DT O
tumor CN102302482A A NN O
metastasis CN102302482A A NN O
, CN102302482A A , O
can CN102302482A A MD O
be CN102302482A A VB O
applied CN102302482A A VBN O
to CN102302482A A TO O
preparing CN102302482A A VBG O
a CN102302482A A DT O
positive CN102302482A A JJ O
control CN102302482A A NN O
reagent CN102302482A A NN O
or CN102302482A A CC O
compound CN102302482A A NN O
of CN102302482A A IN O
a CN102302482A A DT O
PRL-3 CN102302482A A NNP I-UN
enzyme CN102302482A A NN O
inhibitor CN102302482A A NN O
, CN102302482A A , O
and CN102302482A A CC O
is CN102302482A A VBZ O
used CN102302482A A VBN O
as CN102302482A A IN O
one CN102302482A A CD O
component CN102302482A A NN O
or CN102302482A A CC O
precursor CN102302482A A NN O
for CN102302482A A IN O
preparing CN102302482A A VBG O
the CN102302482A A DT O
medicines CN102302482A A NNS O
for CN102302482A A IN O
resisting CN102302482A A VBG O
the CN102302482A A DT O
tumor CN102302482A A NN O
metastasis CN102302482A A NN O
in CN102302482A A IN O
medicine CN102302482A A NN O
development CN102302482A A NN O
. CN102302482A A . O

Pramipexole-contained CN101766605A T JJ O
pharmaceutical CN101766605A T JJ O
composition CN101766605A T NN O
capable CN101766605A T NN O
of CN101766605A T IN O
being CN101766605A T VBG O
dispersed CN101766605A T VBN O
in CN101766605A T IN O
mouth CN101766605A T NN O
. CN101766605A T . O

Preparation CN103214422A T NNP O
methods CN103214422A T NNS O
and CN103214422A T CC O
anti-cancer CN103214422A T JJ O
effect CN103214422A T NN O
of CN103214422A T IN O
novel CN103214422A T NN O
substituted CN103214422A T VBN O
amido CN103214422A T IN O
imidazolone CN103214422A T NN O
derivatives CN103214422A T NNS O
. CN103214422A T . O

Target CN103272241A T NN O
SERS CN103272241A T NNP O
( CN103272241A T ( O
Surface CN103272241A T NNP O
Enhanced CN103272241A T NNP O
Raman CN103272241A T NNP O
Scattering CN103272241A T NNP O
) CN103272241A T ) O
probe CN103272241A T NN O
with CN103272241A T IN O
pH-sensitive CN103272241A T JJ O
drug CN103272241A T NN O
release CN103272241A T NN O
characteristic CN103272241A T JJ O
, CN103272241A T , O
and CN103272241A T CC O
preparation CN103272241A T NN O
method CN103272241A T NN O
thereof CN103272241A T NN O
. CN103272241A T . O

The CN103272241A A DT O
probe CN103272241A A NN O
comprises CN103272241A A VBZ O
a CN103272241A A DT O
Raman CN103272241A A NNP O
molecule-labeled CN103272241A A JJ O
gold CN103272241A A NN O
nanoparticle CN103272241A A NN O
core CN103272241A A NN O
, CN103272241A A , O
a CN103272241A A DT O
silicon CN103272241A A NN O
dioxide CN103272241A A NN O
intermediate CN103272241A A JJ O
layer CN103272241A A NN O
, CN103272241A A , O
a CN103272241A A DT O
mesoporous CN103272241A A JJ O
silica CN103272241A A NN O
layer CN103272241A A NN O
, CN103272241A A , O
a CN103272241A A DT O
pH-sensitive CN103272241A A JJ O
polymer CN103272241A A NN O
layer CN103272241A A NN O
, CN103272241A A , O
a CN103272241A A DT O
shell CN103272241A A NN O
layer CN103272241A A NN O
and CN103272241A A CC O
a CN103272241A A DT O
target CN103272241A A NN O
ligand CN103272241A A NN O
on CN103272241A A IN O
the CN103272241A A DT O
surface CN103272241A A NN O
of CN103272241A A IN O
the CN103272241A A DT O
shell CN103272241A A NN O
layer CN103272241A A NN O
sequentially CN103272241A A RB O
from CN103272241A A IN O
inside CN103272241A A IN O
to CN103272241A A TO O
outside CN103272241A A VB O
, CN103272241A A , O
the CN103272241A A DT O
pH-sensitive CN103272241A A JJ O
polymer CN103272241A A NN O
layer CN103272241A A NN O
is CN103272241A A VBZ O
a CN103272241A A DT O
chitosan/polymethylacrylic CN103272241A A JJ O
acid CN103272241A A NN O
layer CN103272241A A NN O
, CN103272241A A , O
and CN103272241A A CC O
the CN103272241A A DT O
target CN103272241A A NN O
ligand CN103272241A A NN O
is CN103272241A A VBZ O
transferrin CN103272241A A JJ I-UN
. CN103272241A A . O

Bis- CN103610669A T NNP O
( CN103610669A T ( O
p-alkoxy CN103610669A T JJ O
benzene CN103610669A T NN O
acrylketone CN103610669A T NN O
) CN103610669A T ) O
like CN103610669A T IN O
glutathione-S-transferase CN103610669A T JJ I-UN
potential CN103610669A T JJ O
inhibitor CN103610669A T NN O
. CN103610669A T . O

The CN103610669A A DT O
invention CN103610669A A NN O
discloses CN103610669A A VBZ O
a CN103610669A A DT O
bis- CN103610669A A JJ O
( CN103610669A A ( O
p-alkoxy CN103610669A A JJ O
benzene CN103610669A A NN O
acrylketone CN103610669A A NN O
) CN103610669A A ) O
like CN103610669A A IN O
glutathione-S-transferase CN103610669A A JJ I-UN
potential CN103610669A A JJ O
inhibitor CN103610669A A NN O
. CN103610669A A . O

Structure CN103610669A A NN O
and CN103610669A A CC O
living CN103610669A A NN O
features CN103610669A A NNS O
of CN103610669A A IN O
the CN103610669A A DT O
potential CN103610669A A JJ O
inhibitor CN103610669A A NN O
are CN103610669A A VBP O
as CN103610669A A IN O
follows CN103610669A A VBZ O
: CN103610669A A : O
two CN103610669A A CD O
p-alkoxy CN103610669A A JJ O
benzene CN103610669A A NN O
acrylketone CN103610669A A NN O
units CN103610669A A NNS O
are CN103610669A A VBP O
linked CN103610669A A VBN O
to CN103610669A A TO O
two CN103610669A A CD O
amino CN103610669A A NN O
groups CN103610669A A NNS O
, CN103610669A A , O
alcoholic CN103610669A A JJ O
hydroxyl CN103610669A A NN O
groups CN103610669A A NNS O
and CN103610669A A CC O
carboxyl CN103610669A A NN O
groups CN103610669A A NNS O
or CN103610669A A CC O
one CN103610669A A CD O
amino CN103610669A A NN O
group CN103610669A A NN O
and CN103610669A A CC O
one CN103610669A A CD O
alcoholic CN103610669A A JJ O
hydroxyl CN103610669A A NN O
group CN103610669A A NN O
which CN103610669A A WDT O
are CN103610669A A VBP O
spaced CN103610669A A VBN O
by CN103610669A A IN O
less CN103610669A A JJR O
than CN103610669A A IN O
8 CN103610669A A CD O
single CN103610669A A JJ O
bonds CN103610669A A NNS O
through CN103610669A A IN O
amide CN103610669A A NN O
and/or CN103610669A A NN O
ester CN103610669A A NN O
bond CN103610669A A NN O
, CN103610669A A , O
wherein CN103610669A A WP O
compounds CN103610669A A NNS O
obtained CN103610669A A VBN O
are CN103610669A A VBP O
substrate CN103610669A A JJ O
and CN103610669A A CC O
inhibitor CN103610669A A NN O
of CN103610669A A IN O
glutathione-S-transferase CN103610669A A NN I-UN
, CN103610669A A , O
namely CN103610669A A RB O
GST CN103610669A A NNP I-UN
; CN103610669A A : O
the CN103610669A A DT O
GST CN103610669A A NNP I-UN
catalyzes CN103610669A A VBZ O
carbon-carbon CN103610669A A JJ O
bond CN103610669A A NN O
and CN103610669A A CC O
reduced CN103610669A A VBD O
glutathione CN103610669A A NN O
, CN103610669A A , O
namely CN103610669A A RB O
GSH CN103610669A A NNP O
, CN103610669A A , O
of CN103610669A A IN O
alpha CN103610669A A NN O
, CN103610669A A , O
beta-unsaturated CN103610669A A JJ O
ketone CN103610669A A NN O
of CN103610669A A IN O
each CN103610669A A DT O
p-alkoxy CN103610669A A JJ O
benzene CN103610669A A NN O
acrylketone CN103610669A A NN O
unit CN103610669A A NN O
in CN103610669A A IN O
the CN103610669A A DT O
compounds CN103610669A A NNS O
and CN103610669A A CC O
generates CN103610669A A VBZ O
a CN103610669A A DT O
compound CN103610669A A NN O
, CN103610669A A , O
namely CN103610669A A RB O
product CN103610669A A NN O
, CN103610669A A , O
through CN103610669A A IN O
Michael CN103610669A A NNP O
addition CN103610669A A NN O
. CN103610669A A . O

The CN103610669A A DT O
product CN103610669A A NN O
shows CN103610669A A VBZ O
a CN103610669A A DT O
stronger CN103610669A A JJR O
inhibiting CN103610669A A VBG O
efficacy CN103610669A A NN O
on CN103610669A A IN O
the CN103610669A A DT O
GST CN103610669A A NNP I-UN
, CN103610669A A , O
so CN103610669A A IN O
that CN103610669A A IN O
the CN103610669A A DT O
compound CN103610669A A NN O
is CN103610669A A VBZ O
a CN103610669A A DT O
GST CN103610669A A NNP I-UN
potential CN103610669A A JJ O
inhibitor CN103610669A A NN O
; CN103610669A A : O
the CN103610669A A DT O
product CN103610669A A NN O
has CN103610669A A VBZ O
a CN103610669A A DT O
stronger CN103610669A A JJR O
inhibiting CN103610669A A VBG O
efficacy CN103610669A A NN O
on CN103610669A A IN O
human CN103610669A A JJ I-UN
GST CN103610669A A NNP I-UN
isozyme CN103610669A A NN O
mu CN103610669A A NN O
in CN103610669A A IN O
comparison CN103610669A A NN O
with CN103610669A A IN O
human CN103610669A A JJ I-UN
GST CN103610669A A NNP I-UN
isozyme CN103610669A A NN I-UN
alpha CN103610669A A NN I-UN
and CN103610669A A CC I-UN
pi CN103610669A A NN I-UN
; CN103610669A A : O
and CN103610669A A CC O
the CN103610669A A DT O
compounds CN103610669A A NNS O
can CN103610669A A MD O
enter CN103610669A A VB O
into CN103610669A A IN O
cells CN103610669A A NNS O
, CN103610669A A , O
and CN103610669A A CC O
can CN103610669A A MD O
enhance CN103610669A A VB O
inhibiting CN103610669A A VBG O
effect CN103610669A A NN O
of CN103610669A A IN O
cis-platinum CN103610669A A NN O
on CN103610669A A IN O
drug-resistant CN103610669A A JJ O
carcinoma CN103610669A A NN O
cell CN103610669A A NN O
growth CN103610669A A NN O
. CN103610669A A . O

Combinations US20090005411 T NNS O
of US20090005411 T IN O
Organic US20090005411 T NNP O
Compounds US20090005411 T NNP O
. US20090005411 T . O

The US20090005411 A DT O
invention US20090005411 A NN O
provides US20090005411 A VBZ O
a US20090005411 A DT O
pharmaceutical US20090005411 A JJ O
combination US20090005411 A NN O
comprising US20090005411 A NN O
: US20090005411 A : O
a US20090005411 A DT O
) US20090005411 A ) O
compounds US20090005411 A VBZ O
that US20090005411 A IN O
inhibit US20090005411 A VB O
the US20090005411 A DT O
binding US20090005411 A NN O
of US20090005411 A IN O
the US20090005411 A DT O
Smac US20090005411 A NNP I-UN
protein US20090005411 A NN O
to US20090005411 A TO O
IAPs US20090005411 A NNP O
; US20090005411 A : O
and US20090005411 A CC O
b US20090005411 A NN O
) US20090005411 A ) O
a US20090005411 A DT O
taxane US20090005411 A NN O
, US20090005411 A , O
and US20090005411 A CC O
a US20090005411 A DT O
method US20090005411 A NN O
for US20090005411 A IN O
treating US20090005411 A VBG O
or US20090005411 A CC O
preventing US20090005411 A VBG O
a US20090005411 A DT O
proliferative US20090005411 A JJ O
disease US20090005411 A NN O
using US20090005411 A VBG O
such US20090005411 A JJ O
a US20090005411 A DT O
combination US20090005411 A NN O
. US20090005411 A . O

phenethanolamine US7538127 T JJ O
derivatives US7538127 T NNS O
like US7538127 T IN O
1- US7538127 T JJ O
( US7538127 T ( O
4-amino-3,5-dichlorophenyl US7538127 T JJ O
) US7538127 T ) O
-2- US7538127 T FW O
[ US7538127 T FW O
( US7538127 T ( O
6- US7538127 T JJ O
{ US7538127 T ( O
2- US7538127 T JJ O
[ US7538127 T NN O
( US7538127 T ( O
2,6-dichlorobenzyl US7538127 T JJ O
) US7538127 T ) O
oxy US7538127 T MD O
] US7538127 T VB O
ethoxy US7538127 T JJ O
} US7538127 T ) O
hexyl US7538127 T NN O
) US7538127 T ) O
amino US7538127 T NN O
] US7538127 T NNP O
ethanol US7538127 T NN O
; US7538127 T : O
respiratory US7538127 T JJ O
diseases US7538127 T NNS O
like US7538127 T IN O
bronchial US7538127 T JJ O
asthma US7538127 T NN O
; US7538127 T : O
selective US7538127 T JJ O
stimulant US7538127 T NN O
of US7538127 T IN O
beta US7538127 T JJ I-UN
2-adrenoreceptors US7538127 T NNS I-UN
; US7538127 T : O
reductive US7538127 T JJ O
amination US7538127 T NN O
; US7538127 T : O
alkylation US7538127 T NN O
. US7538127 T . O

Indole EP1342723B1 T NNP O
derivatives EP1342723B1 T NNS O
and EP1342723B1 T CC O
use EP1342723B1 T NN O
thereof EP1342723B1 T NN O
in EP1342723B1 T IN O
medicines EP1342723B1 T NNS O
. EP1342723B1 T . O

Application CN103585632A T NN O
of CN103585632A T IN O
bile CN103585632A T JJ O
acid CN103585632A T NN O
chelating CN103585632A T VBG O
agent CN103585632A T JJ O
or/and CN103585632A T NN O
vitamin CN103585632A T NN O
D CN103585632A T NNP O
in CN103585632A T IN O
preparing CN103585632A T VBG O
drug CN103585632A T NN O
for CN103585632A T IN O
preventing CN103585632A T VBG O
and CN103585632A T CC O
treating CN103585632A T VBG O
non-alcoholic CN103585632A T JJ O
fatty CN103585632A T JJ O
liver CN103585632A T NN O
disease CN103585632A T NN O
. CN103585632A T . O

Compound CN1586489A T NNP O
glycyrrhizunate CN1586489A T NN O
capsule CN1586489A T NN O
and CN1586489A T CC O
particles CN1586489A T NNS O
and CN1586489A T CC O
the CN1586489A T DT O
preparing CN1586489A T NN O
method CN1586489A T NN O
. CN1586489A T . O

Preparation CN101041646B T NNP O
method CN101041646B T NN O
and CN101041646B T CC O
usage CN101041646B T NN O
for CN101041646B T IN O
nitrogen-containing CN101041646B T JJ O
chalcone CN101041646B T NN O
derivatives CN101041646B T NNS O
. CN101041646B T . O

N-substituted-4- US6974824 T NNP O
( US6974824 T ( O
m-hydroxyphenyl US6974824 T NN O
) US6974824 T ) O
piperidine US6974824 T NN O
derivated US6974824 T VBN O
and US6974824 T CC O
esters US6974824 T NNS O
thereof US6974824 T VBP O
, US6974824 T , O
used US6974824 T VBD O
to US6974824 T TO O
bind US6974824 T VB O
a US6974824 T DT O
kappa US6974824 T NN I-UN
opioid US6974824 T JJ I-UN
receptor US6974824 T NN I-UN
; US6974824 T : O
treating US6974824 T VBG O
drug US6974824 T NN O
addiction US6974824 T NN O
. US6974824 T . O

Kappa US6974824 A NNP I-UN
opioid US6974824 A MD I-UN
receptor US6974824 A VB I-UN
antagonists US6974824 A NNS O
are US6974824 A VBP O
provided US6974824 A VBN O
that US6974824 A IN O
yield US6974824 A NN O
significant US6974824 A JJ O
improvements US6974824 A NNS O
in US6974824 A IN O
functional US6974824 A JJ O
binding US6974824 A NN O
assays US6974824 A NNS O
to US6974824 A TO O
kappa US6974824 A VB I-UN
opioid US6974824 A JJ I-UN
receptors US6974824 A NNS I-UN
relative US6974824 A VBP O
to US6974824 A TO O
nor-BNI US6974824 A JJ O
, US6974824 A , O
and US6974824 A CC O
the US6974824 A DT O
use US6974824 A NN O
of US6974824 A IN O
these US6974824 A DT O
antagonists US6974824 A NNS O
in US6974824 A IN O
treatment US6974824 A NN O
of US6974824 A IN O
disease US6974824 A NN O
states US6974824 A NNS O
that US6974824 A WDT O
are US6974824 A VBP O
ameliorated US6974824 A VBN O
by US6974824 A IN O
binding US6974824 A VBG O
of US6974824 A IN O
the US6974824 A DT O
kappa US6974824 A NN I-UN
opioid US6974824 A JJ I-UN
receptor US6974824 A NN I-UN
such US6974824 A JJ O
as US6974824 A IN O
heroin US6974824 A NN O
or US6974824 A CC O
cocaine US6974824 A NN O
addictions US6974824 A NNS O
. US6974824 A . O

Abca1 WO2005067904A1 T NNP I-UN
stabilizer WO2005067904A1 T NN O
. WO2005067904A1 T . O

It WO2005067904A1 A PRP O
is WO2005067904A1 A VBZ O
intended WO2005067904A1 A VBN O
to WO2005067904A1 A TO O
provide WO2005067904A1 A VB O
an WO2005067904A1 A DT O
ABCA1 WO2005067904A1 A NNP I-UN
stabilizer WO2005067904A1 A NN O
focusing WO2005067904A1 A VBG O
on WO2005067904A1 A IN O
the WO2005067904A1 A DT O
HDL WO2005067904A1 A NNP O
neogenesis WO2005067904A1 A NN O
system WO2005067904A1 A NN O
which WO2005067904A1 A WDT O
is WO2005067904A1 A VBZ O
pharmacologically WO2005067904A1 A RB O
useful WO2005067904A1 A JJ O
as WO2005067904A1 A IN O
a WO2005067904A1 A DT O
preventive/remedy WO2005067904A1 A NN O
for WO2005067904A1 A IN O
low WO2005067904A1 A JJ O
HDL WO2005067904A1 A NNP O
cholesterolemia WO2005067904A1 A NN O
. WO2005067904A1 A . O

Namely WO2005067904A1 A RB O
, WO2005067904A1 A , O
an WO2005067904A1 A DT O
ABCA1 WO2005067904A1 A NNP I-UN
stabilizer WO2005067904A1 A NN O
, WO2005067904A1 A , O
which WO2005067904A1 A WDT O
comprises WO2005067904A1 A VBZ O
a WO2005067904A1 A DT O
bisphenol WO2005067904A1 A NN O
compound WO2005067904A1 A NN O
selected WO2005067904A1 A VBN O
from WO2005067904A1 A IN O
among WO2005067904A1 A IN O
probucol WO2005067904A1 A JJ O
spiroquinone WO2005067904A1 A NN O
, WO2005067904A1 A , O
probucol WO2005067904A1 A VB O
diphenoquinone WO2005067904A1 A NN O
and WO2005067904A1 A CC O
probucol WO2005067904A1 A NN O
bisphenol WO2005067904A1 A NN O
as WO2005067904A1 A IN O
the WO2005067904A1 A DT O
active WO2005067904A1 A JJ O
ingredient WO2005067904A1 A NN O
, WO2005067904A1 A , O
enables WO2005067904A1 A VBZ O
the WO2005067904A1 A DT O
continuous WO2005067904A1 A JJ O
and WO2005067904A1 A CC O
stable WO2005067904A1 A JJ O
express WO2005067904A1 A NN O
of WO2005067904A1 A IN O
ABCA1 WO2005067904A1 A NNP I-UN
by WO2005067904A1 A IN O
a WO2005067904A1 A DT O
mechanism WO2005067904A1 A NN O
completely WO2005067904A1 A RB O
different WO2005067904A1 A JJ O
from WO2005067904A1 A IN O
those WO2005067904A1 A DT O
in WO2005067904A1 A IN O
the WO2005067904A1 A DT O
conventional WO2005067904A1 A JJ O
art WO2005067904A1 A NN O
, WO2005067904A1 A , O
thereby WO2005067904A1 A RB O
increasing WO2005067904A1 A VBG O
blood WO2005067904A1 A NN O
HDL WO2005067904A1 A NNP O
level WO2005067904A1 A NN O
. WO2005067904A1 A . O

Methods WO2008049856A3 T NNS O
of WO2008049856A3 T IN O
treating WO2008049856A3 T VBG O
pain WO2008049856A3 T NN O
using WO2008049856A3 T VBG O
cdk WO2008049856A3 T JJ I-UN
inhibitors WO2008049856A3 T NNS O
. WO2008049856A3 T . O

The WO2008049856A3 A DT O
present WO2008049856A3 A JJ O
invention WO2008049856A3 A NN O
relates WO2008049856A3 A VBZ O
to WO2008049856A3 A TO O
inhibitors WO2008049856A3 A NNS O
of WO2008049856A3 A IN O
cyclin-dependent WO2008049856A3 A JJ I-UN
kinases WO2008049856A3 A NNS I-UN
and WO2008049856A3 A CC O
therapeutic WO2008049856A3 A JJ O
applications WO2008049856A3 A NNS O
thereof WO2008049856A3 A NN O
. WO2008049856A3 A . O

Furthermore WO2008049856A3 A RB O
, WO2008049856A3 A , O
the WO2008049856A3 A DT O
invention WO2008049856A3 A NN O
relates WO2008049856A3 A VBZ O
to WO2008049856A3 A TO O
methods WO2008049856A3 A NNS O
of WO2008049856A3 A IN O
preventing WO2008049856A3 A VBG O
and/or WO2008049856A3 A JJ O
treating WO2008049856A3 A VBG O
any WO2008049856A3 A DT O
type WO2008049856A3 A NN O
of WO2008049856A3 A IN O
pain WO2008049856A3 A NN O
comprising WO2008049856A3 A VBG O
the WO2008049856A3 A DT O
administration WO2008049856A3 A NN O
of WO2008049856A3 A IN O
an WO2008049856A3 A DT O
effective WO2008049856A3 A JJ O
amount WO2008049856A3 A NN O
of WO2008049856A3 A IN O
at WO2008049856A3 A IN O
least WO2008049856A3 A JJS O
one WO2008049856A3 A CD O
inhibitor WO2008049856A3 A NN O
of WO2008049856A3 A IN O
cyclin-dependent WO2008049856A3 A JJ I-UN
kinases WO2008049856A3 A NNS I-UN
. WO2008049856A3 A . O

Hypovolemic CN102836125A T NNP O
shock CN102836125A T NN O
treatment CN102836125A T NN O
nasal CN102836125A T JJ O
administration CN102836125A T NN O
preparations CN102836125A T NNS O
of CN102836125A T IN O
valproic CN102836125A T NN O
acid CN102836125A T NN O
and CN102836125A T CC O
salts CN102836125A T NNS O
thereof CN102836125A T NN O
. CN102836125A T . O

Amino US20110082097 T NNP O
acid US20110082097 T VBZ O
composition US20110082097 T NN O
for US20110082097 T IN O
improving US20110082097 T VBG O
glucose US20110082097 T JJ O
tolerance US20110082097 T NN O
. US20110082097 T . O

Application CN103405451A T NN O
of CN103405451A T IN O
Chukrasone CN103405451A T NNP O
A CN103405451A T NNP O
in CN103405451A T IN O
medicaments CN103405451A T NNS O
for CN103405451A T IN O
treating CN103405451A T VBG O
tongue CN103405451A T NN O
carcinoma CN103405451A T NN O
. CN103405451A T . O

Use US7824717 T NNP O
of US7824717 T IN O
licochalcone US7824717 T NN O
A US7824717 T NNP O
against US7824717 T IN O
rosacea US7824717 T NN O
. US7824717 T . O

Compositions WO2013078554A1 T NNS O
of WO2013078554A1 T IN O
tigecycline WO2013078554A1 T NN O
and WO2013078554A1 T CC O
uses WO2013078554A1 T VBZ O
thereof WO2013078554A1 T NN O
. WO2013078554A1 T . O

Modulating US20080009447 T VBG O
cytokine US20080009447 T NN O
or US20080009447 T CC O
hormone US20080009447 T NN O
signalling US20080009447 T NN O
in US20080009447 T IN O
an US20080009447 T DT O
animal US20080009447 T JJ O
comprising US20080009447 T NN O
up-regulating US20080009447 T JJ O
the US20080009447 T DT O
expression US20080009447 T NN O
of US20080009447 T IN O
SOCS US20080009447 T NNP I-UN
sequence US20080009447 T NN O
in US20080009447 T IN O
the US20080009447 T DT O
animal US20080009447 T NN O
. US20080009447 T . O

Application CN103356571A T NN O
of CN103356571A T IN O
Sarcaboside CN103356571A T NNP O
B CN103356571A T NNP O
in CN103356571A T IN O
preparation CN103356571A T NN O
of CN103356571A T IN O
medicines CN103356571A T NNS O
for CN103356571A T IN O
treating CN103356571A T VBG O
nasopharynx CN103356571A T JJ O
cancer CN103356571A T NN O
. CN103356571A T . O

Pharmaceutical US20050228024 T JJ O
compositions US20050228024 T NNS O
comprising US20050228024 T VBG O
a US20050228024 T DT O
benzofuran US20050228024 T NN O
derivative US20050228024 T NN O
and US20050228024 T CC O
their US20050228024 T PRP$ O
use US20050228024 T NN O
for US20050228024 T IN O
the US20050228024 T DT O
treatment US20050228024 T NN O
of US20050228024 T IN O
attention US20050228024 T NN O
deficit/hyperactivity US20050228024 T NN O
disorder US20050228024 T NN O
. US20050228024 T . O

Amino CN101265178A T NNP O
acid CN101265178A T JJ O
salt CN101265178A T NN O
of CN101265178A T IN O
( CN101265178A T ( O
S CN101265178A T NNP O
) CN101265178A T ) O
-ibuprofen CN101265178A T NN O
and CN101265178A T CC O
medicinal CN101265178A T JJ O
composition CN101265178A T NN O
thereof CN101265178A T NN O
. CN101265178A T . O

Application CN103239466A T NN O
of CN103239466A T IN O
punicalin CN103239466A T NN O
in CN103239466A T IN O
preparation CN103239466A T NN O
of CN103239466A T IN O
medicine CN103239466A T NN O
for CN103239466A T IN O
treating CN103239466A T VBG O
or CN103239466A T CC O
preventing CN103239466A T VBG O
hepatitis CN103239466A T NN O
C CN103239466A T NNP O
virus CN103239466A T NN O
infection CN103239466A T NN O
. CN103239466A T . O

Bridged WO2012158271A1 T NNP O
polycyclic WO2012158271A1 T JJ O
compounds WO2012158271A1 T NNS O
as WO2012158271A1 T IN O
antiviral WO2012158271A1 T JJ O
agents WO2012158271A1 T NNS O
. WO2012158271A1 T . O

Pyrazolopyrimidine WO2006098519A1 T NNP O
derivative WO2006098519A1 T NN O
or WO2006098519A1 T CC O
pharmaceutically WO2006098519A1 T RB O
acceptable WO2006098519A1 T JJ O
salt WO2006098519A1 T NN O
thereof WO2006098519A1 T NN O
. WO2006098519A1 T . O

A WO2006098519A1 A DT O
pyrazolopyrimidine WO2006098519A1 A JJ O
derivative WO2006098519A1 A NN O
represented WO2006098519A1 A VBN O
by WO2006098519A1 A IN O
the WO2006098519A1 A DT O
general WO2006098519A1 A JJ O
formula WO2006098519A1 A NN O
( WO2006098519A1 A ( O
I WO2006098519A1 A PRP O
) WO2006098519A1 A ) O
and WO2006098519A1 A CC O
a WO2006098519A1 A DT O
pharmaceutically WO2006098519A1 A RB O
acceptable WO2006098519A1 A JJ O
salt WO2006098519A1 A NN O
thereof WO2006098519A1 A NN O
exhibits WO2006098519A1 A VBZ O
excellent WO2006098519A1 A JJ O
MAPKAP-K2 WO2006098519A1 A NNP I-UN
inhibitory WO2006098519A1 A NN O
activity WO2006098519A1 A NN O
. WO2006098519A1 A . O

Poultry CN103446173A T NNP O
solution CN103446173A T NN O
capable CN103446173A T NN O
of CN103446173A T IN O
boosting CN103446173A T VBG O
intestinal CN103446173A T JJ O
tract CN103446173A T NN O
and CN103446173A T CC O
improving CN103446173A T VBG O
resistance CN103446173A T NN O
and CN103446173A T CC O
preparation CN103446173A T NN O
method CN103446173A T NN O
thereof CN103446173A T NN O
. CN103446173A T . O

Health WO2005036989A1 T NNP O
food WO2005036989A1 T NN O
containing WO2005036989A1 T VBG O
hyaluronic WO2005036989A1 T JJ O
acid WO2005036989A1 T NN O
and WO2005036989A1 T CC O
dermatan WO2005036989A1 T JJ O
sulfate WO2005036989A1 T NN O
. WO2005036989A1 T . O

Amino-substituted WO2014029360A1 T JJ O
rutaecarpin WO2014029360A1 T NN O
analog WO2014029360A1 T NN O
and WO2014029360A1 T CC O
synthesis WO2014029360A1 T NN O
method WO2014029360A1 T NN O
and WO2014029360A1 T CC O
use WO2014029360A1 T NN O
thereof WO2014029360A1 T NN O
in WO2014029360A1 T IN O
preparation WO2014029360A1 T NN O
of WO2014029360A1 T IN O
anti-obesity WO2014029360A1 T JJ O
drug WO2014029360A1 T NN O
. WO2014029360A1 T . O

Includes US7645465 T NNP O
acid-treatment US7645465 T NN O
of US7645465 T IN O
ginseng US7645465 T NN O
and US7645465 T CC O
bio-converting US7645465 T JJ O
treatment US7645465 T NN O
, US7645465 T , O
such US7645465 T JJ O
as US7645465 T IN O
lactic US7645465 T JJ O
acid US7645465 T IN O
bacterial US7645465 T JJ O
fermenting US7645465 T NN O
and US7645465 T CC O
intestinal US7645465 T JJ O
bacterial US7645465 T JJ O
fermenting US7645465 T NN O
process US7645465 T NN O
, US7645465 T , O
extracting US7645465 T VBG O
acid US7645465 T NN O
treated US7645465 T VBD O
ginseng US7645465 T NN O
with US7645465 T IN O
organic US7645465 T JJ O
solvent US7645465 T NN O
to US7645465 T TO O
obtain US7645465 T VB O
organic US7645465 T JJ O
extract US7645465 T NN O
, US7645465 T , O
fermenting US7645465 T VBG O
organic US7645465 T JJ O
extract US7645465 T NN O
with US7645465 T IN O
lactic-acid US7645465 T JJ O
bacteria US7645465 T NNS O
Bifidobacterium US7645465 T NNP O
KK-1 US7645465 T NNP O
. US7645465 T . O

A US7645465 A DT O
process US7645465 A NN O
for US7645465 A IN O
preparing US7645465 A VBG O
a US7645465 A DT O
processed US7645465 A JJ O
ginseng US7645465 A NN O
extract US7645465 A NN O
with US7645465 A IN O
enhanced US7645465 A JJ O
pharmacological US7645465 A JJ O
effects US7645465 A NNS O
due US7645465 A JJ O
to US7645465 A TO O
subsequent US7645465 A JJ O
treatment US7645465 A NN O
is US7645465 A VBZ O
disclosed US7645465 A VBN O
. US7645465 A . O

The US7645465 A DT O
subsequent US7645465 A JJ O
treatment US7645465 A NN O
includes US7645465 A VBZ O
an US7645465 A DT O
acid-treatment US7645465 A NN O
of US7645465 A IN O
ginseng US7645465 A NN O
and US7645465 A CC O
a US7645465 A DT O
bio-converting US7645465 A JJ O
treatment US7645465 A NN O
, US7645465 A , O
such US7645465 A JJ O
as US7645465 A IN O
a US7645465 A DT O
lactic US7645465 A JJ O
acid US7645465 A NN O
bacterial US7645465 A JJ O
fermenting US7645465 A NN O
and US7645465 A CC O
an US7645465 A DT O
intestinal US7645465 A JJ O
bacterial US7645465 A JJ O
fermenting US7645465 A NN O
process US7645465 A NN O
. US7645465 A . O

Pyrazole EP2630126A1 T NNP O
compounds EP2630126A1 T VBZ O
acting EP2630126A1 T VBG O
against EP2630126A1 T IN O
allergic EP2630126A1 T NN O
, EP2630126A1 T , O
immune EP2630126A1 T NN O
and EP2630126A1 T CC O
inflammatory EP2630126A1 T JJ O
conditions EP2630126A1 T NNS O
. EP2630126A1 T . O

Ingenol-3-acylates WO2012085189A1 T NNS O
i WO2012085189A1 T NN O
. WO2012085189A1 T . O

Providone US20100104614 T NN O
compositions US20100104614 T NNS O
for US20100104614 T IN O
wound US20100104614 T NN O
healing US20100104614 T NN O
. US20100104614 T . O

Treating WO2012088388A2 T VBG O
multiple WO2012088388A2 T JJ O
myeloma WO2012088388A2 T NN O
. WO2012088388A2 T . O

Treating US7208505 T VBG O
Type US7208505 T NNP O
2 US7208505 T CD O
diabetes US7208505 T NNS O
and/or US7208505 T JJ O
obesity US7208505 T NN O
; US7208505 T : O
compounds US7208505 T NNS O
are US7208505 T VBP O
indoles US7208505 T NNS O
substituted US7208505 T VBN O
at US7208505 T IN O
position US7208505 T NN O
3 US7208505 T CD O
with US7208505 T IN O
a US7208505 T DT O
( US7208505 T ( O
3- US7208505 T JJ O
( US7208505 T ( O
2- US7208505 T JJ O
( US7208505 T ( O
heterocycle-substituted US7208505 T JJ O
) US7208505 T ) O
phenoxy US7208505 T NN O
) US7208505 T ) O
-2-hydroxypropylamino US7208505 T NN O
) US7208505 T ) O
alkyl US7208505 T NN O
group US7208505 T NN O
. US7208505 T . O

The US7208505 A DT O
present US7208505 A JJ O
invention US7208505 A NN O
relates US7208505 A VBZ O
to US7208505 A TO O
a US7208505 A DT O
β3 US7208505 A JJ I-UN
adrenergic US7208505 A JJ I-UN
receptor US7208505 A NN I-UN
agonist US7208505 A NN O
of US7208505 A IN O
formula US7208505 A NN O
( US7208505 A ( O
I US7208505 A PRP O
) US7208505 A ) O
; US7208505 A : O
or US7208505 A CC O
a US7208505 A DT O
pharmaceutical US7208505 A JJ O
salt US7208505 A NN O
thereof US7208505 A NN O
; US7208505 A : O
which US7208505 A WDT O
is US7208505 A VBZ O
capable US7208505 A JJ O
of US7208505 A IN O
increasing US7208505 A VBG O
lipolysis US7208505 A NN O
and US7208505 A CC O
energy US7208505 A NN O
expenditure US7208505 A NN O
in US7208505 A IN O
cells US7208505 A NNS O
and US7208505 A CC O
, US7208505 A , O
therefore US7208505 A RB O
, US7208505 A , O
is US7208505 A VBZ O
useful US7208505 A JJ O
, US7208505 A , O
e.g. US7208505 A NN O
, US7208505 A , O
for US7208505 A IN O
treating US7208505 A VBG O
Type US7208505 A NNP O
2 US7208505 A CD O
diabetes US7208505 A NNS O
and/or US7208505 A VBP O
obesity US7208505 A NN O

Trihemihydrate CA2558629A1 T NNP O
, CA2558629A1 T , O
anhydrate CA2558629A1 T NN O
and CA2558629A1 T CC O
hydrate CA2558629A1 T NN O
forms CA2558629A1 T NNS O
of CA2558629A1 T IN O
cefdinir CA2558629A1 T NN O
. CA2558629A1 T . O

Identification CA2820201A1 T NN O
of CA2820201A1 T IN O
tumor-associated CA2820201A1 T JJ O
antigens CA2820201A1 T NNS O
for CA2820201A1 T IN O
diagnosis CA2820201A1 T NN O
and CA2820201A1 T CC O
therapy CA2820201A1 T NN O
. CA2820201A1 T . O

Composition WO2008096155A1 T NN O
comprising WO2008096155A1 T VBG O
a WO2008096155A1 T DT O
glycolytic WO2008096155A1 T JJ O
inhibitor WO2008096155A1 T NN O
and WO2008096155A1 T CC O
a WO2008096155A1 T DT O
ring WO2008096155A1 T NN O
system WO2008096155A1 T NN O
comprising WO2008096155A1 T VBG O
a WO2008096155A1 T DT O
sulphamate WO2008096155A1 T NN O
group WO2008096155A1 T NN O
for WO2008096155A1 T IN O
the WO2008096155A1 T DT O
treatment WO2008096155A1 T NN O
of WO2008096155A1 T IN O
cancer WO2008096155A1 T NN O
. WO2008096155A1 T . O

The WO2008096155A1 A DT O
present WO2008096155A1 A JJ O
invention WO2008096155A1 A NN O
provides WO2008096155A1 A VBZ O
a WO2008096155A1 A DT O
composition WO2008096155A1 A NN O
comprising WO2008096155A1 A NN O
( WO2008096155A1 A ( O
a WO2008096155A1 A DT O
) WO2008096155A1 A ) O
a WO2008096155A1 A DT O
glycolytic WO2008096155A1 A JJ O
inhibitor WO2008096155A1 A NN O
( WO2008096155A1 A ( O
b WO2008096155A1 A NN O
) WO2008096155A1 A ) O
a WO2008096155A1 A DT O
compound WO2008096155A1 A NN O
comprising WO2008096155A1 A VBG O
a WO2008096155A1 A DT O
ring WO2008096155A1 A NN O
system WO2008096155A1 A NN O
substituted WO2008096155A1 A VBN O
with WO2008096155A1 A IN O
at WO2008096155A1 A IN O
least WO2008096155A1 A JJS O
one WO2008096155A1 A CD O
of WO2008096155A1 A IN O
a WO2008096155A1 A DT O
suiphamate WO2008096155A1 A NN O
group WO2008096155A1 A NN O
and WO2008096155A1 A CC O
an WO2008096155A1 A DT O
alkoxy WO2008096155A1 A JJ O
group WO2008096155A1 A NN O
; WO2008096155A1 A : O
wherein WO2008096155A1 A CC O
( WO2008096155A1 A ( O
a WO2008096155A1 A DT O
) WO2008096155A1 A ) O
and WO2008096155A1 A CC O
( WO2008096155A1 A ( O
b WO2008096155A1 A NN O
) WO2008096155A1 A ) O
are WO2008096155A1 A VBP O
different WO2008096155A1 A JJ O
. WO2008096155A1 A . O

An CN101045704A T DT O
improved CN101045704A T JJ O
process CN101045704A T NN O
for CN101045704A T IN O
preparing CN101045704A T VBG O
pure CN101045704A T NN O
ondansetron CN101045704A T NN O
hydrochloride CN101045704A T NN O
dihydrate CN101045704A T NN O
. CN101045704A T . O

External CN101045060A T NNP O
use CN101045060A T NN O
medicine CN101045060A T NN O
containing CN101045060A T VBG O
tetramethylpyrazine CN101045060A T JJ O
GC CN101045060A T NNP O
glucocorticoid CN101045060A T NN O
with CN101045060A T IN O
its CN101045060A T PRP$ O
skin CN101045060A T JJ O
side-effects CN101045060A T NNS O
reducing CN101045060A T VBG O
obviously CN101045060A T RB O
. CN101045060A T . O

An CN101045060A A DT O
exterior-applied CN101045060A A JJ O
composite CN101045060A A JJ O
medicine CN101045060A A NN O
for CN101045060A A IN O
preventing CN101045060A A VBG O
and CN101045060A A CC O
treating CN101045060A A VBG O
dermatopathy CN101045060A A NN O
with CN101045060A A IN O
obviously CN101045060A A RB O
decreased CN101045060A A VBN O
by-effect CN101045060A A JJ O
contains CN101045060A A NNS O
ligustrazine CN101045060A A JJ O
and CN101045060A A CC O
glucocorticoid CN101045060A A NN O
. CN101045060A A . O

N- US20060154944 T NNP O
( US20060154944 T ( O
3,5-dimethylphenyl US20060154944 T CD O
) US20060154944 T ) O
-1- US20060154944 T NN O
( US20060154944 T ( O
3-fluorophenyl US20060154944 T JJ O
) US20060154944 T ) O
-1,9-dihydrospiro US20060154944 T FW O
[ US20060154944 T JJ O
beta-carboline-4,1'-cyclopropane US20060154944 T NN O
] US20060154944 T NN O
-2 US20060154944 T NNP O
( US20060154944 T ( O
3H US20060154944 T CD O
) US20060154944 T ) O
-carboxamide US20060154944 T NN O
; US20060154944 T : O
affinity US20060154944 T NN O
for US20060154944 T IN O
mitochondrial US20060154944 T JJ O
benzodiazepine US20060154944 T NN O
receptors US20060154944 T NNS O
preventive/therapeutic US20060154944 T JJ O
to US20060154944 T TO O
stress-related US20060154944 T JJ O
diseases US20060154944 T NNS O
; US20060154944 T : O
irritable US20060154944 T JJ O
bowel US20060154944 T NN O
syndrome US20060154944 T NN O
; US20060154944 T : O
anxiolytic US20060154944 T JJ O
agents US20060154944 T NNS O
; US20060154944 T : O
nervous/respiratory US20060154944 T JJ O
system US20060154944 T NN O
disorders US20060154944 T NNS O
; US20060154944 T : O
asthma US20060154944 T NN O
. US20060154944 T . O

Sulfonated CN1660885A T VBN O
sterol CN1660885A T NN O
, CN1660885A T , O
preparing CN1660885A T VBG O
method CN1660885A T NN O
and CN1660885A T CC O
application CN1660885A T NN O
. CN1660885A T . O

Selective EP1345608B1 T JJ O
dopamine EP1345608B1 T NN I-UN
d4 EP1345608B1 T NN I-UN
receptor EP1345608B1 T NN I-UN
agonists EP1345608B1 T NNS O
for EP1345608B1 T IN O
treating EP1345608B1 T VBG O
sexual EP1345608B1 T JJ O
dysfunction EP1345608B1 T NN O
. EP1345608B1 T . O

The EP1345608B1 A DT O
present EP1345608B1 A JJ O
invention EP1345608B1 A NN O
relates EP1345608B1 A VBZ O
to EP1345608B1 A TO O
the EP1345608B1 A DT O
use EP1345608B1 A NN O
of EP1345608B1 A IN O
selective EP1345608B1 A JJ O
dopamine EP1345608B1 A NN I-UN
D4 EP1345608B1 A NNP I-UN
receptor EP1345608B1 A NN I-UN
agonists EP1345608B1 A NNS O
and EP1345608B1 A CC O
to EP1345608B1 A TO O
compositions EP1345608B1 A NNS O
containing EP1345608B1 A VBG O
selective EP1345608B1 A JJ O
dopamine EP1345608B1 A NN I-UN
D4 EP1345608B1 A NNP I-UN
receptor EP1345608B1 A NN I-UN
agonists EP1345608B1 A NNS O
for EP1345608B1 A IN O
the EP1345608B1 A DT O
treatment EP1345608B1 A NN O
of EP1345608B1 A IN O
sexual EP1345608B1 A JJ O
dysfunction EP1345608B1 A NN O
. EP1345608B1 A . O

Novel WO2008107879A1 T NNP O
cannabidiol WO2008107879A1 T NN O
derivatives WO2008107879A1 T NNS O
and WO2008107879A1 T CC O
their WO2008107879A1 T PRP$ O
use WO2008107879A1 T NN O
as WO2008107879A1 T IN O
anti-inflammatory WO2008107879A1 T JJ O
agents WO2008107879A1 T NNS O
. WO2008107879A1 T . O

Antiviral WO2009153791A1 T NNP O
terpenoid WO2009153791A1 T NN O
compounds WO2009153791A1 T NNS O
. WO2009153791A1 T . O

Oral CN1559437A T JJ O
Liquid-supplement CN1559437A T JJ O
salt CN1559437A T NN O
quick-dissolving CN1559437A T JJ O
tablets CN1559437A T NNS O
, CN1559437A T , O
prepn CN1559437A T NN O
. CN1559437A T . O

method CN1559437A T NN O
therefor CN1559437A T NN O
. CN1559437A T . O

Sedative CN102846538A T NNP O
hypnotic CN102846538A T JJ O
pharmaceutical CN102846538A T JJ O
preparation CN102846538A T NN O
and CN102846538A T CC O
its CN102846538A T PRP$ O
preparation CN102846538A T NN O
method CN102846538A T NN O
. CN102846538A T . O

Wound US8409610 T NNP O
care US8409610 T NN O
device US8409610 T NN O
. US8409610 T . O

Gastrodin CN1559417A T NNP O
venous CN1559417A T JJ O
injection CN1559417A T NN O
liquid CN1559417A T NN O
, CN1559417A T , O
and CN1559417A T CC O
its CN1559417A T PRP$ O
prepn CN1559417A T NN O
. CN1559417A T . O

method CN1559417A T NN O
. CN1559417A T . O

Controlled EP1401408A4 T VBN O
heat EP1401408A4 T NN O
induced EP1401408A4 T VBN O
rapid EP1401408A4 T JJ O
delivery EP1401408A4 T NN O
of EP1401408A4 T IN O
pharmaceuticals EP1401408A4 T NNS O
from EP1401408A4 T IN O
skin EP1401408A4 T JJ O
depot EP1401408A4 T NN O
. EP1401408A4 T . O

Choline CA2741941A1 T NNP O
and CA2741941A1 T CC O
tromethamine CA2741941A1 T JJ O
salt CA2741941A1 T NN O
of CA2741941A1 T IN O
licofelone CA2741941A1 T NN O
. CA2741941A1 T . O

Method CN101700224A T NNP O
for CN101700224A T IN O
preparing CN101700224A T VBG O
oral CN101700224A T JJ O
chondroitin CN101700224A T NN O
sulfate CN101700224A T NN O
nanoemulsion CN101700224A T NN O
. CN101700224A T . O

Enhancing US7078386 T VBG O
agent US7078386 T NN O
for US7078386 T IN O
nerve US7078386 T NN O
growth US7078386 T NN O
factor US7078386 T NN O
production US7078386 T NN O
comprising US7078386 T VBG O
a US7078386 T DT O
compound US7078386 T NN O
having US7078386 T VBG O
a US7078386 T DT O
coumarin US7078386 T NN O
backbone US7078386 T NN O
or US7078386 T CC O
a US7078386 T DT O
compound US7078386 T NN O
having US7078386 T VBG O
a US7078386 T DT O
2-dimethyl US7078386 T JJ O
chroman US7078386 T NN O
backbone US7078386 T NN O
. US7078386 T . O

Application CN102940632A T NN O
of CN102940632A T IN O
FK506-A CN102940632A T NNP O
compound CN102940632A T NN O
in CN102940632A T IN O
preparation CN102940632A T NN O
of CN102940632A T IN O
immunosuppressant CN102940632A T NN O
. CN102940632A T . O

Including US20080269282 T VBG O
semicarbazide-sensitive US20080269282 T JJ O
amine US20080269282 T JJ O
oxidase US20080269282 T NN O
( US20080269282 T ( O
vascular US20080269282 T JJ I-UN
adhesion US20080269282 T NN I-UN
protein-1 US20080269282 T NN I-UN
, US20080269282 T , O
VAP-I US20080269282 T NNP I-UN
) US20080269282 T ) O
, US20080269282 T , O
and US20080269282 T CC O
therapeutic US20080269282 T JJ O
use US20080269282 T NN O
in US20080269282 T IN O
inflammatory US20080269282 T NN O
diseases US20080269282 T NNS O
, US20080269282 T , O
diabetes US20080269282 T NNS O
and US20080269282 T CC O
its US20080269282 T PRP$ O
associated US20080269282 T JJ O
complications US20080269282 T NNS O
, US20080269282 T , O
atherosclerosis US20080269282 T NN O
, US20080269282 T , O
neurodegenerative US20080269282 T JJ O
diseases US20080269282 T NNS O
, US20080269282 T , O
obesity US20080269282 T NN O
, US20080269282 T , O
hypertension US20080269282 T NN O
and US20080269282 T CC O
cancer US20080269282 T NN O
; US20080269282 T : O
N1-hydroxy-N2- US20080269282 T NNP O
[ US20080269282 T NNP O
( US20080269282 T ( O
4-bromophenyl US20080269282 T JJ O
) US20080269282 T ) O
carbonyl US20080269282 T NN O
] US20080269282 T JJ O
glycinamide US20080269282 T NN O
. US20080269282 T . O

This US20080269282 A DT O
invention US20080269282 A NN O
is US20080269282 A VBZ O
directed US20080269282 A VBN O
to US20080269282 A TO O
inhibitors US20080269282 A NNS O
of US20080269282 A IN O
copper-containing US20080269282 A JJ O
amine US20080269282 A NN O
oxidases US20080269282 A NNS O
( US20080269282 A ( O
E.C.1.4.3.6 US20080269282 A NNP O
) US20080269282 A ) O
including US20080269282 A VBG O
semicarbazide-sensitive US20080269282 A JJ O
amine US20080269282 A JJ O
oxidase US20080269282 A NN O
( US20080269282 A ( O
SSAO US20080269282 A NNP I-UN
; US20080269282 A : O
also US20080269282 A RB O
known US20080269282 A VBN O
as US20080269282 A IN O
vascular US20080269282 A JJ I-UN
adhesion US20080269282 A NN I-UN
protein-1 US20080269282 A NN I-UN
, US20080269282 A , O
VAP-I US20080269282 A NNP I-UN
) US20080269282 A ) O
, US20080269282 A , O
and US20080269282 A CC O
their US20080269282 A PRP$ O
therapeutic US20080269282 A JJ O
use US20080269282 A NN O
in US20080269282 A IN O
inflammatory US20080269282 A NN O
diseases US20080269282 A NNS O
, US20080269282 A , O
diabetes US20080269282 A NNS O
and US20080269282 A CC O
its US20080269282 A PRP$ O
associated US20080269282 A JJ O
complications US20080269282 A NNS O
, US20080269282 A , O
atherosclerosis US20080269282 A NN O
, US20080269282 A , O
neurodegenerative US20080269282 A JJ O
diseases US20080269282 A NNS O
, US20080269282 A , O
obesity US20080269282 A NN O
, US20080269282 A , O
hypertension US20080269282 A NN O
and US20080269282 A CC O
cancer US20080269282 A NN O
. US20080269282 A . O

Novel US20120207679 T NNP O
Heteroaryl US20120207679 T NNP O
Substituted US20120207679 T NNP O
Benzothiazoles US20120207679 T NNP O
. US20120207679 T . O

Furthermore US20120207679 A RB O
, US20120207679 A , O
the US20120207679 A DT O
invention US20120207679 A NN O
relates US20120207679 A VBZ O
to US20120207679 A TO O
novel US20120207679 A VB O
heteroaryl US20120207679 A NN O
substituted US20120207679 A VBN O
benzothiazole US20120207679 A JJ O
derivatives US20120207679 A NNS O
that US20120207679 A WDT O
are US20120207679 A VBP O
suitable US20120207679 A JJ O
for US20120207679 A IN O
imaging US20120207679 A VBG O
amyloid US20120207679 A JJ I-UN
deposits US20120207679 A NNS O
in US20120207679 A IN O
living US20120207679 A NN O
patients US20120207679 A NNS O
, US20120207679 A , O
their US20120207679 A PRP$ O
compositions US20120207679 A NNS O
, US20120207679 A , O
methods US20120207679 A NNS O
of US20120207679 A IN O
use US20120207679 A NN O
and US20120207679 A CC O
processes US20120207679 A VBZ O
to US20120207679 A TO O
make US20120207679 A VB O
such US20120207679 A JJ O
compounds US20120207679 A NNS O
. US20120207679 A . O

More US20120207679 A RBR O
specifically US20120207679 A RB O
, US20120207679 A , O
the US20120207679 A DT O
present US20120207679 A JJ O
invention US20120207679 A NN O
relates US20120207679 A VBZ O
to US20120207679 A TO O
a US20120207679 A DT O
method US20120207679 A NN O
of US20120207679 A IN O
imaging US20120207679 A VBG O
amyloid US20120207679 A JJ I-UN
deposits US20120207679 A NNS O
in US20120207679 A IN O
brain US20120207679 A NN O
in US20120207679 A IN O
vivo US20120207679 A NN O
to US20120207679 A TO O
allow US20120207679 A VB O
antemortem US20120207679 A JJ O
diagnosis US20120207679 A NN O
of US20120207679 A IN O
Alzheimer US20120207679 A NNP O
's US20120207679 A POS O
disease US20120207679 A NN O
as US20120207679 A RB O
well US20120207679 A RB O
as US20120207679 A IN O
measuring US20120207679 A VBG O
clinical US20120207679 A JJ O
efficacy US20120207679 A NN O
of US20120207679 A IN O
Alzheimer US20120207679 A NNP O
's US20120207679 A POS O
disease US20120207679 A NN O
therapeutic US20120207679 A JJ O
agents US20120207679 A NNS O
. US20120207679 A . O

Bicyclic EP1961745A1 T NNP O
heterocyclic EP1961745A1 T JJ O
compound EP1961745A1 T NN O
. EP1961745A1 T . O

A EP1961745A1 A DT O
compound EP1961745A1 A NN O
represented EP1961745A1 A VBN O
by EP1961745A1 A IN O
the EP1961745A1 A DT O
formula EP1961745A1 A NN O
( EP1961745A1 A ( O
I EP1961745A1 A PRP O
) EP1961745A1 A ) O
, EP1961745A1 A , O
a EP1961745A1 A DT O
salt EP1961745A1 A NN O
thereof EP1961745A1 A NN O
, EP1961745A1 A , O
an EP1961745A1 A DT O
N-oxide EP1961745A1 A JJ O
thereof EP1961745A1 A NN O
, EP1961745A1 A , O
a EP1961745A1 A DT O
solvate EP1961745A1 A NN O
thereof EP1961745A1 A NN O
, EP1961745A1 A , O
or EP1961745A1 A CC O
a EP1961745A1 A DT O
prodrug EP1961745A1 A JJ O
thereof EP1961745A1 A NN O
: EP1961745A1 A : O
wherein EP1961745A1 A NN O
X EP1961745A1 A NNP O
, EP1961745A1 A , O
Y EP1961745A1 A NNP O
, EP1961745A1 A , O
and EP1961745A1 A CC O
W EP1961745A1 A NNP O
each EP1961745A1 A DT O
independently EP1961745A1 A RB O
represent EP1961745A1 A VBP O
a EP1961745A1 A DT O
carbon EP1961745A1 A NN O
atom EP1961745A1 A NN O
or EP1961745A1 A CC O
a EP1961745A1 A DT O
nitrogen EP1961745A1 A JJ O
atom EP1961745A1 A NN O
; EP1961745A1 A : O
Z EP1961745A1 A NNP O
represents EP1961745A1 A VBZ O
CH EP1961745A1 A NNP O
or EP1961745A1 A CC O
a EP1961745A1 A DT O
nitrogen EP1961745A1 A JJ O
atom EP1961745A1 A NN O
; EP1961745A1 A : O
R1 EP1961745A1 A NNP O
represents EP1961745A1 A VBZ O
( EP1961745A1 A ( O
1 EP1961745A1 A CD O
) EP1961745A1 A ) O
C3-10 EP1961745A1 A NNP O
branched EP1961745A1 A VBD O
alkyl EP1961745A1 A RP O
which EP1961745A1 A WDT O
may EP1961745A1 A MD O
be EP1961745A1 A VB O
substituted EP1961745A1 A VBN O
or EP1961745A1 A CC O
( EP1961745A1 A ( O
2 EP1961745A1 A CD O
) EP1961745A1 A ) O
- EP1961745A1 A : O
( EP1961745A1 A ( O
CH2 EP1961745A1 A NNP O
) EP1961745A1 A ) O
m-NR4R5 EP1961745A1 A NN O
; EP1961745A1 A : O
R2 EP1961745A1 A NNP O
and EP1961745A1 A CC O
R3 EP1961745A1 A NNP O
each EP1961745A1 A DT O
independently EP1961745A1 A RB O
represent EP1961745A1 A VBP O
( EP1961745A1 A ( O
1 EP1961745A1 A CD O
) EP1961745A1 A ) O
a EP1961745A1 A DT O
hydrogen EP1961745A1 A NN O
atom EP1961745A1 A NN O
, EP1961745A1 A , O
( EP1961745A1 A ( O
2 EP1961745A1 A CD O
) EP1961745A1 A ) O
C1-4 EP1961745A1 A NNP O
alkyl EP1961745A1 A NN O
which EP1961745A1 A WDT O
may EP1961745A1 A MD O
be EP1961745A1 A VB O
substituted EP1961745A1 A VBN O
with EP1961745A1 A IN O
a EP1961745A1 A DT O
halogen EP1961745A1 A NN O
atom EP1961745A1 A NN O
, EP1961745A1 A , O
hydroxy EP1961745A1 A NN O
which EP1961745A1 A WDT O
may EP1961745A1 A MD O
be EP1961745A1 A VB O
protected EP1961745A1 A VBN O
, EP1961745A1 A , O
amino EP1961745A1 A NN O
which EP1961745A1 A WDT O
may EP1961745A1 A MD O
be EP1961745A1 A VB O
protected EP1961745A1 A VBN O
, EP1961745A1 A , O
or EP1961745A1 A CC O
carboxyl EP1961745A1 A NN O
which EP1961745A1 A WDT O
may EP1961745A1 A MD O
be EP1961745A1 A VB O
protected EP1961745A1 A VBN O
, EP1961745A1 A , O
( EP1961745A1 A ( O
3 EP1961745A1 A CD O
) EP1961745A1 A ) O
C2-4 EP1961745A1 A NNP O
alkenyl EP1961745A1 A NN O
, EP1961745A1 A , O
( EP1961745A1 A ( O
4 EP1961745A1 A CD O
) EP1961745A1 A ) O
C2-4 EP1961745A1 A NNP O
alkynyl EP1961745A1 A NN O
, EP1961745A1 A , O
( EP1961745A1 A ( O
5 EP1961745A1 A CD O
) EP1961745A1 A ) O
nitrile EP1961745A1 A NN O
, EP1961745A1 A , O
( EP1961745A1 A ( O
6 EP1961745A1 A CD O
) EP1961745A1 A ) O
COOR6 EP1961745A1 A NNP O
, EP1961745A1 A , O
( EP1961745A1 A ( O
7 EP1961745A1 A CD O
) EP1961745A1 A ) O
CONR7R8 EP1961745A1 A NNP O
, EP1961745A1 A , O
( EP1961745A1 A ( O
8 EP1961745A1 A CD O
) EP1961745A1 A ) O
COR101 EP1961745A1 A NNP O
, EP1961745A1 A , O
( EP1961745A1 A ( O
9 EP1961745A1 A CD O
) EP1961745A1 A ) O
S EP1961745A1 A NNP O
( EP1961745A1 A ( O
O EP1961745A1 A NNP O
) EP1961745A1 A ) O
nR102 EP1961745A1 A NN O
, EP1961745A1 A , O
or EP1961745A1 A CC O
( EP1961745A1 A ( O
10 EP1961745A1 A CD O
) EP1961745A1 A ) O
a EP1961745A1 A DT O
halogen EP1961745A1 A NN O
atom EP1961745A1 A NN O
, EP1961745A1 A , O
in EP1961745A1 A IN O
which EP1961745A1 A WDT O
R6 EP1961745A1 A NNP O
represents EP1961745A1 A VBZ O
a EP1961745A1 A DT O
hydrogen EP1961745A1 A NN O
atom EP1961745A1 A NN O
or EP1961745A1 A CC O
C1-4 EP1961745A1 A NNP O
alkyl EP1961745A1 A NN O
, EP1961745A1 A , O
R7 EP1961745A1 A NNP O
and EP1961745A1 A CC O
R8 EP1961745A1 A NNP O
each EP1961745A1 A DT O
independently EP1961745A1 A RB O
represent EP1961745A1 A VBP O
a EP1961745A1 A DT O
hydrogen EP1961745A1 A NN O
atom EP1961745A1 A NN O
or EP1961745A1 A CC O
C1-4 EP1961745A1 A NNP O
alkyl EP1961745A1 A NN O
, EP1961745A1 A , O
R101 EP1961745A1 A NNP O
represents EP1961745A1 A VBZ O
a EP1961745A1 A DT O
hydrogen EP1961745A1 A NN O
atom EP1961745A1 A NN O
or EP1961745A1 A CC O
C1-4 EP1961745A1 A NNP O
alkyl EP1961745A1 A NN O
, EP1961745A1 A , O
R102 EP1961745A1 A NNP O
represents EP1961745A1 A VBZ O
C1-4 EP1961745A1 A NNP O
alkyl EP1961745A1 A NN O
, EP1961745A1 A , O
n EP1961745A1 A JJ O
represents EP1961745A1 A VBZ O
1 EP1961745A1 A CD O
or EP1961745A1 A CC O
2 EP1961745A1 A CD O
; EP1961745A1 A : O
and EP1961745A1 A CC O
Ar EP1961745A1 A NNP O
represents EP1961745A1 A VBZ O
an EP1961745A1 A DT O
aromatic EP1961745A1 A JJ O
ring EP1961745A1 A NN O
which EP1961745A1 A WDT O
may EP1961745A1 A MD O
be EP1961745A1 A VB O
substituted EP1961745A1 A VBN O
, EP1961745A1 A , O
is EP1961745A1 A VBZ O
useful EP1961745A1 A JJ O
as EP1961745A1 A IN O
a EP1961745A1 A DT O
pharmacologically EP1961745A1 A RB O
active EP1961745A1 A JJ O
ingredient EP1961745A1 A NN O
having EP1961745A1 A VBG O
a EP1961745A1 A DT O
CRF EP1961745A1 A NNP I-UN
antagonist EP1961745A1 A JJ O
action EP1961745A1 A NN O
in EP1961745A1 A IN O
preventing EP1961745A1 A VBG O
and/or EP1961745A1 A JJ O
treating EP1961745A1 A VBG O
neuropsychiatric EP1961745A1 A JJ O
diseases EP1961745A1 A NNS O
, EP1961745A1 A , O
diseases EP1961745A1 A NNS O
of EP1961745A1 A IN O
peripheral EP1961745A1 A JJ O
organs EP1961745A1 A NNS O
or EP1961745A1 A CC O
the EP1961745A1 A DT O
like EP1961745A1 A JJ O
. EP1961745A1 A . O

Sustained-releasing CN201558397U T JJ O
amikacin CN201558397U T NN O
carrying CN201558397U T VBG O
catheter CN201558397U T NN O
. CN201558397U T . O

Novel CN102793930A T NNP O
bifunctional CN102793930A T JJ O
triphosphate-small CN102793930A T NN O
interfering CN102793930A T VBG O
ribonucleic CN102793930A T JJ O
acid CN102793930A T NN O
( CN102793930A T ( O
3p-siRNA CN102793930A T JJ O
) CN102793930A T ) O
for CN102793930A T IN O
inhibiting CN102793930A T VBG O
proliferation CN102793930A T NN O
of CN102793930A T IN O
tumor CN102793930A T NN O
cells CN102793930A T NNS O
and CN102793930A T CC O
application CN102793930A T NN O
of CN102793930A T IN O
novel CN102793930A T JJ O
bifunctional CN102793930A T JJ O
3p-siRNA CN102793930A T NNS O
. CN102793930A T . O

The CN102793930A A DT O
anti-tumor CN102793930A A JJ O
3p-siRNA CN102793930A A JJ O
specifically CN102793930A A RB O
silences CN102793930A A VBZ O
the CN102793930A A DT O
expression CN102793930A A NN O
of CN102793930A A IN O
a CN102793930A A DT O
tumor CN102793930A A NN O
target CN102793930A A NN O
gene CN102793930A A NN O
survivin CN102793930A A VBP O
through CN102793930A A IN O
a CN102793930A A DT O
RNA CN102793930A A NNP O
interference CN102793930A A NN O
( CN102793930A A ( O
RNAi CN102793930A A NNP O
) CN102793930A A ) O
mechanism CN102793930A A NN O
, CN102793930A A , O
can CN102793930A A MD O
also CN102793930A A RB O
activate CN102793930A A VB O
the CN102793930A A DT O
expression CN102793930A A NN O
activity CN102793930A A NN O
of CN102793930A A IN O
cell CN102793930A A NN O
factors CN102793930A A NNS O
such CN102793930A A JJ O
as CN102793930A A IN O
interferon CN102793930A A NN O
( CN102793930A A ( O
IFN CN102793930A A NNP O
) CN102793930A A ) O
through CN102793930A A IN O
a CN102793930A A DT O
retinoic-acid-inducible CN102793930A A JJ I-UN
gene CN102793930A A NN I-UN
I CN102793930A A PRP I-UN
( CN102793930A A ( O
RIG-I CN102793930A A NNP I-UN
) CN102793930A A ) O
dependency CN102793930A A NN O
mechanism CN102793930A A NN O
and CN102793930A A CC O
exert CN102793930A A VB O
the CN102793930A A DT O
antitumor CN102793930A A NN O
effect CN102793930A A NN O
through CN102793930A A IN O
the CN102793930A A DT O
antitumor CN102793930A A NN O
innate CN102793930A A NN O
immune CN102793930A A JJ O
response CN102793930A A NN O
of CN102793930A A IN O
cells CN102793930A A NNS O
, CN102793930A A , O
and CN102793930A A CC O
is CN102793930A A VBZ O
novel CN102793930A A JJ O
bifunctional CN102793930A A JJ O
anti-tumor CN102793930A A NN O
3p-siRNA CN102793930A A CD O
which CN102793930A A WDT O
can CN102793930A A MD O
perform CN102793930A A VB O
RNAi CN102793930A A NNP O
and CN102793930A A CC O
activate CN102793930A A VB O
the CN102793930A A DT O
innate CN102793930A A NN O
immune CN102793930A A JJ O
response CN102793930A A NN O
of CN102793930A A IN O
cell CN102793930A A NN O
IFN CN102793930A A NNP O
. CN102793930A A . O

Aminotetrazole CA2203237C T NNP O
derivatives CA2203237C T VBZ O
useful CA2203237C T JJ O
as CA2203237C T IN O
nitric CA2203237C T JJ O
oxide CA2203237C T IN O
synthase CA2203237C T NN O
inhibitors CA2203237C T NNS O
. CA2203237C T . O

Compounds CA2203237C A NNS O
having CA2203237C A VBG O
formula CA2203237C A NN O
( CA2203237C A ( O
I CA2203237C A PRP O
) CA2203237C A ) O
and CA2203237C A CC O
pharmaceutically CA2203237C A RB O
acceptable CA2203237C A JJ O
salts CA2203237C A NNS O
thereof CA2203237C A NN O
, CA2203237C A , O
wherein CA2203237C A NN O
B CA2203237C A NNP O
is CA2203237C A VBZ O
NR5R11 CA2203237C A NNP O
, CA2203237C A , O
wherein CA2203237C A NN O
R5 CA2203237C A NNP O
is CA2203237C A VBZ O
selected CA2203237C A VBN O
from CA2203237C A IN O
the CA2203237C A DT O
group CA2203237C A NN O
consisting CA2203237C A VBG O
of CA2203237C A IN O
hydrogen CA2203237C A NN O
, CA2203237C A , O
lower CA2203237C A JJR O
alkyl CA2203237C A NN O
, CA2203237C A , O
lower CA2203237C A JJR O
alkenyl CA2203237C A NN O
, CA2203237C A , O
lower CA2203237C A JJR O
alkynyl CA2203237C A NN O
and CA2203237C A CC O
aryl CA2203237C A NN O
, CA2203237C A , O
and CA2203237C A CC O
R11 CA2203237C A NNP O
is CA2203237C A VBZ O
selected CA2203237C A VBN O
from CA2203237C A IN O
a CA2203237C A DT O
3 CA2203237C A CD O
to CA2203237C A TO O
8 CA2203237C A CD O
member CA2203237C A NN O
heterocyclyl CA2203237C A JJ O
radical CA2203237C A NN O
in CA2203237C A IN O
which CA2203237C A WDT O
at CA2203237C A IN O
least CA2203237C A JJS O
one CA2203237C A CD O
member CA2203237C A NN O
of CA2203237C A IN O
the CA2203237C A DT O
ring CA2203237C A NN O
is CA2203237C A VBZ O
carbon CA2203237C A NN O
and CA2203237C A CC O
in CA2203237C A IN O
which CA2203237C A WDT O
1 CA2203237C A CD O
to CA2203237C A TO O
about CA2203237C A IN O
4 CA2203237C A CD O
members CA2203237C A NNS O
are CA2203237C A VBP O
heteroatoms CA2203237C A NNS O
independently CA2203237C A RB O
selected CA2203237C A VBN O
from CA2203237C A IN O
oxygen CA2203237C A NN O
, CA2203237C A , O
nitrogen CA2203237C A NN O
and CA2203237C A CC O
sulfur CA2203237C A NN O
and CA2203237C A CC O
said CA2203237C A VBD O
heterocyclyl CA2203237C A JJ O
radical CA2203237C A JJ O
may CA2203237C A MD O
be CA2203237C A VB O
optionally CA2203237C A RB O
substituted CA2203237C A VBN O
, CA2203237C A , O
useful CA2203237C A JJ O
as CA2203237C A IN O
nitric CA2203237C A JJ O
oxide CA2203237C A IN O
synthase CA2203237C A NN O
inhibitors CA2203237C A NNS O
. CA2203237C A . O

Carboxamidξ WO2009076512A1 T NNP O
compounds WO2009076512A1 T NNS O
and WO2009076512A1 T CC O
their WO2009076512A1 T PRP$ O
use WO2009076512A1 T NN O
as WO2009076512A1 T IN O
chemokine WO2009076512A1 T NN I-UN
receptor WO2009076512A1 T NN I-UN
agonists WO2009076512A1 T NNS O
. WO2009076512A1 T . O

Chemokine WO2009076512A1 A NNP I-UN
receptor WO2009076512A1 A NN I-UN
antagonists WO2009076512A1 A NNS O
, WO2009076512A1 A , O
in WO2009076512A1 A IN O
particular WO2009076512A1 A JJ O
, WO2009076512A1 A , O
compounds WO2009076512A1 A NNS O
of WO2009076512A1 A IN O
Formula WO2009076512A1 A NNP O
( WO2009076512A1 A ( O
I- WO2009076512A1 A NNP O
A WO2009076512A1 A NNP O
) WO2009076512A1 A ) O
that WO2009076512A1 A WDT O
act WO2009076512A1 A NN O
as WO2009076512A1 A IN O
antagonists WO2009076512A1 A NNS O
of WO2009076512A1 A IN O
the WO2009076512A1 A DT O
chemokine WO2009076512A1 A NN I-UN
CCR2 WO2009076512A1 A NNP I-UN
receptor WO2009076512A1 A NN O
, WO2009076512A1 A , O
including WO2009076512A1 A VBG O
pharmaceutical WO2009076512A1 A JJ O
compositions WO2009076512A1 A NNS O
and WO2009076512A1 A CC O
uses WO2009076512A1 A VBZ O
thereof WO2009076512A1 A NN O
to WO2009076512A1 A TO O
treat WO2009076512A1 A VB O
or WO2009076512A1 A CC O
prevent WO2009076512A1 A VB O
diseases WO2009076512A1 A NNS O
associated WO2009076512A1 A VBN O
with WO2009076512A1 A IN O
monocyte WO2009076512A1 A JJ O
accumulation WO2009076512A1 A NN O
, WO2009076512A1 A , O
lymphocyte WO2009076512A1 A JJ O
accumulation WO2009076512A1 A NN O
or WO2009076512A1 A CC O
leukocyte WO2009076512A1 A JJ O
accumulation WO2009076512A1 A NN O
are WO2009076512A1 A VBP O
described WO2009076512A1 A VBN O
herein WO2009076512A1 A NNS O
. WO2009076512A1 A . O

Purification EP1478638B1 T NN O
of EP1478638B1 T IN O
citalopram EP1478638B1 T NN O
. EP1478638B1 T . O

Bis- WO2009064250A1 T NNP O
( WO2009064250A1 T ( O
sulfonylamino WO2009064250A1 T NN O
) WO2009064250A1 T ) O
derivatives WO2009064250A1 T VBZ O
in WO2009064250A1 T IN O
therapy WO2009064250A1 T NN O
065 WO2009064250A1 T CD O
. WO2009064250A1 T . O

The WO2009064250A1 A DT O
compounds WO2009064250A1 A NNS O
are WO2009064250A1 A VBP O
inhibitors WO2009064250A1 A NNS O
of WO2009064250A1 A IN O
microsomal WO2009064250A1 A JJ I-UN
prostaglandin WO2009064250A1 A NN I-UN
E WO2009064250A1 A NNP I-UN
synthase-1 WO2009064250A1 A NN I-UN
. WO2009064250A1 A . O

Compound CN102526738A T NNP O
ophthalmic CN102526738A T JJ O
preparation CN102526738A T NN O
and CN102526738A T CC O
preparation CN102526738A T NN O
method CN102526738A T NN O
as CN102526738A T RB O
well CN102526738A T RB O
as CN102526738A T IN O
application CN102526738A T NN O
thereof CN102526738A T NN O
. CN102526738A T . O

The CN102526738A A DT O
invention CN102526738A A NN O
relates CN102526738A A VBZ O
to CN102526738A A TO O
a CN102526738A A DT O
compound CN102526738A A NN O
ophthalmic CN102526738A A JJ O
preparation CN102526738A A NN O
, CN102526738A A , O
in CN102526738A A IN O
particular CN102526738A A JJ O
to CN102526738A A TO O
a CN102526738A A DT O
compound CN102526738A A NN O
ophthalmic CN102526738A A JJ O
preparation CN102526738A A NN O
containing CN102526738A A VBG O
aminoglycoside CN102526738A A JJ O
antibiotics CN102526738A A NNS O
and CN102526738A A CC O
nonsteroidal CN102526738A A JJ O
anti-inflammatory CN102526738A A JJ O
drugs CN102526738A A NNS O
, CN102526738A A , O
such CN102526738A A JJ O
as CN102526738A A IN O
gentamicin CN102526738A A NN O
and CN102526738A A CC O
diclofenac CN102526738A A NN O
sodium CN102526738A A NN O
eye CN102526738A A NN O
drops CN102526738A A NNS O
. CN102526738A A . O

The CN102526738A A DT O
pH CN102526738A A JJ O
value CN102526738A A NN O
of CN102526738A A IN O
the CN102526738A A DT O
ophthalmic CN102526738A A JJ O
preparation CN102526738A A NN O
is CN102526738A A VBZ O
7.0-10.0 CN102526738A A JJ O
, CN102526738A A , O
preferably CN102526738A A RB O
7.5-9.5 CN102526738A A CD O
, CN102526738A A , O
more CN102526738A A JJR O
preferably CN102526738A A RB O
8.0-9.0 CN102526738A A CD O
, CN102526738A A , O
and CN102526738A A CC O
further CN102526738A A RB O
preferably CN102526738A A RB O
8.6-8.8 CN102526738A A JJ O
. CN102526738A A . O

The CN102526738A A DT O
invention CN102526738A A NN O
also CN102526738A A RB O
relates CN102526738A A VBZ O
to CN102526738A A TO O
a CN102526738A A DT O
preparation CN102526738A A NN O
method CN102526738A A NN O
as CN102526738A A RB O
well CN102526738A A RB O
as CN102526738A A IN O
application CN102526738A A NN O
of CN102526738A A IN O
the CN102526738A A DT O
compound CN102526738A A NN O
ophthalmic CN102526738A A JJ O
preparation CN102526738A A NN O
. CN102526738A A . O

By CN102526738A A IN O
regulating CN102526738A A VBG O
the CN102526738A A DT O
pH CN102526738A A NN O
value CN102526738A A NN O
, CN102526738A A , O
the CN102526738A A DT O
ophthalmic CN102526738A A JJ O
preparation CN102526738A A NN O
provided CN102526738A A VBN O
by CN102526738A A IN O
the CN102526738A A DT O
invention CN102526738A A NN O
has CN102526738A A VBZ O
the CN102526738A A DT O
advantages CN102526738A A NNS O
of CN102526738A A IN O
small CN102526738A A JJ O
irritation CN102526738A A NN O
and CN102526738A A CC O
good CN102526738A A JJ O
stability CN102526738A A NN O
. CN102526738A A . O

Methods WO2005013884A2 T NNS O
for WO2005013884A2 T IN O
preventing WO2005013884A2 T VBG O
neurological WO2005013884A2 T JJ O
events WO2005013884A2 T NNS O
. WO2005013884A2 T . O

A US7169819 T DT O
pharmaceutical US7169819 T JJ O
formulation US7169819 T NN O
for US7169819 T IN O
parenteral US7169819 T JJ O
delivery US7169819 T NN O
, US7169819 T , O
comprising US7169819 T VBG O
a US7169819 T DT O
retinide US7169819 T NN O
such US7169819 T JJ O
as US7169819 T IN O
fenretinide US7169819 T NN O
in US7169819 T IN O
combination US7169819 T NN O
with US7169819 T IN O
a US7169819 T DT O
solvent US7169819 T NN O
( US7169819 T ( O
an US7169819 T DT O
alcohol US7169819 T NN O
) US7169819 T ) O
and US7169819 T CC O
a US7169819 T DT O
alkoxylate US7169819 T JJ O
castor US7169819 T NN O
oil US7169819 T NN O
, US7169819 T , O
capable US7169819 T NN O
of US7169819 T IN O
dispersing US7169819 T VBG O
or US7169819 T CC O
dissolving US7169819 T VBG O
the US7169819 T DT O
retinide US7169819 T NN O
; US7169819 T : O
anticancer US7169819 T CC O
agent US7169819 T NN O
. US7169819 T . O

Pyruvic CN103610671A T NNP O
acid CN103610671A T VBZ O
medicinal CN103610671A T JJ O
composition CN103610671A T NN O
and CN103610671A T CC O
application CN103610671A T NN O
thereof CN103610671A T NN O
in CN103610671A T IN O
preparing CN103610671A T VBG O
medicament CN103610671A T NN O
for CN103610671A T IN O
treating CN103610671A T VBG O
lung CN103610671A T NN O
cancer CN103610671A T NN O
. CN103610671A T . O

Particulate US20080317855 T NNP O
Compositions US20080317855 T NNP O
Comprising US20080317855 T NNP O
Alginate US20080317855 T NNP O
and/or US20080317855 T VBZ O
Alginic US20080317855 T NNP O
Acid US20080317855 T NNP O
. US20080317855 T . O

Combinations US20070270376 T NNS O
of US20070270376 T IN O
Hyaluronic US20070270376 T NNP O
Acid US20070270376 T NNP O
and US20070270376 T CC O
Polyunsaturated US20070270376 T NNP O
Fatty US20070270376 T NNP O
Acids US20070270376 T NNP O
. US20070270376 T . O

Modulating US7629347 T VBG O
and/or US7629347 T RP O
regulating US7629347 T VBG O
signal US7629347 T JJ O
transduction US7629347 T NN O
of US7629347 T IN O
both US7629347 T DT O
receptor-type US7629347 T JJ I-UN
and US7629347 T CC I-UN
non-receptor US7629347 T JJ I-UN
type US7629347 T NN I-UN
tyrosine US7629347 T NN I-UN
kinases US7629347 T VBZ I-UN
; US7629347 T : O
cancer US7629347 T NN O
; US7629347 T : O
chronic US7629347 T JJ O
myelogic US7629347 T NN O
leukemia US7629347 T NN O
. US7629347 T . O

The US7629347 A DT O
present US7629347 A JJ O
invention US7629347 A NN O
relates US7629347 A VBZ O
to US7629347 A TO O
uses US7629347 A NNS O
of US7629347 A IN O
the US7629347 A DT O
compounds US7629347 A NNS O
of US7629347 A IN O
Formula US7629347 A NNP O
I US7629347 A PRP O
as US7629347 A RB O
well US7629347 A RB O
as US7629347 A IN O
pharmaceutically US7629347 A RB O
acceptable US7629347 A JJ O
salts US7629347 A NNS O
and US7629347 A CC O
stereoisomers US7629347 A NNS O
thereof US7629347 A VBP O
in US7629347 A IN O
methods US7629347 A NNS O
to US7629347 A TO O
treat US7629347 A VB O
a US7629347 A DT O
variety US7629347 A NN O
of US7629347 A IN O
tumors US7629347 A NNS O
in US7629347 A IN O
mammals US7629347 A NNS O
involving US7629347 A VBG O
abnormal US7629347 A JJ O
tyrosine US7629347 A NN O
kinase US7629347 A NN I-UN
signaling US7629347 A NN O
, US7629347 A , O
the US7629347 A DT O
compounds US7629347 A NNS O
represented US7629347 A VBN O
as US7629347 A IN O
: US7629347 A : O
wherein US7629347 A NN O
R1 US7629347 A NNP O
and US7629347 A CC O
R2 US7629347 A NNP O
are US7629347 A VBP O
independently US7629347 A RB O
selected US7629347 A VBN O
from US7629347 A IN O
the US7629347 A DT O
group US7629347 A NN O
consisting US7629347 A VBG O
of US7629347 A IN O
H US7629347 A NNP O
; US7629347 A : O
alkyl US7629347 A NN O
; US7629347 A : O
alkenyl US7629347 A CC O
; US7629347 A : O
alkynyl US7629347 A NN O
; US7629347 A : O
halogen US7629347 A NN O
; US7629347 A : O
aryl US7629347 A CC O
; US7629347 A : O
heteroaryl US7629347 A NN O
containing US7629347 A VBG O
N US7629347 A NNP O
, US7629347 A , O
O US7629347 A NNP O
, US7629347 A , O
or US7629347 A CC O
S US7629347 A NNP O
; US7629347 A : O
the US7629347 A DT O
aryl US7629347 A NN O
and US7629347 A CC O
heteroaryl US7629347 A NN O
may US7629347 A MD O
be US7629347 A VB O
further US7629347 A RB O
substituted US7629347 A VBN O
with US7629347 A IN O
halogen US7629347 A NN O
, US7629347 A , O
an US7629347 A DT O
alkyl US7629347 A NN O
, US7629347 A , O
alkenyl US7629347 A NN O
, US7629347 A , O
and US7629347 A CC O
alkynyl US7629347 A RB O
; US7629347 A : O
NZ1Z2 US7629347 A NNP O
, US7629347 A , O
wherein US7629347 A NN O
Z1 US7629347 A NNP O
and US7629347 A CC O
Z2 US7629347 A NNP O
are US7629347 A VBP O
independently US7629347 A RB O
selected US7629347 A VBN O
from US7629347 A IN O
the US7629347 A DT O
group US7629347 A NN O
consisting US7629347 A VBG O
of US7629347 A IN O
H US7629347 A NNP O
and US7629347 A CC O
alkyl US7629347 A NN O
; US7629347 A : O
and US7629347 A CC O
( US7629347 A ( O
CO US7629347 A NNP O
) US7629347 A ) O
Y US7629347 A NNP O
wherein US7629347 A NN O
Y US7629347 A NNP O
is US7629347 A VBZ O
selected US7629347 A VBN O
from US7629347 A IN O
the US7629347 A DT O
group US7629347 A NN O
consisting US7629347 A VBG O
of US7629347 A IN O
H US7629347 A NNP O
, US7629347 A , O
alkyl US7629347 A NN O
, US7629347 A , O
alkenyl US7629347 A NN O
, US7629347 A , O
alkynyl US7629347 A NN O
, US7629347 A , O
aryl US7629347 A NN O
, US7629347 A , O
heteroaryl US7629347 A NN O
containing US7629347 A VBG O
N US7629347 A NNP O
, US7629347 A , O
O US7629347 A NNP O
, US7629347 A , O
or US7629347 A CC O
S US7629347 A NNP O
, US7629347 A , O
and US7629347 A CC O
the US7629347 A DT O
aryl US7629347 A NN O
and US7629347 A CC O
heteroaryl US7629347 A NN O
may US7629347 A MD O
be US7629347 A VB O
further US7629347 A RB O
substituted US7629347 A VBN O
with US7629347 A IN O
halogen US7629347 A NN O
, US7629347 A , O
alkyl US7629347 A NN O
, US7629347 A , O
alkenyl US7629347 A NN O
, US7629347 A , O
and US7629347 A CC O
alkynyl US7629347 A RB O
; US7629347 A : O
with US7629347 A IN O
the US7629347 A DT O
proviso US7629347 A NN O
that US7629347 A IN O
when US7629347 A WRB O
R1 US7629347 A NNP O
is US7629347 A VBZ O
hydrogen US7629347 A NN O
, US7629347 A , O
R2 US7629347 A NNP O
is US7629347 A VBZ O
a US7629347 A DT O
group US7629347 A NN O
other US7629347 A JJ O
than US7629347 A IN O
hydrogen US7629347 A NN O
. US7629347 A . O

Use WO2009049208A1 T NNP O
of WO2009049208A1 T IN O
nitric WO2009049208A1 T JJ O
oxide WO2009049208A1 T NN O
to WO2009049208A1 T TO O
enhance WO2009049208A1 T VB O
the WO2009049208A1 T DT O
efficacy WO2009049208A1 T NN O
of WO2009049208A1 T IN O
silver WO2009049208A1 T NN O
and WO2009049208A1 T CC O
other WO2009049208A1 T JJ O
topical WO2009049208A1 T JJ O
wound WO2009049208A1 T NN O
care WO2009049208A1 T NN O
agents WO2009049208A1 T NNS O
. WO2009049208A1 T . O

Cefodizime WO2011141004A1 T NNP O
sodium WO2011141004A1 T NN O
hydrate WO2011141004A1 T NN O
, WO2011141004A1 T , O
preparation WO2011141004A1 T NN O
method WO2011141004A1 T NN O
and WO2011141004A1 T CC O
uses WO2011141004A1 T VBZ O
thereof WO2011141004A1 T NN O
. WO2011141004A1 T . O

Agent WO2009008120A1 T NN O
and WO2009008120A1 T CC O
method WO2009008120A1 T NN O
for WO2009008120A1 T IN O
stabilizing WO2009008120A1 T VBG O
membrane WO2009008120A1 T NN O
protein WO2009008120A1 T NN O
. WO2009008120A1 T . O

Protopanoxadiol CN102766184A T NNP O
peroxide CN102766184A T NN O
derivatives CN102766184A T NNS O
as CN102766184A T RB O
well CN102766184A T RB O
as CN102766184A T IN O
preparation CN102766184A T NN O
method CN102766184A T NN O
and CN102766184A T CC O
application CN102766184A T NN O
thereof CN102766184A T NN O
. CN102766184A T . O

2- WO2012031941A2 T JJ O
( WO2012031941A2 T ( O
R²-THIO WO2012031941A2 T NNP O
) WO2012031941A2 T ) O
-10- WO2012031941A2 T VBZ O
[ WO2012031941A2 T JJ O
3- WO2012031941A2 T JJ O
( WO2012031941A2 T ( O
4-R1-PIPERAZIN-1-YL WO2012031941A2 T JJ O
) WO2012031941A2 T ) O
PROPYL WO2012031941A2 T NNP O
] WO2012031941A2 T NNP O
-10H-PHENOTHIAZINE WO2012031941A2 T NNP O
FOR WO2012031941A2 T NNP O
TREATING WO2012031941A2 T NNP O
A WO2012031941A2 T NNP O
β-AMYLOIDOPATHY WO2012031941A2 T NN O
OR WO2012031941A2 T NNP O
AN WO2012031941A2 T NNP O
ALPHA-SYNUCLEOPATHY WO2012031941A2 T NNP O
, WO2012031941A2 T , O
AND WO2012031941A2 T NNP O
METHOD WO2012031941A2 T NNP O
FOR WO2012031941A2 T NNP O
THE WO2012031941A2 T NNP O
DIAGNOSIS WO2012031941A2 T NNP O
OR WO2012031941A2 T NNP O
PREDIAGNOSIS WO2012031941A2 T NNP O
THEREOF WO2012031941A2 T NNP O
. WO2012031941A2 T . O

The WO2012031941A2 A DT O
invention WO2012031941A2 A NN O
also WO2012031941A2 A RB O
relates WO2012031941A2 A VBZ O
to WO2012031941A2 A TO O
a WO2012031941A2 A DT O
method WO2012031941A2 A NN O
for WO2012031941A2 A IN O
the WO2012031941A2 A DT O
diagnosis WO2012031941A2 A NN O
or WO2012031941A2 A CC O
prediagnosis WO2012031941A2 A NN O
of WO2012031941A2 A IN O
a WO2012031941A2 A DT O
β-amyloidopathy WO2012031941A2 A JJ O
or WO2012031941A2 A CC O
an WO2012031941A2 A DT O
α-synucleopathy WO2012031941A2 A JJ O
accompanied WO2012031941A2 A VBN O
by WO2012031941A2 A IN O
a WO2012031941A2 A DT O
cerebral WO2012031941A2 A JJ O
protein WO2012031941A2 A NN O
deposit WO2012031941A2 A NN O
and WO2012031941A2 A CC O
a WO2012031941A2 A DT O
reduced WO2012031941A2 A JJ O
activity WO2012031941A2 A NN O
of WO2012031941A2 A IN O
the WO2012031941A2 A DT O
cerebral WO2012031941A2 A JJ O
ABCC1-transporter WO2012031941A2 A NNP O
, WO2012031941A2 A , O
or WO2012031941A2 A CC O
for WO2012031941A2 A IN O
determining WO2012031941A2 A VBG O
the WO2012031941A2 A DT O
risk WO2012031941A2 A NN O
of WO2012031941A2 A IN O
a WO2012031941A2 A DT O
proband WO2012031941A2 A NN O
suffering WO2012031941A2 A VBG O
from WO2012031941A2 A IN O
such WO2012031941A2 A JJ O
an WO2012031941A2 A DT O
illness WO2012031941A2 A NN O
, WO2012031941A2 A , O
the WO2012031941A2 A DT O
proband WO2012031941A2 A NN O
already WO2012031941A2 A RB O
having WO2012031941A2 A VBG O
accumulated WO2012031941A2 A VBN O
substances WO2012031941A2 A NNS O
transported WO2012031941A2 A VBN O
by WO2012031941A2 A IN O
the WO2012031941A2 A DT O
cerebral WO2012031941A2 A JJ O
ABCC1 WO2012031941A2 A NNP I-UN
transporter WO2012031941A2 A NN O
. WO2012031941A2 A . O

Biodegradable WO2011153493A2 T JJ O
lipids WO2011153493A2 T NNS O
for WO2011153493A2 T IN O
the WO2011153493A2 T DT O
delivery WO2011153493A2 T NN O
of WO2011153493A2 T IN O
active WO2011153493A2 T JJ O
agents WO2011153493A2 T NNS O
. WO2011153493A2 T . O

Methods EP1676574A2 T NNS O
for EP1676574A2 T IN O
promoting EP1676574A2 T VBG O
survival EP1676574A2 T NN O
of EP1676574A2 T IN O
transplanted EP1676574A2 T JJ O
tissues EP1676574A2 T NNS O
and EP1676574A2 T CC O
cells EP1676574A2 T NNS O
. EP1676574A2 T . O

The EP1676574A2 A DT O
agent EP1676574A2 A NN O
is EP1676574A2 A VBZ O
one EP1676574A2 A CD O
that EP1676574A2 A WDT O
acts EP1676574A2 A VBZ O
by EP1676574A2 A IN O
reducing EP1676574A2 A VBG O
the EP1676574A2 A DT O
amount EP1676574A2 A NN O
or EP1676574A2 A CC O
activity EP1676574A2 A NN O
of EP1676574A2 A IN O
tissue EP1676574A2 A NN I-UN
factor EP1676574A2 A NN I-UN
( EP1676574A2 A ( O
TF EP1676574A2 A NNP I-UN
) EP1676574A2 A ) O
on EP1676574A2 A IN O
the EP1676574A2 A DT O
donor EP1676574A2 A NN O
tissue EP1676574A2 A NN O
, EP1676574A2 A , O
such EP1676574A2 A JJ O
as EP1676574A2 A IN O
a EP1676574A2 A DT O
p38 EP1676574A2 A NN I-UN
MAPK EP1676574A2 A NNP O
inhibitor EP1676574A2 A NN O
, EP1676574A2 A , O
a EP1676574A2 A DT O
JNK EP1676574A2 A NNP I-UN
inhibitor EP1676574A2 A NN O
, EP1676574A2 A , O
a EP1676574A2 A DT O
p38 EP1676574A2 A NN I-UN
MAPK/JNK EP1676574A2 A NNP O
dual EP1676574A2 A JJ O
inhibitor EP1676574A2 A NN O
and EP1676574A2 A CC O
a EP1676574A2 A DT O
TF EP1676574A2 A NNP I-UN
antagonist EP1676574A2 A NN O
. EP1676574A2 A . O

Agent WO2007010911A1 T NN O
for WO2007010911A1 T IN O
relieving WO2007010911A1 T VBG O
wound WO2007010911A1 T NN O
and WO2007010911A1 T CC O
promoting WO2007010911A1 T VBG O
wound WO2007010911A1 T JJ O
recovery WO2007010911A1 T NN O
. WO2007010911A1 T . O

Synthesis CN103694133A T NN O
of CN103694133A T IN O
laminine CN103694133A T NN O
schiff CN103694133A T NN O
base CN103694133A T NN O
with CN103694133A T IN O
anticancer CN103694133A T NN O
activity CN103694133A T NN O
and CN103694133A T CC O
pharmaceutical CN103694133A T JJ O
composition CN103694133A T NN O
thereof CN103694133A T NN O
. CN103694133A T . O

Derivatives CN101098861A T NNS O
of CN101098861A T IN O
isothiazol-3 CN101098861A T NN O
( CN101098861A T ( O
2h CN101098861A T CD O
) CN101098861A T ) O
-thione CN101098861A T RB O
1,1-dioxides CN101098861A T JJ O
as CN101098861A T IN O
liver CN101098861A T NN I-UN
x CN101098861A T NNP I-UN
receptor CN101098861A T NN I-UN
modulators CN101098861A T NNS O
. CN101098861A T . O

The CN101098861A A DT O
present CN101098861A A JJ O
invention CN101098861A A NN O
relates CN101098861A A VBZ O
to CN101098861A A TO O
certain CN101098861A A JJ O
novel CN101098861A A JJ O
compounds CN101098861A A NNS O
of CN101098861A A IN O
formula CN101098861A A NN O
( CN101098861A A ( O
I CN101098861A A PRP O
) CN101098861A A ) O
to CN101098861A A TO O
processes CN101098861A A VB O
for CN101098861A A IN O
preparing CN101098861A A VBG O
such CN101098861A A JJ O
compounds CN101098861A A NNS O
, CN101098861A A , O
to CN101098861A A TO O
their CN101098861A A PRP$ O
the CN101098861A A DT O
utility CN101098861A A NN O
in CN101098861A A IN O
modulation CN101098861A A NN O
of CN101098861A A IN O
nuclear CN101098861A A JJ O
hormone CN101098861A A NN O
receptors CN101098861A A NNS O
Liver CN101098861A A NNP I-UN
X CN101098861A A NNP I-UN
Receptor CN101098861A A NNP I-UN
( CN101098861A A ( O
LXR CN101098861A A NNP I-UN
) CN101098861A A ) O
a CN101098861A A DT O
( CN101098861A A ( O
NR1H3 CN101098861A A NNP O
) CN101098861A A ) O
and/or CN101098861A A NN O
ss CN101098861A A NN O
( CN101098861A A ( O
NR1H2 CN101098861A A NNP O
) CN101098861A A ) O
and CN101098861A A CC O
in CN101098861A A IN O
treating CN101098861A A VBG O
and/or CN101098861A A NN O
preventing CN101098861A A VBG O
clinical CN101098861A A JJ O
conditions CN101098861A A NNS O
including CN101098861A A VBG O
cardiovascular CN101098861A A JJ O
diseases CN101098861A A NNS O
such CN101098861A A JJ O
as CN101098861A A IN O
atherosclerosis CN101098861A A NN O
; CN101098861A A : O
inflammatory CN101098861A A JJ O
diseases CN101098861A A NNS O
, CN101098861A A , O
Alzheimer CN101098861A A NNP O
's CN101098861A A POS O
disease CN101098861A A NN O
, CN101098861A A , O
lipid CN101098861A A JJ O
disorders CN101098861A A NNS O
( CN101098861A A ( O
dyslipidemias CN101098861A A NN O
) CN101098861A A ) O
whether CN101098861A A IN O
or CN101098861A A CC O
not CN101098861A A RB O
associated CN101098861A A VBN O
with CN101098861A A IN O
insulin CN101098861A A NN O
resistance CN101098861A A NN O
, CN101098861A A , O
type CN101098861A A VBP O
2 CN101098861A A CD O
diabetes CN101098861A A NNS O
and CN101098861A A CC O
other CN101098861A A JJ O
manifestations CN101098861A A NNS O
of CN101098861A A IN O
the CN101098861A A DT O
metabolic CN101098861A A JJ O
syndrome CN101098861A A NN O
, CN101098861A A , O
to CN101098861A A TO O
methods CN101098861A A NNS O
for CN101098861A A IN O
their CN101098861A A PRP$ O
therapeutic CN101098861A A JJ O
use CN101098861A A NN O
and CN101098861A A CC O
to CN101098861A A TO O
pharmaceutical CN101098861A A JJ O
compositions CN101098861A A NNS O
containing CN101098861A A VBG O
them CN101098861A A PRP O
. CN101098861A A . O

Method CN102161710A T NNP O
for CN102161710A T IN O
preparing CN102161710A T VBG O
tremellan CN102161710A T NN O
with CN102161710A T IN O
low CN102161710A T JJ O
molecular CN102161710A T JJ O
weight CN102161710A T NN O
and CN102161710A T CC O
novel CN102161710A T JJ O
medicinal CN102161710A T JJ O
application CN102161710A T NN O
thereof CN102161710A T NN O
. CN102161710A T . O

The CN102161710A A DT O
invention CN102161710A A NN O
discloses CN102161710A A VBZ O
a CN102161710A A DT O
method CN102161710A A NN O
for CN102161710A A IN O
preparing CN102161710A A VBG O
tremellan CN102161710A A NN O
with CN102161710A A IN O
low CN102161710A A JJ O
molecular CN102161710A A JJ O
weight CN102161710A A NN O
from CN102161710A A IN O
Tremella CN102161710A A NNP O
fueiformis CN102161710A A NN O
Berk CN102161710A A NNP O
and CN102161710A A CC O
application CN102161710A A NN O
of CN102161710A A IN O
the CN102161710A A DT O
tremellan CN102161710A A NN O
with CN102161710A A IN O
low CN102161710A A JJ O
molecular CN102161710A A JJ O
weight CN102161710A A NN O
in CN102161710A A IN O
treatment CN102161710A A NN O
for CN102161710A A IN O
chronic CN102161710A A JJ O
atrophic CN102161710A A JJ O
gastritis CN102161710A A NN O
and CN102161710A A CC O
serving CN102161710A A NN O
as CN102161710A A IN O
an CN102161710A A DT O
adjuvant CN102161710A A JJ O
medicament CN102161710A A NN O
in CN102161710A A IN O
tumor CN102161710A A NN O
therapy CN102161710A A NN O
. CN102161710A A . O

The CN102161710A A DT O
method CN102161710A A NN O
for CN102161710A A IN O
preparing CN102161710A A VBG O
the CN102161710A A DT O
tremellan CN102161710A A NN O
with CN102161710A A IN O
low CN102161710A A JJ O
molecular CN102161710A A JJ O
weight CN102161710A A NN O
comprises CN102161710A A VBZ O
the CN102161710A A DT O
following CN102161710A A JJ O
steps CN102161710A A NNS O
of CN102161710A A IN O
: CN102161710A A : O
cleaning CN102161710A A VBG O
the CN102161710A A DT O
Tremella CN102161710A A NNP O
fueiformis CN102161710A A NN O
Berk CN102161710A A NNP O
, CN102161710A A , O
homogenating CN102161710A A NN O
, CN102161710A A , O
adding CN102161710A A VBG O
solution CN102161710A A NN O
of CN102161710A A IN O
acid CN102161710A A JJ O
water CN102161710A A NN O
, CN102161710A A , O
extracting CN102161710A A VBG O
for CN102161710A A IN O
1 CN102161710A A CD O
to CN102161710A A TO O
3 CN102161710A A CD O
hours CN102161710A A NNS O
by CN102161710A A IN O
using CN102161710A A VBG O
the CN102161710A A DT O
acid CN102161710A A JJ O
water CN102161710A A NN O
at CN102161710A A IN O
certain CN102161710A A JJ O
temperature CN102161710A A NN O
and CN102161710A A CC O
under CN102161710A A IN O
certain CN102161710A A JJ O
pressure CN102161710A A NN O
, CN102161710A A , O
neutralizing CN102161710A A VBG O
extracting CN102161710A A VBG O
solution CN102161710A A NN O
of CN102161710A A IN O
the CN102161710A A DT O
acid CN102161710A A JJ O
water CN102161710A A NN O
until CN102161710A A IN O
the CN102161710A A DT O
extracting CN102161710A A VBG O
solution CN102161710A A NN O
is CN102161710A A VBZ O
neutral CN102161710A A JJ O
by CN102161710A A IN O
using CN102161710A A VBG O
alkaline CN102161710A A JJ O
water CN102161710A A NN O
, CN102161710A A , O
centrifuging CN102161710A A NN O
, CN102161710A A , O
concentrating CN102161710A A VBG O
supernatant CN102161710A A NN O
to CN102161710A A TO O
an CN102161710A A DT O
appropriate CN102161710A A JJ O
volume CN102161710A A NN O
, CN102161710A A , O
and CN102161710A A CC O
preparing CN102161710A A VBG O
the CN102161710A A DT O
tremellan CN102161710A A NN O
through CN102161710A A IN O
ultrafiltration CN102161710A A NN O
membranes CN102161710A A NNS O
with CN102161710A A IN O
different CN102161710A A JJ O
molecular CN102161710A A JJ O
weight CN102161710A A NN O
cutoffs CN102161710A A NNS O
or CN102161710A A CC O
an CN102161710A A DT O
ethanol CN102161710A A JJ O
fractional CN102161710A A JJ O
precipitation CN102161710A A NN O
method CN102161710A A NN O
. CN102161710A A . O

The CN102161710A A DT O
tremellan CN102161710A A NN O
with CN102161710A A IN O
low CN102161710A A JJ O
molecular CN102161710A A JJ O
weight CN102161710A A NN O
prepared CN102161710A A VBN O
by CN102161710A A IN O
the CN102161710A A DT O
method CN102161710A A NN O
is CN102161710A A VBZ O
used CN102161710A A VBN O
for CN102161710A A IN O
treating CN102161710A A VBG O
chronic CN102161710A A JJ O
atrophic CN102161710A A JJ O
gastritis CN102161710A A NN O
and CN102161710A A CC O
carrying CN102161710A A VBG O
out CN102161710A A RP O
pharmacodynamics CN102161710A A NNS O
research CN102161710A A NN O
of CN102161710A A IN O
adjuvant CN102161710A A JJ O
medicaments CN102161710A A NNS O
in CN102161710A A IN O
tumor CN102161710A A NN O
therapy CN102161710A A NN O
, CN102161710A A , O
and CN102161710A A CC O
the CN102161710A A DT O
medicinal CN102161710A A JJ O
effect CN102161710A A NN O
is CN102161710A A VBZ O
high CN102161710A A JJ O
. CN102161710A A . O

Medicament CN101961406B T NN O
for CN101961406B T IN O
treating CN101961406B T VBG O
muscle CN101961406B T NN O
and CN101961406B T CC O
bone CN101961406B T NN O
diseases CN101961406B T NNS O
caused CN101961406B T VBN O
by CN101961406B T IN O
chronic CN101961406B T JJ O
infectious CN101961406B T JJ O
arthritis CN101961406B T NN O
. CN101961406B T . O

Matrix-type CN102793658A T JJ O
preparation CN102793658A T NN O
containing CN102793658A T VBG O
mycophenolic CN102793658A T JJ O
acid CN102793658A T NN O
or CN102793658A T CC O
mycophenolic CN102793658A T JJ O
acid CN102793658A T NN O
salt CN102793658A T NN O
and CN102793658A T CC O
coated CN102793658A T VBD O
tablet CN102793658A T NN O
thereof CN102793658A T NN O
. CN102793658A T . O

Novel WO2006046492A1 T NNP O
ppar WO2006046492A1 T NN O
regulating WO2006046492A1 T NN O
agent WO2006046492A1 T NN O
and WO2006046492A1 T CC O
method WO2006046492A1 T NN O
of WO2006046492A1 T IN O
screening WO2006046492A1 T VBG O
the WO2006046492A1 T DT O
same WO2006046492A1 T JJ O
. WO2006046492A1 T . O

A WO2006046492A1 A DT O
highly WO2006046492A1 A RB O
efficient WO2006046492A1 A JJ O
method WO2006046492A1 A NN O
of WO2006046492A1 A IN O
screening WO2006046492A1 A VBG O
drugs WO2006046492A1 A NNS O
for WO2006046492A1 A IN O
diabetes WO2006046492A1 A NNS O
treatment WO2006046492A1 A NN O
; WO2006046492A1 A : O
and WO2006046492A1 A CC O
novel WO2006046492A1 A JJ O
compounds WO2006046492A1 A NNS O
for WO2006046492A1 A IN O
treatment WO2006046492A1 A NN O
and WO2006046492A1 A CC O
prevention WO2006046492A1 A NN O
of WO2006046492A1 A IN O
PPAR-associated WO2006046492A1 A JJ O
diseases WO2006046492A1 A NNS O
. WO2006046492A1 A . O

There WO2006046492A1 A EX O
is WO2006046492A1 A VBZ O
provided WO2006046492A1 A VBN O
a WO2006046492A1 A DT O
method WO2006046492A1 A NN O
of WO2006046492A1 A IN O
identifying WO2006046492A1 A VBG O
a WO2006046492A1 A DT O
compound WO2006046492A1 A NN O
capable WO2006046492A1 A JJ O
of WO2006046492A1 A IN O
regulating WO2006046492A1 A VBG O
peroxisome WO2006046492A1 A JJ O
proliferator WO2006046492A1 A NN O
activated WO2006046492A1 A VBD O
receptor WO2006046492A1 A NN O
( WO2006046492A1 A ( O
PPAR WO2006046492A1 A NNP O
) WO2006046492A1 A ) O
, WO2006046492A1 A , O
which WO2006046492A1 A WDT O
compound WO2006046492A1 A NN O
has WO2006046492A1 A VBZ O
at WO2006046492A1 A IN O
least WO2006046492A1 A JJS O
one WO2006046492A1 A CD O
activity WO2006046492A1 A NN O
selected WO2006046492A1 A VBN O
from WO2006046492A1 A IN O
the WO2006046492A1 A DT O
group WO2006046492A1 A NN O
consisting WO2006046492A1 A VBG O
of WO2006046492A1 A IN O
the WO2006046492A1 A DT O
activity WO2006046492A1 A NN O
of WO2006046492A1 A IN O
promoting WO2006046492A1 A VBG O
the WO2006046492A1 A DT O
insulin WO2006046492A1 A JJ O
secretion WO2006046492A1 A NN O
of WO2006046492A1 A IN O
pancreatic WO2006046492A1 A JJ O
β-cells WO2006046492A1 A NNS O
and WO2006046492A1 A CC O
the WO2006046492A1 A DT O
activity WO2006046492A1 A NN O
of WO2006046492A1 A IN O
promoting WO2006046492A1 A VBG O
peripheral WO2006046492A1 A JJ O
insulin WO2006046492A1 A NN O
sensitivity WO2006046492A1 A NN O
. WO2006046492A1 A . O

This WO2006046492A1 A DT O
method WO2006046492A1 A NN O
comprises WO2006046492A1 A VBZ O
the WO2006046492A1 A DT O
steps WO2006046492A1 A NNS O
of WO2006046492A1 A IN O
( WO2006046492A1 A ( O
A WO2006046492A1 A DT O
) WO2006046492A1 A ) O
providing WO2006046492A1 A VBG O
candidate WO2006046492A1 A JJ O
compounds WO2006046492A1 A NNS O
; WO2006046492A1 A : O
( WO2006046492A1 A ( O
B WO2006046492A1 A NNP O
) WO2006046492A1 A ) O
with WO2006046492A1 A IN O
respect WO2006046492A1 A NN O
to WO2006046492A1 A TO O
the WO2006046492A1 A DT O
candidate WO2006046492A1 A NN O
compounds WO2006046492A1 A NNS O
, WO2006046492A1 A , O
measuring WO2006046492A1 A VBG O
at WO2006046492A1 A IN O
least WO2006046492A1 A JJS O
one WO2006046492A1 A CD O
activity WO2006046492A1 A NN O
selected WO2006046492A1 A VBN O
from WO2006046492A1 A IN O
the WO2006046492A1 A DT O
group WO2006046492A1 A NN O
consisting WO2006046492A1 A VBG O
of WO2006046492A1 A IN O
the WO2006046492A1 A DT O
activity WO2006046492A1 A NN O
of WO2006046492A1 A IN O
promoting WO2006046492A1 A VBG O
the WO2006046492A1 A DT O
insulin WO2006046492A1 A JJ O
secretion WO2006046492A1 A NN O
of WO2006046492A1 A IN O
pancreatic WO2006046492A1 A JJ O
β-cells WO2006046492A1 A NNS O
and WO2006046492A1 A CC O
the WO2006046492A1 A DT O
activity WO2006046492A1 A NN O
of WO2006046492A1 A IN O
promoting WO2006046492A1 A VBG O
peripheral WO2006046492A1 A JJ O
insulin WO2006046492A1 A NN O
sensitivity WO2006046492A1 A NN O
; WO2006046492A1 A : O
( WO2006046492A1 A ( O
C WO2006046492A1 A NNP O
) WO2006046492A1 A ) O
subjecting WO2006046492A1 A VBG O
the WO2006046492A1 A DT O
candidate WO2006046492A1 A NN O
compounds WO2006046492A1 A VBZ O
to WO2006046492A1 A TO O
an WO2006046492A1 A DT O
assay WO2006046492A1 A NN O
for WO2006046492A1 A IN O
measuring WO2006046492A1 A VBG O
the WO2006046492A1 A DT O
activity WO2006046492A1 A NN O
of WO2006046492A1 A IN O
PPAR WO2006046492A1 A NNP O
; WO2006046492A1 A : O
and WO2006046492A1 A CC O
( WO2006046492A1 A ( O
D WO2006046492A1 A NNP O
) WO2006046492A1 A ) O
identifying WO2006046492A1 A VBG O
those WO2006046492A1 A DT O
judged WO2006046492A1 A VBN O
as WO2006046492A1 A IN O
having WO2006046492A1 A VBG O
an WO2006046492A1 A DT O
activity WO2006046492A1 A NN O
in WO2006046492A1 A IN O
each WO2006046492A1 A DT O
of WO2006046492A1 A IN O
the WO2006046492A1 A DT O
steps WO2006046492A1 A NNS O
( WO2006046492A1 A ( O
B WO2006046492A1 A NNP O
) WO2006046492A1 A ) O
and WO2006046492A1 A CC O
( WO2006046492A1 A ( O
C WO2006046492A1 A NNP O
) WO2006046492A1 A ) O
as WO2006046492A1 A IN O
lead WO2006046492A1 A JJ O
compounds WO2006046492A1 A NNS O
. WO2006046492A1 A . O

Composition EP1616490A1 T NN O
comprising EP1616490A1 T VBG O
lutein EP1616490A1 T NN O
, EP1616490A1 T , O
zinc EP1616490A1 T NN O
and EP1616490A1 T CC O
copper EP1616490A1 T NN O
. EP1616490A1 T . O

Immunoeffector US7501399 T NNP O
compounds US7501399 T NNS O
. US7501399 T . O

PREPARATION WO2004112837A8 T NN O
FOR WO2004112837A8 T NNP O
EXTERNAL WO2004112837A8 T NNP O
PERCUTANEOUS WO2004112837A8 T NNP O
ADMINISTRATION WO2004112837A8 T NNP O
CONTAINING WO2004112837A8 T NNP O
NON-STEROIDAL WO2004112837A8 T JJ O
ANTI-INFLAMMATORY WO2004112837A8 T NNP O
DRUG WO2004112837A8 T NNP O
AND WO2004112837A8 T NNP O
INTERLEUKIN-1α WO2004112837A8 T NNP I-UN
PRODUCTION WO2004112837A8 T NNP O
INHIBITOR WO2004112837A8 T NNP O
. WO2004112837A8 T . O

Also WO2004112837A8 A RB O
provided WO2004112837A8 A VBN O
is WO2004112837A8 A VBZ O
an WO2004112837A8 A DT O
interleukin-1α WO2004112837A8 A JJ I-UN
production WO2004112837A8 A NN O
inhibitor WO2004112837A8 A NN O
which WO2004112837A8 A WDT O
comprises WO2004112837A8 A VBZ O
a WO2004112837A8 A DT O
phenolic WO2004112837A8 A JJ O
radial WO2004112837A8 A NN O
scavenger WO2004112837A8 A NN O
having WO2004112837A8 A VBG O
a WO2004112837A8 A DT O
branched WO2004112837A8 A VBN O
lower WO2004112837A8 A JJR O
alkyl WO2004112837A8 A NN O
group WO2004112837A8 A NN O
and/or WO2004112837A8 A VBD O
an WO2004112837A8 A DT O
alkyl WO2004112837A8 A JJ O
gallate WO2004112837A8 A NN O
. WO2004112837A8 A . O

Rad51 US20070287677 T NNP I-UN
Expression US20070287677 T NNP O
Inhibitors US20070287677 T NNP O
, US20070287677 T , O
Pharmaceutical US20070287677 T NNP O
Agents US20070287677 T NNP O
Containing US20070287677 T VBG O
The US20070287677 T DT O
Inhibitors US20070287677 T NNPS O
As US20070287677 T IN O
Active US20070287677 T JJ O
Ingredients US20070287677 T NNS O
, US20070287677 T , O
And US20070287677 T CC O
Uses US20070287677 T VBZ O
Thereof US20070287677 T NNP O
. US20070287677 T . O

The US20070287677 A DT O
double US20070287677 A NN O
stranded US20070287677 A VBD O
RNA US20070287677 A NNP O
acts US20070287677 A NNS O
as US20070287677 A IN O
siRNA US20070287677 A NN O
against US20070287677 A IN O
the US20070287677 A DT O
Rad51 US20070287677 A NNP I-UN
gene US20070287677 A NN O
. US20070287677 A . O

Method CN102846606A T NNP O
for CN102846606A T IN O
preparing CN102846606A T VBG O
compound CN102846606A T NN O
amoxicillin CN102846606A T NN O
and CN102846606A T CC O
potassium CN102846606A T NN O
clavulanate CN102846606A T NN O
injections CN102846606A T NNS O
. CN102846606A T . O

Cyclohexane CN102731492A T NNP O
derivative CN102731492A T JJ O
, CN102731492A T , O
its CN102731492A T PRP$ O
preparation CN102731492A T NN O
method CN102731492A T NN O
and CN102731492A T CC O
its CN102731492A T PRP$ O
application CN102731492A T NN O
in CN102731492A T IN O
medicines CN102731492A T NNS O
. CN102731492A T . O

Concretely CN102731492A A RB O
speaking CN102731492A A NN O
, CN102731492A A , O
the CN102731492A A DT O
invention CN102731492A A NN O
relates CN102731492A A VBZ O
to CN102731492A A TO O
the CN102731492A A DT O
novel CN102731492A A JJ O
cyclohexane CN102731492A A NN O
derivative CN102731492A A JJ O
shown CN102731492A A VBN O
in CN102731492A A IN O
a CN102731492A A DT O
general CN102731492A A JJ O
formula CN102731492A A NN O
( CN102731492A A ( O
I CN102731492A A PRP O
) CN102731492A A ) O
, CN102731492A A , O
its CN102731492A A PRP$ O
preparation CN102731492A A NN O
method CN102731492A A NN O
, CN102731492A A , O
a CN102731492A A DT O
pharmaceutical CN102731492A A JJ O
composition CN102731492A A NN O
containing CN102731492A A VBG O
the CN102731492A A DT O
derivative CN102731492A A JJ O
and CN102731492A A CC O
a CN102731492A A DT O
use CN102731492A A NN O
of CN102731492A A IN O
the CN102731492A A DT O
derivative CN102731492A A JJ O
as CN102731492A A IN O
a CN102731492A A DT O
therapeutic CN102731492A A JJ O
agent CN102731492A A NN O
, CN102731492A A , O
especially CN102731492A A RB O
a CN102731492A A DT O
GPR119 CN102731492A A NNP I-UN
agonist CN102731492A A NN O
, CN102731492A A , O
and CN102731492A A CC O
an CN102731492A A DT O
application CN102731492A A NN O
of CN102731492A A IN O
the CN102731492A A DT O
derivative CN102731492A A JJ O
in CN102731492A A IN O
preparing CN102731492A A VBG O
drugs CN102731492A A NNS O
for CN102731492A A IN O
treating CN102731492A A VBG O
diabetes CN102731492A A NNS O
, CN102731492A A , O
metabolic CN102731492A A JJ O
disorders CN102731492A A NNS O
, CN102731492A A , O
and CN102731492A A CC O
other CN102731492A A JJ O
diseases CN102731492A A NNS O
. CN102731492A A . O

Methods US20120190698 T NNS O
of US20120190698 T IN O
predicting US20120190698 T VBG O
thiopurine US20120190698 T JJ O
response US20120190698 T NN O
. US20120190698 T . O

In US20120190698 A IN O
one US20120190698 A CD O
embodiment US20120190698 A NN O
, US20120190698 A , O
the US20120190698 A DT O
effective US20120190698 A JJ O
therapeutic US20120190698 A JJ O
efficacy US20120190698 A NN O
of US20120190698 A IN O
thiopurines US20120190698 A NNS O
is US20120190698 A VBZ O
determined US20120190698 A VBN O
by US20120190698 A IN O
the US20120190698 A DT O
presence US20120190698 A NN O
of US20120190698 A IN O
risk US20120190698 A NN O
variants US20120190698 A NNS O
at US20120190698 A IN O
the US20120190698 A DT O
genetic US20120190698 A JJ O
loci US20120190698 A NN O
of US20120190698 A IN O
HLA-DRB1 US20120190698 A NNP I-UN
, US20120190698 A , O
CREM US20120190698 A NNP I-UN
, US20120190698 A , O
TAGAP US20120190698 A NNP I-UN
, US20120190698 A , O
PLCL1 US20120190698 A NNP I-UN
, US20120190698 A , O
GPX4 US20120190698 A NNP I-UN
, US20120190698 A , O
SBNO2 US20120190698 A NNP I-UN
, US20120190698 A , O
MEF2A US20120190698 A NNP I-UN
and/or US20120190698 A VBZ O
LYSMD4 US20120190698 A NNP I-UN
. US20120190698 A . O

In US20120190698 A IN O
another US20120190698 A DT O
embodiment US20120190698 A NN O
, US20120190698 A , O
the US20120190698 A DT O
risk US20120190698 A NN O
variants US20120190698 A NNS O
are US20120190698 A VBP O
located US20120190698 A VBN O
at US20120190698 A IN O
the US20120190698 A DT O
genetic US20120190698 A JJ O
loci US20120190698 A NN O
of US20120190698 A IN O
ARL4C US20120190698 A NNP I-UN
, US20120190698 A , O
IL1R2 US20120190698 A NNP I-UN
, US20120190698 A , O
JAK2 US20120190698 A NNP I-UN
, US20120190698 A , O
19q13 US20120190698 A CD O
, US20120190698 A , O
CARD9 US20120190698 A NNP I-UN
, US20120190698 A , O
SNAPC4 US20120190698 A NNP I-UN
, US20120190698 A , O
and/or US20120190698 A RB O
8q24 US20120190698 A CD O
. US20120190698 A . O

Etacrynic WO2012059090A4 T JJ O
acid WO2012059090A4 T NN O
for WO2012059090A4 T IN O
use WO2012059090A4 T NN O
in WO2012059090A4 T IN O
the WO2012059090A4 T DT O
treatment WO2012059090A4 T NN O
of WO2012059090A4 T IN O
food WO2012059090A4 T NN O
sensitivity WO2012059090A4 T NN O
disorders WO2012059090A4 T NNS O
. WO2012059090A4 T . O

Methods US20060111274 T NNS O
and US20060111274 T CC O
compositions US20060111274 T NNS O
for US20060111274 T IN O
enhancing US20060111274 T VBG O
transport US20060111274 T NN O
across US20060111274 T IN O
biological US20060111274 T JJ O
membranes US20060111274 T NNS O
. US20060111274 T . O

Use US7683034 T NNP O
of US7683034 T IN O
enzyme US7683034 T JJ O
inhibitors US7683034 T NNS O
of US7683034 T IN O
aminopeptidase US7683034 T NN O
N US7683034 T NNP O
and/or US7683034 T NN O
dipeptidylpeptidase US7683034 T NN O
IV US7683034 T NNP O
. US7683034 T . O

The US7683034 A DT O
invention US7683034 A NN O
relates US7683034 A VBZ O
to US7683034 A TO O
a US7683034 A DT O
process US7683034 A NN O
for US7683034 A IN O
the-inhibition US7683034 A NN O
of US7683034 A IN O
the US7683034 A DT O
DNA US7683034 A NNP O
synthesis US7683034 A NN O
necessary US7683034 A JJ O
for US7683034 A IN O
the US7683034 A DT O
proliferation US7683034 A NN O
of US7683034 A IN O
human US7683034 A JJ O
sebaceous US7683034 A JJ O
cells US7683034 A NNS O
( US7683034 A ( O
sebocytes US7683034 A NNS O
) US7683034 A ) O
by US7683034 A IN O
the US7683034 A DT O
isolated US7683034 A JJ O
or US7683034 A CC O
joint US7683034 A JJ O
effect US7683034 A NN O
of US7683034 A IN O
inhibitors US7683034 A NNS O
of US7683034 A IN O
alanyl US7683034 A JJ I-UN
aminopeptidase US7683034 A NN I-UN
( US7683034 A ( O
APN US7683034 A NNP I-UN
) US7683034 A ) O
and US7683034 A CC O
dipetidyl US7683034 A JJ I-UN
peptidase US7683034 A NN I-UN
IV US7683034 A NNP I-UN
( US7683034 A ( O
DP US7683034 A NNP I-UN
IV US7683034 A NNP I-UN
) US7683034 A ) O
expressed US7683034 A VBN O
by US7683034 A IN O
these US7683034 A DT O
cells US7683034 A NNS O
. US7683034 A . O

The US7683034 A DT O
DNA US7683034 A NN O
synthesis US7683034 A NN O
( US7683034 A ( O
proliferation US7683034 A NN O
) US7683034 A ) O
of US7683034 A IN O
human US7683034 A JJ O
sebaceous US7683034 A JJ O
cells US7683034 A NNS O
is US7683034 A VBZ O
inhibited US7683034 A VBN O
by US7683034 A IN O
the US7683034 A DT O
administration US7683034 A NN O
of US7683034 A IN O
the US7683034 A DT O
inhibitors US7683034 A NNS O
of US7683034 A IN O
APN US7683034 A NNP I-UN
and/or US7683034 A NN O
of US7683034 A IN O
DP US7683034 A NNP I-UN
IV US7683034 A NNP I-UN
depending US7683034 A VBG O
on US7683034 A IN O
the US7683034 A DT O
dose US7683034 A NN O
. US7683034 A . O

Method US20110262449 T NNP O
for US20110262449 T IN O
the US20110262449 T DT O
treatment US20110262449 T NN O
of US20110262449 T IN O
gout US20110262449 T NN O
or US20110262449 T CC O
pseudogout US20110262449 T NN O
. US20110262449 T . O

The US20110262449 A DT O
present US20110262449 A JJ O
invention US20110262449 A NN O
relates US20110262449 A VBZ O
to US20110262449 A TO O
a US20110262449 A DT O
new US20110262449 A JJ O
method US20110262449 A NN O
, US20110262449 A , O
and US20110262449 A CC O
the US20110262449 A DT O
process US20110262449 A NN O
to US20110262449 A TO O
manufacture US20110262449 A VB O
a US20110262449 A DT O
medicament US20110262449 A NN O
, US20110262449 A , O
for US20110262449 A IN O
treating US20110262449 A VBG O
gout US20110262449 A NN O
or US20110262449 A CC O
pseudogout US20110262449 A NN O
, US20110262449 A , O
comprising US20110262449 A VBG O
administering US20110262449 A VBG O
an US20110262449 A DT O
effective US20110262449 A JJ O
amount US20110262449 A NN O
of US20110262449 A IN O
inhibitors US20110262449 A NNS O
blocking US20110262449 A VBG O
IL-1 US20110262449 A NNP I-UN
or US20110262449 A CC O
its US20110262449 A PRP$ O
maturation US20110262449 A NN O
by US20110262449 A IN O
the US20110262449 A DT O
NALP3 US20110262449 A NNP I-UN
inflammasome US20110262449 A NN O
. US20110262449 A . O

Such US20050113577 T JJ O
as US20050113577 T IN O
hydrochloride US20050113577 T JJ O
salt US20050113577 T NN O
3- US20050113577 T JJ O
[ US20050113577 T JJ O
5- US20050113577 T JJ O
( US20050113577 T ( O
4-methanesulfonyl-piperazin-1-yl-methyl US20050113577 T JJ O
) US20050113577 T ) O
-1H-indol-2-yl US20050113577 T FW O
] US20050113577 T NNP O
-1H-quinolin-2-one US20050113577 T NN O
; US20050113577 T : O
signal US20050113577 T JJ O
transduction US20050113577 T NN O
; US20050113577 T : O
for US20050113577 T IN O
treatment US20050113577 T NN O
of US20050113577 T IN O
angiogenesis US20050113577 T NN O
, US20050113577 T , O
cancer US20050113577 T NN O
, US20050113577 T , O
tumor US20050113577 T NN O
growth US20050113577 T NN O
, US20050113577 T , O
atherosclerosis US20050113577 T NN O
, US20050113577 T , O
age US20050113577 T NN O
related US20050113577 T VBD O
macular US20050113577 T JJ O
degeneration US20050113577 T NN O
, US20050113577 T , O
diabetic US20050113577 T JJ O
retinopathy US20050113577 T NN O
, US20050113577 T , O
and US20050113577 T CC O
inflammatory US20050113577 T JJ O
diseases US20050113577 T NNS O
. US20050113577 T . O

The US20050113577 A DT O
present US20050113577 A JJ O
invention US20050113577 A NN O
relates US20050113577 A VBZ O
to US20050113577 A TO O
solid US20050113577 A VB O
forms US20050113577 A NNS O
of US20050113577 A IN O
the US20050113577 A DT O
hydrochloride US20050113577 A JJ O
salt US20050113577 A NN O
3- US20050113577 A JJ O
[ US20050113577 A JJ O
5- US20050113577 A JJ O
( US20050113577 A ( O
4-methanesulfonyl-piperazin-1-yl-methyl US20050113577 A JJ O
) US20050113577 A ) O
-1H-indol-2-yl US20050113577 A FW O
] US20050113577 A NNP O
-1H-quinolin-2-one US20050113577 A CD O
which US20050113577 A WDT O
inhibit US20050113577 A NN O
, US20050113577 A , O
regulate US20050113577 A VB O
and/or US20050113577 A JJ O
modulate US20050113577 A NN O
tyrosine US20050113577 A NN O
kinase US20050113577 A NNP O
signal US20050113577 A JJ O
transduction US20050113577 A NN O
, US20050113577 A , O
compositions US20050113577 A NNS O
which US20050113577 A WDT O
contain US20050113577 A VBP O
these US20050113577 A DT O
compounds US20050113577 A NNS O
, US20050113577 A , O
and US20050113577 A CC O
methods US20050113577 A NNS O
of US20050113577 A IN O
using US20050113577 A VBG O
them US20050113577 A PRP O
to US20050113577 A TO O
treat US20050113577 A VB O
tyrosine US20050113577 A JJ I-UN
kinase-dependent US20050113577 A JJ O
diseases US20050113577 A NNS O
and US20050113577 A CC O
conditions US20050113577 A NNS O
, US20050113577 A , O
such US20050113577 A JJ O
as US20050113577 A IN O
angio-genesis US20050113577 A NN O
, US20050113577 A , O
cancer US20050113577 A NN O
, US20050113577 A , O
tumor US20050113577 A NN O
growth US20050113577 A NN O
, US20050113577 A , O
atherosclerosis US20050113577 A NN O
, US20050113577 A , O
age US20050113577 A NN O
related US20050113577 A VBD O
macular US20050113577 A JJ O
degeneration US20050113577 A NN O
, US20050113577 A , O
diabetic US20050113577 A JJ O
retinopathy US20050113577 A NN O
, US20050113577 A , O
inflammatory US20050113577 A JJ O
diseases US20050113577 A NNS O
, US20050113577 A , O
and US20050113577 A CC O
the US20050113577 A DT O
like US20050113577 A JJ O
in US20050113577 A IN O
mammals US20050113577 A NNS O
. US20050113577 A . O

Medicinal CN103127041A T JJ O
composition CN103127041A T NN O
with CN103127041A T IN O
lanthanum CN103127041A T NN O
acetate CN103127041A T NN O
, CN103127041A T , O
preparation CN103127041A T NN O
method CN103127041A T NN O
and CN103127041A T CC O
application CN103127041A T NN O
thereof CN103127041A T NN O
. CN103127041A T . O

Oligomer-corticosteroid US8796248 T JJ O
conjugates US8796248 T NNS O
. US8796248 T . O

The US8796248 A DT O
invention US8796248 A NN O
provides US8796248 A VBZ O
corticosteroids US8796248 A NNS O
that US8796248 A WDT O
are US8796248 A VBP O
chemically US8796248 A RB O
modified US8796248 A VBN O
by US8796248 A IN O
covalent US8796248 A JJ O
attachment US8796248 A NN O
of US8796248 A IN O
a US8796248 A DT O
water US8796248 A NN O
soluble US8796248 A JJ O
oligomer US8796248 A NN O
. US8796248 A . O

A US8796248 A DT O
compound US8796248 A NN O
of US8796248 A IN O
the US8796248 A DT O
invention US8796248 A NN O
, US8796248 A , O
when US8796248 A WRB O
administered US8796248 A VBN O
by US8796248 A IN O
any US8796248 A DT O
of US8796248 A IN O
a US8796248 A DT O
number US8796248 A NN O
of US8796248 A IN O
administration US8796248 A NN O
routes US8796248 A NNS O
, US8796248 A , O
exhibits US8796248 A VBZ O
a US8796248 A DT O
reduced US8796248 A JJ O
biological US8796248 A JJ O
membrane US8796248 A NN O
crossing US8796248 A VBG O
rate US8796248 A NN O
as US8796248 A IN O
compared US8796248 A VBN O
to US8796248 A TO O
the US8796248 A DT O
biological US8796248 A JJ O
membrane US8796248 A NN O
crossing US8796248 A VBG O
rate US8796248 A NN O
of US8796248 A IN O
the US8796248 A DT O
corticosteroid US8796248 A NN O
not US8796248 A RB O
attached US8796248 A VBN O
to US8796248 A TO O
the US8796248 A DT O
water US8796248 A NN O
soluble US8796248 A JJ O
oligomer US8796248 A NN O
. US8796248 A . O

Dosage WO2007054258A1 T NN O
form WO2007054258A1 T NN O
for WO2007054258A1 T IN O
hormonal WO2007054258A1 T JJ O
contraception WO2007054258A1 T NN O
. WO2007054258A1 T . O

Cdk US20120041007 T NNP I-UN
inhibitor US20120041007 T NN O
salts US20120041007 T NNS O
. US20120041007 T . O

The US20120041007 A DT O
present US20120041007 A JJ O
invention US20120041007 A NN O
relates US20120041007 A VBZ O
to US20120041007 A TO O
novel US20120041007 A VB O
crystalline US20120041007 A JJ O
form US20120041007 A NN O
( US20120041007 A ( O
s US20120041007 A JJ O
) US20120041007 A ) O
of US20120041007 A IN O
water-soluble US20120041007 A JJ O
salts US20120041007 A NNS O
and US20120041007 A CC O
of US20120041007 A IN O
free US20120041007 A JJ O
base US20120041007 A NN O
of US20120041007 A IN O
a US20120041007 A DT O
cdk US20120041007 A NN I-UN
inhibitor US20120041007 A NN O
. US20120041007 A . O

Crystal CN101525364A T JJ O
form CN101525364A T NN O
of CN101525364A T IN O
fulvestrant CN101525364A T NN O
and CN101525364A T CC O
preparation CN101525364A T NN O
method CN101525364A T NN O
thereof CN101525364A T NN O
. CN101525364A T . O

Method CN101797238A T NNP O
for CN101797238A T IN O
preparing CN101797238A T VBG O
medicinal CN101797238A T JJ O
preparation CN101797238A T NN O
for CN101797238A T IN O
releasing CN101797238A T VBG O
rifampicin CN101797238A T NN O
on CN101797238A T IN O
upper CN101797238A T JJ O
part CN101797238A T NN O
of CN101797238A T IN O
small CN101797238A T JJ O
intestine CN101797238A T NN O
and CN101797238A T CC O
characteristics CN101797238A T NNS O
of CN101797238A T IN O
medicinal CN101797238A T JJ O
preparation CN101797238A T NN O
. CN101797238A T . O

Delayed US20090042914 T NNP O
release US20090042914 T NN O
formulations US20090042914 T NNS O
of US20090042914 T IN O
6-mercaptopurine US20090042914 T JJ O
. US20090042914 T . O

Rubescensin CN1857252A T NNP O
structural CN1857252A T JJ O
preparation CN1857252A T NN O
composition CN1857252A T NN O
. CN1857252A T . O

The CN1857252A A DT O
present CN1857252A A JJ O
invention CN1857252A A NN O
discloses CN1857252A A VBZ O
a CN1857252A A DT O
kind CN1857252A A NN O
of CN1857252A A IN O
stable CN1857252A A JJ O
rubescensin CN1857252A A NN O
composition CN1857252A A NN O
in CN1857252A A IN O
oil-in-water CN1857252A A JJ O
structure CN1857252A A NN O
, CN1857252A A , O
and CN1857252A A CC O
the CN1857252A A DT O
composition CN1857252A A NN O
contains CN1857252A A VBZ O
rubescensin CN1857252A A NN O
, CN1857252A A , O
rubescensin CN1857252A A NN O
cosolvent CN1857252A A NN O
, CN1857252A A , O
oily CN1857252A A RB O
carrier CN1857252A A NN O
, CN1857252A A , O
water CN1857252A A NN O
and CN1857252A A CC O
surfactant CN1857252A A NN O
. CN1857252A A . O

The CN1857252A A DT O
rubescensin CN1857252A A NN O
is CN1857252A A VBZ O
dissolved CN1857252A A VBN O
in CN1857252A A IN O
the CN1857252A A DT O
rubescensin CN1857252A A NN O
cosolvent CN1857252A A NN O
and CN1857252A A CC O
mixed CN1857252A A JJ O
into CN1857252A A IN O
oily CN1857252A A RB O
carrier CN1857252A A NN O
to CN1857252A A TO O
form CN1857252A A VB O
stable CN1857252A A JJ O
dispersion CN1857252A A NN O
phase CN1857252A A NN O
of CN1857252A A IN O
average CN1857252A A JJ O
grain CN1857252A A NN O
size CN1857252A A NN O
not CN1857252A A RB O
greater CN1857252A A JJR O
than CN1857252A A IN O
0.5 CN1857252A A CD O
micron CN1857252A A NN O
. CN1857252A A . O

Orally CN101836965A T RB O
disintegrating CN101836965A T VBG O
tablet CN101836965A T NN O
containing CN101836965A T VBG O
fexofenadine CN101836965A T NN O
or CN101836965A T CC O
salts CN101836965A T NNS O
of CN101836965A T IN O
fexofenadine CN101836965A T NN O
, CN101836965A T , O
and CN101836965A T CC O
preparation CN101836965A T NN O
method CN101836965A T NN O
thereof CN101836965A T NN O
. CN101836965A T . O

The CN101836965A A DT O
invention CN101836965A A NN O
provides CN101836965A A VBZ O
an CN101836965A A DT O
orally CN101836965A A RB O
disintegrating CN101836965A A VBG O
tablet CN101836965A A NN O
containing CN101836965A A VBG O
fexofenadine CN101836965A A NN O
or CN101836965A A CC O
salts CN101836965A A NNS O
of CN101836965A A IN O
fexofenadine CN101836965A A NN O
, CN101836965A A , O
which CN101836965A A WDT O
is CN101836965A A VBZ O
prepared CN101836965A A VBN O
by CN101836965A A IN O
the CN101836965A A DT O
inclusion CN101836965A A NN O
technology CN101836965A A NN O
. CN101836965A A . O

When CN101836965A A WRB O
main CN101836965A A JJ O
drugs CN101836965A A NNS O
and CN101836965A A CC O
inclusions CN101836965A A NNS O
exist CN101836965A A VBP O
at CN101836965A A IN O
a CN101836965A A DT O
specific CN101836965A A JJ O
ratio CN101836965A A NN O
, CN101836965A A , O
the CN101836965A A DT O
tablet CN101836965A A NN O
can CN101836965A A MD O
effectively CN101836965A A RB O
solve CN101836965A A VB O
the CN101836965A A DT O
problems CN101836965A A NNS O
of CN101836965A A IN O
the CN101836965A A DT O
taste CN101836965A A NN O
and CN101836965A A CC O
disintegration CN101836965A A NN O
of CN101836965A A IN O
the CN101836965A A DT O
main CN101836965A A JJ O
drugs CN101836965A A NNS O
, CN101836965A A , O
is CN101836965A A VBZ O
convenient CN101836965A A JJ O
for CN101836965A A IN O
operating CN101836965A A NN O
, CN101836965A A , O
transporting CN101836965A A VBG O
and CN101836965A A CC O
storing CN101836965A A NN O
, CN101836965A A , O
has CN101836965A A VBZ O
wide CN101836965A A JJ O
application CN101836965A A NN O
range CN101836965A A NN O
and CN101836965A A CC O
is CN101836965A A VBZ O
suitable CN101836965A A JJ O
for CN101836965A A IN O
large-scale CN101836965A A JJ O
production CN101836965A A NN O
. CN101836965A A . O

New CN101693026B T NNP O
use CN101693026B T NN O
of CN101693026B T IN O
isosorbide CN101693026B T JJ O
mononitrate CN101693026B T NN O
in CN101693026B T IN O
preparing CN101693026B T VBG O
medicine CN101693026B T NN O
for CN101693026B T IN O
increasing CN101693026B T VBG O
endometrial CN101693026B T JJ O
thickness CN101693026B T NN O
. CN101693026B T . O

Method WO2010093736A1 T NNP O
for WO2010093736A1 T IN O
facilitating WO2010093736A1 T VBG O
extinction WO2010093736A1 T NN O
training WO2010093736A1 T VBG O
using WO2010093736A1 T VBG O
d-cycloserine WO2010093736A1 T NN O
. WO2010093736A1 T . O

Alkyne-aryl-naphthyridin-4 EP2305677A1 T NNP O
( EP2305677A1 T ( O
1h EP2305677A1 T CD O
) EP2305677A1 T ) O
-one EP2305677A1 T NN O
derivatives EP2305677A1 T NNS O
as EP2305677A1 T IN O
type EP2305677A1 T NN I-UN
IV EP2305677A1 T NNP I-UN
phosphodiesterase EP2305677A1 T NN I-UN
inhibitor EP2305677A1 T NN O
. EP2305677A1 T . O

Compounds EP2305677A1 A NNS O
represented EP2305677A1 A VBN O
by EP2305677A1 A IN O
Formula EP2305677A1 A NNP O
( EP2305677A1 A ( O
I EP2305677A1 A PRP O
) EP2305677A1 A ) O
: EP2305677A1 A : O
or EP2305677A1 A CC O
a EP2305677A1 A DT O
pharmaceutically EP2305677A1 A RB O
acceptable EP2305677A1 A JJ O
salt EP2305677A1 A NN O
thereof EP2305677A1 A NN O
, EP2305677A1 A , O
are EP2305677A1 A VBP O
phosphodiesterase EP2305677A1 A JJ I-UN
4 EP2305677A1 A CD I-UN
inhibitors EP2305677A1 A NNS O
useful EP2305677A1 A JJ O
in EP2305677A1 A IN O
the EP2305677A1 A DT O
treatment EP2305677A1 A NN O
of EP2305677A1 A IN O
asthma EP2305677A1 A NN O
and EP2305677A1 A CC O
inflammation EP2305677A1 A NN O
. EP2305677A1 A . O

Mitoxantrone CN1915220A T NN O
or CN1915220A T CC O
liposome CN1915220A T NN O
of CN1915220A T IN O
mitoxantrone CN1915220A T NN O
hydrochloric CN1915220A T JJ O
acid CN1915220A T NN O
, CN1915220A T , O
and CN1915220A T CC O
preparation CN1915220A T NN O
method CN1915220A T NN O
. CN1915220A T . O

Clopidogrel CN101427992A T NNP O
hydrobromate CN101427992A T NN O
preparation CN101427992A T NN O
and CN101427992A T CC O
method CN101427992A T NN O
of CN101427992A T IN O
producing CN101427992A T VBG O
the CN101427992A T DT O
same CN101427992A T JJ O
. CN101427992A T . O

Methods US8476254 T NNS O
for US8476254 T IN O
treating US8476254 T VBG O
psychosis US8476254 T NN O
associated US8476254 T VBN O
with US8476254 T IN O
interferson-α US8476254 T JJ O
therapy US8476254 T NN O
. US8476254 T . O

The US8476254 A DT O
present US8476254 A JJ O
invention US8476254 A NN O
relates US8476254 A VBZ O
to US8476254 A TO O
the US8476254 A DT O
treatment US8476254 A NN O
of US8476254 A IN O
psychosis US8476254 A NN O
associated US8476254 A VBN O
with US8476254 A IN O
interferon-α US8476254 A JJ O
therapy US8476254 A NN O
by US8476254 A IN O
administering US8476254 A VBG O
an US8476254 A DT O
amount US8476254 A NN O
of US8476254 A IN O
a US8476254 A DT O
glucocorticoid US8476254 A JJ I-UN
receptor US8476254 A NN I-UN
antagonist US8476254 A NN O
effective US8476254 A JJ O
to US8476254 A TO O
ameliorate US8476254 A VB O
the US8476254 A DT O
symptoms US8476254 A NNS O
of US8476254 A IN O
psychosis US8476254 A NN O
in US8476254 A IN O
the US8476254 A DT O
patient US8476254 A NN O
, US8476254 A , O
wherein US8476254 A VBP O
the US8476254 A DT O
patient US8476254 A NN O
is US8476254 A VBZ O
not US8476254 A RB O
otherwise US8476254 A RB O
in US8476254 A IN O
need US8476254 A NN O
of US8476254 A IN O
treatment US8476254 A NN O
with US8476254 A IN O
a US8476254 A DT O
glucocorticoid US8476254 A JJ I-UN
receptor US8476254 A NN I-UN
antagonist US8476254 A NN O
. US8476254 A . O

Composition WO2009020192A1 T NN O
for WO2009020192A1 T IN O
oral WO2009020192A1 T JJ O
intake WO2009020192A1 T NN O
for WO2009020192A1 T IN O
preventing WO2009020192A1 T VBG O
ultraviolet WO2009020192A1 T JJ O
damage WO2009020192A1 T NN O
. WO2009020192A1 T . O

Drops CN1582913A T NNS O
of CN1582913A T IN O
benzohydroxymethylamine CN1582913A T NN O
and CN1582913A T CC O
their CN1582913A T PRP$ O
preparation CN1582913A T NN O
. CN1582913A T . O

In US20080069899 T IN O
mixture US20080069899 T NN O
with US20080069899 T IN O
drug US20080069899 T NN O
that US20080069899 T WDT O
prevents US20080069899 T VBZ O
Dna US20080069899 T NNP O
reproduction US20080069899 T NN O
. US20080069899 T . O

N-oxides WO2007023141A1 T NNS O
as WO2007023141A1 T IN O
prodrugs WO2007023141A1 T NNS O
of WO2007023141A1 T IN O
piperazine WO2007023141A1 T NN O
& WO2007023141A1 T CC O
piperidine WO2007023141A1 T NN O
derivatives WO2007023141A1 T NNS O
. WO2007023141A1 T . O

Surgical US20120115810 T JJ O
compositions US20120115810 T NNS O
for US20120115810 T IN O
reducing US20120115810 T VBG O
the US20120115810 T DT O
incidence US20120115810 T NN O
of US20120115810 T IN O
adhesions US20120115810 T NNS O
. US20120115810 T . O

Amino-piperidine US7176316 T JJ O
derivatives US7176316 T NNS O
. US7176316 T . O

The US7176316 A DT O
compounds US7176316 A NNS O
are US7176316 A VBP O
GlyT-1 US7176316 A JJ I-UN
inhibitors US7176316 A NNS O
and US7176316 A CC O
are US7176316 A VBP O
useful US7176316 A JJ O
for US7176316 A IN O
the US7176316 A DT O
treatment US7176316 A NN O
of US7176316 A IN O
psychoses US7176316 A NNS O
, US7176316 A , O
pain US7176316 A NN O
, US7176316 A , O
dysfunction US7176316 A NN O
in US7176316 A IN O
memory US7176316 A NN O
and US7176316 A CC O
learning US7176316 A NN O
, US7176316 A , O
schizophrenia US7176316 A NN O
, US7176316 A , O
dementia US7176316 A NN O
and US7176316 A CC O
other US7176316 A JJ O
diseases US7176316 A NNS O
in US7176316 A IN O
which US7176316 A WDT O
cognitive US7176316 A JJ O
processes US7176316 A NNS O
are US7176316 A VBP O
impaired US7176316 A VBN O
, US7176316 A , O
such US7176316 A JJ O
as US7176316 A IN O
attention US7176316 A NN O
deficit US7176316 A NN O
disorders US7176316 A NNS O
or US7176316 A CC O
Alzheimer US7176316 A NNP O
's US7176316 A POS O
disease US7176316 A NN O
. US7176316 A . O

Zaleplon CN102824331A T NNP O
double-release CN102824331A T NN O
capsule CN102824331A T NN O
and CN102824331A T CC O
preparation CN102824331A T NN O
method CN102824331A T NN O
thereof CN102824331A T NN O
. CN102824331A T . O

The WO2014061827A1 A DT O
present WO2014061827A1 A JJ O
disclosure WO2014061827A1 A NN O
relates WO2014061827A1 A VBZ O
generally WO2014061827A1 A RB O
to WO2014061827A1 A TO O
alpha-helix WO2014061827A1 A JJ O
mimetic WO2014061827A1 A JJ O
structures WO2014061827A1 A NNS O
and WO2014061827A1 A CC O
specifically WO2014061827A1 A RB O
to WO2014061827A1 A TO O
alpha-helix WO2014061827A1 A JJ O
mimetic WO2014061827A1 A JJ O
structures WO2014061827A1 A NNS O
that WO2014061827A1 A WDT O
are WO2014061827A1 A VBP O
inhibitors WO2014061827A1 A NNS O
of WO2014061827A1 A IN O
β-catenin WO2014061827A1 A NN I-UN
. WO2014061827A1 A . O

The WO2014061827A1 A DT O
disclosure WO2014061827A1 A NN O
also WO2014061827A1 A RB O
relates WO2014061827A1 A VBZ O
to WO2014061827A1 A TO O
applications WO2014061827A1 A NNS O
in WO2014061827A1 A IN O
the WO2014061827A1 A DT O
treatment WO2014061827A1 A NN O
of WO2014061827A1 A IN O
pulmonary WO2014061827A1 A JJ O
fibrosis WO2014061827A1 A NN O
, WO2014061827A1 A , O
including WO2014061827A1 A VBG O
usual WO2014061827A1 A JJ O
interstitial WO2014061827A1 A JJ O
pneumonia WO2014061827A1 A NN O
and WO2014061827A1 A CC O
idiopathic WO2014061827A1 A JJ O
pulmonary WO2014061827A1 A JJ O
fibrosis WO2014061827A1 A NN O
, WO2014061827A1 A , O
and WO2014061827A1 A CC O
pharmaceutical WO2014061827A1 A JJ O
compositions WO2014061827A1 A NNS O
comprising WO2014061827A1 A VBG O
such WO2014061827A1 A JJ O
alpha WO2014061827A1 A JJ O
helix WO2014061827A1 A NN O
mimetic WO2014061827A1 A JJ O
β-catenin WO2014061827A1 A JJ I-UN
inhibitors WO2014061827A1 A NNS O
. WO2014061827A1 A . O

Application CN103142580A T NN O
of CN103142580A T IN O
barbaloin CN103142580A T NN O
. CN103142580A T . O

The CN103142580A A DT O
invention CN103142580A A NN O
discloses CN103142580A A VBZ O
an CN103142580A A DT O
application CN103142580A A NN O
of CN103142580A A IN O
barbaloin CN103142580A A NN O
in CN103142580A A IN O
preparing CN103142580A A VBG O
medicines CN103142580A A NNS O
or CN103142580A A CC O
cosmetics CN103142580A A NNS O
for CN103142580A A IN O
preventing CN103142580A A VBG O
or CN103142580A A CC O
treating CN103142580A A VBG O
acne CN103142580A A NNS O
caused CN103142580A A VBN O
by CN103142580A A IN O
propionibacterium CN103142580A A NN O
acne CN103142580A A NN O
breeding CN103142580A A NN O
. CN103142580A A . O

The CN103142580A A DT O
invention CN103142580A A NN O
discloses CN103142580A A VBZ O
the CN103142580A A DT O
medicines CN103142580A A NNS O
or CN103142580A A CC O
cosmetics CN103142580A A NNS O
which CN103142580A A WDT O
contain CN103142580A A VBP O
the CN103142580A A DT O
barbaloin CN103142580A A NN O
which CN103142580A A WDT O
can CN103142580A A MD O
effectively CN103142580A A RB O
treat CN103142580A A VB O
the CN103142580A A DT O
acne CN103142580A A JJ O
generation CN103142580A A NN O
caused CN103142580A A VBN O
by CN103142580A A IN O
propionibacterium CN103142580A A NN O
acne CN103142580A A NN O
breeding CN103142580A A NN O
. CN103142580A A . O

Antibodies US7807795 T NNS O
to US7807795 T TO O
osteoprotegerin US7807795 T VB I-UN
binding US7807795 T VBG I-UN
proteins US7807795 T NNS I-UN
. US7807795 T . O

A US7807795 A DT O
novel US7807795 A JJ O
polypeptide US7807795 A NN O
, US7807795 A , O
osteoprotegerin US7807795 A IN I-UN
binding US7807795 A VBG I-UN
protein US7807795 A NN I-UN
, US7807795 A , O
involved US7807795 A VBN O
in US7807795 A IN O
osteoclast US7807795 A JJ O
maturation US7807795 A NN O
has US7807795 A VBZ O
been US7807795 A VBN O
identified US7807795 A VBN O
based US7807795 A VBN O
upon US7807795 A IN O
its US7807795 A PRP$ O
affinity US7807795 A NN O
for US7807795 A IN O
osteoprotegerin US7807795 A NN O
. US7807795 A . O

Antibodies US7807795 A NNS O
specifically US7807795 A RB O
binding US7807795 A VBG O
osteoprotegerin US7807795 A RP I-UN
binding US7807795 A VBG I-UN
protein US7807795 A NN I-UN
are US7807795 A VBP O
also US7807795 A RB O
described US7807795 A VBN O
. US7807795 A . O

Method WO2007015510A1 T NNP O
for WO2007015510A1 T IN O
prevention WO2007015510A1 T NN O
of WO2007015510A1 T IN O
degradation WO2007015510A1 T NN O
of WO2007015510A1 T IN O
thermally WO2007015510A1 T RB O
unstable WO2007015510A1 T JJ O
substance WO2007015510A1 T NN O
. WO2007015510A1 T . O

Adenosine EP2087888A1 T NNP I-UN
a1 EP2087888A1 T NN I-UN
receptor EP2087888A1 T NN I-UN
antagonists EP2087888A1 T NNS O
for EP2087888A1 T IN O
the EP2087888A1 T DT O
treatment EP2087888A1 T NN O
of EP2087888A1 T IN O
alkalosis EP2087888A1 T NN O
. EP2087888A1 T . O

The EP2087888A1 A DT O
present EP2087888A1 A JJ O
invention EP2087888A1 A NN O
relates EP2087888A1 A VBZ O
to EP2087888A1 A TO O
adenosine EP2087888A1 A VB I-UN
A1 EP2087888A1 A NNP I-UN
receptor EP2087888A1 A NN I-UN
antagonists EP2087888A1 A NNS O
( EP2087888A1 A ( O
AA1RA EP2087888A1 A NNP O
) EP2087888A1 A ) O
, EP2087888A1 A , O
for EP2087888A1 A IN O
use EP2087888A1 A NN O
in EP2087888A1 A IN O
treating EP2087888A1 A VBG O
alkalosis EP2087888A1 A NN O
. EP2087888A1 A . O

Compounds WO2013056067A1 T NNS O
for WO2013056067A1 T IN O
use WO2013056067A1 T NN O
in WO2013056067A1 T IN O
the WO2013056067A1 T DT O
treatment WO2013056067A1 T NN O
of WO2013056067A1 T IN O
basal WO2013056067A1 T NN O
cell WO2013056067A1 T NN O
carcinoma WO2013056067A1 T NN O
. WO2013056067A1 T . O

Skin CN101062052A T NNP O
trauma CN101062052A T NN O
agent/ointment CN101062052A T NN O
. CN101062052A T . O

Plasminogen US20080280920 T NNP I-UN
Activator US20080280920 T NNP I-UN
Inhibitor-1 US20080280920 T NNP I-UN
Inhibitors US20080280920 T NNP O
. US20080280920 T . O

Inhibitors US20080280920 A NNS O
of US20080280920 A IN O
plasminogen US20080280920 A NN I-UN
activator US20080280920 A NN I-UN
inhibitor-1 US20080280920 A JJ I-UN
( US20080280920 A ( O
PAI-I US20080280920 A NNP I-UN
) US20080280920 A ) O
are US20080280920 A VBP O
provided US20080280920 A VBN O
, US20080280920 A , O
which US20080280920 A WDT O
may US20080280920 A MD O
also US20080280920 A RB O
act US20080280920 A VB O
as US20080280920 A IN O
anti US20080280920 A JJ O
cancer US20080280920 A NN O
agents US20080280920 A NNS O
, US20080280920 A , O
of US20080280920 A IN O
formulae US20080280920 A NN O
( US20080280920 A ( O
I-V US20080280920 A NNP O
) US20080280920 A ) O
. US20080280920 A . O

Double US20080234217 T RB O
stranded US20080234217 T VBN O
nucleotide US20080234217 T JJ O
sequences US20080234217 T NNS O
for US20080234217 T IN O
use US20080234217 T NN O
as US20080234217 T IN O
tools US20080234217 T NNS O
in US20080234217 T IN O
tissue US20080234217 T NN O
targeted US20080234217 T VBN O
gene US20080234217 T NN O
expression US20080234217 T NN O
inhibition US20080234217 T NN O
and US20080234217 T CC O
treatment US20080234217 T NN O
of US20080234217 T IN O
cancer US20080234217 T NN O
, US20080234217 T , O
vascular US20080234217 T JJ O
, US20080234217 T , O
neuronal US20080234217 T JJ O
and US20080234217 T CC O
endocrine US20080234217 T JJ O
diseases US20080234217 T NNS O
. US20080234217 T . O

The US20080234217 A DT O
aptamer US20080234217 A NN O
may US20080234217 A MD O
bind US20080234217 A VB O
to US20080234217 A TO O
human US20080234217 A JJ I-UN
serum US20080234217 A NN I-UN
albumin US20080234217 A NN I-UN
to US20080234217 A TO O
improve US20080234217 A VB O
serum US20080234217 A NN O
half US20080234217 A NN O
life US20080234217 A NN O
. US20080234217 A . O

Bactericides US20080058371 T NNS O
; US20080058371 T : O
produces US20080058371 T VBZ O
little US20080058371 T JJ O
or US20080058371 T CC O
no US20080058371 T DT O
tissue US20080058371 T NN O
damage US20080058371 T NN O
or US20080058371 T CC O
irritation US20080058371 T NN O
at US20080058371 T IN O
the US20080058371 T DT O
injection US20080058371 T NN O
site US20080058371 T NN O
. US20080058371 T . O

An US20080058371 A DT O
antibacterial US20080058371 A JJ O
formulation US20080058371 A NN O
suitable US20080058371 A NN O
for US20080058371 A IN O
injection US20080058371 A NN O
into US20080058371 A IN O
animals US20080058371 A NNS O
containing US20080058371 A VBG O
approximately US20080058371 A RB O
2-10 US20080058371 A JJ O
% US20080058371 A NN O
w/v US20080058371 A NN O
difloxacin US20080058371 A NN O
HCl US20080058371 A NNP O
, US20080058371 A , O
L-arginine US20080058371 A NNP O
base US20080058371 A NN O
, US20080058371 A , O
propylene US20080058371 A NN O
glycol US20080058371 A NN O
, US20080058371 A , O
ethanol US20080058371 A JJ O
and/or US20080058371 A NN O
benzyl US20080058371 A NN O
alcohol US20080058371 A NN O
, US20080058371 A , O
and US20080058371 A CC O
water US20080058371 A NN O
. US20080058371 A . O

The US20080058371 A DT O
formulation US20080058371 A NN O
is US20080058371 A VBZ O
a US20080058371 A DT O
solution US20080058371 A NN O
having US20080058371 A VBG O
a US20080058371 A DT O
pH US20080058371 A NN O
of US20080058371 A IN O
form US20080058371 A NN O
9 US20080058371 A CD O
to US20080058371 A TO O
10 US20080058371 A CD O
. US20080058371 A . O

The US20080058371 A DT O
formulation US20080058371 A NN O
produces US20080058371 A VBZ O
little US20080058371 A JJ O
or US20080058371 A CC O
no US20080058371 A DT O
tissue US20080058371 A NN O
damage US20080058371 A NN O
or US20080058371 A CC O
irritation US20080058371 A NN O
at US20080058371 A IN O
the US20080058371 A DT O
injection US20080058371 A NN O
site US20080058371 A NN O
. US20080058371 A . O

Polymers US20110268690 T NNS O
containing US20110268690 T VBG O
poly US20110268690 T NN O
( US20110268690 T ( O
hydroxyalkanoates US20110268690 T NNS O
) US20110268690 T ) O
and US20110268690 T CC O
agents US20110268690 T NNS O
for US20110268690 T IN O
use US20110268690 T NN O
with US20110268690 T IN O
medical US20110268690 T JJ O
articles US20110268690 T NNS O
and US20110268690 T CC O
methods US20110268690 T NNS O
of US20110268690 T IN O
fabricating US20110268690 T VBG O
the US20110268690 T DT O
same US20110268690 T JJ O
. US20110268690 T . O

Method WO2005018528A3 T NNP O
for WO2005018528A3 T IN O
the WO2005018528A3 T DT O
treatment WO2005018528A3 T NN O
prophylaxis WO2005018528A3 T NN O
and WO2005018528A3 T CC O
differential WO2005018528A3 T JJ O
diagnosis WO2005018528A3 T NN O
of WO2005018528A3 T IN O
prostatitis WO2005018528A3 T NN O
. WO2005018528A3 T . O

Treatment EP2688565A1 T NN O
of EP2688565A1 T IN O
proliferative EP2688565A1 T JJ O
disorders EP2688565A1 T NNS O
with EP2688565A1 T IN O
a EP2688565A1 T DT O
chemiluminescent EP2688565A1 T NN O
agent EP2688565A1 T NN O
. EP2688565A1 T . O

Methods CA2558043A1 T NNS O
of CA2558043A1 T IN O
correcting CA2558043A1 T VBG O
bone CA2558043A1 T NN O
mineralization CA2558043A1 T NN O
defects CA2558043A1 T NNS O
, CA2558043A1 T , O
kits CA2558043A1 T NNS O
therefor CA2558043A1 T VBP O
and CA2558043A1 T CC O
compositions CA2558043A1 T NNS O
therefor CA2558043A1 T VBP O
. CA2558043A1 T . O

A CA2558043A1 A DT O
use CA2558043A1 A NN O
of CA2558043A1 A IN O
a CA2558043A1 A DT O
therapeutically CA2558043A1 A RB O
effective CA2558043A1 A JJ O
amount CA2558043A1 A NN O
of CA2558043A1 A IN O
at CA2558043A1 A IN O
least CA2558043A1 A JJS O
one CA2558043A1 A CD O
cathepsin CA2558043A1 A NN I-UN
B CA2558043A1 A NNP I-UN
inhibitor CA2558043A1 A NN O
for CA2558043A1 A IN O
correcting CA2558043A1 A VBG O
bone CA2558043A1 A NN O
mineralization CA2558043A1 A NN O
defect CA2558043A1 A NN O
. CA2558043A1 A . O

Erlotinib EP2776406A2 T NNP O
salts EP2776406A2 T NNS O
. EP2776406A2 T . O

Administering US7223397 T VBG O
an US7223397 T DT O
agent US7223397 T NN O
which US7223397 T WDT O
upregulates US7223397 T VBZ O
the US7223397 T DT O
expression US7223397 T NN O
of US7223397 T IN O
a US7223397 T DT O
cellular US7223397 T JJ O
target US7223397 T NN O
; US7223397 T : O
administering US7223397 T VBG O
a US7223397 T DT O
dose US7223397 T NN O
of US7223397 T IN O
an US7223397 T DT O
immunotoxin US7223397 T NN O
directed US7223397 T VBN O
against US7223397 T IN O
the US7223397 T DT O
upregulated US7223397 T JJ O
cellular US7223397 T JJ O
target US7223397 T NN O
. US7223397 T . O

A US7223397 A DT O
specific US7223397 A JJ O
example US7223397 A NN O
is US7223397 A VBZ O
given US7223397 A VBN O
in US7223397 A IN O
which US7223397 A WDT O
all-trans-retinoic US7223397 A JJ O
acid US7223397 A NN O
( US7223397 A ( O
RA US7223397 A NNP O
) US7223397 A ) O
is US7223397 A VBZ O
used US7223397 A VBN O
to US7223397 A TO O
induce US7223397 A VB O
high US7223397 A JJ O
levels US7223397 A NNS O
of US7223397 A IN O
CD38 US7223397 A NNP I-UN
cell US7223397 A NN O
surface US7223397 A NN O
antigen US7223397 A NN O
expression US7223397 A NN O
in US7223397 A IN O
several US7223397 A JJ O
myeloid US7223397 A NNS O
and US7223397 A CC O
lymphoid US7223397 A JJ O
leukemia US7223397 A NN O
cells US7223397 A NNS O
. US7223397 A . O

CD38 US7223397 A NNP I-UN
was US7223397 A VBD O
then US7223397 A RB O
used US7223397 A VBN O
as US7223397 A IN O
target US7223397 A NN O
for US7223397 A IN O
delivering US7223397 A VBG O
plant US7223397 A NN O
toxin US7223397 A NN O
( US7223397 A ( O
gelonin US7223397 A NN O
) US7223397 A ) O
to US7223397 A TO O
leukemia US7223397 A VB O
cells US7223397 A NNS O
. US7223397 A . O

Treatment US7223397 A NN O
of US7223397 A IN O
leukemia US7223397 A NN O
cells US7223397 A NNS O
with US7223397 A IN O
RA US7223397 A NNP O
induced US7223397 A VBD O
high US7223397 A JJ O
levels US7223397 A NNS O
of US7223397 A IN O
CD38 US7223397 A NNP I-UN
in US7223397 A IN O
those US7223397 A DT O
cells US7223397 A NNS O
that US7223397 A WDT O
otherwise US7223397 A RB O
had US7223397 A VBD O
low US7223397 A JJ O
CD38 US7223397 A NNP I-UN
expression US7223397 A NN O
. US7223397 A . O

9- US20080108627 T CD O
[ US20080108627 T NN O
( US20080108627 T ( O
3-hydroxy-5-methoxyphenyl US20080108627 T JJ O
) US20080108627 T ) O
amino US20080108627 T NN O
] US20080108627 T JJ O
-1,2-dihydrothieno US20080108627 T NNP O
[ US20080108627 T NNP O
3,2-f US20080108627 T JJ O
] US20080108627 T JJ O
quinoline-8-carbonitrile US20080108627 T JJ O
3,3-dioxide US20080108627 T JJ O
; US20080108627 T : O
protein US20080108627 T CC O
tyrosine US20080108627 T VB I-UN
kinases US20080108627 T NNS I-UN
inhibitor US20080108627 T NN O
, US20080108627 T , O
especially US20080108627 T RB O
erythropoetin-producing US20080108627 T JJ O
hepatoma US20080108627 T NN O
amplified US20080108627 T VBN O
sequence US20080108627 T NN O
( US20080108627 T ( I-UN
Eph US20080108627 T NNP I-UN
) US20080108627 T ) I-UN
receptors US20080108627 T NNS I-UN
antagonist US20080108627 T VBP O
; US20080108627 T : O
antitumor US20080108627 T NN O
, US20080108627 T , O
angiogenesis US20080108627 T NN O
inhibitor US20080108627 T NN O
, US20080108627 T , O
neurodegenerative US20080108627 T JJ O
diseases US20080108627 T NNS O
. US20080108627 T . O

Tetracyclic US20090325894 T NNP O
anthraquinones US20090325894 T NNS O
possessing US20090325894 T VBG O
anti-cancer US20090325894 T JJ O
properties US20090325894 T NNS O
. US20090325894 T . O

Pyrimidine WO2014128486A1 T NNP O
compounds WO2014128486A1 T VBZ O
useful WO2014128486A1 T JJ O
in WO2014128486A1 T IN O
the WO2014128486A1 T DT O
treatment WO2014128486A1 T NN O
of WO2014128486A1 T IN O
diseases WO2014128486A1 T NNS O
mediated WO2014128486A1 T VBN O
by WO2014128486A1 T IN O
ikke WO2014128486A1 T JJ I-UN
and/or WO2014128486A1 T NN O
tbk1 WO2014128486A1 T NN I-UN
mechanisms WO2014128486A1 T NNS O
. WO2014128486A1 T . O

Compounds WO2014128486A1 A NNS O
of WO2014128486A1 A IN O
the WO2014128486A1 A DT O
general WO2014128486A1 A JJ O
formula WO2014128486A1 A NN O
( WO2014128486A1 A ( O
I WO2014128486A1 A PRP O
) WO2014128486A1 A ) O
and WO2014128486A1 A CC O
salts WO2014128486A1 A JJ O
thereof WO2014128486A1 A NN O
are WO2014128486A1 A VBP O
useful WO2014128486A1 A JJ O
in WO2014128486A1 A IN O
the WO2014128486A1 A DT O
treatment WO2014128486A1 A NN O
of WO2014128486A1 A IN O
diseases WO2014128486A1 A NNS O
associated WO2014128486A1 A VBN O
with WO2014128486A1 A IN O
aberrant WO2014128486A1 A JJ O
activity WO2014128486A1 A NN O
of WO2014128486A1 A IN O
the WO2014128486A1 A DT O
protein WO2014128486A1 A NN O
kinases WO2014128486A1 A VBZ O
ΙΚΚε WO2014128486A1 A JJ I-UN
and/or WO2014128486A1 A JJ O
TBK-1 WO2014128486A1 A NNP I-UN
in WO2014128486A1 A IN O
which WO2014128486A1 A WDT O
one WO2014128486A1 A CD O
of WO2014128486A1 A IN O
V WO2014128486A1 A NNP O
and WO2014128486A1 A CC O
W WO2014128486A1 A NNP O
is WO2014128486A1 A VBZ O
N WO2014128486A1 A NNP O
, WO2014128486A1 A , O
and WO2014128486A1 A CC O
the WO2014128486A1 A DT O
other WO2014128486A1 A JJ O
of WO2014128486A1 A IN O
V WO2014128486A1 A NNP O
and WO2014128486A1 A CC O
W WO2014128486A1 A NNP O
is WO2014128486A1 A VBZ O
C-H WO2014128486A1 A NNP O
; WO2014128486A1 A : O
and WO2014128486A1 A CC O
R1 WO2014128486A1 A NNP O
, WO2014128486A1 A , O
R2 WO2014128486A1 A NNP O
, WO2014128486A1 A , O
R3 WO2014128486A1 A NNP O
and WO2014128486A1 A CC O
R4 WO2014128486A1 A NNP O
are WO2014128486A1 A VBP O
as WO2014128486A1 A IN O
defined WO2014128486A1 A VBN O
in WO2014128486A1 A IN O
the WO2014128486A1 A DT O
specification WO2014128486A1 A NN O
. WO2014128486A1 A . O

N-octanoyl US20050106195 T NNP O
amino US20050106195 T NN O
acid US20050106195 T NN O
composition US20050106195 T NN O
for US20050106195 T IN O
slimming US20050106195 T VBG O
the US20050106195 T DT O
human US20050106195 T JJ O
body US20050106195 T NN O
. US20050106195 T . O

Anti-epidemic WO2011057437A1 T JJ O
growth WO2011057437A1 T NN I-UN
factor WO2011057437A1 T NN I-UN
receptor WO2011057437A1 T NN I-UN
antibody WO2011057437A1 T NN O
and WO2011057437A1 T CC O
encoding WO2011057437A1 T VBG O
genes WO2011057437A1 T NNS O
and WO2011057437A1 T CC O
uses WO2011057437A1 T VBZ O
thereof WO2011057437A1 T NN O
. WO2011057437A1 T . O

The WO2011057437A1 A DT O
present WO2011057437A1 A JJ O
invention WO2011057437A1 A NN O
discloses WO2011057437A1 A VBZ O
an WO2011057437A1 A DT O
anti-epidemic WO2011057437A1 A JJ O
growth WO2011057437A1 A NN I-UN
factor WO2011057437A1 A NN I-UN
receptor WO2011057437A1 A NN I-UN
( WO2011057437A1 A ( O
EGFR WO2011057437A1 A NNP I-UN
) WO2011057437A1 A ) O
antibody WO2011057437A1 A NN O
, WO2011057437A1 A , O
genes WO2011057437A1 A NNS O
encoding WO2011057437A1 A VBG O
said WO2011057437A1 A VBD O
antibody WO2011057437A1 A NN O
, WO2011057437A1 A , O
a WO2011057437A1 A DT O
method WO2011057437A1 A NN O
for WO2011057437A1 A IN O
preparing WO2011057437A1 A VBG O
said WO2011057437A1 A VBD O
antibody WO2011057437A1 A NN O
, WO2011057437A1 A , O
inhibitors WO2011057437A1 A NNS O
and WO2011057437A1 A CC O
medicaments WO2011057437A1 A NNS O
comprising WO2011057437A1 A VBG O
said WO2011057437A1 A VBD O
antibody WO2011057437A1 A NN O
and/or WO2011057437A1 A NN O
encoding WO2011057437A1 A VBG O
genes WO2011057437A1 A NNS O
, WO2011057437A1 A , O
and WO2011057437A1 A CC O
uses WO2011057437A1 A NNS O
of WO2011057437A1 A IN O
said WO2011057437A1 A VBD O
antibody WO2011057437A1 A NN O
and/or WO2011057437A1 A NN O
encoding WO2011057437A1 A VBG O
genes WO2011057437A1 A NNS O
for WO2011057437A1 A IN O
prevention WO2011057437A1 A NN O
and/or WO2011057437A1 A NN O
treatment WO2011057437A1 A NN O
of WO2011057437A1 A IN O
tumor WO2011057437A1 A NN O
. WO2011057437A1 A . O

Hydroxamic EP1173427B1 T NNP O
acid EP1173427B1 T NN O
derivative EP1173427B1 T NN O
. EP1173427B1 T . O

A EP1173427B1 A DT O
hydroxamic EP1173427B1 A JJ O
acid EP1173427B1 A NN O
derivative EP1173427B1 A NN O
represented EP1173427B1 A VBN O
by EP1173427B1 A IN O
formula EP1173427B1 A NN O
( EP1173427B1 A ( O
1 EP1173427B1 A CD O
) EP1173427B1 A ) O
or EP1173427B1 A CC O
a EP1173427B1 A DT O
prodrug EP1173427B1 A JJ O
thereof EP1173427B1 A NN O
, EP1173427B1 A , O
or EP1173427B1 A CC O
a EP1173427B1 A DT O
pharmaceutically EP1173427B1 A RB O
acceptable EP1173427B1 A JJ O
salt EP1173427B1 A NN O
thereof EP1173427B1 A NN O
, EP1173427B1 A , O
which EP1173427B1 A WDT O
has EP1173427B1 A VBZ O
a EP1173427B1 A DT O
matrix EP1173427B1 A JJ I-UN
metalo-proteinase EP1173427B1 A JJ I-UN
inhibitor EP1173427B1 A NN O
. EP1173427B1 A . O

Sodium CN103169683A T NNP O
ilaprazole CN103169683A T JJ O
enteric CN103169683A T JJ O
orally CN103169683A T RB O
disintegrating CN103169683A T VBG O
tablet CN103169683A T NN O
and CN103169683A T CC O
preparation CN103169683A T NN O
method CN103169683A T NN O
thereof CN103169683A T NN O
. CN103169683A T . O

Microcapsule WO2008092396A1 T NNP O
formulation WO2008092396A1 T NN O
of WO2008092396A1 T IN O
kitasamycin WO2008092396A1 T NN O
, WO2008092396A1 T , O
process WO2008092396A1 T NN O
for WO2008092396A1 T IN O
preparation WO2008092396A1 T NN O
thereof WO2008092396A1 T NN O
and WO2008092396A1 T CC O
use WO2008092396A1 T NN O
thereof WO2008092396A1 T NN O
. WO2008092396A1 T . O

Valnemulin CN101947203A T NNP O
hydrochloride CN101947203A T NN O
emulsion CN101947203A T NN O
for CN101947203A T IN O
animals CN101947203A T NNS O
and CN101947203A T CC O
preparation CN101947203A T NN O
method CN101947203A T NN O
thereof CN101947203A T NN O
. CN101947203A T . O

Novel CN101255179B T NNP O
amylaceum CN101255179B T NN O
imine CN101255179B T NN O
compound CN101255179B T NN O
as CN101255179B T RB O
well CN101255179B T RB O
as CN101255179B T IN O
preparation CN101255179B T NN O
method CN101255179B T NN O
and CN101255179B T CC O
uses CN101255179B T VBZ O
thereof CN101255179B T NN O
. CN101255179B T . O

Phosphate-modified WO2008142513A2 T JJ O
oligonucleotide WO2008142513A2 T JJ O
analogs WO2008142513A2 T NNS O
with WO2008142513A2 T IN O
immunostimulatory WO2008142513A2 T JJ O
activity WO2008142513A2 T NN O
. WO2008142513A2 T . O

A WO2012053003A1 T DT O
novel WO2012053003A1 T JJ O
herbal WO2012053003A1 T JJ O
oil WO2012053003A1 T NN O
for WO2012053003A1 T IN O
controlling WO2012053003A1 T VBG O
blood WO2012053003A1 T NN O
sugar WO2012053003A1 T NN O
without WO2012053003A1 T IN O
risk WO2012053003A1 T NN O
of WO2012053003A1 T IN O
hypoglycemea WO2012053003A1 T NN O
. WO2012053003A1 T . O

Micronized CN102218071A T VBN O
deflazacort CN102218071A T JJ O
oral CN102218071A T JJ O
preparation CN102218071A T NN O
and CN102218071A T CC O
preparation CN102218071A T NN O
method CN102218071A T NN O
thereof CN102218071A T NN O
. CN102218071A T . O

Substituted WO2014072220A1 T VBN O
pyrimidinyl WO2014072220A1 T NN O
and WO2014072220A1 T CC O
pyridinyl-pyrrolopyridinones WO2014072220A1 T NNS O
, WO2014072220A1 T , O
process WO2014072220A1 T NN O
for WO2014072220A1 T IN O
their WO2014072220A1 T PRP$ O
preparation WO2014072220A1 T NN O
and WO2014072220A1 T CC O
their WO2014072220A1 T PRP$ O
use WO2014072220A1 T NN O
as WO2014072220A1 T IN O
kinase WO2014072220A1 T NN O
inhibitors WO2014072220A1 T NNS O
. WO2014072220A1 T . O

Contacting US20050208103 T VBG O
sclera US20050208103 T NN O
with US20050208103 T IN O
a US20050208103 T DT O
therapeutic US20050208103 T JJ O
or US20050208103 T CC O
diagnostic US20050208103 T JJ O
agent US20050208103 T NN O
so US20050208103 T RB O
as US20050208103 T IN O
to US20050208103 T TO O
permit US20050208103 T VB O
its US20050208103 T PRP$ O
passage US20050208103 T NN O
into US20050208103 T IN O
the US20050208103 T DT O
choroidal US20050208103 T NN O
and US20050208103 T CC O
retinal US20050208103 T JJ O
tissues US20050208103 T NNS O
; US20050208103 T : O
no US20050208103 T DT O
significant US20050208103 T JJ O
systemic US20050208103 T JJ O
absorption US20050208103 T NN O
or US20050208103 T CC O
tissue US20050208103 T NN O
damage US20050208103 T NN O
; US20050208103 T : O
eye US20050208103 T NN O
disorders US20050208103 T NNS O
. US20050208103 T . O

Genetic US20110177099 T JJ O
variations US20110177099 T NNS O
associated US20110177099 T VBN O
with US20110177099 T IN O
drug US20110177099 T NN O
resistance US20110177099 T NN O
. US20110177099 T . O

The US20110177099 A DT O
methods US20110177099 A NNS O
relate US20110177099 A VBP O
to US20110177099 A TO O
determining US20110177099 A VBG O
if US20110177099 A IN O
the US20110177099 A DT O
ABCC3 US20110177099 A NNP I-UN
gene US20110177099 A NN O
is US20110177099 A VBZ O
amplified US20110177099 A VBN O
and/or US20110177099 A NNS O
overexpressed US20110177099 A VBN O
in US20110177099 A IN O
the US20110177099 A DT O
cancer US20110177099 A NN O
. US20110177099 A . O

Dual WO2006044556A3 T JJ O
inhibitors WO2006044556A3 T NNS O
of WO2006044556A3 T IN O
lipoxygenase WO2006044556A3 T NN I-UN
for WO2006044556A3 T IN O
treating WO2006044556A3 T VBG O
diabetes WO2006044556A3 T NNS O
. WO2006044556A3 T . O

Disclosed WO2006044556A3 A VBN O
are WO2006044556A3 A VBP O
methods WO2006044556A3 A NNS O
for WO2006044556A3 A IN O
the WO2006044556A3 A DT O
treatment WO2006044556A3 A NN O
of WO2006044556A3 A IN O
diabetes WO2006044556A3 A NNS O
by WO2006044556A3 A IN O
administering WO2006044556A3 A VBG O
a WO2006044556A3 A DT O
composition WO2006044556A3 A NN O
comprising WO2006044556A3 A VBG O
a WO2006044556A3 A DT O
pharmaceutically WO2006044556A3 A RB O
acceptable WO2006044556A3 A JJ O
amount WO2006044556A3 A NN O
of WO2006044556A3 A IN O
a WO2006044556A3 A DT O
dual WO2006044556A3 A JJ O
inhibitor WO2006044556A3 A NN O
of WO2006044556A3 A IN O
both WO2006044556A3 A DT O
5 WO2006044556A3 A CD I-UN
-lipoxygenase WO2006044556A3 A NN I-UN
( WO2006044556A3 A ( O
5-LO WO2006044556A3 A JJ I-UN
) WO2006044556A3 A ) O
and WO2006044556A3 A CC O
12/15 WO2006044556A3 A CD I-UN
-lipoxygenase WO2006044556A3 A NN I-UN
( WO2006044556A3 A ( O
12/15-LO WO2006044556A3 A JJ I-UN
) WO2006044556A3 A ) O
enzymes WO2006044556A3 A VBZ O
or WO2006044556A3 A CC O
of WO2006044556A3 A IN O
both WO2006044556A3 A DT O
5 WO2006044556A3 A CD I-UN
-lipoxygenase WO2006044556A3 A NN I-UN
( WO2006044556A3 A ( O
5-LO WO2006044556A3 A JJ I-UN
) WO2006044556A3 A ) O
and WO2006044556A3 A CC O
15 WO2006044556A3 A CD I-UN
-lipoxygenase WO2006044556A3 A NN I-UN
( WO2006044556A3 A ( O
15-LQ WO2006044556A3 A JJ I-UN
) WO2006044556A3 A ) O
enzymes WO2006044556A3 A NNS O
. WO2006044556A3 A . O

The WO2006044556A3 A DT O
invention WO2006044556A3 A NN O
is WO2006044556A3 A VBZ O
also WO2006044556A3 A RB O
directed WO2006044556A3 A VBN O
to WO2006044556A3 A TO O
methods WO2006044556A3 A NNS O
of WO2006044556A3 A IN O
controlling WO2006044556A3 A VBG O
blood WO2006044556A3 A NN O
glucose WO2006044556A3 A JJ O
level WO2006044556A3 A NN O
in WO2006044556A3 A IN O
diabetic WO2006044556A3 A JJ O
patients WO2006044556A3 A NNS O
with WO2006044556A3 A IN O
a WO2006044556A3 A DT O
dual WO2006044556A3 A JJ O
inhibitor WO2006044556A3 A NN O
of WO2006044556A3 A IN O
both WO2006044556A3 A DT O
5 WO2006044556A3 A CD I-UN
-lipoxygenase WO2006044556A3 A NN I-UN
( WO2006044556A3 A ( O
5-LO WO2006044556A3 A JJ I-UN
) WO2006044556A3 A ) O
and WO2006044556A3 A CC O
12/15 WO2006044556A3 A CD I-UN
-lipoxygenase WO2006044556A3 A NN I-UN
( WO2006044556A3 A ( O
12/15-LO WO2006044556A3 A JJ I-UN
) WO2006044556A3 A ) O
enzymes WO2006044556A3 A VBZ O
or WO2006044556A3 A CC O
of WO2006044556A3 A IN O
both WO2006044556A3 A DT O
5 WO2006044556A3 A CD I-UN
-lipoxygenase WO2006044556A3 A NN I-UN
( WO2006044556A3 A ( O
5-LO WO2006044556A3 A JJ I-UN
) WO2006044556A3 A ) O
and WO2006044556A3 A CC O
15 WO2006044556A3 A CD I-UN
-lipoxygenase WO2006044556A3 A NN I-UN
( WO2006044556A3 A ( O
15-LO WO2006044556A3 A JJ I-UN
) WO2006044556A3 A ) O
enzymes WO2006044556A3 A RB O
, WO2006044556A3 A , O
such WO2006044556A3 A JJ O
as WO2006044556A3 A IN O
nordihydroguaiareitic WO2006044556A3 A JJ O
acid WO2006044556A3 A NN O
( WO2006044556A3 A ( O
NDGA WO2006044556A3 A NNP O
) WO2006044556A3 A ) O
. WO2006044556A3 A . O

Preparation CN102952202A T NNP O
method CN102952202A T NN O
and CN102952202A T CC O
use CN102952202A T NN O
of CN102952202A T IN O
ultralow-molecular CN102952202A T JJ O
weight CN102952202A T NN O
heparin CN102952202A T NN O
sodium CN102952202A T NN O
. CN102952202A T . O

Solid CN101292966A T JJ O
dispersion CN101292966A T NN O
of CN101292966A T IN O
resveratrol CN101292966A T NN O
and CN101292966A T CC O
glycosides CN101292966A T NNS O
and CN101292966A T CC O
preparation CN101292966A T NN O
method CN101292966A T NN O
thereof CN101292966A T NN O
. CN101292966A T . O

Treatment US20120171118 T NN O
of US20120171118 T IN O
meningeal US20120171118 T NN O
and US20120171118 T CC O
neural US20120171118 T JJ O
diseases US20120171118 T NNS O
. US20120171118 T . O

Nucleotide US20050153315 T NNP O
sequences US20050153315 T NNS O
coding US20050153315 T VBG O
polypeptide US20050153315 T IN O
comprising US20050153315 T VBG O
methylarginase US20050153315 T NN O
activities US20050153315 T NNS O
for US20050153315 T IN O
use US20050153315 T NN O
in US20050153315 T IN O
identifying US20050153315 T VBG O
modulator US20050153315 T NN O
for US20050153315 T IN O
prevention US20050153315 T NN O
and US20050153315 T CC O
treatment US20050153315 T NN O
of US20050153315 T IN O
ischemia-reperfusion US20050153315 T NN O
injuries US20050153315 T NNS O
, US20050153315 T , O
cancer US20050153315 T NN O
, US20050153315 T , O
hypotension US20050153315 T NN O
, US20050153315 T , O
multi-organ US20050153315 T JJ O
failure US20050153315 T NN O
, US20050153315 T , O
arthritis US20050153315 T NN O
, US20050153315 T , O
skin US20050153315 T NN O
, US20050153315 T , O
inflammatory US20050153315 T NN O
, US20050153315 T , O
cardiac US20050153315 T JJ O
and/or US20050153315 T NN O
migraine US20050153315 T NN O
disorders US20050153315 T NNS O
. US20050153315 T . O

Two US20050153315 A CD O
dimethylarginine US20050153315 A JJ I-UN
dimethylaminohydrolase US20050153315 A NN I-UN
( US20050153315 A ( O
DDAH US20050153315 A NNP I-UN
) US20050153315 A ) O
genes US20050153315 A NNS O
have US20050153315 A VBP O
been US20050153315 A VBN O
cloned US20050153315 A VBN O
from US20050153315 A IN O
humans US20050153315 A NNS O
. US20050153315 A . O

These US20050153315 A DT O
genes US20050153315 A NNS O
can US20050153315 A MD O
be US20050153315 A VB O
used US20050153315 A VBN O
to US20050153315 A TO O
screen US20050153315 A VB O
for US20050153315 A IN O
inhibitors US20050153315 A NNS O
and US20050153315 A CC O
activators US20050153315 A NNS O
of US20050153315 A IN O
activity US20050153315 A NN O
and/or US20050153315 A JJ O
expression US20050153315 A NN O
of US20050153315 A IN O
DDAHs US20050153315 A NNP I-UN
. US20050153315 A . O

Inhibitors US20050153315 A NNS O
and US20050153315 A CC O
activators US20050153315 A NNS O
of US20050153315 A IN O
activity US20050153315 A NN O
and/or US20050153315 A JJ O
expression US20050153315 A NN O
of US20050153315 A IN O
DDAHs US20050153315 A NNP I-UN
are US20050153315 A VBP O
useful US20050153315 A JJ O
in US20050153315 A IN O
the US20050153315 A DT O
treatment US20050153315 A NN O
of US20050153315 A IN O
conditions US20050153315 A NNS O
in US20050153315 A IN O
which US20050153315 A WDT O
abnormal US20050153315 A JJ O
metabolism US20050153315 A NN O
of US20050153315 A IN O
nitric US20050153315 A JJ O
oxide US20050153315 A NN O
is US20050153315 A VBZ O
implicated US20050153315 A VBN O
. US20050153315 A . O

Improved US20080188444 T VBN O
lipophilicity US20080188444 T NN O
, US20080188444 T , O
toxicity US20080188444 T NN O
, US20080188444 T , O
bioavailability US20080188444 T NN O
, US20080188444 T , O
and US20080188444 T CC O
pharmacokinetics US20080188444 T NNS O
; US20080188444 T : O
for US20080188444 T IN O
treatment US20080188444 T NN O
of US20080188444 T IN O
cardiovascular US20080188444 T JJ O
and US20080188444 T CC O
neurological US20080188444 T JJ O
disorders US20080188444 T NNS O
; US20080188444 T : O
alzheimer US20080188444 T NN O
's US20080188444 T POS O
disease US20080188444 T NN O
. US20080188444 T . O

Compositions WO2014078942A1 T NNS O
, WO2014078942A1 T , O
uses WO2014078942A1 T NNS O
and WO2014078942A1 T CC O
methods WO2014078942A1 T NNS O
for WO2014078942A1 T IN O
treating WO2014078942A1 T VBG O
or WO2014078942A1 T CC O
preventing WO2014078942A1 T VBG O
dental WO2014078942A1 T JJ O
caries WO2014078942A1 T NNS O
. WO2014078942A1 T . O

Use WO2008135232A1 T NNP O
and WO2008135232A1 T CC O
compositions WO2008135232A1 T NNS O
of WO2008135232A1 T IN O
purine WO2008135232A1 T NN O
derivatives WO2008135232A1 T NNS O
for WO2008135232A1 T IN O
the WO2008135232A1 T DT O
treatment WO2008135232A1 T NN O
of WO2008135232A1 T IN O
proliferative WO2008135232A1 T JJ O
disorders WO2008135232A1 T NNS O
. WO2008135232A1 T . O

The WO2008135232A1 A DT O
present WO2008135232A1 A JJ O
invention WO2008135232A1 A NN O
relates WO2008135232A1 A VBZ O
to WO2008135232A1 A TO O
inhibitors WO2008135232A1 A NNS O
of WO2008135232A1 A IN O
Aurora WO2008135232A1 A NNP I-UN
A WO2008135232A1 A NNP I-UN
, WO2008135232A1 A , O
Aurora WO2008135232A1 A NNP I-UN
B WO2008135232A1 A NNP I-UN
, WO2008135232A1 A , O
Aurora WO2008135232A1 A NNP I-UN
C WO2008135232A1 A NNP I-UN
, WO2008135232A1 A , O
CHK2 WO2008135232A1 A NNP I-UN
, WO2008135232A1 A , O
JNK1 WO2008135232A1 A NNP I-UN
α1 WO2008135232A1 A NNP I-UN
, WO2008135232A1 A , O
JNK3 WO2008135232A1 A NNP I-UN
and WO2008135232A1 A CC O
abl WO2008135232A1 A JJ I-UN
kinase WO2008135232A1 A NN O
and WO2008135232A1 A CC O
their WO2008135232A1 A PRP$ O
biological WO2008135232A1 A JJ O
applications WO2008135232A1 A NNS O
. WO2008135232A1 A . O

Therapeutic EP1985299A1 T JJ O
agent EP1985299A1 T NN O
for EP1985299A1 T IN O
traumatic EP1985299A1 T JJ O
neuropathy EP1985299A1 T JJ O
and/or EP1985299A1 T NN O
movement EP1985299A1 T NN O
disorder EP1985299A1 T NN O
. EP1985299A1 T . O

The EP1985299A1 A DT O
object EP1985299A1 A NN O
is EP1985299A1 A VBZ O
to EP1985299A1 A TO O
provide EP1985299A1 A VB O
a EP1985299A1 A DT O
therapeutic EP1985299A1 A JJ O
drug EP1985299A1 A NN O
for EP1985299A1 A IN O
traumatic EP1985299A1 A JJ O
neural EP1985299A1 A JJ O
disease EP1985299A1 A NN O
( EP1985299A1 A ( O
disorder EP1985299A1 A NN O
) EP1985299A1 A ) O
and/or EP1985299A1 A VBZ O
motor EP1985299A1 A NN O
function EP1985299A1 A NN O
disorder EP1985299A1 A NN O
, EP1985299A1 A , O
more EP1985299A1 A JJR O
particularly EP1985299A1 A RB O
, EP1985299A1 A , O
a EP1985299A1 A DT O
therapeutic EP1985299A1 A JJ O
drug EP1985299A1 A NN O
for EP1985299A1 A IN O
traumatic EP1985299A1 A JJ O
neural EP1985299A1 A JJ O
disease EP1985299A1 A NN O
( EP1985299A1 A ( O
disorder EP1985299A1 A NN O
) EP1985299A1 A ) O
and/or EP1985299A1 A VBZ O
motor EP1985299A1 A NN O
function EP1985299A1 A NN O
disorder EP1985299A1 A NN O
derived EP1985299A1 A VBN O
from EP1985299A1 A IN O
spinal EP1985299A1 A JJ O
cord EP1985299A1 A NN O
injury EP1985299A1 A NN O
. EP1985299A1 A . O

A EP1985299A1 A DT O
keratan EP1985299A1 A JJ O
sulfate EP1985299A1 A NN O
oligosaccharide EP1985299A1 A NN O
or EP1985299A1 A CC O
a EP1985299A1 A DT O
derivative EP1985299A1 A JJ O
thereof EP1985299A1 A NN O
was EP1985299A1 A VBD O
found EP1985299A1 A VBN O
to EP1985299A1 A TO O
have EP1985299A1 A VB O
an EP1985299A1 A DT O
effect EP1985299A1 A NN O
of EP1985299A1 A IN O
improving EP1985299A1 A VBG O
the EP1985299A1 A DT O
traumatic EP1985299A1 A JJ O
neural EP1985299A1 A JJ O
disease EP1985299A1 A NN O
( EP1985299A1 A ( O
disorder EP1985299A1 A NN O
) EP1985299A1 A ) O
and/or EP1985299A1 A VBZ O
motor EP1985299A1 A NN O
function EP1985299A1 A NN O
disorder EP1985299A1 A NN O
derived EP1985299A1 A VBN O
from EP1985299A1 A IN O
spinal EP1985299A1 A JJ O
cord EP1985299A1 A NN O
injury EP1985299A1 A NN O
and EP1985299A1 A CC O
to EP1985299A1 A TO O
be EP1985299A1 A VB O
useful EP1985299A1 A JJ O
as EP1985299A1 A IN O
the EP1985299A1 A DT O
therapeutic EP1985299A1 A JJ O
drug EP1985299A1 A NN O
for EP1985299A1 A IN O
traumatic EP1985299A1 A JJ O
neural EP1985299A1 A JJ O
disease EP1985299A1 A NN O
( EP1985299A1 A ( O
disorder EP1985299A1 A NN O
) EP1985299A1 A ) O
and/or EP1985299A1 A VBZ O
motor EP1985299A1 A NN O
function EP1985299A1 A NN O
disorder EP1985299A1 A NN O
. EP1985299A1 A . O

That EP1985299A1 A DT O
i.s EP1985299A1 A NN O
, EP1985299A1 A , O
according EP1985299A1 A VBG O
to EP1985299A1 A TO O
the EP1985299A1 A DT O
present EP1985299A1 A JJ O
invention EP1985299A1 A NN O
, EP1985299A1 A , O
there EP1985299A1 A EX O
is EP1985299A1 A VBZ O
provided EP1985299A1 A VBN O
a EP1985299A1 A DT O
therapeutic EP1985299A1 A JJ O
drug EP1985299A1 A NN O
for EP1985299A1 A IN O
traumatic EP1985299A1 A JJ O
neural EP1985299A1 A JJ O
disease EP1985299A1 A NN O
( EP1985299A1 A ( O
disorder EP1985299A1 A NN O
) EP1985299A1 A ) O
and/or EP1985299A1 A VBZ O
motor EP1985299A1 A NN O
function EP1985299A1 A NN O
disorder EP1985299A1 A NN O
comprising EP1985299A1 A VBG O
an EP1985299A1 A DT O
effective EP1985299A1 A JJ O
amount EP1985299A1 A NN O
of EP1985299A1 A IN O
the EP1985299A1 A DT O
keratan EP1985299A1 A NN O
sulfate EP1985299A1 A NN O
oligosaccharide EP1985299A1 A NN O
or EP1985299A1 A CC O
the EP1985299A1 A DT O
derivative EP1985299A1 A JJ O
thereof EP1985299A1 A NN O
. EP1985299A1 A . O

Medical CN103613574A T JJ O
application CN103613574A T NN O
of CN103613574A T IN O
2 CN103613574A T CD O
, CN103613574A T , O
2-dimethyl CN103613574A T JJ O
thiochromanone CN103613574A T NN O
compounds CN103613574A T VBZ O
containing CN103613574A T VBG O
piperazine CN103613574A T JJ O
structures CN103613574A T NNS O
and CN103613574A T CC O
analogues CN103613574A T NNS O
thereof CN103613574A T VBP O
. CN103613574A T . O

Application CN102000101A T NN O
of CN102000101A T IN O
scutellarin CN102000101A T NN O
to CN102000101A T TO O
treatment CN102000101A T NN O
of CN102000101A T IN O
microglia-mediated CN102000101A T JJ O
diseases CN102000101A T NNS O
. CN102000101A T . O

The CN102000101A A DT O
scutellarin CN102000101A A NN O
has CN102000101A A VBZ O
the CN102000101A A DT O
novel CN102000101A A JJ O
functions CN102000101A A NNS O
of CN102000101A A IN O
remarkably CN102000101A A RB O
inhibiting CN102000101A A VBG O
the CN102000101A A DT O
generation CN102000101A A NN O
of CN102000101A A IN O
inflammatory CN102000101A A JJ O
mediators CN102000101A A NNS O
, CN102000101A A , O
namely CN102000101A A RB O
nitric CN102000101A A JJ O
oxide CN102000101A A NN O
( CN102000101A A ( O
NO CN102000101A A NNP O
) CN102000101A A ) O
, CN102000101A A , O
a CN102000101A A DT O
tumor CN102000101A A NN I-UN
necrosis CN102000101A A NN I-UN
factor CN102000101A A NN I-UN
( CN102000101A A ( I-UN
TNF CN102000101A A NNP I-UN
) CN102000101A A ) I-UN
alpha CN102000101A A NN I-UN
and CN102000101A A CC O
interleukin CN102000101A A NN I-UN
( CN102000101A A ( I-UN
IL CN102000101A A NNP I-UN
) CN102000101A A ) I-UN
-1beta CN102000101A A VBD I-UN
which CN102000101A A WDT O
activate CN102000101A A VBP O
microglia CN102000101A A NNS O
, CN102000101A A , O
inhibiting CN102000101A A VBG O
the CN102000101A A DT O
expression CN102000101A A NN O
of CN102000101A A IN O
inducible CN102000101A A JJ I-UN
nitric CN102000101A A JJ I-UN
oxide CN102000101A A NN I-UN
synthase CN102000101A A NN I-UN
( CN102000101A A ( O
iNOS CN102000101A A NN I-UN
) CN102000101A A ) O
, CN102000101A A , O
TNF CN102000101A A NNP I-UN
alpha CN102000101A A NN I-UN
and CN102000101A A CC O
IL-1beta CN102000101A A NNP I-UN
messenger CN102000101A A NN O
ribonucleic CN102000101A A NN O
acid CN102000101A A NN O
( CN102000101A A ( O
mRNA CN102000101A A NN O
) CN102000101A A ) O
, CN102000101A A , O
inhibiting CN102000101A A VBG O
the CN102000101A A DT O
generation CN102000101A A NN O
of CN102000101A A IN O
reactive CN102000101A A JJ O
oxygen CN102000101A A NN O
species CN102000101A A NNS O
in CN102000101A A IN O
the CN102000101A A DT O
microglia CN102000101A A NN O
, CN102000101A A , O
reducing CN102000101A A VBG O
the CN102000101A A DT O
activation CN102000101A A NN O
of CN102000101A A IN O
nuclear CN102000101A A JJ I-UN
factor CN102000101A A NN I-UN
( CN102000101A A ( I-UN
NF CN102000101A A NNP I-UN
) CN102000101A A ) I-UN
-kappa CN102000101A A NN I-UN
B CN102000101A A NNP I-UN
and CN102000101A A CC O
remarkably CN102000101A A RB O
alleviating CN102000101A A VBG O
the CN102000101A A DT O
cytotoxicity CN102000101A A NN O
of CN102000101A A IN O
the CN102000101A A DT O
microglia CN102000101A A NN O
to CN102000101A A TO O
neurons CN102000101A A NNS O
. CN102000101A A . O

Combination US20120263677 T NN O
of US20120263677 T IN O
Local US20120263677 T NNP O
and US20120263677 T CC O
Systemic US20120263677 T NNP O
Immunomodulative US20120263677 T NNP O
Therapies US20120263677 T NNP O
for US20120263677 T IN O
Enhanced US20120263677 T NNP O
Treatment US20120263677 T NNP O
of US20120263677 T IN O
Cancer US20120263677 T NNP O
. US20120263677 T . O

A US20120263677 A DT O
method US20120263677 A NN O
for US20120263677 A IN O
the US20120263677 A DT O
treatment US20120263677 A NN O
of US20120263677 A IN O
cancer US20120263677 A NN O
comprising US20120263677 A VBG O
administration US20120263677 A NN O
of US20120263677 A IN O
a US20120263677 A DT O
therapeutically US20120263677 A RB O
effective US20120263677 A JJ O
amount US20120263677 A NN O
of US20120263677 A IN O
an US20120263677 A DT O
intralesional US20120263677 A JJ O
chemoablative US20120263677 A JJ O
pharmaceutical US20120263677 A JJ O
composition US20120263677 A NN O
, US20120263677 A , O
or US20120263677 A CC O
variant US20120263677 A NN O
of US20120263677 A IN O
said US20120263677 A VBD O
composition US20120263677 A NN O
, US20120263677 A , O
in US20120263677 A IN O
combination US20120263677 A NN O
with US20120263677 A IN O
a US20120263677 A DT O
therapeutically US20120263677 A RB O
effective US20120263677 A JJ O
amount US20120263677 A NN O
of US20120263677 A IN O
a US20120263677 A DT O
systemic US20120263677 A JJ O
immunomodulatory US20120263677 A NN O
anticancer US20120263677 A NN O
agent US20120263677 A NN O
. US20120263677 A . O

A US20120263677 A DT O
further US20120263677 A JJ O
method US20120263677 A NN O
for US20120263677 A IN O
the US20120263677 A DT O
treatment US20120263677 A NN O
of US20120263677 A IN O
cancer US20120263677 A NN O
comprising US20120263677 A VBG O
administration US20120263677 A NN O
of US20120263677 A IN O
a US20120263677 A DT O
therapeutically US20120263677 A RB O
effective US20120263677 A JJ O
amount US20120263677 A NN O
of US20120263677 A IN O
an US20120263677 A DT O
intralesional US20120263677 A JJ O
chemoablative US20120263677 A JJ O
pharmaceutical US20120263677 A JJ O
composition US20120263677 A NN O
, US20120263677 A , O
or US20120263677 A CC O
variant US20120263677 A NN O
of US20120263677 A IN O
said US20120263677 A VBD O
composition US20120263677 A NN O
, US20120263677 A , O
in US20120263677 A IN O
combination US20120263677 A NN O
with US20120263677 A IN O
a US20120263677 A DT O
therapeutically US20120263677 A RB O
effective US20120263677 A JJ O
amount US20120263677 A NN O
of US20120263677 A IN O
a US20120263677 A DT O
systemic US20120263677 A JJ O
targeted US20120263677 A JJ O
anticancer US20120263677 A NN O
agent US20120263677 A NN O
. US20120263677 A . O

The US20120263677 A DT O
present US20120263677 A JJ O
invention US20120263677 A NN O
is US20120263677 A VBZ O
further US20120263677 A RB O
directed US20120263677 A VBN O
to US20120263677 A TO O
pharmaceutical US20120263677 A JJ O
compositions US20120263677 A NNS O
for US20120263677 A IN O
treatment US20120263677 A NN O
of US20120263677 A IN O
cancer US20120263677 A NN O
. US20120263677 A . O

The US20120263677 A DT O
intralesional US20120263677 A JJ O
chemoablative US20120263677 A JJ O
pharmaceutical US20120263677 A JJ O
composition US20120263677 A NN O
can US20120263677 A MD O
comprise US20120263677 A VB O
an US20120263677 A DT O
IL US20120263677 A NNP O
chemoablative US20120263677 A JJ O
agent US20120263677 A NN O
comprising US20120263677 A VBG O
primarily US20120263677 A RB O
a US20120263677 A DT O
halogenated US20120263677 A JJ O
xanthene US20120263677 A NN O
. US20120263677 A . O

Method CN102040578A T NNP O
for CN102040578A T IN O
preparing CN102040578A T VBG O
high CN102040578A T JJ O
purity CN102040578A T NN O
tricin CN102040578A T NN O
from CN102040578A T IN O
bamboo CN102040578A T NN O
leaves CN102040578A T NNS O
. CN102040578A T . O

The CN102040578A A DT O
invention CN102040578A A NN O
discloses CN102040578A A VBZ O
a CN102040578A A DT O
method CN102040578A A NN O
for CN102040578A A IN O
preparing CN102040578A A VBG O
high CN102040578A A JJ O
purity CN102040578A A NN O
tricin CN102040578A A NN O
from CN102040578A A IN O
bamboo CN102040578A A NN O
leaves CN102040578A A NNS O
. CN102040578A A . O

The CN102040578A A DT O
method CN102040578A A NN O
comprises CN102040578A A VBZ O
the CN102040578A A DT O
following CN102040578A A JJ O
steps CN102040578A A NNS O
: CN102040578A A : O
( CN102040578A A ( O
a CN102040578A A DT O
) CN102040578A A ) O
performing CN102040578A A VBG O
extraction CN102040578A A NN O
on CN102040578A A IN O
dry CN102040578A A JJ O
bamboo CN102040578A A NN O
leaves CN102040578A A VBZ O
with CN102040578A A IN O
95 CN102040578A A CD O
% CN102040578A A NN O
ethanol CN102040578A A NN O
, CN102040578A A , O
extracting CN102040578A A VBG O
with CN102040578A A IN O
petroleum CN102040578A A NN O
ether CN102040578A A NN O
, CN102040578A A , O
concentrating CN102040578A A VBG O
aqueous CN102040578A A JJ O
phase CN102040578A A NN O
to CN102040578A A TO O
obtain CN102040578A A VB O
extractum CN102040578A A NN O
; CN102040578A A : O
( CN102040578A A ( O
b CN102040578A A NN O
) CN102040578A A ) O
adding CN102040578A A VBG O
the CN102040578A A DT O
extractum CN102040578A A NN O
in CN102040578A A IN O
an CN102040578A A DT O
AB-8 CN102040578A A NNP O
macroporous CN102040578A A JJ O
resin CN102040578A A NN O
column CN102040578A A NN O
, CN102040578A A , O
eluting CN102040578A A VBG O
with CN102040578A A IN O
pure CN102040578A A JJ O
water CN102040578A A NN O
, CN102040578A A , O
then CN102040578A A RB O
eluting CN102040578A A VBG O
with CN102040578A A IN O
80 CN102040578A A CD O
% CN102040578A A NN O
ethanol CN102040578A A NN O
, CN102040578A A , O
concentrating CN102040578A A VBG O
and CN102040578A A CC O
drying CN102040578A A VBG O
eluent CN102040578A A NN O
; CN102040578A A : O
( CN102040578A A ( O
c CN102040578A A NN O
) CN102040578A A ) O
adding CN102040578A A VBG O
hydrochloric CN102040578A A JJ O
acid-methanol CN102040578A A JJ O
solution CN102040578A A NN O
in CN102040578A A IN O
the CN102040578A A DT O
dry CN102040578A A JJ O
product CN102040578A A NN O
obtained CN102040578A A VBN O
in CN102040578A A IN O
the CN102040578A A DT O
step CN102040578A A NN O
( CN102040578A A ( O
b CN102040578A A NN O
) CN102040578A A ) O
, CN102040578A A , O
heating CN102040578A A VBG O
to CN102040578A A TO O
perform CN102040578A A VB O
acid CN102040578A A JJ O
hydrolysis CN102040578A A NN O
process CN102040578A A NN O
; CN102040578A A : O
( CN102040578A A ( O
d CN102040578A A NN O
) CN102040578A A ) O
adding CN102040578A A VBG O
the CN102040578A A DT O
acid CN102040578A A JJ O
hydrolysis CN102040578A A NN O
solution CN102040578A A NN O
obtained CN102040578A A VBN O
in CN102040578A A IN O
the CN102040578A A DT O
step CN102040578A A NN O
( CN102040578A A ( O
c CN102040578A A NN O
) CN102040578A A ) O
in CN102040578A A IN O
a CN102040578A A DT O
C18 CN102040578A A NNP O
column CN102040578A A NN O
for CN102040578A A IN O
elution CN102040578A A NN O
chromatography CN102040578A A NN O
, CN102040578A A , O
collecting CN102040578A A VBG O
tricin CN102040578A A JJ O
fraction CN102040578A A NN O
, CN102040578A A , O
concentrating CN102040578A A VBG O
; CN102040578A A : O
and CN102040578A A CC O
( CN102040578A A ( O
e CN102040578A A NN O
) CN102040578A A ) O
adding CN102040578A A VBG O
the CN102040578A A DT O
concentrate CN102040578A A NN O
obtained CN102040578A A VBN O
in CN102040578A A IN O
the CN102040578A A DT O
step CN102040578A A NN O
( CN102040578A A ( O
d CN102040578A A NN O
) CN102040578A A ) O
in CN102040578A A IN O
a CN102040578A A DT O
gel CN102040578A A JJ O
separation CN102040578A A NN O
column CN102040578A A NN O
, CN102040578A A , O
using CN102040578A A VBG O
pure CN102040578A A JJ O
methanol CN102040578A A NN O
as CN102040578A A IN O
mobile CN102040578A A JJ O
phase CN102040578A A NN O
to CN102040578A A TO O
elute CN102040578A A VB O
, CN102040578A A , O
collecting CN102040578A A VBG O
tricin CN102040578A A JJ O
fraction CN102040578A A NN O
, CN102040578A A , O
and CN102040578A A CC O
concentrating CN102040578A A VBG O
and CN102040578A A CC O
drying CN102040578A A VBG O
to CN102040578A A TO O
obtain CN102040578A A VB O
tricin CN102040578A A NN O
. CN102040578A A . O

In CN102040578A A IN O
the CN102040578A A DT O
invention CN102040578A A NN O
, CN102040578A A , O
the CN102040578A A DT O
simple CN102040578A A JJ O
method CN102040578A A NN O
is CN102040578A A VBZ O
used CN102040578A A VBN O
to CN102040578A A TO O
obtain CN102040578A A VB O
tricin CN102040578A A NN O
with CN102040578A A IN O
high CN102040578A A JJ O
yield CN102040578A A NN O
and CN102040578A A CC O
high CN102040578A A JJ O
purity CN102040578A A NN O
. CN102040578A A . O

Water-soluble US7595342 T JJ O
strontium US7595342 T NN O
salts US7595342 T NNS O
for US7595342 T IN O
use US7595342 T NN O
in US7595342 T IN O
treatment US7595342 T NN O
of US7595342 T IN O
cartilage US7595342 T NN O
and/or US7595342 T VBP O
bone US7595342 T NN O
conditions US7595342 T NNS O
. US7595342 T . O

Flavonoid WO2009026657A1 T NNP O
ppar WO2009026657A1 T NN I-UN
agonists WO2009026657A1 T NNS O
. WO2009026657A1 T . O

The WO2009026657A1 A DT O
present WO2009026657A1 A JJ O
invention WO2009026657A1 A NN O
relates WO2009026657A1 A VBZ O
to WO2009026657A1 A TO O
PPAR WO2009026657A1 A NNP I-UN
agonists WO2009026657A1 A NNS O
, WO2009026657A1 A , O
and WO2009026657A1 A CC O
their WO2009026657A1 A PRP$ O
use WO2009026657A1 A NN O
in WO2009026657A1 A IN O
therapy WO2009026657A1 A NN O
including WO2009026657A1 A VBG O
the WO2009026657A1 A DT O
treatment WO2009026657A1 A NN O
of WO2009026657A1 A IN O
disease WO2009026657A1 A NN O
. WO2009026657A1 A . O

In WO2009026657A1 A IN O
particular WO2009026657A1 A JJ O
, WO2009026657A1 A , O
the WO2009026657A1 A DT O
invention WO2009026657A1 A NN O
relates WO2009026657A1 A VBZ O
to WO2009026657A1 A TO O
flavonoid WO2009026657A1 A VB O
compounds WO2009026657A1 A NNS O
which WO2009026657A1 A WDT O
are WO2009026657A1 A VBP O
PPAR-gamma WO2009026657A1 A JJ I-UN
agonists WO2009026657A1 A NNS O
and/or WO2009026657A1 A VBP O
PPAR WO2009026657A1 A NNP I-UN
alpha/gamma WO2009026657A1 A VBP I-UN
dual WO2009026657A1 A JJ O
agonists WO2009026657A1 A NNS O
. WO2009026657A1 A . O

drugs US7144912 T NNS O
such US7144912 T JJ O
as US7144912 T IN O
( US7144912 T ( O
4-methoxy-5- US7144912 T JJ O
( US7144912 T ( O
1H-indol-2yl-methylene US7144912 T JJ O
) US7144912 T ) O
-2,2'-bi-1H-pyrrole US7144912 T NN O
) US7144912 T ) O
used US7144912 T VBD O
as US7144912 T IN O
anticarcinogenic US7144912 T JJ O
or US7144912 T CC O
antitumor US7144912 T JJ O
agents US7144912 T NNS O
. US7144912 T . O

Curcuminoids EP2413920A1 T NNS O
in EP2413920A1 T IN O
combination EP2413920A1 T NN O
docetaxel EP2413920A1 T NN O
for EP2413920A1 T IN O
the EP2413920A1 T DT O
treatment EP2413920A1 T NN O
of EP2413920A1 T IN O
cancer EP2413920A1 T NN O
and EP2413920A1 T CC O
tumour EP2413920A1 T JJ O
metastasis EP2413920A1 T NN O
. EP2413920A1 T . O

or US20080085855 T CC O
improving US20080085855 T VBG O
the US20080085855 T DT O
integrity US20080085855 T NN O
of US20080085855 T IN O
body US20080085855 T NN O
passageways US20080085855 T NNS O
following US20080085855 T VBG O
surgery US20080085855 T NN O
, US20080085855 T , O
such US20080085855 T JJ O
as US20080085855 T IN O
at US20080085855 T IN O
a US20080085855 T DT O
graft US20080085855 T NN O
site US20080085855 T NN O
, US20080085855 T , O
or US20080085855 T CC O
injury US20080085855 T NN O
. US20080085855 T . O

Delivery US20080085855 T NNP O
devices US20080085855 T NNS O
including US20080085855 T VBG O
one US20080085855 T CD O
or US20080085855 T CC O
more US20080085855 T JJR O
therapeutic US20080085855 T JJ O
agents US20080085855 T NNS O
and US20080085855 T CC O
a US20080085855 T DT O
mesh US20080085855 T NN O
are US20080085855 T VBP O
described.microtubule US20080085855 T JJ O
stabilizing US20080085855 T VBG O
agents US20080085855 T NNS O
, US20080085855 T , O
anti-angiogenic US20080085855 T JJ O
factors US20080085855 T NNS O
, US20080085855 T , O
inhibitors US20080085855 T NNS O
of US20080085855 T IN O
smooth US20080085855 T JJ O
muscle US20080085855 T NN O
cell US20080085855 T NN O
growth US20080085855 T NN O
or US20080085855 T CC O
proliferation US20080085855 T NN O
, US20080085855 T , O
. US20080085855 T . O

The US20080085855 A DT O
present US20080085855 A JJ O
invention US20080085855 A NN O
provides US20080085855 A VBZ O
compositions US20080085855 A NNS O
, US20080085855 A , O
devices US20080085855 A NNS O
, US20080085855 A , O
and US20080085855 A CC O
methods US20080085855 A NNS O
for US20080085855 A IN O
maintaining US20080085855 A VBG O
or US20080085855 A CC O
improving US20080085855 A VBG O
the US20080085855 A DT O
integrity US20080085855 A NN O
of US20080085855 A IN O
body US20080085855 A NN O
passageways US20080085855 A NNS O
following US20080085855 A VBG O
surgery US20080085855 A NN O
, US20080085855 A , O
such US20080085855 A JJ O
as US20080085855 A IN O
at US20080085855 A IN O
a US20080085855 A DT O
graft US20080085855 A NN O
site US20080085855 A NN O
, US20080085855 A , O
or US20080085855 A CC O
injury US20080085855 A NN O
. US20080085855 A . O

Delivery US20080085855 A NNP O
devices US20080085855 A NNS O
including US20080085855 A VBG O
one US20080085855 A CD O
or US20080085855 A CC O
more US20080085855 A JJR O
therapeutic US20080085855 A JJ O
agents US20080085855 A NNS O
and US20080085855 A CC O
a US20080085855 A DT O
mesh US20080085855 A NN O
are US20080085855 A VBP O
described US20080085855 A VBN O
. US20080085855 A . O

Representative US20080085855 A JJ O
examples US20080085855 A NNS O
of US20080085855 A IN O
therapeutic US20080085855 A JJ O
agents US20080085855 A NNS O
include US20080085855 A VBP O
microtubule US20080085855 A JJ O
stabilizing US20080085855 A VBG O
agents US20080085855 A NNS O
, US20080085855 A , O
anti-angiogenic US20080085855 A JJ O
factors US20080085855 A NNS O
, US20080085855 A , O
inhibitors US20080085855 A NNS O
of US20080085855 A IN O
smooth US20080085855 A JJ O
muscle US20080085855 A NN O
cell US20080085855 A NN O
growth US20080085855 A NN O
or US20080085855 A CC O
proliferation US20080085855 A NN O
, US20080085855 A , O
non-steroidal US20080085855 A JJ O
anti-inflammatory US20080085855 A JJ O
drugs US20080085855 A NNS O
, US20080085855 A , O
and US20080085855 A CC O
other US20080085855 A JJ O
factors US20080085855 A NNS O
useful US20080085855 A JJ O
preventing US20080085855 A VBG O
and/or US20080085855 A NN O
reducing US20080085855 A VBG O
a US20080085855 A DT O
proliferative US20080085855 A JJ O
biological US20080085855 A JJ O
response US20080085855 A NN O
that US20080085855 A WDT O
may US20080085855 A MD O
obstruct US20080085855 A VB O
or US20080085855 A CC O
hinder US20080085855 A VB O
the US20080085855 A DT O
optimal US20080085855 A JJ O
functioning US20080085855 A NN O
of US20080085855 A IN O
the US20080085855 A DT O
passageway US20080085855 A NN O
or US20080085855 A CC O
cavity US20080085855 A NN O
. US20080085855 A . O

Method US20110071221 T NNP O
for US20110071221 T IN O
treating US20110071221 T VBG O
conditions US20110071221 T NNS O
mediated US20110071221 T VBN O
by US20110071221 T IN O
ppar US20110071221 T NN O
using US20110071221 T VBG O
macelignan US20110071221 T NN O
. US20110071221 T . O

Nano-micro CN102349871A T JJ O
drug CN102349871A T NN O
delivery CN102349871A T NN O
system CN102349871A T NN O
and CN102349871A T CC O
preparation CN102349871A T NN O
method CN102349871A T NN O
of CN102349871A T IN O
10-hydroxyl CN102349871A T JJ O
camptothecin CN102349871A T NN O
. CN102349871A T . O

Anti-hyperglycemic WO2010131718A1 T JJ O
and/or WO2010131718A1 T NN O
anti-hyperlipidemic WO2010131718A1 T JJ O
agent WO2010131718A1 T NN O
comprising WO2010131718A1 T VBG O
material WO2010131718A1 T NN O
containing WO2010131718A1 T VBG O
avian WO2010131718A1 T JJ O
skin-derived WO2010131718A1 T JJ O
sphingomyelin WO2010131718A1 T NN O
as WO2010131718A1 T IN O
active WO2010131718A1 T JJ O
ingredient WO2010131718A1 T NN O
. WO2010131718A1 T . O

Pharmaceutical EP1958636A1 T JJ O
compositions EP1958636A1 T NNS O
containing EP1958636A1 T VBG O
combined EP1958636A1 T VBN O
antidiabetic EP1958636A1 T JJ O
substances EP1958636A1 T NNS O
for EP1958636A1 T IN O
use EP1958636A1 T NN O
in EP1958636A1 T IN O
type EP1958636A1 T NN O
2 EP1958636A1 T CD O
diabetes EP1958636A1 T NNS O
mellitus EP1958636A1 T NN O
. EP1958636A1 T . O

1,2,3,4- EP1274687B1 T JJ O
tetrahydroisoquinoline EP1274687B1 T NN O
derivatives EP1274687B1 T NNS O
. EP1274687B1 T . O

The EP1274687B1 A DT O
invention EP1274687B1 A NN O
also EP1274687B1 A RB O
concerns EP1274687B1 A VBZ O
related EP1274687B1 A JJ O
aspects EP1274687B1 A NNS O
including EP1274687B1 A VBG O
processes EP1274687B1 A NNS O
for EP1274687B1 A IN O
the EP1274687B1 A DT O
preparation EP1274687B1 A NN O
of EP1274687B1 A IN O
the EP1274687B1 A DT O
compounds EP1274687B1 A NNS O
, EP1274687B1 A , O
pharmaceutical EP1274687B1 A JJ O
compositions EP1274687B1 A NNS O
containing EP1274687B1 A VBG O
one EP1274687B1 A CD O
or EP1274687B1 A CC O
more EP1274687B1 A JJR O
of EP1274687B1 A IN O
those EP1274687B1 A DT O
compounds EP1274687B1 A NNS O
and EP1274687B1 A CC O
especially EP1274687B1 A RB O
their EP1274687B1 A PRP$ O
use EP1274687B1 A NN O
as EP1274687B1 A IN O
orexin EP1274687B1 A NN I-UN
receptor EP1274687B1 A NN I-UN
antagonists EP1274687B1 A NNS O
. EP1274687B1 A . O

Ointment DE102009057267A1 T NN O
, DE102009057267A1 T , O
useful DE102009057267A1 T JJ O
for DE102009057267A1 T IN O
treating DE102009057267A1 T VBG O
Mortellaro DE102009057267A1 T NNP O
's DE102009057267A1 T POS O
disease DE102009057267A1 T NN O
in DE102009057267A1 T IN O
cloven-hoofed DE102009057267A1 T JJ O
animals DE102009057267A1 T NNS O
, DE102009057267A1 T , O
comprises DE102009057267A1 T VBZ O
a DE102009057267A1 T DT O
mixture DE102009057267A1 T NN O
of DE102009057267A1 T IN O
cereal DE102009057267A1 T NN O
hydrolyzate DE102009057267A1 T NN O
, DE102009057267A1 T , O
acid DE102009057267A1 T NN O
whey DE102009057267A1 T NN O
and DE102009057267A1 T CC O
water DE102009057267A1 T NN O
, DE102009057267A1 T , O
where DE102009057267A1 T WRB O
the DE102009057267A1 T DT O
mixture DE102009057267A1 T NN O
is DE102009057267A1 T VBZ O
added DE102009057267A1 T VBN O
with DE102009057267A1 T IN O
calcium DE102009057267A1 T NN O
chloride DE102009057267A1 T NN O
, DE102009057267A1 T , O
magnesium DE102009057267A1 T NN O
chloride DE102009057267A1 T NN O
and DE102009057267A1 T CC O
iron DE102009057267A1 T NN O
saccharate DE102009057267A1 T NN O
. DE102009057267A1 T . O

Slow CN101011363A T JJ O
release CN101011363A T NN O
tablet CN101011363A T NN O
of CN101011363A T IN O
amoxicillin CN101011363A T NN O
. CN101011363A T . O

Methods US20100087509 T NNS O
, US20100087509 T , O
Agents US20100087509 T NNS O
, US20100087509 T , O
and US20100087509 T CC O
Compound US20100087509 T NNP O
Screening US20100087509 T NNP O
Assays US20100087509 T NNP O
for US20100087509 T IN O
Inducing US20100087509 T NNP O
Differentiation US20100087509 T NNP O
of US20100087509 T IN O
Undifferentiated US20100087509 T NNP O
Mammalian US20100087509 T NNP O
Cells US20100087509 T NNP O
into US20100087509 T IN O
Osteoblasts US20100087509 T NNP O
. US20100087509 T . O

Danshensu CN1679528A T NNP O
and CN1679528A T CC O
its CN1679528A T PRP$ O
sodium CN1679528A T NN O
salt CN1679528A T NN O
for CN1679528A T IN O
preventing CN1679528A T VBG O
from CN1679528A T IN O
and CN1679528A T CC O
treating CN1679528A T VBG O
various CN1679528A T JJ O
regressive CN1679528A T JJ O
nervous CN1679528A T JJ O
diseases CN1679528A T NNS O
. CN1679528A T . O

Transdermal US20080188509 T JJ O
Preparations US20080188509 T NNS O
and US20080188509 T CC O
Method US20080188509 T NNP O
for US20080188509 T IN O
Relieving US20080188509 T NNP O
Side US20080188509 T NNP O
Effects US20080188509 T NNPS O
in US20080188509 T IN O
Pergolide US20080188509 T NNP O
Therapy US20080188509 T NNP O
. US20080188509 T . O

Application CN103356600A T NN O
of CN103356600A T IN O
Chukrasone CN103356600A T NNP O
B CN103356600A T NNP O
in CN103356600A T IN O
anti-helicobacter CN103356600A T JJ O
pylori CN103356600A T NN O
medicines CN103356600A T NNS O
. CN103356600A T . O

Skin US20110196040 T NNP O
Penetration US20110196040 T NNP O
Enhancing US20110196040 T NNP O
Systems US20110196040 T NNPS O
for US20110196040 T IN O
Polar US20110196040 T NNP O
Drugs US20110196040 T NNP O
. US20110196040 T . O

Water-soluble CA2506081C T JJ O
mesoporphyrin CA2506081C T NN O
compounds CA2506081C T NNS O
and CA2506081C T CC O
methods CA2506081C T NNS O
of CA2506081C T IN O
preparation CA2506081C T NN O
. CA2506081C T . O

Synergistic EP2425830A1 T JJ O
drug EP2425830A1 T NN O
combination EP2425830A1 T NN O
for EP2425830A1 T IN O
the EP2425830A1 T DT O
treatment EP2425830A1 T NN O
of EP2425830A1 T IN O
cancer EP2425830A1 T NN O
. EP2425830A1 T . O

Aqueous CN1993118B T JJ O
eye CN1993118B T NN O
drops CN1993118B T NNS O
with CN1993118B T IN O
accelerated CN1993118B T JJ O
intraocular CN1993118B T JJ O
migration CN1993118B T NN O
permeability CN1993118B T NN O
. CN1993118B T . O

Novel CN101947313A T NNP O
effervescent CN101947313A T JJ O
tablet CN101947313A T NN O
for CN101947313A T IN O
treating CN101947313A T VBG O
beriberi CN101947313A T NN O
and CN101947313A T CC O
preparation CN101947313A T NN O
process CN101947313A T NN O
thereof CN101947313A T NN O
. CN101947313A T . O

The CN101947313A A DT O
novel CN101947313A A JJ O
effervescent CN101947313A A JJ O
tablet CN101947313A A NN O
for CN101947313A A IN O
treating CN101947313A A VBG O
the CN101947313A A DT O
beriberi CN101947313A A NN O
consists CN101947313A A VBZ O
of CN101947313A A IN O
the CN101947313A A DT O
following CN101947313A A JJ O
materials CN101947313A A NNS O
in CN101947313A A IN O
part CN101947313A A NN O
by CN101947313A A IN O
mass CN101947313A A NN O
: CN101947313A A : O
0.1 CN101947313A A CD O
to CN101947313A A TO O
0.3 CN101947313A A CD O
part CN101947313A A NN O
of CN101947313A A IN O
trivalent CN101947313A A NN O
silver CN101947313A A NN O
ion CN101947313A A NN O
compound CN101947313A A NN O
, CN101947313A A , O
0.2 CN101947313A A CD O
to CN101947313A A TO O
0.4 CN101947313A A CD O
part CN101947313A A NN O
of CN101947313A A IN O
keratinase CN101947313A A NN I-UN
, CN101947313A A , O
0.5 CN101947313A A CD O
to CN101947313A A TO O
5 CN101947313A A CD O
parts CN101947313A A NNS O
of CN101947313A A IN O
water CN101947313A A NN O
soluble CN101947313A A JJ O
keratin CN101947313A A NN I-UN
, CN101947313A A , O
30 CN101947313A A CD O
to CN101947313A A TO O
60 CN101947313A A CD O
parts CN101947313A A NNS O
of CN101947313A A IN O
sodium CN101947313A A NN O
hydrogen CN101947313A A NN O
carbonate CN101947313A A NN O
, CN101947313A A , O
36 CN101947313A A CD O
to CN101947313A A TO O
56 CN101947313A A CD O
parts CN101947313A A NNS O
of CN101947313A A IN O
tartaric CN101947313A A JJ O
acid CN101947313A A NN O
and CN101947313A A CC O
40 CN101947313A A CD O
to CN101947313A A TO O
55 CN101947313A A CD O
parts CN101947313A A NNS O
of CN101947313A A IN O
alcohol CN101947313A A NN O
solution CN101947313A A NN O
containing CN101947313A A VBG O
5 CN101947313A A CD O
percent CN101947313A A NN O
of CN101947313A A IN O
polyvinylpyrrolidone CN101947313A A NN O
. CN101947313A A . O

The CN101947313A A DT O
preparation CN101947313A A NN O
process CN101947313A A NN O
comprises CN101947313A A VBZ O
the CN101947313A A DT O
following CN101947313A A JJ O
steps CN101947313A A NNS O
of CN101947313A A IN O
: CN101947313A A : O
weighing CN101947313A A VBG O
0.1 CN101947313A A CD O
to CN101947313A A TO O
0.3 CN101947313A A CD O
part CN101947313A A NN O
of CN101947313A A IN O
trivalent CN101947313A A NN O
silver CN101947313A A NN O
ion CN101947313A A NN O
compound CN101947313A A NN O
, CN101947313A A , O
0.2 CN101947313A A CD O
to CN101947313A A TO O
0.4 CN101947313A A CD O
part CN101947313A A NN O
of CN101947313A A IN O
keratinase CN101947313A A NN I-UN
, CN101947313A A , O
0.5 CN101947313A A CD O
to CN101947313A A TO O
5 CN101947313A A CD O
parts CN101947313A A NNS O
of CN101947313A A IN O
water CN101947313A A NN O
soluble CN101947313A A JJ O
keratin CN101947313A A NN I-UN
, CN101947313A A , O
30 CN101947313A A CD O
to CN101947313A A TO O
60 CN101947313A A CD O
parts CN101947313A A NNS O
of CN101947313A A IN O
sodium CN101947313A A NN O
hydrogen CN101947313A A NN O
carbonate CN101947313A A NN O
and CN101947313A A CC O
36 CN101947313A A CD O
to CN101947313A A TO O
56 CN101947313A A CD O
parts CN101947313A A NNS O
of CN101947313A A IN O
tartaric CN101947313A A JJ O
acid CN101947313A A NN O
according CN101947313A A VBG O
to CN101947313A A TO O
the CN101947313A A DT O
mass CN101947313A A NN O
ratio CN101947313A A NN O
; CN101947313A A : O
grinding CN101947313A A VBG O
and CN101947313A A CC O
uniformly CN101947313A A JJ O
mixing CN101947313A A NN O
; CN101947313A A : O
adding CN101947313A A VBG O
40 CN101947313A A CD O
to CN101947313A A TO O
55 CN101947313A A CD O
parts CN101947313A A NNS O
of CN101947313A A IN O
alcohol CN101947313A A NN O
solution CN101947313A A NN O
containing CN101947313A A VBG O
5 CN101947313A A CD O
percent CN101947313A A NN O
of CN101947313A A IN O
polyvinylpyrrolidone CN101947313A A NN O
as CN101947313A A IN O
a CN101947313A A DT O
bonding CN101947313A A NN O
agent CN101947313A A NN O
; CN101947313A A : O
drying CN101947313A A VBG O
at CN101947313A A IN O
the CN101947313A A DT O
temperature CN101947313A A NN O
of CN101947313A A IN O
80 CN101947313A A CD O
DEG CN101947313A A NNP O
C CN101947313A A NNP O
for CN101947313A A IN O
2 CN101947313A A CD O
to CN101947313A A TO O
4 CN101947313A A CD O
hours CN101947313A A NNS O
; CN101947313A A : O
and CN101947313A A CC O
weighing CN101947313A A VBG O
0.5 CN101947313A A CD O
to CN101947313A A TO O
2g CN101947313A A CD O
of CN101947313A A IN O
mixture CN101947313A A NN O
, CN101947313A A , O
and CN101947313A A CC O
tableting CN101947313A A VBG O
the CN101947313A A DT O
mixture CN101947313A A NN O
under CN101947313A A IN O
the CN101947313A A DT O
pressure CN101947313A A NN O
of CN101947313A A IN O
5 CN101947313A A CD O
to CN101947313A A TO O
15 CN101947313A A CD O
pounds CN101947313A A NNS O
to CN101947313A A TO O
form CN101947313A A VB O
the CN101947313A A DT O
effervescent CN101947313A A JJ O
tablet CN101947313A A NN O
. CN101947313A A . O

The CN101947313A A DT O
effervescent CN101947313A A NN O
tablet CN101947313A A NN O
has CN101947313A A VBZ O
the CN101947313A A DT O
following CN101947313A A JJ O
effects CN101947313A A NNS O
and CN101947313A A CC O
characteristics CN101947313A A NNS O
of CN101947313A A IN O
: CN101947313A A : O
diminishing CN101947313A A NN O
inflammation CN101947313A A NN O
, CN101947313A A , O
relieving CN101947313A A VBG O
pain CN101947313A A NN O
and CN101947313A A CC O
killing CN101947313A A VBG O
bacteria CN101947313A A NNS O
, CN101947313A A , O
dissolving CN101947313A A VBG O
necrotic CN101947313A A JJ O
keratin CN101947313A A NN I-UN
, CN101947313A A , O
repairing CN101947313A A VBG O
skin CN101947313A A NN O
and CN101947313A A CC O
rapidly CN101947313A A RB O
and CN101947313A A CC O
uniformly CN101947313A A RB O
releasing CN101947313A A VBG O
active CN101947313A A JJ O
ingredients CN101947313A A NNS O
in CN101947313A A IN O
water CN101947313A A NN O
with CN101947313A A IN O
different CN101947313A A JJ O
temperatures CN101947313A A NNS O
( CN101947313A A ( O
20 CN101947313A A CD O
to CN101947313A A TO O
80 CN101947313A A CD O
DEG CN101947313A A NNP O
C CN101947313A A NNP O
) CN101947313A A ) O
. CN101947313A A . O

Gamuzhuer CN102648922A T NNP O
medicinal CN102648922A T JJ O
latex CN102648922A T NN O
preparation CN102648922A T NN O
and CN102648922A T CC O
preparation CN102648922A T NN O
method CN102648922A T NN O
thereof CN102648922A T NN O
. CN102648922A T . O

Anandamide EP2091523A1 T NNP O
. EP2091523A1 T . O

Method US20050274671 T NNP O
for US20050274671 T IN O
preparing US20050274671 T VBG O
a US20050274671 T DT O
compound US20050274671 T NN O
of US20050274671 T IN O
interaction US20050274671 T NN O
of US20050274671 T IN O
active US20050274671 T JJ O
substances US20050274671 T NNS O
with US20050274671 T IN O
a US20050274671 T DT O
porous US20050274671 T JJ O
support US20050274671 T NN O
using US20050274671 T VBG O
supercritical US20050274671 T JJ O
fluid US20050274671 T NN O
. US20050274671 T . O

The US20050274671 A DT O
invention US20050274671 A NN O
concerns US20050274671 A VBZ O
a US20050274671 A DT O
method US20050274671 A NN O
for US20050274671 A IN O
preparing US20050274671 A VBG O
compounds US20050274671 A NNS O
for US20050274671 A IN O
interaction US20050274671 A NN O
of US20050274671 A IN O
an US20050274671 A DT O
active US20050274671 A JJ O
substance US20050274671 A NN O
hardly US20050274671 A RB O
soluble US20050274671 A JJ O
in US20050274671 A IN O
an US20050274671 A DT O
aqueous US20050274671 A JJ O
medium US20050274671 A NN O
with US20050274671 A IN O
a US20050274671 A DT O
porous US20050274671 A JJ O
support US20050274671 A NN O
. US20050274671 A . O

The US20050274671 A DT O
invention US20050274671 A NN O
is US20050274671 A VBZ O
characterized US20050274671 A VBN O
in US20050274671 A IN O
that US20050274671 A DT O
it US20050274671 A PRP O
comprises US20050274671 A VBZ O
the US20050274671 A DT O
following US20050274671 A JJ O
steps US20050274671 A NNS O
: US20050274671 A : O
( US20050274671 A ( O
a US20050274671 A DT O
) US20050274671 A ) O
mixing US20050274671 A VBG O
the US20050274671 A DT O
active US20050274671 A JJ O
substance US20050274671 A NN O
generated US20050274671 A VBN O
by US20050274671 A IN O
supercritical US20050274671 A JJ O
fluid US20050274671 A NN O
and US20050274671 A CC O
the US20050274671 A DT O
specific US20050274671 A JJ O
amount US20050274671 A NN O
of US20050274671 A IN O
porous US20050274671 A JJ O
support US20050274671 A NN O
; US20050274671 A : O
( US20050274671 A ( O
b US20050274671 A NN O
) US20050274671 A ) O
carrying US20050274671 A VBG O
out US20050274671 A RP O
a US20050274671 A DT O
molecular US20050274671 A JJ O
diffusion US20050274671 A NN O
step US20050274671 A NN O
by US20050274671 A IN O
contacting US20050274671 A VBG O
in US20050274671 A IN O
static US20050274671 A JJ O
mode US20050274671 A NN O
a US20050274671 A DT O
supercritical US20050274671 A JJ O
fluid US20050274671 A NN O
with US20050274671 A IN O
the US20050274671 A DT O
mixture US20050274671 A NN O
obtained US20050274671 A VBN O
at US20050274671 A IN O
step US20050274671 A NN O
( US20050274671 A ( O
a US20050274671 A DT O
) US20050274671 A ) O
for US20050274671 A IN O
the US20050274671 A DT O
time US20050274671 A NN O
required US20050274671 A VBN O
to US20050274671 A TO O
improve US20050274671 A VB O
the US20050274671 A DT O
dissolution US20050274671 A NN O
in US20050274671 A IN O
the US20050274671 A DT O
aqueous US20050274671 A JJ O
medium US20050274671 A NN O
of US20050274671 A IN O
the US20050274671 A DT O
mixture US20050274671 A NN O
obtained US20050274671 A VBN O
at US20050274671 A IN O
step US20050274671 A NN O
( US20050274671 A ( O
a US20050274671 A DT O
) US20050274671 A ) O
; US20050274671 A : O
( US20050274671 A ( O
c US20050274671 A NN O
) US20050274671 A ) O
washing US20050274671 A VBG O
the US20050274671 A DT O
interactive US20050274671 A JJ O
compound US20050274671 A NN O
obtained US20050274671 A VBD O
at US20050274671 A IN O
step US20050274671 A NN O
( US20050274671 A ( O
b US20050274671 A NN O
) US20050274671 A ) O
with US20050274671 A IN O
a US20050274671 A DT O
supercritical US20050274671 A JJ O
fluid US20050274671 A NN O
flow US20050274671 A NN O
; US20050274671 A : O
( US20050274671 A ( O
d US20050274671 A NN O
) US20050274671 A ) O
recuperating US20050274671 A VBG O
the US20050274671 A DT O
particles US20050274671 A NNS O
of US20050274671 A IN O
the US20050274671 A DT O
interactive US20050274671 A JJ O
compound US20050274671 A NN O
thus US20050274671 A RB O
formed US20050274671 A VBN O
. US20050274671 A . O

The US20050274671 A DT O
invention US20050274671 A NN O
also US20050274671 A RB O
concerns US20050274671 A VBZ O
a US20050274671 A DT O
compound US20050274671 A NN O
obtainable US20050274671 A JJ O
by US20050274671 A IN O
said US20050274671 A VBD O
method US20050274671 A NN O
. US20050274671 A . O

Compositions US20110166209 T NNS O
and US20110166209 T CC O
methods US20110166209 T NNS O
for US20110166209 T IN O
ameliorating US20110166209 T VBG O
myosin US20110166209 T NN I-UN
viia US20110166209 T NN I-UN
defects US20110166209 T NNS O
. US20110166209 T . O

The US20110166209 A DT O
invention US20110166209 A NN O
provides US20110166209 A VBZ O
compositions US20110166209 A NNS O
and US20110166209 A CC O
methods US20110166209 A NNS O
for US20110166209 A IN O
ameliorating US20110166209 A VBG O
defects US20110166209 A NNS O
in US20110166209 A IN O
myosin US20110166209 A NN I-UN
VIIa US20110166209 A NNP I-UN
( US20110166209 A ( O
MYO7A US20110166209 A NNP I-UN
) US20110166209 A ) O
expression US20110166209 A NN O
and/or US20110166209 A NN O
function US20110166209 A NN O
, US20110166209 A , O
including US20110166209 A VBG O
providing US20110166209 A VBG O
vectors US20110166209 A NNS O
for US20110166209 A IN O
myosin US20110166209 A NN I-UN
VIIa US20110166209 A NNP I-UN
expression US20110166209 A NN O
and US20110166209 A CC O
formulations US20110166209 A NNS O
comprising US20110166209 A VBG O
them US20110166209 A PRP O
, US20110166209 A , O
and US20110166209 A CC O
methods US20110166209 A NNS O
of US20110166209 A IN O
using US20110166209 A VBG O
them US20110166209 A PRP O
, US20110166209 A , O
for US20110166209 A IN O
treating US20110166209 A VBG O
human US20110166209 A JJ O
retinitis US20110166209 A NN O
pigmentosa US20110166209 A NN O
( US20110166209 A ( O
or US20110166209 A CC O
retinal US20110166209 A JJ O
degeneration US20110166209 A NN O
) US20110166209 A ) O
, US20110166209 A , O
and US20110166209 A CC O
blindness US20110166209 A NN O
and US20110166209 A CC O
deafness US20110166209 A NN O
such US20110166209 A JJ O
as US20110166209 A IN O
that US20110166209 A DT O
found US20110166209 A VBD O
in US20110166209 A IN O
Usher US20110166209 A NNP O
syndrome US20110166209 A NN O
. US20110166209 A . O

The US20110166209 A DT O
invention US20110166209 A NN O
provides US20110166209 A VBZ O
in US20110166209 A IN O
vivo US20110166209 A JJ O
gene US20110166209 A NN O
therapy US20110166209 A NN O
for US20110166209 A IN O
ameliorating US20110166209 A VBG O
defects US20110166209 A NNS O
in US20110166209 A IN O
myosin US20110166209 A NN I-UN
VIIa US20110166209 A NNP I-UN
( US20110166209 A ( O
MYO7A US20110166209 A NNP I-UN
) US20110166209 A ) O
expression US20110166209 A NN O
and/or US20110166209 A NN O
function US20110166209 A NN O
, US20110166209 A , O
including US20110166209 A VBG O
compositions US20110166209 A NNS O
and US20110166209 A CC O
methods US20110166209 A NNS O
for US20110166209 A IN O
gene US20110166209 A NN O
transfer US20110166209 A NN O
of US20110166209 A IN O
the US20110166209 A DT O
human US20110166209 A JJ I-UN
myosin US20110166209 A NN I-UN
VIIa US20110166209 A NNP I-UN
( US20110166209 A ( O
MYO7A US20110166209 A NNP I-UN
) US20110166209 A ) O
gene US20110166209 A NN O
( US20110166209 A ( O
the US20110166209 A DT O
MYO7A US20110166209 A NNP I-UN
gene US20110166209 A NN I-UN
. US20110166209 A . O

Fortified EP1411960B1 T NNP O
rice EP1411960B1 T NN O
bran EP1411960B1 T NN O
food EP1411960B1 T NN O
product EP1411960B1 T NN O
for EP1411960B1 T IN O
promoting EP1411960B1 T VBG O
cardiovascular EP1411960B1 T JJ O
health EP1411960B1 T NN O
. EP1411960B1 T . O

Hair US20120263660 T NNP O
Loss US20120263660 T NNP O
Treatment US20120263660 T NNP O
. US20120263660 T . O

This US20120263660 A DT O
invention US20120263660 A NN O
relates US20120263660 A VBZ O
to US20120263660 A TO O
the US20120263660 A DT O
use US20120263660 A NN O
of US20120263660 A IN O
cortisol US20120263660 A NN O
blockers US20120263660 A NNS O
( US20120263660 A ( O
glucocorticoid US20120263660 A JJ I-UN
receptor US20120263660 A NN I-UN
[ US20120263660 A NNP O
GR US20120263660 A NNP I-UN
] US20120263660 A NNP O
antagonists US20120263660 A NNS O
) US20120263660 A ) O
for US20120263660 A IN O
the US20120263660 A DT O
prevention US20120263660 A NN O
or US20120263660 A CC O
treatment US20120263660 A NN O
of US20120263660 A IN O
stress US20120263660 A NN O
induced US20120263660 A VBN O
hair US20120263660 A JJ O
loss US20120263660 A NN O
. US20120263660 A . O

Method CN101570554B T NNP O
for CN101570554B T IN O
preparing CN101570554B T VBG O
zinc CN101570554B T NN O
supplementing CN101570554B T VBG O
agent CN101570554B T JJ O
carboxymethyl CN101570554B T NN O
chitosan CN101570554B T JJ O
oligosaccharide CN101570554B T JJ O
zinc CN101570554B T NN O
. CN101570554B T . O

Medicine CN101288717A T NNP O
composition CN101288717A T NN O
for CN101288717A T IN O
preventing CN101288717A T VBG O
birth CN101288717A T NN O
defect CN101288717A T NN O
and CN101288717A T CC O
improving CN101288717A T VBG O
memory CN101288717A T NN O
. CN101288717A T . O

Parasite CN102743403A T NNP O
expelling CN102743403A T VBG O
tablet CN102743403A T NN O
for CN102743403A T IN O
domestic CN102743403A T JJ O
animals CN102743403A T NNS O
and CN102743403A T CC O
preparation CN102743403A T NN O
method CN102743403A T NN O
thereof CN102743403A T NN O
. CN102743403A T . O

New CN102266324B T NNP O
application CN102266324B T NN O
of CN102266324B T IN O
kappa-opioid CN102266324B T JJ I-UN
receptor CN102266324B T NN I-UN
agonist CN102266324B T NN O
. CN102266324B T . O

The CN102266324B A DT O
invention CN102266324B A NN O
discloses CN102266324B A VBZ O
an CN102266324B A DT O
application CN102266324B A NN O
of CN102266324B A IN O
kappa-opioid CN102266324B A JJ I-UN
receptor CN102266324B A NN I-UN
agonists CN102266324B A NNS O
U50 CN102266324B A NNP O
and CN102266324B A CC O
488H CN102266324B A CD O
in CN102266324B A IN O
preparation CN102266324B A NN O
of CN102266324B A IN O
drugs CN102266324B A NNS O
for CN102266324B A IN O
treating CN102266324B A VBG O
diabetes CN102266324B A NNS O
. CN102266324B A . O

In CN102266324B A IN O
the CN102266324B A DT O
invention CN102266324B A NN O
, CN102266324B A , O
the CN102266324B A DT O
good CN102266324B A JJ O
blood CN102266324B A NN O
sugar CN102266324B A NN O
reducing CN102266324B A VBG O
effect CN102266324B A NN O
of CN102266324B A IN O
kappa-opioid CN102266324B A JJ I-UN
receptor CN102266324B A NN I-UN
agonists CN102266324B A NNS O
U50 CN102266324B A NNP O
and CN102266324B A CC O
488H CN102266324B A CD O
is CN102266324B A VBZ O
creatively CN102266324B A RB O
discovered CN102266324B A VBN O
, CN102266324B A , O
and CN102266324B A CC O
the CN102266324B A DT O
research CN102266324B A NN O
shows CN102266324B A VBZ O
that CN102266324B A IN O
the CN102266324B A DT O
blood CN102266324B A NN O
sugar CN102266324B A NN O
reducing CN102266324B A VBG O
mechanisms CN102266324B A NNS O
of CN102266324B A IN O
kappa-opioid CN102266324B A JJ I-UN
receptor CN102266324B A NN I-UN
agonist CN102266324B A NN O
U50 CN102266324B A NNP O
and CN102266324B A CC O
488H CN102266324B A CD O
are CN102266324B A VBP O
as CN102266324B A IN O
follows CN102266324B A VBZ O
: CN102266324B A : O
( CN102266324B A ( O
1 CN102266324B A CD O
) CN102266324B A ) O
increasing CN102266324B A VBG O
the CN102266324B A DT O
level CN102266324B A NN O
of CN102266324B A IN O
skeletal CN102266324B A JJ O
muscle CN102266324B A NN O
adiponectin CN102266324B A NN I-UN
receptor CN102266324B A NN I-UN
1 CN102266324B A CD I-UN
( CN102266324B A ( O
AdipoR1 CN102266324B A NNP I-UN
) CN102266324B A ) O
and CN102266324B A CC O
enhancing CN102266324B A VBG O
the CN102266324B A DT O
sensitivity CN102266324B A NN O
of CN102266324B A IN O
adiponectin CN102266324B A NN I-UN
and CN102266324B A CC O
insulin CN102266324B A NN I-UN
; CN102266324B A : O
( CN102266324B A ( O
2 CN102266324B A CD O
) CN102266324B A ) O
promoting CN102266324B A VBG O
the CN102266324B A DT O
membrane CN102266324B A NN O
translocation CN102266324B A NN O
of CN102266324B A IN O
glucose CN102266324B A JJ I-UN
transporter CN102266324B A NN I-UN
( CN102266324B A ( O
GLUT4 CN102266324B A NNP I-UN
) CN102266324B A ) O
in CN102266324B A IN O
skeletal CN102266324B A JJ O
muscle CN102266324B A NN O
cell CN102266324B A NN O
and CN102266324B A CC O
increasing CN102266324B A VBG O
the CN102266324B A DT O
glucose CN102266324B A NN O
transport CN102266324B A NN O
capability CN102266324B A NN O
of CN102266324B A IN O
the CN102266324B A DT O
skeletal CN102266324B A JJ O
muscle CN102266324B A NN O
cell CN102266324B A NN O
; CN102266324B A : O
and CN102266324B A CC O
( CN102266324B A ( O
3 CN102266324B A CD O
) CN102266324B A ) O
promoting CN102266324B A VBG O
the CN102266324B A DT O
activation CN102266324B A NN O
of CN102266324B A IN O
AMPK CN102266324B A NNP I-UN
( CN102266324B A ( O
adenosine-monophosphate-activated CN102266324B A JJ I-UN
protein CN102266324B A NN I-UN
kinase CN102266324B A NN I-UN
) CN102266324B A ) O
in CN102266324B A IN O
the CN102266324B A DT O
skeletal CN102266324B A JJ O
muscle CN102266324B A NN O
cell CN102266324B A NN O
and CN102266324B A CC O
enhancing CN102266324B A VBG O
insulin CN102266324B A JJ I-UN
sensitivity CN102266324B A NN O
. CN102266324B A . O

Fused US8324240 T VBN O
amino US8324240 T JJ O
pyridine US8324240 T NN O
as US8324240 T IN O
HSP90 US8324240 T NNP I-UN
inhibitors US8324240 T NNS O
. US8324240 T . O

The US8324240 A DT O
present US8324240 A JJ O
invention US8324240 A NN O
relates US8324240 A VBZ O
to US8324240 A TO O
HSP90 US8324240 A NNP I-UN
inhibitors US8324240 A NNS O
containing US8324240 A VBG O
fused US8324240 A VBD O
amino US8324240 A JJ O
pyridine US8324240 A NN O
core US8324240 A NN O
that US8324240 A WDT O
are US8324240 A VBP O
useful US8324240 A JJ O
as US8324240 A IN O
inhibitors US8324240 A NNS O
of US8324240 A IN O
HSP90 US8324240 A NNP I-UN
and US8324240 A CC O
their US8324240 A PRP$ O
use US8324240 A NN O
in US8324240 A IN O
the US8324240 A DT O
treatment US8324240 A NN O
of US8324240 A IN O
HSP90 US8324240 A NNP I-UN
related US8324240 A JJ O
diseases US8324240 A NNS O
and US8324240 A CC O
disorders US8324240 A NNS O
such US8324240 A JJ O
as US8324240 A IN O
cancer US8324240 A NN O
, US8324240 A , O
an US8324240 A DT O
autoimmune US8324240 A JJ O
disease US8324240 A NN O
, US8324240 A , O
or US8324240 A CC O
a US8324240 A DT O
neurodegenerative US8324240 A JJ O
disease US8324240 A NN O
. US8324240 A . O

Administering US7598228 T VBG O
by US7598228 T IN O
direct US7598228 T JJ O
injection US7598228 T NN O
into US7598228 T IN O
heart US7598228 T NN O
an US7598228 T DT O
expression US7598228 T NN O
vector US7598228 T NN O
comprising US7598228 T VBG O
a US7598228 T DT O
nucleic US7598228 T JJ O
acid US7598228 T NN O
sequence US7598228 T NN O
encoding US7598228 T VBG O
AOP-1 US7598228 T NNP O
operably US7598228 T RB O
linked US7598228 T VBD O
to US7598228 T TO O
a US7598228 T DT O
promoter US7598228 T NN O
, US7598228 T , O
wherein US7598228 T JJ O
expression US7598228 T NN O
of US7598228 T IN O
nucleic US7598228 T JJ O
acid US7598228 T JJ O
sequence US7598228 T NN O
within US7598228 T IN O
cells US7598228 T NNS O
of US7598228 T IN O
heart US7598228 T NN O
enhances US7598228 T NNS O
production US7598228 T NN O
of US7598228 T IN O
AOP-1 US7598228 T NNP O
, US7598228 T , O
protecting US7598228 T VBG O
against US7598228 T IN O
myocardial US7598228 T JJ O
cell US7598228 T NN O
death US7598228 T NN O
. US7598228 T . O

A US7598228 A DT O
prophylactic US7598228 A JJ O
or US7598228 A CC O
therapeutic US7598228 A JJ O
method US7598228 A NN O
for US7598228 A IN O
a US7598228 A DT O
disease US7598228 A NN O
associated US7598228 A VBN O
with US7598228 A IN O
decreased US7598228 A JJ O
expression US7598228 A NN O
of US7598228 A IN O
AOP-1 US7598228 A NNP I-UN
gene US7598228 A NN O
or US7598228 A CC O
AOP-1 US7598228 A NNP I-UN
, US7598228 A , O
comprising US7598228 A VBG O
( US7598228 A ( O
1 US7598228 A CD O
) US7598228 A ) O
transfecting US7598228 A VBG O
a US7598228 A DT O
nucleic US7598228 A JJ O
acid US7598228 A NN O
encoding US7598228 A VBG O
AOP-1 US7598228 A NNP I-UN
or US7598228 A CC O
a US7598228 A DT O
nucleic US7598228 A JJ O
acid US7598228 A NN O
encoding US7598228 A VBG O
a US7598228 A DT O
polypeptide US7598228 A NN O
having US7598228 A VBG O
an US7598228 A DT O
addition US7598228 A NN O
, US7598228 A , O
deletion US7598228 A NN O
or US7598228 A CC O
substitution US7598228 A NN O
of US7598228 A IN O
one US7598228 A CD O
or US7598228 A CC O
more US7598228 A JJR O
amino US7598228 A JJ O
acids US7598228 A NNS O
as US7598228 A IN O
compared US7598228 A VBN O
with US7598228 A IN O
the US7598228 A DT O
amino US7598228 A NN O
acid US7598228 A JJ O
sequence US7598228 A NN O
of US7598228 A IN O
AOP-1 US7598228 A NNP I-UN
while US7598228 A IN O
retaining US7598228 A VBG O
the US7598228 A DT O
function US7598228 A NN O
of US7598228 A IN O
AOP-1 US7598228 A NNP I-UN
, US7598228 A , O
or US7598228 A CC O
( US7598228 A ( O
2 US7598228 A CD O
) US7598228 A ) O
administering US7598228 A VBG O
a US7598228 A DT O
material US7598228 A NN O
enhancing US7598228 A VBG O
the US7598228 A DT O
expression US7598228 A NN O
of US7598228 A IN O
AOP-1 US7598228 A NNP I-UN
gene US7598228 A NN O
, US7598228 A , O
a US7598228 A DT O
material US7598228 A NN O
enhancing US7598228 A VBG O
the US7598228 A DT O
production US7598228 A NN O
of US7598228 A IN O
AOP-1 US7598228 A NNP I-UN
or US7598228 A CC O
a US7598228 A DT O
material US7598228 A JJ O
enhancing US7598228 A VBG O
the US7598228 A DT O
function US7598228 A NN O
of US7598228 A IN O
AOP-1 US7598228 A NNP I-UN
. US7598228 A . O

Molybdenum CN1634944A T NNP O
, CN1634944A T , O
wolfram CN1634944A T NN O
, CN1634944A T , O
molybdenum CN1634944A T NN O
and CN1634944A T CC O
wolfram CN1634944A T NN O
complex CN1634944A T NN O
, CN1634944A T , O
method CN1634944A T NN O
for CN1634944A T IN O
making CN1634944A T VBG O
and CN1634944A T CC O
use CN1634944A T VB O
in CN1634944A T IN O
preparing CN1634944A T VBG O
anticancer CN1634944A T NN O
, CN1634944A T , O
antitumor CN1634944A T JJ O
medicament CN1634944A T NN O
. CN1634944A T . O

SUBSTITUTED WO2012109011A1 T NNP O
[ WO2012109011A1 T NNP O
( WO2012109011A1 T ( O
5H-PYRROLO WO2012109011A1 T JJ O
[ WO2012109011A1 T NNP O
2,1-c WO2012109011A1 T JJ O
] WO2012109011A1 T NNP O
[ WO2012109011A1 T NNP O
1,4 WO2012109011A1 T CD O
] WO2012109011A1 T NNP O
BENZODIAZEPIN-11-YL WO2012109011A1 T NNP O
) WO2012109011A1 T ) O
PIPERAZIN-1-YL WO2012109011A1 T NNP O
] WO2012109011A1 T NNP O
-2,2-DIMETHYLPROPANOIC WO2012109011A1 T NNP O
ACID WO2012109011A1 T NNP O
COMPOUNDS WO2012109011A1 T NNP O
AS WO2012109011A1 T NNP O
DUAL WO2012109011A1 T NNP O
ACTIVITY WO2012109011A1 T NNP O
H1 WO2012109011A1 T NNP I-UN
INVERSE WO2012109011A1 T NNP O
AGONISTS/5-HT2A WO2012109011A1 T NNP O
ANTAGONISTS WO2012109011A1 T NNP O
. WO2012109011A1 T . O

A WO2012109011A1 A DT O
dual WO2012109011A1 A JJ O
H1/5-HT2A WO2012109011A1 A NNP O
receptor WO2012109011A1 A NN I-UN
antagonist WO2012109011A1 A NN O
of WO2012109011A1 A IN O
the WO2012109011A1 A DT O
formula WO2012109011A1 A NN O
: WO2012109011A1 A : O
, WO2012109011A1 A , O
its WO2012109011A1 A PRP$ O
uses WO2012109011A1 A NNS O
, WO2012109011A1 A , O
and WO2012109011A1 A CC O
methods WO2012109011A1 A NNS O
for WO2012109011A1 A IN O
its WO2012109011A1 A PRP$ O
preparation WO2012109011A1 A NN O
are WO2012109011A1 A VBP O
described WO2012109011A1 A VBN O
. WO2012109011A1 A . O

New CN101422463A T NNP O
use CN101422463A T NN O
of CN101422463A T IN O
sodium-ion CN101422463A T NN O
channel CN101422463A T NN O
blocker CN101422463A T NN O
compound CN101422463A T NN O
in CN101422463A T IN O
clearing CN101422463A T VBG O
biosome CN101422463A T JJ O
endotoxin CN101422463A T NN O
. CN101422463A T . O

Methods US20110130421 T NNS O
and US20110130421 T CC O
Compositions US20110130421 T NNS O
for US20110130421 T IN O
the US20110130421 T DT O
Treatment US20110130421 T NNP O
of US20110130421 T IN O
Chronic US20110130421 T NNP O
Renal US20110130421 T NNP O
Hypertension US20110130421 T NNP O
. US20110130421 T . O

Treatment EP2446883A1 T NN O
of EP2446883A1 T IN O
inflammation EP2446883A1 T NN O
. EP2446883A1 T . O

A EP2446883A1 A DT O
method EP2446883A1 A NN O
for EP2446883A1 A IN O
the EP2446883A1 A DT O
treatment EP2446883A1 A NN O
of EP2446883A1 A IN O
inflammation EP2446883A1 A NN O
in EP2446883A1 A IN O
an EP2446883A1 A DT O
individual EP2446883A1 A NN O
is EP2446883A1 A VBZ O
described EP2446883A1 A VBN O
, EP2446883A1 A , O
for EP2446883A1 A IN O
example EP2446883A1 A NN O
a EP2446883A1 A DT O
causal EP2446883A1 A NN O
therapy EP2446883A1 A NN O
of EP2446883A1 A IN O
a EP2446883A1 A DT O
disease EP2446883A1 A NN O
or EP2446883A1 A CC O
condition EP2446883A1 A NN O
for EP2446883A1 A IN O
which EP2446883A1 A WDT O
an EP2446883A1 A DT O
inflammatory EP2446883A1 A NN O
state EP2446883A1 A NN O
is EP2446883A1 A VBZ O
an EP2446883A1 A DT O
underlying EP2446883A1 A JJ O
cause EP2446883A1 A NN O
of EP2446883A1 A IN O
the EP2446883A1 A DT O
disease EP2446883A1 A NN O
, EP2446883A1 A , O
or EP2446883A1 A CC O
a EP2446883A1 A DT O
treatment EP2446883A1 A NN O
of EP2446883A1 A IN O
inflammation EP2446883A1 A NN O
as EP2446883A1 A IN O
a EP2446883A1 A DT O
symptom EP2446883A1 A NN O
of EP2446883A1 A IN O
a EP2446883A1 A DT O
disease EP2446883A1 A NN O
state EP2446883A1 A NN O
, EP2446883A1 A , O
for EP2446883A1 A IN O
example EP2446883A1 A NN O
inflammation EP2446883A1 A NN O
caused EP2446883A1 A VBN O
by EP2446883A1 A IN O
cancer EP2446883A1 A NN O
, EP2446883A1 A , O
cardiovascular EP2446883A1 A JJ O
disease EP2446883A1 A NN O
, EP2446883A1 A , O
an EP2446883A1 A DT O
infection EP2446883A1 A NN O
or EP2446883A1 A CC O
trauma EP2446883A1 A NN O
, EP2446883A1 A , O
by EP2446883A1 A IN O
treating EP2446883A1 A VBG O
the EP2446883A1 A DT O
individual EP2446883A1 A NN O
with EP2446883A1 A IN O
an EP2446883A1 A DT O
agent EP2446883A1 A NN O
capable EP2446883A1 A JJ O
of EP2446883A1 A IN O
attenuating EP2446883A1 A VBG O
the EP2446883A1 A DT O
activity EP2446883A1 A NN O
of EP2446883A1 A IN O
Ubiquitin EP2446883A1 A NNP I-UN
Serine EP2446883A1 A NNP I-UN
Protease EP2446883A1 A NNP I-UN
7 EP2446883A1 A CD I-UN
( EP2446883A1 A ( O
USP7 EP2446883A1 A NNP I-UN
) EP2446883A1 A ) O
protein EP2446883A1 A NN O
, EP2446883A1 A , O
in EP2446883A1 A IN O
particular EP2446883A1 A JJ O
a EP2446883A1 A DT O
USP7 EP2446883A1 A NNP I-UN
inhibitor EP2446883A1 A NN O
chemical EP2446883A1 A NN O
. EP2446883A1 A . O

Sulfur US8309584 T NNP O
containing US8309584 T VBG O
pyrazole-heterocycle US8309584 T NN O
derivatives US8309584 T NNS O
as US8309584 T IN O
cannabinoid US8309584 T JJ I-UN
CB1 US8309584 T NNP I-UN
receptor US8309584 T NN I-UN
antagonists US8309584 T NNS O
. US8309584 T . O

A US8309584 A DT O
novel US8309584 A JJ O
sulfur US8309584 A NN O
containing US8309584 A VBG O
heteroaryl-pyrazole US8309584 A JJ O
compound US8309584 A NN O
of US8309584 A IN O
formula US8309584 A NN O
( US8309584 A ( O
I US8309584 A PRP O
) US8309584 A ) O
or US8309584 A CC O
a US8309584 A DT O
pharmaceutically US8309584 A RB O
acceptable US8309584 A JJ O
salt US8309584 A NN O
thereof US8309584 A NN O
is US8309584 A VBZ O
effective US8309584 A JJ O
as US8309584 A IN O
a US8309584 A DT O
cannabinoid US8309584 A NN I-UN
CB1 US8309584 A NNP I-UN
receptor US8309584 A NN I-UN
inverse US8309584 A JJ O
agonist US8309584 A NN O
or US8309584 A CC O
antagonist US8309584 A NN O
, US8309584 A , O
which US8309584 A WDT O
is US8309584 A VBZ O
useful US8309584 A JJ O
for US8309584 A IN O
preventing US8309584 A VBG O
or US8309584 A CC O
treating US8309584 A VBG O
obesity US8309584 A NN O
and US8309584 A CC O
obesity-related US8309584 A JJ O
metabolic US8309584 A NN O
disorders US8309584 A NNS O
. US8309584 A . O

Substituted US20080227869 T VBN O
nitrobenzene US20080227869 T JJ O
derivatives US20080227869 T NNS O
as US20080227869 T IN O
pharmaceutical US20080227869 T JJ O
and US20080227869 T CC O
other US20080227869 T JJ O
uses US20080227869 T NNS O
thereof US20080227869 T VBP O
. US20080227869 T . O

Formulations CA2153604C T NNS O
containing CA2153604C T VBG O
esculoside CA2153604C T NN O
and CA2153604C T CC O
the CA2153604C T DT O
use CA2153604C T NN O
thereof CA2153604C T NN O
in CA2153604C T IN O
the CA2153604C T DT O
pharmaceutical CA2153604C T JJ O
and CA2153604C T CC O
cosmetic CA2153604C T JJ O
fields CA2153604C T NNS O
. CA2153604C T . O

The CA2153604C A DT O
present CA2153604C A JJ O
invention CA2153604C A NN O
relates CA2153604C A VBZ O
to CA2153604C A TO O
the CA2153604C A DT O
use CA2153604C A NN O
of CA2153604C A IN O
esculoside CA2153604C A JJ O
alone CA2153604C A CD O
or CA2153604C A CC O
in CA2153604C A IN O
combination CA2153604C A NN O
with CA2153604C A IN O
adenylate CA2153604C A JJ I-UN
cyclase CA2153604C A NN I-UN
stimulators CA2153604C A NNS O
, CA2153604C A , O
such CA2153604C A JJ O
as CA2153604C A IN O
forskolin CA2153604C A NN O
or CA2153604C A CC O
Salvia CA2153604C A NNP O
miltiorrhiza CA2153604C A VBP O
diterpenes CA2153604C A NNS O
and/or CA2153604C A RB O
with CA2153604C A IN O
phosphodiesterase CA2153604C A NN I-UN
inhibitors CA2153604C A NNS O
, CA2153604C A , O
such CA2153604C A JJ O
as CA2153604C A IN O
apigenine-skeleton CA2153604C A JJ O
dimeric CA2153604C A JJ O
flavones CA2153604C A NNS O
, CA2153604C A , O
in CA2153604C A IN O
topical CA2153604C A JJ O
formulations CA2153604C A NNS O
for CA2153604C A IN O
the CA2153604C A DT O
treatment CA2153604C A NN O
of CA2153604C A IN O
peripheral CA2153604C A JJ O
vasculopathies CA2153604C A NNS O
related CA2153604C A VBN O
to CA2153604C A TO O
an CA2153604C A DT O
impaired CA2153604C A JJ O
peripheral CA2153604C A JJ O
microcirculation CA2153604C A NN O
, CA2153604C A , O
cellulitis CA2153604C A NN O
or CA2153604C A CC O
unesthetisms CA2153604C A JJ O
connected CA2153604C A VBN O
with CA2153604C A IN O
a CA2153604C A DT O
deposit CA2153604C A NN O
of CA2153604C A IN O
superfluous CA2153604C A JJ O
fat CA2153604C A NN O
. CA2153604C A . O

Composite CN101254168A T JJ O
high-energy CN101254168A T JJ O
nutrient CN101254168A T NN O
fluid CN101254168A T NN O
for CN101254168A T IN O
dog CN101254168A T NN O
, CN101254168A T , O
grimalkin CN101254168A T NN O
and CN101254168A T CC O
fox CN101254168A T NN O
and CN101254168A T CC O
method CN101254168A T NN O
of CN101254168A T IN O
preparing CN101254168A T VBG O
the CN101254168A T DT O
same CN101254168A T JJ O
. CN101254168A T . O

New CN1590395A T NNP O
type CN1590395A T NN O
azesaccharide CN1590395A T NN O
compound CN1590395A T NN O
, CN1590395A T , O
their CN1590395A T PRP$ O
synthesis CN1590395A T NN O
method CN1590395A T NN O
and CN1590395A T CC O
use CN1590395A T NN O
as CN1590395A T IN O
immune CN1590395A T JJ O
inhibitor CN1590395A T NN O
and CN1590395A T CC O
glycocidase CN1590395A T NN O
inhibitor CN1590395A T NN O
. CN1590395A T . O

Said CN1590395A A NNP O
compounds CN1590395A A NNS O
have CN1590395A A VBP O
high CN1590395A A JJ O
immunosuppression CN1590395A A NN O
activity CN1590395A A NN O
and CN1590395A A CC O
glycosidase CN1590395A A NN I-UN
( CN1590395A A ( O
galactosidase CN1590395A A NN I-UN
or CN1590395A A CC O
alpha-glucosidase CN1590395A A VB I-UN
A CN1590395A A DT I-UN
) CN1590395A A ) O
suppressing CN1590395A A NN O
activity CN1590395A A NN O
. CN1590395A A . O

Method EP1863499A1 T NNP O
for EP1863499A1 T IN O
inhibiting EP1863499A1 T VBG O
and/or EP1863499A1 T JJ O
treating EP1863499A1 T VBG O
vaginal EP1863499A1 T JJ O
infection EP1863499A1 T NN O
. EP1863499A1 T . O

Aminopyrazoloquinazolines US20120238542 T NNS O
. US20120238542 T . O

Methods EP2534131A1 T NNS O
of EP2534131A1 T IN O
synthesizing EP2534131A1 T VBG O
and EP2534131A1 T CC O
isolating EP2534131A1 T VBG O
n- EP2534131A1 T JJ O
( EP2534131A1 T ( O
bromoacetyl EP2534131A1 T NN O
) EP2534131A1 T ) O
-3,3-dinitroazetidine EP2534131A1 T NN O
and EP2534131A1 T CC O
a EP2534131A1 T DT O
composition EP2534131A1 T NN O
including EP2534131A1 T VBG O
the EP2534131A1 T DT O
same EP2534131A1 T JJ O
. EP2534131A1 T . O

Use CN1853647A T NNP O
III CN1853647A T NNP O
of CN1853647A T IN O
sealwort CN1853647A T NN O
polysaccharide CN1853647A T NN O
. CN1853647A T . O

Antiproliferative US6943183 T JJ O
agnets US6943183 T NNS O
; US6943183 T : O
anticancer US6943183 T NN O
agents US6943183 T NNS O
; US6943183 T : O
skin US6943183 T NN O
disorders US6943183 T NNS O
; US6943183 T : O
restenosis US6943183 T NN O
. US6943183 T . O

Specifically US6943183 A RB O
, US6943183 A , O
the US6943183 A DT O
present US6943183 A JJ O
invention US6943183 A NN O
relates US6943183 A VBZ O
to US6943183 A TO O
compounds US6943183 A VB O
that US6943183 A DT O
inhibit US6943183 A VB O
the US6943183 A DT O
farnesyl US6943183 A JJ I-UN
transferase US6943183 A NN I-UN
enzyme US6943183 A NN O

Method US7378388 T NNP O
of US7378388 T IN O
utilizing US7378388 T VBG O
neurotrophins US7378388 T NNS O
to US7378388 T TO O
manipulate US7378388 T VB O
reproductive US7378388 T JJ O
capacity US7378388 T NN O
. US7378388 T . O

The US7378388 A DT O
presence US7378388 A NN O
of US7378388 A IN O
endogenous US7378388 A JJ O
neurotrophins US7378388 A NNS O
and US7378388 A CC O
addition US7378388 A NN O
of US7378388 A IN O
exogenous US7378388 A JJ O
neurotrophins US7378388 A NNS O
, US7378388 A , O
particularly US7378388 A RB O
BDNF US7378388 A NNP I-UN
, US7378388 A , O
NT-4/5 US7378388 A NNP O
, US7378388 A , O
and US7378388 A CC O
NGF US7378388 A NNP I-UN
, US7378388 A , O
increase US7378388 A VB O
the US7378388 A DT O
reproductive US7378388 A JJ O
capacity US7378388 A NN O
of US7378388 A IN O
a US7378388 A DT O
female US7378388 A JJ O
patient US7378388 A NN O
by US7378388 A IN O
binding US7378388 A VBG O
to US7378388 A TO O
receptors US7378388 A NNS O
on US7378388 A IN O
the US7378388 A DT O
oocytes US7378388 A NNS O
and US7378388 A CC O
stimulating US7378388 A VBG O
maturation US7378388 A NN O
of US7378388 A IN O
the US7378388 A DT O
oocytes US7378388 A NNS O
. US7378388 A . O

Polycyclic WO2013104257A1 T NNP O
derivatives WO2013104257A1 T NNS O
, WO2013104257A1 T , O
preparation WO2013104257A1 T NN O
method WO2013104257A1 T NN O
and WO2013104257A1 T CC O
medical WO2013104257A1 T JJ O
uses WO2013104257A1 T NNS O
thereof WO2013104257A1 T NN O
. WO2013104257A1 T . O

Disclosed WO2013104257A1 A VBN O
in WO2013104257A1 A IN O
the WO2013104257A1 A DT O
present WO2013104257A1 A JJ O
invention WO2013104257A1 A NN O
are WO2013104257A1 A VBP O
polycyclic WO2013104257A1 A JJ O
derivatives WO2013104257A1 A NNS O
as WO2013104257A1 A IN O
represented WO2013104257A1 A VBN O
by WO2013104257A1 A IN O
general WO2013104257A1 A JJ O
formula WO2013104257A1 A NN O
( WO2013104257A1 A ( O
I WO2013104257A1 A PRP O
) WO2013104257A1 A ) O
, WO2013104257A1 A , O
the WO2013104257A1 A DT O
preparation WO2013104257A1 A NN O
method WO2013104257A1 A NN O
thereof WO2013104257A1 A NN O
, WO2013104257A1 A , O
pharmaceutical WO2013104257A1 A JJ O
compositions WO2013104257A1 A NNS O
containing WO2013104257A1 A VBG O
the WO2013104257A1 A DT O
derivatives WO2013104257A1 A NNS O
and WO2013104257A1 A CC O
uses WO2013104257A1 A VBZ O
thereof WO2013104257A1 A NN O
as WO2013104257A1 A IN O
therapeutical WO2013104257A1 A JJ O
agents WO2013104257A1 A NNS O
, WO2013104257A1 A , O
especially WO2013104257A1 A RB O
the WO2013104257A1 A DT O
GPR40 WO2013104257A1 A NNP I-UN
agonist WO2013104257A1 A NN O
and WO2013104257A1 A CC O
in WO2013104257A1 A IN O
preparation WO2013104257A1 A NN O
of WO2013104257A1 A IN O
drugs WO2013104257A1 A NNS O
for WO2013104257A1 A IN O
treating WO2013104257A1 A VBG O
diseases WO2013104257A1 A NNS O
like WO2013104257A1 A IN O
diabetes WO2013104257A1 A NNS O
and WO2013104257A1 A CC O
metabolic WO2013104257A1 A JJ O
disorders WO2013104257A1 A NNS O
, WO2013104257A1 A , O
etc. WO2013104257A1 A FW O
, WO2013104257A1 A , O
wherein WO2013104257A1 A WP O
each WO2013104257A1 A DT O
substituent WO2013104257A1 A NN O
in WO2013104257A1 A IN O
the WO2013104257A1 A DT O
general WO2013104257A1 A JJ O
formula WO2013104257A1 A NN O
( WO2013104257A1 A ( O
I WO2013104257A1 A PRP O
) WO2013104257A1 A ) O
has WO2013104257A1 A VBZ O
the WO2013104257A1 A DT O
same WO2013104257A1 A JJ O
definition WO2013104257A1 A NN O
as WO2013104257A1 A IN O
in WO2013104257A1 A IN O
the WO2013104257A1 A DT O
description WO2013104257A1 A NN O
. WO2013104257A1 A . O

Process CN103476432A T NN O
for CN103476432A T IN O
producing CN103476432A T VBG O
aqueous CN103476432A T JJ O
solution CN103476432A T NN O
containing CN103476432A T VBG O
fat-soluble CN103476432A T JJ O
substance CN103476432A T NN O
. CN103476432A T . O

Administration WO2009126537A1 T NN O
of WO2009126537A1 T IN O
an WO2009126537A1 T DT O
inhibitor WO2009126537A1 T NN O
of WO2009126537A1 T IN O
hdac WO2009126537A1 T NN I-UN
and WO2009126537A1 T CC O
an WO2009126537A1 T DT O
hmt WO2009126537A1 T NN I-UN
inhibitor WO2009126537A1 T NN O
. WO2009126537A1 T . O

Methods WO2009126537A1 A NNS O
of WO2009126537A1 A IN O
treating WO2009126537A1 A VBG O
patients WO2009126537A1 A NNS O
with WO2009126537A1 A IN O
an WO2009126537A1 A DT O
HDAC WO2009126537A1 A NNP I-UN
inhibitor WO2009126537A1 A NN O
and WO2009126537A1 A CC O
an WO2009126537A1 A DT O
HMT WO2009126537A1 A NNP I-UN
inhibitor WO2009126537A1 A NN O
are WO2009126537A1 A VBP O
provided WO2009126537A1 A VBN O
. WO2009126537A1 A . O

Therapeutic EP1141278B1 T JJ O
pde4d EP1141278B1 T NN I-UN
phosphodiesterase EP1141278B1 T NN O
inhibitors EP1141278B1 T NNS O
. EP1141278B1 T . O

This EP1141278B1 A DT O
patent EP1141278B1 A NN O
describes EP1141278B1 A VBZ O
the EP1141278B1 A DT O
invention EP1141278B1 A NN O
of EP1141278B1 A IN O
a EP1141278B1 A DT O
series EP1141278B1 A NN O
of EP1141278B1 A IN O
novel EP1141278B1 A JJ O
therapeutic EP1141278B1 A JJ O
oligonucleotide EP1141278B1 A NN O
polymers EP1141278B1 A NNS O
targeted EP1141278B1 A VBD O
at EP1141278B1 A IN O
inhibiting EP1141278B1 A VBG O
expression EP1141278B1 A NN O
of EP1141278B1 A IN O
genes EP1141278B1 A NNS O
coding EP1141278B1 A VBG O
for EP1141278B1 A IN O
Phosphodiesterase EP1141278B1 A NNP I-UN
4 EP1141278B1 A CD I-UN
. EP1141278B1 A . O

They EP1141278B1 A PRP O
are EP1141278B1 A VBP O
useful EP1141278B1 A JJ O
as EP1141278B1 A IN O
analytical EP1141278B1 A JJ O
tools EP1141278B1 A NNS O
in EP1141278B1 A IN O
the EP1141278B1 A DT O
study EP1141278B1 A NN O
of EP1141278B1 A IN O
individual EP1141278B1 A JJ O
PDE EP1141278B1 A NNP I-UN
isoforms EP1141278B1 A NNS O
and EP1141278B1 A CC O
in EP1141278B1 A IN O
the EP1141278B1 A DT O
therapeutic EP1141278B1 A JJ O
treatment EP1141278B1 A NN O
of EP1141278B1 A IN O
depression EP1141278B1 A NN O
, EP1141278B1 A , O
thrombosis EP1141278B1 A NN O
, EP1141278B1 A , O
cystic EP1141278B1 A JJ O
fibrosis EP1141278B1 A NN O
, EP1141278B1 A , O
gastric EP1141278B1 A JJ O
lesions EP1141278B1 A NNS O
, EP1141278B1 A , O
pulmonary EP1141278B1 A JJ O
hypertension EP1141278B1 A NN O
, EP1141278B1 A , O
glaucoma EP1141278B1 A NN O
, EP1141278B1 A , O
multiple EP1141278B1 A JJ O
sclerosis EP1141278B1 A NN O
, EP1141278B1 A , O
atopic EP1141278B1 A NN O
dermatitis EP1141278B1 A NN O
, EP1141278B1 A , O
asthma EP1141278B1 A NN O
and EP1141278B1 A CC O
other EP1141278B1 A JJ O
allergic EP1141278B1 A JJ O
disorders EP1141278B1 A NNS O
as EP1141278B1 A RB O
well EP1141278B1 A RB O
as EP1141278B1 A IN O
other EP1141278B1 A JJ O
illnesses EP1141278B1 A NNS O
in EP1141278B1 A IN O
which EP1141278B1 A WDT O
an EP1141278B1 A DT O
increase EP1141278B1 A NN O
of EP1141278B1 A IN O
cyclic EP1141278B1 A JJ O
AMP EP1141278B1 A NNP O
or EP1141278B1 A CC O
a EP1141278B1 A DT O
decrease EP1141278B1 A NN O
in EP1141278B1 A IN O
phosphodiesterase EP1141278B1 A NN I-UN
levels EP1141278B1 A NNS O
is EP1141278B1 A VBZ O
useful EP1141278B1 A JJ O
. EP1141278B1 A . O

Carboxylic WO2008044729A1 T NNP O
acid WO2008044729A1 T RB O
derivative WO2008044729A1 T JJ O
. WO2008044729A1 T . O

Disclosed WO2008044729A1 A VBN O
is WO2008044729A1 A VBZ O
a WO2008044729A1 A DT O
compound WO2008044729A1 A NN O
represented WO2008044729A1 A VBN O
by WO2008044729A1 A IN O
the WO2008044729A1 A DT O
general WO2008044729A1 A JJ O
formula WO2008044729A1 A NN O
( WO2008044729A1 A ( O
I WO2008044729A1 A PRP O
) WO2008044729A1 A ) O
, WO2008044729A1 A , O
a WO2008044729A1 A DT O
salt WO2008044729A1 A NN O
thereof WO2008044729A1 A NN O
, WO2008044729A1 A , O
or WO2008044729A1 A CC O
a WO2008044729A1 A DT O
hydrate WO2008044729A1 A NN O
or WO2008044729A1 A CC O
solvate WO2008044729A1 A NN O
of WO2008044729A1 A IN O
the WO2008044729A1 A DT O
compound WO2008044729A1 A NN O
or WO2008044729A1 A CC O
the WO2008044729A1 A DT O
salt WO2008044729A1 A NN O
, WO2008044729A1 A , O
which WO2008044729A1 A WDT O
has WO2008044729A1 A VBZ O
an WO2008044729A1 A DT O
inhibitory WO2008044729A1 A JJ O
activity WO2008044729A1 A NN O
on WO2008044729A1 A IN O
plasminogen WO2008044729A1 A NN I-UN
activator WO2008044729A1 A NN I-UN
inhibitor-1 WO2008044729A1 A JJ I-UN
( WO2008044729A1 A ( O
PAI-1 WO2008044729A1 A NNP I-UN
) WO2008044729A1 A ) O
. WO2008044729A1 A . O

Polycrystalline CN103108882A T NNP O
type CN103108882A T NN O
object CN103108882A T NN O
of CN103108882A T IN O
CDDO CN103108882A T NNP O
BIEA CN103108882A T NNP O
and CN103108882A T CC O
use CN103108882A T VB O
thereof CN103108882A T NN O
. CN103108882A T . O

Use US7045497 T NNP O
of US7045497 T IN O
peptide US7045497 T NN O
. US7045497 T . O

The US7045497 A DT O
present US7045497 A JJ O
invention US7045497 A NN O
relates US7045497 A VBZ O
to US7045497 A TO O
use US7045497 A VB O
of US7045497 A IN O
peptide US7045497 A NN O
to US7045497 A TO O
which US7045497 A WDT O
G-protein US7045497 A NNP I-UN
coupled US7045497 A VBD I-UN
receptor US7045497 A NN I-UN
protein US7045497 A NN O
recognizes US7045497 A VBZ O
as US7045497 A IN O
a US7045497 A DT O
ligand US7045497 A NN O
. US7045497 A . O

Application CN103446083A T NN O
of CN103446083A T IN O
aplysin CN103446083A T NN O
in CN103446083A T IN O
preparation CN103446083A T NN O
of CN103446083A T IN O
medicine CN103446083A T NN O
for CN103446083A T IN O
treating CN103446083A T VBG O
glioma CN103446083A T NN O
. CN103446083A T . O

Multi-effect CN103495174A T JJ O
external CN103495174A T JJ O
preparation CN103495174A T NN O
used CN103495174A T VBN O
for CN103495174A T IN O
treating CN103495174A T VBG O
superficial CN103495174A T JJ O
skin CN103495174A T JJ O
injury CN103495174A T NN O
and CN103495174A T CC O
application CN103495174A T NN O
thereof CN103495174A T NN O
. CN103495174A T . O

Bone-transplant US20130053354 T JJ O
or US20130053354 T CC O
bone-filling US20130053354 T JJ O
composition US20130053354 T NN O
comprising US20130053354 T VBG O
a US20130053354 T DT O
dihydroxybenzoic US20130053354 T NN O
acid US20130053354 T NN O
derivative US20130053354 T NN O
. US20130053354 T . O

Feminine DE102006030031A1 T NNP O
hygiene DE102006030031A1 T NN O
article DE102006030031A1 T NN O
, DE102006030031A1 T , O
useful DE102006030031A1 T JJ O
for DE102006030031A1 T IN O
the DE102006030031A1 T DT O
prevention DE102006030031A1 T NN O
and DE102006030031A1 T CC O
fight DE102006030031A1 T NN O
against DE102006030031A1 T IN O
candidiasis DE102006030031A1 T NN O
, DE102006030031A1 T , O
comprises DE102006030031A1 T VBZ O
vitamin DE102006030031A1 T JJ O
B12 DE102006030031A1 T NNP O
, DE102006030031A1 T , O
vitamin DE102006030031A1 T NN O
B12 DE102006030031A1 T NNP O
synthesis DE102006030031A1 T NN O
promoting DE102006030031A1 T VBG O
substances DE102006030031A1 T NNS O
, DE102006030031A1 T , O
folic DE102006030031A1 T JJ O
acid DE102006030031A1 T NN O
, DE102006030031A1 T , O
vitamin DE102006030031A1 T NN O
B6 DE102006030031A1 T NNP O
, DE102006030031A1 T , O
zinc DE102006030031A1 T NNP O
oxides DE102006030031A1 T VBZ O
, DE102006030031A1 T , O
cobalt DE102006030031A1 T NN O
, DE102006030031A1 T , O
dimethylbenzimidazole DE102006030031A1 T NN O
and DE102006030031A1 T CC O
biotin DE102006030031A1 T NN O
. DE102006030031A1 T . O

Compositions US20090178148 T NNS O
and US20090178148 T CC O
methods US20090178148 T NNS O
for US20090178148 T IN O
modifying US20090178148 T VBG O
the US20090178148 T DT O
content US20090178148 T NN O
of US20090178148 T IN O
polyunsaturated US20090178148 T JJ O
fatty US20090178148 T JJ O
acids US20090178148 T NNS O
in US20090178148 T IN O
mammalian US20090178148 T JJ O
cells US20090178148 T NNS O
. US20090178148 T . O

The US20090178148 A DT O
present US20090178148 A JJ O
invention US20090178148 A NN O
features US20090178148 A NNS O
compositions US20090178148 A NNS O
( US20090178148 A ( O
e.g. US20090178148 A NN O
, US20090178148 A , O
nucleic US20090178148 A JJ O
acids US20090178148 A NNS O
encoding US20090178148 A VBG O
fat-1 US20090178148 A NN I-UN
, US20090178148 A , O
optionally US20090178148 A RB O
and US20090178148 A CC O
operably US20090178148 A RB O
linked US20090178148 A VBN O
to US20090178148 A TO O
a US20090178148 A DT O
constitutively US20090178148 A RB O
active US20090178148 A JJ O
or US20090178148 A CC O
tissue-specific US20090178148 A JJ O
promoter US20090178148 A NN O
or US20090178148 A CC O
other US20090178148 A JJ O
regulatory US20090178148 A JJ O
sequence US20090178148 A NN O
) US20090178148 A ) O
and US20090178148 A CC O
pharmaceutically US20090178148 A RB O
acceptable US20090178148 A JJ O
formulations US20090178148 A NNS O
including US20090178148 A VBG O
nucleic US20090178148 A JJ O
acids US20090178148 A NNS O
encoding US20090178148 A VBG O
fat-1 US20090178148 A NN I-UN
or US20090178148 A CC O
biologically US20090178148 A RB O
active US20090178148 A JJ O
variants US20090178148 A NNS O
thereof US20090178148 A NN O
and US20090178148 A CC O
methods US20090178148 A NNS O
that US20090178148 A WDT O
can US20090178148 A MD O
be US20090178148 A VB O
used US20090178148 A VBN O
to US20090178148 A TO O
effectively US20090178148 A RB O
modify US20090178148 A VB O
the US20090178148 A DT O
content US20090178148 A NN O
of US20090178148 A IN O
PUFAs US20090178148 A NNP O
in US20090178148 A IN O
animal US20090178148 A NN O
cells US20090178148 A NNS O
( US20090178148 A ( O
i.e. US20090178148 A FW O
, US20090178148 A , O
cells US20090178148 A NNS O
other US20090178148 A JJ O
than US20090178148 A IN O
those US20090178148 A DT O
of US20090178148 A IN O
C. US20090178148 A NNP O
elegans US20090178148 A NNS O
, US20090178148 A , O
for US20090178148 A IN O
example US20090178148 A NN O
, US20090178148 A , O
mammalian US20090178148 A JJ O
cells US20090178148 A NNS O
such US20090178148 A JJ O
as US20090178148 A IN O
myocytes US20090178148 A NNS O
, US20090178148 A , O
neurons US20090178148 A NNS O
( US20090178148 A ( O
whether US20090178148 A IN O
of US20090178148 A IN O
the US20090178148 A DT O
peripheral US20090178148 A JJ O
or US20090178148 A CC O
central US20090178148 A JJ O
nervous US20090178148 A JJ O
system US20090178148 A NN O
) US20090178148 A ) O
, US20090178148 A , O
adipocytes US20090178148 A VBZ O
, US20090178148 A , O
endothelial US20090178148 A JJ O
cells US20090178148 A NNS O
, US20090178148 A , O
and US20090178148 A CC O
cancer US20090178148 A NN O
cells US20090178148 A NNS O
) US20090178148 A ) O
. US20090178148 A . O

Formula CN101890043A T NNP O
and CN101890043A T CC O
using CN101890043A T VBG O
method CN101890043A T NN O
of CN101890043A T IN O
body CN101890043A T NN O
odor CN101890043A T JJ O
removing CN101890043A T VBG O
medicament CN101890043A T NN O
. CN101890043A T . O

Micro WO2005092393A1 T NNP O
rna WO2005092393A1 T NN O
inhibiting WO2005092393A1 T VBG O
the WO2005092393A1 T DT O
expression WO2005092393A1 T NN O
of WO2005092393A1 T IN O
wt1 WO2005092393A1 T JJ I-UN
gene WO2005092393A1 T NN I-UN
and WO2005092393A1 T CC O
utilization WO2005092393A1 T NN O
of WO2005092393A1 T IN O
the WO2005092393A1 T DT O
same WO2005092393A1 T JJ O
. WO2005092393A1 T . O

It WO2005092393A1 A PRP O
is WO2005092393A1 A VBZ O
found WO2005092393A1 A VBN O
out WO2005092393A1 A RP O
that WO2005092393A1 A IN O
a WO2005092393A1 A DT O
miRNA WO2005092393A1 A NN O
targeting WO2005092393A1 A VBG O
the WO2005092393A1 A DT O
vicinity WO2005092393A1 A NN O
of WO2005092393A1 A IN O
the WO2005092393A1 A DT O
stop WO2005092393A1 A JJ O
codon WO2005092393A1 A NN O
of WO2005092393A1 A IN O
WT1 WO2005092393A1 A NNP I-UN
gene WO2005092393A1 A NN I-UN
not WO2005092393A1 A RB O
only WO2005092393A1 A RB O
inhibits WO2005092393A1 A VBZ O
the WO2005092393A1 A DT O
expression WO2005092393A1 A NN O
of WO2005092393A1 A IN O
the WO2005092393A1 A DT O
WT1 WO2005092393A1 A NNP I-UN
gene WO2005092393A1 A NN I-UN
but WO2005092393A1 A CC O
also WO2005092393A1 A RB O
shows WO2005092393A1 A VBZ O
a WO2005092393A1 A DT O
remarkable WO2005092393A1 A JJ O
effect WO2005092393A1 A NN O
of WO2005092393A1 A IN O
inhibiting WO2005092393A1 A VBG O
the WO2005092393A1 A DT O
cell WO2005092393A1 A NN O
proliferation WO2005092393A1 A NN O
of WO2005092393A1 A IN O
a WO2005092393A1 A DT O
cancer WO2005092393A1 A NN O
cell WO2005092393A1 A NN O
line WO2005092393A1 A NN O
. WO2005092393A1 A . O

Sodium CN102078637A T NN O
alginate/tamarind CN102078637A T NN O
gum CN102078637A T NN O
blended CN102078637A T VBD O
drug-loaded CN102078637A T JJ O
membrane CN102078637A T NN O
as CN102078637A T RB O
well CN102078637A T RB O
as CN102078637A T IN O
preparation CN102078637A T NN O
method CN102078637A T NN O
and CN102078637A T CC O
application CN102078637A T NN O
thereof CN102078637A T NN O
. CN102078637A T . O

Inhibition US20110229485 T NN O
of US20110229485 T IN O
the US20110229485 T DT O
nt-3 US20110229485 T JJ I-UN
: US20110229485 T : O
trkc US20110229485 T NN I-UN
bound US20110229485 T NN O
and US20110229485 T CC O
its US20110229485 T PRP$ O
application US20110229485 T NN O
to US20110229485 T TO O
the US20110229485 T DT O
treatment US20110229485 T NN O
of US20110229485 T IN O
cancer US20110229485 T NN O
such US20110229485 T JJ O
as US20110229485 T IN O
neuroblastoma US20110229485 T NN O
. US20110229485 T . O

The US20110229485 A DT O
subject US20110229485 A JJ O
matter US20110229485 A NN O
of US20110229485 A IN O
the US20110229485 A DT O
present US20110229485 A JJ O
disclosure US20110229485 A NN O
relates US20110229485 A VBZ O
to US20110229485 A TO O
an US20110229485 A DT O
in US20110229485 A IN O
vitro US20110229485 A NN O
method US20110229485 A NN O
for US20110229485 A IN O
the US20110229485 A DT O
screening US20110229485 A NN O
of US20110229485 A IN O
anti-cancer US20110229485 A JJ O
compounds US20110229485 A NNS O
based US20110229485 A VBN O
on US20110229485 A IN O
the US20110229485 A DT O
capacity US20110229485 A NN O
for US20110229485 A IN O
these US20110229485 A DT O
compounds US20110229485 A NNS O
to US20110229485 A TO O
interact US20110229485 A VB O
with US20110229485 A IN O
neurotrophin US20110229485 A JJ I-UN
3 US20110229485 A CD I-UN
( US20110229485 A ( O
NT-3 US20110229485 A NNP I-UN
or US20110229485 A CC O
NT3 US20110229485 A NNP I-UN
) US20110229485 A ) O
, US20110229485 A , O
to US20110229485 A TO O
the US20110229485 A DT O
extracellular US20110229485 A JJ O
domain US20110229485 A NN O
, US20110229485 A , O
or US20110229485 A CC O
TrkC US20110229485 A NNP I-UN
receptor US20110229485 A NN O
and/or US20110229485 A NN O
to US20110229485 A TO O
inhibit US20110229485 A VB O
the US20110229485 A DT O
dimerization US20110229485 A NN O
of US20110229485 A IN O
the US20110229485 A DT O
intracellular US20110229485 A JJ O
domain US20110229485 A NN O
of US20110229485 A IN O
the US20110229485 A DT O
TrkC US20110229485 A NNP I-UN
receptor US20110229485 A NN O
expressed US20110229485 A VBD O
in US20110229485 A IN O
tumor US20110229485 A NN O
cells US20110229485 A NNS O
, US20110229485 A , O
particularly US20110229485 A RB O
in US20110229485 A IN O
neuroblastoma US20110229485 A NN O
. US20110229485 A . O

The US20110229485 A DT O
disclosure US20110229485 A NN O
also US20110229485 A RB O
relates US20110229485 A VBZ O
to US20110229485 A TO O
a US20110229485 A DT O
method US20110229485 A NN O
for US20110229485 A IN O
predicting US20110229485 A VBG O
the US20110229485 A DT O
presence US20110229485 A NN O
of US20110229485 A IN O
metastatic US20110229485 A JJ O
cancer US20110229485 A NN O
or US20110229485 A CC O
a US20110229485 A DT O
bad US20110229485 A JJ O
prognosis US20110229485 A NN O
cancer US20110229485 A NN O
, US20110229485 A , O
or US20110229485 A CC O
for US20110229485 A IN O
determining US20110229485 A VBG O
the US20110229485 A DT O
efficiency US20110229485 A NN O
of US20110229485 A IN O
an US20110229485 A DT O
anti-cancer US20110229485 A JJ O
treatment US20110229485 A NN O
based US20110229485 A VBN O
on US20110229485 A IN O
the US20110229485 A DT O
measuring US20110229485 A NN O
of US20110229485 A IN O
the US20110229485 A DT O
expression US20110229485 A NN O
level US20110229485 A NN O
of US20110229485 A IN O
neurotrophin US20110229485 A JJ I-UN
3 US20110229485 A CD I-UN
. US20110229485 A . O

The US20110229485 A DT O
disclosure US20110229485 A NN O
further US20110229485 A JJ O
comprises US20110229485 A VBZ O
kits US20110229485 A NNS O
and US20110229485 A CC O
compounds US20110229485 A NNS O
as US20110229485 A IN O
a US20110229485 A DT O
medicament US20110229485 A NN O
for US20110229485 A IN O
the US20110229485 A DT O
treatment US20110229485 A NN O
of US20110229485 A IN O
neuroblastoma US20110229485 A NN O
or US20110229485 A CC O
cancer US20110229485 A NN O
overexpressing US20110229485 A VBG O
neurotrophin US20110229485 A JJ I-UN
3 US20110229485 A CD I-UN
by US20110229485 A IN O
the US20110229485 A DT O
tumor US20110229485 A NN O
cells US20110229485 A NNS O
. US20110229485 A . O

Aqueous CN1748704B T JJ O
preparation CN1748704B T NN O
for CN1748704B T IN O
injection CN1748704B T NN O
and CN1748704B T CC O
its CN1748704B T PRP$ O
stabilizing CN1748704B T NN O
method CN1748704B T NN O
. CN1748704B T . O

Preparation CN1631895A T NNP O
method CN1631895A T NN O
of CN1631895A T IN O
amygdalin CN1631895A T NN O
and CN1631895A T CC O
its CN1631895A T PRP$ O
application CN1631895A T NN O
in CN1631895A T IN O
preparation CN1631895A T NN O
of CN1631895A T IN O
amygdalin CN1631895A T JJ O
preparation CN1631895A T NN O
for CN1631895A T IN O
promoting CN1631895A T VBG O
the CN1631895A T DT O
blood CN1631895A T NN O
circulation CN1631895A T NN O
of CN1631895A T IN O
heart CN1631895A T NN O
, CN1631895A T , O
brain CN1631895A T NN O
, CN1631895A T , O
pancreas CN1631895A T NNS O
and CN1631895A T CC O
wound CN1631895A T NN O
. CN1631895A T . O

Antiaging WO2006118079A1 T VBG O
agnet WO2006118079A1 T NN O
for WO2006118079A1 T IN O
skin WO2006118079A1 T NN O
. WO2006118079A1 T . O

It WO2006118079A1 A PRP O
is WO2006118079A1 A VBZ O
intended WO2006118079A1 A VBN O
to WO2006118079A1 A TO O
provide WO2006118079A1 A VB O
a WO2006118079A1 A DT O
skin WO2006118079A1 A JJ O
preparation WO2006118079A1 A NN O
for WO2006118079A1 A IN O
external WO2006118079A1 A JJ O
use WO2006118079A1 A NN O
which WO2006118079A1 A WDT O
contains WO2006118079A1 A VBZ O
, WO2006118079A1 A , O
as WO2006118079A1 A IN O
the WO2006118079A1 A DT O
active WO2006118079A1 A JJ O
ingredients WO2006118079A1 A NNS O
, WO2006118079A1 A , O
curcumenone WO2006118079A1 A NN O
, WO2006118079A1 A , O
4S-dihydrocurcumenone WO2006118079A1 A JJ O
and/or WO2006118079A1 A NN O
curcarabranol WO2006118079A1 A NN O
. WO2006118079A1 A . O

Since WO2006118079A1 A IN O
these WO2006118079A1 A DT O
compounds WO2006118079A1 A NNS O
have WO2006118079A1 A VBP O
effects WO2006118079A1 A NNS O
of WO2006118079A1 A IN O
preventing WO2006118079A1 A VBG O
hyaluronic WO2006118079A1 A JJ O
acid WO2006118079A1 A NN O
from WO2006118079A1 A IN O
degradation WO2006118079A1 A NN O
and WO2006118079A1 A CC O
activating WO2006118079A1 A VBG O
fibroblasts WO2006118079A1 A NNS O
, WO2006118079A1 A , O
the WO2006118079A1 A DT O
above WO2006118079A1 A JJ O
skin WO2006118079A1 A NN O
preparation WO2006118079A1 A NN O
for WO2006118079A1 A IN O
external WO2006118079A1 A JJ O
use WO2006118079A1 A NN O
is WO2006118079A1 A VBZ O
useful WO2006118079A1 A JJ O
as WO2006118079A1 A IN O
an WO2006118079A1 A DT O
antiaging WO2006118079A1 A NN O
agent WO2006118079A1 A NN O
. WO2006118079A1 A . O

Enrofloxacin CN102988286A T NNP O
injection CN102988286A T NN O
. CN102988286A T . O

Benzoyl-piperidine EP1987019A1 T JJ O
derivatives EP1987019A1 T NNS O
as EP1987019A1 T IN O
5ht2/d3 EP1987019A1 T CD O
modulators EP1987019A1 T NNS O
. EP1987019A1 T . O

Steroids CA2250309C T NNS O
as CA2250309C T IN O
neurochemical CA2250309C T JJ O
initiators CA2250309C T NNS O
of CA2250309C T IN O
change CA2250309C T NN O
in CA2250309C T IN O
human CA2250309C T JJ O
blood CA2250309C T NN O
levels CA2250309C T NNS O
of CA2250309C T IN O
lh CA2250309C T NN O
or CA2250309C T CC O
fsh CA2250309C T NN O
. CA2250309C T . O

The CA2250309C A DT O
invention CA2250309C A NN O
relates CA2250309C A VBZ O
to CA2250309C A TO O
a CA2250309C A DT O
method CA2250309C A NN O
of CA2250309C A IN O
altering CA2250309C A VBG O
the CA2250309C A DT O
blood CA2250309C A NN O
levels CA2250309C A NNS O
of CA2250309C A IN O
LH CA2250309C A NNP I-UN
or CA2250309C A CC O
FSH CA2250309C A NNP I-UN
in CA2250309C A IN O
an CA2250309C A DT O
individual CA2250309C A NN O
. CA2250309C A . O

Novel CN102863512A T NNP O
antiviral CN102863512A T JJ O
compound CN102863512A T NN O
. CN102863512A T . O

Zolmitriptan WO2006055964A3 T NNP O
crystal WO2006055964A3 T NN O
forms WO2006055964A3 T NNS O
. WO2006055964A3 T . O

Application CN1823811A T NN O
of CN1823811A T IN O
physalis CN1823811A T NN O
alkekengi CN1823811A T NNS O
polysaccharide CN1823811A T VBP O
in CN1823811A T IN O
preparation CN1823811A T NN O
of CN1823811A T IN O
medicine CN1823811A T NN O
and CN1823811A T CC O
health CN1823811A T NN O
care CN1823811A T NN O
product CN1823811A T NN O
for CN1823811A T IN O
treating CN1823811A T VBG O
diabetes CN1823811A T NNS O
. CN1823811A T . O

A WO2012144661A1 A DT O
compound WO2012144661A1 A NN O
having WO2012144661A1 A VBG O
TRPV4 WO2012144661A1 A NNP I-UN
inhibitory WO2012144661A1 A JJ O
activity WO2012144661A1 A NN O
or WO2012144661A1 A CC O
a WO2012144661A1 A DT O
pharmaceutically WO2012144661A1 A RB O
acceptable WO2012144661A1 A JJ O
salt WO2012144661A1 A NN O
thereof WO2012144661A1 A NN O
is WO2012144661A1 A VBZ O
provided WO2012144661A1 A VBN O
. WO2012144661A1 A . O

Novel WO2006048248A3 T NNP O
anthranilamide WO2006048248A3 T RB O
pyridinureas WO2006048248A3 T RB O
as WO2006048248A3 T IN O
vegf WO2006048248A3 T JJ O
receptor WO2006048248A3 T NN O
kinase WO2006048248A3 T NN O
imhibitors WO2006048248A3 T NNS O
. WO2006048248A3 T . O

Adhesive US20070280972 T JJ O
solid US20070280972 T JJ O
gel-forming US20070280972 T JJ O
formulations US20070280972 T NNS O
for US20070280972 T IN O
dermal US20070280972 T JJ O
drug US20070280972 T NN O
delivery US20070280972 T NN O
. US20070280972 T . O

Multifunctional CN102772394A T NNP O
antiseptic CN102772394A T JJ O
and CN102772394A T CC O
detersive CN102772394A T JJ O
medicament CN102772394A T NN O
for CN102772394A T IN O
external CN102772394A T JJ O
use CN102772394A T NN O
. CN102772394A T . O

Compositions CA2433386C T NNS O
and CA2433386C T CC O
methods CA2433386C T NNS O
involving CA2433386C T VBG O
an CA2433386C T DT O
essential CA2433386C T JJ O
staphylococcus CA2433386C T NN O
aureus CA2433386C T JJ O
gene CA2433386C T NN O
and CA2433386C T CC O
its CA2433386C T PRP$ O
encoded CA2433386C T JJ O
protein CA2433386C T NN O
staau_r9 CA2433386C T NN O
. CA2433386C T . O

Supplementation CA2443543C T NN O
of CA2443543C T IN O
equine CA2443543C T JJ O
feedstuffs CA2443543C T NNS O
. CA2443543C T . O

Mitf US20120252904 T NNP I-UN
as US20120252904 T IN O
a US20120252904 T DT O
marker US20120252904 T NN O
for US20120252904 T IN O
predisposition US20120252904 T NN O
to US20120252904 T TO O
cancer US20120252904 T NN O
. US20120252904 T . O

The US20120252904 A DT O
present US20120252904 A JJ O
invention US20120252904 A NN O
relates US20120252904 A VBZ O
to US20120252904 A TO O
a US20120252904 A DT O
mutant US20120252904 A NN O
of US20120252904 A IN O
MITF US20120252904 A NNP I-UN
which US20120252904 A WDT O
is US20120252904 A VBZ O
useful US20120252904 A JJ O
as US20120252904 A IN O
a US20120252904 A DT O
marker US20120252904 A NN O
for US20120252904 A IN O
predisposition US20120252904 A NN O
to US20120252904 A TO O
the US20120252904 A DT O
development US20120252904 A NN O
of US20120252904 A IN O
cancer US20120252904 A NN O
and US20120252904 A CC O
to US20120252904 A TO O
uses US20120252904 A NNS O
thereof US20120252904 A NNS O
in US20120252904 A IN O
diagnosis US20120252904 A NN O
and US20120252904 A CC O
preventive US20120252904 A JJ O
treatments US20120252904 A NNS O
, US20120252904 A , O
sumoylation US20120252904 A NN O
being US20120252904 A VBG O
reduced US20120252904 A VBN O
or US20120252904 A CC O
absent US20120252904 A VBN O
in US20120252904 A IN O
this US20120252904 A DT O
mutant US20120252904 A NN O
. US20120252904 A . O

Use WO2007071653A1 T NNP O
of WO2007071653A1 T IN O
aminoalcohol WO2007071653A1 T NN O
derivatives WO2007071653A1 T NNS O
for WO2007071653A1 T IN O
the WO2007071653A1 T DT O
treatment WO2007071653A1 T NN O
of WO2007071653A1 T IN O
overactive WO2007071653A1 T JJ O
bladder WO2007071653A1 T NN O
. WO2007071653A1 T . O

The WO2007071653A1 A DT O
present WO2007071653A1 A JJ O
invention WO2007071653A1 A NN O
relates WO2007071653A1 A VBZ O
to WO2007071653A1 A TO O
the WO2007071653A1 A DT O
use WO2007071653A1 A NN O
of WO2007071653A1 A IN O
new WO2007071653A1 A JJ O
beta-agonists WO2007071653A1 A NNS O
of WO2007071653A1 A IN O
general WO2007071653A1 A JJ O
formula WO2007071653A1 A NN O
( WO2007071653A1 A ( O
Ia WO2007071653A1 A NNP O
) WO2007071653A1 A ) O
or WO2007071653A1 A CC O
( WO2007071653A1 A ( O
Ib WO2007071653A1 A NNP O
) WO2007071653A1 A ) O
wherein WO2007071653A1 A VBP O
the WO2007071653A1 A DT O
groups WO2007071653A1 A NNS O
R1 WO2007071653A1 A NNP O
to WO2007071653A1 A TO O
R12 WO2007071653A1 A NNP O
and WO2007071653A1 A CC O
R1 WO2007071653A1 A NNP O
to WO2007071653A1 A TO O
R7 WO2007071653A1 A NNP O
, WO2007071653A1 A , O
respectively WO2007071653A1 A RB O
, WO2007071653A1 A , O
have WO2007071653A1 A VBP O
the WO2007071653A1 A DT O
meanings WO2007071653A1 A NNS O
given WO2007071653A1 A VBN O
in WO2007071653A1 A IN O
the WO2007071653A1 A DT O
claims WO2007071653A1 A NNS O
and WO2007071653A1 A CC O
specification WO2007071653A1 A NN O
, WO2007071653A1 A , O
the WO2007071653A1 A DT O
tautomers WO2007071653A1 A NNS O
, WO2007071653A1 A , O
the WO2007071653A1 A DT O
enantiomers WO2007071653A1 A NNS O
, WO2007071653A1 A , O
the WO2007071653A1 A DT O
diastereomers WO2007071653A1 A NNS O
, WO2007071653A1 A , O
the WO2007071653A1 A DT O
mixtures WO2007071653A1 A NNS O
thereof WO2007071653A1 A VBP O
, WO2007071653A1 A , O
the WO2007071653A1 A DT O
prodrugs WO2007071653A1 A NNS O
thereof WO2007071653A1 A NN O
and WO2007071653A1 A CC O
the WO2007071653A1 A DT O
salts WO2007071653A1 A NNS O
thereof WO2007071653A1 A VBP O
, WO2007071653A1 A , O
particularly WO2007071653A1 A RB O
the WO2007071653A1 A DT O
physiologically WO2007071653A1 A RB O
acceptable WO2007071653A1 A JJ O
salts WO2007071653A1 A NNS O
thereof WO2007071653A1 A VBP O
with WO2007071653A1 A IN O
inorganic WO2007071653A1 A JJ O
or WO2007071653A1 A CC O
organic WO2007071653A1 A JJ O
acids WO2007071653A1 A NNS O
or WO2007071653A1 A CC O
bases WO2007071653A1 A NNS O
, WO2007071653A1 A , O
for WO2007071653A1 A IN O
preparing WO2007071653A1 A VBG O
a WO2007071653A1 A DT O
medicament WO2007071653A1 A NN O
for WO2007071653A1 A IN O
the WO2007071653A1 A DT O
treatment WO2007071653A1 A NN O
of WO2007071653A1 A IN O
overactive WO2007071653A1 A JJ O
bladder WO2007071653A1 A NN O
. WO2007071653A1 A . O

Hepatitis US20080200512 T NNP O
C US20080200512 T NNP O
virus US20080200512 T NN O
polymerase US20080200512 T NN O
inhibitors US20080200512 T NNS O
. US20080200512 T . O

Drug WO2014025890A1 T NN O
delivery WO2014025890A1 T NN O
vehicle WO2014025890A1 T NN O
comprising WO2014025890A1 T VBG O
conjugates WO2014025890A1 T NNS O
between WO2014025890A1 T IN O
targeting WO2014025890A1 T VBG O
polyamino WO2014025890A1 T NN O
acids WO2014025890A1 T NNS O
and WO2014025890A1 T CC O
fatty WO2014025890A1 T JJ O
acids WO2014025890A1 T NNS O
. WO2014025890A1 T . O

Compound CN103054861A T NNP O
solid CN103054861A T JJ O
preparation CN103054861A T NN O
containing CN103054861A T VBG O
tranexamic CN103054861A T JJ O
acid CN103054861A T NN O
. CN103054861A T . O

4-sulfonyl-substituted EP1781602A1 T JJ O
benzoylalanine EP1781602A1 T NN O
derivatives EP1781602A1 T NNS O
useful EP1781602A1 T JJ O
as EP1781602A1 T IN O
kynurenine-aminotransferase EP1781602A1 T JJ I-UN
inhibitors EP1781602A1 T NNS O
. EP1781602A1 T . O

The EP1781602A1 A DT O
compounds EP1781602A1 A NNS O
of EP1781602A1 A IN O
the EP1781602A1 A DT O
invention EP1781602A1 A NN O
reduce EP1781602A1 A VB O
the EP1781602A1 A DT O
synthesis EP1781602A1 A NN O
of EP1781602A1 A IN O
kynurenic EP1781602A1 A JJ O
acid EP1781602A1 A NN O
thus EP1781602A1 A RB O
inhibiting EP1781602A1 A VBG O
the EP1781602A1 A DT O
enzyme EP1781602A1 A JJ O
kynurenine EP1781602A1 A NN I-UN
aminotransferase EP1781602A1 A NN I-UN
and EP1781602A1 A CC O
can EP1781602A1 A MD O
be EP1781602A1 A VB O
used EP1781602A1 A VBN O
for EP1781602A1 A IN O
the EP1781602A1 A DT O
preparation EP1781602A1 A NN O
of EP1781602A1 A IN O
medicaments EP1781602A1 A NNS O
for EP1781602A1 A IN O
the EP1781602A1 A DT O
treatment EP1781602A1 A NN O
of EP1781602A1 A IN O
those EP1781602A1 A DT O
psychiatric EP1781602A1 A JJ O
and EP1781602A1 A CC O
neurological EP1781602A1 A JJ O
diseases EP1781602A1 A NNS O
which EP1781602A1 A WDT O
benefit EP1781602A1 A VBP O
from EP1781602A1 A IN O
an EP1781602A1 A DT O
increase EP1781602A1 A NN O
in EP1781602A1 A IN O
glutamatergic EP1781602A1 A JJ O
and/or EP1781602A1 A NN O
cholinergic EP1781602A1 A NN O
neurotransmission EP1781602A1 A NN O
, EP1781602A1 A , O
such EP1781602A1 A JJ O
as EP1781602A1 A IN O
depression EP1781602A1 A NN O
, EP1781602A1 A , O
bipolar EP1781602A1 A JJ O
illness EP1781602A1 A NN O
, EP1781602A1 A , O
anxiety EP1781602A1 A NN O
, EP1781602A1 A , O
Alzheimer EP1781602A1 A NNP O
's EP1781602A1 A POS O
disease EP1781602A1 A NN O
. EP1781602A1 A . O

Application CN102920687A T NN O
of CN102920687A T IN O
1- CN102920687A T JJ O
( CN102920687A T ( O
3,4,5-trihydroxy CN102920687A T JJ O
) CN102920687A T ) O
phenyl-1-dinone CN102920687A T NN O
in CN102920687A T IN O
preparation CN102920687A T NN O
of CN102920687A T IN O
medicament CN102920687A T NN O
for CN102920687A T IN O
preventing CN102920687A T VBG O
or CN102920687A T CC O
treating CN102920687A T VBG O
melanoma CN102920687A T NN O
. CN102920687A T . O

Methods EP2582832A1 T NNS O
and EP2582832A1 T CC O
pharmaceutical EP2582832A1 T JJ O
compositions EP2582832A1 T NNS O
for EP2582832A1 T IN O
treating EP2582832A1 T VBG O
the EP2582832A1 T DT O
animal EP2582832A1 T JJ O
central EP2582832A1 T JJ O
nervous EP2582832A1 T JJ O
system EP2582832A1 T NN O
for EP2582832A1 T IN O
psychiatric EP2582832A1 T JJ O
disorders EP2582832A1 T NNS O
. EP2582832A1 T . O

The EP2582832A1 A DT O
present EP2582832A1 A JJ O
invention EP2582832A1 A NN O
comprises EP2582832A1 A VBZ O
methods EP2582832A1 A NNS O
and EP2582832A1 A CC O
pharmaceutical EP2582832A1 A JJ O
compositions EP2582832A1 A NNS O
for EP2582832A1 A IN O
intranasal EP2582832A1 A JJ O
delivery EP2582832A1 A NN O
of EP2582832A1 A IN O
effective EP2582832A1 A JJ O
amounts EP2582832A1 A NNS O
of EP2582832A1 A IN O
DFO EP2582832A1 A NNP O
directly EP2582832A1 A RB O
to EP2582832A1 A TO O
the EP2582832A1 A DT O
CNS EP2582832A1 A NNP O
, EP2582832A1 A , O
in EP2582832A1 A IN O
particular EP2582832A1 A JJ O
the EP2582832A1 A DT O
brain EP2582832A1 A NN O
treatments EP2582832A1 A NNS O
that EP2582832A1 A WDT O
inhibit EP2582832A1 A VBP O
GSK3b EP2582832A1 A NNP I-UN
in EP2582832A1 A IN O
patients EP2582832A1 A NNS O
with EP2582832A1 A IN O
psychiatric EP2582832A1 A JJ O
disorders EP2582832A1 A NNS O
including EP2582832A1 A VBG O
, EP2582832A1 A , O
but EP2582832A1 A CC O
not EP2582832A1 A RB O
limited EP2582832A1 A JJ O
to EP2582832A1 A TO O
, EP2582832A1 A , O
bipolar EP2582832A1 A JJ O
disorder EP2582832A1 A NN O
, EP2582832A1 A , O
depression EP2582832A1 A NN O
, EP2582832A1 A , O
ADHD EP2582832A1 A NNP O
and EP2582832A1 A CC O
schizophrenia EP2582832A1 A NN O
. EP2582832A1 A . O

Moreover EP2582832A1 A RB O
, EP2582832A1 A , O
a EP2582832A1 A DT O
treatment EP2582832A1 A NN O
for EP2582832A1 A IN O
treating EP2582832A1 A VBG O
impairment EP2582832A1 A NN O
of EP2582832A1 A IN O
neural EP2582832A1 A JJ O
plasticity EP2582832A1 A NN O
through EP2582832A1 A IN O
inhibition EP2582832A1 A NN O
of EP2582832A1 A IN O
GSK3b EP2582832A1 A NNP I-UN
is EP2582832A1 A VBZ O
provided EP2582832A1 A VBN O
as EP2582832A1 A RB O
well EP2582832A1 A RB O
as EP2582832A1 A IN O
prevention EP2582832A1 A NN O
of EP2582832A1 A IN O
apoptosis EP2582832A1 A NN O
of EP2582832A1 A IN O
cells EP2582832A1 A NNS O
through EP2582832A1 A IN O
inhibition EP2582832A1 A NN O
of EP2582832A1 A IN O
GSK3b EP2582832A1 A NNP I-UN
. EP2582832A1 A . O

Phosphine CN101326191B T NNP O
transition CN101326191B T NN O
metal CN101326191B T NN O
complex CN101326191B T NN O
, CN101326191B T , O
method CN101326191B T NN O
for CN101326191B T IN O
producing CN101326191B T VBG O
same CN101326191B T JJ O
and CN101326191B T CC O
antitumor CN101326191B T JJ O
agent CN101326191B T NN O
containing CN101326191B T VBG O
same CN101326191B T JJ O
. CN101326191B T . O

Limited US20110236397 T JJ O
proteolysis US20110236397 T NN O
of US20110236397 T IN O
cd2ap US20110236397 T NN I-UN
and US20110236397 T CC O
progression US20110236397 T NN O
of US20110236397 T IN O
renal US20110236397 T JJ O
disease US20110236397 T NN O
. US20110236397 T . O

Compositions US20110236397 A NNS O
which US20110236397 A WDT O
specifically US20110236397 A RB O
block US20110236397 A VBP O
cathepsin US20110236397 A NN O
L US20110236397 A NNP O
function US20110236397 A NN O
in US20110236397 A IN O
podocytes US20110236397 A NNS O
, US20110236397 A , O
compositions US20110236397 A NNS O
which US20110236397 A WDT O
protect US20110236397 A VBP O
cytoskeletal US20110236397 A JJ I-UN
adaptor US20110236397 A NN I-UN
protein US20110236397 A NN I-UN
( US20110236397 A ( O
CD2AP US20110236397 A NNP I-UN
) US20110236397 A ) O
for US20110236397 A IN O
degradation US20110236397 A NN O
, US20110236397 A , O
compositions US20110236397 A NNS O
which US20110236397 A WDT O
modulate US20110236397 A VBP O
expression US20110236397 A NN O
or US20110236397 A CC O
function US20110236397 A NN O
of US20110236397 A IN O
cytoskeletal US20110236397 A JJ I-UN
adaptor US20110236397 A NN I-UN
protein US20110236397 A NN I-UN
( US20110236397 A ( O
CD2AP US20110236397 A NNP I-UN
) US20110236397 A ) O
, US20110236397 A , O
protect US20110236397 A VBP O
against US20110236397 A IN O
renal US20110236397 A JJ O
diseases US20110236397 A NNS O
or US20110236397 A CC O
disorders US20110236397 A NNS O
. US20110236397 A . O

Enantiomeric EP1626709A1 T JJ O
amphetamine EP1626709A1 T NN O
compositions EP1626709A1 T NNS O
for EP1626709A1 T IN O
the EP1626709A1 T DT O
treatment EP1626709A1 T NN O
of EP1626709A1 T IN O
adhd EP1626709A1 T NN O
. EP1626709A1 T . O

Itching-relieving CN102397231A T JJ O
and CN102397231A T CC O
skin-moisturizing CN102397231A T JJ O
soaking CN102397231A T VBG O
bath CN102397231A T NN O
paste CN102397231A T NN O
. CN102397231A T . O

The CN102397231A A DT O
invention CN102397231A A NN O
relates CN102397231A A VBZ O
to CN102397231A A TO O
the CN102397231A A DT O
technical CN102397231A A JJ O
field CN102397231A A NN O
of CN102397231A A IN O
a CN102397231A A DT O
bath CN102397231A A NN O
supply CN102397231A A NN O
and CN102397231A A CC O
discloses CN102397231A A VBZ O
an CN102397231A A DT O
itching-relieving CN102397231A A JJ O
and CN102397231A A CC O
skin-moisturizing CN102397231A A JJ O
soaking CN102397231A A VBG O
bath CN102397231A A NN O
paste CN102397231A A NN O
. CN102397231A A . O

A CN102397231A A DT O
preparation CN102397231A A NN O
process CN102397231A A NN O
of CN102397231A A IN O
the CN102397231A A DT O
itching-relieving CN102397231A A JJ O
and CN102397231A A CC O
skin-moisturizing CN102397231A A JJ O
soaking CN102397231A A VBG O
bath CN102397231A A NN O
paste CN102397231A A NN O
comprises CN102397231A A VBZ O
the CN102397231A A DT O
following CN102397231A A JJ O
steps CN102397231A A NNS O
of CN102397231A A IN O
: CN102397231A A : O
preparing CN102397231A A VBG O
the CN102397231A A DT O
following CN102397231A A JJ O
formula CN102397231A A NN O
medicaments CN102397231A A NNS O
in CN102397231A A IN O
percentage CN102397231A A NN O
by CN102397231A A IN O
weight CN102397231A A NN O
: CN102397231A A : O
2 CN102397231A A CD O
percent CN102397231A A NN O
of CN102397231A A IN O
ginseng CN102397231A A NN O
extract CN102397231A A NN O
, CN102397231A A , O
2 CN102397231A A CD O
percent CN102397231A A NN O
of CN102397231A A IN O
lucid CN102397231A A NN O
ganoderma CN102397231A A NN O
, CN102397231A A , O
4 CN102397231A A CD O
percent CN102397231A A NN O
of CN102397231A A IN O
twotooth CN102397231A A JJ O
achyranthes CN102397231A A NNS O
root CN102397231A A NN O
, CN102397231A A , O
5 CN102397231A A CD O
percent CN102397231A A NN O
of CN102397231A A IN O
divaricate CN102397231A A NN O
saposhnikovia CN102397231A A NN O
root CN102397231A A NN O
, CN102397231A A , O
4 CN102397231A A CD O
percent CN102397231A A NN O
of CN102397231A A IN O
rhizoma CN102397231A A NN O
atractylodis CN102397231A A NN O
, CN102397231A A , O
7 CN102397231A A CD O
percent CN102397231A A NN O
of CN102397231A A IN O
sinkiang CN102397231A A NN O
arnebia CN102397231A A NN O
root CN102397231A A NN O
, CN102397231A A , O
3 CN102397231A A CD O
percent CN102397231A A NN O
of CN102397231A A IN O
angelica CN102397231A A NN O
, CN102397231A A , O
3 CN102397231A A CD O
percent CN102397231A A NN O
of CN102397231A A IN O
medcinal CN102397231A A JJ O
evodia CN102397231A A NN O
fruit CN102397231A A NN O
, CN102397231A A , O
4 CN102397231A A CD O
percent CN102397231A A NN O
of CN102397231A A IN O
ephedra CN102397231A A NN O
, CN102397231A A , O
3 CN102397231A A CD O
percent CN102397231A A NN O
of CN102397231A A IN O
pawpaw CN102397231A A NN O
, CN102397231A A , O
1 CN102397231A A CD O
percent CN102397231A A NN O
of CN102397231A A IN O
ginkgo CN102397231A A NN O
and CN102397231A A CC O
1 CN102397231A A CD O
percent CN102397231A A NN O
of CN102397231A A IN O
lotus CN102397231A A JJ O
leaf CN102397231A A NN O
; CN102397231A A : O
soaking CN102397231A A VBG O
the CN102397231A A DT O
formula CN102397231A A NN O
medicaments CN102397231A A NNS O
by CN102397231A A IN O
mixing CN102397231A A VBG O
the CN102397231A A DT O
formula CN102397231A A NN O
medicaments CN102397231A A NNS O
withand CN102397231A A VBP O
millet CN102397231A A NN O
wine CN102397231A A NN O
for CN102397231A A IN O
two CN102397231A A CD O
times CN102397231A A NNS O
; CN102397231A A : O
combining CN102397231A A VBG O
the CN102397231A A DT O
medical CN102397231A A JJ O
solution CN102397231A A NN O
which CN102397231A A WDT O
is CN102397231A A VBZ O
prepared CN102397231A A VBN O
by CN102397231A A IN O
soaking CN102397231A A VBG O
the CN102397231A A DT O
formula CN102397231A A NN O
medicaments CN102397231A A NNS O
in CN102397231A A IN O
the CN102397231A A DT O
millet CN102397231A A NN O
wine CN102397231A A NN O
for CN102397231A A IN O
two CN102397231A A CD O
times CN102397231A A NNS O
; CN102397231A A : O
uniformly CN102397231A A RB O
mixing CN102397231A A VBG O
the CN102397231A A DT O
medical CN102397231A A JJ O
solution CN102397231A A NN O
; CN102397231A A : O
decocting CN102397231A A VBG O
the CN102397231A A DT O
residue CN102397231A A NN O
of CN102397231A A IN O
the CN102397231A A DT O
medicinal CN102397231A A JJ O
materials CN102397231A A NNS O
in CN102397231A A IN O
water CN102397231A A NN O
for CN102397231A A IN O
two CN102397231A A CD O
times CN102397231A A NNS O
; CN102397231A A : O
combining CN102397231A A VBG O
the CN102397231A A DT O
decoction CN102397231A A NN O
which CN102397231A A WDT O
is CN102397231A A VBZ O
prepared CN102397231A A VBN O
by CN102397231A A IN O
decocting CN102397231A A VBG O
the CN102397231A A DT O
residue CN102397231A A NN O
of CN102397231A A IN O
the CN102397231A A DT O
medicinal CN102397231A A JJ O
materials CN102397231A A NNS O
in CN102397231A A IN O
water CN102397231A A NN O
for CN102397231A A IN O
two CN102397231A A CD O
times CN102397231A A NNS O
; CN102397231A A : O
uniformly CN102397231A A RB O
mixing CN102397231A A VBG O
the CN102397231A A DT O
decoction CN102397231A A NN O
; CN102397231A A : O
cooling CN102397231A A VBG O
the CN102397231A A DT O
decoction CN102397231A A NN O
until CN102397231A A IN O
the CN102397231A A DT O
temperature CN102397231A A NN O
of CN102397231A A IN O
the CN102397231A A DT O
decoction CN102397231A A NN O
reaches CN102397231A A VBZ O
room CN102397231A A NN O
temperature CN102397231A A NN O
; CN102397231A A : O
adding CN102397231A A VBG O
ethanol CN102397231A A NN O
of CN102397231A A IN O
which CN102397231A A WDT O
the CN102397231A A DT O
concentration CN102397231A A NN O
is CN102397231A A VBZ O
95 CN102397231A A CD O
percent CN102397231A A NN O
into CN102397231A A IN O
the CN102397231A A DT O
decoction CN102397231A A NN O
; CN102397231A A : O
uniformly CN102397231A A RB O
mixing CN102397231A A VBG O
the CN102397231A A DT O
decoction CN102397231A A NN O
withand CN102397231A A VBP O
the CN102397231A A DT O
ethanol CN102397231A A NN O
; CN102397231A A : O
after CN102397231A A IN O
standing CN102397231A A VBG O
the CN102397231A A DT O
mixture CN102397231A A NN O
for CN102397231A A IN O
28 CN102397231A A CD O
to CN102397231A A TO O
36 CN102397231A A CD O
hours CN102397231A A NNS O
, CN102397231A A , O
filtering CN102397231A A VBG O
the CN102397231A A DT O
mixture CN102397231A A NN O
and CN102397231A A CC O
performing CN102397231A A JJ O
water CN102397231A A NN O
extraction CN102397231A A NN O
and CN102397231A A CC O
alcohol CN102397231A A NN O
precipitation CN102397231A A NN O
; CN102397231A A : O
uniformly CN102397231A A RB O
mixing CN102397231A A VBG O
the CN102397231A A DT O
supernatant CN102397231A A JJ O
fluid CN102397231A A NN O
withand CN102397231A A VBP O
the CN102397231A A DT O
medical CN102397231A A JJ O
solution CN102397231A A NN O
which CN102397231A A WDT O
is CN102397231A A VBZ O
prepared CN102397231A A VBN O
by CN102397231A A IN O
soaking CN102397231A A VBG O
the CN102397231A A DT O
formula CN102397231A A NN O
medicaments CN102397231A A NNS O
in CN102397231A A IN O
the CN102397231A A DT O
millet CN102397231A A NN O
wine CN102397231A A NN O
for CN102397231A A IN O
two CN102397231A A CD O
times CN102397231A A NNS O
; CN102397231A A : O
concentrating CN102397231A A VBG O
the CN102397231A A DT O
medical CN102397231A A JJ O
solution CN102397231A A NN O
by CN102397231A A IN O
heating CN102397231A A VBG O
the CN102397231A A DT O
medical CN102397231A A JJ O
solution CN102397231A A NN O
until CN102397231A A IN O
the CN102397231A A DT O
medical CN102397231A A JJ O
solution CN102397231A A NN O
becomes CN102397231A A VBZ O
pasty CN102397231A A JJ O
; CN102397231A A : O
adding CN102397231A A VBG O
20 CN102397231A A CD O
percent CN102397231A A NN O
of CN102397231A A IN O
deep-sea CN102397231A A NN O
minerals CN102397231A A NNS O
, CN102397231A A , O
10 CN102397231A A CD O
percent CN102397231A A NN O
of CN102397231A A IN O
deep-sea CN102397231A A NN O
seaweed CN102397231A A NN O
, CN102397231A A , O
3 CN102397231A A CD O
percent CN102397231A A NN O
of CN102397231A A IN O
rose CN102397231A A VBD O
essential CN102397231A A JJ O
oil CN102397231A A NN O
, CN102397231A A , O
5 CN102397231A A CD O
percent CN102397231A A NN O
of CN102397231A A IN O
aloe CN102397231A A JJ O
vera CN102397231A A NN O
gel CN102397231A A NN O
, CN102397231A A , O
1 CN102397231A A CD O
percent CN102397231A A NN O
of CN102397231A A IN O
borneol CN102397231A A NN O
and CN102397231A A CC O
a CN102397231A A DT O
proper CN102397231A A JJ O
amount CN102397231A A NN O
of CN102397231A A IN O
rice CN102397231A A NN O
vinegar CN102397231A A NN O
into CN102397231A A IN O
the CN102397231A A DT O
paste CN102397231A A NN O
; CN102397231A A : O
uniformly CN102397231A A RB O
mixing CN102397231A A VBG O
the CN102397231A A DT O
added CN102397231A A JJ O
materials CN102397231A A NNS O
withand CN102397231A A VBP O
the CN102397231A A DT O
paste CN102397231A A NN O
; CN102397231A A : O
filling CN102397231A A VBG O
the CN102397231A A DT O
mixture CN102397231A A NN O
into CN102397231A A IN O
bottles CN102397231A A NNS O
; CN102397231A A : O
and CN102397231A A CC O
vacuumizing CN102397231A A VBG O
and CN102397231A A CC O
sealing CN102397231A A VBG O
the CN102397231A A DT O
bottles CN102397231A A NNS O
. CN102397231A A . O

The CN102397231A A DT O
itching-relieving CN102397231A A JJ O
and CN102397231A A CC O
skin-moisturizing CN102397231A A JJ O
soaking CN102397231A A VBG O
bath CN102397231A A NN O
paste CN102397231A A NN O
is CN102397231A A VBZ O
clean CN102397231A A JJ O
, CN102397231A A , O
health-care CN102397231A A JJ O
and CN102397231A A CC O
bacteriocidal CN102397231A A JJ O
, CN102397231A A , O
is CN102397231A A VBZ O
convenient CN102397231A A JJ O
to CN102397231A A TO O
use CN102397231A A VB O
, CN102397231A A , O
can CN102397231A A MD O
relieve CN102397231A A VB O
itching CN102397231A A NN O
and CN102397231A A CC O
moisturize CN102397231A A VB O
skin CN102397231A A NN O
, CN102397231A A , O
promote CN102397231A A VBP O
blood CN102397231A A NN O
circulation CN102397231A A NN O
to CN102397231A A TO O
remove CN102397231A A VB O
meridian CN102397231A A JJ O
obstruction CN102397231A A NN O
, CN102397231A A , O
and CN102397231A A CC O
nourish CN102397231A A JJ O
Yin CN102397231A A NNP O
and CN102397231A A CC O
generate CN102397231A A VB O
body CN102397231A A NN O
fluid CN102397231A A NN O
, CN102397231A A , O
and CN102397231A A CC O
is CN102397231A A VBZ O
widely CN102397231A A RB O
applied CN102397231A A VBN O
to CN102397231A A TO O
the CN102397231A A DT O
prevention CN102397231A A NN O
of CN102397231A A IN O
skin CN102397231A A JJ O
itching CN102397231A A NN O
of CN102397231A A IN O
various CN102397231A A JJ O
symptoms CN102397231A A NNS O
. CN102397231A A . O

N-heterocyclic EP1278521B1 T JJ O
substituted EP1278521B1 T VBD O
salicylates EP1278521B1 T NNS O
for EP1278521B1 T IN O
the EP1278521B1 T DT O
treatment EP1278521B1 T NN O
of EP1278521B1 T IN O
cancer EP1278521B1 T NN O
. EP1278521B1 T . O

Preparations WO2009080778A4 T NNS O
with WO2009080778A4 T IN O
rosehip WO2009080778A4 T NN O
extracts WO2009080778A4 T NNS O
, WO2009080778A4 T , O
and WO2009080778A4 T CC O
method WO2009080778A4 T NN O
of WO2009080778A4 T IN O
producing WO2009080778A4 T VBG O
rosehip WO2009080778A4 T NN O
extracts WO2009080778A4 T NNS O
. WO2009080778A4 T . O

Plaster CN103462941A T NN O
for CN103462941A T IN O
treating CN103462941A T VBG O
oral CN103462941A T JJ O
ulcer CN103462941A T NN O
and CN103462941A T CC O
preparation CN103462941A T NN O
method CN103462941A T NN O
of CN103462941A T IN O
plaster CN103462941A T NN O
. CN103462941A T . O

Drug CN102327315A T NNP O
combination CN102327315A T NN O
containing CN102327315A T VBG O
astragalus CN102327315A T NN O
and CN102327315A T CC O
use CN102327315A T NN O
thereof CN102327315A T NN O
. CN102327315A T . O

Vitamin CN1823829A T NNP O
micro CN1823829A T PRP O
element CN1823829A T JJ O
mineral CN1823829A T JJ O
calcium CN1823829A T NN O
nutritive CN1823829A T JJ O
product CN1823829A T NN O
for CN1823829A T IN O
preventing CN1823829A T VBG O
pseudomyopia CN1823829A T NN O
and CN1823829A T CC O
roal CN1823829A T NN O
myopia CN1823829A T NN O
and CN1823829A T CC O
its CN1823829A T PRP$ O
manufacturing CN1823829A T NN O
method CN1823829A T NN O
. CN1823829A T . O

Neuronal WO2013177510A1 T NNP I-UN
nicotinic WO2013177510A1 T JJ I-UN
receptor WO2013177510A1 T NN I-UN
agonists WO2013177510A1 T NNS O
for WO2013177510A1 T IN O
treating WO2013177510A1 T VBG O
schizophrenia WO2013177510A1 T NN O
in WO2013177510A1 T IN O
patients WO2013177510A1 T NNS O
with WO2013177510A1 T IN O
variants WO2013177510A1 T NNS O
of WO2013177510A1 T IN O
comt WO2013177510A1 T JJ I-UN
gene WO2013177510A1 T NN I-UN
. WO2013177510A1 T . O

This WO2013177510A1 A DT O
application WO2013177510A1 A NN O
is WO2013177510A1 A VBZ O
directed WO2013177510A1 A VBN O
to WO2013177510A1 A TO O
α-neuronal WO2013177510A1 A JJ I-UN
nicotinic WO2013177510A1 A JJ I-UN
receptor WO2013177510A1 A NN I-UN
agonists WO2013177510A1 A NNS O
selective WO2013177510A1 A VBP O
for WO2013177510A1 A IN O
α7-subtype WO2013177510A1 A NN O
that WO2013177510A1 A WDT O
are WO2013177510A1 A VBP O
useful WO2013177510A1 A JJ O
for WO2013177510A1 A IN O
improving WO2013177510A1 A VBG O
cognition WO2013177510A1 A NN O
impairment WO2013177510A1 A NN O
in WO2013177510A1 A IN O
patients WO2013177510A1 A NNS O
having WO2013177510A1 A VBG O
schizophrenia WO2013177510A1 A NN O
, WO2013177510A1 A , O
a WO2013177510A1 A DT O
schizophreniform WO2013177510A1 A NN O
disorder WO2013177510A1 A NN O
or WO2013177510A1 A CC O
a WO2013177510A1 A DT O
related WO2013177510A1 A JJ O
schizophrenia WO2013177510A1 A NN O
spectrum WO2013177510A1 A NN O
psychotic WO2013177510A1 A JJ O
disorder WO2013177510A1 A NN O
. WO2013177510A1 A . O

New EP2117540A1 T NNP O
use EP2117540A1 T NN O
of EP2117540A1 T IN O
glutaminyl EP2117540A1 T JJ I-UN
cyclase EP2117540A1 T NN I-UN
inhibitors EP2117540A1 T NNS O
. EP2117540A1 T . O

The EP2117540A1 A DT O
present EP2117540A1 A JJ O
invention EP2117540A1 A NN O
relates EP2117540A1 A VBZ O
in EP2117540A1 A IN O
general EP2117540A1 A JJ O
to EP2117540A1 A TO O
an EP2117540A1 A DT O
inhibitor EP2117540A1 A NN O
of EP2117540A1 A IN O
a EP2117540A1 A DT O
glutaminyl EP2117540A1 A JJ I-UN
peptide EP2117540A1 A NN I-UN
cyclotransferase EP2117540A1 A NN I-UN
, EP2117540A1 A , O
and EP2117540A1 A CC O
use EP2117540A1 A VB O
thereof EP2117540A1 A NN O
for EP2117540A1 A IN O
the EP2117540A1 A DT O
treatment EP2117540A1 A NN O
and/or EP2117540A1 A JJ O
prevention EP2117540A1 A NN O
of EP2117540A1 A IN O
a EP2117540A1 A DT O
disease EP2117540A1 A NN O
or EP2117540A1 A CC O
disorder EP2117540A1 A NN O
selected EP2117540A1 A VBN O
from EP2117540A1 A IN O
the EP2117540A1 A DT O
group EP2117540A1 A NN O
consisting EP2117540A1 A VBG O
of EP2117540A1 A IN O
inflammatory EP2117540A1 A JJ O
diseases EP2117540A1 A NNS O
selected EP2117540A1 A VBN O
from EP2117540A1 A IN O
a. EP2117540A1 A JJ O
neurodegenerative EP2117540A1 A JJ O
diseases EP2117540A1 A NNS O
, EP2117540A1 A , O
e.g EP2117540A1 A NN O
. EP2117540A1 A . O

Allicin CN101112360A T NNP O
fatty CN101112360A T JJ O
milk CN101112360A T NN O
injection CN101112360A T NN O
and CN101112360A T CC O
preparation CN101112360A T NN O
technics CN101112360A T NNS O
thereof CN101112360A T NN O
. CN101112360A T . O

Method CN1568953A T NNP O
for CN1568953A T IN O
preparing CN1568953A T VBG O
mental CN1568953A T JJ O
disease CN1568953A T NN O
resistant CN1568953A T JJ O
medicine CN1568953A T NN O
containing CN1568953A T VBG O
succinic CN1568953A T JJ O
acid CN1568953A T NN O
. CN1568953A T . O

SUBSTITUTED US20090197878 T NNP O
BENZO US20090197878 T NNP O
[ US20090197878 T NNP O
d US20090197878 T NN O
] US20090197878 T NNP O
[ US20090197878 T VBZ O
1,3 US20090197878 T CD O
] US20090197878 T JJ O
OXAZIN-2 US20090197878 T NNP O
( US20090197878 T ( O
4H US20090197878 T CD O
) US20090197878 T ) O
-ONES US20090197878 T NN O
AND US20090197878 T NNP O
RELATED US20090197878 T NNP O
DERIVATIVES US20090197878 T NNP O
AND US20090197878 T NNP O
THEIR US20090197878 T NNP O
USES US20090197878 T NNP O
FOR US20090197878 T NNP O
MODULATING US20090197878 T NNP O
THE US20090197878 T NNP O
PROGESTERONE US20090197878 T NNP O
RECEPTOR US20090197878 T NNP O
. US20090197878 T . O

Biomarkers US20100209350 T NNS O
for US20100209350 T IN O
Adipose US20100209350 T NNP O
Tissue US20100209350 T NNP O
Activity US20100209350 T NNP O
. US20100209350 T . O

In US20100209350 A IN O
one US20100209350 A CD O
embodiment US20100209350 A NN O
, US20100209350 A , O
the US20100209350 A DT O
composition US20100209350 A NN O
comprises US20100209350 A VBZ O
a US20100209350 A DT O
solid US20100209350 A JJ O
support US20100209350 A NN O
comprising US20100209350 A VBG O
probes US20100209350 A NNS O
for US20100209350 A IN O
measuring US20100209350 A VBG O
a US20100209350 A DT O
biomarker US20100209350 A NN O
panel US20100209350 A NN O
comprising US20100209350 A NN O
, US20100209350 A , O
for US20100209350 A IN O
example US20100209350 A NN O
, US20100209350 A , O
adiponectin US20100209350 A NN I-UN
, US20100209350 A , O
resistin US20100209350 A NN I-UN
, US20100209350 A , O
PAI-1 US20100209350 A NNP I-UN
, US20100209350 A , O
optionally US20100209350 A RB O
leptin US20100209350 A JJ I-UN
and US20100209350 A CC O
optionally US20100209350 A RB O
visfatin US20100209350 A NNS I-UN
. US20100209350 A . O

Novel EP1784381A1 T NNP O
substituted EP1784381A1 T VBD O
aryloxy EP1784381A1 T JJ O
alkylamines EP1784381A1 T NNS O
and EP1784381A1 T CC O
their EP1784381A1 T PRP$ O
use EP1784381A1 T NN O
as EP1784381A1 T IN O
monoamine EP1784381A1 T JJ O
neurotransmitter EP1784381A1 T IN O
re-uptake EP1784381A1 T JJ O
inhibitors EP1784381A1 T NNS O
. EP1784381A1 T . O

Anticholinergic CN103553996A T NNP O
pharmaceutical CN103553996A T JJ O
composition CN103553996A T NN O
. CN103553996A T . O

Aryl WO2011138657A1 T NNP O
substituted WO2011138657A1 T VBD O
olefinic WO2011138657A1 T JJ O
compounds WO2011138657A1 T NNS O
as WO2011138657A1 T IN O
pde10a WO2011138657A1 T JJ I-UN
inhibitors WO2011138657A1 T NNS O
. WO2011138657A1 T . O

The WO2011138657A1 A DT O
present WO2011138657A1 A JJ O
invention WO2011138657A1 A NN O
provides WO2011138657A1 A VBZ O
aryl WO2011138657A1 A RB O
substituted WO2011138657A1 A VBN O
olefinic WO2011138657A1 A JJ O
compounds WO2011138657A1 A NNS O
as WO2011138657A1 A IN O
Phosphodiesterase WO2011138657A1 A NNP I-UN
1 WO2011138657A1 A CD I-UN
0A WO2011138657A1 A CD I-UN
( WO2011138657A1 A ( O
PDE WO2011138657A1 A NNP I-UN
1 WO2011138657A1 A CD I-UN
0A WO2011138657A1 A CD I-UN
) WO2011138657A1 A ) O
inhibitors WO2011138657A1 A NNS O
. WO2011138657A1 A . O

In WO2011138657A1 A IN O
particular WO2011138657A1 A JJ O
, WO2011138657A1 A , O
compounds WO2011138657A1 A VBZ O
described WO2011138657A1 A JJ O
herein WO2011138657A1 A NNS O
are WO2011138657A1 A VBP O
useful WO2011138657A1 A JJ O
for WO2011138657A1 A IN O
treating WO2011138657A1 A VBG O
or WO2011138657A1 A CC O
preventing WO2011138657A1 A VBG O
diseases WO2011138657A1 A NNS O
, WO2011138657A1 A , O
conditions WO2011138657A1 A NNS O
and/or WO2011138657A1 A VBP O
disorders WO2011138657A1 A NNS O
by WO2011138657A1 A IN O
inhibiting WO2011138657A1 A VBG O
Phosphodiesterase WO2011138657A1 A NNP I-UN
1 WO2011138657A1 A CD I-UN
0A WO2011138657A1 A CD I-UN
enzyme WO2011138657A1 A NN O
. WO2011138657A1 A . O

Para-amino US20050054582 T NNP O
benzoic US20050054582 T NN O
acids US20050054582 T NNS O
as US20050054582 T IN O
integrin US20050054582 T JJ O
antagonists US20050054582 T NNS O
. US20050054582 T . O

Compositions WO2012104571A1 T NNS O
of WO2012104571A1 T IN O
monoterpenoids WO2012104571A1 T NNS O
for WO2012104571A1 T IN O
the WO2012104571A1 T DT O
treatment WO2012104571A1 T NN O
of WO2012104571A1 T IN O
influenza WO2012104571A1 T NN O
. WO2012104571A1 T . O

Preparation CN102477014A T NNP O
method CN102477014A T NN O
of CN102477014A T IN O
histamine CN102477014A T JJ O
dihydrochloride CN102477014A T NN O
. CN102477014A T . O

Oxazolidinone US20090012089 T NNP O
Compounds US20090012089 T NNP O
and US20090012089 T CC O
Their US20090012089 T NNP O
Use US20090012089 T NNP O
as US20090012089 T IN O
Metabotropic US20090012089 T NNP O
Glutamate US20090012089 T NNP O
Receptor US20090012089 T NNP O
Potentiators US20090012089 T NNPS O
. US20090012089 T . O

Method US6906092 T NNP O
of US6906092 T IN O
inhibiting US6906092 T VBG O
matrix US6906092 T NN I-UN
metalloproteinases US6906092 T NNS I-UN
. US6906092 T . O

The US6906092 A DT O
present US6906092 A JJ O
invention US6906092 A NN O
relates US6906092 A VBZ O
to US6906092 A TO O
a US6906092 A DT O
method US6906092 A NN O
of US6906092 A IN O
inhibiting US6906092 A VBG O
matrix US6906092 A NN I-UN
metalloproteinases US6906092 A NNS I-UN
using US6906092 A VBG O
compounds US6906092 A NNS O
that US6906092 A WDT O
are US6906092 A VBP O
dibenzofuran US6906092 A JJ O
sulfonamide US6906092 A NN O
derivatives US6906092 A NNS O
having US6906092 A VBG O
the US6906092 A DT O
Formula US6906092 A NNP O
I US6906092 A PRP O
More US6906092 A JJR O
particularly US6906092 A RB O
, US6906092 A , O
the US6906092 A DT O
present US6906092 A JJ O
invention US6906092 A NN O
relates US6906092 A VBZ O
to US6906092 A TO O
a US6906092 A DT O
method US6906092 A NN O
of US6906092 A IN O
treating US6906092 A VBG O
diseases US6906092 A NNS O
in US6906092 A IN O
which US6906092 A WDT O
matrix US6906092 A NN I-UN
metalloproteinases US6906092 A NNS I-UN
are US6906092 A VBP O
involved US6906092 A VBN O
such US6906092 A JJ O
as US6906092 A IN O
multiple US6906092 A JJ O
sclerosis US6906092 A NN O
, US6906092 A , O
atherosclerotic US6906092 A JJ O
plaque US6906092 A NN O
rupture US6906092 A NN O
, US6906092 A , O
restenosis US6906092 A NN O
, US6906092 A , O
aortic US6906092 A JJ O
aneurism US6906092 A NN O
, US6906092 A , O
heart US6906092 A NN O
failure US6906092 A NN O
, US6906092 A , O
periodontal US6906092 A JJ O
disease US6906092 A NN O
, US6906092 A , O
corneal US6906092 A JJ O
ulceration US6906092 A NN O
, US6906092 A , O
burns US6906092 A NNS O
, US6906092 A , O
decubital US6906092 A JJ O
ulcers US6906092 A NNS O
, US6906092 A , O
chronic US6906092 A JJ O
ulcers US6906092 A NNS O
or US6906092 A CC O
wounds US6906092 A NNS O
, US6906092 A , O
cancer US6906092 A NN O
metastasis US6906092 A NN O
, US6906092 A , O
tumor US6906092 A NN O
angiogenesis US6906092 A NN O
, US6906092 A , O
arthritis US6906092 A NN O
, US6906092 A , O
or US6906092 A CC O
other US6906092 A JJ O
autoimmune US6906092 A NN O
or US6906092 A CC O
inflammatory US6906092 A NN O
diseases US6906092 A NNS O
dependent US6906092 A JJ O
upon US6906092 A IN O
tissue US6906092 A NN O
invasion US6906092 A NN O
by US6906092 A IN O
leukocytes US6906092 A NNS O
. US6906092 A . O

Substituted US6946489 T VBN O
biphenyl US6946489 T JJ O
derivatives US6946489 T NNS O
. US6946489 T . O

The US6946489 A DT O
compounds US6946489 A NNS O
act US6946489 A NN O
as US6946489 A IN O
inhibitors US6946489 A NNS O
of US6946489 A IN O
factors US6946489 A NNS I-UN
Xa US6946489 A NNP I-UN
and US6946489 A CC I-UN
VIIa US6946489 A NNP I-UN
and US6946489 A CC O
can US6946489 A MD O
therefore US6946489 A RB O
be US6946489 A VB O
employed US6946489 A VBN O
for US6946489 A IN O
the US6946489 A DT O
control US6946489 A NN O
and US6946489 A CC O
prevention US6946489 A NN O
of US6946489 A IN O
thromboembolic US6946489 A JJ O
conditions US6946489 A NNS O
such US6946489 A JJ O
as US6946489 A IN O
thrombosis US6946489 A NN O
, US6946489 A , O
myocardial US6946489 A JJ O
infarct US6946489 A NN O
, US6946489 A , O
arteriosclerosis US6946489 A NN O
, US6946489 A , O
inflammation US6946489 A NN O
, US6946489 A , O
apoplexy US6946489 A NN O
, US6946489 A , O
angina US6946489 A JJ O
pectoris US6946489 A NN O
, US6946489 A , O
restenosis US6946489 A NN O
after US6946489 A IN O
angioplasty US6946489 A JJ O
and US6946489 A CC O
intermittent US6946489 A JJ O
claudication US6946489 A NN O
. US6946489 A . O

Lipstatin US7393545 T NNP O
derivative—soluble US7393545 T JJ O
fiber US7393545 T NN O
tablets US7393545 T NNS O
. US7393545 T . O

Compositions US20090048198 T NNS O
and US20090048198 T CC O
methods US20090048198 T NNS O
for US20090048198 T IN O
nucleic US20090048198 T JJ O
acid US20090048198 T JJ O
delivery US20090048198 T NN O
systems US20090048198 T NNS O
. US20090048198 T . O

Composition CN101091700B T NN O
of CN101091700B T IN O
slow CN101091700B T JJ O
( CN101091700B T ( O
controlled CN101091700B T VBN O
) CN101091700B T ) O
releasing CN101091700B T VBG O
preparation CN101091700B T NN O
of CN101091700B T IN O
Quetiadine CN101091700B T NNP O
Hemifumarate CN101091700B T NNP O
, CN101091700B T , O
and CN101091700B T CC O
application CN101091700B T NN O
. CN101091700B T . O

Combination US20110250142 T NN O
therapies US20110250142 T NNS O
for US20110250142 T IN O
treatment US20110250142 T NN O
of US20110250142 T IN O
hypertension US20110250142 T NN O
and US20110250142 T CC O
complications US20110250142 T NNS O
in US20110250142 T IN O
patients US20110250142 T NNS O
with US20110250142 T IN O
diabetes US20110250142 T NNS O
or US20110250142 T CC O
metabolic US20110250142 T JJ O
syndrome US20110250142 T NN O
. US20110250142 T . O

More US20110250142 A RBR O
particularly US20110250142 A RB O
, US20110250142 A , O
aspects US20110250142 A NNS O
of US20110250142 A IN O
the US20110250142 A DT O
present US20110250142 A JJ O
invention US20110250142 A NN O
are US20110250142 A VBP O
related US20110250142 A VBN O
to US20110250142 A TO O
using US20110250142 A VBG O
a US20110250142 A DT O
combination US20110250142 A NN O
of US20110250142 A IN O
cicletanine US20110250142 A NN O
and US20110250142 A CC O
a US20110250142 A DT O
second US20110250142 A JJ O
antihypertensive US20110250142 A JJ O
agent US20110250142 A NN O
( US20110250142 A ( O
preferably US20110250142 A RB O
a US20110250142 A DT O
calcium US20110250142 A NN O
antagonist US20110250142 A NN O
, US20110250142 A , O
an US20110250142 A DT O
ACE US20110250142 A NNP I-UN
inhibitor US20110250142 A NN O
, US20110250142 A , O
or US20110250142 A CC O
an US20110250142 A DT O
angiotensin US20110250142 A JJ O
II US20110250142 A NNP O
receptor US20110250142 A NN O
antagonist US20110250142 A NN O
) US20110250142 A ) O
for US20110250142 A IN O
treating US20110250142 A VBG O
and/or US20110250142 A JJ O
preventing US20110250142 A VBG O
hypertension US20110250142 A NN O
and US20110250142 A CC O
complications US20110250142 A NNS O
in US20110250142 A IN O
patients US20110250142 A NNS O
with US20110250142 A IN O
diabetes US20110250142 A NNS O
and/or US20110250142 A VBP O
metabolic US20110250142 A JJ O
syndrome US20110250142 A NN O
. US20110250142 A . O

Methods US20110021981 T NNS O
And US20110021981 T CC O
Compositions US20110021981 T NNP O
For US20110021981 T IN O
Treating US20110021981 T VBG O
Trauma-Hemorrhage US20110021981 T NN O
Using US20110021981 T NNP O
Estrogen US20110021981 T NNP O
And US20110021981 T CC O
Derivatives US20110021981 T NNP O
Thereof US20110021981 T NNP O
. US20110021981 T . O

Application CN103006633A T NN O
of CN103006633A T IN O
hydroxysafflor CN103006633A T NN O
yellow CN103006633A T IN O
A CN103006633A T NNP O
in CN103006633A T IN O
preparation CN103006633A T NN O
of CN103006633A T IN O
medicament CN103006633A T NN O
for CN103006633A T IN O
resisting CN103006633A T VBG O
Alzheimer CN103006633A T NNP O
disease CN103006633A T NN O
. CN103006633A T . O

Body US20060034939 T NNP O
cavity US20060034939 T NN O
washer US20060034939 T NN O
, US20060034939 T , O
device US20060034939 T NN O
for US20060034939 T IN O
washing US20060034939 T VBG O
body US20060034939 T NN O
cavity US20060034939 T NN O
and US20060034939 T CC O
method US20060034939 T NN O
of US20060034939 T IN O
washing US20060034939 T VBG O
body US20060034939 T NN O
cavity US20060034939 T NN O
. US20060034939 T . O

2- US7709480 T JJ O
( US7709480 T ( O
3,4-dichlorophenylamino US7709480 T JJ O
) US7709480 T ) O
-4-thiocyanato-5-nitro-pyrimidine US7709480 T NN O
; US7709480 T : O
2-chloro-4- US7709480 T JJ O
( US7709480 T ( O
2-acetylamino-ethylamino US7709480 T JJ O
) US7709480 T ) O
-5-trifluoromethyl-pyrimidine US7709480 T NN O
; US7709480 T : O
lung US7709480 T NN O
cancer US7709480 T NN O
. US7709480 T . O

Compounds US7425568 T NNS O
, US7425568 T , O
which US7425568 T WDT O
are US7425568 T VBP O
potent US7425568 T JJ O
inhibitors US7425568 T NNS O
of US7425568 T IN O
Na+ US7425568 T NNP O
/Ca2+ US7425568 T NNP O
exchange US7425568 T NN O
mechanism US7425568 T NN O
and US7425568 T CC O
are US7425568 T VBP O
useful US7425568 T JJ O
in US7425568 T IN O
the US7425568 T DT O
treatment US7425568 T NN O
of US7425568 T IN O
arrhythmias US7425568 T NN O
. US7425568 T . O

Oligomer-Beta US20100227865 T JJ O
Blocker US20100227865 T NNP O
Conjugates US20100227865 T NNP O
. US20100227865 T . O

Oral CN1903211A T NNP O
disintegrant CN1903211A T JJ O
tablets CN1903211A T NNS O
type CN1903211A T VBP O
medicine CN1903211A T NN O
for CN1903211A T IN O
treating CN1903211A T VBG O
liver CN1903211A T JJ O
disease CN1903211A T NN O
. CN1903211A T . O

3- WO2010114179A1 T JJ O
[ WO2010114179A1 T NN O
1,4 WO2010114179A1 T CD O
] WO2010114179A1 T JJ O
oxazepane-4-pyrimidone WO2010114179A1 T JJ O
derivatives WO2010114179A1 T NNS O
. WO2010114179A1 T . O

A WO2010114179A1 A DT O
compound WO2010114179A1 A NN O
represented WO2010114179A1 A VBN O
by WO2010114179A1 A IN O
the WO2010114179A1 A DT O
formula WO2010114179A1 A NN O
( WO2010114179A1 A ( O
I WO2010114179A1 A PRP O
) WO2010114179A1 A ) O
or WO2010114179A1 A CC O
a WO2010114179A1 A DT O
pharmaceutically WO2010114179A1 A RB O
acceptable WO2010114179A1 A JJ O
salt WO2010114179A1 A NN O
thereof WO2010114179A1 A NN O
: WO2010114179A1 A : O
wherein WO2010114179A1 A NN O
Z WO2010114179A1 A NNP O
represents WO2010114179A1 A VBZ O
nitrogen WO2010114179A1 A JJ O
atom WO2010114179A1 A NN O
, WO2010114179A1 A , O
C-F WO2010114179A1 A NNP O
or WO2010114179A1 A CC O
the WO2010114179A1 A DT O
like WO2010114179A1 A JJ O
; WO2010114179A1 A : O
R1 WO2010114179A1 A NNP O
represents WO2010114179A1 A VBZ O
a WO2010114179A1 A DT O
C1-C3 WO2010114179A1 A JJ O
alkyl WO2010114179A1 A NN O
group WO2010114179A1 A NN O
; WO2010114179A1 A : O
Y WO2010114179A1 A CC O
represents WO2010114179A1 A VBZ O
oxygen WO2010114179A1 A JJ O
atom WO2010114179A1 A NN O
or WO2010114179A1 A CC O
N-R7 WO2010114179A1 A NNP O
; WO2010114179A1 A : O
R2 WO2010114179A1 A NNP O
, WO2010114179A1 A , O
R3 WO2010114179A1 A NNP O
, WO2010114179A1 A , O
R4 WO2010114179A1 A NNP O
, WO2010114179A1 A , O
R5 WO2010114179A1 A NNP O
, WO2010114179A1 A , O
R6 WO2010114179A1 A NNP O
and WO2010114179A1 A CC O
R7 WO2010114179A1 A NNP O
each WO2010114179A1 A DT O
independently WO2010114179A1 A RB O
represents WO2010114179A1 A VBZ O
hydrogen WO2010114179A1 A NN O
atom WO2010114179A1 A NN O
, WO2010114179A1 A , O
a WO2010114179A1 A DT O
C1-C6 WO2010114179A1 A NNP O
alkyl WO2010114179A1 A NN O
group WO2010114179A1 A NN O
, WO2010114179A1 A , O
or WO2010114179A1 A CC O
a WO2010114179A1 A DT O
group WO2010114179A1 A NN O
represented WO2010114179A1 A VBN O
by WO2010114179A1 A IN O
the WO2010114179A1 A DT O
formula WO2010114179A1 A NN O
( WO2010114179A1 A ( O
II WO2010114179A1 A NNP O
) WO2010114179A1 A ) O
: WO2010114179A1 A : O
which WO2010114179A1 A WDT O
is WO2010114179A1 A VBZ O
used WO2010114179A1 A VBN O
for WO2010114179A1 A IN O
preventive WO2010114179A1 A JJ O
and/or WO2010114179A1 A JJ O
therapeutic WO2010114179A1 A JJ O
treatment WO2010114179A1 A NN O
of WO2010114179A1 A IN O
a WO2010114179A1 A DT O
disease WO2010114179A1 A NN O
caused WO2010114179A1 A VBN O
by WO2010114179A1 A IN O
tau WO2010114179A1 A NN I-UN
protein WO2010114179A1 A NN I-UN
kinase WO2010114179A1 A VBD I-UN
1 WO2010114179A1 A CD I-UN
hyperactivity WO2010114179A1 A NN O
such WO2010114179A1 A JJ O
as WO2010114179A1 A IN O
a WO2010114179A1 A DT O
neurodegenerative WO2010114179A1 A JJ O
diseases WO2010114179A1 A NNS O
( WO2010114179A1 A ( O
e.g WO2010114179A1 A NN O
. WO2010114179A1 A . O

1- CN101440096A T JJ O
( CN101440096A T ( O
3',4',5'- CN101440096A T JJ O
trisubstituted CN101440096A T VBN O
phenyl CN101440096A T NN O
) CN101440096A T ) O
- CN101440096A T : O
tetrahydroisoquinoline CN101440096A T NN O
compound CN101440096A T NN O
and CN101440096A T CC O
its CN101440096A T PRP$ O
use CN101440096A T NN O
. CN101440096A T . O

PSMA US7850971 T NNP O
antibodies US7850971 T NNS O
and US7850971 T CC O
protein US7850971 T NN O
multimers US7850971 T NNS O
. US7850971 T . O

Febuxostat CN101711743B T NNP O
dry CN101711743B T JJ O
suspension CN101711743B T NN O
and CN101711743B T CC O
preparation CN101711743B T NN O
method CN101711743B T NN O
thereof CN101711743B T NN O
. CN101711743B T . O

Applications CN103550215A T NNS O
of CN103550215A T IN O
peptides CN103550215A T NNS O
compound CN103550215A T NN O
in CN103550215A T IN O
rhizome CN103550215A T JJ O
sparganii CN103550215A T NN O
. CN103550215A T . O

The CN103550215A A DT O
peptides CN103550215A A NNS O
compound CN103550215A A NN O
obtained CN103550215A A VBN O
by CN103550215A A IN O
separating CN103550215A A VBG O
and CN103550215A A CC O
purifying CN103550215A A VBG O
rhizome CN103550215A A JJ O
sparganii CN103550215A A NN O
, CN103550215A A , O
and CN103550215A A CC O
applications CN103550215A A NNS O
thereof CN103550215A A NNS O
are CN103550215A A VBP O
provided CN103550215A A VBN O
for CN103550215A A IN O
the CN103550215A A DT O
first CN103550215A A JJ O
time CN103550215A A NN O
, CN103550215A A , O
the CN103550215A A DT O
compound CN103550215A A NN O
plays CN103550215A A VBZ O
a CN103550215A A DT O
role CN103550215A A NN O
in CN103550215A A IN O
prolonging CN103550215A A VBG O
the CN103550215A A DT O
prothrombin CN103550215A A NN I-UN
time CN103550215A A NN O
( CN103550215A A ( O
PT CN103550215A A NNP O
) CN103550215A A ) O
, CN103550215A A , O
activated CN103550215A A VBN O
partial CN103550215A A JJ O
thromboplastin CN103550215A A NN O
time CN103550215A A NN O
( CN103550215A A ( O
APTT CN103550215A A NNP O
) CN103550215A A ) O
and CN103550215A A CC O
thrombin CN103550215A A JJ I-UN
time CN103550215A A NN O
( CN103550215A A ( O
TT CN103550215A A NNP O
) CN103550215A A ) O
, CN103550215A A , O
has CN103550215A A VBZ O
good CN103550215A A JJ O
anticoagulation CN103550215A A NN O
activity CN103550215A A NN O
, CN103550215A A , O
and CN103550215A A CC O
provides CN103550215A A VBZ O
a CN103550215A A DT O
powerful CN103550215A A JJ O
basis CN103550215A A NN O
for CN103550215A A IN O
developing CN103550215A A VBG O
natural CN103550215A A JJ O
antithrombosis CN103550215A A NN O
medicaments CN103550215A A NNS O
. CN103550215A A . O

Oral US20050163839 T NNP O
controlled US20050163839 T VBD O
release US20050163839 T VB O
pharmaceutical US20050163839 T JJ O
composition US20050163839 T NN O
containing US20050163839 T VBG O
metaxalone US20050163839 T NN O
as US20050163839 T IN O
active US20050163839 T JJ O
agent US20050163839 T NN O
. US20050163839 T . O

New CN101336924B T NNP O
use CN101336924B T NN O
of CN101336924B T IN O
cardiac CN101336924B T JJ O
glycoside CN101336924B T NN O
in CN101336924B T IN O
calotropis CN101336924B T NN O
gigantea CN101336924B T NN O
for CN101336924B T IN O
anti-tumour CN101336924B T NN O
. CN101336924B T . O

Dedicated CN103417538A T VBN O
liquid CN103417538A T JJ O
medicine CN103417538A T NN O
, CN103417538A T , O
dedicated CN103417538A T VBN O
tool CN103417538A T NN O
and CN103417538A T CC O
method CN103417538A T NN O
for CN103417538A T IN O
building CN103417538A T VBG O
animal CN103417538A T JJ O
model CN103417538A T NN O
of CN103417538A T IN O
parkinson CN103417538A T NN O
's CN103417538A T POS O
disease CN103417538A T NN O
through CN103417538A T IN O
intracerebral CN103417538A T JJ O
administration CN103417538A T NN O
. CN103417538A T . O

Ganciclovir CN103462930A T NNP O
capsule CN103462930A T NN O
preparation CN103462930A T NN O
and CN103462930A T CC O
preparation CN103462930A T NN O
method CN103462930A T NN O
thereof CN103462930A T NN O
. CN103462930A T . O

Weight CN103202882A T NNP O
losing CN103202882A T VBG O
method CN103202882A T NN O
for CN103202882A T IN O
quickly CN103202882A T RB O
decomposing CN103202882A T VBG O
fat CN103202882A T JJ O
and CN103202882A T CC O
navel CN103202882A T JJ O
patch CN103202882A T NN O
. CN103202882A T . O

The CN103202882A A DT O
invention CN103202882A A NN O
discloses CN103202882A A VBZ O
a CN103202882A A DT O
weight CN103202882A A NN O
losing CN103202882A A VBG O
method CN103202882A A NN O
for CN103202882A A IN O
quickly CN103202882A A RB O
decomposing CN103202882A A VBG O
fat CN103202882A A NN O
. CN103202882A A . O

The CN103202882A A DT O
method CN103202882A A NN O
is CN103202882A A VBZ O
characterized CN103202882A A VBN O
by CN103202882A A IN O
comprising CN103202882A A VBG O
the CN103202882A A DT O
following CN103202882A A JJ O
steps CN103202882A A NNS O
of CN103202882A A IN O
: CN103202882A A : O
during CN103202882A A IN O
weight CN103202882A A NN O
losing CN103202882A A NN O
, CN103202882A A , O
drinking CN103202882A A VBG O
a CN103202882A A DT O
cup CN103202882A A NN O
of CN103202882A A IN O
aqueous CN103202882A A JJ O
solution CN103202882A A NN O
of CN103202882A A IN O
vitamin CN103202882A A NN O
B CN103202882A A NNP O
serving CN103202882A A NN O
as CN103202882A A IN O
an CN103202882A A DT O
active CN103202882A A JJ O
ingredient CN103202882A A NN O
with CN103202882A A IN O
the CN103202882A A DT O
effect CN103202882A A NN O
of CN103202882A A IN O
metabolizing CN103202882A A VBG O
the CN103202882A A DT O
fat CN103202882A A NN O
and CN103202882A A CC O
lacking CN103202882A A NN O
in CN103202882A A IN O
body CN103202882A A NN O
; CN103202882A A : O
after CN103202882A A IN O
the CN103202882A A DT O
solution CN103202882A A NN O
of CN103202882A A IN O
the CN103202882A A DT O
vitamin CN103202882A A NN O
B CN103202882A A NNP O
is CN103202882A A VBZ O
drunk CN103202882A A JJ O
, CN103202882A A , O
taking CN103202882A A VBG O
exercise CN103202882A A NN O
with CN103202882A A IN O
a CN103202882A A DT O
simulated CN103202882A A JJ O
biological CN103202882A A JJ O
motion CN103202882A A NN O
instrument CN103202882A A NN O
for CN103202882A A IN O
30 CN103202882A A CD O
to CN103202882A A TO O
45 CN103202882A A CD O
minutes CN103202882A A NNS O
to CN103202882A A TO O
produce CN103202882A A VB O
the CN103202882A A DT O
metabolic CN103202882A A JJ O
cycle CN103202882A A NN O
bionic CN103202882A A JJ O
effect CN103202882A A NN O
so CN103202882A A RB O
as CN103202882A A IN O
to CN103202882A A TO O
repair CN103202882A A VB O
cells CN103202882A A NNS O
, CN103202882A A , O
decompose CN103202882A A VB O
the CN103202882A A DT O
fat CN103202882A A NN O
and CN103202882A A CC O
expel CN103202882A A VB O
toxin CN103202882A A NN O
; CN103202882A A : O
and CN103202882A A CC O
sticking CN103202882A A VBG O
a CN103202882A A DT O
navel CN103202882A A JJ O
patch CN103202882A A NN O
to CN103202882A A TO O
the CN103202882A A DT O
navel CN103202882A A NN O
for CN103202882A A IN O
10 CN103202882A A CD O
to CN103202882A A TO O
18 CN103202882A A CD O
hours CN103202882A A NNS O
so CN103202882A A RB O
as CN103202882A A IN O
to CN103202882A A TO O
effectively CN103202882A A RB O
limit CN103202882A A VB O
the CN103202882A A DT O
absorption CN103202882A A NN O
of CN103202882A A IN O
fat CN103202882A A NN O
in CN103202882A A IN O
food CN103202882A A NN O
, CN103202882A A , O
accelerate CN103202882A A VBP O
the CN103202882A A DT O
metabolism CN103202882A A NN O
of CN103202882A A IN O
the CN103202882A A DT O
decomposed CN103202882A A JJ O
and CN103202882A A CC O
semi-decomposed CN103202882A A JJ O
fat CN103202882A A NN O
and CN103202882A A CC O
control CN103202882A A VB O
the CN103202882A A DT O
diseases CN103202882A A NNS O
, CN103202882A A , O
wherein CN103202882A A VBP O
the CN103202882A A DT O
navel CN103202882A A JJ O
patch CN103202882A A NN O
is CN103202882A A VBZ O
used CN103202882A A VBN O
once CN103202882A A RB O
to CN103202882A A TO O
twice CN103202882A A VB O
every CN103202882A A DT O
day CN103202882A A NN O
, CN103202882A A , O
and CN103202882A A CC O
ten CN103202882A A JJ O
days CN103202882A A NNS O
constitute CN103202882A A VBP O
a CN103202882A A DT O
treatment CN103202882A A NN O
course CN103202882A A NN O
. CN103202882A A . O

The CN103202882A A DT O
method CN103202882A A NN O
has CN103202882A A VBZ O
the CN103202882A A DT O
advantages CN103202882A A NNS O
that CN103202882A A IN O
the CN103202882A A DT O
requirements CN103202882A A NNS O
of CN103202882A A IN O
World CN103202882A A NNP O
Health CN103202882A A NNP O
Organization CN103202882A A NNP O
are CN103202882A A VBP O
met CN103202882A A VBN O
, CN103202882A A , O
three CN103202882A A CD O
meals CN103202882A A NNS O
are CN103202882A A VBP O
eaten CN103202882A A VBN O
as CN103202882A A IN O
usual CN103202882A A JJ O
, CN103202882A A , O
diarrhea CN103202882A A JJ O
, CN103202882A A , O
weakness CN103202882A A NN O
and CN103202882A A CC O
rebound CN103202882A A NN O
are CN103202882A A VBP O
avoided CN103202882A A VBN O
, CN103202882A A , O
the CN103202882A A DT O
method CN103202882A A NN O
is CN103202882A A VBZ O
scientific CN103202882A A JJ O
, CN103202882A A , O
reasonable CN103202882A A JJ O
and CN103202882A A CC O
safe CN103202882A A JJ O
, CN103202882A A , O
the CN103202882A A DT O
weight CN103202882A A NN O
losing CN103202882A A VBG O
effect CN103202882A A NN O
is CN103202882A A VBZ O
good CN103202882A A JJ O
and CN103202882A A CC O
the CN103202882A A DT O
like CN103202882A A JJ O
. CN103202882A A . O

Xanthenone-4-Acetic US20110201678 T JJ O
Acid US20110201678 T NNP O
Derivatives US20110201678 T NNP O
. US20110201678 T . O

This US20110201678 A DT O
invention US20110201678 A NN O
relates US20110201678 A VBZ O
to US20110201678 A TO O
novel US20110201678 A VB O
compounds US20110201678 A NNS O
that US20110201678 A WDT O
are US20110201678 A VBP O
xanthenone-4-acetic US20110201678 A JJ O
acid US20110201678 A JJ O
derivatives US20110201678 A NNS O
and US20110201678 A CC O
pharmaceutically US20110201678 A RB O
acceptable US20110201678 A JJ O
salts US20110201678 A NNS O
thereof US20110201678 A NN O
. US20110201678 A . O

More US20110201678 A RBR O
specifically US20110201678 A RB O
, US20110201678 A , O
this US20110201678 A DT O
invention US20110201678 A NN O
relates US20110201678 A VBZ O
to US20110201678 A TO O
novel US20110201678 A VB O
xanthenone-4-acetic US20110201678 A JJ O
acid US20110201678 A NN O
derivatives US20110201678 A NNS O
that US20110201678 A WDT O
are US20110201678 A VBP O
derivatives US20110201678 A NNS O
of US20110201678 A IN O
AS US20110201678 A IN O
1404 US20110201678 A CD O
. US20110201678 A . O

This US20110201678 A DT O
invention US20110201678 A NN O
also US20110201678 A RB O
provides US20110201678 A VBZ O
compositions US20110201678 A NNS O
comprising US20110201678 A VBG O
one US20110201678 A CD O
or US20110201678 A CC O
more US20110201678 A JJR O
compounds US20110201678 A NNS O
of US20110201678 A IN O
this US20110201678 A DT O
invention US20110201678 A NN O
and US20110201678 A CC O
a US20110201678 A DT O
carrier US20110201678 A NN O
, US20110201678 A , O
and US20110201678 A CC O
the US20110201678 A DT O
use US20110201678 A NN O
of US20110201678 A IN O
the US20110201678 A DT O
disclosed US20110201678 A JJ O
compounds US20110201678 A NNS O
and US20110201678 A CC O
compositions US20110201678 A NNS O
in US20110201678 A IN O
methods US20110201678 A NNS O
of US20110201678 A IN O
treating US20110201678 A VBG O
diseases US20110201678 A NNS O
and US20110201678 A CC O
conditions US20110201678 A NNS O
that US20110201678 A WDT O
are US20110201678 A VBP O
beneficially US20110201678 A RB O
treated US20110201678 A VBN O
by US20110201678 A IN O
administering US20110201678 A VBG O
a US20110201678 A DT O
vascular US20110201678 A JJ O
disrupting US20110201678 A NN O
agent US20110201678 A NN O
, US20110201678 A , O
such US20110201678 A JJ O
as US20110201678 A IN O
AS US20110201678 A IN O
1404 US20110201678 A CD O
. US20110201678 A . O

Domestic CN101028417A T JJ O
fungus CN101028417A T JJ O
oral CN101028417A T JJ O
liquid CN101028417A T NN O
. CN101028417A T . O

Agent WO2008081934A1 T NN O
for WO2008081934A1 T IN O
facilitating WO2008081934A1 T VBG O
the WO2008081934A1 T DT O
development WO2008081934A1 T NN O
of WO2008081934A1 T IN O
brain WO2008081934A1 T NN O
in WO2008081934A1 T IN O
infant WO2008081934A1 T JJ O
comprising WO2008081934A1 T VBG O
milk-derived WO2008081934A1 T JJ O
phospholipid WO2008081934A1 T NN O
and WO2008081934A1 T CC O
food WO2008081934A1 T NN O
composition WO2008081934A1 T NN O
comprising WO2008081934A1 T VBG O
the WO2008081934A1 T DT O
same WO2008081934A1 T JJ O
. WO2008081934A1 T . O

Chewable CN101822651A T JJ O
capsule CN101822651A T NN O
and CN101822651A T CC O
preparation CN101822651A T NN O
method CN101822651A T NN O
thereof CN101822651A T NN O
. CN101822651A T . O

Porphyrin US20120283236 T NNP O
Catalysts US20120283236 T NNS O
and US20120283236 T CC O
Methods US20120283236 T NNS O
of US20120283236 T IN O
Use US20120283236 T NNP O
Thereof US20120283236 T NNP O
. US20120283236 T . O

Novel WO2013150534A1 T NNP O
targeting WO2013150534A1 T VBG O
agents WO2013150534A1 T NNS O
for WO2013150534A1 T IN O
diagnostic WO2013150534A1 T JJ O
and WO2013150534A1 T CC O
therapeutic WO2013150534A1 T JJ O
indications WO2013150534A1 T NNS O
. WO2013150534A1 T . O

The WO2013150534A1 A DT O
invention WO2013150534A1 A NN O
relates WO2013150534A1 A VBZ O
to WO2013150534A1 A TO O
compounds WO2013150534A1 A NNS O
and WO2013150534A1 A CC O
use WO2013150534A1 A NN O
thereof WO2013150534A1 A NN O
in WO2013150534A1 A IN O
the WO2013150534A1 A DT O
diagnosis WO2013150534A1 A NN O
and/or WO2013150534A1 A NN O
in WO2013150534A1 A IN O
treatment WO2013150534A1 A NN O
of WO2013150534A1 A IN O
medical WO2013150534A1 A JJ O
disorders WO2013150534A1 A NNS O
. WO2013150534A1 A . O

In WO2013150534A1 A IN O
some WO2013150534A1 A DT O
embodiments WO2013150534A1 A NNS O
, WO2013150534A1 A , O
the WO2013150534A1 A DT O
compounds WO2013150534A1 A NNS O
may WO2013150534A1 A MD O
be WO2013150534A1 A VB O
used WO2013150534A1 A VBN O
for WO2013150534A1 A IN O
detecting WO2013150534A1 A VBG O
a WO2013150534A1 A DT O
cancer WO2013150534A1 A NN O
. WO2013150534A1 A . O

The WO2013150534A1 A DT O
compound WO2013150534A1 A NN O
may WO2013150534A1 A MD O
include WO2013150534A1 A VB O
a WO2013150534A1 A DT O
di-acid WO2013150534A1 A JJ O
moiety WO2013150534A1 A NN O
. WO2013150534A1 A . O

In WO2013150534A1 A IN O
some WO2013150534A1 A DT O
embodiments WO2013150534A1 A NNS O
the WO2013150534A1 A DT O
di-acid WO2013150534A1 A JJ O
moiety WO2013150534A1 A NN O
comprises WO2013150534A1 A VBZ O
a WO2013150534A1 A DT O
di-carboxylic WO2013150534A1 A JJ O
acid WO2013150534A1 A NN O
and WO2013150534A1 A CC O
in WO2013150534A1 A IN O
some WO2013150534A1 A DT O
embodiments WO2013150534A1 A NNS O
the WO2013150534A1 A DT O
di- WO2013150534A1 A JJ O
acid WO2013150534A1 A NN O
moiety WO2013150534A1 A NN O
comprises WO2013150534A1 A VBZ O
a WO2013150534A1 A DT O
di-tetrazole WO2013150534A1 A JJ O
. WO2013150534A1 A . O

Method CN102225050A T NNP O
for CN102225050A T IN O
preparing CN102225050A T VBG O
famotidine CN102225050A T JJ O
sodium CN102225050A T NN O
chloride CN102225050A T NN O
injection CN102225050A T NN O
by CN102225050A T IN O
inclusion CN102225050A T NN O
method CN102225050A T NN O
and CN102225050A T CC O
product CN102225050A T NN O
prepared CN102225050A T VBN O
by CN102225050A T IN O
using CN102225050A T VBG O
the CN102225050A T DT O
same CN102225050A T JJ O
. CN102225050A T . O

Methods CA2665501A1 T NNS O
and CA2665501A1 T CC O
compositions CA2665501A1 T NNS O
for CA2665501A1 T IN O
the CA2665501A1 T DT O
treatment CA2665501A1 T NN O
and CA2665501A1 T CC O
prevention CA2665501A1 T NN O
of CA2665501A1 T IN O
bone CA2665501A1 T NN O
loss CA2665501A1 T NN O
. CA2665501A1 T . O

The CA2665501A1 A DT O
compositions CA2665501A1 A NNS O
further CA2665501A1 A RBR O
comprise CA2665501A1 A NN O
at CA2665501A1 A IN O
least CA2665501A1 A JJS O
one CA2665501A1 A CD O
of CA2665501A1 A IN O
a CA2665501A1 A DT O
bisphosphonate CA2665501A1 A NN O
, CA2665501A1 A , O
a CA2665501A1 A DT O
selective CA2665501A1 A JJ O
estrogen CA2665501A1 A NN I-UN
receptor CA2665501A1 A NN I-UN
modulator CA2665501A1 A NN O
, CA2665501A1 A , O
or CA2665501A1 A CC O
a CA2665501A1 A DT O
hormone CA2665501A1 A NN O
. CA2665501A1 A . O

content US7029692 T NN O
of US7029692 T IN O
monoterpene US7029692 T NN O
ketone US7029692 T NN O
in US7029692 T IN O
the US7029692 T DT O
nicotine-containing US7029692 T JJ O
layer US7029692 T NN O
is US7029692 T VBZ O
0.1 US7029692 T CD O
to US7029692 T TO O
5.0 US7029692 T CD O
% US7029692 T NN O
-wt US7029692 T NN O
of US7029692 T IN O
the US7029692 T DT O
weight US7029692 T NN O
; US7029692 T : O
masks US7029692 T VBZ O
the US7029692 T DT O
unpleasant US7029692 T JJ O
smell US7029692 T NN O
of US7029692 T IN O
nicotine US7029692 T NN O
. US7029692 T . O

Gaseous EP2571541A2 T JJ O
nitric EP2571541A2 T JJ O
oxide-sequestering EP2571541A2 T JJ O
products EP2571541A2 T NNS O
and EP2571541A2 T CC O
processes EP2571541A2 T NNS O
of EP2571541A2 T IN O
preparing EP2571541A2 T VBG O
same EP2571541A2 T JJ O
. EP2571541A2 T . O

2,3-Dimethylindolo US20050288296 T JJ O
[ US20050288296 T NNP O
2,3-b US20050288296 T JJ O
] US20050288296 T NNP O
quinoxaline-6-yl-acetamide US20050288296 T NN O
; US20050288296 T : O
9-Chloro-2,3-dimethyl-6- US20050288296 T CD O
( US20050288296 T ( O
aminoethylamino-2-oxoethyl US20050288296 T NN O
) US20050288296 T ) O
-6H-indolo US20050288296 T VBZ O
[ US20050288296 T JJ O
2,3-b US20050288296 T JJ O
] US20050288296 T NNP O
quinoxaline US20050288296 T NN O
; US20050288296 T : O
autoimmune US20050288296 T JJ O
diseases US20050288296 T NNS O
. US20050288296 T . O

Cabanillasin EP2468718A1 T NNP O
, EP2468718A1 T , O
a EP2468718A1 T DT O
new EP2468718A1 T JJ O
antifungal EP2468718A1 T JJ O
compound EP2468718A1 T NN O
, EP2468718A1 T , O
produced EP2468718A1 T VBN O
by EP2468718A1 T IN O
entomopathogenic EP2468718A1 T JJ O
xenorhabdus EP2468718A1 T NN O
cabanillasii EP2468718A1 T NN O
. EP2468718A1 T . O

Central US7005432 T NNP O
nervous US7005432 T JJ O
system US7005432 T NN O
disorder US7005432 T NN O
; US7005432 T : O
antidepressants US7005432 T NNS O
; US7005432 T : O
analgesics US7005432 T NNS O
. US7005432 T . O

These US7005432 A DT O
compounds US7005432 A NNS O
are US7005432 A VBP O
NMDA US7005432 A NNP I-UN
NR-2B US7005432 A NNP I-UN
receptor US7005432 A NN O
subtype US7005432 A NN O
specific US7005432 A JJ O
blockers US7005432 A NNS O
and US7005432 A CC O
are US7005432 A VBP O
useful US7005432 A JJ O
in US7005432 A IN O
the US7005432 A DT O
treatment US7005432 A NN O
of US7005432 A IN O
neurodegeneration US7005432 A NN O
, US7005432 A , O
depression US7005432 A NN O
and US7005432 A CC O
pain US7005432 A NN O
. US7005432 A . O

Methods US20120232087 T NNS O
and US20120232087 T CC O
compositions US20120232087 T NNS O
for US20120232087 T IN O
treating US20120232087 T VBG O
solid US20120232087 T JJ O
tumors US20120232087 T NNS O
and US20120232087 T CC O
other US20120232087 T JJ O
malignancies US20120232087 T NNS O
. US20120232087 T . O

A US20120232087 A DT O
combination US20120232087 A NN O
of US20120232087 A IN O
a US20120232087 A DT O
kinase US20120232087 A NN I-UN
inhibitors US20120232087 A NNS O
of US20120232087 A IN O
mTOR US20120232087 A NN I-UN
and US20120232087 A CC O
downstream US20120232087 A NN O
effector US20120232087 A NN O
and US20120232087 A CC O
a US20120232087 A DT O
hedgehog US20120232087 A JJ O
pathway US20120232087 A NN O
inhibitor US20120232087 A NN O
for US20120232087 A IN O
the US20120232087 A DT O
treatment US20120232087 A NN O
of US20120232087 A IN O
cancer US20120232087 A NN O
. US20120232087 A . O

Darifenacin US8748476 T NNP O
for US8748476 T IN O
use US8748476 T NN O
in US8748476 T IN O
the US8748476 T DT O
treatment US8748476 T NN O
of US8748476 T IN O
urgency US8748476 T NN O
induced US8748476 T VBN O
by US8748476 T IN O
overactive US8748476 T JJ O
bladder US8748476 T NN O
. US8748476 T . O

Hybrid US20110245287 T NNP O
Opioid US20110245287 T NNP O
Compounds US20110245287 T NNP O
and US20110245287 T CC O
Compositions US20110245287 T NNP O
. US20110245287 T . O

Method CN101543530A T NNP O
for CN101543530A T IN O
preparing CN101543530A T VBG O
Tibetan CN101543530A T NNP O
medicament CN101543530A T JJ O
seven-ingredient CN101543530A T JJ O
scrap-iron CN101543530A T JJ O
preparation CN101543530A T NN O
for CN101543530A T IN O
treating CN101543530A T VBG O
hepatic CN101543530A T JJ O
diseases CN101543530A T NNS O
. CN101543530A T . O

The CN101543530A A DT O
invention CN101543530A A NN O
relates CN101543530A A VBZ O
to CN101543530A A TO O
a CN101543530A A DT O
method CN101543530A A NN O
for CN101543530A A IN O
preparing CN101543530A A VBG O
a CN101543530A A DT O
medicament CN101543530A A NN O
, CN101543530A A , O
in CN101543530A A IN O
particular CN101543530A A JJ O
to CN101543530A A TO O
a CN101543530A A DT O
method CN101543530A A NN O
for CN101543530A A IN O
preparing CN101543530A A VBG O
a CN101543530A A DT O
Tibetan CN101543530A A NNP O
medicament CN101543530A A NN O
seven-ingredient CN101543530A A JJ O
scrap-iron CN101543530A A JJ O
preparation CN101543530A A NN O
for CN101543530A A IN O
treating CN101543530A A VBG O
hepatic CN101543530A A JJ O
diseases CN101543530A A NNS O
. CN101543530A A . O

The CN101543530A A DT O
method CN101543530A A NN O
comprises CN101543530A A VBZ O
the CN101543530A A DT O
following CN101543530A A JJ O
steps CN101543530A A NNS O
: CN101543530A A : O
scrap CN101543530A A NN O
iron CN101543530A A NN O
preparation CN101543530A A NN O
with CN101543530A A IN O
myrobalan CN101543530A A NN O
, CN101543530A A , O
gypsum CN101543530A A NN O
rubrum CN101543530A A NN O
preparation CN101543530A A NN O
with CN101543530A A IN O
milk CN101543530A A NN O
, CN101543530A A , O
lying CN101543530A A VBG O
squirrel CN101543530A A JJ O
droppings CN101543530A A NNS O
paste CN101543530A A NN O
extraction CN101543530A A NN O
, CN101543530A A , O
mixing CN101543530A A NN O
, CN101543530A A , O
drying CN101543530A A VBG O
, CN101543530A A , O
grinding CN101543530A A VBG O
, CN101543530A A , O
and CN101543530A A CC O
capsule CN101543530A A NN O
fabrication CN101543530A A NN O
. CN101543530A A . O

The CN101543530A A DT O
method CN101543530A A NN O
has CN101543530A A VBZ O
the CN101543530A A DT O
advantages CN101543530A A NNS O
of CN101543530A A IN O
simple CN101543530A A JJ O
process CN101543530A A NN O
and CN101543530A A CC O
convenient CN101543530A A NN O
operation CN101543530A A NN O
, CN101543530A A , O
and CN101543530A A CC O
the CN101543530A A DT O
prepared CN101543530A A JJ O
capsule CN101543530A A NN O
preparation CN101543530A A NN O
has CN101543530A A VBZ O
good CN101543530A A JJ O
drug CN101543530A A NN O
action CN101543530A A NN O
and CN101543530A A CC O
is CN101543530A A VBZ O
suitable CN101543530A A JJ O
for CN101543530A A IN O
popularization CN101543530A A NN O
and CN101543530A A CC O
application CN101543530A A NN O
. CN101543530A A . O

Composition US20090291928 T NN O
for US20090291928 T IN O
amelioration/prevention US20090291928 T NN O
of US20090291928 T IN O
adverse US20090291928 T JJ O
side US20090291928 T NN O
effect US20090291928 T NN O
in US20090291928 T IN O
steroid US20090291928 T JJ O
therapy US20090291928 T NN O
. US20090291928 T . O

Ornidazole CN103751145A T NNP O
capsule CN103751145A T NN O
with CN103751145A T IN O
improved CN103751145A T JJ O
uniformity CN103751145A T NN O
. CN103751145A T . O

Oral EP1010423B1 T JJ O
pharmaceutical EP1010423B1 T JJ O
preparation EP1010423B1 T NN O
comprising EP1010423B1 T VBG O
an EP1010423B1 T DT O
antiulcer EP1010423B1 T NN O
benzimidazole EP1010423B1 T NN O
derivative EP1010423B1 T NN O
, EP1010423B1 T , O
and EP1010423B1 T CC O
process EP1010423B1 T NN O
for EP1010423B1 T IN O
its EP1010423B1 T PRP$ O
production EP1010423B1 T NN O
. EP1010423B1 T . O

Semisynthesis US20080167369 T NNP O
Process US20080167369 T NNP O
for US20080167369 T IN O
the US20080167369 T DT O
Preparation US20080167369 T NNP O
of US20080167369 T IN O
10-Deacytyl-N-Debenzoyl-Paclitaxel US20080167369 T JJ O
. US20080167369 T . O

Terra CN103705888A T NNP O
flava CN103705888A T NN O
usta CN103705888A T NN O
, CN103705888A T , O
felwort CN103705888A T NN O
, CN103705888A T , O
blackberry CN103705888A T VBP O
lily CN103705888A T RB O
and CN103705888A T CC O
pearl CN103705888A T VB O
grains CN103705888A T NNS O
and CN103705888A T CC O
powder CN103705888A T NN O
for CN103705888A T IN O
relieving CN103705888A T VBG O
vomiting CN103705888A T NN O
. CN103705888A T . O

Ozagrel CN102429903A T NNP O
sodium CN102429903A T NN O
medicinal CN102429903A T JJ O
composition CN102429903A T NN O
for CN102429903A T IN O
injection CN102429903A T NN O
. CN102429903A T . O

The CN102429903A A DT O
invention CN102429903A A NN O
discloses CN102429903A A VBZ O
an CN102429903A A DT O
ozagrel CN102429903A A JJ O
sodium CN102429903A A NN O
medicinal CN102429903A A JJ O
composition CN102429903A A NN O
for CN102429903A A IN O
injection CN102429903A A NN O
. CN102429903A A . O

Ozagrel CN102429903A A NNP O
sodium CN102429903A A NN O
injection CN102429903A A NN O
consists CN102429903A A VBZ O
of CN102429903A A IN O
ozagrel CN102429903A A JJ O
sodium CN102429903A A NN O
, CN102429903A A , O
sodium CN102429903A A NN O
citrate CN102429903A A NN O
and CN102429903A A CC O
calcium CN102429903A A NN O
disodium CN102429903A A NN O
edetate CN102429903A A NN O
, CN102429903A A , O
wherein CN102429903A A WP O
each CN102429903A A DT O
piece CN102429903A A NN O
of CN102429903A A IN O
injection CN102429903A A NN O
contains CN102429903A A NNS O
40-100 CN102429903A A JJ O
mg CN102429903A A NN O
of CN102429903A A IN O
ozagrel CN102429903A A JJ O
sodium CN102429903A A NN O
, CN102429903A A , O
4-10 CN102429903A A JJ O
mg CN102429903A A NN O
of CN102429903A A IN O
sodium CN102429903A A NN O
citrate CN102429903A A NN O
and CN102429903A A CC O
0.02-0.05 CN102429903A A JJ O
mg CN102429903A A NN O
of CN102429903A A IN O
calcium CN102429903A A NN O
disodium CN102429903A A NN O
edentate CN102429903A A NN O
. CN102429903A A . O

A CN102429903A A DT O
preparation CN102429903A A NN O
method CN102429903A A NN O
of CN102429903A A IN O
the CN102429903A A DT O
composition CN102429903A A NN O
comprises CN102429903A A VBZ O
the CN102429903A A DT O
following CN102429903A A JJ O
steps CN102429903A A NNS O
of CN102429903A A IN O
: CN102429903A A : O
adding CN102429903A A VBG O
a CN102429903A A DT O
prescription CN102429903A A NN O
dose CN102429903A A NN O
of CN102429903A A IN O
sodium CN102429903A A NN O
citrate CN102429903A A NN O
and CN102429903A A CC O
calcium CN102429903A A NN O
disodium CN102429903A A NN O
edentate CN102429903A A NN O
into CN102429903A A IN O
a CN102429903A A DT O
prescription CN102429903A A NN O
dose CN102429903A A NN O
of CN102429903A A IN O
90 CN102429903A A CD O
percent CN102429903A A NN O
injection CN102429903A A NN O
water CN102429903A A NN O
at CN102429903A A IN O
the CN102429903A A DT O
temperature CN102429903A A NN O
of CN102429903A A IN O
55-65 CN102429903A A JJ O
DEG CN102429903A A NNP O
C CN102429903A A NNP O
and CN102429903A A CC O
stirring CN102429903A A VBG O
to CN102429903A A TO O
dissolve CN102429903A A VB O
; CN102429903A A : O
adding CN102429903A A VBG O
a CN102429903A A DT O
prescription CN102429903A A NN O
dose CN102429903A A NN O
of CN102429903A A IN O
ozagrel CN102429903A A JJ O
sodium CN102429903A A NN O
and CN102429903A A CC O
stirring CN102429903A A VBG O
until CN102429903A A IN O
the CN102429903A A DT O
ozagrel CN102429903A A JJ O
sodium CN102429903A A NN O
is CN102429903A A VBZ O
fully CN102429903A A RB O
dissolved CN102429903A A VBN O
; CN102429903A A : O
measuring CN102429903A A VBG O
an CN102429903A A DT O
initial CN102429903A A JJ O
pH CN102429903A A NN O
value CN102429903A A NN O
, CN102429903A A , O
and CN102429903A A CC O
adjusting CN102429903A A VBG O
the CN102429903A A DT O
pH CN102429903A A NN O
value CN102429903A A NN O
to CN102429903A A TO O
be CN102429903A A VB O
within CN102429903A A IN O
a CN102429903A A DT O
range CN102429903A A NN O
of CN102429903A A IN O
7.5-9.5 CN102429903A A JJ O
by CN102429903A A IN O
using CN102429903A A VBG O
4 CN102429903A A CD O
percent CN102429903A A JJ O
sodium CN102429903A A NN O
hydroxide CN102429903A A NN O
solution CN102429903A A NN O
and CN102429903A A CC O
10 CN102429903A A CD O
percent CN102429903A A NN O
sodium CN102429903A A NN O
citrate CN102429903A A NN O
solution CN102429903A A NN O
according CN102429903A A VBG O
to CN102429903A A TO O
the CN102429903A A DT O
initial CN102429903A A JJ O
pH CN102429903A A NN O
value CN102429903A A NN O
; CN102429903A A : O
adding CN102429903A A VBG O
medicinal CN102429903A A JJ O
carbon CN102429903A A NN O
and CN102429903A A CC O
stirring CN102429903A A NN O
; CN102429903A A : O
performing CN102429903A A VBG O
extraction CN102429903A A NN O
filtration CN102429903A A NN O
, CN102429903A A , O
replenishing CN102429903A A VBG O
injection CN102429903A A NN O
water CN102429903A A NN O
to CN102429903A A TO O
full CN102429903A A JJ O
amount CN102429903A A NN O
and CN102429903A A CC O
uniformly CN102429903A A JJ O
mixing CN102429903A A NN O
; CN102429903A A : O
performing CN102429903A A VBG O
fine CN102429903A A JJ O
filtration CN102429903A A NN O
; CN102429903A A : O
canning CN102429903A A NN O
; CN102429903A A : O
sterilizing CN102429903A A VBG O
; CN102429903A A : O
performing CN102429903A A VBG O
light CN102429903A A JJ O
inspection CN102429903A A NN O
; CN102429903A A : O
and CN102429903A A CC O
warehousing CN102429903A A VBG O
to CN102429903A A TO O
obtain CN102429903A A VB O
the CN102429903A A DT O
ozagrel CN102429903A A NN O
sodium CN102429903A A NN O
injection CN102429903A A NN O
. CN102429903A A . O

The CN102429903A A DT O
ozagrel CN102429903A A NN O
sodium CN102429903A A NN O
medicinal CN102429903A A JJ O
composition CN102429903A A NN O
has CN102429903A A VBZ O
high CN102429903A A JJ O
light CN102429903A A JJ O
stability CN102429903A A NN O
, CN102429903A A , O
clarity CN102429903A A NN O
and CN102429903A A CC O
stability CN102429903A A NN O
and CN102429903A A CC O
does CN102429903A A VBZ O
not CN102429903A A RB O
produce CN102429903A A VB O
crystals CN102429903A A NNS O
, CN102429903A A , O
and CN102429903A A CC O
has CN102429903A A VBZ O
the CN102429903A A DT O
more CN102429903A A RBR O
obvious CN102429903A A JJ O
advantages CN102429903A A NNS O
of CN102429903A A IN O
improving CN102429903A A VBG O
the CN102429903A A DT O
product CN102429903A A NN O
yield CN102429903A A NN O
, CN102429903A A , O
reducing CN102429903A A VBG O
the CN102429903A A DT O
cost CN102429903A A NN O
, CN102429903A A , O
realizing CN102429903A A VBG O
industrialization CN102429903A A NN O
and CN102429903A A CC O
guaranteeing CN102429903A A VBG O
better CN102429903A A JJR O
application CN102429903A A NN O
to CN102429903A A TO O
clinical CN102429903A A JJ O
use CN102429903A A NN O
. CN102429903A A . O

The WO2008089659A1 T DT O
use WO2008089659A1 T NN O
of WO2008089659A1 T IN O
dopamine WO2008089659A1 T NN O
transporters WO2008089659A1 T NNS O
and WO2008089659A1 T CC O
noradrenaline WO2008089659A1 T JJ O
transporters WO2008089659A1 T NNS O
dual WO2008089659A1 T JJ O
inhibitors WO2008089659A1 T NNS O
. WO2008089659A1 T . O

Biaryl US20130059853 T NNP O
phosphodiesterase US20130059853 T NN I-UN
inhibitors US20130059853 T NNS O
. US20130059853 T . O

Novel US20130059853 A NNP O
biaryl US20130059853 A NN O
compounds US20130059853 A NNS O
with US20130059853 A IN O
phosphodiesterase US20130059853 A JJ I-UN
inhibitory US20130059853 A JJ O
activity US20130059853 A NN O
of US20130059853 A IN O
the US20130059853 A DT O
general US20130059853 A JJ O
formula US20130059853 A NN O
( US20130059853 A ( O
I US20130059853 A PRP O
) US20130059853 A ) O
, US20130059853 A , O
wherein US20130059853 A JJ O
R1 US20130059853 A NNP O
, US20130059853 A , O
R2 US20130059853 A NNP O
, US20130059853 A , O
R3 US20130059853 A NNP O
, US20130059853 A , O
X US20130059853 A NNP O
, US20130059853 A , O
Y US20130059853 A NNP O
, US20130059853 A , O
Z1 US20130059853 A NNP O
, US20130059853 A , O
Z2 US20130059853 A NNP O
, US20130059853 A , O
Z3 US20130059853 A NNP O
, US20130059853 A , O
and US20130059853 A CC O
Z4 US20130059853 A NNP O
have US20130059853 A VBP O
the US20130059853 A DT O
meanings US20130059853 A NNS O
defined US20130059853 A VBD O
herein US20130059853 A RB O
, US20130059853 A , O
as US20130059853 A RB O
well US20130059853 A RB O
as US20130059853 A IN O
their US20130059853 A PRP$ O
use US20130059853 A NN O
as US20130059853 A IN O
therapeutic US20130059853 A JJ O
agents US20130059853 A NNS O
in US20130059853 A IN O
the US20130059853 A DT O
treatment US20130059853 A NN O
of US20130059853 A IN O
inflammatory US20130059853 A NN O
diseases US20130059853 A NNS O
and US20130059853 A CC O
conditions US20130059853 A NNS O
. US20130059853 A . O

Medicinal US20120142631 T NNP O
antidiaper US20120142631 T NN O
rash US20120142631 T NN O
cream US20120142631 T NN O
incorporating US20120142631 T VBG O
a US20120142631 T DT O
biopolymer US20120142631 T NN O
and US20120142631 T CC O
a US20120142631 T DT O
process US20120142631 T NN O
to US20120142631 T TO O
make US20120142631 T VB O
it US20120142631 T PRP O
. US20120142631 T . O

Preparation CN103284948A T NN O
and CN103284948A T CC O
application CN103284948A T NN O
of CN103284948A T IN O
polymer CN103284948A T JJ O
composition CN103284948A T NN O
loaded CN103284948A T VBN O
with CN103284948A T IN O
sirolimus CN103284948A T JJ O
compound CN103284948A T NN O
or CN103284948A T CC O
its CN103284948A T PRP$ O
derivative CN103284948A T JJ O
. CN103284948A T . O

Methazolamide CN101564379A T NNP O
lipidosome CN101564379A T NN O
and CN101564379A T CC O
manufacture CN101564379A T NN O
method CN101564379A T NN O
thereof CN101564379A T NN O
. CN101564379A T . O

Oxazolo-naphthyl WO2006023865A1 T JJ O
acids WO2006023865A1 T NNS O
as WO2006023865A1 T IN O
plaminogen WO2006023865A1 T NN I-UN
activator WO2006023865A1 T NN I-UN
inhibtor WO2006023865A1 T NN I-UN
type-1 WO2006023865A1 T JJ I-UN
( WO2006023865A1 T ( O
pai-1 WO2006023865A1 T JJ I-UN
) WO2006023865A1 T ) O
modulators WO2006023865A1 T NNS O
useful WO2006023865A1 T JJ O
in WO2006023865A1 T IN O
the WO2006023865A1 T DT O
treatment WO2006023865A1 T NN O
of WO2006023865A1 T IN O
thrombosis WO2006023865A1 T NN O
and WO2006023865A1 T CC O
cardiovascular WO2006023865A1 T JJ O
diseases WO2006023865A1 T NNS O
. WO2006023865A1 T . O

The WO2006023865A1 A DT O
present WO2006023865A1 A JJ O
invention WO2006023865A1 A NN O
relates WO2006023865A1 A VBZ O
to WO2006023865A1 A TO O
oxazolo-naphthyl WO2006023865A1 A JJ O
acids WO2006023865A1 A NNS O
of WO2006023865A1 A IN O
the WO2006023865A1 A DT O
formula WO2006023865A1 A NN O
( WO2006023865A1 A ( O
I WO2006023865A1 A PRP O
) WO2006023865A1 A ) O
and WO2006023865A1 A CC O
methods WO2006023865A1 A NNS O
of WO2006023865A1 A IN O
using WO2006023865A1 A VBG O
them WO2006023865A1 A PRP O
to WO2006023865A1 A TO O
modulate WO2006023865A1 A VB O
PAI-1 WO2006023865A1 A NNP I-UN
expression WO2006023865A1 A NN O
and WO2006023865A1 A CC O
to WO2006023865A1 A TO O
treat WO2006023865A1 A VB O
PAI-1 WO2006023865A1 A NNP I-UN
related WO2006023865A1 A JJ O
disorders WO2006023865A1 A NNS O
. WO2006023865A1 A . O

Application CN102772800A T NN O
of CN102772800A T IN O
medicament CN102772800A T NN O
of CN102772800A T IN O
target CN102772800A T NN O
adenosine CN102772800A T JJ O
receptor CN102772800A T NN O
A2BAR CN102772800A T NNP I-UN
in CN102772800A T IN O
preparing CN102772800A T VBG O
medicament CN102772800A T NN O
for CN102772800A T IN O
preventing CN102772800A T VBG O
or CN102772800A T CC O
treating CN102772800A T VBG O
autoimmune CN102772800A T JJ O
diseases CN102772800A T NNS O
. CN102772800A T . O

The CN102772800A A DT O
invention CN102772800A A NN O
relates CN102772800A A VBZ O
to CN102772800A A TO O
the CN102772800A A DT O
field CN102772800A A NN O
of CN102772800A A IN O
bio-medicines CN102772800A A NNS O
, CN102772800A A , O
and CN102772800A A CC O
discloses CN102772800A A VBZ O
application CN102772800A A NN O
of CN102772800A A IN O
a CN102772800A A DT O
medicament CN102772800A A NN O
of CN102772800A A IN O
target CN102772800A A NN O
adenosine CN102772800A A JJ O
receptor CN102772800A A NN O
A2BAR CN102772800A A NNP I-UN
in CN102772800A A IN O
preparing CN102772800A A VBG O
a CN102772800A A DT O
medicament CN102772800A A NN O
for CN102772800A A IN O
preventing CN102772800A A VBG O
or CN102772800A A CC O
treating CN102772800A A VBG O
autoimmune CN102772800A A JJ O
diseases CN102772800A A NNS O
. CN102772800A A . O

Studies CN102772800A A NNS O
discover CN102772800A A VBP O
that CN102772800A A IN O
: CN102772800A A : O
compared CN102772800A A VBN O
with CN102772800A A IN O
a CN102772800A A DT O
healthy CN102772800A A JJ O
wild CN102772800A A NN O
mouse CN102772800A A NN O
, CN102772800A A , O
the CN102772800A A DT O
expression CN102772800A A NN O
of CN102772800A A IN O
adenosine CN102772800A A JJ O
receptor CN102772800A A NN O
A2BAR CN102772800A A NNP I-UN
in CN102772800A A IN O
the CN102772800A A DT O
immune CN102772800A A JJ O
tissue CN102772800A A NN O
in CN102772800A A IN O
an CN102772800A A DT O
EAE CN102772800A A NNP O
( CN102772800A A ( O
Experimental CN102772800A A NNP O
Autoimmune CN102772800A A NNP O
Encephalomyelitis CN102772800A A NNP O
) CN102772800A A ) O
mouse CN102772800A A NN O
is CN102772800A A VBZ O
up-regulated CN102772800A A JJ O
. CN102772800A A . O

After CN102772800A A IN O
two CN102772800A A CD O
antagonists CN102772800A A NNS O
of CN102772800A A IN O
the CN102772800A A DT O
adenosine CN102772800A A NN O
receptor CN102772800A A NN O
A2BAR CN102772800A A NNP I-UN
, CN102772800A A , O
CVT-6883 CN102772800A A NNP O
and CN102772800A A CC O
MRS-1754 CN102772800A A NNP O
are CN102772800A A VBP O
administrated CN102772800A A VBN O
to CN102772800A A TO O
the CN102772800A A DT O
EAE CN102772800A A NNP O
mouse CN102772800A A NN O
, CN102772800A A , O
the CN102772800A A DT O
onset CN102772800A A JJ O
time CN102772800A A NN O
of CN102772800A A IN O
the CN102772800A A DT O
EAE CN102772800A A NNP O
mouse CN102772800A A NN O
is CN102772800A A VBZ O
delayed CN102772800A A VBN O
, CN102772800A A , O
the CN102772800A A DT O
attack CN102772800A A NN O
symptom CN102772800A A NN O
is CN102772800A A VBZ O
relieved CN102772800A A VBN O
, CN102772800A A , O
the CN102772800A A DT O
attack CN102772800A A NN O
rate CN102772800A A NN O
is CN102772800A A VBZ O
reduced CN102772800A A VBN O
, CN102772800A A , O
and CN102772800A A CC O
infiltration CN102772800A A NN O
of CN102772800A A IN O
CNS CN102772800A A NNP O
( CN102772800A A ( O
central CN102772800A A JJ O
nervous CN102772800A A JJ O
system CN102772800A A NN O
) CN102772800A A ) O
inflammatory CN102772800A A NN O
cells CN102772800A A NNS O
is CN102772800A A VBZ O
reduced CN102772800A A VBN O
. CN102772800A A . O

The CN102772800A A DT O
application CN102772800A A NN O
has CN102772800A A VBZ O
the CN102772800A A DT O
advantages CN102772800A A NNS O
that CN102772800A A IN O
the CN102772800A A DT O
expression CN102772800A A NN O
of CN102772800A A IN O
the CN102772800A A DT O
adenosine CN102772800A A NN O
receptor CN102772800A A NN O
A2BAR CN102772800A A NNP I-UN
in CN102772800A A IN O
an CN102772800A A DT O
MS CN102772800A A NNP O
( CN102772800A A ( O
metabolic CN102772800A A JJ O
syndrome CN102772800A A NN O
) CN102772800A A ) O
patient CN102772800A A NN O
and CN102772800A A CC O
an CN102772800A A DT O
animal CN102772800A A JJ O
model CN102772800A A NN O
EAE CN102772800A A NNP O
thereof CN102772800A A NN O
is CN102772800A A VBZ O
up-regulated CN102772800A A JJ O
, CN102772800A A , O
the CN102772800A A DT O
antagonist CN102772800A A JJ O
CVT-6883 CN102772800A A NNP O
of CN102772800A A IN O
the CN102772800A A DT O
adenosine CN102772800A A NN O
receptor CN102772800A A NN O
A2BAR CN102772800A A NNP I-UN
can CN102772800A A MD O
be CN102772800A A VB O
used CN102772800A A VBN O
for CN102772800A A IN O
effectively CN102772800A A RB O
relieving CN102772800A A VBG O
the CN102772800A A DT O
EAE CN102772800A A NNP O
attach CN102772800A A NN O
symptom CN102772800A A NN O
. CN102772800A A . O

At CN102772800A A IN O
present CN102772800A A JJ O
, CN102772800A A , O
the CN102772800A A DT O
antagonist CN102772800A A JJ O
CVT-6883 CN102772800A A NNP O
of CN102772800A A IN O
the CN102772800A A DT O
adenosine CN102772800A A NN O
receptor CN102772800A A NN O
A2BAR CN102772800A A NNP I-UN
is CN102772800A A VBZ O
used CN102772800A A VBN O
in CN102772800A A IN O
clinical CN102772800A A JJ O
experimental CN102772800A A JJ O
medicament CN102772800A A NN O
for CN102772800A A IN O
treating CN102772800A A VBG O
asthma CN102772800A A NN O
, CN102772800A A , O
has CN102772800A A VBZ O
great CN102772800A A JJ O
possibility CN102772800A A NN O
in CN102772800A A IN O
serving CN102772800A A VBG O
as CN102772800A A IN O
a CN102772800A A DT O
medicament CN102772800A A NN O
for CN102772800A A IN O
treating CN102772800A A VBG O
MS CN102772800A A NNP O
diseases CN102772800A A NNS O
, CN102772800A A , O
and CN102772800A A CC O
provides CN102772800A A VBZ O
a CN102772800A A DT O
new CN102772800A A JJ O
action CN102772800A A NN O
target CN102772800A A NN O
and CN102772800A A CC O
medicinal CN102772800A A JJ O
source CN102772800A A NN O
for CN102772800A A IN O
treating CN102772800A A VBG O
MS CN102772800A A NNP O
diseases CN102772800A A NNS O
. CN102772800A A . O

Methods US20090117079 T NNS O
and US20090117079 T CC O
materials US20090117079 T NNS O
for US20090117079 T IN O
treating US20090117079 T VBG O
or US20090117079 T CC O
preventing US20090117079 T VBG O
diseases/disorders US20090117079 T NNS O
mediated US20090117079 T VBN O
by US20090117079 T IN O
alcohol US20090117079 T NN I-UN
dehydrogenase US20090117079 T NN I-UN
. US20090117079 T . O

The US20090117079 A DT O
present US20090117079 A JJ O
disclosure US20090117079 A NN O
relates US20090117079 A VBZ O
generally US20090117079 A RB O
to US20090117079 A TO O
methods US20090117079 A NNS O
and US20090117079 A CC O
materials US20090117079 A NNS O
for US20090117079 A IN O
treating US20090117079 A VBG O
and/or US20090117079 A NN O
preventing US20090117079 A VBG O
a US20090117079 A DT O
disease US20090117079 A NN O
or US20090117079 A CC O
disorder US20090117079 A NN O
in US20090117079 A IN O
a US20090117079 A DT O
subject US20090117079 A NN O
that US20090117079 A WDT O
is US20090117079 A VBZ O
mediated US20090117079 A VBN O
by US20090117079 A IN O
alcohol US20090117079 A NN I-UN
dehydrogenase US20090117079 A NN I-UN
by US20090117079 A IN O
administering US20090117079 A VBG O
to US20090117079 A TO O
the US20090117079 A DT O
subject US20090117079 A NN O
a US20090117079 A DT O
therapeutically US20090117079 A RB O
effective US20090117079 A JJ O
amount US20090117079 A NN O
of US20090117079 A IN O
one US20090117079 A CD O
or US20090117079 A CC O
more US20090117079 A JJR O
agents US20090117079 A NNS O
that US20090117079 A IN O
prevents US20090117079 A NNS O
and/or US20090117079 A VBP O
inhibits US20090117079 A VBZ O
the US20090117079 A DT O
metabolism US20090117079 A NN O
of US20090117079 A IN O
methanol US20090117079 A NN O
by US20090117079 A IN O
alcohol US20090117079 A NN I-UN
dehydrogenase US20090117079 A NN I-UN
. US20090117079 A . O

Sustained CN102028666A T VBN O
release CN102028666A T NN O
tablet CN102028666A T NN O
containing CN102028666A T VBG O
famciclovir CN102028666A T NN O
and CN102028666A T CC O
preparation CN102028666A T NN O
method CN102028666A T NN O
thereof CN102028666A T NN O
. CN102028666A T . O

Microrna-140-5p WO2012145743A1 T NNP I-UN
as WO2012145743A1 T IN O
a WO2012145743A1 T DT O
tumor WO2012145743A1 T NN O
suppressor WO2012145743A1 T NN O
and WO2012145743A1 T CC O
sensitizing WO2012145743A1 T NN O
agent WO2012145743A1 T NN O
for WO2012145743A1 T IN O
chemotherapy WO2012145743A1 T NN O
. WO2012145743A1 T . O

The WO2012145743A1 A DT O
present WO2012145743A1 A JJ O
invention WO2012145743A1 A NN O
provides WO2012145743A1 A VBZ O
a WO2012145743A1 A DT O
method WO2012145743A1 A NN O
of WO2012145743A1 A IN O
improving WO2012145743A1 A VBG O
a WO2012145743A1 A DT O
therapeutic WO2012145743A1 A JJ O
response WO2012145743A1 A NN O
to WO2012145743A1 A TO O
a WO2012145743A1 A DT O
cancer WO2012145743A1 A NN O
treatment WO2012145743A1 A NN O
, WO2012145743A1 A , O
in WO2012145743A1 A IN O
a WO2012145743A1 A DT O
subject WO2012145743A1 A NN O
, WO2012145743A1 A , O
the WO2012145743A1 A DT O
method WO2012145743A1 A NN O
comprising WO2012145743A1 A VBG O
administering WO2012145743A1 A VBG O
an WO2012145743A1 A DT O
effective WO2012145743A1 A JJ O
amount WO2012145743A1 A NN O
of WO2012145743A1 A IN O
an WO2012145743A1 A DT O
agent WO2012145743A1 A NN O
that WO2012145743A1 A WDT O
enhances WO2012145743A1 A VBZ O
the WO2012145743A1 A DT O
expression WO2012145743A1 A NN O
of WO2012145743A1 A IN O
microRNA-140-5p WO2012145743A1 A NN I-UN
or WO2012145743A1 A CC O
an WO2012145743A1 A DT O
agent WO2012145743A1 A NN O
that WO2012145743A1 A WDT O
mimics WO2012145743A1 A VBZ O
the WO2012145743A1 A DT O
effects WO2012145743A1 A NNS O
of WO2012145743A1 A IN O
microRNA-140-5p WO2012145743A1 A NN I-UN
. WO2012145743A1 A . O

Further WO2012145743A1 A RB O
provided WO2012145743A1 A VBN O
is WO2012145743A1 A VBZ O
a WO2012145743A1 A DT O
method WO2012145743A1 A NN O
of WO2012145743A1 A IN O
treating WO2012145743A1 A VBG O
a WO2012145743A1 A DT O
cancer WO2012145743A1 A NN O
in WO2012145743A1 A IN O
a WO2012145743A1 A DT O
subject WO2012145743A1 A NN O
in WO2012145743A1 A IN O
need WO2012145743A1 A NN O
of WO2012145743A1 A IN O
such WO2012145743A1 A JJ O
treatment WO2012145743A1 A NN O
comprising WO2012145743A1 A VBG O
the WO2012145743A1 A DT O
step WO2012145743A1 A NN O
of WO2012145743A1 A IN O
administering WO2012145743A1 A VBG O
an WO2012145743A1 A DT O
effective WO2012145743A1 A JJ O
amount WO2012145743A1 A NN O
of WO2012145743A1 A IN O
a WO2012145743A1 A DT O
microRNA-140-5p WO2012145743A1 A NN I-UN
or WO2012145743A1 A CC O
an WO2012145743A1 A DT O
agent WO2012145743A1 A NN O
that WO2012145743A1 A WDT O
enhances WO2012145743A1 A VBZ O
the WO2012145743A1 A DT O
expression WO2012145743A1 A NN O
of WO2012145743A1 A IN O
microRNA-140-5p WO2012145743A1 A NN I-UN
. WO2012145743A1 A . O

Amino-tropane WO2006021657A1 T NNP O
derivatives WO2006021657A1 T NNS O
, WO2006021657A1 T , O
preparation WO2006021657A1 T NN O
thereof WO2006021657A1 T NN O
and WO2006021657A1 T CC O
therapeutic WO2006021657A1 T JJ O
use WO2006021657A1 T NN O
thereof WO2006021657A1 T NN O
. WO2006021657A1 T . O

The WO2006021657A1 A DT O
invention WO2006021657A1 A NN O
concerns WO2006021657A1 A VBZ O
amino-tropane WO2006021657A1 A JJ O
derivatives WO2006021657A1 A NNS O
of WO2006021657A1 A IN O
general WO2006021657A1 A JJ O
formula WO2006021657A1 A NN O
( WO2006021657A1 A ( O
I WO2006021657A1 A PRP O
) WO2006021657A1 A ) O
, WO2006021657A1 A , O
wherein WO2006021657A1 A NN O
: WO2006021657A1 A : O
Ra WO2006021657A1 A NNP O
R WO2006021657A1 A NNP O
a WO2006021657A1 A DT O
' WO2006021657A1 A POS O
et WO2006021657A1 A JJ O
R5 WO2006021657A1 A NNP O
represent WO2006021657A1 A NN O
hydrogen WO2006021657A1 A NN O
atoms WO2006021657A1 A NNS O
or WO2006021657A1 A CC O
alkyl WO2006021657A1 A JJ O
groups WO2006021657A1 A NNS O
; WO2006021657A1 A : O
R1 WO2006021657A1 A NNP O
represents WO2006021657A1 A VBZ O
a WO2006021657A1 A DT O
hydrogen WO2006021657A1 A NN O
atom WO2006021657A1 A NN O
or WO2006021657A1 A CC O
an WO2006021657A1 A DT O
alkyl WO2006021657A1 A NN O
, WO2006021657A1 A , O
cycloalkyl WO2006021657A1 A NN O
, WO2006021657A1 A , O
heterocycloalkyl WO2006021657A1 A NN O
or WO2006021657A1 A CC O
aryl WO2006021657A1 A JJ O
group WO2006021657A1 A NN O
; WO2006021657A1 A : O
R2 WO2006021657A1 A NNP O
represents WO2006021657A1 A VBZ O
a WO2006021657A1 A DT O
group WO2006021657A1 A NN O
of WO2006021657A1 A IN O
formula WO2006021657A1 A NN O
- WO2006021657A1 A : O
( WO2006021657A1 A ( O
CH2 WO2006021657A1 A NNP O
) WO2006021657A1 A ) O
x- WO2006021657A1 A NN O
( WO2006021657A1 A ( O
CO WO2006021657A1 A NNP O
) WO2006021657A1 A ) O
y-Y WO2006021657A1 A NN O
or WO2006021657A1 A CC O
- WO2006021657A1 A : O
( WO2006021657A1 A ( O
CO WO2006021657A1 A NNP O
) WO2006021657A1 A ) O
y- WO2006021657A1 A NN O
( WO2006021657A1 A ( O
CH2 WO2006021657A1 A NNP O
) WO2006021657A1 A ) O
x-Y WO2006021657A1 A NN O
, WO2006021657A1 A , O
wherein WO2006021657A1 A WP O
Y WO2006021657A1 A VBZ O
represents WO2006021657A1 A VBZ O
a WO2006021657A1 A DT O
hydrogen WO2006021657A1 A NN O
atom WO2006021657A1 A NN O
or WO2006021657A1 A CC O
a WO2006021657A1 A DT O
hydroxy WO2006021657A1 A NN O
, WO2006021657A1 A , O
alkyl WO2006021657A1 A NN O
, WO2006021657A1 A , O
cycloalkyl WO2006021657A1 A NN O
, WO2006021657A1 A , O
alkoxy WO2006021657A1 A NN O
, WO2006021657A1 A , O
aryl WO2006021657A1 A NN O
, WO2006021657A1 A , O
heteroaryl WO2006021657A1 A NN O
group WO2006021657A1 A NN O
or WO2006021657A1 A CC O
NR11R12 WO2006021657A1 A NNP O
; WO2006021657A1 A : O
R3 WO2006021657A1 A NNP O
represents WO2006021657A1 A VBZ O
1 WO2006021657A1 A CD O
to WO2006021657A1 A TO O
3 WO2006021657A1 A CD O
groups WO2006021657A1 A NNS O
selected WO2006021657A1 A VBN O
among WO2006021657A1 A IN O
halogen WO2006021657A1 A NN O
atoms WO2006021657A1 A NNS O
and WO2006021657A1 A CC O
alkyl WO2006021657A1 A NN O
, WO2006021657A1 A , O
cycloalkyl WO2006021657A1 A NN O
OR WO2006021657A1 A NNP O
, WO2006021657A1 A , O
-NRR WO2006021657A1 A NNP O
' WO2006021657A1 A POS O
, WO2006021657A1 A , O
-CO-NRR WO2006021657A1 A NNP O
' WO2006021657A1 A POS O
, WO2006021657A1 A , O
-NR-CO-R WO2006021657A1 A NNP O
' WO2006021657A1 A POS O
, WO2006021657A1 A , O
-NR-CO-NRR WO2006021657A1 A NNP O
' WO2006021657A1 A POS O
, WO2006021657A1 A , O
-NR-COOR WO2006021657A1 A NNP O
' WO2006021657A1 A POS O
, WO2006021657A1 A , O
-NO2 WO2006021657A1 A NNP O
, WO2006021657A1 A , O
-CN WO2006021657A1 A NNP O
and WO2006021657A1 A CC O
-COOR WO2006021657A1 A NNP O
groups WO2006021657A1 A NNS O
; WO2006021657A1 A : O
R4 WO2006021657A1 A NNP O
is WO2006021657A1 A VBZ O
selected WO2006021657A1 A VBN O
among WO2006021657A1 A IN O
a WO2006021657A1 A DT O
group WO2006021657A1 A NN O
of WO2006021657A1 A IN O
formula WO2006021657A1 A NN O
( WO2006021657A1 A ( O
a WO2006021657A1 A DT O
) WO2006021657A1 A ) O
, WO2006021657A1 A , O
( WO2006021657A1 A ( O
b WO2006021657A1 A NN O
) WO2006021657A1 A ) O
, WO2006021657A1 A , O
( WO2006021657A1 A ( O
c WO2006021657A1 A NN O
) WO2006021657A1 A ) O
or WO2006021657A1 A CC O
( WO2006021657A1 A ( O
d WO2006021657A1 A NN O
) WO2006021657A1 A ) O
: WO2006021657A1 A : O
or WO2006021657A1 A CC O
a WO2006021657A1 A DT O
group WO2006021657A1 A NN O
of WO2006021657A1 A IN O
formula WO2006021657A1 A NN O
-A-R18 WO2006021657A1 A NNP O
, WO2006021657A1 A , O
-A-CH=N-R19 WO2006021657A1 A NNP O
, WO2006021657A1 A , O
-A-N WO2006021657A1 A NNP O
( WO2006021657A1 A ( O
R20 WO2006021657A1 A NNP O
) WO2006021657A1 A ) O
-A'-R19 WO2006021657A1 A NN O
, WO2006021657A1 A , O
-A-CO-N WO2006021657A1 A NNP O
( WO2006021657A1 A ( O
R2O WO2006021657A1 A NNP O
) WO2006021657A1 A ) O
-A'-R19 WO2006021657A1 A NN O
, WO2006021657A1 A , O
-A-CH WO2006021657A1 A NNP O
( WO2006021657A1 A ( O
NH2 WO2006021657A1 A NNP O
) WO2006021657A1 A ) O
-R19 WO2006021657A1 A NN O
, WO2006021657A1 A , O
-A-N WO2006021657A1 A NNP O
( WO2006021657A1 A ( O
R20 WO2006021657A1 A NNP O
) WO2006021657A1 A ) O
-COO-A WO2006021657A1 A NNP O
' WO2006021657A1 A POS O
or WO2006021657A1 A CC O
- WO2006021657A1 A : O
( WO2006021657A1 A ( O
CH2 WO2006021657A1 A NNP O
) WO2006021657A1 A ) O
r-heteroaryl WO2006021657A1 A NN O
. WO2006021657A1 A . O

The WO2006021657A1 A DT O
invention WO2006021657A1 A NN O
also WO2006021657A1 A RB O
concerns WO2006021657A1 A VBZ O
a WO2006021657A1 A DT O
method WO2006021657A1 A NN O
for WO2006021657A1 A IN O
preparing WO2006021657A1 A VBG O
said WO2006021657A1 A VBD O
derivatives WO2006021657A1 A NNS O
and WO2006021657A1 A CC O
the WO2006021657A1 A DT O
therapeutic WO2006021657A1 A JJ O
use WO2006021657A1 A NN O
thereof WO2006021657A1 A NN O
. WO2006021657A1 A . O

Compounds US20090105203 T NNS O
for US20090105203 T IN O
treating US20090105203 T VBG O
viral US20090105203 T JJ O
infections US20090105203 T NNS O
. US20090105203 T . O

Tetrahydrofuro EP2046796A1 T NNP O
[ EP2046796A1 T NNP O
3 EP2046796A1 T CD O
, EP2046796A1 T , O
2 EP2046796A1 T CD O
-b EP2046796A1 T JJ O
] EP2046796A1 T RB O
pyrr0l-3-ones EP2046796A1 T NNS O
as EP2046796A1 T IN O
cathepsin EP2046796A1 T NN I-UN
k EP2046796A1 T NN I-UN
inhibitors EP2046796A1 T NNS O
. EP2046796A1 T . O

The EP2046796A1 A DT O
present EP2046796A1 A JJ O
invention EP2046796A1 A NN O
relates EP2046796A1 A VBZ O
to EP2046796A1 A TO O
compounds EP2046796A1 A NNS O
of EP2046796A1 A IN O
formula EP2046796A1 A NN O
( EP2046796A1 A ( O
I EP2046796A1 A PRP O
) EP2046796A1 A ) O
, EP2046796A1 A , O
and EP2046796A1 A CC O
pharmaceutically EP2046796A1 A RB O
acceptable EP2046796A1 A JJ O
salts EP2046796A1 A NNS O
thereof EP2046796A1 A NN O
, EP2046796A1 A , O
wherein EP2046796A1 A NN O
: EP2046796A1 A : O
X EP2046796A1 A NN O
is EP2046796A1 A VBZ O
CH EP2046796A1 A NNP O
or EP2046796A1 A CC O
N EP2046796A1 A NNP O
; EP2046796A1 A : O
one EP2046796A1 A CD O
of EP2046796A1 A IN O
R1 EP2046796A1 A NNP O
and EP2046796A1 A CC O
R2 EP2046796A1 A NNP O
is EP2046796A1 A VBZ O
H EP2046796A1 A NNP O
, EP2046796A1 A , O
and EP2046796A1 A CC O
the EP2046796A1 A DT O
other EP2046796A1 A JJ O
is EP2046796A1 A VBZ O
selected EP2046796A1 A VBN O
from EP2046796A1 A IN O
from EP2046796A1 A IN O
OR6 EP2046796A1 A NNP O
, EP2046796A1 A , O
SR6 EP2046796A1 A NNP O
, EP2046796A1 A , O
NR6R7 EP2046796A1 A NNP O
, EP2046796A1 A , O
N3 EP2046796A1 A NNP O
, EP2046796A1 A , O
Me EP2046796A1 A NNP O
, EP2046796A1 A , O
Et EP2046796A1 A NNP O
, EP2046796A1 A , O
CF3 EP2046796A1 A NNP O
, EP2046796A1 A , O
SOR8 EP2046796A1 A NNP O
and EP2046796A1 A CC O
SO2R8 EP2046796A1 A NNP O
; EP2046796A1 A : O
R3 EP2046796A1 A NNP O
is EP2046796A1 A VBZ O
selected EP2046796A1 A VBN O
from EP2046796A1 A IN O
tert-butylmethyl EP2046796A1 A JJ O
, EP2046796A1 A , O
iso-propylmethyl EP2046796A1 A JJ O
, EP2046796A1 A , O
sec-butyl EP2046796A1 A JJ O
, EP2046796A1 A , O
tert-butyl EP2046796A1 A JJ O
, EP2046796A1 A , O
cyclopentyl EP2046796A1 A NN O
and EP2046796A1 A CC O
cyclohexyl EP2046796A1 A NN O
; EP2046796A1 A : O
R4 EP2046796A1 A NNP O
is EP2046796A1 A VBZ O
optionally EP2046796A1 A RB O
substituted EP2046796A1 A VBN O
C1-8 EP2046796A1 A NNP O
alkyl EP2046796A1 A NN O
or EP2046796A1 A CC O
optionally EP2046796A1 A RB O
substituted EP2046796A1 A VBN O
C3-8 EP2046796A1 A NNP O
cycloalkyl EP2046796A1 A NN O
; EP2046796A1 A : O
R6 EP2046796A1 A NNP O
and EP2046796A1 A CC O
R7 EP2046796A1 A NNP O
are EP2046796A1 A VBP O
each EP2046796A1 A DT O
independently EP2046796A1 A RB O
selected EP2046796A1 A VBN O
from EP2046796A1 A IN O
H EP2046796A1 A NNP O
, EP2046796A1 A , O
C1-8-alkyl EP2046796A1 A NNP O
and EP2046796A1 A CC O
C3-8-cycloalkyl EP2046796A1 A NNP O
, EP2046796A1 A , O
or EP2046796A1 A CC O
R6 EP2046796A1 A NNP O
and EP2046796A1 A CC O
R7 EP2046796A1 A NNP O
are EP2046796A1 A VBP O
linked EP2046796A1 A VBN O
to EP2046796A1 A TO O
form EP2046796A1 A VB O
a EP2046796A1 A DT O
cyclic EP2046796A1 A JJ O
group EP2046796A1 A NN O
together EP2046796A1 A RB O
with EP2046796A1 A IN O
the EP2046796A1 A DT O
nitrogen EP2046796A1 A NN O
to EP2046796A1 A TO O
which EP2046796A1 A WDT O
they EP2046796A1 A PRP O
are EP2046796A1 A VBP O
attached EP2046796A1 A VBN O
; EP2046796A1 A : O
and EP2046796A1 A CC O
R8 EP2046796A1 A NNP O
is EP2046796A1 A VBZ O
C1-8-alkyl EP2046796A1 A JJ O
or EP2046796A1 A CC O
C3-8-cycloalkyl EP2046796A1 A JJ O
. EP2046796A1 A . O

The EP2046796A1 A DT O
invention EP2046796A1 A NN O
further EP2046796A1 A RB O
relates EP2046796A1 A VBZ O
to EP2046796A1 A TO O
pharmaceutical EP2046796A1 A JJ O
compositions EP2046796A1 A NNS O
comprising EP2046796A1 A VBG O
compounds EP2046796A1 A NNS O
of EP2046796A1 A IN O
formula EP2046796A1 A NN O
( EP2046796A1 A ( O
I EP2046796A1 A PRP O
) EP2046796A1 A ) O
, EP2046796A1 A , O
and EP2046796A1 A CC O
the EP2046796A1 A DT O
use EP2046796A1 A NN O
of EP2046796A1 A IN O
such EP2046796A1 A JJ O
compounds EP2046796A1 A NNS O
in EP2046796A1 A IN O
the EP2046796A1 A DT O
treatment EP2046796A1 A NN O
of EP2046796A1 A IN O
a EP2046796A1 A DT O
disease EP2046796A1 A NN O
selected EP2046796A1 A VBN O
from EP2046796A1 A IN O
osteoporosis EP2046796A1 A NN O
, EP2046796A1 A , O
Paget EP2046796A1 A NNP O
's EP2046796A1 A POS O
disease EP2046796A1 A NN O
, EP2046796A1 A , O
Chagas EP2046796A1 A NNP O
's EP2046796A1 A POS O
disease EP2046796A1 A NN O
, EP2046796A1 A , O
malaria EP2046796A1 A NN O
, EP2046796A1 A , O
gingival EP2046796A1 A NN O
diseases EP2046796A1 A NNS O
, EP2046796A1 A , O
hypercalaemia EP2046796A1 A NN O
, EP2046796A1 A , O
metabolic EP2046796A1 A JJ O
bone EP2046796A1 A NN O
disease EP2046796A1 A NN O
, EP2046796A1 A , O
diseases EP2046796A1 A VBZ O
involving EP2046796A1 A VBG O
matrix EP2046796A1 A NN O
or EP2046796A1 A CC O
cartilage EP2046796A1 A NN O
degradation EP2046796A1 A NN O
, EP2046796A1 A , O
and EP2046796A1 A CC O
bone EP2046796A1 A NN O
cancer EP2046796A1 A NN O
disorders EP2046796A1 A NNS O
such EP2046796A1 A JJ O
as EP2046796A1 A IN O
bone EP2046796A1 A NN O
metastases EP2046796A1 A NNS O
and EP2046796A1 A CC O
associated EP2046796A1 A VBN O
pain EP2046796A1 A NN O
. EP2046796A1 A . O

Process CA2857096A1 T NN O
for CA2857096A1 T IN O
recovery CA2857096A1 T NN O
of CA2857096A1 T IN O
nalmefene CA2857096A1 T JJ O
hydrochloride CA2857096A1 T NN O
. CA2857096A1 T . O

Application CN101829084A T NN O
of CN101829084A T IN O
aminobenzoyl CN101829084A T JJ O
silybin CN101829084A T NN O
for CN101829084A T IN O
preparing CN101829084A T VBG O
virus CN101829084A T NN O
hepatitis CN101829084A T NN O
B CN101829084A T NNP O
medicine CN101829084A T NN O
. CN101829084A T . O

The CN101829084A A DT O
invention CN101829084A A NN O
relates CN101829084A A VBZ O
to CN101829084A A TO O
the CN101829084A A DT O
application CN101829084A A NN O
of CN101829084A A IN O
aminobenzoyl CN101829084A A JJ O
silybin CN101829084A A NN O
for CN101829084A A IN O
preparing CN101829084A A VBG O
a CN101829084A A DT O
virus CN101829084A A NN O
hepatitis CN101829084A A NN O
B CN101829084A A NNP O
medicine CN101829084A A NN O
, CN101829084A A , O
in CN101829084A A IN O
particular CN101829084A A JJ O
to CN101829084A A TO O
the CN101829084A A DT O
application CN101829084A A NN O
of CN101829084A A IN O
23-bit CN101829084A A JJ O
p-aminobenzoyl CN101829084A A NN O
substituted CN101829084A A VBD O
silybin CN101829084A A JJ O
ester CN101829084A A NN O
or CN101829084A A CC O
pharmaceutically CN101829084A A RB O
acceptable CN101829084A A JJ O
salts CN101829084A A NNS O
thereof CN101829084A A NN O
for CN101829084A A IN O
preparing CN101829084A A VBG O
a CN101829084A A DT O
medicine CN101829084A A NN O
for CN101829084A A IN O
eliminating CN101829084A A VBG O
hepatitis CN101829084A A NN I-UN
B CN101829084A A NNP I-UN
virus CN101829084A A NN I-UN
surface CN101829084A A NN I-UN
antigen CN101829084A A NN I-UN
and CN101829084A A CC O
hepatitis CN101829084A A NN I-UN
B CN101829084A A NNP I-UN
e-antigen CN101829084A A NN I-UN
and CN101829084A A CC O
inhibiting CN101829084A A VBG O
HBV CN101829084A A NNP O
DNA CN101829084A A NNP O
reproduction CN101829084A A NN O
. CN101829084A A . O

The CN101829084A A DT O
aminobenzoyl CN101829084A A NN O
silybin CN101829084A A NN O
has CN101829084A A VBZ O
obvious CN101829084A A JJ O
activity CN101829084A A NN O
for CN101829084A A IN O
inhibiting CN101829084A A VBG O
HBsAg CN101829084A A NNP I-UN
and CN101829084A A CC O
HBeAg CN101829084A A NNP I-UN
, CN101829084A A , O
the CN101829084A A DT O
intensities CN101829084A A NNS O
for CN101829084A A IN O
eliminating CN101829084A A VBG O
the CN101829084A A DT O
HBsAg CN101829084A A NNP I-UN
and CN101829084A A CC O
the CN101829084A A DT O
HBeAg CN101829084A A NNP I-UN
are CN101829084A A VBP O
respectively CN101829084A A RB O
of CN101829084A A IN O
73.9 CN101829084A A CD O
percent CN101829084A A NN O
and CN101829084A A CC O
95.3 CN101829084A A CD O
percent CN101829084A A NN O
when CN101829084A A WRB O
the CN101829084A A DT O
concentration CN101829084A A NN O
is CN101829084A A VBZ O
100 CN101829084A A CD O
milligram/milliliter CN101829084A A NN O
and CN101829084A A CC O
are CN101829084A A VBP O
respectively CN101829084A A RB O
higher CN101829084A A JJR O
than CN101829084A A IN O
that CN101829084A A DT O
of CN101829084A A IN O
a CN101829084A A DT O
positive CN101829084A A JJ O
control CN101829084A A NN O
medicine CN101829084A A NN O
alpha-interferon CN101829084A A NN O
by CN101829084A A IN O
4.6 CN101829084A A CD O
times CN101829084A A NNS O
and CN101829084A A CC O
5.6 CN101829084A A CD O
times CN101829084A A NNS O
, CN101829084A A , O
and CN101829084A A CC O
meanwhile CN101829084A A RB O
, CN101829084A A , O
under CN101829084A A IN O
the CN101829084A A DT O
same CN101829084A A JJ O
concentration CN101829084A A NN O
, CN101829084A A , O
the CN101829084A A DT O
inhabitation CN101829084A A NN O
ratio CN101829084A A NN O
of CN101829084A A IN O
the CN101829084A A DT O
aminobenzoyl CN101829084A A NN O
silybin CN101829084A A NN O
for CN101829084A A IN O
the CN101829084A A DT O
HBV CN101829084A A NNP O
DNA CN101829084A A NNP O
is CN101829084A A VBZ O
larger CN101829084A A JJR O
than CN101829084A A IN O
96 CN101829084A A CD O
percent CN101829084A A NN O
. CN101829084A A . O

The CN101829084A A DT O
invention CN101829084A A NN O
indicates CN101829084A A VBZ O
the CN101829084A A DT O
application CN101829084A A NN O
of CN101829084A A IN O
flavanolignan CN101829084A A NN O
or CN101829084A A CC O
the CN101829084A A DT O
pharmaceutically CN101829084A A RB O
acceptable CN101829084A A JJ O
salt CN101829084A A NN O
which CN101829084A A WDT O
can CN101829084A A MD O
be CN101829084A A VB O
used CN101829084A A VBN O
for CN101829084A A IN O
preparing CN101829084A A VBG O
a CN101829084A A DT O
non-nucleoside CN101829084A A JJ O
medicine CN101829084A A NN O
for CN101829084A A IN O
eliminating CN101829084A A VBG O
the CN101829084A A DT O
HBsAg CN101829084A A NNP I-UN
and CN101829084A A CC O
the CN101829084A A DT O
HBeAg CN101829084A A NNP I-UN
, CN101829084A A , O
inhibiting CN101829084A A VBG O
HBV CN101829084A A NNP O
DNA CN101829084A A NNP O
reproduction CN101829084A A NN O
, CN101829084A A , O
treating CN101829084A A VBG O
hepatitis CN101829084A A NN O
B CN101829084A A NNP O
virus CN101829084A A NN O
infection CN101829084A A NN O
diseases CN101829084A A NNS O
. CN101829084A A . O

Novel CN103012187A T NNP O
diacetyl CN103012187A T VBZ O
acetic CN103012187A T JJ O
acid CN103012187A T NNS O
quadrol CN103012187A T VBP O
compound CN103012187A T NN O
and CN103012187A T CC O
drug CN103012187A T NN O
combination CN103012187A T NN O
thereof CN103012187A T NN O
. CN103012187A T . O

More CN102367251A T RBR O
stable CN102367251A T JJ O
tropisetron CN102367251A T NN O
compound CN102367251A T NN O
and CN102367251A T CC O
pharmaceutical CN102367251A T JJ O
composition CN102367251A T NN O
thereof CN102367251A T NN O
. CN102367251A T . O

Bis-Heterocyclic US20090197909 T JJ O
Imidazolyl US20090197909 T NNP O
Compounds US20090197909 T NNP O
. US20090197909 T . O

The US20090197909 A DT O
patent US20090197909 A NN O
application US20090197909 A NN O
relates US20090197909 A VBZ O
to US20090197909 A TO O
new US20090197909 A JJ O
heterocyclic US20090197909 A JJ O
compounds US20090197909 A NNS O
of US20090197909 A IN O
the US20090197909 A DT O
general US20090197909 A JJ O
formula US20090197909 A NN O
( US20090197909 A ( O
I US20090197909 A PRP O
) US20090197909 A ) O
in US20090197909 A IN O
which US20090197909 A WDT O
R US20090197909 A NNP O
, US20090197909 A , O
R1 US20090197909 A NNP O
, US20090197909 A , O
R2 US20090197909 A NNP O
, US20090197909 A , O
R3 US20090197909 A NNP O
, US20090197909 A , O
R4 US20090197909 A NNP O
and US20090197909 A CC O
n US20090197909 A RB O
have US20090197909 A VBP O
the US20090197909 A DT O
definitions US20090197909 A NNS O
elucidated US20090197909 A VBD O
in US20090197909 A IN O
more US20090197909 A RBR O
detail US20090197909 A NN O
in US20090197909 A IN O
the US20090197909 A DT O
description US20090197909 A NN O
, US20090197909 A , O
to US20090197909 A TO O
a US20090197909 A DT O
process US20090197909 A NN O
for US20090197909 A IN O
preparing US20090197909 A VBG O
them US20090197909 A PRP O
and US20090197909 A CC O
to US20090197909 A TO O
the US20090197909 A DT O
use US20090197909 A NN O
of US20090197909 A IN O
these US20090197909 A DT O
C US20090197909 A NNP O
compounds US20090197909 A NNS O
as US20090197909 A IN O
medicaments US20090197909 A NNS O
, US20090197909 A , O
particularly US20090197909 A RB O
as US20090197909 A IN O
aldosterone US20090197909 A NN I-UN
synthase US20090197909 A NN I-UN
inhibitors US20090197909 A NNS O
. US20090197909 A . O

N3-heteroaryl WO2008083354A1 T NNP O
substituted WO2008083354A1 T VBD O
triazoles WO2008083354A1 T NNS O
and WO2008083354A1 T CC O
n5-heteroaryl WO2008083354A1 T JJ O
substituted WO2008083354A1 T JJ O
triazoles WO2008083354A1 T NNS O
useful WO2008083354A1 T JJ O
as WO2008083354A1 T IN O
axl WO2008083354A1 T JJ I-UN
inhibitors WO2008083354A1 T NNS O
. WO2008083354A1 T . O

N3-Heteroaryl WO2008083354A1 A NNP O
substituted WO2008083354A1 A VBD O
triazoles WO2008083354A1 A NNS O
and WO2008083354A1 A CC O
N5-heteroaryl WO2008083354A1 A NNP O
substituted WO2008083354A1 A VBD O
triazoles WO2008083354A1 A NNS O
and WO2008083354A1 A CC O
pharmaceutical WO2008083354A1 A JJ O
compositions WO2008083354A1 A NNS O
containing WO2008083354A1 A VBG O
the WO2008083354A1 A DT O
compounds WO2008083354A1 A NNS O
are WO2008083354A1 A VBP O
disclosed WO2008083354A1 A VBN O
as WO2008083354A1 A IN O
being WO2008083354A1 A VBG O
useful WO2008083354A1 A JJ O
in WO2008083354A1 A IN O
inhibiting WO2008083354A1 A VBG O
the WO2008083354A1 A DT O
activity WO2008083354A1 A NN O
of WO2008083354A1 A IN O
the WO2008083354A1 A DT O
receptor WO2008083354A1 A NN I-UN
protein WO2008083354A1 A NN I-UN
tyrosine WO2008083354A1 A JJ I-UN
kinase WO2008083354A1 A NN I-UN
Axl WO2008083354A1 A NNP I-UN
. WO2008083354A1 A . O

Methods WO2008083354A1 A NNS O
of WO2008083354A1 A IN O
using WO2008083354A1 A VBG O
the WO2008083354A1 A DT O
compounds WO2008083354A1 A NNS O
in WO2008083354A1 A IN O
treating WO2008083354A1 A VBG O
diseases WO2008083354A1 A NNS O
or WO2008083354A1 A CC O
conditions WO2008083354A1 A NNS O
associated WO2008083354A1 A VBN O
with WO2008083354A1 A IN O
Axl WO2008083354A1 A NNP I-UN
activity WO2008083354A1 A NN O
are WO2008083354A1 A VBP O
also WO2008083354A1 A RB O
disclosed WO2008083354A1 A VBN O
. WO2008083354A1 A . O

Oral EP1711182A1 T NNP O
cyclodextrin EP1711182A1 T NN O
complexes EP1711182A1 T NNS O
of EP1711182A1 T IN O
antituberculosis EP1711182A1 T NN O
drugs EP1711182A1 T NNS O
. EP1711182A1 T . O

Crystalline WO2013007361A1 T NNP O
( WO2013007361A1 T ( O
1r,4r WO2013007361A1 T CD O
) WO2013007361A1 T ) O
-6'-fluoro-n WO2013007361A1 T NN O
, WO2013007361A1 T , O
n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro WO2013007361A1 T JJ O
[ WO2013007361A1 T JJ O
cyclohexane-1,1'-pyrano WO2013007361A1 T NN O
[ WO2013007361A1 T NN O
3,4 WO2013007361A1 T CD O
, WO2013007361A1 T , O
b WO2013007361A1 T NN O
] WO2013007361A1 T NNP O
indol WO2013007361A1 T NN O
] WO2013007361A1 T NNP O
-4-amine WO2013007361A1 T NNP O
. WO2013007361A1 T . O

Amorphous US20050152845 T JJ O
fluticasone US20050152845 T NN O
2-furoate US20050152845 T JJ O
, US20050152845 T , O
pharmaceutical US20050152845 T JJ O
compositions US20050152845 T NNS O
thereof US20050152845 T NN O
and US20050152845 T CC O
its US20050152845 T PRP$ O
conversion US20050152845 T NN O
to US20050152845 T TO O
the US20050152845 T DT O
crystalline US20050152845 T NN O
unsolvated US20050152845 T JJ O
form US20050152845 T NN O
. US20050152845 T . O

Oseltamivir EP2005945A2 T NNP O
phosphate EP2005945A2 T NN O
granule EP2005945A2 T NN O
and EP2005945A2 T CC O
preparation EP2005945A2 T NN O
mehtod EP2005945A2 T NN O
thereof EP2005945A2 T NN O
. EP2005945A2 T . O

Conjugates WO2007064762A3 T NNS O
of WO2007064762A3 T IN O
amino WO2007064762A3 T NN O
acids WO2007064762A3 T NNS O
and WO2007064762A3 T CC O
vitamin WO2007064762A3 T NN O
b3 WO2007064762A3 T NN O
for WO2007064762A3 T IN O
percutaneous WO2007064762A3 T JJ O
delivery WO2007064762A3 T NN O
of WO2007064762A3 T IN O
vitamin WO2007064762A3 T NN O
b3 WO2007064762A3 T NN O
. WO2007064762A3 T . O

for US7501441 T IN O
treating US7501441 T VBG O
uterine US7501441 T JJ O
fibroid US7501441 T JJ O
disease US7501441 T NN O
; US7501441 T : O
[ US7501441 T CC O
2- US7501441 T JJ O
( US7501441 T ( O
4-hydroxyphenyl US7501441 T JJ O
) US7501441 T ) O
-6-hydroxynaphthalen-1-yl US7501441 T FW O
] US7501441 T JJ O
[ US7501441 T JJ O
4- US7501441 T JJ O
( US7501441 T ( O
2- US7501441 T JJ O
( US7501441 T ( O
1-piperidinyl US7501441 T JJ O
) US7501441 T ) O
ethoxy US7501441 T NN O
) US7501441 T ) O
phenyl US7501441 T NN O
] US7501441 T NNP O
methane US7501441 T NN O
; US7501441 T : O
therapy US7501441 T NN O
for US7501441 T IN O
post US7501441 T NN O
manupausal US7501441 T NN O
women US7501441 T NNS O
. US7501441 T . O

The US7501441 A DT O
present US7501441 A JJ O
invention US7501441 A NN O
is US7501441 A VBZ O
a US7501441 A DT O
method US7501441 A NN O
for US7501441 A IN O
treating US7501441 A VBG O
uterine US7501441 A JJ O
fibroid US7501441 A JJ O
disease US7501441 A NN O
using US7501441 A VBG O
a US7501441 A DT O
compound US7501441 A NN O
of US7501441 A IN O
formula US7501441 A NN O
I US7501441 A PRP O
wherein US7501441 A VBP O
R1 US7501441 A NNP O
is US7501441 A VBZ O
—H US7501441 A NNP O
, US7501441 A , O
—OH US7501441 A NNP O
, US7501441 A , O
—O US7501441 A NNP O
( US7501441 A ( O
C1-C4 US7501441 A NNP O
alkyl US7501441 A NN O
) US7501441 A ) O
, US7501441 A , O
—OCOC6H5 US7501441 A UH O
, US7501441 A , O
—OCO US7501441 A JJ O
( US7501441 A ( O
C1-C6 US7501441 A NNP O
alkyl US7501441 A NN O
) US7501441 A ) O
, US7501441 A , O
or US7501441 A CC O
—OSO2 US7501441 A NNP O
( US7501441 A ( O
C4-C6 US7501441 A NNP O
alkyl US7501441 A NN O
) US7501441 A ) O
; US7501441 A : O
R2 US7501441 A NNP O
is US7501441 A VBZ O
—H US7501441 A NNP O
, US7501441 A , O
—OH US7501441 A NNP O
, US7501441 A , O
—O US7501441 A NNP O
( US7501441 A ( O
C1-C4 US7501441 A NNP O
alkyl US7501441 A NN O
) US7501441 A ) O
, US7501441 A , O
—OCOC6H5 US7501441 A UH O
, US7501441 A , O
—OCO US7501441 A JJ O
( US7501441 A ( O
C1-C6 US7501441 A NNP O
alkyl US7501441 A NN O
) US7501441 A ) O
or US7501441 A CC O
—OSO2 US7501441 A $ O
( US7501441 A ( O
C4-C6 US7501441 A NNP O
alkyl US7501441 A NN O
) US7501441 A ) O
; US7501441 A : O
n US7501441 A CC O
is US7501441 A VBZ O
2 US7501441 A CD O
or US7501441 A CC O
3 US7501441 A CD O
; US7501441 A : O
and US7501441 A CC O
R3 US7501441 A NNP O
is US7501441 A VBZ O
1-piperidinyl US7501441 A JJ O
, US7501441 A , O
1-pyrrolidinyl US7501441 A JJ O
, US7501441 A , O
methyl-1-pyrrolidinyl US7501441 A JJ O
, US7501441 A , O
dimethyl-1-pyrrolidinyl US7501441 A JJ O
, US7501441 A , O
4-morpholino US7501441 A JJ O
, US7501441 A , O
dimethylamino US7501441 A NN O
, US7501441 A , O
diethylamino US7501441 A NN O
, US7501441 A , O
or US7501441 A CC O
1-hexamethyleneimino US7501441 A JJ O
; US7501441 A : O
or US7501441 A CC O
a US7501441 A DT O
pharmaceutically US7501441 A RB O
acceptable US7501441 A JJ O
salt US7501441 A NN O
thereof US7501441 A NN O
. US7501441 A . O

Preventive WO2006082821A1 T JJ O
or WO2006082821A1 T CC O
therapeutic WO2006082821A1 T JJ O
agent WO2006082821A1 T NN O
for WO2006082821A1 T IN O
herpesvirus-related WO2006082821A1 T JJ O
disease WO2006082821A1 T NN O
. WO2006082821A1 T . O

Solid US20110046184 T JJ O
state US20110046184 T NN O
forms US20110046184 T NNS O
of US20110046184 T IN O
racemic US20110046184 T JJ O
ilaprazole US20110046184 T NN O
. US20110046184 T . O

Treatment US20110060005 T NN O
of US20110060005 T IN O
mitochondrial US20110060005 T JJ O
disorders US20110060005 T NNS O
using US20110060005 T VBG O
a US20110060005 T DT O
farnesyl US20110060005 T JJ I-UN
transferase US20110060005 T NN I-UN
inhibitor US20110060005 T NN O
. US20110060005 T . O

The US20110060005 A DT O
treatment US20110060005 A NN O
includes US20110060005 A VBZ O
administering US20110060005 A VBG O
to US20110060005 A TO O
a US20110060005 A DT O
subject US20110060005 A NN O
an US20110060005 A DT O
amount US20110060005 A NN O
of US20110060005 A IN O
a US20110060005 A DT O
farnesyl US20110060005 A JJ I-UN
transferase US20110060005 A NN I-UN
inhibitor US20110060005 A NN O
, US20110060005 A , O
wherein US20110060005 A VBP O
the US20110060005 A DT O
amount US20110060005 A NN O
administered US20110060005 A VBD O
is US20110060005 A VBZ O
sufficient US20110060005 A JJ O
to US20110060005 A TO O
stimulate US20110060005 A VB O
mitophagy US20110060005 A NN O
in US20110060005 A IN O
said US20110060005 A VBD O
subject US20110060005 A NN O
. US20110060005 A . O

Treatments US20110060005 A NNS O
in US20110060005 A IN O
accordance US20110060005 A NN O
with US20110060005 A IN O
the US20110060005 A DT O
present US20110060005 A JJ O
invention US20110060005 A NN O
may US20110060005 A MD O
also US20110060005 A RB O
include US20110060005 A VB O
an US20110060005 A DT O
acetylcholinesterase US20110060005 A NN I-UN
inhibitor US20110060005 A NN O
, US20110060005 A , O
an US20110060005 A DT O
activator US20110060005 A NN O
of US20110060005 A IN O
neurotrophic US20110060005 A JJ I-UN
receptors US20110060005 A NNS I-UN
, US20110060005 A , O
an US20110060005 A DT O
NMDA US20110060005 A NNP I-UN
anatagonist US20110060005 A NN O
, US20110060005 A , O
an US20110060005 A DT O
amyloid US20110060005 A JJ I-UN
deposit US20110060005 A NN O
inhibitor US20110060005 A NN O
, US20110060005 A , O
an US20110060005 A DT O
antipsychotic US20110060005 A JJ O
agent US20110060005 A NN O
, US20110060005 A , O
an US20110060005 A DT O
antidepressant US20110060005 A NN O
, US20110060005 A , O
an US20110060005 A DT O
anxiolytic US20110060005 A JJ O
, US20110060005 A , O
or US20110060005 A CC O
an US20110060005 A DT O
antioxidant US20110060005 A NN O
. US20110060005 A . O

Hydrazinocarbonyl-thieno US20080146542 T JJ O
[ US20080146542 T NNP O
2,3-C US20080146542 T JJ O
] US20080146542 T NN O
pyrazoles US20080146542 T NNS O
, US20080146542 T , O
Process US20080146542 T NNP O
for US20080146542 T IN O
Preparing US20080146542 T VBG O
Them US20080146542 T NNP O
, US20080146542 T , O
Compositions US20080146542 T NNP O
Containing US20080146542 T NNP O
Them US20080146542 T NNP O
and US20080146542 T CC O
Use US20080146542 T NNP O
Thereof US20080146542 T NNP O
. US20080146542 T . O

1,2,5-substituted WO2014151367A1 T JJ O
benzimidazoles WO2014151367A1 T NNS O
as WO2014151367A1 T IN O
flap WO2014151367A1 T JJ O
modulators WO2014151367A1 T NNS O
. WO2014151367A1 T . O

Anti-allergic CN103536688A T JJ O
inflammation CN103536688A T NN O
drop CN103536688A T NN O
. CN103536688A T . O

Process WO2010139980A1 T NN O
for WO2010139980A1 T IN O
preparing WO2010139980A1 T VBG O
crystalline WO2010139980A1 T NN O
dasatinib WO2010139980A1 T NN O
monohydrate WO2010139980A1 T NN O
. WO2010139980A1 T . O

Azithromycin CN101129398B T NNP O
dispersible CN101129398B T JJ O
tablet CN101129398B T NN O
and CN101129398B T CC O
method CN101129398B T NN O
of CN101129398B T IN O
preparing CN101129398B T VBG O
the CN101129398B T DT O
same CN101129398B T JJ O
. CN101129398B T . O

Smokeless CN103263438A T NNP O
moxa CN103263438A T CC O
cone CN103263438A T NN O
and CN103263438A T CC O
preparation CN103263438A T NN O
method CN103263438A T NN O
thereof CN103263438A T NN O
. CN103263438A T . O

Pharmaceutical US20080139652 T JJ O
Composition US20080139652 T NNP O
Containing US20080139652 T NNP O
Prostaglandin US20080139652 T NNP O
. US20080139652 T . O

Medicament CN103751237A T NN O
of CN103751237A T IN O
dsRNA CN103751237A T NN O
and CN103751237A T CC O
saikosaponin CN103751237A T NN O
. CN103751237A T . O

Steroid WO2014057957A1 T NNP O
compound WO2014057957A1 T NN O
, WO2014057957A1 T , O
and WO2014057957A1 T CC O
medicine WO2014057957A1 T NN O
comprising WO2014057957A1 T NN O
same WO2014057957A1 T JJ O
. WO2014057957A1 T . O

Spiro US20090062270 T NNP O
2,4 US20090062270 T CD O
pyrimidinediamine US20090062270 T NN O
compounds US20090062270 T NNS O
and US20090062270 T CC O
their US20090062270 T PRP$ O
uses US20090062270 T NNS O
. US20090062270 T . O

Therapeutic WO2010027090A1 T JJ O
agent WO2010027090A1 T NN O
for WO2010027090A1 T IN O
uremia WO2010027090A1 T NN O
. WO2010027090A1 T . O

Bone US7071178 T NN O
disorders US7071178 T NNS O
; US7071178 T : O
osteoporosis US7071178 T NN O
. US7071178 T . O

Ganoderic CN102440969A T NNP O
acid CN102440969A T NN O
monomer CN102440969A T NN O
T CN102440969A T NNP O
tablet CN102440969A T NN O
and CN102440969A T CC O
its CN102440969A T PRP$ O
preparation CN102440969A T NN O
method CN102440969A T NN O
. CN102440969A T . O

Warming US20100239641 T VBG O
vapor US20100239641 T NN O
pad US20100239641 T NN O
. US20100239641 T . O

A US20100239641 A DT O
warming US20100239641 A VBG O
vapor US20100239641 A NN O
pad US20100239641 A NN O
to US20100239641 A TO O
treat US20100239641 A VB O
respiratory US20100239641 A JJ O
syncytial US20100239641 A JJ O
virus US20100239641 A NN O
infections US20100239641 A NNS O
in US20100239641 A IN O
babies US20100239641 A NNS O
, US20100239641 A , O
children US20100239641 A NNS O
and US20100239641 A CC O
adults US20100239641 A NNS O
includes US20100239641 A VBZ O
a US20100239641 A DT O
fabric US20100239641 A NN O
impregnated US20100239641 A VBN O
with US20100239641 A IN O
a US20100239641 A DT O
topical US20100239641 A JJ O
ointment US20100239641 A NN O
providing US20100239641 A VBG O
medicated US20100239641 A VBD O
vapors US20100239641 A NNS O
to US20100239641 A TO O
relieve US20100239641 A VB O
a US20100239641 A DT O
user US20100239641 A NN O
's US20100239641 A POS O
cough US20100239641 A NN O
, US20100239641 A , O
with US20100239641 A IN O
the US20100239641 A DT O
fabric US20100239641 A NN O
being US20100239641 A VBG O
superimposed US20100239641 A VBN O
on US20100239641 A IN O
an US20100239641 A DT O
elastic US20100239641 A JJ O
thermal US20100239641 A NN O
wrap US20100239641 A NN O
for US20100239641 A IN O
application US20100239641 A NN O
as US20100239641 A IN O
a US20100239641 A DT O
single US20100239641 A JJ O
layer US20100239641 A NN O
on US20100239641 A IN O
the US20100239641 A DT O
user US20100239641 A NN O
's US20100239641 A POS O
chest US20100239641 A NN O
. US20100239641 A . O

Methods WO2012064928A1 T NNS O
and WO2012064928A1 T CC O
compositions WO2012064928A1 T NNS O
for WO2012064928A1 T IN O
treating WO2012064928A1 T VBG O
thyroid WO2012064928A1 T JJ O
hormone WO2012064928A1 T NN O
related WO2012064928A1 T JJ O
disorders WO2012064928A1 T NNS O
. WO2012064928A1 T . O

The WO2012064928A1 A DT O
invention WO2012064928A1 A NN O
generally WO2012064928A1 A RB O
relates WO2012064928A1 A VBZ O
to WO2012064928A1 A TO O
methods WO2012064928A1 A NNS O
of WO2012064928A1 A IN O
improving WO2012064928A1 A VBG O
thyroid WO2012064928A1 A JJ O
hormone WO2012064928A1 A NN O
sensitivity WO2012064928A1 A NN O
or WO2012064928A1 A CC O
treating WO2012064928A1 A VBG O
a WO2012064928A1 A DT O
thyroid WO2012064928A1 A NN O
hormone WO2012064928A1 A NN O
resistance WO2012064928A1 A NN O
related WO2012064928A1 A VBN O
disorder WO2012064928A1 A NN O
in WO2012064928A1 A IN O
a WO2012064928A1 A DT O
patient WO2012064928A1 A NN O
in WO2012064928A1 A IN O
need WO2012064928A1 A NN O
thereof WO2012064928A1 A NN O
, WO2012064928A1 A , O
comprising WO2012064928A1 A VBG O
administering WO2012064928A1 A VBG O
a WO2012064928A1 A DT O
pharmaceutically WO2012064928A1 A RB O
effective WO2012064928A1 A JJ O
amount WO2012064928A1 A NN O
of WO2012064928A1 A IN O
a WO2012064928A1 A DT O
MetAP-2 WO2012064928A1 A NNP I-UN
inhibitor WO2012064928A1 A NN O
. WO2012064928A1 A . O

Such WO2012064928A1 A JJ O
methods WO2012064928A1 A NNS O
may WO2012064928A1 A MD O
include WO2012064928A1 A VB O
administering WO2012064928A1 A VBG O
a WO2012064928A1 A DT O
MetAP-2 WO2012064928A1 A JJ I-UN
inhibitor WO2012064928A1 A NN O
at WO2012064928A1 A IN O
a WO2012064928A1 A DT O
dose WO2012064928A1 A NN O
that WO2012064928A1 A WDT O
does WO2012064928A1 A VBZ O
not WO2012064928A1 A RB O
substantially WO2012064928A1 A RB O
modulate WO2012064928A1 A JJ O
angiogenesis WO2012064928A1 A NN O
. WO2012064928A1 A . O

Composition DE102004003030A1 T NN O
containing DE102004003030A1 T VBG O
a DE102004003030A1 T DT O
dihydroanthracene-disulfonic DE102004003030A1 T JJ O
acid DE102004003030A1 T NN O
derivative DE102004003030A1 T NN O
, DE102004003030A1 T , O
useful DE102004003030A1 T JJ O
for DE102004003030A1 T IN O
treating DE102004003030A1 T VBG O
inflammation DE102004003030A1 T NN O
of DE102004003030A1 T IN O
internal DE102004003030A1 T JJ O
organs DE102004003030A1 T NNS O
, DE102004003030A1 T , O
e.g DE102004003030A1 T NN O
. DE102004003030A1 T . O

ulcers DE102004003030A1 T NNS O
, DE102004003030A1 T , O
and DE102004003030A1 T CC O
cancer DE102004003030A1 T NN O
. DE102004003030A1 T . O

Acadesine WO2012143624A2 T NNP O
derivatives WO2012143624A2 T NNS O
, WO2012143624A2 T , O
products WO2012143624A2 T NNS O
and WO2012143624A2 T CC O
compositions WO2012143624A2 T NNS O
including WO2012143624A2 T VBG O
same WO2012143624A2 T JJ O
, WO2012143624A2 T , O
therapeutic WO2012143624A2 T JJ O
uses WO2012143624A2 T NNS O
thereof WO2012143624A2 T NN O
, WO2012143624A2 T , O
and WO2012143624A2 T CC O
methods WO2012143624A2 T NNS O
for WO2012143624A2 T IN O
synthesizing WO2012143624A2 T VBG O
same WO2012143624A2 T JJ O
. WO2012143624A2 T . O

New WO2012007555A3 T NNP O
ziprasidone WO2012007555A3 T NN O
salts WO2012007555A3 T NNS O
and WO2012007555A3 T CC O
methods WO2012007555A3 T NNS O
of WO2012007555A3 T IN O
their WO2012007555A3 T PRP$ O
formation WO2012007555A3 T NN O
. WO2012007555A3 T . O

Therapeutic WO2012076916A1 T JJ O
association WO2012076916A1 T NN O
of WO2012076916A1 T IN O
5 WO2012076916A1 T CD O
- WO2012076916A1 T : O
hydroxy WO2012076916A1 T NN O
- WO2012076916A1 T : O
tryptophan WO2012076916A1 T NN O
and WO2012076916A1 T CC O
caffeine WO2012076916A1 T NN O
for WO2012076916A1 T IN O
the WO2012076916A1 T DT O
treatment WO2012076916A1 T NN O
of WO2012076916A1 T IN O
the WO2012076916A1 T DT O
symptom WO2012076916A1 T NN O
of WO2012076916A1 T IN O
parkinson WO2012076916A1 T NN O
's WO2012076916A1 T POS O
disease WO2012076916A1 T NN O
, WO2012076916A1 T , O
daytime WO2012076916A1 T JJ O
sleepiness WO2012076916A1 T NN O
. WO2012076916A1 T . O

Safety EP1397170B1 T NNP O
shield EP1397170B1 T NN O
system EP1397170B1 T NN O
for EP1397170B1 T IN O
prefilled EP1397170B1 T JJ O
syringes EP1397170B1 T NNS O
. EP1397170B1 T . O

Salt EP2238108A1 T NNP O
forms EP2238108A1 T NNS O
of EP2238108A1 T IN O
a EP2238108A1 T DT O
6-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene EP2238108A1 T JJ O
derivative EP2238108A1 T NN O
, EP2238108A1 T , O
process EP2238108A1 T NN O
for EP2238108A1 T IN O
their EP2238108A1 T PRP$ O
manufacture EP2238108A1 T NN O
and EP2238108A1 T CC O
pharmaceutical EP2238108A1 T JJ O
compositions EP2238108A1 T NNS O
containing EP2238108A1 T VBG O
same EP2238108A1 T JJ O
. EP2238108A1 T . O

Topical US20110082125 T JJ O
Ophthalmic US20110082125 T NNP O
or US20110082125 T CC O
Otic US20110082125 T NNP O
Solution US20110082125 T NNP O
Formulations US20110082125 T NNP O
Containing US20110082125 T NNP O
Moxifloxacin US20110082125 T NNP O
Hydrocholoride US20110082125 T NNP O
and US20110082125 T CC O
Dexamethasone US20110082125 T NNP O
Phosphate US20110082125 T NNP O
. US20110082125 T . O

Embedded US20090035368 T VBN O
micellar US20090035368 T JJ O
nanoparticles US20090035368 T NNS O
. US20090035368 T . O

Pill CN101953811A T NNP O
composition CN101953811A T NN O
used CN101953811A T VBN O
for CN101953811A T IN O
preventing CN101953811A T VBG O
and CN101953811A T CC O
treating CN101953811A T VBG O
Alzheimer CN101953811A T NNP O
disease CN101953811A T NN O
and CN101953811A T CC O
preparation CN101953811A T NN O
method CN101953811A T NN O
thereof CN101953811A T NN O
. CN101953811A T . O

Isoquinolines WO2008103615A1 T NNS O
useful WO2008103615A1 T JJ O
as WO2008103615A1 T IN O
inducible WO2008103615A1 T JJ I-UN
nitric WO2008103615A1 T JJ I-UN
oxide WO2008103615A1 T IN I-UN
synthase WO2008103615A1 T NN I-UN
inhibitors WO2008103615A1 T NNS O
. WO2008103615A1 T . O

Methods WO2008103615A1 A NNS O
of WO2008103615A1 A IN O
inhibition WO2008103615A1 A NN O
of WO2008103615A1 A IN O
nitric WO2008103615A1 A JJ I-UN
oxide WO2008103615A1 A JJ I-UN
synthase WO2008103615A1 A NN I-UN
activity WO2008103615A1 A NN O
in WO2008103615A1 A IN O
a WO2008103615A1 A DT O
human WO2008103615A1 A JJ O
or WO2008103615A1 A CC O
animal WO2008103615A1 A NN O
subject WO2008103615A1 A NN O
are WO2008103615A1 A VBP O
also WO2008103615A1 A RB O
provided WO2008103615A1 A VBN O
for WO2008103615A1 A IN O
the WO2008103615A1 A DT O
treatment WO2008103615A1 A NN O
disease WO2008103615A1 A NN O
. WO2008103615A1 A . O

Method WO2009085262A1 T NNP O
of WO2009085262A1 T IN O
treating WO2009085262A1 T VBG O
cancer WO2009085262A1 T NN O
with WO2009085262A1 T IN O
immunomodulatory WO2009085262A1 T JJ O
compounds WO2009085262A1 T NNS O
and WO2009085262A1 T CC O
igg WO2009085262A1 T NN O
. WO2009085262A1 T . O

Microemulsion CN100998592A T NN O
containing CN100998592A T VBG O
matrine CN100998592A T NN O
. CN100998592A T . O

compounds CN101743232A T NNS O
and CN101743232A T CC O
methods CN101743232A T NNS O
for CN101743232A T IN O
modulating CN101743232A T VBG O
fxr CN101743232A T NN I-UN
. CN101743232A T . O

Compounds CN101743232A A NNS O
of CN101743232A A IN O
formula CN101743232A A NN O
( CN101743232A A ( O
I CN101743232A A PRP O
) CN101743232A A ) O
: CN101743232A A : O
formula CN101743232A A NN O
( CN101743232A A ( O
I CN101743232A A PRP O
) CN101743232A A ) O
wherein CN101743232A A NN O
variables CN101743232A A NNS O
are CN101743232A A VBP O
as CN101743232A A IN O
defined CN101743232A A JJ O
herein CN101743232A A NN O
and CN101743232A A CC O
their CN101743232A A PRP$ O
pharmaceutical CN101743232A A JJ O
compositions CN101743232A A NNS O
and CN101743232A A CC O
methods CN101743232A A NNS O
of CN101743232A A IN O
use CN101743232A A NN O
are CN101743232A A VBP O
disclosed CN101743232A A VBN O
as CN101743232A A IN O
useful CN101743232A A JJ O
for CN101743232A A IN O
treating CN101743232A A VBG O
dyslipidemia CN101743232A A NN O
and CN101743232A A CC O
diseases CN101743232A A NNS O
related CN101743232A A VBN O
to CN101743232A A TO O
dyslipidemia CN101743232A A NN O
. CN101743232A A . O

Calcium WO2009035265A2 T NN O
phosphate WO2009035265A2 T NN O
microspheres WO2009035265A2 T NNS O
drug WO2009035265A2 T NN O
delivery WO2009035265A2 T NN O
system WO2009035265A2 T NN O
and WO2009035265A2 T CC O
process WO2009035265A2 T NN O
for WO2009035265A2 T IN O
preparing WO2009035265A2 T VBG O
the WO2009035265A2 T DT O
same WO2009035265A2 T JJ O
. WO2009035265A2 T . O

Bicyclic WO2012091010A1 T NNP O
pyrimidine WO2012091010A1 T NN O
derivative WO2012091010A1 T NN O
. WO2012091010A1 T . O

The WO2012091010A1 A DT O
purpose WO2012091010A1 A NN O
of WO2012091010A1 A IN O
the WO2012091010A1 A DT O
present WO2012091010A1 A JJ O
invention WO2012091010A1 A NN O
is WO2012091010A1 A VBZ O
to WO2012091010A1 A TO O
provide WO2012091010A1 A VB O
: WO2012091010A1 A : O
a WO2012091010A1 A DT O
compound WO2012091010A1 A NN O
which WO2012091010A1 A WDT O
has WO2012091010A1 A VBZ O
a WO2012091010A1 A DT O
MGAT WO2012091010A1 A NNP I-UN
inhibitory WO2012091010A1 A NN O
effect WO2012091010A1 A NN O
and WO2012091010A1 A CC O
is WO2012091010A1 A VBZ O
useful WO2012091010A1 A JJ O
as WO2012091010A1 A IN O
a WO2012091010A1 A DT O
pharmaceutical WO2012091010A1 A JJ O
product WO2012091010A1 A NN O
, WO2012091010A1 A , O
or WO2012091010A1 A CC O
a WO2012091010A1 A DT O
physiologically WO2012091010A1 A RB O
acceptable WO2012091010A1 A JJ O
salt WO2012091010A1 A NN O
of WO2012091010A1 A IN O
the WO2012091010A1 A DT O
compound WO2012091010A1 A NN O
; WO2012091010A1 A : O
and WO2012091010A1 A CC O
a WO2012091010A1 A DT O
pharmaceutical WO2012091010A1 A JJ O
composition WO2012091010A1 A NN O
which WO2012091010A1 A WDT O
contains WO2012091010A1 A VBZ O
the WO2012091010A1 A DT O
compound WO2012091010A1 A NN O
or WO2012091010A1 A CC O
a WO2012091010A1 A DT O
physiologically WO2012091010A1 A RB O
acceptable WO2012091010A1 A JJ O
salt WO2012091010A1 A NN O
of WO2012091010A1 A IN O
the WO2012091010A1 A DT O
compound WO2012091010A1 A NN O
. WO2012091010A1 A . O

Transdermal CN1969971A T JJ O
absorption CN1969971A T NN O
formulation CN1969971A T NN O
of CN1969971A T IN O
total CN1969971A T JJ O
alkaloid CN1969971A T NN O
of CN1969971A T IN O
common CN1969971A T JJ O
monkshood CN1969971A T NN O
root CN1969971A T NN O
and CN1969971A T CC O
preparation CN1969971A T NN O
process CN1969971A T NN O
thereof CN1969971A T NN O
. CN1969971A T . O

Pharmaceutical WO2013185933A1 T JJ O
composition WO2013185933A1 T NN O
for WO2013185933A1 T IN O
liver WO2013185933A1 T JJ O
regeneration WO2013185933A1 T NN O
. WO2013185933A1 T . O

Medicament WO2008093247A3 T NN O
for WO2008093247A3 T IN O
the WO2008093247A3 T DT O
treatment WO2008093247A3 T NN O
of WO2008093247A3 T IN O
endometriosis WO2008093247A3 T NN O
. WO2008093247A3 T . O

Medicinal CN102949523A T JJ O
composition CN102949523A T NN O
used CN102949523A T VBN O
for CN102949523A T IN O
relieving CN102949523A T VBG O
visual CN102949523A T JJ O
fatigue CN102949523A T NN O
and CN102949523A T CC O
preparation CN102949523A T NN O
method CN102949523A T NN O
of CN102949523A T IN O
capsules CN102949523A T NNS O
thereof CN102949523A T NNS O
. CN102949523A T . O

Illudin CA2530543C T NNP O
analogs CA2530543C T NNS O
as CA2530543C T IN O
anti-tumor CA2530543C T JJ O
agents CA2530543C T NNS O
. CA2530543C T . O

Crystalline WO2009025876A3 T NNP O
forms WO2009025876A3 T NNS O
of WO2009025876A3 T IN O
erlotinib WO2009025876A3 T NN O
hcl WO2009025876A3 T NN O
and WO2009025876A3 T CC O
formulations WO2009025876A3 T NNS O
thereof WO2009025876A3 T VBP O
. WO2009025876A3 T . O

Quinazoline US20110230505 T JJ O
inhibitors US20110230505 T NNS O
of US20110230505 T IN O
bace US20110230505 T NN I-UN
1 US20110230505 T CD I-UN
and US20110230505 T CC O
methods US20110230505 T NNS O
of US20110230505 T IN O
using US20110230505 T VBG O
. US20110230505 T . O

Compound CN1903835A T NNP O
, CN1903835A T , O
composition CN1903835A T NN O
and CN1903835A T CC O
method CN1903835A T NN O
for CN1903835A T IN O
preventing CN1903835A T VBG O
neurodegeneration CN1903835A T NN O
in CN1903835A T IN O
acute CN1903835A T NN O
and CN1903835A T CC O
chronic CN1903835A T JJ O
injury CN1903835A T NN O
of CN1903835A T IN O
central CN1903835A T JJ O
nervous CN1903835A T JJ O
system CN1903835A T NN O
. CN1903835A T . O

Preparation CN103694084A T NNP O
method CN103694084A T NN O
and CN103694084A T CC O
application CN103694084A T NN O
of CN103694084A T IN O
menthol CN103694084A T NN O
water-soluble CN103694084A T JJ O
compound CN103694084A T NN O
. CN103694084A T . O

Preparation CN102657620A T NNP O
method CN102657620A T NN O
of CN102657620A T IN O
azithromycin CN102657620A T JJ O
pellet CN102657620A T NN O
. CN102657620A T . O

The CN102657620A A DT O
invention CN102657620A A NN O
provides CN102657620A A VBZ O
a CN102657620A A DT O
preparation CN102657620A A NN O
method CN102657620A A NN O
of CN102657620A A IN O
an CN102657620A A DT O
azithromycin CN102657620A A JJ O
pellet CN102657620A A NN O
, CN102657620A A , O
and CN102657620A A CC O
relates CN102657620A A VBZ O
to CN102657620A A TO O
a CN102657620A A DT O
manufacture CN102657620A A NN O
technology CN102657620A A NN O
of CN102657620A A IN O
a CN102657620A A DT O
novel CN102657620A A JJ O
azithromycin CN102657620A A NN O
preparation CN102657620A A NN O
. CN102657620A A . O

The CN102657620A A DT O
preparation CN102657620A A NN O
method CN102657620A A NN O
comprises CN102657620A A VBZ O
the CN102657620A A DT O
following CN102657620A A JJ O
steps CN102657620A A NNS O
: CN102657620A A : O
uniformly CN102657620A A RB O
mixing CN102657620A A VBG O
1 CN102657620A A CD O
part CN102657620A A NN O
by CN102657620A A IN O
weight CN102657620A A NN O
of CN102657620A A IN O
azithromycin CN102657620A A NN O
and CN102657620A A CC O
0.5 CN102657620A A CD O
to CN102657620A A TO O
30 CN102657620A A CD O
parts CN102657620A A NNS O
by CN102657620A A IN O
weight CN102657620A A NN O
of CN102657620A A IN O
auxiliary CN102657620A A JJ O
material CN102657620A A NN O
; CN102657620A A : O
adding CN102657620A A VBG O
0.2 CN102657620A A CD O
to CN102657620A A TO O
3 CN102657620A A CD O
parts CN102657620A A NNS O
by CN102657620A A IN O
weight CN102657620A A NN O
of CN102657620A A IN O
wetting CN102657620A A VBG O
agent CN102657620A A NN O
to CN102657620A A TO O
prepare CN102657620A A VB O
a CN102657620A A DT O
pellet CN102657620A A NN O
core CN102657620A A NN O
; CN102657620A A : O
and CN102657620A A CC O
drying CN102657620A A NN O
, CN102657620A A , O
and CN102657620A A CC O
coating CN102657620A A VBG O
the CN102657620A A DT O
pellet CN102657620A A NN O
core CN102657620A A NN O
to CN102657620A A TO O
realize CN102657620A A VB O
the CN102657620A A DT O
weight CN102657620A A NN O
of CN102657620A A IN O
the CN102657620A A DT O
pellet CN102657620A A NN O
core CN102657620A A NN O
to CN102657620A A TO O
be CN102657620A A VB O
gained CN102657620A A VBN O
by CN102657620A A IN O
5 CN102657620A A CD O
to CN102657620A A TO O
30 CN102657620A A CD O
percent CN102657620A A NN O
. CN102657620A A . O

The CN102657620A A DT O
azithromcin CN102657620A A JJ O
pellet CN102657620A A NN O
prepared CN102657620A A VBN O
by CN102657620A A IN O
the CN102657620A A DT O
preparation CN102657620A A NN O
method CN102657620A A NN O
is CN102657620A A VBZ O
easily CN102657620A A RB O
swallowed CN102657620A A VBN O
and CN102657620A A CC O
not CN102657620A A RB O
bitter CN102657620A A JJ O
, CN102657620A A , O
can CN102657620A A MD O
be CN102657620A A VB O
used CN102657620A A VBN O
as CN102657620A A IN O
an CN102657620A A DT O
intermediate CN102657620A A JJ O
product CN102657620A A NN O
for CN102657620A A IN O
producing CN102657620A A VBG O
granules CN102657620A A NNS O
and CN102657620A A CC O
suspensions CN102657620A A NNS O
, CN102657620A A , O
or CN102657620A A CC O
directly CN102657620A A RB O
subpackged CN102657620A A VBN O
into CN102657620A A IN O
finished CN102657620A A VBN O
products CN102657620A A NNS O
, CN102657620A A , O
is CN102657620A A VBZ O
suitable CN102657620A A JJ O
for CN102657620A A IN O
patients CN102657620A A NNS O
with CN102657620A A IN O
difficulty CN102657620A A NN O
in CN102657620A A IN O
swallowing CN102657620A A VBG O
, CN102657620A A , O
and CN102657620A A CC O
is CN102657620A A VBZ O
especially CN102657620A A RB O
suitable CN102657620A A JJ O
for CN102657620A A IN O
infants CN102657620A A NNS O
if CN102657620A A IN O
being CN102657620A A VBG O
added CN102657620A A VBN O
with CN102657620A A IN O
proper CN102657620A A JJ O
flavoring CN102657620A A VBG O
agents CN102657620A A NNS O
and CN102657620A A CC O
suspending CN102657620A A VBG O
agents CN102657620A A NNS O
. CN102657620A A . O

Viscous US20110129422 T JJ O
Terpolymers US20110129422 T NNS O
as US20110129422 T IN O
Drug US20110129422 T NNP O
Delivery US20110129422 T NNP O
Platform US20110129422 T NNP O
. US20110129422 T . O

Drug WO2013004999A1 T NN O
combinations WO2013004999A1 T NNS O
and WO2013004999A1 T CC O
uses WO2013004999A1 T NNS O
in WO2013004999A1 T IN O
treating WO2013004999A1 T VBG O
a WO2013004999A1 T DT O
coughing WO2013004999A1 T JJ O
condition WO2013004999A1 T NN O
. WO2013004999A1 T . O

Using US20050208496 T VBG O
enhanced US20050208496 T VBN O
interleukin US20050208496 T JJ I-UN
gene US20050208496 T NN O
expression US20050208496 T NN O
as US20050208496 T IN O
diagnostic US20050208496 T JJ O
indicator US20050208496 T NN O
of US20050208496 T IN O
respiratory US20050208496 T NN O
system US20050208496 T NN O
disorders US20050208496 T NNS O
. US20050208496 T . O

The US20050208496 A DT O
present US20050208496 A JJ O
invention US20050208496 A NN O
identified US20050208496 A VBN O
genes US20050208496 A NNS O
whose US20050208496 A WP$ O
expression US20050208496 A NN O
levels US20050208496 A NNS O
varied US20050208496 A VBN O
between US20050208496 A IN O
respiratory US20050208496 A JJ O
epithelial US20050208496 A JJ O
cells US20050208496 A NNS O
that US20050208496 A WDT O
had US20050208496 A VBD O
been US20050208496 A VBN O
stimulated US20050208496 A VBN O
by US20050208496 A IN O
IL-13 US20050208496 A NNP I-UN
to US20050208496 A TO O
induce US20050208496 A VB O
the US20050208496 A DT O
goblet US20050208496 A NN O
cell US20050208496 A NN O
differentiation US20050208496 A NN O
, US20050208496 A , O
and US20050208496 A CC O
unstimulated US20050208496 A JJ O
respiratory US20050208496 A NN O
epithelial US20050208496 A JJ O
cells US20050208496 A NNS O
. US20050208496 A . O

treating US20080063661 T VBG O
a US20080063661 T DT O
wart US20080063661 T NN O
with US20080063661 T IN O
a US20080063661 T DT O
fusion US20080063661 T NN O
protein US20080063661 T NN O
comprising US20080063661 T NN O
( US20080063661 T ( O
1 US20080063661 T CD O
) US20080063661 T ) O
a US20080063661 T DT O
heat US20080063661 T NN I-UN
shock US20080063661 T NN I-UN
protein US20080063661 T NN I-UN
and US20080063661 T CC O
( US20080063661 T ( O
2 US20080063661 T CD O
) US20080063661 T ) O
a US20080063661 T DT O
human US20080063661 T JJ O
papilloma US20080063661 T NN O
virus US20080063661 T NN O
( US20080063661 T ( O
HPV US20080063661 T NNP O
) US20080063661 T ) O
protein US20080063661 T NN O
; US20080063661 T : O
Mycobacterium US20080063661 T NNP O
bovis US20080063661 T VBZ O
heat US20080063661 T NN I-UN
shock US20080063661 T NN I-UN
protein US20080063661 T NN I-UN
; US20080063661 T : O
HPV US20080063661 T NNP O
is US20080063661 T VBZ O
an US20080063661 T DT O
E7 US20080063661 T NNP I-UN
protein US20080063661 T NN I-UN
; US20080063661 T : O
cervical US20080063661 T JJ O
dysplasia US20080063661 T NN O
, US20080063661 T , O
anal US20080063661 T JJ O
cancer US20080063661 T NN O
, US20080063661 T , O
anal US20080063661 T JJ O
dysplasia US20080063661 T NN O
. US20080063661 T . O

Disclosed US20080063661 A VBN O
is US20080063661 A VBZ O
a US20080063661 A DT O
method US20080063661 A NN O
of US20080063661 A IN O
treating US20080063661 A VBG O
a US20080063661 A DT O
wart US20080063661 A NN O
in US20080063661 A IN O
a US20080063661 A DT O
subject US20080063661 A NN O
by US20080063661 A IN O
administering US20080063661 A VBG O
to US20080063661 A TO O
the US20080063661 A DT O
subject US20080063661 A NN O
a US20080063661 A DT O
composition US20080063661 A NN O
containing US20080063661 A NN O
( US20080063661 A ( O
1 US20080063661 A CD O
) US20080063661 A ) O
a US20080063661 A DT O
heat US20080063661 A NN I-UN
shock US20080063661 A NN I-UN
protein US20080063661 A NN I-UN
or US20080063661 A CC O
an US20080063661 A DT O
immunostimulatory US20080063661 A JJ O
fragment US20080063661 A NN O
thereof US20080063661 A NN O
, US20080063661 A , O
and US20080063661 A CC O
( US20080063661 A ( O
2 US20080063661 A CD O
) US20080063661 A ) O
a US20080063661 A DT O
protein US20080063661 A NN O
of US20080063661 A IN O
a US20080063661 A DT O
human US20080063661 A JJ O
papilloma US20080063661 A NN O
virus US20080063661 A NN O
or US20080063661 A CC O
an US20080063661 A DT O
antigenic US20080063661 A JJ O
fragment US20080063661 A NN O
thereof US20080063661 A NN O
. US20080063661 A . O

Also US20080063661 A RB O
disclosed US20080063661 A VBN O
is US20080063661 A VBZ O
a US20080063661 A DT O
method US20080063661 A NN O
of US20080063661 A IN O
treating US20080063661 A VBG O
a US20080063661 A DT O
human US20080063661 A JJ O
papilloma US20080063661 A NN O
virus US20080063661 A NN O
infection US20080063661 A NN O
in US20080063661 A IN O
a US20080063661 A DT O
subject US20080063661 A NN O
infected US20080063661 A VBD O
or US20080063661 A CC O
suspected US20080063661 A VBN O
of US20080063661 A IN O
being US20080063661 A VBG O
infected US20080063661 A VBN O
with US20080063661 A IN O
a US20080063661 A DT O
human US20080063661 A JJ O
papilloma US20080063661 A NN O
virus US20080063661 A NN O
of US20080063661 A IN O
a US20080063661 A DT O
first US20080063661 A JJ O
type US20080063661 A NN O
by US20080063661 A IN O
administering US20080063661 A VBG O
to US20080063661 A TO O
the US20080063661 A DT O
subject US20080063661 A NN O
a US20080063661 A DT O
composition US20080063661 A NN O
containing US20080063661 A NN O
( US20080063661 A ( O
1 US20080063661 A CD O
) US20080063661 A ) O
a US20080063661 A DT O
heat US20080063661 A NN I-UN
shock US20080063661 A NN I-UN
protein US20080063661 A NN I-UN
or US20080063661 A CC O
an US20080063661 A DT O
antigenic US20080063661 A JJ O
fragment US20080063661 A NN O
thereof US20080063661 A NN O
, US20080063661 A , O
and US20080063661 A CC O
( US20080063661 A ( O
2 US20080063661 A CD O
) US20080063661 A ) O
a US20080063661 A DT O
protein US20080063661 A NN O
of US20080063661 A IN O
a US20080063661 A DT O
human US20080063661 A JJ O
papilloma US20080063661 A NN O
virus US20080063661 A NN O
of US20080063661 A IN O
a US20080063661 A DT O
second US20080063661 A JJ O
type US20080063661 A NN O
or US20080063661 A CC O
an US20080063661 A DT O
antigenic US20080063661 A JJ O
fragment US20080063661 A NN O
thereof US20080063661 A NN O
, US20080063661 A , O
where US20080063661 A WRB O
the US20080063661 A DT O
first US20080063661 A JJ O
type US20080063661 A NN O
and US20080063661 A CC O
second US20080063661 A JJ O
type US20080063661 A NN O
are US20080063661 A VBP O
different US20080063661 A JJ O
. US20080063661 A . O

Garden CN102793775A T NNP O
burnet CN102793775A T NN O
rhizoma CN102793775A T NN O
corydalis CN102793775A T NN O
paste CN102793775A T NN O
. CN102793775A T . O

The CN102793775A A DT O
invention CN102793775A A NN O
discloses CN102793775A A VBZ O
garden CN102793775A A JJ O
burnet CN102793775A A NN O
rhizoma CN102793775A A NN O
corydalis CN102793775A A NN O
paste CN102793775A A NN O
, CN102793775A A , O
which CN102793775A A WDT O
is CN102793775A A VBZ O
the CN102793775A A DT O
latest CN102793775A A JJS O
product CN102793775A A NN O
for CN102793775A A IN O
reliving CN102793775A A VBG O
pain CN102793775A A NN O
and CN102793775A A CC O
itching CN102793775A A NN O
. CN102793775A A . O

The CN102793775A A DT O
garden CN102793775A A NN O
burnet CN102793775A A NN O
rhizoma CN102793775A A NN O
corydalis CN102793775A A NN O
paste CN102793775A A NN O
is CN102793775A A VBZ O
prepared CN102793775A A VBN O
from CN102793775A A IN O
magnesium CN102793775A A NN O
chloride CN102793775A A NN O
, CN102793775A A , O
garden CN102793775A A JJ O
burnet CN102793775A A NN O
, CN102793775A A , O
talcum CN102793775A A JJ O
powder CN102793775A A NN O
and CN102793775A A CC O
rhizoma CN102793775A A NN O
corydalis CN102793775A A NN O
. CN102793775A A . O

The CN102793775A A DT O
product CN102793775A A NN O
has CN102793775A A VBZ O
the CN102793775A A DT O
specific CN102793775A A JJ O
effects CN102793775A A NNS O
of CN102793775A A IN O
clearing CN102793775A A VBG O
heat CN102793775A A NN O
, CN102793775A A , O
detoxifying CN102793775A A VBG O
, CN102793775A A , O
diminishing CN102793775A A VBG O
swelling CN102793775A A NN O
, CN102793775A A , O
pushing CN102793775A A VBG O
the CN102793775A A DT O
pus CN102793775A A NN O
, CN102793775A A , O
removing CN102793775A A VBG O
stasis CN102793775A A NN O
, CN102793775A A , O
dropping CN102793775A A VBG O
away CN102793775A A RB O
knots CN102793775A A NNS O
, CN102793775A A , O
relieving CN102793775A A VBG O
pain CN102793775A A NN O
, CN102793775A A , O
relieving CN102793775A A VBG O
itching CN102793775A A NN O
, CN102793775A A , O
killing CN102793775A A VBG O
germs CN102793775A A NNS O
, CN102793775A A , O
preventing CN102793775A A VBG O
infections CN102793775A A NNS O
, CN102793775A A , O
stopping CN102793775A A VBG O
bleeding CN102793775A A NN O
and CN102793775A A CC O
cooling CN102793775A A VBG O
the CN102793775A A DT O
blood CN102793775A A NN O
. CN102793775A A . O

The CN102793775A A DT O
product CN102793775A A NN O
can CN102793775A A MD O
treat CN102793775A A VB O
red CN102793775A A JJ O
and CN102793775A A CC O
white CN102793775A A JJ O
innominate CN102793775A A NN O
inflanunatories CN102793775A A NNS O
such CN102793775A A JJ O
as CN102793775A A IN O
malignant CN102793775A A JJ O
boil CN102793775A A NN O
, CN102793775A A , O
furuncle CN102793775A A NN O
and CN102793775A A CC O
carbuncle CN102793775A A NN O
and CN102793775A A CC O
has CN102793775A A VBZ O
obvious CN102793775A A JJ O
treating CN102793775A A VBG O
effects CN102793775A A NNS O
for CN102793775A A IN O
treating CN102793775A A VBG O
various CN102793775A A JJ O
inflammations CN102793775A A NNS O
such CN102793775A A JJ O
as CN102793775A A IN O
the CN102793775A A DT O
breast CN102793775A A NN O
cancer CN102793775A A NN O
. CN102793775A A . O

Oral CN101371825A T JJ O
sticking CN101371825A T VBG O
tablets CN101371825A T NNS O
using CN101371825A T VBG O
fluticasone CN101371825A T NN O
propionate CN101371825A T NN O
as CN101371825A T IN O
active CN101371825A T JJ O
component CN101371825A T NN O
. CN101371825A T . O

Dimeric EP2651919A1 T NNP O
iap EP2651919A1 T NN O
inhibitors EP2651919A1 T NNS O
. EP2651919A1 T . O

Method US20090069338 T NNP O
for US20090069338 T IN O
predicting US20090069338 T VBG O
skin US20090069338 T JJ O
sensitizing US20090069338 T VBG O
activity US20090069338 T NN O
of US20090069338 T IN O
compounds US20090069338 T NNS O
. US20090069338 T . O

Fused WO2009071895A1 T VBN O
thiazole WO2009071895A1 T NN O
and WO2009071895A1 T CC O
thiophene WO2009071895A1 T NN O
derivatives WO2009071895A1 T NNS O
as WO2009071895A1 T IN O
kinase WO2009071895A1 T NN I-UN
inhibitors WO2009071895A1 T NNS O
. WO2009071895A1 T . O

A WO2009071895A1 A DT O
series WO2009071895A1 A NN O
of WO2009071895A1 A IN O
fused WO2009071895A1 A JJ O
bicyclic WO2009071895A1 A JJ O
thiazole WO2009071895A1 A NN O
and WO2009071895A1 A CC O
thiophene WO2009071895A1 A NN O
derivatives WO2009071895A1 A NNS O
which WO2009071895A1 A WDT O
are WO2009071895A1 A VBP O
substituted WO2009071895A1 A VBN O
in WO2009071895A1 A IN O
the WO2009071895A1 A DT O
2-position WO2009071895A1 A JJ O
by WO2009071895A1 A IN O
an WO2009071895A1 A DT O
optionally WO2009071895A1 A RB O
substituted WO2009071895A1 A VBN O
morpholin-4-yl WO2009071895A1 A JJ O
moiety WO2009071895A1 A NN O
, WO2009071895A1 A , O
and WO2009071895A1 A CC O
in WO2009071895A1 A IN O
the WO2009071895A1 A DT O
4-position WO2009071895A1 A NN O
by WO2009071895A1 A IN O
hydroxy WO2009071895A1 A NN O
, WO2009071895A1 A , O
oxo WO2009071895A1 A NN O
or WO2009071895A1 A CC O
an WO2009071895A1 A DT O
amine WO2009071895A1 A JJ O
moiety WO2009071895A1 A NN O
, WO2009071895A1 A , O
being WO2009071895A1 A VBG O
selective WO2009071895A1 A JJ O
inhibitors WO2009071895A1 A NNS O
of WO2009071895A1 A IN O
PI3 WO2009071895A1 A NNP I-UN
kinase WO2009071895A1 A NNP O
enzymes WO2009071895A1 A RB O
, WO2009071895A1 A , O
are WO2009071895A1 A VBP O
accordingly WO2009071895A1 A RB O
of WO2009071895A1 A IN O
benefit WO2009071895A1 A NN O
in WO2009071895A1 A IN O
medicine WO2009071895A1 A NN O
, WO2009071895A1 A , O
for WO2009071895A1 A IN O
example WO2009071895A1 A NN O
in WO2009071895A1 A IN O
the WO2009071895A1 A DT O
treatment WO2009071895A1 A NN O
of WO2009071895A1 A IN O
inflammatory WO2009071895A1 A NN O
, WO2009071895A1 A , O
autoimmune WO2009071895A1 A NN O
, WO2009071895A1 A , O
cardiovascular WO2009071895A1 A JJ O
, WO2009071895A1 A , O
neurodegenerative WO2009071895A1 A JJ O
, WO2009071895A1 A , O
metabolic WO2009071895A1 A JJ O
, WO2009071895A1 A , O
oncological WO2009071895A1 A JJ O
, WO2009071895A1 A , O
nociceptive WO2009071895A1 A JJ O
or WO2009071895A1 A CC O
ophthalmic WO2009071895A1 A JJ O
conditions WO2009071895A1 A NNS O
. WO2009071895A1 A . O

Acetaminophen US20090092668 T NNP O
formulation US20090092668 T NN O
for US20090092668 T IN O
joint US20090092668 T JJ O
pain US20090092668 T NN O
relief US20090092668 T NN O
. US20090092668 T . O

Treatment US20100317603 T NN O
of US20100317603 T IN O
Cancer US20100317603 T NNP O
and US20100317603 T CC O
Inflammatory US20100317603 T NNP O
Disorder US20100317603 T NNP O
. US20100317603 T . O

Injectio CN1907291A T NNP O
for CN1907291A T IN O
nanometer CN1907291A T JJ O
notoginsenoside CN1907291A T NN O
and CN1907291A T CC O
its CN1907291A T PRP$ O
preparing CN1907291A T NN O
method CN1907291A T NN O
. CN1907291A T . O

Tumor-targeted CN103536919A T JJ O
photodynamic CN103536919A T JJ O
medicine CN103536919A T NN O
carrying CN103536919A T VBG O
nanoparticle CN103536919A T NN O
as CN103536919A T RB O
well CN103536919A T RB O
as CN103536919A T IN O
preparation CN103536919A T NN O
method CN103536919A T NN O
and CN103536919A T CC O
application CN103536919A T NN O
thereof CN103536919A T NN O
. CN103536919A T . O

Pyrido US7601836 T NNP O
[ US7601836 T NNP O
2,3-D US7601836 T JJ O
] US7601836 T NNP O
pyrimidine US7601836 T NN O
inhibitors US7601836 T NNS O
of US7601836 T IN O
phosphodiesterase US7601836 T NN I-UN
( US7601836 T ( I-UN
PDE US7601836 T NNP I-UN
) US7601836 T ) I-UN
7 US7601836 T CD I-UN
. US7601836 T . O

Pyrido US7601836 A NNP O
[ US7601836 A NNP O
2,3-d US7601836 A JJ O
] US7601836 A NNP O
pyrimidine US7601836 A NN O
phosphodiesterase US7601836 A NN I-UN
7 US7601836 A CD I-UN
( US7601836 A ( O
PDE US7601836 A NNP I-UN
7 US7601836 A CD I-UN
) US7601836 A ) O
inhibitors US7601836 A NNS O
are US7601836 A VBP O
provided US7601836 A VBN O
which US7601836 A WDT O
are US7601836 A VBP O
useful US7601836 A JJ O
in US7601836 A IN O
treating US7601836 A VBG O
T-cell US7601836 A NNP O
mediated US7601836 A JJ O
diseases US7601836 A NNS O
, US7601836 A , O
said US7601836 A VBD O
inhibitors US7601836 A NNS O
include US7601836 A VBP O
: US7601836 A : O
( US7601836 A ( O
i US7601836 A NN O
) US7601836 A ) O
2- US7601836 A CD O
[ US7601836 A JJ O
[ US7601836 A CD O
4- US7601836 A JJ O
[ US7601836 A NNP O
[ US7601836 A NNP O
[ US7601836 A NNP O
4- US7601836 A JJ O
( US7601836 A ( O
Aminosulfonyl US7601836 A NNP O
) US7601836 A ) O
phenyl US7601836 A NN O
] US7601836 A NNP O
methyl US7601836 A NN O
] US7601836 A NNP O
amino US7601836 A NN O
] US7601836 A NNP O
pyrido US7601836 A NN O
[ US7601836 A NNP O
2,3-d US7601836 A JJ O
] US7601836 A NNP O
pyrimidin-2-yl US7601836 A NN O
] US7601836 A NNP O
amino US7601836 A NN O
] US7601836 A NNP O
-4-methyl-5-thiazolecarboxylic US7601836 A NNP O
acid US7601836 A NN O
, US7601836 A , O
ethyl US7601836 A JJ O
ester US7601836 A NN O
; US7601836 A : O
and US7601836 A CC O
4-Methyl-2- US7601836 A JJ O
[ US7601836 A NNP O
[ US7601836 A NNP O
4- US7601836 A JJ O
[ US7601836 A NNP O
[ US7601836 A NNP O
[ US7601836 A NNP O
4- US7601836 A JJ O
( US7601836 A ( O
methylsulfonyl US7601836 A NN O
) US7601836 A ) O
phenyl US7601836 A NN O
] US7601836 A NNP O
methyl US7601836 A NN O
] US7601836 A NNP O
amino US7601836 A NN O
] US7601836 A NNP O
pyrido US7601836 A NN O
[ US7601836 A NNP O
2,3-d US7601836 A JJ O
] US7601836 A NNP O
pyrimidin-2-yl US7601836 A NN O
] US7601836 A NNP O
amino US7601836 A NN O
] US7601836 A NNP O
-5-thiazolecarboxylic US7601836 A NNP O
acid US7601836 A NN O
, US7601836 A , O
ethyl US7601836 A JJ O
ester US7601836 A NN O
; US7601836 A : O
or US7601836 A CC O
( US7601836 A ( O
ii US7601836 A NN O
) US7601836 A ) O
an US7601836 A DT O
enantiomer US7601836 A NN O
, US7601836 A , O
diastereomer US7601836 A NN O
, US7601836 A , O
tautomer US7601836 A NN O
or US7601836 A CC O
pharmaceutically US7601836 A RB O
acceptable US7601836 A JJ O
salt US7601836 A NN O
of US7601836 A IN O
( US7601836 A ( O
i US7601836 A NN O
) US7601836 A ) O
. US7601836 A . O

Oral CN101269005A T JJ O
preparation CN101269005A T NN O
containing CN101269005A T VBG O
erythromycin CN101269005A T NN O
, CN101269005A T , O
preparation CN101269005A T NN O
method CN101269005A T NN O
and CN101269005A T CC O
application CN101269005A T NN O
thereof CN101269005A T NN O
. CN101269005A T . O

Spray CA2333442C T NNP O
composition CA2333442C T NN O
. CA2333442C T . O

An CA2333442C A DT O
aqueous-based CA2333442C A JJ O
sprayable CA2333442C A JJ O
composition CA2333442C A NN O
comprises CA2333442C A VBZ O
a CA2333442C A DT O
therapeutic CA2333442C A JJ O
or CA2333442C A CC O
palliative CA2333442C A JJ O
agent CA2333442C A NN O
, CA2333442C A , O
water CA2333442C A NN O
and CA2333442C A CC O
a CA2333442C A DT O
mixture CA2333442C A NN O
of CA2333442C A IN O
microcrystalline CA2333442C A NN O
cellulose CA2333442C A NN O
and CA2333442C A CC O
alkali CA2333442C A JJ O
metal CA2333442C A NN O
carboxyalkylcellulose CA2333442C A NN O
. CA2333442C A . O

In CA2333442C A IN O
one CA2333442C A CD O
embodiment CA2333442C A NN O
, CA2333442C A , O
the CA2333442C A DT O
composition CA2333442C A NN O
is CA2333442C A VBZ O
a CA2333442C A DT O
non-Newtonian CA2333442C A JJ O
nasal CA2333442C A NN O
spray CA2333442C A NN O
exhibiting CA2333442C A VBG O
a CA2333442C A DT O
very CA2333442C A RB O
rapid CA2333442C A JJ O
viscosity CA2333442C A NN O
recovery CA2333442C A NN O
upon CA2333442C A IN O
removal CA2333442C A NN O
of CA2333442C A IN O
shear CA2333442C A JJ O
forces CA2333442C A NNS O
. CA2333442C A . O

Medicament CN101199787B T NNP O
compound CN101199787B T NN O
for CN101199787B T IN O
treating CN101199787B T VBG O
skin CN101199787B T JJ O
disease CN101199787B T NN O
. CN101199787B T . O

Novel EP1023435B1 T NNP O
lactic EP1023435B1 T JJ O
acid EP1023435B1 T NN O
bacteria EP1023435B1 T NN O
species EP1023435B1 T NNS O
. EP1023435B1 T . O

The EP1023435B1 A DT O
invention EP1023435B1 A NN O
concerns EP1023435B1 A VBZ O
a EP1023435B1 A DT O
lactic EP1023435B1 A JJ O
acid EP1023435B1 A NN O
bacteria EP1023435B1 A NNS O
strain EP1023435B1 A VBP O
( EP1023435B1 A ( O
1 EP1023435B1 A CD O
) EP1023435B1 A ) O
, EP1023435B1 A , O
whereof EP1023435B1 A VBP O
the EP1023435B1 A DT O
RNA EP1023435B1 A NNP O
ribosome EP1023435B1 A NN O
16S EP1023435B1 A CD O
is EP1023435B1 A VBZ O
characteristic EP1023435B1 A JJ O
of EP1023435B1 A IN O
the EP1023435B1 A DT O
genus EP1023435B1 A NN O
Streptococcus EP1023435B1 A NNP O
( EP1023435B1 A ( O
2 EP1023435B1 A CD O
) EP1023435B1 A ) O
, EP1023435B1 A , O
whose EP1023435B1 A WP$ O
profile EP1023435B1 A NN O
in EP1023435B1 A IN O
crude EP1023435B1 A NN O
proteins EP1023435B1 A NNS O
, EP1023435B1 A , O
obtained EP1023435B1 A VBN O
after EP1023435B1 A IN O
migration EP1023435B1 A NN O
of EP1023435B1 A IN O
crude EP1023435B1 A NN O
proteins EP1023435B1 A NNS O
on EP1023435B1 A IN O
SDS-PAGE EP1023435B1 A NNP O
gel EP1023435B1 A NN O
electrophoresis EP1023435B1 A NN O
, EP1023435B1 A , O
is EP1023435B1 A VBZ O
characteristic EP1023435B1 A JJ O
of EP1023435B1 A IN O
that EP1023435B1 A DT O
of EP1023435B1 A IN O
the EP1023435B1 A DT O
CNCM EP1023435B1 A NNP O
I-1926 EP1023435B1 A NNP O
lactic EP1023435B1 A JJ O
acid EP1023435B1 A NN O
bacteria EP1023435B1 A NNS O
strain EP1023435B1 A VBP O
, EP1023435B1 A , O
but EP1023435B1 A CC O
distinct EP1023435B1 A JJ O
from EP1023435B1 A IN O
those EP1023435B1 A DT O
of EP1023435B1 A IN O
species EP1023435B1 A NNS O
recognised EP1023435B1 A VBN O
as EP1023435B1 A IN O
belonging EP1023435B1 A NN O
to EP1023435B1 A TO O
the EP1023435B1 A DT O
genus EP1023435B1 A NN O
Streptococcus EP1023435B1 A NNP O
, EP1023435B1 A , O
namely EP1023435B1 A RB O
S. EP1023435B1 A NNP O
acidominimus EP1023435B1 A NN O
, EP1023435B1 A , O
S.agalactiae EP1023435B1 A NNP O
, EP1023435B1 A , O
S. EP1023435B1 A NNP O
alactolyticus EP1023435B1 A NN O
, EP1023435B1 A , O
S. EP1023435B1 A NNP O
anginosus EP1023435B1 A NN O
, EP1023435B1 A , O
S. EP1023435B1 A NNP O
bovis EP1023435B1 A NN O
, EP1023435B1 A , O
S. EP1023435B1 A NNP O
canis EP1023435B1 A NN O
, EP1023435B1 A , O
S. EP1023435B1 A NNP O
caprinus EP1023435B1 A NN O
, EP1023435B1 A , O
S. EP1023435B1 A NNP O
constellatus EP1023435B1 A NN O
, EP1023435B1 A , O
S. EP1023435B1 A NNP O
cricetus EP1023435B1 A NN O
, EP1023435B1 A , O
S. EP1023435B1 A NNP O
cristatus EP1023435B1 A NN O
, EP1023435B1 A , O
S. EP1023435B1 A NNP O
difficile EP1023435B1 A NN O
, EP1023435B1 A , O
S. EP1023435B1 A NNP O
downei EP1023435B1 A NN O
, EP1023435B1 A , O
S. EP1023435B1 A NNP O
dysgalactiae EP1023435B1 A VBZ O
ssp EP1023435B1 A NN O
. EP1023435B1 A . O

dysgalactiae EP1023435B1 A NN O
, EP1023435B1 A , O
S. EP1023435B1 A NNP O
dysgalactiae EP1023435B1 A VBZ O
ssp EP1023435B1 A NN O
. EP1023435B1 A . O

equisimilis EP1023435B1 A NN O
, EP1023435B1 A , O
S. EP1023435B1 A NNP O
equi EP1023435B1 A NN O
, EP1023435B1 A , O
S. EP1023435B1 A NNP O
equi EP1023435B1 A VBZ O
ssp EP1023435B1 A NN O
. EP1023435B1 A . O

equi EP1023435B1 A NN O
, EP1023435B1 A , O
S. EP1023435B1 A NNP O
equi EP1023435B1 A VBZ O
ssp EP1023435B1 A NN O
. EP1023435B1 A . O

zooepidemicus EP1023435B1 A NN O
, EP1023435B1 A , O
S. EP1023435B1 A NNP O
equinus EP1023435B1 A NN O
, EP1023435B1 A , O
S.ferus EP1023435B1 A NNP O
, EP1023435B1 A , O
S. EP1023435B1 A NNP O
gallolyticus EP1023435B1 A NN O
, EP1023435B1 A , O
S. EP1023435B1 A NNP O
gordonii EP1023435B1 A NN O
, EP1023435B1 A , O
S. EP1023435B1 A NNP O
hyointestinalis EP1023435B1 A NN O
, EP1023435B1 A , O
S. EP1023435B1 A NNP O
hyovaginalis EP1023435B1 A NN O
, EP1023435B1 A , O
S. EP1023435B1 A NNP O
iniae EP1023435B1 A NN O
, EP1023435B1 A , O
S. EP1023435B1 A NNP O
intermedius EP1023435B1 A NN O
, EP1023435B1 A , O
S. EP1023435B1 A NNP O
intestinalis EP1023435B1 A NN O
, EP1023435B1 A , O
S. EP1023435B1 A NNP O
macacae EP1023435B1 A NNP O
, EP1023435B1 A , O
S. EP1023435B1 A NNP O
mitis EP1023435B1 A NN O
, EP1023435B1 A , O
S. EP1023435B1 A NNP O
mutans EP1023435B1 A NNS O
, EP1023435B1 A , O
S. EP1023435B1 A NNP O
oralis EP1023435B1 A UH O
, EP1023435B1 A , O
S. EP1023435B1 A NNP O
parasanguinis EP1023435B1 A NN O
, EP1023435B1 A , O
S. EP1023435B1 A NNP O
parauberis EP1023435B1 A NN O
, EP1023435B1 A , O
S. EP1023435B1 A NNP O
phocae EP1023435B1 A NN O
, EP1023435B1 A , O
S. EP1023435B1 A NNP O
pleomorphus EP1023435B1 A RB O
, EP1023435B1 A , O
S. EP1023435B1 A NNP O
pneumoniae EP1023435B1 A NN O
, EP1023435B1 A , O
S. EP1023435B1 A NNP O
porcinus EP1023435B1 A NN O
, EP1023435B1 A , O
S. EP1023435B1 A NNP O
pyogenes EP1023435B1 A NNS O
, EP1023435B1 A , O
S. EP1023435B1 A NNP O
ratti EP1023435B1 A NN O
, EP1023435B1 A , O
S. EP1023435B1 A NNP O
salivarius EP1023435B1 A NN O
, EP1023435B1 A , O
S. EP1023435B1 A NNP O
sanguinis EP1023435B1 A NN O
, EP1023435B1 A , O
S. EP1023435B1 A NNP O
shiloi EP1023435B1 A NN O
, EP1023435B1 A , O
S. EP1023435B1 A NNP O
sobrinus EP1023435B1 A NN O
, EP1023435B1 A , O
S. EP1023435B1 A NNP O
suis EP1023435B1 A NN O
, EP1023435B1 A , O
S. EP1023435B1 A NNP O
thermophilus EP1023435B1 A CC O
, EP1023435B1 A , O
S. EP1023435B1 A NNP O
thoraltensis EP1023435B1 A NN O
, EP1023435B1 A , O
S. EP1023435B1 A NNP O
uberis EP1023435B1 A NNP O
, EP1023435B1 A , O
S. EP1023435B1 A NNP O
vestibularis EP1023435B1 A NNP O
, EP1023435B1 A , O
S. EP1023435B1 A NNP O
viridans EP1023435B1 A NNPS O
. EP1023435B1 A . O

The EP1023435B1 A DT O
invention EP1023435B1 A NN O
also EP1023435B1 A RB O
concerns EP1023435B1 A VBZ O
the EP1023435B1 A DT O
use EP1023435B1 A NN O
of EP1023435B1 A IN O
said EP1023435B1 A VBD O
lactic EP1023435B1 A JJ O
acid EP1023435B1 A NN O
bacteria EP1023435B1 A NNS O
strain EP1023435B1 A VBP O
, EP1023435B1 A , O
or EP1023435B1 A CC O
a EP1023435B1 A DT O
polysaccharide EP1023435B1 A NN O
secreted EP1023435B1 A VBN O
by EP1023435B1 A IN O
said EP1023435B1 A VBD O
strain EP1023435B1 A NN O
, EP1023435B1 A , O
for EP1023435B1 A IN O
preparing EP1023435B1 A VBG O
a EP1023435B1 A DT O
food EP1023435B1 A NN O
composition EP1023435B1 A NN O
, EP1023435B1 A , O
in EP1023435B1 A IN O
particular EP1023435B1 A JJ O
a EP1023435B1 A DT O
lactic EP1023435B1 A JJ O
milk EP1023435B1 A NN O
or EP1023435B1 A CC O
fresh EP1023435B1 A JJ O
cheese EP1023435B1 A NN O
. EP1023435B1 A . O

The EP1023435B1 A DT O
invention EP1023435B1 A NN O
further EP1023435B1 A RB O
concerns EP1023435B1 A VBZ O
a EP1023435B1 A DT O
food EP1023435B1 A NN O
or EP1023435B1 A CC O
pharmaceutical EP1023435B1 A JJ O
composition EP1023435B1 A NN O
comprising EP1023435B1 A VBG O
a EP1023435B1 A DT O
lactic EP1023435B1 A JJ O
acid EP1023435B1 A NN O
bacteria EP1023435B1 A NNS O
or EP1023435B1 A CC O
a EP1023435B1 A DT O
polysaccharide EP1023435B1 A NN O
constituted EP1023435B1 A VBN O
by EP1023435B1 A IN O
a EP1023435B1 A DT O
chain EP1023435B1 A NN O
of EP1023435B1 A IN O
glucose EP1023435B1 A NN O
, EP1023435B1 A , O
galactose EP1023435B1 A JJ O
and EP1023435B1 A CC O
N-acetylglucosamine EP1023435B1 A JJ O
in EP1023435B1 A IN O
a EP1023435B1 A DT O
ratio EP1023435B1 A NN O
of EP1023435B1 A IN O
3:2:1 EP1023435B1 A CD O
respectively EP1023435B1 A RB O
. EP1023435B1 A . O

Chromane WO2007026218A2 T NNP O
substituted WO2007026218A2 T VBD O
2-alkyl WO2007026218A2 T JJ O
imidazopyridine WO2007026218A2 T NN O
derivatives WO2007026218A2 T NNS O
and WO2007026218A2 T CC O
use WO2007026218A2 T VB O
thereof WO2007026218A2 T NN O
as WO2007026218A2 T IN O
acid WO2007026218A2 T JJ O
pump WO2007026218A2 T NN O
antagonists WO2007026218A2 T NNS O
. WO2007026218A2 T . O

Salts US8829013 T NNS O
of US8829013 T IN O
the US8829013 T DT O
Janus US8829013 T NNP O
kinase US8829013 T NN O
inhibitor US8829013 T NN O
( US8829013 T ( O
R US8829013 T NNP O
) US8829013 T ) O
-3- US8829013 T NN O
( US8829013 T ( O
4- US8829013 T JJ O
( US8829013 T ( O
7H-pyrrolo US8829013 T JJ O
[ US8829013 T NNP O
2,3-D US8829013 T JJ O
] US8829013 T NNP O
pyrimidin-4-yl US8829013 T NN O
) US8829013 T ) O
-1H-pyrazol-1-yl US8829013 T NN O
) US8829013 T ) O
-3-cyclopentylpropanenitrile US8829013 T NN O
. US8829013 T . O

Application CN102872037A T NN O
of CN102872037A T IN O
Gypensapogenin CN102872037A T NNP O
B CN102872037A T NNP O
in CN102872037A T IN O
medicaments CN102872037A T NNS O
against CN102872037A T IN O
aseptic CN102872037A T JJ O
inflammation CN102872037A T NN O
. CN102872037A T . O

Azepinoindole CA2633243C T NNP O
derivatives CA2633243C T NNS O
as CA2633243C T IN O
pharmaceutical CA2633243C T JJ O
agents CA2633243C T NNS O
. CA2633243C T . O

The CA2633243C A DT O
present CA2633243C A JJ O
invention CA2633243C A NN O
relates CA2633243C A VBZ O
to CA2633243C A TO O
compounds CA2633243C A NNS O
of CA2633243C A IN O
formula CA2633243C A NN O
I CA2633243C A PRP O
, CA2633243C A , O
which CA2633243C A WDT O
exhibit CA2633243C A VBP O
affinity CA2633243C A NN O
for CA2633243C A IN O
the CA2633243C A DT O
farnesoid CA2633243C A JJ I-UN
X CA2633243C A NNP I-UN
receptor CA2633243C A NN I-UN
. CA2633243C A . O

gene US20110178154 T NN O
expression US20110178154 T NN O
profile US20110178154 T IN O
that US20110178154 T DT O
predicts US20110178154 T VBZ O
ovarian US20110178154 T JJ O
cancer US20110178154 T NN O
subject US20110178154 T JJ O
response US20110178154 T NN O
to US20110178154 T TO O
chemotherapy US20110178154 T NN O
. US20110178154 T . O

Yinhuang CN103272113A T NNP O
granule CN103272113A T NN O
for CN103272113A T IN O
clearing CN103272113A T VBG O
away CN103272113A T RB O
the CN103272113A T DT O
lung-heat CN103272113A T NN O
and CN103272113A T CC O
preparation CN103272113A T NN O
method CN103272113A T NN O
thereof CN103272113A T NN O
. CN103272113A T . O

Externally CN101011511A T RB O
applied CN101011511A T VBN O
medicament CN101011511A T NN O
for CN101011511A T IN O
treating CN101011511A T VBG O
soft CN101011511A T JJ O
tissue CN101011511A T NN O
injury CN101011511A T NN O
. CN101011511A T . O

The CN101011511A A DT O
invention CN101011511A A NN O
relates CN101011511A A VBZ O
to CN101011511A A TO O
an CN101011511A A DT O
externally-used CN101011511A A JJ O
medicinal CN101011511A A JJ O
composition CN101011511A A NN O
for CN101011511A A IN O
treating CN101011511A A VBG O
soft CN101011511A A JJ O
tissue CN101011511A A NN O
injury CN101011511A A NN O
, CN101011511A A , O
wherein CN101011511A A VBP O
the CN101011511A A DT O
raw CN101011511A A JJ O
materials CN101011511A A NNS O
of CN101011511A A IN O
the CN101011511A A DT O
effective CN101011511A A JJ O
constituents CN101011511A A NNS O
comprise CN101011511A A NN O
( CN101011511A A ( O
by CN101011511A A IN O
weight CN101011511A A NN O
ratio CN101011511A A NN O
) CN101011511A A ) O
Sichuan CN101011511A A NNP O
aconite CN101011511A A JJ O
root CN101011511A A NN O
8-12 CN101011511A A CD O
, CN101011511A A , O
safflower CN101011511A A JJR O
8-10 CN101011511A A JJ O
, CN101011511A A , O
arisaema CN101011511A A JJ O
tuber CN101011511A A NN O
7-11 CN101011511A A CD O
, CN101011511A A , O
Rhododendron CN101011511A A NNP O
molle CN101011511A A NNP O
8-12 CN101011511A A CD O
, CN101011511A A , O
Clematis CN101011511A A NNP O
chinensis CN101011511A A NN O
7-11 CN101011511A A CD O
, CN101011511A A , O
rhizome CN101011511A A NN O
of CN101011511A A IN O
Sichuan CN101011511A A JJ O
lovage CN101011511A A NN O
8-12 CN101011511A A CD O
, CN101011511A A , O
tetrandra CN101011511A A JJ O
root CN101011511A A NN O
7-11 CN101011511A A CD O
, CN101011511A A , O
corydalis CN101011511A A JJ O
tuber CN101011511A A NN O
8-12 CN101011511A A CD O
, CN101011511A A , O
Tripterygium CN101011511A A NNP O
wilfordii CN101011511A A VBZ O
7-11 CN101011511A A CD O
, CN101011511A A , O
peach CN101011511A A NN O
kernel CN101011511A A VBD O
7-11 CN101011511A A CD O
and CN101011511A A CC O
borneol CN101011511A A VB O
0.4-0.5 CN101011511A A NN O
. CN101011511A A . O

Gabapentin CN102688216A T NNP O
tablet CN102688216A T NN O
and CN102688216A T CC O
preparation CN102688216A T NN O
method CN102688216A T NN O
thereof CN102688216A T NN O
. CN102688216A T . O

Double-stranded US7348314 T JJ O
ribonucleic US7348314 T NN O
acid US7348314 T NN O
. US7348314 T . O

4-Aminoquinoline US20080262031 T JJ O
Derivatives US20080262031 T NNS O
as US20080262031 T IN O
Antimalarials US20080262031 T NNS O
. US20080262031 T . O

Storage CA2419877C T NN O
stable CA2419877C T JJ O
tretinoin CA2419877C T NN O
and CA2419877C T CC O
4-hydroxy CA2419877C T JJ O
anisole CA2419877C T NN O
containing CA2419877C T VBG O
topical CA2419877C T JJ O
composition CA2419877C T NN O
. CA2419877C T . O

Methods US8343942 T NNS O
for US8343942 T IN O
treating US8343942 T VBG O
interstitial US8343942 T JJ O
cystitis US8343942 T NN O
. US8343942 T . O

Described US8343942 A VBN O
herein US8343942 A NNS O
are US8343942 A VBP O
methods US8343942 A NNS O
for US8343942 A IN O
treating US8343942 A VBG O
interstitial US8343942 A JJ O
cystitis US8343942 A NN O
in US8343942 A IN O
a US8343942 A DT O
subject US8343942 A JJ O
comprising US8343942 A VBG O
administering US8343942 A VBG O
to US8343942 A TO O
the US8343942 A DT O
subject US8343942 A NN O
an US8343942 A DT O
effective US8343942 A JJ O
amount US8343942 A NN O
of US8343942 A IN O
a US8343942 A DT O
compound US8343942 A NN O
which US8343942 A WDT O
is US8343942 A VBZ O
a US8343942 A DT O
modified US8343942 A JJ O
hyaluronan US8343942 A NN O
or US8343942 A CC O
a US8343942 A DT O
pharmaceutically US8343942 A RB O
acceptable US8343942 A JJ O
salt US8343942 A NN O
or US8343942 A CC O
ester US8343942 A NN O
thereof US8343942 A NN O
, US8343942 A , O
wherein US8343942 A NN O
said US8343942 A VBD O
hyaluronan US8343942 A NN O
or US8343942 A CC O
its US8343942 A PRP$ O
pharmaceutically US8343942 A RB O
acceptable US8343942 A JJ O
salt US8343942 A NN O
or US8343942 A CC O
ester US8343942 A NN O
comprises US8343942 A NNS O
at US8343942 A IN O
least US8343942 A JJS O
one US8343942 A CD O
sulfate US8343942 A NN O
group US8343942 A NN O
and US8343942 A CC O
the US8343942 A DT O
primary US8343942 A JJ O
C-6 US8343942 A NNP O
hydroxyl US8343942 A NN O
proton US8343942 A NN O
of US8343942 A IN O
at US8343942 A IN O
least US8343942 A JJS O
one US8343942 A CD O
N-acetyl-glucosamine US8343942 A JJ O
residue US8343942 A NN O
is US8343942 A VBZ O
substituted US8343942 A VBN O
with US8343942 A IN O
an US8343942 A DT O
unsubstituted US8343942 A JJ O
alkyl US8343942 A NN O
group US8343942 A NN O
or US8343942 A CC O
fluoroalkyl US8343942 A NN O
group US8343942 A NN O
. US8343942 A . O

Combinations EP2694072A1 T NNS O
of EP2694072A1 T IN O
akt EP2694072A1 T JJ I-UN
inhibitor EP2694072A1 T NN O
compounds EP2694072A1 T NNS O
and EP2694072A1 T CC O
abiraterone EP2694072A1 T NN O
, EP2694072A1 T , O
and EP2694072A1 T CC O
methods EP2694072A1 T NNS O
of EP2694072A1 T IN O
use EP2694072A1 T NN O
. EP2694072A1 T . O

Medicinal CN102091179A T JJ O
moxibustion CN102091179A T NN O
oil CN102091179A T NN O
and CN102091179A T CC O
manufacturing CN102091179A T NN O
method CN102091179A T NN O
thereof CN102091179A T NN O
. CN102091179A T . O

Muscarinic US20100120752 T JJ O
agonists US20100120752 T NNS O
to US20100120752 T TO O
treat US20100120752 T VB O
impulse US20100120752 T JJ O
control US20100120752 T NN O
disorders US20100120752 T NNS O
. US20100120752 T . O

Heterocyclic US7718673 T NNP O
amides US7718673 T NNS O
such US7718673 T JJ O
as US7718673 T IN O
beta- US7718673 T NN O
( US7718673 T ( O
( US7718673 T ( O
( US7718673 T ( O
1- US7718673 T CD O
( US7718673 T ( O
4- US7718673 T CD O
( US7718673 T ( O
( US7718673 T ( O
4,5-dihydro-1H-imidazol-2-yl US7718673 T CD O
) US7718673 T ) O
amino US7718673 T NN O
) US7718673 T ) O
-1-oxobutyl US7718673 T NN O
) US7718673 T ) O
-4 US7718673 T NNP O
-piperidinyl US7718673 T NNP O
) US7718673 T ) O
carbonyl US7718673 T NN O
) US7718673 T ) O
amino US7718673 T NN O
) US7718673 T ) O
- US7718673 T : O
, US7718673 T , O
( US7718673 T ( O
beta US7718673 T IN O
3S US7718673 T CD O
) US7718673 T ) O
-3-quinolinepropanoic US7718673 T NN O
acid US7718673 T NN O
, US7718673 T , O
used US7718673 T VBD O
as US7718673 T IN O
antagonists US7718673 T NNS O
for US7718673 T IN O
cellular US7718673 T JJ O
adhesion US7718673 T NN O
molecules US7718673 T NNS O
. US7718673 T . O

Cathepsin WO2014091443A1 T NNP I-UN
c WO2014091443A1 T NN I-UN
inhibitors WO2014091443A1 T NNS O
for WO2014091443A1 T IN O
treating WO2014091443A1 T VBG O
cystic WO2014091443A1 T JJ O
fibrosis WO2014091443A1 T NN O
, WO2014091443A1 T , O
non-cystic WO2014091443A1 T JJ O
fibrosis WO2014091443A1 T NN O
bronchiectasis WO2014091443A1 T NN O
, WO2014091443A1 T , O
and WO2014091443A1 T CC O
anca-associated WO2014091443A1 T JJ O
vasculitis WO2014091443A1 T NN O
. WO2014091443A1 T . O

The WO2014091443A1 A DT O
present WO2014091443A1 A JJ O
invention WO2014091443A1 A NN O
relates WO2014091443A1 A VBZ O
to WO2014091443A1 A TO O
methods WO2014091443A1 A NNS O
of WO2014091443A1 A IN O
treatment WO2014091443A1 A NN O
of WO2014091443A1 A IN O
diseases WO2014091443A1 A NNS O
mediated WO2014091443A1 A VBN O
by WO2014091443A1 A IN O
the WO2014091443A1 A DT O
cathepsin WO2014091443A1 A NN I-UN
C WO2014091443A1 A NNP I-UN
enzyme WO2014091443A1 A NN O
such WO2014091443A1 A JJ O
as WO2014091443A1 A IN O
cystic WO2014091443A1 A JJ O
fibrosis WO2014091443A1 A NN O
, WO2014091443A1 A , O
non-cystic WO2014091443A1 A JJ O
fibrosis WO2014091443A1 A NN O
bronchiectasis WO2014091443A1 A NN O
, WO2014091443A1 A , O
and WO2014091443A1 A CC O
anti-neutrophil WO2014091443A1 A JJ O
cytoplasmic WO2014091443A1 A JJ O
auto WO2014091443A1 A NN O
antibody WO2014091443A1 A NN O
- WO2014091443A1 A : O
related WO2014091443A1 A JJ O
diseases WO2014091443A1 A NNS O
. WO2014091443A1 A . O

Female CN201076616Y T NNP O
health CN201076616Y T NN O
care CN201076616Y T NN O
suppository CN201076616Y T NN O
pill CN201076616Y T NN O
. CN201076616Y T . O

Androgen US20060106067 T NNP I-UN
receptor US20060106067 T NN I-UN
agonist US20060106067 T NN O
; US20060106067 T : O
prostate US20060106067 T NN O
cancer US20060106067 T NN O
, US20060106067 T , O
hypogonadism US20060106067 T NN O
; US20060106067 T : O
4- US20060106067 T JJ O
[ US20060106067 T JJ O
4- US20060106067 T JJ O
( US20060106067 T ( O
hydroxymethyl US20060106067 T NN O
) US20060106067 T ) O
-1-piperidinyl US20060106067 T VBZ O
] US20060106067 T JJ O
-1-naphthonitrile US20060106067 T NN O
; US20060106067 T : O
4- US20060106067 T JJ O
( US20060106067 T ( O
4-hydroxy-2-methyl-1-pyrrolidinyl-1-benzothiophene-7-carbonitrile US20060106067 T JJ O
. US20060106067 T . O

The US20060106067 A DT O
formula US20060106067 A NN O
represents US20060106067 A VBZ O
a US20060106067 A DT O
single US20060106067 A JJ O
bond US20060106067 A NN O
or US20060106067 A CC O
a US20060106067 A DT O
double US20060106067 A JJ O
bond US20060106067 A NN O
] US20060106067 A NN O
or US20060106067 A CC O
a US20060106067 A DT O
salt US20060106067 A NN O
thereof US20060106067 A NN O
, US20060106067 A , O
which US20060106067 A WDT O
is US20060106067 A VBZ O
useful US20060106067 A JJ O
as US20060106067 A IN O
an US20060106067 A DT I-UN
androgen US20060106067 A NN I-UN
receptor US20060106067 A NN O
modulator US20060106067 A NN O
. US20060106067 A . O

Pqs WO2007054283A3 T NNP O
and WO2007054283A3 T CC O
its WO2007054283A3 T PRP$ O
conjugates WO2007054283A3 T NNS O
as WO2007054283A3 T IN O
adjuvants WO2007054283A3 T NNS O
and WO2007054283A3 T CC O
their WO2007054283A3 T PRP$ O
uses WO2007054283A3 T NNS O
in WO2007054283A3 T IN O
pharmaceutical WO2007054283A3 T JJ O
compositions WO2007054283A3 T NNS O
. WO2007054283A3 T . O

The WO2007054283A3 A DT O
present WO2007054283A3 A JJ O
invention WO2007054283A3 A NN O
relates WO2007054283A3 A VBZ O
to WO2007054283A3 A TO O
new WO2007054283A3 A JJ O
adjuvants WO2007054283A3 A NNS O
and WO2007054283A3 A CC O
the WO2007054283A3 A DT O
uses WO2007054283A3 A NNS O
in WO2007054283A3 A IN O
pharmaceutical WO2007054283A3 A JJ O
compositions WO2007054283A3 A NNS O
, WO2007054283A3 A , O
like WO2007054283A3 A IN O
in WO2007054283A3 A IN O
vaccines WO2007054283A3 A NNS O
. WO2007054283A3 A . O

In WO2007054283A3 A IN O
particular WO2007054283A3 A JJ O
, WO2007054283A3 A , O
the WO2007054283A3 A DT O
present WO2007054283A3 A JJ O
invention WO2007054283A3 A NN O
provides WO2007054283A3 A VBZ O
new WO2007054283A3 A JJ O
compounds WO2007054283A3 A NNS O
useful WO2007054283A3 A JJ O
as WO2007054283A3 A IN O
adjuvants WO2007054283A3 A NNS O
and/or WO2007054283A3 A JJ O
immunomodulators WO2007054283A3 A NNS O
for WO2007054283A3 A IN O
prophylactic WO2007054283A3 A JJ O
and/or WO2007054283A3 A NN O
therapeutic WO2007054283A3 A JJ O
vaccination WO2007054283A3 A NN O
in WO2007054283A3 A IN O
the WO2007054283A3 A DT O
treatment WO2007054283A3 A NN O
of WO2007054283A3 A IN O
infectious WO2007054283A3 A JJ O
diseases WO2007054283A3 A NNS O
, WO2007054283A3 A , O
inflammatory WO2007054283A3 A NN O
diseases WO2007054283A3 A NNS O
, WO2007054283A3 A , O
autoimmune WO2007054283A3 A NN O
diseases WO2007054283A3 A NNS O
, WO2007054283A3 A , O
tumours WO2007054283A3 A NNS O
, WO2007054283A3 A , O
allergies WO2007054283A3 A NNS O
as WO2007054283A3 A RB O
well WO2007054283A3 A RB O
as WO2007054283A3 A IN O
for WO2007054283A3 A IN O
the WO2007054283A3 A DT O
control WO2007054283A3 A NN O
of WO2007054283A3 A IN O
fertility WO2007054283A3 A NN O
in WO2007054283A3 A IN O
human WO2007054283A3 A NN O
or WO2007054283A3 A CC O
animal WO2007054283A3 A NN O
populations WO2007054283A3 A NNS O
. WO2007054283A3 A . O

The WO2007054283A3 A DT O
compounds WO2007054283A3 A NNS O
are WO2007054283A3 A VBP O
particularly WO2007054283A3 A RB O
useful WO2007054283A3 A JJ O
not WO2007054283A3 A RB O
only WO2007054283A3 A RB O
as WO2007054283A3 A IN O
systemic WO2007054283A3 A JJ O
, WO2007054283A3 A , O
but WO2007054283A3 A CC O
preferably WO2007054283A3 A RB O
as WO2007054283A3 A IN O
mucosal WO2007054283A3 A NN O
adjuvants WO2007054283A3 A NNS O
. WO2007054283A3 A . O

In WO2007054283A3 A IN O
addition WO2007054283A3 A NN O
, WO2007054283A3 A , O
the WO2007054283A3 A DT O
invention WO2007054283A3 A NN O
relates WO2007054283A3 A VBZ O
to WO2007054283A3 A TO O
its WO2007054283A3 A PRP$ O
uses WO2007054283A3 A NNS O
as WO2007054283A3 A IN O
active WO2007054283A3 A JJ O
ingredients WO2007054283A3 A NNS O
in WO2007054283A3 A IN O
pharmaceutical WO2007054283A3 A JJ O
compositions WO2007054283A3 A NNS O
. WO2007054283A3 A . O

Medication CN1660100A T NN O
for CN1660100A T IN O
treating CN1660100A T VBG O
diabetes CN1660100A T NNS O
and CN1660100A T CC O
complication CN1660100A T NN O
. CN1660100A T . O

Quinoline- WO2013051024A3 T NNP O
, WO2013051024A3 T , O
quinoxaline WO2013051024A3 T NN O
or WO2013051024A3 T CC O
benzothiazole WO2013051024A3 T NN O
based WO2013051024A3 T VBN O
cysteinyl WO2013051024A3 T JJ O
leukotriene WO2013051024A3 T NN O
antagonists WO2013051024A3 T NNS O
( WO2013051024A3 T ( O
ltc4 WO2013051024A3 T NN O
) WO2013051024A3 T ) O
. WO2013051024A3 T . O

Calcium CN103356500A T NNP O
rosuvastatin CN103356500A T NN O
and CN103356500A T CC O
fenofibric CN103356500A T JJ O
acid CN103356500A T NN O
choline CN103356500A T NN O
salt CN103356500A T VBD O
time-selecting CN103356500A T JJ O
osmotic CN103356500A T JJ O
pump CN103356500A T NN O
controlled CN103356500A T VBD O
release CN103356500A T NN O
tablet CN103356500A T NN O
and CN103356500A T CC O
preparation CN103356500A T NN O
method CN103356500A T NN O
thereof CN103356500A T NN O
. CN103356500A T . O

This US20080293709 A DT O
invention US20080293709 A NN O
relates US20080293709 A VBZ O
to US20080293709 A TO O
novel US20080293709 A VB O
compounds US20080293709 A NNS O
having US20080293709 A VBG O
the US20080293709 A DT O
structural US20080293709 A JJ O
formula US20080293709 A NN O
I US20080293709 A PRP O
below US20080293709 A IN O
: US20080293709 A : O
and US20080293709 A CC O
to US20080293709 A TO O
their US20080293709 A PRP$ O
pharmaceutically US20080293709 A RB O
acceptable US20080293709 A JJ O
salts US20080293709 A NNS O
, US20080293709 A , O
compositions US20080293709 A NNS O
and US20080293709 A CC O
methods US20080293709 A NNS O
of US20080293709 A IN O
use US20080293709 A NN O
. US20080293709 A . O

These US20080293709 A DT O
novel US20080293709 A JJ O
compounds US20080293709 A NNS O
provide US20080293709 A VBP O
a US20080293709 A DT O
treatment US20080293709 A NN O
or US20080293709 A CC O
prophylaxis US20080293709 A NN O
of US20080293709 A IN O
cognitive US20080293709 A JJ O
impairment US20080293709 A NN O
, US20080293709 A , O
Alzheimer US20080293709 A NNP O
Disease US20080293709 A NNP O
, US20080293709 A , O
neurodegeneration US20080293709 A NN O
and US20080293709 A CC O
dementia US20080293709 A NN O
. US20080293709 A . O

Functional CA2283464C T NNP O
dna CA2283464C T NN O
clone CA2283464C T NN O
for CA2283464C T IN O
hepatitis CA2283464C T NN O
c CA2283464C T NN O
virus CA2283464C T NN O
( CA2283464C T ( O
hcv CA2283464C T NN O
) CA2283464C T ) O
and CA2283464C T CC O
uses CA2283464C T VBZ O
thereof CA2283464C T NN O
. CA2283464C T . O

Methods US20100196335 T NNS O
and US20100196335 T CC O
Compositions US20100196335 T NNP O
for US20100196335 T IN O
Regulated US20100196335 T NNP O
Expressions US20100196335 T NNP O
of US20100196335 T IN O
Nucleic US20100196335 T NNP O
Acid US20100196335 T NNP O
at US20100196335 T IN O
Post-Transcriptional US20100196335 T NNP O
Level US20100196335 T NNP O
. US20100196335 T . O

Anti- WO2013024487A1 T JJ O
vitiligo WO2013024487A1 T NN O
composition WO2013024487A1 T NN O
. WO2013024487A1 T . O

Comprising US20080286209 T VBG O
isoprenoid-based US20080286209 T JJ O
compounds US20080286209 T NNS O
( US20080286209 T ( O
e.g. US20080286209 T NN O
, US20080286209 T , O
farnesol US20080286209 T JJ O
and/or US20080286209 T NN O
farnesol US20080286209 T NN O
analogues US20080286209 T NNS O
or US20080286209 T CC O
derivatives US20080286209 T NNS O
) US20080286209 T ) O
or US20080286209 T CC O
dehydroisoprenoid-based US20080286209 T JJ O
compounds US20080286209 T NNS O
, US20080286209 T , O
for US20080286209 T IN O
use US20080286209 T NN O
in US20080286209 T IN O
treating US20080286209 T VBG O
( US20080286209 T ( O
e.g. US20080286209 T NN O
, US20080286209 T , O
suppressing US20080286209 T VBG O
) US20080286209 T ) O
alcohol US20080286209 T NN O
withdrawal US20080286209 T NN O
syndrome US20080286209 T NN O
and US20080286209 T CC O
associated US20080286209 T JJ O
neurological US20080286209 T JJ O
symptoms US20080286209 T NNS O
( US20080286209 T ( O
e.g. US20080286209 T NN O
, US20080286209 T , O
depression US20080286209 T NN O
, US20080286209 T , O
tremor US20080286209 T NN O
, US20080286209 T , O
anxiety US20080286209 T NN O
) US20080286209 T ) O
. US20080286209 T . O

Animal US20100034901 T NNP O
feed US20100034901 T NN O
compositions US20100034901 T NNS O
. US20100034901 T . O

The US20100034901 A DT O
invention US20100034901 A NN O
provides US20100034901 A VBZ O
compositions US20100034901 A NNS O
and US20100034901 A CC O
methods US20100034901 A NNS O
for US20100034901 A IN O
preventing US20100034901 A VBG O
and US20100034901 A CC O
treating US20100034901 A VBG O
osteochondrosis US20100034901 A NN O
, US20100034901 A , O
lameness US20100034901 A NN O
, US20100034901 A , O
and US20100034901 A CC O
leg US20100034901 A NN O
weakness US20100034901 A NN O
by US20100034901 A IN O
administration US20100034901 A NN O
of US20100034901 A IN O
supplemental US20100034901 A JJ O
boron US20100034901 A NN O
and US20100034901 A CC O
vitamin US20100034901 A NN O
C US20100034901 A NNP O
containing US20100034901 A VBG O
compounds US20100034901 A NNS O
to US20100034901 A TO O
animals US20100034901 A NNS O
and US20100034901 A CC O
humans US20100034901 A NNS O
. US20100034901 A . O

The US20100034901 A DT O
supplemental US20100034901 A JJ O
boron US20100034901 A NN O
and US20100034901 A CC O
vitamin US20100034901 A NN O
C US20100034901 A NNP O
containing US20100034901 A NN O
compounds US20100034901 A NNS O
are US20100034901 A VBP O
provided US20100034901 A VBN O
in US20100034901 A IN O
animal US20100034901 A JJ O
feed US20100034901 A NN O
compositions US20100034901 A NNS O
or US20100034901 A CC O
as US20100034901 A IN O
supplements US20100034901 A NNS O
for US20100034901 A IN O
animal US20100034901 A JJ O
feed US20100034901 A NN O
. US20100034901 A . O

Also US20100034901 A RB O
provided US20100034901 A VBN O
by US20100034901 A IN O
this US20100034901 A DT O
invention US20100034901 A NN O
are US20100034901 A VBP O
animal US20100034901 A JJ O
feed US20100034901 A NN O
compositions US20100034901 A NNS O
that US20100034901 A WDT O
are US20100034901 A VBP O
supplemented US20100034901 A VBN O
with US20100034901 A IN O
boron US20100034901 A NN O
and US20100034901 A CC O
vitamin US20100034901 A NN O
C US20100034901 A NNP O
containing US20100034901 A VBG O
compounds US20100034901 A NNS O
and US20100034901 A CC O
which US20100034901 A WDT O
have US20100034901 A VBP O
reduced US20100034901 A VBN O
phosphorus US20100034901 A NN O
content US20100034901 A NN O
. US20100034901 A . O

The US20100034901 A DT O
invention US20100034901 A NN O
also US20100034901 A RB O
provides US20100034901 A VBZ O
a US20100034901 A DT O
method US20100034901 A NN O
for US20100034901 A IN O
decreasing US20100034901 A VBG O
the US20100034901 A DT O
amount US20100034901 A NN O
of US20100034901 A IN O
phosphorus US20100034901 A NN O
excreted US20100034901 A VBN O
by US20100034901 A IN O
an US20100034901 A DT O
animal US20100034901 A NN O
, US20100034901 A , O
a US20100034901 A DT O
method US20100034901 A NN O
of US20100034901 A IN O
increasing US20100034901 A VBG O
the US20100034901 A DT O
efficiency US20100034901 A NN O
of US20100034901 A IN O
absorption US20100034901 A NN O
of US20100034901 A IN O
phosphorus US20100034901 A NN O
by US20100034901 A IN O
an US20100034901 A DT O
animal US20100034901 A NN O
, US20100034901 A , O
a US20100034901 A DT O
method US20100034901 A NN O
of US20100034901 A IN O
reducing US20100034901 A VBG O
environmental US20100034901 A JJ O
phosphorus US20100034901 A NN O
pollution US20100034901 A NN O
by US20100034901 A IN O
administering US20100034901 A VBG O
supplemental US20100034901 A JJ O
boron US20100034901 A NN O
and US20100034901 A CC O
vitamin US20100034901 A NN O
C US20100034901 A NNP O
to US20100034901 A TO O
the US20100034901 A DT O
animal US20100034901 A NN O
. US20100034901 A . O

The US20100034901 A DT O
invention US20100034901 A NN O
also US20100034901 A RB O
provides US20100034901 A VBZ O
a US20100034901 A DT O
method US20100034901 A NN O
of US20100034901 A IN O
reducing US20100034901 A VBG O
pre-weaning US20100034901 A JJ O
mortality US20100034901 A NN O
in US20100034901 A IN O
an US20100034901 A DT O
animal US20100034901 A NN O
by US20100034901 A IN O
feeding US20100034901 A VBG O
pregnant US20100034901 A JJ O
, US20100034901 A , O
nursing US20100034901 A NN O
or US20100034901 A CC O
lactating US20100034901 A NN O
animals US20100034901 A NNS O
by US20100034901 A IN O
administering US20100034901 A VBG O
supplemental US20100034901 A JJ O
boron US20100034901 A NN O
and US20100034901 A CC O
vitamin US20100034901 A NN O
C US20100034901 A NNP O
containing US20100034901 A VBG O
compounds US20100034901 A NNS O
. US20100034901 A . O

Pharmaceutical US20100273844 T JJ O
compositions US20100273844 T NNS O
for US20100273844 T IN O
treating US20100273844 T VBG O
or US20100273844 T CC O
preventing US20100273844 T VBG O
migaines US20100273844 T NNS O
. US20100273844 T . O

The US20100273844 A DT O
present US20100273844 A JJ O
invention US20100273844 A NN O
provides US20100273844 A VBZ O
a US20100273844 A DT O
method US20100273844 A NN O
for US20100273844 A IN O
treating US20100273844 A VBG O
or US20100273844 A CC O
preventing US20100273844 A VBG O
one US20100273844 A CD O
or US20100273844 A CC O
more US20100273844 A JJR O
types US20100273844 A NNS O
of US20100273844 A IN O
migraines US20100273844 A NNS O
by US20100273844 A IN O
administering US20100273844 A VBG O
a US20100273844 A DT O
monoamine US20100273844 A JJ I-UN
oxidase US20100273844 A NN I-UN
inhibitor US20100273844 A NN O
, US20100273844 A , O
preferably US20100273844 A RB O
isocarboxazid US20100273844 A NN O
, US20100273844 A , O
in US20100273844 A IN O
a US20100273844 A DT O
rapid-release US20100273844 A JJ O
formulation US20100273844 A NN O
. US20100273844 A . O

The US20100273844 A DT O
present US20100273844 A JJ O
invention US20100273844 A NN O
also US20100273844 A RB O
provides US20100273844 A VBZ O
a US20100273844 A DT O
pharmaceutical US20100273844 A JJ O
composition US20100273844 A NN O
suitable US20100273844 A NN O
for US20100273844 A IN O
treating US20100273844 A VBG O
or US20100273844 A CC O
preventing US20100273844 A VBG O
migraines US20100273844 A NNS O
and US20100273844 A CC O
having US20100273844 A VBG O
at US20100273844 A IN O
least US20100273844 A JJS O
one US20100273844 A CD O
monoamine US20100273844 A NN I-UN
oxidase US20100273844 A NN I-UN
inhibitor US20100273844 A NN O
. US20100273844 A . O

Drug WO2014054798A1 T NN O
for WO2014054798A1 T IN O
inhibiting WO2014054798A1 T VBG O
malignant WO2014054798A1 T JJ O
tumor WO2014054798A1 T NN O
metastasis WO2014054798A1 T NN O
. WO2014054798A1 T . O

( WO2014054798A1 A ( O
i WO2014054798A1 A NN O
) WO2014054798A1 A ) O
Angiotensin WO2014054798A1 A NNP O
II WO2014054798A1 A NNP O
receptor WO2014054798A1 A NN O
antagonists WO2014054798A1 A NNS O
( WO2014054798A1 A ( O
ii WO2014054798A1 A NN O
) WO2014054798A1 A ) O
HMG-CoA WO2014054798A1 A NNP I-UN
reductase WO2014054798A1 A NN I-UN
inhibitors WO2014054798A1 A NNS O
( WO2014054798A1 A ( O
iii WO2014054798A1 A NN O
) WO2014054798A1 A ) O
Ghrelin WO2014054798A1 A NNP I-UN
and WO2014054798A1 A CC O
derivatives WO2014054798A1 A NNS O
thereof WO2014054798A1 A VBP O
( WO2014054798A1 A ( O
iv WO2014054798A1 A NN O
) WO2014054798A1 A ) O
Adrenomedullin WO2014054798A1 A NNP I-UN
and WO2014054798A1 A CC O
derivatives WO2014054798A1 A NNS O
thereof WO2014054798A1 A VBP O

Triazolopyrazine EP2018383A1 T NNP O
derivatives EP2018383A1 T VBZ O
useful EP2018383A1 T JJ O
as EP2018383A1 T IN O
anti-cancer EP2018383A1 T JJ O
agents EP2018383A1 T NNS O
. EP2018383A1 T . O

Manufacture US20110052645 T NN O
of US20110052645 T IN O
multiple US20110052645 T JJ O
minicapsules US20110052645 T NNS O
. US20110052645 T . O

An US20110052645 A DT O
extrusion US20110052645 A NN O
process US20110052645 A NN O
comprises US20110052645 A VBZ O
extruding US20110052645 A VBG O
a US20110052645 A DT O
material US20110052645 A NN O
that US20110052645 A WDT O
is US20110052645 A VBZ O
flowable US20110052645 A JJ O
when US20110052645 A WRB O
heated US20110052645 A VBN O
and US20110052645 A CC O
passing US20110052645 A VBG O
the US20110052645 A DT O
extrudate US20110052645 A NN O
thus US20110052645 A RB O
formed US20110052645 A VBN O
through US20110052645 A IN O
a US20110052645 A DT O
nozzle US20110052645 A JJ O
10 US20110052645 A CD O
to US20110052645 A TO O
shape US20110052645 A VB O
the US20110052645 A DT O
extrudate US20110052645 A NN O
into US20110052645 A IN O
a US20110052645 A DT O
plurality US20110052645 A NN O
of US20110052645 A IN O
substantially US20110052645 A RB O
uniformly US20110052645 A JJ O
shaped US20110052645 A JJ O
elements US20110052645 A NNS O
such US20110052645 A JJ O
as US20110052645 A IN O
minispheres US20110052645 A NNS O
or US20110052645 A CC O
minicapsules US20110052645 A NNS O
. US20110052645 A . O

Cannabinoid US7482339 T NNP I-UN
receptor US7482339 T NN I-UN
agonists US7482339 T NNS O
; US7482339 T : O
antipruritic US7482339 T JJ O
agents US7482339 T NNS O
, US7482339 T , O
analgesics US7482339 T NNS O
, US7482339 T , O
bronchodilator US7482339 T NN O
agents US7482339 T NNS O
. US7482339 T . O

Tetracyclic EP1599202A1 T JJ O
pyrazole EP1599202A1 T NN O
derivatives EP1599202A1 T NNS O
as EP1599202A1 T IN O
kinase EP1599202A1 T NN O
inhibitors EP1599202A1 T NNS O
, EP1599202A1 T , O
process EP1599202A1 T NN O
for EP1599202A1 T IN O
their EP1599202A1 T PRP$ O
preparation EP1599202A1 T NN O
and EP1599202A1 T CC O
pharmaceutical EP1599202A1 T JJ O
compositions EP1599202A1 T NNS O
comprising EP1599202A1 T VBG O
them EP1599202A1 T PRP O
. EP1599202A1 T . O

Phenserine WO2010117727A3 T NNP O
and WO2010117727A3 T CC O
posiphen WO2010117727A3 T NN O
for WO2010117727A3 T IN O
treating WO2010117727A3 T VBG O
neuropsychiatric WO2010117727A3 T JJ O
and WO2010117727A3 T CC O
neurodegenerative WO2010117727A3 T JJ O
conditions WO2010117727A3 T NNS O
. WO2010117727A3 T . O

Tebipenem CN103054815A T NNP O
pivoxil CN103054815A T VBZ O
oral CN103054815A T JJ O
solid CN103054815A T JJ O
preparation CN103054815A T NN O
and CN103054815A T CC O
preparation CN103054815A T NN O
method CN103054815A T NN O
thereof CN103054815A T NN O
. CN103054815A T . O

Application CN101947230A T NN O
of CN101947230A T IN O
5'-AMP CN101947230A T JJ O
for CN101947230A T IN O
treating CN101947230A T VBG O
urarthritis CN101947230A T NN O
. CN101947230A T . O

Plague CN1876069A T NNP O
preventive CN1876069A T JJ O
oil CN1876069A T NN O
and CN1876069A T CC O
method CN1876069A T NN O
for CN1876069A T IN O
preparing CN1876069A T VBG O
same CN1876069A T JJ O
. CN1876069A T . O

Benzofuran US7273886 T NNP O
inhibitors US7273886 T NNS O
of US7273886 T IN O
factor US7273886 T NN O
VIIa US7273886 T NNP O
. US7273886 T . O

Method US20110008328 T NN O
for US20110008328 T IN O
controlling US20110008328 T VBG O
glucose US20110008328 T JJ O
uptake US20110008328 T JJ O
and US20110008328 T CC O
insulin US20110008328 T JJ I-UN
sensitivity US20110008328 T NN O
. US20110008328 T . O

The US20110008328 A DT O
invention US20110008328 A NN O
provides US20110008328 A VBZ O
methods US20110008328 A NNS O
for US20110008328 A IN O
treating US20110008328 A VBG O
diabetes US20110008328 A NNS O
and US20110008328 A CC O
related US20110008328 A JJ O
disorders US20110008328 A NNS O
, US20110008328 A , O
such US20110008328 A JJ O
as US20110008328 A IN O
metabolic US20110008328 A JJ O
syndromes US20110008328 A NNS O
( US20110008328 A ( O
which US20110008328 A WDT O
includes US20110008328 A VBZ O
insulin US20110008328 A NN I-UN
resistance US20110008328 A NN O
) US20110008328 A ) O
, US20110008328 A , O
by US20110008328 A IN O
administering US20110008328 A VBG O
an US20110008328 A DT O
inhibitor US20110008328 A NN O
of US20110008328 A IN O
osteopontin US20110008328 A NN I-UN
( US20110008328 A ( O
OPN US20110008328 A NNP I-UN
) US20110008328 A ) O
, US20110008328 A , O
which US20110008328 A WDT O
includes US20110008328 A VBZ O
an US20110008328 A DT O
antibody US20110008328 A NN O
, US20110008328 A , O
antibody US20110008328 A NN O
fragment US20110008328 A NN O
, US20110008328 A , O
siRNA US20110008328 A NN O
, US20110008328 A , O
and US20110008328 A CC O
aptamer US20110008328 A NN O
. US20110008328 A . O

Also US20110008328 A RB O
disclosed US20110008328 A VBN O
are US20110008328 A VBP O
methods US20110008328 A NNS O
for US20110008328 A IN O
increasing US20110008328 A VBG O
glucose US20110008328 A JJ O
uptake US20110008328 A NN O
by US20110008328 A IN O
cells US20110008328 A NNS O
in US20110008328 A IN O
a US20110008328 A DT O
subject US20110008328 A NN O
, US20110008328 A , O
by US20110008328 A IN O
administering US20110008328 A VBG O
an US20110008328 A DT O
inhibitor US20110008328 A NN O
of US20110008328 A IN O
OPN US20110008328 A NNP I-UN
. US20110008328 A . O

Sheep CN101524475A T JJ O
ossein CN101524475A T IN O
tendon-and-bone CN101524475A T JJ O
strengthening CN101524475A T VBG O
calcium CN101524475A T NN O
for CN101524475A T IN O
preventing CN101524475A T VBG O
fatigue CN101524475A T NN O
and CN101524475A T CC O
tonifying CN101524475A T VBG O
kidney CN101524475A T NN O
. CN101524475A T . O

Medicinal US20060052440 T JJ O
composition US20060052440 T NN O
for US20060052440 T IN O
treating US20060052440 T VBG O
sudden US20060052440 T JJ O
deafness US20060052440 T NN O
. US20060052440 T . O

Retrovirus CA2426348C T NNP O
isolated CA2426348C T VBD O
from CA2426348C T IN O
humans CA2426348C T NNS O
. CA2426348C T . O

Preparation CN101057925B T NNP O
technology CN101057925B T NN O
for CN101057925B T IN O
'jieguqili CN101057925B T NNP O
' CN101057925B T POS O
capsule CN101057925B T NN O
. CN101057925B T . O

Medicine CN103479784A T NNP O
for CN103479784A T IN O
treating CN103479784A T VBG O
rhinitis CN103479784A T NN O
. CN103479784A T . O

Composition CN103340904A T NN O
for CN103340904A T IN O
treating CN103340904A T VBG O
osteoarthritis CN103340904A T NN O
. CN103340904A T . O

Reversible US20090074885 T JJ O
Hydrophobic US20090074885 T NNP O
Modification US20090074885 T NNP O
of US20090074885 T IN O
Drugs US20090074885 T NNP O
for US20090074885 T IN O
Improved US20090074885 T NNP O
Delivery US20090074885 T NNP O
to US20090074885 T TO O
Cells US20090074885 T NNP O
. US20090074885 T . O

Scarless CN103405492A T NNP O
pain CN103405492A T NN O
relieving CN103405492A T VBG O
paste CN103405492A T NN O
for CN103405492A T IN O
burn CN103405492A T NN O
and CN103405492A T CC O
preparation CN103405492A T NN O
method CN103405492A T NN O
thereof CN103405492A T NN O
. CN103405492A T . O

Ursodeoxycholic CN101897712A T JJ O
acid CN101897712A T NN O
phospholipid CN101897712A T JJ O
composition CN101897712A T NN O
and CN101897712A T CC O
preparation CN101897712A T NN O
method CN101897712A T NN O
thereof CN101897712A T NN O
. CN101897712A T . O

Mannose WO2011033305A1 T NNP O
6-phosphate WO2011033305A1 T NN O
for WO2011033305A1 T IN O
use WO2011033305A1 T NN O
in WO2011033305A1 T IN O
promoting WO2011033305A1 T VBG O
peripheral WO2011033305A1 T JJ O
nerve WO2011033305A1 T NN O
function WO2011033305A1 T NN O
after WO2011033305A1 T IN O
injury WO2011033305A1 T NN O
. WO2011033305A1 T . O

Carbohydrate US20110136758 T NNP O
compositions US20110136758 T NNS O
from US20110136758 T IN O
basidiomycete US20110136758 T JJ O
fungi US20110136758 T NNS O
as US20110136758 T IN O
biocidal US20110136758 T JJ O
agents US20110136758 T NNS O
active US20110136758 T JJ O
against US20110136758 T IN O
pathogens US20110136758 T NNS O
. US20110136758 T . O

Inhibitors WO2014055768A1 T NNS O
of WO2014055768A1 T IN O
protein WO2014055768A1 T NN I-UN
tyrosine WO2014055768A1 T NN I-UN
phosphatases WO2014055768A1 T NNS I-UN
. WO2014055768A1 T . O

Novel WO2014055768A1 A NNP O
protein WO2014055768A1 A NN I-UN
tyrosine WO2014055768A1 A NN I-UN
phosphatase WO2014055768A1 A NN I-UN
( WO2014055768A1 A ( O
PTP WO2014055768A1 A NNP I-UN
) WO2014055768A1 A ) O
inhibitor WO2014055768A1 A NN O
compounds WO2014055768A1 A NNS O
synthesized WO2014055768A1 A VBN O
from WO2014055768A1 A IN O
phosphonodifluoromethyl WO2014055768A1 A JJ O
phenylalanine WO2014055768A1 A NN O
( WO2014055768A1 A ( O
F2Pmp WO2014055768A1 A NNP O
) WO2014055768A1 A ) O
are WO2014055768A1 A VBP O
provided WO2014055768A1 A VBN O
. WO2014055768A1 A . O

Use WO2014055768A1 A NN O
of WO2014055768A1 A IN O
these WO2014055768A1 A DT O
compounds WO2014055768A1 A NNS O
for WO2014055768A1 A IN O
inhibiting WO2014055768A1 A VBG O
a WO2014055768A1 A DT O
PTP WO2014055768A1 A NNP I-UN
enzyme WO2014055768A1 A NN O
( WO2014055768A1 A ( O
such WO2014055768A1 A JJ O
as WO2014055768A1 A IN O
PTP-MEG2 WO2014055768A1 A NNP O
) WO2014055768A1 A ) O
, WO2014055768A1 A , O
as WO2014055768A1 A RB O
well WO2014055768A1 A RB O
as WO2014055768A1 A IN O
treating WO2014055768A1 A VBG O
a WO2014055768A1 A DT O
disease WO2014055768A1 A NN O
, WO2014055768A1 A , O
disorder WO2014055768A1 A NN O
, WO2014055768A1 A , O
or WO2014055768A1 A CC O
condition WO2014055768A1 A NN O
associated WO2014055768A1 A VBN O
with WO2014055768A1 A IN O
inappropriate WO2014055768A1 A JJ O
activity WO2014055768A1 A NN O
of WO2014055768A1 A IN O
a WO2014055768A1 A DT O
PTP WO2014055768A1 A NNP I-UN
( WO2014055768A1 A ( O
such WO2014055768A1 A JJ O
as WO2014055768A1 A IN O
type WO2014055768A1 A NN O
2 WO2014055768A1 A CD O
diabetes WO2014055768A1 A NNS O
) WO2014055768A1 A ) O
, WO2014055768A1 A , O
is WO2014055768A1 A VBZ O
also WO2014055768A1 A RB O
provided WO2014055768A1 A VBN O
. WO2014055768A1 A . O

Triterpenoid EP1289977B1 T NNP O
derivatives EP1289977B1 T NNS O
and EP1289977B1 T CC O
their EP1289977B1 T PRP$ O
use EP1289977B1 T NN O
as EP1289977B1 T IN O
antiproliferative EP1289977B1 T JJ O
agents EP1289977B1 T NNS O
. EP1289977B1 T . O

Medicine CN101229278A T NNP O
compounds CN101229278A T VBZ O
for CN101229278A T IN O
treating CN101229278A T VBG O
rectum CN101229278A T NN O
cancer CN101229278A T NN O
and CN101229278A T CC O
gastric CN101229278A T JJ O
cancer CN101229278A T NN O
. CN101229278A T . O

The CN101229278A A DT O
invention CN101229278A A NN O
which CN101229278A A WDT O
discloses CN101229278A A VBZ O
a CN101229278A A DT O
medicine CN101229278A A JJ O
combination CN101229278A A NN O
for CN101229278A A IN O
rectal CN101229278A A JJ O
cancer CN101229278A A NN O
and CN101229278A A CC O
gastric CN101229278A A JJ O
cancer CN101229278A A NN O
treatment CN101229278A A NN O
, CN101229278A A , O
characterized CN101229278A A VBN O
in CN101229278A A IN O
that CN101229278A A DT O
the CN101229278A A DT O
invention CN101229278A A NN O
consists CN101229278A A VBZ O
of CN101229278A A IN O
the CN101229278A A DT O
components CN101229278A A NNS O
with CN101229278A A IN O
the CN101229278A A DT O
weight CN101229278A A JJ O
proportion CN101229278A A NN O
: CN101229278A A : O
walnut CN101229278A A NN O
of CN101229278A A IN O
4 CN101229278A A CD O
to CN101229278A A TO O
10 CN101229278A A CD O
portions CN101229278A A NNS O
, CN101229278A A , O
jujube CN101229278A A NN O
of CN101229278A A IN O
4 CN101229278A A CD O
to CN101229278A A TO O
10 CN101229278A A CD O
portions CN101229278A A NNS O
, CN101229278A A , O
safflower CN101229278A A JJR O
of CN101229278A A IN O
7 CN101229278A A CD O
to CN101229278A A TO O
13 CN101229278A A CD O
portions CN101229278A A NNS O
, CN101229278A A , O
brown CN101229278A A JJ O
sugar CN101229278A A NN O
of CN101229278A A IN O
7 CN101229278A A CD O
to CN101229278A A TO O
13 CN101229278A A CD O
portions CN101229278A A NNS O
, CN101229278A A , O
chestnut CN101229278A A NN O
tree CN101229278A A JJ O
bacteria CN101229278A A NNS O
or CN101229278A A CC O
walnut CN101229278A A JJ O
tree CN101229278A A JJ O
bacteria CN101229278A A NNS O
of CN101229278A A IN O
12 CN101229278A A CD O
to CN101229278A A TO O
18 CN101229278A A CD O
portions CN101229278A A NNS O
, CN101229278A A , O
ailanthus CN101229278A A RB O
root CN101229278A A JJ O
bark CN101229278A A NN O
of CN101229278A A IN O
20 CN101229278A A CD O
to CN101229278A A TO O
40 CN101229278A A CD O
portions CN101229278A A NNS O
, CN101229278A A , O
tea CN101229278A A NN O
of CN101229278A A IN O
7 CN101229278A A CD O
to CN101229278A A TO O
13 CN101229278A A CD O
portions CN101229278A A NNS O
and CN101229278A A CC O
the CN101229278A A DT O
components CN101229278A A NNS O
are CN101229278A A VBP O
made CN101229278A A VBN O
into CN101229278A A IN O
decoction CN101229278A A NN O
; CN101229278A A : O
Vitamin CN101229278A A NNP O
C CN101229278A A NNP O
, CN101229278A A , O
vitamin CN101229278A A NN O
complex CN101229278A A NN O
B CN101229278A A NNP O
and CN101229278A A CC O
vitamin CN101229278A A NN O
B12 CN101229278A A NNP O
are CN101229278A A VBP O
injected CN101229278A A VBN O
into CN101229278A A IN O
muscles CN101229278A A NNS O
and CN101229278A A CC O
the CN101229278A A DT O
three CN101229278A A CD O
vitamins CN101229278A A NNS O
are CN101229278A A VBP O
mixed CN101229278A A JJ O
and CN101229278A A CC O
injected CN101229278A A JJ O
; CN101229278A A : O
the CN101229278A A DT O
invention CN101229278A A NN O
provides CN101229278A A VBZ O
a CN101229278A A DT O
medicine CN101229278A A NN O
combination CN101229278A A NN O
which CN101229278A A WDT O
has CN101229278A A VBZ O
fast CN101229278A A VBN O
and CN101229278A A CC O
good CN101229278A A JJ O
effect CN101229278A A NN O
of CN101229278A A IN O
curing CN101229278A A VBG O
the CN101229278A A DT O
rectal CN101229278A A JJ O
cancer CN101229278A A NN O
and CN101229278A A CC O
the CN101229278A A DT O
gastric CN101229278A A JJ O
cancer CN101229278A A NN O
. CN101229278A A . O

Agent CN103193644A T NN O
for CN103193644A T IN O
treating CN103193644A T VBG O
pain CN103193644A T NN O
diseases CN103193644A T NNS O
. CN103193644A T . O

Compounds US20110245243 T NNS O
and US20110245243 T CC O
compositions US20110245243 T NNS O
as US20110245243 T IN O
cathepsin US20110245243 T NN I-UN
s US20110245243 T NN I-UN
inhibitors US20110245243 T NNS O
. US20110245243 T . O

The US20110245243 A DT O
invention US20110245243 A NN O
provides US20110245243 A VBZ O
compounds US20110245243 A NNS O
, US20110245243 A , O
pharmaceutical US20110245243 A JJ O
compositions US20110245243 A NNS O
comprising US20110245243 A VBG O
such US20110245243 A JJ O
compounds US20110245243 A NNS O
and US20110245243 A CC O
methods US20110245243 A NNS O
of US20110245243 A IN O
using US20110245243 A VBG O
such US20110245243 A JJ O
compounds US20110245243 A NNS O
to US20110245243 A TO O
treat US20110245243 A VB O
or US20110245243 A CC O
prevent US20110245243 A VB O
diseases US20110245243 A NNS O
or US20110245243 A CC O
disorders US20110245243 A NNS O
associated US20110245243 A VBN O
with US20110245243 A IN O
the US20110245243 A DT O
activity US20110245243 A NN O
of US20110245243 A IN O
Cathepsin US20110245243 A NNP I-UN
S US20110245243 A NNP I-UN
. US20110245243 A . O

Levorotatory-pantoprazole CN103536563A T JJ O
sodium CN103536563A T NN O
composition CN103536563A T NN O
freeze-dried CN103536563A T JJ O
powder CN103536563A T NN O
for CN103536563A T IN O
injection CN103536563A T NN O
. CN103536563A T . O

COMPOSITIONS EP1963508A2 T NNP O
AND EP1963508A2 T NNP O
METHODS EP1963508A2 T NNP O
OF EP1963508A2 T NNP O
USING EP1963508A2 T NNP O
siRNA EP1963508A2 T NN O
TO EP1963508A2 T NNP O
KNOCKDOWN EP1963508A2 T NNP O
GENE EP1963508A2 T NNP O
EXPRESSION EP1963508A2 T NNP O
AND EP1963508A2 T NNP O
TO EP1963508A2 T NNP O
IMPROVE EP1963508A2 T NNP O
SOLID EP1963508A2 T NNP O
ORGAN EP1963508A2 T NNP O
AND EP1963508A2 T NNP O
CELL EP1963508A2 T NNP O
TRANSPLANTATION EP1963508A2 T NNP O
. EP1963508A2 T . O

This EP1963508A2 A DT O
invention EP1963508A2 A NN O
describes EP1963508A2 A VBZ O
compositions EP1963508A2 A NNS O
and EP1963508A2 A CC O
methods EP1963508A2 A NNS O
using EP1963508A2 A VBG O
siRNA EP1963508A2 A NN O
to EP1963508A2 A TO O
target EP1963508A2 A VB O
various EP1963508A2 A JJ O
genes EP1963508A2 A NNS O
expressed EP1963508A2 A VBN O
in EP1963508A2 A IN O
cells EP1963508A2 A NNS O
of EP1963508A2 A IN O
transplanted EP1963508A2 A JJ O
organs EP1963508A2 A NNS O
or EP1963508A2 A CC O
tissues EP1963508A2 A NNS O
and/or EP1963508A2 A VBP O
genes EP1963508A2 A NNS O
expressed EP1963508A2 A VBN O
in EP1963508A2 A IN O
the EP1963508A2 A DT O
host EP1963508A2 A NN O
to EP1963508A2 A TO O
improve EP1963508A2 A VB O
the EP1963508A2 A DT O
success EP1963508A2 A NN O
of EP1963508A2 A IN O
the EP1963508A2 A DT O
transplantation EP1963508A2 A NN O
. EP1963508A2 A . O

NOVEL WO2011107248A1 T NNP O
COMPOUNDS WO2011107248A1 T NNP O
FOR WO2011107248A1 T NNP O
MODULATION WO2011107248A1 T NNP O
OF WO2011107248A1 T NNP O
ORPHAN WO2011107248A1 T NNP O
NUCLEAR WO2011107248A1 T NNP O
RECEPTOR WO2011107248A1 T NNP O
RAR-RELATED WO2011107248A1 T NNP I-UN
ORPHAN WO2011107248A1 T NNP I-UN
RECEPTOR-GAMMA WO2011107248A1 T NNP I-UN
( WO2011107248A1 T ( O
RORγ WO2011107248A1 T NNP I-UN
GAMMA WO2011107248A1 T NNP O
, WO2011107248A1 T , O
NR1F3 WO2011107248A1 T NNP I-UN
) WO2011107248A1 T ) O
ACTIVITY WO2011107248A1 T NNP O
AND WO2011107248A1 T NNP O
FOR WO2011107248A1 T IN O
THE WO2011107248A1 T NNP O
TREATMENT WO2011107248A1 T NNP O
OF WO2011107248A1 T NNP O
CHRONIC WO2011107248A1 T NNP O
INFLAMMATORY WO2011107248A1 T NNP O
AND WO2011107248A1 T NNP O
AUTOIMMUNE WO2011107248A1 T NNP O
DISEASE WO2011107248A1 T NNP O
. WO2011107248A1 T . O

The WO2011107248A1 A DT O
invention WO2011107248A1 A NN O
provides WO2011107248A1 A VBZ O
modulators WO2011107248A1 A NNS O
for WO2011107248A1 A IN O
the WO2011107248A1 A DT O
orphan WO2011107248A1 A JJ O
nuclear WO2011107248A1 A JJ O
receptor WO2011107248A1 A NN O
RORγ WO2011107248A1 A NNP I-UN
and WO2011107248A1 A CC O
methods WO2011107248A1 A NNS O
for WO2011107248A1 A IN O
treating WO2011107248A1 A VBG O
RORγ WO2011107248A1 A NNP I-UN
mediated WO2011107248A1 A VBD O
diseases WO2011107248A1 A NNS O
by WO2011107248A1 A IN O
administrating WO2011107248A1 A VBG O
these WO2011107248A1 A DT O
novel WO2011107248A1 A JJ O
RORγ WO2011107248A1 A NNP I-UN
modulators WO2011107248A1 A NNS O
to WO2011107248A1 A TO O
a WO2011107248A1 A DT O
human WO2011107248A1 A JJ O
or WO2011107248A1 A CC O
a WO2011107248A1 A DT O
mammal WO2011107248A1 A NN O
in WO2011107248A1 A IN O
need WO2011107248A1 A NN O
thereof WO2011107248A1 A NN O
. WO2011107248A1 A . O

Sustained CN101229169B T VBN O
release CN101229169B T NN O
formulations CN101229169B T NNS O
comprising CN101229169B T VBG O
lamotrigine CN101229169B T NN O
. CN101229169B T . O

External CN1927292A T JJ O
use CN1927292A T NN O
drug CN1927292A T NN O
for CN1927292A T IN O
treating CN1927292A T VBG O
burn CN1927292A T NN O
, CN1927292A T , O
bedsore CN1927292A T NN O
, CN1927292A T , O
chronic CN1927292A T JJ O
ulcer CN1927292A T NN O
and CN1927292A T CC O
etc CN1927292A T NN O
. CN1927292A T . O

and CN1927292A T CC O
preparation CN1927292A T NN O
method CN1927292A T NN O
thereof CN1927292A T NN O
. CN1927292A T . O

Compositions US20100273870 T NNS O
and US20100273870 T CC O
methods US20100273870 T NNS O
for US20100273870 T IN O
treating US20100273870 T VBG O
demodex US20100273870 T NN O
infestations US20100273870 T NNS O
. US20100273870 T . O

Methods WO2010066858A1 T NNS O
for WO2010066858A1 T IN O
the WO2010066858A1 T DT O
treatment WO2010066858A1 T NN O
and WO2010066858A1 T CC O
the WO2010066858A1 T DT O
prognosis WO2010066858A1 T NN O
of WO2010066858A1 T IN O
cancer WO2010066858A1 T NN O
. WO2010066858A1 T . O

The WO2010066858A1 A DT O
invention WO2010066858A1 A NN O
relates WO2010066858A1 A VBZ O
to WO2010066858A1 A TO O
an WO2010066858A1 A DT O
inhibitor WO2010066858A1 A NN O
of WO2010066858A1 A IN O
IL4I1 WO2010066858A1 A NNP I-UN
for WO2010066858A1 A IN O
use WO2010066858A1 A NN O
in WO2010066858A1 A IN O
a WO2010066858A1 A DT O
method WO2010066858A1 A NN O
for WO2010066858A1 A IN O
treatment WO2010066858A1 A NN O
of WO2010066858A1 A IN O
cancer WO2010066858A1 A NN O
displaying WO2010066858A1 A VBG O
IL4I1-expressing WO2010066858A1 A NNP O
cells WO2010066858A1 A NNS O
in WO2010066858A1 A IN O
the WO2010066858A1 A DT O
human WO2010066858A1 A NN O
or WO2010066858A1 A CC O
animal WO2010066858A1 A NN O
body WO2010066858A1 A NN O
, WO2010066858A1 A , O
provided WO2010066858A1 A VBD O
that WO2010066858A1 A IN O
said WO2010066858A1 A VBD O
cancer WO2010066858A1 A NN O
is WO2010066858A1 A VBZ O
not WO2010066858A1 A RB O
follicular WO2010066858A1 A JJ O
lymphoma WO2010066858A1 A NN O
. WO2010066858A1 A . O

In WO2010066858A1 A IN O
another WO2010066858A1 A DT O
aspect WO2010066858A1 A NN O
, WO2010066858A1 A , O
the WO2010066858A1 A DT O
invention WO2010066858A1 A NN O
relates WO2010066858A1 A VBZ O
to WO2010066858A1 A TO O
a WO2010066858A1 A DT O
method WO2010066858A1 A NN O
for WO2010066858A1 A IN O
determining WO2010066858A1 A VBG O
the WO2010066858A1 A DT O
prognosis WO2010066858A1 A NN O
of WO2010066858A1 A IN O
a WO2010066858A1 A DT O
subject WO2010066858A1 A JJ O
suffering WO2010066858A1 A NN O
from WO2010066858A1 A IN O
a WO2010066858A1 A DT O
cancer WO2010066858A1 A NN O
, WO2010066858A1 A , O
provided WO2010066858A1 A VBD O
that WO2010066858A1 A IN O
said WO2010066858A1 A VBD O
cancer WO2010066858A1 A NN O
is WO2010066858A1 A VBZ O
not WO2010066858A1 A RB O
follicular WO2010066858A1 A JJ O
lymphoma WO2010066858A1 A NN O
, WO2010066858A1 A , O
comprising WO2010066858A1 A VBG O
the WO2010066858A1 A DT O
step WO2010066858A1 A NN O
of WO2010066858A1 A IN O
detecting WO2010066858A1 A VBG O
the WO2010066858A1 A DT O
presence WO2010066858A1 A NN O
of WO2010066858A1 A IN O
IL4I1 WO2010066858A1 A NNP I-UN
in WO2010066858A1 A IN O
a WO2010066858A1 A DT O
sample WO2010066858A1 A NN O
obtained WO2010066858A1 A VBN O
from WO2010066858A1 A IN O
said WO2010066858A1 A VBD O
subject WO2010066858A1 A JJ O
, WO2010066858A1 A , O
wherein WO2010066858A1 A WP O
the WO2010066858A1 A DT O
presence WO2010066858A1 A NN O
of WO2010066858A1 A IN O
IL4I1 WO2010066858A1 A NNP I-UN
indicates WO2010066858A1 A VBZ O
that WO2010066858A1 A IN O
the WO2010066858A1 A DT O
subject WO2010066858A1 A NN O
has WO2010066858A1 A VBZ O
a WO2010066858A1 A DT O
poor WO2010066858A1 A JJ O
prognosis WO2010066858A1 A NN O
. WO2010066858A1 A . O

The WO2010066858A1 A DT O
invention WO2010066858A1 A NN O
also WO2010066858A1 A RB O
relates WO2010066858A1 A VBZ O
to WO2010066858A1 A TO O
a WO2010066858A1 A DT O
method WO2010066858A1 A NN O
for WO2010066858A1 A IN O
determining WO2010066858A1 A VBG O
the WO2010066858A1 A DT O
prognosis WO2010066858A1 A NN O
of WO2010066858A1 A IN O
a WO2010066858A1 A DT O
subject WO2010066858A1 A JJ O
suffering WO2010066858A1 A NN O
from WO2010066858A1 A IN O
a WO2010066858A1 A DT O
follicular WO2010066858A1 A JJ O
lymphoma WO2010066858A1 A NN O
, WO2010066858A1 A , O
comprising WO2010066858A1 A VBG O
the WO2010066858A1 A DT O
step WO2010066858A1 A NN O
of WO2010066858A1 A IN O
detecting WO2010066858A1 A VBG O
the WO2010066858A1 A DT O
presence WO2010066858A1 A NN O
of WO2010066858A1 A IN O
IL4I1 WO2010066858A1 A NNP I-UN
in WO2010066858A1 A IN O
a WO2010066858A1 A DT O
sample WO2010066858A1 A NN O
obtained WO2010066858A1 A VBN O
from WO2010066858A1 A IN O
said WO2010066858A1 A VBD O
subject WO2010066858A1 A JJ O
, WO2010066858A1 A , O
wherein WO2010066858A1 A WP O
the WO2010066858A1 A DT O
presence WO2010066858A1 A NN O
of WO2010066858A1 A IN O
IL4I1 WO2010066858A1 A NNP I-UN
indicates WO2010066858A1 A VBZ O
that WO2010066858A1 A IN O
the WO2010066858A1 A DT O
subject WO2010066858A1 A NN O
has WO2010066858A1 A VBZ O
a WO2010066858A1 A DT O
good WO2010066858A1 A JJ O
prognosis WO2010066858A1 A NN O
. WO2010066858A1 A . O

Fenofibrate CN103599089A T NNP O
oil-soluble CN103599089A T JJ O
sustained-release CN103599089A T JJ O
medicine CN103599089A T NN O
preparation CN103599089A T NN O
composition CN103599089A T NN O
. CN103599089A T . O

Bilayer US20130309307 T NNP O
Pharmaceutical US20130309307 T NNP O
Tablet US20130309307 T NNP O
Comprising US20130309307 T NNP O
Telmisartan US20130309307 T NNP O
and US20130309307 T CC O
a US20130309307 T DT O
Diuretic US20130309307 T NNP O
and US20130309307 T CC O
Preparation US20130309307 T NNP O
Thereof US20130309307 T NNP O
. US20130309307 T . O

System US20110217239 T NN O
and US20110217239 T CC O
method US20110217239 T NN O
of US20110217239 T IN O
evaluating US20110217239 T VBG O
a US20110217239 T DT O
protein US20110217239 T NN O
of US20110217239 T IN O
interest US20110217239 T NN O
on US20110217239 T IN O
tumor US20110217239 T NN O
growth US20110217239 T NN O
inhibition US20110217239 T NN O
while US20110217239 T IN O
following US20110217239 T VBG O
the US20110217239 T DT O
tumor US20110217239 T NN O
in US20110217239 T IN O
vivo US20110217239 T NN O
or US20110217239 T CC O
in US20110217239 T IN O
vitro US20110217239 T NN O
. US20110217239 T . O

Letrazole CN101991556A T NNP O
film CN101991556A T NN O
coated CN101991556A T VBD O
tablet CN101991556A T NN O
and CN101991556A T CC O
preparation CN101991556A T NN O
method CN101991556A T NN O
thereof CN101991556A T NN O
. CN101991556A T . O

Plaster CN101757077A T NN O
for CN101757077A T IN O
treating CN101757077A T VBG O
osteoproliferation CN101757077A T NN O
. CN101757077A T . O

Supramolecular US20100292272 T JJ O
co-colloids US20100292272 T NNS O
produced US20100292272 T VBD O
using US20100292272 T VBG O
macrocyclic US20100292272 T JJ O
polyanionic US20100292272 T JJ O
systems US20100292272 T NNS O
. US20100292272 T . O

Benzenesulfonanilide US20110053995 T NNP O
compound US20110053995 T NN O
inhibitors US20110053995 T NNS O
of US20110053995 T IN O
urea US20110053995 T JJ I-UN
transporters US20110053995 T NNS I-UN
. US20110053995 T . O

Provided US20110053995 A VBN O
herein US20110053995 A NN O
are US20110053995 A VBP O
small US20110053995 A JJ O
molecule US20110053995 A NN O
compounds US20110053995 A NNS O
that US20110053995 A WDT O
alter US20110053995 A VBP O
the US20110053995 A DT O
transport US20110053995 A NN O
activity US20110053995 A NN O
of US20110053995 A IN O
solute US20110053995 A NN I-UN
transporters US20110053995 A NNS I-UN
, US20110053995 A , O
particularly US20110053995 A RB O
urea US20110053995 A JJ I-UN
transporters US20110053995 A NNS I-UN
. US20110053995 A . O

Methods US20110053995 A NNS O
for US20110053995 A IN O
identifying US20110053995 A VBG O
and US20110053995 A CC O
using US20110053995 A VBG O
these US20110053995 A DT O
agents US20110053995 A NNS O
that US20110053995 A WDT O
inhibit US20110053995 A VBP O
urea US20110053995 A JJ I-UN
transporters US20110053995 A NNS I-UN
are US20110053995 A VBP O
described US20110053995 A VBN O
herein US20110053995 A NNS O
. US20110053995 A . O

Novel US20120142745 T NNP O
phenyl US20120142745 T NN O
oxadiazole US20120142745 T NN O
derivatives US20120142745 T NNS O
as US20120142745 T IN O
sphingosine US20120142745 T JJ I-UN
1-phosphate US20120142745 T JJ I-UN
( US20120142745 T ( I-UN
s1p US20120142745 T NN I-UN
) US20120142745 T ) I-UN
receptor US20120142745 T NN I-UN
modulators US20120142745 T NNS O
. US20120142745 T . O

The US20120142745 A DT O
present US20120142745 A JJ O
invention US20120142745 A NN O
relates US20120142745 A VBZ O
to US20120142745 A TO O
novel US20120142745 A VB O
phenyl US20120142745 A JJ O
oxadiazole US20120142745 A JJ O
derivatives US20120142745 A NNS O
, US20120142745 A , O
processes US20120142745 A NNS O
for US20120142745 A IN O
preparing US20120142745 A VBG O
them US20120142745 A PRP O
, US20120142745 A , O
pharmaceutical US20120142745 A JJ O
compositions US20120142745 A NNS O
containing US20120142745 A VBG O
them US20120142745 A PRP O
and US20120142745 A CC O
their US20120142745 A PRP$ O
use US20120142745 A NN O
as US20120142745 A IN O
pharmaceuticals US20120142745 A NNS O
as US20120142745 A IN O
modulators US20120142745 A NNS O
of US20120142745 A IN O
sphingosine-1-phosphate US20120142745 A JJ I-UN
receptors US20120142745 A NNS I-UN
. US20120142745 A . O

Octadecen CN102875375A T NNP O
BHBB CN102875375A T NNP O
compound CN102875375A T NN O
, CN102875375A T , O
its CN102875375A T PRP$ O
preparation CN102875375A T NN O
method CN102875375A T NN O
and CN102875375A T CC O
application CN102875375A T NN O
thereof CN102875375A T NN O
. CN102875375A T . O

For US20050020836 T IN O
therapy US20050020836 T NN O
of US20050020836 T IN O
hyperproliferative US20050020836 T JJ O
disorder US20050020836 T NN O
in US20050020836 T IN O
a US20050020836 T DT O
mammal US20050020836 T NN O
. US20050020836 T . O

Benzo US7342016 T NNP O
( US7342016 T ( O
5,6 US7342016 T CD O
) US7342016 T ) O
cyclohepta US7342016 T NN O
( US7342016 T ( O
1,2-b US7342016 T JJ O
) US7342016 T ) O
pyridine US7342016 T NN O
derivatives US7342016 T NNS O
; US7342016 T : O
use US7342016 T NN O
in US7342016 T IN O
combination US7342016 T NN O
with US7342016 T IN O
antineoplastic US7342016 T JJ O
agents US7342016 T NNS O
such US7342016 T JJ O
as US7342016 T IN O
cisplatin US7342016 T NN O
. US7342016 T . O

The US7342016 A DT O
compounds US7342016 A NNS O
are US7342016 A VBP O
useful US7342016 A JJ O
for US7342016 A IN O
inhibiting US7342016 A VBG O
farnesyl US7342016 A JJ I-UN
protein US7342016 A NN I-UN
transferase US7342016 A NN I-UN
. US7342016 A . O

External CN101559063A T JJ O
medicament CN101559063A T NN O
for CN101559063A T IN O
curing CN101559063A T VBG O
herpes CN101559063A T NNS O
zoster CN101559063A T NN O
and CN101559063A T CC O
preparation CN101559063A T NN O
method CN101559063A T NN O
thereof CN101559063A T NN O
. CN101559063A T . O

Halogenated CN102503882A T VBN O
benzaldehyde CN102503882A T JJ O
indole CN102503882A T JJ O
Schiff CN102503882A T NNP O
base CN102503882A T NN O
as CN102503882A T RB O
well CN102503882A T RB O
as CN102503882A T IN O
preparation CN102503882A T NN O
method CN102503882A T NN O
and CN102503882A T CC O
application CN102503882A T NN O
thereof CN102503882A T NN O
. CN102503882A T . O

Use WO2011119125A1 T NNP O
of WO2011119125A1 T IN O
lithium WO2011119125A1 T NN O
oxalate WO2011119125A1 T NN O
in WO2011119125A1 T IN O
production WO2011119125A1 T NN O
of WO2011119125A1 T IN O
a WO2011119125A1 T DT O
therapeutic WO2011119125A1 T JJ O
preparation WO2011119125A1 T NN O
with WO2011119125A1 T IN O
anti-tumour WO2011119125A1 T JJ O
activity WO2011119125A1 T NN O
in WO2011119125A1 T IN O
relation WO2011119125A1 T NN O
to WO2011119125A1 T TO O
malignant WO2011119125A1 T VB O
cells WO2011119125A1 T NNS O
, WO2011119125A1 T , O
a WO2011119125A1 T DT O
therapeutic WO2011119125A1 T JJ O
preparation WO2011119125A1 T NN O
based WO2011119125A1 T VBN O
thereon WO2011119125A1 T NN O
and WO2011119125A1 T CC O
a WO2011119125A1 T DT O
method WO2011119125A1 T NN O
of WO2011119125A1 T IN O
treatment WO2011119125A1 T NN O
. WO2011119125A1 T . O

Micro-RNAS US20100286249 T JJ O
Modulating US20100286249 T NNP O
Immunity US20100286249 T NNP O
and US20100286249 T CC O
Inflammation US20100286249 T NNP O
. US20100286249 T . O

Use WO2012154807A1 T NNP O
of WO2012154807A1 T IN O
jasmonates WO2012154807A1 T NNS O
for WO2012154807A1 T IN O
modulating WO2012154807A1 T VBG O
melatonin WO2012154807A1 T JJ O
production WO2012154807A1 T NN O
and WO2012154807A1 T CC O
calcification WO2012154807A1 T NN O
of WO2012154807A1 T IN O
the WO2012154807A1 T DT O
pineal WO2012154807A1 T NN O
gland WO2012154807A1 T NN O
. WO2012154807A1 T . O

Compound CN103156849A T NNP O
pseudoephedrine CN103156849A T NN O
hydrochloride CN103156849A T NN O
enteric-coated CN103156849A T JJ O
tablet CN103156849A T NN O
and CN103156849A T CC O
preparation CN103156849A T NN O
method CN103156849A T NN O
thereof CN103156849A T NN O
. CN103156849A T . O

Preparing CN101544578A T VBG O
method CN101544578A T NN O
for CN101544578A T IN O
phenyl CN101544578A T JJ O
acetic CN101544578A T JJ O
acid CN101544578A T NN O
derivates CN101544578A T NNS O
and CN101544578A T CC O
applications CN101544578A T NNS O
in CN101544578A T IN O
medicament CN101544578A T NN O
. CN101544578A T . O

The CN101544578A A DT O
compound CN101544578A A NN O
has CN101544578A A VBZ O
the CN101544578A A DT O
insulin CN101544578A A JJ I-UN
sensitization CN101544578A A NN O
activity CN101544578A A NN O
, CN101544578A A , O
thus CN101544578A A RB O
it CN101544578A A PRP O
can CN101544578A A MD O
be CN101544578A A VB O
used CN101544578A A VBN O
for CN101544578A A IN O
preparing CN101544578A A VBG O
the CN101544578A A DT O
antidiabetic CN101544578A A JJ O
medicament CN101544578A A NN O
and CN101544578A A CC O
decreasing CN101544578A A VBG O
blood CN101544578A A NN O
sugar CN101544578A A NN O
concentration CN101544578A A NN O
of CN101544578A A IN O
the CN101544578A A DT O
diabetes CN101544578A A NNS O
patient CN101544578A A JJ O
and CN101544578A A CC O
preventing CN101544578A A VBG O
the CN101544578A A DT O
complication CN101544578A A NN O
generation CN101544578A A NN O
of CN101544578A A IN O
the CN101544578A A DT O
diabetes CN101544578A A NNS O
patient CN101544578A A NN O
. CN101544578A A . O

Substituted EP1878726A1 T VBN O
sulphoximines EP1878726A1 T NNS O
as EP1878726A1 T IN O
Tie2 EP1878726A1 T NNP I-UN
inhibitors EP1878726A1 T NNS O
and EP1878726A1 T CC O
salts EP1878726A1 T NNS O
thereof EP1878726A1 T NN O
, EP1878726A1 T , O
pharmaceutical EP1878726A1 T JJ O
compositions EP1878726A1 T NNS O
comprising EP1878726A1 T VBG O
the EP1878726A1 T DT O
same EP1878726A1 T JJ O
, EP1878726A1 T , O
methods EP1878726A1 T NNS O
of EP1878726A1 T IN O
preparing EP1878726A1 T VBG O
the EP1878726A1 T DT O
same EP1878726A1 T JJ O
and EP1878726A1 T CC O
uses EP1878726A1 T NNS O
of EP1878726A1 T IN O
the EP1878726A1 T DT O
same EP1878726A1 T JJ O
. EP1878726A1 T . O

The EP1878726A1 A DT O
invention EP1878726A1 A NN O
relates EP1878726A1 A VBZ O
to EP1878726A1 A TO O
substituted EP1878726A1 A VB O
sulphoximines EP1878726A1 A NNS O
according EP1878726A1 A VBG O
to EP1878726A1 A TO O
the EP1878726A1 A DT O
general EP1878726A1 A JJ O
formula EP1878726A1 A NN O
( EP1878726A1 A ( O
I EP1878726A1 A PRP O
) EP1878726A1 A ) O
: EP1878726A1 A : O
in EP1878726A1 A IN O
which EP1878726A1 A WDT O
A EP1878726A1 A NNP O
, EP1878726A1 A , O
E EP1878726A1 A NNP O
, EP1878726A1 A , O
G EP1878726A1 A NNP O
, EP1878726A1 A , O
X EP1878726A1 A NNP O
, EP1878726A1 A , O
R1 EP1878726A1 A NNP O
, EP1878726A1 A , O
R2 EP1878726A1 A NNP O
, EP1878726A1 A , O
R3 EP1878726A1 A NNP O
, EP1878726A1 A , O
R4 EP1878726A1 A NNP O
, EP1878726A1 A , O
R5 EP1878726A1 A NNP O
, EP1878726A1 A , O
R6 EP1878726A1 A NNP O
, EP1878726A1 A , O
R7 EP1878726A1 A NNP O
, EP1878726A1 A , O
R8 EP1878726A1 A NNP O
, EP1878726A1 A , O
m EP1878726A1 A NN O
, EP1878726A1 A , O
p EP1878726A1 A NN O
, EP1878726A1 A , O
q EP1878726A1 A NN O
, EP1878726A1 A , O
are EP1878726A1 A VBP O
given EP1878726A1 A VBN O
in EP1878726A1 A IN O
the EP1878726A1 A DT O
claims EP1878726A1 A NNS O
, EP1878726A1 A , O
and EP1878726A1 A CC O
salts EP1878726A1 A NNS O
thereof EP1878726A1 A RB O
, EP1878726A1 A , O
to EP1878726A1 A TO O
pharmaceutical EP1878726A1 A JJ O
compositions EP1878726A1 A NNS O
comprising EP1878726A1 A VBG O
said EP1878726A1 A VBD O
substituted EP1878726A1 A VBN O
sulphoximines EP1878726A1 A NNS O
, EP1878726A1 A , O
to EP1878726A1 A TO O
methods EP1878726A1 A NNS O
of EP1878726A1 A IN O
preparing EP1878726A1 A VBG O
said EP1878726A1 A VBD O
substituted EP1878726A1 A JJ O
sulphoximines EP1878726A1 A NNS O
as EP1878726A1 A RB O
well EP1878726A1 A RB O
as EP1878726A1 A IN O
the EP1878726A1 A DT O
use EP1878726A1 A NN O
thereof EP1878726A1 A NN O
for EP1878726A1 A IN O
manufacturing EP1878726A1 A VBG O
a EP1878726A1 A DT O
pharmaceutical EP1878726A1 A JJ O
composition EP1878726A1 A NN O
for EP1878726A1 A IN O
the EP1878726A1 A DT O
treatment EP1878726A1 A NN O
of EP1878726A1 A IN O
diseases EP1878726A1 A NNS O
of EP1878726A1 A IN O
dysregulated EP1878726A1 A JJ O
vascular EP1878726A1 A JJ O
growth EP1878726A1 A NN O
or EP1878726A1 A CC O
of EP1878726A1 A IN O
diseases EP1878726A1 A NNS O
which EP1878726A1 A WDT O
are EP1878726A1 A VBP O
accompanied EP1878726A1 A VBN O
with EP1878726A1 A IN O
dysregulated EP1878726A1 A JJ O
vascular EP1878726A1 A JJ O
growth EP1878726A1 A NN O
, EP1878726A1 A , O
wherein EP1878726A1 A VBP O
the EP1878726A1 A DT O
compounds EP1878726A1 A NNS O
effectively EP1878726A1 A RB O
interfere EP1878726A1 A VBP O
with EP1878726A1 A IN O
Tie2 EP1878726A1 A NNP I-UN
signalling EP1878726A1 A VBG O
. EP1878726A1 A . O

medicine CN1823823A T NN O
and CN1823823A T CC O
food CN1823823A T NN O
dual CN1823823A T JJ O
purpose CN1823823A T NN O
vitamin CN1823823A T NN O
microelement CN1823823A T NN O
nutritive CN1823823A T JJ O
product CN1823823A T NN O
for CN1823823A T IN O
preventing CN1823823A T VBG O
and CN1823823A T CC O
treating CN1823823A T VBG O
synchysis CN1823823A T NN O
and CN1823823A T CC O
its CN1823823A T PRP$ O
manufacturing CN1823823A T NN O
method CN1823823A T NN O
. CN1823823A T . O

Pharmaceutical CN103735565A T JJ O
composition CN103735565A T NN O
for CN103735565A T IN O
preventing CN103735565A T VBG O
primary CN103735565A T JJ O
hypertension CN103735565A T NN O
and CN103735565A T CC O
application CN103735565A T NN O
thereof CN103735565A T NN O
. CN103735565A T . O

Novel WO2009052625A1 T NNP O
crystalline WO2009052625A1 T NN O
salts WO2009052625A1 T NNS O
of WO2009052625A1 T IN O
montelukast WO2009052625A1 T NN O
. WO2009052625A1 T . O

Receptor-avid US20100022449 T NNP O
exogenous US20100022449 T JJ O
optical US20100022449 T JJ O
contrast US20100022449 T NN O
and US20100022449 T CC O
therapeutic US20100022449 T JJ O
agents US20100022449 T NNS O
. US20100022449 T . O

Compounds US20120058998 T NNS O
, US20120058998 T , O
Compositions US20120058998 T NNS O
and US20120058998 T CC O
Methods US20120058998 T NNS O
for US20120058998 T IN O
the US20120058998 T DT O
Treatment US20120058998 T NNP O
of US20120058998 T IN O
Inflammatory US20120058998 T NNP O
Diseases US20120058998 T NNP O
. US20120058998 T . O

A US20120058998 A DT O
method US20120058998 A NN O
of US20120058998 A IN O
inhibiting US20120058998 A VBG O
the US20120058998 A DT O
inflammatory US20120058998 A NN O
process US20120058998 A NN O
, US20120058998 A , O
the US20120058998 A DT O
method US20120058998 A NN O
comprising US20120058998 A VBG O
administering US20120058998 A VBG O
to US20120058998 A TO O
a US20120058998 A DT O
mammal US20120058998 A JJ O
suffering US20120058998 A NN O
from US20120058998 A IN O
inflammation US20120058998 A NN O
a US20120058998 A DT O
therapeutically US20120058998 A RB O
effective US20120058998 A JJ O
amount US20120058998 A NN O
of US20120058998 A IN O
a US20120058998 A DT O
pharmaceutical US20120058998 A JJ O
composition US20120058998 A NN O
comprising US20120058998 A VBG O
a US20120058998 A DT O
compound US20120058998 A NN O
where US20120058998 A WRB O
: US20120058998 A : O
R US20120058998 A NN O
is US20120058998 A VBZ O
a US20120058998 A DT O
C1-C10 US20120058998 A JJ O
alkylene US20120058998 A NN O
group US20120058998 A NN O
, US20120058998 A , O
in US20120058998 A IN O
which US20120058998 A WDT O
, US20120058998 A , O
when US20120058998 A WRB O
the US20120058998 A DT O
number US20120058998 A NN O
of US20120058998 A IN O
carbon US20120058998 A NN O
atoms US20120058998 A NNS O
is US20120058998 A VBZ O
at US20120058998 A IN O
least US20120058998 A JJS O
2 US20120058998 A CD O
, US20120058998 A , O
there US20120058998 A EX O
are US20120058998 A VBP O
optionally US20120058998 A RB O
1 US20120058998 A CD O
or US20120058998 A CC O
2 US20120058998 A CD O
non-adjacent US20120058998 A JJ O
double US20120058998 A JJ O
bonds US20120058998 A NNS O
; US20120058998 A : O
1 US20120058998 A CD O
to US20120058998 A TO O
3 US20120058998 A CD O
non-adjacent US20120058998 A JJ O
methylene US20120058998 A NN O
groups US20120058998 A NNS O
are US20120058998 A VBP O
optionally US20120058998 A RB O
replaced US20120058998 A VBN O
by US20120058998 A IN O
NR1 US20120058998 A NNP O
( US20120058998 A ( O
where US20120058998 A WRB O
R1 US20120058998 A NNP O
is US20120058998 A VBZ O
H US20120058998 A NNP O
, US20120058998 A , O
alkyl US20120058998 A NN O
, US20120058998 A , O
or US20120058998 A CC O
acyl US20120058998 A NN O
) US20120058998 A ) O
, US20120058998 A , O
O US20120058998 A NNP O
, US20120058998 A , O
or US20120058998 A CC O
S US20120058998 A NNP O
; US20120058998 A : O
and US20120058998 A CC O
1 US20120058998 A CD O
or US20120058998 A CC O
2 US20120058998 A CD O
methylene US20120058998 A NN O
groups US20120058998 A NNS O
are US20120058998 A VBP O
optionally US20120058998 A RB O
replaced US20120058998 A VBN O
by US20120058998 A IN O
a US20120058998 A DT O
carbonyl US20120058998 A NN O
or US20120058998 A CC O
hydroxymethylene US20120058998 A NN O
group US20120058998 A NN O
and US20120058998 A CC O
pharmaceutically US20120058998 A RB O
acceptable US20120058998 A JJ O
esters US20120058998 A NNS O
or US20120058998 A CC O
salts US20120058998 A NNS O
of US20120058998 A IN O
the US20120058998 A DT O
compounds US20120058998 A NNS O
and US20120058998 A CC O
wherein US20120058998 A VB O
the US20120058998 A DT O
inflammatory US20120058998 A JJ O
process US20120058998 A NN O
results US20120058998 A NNS O
from US20120058998 A IN O
a US20120058998 A DT O
disease US20120058998 A NN O
selected US20120058998 A VBN O
from US20120058998 A IN O
the US20120058998 A DT O
group US20120058998 A NN O
consisting US20120058998 A VBG O
of US20120058998 A IN O
ulcerative US20120058998 A JJ O
colitis US20120058998 A NN O
, US20120058998 A , O
endotoxic US20120058998 A NN O
shock US20120058998 A NN O
, US20120058998 A , O
rheumatoid US20120058998 A JJ O
arthritis US20120058998 A NN O
, US20120058998 A , O
juvenile US20120058998 A NN O
arthritis US20120058998 A NN O
, US20120058998 A , O
osteoarthritis US20120058998 A NN O
, US20120058998 A , O
psoriasis US20120058998 A NN O
, US20120058998 A , O
Crohn US20120058998 A NNP O
's US20120058998 A POS O
disease US20120058998 A NN O
, US20120058998 A , O
inflammatory US20120058998 A JJ O
bowel US20120058998 A NN O
disease US20120058998 A NN O
, US20120058998 A , O
multiple US20120058998 A JJ O
sclerosis US20120058998 A NN O
, US20120058998 A , O
insulin US20120058998 A NN I-UN
dependent US20120058998 A JJ O
diabetes US20120058998 A VBZ O
mellitus US20120058998 A NN O
, US20120058998 A , O
gout US20120058998 A NN O
, US20120058998 A , O
psoriatic US20120058998 A JJ O
arthritis US20120058998 A NN O
, US20120058998 A , O
reactive US20120058998 A JJ O
arthritis US20120058998 A NN O
, US20120058998 A , O
vital US20120058998 A JJ O
or US20120058998 A CC O
post-viral US20120058998 A JJ O
arthritis US20120058998 A NN O
and US20120058998 A CC O
ankylosing US20120058998 A VBG O
spondylarthritis US20120058998 A NN O
. US20120058998 A . O

New WO2009032326A1 T NNP O
tetracycline WO2009032326A1 T NN O
derivatives WO2009032326A1 T NNS O
as WO2009032326A1 T IN O
antiinfective WO2009032326A1 T JJ O
agents WO2009032326A1 T NNS O
. WO2009032326A1 T . O

Compression US6858228 T NN O
of US6858228 T IN O
drug US6858228 T NN O
and US6858228 T CC O
adjuvant US6858228 T NN O
. US6858228 T . O

Synergic WO2006129134A1 T JJ O
combinations WO2006129134A1 T NNS O
comprising WO2006129134A1 T VBG O
a WO2006129134A1 T DT O
styrylquinoline WO2006129134A1 T NN O
compound WO2006129134A1 T NN O
and WO2006129134A1 T CC O
other WO2006129134A1 T JJ O
hiv WO2006129134A1 T JJ O
infection WO2006129134A1 T NN O
therapeutic WO2006129134A1 T JJ O
agents WO2006129134A1 T NNS O
. WO2006129134A1 T . O

The WO2006129134A1 A DT O
invention WO2006129134A1 A NN O
relates WO2006129134A1 A VBZ O
to WO2006129134A1 A TO O
a WO2006129134A1 A DT O
combination WO2006129134A1 A NN O
comprising WO2006129134A1 A VBG O
a WO2006129134A1 A DT O
quinoline WO2006129134A1 A NN O
compound WO2006129134A1 A NN O
or WO2006129134A1 A CC O
its WO2006129134A1 A PRP$ O
salt WO2006129134A1 A NN O
, WO2006129134A1 A , O
according WO2006129134A1 A VBG O
to WO2006129134A1 A TO O
general WO2006129134A1 A JJ O
formula WO2006129134A1 A NN O
( WO2006129134A1 A ( O
I WO2006129134A1 A PRP O
) WO2006129134A1 A ) O
and WO2006129134A1 A CC O
at WO2006129134A1 A IN O
least WO2006129134A1 A JJS O
one WO2006129134A1 A CD O
HIV WO2006129134A1 A NNP O
infection WO2006129134A1 A NN O
therapeutic WO2006129134A1 A JJ O
agent WO2006129134A1 A NN O
selected WO2006129134A1 A VBN O
from WO2006129134A1 A IN O
the WO2006129134A1 A DT O
group WO2006129134A1 A NN O
consisting WO2006129134A1 A VBG O
of WO2006129134A1 A IN O
entry WO2006129134A1 A NN O
inhibitors WO2006129134A1 A NNS O
, WO2006129134A1 A , O
reverse-transcriptase WO2006129134A1 A JJ I-UN
inhibitors WO2006129134A1 A NNS O
, WO2006129134A1 A , O
strand-transfer WO2006129134A1 A JJ O
inhibitors WO2006129134A1 A NNS O
, WO2006129134A1 A , O
protease WO2006129134A1 A NN I-UN
inhibitors WO2006129134A1 A NNS O
, WO2006129134A1 A , O
and WO2006129134A1 A CC O
maturation WO2006129134A1 A NN O
inhibitors WO2006129134A1 A NNS O
. WO2006129134A1 A . O

Substituted US7566721 T VBN O
thienol US7566721 T JJ O
[ US7566721 T JJ O
2,3-d US7566721 T JJ O
] US7566721 T NN O
pyrimidines US7566721 T NNS O
as US7566721 T IN O
kinase US7566721 T NN O
inhibitors US7566721 T NNS O
. US7566721 T . O

Compounds US7566721 A NNS O
of US7566721 A IN O
the US7566721 A DT O
formula US7566721 A NN O
and US7566721 A CC O
pharmaceutically US7566721 A RB O
acceptable US7566721 A JJ O
salts US7566721 A NNS O
thereof US7566721 A NN O
, US7566721 A , O
wherein US7566721 A NN O
X1 US7566721 A NNP O
, US7566721 A , O
X2 US7566721 A NNP O
, US7566721 A , O
X3 US7566721 A NNP O
, US7566721 A , O
and US7566721 A CC O
Q1 US7566721 A NNP O
are US7566721 A VBP O
defined US7566721 A VBN O
herein US7566721 A RB O
, US7566721 A , O
inhibit US7566721 A VB O
the US7566721 A DT O
IGF-1R US7566721 A NNP I-UN
enzyme US7566721 A NN O
and US7566721 A CC O
are US7566721 A VBP O
useful US7566721 A JJ O
for US7566721 A IN O
the US7566721 A DT O
treatment US7566721 A NN O
and/or US7566721 A JJ O
prevention US7566721 A NN O
of US7566721 A IN O
hyperproliferative US7566721 A JJ O
diseases US7566721 A NNS O
such US7566721 A JJ O
as US7566721 A IN O
cancer US7566721 A NN O
, US7566721 A , O
inflammation US7566721 A NN O
, US7566721 A , O
psoriasis US7566721 A NN O
, US7566721 A , O
allergy/asthma US7566721 A NN O
, US7566721 A , O
disease US7566721 A NN O
and US7566721 A CC O
conditions US7566721 A NNS O
of US7566721 A IN O
the US7566721 A DT O
immune US7566721 A NN O
system US7566721 A NN O
, US7566721 A , O
disease US7566721 A NN O
and US7566721 A CC O
conditions US7566721 A NNS O
of US7566721 A IN O
the US7566721 A DT O
central US7566721 A JJ O
nervous US7566721 A JJ O
system US7566721 A NN O
. US7566721 A . O

Granula CN1872185A T NNP O
of CN1872185A T IN O
possessing CN1872185A T VBG O
function CN1872185A T NN O
for CN1872185A T IN O
improving CN1872185A T VBG O
sleeping CN1872185A T NN O
. CN1872185A T . O

Anti-tumor WO2014070214A1 T JJ O
agent WO2014070214A1 T NN O
otx-008 WO2014070214A1 T JJ O
targets WO2014070214A1 T NNS O
human WO2014070214A1 T JJ I-UN
galectin-1 WO2014070214A1 T NN I-UN
. WO2014070214A1 T . O

Disclosed WO2014070214A1 A VBN O
herein WO2014070214A1 A NNS O
are WO2014070214A1 A VBP O
compositions WO2014070214A1 A NNS O
comprising WO2014070214A1 A VBG O
a WO2014070214A1 A DT O
galectin-1 WO2014070214A1 A JJ I-UN
-targeting WO2014070214A1 A NN O
compound WO2014070214A1 A NN O
in WO2014070214A1 A IN O
a WO2014070214A1 A DT O
therapeutically WO2014070214A1 A RB O
effective WO2014070214A1 A JJ O
composition WO2014070214A1 A NN O
for WO2014070214A1 A IN O
treating WO2014070214A1 A VBG O
cancer WO2014070214A1 A NN O
. WO2014070214A1 A . O

In WO2014070214A1 A IN O
an WO2014070214A1 A DT O
aspect WO2014070214A1 A NN O
, WO2014070214A1 A , O
a WO2014070214A1 A DT O
galectin-1 WO2014070214A1 A JJ I-UN
-targeting WO2014070214A1 A NN O
compound WO2014070214A1 A NN O
is WO2014070214A1 A VBZ O
OTX-008 WO2014070214A1 A NNP O
. WO2014070214A1 A . O

Use EP1014967B1 T NNP O
of EP1014967B1 T IN O
zinc EP1014967B1 T NN O
salts EP1014967B1 T NNS O
of EP1014967B1 T IN O
conjugated EP1014967B1 T JJ O
linoleic EP1014967B1 T JJ O
acids EP1014967B1 T NNS O
to EP1014967B1 T TO O
treat EP1014967B1 T VB O
skin EP1014967B1 T JJ O
disorders EP1014967B1 T NNS O
. EP1014967B1 T . O

Diagnosis US20120058087 T NN O
of US20120058087 T IN O
endometritis US20120058087 T NN O
. US20120058087 T . O

Modified US20080145339 T NNP O
rolling US20080145339 T VBG O
circle US20080145339 T NN O
initiator US20080145339 T NN O
protein US20080145339 T NN O
for US20080145339 T IN O
use US20080145339 T NN O
as US20080145339 T IN O
therapeutic US20080145339 T JJ O
tool US20080145339 T NN O
in US20080145339 T IN O
suppression US20080145339 T NN O
of US20080145339 T IN O
viral US20080145339 T JJ O
replication US20080145339 T NN O
and US20080145339 T CC O
disorders US20080145339 T NNS O
. US20080145339 T . O

AAV US20080145339 A NNP O
Rep78 US20080145339 A NNP O
mutants US20080145339 A NNS O
comprising US20080145339 A VBG O
a US20080145339 A DT O
modified US20080145339 A VBN O
AAV US20080145339 A NNP I-UN
Rep78 US20080145339 A NNP I-UN
protein US20080145339 A NN O
that US20080145339 A WDT O
possesses US20080145339 A VBZ O
different US20080145339 A JJ O
biochemical US20080145339 A JJ O
and US20080145339 A CC O
biological US20080145339 A JJ O
functions US20080145339 A NNS O
as US20080145339 A IN O
compared US20080145339 A VBN O
to US20080145339 A TO O
the US20080145339 A DT O
wild-type US20080145339 A JJ O
AAV US20080145339 A NNP I-UN
Rep78 US20080145339 A NNP I-UN
protein US20080145339 A NN O
are US20080145339 A VBP O
disclosed US20080145339 A VBN O
. US20080145339 A . O

Particularly US20080145339 A RB O
, US20080145339 A , O
the US20080145339 A DT O
AAV US20080145339 A NNP I-UN
Rep78 US20080145339 A NNP I-UN
mutants US20080145339 A NNS O
that US20080145339 A WDT O
bind US20080145339 A VBP O
to US20080145339 A TO O
at US20080145339 A IN O
least US20080145339 A JJS O
one US20080145339 A CD O
of US20080145339 A IN O
a US20080145339 A DT O
papillomavirus US20080145339 A NN O
DNA US20080145339 A NN O
or US20080145339 A CC O
an US20080145339 A DT O
AAV US20080145339 A NNP O
DNA US20080145339 A NNP O
or US20080145339 A CC O
an US20080145339 A DT O
oncogene US20080145339 A NN O
or US20080145339 A CC O
HIV US20080145339 A NNP O
DNA US20080145339 A NNP O
differently US20080145339 A RB O
as US20080145339 A RB O
compared US20080145339 A VBN O
to US20080145339 A TO O
the US20080145339 A DT O
wild-type US20080145339 A JJ O
AAV US20080145339 A NNP I-UN
Rep78 US20080145339 A NNP I-UN
protein US20080145339 A NN O
, US20080145339 A , O
assays US20080145339 A VBZ O
to US20080145339 A TO O
select US20080145339 A VB O
such US20080145339 A JJ O
mutants US20080145339 A NNS O
, US20080145339 A , O
and US20080145339 A CC O
pharmaceutical US20080145339 A JJ O
compositions US20080145339 A NNS O
containing US20080145339 A VBG O
the US20080145339 A DT O
AAV US20080145339 A NNP I-UN
Rep78 US20080145339 A NNP I-UN
mutants US20080145339 A NNS O
are US20080145339 A VBP O
disclosed US20080145339 A VBN O
. US20080145339 A . O

The US20080145339 A DT O
present US20080145339 A JJ O
invention US20080145339 A NN O
further US20080145339 A RBR O
discloses US20080145339 A VBZ O
DNA US20080145339 A NNP O
sequences US20080145339 A NNS O
encoding US20080145339 A VBG O
at US20080145339 A IN O
least US20080145339 A JJS O
one US20080145339 A CD O
AAV US20080145339 A NNP I-UN
Rep78 US20080145339 A NNP I-UN
mutant US20080145339 A NN O
that US20080145339 A WDT O
possesses US20080145339 A VBZ O
different US20080145339 A JJ O
biochemical US20080145339 A JJ O
and US20080145339 A CC O
biological US20080145339 A JJ O
functions US20080145339 A NNS O
as US20080145339 A IN O
compared US20080145339 A VBN O
to US20080145339 A TO O
the US20080145339 A DT O
wild-type US20080145339 A JJ O
AAV US20080145339 A NNP I-UN
Rep78 US20080145339 A NNP I-UN
protein US20080145339 A NN O
and US20080145339 A CC O
pharmaceutical US20080145339 A JJ O
compositions US20080145339 A NNS O
comprising US20080145339 A VBG O
the US20080145339 A DT O
DNA US20080145339 A NN O
sequences US20080145339 A NNS O
. US20080145339 A . O

The US20080145339 A DT O
present US20080145339 A JJ O
invention US20080145339 A NN O
additionally US20080145339 A RB O
is US20080145339 A VBZ O
directed US20080145339 A VBN O
to US20080145339 A TO O
a US20080145339 A DT O
method US20080145339 A NN O
of US20080145339 A IN O
inhibiting US20080145339 A VBG O
papillomavirus US20080145339 A NN O
associated US20080145339 A VBN O
diseases US20080145339 A NNS O
comprising US20080145339 A VBG O
administering US20080145339 A VBG O
pharmaceutical US20080145339 A JJ O
compositions US20080145339 A NNS O
containing US20080145339 A VBG O
AAV US20080145339 A NNP I-UN
Rep78 US20080145339 A NNP I-UN
mutants US20080145339 A NNS O
or US20080145339 A CC O
the US20080145339 A DT O
DNA US20080145339 A NN O
sequences US20080145339 A VBZ O
encoding US20080145339 A VBG O
the US20080145339 A DT O
mutants US20080145339 A NNS O
. US20080145339 A . O

Also US20080145339 A RB O
discloses US20080145339 A NNS O
are US20080145339 A VBP O
DNA US20080145339 A NNP O
sequences US20080145339 A NNS O
comprising US20080145339 A VBG O
the US20080145339 A DT O
full US20080145339 A JJ O
length US20080145339 A NN O
AAV US20080145339 A NNP O
genome US20080145339 A NN O
modified US20080145339 A VBD O
to US20080145339 A TO O
where US20080145339 A WRB O
the US20080145339 A DT O
AAV US20080145339 A NNP I-UN
Rep78 US20080145339 A NNP I-UN
protein US20080145339 A NN O
is US20080145339 A VBZ O
replaced US20080145339 A VBN O
with US20080145339 A IN O
an US20080145339 A DT O
AAV US20080145339 A NNP I-UN
Rep US20080145339 A NNP I-UN
mutant US20080145339 A NN O
that US20080145339 A WDT O
binds US20080145339 A VBZ O
weakly US20080145339 A RB O
or US20080145339 A CC O
not US20080145339 A RB O
at US20080145339 A IN O
all US20080145339 A DT O
to US20080145339 A TO O
a US20080145339 A DT O
papillomavirus US20080145339 A NN O
DNA US20080145339 A NN O
or US20080145339 A CC O
an US20080145339 A DT O
AAV US20080145339 A NNP O
DNA US20080145339 A NN O
or US20080145339 A CC O
both US20080145339 A DT O
differently US20080145339 A RB O
as US20080145339 A IN O
compared US20080145339 A VBN O
to US20080145339 A TO O
the US20080145339 A DT O
wild-type US20080145339 A JJ O
AAV US20080145339 A NNP I-UN
Rep78 US20080145339 A NNP I-UN
protein US20080145339 A NN O
and US20080145339 A CC O
its US20080145339 A PRP$ O
use US20080145339 A NN O
in US20080145339 A IN O
producing US20080145339 A VBG O
recombinant US20080145339 A JJ O
AAV US20080145339 A NNP O
at US20080145339 A IN O
increased US20080145339 A JJ O
levels US20080145339 A NNS O
production US20080145339 A NN O
over US20080145339 A IN O
wild-type US20080145339 A JJ O
levels US20080145339 A NNS O
of US20080145339 A IN O
production US20080145339 A NN O
. US20080145339 A . O

Further US20080145339 A RB O
disclosed US20080145339 A VBN O
is US20080145339 A VBZ O
a US20080145339 A DT O
method US20080145339 A NN O
of US20080145339 A IN O
inhibiting US20080145339 A VBG O
papillomavirus-associated US20080145339 A JJ O
diseases US20080145339 A NNS O
, US20080145339 A , O
cancer US20080145339 A NN O
, US20080145339 A , O
and US20080145339 A CC O
HIV-associated US20080145339 A JJ O
diseases US20080145339 A NNS O
comprising US20080145339 A VBG O
administering US20080145339 A VBG O
a US20080145339 A DT O
pharmaceutical US20080145339 A JJ O
composition US20080145339 A NN O
comprising US20080145339 A VBG O
a US20080145339 A DT O
wild-type US20080145339 A JJ O
AAV US20080145339 A NNP I-UN
Rep78 US20080145339 A NNP I-UN
or US20080145339 A CC O
a US20080145339 A DT O
mutant US20080145339 A JJ O
thereof US20080145339 A NN O
to US20080145339 A TO O
a US20080145339 A DT O
patient US20080145339 A NN O
afflicted US20080145339 A VBN O
with US20080145339 A IN O
a US20080145339 A DT O
papillomavirus-associated US20080145339 A JJ O
disease US20080145339 A NN O
, US20080145339 A , O
cancer US20080145339 A NN O
, US20080145339 A , O
or US20080145339 A CC O
HIV-associated US20080145339 A JJ O
diseases US20080145339 A NNS O
. US20080145339 A . O

Particularly US20080145339 A RB O
, US20080145339 A , O
useful US20080145339 A JJ O
in US20080145339 A IN O
treating US20080145339 A VBG O
papillomavirus-associated US20080145339 A JJ O
diseases US20080145339 A NNS O
are US20080145339 A VBP O
the US20080145339 A DT O
AAV US20080145339 A NNP I-UN
Rep78 US20080145339 A NNP I-UN
or US20080145339 A CC O
mutant US20080145339 A JJ O
thereof US20080145339 A NN O
that US20080145339 A WDT O
binds US20080145339 A VBZ O
to US20080145339 A TO O
nucleotides US20080145339 A VB O
14-56 US20080145339 A CD O
of US20080145339 A IN O
p97 US20080145339 A NN O
of US20080145339 A IN O
HPV-16 US20080145339 A NNP O
and US20080145339 A CC O
inhibits US20080145339 A VBZ O
expression US20080145339 A NN O
of US20080145339 A IN O
HPV US20080145339 A NNP O
oncoproteins US20080145339 A NNS O
. US20080145339 A . O

An US20080145339 A DT O
AAV US20080145339 A NNP I-UN
Rep78 US20080145339 A NNP I-UN
regulation US20080145339 A NN O
element US20080145339 A NN O
of US20080145339 A IN O
a US20080145339 A DT O
DNA US20080145339 A NN O
sequence US20080145339 A NN O
comprising US20080145339 A VBG O
about US20080145339 A IN O
nucleotides US20080145339 A JJ O
14-56 US20080145339 A CD O
of US20080145339 A IN O
the US20080145339 A DT O
nucleotide US20080145339 A JJ O
sequence US20080145339 A NN O
of US20080145339 A IN O
FIG US20080145339 A NNP O
. US20080145339 A . O

2 US20080145339 A CD O
and US20080145339 A CC O
an US20080145339 A DT O
AAV US20080145339 A NNP I-UN
Rep78 US20080145339 A NNP I-UN
regulatable US20080145339 A JJ O
promoter US20080145339 A NN O
comprising US20080145339 A VBG O
the US20080145339 A DT O
regulation US20080145339 A NN O
element US20080145339 A NN O
and US20080145339 A CC O
a US20080145339 A DT O
promoter US20080145339 A NN O
sequence US20080145339 A NN O
except US20080145339 A IN O
for US20080145339 A IN O
the US20080145339 A DT O
HPV-16 US20080145339 A NNP O
p97 US20080145339 A NN O
promoter US20080145339 A NN O
. US20080145339 A . O

Five-membered CN103254203A T JJ O
urea CN103254203A T JJ O
ring-coumarin CN103254203A T JJ O
derivative CN103254203A T NN O
or CN103254203A T CC O
pharmaceutical CN103254203A T JJ O
salt CN103254203A T NN O
and CN103254203A T CC O
application CN103254203A T NN O
thereof CN103254203A T NN O
. CN103254203A T . O

The CN103254203A A DT O
invention CN103254203A A NN O
relates CN103254203A A VBZ O
to CN103254203A A TO O
a CN103254203A A DT O
small CN103254203A A JJ O
molecule CN103254203A A NN O
medicament CN103254203A A NN O
based CN103254203A A VBN O
on CN103254203A A IN O
PI3K CN103254203A A NNP I-UN
( CN103254203A A ( O
Phosphatidyl CN103254203A A NNP I-UN
Inositol CN103254203A A NNP I-UN
3-kinase CN103254203A A NNP I-UN
) CN103254203A A ) O
/mTOR CN103254203A A NN O
( CN103254203A A ( O
Mammalian CN103254203A A JJ I-UN
Target CN103254203A A NN I-UN
of CN103254203A A IN I-UN
Rapamycin CN103254203A A NNP I-UN
) CN103254203A A ) O
double CN103254203A A JJ O
targets CN103254203A A NNS O
, CN103254203A A , O
belongs CN103254203A A NNS O
to CN103254203A A TO O
the CN103254203A A DT O
technical CN103254203A A JJ O
field CN103254203A A NN O
of CN103254203A A IN O
chemical CN103254203A A NN O
medicines CN103254203A A NNS O
, CN103254203A A , O
and CN103254203A A CC O
in CN103254203A A IN O
particular CN103254203A A JJ O
relates CN103254203A A NNS O
to CN103254203A A TO O
a CN103254203A A DT O
five-membered CN103254203A A JJ O
urea CN103254203A A JJ O
ring-coumarin CN103254203A A JJ O
derivative CN103254203A A NN O
or CN103254203A A CC O
a CN103254203A A DT O
pharmaceutical CN103254203A A JJ O
salt CN103254203A A NN O
and CN103254203A A CC O
an CN103254203A A DT O
application CN103254203A A NN O
thereof CN103254203A A NN O
. CN103254203A A . O

enzyme US7081464 T JJ O
inhibitors US7081464 T NNS O
of US7081464 T IN O
tumor US7081464 T NN I-UN
necrosis US7081464 T NN I-UN
factor US7081464 T NN I-UN
alpha US7081464 T NN I-UN
and US7081464 T CC O
phosphodiesterase US7081464 T NN O
; US7081464 T : O
anticachetic US7081464 T JJ O
, US7081464 T , O
antiasthmatic US7081464 T JJ O
, US7081464 T , O
antiinflammatory US7081464 T JJ O
agents US7081464 T NNS O
. US7081464 T . O

Novel US7081464 A NNP O
amides US7081464 A NNS O
and US7081464 A CC O
imides US7081464 A NNS O
are US7081464 A VBP O
inhibitors US7081464 A NNS O
of US7081464 A IN O
tumor US7081464 A NN I-UN
necrosis US7081464 A NN I-UN
factorα US7081464 A NN I-UN
and US7081464 A CC O
phosphodiesterase US7081464 A NN O
and US7081464 A CC O
can US7081464 A MD O
be US7081464 A VB O
used US7081464 A VBN O
to US7081464 A TO O
combat US7081464 A VB O
cachexia US7081464 A NN O
, US7081464 A , O
endotoxic US7081464 A NN O
shock US7081464 A NN O
, US7081464 A , O
retrovirus US7081464 A NN O
replication US7081464 A NN O
, US7081464 A , O
asthma US7081464 A NN O
, US7081464 A , O
and US7081464 A CC O
inflammatory US7081464 A JJ O
conditions US7081464 A NNS O
. US7081464 A . O

5- WO2009094845A1 T JJ O
( WO2009094845A1 T ( O
3-heteroaromatic WO2009094845A1 T JJ O
ring WO2009094845A1 T NN O
substituted WO2009094845A1 T VBD O
phenyl WO2009094845A1 T NN O
) WO2009094845A1 T ) O
tetrazole WO2009094845A1 T NN O
compounds WO2009094845A1 T NNS O
and WO2009094845A1 T CC O
their WO2009094845A1 T PRP$ O
uses WO2009094845A1 T NNS O
for WO2009094845A1 T IN O
anti-hiv/aids WO2009094845A1 T NNS O
. WO2009094845A1 T . O

Hedgehog US20090203713 T NNP I-UN
pathway US20090203713 T NN O
antagonists US20090203713 T NNS O
to US20090203713 T TO O
treat US20090203713 T VB O
disease US20090203713 T NN O
. US20090203713 T . O

Compounds US20090203713 A NNS O
, US20090203713 A , O
compositions US20090203713 A NNS O
, US20090203713 A , O
kits US20090203713 A NNS O
and US20090203713 A CC O
methods US20090203713 A NNS O
for US20090203713 A IN O
modulating US20090203713 A VBG O
hedgehog US20090203713 A JJ I-UN
pathway US20090203713 A NN O
activity US20090203713 A NN O
, US20090203713 A , O
and US20090203713 A CC O
treating US20090203713 A VBG O
conditions US20090203713 A NNS O
related US20090203713 A VBN O
to US20090203713 A TO O
abnormal US20090203713 A VB O
or US20090203713 A CC O
aberrant US20090203713 A VB O
hedgehog US20090203713 A JJ I-UN
pathway US20090203713 A NN O
activity US20090203713 A NN O
, US20090203713 A , O
are US20090203713 A VBP O
disclosed US20090203713 A VBN O
. US20090203713 A . O

Pharmaceutical WO2014047780A1 T JJ O
composition WO2014047780A1 T NN O
containing WO2014047780A1 T VBG O
apigenin WO2014047780A1 T NN O
and WO2014047780A1 T CC O
apigenin WO2014047780A1 T JJ O
derivative WO2014047780A1 T NN O
and WO2014047780A1 T CC O
oridonin WO2014047780A1 T NN O
and WO2014047780A1 T CC O
oridonin WO2014047780A1 T JJ O
derivative WO2014047780A1 T NN O
and WO2014047780A1 T CC O
use WO2014047780A1 T NN O
thereof WO2014047780A1 T NN O
. WO2014047780A1 T . O

Pharmaceutical WO2012070890A3 T JJ O
composition WO2012070890A3 T NN O
comprising WO2012070890A3 T VBG O
extract WO2012070890A3 T NN O
of WO2012070890A3 T IN O
lonicera WO2012070890A3 T NN O
japonica WO2012070890A3 T NN O
for WO2012070890A3 T IN O
prevention WO2012070890A3 T NN O
and WO2012070890A3 T CC O
treatment WO2012070890A3 T NN O
of WO2012070890A3 T IN O
gastroesophageal WO2012070890A3 T NN O
reflux WO2012070890A3 T NN O
disease WO2012070890A3 T NN O
. WO2012070890A3 T . O

Novel EP2280940A1 T JJ O
n- EP2280940A1 T JJ O
( EP2280940A1 T ( O
2-amino-phenyl EP2280940A1 T JJ O
) EP2280940A1 T ) O
-acrylamides EP2280940A1 T NNS O
. EP2280940A1 T . O

The EP2280940A1 A DT O
present EP2280940A1 A JJ O
invention EP2280940A1 A NN O
is EP2280940A1 A VBZ O
directed EP2280940A1 A VBN O
to EP2280940A1 A TO O
the EP2280940A1 A DT O
compounds EP2280940A1 A NNS O
of EP2280940A1 A IN O
formula EP2280940A1 A NN O
( EP2280940A1 A ( O
I EP2280940A1 A PRP O
) EP2280940A1 A ) O
, EP2280940A1 A , O
wherein EP2280940A1 A WP O
R1 EP2280940A1 A NNP O
to EP2280940A1 A TO O
R4 EP2280940A1 A NNP O
have EP2280940A1 A VB O
the EP2280940A1 A DT O
significances EP2280940A1 A NNS O
given EP2280940A1 A VBN O
herein EP2280940A1 A NNS O
, EP2280940A1 A , O
to EP2280940A1 A TO O
processes EP2280940A1 A VB O
for EP2280940A1 A IN O
the EP2280940A1 A DT O
manufacture EP2280940A1 A NN O
of EP2280940A1 A IN O
said EP2280940A1 A VBD O
compounds EP2280940A1 A NNS O
as EP2280940A1 A RB O
well EP2280940A1 A RB O
as EP2280940A1 A IN O
medicaments EP2280940A1 A NNS O
containing EP2280940A1 A VBG O
said EP2280940A1 A VBD O
compounds EP2280940A1 A NNS O
. EP2280940A1 A . O

The EP2280940A1 A DT O
compounds EP2280940A1 A NNS O
according EP2280940A1 A VBG O
to EP2280940A1 A TO O
this EP2280940A1 A DT O
invention EP2280940A1 A NN O
show EP2280940A1 A VB O
anti-proliferative EP2280940A1 A JJ O
and EP2280940A1 A CC O
differentiation-inducing EP2280940A1 A JJ O
activity EP2280940A1 A NN O
and EP2280940A1 A CC O
are EP2280940A1 A VBP O
thus EP2280940A1 A RB O
useful EP2280940A1 A JJ O
for EP2280940A1 A IN O
the EP2280940A1 A DT O
treatment EP2280940A1 A NN O
of EP2280940A1 A IN O
diseases EP2280940A1 A NNS O
such EP2280940A1 A JJ O
as EP2280940A1 A IN O
cancer EP2280940A1 A NN O
in EP2280940A1 A IN O
humans EP2280940A1 A NNS O
or EP2280940A1 A CC O
animals EP2280940A1 A NNS O
. EP2280940A1 A . O

Novel US20070116698 T NNP O
methods US20070116698 T NNS O
and US20070116698 T CC O
medicament US20070116698 T NN O
for US20070116698 T IN O
treating US20070116698 T VBG O
infectious US20070116698 T JJ O
diseases US20070116698 T NNS O
involving US20070116698 T VBG O
microbial US20070116698 T JJ O
biofilms US20070116698 T NNS O
. US20070116698 T . O

The US20070116698 A DT O
present US20070116698 A JJ O
invention US20070116698 A NN O
provides US20070116698 A VBZ O
a US20070116698 A DT O
method US20070116698 A NN O
for US20070116698 A IN O
prophylaxis US20070116698 A NN O
and US20070116698 A CC O
therapy US20070116698 A NN O
of US20070116698 A IN O
infectious US20070116698 A JJ O
diseases US20070116698 A NNS O
caused US20070116698 A VBN O
by US20070116698 A IN O
microorganisms US20070116698 A JJ O
present US20070116698 A NN O
in US20070116698 A IN O
biofilms US20070116698 A JJ O
adherent US20070116698 A NN O
to US20070116698 A TO O
cell US20070116698 A VB O
surfaces US20070116698 A NNS O
comprising US20070116698 A VBG O
the US20070116698 A DT O
step US20070116698 A NN O
of US20070116698 A IN O
administering US20070116698 A VBG O
to US20070116698 A TO O
an US20070116698 A DT O
individual US20070116698 A NN O
in US20070116698 A IN O
need US20070116698 A NN O
thereof US20070116698 A VBP O
a US20070116698 A DT O
composition US20070116698 A NN O
comprising US20070116698 A VBG O
a US20070116698 A DT O
combination US20070116698 A NN O
of US20070116698 A IN O
at US20070116698 A IN O
least US20070116698 A JJS O
one US20070116698 A CD O
compound US20070116698 A NN O
chosen US20070116698 A NN O
from US20070116698 A IN O
the US20070116698 A DT O
group US20070116698 A NN O
of US20070116698 A IN O
peroxidase US20070116698 A NN I-UN
, US20070116698 A , O
lactoferrin US20070116698 A NN I-UN
, US20070116698 A , O
lactoferrin US20070116698 A NN I-UN
peptides US20070116698 A NNS I-UN
, US20070116698 A , O
lysozyme US20070116698 A NN I-UN
and US20070116698 A CC O
immunoglobulins US20070116698 A NNS I-UN
and US20070116698 A CC O
at US20070116698 A IN O
least US20070116698 A JJS O
one US20070116698 A CD O
growth US20070116698 A NN O
factor US20070116698 A NN O
. US20070116698 A . O

Method CN101269164A T NNP O
of CN101269164A T IN O
preparing CN101269164A T VBG O
virus CN101269164A T JJ O
bacterium CN101269164A T NN O
blood CN101269164A T NN O
serum CN101269164A T NN O
Chinese CN101269164A T NNP O
aloe CN101269164A T VBZ O
vaccine CN101269164A T JJ O
powder CN101269164A T NN O
preparation CN101269164A T NN O
and CN101269164A T CC O
oral CN101269164A T JJ O
liquid CN101269164A T NN O
for CN101269164A T IN O
livestock CN101269164A T NN O
, CN101269164A T , O
poultry CN101269164A T NN O
biology CN101269164A T NN O
and CN101269164A T CC O
aquatic CN101269164A T JJ O
animal CN101269164A T NN O
. CN101269164A T . O

Pharmaceutical US20100069330 T JJ O
Compositions US20100069330 T NNS O
and US20100069330 T CC O
Methods US20100069330 T NNS O
for US20100069330 T IN O
Preparing US20100069330 T VBG O
and US20100069330 T CC O
Using US20100069330 T NNP O
Lipophilic US20100069330 T NNP O
Organosulfur US20100069330 T NNP O
Cell US20100069330 T NNP O
Proliferation US20100069330 T NNP O
Inhibitors US20100069330 T NNP O
. US20100069330 T . O

Carbocyclic US6908942 T NNP O
oxy US6908942 T PRP O
amines US6908942 T NNS O
such US6908942 T JJ O
as US6908942 T IN O
2,2-dimethyl-3- US6908942 T JJ O
( US6908942 T ( O
4-fluorobenzyl US6908942 T JJ O
) US6908942 T ) O
ether-4-methoxy-6- US6908942 T NN O
( US6908942 T ( O
4-methoxybenzyl US6908942 T JJ O
) US6908942 T ) O
amino US6908942 T NN O
Benzopyran US6908942 T NNP O
and US6908942 T CC O
libraries US6908942 T NNS O
, US6908942 T , O
used US6908942 T VBD O
for US6908942 T IN O
prophylaxis US6908942 T NN O
of US6908942 T IN O
eating US6908942 T VBG O
disorders US6908942 T NNS O
induced US6908942 T VBN O
by US6908942 T IN O
lipid US6908942 T JJ O
peroxidation US6908942 T NN O
; US6908942 T : O
antioxidants US6908942 T NNS O
. US6908942 T . O

Oral WO2013124340A1 T JJ O
pharmaceutical WO2013124340A1 T JJ O
compositions WO2013124340A1 T NNS O
of WO2013124340A1 T IN O
dabigatran WO2013124340A1 T NN O
etexilate WO2013124340A1 T NN O
. WO2013124340A1 T . O

Agents US20070265194 T NNS O
for US20070265194 T IN O
the US20070265194 T DT O
treatment US20070265194 T NN O
of US20070265194 T IN O
viral US20070265194 T JJ O
infections US20070265194 T NNS O
. US20070265194 T . O

Preferably US20070265194 A RB O
, US20070265194 A , O
the US20070265194 A DT O
protesome US20070265194 A NN O
in US20070265194 A IN O
hibitor US20070265194 A NN O
inhibits US20070265194 A NNS O
or US20070265194 A CC O
regulates US20070265194 A VBZ O
a US20070265194 A DT O
ubiquitin US20070265194 A JJ I-UN
proteasome US20070265194 A JJ O
pathway US20070265194 A NN O
. US20070265194 A . O

Pyridylpyrimidine EP1721609A2 T NNP O
derivatives EP1721609A2 T NNS O
as EP1721609A2 T IN O
effective EP1721609A2 T JJ O
compounds EP1721609A2 T NNS O
against EP1721609A2 T IN O
prion EP1721609A2 T NN O
infections EP1721609A2 T NNS O
and EP1721609A2 T CC O
prion EP1721609A2 T NN O
diseases EP1721609A2 T NNS O
. EP1721609A2 T . O

Microcapsules US20100173002 T NNS O
with US20100173002 T IN O
improved US20100173002 T JJ O
shells US20100173002 T NNS O
. US20100173002 T . O

Stolonoxides US7153885 T NNS O
. US7153885 T . O

Pharmaceutical CN103690552A T JJ O
composition CN103690552A T NN O
and CN103690552A T CC O
application CN103690552A T NN O
thereof CN103690552A T NN O
to CN103690552A T TO O
preparing CN103690552A T VBG O
pharmaceutical CN103690552A T JJ O
preparation CN103690552A T NN O
for CN103690552A T IN O
treating CN103690552A T VBG O
hepatitis CN103690552A T NN O
B CN103690552A T NNP O
. CN103690552A T . O

Antiinflammatory WO2014118195A1 T NNP O
and WO2014118195A1 T CC O
antitumor WO2014118195A1 T VB O
2-oxothiazoles WO2014118195A1 T NNS O
and WO2014118195A1 T CC O
2-oxothiophenes WO2014118195A1 T JJ O
compounds WO2014118195A1 T NNS O
. WO2014118195A1 T . O

A WO2014118195A1 A DT O
compound WO2014118195A1 A NN O
of WO2014118195A1 A IN O
formula WO2014118195A1 A NN O
( WO2014118195A1 A ( O
I WO2014118195A1 A PRP O
) WO2014118195A1 A ) O
wherein WO2014118195A1 A NN O
X WO2014118195A1 A NNP O
is WO2014118195A1 A VBZ O
O WO2014118195A1 A NNP O
, WO2014118195A1 A , O
C WO2014118195A1 A NNP O
O WO2014118195A1 A NNP O
or WO2014118195A1 A CC O
S WO2014118195A1 A NNP O
; WO2014118195A1 A : O
Y WO2014118195A1 A NNP O
is WO2014118195A1 A VBZ O
N WO2014118195A1 A NNP O
or WO2014118195A1 A CC O
CH WO2014118195A1 A NNP O
; WO2014118195A1 A : O
R2 WO2014118195A1 A NNP O
and WO2014118195A1 A CC O
R4 WO2014118195A1 A NNP O
are WO2014118195A1 A VBP O
each WO2014118195A1 A DT O
independently WO2014118195A1 A RB O
H WO2014118195A1 A NNP O
, WO2014118195A1 A , O
- WO2014118195A1 A : O
( WO2014118195A1 A ( O
CH2 WO2014118195A1 A NNP O
) WO2014118195A1 A ) O
pCOOH WO2014118195A1 A NN O
, WO2014118195A1 A , O
- WO2014118195A1 A : O
( WO2014118195A1 A ( O
CH2 WO2014118195A1 A NNP O
) WO2014118195A1 A ) O
pCON WO2014118195A1 A NN O
( WO2014118195A1 A ( O
R5 WO2014118195A1 A NNP O
) WO2014118195A1 A ) O
2 WO2014118195A1 A CD O
or WO2014118195A1 A CC O
- WO2014118195A1 A : O
( WO2014118195A1 A ( O
CH2 WO2014118195A1 A NNP O
) WO2014118195A1 A ) O
pCOOC WO2014118195A1 A VBZ O
1-6alkyI WO2014118195A1 A JJ O
; WO2014118195A1 A : O
or WO2014118195A1 A CC O
R2 WO2014118195A1 A NNP O
and WO2014118195A1 A CC O
R4 WO2014118195A1 A NNP O
together WO2014118195A1 A RB O
form WO2014118195A1 A VBD O
a WO2014118195A1 A DT O
6-membered WO2014118195A1 A JJ O
phenyl WO2014118195A1 A NN O
ring WO2014118195A1 A VBG O
fused WO2014118195A1 A VBN O
to WO2014118195A1 A TO O
the WO2014118195A1 A DT O
five WO2014118195A1 A CD O
membered WO2014118195A1 A VBD O
ring WO2014118195A1 A NN O
; WO2014118195A1 A : O
each WO2014118195A1 A DT O
R1 WO2014118195A1 A NNP O
is WO2014118195A1 A VBZ O
independently WO2014118195A1 A RB O
selected WO2014118195A1 A VBN O
from WO2014118195A1 A IN O
H WO2014118195A1 A NNP O
, WO2014118195A1 A , O
halo WO2014118195A1 A NN O
( WO2014118195A1 A ( O
e.g WO2014118195A1 A NN O
. WO2014118195A1 A . O

fluoro WO2014118195A1 A NN O
or WO2014118195A1 A CC O
chloro WO2014118195A1 A NN O
) WO2014118195A1 A ) O
, WO2014118195A1 A , O
C6-10aryl WO2014118195A1 A NNP O
, WO2014118195A1 A , O
C7-12arylalkyl WO2014118195A1 A NNP O
, WO2014118195A1 A , O
C2-12alkenyl WO2014118195A1 A NNP O
; WO2014118195A1 A : O
OC1-2 WO2014118195A1 A NNP O
alkyl WO2014118195A1 A NN O
, WO2014118195A1 A , O
OC2-12 WO2014118195A1 A NNP O
aikenyl WO2014118195A1 A NN O
or WO2014118195A1 A CC O
a WO2014118195A1 A DT O
C1-12 WO2014118195A1 A JJ O
alkyl WO2014118195A1 A NN O
group WO2014118195A1 A NN O
; WO2014118195A1 A : O
each WO2014118195A1 A DT O
R5 WO2014118195A1 A NNP O
is WO2014118195A1 A VBZ O
H WO2014118195A1 A NNP O
or WO2014118195A1 A CC O
C1-6 WO2014118195A1 A NNP O
alkyl WO2014118195A1 A NN O
; WO2014118195A1 A : O
each WO2014118195A1 A DT O
p WO2014118195A1 A NN O
is WO2014118195A1 A VBZ O
0 WO2014118195A1 A CD O
to WO2014118195A1 A TO O
3 WO2014118195A1 A CD O
; WO2014118195A1 A : O
n WO2014118195A1 A CC O
is WO2014118195A1 A VBZ O
1 WO2014118195A1 A CD O
to WO2014118195A1 A TO O
4 WO2014118195A1 A CD O
; WO2014118195A1 A : O
or WO2014118195A1 A CC O
a WO2014118195A1 A DT O
salt WO2014118195A1 A NN O
, WO2014118195A1 A , O
ester WO2014118195A1 A NN O
, WO2014118195A1 A , O
solvate WO2014118195A1 A NN O
, WO2014118195A1 A , O
N-oxide WO2014118195A1 A NNP O
, WO2014118195A1 A , O
or WO2014118195A1 A CC O
prodrug WO2014118195A1 A JJ O
thereof WO2014118195A1 A NN O
, WO2014118195A1 A , O
e.g WO2014118195A1 A NN O
. WO2014118195A1 A . O

a WO2014118195A1 A DT O
salt WO2014118195A1 A NN O
thereof WO2014118195A1 A NN O
. WO2014118195A1 A . O

Etimicin CN1569010A T NNP O
sulfate CN1569010A T NN O
preparation CN1569010A T NN O
and CN1569010A T CC O
its CN1569010A T PRP$ O
preparing CN1569010A T NN O
method CN1569010A T NN O
. CN1569010A T . O

Compounds EP1230235B1 T NNS O
with EP1230235B1 T IN O
antibacterial EP1230235B1 T JJ O
and EP1230235B1 T CC O
antiparasitic EP1230235B1 T JJ O
properties EP1230235B1 T NNS O
. EP1230235B1 T . O

There EP1230235B1 A EX O
are EP1230235B1 A VBP O
provided EP1230235B1 A VBN O
novel EP1230235B1 A JJ O
compounds EP1230235B1 A NNS O
which EP1230235B1 A WDT O
have EP1230235B1 A VBP O
both EP1230235B1 A DT O
antibacterial EP1230235B1 A JJ O
and EP1230235B1 A CC O
antiparasitic EP1230235B1 A JJ O
properties EP1230235B1 A NNS O
, EP1230235B1 A , O
thereby EP1230235B1 A RB O
reducing EP1230235B1 A VBG O
the EP1230235B1 A DT O
need EP1230235B1 A NN O
for EP1230235B1 A IN O
using EP1230235B1 A VBG O
several EP1230235B1 A JJ O
compounds EP1230235B1 A NNS O
in EP1230235B1 A IN O
combined EP1230235B1 A JJ O
antibacterial EP1230235B1 A JJ O
and EP1230235B1 A CC O
antiparasitic EP1230235B1 A JJ O
treatment EP1230235B1 A NN O
of EP1230235B1 A IN O
livestock EP1230235B1 A NN O
. EP1230235B1 A . O

The EP1230235B1 A DT O
present EP1230235B1 A JJ O
novel EP1230235B1 A JJ O
compounds EP1230235B1 A NNS O
are EP1230235B1 A VBP O
especially EP1230235B1 A RB O
well EP1230235B1 A RB O
suited EP1230235B1 A VBN O
for EP1230235B1 A IN O
treatment EP1230235B1 A NN O
of EP1230235B1 A IN O
coccidiosis EP1230235B1 A NN O
, EP1230235B1 A , O
and EP1230235B1 A CC O
they EP1230235B1 A PRP O
are EP1230235B1 A VBP O
represented EP1230235B1 A VBN O
by EP1230235B1 A IN O
general EP1230235B1 A JJ O
formula EP1230235B1 A NN O
( EP1230235B1 A ( O
I EP1230235B1 A PRP O
) EP1230235B1 A ) O
wherein EP1230235B1 A VBD O
R1-R6 EP1230235B1 A NNP O
, EP1230235B1 A , O
X EP1230235B1 A NNP O
and EP1230235B1 A CC O
A EP1230235B1 A NNP O
are EP1230235B1 A VBP O
as EP1230235B1 A IN O
defined EP1230235B1 A VBN O
in EP1230235B1 A IN O
the EP1230235B1 A DT O
specification EP1230235B1 A NN O
. EP1230235B1 A . O

Novel WO2014162106A1 T NNP O
chalcone WO2014162106A1 T NN O
derivatives WO2014162106A1 T NNS O
having WO2014162106A1 T VBG O
an WO2014162106A1 T DT O
anti-allergic WO2014162106A1 T JJ O
activity WO2014162106A1 T NN O
. WO2014162106A1 T . O

The WO2014162106A1 A DT O
present WO2014162106A1 A JJ O
invention WO2014162106A1 A NN O
concerns WO2014162106A1 A NNS O
compounds WO2014162106A1 A NNS O
of WO2014162106A1 A IN O
formula WO2014162106A1 A NN O
( WO2014162106A1 A ( O
I WO2014162106A1 A PRP O
) WO2014162106A1 A ) O
; WO2014162106A1 A : O
in WO2014162106A1 A IN O
which WO2014162106A1 A WDT O
; WO2014162106A1 A : O
- WO2014162106A1 A : O
R2 WO2014162106A1 A NN O
, WO2014162106A1 A , O
R4 WO2014162106A1 A NNP O
and WO2014162106A1 A CC O
R6 WO2014162106A1 A NNP O
, WO2014162106A1 A , O
identical WO2014162106A1 A JJ O
or WO2014162106A1 A CC O
different WO2014162106A1 A JJ O
, WO2014162106A1 A , O
represent WO2014162106A1 A VB O
a WO2014162106A1 A DT O
hydrogen WO2014162106A1 A NN O
, WO2014162106A1 A , O
chlorine WO2014162106A1 A NN O
, WO2014162106A1 A , O
bromine WO2014162106A1 A NN O
, WO2014162106A1 A , O
iodine WO2014162106A1 A NN O
or WO2014162106A1 A CC O
fluorine WO2014162106A1 A NN O
atom WO2014162106A1 A NN O
, WO2014162106A1 A , O
or WO2014162106A1 A CC O
an WO2014162106A1 A DT O
-OH WO2014162106A1 A NN O
or WO2014162106A1 A CC O
-O-alkyl WO2014162106A1 A VB O
group WO2014162106A1 A NN O
comprising WO2014162106A1 A VBG O
1 WO2014162106A1 A CD O
to WO2014162106A1 A TO O
6 WO2014162106A1 A CD O
carbon WO2014162106A1 A NN O
atoms WO2014162106A1 A NNS O
; WO2014162106A1 A : O
-R2 WO2014162106A1 A NNP O
and WO2014162106A1 A CC O
R4 WO2014162106A1 A NNP O
, WO2014162106A1 A , O
identical WO2014162106A1 A JJ O
or WO2014162106A1 A CC O
different WO2014162106A1 A JJ O
, WO2014162106A1 A , O
represent WO2014162106A1 A VB O
a WO2014162106A1 A DT O
hydrogen WO2014162106A1 A NN O
atom WO2014162106A1 A NN O
, WO2014162106A1 A , O
or WO2014162106A1 A CC O
an WO2014162106A1 A DT O
-- WO2014162106A1 A : O
OH WO2014162106A1 A UH O
or WO2014162106A1 A CC O
-Q-alkyl WO2014162106A1 A JJ O
group WO2014162106A1 A NN O
comprising WO2014162106A1 A VBG O
1 WO2014162106A1 A CD O
to WO2014162106A1 A TO O
6 WO2014162106A1 A CD O
carbon WO2014162106A1 A NN O
atoms WO2014162106A1 A NNS O
; WO2014162106A1 A : O
in WO2014162106A1 A IN O
which WO2014162106A1 A WDT O
R2 WO2014162106A1 A NNP O
' WO2014162106A1 A POS O
and/or WO2014162106A1 A NN O
R4 WO2014162106A1 A NNP O
' WO2014162106A1 A POS O
represent WO2014162106A1 A NN O
( WO2014162106A1 A ( O
s WO2014162106A1 A PRP O
) WO2014162106A1 A ) O
a WO2014162106A1 A DT O
methoxy WO2014162106A1 A JJ O
group WO2014162106A1 A NN O
; WO2014162106A1 A : O
- WO2014162106A1 A : O
n WO2014162106A1 A NN O
is WO2014162106A1 A VBZ O
equal WO2014162106A1 A JJ O
to WO2014162106A1 A TO O
1 WO2014162106A1 A CD O
, WO2014162106A1 A , O
2 WO2014162106A1 A CD O
or WO2014162106A1 A CC O
3 WO2014162106A1 A CD O
; WO2014162106A1 A : O
- WO2014162106A1 A : O
X WO2014162106A1 A NN O
= WO2014162106A1 A NN O
CH2 WO2014162106A1 A NNP O
, WO2014162106A1 A , O
G WO2014162106A1 A NNP O
, WO2014162106A1 A , O
S WO2014162106A1 A NNP O
or WO2014162106A1 A CC O
N WO2014162106A1 A NNP O
( WO2014162106A1 A ( O
R7 WO2014162106A1 A NNP O
) WO2014162106A1 A ) O
; WO2014162106A1 A : O
and WO2014162106A1 A CC O
- WO2014162106A1 A : O
R7 WO2014162106A1 A NN O
represents WO2014162106A1 A VBZ O
a WO2014162106A1 A DT O
hydrogen WO2014162106A1 A NN O
atom WO2014162106A1 A NN O
or WO2014162106A1 A CC O
an WO2014162106A1 A DT O
alkyl WO2014162106A1 A JJ O
group WO2014162106A1 A NN O
comprising WO2014162106A1 A VBG O
1 WO2014162106A1 A CD O
to WO2014162106A1 A TO O
6 WO2014162106A1 A CD O
carbon WO2014162106A1 A NN O
atoms WO2014162106A1 A NNS O
; WO2014162106A1 A : O
and WO2014162106A1 A CC O
the WO2014162106A1 A DT O
pharmaceutically WO2014162106A1 A RB O
acceptable WO2014162106A1 A JJ O
hydrates WO2014162106A1 A NNS O
, WO2014162106A1 A , O
solvates WO2014162106A1 A NNS O
and WO2014162106A1 A CC O
salts WO2014162106A1 A NNS O
thereof WO2014162106A1 A NN O
. WO2014162106A1 A . O

Genes US7595156 T NNS O
for US7595156 T IN O
synthesis US7595156 T NN O
of US7595156 T IN O
FR-008 US7595156 T NNP O
polyketides US7595156 T NNS O
. US7595156 T . O

This US7595156 A DT O
base US7595156 A NN O
sequence US7595156 A NN O
comprises US7595156 A VBZ O
genes US7595156 A NNS O
coding US7595156 A VBG O
for US7595156 A IN O
ketosynthase US7595156 A NN I-UN
( US7595156 A ( O
KS US7595156 A NNP I-UN
) US7595156 A ) O
, US7595156 A , O
acyl US7595156 A JJ I-UN
transferase US7595156 A NN I-UN
( US7595156 A ( O
AT US7595156 A NNP I-UN
) US7595156 A ) O
, US7595156 A , O
acyl US7595156 A RB I-UN
carrier US7595156 A NN I-UN
protein US7595156 A NN I-UN
( US7595156 A ( O
ACP US7595156 A NNP I-UN
) US7595156 A ) O
, US7595156 A , O
ketoreductase US7595156 A FW I-UN
( US7595156 A ( O
KR US7595156 A NNP I-UN
) US7595156 A ) O
, US7595156 A , O
dehydratase US7595156 A NN I-UN
( US7595156 A ( O
DH US7595156 A NNP I-UN
) US7595156 A ) O
and US7595156 A CC O
enoyl US7595156 A JJ I-UN
reductase US7595156 A NN I-UN
( US7595156 A ( O
ER US7595156 A NNP I-UN
) US7595156 A ) O
domains US7595156 A VBZ O
, US7595156 A , O
and US7595156 A CC O
genes US7595156 A NNS O
coding US7595156 A VBG O
for US7595156 A IN O
modifier US7595156 A JJR O
enzymes US7595156 A NNS O
, US7595156 A , O
such US7595156 A JJ O
as US7595156 A IN O
ABC US7595156 A NNP I-UN
transporter US7595156 A NN I-UN
, US7595156 A , O
cytochrome US7595156 A JJ I-UN
P450 US7595156 A NNP I-UN
monooxygenase US7595156 A NN I-UN
, US7595156 A , O
ferredoxin US7595156 A NN I-UN
, US7595156 A , O
thioesterase US7595156 A NN I-UN
, US7595156 A , O
sugar US7595156 A NN I-UN
synthetic US7595156 A JJ I-UN
protein US7595156 A NN I-UN
, US7595156 A , O
FAD-dependent US7595156 A JJ I-UN
monooxygenase US7595156 A NN I-UN
, US7595156 A , O
4-amino-4-deoxychorismate US7595156 A JJ I-UN
( US7595156 A ( I-UN
ADC US7595156 A NNP I-UN
) US7595156 A ) I-UN
synthase US7595156 A NN I-UN
and US7595156 A CC O
ADC US7595156 A NNP I-UN
lyase US7595156 A NN I-UN
. US7595156 A . O

Treatment EP1712226A2 T NN O
of EP1712226A2 T IN O
a EP1712226A2 T DT O
Hemoglobinopathy EP1712226A2 T NNP O
. EP1712226A2 T . O

Disclosed EP1712226A2 A VBN O
are EP1712226A2 A VBP O
methods EP1712226A2 A NNS O
for EP1712226A2 A IN O
treating EP1712226A2 A VBG O
a EP1712226A2 A DT O
patient EP1712226A2 A NN O
identified EP1712226A2 A VBN O
as EP1712226A2 A IN O
having EP1712226A2 A VBG O
a EP1712226A2 A DT O
hemoglobinopathy EP1712226A2 A NN O
that EP1712226A2 A WDT O
is EP1712226A2 A VBZ O
characterized EP1712226A2 A VBN O
by EP1712226A2 A IN O
a EP1712226A2 A DT O
reduced EP1712226A2 A JJ O
affinity EP1712226A2 A NN O
of EP1712226A2 A IN O
hemoglobin EP1712226A2 A NN I-UN
for EP1712226A2 A IN O
oxygen EP1712226A2 A NN O
. EP1712226A2 A . O

Salt US20120178809 T NNP O
of US20120178809 T IN O
Dimethylaminomethyl-Phenyl-Cyclohexane US20120178809 T NNP O
and US20120178809 T CC O
Crystalline US20120178809 T NNP O
Forms US20120178809 T NNP O
Thereof US20120178809 T NNP O
. US20120178809 T . O

Novel US20120178809 A NNP O
3- US20120178809 A JJ O
[ US20120178809 A NNP O
2- US20120178809 A CD O
( US20120178809 A ( O
dimethylamino US20120178809 A NN O
) US20120178809 A ) O
methyl- US20120178809 A NN O
( US20120178809 A ( O
cyclohex-1-yl US20120178809 A JJ O
) US20120178809 A ) O
] US20120178809 A FW O
-phenol US20120178809 A JJ O
maleate US20120178809 A NN O
compounds US20120178809 A NNS O
corresponding US20120178809 A VBG O
to US20120178809 A TO O
formula US20120178809 A VB O
I US20120178809 A PRP O
and US20120178809 A CC O
processes US20120178809 A NNS O
for US20120178809 A IN O
preparing US20120178809 A VBG O
these US20120178809 A DT O
compounds US20120178809 A NNS O
are US20120178809 A VBP O
provided US20120178809 A VBN O
. US20120178809 A . O

Pharmaceutical US20120178809 A JJ O
compositions US20120178809 A NNS O
including US20120178809 A VBG O
these US20120178809 A DT O
compounds US20120178809 A NNS O
and US20120178809 A CC O
methods US20120178809 A NNS O
of US20120178809 A IN O
treating US20120178809 A VBG O
or US20120178809 A CC O
alleviating US20120178809 A VBG O
pain US20120178809 A NN O
with US20120178809 A IN O
these US20120178809 A DT O
compounds US20120178809 A NNS O
are US20120178809 A VBP O
also US20120178809 A RB O
provided US20120178809 A VBN O
. US20120178809 A . O

Pharmaceutical CN101810601A T JJ O
composition CN101810601A T NN O
containing CN101810601A T VBG O
idebenone CN101810601A T NN O
for CN101810601A T IN O
the CN101810601A T DT O
treatment CN101810601A T NN O
of CN101810601A T IN O
liver CN101810601A T NN O
disorders CN101810601A T NNS O
. CN101810601A T . O

Treatment US8487003 T NN O
of US8487003 T IN O
cancer US8487003 T NN O
by US8487003 T IN O
administration US8487003 T NN O
of US8487003 T IN O
perfluorooctanoic US8487003 T JJ O
acid US8487003 T NN O
. US8487003 T . O

Pharmaceutical CN101596190A T JJ O
application CN101596190A T NN O
of CN101596190A T IN O
D-cycloserine CN101596190A T NNP O
. CN101596190A T . O

The CN101596190A A DT O
invention CN101596190A A NN O
provides CN101596190A A VBZ O
a CN101596190A A DT O
new CN101596190A A JJ O
pharmaceutical CN101596190A A JJ O
application CN101596190A A NN O
of CN101596190A A IN O
D-cycloserine CN101596190A A NNP O
, CN101596190A A , O
in CN101596190A A IN O
particular CN101596190A A JJ O
to CN101596190A A TO O
application CN101596190A A NN O
which CN101596190A A WDT O
utilizes CN101596190A A VBZ O
D-cycloserine CN101596190A A NNP O
to CN101596190A A TO O
promote CN101596190A A VB O
the CN101596190A A DT O
decay CN101596190A A NN O
or CN101596190A A CC O
oblivion CN101596190A A NN O
of CN101596190A A IN O
disgust CN101596190A A NN O
memories CN101596190A A NNS O
and CN101596190A A CC O
fear CN101596190A A NN O
memories CN101596190A A NNS O
and CN101596190A A CC O
can CN101596190A A MD O
be CN101596190A A VB O
used CN101596190A A VBN O
for CN101596190A A IN O
preparing CN101596190A A VBG O
a CN101596190A A DT O
medicine CN101596190A A NN O
for CN101596190A A IN O
preventing CN101596190A A VBG O
and/or CN101596190A A JJ O
treating CN101596190A A VBG O
mental CN101596190A A JJ O
sickness CN101596190A A NN O
and/or CN101596190A A NN O
symptoms CN101596190A A NNS O
correlative CN101596190A A VBP O
to CN101596190A A TO O
BDNF CN101596190A A NNP I-UN
gene CN101596190A A NN O
variation CN101596190A A NN O
. CN101596190A A . O

The CN101596190A A DT O
mental CN101596190A A JJ O
sickness CN101596190A A NN O
and/or CN101596190A A NN O
symptoms CN101596190A A NNS O
comprise CN101596190A A VBP O
anxiety CN101596190A A NN O
neurosis CN101596190A A NN O
, CN101596190A A , O
melancholia CN101596190A A NN O
, CN101596190A A , O
post-traumatic CN101596190A A JJ O
stress CN101596190A A NN O
syndrome CN101596190A A NN O
, CN101596190A A , O
and CN101596190A A CC O
the CN101596190A A DT O
like CN101596190A A JJ O
correlative CN101596190A A NN O
to CN101596190A A TO O
the CN101596190A A DT O
BDNF CN101596190A A NNP I-UN
gene CN101596190A A NN O
variation CN101596190A A NN O
, CN101596190A A , O
and CN101596190A A CC O
the CN101596190A A DT O
BDNF CN101596190A A NNP I-UN
gene CN101596190A A NN O
variation CN101596190A A NN O
stated CN101596190A A VBN O
herein CN101596190A A NN O
comprises CN101596190A A VBZ O
that CN101596190A A IN O
valine CN101596190A A NN O
at CN101596190A A IN O
the CN101596190A A DT O
66th CN101596190A A CD O
position CN101596190A A NN O
of CN101596190A A IN O
the CN101596190A A DT O
BDNF CN101596190A A NNP I-UN
is CN101596190A A VBZ O
mutated CN101596190A A VBN O
into CN101596190A A IN O
methionine CN101596190A A NN O
. CN101596190A A . O

Application CN103251667A T NN O
of CN103251667A T IN O
general CN103251667A T JJ O
inula CN103251667A T NN O
helenium CN103251667A T NN O
sesquiterpene CN103251667A T NN O
lactone CN103251667A T NN O
in CN103251667A T IN O
preparation CN103251667A T NN O
of CN103251667A T IN O
medicine CN103251667A T NN O
for CN103251667A T IN O
treating CN103251667A T VBG O
rheumatoid CN103251667A T JJ O
arthritis CN103251667A T NN O
. CN103251667A T . O

The CN103251667A A DT O
results CN103251667A A NNS O
of CN103251667A A IN O
animal CN103251667A A JJ O
pharmacodynamic CN103251667A A JJ O
tests CN103251667A A NNS O
show CN103251667A A VBP O
that CN103251667A A IN O
the CN103251667A A DT O
general CN103251667A A JJ O
inula CN103251667A A NN O
helenium CN103251667A A NN O
sesquiterpene CN103251667A A NN O
lactone CN103251667A A NN O
, CN103251667A A , O
the CN103251667A A DT O
alantolactone CN103251667A A NN O
and CN103251667A A CC O
the CN103251667A A DT O
isoalantolactone CN103251667A A NN O
all CN103251667A A DT O
can CN103251667A A MD O
inhibit CN103251667A A VB O
the CN103251667A A DT O
clinical CN103251667A A JJ O
onset CN103251667A A NN O
of CN103251667A A IN O
CIA CN103251667A A NNP O
( CN103251667A A ( O
Collagen-induced CN103251667A A NNP O
Arthritis CN103251667A A NNP O
) CN103251667A A ) O
, CN103251667A A , O
obviously CN103251667A A RB O
inhibit CN103251667A A VBZ O
the CN103251667A A DT O
morbidity CN103251667A A NN O
of CN103251667A A IN O
CIA CN103251667A A NNP O
, CN103251667A A , O
obviously CN103251667A A RB O
reduce CN103251667A A VB O
the CN103251667A A DT O
level CN103251667A A NN O
of CN103251667A A IN O
IFN CN103251667A A NNP I-UN
( CN103251667A A ( I-UN
Interferon CN103251667A A NNP I-UN
) CN103251667A A ) I-UN
-gamma CN103251667A A NN I-UN
, CN103251667A A , O
and CN103251667A A CC O
remarkably CN103251667A A RB O
inhibit CN103251667A A VB O
the CN103251667A A DT O
generation CN103251667A A NN O
of CN103251667A A IN O
IL CN103251667A A NNP I-UN
( CN103251667A A ( I-UN
Interleukin CN103251667A A NNP I-UN
) CN103251667A A ) I-UN
-17 CN103251667A A NN I-UN
. CN103251667A A . O

Methods WO2014139014A1 T NNS O
and WO2014139014A1 T CC O
compositions WO2014139014A1 T NNS O
for WO2014139014A1 T IN O
the WO2014139014A1 T DT O
inhibition WO2014139014A1 T NN O
of WO2014139014A1 T IN O
vascular WO2014139014A1 T JJ I-UN
endothelial WO2014139014A1 T JJ I-UN
growth WO2014139014A1 T NN I-UN
factor WO2014139014A1 T NN I-UN
activity WO2014139014A1 T NN O
and WO2014139014A1 T CC O
vascular WO2014139014A1 T JJ O
permeability WO2014139014A1 T NN O
. WO2014139014A1 T . O

Methods WO2014139014A1 A NNS O
of WO2014139014A1 A IN O
altering WO2014139014A1 A VBG O
microenvironmental WO2014139014A1 A JJ O
levels WO2014139014A1 A NNS O
of WO2014139014A1 A IN O
Vascular WO2014139014A1 A NNP I-UN
Endothelial WO2014139014A1 A NNP I-UN
Growth WO2014139014A1 A NNP I-UN
Factor WO2014139014A1 A NNP I-UN
in WO2014139014A1 A IN O
a WO2014139014A1 A DT O
subject WO2014139014A1 A NN O
are WO2014139014A1 A VBP O
disclosed WO2014139014A1 A VBN O
. WO2014139014A1 A . O

The WO2014139014A1 A DT O
methods WO2014139014A1 A NNS O
include WO2014139014A1 A VBP O
providing WO2014139014A1 A VBG O
a WO2014139014A1 A DT O
Granzyme WO2014139014A1 A NNP I-UN
B WO2014139014A1 A NNP I-UN
( WO2014139014A1 A ( O
GzmB WO2014139014A1 A NNP I-UN
) WO2014139014A1 A ) O
inhibitor WO2014139014A1 A NN O
to WO2014139014A1 A TO O
an WO2014139014A1 A DT O
area WO2014139014A1 A NN O
of WO2014139014A1 A IN O
inflammation WO2014139014A1 A NN O
. WO2014139014A1 A . O

The WO2014139014A1 A DT O
Granzyme WO2014139014A1 A NNP I-UN
B WO2014139014A1 A NNP I-UN
inhibitor WO2014139014A1 A NN O
can WO2014139014A1 A MD O
be WO2014139014A1 A VB O
comprised WO2014139014A1 A VBN O
of WO2014139014A1 A IN O
, WO2014139014A1 A , O
but WO2014139014A1 A CC O
not WO2014139014A1 A RB O
limited WO2014139014A1 A JJ O
to WO2014139014A1 A TO O
, WO2014139014A1 A , O
a WO2014139014A1 A DT O
nucleic WO2014139014A1 A JJ O
acid WO2014139014A1 A NN O
, WO2014139014A1 A , O
a WO2014139014A1 A DT O
polypeptide WO2014139014A1 A NN O
, WO2014139014A1 A , O
a WO2014139014A1 A DT O
Granzyme WO2014139014A1 A NNP I-UN
B WO2014139014A1 A NNP I-UN
specific WO2014139014A1 A JJ O
antibody WO2014139014A1 A NN O
, WO2014139014A1 A , O
a WO2014139014A1 A DT O
Granzyme WO2014139014A1 A NNP I-UN
B WO2014139014A1 A NNP I-UN
antibody WO2014139014A1 A NN O
derivative WO2014139014A1 A JJ O
, WO2014139014A1 A , O
or WO2014139014A1 A CC O
a WO2014139014A1 A DT O
small WO2014139014A1 A JJ O
molecule WO2014139014A1 A NN O
. WO2014139014A1 A . O

Transdermal US20050100589 T JJ O
administration US20050100589 T NN O
of US20050100589 T IN O
ace US20050100589 T JJ I-UN
inhibitors US20050100589 T NNS O
. US20050100589 T . O

Disclosed US20050100589 A VBN O
is US20050100589 A VBZ O
a US20050100589 A DT O
dermal US20050100589 A JJ O
composition US20050100589 A NN O
comprising US20050100589 A VBG O
enalapril US20050100589 A JJ O
ethyl US20050100589 A JJ O
ester US20050100589 A NN O
or US20050100589 A CC O
another US20050100589 A DT O
prodrug US20050100589 A JJ O
corresponding US20050100589 A NN O
to US20050100589 A TO O
a US20050100589 A DT O
pharmaceutically US20050100589 A RB O
active US20050100589 A JJ O
form US20050100589 A NN O
of US20050100589 A IN O
an US20050100589 A DT O
ACE US20050100589 A NNP I-UN
inhibitor US20050100589 A NN O
in US20050100589 A IN O
an US20050100589 A DT O
amount US20050100589 A NN O
corresponding US20050100589 A VBG O
to US20050100589 A TO O
a US20050100589 A DT O
therapeutically US20050100589 A RB O
effective US20050100589 A JJ O
amount US20050100589 A NN O
of US20050100589 A IN O
enalaprilat US20050100589 A JJ O
( US20050100589 A ( O
or US20050100589 A CC O
other US20050100589 A JJ O
pharmaceutically US20050100589 A RB O
active US20050100589 A JJ O
form US20050100589 A NN O
of US20050100589 A IN O
enalapri US20050100589 A NN O
) US20050100589 A ) O
or US20050100589 A CC O
pharmaceutically US20050100589 A RB O
active US20050100589 A JJ O
form US20050100589 A NN O
of US20050100589 A IN O
the US20050100589 A DT O
ACE US20050100589 A NNP I-UN
inhibitor US20050100589 A NN O
in US20050100589 A IN O
admixture US20050100589 A NN O
with US20050100589 A IN O
a US20050100589 A DT O
pharmaceutically US20050100589 A RB O
acceptable US20050100589 A JJ O
carrier US20050100589 A NN O
. US20050100589 A . O

Inhalable US20110311618 T JJ O
particles US20110311618 T NNS O
comprising US20110311618 T VBG O
tiotropium US20110311618 T NN O
. US20110311618 T . O

The US20110311618 A DT O
present US20110311618 A JJ O
invention US20110311618 A NN O
relates US20110311618 A VBZ O
to US20110311618 A TO O
inhalable US20110311618 A JJ O
particles US20110311618 A NNS O
comprising US20110311618 A VBG O
a US20110311618 A DT O
stabilized US20110311618 A VBN O
amorphous US20110311618 A JJ O
form US20110311618 A NN O
of US20110311618 A IN O
tiotropium US20110311618 A NN O
with US20110311618 A IN O
a US20110311618 A DT O
stabilizing US20110311618 A NN O
agent US20110311618 A NN O
. US20110311618 A . O

It US20110311618 A PRP O
also US20110311618 A RB O
relates US20110311618 A VBZ O
to US20110311618 A TO O
inhalable US20110311618 A JJ O
particles US20110311618 A NNS O
comprising US20110311618 A VBG O
a US20110311618 A DT O
stabilized US20110311618 A VBN O
amorphous US20110311618 A JJ O
form US20110311618 A NN O
of US20110311618 A IN O
tiotropium US20110311618 A NN O
with US20110311618 A IN O
a US20110311618 A DT O
stabilizing US20110311618 A NN O
agent US20110311618 A NN O
mixed US20110311618 A JJ O
with US20110311618 A IN O
one US20110311618 A CD O
or US20110311618 A CC O
more US20110311618 A JJR O
coarse US20110311618 A JJ O
excipients US20110311618 A NNS O
having US20110311618 A VBG O
a US20110311618 A DT O
mean US20110311618 A JJ O
particle US20110311618 A NN O
size US20110311618 A NN O
of US20110311618 A IN O
15 US20110311618 A CD O
to US20110311618 A TO O
250 US20110311618 A CD O
μm US20110311618 A NNS O
. US20110311618 A . O

It US20110311618 A PRP O
also US20110311618 A RB O
relates US20110311618 A VBZ O
to US20110311618 A TO O
a US20110311618 A DT O
pharmaceutical US20110311618 A JJ O
composition US20110311618 A NN O
comprising US20110311618 A VBG O
the US20110311618 A DT O
inhalable US20110311618 A JJ O
particles US20110311618 A NNS O
of US20110311618 A IN O
the US20110311618 A DT O
invention US20110311618 A NN O
, US20110311618 A , O
to US20110311618 A TO O
a US20110311618 A DT O
process US20110311618 A NN O
for US20110311618 A IN O
their US20110311618 A PRP$ O
preparation US20110311618 A NN O
, US20110311618 A , O
and US20110311618 A CC O
to US20110311618 A TO O
their US20110311618 A PRP$ O
use US20110311618 A NN O
for US20110311618 A IN O
the US20110311618 A DT O
preparation US20110311618 A NN O
of US20110311618 A IN O
a US20110311618 A DT O
medicament US20110311618 A NN O
for US20110311618 A IN O
the US20110311618 A DT O
treatment US20110311618 A NN O
of US20110311618 A IN O
asthma US20110311618 A NN O
or US20110311618 A CC O
chronic US20110311618 A JJ O
obstructive US20110311618 A JJ O
pulmonary US20110311618 A JJ O
disease US20110311618 A NN O
( US20110311618 A ( O
COPD US20110311618 A NNP O
) US20110311618 A ) O
. US20110311618 A . O

oral US7531557 T JJ O
bioavailablility US7531557 T NN O
, US7531557 T , O
oral US7531557 T JJ O
administration US7531557 T NN O
; US7531557 T : O
inhibition US7531557 T NN O
of US7531557 T IN O
orexigenic US7531557 T JJ O
effects US7531557 T NNS O
; US7531557 T : O
side US7531557 T NN O
effects US7531557 T NNS O
reduction US7531557 T NN O
; US7531557 T : O
alcoholism US7531557 T NN O
; US7531557 T : O
6- US7531557 T JJ O
( US7531557 T ( O
2-Fluoro-4- US7531557 T JJ O
{ US7531557 T ( O
[ US7531557 T JJ O
2- US7531557 T JJ O
( US7531557 T ( O
tetrahydro-pyran-4-yl US7531557 T JJ O
) US7531557 T ) O
-ethylamino US7531557 T NN O
] US7531557 T JJ O
-methyl US7531557 T NN O
} US7531557 T ) O
-phenoxy US7531557 T NNP O
) US7531557 T ) O
-nicotinamide US7531557 T NN O
. US7531557 T . O

Medicament CN101574343B T JJ O
composition CN101574343B T NN O
for CN101574343B T IN O
treating CN101574343B T VBG O
diabetes CN101574343B T NNS O
. CN101574343B T . O

1-benzyl-5-piperazin-1-yl-3,4 EP1708713B1 T JJ O
dihydro-1h-quinazolin-2-one EP1708713B1 T NN O
derivatives EP1708713B1 T NNS O
and EP1708713B1 T CC O
the EP1708713B1 T DT O
respective EP1708713B1 T JJ O
1h-benzo EP1708713B1 T JJ O
( EP1708713B1 T ( O
1,2,6 EP1708713B1 T CD O
) EP1708713B1 T ) O
thiadiazine-2,2-dioxide EP1708713B1 T NN O
and EP1708713B1 T CC O
1,4-dihydro-benzo EP1708713B1 T JJ O
( EP1708713B1 T ( O
d EP1708713B1 T NN O
) EP1708713B1 T ) O
( EP1708713B1 T ( O
1,3 EP1708713B1 T CD O
) EP1708713B1 T ) O
oxazin-2-one EP1708713B1 T NN O
derivatives EP1708713B1 T NNS O
as EP1708713B1 T IN O
modulators EP1708713B1 T NNS O
of EP1708713B1 T IN O
the EP1708713B1 T DT O
5-hydroxytryptamine EP1708713B1 T JJ O
receptor EP1708713B1 T NN O
( EP1708713B1 T ( O
5-ht EP1708713B1 T JJ O
) EP1708713B1 T ) O
for EP1708713B1 T IN O
the EP1708713B1 T DT O
treatment EP1708713B1 T NN O
of EP1708713B1 T IN O
diseases EP1708713B1 T NNS O
of EP1708713B1 T IN O
the EP1708713B1 T DT O
central EP1708713B1 T JJ O
nervous EP1708713B1 T JJ O
system EP1708713B1 T NN O
. EP1708713B1 T . O

Novel WO2007046747A1 T NNP O
bicyclic WO2007046747A1 T JJ O
sulfonamides WO2007046747A1 T NNS O
for WO2007046747A1 T IN O
use WO2007046747A1 T NN O
as WO2007046747A1 T IN O
glucocorticoid WO2007046747A1 T JJ I-UN
receptor WO2007046747A1 T NN I-UN
modulators WO2007046747A1 T NNS O
in WO2007046747A1 T IN O
the WO2007046747A1 T DT O
treatment WO2007046747A1 T NN O
of WO2007046747A1 T IN O
inflammatory WO2007046747A1 T JJ O
diseases WO2007046747A1 T NNS O
. WO2007046747A1 T . O

Compounds WO2007046747A1 A NNS O
of WO2007046747A1 A IN O
formula WO2007046747A1 A NN O
( WO2007046747A1 A ( O
I WO2007046747A1 A PRP O
) WO2007046747A1 A ) O
: WO2007046747A1 A : O
or WO2007046747A1 A CC O
a WO2007046747A1 A DT O
pharmaceutically WO2007046747A1 A RB O
acceptable WO2007046747A1 A JJ O
salt WO2007046747A1 A NN O
thereof WO2007046747A1 A NN O
; WO2007046747A1 A : O
compositions WO2007046747A1 A NNS O
comprising WO2007046747A1 A VBG O
them WO2007046747A1 A PRP O
, WO2007046747A1 A , O
processes WO2007046747A1 A VBZ O
for WO2007046747A1 A IN O
preparing WO2007046747A1 A VBG O
them WO2007046747A1 A PRP O
and WO2007046747A1 A CC O
their WO2007046747A1 A PRP$ O
use WO2007046747A1 A NN O
in WO2007046747A1 A IN O
medical WO2007046747A1 A JJ O
therapy WO2007046747A1 A NN O
( WO2007046747A1 A ( O
for WO2007046747A1 A IN O
example WO2007046747A1 A NN O
modulating WO2007046747A1 A VBG O
the WO2007046747A1 A DT O
glucocorticoid WO2007046747A1 A NN I-UN
receptor WO2007046747A1 A NN I-UN
in WO2007046747A1 A IN O
a WO2007046747A1 A DT O
warm WO2007046747A1 A NN O
blooded WO2007046747A1 A VBN O
animal WO2007046747A1 A NN O
) WO2007046747A1 A ) O
. WO2007046747A1 A . O

Poly CA2382631C T NNP O
( CA2382631C T ( O
ether-thioether CA2382631C T NN O
) CA2382631C T ) O
, CA2382631C T , O
poly CA2382631C T JJ O
( CA2382631C T ( O
ether-sulfoxide CA2382631C T JJ O
) CA2382631C T ) O
and CA2382631C T CC O
poly CA2382631C T JJ O
( CA2382631C T ( O
ether-sulfone CA2382631C T NN O
) CA2382631C T ) O
nucleic CA2382631C T NN O
acids CA2382631C T NNS O
. CA2382631C T . O

Medicament CN102772729A T NN O
for CN102772729A T IN O
treating CN102772729A T VBG O
nasitis CN102772729A T NN O
and CN102772729A T CC O
preparation CN102772729A T NN O
method CN102772729A T NN O
thereof CN102772729A T NN O
. CN102772729A T . O

Fermented WO2013187755A1 T VBN O
infant WO2013187755A1 T JJ O
formula WO2013187755A1 T NN O
with WO2013187755A1 T IN O
non WO2013187755A1 T JJ O
digestible WO2013187755A1 T JJ O
oligosaccharides WO2013187755A1 T NNS O
. WO2013187755A1 T . O

Cyclothiocarbamate US8329690 T NNP O
derivatives US8329690 T NNS O
as US8329690 T IN O
progesterone US8329690 T NN I-UN
receptor US8329690 T NN I-UN
modulators US8329690 T NNS O
. US8329690 T . O

Methods US8329690 A NNS O
of US8329690 A IN O
using US8329690 A VBG O
compounds US8329690 A NNS O
which US8329690 A WDT O
are US8329690 A VBP O
progesterone US8329690 A JJ I-UN
receptor US8329690 A NN I-UN
agonists US8329690 A NNS O
for US8329690 A IN O
contraception US8329690 A NN O
and US8329690 A CC O
the US8329690 A DT O
treatment US8329690 A NN O
of US8329690 A IN O
progesterone-related US8329690 A JJ O
maladies US8329690 A NNS O
alone US8329690 A RB O
or US8329690 A CC O
in US8329690 A IN O
combination US8329690 A NN O
with US8329690 A IN O
an US8329690 A DT O
estrogen US8329690 A NN I-UN
receptor US8329690 A NN I-UN
agonist US8329690 A NN O
or US8329690 A CC O
progesterone US8329690 A NN I-UN
receptor US8329690 A NN I-UN
antagonist US8329690 A NN O
are US8329690 A VBP O
provided US8329690 A VBN O
. US8329690 A . O

Pharmaceutical WO2006091009A1 T JJ O
composition WO2006091009A1 T NN O
for WO2006091009A1 T IN O
the WO2006091009A1 T DT O
treatment WO2006091009A1 T NN O
of WO2006091009A1 T IN O
cancer WO2006091009A1 T NN O
comprising WO2006091009A1 T VBG O
lmh-ra WO2006091009A1 T JJ O
complex WO2006091009A1 T NN O
. WO2006091009A1 T . O

Provided WO2006091009A1 A VBN O
is WO2006091009A1 A VBZ O
a WO2006091009A1 A DT O
pharmaceutical WO2006091009A1 A JJ O
composition WO2006091009A1 A NN O
for WO2006091009A1 A IN O
the WO2006091009A1 A DT O
treatment WO2006091009A1 A NN O
of WO2006091009A1 A IN O
liver WO2006091009A1 A NN O
cancer WO2006091009A1 A NN O
, WO2006091009A1 A , O
including WO2006091009A1 A VBG O
a WO2006091009A1 A DT O
layered WO2006091009A1 A JJ O
metal WO2006091009A1 A NN O
hydroxide-retinoic WO2006091009A1 A JJ O
acid WO2006091009A1 A NN O
( WO2006091009A1 A ( O
LMH-RA WO2006091009A1 A NNP O
) WO2006091009A1 A ) O
hybrid WO2006091009A1 A NN O
as WO2006091009A1 A IN O
a WO2006091009A1 A DT O
novel WO2006091009A1 A JJ O
drug WO2006091009A1 A NN O
delivery WO2006091009A1 A NN O
system WO2006091009A1 A NN O
which WO2006091009A1 A WDT O
shows WO2006091009A1 A VBZ O
few WO2006091009A1 A JJ O
side WO2006091009A1 A JJ O
effects WO2006091009A1 A NNS O
of WO2006091009A1 A IN O
retinoic WO2006091009A1 A NN O
acid WO2006091009A1 A NN O
, WO2006091009A1 A , O
good WO2006091009A1 A JJ O
drug WO2006091009A1 A NN O
stability WO2006091009A1 A NN O
, WO2006091009A1 A , O
sustained WO2006091009A1 A VBN O
drug WO2006091009A1 A NN O
release WO2006091009A1 A NN O
, WO2006091009A1 A , O
and WO2006091009A1 A CC O
improved WO2006091009A1 A JJ O
drug WO2006091009A1 A NN O
delivery WO2006091009A1 A NN O
efficiency WO2006091009A1 A NN O
. WO2006091009A1 A . O

Powder CN103110643A T NNP O
injection CN103110643A T NN O
of CN103110643A T IN O
drug CN103110643A T NN O
composition CN103110643A T NN O
of CN103110643A T IN O
ceftazidime CN103110643A T NN O
for CN103110643A T IN O
injection CN103110643A T NN O
. CN103110643A T . O

The CN103110643A A DT O
invention CN103110643A A NN O
provides CN103110643A A VBZ O
powder CN103110643A A JJR O
injection CN103110643A A NN O
of CN103110643A A IN O
a CN103110643A A DT O
drug CN103110643A A NN O
composition CN103110643A A NN O
of CN103110643A A IN O
ceftazidime CN103110643A A NN O
for CN103110643A A IN O
injection CN103110643A A NN O
, CN103110643A A , O
relating CN103110643A A VBG O
to CN103110643A A TO O
the CN103110643A A DT O
fields CN103110643A A NNS O
of CN103110643A A IN O
pharmaceutical CN103110643A A JJ O
preparations CN103110643A A NNS O
and CN103110643A A CC O
preparation CN103110643A A NN O
methods CN103110643A A NNS O
and CN103110643A A CC O
mainly CN103110643A A RB O
solving CN103110643A A VBG O
the CN103110643A A DT O
problems CN103110643A A NNS O
that CN103110643A A WDT O
single CN103110643A A JJ O
preparations CN103110643A A NNS O
of CN103110643A A IN O
ceftazidime CN103110643A A NN O
and CN103110643A A CC O
metronidazole CN103110643A A NN O
in CN103110643A A IN O
the CN103110643A A DT O
prior CN103110643A A JJ O
art CN103110643A A NN O
have CN103110643A A VBP O
great CN103110643A A JJ O
dosages CN103110643A A NNS O
, CN103110643A A , O
poor CN103110643A A JJ O
treatment CN103110643A A NN O
effects CN103110643A A NNS O
after CN103110643A A IN O
being CN103110643A A VBG O
combined CN103110643A A VBN O
and CN103110643A A CC O
big CN103110643A A JJ O
side CN103110643A A NN O
effects CN103110643A A NNS O
. CN103110643A A . O

The CN103110643A A DT O
drug CN103110643A A NN O
composition CN103110643A A NN O
comprises CN103110643A A VBZ O
main CN103110643A A JJ O
drugs CN103110643A A NNS O
such CN103110643A A JJ O
as CN103110643A A IN O
ceftazidime CN103110643A A NN O
and CN103110643A A CC O
metronidazole CN103110643A A JJ O
lipid CN103110643A A JJ O
microspheres CN103110643A A NNS O
and CN103110643A A CC O
an CN103110643A A DT O
auxiliary CN103110643A A JJ O
material CN103110643A A NN O
arginine CN103110643A A NN O
, CN103110643A A , O
wherein CN103110643A A VBP O
the CN103110643A A DT O
weight CN103110643A A NN O
ratio CN103110643A A NN O
of CN103110643A A IN O
ceftazidime CN103110643A A NN O
to CN103110643A A TO O
metronidazole CN103110643A A VB O
lipid CN103110643A A JJ O
microspheres CN103110643A A NNS O
is CN103110643A A VBZ O
( CN103110643A A ( O
100:3 CN103110643A A CD O
) CN103110643A A ) O
- CN103110643A A : O
( CN103110643A A ( O
100:10 CN103110643A A CD O
) CN103110643A A ) O
; CN103110643A A : O
the CN103110643A A DT O
weight CN103110643A A NN O
ratio CN103110643A A NN O
of CN103110643A A IN O
ceftazidime CN103110643A A NN O
to CN103110643A A TO O
arginine CN103110643A A VB O
is CN103110643A A VBZ O
100:27 CN103110643A A CD O
; CN103110643A A : O
and CN103110643A A CC O
the CN103110643A A DT O
weight CN103110643A A NN O
of CN103110643A A IN O
the CN103110643A A DT O
metronidazole CN103110643A A NN O
lipid CN103110643A A JJ O
microspheres CN103110643A A NNS O
is CN103110643A A VBZ O
based CN103110643A A VBN O
on CN103110643A A IN O
metronidazole CN103110643A A NN O
. CN103110643A A . O

The CN103110643A A DT O
drug CN103110643A A NN O
composition CN103110643A A NN O
is CN103110643A A VBZ O
prepared CN103110643A A VBN O
into CN103110643A A IN O
powder CN103110643A A NN O
injection CN103110643A A NN O
. CN103110643A A . O

The CN103110643A A DT O
pH CN103110643A A JJ O
value CN103110643A A NN O
of CN103110643A A IN O
water CN103110643A A NN O
solution CN103110643A A NN O
of CN103110643A A IN O
the CN103110643A A DT O
drug CN103110643A A NN O
composition CN103110643A A NN O
is CN103110643A A VBZ O
5.0-7.0 CN103110643A A JJ O
. CN103110643A A . O

The CN103110643A A DT O
powder CN103110643A A NN O
injection CN103110643A A NN O
of CN103110643A A IN O
the CN103110643A A DT O
drug CN103110643A A NN O
composition CN103110643A A NN O
provided CN103110643A A VBN O
by CN103110643A A IN O
the CN103110643A A DT O
invention CN103110643A A NN O
not CN103110643A A RB O
only CN103110643A A RB O
has CN103110643A A VBZ O
high CN103110643A A JJ O
curative CN103110643A A JJ O
effect CN103110643A A NN O
but CN103110643A A CC O
also CN103110643A A RB O
can CN103110643A A MD O
reduce CN103110643A A VB O
the CN103110643A A DT O
dosage CN103110643A A NN O
of CN103110643A A IN O
metronidazole CN103110643A A NN O
by CN103110643A A IN O
over CN103110643A A IN O
80 CN103110643A A CD O
% CN103110643A A NN O
, CN103110643A A , O
thus CN103110643A A RB O
greatly CN103110643A A RB O
reducing CN103110643A A VBG O
or CN103110643A A CC O
avoiding CN103110643A A VBG O
the CN103110643A A DT O
toxic CN103110643A A NN O
and CN103110643A A CC O
side CN103110643A A NN O
effects CN103110643A A NNS O
, CN103110643A A , O
especially CN103110643A A RB O
gastrointestinal CN103110643A A JJ O
reactions CN103110643A A NNS O
including CN103110643A A VBG O
nausea CN103110643A A NN O
, CN103110643A A , O
emesis CN103110643A A NN O
, CN103110643A A , O
anorexia CN103110643A A NN O
, CN103110643A A , O
abdominal CN103110643A A JJ O
cramp CN103110643A A NN O
and CN103110643A A CC O
neurotoxicity CN103110643A A NN O
, CN103110643A A , O
of CN103110643A A IN O
metronidazole CN103110643A A NN O
and CN103110643A A CC O
further CN103110643A A RBR O
reducing CN103110643A A VBG O
the CN103110643A A DT O
occurrence CN103110643A A NN O
rate CN103110643A A NN O
of CN103110643A A IN O
adverse CN103110643A A JJ O
reactions CN103110643A A NNS O
. CN103110643A A . O

Angiostatic CA2425849C T JJ O
steroids CA2425849C T NNS O
. CA2425849C T . O

Methods US20100040637 T NNS O
and US20100040637 T CC O
Composition US20100040637 T NNP O
for US20100040637 T IN O
Treating US20100040637 T NNP O
Diseases US20100040637 T NNP O
Targeting US20100040637 T NNP O
Prominin-1 US20100040637 T NNP I-UN
( US20100040637 T ( O
CD133 US20100040637 T NNP I-UN
) US20100040637 T ) O
. US20100040637 T . O

Methods US20100040637 A NNS O
and US20100040637 A CC O
compositions US20100040637 A NNS O
for US20100040637 A IN O
detecting US20100040637 A VBG O
and US20100040637 A CC O
treating US20100040637 A VBG O
diseases US20100040637 A NNS O
, US20100040637 A , O
especially US20100040637 A RB O
cancer US20100040637 A NN O
, US20100040637 A , O
and US20100040637 A CC O
particularly US20100040637 A RB O
breast US20100040637 A NN O
, US20100040637 A , O
bladder US20100040637 A NN O
, US20100040637 A , O
colon US20100040637 A NN O
, US20100040637 A , O
gastrointestinal US20100040637 A JJ O
, US20100040637 A , O
kidney US20100040637 A NN O
, US20100040637 A , O
liver US20100040637 A NN O
, US20100040637 A , O
lung US20100040637 A NN O
, US20100040637 A , O
melanoma US20100040637 A NN O
, US20100040637 A , O
ovary US20100040637 A JJ O
, US20100040637 A , O
pancreatic US20100040637 A JJ O
, US20100040637 A , O
pharyngeal US20100040637 A JJ O
, US20100040637 A , O
prostate US20100040637 A JJ O
cancer US20100040637 A NN O
and US20100040637 A CC O
renal US20100040637 A JJ O
, US20100040637 A , O
associated US20100040637 A VBN O
with US20100040637 A IN O
differential US20100040637 A JJ O
expression US20100040637 A NN O
of US20100040637 A IN O
prominin-1 US20100040637 A NN I-UN
( US20100040637 A ( O
CD133 US20100040637 A NNP I-UN
) US20100040637 A ) O
in US20100040637 A IN O
disease US20100040637 A NN O
cells US20100040637 A NNS O
compared US20100040637 A VBN O
to US20100040637 A TO O
healthy US20100040637 A JJ O
cells US20100040637 A NNS O
. US20100040637 A . O

Also US20100040637 A RB O
provided US20100040637 A VBN O
are US20100040637 A VBP O
antagonists US20100040637 A NNS O
or US20100040637 A CC O
agonists US20100040637 A NNS O
of US20100040637 A IN O
prominin-1 US20100040637 A NN I-UN
, US20100040637 A , O
and US20100040637 A CC O
methods US20100040637 A NNS O
for US20100040637 A IN O
screening US20100040637 A VBG O
agents US20100040637 A NNS O
that US20100040637 A WDT O
modulate US20100040637 A VBP O
the US20100040637 A DT O
prominin-1 US20100040637 A JJ I-UN
level US20100040637 A NN O
or US20100040637 A CC O
activity US20100040637 A NN O
in US20100040637 A IN O
vivo US20100040637 A NN O
or US20100040637 A CC O
in US20100040637 A IN O
vitro US20100040637 A NN O
. US20100040637 A . O

Chinese CN102579931A T JJ O
gall CN102579931A T NN O
sulfur CN102579931A T NN O
powder CN102579931A T NN O
and CN102579931A T CC O
preparation CN102579931A T NN O
method CN102579931A T NN O
thereof CN102579931A T NN O
. CN102579931A T . O

E-2- CA2321122C T JJ O
[ CA2321122C T JJ O
4- CA2321122C T JJ O
( CA2321122C T ( O
4-chloro-1,2-diphenyl-but-1-enyl CA2321122C T JJ O
) CA2321122C T ) O
phenoxy CA2321122C T NN O
] CA2321122C T NN O
ethanol CA2321122C T NN O
and CA2321122C T CC O
pharmaceutical CA2321122C T JJ O
compositions CA2321122C T NNS O
thereof CA2321122C T NN O
. CA2321122C T . O

Antitumor EP2370097A1 T NNP O
combinations EP2370097A1 T NNS O
containing EP2370097A1 T VBG O
antibodies EP2370097A1 T NNS O
recognizing EP2370097A1 T VBG O
specifically EP2370097A1 T RB O
cd38 EP2370097A1 T JJ I-UN
and EP2370097A1 T CC O
cylophosphamide EP2370097A1 T NN O
. EP2370097A1 T . O

Pharmaceutical EP2370097A1 A JJ O
composition EP2370097A1 A NN O
comprising EP2370097A1 A VBG O
an EP2370097A1 A DT O
antibody EP2370097A1 A NN O
specifically EP2370097A1 A RB O
recognizing EP2370097A1 A VBG O
CD38 EP2370097A1 A NNP I-UN
and EP2370097A1 A CC O
cyclophosphamide EP2370097A1 A NN O
. EP2370097A1 A . O

Isolated EP1930420A1 T VBN O
nucleic EP1930420A1 T JJ O
acid EP1930420A1 T JJ O
molecules EP1930420A1 T NNS O
encoding EP1930420A1 T VBG O
a EP1930420A1 T DT O
bacterial EP1930420A1 T JJ O
uracil EP1930420A1 T JJ I-UN
phosphoribosyl-transferase EP1930420A1 T NN I-UN
enzyme EP1930420A1 T NN I-UN
, EP1930420A1 T , O
cells EP1930420A1 T NNS O
transformed EP1930420A1 T VBD O
therewith EP1930420A1 T NN O
and EP1930420A1 T CC O
uses EP1930420A1 T VBZ O
thereof EP1930420A1 T NN O
. EP1930420A1 T . O

Disclosed EP1930420A1 A VBN O
herein EP1930420A1 A NNS O
are EP1930420A1 A VBP O
novel EP1930420A1 A JJ O
polynucleotides EP1930420A1 A NNS O
encoding EP1930420A1 A VBG O
a EP1930420A1 A DT O
uracil EP1930420A1 A JJ I-UN
phosphoribosyl EP1930420A1 A NN I-UN
transferase EP1930420A1 A NN I-UN
, EP1930420A1 A , O
each EP1930420A1 A DT O
being EP1930420A1 A VBG O
derived EP1930420A1 A VBN O
from EP1930420A1 A IN O
Salmonella EP1930420A1 A NNP O
typhimurium EP1930420A1 A NN O
. EP1930420A1 A . O

The EP1930420A1 A DT O
disclosed EP1930420A1 A JJ O
uracil EP1930420A1 A NN I-UN
phosphoribosyl EP1930420A1 A NN I-UN
transferase EP1930420A1 A NN I-UN
protein EP1930420A1 A NN O
is EP1930420A1 A VBZ O
useful EP1930420A1 A JJ O
in EP1930420A1 A IN O
sensitizing EP1930420A1 A VBG O
human EP1930420A1 A JJ O
cancer EP1930420A1 A NN O
cells EP1930420A1 A NNS O
to EP1930420A1 A TO O
treatment EP1930420A1 A NN O
with EP1930420A1 A IN O
anti-cancer EP1930420A1 A JJ O
agents EP1930420A1 A NNS O
such EP1930420A1 A JJ O
as EP1930420A1 A IN O
5-Fluorouracil EP1930420A1 A JJ O
. EP1930420A1 A . O

Application CN103462961A T NN O
of CN103462961A T IN O
Incarviatone CN103462961A T NNP O
A CN103462961A T NNP O
in CN103462961A T IN O
medicaments CN103462961A T NNS O
for CN103462961A T IN O
treating CN103462961A T VBG O
bladder CN103462961A T NN O
cancer CN103462961A T NN O
. CN103462961A T . O

Synthesis CN103396521A T NN O
and CN103396521A T CC O
micellization CN103396521A T NN O
application CN103396521A T NN O
of CN103396521A T IN O
amphiphilic CN103396521A T JJ O
beta-cyclodextrin CN103396521A T JJ O
star CN103396521A T NN O
polymer CN103396521A T NN O
. CN103396521A T . O

Sulfonamide EP2079701A1 T RB O
substituted EP2079701A1 T VBN O
pyrazoline EP2079701A1 T NN O
compounds EP2079701A1 T NNS O
, EP2079701A1 T , O
their EP2079701A1 T PRP$ O
preparation EP2079701A1 T NN O
and EP2079701A1 T CC O
use EP2079701A1 T NN O
as EP2079701A1 T IN O
cb1 EP2079701A1 T NN O
modulators EP2079701A1 T NNS O
. EP2079701A1 T . O

The EP2079701A1 A DT O
present EP2079701A1 A JJ O
invention EP2079701A1 A NN O
relates EP2079701A1 A VBZ O
to EP2079701A1 A TO O
substituted EP2079701A1 A VB O
pyrazoline EP2079701A1 A JJ O
compounds EP2079701A1 A NNS O
of EP2079701A1 A IN O
general EP2079701A1 A JJ O
formula EP2079701A1 A NN O
( EP2079701A1 A ( O
I EP2079701A1 A PRP O
) EP2079701A1 A ) O
, EP2079701A1 A , O
methods EP2079701A1 A NNS O
for EP2079701A1 A IN O
their EP2079701A1 A PRP$ O
preparation EP2079701A1 A NN O
, EP2079701A1 A , O
medicaments EP2079701A1 A NNS O
comprising EP2079701A1 A VBG O
these EP2079701A1 A DT O
compounds EP2079701A1 A NNS O
as EP2079701A1 A RB O
well EP2079701A1 A RB O
as EP2079701A1 A IN O
their EP2079701A1 A PRP$ O
use EP2079701A1 A NN O
for EP2079701A1 A IN O
the EP2079701A1 A DT O
preparation EP2079701A1 A NN O
of EP2079701A1 A IN O
a EP2079701A1 A DT O
medicament EP2079701A1 A NN O
for EP2079701A1 A IN O
the EP2079701A1 A DT O
treatment EP2079701A1 A NN O
of EP2079701A1 A IN O
humans EP2079701A1 A NNS O
and EP2079701A1 A CC O
animals EP2079701A1 A NNS O
. EP2079701A1 A . O

Application CN101708186A T NN O
of CN101708186A T IN O
arsenical CN101708186A T JJ O
sulphide CN101708186A T NN O
, CN101708186A T , O
such CN101708186A T JJ O
as CN101708186A T IN O
realgar CN101708186A T NN O
and CN101708186A T CC O
the CN101708186A T DT O
like CN101708186A T JJ O
, CN101708186A T , O
in CN101708186A T IN O
preparing CN101708186A T VBG O
medicine CN101708186A T NN O
resisting CN101708186A T VBG O
malignant CN101708186A T JJ O
tumours CN101708186A T NNS O
and CN101708186A T CC O
application CN101708186A T NN O
of CN101708186A T IN O
arsenical CN101708186A T JJ O
sulphide CN101708186A T NN O
in CN101708186A T IN O
preparing CN101708186A T VBG O
medicine CN101708186A T NN O
resisting CN101708186A T VBG O
bacteria CN101708186A T NNS O
. CN101708186A T . O

COMBINATION EP2588107A1 T NNP O
OF EP2588107A1 T IN O
A EP2588107A1 T NNP O
cMET EP2588107A1 T NN I-UN
INHIBITOR EP2588107A1 T NNP O
AND EP2588107A1 T CC O
AN EP2588107A1 T NNP O
ANTIBODY EP2588107A1 T NNP O
TO EP2588107A1 T NNP O
HGF EP2588107A1 T NNP I-UN
AND/OR EP2588107A1 T NNP O
cMET EP2588107A1 T NN I-UN
. EP2588107A1 T . O

Amyotrophic EP1539169A2 T JJ O
lateral EP1539169A2 T JJ O
sclerosis EP1539169A2 T NN O
treatment EP1539169A2 T NN O
with EP1539169A2 T IN O
cyclooxygenase-2 EP1539169A2 T JJ I-UN
inhibitors EP1539169A2 T NNS O
. EP1539169A2 T . O

The EP1539169A2 A DT O
method EP1539169A2 A NN O
comprises EP1539169A2 A VBZ O
administering EP1539169A2 A VBG O
to EP1539169A2 A TO O
a EP1539169A2 A DT O
subject EP1539169A2 A JJ O
one EP1539169A2 A CD O
or EP1539169A2 A CC O
more EP1539169A2 A JJR O
cyclooxygenase-2 EP1539169A2 A JJ I-UN
selective EP1539169A2 A JJ O
inhibitor EP1539169A2 A NN O
( EP1539169A2 A ( O
s EP1539169A2 A JJ O
) EP1539169A2 A ) O
or EP1539169A2 A CC O
isomer EP1539169A2 A NN O
( EP1539169A2 A ( O
s EP1539169A2 A JJ O
) EP1539169A2 A ) O
or EP1539169A2 A CC O
pharmaceutically EP1539169A2 A RB O
acceptable EP1539169A2 A JJ O
salt EP1539169A2 A NN O
( EP1539169A2 A ( O
s EP1539169A2 A NN O
) EP1539169A2 A ) O
, EP1539169A2 A , O
ester EP1539169A2 A FW O
( EP1539169A2 A ( O
s EP1539169A2 A NN O
) EP1539169A2 A ) O
, EP1539169A2 A , O
or EP1539169A2 A CC O
prodrug EP1539169A2 A NN O
( EP1539169A2 A ( O
s EP1539169A2 A PRP O
) EP1539169A2 A ) O
thereof EP1539169A2 A NN O
, EP1539169A2 A , O
in EP1539169A2 A IN O
combination EP1539169A2 A NN O
with EP1539169A2 A IN O
one EP1539169A2 A CD O
or EP1539169A2 A CC O
more EP1539169A2 A JJR O
second EP1539169A2 A JJ O
drugs EP1539169A2 A NNS O
, EP1539169A2 A , O
wherein EP1539169A2 A VBP O
the EP1539169A2 A DT O
amount EP1539169A2 A NN O
of EP1539169A2 A IN O
the EP1539169A2 A DT O
cyclooxygenase-2 EP1539169A2 A JJ I-UN
selective EP1539169A2 A JJ O
inhibitor EP1539169A2 A NN O
( EP1539169A2 A ( O
s EP1539169A2 A JJ O
) EP1539169A2 A ) O
or EP1539169A2 A CC O
isomer EP1539169A2 A NN O
( EP1539169A2 A ( O
s EP1539169A2 A JJ O
) EP1539169A2 A ) O
or EP1539169A2 A CC O
pharmaceutically EP1539169A2 A RB O
acceptable EP1539169A2 A JJ O
salt EP1539169A2 A NN O
( EP1539169A2 A ( O
s EP1539169A2 A NN O
) EP1539169A2 A ) O
, EP1539169A2 A , O
ester EP1539169A2 A FW O
( EP1539169A2 A ( O
s EP1539169A2 A NN O
) EP1539169A2 A ) O
, EP1539169A2 A , O
or EP1539169A2 A CC O
prodrug EP1539169A2 A NN O
( EP1539169A2 A ( O
s EP1539169A2 A PRP O
) EP1539169A2 A ) O
thereof EP1539169A2 A NN O
in EP1539169A2 A IN O
combination EP1539169A2 A NN O
with EP1539169A2 A IN O
the EP1539169A2 A DT O
amount EP1539169A2 A NN O
of EP1539169A2 A IN O
second EP1539169A2 A JJ O
drug EP1539169A2 A NN O
( EP1539169A2 A ( O
s EP1539169A2 A PRP O
) EP1539169A2 A ) O
constitutes EP1539169A2 A VBZ O
an EP1539169A2 A DT O
ALS EP1539169A2 A NNP O
treatment EP1539169A2 A NN O
, EP1539169A2 A , O
inhibition EP1539169A2 A NN O
or EP1539169A2 A CC O
prevention EP1539169A2 A NN O
effective EP1539169A2 A JJ O
amount EP1539169A2 A NN O
. EP1539169A2 A . O

Pulmonary CN101773478B T JJ O
targeting CN101773478B T VBG O
microsphere CN101773478B T NN O
of CN101773478B T IN O
veterinary CN101773478B T JJ O
ceftiofur CN101773478B T NN O
hydrochloride CN101773478B T NN O
and CN101773478B T CC O
preparation CN101773478B T NN O
method CN101773478B T NN O
thereof CN101773478B T NN O
. CN101773478B T . O

Process US20110183956 T NN O
for US20110183956 T IN O
the US20110183956 T DT O
synthesis US20110183956 T NN O
of US20110183956 T IN O
ezetimibe US20110183956 T NN O
and US20110183956 T CC O
intermediates US20110183956 T VBZ O
useful US20110183956 T JJ O
therefor US20110183956 T NN O
. US20110183956 T . O

Pyrimidyl US7582644 T NNP O
sulphone US7582644 T NN O
amide US7582644 T NN O
derivatives US7582644 T NNS O
as US7582644 T IN O
chemokine US7582644 T NN I-UN
receptor US7582644 T NN I-UN
modulators US7582644 T NNS O
. US7582644 T . O

Compound CN101003513A T NN O
in CN101003513A T IN O
quinazoline CN101003513A T JJ O
class CN101003513A T NN O
or CN101003513A T CC O
its CN101003513A T PRP$ O
pharmaceutical CN101003513A T JJ O
salt CN101003513A T NN O
preparation CN101003513A T NN O
method CN101003513A T NN O
, CN101003513A T , O
and CN101003513A T CC O
medical CN101003513A T JJ O
usage CN101003513A T NN O
. CN101003513A T . O

The CN101003513A A DT O
quinazoline CN101003513A A JJ O
compounds CN101003513A A NNS O
or CN101003513A A CC O
their CN101003513A A PRP$ O
pharmaceutically CN101003513A A RB O
acceptable CN101003513A A JJ O
salts CN101003513A A NNS O
as CN101003513A A IN O
shown CN101003513A A VBN O
in CN101003513A A IN O
general CN101003513A A JJ O
formula CN101003513A A NN O
I CN101003513A A PRP O
can CN101003513A A MD O
inhibit CN101003513A A VB O
epidermal CN101003513A A JJ I-UN
growth CN101003513A A NN I-UN
factor CN101003513A A NN I-UN
receptor CN101003513A A NN I-UN
protein CN101003513A A NN O
on CN101003513A A IN O
bacteria CN101003513A A NNS O
surface CN101003513A A VBP O
thus CN101003513A A RB O
can CN101003513A A MD O
be CN101003513A A VB O
used CN101003513A A VBN O
to CN101003513A A TO O
treat CN101003513A A VB O
hyperplasia CN101003513A A JJ O
diseases CN101003513A A NNS O
such CN101003513A A JJ O
as CN101003513A A IN O
cancer CN101003513A A NN O
. CN101003513A A . O

N-Hydroxy-N- US20060276409 T NNP O
( US20060276409 T ( O
1- US20060276409 T JJ O
( US20060276409 T ( O
2-carbamoylalkylaminocarbonyl US20060276409 T JJ O
) US20060276409 T ) O
ethyl US20060276409 T NN O
) US20060276409 T ) O
formamides US20060276409 T NNS O
: US20060276409 T : O
[ US20060276409 T NN O
( US20060276409 T ( O
Formyl-hydroxy-amino US20060276409 T NNP O
) US20060276409 T ) O
-methyl US20060276409 T VBZ O
] US20060276409 T JJ O
-3-cyclopentyl-propionic US20060276409 T JJ O
acid US20060276409 T NN O
( US20060276409 T ( O
1-dimethyl-carbamoyl-2,2-dimethyl-propyl US20060276409 T JJ O
) US20060276409 T ) O
-amide US20060276409 T NN O
; US20060276409 T : O
bacterial US20060276409 T JJ O
polypeptide US20060276409 T NN I-UN
deformylase US20060276409 T NN I-UN
inhibitors US20060276409 T NNS O
. US20060276409 T . O

Medicament CN101732514A T NN O
for CN101732514A T IN O
treating CN101732514A T VBG O
rheumatism CN101732514A T NN O
, CN101732514A T , O
rheumatoid CN101732514A T JJ O
arthritis CN101732514A T NN O
, CN101732514A T , O
cervical CN101732514A T JJ O
osteoarthritis CN101732514A T NN O
and CN101732514A T CC O
lumbar CN101732514A T NN O
osteoarthritis CN101732514A T NN O
. CN101732514A T . O

Methods US7998492 T NNS O
and US7998492 T CC O
products US7998492 T NNS O
related US7998492 T VBN O
to US7998492 T TO O
treatment US7998492 T NN O
and US7998492 T CC O
prevention US7998492 T NN O
of US7998492 T IN O
hepatitis US7998492 T NN O
C US7998492 T NNP O
virus US7998492 T NN O
infection US7998492 T NN O
. US7998492 T . O

S-ornidazole CN102846540A T JJ O
and CN102846540A T CC O
sodium CN102846540A T JJ O
chloride CN102846540A T NN O
injection CN102846540A T NN O
. CN102846540A T . O

Novel WO2010002209A3 T NNP O
compounds WO2010002209A3 T NNS O
, WO2010002209A3 T , O
isomer WO2010002209A3 T NN O
thereof WO2010002209A3 T NN O
, WO2010002209A3 T , O
or WO2010002209A3 T CC O
pharmaceutically WO2010002209A3 T RB O
acceptable WO2010002209A3 T JJ O
salts WO2010002209A3 T NNS O
thereof WO2010002209A3 T VBP O
as WO2010002209A3 T IN O
vanilloid WO2010002209A3 T JJ I-UN
receptor WO2010002209A3 T NN I-UN
antagonist WO2010002209A3 T NN O
and WO2010002209A3 T CC O
pharmaceutical WO2010002209A3 T JJ O
compositions WO2010002209A3 T NNS O
containing WO2010002209A3 T VBG O
the WO2010002209A3 T DT O
same WO2010002209A3 T JJ O
. WO2010002209A3 T . O

This WO2010002209A3 A DT O
present WO2010002209A3 A JJ O
invention WO2010002209A3 A NN O
relates WO2010002209A3 A VBZ O
to WO2010002209A3 A TO O
novel WO2010002209A3 A VB O
compounds WO2010002209A3 A NNS O
, WO2010002209A3 A , O
isomer WO2010002209A3 A JJ O
thereof WO2010002209A3 A NN O
or WO2010002209A3 A CC O
pharmaceutically WO2010002209A3 A RB O
acceptable WO2010002209A3 A JJ O
salts WO2010002209A3 A NNS O
thereof WO2010002209A3 A VBP O
as WO2010002209A3 A IN O
vanilloid WO2010002209A3 A JJ I-UN
receptor WO2010002209A3 A NN I-UN
( WO2010002209A3 A ( O
Vanilloid WO2010002209A3 A NNP I-UN
Receptor WO2010002209A3 A NNP I-UN
1 WO2010002209A3 A CD I-UN
; WO2010002209A3 A : O
VR1 WO2010002209A3 A NNP I-UN
; WO2010002209A3 A : O
TRPV1 WO2010002209A3 A NNP I-UN
) WO2010002209A3 A ) O
antagonist WO2010002209A3 A NN O
; WO2010002209A3 A : O
and WO2010002209A3 A CC O
a WO2010002209A3 A DT O
pharmaceutical WO2010002209A3 A JJ O
composition WO2010002209A3 A NN O
containing WO2010002209A3 A VBG O
the WO2010002209A3 A DT O
same WO2010002209A3 A JJ O
. WO2010002209A3 A . O

Application CN102796084A T NN O
of CN102796084A T IN O
active CN102796084A T JJ O
substance CN102796084A T NN O
to CN102796084A T TO O
treatment CN102796084A T NN O
of CN102796084A T IN O
hepatitis CN102796084A T NN O
C CN102796084A T NNP O
and CN102796084A T CC O
preparation CN102796084A T NN O
method CN102796084A T NN O
thereof CN102796084A T NN O
. CN102796084A T . O

The CN102796084A A DT O
active CN102796084A A JJ O
substance CN102796084A A NN O
is CN102796084A A VBZ O
a CN102796084A A DT O
non-structural CN102796084A A JJ I-UN
protein CN102796084A A NN I-UN
5A CN102796084A A CD I-UN
inhibitor CN102796084A A NN O
or CN102796084A A CC O
a CN102796084A A DT O
pharmaceutically-acceptable CN102796084A A JJ O
salt CN102796084A A NN O
thereof CN102796084A A NN O
, CN102796084A A , O
is CN102796084A A VBZ O
a CN102796084A A DT O
compound CN102796084A A NN O
shown CN102796084A A VBN O
as CN102796084A A IN O
a CN102796084A A DT O
formula CN102796084A A NN O
( CN102796084A A ( O
1 CN102796084A A CD O
) CN102796084A A ) O
C42H50N8O6 CN102796084A A NNP O
, CN102796084A A , O
and CN102796084A A CC O
is CN102796084A A VBZ O
762.39 CN102796084A A CD O
in CN102796084A A IN O
mass CN102796084A A NN O
. CN102796084A A . O

Pharmaceutical CN103599537A T JJ O
composition CN103599537A T NN O
of CN103599537A T IN O
calcium CN103599537A T NN I-UN
channel CN103599537A T NNS I-UN
blocker/thiazide CN103599537A T IN O
diuretic/5-methyltetrahydrofolate CN103599537A T NN O
. CN103599537A T . O

The CN103599537A A DT O
invention CN103599537A A NN O
relates CN103599537A A VBZ O
to CN103599537A A TO O
a CN103599537A A DT O
pharmaceutical CN103599537A A JJ O
composition CN103599537A A NN O
containing CN103599537A A VBG O
a CN103599537A A DT O
calcium CN103599537A A NN I-UN
channel CN103599537A A NN I-UN
blocker CN103599537A A NN O
( CN103599537A A ( O
CCB CN103599537A A NNP O
) CN103599537A A ) O
, CN103599537A A , O
thiazide CN103599537A A JJ O
diuretic CN103599537A A JJ O
and CN103599537A A CC O
5-methyltetrahydrofolate CN103599537A A JJ O
, CN103599537A A , O
and CN103599537A A CC O
use CN103599537A A NN O
of CN103599537A A IN O
the CN103599537A A DT O
pharmaceutical CN103599537A A JJ O
composition CN103599537A A NN O
. CN103599537A A . O

Heterocyclic US6924278 T NNP O
carboxy US6924278 T JJ O
amines US6924278 T NNS O
such US6924278 T JJ O
as US6924278 T IN O
( US6924278 T ( O
2R US6924278 T CD O
) US6924278 T ) O
-1- US6924278 T NN O
[ US6924278 T JJ O
3,5-Bis US6924278 T JJ O
( US6924278 T ( O
trifluoromethyl US6924278 T NN O
) US6924278 T ) O
benzoyl US6924278 T NN O
] US6924278 T NNP O
-4- US6924278 T NNP O
[ US6924278 T NNP O
4- US6924278 T JJ O
( US6924278 T ( O
( US6924278 T ( O
3S US6924278 T CD O
) US6924278 T ) O
-3-ethylmorpholino US6924278 T NN O
) US6924278 T ) O
-2-butynyl US6924278 T VBZ O
] US6924278 T JJ O
-2- US6924278 T NNP O
[ US6924278 T NNP O
( US6924278 T ( O
1H-indol-3-yl US6924278 T JJ O
) US6924278 T ) O
methyl US6924278 T NN O
] US6924278 T NNP O
piperazine US6924278 T NN O
, US6924278 T , O
used US6924278 T VBD O
as US6924278 T IN O
substance US6924278 T NN I-UN
P US6924278 T NNP I-UN
and US6924278 T CC O
neurokinin US6924278 T JJ I-UN
antagonist US6924278 T NN O
for US6924278 T IN O
prophylaxis US6924278 T NN O
of US6924278 T IN O
diseases US6924278 T NNS O
. US6924278 T . O

Skinniness CN101199855A T NNP O
hormone CN101199855A T NN O
packing CN101199855A T VBG O
matter CN101199855A T NN O
water CN101199855A T NN O
solution CN101199855A T NN O
and CN101199855A T CC O
application CN101199855A T NN O
thereof CN101199855A T NN O
. CN101199855A T . O

Solid US20070231395 T JJ O
Pharmaceutical US20070231395 T NNP O
Preparation US20070231395 T NNP O
for US20070231395 T IN O
Dialysis US20070231395 T NNP O
. US20070231395 T . O

A US20070231395 A DT O
solid US20070231395 A JJ O
pharmaceutical US20070231395 A JJ O
preparation US20070231395 A NN O
for US20070231395 A IN O
dialysis US20070231395 A NN O
which US20070231395 A WDT O
does US20070231395 A VBZ O
not US20070231395 A RB O
contain US20070231395 A VB O
any US20070231395 A DT O
acetic US20070231395 A JJ O
acid US20070231395 A NN O
and US20070231395 A CC O
a US20070231395 A DT O
production US20070231395 A NN O
process US20070231395 A NN O
thereof US20070231395 A NN O
. US20070231395 A . O

The US20070231395 A DT O
solid US20070231395 A JJ O
pharmaceutical US20070231395 A JJ O
preparation US20070231395 A NN O
for US20070231395 A IN O
dialysis US20070231395 A NN O
contains US20070231395 A NNS O
two US20070231395 A CD O
pharmaceutical US20070231395 A JJ O
preparations US20070231395 A NNS O
: US20070231395 A : O
a US20070231395 A DT O
solid US20070231395 A JJ O
pharmaceutical US20070231395 A JJ O
preparation US20070231395 A NN O
( US20070231395 A ( O
A US20070231395 A DT O
) US20070231395 A ) O
composed US20070231395 A VBN O
of US20070231395 A IN O
particles US20070231395 A NNS O
having US20070231395 A VBG O
an US20070231395 A DT O
average US20070231395 A JJ O
particle US20070231395 A NN O
size US20070231395 A NN O
of US20070231395 A IN O
about US20070231395 A IN O
100 US20070231395 A CD O
μm US20070231395 A NNS O
to US20070231395 A TO O
1,500 US20070231395 A CD O
μm US20070231395 A NNS O
and US20070231395 A CC O
containing US20070231395 A VBG O
one US20070231395 A CD O
or US20070231395 A CC O
more US20070231395 A JJR O
electrolytes US20070231395 A NNS O
selected US20070231395 A VBN O
from US20070231395 A IN O
sodium US20070231395 A NN O
chloride US20070231395 A NN O
, US20070231395 A , O
calcium US20070231395 A NN O
chloride US20070231395 A NN O
, US20070231395 A , O
magnesium US20070231395 A NN O
chloride US20070231395 A NN O
, US20070231395 A , O
and US20070231395 A CC O
potassium US20070231395 A NN O
chloride US20070231395 A NN O
, US20070231395 A , O
and US20070231395 A CC O
an US20070231395 A DT O
organic US20070231395 A JJ O
acid US20070231395 A NN O
other US20070231395 A JJ O
than US20070231395 A IN O
acetic US20070231395 A JJ O
acid US20070231395 A NN O
and/or US20070231395 A VBZ O
a US20070231395 A DT O
salt US20070231395 A NN O
of US20070231395 A IN O
the US20070231395 A DT O
organic US20070231395 A JJ O
acid US20070231395 A NN O
; US20070231395 A : O
and US20070231395 A CC O
a US20070231395 A DT O
solid US20070231395 A JJ O
pharmaceutical US20070231395 A JJ O
preparation US20070231395 A NN O
( US20070231395 A ( O
B US20070231395 A NNP O
) US20070231395 A ) O
containing US20070231395 A VBG O
sodium US20070231395 A NN O
bicarbonate US20070231395 A NN O
. US20070231395 A . O

Novel EP1720544A1 T NNP O
azabicyclic EP1720544A1 T JJ O
derivatives EP1720544A1 T NNS O
, EP1720544A1 T , O
preparation EP1720544A1 T NN O
method EP1720544A1 T NN O
thereof EP1720544A1 T NN O
and EP1720544A1 T CC O
pharmaceutical EP1720544A1 T JJ O
compositions EP1720544A1 T NNS O
containing EP1720544A1 T VBG O
same EP1720544A1 T JJ O
. EP1720544A1 T . O

Aged CA2427261C T VBN O
companion CA2427261C T NN O
pet CA2427261C T NN O
diet CA2427261C T NN O
. CA2427261C T . O

Lactase CN102510758A T NNP I-UN
preparation CN102510758A T NN O
. CN102510758A T . O

Disclosed CN102510758A A VBN O
is CN102510758A A VBZ O
a CN102510758A A DT O
lactase CN102510758A A NN I-UN
preparation CN102510758A A NN O
which CN102510758A A WDT O
does CN102510758A A VBZ O
not CN102510758A A RB O
undergo CN102510758A A VB O
the CN102510758A A DT O
deactivation CN102510758A A NN O
of CN102510758A A IN O
lactase CN102510758A A NN I-UN
even CN102510758A A RB O
when CN102510758A A WRB O
the CN102510758A A DT O
preparation CN102510758A A NN O
is CN102510758A A VBZ O
ingested CN102510758A A VBN O
prior CN102510758A A RB O
to CN102510758A A TO O
the CN102510758A A DT O
ingestion CN102510758A A NN O
of CN102510758A A IN O
a CN102510758A A DT O
lactose-containing CN102510758A A JJ O
food CN102510758A A NN O
or CN102510758A A CC O
beverage CN102510758A A NN O
such CN102510758A A JJ O
as CN102510758A A IN O
a CN102510758A A DT O
milk CN102510758A A NN O
product CN102510758A A NN O
and CN102510758A A CC O
therefore CN102510758A A RB O
can CN102510758A A MD O
decompose CN102510758A A VB O
lactose CN102510758A A JJ O
stably CN102510758A A NN O
and CN102510758A A CC O
which CN102510758A A WDT O
can CN102510758A A MD O
prevent CN102510758A A VB O
the CN102510758A A DT O
symptoms CN102510758A A NNS O
of CN102510758A A IN O
lactose CN102510758A A JJ O
tolerance CN102510758A A NN O
. CN102510758A A . O

Specifically CN102510758A A RB O
disclosed CN102510758A A VBN O
is CN102510758A A VBZ O
a CN102510758A A DT O
lactase CN102510758A A JJ I-UN
preparation CN102510758A A NN O
comprising CN102510758A A VBG O
lactase CN102510758A A NN I-UN
and CN102510758A A CC O
at CN102510758A A IN O
least CN102510758A A JJS O
one CN102510758A A CD O
component CN102510758A A NN O
selected CN102510758A A VBN O
from CN102510758A A IN O
trisodium CN102510758A A NN O
citrate CN102510758A A NN O
, CN102510758A A , O
potassium CN102510758A A NN O
sodium CN102510758A A NN O
tartrate CN102510758A A NN O
, CN102510758A A , O
calcium CN102510758A A NN O
carbonate CN102510758A A NN O
, CN102510758A A , O
sodium CN102510758A A NN O
carbonate CN102510758A A NN O
and CN102510758A A CC O
calcium CN102510758A A NN O
hydrogen CN102510758A A NN O
phosphate CN102510758A A NN O
which CN102510758A A WDT O
acts CN102510758A A VBZ O
as CN102510758A A IN O
an CN102510758A A DT O
antacid CN102510758A A NN O
. CN102510758A A . O

The CN102510758A A DT O
lactase CN102510758A A NN I-UN
preparation CN102510758A A NN O
is CN102510758A A VBZ O
characterized CN102510758A A VBN O
by CN102510758A A IN O
being CN102510758A A VBG O
intended CN102510758A A VBN O
to CN102510758A A TO O
be CN102510758A A VB O
ingested CN102510758A A VBN O
prior CN102510758A A RB O
to CN102510758A A TO O
the CN102510758A A DT O
ingestion CN102510758A A NN O
of CN102510758A A IN O
a CN102510758A A DT O
lactose-containing CN102510758A A JJ O
food CN102510758A A NN O
or CN102510758A A CC O
beverage CN102510758A A NN O
to CN102510758A A TO O
decompose CN102510758A A VB O
lactose CN102510758A A JJ O
. CN102510758A A . O

Crystalline US8030326 T NNP O
forms US8030326 T NNS O
of US8030326 T IN O
rapamycin US8030326 T JJ O
analogs US8030326 T NNS O
. US8030326 T . O

Mutein US20070293425 T NNP O
of US20070293425 T IN O
a US20070293425 T DT O
Bone US20070293425 T NNP O
Morphogenetic US20070293425 T NNP O
Protein US20070293425 T NNP O
and US20070293425 T CC O
Use US20070293425 T NNP O
Thereof US20070293425 T NNP O
. US20070293425 T . O

The US20070293425 A DT O
present US20070293425 A JJ O
invention US20070293425 A NN O
is US20070293425 A VBZ O
related US20070293425 A VBN O
to US20070293425 A TO O
a US20070293425 A DT O
mutein US20070293425 A NN O
of US20070293425 A IN O
a US20070293425 A DT O
bone US20070293425 A NN O
morphogenetic US20070293425 A JJ O
protein US20070293425 A NN O
, US20070293425 A , O
whereby US20070293425 A WRB O
the US20070293425 A DT O
mutein US20070293425 A NN O
comprises US20070293425 A VBZ O
an US20070293425 A DT O
amino US20070293425 A NN O
acid US20070293425 A NN O
substitution US20070293425 A NN O
compared US20070293425 A VBN O
to US20070293425 A TO O
the US20070293425 A DT O
wildtype US20070293425 A NN O
of US20070293425 A IN O
the US20070293425 A DT O
bone US20070293425 A NN O
morphogenetic US20070293425 A JJ O
protein US20070293425 A NN O
at US20070293425 A IN O
the US20070293425 A DT O
amino US20070293425 A NN O
acid US20070293425 A JJ O
position US20070293425 A NN O
corresponding US20070293425 A VBG O
to US20070293425 A TO O
amino US20070293425 A VB O
acid US20070293425 A JJ O
position US20070293425 A NN O
51 US20070293425 A CD O
of US20070293425 A IN O
human US20070293425 A JJ I-UN
BMP-2 US20070293425 A NNP I-UN
. US20070293425 A . O

Chelate CA2340545C T NNP O
compound-containing CA2340545C T JJ O
antibacterial CA2340545C T JJ O
agent CA2340545C T NN O
for CA2340545C T IN O
helicobacter CA2340545C T NN O
pylori CA2340545C T NN O
. CA2340545C T . O

2- US20080103126 T JJ O
[ US20080103126 T NNP O
[ US20080103126 T NNP O
3- US20080103126 T JJ O
( US20080103126 T ( O
2-benzo US20080103126 T JJ O
[ US20080103126 T NN O
b US20080103126 T NN O
] US20080103126 T NNP O
thiophen-5-yl-ethoxy US20080103126 T NN O
) US20080103126 T ) O
propyl US20080103126 T NN O
] US20080103126 T NNP O
( US20080103126 T ( O
methyl US20080103126 T NN O
) US20080103126 T ) O
amino US20080103126 T NN O
] US20080103126 T NNP O
-1-ethanol US20080103126 T NNP O
; US20080103126 T : O
antihypoxic US20080103126 T JJ O
agent US20080103126 T NN O
; US20080103126 T : O
synergistic US20080103126 T JJ O
mixture US20080103126 T NN O
with US20080103126 T IN O
acetylcholine US20080103126 T JJ I-UN
esterase US20080103126 T NN I-UN
inhibitor US20080103126 T NN O
( US20080103126 T ( O
Tacrine US20080103126 T NNP O
, US20080103126 T , O
Donepezil US20080103126 T NNP O
, US20080103126 T , O
Rivastigmine US20080103126 T NNP O
) US20080103126 T ) O
; US20080103126 T : O
neurodegenerative US20080103126 T JJ O
diseases US20080103126 T NNS O
, US20080103126 T , O
ischemic US20080103126 T JJ O
cerebral US20080103126 T JJ O
lesion US20080103126 T NN O
, US20080103126 T , O
cerebral US20080103126 T JJ O
apoplexy US20080103126 T NN O
, US20080103126 T , O
Alzheimer US20080103126 T NNP O
's US20080103126 T POS O
disease US20080103126 T NN O
, US20080103126 T , O
cognition US20080103126 T NN O
activator US20080103126 T NN O
. US20080103126 T . O

An US20080103126 A DT O
alkyl US20080103126 A NN O
ether US20080103126 A RB O
derivative US20080103126 A JJ O
represented US20080103126 A VBN O
by US20080103126 A IN O
the US20080103126 A DT O
formula US20080103126 A NN O
: US20080103126 A : O
wherein US20080103126 A NN O
R1 US20080103126 A NNP O
, US20080103126 A , O
R2 US20080103126 A NNP O
, US20080103126 A , O
R3 US20080103126 A NNP O
, US20080103126 A , O
R4 US20080103126 A NNP O
, US20080103126 A , O
m US20080103126 A NN O
and US20080103126 A CC O
n US20080103126 A NN O
are US20080103126 A VBP O
as US20080103126 A IN O
defined US20080103126 A VBN O
in US20080103126 A IN O
the US20080103126 A DT O
specification US20080103126 A NN O
, US20080103126 A , O
or US20080103126 A CC O
salts US20080103126 A NNS O
thereof US20080103126 A JJ O
exhibits US20080103126 A NNS O
synergistically US20080103126 A RB O
improved US20080103126 A VBN O
anti-hypoxic US20080103126 A JJ O
activity US20080103126 A NN O
when US20080103126 A WRB O
combined US20080103126 A VBN O
with US20080103126 A IN O
a US20080103126 A DT O
compound US20080103126 A NN O
having US20080103126 A VBG O
an US20080103126 A DT O
acetylcholine US20080103126 A JJ I-UN
esterase US20080103126 A NN I-UN
inhibitory US20080103126 A NN O
activity US20080103126 A NN O
. US20080103126 A . O

For US7265131 T IN O
therapy US7265131 T NN O
of US7265131 T IN O
disease-states US7265131 T NNS O
associated US7265131 T VBN O
with US7265131 T IN O
nuclear US7265131 T JJ I-UN
receptor US7265131 T NN I-UN
activity US7265131 T NN O
. US7265131 T . O

Compounds US7265131 A NNS O
of US7265131 A IN O
formula US7265131 A NN O
( US7265131 A ( O
I US7265131 A PRP O
) US7265131 A ) O
: US7265131 A : O
wherein US7265131 A NN O
n US7265131 A NN O
, US7265131 A , O
R1 US7265131 A NNP O
, US7265131 A , O
R2 US7265131 A NNP O
, US7265131 A , O
R3 US7265131 A NNP O
and US7265131 A CC O
R7 US7265131 A NNP O
are US7265131 A VBP O
disclosed US7265131 A VBN O
herein US7265131 A NN O
, US7265131 A , O
are US7265131 A VBP O
useful US7265131 A JJ O
in US7265131 A IN O
treating US7265131 A VBG O
disease-states US7265131 A NNS O
associated US7265131 A VBN O
with US7265131 A IN O
nuclear US7265131 A JJ I-UN
receptor US7265131 A NN I-UN
activity US7265131 A NN O
. US7265131 A . O

Protein EP2725101A1 T NNP O
comprising EP2725101A1 T VBG O
truncated EP2725101A1 T JJ O
form EP2725101A1 T NN O
of EP2725101A1 T IN O
extracellular EP2725101A1 T JJ I-UN
domain EP2725101A1 T NN I-UN
protein EP2725101A1 T NN I-UN
of EP2725101A1 T IN I-UN
frizzled EP2725101A1 T JJ I-UN
2 EP2725101A1 T CD I-UN
, EP2725101A1 T , O
and EP2725101A1 T CC O
pharmaceutical EP2725101A1 T JJ O
composition EP2725101A1 T NN O
for EP2725101A1 T IN O
treating EP2725101A1 T VBG O
bone EP2725101A1 T NN O
diseases EP2725101A1 T NNS O
which EP2725101A1 T WDT O
comprises EP2725101A1 T NNS O
said EP2725101A1 T VBD O
protein EP2725101A1 T NN O
. EP2725101A1 T . O

The EP2725101A1 A DT O
present EP2725101A1 A JJ O
invention EP2725101A1 A NN O
provides EP2725101A1 A VBZ O
a EP2725101A1 A DT O
protein EP2725101A1 A NN O
comprising EP2725101A1 A VBG O
a EP2725101A1 A DT O
truncated EP2725101A1 A JJ O
form EP2725101A1 A NN O
of EP2725101A1 A IN O
an EP2725101A1 A DT O
extracellular EP2725101A1 A JJ I-UN
region EP2725101A1 A NN I-UN
protein EP2725101A1 A NN I-UN
of EP2725101A1 A IN I-UN
Frizzled EP2725101A1 A NNP I-UN
2 EP2725101A1 A CD I-UN
, EP2725101A1 A , O
which EP2725101A1 A WDT O
has EP2725101A1 A VBZ O
higher EP2725101A1 A JJR O
secretion EP2725101A1 A NN O
activity EP2725101A1 A NN O
than EP2725101A1 A IN O
that EP2725101A1 A DT O
of EP2725101A1 A IN O
a EP2725101A1 A DT O
known EP2725101A1 A VBN O
protein EP2725101A1 A NN O
comprising EP2725101A1 A VBG O
an EP2725101A1 A DT O
extralellular EP2725101A1 A JJ I-UN
cysteine-rich EP2725101A1 A JJ I-UN
domain EP2725101A1 A NN I-UN
of EP2725101A1 A IN I-UN
Frizzled EP2725101A1 A NNP I-UN
2 EP2725101A1 A CD I-UN
in EP2725101A1 A IN O
a EP2725101A1 A DT O
production EP2725101A1 A NN O
cell EP2725101A1 A NN O
and EP2725101A1 A CC O
bone EP2725101A1 A JJ O
mass-increasing EP2725101A1 A NN O
activity EP2725101A1 A NN O
higher EP2725101A1 A JJR O
than EP2725101A1 A IN O
or EP2725101A1 A CC O
equal EP2725101A1 A JJ O
to EP2725101A1 A TO O
that EP2725101A1 A DT O
of EP2725101A1 A IN O
the EP2725101A1 A DT O
known EP2725101A1 A VBN O
protein EP2725101A1 A NN O
, EP2725101A1 A , O
or EP2725101A1 A CC O
DNA EP2725101A1 A NNP O
encoding EP2725101A1 A VBG O
said EP2725101A1 A VBD O
protein EP2725101A1 A NN O
. EP2725101A1 A . O

Chlorpronaline CN1561977A T NNP O
hydrochloride CN1561977A T NN O
dripping CN1561977A T VBG O
pill CN1561977A T NN O
and CN1561977A T CC O
its CN1561977A T PRP$ O
preparing CN1561977A T NN O
method CN1561977A T NN O
. CN1561977A T . O

Diethylcarbamyl-substituted CN101328169B T JJ O
thiazole CN101328169B T JJ O
dihydropyrimidine CN101328169B T NN O
. CN101328169B T . O

Cefodizime CN102010432A T NNP O
sodium CN102010432A T NN O
compound CN102010432A T NN O
and CN102010432A T CC O
novel CN102010432A T JJ O
method CN102010432A T NN O
thereof CN102010432A T NN O
. CN102010432A T . O

Application CN103120689A T NN O
of CN103120689A T IN O
pyrazol CN103120689A T NN O
compound CN103120689A T NN O
as CN103120689A T IN O
mycobacterium CN103120689A T JJ O
tuberculosis CN103120689A T NN O
inhibitor CN103120689A T NN O
. CN103120689A T . O

Pyrazine CN101812025A T NNP O
aromatic CN101812025A T JJ O
acid CN101812025A T NN O
ester CN101812025A T NN O
compound CN101812025A T NN O
, CN101812025A T , O
preparation CN101812025A T NN O
method CN101812025A T NN O
and CN101812025A T CC O
medical CN101812025A T JJ O
application CN101812025A T NN O
. CN101812025A T . O

Compositions US20130023512 T NNS O
for US20130023512 T IN O
Combating US20130023512 T VBG O
Beta-Lactamase-Medicated US20130023512 T NNP O
Antibiotic US20130023512 T NNP O
Resistance US20130023512 T NNP O
Using US20130023512 T NNP O
Beta-Lactamase US20130023512 T NNP I-UN
Inhibitors US20130023512 T NNP O
Useful US20130023512 T NNP O
For US20130023512 T IN O
Injection US20130023512 T NNP O
. US20130023512 T . O

The US20130023512 A DT O
invention US20130023512 A NN O
describes US20130023512 A VBZ O
a US20130023512 A DT O
composition US20130023512 A NN O
for US20130023512 A IN O
combating US20130023512 A VBG O
beta-lactamase-mediated US20130023512 A JJ O
antibiotic US20130023512 A JJ O
resistance US20130023512 A NN O
using US20130023512 A VBG O
beta-lactamase US20130023512 A JJ I-UN
inhibitor US20130023512 A NN O
useful US20130023512 A JJ O
for US20130023512 A IN O
injection US20130023512 A NN O
, US20130023512 A , O
capable US20130023512 A JJ O
of US20130023512 A IN O
pharmaceutical US20130023512 A JJ O
application US20130023512 A NN O
. US20130023512 A . O

Deuterium-enriched US20090082405 T JJ O
pioglitazone US20090082405 T NN O
. US20090082405 T . O

Benzoimidazolone-carboxamide WO2006133104A3 T JJ O
compounds WO2006133104A3 T NNS O
as WO2006133104A3 T IN O
5-ht4 WO2006133104A3 T JJ I-UN
receptor WO2006133104A3 T NN O
agonists WO2006133104A3 T NNS O
. WO2006133104A3 T . O

The WO2006133104A3 A DT O
invention WO2006133104A3 A NN O
provides WO2006133104A3 A VBZ O
novel WO2006133104A3 A JJ O
benzoimidazolone-carboxamide WO2006133104A3 A JJ O
5-HT4 WO2006133104A3 A JJ I-UN
receptor WO2006133104A3 A NN O
agonist WO2006133104A3 A NN O
compounds WO2006133104A3 A NNS O
. WO2006133104A3 A . O

The WO2006133104A3 A DT O
invention WO2006133104A3 A NN O
also WO2006133104A3 A RB O
provides WO2006133104A3 A VBZ O
pharmaceutical WO2006133104A3 A JJ O
compositions WO2006133104A3 A NNS O
comprising WO2006133104A3 A VBG O
such WO2006133104A3 A JJ O
compounds WO2006133104A3 A NNS O
, WO2006133104A3 A , O
methods WO2006133104A3 A NNS O
of WO2006133104A3 A IN O
using WO2006133104A3 A VBG O
such WO2006133104A3 A JJ O
compounds WO2006133104A3 A NNS O
to WO2006133104A3 A TO O
treat WO2006133104A3 A VB O
diseases WO2006133104A3 A NNS O
associated WO2006133104A3 A VBN O
with WO2006133104A3 A IN O
5-HT4 WO2006133104A3 A JJ I-UN
receptor WO2006133104A3 A NN O
activity WO2006133104A3 A NN O
, WO2006133104A3 A , O
and WO2006133104A3 A CC O
processes WO2006133104A3 A NNS O
and WO2006133104A3 A CC O
intermediates WO2006133104A3 A NNS O
useful WO2006133104A3 A JJ O
for WO2006133104A3 A IN O
preparing WO2006133104A3 A VBG O
such WO2006133104A3 A JJ O
compounds WO2006133104A3 A NNS O
. WO2006133104A3 A . O

6-arylmethyl US8809348 T JJ O
substituted US8809348 T VBD O
pyrazolo US8809348 T JJ O
[ US8809348 T JJ O
3,4-d US8809348 T JJ O
] US8809348 T NN O
pyrimidines US8809348 T NNS O
. US8809348 T . O

Thiazole CN102358742A T NNP O
compound CN102358742A T NN O
with CN102358742A T IN O
antitumor CN102358742A T JJ O
activity CN102358742A T NN O
. CN102358742A T . O

The CN102358742A A DT O
invention CN102358742A A NN O
belongs CN102358742A A VBZ O
to CN102358742A A TO O
the CN102358742A A DT O
technical CN102358742A A JJ O
field CN102358742A A NN O
of CN102358742A A IN O
antitumor CN102358742A A NN O
drugs CN102358742A A NNS O
, CN102358742A A , O
and CN102358742A A CC O
provides CN102358742A A VBZ O
a CN102358742A A DT O
thiazole CN102358742A A NN O
compound CN102358742A A NN O
having CN102358742A A VBG O
a CN102358742A A DT O
structure CN102358742A A NN O
shown CN102358742A A VBN O
in CN102358742A A IN O
the CN102358742A A DT O
general CN102358742A A JJ O
structural CN102358742A A JJ O
formula CN102358742A A NN O
I CN102358742A A PRP O
, CN102358742A A , O
and CN102358742A A CC O
pharmaceutically CN102358742A A RB O
acceptable CN102358742A A JJ O
salts CN102358742A A NNS O
of CN102358742A A IN O
the CN102358742A A DT O
thiazole CN102358742A A JJ O
compound CN102358742A A NN O
. CN102358742A A . O

In CN102358742A A IN O
the CN102358742A A DT O
general CN102358742A A JJ O
structural CN102358742A A JJ O
formula CN102358742A A NN O
I CN102358742A A PRP O
, CN102358742A A , O
R1 CN102358742A A NNP O
represents CN102358742A A VBZ O
hydrogen CN102358742A A NN O
, CN102358742A A , O
methyl CN102358742A A NN O
or CN102358742A A CC O
ethyl CN102358742A A NN O
, CN102358742A A , O
and CN102358742A A CC O
R2 CN102358742A A NNP O
and CN102358742A A CC O
R3 CN102358742A A NNP O
represent CN102358742A A VBP O
hydrogen CN102358742A A NN O
, CN102358742A A , O
chlorine CN102358742A A NN O
, CN102358742A A , O
bromine CN102358742A A NN O
, CN102358742A A , O
methyl CN102358742A A NN O
, CN102358742A A , O
trifluoromethyl CN102358742A A NN O
, CN102358742A A , O
methoxycarbonyl CN102358742A A NN O
, CN102358742A A , O
ethoxycarbonyl CN102358742A A NN O
or CN102358742A A CC O
carbonyl CN102358742A A NN O
. CN102358742A A . O

The CN102358742A A DT O
invention CN102358742A A NN O
also CN102358742A A RB O
relates CN102358742A A VBZ O
to CN102358742A A TO O
a CN102358742A A DT O
preparation CN102358742A A NN O
method CN102358742A A NN O
of CN102358742A A IN O
the CN102358742A A DT O
thiazole CN102358742A A JJ O
compound CN102358742A A NN O
. CN102358742A A . O

Simultaneously CN102358742A A RB O
, CN102358742A A , O
the CN102358742A A DT O
invention CN102358742A A NN O
also CN102358742A A RB O
discloses CN102358742A A VBZ O
a CN102358742A A DT O
medicinal CN102358742A A JJ O
composition CN102358742A A NN O
containing CN102358742A A VBG O
an CN102358742A A DT O
active CN102358742A A JJ O
ingredient CN102358742A A NN O
of CN102358742A A IN O
the CN102358742A A DT O
thiazole CN102358742A A JJ O
compound CN102358742A A NN O
or CN102358742A A CC O
the CN102358742A A DT O
pharmaceutically CN102358742A A RB O
acceptable CN102358742A A JJ O
salts CN102358742A A NNS O
of CN102358742A A IN O
the CN102358742A A DT O
thiazole CN102358742A A NN O
compound CN102358742A A NN O
, CN102358742A A , O
and CN102358742A A CC O
application CN102358742A A NN O
of CN102358742A A IN O
the CN102358742A A DT O
thiazole CN102358742A A NN O
compound CN102358742A A NN O
and CN102358742A A CC O
the CN102358742A A DT O
pharmaceutically CN102358742A A RB O
acceptable CN102358742A A JJ O
salts CN102358742A A NNS O
of CN102358742A A IN O
the CN102358742A A DT O
thiazole CN102358742A A JJ O
compound CN102358742A A NN O
in CN102358742A A IN O
preparation CN102358742A A NN O
of CN102358742A A IN O
antitumor CN102358742A A NN O
drugs CN102358742A A NNS O
. CN102358742A A . O

Anti-influenza CN101289455B T JJ O
virus CN101289455B T NN O
precursor CN101289455B T NN O
drug CN101289455B T NN O
and CN101289455B T CC O
uses CN101289455B T VBZ O
thereof CN101289455B T NN O
. CN101289455B T . O

Composition WO2012035685A1 T NN O
for WO2012035685A1 T IN O
promoting WO2012035685A1 T VBG O
hyaluronic WO2012035685A1 T JJ O
acid WO2012035685A1 T NN O
production WO2012035685A1 T NN O
. WO2012035685A1 T . O

Pharmaceutical US20120308568 T JJ O
composition US20120308568 T NN O
for US20120308568 T IN O
inhibiting US20120308568 T VBG O
abnormal US20120308568 T JJ O
proliferation US20120308568 T NN O
of US20120308568 T IN O
cells US20120308568 T NNS O
. US20120308568 T . O

The US20120308568 A DT O
present US20120308568 A JJ O
invention US20120308568 A NN O
relates US20120308568 A VBZ O
to US20120308568 A TO O
a US20120308568 A DT O
pharmaceutical US20120308568 A JJ O
composition US20120308568 A NN O
for US20120308568 A IN O
preventing US20120308568 A VBG O
or US20120308568 A CC O
treating US20120308568 A VBG O
diseases US20120308568 A NNS O
related US20120308568 A VBN O
to US20120308568 A TO O
abnormal US20120308568 A JJ O
proliferation US20120308568 A NN O
of US20120308568 A IN O
cells US20120308568 A NNS O
, US20120308568 A , O
comprising US20120308568 A VBG O
a US20120308568 A DT O
cytoplasmic US20120308568 A JJ O
heat US20120308568 A NN I-UN
shock US20120308568 A NN I-UN
protein US20120308568 A NN I-UN
( US20120308568 A ( I-UN
Hsp US20120308568 A NNP I-UN
) US20120308568 A ) I-UN
60 US20120308568 A CD I-UN
kDa US20120308568 A JJ O
inhibitor US20120308568 A NN O
as US20120308568 A IN O
an US20120308568 A DT O
active US20120308568 A JJ O
ingredient US20120308568 A NN O
, US20120308568 A , O
and US20120308568 A CC O
to US20120308568 A TO O
a US20120308568 A DT O
screening US20120308568 A NN O
method US20120308568 A NN O
and US20120308568 A CC O
a US20120308568 A DT O
kit US20120308568 A NN O
using US20120308568 A VBG O
the US20120308568 A DT O
composition US20120308568 A NN O
. US20120308568 A . O

According US20120308568 A VBG O
to US20120308568 A TO O
the US20120308568 A DT O
present US20120308568 A JJ O
invention US20120308568 A NN O
, US20120308568 A , O
substances US20120308568 A NNS O
which US20120308568 A WDT O
inhibit US20120308568 A VBP O
expression US20120308568 A NN O
of US20120308568 A IN O
cytoplasmic US20120308568 A JJ O
Hsp US20120308568 A NNP I-UN
60 US20120308568 A CD I-UN
genes US20120308568 A NNS I-UN
or US20120308568 A CC O
inhibit US20120308568 A NN O
activity US20120308568 A NN O
of US20120308568 A IN O
cytoplasmic US20120308568 A JJ O
Hsp US20120308568 A NNP I-UN
60 US20120308568 A CD I-UN
or US20120308568 A CC O
inhibit US20120308568 A VB O
binding US20120308568 A VBG O
between US20120308568 A IN O
cytoplasmic US20120308568 A JJ O
Hsp US20120308568 A NNP I-UN
60 US20120308568 A CD I-UN
and US20120308568 A CC O
IKK US20120308568 A NNP I-UN
protein US20120308568 A VBP O
prevent US20120308568 A JJ O
interaction US20120308568 A NN O
between US20120308568 A IN O
cytoplasmic US20120308568 A JJ O
Hsp US20120308568 A NNP I-UN
60 US20120308568 A CD I-UN
and US20120308568 A CC O
IKK US20120308568 A NNP I-UN
complexes US20120308568 A NNS O
to US20120308568 A TO O
make US20120308568 A VB O
NF-κB US20120308568 A JJ I-UN
path US20120308568 A NN O
inactive US20120308568 A NN O
, US20120308568 A , O
and US20120308568 A CC O
thus US20120308568 A RB O
induce US20120308568 A VB O
apoptosis US20120308568 A NN O
. US20120308568 A . O

Polycrystal CN102557972A T JJ O
substance CN102557972A T NN O
of CN102557972A T IN O
acetyl CN102557972A T JJ O
chloride CN102557972A T JJ O
levocarnitine CN102557972A T NN O
. CN102557972A T . O

2,4- EP2585461A1 T JJ O
diaryl EP2585461A1 T NN O
- EP2585461A1 T : O
substituted EP2585461A1 T VBN O
[ EP2585461A1 T JJ O
1,8 EP2585461A1 T CD O
] EP2585461A1 T JJ O
naphthyridines EP2585461A1 T NNS O
as EP2585461A1 T IN O
kinase EP2585461A1 T NN O
inhibitors EP2585461A1 T NNS O
for EP2585461A1 T IN O
use EP2585461A1 T NN O
against EP2585461A1 T IN O
cancer EP2585461A1 T NN O
. EP2585461A1 T . O

Process EP2226070A1 T NN O
for EP2226070A1 T IN O
determining EP2226070A1 T VBG O
the EP2226070A1 T DT O
optimal EP2226070A1 T JJ O
dosage EP2226070A1 T NN O
of EP2226070A1 T IN O
antivitamins EP2226070A1 T NNS O
K EP2226070A1 T NNP O
in EP2226070A1 T IN O
anticoagulant EP2226070A1 T JJ O
therapy EP2226070A1 T NN O
. EP2226070A1 T . O

Determining EP2226070A1 A VBG O
optimal EP2226070A1 A JJ O
dosage EP2226070A1 A NN O
( EP2226070A1 A ( O
D EP2226070A1 A NNP O
o EP2226070A1 A RB O
) EP2226070A1 A ) O
of EP2226070A1 A IN O
vitamin EP2226070A1 A NN O
K EP2226070A1 A NNP O
, EP2226070A1 A , O
comprises EP2226070A1 A VBZ O
: EP2226070A1 A : O
recording EP2226070A1 A VBG O
value EP2226070A1 A NN O
I EP2226070A1 A PRP O
oof EP2226070A1 A VBP O
optimal EP2226070A1 A JJ O
target EP2226070A1 A NN O
INR EP2226070A1 A NNP O
; EP2226070A1 A : O
recording EP2226070A1 A VBG O
international EP2226070A1 A JJ O
normalized EP2226070A1 A VBN O
ratio EP2226070A1 A NN O
( EP2226070A1 A ( O
INR EP2226070A1 A NNP O
) EP2226070A1 A ) O
values EP2226070A1 A NNS O
measured EP2226070A1 A VBN O
in EP2226070A1 A IN O
a EP2226070A1 A DT O
time EP2226070A1 A NN O
T EP2226070A1 A NNP O
1 EP2226070A1 A CD O
; EP2226070A1 A : O
from EP2226070A1 A IN O
a EP2226070A1 A DT O
gradient EP2226070A1 A NN O
P EP2226070A1 A NNP O
1 EP2226070A1 A CD O
, EP2226070A1 A , O
extrapolating EP2226070A1 A VBG O
and EP2226070A1 A CC O
recording EP2226070A1 A VBG O
a EP2226070A1 A DT O
I EP2226070A1 A PRP O
m EP2226070A1 A VBP O
a EP2226070A1 A DT O
xvalue EP2226070A1 A NN O
of EP2226070A1 A IN O
INR EP2226070A1 A NNP O
theoretically EP2226070A1 A RB O
reached EP2226070A1 A VBD O
from EP2226070A1 A IN O
the EP2226070A1 A DT O
day EP2226070A1 A NN O
; EP2226070A1 A : O
recording EP2226070A1 A VBG O
INR EP2226070A1 A NNP O
values EP2226070A1 A NNS O
measured EP2226070A1 A VBN O
in EP2226070A1 A IN O
a EP2226070A1 A DT O
period EP2226070A1 A NN O
T EP2226070A1 A NNP O
2 EP2226070A1 A CD O
; EP2226070A1 A : O
from EP2226070A1 A IN O
the EP2226070A1 A DT O
gradient EP2226070A1 A NN O
P2 EP2226070A1 A NNP O
, EP2226070A1 A , O
extrapolating EP2226070A1 A VBG O
and EP2226070A1 A CC O
recording EP2226070A1 A VBG O
a EP2226070A1 A DT O
INR EP2226070A1 A NNP O
I EP2226070A1 A PRP O
m EP2226070A1 A VBP O
i EP2226070A1 A JJ O
n EP2226070A1 A VBP O
ivalue EP2226070A1 A JJ O
theoretically EP2226070A1 A RB O
reached EP2226070A1 A VBN O
from EP2226070A1 A IN O
the EP2226070A1 A DT O
day EP2226070A1 A NN O
; EP2226070A1 A : O
calculating EP2226070A1 A VBG O
difference EP2226070A1 A NN O
between EP2226070A1 A IN O
INR EP2226070A1 A NNP O
I EP2226070A1 A PRP O
m EP2226070A1 A VBP O
a EP2226070A1 A DT O
x EP2226070A1 A JJ O
iand EP2226070A1 A NN O
I EP2226070A1 A PRP O
m EP2226070A1 A VBP O
i EP2226070A1 A JJ O
n EP2226070A1 A VBP O
ivalues EP2226070A1 A NNS O
and EP2226070A1 A CC O
a EP2226070A1 A DT O
factor EP2226070A1 A NN O
F EP2226070A1 A NNP O
; EP2226070A1 A : O
and EP2226070A1 A CC O
determining EP2226070A1 A VBG O
the EP2226070A1 A DT O
difference EP2226070A1 A NN O
between EP2226070A1 A IN O
values EP2226070A1 A NNS O
I EP2226070A1 A PRP O
oand EP2226070A1 A VBP O
I EP2226070A1 A PRP O
m EP2226070A1 A VBP O
i EP2226070A1 A JJ O
n EP2226070A1 A VBP O
i EP2226070A1 A NN O
. EP2226070A1 A . O

Determining EP2226070A1 A VBG O
optimal EP2226070A1 A JJ O
dosage EP2226070A1 A NN O
( EP2226070A1 A ( O
D EP2226070A1 A NNP O
o EP2226070A1 A RB O
) EP2226070A1 A ) O
of EP2226070A1 A IN O
vitamin EP2226070A1 A NN O
K EP2226070A1 A NNP O
for EP2226070A1 A IN O
anticoagulant EP2226070A1 A JJ O
therapy EP2226070A1 A NN O
for EP2226070A1 A IN O
achieving EP2226070A1 A VBG O
and EP2226070A1 A CC O
constantly EP2226070A1 A RB O
maintaining EP2226070A1 A VBG O
the EP2226070A1 A DT O
value EP2226070A1 A NN O
of EP2226070A1 A IN O
international EP2226070A1 A JJ O
normalized EP2226070A1 A VBN O
ratio EP2226070A1 A NN O
( EP2226070A1 A ( O
INR EP2226070A1 A NNP O
) EP2226070A1 A ) O
target EP2226070A1 A NN O
I EP2226070A1 A PRP O
opreviously EP2226070A1 A RB O
determined EP2226070A1 A VBN O
by EP2226070A1 A IN O
the EP2226070A1 A DT O
prescriber EP2226070A1 A NN O
according EP2226070A1 A VBG O
to EP2226070A1 A TO O
the EP2226070A1 A DT O
pathology EP2226070A1 A NN O
of EP2226070A1 A IN O
the EP2226070A1 A DT O
treated EP2226070A1 A JJ O
patient EP2226070A1 A NN O
, EP2226070A1 A , O
comprises EP2226070A1 A NNS O
: EP2226070A1 A : O
( EP2226070A1 A ( O
a EP2226070A1 A DT O
) EP2226070A1 A ) O
recording EP2226070A1 A VBG O
the EP2226070A1 A DT O
I EP2226070A1 A PRP O
ovalue EP2226070A1 A VBP O
of EP2226070A1 A IN O
the EP2226070A1 A DT O
optimal EP2226070A1 A JJ O
target EP2226070A1 A NN O
INR EP2226070A1 A NNP O
; EP2226070A1 A : O
( EP2226070A1 A ( O
b EP2226070A1 A NN O
) EP2226070A1 A ) O
recording EP2226070A1 A VBG O
the EP2226070A1 A DT O
INR EP2226070A1 A NNP O
values EP2226070A1 A NNS O
measured EP2226070A1 A VBN O
in EP2226070A1 A IN O
a EP2226070A1 A DT O
given EP2226070A1 A VBN O
time EP2226070A1 A NN O
( EP2226070A1 A ( O
T EP2226070A1 A NNP O
1 EP2226070A1 A CD O
) EP2226070A1 A ) O
by EP2226070A1 A IN O
an EP2226070A1 A DT O
over EP2226070A1 A IN O
dose EP2226070A1 A NN O
( EP2226070A1 A ( O
D EP2226070A1 A NNP O
maxi EP2226070A1 A NN O
) EP2226070A1 A ) O
of EP2226070A1 A IN O
the EP2226070A1 A DT O
antivitamin EP2226070A1 A NN O
K EP2226070A1 A NNP O
previously EP2226070A1 A RB O
determined EP2226070A1 A VBN O
by EP2226070A1 A IN O
the EP2226070A1 A DT O
prescriber EP2226070A1 A NN O
over EP2226070A1 A IN O
the EP2226070A1 A DT O
recommended EP2226070A1 A JJ O
dosage EP2226070A1 A NN O
, EP2226070A1 A , O
for EP2226070A1 A IN O
determining EP2226070A1 A VBG O
a EP2226070A1 A DT O
first EP2226070A1 A JJ O
gradient EP2226070A1 A NN O
( EP2226070A1 A ( O
P EP2226070A1 A NNP O
1 EP2226070A1 A CD O
) EP2226070A1 A ) O
of EP2226070A1 A IN O
INR EP2226070A1 A NNP O
values EP2226070A1 A NNS O
according EP2226070A1 A VBG O
to EP2226070A1 A TO O
the EP2226070A1 A DT O
time EP2226070A1 A NN O
T EP2226070A1 A NNP O
1 EP2226070A1 A CD O
; EP2226070A1 A : O
( EP2226070A1 A ( O
c EP2226070A1 A NN O
) EP2226070A1 A ) O
from EP2226070A1 A IN O
the EP2226070A1 A DT O
gradient EP2226070A1 A NN O
P EP2226070A1 A NNP O
1 EP2226070A1 A CD O
, EP2226070A1 A , O
extrapolating EP2226070A1 A VBG O
and EP2226070A1 A CC O
recording EP2226070A1 A VBG O
a EP2226070A1 A DT O
I EP2226070A1 A PRP O
maxvalue EP2226070A1 A NN O
of EP2226070A1 A IN O
INR EP2226070A1 A NNP O
theoretically EP2226070A1 A RB O
reached EP2226070A1 A VBD O
from EP2226070A1 A IN O
the EP2226070A1 A DT O
day EP2226070A1 A NN O
where EP2226070A1 A WRB O
the EP2226070A1 A DT O
value EP2226070A1 A NN O
I EP2226070A1 A PRP O
oof EP2226070A1 A VBP O
the EP2226070A1 A DT O
target EP2226070A1 A NN O
INR EP2226070A1 A NNP O
is EP2226070A1 A VBZ O
reached EP2226070A1 A VBN O
and EP2226070A1 A CC O
at EP2226070A1 A IN O
the EP2226070A1 A DT O
end EP2226070A1 A NN O
of EP2226070A1 A IN O
a EP2226070A1 A DT O
determined EP2226070A1 A JJ O
period EP2226070A1 A NN O
T EP2226070A1 A NNP O
o EP2226070A1 A NN O
; EP2226070A1 A : O
recording EP2226070A1 A VBG O
the EP2226070A1 A DT O
INR EP2226070A1 A NNP O
values EP2226070A1 A NNS O
measured EP2226070A1 A VBN O
in EP2226070A1 A IN O
a EP2226070A1 A DT O
given EP2226070A1 A VBN O
period EP2226070A1 A NN O
T EP2226070A1 A NNP O
2from EP2226070A1 A CD O
an EP2226070A1 A DT O
underdosing EP2226070A1 A JJ O
D EP2226070A1 A NNP O
miniof EP2226070A1 A VBD O
the EP2226070A1 A DT O
antivitamin EP2226070A1 A NN O
K EP2226070A1 A NNP O
fixed EP2226070A1 A VBN O
by EP2226070A1 A IN O
the EP2226070A1 A DT O
prescriber EP2226070A1 A NN O
below EP2226070A1 A IN O
the EP2226070A1 A DT O
recommended EP2226070A1 A JJ O
dosage EP2226070A1 A NN O
, EP2226070A1 A , O
for EP2226070A1 A IN O
determining EP2226070A1 A VBG O
a EP2226070A1 A DT O
second EP2226070A1 A JJ O
gradient EP2226070A1 A NN O
P EP2226070A1 A NNP O
2of EP2226070A1 A CD O
values EP2226070A1 A NNS O
INR EP2226070A1 A NNP O
according EP2226070A1 A VBG O
to EP2226070A1 A TO O
the EP2226070A1 A DT O
time EP2226070A1 A NN O
T EP2226070A1 A NNP O
2 EP2226070A1 A CD O
; EP2226070A1 A : O
( EP2226070A1 A ( O
d EP2226070A1 A NN O
) EP2226070A1 A ) O
from EP2226070A1 A IN O
the EP2226070A1 A DT O
gradient EP2226070A1 A NN O
P2 EP2226070A1 A NNP O
, EP2226070A1 A , O
extrapolating EP2226070A1 A VBG O
and EP2226070A1 A CC O
recording EP2226070A1 A VBG O
a EP2226070A1 A DT O
INR EP2226070A1 A NNP O
I EP2226070A1 A PRP O
minivalue EP2226070A1 A VBP O
theoretically EP2226070A1 A RB O
reached EP2226070A1 A VBN O
from EP2226070A1 A IN O
the EP2226070A1 A DT O
day EP2226070A1 A NN O
where EP2226070A1 A WRB O
the EP2226070A1 A DT O
value EP2226070A1 A NN O
I EP2226070A1 A PRP O
oof EP2226070A1 A VBP O
the EP2226070A1 A DT O
target EP2226070A1 A NN O
INR EP2226070A1 A NNP O
is EP2226070A1 A VBZ O
reached EP2226070A1 A VBN O
and EP2226070A1 A CC O
at EP2226070A1 A IN O
the EP2226070A1 A DT O
end EP2226070A1 A NN O
of EP2226070A1 A IN O
the EP2226070A1 A DT O
fixed EP2226070A1 A JJ O
period EP2226070A1 A NN O
T EP2226070A1 A NNP O
0 EP2226070A1 A CD O
; EP2226070A1 A : O
( EP2226070A1 A ( O
e EP2226070A1 A NN O
) EP2226070A1 A ) O
calculating EP2226070A1 A VBG O
the EP2226070A1 A DT O
difference EP2226070A1 A NN O
between EP2226070A1 A IN O
the EP2226070A1 A DT O
theoretically EP2226070A1 A RB O
calculated EP2226070A1 A JJ O
INR EP2226070A1 A NNP O
I EP2226070A1 A PRP O
maxiand EP2226070A1 A VBP O
I EP2226070A1 A PRP O
minivalues EP2226070A1 A NNS O
, EP2226070A1 A , O
a EP2226070A1 A DT O
factor EP2226070A1 A NN O
F EP2226070A1 A NNP O
for EP2226070A1 A IN O
correcting EP2226070A1 A VBG O
dose EP2226070A1 A NN O
of EP2226070A1 A IN O
the EP2226070A1 A DT O
antivitamin EP2226070A1 A NN O
K EP2226070A1 A NNP O
expressed EP2226070A1 A VBN O
by EP2226070A1 A IN O
a EP2226070A1 A DT O
formula EP2226070A1 A NN O
as EP2226070A1 A IN O
given EP2226070A1 A VBN O
in EP2226070A1 A IN O
the EP2226070A1 A DT O
specification EP2226070A1 A NN O
; EP2226070A1 A : O
( EP2226070A1 A ( O
g EP2226070A1 A NN O
) EP2226070A1 A ) O
determining EP2226070A1 A VBG O
the EP2226070A1 A DT O
difference EP2226070A1 A NN O
between EP2226070A1 A IN O
the EP2226070A1 A DT O
values EP2226070A1 A NNS O
I EP2226070A1 A PRP O
oof EP2226070A1 A VBP O
the EP2226070A1 A DT O
optimal EP2226070A1 A JJ O
target EP2226070A1 A NN O
INR EP2226070A1 A NNP O
and EP2226070A1 A CC O
I EP2226070A1 A PRP O
miniof EP2226070A1 A VBP O
the EP2226070A1 A DT O
calculated EP2226070A1 A JJ O
INR EP2226070A1 A NNP O
minimum EP2226070A1 A NN O
, EP2226070A1 A , O
and EP2226070A1 A CC O
the EP2226070A1 A DT O
F EP2226070A1 A NNP O
factor EP2226070A1 A NN O
for EP2226070A1 A IN O
correcting EP2226070A1 A VBG O
the EP2226070A1 A DT O
antivitamin EP2226070A1 A NN O
K EP2226070A1 A NNP O
dose EP2226070A1 A NN O
, EP2226070A1 A , O
the EP2226070A1 A DT O
suitable EP2226070A1 A JJ O
dose EP2226070A1 A JJ O
D EP2226070A1 A NNP O
ofor EP2226070A1 A MD O
achieving EP2226070A1 A VBG O
and EP2226070A1 A CC O
maintaining EP2226070A1 A VBG O
a EP2226070A1 A DT O
constant EP2226070A1 A JJ O
value EP2226070A1 A NN O
I EP2226070A1 A PRP O
oof EP2226070A1 A VBP O
previously EP2226070A1 A RB O
fixed EP2226070A1 A VBN O
INR EP2226070A1 A NNP O
target EP2226070A1 A NN O
using EP2226070A1 A VBG O
a EP2226070A1 A DT O
formula EP2226070A1 A NN O
as EP2226070A1 A IN O
given EP2226070A1 A VBN O
in EP2226070A1 A IN O
the EP2226070A1 A DT O
specification EP2226070A1 A NN O
. EP2226070A1 A . O

Non-steroidal WO2008124878A1 T JJ O
compounds WO2008124878A1 T NNS O
. WO2008124878A1 T . O

Nanometer CN102499944A T NNP O
silver CN102499944A T NN O
antibiotic CN102499944A T JJ O
and CN102499944A T CC O
antiviral CN102499944A T JJ O
compound CN102499944A T NN O
liquid CN102499944A T NN O
and CN102499944A T CC O
its CN102499944A T PRP$ O
preparation CN102499944A T NN O
method CN102499944A T NN O
and CN102499944A T CC O
products CN102499944A T NNS O
. CN102499944A T . O

Intravenous CN1768742A T JJ O
formulation CN1768742A T NN O
of CN1768742A T IN O
ornidazole CN1768742A T NN O
and CN1768742A T CC O
its CN1768742A T PRP$ O
preparation CN1768742A T NN O
method CN1768742A T NN O
. CN1768742A T . O

Macromolecule-cis-platinum CN102499986A T NNP O
compound CN102499986A T NN O
, CN102499986A T , O
preparation CN102499986A T NN O
method CN102499986A T NN O
and CN102499986A T CC O
application CN102499986A T NN O
thereof CN102499986A T NN O
. CN102499986A T . O

Personal US20060199791 T JJ O
hygiene US20060199791 T NN O
and US20060199791 T CC O
hard US20060199791 T JJ O
surface US20060199791 T NN O
cleaning US20060199791 T NN O
agent US20060199791 T NN O
; US20060199791 T : O
acne US20060199791 T CC O
, US20060199791 T , O
skin US20060199791 T JJ O
complaints US20060199791 T NNS O
; US20060199791 T : O
effective US20060199791 T JJ O
against US20060199791 T IN O
antibiotic US20060199791 T JJ O
resistant US20060199791 T JJ O
bacteria US20060199791 T NNS O
. US20060199791 T . O

P38 US20130040962 T NNP I-UN
MAP US20130040962 T NNP I-UN
Kinase US20130040962 T NNP I-UN
Inhibitors US20130040962 T NNP O
. US20130040962 T . O

There US20130040962 A EX O
is US20130040962 A VBZ O
provided US20130040962 A VBN O
a US20130040962 A DT O
compound US20130040962 A NN O
of US20130040962 A IN O
formula US20130040962 A NN O
( US20130040962 A ( O
I US20130040962 A PRP O
) US20130040962 A ) O
: US20130040962 A : O
wherein US20130040962 A NN O
: US20130040962 A : O
J US20130040962 A JJ O
represents US20130040962 A VBZ O
( US20130040962 A ( O
A US20130040962 A DT O
) US20130040962 A ) O
: US20130040962 A : O
or US20130040962 A CC O
( US20130040962 A ( O
B US20130040962 A NNP O
) US20130040962 A ) O
: US20130040962 A : O
compositions US20130040962 A NNS O
comprising US20130040962 A VBG O
same US20130040962 A JJ O
, US20130040962 A , O
processes US20130040962 A NNS O
for US20130040962 A IN O
preparing US20130040962 A VBG O
said US20130040962 A VBD O
compounds US20130040962 A NNS O
and US20130040962 A CC O
use US20130040962 A NN O
thereof US20130040962 A NN O
in US20130040962 A IN O
treatment US20130040962 A NN O
, US20130040962 A , O
particularly US20130040962 A RB O
in US20130040962 A IN O
the US20130040962 A DT O
treatment US20130040962 A NN O
of US20130040962 A IN O
inflammatory US20130040962 A JJ O
disease US20130040962 A NN O
, US20130040962 A , O
such US20130040962 A JJ O
as US20130040962 A IN O
asthma US20130040962 A NN O
, US20130040962 A , O
COPD US20130040962 A NNP O
and US20130040962 A CC O
15 US20130040962 A CD O
rheumatoid US20130040962 A NN O
arthritis US20130040962 A NN O
. US20130040962 A . O

Plaster CN101417060A T NNP O
capable CN101417060A T JJ O
of CN101417060A T IN O
treating CN101417060A T VBG O
trauma CN101417060A T NN O
, CN101417060A T , O
traumatic CN101417060A T JJ O
injury CN101417060A T NN O
, CN101417060A T , O
alopecia CN101417060A T NN O
areata CN101417060A T NNS O
and CN101417060A T CC O
burn CN101417060A T NN O
and CN101417060A T CC O
scald CN101417060A T NN O
. CN101417060A T . O

Cefaclor CN103463093A T NNP O
dry CN103463093A T JJ O
suspension CN103463093A T NN O
composition CN103463093A T NN O
and CN103463093A T CC O
preparation CN103463093A T NN O
method CN103463093A T NN O
thereof CN103463093A T NN O
. CN103463093A T . O

Treatment EP1708712A1 T NN O
of EP1708712A1 T IN O
malignant EP1708712A1 T JJ O
gliomas EP1708712A1 T NN O
with EP1708712A1 T IN O
tgf-beta EP1708712A1 T JJ I-UN
inhibitors EP1708712A1 T NNS O
. EP1708712A1 T . O

The EP1708712A1 A DT O
invention EP1708712A1 A NN O
concerns EP1708712A1 A NNS O
methods EP1708712A1 A NNS O
of EP1708712A1 A IN O
treating EP1708712A1 A VBG O
malignant EP1708712A1 A JJ O
gliomas EP1708712A1 A NN O
, EP1708712A1 A , O
by EP1708712A1 A IN O
administering EP1708712A1 A VBG O
inhibitors EP1708712A1 A NNS O
of EP1708712A1 A IN O
TGF-β EP1708712A1 A NNP I-UN
the EP1708712A1 A DT O
TGF-β EP1708712A1 A NNP I-UN
signaling EP1708712A1 A VBG O
pathway EP1708712A1 A RB O
, EP1708712A1 A , O
including EP1708712A1 A VBG O
molecules EP1708712A1 A NNS O
preferably EP1708712A1 A RB O
binding EP1708712A1 A VBG O
to EP1708712A1 A TO O
the EP1708712A1 A DT O
type EP1708712A1 A NN I-UN
I EP1708712A1 A PRP I-UN
TGF-β EP1708712A1 A NNP I-UN
receptor EP1708712A1 A NN I-UN
( EP1708712A1 A ( O
TGFβ-R1 EP1708712A1 A NNP I-UN
) EP1708712A1 A ) O
. EP1708712A1 A . O

The EP1708712A1 A DT O
invention EP1708712A1 A NN O
also EP1708712A1 A RB O
concerns EP1708712A1 A VBZ O
methods EP1708712A1 A NNS O
for EP1708712A1 A IN O
reversing EP1708712A1 A VBG O
the EP1708712A1 A DT O
TGF-β-mediated EP1708712A1 A JJ O
effect EP1708712A1 A NN O
on EP1708712A1 A IN O
glioma EP1708712A1 A NN O
cells EP1708712A1 A NNS O
to EP1708712A1 A TO O
make EP1708712A1 A VB O
them EP1708712A1 A PRP O
less EP1708712A1 A JJR O
refractile EP1708712A1 A NN O
to EP1708712A1 A TO O
signaling EP1708712A1 A VBG O
and EP1708712A1 A CC O
other EP1708712A1 A JJ O
immune EP1708712A1 A JJ O
cells EP1708712A1 A NNS O
, EP1708712A1 A , O
comprising EP1708712A1 A VBG O
contacting EP1708712A1 A VBG O
a EP1708712A1 A DT O
glioma EP1708712A1 A NN O
cell EP1708712A1 A NN O
or EP1708712A1 A CC O
tissue EP1708712A1 A NN O
in EP1708712A1 A IN O
vivo EP1708712A1 A NN O
or EP1708712A1 A CC O
in EP1708712A1 A IN O
vitro EP1708712A1 A NN O
, EP1708712A1 A , O
with EP1708712A1 A IN O
an EP1708712A1 A DT O
inhibitor EP1708712A1 A NN O
of EP1708712A1 A IN O
TGF-β EP1708712A1 A NNP I-UN
. EP1708712A1 A . O

Arylvinylazacycloalkane WO2011112428A3 T NNP O
compounds WO2011112428A3 T NNS O
for WO2011112428A3 T IN O
constipation WO2011112428A3 T NN O
. WO2011112428A3 T . O

Use WO2010008263A1 T NNP O
of WO2010008263A1 T IN O
thalidomide WO2010008263A1 T NN O
to WO2010008263A1 T TO O
inhibit WO2010008263A1 T VB O
the WO2010008263A1 T DT O
osteoclast-activation WO2010008263A1 T NN O
process WO2010008263A1 T NN O
associated WO2010008263A1 T VBN O
with WO2010008263A1 T IN O
multiple WO2010008263A1 T JJ O
myeloma WO2010008263A1 T NN O
disease WO2010008263A1 T NN O
. WO2010008263A1 T . O

Hydrazines EP2247583A1 T NNS O
in EP2247583A1 T IN O
glaucoma EP2247583A1 T NN O
therapy EP2247583A1 T NN O
. EP2247583A1 T . O

Application CN102247347A T NN O
of CN102247347A T IN O
taurine CN102247347A T NN O
in CN102247347A T IN O
preparing CN102247347A T VBG O
medicament CN102247347A T NN O
for CN102247347A T IN O
preventing CN102247347A T VBG O
nerve CN102247347A T NN O
cell CN102247347A T NN O
damage CN102247347A T NN O
caused CN102247347A T VBN O
by CN102247347A T IN O
dependence CN102247347A T NN O
producing CN102247347A T VBG O
medicaments CN102247347A T NNS O
. CN102247347A T . O

Novel US20100069449 T NNP O
oxazolidinone US20100069449 T PRP O
derivative US20100069449 T JJ O
with US20100069449 T IN O
difluorophenyl US20100069449 T JJ O
moiety US20100069449 T NN O
, US20100069449 T , O
pharmaceutically US20100069449 T RB O
acceptable US20100069449 T JJ O
salt US20100069449 T NN O
thereof US20100069449 T NN O
, US20100069449 T , O
preparation US20100069449 T NN O
method US20100069449 T NN O
thereof US20100069449 T NN O
and US20100069449 T CC O
antibiotic US20100069449 T JJ O
composition US20100069449 T NN O
containing US20100069449 T VBG O
the US20100069449 T DT O
same US20100069449 T JJ O
as US20100069449 T IN O
an US20100069449 T DT O
active US20100069449 T JJ O
ingredient US20100069449 T NN O
. US20100069449 T . O

Histone US20120035257 T NNP O
Deacetylase US20120035257 T NNP O
Inhibitors US20120035257 T NNP O
. US20120035257 T . O

Compositions CA2799416A1 T NNS O
and CA2799416A1 T CC O
methods CA2799416A1 T NNS O
for CA2799416A1 T IN O
targeting CA2799416A1 T VBG O
a3g CA2799416A1 T NN O
: CA2799416A1 T : O
rna CA2799416A1 T NN O
complexes CA2799416A1 T NNS O
. CA2799416A1 T . O

Methods WO2010042991A1 T NNS O
of WO2010042991A1 T IN O
treatment WO2010042991A1 T NN O
utilising WO2010042991A1 T JJ O
glucan WO2010042991A1 T JJ O
formulations WO2010042991A1 T NNS O
. WO2010042991A1 T . O

Benzimidazole CN103087045A T NNP O
heterocyclic CN103087045A T JJ O
compound CN103087045A T NN O
, CN103087045A T , O
pharmaceutical CN103087045A T JJ O
composition CN103087045A T NN O
and CN103087045A T CC O
application CN103087045A T NN O
thereof CN103087045A T NN O
. CN103087045A T . O

protein US20090069297 T NN O
kinase US20090069297 T NN I-UN
inhibnitors US20090069297 T NNS O
such US20090069297 T JJ O
as US20090069297 T IN O
N- US20090069297 T NNP O
( US20090069297 T ( O
4- US20090069297 T JJ O
( US20090069297 T ( O
( US20090069297 T ( O
7- US20090069297 T CD O
( US20090069297 T ( O
methyloxy US20090069297 T NN O
) US20090069297 T ) O
-1,5-naphthyridin-4-yl US20090069297 T NN O
) US20090069297 T ) O
oxy US20090069297 T NN O
) US20090069297 T ) O
phenyl US20090069297 T NN O
) US20090069297 T ) O
-4-phenyl-1-phthalazinamine US20090069297 T NN O
, US20090069297 T , O
for US20090069297 T IN O
influencing US20090069297 T VBG O
the US20090069297 T DT O
process US20090069297 T NN O
of US20090069297 T IN O
cell US20090069297 T NN O
cycle US20090069297 T NN O
and US20090069297 T CC O
cell US20090069297 T NN O
proliferation US20090069297 T NN O
to US20090069297 T TO O
treat US20090069297 T VB O
cancer US20090069297 T NN O
; US20090069297 T : O
anticarcinogenic US20090069297 T JJ O
agents US20090069297 T NNS O
. US20090069297 T . O

The US20090069297 A DT O
present US20090069297 A JJ O
invention US20090069297 A NN O
relates US20090069297 A VBZ O
to US20090069297 A TO O
chemical US20090069297 A VB O
compounds US20090069297 A NNS O
having US20090069297 A VBG O
a US20090069297 A DT O
general US20090069297 A JJ O
formula US20090069297 A NN O
I US20090069297 A PRP O
wherein US20090069297 A VBP O
A1-8 US20090069297 A JJ O
, US20090069297 A , O
D′ US20090069297 A NNP O
, US20090069297 A , O
L1 US20090069297 A NNP O
, US20090069297 A , O
L2 US20090069297 A NNP O
, US20090069297 A , O
R1 US20090069297 A NNP O
, US20090069297 A , O
R6-8 US20090069297 A NNP O
and US20090069297 A CC O
n US20090069297 A NNS O
are US20090069297 A VBP O
defined US20090069297 A VBN O
herein US20090069297 A NN O
, US20090069297 A , O
and US20090069297 A CC O
synthetic US20090069297 A JJ O
intermediates US20090069297 A NNS O
, US20090069297 A , O
which US20090069297 A WDT O
are US20090069297 A VBP O
capable US20090069297 A JJ O
of US20090069297 A IN O
modulating US20090069297 A VBG O
various US20090069297 A JJ O
protein US20090069297 A JJ O
kinase US20090069297 A NN I-UN
receptor US20090069297 A NN O
enzymes US20090069297 A NNS O
and US20090069297 A CC O
, US20090069297 A , O
thereby US20090069297 A RB O
, US20090069297 A , O
influencing US20090069297 A VBG O
various US20090069297 A JJ O
disease US20090069297 A NN O
states US20090069297 A NNS O
and US20090069297 A CC O
conditions US20090069297 A NNS O
related US20090069297 A VBN O
to US20090069297 A TO O
the US20090069297 A DT O
activities US20090069297 A NNS O
of US20090069297 A IN O
such US20090069297 A JJ O
kinases US20090069297 A NNS O
. US20090069297 A . O

For US20090069297 A IN O
example US20090069297 A NN O
, US20090069297 A , O
the US20090069297 A DT O
compounds US20090069297 A NNS O
are US20090069297 A VBP O
capable US20090069297 A JJ O
of US20090069297 A IN O
modulating US20090069297 A VBG O
Aurora US20090069297 A NNP O
kinase US20090069297 A NN I-UN
thereby US20090069297 A RB O
influencing US20090069297 A VBG O
the US20090069297 A DT O
process US20090069297 A NN O
of US20090069297 A IN O
cell US20090069297 A NN O
cycle US20090069297 A NN O
and US20090069297 A CC O
cell US20090069297 A NN O
proliferation US20090069297 A NN O
to US20090069297 A TO O
treat US20090069297 A VB O
cancer US20090069297 A NN O
and US20090069297 A CC O
cancer-related US20090069297 A JJ O
diseases US20090069297 A NNS O
. US20090069297 A . O

The US20090069297 A DT O
invention US20090069297 A NN O
also US20090069297 A RB O
includes US20090069297 A VBZ O
pharmaceutical US20090069297 A JJ O
compositions US20090069297 A NNS O
, US20090069297 A , O
including US20090069297 A VBG O
the US20090069297 A DT O
compounds US20090069297 A NNS O
, US20090069297 A , O
and US20090069297 A CC O
methods US20090069297 A NNS O
of US20090069297 A IN O
treating US20090069297 A VBG O
disease US20090069297 A NN O
states US20090069297 A NNS O
related US20090069297 A VBN O
to US20090069297 A TO O
the US20090069297 A DT O
activity US20090069297 A NN O
of US20090069297 A IN O
Aurora US20090069297 A NNP I-UN
kinase US20090069297 A NN I-UN
. US20090069297 A . O

Prophylactic EP2025347A1 T JJ O
and EP2025347A1 T CC O
therapeutic EP2025347A1 T JJ O
agent EP2025347A1 T NN O
for EP2025347A1 T IN O
cancer EP2025347A1 T NN O
. EP2025347A1 T . O

A EP2025347A1 A DT O
Ras EP2025347A1 A NNP I-UN
, EP2025347A1 A , O
Raf EP2025347A1 A NNP I-UN
, EP2025347A1 A , O
MEK EP2025347A1 A NNP I-UN
, EP2025347A1 A , O
ERK EP2025347A1 A NNP I-UN
or EP2025347A1 A CC O
RSK EP2025347A1 A NNP I-UN
inhibitor EP2025347A1 A NN O
, EP2025347A1 A , O
namely EP2025347A1 A RB O
a EP2025347A1 A DT O
P-glycoprotein EP2025347A1 A JJ O
expression EP2025347A1 A NN O
inhibitor EP2025347A1 A NN O
or EP2025347A1 A CC O
a EP2025347A1 A DT O
BCRP EP2025347A1 A NNP I-UN
expression EP2025347A1 A NN O
inhibitor EP2025347A1 A NN O
, EP2025347A1 A , O
can EP2025347A1 A MD O
be EP2025347A1 A VB O
screened EP2025347A1 A VBN O
by EP2025347A1 A IN O
utilizing EP2025347A1 A VBG O
the EP2025347A1 A DT O
MAPK EP2025347A1 A NNP I-UN
signaling EP2025347A1 A VBG O
activity EP2025347A1 A NN O
as EP2025347A1 A IN O
an EP2025347A1 A DT O
indicator EP2025347A1 A NN O
. EP2025347A1 A . O

Methods US20090110712 T NNS O
and US20090110712 T CC O
systems US20090110712 T NNS O
for US20090110712 T IN O
use US20090110712 T NN O
of US20090110712 T IN O
photolyzable US20090110712 T JJ O
nitric US20090110712 T JJ O
oxide US20090110712 T NN O
donors US20090110712 T NNS O
. US20090110712 T . O

Six-membered CN101341124A T JJ O
heterocycles CN101341124A T NNS O
useful CN101341124A T JJ O
as CN101341124A T IN O
serine CN101341124A T JJ I-UN
protease CN101341124A T NN I-UN
inhibitors CN101341124A T NNS O
. CN101341124A T . O

The CN101341124A A DT O
compounds CN101341124A A NNS O
of CN101341124A A IN O
Formula CN101341124A A NNP O
( CN101341124A A ( O
I CN101341124A A PRP O
) CN101341124A A ) O
are CN101341124A A VBP O
useful CN101341124A A JJ O
as CN101341124A A IN O
selective CN101341124A A JJ O
inhibitors CN101341124A A NNS O
of CN101341124A A IN O
serine CN101341124A A JJ I-UN
protease CN101341124A A NN I-UN
enzymes CN101341124A A NNS O
of CN101341124A A IN O
the CN101341124A A DT O
coagulation CN101341124A A NN O
cascade CN101341124A A VBD O
and/or CN101341124A A JJ O
contact CN101341124A A NN O
activation CN101341124A A NN O
system CN101341124A A NN O
; CN101341124A A : O
for CN101341124A A IN O
example CN101341124A A NN O
thrombin CN101341124A A NN I-UN
, CN101341124A A , O
factor CN101341124A A NN I-UN
Xa CN101341124A A NNP I-UN
, CN101341124A A , O
factor CN101341124A A NN I-UN
XIa CN101341124A A NNP I-UN
, CN101341124A A , O
factor CN101341124A A NN I-UN
IXa CN101341124A A NNP I-UN
, CN101341124A A , O
factor CN101341124A A NN I-UN
VIIa CN101341124A A NNP I-UN
and/or CN101341124A A NN O
plasma CN101341124A A NN I-UN
kallikrein CN101341124A A NN I-UN
. CN101341124A A . O

In CN101341124A A IN O
particular CN101341124A A JJ O
, CN101341124A A , O
it CN101341124A A PRP O
relates CN101341124A A VBZ O
to CN101341124A A TO O
compounds CN101341124A A VB O
that CN101341124A A DT O
are CN101341124A A VBP O
selective CN101341124A A JJ O
factor CN101341124A A NN I-UN
XIa CN101341124A A NNP I-UN
inhibitors CN101341124A A NNS O
or CN101341124A A CC O
dual CN101341124A A JJ O
inhibitors CN101341124A A NNS O
of CN101341124A A IN O
fXIa CN101341124A A NN I-UN
and CN101341124A A CC O
plasma CN101341124A A NN I-UN
kallikrein CN101341124A A NN I-UN
. CN101341124A A . O

Bilayer CN102188425A T NNP O
tablet CN102188425A T NN O
containing CN102188425A T VBG O
niacin CN102188425A T NNS O
and CN102188425A T CC O
simvastatin CN102188425A T NN O
, CN102188425A T , O
and CN102188425A T CC O
preparation CN102188425A T NN O
method CN102188425A T NN O
thereof CN102188425A T NN O
. CN102188425A T . O

Cancer US20110076342 T NNP O
peptide US20110076342 T NN O
therapeutics US20110076342 T NNS O
. US20110076342 T . O

Fibrinogen US20100256161 T NNP I-UN
receptor US20100256161 T NN I-UN
antagonists US20100256161 T NNS O
and US20100256161 T CC O
their US20100256161 T PRP$ O
use US20100256161 T NN O
. US20100256161 T . O

Plaster US7094421 T NN O
containing US7094421 T VBG O
4-biphenylacetic US7094421 T JJ O
acid US7094421 T NN O
. US7094421 T . O

Cought CN1579401A T NNP O
and CN1579401A T CC O
asthma CN1579401A T JJ O
relieaving CN1579401A T VBG O
preparation CN1579401A T NN O
and CN1579401A T CC O
its CN1579401A T PRP$ O
preparation CN1579401A T NN O
method CN1579401A T NN O
. CN1579401A T . O

Controlled-release US20110294887 T JJ O
solution US20110294887 T NN O
formulations US20110294887 T NNS O
of US20110294887 T IN O
pregabalin US20110294887 T NN O
. US20110294887 T . O

Compounds EP0708660B1 T NNS O
useful EP0708660B1 T JJ O
for EP0708660B1 T IN O
preparing EP0708660B1 T VBG O
prodrugs EP0708660B1 T NNS O
of EP0708660B1 T IN O
protein EP0708660B1 T NN O
tyrosine EP0708660B1 T JJ O
kinase EP0708660B1 T NN O
inhibitors EP0708660B1 T NNS O
. EP0708660B1 T . O

Tilidine CN101288645A T NNP O
medicine CN101288645A T NN O
resin CN101288645A T NN O
oral CN101288645A T JJ O
turbid CN101288645A T NN O
suspension CN101288645A T NN O
and CN101288645A T CC O
preparation CN101288645A T NN O
method CN101288645A T NN O
thereof CN101288645A T NN O
. CN101288645A T . O

Process US7074921 T NN O
for US7074921 T IN O
the US7074921 T DT O
preparation US7074921 T NN O
of US7074921 T IN O
3,7-disubstituted-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine US7074921 T JJ O
compounds US7074921 T NNS O
. US7074921 T . O

Convergent CN103120720A T NN O
and CN103120720A T CC O
divergent CN103120720A T NN O
agent CN103120720A T NN O
and CN103120720A T CC O
preparation CN103120720A T NN O
method CN103120720A T NN O
thereof CN103120720A T NN O
. CN103120720A T . O

Medicine CN101229159A T NNP O
for CN101229159A T IN O
treating CN101229159A T VBG O
infectious CN101229159A T JJ O
diarrhea CN101229159A T NN O
and CN101229159A T CC O
peptic CN101229159A T JJ O
ulcer CN101229159A T NN O
, CN101229159A T , O
preparing CN101229159A T VBG O
method CN101229159A T NN O
and CN101229159A T CC O
applications CN101229159A T NNS O
thereof CN101229159A T VBP O
. CN101229159A T . O

Method US20100256157 T NNP O
of US20100256157 T IN O
treatment US20100256157 T NN O
. US20100256157 T . O

Use EP1044008B1 T NNP O
of EP1044008B1 T IN O
aliphatic EP1044008B1 T JJ O
polyamines EP1044008B1 T NNS O
for EP1044008B1 T IN O
reducing EP1044008B1 T VBG O
oxalate EP1044008B1 T NN O
. EP1044008B1 T . O

Amids WO2012006958A1 T NNS O
substituted WO2012006958A1 T VBD O
indazole WO2012006958A1 T JJ O
derivativees WO2012006958A1 T NNS O
as WO2012006958A1 T IN O
ploy WO2012006958A1 T NN I-UN
( WO2012006958A1 T ( I-UN
adp-ribose WO2012006958A1 T JJ I-UN
) WO2012006958A1 T ) I-UN
polymerase WO2012006958A1 T NN I-UN
inhibitors WO2012006958A1 T NNS O
. WO2012006958A1 T . O

Amide WO2012006958A1 A RB O
substituted WO2012006958A1 A VBN O
indazoles WO2012006958A1 A NNS O
and WO2012006958A1 A CC O
benzotriazoles WO2012006958A1 A NNS O
as WO2012006958A1 A IN O
inhibitors WO2012006958A1 A NNS O
of WO2012006958A1 A IN O
the WO2012006958A1 A DT O
enzyme WO2012006958A1 A NN O
poly WO2012006958A1 A NN I-UN
( WO2012006958A1 A ( I-UN
ADP-ribose WO2012006958A1 A NNP I-UN
) WO2012006958A1 A ) I-UN
polymerase WO2012006958A1 A NN I-UN
( WO2012006958A1 A ( O
PARP WO2012006958A1 A NNP I-UN
) WO2012006958A1 A ) O
. WO2012006958A1 A . O

Use EP1185306B1 T NNP O
of EP1185306B1 T IN O
viral EP1185306B1 T JJ O
vectors EP1185306B1 T NNS O
and EP1185306B1 T CC O
charged EP1185306B1 T VBD O
molecules EP1185306B1 T NNS O
for EP1185306B1 T IN O
gene EP1185306B1 T NN O
therapy EP1185306B1 T NN O
. EP1185306B1 T . O

New US20100286196 T NNP O
inhibitor US20100286196 T NN O
of US20100286196 T IN O
dd-peptidase US20100286196 T NN I-UN
and US20100286196 T CC O
its US20100286196 T PRP$ O
use US20100286196 T NN O
as US20100286196 T IN O
antibiotic US20100286196 T JJ O
or US20100286196 T CC O
anticancer US20100286196 T JJ O
drug US20100286196 T NN O
. US20100286196 T . O

Para-alkyl-substituted EP1778622A1 T JJ O
n- EP1778622A1 T JJ O
( EP1778622A1 T ( O
4-hydroxy-3-methoxy-benzyl EP1778622A1 T JJ O
) EP1778622A1 T ) O
cinnamamides EP1778622A1 T NNS O
and EP1778622A1 T CC O
the EP1778622A1 T DT O
use EP1778622A1 T NN O
thereof EP1778622A1 T NN O
for EP1778622A1 T IN O
producing EP1778622A1 T VBG O
drugs EP1778622A1 T NNS O
. EP1778622A1 T . O

Compositions US20090215852 T NNS O
and US20090215852 T CC O
methods US20090215852 T NNS O
for US20090215852 T IN O
ameliorating US20090215852 T VBG O
cachexia US20090215852 T NN O
. US20090215852 T . O

The US20090215852 A DT O
invention US20090215852 A NN O
provides US20090215852 A VBZ O
compositions US20090215852 A NNS O
and US20090215852 A CC O
therapies US20090215852 A NNS O
comprising US20090215852 A VBG O
use US20090215852 A NN O
of US20090215852 A IN O
a US20090215852 A DT O
beta US20090215852 A NN O
adrenergic US20090215852 A JJ O
antagonist US20090215852 A NN O
( US20090215852 A ( O
also US20090215852 A RB O
called US20090215852 A VBN O
“beta US20090215852 A NN O
blockers” US20090215852 A NN O
, US20090215852 A , O
e.g. US20090215852 A NN O
, US20090215852 A , O
propranolol US20090215852 A NN O
) US20090215852 A ) O
in US20090215852 A IN O
combination US20090215852 A NN O
with US20090215852 A IN O
an US20090215852 A DT O
anti-inflammatory US20090215852 A JJ O
agent US20090215852 A NN O
, US20090215852 A , O
e.g. US20090215852 A NN O
, US20090215852 A , O
a US20090215852 A DT O
nonsteroidal US20090215852 A JJ O
anti-inflammatory US20090215852 A JJ O
drug US20090215852 A NN O
( US20090215852 A ( O
NSAID US20090215852 A NNP O
) US20090215852 A ) O
, US20090215852 A , O
an US20090215852 A DT I-UN
angiotensin-converting US20090215852 A JJ I-UN
enzyme US20090215852 A NN I-UN
( US20090215852 A ( O
ACE US20090215852 A NNP I-UN
) US20090215852 A ) O
inhibitor US20090215852 A NN O
, US20090215852 A , O
an US20090215852 A DT O
angiotensin US20090215852 A NN O
receptor US20090215852 A NN O
blocker US20090215852 A NN O
( US20090215852 A ( O
ARB US20090215852 A NNP O
) US20090215852 A ) O
, US20090215852 A , O
an US20090215852 A DT O
anabolic US20090215852 A JJ O
steroid US20090215852 A NN O
, US20090215852 A , O
a US20090215852 A DT O
natural US20090215852 A JJ O
oil US20090215852 A NN O
or US20090215852 A CC O
fatty US20090215852 A JJ O
acid US20090215852 A NN O
or US20090215852 A CC O
any US20090215852 A DT O
combination US20090215852 A NN O
thereof US20090215852 A NN O
. US20090215852 A . O

Combination US20120321637 T NN O
cancer US20120321637 T NN O
therapy US20120321637 T NN O
with US20120321637 T IN O
herv US20120321637 T JJ O
inhibition US20120321637 T NN O
. US20120321637 T . O

Use EP1743631A2 T NNP O
of EP1743631A2 T IN O
an EP1743631A2 T DT O
amphetamine EP1743631A2 T JJ O
composition EP1743631A2 T NN O
for EP1743631A2 T IN O
regulating EP1743631A2 T VBG O
memory EP1743631A2 T NN O
consolidation EP1743631A2 T NN O
. EP1743631A2 T . O

Combinations WO2010080757A3 T NNS O
with WO2010080757A3 T IN O
an WO2010080757A3 T DT O
alpha-4beta-2 WO2010080757A3 T JJ O
nicotinic WO2010080757A3 T JJ O
agonist WO2010080757A3 T NN O
. WO2010080757A3 T . O

Drug EP1977766A1 T NN O
delivery EP1977766A1 T NN O
material EP1977766A1 T NN O
. EP1977766A1 T . O

From US8263142 T IN O
olives US8263142 T NNS O
; US8263142 T : O
incubating US8263142 T VBG O
the US8263142 T DT O
acidified US8263142 T JJ O
water US8263142 T NN O
until US8263142 T IN O
at US8263142 T IN O
least US8263142 T JJS O
75 US8263142 T CD O
percent US8263142 T NN O
of US8263142 T IN O
oleoeuropein US8263142 T NN O
has US8263142 T VBZ O
been US8263142 T VBN O
converted US8263142 T VBN O
to US8263142 T TO O
hydroxytyrosol US8263142 T VB O
; US8263142 T : O
nutraceuticals US8263142 T NNS O
in US8263142 T IN O
tablet US8263142 T NN O
, US8263142 T , O
capsule US8263142 T NN O
, US8263142 T , O
pill US8263142 T NN O
or US8263142 T CC O
confection US8263142 T NN O
form US8263142 T NN O
; US8263142 T : O
antioxidants US8263142 T NNS O
. US8263142 T . O

METHOD WO2014083107A1 T NNP O
OF WO2014083107A1 T NNP O
PREPARATION WO2014083107A1 T NNP O
OF WO2014083107A1 T NNP O
CRYSTAL WO2014083107A1 T NNP O
FORMS WO2014083107A1 T NNP O
OF WO2014083107A1 T IN O
4- WO2014083107A1 T NNP O
( WO2014083107A1 T ( O
CYCLOPROPYLMETHOXY WO2014083107A1 T NNP O
) WO2014083107A1 T ) O
-N- WO2014083107A1 T NN O
( WO2014083107A1 T ( O
3,5-DICHLORO-1-OXIDOPYRIDYN-4-yl WO2014083107A1 T JJ O
) WO2014083107A1 T ) O
-5-METHOXYPYRIDINE-2-CARBOXAMIDE WO2014083107A1 T NN O
AND WO2014083107A1 T NNP O
CRISTAL WO2014083107A1 T NNP O
FORMS WO2014083107A1 T NNP O
THEREOF WO2014083107A1 T NNP O
. WO2014083107A1 T . O

The WO2014083107A1 A DT O
present WO2014083107A1 A JJ O
invention WO2014083107A1 A NN O
relates WO2014083107A1 A VBZ O
to WO2014083107A1 A TO O
a WO2014083107A1 A DT O
process WO2014083107A1 A NN O
of WO2014083107A1 A IN O
preparation WO2014083107A1 A NN O
of WO2014083107A1 A IN O
Crystal WO2014083107A1 A NNP O
Forms WO2014083107A1 A NNP O
of WO2014083107A1 A IN O
4- WO2014083107A1 A NNP O
( WO2014083107A1 A ( O
cyclopropylmethoxy WO2014083107A1 A NN O
) WO2014083107A1 A ) O
-N- WO2014083107A1 A NN O
( WO2014083107A1 A ( O
3,5-dichloro-1-oxidopyridin-4-yl WO2014083107A1 A JJ O
) WO2014083107A1 A ) O
-5-methoxypyridine-2- WO2014083107A1 A FW O
carboxamide WO2014083107A1 A NN O
of WO2014083107A1 A IN O
formula WO2014083107A1 A NN O
( WO2014083107A1 A ( O
I WO2014083107A1 A PRP O
) WO2014083107A1 A ) O
, WO2014083107A1 A , O
said WO2014083107A1 A VBD O
Crystal WO2014083107A1 A NNP O
Forms WO2014083107A1 A NNP O
which WO2014083107A1 A WDT O
are WO2014083107A1 A VBP O
designated WO2014083107A1 A VBN O
as WO2014083107A1 A IN O
Crystal WO2014083107A1 A NNP O
Forms WO2014083107A1 A NNP O
A WO2014083107A1 A NNP O
to WO2014083107A1 A TO O
I WO2014083107A1 A PRP O
A WO2014083107A1 A DT O
and WO2014083107A1 A CC O
their WO2014083107A1 A PRP$ O
use WO2014083107A1 A NN O
as WO2014083107A1 A IN O
a WO2014083107A1 A DT O
medicament WO2014083107A1 A NN O
. WO2014083107A1 A . O

Tetrandrine CN102898433A T NNP O
gallate CN102898433A T NN O
and CN102898433A T CC O
drug CN102898433A T NN O
composition CN102898433A T NN O
, CN102898433A T , O
preparation CN102898433A T NN O
method CN102898433A T NN O
and CN102898433A T CC O
applications CN102898433A T NNS O
thereof CN102898433A T VBP O
. CN102898433A T . O

Inhibition US20080031817 T NN O
Of US20080031817 T IN O
Superoxide US20080031817 T NNP O
Dismutase US20080031817 T NNP O
By US20080031817 T IN O
Tetrathiomolybdate US20080031817 T NNP O
: US20080031817 T : O
Identification US20080031817 T NN O
Of US20080031817 T IN O
New US20080031817 T NNP O
Anti-Angiogenic US20080031817 T NNP O
And US20080031817 T CC O
Antitumor US20080031817 T NNP O
Agents US20080031817 T NNP O
. US20080031817 T . O

Slow CN1857262A T NNP O
released CN1857262A T VBD O
compound CN1857262A T NN O
amoxicillin/clavulanate CN1857262A T NN O
preparation CN1857262A T NN O
. CN1857262A T . O

Lumbago CN102772599A T RB O
plaster CN102772599A T NN O
. CN102772599A T . O

Pharmaceutical CA2175429C T JJ O
compositions CA2175429C T NNS O
and CA2175429C T CC O
methods CA2175429C T NNS O
. CA2175429C T . O

Plaster CN102178894A T NN O
and CN102178894A T CC O
preparation CN102178894A T NN O
method CN102178894A T NN O
of CN102178894A T IN O
plaster CN102178894A T NN O
. CN102178894A T . O

PHARMACEUTICAL US20100292166 T NNP O
COMPOSITION US20100292166 T NNP O
FOR US20100292166 T NNP O
TREATING US20100292166 T NNP O
MALIGNANT US20100292166 T NNP O
TUMORS US20100292166 T NNP O
CONTAINING US20100292166 T NNP O
HUMAN US20100292166 T NNP I-UN
p31 US20100292166 T NN I-UN
GENES US20100292166 T NNP O
. US20100292166 T . O

A US20100292166 A DT O
pharmaceutical US20100292166 A JJ O
composition US20100292166 A NN O
for US20100292166 A IN O
the US20100292166 A DT O
treatment US20100292166 A NN O
of US20100292166 A IN O
malignant US20100292166 A JJ O
tumors US20100292166 A NNS O
comprising US20100292166 A VBG O
a US20100292166 A DT O
human US20100292166 A JJ I-UN
p31comet US20100292166 A NN O
gene US20100292166 A NN O
encoding US20100292166 A VBG O
protein US20100292166 A NNS O
represented US20100292166 A VBN O
by US20100292166 A IN O
SEQ US20100292166 A NNP O
ID US20100292166 A NNP O
NO US20100292166 A NNP O
: US20100292166 A : O
3 US20100292166 A CD O
or US20100292166 A CC O
4 US20100292166 A CD O
as US20100292166 A IN O
an US20100292166 A DT O
effective US20100292166 A JJ O
component US20100292166 A NN O
is US20100292166 A VBZ O
provided US20100292166 A VBN O
. US20100292166 A . O

Use EP1307205B1 T NNP O
of EP1307205B1 T IN O
7alpha-hydroxy-estradiol EP1307205B1 T NNP O
, EP1307205B1 T , O
7alpha-hydroxy-dehydroepiandrosterone EP1307205B1 T CD O
and EP1307205B1 T CC O
7alpha-hydroxy-pregnenolone EP1307205B1 T CD O
derivatives EP1307205B1 T NNS O
for EP1307205B1 T IN O
treating EP1307205B1 T VBG O
acute EP1307205B1 T JJ O
cellular EP1307205B1 T JJ O
degeneration EP1307205B1 T NN O
. EP1307205B1 T . O

Enhanced EP2307022A1 T NNP O
nsaid EP2307022A1 T JJ O
formulations EP2307022A1 T NNS O
. EP2307022A1 T . O

Methods WO2013158874A1 T NNS O
of WO2013158874A1 T IN O
producing WO2013158874A1 T VBG O
anamorelin WO2013158874A1 T NN O
hydrochloride WO2013158874A1 T NN O
having WO2013158874A1 T VBG O
controlled WO2013158874A1 T VBN O
chloride WO2013158874A1 T JJ O
content WO2013158874A1 T NN O
. WO2013158874A1 T . O

Antiinflammatory US20080269280 T JJ O
agents US20080269280 T NNS O
; US20080269280 T : O
rheumatic US20080269280 T JJ O
diseases US20080269280 T NNS O
; US20080269280 T : O
multiple US20080269280 T JJ O
sclerosis US20080269280 T NN O
. US20080269280 T . O

Compounds US20080269280 A NNS O
are US20080269280 A VBP O
provided US20080269280 A VBN O
that US20080269280 A IN O
act US20080269280 A NN O
as US20080269280 A IN O
potent US20080269280 A JJ O
antagonists US20080269280 A NNS O
of US20080269280 A IN O
the US20080269280 A DT O
CCR1 US20080269280 A NNP I-UN
receptor US20080269280 A NN O
, US20080269280 A , O
and US20080269280 A CC O
have US20080269280 A VBP O
in US20080269280 A IN O
vivo US20080269280 A JJ O
anti-inflammatory US20080269280 A JJ O
activity US20080269280 A NN O
. US20080269280 A . O

The US20080269280 A DT O
compounds US20080269280 A NNS O
are US20080269280 A VBP O
generally US20080269280 A RB O
monocyclic US20080269280 A JJ O
and US20080269280 A CC O
bicyclic US20080269280 A JJ O
compounds US20080269280 A NNS O
and US20080269280 A CC O
are US20080269280 A VBP O
useful US20080269280 A JJ O
in US20080269280 A IN O
pharmaceutical US20080269280 A JJ O
compositions US20080269280 A NNS O
, US20080269280 A , O
methods US20080269280 A NNS O
for US20080269280 A IN O
the US20080269280 A DT O
treatment US20080269280 A NN O
of US20080269280 A IN O
CCR1-mediated US20080269280 A JJ O
diseases US20080269280 A NNS O
, US20080269280 A , O
and US20080269280 A CC O
as US20080269280 A IN O
controls US20080269280 A NNS O
in US20080269280 A IN O
assays US20080269280 A NNS O
for US20080269280 A IN O
the US20080269280 A DT O
identification US20080269280 A NN O
of US20080269280 A IN O
competitive US20080269280 A JJ O
CCR1 US20080269280 A NNP I-UN
antagonists US20080269280 A NNS O
. US20080269280 A . O

Nitration US7067681 T NN O
of US7067681 T IN O
tetracyclines US7067681 T NNS O
and US7067681 T CC O
derivatives US7067681 T NNS O
, US7067681 T , O
then US7067681 T RB O
reducing US7067681 T VBG O
, US7067681 T , O
diazotizing US7067681 T VBG O
and US7067681 T CC O
alkylation US7067681 T NN O
on US7067681 T IN O
the US7067681 T DT O
presence US7067681 T NN O
of US7067681 T IN O
palladium US7067681 T NN O
chloride US7067681 T NN O
; US7067681 T : O
catalysis US7067681 T NN O
; US7067681 T : O
antibiotics US7067681 T NNS O
. US7067681 T . O

Aryl US20060293285 T NNP O
Phosphate US20060293285 T NNP O
Derivatives US20060293285 T NNP O
of US20060293285 T IN O
d4T US20060293285 T NN O
. US20060293285 T . O

In US20060293285 A IN O
particular US20060293285 A JJ O
, US20060293285 A , O
these US20060293285 A DT O
derivatives US20060293285 A NNS O
are US20060293285 A VBP O
potent US20060293285 A JJ O
inhibitors US20060293285 A NNS O
of US20060293285 A IN O
HIV US20060293285 A NNP I-UN
reverse US20060293285 A NN I-UN
transcriptase US20060293285 A NN I-UN
. US20060293285 A . O

CA125 US20100331536 T NNP I-UN
gene US20100331536 T NN O
and US20100331536 T CC O
its US20100331536 T PRP$ O
use US20100331536 T NN O
for US20100331536 T IN O
diagnostic US20100331536 T JJ O
and US20100331536 T CC O
therapeutic US20100331536 T JJ O
interventions US20100331536 T NNS O
. US20100331536 T . O

The US20100331536 A DT O
CA125 US20100331536 A NNP I-UN
gene US20100331536 A NN O
has US20100331536 A VBZ O
been US20100331536 A VBN O
cloned US20100331536 A VBN O
and US20100331536 A CC O
multiple US20100331536 A JJ O
repeat US20100331536 A NN O
sequences US20100331536 A NNS O
as US20100331536 A RB O
well US20100331536 A RB O
as US20100331536 A IN O
the US20100331536 A DT O
carboxy US20100331536 A NN O
terminus US20100331536 A NN O
have US20100331536 A VBP O
been US20100331536 A VBN O
identified US20100331536 A VBN O
. US20100331536 A . O

The US20100331536 A DT O
CA125 US20100331536 A NNP I-UN
molecule US20100331536 A NN O
comprises US20100331536 A NNS O
three US20100331536 A CD O
major US20100331536 A JJ O
domains US20100331536 A NNS O
: US20100331536 A : O
an US20100331536 A DT O
extracellular US20100331536 A JJ O
amino US20100331536 A NN O
terminal US20100331536 A NN O
domain US20100331536 A NN O
( US20100331536 A ( O
Domain US20100331536 A NNP O
1 US20100331536 A CD O
) US20100331536 A ) O
; US20100331536 A : O
a US20100331536 A DT O
large US20100331536 A JJ O
multiple US20100331536 A JJ O
repeat US20100331536 A NN O
domain US20100331536 A NN O
( US20100331536 A ( O
Domain US20100331536 A NNP O
2 US20100331536 A CD O
) US20100331536 A ) O
; US20100331536 A : O
and US20100331536 A CC O
a US20100331536 A DT O
carboxy US20100331536 A JJ O
terminal US20100331536 A NN O
domain US20100331536 A NN O
( US20100331536 A ( O
Domain US20100331536 A NNP O
3 US20100331536 A CD O
) US20100331536 A ) O
which US20100331536 A WDT O
includes US20100331536 A VBZ O
a US20100331536 A DT O
transmembrane US20100331536 A NN O
anchor US20100331536 A NN O
with US20100331536 A IN O
a US20100331536 A DT O
short US20100331536 A JJ O
cytoplasmic US20100331536 A NN O
domain US20100331536 A NN O
. US20100331536 A . O

More US20100331536 A JJR O
than US20100331536 A IN O
60 US20100331536 A CD O
repeat US20100331536 A NN O
units US20100331536 A NNS O
have US20100331536 A VBP O
been US20100331536 A VBN O
identified US20100331536 A VBN O
, US20100331536 A , O
sequenced US20100331536 A VBN O
, US20100331536 A , O
and US20100331536 A CC O
contiguously US20100331536 A RB O
placed US20100331536 A VBN O
in US20100331536 A IN O
the US20100331536 A DT O
CA125 US20100331536 A NNP I-UN
domain US20100331536 A NN O
structure US20100331536 A NN O
. US20100331536 A . O

More US20100331536 A RBR O
specifically US20100331536 A RB O
, US20100331536 A , O
this US20100331536 A DT O
invention US20100331536 A NN O
is US20100331536 A VBZ O
directed US20100331536 A VBN O
to US20100331536 A TO O
a US20100331536 A DT O
CA125 US20100331536 A NNP I-UN
cDNA US20100331536 A NN O
sequence US20100331536 A NN O
which US20100331536 A WDT O
can US20100331536 A MD O
be US20100331536 A VB O
introduced US20100331536 A VBN O
into US20100331536 A IN O
animal US20100331536 A NN O
or US20100331536 A CC O
human US20100331536 A JJ O
cells US20100331536 A NNS O
to US20100331536 A TO O
achieve US20100331536 A VB O
transcription US20100331536 A NN O
or US20100331536 A CC O
expression US20100331536 A NN O
of US20100331536 A IN O
the US20100331536 A DT O
cDNA US20100331536 A NN O
. US20100331536 A . O

Vermiculite CN101653452B T NNP O
extracting CN101653452B T VBG O
solution CN101653452B T NN O
and CN101653452B T CC O
application CN101653452B T NN O
thereof CN101653452B T NN O
. CN101653452B T . O

Drop CN103613490A T NNP O
diterpenoid CN103613490A T NN O
type CN103613490A T NN O
compound CN103613490A T NN O
as CN103613490A T RB O
well CN103613490A T RB O
as CN103613490A T IN O
preparation CN103613490A T NN O
method CN103613490A T NN O
and CN103613490A T CC O
application CN103613490A T NN O
thereof CN103613490A T NN O
. CN103613490A T . O

Pharmaceutical WO2012006683A1 T JJ O
compositions WO2012006683A1 T NNS O
for WO2012006683A1 T IN O
sustained WO2012006683A1 T JJ O
delivery WO2012006683A1 T NN O
of WO2012006683A1 T IN O
benzodiazepine WO2012006683A1 T NN O
antagonists WO2012006683A1 T NNS O
. WO2012006683A1 T . O

Immunophilin US20100196355 T NNP O
Ligands US20100196355 T NNP O
and US20100196355 T CC O
Methods US20100196355 T NNP O
for US20100196355 T IN O
Modulating US20100196355 T NNP O
Immunophilin US20100196355 T NNP O
and US20100196355 T CC O
Calcium US20100196355 T NNP O
Channel US20100196355 T NNP O
Activity US20100196355 T NNP O
. US20100196355 T . O

Boron-based WO2013134230A1 T JJ O
4-hydroxytamoxifen WO2013134230A1 T JJ O
and WO2013134230A1 T CC O
endoxifen WO2013134230A1 T JJ O
prodrugs WO2013134230A1 T NNS O
as WO2013134230A1 T IN O
treatment WO2013134230A1 T NN O
for WO2013134230A1 T IN O
breast WO2013134230A1 T NN O
cancer WO2013134230A1 T NN O
. WO2013134230A1 T . O

Appear US7476657 T VB O
to US7476657 T TO O
function US7476657 T VB O
at US7476657 T IN O
least US7476657 T JJS O
in US7476657 T IN O
part US7476657 T NN O
by US7476657 T IN O
inhibiting US7476657 T VBG O
G2 US7476657 T NNP O
cell US7476657 T NN O
cycle US7476657 T NN O
checkpoint US7476657 T NN O
; US7476657 T : O
useful US7476657 T JJ O
in US7476657 T IN O
treating US7476657 T VBG O
metastatic US7476657 T JJ O
and US7476657 T CC O
non-metastatic US7476657 T JJ O
solid US7476657 T JJ O
or US7476657 T CC O
liquid US7476657 T JJ O
tumors US7476657 T NNS O
. US7476657 T . O

Selenium-enriched CN103301180A T JJ O
ganoderan CN103301180A T NN O
and CN103301180A T CC O
preparation CN103301180A T NN O
method CN103301180A T NN O
thereof CN103301180A T NN O
. CN103301180A T . O

ROS US20120208824 T NNP O
Kinase US20120208824 T NNP O
in US20120208824 T IN O
Lung US20120208824 T NNP O
Cancer US20120208824 T NNP O
. US20120208824 T . O

Bicyclic CN103153994A T NNP O
heteroaryl CN103153994A T NN O
kinase CN103153994A T NN I-UN
inhibitors CN103153994A T NNS O
and CN103153994A T CC O
methods CN103153994A T NNS O
of CN103153994A T IN O
use CN103153994A T NN O
. CN103153994A T . O

Provided CN103153994A A VBN O
are CN103153994A A VBP O
compounds CN103153994A A NNS O
having CN103153994A A VBG O
an CN103153994A A DT O
inhibitory CN103153994A A JJ O
effect CN103153994A A NN O
on CN103153994A A IN O
kinases CN103153994A A NNS I-UN
including CN103153994A A VBG O
Mixed CN103153994A A JJ I-UN
Lineage CN103153994A A NNP I-UN
Kinases CN103153994A A NNP I-UN
. CN103153994A A . O

Also CN103153994A A RB O
provided CN103153994A A VBN O
are CN103153994A A VBP O
pharmaceutical CN103153994A A JJ O
compositions CN103153994A A NNS O
, CN103153994A A , O
methods CN103153994A A NNS O
of CN103153994A A IN O
preparing CN103153994A A VBG O
the CN103153994A A DT O
compounds CN103153994A A NNS O
, CN103153994A A , O
synthetic CN103153994A A JJ O
intermediates CN103153994A A NNS O
, CN103153994A A , O
and CN103153994A A CC O
methods CN103153994A A NNS O
of CN103153994A A IN O
using CN103153994A A VBG O
the CN103153994A A DT O
compounds CN103153994A A NNS O
, CN103153994A A , O
independently CN103153994A A RB O
or CN103153994A A CC O
in CN103153994A A IN O
combination CN103153994A A NN O
with CN103153994A A IN O
other CN103153994A A JJ O
therapeutic CN103153994A A JJ O
agents CN103153994A A NNS O
, CN103153994A A , O
for CN103153994A A IN O
treating CN103153994A A VBG O
diseases CN103153994A A NNS O
and CN103153994A A CC O
conditions CN103153994A A NNS O
that CN103153994A A WDT O
are CN103153994A A VBP O
affected CN103153994A A VBN O
by CN103153994A A IN O
Mixed CN103153994A A NNP I-UN
Lineage CN103153994A A NNP I-UN
Kinase CN103153994A A NNP I-UN
inhibition CN103153994A A NN O
. CN103153994A A . O

Also CN103153994A A RB O
provided CN103153994A A VBN O
are CN103153994A A VBP O
methods CN103153994A A NNS O
of CN103153994A A IN O
treatment CN103153994A A NN O
of CN103153994A A IN O
neuropsychiatric CN103153994A A JJ O
disorders CN103153994A A NNS O
that CN103153994A A WDT O
comprise CN103153994A A VBP O
the CN103153994A A DT O
inhibition CN103153994A A NN O
of CN103153994A A IN O
Mixed CN103153994A A NNP I-UN
Lineage CN103153994A A NNP I-UN
Kinases CN103153994A A NNP I-UN
. CN103153994A A . O

Pharmaceutical US20110251220 T JJ O
compositions US20110251220 T NNS O
comprising US20110251220 T VBG O
gamma US20110251220 T JJ O
secretase US20110251220 T NN O
modulators US20110251220 T NNS O
. US20110251220 T . O

Pharmaceutical EP2292587A1 T JJ O
composition EP2292587A1 T NN O
for EP2292587A1 T IN O
inhibiting EP2292587A1 T VBG O
the EP2292587A1 T DT O
transcription EP2292587A1 T NN O
factor EP2292587A1 T NN O
inducible EP2292587A1 T JJ O
by EP2292587A1 T IN O
hypoxia EP2292587A1 T NN O
, EP2292587A1 T , O
modulators EP2292587A1 T NNS O
of EP2292587A1 T IN O
pathological EP2292587A1 T JJ O
processes EP2292587A1 T NNS O
of EP2292587A1 T IN O
angiogenesis EP2292587A1 T NN O
, EP2292587A1 T , O
oncogenesis EP2292587A1 T NN O
, EP2292587A1 T , O
inflammation EP2292587A1 T NN O
, EP2292587A1 T , O
apoptosis EP2292587A1 T NN O
, EP2292587A1 T , O
and EP2292587A1 T CC O
cellular EP2292587A1 T JJ O
therapy EP2292587A1 T NN O
. EP2292587A1 T . O

Soft CN1729979A T JJ O
capsule CN1729979A T NN O
of CN1729979A T IN O
fibrauretine CN1729979A T JJ O
composition CN1729979A T NN O
. CN1729979A T . O

Solubilized WO2009002425A3 T VBN O
formulation WO2009002425A3 T NN O
of WO2009002425A3 T IN O
docetaxel WO2009002425A3 T NN O
without WO2009002425A3 T IN O
tween WO2009002425A3 T JJ O
80 WO2009002425A3 T CD O
. WO2009002425A3 T . O

Administering US7199116 T VBG O
7-oxo-dehydroepiandrosterone US7199116 T CD O
( US7199116 T ( O
DHEA US7199116 T NNP O
) US7199116 T ) O
or US7199116 T CC O
prodrug US7199116 T JJ O
incapable US7199116 T NN O
of US7199116 T IN O
in US7199116 T IN O
vivo US7199116 T JJ O
conversion US7199116 T NN O
to US7199116 T TO O
testosterone US7199116 T NN O
. US7199116 T . O

Content CN101693076A T JJ O
measuring CN101693076A T VBG O
method CN101693076A T NN O
of CN101693076A T IN O
vitexin CN101693076A T NN O
in CN101693076A T IN O
tropaeolum CN101693076A T JJ O
heat-clearing CN101693076A T JJ O
granules CN101693076A T NNS O
. CN101693076A T . O

Administering US7261907 T VBG O
to US7261907 T TO O
an US7261907 T DT O
animal US7261907 T NN O
subject US7261907 T NN O
in US7261907 T IN O
need US7261907 T NN O
thereof US7261907 T VBP O
an US7261907 T DT O
effective US7261907 T JJ O
amount US7261907 T NN O
of US7261907 T IN O
a US7261907 T DT O
composition US7261907 T NN O
comprising US7261907 T VBG O
a US7261907 T DT O
clathrate US7261907 T NN O
of US7261907 T IN O
aliphatic US7261907 T JJ O
material US7261907 T NN O
and US7261907 T CC O
monoclinic US7261907 T JJ O
sulfur US7261907 T NN O
, US7261907 T , O
wherein US7261907 T VBP O
the US7261907 T DT O
aliphatic US7261907 T JJ O
material US7261907 T NN O
is US7261907 T VBZ O
encapsulated US7261907 T VBN O
by US7261907 T IN O
the US7261907 T DT O
monoclinic US7261907 T JJ O
sulfur US7261907 T NN O
. US7261907 T . O

Eltoprazine US20110183995 T NN O
for US20110183995 T IN O
suppression US20110183995 T NN O
of US20110183995 T IN O
l-dopa US20110183995 T NN O
induced US20110183995 T JJ O
dyskinesias US20110183995 T NN O
. US20110183995 T . O

Cyanine EP1559374A1 T JJ O
dyes EP1559374A1 T NNS O
. EP1559374A1 T . O

Method WO2006137106A3 T NNP O
for WO2006137106A3 T IN O
the WO2006137106A3 T DT O
potentiation WO2006137106A3 T NN O
of WO2006137106A3 T IN O
opioid WO2006137106A3 T JJ O
analgesics WO2006137106A3 T NNS O
effects WO2006137106A3 T NNS O
on WO2006137106A3 T IN O
pain WO2006137106A3 T NN O
. WO2006137106A3 T . O

According WO2006137106A3 A VBG O
to WO2006137106A3 A TO O
the WO2006137106A3 A DT O
invention WO2006137106A3 A NN O
there WO2006137106A3 A EX O
is WO2006137106A3 A VBZ O
provided WO2006137106A3 A VBN O
use WO2006137106A3 A NN O
of WO2006137106A3 A IN O
an WO2006137106A3 A DT O
anti-TrkA WO2006137106A3 A JJ O
antibody WO2006137106A3 A NN O
capable WO2006137106A3 A JJ O
of WO2006137106A3 A IN O
inhibiting WO2006137106A3 A VBG O
the WO2006137106A3 A DT O
binding WO2006137106A3 A NN O
between WO2006137106A3 A IN O
NGF WO2006137106A3 A NNP I-UN
and WO2006137106A3 A CC O
TrkA WO2006137106A3 A NNP I-UN
combined WO2006137106A3 A VBD O
with WO2006137106A3 A IN O
at WO2006137106A3 A IN O
least WO2006137106A3 A JJS O
one WO2006137106A3 A CD O
opioid WO2006137106A3 A JJ O
analgesic WO2006137106A3 A NN O
for WO2006137106A3 A IN O
the WO2006137106A3 A DT O
preparation WO2006137106A3 A NN O
of WO2006137106A3 A IN O
a WO2006137106A3 A DT O
medicament WO2006137106A3 A NN O
for WO2006137106A3 A IN O
treating WO2006137106A3 A VBG O
and/or WO2006137106A3 A JJ O
preventing WO2006137106A3 A VBG O
pain WO2006137106A3 A NN O
. WO2006137106A3 A . O

Method WO2012018759A3 T NNP O
of WO2012018759A3 T IN O
treatment WO2012018759A3 T NN O
of WO2012018759A3 T IN O
androgen-mediated WO2012018759A3 T JJ O
cancers WO2012018759A3 T NNS O
. WO2012018759A3 T . O

The WO2012018759A3 A DT O
methods WO2012018759A3 A NNS O
include WO2012018759A3 A VBP O
administering WO2012018759A3 A VBG O
a WO2012018759A3 A DT O
therapeutically WO2012018759A3 A RB O
effective WO2012018759A3 A JJ O
amount WO2012018759A3 A NN O
of WO2012018759A3 A IN O
a WO2012018759A3 A DT O
pharmaceutical WO2012018759A3 A JJ O
product WO2012018759A3 A NN O
that WO2012018759A3 A WDT O
includes WO2012018759A3 A VBZ O
at WO2012018759A3 A IN O
least WO2012018759A3 A JJS O
one WO2012018759A3 A CD O
selective WO2012018759A3 A NN O
and WO2012018759A3 A CC O
reversible WO2012018759A3 A JJ O
monoamine WO2012018759A3 A NN I-UN
oxidase WO2012018759A3 A NN I-UN
A WO2012018759A3 A DT I-UN
inhibitor WO2012018759A3 A NN O
. WO2012018759A3 A . O

Composition WO2008010527A1 T NN O
for WO2008010527A1 T IN O
amelioration WO2008010527A1 T NN O
of WO2008010527A1 T IN O
defecation WO2008010527A1 T NN O
. WO2008010527A1 T . O

Indole EP1691807A1 T NNP O
derivatives EP1691807A1 T NNS O
for EP1691807A1 T IN O
the EP1691807A1 T DT O
treatment EP1691807A1 T NN O
of EP1691807A1 T IN O
bone EP1691807A1 T NN O
diseases EP1691807A1 T NNS O
. EP1691807A1 T . O

This EP1691807A1 A DT O
invention EP1691807A1 A NN O
relates EP1691807A1 A VBZ O
to EP1691807A1 A TO O
a EP1691807A1 A DT O
method EP1691807A1 A NN O
for EP1691807A1 A IN O
preventing EP1691807A1 A VBG O
and/or EP1691807A1 A JJ O
treating EP1691807A1 A VBG O
bone EP1691807A1 A NN O
diseases EP1691807A1 A NNS O
which EP1691807A1 A WDT O
comprises EP1691807A1 A VBZ O
administering EP1691807A1 A VBG O
a EP1691807A1 A DT O
potentiator EP1691807A1 A NN O
of EP1691807A1 A IN O
TGF-beta EP1691807A1 A NNP I-UN
activity EP1691807A1 A NN O
such EP1691807A1 A JJ O
as EP1691807A1 A IN O
the EP1691807A1 A DT O
compound EP1691807A1 A NN O
of EP1691807A1 A IN O
the EP1691807A1 A DT O
formula EP1691807A1 A NN O
[ EP1691807A1 A NN O
I EP1691807A1 A PRP O
] EP1691807A1 A VBP O
or EP1691807A1 A CC O
pharmaceutically EP1691807A1 A RB O
acceptable EP1691807A1 A JJ O
salts EP1691807A1 A NNS O
thereof EP1691807A1 A VBP O
to EP1691807A1 A TO O
human EP1691807A1 A JJ O
being EP1691807A1 A VBG O
or EP1691807A1 A CC O
animals EP1691807A1 A NNS O
. EP1691807A1 A . O

Medicine CN101390848B T NNP O
composition CN101390848B T NN O
azithromycin CN101390848B T VBD O
enteric-coated CN101390848B T JJ O
capsules CN101390848B T NNS O
. CN101390848B T . O

The CN101390848B A DT O
invention CN101390848B A NN O
discloses CN101390848B A VBZ O
a CN101390848B A DT O
medicine CN101390848B A JJ O
combination CN101390848B A NN O
of CN101390848B A IN O
azithromycin CN101390848B A JJ O
enteric-coated CN101390848B A JJ O
capsule CN101390848B A NN O
, CN101390848B A , O
which CN101390848B A WDT O
contains CN101390848B A VBZ O
capsule CN101390848B A NN O
shell CN101390848B A NN O
, CN101390848B A , O
a CN101390848B A DT O
small CN101390848B A JJ O
pill CN101390848B A NN O
arranged CN101390848B A VBN O
in CN101390848B A IN O
the CN101390848B A DT O
capsule CN101390848B A NN O
shell CN101390848B A NN O
and CN101390848B A CC O
adopts CN101390848B A NNS O
azithromycin CN101390848B A VBP O
as CN101390848B A IN O
the CN101390848B A DT O
main CN101390848B A JJ O
ingredient CN101390848B A NN O
; CN101390848B A : O
the CN101390848B A DT O
surface CN101390848B A NN O
of CN101390848B A IN O
each CN101390848B A DT O
pill CN101390848B A NN O
is CN101390848B A VBZ O
coated CN101390848B A VBN O
with CN101390848B A IN O
enteric CN101390848B A JJ O
coating CN101390848B A NN O
; CN101390848B A : O
the CN101390848B A DT O
capsule CN101390848B A NN O
shell CN101390848B A NN O
is CN101390848B A VBZ O
common CN101390848B A JJ O
capsule CN101390848B A NN O
shell CN101390848B A NN O
. CN101390848B A . O

The CN101390848B A DT O
preparation CN101390848B A NN O
method CN101390848B A NN O
includes CN101390848B A VBZ O
that CN101390848B A IN O
: CN101390848B A : O
a. CN101390848B A NN O
azithromycin CN101390848B A NN O
, CN101390848B A , O
dextrin CN101390848B A NN O
and CN101390848B A CC O
starch CN101390848B A NN O
are CN101390848B A VBP O
respectively CN101390848B A RB O
sieved CN101390848B A VBN O
and CN101390848B A CC O
mixed CN101390848B A JJ O
evenly CN101390848B A RB O
; CN101390848B A : O
b. CN101390848B A CC O
hydroxypropyl CN101390848B A VB O
methylcellulose CN101390848B A NN O
with CN101390848B A IN O
the CN101390848B A DT O
concentration CN101390848B A NN O
of CN101390848B A IN O
4 CN101390848B A CD O
% CN101390848B A NN O
is CN101390848B A VBZ O
added CN101390848B A VBN O
to CN101390848B A TO O
the CN101390848B A DT O
mixture CN101390848B A NN O
of CN101390848B A IN O
azithromycin CN101390848B A NN O
, CN101390848B A , O
dextrin CN101390848B A NN O
and CN101390848B A CC O
starch CN101390848B A NN O
to CN101390848B A TO O
prepare CN101390848B A VB O
adhesion CN101390848B A NN O
agent CN101390848B A NN O
; CN101390848B A : O
c. CN101390848B A VBZ O
the CN101390848B A DT O
adhesion CN101390848B A NN O
agent CN101390848B A NN O
is CN101390848B A VBZ O
placed CN101390848B A VBN O
in CN101390848B A IN O
an CN101390848B A DT O
extruder CN101390848B A NN O
to CN101390848B A TO O
extrude CN101390848B A VB O
granules CN101390848B A NNS O
and CN101390848B A CC O
rolled CN101390848B A VBD O
to CN101390848B A TO O
be CN101390848B A VB O
circle CN101390848B A VBN O
in CN101390848B A IN O
a CN101390848B A DT O
rolling-circle CN101390848B A NN O
machine CN101390848B A NN O
, CN101390848B A , O
so CN101390848B A RB O
as CN101390848B A IN O
to CN101390848B A TO O
obtain CN101390848B A VB O
pills CN101390848B A NNS O
after CN101390848B A IN O
drying CN101390848B A VBG O
; CN101390848B A : O
d. CN101390848B A CC O
enteric CN101390848B A JJ O
coating CN101390848B A NN O
liquid CN101390848B A NN O
is CN101390848B A VBZ O
prepared CN101390848B A VBN O
, CN101390848B A , O
then CN101390848B A RB O
the CN101390848B A DT O
pills CN101390848B A NNS O
are CN101390848B A VBP O
coated CN101390848B A VBN O
with CN101390848B A IN O
the CN101390848B A DT O
enteric CN101390848B A JJ O
coating CN101390848B A NN O
; CN101390848B A : O
e. CN101390848B A CC O
the CN101390848B A DT O
coated CN101390848B A JJ O
pills CN101390848B A NNS O
are CN101390848B A VBP O
cured CN101390848B A VBN O
; CN101390848B A : O
f. CN101390848B A VB O
the CN101390848B A DT O
steps CN101390848B A NNS O
of CN101390848B A IN O
intermediate CN101390848B A JJ O
product CN101390848B A NN O
diction CN101390848B A NN O
, CN101390848B A , O
encapsulation CN101390848B A NN O
, CN101390848B A , O
whole CN101390848B A JJ O
inspection CN101390848B A NN O
, CN101390848B A , O
packing CN101390848B A VBG O
and CN101390848B A CC O
storage CN101390848B A NN O
are CN101390848B A VBP O
carried CN101390848B A VBN O
out CN101390848B A RP O
. CN101390848B A . O

The CN101390848B A DT O
extrusion CN101390848B A NN O
granulation CN101390848B A NN O
rolling-circle CN101390848B A NN O
method CN101390848B A NN O
is CN101390848B A VBZ O
adopted CN101390848B A VBN O
to CN101390848B A TO O
prepare CN101390848B A VB O
pills CN101390848B A NNS O
and CN101390848B A CC O
the CN101390848B A DT O
enteric CN101390848B A JJ O
coating CN101390848B A NN O
is CN101390848B A VBZ O
processed CN101390848B A VBN O
so CN101390848B A RB O
that CN101390848B A IN O
the CN101390848B A DT O
gastric CN101390848B A JJ O
stimulation CN101390848B A NN O
caused CN101390848B A VBN O
by CN101390848B A IN O
the CN101390848B A DT O
azithromycin CN101390848B A NN O
is CN101390848B A VBZ O
further CN101390848B A JJ O
reduced CN101390848B A VBN O
; CN101390848B A : O
the CN101390848B A DT O
release CN101390848B A NN O
failure CN101390848B A NN O
of CN101390848B A IN O
azithromycin CN101390848B A NN O
caused CN101390848B A VBN O
by CN101390848B A IN O
the CN101390848B A DT O
gastric CN101390848B A JJ O
acid CN101390848B A NN O
is CN101390848B A VBZ O
prevented CN101390848B A VBN O
so CN101390848B A RB O
that CN101390848B A IN O
the CN101390848B A DT O
bioavailability CN101390848B A NN O
is CN101390848B A VBZ O
improved CN101390848B A VBN O
and CN101390848B A CC O
the CN101390848B A DT O
side CN101390848B A NN O
effects CN101390848B A NNS O
are CN101390848B A VBP O
reduced CN101390848B A VBN O
. CN101390848B A . O

Quality CN101926843A T NNP O
control CN101926843A T NN O
method CN101926843A T NN O
of CN101926843A T IN O
Xinnaoqing CN101926843A T VBG O
soft CN101926843A T JJ O
capsules CN101926843A T NNS O
. CN101926843A T . O

Pyrazole-carboxamide US20110039829 T JJ O
derivatives US20110039829 T NNS O
as US20110039829 T IN O
p2y12 US20110039829 T NN I-UN
antagonists US20110039829 T NNS O
. US20110039829 T . O

They US20110039829 A PRP O
are US20110039829 A VBP O
reversible US20110039829 A JJ O
antagonists US20110039829 A NNS O
of US20110039829 A IN O
the US20110039829 A DT O
platelet US20110039829 A NN O
ADP US20110039829 A NNP O
receptor US20110039829 A NN O
P2Y12 US20110039829 A NNP I-UN
, US20110039829 A , O
and US20110039829 A CC O
can US20110039829 A MD O
in US20110039829 A IN O
general US20110039829 A JJ O
be US20110039829 A VB O
applied US20110039829 A VBN O
in US20110039829 A IN O
conditions US20110039829 A NNS O
in US20110039829 A IN O
which US20110039829 A WDT O
an US20110039829 A DT O
undesired US20110039829 A JJ O
activation US20110039829 A NN O
of US20110039829 A IN O
the US20110039829 A DT O
platelet US20110039829 A NN O
ADP US20110039829 A NNP O
receptor US20110039829 A NN O
P2Y12 US20110039829 A NNP I-UN
is US20110039829 A VBZ O
present US20110039829 A JJ O
or US20110039829 A CC O
for US20110039829 A IN O
the US20110039829 A DT O
cure US20110039829 A NN O
or US20110039829 A CC O
prevention US20110039829 A NN O
of US20110039829 A IN O
which US20110039829 A WDT O
an US20110039829 A DT O
inhibition US20110039829 A NN O
of US20110039829 A IN O
the US20110039829 A DT O
platelet US20110039829 A NN O
ADP US20110039829 A NNP O
receptor US20110039829 A NN O
P2Y12 US20110039829 A NNP I-UN
is US20110039829 A VBZ O
intended US20110039829 A VBN O
. US20110039829 A . O

Benzimidazole CN101205214A T NNP O
compounds CN101205214A T NNS O
for CN101205214A T IN O
antiphlogistic CN101205214A T JJ O
and CN101205214A T CC O
analgesic CN101205214A T JJ O
actions CN101205214A T NNS O
. CN101205214A T . O

Cosmetic WO2007104867A3 T NNP O
, WO2007104867A3 T , O
pharmaceutical WO2007104867A3 T JJ O
, WO2007104867A3 T , O
food WO2007104867A3 T NN O
and WO2007104867A3 T CC O
veterinary WO2007104867A3 T JJ O
compositions WO2007104867A3 T NNS O
whose WO2007104867A3 T WP$ O
activating WO2007104867A3 T VBG O
action WO2007104867A3 T NN O
on WO2007104867A3 T IN O
genes WO2007104867A3 T NNS O
of WO2007104867A3 T IN O
sirtuin WO2007104867A3 T JJ O
type WO2007104867A3 T NN O
makes WO2007104867A3 T VBZ O
it WO2007104867A3 T PRP O
possible WO2007104867A3 T JJ O
to WO2007104867A3 T TO O
delay WO2007104867A3 T VB O
ageing WO2007104867A3 T VBG O
in WO2007104867A3 T IN O
mammals WO2007104867A3 T NNS O
and WO2007104867A3 T CC O
the WO2007104867A3 T DT O
harmful WO2007104867A3 T JJ O
effects WO2007104867A3 T NNS O
thereof WO2007104867A3 T NN O
. WO2007104867A3 T . O

A WO2007104867A3 A DT O
specific WO2007104867A3 A JJ O
test WO2007104867A3 A NN O
has WO2007104867A3 A VBZ O
been WO2007104867A3 A VBN O
carried WO2007104867A3 A VBN O
out WO2007104867A3 A IN O
and WO2007104867A3 A CC O
shows WO2007104867A3 A VBZ O
that WO2007104867A3 A IN O
Pε-viniferin WO2007104867A3 A NNP O
and WO2007104867A3 A CC O
an WO2007104867A3 A DT O
extract WO2007104867A3 A NN O
of WO2007104867A3 A IN O
vine WO2007104867A3 A JJ O
shoot WO2007104867A3 A NN O
containing WO2007104867A3 A VBG O
it WO2007104867A3 A PRP O
, WO2007104867A3 A , O
and WO2007104867A3 A CC O
also WO2007104867A3 A RB O
other WO2007104867A3 A JJ O
oligomers WO2007104867A3 A NNS O
of WO2007104867A3 A IN O
resveratrol WO2007104867A3 A NN O
, WO2007104867A3 A , O
completely WO2007104867A3 A RB O
activate WO2007104867A3 A VBP O
the WO2007104867A3 A DT O
SIRTl WO2007104867A3 A NNP I-UN
enzyme WO2007104867A3 A NN O
. WO2007104867A3 A . O

Stable US20120214877 T JJ O
rasagiline US20120214877 T NN O
composition US20120214877 T NN O
. US20120214877 T . O

Multicomponent WO2013189910A1 T JJ O
crystals WO2013189910A1 T NNS O
comprising WO2013189910A1 T VBG O
imatinib WO2013189910A1 T JJ O
mesilate WO2013189910A1 T NN O
and WO2013189910A1 T CC O
selected WO2013189910A1 T VBN O
co-crystal WO2013189910A1 T JJ O
formers WO2013189910A1 T NNS O
. WO2013189910A1 T . O

Edible US20120277179 T JJ O
Energy US20120277179 T NNP O
Composition US20120277179 T NNP O
. US20120277179 T . O

Norcantharidin CN102973503A T NNP O
derivative CN102973503A T JJ O
lipid CN102973503A T NN O
microsphere CN102973503A T WRB O
injection CN102973503A T NN O
and CN102973503A T CC O
preparation CN102973503A T NN O
method CN102973503A T NN O
thereof CN102973503A T NN O
. CN102973503A T . O

Benzothiazine CN103275035A T NNP O
compound CN103275035A T NN O
, CN103275035A T , O
and CN103275035A T CC O
preparation CN103275035A T NN O
method CN103275035A T NN O
and CN103275035A T CC O
anti-tumor CN103275035A T JJ O
purpose CN103275035A T NN O
thereof CN103275035A T NN O
. CN103275035A T . O

Liquid US20050244489 T NNP O
compositions US20050244489 T NNS O
for US20050244489 T IN O
soft US20050244489 T JJ O
sustained-release US20050244489 T JJ O
capsules US20050244489 T NNS O
and US20050244489 T CC O
method US20050244489 T NN O
for US20050244489 T IN O
production US20050244489 T NN O
. US20050244489 T . O

Water-dispersible US20090092727 T JJ O
phytosterol-surfactant US20090092727 T JJ O
conglomerate US20090092727 T NN O
particles US20090092727 T NNS O
. US20090092727 T . O

1-naphthyl CN102206177A T JJ O
benzophenone CN102206177A T NN O
derivatives CN102206177A T NNS O
, CN102206177A T , O
and CN102206177A T CC O
preparation CN102206177A T NN O
method CN102206177A T NN O
and CN102206177A T CC O
application CN102206177A T NN O
thereof CN102206177A T NN O
. CN102206177A T . O

The CN102206177A A DT O
invention CN102206177A A NN O
belongs CN102206177A A VBZ O
to CN102206177A A TO O
the CN102206177A A DT O
technical CN102206177A A JJ O
field CN102206177A A NN O
of CN102206177A A IN O
medicaments CN102206177A A NNS O
, CN102206177A A , O
and CN102206177A A CC O
specifically CN102206177A A RB O
relates CN102206177A A VBZ O
to CN102206177A A TO O
1-naphthyl CN102206177A A JJ O
benzophenone CN102206177A A NN O
derivatives CN102206177A A NNS O
with CN102206177A A IN O
a CN102206177A A DT O
structural CN102206177A A JJ O
formula CN102206177A A NN O
shown CN102206177A A VBN O
in CN102206177A A IN O
formula CN102206177A A NN O
( CN102206177A A ( O
I CN102206177A A PRP O
) CN102206177A A ) O
, CN102206177A A , O
pharmaceutical CN102206177A A JJ O
salts CN102206177A A NNS O
thereof CN102206177A A NN O
, CN102206177A A , O
stereochemical CN102206177A A JJ O
isomers CN102206177A A NNS O
thereof CN102206177A A VBP O
, CN102206177A A , O
hydrates CN102206177A A NNS O
and CN102206177A A CC O
solvates CN102206177A A NNS O
thereof CN102206177A A VBP O
, CN102206177A A , O
polycrystals CN102206177A A NNS O
or CN102206177A A CC O
eutectic CN102206177A A JJ O
crystals CN102206177A A NNS O
thereof CN102206177A A VBP O
, CN102206177A A , O
precursors CN102206177A A NNS O
and CN102206177A A CC O
derivatives CN102206177A A NNS O
with CN102206177A A IN O
identical CN102206177A A JJ O
biological CN102206177A A JJ O
functions CN102206177A A NNS O
thereof CN102206177A A VBP O
, CN102206177A A , O
a CN102206177A A DT O
preparation CN102206177A A NN O
method CN102206177A A NN O
thereof CN102206177A A NN O
, CN102206177A A , O
a CN102206177A A DT O
composition CN102206177A A NN O
containing CN102206177A A VBG O
one CN102206177A A CD O
or CN102206177A A CC O
more CN102206177A A JJR O
the CN102206177A A DT O
1-naphthyl CN102206177A A JJ O
benzophenone CN102206177A A NN O
derivatives CN102206177A A NNS O
and CN102206177A A CC O
application CN102206177A A NN O
thereof CN102206177A A NN O
in CN102206177A A IN O
the CN102206177A A DT O
relating CN102206177A A NN O
drugs CN102206177A A NNS O
for CN102206177A A IN O
treating CN102206177A A VBG O
AIDS CN102206177A A NNP O
( CN102206177A A ( O
acquired CN102206177A A VBN O
immune CN102206177A A RB O
deficiency CN102206177A A NN O
syndrome CN102206177A A NN O
) CN102206177A A ) O
and CN102206177A A CC O
the CN102206177A A DT O
like CN102206177A A JJ O
. CN102206177A A . O

Pharmacological CN102206177A A JJ O
experiment CN102206177A A NN O
results CN102206177A A NNS O
show CN102206177A A VBP O
that CN102206177A A IN O
most CN102206177A A JJS O
of CN102206177A A IN O
the CN102206177A A DT O
1-naphthyl CN102206177A A JJ O
benzophenone CN102206177A A NN O
derivatives CN102206177A A NNS O
have CN102206177A A VBP O
strong CN102206177A A JJ O
inhibition CN102206177A A NN O
activity CN102206177A A NN O
( CN102206177A A ( O
nanomolar CN102206177A A JJ O
level CN102206177A A NN O
) CN102206177A A ) O
to CN102206177A A TO O
the CN102206177A A DT O
duplication CN102206177A A NN O
of CN102206177A A IN O
wile-type CN102206177A A JJ O
HIV CN102206177A A NNP O
( CN102206177A A ( O
human CN102206177A A JJ O
immunodeficiency CN102206177A A NN O
virus CN102206177A A NN O
) CN102206177A A ) O
-1strain CN102206177A A NN O
( CN102206177A A ( O
IIIB CN102206177A A NNP O
) CN102206177A A ) O
, CN102206177A A , O
and CN102206177A A CC O
partial CN102206177A A JJ O
1-naphthyl CN102206177A A JJ O
benzophenone CN102206177A A NN O
derivatives CN102206177A A NNS O
have CN102206177A A VBP O
strong CN102206177A A JJ O
inhibition CN102206177A A NN O
activity CN102206177A A NN O
to CN102206177A A TO O
multiple CN102206177A A VB O
drug-resistant CN102206177A A JJ O
HIV-1 CN102206177A A NNP O
strain CN102206177A A NN O
( CN102206177A A ( O
K103N CN102206177A A NNP O
+ CN102206177A A NNP O
Y181C CN102206177A A NNP O
) CN102206177A A ) O
, CN102206177A A , O
so CN102206177A A RB O
that CN102206177A A IN O
the CN102206177A A DT O
1-naphthyl CN102206177A A JJ O
benzophenone CN102206177A A NN O
derivatives CN102206177A A NNS O
can CN102206177A A MD O
be CN102206177A A VB O
used CN102206177A A VBN O
as CN102206177A A IN O
anti-HIV CN102206177A A JJ O
drug CN102206177A A NN O
candidates CN102206177A A NNS O
. CN102206177A A . O

NOVEL US20100063122 T JJ O
2- US20100063122 T JJ O
( US20100063122 T ( O
2-HYDROXYPHENYL US20100063122 T JJ O
) US20100063122 T ) O
BENZIMlDAZOLES US20100063122 T NNP O
USEFUL US20100063122 T NNP O
FOR US20100063122 T NNP O
TREATING US20100063122 T NNP O
OBESITY US20100063122 T NNP O
AND US20100063122 T NNP O
DIABETES US20100063122 T NNP O
. US20100063122 T . O

3-pyrrole CN101200446A T JJ O
ring CN101200446A T NN O
caproic CN101200446A T NN O
subunit-2-dihydroindolone CN101200446A T JJ O
derivatives CN101200446A T NNS O
and CN101200446A T CC O
uses CN101200446A T VBZ O
thereof CN101200446A T NN O
. CN101200446A T . O

Halogen-substituted WO2014104372A1 T JJ O
heterocyclic WO2014104372A1 T JJ O
compound WO2014104372A1 T NN O
. WO2014104372A1 T . O

Provided WO2014104372A1 A VBN O
is WO2014104372A1 A VBZ O
a WO2014104372A1 A DT O
novel WO2014104372A1 A JJ O
α-halogen WO2014104372A1 A NN O
substituted WO2014104372A1 A VBD O
thiophene WO2014104372A1 A NN O
compound WO2014104372A1 A NN O
which WO2014104372A1 A WDT O
has WO2014104372A1 A VBZ O
strong WO2014104372A1 A JJ O
LPA WO2014104372A1 A NNP I-UN
receptor WO2014104372A1 A NN O
antagonist WO2014104372A1 A NN O
activity WO2014104372A1 A NN O
and WO2014104372A1 A CC O
is WO2014104372A1 A VBZ O
useful WO2014104372A1 A JJ O
as WO2014104372A1 A IN O
a WO2014104372A1 A DT O
pharmaceutical WO2014104372A1 A JJ O
product WO2014104372A1 A NN O
, WO2014104372A1 A , O
or WO2014104372A1 A CC O
a WO2014104372A1 A DT O
pharmacologically WO2014104372A1 A RB O
acceptable WO2014104372A1 A JJ O
salt WO2014104372A1 A NN O
thereof WO2014104372A1 A NN O
. WO2014104372A1 A . O

Oxaliplatin CN101897668A T NNP O
liposome CN101897668A T NN O
, CN101897668A T , O
preparation CN101897668A T NN O
method CN101897668A T NN O
and CN101897668A T CC O
application CN101897668A T NN O
thereof CN101897668A T NN O
. CN101897668A T . O

The CN101897668A A DT O
invention CN101897668A A NN O
discloses CN101897668A A VBZ O
an CN101897668A A DT O
oxaliplatin CN101897668A A JJ O
liposome CN101897668A A NN O
, CN101897668A A , O
a CN101897668A A DT O
preparation CN101897668A A NN O
method CN101897668A A NN O
and CN101897668A A CC O
application CN101897668A A NN O
thereof CN101897668A A NN O
. CN101897668A A . O

The CN101897668A A DT O
oxaliplatin CN101897668A A JJ O
liposome CN101897668A A NN O
contains CN101897668A A NNS O
oxaliplatin CN101897668A A VBP O
, CN101897668A A , O
phospholipid CN101897668A A JJ O
and CN101897668A A CC O
cholesterol CN101897668A A NN O
, CN101897668A A , O
wherein CN101897668A A NN O
, CN101897668A A , O
based CN101897668A A VBN O
on CN101897668A A IN O
the CN101897668A A DT O
total CN101897668A A JJ O
weight CN101897668A A NN O
of CN101897668A A IN O
the CN101897668A A DT O
phospholipid CN101897668A A NN O
, CN101897668A A , O
the CN101897668A A DT O
phospholipid CN101897668A A JJ O
comprises CN101897668A A VBZ O
the CN101897668A A DT O
following CN101897668A A JJ O
components CN101897668A A NNS O
in CN101897668A A IN O
percentage CN101897668A A NN O
by CN101897668A A IN O
weight CN101897668A A NN O
: CN101897668A A : O
75 CN101897668A A CD O
to CN101897668A A TO O
90 CN101897668A A CD O
percent CN101897668A A NN O
of CN101897668A A IN O
phosphatidylcholine CN101897668A A NN O
( CN101897668A A ( O
PC CN101897668A A NN O
) CN101897668A A ) O
, CN101897668A A , O
and CN101897668A A CC O
10 CN101897668A A CD O
to CN101897668A A TO O
25 CN101897668A A CD O
percent CN101897668A A NN O
of CN101897668A A IN O
phosphatidyl CN101897668A A NN O
glycerol CN101897668A A NN O
( CN101897668A A ( O
PG CN101897668A A NNP O
) CN101897668A A ) O
and CN101897668A A CC O
phosphatidic CN101897668A A JJ O
acid CN101897668A A NN O
( CN101897668A A ( O
PA CN101897668A A NNP O
) CN101897668A A ) O
; CN101897668A A : O
the CN101897668A A DT O
weight CN101897668A A NN O
ratio CN101897668A A NN O
of CN101897668A A IN O
the CN101897668A A DT O
oxaliplatin CN101897668A A NN O
to CN101897668A A TO O
the CN101897668A A DT O
phospholipid CN101897668A A NN O
is CN101897668A A VBZ O
1:3-20 CN101897668A A JJ O
, CN101897668A A , O
and CN101897668A A CC O
the CN101897668A A DT O
weight CN101897668A A NN O
ratio CN101897668A A NN O
of CN101897668A A IN O
the CN101897668A A DT O
cholesterol CN101897668A A NN O
to CN101897668A A TO O
the CN101897668A A DT O
phospholipid CN101897668A A NN O
is CN101897668A A VBZ O
1:2-10 CN101897668A A JJ O
. CN101897668A A . O

Longikaurin CN103145726A T VB O
A CN103145726A T NNP O
as CN103145726A T RB O
well CN103145726A T RB O
as CN103145726A T IN O
medicinal CN103145726A T JJ O
composition CN103145726A T NN O
and CN103145726A T CC O
application CN103145726A T NN O
thereof CN103145726A T NN O
. CN103145726A T . O

The CN103145726A A DT O
invention CN103145726A A NN O
belongs CN103145726A A VBZ O
to CN103145726A A TO O
the CN103145726A A DT O
field CN103145726A A NN O
of CN103145726A A IN O
medicines CN103145726A A NNS O
, CN103145726A A , O
and CN103145726A A CC O
in CN103145726A A IN O
particular CN103145726A A JJ O
relates CN103145726A A NNS O
to CN103145726A A TO O
longikaurin CN103145726A A VB O
A CN103145726A A NNP O
which CN103145726A A WDT O
is CN103145726A A VBZ O
extracted CN103145726A A VBN O
and CN103145726A A CC O
separated CN103145726A A VBN O
from CN103145726A A IN O
isodon CN103145726A A JJ O
ternifolius CN103145726A A NN O
and CN103145726A A CC O
is CN103145726A A VBZ O
as CN103145726A A RB O
shown CN103145726A A VBN O
in CN103145726A A IN O
the CN103145726A A DT O
structural CN103145726A A JJ O
formula CN103145726A A NN O
( CN103145726A A ( O
I CN103145726A A PRP O
) CN103145726A A ) O
, CN103145726A A , O
as CN103145726A A RB O
well CN103145726A A RB O
as CN103145726A A IN O
a CN103145726A A DT O
medicinal CN103145726A A JJ O
composition CN103145726A A NN O
and CN103145726A A CC O
an CN103145726A A DT O
application CN103145726A A NN O
of CN103145726A A IN O
the CN103145726A A DT O
longikaurin CN103145726A A NN O
A CN103145726A A NNP O
. CN103145726A A . O

In CN103145726A A IN O
vitro CN103145726A A JJ O
anti-tumor CN103145726A A JJ O
activity CN103145726A A NN O
screening CN103145726A A NN O
shows CN103145726A A VBZ O
that CN103145726A A IN O
the CN103145726A A DT O
longikaurin CN103145726A A NN O
A CN103145726A A NN O
shows CN103145726A A VBZ O
strong CN103145726A A JJ O
inhibitory CN103145726A A NN O
activity CN103145726A A NN O
to CN103145726A A TO O
experimental CN103145726A A VB O
cell CN103145726A A NN O
strains CN103145726A A NNS O
( CN103145726A A ( O
SMMC-7721 CN103145726A A NNP O
and CN103145726A A CC O
HepG2 CN103145726A A NNP O
) CN103145726A A ) O
of CN103145726A A IN O
liver CN103145726A A NN O
cancer CN103145726A A NN O
and CN103145726A A CC O
experimental CN103145726A A JJ O
cell CN103145726A A NN O
strains CN103145726A A NNS O
( CN103145726A A ( O
CNE1 CN103145726A A NNP O
and CN103145726A A CC O
CNE2 CN103145726A A NNP O
) CN103145726A A ) O
of CN103145726A A IN O
nasopharyngeal CN103145726A A JJ O
cancer CN103145726A A NN O
. CN103145726A A . O

The CN103145726A A DT O
longikaurin CN103145726A A NN O
A CN103145726A A NNP O
can CN103145726A A MD O
be CN103145726A A VB O
singly CN103145726A A RB O
applied CN103145726A A VBN O
to CN103145726A A TO O
the CN103145726A A DT O
preparation CN103145726A A NN O
of CN103145726A A IN O
medicines CN103145726A A NNS O
for CN103145726A A IN O
resisting CN103145726A A VBG O
the CN103145726A A DT O
liver CN103145726A A NN O
cancer CN103145726A A NN O
and CN103145726A A CC O
nasopharyngeal CN103145726A A JJ O
cancer CN103145726A A NN O
, CN103145726A A , O
and CN103145726A A CC O
can CN103145726A A MD O
also CN103145726A A RB O
be CN103145726A A VB O
used CN103145726A A VBN O
for CN103145726A A IN O
forming CN103145726A A VBG O
various CN103145726A A JJ O
preparation CN103145726A A NN O
types CN103145726A A NNS O
and CN103145726A A CC O
medicinal CN103145726A A JJ O
compositions CN103145726A A NNS O
of CN103145726A A IN O
the CN103145726A A DT O
medicines CN103145726A A NNS O
for CN103145726A A IN O
resisting CN103145726A A VBG O
the CN103145726A A DT O
liver CN103145726A A NN O
cancer CN103145726A A NN O
and CN103145726A A CC O
nasopharyngeal CN103145726A A JJ O
cancer CN103145726A A NN O
with CN103145726A A IN O
other CN103145726A A JJ O
medicinal CN103145726A A JJ O
adjuvant CN103145726A A JJ O
materials CN103145726A A NNS O
. CN103145726A A . O

Ameliorating WO2013137009A1 T VBG O
agent WO2013137009A1 T NN O
for WO2013137009A1 T IN O
chronic WO2013137009A1 T JJ O
obstructive WO2013137009A1 T JJ O
pulmonary WO2013137009A1 T JJ O
disease WO2013137009A1 T NN O
. WO2013137009A1 T . O

Preparation CN103040801A T NN O
and CN103040801A T CC O
medical CN103040801A T JJ O
application CN103040801A T NN O
of CN103040801A T IN O
aromatic CN103040801A T JJ O
ring CN103040801A T NN O
substituted CN103040801A T VBD O
ethyl CN103040801A T JJ O
valerate CN103040801A T NN O
. CN103040801A T . O

Combinations WO2006128674A2 T NNS O
of WO2006128674A2 T IN O
indacaterol WO2006128674A2 T NN O
derivatives WO2006128674A2 T NNS O
and WO2006128674A2 T CC O
other WO2006128674A2 T JJ O
agents WO2006128674A2 T NNS O
for WO2006128674A2 T IN O
the WO2006128674A2 T DT O
treatment WO2006128674A2 T NN O
of WO2006128674A2 T IN O
airway WO2006128674A2 T NN O
diseases WO2006128674A2 T NNS O
. WO2006128674A2 T . O

A WO2006128674A2 A DT O
medicament WO2006128674A2 A NN O
comprising WO2006128674A2 A NN O
, WO2006128674A2 A , O
separately WO2006128674A2 A RB O
or WO2006128674A2 A CC O
together WO2006128674A2 A RB O
, WO2006128674A2 A , O
( WO2006128674A2 A ( O
A WO2006128674A2 A NNP O
) WO2006128674A2 A ) O
a WO2006128674A2 A DT O
compound WO2006128674A2 A NN O
of WO2006128674A2 A IN O
formula WO2006128674A2 A NN O
( WO2006128674A2 A ( O
I WO2006128674A2 A PRP O
) WO2006128674A2 A ) O
in WO2006128674A2 A IN O
free WO2006128674A2 A JJ O
or WO2006128674A2 A CC O
salt WO2006128674A2 A NN O
or WO2006128674A2 A CC O
solvate WO2006128674A2 A JJ O
form WO2006128674A2 A NN O
, WO2006128674A2 A , O
where WO2006128674A2 A WRB O
W WO2006128674A2 A NNP O
, WO2006128674A2 A , O
Rx WO2006128674A2 A NNP O
, WO2006128674A2 A , O
Ry WO2006128674A2 A NNP O
, WO2006128674A2 A , O
R1 WO2006128674A2 A NNP O
, WO2006128674A2 A , O
R2 WO2006128674A2 A NNP O
, WO2006128674A2 A , O
R3 WO2006128674A2 A NNP O
, WO2006128674A2 A , O
R4 WO2006128674A2 A NNP O
, WO2006128674A2 A , O
R5 WO2006128674A2 A NNP O
, WO2006128674A2 A , O
R6 WO2006128674A2 A NNP O
and WO2006128674A2 A CC O
R7 WO2006128674A2 A NNP O
have WO2006128674A2 A VBP O
the WO2006128674A2 A DT O
meanings WO2006128674A2 A NNS O
as WO2006128674A2 A IN O
indicated WO2006128674A2 A VBN O
in WO2006128674A2 A IN O
the WO2006128674A2 A DT O
specification WO2006128674A2 A NN O
, WO2006128674A2 A , O
and WO2006128674A2 A CC O
( WO2006128674A2 A ( O
B WO2006128674A2 A NNP O
) WO2006128674A2 A ) O
one WO2006128674A2 A CD O
or WO2006128674A2 A CC O
more WO2006128674A2 A JJR O
of WO2006128674A2 A IN O
compounds WO2006128674A2 A NNS O
selected WO2006128674A2 A VBN O
from WO2006128674A2 A IN O
the WO2006128674A2 A DT O
group WO2006128674A2 A NN O
consisting WO2006128674A2 A VBG O
of WO2006128674A2 A IN O
A2A WO2006128674A2 A NNP I-UN
agonists WO2006128674A2 A NNS O
, WO2006128674A2 A , O
A2B WO2006128674A2 A NNP I-UN
antagonists WO2006128674A2 A VBZ O
, WO2006128674A2 A , O
antihistamines WO2006128674A2 A NNS O
, WO2006128674A2 A , O
caspase WO2006128674A2 A NN I-UN
inhibitors WO2006128674A2 A NNS O
, WO2006128674A2 A , O
ENaC WO2006128674A2 A NNP I-UN
inhibitors WO2006128674A2 A NNS O
, WO2006128674A2 A , O
LTB4 WO2006128674A2 A NNP O
antagonists WO2006128674A2 A VBZ O
, WO2006128674A2 A , O
LTD4 WO2006128674A2 A NNP O
antagonists WO2006128674A2 A NNS O
and WO2006128674A2 A CC O
serine WO2006128674A2 A JJ I-UN
protease WO2006128674A2 A NN I-UN
inhibitors WO2006128674A2 A NNS O
, WO2006128674A2 A , O
for WO2006128674A2 A IN O
simultaneous WO2006128674A2 A JJ O
, WO2006128674A2 A , O
sequential WO2006128674A2 A JJ O
or WO2006128674A2 A CC O
separate WO2006128674A2 A JJ O
administration WO2006128674A2 A NN O
in WO2006128674A2 A IN O
the WO2006128674A2 A DT O
treatment WO2006128674A2 A NN O
of WO2006128674A2 A IN O
an WO2006128674A2 A DT O
inflammatory WO2006128674A2 A NN O
or WO2006128674A2 A CC O
obstructive WO2006128674A2 A JJ O
airways WO2006128674A2 A NNS O
disease WO2006128674A2 A NN O
. WO2006128674A2 A . O

Deuterium-enriched US20090076055 T JJ O
vinflunine US20090076055 T NN O
. US20090076055 T . O

Salts EP1577311A1 T NNS O
of EP1577311A1 T IN O
a EP1577311A1 T DT O
pyridazino EP1577311A1 T NN O
aquinoline EP1577311A1 T NN O
derivative EP1577311A1 T NN O
and EP1577311A1 T CC O
use EP1577311A1 T NN O
for EP1577311A1 T IN O
the EP1577311A1 T DT O
treatment EP1577311A1 T NN O
of EP1577311A1 T IN O
pain EP1577311A1 T NN O
. EP1577311A1 T . O

A EP1577311A1 A DT O
compound EP1577311A1 A NN O
, EP1577311A1 A , O
7-chloro-4-hydroxy-2- EP1577311A1 A JJ O
( EP1577311A1 A ( O
2-chloro-4-methylphenyl EP1577311A1 A JJ O
) EP1577311A1 A ) O
-1,2,5,10-tetrahydropyridazino EP1577311A1 A NN O
[ EP1577311A1 A JJ O
4,5-b EP1577311A1 A JJ O
] EP1577311A1 A NN O
quinoline-1,10-dione EP1577311A1 A NN O
, EP1577311A1 A , O
pharmaceutically-acceptable EP1577311A1 A JJ O
salts EP1577311A1 A NNS O
thereof EP1577311A1 A NN O
, EP1577311A1 A , O
a EP1577311A1 A DT O
method EP1577311A1 A NN O
for EP1577311A1 A IN O
treating EP1577311A1 A VBG O
pain EP1577311A1 A NN O
comprising EP1577311A1 A VBG O
administration EP1577311A1 A NN O
of EP1577311A1 A IN O
a EP1577311A1 A DT O
pain-ameliorating EP1577311A1 A JJ O
effective EP1577311A1 A JJ O
amount EP1577311A1 A NN O
of EP1577311A1 A IN O
the EP1577311A1 A DT O
compound EP1577311A1 A NN O
and EP1577311A1 A CC O
pharmaceutical EP1577311A1 A JJ O
compositions EP1577311A1 A NNS O
containing EP1577311A1 A VBG O
the EP1577311A1 A DT O
compound EP1577311A1 A NN O
are EP1577311A1 A VBP O
disclosed EP1577311A1 A VBN O
. EP1577311A1 A . O

Low-dose US20120022114 T JJ O
, US20120022114 T , O
non-irritating US20120022114 T JJ O
nicotine US20120022114 T NN O
nasal US20120022114 T NN O
composition US20120022114 T NN O
to US20120022114 T TO O
reduce US20120022114 T VB O
the US20120022114 T DT O
desire US20120022114 T NN O
to US20120022114 T TO O
smoke US20120022114 T VB O
. US20120022114 T . O

Medical CN1939290A T JJ O
usage CN1939290A T NN O
of CN1939290A T IN O
colchicine CN1939290A T NN O
and CN1939290A T CC O
its CN1939290A T PRP$ O
derivative CN1939290A T NN O
. CN1939290A T . O

Inhibiting US6890937 T VBG O
the US6890937 T DT O
activity US6890937 T NN O
of US6890937 T IN O
one US6890937 T CD O
or US6890937 T CC O
more US6890937 T JJR O
of US6890937 T IN O
MMP-2 US6890937 T NNP I-UN
, US6890937 T , O
MMP-9 US6890937 T NNP I-UN
and US6890937 T CC O
MMP-13 US6890937 T NNP I-UN
, US6890937 T , O
while US6890937 T IN O
exhibiting US6890937 T VBG O
substantially US6890937 T RB O
less US6890937 T JJR O
inhibitory US6890937 T JJ O
activity US6890937 T NN O
against US6890937 T IN O
MMP-1 US6890937 T NNP I-UN
. US6890937 T . O

A US6890937 A DT O
treatment US6890937 A NN O
process US6890937 A NN O
is US6890937 A VBZ O
disclosed US6890937 A VBN O
that US6890937 A IN O
comprises US6890937 A VBZ O
administering US6890937 A VBG O
an US6890937 A DT O
effective US6890937 A JJ O
amount US6890937 A NN O
of US6890937 A IN O
an US6890937 A DT O
aromatic US6890937 A JJ O
sulfone US6890937 A NN O
hydroxamic US6890937 A JJ O
acid US6890937 A NN O
that US6890937 A IN O
exhibits US6890937 A VBZ O
excellent US6890937 A JJ O
inhibitory US6890937 A JJ O
activity US6890937 A NN O
of US6890937 A IN O
one US6890937 A CD O
or US6890937 A CC O
more US6890937 A JJR O
matrix US6890937 A JJ O
metalloprotease US6890937 A NN O
( US6890937 A ( O
MMP US6890937 A NNP O
) US6890937 A ) O
enzymes US6890937 A RB O
, US6890937 A , O
such US6890937 A JJ O
as US6890937 A IN O
MMP-2 US6890937 A NNP I-UN
, US6890937 A , O
MMP-9 US6890937 A NNP I-UN
, US6890937 A , O
and US6890937 A CC O
MMP-13 US6890937 A NNP I-UN
, US6890937 A , O
while US6890937 A IN O
exhibiting US6890937 A VBG O
substantially US6890937 A RB O
less US6890937 A JJR O
inhibition US6890937 A NN O
at US6890937 A IN O
least US6890937 A JJS O
of US6890937 A IN O
MMP-1 US6890937 A NNP I-UN
to US6890937 A TO O
a US6890937 A DT O
host US6890937 A NN O
having US6890937 A VBG O
a US6890937 A DT O
condition US6890937 A NN O
associated US6890937 A VBN O
with US6890937 A IN O
pathological US6890937 A JJ O
matrix US6890937 A NN O
metalloprotease US6890937 A NN O
activity US6890937 A NN O
. US6890937 A . O

2,5-diarypyrimidine US6887875 T JJ O
compounds US6887875 T NNS O
. US6887875 T . O

Compounds US6887875 A NNS O
of US6887875 A IN O
Formula US6887875 A NNP O
I US6887875 A PRP O
are US6887875 A VBP O
also US6887875 A RB O
useful US6887875 A JJ O
as US6887875 A IN O
probes US6887875 A NNS O
for US6887875 A IN O
the US6887875 A DT O
localization US6887875 A NN O
of US6887875 A IN O
CRF US6887875 A NNP I-UN
receptors US6887875 A NNS I-UN
and US6887875 A CC O
as US6887875 A IN O
standards US6887875 A NNS O
in US6887875 A IN O
assays US6887875 A NNS O
for US6887875 A IN O
CRF US6887875 A NNP I-UN
receptor US6887875 A NN I-UN
binding US6887875 A NN O
. US6887875 A . O

Flavonoid CN101613334B T NNP O
derivative CN101613334B T NN O
and CN101613334B T CC O
medical CN101613334B T JJ O
application CN101613334B T NN O
thereof CN101613334B T NN O
. CN101613334B T . O

Compositions WO2014165057A1 T NNS O
and WO2014165057A1 T CC O
methods WO2014165057A1 T NNS O
for WO2014165057A1 T IN O
treating WO2014165057A1 T VBG O
infectious WO2014165057A1 T JJ O
disease WO2014165057A1 T NN O
. WO2014165057A1 T . O

Otilonium CN101053562A T NNP O
bromide CN101053562A T NN O
capsule CN101053562A T NN O
. CN101053562A T . O

The CN101053562A A DT O
present CN101053562A A JJ O
invention CN101053562A A NN O
discloses CN101053562A A VBZ O
a CN101053562A A DT O
medical CN101053562A A JJ O
composition CN101053562A A NN O
comprising CN101053562A A VBG O
effective CN101053562A A JJ O
amount CN101053562A A NN O
of CN101053562A A IN O
otilonium CN101053562A A NN O
Br CN101053562A A NNP O
for CN101053562A A IN O
treating CN101053562A A VBG O
irritable CN101053562A A JJ O
bowel CN101053562A A NN O
syndrome CN101053562A A NN O
or CN101053562A A CC O
stomach CN101053562A A NN O
convulsion CN101053562A A NN O
. CN101053562A A . O

Said CN101053562A A NNP O
composition CN101053562A A NN O
will CN101053562A A MD O
disperse CN101053562A A VB O
into CN101053562A A IN O
small CN101053562A A JJ O
granules CN101053562A A NNS O
within CN101053562A A IN O
five CN101053562A A CD O
minutes CN101053562A A NNS O
in CN101053562A A IN O
water CN101053562A A NN O
and CN101053562A A CC O
the CN101053562A A DT O
in CN101053562A A IN O
vitro CN101053562A A JJ O
dissolve-out CN101053562A A NN O
will CN101053562A A MD O
be CN101053562A A VB O
above CN101053562A A IN O
90 CN101053562A A CD O
% CN101053562A A NN O
, CN101053562A A , O
which CN101053562A A WDT O
will CN101053562A A MD O
hence CN101053562A A VB O
dispel CN101053562A A VB O
the CN101053562A A DT O
convulsion CN101053562A A NN O
rapidly CN101053562A A RB O
. CN101053562A A . O

The CN101053562A A DT O
preferred CN101053562A A JJ O
composition CN101053562A A NN O
is CN101053562A A VBZ O
of CN101053562A A IN O
capsule CN101053562A A NN O
type CN101053562A A NN O
. CN101053562A A . O

Application CN101606929A T NN O
of CN101606929A T IN O
deoxypodophyllotoxin CN101606929A T NN O
. CN101606929A T . O

Preparation CN101104646A T NNP O
method CN101104646A T NN O
for CN101104646A T IN O
eucheuma CN101104646A T JJ O
gelatinae CN101104646A T NN O
polysaccharide CN101104646A T NN O
selenide CN101104646A T NN O
and CN101104646A T CC O
application CN101104646A T NN O
. CN101104646A T . O

Combination WO2011017488A2 T NN O
of WO2011017488A2 T IN O
a WO2011017488A2 T DT O
selective WO2011017488A2 T JJ O
ppar-gamma WO2011017488A2 T NN I-UN
modulator WO2011017488A2 T NN O
and WO2011017488A2 T CC O
an WO2011017488A2 T DT O
incretin WO2011017488A2 T NN O
for WO2011017488A2 T IN O
the WO2011017488A2 T DT O
treatment WO2011017488A2 T NN O
of WO2011017488A2 T IN O
diabetes WO2011017488A2 T NNS O
and WO2011017488A2 T CC O
obesity WO2011017488A2 T NN O
. WO2011017488A2 T . O

The WO2011017488A2 A DT O
compositions WO2011017488A2 A NNS O
comprise WO2011017488A2 A VBP O
a WO2011017488A2 A DT O
combination WO2011017488A2 A NN O
of WO2011017488A2 A IN O
a WO2011017488A2 A DT O
selective WO2011017488A2 A JJ O
PPARγ WO2011017488A2 A NNP I-UN
modulator WO2011017488A2 A NN O
and WO2011017488A2 A CC O
an WO2011017488A2 A DT O
incretin WO2011017488A2 A NN O
. WO2011017488A2 A . O

The WO2011017488A2 A DT O
methods WO2011017488A2 A NNS O
include WO2011017488A2 A VBP O
the WO2011017488A2 A DT O
administration WO2011017488A2 A NN O
of WO2011017488A2 A IN O
the WO2011017488A2 A DT O
combination WO2011017488A2 A NN O
of WO2011017488A2 A IN O
a WO2011017488A2 A DT O
selective WO2011017488A2 A JJ O
PPARγ WO2011017488A2 A NNP I-UN
modulator WO2011017488A2 A NN O
and WO2011017488A2 A CC O
an WO2011017488A2 A DT O
incretin WO2011017488A2 A NN O
. WO2011017488A2 A . O

Nerve CN103127494A T NNP O
regeneration CN103127494A T NN O
biogum CN103127494A T NN O
and CN103127494A T CC O
preparation CN103127494A T NN O
method CN103127494A T NN O
and CN103127494A T CC O
application CN103127494A T NN O
thereof CN103127494A T NN O
. CN103127494A T . O

The CN103127494A A DT O
nerve CN103127494A A NN O
regeneration CN103127494A A NN O
biogum CN103127494A A NN O
is CN103127494A A VBZ O
prepared CN103127494A A VBN O
from CN103127494A A IN O
fibrinogen CN103127494A A NN O
, CN103127494A A , O
NaCl CN103127494A A NNP O
, CN103127494A A , O
hemopexin CN103127494A A NN I-UN
and CN103127494A A CC O
12 CN103127494A A CD O
neurotrophic CN103127494A A JJ O
factors CN103127494A A NNS O
, CN103127494A A , O
wherein CN103127494A A VBP O
the CN103127494A A DT O
fibrinogen CN103127494A A NN O
, CN103127494A A , O
the CN103127494A A DT O
hemopexin CN103127494A A NN I-UN
and CN103127494A A CC O
the CN103127494A A DT O
NaCl CN103127494A A NNP O
form CN103127494A A NN O
a CN103127494A A DT O
base CN103127494A A JJ O
support CN103127494A A NN O
matrix CN103127494A A NN O
. CN103127494A A . O

Composition DE102010051776A1 T NN O
, DE102010051776A1 T , O
useful DE102010051776A1 T JJ O
to DE102010051776A1 T TO O
treat DE102010051776A1 T VB O
urinary DE102010051776A1 T JJ O
tract DE102010051776A1 T NN O
diseases DE102010051776A1 T NNS O
, DE102010051776A1 T , O
preferably DE102010051776A1 T RB O
cystitis DE102010051776A1 T NN O
comprises DE102010051776A1 T VBZ O
a DE102010051776A1 T DT O
carbon DE102010051776A1 T NN O
with DE102010051776A1 T IN O
specified DE102010051776A1 T JJ O
range DE102010051776A1 T NN O
of DE102010051776A1 T IN O
charcoal DE102010051776A1 T NN O
, DE102010051776A1 T , O
which DE102010051776A1 T WDT O
carried DE102010051776A1 T VBN O
by DE102010051776A1 T IN O
an DE102010051776A1 T DT O
aqueous DE102010051776A1 T JJ O
vector DE102010051776A1 T NN O
to DE102010051776A1 T TO O
become DE102010051776A1 T VB O
a DE102010051776A1 T DT O
carbon-basic DE102010051776A1 T JJ O
aqueous DE102010051776A1 T JJ O
vector DE102010051776A1 T NN O
. DE102010051776A1 T . O

Composition CN1850166A T NN O
of CN1850166A T IN O
white CN1850166A T JJ O
mulberry CN1850166A T JJ O
leaf CN1850166A T NN O
blood-sugar-reducing CN1850166A T JJ O
effective CN1850166A T JJ O
components CN1850166A T NNS O
and CN1850166A T CC O
preparing CN1850166A T VBG O
method CN1850166A T NN O
. CN1850166A T . O

Stable CN102652748A T JJ O
elvucitabine CN102652748A T JJ O
pharmaceutical CN102652748A T JJ O
composition CN102652748A T NN O
and CN102652748A T CC O
preparation CN102652748A T NN O
method CN102652748A T NN O
thereof CN102652748A T NN O
. CN102652748A T . O

Active US20070088024 T JJ O
substance US20070088024 T NN O
combination US20070088024 T NN O
comprising US20070088024 T VBG O
a US20070088024 T DT O
carbinol US20070088024 T NN O
combined US20070088024 T VBN O
to US20070088024 T TO O
at US20070088024 T IN O
least US20070088024 T JJS O
an US20070088024 T DT O
NSAID US20070088024 T NNP O
. US20070088024 T . O

Di/tri-aza-spiro-c9-c11alkanes WO2012101487A1 T NNS O
. WO2012101487A1 T . O

Omeprazole CN103550213A T NNP O
sodium CN103550213A T NN O
composition CN103550213A T NN O
for CN103550213A T IN O
injection CN103550213A T NN O
and CN103550213A T CC O
preparation CN103550213A T NN O
method CN103550213A T NN O
thereof CN103550213A T NN O
. CN103550213A T . O

Compositions WO2006019855A1 T NNS O
capable WO2006019855A1 T JJ O
of WO2006019855A1 T IN O
inhibiting WO2006019855A1 T VBG O
reactive WO2006019855A1 T JJ O
oxygen WO2006019855A1 T NN O
and WO2006019855A1 T CC O
carbonyl WO2006019855A1 T NN O
species WO2006019855A1 T NNS O
. WO2006019855A1 T . O

Crystalline CN101037419A T NNP O
parecoxib CN101037419A T NN O
sodium CN101037419A T NN O
. CN101037419A T . O

A CN101037419A A DT O
process CN101037419A A NN O
for CN101037419A A IN O
producing CN101037419A A VBG O
crystalline CN101037419A A JJ O
form CN101037419A A NN O
I CN101037419A A PRP O
of CN101037419A A IN O
cabergoline CN101037419A A NN O
, CN101037419A A , O
which CN101037419A A WDT O
process CN101037419A A NN O
comprises CN101037419A A VBZ O
the CN101037419A A DT O
preparation CN101037419A A NN O
of CN101037419A A IN O
Form CN101037419A A NNP O
V CN101037419A A NNP O
using CN101037419A A VBG O
heptane CN101037419A A NN O
as CN101037419A A IN O
precipitation CN101037419A A NN O
solvent CN101037419A A NN O
, CN101037419A A , O
and CN101037419A A CC O
its CN101037419A A PRP$ O
exclusive CN101037419A A JJ O
conversion CN101037419A A NN O
into CN101037419A A IN O
crystalline CN101037419A A JJ O
Form CN101037419A A NNP O
I CN101037419A A PRP O
of CN101037419A A IN O
cabergoline CN101037419A A NN O
. CN101037419A A . O

The CN101037419A A DT O
present CN101037419A A JJ O
crystallization CN101037419A A NN O
process CN101037419A A NN O
from CN101037419A A IN O
toluene-heptane CN101037419A A JJ O
solvent CN101037419A A NN O
system CN101037419A A NN O
for CN101037419A A IN O
form CN101037419A A NN O
V CN101037419A A NNP O
involves CN101037419A A VBZ O
''reverse CN101037419A A POS O
addition CN101037419A A NN O
'' CN101037419A A '' O
of CN101037419A A IN O
toluene-cabergoline CN101037419A A JJ O
concentrate CN101037419A A NN O
to CN101037419A A TO O
cold CN101037419A A VB O
heptane CN101037419A A NN O
. CN101037419A A . O

Formulations US20100137267 T NNS O
for US20100137267 T IN O
treatment US20100137267 T NN O
of US20100137267 T IN O
adipose US20100137267 T JJ O
tissue US20100137267 T NN O
, US20100137267 T , O
cutaneous US20100137267 T JJ O
tissue US20100137267 T NN O
and US20100137267 T CC O
disorders US20100137267 T NNS O
, US20100137267 T , O
and US20100137267 T CC O
muscular US20100137267 T JJ O
tissue US20100137267 T NN O
. US20100137267 T . O

Methods US20100137267 A NNS O
comprise US20100137267 A VBP O
administering US20100137267 A VBG O
a US20100137267 A DT O
composition US20100137267 A NN O
comprising US20100137267 A VBG O
at US20100137267 A IN O
least US20100137267 A JJS O
one US20100137267 A CD O
compound US20100137267 A NN O
that US20100137267 A WDT O
reduces US20100137267 A VBZ O
desensitization US20100137267 A NN O
of US20100137267 A IN O
beta US20100137267 A NN O
adrenergic US20100137267 A JJ O
receptors US20100137267 A NNS O
, US20100137267 A , O
for US20100137267 A IN O
example US20100137267 A NN O
a US20100137267 A DT O
glucocorticosteroid US20100137267 A NN O
, US20100137267 A , O
and/or US20100137267 A NN O
at US20100137267 A IN O
least US20100137267 A JJS O
one US20100137267 A CD O
long-acting US20100137267 A JJ O
beta-2 US20100137267 A JJ I-UN
adrenergic US20100137267 A NN I-UN
receptor US20100137267 A NN I-UN
agonist US20100137267 A NN O
, US20100137267 A , O
for US20100137267 A IN O
example US20100137267 A NN O
, US20100137267 A , O
formoterol US20100137267 A NN O
. US20100137267 A . O

Compositions US20100137267 A NNS O
to US20100137267 A TO O
be US20100137267 A VB O
administered US20100137267 A VBN O
include US20100137267 A VBP O
sustained US20100137267 A JJ O
release US20100137267 A NN O
formulations US20100137267 A NNS O
comprising US20100137267 A VBG O
at US20100137267 A IN O
least US20100137267 A JJS O
one US20100137267 A CD O
long-acting US20100137267 A JJ O
beta-2 US20100137267 A JJ I-UN
adrenergic US20100137267 A NN I-UN
receptor US20100137267 A NN I-UN
agonist US20100137267 A NN O
, US20100137267 A , O
at US20100137267 A IN O
least US20100137267 A JJS O
one US20100137267 A CD O
compound US20100137267 A NN O
that US20100137267 A WDT O
reduces US20100137267 A VBZ O
desensitization US20100137267 A NN O
of US20100137267 A IN O
beta US20100137267 A NN O
adrenergic US20100137267 A JJ O
receptors US20100137267 A NNS O
, US20100137267 A , O
or US20100137267 A CC O
both US20100137267 A DT O
in US20100137267 A IN O
a US20100137267 A DT O
sustained US20100137267 A JJ O
crystalline US20100137267 A NN O
microparticle US20100137267 A NN O
form US20100137267 A NN O
. US20100137267 A . O

Drug CN103393946A T NN O
for CN103393946A T IN O
treating CN103393946A T VBG O
type-2 CN103393946A T JJ O
diabetes CN103393946A T NNS O
. CN103393946A T . O

Receptors EP1950226A2 T NNS O
for EP1950226A2 T IN O
human EP1950226A2 T JJ I-UN
interleukin-12 EP1950226A2 T NN I-UN
. EP1950226A2 T . O

The EP1950226A2 A DT O
present EP1950226A2 A JJ O
invention EP1950226A2 A NN O
is EP1950226A2 A VBZ O
directed EP1950226A2 A VBN O
to EP1950226A2 A TO O
IL-12 EP1950226A2 A NNP I-UN
receptor EP1950226A2 A NN I-UN
proteins EP1950226A2 A VBZ O
comprising EP1950226A2 A VBG O
a EP1950226A2 A DT O
complex EP1950226A2 A NN O
of EP1950226A2 A IN O
the EP1950226A2 A DT O
beta1 EP1950226A2 A NN O
receptor EP1950226A2 A NN O
protein EP1950226A2 A NN O
with EP1950226A2 A IN O
the EP1950226A2 A DT O
beta2 EP1950226A2 A NN O
receptor EP1950226A2 A NN O
protein EP1950226A2 A NN O
, EP1950226A2 A , O
which EP1950226A2 A WDT O
complex EP1950226A2 A VBP O
is EP1950226A2 A VBZ O
capable EP1950226A2 A JJ O
of EP1950226A2 A IN O
binding EP1950226A2 A VBG O
to EP1950226A2 A TO O
human EP1950226A2 A JJ I-UN
IL-12 EP1950226A2 A NNP I-UN
with EP1950226A2 A IN O
high EP1950226A2 A JJ O
affinity EP1950226A2 A NN O
. EP1950226A2 A . O

When EP1950226A2 A WRB O
expressed EP1950226A2 A VBN O
in EP1950226A2 A IN O
host EP1950226A2 A NN O
cells EP1950226A2 A NNS O
the EP1950226A2 A DT O
nucleic EP1950226A2 A JJ O
acid EP1950226A2 A NN O
gives EP1950226A2 A VBZ O
rise EP1950226A2 A NN O
to EP1950226A2 A TO O
substantially EP1950226A2 A RB O
homogeneous EP1950226A2 A JJ O
IL-12 EP1950226A2 A NNP I-UN
receptor EP1950226A2 A NN I-UN
proteins EP1950226A2 A NNS O
. EP1950226A2 A . O

Further EP1950226A2 A RB O
, EP1950226A2 A , O
the EP1950226A2 A DT O
invention EP1950226A2 A NN O
relates EP1950226A2 A VBZ O
to EP1950226A2 A TO O
antibodies EP1950226A2 A NNS O
capable EP1950226A2 A JJ O
of EP1950226A2 A IN O
binding EP1950226A2 A VBG O
to EP1950226A2 A TO O
cells EP1950226A2 A NNS O
expressing EP1950226A2 A VBG O
the EP1950226A2 A DT O
IL-12 EP1950226A2 A NNP I-UN
receptor EP1950226A2 A NN I-UN
molecules EP1950226A2 A NNS O
. EP1950226A2 A . O

Compositions WO2014142995A1 T NNS O
and WO2014142995A1 T CC O
methods WO2014142995A1 T NNS O
including WO2014142995A1 T VBG O
leelamine WO2014142995A1 T NN O
and WO2014142995A1 T CC O
arachidonyl WO2014142995A1 T JJ O
trifluoromethyl WO2014142995A1 T NN O
ketone WO2014142995A1 T NN O
relating WO2014142995A1 T VBG O
to WO2014142995A1 T TO O
treatment WO2014142995A1 T NN O
of WO2014142995A1 T IN O
cancer WO2014142995A1 T NN O
. WO2014142995A1 T . O

Composition CN103505735A T NN O
containing CN103505735A T VBG O
r-aminobutyric CN103505735A T JJ O
acid CN103505735A T NN O
, CN103505735A T , O
taurine CN103505735A T NN O
and CN103505735A T CC O
antiepileptic CN103505735A T JJ O
drugs CN103505735A T NNS O
. CN103505735A T . O

Fat CN103118675A T NNP O
and CN103118675A T CC O
oil CN103118675A T NN O
composition CN103118675A T NN O
for CN103118675A T IN O
promoting CN103118675A T VBG O
insulin CN103118675A T JJ I-UN
secretion CN103118675A T NN O
. CN103118675A T . O

Provided CN103118675A A VBN O
is CN103118675A A VBZ O
a CN103118675A A DT O
fat CN103118675A A JJ O
and CN103118675A A CC O
oil CN103118675A A NN O
composition CN103118675A A NN O
for CN103118675A A IN O
promoting CN103118675A A VBG O
insulin CN103118675A A NN I-UN
secretion CN103118675A A NN O
, CN103118675A A , O
the CN103118675A A DT O
composition CN103118675A A NN O
being CN103118675A A VBG O
very CN103118675A A RB O
safe CN103118675A A JJ O
, CN103118675A A , O
devoid CN103118675A A NN O
of CN103118675A A IN O
concerns CN103118675A A NNS O
of CN103118675A A IN O
side CN103118675A A NN O
effects CN103118675A A NNS O
even CN103118675A A RB O
when CN103118675A A WRB O
ingested CN103118675A A VBN O
continuously CN103118675A A RB O
, CN103118675A A , O
and CN103118675A A CC O
effective CN103118675A A JJ O
in CN103118675A A IN O
preventing CN103118675A A VBG O
diabetes CN103118675A A NNS O
and CN103118675A A CC O
other CN103118675A A JJ O
uses CN103118675A A NNS O
. CN103118675A A . O

This CN103118675A A DT O
fat CN103118675A A NN O
and CN103118675A A CC O
oil CN103118675A A NN O
composition CN103118675A A NN O
for CN103118675A A IN O
promoting CN103118675A A VBG O
insulin CN103118675A A NN I-UN
secretion CN103118675A A NN O
is CN103118675A A VBZ O
characterized CN103118675A A VBN O
in CN103118675A A IN O
containing CN103118675A A VBG O
a CN103118675A A DT O
triacylglycerol CN103118675A A NN O
and CN103118675A A CC O
an CN103118675A A DT O
emulsifier CN103118675A A NN O
as CN103118675A A IN O
active CN103118675A A JJ O
ingredients CN103118675A A NNS O
, CN103118675A A , O
the CN103118675A A DT O
triacylglycerol CN103118675A A NN O
having CN103118675A A VBG O
one CN103118675A A CD O
or CN103118675A A CC O
two CN103118675A A CD O
medium-chain CN103118675A A JJ O
fatty CN103118675A A JJ O
acid CN103118675A A NN O
residues CN103118675A A NNS O
in CN103118675A A IN O
a CN103118675A A DT O
molecule CN103118675A A NN O
and CN103118675A A CC O
containing CN103118675A A NN O
, CN103118675A A , O
as CN103118675A A IN O
constituent CN103118675A A JJ O
fatty CN103118675A A JJ O
acids CN103118675A A NNS O
, CN103118675A A , O
a CN103118675A A DT O
C6-12 CN103118675A A JJ O
medium-chain CN103118675A A NN O
fatty CN103118675A A JJ O
acid CN103118675A A NN O
and CN103118675A A CC O
a CN103118675A A DT O
C16-24 CN103118675A A JJ O
long-chain CN103118675A A JJ O
fatty CN103118675A A JJ O
acid CN103118675A A NN O
; CN103118675A A : O
and CN103118675A A CC O
the CN103118675A A DT O
emulsifier CN103118675A A NN O
being CN103118675A A VBG O
at CN103118675A A IN O
least CN103118675A A JJS O
one CN103118675A A CD O
selected CN103118675A A VBN O
from CN103118675A A IN O
the CN103118675A A DT O
group CN103118675A A NN O
consisting CN103118675A A VBG O
of CN103118675A A IN O
a CN103118675A A DT O
phospholipid CN103118675A A NN O
, CN103118675A A , O
a CN103118675A A DT O
sucrose CN103118675A A JJ O
fatty CN103118675A A JJ O
acid CN103118675A A NN O
ester CN103118675A A NN O
, CN103118675A A , O
a CN103118675A A DT O
polyglycerol CN103118675A A NN O
fatty CN103118675A A JJ O
acid CN103118675A A NN O
ester CN103118675A A NN O
, CN103118675A A , O
and CN103118675A A CC O
a CN103118675A A DT O
monoglycerol CN103118675A A NN O
fatty CN103118675A A JJ O
acid CN103118675A A JJ O
ester CN103118675A A NN O
. CN103118675A A . O

Use CN101361753A T NNP O
of CN101361753A T IN O
poly CN101361753A T NN O
( CN101361753A T ( O
styrene-alternate-sodium CN101361753A T JJ O
maleate CN101361753A T NN O
) CN101361753A T ) O
. CN101361753A T . O

Amorphous WO2009002538A3 T JJ O
erlotinib WO2009002538A3 T NN O
, WO2009002538A3 T , O
processes WO2009002538A3 T VBZ O
for WO2009002538A3 T IN O
the WO2009002538A3 T DT O
preparation WO2009002538A3 T NN O
thereof WO2009002538A3 T NN O
, WO2009002538A3 T , O
and WO2009002538A3 T CC O
processes WO2009002538A3 T VBZ O
to WO2009002538A3 T TO O
prepare WO2009002538A3 T VB O
additional WO2009002538A3 T JJ O
forms WO2009002538A3 T NNS O
of WO2009002538A3 T IN O
erlotinib WO2009002538A3 T NN O
. WO2009002538A3 T . O

Mammalian US7358086 T JJ O
two-hybrid US7358086 T JJ O
system US7358086 T NN O
for US7358086 T IN O
screening US7358086 T VBG O
for US7358086 T IN O
modulators US7358086 T NNS O
of US7358086 T IN O
the US7358086 T DT O
accumulation US7358086 T NN O
of US7358086 T IN O
metabolic US7358086 T JJ O
products US7358086 T NNS O
. US7358086 T . O

Wind-expelling CN101422531B T JJ O
pain-assuaging CN101422531B T JJ O
paste CN101422531B T NN O
capable CN101422531B T JJ O
of CN101422531B T IN O
treating CN101422531B T VBG O
lumbar CN101422531B T JJ O
intervertebral CN101422531B T JJ O
disc CN101422531B T NN O
protrusion CN101422531B T NN O
. CN101422531B T . O

B-1 US20060073191 T NNP O
, US20060073191 T , O
4-mannobiose-containing US20060073191 T JJ O
composition US20060073191 T NN O
. US20060073191 T . O

Aminoglycoside CN101074249A T IN O
antibiotics CN101074249A T NNS O
derivative CN101074249A T JJ O
. CN101074249A T . O

An CN101074249A A DT O
amino CN101074249A A NN O
glycoside CN101074249A A NN O
antibiotics CN101074249A A NNS O
derivative CN101074249A A JJ O
, CN101074249A A , O
its CN101074249A A PRP$ O
production CN101074249A A NN O
, CN101074249A A , O
medicinal CN101074249A A JJ O
composition CN101074249A A NN O
containing CN101074249A A VBG O
it CN101074249A A PRP O
and CN101074249A A CC O
its CN101074249A A PRP$ O
usage CN101074249A A NN O
for CN101074249A A IN O
preparing CN101074249A A VBG O
medicines CN101074249A A NNS O
in CN101074249A A IN O
treatment CN101074249A A NN O
and CN101074249A A CC O
prevention CN101074249A A NN O
infectious CN101074249A A JJ O
diseases CN101074249A A NNS O
are CN101074249A A VBP O
disclosed CN101074249A A VBN O
. CN101074249A A . O

It CN101074249A A PRP O
's CN101074249A A VBZ O
soluble CN101074249A A JJ O
, CN101074249A A , O
safe CN101074249A A JJ O
, CN101074249A A , O
convenient CN101074249A A JJ O
and CN101074249A A CC O
non-toxic CN101074249A A JJ O
, CN101074249A A , O
has CN101074249A A VBZ O
wide CN101074249A A JJ O
antibacterial CN101074249A A JJ O
spectrum CN101074249A A NN O
, CN101074249A A , O
higher CN101074249A A JJR O
antibacterial CN101074249A A JJ O
activity CN101074249A A NN O
and CN101074249A A CC O
better CN101074249A A JJR O
clinical CN101074249A A JJ O
value CN101074249A A NN O
. CN101074249A A . O

Use CN1961872A T NNP O
of CN1961872A T IN O
choline CN1961872A T NN O
in CN1961872A T IN O
preparation CN1961872A T NN O
of CN1961872A T IN O
medicament CN1961872A T NN O
having CN1961872A T VBG O
central CN1961872A T JJ O
or CN1961872A T CC O
peripheral CN1961872A T JJ O
pain CN1961872A T NN O
easing CN1961872A T VBG O
function CN1961872A T NN O
. CN1961872A T . O

The CN1961872A A DT O
invention CN1961872A A NN O
relates CN1961872A A VBZ O
to CN1961872A A TO O
the CN1961872A A DT O
use CN1961872A A NN O
of CN1961872A A IN O
sincaline CN1961872A A JJ O
compounds CN1961872A A NNS O
in CN1961872A A IN O
the CN1961872A A DT O
treatment CN1961872A A NN O
of CN1961872A A IN O
central CN1961872A A JJ O
or CN1961872A A CC O
peripheral CN1961872A A JJ O
pains CN1961872A A NNS O
. CN1961872A A . O

Hsp90 US20120208806 T NNP I-UN
Inhibitors US20120208806 T NNP O
. US20120208806 T . O

The US20120208806 A DT O
present US20120208806 A JJ O
application US20120208806 A NN O
provides US20120208806 A VBZ O
compounds US20120208806 A NNS O
useful US20120208806 A JJ O
in US20120208806 A IN O
the US20120208806 A DT O
inhibition US20120208806 A NN O
of US20120208806 A IN O
Hsp90 US20120208806 A NNP I-UN
, US20120208806 A , O
and US20120208806 A CC O
hence US20120208806 A RB O
in US20120208806 A IN O
the US20120208806 A DT O
treatment US20120208806 A NN O
of US20120208806 A IN O
disease US20120208806 A NN O
. US20120208806 A . O

Improved WO2011042918A3 T VBN O
processes WO2011042918A3 T NNS O
for WO2011042918A3 T IN O
preparing WO2011042918A3 T VBG O
prasugrel WO2011042918A3 T NN O
and WO2011042918A3 T CC O
pharmaceutically WO2011042918A3 T RB O
acceptable WO2011042918A3 T JJ O
salts WO2011042918A3 T NNS O
thereof WO2011042918A3 T NN O
. WO2011042918A3 T . O

Use EP1351680B8 T NNP O
of EP1351680B8 T IN O
anethole-dithiolethione EP1351680B8 T NN O
for EP1351680B8 T IN O
preventing EP1351680B8 T VBG O
and EP1351680B8 T CC O
treating EP1351680B8 T VBG O
drug-induced EP1351680B8 T JJ O
tendon EP1351680B8 T JJ O
toxicity EP1351680B8 T NN O
. EP1351680B8 T . O

Sod US20060264408 T NNP O
minic US20060264408 T JJ O
multifunctional US20060264408 T JJ O
compounds US20060264408 T NNS O
for US20060264408 T IN O
treating US20060264408 T VBG O
inflammatory US20060264408 T JJ O
bowel US20060264408 T NN O
disease US20060264408 T NN O
. US20060264408 T . O

neutralizing US20070059241 T VBG O
monoclonal US20070059241 T JJ O
antibodies US20070059241 T NNS O
against US20070059241 T IN O
human US20070059241 T JJ I-UN
Insulin-like US20070059241 T JJ I-UN
Growth US20070059241 T NNP I-UN
Factor US20070059241 T NNP I-UN
Receptor-I US20070059241 T NNP I-UN
( US20070059241 T ( O
IGFR1 US20070059241 T NNP I-UN
) US20070059241 T ) O
; US20070059241 T : O
anticancer US20070059241 T JJ O
agent US20070059241 T NN O
. US20070059241 T . O

The US20070059241 A DT O
present US20070059241 A JJ O
invention US20070059241 A NN O
includes US20070059241 A VBZ O
fully US20070059241 A RB O
human US20070059241 A JJ O
, US20070059241 A , O
neutralizing US20070059241 A JJ O
, US20070059241 A , O
monoclonal US20070059241 A JJ O
antibodies US20070059241 A NNS O
against US20070059241 A IN O
human US20070059241 A JJ I-UN
Insulin-like US20070059241 A JJ I-UN
Growth US20070059241 A NNP I-UN
Factor US20070059241 A NNP I-UN
Receptor-I US20070059241 A NNP I-UN
( US20070059241 A ( O
IGFR1 US20070059241 A NNP I-UN
) US20070059241 A ) O
. US20070059241 A . O

Depot US20080287464 T NNP O
Formulations US20080287464 T NNP O
. US20080287464 T . O

Quality CN101007030A T NNP O
control CN101007030A T VBP O
methods CN101007030A T NNS O
of CN101007030A T IN O
leaves CN101007030A T NNS O
of CN101007030A T IN O
cordyalis CN101007030A T NN O
esquirolii CN101007030A T NN O
and CN101007030A T CC O
its CN101007030A T PRP$ O
preparation CN101007030A T NN O
. CN101007030A T . O

Anti-cancer CN101919819A T JJ O
drug CN101919819A T NN O
preparation CN101919819A T NN O
taking CN101919819A T VBG O
Solutol CN101919819A T NNP O
HS CN101919819A T NNP O
15 CN101919819A T CD O
as CN101919819A T IN O
solubilizer CN101919819A T NN O
. CN101919819A T . O

The US20100286280 A DT O
assays US20100286280 A NNS O
identify US20100286280 A VB O
compounds US20100286280 A NNS O
which US20100286280 A WDT O
both US20100286280 A DT O
inhibit US20100286280 A VBP O
eppin-semenogelin US20100286280 A JJ O
binding US20100286280 A NN O
and US20100286280 A CC O
inhibit US20100286280 A NN O
sperm US20100286280 A JJ O
motility US20100286280 A NN O
, US20100286280 A , O
and US20100286280 A CC O
can US20100286280 A MD O
be US20100286280 A VB O
carried US20100286280 A VBN O
out US20100286280 A RP O
in US20100286280 A IN O
a US20100286280 A DT O
high US20100286280 A JJ O
throughput US20100286280 A NN O
manner US20100286280 A NN O
, US20100286280 A , O
using US20100286280 A VBG O
labeled US20100286280 A VBN O
recombinant US20100286280 A JJ O
Eppin US20100286280 A NNP I-UN
and US20100286280 A CC O
semenogelin US20100286280 A NN I-UN
. US20100286280 A . O

Purine US20100120799 T NNP O
derivatives US20100120799 T NNS O
as US20100120799 T IN O
immunomodulators US20100120799 T NNS O
. US20100120799 T . O

Defervescence CN101336960A T NNP O
paste CN101336960A T NN O
. CN101336960A T . O

Carbidopa/levodopa/folic CN103127116A T NNP O
acid CN103127116A T VBP O
compound CN103127116A T NN O
medicine CN103127116A T NN O
composition CN103127116A T NN O
and CN103127116A T CC O
use CN103127116A T NN O
thereof CN103127116A T NN O
. CN103127116A T . O

Intralesional WO2006138038A1 T NNP O
treatment WO2006138038A1 T NN O
of WO2006138038A1 T IN O
psoriasis WO2006138038A1 T NN O
. WO2006138038A1 T . O

Substituted US7572787 T VBN O
naphthalene US7572787 T JJ O
sulfonamides US7572787 T NNS O
. US7572787 T . O

Use CN101337065B T NNP O
of CN101337065B T IN O
MG132 CN101337065B T NNP O
in CN101337065B T IN O
preparing CN101337065B T VBG O
medicine CN101337065B T NN O
for CN101337065B T IN O
synergistic CN101337065B T JJ O
inductive CN101337065B T JJ O
differentiation CN101337065B T NN O
therapy CN101337065B T NN O
of CN101337065B T IN O
leukaemia CN101337065B T NN O
. CN101337065B T . O

The CN101337065B A DT O
compound CN101337065B A NN O
MG132 CN101337065B A NNP O
with CN101337065B A IN O
the CN101337065B A DT O
single CN101337065B A JJ O
effect CN101337065B A NN O
can CN101337065B A MD O
not CN101337065B A RB O
induce CN101337065B A VB O
the CN101337065B A DT O
leukemia CN101337065B A NN O
cells CN101337065B A NNS O
to CN101337065B A TO O
be CN101337065B A VB O
differentiated CN101337065B A VBN O
, CN101337065B A , O
but CN101337065B A CC O
promote CN101337065B A VBP O
the CN101337065B A DT O
differentiation CN101337065B A NN O
induction CN101337065B A NN O
effect CN101337065B A NN O
of CN101337065B A IN O
the CN101337065B A DT O
retinoic CN101337065B A JJ O
acid CN101337065B A JJ O
drug CN101337065B A NN O
on CN101337065B A IN O
the CN101337065B A DT O
leukemia CN101337065B A NN O
cells CN101337065B A NNS O
, CN101337065B A , O
which CN101337065B A WDT O
is CN101337065B A VBZ O
presented CN101337065B A VBN O
as CN101337065B A IN O
the CN101337065B A DT O
promotion CN101337065B A NN O
of CN101337065B A IN O
the CN101337065B A DT O
anti-proliferative CN101337065B A JJ O
effect CN101337065B A NN O
and CN101337065B A CC O
the CN101337065B A DT O
cell CN101337065B A NN O
cycle CN101337065B A NN O
arresting CN101337065B A VBG O
effect CN101337065B A NN O
of CN101337065B A IN O
the CN101337065B A DT O
retinoic CN101337065B A JJ O
acid CN101337065B A JJ O
drug CN101337065B A NN O
on CN101337065B A IN O
the CN101337065B A DT O
leukemia CN101337065B A NN O
cells CN101337065B A NNS O
, CN101337065B A , O
promote CN101337065B A VBP O
the CN101337065B A DT O
expression CN101337065B A NN O
of CN101337065B A IN O
the CN101337065B A DT O
differentiation CN101337065B A NN O
specific CN101337065B A JJ O
antigen CN101337065B A NN O
CD11b CN101337065B A NNP I-UN
on CN101337065B A IN O
the CN101337065B A DT O
leukemia CN101337065B A NN O
cell CN101337065B A NN O
surface CN101337065B A NN O
, CN101337065B A , O
and CN101337065B A CC O
increasing CN101337065B A VBG O
the CN101337065B A DT O
number CN101337065B A NN O
of CN101337065B A IN O
segmented CN101337065B A JJ O
cells CN101337065B A NNS O
. CN101337065B A . O

Combination EP2236139A1 T NNP O
therapy EP2236139A1 T NN O
of EP2236139A1 T IN O
erlotinib EP2236139A1 T NN O
with EP2236139A1 T IN O
an EP2236139A1 T DT O
anti-IGF-1R EP2236139A1 T JJ O
antibody EP2236139A1 T NN O
, EP2236139A1 T , O
which EP2236139A1 T WDT O
does EP2236139A1 T VBZ O
not EP2236139A1 T RB O
inhibit EP2236139A1 T VB O
binding EP2236139A1 T NN O
of EP2236139A1 T IN O
insulin EP2236139A1 T NN I-UN
to EP2236139A1 T TO O
the EP2236139A1 T DT O
insulin EP2236139A1 T NN I-UN
receptor EP2236139A1 T NN I-UN
. EP2236139A1 T . O

Intelligent CN102861340A T JJ O
nano CN102861340A T NN O
delivery CN102861340A T NN O
system CN102861340A T NN O
, CN102861340A T , O
preparation CN102861340A T NN O
method CN102861340A T NN O
and CN102861340A T CC O
application CN102861340A T NN O
thereof CN102861340A T NN O
. CN102861340A T . O

Molecule CN102861340A A NNP O
delivery CN102861340A A NN O
of CN102861340A A IN O
an CN102861340A A DT O
embodiment CN102861340A A NN O
of CN102861340A A IN O
the CN102861340A A DT O
intelligent CN102861340A A JJ O
nanoparticle CN102861340A A JJ O
drug CN102861340A A NN O
delivery CN102861340A A NN O
system CN102861340A A NN O
includes CN102861340A A VBZ O
but CN102861340A A CC O
is CN102861340A A VBZ O
not CN102861340A A RB O
limited CN102861340A A VBN O
to CN102861340A A TO O
the CN102861340A A DT O
following CN102861340A A JJ O
molecules CN102861340A A NNS O
: CN102861340A A : O
telomerase CN102861340A A NN O
cell CN102861340A A NN O
delivery CN102861340A A NN O
; CN102861340A A : O
antioxidant CN102861340A A JJ O
enzyme CN102861340A A NN O
( CN102861340A A ( O
such CN102861340A A JJ O
as CN102861340A A IN O
SOD CN102861340A A NNP I-UN
( CN102861340A A ( O
superoxide CN102861340A A JJ I-UN
dismutase CN102861340A A NN I-UN
) CN102861340A A ) O
and CN102861340A A CC O
HPX CN102861340A A NNP I-UN
( CN102861340A A ( O
hydrogen CN102861340A A JJ I-UN
peroxidase CN102861340A A NN I-UN
) CN102861340A A ) O
) CN102861340A A ) O
cell CN102861340A A NN O
delivery CN102861340A A NN O
; CN102861340A A : O
cancer CN102861340A A NN O
suppressor CN102861340A A NN O
protein CN102861340A A NN O
( CN102861340A A ( O
such CN102861340A A JJ O
as CN102861340A A IN O
p53 CN102861340A A NN I-UN
and CN102861340A A CC O
PTEN CN102861340A A NNP I-UN
( CN102861340A A ( O
phosphatase CN102861340A A NN I-UN
and CN102861340A A CC I-UN
tensin CN102861340A A NN I-UN
homolog CN102861340A A NN I-UN
deleted CN102861340A A VBN I-UN
on CN102861340A A IN I-UN
chromosome CN102861340A A NN I-UN
ten CN102861340A A NN I-UN
) CN102861340A A ) O
) CN102861340A A ) O
cell CN102861340A A NN O
delivery CN102861340A A NN O
; CN102861340A A : O
and CN102861340A A CC O
organic CN102861340A A JJ O
chemical CN102861340A A NN O
and CN102861340A A CC O
biochemical CN102861340A A JJ O
small CN102861340A A JJ O
molecules CN102861340A A NNS O
( CN102861340A A ( O
such CN102861340A A JJ O
as CN102861340A A IN O
atorvastatin-lipitor CN102861340A A NN O
and CN102861340A A CC O
coenzyme CN102861340A A VB O
Q-10 CN102861340A A NNP O
) CN102861340A A ) O
cell CN102861340A A NN O
delivery CN102861340A A NN O
. CN102861340A A . O

Method WO2011058443A1 T NNP O
and WO2011058443A1 T CC O
device WO2011058443A1 T NN O
to WO2011058443A1 T TO O
induce WO2011058443A1 T VB O
collagen WO2011058443A1 T NN O
biomineralisation WO2011058443A1 T NN O
. WO2011058443A1 T . O

Food WO2008081834A1 T NNP O
containing WO2008081834A1 T VBG O
glycogen WO2008081834A1 T NN O
and WO2008081834A1 T CC O
use WO2008081834A1 T NN O
thereof WO2008081834A1 T NN O
. WO2008081834A1 T . O

Process WO2010082072A1 T NN O
for WO2010082072A1 T IN O
the WO2010082072A1 T DT O
preparation WO2010082072A1 T NN O
of WO2010082072A1 T IN O
rosuvastatin WO2010082072A1 T NN O
salts WO2010082072A1 T NNS O
. WO2010082072A1 T . O

Tumor US7030099 T NNP O
specific US7030099 T JJ O
promoters US7030099 T NNS O
of US7030099 T IN O
the US7030099 T DT O
midkine US7030099 T NN I-UN
gene US7030099 T NN I-UN
that US7030099 T WDT O
allow US7030099 T VBP O
for US7030099 T IN O
selective US7030099 T JJ O
expression US7030099 T NN O
in US7030099 T IN O
P53-inactivated US7030099 T NNP O
cells US7030099 T NNS O
. US7030099 T . O

A US7030099 A DT O
DNA US7030099 A NN O
comprising US7030099 A VBG O
a US7030099 A DT O
609 US7030099 A CD O
bp US7030099 A NN O
base US7030099 A NN O
sequence US7030099 A NN O
from US7030099 A IN O
−559 US7030099 A NN O
to US7030099 A TO O
+50 US7030099 A VB O
when US7030099 A WRB O
the US7030099 A DT O
first US7030099 A JJ O
base US7030099 A NN O
sequence US7030099 A NN O
of US7030099 A IN O
exon US7030099 A JJ O
1 US7030099 A CD O
of US7030099 A IN O
the US7030099 A DT O
midkine US7030099 A NN I-UN
gene US7030099 A NN I-UN
, US7030099 A , O
a US7030099 A DT O
human US7030099 A JJ O
retinoic US7030099 A NN O
acid-responsive US7030099 A JJ O
growth/differentiation US7030099 A NN O
factor US7030099 A NN O
was US7030099 A VBD O
set US7030099 A VBN O
as US7030099 A IN O
+1 US7030099 A NN O
, US7030099 A , O
or US7030099 A CC O
a US7030099 A DT O
DNA US7030099 A NN O
comprising US7030099 A VBG O
a US7030099 A DT O
251 US7030099 A CD O
bp US7030099 A NN O
base US7030099 A NN O
sequence US7030099 A NN O
from US7030099 A IN O
−213 US7030099 A NN O
to US7030099 A TO O
+38 US7030099 A VB O
when US7030099 A WRB O
the US7030099 A DT O
transcription US7030099 A NN O
initiation US7030099 A NN O
point US7030099 A NN O
of US7030099 A IN O
the US7030099 A DT O
c-erbB-2 US7030099 A JJ I-UN
gene US7030099 A NN O
belonging US7030099 A VBG O
to US7030099 A TO O
the US7030099 A DT O
EGF US7030099 A NNP I-UN
receptor US7030099 A NN I-UN
family US7030099 A NN O
and US7030099 A CC O
having US7030099 A VBG O
a US7030099 A DT O
tyrosine US7030099 A JJ O
kinase US7030099 A NN O
activity US7030099 A NN O
was US7030099 A VBD O
set US7030099 A VBN O
as US7030099 A IN O
+1 US7030099 A NN O
has US7030099 A VBZ O
a US7030099 A DT O
tumor-specific US7030099 A JJ O
transcription US7030099 A NN O
activity US7030099 A NN O
, US7030099 A , O
and US7030099 A CC O
the US7030099 A DT O
promoter US7030099 A NN O
activity US7030099 A NN O
thereof US7030099 A NN O
is US7030099 A VBZ O
high US7030099 A JJ O
, US7030099 A , O
and US7030099 A CC O
therefore US7030099 A RB O
is US7030099 A VBZ O
very US7030099 A RB O
important US7030099 A JJ O
as US7030099 A IN O
a US7030099 A DT O
tumor-specific US7030099 A JJ O
promoter US7030099 A NN O
for US7030099 A IN O
use US7030099 A NN O
in US7030099 A IN O
the US7030099 A DT O
suicide US7030099 A JJ O
gene US7030099 A NN O
therapy US7030099 A NN O
that US7030099 A WDT O
combines US7030099 A VBZ O
the US7030099 A DT O
use US7030099 A NN O
of US7030099 A IN O
a US7030099 A DT O
gene US7030099 A NN O
for US7030099 A IN O
a US7030099 A DT O
drug US7030099 A NN O
metabolizing US7030099 A VBG O
enzyme US7030099 A NN O
and US7030099 A CC O
a US7030099 A DT O
prodrug US7030099 A NN O
for US7030099 A IN O
cancer US7030099 A NN O
therapy US7030099 A NN O
, US7030099 A , O
the US7030099 A DT O
gene US7030099 A NN O
therapy US7030099 A NN O
of US7030099 A IN O
cancer US7030099 A NN O
using US7030099 A VBG O
an US7030099 A DT O
expression US7030099 A NN O
vector US7030099 A NN O
that US7030099 A WDT O
contains US7030099 A VBZ O
a US7030099 A DT O
gene US7030099 A NN O
encoding US7030099 A VBG O
a US7030099 A DT O
cytokine US7030099 A NN O
, US7030099 A , O
and US7030099 A CC O
the US7030099 A DT O
gene US7030099 A NN O
therapy US7030099 A NN O
of US7030099 A IN O
cancer US7030099 A NN O
using US7030099 A VBG O
an US7030099 A DT O
oncolytic US7030099 A JJ O
virus US7030099 A NN O
. US7030099 A . O

Derivatives WO2007026959A3 T NNS O
of WO2007026959A3 T IN O
4-piperazin-1-yl-4-benz0 WO2007026959A3 T JJ O
[ WO2007026959A3 T NN O
b WO2007026959A3 T NN O
] WO2007026959A3 T NNP O
thiophene WO2007026959A3 T NN O
suitable WO2007026959A3 T NN O
for WO2007026959A3 T IN O
the WO2007026959A3 T DT O
treatment WO2007026959A3 T NN O
of WO2007026959A3 T IN O
cns WO2007026959A3 T NN O
disorders WO2007026959A3 T NNS O
. WO2007026959A3 T . O

A WO2007026959A3 A DT O
heterocyclic WO2007026959A3 A JJ O
compound WO2007026959A3 A NN O
or WO2007026959A3 A CC O
a WO2007026959A3 A DT O
salt WO2007026959A3 A JJ O
thereof WO2007026959A3 A NN O
represented WO2007026959A3 A VBN O
by WO2007026959A3 A IN O
the WO2007026959A3 A DT O
formula WO2007026959A3 A NN O
( WO2007026959A3 A ( O
1 WO2007026959A3 A CD O
) WO2007026959A3 A ) O
: WO2007026959A3 A : O
where WO2007026959A3 A WRB O
R2 WO2007026959A3 A NNP O
represents WO2007026959A3 A VBZ O
a WO2007026959A3 A DT O
hydrogen WO2007026959A3 A NN O
atom WO2007026959A3 A NN O
or WO2007026959A3 A CC O
a WO2007026959A3 A DT O
lower WO2007026959A3 A JJR O
alkyl WO2007026959A3 A NN O
group WO2007026959A3 A NN O
; WO2007026959A3 A : O
A WO2007026959A3 A NNP O
represents WO2007026959A3 A VBZ O
a WO2007026959A3 A DT O
lower WO2007026959A3 A JJR O
alkylene WO2007026959A3 A NN O
group WO2007026959A3 A NN O
or WO2007026959A3 A CC O
lower WO2007026959A3 A JJR O
alkenylene WO2007026959A3 A NN O
group WO2007026959A3 A NN O
; WO2007026959A3 A : O
and WO2007026959A3 A CC O
R1 WO2007026959A3 A NNP O
represents WO2007026959A3 A VBZ O
an WO2007026959A3 A DT O
aromatic WO2007026959A3 A JJ O
group WO2007026959A3 A NN O
or WO2007026959A3 A CC O
a WO2007026959A3 A DT O
heterocyclic WO2007026959A3 A JJ O
group WO2007026959A3 A NN O
. WO2007026959A3 A . O

The WO2007026959A3 A DT O
compound WO2007026959A3 A NN O
of WO2007026959A3 A IN O
the WO2007026959A3 A DT O
present WO2007026959A3 A JJ O
invention WO2007026959A3 A NN O
has WO2007026959A3 A VBZ O
a WO2007026959A3 A DT O
wide WO2007026959A3 A JJ O
treatment WO2007026959A3 A NN O
spectrum WO2007026959A3 A NN O
for WO2007026959A3 A IN O
mental WO2007026959A3 A JJ O
disorders WO2007026959A3 A NNS O
including WO2007026959A3 A VBG O
central WO2007026959A3 A JJ O
nervous WO2007026959A3 A JJ O
system WO2007026959A3 A NN O
disorders WO2007026959A3 A NNS O
, WO2007026959A3 A , O
no WO2007026959A3 A DT O
side WO2007026959A3 A NN O
effects WO2007026959A3 A NNS O
and WO2007026959A3 A CC O
high WO2007026959A3 A JJ O
safety WO2007026959A3 A NN O
. WO2007026959A3 A . O

3 WO2011011420A3 T CD O
, WO2011011420A3 T , O
4-methylenedioxyphenyl WO2011011420A3 T JJ O
inhibitors WO2011011420A3 T NNS O
of WO2011011420A3 T IN O
gaba WO2011011420A3 T JJ I-UN
aminotransferase WO2011011420A3 T NN I-UN
and/or WO2011011420A3 T NN O
gaba WO2011011420A3 T NNS O
reuptake WO2011011420A3 T VBP O
transporter WO2011011420A3 T JJ O
inhibitor WO2011011420A3 T NN O
. WO2011011420A3 T . O

The WO2011011420A3 A DT O
present WO2011011420A3 A JJ O
invention WO2011011420A3 A NN O
relates WO2011011420A3 A VBZ O
to WO2011011420A3 A TO O
new WO2011011420A3 A JJ O
3,4-methylenedioxyphenyl WO2011011420A3 A JJ O
inhibitors WO2011011420A3 A NNS O
of WO2011011420A3 A IN O
GABA WO2011011420A3 A NNP I-UN
aminotransferase WO2011011420A3 A NN I-UN
activity WO2011011420A3 A NN O
and/or WO2011011420A3 A VBP O
GABA WO2011011420A3 A NNP O
reuptake WO2011011420A3 A VBP O
transporter WO2011011420A3 A NN O
activity WO2011011420A3 A NN O
, WO2011011420A3 A , O
pharmaceutical WO2011011420A3 A JJ O
compositions WO2011011420A3 A NNS O
thereof WO2011011420A3 A NN O
, WO2011011420A3 A , O
and WO2011011420A3 A CC O
methods WO2011011420A3 A NNS O
of WO2011011420A3 A IN O
use WO2011011420A3 A NN O
thereof WO2011011420A3 A NN O
. WO2011011420A3 A . O

Mir-101 US20100311815 T JJ O
cancer US20100311815 T NN O
markers US20100311815 T NNS O
. US20100311815 T . O

2-substituted EP1753714A2 T JJ O
and EP1753714A2 T CC O
4-substituted EP1753714A2 T JJ O
aryl EP1753714A2 T NN O
nitrone EP1753714A2 T NN O
compouds EP1753714A2 T NN O
. EP1753714A2 T . O

Carbocyclic US8080541 T JJ O
GlyT-1 US8080541 T NNP I-UN
receptor US8080541 T NN O
antagonists US8080541 T NNS O
. US8080541 T . O

New WO2012013967A3 T NNP O
uses WO2012013967A3 T NNS O
. WO2012013967A3 T . O

Sulfamoyl-arylamides WO2014033176A1 T NNS O
and WO2014033176A1 T CC O
the WO2014033176A1 T DT O
use WO2014033176A1 T NN O
thereof WO2014033176A1 T NN O
as WO2014033176A1 T IN O
medicaments WO2014033176A1 T NNS O
for WO2014033176A1 T IN O
the WO2014033176A1 T DT O
treatment WO2014033176A1 T NN O
of WO2014033176A1 T IN O
hepatitis WO2014033176A1 T NN O
b WO2014033176A1 T NN O
. WO2014033176A1 T . O

Kinesin US20090214529 T NNP I-UN
inhibitors US20090214529 T NNS O
. US20090214529 T . O

These US20090214529 A DT O
compounds US20090214529 A NNS O
can US20090214529 A MD O
be US20090214529 A VB O
used US20090214529 A VBN O
to US20090214529 A TO O
treat US20090214529 A VB O
a US20090214529 A DT O
kinesin US20090214529 A NN I-UN
Eg5 US20090214529 A NNP I-UN
protein-mediated US20090214529 A JJ O
disorder US20090214529 A NN O
. US20090214529 A . O

Use WO2010023390A1 T NNP O
of WO2010023390A1 T IN O
an WO2010023390A1 T DT O
n-acyl WO2010023390A1 T JJ O
amino WO2010023390A1 T NN O
acid WO2010023390A1 T NN O
selected WO2010023390A1 T VBN O
from WO2010023390A1 T IN O
among WO2010023390A1 T IN O
n-palmitoyl WO2010023390A1 T JJ O
alanine WO2010023390A1 T NN O
, WO2010023390A1 T , O
n-palmitoyl WO2010023390A1 T JJ O
glycine WO2010023390A1 T NN O
, WO2010023390A1 T , O
and WO2010023390A1 T CC O
n-palmitoyl WO2010023390A1 T JJ O
isoleucine WO2010023390A1 T NN O
as WO2010023390A1 T IN O
a WO2010023390A1 T DT O
regulating WO2010023390A1 T VBG O
active WO2010023390A1 T JJ O
agent WO2010023390A1 T NN O
of WO2010023390A1 T IN O
the WO2010023390A1 T DT O
genetic WO2010023390A1 T JJ O
profile WO2010023390A1 T NN O
of WO2010023390A1 T IN O
senescent WO2010023390A1 T NN O
replicating WO2010023390A1 T VBG O
fibroblasts WO2010023390A1 T NNS O
of WO2010023390A1 T IN O
the WO2010023390A1 T DT O
human WO2010023390A1 T JJ O
skin WO2010023390A1 T NN O
dermis WO2010023390A1 T NN O
. WO2010023390A1 T . O

The WO2010023390A1 A DT O
invention WO2010023390A1 A NN O
relates WO2010023390A1 A VBZ O
to WO2010023390A1 A TO O
use WO2010023390A1 A VB O
of WO2010023390A1 A IN O
an WO2010023390A1 A DT O
N-acyl WO2010023390A1 A NNP O
amino WO2010023390A1 A NN O
acid WO2010023390A1 A NN O
selected WO2010023390A1 A VBN O
from WO2010023390A1 A IN O
among WO2010023390A1 A IN O
N-palmitoyl WO2010023390A1 A NNP O
alanine WO2010023390A1 A NN O
, WO2010023390A1 A , O
N-palmitoyl WO2010023390A1 A NNP O
glycine WO2010023390A1 A NN O
, WO2010023390A1 A , O
and WO2010023390A1 A CC O
N-palmitoyl WO2010023390A1 A NNP O
isoleucine WO2010023390A1 A NN O
as WO2010023390A1 A IN O
a WO2010023390A1 A DT O
regulating WO2010023390A1 A VBG O
active WO2010023390A1 A JJ O
agent WO2010023390A1 A NN O
of WO2010023390A1 A IN O
the WO2010023390A1 A DT O
genetic WO2010023390A1 A JJ O
profile WO2010023390A1 A NN O
of WO2010023390A1 A IN O
senescent WO2010023390A1 A NN O
replicating WO2010023390A1 A VBG O
fibroblasts WO2010023390A1 A NNS O
of WO2010023390A1 A IN O
the WO2010023390A1 A DT O
human WO2010023390A1 A JJ O
skin WO2010023390A1 A NN O
dermis WO2010023390A1 A NN O
, WO2010023390A1 A , O
to WO2010023390A1 A TO O
an WO2010023390A1 A DT O
anti-aging WO2010023390A1 A JJ O
cosmetic WO2010023390A1 A JJ O
composition WO2010023390A1 A NN O
comprising WO2010023390A1 A VBG O
same WO2010023390A1 A JJ O
, WO2010023390A1 A , O
and WO2010023390A1 A CC O
to WO2010023390A1 A TO O
the WO2010023390A1 A DT O
implementation WO2010023390A1 A NN O
of WO2010023390A1 A IN O
a WO2010023390A1 A DT O
therapeutic WO2010023390A1 A JJ O
method WO2010023390A1 A NN O
intended WO2010023390A1 A VBN O
to WO2010023390A1 A TO O
retard WO2010023390A1 A VB O
the WO2010023390A1 A DT O
appearance WO2010023390A1 A NN O
of WO2010023390A1 A IN O
wrinkles WO2010023390A1 A NNS O
and/or WO2010023390A1 A RB O
slow WO2010023390A1 A VBP O
the WO2010023390A1 A DT O
aging WO2010023390A1 A NN O
of WO2010023390A1 A IN O
skin WO2010023390A1 A JJ O
cells WO2010023390A1 A NNS O
of WO2010023390A1 A IN O
the WO2010023390A1 A DT O
human WO2010023390A1 A JJ O
body WO2010023390A1 A NN O
. WO2010023390A1 A . O

11- EP1682514A1 T JJ O
o-methylgeldanamycin EP1682514A1 T JJ O
compounds EP1682514A1 T NNS O
. EP1682514A1 T . O

Dihydropyridone EP2393781A1 T NNP O
ureas EP2393781A1 T JJ O
as EP2393781A1 T IN O
p2x7 EP2393781A1 T JJ I-UN
modulators EP2393781A1 T NNS O
. EP2393781A1 T . O

Also EP2393781A1 A RB O
disclosed EP2393781A1 A VBN O
are EP2393781A1 A VBP O
methods EP2393781A1 A NNS O
of EP2393781A1 A IN O
making EP2393781A1 A VBG O
the EP2393781A1 A DT O
compounds EP2393781A1 A NNS O
and EP2393781A1 A CC O
using EP2393781A1 A VBG O
the EP2393781A1 A DT O
compounds EP2393781A1 A NNS O
for EP2393781A1 A IN O
treatment EP2393781A1 A NN O
of EP2393781A1 A IN O
diseases EP2393781A1 A NNS O
associated EP2393781A1 A VBN O
with EP2393781A1 A IN O
the EP2393781A1 A DT O
P2X7 EP2393781A1 A NNP I-UN
purinergic EP2393781A1 A NN O
receptor EP2393781A1 A NN O
. EP2393781A1 A . O

Aryl/Alkyl US20120283213 T NNP O
Succinic US20120283213 T NNP O
Anhydride US20120283213 T NNP O
Hyaluronan US20120283213 T NNP O
Derivatives US20120283213 T NNP O
. US20120283213 T . O

Antimicrobial US20110129512 T JJ O
Releasing US20110129512 T VBG O
Polymers US20110129512 T NNS O
. US20110129512 T . O

Compound CN101797374A T NNP O
minocycline CN101797374A T NN O
hydrochloride CN101797374A T NN O
soluble CN101797374A T JJ O
powder CN101797374A T NN O
for CN101797374A T IN O
treating CN101797374A T VBG O
respiratory CN101797374A T NN O
diseases CN101797374A T NNS O
of CN101797374A T IN O
poultry CN101797374A T NN O
. CN101797374A T . O

Use US6872705 T NNP O
of US6872705 T IN O
antimicrobial US6872705 T JJ O
peptides US6872705 T NNS O
as US6872705 T IN O
preservatives US6872705 T NNS O
in US6872705 T IN O
ophthalmic US6872705 T JJ O
preparations US6872705 T NNS O
, US6872705 T , O
including US6872705 T VBG O
solutions US6872705 T NNS O
, US6872705 T , O
emulsions US6872705 T NNS O
, US6872705 T , O
and US6872705 T CC O
suspensions US6872705 T NNS O
. US6872705 T . O

Application CN103479659A T NN O
of CN103479659A T IN O
three CN103479659A T CD O
kinds CN103479659A T NNS O
of CN103479659A T IN O
oroxin CN103479659A T NN O
in CN103479659A T IN O
preparing CN103479659A T VBG O
drug CN103479659A T NN O
for CN103479659A T IN O
resisting CN103479659A T VBG O
staphylococcus CN103479659A T NN O
aureus CN103479659A T JJ O
infection CN103479659A T NN O
. CN103479659A T . O

Compound CN101474375B T NNP O
Cordyceps CN101474375B T NNP O
militaris CN101474375B T NNP O
L. CN101474375B T NNP O
Link CN101474375B T NNP O
preparation CN101474375B T NN O
and CN101474375B T CC O
production CN101474375B T NN O
method CN101474375B T NN O
and CN101474375B T CC O
application CN101474375B T NN O
. CN101474375B T . O

Use EP2633859A1 T NNP O
of EP2633859A1 T IN O
biological EP2633859A1 T JJ O
surfactant EP2633859A1 T NN O
as EP2633859A1 T IN O
anti-inflammatory EP2633859A1 T JJ O
agent EP2633859A1 T NN O
and EP2633859A1 T CC O
tissue EP2633859A1 T NN O
preservative EP2633859A1 T JJ O
solution EP2633859A1 T NN O
. EP2633859A1 T . O

Medicaments CN101239072B T NNS O
for CN101239072B T IN O
treating CN101239072B T VBG O
syphilis CN101239072B T JJ O
disease CN101239072B T NN O
and CN101239072B T CC O
preparation CN101239072B T NN O
thereof CN101239072B T NN O
. CN101239072B T . O

Mesenchymal CN102719397A T JJ O
stem CN102719397A T NN O
cell CN102719397A T NN O
and CN102719397A T CC O
application CN102719397A T NN O
thereof CN102719397A T NN O
in CN102719397A T IN O
resisting CN102719397A T VBG O
HIV-1 CN102719397A T NNP O
( CN102719397A T ( O
human CN102719397A T JJ O
immunodeficiency CN102719397A T NN O
virus CN102719397A T NN O
) CN102719397A T ) O
. CN102719397A T . O

Nitrogen-containing EP2048142A2 T NN O
condensed EP2048142A2 T VBD O
cyclic EP2048142A2 T JJ O
compound EP2048142A2 T NN O
having EP2048142A2 T VBG O
a EP2048142A2 T DT O
pyrazolyl EP2048142A2 T NN O
group EP2048142A2 T NN O
as EP2048142A2 T IN O
a EP2048142A2 T DT O
substituent EP2048142A2 T NN O
group EP2048142A2 T NN O
and EP2048142A2 T CC O
pharmaceutical EP2048142A2 T JJ O
composition EP2048142A2 T NN O
thereof EP2048142A2 T NN O
. EP2048142A2 T . O

The EP2048142A2 A DT O
present EP2048142A2 A JJ O
invention EP2048142A2 A NN O
provides EP2048142A2 A VBZ O
a EP2048142A2 A DT O
compound EP2048142A2 A NN O
having EP2048142A2 A VBG O
an EP2048142A2 A DT O
excellent EP2048142A2 A JJ O
inhibitory EP2048142A2 A NN O
action EP2048142A2 A NN O
on EP2048142A2 A IN O
activation EP2048142A2 A NN O
of EP2048142A2 A IN O
STAT6 EP2048142A2 A NNP I-UN
and EP2048142A2 A CC O
a EP2048142A2 A DT O
pharmaceutical EP2048142A2 A JJ O
composition EP2048142A2 A NN O
thereof EP2048142A2 A NN O
. EP2048142A2 A . O

Bicyclyl US20050288376 T NNP O
or US20050288376 T CC O
heterobicyclylmethanesulfonylanimo-substituted US20050288376 T JJ O
N-hydroxyformamides US20050288376 T NNS O
. US20050288376 T . O

IL-13 US8318910 T NNP I-UN
receptor US8318910 T NN I-UN
antibodies US8318910 T NNS O
. US8318910 T . O

This US8318910 A DT O
invention US8318910 A NN O
relates US8318910 A VBZ O
to US8318910 A TO O
monoclonal US8318910 A VB O
and US8318910 A CC O
polyclonal US8318910 A JJ O
antibodies US8318910 A NNS O
capable US8318910 A JJ O
of US8318910 A IN O
specifically US8318910 A RB O
recognizing US8318910 A VBG O
IL-13 US8318910 A NNP I-UN
receptor US8318910 A NN I-UN
α US8318910 A NN I-UN
and US8318910 A CC O
uses US8318910 A VBZ O
thereof US8318910 A NN O
. US8318910 A . O

Use CN101400353A T NNP O
of CN101400353A T IN O
5H-dibenz/b CN101400353A T JJ O
, CN101400353A T , O
f/azepine-5-carboxamide CN101400353A T JJ O
derivatives CN101400353A T NNS O
in CN101400353A T IN O
the CN101400353A T DT O
treatment CN101400353A T NN O
of CN101400353A T IN O
neuropathic CN101400353A T JJ O
pain CN101400353A T NN O
and CN101400353A T CC O
neurological CN101400353A T JJ O
disorders CN101400353A T NNS O
. CN101400353A T . O

Use CA2340921C T NNP O
of CA2340921C T IN O
taxanes CA2340921C T NNS O
to CA2340921C T TO O
treat CA2340921C T VB O
brain CA2340921C T NN O
cancer CA2340921C T NN O
. CA2340921C T . O

Preparation CN103027846A T NNP O
method CN103027846A T NN O
and CN103027846A T CC O
process CN103027846A T NN O
for CN103027846A T IN O
antibacterial CN103027846A T JJ O
modification CN103027846A T NN O
of CN103027846A T IN O
ceramic CN103027846A T JJ O
whiskers CN103027846A T NNS O
. CN103027846A T . O

Deuterium-enriched US20090076010 T JJ O
lamotrigine US20090076010 T NN O
. US20090076010 T . O

Econazole CN102875472A T JJ O
nitrate CN102875472A T NN O
compound CN102875472A T NN O
crystal CN102875472A T NN O
and CN102875472A T CC O
preparation CN102875472A T NN O
method CN102875472A T NN O
and CN102875472A T CC O
drug CN102875472A T NN O
composition CN102875472A T NN O
thereof CN102875472A T NN O
. CN102875472A T . O

Extractions US20120046366 T NNS O
of US20120046366 T IN O
Fixed US20120046366 T NNP O
Oil US20120046366 T NNP O
and US20120046366 T CC O
Thymoquinone US20120046366 T NNP O
Rich US20120046366 T NNP O
Fractions US20120046366 T NNP O
( US20120046366 T ( O
TQRF US20120046366 T NNP O
) US20120046366 T ) O
. US20120046366 T . O

Substituted US20090306129 T VBN O
pyrazolo US20090306129 T JJ O
[ US20090306129 T JJ O
3,4-b US20090306129 T JJ O
] US20090306129 T NN O
pyridines US20090306129 T NNS O
as US20090306129 T IN O
phosphodiesterase US20090306129 T NN I-UN
inhibitors US20090306129 T NNS O
. US20090306129 T . O

The US20090306129 A DT O
present US20090306129 A JJ O
invention US20090306129 A NN O
relates US20090306129 A VBZ O
to US20090306129 A TO O
phosphodiesterase US20090306129 A VB I-UN
( US20090306129 A ( I-UN
PDE US20090306129 A NNP I-UN
) US20090306129 A ) I-UN
type US20090306129 A NN I-UN
IV US20090306129 A NNP I-UN
selective US20090306129 A JJ O
inhibitors US20090306129 A NNS O
. US20090306129 A . O

Processes US20090306129 A NNS O
for US20090306129 A IN O
the US20090306129 A DT O
preparation US20090306129 A NN O
of US20090306129 A IN O
disclosed US20090306129 A JJ O
compounds US20090306129 A NNS O
, US20090306129 A , O
pharmaceutical US20090306129 A JJ O
compositions US20090306129 A NNS O
containing US20090306129 A VBG O
the US20090306129 A DT O
disclosed US20090306129 A JJ O
compounds US20090306129 A NNS O
and US20090306129 A CC O
their US20090306129 A PRP$ O
use US20090306129 A NN O
as US20090306129 A IN O
PDE US20090306129 A NNP I-UN
type US20090306129 A NN I-UN
IV US20090306129 A NNP I-UN
selective US20090306129 A JJ O
inhibitors US20090306129 A NNS O
are US20090306129 A VBP O
provided US20090306129 A VBN O
. US20090306129 A . O

PROCESS WO2011017299A3 T NN O
FOR WO2011017299A3 T IN O
PREPARING WO2011017299A3 T VBG O
A WO2011017299A3 T DT O
2-ALKYNYL WO2011017299A3 T JJ O
SUBSTITUTED WO2011017299A3 T NNP O
5-AMINO-PYRAZOLO- WO2011017299A3 T JJ O
[ WO2011017299A3 T NNP O
4,3-e WO2011017299A3 T JJ O
] WO2011017299A3 T NNP O
-1,2,4-TRIAZOLO WO2011017299A3 T NNP O
[ WO2011017299A3 T NNP O
1,5-c WO2011017299A3 T JJ O
] WO2011017299A3 T NNP O
PYRIMIDINE WO2011017299A3 T NNP O
. WO2011017299A3 T . O

Method US20120316240 T NNP O
of US20120316240 T IN O
diagnosis US20120316240 T NN O
. US20120316240 T . O

Disclosed US20120316240 A VBN O
herein US20120316240 A NNS O
are US20120316240 A VBP O
methods US20120316240 A NNS O
that US20120316240 A WDT O
generally US20120316240 A RB O
to US20120316240 A TO O
the US20120316240 A DT O
fields US20120316240 A NNS O
of US20120316240 A IN O
pharmaceutical US20120316240 A JJ O
chemistry US20120316240 A NN O
, US20120316240 A , O
biochemistry US20120316240 A NN O
, US20120316240 A , O
molecular US20120316240 A JJ O
biology US20120316240 A NN O
and US20120316240 A CC O
medicine US20120316240 A NN O
. US20120316240 A . O

More US20120316240 A RBR O
particularly US20120316240 A RB O
, US20120316240 A , O
aspects US20120316240 A NNS O
of US20120316240 A IN O
the US20120316240 A DT O
invention US20120316240 A NN O
concern US20120316240 A NN O
methods US20120316240 A NNS O
to US20120316240 A TO O
identify US20120316240 A VB O
a US20120316240 A DT O
predisposition US20120316240 A NN O
for US20120316240 A IN O
fibrosis US20120316240 A NN O
in US20120316240 A IN O
a US20120316240 A DT O
biological US20120316240 A JJ O
sample US20120316240 A NN O
, US20120316240 A , O
methods US20120316240 A NNS O
of US20120316240 A IN O
identifying US20120316240 A VBG O
agents US20120316240 A NNS O
that US20120316240 A WDT O
modulate US20120316240 A VBP O
the US20120316240 A DT O
onset US20120316240 A NN O
of US20120316240 A IN O
fibrosis US20120316240 A NN O
, US20120316240 A , O
methods US20120316240 A NNS O
of US20120316240 A IN O
making US20120316240 A VBG O
a US20120316240 A DT O
formulation US20120316240 A NN O
that US20120316240 A WDT O
inhibits US20120316240 A VBZ O
the US20120316240 A DT O
onset US20120316240 A NN O
or US20120316240 A CC O
progression US20120316240 A NN O
of US20120316240 A IN O
fibrosis US20120316240 A NN O
, US20120316240 A , O
and US20120316240 A CC O
methods US20120316240 A NNS O
of US20120316240 A IN O
monitoring US20120316240 A VBG O
the US20120316240 A DT O
progression US20120316240 A NN O
of US20120316240 A IN O
fibrosis US20120316240 A NN O
or US20120316240 A CC O
the US20120316240 A DT O
efficacy US20120316240 A NN O
of US20120316240 A IN O
a US20120316240 A DT O
fibrosis US20120316240 A NN O
treatment US20120316240 A NN O
. US20120316240 A . O

Medical CN101502506B T JJ O
use CN101502506B T NN O
of CN101502506B T IN O
3- CN101502506B T JJ O
( CN101502506B T ( O
3,4-dihydroxyphenyl CN101502506B T JJ O
) CN101502506B T ) O
-acrylic CN101502506B T JJ O
acid CN101502506B T JJ O
2- CN101502506B T JJ O
( CN101502506B T ( O
3,4-dihydroxyphenyl CN101502506B T JJ O
) CN101502506B T ) O
-ethyl CN101502506B T NN O
ester CN101502506B T NN O
. CN101502506B T . O

Combination US20120202819 T NNP O
therapy US20120202819 T NN O
using US20120202819 T VBG O
a US20120202819 T DT O
beta US20120202819 T NN I-UN
3 US20120202819 T CD I-UN
adrenergic US20120202819 T JJ I-UN
receptor US20120202819 T NN I-UN
agonists US20120202819 T NNS O
and US20120202819 T CC O
an US20120202819 T DT O
antimuscarinic US20120202819 T JJ O
agent US20120202819 T NN O
. US20120202819 T . O

Described US20120202819 A NNP O
herein US20120202819 A NN O
is US20120202819 A VBZ O
an US20120202819 A DT O
improved US20120202819 A JJ O
method US20120202819 A NN O
of US20120202819 A IN O
treating US20120202819 A VBG O
overactive US20120202819 A JJ O
bladder US20120202819 A NN O
, US20120202819 A , O
wherein US20120202819 A VBP O
the US20120202819 A DT O
method US20120202819 A NN O
comprises US20120202819 A VBZ O
administering US20120202819 A VBG O
to US20120202819 A TO O
a US20120202819 A DT O
patient US20120202819 A NN O
in US20120202819 A IN O
need US20120202819 A NN O
thereof US20120202819 A VBP O
a US20120202819 A DT O
beta US20120202819 A NN I-UN
3 US20120202819 A CD I-UN
adrenergic US20120202819 A JJ I-UN
receptor US20120202819 A NN I-UN
agonist US20120202819 A NN O
, US20120202819 A , O
an US20120202819 A DT O
antimuscarinic US20120202819 A JJ O
agent US20120202819 A NN O
, US20120202819 A , O
and US20120202819 A CC O
an US20120202819 A DT O
optional US20120202819 A JJ O
selective US20120202819 A JJ O
M2 US20120202819 A NNP I-UN
antagonist US20120202819 A NN O
. US20120202819 A . O

Methods US20120245117 T NNS O
of US20120245117 T IN O
treating US20120245117 T VBG O
squamous US20120245117 T JJ O
cell US20120245117 T NN O
lung US20120245117 T NN O
cancer US20120245117 T NN O
with US20120245117 T IN O
4-iodo-3-nitrobenzamide US20120245117 T JJ O
in US20120245117 T IN O
combination US20120245117 T NN O
with US20120245117 T IN O
gemcitabine US20120245117 T NN O
and US20120245117 T CC O
carboplatin US20120245117 T NN O
. US20120245117 T . O

Antitumoral WO2010000817A1 T NNP O
macrolides WO2010000817A1 T NNS O
. WO2010000817A1 T . O

Medicine CN1568965A T NNP O
for CN1568965A T IN O
treating CN1568965A T VBG O
osteoporosis CN1568965A T NN O
and CN1568965A T CC O
its CN1568965A T PRP$ O
preparing CN1568965A T NN O
method CN1568965A T NN O
. CN1568965A T . O

Anticholinergic WO2005055999A1 T NNP O
agent WO2005055999A1 T NN O
. WO2005055999A1 T . O

Composition WO2014084434A1 T NN O
for WO2014084434A1 T IN O
preventing WO2014084434A1 T VBG O
and WO2014084434A1 T CC O
treating WO2014084434A1 T VBG O
rotator WO2014084434A1 T NN O
cuff WO2014084434A1 T JJ O
injury WO2014084434A1 T NN O
, WO2014084434A1 T , O
containing WO2014084434A1 T VBG O
cyanidin WO2014084434A1 T NN O
or WO2014084434A1 T CC O
delphinidin WO2014084434A1 T NN O
as WO2014084434A1 T IN O
active WO2014084434A1 T JJ O
ingredient WO2014084434A1 T NN O
. WO2014084434A1 T . O

Medicine CN1919208A T NNP O
for CN1919208A T IN O
treating CN1919208A T VBG O
epithelium CN1919208A T JJ O
tumor CN1919208A T NN O
. CN1919208A T . O

For US7115777 T IN O
therapy US7115777 T NN O
of US7115777 T IN O
hypertension US7115777 T NN O
, US7115777 T , O
congestive US7115777 T JJ O
heart US7115777 T NN O
failure US7115777 T NN O
, US7115777 T , O
cardiac US7115777 T JJ O
hypertrophy US7115777 T NN O
, US7115777 T , O
cardiac US7115777 T JJ O
fibrosis US7115777 T NN O
, US7115777 T , O
cardiomyopathy US7115777 T JJ O
postinfarction US7115777 T NN O
, US7115777 T , O
complications US7115777 T NNS O
resulting US7115777 T VBG O
from US7115777 T IN O
diabetes US7115777 T NNS O
, US7115777 T , O
such US7115777 T JJ O
as US7115777 T IN O
nephropathy US7115777 T JJ O
, US7115777 T , O
vasculopathy US7115777 T JJ O
and US7115777 T CC O
neuropathy US7115777 T JJ O
, US7115777 T , O
diseases US7115777 T NNS O
of US7115777 T IN O
the US7115777 T DT O
coronary US7115777 T JJ O
vessels US7115777 T NNS O
, US7115777 T , O
restenosis US7115777 T NN O
following US7115777 T VBG O
angioplasty US7115777 T NN O
. US7115777 T . O

Prenatal US7994217 T JJ O
multivitamin/multimineral US7994217 T JJ O
supplement US7994217 T NN O
. US7994217 T . O

Application CN102370653A T NN O
of CN102370653A T IN O
eplerenone CN102370653A T NN O
in CN102370653A T IN O
preparing CN102370653A T VBG O
medicaments CN102370653A T NNS O
for CN102370653A T IN O
treating CN102370653A T VBG O
pulmonary CN102370653A T JJ O
fibrosis CN102370653A T NN O
. CN102370653A T . O

Use CA2207503C T NNP O
of CA2207503C T IN O
aminopurine CA2207503C T JJ O
antiviral CA2207503C T JJ O
agents CA2207503C T NNS O
for CA2207503C T IN O
the CA2207503C T DT O
treatment CA2207503C T NN O
and CA2207503C T CC O
prophylaxis CA2207503C T NN O
of CA2207503C T IN O
latent CA2207503C T JJ O
herpesvirus CA2207503C T NN O
infections CA2207503C T NNS O
. CA2207503C T . O

Medicament CN101810729A T NN O
for CN101810729A T IN O
treating CN101810729A T VBG O
pedopathy CN101810729A T NN O
and CN101810729A T CC O
preparation CN101810729A T NN O
method CN101810729A T NN O
thereof CN101810729A T NN O
. CN101810729A T . O

Methods US20110230473 T NNS O
and US20110230473 T CC O
Compositions US20110230473 T NNP O
for US20110230473 T IN O
Treating US20110230473 T VBG O
Status US20110230473 T NNP O
Epilepticus US20110230473 T NNP O
and US20110230473 T CC O
Seizures US20110230473 T NNP O
Causing US20110230473 T NNP O
Status US20110230473 T NNP O
Epilepticus US20110230473 T NNP O
. US20110230473 T . O

Disclosed US20110230473 A VBN O
herein US20110230473 A NNS O
are US20110230473 A VBP O
methods US20110230473 A NNS O
, US20110230473 A , O
kits US20110230473 A NNS O
and US20110230473 A CC O
compositions US20110230473 A NNS O
for US20110230473 A IN O
treating US20110230473 A VBG O
, US20110230473 A , O
preventing US20110230473 A VBG O
, US20110230473 A , O
inhibiting US20110230473 A VBG O
, US20110230473 A , O
or US20110230473 A CC O
reducing US20110230473 A VBG O
a US20110230473 A DT O
seizure US20110230473 A NN O
, US20110230473 A , O
status US20110230473 A NN O
epilepticus US20110230473 A NN O
, US20110230473 A , O
neuropathogenesis US20110230473 A NN O
or US20110230473 A CC O
a US20110230473 A DT O
neuropathology US20110230473 A NN O
caused US20110230473 A VBN O
by US20110230473 A IN O
overstimulation US20110230473 A NN O
of US20110230473 A IN O
the US20110230473 A DT O
NMDA US20110230473 A NNP I-UN
receptor US20110230473 A NN I-UN
pathway US20110230473 A NN O
and/or US20110230473 A NN O
exposure US20110230473 A NN O
to US20110230473 A TO O
an US20110230473 A DT O
OP US20110230473 A NNP O
compound US20110230473 A NN O
. US20110230473 A . O

Micro-emulsion CN101543473A T NNP O
composition CN101543473A T NN O
of CN101543473A T IN O
etoposide CN101543473A T JJ O
oral CN101543473A T JJ O
medicament CN101543473A T NN O
, CN101543473A T , O
preparation CN101543473A T NN O
method CN101543473A T NN O
and CN101543473A T CC O
application CN101543473A T NN O
thereof CN101543473A T NN O
. CN101543473A T . O

Compound CN101332195A T NNP O
branched CN101332195A T VBD O
chain CN101332195A T NN O
amino CN101332195A T NN O
acid CN101332195A T JJ O
injection CN101332195A T NN O
. CN101332195A T . O

Crystalline EP2650291A1 T NNP O
Antifungal EP2650291A1 T NNP O
Compounds EP2650291A1 T NNP O
. EP2650291A1 T . O

Use US20090191253 T NNP O
of US20090191253 T IN O
K-252a US20090191253 T NNP O
and US20090191253 T CC O
Kinase US20090191253 T NNP I-UN
Inhibitors US20090191253 T NNP O
for US20090191253 T IN O
the US20090191253 T DT O
Prevention US20090191253 T NNP O
or US20090191253 T CC O
Treatment US20090191253 T NNP O
of US20090191253 T IN O
HMGB1-Associated US20090191253 T NNP O
Pathologies US20090191253 T NNP O
. US20090191253 T . O

The US20090191253 A DT O
present US20090191253 A JJ O
invention US20090191253 A NN O
relates US20090191253 A VBZ O
to US20090191253 A TO O
the US20090191253 A DT O
use US20090191253 A NN O
of US20090191253 A IN O
K-252a US20090191253 A NNP O
, US20090191253 A , O
a US20090191253 A DT O
physiologically US20090191253 A RB O
active US20090191253 A JJ O
substance US20090191253 A NN O
produced US20090191253 A VBN O
by US20090191253 A IN O
microorganisms US20090191253 A NNS O
, US20090191253 A , O
and US20090191253 A CC O
of US20090191253 A IN O
its US20090191253 A PRP$ O
salts US20090191253 A NNS O
or US20090191253 A CC O
synthetic US20090191253 A JJ O
and/or US20090191253 A NN O
chemically US20090191253 A RB O
modified US20090191253 A VBD O
derivatives US20090191253 A NNS O
for US20090191253 A IN O
the US20090191253 A DT O
prevention US20090191253 A NN O
or US20090191253 A CC O
treatment US20090191253 A NN O
of US20090191253 A IN O
HMGB1 US20090191253 A NNP I-UN
associated US20090191253 A JJ O
pathologies US20090191253 A NNS O
. US20090191253 A . O

Ce WO2007072764A1 T NNP O
forming/maturing WO2007072764A1 T NN O
agent WO2007072764A1 T NN O
, WO2007072764A1 T , O
parakeratosis WO2007072764A1 T NN O
inhibitor WO2007072764A1 T NN O
, WO2007072764A1 T , O
skin WO2007072764A1 T FW O
barrier WO2007072764A1 T JJR O
function WO2007072764A1 T NN O
recovery WO2007072764A1 T NN O
accelerator WO2007072764A1 T NN O
, WO2007072764A1 T , O
and WO2007072764A1 T CC O
skincare WO2007072764A1 T JJ O
composition WO2007072764A1 T NN O
for WO2007072764A1 T IN O
external WO2007072764A1 T JJ O
application WO2007072764A1 T NN O
to WO2007072764A1 T TO O
skin WO2007072764A1 T VB O
. WO2007072764A1 T . O

Small EP2667872A2 T JJ O
molecule EP2667872A2 T NN O
rnase EP2667872A2 T NN I-UN
inhibitors EP2667872A2 T NNS O
and EP2667872A2 T CC O
methods EP2667872A2 T NNS O
of EP2667872A2 T IN O
use EP2667872A2 T NN O
. EP2667872A2 T . O

Small EP2667872A2 A JJ O
molecule EP2667872A2 A NN O
inhibitors EP2667872A2 A NNS O
of EP2667872A2 A IN O
bacterial EP2667872A2 A JJ O
ribonuclease EP2667872A2 A NN I-UN
( EP2667872A2 A ( O
e.g. EP2667872A2 A JJ O
, EP2667872A2 A , O
RnpA EP2667872A2 A NNP I-UN
) EP2667872A2 A ) O
and EP2667872A2 A CC O
methods EP2667872A2 A NNS O
for EP2667872A2 A IN O
their EP2667872A2 A PRP$ O
synthesis EP2667872A2 A NN O
and EP2667872A2 A CC O
use EP2667872A2 A NN O
are EP2667872A2 A VBP O
described EP2667872A2 A VBN O
herein EP2667872A2 A NNS O
. EP2667872A2 A . O

The EP2667872A2 A DT O
methods EP2667872A2 A NNS O
of EP2667872A2 A IN O
using EP2667872A2 A VBG O
the EP2667872A2 A DT O
compounds EP2667872A2 A NNS O
include EP2667872A2 A VBP O
treating EP2667872A2 A VBG O
and EP2667872A2 A CC O
preventing EP2667872A2 A VBG O
microbial EP2667872A2 A JJ O
infections EP2667872A2 A NNS O
and EP2667872A2 A CC O
inhibiting EP2667872A2 A VBG O
bacterial EP2667872A2 A JJ O
ribonuclease EP2667872A2 A NN I-UN
. EP2667872A2 A . O

Perfusate CN102068684A T NNP O
and CN102068684A T CC O
preparation CN102068684A T NN O
method CN102068684A T NN O
thereof CN102068684A T NN O
for CN102068684A T IN O
treating CN102068684A T VBG O
cow CN102068684A T JJ O
recessive CN102068684A T JJ O
mastitis CN102068684A T NN O
. CN102068684A T . O

Cancer-suppressing CN101411845B T JJ O
analgesic CN101411845B T JJ O
medicament CN101411845B T NN O
. CN101411845B T . O

Cyclocarya CN103127158A T NNP O
paliurus CN103127158A T NN O
extract CN103127158A T NN O
and CN103127158A T CC O
application CN103127158A T NN O
thereof CN103127158A T NN O
. CN103127158A T . O

The CN103127158A A DT O
cyclocarya CN103127158A A NN O
paliurus CN103127158A A NN O
extract CN103127158A A NN O
can CN103127158A A MD O
significantly CN103127158A A RB O
promote CN103127158A A VB O
the CN103127158A A DT O
secretion CN103127158A A NN O
of CN103127158A A IN O
insulin CN103127158A A NN I-UN
by CN103127158A A IN O
islet CN103127158A A NN O
beta CN103127158A A NN O
cells CN103127158A A NNS O
so CN103127158A A RB O
as CN103127158A A IN O
to CN103127158A A TO O
enhance CN103127158A A VB O
glucose CN103127158A A JJ O
tolerance CN103127158A A NN O
of CN103127158A A IN O
mice CN103127158A A NN O
and CN103127158A A CC O
regulate CN103127158A A VB O
blood CN103127158A A NN O
sugar CN103127158A A NN O
, CN103127158A A , O
and CN103127158A A CC O
therefore CN103127158A A RB O
the CN103127158A A DT O
cyclocarya CN103127158A A NN O
paliurus CN103127158A A NN O
extract CN103127158A A NN O
can CN103127158A A MD O
be CN103127158A A VB O
used CN103127158A A VBN O
for CN103127158A A IN O
preparing CN103127158A A VBG O
drugs CN103127158A A NNS O
for CN103127158A A IN O
preventing CN103127158A A VBG O
and CN103127158A A CC O
treating CN103127158A A VBG O
diabetes CN103127158A A NNS O
, CN103127158A A , O
and CN103127158A A CC O
the CN103127158A A DT O
direction CN103127158A A NN O
is CN103127158A A VBZ O
pointed CN103127158A A VBN O
out CN103127158A A RP O
for CN103127158A A IN O
further CN103127158A A JJ O
developing CN103127158A A NN O
and CN103127158A A CC O
utilizing CN103127158A A VBG O
the CN103127158A A DT O
medical CN103127158A A JJ O
value CN103127158A A NN O
of CN103127158A A IN O
cyclocarya CN103127158A A JJ O
paliurus CN103127158A A NN O
. CN103127158A A . O

Composition US20120064176 T NN O
for US20120064176 T IN O
preventing US20120064176 T VBG O
and US20120064176 T CC O
treating US20120064176 T VBG O
fatty US20120064176 T JJ O
liver US20120064176 T NN O
. US20120064176 T . O

The US20120064176 A DT O
composition US20120064176 A NN O
includes US20120064176 A VBZ O
a US20120064176 A DT O
lactoferrin US20120064176 A NN I-UN
and US20120064176 A CC O
a US20120064176 A DT O
trivalent US20120064176 A JJ O
chromium US20120064176 A NN O
compound US20120064176 A NN O
. US20120064176 A . O

Nerve-regenerating US20100016433 T JJ O
agent US20100016433 T NN O
. US20100016433 T . O

Non-gas US7387790 T JJ O
containing US7387790 T NN O
nanoparticles US7387790 T NNS O
comprising US7387790 T VBG O
a US7387790 T DT O
mixture US7387790 T NN O
of US7387790 T IN O
select US7387790 T JJ O
lipids US7387790 T NNS O
capable US7387790 T JJ O
of US7387790 T IN O
being US7387790 T VBG O
internalized US7387790 T VBN O
within US7387790 T IN O
a US7387790 T DT O
targeted US7387790 T JJ O
tissue US7387790 T NN O
or US7387790 T CC O
cell US7387790 T NN O
sufficient US7387790 T JJ O
to US7387790 T TO O
achieve US7387790 T VB O
a US7387790 T DT O
desired US7387790 T JJ O
effect US7387790 T NN O
; US7387790 T : O
anticancer US7387790 T NN O
agents US7387790 T NNS O
. US7387790 T . O

Methods US20120220632 T NNS O
For US20120220632 T IN O
Treatment US20120220632 T NNP O
of US20120220632 T IN O
Fabry US20120220632 T NNP O
Disease US20120220632 T NNP O
. US20120220632 T . O

Provided US20120220632 A VBN O
are US20120220632 A VBP O
in US20120220632 A IN O
vitro US20120220632 A NN O
and US20120220632 A CC O
in US20120220632 A IN O
vivo US20120220632 A JJ O
methods US20120220632 A NNS O
for US20120220632 A IN O
determining US20120220632 A VBG O
whether US20120220632 A IN O
a US20120220632 A DT O
patient US20120220632 A NN O
with US20120220632 A IN O
Fabry US20120220632 A NNP O
disease US20120220632 A NN O
will US20120220632 A MD O
respond US20120220632 A VB O
to US20120220632 A TO O
treatment US20120220632 A NN O
with US20120220632 A IN O
a US20120220632 A DT O
specific US20120220632 A JJ O
pharmacological US20120220632 A JJ O
chaperone US20120220632 A NN O
. US20120220632 A . O

Infections US7371762 T NNS O
caused US7371762 T VBN O
by US7371762 T IN O
Gram US7371762 T NNP O
positive US7371762 T JJ O
and/or US7371762 T NN O
negative US7371762 T JJ O
pathogens US7371762 T NNS O
. US7371762 T . O

Method CN101919831B T NNP O
for CN101919831B T IN O
inhibiting CN101919831B T VBG O
content CN101919831B T JJ O
decrease CN101919831B T NN O
of CN101919831B T IN O
Vit CN101919831B T NNP O
K1 CN101919831B T NNP O
after CN101919831B T IN O
sterilization CN101919831B T NN O
. CN101919831B T . O

Isothiocyanates EP2409693A2 T NNS O
and EP2409693A2 T CC O
derivatives EP2409693A2 T NNS O
for EP2409693A2 T IN O
use EP2409693A2 T NN O
in EP2409693A2 T IN O
the EP2409693A2 T DT O
treatment EP2409693A2 T NN O
and EP2409693A2 T CC O
/ EP2409693A2 T NN O
or EP2409693A2 T CC O
prevention EP2409693A2 T NN O
of EP2409693A2 T IN O
polymorphous EP2409693A2 T JJ O
light EP2409693A2 T JJ O
eruptions EP2409693A2 T NNS O
. EP2409693A2 T . O

Pharmaceutical EP2478902A1 T JJ O
composition EP2478902A1 T NN O
for EP2478902A1 T IN O
reducing EP2478902A1 T VBG O
weight EP2478902A1 T NN O
and EP2478902A1 T CC O
method EP2478902A1 T NN O
for EP2478902A1 T IN O
the EP2478902A1 T DT O
production EP2478902A1 T NN O
thereof EP2478902A1 T NN O
. EP2478902A1 T . O

Method US20080233595 T NNP O
for US20080233595 T IN O
diagnosing US20080233595 T VBG O
intertility US20080233595 T NN O
. US20080233595 T . O

The US20080233595 A DT O
invention US20080233595 A NN O
relates US20080233595 A VBZ O
to US20080233595 A TO O
methods US20080233595 A NNS O
for US20080233595 A IN O
diagnosing US20080233595 A VBG O
conditions US20080233595 A NNS O
characterized US20080233595 A VBN O
by US20080233595 A IN O
altered US20080233595 A JJ O
expression US20080233595 A NN O
of US20080233595 A IN O
a US20080233595 A DT O
pregnancy US20080233595 A NN I-UN
related US20080233595 A VBN I-UN
serine US20080233595 A JJ I-UN
protease US20080233595 A NN I-UN
( US20080233595 A ( O
PRSP US20080233595 A NNP I-UN
) US20080233595 A ) O
protein US20080233595 A NN O
in US20080233595 A IN O
a US20080233595 A DT O
mammal US20080233595 A NN O
. US20080233595 A . O

The US20080233595 A DT O
methods US20080233595 A NNS O
include US20080233595 A VBP O
detecting US20080233595 A VBG O
expression US20080233595 A NN O
of US20080233595 A IN O
PRSP US20080233595 A NNP I-UN
, US20080233595 A , O
such US20080233595 A JJ O
as US20080233595 A IN O
SEQ US20080233595 A NNP O
ID US20080233595 A NNP O
NP33 US20080233595 A NNP O
. US20080233595 A . O

Composition WO2008093848A1 T NN O
for WO2008093848A1 T IN O
decreasing WO2008093848A1 T VBG O
inflammation WO2008093848A1 T NN O
marker WO2008093848A1 T NN O
comprising WO2008093848A1 T VBG O
phosphatidylcholine WO2008093848A1 T NN O
. WO2008093848A1 T . O

Skin US20090110657 T NNP O
care US20090110657 T NN O
compositions US20090110657 T NNS O
. US20090110657 T . O

Application CN102872028A T NN O
of CN102872028A T IN O
Gypensapogenin CN102872028A T NNP O
A CN102872028A T NNP O
in CN102872028A T IN O
medicaments CN102872028A T NNS O
against CN102872028A T IN O
helicobacter CN102872028A T NN O
pylori CN102872028A T NN O
. CN102872028A T . O

External CN101897731A T JJ O
spraying CN101897731A T NN O
agent CN101897731A T NN O
based CN101897731A T VBN O
on CN101897731A T IN O
complex CN101897731A T JJ O
biological CN101897731A T JJ O
acid CN101897731A T NN O
. CN101897731A T . O

Psychological US6936601 T JJ O
disorders US6936601 T NNS O
; US6936601 T : O
synergistic US6936601 T JJ O
mixture US6936601 T NN O
. US6936601 T . O

Navel-applied CN103495070A T JJ O
agent CN103495070A T NN O
for CN103495070A T IN O
treating CN103495070A T VBG O
bowel CN103495070A T NN O
dysfunction CN103495070A T NN O
after CN103495070A T IN O
abdominal CN103495070A T JJ O
surgery CN103495070A T NN O
. CN103495070A T . O

Cold-system CN102114038B T JJ O
preparation CN102114038B T NN O
method CN102114038B T NN O
of CN102114038B T IN O
south CN102114038B T JJ O
calcite CN102114038B T NN O
as CN102114038B T IN O
a CN102114038B T DT O
Tibetan CN102114038B T NNP O
medicine CN102114038B T NN O
. CN102114038B T . O

Novel US20050245463 T NNP O
antiretroviral US20050245463 T JJ O
sulfolipids US20050245463 T NNS O
extracted US20050245463 T VBD O
from US20050245463 T IN O
spirulinae US20050245463 T NN O
, US20050245463 T , O
method US20050245463 T NN O
for US20050245463 T IN O
obtaining US20050245463 T VBG O
same US20050245463 T JJ O
, US20050245463 T , O
compositions US20050245463 T NNS O
containing US20050245463 T VBG O
same US20050245463 T JJ O
and US20050245463 T CC O
use US20050245463 T VB O
thereof US20050245463 T NN O
as US20050245463 T IN O
inhibitors US20050245463 T NNS O
of US20050245463 T IN O
the US20050245463 T DT O
hiv US20050245463 T NN I-UN
virus US20050245463 T NN I-UN
reverse US20050245463 T NN I-UN
transcriptase US20050245463 T NN I-UN
. US20050245463 T . O

The US20050245463 A DT O
invention US20050245463 A NN O
further US20050245463 A RB O
relates US20050245463 A VBZ O
to US20050245463 A TO O
a US20050245463 A DT O
spirulin US20050245463 A NN O
biomass US20050245463 A NN O
rich US20050245463 A JJ O
in US20050245463 A IN O
sulfolipids US20050245463 A NNS O
which US20050245463 A WDT O
has US20050245463 A VBZ O
an US20050245463 A DT O
inhibitory US20050245463 A JJ O
activity US20050245463 A NN O
towards US20050245463 A IN O
HIV-1 US20050245463 A NNP I-UN
and US20050245463 A CC I-UN
HIV-2 US20050245463 A NNP I-UN
reverse US20050245463 A NN I-UN
transcriptase US20050245463 A NN I-UN
, US20050245463 A , O
and US20050245463 A CC O
to US20050245463 A TO O
the US20050245463 A DT O
use US20050245463 A NN O
of US20050245463 A IN O
said US20050245463 A VBD O
sulfolipids US20050245463 A NNS O
, US20050245463 A , O
or US20050245463 A CC O
of US20050245463 A IN O
an US20050245463 A DT O
extract US20050245463 A NN O
of US20050245463 A IN O
spirulin US20050245463 A JJ O
biomass US20050245463 A NN O
rich US20050245463 A NN O
in US20050245463 A IN O
sulfolipids US20050245463 A NNS O
, US20050245463 A , O
for US20050245463 A IN O
the US20050245463 A DT O
preparation US20050245463 A NN O
of US20050245463 A IN O
a US20050245463 A DT O
drug US20050245463 A NN O
for US20050245463 A IN O
the US20050245463 A DT O
prophylactic US20050245463 A JJ O
or US20050245463 A CC O
curative US20050245463 A JJ O
treatment US20050245463 A NN O
of US20050245463 A IN O
AIDS US20050245463 A NNP O
. US20050245463 A . O

Sialic EP2610263A1 T JJ O
acid EP2610263A1 T NN O
dimers EP2610263A1 T NNS O
. EP2610263A1 T . O

Terazosin CN102018685A T NNP O
pellicle CN102018685A T NN O
and CN102018685A T CC O
preparation CN102018685A T NN O
method CN102018685A T NN O
thereof CN102018685A T NN O
. CN102018685A T . O

Oral WO2009089138A1 T JJ O
administration WO2009089138A1 T NN O
of WO2009089138A1 T IN O
ixabepilone WO2009089138A1 T NN O
. WO2009089138A1 T . O

Maribavir US20120283210 T NNP O
isomers US20120283210 T NNS O
, US20120283210 T , O
compositions US20120283210 T NNS O
, US20120283210 T , O
methods US20120283210 T NNS O
of US20120283210 T IN O
making US20120283210 T VBG O
and US20120283210 T CC O
methods US20120283210 T NNS O
of US20120283210 T IN O
using US20120283210 T VBG O
. US20120283210 T . O

Methods US20110268822 T NNS O
for US20110268822 T IN O
synthesizing US20110268822 T VBG O
kotalanol US20110268822 T NN O
and US20110268822 T CC O
stereoisomers US20110268822 T NNS O
and US20110268822 T CC O
analogues US20110268822 T NNS O
thereof US20110268822 T VBP O
, US20110268822 T , O
and US20110268822 T CC O
novel US20110268822 T JJ O
compounds US20110268822 T NNS O
produced US20110268822 T VBN O
thereby US20110268822 T RB O
. US20110268822 T . O

Acyl CN101220000A T NNP O
chloride CN101220000A T NN O
and CN101220000A T CC O
sulfonyl CN101220000A T JJ O
chloride CN101220000A T NN O
derivant CN101220000A T NN O
, CN101220000A T , O
and CN101220000A T CC O
uses CN101220000A T VBZ O
thereof CN101220000A T NN O
. CN101220000A T . O

Pharmaceutical EP2105143A1 T JJ O
compositions EP2105143A1 T NNS O
based EP2105143A1 T VBN O
on EP2105143A1 T IN O
salts EP2105143A1 T NNS O
of EP2105143A1 T IN O
tiotropium EP2105143A1 T NN O
and EP2105143A1 T CC O
ciclesonide EP2105143A1 T NN O
. EP2105143A1 T . O

Reaction CA2339290C T NN O
products CA2339290C T NNS O
of CA2339290C T IN O
hyaluronic CA2339290C T JJ O
acid CA2339290C T NN O
and CA2339290C T CC O
natural CA2339290C T JJ O
amino CA2339290C T NN O
acids CA2339290C T NNS O
and CA2339290C T CC O
their CA2339290C T PRP$ O
use CA2339290C T NN O
in CA2339290C T IN O
cosmetic CA2339290C T JJ O
and CA2339290C T CC O
pharmaceutical CA2339290C T JJ O
compositions CA2339290C T NNS O
. CA2339290C T . O

Lotus CN101862374A T NNP O
plumule CN101862374A T NN O
and CN101862374A T CC O
new CN101862374A T JJ O
application CN101862374A T NN O
of CN101862374A T IN O
extractive CN101862374A T JJ O
thereof CN101862374A T NN O
. CN101862374A T . O

The CN101862374A A DT O
invention CN101862374A A NN O
provides CN101862374A A VBZ O
a CN101862374A A DT O
new CN101862374A A JJ O
application CN101862374A A NN O
of CN101862374A A IN O
lotus CN101862374A A NN O
plumule CN101862374A A NN O
, CN101862374A A , O
in CN101862374A A IN O
particular CN101862374A A JJ O
to CN101862374A A TO O
the CN101862374A A DT O
application CN101862374A A NN O
of CN101862374A A IN O
the CN101862374A A DT O
lotus CN101862374A A NN O
plumule CN101862374A A NN O
, CN101862374A A , O
lotus CN101862374A A NN O
plumule CN101862374A A NN O
total CN101862374A A JJ O
alkaloid CN101862374A A NN O
, CN101862374A A , O
bisbenzylisoquinoline- CN101862374A A JJ O
( CN101862374A A ( O
7-0-11 CN101862374A A JJ O
' CN101862374A A '' O
) CN101862374A A ) O
-monoether CN101862374A A PRP$ O
key CN101862374A A JJ O
alkaloid CN101862374A A JJ O
derivant CN101862374A A NN O
or CN101862374A A CC O
analogue CN101862374A A NN O
in CN101862374A A IN O
preparing CN101862374A A VBG O
a CN101862374A A DT O
drug CN101862374A A NN O
or CN101862374A A CC O
health CN101862374A A NN O
care CN101862374A A NN O
food CN101862374A A NN O
of CN101862374A A IN O
5 CN101862374A A CD I-UN
alpha-reductase CN101862374A A JJ I-UN
inhibitor CN101862374A A NN O
. CN101862374A A . O

The CN101862374A A DT O
invention CN101862374A A NN O
also CN101862374A A RB O
provides CN101862374A A VBZ O
a CN101862374A A DT O
5 CN101862374A A CD I-UN
alpha-reductase CN101862374A A JJ I-UN
inhibitor CN101862374A A NN O
. CN101862374A A . O

The CN101862374A A DT O
lotus CN101862374A A NN O
plumule CN101862374A A NN O
of CN101862374A A IN O
the CN101862374A A DT O
invention CN101862374A A NN O
serves CN101862374A A VBZ O
as CN101862374A A IN O
the CN101862374A A DT O
5 CN101862374A A CD I-UN
alpha-reductase CN101862374A A JJ I-UN
inhibitor CN101862374A A NN O
and CN101862374A A CC O
can CN101862374A A MD O
serve CN101862374A A VB O
as CN101862374A A IN O
drug CN101862374A A NN O
, CN101862374A A , O
health CN101862374A A NN O
care CN101862374A A NN O
food CN101862374A A NN O
or CN101862374A A CC O
food CN101862374A A NN O
additive CN101862374A A NN O
. CN101862374A A . O

The CN101862374A A DT O
lotus CN101862374A A NN O
plumule CN101862374A A NN O
and CN101862374A A CC O
the CN101862374A A DT O
active CN101862374A A JJ O
ingredients CN101862374A A NNS O
thereof CN101862374A A NN O
of CN101862374A A IN O
the CN101862374A A DT O
invention CN101862374A A NN O
are CN101862374A A VBP O
used CN101862374A A VBN O
for CN101862374A A IN O
inhibiting CN101862374A A VBG O
5 CN101862374A A CD I-UN
alpha-reductase CN101862374A A JJ I-UN
, CN101862374A A , O
can CN101862374A A MD O
reduce CN101862374A A VB O
prostate CN101862374A A NN O
gland CN101862374A A NN O
, CN101862374A A , O
can CN101862374A A MD O
quickly CN101862374A A RB O
remove CN101862374A A VB O
the CN101862374A A DT O
obstruction CN101862374A A NN O
symptom CN101862374A A NN O
of CN101862374A A IN O
benign CN101862374A A JJ O
prostatic CN101862374A A JJ O
hyperplasia CN101862374A A NN O
, CN101862374A A , O
can CN101862374A A MD O
treat CN101862374A A VB O
seborrheic CN101862374A A JJ O
alopecia CN101862374A A NN O
and CN101862374A A CC O
acne CN101862374A A NN O
, CN101862374A A , O
has CN101862374A A VBZ O
specific CN101862374A A JJ O
potency CN101862374A A NN O
and CN101862374A A CC O
controllable CN101862374A A JJ O
quality CN101862374A A NN O
, CN101862374A A , O
is CN101862374A A VBZ O
safe CN101862374A A JJ O
and CN101862374A A CC O
provides CN101862374A A VBZ O
a CN101862374A A DT O
new CN101862374A A JJ O
option CN101862374A A NN O
for CN101862374A A IN O
clinic CN101862374A A NN O
. CN101862374A A . O

Pharmaceutical US8258132 T JJ O
composition US8258132 T NN O
of US8258132 T IN O
a US8258132 T DT O
tachykinin US8258132 T NN I-UN
receptor US8258132 T NN I-UN
antagonist US8258132 T NN O
. US8258132 T . O

Composition WO2013184023A1 T NN O
for WO2013184023A1 T IN O
treating WO2013184023A1 T VBG O
multiple WO2013184023A1 T JJ O
sclerosis WO2013184023A1 T NN O
( WO2013184023A1 T ( O
variants WO2013184023A1 T NNS O
) WO2013184023A1 T ) O
. WO2013184023A1 T . O

The WO2013184023A1 A DT O
invention WO2013184023A1 A NN O
relates WO2013184023A1 A VBZ O
to WO2013184023A1 A TO O
the WO2013184023A1 A DT O
chemical-pharmaceutical WO2013184023A1 A JJ O
industry WO2013184023A1 A NN O
, WO2013184023A1 A , O
to WO2013184023A1 A TO O
the WO2013184023A1 A DT O
field WO2013184023A1 A NN O
of WO2013184023A1 A IN O
psychoneurology WO2013184023A1 A NN O
and WO2013184023A1 A CC O
specifically WO2013184023A1 A RB O
to WO2013184023A1 A TO O
means WO2013184023A1 A NNS O
for WO2013184023A1 A IN O
treating WO2013184023A1 A VBG O
multiple WO2013184023A1 A JJ O
sclerosis WO2013184023A1 A NN O
. WO2013184023A1 A . O

The WO2013184023A1 A DT O
composition WO2013184023A1 A NN O
( WO2013184023A1 A ( O
in WO2013184023A1 A IN O
a WO2013184023A1 A DT O
solid WO2013184023A1 A JJ O
oral WO2013184023A1 A JJ O
dosage WO2013184023A1 A NN O
form WO2013184023A1 A NN O
) WO2013184023A1 A ) O
is WO2013184023A1 A VBZ O
suitable WO2013184023A1 A JJ O
for WO2013184023A1 A IN O
sublingual WO2013184023A1 A JJ O
or WO2013184023A1 A CC O
buccal WO2013184023A1 A JJ O
administration WO2013184023A1 A NN O
or WO2013184023A1 A CC O
for WO2013184023A1 A IN O
administration WO2013184023A1 A NN O
via WO2013184023A1 A IN O
the WO2013184023A1 A DT O
gingival WO2013184023A1 A NN O
mucosa WO2013184023A1 A NN O
, WO2013184023A1 A , O
and WO2013184023A1 A CC O
contains WO2013184023A1 A NNS O
( WO2013184023A1 A ( O
Z WO2013184023A1 A NNP O
) WO2013184023A1 A ) O
-2-cyano-3-hydroxy-but-2-enoic WO2013184023A1 A VBZ O
acid- WO2013184023A1 A JJ O
( WO2013184023A1 A ( O
4'-trifluoromethylphenyl WO2013184023A1 A JJ O
) WO2013184023A1 A ) O
-amide WO2013184023A1 A NN O
( WO2013184023A1 A ( O
Teriflunomide WO2013184023A1 A NNP O
) WO2013184023A1 A ) O
as WO2013184023A1 A IN O
active WO2013184023A1 A JJ O
agent WO2013184023A1 A NN O
. WO2013184023A1 A . O

N-acylamino US7053245 T JJ O
benzyl US7053245 T NN O
ether US7053245 T NN O
derivatives US7053245 T NNS O
. US7053245 T . O

Method CA2516364A1 T NNP O
of CA2516364A1 T IN O
modulation CA2516364A1 T NN O
. CA2516364A1 T . O

A CA2516364A1 A DT O
method CA2516364A1 A NN O
of CA2516364A1 A IN O
modulating CA2516364A1 A VBG O
motor CA2516364A1 A NN O
neuron CA2516364A1 A NN O
activity CA2516364A1 A NN O
in CA2516364A1 A IN O
a CA2516364A1 A DT O
patient CA2516364A1 A NN O
in CA2516364A1 A IN O
need CA2516364A1 A NN O
thereof CA2516364A1 A NN O
, CA2516364A1 A , O
the CA2516364A1 A DT O
method CA2516364A1 A NN O
comprising CA2516364A1 A VBG O
the CA2516364A1 A DT O
step CA2516364A1 A NN O
of CA2516364A1 A IN O
administering CA2516364A1 A VBG O
to CA2516364A1 A TO O
said CA2516364A1 A VBD O
patient CA2516364A1 A NN O
a CA2516364A1 A DT O
therapeutically CA2516364A1 A RB O
effective CA2516364A1 A JJ O
amount CA2516364A1 A NN O
of CA2516364A1 A IN O
at CA2516364A1 A IN O
least CA2516364A1 A JJS O
one CA2516364A1 A CD O
Müllerian CA2516364A1 A JJ I-UN
inhibitory CA2516364A1 A NN I-UN
substance CA2516364A1 A NN I-UN
receptor CA2516364A1 A NN I-UN
agonist CA2516364A1 A NN O
or CA2516364A1 A CC O
antagonist CA2516364A1 A NN O
. CA2516364A1 A . O

Substituted EP2297105A1 T NNP O
amides EP2297105A1 T NNS O
, EP2297105A1 T , O
method EP2297105A1 T NN O
of EP2297105A1 T IN O
making EP2297105A1 T VBG O
, EP2297105A1 T , O
and EP2297105A1 T CC O
use EP2297105A1 T NN O
as EP2297105A1 T IN O
btk EP2297105A1 T NN O
inhibitors EP2297105A1 T NNS O
. EP2297105A1 T . O

Compounds EP2297105A1 A NNS O
of EP2297105A1 A IN O
Formula EP2297105A1 A NNP O
I EP2297105A1 A PRP O
that EP2297105A1 A WDT O
inhibit EP2297105A1 A VBP O
Btk EP2297105A1 A NNP I-UN
are EP2297105A1 A VBP O
described EP2297105A1 A VBN O
herein EP2297105A1 A NNS O
. EP2297105A1 A . O

Methods EP2297105A1 A NNS O
of EP2297105A1 A IN O
treating EP2297105A1 A VBG O
patients EP2297105A1 A NNS O
suffering EP2297105A1 A VBG O
from EP2297105A1 A IN O
certain EP2297105A1 A JJ O
diseases EP2297105A1 A NNS O
responsive EP2297105A1 A VBP O
to EP2297105A1 A TO O
inhibition EP2297105A1 A NN O
of EP2297105A1 A IN O
Btk EP2297105A1 A NNP I-UN
activity EP2297105A1 A NN O
and/ EP2297105A1 A NN O
or EP2297105A1 A CC O
B-cell EP2297105A1 A NNP O
activity EP2297105A1 A NN O
are EP2297105A1 A VBP O
described EP2297105A1 A VBN O
. EP2297105A1 A . O

Methods EP2297105A1 A NNS O
for EP2297105A1 A IN O
determining EP2297105A1 A VBG O
the EP2297105A1 A DT O
presence EP2297105A1 A NN O
of EP2297105A1 A IN O
Btk EP2297105A1 A NNP I-UN
in EP2297105A1 A IN O
a EP2297105A1 A DT O
sample EP2297105A1 A NN O
are EP2297105A1 A VBP O
described EP2297105A1 A VBN O
. EP2297105A1 A . O

Application CN103393653A T NN O
of CN103393653A T IN O
Sarcaboside CN103393653A T NNP O
B CN103393653A T NNP O
to CN103393653A T TO O
medicament CN103393653A T VB O
for CN103393653A T IN O
treatment CN103393653A T NN O
of CN103393653A T IN O
carcinoma CN103393653A T NN O
of CN103393653A T IN O
bile CN103393653A T JJ O
duct CN103393653A T NN O
. CN103393653A T . O

Composition US20120021013 T NN O
Containing US20120021013 T VBG O
Sulfoalkyl US20120021013 T NNP O
Ether US20120021013 T NNP O
Cyclodextrin US20120021013 T NNP O
and US20120021013 T CC O
Latanoprost US20120021013 T NNP O
. US20120021013 T . O

An US20120021013 A DT O
aqueous US20120021013 A JJ O
composition US20120021013 A NN O
of US20120021013 A IN O
latanoprost US20120021013 A NN O
and US20120021013 A CC O
SAE-CD US20120021013 A NNP O
is US20120021013 A VBZ O
provided US20120021013 A VBN O
. US20120021013 A . O

The US20120021013 A DT O
composition US20120021013 A NN O
possesses US20120021013 A VBZ O
improved US20120021013 A JJ O
stability US20120021013 A NN O
over US20120021013 A IN O
otherwise US20120021013 A RB O
similar US20120021013 A JJ O
compositions US20120021013 A NNS O
excluding US20120021013 A VBG O
SAE-CD US20120021013 A NNP O
. US20120021013 A . O

Methods US20120021013 A NNS O
of US20120021013 A IN O
and US20120021013 A CC O
systems US20120021013 A NNS O
for US20120021013 A IN O
treating US20120021013 A VBG O
diseases US20120021013 A NNS O
, US20120021013 A , O
disorders US20120021013 A NNS O
, US20120021013 A , O
conditions US20120021013 A NNS O
or US20120021013 A CC O
symptoms US20120021013 A NNS O
of US20120021013 A IN O
the US20120021013 A DT O
eye US20120021013 A NN O
that US20120021013 A WDT O
are US20120021013 A VBP O
therapeutically US20120021013 A RB O
responsive US20120021013 A JJ O
to US20120021013 A TO O
latanoprost US20120021013 A VB O
are US20120021013 A VBP O
also US20120021013 A RB O
provided US20120021013 A VBN O
. US20120021013 A . O

Styryl US20050014690 T NNP O
acrylonitrile US20050014690 T JJ O
compounds US20050014690 T NNS O
and US20050014690 T CC O
their US20050014690 T PRP$ O
use US20050014690 T NN O
to US20050014690 T TO O
promote US20050014690 T VB O
myelopoiesis US20050014690 T NN O
. US20050014690 T . O

Method CA2464777C T NNP O
of CA2464777C T IN O
suppressing CA2464777C T VBG O
the CA2464777C T DT O
germination CA2464777C T NN O
of CA2464777C T IN O
candida CA2464777C T NN O
albicans CA2464777C T NNS O
using CA2464777C T VBG O
whey-derived CA2464777C T JJ O
free CA2464777C T JJ O
fatty CA2464777C T JJ O
acids CA2464777C T NNS O
. CA2464777C T . O

Compound CN202263199U T NNP O
Clarinex CN202263199U T NNP O
pseudoephedrine CN202263199U T NN O
sulfate CN202263199U T NN O
sustained CN202263199U T VBD O
release CN202263199U T JJ O
tablet CN202263199U T NN O
pharmaceutical CN202263199U T JJ O
composition CN202263199U T NN O
. CN202263199U T . O

Application CN103405450A T NN O
of CN103405450A T IN O
Chukrasone CN103405450A T NNP O
A CN103405450A T NNP O
in CN103405450A T IN O
medicaments CN103405450A T NNS O
for CN103405450A T IN O
treating CN103405450A T VBG O
cervical CN103405450A T JJ O
carcinoma CN103405450A T NN O
. CN103405450A T . O

Treating DE102004015752A1 T VBG O
or DE102004015752A1 T CC O
preventing DE102004015752A1 T VBG O
renal DE102004015752A1 T JJ O
diseases DE102004015752A1 T NNS O
, DE102004015752A1 T , O
especially DE102004015752A1 T RB O
renal DE102004015752A1 T JJ O
ischemia DE102004015752A1 T NN O
, DE102004015752A1 T , O
post DE102004015752A1 T NN O
ischemia DE102004015752A1 T NN O
and DE102004015752A1 T CC O
( DE102004015752A1 T ( O
re DE102004015752A1 T NN O
) DE102004015752A1 T ) O
perfusion DE102004015752A1 T NN O
disorders DE102004015752A1 T NNS O
, DE102004015752A1 T , O
using DE102004015752A1 T VBG O
gabapentin DE102004015752A1 T JJ O
lactam DE102004015752A1 T NN O
as DE102004015752A1 T IN O
cytoprotective DE102004015752A1 T JJ O
preconditioning DE102004015752A1 T NN O
agent DE102004015752A1 T NN O
. DE102004015752A1 T . O

GBP-L DE102004015752A1 A JJ O
0.01-0.1 DE102004015752A1 A JJ O
mM DE102004015752A1 A NN O
at DE102004015752A1 A IN O
showed DE102004015752A1 A VBD O
a DE102004015752A1 A DT O
concentration-dependent DE102004015752A1 A JJ O
cytoprotective DE102004015752A1 A JJ O
effect DE102004015752A1 A NN O
, DE102004015752A1 A , O
as DE102004015752A1 A IN O
evaluated DE102004015752A1 A VBN O
by DE102004015752A1 A IN O
the DE102004015752A1 A DT O
increased DE102004015752A1 A VBN O
intracellular DE102004015752A1 A JJ O
potassium DE102004015752A1 A NN O
content DE102004015752A1 A NN O
, DE102004015752A1 A , O
reduced DE102004015752A1 A JJ O
loss DE102004015752A1 A NN O
of DE102004015752A1 A IN O
the DE102004015752A1 A DT O
marker DE102004015752A1 A NN O
enzymes DE102004015752A1 A VBZ O
lactate DE102004015752A1 A JJ I-UN
dehydrogenase DE102004015752A1 A NN I-UN
( DE102004015752A1 A ( O
LDH DE102004015752A1 A NNP I-UN
) DE102004015752A1 A ) O
and DE102004015752A1 A CC O
glutamate DE102004015752A1 A JJ I-UN
dehydrogenase DE102004015752A1 A NN I-UN
( DE102004015752A1 A ( O
GIDH DE102004015752A1 A NNP I-UN
) DE102004015752A1 A ) O
, DE102004015752A1 A , O
increased DE102004015752A1 A JJ O
lactate DE102004015752A1 A NN O
gluconeogenesis DE102004015752A1 A NN O
, DE102004015752A1 A , O
reduced DE102004015752A1 A VBD O
release DE102004015752A1 A NN O
of DE102004015752A1 A IN O
oxygen DE102004015752A1 A NN O
radicals DE102004015752A1 A NNS O
( DE102004015752A1 A ( O
as DE102004015752A1 A IN O
thiobarbituric DE102004015752A1 A JJ O
acid DE102004015752A1 A NN O
reactive DE102004015752A1 A JJ O
substances DE102004015752A1 A NNS O
) DE102004015752A1 A ) O
and DE102004015752A1 A CC O
reduced DE102004015752A1 A JJ O
indications DE102004015752A1 A NNS O
of DE102004015752A1 A IN O
nuclear DE102004015752A1 A JJ O
damage DE102004015752A1 A NN O
( DE102004015752A1 A ( O
by DE102004015752A1 A IN O
trypan DE102004015752A1 A NN O
blue DE102004015752A1 A NN O
staining DE102004015752A1 A VBG O
) DE102004015752A1 A ) O
. DE102004015752A1 A . O

Typically DE102004015752A1 A RB O
in DE102004015752A1 A IN O
presence DE102004015752A1 A NN O
of DE102004015752A1 A IN O
0.05 DE102004015752A1 A CD O
mM DE102004015752A1 A JJ O
GBP-L DE102004015752A1 A NNP O
the DE102004015752A1 A DT O
loss DE102004015752A1 A NN O
in DE102004015752A1 A IN O
LDH DE102004015752A1 A NNP I-UN
activity DE102004015752A1 A NN O
was DE102004015752A1 A VBD O
reduced DE102004015752A1 A VBN O
by DE102004015752A1 A IN O
41 DE102004015752A1 A CD O
% DE102004015752A1 A NN O
under DE102004015752A1 A IN O
N2 DE102004015752A1 A NNP O
and DE102004015752A1 A CC O
by DE102004015752A1 A IN O
16 DE102004015752A1 A CD O
% DE102004015752A1 A NN O
under DE102004015752A1 A IN O
O2 DE102004015752A1 A NNP O
and DE102004015752A1 A CC O
the DE102004015752A1 A DT O
loss DE102004015752A1 A NN O
in DE102004015752A1 A IN O
GIDH DE102004015752A1 A NNP I-UN
activity DE102004015752A1 A NN O
was DE102004015752A1 A VBD O
reduced DE102004015752A1 A VBN O
by DE102004015752A1 A IN O
68 DE102004015752A1 A CD O
% DE102004015752A1 A NN O
under DE102004015752A1 A IN O
N2 DE102004015752A1 A NNP O
and DE102004015752A1 A CC O
by DE102004015752A1 A IN O
64 DE102004015752A1 A CD O
% DE102004015752A1 A NN O
under DE102004015752A1 A IN O
O2 DE102004015752A1 A NNP O
. DE102004015752A1 A . O

Method US20100272814 T NNP O
and US20100272814 T CC O
means US20100272814 T NNS O
for US20100272814 T IN O
producing US20100272814 T VBG O
bronchorelaxation US20100272814 T NN O
. US20100272814 T . O

Methods WO2006042249A3 T NNS O
and WO2006042249A3 T CC O
compositions WO2006042249A3 T NNS O
for WO2006042249A3 T IN O
treating WO2006042249A3 T VBG O
migraine WO2006042249A3 T NN O
pain WO2006042249A3 T NN O
. WO2006042249A3 T . O

Therapy US6838453 T NN O
for US6838453 T IN O
osteoporosis US6838453 T NN O
. US6838453 T . O

The US6838453 A DT O
invention US6838453 A NN O
concerns US6838453 A NNS O
vitronectin US6838453 A JJ I-UN
receptor US6838453 A NN I-UN
antagonist US6838453 A JJ O
compounds US6838453 A NNS O
of US6838453 A IN O
formula US6838453 A NN O
( US6838453 A ( O
3 US6838453 A CD O
) US6838453 A ) O
: US6838453 A : O
R1—Y—A—B—D—E—F—G US6838453 A NNP O
wherein US6838453 A NN O
R1 US6838453 A NNP O
, US6838453 A , O
Y US6838453 A NNP O
, US6838453 A , O
A US6838453 A NNP O
, US6838453 A , O
B US6838453 A NNP O
, US6838453 A , O
D US6838453 A NNP O
, US6838453 A , O
E US6838453 A NNP O
, US6838453 A , O
F US6838453 A NNP O
, US6838453 A , O
and US6838453 A CC O
G US6838453 A NNP O
are US6838453 A VBP O
as US6838453 A IN O
defined US6838453 A VBN O
in US6838453 A IN O
the US6838453 A DT O
description US6838453 A NN O
, US6838453 A , O
their US6838453 A PRP$ O
physiologically US6838453 A RB O
acceptable US6838453 A JJ O
salts US6838453 A NNS O
and US6838453 A CC O
their US6838453 A PRP$ O
prodrugs US6838453 A NNS O
, US6838453 A , O
methods US6838453 A NNS O
for US6838453 A IN O
preparing US6838453 A VBG O
compounds US6838453 A NNS O
of US6838453 A IN O
formula US6838453 A NN O
( US6838453 A ( O
I US6838453 A PRP O
) US6838453 A ) O
, US6838453 A , O
their US6838453 A PRP$ O
use US6838453 A NN O
, US6838453 A , O
in US6838453 A IN O
particular US6838453 A JJ O
as US6838453 A IN O
medicine US6838453 A NN O
and US6838453 A CC O
pharmaceutical US6838453 A JJ O
compositions US6838453 A NNS O
containing US6838453 A VBG O
them US6838453 A PRP O
. US6838453 A . O

Novel US20120015993 T NNP O
Pharmaceutical US20120015993 T NNP O
Forms US20120015993 T NNP O
, US20120015993 T , O
and US20120015993 T CC O
Methods US20120015993 T NNP O
of US20120015993 T IN O
Making US20120015993 T NNP O
and US20120015993 T CC O
Using US20120015993 T VBG O
the US20120015993 T DT O
Same US20120015993 T NNP O
. US20120015993 T . O

Dibutyltin CN101851251B T NNP O
( CN101851251B T ( O
IV CN101851251B T NNP O
) CN101851251B T ) O
complex CN101851251B T NN O
for CN101851251B T IN O
acyl CN101851251B T JJ O
hydrazone CN101851251B T CD O
Schiff-base CN101851251B T JJ O
ligand CN101851251B T NN O
and CN101851251B T CC O
preparation CN101851251B T NN O
method CN101851251B T NN O
and CN101851251B T CC O
application CN101851251B T NN O
thereof CN101851251B T NN O
. CN101851251B T . O

Method US7144710 T NNP O
for US7144710 T IN O
detecting US7144710 T VBG O
inflammation US7144710 T NN O
and US7144710 T CC O
inflammatory US7144710 T JJ O
conditions US7144710 T NNS O
. US7144710 T . O

Methods US7144710 A NNS O
for US7144710 A IN O
detecting US7144710 A VBG O
the US7144710 A DT O
inflammatory US7144710 A NN O
biomarkers US7144710 A NNS O
molecule US7144710 A VBP O
CD US7144710 A NN I-UN
163 US7144710 A CD I-UN
in US7144710 A IN O
biological US7144710 A JJ O
samples US7144710 A NNS O
are US7144710 A VBP O
provided US7144710 A VBN O
. US7144710 A . O

Pyrimidine WO2007066103A1 T NNP O
derivatives WO2007066103A1 T NNS O
as WO2007066103A1 T IN O
class WO2007066103A1 T NN O
i WO2007066103A1 T NN O
pi3k WO2007066103A1 T VBP O
inhibitor WO2007066103A1 T NN O
. WO2007066103A1 T . O

Method WO2013094489A1 T NNP O
for WO2013094489A1 T IN O
preparing WO2013094489A1 T VBG O
hair WO2013094489A1 T NN O
growth WO2013094489A1 T NN O
agent WO2013094489A1 T NN O
, WO2013094489A1 T , O
and WO2013094489A1 T CC O
composition WO2013094489A1 T NN O
prepared WO2013094489A1 T VBN O
by WO2013094489A1 T IN O
said WO2013094489A1 T VBD O
method WO2013094489A1 T NN O
. WO2013094489A1 T . O

Gel US20100069482 T NNP O
useful US20100069482 T JJ O
for US20100069482 T IN O
the US20100069482 T DT O
delivery US20100069482 T NN O
of US20100069482 T IN O
ophthalmic US20100069482 T JJ O
drugs US20100069482 T NNS O
. US20100069482 T . O

Use US20110190311 T NNP O
of US20110190311 T IN O
cdk US20110190311 T NN I-UN
inhibitor US20110190311 T NN O
for US20110190311 T IN O
the US20110190311 T DT O
treatment US20110190311 T NN O
of US20110190311 T IN O
glioma US20110190311 T NN O
. US20110190311 T . O

The US20110190311 A DT O
invention US20110190311 A NN O
provides US20110190311 A VBZ O
a US20110190311 A DT O
low US20110190311 A JJ O
molecular US20110190311 A JJ O
weight US20110190311 A NN O
ATP-competitive US20110190311 A JJ O
CDK US20110190311 A NNP I-UN
inhibitor US20110190311 A NN O
able US20110190311 A JJ O
to US20110190311 A TO O
cross US20110190311 A VB O
the US20110190311 A DT O
blood US20110190311 A NN O
brain US20110190311 A NN O
barrier US20110190311 A NN O
for US20110190311 A IN O
use US20110190311 A NN O
in US20110190311 A IN O
the US20110190311 A DT O
treatment US20110190311 A NN O
of US20110190311 A IN O
malignant US20110190311 A JJ O
glioma US20110190311 A NN O
and US20110190311 A CC O
, US20110190311 A , O
in US20110190311 A IN O
particular US20110190311 A JJ O
, US20110190311 A , O
of US20110190311 A IN O
glioblastoma US20110190311 A NN O
. US20110190311 A . O

Preparation CN1575813A T NN O
for CN1575813A T IN O
eyes CN1575813A T NNS O
and CN1575813A T CC O
preparing CN1575813A T VBG O
method CN1575813A T NN O
thereof CN1575813A T NN O
. CN1575813A T . O

Use WO2011161282A1 T NNP O
of WO2011161282A1 T IN O
rapamycin WO2011161282A1 T NN O
for WO2011161282A1 T IN O
the WO2011161282A1 T DT O
treatment WO2011161282A1 T NN O
of WO2011161282A1 T IN O
the WO2011161282A1 T DT O
cognitive WO2011161282A1 T JJ O
deficits WO2011161282A1 T NNS O
associated WO2011161282A1 T VBN O
with WO2011161282A1 T IN O
down WO2011161282A1 T RP O
's WO2011161282A1 T POS O
syndrome WO2011161282A1 T NN O
. WO2011161282A1 T . O

The WO2011161282A1 A DT O
present WO2011161282A1 A JJ O
invention WO2011161282A1 A NN O
relates WO2011161282A1 A VBZ O
to WO2011161282A1 A TO O
the WO2011161282A1 A DT O
use WO2011161282A1 A NN O
of WO2011161282A1 A IN O
a WO2011161282A1 A DT O
composition WO2011161282A1 A NN O
comprising WO2011161282A1 A VBG O
an WO2011161282A1 A DT O
inhibitor WO2011161282A1 A NN O
of WO2011161282A1 A IN O
the WO2011161282A1 A DT O
protein WO2011161282A1 A NN O
mTOR WO2011161282A1 A NN I-UN
, WO2011161282A1 A , O
wherein WO2011161282A1 A NN O
said WO2011161282A1 A VBD O
inhibitor WO2011161282A1 A NN O
is WO2011161282A1 A VBZ O
selected WO2011161282A1 A VBN O
from WO2011161282A1 A IN O
among WO2011161282A1 A IN O
rapamycin WO2011161282A1 A NN O
, WO2011161282A1 A , O
temsirolimus WO2011161282A1 A NN O
, WO2011161282A1 A , O
everolimus WO2011161282A1 A NN O
or WO2011161282A1 A CC O
deforolimus WO2011161282A1 A NN O
. WO2011161282A1 A . O

Methods CA2840626A1 T NNS O
of CA2840626A1 T IN O
treating CA2840626A1 T VBG O
recurrent CA2840626A1 T NN O
meibomian CA2840626A1 T JJ O
glands CA2840626A1 T NNS O
disorder CA2840626A1 T NN O
and CA2840626A1 T CC O
thereby CA2840626A1 T RB O
decreasing CA2840626A1 T VBG O
the CA2840626A1 T DT O
frequency CA2840626A1 T NN O
of CA2840626A1 T IN O
recurrence CA2840626A1 T NN O
. CA2840626A1 T . O

5- US20090281101 T JJ O
( US20090281101 T ( O
3- US20090281101 T JJ O
( US20090281101 T ( O
3- US20090281101 T JJ O
( US20090281101 T ( O
4-hexanoylphenyl US20090281101 T JJ O
) US20090281101 T ) O
-2,5-dioxoimidazolidin-4-yl US20090281101 T NN O
) US20090281101 T ) O
propyl US20090281101 T NN O
) US20090281101 T ) O
thiophene-2-carboxylic US20090281101 T JJ O
acid US20090281101 T NN O
; US20090281101 T : O
prostaglandin US20090281101 T CC O
agonist US20090281101 T VBP O
; US20090281101 T : O
ocular US20090281101 T JJ O
hypotensive US20090281101 T JJ O
agent US20090281101 T NN O
; US20090281101 T : O
post-sergical US20090281101 T JJ O
and US20090281101 T CC O
post-laser US20090281101 T JJ O
trabeculectomy US20090281101 T NN O
ocular US20090281101 T JJ O
hypertensive US20090281101 T JJ O
episodes US20090281101 T NNS O
, US20090281101 T , O
glaucoma US20090281101 T NN O
, US20090281101 T , O
and US20090281101 T CC O
as US20090281101 T IN O
presurgical US20090281101 T JJ O
adjuncts US20090281101 T NNS O
. US20090281101 T . O

Compounds US20090281101 A NNS O
comprising US20090281101 A VBG O
a US20090281101 A DT O
structure US20090281101 A NN O
or US20090281101 A CC O
a US20090281101 A DT O
pharmaceutically US20090281101 A RB O
acceptable US20090281101 A JJ O
salt US20090281101 A NN O
thereof US20090281101 A NN O
, US20090281101 A , O
or US20090281101 A CC O
a US20090281101 A DT O
prodrug US20090281101 A JJ O
thereof US20090281101 A NN O
; US20090281101 A : O
wherein US20090281101 A CC O
a US20090281101 A DT O
dashed US20090281101 A JJ O
line US20090281101 A NN O
represents US20090281101 A VBZ O
the US20090281101 A DT O
presence US20090281101 A NN O
or US20090281101 A CC O
absence US20090281101 A NN O
of US20090281101 A IN O
a US20090281101 A DT O
bond US20090281101 A NN O
are US20090281101 A VBP O
disclosed US20090281101 A VBN O
, US20090281101 A , O
wherein US20090281101 A JJ O
Y US20090281101 A NNP O
, US20090281101 A , O
A US20090281101 A NNP O
, US20090281101 A , O
B US20090281101 A NNP O
, US20090281101 A , O
and US20090281101 A CC O
J US20090281101 A NNP O
are US20090281101 A VBP O
as US20090281101 A IN O
described US20090281101 A NNS O
. US20090281101 A . O

Methods US20090281101 A NNS O
, US20090281101 A , O
compositions US20090281101 A NNS O
, US20090281101 A , O
and US20090281101 A CC O
medicaments US20090281101 A NNS O
related US20090281101 A VBN O
thereto US20090281101 A NN O
are US20090281101 A VBP O
also US20090281101 A RB O
disclosed US20090281101 A VBN O
. US20090281101 A . O

Prostamide US20060106078 T NNP I-UN
receptor US20060106078 T NN I-UN
antagonists US20060106078 T NNS O
. US20060106078 T . O

The US20060106078 A DT O
present US20060106078 A JJ O
invention US20060106078 A NN O
provides US20060106078 A VBZ O
prostamide US20060106078 A JJ I-UN
receptor US20060106078 A NN I-UN
antagonist US20060106078 A NN O
compounds US20060106078 A NNS O
that US20060106078 A WDT O
may US20060106078 A MD O
be US20060106078 A VB O
represented US20060106078 A VBN O
by US20060106078 A IN O
the US20060106078 A DT O
general US20060106078 A JJ O
formula US20060106078 A NN O
I. US20060106078 A NNP O
wherein US20060106078 A VBZ O
A US20060106078 A NNP O
, US20060106078 A , O
R1 US20060106078 A NNP O
, US20060106078 A , O
R2 US20060106078 A NNP O
, US20060106078 A , O
R3 US20060106078 A NNP O
, US20060106078 A , O
R4 US20060106078 A NNP O
and US20060106078 A CC O
R6 US20060106078 A NNP O
are US20060106078 A VBP O
as US20060106078 A IN O
defined US20060106078 A VBN O
in US20060106078 A IN O
the US20060106078 A DT O
specification US20060106078 A NN O
. US20060106078 A . O

Method EP2603096A1 T NNP O
for EP2603096A1 T IN O
treating EP2603096A1 T VBG O
fatty EP2603096A1 T JJ O
liver EP2603096A1 T NN O
diseases EP2603096A1 T NNS O
, EP2603096A1 T , O
in EP2603096A1 T IN O
particular EP2603096A1 T JJ O
non-alcoholic EP2603096A1 T JJ O
steatohepatitis.. EP2603096A1 T NN O

Method WO2008133132A1 T NNP O
for WO2008133132A1 T IN O
improvement WO2008133132A1 T NN O
in WO2008133132A1 T IN O
activities WO2008133132A1 T NNS O
of WO2008133132A1 T IN O
reactive WO2008133132A1 T JJ O
oxygen WO2008133132A1 T NN O
species-scavenging WO2008133132A1 T JJ O
enzymes WO2008133132A1 T NNS O
. WO2008133132A1 T . O

An WO2008133132A1 A DT O
organism WO2008133132A1 A NN O
having WO2008133132A1 A VBG O
an WO2008133132A1 A DT O
ROS-scavenging WO2008133132A1 A JJ O
enzyme WO2008133132A1 A NN O
( WO2008133132A1 A ( O
e.g. WO2008133132A1 A JJ O
, WO2008133132A1 A , O
superoxide WO2008133132A1 A JJ I-UN
dismutase WO2008133132A1 A NN I-UN
, WO2008133132A1 A , O
catalase WO2008133132A1 A NN I-UN
, WO2008133132A1 A , O
peroxidase WO2008133132A1 A NN I-UN
) WO2008133132A1 A ) O
is WO2008133132A1 A VBZ O
administered WO2008133132A1 A VBN O
with WO2008133132A1 A IN O
one WO2008133132A1 A CD O
or WO2008133132A1 A CC O
more WO2008133132A1 A JJR O
substances WO2008133132A1 A NNS O
selected WO2008133132A1 A VBN O
from WO2008133132A1 A IN O
the WO2008133132A1 A DT O
group WO2008133132A1 A NN O
consisting WO2008133132A1 A VBG O
of WO2008133132A1 A IN O
erythritol WO2008133132A1 A NN O
, WO2008133132A1 A , O
mannitol WO2008133132A1 A NN O
, WO2008133132A1 A , O
sorbitol WO2008133132A1 A NN O
and WO2008133132A1 A CC O
xylitol WO2008133132A1 A NN O
at WO2008133132A1 A IN O
a WO2008133132A1 A DT O
dosage WO2008133132A1 A NN O
concentration WO2008133132A1 A NN O
of WO2008133132A1 A IN O
0.01 WO2008133132A1 A CD O
to WO2008133132A1 A TO O
10 WO2008133132A1 A CD O
% WO2008133132A1 A NN O
to WO2008133132A1 A TO O
thereby WO2008133132A1 A VB O
induce WO2008133132A1 A VB O
the WO2008133132A1 A DT O
increase WO2008133132A1 A NN O
in WO2008133132A1 A IN O
the WO2008133132A1 A DT O
amount WO2008133132A1 A NN O
or WO2008133132A1 A CC O
the WO2008133132A1 A DT O
enhancement WO2008133132A1 A NN O
of WO2008133132A1 A IN O
the WO2008133132A1 A DT O
activity WO2008133132A1 A NN O
of WO2008133132A1 A IN O
the WO2008133132A1 A DT O
ROS-scavenging WO2008133132A1 A NNP O
enzyme WO2008133132A1 A NN O
in WO2008133132A1 A IN O
the WO2008133132A1 A DT O
organism WO2008133132A1 A NN O
. WO2008133132A1 A . O

Ivermectin US20110201567 T NNP O
Antagonizes US20110201567 T NNP O
Ethanol US20110201567 T NNP O
Inhibition US20110201567 T NNP O
in US20110201567 T IN O
P2X4 US20110201567 T NNP I-UN
Receptors US20110201567 T NNPS O
. US20110201567 T . O

3- EP2419405A1 T JJ O
( EP2419405A1 T ( O
phenoxypyrrolidin-3-yl-methyl EP2419405A1 T JJ O
) EP2419405A1 T ) O
heteroaryl EP2419405A1 T NN O
, EP2419405A1 T , O
3- EP2419405A1 T JJ O
( EP2419405A1 T ( O
phenylpyrrolidin-3-ylmethoxy EP2419405A1 T JJ O
) EP2419405A1 T ) O
heteroaryl EP2419405A1 T NN O
, EP2419405A1 T , O
and EP2419405A1 T CC O
3- EP2419405A1 T JJ O
( EP2419405A1 T ( O
heteroarylpyrrolidin-3-ylmethoxy EP2419405A1 T JJ O
) EP2419405A1 T ) O
heteroaryl EP2419405A1 T NN O
compounds EP2419405A1 T NNS O
. EP2419405A1 T . O

Determining US6982096 T VBG O
a US6982096 T DT O
therapeutic US6982096 T JJ O
dosage US6982096 T NN O
of US6982096 T IN O
arsenic US6982096 T JJ O
trioxide US6982096 T NN O
based US6982096 T VBN O
upon US6982096 T IN O
the US6982096 T DT O
predetermined US6982096 T JJ O
weight US6982096 T NN O
of US6982096 T IN O
the US6982096 T DT O
patient US6982096 T NN O
and US6982096 T CC O
administering US6982096 T NN O
; US6982096 T : O
Leukemia US6982096 T NNP O
; US6982096 T : O
lymphomas US6982096 T CC O
; US6982096 T : O
solid US6982096 T JJ O
tumors US6982096 T NNS O
; US6982096 T : O
anticarcinoma US6982096 T NN O
and US6982096 T CC O
-tumor US6982096 T NN O
agents US6982096 T NNS O
. US6982096 T . O

Medical US7214692 T JJ O
use US7214692 T NN O
for US7214692 T IN O
tachykinin US7214692 T NN I-UN
antagonists US7214692 T NNS O
. US7214692 T . O

The US7214692 A DT O
present US7214692 A JJ O
invention US7214692 A NN O
relates US7214692 A VBZ O
to US7214692 A TO O
the US7214692 A DT O
use US7214692 A NN O
of US7214692 A IN O
tachykinin US7214692 A NN I-UN
antagonists US7214692 A NNS O
, US7214692 A , O
including US7214692 A VBG O
substance US7214692 A NN I-UN
P US7214692 A NNP I-UN
antagonists US7214692 A NNS O
and US7214692 A CC O
other US7214692 A JJ O
neurokinin US7214692 A JJ I-UN
antagonists US7214692 A NNS O
, US7214692 A , O
in US7214692 A IN O
the US7214692 A DT O
treatment US7214692 A NN O
of US7214692 A IN O
emesis US7214692 A NN O
. US7214692 A . O

Also US7214692 A RB O
described US7214692 A VBN O
are US7214692 A VBP O
novel US7214692 A JJ O
tachykinin US7214692 A JJ I-UN
antagonists US7214692 A NNS O
of US7214692 A IN O
formula US7214692 A NN O
( US7214692 A ( O
I US7214692 A PRP O
) US7214692 A ) O
, US7214692 A , O
processes US7214692 A VBZ O
for US7214692 A IN O
their US7214692 A PRP$ O
preparation US7214692 A NN O
, US7214692 A , O
pharmaceutical US7214692 A JJ O
compositions US7214692 A NNS O
containing US7214692 A VBG O
them US7214692 A PRP O
and US7214692 A CC O
their US7214692 A PRP$ O
medical US7214692 A JJ O
use US7214692 A NN O
. US7214692 A . O

2-carboxy US20090274655 T JJ O
thiophene US20090274655 T NN O
derivatives US20090274655 T NNS O
as US20090274655 T IN O
anti US20090274655 T JJ O
viral US20090274655 T JJ O
agents US20090274655 T NNS O
. US20090274655 T . O

Anti-viral US20090274655 A JJ O
agents US20090274655 A NNS O
of US20090274655 A IN O
compounds US20090274655 A NNS O
of US20090274655 A IN O
Formula US20090274655 A NNP O
( US20090274655 A ( O
I US20090274655 A PRP O
) US20090274655 A ) O
: US20090274655 A : O
wherein US20090274655 A NN O
A US20090274655 A NNP O
, US20090274655 A , O
R1 US20090274655 A NNP O
, US20090274655 A , O
R2 US20090274655 A NNP O
and US20090274655 A CC O
R3 US20090274655 A NNP O
are US20090274655 A VBP O
as US20090274655 A IN O
defined US20090274655 A VBN O
in US20090274655 A IN O
the US20090274655 A DT O
specification US20090274655 A NN O
, US20090274655 A , O
processes US20090274655 A NNS O
for US20090274655 A IN O
their US20090274655 A PRP$ O
preparation US20090274655 A NN O
and US20090274655 A CC O
their US20090274655 A PRP$ O
use US20090274655 A NN O
in US20090274655 A IN O
HCV US20090274655 A NNP O
treatment US20090274655 A NN O
are US20090274655 A VBP O
provided US20090274655 A VBN O
. US20090274655 A . O

Compound CN101732695A T NN O
of CN101732695A T IN O
brain CN101732695A T NN O
protein CN101732695A T NN O
hydrolyzate CN101732695A T NN O
and CN101732695A T CC O
maleic CN101732695A T NN O
acid CN101732695A T NN O
and CN101732695A T CC O
method CN101732695A T NN O
for CN101732695A T IN O
preparing CN101732695A T VBG O
same CN101732695A T JJ O
. CN101732695A T . O

The CN101732695A A DT O
invention CN101732695A A NN O
provides CN101732695A A VBZ O
compound CN101732695A A NN O
of CN101732695A A IN O
brain CN101732695A A NN O
protein CN101732695A A NN O
hydrolyzate CN101732695A A NN O
and CN101732695A A CC O
maleic CN101732695A A NN O
acid CN101732695A A NN O
and CN101732695A A CC O
a CN101732695A A DT O
method CN101732695A A NN O
for CN101732695A A IN O
preparing CN101732695A A VBG O
the CN101732695A A DT O
same CN101732695A A JJ O
and CN101732695A A CC O
also CN101732695A A RB O
provides CN101732695A A VBZ O
a CN101732695A A DT O
method CN101732695A A NN O
for CN101732695A A IN O
preparing CN101732695A A VBG O
dispersible CN101732695A A JJ O
tablets CN101732695A A NNS O
of CN101732695A A IN O
the CN101732695A A DT O
medicinal CN101732695A A JJ O
compound CN101732695A A NN O
of CN101732695A A IN O
brain CN101732695A A NN O
protein CN101732695A A NN O
hydrolyzate CN101732695A A NN O
and CN101732695A A CC O
maleic CN101732695A A NN O
acid CN101732695A A NN O
, CN101732695A A , O
belonging CN101732695A A VBG O
to CN101732695A A TO O
the CN101732695A A DT O
technical CN101732695A A JJ O
field CN101732695A A NN O
of CN101732695A A IN O
the CN101732695A A DT O
medicament CN101732695A A NN O
. CN101732695A A . O

The CN101732695A A DT O
medicinal CN101732695A A JJ O
compound CN101732695A A NN O
of CN101732695A A IN O
brain CN101732695A A NN O
protein CN101732695A A NN O
hydrolyzate CN101732695A A NN O
and CN101732695A A CC O
maleic CN101732695A A NN O
acid CN101732695A A NN O
is CN101732695A A VBZ O
the CN101732695A A DT O
peptidergic CN101732695A A JJ O
neural CN101732695A A JJ O
nutritional CN101732695A A JJ O
medicament CN101732695A A NN O
specially CN101732695A A RB O
used CN101732695A A VBN O
for CN101732695A A IN O
the CN101732695A A DT O
brain CN101732695A A NN O
and CN101732695A A CC O
can CN101732695A A MD O
act CN101732695A A VB O
on CN101732695A A IN O
the CN101732695A A DT O
central CN101732695A A JJ O
nervous CN101732695A A JJ O
system CN101732695A A NN O
in CN101732695A A IN O
various CN101732695A A JJ O
ways CN101732695A A NNS O
to CN101732695A A TO O
adjust CN101732695A A VB O
and CN101732695A A CC O
improve CN101732695A A VB O
the CN101732695A A DT O
neuronal CN101732695A A JJ O
differentiation CN101732695A A NN O
. CN101732695A A . O

The CN101732695A A DT O
medicinal CN101732695A A JJ O
compound CN101732695A A NN O
of CN101732695A A IN O
brain CN101732695A A NN O
protein CN101732695A A NN O
hydrolyzate CN101732695A A NN O
and CN101732695A A CC O
maleic CN101732695A A JJ O
acid CN101732695A A NN O
can CN101732695A A MD O
promote CN101732695A A VB O
the CN101732695A A DT O
synthesis CN101732695A A NN O
of CN101732695A A IN O
the CN101732695A A DT O
brain CN101732695A A NN O
protein CN101732695A A NN O
through CN101732695A A IN O
a CN101732695A A DT O
blood-brain CN101732695A A JJ O
barrier CN101732695A A NN O
, CN101732695A A , O
has CN101732695A A VBZ O
the CN101732695A A DT O
efficacy CN101732695A A NN O
of CN101732695A A IN O
preventing CN101732695A A VBG O
hypoxia CN101732695A A NN O
, CN101732695A A , O
improving CN101732695A A VBG O
the CN101732695A A DT O
brain CN101732695A A NN O
energy CN101732695A A NN O
metabolism CN101732695A A NN O
and CN101732695A A CC O
providing CN101732695A A VBG O
neurotransmitter CN101732695A A RB O
, CN101732695A A , O
peptide CN101732695A A JJ O
hormones CN101732695A A NNS O
and CN101732695A A CC O
coenzyme CN101732695A A NN O
precursors CN101732695A A NNS O
and CN101732695A A CC O
can CN101732695A A MD O
be CN101732695A A VB O
used CN101732695A A VBN O
for CN101732695A A IN O
preparing CN101732695A A VBG O
the CN101732695A A DT O
medicament CN101732695A A NN O
for CN101732695A A IN O
improving CN101732695A A VBG O
insomnia CN101732695A A NN O
, CN101732695A A , O
headache CN101732695A A NN O
, CN101732695A A , O
memory CN101732695A A NN O
loss CN101732695A A NN O
, CN101732695A A , O
irritability CN101732695A A NN O
and CN101732695A A CC O
other CN101732695A A JJ O
symptoms CN101732695A A NNS O
, CN101732695A A , O
promoting CN101732695A A VBG O
the CN101732695A A DT O
rehabilitation CN101732695A A NN O
of CN101732695A A IN O
acute CN101732695A A JJ O
cerebral CN101732695A A JJ O
infarction CN101732695A A NN O
and CN101732695A A CC O
acute CN101732695A A NN O
brain CN101732695A A NN O
injury CN101732695A A NN O
and CN101732695A A CC O
treating CN101732695A A VBG O
brain CN101732695A A NN O
dysfunction CN101732695A A NN O
. CN101732695A A . O

Pharmaceutical US20090227534 T JJ O
Composition US20090227534 T NNP O
Comprising US20090227534 T VBG O
the US20090227534 T DT O
Combination US20090227534 T NNP O
of US20090227534 T IN O
a US20090227534 T DT O
Ketorolac US20090227534 T NNP O
Salt US20090227534 T NNP O
and US20090227534 T CC O
Vitamins US20090227534 T NNP O
of US20090227534 T IN O
the-B-Complex US20090227534 T NN O
for US20090227534 T IN O
the US20090227534 T DT O
Treatment US20090227534 T NNP O
of US20090227534 T IN O
Neuralgia US20090227534 T NNP O
. US20090227534 T . O

Method US20120046368 T NNP O
for US20120046368 T IN O
purifying US20120046368 T VBG O
3,4-dihydroxyphenylglycol US20120046368 T JJ O
( US20120046368 T ( O
dhpg US20120046368 T NN O
) US20120046368 T ) O
from US20120046368 T IN O
plant US20120046368 T NN O
products US20120046368 T NNS O
. US20120046368 T . O

Novel WO2009119710A1 T NNP O
antibiotic WO2009119710A1 T JJ O
sf2896 WO2009119710A1 T NN O
substance WO2009119710A1 T NN O
, WO2009119710A1 T , O
process WO2009119710A1 T NN O
for WO2009119710A1 T IN O
production WO2009119710A1 T NN O
thereof WO2009119710A1 T NN O
, WO2009119710A1 T , O
and WO2009119710A1 T CC O
pharmaceutical WO2009119710A1 T JJ O
composition WO2009119710A1 T NN O
. WO2009119710A1 T . O

Trinuclear CN101195638A T NNP O
phosphamide CN101195638A T NN O
ester CN101195638A T NN O
compounds CN101195638A T VBZ O
containing CN101195638A T VBG O
tegafur CN101195638A T NNS O
and CN101195638A T CC O
aza-silicon CN101195638A T NN O
. CN101195638A T . O

Preparation EP1320356B2 T NN O
of EP1320356B2 T IN O
vitamin EP1320356B2 T JJ O
emulsions EP1320356B2 T NNS O
and EP1320356B2 T CC O
concentrates EP1320356B2 T NNS O
thereof EP1320356B2 T VBP O
. EP1320356B2 T . O

Application CN103316007A T NN O
of CN103316007A T IN O
Myriberine CN103316007A T NNP O
A CN103316007A T NNP O
in CN103316007A T IN O
preparation CN103316007A T NN O
of CN103316007A T IN O
anti-hypoxic CN103316007A T JJ O
drug CN103316007A T NN O
. CN103316007A T . O

Bilastine CN103214454A T NNP O
crystal CN103214454A T NN O
and CN103214454A T CC O
preparation CN103214454A T NN O
method CN103214454A T NN O
thereof CN103214454A T NN O
. CN103214454A T . O

Compound CN1883285A T NNP O
sleep CN1883285A T NN O
assistant CN1883285A T NN O
health CN1883285A T NN O
product CN1883285A T NN O
. CN1883285A T . O

Application CN102058850A T NN O
of CN102058850A T IN O
medicine CN102058850A T NN O
composition CN102058850A T NN O
using CN102058850A T VBG O
oil CN102058850A T NN O
of CN102058850A T IN O
zedoary CN102058850A T JJ O
turmeric CN102058850A T NN O
and CN102058850A T CC O
borneol CN102058850A T NN O
as CN102058850A T IN O
raw CN102058850A T JJ O
materials CN102058850A T NNS O
. CN102058850A T . O

Lentivirus-based US20110142880 T JJ O
immunogenic US20110142880 T JJ O
vectors US20110142880 T NNS O
. US20110142880 T . O

CYCLIC WO2009017664A1 T NNP O
INHIBITORS WO2009017664A1 T NNP O
OF WO2009017664A1 T IN O
11β-HYDROXYSTERIOD WO2009017664A1 T JJ I-UN
DEHYDROGENASE WO2009017664A1 T NNP I-UN
1 WO2009017664A1 T CD O
. WO2009017664A1 T . O

This WO2009017664A1 A DT O
invention WO2009017664A1 A NN O
relates WO2009017664A1 A VBZ O
to WO2009017664A1 A TO O
novel WO2009017664A1 A VB O
compounds WO2009017664A1 A NNS O
of WO2009017664A1 A IN O
the WO2009017664A1 A DT O
Formula WO2009017664A1 A NNP O
( WO2009017664A1 A ( O
I WO2009017664A1 A PRP O
) WO2009017664A1 A ) O
, WO2009017664A1 A , O
( WO2009017664A1 A ( O
Ia WO2009017664A1 A NNP O
) WO2009017664A1 A ) O
, WO2009017664A1 A , O
( WO2009017664A1 A ( O
Ib WO2009017664A1 A NNP O
) WO2009017664A1 A ) O
, WO2009017664A1 A , O
( WO2009017664A1 A ( O
Ic WO2009017664A1 A NNP O
) WO2009017664A1 A ) O
, WO2009017664A1 A , O
( WO2009017664A1 A ( O
Id WO2009017664A1 A NNP O
) WO2009017664A1 A ) O
, WO2009017664A1 A , O
( WO2009017664A1 A ( O
Ie WO2009017664A1 A NNP O
) WO2009017664A1 A ) O
, WO2009017664A1 A , O
( WO2009017664A1 A ( O
If WO2009017664A1 A IN O
) WO2009017664A1 A ) O
, WO2009017664A1 A , O
( WO2009017664A1 A ( O
Ig WO2009017664A1 A NNP O
) WO2009017664A1 A ) O
, WO2009017664A1 A , O
( WO2009017664A1 A ( O
Ih WO2009017664A1 A NNP O
) WO2009017664A1 A ) O
; WO2009017664A1 A : O
( WO2009017664A1 A ( O
Ii WO2009017664A1 A NNP O
) WO2009017664A1 A ) O
; WO2009017664A1 A : O
( WO2009017664A1 A ( O
Ij WO2009017664A1 A NNP O
) WO2009017664A1 A ) O
, WO2009017664A1 A , O
( WO2009017664A1 A ( O
Ik WO2009017664A1 A NNP O
) WO2009017664A1 A ) O
, WO2009017664A1 A , O
( WO2009017664A1 A ( O
II WO2009017664A1 A NNP O
) WO2009017664A1 A ) O
pharmaceutically WO2009017664A1 A RB O
acceptable WO2009017664A1 A JJ O
salts WO2009017664A1 A NNS O
thereof WO2009017664A1 A NN O
, WO2009017664A1 A , O
and WO2009017664A1 A CC O
pharmaceutical WO2009017664A1 A JJ O
compositions WO2009017664A1 A NNS O
thereof WO2009017664A1 A NN O
, WO2009017664A1 A , O
which WO2009017664A1 A WDT O
are WO2009017664A1 A VBP O
useful WO2009017664A1 A JJ O
for WO2009017664A1 A IN O
the WO2009017664A1 A DT O
therapeutic WO2009017664A1 A JJ O
treatment WO2009017664A1 A NN O
of WO2009017664A1 A IN O
diseases WO2009017664A1 A NNS O
associated WO2009017664A1 A VBN O
with WO2009017664A1 A IN O
the WO2009017664A1 A DT O
modulation WO2009017664A1 A NN O
or WO2009017664A1 A CC O
inhibition WO2009017664A1 A NN O
of WO2009017664A1 A IN O
11 WO2009017664A1 A CD I-UN
β-HSD1 WO2009017664A1 A JJ I-UN
in WO2009017664A1 A IN O
mammals WO2009017664A1 A NNS O
. WO2009017664A1 A . O

Beta-Cyclodextrin US20110071108 T JJ O
Derivatives US20110071108 T NNS O
as US20110071108 T IN O
Antibacterial US20110071108 T JJ O
Agents US20110071108 T NNS O
. US20110071108 T . O

Ornidazole CN102525889A T NNP O
ophthalmic CN102525889A T JJ O
gel CN102525889A T NN O
and CN102525889A T CC O
preparation CN102525889A T NN O
method CN102525889A T NN O
and CN102525889A T CC O
application CN102525889A T NN O
thereof CN102525889A T NN O
. CN102525889A T . O

Improved WO2012079121A1 T VBN O
mineral WO2012079121A1 T NN O
based WO2012079121A1 T VBN O
composition WO2012079121A1 T NN O
and WO2012079121A1 T CC O
methods WO2012079121A1 T NNS O
of WO2012079121A1 T IN O
use WO2012079121A1 T NN O
. WO2012079121A1 T . O

Pharmaceutical US20110184007 T JJ O
compositions US20110184007 T NNS O
configured US20110184007 T VBD O
to US20110184007 T TO O
deter US20110184007 T VB O
dosage US20110184007 T NN O
form US20110184007 T NN O
splitting US20110184007 T NN O
. US20110184007 T . O

Method CN1660129A T NNP O
for CN1660129A T IN O
preparing CN1660129A T VBG O
agent CN1660129A T NN O
of CN1660129A T IN O
cyclodextrin-cellulose CN1660129A T NN O
for CN1660129A T IN O
adsorbing CN1660129A T VBG O
uric CN1660129A T JJ O
acid CN1660129A T NN O
. CN1660129A T . O

Pharmaceutical WO2013084153A1 T JJ O
composition WO2013084153A1 T NN O
comprising WO2013084153A1 T VBG O
a WO2013084153A1 T DT O
trpa1 WO2013084153A1 T JJ I-UN
antagonist WO2013084153A1 T NN O
and WO2013084153A1 T CC O
an WO2013084153A1 T DT O
anticholinergic WO2013084153A1 T JJ O
agent WO2013084153A1 T NN O
. WO2013084153A1 T . O

The WO2013084153A1 A DT O
present WO2013084153A1 A JJ O
invention WO2013084153A1 A NN O
relates WO2013084153A1 A VBZ O
to WO2013084153A1 A TO O
a WO2013084153A1 A DT O
pharmaceutical WO2013084153A1 A JJ O
composition WO2013084153A1 A NN O
comprising WO2013084153A1 A VBG O
a WO2013084153A1 A DT O
transient WO2013084153A1 A NN I-UN
receptor WO2013084153A1 A NN I-UN
potential WO2013084153A1 A JJ I-UN
ankyrin-1 WO2013084153A1 A JJ I-UN
receptor WO2013084153A1 A NN I-UN
( WO2013084153A1 A ( O
`` WO2013084153A1 A `` O
TRPA1 WO2013084153A1 A NNP I-UN
'' WO2013084153A1 A '' O
) WO2013084153A1 A ) O
antagonist WO2013084153A1 A NN O
and WO2013084153A1 A CC O
an WO2013084153A1 A DT O
anticholinergic WO2013084153A1 A JJ O
agent WO2013084153A1 A NN O
. WO2013084153A1 A . O

Particularly WO2013084153A1 A RB O
, WO2013084153A1 A , O
the WO2013084153A1 A DT O
present WO2013084153A1 A JJ O
invention WO2013084153A1 A NN O
provides WO2013084153A1 A VBZ O
a WO2013084153A1 A DT O
pharmaceutical WO2013084153A1 A JJ O
composition WO2013084153A1 A NN O
comprising WO2013084153A1 A VBG O
a WO2013084153A1 A DT O
TRPA1 WO2013084153A1 A NNP I-UN
antagonist WO2013084153A1 A NN O
having WO2013084153A1 A VBG O
IC50 WO2013084153A1 A NNP O
for WO2013084153A1 A IN O
inhibiting WO2013084153A1 A VBG O
human WO2013084153A1 A JJ I-UN
TRPA1 WO2013084153A1 A NNP I-UN
receptor WO2013084153A1 A NN O
activity WO2013084153A1 A NN O
of WO2013084153A1 A IN O
less WO2013084153A1 A JJR O
than WO2013084153A1 A IN O
1 WO2013084153A1 A CD O
micromolar WO2013084153A1 A JJ O
and WO2013084153A1 A CC O
an WO2013084153A1 A DT O
anticholinergic WO2013084153A1 A JJ O
agent WO2013084153A1 A NN O
; WO2013084153A1 A : O
a WO2013084153A1 A DT O
process WO2013084153A1 A NN O
for WO2013084153A1 A IN O
preparing WO2013084153A1 A VBG O
such WO2013084153A1 A JJ O
composition WO2013084153A1 A NN O
; WO2013084153A1 A : O
and WO2013084153A1 A CC O
its WO2013084153A1 A PRP$ O
use WO2013084153A1 A NN O
in WO2013084153A1 A IN O
treating WO2013084153A1 A VBG O
a WO2013084153A1 A DT O
respiratory WO2013084153A1 A NN O
disorder WO2013084153A1 A NN O
in WO2013084153A1 A IN O
a WO2013084153A1 A DT O
subject WO2013084153A1 A NN O
. WO2013084153A1 A . O

Β-aminocarbonyl WO2014146494A1 T JJ O
compound WO2014146494A1 T NN O
, WO2014146494A1 T , O
preparation WO2014146494A1 T NN O
method WO2014146494A1 T NN O
, WO2014146494A1 T , O
pharmaceutical WO2014146494A1 T JJ O
composition WO2014146494A1 T NN O
and WO2014146494A1 T CC O
use WO2014146494A1 T NN O
thereof WO2014146494A1 T NN O
. WO2014146494A1 T . O

In WO2014146494A1 A IN O
particular WO2014146494A1 A JJ O
, WO2014146494A1 A , O
the WO2014146494A1 A DT O
present WO2014146494A1 A JJ O
invention WO2014146494A1 A NN O
relates WO2014146494A1 A VBZ O
to WO2014146494A1 A TO O
a WO2014146494A1 A DT O
novel WO2014146494A1 A JJ O
β-aminocarbonyl WO2014146494A1 A JJ O
compound WO2014146494A1 A NN O
as WO2014146494A1 A IN O
represented WO2014146494A1 A VBN O
by WO2014146494A1 A IN O
general WO2014146494A1 A JJ O
formula WO2014146494A1 A NN O
I WO2014146494A1 A PRP O
, WO2014146494A1 A , O
or WO2014146494A1 A CC O
tautomer WO2014146494A1 A NN O
, WO2014146494A1 A , O
enantiomer WO2014146494A1 A NN O
, WO2014146494A1 A , O
racemate WO2014146494A1 A NN O
and WO2014146494A1 A CC O
pharmaceutically WO2014146494A1 A RB O
acceptable WO2014146494A1 A JJ O
salt WO2014146494A1 A NN O
thereof WO2014146494A1 A NN O
, WO2014146494A1 A , O
preparation WO2014146494A1 A NN O
method WO2014146494A1 A NN O
and WO2014146494A1 A CC O
pharmaceutical WO2014146494A1 A JJ O
composition WO2014146494A1 A NN O
thereof WO2014146494A1 A NN O
, WO2014146494A1 A , O
and WO2014146494A1 A CC O
use WO2014146494A1 A RB O
thereof WO2014146494A1 A NN O
as WO2014146494A1 A IN O
a WO2014146494A1 A DT O
dipeptidyl WO2014146494A1 A JJ I-UN
peptidase WO2014146494A1 A NN I-UN
IV WO2014146494A1 A NNP I-UN
( WO2014146494A1 A ( O
DPP-4 WO2014146494A1 A NNP I-UN
) WO2014146494A1 A ) O
inhibitor WO2014146494A1 A NN O
. WO2014146494A1 A . O

The WO2014146494A1 A DT O
compound WO2014146494A1 A NN O
or WO2014146494A1 A CC O
pharmaceutical WO2014146494A1 A JJ O
composition WO2014146494A1 A NN O
thereof WO2014146494A1 A NN O
can WO2014146494A1 A MD O
be WO2014146494A1 A VB O
used WO2014146494A1 A VBN O
as WO2014146494A1 A IN O
a WO2014146494A1 A DT O
DPP-4 WO2014146494A1 A NNP I-UN
inhibitor WO2014146494A1 A NN O
to WO2014146494A1 A TO O
treat WO2014146494A1 A VB O
type WO2014146494A1 A JJ O
II WO2014146494A1 A NNP O
diabetes WO2014146494A1 A NNS O
, WO2014146494A1 A , O
hyperglycaemia WO2014146494A1 A NN O
, WO2014146494A1 A , O
obesity WO2014146494A1 A NN O
, WO2014146494A1 A , O
or WO2014146494A1 A CC O
insulin-resistance WO2014146494A1 A NN O
syndromes WO2014146494A1 A NNS O
. WO2014146494A1 A . O

Bromophenol CN102911182A T NNP O
compound CN102911182A T NN O
and CN102911182A T CC O
application CN102911182A T NN O
thereof CN102911182A T NN O
. CN102911182A T . O

The CN102911182A A DT O
invention CN102911182A A NN O
relates CN102911182A A VBZ O
to CN102911182A A TO O
the CN102911182A A DT O
field CN102911182A A NN O
of CN102911182A A IN O
medicine CN102911182A A NN O
, CN102911182A A , O
in CN102911182A A IN O
particular CN102911182A A JJ O
to CN102911182A A TO O
a CN102911182A A DT O
bromophenol CN102911182A A NN O
compound CN102911182A A NN O
applied CN102911182A A VBD O
to CN102911182A A TO O
a CN102911182A A DT O
receptor CN102911182A A NN O
inhibitor CN102911182A A NN O
or CN102911182A A CC O
a CN102911182A A DT O
malignant CN102911182A A JJ O
tumor CN102911182A A NN O
drug CN102911182A A NN O
of CN102911182A A IN O
a CN102911182A A DT O
receptor CN102911182A A NN I-UN
tyrosine CN102911182A A NN I-UN
kinasec-kit CN102911182A A NN I-UN
which CN102911182A A WDT O
is CN102911182A A VBZ O
also CN102911182A A RB O
called CN102911182A A VBN O
KIT CN102911182A A NNP I-UN
, CN102911182A A , O
CD117 CN102911182A A NNP I-UN
, CN102911182A A , O
stem CN102911182A A NN I-UN
cell CN102911182A A NN I-UN
factor CN102911182A A NN I-UN
receptor CN102911182A A NN I-UN
and CN102911182A A CC O
mast CN102911182A A NN I-UN
cell CN102911182A A NN I-UN
growth CN102911182A A NN I-UN
factor CN102911182A A NN I-UN
receptor CN102911182A A NN I-UN
. CN102911182A A . O

The CN102911182A A DT O
molecular CN102911182A A JJ O
biology CN102911182A A NN O
experiment CN102911182A A NN O
and CN102911182A A CC O
pharmacological CN102911182A A JJ O
experiment CN102911182A A NN O
verify CN102911182A A NN O
that CN102911182A A IN O
the CN102911182A A DT O
compound CN102911182A A NN O
has CN102911182A A VBZ O
a CN102911182A A DT O
good CN102911182A A JJ O
inhibiting CN102911182A A NN O
effect CN102911182A A NN O
on CN102911182A A IN O
the CN102911182A A DT O
receptor CN102911182A A NN O
tyrosine CN102911182A A JJ I-UN
kinasec-kit CN102911182A A NN I-UN
and CN102911182A A CC O
an CN102911182A A DT O
important CN102911182A A JJ O
value CN102911182A A NN O
for CN102911182A A IN O
treatment CN102911182A A NN O
of CN102911182A A IN O
the CN102911182A A DT O
malignant CN102911182A A JJ O
tumor CN102911182A A NN O
. CN102911182A A . O

Treatment WO2008026075A3 T NN O
of WO2008026075A3 T IN O
intracellular WO2008026075A3 T JJ O
bacterial WO2008026075A3 T JJ O
infections WO2008026075A3 T NNS O
with WO2008026075A3 T IN O
a WO2008026075A3 T DT O
protein WO2008026075A3 T NN O
kinase WO2008026075A3 T NN I-UN
inhibitor WO2008026075A3 T NN O
or WO2008026075A3 T CC O
an WO2008026075A3 T DT O
as160 WO2008026075A3 T JJ I-UN
polypeptide WO2008026075A3 T NN O
activator WO2008026075A3 T NN O
. WO2008026075A3 T . O

Products WO2008026075A3 A NNS O
for WO2008026075A3 A IN O
treating WO2008026075A3 A VBG O
intracellular WO2008026075A3 A JJ O
bacterial WO2008026075A3 A JJ O
infections WO2008026075A3 A NNS O
comprising WO2008026075A3 A VBG O
a WO2008026075A3 A DT O
protein WO2008026075A3 A NN O
kinase WO2008026075A3 A NN I-UN
inhibitor WO2008026075A3 A NN O
and/or WO2008026075A3 A VBD O
an WO2008026075A3 A DT O
activator WO2008026075A3 A NN O
of WO2008026075A3 A IN O
AS160 WO2008026075A3 A NNP I-UN
polypeptide- WO2008026075A3 A NN O
. WO2008026075A3 A . O

The WO2008026075A3 A DT O
protein WO2008026075A3 A NN O
kinase WO2008026075A3 A VBD I-UN
inhibitor WO2008026075A3 A NN O
may WO2008026075A3 A MD O
be WO2008026075A3 A VB O
a WO2008026075A3 A DT O
H-89 WO2008026075A3 A JJ O
derivative WO2008026075A3 A NN O
. WO2008026075A3 A . O

Manufacture EP1977643A1 T NN O
of EP1977643A1 T IN O
a EP1977643A1 T DT O
viable EP1977643A1 T JJ O
, EP1977643A1 T , O
storable EP1977643A1 T JJ O
worm EP1977643A1 T NN O
egg EP1977643A1 T NN O
suspension EP1977643A1 T NN O
. EP1977643A1 T . O

Hydrophobic US20110027183 T NNP O
Modified US20110027183 T NNP O
Pres-Derived US20110027183 T NNP O
Peptides US20110027183 T NNP O
of US20110027183 T IN O
Hepatitis US20110027183 T NNP O
B US20110027183 T NNP O
Virus US20110027183 T NNP O
( US20110027183 T ( O
HBV US20110027183 T NNP O
) US20110027183 T ) O
and US20110027183 T CC O
Their US20110027183 T PRP$ O
Use US20110027183 T NN O
as US20110027183 T IN O
Vehicles US20110027183 T NNS O
for US20110027183 T IN O
the US20110027183 T DT O
Specific US20110027183 T JJ O
Delivery US20110027183 T NNP O
of US20110027183 T IN O
Compounds US20110027183 T NNP O
to US20110027183 T TO O
the US20110027183 T DT O
Liver US20110027183 T NNP O
. US20110027183 T . O

Any US20110027183 A DT O
kind US20110027183 A NN O
of US20110027183 A IN O
compound US20110027183 A NN O
, US20110027183 A , O
but US20110027183 A CC O
in US20110027183 A IN O
particular US20110027183 A JJ O
drugs US20110027183 A NNS O
, US20110027183 A , O
such US20110027183 A JJ O
as US20110027183 A IN O
interferons US20110027183 A NNS O
, US20110027183 A , O
viral US20110027183 A JJ O
reverse US20110027183 A NN I-UN
transcriptase US20110027183 A NN I-UN
inhibitors US20110027183 A NNS O
or US20110027183 A CC O
core US20110027183 A NN O
assembly US20110027183 A NN O
inhibitors US20110027183 A NNS O
, US20110027183 A , O
and/or US20110027183 A JJ O
labels US20110027183 A NNS O
can US20110027183 A MD O
be US20110027183 A VB O
specifically US20110027183 A RB O
targeted US20110027183 A VBN O
to US20110027183 A TO O
the US20110027183 A DT O
liver US20110027183 A NN O
and US20110027183 A CC O
so US20110027183 A RB O
be US20110027183 A VB O
enriched US20110027183 A VBN O
in US20110027183 A IN O
the US20110027183 A DT O
liver US20110027183 A NN O
. US20110027183 A . O

Methods US20090181908 T NNS O
and US20090181908 T CC O
compositions US20090181908 T NNS O
for US20090181908 T IN O
treating US20090181908 T VBG O
keratin US20090181908 T NN O
hyperproliferative US20090181908 T JJ O
disorders US20090181908 T NNS O
. US20090181908 T . O

A US20090181908 A DT O
method US20090181908 A NN O
for US20090181908 A IN O
keratin US20090181908 A JJ O
hyperproliferation US20090181908 A NN O
disorders US20090181908 A NNS O
such US20090181908 A JJ O
as US20090181908 A IN O
corns US20090181908 A NNS O
, US20090181908 A , O
calluses US20090181908 A NNS O
, US20090181908 A , O
or US20090181908 A CC O
keratosis US20090181908 A NN O
pilaris US20090181908 A NN O
( US20090181908 A ( O
KP US20090181908 A NNP O
) US20090181908 A ) O
by US20090181908 A IN O
administering US20090181908 A VBG O
to US20090181908 A TO O
a US20090181908 A DT O
subject US20090181908 A NN O
experiencing US20090181908 A VBG O
the US20090181908 A DT O
disorder US20090181908 A NN O
a US20090181908 A DT O
therapeutically US20090181908 A RB O
effective US20090181908 A JJ O
amount US20090181908 A NN O
of US20090181908 A IN O
an US20090181908 A DT O
RNA US20090181908 A NNP O
sequence US20090181908 A NN O
which US20090181908 A WDT O
inhibits US20090181908 A VBZ O
expression US20090181908 A NN O
of US20090181908 A IN O
a US20090181908 A DT O
gene US20090181908 A NN O
encoding US20090181908 A VBG O
for US20090181908 A IN O
a US20090181908 A DT O
keratin US20090181908 A NN O
selected US20090181908 A VBN O
from US20090181908 A IN O
the US20090181908 A DT O
group US20090181908 A NN O
consisting US20090181908 A VBG O
of US20090181908 A IN O
K6a US20090181908 A NNP I-UN
, US20090181908 A , O
K6b US20090181908 A NNP I-UN
, US20090181908 A , O
K16 US20090181908 A NNP I-UN
, US20090181908 A , O
K17 US20090181908 A NNP I-UN
, US20090181908 A , O
and US20090181908 A CC O
combinations US20090181908 A NNS O
thereof US20090181908 A VBP O
. US20090181908 A . O

Compound WO2013185353A1 T NN O
as WO2013185353A1 T IN O
wnt WO2013185353A1 T JJ O
signaling WO2013185353A1 T VBG O
inhibitor WO2013185353A1 T NN O
, WO2013185353A1 T , O
composition WO2013185353A1 T NN O
, WO2013185353A1 T , O
and WO2013185353A1 T CC O
use WO2013185353A1 T NN O
thereof WO2013185353A1 T NN O
. WO2013185353A1 T . O

Combinations EP1676576A1 T NNS O
comprising EP1676576A1 T VBG O
camptothecin EP1676576A1 T NN O
and EP1676576A1 T CC O
their EP1676576A1 T PRP$ O
use EP1676576A1 T NN O
for EP1676576A1 T IN O
the EP1676576A1 T DT O
treatment EP1676576A1 T NN O
of EP1676576A1 T IN O
neoplastic EP1676576A1 T JJ O
diseases EP1676576A1 T NNS O
. EP1676576A1 T . O

Crystalline US7745448 T JJ O
N- US7745448 T NNP O
( US7745448 T ( O
4- US7745448 T JJ O
( US7745448 T ( O
4-aminothieno US7745448 T JJ O
[ US7745448 T NNP O
2,3-d US7745448 T JJ O
] US7745448 T NNP O
pyrimidin-5-yl US7745448 T NN O
) US7745448 T ) O
phenyl US7745448 T NN O
) US7745448 T ) O
-N′- US7745448 T NN O
( US7745448 T ( O
2-fluoro-5- US7745448 T JJ O
( US7745448 T ( O
trifluoromethyl US7745448 T NN O
) US7745448 T ) O
phenyl US7745448 T NN O
) US7745448 T ) O
urea US7745448 T JJ O
ethanolate US7745448 T NN O
. US7745448 T . O

Lyaseenzymes US20120177722 T NNS O
, US20120177722 T , O
Nucleic US20120177722 T NNP O
Acids US20120177722 T NNP O
Encoding US20120177722 T NNP O
Them US20120177722 T NNP O
and US20120177722 T CC O
Methods US20120177722 T NNP O
For US20120177722 T IN O
Making US20120177722 T NNP O
and US20120177722 T CC O
Using US20120177722 T NNP O
Them US20120177722 T NNP O
. US20120177722 T . O

Hydroquinone EP1904057B1 T NN O
ansamycins EP1904057B1 T VBZ O
in EP1904057B1 T IN O
the EP1904057B1 T DT O
treatment EP1904057B1 T NN O
of EP1904057B1 T IN O
gastrointestinal EP1904057B1 T JJ O
stromal EP1904057B1 T JJ O
tumors EP1904057B1 T NNS O
. EP1904057B1 T . O

The EP1904057B1 A DT O
present EP1904057B1 A JJ O
invention EP1904057B1 A NN O
provides EP1904057B1 A VBZ O
methods EP1904057B1 A NNS O
for EP1904057B1 A IN O
treating EP1904057B1 A VBG O
hyperproliferative EP1904057B1 A JJ O
disorders EP1904057B1 A NNS O
such EP1904057B1 A JJ O
as EP1904057B1 A IN O
cancer EP1904057B1 A NN O
by EP1904057B1 A IN O
administering EP1904057B1 A VBG O
hydroquinone EP1904057B1 A NN O
ansamycin EP1904057B1 A NN O
compounds EP1904057B1 A NNS O
. EP1904057B1 A . O

For US7183320 T IN O
therapy US7183320 T NN O
of US7183320 T IN O
neoplastic US7183320 T JJ O
diseases US7183320 T NNS O
. US7183320 T . O

Substituted WO2006004931A3 T VBN O
azepine WO2006004931A3 T JJ O
derivatives WO2006004931A3 T NNS O
as WO2006004931A3 T IN O
serotonin WO2006004931A3 T NN O
receptor WO2006004931A3 T NN O
modulators WO2006004931A3 T NNS O
. WO2006004931A3 T . O

These WO2006004931A3 A DT O
compounds WO2006004931A3 A NNS O
are WO2006004931A3 A VBP O
serotonin WO2006004931A3 A JJ I-UN
receptor WO2006004931A3 A NN I-UN
( WO2006004931A3 A ( O
5-HT WO2006004931A3 A JJ O
) WO2006004931A3 A ) O
ligands WO2006004931A3 A NNS O
and WO2006004931A3 A CC O
are WO2006004931A3 A VBP O
useful WO2006004931A3 A JJ O
for WO2006004931A3 A IN O
treating WO2006004931A3 A VBG O
diseases WO2006004931A3 A NNS O
, WO2006004931A3 A , O
disorders WO2006004931A3 A NNS O
, WO2006004931A3 A , O
and WO2006004931A3 A CC O
conditions WO2006004931A3 A NNS O
wherein WO2006004931A3 A VBP O
modulation WO2006004931A3 A NN O
of WO2006004931A3 A IN O
the WO2006004931A3 A DT O
activity WO2006004931A3 A NN O
of WO2006004931A3 A IN O
serotonin WO2006004931A3 A NN I-UN
receptors WO2006004931A3 A NNS I-UN
( WO2006004931A3 A ( O
5-HT WO2006004931A3 A JJ O
) WO2006004931A3 A ) O
is WO2006004931A3 A VBZ O
desired WO2006004931A3 A VBN O
( WO2006004931A3 A ( O
e.g WO2006004931A3 A NN O
. WO2006004931A3 A . O

Use CN102210698A T NNP O
of CN102210698A T IN O
composition CN102210698A T NN O
containing CN102210698A T VBG O
3-aminopyridine-2-formaldehyde CN102210698A T JJ O
thiosemicarbazone CN102210698A T NN O
in CN102210698A T IN O
treatment CN102210698A T NN O
of CN102210698A T IN O
cancers CN102210698A T NNS O
. CN102210698A T . O

Inhibitors WO2014076104A1 T NNS O
of WO2014076104A1 T IN O
bruton WO2014076104A1 T NN I-UN
's WO2014076104A1 T POS I-UN
tyrosine WO2014076104A1 T JJ I-UN
kinase WO2014076104A1 T NN I-UN
. WO2014076104A1 T . O

This WO2014076104A1 A DT O
application WO2014076104A1 A NN O
discloses WO2014076104A1 A VBZ O
compounds WO2014076104A1 A VBZ O
according WO2014076104A1 A VBG O
to WO2014076104A1 A TO O
generic WO2014076104A1 A JJ O
Formula WO2014076104A1 A NNP O
( WO2014076104A1 A ( O
I WO2014076104A1 A PRP O
) WO2014076104A1 A ) O
: WO2014076104A1 A : O
wherein WO2014076104A1 A NN O
all WO2014076104A1 A DT O
variables WO2014076104A1 A NNS O
are WO2014076104A1 A VBP O
defined WO2014076104A1 A VBN O
as WO2014076104A1 A IN O
described WO2014076104A1 A JJ O
herein WO2014076104A1 A NN O
, WO2014076104A1 A , O
which WO2014076104A1 A WDT O
inhibit WO2014076104A1 A VBP O
Btk WO2014076104A1 A NNP I-UN
. WO2014076104A1 A . O

The WO2014076104A1 A DT O
compounds WO2014076104A1 A NNS O
disclosed WO2014076104A1 A VBN O
herein WO2014076104A1 A NNS O
are WO2014076104A1 A VBP O
useful WO2014076104A1 A JJ O
to WO2014076104A1 A TO O
modulate WO2014076104A1 A VB O
the WO2014076104A1 A DT O
activity WO2014076104A1 A NN O
of WO2014076104A1 A IN O
Btk WO2014076104A1 A NNP I-UN
and WO2014076104A1 A CC O
treat WO2014076104A1 A NN O
diseases WO2014076104A1 A NNS O
associated WO2014076104A1 A VBN O
with WO2014076104A1 A IN O
excessive WO2014076104A1 A JJ O
Btk WO2014076104A1 A NNP I-UN
activity WO2014076104A1 A NN O
. WO2014076104A1 A . O

Metal US20060165591 T NNP O
complex-containing US20060165591 T JJ O
pharmaceutical US20060165591 T JJ O
agents US20060165591 T NNS O
. US20060165591 T . O

Bi WO2011143106A1 T NNP O
- WO2011143106A1 T : O
functional WO2011143106A1 T JJ O
pyrazolopyridine WO2011143106A1 T NN O
compounds WO2011143106A1 T NNS O
. WO2011143106A1 T . O

Small US20080032966 T JJ O
Molecule US20080032966 T NNP O
Inhibitors US20080032966 T NNP O
of US20080032966 T IN O
Mrp1 US20080032966 T NNP I-UN
and US20080032966 T CC O
Other US20080032966 T JJ O
Multidrug US20080032966 T NNP O
Transporters US20080032966 T NNP O
. US20080032966 T . O

Nucleic CN101007838A T NNP O
acid CN101007838A T NN O
molecule CN101007838A T NN O
RTN4BSR22 CN101007838A T NNP O
and CN101007838A T CC O
its CN101007838A T PRP$ O
application CN101007838A T NN O
in CN101007838A T IN O
preparing CN101007838A T VBG O
anticancer CN101007838A T JJ O
medicine CN101007838A T NN O
. CN101007838A T . O

Combination WO2004105756A3 T NN O
comprising WO2004105756A3 T NN O
( WO2004105756A3 T ( O
a WO2004105756A3 T DT O
) WO2004105756A3 T ) O
a WO2004105756A3 T DT O
neuroprotecting WO2004105756A3 T JJ O
agent WO2004105756A3 T NN O
and WO2004105756A3 T CC O
( WO2004105756A3 T ( O
b WO2004105756A3 T NN O
) WO2004105756A3 T ) O
an WO2004105756A3 T DT O
agent WO2004105756A3 T NN O
binding WO2004105756A3 T VBG O
to WO2004105756A3 T TO O
gadph WO2004105756A3 T VB O
and WO2004105756A3 T CC O
pharmaceutical WO2004105756A3 T JJ O
use WO2004105756A3 T NN O
thereof WO2004105756A3 T NN O
. WO2004105756A3 T . O

3-pyrrolo-cyclohexylene-2-dihydro-indolinone WO2008067756A1 T JJ O
derivatives WO2008067756A1 T NNS O
and WO2008067756A1 T CC O
uses WO2008067756A1 T VBZ O
thereof WO2008067756A1 T NN O
. WO2008067756A1 T . O

The WO2008067756A1 A DT O
bioassay WO2008067756A1 A NN O
show WO2008067756A1 A NN O
that WO2008067756A1 A IN O
the WO2008067756A1 A DT O
above WO2008067756A1 A JJ O
compounds WO2008067756A1 A NNS O
and WO2008067756A1 A CC O
their WO2008067756A1 A PRP$ O
pharmaceutically WO2008067756A1 A RB O
acceptable WO2008067756A1 A JJ O
salts WO2008067756A1 A NNS O
can WO2008067756A1 A MD O
modulate WO2008067756A1 A VB O
the WO2008067756A1 A DT O
activity WO2008067756A1 A NN O
of WO2008067756A1 A IN O
protein WO2008067756A1 A NN O
kinases WO2008067756A1 A NNS I-UN
( WO2008067756A1 A ( O
PKs WO2008067756A1 A NNP O
) WO2008067756A1 A ) O
, WO2008067756A1 A , O
inhibit WO2008067756A1 A VBP O
the WO2008067756A1 A DT O
activity WO2008067756A1 A NN O
of WO2008067756A1 A IN O
tyrosine WO2008067756A1 A NN I-UN
kinases WO2008067756A1 A NNS I-UN
( WO2008067756A1 A ( O
PTKs WO2008067756A1 A NNP I-UN
) WO2008067756A1 A ) O
and WO2008067756A1 A CC O
inhibit WO2008067756A1 A VB O
many WO2008067756A1 A JJ O
kinds WO2008067756A1 A NNS O
of WO2008067756A1 A IN O
tumor WO2008067756A1 A NN O
cells WO2008067756A1 A NNS O
as WO2008067756A1 A RB O
well WO2008067756A1 A RB O
as WO2008067756A1 A IN O
. WO2008067756A1 A . O

Novel CN101258159A T NNP O
c18 CN101258159A T NN O
modified CN101258159A T VBD O
retrosteroids CN101258159A T NNS O
as CN101258159A T IN O
progesterone CN101258159A T NN I-UN
receptor CN101258159A T NN I-UN
modulator CN101258159A T NN O
compounds CN101258159A T NNS O
. CN101258159A T . O

Described CN101258159A A VBN O
herein CN101258159A A NNS O
are CN101258159A A VBP O
new CN101258159A A JJ O
retrosteroidal CN101258159A A JJ O
compounds CN101258159A A NNS O
of CN101258159A A IN O
general CN101258159A A JJ O
formula CN101258159A A NN O
( CN101258159A A ( O
I CN101258159A A PRP O
) CN101258159A A ) O
, CN101258159A A , O
representing CN101258159A A VBG O
progesterone CN101258159A A NN I-UN
receptor CN101258159A A NN I-UN
modulators CN101258159A A NNS O
, CN101258159A A , O
and CN101258159A A CC O
their CN101258159A A PRP$ O
production CN101258159A A NN O
, CN101258159A A , O
and CN101258159A A CC O
pharmaceutical CN101258159A A JJ O
preparations CN101258159A A NNS O
containing CN101258159A A VBG O
these CN101258159A A DT O
compounds CN101258159A A NNS O
. CN101258159A A . O

Pravastatin WO2011049122A1 T NNP O
sodium WO2011049122A1 T NN O
tablet WO2011049122A1 T NN O
rapidly WO2011049122A1 T RB O
disintegrating WO2011049122A1 T VBG O
in WO2011049122A1 T IN O
oral WO2011049122A1 T JJ O
cavity WO2011049122A1 T NN O
and WO2011049122A1 T CC O
method WO2011049122A1 T NN O
for WO2011049122A1 T IN O
producing WO2011049122A1 T VBG O
same WO2011049122A1 T JJ O
. WO2011049122A1 T . O

5-benzylidene-2,4-thiazolidinedione CN101973957A T JJ O
derivatives CN101973957A T NNS O
and CN101973957A T CC O
preparation CN101973957A T NN O
method CN101973957A T NN O
and CN101973957A T CC O
application CN101973957A T NN O
thereof CN101973957A T NN O
. CN101973957A T . O

Pharmaceutical WO2014051359A1 T JJ O
composition WO2014051359A1 T NN O
comprising WO2014051359A1 T VBG O
neferine WO2014051359A1 T NN O
as WO2014051359A1 T IN O
active WO2014051359A1 T JJ O
ingredient WO2014051359A1 T NN O
for WO2014051359A1 T IN O
preventing WO2014051359A1 T VBG O
or WO2014051359A1 T CC O
treating WO2014051359A1 T VBG O
hepatoma WO2014051359A1 T NN O
. WO2014051359A1 T . O

Substituted US20110003818 T VBN O
2-Carboxamide US20110003818 T JJ O
Cycloamino US20110003818 T NNP O
Ureas US20110003818 T NNP O
. US20110003818 T . O

Ruthenium CN101020700A T NNP O
porphyrin CN101020700A T NN O
complex CN101020700A T NN O
and CN101020700A T CC O
its CN101020700A T PRP$ O
prepn CN101020700A T NN O
process CN101020700A T NN O
and CN101020700A T CC O
application CN101020700A T NN O
as CN101020700A T IN O
photosensitizer CN101020700A T NN O
for CN101020700A T IN O
photodynamic CN101020700A T JJ O
therapy CN101020700A T NN O
. CN101020700A T . O

Phosphatidylcholine WO2012049647A1 T NN O
in WO2012049647A1 T IN O
the WO2012049647A1 T DT O
treatment WO2012049647A1 T NN O
ophosphatidylcholinef WO2012049647A1 T NN O
tumours WO2012049647A1 T NNS O
. WO2012049647A1 T . O

Derivatives EP1584619A1 T NNS O
of EP1584619A1 T IN O
quinoline EP1584619A1 T NN O
as EP1584619A1 T IN O
inhibitors EP1584619A1 T NNS O
for EP1584619A1 T IN O
MEK EP1584619A1 T NNP I-UN
. EP1584619A1 T . O

Compounds EP1584619A1 A NNS O
are EP1584619A1 A VBP O
useful EP1584619A1 A JJ O
as EP1584619A1 A IN O
pharmaceuticals EP1584619A1 A NNS O
for EP1584619A1 A IN O
the EP1584619A1 A DT O
inhibition EP1584619A1 A NN O
of EP1584619A1 A IN O
MEK EP1584619A1 A NNP I-UN
activity EP1584619A1 A NN O
. EP1584619A1 A . O

Hydrate US20100234410 T NNP O
for US20100234410 T IN O
medical US20100234410 T JJ O
purposes US20100234410 T NNS O
. US20100234410 T . O

Stabilized CA2623858A1 T VBN O
chlorine CA2623858A1 T NN O
dioxide CA2623858A1 T NN O
and CA2623858A1 T CC O
hypochlorous CA2623858A1 T JJ O
acid CA2623858A1 T NN O
in CA2623858A1 T IN O
a CA2623858A1 T DT O
liquid CA2623858A1 T JJ O
biocide CA2623858A1 T NN O
. CA2623858A1 T . O

Radix CN103041168A T NNP O
rehmanniae CN103041168A T NN O
and CN103041168A T CC O
tangerine CN103041168A T NN O
peel CN103041168A T NN O
pain CN103041168A T NN O
and CN103041168A T CC O
swelling CN103041168A T VBG O
ointment CN103041168A T NN O
. CN103041168A T . O

Methods US20080234382 T NNS O
for US20080234382 T IN O
the US20080234382 T DT O
preparation US20080234382 T NN O
, US20080234382 T , O
formulation US20080234382 T NN O
and US20080234382 T CC O
use US20080234382 T NN O
of US20080234382 T IN O
lithium US20080234382 T NN O
valproate US20080234382 T NN O
. US20080234382 T . O

Small US20120121689 T JJ O
interfering US20120121689 T VBG O
rna US20120121689 T JJ O
delivery US20120121689 T NN O
. US20120121689 T . O

Ethanamine WO2010074647A1 T NNP O
compounds WO2010074647A1 T NNS O
and WO2010074647A1 T CC O
their WO2010074647A1 T PRP$ O
use WO2010074647A1 T NN O
for WO2010074647A1 T IN O
treating WO2010074647A1 T VBG O
depression WO2010074647A1 T NN O
. WO2010074647A1 T . O

The WO2010074647A1 A DT O
present WO2010074647A1 A JJ O
invention WO2010074647A1 A NN O
relates WO2010074647A1 A VBZ O
to WO2010074647A1 A TO O
ethanamine WO2010074647A1 A VB O
compounds WO2010074647A1 A NNS O
, WO2010074647A1 A , O
namely WO2010074647A1 A RB O
1- WO2010074647A1 A JJ O
( WO2010074647A1 A ( O
3-f WO2010074647A1 A JJ O
luorophenyl WO2010074647A1 A NN O
) WO2010074647A1 A ) O
-2-methyl-2- WO2010074647A1 A NN O
( WO2010074647A1 A ( O
pyridine-2-yl WO2010074647A1 A JJ O
) WO2010074647A1 A ) O
propan-1-amine WO2010074647A1 A NN O
and WO2010074647A1 A CC O
2-methyl-l-phenyl-2- WO2010074647A1 A JJ O
( WO2010074647A1 A ( O
pyridine-2yl WO2010074647A1 A JJ O
) WO2010074647A1 A ) O
propan-1-amine WO2010074647A1 A NN O
, WO2010074647A1 A , O
the WO2010074647A1 A DT O
enantiomers WO2010074647A1 A NNS O
and WO2010074647A1 A CC O
salts WO2010074647A1 A NNS O
thereof WO2010074647A1 A NNS O
and WO2010074647A1 A CC O
their WO2010074647A1 A PRP$ O
use WO2010074647A1 A NN O
for WO2010074647A1 A IN O
the WO2010074647A1 A DT O
treatment WO2010074647A1 A NN O
of WO2010074647A1 A IN O
depression WO2010074647A1 A NN O
. WO2010074647A1 A . O

Piperididinyl CA2325471C T NNP O
and CA2325471C T CC O
n-amidinopiperidinyl CA2325471C T JJ O
derivatives CA2325471C T NNS O
. CA2325471C T . O

This CA2325471C A DT O
invention CA2325471C A NN O
is CA2325471C A VBZ O
directed CA2325471C A VBN O
to CA2325471C A TO O
a CA2325471C A DT O
compound CA2325471C A NN O
of CA2325471C A IN O
formula CA2325471C A NN O
( CA2325471C A ( O
I CA2325471C A PRP O
) CA2325471C A ) O
which CA2325471C A WDT O
is CA2325471C A VBZ O
useful CA2325471C A JJ O
for CA2325471C A IN O
inhibiting CA2325471C A VBG O
the CA2325471C A DT O
activity CA2325471C A NN O
of CA2325471C A IN O
Factor CA2325471C A NNP I-UN
Xa CA2325471C A NNP I-UN
, CA2325471C A , O
by CA2325471C A IN O
combining CA2325471C A VBG O
said CA2325471C A VBD O
compound CA2325471C A NN O
with CA2325471C A IN O
a CA2325471C A DT O
composition CA2325471C A NN O
containing CA2325471C A VBG O
Factor CA2325471C A NNP I-UN
Xa CA2325471C A NNP I-UN
. CA2325471C A . O

The CA2325471C A DT O
present CA2325471C A JJ O
invention CA2325471C A NN O
is CA2325471C A VBZ O
also CA2325471C A RB O
directed CA2325471C A VBN O
to CA2325471C A TO O
compositions CA2325471C A NNS O
containing CA2325471C A VBG O
compounds CA2325471C A NNS O
of CA2325471C A IN O
formula CA2325471C A NN O
( CA2325471C A ( O
I CA2325471C A PRP O
) CA2325471C A ) O
, CA2325471C A , O
methods CA2325471C A NNS O
for CA2325471C A IN O
their CA2325471C A PRP$ O
preparation CA2325471C A NN O
, CA2325471C A , O
their CA2325471C A PRP$ O
use CA2325471C A NN O
, CA2325471C A , O
such CA2325471C A JJ O
as CA2325471C A IN O
in CA2325471C A IN O
inhibiting CA2325471C A VBG O
the CA2325471C A DT O
formation CA2325471C A NN O
of CA2325471C A IN O
thrombin CA2325471C A NN I-UN
or CA2325471C A CC O
for CA2325471C A IN O
treating CA2325471C A VBG O
a CA2325471C A DT O
patient CA2325471C A NN O
suffering CA2325471C A NN O
from CA2325471C A IN O
, CA2325471C A , O
or CA2325471C A CC O
subject CA2325471C A JJ O
to CA2325471C A TO O
, CA2325471C A , O
a CA2325471C A DT O
disease CA2325471C A NN O
state CA2325471C A NN O
associated CA2325471C A VBN O
with CA2325471C A IN O
a CA2325471C A DT O
physiologically CA2325471C A RB O
detrimental CA2325471C A JJ O
excess CA2325471C A JJ O
amount CA2325471C A NN O
of CA2325471C A IN O
thrombin CA2325471C A NN I-UN
. CA2325471C A . O

Method WO2009134524A2 T NNP O
and WO2009134524A2 T CC O
system WO2009134524A2 T NN O
for WO2009134524A2 T IN O
the WO2009134524A2 T DT O
treatment WO2009134524A2 T NN O
of WO2009134524A2 T IN O
chronic WO2009134524A2 T JJ O
obstructive WO2009134524A2 T JJ O
pulmonary WO2009134524A2 T JJ O
disease WO2009134524A2 T NN O
with WO2009134524A2 T IN O
nebulized WO2009134524A2 T JJ O
anticholinergic WO2009134524A2 T JJ O
administrations WO2009134524A2 T NNS O
. WO2009134524A2 T . O

Use CN102743365A T NNP O
of CN102743365A T IN O
compound CN102743365A T NN O
or CN102743365A T CC O
its CN102743365A T PRP$ O
pharmaceutically CN102743365A T RB O
acceptable CN102743365A T JJ O
salt CN102743365A T NN O
in CN102743365A T IN O
prevention CN102743365A T NN O
and CN102743365A T CC O
treatment CN102743365A T NN O
on CN102743365A T IN O
senile CN102743365A T JJ O
dementia CN102743365A T NN O
. CN102743365A T . O

The CN102743365A A DT O
compound CN102743365A A NN O
or CN102743365A A CC O
its CN102743365A A PRP$ O
pharmaceutically CN102743365A A RB O
acceptable CN102743365A A JJ O
salt CN102743365A A NN O
can CN102743365A A MD O
penetrate CN102743365A A VB O
a CN102743365A A DT O
blood CN102743365A A NN O
brain CN102743365A A NN O
barrier CN102743365A A NN O
and CN102743365A A CC O
then CN102743365A A RB O
bind CN102743365A A VB O
with CN102743365A A IN O
a CN102743365A A DT O
heavy CN102743365A A JJ O
metal CN102743365A A NN O
to CN102743365A A TO O
form CN102743365A A VB O
a CN102743365A A DT O
chelate CN102743365A A NN O
thereby CN102743365A A NN O
inhibiting CN102743365A A VBG O
production CN102743365A A NN O
of CN102743365A A IN O
amyloid CN102743365A A NN I-UN
in CN102743365A A IN O
the CN102743365A A DT O
brain CN102743365A A NN O
, CN102743365A A , O
preventing CN102743365A A VBG O
polymerization CN102743365A A NN O
and CN102743365A A CC O
accumulation CN102743365A A NN O
of CN102743365A A IN O
amyloid CN102743365A A NN I-UN
, CN102743365A A , O
dissolving CN102743365A A VBG O
produced CN102743365A A VBN O
amyloid CN102743365A A JJ I-UN
plaques CN102743365A A NNS O
and CN102743365A A CC O
promoting CN102743365A A VBG O
amyloid CN102743365A A JJ I-UN
degradation CN102743365A A NN O
. CN102743365A A . O

New CN1948305A T NNP O
dioxo CN1948305A T JJ O
morpholine CN1948305A T NN O
kind CN1948305A T NN O
compound CN1948305A T NN O
, CN1948305A T , O
its CN1948305A T PRP$ O
preparation CN1948305A T NN O
method CN1948305A T NN O
and CN1948305A T CC O
use CN1948305A T NN O
. CN1948305A T . O

Tricyclic EP2300476A1 T NNP O
nitrogen EP2300476A1 T NN O
containing EP2300476A1 T VBG O
compounds EP2300476A1 T NNS O
and EP2300476A1 T CC O
their EP2300476A1 T PRP$ O
use EP2300476A1 T NN O
as EP2300476A1 T IN O
antibacterials EP2300476A1 T NNS O
. EP2300476A1 T . O

Spiro-amino-imidazo-fused WO2012112462A1 T JJ O
heterocyclic WO2012112462A1 T JJ O
compounds WO2012112462A1 T NNS O
as WO2012112462A1 T IN O
beta-secretase WO2012112462A1 T JJ I-UN
modulators WO2012112462A1 T NNS O
and WO2012112462A1 T CC O
methods WO2012112462A1 T NNS O
of WO2012112462A1 T IN O
use WO2012112462A1 T NN O
. WO2012112462A1 T . O

The WO2012112462A1 A DT O
present WO2012112462A1 A JJ O
invention WO2012112462A1 A NN O
provides WO2012112462A1 A VBZ O
a WO2012112462A1 A DT O
new WO2012112462A1 A JJ O
class WO2012112462A1 A NN O
of WO2012112462A1 A IN O
compounds WO2012112462A1 A NNS O
useful WO2012112462A1 A JJ O
for WO2012112462A1 A IN O
the WO2012112462A1 A DT O
modulation WO2012112462A1 A NN O
of WO2012112462A1 A IN O
beta-secretase WO2012112462A1 A NN I-UN
enzyme WO2012112462A1 A NN O
( WO2012112462A1 A ( O
BACE WO2012112462A1 A NNP I-UN
) WO2012112462A1 A ) O
activity WO2012112462A1 A NN O
. WO2012112462A1 A . O

The WO2012112462A1 A DT O
invention WO2012112462A1 A NN O
also WO2012112462A1 A RB O
provides WO2012112462A1 A VBZ O
pharmaceutical WO2012112462A1 A JJ O
compositions WO2012112462A1 A NNS O
comprising WO2012112462A1 A VBG O
the WO2012112462A1 A DT O
compounds WO2012112462A1 A NNS O
, WO2012112462A1 A , O
and WO2012112462A1 A CC O
corresponding WO2012112462A1 A VBG O
uses WO2012112462A1 A NNS O
of WO2012112462A1 A IN O
the WO2012112462A1 A DT O
compounds WO2012112462A1 A NNS O
and WO2012112462A1 A CC O
compositions WO2012112462A1 A NNS O
for WO2012112462A1 A IN O
treatment WO2012112462A1 A NN O
of WO2012112462A1 A IN O
disorders WO2012112462A1 A NNS O
and/or WO2012112462A1 A VBP O
conditions WO2012112462A1 A NNS O
related WO2012112462A1 A VBN O
to WO2012112462A1 A TO O
plaque WO2012112462A1 A VB O
formation WO2012112462A1 A NN O
and WO2012112462A1 A CC O
deposition WO2012112462A1 A NN O
, WO2012112462A1 A , O
resulting WO2012112462A1 A VBG O
from WO2012112462A1 A IN O
the WO2012112462A1 A DT O
activity WO2012112462A1 A NN O
of WO2012112462A1 A IN O
BACE WO2012112462A1 A NNP I-UN
. WO2012112462A1 A . O

Such WO2012112462A1 A JJ O
BACE WO2012112462A1 A NNP I-UN
mediated WO2012112462A1 A VBD O
disorders WO2012112462A1 A NNS O
include WO2012112462A1 A VBP O
, WO2012112462A1 A , O
for WO2012112462A1 A IN O
example WO2012112462A1 A NN O
, WO2012112462A1 A , O
Alzheimer WO2012112462A1 A NNP O
's WO2012112462A1 A POS O
Disease WO2012112462A1 A NNP O
, WO2012112462A1 A , O
cognitive WO2012112462A1 A JJ O
deficits WO2012112462A1 A NNS O
and WO2012112462A1 A CC O
impairments WO2012112462A1 A NNS O
, WO2012112462A1 A , O
schizophrenia WO2012112462A1 A NN O
and WO2012112462A1 A CC O
other WO2012112462A1 A JJ O
central WO2012112462A1 A JJ O
nervous WO2012112462A1 A JJ O
system WO2012112462A1 A NN O
conditions WO2012112462A1 A NNS O
and WO2012112462A1 A CC O
disorders WO2012112462A1 A NNS O
. WO2012112462A1 A . O

Sugar WO2010094837A3 T NNP O
product WO2010094837A3 T NN O
. WO2010094837A3 T . O

Synergistic EP1893206A2 T JJ O
modulation EP1893206A2 T NN O
of EP1893206A2 T IN O
flt3 EP1893206A2 T JJ I-UN
kinase EP1893206A2 T NN O
using EP1893206A2 T VBG O
aminoquinoline EP1893206A2 T NN O
and EP1893206A2 T CC O
aminoquinazoline EP1893206A2 T JJ O
kinase EP1893206A2 T NN O
modulators EP1893206A2 T NNS O
. EP1893206A2 T . O

The EP1893206A2 A DT O
invention EP1893206A2 A NN O
is EP1893206A2 A VBZ O
directed EP1893206A2 A VBN O
to EP1893206A2 A TO O
a EP1893206A2 A DT O
method EP1893206A2 A NN O
of EP1893206A2 A IN O
inhibiting EP1893206A2 A VBG O
FLT3 EP1893206A2 A NNP I-UN
tyrosine EP1893206A2 A JJ O
kinase EP1893206A2 A NN O
activity EP1893206A2 A NN O
or EP1893206A2 A CC O
expression EP1893206A2 A NN O
or EP1893206A2 A CC O
reducing EP1893206A2 A VBG O
FLT3 EP1893206A2 A JJ I-UN
kinase EP1893206A2 A NN O
activity EP1893206A2 A NN O
or EP1893206A2 A CC O
expression EP1893206A2 A NN O
in EP1893206A2 A IN O
a EP1893206A2 A DT O
cell EP1893206A2 A NN O
or EP1893206A2 A CC O
a EP1893206A2 A DT O
subject EP1893206A2 A JJ O
comprising EP1893206A2 A VBG O
the EP1893206A2 A DT O
administration EP1893206A2 A NN O
of EP1893206A2 A IN O
a EP1893206A2 A DT O
farnesyl EP1893206A2 A JJ O
transferase EP1893206A2 A NN O
inhibitor EP1893206A2 A NN O
and EP1893206A2 A CC O
a EP1893206A2 A DT O
FLT3 EP1893206A2 A NNP I-UN
kinase EP1893206A2 A NN O
inhibitor EP1893206A2 A NN O
selected EP1893206A2 A VBN O
from EP1893206A2 A IN O
aminoquinoline EP1893206A2 A NN O
and EP1893206A2 A CC O
aminoquinazoline EP1893206A2 A JJ O
compounds EP1893206A2 A NNS O
of EP1893206A2 A IN O
Formula EP1893206A2 A NNP O
( EP1893206A2 A ( O
I’ EP1893206A2 A NNP O
) EP1893206A2 A ) O
: EP1893206A2 A : O
where EP1893206A2 A WRB O
R1 EP1893206A2 A NNP O
, EP1893206A2 A , O
R2 EP1893206A2 A NNP O
, EP1893206A2 A , O
R3 EP1893206A2 A NNP O
, EP1893206A2 A , O
B EP1893206A2 A NNP O
, EP1893206A2 A , O
Z EP1893206A2 A NNP O
, EP1893206A2 A , O
Q EP1893206A2 A NNP O
, EP1893206A2 A , O
p EP1893206A2 A NN O
, EP1893206A2 A , O
q EP1893206A2 A NN O
and EP1893206A2 A CC O
X EP1893206A2 A NN O
are EP1893206A2 A VBP O
as EP1893206A2 A IN O
defined EP1893206A2 A JJ O
herein EP1893206A2 A NN O
. EP1893206A2 A . O

Included EP1893206A2 A VBN O
within EP1893206A2 A IN O
the EP1893206A2 A DT O
present EP1893206A2 A JJ O
invention EP1893206A2 A NN O
is EP1893206A2 A VBZ O
both EP1893206A2 A DT O
prophylactic EP1893206A2 A JJ O
and EP1893206A2 A CC O
therapeutic EP1893206A2 A JJ O
methods EP1893206A2 A NNS O
for EP1893206A2 A IN O
treating EP1893206A2 A VBG O
a EP1893206A2 A DT O
subject EP1893206A2 A NN O
at EP1893206A2 A IN O
risk EP1893206A2 A NN O
of EP1893206A2 A IN O
( EP1893206A2 A ( O
or EP1893206A2 A CC O
susceptible EP1893206A2 A VB O
to EP1893206A2 A TO O
) EP1893206A2 A ) O
developing EP1893206A2 A VBG O
a EP1893206A2 A DT O
cell EP1893206A2 A NN O
proliferative EP1893206A2 A JJ O
disorder EP1893206A2 A NN O
or EP1893206A2 A CC O
a EP1893206A2 A DT O
disorder EP1893206A2 A NN O
related EP1893206A2 A VBN O
to EP1893206A2 A TO O
FLT3 EP1893206A2 A NNP I-UN
. EP1893206A2 A . O

Pyrazole US20080153893 T NNP O
Carboxamides US20080153893 T NNP O
as US20080153893 T IN O
Inhibitors US20080153893 T NNS O
of US20080153893 T IN O
11-Beta-Hydroxysteroid US20080153893 T JJ O
Dehydrogenase-1 US20080153893 T NNP O
. US20080153893 T . O

Anticancer CN101390828B T NNP O
composition CN101390828B T NN O
loaded CN101390828B T VBD O
with CN101390828B T IN O
anti-metabolism CN101390828B T NN O
medicine CN101390828B T NN O
and CN101390828B T CC O
synergist CN101390828B T NN O
thereof CN101390828B T NN O
. CN101390828B T . O

Oligonucleotide US20070274936 T NNP O
and US20070274936 T CC O
the US20070274936 T DT O
Use US20070274936 T NNP O
Thereof US20070274936 T NNP O
for US20070274936 T IN O
Modulating US20070274936 T VBG O
an US20070274936 T DT O
Isoform US20070274936 T NNP I-UN
C US20070274936 T NNP I-UN
Beta-1 US20070274936 T NNP I-UN
Protein-Kinase US20070274936 T NNP I-UN
in US20070274936 T IN O
the US20070274936 T DT O
Form US20070274936 T NNP O
of US20070274936 T IN O
a US20070274936 T DT O
Skin US20070274936 T NNP O
Depigmentation US20070274936 T NNP O
Agent US20070274936 T NNP O
. US20070274936 T . O

These US20070274936 A DT O
oligonucleotide US20070274936 A JJ O
sequences US20070274936 A NNS O
are US20070274936 A VBP O
capable US20070274936 A JJ O
of US20070274936 A IN O
hybridising US20070274936 A VBG O
with US20070274936 A IN O
the US20070274936 A DT O
genes US20070274936 A NNS O
or US20070274936 A CC O
with US20070274936 A IN O
products US20070274936 A NNS O
of US20070274936 A IN O
the US20070274936 A DT O
genes US20070274936 A NNS O
coding US20070274936 A VBG O
for US20070274936 A IN O
the US20070274936 A DT O
PKC-beta US20070274936 A NNP I-UN
1 US20070274936 A CD I-UN
. US20070274936 A . O

Controlled-release US20110217371 T JJ O
microparticles US20110217371 T NNS O
and US20110217371 T CC O
method US20110217371 T NN O
of US20110217371 T IN O
preparing US20110217371 T VBG O
same US20110217371 T JJ O
. US20110217371 T . O

Polypeptide US20050234222 T RB O
comprising US20050234222 T VBG O
at US20050234222 T IN O
least US20050234222 T JJS O
one US20050234222 T CD O
alpha-helix US20050234222 T JJ O
having US20050234222 T VBG O
synthetically US20050234222 T RB O
attached US20050234222 T VBN O
thereto US20050234222 T NN O
a US20050234222 T DT O
plurality US20050234222 T NN O
of US20050234222 T IN O
therapeutic US20050234222 T JJ O
or US20050234222 T CC O
diagnostic US20050234222 T JJ O
moieties US20050234222 T NNS O
. US20050234222 T . O

Invert CN101716181B T NNP O
sugar CN101716181B T NN O
medicament CN101716181B T NN O
composition CN101716181B T NN O
liposome CN101716181B T POS O
injection CN101716181B T NN O
and CN101716181B T CC O
new CN101716181B T JJ O
application CN101716181B T NN O
thereof CN101716181B T NN O
. CN101716181B T . O

Spiro EP1695977A2 T NNP O
[ EP1695977A2 T NNP O
isobenzofuran-1,4'piperidin EP1695977A2 T JJ O
] EP1695977A2 T NNP O
-3-ones EP1695977A2 T NNS O
and EP1695977A2 T CC O
3H-spiroisobenzofuran-1 EP1695977A2 T JJ O
, EP1695977A2 T , O
4'-piperidines EP1695977A2 T JJ O
. EP1695977A2 T . O

This EP1695977A2 A DT O
invention EP1695977A2 A NN O
relates EP1695977A2 A VBZ O
generally EP1695977A2 A RB O
to EP1695977A2 A TO O
substituted EP1695977A2 A VBN O
spiro EP1695977A2 A JJ O
[ EP1695977A2 A JJ O
isobenzofuran-1,4'-piperidin EP1695977A2 A JJ O
] EP1695977A2 A NN O
-3-ones EP1695977A2 A NNS O
and EP1695977A2 A CC O
3H-spiroisobenzofuran-1,4'-piperidines EP1695977A2 A NNS O
that EP1695977A2 A WDT O
are EP1695977A2 A VBP O
modulators EP1695977A2 A NNS O
of EP1695977A2 A IN O
mammalian EP1695977A2 A JJ I-UN
neuropeptide EP1695977A2 A NN I-UN
Y5 EP1695977A2 A NNP I-UN
( EP1695977A2 A ( I-UN
NPY5 EP1695977A2 A NNP I-UN
) EP1695977A2 A ) I-UN
receptors EP1695977A2 A NNS I-UN
, EP1695977A2 A , O
and EP1695977A2 A CC O
to EP1695977A2 A TO O
the EP1695977A2 A DT O
use EP1695977A2 A NN O
of EP1695977A2 A IN O
such EP1695977A2 A JJ O
compounds EP1695977A2 A NNS O
for EP1695977A2 A IN O
treating EP1695977A2 A VBG O
a EP1695977A2 A DT O
variety EP1695977A2 A NN O
of EP1695977A2 A IN O
physiological EP1695977A2 A JJ O
disorders EP1695977A2 A NNS O
associated EP1695977A2 A VBN O
with EP1695977A2 A IN O
NPY5 EP1695977A2 A NNP I-UN
receptor EP1695977A2 A NN O
activation EP1695977A2 A NN O
, EP1695977A2 A , O
such EP1695977A2 A JJ O
as EP1695977A2 A IN O
feeding EP1695977A2 A VBG O
disorders EP1695977A2 A NNS O
, EP1695977A2 A , O
psychiatric EP1695977A2 A JJ O
disorders EP1695977A2 A NNS O
and EP1695977A2 A CC O
cardiovascular EP1695977A2 A JJ O
diseases EP1695977A2 A NNS O
. EP1695977A2 A . O

The EP1695977A2 A DT O
invention EP1695977A2 A NN O
further EP1695977A2 A RB O
relates EP1695977A2 A VBZ O
to EP1695977A2 A TO O
the EP1695977A2 A DT O
use EP1695977A2 A NN O
such EP1695977A2 A JJ O
compounds EP1695977A2 A NNS O
as EP1695977A2 A IN O
probes EP1695977A2 A NNS O
for EP1695977A2 A IN O
the EP1695977A2 A DT O
detection EP1695977A2 A NN O
and EP1695977A2 A CC O
localization EP1695977A2 A NN O
of EP1695977A2 A IN O
NPY5 EP1695977A2 A NNP I-UN
receptors EP1695977A2 A NNS O
. EP1695977A2 A . O

Hematopoietic US20070135354 T JJ O
stimulation US20070135354 T NN O
. US20070135354 T . O

Ophthalmic CA2323810C T JJ O
solution CA2323810C T NN O
comprising CA2323810C T VBG O
glycogen CA2323810C T NN O
. CA2323810C T . O

Pain-eliminating CN101474281B T JJ O
paste CN101474281B T NN O
for CN101474281B T IN O
zoster CN101474281B T NN O
and CN101474281B T CC O
preparation CN101474281B T NN O
method CN101474281B T NN O
thereof CN101474281B T NN O
. CN101474281B T . O

Triazinone WO2013147183A1 T NN O
compound WO2013147183A1 T NN O
and WO2013147183A1 T CC O
t-type WO2013147183A1 T JJ I-UN
calcium WO2013147183A1 T NN I-UN
channel WO2013147183A1 T NN I-UN
inhibitor WO2013147183A1 T NN O
. WO2013147183A1 T . O

[ WO2013147183A1 A NN O
Problem WO2013147183A1 A NNP O
] WO2013147183A1 A NNP O
To WO2013147183A1 A TO O
provide WO2013147183A1 A VB O
a WO2013147183A1 A DT O
novel WO2013147183A1 A JJ O
triazinone WO2013147183A1 A NN O
compound WO2013147183A1 A NN O
which WO2013147183A1 A WDT O
has WO2013147183A1 A VBZ O
an WO2013147183A1 A DT O
inhibitory WO2013147183A1 A JJ O
activity WO2013147183A1 A NN O
on WO2013147183A1 A IN O
a WO2013147183A1 A DT O
T-type WO2013147183A1 A JJ I-UN
voltage-dependent WO2013147183A1 A JJ I-UN
calcium WO2013147183A1 A NN I-UN
channel WO2013147183A1 A NN I-UN
and WO2013147183A1 A CC O
is WO2013147183A1 A VBZ O
useful WO2013147183A1 A JJ O
particularly WO2013147183A1 A RB O
for WO2013147183A1 A IN O
the WO2013147183A1 A DT O
treatment WO2013147183A1 A NN O
of WO2013147183A1 A IN O
pain WO2013147183A1 A NN O
. WO2013147183A1 A . O

An CN101007052A T DT O
antitumor CN101007052A T NN O
medicine CN101007052A T NN O
and CN101007052A T CC O
its CN101007052A T PRP$ O
preparation CN101007052A T NN O
method CN101007052A T NN O
. CN101007052A T . O

Anticancer CN101332199A T NNP O
composition CN101332199A T NN O
containing CN101332199A T VBG O
phosphoinositide CN101332199A T JJ I-UN
3-kinase CN101332199A T JJ I-UN
inhibitor CN101332199A T NN O
and CN101332199A T CC O
topology CN101332199A T NN O
enzyme CN101332199A T NN O
inhibitor CN101332199A T NN O
. CN101332199A T . O

An CN101332199A A DT O
anti-cancer CN101332199A A JJ O
combination CN101332199A A NN O
containing CN101332199A A VBG O
a CN101332199A A DT O
phosphoinositide3-kinase CN101332199A A JJ I-UN
inhibitor CN101332199A A NN O
( CN101332199A A ( O
PI3Ki CN101332199A A NNP O
) CN101332199A A ) O
and/or CN101332199A A VBZ O
a CN101332199A A DT O
topoisomerase CN101332199A A NN I-UN
inhibitor CN101332199A A NN O
is CN101332199A A VBZ O
a CN101332199A A DT O
sustained-release CN101332199A A JJ O
injection CN101332199A A NN O
, CN101332199A A , O
which CN101332199A A WDT O
contains CN101332199A A VBZ O
a CN101332199A A DT O
sustained-release CN101332199A A NN O
microsphere CN101332199A A NN O
and CN101332199A A CC O
a CN101332199A A DT O
menstruum CN101332199A A NN O
. CN101332199A A . O

The CN101332199A A DT O
sustained-release CN101332199A A NN O
microsphere CN101332199A A NN O
contains CN101332199A A VBZ O
PI3Ki CN101332199A A NNP O
and/or CN101332199A A NN O
topoisomerase CN101332199A A NN I-UN
inhibitor CN101332199A A NN O
and CN101332199A A CC O
sustained-release CN101332199A A JJ O
auxiliary CN101332199A A JJ O
materials CN101332199A A NNS O
; CN101332199A A : O
the CN101332199A A DT O
menstruum CN101332199A A NN O
is CN101332199A A VBZ O
an CN101332199A A DT O
ordinary CN101332199A A JJ O
menstruum CN101332199A A NN O
or CN101332199A A CC O
a CN101332199A A DT O
special CN101332199A A JJ O
menstruum CN101332199A A NN O
containing CN101332199A A VBG O
a CN101332199A A DT O
suspending CN101332199A A NN O
agent CN101332199A A NN O
. CN101332199A A . O

Application CN103467421A T NN O
of CN103467421A T IN O
radix CN103467421A T NN O
stemonae CN103467421A T NN O
sessilifoliae CN103467421A T VBD O
non-alkaloid CN103467421A T JJ O
extract CN103467421A T NN O
and CN103467421A T CC O
monomers CN103467421A T NNS O
to CN103467421A T TO O
preparation CN103467421A T NN O
of CN103467421A T IN O
antitumor CN103467421A T JJ O
drug CN103467421A T NN O
. CN103467421A T . O

Vertebrate US7144997 T NNP O
embryonic US7144997 T JJ O
patterning-inducing US7144997 T NN O
proteins US7144997 T NNS O
, US7144997 T , O
compositions US7144997 T NNS O
and US7144997 T CC O
uses US7144997 T NNS O
related US7144997 T VBN O
therto US7144997 T NNS O
. US7144997 T . O

Heterocyclic WO2007022946A1 T NNP O
compounds WO2007022946A1 T NNS O
and WO2007022946A1 T CC O
their WO2007022946A1 T PRP$ O
use WO2007022946A1 T NN O
as WO2007022946A1 T IN O
binding WO2007022946A1 T VBG O
partners WO2007022946A1 T NNS O
for WO2007022946A1 T IN O
5-ht5 WO2007022946A1 T JJ I-UN
receptors WO2007022946A1 T NNS O
. WO2007022946A1 T . O

The WO2007022946A1 A DT O
invention WO2007022946A1 A NN O
also WO2007022946A1 A RB O
relates WO2007022946A1 A VBZ O
to WO2007022946A1 A TO O
the WO2007022946A1 A DT O
use WO2007022946A1 A NN O
of WO2007022946A1 A IN O
said WO2007022946A1 A VBD O
compounds WO2007022946A1 A NNS O
as WO2007022946A1 A IN O
binding WO2007022946A1 A VBG O
partners WO2007022946A1 A NNS O
for WO2007022946A1 A IN O
5-HT5 WO2007022946A1 A JJ I-UN
receptors WO2007022946A1 A NNS O
for WO2007022946A1 A IN O
treating WO2007022946A1 A VBG O
diseases WO2007022946A1 A NNS O
that WO2007022946A1 A WDT O
are WO2007022946A1 A VBP O
modulated WO2007022946A1 A VBN O
by WO2007022946A1 A IN O
a WO2007022946A1 A DT O
5-HT5 WO2007022946A1 A JJ I-UN
receptor WO2007022946A1 A NN O
activity WO2007022946A1 A NN O
, WO2007022946A1 A , O
in WO2007022946A1 A IN O
particular WO2007022946A1 A JJ O
, WO2007022946A1 A , O
for WO2007022946A1 A IN O
treating WO2007022946A1 A VBG O
neurodegenerative WO2007022946A1 A JJ O
and WO2007022946A1 A CC O
neuropsychiatric WO2007022946A1 A JJ O
disorders WO2007022946A1 A NNS O
as WO2007022946A1 A RB O
well WO2007022946A1 A RB O
as WO2007022946A1 A IN O
signs WO2007022946A1 A NNS O
, WO2007022946A1 A , O
symptoms WO2007022946A1 A NNS O
and WO2007022946A1 A CC O
dysfunctions WO2007022946A1 A NNS O
. WO2007022946A1 A . O

Extended US20120041068 T VBN O
Release US20120041068 T NNP O
Pharmaceutical US20120041068 T NNP O
Preparations US20120041068 T NNP O
for US20120041068 T IN O
Active US20120041068 T NNP O
Pharmaceutical US20120041068 T NNP O
Ingredients US20120041068 T NNP O
with US20120041068 T IN O
pH US20120041068 T JJ O
Dependent US20120041068 T NNP O
Solubility US20120041068 T NNP O
. US20120041068 T . O

Mcl-1 WO2013112878A1 T JJ I-UN
modulating WO2013112878A1 T NN O
compositions WO2013112878A1 T NNS O
. WO2013112878A1 T . O

The WO2013112878A1 A DT O
present WO2013112878A1 A JJ O
invention WO2013112878A1 A NN O
relates WO2013112878A1 A VBZ O
to WO2013112878A1 A TO O
marinopyrrole WO2013112878A1 A VB O
A WO2013112878A1 A NNP O
derivatives WO2013112878A1 A NNS O
and WO2013112878A1 A CC O
pyoluteorin WO2013112878A1 A NN O
derivatives WO2013112878A1 A NNS O
and WO2013112878A1 A CC O
methods WO2013112878A1 A NNS O
of WO2013112878A1 A IN O
treatment WO2013112878A1 A NN O
of WO2013112878A1 A IN O
disorders WO2013112878A1 A NNS O
associated WO2013112878A1 A VBN O
with WO2013112878A1 A IN O
misregulation WO2013112878A1 A NN O
of WO2013112878A1 A IN O
Mcl-l WO2013112878A1 A NNP I-UN
, WO2013112878A1 A , O
e.g. WO2013112878A1 A NN O
, WO2013112878A1 A , O
leukemia WO2013112878A1 A NN O
, WO2013112878A1 A , O
lymphoma WO2013112878A1 A NN O
, WO2013112878A1 A , O
multiple WO2013112878A1 A JJ O
myeloma WO2013112878A1 A NN O
, WO2013112878A1 A , O
melanoma WO2013112878A1 A NN O
, WO2013112878A1 A , O
or WO2013112878A1 A CC O
pancreatic WO2013112878A1 A JJ O
cancer WO2013112878A1 A NN O
. WO2013112878A1 A . O

We WO2013112878A1 A PRP O
describe WO2013112878A1 A VBP O
exemplary WO2013112878A1 A JJ O
compounds WO2013112878A1 A NNS O
, WO2013112878A1 A , O
which WO2013112878A1 A WDT O
may WO2013112878A1 A MD O
be WO2013112878A1 A VB O
contained WO2013112878A1 A VBN O
in WO2013112878A1 A IN O
pharmaceutical WO2013112878A1 A JJ O
compositions WO2013112878A1 A NNS O
, WO2013112878A1 A , O
and WO2013112878A1 A CC O
their WO2013112878A1 A PRP$ O
use WO2013112878A1 A NN O
as WO2013112878A1 A IN O
therapeutic WO2013112878A1 A JJ O
agents WO2013112878A1 A NNS O
either WO2013112878A1 A CC O
alone WO2013112878A1 A RB O
or WO2013112878A1 A CC O
in WO2013112878A1 A IN O
combination WO2013112878A1 A NN O
with WO2013112878A1 A IN O
other WO2013112878A1 A JJ O
anti-cancer WO2013112878A1 A JJ O
treatments WO2013112878A1 A NNS O
, WO2013112878A1 A , O
e.g. WO2013112878A1 A NN O
, WO2013112878A1 A , O
anti-Bcl- WO2013112878A1 A JJ O
2 WO2013112878A1 A CD I-UN
agents WO2013112878A1 A NNS O
. WO2013112878A1 A . O

Pharmaceutical WO2011013668A1 T JJ O
composition WO2011013668A1 T NN O
for WO2011013668A1 T IN O
treatment WO2011013668A1 T NN O
of WO2011013668A1 T IN O
ischemic WO2011013668A1 T JJ O
events WO2011013668A1 T NNS O
. WO2011013668A1 T . O

Disclosed WO2011013668A1 A VBN O
is WO2011013668A1 A VBZ O
a WO2011013668A1 A DT O
therapeutic WO2011013668A1 A JJ O
pharmaceutical WO2011013668A1 A JJ O
composition WO2011013668A1 A NN O
comprising WO2011013668A1 A VBG O
a WO2011013668A1 A DT O
thrombolytic WO2011013668A1 A JJ O
agent WO2011013668A1 A NN O
and WO2011013668A1 A CC O
an WO2011013668A1 A DT O
inhibitor WO2011013668A1 A NN O
capable WO2011013668A1 A JJ O
of WO2011013668A1 A IN O
inhibiting WO2011013668A1 A VBG O
a WO2011013668A1 A DT O
signaling WO2011013668A1 A NN O
that WO2011013668A1 A WDT O
is WO2011013668A1 A VBZ O
mediated WO2011013668A1 A VBN O
by WO2011013668A1 A IN O
a WO2011013668A1 A DT O
receptor WO2011013668A1 A NN O
of WO2011013668A1 A IN O
a WO2011013668A1 A DT O
vascular WO2011013668A1 A JJ I-UN
endothelial WO2011013668A1 A JJ I-UN
growth WO2011013668A1 A NN I-UN
factor WO2011013668A1 A NN I-UN
( WO2011013668A1 A ( O
VEGF WO2011013668A1 A NNP I-UN
) WO2011013668A1 A ) O
. WO2011013668A1 A . O

Adhesive WO2010038647A1 T JJ O
patch WO2010038647A1 T NN O
and WO2010038647A1 T CC O
adhesive WO2010038647A1 T JJ O
patch WO2010038647A1 T NN O
kit WO2010038647A1 T NN O
. WO2010038647A1 T . O

Use US20110034486 T NNP O
of US20110034486 T IN O
pterocarpans US20110034486 T NNS O
as US20110034486 T IN O
active US20110034486 T JJ O
anti-cellulite US20110034486 T JJ O
ingredients US20110034486 T NNS O
. US20110034486 T . O

Amide WO2007086799A1 T RB O
substituted WO2007086799A1 T VBN O
quinolines WO2007086799A1 T NNS O
. WO2007086799A1 T . O

Treatment CA2589561A1 T NN O
of CA2589561A1 T IN O
neurodegenerative CA2589561A1 T JJ O
diseases CA2589561A1 T NNS O
by CA2589561A1 T IN O
the CA2589561A1 T DT O
use CA2589561A1 T NN O
of CA2589561A1 T IN O
laptm4a CA2589561A1 T NN O
. CA2589561A1 T . O

Hereby CA2589561A1 A NNP O
the CA2589561A1 A DT O
LAPTM4A-interacting CA2589561A1 A NNP O
molecule CA2589561A1 A NN O
is CA2589561A1 A VBZ O
preferably CA2589561A1 A RB O
an CA2589561A1 A DT O
inhibitor CA2589561A1 A NN O
of CA2589561A1 A IN O
LAPTM4A CA2589561A1 A NNP I-UN
and CA2589561A1 A CC O
particularly CA2589561A1 A RB O
it CA2589561A1 A PRP O
has CA2589561A1 A VBZ O
the CA2589561A1 A DT O
capacity CA2589561A1 A NN O
to CA2589561A1 A TO O
modulate CA2589561A1 A VB O
the CA2589561A1 A DT O
activity CA2589561A1 A NN O
of CA2589561A1 A IN O
gamma-secretase CA2589561A1 A JJ I-UN
and/or CA2589561A1 A JJ O
beta-secretase CA2589561A1 A NN I-UN
. CA2589561A1 A . O

Furthermore CA2589561A1 A RB O
the CA2589561A1 A DT O
invention CA2589561A1 A NN O
concerns CA2589561A1 A VBZ O
a CA2589561A1 A DT O
process CA2589561A1 A NN O
for CA2589561A1 A IN O
identifying CA2589561A1 A VBG O
a CA2589561A1 A DT O
gamma-secretase CA2589561A1 A JJ I-UN
and/or CA2589561A1 A NN O
a CA2589561A1 A DT O
beta-secretase CA2589561A1 A JJ I-UN
modulator CA2589561A1 A NN O
, CA2589561A1 A , O
comprising CA2589561A1 A VBG O
the CA2589561A1 A DT O
following CA2589561A1 A JJ O
steps CA2589561A1 A NNS O
: CA2589561A1 A : O
a. CA2589561A1 A NN O
identifying CA2589561A1 A NN O
of CA2589561A1 A IN O
a CA2589561A1 A DT O
LAPTM4A-interacting CA2589561A1 A JJ O
molecule CA2589561A1 A NN O
by CA2589561A1 A IN O
determining CA2589561A1 A VBG O
whether CA2589561A1 A IN O
a CA2589561A1 A DT O
given CA2589561A1 A VBN O
test CA2589561A1 A NN O
compound CA2589561A1 A NN O
is CA2589561A1 A VBZ O
a CA2589561A1 A DT O
LAPTM4A-interacting CA2589561A1 A JJ O
molecule CA2589561A1 A NN O
, CA2589561A1 A , O
b. CA2589561A1 A IN O
determining CA2589561A1 A VBG O
whether CA2589561A1 A IN O
the CA2589561A1 A DT O
LAPTM4A-interacting CA2589561A1 A NNP O
molecule CA2589561A1 A NN O
of CA2589561A1 A IN O
step CA2589561A1 A NN O
a CA2589561A1 A DT O
) CA2589561A1 A ) O
is CA2589561A1 A VBZ O
capable CA2589561A1 A JJ O
of CA2589561A1 A IN O
modulating CA2589561A1 A VBG O
gamma-secretase CA2589561A1 A JJ I-UN
and/or CA2589561A1 A JJ O
beta-secretase CA2589561A1 A NN I-UN
activity CA2589561A1 A NN O
. CA2589561A1 A . O

2-Amino-3-alkoxy-6-fluorobicyclo US20050119345 T JJ O
[ US20050119345 T NN O
3.1.0 US20050119345 T CD O
] US20050119345 T JJ O
hexane-2,6-dicarboxylic US20050119345 T JJ O
acid US20050119345 T NN O
derivatives US20050119345 T NNS O
; US20050119345 T : O
effective US20050119345 T JJ O
for US20050119345 T IN O
treating US20050119345 T VBG O
and US20050119345 T CC O
preventing US20050119345 T VBG O
psychiatric US20050119345 T JJ O
disorders US20050119345 T NNS O
such US20050119345 T JJ O
as US20050119345 T IN O
schizophrenia US20050119345 T NN O
, US20050119345 T , O
anxiety US20050119345 T NN O
, US20050119345 T , O
bipolar US20050119345 T JJ O
disorder US20050119345 T NN O
and US20050119345 T CC O
epilepsy US20050119345 T NN O
, US20050119345 T , O
neurological US20050119345 T JJ O
diseases US20050119345 T NNS O
such US20050119345 T JJ O
as US20050119345 T IN O
drug US20050119345 T NN O
dependence US20050119345 T NN O
, US20050119345 T , O
Alzheimer US20050119345 T NNP O
's US20050119345 T POS O
disease US20050119345 T NN O
, US20050119345 T , O
Huntington US20050119345 T NNP O
's US20050119345 T POS O
chorea US20050119345 T NN O
. US20050119345 T . O

An US20050119345 A DT O
antidepressant US20050119345 A JJ O
comprising US20050119345 A NN O
, US20050119345 A , O
as US20050119345 A IN O
an US20050119345 A DT O
active US20050119345 A JJ O
ingredient US20050119345 A NN O
, US20050119345 A , O
a US20050119345 A DT O
compound US20050119345 A NN O
having US20050119345 A VBG O
an US20050119345 A DT O
antagonistic US20050119345 A JJ O
effect US20050119345 A NN O
on US20050119345 A IN O
group US20050119345 A NN I-UN
II US20050119345 A NNP I-UN
metabotropic US20050119345 A NN I-UN
glutamate US20050119345 A NN I-UN
receptors US20050119345 A NNS I-UN
, US20050119345 A , O
as US20050119345 A RB O
well US20050119345 A RB O
as US20050119345 A IN O
a US20050119345 A DT O
2-amino-3-alkoxy-6-fluoro-bicyclo US20050119345 A JJ O
[ US20050119345 A NN O
3.1.0 US20050119345 A CD O
] US20050119345 A JJ O
hexane-2,6-dicarboxylic US20050119345 A JJ O
acid US20050119345 A NN O
derivative US20050119345 A NN O
of US20050119345 A IN O
Formula US20050119345 A NNP O
[ US20050119345 A NNP O
I US20050119345 A PRP O
] US20050119345 A VBP O
: US20050119345 A : O
[ US20050119345 A NN O
wherein US20050119345 A NN O
R1 US20050119345 A NNP O
and US20050119345 A CC O
R2 US20050119345 A NNP O
, US20050119345 A , O
which US20050119345 A WDT O
may US20050119345 A MD O
be US20050119345 A VB O
the US20050119345 A DT O
same US20050119345 A JJ O
or US20050119345 A CC O
different US20050119345 A JJ O
, US20050119345 A , O
each US20050119345 A DT O
represent US20050119345 A NN O
a US20050119345 A DT O
hydroxyl US20050119345 A NN O
group US20050119345 A NN O
, US20050119345 A , O
a US20050119345 A DT O
C1-10 US20050119345 A NNP O
alkoxy US20050119345 A NN O
group US20050119345 A NN O
, US20050119345 A , O
etc US20050119345 A FW O
. US20050119345 A . O

Application CN102885807A T NN O
of CN102885807A T IN O
Aphanamixoid CN102885807A T NNP O
A CN102885807A T NNP O
to CN102885807A T TO O
preparation CN102885807A T NN O
of CN102885807A T IN O
drug CN102885807A T NN O
for CN102885807A T IN O
promoting CN102885807A T VBG O
intestinal CN102885807A T JJ O
peristalsis CN102885807A T NN O
. CN102885807A T . O

Chewing CA2601795A1 T VBG O
gum CA2601795A1 T JJ O
compositions CA2601795A1 T NNS O
of CA2601795A1 T IN O
varenicline CA2601795A1 T NN O
. CA2601795A1 T . O

Curcumin CN103720675A T NNP O
prodrug CN103720675A T NN O
micelle CN103720675A T NN O
with CN103720675A T IN O
oxidation CN103720675A T NN O
and CN103720675A T CC O
reduction CN103720675A T NN O
sensitivity CN103720675A T NN O
, CN103720675A T , O
micellar CN103720675A T JJ O
monomer CN103720675A T NN O
and CN103720675A T CC O
preparation CN103720675A T NN O
method CN103720675A T NN O
of CN103720675A T IN O
micellar CN103720675A T JJ O
monomer CN103720675A T NN O
. CN103720675A T . O

Gastric DE102010022587A1 T JJ O
juice-resistant DE102010022587A1 T JJ O
composition DE102010022587A1 T NN O
for DE102010022587A1 T IN O
oral DE102010022587A1 T JJ O
ingestion DE102010022587A1 T NN O
of DE102010022587A1 T IN O
plant-based DE102010022587A1 T JJ O
components DE102010022587A1 T NNS O
, DE102010022587A1 T , O
useful DE102010022587A1 T JJ O
for DE102010022587A1 T IN O
preventing DE102010022587A1 T VBG O
colorectal DE102010022587A1 T JJ O
cancer DE102010022587A1 T NN O
, DE102010022587A1 T , O
comprises DE102010022587A1 T VBZ O
glucosinolate DE102010022587A1 T NN O
, DE102010022587A1 T , O
and DE102010022587A1 T CC O
a DE102010022587A1 T DT O
construct DE102010022587A1 T NN O
of DE102010022587A1 T IN O
glucan-melanin-chitin DE102010022587A1 T NN O
complex DE102010022587A1 T NN O
coated DE102010022587A1 T VBN O
with DE102010022587A1 T IN O
plant-based DE102010022587A1 T JJ O
component DE102010022587A1 T NN O
. DE102010022587A1 T . O

Gastric DE102010022587A1 A JJ O
juice-resistant DE102010022587A1 A JJ O
composition DE102010022587A1 A NN O
for DE102010022587A1 A IN O
oral DE102010022587A1 A JJ O
ingestion DE102010022587A1 A NN O
of DE102010022587A1 A IN O
plant-based DE102010022587A1 A JJ O
components DE102010022587A1 A NNS O
for DE102010022587A1 A IN O
preventing DE102010022587A1 A VBG O
colorectal DE102010022587A1 A JJ O
cancer DE102010022587A1 A NN O
comprises DE102010022587A1 A NNS O
: DE102010022587A1 A : O
a DE102010022587A1 A DT O
glucosinolate DE102010022587A1 A NN O
or DE102010022587A1 A CC O
a DE102010022587A1 A DT O
mixture DE102010022587A1 A NN O
of DE102010022587A1 A IN O
glucosinolates DE102010022587A1 A NNS O
, DE102010022587A1 A , O
which DE102010022587A1 A WDT O
are DE102010022587A1 A VBP O
coated DE102010022587A1 A VBN O
with DE102010022587A1 A IN O
a DE102010022587A1 A DT O
gastric DE102010022587A1 A JJ O
juice-resistant DE102010022587A1 A JJ O
layer DE102010022587A1 A NN O
; DE102010022587A1 A : O
and DE102010022587A1 A CC O
at DE102010022587A1 A IN O
least DE102010022587A1 A JJS O
one DE102010022587A1 A CD O
three-dimensional DE102010022587A1 A JJ O
construct DE102010022587A1 A NN O
of DE102010022587A1 A IN O
a DE102010022587A1 A DT O
glucan-melanin-chitin DE102010022587A1 A JJ O
complex DE102010022587A1 A NN O
, DE102010022587A1 A , O
which DE102010022587A1 A WDT O
is DE102010022587A1 A VBZ O
coated DE102010022587A1 A VBN O
with DE102010022587A1 A IN O
at DE102010022587A1 A IN O
least DE102010022587A1 A JJS O
one DE102010022587A1 A CD O
plant-based DE102010022587A1 A JJ O
component DE102010022587A1 A NN O
, DE102010022587A1 A , O
where DE102010022587A1 A WRB O
the DE102010022587A1 A DT O
respective DE102010022587A1 A JJ O
component DE102010022587A1 A NN O
layer DE102010022587A1 A NN O
applied DE102010022587A1 A VBN O
on DE102010022587A1 A IN O
the DE102010022587A1 A DT O
glucan-melanin-chitin DE102010022587A1 A NN O
complex DE102010022587A1 A NN O
is DE102010022587A1 A VBZ O
respectively DE102010022587A1 A RB O
coated DE102010022587A1 A VBN O
with DE102010022587A1 A IN O
a DE102010022587A1 A DT O
separating DE102010022587A1 A VBG O
layer DE102010022587A1 A NN O
soluble DE102010022587A1 A JJ O
in DE102010022587A1 A IN O
the DE102010022587A1 A DT O
intestine DE102010022587A1 A NN O
for DE102010022587A1 A IN O
isolating DE102010022587A1 A VBG O
an DE102010022587A1 A DT O
additional DE102010022587A1 A JJ O
plant-based DE102010022587A1 A JJ O
component DE102010022587A1 A NN O
present DE102010022587A1 A NN O
in DE102010022587A1 A IN O
the DE102010022587A1 A DT O
composition DE102010022587A1 A NN O
. DE102010022587A1 A . O

- DE102010022587A1 A : O
ACTIVITY DE102010022587A1 A NN O
: DE102010022587A1 A : O
Cytostatic DE102010022587A1 A JJ O
. DE102010022587A1 A . O

No DE102010022587A1 A DT O
biological DE102010022587A1 A JJ O
data DE102010022587A1 A NNS O
given DE102010022587A1 A VBN O
. DE102010022587A1 A . O

- DE102010022587A1 A : O
MECHANISM DE102010022587A1 A NN O
OF DE102010022587A1 A IN O
ACTION DE102010022587A1 A NNP O
: DE102010022587A1 A : O
None DE102010022587A1 A NN O
given DE102010022587A1 A VBN O
. DE102010022587A1 A . O

DNA US7700765 T NN O
minor US7700765 T JJ O
groove US7700765 T NN O
binding US7700765 T VBG O
compounds US7700765 T NNS O
. US7700765 T . O

There US7700765 A EX O
is US7700765 A VBZ O
provided US7700765 A VBN O
an US7700765 A DT O
oligopeptide US7700765 A JJ O
compound US7700765 A NN O
comprising US7700765 A NN O
: US7700765 A : O
( US7700765 A ( O
a US7700765 A DT O
) US7700765 A ) O
at US7700765 A IN O
least US7700765 A JJS O
one US7700765 A CD O
nitrogen-containing US7700765 A JJ O
basic US7700765 A JJ O
group US7700765 A NN O
attached US7700765 A VBD O
to US7700765 A TO O
at US7700765 A IN O
least US7700765 A JJS O
one US7700765 A CD O
end US7700765 A NN O
of US7700765 A IN O
the US7700765 A DT O
oligopeptide US7700765 A NN O
; US7700765 A : O
and US7700765 A CC O
( US7700765 A ( O
b US7700765 A NN O
) US7700765 A ) O
two US7700765 A CD O
or US7700765 A CC O
more US7700765 A JJR O
heterocyclic US7700765 A JJ O
monomers US7700765 A NNS O
, US7700765 A , O
at US7700765 A IN O
least US7700765 A JJS O
one US7700765 A CD O
of US7700765 A IN O
which US7700765 A WDT O
is US7700765 A VBZ O
substituted US7700765 A VBN O
in US7700765 A IN O
the US7700765 A DT O
heterocyclic US7700765 A JJ O
part US7700765 A NN O
by US7700765 A IN O
a US7700765 A DT O
branched US7700765 A VBN O
, US7700765 A , O
cyclic US7700765 A JJ O
or US7700765 A CC O
part US7700765 A NN O
cyclic US7700765 A JJ O
C3-5 US7700765 A NNP O
alkyl US7700765 A NN O
group US7700765 A NN O
, US7700765 A , O
or US7700765 A CC O
a US7700765 A DT O
pharmaceutically US7700765 A RB O
acceptable US7700765 A JJ O
salt US7700765 A NN O
or US7700765 A CC O
solvate US7700765 A NN O
thereof US7700765 A NN O
; US7700765 A : O
which US7700765 A WDT O
compound US7700765 A NN O
, US7700765 A , O
salt US7700765 A NN O
or US7700765 A CC O
solvate US7700765 A VB O
binds US7700765 A NNS O
to US7700765 A TO O
the US7700765 A DT O
minor US7700765 A JJ O
groove US7700765 A NN O
of US7700765 A IN O
DNA US7700765 A NNP O
. US7700765 A . O

Composition WO2014035961A1 T NN O
and WO2014035961A1 T CC O
use WO2014035961A1 T NN O
for WO2014035961A1 T IN O
increasing WO2014035961A1 T VBG O
t WO2014035961A1 T NN O
cells WO2014035961A1 T NNS O
. WO2014035961A1 T . O

Drug US20080279954 T NN O
delivery US20080279954 T NN O
; US20080279954 T : O
therapeutic US20080279954 T JJ O
agent US20080279954 T NN O
and US20080279954 T CC O
crosslinked US20080279954 T VBD O
polymer US20080279954 T NN O
network US20080279954 T NN O
. US20080279954 T . O

Novel US20130053376 T NNP O
tyrosine US20130053376 T NN O
kinase US20130053376 T NN O
inhibitors US20130053376 T NNS O
. US20130053376 T . O

S-omeprazole CN101129367B T JJ O
solid CN101129367B T JJ O
dispersion CN101129367B T NN O
and CN101129367B T CC O
composition CN101129367B T NN O
containing CN101129367B T VBG O
the CN101129367B T DT O
dispersion CN101129367B T NN O
. CN101129367B T . O

Methods US20120213803 T NNS O
for US20120213803 T IN O
diagnosing US20120213803 T VBG O
and US20120213803 T CC O
treating US20120213803 T VBG O
encephalitis US20120213803 T NN O
or US20120213803 T CC O
epilepsy US20120213803 T NN O
. US20120213803 T . O

This US20120213803 A DT O
invention US20120213803 A NN O
provides US20120213803 A VBZ O
methods US20120213803 A NNS O
of US20120213803 A IN O
diagnosing US20120213803 A VBG O
or US20120213803 A CC O
determining US20120213803 A VBG O
a US20120213803 A DT O
cause US20120213803 A NN O
of US20120213803 A IN O
an US20120213803 A DT O
autoimmune US20120213803 A JJ O
encephalitis US20120213803 A NN O
or US20120213803 A CC O
an US20120213803 A DT O
epilepsy US20120213803 A NN O
in US20120213803 A IN O
a US20120213803 A DT O
subject US20120213803 A NN O
and US20120213803 A CC O
of US20120213803 A IN O
diagnosing US20120213803 A VBG O
a US20120213803 A DT O
tumor US20120213803 A NN O
in US20120213803 A IN O
a US20120213803 A DT O
subject US20120213803 A NN O
, US20120213803 A , O
comprising US20120213803 A VBG O
the US20120213803 A DT O
step US20120213803 A NN O
of US20120213803 A IN O
testing US20120213803 A VBG O
a US20120213803 A DT O
biological US20120213803 A JJ O
sample US20120213803 A NN O
of US20120213803 A IN O
the US20120213803 A DT O
subject US20120213803 A NN O
for US20120213803 A IN O
an US20120213803 A DT O
anti-body US20120213803 A NN O
to US20120213803 A TO O
a US20120213803 A DT O
GABAB US20120213803 A NNP I-UN
receptor US20120213803 A NN I-UN
. US20120213803 A . O

This US20120213803 A DT O
invention US20120213803 A NN O
further US20120213803 A RB O
provides US20120213803 A VBZ O
methods US20120213803 A NNS O
of US20120213803 A IN O
treating US20120213803 A VBG O
an US20120213803 A DT O
autoimmune US20120213803 A JJ O
encephalitis US20120213803 A NN O
or US20120213803 A CC O
an US20120213803 A DT O
epilepsy US20120213803 A NN O
, US20120213803 A , O
comprising US20120213803 A VBG O
the US20120213803 A DT O
steps US20120213803 A NNS O
of US20120213803 A IN O
detecting US20120213803 A VBG O
an US20120213803 A DT O
antibody US20120213803 A NN O
to US20120213803 A TO O
a US20120213803 A DT O
GABAB US20120213803 A NNP I-UN
receptor US20120213803 A NN I-UN
and US20120213803 A CC O
treating US20120213803 A VBG O
a US20120213803 A DT O
tumor US20120213803 A NN O
associated US20120213803 A VBN O
with US20120213803 A IN O
the US20120213803 A DT O
disease US20120213803 A NN O
. US20120213803 A . O

16-site CN101190914B T JJ O
substituted CN101190914B T VBD O
double CN101190914B T JJ O
functional CN101190914B T JJ O
group CN101190914B T NN O
huperzine CN101190914B T NN O
B CN101190914B T NNP O
derivative CN101190914B T NN O
, CN101190914B T , O
preparation CN101190914B T NN O
method CN101190914B T NN O
and CN101190914B T CC O
use CN101190914B T NN O
thereof CN101190914B T NN O
. CN101190914B T . O

The CN101190914B A DT O
derivative CN101190914B A NN O
provided CN101190914B A VBN O
in CN101190914B A IN O
the CN101190914B A DT O
invention CN101190914B A NN O
also CN101190914B A RB O
expresses CN101190914B A VBZ O
higher CN101190914B A JJR O
inhibitory CN101190914B A JJ O
activity CN101190914B A NN O
of CN101190914B A IN O
acetylcholinesterase CN101190914B A NN I-UN
than CN101190914B A IN O
that CN101190914B A DT O
of CN101190914B A IN O
the CN101190914B A DT O
lead CN101190914B A JJ O
compound CN101190914B A NN O
of CN101190914B A IN O
the CN101190914B A DT O
huperzine CN101190914B A NN O
B CN101190914B A NNP O
in CN101190914B A IN O
a CN101190914B A DT O
test CN101190914B A NN O
of CN101190914B A IN O
vitro CN101190914B A JJ O
bioactivity CN101190914B A NN O
. CN101190914B A . O

The CN101190914B A DT O
huperzine CN101190914B A NN O
B CN101190914B A NNP O
derivative CN101190914B A NN O
with CN101190914B A IN O
16 CN101190914B A CD O
substituted CN101190914B A JJ O
dual CN101190914B A JJ O
function CN101190914B A NN O
groups CN101190914B A NNS O
has CN101190914B A VBZ O
relatively CN101190914B A RB O
strong CN101190914B A JJ O
inhibiting CN101190914B A VBG O
effect CN101190914B A NN O
on CN101190914B A IN O
butyrylcholine CN101190914B A NN I-UN
esterase CN101190914B A NN I-UN
and CN101190914B A CC O
is CN101190914B A VBZ O
expected CN101190914B A VBN O
to CN101190914B A TO O
become CN101190914B A VB O
a CN101190914B A DT O
candidate CN101190914B A JJ O
drug CN101190914B A NN O
with CN101190914B A IN O
high CN101190914B A JJ O
therapeutic CN101190914B A JJ O
index CN101190914B A NN O
and CN101190914B A CC O
little CN101190914B A JJ O
side CN101190914B A NN O
effect CN101190914B A NN O
to CN101190914B A TO O
treat CN101190914B A VB O
degenerative CN101190914B A JJ O
brain CN101190914B A NN O
disorder CN101190914B A NN O
after CN101190914B A IN O
further CN101190914B A JJ O
optimization CN101190914B A NN O
and CN101190914B A CC O
screening CN101190914B A NN O
. CN101190914B A . O

Tert-butyl-substituted EP1834959A2 T JJ O
aromatic EP1834959A2 T JJ O
steroids EP1834959A2 T NNS O
having EP1834959A2 T VBG O
cytoprotective EP1834959A2 T JJ O
activity EP1834959A2 T NN O
. EP1834959A2 T . O

Anti-inflammatory US20100135983 T JJ O
compositions US20100135983 T NNS O
and US20100135983 T CC O
methods US20100135983 T NNS O
. US20100135983 T . O

According US20100135983 A VBG O
to US20100135983 A TO O
various US20100135983 A JJ O
embodiments US20100135983 A NNS O
, US20100135983 A , O
the US20100135983 A DT O
compositions US20100135983 A NNS O
, US20100135983 A , O
methods US20100135983 A NNS O
, US20100135983 A , O
devices US20100135983 A NNS O
, US20100135983 A , O
and US20100135983 A CC O
systems US20100135983 A NNS O
relate US20100135983 A VBP O
to US20100135983 A TO O
modulating US20100135983 A VBG O
one US20100135983 A CD O
or US20100135983 A CC O
more US20100135983 A JJR O
of US20100135983 A IN O
Toll-like US20100135983 A JJ I-UN
receptors US20100135983 A NNS I-UN
, US20100135983 A , O
Src US20100135983 A NNP I-UN
family US20100135983 A NN O
kinases US20100135983 A NNS O
, US20100135983 A , O
NF-kB US20100135983 A NNP I-UN
molecules US20100135983 A NNS O
, US20100135983 A , O
proteases US20100135983 A NNS I-UN
, US20100135983 A , O
or US20100135983 A CC O
proteasomes US20100135983 A NNS I-UN
. US20100135983 A . O

DIAMIDE WO2010123766A1 T NNP O
COMPOUNDS WO2010123766A1 T NNP O
HAVING WO2010123766A1 T NNP O
MUSCARINIC WO2010123766A1 T NNP I-UN
RECEPTOR WO2010123766A1 T NNP I-UN
ANTAGONIST WO2010123766A1 T NNP O
AND WO2010123766A1 T NNP O
β2 WO2010123766A1 T NNP I-UN
ADRENERGIC WO2010123766A1 T NNP I-UN
RECEPTOR WO2010123766A1 T NNP I-UN
AGONIST WO2010123766A1 T NNP O
ACTIVITY WO2010123766A1 T NNP O
. WO2010123766A1 T . O

Such WO2010123766A1 A JJ O
compounds WO2010123766A1 A NNS O
possess WO2010123766A1 A VBP O
both WO2010123766A1 A DT O
muscarinic WO2010123766A1 A JJ I-UN
receptor WO2010123766A1 A NN I-UN
antagonist WO2010123766A1 A NN O
and WO2010123766A1 A CC O
β2 WO2010123766A1 A NNP I-UN
adrenergic WO2010123766A1 A VBP I-UN
receptor WO2010123766A1 A NN I-UN
agonist WO2010123766A1 A NN O
activities WO2010123766A1 A NNS O
. WO2010123766A1 A . O

Sobering-up CN101284058A T JJ O
agent CN101284058A T NN O
and CN101284058A T CC O
its CN101284058A T PRP$ O
preparation CN101284058A T NN O
process CN101284058A T NN O
. CN101284058A T . O

Product US20120107410 T NN O
for US20120107410 T IN O
the US20120107410 T DT O
preparation US20120107410 T NN O
of US20120107410 T IN O
dermatological US20120107410 T JJ O
, US20120107410 T , O
cosmetic US20120107410 T JJ O
or US20120107410 T CC O
cosmeceutical US20120107410 T JJ O
compositions US20120107410 T NNS O
intended US20120107410 T VBN O
for US20120107410 T IN O
skin US20120107410 T NN O
treatment US20120107410 T NN O
. US20120107410 T . O

The US20120107410 A DT O
present US20120107410 A JJ O
invention US20120107410 A NN O
relates US20120107410 A VBZ O
to US20120107410 A TO O
a US20120107410 A DT O
product US20120107410 A NN O
obtained US20120107410 A VBN O
from US20120107410 A IN O
gastropod US20120107410 A JJ O
spawn US20120107410 A NN O
, US20120107410 A , O
to US20120107410 A TO O
be US20120107410 A VB O
used US20120107410 A VBN O
to US20120107410 A TO O
prepare US20120107410 A VB O
dermatological US20120107410 A JJ O
, US20120107410 A , O
cosmetic US20120107410 A JJ O
or US20120107410 A CC O
cosmeceutical US20120107410 A JJ O
compositions US20120107410 A NNS O
designed US20120107410 A VBN O
for US20120107410 A IN O
skin US20120107410 A NN O
care US20120107410 A NN O
; US20120107410 A : O
said US20120107410 A VBD O
product US20120107410 A NN O
has US20120107410 A VBZ O
the US20120107410 A DT O
capacity US20120107410 A NN O
to US20120107410 A TO O
activate US20120107410 A VB O
and US20120107410 A CC O
mobilise US20120107410 A VB O
skin US20120107410 A JJ O
stem US20120107410 A NN O
cells US20120107410 A NNS O
, US20120107410 A , O
as US20120107410 A RB O
well US20120107410 A RB O
as US20120107410 A IN O
prevent US20120107410 A NN O
the US20120107410 A DT O
loss US20120107410 A NN O
thereof US20120107410 A NN O
that US20120107410 A WDT O
takes US20120107410 A VBZ O
place US20120107410 A NN O
as US20120107410 A IN O
a US20120107410 A DT O
consequence US20120107410 A NN O
of US20120107410 A IN O
chronological US20120107410 A JJ O
and US20120107410 A CC O
premature US20120107410 A JJ O
ageing US20120107410 A NN O
. US20120107410 A . O

The US20120107410 A DT O
present US20120107410 A JJ O
invention US20120107410 A NN O
also US20120107410 A RB O
relates US20120107410 A VBZ O
to US20120107410 A TO O
the US20120107410 A DT O
process US20120107410 A NN O
followed US20120107410 A VBD O
in US20120107410 A IN O
order US20120107410 A NN O
to US20120107410 A TO O
obtain US20120107410 A VB O
said US20120107410 A VBD O
product US20120107410 A NN O
. US20120107410 A . O

Use WO2009109109A1 T NNP O
of WO2009109109A1 T IN O
tea WO2009109109A1 T NN O
polyphenols WO2009109109A1 T NNS O
in WO2009109109A1 T IN O
preparing WO2009109109A1 T VBG O
medicaments WO2009109109A1 T NNS O
for WO2009109109A1 T IN O
prevention WO2009109109A1 T NN O
or WO2009109109A1 T CC O
treatment WO2009109109A1 T NN O
of WO2009109109A1 T IN O
tumors WO2009109109A1 T NNS O
. WO2009109109A1 T . O

Alprazolam CA2401424C T NNP O
inclusion CA2401424C T NN O
complexes CA2401424C T NNS O
and CA2401424C T CC O
pharmaceutical CA2401424C T JJ O
compositions CA2401424C T NNS O
thereof CA2401424C T NN O
. CA2401424C T . O

Unsymmetrical EP2350080A1 T JJ O
pyrrolobenzodiazepine-dimers EP2350080A1 T NNS O
for EP2350080A1 T IN O
treatment EP2350080A1 T NN O
of EP2350080A1 T IN O
proliferative EP2350080A1 T JJ O
diseases EP2350080A1 T NNS O
. EP2350080A1 T . O

Compositions US20100069476 T NNS O
and US20100069476 T CC O
methods US20100069476 T NNS O
for US20100069476 T IN O
reduction US20100069476 T NN O
of US20100069476 T IN O
cutaneous US20100069476 T JJ O
photoageing US20100069476 T NN O
. US20100069476 T . O

Inhibitors US7138417 T NNS O
of US7138417 T IN O
integrin US7138417 T JJ I-UN
αvβ6 US7138417 T NN I-UN
. US7138417 T . O

Novel US7138417 A NNP O
biphenyl US7138417 A NN O
derivatives US7138417 A NNS O
of US7138417 A IN O
the US7138417 A DT O
general US7138417 A JJ O
formula US7138417 A NN O
I US7138417 A PRP O
in US7138417 A IN O
which US7138417 A WDT O
R1 US7138417 A NNP O
, US7138417 A , O
R1′ US7138417 A NNP O
, US7138417 A , O
R1″ US7138417 A NNP O
, US7138417 A , O
R2 US7138417 A NNP O
, US7138417 A , O
R2′ US7138417 A NNP O
, US7138417 A , O
R3 US7138417 A NNP O
and US7138417 A CC O
n US7138417 A RB O
are US7138417 A VBP O
as US7138417 A RB O
defined US7138417 A VBN O
in US7138417 A IN O
Patent US7138417 A NNP O
claim US7138417 A NN O
1 US7138417 A CD O
, US7138417 A , O
stereoisomers US7138417 A NNS O
thereof US7138417 A VBP O
and US7138417 A CC O
physiologically US7138417 A RB O
acceptable US7138417 A JJ O
salts US7138417 A NNS O
or US7138417 A CC O
solvates US7138417 A NNS O
thereof US7138417 A NNS O
are US7138417 A VBP O
novel US7138417 A JJ O
integrin US7138417 A NN O
inhibitors US7138417 A NNS O
which US7138417 A WDT O
preferentially US7138417 A RB O
inhibit US7138417 A VBP O
the US7138417 A DT O
αvβ6 US7138417 A NNP I-UN
integrin US7138417 A NN I-UN
receptor US7138417 A NN O
. US7138417 A . O

Quinazolin-4-one EP2010504A1 T JJ O
derivatives EP2010504A1 T NNS O
, EP2010504A1 T , O
process EP2010504A1 T NN O
for EP2010504A1 T IN O
their EP2010504A1 T PRP$ O
preparation EP2010504A1 T NN O
and EP2010504A1 T CC O
pharmaceutical EP2010504A1 T JJ O
compositions EP2010504A1 T NNS O
containing EP2010504A1 T VBG O
them EP2010504A1 T PRP O
. EP2010504A1 T . O

The EP2010504A1 A DT O
invention EP2010504A1 A NN O
relates EP2010504A1 A VBZ O
to EP2010504A1 A TO O
chemical EP2010504A1 A VB O
compounds EP2010504A1 A NNS O
of EP2010504A1 A IN O
the EP2010504A1 A DT O
formula EP2010504A1 A NN O
( EP2010504A1 A ( O
I EP2010504A1 A PRP O
) EP2010504A1 A ) O
: EP2010504A1 A : O
or EP2010504A1 A CC O
pharmaceutically EP2010504A1 A RB O
acceptable EP2010504A1 A JJ O
salts EP2010504A1 A NNS O
thereof EP2010504A1 A NN O
, EP2010504A1 A , O
which EP2010504A1 A WDT O
possess EP2010504A1 A VBP O
B-Raf EP2010504A1 A NNP I-UN
inhibitory EP2010504A1 A NN O
activity EP2010504A1 A NN O
and EP2010504A1 A CC O
are EP2010504A1 A VBP O
accordingly EP2010504A1 A RB O
useful EP2010504A1 A JJ O
for EP2010504A1 A IN O
their EP2010504A1 A PRP$ O
anti-cancer EP2010504A1 A JJ O
activity EP2010504A1 A NN O
and EP2010504A1 A CC O
thus EP2010504A1 A RB O
in EP2010504A1 A IN O
methods EP2010504A1 A NNS O
of EP2010504A1 A IN O
treatment EP2010504A1 A NN O
of EP2010504A1 A IN O
the EP2010504A1 A DT O
human EP2010504A1 A NN O
or EP2010504A1 A CC O
animal EP2010504A1 A NN O
body EP2010504A1 A NN O
. EP2010504A1 A . O

Compounds US20120316196 T NNS O
Which US20120316196 T WDT O
Have US20120316196 T VBP O
Activity US20120316196 T NNP O
at US20120316196 T IN O
M1 US20120316196 T NNP I-UN
Receptor US20120316196 T NNP I-UN
and US20120316196 T CC O
Their US20120316196 T NNP O
Uses US20120316196 T VBZ O
in US20120316196 T IN O
Medicine US20120316196 T NNP O
. US20120316196 T . O

Modified US8026272 T VBN O
lysine-mimetic US8026272 T JJ O
compounds US8026272 T NNS O
. US8026272 T . O

Preparation CN102188368A T NNP O
technology CN102188368A T NN O
of CN102188368A T IN O
compound CN102188368A T NN O
sodium CN102188368A T NN O
chloride CN102188368A T NN O
eye CN102188368A T NN O
drop CN102188368A T NN O
solution CN102188368A T NN O
. CN102188368A T . O

Injectable CN100581544C T JJ O
pharmaceutical CN100581544C T JJ O
composition CN100581544C T NN O
for CN100581544C T IN O
treatment CN100581544C T NN O
and CN100581544C T CC O
reversal CN100581544C T NN O
of CN100581544C T IN O
erectile CN100581544C T JJ O
dysfunction CN100581544C T NN O
. CN100581544C T . O

Diazaspiro WO2010067102A1 T NNP O
[ WO2010067102A1 T VBD O
5.5 WO2010067102A1 T CD O
] WO2010067102A1 T NNP O
undecane WO2010067102A1 T JJ O
derivatives WO2010067102A1 T NNS O
and WO2010067102A1 T CC O
related WO2010067102A1 T JJ O
compounds WO2010067102A1 T NNS O
as WO2010067102A1 T IN O
muscarinic-receptor WO2010067102A1 T NN O
antagonists WO2010067102A1 T NNS O
and WO2010067102A1 T CC O
beta-adrenoreceptor WO2010067102A1 T NN O
agonists WO2010067102A1 T NNS O
for WO2010067102A1 T IN O
the WO2010067102A1 T DT O
treatment WO2010067102A1 T NN O
of WO2010067102A1 T IN O
pulmonary WO2010067102A1 T JJ O
disorders WO2010067102A1 T NNS O
. WO2010067102A1 T . O

1,4 WO2013026587A1 T CD O
disubstituted WO2013026587A1 T JJ O
pyrrolidine WO2013026587A1 T NN O
- WO2013026587A1 T : O
3 WO2013026587A1 T CD O
- WO2013026587A1 T : O
yl WO2013026587A1 T NN O
-amine WO2013026587A1 T JJ O
derivatives WO2013026587A1 T NNS O
and WO2013026587A1 T CC O
their WO2013026587A1 T PRP$ O
use WO2013026587A1 T NN O
for WO2013026587A1 T IN O
the WO2013026587A1 T DT O
treatment WO2013026587A1 T NN O
of WO2013026587A1 T IN O
metabolic WO2013026587A1 T JJ O
disorders WO2013026587A1 T NNS O
. WO2013026587A1 T . O

The WO2013026587A1 A DT O
compounds WO2013026587A1 A NNS O
have WO2013026587A1 A VBP O
activity WO2013026587A1 A NN O
as WO2013026587A1 A IN O
agonists WO2013026587A1 A NNS O
of WO2013026587A1 A IN O
GPR1 WO2013026587A1 A NNP I-UN
19 WO2013026587A1 A CD I-UN
. WO2013026587A1 A . O

Compounds WO2013026587A1 A NNS O
having WO2013026587A1 A VBG O
stereochemistry WO2013026587A1 A NN O
of WO2013026587A1 A IN O
formula WO2013026587A1 A NN O
( WO2013026587A1 A ( O
la WO2013026587A1 A NN O
) WO2013026587A1 A ) O
may WO2013026587A1 A MD O
also WO2013026587A1 A RB O
demonstrate WO2013026587A1 A VB O
DPP-IV WO2013026587A1 A NNP I-UN
inhibitory WO2013026587A1 A NN O
activity WO2013026587A1 A NN O
. WO2013026587A1 A . O

[ WO2010071872A2 T RB O
2.2.2 WO2010071872A2 T CD O
] WO2010071872A2 T JJ O
bicyclic WO2010071872A2 T JJ O
derivatives WO2010071872A2 T NNS O
and WO2010071872A2 T CC O
methods WO2010071872A2 T NNS O
of WO2010071872A2 T IN O
use WO2010071872A2 T NN O
. WO2010071872A2 T . O

Administration WO2010071872A2 A NN O
of WO2010071872A2 A IN O
a WO2010071872A2 A DT O
salt WO2010071872A2 A NN O
of WO2010071872A2 A IN O
bi-cyclo WO2010071872A2 A JJ O
[ WO2010071872A2 A NN O
2.2.2 WO2010071872A2 A CD O
] WO2010071872A2 A JJ O
octane-2-carbonic WO2010071872A2 A JJ O
acid WO2010071872A2 A NN O
reduces WO2010071872A2 A NNS O
dysphoria WO2010071872A2 A VBP O
in WO2010071872A2 A IN O
dysphoric WO2010071872A2 A JJ O
subjects WO2010071872A2 A NNS O
, WO2010071872A2 A , O
ameliorates WO2010071872A2 A VBZ O
ethanol WO2010071872A2 A JJ O
craving WO2010071872A2 A VBG O
in WO2010071872A2 A IN O
alcoholics WO2010071872A2 A NNS O
, WO2010071872A2 A , O
reduces WO2010071872A2 A VBZ O
the WO2010071872A2 A DT O
erythrocyte WO2010071872A2 A JJ O
sedimentation WO2010071872A2 A NN O
rate WO2010071872A2 A NN O
and WO2010071872A2 A CC O
the WO2010071872A2 A DT O
level WO2010071872A2 A NN O
of WO2010071872A2 A IN O
liver WO2010071872A2 A JJ O
function WO2010071872A2 A NN O
markers WO2010071872A2 A NNS O
( WO2010071872A2 A ( O
AST WO2010071872A2 A NNP I-UN
, WO2010071872A2 A , O
ALT WO2010071872A2 A NNP I-UN
, WO2010071872A2 A , O
and WO2010071872A2 A CC O
bilirubin WO2010071872A2 A NN O
) WO2010071872A2 A ) O
in WO2010071872A2 A IN O
human WO2010071872A2 A JJ O
subjects WO2010071872A2 A NNS O
, WO2010071872A2 A , O
and WO2010071872A2 A CC O
reduces WO2010071872A2 A VBZ O
the WO2010071872A2 A DT O
number WO2010071872A2 A NN O
or WO2010071872A2 A CC O
strength WO2010071872A2 A NN O
of WO2010071872A2 A IN O
seizures WO2010071872A2 A NNS O
in WO2010071872A2 A IN O
epileptics WO2010071872A2 A NNS O
. WO2010071872A2 A . O

Disposable CN101919620A T JJ O
medical CN101919620A T JJ O
hand-washing CN101919620A T NN O
brush CN101919620A T NN O
. CN101919620A T . O

Application CN101214240A T NN O
of CN101214240A T IN O
indole-2 CN101214240A T JJ O
, CN101214240A T , O
3-diketone CN101214240A T JJ O
in CN101214240A T IN O
preparing CN101214240A T VBG O
antiphlogistic CN101214240A T JJ O
medicament CN101214240A T NN O
. CN101214240A T . O

Fused US20100324088 T VBN O
Pyridone US20100324088 T NNP O
M1 US20100324088 T NNP I-UN
Receptor US20100324088 T NNP I-UN
Positive US20100324088 T NNP O
Allosteric US20100324088 T NNP O
Modulators US20100324088 T NNP O
. US20100324088 T . O

The US20100324088 A DT O
present US20100324088 A JJ O
invention US20100324088 A NN O
is US20100324088 A VBZ O
directed US20100324088 A VBN O
to US20100324088 A TO O
fused US20100324088 A VBN O
pyridone US20100324088 A NN O
compounds US20100324088 A NNS O
of US20100324088 A IN O
formula US20100324088 A NN O
( US20100324088 A ( O
I US20100324088 A PRP O
) US20100324088 A ) O
( US20100324088 A ( O
I US20100324088 A PRP O
) US20100324088 A ) O
that US20100324088 A WDT O
are US20100324088 A VBP O
M1 US20100324088 A NNP I-UN
receptor US20100324088 A NN I-UN
positive US20100324088 A JJ O
allosteric US20100324088 A JJ O
modulators US20100324088 A NNS O
and US20100324088 A CC O
that US20100324088 A DT O
are US20100324088 A VBP O
useful US20100324088 A JJ O
in US20100324088 A IN O
the US20100324088 A DT O
treatment US20100324088 A NN O
of US20100324088 A IN O
diseases US20100324088 A NNS O
in US20100324088 A IN O
which US20100324088 A WDT O
the US20100324088 A DT O
M1 US20100324088 A NNP I-UN
receptor US20100324088 A NN I-UN
is US20100324088 A VBZ O
involved US20100324088 A VBN O
, US20100324088 A , O
such US20100324088 A JJ O
as US20100324088 A IN O
Alzheimer US20100324088 A NNP O
's US20100324088 A POS O
disease US20100324088 A NN O
, US20100324088 A , O
schizophrenia US20100324088 A NN O
, US20100324088 A , O
pain US20100324088 A NN O
or US20100324088 A CC O
sleep US20100324088 A NN O
disorders US20100324088 A NNS O
. US20100324088 A . O

The US20100324088 A DT O
invention US20100324088 A NN O
is US20100324088 A VBZ O
also US20100324088 A RB O
directed US20100324088 A VBN O
to US20100324088 A TO O
pharmaceutical US20100324088 A JJ O
compositions US20100324088 A NNS O
comprising US20100324088 A VBG O
the US20100324088 A DT O
compounds US20100324088 A NNS O
, US20100324088 A , O
and US20100324088 A CC O
to US20100324088 A TO O
the US20100324088 A DT O
use US20100324088 A NN O
of US20100324088 A IN O
the US20100324088 A DT O
compounds US20100324088 A NNS O
and US20100324088 A CC O
compositions US20100324088 A NNS O
in US20100324088 A IN O
the US20100324088 A DT O
treatment US20100324088 A NN O
of US20100324088 A IN O
diseases US20100324088 A NNS O
mediated US20100324088 A VBN O
by US20100324088 A IN O
the US20100324088 A DT O
M1 US20100324088 A NNP I-UN
receptor US20100324088 A NN I-UN
. US20100324088 A . O

Novel CN102911147A T NNP O
compound CN102911147A T NN O
, CN102911147A T , O
preparation CN102911147A T NN O
method CN102911147A T NN O
and CN102911147A T CC O
application CN102911147A T NN O
thereof CN102911147A T NN O
and CN102911147A T CC O
medicament CN102911147A T JJ O
composition CN102911147A T NN O
and CN102911147A T CC O
preparation CN102911147A T NN O
of CN102911147A T IN O
novel CN102911147A T JJ O
compound CN102911147A T NN O
. CN102911147A T . O

N-substituted CN101899008B T JJ O
pyrimidine CN101899008B T NN O
sulfonyl-substituted CN101899008B T JJ O
benzamide CN101899008B T NN O
type CN101899008B T NN O
small CN101899008B T JJ O
molecular CN101899008B T JJ O
inhibitor CN101899008B T NN O
for CN101899008B T IN O
Bcl-2 CN101899008B T NNP I-UN
protein CN101899008B T NN O
and CN101899008B T CC O
application CN101899008B T NN O
thereof CN101899008B T NN O
. CN101899008B T . O

The CN101899008B A DT O
invention CN101899008B A NN O
relates CN101899008B A VBZ O
to CN101899008B A TO O
an CN101899008B A DT O
N-substituted CN101899008B A JJ O
pyrimidine CN101899008B A NN O
sulfonyl-substituted CN101899008B A JJ O
benzamide CN101899008B A NN O
type CN101899008B A NN O
small CN101899008B A JJ O
molecular CN101899008B A JJ O
inhibitor CN101899008B A NN O
for CN101899008B A IN O
an CN101899008B A DT O
antiapoptotic CN101899008B A JJ O
member CN101899008B A NN O
of CN101899008B A IN O
Bcl-2 CN101899008B A NNP I-UN
protein CN101899008B A NN O
family CN101899008B A NN O
and CN101899008B A CC O
an CN101899008B A DT O
application CN101899008B A NN O
thereof CN101899008B A NN O
. CN101899008B A . O

The CN101899008B A DT O
N-substituted CN101899008B A JJ O
pyrimidine CN101899008B A NN O
sulfonyl-substituted CN101899008B A JJ O
benzamide CN101899008B A NN O
type CN101899008B A NN O
compounds CN101899008B A NNS O
related CN101899008B A VBN O
in CN101899008B A IN O
the CN101899008B A DT O
invention CN101899008B A NN O
are CN101899008B A VBP O
represented CN101899008B A VBN O
in CN101899008B A IN O
the CN101899008B A DT O
formula CN101899008B A NN O
1 CN101899008B A CD O
and CN101899008B A CC O
have CN101899008B A VBP O
the CN101899008B A DT O
action CN101899008B A NN O
of CN101899008B A IN O
inhibiting CN101899008B A VBG O
the CN101899008B A DT O
antiapoptotic CN101899008B A JJ O
member CN101899008B A NN O
of CN101899008B A IN O
Bcl-2 CN101899008B A NNP I-UN
protein CN101899008B A NNS O
family CN101899008B A NN O
( CN101899008B A ( O
such CN101899008B A JJ O
as CN101899008B A IN O
Bcl-2 CN101899008B A NNP I-UN
, CN101899008B A , O
Bcl-xL CN101899008B A NNP I-UN
, CN101899008B A , O
Mcl-1 CN101899008B A NNP I-UN
and CN101899008B A CC O
the CN101899008B A DT O
like CN101899008B A JJ O
) CN101899008B A ) O
, CN101899008B A , O
and CN101899008B A CC O
the CN101899008B A DT O
detailed CN101899008B A JJ O
definition CN101899008B A NN O
of CN101899008B A IN O
each CN101899008B A DT O
group CN101899008B A NN O
is CN101899008B A VBZ O
shown CN101899008B A VBN O
in CN101899008B A IN O
the CN101899008B A DT O
specifications CN101899008B A NNS O
. CN101899008B A . O

The CN101899008B A DT O
compounds CN101899008B A NNS O
( CN101899008B A ( O
and CN101899008B A CC O
stereoisomers CN101899008B A NNS O
thereof CN101899008B A VBP O
if CN101899008B A IN O
existing CN101899008B A VBG O
) CN101899008B A ) O
, CN101899008B A , O
medicinal CN101899008B A JJ O
salts CN101899008B A NNS O
thereof CN101899008B A NN O
, CN101899008B A , O
hydrates CN101899008B A VBZ O
thereof CN101899008B A NNS O
, CN101899008B A , O
solvates CN101899008B A NNS O
thereof CN101899008B A VBP O
and CN101899008B A CC O
medicinal CN101899008B A JJ O
compositions CN101899008B A NNS O
thereof CN101899008B A NNS O
can CN101899008B A MD O
be CN101899008B A VB O
used CN101899008B A VBN O
for CN101899008B A IN O
treating CN101899008B A VBG O
diseases CN101899008B A NNS O
or CN101899008B A CC O
symptoms CN101899008B A NNS O
related CN101899008B A VBN O
to CN101899008B A TO O
the CN101899008B A DT O
high CN101899008B A JJ O
expression CN101899008B A NN O
of CN101899008B A IN O
the CN101899008B A DT O
antiapoptotic CN101899008B A JJ O
member CN101899008B A NN O
of CN101899008B A IN O
Bcl-2 CN101899008B A NNP I-UN
protein CN101899008B A NN O
family CN101899008B A NN O
, CN101899008B A , O
or CN101899008B A CC O
can CN101899008B A MD O
be CN101899008B A VB O
used CN101899008B A VBN O
for CN101899008B A IN O
treating CN101899008B A VBG O
tumors CN101899008B A NNS O
or CN101899008B A CC O
can CN101899008B A MD O
be CN101899008B A VB O
used CN101899008B A VBN O
as CN101899008B A IN O
an CN101899008B A DT O
synergist CN101899008B A NN O
or CN101899008B A CC O
used CN101899008B A VBN O
together CN101899008B A RB O
with CN101899008B A IN O
other CN101899008B A JJ O
antitumor CN101899008B A NN O
medicines CN101899008B A NNS O
for CN101899008B A IN O
treating CN101899008B A VBG O
tumors CN101899008B A NNS O
. CN101899008B A . O

Furanone WO2008040097A1 T CD O
compounds WO2008040097A1 T NNS O
and WO2008040097A1 T CC O
lactam WO2008040097A1 T NN O
analogues WO2008040097A1 T NNS O
thereof WO2008040097A1 T VBP O
. WO2008040097A1 T . O

Inhibition CA2210998C T NN O
of CA2210998C T IN O
neovascularization CA2210998C T NN O
using CA2210998C T VBG O
vegf-specific CA2210998C T JJ O
oligonucleotides CA2210998C T NNS O
. CA2210998C T . O

Use CA2399840C T NNP O
of CA2399840C T IN O
roflumilast CA2399840C T NN O
or CA2399840C T CC O
pumafentrine CA2399840C T NN O
in CA2399840C T IN O
combination CA2399840C T NN O
with CA2399840C T IN O
methotrexate CA2399840C T NN O
for CA2399840C T IN O
the CA2399840C T DT O
treatment CA2399840C T NN O
of CA2399840C T IN O
arthritic CA2399840C T JJ O
diseases CA2399840C T NNS O
. CA2399840C T . O

The CA2399840C A DT O
invention CA2399840C A NN O
relates CA2399840C A VBZ O
to CA2399840C A TO O
the CA2399840C A DT O
combined CA2399840C A JJ O
administration CA2399840C A NN O
of CA2399840C A IN O
a CA2399840C A DT O
PDE4 CA2399840C A NNP I-UN
or CA2399840C A CC O
PDE3/4 CA2399840C A NNP I-UN
inhibitor CA2399840C A NN O
and CA2399840C A CC O
a CA2399840C A DT O
disease CA2399840C A NN O
modifying CA2399840C A VBG O
anti-rheumatic CA2399840C A JJ O
drug CA2399840C A NN O
( CA2399840C A ( O
DMARDs CA2399840C A NNP O
) CA2399840C A ) O
or CA2399840C A CC O
anti-rheumatic CA2399840C A JJ O
or CA2399840C A CC O
anti-arthritic CA2399840C A JJ O
drug CA2399840C A NN O
. CA2399840C A . O

Tricyclic WO2010027567A3 T JJ O
spirocycle WO2010027567A3 T NN O
derivatives WO2010027567A3 T NNS O
and WO2010027567A3 T CC O
methods WO2010027567A3 T NNS O
of WO2010027567A3 T IN O
use WO2010027567A3 T NN O
thereof WO2010027567A3 T NN O
. WO2010027567A3 T . O

The WO2010027567A3 A DT O
present WO2010027567A3 A JJ O
invention WO2010027567A3 A NN O
relates WO2010027567A3 A VBZ O
to WO2010027567A3 A TO O
novel WO2010027567A3 A VB O
Tricyclic WO2010027567A3 A NNP O
Spirocycle WO2010027567A3 A NNP O
Derivatives WO2010027567A3 A NNP O
, WO2010027567A3 A , O
pharmaceutical WO2010027567A3 A JJ O
compositions WO2010027567A3 A NNS O
comprising WO2010027567A3 A VBG O
the WO2010027567A3 A DT O
Tricyclic WO2010027567A3 A NNP O
Spirocycle WO2010027567A3 A NNP O
Derivatives WO2010027567A3 A NNP O
and WO2010027567A3 A CC O
the WO2010027567A3 A DT O
use WO2010027567A3 A NN O
of WO2010027567A3 A IN O
these WO2010027567A3 A DT O
compounds WO2010027567A3 A NNS O
for WO2010027567A3 A IN O
treating WO2010027567A3 A VBG O
or WO2010027567A3 A CC O
preventing WO2010027567A3 A VBG O
allergy WO2010027567A3 A NN O
, WO2010027567A3 A , O
an WO2010027567A3 A DT O
allergy-induced WO2010027567A3 A JJ O
airway WO2010027567A3 A NN O
response WO2010027567A3 A NN O
, WO2010027567A3 A , O
congestion WO2010027567A3 A NN O
, WO2010027567A3 A , O
a WO2010027567A3 A DT O
cardiovascular WO2010027567A3 A JJ O
disease WO2010027567A3 A NN O
, WO2010027567A3 A , O
an WO2010027567A3 A DT O
inflammatory WO2010027567A3 A JJ O
disease WO2010027567A3 A NN O
, WO2010027567A3 A , O
a WO2010027567A3 A DT O
gastrointestinal WO2010027567A3 A JJ O
disorder WO2010027567A3 A NN O
, WO2010027567A3 A , O
a WO2010027567A3 A DT O
neurological WO2010027567A3 A JJ O
disoder WO2010027567A3 A NN O
, WO2010027567A3 A , O
a WO2010027567A3 A DT O
metabolic WO2010027567A3 A JJ O
disorder WO2010027567A3 A NN O
, WO2010027567A3 A , O
obesity WO2010027567A3 A NN O
or WO2010027567A3 A CC O
an WO2010027567A3 A DT O
obesity-related WO2010027567A3 A JJ O
disorder WO2010027567A3 A NN O
, WO2010027567A3 A , O
diabetes WO2010027567A3 A VBZ O
, WO2010027567A3 A , O
a WO2010027567A3 A DT O
diabetic WO2010027567A3 A JJ O
complication WO2010027567A3 A NN O
, WO2010027567A3 A , O
impaired WO2010027567A3 A VBD O
glucose WO2010027567A3 A JJ O
tolerance WO2010027567A3 A NN O
or WO2010027567A3 A CC O
impaired WO2010027567A3 A JJ O
fasting WO2010027567A3 A NN O
glucose WO2010027567A3 A NN O
. WO2010027567A3 A . O

Amino CN101475615B T NNP O
acid CN101475615B T JJ O
glucide CN101475615B T NN O
compound CN101475615B T NN O
and CN101475615B T CC O
its CN101475615B T PRP$ O
use CN101475615B T NN O
. CN101475615B T . O

The CN101475615B A DT O
design CN101475615B A NN O
of CN101475615B A IN O
the CN101475615B A DT O
amino CN101475615B A NN O
acid CN101475615B A JJ O
saccharide CN101475615B A NN O
compound CN101475615B A NN O
is CN101475615B A VBZ O
based CN101475615B A VBN O
on CN101475615B A IN O
a CN101475615B A DT O
PTP-1B CN101475615B A NNP I-UN
double CN101475615B A JJ O
binding CN101475615B A NN O
site CN101475615B A NN O
, CN101475615B A , O
and CN101475615B A CC O
the CN101475615B A DT O
amino CN101475615B A NN O
acid CN101475615B A JJ O
saccharide CN101475615B A NN O
compound CN101475615B A NN O
is CN101475615B A VBZ O
obtained CN101475615B A VBN O
by CN101475615B A IN O
modifying CN101475615B A VBG O
small CN101475615B A JJ O
molecular CN101475615B A JJ O
monosaccharides CN101475615B A NNS O
. CN101475615B A . O

An CN101475615B A DT O
in CN101475615B A IN O
vitro CN101475615B A JJ O
bioactivity CN101475615B A NN O
test CN101475615B A NN O
shows CN101475615B A VBZ O
that CN101475615B A IN O
the CN101475615B A DT O
amino CN101475615B A NN O
acid CN101475615B A JJ O
saccharide CN101475615B A NN O
compound CN101475615B A NN O
has CN101475615B A VBZ O
good CN101475615B A JJ O
activity CN101475615B A NN O
of CN101475615B A IN O
inhibiting CN101475615B A VBG O
PTP-1B CN101475615B A NNP I-UN
and CN101475615B A CC O
anti-tumor CN101475615B A JJ O
activity CN101475615B A NN O
. CN101475615B A . O

Treated WO2013138312A1 T VBN O
platy WO2013138312A1 T NN O
substrates WO2013138312A1 T NNS O
. WO2013138312A1 T . O

Therapeutic WO2007037258A1 T JJ O
agent WO2007037258A1 T NN O
for WO2007037258A1 T IN O
attention WO2007037258A1 T NN O
deficit/hyperactivity WO2007037258A1 T NN O
disorder WO2007037258A1 T NN O
. WO2007037258A1 T . O

Novel US20090182058 T NNP O
Chalcone US20090182058 T NNP O
Derivatives US20090182058 T VBZ O
With US20090182058 T IN O
Antimitotic US20090182058 T JJ O
Activity US20090182058 T NNP O
. US20090182058 T . O

Oxcarbazepine US20090143360 T NNP O
Formulation US20090143360 T NNP O
. US20090143360 T . O

Application CN102406652A T NN O
of CN102406652A T IN O
forsythin CN102406652A T NN O
in CN102406652A T IN O
preparation CN102406652A T NN O
of CN102406652A T IN O
medicines CN102406652A T NNS O
for CN102406652A T IN O
treating CN102406652A T VBG O
chronic CN102406652A T JJ O
myeloid CN102406652A T NN O
leukemia CN102406652A T NN O
. CN102406652A T . O

Animal CN1799631B T NNP O
model CN1799631B T NN O
for CN1799631B T IN O
fetal CN1799631B T JJ O
alcohol CN1799631B T NN O
syndrome CN1799631B T NN O
and CN1799631B T CC O
methods CN1799631B T NNS O
of CN1799631B T IN O
treatment CN1799631B T NN O
. CN1799631B T . O

Moreover CN1799631B A RB O
, CN1799631B A , O
the CN1799631B A DT O
invention CN1799631B A NN O
provides CN1799631B A VBZ O
methods CN1799631B A NNS O
for CN1799631B A IN O
preventing CN1799631B A VBG O
or CN1799631B A CC O
treating CN1799631B A VBG O
FAS CN1799631B A NNP O
in CN1799631B A IN O
an CN1799631B A DT O
animal CN1799631B A NN O
by CN1799631B A IN O
administering CN1799631B A VBG O
an CN1799631B A DT O
agent CN1799631B A NN O
, CN1799631B A , O
suchan CN1799631B A JJ O
agent CN1799631B A NN O
includes CN1799631B A VBZ O
vitamin CN1799631B A JJ O
C CN1799631B A NNP O
and CN1799631B A CC O
a CN1799631B A DT O
catalase CN1799631B A NN I-UN
, CN1799631B A , O
which CN1799631B A WDT O
causes CN1799631B A VBZ O
or CN1799631B A CC O
enhances CN1799631B A VBZ O
an CN1799631B A DT O
expression CN1799631B A NN O
of CN1799631B A IN O
Pax6 CN1799631B A NNP I-UN
that CN1799631B A WDT O
is CN1799631B A VBZ O
a CN1799631B A DT O
neural CN1799631B A JJ O
and CN1799631B A CC O
eye CN1799631B A NN O
marker CN1799631B A NN O
. CN1799631B A . O

In CN1799631B A IN O
addition CN1799631B A NN O
, CN1799631B A , O
the CN1799631B A DT O
invention CN1799631B A NN O
provides CN1799631B A VBZ O
methods CN1799631B A NNS O
for CN1799631B A IN O
preventing CN1799631B A VBG O
or CN1799631B A CC O
treating CN1799631B A VBG O
FAS CN1799631B A NNP O
by CN1799631B A IN O
administering CN1799631B A VBG O
an CN1799631B A DT O
agent CN1799631B A NN O
, CN1799631B A , O
such CN1799631B A JJ O
as CN1799631B A IN O
vitamin CN1799631B A NN O
C CN1799631B A NNP O
, CN1799631B A , O
which CN1799631B A WDT O
causes CN1799631B A VBZ O
suppression CN1799631B A NN O
of CN1799631B A IN O
NF-kappaB CN1799631B A NNP I-UN
activation CN1799631B A NN O
. CN1799631B A . O

Histone WO2009152735A1 T NNP I-UN
deacetylase WO2009152735A1 T NN I-UN
inhibitors WO2009152735A1 T NNS O
and WO2009152735A1 T CC O
uses WO2009152735A1 T VBZ O
thereof WO2009152735A1 T NN O
. WO2009152735A1 T . O

Histone WO2009152735A1 A NNP I-UN
deacetylase WO2009152735A1 A NN I-UN
inhibitors WO2009152735A1 A NNS O
and WO2009152735A1 A CC O
uses WO2009152735A1 A VBZ O
thereof WO2009152735A1 A NN O
. WO2009152735A1 A . O

The WO2009152735A1 A DT O
histone WO2009152735A1 A NN I-UN
deacetylase WO2009152735A1 A NN I-UN
inhibitors WO2009152735A1 A NNS O
are WO2009152735A1 A VBP O
useful WO2009152735A1 A JJ O
in WO2009152735A1 A IN O
the WO2009152735A1 A DT O
treatment WO2009152735A1 A NN O
of WO2009152735A1 A IN O
malignant WO2009152735A1 A JJ O
tumor WO2009152735A1 A NN O
and WO2009152735A1 A CC O
the WO2009152735A1 A DT O
diseases WO2009152735A1 A NNS O
associated WO2009152735A1 A VBN O
with WO2009152735A1 A IN O
differentiation WO2009152735A1 A NN O
and WO2009152735A1 A CC O
proliferation WO2009152735A1 A NN O
. WO2009152735A1 A . O

The WO2009152735A1 A DT O
histone WO2009152735A1 A NN I-UN
deacetylase WO2009152735A1 A NN I-UN
inhibitors WO2009152735A1 A NNS O
are WO2009152735A1 A VBP O
the WO2009152735A1 A DT O
compounds WO2009152735A1 A NNS O
or WO2009152735A1 A CC O
salts WO2009152735A1 A NNS O
thereof WO2009152735A1 A RB O
represented WO2009152735A1 A VBN O
as WO2009152735A1 A IN O
the WO2009152735A1 A DT O
formula WO2009152735A1 A NN O
illustrated WO2009152735A1 A VBN O
below WO2009152735A1 A IN O
. WO2009152735A1 A . O

Medicinal CN102885820A T JJ O
composition CN102885820A T NN O
containing CN102885820A T VBG O
ceftiofur CN102885820A T JJ O
bisbenzylethylenediamine CN102885820A T NN O
. CN102885820A T . O

Composition CN1895241B T NN O
of CN1895241B T IN O
long-acting CN1895241B T JJ O
oral CN1895241B T JJ O
pills CN1895241B T NNS O
of CN1895241B T IN O
Yansuan CN1895241B T NNP O
Tanshuluoxin CN1895241B T NNP O
and CN1895241B T CC O
its CN1895241B T PRP$ O
production CN1895241B T NN O
method CN1895241B T NN O
. CN1895241B T . O

Cosmetic DE102007032664A1 T JJ O
or DE102007032664A1 T CC O
dermatological DE102007032664A1 T JJ O
preparations DE102007032664A1 T NNS O
for DE102007032664A1 T IN O
skin DE102007032664A1 T NN O
care DE102007032664A1 T NN O
, DE102007032664A1 T , O
protection DE102007032664A1 T NN O
and DE102007032664A1 T CC O
cleaning DE102007032664A1 T NN O
, DE102007032664A1 T , O
containing DE102007032664A1 T VBG O
apiogalacturonan DE102007032664A1 T JJ O
compounds DE102007032664A1 T NNS O
or DE102007032664A1 T CC O
extracts DE102007032664A1 T NNS O
thereof DE102007032664A1 T VBP O
from DE102007032664A1 T IN O
seaweed DE102007032664A1 T NN O
, DE102007032664A1 T , O
together DE102007032664A1 T RB O
with DE102007032664A1 T IN O
molecular DE102007032664A1 T JJ O
oxygen DE102007032664A1 T NN O
. DE102007032664A1 T . O

Pyrrolidine EP1532109A1 T NNP O
derivatives EP1532109A1 T NNS O
as EP1532109A1 T IN O
oxytocin EP1532109A1 T JJ O
antagonists EP1532109A1 T NNS O
. EP1532109A1 T . O

Therapeutic US20090012145 T JJ O
esters US20090012145 T NNS O
. US20090012145 T . O

Noncyclic US7192970 T JJ O
1,3-dicarbonyl US7192970 T JJ O
compounds US7192970 T NNS O
as US7192970 T IN O
dual US7192970 T JJ O
PPAR US7192970 T NNP I-UN
agonists US7192970 T NNS O
with US7192970 T IN O
potent US7192970 T JJ O
antihyperglycemic US7192970 T JJ O
and US7192970 T CC O
antihyperlipidemic US7192970 T JJ O
activity US7192970 T NN O
. US7192970 T . O

These US7192970 A DT O
compounds US7192970 A NNS O
, US7192970 A , O
as US7192970 A IN O
peroxisome US7192970 A JJ I-UN
proliferator-activated US7192970 A JJ I-UN
receptor US7192970 A NN I-UN
( US7192970 A ( O
PPAR US7192970 A NNP I-UN
) US7192970 A ) O
dual US7192970 A JJ O
agonists US7192970 A NNS O
for US7192970 A IN O
both US7192970 A DT O
RXR/PPARgamma US7192970 A NNP O
and US7192970 A CC O
RXR/PPARalpha US7192970 A NNP O
heterodimers US7192970 A NNS O
, US7192970 A , O
are US7192970 A VBP O
useful US7192970 A JJ O
in US7192970 A IN O
the US7192970 A DT O
treatment US7192970 A NN O
and/or US7192970 A JJ O
prevention US7192970 A NN O
of US7192970 A IN O
type US7192970 A NN O
2 US7192970 A CD O
diabetes US7192970 A NNS O
and US7192970 A CC O
associated US7192970 A VBN O
metabolic US7192970 A JJ O
syndrome US7192970 A NN O
such US7192970 A JJ O
as US7192970 A IN O
hypertension US7192970 A NN O
, US7192970 A , O
obesity US7192970 A NN O
, US7192970 A , O
insulin US7192970 A NN I-UN
resistance US7192970 A NN O
, US7192970 A , O
hyperlipidemia US7192970 A NN O
, US7192970 A , O
hyperglycemia US7192970 A NN O
, US7192970 A , O
hypercholesterolemia US7192970 A NN O
, US7192970 A , O
atherosclerosis US7192970 A NN O
, US7192970 A , O
coronary US7192970 A JJ O
artery US7192970 A NN O
disease US7192970 A NN O
, US7192970 A , O
and US7192970 A CC O
other US7192970 A JJ O
cardiovascular US7192970 A JJ O
disorders US7192970 A NNS O

Formulations US20110038908 T NNS O
and US20110038908 T CC O
methods US20110038908 T NNS O
employing US20110038908 T VBG O
anhydrous US20110038908 T JJ O
disinfectant US20110038908 T NN O
. US20110038908 T . O

Nonoxynol CN103751095A T NNP O
vaginal CN103751095A T JJ O
expansion CN103751095A T NN O
suppository CN103751095A T NN O
, CN103751095A T , O
as CN103751095A T RB O
well CN103751095A T RB O
as CN103751095A T IN O
preparation CN103751095A T NN O
method CN103751095A T NN O
and CN103751095A T CC O
detection CN103751095A T NN O
method CN103751095A T NN O
thereof CN103751095A T NN O
. CN103751095A T . O

A US20090018210 T DT O
Method US20090018210 T NNP O
for US20090018210 T IN O
Promoting US20090018210 T VBG O
Fat US20090018210 T NNP O
Degradation US20090018210 T NNP O
. US20090018210 T . O

A US20090018210 A DT O
novel US20090018210 A NN O
, US20090018210 A , O
new US20090018210 A JJ O
, US20090018210 A , O
and US20090018210 A CC O
highly US20090018210 A RB O
effective US20090018210 A JJ O
agent US20090018210 A NN O
for US20090018210 A IN O
promoting US20090018210 A VBG O
fat US20090018210 A JJ O
degradation US20090018210 A NN O
that US20090018210 A IN O
contains US20090018210 A VBZ O
astaxanthin US20090018210 A JJ O
and/or US20090018210 A IN O
an US20090018210 A DT O
ester US20090018210 A NN O
thereof US20090018210 A NN O
as US20090018210 A IN O
active US20090018210 A JJ O
ingredient US20090018210 A NN O
is US20090018210 A VBZ O
provided US20090018210 A VBN O
. US20090018210 A . O

The US20090018210 A DT O
agent US20090018210 A NN O
for US20090018210 A IN O
promoting US20090018210 A VBG O
fat US20090018210 A JJ O
degradation US20090018210 A NN O
of US20090018210 A IN O
the US20090018210 A DT O
present US20090018210 A JJ O
invention US20090018210 A NN O
has US20090018210 A VBZ O
an US20090018210 A DT O
effect US20090018210 A NN O
of US20090018210 A IN O
reducing US20090018210 A VBG O
fat US20090018210 A JJ O
by US20090018210 A IN O
lipolysis US20090018210 A NN O
of US20090018210 A IN O
fat US20090018210 A NN O
in US20090018210 A IN O
either US20090018210 A CC O
a US20090018210 A DT O
subject US20090018210 A NN O
who US20090018210 A WP O
is US20090018210 A VBZ O
in US20090018210 A IN O
a US20090018210 A DT O
condition US20090018210 A NN O
in US20090018210 A IN O
which US20090018210 A WDT O
fat US20090018210 A NN O
has US20090018210 A VBZ O
already US20090018210 A RB O
accumulated US20090018210 A VBN O
or US20090018210 A CC O
a US20090018210 A DT O
subject US20090018210 A NN O
who US20090018210 A WP O
is US20090018210 A VBZ O
in US20090018210 A IN O
a US20090018210 A DT O
condition US20090018210 A NN O
in US20090018210 A IN O
which US20090018210 A WDT O
fat US20090018210 A NN O
has US20090018210 A VBZ O
not US20090018210 A RB O
yet US20090018210 A RB O
been US20090018210 A VBN O
accumulated US20090018210 A VBN O
. US20090018210 A . O

Accordingly US20090018210 A RB O
, US20090018210 A , O
the US20090018210 A DT O
agent US20090018210 A NN O
for US20090018210 A IN O
promoting US20090018210 A VBG O
fat US20090018210 A JJ O
degradation US20090018210 A NN O
of US20090018210 A IN O
the US20090018210 A DT O
present US20090018210 A JJ O
invention US20090018210 A NN O
can US20090018210 A MD O
restore US20090018210 A VB O
hypertrophied US20090018210 A JJ O
adipocytes US20090018210 A NNS O
to US20090018210 A TO O
a US20090018210 A DT O
normal US20090018210 A JJ O
size US20090018210 A NN O
. US20090018210 A . O

Methods WO2012064981A2 T NNS O
to WO2012064981A2 T TO O
test WO2012064981A2 T VB O
allergic WO2012064981A2 T JJ O
conditions WO2012064981A2 T NNS O
. WO2012064981A2 T . O

Disclosed WO2012064981A2 A VBN O
are WO2012064981A2 A VBP O
methods WO2012064981A2 A NNS O
to WO2012064981A2 A TO O
treat WO2012064981A2 A VB O
allergic WO2012064981A2 A JJ O
conditions WO2012064981A2 A NNS O
, WO2012064981A2 A , O
including WO2012064981A2 A VBG O
pulmonary WO2012064981A2 A JJ O
and WO2012064981A2 A CC O
non- WO2012064981A2 A JJ O
pulmonary WO2012064981A2 A JJ O
conditions WO2012064981A2 A NNS O
, WO2012064981A2 A , O
in WO2012064981A2 A IN O
a WO2012064981A2 A DT O
subject WO2012064981A2 A NN O
by WO2012064981A2 A IN O
administering WO2012064981A2 A VBG O
a WO2012064981A2 A DT O
composition WO2012064981A2 A NN O
that WO2012064981A2 A IN O
inhibits WO2012064981A2 A VBZ O
Pirn WO2012064981A2 A NNP I-UN
kinase WO2012064981A2 A NN I-UN
. WO2012064981A2 A . O

Also WO2012064981A2 A RB O
disclosed WO2012064981A2 A VBN O
are WO2012064981A2 A VBP O
methods WO2012064981A2 A NNS O
to WO2012064981A2 A TO O
treat WO2012064981A2 A VB O
allergic WO2012064981A2 A JJ O
conditions WO2012064981A2 A NNS O
in WO2012064981A2 A IN O
a WO2012064981A2 A DT O
subject WO2012064981A2 A NN O
by WO2012064981A2 A IN O
administering WO2012064981A2 A VBG O
a WO2012064981A2 A DT O
composition WO2012064981A2 A NN O
that WO2012064981A2 A WDT O
induces WO2012064981A2 A VBZ O
expression WO2012064981A2 A NN O
of WO2012064981A2 A IN O
Runx3 WO2012064981A2 A NNP I-UN
. WO2012064981A2 A . O

Delta US20080254116 T NNP O
and US20080254116 T CC O
Epsilon US20080254116 T NNP O
Crystal US20080254116 T NNP O
Forms US20080254116 T NNP O
of US20080254116 T IN O
Imatinib US20080254116 T NNP O
Mesylate US20080254116 T NNP O
. US20080254116 T . O

Indication WO2010062205A4 T NN O
of WO2010062205A4 T IN O
use WO2010062205A4 T NN O
of WO2010062205A4 T IN O
erdosteine WO2010062205A4 T NN O
as WO2010062205A4 T IN O
antidote WO2010062205A4 T NN O
in WO2010062205A4 T IN O
a WO2010062205A4 T DT O
large WO2010062205A4 T JJ O
number WO2010062205A4 T NN O
of WO2010062205A4 T IN O
intoxications WO2010062205A4 T NNS O
, WO2010062205A4 T , O
especially WO2010062205A4 T RB O
in WO2010062205A4 T IN O
heavy WO2010062205A4 T JJ O
metals WO2010062205A4 T NNS O
like WO2010062205A4 T IN O
lead WO2010062205A4 T NN O
or WO2010062205A4 T CC O
mercury WO2010062205A4 T NN O
, WO2010062205A4 T , O
and WO2010062205A4 T CC O
paracetamol WO2010062205A4 T NN O
. WO2010062205A4 T . O

Improved WO2008082250A1 T NNP O
process WO2008082250A1 T NN O
for WO2008082250A1 T IN O
the WO2008082250A1 T DT O
preparation WO2008082250A1 T NN O
of WO2008082250A1 T IN O
non-crystalline WO2008082250A1 T JJ O
atorvastatin WO2008082250A1 T NN O
calcium WO2008082250A1 T NN O
. WO2008082250A1 T . O

Hydroxystilbene EP1119248B1 T NNP O
compounds EP1119248B1 T NNS O
used EP1119248B1 T VBD O
as EP1119248B1 T IN O
microbicidal EP1119248B1 T JJ O
active EP1119248B1 T JJ O
substances EP1119248B1 T NNS O
. EP1119248B1 T . O

Sequestrants WO2014150873A1 T NNS O
of WO2014150873A1 T IN O
advanced WO2014150873A1 T JJ O
glycation WO2014150873A1 T NN O
end WO2014150873A1 T NN O
product WO2014150873A1 T NN O
( WO2014150873A1 T ( O
age WO2014150873A1 T NN O
) WO2014150873A1 T ) O
precursors WO2014150873A1 T NNS O
. WO2014150873A1 T . O

Racecadotril CN103565750A T NNP O
particle CN103565750A T NN O
as CN103565750A T RB O
well CN103565750A T RB O
as CN103565750A T IN O
preparation CN103565750A T NN O
method CN103565750A T NN O
thereof CN103565750A T NN O
. CN103565750A T . O

Methods US7056655 T NNS O
for US7056655 T IN O
monitoring US7056655 T NN O
and US7056655 T CC O
guiding US7056655 T VBG O
therapeutic US7056655 T JJ O
suppression US7056655 T NN O
of US7056655 T IN O
parathyroid US7056655 T NN I-UN
hormone US7056655 T NN I-UN
in US7056655 T IN O
renal US7056655 T JJ O
patients US7056655 T NNS O
having US7056655 T VBG O
secondary US7056655 T JJ O
hyperparathyroidism US7056655 T NN O
. US7056655 T . O

The US7056655 A DT O
present US7056655 A JJ O
invention US7056655 A NN O
relates US7056655 A VBZ O
to US7056655 A TO O
novel US7056655 A VB O
methods US7056655 A NNS O
for US7056655 A IN O
monitoring US7056655 A NN O
and US7056655 A CC O
guiding US7056655 A VBG O
therapeutic US7056655 A JJ O
suppression US7056655 A NN O
of US7056655 A IN O
parathyroid US7056655 A NN I-UN
hormone US7056655 A NN I-UN
in US7056655 A IN O
renal US7056655 A JJ O
patients US7056655 A NNS O
having US7056655 A VBG O
secondary US7056655 A JJ O
hyperparathyroidism US7056655 A NN O
. US7056655 A . O

One US7056655 A CD O
determines US7056655 A NNS O
and US7056655 A CC O
monitors US7056655 A NNS O
the US7056655 A DT O
level US7056655 A NN O
of US7056655 A IN O
parathyroid US7056655 A JJ I-UN
hormone US7056655 A NN I-UN
agonist US7056655 A NN O
and US7056655 A CC O
parathyroid US7056655 A VB I-UN
hormone US7056655 A NN I-UN
antagonist US7056655 A NN O
in US7056655 A IN O
the US7056655 A DT O
renal US7056655 A JJ O
patient US7056655 A NN O
. US7056655 A . O

The US7056655 A DT O
parathyroid US7056655 A NN I-UN
hormone US7056655 A NN I-UN
suppressing US7056655 A VBG O
therapeutic US7056655 A JJ O
is US7056655 A VBZ O
administered US7056655 A VBN O
to US7056655 A TO O
the US7056655 A DT O
patient US7056655 A NN O
so US7056655 A RB O
as US7056655 A IN O
to US7056655 A TO O
minimize US7056655 A VB O
the US7056655 A DT O
level US7056655 A NN O
of US7056655 A IN O
parathyroid US7056655 A JJ I-UN
hormone US7056655 A NN I-UN
antagonist US7056655 A NN O
. US7056655 A . O

Compounds WO2008024304A3 T NNS O
for WO2008024304A3 T IN O
treatment WO2008024304A3 T NN O
of WO2008024304A3 T IN O
proliferative WO2008024304A3 T JJ O
disorders WO2008024304A3 T NNS O
. WO2008024304A3 T . O

Polymorphic CA2563793A1 T JJ O
forms CA2563793A1 T NNS O
of CA2563793A1 T IN O
nateglinide CA2563793A1 T NN O
. CA2563793A1 T . O

Provided CA2563793A1 A VBN O
are CA2563793A1 A VBP O
crystalline CA2563793A1 A JJ O
forms CA2563793A1 A NNS O
of CA2563793A1 A IN O
nateglinide CA2563793A1 A NN O
and CA2563793A1 A CC O
processes CA2563793A1 A NNS O
for CA2563793A1 A IN O
their CA2563793A1 A PRP$ O
preparation CA2563793A1 A NN O
. CA2563793A1 A . O

Cucurbitacin WO2008071968A1 T NNP O
b WO2008071968A1 T NN O
and WO2008071968A1 T CC O
uses WO2008071968A1 T VBZ O
thereof WO2008071968A1 T NN O
. WO2008071968A1 T . O

Novel EP1942093A1 T NNP O
cyclohexenone EP1942093A1 T NN O
compounds EP1942093A1 T NNS O
from EP1942093A1 T IN O
antrodia EP1942093A1 T NN O
camphorata EP1942093A1 T NN O
and EP1942093A1 T CC O
application EP1942093A1 T NN O
thereof EP1942093A1 T NN O
. EP1942093A1 T . O

Treatment US7767682 T NN O
of US7767682 T IN O
renal US7767682 T JJ O
diseases US7767682 T NNS O
or US7767682 T CC O
conditions US7767682 T NNS O
associated US7767682 T VBN O
with US7767682 T IN O
abnormal US7767682 T JJ O
ion US7767682 T NN O
flux US7767682 T NN O
in US7767682 T IN O
a US7767682 T DT O
mammal US7767682 T JJ O
such US7767682 T JJ O
as US7767682 T IN O
a US7767682 T DT O
human US7767682 T JJ O
which US7767682 T WDT O
comprises US7767682 T VBZ O
the US7767682 T DT O
administration US7767682 T NN O
of US7767682 T IN O
a US7767682 T DT O
hPPAR US7767682 T NN I-UN
gamma US7767682 T NN I-UN
modulator US7767682 T NN O
or US7767682 T CC O
salt US7767682 T NN O
or US7767682 T CC O
solvate US7767682 T NN O
thereof US7767682 T NNS O
, US7767682 T , O
such US7767682 T JJ O
as US7767682 T IN O
farglitazar US7767682 T NN O
or US7767682 T CC O
rosiglitazone US7767682 T NN O
. US7767682 T . O

Methods US7767682 A NNS O
of US7767682 A IN O
prevention US7767682 A NN O
or US7767682 A CC O
treatment US7767682 A NN O
of US7767682 A IN O
renal US7767682 A JJ O
diseases US7767682 A NNS O
or US7767682 A CC O
conditions US7767682 A NNS O
associated US7767682 A VBN O
with US7767682 A IN O
abnormal US7767682 A JJ O
ion US7767682 A NN O
flux US7767682 A NN O
, US7767682 A , O
in US7767682 A IN O
particular US7767682 A JJ O
autosomal US7767682 A JJ O
dominant US7767682 A JJ O
polycystic US7767682 A JJ O
kidney US7767682 A NN O
disease US7767682 A NN O
, US7767682 A , O
with US7767682 A IN O
a US7767682 A DT O
modulator US7767682 A NN O
of US7767682 A IN O
human US7767682 A JJ I-UN
peroxisome US7767682 A NN I-UN
proliferator US7767682 A NN I-UN
activated US7767682 A VBD I-UN
receptor US7767682 A NN I-UN
gamma US7767682 A NN I-UN
. US7767682 A . O

Use EP1714652A2 T NNP O
of EP1714652A2 T IN O
thiazolidinediones EP1714652A2 T NNS O
to EP1714652A2 T TO O
prevent EP1714652A2 T VB O
or EP1714652A2 T CC O
delay EP1714652A2 T VB O
onset EP1714652A2 T NN O
of EP1714652A2 T IN O
niddm EP1714652A2 T NN O
. EP1714652A2 T . O

Micro-RNA US20120071541 T NNP O
Associated US20120071541 T NNP O
With US20120071541 T IN O
Rheumatoid US20120071541 T NNP O
Arthritis US20120071541 T NNP O
. US20120071541 T . O

An US20120071541 A DT O
object US20120071541 A NN O
of US20120071541 A IN O
the US20120071541 A DT O
present US20120071541 A JJ O
invention US20120071541 A NN O
is US20120071541 A VBZ O
to US20120071541 A TO O
provide US20120071541 A VB O
a US20120071541 A DT O
novel US20120071541 A JJ O
marker US20120071541 A NN O
for US20120071541 A IN O
rheumatoid US20120071541 A JJ O
arthritis US20120071541 A NN O
( US20120071541 A ( O
RA US20120071541 A NNP O
) US20120071541 A ) O
, US20120071541 A , O
and US20120071541 A CC O
more US20120071541 A RBR O
specifically US20120071541 A RB O
, US20120071541 A , O
to US20120071541 A TO O
provide US20120071541 A VB O
a US20120071541 A DT O
marker US20120071541 A NN O
whose US20120071541 A WP$ O
expression US20120071541 A NN O
may US20120071541 A MD O
be US20120071541 A VB O
specifically US20120071541 A RB O
increased US20120071541 A VBN O
or US20120071541 A CC O
decreased US20120071541 A VBN O
in US20120071541 A IN O
RA US20120071541 A NNP O
. US20120071541 A . O

Another US20120071541 A DT O
object US20120071541 A NN O
of US20120071541 A IN O
the US20120071541 A DT O
present US20120071541 A JJ O
invention US20120071541 A NN O
is US20120071541 A VBZ O
to US20120071541 A TO O
confirm US20120071541 A VB O
whether US20120071541 A IN O
or US20120071541 A CC O
not US20120071541 A RB O
miRNA US20120071541 A JJ O
serving US20120071541 A VBG O
as US20120071541 A IN O
the US20120071541 A DT O
marker US20120071541 A NN O
is US20120071541 A VBZ O
involved US20120071541 A VBN O
as US20120071541 A IN O
the US20120071541 A DT O
etiology US20120071541 A NN O
of US20120071541 A IN O
RA US20120071541 A NNP O
, US20120071541 A , O
and US20120071541 A CC O
to US20120071541 A TO O
provide US20120071541 A VB O
an US20120071541 A DT O
inspection US20120071541 A NN O
method US20120071541 A NN O
for US20120071541 A IN O
RA US20120071541 A NNP O
and US20120071541 A CC O
a US20120071541 A DT O
therapeutic US20120071541 A JJ O
agent US20120071541 A NN O
for US20120071541 A IN O
RA US20120071541 A NNP O
each US20120071541 A DT O
using US20120071541 A VBG O
the US20120071541 A DT O
miRNA US20120071541 A NN O
involved US20120071541 A VBN O
. US20120071541 A . O

The US20120071541 A DT O
marker US20120071541 A NN O
includes US20120071541 A VBZ O
miRNA US20120071541 A NN O
( US20120071541 A ( O
for US20120071541 A IN O
example US20120071541 A NN O
, US20120071541 A , O
miR124a US20120071541 A NN O
) US20120071541 A ) O
whose US20120071541 A WP$ O
expression US20120071541 A NN O
is US20120071541 A VBZ O
specifically US20120071541 A RB O
increased US20120071541 A VBN O
or US20120071541 A CC O
decreased US20120071541 A VBN O
in US20120071541 A IN O
RA US20120071541 A NNP O
synovial US20120071541 A JJ O
cells US20120071541 A NNS O
based US20120071541 A VBN O
on US20120071541 A IN O
a US20120071541 A DT O
small US20120071541 A JJ O
RNA US20120071541 A NNP O
expression US20120071541 A NN O
profile US20120071541 A NN O
in US20120071541 A IN O
the US20120071541 A DT O
RA US20120071541 A NNP O
synovial US20120071541 A JJ O
cells US20120071541 A NNS O
. US20120071541 A . O

In US20120071541 A IN O
addition US20120071541 A NN O
, US20120071541 A , O
the US20120071541 A DT O
therapeutic US20120071541 A JJ O
agent US20120071541 A NN O
for US20120071541 A IN O
RA US20120071541 A NNP O
includes US20120071541 A VBZ O
miRNA US20120071541 A NN O
( US20120071541 A ( O
for US20120071541 A IN O
example US20120071541 A NN O
, US20120071541 A , O
miR124a US20120071541 A NN O
) US20120071541 A ) O
as US20120071541 A IN O
an US20120071541 A DT O
active US20120071541 A JJ O
ingredient US20120071541 A NN O
. US20120071541 A . O

Substituted WO2006124813A3 T VBN O
7 WO2006124813A3 T CD O
, WO2006124813A3 T , O
8-dihydro-1h-pyrimido WO2006124813A3 T JJ O
[ WO2006124813A3 T JJ O
4,5-b WO2006124813A3 T JJ O
] WO2006124813A3 T NN O
[ WO2006124813A3 T $ O
1,4 WO2006124813A3 T CD O
] WO2006124813A3 T JJ O
diazepin-4-amines WO2006124813A3 T NNS O
as WO2006124813A3 T IN O
? WO2006124813A3 T . O
kinase WO2006124813A3 T NN I-UN
inhibitors WO2006124813A3 T NNS O
. WO2006124813A3 T . O

Compounds WO2006124813A3 A NNS O
having WO2006124813A3 A VBG O
the WO2006124813A3 A DT O
Formula WO2006124813A3 A NNP O
( WO2006124813A3 A ( O
I WO2006124813A3 A PRP O
) WO2006124813A3 A ) O
are WO2006124813A3 A VBP O
useful WO2006124813A3 A JJ O
for WO2006124813A3 A IN O
inhibiting WO2006124813A3 A VBG O
protein WO2006124813A3 A JJ I-UN
tyrosine WO2006124813A3 A NN I-UN
kinases WO2006124813A3 A NNS I-UN
. WO2006124813A3 A . O

Flavour CN103750301A T CD O
composition CN103750301A T NN O
capable CN103750301A T JJ O
of CN103750301A T IN O
enhancing CN103750301A T VBG O
immunity CN103750301A T NN O
. CN103750301A T . O

2-aryl-6-arylí»-glucoside CN101348509A T JJ O
compound CN101348509A T NN O
, CN101348509A T , O
and CN101348509A T CC O
preparation CN101348509A T NN O
and CN101348509A T CC O
use CN101348509A T NN O
thereof CN101348509A T NN O
. CN101348509A T . O

The CN101348509A A DT O
compound CN101348509A A NN O
having CN101348509A A VBG O
the CN101348509A A DT O
following CN101348509A A JJ O
structural CN101348509A A JJ O
formula CN101348509A A NN O
is CN101348509A A VBZ O
used CN101348509A A VBN O
for CN101348509A A IN O
preparation CN101348509A A NN O
of CN101348509A A IN O
a CN101348509A A DT O
small-molecular CN101348509A A JJ O
inhibitor/anti-neoplasm CN101348509A A JJ O
drug CN101348509A A NN O
belonging CN101348509A A NN O
to CN101348509A A TO O
the CN101348509A A DT O
bcl-2 CN101348509A A JJ I-UN
protein CN101348509A A NN O
family CN101348509A A NN O
. CN101348509A A . O

Preparation CN101601846A T NNP O
method CN101601846A T NN O
of CN101601846A T IN O
heracleum CN101601846A T NN O
hemsleyanum CN101601846A T NN O
michaux CN101601846A T NN O
and CN101601846A T CC O
herba CN101601846A T NN O
artemisiae CN101601846A T VBP O
capillaris CN101601846A T JJ O
oral CN101601846A T JJ O
wine CN101601846A T NN O
. CN101601846A T . O

Alopecia US20080249117 T NNP O
therapy US20080249117 T NN O
using US20080249117 T VBG O
tetrazole US20080249117 T JJ O
compound US20080249117 T NN O
. US20080249117 T . O

The US20080249117 A DT O
invention US20080249117 A NN O
relates US20080249117 A VBZ O
to US20080249117 A TO O
a US20080249117 A DT O
cosmetic US20080249117 A JJ O
composition US20080249117 A NN O
containing US20080249117 A VBG O
at US20080249117 A IN O
least US20080249117 A JJS O
one US20080249117 A CD O
15-hydroxy-prostaglandin US20080249117 A JJ I-UN
dehydrogenase US20080249117 A NN I-UN
inhibitor US20080249117 A NN O
and US20080249117 A CC O
cosmetically US20080249117 A RB O
acceptable US20080249117 A JJ O
excipients US20080249117 A NNS O
. US20080249117 A . O

It US20080249117 A PRP O
also US20080249117 A RB O
relates US20080249117 A VBZ O
to US20080249117 A TO O
a US20080249117 A DT O
method US20080249117 A NN O
of US20080249117 A IN O
cosmetic US20080249117 A JJ O
treatment US20080249117 A NN O
for US20080249117 A IN O
promoting US20080249117 A VBG O
the US20080249117 A DT O
growth US20080249117 A NN O
and/or US20080249117 A IN O
preventing US20080249117 A VBG O
or US20080249117 A CC O
delaying US20080249117 A VBG O
the US20080249117 A DT O
loss US20080249117 A NN O
of US20080249117 A IN O
hair US20080249117 A NN O
, US20080249117 A , O
and US20080249117 A CC O
the US20080249117 A DT O
use US20080249117 A NN O
of US20080249117 A IN O
a US20080249117 A DT O
15-hydroxyprostaglandin US20080249117 A JJ I-UN
dehydrogenase US20080249117 A NN I-UN
inhibitor US20080249117 A NN O
for US20080249117 A IN O
the US20080249117 A DT O
preparation US20080249117 A NN O
of US20080249117 A IN O
a US20080249117 A DT O
composition US20080249117 A NN O
intended US20080249117 A VBN O
for US20080249117 A IN O
controlling US20080249117 A VBG O
hair US20080249117 A JJ O
loss US20080249117 A NN O
and/or US20080249117 A NN O
for US20080249117 A IN O
promoting US20080249117 A VBG O
hair US20080249117 A NN O
regrowth US20080249117 A NN O
. US20080249117 A . O

Small-molecule US20100184837 T JJ O
nucleotide US20100184837 T JJ O
aptamer US20100184837 T NN O
for US20100184837 T IN O
hepatitis US20100184837 T NN O
C US20100184837 T NNP O
virus US20100184837 T NN O
, US20100184837 T , O
preparation US20100184837 T NN O
method US20100184837 T NN O
and US20100184837 T CC O
use US20100184837 T NN O
thereof US20100184837 T NN O
. US20100184837 T . O

Method US20090054482 T NNP O
of US20090054482 T IN O
making US20090054482 T VBG O
and US20090054482 T CC O
administering US20090054482 T VBG O
quinoline US20090054482 T JJ O
derivatives US20090054482 T NNS O
as US20090054482 T IN O
anti-cancer US20090054482 T JJ O
agents US20090054482 T NNS O
. US20090054482 T . O

Application CN103006628A T NN O
of CN103006628A T IN O
formaldehyde CN103006628A T NN O
in CN103006628A T IN O
preparation CN103006628A T NN O
of CN103006628A T IN O
injection CN103006628A T NN O
for CN103006628A T IN O
treating CN103006628A T VBG O
animal CN103006628A T NN O
and CN103006628A T CC O
human CN103006628A T JJ O
infectious CN103006628A T JJ O
disease CN103006628A T NN O
. CN103006628A T . O

Isothiazole CN101781268B T NNP O
ketone CN101781268B T NN O
substituted CN101781268B T VBD O
benzene CN101781268B T JJ O
dicarboxylic CN101781268B T JJ O
acid CN101781268B T NN O
derivative CN101781268B T JJ O
and CN101781268B T CC O
usage CN101781268B T JJ O
thereof CN101781268B T NN O
in CN101781268B T IN O
preparation CN101781268B T NN O
of CN101781268B T IN O
beta-secretase CN101781268B T JJ I-UN
inhibitor CN101781268B T NN O
. CN101781268B T . O

The CN101781268B A DT O
invention CN101781268B A NN O
relates CN101781268B A VBZ O
to CN101781268B A TO O
an CN101781268B A DT O
isothiazole CN101781268B A JJ O
ketone CN101781268B A NN O
substituted CN101781268B A VBD O
benzene CN101781268B A JJ O
dicarboxylic CN101781268B A JJ O
acid CN101781268B A NN O
derivative CN101781268B A NN O
and CN101781268B A CC O
the CN101781268B A DT O
usage CN101781268B A JJ O
thereof CN101781268B A NN O
in CN101781268B A IN O
preparation CN101781268B A NN O
of CN101781268B A IN O
beta-secretase CN101781268B A JJ I-UN
inhibitor CN101781268B A NN O
. CN101781268B A . O

The CN101781268B A DT O
invention CN101781268B A NN O
further CN101781268B A RB O
relates CN101781268B A VBZ O
to CN101781268B A TO O
a CN101781268B A DT O
preparation CN101781268B A NN O
method CN101781268B A NN O
, CN101781268B A , O
a CN101781268B A DT O
pharmaceutical CN101781268B A JJ O
composition CN101781268B A NN O
containing CN101781268B A VBG O
the CN101781268B A DT O
compound CN101781268B A NN O
, CN101781268B A , O
and CN101781268B A CC O
the CN101781268B A DT O
usage CN101781268B A NN O
of CN101781268B A IN O
the CN101781268B A DT O
compound CN101781268B A NN O
in CN101781268B A IN O
the CN101781268B A DT O
preparation CN101781268B A NN O
of CN101781268B A IN O
medicine CN101781268B A NN O
for CN101781268B A IN O
treating CN101781268B A VBG O
and/or CN101781268B A JJ O
preventing CN101781268B A NN O
diseases CN101781268B A NNS O
or CN101781268B A CC O
symptoms CN101781268B A NNS O
relating CN101781268B A VBG O
to CN101781268B A TO O
beta-amyloid CN101781268B A JJ I-UN
peptide CN101781268B A JJ I-UN
aggregation CN101781268B A NN I-UN
or CN101781268B A CC O
settlement CN101781268B A NN O
. CN101781268B A . O

The CN101781268B A DT O
compound CN101781268B A NN O
can CN101781268B A MD O
be CN101781268B A VB O
used CN101781268B A VBN O
as CN101781268B A IN O
the CN101781268B A DT O
beta-secretase CN101781268B A JJ I-UN
inhibitor CN101781268B A NN O
. CN101781268B A . O

Particles CA2729582A1 T NNS O
containing CA2729582A1 T VBG O
an CA2729582A1 T DT O
opioid CA2729582A1 T JJ O
receptor CA2729582A1 T NN O
antagonist CA2729582A1 T NN O
and CA2729582A1 T CC O
methods CA2729582A1 T NNS O
of CA2729582A1 T IN O
use CA2729582A1 T NN O
. CA2729582A1 T . O

Salbutamol CN1568949A T NNP O
Sulfate CN1568949A T NNP O
drop CN1568949A T NN O
pills CN1568949A T NNS O
and CN1568949A T CC O
preparation CN1568949A T NN O
method CN1568949A T NN O
thereof CN1568949A T NN O
. CN1568949A T . O

Medicine CN1579408A T NNP O
for CN1579408A T IN O
spasmolysis CN1579408A T NN O
and CN1579408A T CC O
relieving CN1579408A T VBG O
pain CN1579408A T NN O
and CN1579408A T CC O
preparation CN1579408A T NN O
method CN1579408A T NN O
. CN1579408A T . O

Application CN102000079B T NN O
of CN102000079B T IN O
nicotinamide CN102000079B T JJ I-UN
mononucleotide CN102000079B T NN I-UN
ribose CN102000079B T VB I-UN
phosphate CN102000079B T JJ I-UN
transferase CN102000079B T NN I-UN
inhibitor CN102000079B T NN O
. CN102000079B T . O

The CN102000079B A DT O
invention CN102000079B A NN O
discloses CN102000079B A VBZ O
an CN102000079B A DT O
application CN102000079B A NN O
of CN102000079B A IN O
a CN102000079B A DT O
nicotinamide CN102000079B A JJ I-UN
mononucleotide CN102000079B A NN I-UN
ribose CN102000079B A VB I-UN
phosphate CN102000079B A JJ I-UN
transferase CN102000079B A NN I-UN
inhibitor CN102000079B A NN O
. CN102000079B A . O

The CN102000079B A DT O
nicotinamide CN102000079B A JJ I-UN
mononucleotide CN102000079B A NN I-UN
ribose CN102000079B A VB I-UN
phosphate CN102000079B A JJ I-UN
transferase CN102000079B A NN I-UN
inhibitor CN102000079B A NN O
can CN102000079B A MD O
effectively CN102000079B A RB O
prevent CN102000079B A VB O
or CN102000079B A CC O
treat CN102000079B A VB O
thrombocyte CN102000079B A JJ O
hyperfunction CN102000079B A NN O
, CN102000079B A , O
and CN102000079B A CC O
blood CN102000079B A NN O
hypercoagulative CN102000079B A JJ O
state CN102000079B A NN O
or CN102000079B A CC O
thrombi CN102000079B A NN O
, CN102000079B A , O
has CN102000079B A VBZ O
the CN102000079B A DT O
advantages CN102000079B A NNS O
of CN102000079B A IN O
favorable CN102000079B A JJ O
curative CN102000079B A JJ O
effect CN102000079B A NN O
, CN102000079B A , O
small CN102000079B A JJ O
side CN102000079B A NN O
effect CN102000079B A NN O
and CN102000079B A CC O
high CN102000079B A JJ O
safety CN102000079B A NN O
, CN102000079B A , O
and CN102000079B A CC O
has CN102000079B A VBZ O
an CN102000079B A DT O
important CN102000079B A JJ O
meaning CN102000079B A NN O
for CN102000079B A IN O
treating CN102000079B A VBG O
coagulation CN102000079B A NN O
hyperfunction CN102000079B A NN O
diseases CN102000079B A NNS O
. CN102000079B A . O

Pharmaceutical EP0840599B1 T JJ O
compositions EP0840599B1 T NNS O
of EP0840599B1 T IN O
conjugated EP0840599B1 T JJ O
estrogens EP0840599B1 T NNS O
and EP0840599B1 T CC O
methods EP0840599B1 T NNS O
for EP0840599B1 T IN O
their EP0840599B1 T PRP$ O
use EP0840599B1 T NN O
. EP0840599B1 T . O

Pharmaceutical US8501764 T JJ O
formulation US8501764 T NN O
and US8501764 T CC O
process US8501764 T NN O
comprising US8501764 T VBG O
a US8501764 T DT O
solid US8501764 T JJ O
dispersion US8501764 T NN O
of US8501764 T IN O
macrolide US8501764 T NN O
( US8501764 T ( O
tacrolimus US8501764 T NN O
) US8501764 T ) O
. US8501764 T . O

Methods US20120141603 T NNS O
and US20120141603 T CC O
compositions US20120141603 T NNS O
for US20120141603 T IN O
lung US20120141603 T NN O
cancer US20120141603 T NN O
prognosis US20120141603 T NN O
. US20120141603 T . O

The CN101036787A T DT O
application CN101036787A T NN O
of CN101036787A T IN O
medicine CN101036787A T JJ O
composition CN101036787A T NN O
containing CN101036787A T VBG O
proton CN101036787A T NN I-UN
pump CN101036787A T NN I-UN
inhibitor CN101036787A T NN O
in CN101036787A T IN O
the CN101036787A T DT O
novel CN101036787A T JJ O
gastroenteritic CN101036787A T JJ O
compound CN101036787A T NN O
capsule CN101036787A T NN O
and CN101036787A T CC O
the CN101036787A T DT O
preparation CN101036787A T NN O
. CN101036787A T . O

The CN101036787A A DT O
invention CN101036787A A NN O
relates CN101036787A A VBZ O
to CN101036787A A TO O
a CN101036787A A DT O
preparation CN101036787A A NN O
and CN101036787A A CC O
application CN101036787A A NN O
of CN101036787A A IN O
drug CN101036787A A NN O
combination CN101036787A A NN O
containing CN101036787A A VBG O
proton CN101036787A A JJ I-UN
pump CN101036787A A NN I-UN
inhibitor CN101036787A A NN O
in CN101036787A A IN O
new CN101036787A A JJ O
type CN101036787A A JJ O
gastrointestinal CN101036787A A NN O
complex CN101036787A A NN O
capsule CN101036787A A NN O
, CN101036787A A , O
belonging CN101036787A A VBG O
to CN101036787A A TO O
pharmacy CN101036787A A NN O
domain CN101036787A A NN O
. CN101036787A A . O

The CN101036787A A DT O
drug CN101036787A A NN O
combination CN101036787A A NN O
comprises CN101036787A A VBZ O
proton CN101036787A A JJ I-UN
pump CN101036787A A NN I-UN
inhibitor CN101036787A A NN O
of CN101036787A A IN O
medicinal CN101036787A A JJ O
dose CN101036787A A NN O
or CN101036787A A CC O
stereoisomer CN101036787A A NN O
thereof CN101036787A A NN O
and CN101036787A A CC O
salt CN101036787A A NN O
thereof CN101036787A A NN O
used CN101036787A A VBN O
as CN101036787A A IN O
medicine CN101036787A A NN O
, CN101036787A A , O
gastrointestinal CN101036787A A JJ O
motility-drug CN101036787A A NN O
of CN101036787A A IN O
medicinal CN101036787A A JJ O
dose CN101036787A A NN O
, CN101036787A A , O
or CN101036787A A CC O
salt CN101036787A A NN O
thereof CN101036787A A NNS O
used CN101036787A A VBD O
as CN101036787A A IN O
medicine CN101036787A A NN O
or CN101036787A A CC O
carrier CN101036787A A NN O
or CN101036787A A CC O
excipient CN101036787A A NN O
thereof CN101036787A A NN O
used CN101036787A A VBN O
as CN101036787A A IN O
medicine CN101036787A A NN O
. CN101036787A A . O

PERIPHERIALLY EP2675276A1 T NNP O
ACTING EP2675276A1 T NNP O
µ EP2675276A1 T NNP I-UN
OPIOID EP2675276A1 T NNP I-UN
ANTAGONISTS EP2675276A1 T NNP O
. EP2675276A1 T . O

The EP2675276A1 A DT O
present EP2675276A1 A JJ O
invention EP2675276A1 A NN O
relates EP2675276A1 A VBZ O
to EP2675276A1 A TO O
a EP2675276A1 A DT O
novel EP2675276A1 A JJ O
functional EP2675276A1 A JJ O
peripherally-acting EP2675276A1 A NN O
μ EP2675276A1 A NNP I-UN
opioid EP2675276A1 A NN I-UN
receptor EP2675276A1 A NN I-UN
antagonist EP2675276A1 A NN O
of EP2675276A1 A IN O
Formula EP2675276A1 A NNP O
I EP2675276A1 A PRP O
: EP2675276A1 A : O
The EP2675276A1 A DT O
novel EP2675276A1 A JJ O
compounds EP2675276A1 A NNS O
of EP2675276A1 A IN O
the EP2675276A1 A DT O
present EP2675276A1 A JJ O
invention EP2675276A1 A NN O
have EP2675276A1 A VBP O
reduced EP2675276A1 A VBN O
oral EP2675276A1 A JJ O
bioavailability EP2675276A1 A NN O
without EP2675276A1 A IN O
compromising EP2675276A1 A VBG O
opiate-induced EP2675276A1 A JJ O
analgesia EP2675276A1 A NN O
in EP2675276A1 A IN O
the EP2675276A1 A DT O
CNS EP2675276A1 A NNP O
. EP2675276A1 A . O

Substituted US20100075966 T VBN O
Dihydroimidazoles US20100075966 T NNS O
and US20100075966 T CC O
their US20100075966 T PRP$ O
Use US20100075966 T NN O
in US20100075966 T IN O
the US20100075966 T DT O
Treatment US20100075966 T NNP O
of US20100075966 T IN O
Tumors US20100075966 T NNPS O
. US20100075966 T . O

The US20100075966 A DT O
invention US20100075966 A NN O
relates US20100075966 A VBZ O
to US20100075966 A TO O
dihydroimidazoles US20100075966 A NNS O
of US20100075966 A IN O
formula US20100075966 A JJ O
rac- US20100075966 A NN O
( US20100075966 A ( O
I US20100075966 A PRP O
) US20100075966 A ) O
, US20100075966 A , O
wherein US20100075966 A VBD O
the US20100075966 A DT O
radicals US20100075966 A NNS O
and US20100075966 A CC O
symbols US20100075966 A NNS O
are US20100075966 A VBP O
as US20100075966 A IN O
defined US20100075966 A JJ O
herein US20100075966 A NN O
; US20100075966 A : O
their US20100075966 A PRP$ O
use US20100075966 A NN O
as US20100075966 A IN O
inhibitors US20100075966 A NNS O
of US20100075966 A IN O
the US20100075966 A DT O
interaction US20100075966 A NN O
of US20100075966 A IN O
the US20100075966 A DT O
MDM2 US20100075966 A NNP I-UN
protein US20100075966 A NN O
with US20100075966 A IN O
a US20100075966 A DT O
p53-like US20100075966 A JJ O
peptide US20100075966 A NN O
, US20100075966 A , O
new US20100075966 A JJ O
pharmaceutical US20100075966 A JJ O
formulations US20100075966 A NNS O
comprising US20100075966 A VBG O
said US20100075966 A VBD O
compounds US20100075966 A NNS O
, US20100075966 A , O
said US20100075966 A VBD O
compounds US20100075966 A NNS O
for US20100075966 A IN O
use US20100075966 A NN O
in US20100075966 A IN O
the US20100075966 A DT O
therapeutic US20100075966 A JJ O
treatment US20100075966 A NN O
of US20100075966 A IN O
warm-blooded US20100075966 A JJ O
animals US20100075966 A NNS O
, US20100075966 A , O
especially US20100075966 A RB O
humans US20100075966 A NNS O
, US20100075966 A , O
their US20100075966 A PRP$ O
use US20100075966 A NN O
in US20100075966 A IN O
the US20100075966 A DT O
treatment US20100075966 A NN O
of US20100075966 A IN O
proliferative US20100075966 A JJ O
diseases US20100075966 A NNS O
or US20100075966 A CC O
for US20100075966 A IN O
the US20100075966 A DT O
manufacture US20100075966 A NN O
of US20100075966 A IN O
pharmaceutical US20100075966 A JJ O
formulations US20100075966 A NNS O
useful US20100075966 A JJ O
in US20100075966 A IN O
the US20100075966 A DT O
treatment US20100075966 A NN O
of US20100075966 A IN O
proliferative US20100075966 A JJ O
diseases US20100075966 A NNS O
that US20100075966 A WDT O
respond US20100075966 A VBP O
to US20100075966 A TO O
modulation US20100075966 A NN O
of US20100075966 A IN O
the US20100075966 A DT O
interaction US20100075966 A NN O
of US20100075966 A IN O
the US20100075966 A DT O
MDM2 US20100075966 A NNP I-UN
protein US20100075966 A NN O
with US20100075966 A IN O
a US20100075966 A DT O
p53-like US20100075966 A JJ O
peptide US20100075966 A NN O
, US20100075966 A , O
a US20100075966 A DT O
pharmaceutical US20100075966 A JJ O
formulation US20100075966 A NN O
e.g US20100075966 A NN O
. US20100075966 A . O

useful US20100075966 A JJ O
in US20100075966 A IN O
the US20100075966 A DT O
treatment US20100075966 A NN O
of US20100075966 A IN O
proliferative US20100075966 A JJ O
diseases US20100075966 A NNS O
that US20100075966 A WDT O
respond US20100075966 A VBP O
to US20100075966 A TO O
modulation US20100075966 A NN O
of US20100075966 A IN O
the US20100075966 A DT O
interaction US20100075966 A NN O
of US20100075966 A IN O
the US20100075966 A DT O
MDM2 US20100075966 A NNP I-UN
protein US20100075966 A NN O
with US20100075966 A IN O
a US20100075966 A DT O
p53-like US20100075966 A JJ O
peptide US20100075966 A NN O
comprising US20100075966 A NN O
said US20100075966 A VBD O
compound US20100075966 A NN O
, US20100075966 A , O
methods US20100075966 A NNS O
of US20100075966 A IN O
treatment US20100075966 A NN O
comprising US20100075966 A VBG O
administration US20100075966 A NN O
of US20100075966 A IN O
said US20100075966 A VBD O
compounds US20100075966 A NNS O
to US20100075966 A TO O
a US20100075966 A DT O
warm-blooded US20100075966 A JJ O
animal US20100075966 A NN O
, US20100075966 A , O
and/or US20100075966 A JJ O
processes US20100075966 A NNS O
for US20100075966 A IN O
the US20100075966 A DT O
manufacture US20100075966 A NN O
of US20100075966 A IN O
said US20100075966 A VBD O
compounds US20100075966 A NNS O
. US20100075966 A . O

Multiple US20120302519 T NNP O
substituted US20120302519 T VBD O
fluoromethanes US20120302519 T NNS O
as US20120302519 T IN O
selective US20120302519 T JJ O
and US20120302519 T CC O
bioactive US20120302519 T JJ O
isosteres US20120302519 T NNS O
. US20120302519 T . O

Serum US20120201750 T NNP O
biomarkers US20120201750 T NNS O
for US20120201750 T IN O
melanoma US20120201750 T NN O
metastasis US20120201750 T NN O
. US20120201750 T . O

In US20120201750 A IN O
particular US20120201750 A JJ O
, US20120201750 A , O
the US20120201750 A DT O
present US20120201750 A JJ O
invention US20120201750 A NN O
provides US20120201750 A VBZ O
a US20120201750 A DT O
serum US20120201750 A JJ O
gene US20120201750 A NN O
expression US20120201750 A NN O
signature US20120201750 A NN O
that US20120201750 A WDT O
is US20120201750 A VBZ O
different US20120201750 A JJ O
between US20120201750 A IN O
highly US20120201750 A RB O
aggressive US20120201750 A JJ O
and US20120201750 A CC O
more US20120201750 A RBR O
metastatic US20120201750 A JJ O
versus US20120201750 A NN O
less US20120201750 A RBR O
aggressive US20120201750 A JJ O
and US20120201750 A CC O
less US20120201750 A RBR O
metastatic US20120201750 A JJ O
melanomas US20120201750 A NN O
by US20120201750 A IN O
quantitatively US20120201750 A RB O
measuring US20120201750 A VBG O
the US20120201750 A DT O
levels US20120201750 A NNS O
of US20120201750 A IN O
, US20120201750 A , O
inter US20120201750 A NN O
alia US20120201750 A NNS O
, US20120201750 A , O
lymphoid-specific US20120201750 A JJ I-UN
helicase US20120201750 A NN I-UN
( US20120201750 A ( O
HELLS US20120201750 A NNP I-UN
) US20120201750 A ) O
and US20120201750 A CC O
condensing US20120201750 A VBG I-UN
complex US20120201750 A JJ I-UN
subunit US20120201750 A NN I-UN
2 US20120201750 A CD I-UN
( US20120201750 A ( O
NCAPH US20120201750 A NNP I-UN
) US20120201750 A ) O
transcripts US20120201750 A NNS O
in US20120201750 A IN O
a US20120201750 A DT O
subject US20120201750 A NN O
. US20120201750 A . O

METHOD EP1689370B1 T NNP O
FOR EP1689370B1 T NNP O
THE EP1689370B1 T NNP O
PRODUCTION EP1689370B1 T NNP O
OF EP1689370B1 T IN O
A EP1689370B1 T NNP O
SOLID EP1689370B1 T NNP O
, EP1689370B1 T , O
ORALLY EP1689370B1 T NNP O
APPLICABLE EP1689370B1 T NNP O
PHARMACEUTICAL EP1689370B1 T NNP O
COMPOSITION EP1689370B1 T NNP O
COMPRISING EP1689370B1 T NNP O
5-Chlor-N EP1689370B1 T JJ O
( EP1689370B1 T ( O
{ EP1689370B1 T ( O
( EP1689370B1 T ( O
5-2-oxo-3- EP1689370B1 T JJ O
[ EP1689370B1 T NN O
4- EP1689370B1 T JJ O
( EP1689370B1 T ( O
3-oxo-4-morpholinyl EP1689370B1 T JJ O
) EP1689370B1 T ) O
-phenyl EP1689370B1 T FW O
] EP1689370B1 T FW O
-1 EP1689370B1 T FW O
, EP1689370B1 T , O
3- EP1689370B1 T JJ O
oxazolidin-5-yl EP1689370B1 T JJ O
} EP1689370B1 T ) O
-methyl EP1689370B1 T NN O
) EP1689370B1 T ) O
-2-thiophencarboxamide EP1689370B1 T NN O
. EP1689370B1 T . O

Minodronic CN103183709A T NNP O
acid CN103183709A T VBD O
new CN103183709A T JJ O
crystal CN103183709A T JJ O
form CN103183709A T NN O
, CN103183709A T , O
preparation CN103183709A T NN O
method CN103183709A T NN O
and CN103183709A T CC O
application CN103183709A T NN O
. CN103183709A T . O

The CN103183709A A DT O
invention CN103183709A A NN O
provides CN103183709A A VBZ O
a CN103183709A A DT O
minodronic CN103183709A A JJ O
acid CN103183709A A NN O
new CN103183709A A JJ O
crystal CN103183709A A JJ O
form CN103183709A A NN O
, CN103183709A A , O
a CN103183709A A DT O
preparation CN103183709A A NN O
method CN103183709A A NN O
and CN103183709A A CC O
an CN103183709A A DT O
application CN103183709A A NN O
, CN103183709A A , O
the CN103183709A A DT O
new CN103183709A A JJ O
crystal CN103183709A A JJ O
form CN103183709A A NN O
uses CN103183709A A VBZ O
Cu-Ka CN103183709A A NNP O
radiation CN103183709A A NN O
, CN103183709A A , O
a CN103183709A A DT O
X CN103183709A A NNP O
ray CN103183709A A NN O
powder CN103183709A A NN O
diffraction CN103183709A A NN O
spectrum CN103183709A A VBD O
shown CN103183709A A VBN O
with CN103183709A A IN O
angle CN103183709A A NN O
of CN103183709A A IN O
2 CN103183709A A CD O
theta CN103183709A A NNS O
degree CN103183709A A NN O
is CN103183709A A VBZ O
shown CN103183709A A VBN O
as CN103183709A A IN O
a CN103183709A A DT O
graph CN103183709A A NN O
1 CN103183709A A CD O
, CN103183709A A , O
a CN103183709A A DT O
thermogravimetry CN103183709A A NN O
analysis CN103183709A A NN O
graph CN103183709A A NN O
of CN103183709A A IN O
the CN103183709A A DT O
new CN103183709A A JJ O
crystal CN103183709A A JJ O
form CN103183709A A NN O
is CN103183709A A VBZ O
shown CN103183709A A VBN O
as CN103183709A A IN O
a CN103183709A A DT O
graph CN103183709A A NN O
2 CN103183709A A CD O
, CN103183709A A , O
the CN103183709A A DT O
crystallization CN103183709A A NN O
dehydrated CN103183709A A VBD O
temperature CN103183709A A NN O
of CN103183709A A IN O
the CN103183709A A DT O
new CN103183709A A JJ O
crystal CN103183709A A JJ O
form CN103183709A A NN O
is CN103183709A A VBZ O
147-162 CN103183709A A JJ O
DEG CN103183709A A NNP O
C CN103183709A A NNP O
, CN103183709A A , O
the CN103183709A A DT O
preparation CN103183709A A NN O
method CN103183709A A NN O
comprises CN103183709A A VBZ O
the CN103183709A A DT O
following CN103183709A A JJ O
steps CN103183709A A NNS O
: CN103183709A A : O
dissolving CN103183709A A VBG O
the CN103183709A A DT O
minodronic CN103183709A A JJ O
acid CN103183709A A NN O
raw CN103183709A A JJ O
material CN103183709A A NN O
in CN103183709A A IN O
a CN103183709A A DT O
solvent CN103183709A A NN O
, CN103183709A A , O
heating CN103183709A A NN O
and CN103183709A A CC O
preparing CN103183709A A VBG O
the CN103183709A A DT O
minodronic CN103183709A A JJ O
acid-containing CN103183709A A JJ O
solution CN103183709A A NN O
, CN103183709A A , O
wherein CN103183709A A VBP O
the CN103183709A A DT O
solvent CN103183709A A NN O
is CN103183709A A VBZ O
dilute CN103183709A A JJ O
hydrochloric CN103183709A A JJ O
acid CN103183709A A NN O
, CN103183709A A , O
dilute CN103183709A A JJ O
glacial CN103183709A A JJ O
acetic CN103183709A A JJ O
acid CN103183709A A NN O
or CN103183709A A CC O
dilute CN103183709A A NN O
sulfuric CN103183709A A JJ O
acid CN103183709A A NN O
; CN103183709A A : O
slowly CN103183709A A RB O
cooling CN103183709A A VBG O
to CN103183709A A TO O
the CN103183709A A DT O
temperature CN103183709A A NN O
to CN103183709A A TO O
20-40 CN103183709A A JJ O
DEG CN103183709A A NNP O
C CN103183709A A NNP O
under CN103183709A A IN O
stirring CN103183709A A VBG O
, CN103183709A A , O
standing CN103183709A A VBG O
for CN103183709A A IN O
8-36 CN103183709A A JJ O
hours CN103183709A A NNS O
, CN103183709A A , O
precipitating CN103183709A A VBG O
the CN103183709A A DT O
crystals CN103183709A A NNS O
; CN103183709A A : O
filtering CN103183709A A VBG O
, CN103183709A A , O
collecting CN103183709A A VBG O
the CN103183709A A DT O
crystals CN103183709A A NNS O
and CN103183709A A CC O
drying CN103183709A A NN O
, CN103183709A A , O
and CN103183709A A CC O
the CN103183709A A DT O
application CN103183709A A NN O
is CN103183709A A VBZ O
the CN103183709A A DT O
application CN103183709A A NN O
of CN103183709A A IN O
the CN103183709A A DT O
minodronic CN103183709A A JJ O
acid-hydrate CN103183709A A JJ O
crystal CN103183709A A NN O
form CN103183709A A NN O
used CN103183709A A VBN O
for CN103183709A A IN O
preparing CN103183709A A VBG O
a CN103183709A A DT O
pharmaceutical CN103183709A A JJ O
composition CN103183709A A NN O
for CN103183709A A IN O
treating CN103183709A A VBG O
osteoporosis CN103183709A A NN O
. CN103183709A A . O

The CN103183709A A DT O
crystal CN103183709A A JJ O
form CN103183709A A NN O
of CN103183709A A IN O
the CN103183709A A DT O
minodronic CN103183709A A JJ O
acid-hydrate CN103183709A A JJ O
new CN103183709A A JJ O
crystal CN103183709A A JJ O
form CN103183709A A NN O
is CN103183709A A VBZ O
stable CN103183709A A JJ O
, CN103183709A A , O
and CN103183709A A CC O
is CN103183709A A VBZ O
the CN103183709A A DT O
optimal CN103183709A A JJ O
crystal CN103183709A A JJ O
form CN103183709A A NN O
for CN103183709A A IN O
preparing CN103183709A A VBG O
the CN103183709A A DT O
minodronic CN103183709A A JJ O
acid CN103183709A A NN O
pharmaceutical CN103183709A A JJ O
composition CN103183709A A NN O
. CN103183709A A . O

Troxipide CN102462669A T NNP O
dispersible CN102462669A T JJ O
tablet CN102462669A T NN O
and CN102462669A T CC O
preparation CN102462669A T NN O
method CN102462669A T NN O
thereof CN102462669A T NN O
. CN102462669A T . O

Medicinal CN1785198A T NNP O
composite CN1785198A T JJ O
prepn CN1785198A T NN O
. CN1785198A T . O

contg CN1785198A T NN O
ranitidine CN1785198A T NN O
hydrochloride CN1785198A T NN O
and CN1785198A T CC O
sucralfate CN1785198A T NN O
. CN1785198A T . O

Cancer US20090220495 T NNP O
Related US20090220495 T NNP O
Genes US20090220495 T NNP O
( US20090220495 T ( O
PRLR US20090220495 T NNP I-UN
) US20090220495 T ) O
. US20090220495 T . O

Specifically US20090220495 A RB O
it US20090220495 A PRP O
relates US20090220495 A VBZ O
to US20090220495 A TO O
methods US20090220495 A NNS O
for US20090220495 A IN O
detecting US20090220495 A VBG O
cancer US20090220495 A NN O
or US20090220495 A CC O
the US20090220495 A DT O
likelihood US20090220495 A NN O
of US20090220495 A IN O
developing US20090220495 A VBG O
cancer US20090220495 A NN O
based US20090220495 A VBN O
on US20090220495 A IN O
the US20090220495 A DT O
presence US20090220495 A NN O
or US20090220495 A CC O
absence US20090220495 A NN O
of US20090220495 A IN O
expression US20090220495 A NN O
of US20090220495 A IN O
a US20090220495 A DT O
PRLR US20090220495 A NNP I-UN
gene US20090220495 A NN O
or US20090220495 A CC O
protein US20090220495 A NN O
. US20090220495 A . O

The US20090220495 A DT O
invention US20090220495 A NN O
also US20090220495 A RB O
provides US20090220495 A VBZ O
methods US20090220495 A NNS O
and US20090220495 A CC O
molecules US20090220495 A NNS O
for US20090220495 A IN O
upregulating US20090220495 A VBG O
or US20090220495 A CC O
downregulating US20090220495 A VBG O
PRLR US20090220495 A NNP I-UN
gene US20090220495 A NN O
expression US20090220495 A NN O
and US20090220495 A CC O
PRLR US20090220495 A NNP I-UN
protein US20090220495 A NN O
activity US20090220495 A NN O
. US20090220495 A . O

Inhibiting US20080114025 T VBG O
a US20080114025 T DT O
variety US20080114025 T NN O
of US20080114025 T IN O
pain US20080114025 T NN O
, US20080114025 T , O
inflammation US20080114025 T NN O
, US20080114025 T , O
spasm US20080114025 T NN O
and US20080114025 T CC O
restenosis US20080114025 T NN O
processes US20080114025 T NNS O
resulting US20080114025 T VBG O
from US20080114025 T IN O
cardiovascular US20080114025 T NN O
or US20080114025 T CC O
general US20080114025 T JJ O
vascular US20080114025 T JJ O
therapeutic US20080114025 T NN O
and US20080114025 T CC O
diagnostic US20080114025 T JJ O
procedures US20080114025 T NNS O
; US20080114025 T : O
use US20080114025 T NN O
of US20080114025 T IN O
ADP US20080114025 T NNP I-UN
receptor US20080114025 T NN I-UN
antagonist US20080114025 T NN O
and US20080114025 T CC O
a US20080114025 T DT O
thromboxane US20080114025 T NN I-UN
A2 US20080114025 T NNP I-UN
receptor US20080114025 T NN I-UN
antagonist US20080114025 T NN O
. US20080114025 T . O

Inhibitors CN101932560B T NNS O
for CN101932560B T IN O
matrix CN101932560B T NN I-UN
metalloproteinases CN101932560B T NNS I-UN
, CN101932560B T , O
pharmaceutical CN101932560B T JJ O
compositions CN101932560B T NNS O
containing CN101932560B T VBG O
them CN101932560B T PRP O
and CN101932560B T CC O
their CN101932560B T PRP$ O
uses CN101932560B T NNS O
. CN101932560B T . O

Inhibitors CN101932560B A NNS O
for CN101932560B A IN O
matrix CN101932560B A NN I-UN
metalloproteinases CN101932560B A NNS I-UN
, CN101932560B A , O
pharmaceutical CN101932560B A JJ O
compositions CN101932560B A NNS O
containing CN101932560B A VBG O
them CN101932560B A PRP O
and CN101932560B A CC O
their CN101932560B A PRP$ O
uses CN101932560B A NNS O
. CN101932560B A . O

The CN101932560B A DT O
inhibitors CN101932560B A NNS O
for CN101932560B A IN O
matrix CN101932560B A NN I-UN
metalloproteinases CN101932560B A NNS I-UN
have CN101932560B A VBP O
the CN101932560B A DT O
formula CN101932560B A NN O
( CN101932560B A ( O
I CN101932560B A PRP O
) CN101932560B A ) O
, CN101932560B A , O
wherein CN101932560B A JJ O
W CN101932560B A NNP O
, CN101932560B A , O
X1 CN101932560B A NNP O
, CN101932560B A , O
X2 CN101932560B A NNP O
, CN101932560B A , O
R1 CN101932560B A NNP O
, CN101932560B A , O
R2 CN101932560B A NNP O
are CN101932560B A VBP O
as CN101932560B A IN O
defined CN101932560B A VBN O
in CN101932560B A IN O
the CN101932560B A DT O
description CN101932560B A NN O
. CN101932560B A . O

They CN101932560B A PRP O
are CN101932560B A VBP O
useful CN101932560B A JJ O
for CN101932560B A IN O
the CN101932560B A DT O
prevention CN101932560B A NN O
or CN101932560B A CC O
treatment CN101932560B A NN O
of CN101932560B A IN O
diseases CN101932560B A NNS O
regulated CN101932560B A VBN O
by CN101932560B A IN O
matrix CN101932560B A NN I-UN
metalloproteinases CN101932560B A NNS I-UN
, CN101932560B A , O
in CN101932560B A IN O
particular CN101932560B A JJ O
corneal CN101932560B A NN O
ulceration CN101932560B A NN O
, CN101932560B A , O
pulmonary CN101932560B A JJ O
emphysema CN101932560B A NN O
or CN101932560B A CC O
dermal CN101932560B A JJ O
ulceration CN101932560B A NN O
resulted CN101932560B A VBD O
from CN101932560B A IN O
chemical CN101932560B A JJ O
injury CN101932560B A NN O
, CN101932560B A , O
or CN101932560B A CC O
pulmonary CN101932560B A JJ O
emphysema CN101932560B A NN O
caused CN101932560B A VBN O
by CN101932560B A IN O
smoking CN101932560B A VBG O
or CN101932560B A CC O
drowning CN101932560B A NN O
. CN101932560B A . O

Volume-expansion CN1559391A T NN O
protection CN1559391A T NN O
agent CN1559391A T NN O
, CN1559391A T , O
and CN1559391A T CC O
application CN1559391A T NN O
in CN1559391A T IN O
treating CN1559391A T VBG O
blood-loss CN1559391A T NN O
shock CN1559391A T NN O
. CN1559391A T . O

6 US20110144084 T CD O
substituted US20110144084 T VBD O
2- US20110144084 T JJ O
heterocyclylamino US20110144084 T NN O
pyrazine US20110144084 T NN O
compounds US20110144084 T VBZ O
as US20110144084 T IN O
chk-1 US20110144084 T JJ I-UN
inhibitors US20110144084 T NNS O
. US20110144084 T . O

The US20110144084 A DT O
present US20110144084 A JJ O
invention US20110144084 A NN O
is US20110144084 A VBZ O
directed US20110144084 A VBN O
to US20110144084 A TO O
compounds US20110144084 A NNS O
of US20110144084 A IN O
formula US20110144084 A NN O
( US20110144084 A ( O
I US20110144084 A PRP O
) US20110144084 A ) O
, US20110144084 A , O
and US20110144084 A CC O
pharmaceutically US20110144084 A RB O
acceptable US20110144084 A JJ O
salts US20110144084 A NNS O
thereof US20110144084 A NNS O
, US20110144084 A , O
their US20110144084 A PRP$ O
synthesis US20110144084 A NN O
, US20110144084 A , O
and US20110144084 A CC O
their US20110144084 A PRP$ O
use US20110144084 A NN O
as US20110144084 A IN O
CHK-1 US20110144084 A JJ I-UN
inhibitors US20110144084 A NNS O
. US20110144084 A . O

Parenteral WO2009136370A1 T JJ O
supplement WO2009136370A1 T NN O
with WO2009136370A1 T IN O
traceelemξntsfor WO2009136370A1 T JJ O
treatment WO2009136370A1 T NN O
of WO2009136370A1 T IN O
i. WO2009136370A1 T NN O
a. WO2009136370A1 T NN O
sirs WO2009136370A1 T NNS O
, WO2009136370A1 T , O
burns WO2009136370A1 T VBZ O
selenium-defenciencies WO2009136370A1 T NNS O
. WO2009136370A1 T . O

Antineoplastic WO2006110119A1 T JJ O
preparation WO2006110119A1 T NN O
. WO2006110119A1 T . O

Use US20050238635 T NNP O
of US20050238635 T IN O
hyrogen US20050238635 T NN O
peroxide US20050238635 T IN O
producting US20050238635 T VBG O
enzyme US20050238635 T NN O
for US20050238635 T IN O
treatment US20050238635 T NN O
of US20050238635 T IN O
otitis US20050238635 T JJ O
media US20050238635 T NNS O
. US20050238635 T . O

This US20050238635 A DT O
enzyme US20050238635 A NN O
is US20050238635 A VBZ O
preferably US20050238635 A RB O
NADH US20050238635 A NNP I-UN
oxidase US20050238635 A NN I-UN
. US20050238635 A . O

ENA-78 US20080045582 T JJ I-UN
Gene US20080045582 T NNP O
Polymorphisms US20080045582 T NNP O
and US20080045582 T CC O
Protein US20080045582 T NNP O
Concentrations US20080045582 T NNP O
as US20080045582 T IN O
Diagnostic US20080045582 T NNP O
and US20080045582 T CC O
Prognostic US20080045582 T NNP O
Tools US20080045582 T NNP O
. US20080045582 T . O

The US20080045582 A DT O
invention US20080045582 A NN O
concerns US20080045582 A NNS O
polymorphisms US20080045582 A NNS O
in US20080045582 A IN O
the US20080045582 A DT O
CXCL5 US20080045582 A NNP I-UN
gene US20080045582 A NN O
and US20080045582 A CC O
the US20080045582 A DT O
concentration US20080045582 A NN O
of US20080045582 A IN O
epithelial US20080045582 A JJ I-UN
neutrophil US20080045582 A NN I-UN
activating US20080045582 A VBG I-UN
peptide US20080045582 A NN I-UN
( US20080045582 A ( O
ENA-78 US20080045582 A NNP I-UN
) US20080045582 A ) O
in US20080045582 A IN O
patients US20080045582 A NNS O
. US20080045582 A . O

The US20080045582 A DT O
invention US20080045582 A NN O
further US20080045582 A RB O
relates US20080045582 A VBZ O
to US20080045582 A TO O
the US20080045582 A DT O
use US20080045582 A NN O
of US20080045582 A IN O
such US20080045582 A JJ O
methods US20080045582 A NNS O
and US20080045582 A CC O
systems US20080045582 A NNS O
in US20080045582 A IN O
the US20080045582 A DT O
diagnosis US20080045582 A NN O
, US20080045582 A , O
prognosis US20080045582 A NN O
, US20080045582 A , O
and US20080045582 A CC O
treatment US20080045582 A NN O
selection US20080045582 A NN O
for US20080045582 A IN O
inflammatory US20080045582 A NN O
disorders US20080045582 A NNS O
associated US20080045582 A VBN O
with US20080045582 A IN O
elevated US20080045582 A JJ O
ENA-78 US20080045582 A JJ I-UN
concentrations US20080045582 A NNS O
. US20080045582 A . O

Chalcone CN101244048B T NNP O
compounds CN101244048B T NNS O
and CN101244048B T CC O
uses CN101244048B T NNS O
of CN101244048B T IN O
the CN101244048B T DT O
composition CN101244048B T NN O
. CN101244048B T . O

The CN101244048B A DT O
invention CN101244048B A NN O
discloses CN101244048B A VBZ O
the CN101244048B A DT O
application CN101244048B A NN O
of CN101244048B A IN O
chalcone CN101244048B A NN O
ketones CN101244048B A NNS O
compound CN101244048B A NN O
and CN101244048B A CC O
the CN101244048B A DT O
salt CN101244048B A NN O
as CN101244048B A IN O
shown CN101244048B A VBN O
in CN101244048B A IN O
formula CN101244048B A NN O
I CN101244048B A PRP O
in CN101244048B A IN O
inhibiting CN101244048B A VBG O
cell CN101244048B A NN O
mitosis CN101244048B A NN O
; CN101244048B A : O
wherein CN101244048B A CC O
, CN101244048B A , O
the CN101244048B A DT O
application CN101244048B A NN O
can CN101244048B A MD O
produce CN101244048B A VB O
the CN101244048B A DT O
efficacy CN101244048B A NN O
of CN101244048B A IN O
inhibiting CN101244048B A VBG O
tumor CN101244048B A NN O
or CN101244048B A CC O
inhibiting CN101244048B A NN O
over CN101244048B A IN O
proliferation CN101244048B A NN O
of CN101244048B A IN O
cell CN101244048B A NN O
. CN101244048B A . O

The CN101244048B A DT O
invention CN101244048B A NN O
also CN101244048B A RB O
discloses CN101244048B A VBZ O
the CN101244048B A DT O
application CN101244048B A NN O
of CN101244048B A IN O
the CN101244048B A DT O
compounds CN101244048B A NNS O
and CN101244048B A CC O
the CN101244048B A DT O
salt CN101244048B A NN O
in CN101244048B A IN O
treating CN101244048B A VBG O
tumor CN101244048B A NN O
; CN101244048B A : O
the CN101244048B A DT O
usage CN101244048B A NN O
can CN101244048B A MD O
play CN101244048B A VB O
the CN101244048B A DT O
role CN101244048B A NN O
of CN101244048B A IN O
inhibiting CN101244048B A VBG O
over CN101244048B A IN O
proliferation CN101244048B A NN O
of CN101244048B A IN O
cell CN101244048B A NN O
through CN101244048B A IN O
inhibiting CN101244048B A VBG O
cell CN101244048B A NN O
mitosis CN101244048B A NN O
; CN101244048B A : O
in CN101244048B A IN O
the CN101244048B A DT O
formula CN101244048B A NN O
( CN101244048B A ( O
as CN101244048B A IN O
shown CN101244048B A VBN O
in CN101244048B A IN O
the CN101244048B A DT O
figure CN101244048B A NN O
) CN101244048B A ) O
, CN101244048B A , O
R1 CN101244048B A NNP O
, CN101244048B A , O
R2 CN101244048B A NNP O
, CN101244048B A , O
R3 CN101244048B A NNP O
and CN101244048B A CC O
R4 CN101244048B A NNP O
can CN101244048B A MD O
be CN101244048B A VB O
independently CN101244048B A RB O
selected CN101244048B A VBN O
from CN101244048B A IN O
hydrogen CN101244048B A NN O
, CN101244048B A , O
hydroxy CN101244048B A NN O
, CN101244048B A , O
C1-C8 CN101244048B A NNP O
alkoxy CN101244048B A NN O
, CN101244048B A , O
C1-C4 CN101244048B A NNP O
acyl CN101244048B A NN O
and CN101244048B A CC O
halogen CN101244048B A NN O
. CN101244048B A . O

2- EP1789402A1 T JJ O
{ EP1789402A1 T ( O
-3-2- EP1789402A1 T NN O
( EP1789402A1 T ( O
phenyl EP1789402A1 T NN O
) EP1789402A1 T ) O
-oxazol-4-ylmethoxymethyl EP1789402A1 T NN O
! EP1789402A1 T . O
-cyclohexylmethoxy EP1789402A1 T JJ O
} EP1789402A1 T ) O
; EP1789402A1 T : O
-propionic EP1789402A1 T JJ O
acid EP1789402A1 T NN O
derivatives EP1789402A1 T NNS O
used EP1789402A1 T VBN O
as EP1789402A1 T IN O
ppar EP1789402A1 T NN O
ligandes EP1789402A1 T NNS O
( EP1789402A1 T ( O
peroxisome EP1789402A1 T JJ O
proliferator-activated EP1789402A1 T JJ O
receptors EP1789402A1 T NNS O
) EP1789402A1 T ) O
for EP1789402A1 T IN O
the EP1789402A1 T DT O
treatment EP1789402A1 T NN O
of EP1789402A1 T IN O
hyperlipidaemie EP1789402A1 T NN O
and EP1789402A1 T CC O
diabetes EP1789402A1 T NNS O
. EP1789402A1 T . O

The EP1789402A1 A DT O
inventive EP1789402A1 A JJ O
compounds EP1789402A1 A NNS O
are EP1789402A1 A VBP O
suitable EP1789402A1 A JJ O
for EP1789402A1 A IN O
treating EP1789402A1 A VBG O
and/or EP1789402A1 A JJ O
preventing EP1789402A1 A VBG O
disorders EP1789402A1 A NNS O
of EP1789402A1 A IN O
the EP1789402A1 A DT O
fatty EP1789402A1 A JJ O
acid EP1789402A1 A JJ O
metabolism EP1789402A1 A NN O
and EP1789402A1 A CC O
disorders EP1789402A1 A NNS O
of EP1789402A1 A IN O
glucose EP1789402A1 A JJ O
utilization EP1789402A1 A NN O
in EP1789402A1 A IN O
addition EP1789402A1 A NN O
to EP1789402A1 A TO O
disorders EP1789402A1 A NNS O
, EP1789402A1 A , O
in EP1789402A1 A IN O
which EP1789402A1 A WDT O
insulin EP1789402A1 A NN I-UN
resistance EP1789402A1 A NN O
plays EP1789402A1 A VBZ O
a EP1789402A1 A DT O
part EP1789402A1 A NN O
. EP1789402A1 A . O

Veterinary CN101618025B T JJ O
doxycycline CN101618025B T NN O
hydrochloride CN101618025B T NN O
freeze-dried CN101618025B T JJ O
preparation CN101618025B T NN O
and CN101618025B T CC O
preparation CN101618025B T NN O
method CN101618025B T NN O
thereof CN101618025B T NN O
. CN101618025B T . O

Inhibitors CA2254759C T NNS O
of CA2254759C T IN O
prenyl CA2254759C T NN O
transferases CA2254759C T NNS O
. CA2254759C T . O

Therapeutic CN101103969A T JJ O
formulations CN101103969A T NNS O
for CN101103969A T IN O
the CN101103969A T DT O
treatment CN101103969A T NN O
of CN101103969A T IN O
beta-amyloid CN101103969A T JJ I-UN
related CN101103969A T JJ O
diseases CN101103969A T NNS O
. CN101103969A T . O

The CN101103969A A DT O
method CN101103969A A NN O
is CN101103969A A VBZ O
used CN101103969A A VBN O
for CN101103969A A IN O
preventing CN101103969A A VBG O
or CN101103969A A CC O
treating CN101103969A A VBG O
an CN101103969A A DT O
amyloid-beta CN101103969A A JJ I-UN
related CN101103969A A JJ O
disease CN101103969A A NN O
in CN101103969A A IN O
a CN101103969A A DT O
subject CN101103969A A NN O
. CN101103969A A . O

The CN101103969A A DT O
method CN101103969A A NN O
comprises CN101103969A A VBZ O
administering CN101103969A A VBG O
to CN101103969A A TO O
a CN101103969A A DT O
subject CN101103969A A NN O
in CN101103969A A IN O
need CN101103969A A NN O
thereof CN101103969A A VBP O
an CN101103969A A DT O
effective CN101103969A A JJ O
amount CN101103969A A NN O
of CN101103969A A IN O
a CN101103969A A DT O
first CN101103969A A JJ O
agent CN101103969A A NN O
that CN101103969A A WDT O
prevents CN101103969A A VBZ O
or CN101103969A A CC O
treats CN101103969A A NNS O
amyloid-beta CN101103969A A RB I-UN
related CN101103969A A JJ O
disease CN101103969A A NN O
, CN101103969A A , O
and CN101103969A A CC O
a CN101103969A A DT O
second CN101103969A A JJ O
agent CN101103969A A NN O
that CN101103969A A WDT O
is CN101103969A A VBZ O
( CN101103969A A ( O
i CN101103969A A NN O
) CN101103969A A ) O
a CN101103969A A DT O
peptide CN101103969A A NN O
or CN101103969A A CC O
peptidomimetic CN101103969A A JJ O
that CN101103969A A IN O
modulates CN101103969A A VBZ O
amyloid-beta CN101103969A A JJ I-UN
fibril CN101103969A A JJ O
formulation CN101103969A A NN O
or CN101103969A A CC O
induces CN101103969A A VBZ O
a CN101103969A A DT O
prophylactic CN101103969A A JJ O
or CN101103969A A CC O
therapeutic CN101103969A A JJ O
immune CN101103969A A JJ O
response CN101103969A A NN O
against CN101103969A A IN O
amyloid-beta CN101103969A A JJ I-UN
fibril CN101103969A A JJ O
formulation CN101103969A A NN O
, CN101103969A A , O
or CN101103969A A CC O
( CN101103969A A ( O
ii CN101103969A A NN O
) CN101103969A A ) O
an CN101103969A A DT O
immune CN101103969A A JJ O
system CN101103969A A NN O
modulator CN101103969A A NN O
that CN101103969A A WDT O
prevents CN101103969A A VBZ O
or CN101103969A A CC O
inhibits CN101103969A A VBZ O
amyloid-beta CN101103969A A JJ I-UN
fibril CN101103969A A JJ O
formulation CN101103969A A NN O
. CN101103969A A . O

Film-coated WO2008069262A1 T JJ O
preparation WO2008069262A1 T NN O
having WO2008069262A1 T VBG O
improved WO2008069262A1 T VBN O
stability WO2008069262A1 T NN O
. WO2008069262A1 T . O

Derivatives US20100029758 T NNS O
of US20100029758 T IN O
isoflavones US20100029758 T NNS O
. US20100029758 T . O

Improved EP0873110B1 T VBN O
hemostatic EP0873110B1 T JJ O
composition EP0873110B1 T NN O
for EP0873110B1 T IN O
treating EP0873110B1 T VBG O
gingival EP0873110B1 T JJ O
area EP0873110B1 T NN O
. EP0873110B1 T . O

A EP1549301A2 T DT O
method EP1549301A2 T NN O
for EP1549301A2 T IN O
using EP1549301A2 T VBG O
tethered EP1549301A2 T JJ O
bis EP1549301A2 T NN O
( EP1549301A2 T ( O
polyhydroxyphenyls EP1549301A2 T NN O
) EP1549301A2 T ) O
and EP1549301A2 T CC O
o-alkyl EP1549301A2 T JJ O
derivatives EP1549301A2 T NNS O
thereof EP1549301A2 T VBP O
in EP1549301A2 T IN O
treating EP1549301A2 T VBG O
inflammatory EP1549301A2 T JJ O
conditions EP1549301A2 T NNS O
of EP1549301A2 T IN O
the EP1549301A2 T DT O
central EP1549301A2 T JJ O
nervous EP1549301A2 T JJ O
system EP1549301A2 T NN O
. EP1549301A2 T . O

The EP1549301A2 A DT O
present EP1549301A2 A JJ O
invention EP1549301A2 A NN O
involves EP1549301A2 A VBZ O
the EP1549301A2 A DT O
use EP1549301A2 A NN O
tethered EP1549301A2 A VBD O
bis EP1549301A2 A NN O
( EP1549301A2 A ( O
polyhydroxyphenyl EP1549301A2 A NN O
) EP1549301A2 A ) O
compounds EP1549301A2 A VBZ O
to EP1549301A2 A TO O
slow EP1549301A2 A VB O
the EP1549301A2 A DT O
progression EP1549301A2 A NN O
of EP1549301A2 A IN O
neurological EP1549301A2 A JJ O
diseases EP1549301A2 A NNS O
in EP1549301A2 A IN O
which EP1549301A2 A WDT O
pro-inflammatory EP1549301A2 A JJ O
cytokine EP1549301A2 A NN I-UN
stimulation EP1549301A2 A NN O
of EP1549301A2 A IN O
microglial EP1549301A2 A JJ O
cells EP1549301A2 A NNS O
is EP1549301A2 A VBZ O
reasonably EP1549301A2 A RB O
anticipated EP1549301A2 A VBN O
to EP1549301A2 A TO O
make EP1549301A2 A VB O
a EP1549301A2 A DT O
significant EP1549301A2 A JJ O
contribution EP1549301A2 A NN O
to EP1549301A2 A TO O
disease EP1549301A2 A VB O
pathology EP1549301A2 A NN O
. EP1549301A2 A . O

Use CA2414921C T NNP O
of CA2414921C T IN O
diclofenac CA2414921C T NN O
for CA2414921C T IN O
treatment CA2414921C T NN O
of CA2414921C T IN O
burns CA2414921C T NNS O
. CA2414921C T . O

The CA2414921C A DT O
invention CA2414921C A NN O
relates CA2414921C A VBZ O
to CA2414921C A TO O
the CA2414921C A DT O
topical CA2414921C A JJ O
use CA2414921C A NN O
of CA2414921C A IN O
diclofenac CA2414921C A NN O
, CA2414921C A , O
and CA2414921C A CC O
topically CA2414921C A RB O
acceptable CA2414921C A JJ O
salts CA2414921C A NNS O
thereof CA2414921C A NN O
, CA2414921C A , O
( CA2414921C A ( O
for CA2414921C A IN O
the CA2414921C A DT O
manufacture CA2414921C A NN O
of CA2414921C A IN O
a CA2414921C A DT O
topical CA2414921C A JJ O
medicament CA2414921C A NN O
) CA2414921C A ) O
for CA2414921C A IN O
the CA2414921C A DT O
topical CA2414921C A JJ O
treatment CA2414921C A NN O
of CA2414921C A IN O
burns CA2414921C A NNS O
. CA2414921C A . O

Heteroarylphenylurea US8609656 T NNP O
derivative US8609656 T NN O
. US8609656 T . O

Compound CN103347509A T NN O
and CN103347509A T CC O
composition CN103347509A T NN O
for CN103347509A T IN O
treatment CN103347509A T NN O
of CN103347509A T IN O
cancer CN103347509A T NN O
. CN103347509A T . O

New CN103347509A A NNP O
uses CN103347509A A NNS O
for CN103347509A A IN O
phenylketone CN103347509A A NN O
carboxylate CN103347509A A NN O
compounds CN103347509A A NNS O
and CN103347509A A CC O
substituted CN103347509A A VBD O
aromatic CN103347509A A JJ O
compounds CN103347509A A NNS O
of CN103347509A A IN O
Formula CN103347509A A NNP O
I CN103347509A A PRP O
, CN103347509A A , O
Formula CN103347509A A NNP O
I.1 CN103347509A A NNP O
, CN103347509A A , O
Formula CN103347509A A NNP O
I.2 CN103347509A A NNP O
, CN103347509A A , O
Formula CN103347509A A NNP O
IA CN103347509A A NNP O
, CN103347509A A , O
Formula CN103347509A A NNP O
IB CN103347509A A NNP O
, CN103347509A A , O
Formula CN103347509A A NNP O
IC CN103347509A A NNP O
and CN103347509A A CC O
Formula CN103347509A A NNP O
II CN103347509A A NNP O
and CN103347509A A CC O
their CN103347509A A PRP$ O
pharmaceutical CN103347509A A JJ O
acceptable CN103347509A A JJ O
salts CN103347509A A NNS O
for CN103347509A A IN O
the CN103347509A A DT O
treatment CN103347509A A NN O
of CN103347509A A IN O
cancer CN103347509A A NN O
. CN103347509A A . O

The CN103347509A A DT O
use CN103347509A A NN O
of CN103347509A A IN O
a CN103347509A A DT O
combination CN103347509A A NN O
of CN103347509A A IN O
two CN103347509A A CD O
of CN103347509A A IN O
these CN103347509A A DT O
compounds CN103347509A A NNS O
is CN103347509A A VBZ O
described CN103347509A A VBN O
and CN103347509A A CC O
the CN103347509A A DT O
use CN103347509A A NN O
of CN103347509A A IN O
the CN103347509A A DT O
combination CN103347509A A NN O
of CN103347509A A IN O
one CN103347509A A CD O
of CN103347509A A IN O
these CN103347509A A DT O
compounds CN103347509A A NNS O
with CN103347509A A IN O
an CN103347509A A DT O
anticancer CN103347509A A NN O
agent CN103347509A A NN O
such CN103347509A A JJ O
as CN103347509A A IN O
decarbazine CN103347509A A NN O
, CN103347509A A , O
doxorubicin CN103347509A A NN O
, CN103347509A A , O
daunorubicin CN103347509A A NN O
, CN103347509A A , O
cyclophosphamide CN103347509A A NN O
, CN103347509A A , O
busulfex CN103347509A A NN O
, CN103347509A A , O
busulfan CN103347509A A NN O
, CN103347509A A , O
vinblastine CN103347509A A NN O
, CN103347509A A , O
vincristine CN103347509A A NN O
, CN103347509A A , O
bleomycin CN103347509A A NN O
, CN103347509A A , O
etoposide CN103347509A A RB O
, CN103347509A A , O
topotecan CN103347509A A JJ O
, CN103347509A A , O
irinotecan CN103347509A A JJ O
, CN103347509A A , O
taxotere CN103347509A A RB O
, CN103347509A A , O
taxol CN103347509A A NN O
, CN103347509A A , O
5-fluorouracil CN103347509A A JJ O
, CN103347509A A , O
methotrexate CN103347509A A NN O
, CN103347509A A , O
gemcitabine CN103347509A A NN O
, CN103347509A A , O
cisplatin CN103347509A A NN O
, CN103347509A A , O
carboplatin CN103347509A A NN O
and CN103347509A A CC O
chlorambucil CN103347509A A NN O
. CN103347509A A . O

Methods US20100273851 T NNS O
of US20100273851 T IN O
using US20100273851 T VBG O
proteinacious US20100273851 T JJ O
channels US20100273851 T NNS O
to US20100273851 T TO O
identify US20100273851 T VB O
pharmaceutical US20100273851 T JJ O
treatments US20100273851 T NNS O
and US20100273851 T CC O
risks US20100273851 T NNS O
, US20100273851 T , O
and US20100273851 T CC O
treatments US20100273851 T NNS O
resulting US20100273851 T VBG O
therefrom US20100273851 T NN O
. US20100273851 T . O

The US20100273851 A DT O
methods US20100273851 A NNS O
entail US20100273851 A VBP O
administering US20100273851 A VBG O
a US20100273851 A DT O
pharmaceutical US20100273851 A JJ O
to US20100273851 A TO O
a US20100273851 A DT O
lipid US20100273851 A JJ O
membrane US20100273851 A NN O
of US20100273851 A IN O
a US20100273851 A DT O
mammalian US20100273851 A JJ O
cell US20100273851 A NN O
, US20100273851 A , O
and US20100273851 A CC O
then US20100273851 A RB O
determining US20100273851 A VBG O
the US20100273851 A DT O
effect US20100273851 A NN O
of US20100273851 A IN O
the US20100273851 A DT O
pharmaceutical US20100273851 A JJ O
on US20100273851 A IN O
the US20100273851 A DT O
electrophysiology US20100273851 A NN O
of US20100273851 A IN O
at US20100273851 A IN O
least US20100273851 A JJS O
one US20100273851 A CD O
proteinacious US20100273851 A JJ O
channel US20100273851 A NN O
of US20100273851 A IN O
the US20100273851 A DT O
lipid US20100273851 A JJ O
membrane US20100273851 A NN O
, US20100273851 A , O
wherein US20100273851 A VBP O
the US20100273851 A DT O
proteinacious US20100273851 A JJ O
channel US20100273851 A NN O
is US20100273851 A VBZ O
a US20100273851 A DT O
Kv7 US20100273851 A NNP I-UN
potassium US20100273851 A NN I-UN
channel US20100273851 A NN I-UN
and/or US20100273851 A VBZ O
a US20100273851 A DT O
L-type US20100273851 A JJ I-UN
calcium US20100273851 A NN I-UN
channel US20100273851 A NN I-UN
of US20100273851 A IN O
an US20100273851 A DT O
airway US20100273851 A JJ O
smooth US20100273851 A JJ O
muscle US20100273851 A NN O
cell US20100273851 A NN O
( US20100273851 A ( O
ASMC US20100273851 A NNP O
) US20100273851 A ) O
. US20100273851 A . O

Liquid CN101669926A T NNP O
preparation CN101669926A T NN O
for CN101669926A T IN O
dosing CN101669926A T VBG O
nasal CN101669926A T JJ O
cavities CN101669926A T NNS O
and CN101669926A T CC O
method CN101669926A T NN O
for CN101669926A T IN O
making CN101669926A T VBG O
the CN101669926A T DT O
same CN101669926A T JJ O
. CN101669926A T . O

Anti-hemorrhage US20090318361 T JJ O
medication US20090318361 T NN O
pack US20090318361 T NN O
. US20090318361 T . O

An US20090318361 A DT O
anti-hemorrhage US20090318361 A JJ O
medication US20090318361 A NN O
pack US20090318361 A NN O
for US20090318361 A IN O
administering US20090318361 A VBG O
an US20090318361 A DT O
anti-hemorrhage US20090318361 A JJ O
drug US20090318361 A NN O
, US20090318361 A , O
in US20090318361 A IN O
particular US20090318361 A JJ O
for US20090318361 A IN O
the US20090318361 A DT O
treatment US20090318361 A NN O
of US20090318361 A IN O
hemorrhage US20090318361 A NN O
caused US20090318361 A VBN O
by US20090318361 A IN O
trauma US20090318361 A NN O
in US20090318361 A IN O
emergency US20090318361 A NN O
situations US20090318361 A NNS O
comprises US20090318361 A VBZ O
an US20090318361 A DT O
active US20090318361 A JJ O
ingredient US20090318361 A NN O
selected US20090318361 A VBN O
from US20090318361 A IN O
the US20090318361 A DT O
group US20090318361 A NN O
comprising US20090318361 A VBG O
the US20090318361 A DT O
1-24 US20090318361 A JJ O
amino US20090318361 A NN O
acid US20090318361 A JJ O
sequence US20090318361 A NN O
of US20090318361 A IN O
the US20090318361 A DT O
adrenocorticotropic US20090318361 A NN I-UN
hormone US20090318361 A NN I-UN
( US20090318361 A ( O
ACTH US20090318361 A NNP I-UN
1-24 US20090318361 A CD I-UN
) US20090318361 A ) O
and US20090318361 A CC O
all US20090318361 A DT O
its US20090318361 A PRP$ O
fragments US20090318361 A NNS O
and US20090318361 A CC O
analogues US20090318361 A NNS O
, US20090318361 A , O
and US20090318361 A CC O
analogues US20090318361 A NNS O
of US20090318361 A IN O
fragments US20090318361 A NNS O
, US20090318361 A , O
with US20090318361 A IN O
agonist US20090318361 A JJ O
activity US20090318361 A NN O
on US20090318361 A IN O
the US20090318361 A DT O
MC4 US20090318361 A NNP I-UN
melanocortin US20090318361 A NN I-UN
receptors US20090318361 A NNS I-UN
, US20090318361 A , O
and US20090318361 A CC O
all US20090318361 A PDT O
the US20090318361 A DT O
synthesis US20090318361 A NN O
agonists US20090318361 A NNS O
, US20090318361 A , O
including US20090318361 A VBG O
those US20090318361 A DT O
with US20090318361 A IN O
a US20090318361 A DT O
nonpeptidic US20090318361 A JJ O
structure US20090318361 A NN O
, US20090318361 A , O
of US20090318361 A IN O
the US20090318361 A DT O
MC4 US20090318361 A NNP I-UN
melanocortin US20090318361 A NN I-UN
receptors US20090318361 A NNS I-UN
. US20090318361 A . O

Macrocyclic EP2704709A1 T NNP O
lactones EP2704709A1 T NNS O
and EP2704709A1 T CC O
use EP2704709A1 T NN O
thereof EP2704709A1 T NN O
. EP2704709A1 T . O

such US7205295 T JJ O
as US7205295 T IN O
4- US7205295 T JJ O
( US7205295 T ( O
4-tert-Butyl-benzyl US7205295 T JJ O
) US7205295 T ) O
-6- US7205295 T NN O
( US7205295 T ( O
4-oxo-2-thioxo-thiazolidin-5-ylidenemethyl US7205295 T JJ O
) US7205295 T ) O
-4H-1,4-benzoxazin-3-one US7205295 T NN O
; US7205295 T : O
phosphoinositide-3-kinases US7205295 T NNS I-UN
( US7205295 T ( O
PI3Ks US7205295 T NNP I-UN
) US7205295 T ) O
; US7205295 T : O
for US7205295 T IN O
treatment/prevention US7205295 T NN O
of US7205295 T IN O
inflammatory US7205295 T NN O
diseases US7205295 T NNS O
, US7205295 T , O
cardiovascular US7205295 T JJ O
diseases US7205295 T NNS O
, US7205295 T , O
and US7205295 T CC O
cancers US7205295 T NNS O
. US7205295 T . O

Bifunctional EP2691402A1 T JJ O
hydroxy-bisphosphonic EP2691402A1 T JJ O
acid EP2691402A1 T NN O
derivatives EP2691402A1 T NNS O
. EP2691402A1 T . O

Fused WO2011029279A1 T VBN O
heteroaryl WO2011029279A1 T NN O
compounds WO2011029279A1 T NNS O
, WO2011029279A1 T , O
preparation WO2011029279A1 T NN O
method WO2011029279A1 T NN O
and WO2011029279A1 T CC O
use WO2011029279A1 T NN O
thereof WO2011029279A1 T NN O
. WO2011029279A1 T . O

The WO2011029279A1 A DT O
method WO2011029279A1 A NN O
for WO2011029279A1 A IN O
preparing WO2011029279A1 A VBG O
these WO2011029279A1 A DT O
compounds WO2011029279A1 A NNS O
and WO2011029279A1 A CC O
the WO2011029279A1 A DT O
use WO2011029279A1 A NN O
of WO2011029279A1 A IN O
these WO2011029279A1 A DT O
compounds WO2011029279A1 A NNS O
as WO2011029279A1 A IN O
phosphoinositide WO2011029279A1 A JJ I-UN
3-kinase WO2011029279A1 A CD I-UN
( WO2011029279A1 A ( O
PI3K WO2011029279A1 A NNP I-UN
) WO2011029279A1 A ) O
inhibitors WO2011029279A1 A NNS O
and WO2011029279A1 A CC O
anticancer WO2011029279A1 A NN O
agents WO2011029279A1 A NNS O
are WO2011029279A1 A VBP O
also WO2011029279A1 A RB O
disclosed WO2011029279A1 A VBN O
. WO2011029279A1 A . O

Optical WO2007077469A1 T JJ O
isomers WO2007077469A1 T NNS O
of WO2007077469A1 T IN O
dihydro-2,3-benzodiazepines WO2007077469A1 T NNS O
and WO2007077469A1 T CC O
their WO2007077469A1 T PRP$ O
stereoselective WO2007077469A1 T JJ O
synthesis WO2007077469A1 T NN O
. WO2007077469A1 T . O

External-use CN101433544B T NNP O
pharmaceutical CN101433544B T JJ O
composition CN101433544B T NN O
formulation CN101433544B T NN O
with CN101433544B T IN O
antiphlogistic CN101433544B T JJ O
, CN101433544B T , O
swelling-dispersing CN101433544B T JJ O
and CN101433544B T CC O
analgesic CN101433544B T JJ O
functions CN101433544B T NNS O
, CN101433544B T , O
and CN101433544B T CC O
use CN101433544B T NN O
. CN101433544B T . O

Novel US20120309816 T NNP O
viral US20120309816 T JJ O
vector US20120309816 T NN O
construct US20120309816 T NN O
for US20120309816 T IN O
neuron US20120309816 T NN O
specific US20120309816 T JJ O
optimized US20120309816 T VBN O
continuous US20120309816 T JJ O
DOPA US20120309816 T NNP O
synthesis US20120309816 T NN O
in US20120309816 T IN O
vivo US20120309816 T NN O
. US20120309816 T . O

The US20120309816 A DT O
present US20120309816 A JJ O
invention US20120309816 A NN O
relates US20120309816 A VBZ O
to US20120309816 A TO O
a US20120309816 A DT O
one-vector US20120309816 A JJ O
expression US20120309816 A NN O
system US20120309816 A NN O
comprising US20120309816 A VBG O
a US20120309816 A DT O
sequence US20120309816 A NN O
encoding US20120309816 A VBG O
two US20120309816 A CD O
polypeptides US20120309816 A NNS O
, US20120309816 A , O
such US20120309816 A JJ O
as US20120309816 A IN O
tyrosine US20120309816 A JJ I-UN
hydroxylase US20120309816 A NN I-UN
( US20120309816 A ( O
TH US20120309816 A NNP I-UN
) US20120309816 A ) O
and US20120309816 A CC O
GTP-cyclohydrolase US20120309816 A JJ I-UN
1 US20120309816 A CD I-UN
( US20120309816 A ( O
GCH1 US20120309816 A NNP I-UN
) US20120309816 A ) O
. US20120309816 A . O

Two-chamber-bag CN103263383A T NNP O
aqueous CN103263383A T JJ O
sodium CN103263383A T NN O
pyruvate CN103263383A T NN O
solution CN103263383A T NN O
kit CN103263383A T NN O
and CN103263383A T CC O
use CN103263383A T NN O
thereof CN103263383A T NN O
. CN103263383A T . O

External CN101357165B T JJ O
medicine CN101357165B T NN O
for CN101357165B T IN O
treating CN101357165B T VBG O
parotiditis CN101357165B T NN O
. CN101357165B T . O

Pharmaceutical EP1769799A2 T JJ O
compositions EP1769799A2 T NNS O
containing EP1769799A2 T VBG O
steroidal EP1769799A2 T JJ O
structures EP1769799A2 T NNS O
and EP1769799A2 T CC O
uses EP1769799A2 T VBZ O
thereof EP1769799A2 T NN O
. EP1769799A2 T . O

Dual US20090291975 T JJ O
opioid US20090291975 T NN O
pain US20090291975 T NN O
therapy US20090291975 T NN O
. US20090291975 T . O

Substituted CN101006059A T VBN O
tetrahydroisoquinolines CN101006059A T NNS O
used CN101006059A T VBN O
in CN101006059A T IN O
the CN101006059A T DT O
form CN101006059A T NN O
of CN101006059A T IN O
MMP CN101006059A T NNP I-UN
inhibitors CN101006059A T NNS O
, CN101006059A T , O
method CN101006059A T NN O
for CN101006059A T IN O
the CN101006059A T DT O
production CN101006059A T NN O
and CN101006059A T CC O
use CN101006059A T NN O
thereof CN101006059A T NN O
in CN101006059A T IN O
the CN101006059A T DT O
form CN101006059A T NN O
of CN101006059A T IN O
drugs CN101006059A T NNS O
. CN101006059A T . O

Dose WO2009074835A1 T NNP O
reduction WO2009074835A1 T NN O
of WO2009074835A1 T IN O
a WO2009074835A1 T DT O
cannabinoid WO2009074835A1 T JJ I-UN
cb1 WO2009074835A1 T NN I-UN
receptor WO2009074835A1 T NN I-UN
antagonist WO2009074835A1 T NN O
in WO2009074835A1 T IN O
the WO2009074835A1 T DT O
treatment WO2009074835A1 T NN O
of WO2009074835A1 T IN O
overweight WO2009074835A1 T NN O
or WO2009074835A1 T CC O
obesity WO2009074835A1 T NN O
. WO2009074835A1 T . O

O- WO2009074835A1 A NNP O
( WO2009074835A1 A ( O
3-Piperidino-2-hydroxy-1-propyl WO2009074835A1 A CD O
) WO2009074835A1 A ) O
-nicotinic WO2009074835A1 A JJ O
amidoxime WO2009074835A1 A NN O
or WO2009074835A1 A CC O
a WO2009074835A1 A DT O
pharmaceutically WO2009074835A1 A RB O
acceptable WO2009074835A1 A JJ O
acid WO2009074835A1 A JJ O
addition WO2009074835A1 A NN O
salt WO2009074835A1 A NN O
thereof WO2009074835A1 A NN O
is WO2009074835A1 A VBZ O
administered WO2009074835A1 A VBN O
to WO2009074835A1 A TO O
patients WO2009074835A1 A NNS O
suffering WO2009074835A1 A VBG O
from WO2009074835A1 A IN O
overweight WO2009074835A1 A NN O
or WO2009074835A1 A CC O
obesity WO2009074835A1 A NN O
and WO2009074835A1 A CC O
treated WO2009074835A1 A VBN O
with WO2009074835A1 A IN O
a WO2009074835A1 A DT O
cannabinoid WO2009074835A1 A JJ I-UN
CB1 WO2009074835A1 A NNP I-UN
receptor WO2009074835A1 A NN I-UN
antagonist WO2009074835A1 A NN O
such WO2009074835A1 A JJ O
as WO2009074835A1 A IN O
rimonabant WO2009074835A1 A NN O
to WO2009074835A1 A TO O
reduce WO2009074835A1 A VB O
the WO2009074835A1 A DT O
unfavourable WO2009074835A1 A JJ O
psychiatric WO2009074835A1 A JJ O
side WO2009074835A1 A NN O
effect WO2009074835A1 A NN O
of WO2009074835A1 A IN O
the WO2009074835A1 A DT O
latter WO2009074835A1 A NN O
. WO2009074835A1 A . O

Broad WO2012166665A2 T NNP O
spectrum WO2012166665A2 T NN O
antibiotics WO2012166665A2 T NNS O
. WO2012166665A2 T . O

Combination WO2011127519A1 T NNP O
treatment WO2011127519A1 T NN O
with WO2011127519A1 T IN O
vegf-c WO2011127519A1 T JJ I-UN
antagonists WO2011127519A1 T NNS O
. WO2011127519A1 T . O

The WO2011127519A1 A DT O
invention WO2011127519A1 A NN O
relates WO2011127519A1 A VBZ O
to WO2011127519A1 A TO O
a WO2011127519A1 A DT O
method WO2011127519A1 A NN O
and WO2011127519A1 A CC O
kit WO2011127519A1 A NN O
for WO2011127519A1 A IN O
treating WO2011127519A1 A VBG O
cancer WO2011127519A1 A NN O
in WO2011127519A1 A IN O
a WO2011127519A1 A DT O
human WO2011127519A1 A JJ O
subject WO2011127519A1 A NN O
, WO2011127519A1 A , O
the WO2011127519A1 A DT O
method WO2011127519A1 A NN O
comprising WO2011127519A1 A VBG O
administering WO2011127519A1 A VBG O
to WO2011127519A1 A TO O
the WO2011127519A1 A DT O
subject WO2011127519A1 A NN O
in WO2011127519A1 A IN O
combination WO2011127519A1 A NN O
therapeutically WO2011127519A1 A RB O
effective WO2011127519A1 A JJ O
amounts WO2011127519A1 A NNS O
of WO2011127519A1 A IN O
a WO2011127519A1 A DT O
VEGF-C WO2011127519A1 A JJ I-UN
antagonist WO2011127519A1 A NN O
and WO2011127519A1 A CC O
an WO2011127519A1 A DT O
anti-neoplastic WO2011127519A1 A JJ O
composition WO2011127519A1 A NN O
, WO2011127519A1 A , O
and WO2011127519A1 A CC O
the WO2011127519A1 A DT O
kit WO2011127519A1 A NN O
comprising WO2011127519A1 A VBG O
a WO2011127519A1 A DT O
VEGF-C WO2011127519A1 A JJ I-UN
antagonist WO2011127519A1 A NN O
for WO2011127519A1 A IN O
administering WO2011127519A1 A VBG O
to WO2011127519A1 A TO O
the WO2011127519A1 A DT O
subject WO2011127519A1 A NN O
in WO2011127519A1 A IN O
combination WO2011127519A1 A NN O
with WO2011127519A1 A IN O
an WO2011127519A1 A DT O
anti-neoplastic WO2011127519A1 A JJ O
composition WO2011127519A1 A NN O
. WO2011127519A1 A . O

The WO2011127519A1 A DT O
invention WO2011127519A1 A NN O
further WO2011127519A1 A RB O
relates WO2011127519A1 A VBZ O
to WO2011127519A1 A TO O
methods WO2011127519A1 A NNS O
for WO2011127519A1 A IN O
: WO2011127519A1 A : O
increasing WO2011127519A1 A VBG O
the WO2011127519A1 A DT O
duration WO2011127519A1 A NN O
of WO2011127519A1 A IN O
survival WO2011127519A1 A NN O
of WO2011127519A1 A IN O
, WO2011127519A1 A , O
increasing WO2011127519A1 A VBG O
the WO2011127519A1 A DT O
progression-free WO2011127519A1 A JJ O
survival WO2011127519A1 A NN O
of WO2011127519A1 A IN O
, WO2011127519A1 A , O
increasing WO2011127519A1 A VBG O
the WO2011127519A1 A DT O
duration WO2011127519A1 A NN O
of WO2011127519A1 A IN O
response WO2011127519A1 A NN O
of WO2011127519A1 A IN O
, WO2011127519A1 A , O
or WO2011127519A1 A CC O
treating WO2011127519A1 A NN O
, WO2011127519A1 A , O
a WO2011127519A1 A DT O
subject WO2011127519A1 A NN O
or WO2011127519A1 A CC O
a WO2011127519A1 A DT O
group WO2011127519A1 A NN O
of WO2011127519A1 A IN O
human WO2011127519A1 A JJ O
subjects WO2011127519A1 A NNS O
susceptible WO2011127519A1 A JJ O
to WO2011127519A1 A TO O
or WO2011127519A1 A CC O
diagnosed WO2011127519A1 A VBN O
as WO2011127519A1 A IN O
having WO2011127519A1 A VBG O
a WO2011127519A1 A DT O
cancer WO2011127519A1 A NN O
; WO2011127519A1 A : O
or WO2011127519A1 A CC O
treating WO2011127519A1 A VBG O
a WO2011127519A1 A DT O
human WO2011127519A1 A JJ O
subject WO2011127519A1 A NN O
or WO2011127519A1 A CC O
a WO2011127519A1 A DT O
group WO2011127519A1 A NN O
of WO2011127519A1 A IN O
human WO2011127519A1 A JJ O
subjects WO2011127519A1 A NNS O
having WO2011127519A1 A VBG O
metastatic WO2011127519A1 A JJ O
colorectal WO2011127519A1 A JJ O
cancer WO2011127519A1 A NN O
, WO2011127519A1 A , O
prostate WO2011127519A1 A NN O
cancer WO2011127519A1 A NN O
, WO2011127519A1 A , O
pancreatic WO2011127519A1 A JJ O
cancer WO2011127519A1 A NN O
or WO2011127519A1 A CC O
glioblastoma WO2011127519A1 A NN O
, WO2011127519A1 A , O
the WO2011127519A1 A DT O
methods WO2011127519A1 A NNS O
comprising WO2011127519A1 A VBG O
administering WO2011127519A1 A VBG O
to WO2011127519A1 A TO O
the WO2011127519A1 A DT O
subject WO2011127519A1 A NN O
or WO2011127519A1 A CC O
subjects WO2011127519A1 A NNS O
in WO2011127519A1 A IN O
the WO2011127519A1 A DT O
group WO2011127519A1 A NN O
in WO2011127519A1 A IN O
combination WO2011127519A1 A NN O
effective WO2011127519A1 A JJ O
amounts WO2011127519A1 A NNS O
of WO2011127519A1 A IN O
a WO2011127519A1 A DT O
VEGF-C WO2011127519A1 A JJ I-UN
antagonist WO2011127519A1 A NN O
and WO2011127519A1 A CC O
an WO2011127519A1 A DT O
anti-neoplastic WO2011127519A1 A JJ O
composition WO2011127519A1 A NN O
. WO2011127519A1 A . O

Novel WO2007003554A1 T NNP O
medicinal WO2007003554A1 T JJ O
combinations WO2007003554A1 T NNS O
which WO2007003554A1 T WDT O
are WO2007003554A1 T VBP O
used WO2007003554A1 T VBN O
for WO2007003554A1 T IN O
treating WO2007003554A1 T VBG O
respiratory WO2007003554A1 T NN O
tract WO2007003554A1 T NN O
diseases WO2007003554A1 T NNS O
and WO2007003554A1 T CC O
contain WO2007003554A1 T VB O
beta-2 WO2007003554A1 T JJ O
long-acting WO2007003554A1 T JJ O
agonists WO2007003554A1 T NNS O
and WO2007003554A1 T CC O
at WO2007003554A1 T IN O
least WO2007003554A1 T JJS O
one WO2007003554A1 T CD O
other WO2007003554A1 T JJ O
type WO2007003554A1 T NN O
of WO2007003554A1 T IN O
active WO2007003554A1 T JJ O
substance.. WO2007003554A1 T NN O

Silybin CN101143142A T NNP O
supersaturated CN101143142A T VBD O
self-emulsion CN101143142A T JJ O
composition CN101143142A T NN O
and CN101143142A T CC O
preparation CN101143142A T NN O
method CN101143142A T NN O
thereof CN101143142A T NN O
. CN101143142A T . O

Gsk3 WO2014059383A1 T NNP O
inhibitors WO2014059383A1 T NNS O
and WO2014059383A1 T CC O
methods WO2014059383A1 T NNS O
of WO2014059383A1 T IN O
use WO2014059383A1 T NN O
thereof WO2014059383A1 T NN O
. WO2014059383A1 T . O

Compounds WO2014059383A1 A NNS O
of WO2014059383A1 A IN O
the WO2014059383A1 A DT O
present WO2014059383A1 A JJ O
invention WO2014059383A1 A NN O
are WO2014059383A1 A VBP O
useful WO2014059383A1 A JJ O
for WO2014059383A1 A IN O
inhibiting WO2014059383A1 A VBG O
kinase WO2014059383A1 A NN O
( WO2014059383A1 A ( O
e.g. WO2014059383A1 A JJ O
, WO2014059383A1 A , O
GSK3 WO2014059383A1 A NNP O
( WO2014059383A1 A ( O
e.g. WO2014059383A1 A NN O
, WO2014059383A1 A , O
GSK3a WO2014059383A1 A NNP I-UN
or WO2014059383A1 A CC O
GSK3P WO2014059383A1 A NNP I-UN
) WO2014059383A1 A ) O
or WO2014059383A1 A CC O
CK1 WO2014059383A1 A NNP I-UN
) WO2014059383A1 A ) O
activity WO2014059383A1 A NN O
. WO2014059383A1 A . O

Pyrazolo CN101717402A T NNP O
N-substituted CN101717402A T JJ O
dehydronorcantharidin CN101717402A T NN O
imide CN101717402A T NN O
derivative CN101717402A T JJ O
and CN101717402A T CC O
synthesis CN101717402A T NN O
method CN101717402A T NN O
and CN101717402A T CC O
application CN101717402A T NN O
thereof CN101717402A T NN O
. CN101717402A T . O

Compound CN202699643U T NNP O
tamsulosin-finasteride CN202699643U T JJ O
capsule CN202699643U T NN O
. CN202699643U T . O

Polyamines WO2007021839A2 T NNS O
useful WO2007021839A2 T JJ O
as WO2007021839A2 T IN O
anti-parasitic WO2007021839A2 T JJ O
and WO2007021839A2 T CC O
anti-cancer WO2007021839A2 T JJ O
therapeutics WO2007021839A2 T NNS O
and WO2007021839A2 T CC O
as WO2007021839A2 T IN O
lysine-specific WO2007021839A2 T JJ I-UN
demethylase WO2007021839A2 T NN I-UN
inhibitors WO2007021839A2 T NNS O
. WO2007021839A2 T . O

The WO2007021839A2 A DT O
compounds WO2007021839A2 A NNS O
are WO2007021839A2 A VBP O
also WO2007021839A2 A RB O
useful WO2007021839A2 A JJ O
as WO2007021839A2 A IN O
inhibitors WO2007021839A2 A NNS O
of WO2007021839A2 A IN O
the WO2007021839A2 A DT O
enzyme WO2007021839A2 A JJ O
lysine-specific WO2007021839A2 A JJ I-UN
demethylase-1 WO2007021839A2 A NN I-UN
. WO2007021839A2 A . O

Fluoro-carbostyril CN101792443A T JJ O
derivative CN101792443A T NN O
as CN101792443A T RB O
well CN101792443A T RB O
as CN101792443A T IN O
preparation CN101792443A T NN O
method CN101792443A T NN O
and CN101792443A T CC O
application CN101792443A T NN O
thereof CN101792443A T NN O
. CN101792443A T . O

Nanoparticulate US20120076863 T NNP O
stabilized US20120076863 T VBD O
anti-hypertensive US20120076863 T JJ O
compositions US20120076863 T NNS O
. US20120076863 T . O

Anti-tumor CN102617588A T NNP O
compound CN102617588A T NN O
, CN102617588A T , O
and CN102617588A T CC O
preparation CN102617588A T NN O
method CN102617588A T NN O
and CN102617588A T CC O
application CN102617588A T NN O
thereof CN102617588A T NN O
. CN102617588A T . O

Methylated CN103374079A T VBN O
fucus CN103374079A T NN O
evanescens CN103374079A T VBZ O
oligose CN103374079A T JJ O
or CN103374079A T CC O
methylated CN103374079A T VBN O
sulfated CN103374079A T JJ O
fucus CN103374079A T NN O
evanescens CN103374079A T NNS O
oligose CN103374079A T VBP O
or CN103374079A T CC O
salt CN103374079A T VBP O
thereof CN103374079A T VBN O
as CN103374079A T RB O
well CN103374079A T RB O
as CN103374079A T IN O
preparation CN103374079A T NN O
method CN103374079A T NN O
and CN103374079A T CC O
application CN103374079A T NN O
thereof CN103374079A T NN O
. CN103374079A T . O

Oxidized US20080261865 T VBN O
Lipids US20080261865 T NNS O
and US20080261865 T CC O
Uses US20080261865 T VBZ O
Thereof US20080261865 T NNP O
in US20080261865 T IN O
the US20080261865 T DT O
Treatment US20080261865 T NNP O
of US20080261865 T IN O
Inflammatory US20080261865 T NNP O
Diseases US20080261865 T NNP O
and US20080261865 T CC O
Disorders US20080261865 T NNP O
. US20080261865 T . O

Multifunctional CN102151299A T JJ O
bromhidrosis CN102151299A T NN O
powder CN102151299A T NN O
. CN102151299A T . O

Hydrotalcite CN101366722A T NNP O
doxifluridine CN101366722A T NN O
slow CN101366722A T JJ O
release CN101366722A T NN O
formulation CN101366722A T NN O
and CN101366722A T CC O
preparation CN101366722A T NN O
method CN101366722A T NN O
thereof CN101366722A T NN O
. CN101366722A T . O

Treatment US20050123536 T NN O
of US20050123536 T IN O
immunological US20050123536 T JJ O
disorders US20050123536 T NNS O
using US20050123536 T VBG O
anti-dc30 US20050123536 T JJ O
antibodies US20050123536 T NNS O
. US20050123536 T . O

The US20050123536 A DT O
present US20050123536 A JJ O
invention US20050123536 A NN O
relates US20050123536 A VBZ O
to US20050123536 A TO O
methods US20050123536 A NNS O
for US20050123536 A IN O
the US20050123536 A DT O
treatment US20050123536 A NN O
of US20050123536 A IN O
immunological US20050123536 A JJ O
disorders US20050123536 A NNS O
other US20050123536 A JJ O
than US20050123536 A IN O
cancer US20050123536 A NN O
, US20050123536 A , O
comprising US20050123536 A VBG O
administering US20050123536 A VBG O
proteins US20050123536 A NNS O
characterized US20050123536 A VBN O
by US20050123536 A IN O
their US20050123536 A PRP$ O
ability US20050123536 A NN O
to US20050123536 A TO O
bind US20050123536 A VB O
to US20050123536 A TO O
CD30 US20050123536 A NNP I-UN
and US20050123536 A CC O
exert US20050123536 A VB O
a US20050123536 A DT O
cytostatic US20050123536 A JJ O
or US20050123536 A CC O
cytotoxic US20050123536 A JJ O
effect US20050123536 A NN O
on US20050123536 A IN O
an US20050123536 A DT O
activated US20050123536 A JJ O
lymphocyte US20050123536 A NN O
. US20050123536 A . O

AC10 US20050123536 A NNP O
and US20050123536 A CC O
HeFi-1 US20050123536 A NNP O
derivatives US20050123536 A NNS O
, US20050123536 A , O
and US20050123536 A CC O
antibodies US20050123536 A NNS O
that US20050123536 A WDT O
compete US20050123536 A VBP O
with US20050123536 A IN O
AC10 US20050123536 A NNP O
and US20050123536 A CC O
HeFi-1 US20050123536 A NNP O
for US20050123536 A IN O
binding US20050123536 A VBG O
to US20050123536 A TO O
CD30 US20050123536 A NNP I-UN
. US20050123536 A . O

1,2,3-triazole-based EP2534138A1 T JJ O
peptidomimetic EP2534138A1 T JJ O
integrin EP2534138A1 T NN I-UN
inhibitors EP2534138A1 T NNS O
for EP2534138A1 T IN O
the EP2534138A1 T DT O
diagnosis EP2534138A1 T NN O
and EP2534138A1 T CC O
therapy EP2534138A1 T NN O
of EP2534138A1 T IN O
tumors EP2534138A1 T NNS O
. EP2534138A1 T . O

Polymorph CN102838617A T NNP O
and CN102838617A T CC O
pharmaceutical CN102838617A T JJ O
composition CN102838617A T NN O
of CN102838617A T IN O
( CN102838617A T ( O
S CN102838617A T NNP O
) CN102838617A T ) O
-2- CN102838617A T NN O
( CN102838617A T ( O
2- CN102838617A T JJ O
nicotinoyloxyjatropha-6,7-dihydrothieno CN102838617A T JJ O
[ CN102838617A T JJ O
3,2-c CN102838617A T JJ O
] CN102838617A T NN O
pyridine-5 CN102838617A T NN O
( CN102838617A T ( O
4H CN102838617A T CD O
) CN102838617A T ) O
-yl CN102838617A T NN O
) CN102838617A T ) O
-2- CN102838617A T NN O
( CN102838617A T ( O
2-chlorphenyl CN102838617A T JJ O
) CN102838617A T ) O
-methyl CN102838617A T NN O
acetate CN102838617A T NN O
. CN102838617A T . O

Pectin-containing US20120022104 T NNP O
jelly US20120022104 T RB O
formulation US20120022104 T NN O
. US20120022104 T . O

Ultraviolet EP2043628A2 T NNP O
absorbing EP2043628A2 T VBG O
ophthalmic EP2043628A2 T JJ O
compositions EP2043628A2 T NNS O
. EP2043628A2 T . O

Deuterium-enriched US20090082422 T JJ O
levetiracetam US20090082422 T NN O
. US20090082422 T . O

Potent US20090043129 T NN O
and US20090043129 T CC O
selective US20090043129 T JJ O
ligands US20090043129 T NNS O
of US20090043129 T IN O
cannabinoid US20090043129 T JJ I-UN
receptors US20090043129 T NNS I-UN
. US20090043129 T . O

The US20090043129 A DT O
present US20090043129 A JJ O
invention US20090043129 A NN O
relates US20090043129 A VBZ O
to US20090043129 A TO O
high US20090043129 A JJ O
affinity US20090043129 A NN O
compounds US20090043129 A NNS O
, US20090043129 A , O
able US20090043129 A JJ O
to US20090043129 A TO O
bind US20090043129 A VB O
CB1 US20090043129 A NNP I-UN
and US20090043129 A CC O
CB2 US20090043129 A NNP I-UN
endocannabinoid US20090043129 A JJ O
receptors US20090043129 A NNS O
. US20090043129 A . O

N-acyl WO2012101064A1 T JJ O
pyrimidine WO2012101064A1 T NN O
biaryl WO2012101064A1 T NN O
compounds WO2012101064A1 T VBZ O
as WO2012101064A1 T IN O
protein WO2012101064A1 T NN I-UN
kinase WO2012101064A1 T NN I-UN
inhibitors WO2012101064A1 T NNS O
. WO2012101064A1 T . O

These WO2012101064A1 A DT O
compounds WO2012101064A1 A NNS O
inhibit WO2012101064A1 A VBP O
the WO2012101064A1 A DT O
activity WO2012101064A1 A NN O
of WO2012101064A1 A IN O
CDK9 WO2012101064A1 A NNP I-UN
and WO2012101064A1 A CC O
are WO2012101064A1 A VBP O
thus WO2012101064A1 A RB O
useful WO2012101064A1 A JJ O
as WO2012101064A1 A IN O
pharmaceuticals WO2012101064A1 A NNS O
and WO2012101064A1 A CC O
as WO2012101064A1 A IN O
components WO2012101064A1 A NNS O
of WO2012101064A1 A IN O
pharmaceutical WO2012101064A1 A JJ O
compositions WO2012101064A1 A NNS O
. WO2012101064A1 A . O

Also WO2012101064A1 A RB O
provided WO2012101064A1 A VBN O
are WO2012101064A1 A VBP O
methods WO2012101064A1 A NNS O
of WO2012101064A1 A IN O
treating WO2012101064A1 A VBG O
a WO2012101064A1 A DT O
disease WO2012101064A1 A NN O
or WO2012101064A1 A CC O
condition WO2012101064A1 A NN O
mediated WO2012101064A1 A VBN O
by WO2012101064A1 A IN O
CDK9 WO2012101064A1 A NNP I-UN
using WO2012101064A1 A VBG O
the WO2012101064A1 A DT O
compounds WO2012101064A1 A NNS O
described WO2012101064A1 A VBD O
herein WO2012101064A1 A NN O
or WO2012101064A1 A CC O
pharmaceutical WO2012101064A1 A JJ O
compositions WO2012101064A1 A NNS O
comprising WO2012101064A1 A VBG O
such WO2012101064A1 A JJ O
compounds WO2012101064A1 A NNS O
. WO2012101064A1 A . O

Utilization EP1368023B1 T NN O
of EP1368023B1 T IN O
buprenorphine EP1368023B1 T NN O
in EP1368023B1 T IN O
urinary EP1368023B1 T JJ O
incontinence EP1368023B1 T NN O
therapy EP1368023B1 T NN O
. EP1368023B1 T . O

The EP1368023B1 A DT O
invention EP1368023B1 A NN O
relates EP1368023B1 A VBZ O
to EP1368023B1 A TO O
the EP1368023B1 A DT O
utilization EP1368023B1 A NN O
of EP1368023B1 A IN O
buprenorphine EP1368023B1 A NN O
in EP1368023B1 A IN O
the EP1368023B1 A DT O
production EP1368023B1 A NN O
of EP1368023B1 A IN O
a EP1368023B1 A DT O
medicament EP1368023B1 A NN O
for EP1368023B1 A IN O
the EP1368023B1 A DT O
treatment EP1368023B1 A NN O
of EP1368023B1 A IN O
increased EP1368023B1 A JJ O
urinary EP1368023B1 A JJ O
urgency EP1368023B1 A NN O
, EP1368023B1 A , O
urinary EP1368023B1 A JJ O
frequency EP1368023B1 A NN O
and/or EP1368023B1 A NN O
urinary EP1368023B1 A JJ O
incontinence EP1368023B1 A NN O
and EP1368023B1 A CC O
to EP1368023B1 A TO O
the EP1368023B1 A DT O
corresponding EP1368023B1 A JJ O
medicaments EP1368023B1 A NNS O
and EP1368023B1 A CC O
method EP1368023B1 A NN O
for EP1368023B1 A IN O
the EP1368023B1 A DT O
treatment EP1368023B1 A NN O
of EP1368023B1 A IN O
urinary EP1368023B1 A JJ O
urgency EP1368023B1 A NN O
, EP1368023B1 A , O
urinary EP1368023B1 A JJ O
frequency EP1368023B1 A NN O
and/or EP1368023B1 A NN O
urinary EP1368023B1 A JJ O
incontinence EP1368023B1 A NN O
. EP1368023B1 A . O

2-oxindole CN101863823A T JJ O
compounds CN101863823A T NNS O
, CN101863823A T , O
and CN101863823A T CC O
ring-enlargement CN101863823A T JJ O
derivatives CN101863823A T NNS O
, CN101863823A T , O
preparation CN101863823A T NN O
method CN101863823A T NN O
and CN101863823A T CC O
application CN101863823A T NN O
thereof CN101863823A T NN O
. CN101863823A T . O

Conjugated WO2009111830A1 T VBN O
unsaturated WO2009111830A1 T JJ O
compounds WO2009111830A1 T NNS O
. WO2009111830A1 T . O

Pharmaceutical EP1142573B1 T JJ O
compositions EP1142573B1 T NNS O
comprising EP1142573B1 T VBG O
faropenem EP1142573B1 T JJ O
sodium EP1142573B1 T NN O
and EP1142573B1 T CC O
a EP1142573B1 T DT O
diamineacetate EP1142573B1 T NN O
compound EP1142573B1 T NN O
for EP1142573B1 T IN O
improving EP1142573B1 T VBG O
gastrointestinal EP1142573B1 T JJ O
absorption EP1142573B1 T NN O
. EP1142573B1 T . O

And US20080249105 T CC O
Erectile US20080249105 T NNP O
Dysfunction US20080249105 T NNP O
; US20080249105 T : O
rho US20080249105 T JJ I-UN
kinase US20080249105 T NN I-UN
inhibitors US20080249105 T NNS O
; US20080249105 T : O
[ US20080249105 T CC O
3-fluoro-4- US20080249105 T JJ O
( US20080249105 T ( O
1H-pyrrolo US20080249105 T JJ O
[ US20080249105 T NNP O
2,3-b US20080249105 T JJ O
] US20080249105 T NNP O
pyridin-4-yloxy US20080249105 T NN O
) US20080249105 T ) O
phenyl US20080249105 T NN O
] US20080249105 T JJ O
amine US20080249105 T NN O
. US20080249105 T . O

Treating US8383178 T VBG O
fish US8383178 T NN O
oils US8383178 T NNS O
with US8383178 T IN O
certain US8383178 T JJ O
amines/amides US8383178 T NNS O
to US8383178 T TO O
reduce US8383178 T VB O
oxidation US8383178 T NN O
. US8383178 T . O

Medicament CN101313899B T JJ O
composition CN101313899B T NN O
for CN101313899B T IN O
eyes CN101313899B T NNS O
containing CN101313899B T VBG O
sodium CN101313899B T NN O
bromfenac CN101313899B T NN O
. CN101313899B T . O

Treating US7138396 T VBG O
androgen-dependent US7138396 T JJ O
diseases US7138396 T NNS O
, US7138396 T , O
particularly US7138396 T RB O
benign US7138396 T JJ O
prostatic US7138396 T JJ O
hyperplasia US7138396 T NN O
, US7138396 T , O
with US7138396 T IN O
a US7138396 T DT O
piperidinyl- US7138396 T JJ O
or US7138396 T CC O
piperazinyl- US7138396 T JJ O
N- US7138396 T NNP O
( US7138396 T ( O
4-substituted US7138396 T JJ O
pentamethylene US7138396 T NN O
) US7138396 T ) O
- US7138396 T : O
or US7138396 T CC O
N- US7138396 T JJ O
( US7138396 T ( O
4-substituted US7138396 T JJ O
iminodiethylene US7138396 T NN O
) US7138396 T ) O
- US7138396 T : O
acetamide US7138396 T RB O
derivative US7138396 T JJ O
, US7138396 T , O
optionally US7138396 T RB O
in US7138396 T IN O
combination US7138396 T NN O
with US7138396 T IN O
an US7138396 T DT O
alpha-1 US7138396 T JJ O
adrenergic US7138396 T JJ O
antagonist US7138396 T NN O
. US7138396 T . O

There US7138396 A EX O
are US7138396 A VBP O
disclosed US7138396 A JJ O
compounds US7138396 A NNS O
of US7138396 A IN O
the US7138396 A DT O
formula US7138396 A NN O
( US7138396 A ( O
I US7138396 A PRP O
) US7138396 A ) O
: US7138396 A : O
prodrugs US7138396 A NN O
thereof US7138396 A NN O
, US7138396 A , O
or US7138396 A CC O
pharmaceutically US7138396 A RB O
acceptable US7138396 A JJ O
salts US7138396 A NNS O
of US7138396 A IN O
the US7138396 A DT O
compounds US7138396 A NNS O
or US7138396 A CC O
of US7138396 A IN O
said US7138396 A VBD O
prodrugs US7138396 A NNS O
which US7138396 A WDT O
are US7138396 A VBP O
useful US7138396 A JJ O
as US7138396 A IN O
inhibitors US7138396 A NNS O
of US7138396 A IN O
Type US7138396 A NNP I-UN
3 US7138396 A CD I-UN
17β-Hydroxysteroid US7138396 A JJ I-UN
Dehydrogenase US7138396 A NNP I-UN
. US7138396 A . O

Pharmaceutical US20080300238 T JJ O
composition US20080300238 T NN O
comprising US20080300238 T VBG O
a US20080300238 T DT O
renin US20080300238 T NN I-UN
inhibitor US20080300238 T NN O
, US20080300238 T , O
a US20080300238 T DT O
calcium US20080300238 T NN O
channel US20080300238 T NN O
blocker US20080300238 T NN O
and US20080300238 T CC O
a US20080300238 T DT O
diuretic US20080300238 T JJ O
. US20080300238 T . O

The US20080300238 A DT O
invention US20080300238 A NN O
relates US20080300238 A VBZ O
to US20080300238 A TO O
a US20080300238 A DT O
pharmaceutical US20080300238 A JJ O
composition US20080300238 A NN O
comprising US20080300238 A NN O
( US20080300238 A ( O
i US20080300238 A NN O
) US20080300238 A ) O
a US20080300238 A DT O
renin US20080300238 A NN I-UN
inhibitor US20080300238 A NN O
, US20080300238 A , O
( US20080300238 A ( O
ii US20080300238 A NN O
) US20080300238 A ) O
a US20080300238 A DT O
calcium US20080300238 A NN O
channel US20080300238 A NN O
blocker US20080300238 A NN O
( US20080300238 A ( O
CCB US20080300238 A NNP O
) US20080300238 A ) O
, US20080300238 A , O
and US20080300238 A CC O
a US20080300238 A DT O
diuretic US20080300238 A JJ O
and US20080300238 A CC O
to US20080300238 A TO O
a US20080300238 A DT O
method US20080300238 A NN O
of US20080300238 A IN O
using US20080300238 A VBG O
such US20080300238 A JJ O
composition US20080300238 A NN O
for US20080300238 A IN O
the US20080300238 A DT O
treatment US20080300238 A NN O
of US20080300238 A IN O
cardiovascular US20080300238 A JJ O
disease US20080300238 A NN O
. US20080300238 A . O

Ifn EP1019500B1 T NNP O
receptor EP1019500B1 T NN O
1 EP1019500B1 T CD O
binding EP1019500B1 T NN O
proteins EP1019500B1 T NNS O
, EP1019500B1 T , O
dna EP1019500B1 T NN O
encoding EP1019500B1 T VBG O
them EP1019500B1 T PRP O
, EP1019500B1 T , O
and EP1019500B1 T CC O
methods EP1019500B1 T NNS O
of EP1019500B1 T IN O
modulating EP1019500B1 T VBG O
cellular EP1019500B1 T JJ O
response EP1019500B1 T NN O
to EP1019500B1 T TO O
interferons EP1019500B1 T NNS O
. EP1019500B1 T . O

Novel EP1019500B1 A NNP O
proteins EP1019500B1 A VBZ O
IR1B1 EP1019500B1 A NNP I-UN
and EP1019500B1 A CC O
IR1B4 EP1019500B1 A NNP I-UN
have EP1019500B1 A VBP O
been EP1019500B1 A VBN O
isolated EP1019500B1 A VBN O
which EP1019500B1 A WDT O
bind EP1019500B1 A VBP O
to EP1019500B1 A TO O
the EP1019500B1 A DT O
type EP1019500B1 A NN I-UN
I EP1019500B1 A PRP I-UN
IFN EP1019500B1 A NNP I-UN
receptor EP1019500B1 A NN I-UN
IFNAR1 EP1019500B1 A NNP I-UN
and EP1019500B1 A CC O
function EP1019500B1 A NN O
in EP1019500B1 A IN O
the EP1019500B1 A DT O
cellular EP1019500B1 A JJ O
response EP1019500B1 A NN O
to EP1019500B1 A TO O
IFNs EP1019500B1 A NNP O
. EP1019500B1 A . O

Process WO2011048612A3 T NN O
for WO2011048612A3 T IN O
preparation WO2011048612A3 T NN O
of WO2011048612A3 T IN O
propargylated WO2011048612A3 T JJ O
aminoindans WO2011048612A3 T NNS O
or WO2011048612A3 T CC O
pharmaceutically WO2011048612A3 T RB O
acceptable WO2011048612A3 T JJ O
salts WO2011048612A3 T NNS O
thereof WO2011048612A3 T NN O
. WO2011048612A3 T . O

Dietotherapeutic CN1739574A T JJ O
nutrient CN1739574A T NN O
for CN1739574A T IN O
preventing CN1739574A T VBG O
and CN1739574A T CC O
treating CN1739574A T VBG O
gout CN1739574A T NN O
and CN1739574A T CC O
its CN1739574A T PRP$ O
prepn CN1739574A T NN O
process CN1739574A T NN O
. CN1739574A T . O

The CN1739574A A DT O
dietotherapeutic CN1739574A A JJ O
nutrient CN1739574A A NN O
for CN1739574A A IN O
preventing CN1739574A A VBG O
and CN1739574A A CC O
treating CN1739574A A VBG O
gout CN1739574A A NN O
consists CN1739574A A VBZ O
of CN1739574A A IN O
alkaline CN1739574A A JJ O
potassium-sodium CN1739574A A JJ O
matter CN1739574A A NN O
, CN1739574A A , O
nucleotide CN1739574A A RB O
, CN1739574A A , O
vitamin CN1739574A A NN O
and CN1739574A A CC O
trace CN1739574A A NN O
elements CN1739574A A NNS O
. CN1739574A A . O

The CN1739574A A DT O
dietotherapeutic CN1739574A A JJ O
nutrient CN1739574A A NN O
operates CN1739574A A VBZ O
on CN1739574A A IN O
that CN1739574A A IN O
the CN1739574A A DT O
alkaline CN1739574A A JJ O
potassium-sodium CN1739574A A JJ O
matter CN1739574A A NN O
makes CN1739574A A VBZ O
alcoholic CN1739574A A JJ O
urate CN1739574A A JJ O
formed CN1739574A A VBN O
in CN1739574A A IN O
body CN1739574A A NN O
to CN1739574A A TO O
create CN1739574A A VB O
salt CN1739574A A NN O
capable CN1739574A A JJ O
of CN1739574A A IN O
dissolving CN1739574A A VBG O
in CN1739574A A IN O
water CN1739574A A NN O
and CN1739574A A CC O
being CN1739574A A VBG O
removed CN1739574A A VBN O
in CN1739574A A IN O
alkaline CN1739574A A JJ O
condition CN1739574A A NN O
, CN1739574A A , O
the CN1739574A A DT O
nucleotide CN1739574A A JJ O
avoids CN1739574A A NNS O
purine CN1739574A A NN O
to CN1739574A A TO O
synthesize CN1739574A A VB O
urate CN1739574A A JJ O
, CN1739574A A , O
and CN1739574A A CC O
the CN1739574A A DT O
vitamin CN1739574A A NN O
and CN1739574A A CC O
the CN1739574A A DT O
trace CN1739574A A NN O
elements CN1739574A A VBZ O
reinforce CN1739574A A VB O
the CN1739574A A DT O
activity CN1739574A A NN O
of CN1739574A A IN O
enzyme CN1739574A A NN O
, CN1739574A A , O
protect CN1739574A A VBP O
the CN1739574A A DT O
functions CN1739574A A NNS O
of CN1739574A A IN O
cell CN1739574A A NN O
and CN1739574A A CC O
organ CN1739574A A NN O
, CN1739574A A , O
recover CN1739574A A VB O
nucleotide CN1739574A A RB O
and CN1739574A A CC O
make CN1739574A A VB O
purine CN1739574A A NN O
to CN1739574A A TO O
synthesize CN1739574A A VB O
nucleic CN1739574A A JJ O
acid CN1739574A A NN O
to CN1739574A A TO O
reduce CN1739574A A VB O
purine CN1739574A A NN O
and CN1739574A A CC O
urate CN1739574A A NN O
and CN1739574A A CC O
avoid CN1739574A A VB O
gout CN1739574A A NN O
. CN1739574A A . O

The CN1739574A A DT O
dietotherapeutic CN1739574A A JJ O
nutrient CN1739574A A NN O
has CN1739574A A VBZ O
obvious CN1739574A A JJ O
curative CN1739574A A JJ O
effect CN1739574A A NN O
, CN1739574A A , O
no CN1739574A A DT O
toxic CN1739574A A JJ O
side CN1739574A A NN O
effect CN1739574A A NN O
, CN1739574A A , O
simple CN1739574A A JJ O
preparation CN1739574A A NN O
process CN1739574A A NN O
, CN1739574A A , O
and CN1739574A A CC O
low CN1739574A A JJ O
cost CN1739574A A NN O
. CN1739574A A . O

Combination WO2011044072A1 T NN O
of WO2011044072A1 T IN O
raf-265 WO2011044072A1 T NN O
and WO2011044072A1 T CC O
an WO2011044072A1 T DT O
activator WO2011044072A1 T NN O
of WO2011044072A1 T IN O
ampk WO2011044072A1 T NN I-UN
for WO2011044072A1 T IN O
use WO2011044072A1 T NN O
in WO2011044072A1 T IN O
the WO2011044072A1 T DT O
treatment WO2011044072A1 T NN O
of WO2011044072A1 T IN O
a WO2011044072A1 T DT O
proliferative WO2011044072A1 T JJ O
disease WO2011044072A1 T NN O
. WO2011044072A1 T . O

Provided WO2011044072A1 A VBN O
are WO2011044072A1 A VBP O
compositions WO2011044072A1 A NNS O
and WO2011044072A1 A CC O
uses WO2011044072A1 A NNS O
of WO2011044072A1 A IN O
the WO2011044072A1 A DT O
benzimidazole WO2011044072A1 A NN O
pyridyl WO2011044072A1 A NN O
ether WO2011044072A1 A DT O
{ WO2011044072A1 A ( O
1-methyl-5- WO2011044072A1 A JJ O
[ WO2011044072A1 A NN O
2- WO2011044072A1 A JJ O
( WO2011044072A1 A ( O
5-tri-fluoromethyl-1H-imidazol-2-yl WO2011044072A1 A JJ O
) WO2011044072A1 A ) O
-pyridin-4-yloxy WO2011044072A1 A FW O
] WO2011044072A1 A FW O
-1H-benzoimidazol-2-yl WO2011044072A1 A FW O
} WO2011044072A1 A ) O
- WO2011044072A1 A : O
( WO2011044072A1 A ( O
4-trifluoromethylphenyl WO2011044072A1 A JJ O
) WO2011044072A1 A ) O
-amine WO2011044072A1 A NN O
and WO2011044072A1 A CC O
pharmaceutically WO2011044072A1 A RB O
acceptable WO2011044072A1 A JJ O
salts WO2011044072A1 A NNS O
thereof WO2011044072A1 A VBP O
in WO2011044072A1 A IN O
combination WO2011044072A1 A NN O
with WO2011044072A1 A IN O
an WO2011044072A1 A DT O
activator WO2011044072A1 A NN O
of WO2011044072A1 A IN O
AMPK WO2011044072A1 A NNP I-UN
( WO2011044072A1 A ( O
AMP-activated WO2011044072A1 A JJ I-UN
protein WO2011044072A1 A NN I-UN
kinase WO2011044072A1 A NN I-UN
) WO2011044072A1 A ) O
for WO2011044072A1 A IN O
the WO2011044072A1 A DT O
treatment WO2011044072A1 A NN O
of WO2011044072A1 A IN O
proliferative WO2011044072A1 A JJ O
diseases WO2011044072A1 A NNS O
. WO2011044072A1 A . O

Methods EP1968595A2 T NNS O
of EP1968595A2 T IN O
treating EP1968595A2 T VBG O
cancer EP1968595A2 T NN O
and EP1968595A2 T CC O
other EP1968595A2 T JJ O
conditions EP1968595A2 T NNS O
or EP1968595A2 T CC O
disease EP1968595A2 T VB O
states EP1968595A2 T NNS O
using EP1968595A2 T VBG O
l-cytosine EP1968595A2 T JJ O
nucleoside EP1968595A2 T JJ O
analogs EP1968595A2 T NNS O
. EP1968595A2 T . O

Synergistic US20130053339 T JJ O
phytochemical US20130053339 T JJ O
composition US20130053339 T NN O
and US20130053339 T CC O
a US20130053339 T DT O
process US20130053339 T NN O
for US20130053339 T IN O
preparation US20130053339 T NN O
thereof US20130053339 T NN O
. US20130053339 T . O

Agent WO2008090749A1 T NN O
for WO2008090749A1 T IN O
modification WO2008090749A1 T NN O
of WO2008090749A1 T IN O
sh WO2008090749A1 T NN O
group WO2008090749A1 T NN O
. WO2008090749A1 T . O

Eye CN102389412B T NNP O
drops CN102389412B T NNS O
for CN102389412B T IN O
treating CN102389412B T VBG O
cataract CN102389412B T NN O
. CN102389412B T . O

Pyrazolo US8541429 T NNP O
quinazoline US8541429 T NN O
derivatives US8541429 T NNS O
, US8541429 T , O
process US8541429 T NN O
for US8541429 T IN O
their US8541429 T PRP$ O
preparation US8541429 T NN O
and US8541429 T CC O
their US8541429 T PRP$ O
use US8541429 T NN O
as US8541429 T IN O
kinase US8541429 T NN O
inhibitors US8541429 T NNS O
. US8541429 T . O

Use CN101559050A T NNP O
of CN101559050A T IN O
butin CN101559050A T NN O
and CN101559050A T CC O
derivatives CN101559050A T NNS O
thereof CN101559050A T VBP O
for CN101559050A T IN O
preparing CN101559050A T VBG O
drugs CN101559050A T NNS O
having CN101559050A T VBG O
inhibitive CN101559050A T JJ O
effect CN101559050A T NN O
on CN101559050A T IN O
immune CN101559050A T NN O
system CN101559050A T NN O
. CN101559050A T . O

2-methylene-19-nor- EP1828115A2 T JJ O
( EP1828115A2 T ( O
20s EP1828115A2 T CD O
) EP1828115A2 T ) O
-1alpha-hydroxy-trishomopregnacalciferol EP1828115A2 T NN O
. EP1828115A2 T . O

Nitrosated WO2006040676A1 T VBN O
benzopyran WO2006040676A1 T JJ O
compounds WO2006040676A1 T NNS O
as WO2006040676A1 T IN O
novel WO2006040676A1 T JJ O
cyclooxygenase-2 WO2006040676A1 T JJ I-UN
selective WO2006040676A1 T JJ O
inhibitors WO2006040676A1 T NNS O
. WO2006040676A1 T . O

This WO2006040676A1 A DT O
invention WO2006040676A1 A NN O
specifically WO2006040676A1 A RB O
relates WO2006040676A1 A VBZ O
to WO2006040676A1 A TO O
novel WO2006040676A1 A VB O
cyclooxygenase WO2006040676A1 A NN I-UN
2 WO2006040676A1 A CD I-UN
( WO2006040676A1 A ( O
COX-2 WO2006040676A1 A NNP I-UN
) WO2006040676A1 A ) O
selective WO2006040676A1 A JJ O
inhibitor WO2006040676A1 A NN O
compounds WO2006040676A1 A VBZ O
that WO2006040676A1 A IN O
donate WO2006040676A1 A NN O
, WO2006040676A1 A , O
transfer WO2006040676A1 A NN O
or WO2006040676A1 A CC O
release WO2006040676A1 A VB O
nitric WO2006040676A1 A JJ O
oxide WO2006040676A1 A NN O
, WO2006040676A1 A , O
stimulate WO2006040676A1 A VBP O
endogenous WO2006040676A1 A JJ O
synthesis WO2006040676A1 A NN O
of WO2006040676A1 A IN O
nitric WO2006040676A1 A JJ O
oxide WO2006040676A1 A NN O
, WO2006040676A1 A , O
elevate WO2006040676A1 A VBP O
endogenous WO2006040676A1 A JJ O
levels WO2006040676A1 A NNS O
of WO2006040676A1 A IN O
endothelium-derived WO2006040676A1 A JJ O
relaxing WO2006040676A1 A JJ O
factor WO2006040676A1 A NN O
or WO2006040676A1 A CC O
is WO2006040676A1 A VBZ O
a WO2006040676A1 A DT O
substrate WO2006040676A1 A NN O
for WO2006040676A1 A IN O
nitric WO2006040676A1 A JJ I-UN
oxide WO2006040676A1 A JJ I-UN
synthase WO2006040676A1 A NN I-UN
. WO2006040676A1 A . O

This WO2006040676A1 A DT O
invention WO2006040676A1 A NN O
also WO2006040676A1 A RB O
relates WO2006040676A1 A VBZ O
to WO2006040676A1 A TO O
pharmaceutical WO2006040676A1 A JJ O
compositions WO2006040676A1 A NNS O
and WO2006040676A1 A CC O
methods WO2006040676A1 A NNS O
for WO2006040676A1 A IN O
treating WO2006040676A1 A VBG O
COX-2 WO2006040676A1 A NNP I-UN
mediated WO2006040676A1 A VBD O
disorders WO2006040676A1 A NNS O
, WO2006040676A1 A , O
such WO2006040676A1 A JJ O
as WO2006040676A1 A IN O
inflammation WO2006040676A1 A NN O
and WO2006040676A1 A CC O
inflammation WO2006040676A1 A NN O
related WO2006040676A1 A VBN O
disorders WO2006040676A1 A NNS O
. WO2006040676A1 A . O

Fat US20100298274 T NNP O
containing US20100298274 T VBG O
composition US20100298274 T NN O
. US20100298274 T . O

Super-oxide US20100256178 T JJ I-UN
dismutase US20100256178 T NN I-UN
mimetics US20100256178 T NNS O
. US20100256178 T . O

Substituted US20110201604 T VBN O
Fused US20110201604 T JJ O
Imidazole US20110201604 T NNP O
Derivatives US20110201604 T NNP O
, US20110201604 T , O
Pharmaceutical US20110201604 T NNP O
Compositions US20110201604 T NNP O
, US20110201604 T , O
and US20110201604 T CC O
Methods US20110201604 T NNS O
of US20110201604 T IN O
Use US20110201604 T NNP O
Thereof US20110201604 T NNP O
. US20110201604 T . O

Substituted WO2009034581A1 T VBN O
indolyl WO2009034581A1 T JJ O
compounds WO2009034581A1 T NNS O
and WO2009034581A1 T CC O
their WO2009034581A1 T PRP$ O
use WO2009034581A1 T NN O
as WO2009034581A1 T IN O
5-ht6 WO2009034581A1 T JJ I-UN
ligands WO2009034581A1 T NNS O
. WO2009034581A1 T . O

These WO2009034581A1 A DT O
compounds WO2009034581A1 A NNS O
are WO2009034581A1 A VBP O
useful WO2009034581A1 A JJ O
in WO2009034581A1 A IN O
the WO2009034581A1 A DT O
treatment WO2009034581A1 A NN O
of WO2009034581A1 A IN O
various WO2009034581A1 A JJ O
disorders WO2009034581A1 A NNS O
that WO2009034581A1 A WDT O
are WO2009034581A1 A VBP O
related WO2009034581A1 A VBN O
to WO2009034581A1 A TO O
5-HT6 WO2009034581A1 A JJ I-UN
receptor WO2009034581A1 A NN O
functions WO2009034581A1 A NNS O
. WO2009034581A1 A . O

4'-cyano- US20050038111 T JJ O
alpha US20050038111 T NN O
' US20050038111 T '' O
, US20050038111 T , O
alpha US20050038111 T NN O
' US20050038111 T '' O
, US20050038111 T , O
alpha US20050038111 T IN O
'-trifluoro-3- US20050038111 T JJ O
( US20050038111 T ( O
4-fluorophenylsulphonyl US20050038111 T JJ O
) US20050038111 T ) O
-2-hydroxy-2-methylpropiono-m-toluidide US20050038111 T NN O
; US20050038111 T : O
anti-oestrogen US20050038111 T NN O
( US20050038111 T ( O
eg US20050038111 T JJ O
, US20050038111 T , O
tamoxifen US20050038111 T JJ O
citrate US20050038111 T NN O
) US20050038111 T ) O
and/or US20050038111 T VBZ O
an US20050038111 T DT O
aromatase US20050038111 T NN I-UN
inhibitor US20050038111 T NN O
( US20050038111 T ( O
eg US20050038111 T JJ O
, US20050038111 T , O
anastrozole US20050038111 T JJ O
) US20050038111 T ) O
; US20050038111 T : O
preventing US20050038111 T VBG O
side US20050038111 T NN O
effect US20050038111 T NN O
; US20050038111 T : O
bioavailability US20050038111 T NN O
; US20050038111 T : O
storage US20050038111 T NN O
stability US20050038111 T NN O
; US20050038111 T : O
prostate US20050038111 T JJ O
cancer US20050038111 T NN O
. US20050038111 T . O

The US20050038111 A DT O
present US20050038111 A JJ O
invention US20050038111 A NN O
relates US20050038111 A VBZ O
to US20050038111 A TO O
a US20050038111 A DT O
pharmaceutical US20050038111 A JJ O
product US20050038111 A NN O
for US20050038111 A IN O
administration US20050038111 A NN O
to US20050038111 A TO O
a US20050038111 A DT O
patient US20050038111 A NN O
, US20050038111 A , O
the US20050038111 A DT O
product US20050038111 A NN O
comprising US20050038111 A VBG O
4′-cyano-α′ US20050038111 A JJ O
, US20050038111 A , O
α′ US20050038111 A JJ O
, US20050038111 A , O
α′-trifluoro-3- US20050038111 A JJ O
( US20050038111 A ( O
4-fluorophenylsulphonyl US20050038111 A JJ O
) US20050038111 A ) O
-2-hydroxy-2-methylpropiono-m-toluidide US20050038111 A NN O
, US20050038111 A , O
or US20050038111 A CC O
a US20050038111 A DT O
pharmaceutically US20050038111 A RB O
acceptable US20050038111 A JJ O
salt US20050038111 A NN O
or US20050038111 A CC O
solvate US20050038111 A NN O
thereof US20050038111 A NN O
, US20050038111 A , O
in US20050038111 A IN O
solid US20050038111 A JJ O
dispersion US20050038111 A NN O
with US20050038111 A IN O
an US20050038111 A DT O
enteric US20050038111 A JJ O
polymer US20050038111 A NN O
having US20050038111 A VBG O
a US20050038111 A DT O
pKa US20050038111 A NN O
from US20050038111 A IN O
3 US20050038111 A CD O
to US20050038111 A TO O
6 US20050038111 A CD O
, US20050038111 A , O
the US20050038111 A DT O
product US20050038111 A NN O
further US20050038111 A RB O
comprising US20050038111 A VBG O
an US20050038111 A DT O
anti-oestrogen US20050038111 A NN O
( US20050038111 A ( O
eg US20050038111 A JJ O
, US20050038111 A , O
tamoxifen US20050038111 A JJ O
citrate US20050038111 A NN O
) US20050038111 A ) O
and/or US20050038111 A VBZ O
an US20050038111 A DT O
aromatase US20050038111 A NN I-UN
inhibitor US20050038111 A NN O
( US20050038111 A ( O
eg US20050038111 A JJ O
, US20050038111 A , O
anastrozole US20050038111 A JJ O
) US20050038111 A ) O
. US20050038111 A . O

Method EP1896010A2 T NNP O
and EP1896010A2 T CC O
composition EP1896010A2 T NN O
to EP1896010A2 T TO O
treat EP1896010A2 T VB O
skin EP1896010A2 T JJ O
ulcers EP1896010A2 T NNS O
. EP1896010A2 T . O

Methods US20110217280 T NNS O
for US20110217280 T IN O
treating US20110217280 T VBG O
neuropsychiatric US20110217280 T JJ O
conditions US20110217280 T NNS O
. US20110217280 T . O

The US20110217280 A DT O
methods US20110217280 A NNS O
include US20110217280 A VBP O
systemic US20110217280 A JJ O
administration US20110217280 A NN O
of US20110217280 A IN O
a US20110217280 A DT O
pharmacological US20110217280 A JJ O
composition US20110217280 A NN O
containing US20110217280 A VBG O
a US20110217280 A DT O
therapeutically US20110217280 A RB O
effective US20110217280 A JJ O
amount US20110217280 A NN O
of US20110217280 A IN O
a US20110217280 A DT O
PAK US20110217280 A NNP I-UN
activator US20110217280 A NN O
. US20110217280 A . O

Pharmaceutical US20080051427 T JJ O
Compositions US20080051427 T NNS O
and US20080051427 T CC O
Methods US20080051427 T NNS O
of US20080051427 T IN O
Using US20080051427 T VBG O
Same US20080051427 T NNP O
. US20080051427 T . O

A US20080051427 A DT O
pharmaceutical US20080051427 A JJ O
composition US20080051427 A NN O
is US20080051427 A VBZ O
provided US20080051427 A VBN O
that US20080051427 A IN O
comprises US20080051427 A VBZ O
a US20080051427 A DT O
solid US20080051427 A JJ O
dispersion US20080051427 A NN O
of US20080051427 A IN O
implitapide US20080051427 A NN O
. US20080051427 A . O

Such US20080051427 A JJ O
solid US20080051427 A JJ O
dispersions US20080051427 A NNS O
may US20080051427 A MD O
include US20080051427 A VB O
implitapide US20080051427 A JJ O
and US20080051427 A CC O
least US20080051427 A JJS O
one US20080051427 A CD O
pharmaceutically US20080051427 A RB O
acceptable US20080051427 A JJ O
excipient US20080051427 A NN O
. US20080051427 A . O

In US20080051427 A IN O
some US20080051427 A DT O
embodiments US20080051427 A NNS O
, US20080051427 A , O
the US20080051427 A DT O
disclosed US20080051427 A VBN O
solid US20080051427 A JJ O
dispersions US20080051427 A NNS O
comprise US20080051427 A VBP O
substantially US20080051427 A RB O
amorphous US20080051427 A JJ O
implitapide US20080051427 A NN O
. US20080051427 A . O

Food CN1823819A T NN O
and CN1823819A T CC O
medicine CN1823819A T NN O
dual CN1823819A T JJ O
purpose CN1823819A T JJ O
product CN1823819A T NN O
for CN1823819A T IN O
preventing CN1823819A T VBG O
and CN1823819A T CC O
treating CN1823819A T VBG O
vision CN1823819A T NN O
injury CN1823819A T NN O
syndrome CN1823819A T NN O
duo CN1823819A T NN O
to CN1823819A T TO O
TV CN1823819A T NN O
and CN1823819A T CC O
computer CN1823819A T NN O
display CN1823819A T NN O
light CN1823819A T NN O
and CN1823819A T CC O
its CN1823819A T PRP$ O
manufacturing CN1823819A T NN O
method CN1823819A T NN O
. CN1823819A T . O

5-fluoro-n- WO2014060375A3 T JJ O
( WO2014060375A3 T ( O
pyridin-2-yl WO2014060375A3 T JJ O
) WO2014060375A3 T ) O
pyridin-2-amine WO2014060375A3 T JJ O
derivatives WO2014060375A3 T NNS O
containing WO2014060375A3 T VBG O
a WO2014060375A3 T DT O
sulfone WO2014060375A3 T NN O
group WO2014060375A3 T NN O
. WO2014060375A3 T . O

2-anilino-4-heteroaryl WO2008099075A1 T JJ O
pyrimidine WO2008099075A1 T NN O
derivatives WO2008099075A1 T NNS O
, WO2008099075A1 T , O
and WO2008099075A1 T CC O
preparation WO2008099075A1 T NN O
thereof WO2008099075A1 T NN O
as WO2008099075A1 T IN O
medicaments WO2008099075A1 T NNS O
, WO2008099075A1 T , O
pharmaceutical WO2008099075A1 T JJ O
compositions WO2008099075A1 T NNS O
, WO2008099075A1 T , O
and WO2008099075A1 T CC O
in WO2008099075A1 T IN O
particular WO2008099075A1 T JJ O
ikk WO2008099075A1 T NN O
inhibitors WO2008099075A1 T NNS O
. WO2008099075A1 T . O

excitatory US7572796 T NN O
amino US7572796 T NN O
acid US7572796 T NN O
antagonists US7572796 T NNS O
for US7572796 T IN O
treating US7572796 T VBG O
neurodegenerative US7572796 T JJ O
diseases US7572796 T NNS O
as US7572796 T IN O
cerebrovascular US7572796 T NN O
diseases US7572796 T NNS O
, US7572796 T , O
epilepsy US7572796 T NN O
, US7572796 T , O
schizophrenia US7572796 T NN O
, US7572796 T , O
Alzheimer US7572796 T NNP O
's US7572796 T POS O
disease US7572796 T NN O
, US7572796 T , O
Parkinson US7572796 T NNP O
's US7572796 T POS O
disease US7572796 T NN O
, US7572796 T , O
Huntington US7572796 T NNP O
's US7572796 T POS O
disease US7572796 T NN O
, US7572796 T , O
cerebral US7572796 T JJ O
ischaemia US7572796 T NN O
, US7572796 T , O
infarction US7572796 T NN O
, US7572796 T , O
psychoses US7572796 T VBZ O
; US7572796 T : O
6- US7572796 T JJ O
{ US7572796 T ( O
3- US7572796 T JJ O
[ US7572796 T NN O
4- US7572796 T JJ O
( US7572796 T ( O
4-fluorobenzyl US7572796 T JJ O
) US7572796 T ) O
-1-piperidyl US7572796 T FW O
] US7572796 T FW O
propyl US7572796 T NN O
} US7572796 T ) O
-1H-indole-3-carbonitrile US7572796 T NN O
. US7572796 T . O

Substituted US7572796 A JJ O
indoles US7572796 A NNS O
of US7572796 A IN O
the US7572796 A DT O
formula US7572796 A NN O
( US7572796 A ( O
I US7572796 A PRP O
) US7572796 A ) O
and US7572796 A CC O
physiologically US7572796 A RB O
acceptable US7572796 A JJ O
derivatives US7572796 A NNS O
and US7572796 A CC O
salts US7572796 A NNS O
thereof US7572796 A NN O
, US7572796 A , O
in US7572796 A IN O
which US7572796 A WDT O
R1 US7572796 A NNP O
, US7572796 A , O
D US7572796 A NNP O
, US7572796 A , O
E US7572796 A NNP O
, US7572796 A , O
R12 US7572796 A NNP O
, US7572796 A , O
p US7572796 A NN O
, US7572796 A , O
X1 US7572796 A NNP O
, US7572796 A , O
E US7572796 A NNP O
, US7572796 A , O
G US7572796 A NNP O
, US7572796 A , O
X2 US7572796 A NNP O
and US7572796 A CC O
Z US7572796 A NNP O
are US7572796 A VBP O
as US7572796 A IN O
defined US7572796 A VBN O
in US7572796 A IN O
claim US7572796 A NN O
1 US7572796 A CD O
, US7572796 A , O
exhibit US7572796 A NN O
particular US7572796 A JJ O
actions US7572796 A NNS O
on US7572796 A IN O
the US7572796 A DT O
central US7572796 A JJ O
nervous US7572796 A JJ O
system US7572796 A NN O
, US7572796 A , O
especially US7572796 A RB O
5HT US7572796 A CD O
reuptake-inhibiting US7572796 A JJ O
and US7572796 A CC O
5 US7572796 A CD I-UN
HTx-agonistic US7572796 A JJ O
and/or US7572796 A JJ O
-antagonistic US7572796 A JJ O
actions US7572796 A NNS O
and US7572796 A CC O
in US7572796 A IN O
particular US7572796 A JJ O
serotonin-agonistic US7572796 A JJ O
and US7572796 A CC O
-antagonistic US7572796 A JJ O
properties US7572796 A NNS O
and US7572796 A CC O
can US7572796 A MD O
be US7572796 A VB O
employed US7572796 A VBN O
as US7572796 A IN O
antipsychotics US7572796 A NNS O
, US7572796 A , O
neuroleptics US7572796 A NNS O
, US7572796 A , O
antidepressants US7572796 A NNS O
, US7572796 A , O
anxiolytics US7572796 A NNS O
and/or US7572796 A VBP O
antihypertonics US7572796 A NNS O
. US7572796 A . O

Application CN102475701A T NN O
of CN102475701A T IN O
pyrone CN102475701A T NN O
compound CN102475701A T NN O
. CN102475701A T . O

Cosmeceutical US20090221625 T JJ O
composition US20090221625 T NN O
. US20090221625 T . O

Methods WO2011066006A2 T NNS O
for WO2011066006A2 T IN O
treating WO2011066006A2 T VBG O
aids WO2011066006A2 T NNS O
. WO2011066006A2 T . O

Stabilized WO2014085526A1 T VBN O
vancomycin WO2014085526A1 T JJ O
formulations WO2014085526A1 T NNS O
. WO2014085526A1 T . O

Use EP1372627B1 T NNP O
of EP1372627B1 T IN O
breakers EP1372627B1 T NNS O
of EP1372627B1 T IN O
advanced EP1372627B1 T JJ O
glycation EP1372627B1 T NN O
endproducts EP1372627B1 T NNS O
for EP1372627B1 T IN O
treating EP1372627B1 T VBG O
deleterious EP1372627B1 T JJ O
effects EP1372627B1 T NNS O
of EP1372627B1 T IN O
aging EP1372627B1 T VBG O
and EP1372627B1 T CC O
debilitating EP1372627B1 T VBG O
diseases EP1372627B1 T NNS O
. EP1372627B1 T . O

1,1,1-trifluoro-3-amino-3-heteroaryl-2-propanoles WO2010049073A1 T NNS O
, WO2010049073A1 T , O
a WO2010049073A1 T DT O
process WO2010049073A1 T NN O
for WO2010049073A1 T IN O
their WO2010049073A1 T PRP$ O
production WO2010049073A1 T NN O
and WO2010049073A1 T CC O
their WO2010049073A1 T PRP$ O
use WO2010049073A1 T NN O
as WO2010049073A1 T IN O
anti-inflammatory WO2010049073A1 T JJ O
agents WO2010049073A1 T NNS O
. WO2010049073A1 T . O

Synergistic US20120045522 T JJ O
fungicidal US20120045522 T NN O
and US20120045522 T CC O
algicidal US20120045522 T JJ O
compositions US20120045522 T NNS O
including US20120045522 T VBG O
7-hydroxy-indanone US20120045522 T JJ O
benzoylhydrazones US20120045522 T NNS O
and US20120045522 T CC O
copper US20120045522 T NN O
. US20120045522 T . O

Antifungal WO2009129525A2 T NNP O
and WO2009129525A2 T CC O
anti-cariogenic WO2009129525A2 T JJ O
cellobio-oligosaccharides WO2009129525A2 T NNS O
produced WO2009129525A2 T VBN O
by WO2009129525A2 T IN O
dextransucrase WO2009129525A2 T NN O
. WO2009129525A2 T . O

Paste CN103393751A T NN O
for CN103393751A T IN O
relieving CN103393751A T VBG O
cough CN103393751A T NN O
and CN103393751A T CC O
preparation CN103393751A T NN O
method CN103393751A T NN O
thereof CN103393751A T NN O
. CN103393751A T . O

Coupled CN1593658A T VBN O
compound CN1593658A T NN O
of CN1593658A T IN O
3-amino-2-oxazolidinone CN1593658A T CD O
and CN1593658A T CC O
preparation CN1593658A T NN O
method CN1593658A T NN O
thereof CN1593658A T NN O
. CN1593658A T . O

The CN1593658A A DT O
invention CN1593658A A NN O
discloses CN1593658A A VBZ O
a CN1593658A A DT O
3-amino-2-oxazolidinone CN1593658A A JJ O
( CN1593658A A ( O
AOZ CN1593658A A NNP O
) CN1593658A A ) O
coupling CN1593658A A VBG O
substance CN1593658A A NN O
with CN1593658A A IN O
a CN1593658A A DT O
general CN1593658A A JJ O
formula CN1593658A A NN O
( CN1593658A A ( O
I CN1593658A A PRP O
) CN1593658A A ) O
, CN1593658A A , O
which CN1593658A A WDT O
is CN1593658A A VBZ O
composed CN1593658A A VBN O
by CN1593658A A IN O
optimizing CN1593658A A VBG O
cow CN1593658A A NN O
serum CN1593658A A NN O
protein CN1593658A A NN O
from CN1593658A A IN O
3-amino-2-oxazolidinone CN1593658A A JJ O
haptene CN1593658A A NN O
and CN1593658A A CC O
carrying CN1593658A A VBG O
agent CN1593658A A JJ O
substance CN1593658A A NN O
for CN1593658A A IN O
producing CN1593658A A VBG O
immunogen CN1593658A A NN O
performance CN1593658A A NN O
, CN1593658A A , O
wherein CN1593658A A WP O
n CN1593658A A NN O
is CN1593658A A VBZ O
the CN1593658A A DT O
number CN1593658A A NN O
of CN1593658A A IN O
molecules CN1593658A A NNS O
of CN1593658A A IN O
AOZ CN1593658A A NNP O
combining CN1593658A A VBG O
with CN1593658A A IN O
a CN1593658A A DT O
cow CN1593658A A NN O
serum CN1593658A A NN O
protein CN1593658A A NN O
, CN1593658A A , O
BSA CN1593658A A NNP I-UN
is CN1593658A A VBZ O
cow CN1593658A A JJ O
serum CN1593658A A NN O
protein CN1593658A A NN O
, CN1593658A A , O
its CN1593658A A PRP$ O
molecular CN1593658A A JJ O
weight CN1593658A A NN O
range CN1593658A A NN O
is CN1593658A A VBZ O
between CN1593658A A IN O
6.6KDa-6.9KDa CN1593658A A JJ O
. CN1593658A A . O

Alzheimer US7253162 T NNP O
's US7253162 T POS O
disease US7253162 T NN O
; US7253162 T : O
cognition US7253162 T NN O
activators US7253162 T NNS O
; US7253162 T : O
central US7253162 T JJ O
nervous US7253162 T JJ O
system US7253162 T NN O
disorders US7253162 T NNS O
. US7253162 T . O

Isoxazole US7915281 T NNP O
, US7915281 T , O
dihydroisoxazole US7915281 T NN O
, US7915281 T , O
and US7915281 T CC O
oxadiazole US7915281 T RB O
substituted US7915281 T VBD O
imidazo US7915281 T JJ O
ring US7915281 T NN O
compounds US7915281 T NNS O
and US7915281 T CC O
method US7915281 T NN O
. US7915281 T . O

imidazo US7915281 A JJ O
[ US7915281 A NNP O
4,5-c US7915281 A JJ O
] US7915281 A NNP O
pyridine US7915281 A NN O
, US7915281 A , O
imidazo US7915281 A JJ O
[ US7915281 A NNP O
4,5-c US7915281 A JJ O
] US7915281 A NNP O
quinoline US7915281 A NN O
, US7915281 A , O
6,7,8,9-tetrahydro US7915281 A JJ O
imidazo US7915281 A NN O
[ US7915281 A NNP O
4,5-c US7915281 A JJ O
] US7915281 A NNP O
quinoline US7915281 A NN O
, US7915281 A , O
and US7915281 A CC O
imidazo US7915281 A JJ O
[ US7915281 A NNP O
4,5-c US7915281 A JJ O
] US7915281 A NNP O
naphthyridine US7915281 A NN O
compounds US7915281 A NNS O
) US7915281 A ) O
having US7915281 A VBG O
an US7915281 A DT O
isoxazole US7915281 A NN O
, US7915281 A , O
dihydroisoxazole US7915281 A NN O
, US7915281 A , O
or US7915281 A CC O
oxadiazole US7915281 A JJ O
substituent US7915281 A NN O
at US7915281 A IN O
the US7915281 A DT O
1-position US7915281 A NN O
, US7915281 A , O
pharmaceutical US7915281 A JJ O
compositions US7915281 A NNS O
containing US7915281 A VBG O
the US7915281 A DT O
compounds US7915281 A NNS O
, US7915281 A , O
intermediates US7915281 A NNS O
, US7915281 A , O
and US7915281 A CC O
methods US7915281 A NNS O
of US7915281 A IN O
making US7915281 A VBG O
and US7915281 A CC O
methods US7915281 A NNS O
of US7915281 A IN O
use US7915281 A NN O
of US7915281 A IN O
these US7915281 A DT O
compounds US7915281 A NNS O
as US7915281 A IN O
immunomodulators US7915281 A NNS O
, US7915281 A , O
for US7915281 A IN O
modulating US7915281 A VBG O
cytokine US7915281 A JJ I-UN
biosynthesis US7915281 A NN O
in US7915281 A IN O
animals US7915281 A NNS O
and US7915281 A CC O
in US7915281 A IN O
the US7915281 A DT O
treatment US7915281 A NN O
of US7915281 A IN O
diseases US7915281 A NNS O
including US7915281 A VBG O
viral US7915281 A JJ O
and US7915281 A CC O
neoplastic US7915281 A JJ O
diseases US7915281 A NNS O
are US7915281 A VBP O
disclosed US7915281 A VBN O
. US7915281 A . O

Lycium CN103342755A T NNP O
barbarum CN103342755A T NN O
polysaccharide CN103342755A T RB O
homogeneous CN103342755A T JJ O
fraction CN103342755A T NN O
IV CN103342755A T NNP O
, CN103342755A T , O
and CN103342755A T CC O
preparation CN103342755A T NN O
method CN103342755A T NN O
and CN103342755A T CC O
application CN103342755A T NN O
thereof CN103342755A T NN O
. CN103342755A T . O

The CN103342755A A DT O
invention CN103342755A A NN O
also CN103342755A A RB O
discloses CN103342755A A VBZ O
the CN103342755A A DT O
preparation CN103342755A A NN O
method CN103342755A A NN O
of CN103342755A A IN O
the CN103342755A A DT O
lycium CN103342755A A NN O
barbarum CN103342755A A NN O
polysaccharide CN103342755A A RB O
homogeneous CN103342755A A JJ O
fraction CN103342755A A NN O
IV CN103342755A A NNP O
and CN103342755A A CC O
an CN103342755A A DT O
application CN103342755A A NN O
of CN103342755A A IN O
the CN103342755A A DT O
lycium CN103342755A A NN O
barbarum CN103342755A A NN O
polysaccharide CN103342755A A RB O
homogeneous CN103342755A A JJ O
fraction CN103342755A A NN O
IV CN103342755A A NNP O
in CN103342755A A IN O
preparing CN103342755A A VBG O
drugs CN103342755A A NNS O
for CN103342755A A IN O
treating CN103342755A A VBG O
glucose CN103342755A A NN O
and CN103342755A A CC O
lipid CN103342755A A JJ O
metabolism CN103342755A A NN O
disorders CN103342755A A NNS O
and CN103342755A A CC O
insulin CN103342755A A NN I-UN
resistance CN103342755A A NN O
in CN103342755A A IN O
diabetes CN103342755A A NNS O
. CN103342755A A . O

Heteroaryl US8541425 T NNP O
substituted US8541425 T VBD O
pyrrolo US8541425 T JJ O
[ US8541425 T JJ O
2,3-b US8541425 T JJ O
] US8541425 T NN O
pyridines US8541425 T NNS O
and US8541425 T CC O
pyrrolo US8541425 T JJ O
[ US8541425 T NNP O
2,3-b US8541425 T JJ O
] US8541425 T NNP O
pyrimidines US8541425 T NNS O
as US8541425 T IN O
Janus US8541425 T NNP I-UN
kinase US8541425 T NN I-UN
inhibitors US8541425 T NNS O
. US8541425 T . O

The US8541425 A DT O
present US8541425 A JJ O
invention US8541425 A NN O
provides US8541425 A VBZ O
heteroaryl US8541425 A RB O
substituted US8541425 A VBN O
pyrrolo US8541425 A JJ O
[ US8541425 A JJ O
2,3-b US8541425 A JJ O
] US8541425 A NN O
pyridines US8541425 A NNS O
and US8541425 A CC O
heteroaryl US8541425 A NN O
substituted US8541425 A VBD O
pyrrolo US8541425 A JJ O
[ US8541425 A JJ O
2,3-b US8541425 A JJ O
] US8541425 A NN O
pyrimidines US8541425 A NNS O
that US8541425 A WDT O
modulate US8541425 A VBP O
the US8541425 A DT O
activity US8541425 A NN O
of US8541425 A IN O
Janus US8541425 A NNP I-UN
kinases US8541425 A NNS I-UN
and US8541425 A CC O
are US8541425 A VBP O
useful US8541425 A JJ O
in US8541425 A IN O
the US8541425 A DT O
treatment US8541425 A NN O
of US8541425 A IN O
diseases US8541425 A NNS O
related US8541425 A VBN O
to US8541425 A TO O
activity US8541425 A NN O
of US8541425 A IN O
Janus US8541425 A NNP I-UN
kinases US8541425 A NNS I-UN
including US8541425 A VBG O
, US8541425 A , O
for US8541425 A IN O
example US8541425 A NN O
, US8541425 A , O
immune-related US8541425 A JJ O
diseases US8541425 A NNS O
, US8541425 A , O
skin US8541425 A NN O
disorders US8541425 A NNS O
, US8541425 A , O
myeloid US8541425 A JJ O
proliferative US8541425 A NN O
disorders US8541425 A NNS O
, US8541425 A , O
cancer US8541425 A NN O
, US8541425 A , O
and US8541425 A CC O
other US8541425 A JJ O
diseases US8541425 A NNS O
. US8541425 A . O

Self-assembling US20100331273 T JJ O
complex US20100331273 T NN O
for US20100331273 T IN O
targeting US20100331273 T VBG O
chemical US20100331273 T NN O
agents US20100331273 T NNS O
to US20100331273 T TO O
cells US20100331273 T NNS O
. US20100331273 T . O

Pharmaceutical EP1731156A1 T JJ O
compositions EP1731156A1 T NNS O
to EP1731156A1 T TO O
treat EP1731156A1 T VB O
or EP1731156A1 T CC O
prevent EP1731156A1 T VB O
cerebral EP1731156A1 T JJ O
oedema EP1731156A1 T NN O
. EP1731156A1 T . O

administering US7799773 T VBG O
7-Benzyloxy-3-cyclobutyl-2,3,4,5-tetrahydro-1H-benzo US7799773 T JJ O
[ US7799773 T NNP O
d US7799773 T NN O
] US7799773 T NNP O
azepine US7799773 T NN O
, US7799773 T , O
for US7799773 T IN O
the US7799773 T DT O
treatment US7799773 T NN O
of US7799773 T IN O
Alzheimer US7799773 T NNP O
's US7799773 T POS O
disease US7799773 T NN O
, US7799773 T , O
cognitive US7799773 T JJ O
impairment US7799773 T NN O
, US7799773 T , O
dementia US7799773 T NN O
, US7799773 T , O
epilepsy US7799773 T NN O
, US7799773 T , O
neuropathic US7799773 T JJ O
pain US7799773 T NN O
, US7799773 T , O
Parkinson US7799773 T NNP O
's US7799773 T POS O
disease US7799773 T NN O
, US7799773 T , O
schizophrenia US7799773 T NN O
, US7799773 T , O
attention US7799773 T NN O
deficit US7799773 T NN O
disorder US7799773 T NN O
or US7799773 T CC O
depression US7799773 T NN O
in US7799773 T IN O
humans US7799773 T NNS O
. US7799773 T . O

Method EP2632459A2 T NNP O
of EP2632459A2 T IN O
treating EP2632459A2 T VBG O
neuroendocrine EP2632459A2 T JJ O
tumors EP2632459A2 T NNS O
. EP2632459A2 T . O

Racecadotril CN102166197A T NNP O
granules CN102166197A T NNS O
and CN102166197A T CC O
production CN102166197A T NN O
process CN102166197A T NN O
thereof CN102166197A T NN O
. CN102166197A T . O

Application CN1771925A T NN O
of CN1771925A T IN O
recombinant CN1771925A T JJ O
allophycocyanin CN1771925A T NN O
in CN1771925A T IN O
preparing CN1771925A T VBG O
medicine CN1771925A T NN O
for CN1771925A T IN O
treating CN1771925A T VBG O
liver CN1771925A T NN O
cancer CN1771925A T NN O
. CN1771925A T . O

The CN1771925A A DT O
recombinant CN1771925A A NN O
allophycocyanin CN1771925A A NN O
has CN1771925A A VBZ O
obvious CN1771925A A JJ O
tumor CN1771925A A NN O
growth CN1771925A A NN O
inhibiting CN1771925A A VBG O
effect CN1771925A A NN O
, CN1771925A A , O
and CN1771925A A CC O
the CN1771925A A DT O
immunopotentiation CN1771925A A NN O
characteristic CN1771925A A NN O
of CN1771925A A IN O
raising CN1771925A A VBG O
the CN1771925A A DT O
immunological CN1771925A A JJ O
function CN1771925A A NN O
of CN1771925A A IN O
T CN1771925A A NNP O
cell CN1771925A A NN O
, CN1771925A A , O
promoting CN1771925A A VBG O
the CN1771925A A DT O
proliferation CN1771925A A NN O
of CN1771925A A IN O
T CN1771925A A NNP O
cell CN1771925A A NN O
and CN1771925A A CC O
increasing CN1771925A A VBG O
cell CN1771925A A NN O
factor CN1771925A A NN O
IL-2 CN1771925A A NNP I-UN
and CN1771925A A CC O
gamma-IFN CN1771925A A NN I-UN
. CN1771925A A . O

Pulsed US20080069870 T JJ O
release US20080069870 T NN O
; US20080069870 T : O
oral US20080069870 T JJ O
administering US20080069870 T NN O
. US20080069870 T . O

Aspirin-triggered US7227031 T JJ O
lipoxins US7227031 T NNS O
as US7227031 T IN O
modulators US7227031 T NNS O
of US7227031 T IN O
diseases US7227031 T NNS O
associated US7227031 T VBN O
with US7227031 T IN O
polymorphoneutrophil US7227031 T JJ O
inflammation US7227031 T NN O
; US7227031 T : O
antiinflammatory US7227031 T JJ O
agents US7227031 T NNS O
. US7227031 T . O

Aspirin US7227031 A NNP O
( US7227031 A ( O
ASA US7227031 A NNP O
) US7227031 A ) O
triggers US7227031 A VBZ O
a US7227031 A DT O
switch US7227031 A NN O
in US7227031 A IN O
the US7227031 A DT O
biosynthesis US7227031 A NN O
of US7227031 A IN O
lipid US7227031 A JJ O
mediators US7227031 A NNS O
, US7227031 A , O
inhibiting US7227031 A VBG O
prostanoid US7227031 A JJ O
production US7227031 A NN O
and US7227031 A CC O
initiating US7227031 A VBG O
15-epi-lipoxin US7227031 A JJ O
generation US7227031 A NN O
, US7227031 A , O
through US7227031 A IN O
the US7227031 A DT O
acetylation US7227031 A NN O
of US7227031 A IN O
cyclooxygenase US7227031 A NN I-UN
II US7227031 A NNP I-UN
. US7227031 A . O

Administration EP1868572A2 T NN O
of EP1868572A2 T IN O
glutathione EP1868572A2 T NN O
( EP1868572A2 T ( O
reduced EP1868572A2 T VBN O
) EP1868572A2 T ) O
via EP1868572A2 T IN O
intravenous EP1868572A2 T JJ O
or EP1868572A2 T CC O
encapsulated EP1868572A2 T VBN O
in EP1868572A2 T IN O
liposome EP1868572A2 T NN O
for EP1868572A2 T IN O
treatment EP1868572A2 T NN O
of EP1868572A2 T IN O
tnf-alpha EP1868572A2 T JJ I-UN
effects EP1868572A2 T NNS O
and EP1868572A2 T CC O
elu-like EP1868572A2 T JJ O
viral EP1868572A2 T NN O
symptoms EP1868572A2 T NNS O
. EP1868572A2 T . O

The EP1868572A2 A DT O
invention EP1868572A2 A NN O
is EP1868572A2 A VBZ O
a EP1868572A2 A DT O
method EP1868572A2 A NN O
of EP1868572A2 A IN O
treatment EP1868572A2 A NN O
of EP1868572A2 A IN O
the EP1868572A2 A DT O
symptoms EP1868572A2 A NNS O
related EP1868572A2 A VBN O
to EP1868572A2 A TO O
inflammation EP1868572A2 A NN O
that EP1868572A2 A WDT O
accompanies EP1868572A2 A VBZ O
the EP1868572A2 A DT O
release EP1868572A2 A NN O
of EP1868572A2 A IN O
Tumor EP1868572A2 A NNP I-UN
Necrosis EP1868572A2 A NNP I-UN
Factor EP1868572A2 A NNP I-UN
- EP1868572A2 A : I-UN
alpha EP1868572A2 A NN I-UN
in EP1868572A2 A IN O
diseases EP1868572A2 A NNS O
such EP1868572A2 A JJ O
as EP1868572A2 A IN O
viral EP1868572A2 A JJ O
infection EP1868572A2 A NN O
such EP1868572A2 A JJ O
as EP1868572A2 A IN O
those EP1868572A2 A DT O
affecting EP1868572A2 A VBG O
the EP1868572A2 A DT O
respiratory EP1868572A2 A NN O
tract EP1868572A2 A NN O
by EP1868572A2 A IN O
providing EP1868572A2 A VBG O
systemic EP1868572A2 A JJ O
glutathione EP1868572A2 A NN O
( EP1868572A2 A ( O
reduced EP1868572A2 A VBN O
) EP1868572A2 A ) O
by EP1868572A2 A IN O
oral EP1868572A2 A JJ O
administration EP1868572A2 A NN O
of EP1868572A2 A IN O
glutathione EP1868572A2 A NN O
( EP1868572A2 A ( O
reduced EP1868572A2 A VBN O
) EP1868572A2 A ) O
in EP1868572A2 A IN O
a EP1868572A2 A DT O
liposome EP1868572A2 A JJ O
encapsulation EP1868572A2 A NN O
or EP1868572A2 A CC O
by EP1868572A2 A IN O
the EP1868572A2 A DT O
intravenous EP1868572A2 A JJ O
administration EP1868572A2 A NN O
of EP1868572A2 A IN O
reduced EP1868572A2 A JJ O
glutathione EP1868572A2 A NN O
. EP1868572A2 A . O

The EP1868572A2 A DT O
administration EP1868572A2 A NN O
of EP1868572A2 A IN O
a EP1868572A2 A DT O
therapeutically EP1868572A2 A RB O
effective EP1868572A2 A JJ O
amount EP1868572A2 A NN O
of EP1868572A2 A IN O
oral EP1868572A2 A JJ O
liposomal EP1868572A2 A JJ O
glutathione EP1868572A2 A NN O
( EP1868572A2 A ( O
reduced EP1868572A2 A VBN O
) EP1868572A2 A ) O
results EP1868572A2 A NNS O
in EP1868572A2 A IN O
improvement EP1868572A2 A NN O
of EP1868572A2 A IN O
symptoms EP1868572A2 A NNS O
of EP1868572A2 A IN O
disease EP1868572A2 A NN O
induced EP1868572A2 A VBN O
by EP1868572A2 A IN O
the EP1868572A2 A DT O
release EP1868572A2 A NN O
of EP1868572A2 A IN O
TNF- EP1868572A2 A NNP I-UN
a EP1868572A2 A DT I-UN
in EP1868572A2 A IN O
infectious EP1868572A2 A JJ O
disease EP1868572A2 A NN O
states EP1868572A2 A NNS O
such EP1868572A2 A JJ O
as EP1868572A2 A IN O
respiratory EP1868572A2 A NN O
and EP1868572A2 A CC O
other EP1868572A2 A JJ O
viruses EP1868572A2 A NNS O
. EP1868572A2 A . O

Application CN102727475A T NN O
of CN102727475A T IN O
retinoic CN102727475A T NN O
acid CN102727475A T NN O
and CN102727475A T CC O
its CN102727475A T PRP$ O
derivatives CN102727475A T NNS O
in CN102727475A T IN O
preparation CN102727475A T NN O
of CN102727475A T IN O
drugs CN102727475A T NNS O
preventing CN102727475A T VBG O
and CN102727475A T CC O
treating CN102727475A T VBG O
Alzheimer CN102727475A T NNP O
's CN102727475A T POS O
disease CN102727475A T NN O
. CN102727475A T . O

According CN102727475A A VBG O
to CN102727475A A TO O
the CN102727475A A DT O
invention CN102727475A A NN O
, CN102727475A A , O
retinoic CN102727475A A JJ O
acid CN102727475A A NN O
and CN102727475A A CC O
its CN102727475A A PRP$ O
derivatives CN102727475A A NNS O
can CN102727475A A MD O
inhibit CN102727475A A VB O
amyloid CN102727475A A JJ O
protein CN102727475A A NN O
induced CN102727475A A VBD O
inflammatory CN102727475A A JJ O
response CN102727475A A NN O
during CN102727475A A IN O
Alzheimer CN102727475A A NNP O
's CN102727475A A POS O
disease CN102727475A A NN O
attacks CN102727475A A NNS O
by CN102727475A A IN O
specifically CN102727475A A RB O
inhibiting CN102727475A A VBG O
the CN102727475A A DT O
activity CN102727475A A NN O
of CN102727475A A IN O
transcription CN102727475A A NN I-UN
factor CN102727475A A NN I-UN
AP-1 CN102727475A A NNP I-UN
, CN102727475A A , O
thus CN102727475A A RB O
delaying CN102727475A A VBG O
the CN102727475A A DT O
occurrence CN102727475A A NN O
and CN102727475A A CC O
development CN102727475A A NN O
of CN102727475A A IN O
Alzheimer CN102727475A A NNP O
's CN102727475A A POS O
disease CN102727475A A NN O
. CN102727475A A . O

Retinoic CN102727475A A NNP O
acid CN102727475A A NN O
and CN102727475A A CC O
its CN102727475A A PRP$ O
derivatives CN102727475A A NNS O
can CN102727475A A MD O
substantially CN102727475A A RB O
improve CN102727475A A VB O
dyskinesias CN102727475A A NN O
of CN102727475A A IN O
SAM-P/8 CN102727475A A NNP O
mice CN102727475A A NN O
, CN102727475A A , O
obviously CN102727475A A RB O
enhance CN102727475A A JJ O
brain CN102727475A A NN O
tissue CN102727475A A NN O
SOD CN102727475A A NNP I-UN
activity CN102727475A A NN O
of CN102727475A A IN O
SAM-P/8 CN102727475A A NNP O
mice CN102727475A A NN O
, CN102727475A A , O
reduce CN102727475A A VB O
brain CN102727475A A NN O
tissue CN102727475A A NN O
MDA CN102727475A A NNP O
content CN102727475A A NN O
, CN102727475A A , O
lower CN102727475A A JJR O
brain CN102727475A A NN O
tissue CN102727475A A NN O
cholinesterase CN102727475A A NN I-UN
activity CN102727475A A NN O
, CN102727475A A , O
strengthen CN102727475A A VBP O
the CN102727475A A DT O
activity CN102727475A A NN O
of CN102727475A A IN O
brain CN102727475A A NN O
tissue CN102727475A A NN O
Na CN102727475A A NNP O
< CN102727475A A NNP O
+ CN102727475A A NNP O
> CN102727475A A NNP O
-K CN102727475A A NNP O
< CN102727475A A NNP O
+ CN102727475A A NNP O
> CN102727475A A NNP O
-ATP CN102727475A A NNP O
enzyme CN102727475A A NN O
and CN102727475A A CC O
Ca CN102727475A A NNP O
< CN102727475A A NNP O
2+ CN102727475A A CD O
> CN102727475A A NNP O
-ATP CN102727475A A NNP O
enzyme CN102727475A A NN O
. CN102727475A A . O

Tetracyclic EP2308880A1 T NNP O
compound EP2308880A1 T NN O
. EP2308880A1 T . O

Highly CN101297973A T NNP O
bioadhesive CN101297973A T JJ O
and CN101297973A T CC O
thermosensitive CN101297973A T JJ O
hydrogel CN101297973A T NN O
, CN101297973A T , O
and CN101297973A T CC O
preparation CN101297973A T NN O
method CN101297973A T NN O
and CN101297973A T CC O
application CN101297973A T NN O
thereof CN101297973A T NN O
. CN101297973A T . O

Medicine CN101229158B T NNP O
compounds CN101229158B T VBZ O
for CN101229158B T IN O
treating CN101229158B T VBG O
tumour CN101229158B T NN O
and CN101229158B T CC O
applications CN101229158B T NNS O
thereof CN101229158B T VBP O
. CN101229158B T . O

Novel US20110135580 T NNP O
Medicament US20110135580 T NNP O
Combinations US20110135580 T NNP O
for US20110135580 T IN O
the US20110135580 T DT O
Treatment US20110135580 T NNP O
of US20110135580 T IN O
Respiratory US20110135580 T NNP O
Diseases US20110135580 T NNP O
. US20110135580 T . O

Derivatives US20080096829 T NNS O
of US20080096829 T IN O
erythromycin US20080096829 T NN O
A US20080096829 T NNP O
and US20080096829 T CC O
azithromycin US20080096829 T JJ O
having US20080096829 T VBG O
quinoline US20080096829 T NN O
, US20080096829 T , O
[ US20080096829 T VBZ O
1,3 US20080096829 T CD O
] US20080096829 T NN O
oxazino US20080096829 T NN O
[ US20080096829 T NNP O
5,4,3-ij US20080096829 T JJ O
] US20080096829 T NNP O
quinoline US20080096829 T NN O
, US20080096829 T , O
or US20080096829 T CC O
[ US20080096829 T $ O
1,4 US20080096829 T CD O
] US20080096829 T NNP O
oxazepino US20080096829 T NN O
[ US20080096829 T NNP O
2,3,4-ij US20080096829 T JJ O
] US20080096829 T NNP O
quinoline US20080096829 T NN O
substituent US20080096829 T NN O
; US20080096829 T : O
macrolide-resistant US20080096829 T JJ O
bacterial US20080096829 T JJ O
infections US20080096829 T NNS O
; US20080096829 T : O
Staphylococcus US20080096829 T NNP O
, US20080096829 T , O
Streptopococcus US20080096829 T NNP O
, US20080096829 T , O
Moraxella US20080096829 T NNP O
, US20080096829 T , O
Hemophilus US20080096829 T NNP O
, US20080096829 T , O
Enterococcus US20080096829 T NNP O
, US20080096829 T , O
Chlamydia US20080096829 T NNP O
, US20080096829 T , O
Mycoplasma US20080096829 T NNP O
, US20080096829 T , O
or US20080096829 T CC O
Legionella US20080096829 T NNP O
. US20080096829 T . O

Farnesyl US7053105 T NNP I-UN
transferase US7053105 T NN I-UN
inhibiting US7053105 T VBG O
quinoline US7053105 T NN O
and US7053105 T CC O
quinazoline US7053105 T JJ O
derivatives US7053105 T NNS O
as US7053105 T IN O
farnesyl US7053105 T JJ O
transferase US7053105 T NN I-UN
inhibitors US7053105 T NNS O
. US7053105 T . O

This US7053105 A DT O
invention US7053105 A NN O
comprises US7053105 A VBZ O
the US7053105 A DT O
novel US7053105 A JJ O
compounds US7053105 A NNS O
of US7053105 A IN O
formula US7053105 A NN O
( US7053105 A ( O
I US7053105 A PRP O
) US7053105 A ) O
wherein US7053105 A NN O
r US7053105 A NN O
, US7053105 A , O
s US7053105 A NN O
, US7053105 A , O
t US7053105 A NN O
, US7053105 A , O
Y1—Y2 US7053105 A NNP O
, US7053105 A , O
R1 US7053105 A NNP O
, US7053105 A , O
R2 US7053105 A NNP O
, US7053105 A , O
R3 US7053105 A NNP O
, US7053105 A , O
R4 US7053105 A NNP O
, US7053105 A , O
R5 US7053105 A NNP O
and US7053105 A CC O
R7 US7053105 A NNP O
have US7053105 A VBP O
defined US7053105 A VBN O
meanings US7053105 A NNS O
, US7053105 A , O
having US7053105 A VBG O
farnesyl US7053105 A JJ I-UN
transferase US7053105 A NN O
inhibiting US7053105 A NN O
activity US7053105 A NN O
; US7053105 A : O
their US7053105 A PRP$ O
preparation US7053105 A NN O
, US7053105 A , O
compositions US7053105 A NNS O
containing US7053105 A VBG O
them US7053105 A PRP O
and US7053105 A CC O
their US7053105 A PRP$ O
use US7053105 A NN O
as US7053105 A IN O
a US7053105 A DT O
medicine US7053105 A NN O
. US7053105 A . O

Pharmaceutical CN101530618B T JJ O
composition CN101530618B T NN O
for CN101530618B T IN O
the CN101530618B T DT O
treatment CN101530618B T NN O
of CN101530618B T IN O
chronic CN101530618B T JJ O
obstructive CN101530618B T JJ O
pulmonary CN101530618B T JJ O
disease CN101530618B T NN O
and CN101530618B T CC O
bronchial CN101530618B T JJ O
asthma CN101530618B T NN O
. CN101530618B T . O

Tastemasked EP2275141A1 T NNP O
pharmaceutical EP2275141A1 T JJ O
compositions EP2275141A1 T NNS O
. EP2275141A1 T . O

Doxycycline CN101190230A T NNP O
hydrochloride CN101190230A T NN O
chewable CN101190230A T JJ O
tablets CN101190230A T NNS O
for CN101190230A T IN O
dog CN101190230A T NN O
or CN101190230A T CC O
cat CN101190230A T NN O
. CN101190230A T . O

Modulation US20120302491 T NN O
of US20120302491 T IN O
estrogen US20120302491 T JJ O
receptor-related US20120302491 T JJ O
receptor US20120302491 T NN O
gamma US20120302491 T NN O
( US20120302491 T ( O
err US20120302491 T JJ O
gamma US20120302491 T NN O
) US20120302491 T ) O
and US20120302491 T CC O
uses US20120302491 T VBZ O
therefor US20120302491 T NN O
. US20120302491 T . O

This US20120302491 A DT O
application US20120302491 A NN O
provides US20120302491 A VBZ O
methods US20120302491 A NNS O
of US20120302491 A IN O
increasing US20120302491 A VBG O
vascularization US20120302491 A NN O
, US20120302491 A , O
muscle US20120302491 A NN O
performance US20120302491 A NN O
, US20120302491 A , O
muscle US20120302491 A NN O
rehabilitation US20120302491 A NN O
, US20120302491 A , O
and/or US20120302491 A JJ O
mitochondrial US20120302491 A JJ O
activity US20120302491 A NN O
in US20120302491 A IN O
subjects US20120302491 A NNS O
in US20120302491 A IN O
need US20120302491 A NN O
thereof US20120302491 A NNS O
, US20120302491 A , O
by US20120302491 A IN O
administering US20120302491 A VBG O
a US20120302491 A DT O
therapeutically US20120302491 A RB O
effective US20120302491 A JJ O
amount US20120302491 A NN O
of US20120302491 A IN O
one US20120302491 A CD O
or US20120302491 A CC O
more US20120302491 A JJR O
agents US20120302491 A NNS O
that US20120302491 A WDT O
increases US20120302491 A VBZ O
ERRγ US20120302491 A NNP O
activity US20120302491 A NN O
to US20120302491 A TO O
the US20120302491 A DT O
subject US20120302491 A NN O
. US20120302491 A . O

Such US20120302491 A JJ O
agents US20120302491 A NNS O
can US20120302491 A MD O
include US20120302491 A VB O
one US20120302491 A CD O
or US20120302491 A CC O
more US20120302491 A JJR O
ERRγ US20120302491 A JJ O
agonists US20120302491 A NNS O
. US20120302491 A . O

In US20120302491 A IN O
some US20120302491 A DT O
examples US20120302491 A NNS O
the US20120302491 A DT O
method US20120302491 A NN O
does US20120302491 A VBZ O
not US20120302491 A RB O
require US20120302491 A VB O
that US20120302491 A IN O
the US20120302491 A DT O
subject US20120302491 A NN O
exercise US20120302491 A NN O
, US20120302491 A , O
and US20120302491 A CC O
as US20120302491 A IN O
such US20120302491 A JJ O
, US20120302491 A , O
the US20120302491 A DT O
subject US20120302491 A NN O
may US20120302491 A MD O
be US20120302491 A VB O
sedentary US20120302491 A JJ O
( US20120302491 A ( O
such US20120302491 A JJ O
as US20120302491 A IN O
bedridden US20120302491 A NN O
or US20120302491 A CC O
in US20120302491 A IN O
a US20120302491 A DT O
wheelchair US20120302491 A NN O
) US20120302491 A ) O
. US20120302491 A . O

Compositions US20110071215 T NNS O
and US20110071215 T CC O
methods US20110071215 T NNS O
for US20110071215 T IN O
diagnosis US20110071215 T NN O
, US20110071215 T , O
prognosis US20110071215 T NN O
and US20110071215 T CC O
treatment US20110071215 T NN O
of US20110071215 T IN O
mesothelioma US20110071215 T NN O
. US20110071215 T . O

Application CN103169693A T NN O
of CN103169693A T IN O
wogonin CN103169693A T NN O
derivant CN103169693A T NN O
in CN103169693A T IN O
preparation CN103169693A T NN O
of CN103169693A T IN O
drug CN103169693A T NN O
for CN103169693A T IN O
treating CN103169693A T VBG O
liver CN103169693A T NN O
cancer CN103169693A T NN O
. CN103169693A T . O

Algal EP2651425A1 T NNP O
extract-based EP2651425A1 T JJ O
composition EP2651425A1 T NN O
for EP2651425A1 T IN O
oro-dental EP2651425A1 T JJ O
use EP2651425A1 T NN O
. EP2651425A1 T . O

Transmucosal US20110071203 T NNP O
veterinary US20110071203 T JJ O
composition US20110071203 T NN O
comprising US20110071203 T VBG O
detomidine US20110071203 T NN O
. US20110071203 T . O

Acetic WO2010044441A1 T JJ O
acid WO2010044441A1 T NN O
amide WO2010044441A1 T RB O
derivative WO2010044441A1 T JJ O
having WO2010044441A1 T VBG O
inhibitory WO2010044441A1 T JJ O
activity WO2010044441A1 T NN O
on WO2010044441A1 T IN O
vascular WO2010044441A1 T JJ I-UN
endothelial WO2010044441A1 T JJ I-UN
lipase WO2010044441A1 T NN I-UN
. WO2010044441A1 T . O

Disclosed WO2010044441A1 A VBN O
is WO2010044441A1 A VBZ O
a WO2010044441A1 A DT O
compound WO2010044441A1 A NN O
useful WO2010044441A1 A JJ O
as WO2010044441A1 A IN O
a WO2010044441A1 A DT O
vascular WO2010044441A1 A JJ I-UN
endothelial WO2010044441A1 A JJ I-UN
lipase WO2010044441A1 A NN I-UN
inhibitor WO2010044441A1 A NN O
. WO2010044441A1 A . O

Specifically WO2010044441A1 A RB O
disclosed WO2010044441A1 A VBN O
is WO2010044441A1 A VBZ O
a WO2010044441A1 A DT O
pharmaceutical WO2010044441A1 A JJ O
composition WO2010044441A1 A NN O
having WO2010044441A1 A VBG O
an WO2010044441A1 A DT O
inhibitory WO2010044441A1 A JJ O
activity WO2010044441A1 A NN O
on WO2010044441A1 A IN O
vascular WO2010044441A1 A JJ I-UN
endothelial WO2010044441A1 A JJ I-UN
lipase WO2010044441A1 A NN I-UN
, WO2010044441A1 A , O
which WO2010044441A1 A WDT O
comprises WO2010044441A1 A VBZ O
a WO2010044441A1 A DT O
compound WO2010044441A1 A NN O
represented WO2010044441A1 A VBN O
by WO2010044441A1 A IN O
formula WO2010044441A1 A NN O
( WO2010044441A1 A ( O
I WO2010044441A1 A PRP O
) WO2010044441A1 A ) O
, WO2010044441A1 A , O
a WO2010044441A1 A DT O
pharmaceutically WO2010044441A1 A RB O
acceptable WO2010044441A1 A JJ O
salt WO2010044441A1 A NN O
of WO2010044441A1 A IN O
the WO2010044441A1 A DT O
compound WO2010044441A1 A NN O
, WO2010044441A1 A , O
or WO2010044441A1 A CC O
a WO2010044441A1 A DT O
solvate WO2010044441A1 A NN O
of WO2010044441A1 A IN O
the WO2010044441A1 A DT O
compound WO2010044441A1 A NN O
or WO2010044441A1 A CC O
the WO2010044441A1 A DT O
pharmaceutically WO2010044441A1 A RB O
acceptable WO2010044441A1 A JJ O
salt WO2010044441A1 A NN O
. WO2010044441A1 A . O

Pyrimidine WO2008032041A1 T NNP O
derivatives WO2008032041A1 T NNS O
having WO2008032041A1 T VBG O
inhibitory WO2008032041A1 T JJ O
activity WO2008032041A1 T NN O
against WO2008032041A1 T IN O
pi3k WO2008032041A1 T NN O
enzymes WO2008032041A1 T NNS O
. WO2008032041A1 T . O

Nitrogen US7064204 T NNP O
compounds US7064204 T NNS O
such US7064204 T JJ O
as US7064204 T IN O
4- US7064204 T JJ O
( US7064204 T ( O
5-amino-7-phenethyl-7H-pyrazolo US7064204 T JJ O
( US7064204 T ( O
4,3-e US7064204 T JJ O
) US7064204 T ) O
( US7064204 T ( O
1,2,4 US7064204 T CD O
) US7064204 T ) O
triazolo US7064204 T NN O
( US7064204 T ( O
1,5-c US7064204 T JJ O
) US7064204 T ) O
pyrimidin-2-yl US7064204 T NN O
) US7064204 T ) O
-phenol US7064204 T NN O
, US7064204 T , O
used US7064204 T VBD O
as US7064204 T IN O
adenosine US7064204 T JJ I-UN
receptor US7064204 T NN I-UN
antagonists US7064204 T NNS O
, US7064204 T , O
for US7064204 T IN O
prophylaxis US7064204 T NN O
of US7064204 T IN O
nervous US7064204 T JJ O
, US7064204 T , O
cardiovascular US7064204 T JJ O
, US7064204 T , O
respiratory US7064204 T NN O
, US7064204 T , O
urogenital US7064204 T JJ O
and US7064204 T CC O
immune US7064204 T JJ O
disorders US7064204 T NNS O
. US7064204 T . O

New US7064204 A NNP O
compounds US7064204 A NNS O
having US7064204 A VBG O
a US7064204 A DT O
tricyclic US7064204 A JJ O
pyrazolotriazolopyrimidine US7064204 A NN O
ring US7064204 A NN O
structure US7064204 A NN O
are US7064204 A VBP O
provided US7064204 A VBN O
and US7064204 A CC O
methods US7064204 A NNS O
of US7064204 A IN O
using US7064204 A VBG O
those US7064204 A DT O
compounds US7064204 A NNS O
for US7064204 A IN O
a US7064204 A DT O
variety US7064204 A NN O
of US7064204 A IN O
therapeutic US7064204 A JJ O
indications US7064204 A NNS O
. US7064204 A . O

Novel US20050059617 T NNP O
anitsense US20050059617 T NN O
oligonucleotide US20050059617 T NN O
derivatives US20050059617 T NNS O
against US20050059617 T IN O
to US20050059617 T TO O
hepatitis US20050059617 T VB O
c US20050059617 T JJ O
virus US20050059617 T NN O
. US20050059617 T . O

An US20050059617 A DT O
antisense US20050059617 A JJ O
oligonucleotide US20050059617 A NN O
derivative US20050059617 A NN O
against US20050059617 A IN O
HCV US20050059617 A NNP O
is US20050059617 A VBZ O
provided US20050059617 A VBN O
which US20050059617 A WDT O
contains US20050059617 A VBZ O
one US20050059617 A CD O
or US20050059617 A CC O
more US20050059617 A JJR O
nucleotide US20050059617 A JJ O
analogue US20050059617 A NN O
units US20050059617 A NNS O
having US20050059617 A VBG O
a US20050059617 A DT O
modified US20050059617 A JJ O
sugar US20050059617 A NN O
portion US20050059617 A NN O
and US20050059617 A CC O
represented US20050059617 A VBN O
by US20050059617 A IN O
the US20050059617 A DT O
following US20050059617 A JJ O
general US20050059617 A JJ O
formula US20050059617 A NN O
where US20050059617 A WRB O
B US20050059617 A NNP O
denotes US20050059617 A VBZ O
a US20050059617 A DT O
pyrimidine US20050059617 A NN O
or US20050059617 A CC O
purine US20050059617 A NN O
nucleic US20050059617 A JJ O
acid US20050059617 A JJ O
base US20050059617 A NN O
or US20050059617 A CC O
an US20050059617 A DT O
analogue US20050059617 A JJ O
thereof US20050059617 A NN O
. US20050059617 A . O

The US20050059617 A DT O
derivative US20050059617 A NN O
of US20050059617 A IN O
the US20050059617 A DT O
present US20050059617 A JJ O
invention US20050059617 A NN O
is US20050059617 A VBZ O
an US20050059617 A DT O
antisense US20050059617 A NN O
against US20050059617 A IN O
hepatitis US20050059617 A NN O
C US20050059617 A NNP O
virus US20050059617 A NN O
( US20050059617 A ( O
HCV US20050059617 A NNP O
) US20050059617 A ) O
gene US20050059617 A NN O
, US20050059617 A , O
binds US20050059617 A VBZ O
to US20050059617 A TO O
HCV-RNA US20050059617 A NNP O
with US20050059617 A IN O
high US20050059617 A JJ O
affinity US20050059617 A NN O
within US20050059617 A IN O
cells US20050059617 A NNS O
, US20050059617 A , O
can US20050059617 A MD O
control US20050059617 A VB O
and US20050059617 A CC O
inhibit US20050059617 A VB O
the US20050059617 A DT O
expression US20050059617 A NN O
of US20050059617 A IN O
its US20050059617 A PRP$ O
gene US20050059617 A NN O
with US20050059617 A IN O
high US20050059617 A JJ O
efficiency US20050059617 A NN O
, US20050059617 A , O
and US20050059617 A CC O
shows US20050059617 A VBZ O
high US20050059617 A JJ O
resistance US20050059617 A NN O
to US20050059617 A TO O
nucleases US20050059617 A NNS O
. US20050059617 A . O

The US20050059617 A DT O
BNA US20050059617 A NNP O
antisense US20050059617 A JJ O
oligonucleotide US20050059617 A NN O
of US20050059617 A IN O
the US20050059617 A DT O
present US20050059617 A JJ O
invention US20050059617 A NN O
is US20050059617 A VBZ O
also US20050059617 A RB O
effective US20050059617 A JJ O
in US20050059617 A IN O
an US20050059617 A DT O
antisense US20050059617 A NN O
method US20050059617 A NN O
targeting US20050059617 A VBG O
HCV US20050059617 A NNP O
, US20050059617 A , O
no US20050059617 A DT O
matter US20050059617 A NN O
what US20050059617 A WP O
secondary US20050059617 A JJ O
structures US20050059617 A NNS O
, US20050059617 A , O
such US20050059617 A JJ O
as US20050059617 A IN O
loops US20050059617 A NNS O
or US20050059617 A CC O
stems US20050059617 A NNS O
, US20050059617 A , O
in US20050059617 A IN O
a US20050059617 A DT O
target US20050059617 A NN O
RNA US20050059617 A NNP O
nucleic US20050059617 A JJ O
acid US20050059617 A NN O
are US20050059617 A VBP O
. US20050059617 A . O

Antibiotics US20080070884 T NNS O
; US20080070884 T : O
novel US20080070884 T JJ O
class US20080070884 T NN O
of US20080070884 T IN O
cell US20080070884 T NN O
wall US20080070884 T NN O
biosynthesis US20080070884 T NN O
inhibitors US20080070884 T NNS O
without US20080070884 T IN O
cross-resistances US20080070884 T NNS O
to US20080070884 T TO O
known US20080070884 T VB O
classes US20080070884 T NNS O
of US20080070884 T IN O
antibiotics US20080070884 T NNS O
; US20080070884 T : O
active US20080070884 T JJ O
analogs US20080070884 T NNS O
of US20080070884 T IN O
lysobactin US20080070884 T NN O
with US20080070884 T IN O
a US20080070884 T DT O
higher US20080070884 T JJR O
ring US20080070884 T NN O
stability US20080070884 T NN O
. US20080070884 T . O

Normalization WO2007040966A1 T NN O
or WO2007040966A1 T CC O
remission WO2007040966A1 T NN O
of WO2007040966A1 T IN O
microalbuminuria WO2007040966A1 T NN O
. WO2007040966A1 T . O

A WO2007040966A1 A DT O
method WO2007040966A1 A NN O
of WO2007040966A1 A IN O
normalizing WO2007040966A1 A VBG O
microalbuminuria WO2007040966A1 A NNS O
in WO2007040966A1 A IN O
a WO2007040966A1 A DT O
patient WO2007040966A1 A NN O
, WO2007040966A1 A , O
comprising WO2007040966A1 A VBG O
administering WO2007040966A1 A VBG O
to WO2007040966A1 A TO O
the WO2007040966A1 A DT O
patient WO2007040966A1 A NN O
in WO2007040966A1 A IN O
need WO2007040966A1 A NN O
thereof WO2007040966A1 A VBP O
a WO2007040966A1 A DT O
therapeutically WO2007040966A1 A RB O
effective WO2007040966A1 A JJ O
amount WO2007040966A1 A NN O
of WO2007040966A1 A IN O
an WO2007040966A1 A DT O
angiotensin WO2007040966A1 A NN O
II WO2007040966A1 A NNP O
antagonist WO2007040966A1 A NN O
. WO2007040966A1 A . O

The US7078054 T DT O
capsule US7078054 T NN O
shell US7078054 T NN O
contains US7078054 T VBZ O
a US7078054 T DT O
migrateable US7078054 T JJ O
component US7078054 T NN O
( US7078054 T ( O
other US7078054 T JJ O
than US7078054 T IN O
glycerol US7078054 T NN O
) US7078054 T ) O
which US7078054 T WDT O
is US7078054 T VBZ O
also US7078054 T RB O
present US7078054 T JJ O
in US7078054 T IN O
the US7078054 T DT O
capsule US7078054 T NN O
filling.. US7078054 T NN O

Use EP1848455A1 T NNP O
of EP1848455A1 T IN O
calcitonin EP1848455A1 T NN I-UN
and EP1848455A1 T CC O
calcitonin-like EP1848455A1 T JJ I-UN
peptides EP1848455A1 T NNS I-UN
to EP1848455A1 T TO O
treat EP1848455A1 T VB O
and EP1848455A1 T CC O
prevent EP1848455A1 T VB O
multiple EP1848455A1 T JJ O
sclerosis EP1848455A1 T NN O
. EP1848455A1 T . O

Methods EP1848455A1 A NNS O
for EP1848455A1 A IN O
treating EP1848455A1 A VBG O
and EP1848455A1 A CC O
preventing EP1848455A1 A VBG O
multiple EP1848455A1 A JJ O
sclerosis EP1848455A1 A NN O
by EP1848455A1 A IN O
administering EP1848455A1 A VBG O
to EP1848455A1 A TO O
a EP1848455A1 A DT O
patient EP1848455A1 A NN O
an EP1848455A1 A DT O
effective EP1848455A1 A JJ O
amount EP1848455A1 A NN O
of EP1848455A1 A IN O
calcitonin EP1848455A1 A NN I-UN
, EP1848455A1 A , O
calcitonin-like EP1848455A1 A JJ I-UN
peptides EP1848455A1 A NNS I-UN
or EP1848455A1 A CC O
calcitonin EP1848455A1 A NN I-UN
mimetics EP1848455A1 A NNS O
to EP1848455A1 A TO O
a EP1848455A1 A DT O
patient EP1848455A1 A NN O
. EP1848455A1 A . O

Additionally EP1848455A1 A RB O
, EP1848455A1 A , O
1,25-dihydroxyvitamin EP1848455A1 A JJ O
D EP1848455A1 A NNP O
analogs EP1848455A1 A NNS O
can EP1848455A1 A MD O
be EP1848455A1 A VB O
used EP1848455A1 A VBN O
in EP1848455A1 A IN O
combination EP1848455A1 A NN O
with EP1848455A1 A IN O
the EP1848455A1 A DT O
calcitonin EP1848455A1 A NN I-UN
, EP1848455A1 A , O
calcitonin-like EP1848455A1 A JJ I-UN
peptides EP1848455A1 A NNS I-UN
or EP1848455A1 A CC O
calcitonin EP1848455A1 A NN I-UN
mimetics EP1848455A1 A NNS O
. EP1848455A1 A . O

Orally CN103751138A T RB O
disintegrating CN103751138A T VBG O
tablet CN103751138A T NN O
containing CN103751138A T VBG O
lasofoxifene CN103751138A T JJ O
tartrate CN103751138A T NN O
and CN103751138A T CC O
preparation CN103751138A T NN O
method CN103751138A T NN O
thereof CN103751138A T NN O
. CN103751138A T . O

Arylcarbonylpiperazines EP1517898A1 T NNS O
and EP1517898A1 T CC O
heteroarylcarbonylpiperazines EP1517898A1 T NNS O
and EP1517898A1 T CC O
the EP1517898A1 T DT O
use EP1517898A1 T NN O
thereof EP1517898A1 T NN O
for EP1517898A1 T IN O
treating EP1517898A1 T VBG O
benign EP1517898A1 T NN O
and EP1517898A1 T CC O
malignant EP1517898A1 T JJ O
tumour EP1517898A1 T NN O
diseases EP1517898A1 T NNS O
. EP1517898A1 T . O

Use US20100062081 T NNP O
of US20100062081 T IN O
tellurium US20100062081 T NN O
containing US20100062081 T VBG O
compounds US20100062081 T NNS O
as US20100062081 T IN O
nerve US20100062081 T NN O
protecting US20100062081 T VBG O
agents US20100062081 T NNS O
. US20100062081 T . O

2-AMINO-9- US20110105540 T JJ O
[ US20110105540 T JJ O
4- US20110105540 T JJ O
( US20110105540 T ( O
4-METHOXY-PHENOXY US20110105540 T JJ O
) US20110105540 T ) O
-PIPERIDIN-1-YL US20110105540 T FW O
] US20110105540 T FW O
-4-PHENYL-INDENO US20110105540 T FW O
[ US20110105540 T FW O
1,2-D US20110105540 T JJ O
] US20110105540 T JJ O
PYRIMIDIN-5-ONE US20110105540 T NNP O
AND US20110105540 T NNP O
ITS US20110105540 T NNP O
USE US20110105540 T NNP O
AS US20110105540 T IN O
A US20110105540 T NNP O
HIGHLY US20110105540 T NNP O
SELECTIVE US20110105540 T NNP O
ADENOSINE US20110105540 T NNP I-UN
A2a US20110105540 T NNP I-UN
RECEPTOR US20110105540 T NNP I-UN
ANTAGONIST US20110105540 T NNP O
. US20110105540 T . O

Oxcarbazepine CN103735527A T NNP O
tablets CN103735527A T NNS O
and CN103735527A T CC O
preparation CN103735527A T NN O
method CN103735527A T NN O
thereof CN103735527A T NN O
. CN103735527A T . O

Therapeutic US7504415 T JJ O
agent US7504415 T NN O
for US7504415 T IN O
glomerular US7504415 T JJ O
disease US7504415 T NN O
. US7504415 T . O

Tolterodine CN101269047A T JJ O
tartrate CN101269047A T NN O
sustained-release CN101269047A T NN O
dropping CN101269047A T NN O
pill CN101269047A T NN O
and CN101269047A T CC O
preparation CN101269047A T NN O
method CN101269047A T NN O
thereof CN101269047A T NN O
. CN101269047A T . O

Method US20110159045 T NNP O
of US20110159045 T IN O
treating US20110159045 T VBG O
dysglycemia US20110159045 T NN O
and US20110159045 T CC O
glucose US20110159045 T JJ O
excursions US20110159045 T NNS O
. US20110159045 T . O

The US20110159045 A DT O
present US20110159045 A JJ O
invention US20110159045 A NN O
also US20110159045 A RB O
relates US20110159045 A VBZ O
to US20110159045 A TO O
a US20110159045 A DT O
use US20110159045 A NN O
of US20110159045 A IN O
a US20110159045 A DT O
modified US20110159045 A JJ O
release US20110159045 A NN O
pharmaceutical US20110159045 A JJ O
composition US20110159045 A NN O
comprising US20110159045 A VBG O
a US20110159045 A DT O
therapeutically US20110159045 A RB O
effective US20110159045 A JJ O
amount US20110159045 A NN O
of US20110159045 A IN O
an US20110159045 A DT O
insulin-sensitizing US20110159045 A JJ O
oral US20110159045 A JJ O
hypoglycemic US20110159045 A JJ O
agent US20110159045 A NN O
for US20110159045 A IN O
sensitizing US20110159045 A VBG O
pre-prandial US20110159045 A JJ O
( US20110159045 A ( O
basal US20110159045 A NN O
) US20110159045 A ) O
insulin US20110159045 A NN I-UN
levels US20110159045 A NNS O
and/or US20110159045 A VBP O
reducing US20110159045 A VBG O
postprandial US20110159045 A JJ O
glucose US20110159045 A JJ O
excursions US20110159045 A NNS O
in US20110159045 A IN O
a US20110159045 A DT O
normal US20110159045 A JJ O
patient US20110159045 A NN O
or US20110159045 A CC O
a US20110159045 A DT O
patient US20110159045 A NN O
having US20110159045 A VBG O
an US20110159045 A DT O
insulin-related US20110159045 A JJ O
disorder US20110159045 A NN O
. US20110159045 A . O

'Taohong CN101259237A T JJ O
Gongliu CN101259237A T NNP O
Wan CN101259237A T NNP O
' CN101259237A T POS O
. CN101259237A T . O

Tiaohong CN101259237A A NNP O
Gongliu CN101259237A A NNP O
Pill CN101259237A A NNP O
relates CN101259237A A VBZ O
to CN101259237A A TO O
an CN101259237A A DT O
oral CN101259237A A JJ O
administration CN101259237A A NN O
pill CN101259237A A NN O
of CN101259237A A IN O
Chinese CN101259237A A JJ O
patent CN101259237A A NN O
medicine CN101259237A A NN O
for CN101259237A A IN O
curing CN101259237A A VBG O
myoma CN101259237A A NN O
uteri CN101259237A A NN O
and CN101259237A A CC O
metrocystosis CN101259237A A NN O
. CN101259237A A . O

The CN101259237A A DT O
prescription CN101259237A A NN O
comprises CN101259237A A VBZ O
20g CN101259237A A CD O
of CN101259237A A IN O
peach CN101259237A A NN O
kernel CN101259237A A NN O
, CN101259237A A , O
20g CN101259237A A CD O
of CN101259237A A IN O
safflower CN101259237A A NN O
, CN101259237A A , O
20g CN101259237A A CD O
of CN101259237A A IN O
angelica CN101259237A A NN O
, CN101259237A A , O
20g CN101259237A A CD O
of CN101259237A A IN O
red CN101259237A A JJ O
peony CN101259237A A NN O
, CN101259237A A , O
20g CN101259237A A CD O
of CN101259237A A IN O
glabrous CN101259237A A JJ O
greenbrier CN101259237A A NN O
rhizome CN101259237A A NN O
, CN101259237A A , O
20g CN101259237A A CD O
of CN101259237A A IN O
cassia CN101259237A A NN O
twig CN101259237A A NN O
, CN101259237A A , O
20g CN101259237A A CD O
of CN101259237A A IN O
alga CN101259237A A NN O
, CN101259237A A , O
20g CN101259237A A CD O
of CN101259237A A IN O
oyster CN101259237A A NN O
, CN101259237A A , O
20g CN101259237A A CD O
of CN101259237A A IN O
turtle CN101259237A A NN O
shell CN101259237A A NN O
, CN101259237A A , O
20g CN101259237A A CD O
of CN101259237A A IN O
rhizoma CN101259237A A NN O
sparganii CN101259237A A NN O
, CN101259237A A , O
20g CN101259237A A CD O
of CN101259237A A IN O
zedoray CN101259237A A NN O
rhizome CN101259237A A NN O
, CN101259237A A , O
15g CN101259237A A CD O
of CN101259237A A IN O
honeysuckle CN101259237A A NN O
, CN101259237A A , O
15g CN101259237A A CD O
of CN101259237A A IN O
Hedyotis CN101259237A A NNP O
diffusa CN101259237A A NN O
, CN101259237A A , O
10g CN101259237A A CD O
of CN101259237A A IN O
mastic CN101259237A A JJ O
gum CN101259237A A NN O
, CN101259237A A , O
10g CN101259237A A CD O
of CN101259237A A IN O
myrrh CN101259237A A NN O
, CN101259237A A , O
15g CN101259237A A CD O
of CN101259237A A IN O
bloodsucker CN101259237A A NN O
and CN101259237A A CC O
10g CN101259237A A CD O
of CN101259237A A IN O
glaubers CN101259237A A NNS O
salt CN101259237A A VBP O
mirabilite CN101259237A A RB O
. CN101259237A A . O

The CN101259237A A DT O
raw CN101259237A A JJ O
materials CN101259237A A NNS O
are CN101259237A A VBP O
carefully CN101259237A A RB O
selected CN101259237A A VBN O
, CN101259237A A , O
added CN101259237A A VBD O
according CN101259237A A VBG O
to CN101259237A A TO O
weight CN101259237A A JJ O
portions CN101259237A A NNS O
of CN101259237A A IN O
the CN101259237A A DT O
prescription CN101259237A A NN O
, CN101259237A A , O
ground CN101259237A A NN O
into CN101259237A A IN O
fine CN101259237A A JJ O
power CN101259237A A NN O
, CN101259237A A , O
filtered CN101259237A A VBN O
through CN101259237A A IN O
a CN101259237A A DT O
100-mesh CN101259237A A JJ O
screen CN101259237A A NN O
, CN101259237A A , O
and CN101259237A A CC O
made CN101259237A A VBD O
into CN101259237A A IN O
pills CN101259237A A NNS O
with CN101259237A A IN O
0.1g CN101259237A A CD O
for CN101259237A A IN O
each CN101259237A A DT O
. CN101259237A A . O

The CN101259237A A DT O
Tiaohong CN101259237A A NNP O
Gongliu CN101259237A A NNP O
Pill CN101259237A A NNP O
has CN101259237A A VBZ O
the CN101259237A A DT O
efficacy CN101259237A A NN O
of CN101259237A A IN O
promoting CN101259237A A VBG O
blood CN101259237A A NN O
circulation CN101259237A A NN O
for CN101259237A A IN O
removing CN101259237A A VBG O
blood CN101259237A A NN O
stasis CN101259237A A NN O
, CN101259237A A , O
softening CN101259237A A VBG O
and CN101259237A A CC O
resolving CN101259237A A VBG O
hard CN101259237A A JJ O
mass CN101259237A A NN O
and CN101259237A A CC O
is CN101259237A A VBZ O
used CN101259237A A VBN O
for CN101259237A A IN O
curing CN101259237A A VBG O
myoma CN101259237A A NN O
uteri CN101259237A A NN O
and CN101259237A A CC O
metrocystosis CN101259237A A NN O
with CN101259237A A IN O
the CN101259237A A DT O
effect CN101259237A A NN O
of CN101259237A A IN O
treating CN101259237A A VBG O
both CN101259237A A DT O
manifestation CN101259237A A NN O
and CN101259237A A CC O
root CN101259237A A NN O
cause CN101259237A A NN O
of CN101259237A A IN O
disease CN101259237A A NN O
and CN101259237A A CC O
the CN101259237A A DT O
aim CN101259237A A NN O
of CN101259237A A IN O
difficult CN101259237A A JJ O
recrudescence CN101259237A A NN O
after CN101259237A A IN O
healing CN101259237A A VBG O
. CN101259237A A . O

New WO2014074017A1 T NNP O
medicinal WO2014074017A1 T JJ O
composition WO2014074017A1 T NN O
for WO2014074017A1 T IN O
pain WO2014074017A1 T NN O
management WO2014074017A1 T NN O
in WO2014074017A1 T IN O
the WO2014074017A1 T DT O
case WO2014074017A1 T NN O
of WO2014074017A1 T IN O
smooth WO2014074017A1 T JJ O
muscle WO2014074017A1 T NN O
spasm WO2014074017A1 T NN O
. WO2014074017A1 T . O

Crystalline US20080280945 T NNP O
forms US20080280945 T NNS O
of US20080280945 T IN O
an US20080280945 T DT O
HIV US20080280945 T NNP I-UN
integrase US20080280945 T NN I-UN
inhibitor US20080280945 T NN O
. US20080280945 T . O

The US20080280945 A DT O
compound US20080280945 A NN O
and US20080280945 A CC O
its US20080280945 A PRP$ O
crystalline US20080280945 A NN O
forms US20080280945 A NNS O
thereof US20080280945 A WDT O
are US20080280945 A VBP O
HIV US20080280945 A NNP I-UN
integrase US20080280945 A NN I-UN
inhibitors US20080280945 A NNS O
useful US20080280945 A JJ O
for US20080280945 A IN O
the US20080280945 A DT O
prophylaxis US20080280945 A NN O
or US20080280945 A CC O
treatment US20080280945 A NN O
of US20080280945 A IN O
HIV US20080280945 A NNP O
infection US20080280945 A NN O
or US20080280945 A CC O
for US20080280945 A IN O
the US20080280945 A DT O
prophylaxis US20080280945 A NN O
, US20080280945 A , O
treatment US20080280945 A NN O
or US20080280945 A CC O
delay US20080280945 A NN O
in US20080280945 A IN O
the US20080280945 A DT O
onset US20080280945 A NN O
or US20080280945 A CC O
progression US20080280945 A NN O
of US20080280945 A IN O
AIDS US20080280945 A NNP O
. US20080280945 A . O

Tannic CN103040849A T JJ O
acid CN103040849A T NN O
preparation CN103040849A T NN O
for CN103040849A T IN O
treating CN103040849A T VBG O
burn CN103040849A T NN O
, CN103040849A T , O
bedsore CN103040849A T NN O
and CN103040849A T CC O
diaper CN103040849A T NN O
dermatitis CN103040849A T NN O
and CN103040849A T CC O
preparation CN103040849A T NN O
method CN103040849A T NN O
thereof CN103040849A T NN O
. CN103040849A T . O

The CN103040849A A DT O
invention CN103040849A A NN O
relates CN103040849A A VBZ O
to CN103040849A A TO O
a CN103040849A A DT O
tannic CN103040849A A JJ O
acid CN103040849A A NN O
preparation CN103040849A A NN O
and CN103040849A A CC O
a CN103040849A A DT O
preparation CN103040849A A NN O
method CN103040849A A NN O
, CN103040849A A , O
and CN103040849A A CC O
the CN103040849A A DT O
tannic CN103040849A A JJ O
acid CN103040849A A NN O
preparation CN103040849A A NN O
is CN103040849A A VBZ O
characterized CN103040849A A VBN O
by CN103040849A A IN O
comprising CN103040849A A VBG O
, CN103040849A A , O
by CN103040849A A IN O
weight CN103040849A A NN O
, CN103040849A A , O
2-30 CN103040849A A JJ O
% CN103040849A A NN O
of CN103040849A A IN O
tannic CN103040849A A JJ O
acid CN103040849A A NN O
, CN103040849A A , O
40-75 CN103040849A A CD O
% CN103040849A A NN O
of CN103040849A A IN O
pharmaceutical CN103040849A A JJ O
adjuvants CN103040849A A NNS O
, CN103040849A A , O
and CN103040849A A CC O
20-50 CN103040849A A JJ O
% CN103040849A A NN O
of CN103040849A A IN O
water CN103040849A A NN O
. CN103040849A A . O

The CN103040849A A DT O
pharmaceutical CN103040849A A JJ O
adjuvants CN103040849A A NNS O
used CN103040849A A VBN O
in CN103040849A A IN O
the CN103040849A A DT O
preparation CN103040849A A NN O
comprise CN103040849A A NN O
glycerin CN103040849A A NN O
, CN103040849A A , O
monoglyceride CN103040849A A JJ O
stearate CN103040849A A NN O
, CN103040849A A , O
beeswax CN103040849A A NN O
, CN103040849A A , O
Vaseline CN103040849A A NNP O
, CN103040849A A , O
paraffin CN103040849A A NN O
, CN103040849A A , O
tween CN103040849A A NN O
, CN103040849A A , O
span CN103040849A A NN O
, CN103040849A A , O
sodium CN103040849A A NN O
bisulfate CN103040849A A NN O
, CN103040849A A , O
ethylparaben CN103040849A A NN O
, CN103040849A A , O
etc CN103040849A A FW O
. CN103040849A A . O

The CN103040849A A DT O
preparation CN103040849A A NN O
method CN103040849A A NN O
comprises CN103040849A A VBZ O
the CN103040849A A DT O
following CN103040849A A JJ O
steps CN103040849A A NNS O
: CN103040849A A : O
dissolving CN103040849A A VBG O
tannic CN103040849A A JJ O
acid CN103040849A A NN O
by CN103040849A A IN O
a CN103040849A A DT O
little CN103040849A A JJ O
water CN103040849A A NN O
or CN103040849A A CC O
ethanol CN103040849A A NN O
, CN103040849A A , O
heating CN103040849A A VBG O
to CN103040849A A TO O
55-85 CN103040849A A JJ O
DEG CN103040849A A NNP O
C CN103040849A A NNP O
to CN103040849A A TO O
prepare CN103040849A A VB O
an CN103040849A A DT O
oil CN103040849A A NN O
phase CN103040849A A NN O
and CN103040849A A CC O
a CN103040849A A DT O
water CN103040849A A NN O
phase CN103040849A A NN O
, CN103040849A A , O
finally CN103040849A A RB O
adding CN103040849A A VBG O
the CN103040849A A DT O
water CN103040849A A NN O
phase CN103040849A A NN O
into CN103040849A A IN O
the CN103040849A A DT O
oil CN103040849A A NN O
phase CN103040849A A NN O
under CN103040849A A IN O
uniform CN103040849A A JJ O
stirring CN103040849A A NN O
, CN103040849A A , O
and CN103040849A A CC O
performing CN103040849A A VBG O
condensation CN103040849A A NN O
and CN103040849A A CC O
split CN103040849A A NN O
charging CN103040849A A VBG O
to CN103040849A A TO O
obtain CN103040849A A VB O
the CN103040849A A DT O
tannic CN103040849A A JJ O
acid CN103040849A A NN O
preparation CN103040849A A NN O
. CN103040849A A . O

The CN103040849A A DT O
preparation CN103040849A A NN O
comprises CN103040849A A VBZ O
paste CN103040849A A NN O
agents CN103040849A A NNS O
( CN103040849A A ( O
ointment CN103040849A A NN O
, CN103040849A A , O
plaster CN103040849A A NN O
) CN103040849A A ) O
, CN103040849A A , O
cream CN103040849A A NN O
, CN103040849A A , O
emulsion CN103040849A A NN O
, CN103040849A A , O
oil CN103040849A A NN O
agents CN103040849A A NNS O
, CN103040849A A , O
water CN103040849A A NN O
aqua CN103040849A A NN O
, CN103040849A A , O
and CN103040849A A CC O
the CN103040849A A DT O
like CN103040849A A JJ O
, CN103040849A A , O
and CN103040849A A CC O
the CN103040849A A DT O
tannic CN103040849A A JJ O
acid CN103040849A A NN O
content CN103040849A A NN O
can CN103040849A A MD O
be CN103040849A A VB O
determined CN103040849A A VBN O
by CN103040849A A IN O
a CN103040849A A DT O
spectrophotometric CN103040849A A JJ O
method CN103040849A A NN O
. CN103040849A A . O

The CN103040849A A DT O
prepared CN103040849A A JJ O
tannic CN103040849A A JJ O
acid CN103040849A A NN O
preparation CN103040849A A NN O
conforms CN103040849A A NNS O
with CN103040849A A IN O
medicine CN103040849A A NN O
standards CN103040849A A NNS O
, CN103040849A A , O
and CN103040849A A CC O
is CN103040849A A VBZ O
suitable CN103040849A A JJ O
for CN103040849A A IN O
the CN103040849A A DT O
treatment CN103040849A A NN O
of CN103040849A A IN O
burn CN103040849A A NN O
, CN103040849A A , O
bedsore CN103040849A A NN O
and CN103040849A A CC O
diaper CN103040849A A NN O
dermatitis CN103040849A A NN O
( CN103040849A A ( O
neonatal CN103040849A A JJ O
red CN103040849A A JJ O
buttock CN103040849A A NN O
) CN103040849A A ) O
and CN103040849A A CC O
the CN103040849A A DT O
like CN103040849A A JJ O
. CN103040849A A . O

Process WO2006053112A1 T NN O
for WO2006053112A1 T IN O
preparing WO2006053112A1 T VBG O
trisubstituted WO2006053112A1 T JJ O
pyrimidine WO2006053112A1 T NN O
compounds WO2006053112A1 T NNS O
. WO2006053112A1 T . O

Therapeutic WO2013132428A1 T JJ O
preparation WO2013132428A1 T NN O
and WO2013132428A1 T CC O
process WO2013132428A1 T NN O
for WO2013132428A1 T IN O
preparing WO2013132428A1 T VBG O
said WO2013132428A1 T VBD O
therapeutic WO2013132428A1 T JJ O
preparation WO2013132428A1 T NN O
. WO2013132428A1 T . O

Compound CN103040828A T NNP O
diphenoxylate CN103040828A T NN O
tablet CN103040828A T NN O
and CN103040828A T CC O
preparation CN103040828A T NN O
method CN103040828A T NN O
thereof CN103040828A T NN O
. CN103040828A T . O

Agents US20090202660 T NNS O
and US20090202660 T CC O
Methods US20090202660 T NNS O
for US20090202660 T IN O
Osteogenic US20090202660 T NNP O
Oxysterols US20090202660 T NNP O
Inhibition US20090202660 T NNP O
of US20090202660 T IN O
Oxidative US20090202660 T NNP O
Stress US20090202660 T NNP O
on US20090202660 T IN O
Osteogenic US20090202660 T NNP O
Cellular US20090202660 T NNP O
Differentiation US20090202660 T NNP O
. US20090202660 T . O

Exemplary US20090202660 A JJ O
agents US20090202660 A NNS O
include US20090202660 A VBP O
oxysterols US20090202660 A NNS O
, US20090202660 A , O
rhBMP2 US20090202660 A NN I-UN
, US20090202660 A , O
alone US20090202660 A RB O
or US20090202660 A CC O
in US20090202660 A IN O
combination US20090202660 A NN O
which US20090202660 A WDT O
are US20090202660 A VBP O
demonstrated US20090202660 A VBN O
to US20090202660 A TO O
specifically US20090202660 A RB O
combat US20090202660 A VB O
oxidative US20090202660 A JJ O
stress US20090202660 A NN O
caused US20090202660 A VBN O
by US20090202660 A IN O
inflammatory US20090202660 A JJ O
oxidized US20090202660 A JJ O
lipids US20090202660 A NNS O
, US20090202660 A , O
such US20090202660 A JJ O
as US20090202660 A IN O
xanthine/xanthine US20090202660 A JJ O
oxidase US20090202660 A NN O
and US20090202660 A CC O
minimally US20090202660 A RB O
oxidized US20090202660 A JJ O
LDL US20090202660 A NNP O
. US20090202660 A . O

Molecular US20090162390 T JJ O
Scaffolds US20090162390 T NNP O
for US20090162390 T IN O
HIV-1 US20090162390 T NNP O
Immunogens US20090162390 T NNP O
. US20090162390 T . O

Synthesis CN102146108A T NN O
of CN102146108A T IN O
3'-triazoepirubicin CN102146108A T JJ O
with CN102146108A T IN O
anticancer CN102146108A T JJ O
activity CN102146108A T NN O
. CN102146108A T . O

Penicillide CN103087040A T NNP O
derivative CN103087040A T JJ O
, CN103087040A T , O
preparation CN103087040A T NN O
method CN103087040A T NN O
thereof CN103087040A T NN O
, CN103087040A T , O
and CN103087040A T CC O
medicinal CN103087040A T JJ O
purpose CN103087040A T NN O
thereof CN103087040A T NN O
. CN103087040A T . O

Diphyllin WO2008058897A2 T NNP O
and WO2008058897A2 T CC O
other WO2008058897A2 T JJ O
lignans WO2008058897A2 T NNS O
as WO2008058897A2 T IN O
a WO2008058897A2 T DT O
medicament WO2008058897A2 T NN O
for WO2008058897A2 T IN O
v-atpase WO2008058897A2 T NN O
mediated WO2008058897A2 T JJ O
disease WO2008058897A2 T NN O
. WO2008058897A2 T . O

N-heteroaryl US20110082144 T JJ O
indole US20110082144 T NN O
carboxamides US20110082144 T NNS O
and US20110082144 T CC O
analogues US20110082144 T NNS O
thereof US20110082144 T VBP O
, US20110082144 T , O
for US20110082144 T IN O
use US20110082144 T NN O
as US20110082144 T IN O
glucokinase US20110082144 T NN I-UN
activators US20110082144 T NNS O
in US20110082144 T IN O
the US20110082144 T DT O
treatment US20110082144 T NN O
of US20110082144 T IN O
diabetes US20110082144 T NNS O
. US20110082144 T . O

This US20110082144 A DT O
invention US20110082144 A NN O
relates US20110082144 A VBZ O
to US20110082144 A TO O
compounds US20110082144 A VB O
that US20110082144 A DT O
are US20110082144 A VBP O
activators US20110082144 A NNS O
of US20110082144 A IN O
glucokinase US20110082144 A NN I-UN
and US20110082144 A CC O
thus US20110082144 A RB O
may US20110082144 A MD O
be US20110082144 A VB O
useful US20110082144 A JJ O
for US20110082144 A IN O
the US20110082144 A DT O
management US20110082144 A NN O
, US20110082144 A , O
treatment US20110082144 A NN O
, US20110082144 A , O
control US20110082144 A NN O
, US20110082144 A , O
or US20110082144 A CC O
adjunct US20110082144 A JJ O
treatment US20110082144 A NN O
of US20110082144 A IN O
diseases US20110082144 A NNS O
, US20110082144 A , O
where US20110082144 A WRB O
increasing US20110082144 A VBG O
glucokinase US20110082144 A NN I-UN
activity US20110082144 A NN O
is US20110082144 A VBZ O
beneficial US20110082144 A JJ O
. US20110082144 A . O

Combination US20120052005 T NNP O
therapy US20120052005 T NN O
to US20120052005 T TO O
improve US20120052005 T VB O
drug US20120052005 T NN O
efficiency US20120052005 T NN O
. US20120052005 T . O

Compositions US20120052005 A NNS O
and US20120052005 A CC O
methods US20120052005 A NNS O
for US20120052005 A IN O
increasing US20120052005 A VBG O
drug US20120052005 A NN O
bioavailability US20120052005 A NN O
and/or US20120052005 A IN O
preventing US20120052005 A VBG O
multi-drug US20120052005 A JJ O
resistance US20120052005 A NN O
through US20120052005 A IN O
inhibition US20120052005 A NN O
of US20120052005 A IN O
ABCG2 US20120052005 A NNP I-UN
by US20120052005 A IN O
xanthine US20120052005 A NNP O
compounds US20120052005 A NNS O
are US20120052005 A VBP O
disclosed US20120052005 A VBN O
. US20120052005 A . O

Solid US20100120702 T JJ O
preparation US20100120702 T NN O
for US20100120702 T IN O
dialysis US20100120702 T NN O
. US20100120702 T . O

Arbidol CN101904826A T NNP O
HCl CN101904826A T NNP O
orally CN101904826A T RB O
disintegrating CN101904826A T VBG O
tablet CN101904826A T NN O
and CN101904826A T CC O
preparation CN101904826A T NN O
method CN101904826A T NN O
thereof CN101904826A T NN O
. CN101904826A T . O

Transient US20090131302 T NNP I-UN
receptor US20090131302 T NN I-UN
potential US20090131302 T NN I-UN
vanilloid US20090131302 T NN I-UN
1 US20090131302 T CD I-UN
and US20090131302 T CC O
uses US20090131302 T VBZ O
thereof US20090131302 T NN O
. US20090131302 T . O

Further US20090131302 A RB O
, US20090131302 A , O
the US20090131302 A DT O
present US20090131302 A JJ O
invention US20090131302 A NN O
describes US20090131302 A VBZ O
a US20090131302 A DT O
potentially US20090131302 A RB O
important US20090131302 A JJ O
role US20090131302 A NN O
for US20090131302 A IN O
the US20090131302 A DT O
transient US20090131302 A NN O
receptor US20090131302 A NN O
potential US20090131302 A JJ O
vanilloid US20090131302 A NN O
1 US20090131302 A CD O
( US20090131302 A ( O
TRPV1 US20090131302 A NNP I-UN
) US20090131302 A ) O
in US20090131302 A IN O
initiation US20090131302 A NN O
and US20090131302 A CC O
maintenance US20090131302 A NN O
of US20090131302 A IN O
the US20090131302 A DT O
chronic US20090131302 A JJ O
visceral US20090131302 A JJ O
hypersensitivity US20090131302 A NN O
and US20090131302 A CC O
its US20090131302 A PRP$ O
role US20090131302 A NN O
in US20090131302 A IN O
development US20090131302 A NN O
of US20090131302 A IN O
irritable US20090131302 A JJ O
bowel US20090131302 A NN O
syndrome US20090131302 A NN O
. US20090131302 A . O

Cisplatin CN101732345A T NNP O
spinal CN101732345A T JJ O
tumor CN101732345A T NN O
slow-release CN101732345A T NN O
implant CN101732345A T NN O
and CN101732345A T CC O
preparation CN101732345A T NN O
method CN101732345A T NN O
thereof CN101732345A T NN O
. CN101732345A T . O

Agent CN102657653A T NN O
for CN102657653A T IN O
selectively CN102657653A T RB O
killing CN102657653A T VBG O
tumor CN102657653A T NN O
stem CN102657653A T NN O
cells CN102657653A T NNS O
and CN102657653A T CC O
use CN102657653A T NN O
thereof CN102657653A T NN O
. CN102657653A T . O

Use US20080020030 T NNP O
Of US20080020030 T IN O
7-T-Butoxyiminomethylcamptothecin US20080020030 T NNP O
For US20080020030 T IN O
The US20080020030 T DT O
Preparation US20080020030 T NNP O
Of US20080020030 T IN O
A US20080020030 T NNP O
Medicament US20080020030 T NNP O
For US20080020030 T IN O
The US20080020030 T DT O
Treatment US20080020030 T NNP O
Of US20080020030 T IN O
Uterine US20080020030 T NNP O
Neoplasms US20080020030 T NNP O
. US20080020030 T . O

Formulation CN103462909A T NN O
of CN103462909A T IN O
nizatidine CN103462909A T NN O
for CN103462909A T IN O
injection CN103462909A T NN O
and CN103462909A T CC O
preparation CN103462909A T NN O
technology CN103462909A T NN O
thereof CN103462909A T NN O
. CN103462909A T . O

Treating US20080070846 T VBG O
acute US20080070846 T JJ O
exacerbations US20080070846 T NNS O
of US20080070846 T IN O
asthma US20080070846 T NN O
using US20080070846 T VBG O
a US20080070846 T DT O
ketolide US20080070846 T NN O
. US20080070846 T . O

Large CN1899430A T JJ O
size CN1899430A T NN O
Qingkailing CN1899430A T VBG O
dripping CN1899430A T VBG O
pill CN1899430A T NN O
and CN1899430A T CC O
its CN1899430A T PRP$ O
preparing CN1899430A T NN O
method CN1899430A T NN O
. CN1899430A T . O

Treatment WO2013169194A1 T NN O
of WO2013169194A1 T IN O
postpartum WO2013169194A1 T NN O
haemorrhage WO2013169194A1 T NN O
with WO2013169194A1 T IN O
chemically WO2013169194A1 T RB O
modified WO2013169194A1 T VBN O
heparin WO2013169194A1 T NN O
or WO2013169194A1 T CC O
heparan WO2013169194A1 T NN O
sulphate WO2013169194A1 T NN O
and WO2013169194A1 T CC O
a WO2013169194A1 T DT O
uterotonic WO2013169194A1 T JJ O
agent WO2013169194A1 T NN O
. WO2013169194A1 T . O

Nutritional EP2647374A1 T JJ O
compositions EP2647374A1 T NNS O
including EP2647374A1 T VBG O
beta-hydroxy-beta-methylbutyrate EP2647374A1 T NN O
for EP2647374A1 T IN O
regulating EP2647374A1 T VBG O
transcription EP2647374A1 T NN O
factors EP2647374A1 T NNS O
. EP2647374A1 T . O

The EP2647374A1 A DT O
nutritional EP2647374A1 A JJ O
compositions EP2647374A1 A NNS O
may EP2647374A1 A MD O
be EP2647374A1 A VB O
administered EP2647374A1 A VBN O
to EP2647374A1 A TO O
prevent EP2647374A1 A VB O
and/or EP2647374A1 A JJ O
reduce EP2647374A1 A VB O
and/or EP2647374A1 A JJ O
treat EP2647374A1 A NN O
diseases EP2647374A1 A NNS O
and EP2647374A1 A CC O
conditions EP2647374A1 A NNS O
associated EP2647374A1 A VBN O
with EP2647374A1 A IN O
downregulation EP2647374A1 A NN O
of EP2647374A1 A IN O
serine-threonine EP2647374A1 A JJ I-UN
kinase EP2647374A1 A NN I-UN
protein EP2647374A1 A NN I-UN
kinase EP2647374A1 A NN I-UN
B EP2647374A1 A NNP I-UN
( EP2647374A1 A ( O
Akt/PKB EP2647374A1 A NNP O
) EP2647374A1 A ) O
signaling EP2647374A1 A VBG O
pathways EP2647374A1 A NNS O
, EP2647374A1 A , O
with EP2647374A1 A IN O
the EP2647374A1 A DT O
concomitant EP2647374A1 A NN O
FOXO EP2647374A1 A NNP O
transcription EP2647374A1 A NN O
factors EP2647374A1 A NNS O
activation EP2647374A1 A NN O
, EP2647374A1 A , O
such EP2647374A1 A JJ O
as EP2647374A1 A IN O
muscle EP2647374A1 A NN O
wasting EP2647374A1 A NN O
, EP2647374A1 A , O
diabetes EP2647374A1 A VBZ O
, EP2647374A1 A , O
infertility EP2647374A1 A NN O
, EP2647374A1 A , O
neurodegeneration EP2647374A1 A NN O
, EP2647374A1 A , O
and EP2647374A1 A CC O
immune EP2647374A1 A JJ O
system EP2647374A1 A NN O
dysfunction EP2647374A1 A NN O
. EP2647374A1 A . O

Azine-Carboxamides US20070259849 T NNS O
as US20070259849 T IN O
Anti-Cancer US20070259849 T JJ O
Agents US20070259849 T NNS O
. US20070259849 T . O

The US20070259849 A DT O
invention US20070259849 A NN O
relates US20070259849 A VBZ O
to US20070259849 A TO O
chemical US20070259849 A VB O
compounds US20070259849 A NNS O
, US20070259849 A , O
of US20070259849 A IN O
the US20070259849 A DT O
formula US20070259849 A NN O
( US20070259849 A ( O
I US20070259849 A PRP O
) US20070259849 A ) O
: US20070259849 A : O
or US20070259849 A CC O
pharmaceutically US20070259849 A RB O
acceptable US20070259849 A JJ O
salts US20070259849 A NNS O
thereof US20070259849 A NN O
, US20070259849 A , O
which US20070259849 A WDT O
possess US20070259849 A VBP O
B-Raf US20070259849 A NNP I-UN
inhibitory US20070259849 A NN O
activity US20070259849 A NN O
and US20070259849 A CC O
are US20070259849 A VBP O
accordingly US20070259849 A RB O
useful US20070259849 A JJ O
for US20070259849 A IN O
their US20070259849 A PRP$ O
anti US20070259849 A JJ O
cancer US20070259849 A NN O
activity US20070259849 A NN O
and US20070259849 A CC O
thus US20070259849 A RB O
in US20070259849 A IN O
methods US20070259849 A NNS O
of US20070259849 A IN O
treatment US20070259849 A NN O
of US20070259849 A IN O
the US20070259849 A DT O
human US20070259849 A NN O
or US20070259849 A CC O
animal US20070259849 A NN O
body US20070259849 A NN O
. US20070259849 A . O

Process EP2406227A1 T NN O
for EP2406227A1 T IN O
manufacturing EP2406227A1 T VBG O
5- EP2406227A1 T JJ O
( EP2406227A1 T ( O
2- EP2406227A1 T JJ O
{ EP2406227A1 T ( O
[ EP2406227A1 T JJ O
6- EP2406227A1 T JJ O
( EP2406227A1 T ( O
2,2-difluoro-2-phenylethoxy EP2406227A1 T JJ O
) EP2406227A1 T ) O
hexyl EP2406227A1 T NN O
] EP2406227A1 T NNP O
amino EP2406227A1 T NN O
} EP2406227A1 T ) O
-1- EP2406227A1 T NNP O
hydroxyethyl EP2406227A1 T NN O
) EP2406227A1 T ) O
-8-hydroxyquinolin-2 EP2406227A1 T NN O
( EP2406227A1 T ( O
1h EP2406227A1 T CD O
) EP2406227A1 T ) O
-one.. EP2406227A1 T NN O

Benzoind0l-2-one WO2009016081A3 T JJ O
derivatives WO2009016081A3 T NNS O
for WO2009016081A3 T IN O
use WO2009016081A3 T NN O
in WO2009016081A3 T IN O
therapy WO2009016081A3 T NN O
. WO2009016081A3 T . O

17beta-cyano-18a-homo-19-nor-androst-4-ene EP2178899A1 T JJ O
derivative EP2178899A1 T NN O
, EP2178899A1 T , O
use EP2178899A1 T NN O
thereof EP2178899A1 T NN O
and EP2178899A1 T CC O
medicaments EP2178899A1 T NNS O
containing EP2178899A1 T VBG O
said EP2178899A1 T VBD O
derivative EP2178899A1 T JJ O
. EP2178899A1 T . O

Homopiperazine US20080207597 T NNP O
compounds US20080207597 T VBZ O
that US20080207597 T IN O
inhibit US20080207597 T NN O
ribosomal US20080207597 T JJ O
frameshifting US20080207597 T NN O
by US20080207597 T IN O
binding US20080207597 T VBG O
to US20080207597 T TO O
rna US20080207597 T VB O
pseudoknot US20080207597 T JJ O
structure US20080207597 T NN O
of US20080207597 T IN O
sars US20080207597 T NNS O
coronavirus US20080207597 T NN O
. US20080207597 T . O

1- WO2007006707A1 T JJ O
[ WO2007006707A1 T NN O
2 WO2007006707A1 T CD O
' WO2007006707A1 T '' O
, WO2007006707A1 T , O
3 WO2007006707A1 T CD O
' WO2007006707A1 T '' O
-dideoxy-3 WO2007006707A1 T NN O
' WO2007006707A1 T POS O
c- WO2007006707A1 T NN O
( WO2007006707A1 T ( O
hydroxymethyl WO2007006707A1 T NN O
) WO2007006707A1 T ) O
- WO2007006707A1 T : O
beta-d-erythro-pentofuranosyl WO2007006707A1 T JJ O
] WO2007006707A1 T JJ O
cytosine WO2007006707A1 T NN O
derivatives WO2007006707A1 T NNS O
as WO2007006707A1 T IN O
hiv WO2007006707A1 T JJ O
inhibitors WO2007006707A1 T NNS O
. WO2007006707A1 T . O

Compounds WO2007006707A1 A NNS O
of WO2007006707A1 A IN O
the WO2007006707A1 A DT O
formula WO2007006707A1 A NN O
( WO2007006707A1 A ( O
I WO2007006707A1 A PRP O
) WO2007006707A1 A ) O
wherein WO2007006707A1 A NN O
: WO2007006707A1 A : O
R1 WO2007006707A1 A NNP O
is WO2007006707A1 A VBZ O
independently WO2007006707A1 A RB O
H1 WO2007006707A1 A NNP O
-OR3 WO2007006707A1 A NNP O
, WO2007006707A1 A , O
-NHR4 WO2007006707A1 A NNP O
; WO2007006707A1 A : O
C1-C4 WO2007006707A1 A NNP O
alkyl WO2007006707A1 A NN O
; WO2007006707A1 A : O
or WO2007006707A1 A CC O
, WO2007006707A1 A , O
when WO2007006707A1 A WRB O
n WO2007006707A1 A NN O
is WO2007006707A1 A VBZ O
2 WO2007006707A1 A CD O
, WO2007006707A1 A , O
adjacent WO2007006707A1 A JJ O
R1 WO2007006707A1 A NNP O
together WO2007006707A1 A RB O
define WO2007006707A1 A VBP O
an WO2007006707A1 A DT O
olefin WO2007006707A1 A NN O
ic WO2007006707A1 A NN O
bond WO2007006707A1 A NN O
; WO2007006707A1 A : O
R2 WO2007006707A1 A NNP O
is WO2007006707A1 A VBZ O
H WO2007006707A1 A NNP O
; WO2007006707A1 A : O
or WO2007006707A1 A CC O
when WO2007006707A1 A WRB O
the WO2007006707A1 A DT O
gem WO2007006707A1 A NN O
R1 WO2007006707A1 A NNP O
is WO2007006707A1 A VBZ O
C1-C4 WO2007006707A1 A NNP O
alkyl WO2007006707A1 A NN O
, WO2007006707A1 A , O
that WO2007006707A1 A IN O
R2 WO2007006707A1 A NNP O
may WO2007006707A1 A MD O
also WO2007006707A1 A RB O
be WO2007006707A1 A VB O
C1-C4 WO2007006707A1 A NNP O
alkyl WO2007006707A1 A NN O
; WO2007006707A1 A : O
or WO2007006707A1 A CC O
when WO2007006707A1 A WRB O
the WO2007006707A1 A DT O
gem WO2007006707A1 A NN O
R1 WO2007006707A1 A NNP O
is WO2007006707A1 A VBZ O
-OR3 WO2007006707A1 A NNP O
, WO2007006707A1 A , O
that WO2007006707A1 A IN O
R2 WO2007006707A1 A NNP O
may WO2007006707A1 A MD O
also WO2007006707A1 A RB O
be WO2007006707A1 A VB O
-C WO2007006707A1 A NNP O
( WO2007006707A1 A ( O
=O WO2007006707A1 A NNP O
) WO2007006707A1 A ) O
OH WO2007006707A1 A NNP O
or WO2007006707A1 A CC O
a WO2007006707A1 A DT O
pharmaceutically WO2007006707A1 A RB O
acceptable WO2007006707A1 A JJ O
ester WO2007006707A1 A NN O
thereof WO2007006707A1 A NN O
; WO2007006707A1 A : O
R3 WO2007006707A1 A NNP O
is WO2007006707A1 A VBZ O
independently WO2007006707A1 A RB O
H WO2007006707A1 A NNP O
, WO2007006707A1 A , O
or WO2007006707A1 A CC O
a WO2007006707A1 A DT O
pharmaceutically WO2007006707A1 A RB O
acceptable WO2007006707A1 A JJ O
ester WO2007006707A1 A NN O
thereof WO2007006707A1 A NN O
; WO2007006707A1 A : O
R4 WO2007006707A1 A NNP O
is WO2007006707A1 A VBZ O
independently WO2007006707A1 A RB O
H WO2007006707A1 A NNP O
or WO2007006707A1 A CC O
a WO2007006707A1 A DT O
pharmaceutically WO2007006707A1 A RB O
acceptable WO2007006707A1 A JJ O
amide WO2007006707A1 A JJ O
thereof WO2007006707A1 A NN O
; WO2007006707A1 A : O
R5 WO2007006707A1 A NNP O
and WO2007006707A1 A CC O
R6 WO2007006707A1 A NNP O
are WO2007006707A1 A VBP O
H WO2007006707A1 A NNP O
or WO2007006707A1 A CC O
an WO2007006707A1 A DT O
amine WO2007006707A1 A JJ O
prodrug WO2007006707A1 A NN O
moiety WO2007006707A1 A NN O
n WO2007006707A1 A NN O
is WO2007006707A1 A VBZ O
1 WO2007006707A1 A CD O
, WO2007006707A1 A , O
2 WO2007006707A1 A CD O
or WO2007006707A1 A CC O
3 WO2007006707A1 A CD O
; WO2007006707A1 A : O
and WO2007006707A1 A CC O
pharmaceutically WO2007006707A1 A RB O
acceptable WO2007006707A1 A JJ O
salts WO2007006707A1 A NNS O
thereof WO2007006707A1 A VBP O
; WO2007006707A1 A : O
have WO2007006707A1 A VBP O
utility WO2007006707A1 A NN O
in WO2007006707A1 A IN O
the WO2007006707A1 A DT O
treatment WO2007006707A1 A NN O
or WO2007006707A1 A CC O
prophylaxis WO2007006707A1 A NN O
of WO2007006707A1 A IN O
HIV WO2007006707A1 A NNP O
, WO2007006707A1 A , O
especially WO2007006707A1 A RB O
reverse WO2007006707A1 A JJ I-UN
transcriptase WO2007006707A1 A NN I-UN
mutants WO2007006707A1 A NNS O
which WO2007006707A1 A WDT O
allow WO2007006707A1 A VBP O
an WO2007006707A1 A DT O
obligate WO2007006707A1 A NN O
chain WO2007006707A1 A NN O
terminating WO2007006707A1 A VBG O
nucleoside- WO2007006707A1 A JJ O
or WO2007006707A1 A CC O
nucleotide WO2007006707A1 A JJ O
phosphate WO2007006707A1 A NN O
to WO2007006707A1 A TO O
be WO2007006707A1 A VB O
excised WO2007006707A1 A VBN O
from WO2007006707A1 A IN O
the WO2007006707A1 A DT O
nascent WO2007006707A1 A JJ O
DNA WO2007006707A1 A NNP O
strand WO2007006707A1 A NN O
by WO2007006707A1 A IN O
ATP- WO2007006707A1 A NNP O
or WO2007006707A1 A CC O
pyrophosphate-mediated WO2007006707A1 A JJ O
excision WO2007006707A1 A NN O
. WO2007006707A1 A . O

Increasing US20110200693 T VBG O
the US20110200693 T DT O
efficiency US20110200693 T NN O
of US20110200693 T IN O
utilization US20110200693 T NN O
of US20110200693 T IN O
ingested US20110200693 T JJ O
creatine US20110200693 T NN O
. US20110200693 T . O

Application CN103027906A T NN O
of CN103027906A T IN O
arctigenin CN103027906A T NN O
in CN103027906A T IN O
treating CN103027906A T VBG O
anemia CN103027906A T NN O
. CN103027906A T . O

The CN103027906A A DT O
invention CN103027906A A NN O
discloses CN103027906A A VBZ O
novel CN103027906A A JJ O
medical CN103027906A A JJ O
application CN103027906A A NN O
of CN103027906A A IN O
arctigenin CN103027906A A NN O
, CN103027906A A , O
belonging CN103027906A A VBG O
to CN103027906A A TO O
the CN103027906A A DT O
field CN103027906A A NN O
of CN103027906A A IN O
medicines CN103027906A A NNS O
. CN103027906A A . O

Specifically CN103027906A A RB O
, CN103027906A A , O
the CN103027906A A DT O
invention CN103027906A A NN O
discloses CN103027906A A VBZ O
a CN103027906A A DT O
use CN103027906A A NN O
of CN103027906A A IN O
arctigenin CN103027906A A NN O
in CN103027906A A IN O
preparing CN103027906A A VBG O
a CN103027906A A DT O
drug CN103027906A A NN O
for CN103027906A A IN O
treating CN103027906A A VBG O
anemia CN103027906A A NN O
. CN103027906A A . O

Daily CN103027906A A JJ O
dosage CN103027906A A NN O
of CN103027906A A IN O
the CN103027906A A DT O
arctigenin CN103027906A A NN O
in CN103027906A A IN O
treating CN103027906A A VBG O
anemia CN103027906A A NN O
is CN103027906A A VBZ O
preferably CN103027906A A RB O
0.1mg/kg.d CN103027906A A CD O
to CN103027906A A TO O
10mg/kg.d CN103027906A A CD O
. CN103027906A A . O

According CN103027906A A VBG O
to CN103027906A A TO O
the CN103027906A A DT O
embodiment CN103027906A A NN O
of CN103027906A A IN O
the CN103027906A A DT O
pesticide CN103027906A A NN O
effect CN103027906A A NN O
, CN103027906A A , O
the CN103027906A A DT O
arctigenin CN103027906A A NN O
has CN103027906A A VBZ O
a CN103027906A A DT O
positive CN103027906A A JJ O
effect CN103027906A A NN O
of CN103027906A A IN O
treating CN103027906A A VBG O
chronic CN103027906A A JJ O
inflammation CN103027906A A NN O
anemia CN103027906A A NN O
, CN103027906A A , O
aplastic CN103027906A A JJ O
anemia CN103027906A A NN O
, CN103027906A A , O
hemolytic CN103027906A A JJ O
anemia CN103027906A A NN O
and CN103027906A A CC O
renal CN103027906A A JJ O
anemia CN103027906A A NN O
, CN103027906A A , O
therefore CN103027906A A RB O
, CN103027906A A , O
the CN103027906A A DT O
arctigenin CN103027906A A NN O
has CN103027906A A VBZ O
good CN103027906A A JJ O
clinical CN103027906A A JJ O
application CN103027906A A NN O
prospect CN103027906A A NN O
in CN103027906A A IN O
treating CN103027906A A VBG O
anemia CN103027906A A NN O
. CN103027906A A . O

Iloperidone CN102805745A T NNP O
composition CN102805745A T NN O
and CN102805745A T CC O
preparation CN102805745A T NN O
method CN102805745A T NN O
thereof CN102805745A T NN O
. CN102805745A T . O

Tricyclic WO2006040148A1 T JJ O
indole WO2006040148A1 T NN O
derivatives WO2006040148A1 T NNS O
for WO2006040148A1 T IN O
use WO2006040148A1 T NN O
in WO2006040148A1 T IN O
the WO2006040148A1 T DT O
treatment WO2006040148A1 T NN O
of WO2006040148A1 T IN O
alzheimer’s WO2006040148A1 T JJ O
disease WO2006040148A1 T NN O
. WO2006040148A1 T . O

The WO2006040148A1 A DT O
present WO2006040148A1 A JJ O
invention WO2006040148A1 A NN O
relates WO2006040148A1 A VBZ O
to WO2006040148A1 A TO O
novel WO2006040148A1 A VB O
ketone WO2006040148A1 A CD O
compounds WO2006040148A1 A NNS O
of WO2006040148A1 A IN O
formula WO2006040148A1 A NN O
( WO2006040148A1 A ( O
I WO2006040148A1 A PRP O
) WO2006040148A1 A ) O
having WO2006040148A1 A VBG O
Asp2 WO2006040148A1 A NNP I-UN
( WO2006040148A1 A ( O
β-secretase WO2006040148A1 A JJ I-UN
, WO2006040148A1 A , O
BACE1 WO2006040148A1 A NNP I-UN
or WO2006040148A1 A CC O
Memapsin-2 WO2006040148A1 A NNP I-UN
) WO2006040148A1 A ) O
inhibitory WO2006040148A1 A NN O
activity WO2006040148A1 A NN O
, WO2006040148A1 A , O
processes WO2006040148A1 A NNS O
for WO2006040148A1 A IN O
their WO2006040148A1 A PRP$ O
preparation WO2006040148A1 A NN O
, WO2006040148A1 A , O
to WO2006040148A1 A TO O
compositions WO2006040148A1 A NNS O
containing WO2006040148A1 A VBG O
them WO2006040148A1 A PRP O
and WO2006040148A1 A CC O
to WO2006040148A1 A TO O
their WO2006040148A1 A PRP$ O
use WO2006040148A1 A NN O
in WO2006040148A1 A IN O
the WO2006040148A1 A DT O
treatment WO2006040148A1 A NN O
of WO2006040148A1 A IN O
diseases WO2006040148A1 A NNS O
characterised WO2006040148A1 A VBN O
by WO2006040148A1 A IN O
elevated WO2006040148A1 A JJ O
β- WO2006040148A1 A JJ I-UN
amyloid WO2006040148A1 A NN I-UN
levels WO2006040148A1 A NNS O
or WO2006040148A1 A CC O
β-amyloid WO2006040148A1 A JJ I-UN
deposits WO2006040148A1 A NNS O
, WO2006040148A1 A , O
particularly WO2006040148A1 A RB O
Alzheimer WO2006040148A1 A NNP O
's WO2006040148A1 A POS O
disease WO2006040148A1 A NN O
. WO2006040148A1 A . O

Deuterium CA2816104A1 T NN O
enriched CA2816104A1 T VBD O
rasagiline CA2816104A1 T NN O
. CA2816104A1 T . O

Aminocycloalkyl US7687536 T NNP O
cinnamide US7687536 T NN O
compounds US7687536 T NNS O
for US7687536 T IN O
arrhythmia US7687536 T NN O
and US7687536 T CC O
as US7687536 T IN O
analgesics US7687536 T NNS O
and US7687536 T CC O
anesthetics US7687536 T NNS O
. US7687536 T . O

Composition WO2011163321A2 T NN O
and WO2011163321A2 T CC O
method WO2011163321A2 T NN O
of WO2011163321A2 T IN O
treating WO2011163321A2 T VBG O
lipid WO2011163321A2 T JJ O
encapsulated WO2011163321A2 T VBN O
virus WO2011163321A2 T NN O
infections WO2011163321A2 T NNS O
. WO2011163321A2 T . O

Substituted CA2189221C T NNP O
sulfonimidamides CA2189221C T NNS O
, CA2189221C T , O
processes CA2189221C T NNS O
for CA2189221C T IN O
their CA2189221C T PRP$ O
preparation CA2189221C T NN O
, CA2189221C T , O
their CA2189221C T PRP$ O
use CA2189221C T NN O
as CA2189221C T IN O
a CA2189221C T DT O
medicament CA2189221C T NN O
or CA2189221C T CC O
diagnostic CA2189221C T JJ O
, CA2189221C T , O
and CA2189221C T CC O
medicament CA2189221C T NN O
comprising CA2189221C T VBG O
them CA2189221C T PRP O
. CA2189221C T . O

Granules US20080085308 T NNS O
Comprising US20080085308 T VBG O
Paracetamol US20080085308 T NNP O
, US20080085308 T , O
a US20080085308 T DT O
Nsaid US20080085308 T NNP O
and US20080085308 T CC O
a US20080085308 T DT O
Sugar US20080085308 T NNP O
Alchohol US20080085308 T NNP O
Made US20080085308 T VBN O
by US20080085308 T IN O
Melt US20080085308 T NNP O
Extrusion US20080085308 T NNP O
. US20080085308 T . O

A US20080085308 A DT O
pharmaceutical US20080085308 A JJ O
composition US20080085308 A NN O
comprising US20080085308 A VBG O
a US20080085308 A DT O
granular US20080085308 A JJ O
component US20080085308 A NN O
comprising US20080085308 A VBG O
a US20080085308 A DT O
plurality US20080085308 A NN O
of US20080085308 A IN O
solidified US20080085308 A JJ O
melt US20080085308 A NN O
granules US20080085308 A NNS O
of US20080085308 A IN O
a US20080085308 A DT O
sugar US20080085308 A NN O
alcohol US20080085308 A NN O
having US20080085308 A VBG O
a US20080085308 A DT O
salt US20080085308 A NN O
of US20080085308 A IN O
a US20080085308 A DT O
non-steroidal US20080085308 A JJ O
anti-inflammatory US20080085308 A JJ O
drug US20080085308 A NN O
( US20080085308 A ( O
NSAID US20080085308 A NNP O
salt US20080085308 A NN O
) US20080085308 A ) O
and US20080085308 A CC O
paracetamol US20080085308 A NN O
contained US20080085308 A VBN O
therein US20080085308 A RB O
. US20080085308 A . O

3- WO2008132162A1 T JJ O
( WO2008132162A1 T ( O
sulphonylamino WO2008132162A1 T NN O
) WO2008132162A1 T ) O
-phenyl-2 WO2008132162A1 T NN O
-hydroxy-ethylamino WO2008132162A1 T NN O
derivatives WO2008132162A1 T NNS O
useful WO2008132162A1 T JJ O
as WO2008132162A1 T IN O
beta-agonists WO2008132162A1 T NNS O
, WO2008132162A1 T , O
processes WO2008132162A1 T NNS O
for WO2008132162A1 T IN O
preparing WO2008132162A1 T VBG O
them WO2008132162A1 T PRP O
and WO2008132162A1 T CC O
their WO2008132162A1 T PRP$ O
use WO2008132162A1 T NN O
as WO2008132162A1 T IN O
medicaments WO2008132162A1 T NNS O
. WO2008132162A1 T . O

New WO2009147211A1 T NNP O
compounds WO2009147211A1 T NNS O
v WO2009147211A1 T NN O
. WO2009147211A1 T . O

The WO2009147211A1 A DT O
present WO2009147211A1 A JJ O
invention WO2009147211A1 A NN O
relates WO2009147211A1 A VBZ O
to WO2009147211A1 A TO O
new WO2009147211A1 A JJ O
compounds WO2009147211A1 A NNS O
of WO2009147211A1 A IN O
formula WO2009147211A1 A NN O
( WO2009147211A1 A ( O
I WO2009147211A1 A PRP O
) WO2009147211A1 A ) O
, WO2009147211A1 A , O
to WO2009147211A1 A TO O
pharmaceutical WO2009147211A1 A JJ O
compositions WO2009147211A1 A NNS O
comprising WO2009147211A1 A VBG O
these WO2009147211A1 A DT O
compounds WO2009147211A1 A NNS O
and WO2009147211A1 A CC O
to WO2009147211A1 A TO O
the WO2009147211A1 A DT O
use WO2009147211A1 A NN O
of WO2009147211A1 A IN O
these WO2009147211A1 A DT O
compounds WO2009147211A1 A NNS O
as WO2009147211A1 A IN O
leptin WO2009147211A1 A JJ I-UN
receptor WO2009147211A1 A NN I-UN
modulator WO2009147211A1 A NN O
mimetics WO2009147211A1 A NNS O
in WO2009147211A1 A IN O
the WO2009147211A1 A DT O
preparation WO2009147211A1 A NN O
of WO2009147211A1 A IN O
medicaments WO2009147211A1 A NNS O
against WO2009147211A1 A IN O
conditions WO2009147211A1 A NNS O
associated WO2009147211A1 A VBN O
with WO2009147211A1 A IN O
weight WO2009147211A1 A JJ O
gain WO2009147211A1 A NN O
, WO2009147211A1 A , O
type WO2009147211A1 A JJ O
2 WO2009147211A1 A CD O
diabetes WO2009147211A1 A NNS O
and WO2009147211A1 A CC O
dyslipidemias WO2009147211A1 A NN O
. WO2009147211A1 A . O

Tetriacyclodipyranyl WO2009059452A1 T NNP O
coumarins WO2009059452A1 T NNS O
and WO2009059452A1 T CC O
the WO2009059452A1 T DT O
anti-hiv WO2009059452A1 T JJ O
and WO2009059452A1 T CC O
anti-tuberculosis WO2009059452A1 T JJ O
uses WO2009059452A1 T NNS O
thereof WO2009059452A1 T NN O
. WO2009059452A1 T . O

Tetracyclodipyranyl WO2009059452A1 A NNP O
coumarins WO2009059452A1 A NNS O
of WO2009059452A1 A IN O
formula WO2009059452A1 A NN O
( WO2009059452A1 A ( O
1 WO2009059452A1 A CD O
) WO2009059452A1 A ) O
, WO2009059452A1 A , O
wherein WO2009059452A1 A VBD O
the WO2009059452A1 A DT O
substituents WO2009059452A1 A NNS O
defined WO2009059452A1 A VBD O
as WO2009059452A1 A IN O
the WO2009059452A1 A DT O
description WO2009059452A1 A NN O
. WO2009059452A1 A . O

The WO2009059452A1 A DT O
compounds WO2009059452A1 A NNS O
has WO2009059452A1 A VBZ O
anti-HIV WO2009059452A1 A JJ O
and WO2009059452A1 A CC O
anti-tuberculosis WO2009059452A1 A JJ O
activity WO2009059452A1 A NN O
. WO2009059452A1 A . O

Reducing EP1345616A4 T VBG O
cellular EP1345616A4 T JJ O
damage EP1345616A4 T NN O
in EP1345616A4 T IN O
the EP1345616A4 T DT O
human EP1345616A4 T JJ O
body EP1345616A4 T NN O
. EP1345616A4 T . O

Providing EP1345616A4 A VBG O
and EP1345616A4 A CC O
using EP1345616A4 A VBG O
a EP1345616A4 A DT O
dietary EP1345616A4 A JJ O
supplement EP1345616A4 A NN O
to EP1345616A4 A TO O
reduce EP1345616A4 A VB O
cellular EP1345616A4 A JJ O
damage EP1345616A4 A NN O
within EP1345616A4 A IN O
the EP1345616A4 A DT O
human EP1345616A4 A JJ O
body EP1345616A4 A NN O
. EP1345616A4 A . O

The EP1345616A4 A DT O
dietary EP1345616A4 A JJ O
supplement EP1345616A4 A NN O
includes EP1345616A4 A VBZ O
reconstituted EP1345616A4 A VBN O
Morinda EP1345616A4 A NNP O
citrifolia EP1345616A4 A NN O
fruit EP1345616A4 A NN O
juice EP1345616A4 A NN O
from EP1345616A4 A IN O
pure EP1345616A4 A JJ O
juice EP1345616A4 A NN O
puree EP1345616A4 A NN O
of EP1345616A4 A IN O
French EP1345616A4 A JJ O
Polynesia EP1345616A4 A NNP O
, EP1345616A4 A , O
and EP1345616A4 A CC O
may EP1345616A4 A MD O
include EP1345616A4 A VB O
other EP1345616A4 A JJ O
natural EP1345616A4 A JJ O
juices EP1345616A4 A NNS O
, EP1345616A4 A , O
such EP1345616A4 A JJ O
as EP1345616A4 A IN O
a EP1345616A4 A DT O
natural EP1345616A4 A JJ O
grape EP1345616A4 A NN O
juice EP1345616A4 A NN O
concentrate EP1345616A4 A NN O
, EP1345616A4 A , O
a EP1345616A4 A DT O
natural EP1345616A4 A JJ O
blueberry EP1345616A4 A NN O
juice EP1345616A4 A NN O
concentrate EP1345616A4 A NN O
, EP1345616A4 A , O
and/or EP1345616A4 A VBZ O
another EP1345616A4 A DT O
natural EP1345616A4 A JJ O
juice EP1345616A4 A NN O
concentrate EP1345616A4 A NN O
. EP1345616A4 A . O

The EP1345616A4 A DT O
dietary EP1345616A4 A JJ O
supplement EP1345616A4 A NN O
includes EP1345616A4 A VBZ O
a EP1345616A4 A DT O
combination EP1345616A4 A NN O
of EP1345616A4 A IN O
compounds EP1345616A4 A NNS O
that EP1345616A4 A WDT O
work EP1345616A4 A VBP O
at EP1345616A4 A IN O
the EP1345616A4 A DT O
cellular EP1345616A4 A JJ O
level EP1345616A4 A NN O
to EP1345616A4 A TO O
increase EP1345616A4 A VB O
the EP1345616A4 A DT O
positive EP1345616A4 A JJ O
functionality EP1345616A4 A NN O
of EP1345616A4 A IN O
cells EP1345616A4 A NNS O
in EP1345616A4 A IN O
the EP1345616A4 A DT O
body EP1345616A4 A NN O
, EP1345616A4 A , O
including EP1345616A4 A VBG O
cell EP1345616A4 A NN O
regeneration EP1345616A4 A NN O
and EP1345616A4 A CC O
cell EP1345616A4 A NN O
function EP1345616A4 A NN O
, EP1345616A4 A , O
to EP1345616A4 A TO O
increase EP1345616A4 A VB O
the EP1345616A4 A DT O
ability EP1345616A4 A NN O
of EP1345616A4 A IN O
cells EP1345616A4 A NNS O
to EP1345616A4 A TO O
absorb EP1345616A4 A VB O
and EP1345616A4 A CC O
utilize EP1345616A4 A VB O
nutrients EP1345616A4 A NNS O
, EP1345616A4 A , O
such EP1345616A4 A JJ O
as EP1345616A4 A IN O
vitamins EP1345616A4 A NNS O
and EP1345616A4 A CC O
minerals EP1345616A4 A NNS O
, EP1345616A4 A , O
and EP1345616A4 A CC O
to EP1345616A4 A TO O
. EP1345616A4 A . O

Furthermore EP1345616A4 A RB O
, EP1345616A4 A , O
the EP1345616A4 A DT O
dietary EP1345616A4 A JJ O
supplement EP1345616A4 A NN O
scavenges EP1345616A4 A NNS O
lipid EP1345616A4 A VBP O
hydroperoxides EP1345616A4 A NNS O
and EP1345616A4 A CC O
superoxide EP1345616A4 A JJ O
anion EP1345616A4 A NN O
free EP1345616A4 A JJ O
radicals EP1345616A4 A NNS O
within EP1345616A4 A IN O
the EP1345616A4 A DT O
body EP1345616A4 A NN O
to EP1345616A4 A TO O
reduce EP1345616A4 A VB O
cellular EP1345616A4 A JJ O
damage EP1345616A4 A NN O
. EP1345616A4 A . O

Gallic CN101134723A T NNP O
acid CN101134723A T NN O
and CN101134723A T CC O
divalent CN101134723A T NN O
metal CN101134723A T NN O
ionic CN101134723A T JJ O
compound CN101134723A T NN O
and CN101134723A T CC O
preparation CN101134723A T NN O
method CN101134723A T NN O
and CN101134723A T CC O
application CN101134723A T NN O
thereof CN101134723A T NN O
. CN101134723A T . O

Application CN102670625A T NN O
of CN102670625A T IN O
urea CN102670625A T JJ O
compound CN102670625A T NN O
. CN102670625A T . O

The CN102670625A A DT O
invention CN102670625A A NN O
discloses CN102670625A A VBZ O
an CN102670625A A DT O
application CN102670625A A NN O
of CN102670625A A IN O
a CN102670625A A DT O
urea CN102670625A A JJ O
compound CN102670625A A NN O
( CN102670625A A ( O
shown CN102670625A A VBN O
in CN102670625A A IN O
figure CN102670625A A NN O
1 CN102670625A A CD O
) CN102670625A A ) O
in CN102670625A A IN O
preparation CN102670625A A NN O
of CN102670625A A IN O
a CN102670625A A DT O
nicotinamide CN102670625A A JJ I-UN
phosphoribosyltransferase CN102670625A A NN I-UN
inhibitor CN102670625A A NN O
. CN102670625A A . O

The CN102670625A A DT O
compound CN102670625A A NN O
I CN102670625A A PRP O
shows CN102670625A A VBP O
good CN102670625A A JJ O
inhibiting CN102670625A A NN O
activity CN102670625A A NN O
on CN102670625A A IN O
nicotinamide CN102670625A A JJ I-UN
phosphoribosyltransferase CN102670625A A NN I-UN
, CN102670625A A , O
can CN102670625A A MD O
be CN102670625A A VB O
used CN102670625A A VBN O
for CN102670625A A IN O
preparing CN102670625A A VBG O
medicines CN102670625A A NNS O
for CN102670625A A IN O
prevention CN102670625A A NN O
and/or CN102670625A A NN O
treatment CN102670625A A NN O
of CN102670625A A IN O
diseases CN102670625A A NNS O
by CN102670625A A IN O
inhibiting CN102670625A A VBG O
nicotinamide CN102670625A A JJ I-UN
phosphoribosyltransferase CN102670625A A NN I-UN
, CN102670625A A , O
and CN102670625A A CC O
also CN102670625A A RB O
can CN102670625A A MD O
be CN102670625A A VB O
used CN102670625A A VBN O
for CN102670625A A IN O
preventing CN102670625A A VBG O
and CN102670625A A CC O
treating CN102670625A A VBG O
cancer CN102670625A A NN O
. CN102670625A A . O

Drug CN103622923A T NN O
delivery CN103622923A T NN O
system CN103622923A T NN O
for CN103622923A T IN O
16-dehydropregnenolone CN103622923A T JJ O
lipidosome CN103622923A T NN O
for CN103622923A T IN O
injection CN103622923A T NN O
and CN103622923A T CC O
preparation CN103622923A T NN O
method CN103622923A T NN O
of CN103622923A T IN O
same CN103622923A T JJ O
. CN103622923A T . O

Slow-release CN1868463A T JJ O
prepn CN1868463A T NN O
. CN1868463A T . O

contg CN1868463A T NN O
. CN1868463A T . O

alpha-lipoic CN1868463A T JJ O
acid CN1868463A T NN O
or CN1868463A T CC O
its CN1868463A T PRP$ O
derivatives CN1868463A T NNS O
, CN1868463A T , O
and CN1868463A T CC O
preparing CN1868463A T VBG O
method CN1868463A T NN O
therefor CN1868463A T NN O
. CN1868463A T . O

PHARMACEUTICAL EP1411900B1 T JJ O
COMPOSITIONS EP1411900B1 T NNP O
FOR EP1411900B1 T IN O
THE EP1411900B1 T NNP O
COORDINATED EP1411900B1 T NNP O
DELIVERY EP1411900B1 T NNP O
OF EP1411900B1 T NNP O
NSAIDs EP1411900B1 T NNP O
. EP1411900B1 T . O

Substituted US20100286165 T VBN O
oxindole US20100286165 T JJ O
compounds US20100286165 T NNS O
. US20100286165 T . O

Lipolytic US20120046256 T JJ O
Methods US20120046256 T NNS O
for US20120046256 T IN O
Regional US20120046256 T NNP O
Adiposity US20120046256 T NNP O
Comprising US20120046256 T NNP O
Salmeterol US20120046256 T NNP O
or US20120046256 T CC O
Formoterol US20120046256 T NNP O
. US20120046256 T . O

Compositions US20120046256 A NNS O
, US20120046256 A , O
formulations US20120046256 A NNS O
, US20120046256 A , O
methods US20120046256 A NNS O
, US20120046256 A , O
and US20120046256 A CC O
systems US20120046256 A NNS O
for US20120046256 A IN O
treating US20120046256 A VBG O
regional US20120046256 A JJ O
fat US20120046256 A NN O
deposits US20120046256 A NNS O
comprise US20120046256 A VBP O
contacting US20120046256 A VBG O
a US20120046256 A DT O
targeted US20120046256 A JJ O
fat US20120046256 A JJ O
deposit US20120046256 A NN O
with US20120046256 A IN O
a US20120046256 A DT O
composition US20120046256 A NN O
comprising US20120046256 A VBG O
long US20120046256 A JJ O
acting US20120046256 A VBG O
beta-2 US20120046256 A JJ I-UN
adrenergic US20120046256 A JJ I-UN
receptor US20120046256 A NN I-UN
agonist US20120046256 A NN O
and US20120046256 A CC O
a US20120046256 A DT O
compound US20120046256 A NN O
that US20120046256 A WDT O
reduces US20120046256 A VBZ O
desensitization US20120046256 A NN O
of US20120046256 A IN O
the US20120046256 A DT O
target US20120046256 A NN O
tissue US20120046256 A NN O
to US20120046256 A TO O
the US20120046256 A DT O
long US20120046256 A JJ O
acting US20120046256 A JJ O
beta-2 US20120046256 A NN I-UN
adrenergic US20120046256 A JJ I-UN
receptor US20120046256 A NN I-UN
agonist US20120046256 A NN O
, US20120046256 A , O
for US20120046256 A IN O
example US20120046256 A NN O
, US20120046256 A , O
glucocorticosteroids US20120046256 A NNS O
and/or US20120046256 A VBP O
ketotifen US20120046256 A NN O
. US20120046256 A . O

Oxime WO2012111995A1 T NNP O
derivatives WO2012111995A1 T NNS O
as WO2012111995A1 T IN O
gpr119 WO2012111995A1 T JJ I-UN
agonists WO2012111995A1 T NNS O
. WO2012111995A1 T . O

The WO2012111995A1 A DT O
oxime WO2012111995A1 A NN O
derivatives WO2012111995A1 A VBZ O
according WO2012111995A1 A VBG O
to WO2012111995A1 A TO O
the WO2012111995A1 A DT O
present WO2012111995A1 A JJ O
invention WO2012111995A1 A NN O
act WO2012111995A1 A NN O
as WO2012111995A1 A IN O
GPR119 WO2012111995A1 A NNP I-UN
agonists WO2012111995A1 A VBZ O
to WO2012111995A1 A TO O
stimulate WO2012111995A1 A VB O
the WO2012111995A1 A DT O
secretion WO2012111995A1 A NN O
of WO2012111995A1 A IN O
insulin WO2012111995A1 A NN O
and WO2012111995A1 A CC O
promote WO2012111995A1 A VB O
GLP-1 WO2012111995A1 A NNP I-UN
formation WO2012111995A1 A NN O
for WO2012111995A1 A IN O
preventing WO2012111995A1 A VBG O
or WO2012111995A1 A CC O
treating WO2012111995A1 A VBG O
type WO2012111995A1 A JJ O
2 WO2012111995A1 A CD O
diabetes WO2012111995A1 A NNS O
, WO2012111995A1 A , O
complications WO2012111995A1 A NNS O
of WO2012111995A1 A IN O
diabetes WO2012111995A1 A NNS O
, WO2012111995A1 A , O
obesity WO2012111995A1 A NN O
, WO2012111995A1 A , O
dyslipidemia WO2012111995A1 A NN O
or WO2012111995A1 A CC O
osteoporosis WO2012111995A1 A NN O
. WO2012111995A1 A . O

1h-pyrrolo WO2008025947A1 T JJ O
[ WO2008025947A1 T NNP O
2,3-b WO2008025947A1 T JJ O
] WO2008025947A1 T NNP O
pyridine WO2008025947A1 T NN O
derivatives WO2008025947A1 T NNS O
useful WO2008025947A1 T JJ O
as WO2008025947A1 T IN O
hsp90 WO2008025947A1 T JJ I-UN
inhibitors WO2008025947A1 T NNS O
. WO2008025947A1 T . O

Compounds WO2008025947A1 A NNS O
of WO2008025947A1 A IN O
formula WO2008025947A1 A NN O
( WO2008025947A1 A ( O
I WO2008025947A1 A PRP O
) WO2008025947A1 A ) O
have WO2008025947A1 A VBP O
HSP90 WO2008025947A1 A NNP I-UN
inhibitory WO2008025947A1 A JJ O
activity WO2008025947A1 A NN O
: WO2008025947A1 A : O
ring WO2008025947A1 A NN O
A WO2008025947A1 A DT O
is WO2008025947A1 A VBZ O
an WO2008025947A1 A DT O
aryl WO2008025947A1 A NN O
or WO2008025947A1 A CC O
heteroaryl WO2008025947A1 A VB O
ring WO2008025947A1 A NN O
or WO2008025947A1 A CC O
ring WO2008025947A1 A NN O
system WO2008025947A1 A NN O
; WO2008025947A1 A : O
R1 WO2008025947A1 A NNP O
is WO2008025947A1 A VBZ O
hydrogen WO2008025947A1 A NN O
, WO2008025947A1 A , O
fluoro WO2008025947A1 A NN O
, WO2008025947A1 A , O
chloro WO2008025947A1 A NN O
, WO2008025947A1 A , O
bromo WO2008025947A1 A NN O
, WO2008025947A1 A , O
or WO2008025947A1 A CC O
a WO2008025947A1 A DT O
radical WO2008025947A1 A JJ O
of WO2008025947A1 A IN O
formula WO2008025947A1 A NN O
( WO2008025947A1 A ( O
1A WO2008025947A1 A CD O
) WO2008025947A1 A ) O
: WO2008025947A1 A : O
-X-Alk1- WO2008025947A1 A NN O
( WO2008025947A1 A ( O
Z WO2008025947A1 A NNP O
) WO2008025947A1 A ) O
m- WO2008025947A1 A NN O
( WO2008025947A1 A ( O
Alk2 WO2008025947A1 A NNP O
) WO2008025947A1 A ) O
n-Q WO2008025947A1 A NN O
( WO2008025947A1 A ( O
IA WO2008025947A1 A NNP O
) WO2008025947A1 A ) O
wherein WO2008025947A1 A NN O
X WO2008025947A1 A NNP O
is WO2008025947A1 A VBZ O
a WO2008025947A1 A DT O
bond WO2008025947A1 A NN O
, WO2008025947A1 A , O
-O- WO2008025947A1 A NNP O
, WO2008025947A1 A , O
-S- WO2008025947A1 A NNP O
, WO2008025947A1 A , O
-S WO2008025947A1 A NNP O
( WO2008025947A1 A ( O
O WO2008025947A1 A NNP O
) WO2008025947A1 A ) O
- WO2008025947A1 A : O
, WO2008025947A1 A , O
-SO2- WO2008025947A1 A FW O
, WO2008025947A1 A , O
or WO2008025947A1 A CC O
-NH- WO2008025947A1 A NN O
, WO2008025947A1 A , O
Z WO2008025947A1 A NNP O
is WO2008025947A1 A VBZ O
-O- WO2008025947A1 A NNP O
, WO2008025947A1 A , O
-S- WO2008025947A1 A NNP O
, WO2008025947A1 A , O
- WO2008025947A1 A : O
( WO2008025947A1 A ( O
C=O WO2008025947A1 A NNP O
) WO2008025947A1 A ) O
- WO2008025947A1 A : O
, WO2008025947A1 A , O
- WO2008025947A1 A : O
( WO2008025947A1 A ( O
C=S WO2008025947A1 A NNP O
) WO2008025947A1 A ) O
- WO2008025947A1 A : O
, WO2008025947A1 A , O
-S WO2008025947A1 A NNP O
( WO2008025947A1 A ( O
O WO2008025947A1 A NNP O
) WO2008025947A1 A ) O
- WO2008025947A1 A : O
, WO2008025947A1 A , O
-SO2- WO2008025947A1 A UH O
, WO2008025947A1 A , O
-NRA- WO2008025947A1 A JJ O
, WO2008025947A1 A , O
or WO2008025947A1 A CC O
, WO2008025947A1 A , O
in WO2008025947A1 A IN O
either WO2008025947A1 A DT O
orientation WO2008025947A1 A NN O
-C WO2008025947A1 A NN O
( WO2008025947A1 A ( O
=O WO2008025947A1 A JJ O
) WO2008025947A1 A ) O
O- WO2008025947A1 A NNP O
, WO2008025947A1 A , O
-C WO2008025947A1 A NNP O
( WO2008025947A1 A ( O
=O WO2008025947A1 A NNP O
) WO2008025947A1 A ) O
NRA- WO2008025947A1 A NNP O
, WO2008025947A1 A , O
-C WO2008025947A1 A NNP O
( WO2008025947A1 A ( O
=S WO2008025947A1 A NNP O
) WO2008025947A1 A ) O
NRA- WO2008025947A1 A NNP O
, WO2008025947A1 A , O
-SO2NRA- WO2008025947A1 A NNP O
, WO2008025947A1 A , O
-NRAC WO2008025947A1 A NNP O
( WO2008025947A1 A ( O
=O WO2008025947A1 A NNP O
) WO2008025947A1 A ) O
- WO2008025947A1 A : O
, WO2008025947A1 A , O
or WO2008025947A1 A CC O
-NRASO2- WO2008025947A1 A VB O
wherein WO2008025947A1 A JJ O
RA WO2008025947A1 A NNP O
is WO2008025947A1 A VBZ O
hydrogen WO2008025947A1 A JJ O
or WO2008025947A1 A CC O
C1-C6 WO2008025947A1 A JJ O
alkyl WO2008025947A1 A NN O
in WO2008025947A1 A IN O
which WO2008025947A1 A WDT O
one WO2008025947A1 A CD O
or WO2008025947A1 A CC O
more WO2008025947A1 A JJR O
hydrogens WO2008025947A1 A NNS O
is WO2008025947A1 A VBZ O
optionally WO2008025947A1 A RB O
substituted WO2008025947A1 A VBN O
by WO2008025947A1 A IN O
fluorine WO2008025947A1 A NN O
; WO2008025947A1 A : O
Alk1 WO2008025947A1 A NNP O
and WO2008025947A1 A CC O
AIk2 WO2008025947A1 A NNP O
are WO2008025947A1 A VBP O
optionally WO2008025947A1 A RB O
substituted WO2008025947A1 A JJ O
divalent WO2008025947A1 A JJ O
C1-C3 WO2008025947A1 A JJ O
alkylene WO2008025947A1 A NN O
: WO2008025947A1 A : O
or WO2008025947A1 A CC O
C2-C3 WO2008025947A1 A JJ O
alkenylene WO2008025947A1 A NN O
radicals WO2008025947A1 A NNS O
, WO2008025947A1 A , O
m WO2008025947A1 A NN O
and WO2008025947A1 A CC O
n WO2008025947A1 A NN O
are WO2008025947A1 A VBP O
independently WO2008025947A1 A RB O
0 WO2008025947A1 A CD O
or WO2008025947A1 A CC O
1 WO2008025947A1 A CD O
, WO2008025947A1 A , O
and WO2008025947A1 A CC O
Q WO2008025947A1 A NNP O
is WO2008025947A1 A VBZ O
hydrogen WO2008025947A1 A NN O
or WO2008025947A1 A CC O
an WO2008025947A1 A DT O
optionally WO2008025947A1 A RB O
substituted WO2008025947A1 A VBN O
carbocyclic WO2008025947A1 A NN O
or WO2008025947A1 A CC O
heterocyclic WO2008025947A1 A JJ O
radical WO2008025947A1 A JJ O
; WO2008025947A1 A : O
R2 WO2008025947A1 A NNP O
is WO2008025947A1 A VBZ O
cyano WO2008025947A1 A VBN O
( WO2008025947A1 A ( O
-CN WO2008025947A1 A NN O
) WO2008025947A1 A ) O
, WO2008025947A1 A , O
fluoro WO2008025947A1 A RB O
, WO2008025947A1 A , O
chloro WO2008025947A1 A NN O
, WO2008025947A1 A , O
bromo WO2008025947A1 A NN O
, WO2008025947A1 A , O
methyl WO2008025947A1 A NN O
, WO2008025947A1 A , O
ethyl WO2008025947A1 A NN O
, WO2008025947A1 A , O
-OH WO2008025947A1 A NNP O
, WO2008025947A1 A , O
-CH2OH WO2008025947A1 A NNP O
, WO2008025947A1 A , O
-C WO2008025947A1 A NNP O
( WO2008025947A1 A ( O
=O WO2008025947A1 A NNP O
) WO2008025947A1 A ) O
NH2 WO2008025947A1 A NNP O
, WO2008025947A1 A , O
-C WO2008025947A1 A NNP O
( WO2008025947A1 A ( O
=O WO2008025947A1 A NNP O
) WO2008025947A1 A ) O
H WO2008025947A1 A NNP O
, WO2008025947A1 A , O
-C WO2008025947A1 A NNP O
( WO2008025947A1 A ( O
=O WO2008025947A1 A NNP O
) WO2008025947A1 A ) O
CH3 WO2008025947A1 A NNP O
, WO2008025947A1 A , O
or WO2008025947A1 A CC O
-NH2 WO2008025947A1 A NN O
; WO2008025947A1 A : O
R3 WO2008025947A1 A NNP O
and WO2008025947A1 A CC O
R4 WO2008025947A1 A NNP O
are WO2008025947A1 A VBP O
independently WO2008025947A1 A RB O
selected WO2008025947A1 A VBN O
from WO2008025947A1 A IN O
hydrogen WO2008025947A1 A NN O
, WO2008025947A1 A , O
fluoro WO2008025947A1 A NN O
, WO2008025947A1 A , O
chloro WO2008025947A1 A NN O
, WO2008025947A1 A , O
bromo WO2008025947A1 A NN O
, WO2008025947A1 A , O
cyano WO2008025947A1 A NN O
( WO2008025947A1 A ( O
-CN WO2008025947A1 A NNP O
) WO2008025947A1 A ) O
, WO2008025947A1 A , O
C1-C3alkyl WO2008025947A1 A NNP O
optionally WO2008025947A1 A RB O
substituted WO2008025947A1 A VBD O
with WO2008025947A1 A IN O
one WO2008025947A1 A CD O
or WO2008025947A1 A CC O
more WO2008025947A1 A JJR O
fluorine WO2008025947A1 A JJ O
substituents WO2008025947A1 A NNS O
, WO2008025947A1 A , O
C1-C3alkoxy WO2008025947A1 A NNP O
optionally WO2008025947A1 A RB O
substituted WO2008025947A1 A VBD O
with WO2008025947A1 A IN O
one WO2008025947A1 A CD O
or WO2008025947A1 A CC O
more WO2008025947A1 A JJR O
fluorine WO2008025947A1 A JJ O
substituents WO2008025947A1 A NNS O
, WO2008025947A1 A , O
-CH=CH2 WO2008025947A1 A NNP O
, WO2008025947A1 A , O
-C≡CH WO2008025947A1 A NNP O
, WO2008025947A1 A , O
cyclopropyl WO2008025947A1 A NN O
and WO2008025947A1 A CC O
-NH2 WO2008025947A1 A NN O
, WO2008025947A1 A , O
or WO2008025947A1 A CC O
R3 WO2008025947A1 A NNP O
and WO2008025947A1 A CC O
R4 WO2008025947A1 A NNP O
together WO2008025947A1 A RB O
represent WO2008025947A1 A VBP O
methylenedioxy WO2008025947A1 A NN O
( WO2008025947A1 A ( O
-OCH2O- WO2008025947A1 A JJ O
) WO2008025947A1 A ) O
or WO2008025947A1 A CC O
ethylenedioxy WO2008025947A1 A JJ O
( WO2008025947A1 A ( O
-OCH2CH2O- WO2008025947A1 A JJ O
) WO2008025947A1 A ) O
in WO2008025947A1 A IN O
either WO2008025947A1 A DT O
of WO2008025947A1 A IN O
which WO2008025947A1 A WDT O
one WO2008025947A1 A CD O
or WO2008025947A1 A CC O
more WO2008025947A1 A JJR O
hydrogens WO2008025947A1 A NNS O
are WO2008025947A1 A VBP O
optionally WO2008025947A1 A RB O
replaced WO2008025947A1 A VBN O
by WO2008025947A1 A IN O
fluorine WO2008025947A1 A NN O
; WO2008025947A1 A : O
S1 WO2008025947A1 A NNP O
is WO2008025947A1 A VBZ O
as WO2008025947A1 A RB O
defined WO2008025947A1 A VBN O
in WO2008025947A1 A IN O
the WO2008025947A1 A DT O
description WO2008025947A1 A NN O
. WO2008025947A1 A . O

Novel WO2006134613A3 T NNP O
5-substituted WO2006134613A3 T JJ O
indole WO2006134613A3 T NN O
derivatives WO2006134613A3 T NNS O
as WO2006134613A3 T IN O
dipeptidyl WO2006134613A3 T JJ I-UN
peptidase WO2006134613A3 T NN I-UN
iv WO2006134613A3 T NN I-UN
( WO2006134613A3 T ( O
dpp-iv WO2006134613A3 T JJ I-UN
) WO2006134613A3 T ) O
inhibitors WO2006134613A3 T NNS O
. WO2006134613A3 T . O

The WO2006134613A3 A DT O
present WO2006134613A3 A JJ O
invention WO2006134613A3 A NN O
relates WO2006134613A3 A VBZ O
to WO2006134613A3 A TO O
5-substituted WO2006134613A3 A JJ O
indole WO2006134613A3 A JJ O
derivatives WO2006134613A3 A NNS O
of WO2006134613A3 A IN O
formula WO2006134613A3 A NN O
( WO2006134613A3 A ( O
I WO2006134613A3 A PRP O
) WO2006134613A3 A ) O
: WO2006134613A3 A : O
having WO2006134613A3 A VBG O
inhibitory WO2006134613A3 A JJ O
potential WO2006134613A3 A NN O
of WO2006134613A3 A IN O
dipeptidyl WO2006134613A3 A JJ I-UN
peptidase WO2006134613A3 A NN I-UN
IV WO2006134613A3 A NNP I-UN
( WO2006134613A3 A ( O
DPP WO2006134613A3 A NNP I-UN
IV WO2006134613A3 A NNP I-UN
) WO2006134613A3 A ) O
enzyme WO2006134613A3 A NN O
where WO2006134613A3 A WRB O
x WO2006134613A3 A NN O
and WO2006134613A3 A CC O
R1 WO2006134613A3 A NNP O
are WO2006134613A3 A VBP O
defined WO2006134613A3 A VBN O
as WO2006134613A3 A IN O
defined WO2006134613A3 A VBN O
in WO2006134613A3 A IN O
the WO2006134613A3 A DT O
specification WO2006134613A3 A NN O

System US20090197828 T NN O
, US20090197828 T , O
method US20090197828 T NN O
and US20090197828 T CC O
package US20090197828 T NN O
for US20090197828 T IN O
providing US20090197828 T VBG O
a US20090197828 T DT O
sucrose US20090197828 T JJ O
solution US20090197828 T NN O
. US20090197828 T . O

Reverse US20130052279 T NNP O
micelle US20130052279 T NN O
system US20130052279 T NN O
comprising US20130052279 T VBG O
metal US20130052279 T JJ O
ions US20130052279 T NNS O
and US20130052279 T CC O
use US20130052279 T NN O
thereof US20130052279 T NN O
. US20130052279 T . O

Levofloxacin CN102106842A T NNP O
hydrochloride CN102106842A T NN O
micropill CN102106842A T NN O
capsule CN102106842A T NN O
and CN102106842A T CC O
preparation CN102106842A T NN O
method CN102106842A T NN O
thereof CN102106842A T NN O
. CN102106842A T . O

Coordinated CN101229377A T VBN O
use CN101229377A T NN O
method CN101229377A T NN O
of CN101229377A T IN O
trinosin CN101229377A T NN O
magnesium CN101229377A T NN O
chloride CN101229377A T NN O
and CN101229377A T CC O
sodium CN101229377A T NN O
chloride CN101229377A T NN O
injecta CN101229377A T NN O
. CN101229377A T . O

Polymers US8506945 T NNS O
with US8506945 T IN O
structure-defined US8506945 T JJ O
functions US8506945 T NNS O
. US8506945 T . O

Paediatrics CN101199531A T NNS O
aminophylline CN101199531A T VBP O
insant CN101199531A T JJ O
sheet CN101199531A T NN O
. CN101199531A T . O

Methods WO2012125828A8 T NNS O
of WO2012125828A8 T IN O
treating WO2012125828A8 T VBG O
breast WO2012125828A8 T NN O
cancer WO2012125828A8 T NN O
with WO2012125828A8 T IN O
anthracycline WO2012125828A8 T JJ O
therapy WO2012125828A8 T NN O
. WO2012125828A8 T . O

Pre-or US20110014227 T JJ O
post-exposure US20110014227 T NN O
treatment US20110014227 T NN O
for US20110014227 T IN O
filovirus US20110014227 T NN O
or US20110014227 T CC O
arenavirus US20110014227 T JJ O
infection US20110014227 T NN O
. US20110014227 T . O

Estrogen US7022733 T NNP I-UN
receptor US7022733 T NN I-UN
modulators US7022733 T NNS O
for US7022733 T IN O
treating US7022733 T VBG O
or US7022733 T CC O
inhibiting US7022733 T VBG O
endometriosis US7022733 T NN O
. US7022733 T . O

This US7022733 A DT O
invention US7022733 A NN O
provides US7022733 A VBZ O
estrogen US7022733 A JJ I-UN
receptor US7022733 A NN I-UN
modulators US7022733 A NNS O
of US7022733 A IN O
formula US7022733 A NN O
I US7022733 A PRP O
, US7022733 A , O
having US7022733 A VBG O
the US7022733 A DT O
structure US7022733 A NN O
wherein US7022733 A NN O
R US7022733 A NNP O
, US7022733 A , O
R′ US7022733 A NNP O
, US7022733 A , O
A US7022733 A NNP O
, US7022733 A , O
A′ US7022733 A NNP O
, US7022733 A , O
X US7022733 A NNP O
, US7022733 A , O
Y US7022733 A NNP O
, US7022733 A , O
and US7022733 A CC O
Y US7022733 A NNP O
are US7022733 A VBP O
as US7022733 A IN O
defined US7022733 A VBN O
in US7022733 A IN O
the US7022733 A DT O
specification US7022733 A NN O
, US7022733 A , O
or US7022733 A CC O
a US7022733 A DT O
pharmaceutically US7022733 A RB O
acceptable US7022733 A JJ O
salt US7022733 A NN O
thereof US7022733 A NN O
. US7022733 A . O

Pyrimidinone WO2013151923A1 T NNP O
carboxamides WO2013151923A1 T VBZ O
as WO2013151923A1 T IN O
inhibitors WO2013151923A1 T NNS O
of WO2013151923A1 T IN O
endothelial WO2013151923A1 T JJ I-UN
lipase WO2013151923A1 T NN I-UN
. WO2013151923A1 T . O

These WO2013151923A1 A DT O
compounds WO2013151923A1 A NNS O
are WO2013151923A1 A VBP O
endothelial WO2013151923A1 A JJ I-UN
lipase WO2013151923A1 A NN I-UN
inhibitors WO2013151923A1 A NNS O
which WO2013151923A1 A WDT O
may WO2013151923A1 A MD O
be WO2013151923A1 A VB O
used WO2013151923A1 A VBN O
as WO2013151923A1 A IN O
medicaments WO2013151923A1 A NNS O
. WO2013151923A1 A . O

Escin CN102755297A T NNP O
B CN102755297A T NNP O
freeze-dried CN102755297A T JJ O
powder CN102755297A T NN O
injection CN102755297A T NN O
and CN102755297A T CC O
preparation CN102755297A T NN O
method CN102755297A T NN O
and CN102755297A T CC O
application CN102755297A T NN O
thereof CN102755297A T NN O
. CN102755297A T . O

The CN102755297A A DT O
invention CN102755297A A NN O
provides CN102755297A A VBZ O
an CN102755297A A DT O
escin CN102755297A A NN O
B CN102755297A A NNP O
freeze-dried CN102755297A A JJ O
powder CN102755297A A NN O
injection CN102755297A A NN O
, CN102755297A A , O
which CN102755297A A WDT O
is CN102755297A A VBZ O
prepared CN102755297A A VBN O
from CN102755297A A IN O
a CN102755297A A DT O
therapeutic CN102755297A A JJ O
dose CN102755297A A NN O
of CN102755297A A IN O
main CN102755297A A JJ O
medicament CN102755297A A NN O
and CN102755297A A CC O
pharmaceutically-acceptable CN102755297A A JJ O
latent CN102755297A A NN O
solvent CN102755297A A NN O
and CN102755297A A CC O
freeze-dried CN102755297A A JJ O
excipient CN102755297A A NN O
. CN102755297A A . O

The CN102755297A A DT O
escin CN102755297A A NN O
B CN102755297A A NNP O
freeze-dried CN102755297A A JJ O
powder CN102755297A A NN O
injection CN102755297A A NN O
prepared CN102755297A A VBD O
according CN102755297A A VBG O
to CN102755297A A TO O
a CN102755297A A DT O
prescription CN102755297A A NN O
mixture CN102755297A A NN O
ratio CN102755297A A NN O
and CN102755297A A CC O
a CN102755297A A DT O
preparation CN102755297A A NN O
process CN102755297A A NN O
provided CN102755297A A VBN O
by CN102755297A A IN O
the CN102755297A A DT O
invention CN102755297A A NN O
has CN102755297A A VBZ O
the CN102755297A A DT O
characteristics CN102755297A A NNS O
of CN102755297A A IN O
high CN102755297A A JJ O
re-dissolving CN102755297A A JJ O
property CN102755297A A NN O
, CN102755297A A , O
stable CN102755297A A JJ O
quality CN102755297A A NN O
and CN102755297A A CC O
high CN102755297A A JJ O
compatibility CN102755297A A NN O
computability CN102755297A A NN O
with CN102755297A A IN O
conventional CN102755297A A JJ O
transfusion CN102755297A A NN O
. CN102755297A A . O

The CN102755297A A DT O
escin CN102755297A A NN O
B CN102755297A A NNP O
freeze-dried CN102755297A A JJ O
powder CN102755297A A NN O
injection CN102755297A A NN O
is CN102755297A A VBZ O
used CN102755297A A VBN O
for CN102755297A A IN O
treating CN102755297A A VBG O
various CN102755297A A JJ O
inflammatory CN102755297A A NN O
and CN102755297A A CC O
traumatic CN102755297A A JJ O
edemas CN102755297A A NN O
. CN102755297A A . O

Modified US20110086096 T JJ O
release US20110086096 T NN O
1- US20110086096 T JJ O
[ US20110086096 T NNP O
( US20110086096 T ( O
3-hydroxy-adamant-1-ylamino US20110086096 T JJ O
) US20110086096 T ) O
-acetyl US20110086096 T FW O
] US20110086096 T FW O
-pyrrolidine-2 US20110086096 T FW O
( US20110086096 T ( O
s US20110086096 T PRP O
) US20110086096 T ) O
-carbonitrile US20110086096 T IN O
formulation US20110086096 T NN O
. US20110086096 T . O

Sinomenine CN102617470A T NNP O
4-hydroxy CN102617470A T JJ O
etherification CN102617470A T NN O
and CN102617470A T CC O
esterification CN102617470A T NN O
derivatives CN102617470A T NNS O
and CN102617470A T CC O
preparation CN102617470A T NN O
method CN102617470A T NN O
and CN102617470A T CC O
application CN102617470A T NN O
thereof CN102617470A T NN O
. CN102617470A T . O

6-1h-imidazo-quinazoline US20110118289 T JJ O
and US20110118289 T CC O
quinolines US20110118289 T JJ O
derivatives US20110118289 T NNS O
, US20110118289 T , O
new US20110118289 T JJ O
mao US20110118289 T NN I-UN
inhibitors US20110118289 T NNS O
and US20110118289 T CC O
imidazoline US20110118289 T JJ O
receptor US20110118289 T NN O
ligands US20110118289 T NNS O
. US20110118289 T . O

The US20110118289 A DT O
present US20110118289 A JJ O
invention US20110118289 A NN O
is US20110118289 A VBZ O
directed US20110118289 A VBN O
to US20110118289 A TO O
6- US20110118289 A JJ O
( US20110118289 A ( O
1H-imidazo-1-yl US20110118289 A JJ O
) US20110118289 A ) O
-2-aryl US20110118289 A NN O
and US20110118289 A CC O
2-heteroaryl US20110118289 A JJ O
quinazoline US20110118289 A NN O
and US20110118289 A CC O
quinolines US20110118289 A NNS O
derivatives US20110118289 A NNS O
, US20110118289 A , O
compounds US20110118289 A NNS O
of US20110118289 A IN O
formula US20110118289 A NN O
( US20110118289 A ( O
I US20110118289 A PRP O
) US20110118289 A ) O
, US20110118289 A , O
their US20110118289 A PRP$ O
pharmaceutical US20110118289 A JJ O
acceptable US20110118289 A JJ O
salts US20110118289 A NNS O
and US20110118289 A CC O
solvates US20110118289 A NNS O
and US20110118289 A CC O
corresponding US20110118289 A VBG O
pharmaceutical US20110118289 A JJ O
compositions US20110118289 A NNS O
, US20110118289 A , O
that US20110118289 A WDT O
acts US20110118289 A VBZ O
as US20110118289 A IN O
Monoamine US20110118289 A NNP I-UN
Oxidase US20110118289 A NNP I-UN
( US20110118289 A ( O
MAO US20110118289 A NNP I-UN
) US20110118289 A ) O
inhibitors US20110118289 A NNS O
and US20110118289 A CC O
Imidazoline US20110118289 A NNP I-UN
Receptor US20110118289 A NNP I-UN
ligands US20110118289 A VBZ O
: US20110118289 A : O
wherein US20110118289 A NN O
: US20110118289 A : O
X US20110118289 A NN O
is US20110118289 A VBZ O
independently US20110118289 A RB O
selected US20110118289 A VBN O
from US20110118289 A IN O
—CH US20110118289 A NNP O
group US20110118289 A NN O
or US20110118289 A CC O
a US20110118289 A DT O
nitrogen US20110118289 A JJ O
atom US20110118289 A NN O
( US20110118289 A ( O
—N US20110118289 A NNP O
) US20110118289 A ) O
, US20110118289 A , O
W US20110118289 A NNP O
is US20110118289 A VBZ O
independently US20110118289 A RB O
selected US20110118289 A VBN O
from US20110118289 A IN O
an US20110118289 A DT O
aryl US20110118289 A NN O
group US20110118289 A NN O
, US20110118289 A , O
an US20110118289 A DT O
heteroaryl US20110118289 A NN O
group US20110118289 A NN O
, US20110118289 A , O
or US20110118289 A CC O
a US20110118289 A DT O
benzocondensed US20110118289 A JJ O
heteroaryl US20110118289 A NN O
group US20110118289 A NN O
such US20110118289 A JJ O
as US20110118289 A IN O
1,3-benzodioxole US20110118289 A JJ O
, US20110118289 A , O
benzofuran US20110118289 A JJ O
, US20110118289 A , O
2,3-dihydrobenzofuran US20110118289 A JJ O
, US20110118289 A , O
benzothiophene US20110118289 A JJ O
, US20110118289 A , O
2,3-dihydrobenzothiophene US20110118289 A JJ O
, US20110118289 A , O
indole US20110118289 A JJ O
, US20110118289 A , O
2,3-dihydroindole US20110118289 A JJ O
, US20110118289 A , O
benzimidazole US20110118289 A JJ O
, US20110118289 A , O
benzoxazole US20110118289 A JJ O
, US20110118289 A , O
benzothiazole US20110118289 A JJ O
, US20110118289 A , O
2H-3,4-dihydrobenzopyran US20110118289 A JJ O
, US20110118289 A , O
[ US20110118289 A JJ O
1,4 US20110118289 A CD O
] US20110118289 A JJ O
-benzodioxine US20110118289 A NN O
, US20110118289 A , O
2,3-dihydro- US20110118289 A JJ O
[ US20110118289 A NN O
1,4 US20110118289 A CD O
] US20110118289 A JJ O
-benzodioxine US20110118289 A NN O
( US20110118289 A ( O
1,4-benzodioxan US20110118289 A JJ O
) US20110118289 A ) O
. US20110118289 A . O

Novel EP2501669A2 T NNP O
arylated EP2501669A2 T VBD O
camphenes EP2501669A2 T NNS O
, EP2501669A2 T , O
processes EP2501669A2 T NNS O
for EP2501669A2 T IN O
their EP2501669A2 T PRP$ O
preparation EP2501669A2 T NN O
and EP2501669A2 T CC O
uses EP2501669A2 T VBZ O
thereof EP2501669A2 T NN O
. EP2501669A2 T . O

The EP2501669A2 A DT O
present EP2501669A2 A JJ O
invention EP2501669A2 A NN O
relates EP2501669A2 A VBZ O
to EP2501669A2 A TO O
arylated EP2501669A2 A VB O
camphenes EP2501669A2 A NNS O
, EP2501669A2 A , O
processes EP2501669A2 A NNS O
for EP2501669A2 A IN O
their EP2501669A2 A PRP$ O
preparation EP2501669A2 A NN O
and EP2501669A2 A CC O
uses EP2501669A2 A VBZ O
thereof EP2501669A2 A NN O
for EP2501669A2 A IN O
the EP2501669A2 A DT O
manufacture EP2501669A2 A NN O
of EP2501669A2 A IN O
medicaments EP2501669A2 A NNS O
for EP2501669A2 A IN O
the EP2501669A2 A DT O
treatment EP2501669A2 A NN O
of EP2501669A2 A IN O
diseases EP2501669A2 A NNS O
, EP2501669A2 A , O
disorders EP2501669A2 A NNS O
or EP2501669A2 A CC O
conditions EP2501669A2 A NNS O
associated EP2501669A2 A VBN O
with EP2501669A2 A IN O
, EP2501669A2 A , O
or EP2501669A2 A CC O
benefiting EP2501669A2 A VBG O
from EP2501669A2 A IN O
stimulation EP2501669A2 A NN O
of EP2501669A2 A IN O
CB2 EP2501669A2 A NNP I-UN
receptors EP2501669A2 A NNS I-UN
. EP2501669A2 A . O

Liver WO2005072763A1 T NNP O
fibrosis WO2005072763A1 T NN O
inhibitor WO2005072763A1 T NN O
. WO2005072763A1 T . O

Threshold US20100227891 T NNP O
blood US20100227891 T NN O
omeprazole US20100227891 T JJ O
concentration US20100227891 T NN O
is US20100227891 T VBZ O
50 US20100227891 T CD O
ng/ml US20100227891 T NN O
for US20100227891 T IN O
the US20100227891 T DT O
maintenance US20100227891 T NN O
of US20100227891 T IN O
intragastric US20100227891 T JJ O
ph US20100227891 T NN O
of US20100227891 T IN O
at US20100227891 T IN O
least US20100227891 T JJS O
4.0 US20100227891 T CD O
after US20100227891 T IN O
oral US20100227891 T JJ O
dosing US20100227891 T VBG O
with US20100227891 T IN O
cma-omeprazole US20100227891 T JJ O
, US20100227891 T , O
agn US20100227891 T JJ O
201904-z US20100227891 T CD O
. US20100227891 T . O

Dyrks US20060265763 T NNS O
as US20060265763 T IN O
modifiersof US20060265763 T NN O
the US20060265763 T DT O
apc US20060265763 T NN I-UN
and US20060265763 T CC O
axin US20060265763 T NN I-UN
pathways US20060265763 T NNS O
and US20060265763 T CC O
methods US20060265763 T NNS O
of US20060265763 T IN O
use US20060265763 T NN O
. US20060265763 T . O

Human US20060265763 A NNP O
DYRK US20060265763 A NNP O
genes US20060265763 A NNS O
are US20060265763 A VBP O
identified US20060265763 A VBN O
as US20060265763 A IN O
modulators US20060265763 A NNS O
of US20060265763 A IN O
the US20060265763 A DT O
APC US20060265763 A NNP I-UN
and US20060265763 A CC O
Axin US20060265763 A NNP I-UN
pathways US20060265763 A NNS O
, US20060265763 A , O
and US20060265763 A CC O
thus US20060265763 A RB O
are US20060265763 A VBP O
therapeutic US20060265763 A JJ O
targets US20060265763 A NNS O
for US20060265763 A IN O
disorders US20060265763 A NNS O
associated US20060265763 A VBN O
with US20060265763 A IN O
defective US20060265763 A JJ O
APC US20060265763 A NNP I-UN
and US20060265763 A CC O
Axin US20060265763 A NNP I-UN
function US20060265763 A NN O
. US20060265763 A . O

Methods US20060265763 A NNS O
for US20060265763 A IN O
identifying US20060265763 A VBG O
modulators US20060265763 A NNS O
of US20060265763 A IN O
APC US20060265763 A NNP I-UN
and US20060265763 A CC O
Axin US20060265763 A NNP I-UN
, US20060265763 A , O
comprising US20060265763 A VBG O
screening US20060265763 A VBG O
for US20060265763 A IN O
agents US20060265763 A NNS O
that US20060265763 A WDT O
modulate US20060265763 A VBP O
the US20060265763 A DT O
activity US20060265763 A NN O
of US20060265763 A IN O
DYRK US20060265763 A NNP O
are US20060265763 A VBP O
provided US20060265763 A VBN O
. US20060265763 A . O

Medicine CN103191319A T NNP O
for CN103191319A T IN O
treating CN103191319A T VBG O
epistaxis CN103191319A T NN O
and CN103191319A T CC O
preparation CN103191319A T NN O
method CN103191319A T NN O
thereof CN103191319A T NN O
. CN103191319A T . O

Methods WO2011054820A1 T NNS O
and WO2011054820A1 T CC O
compositions WO2011054820A1 T NNS O
for WO2011054820A1 T IN O
the WO2011054820A1 T DT O
treatment WO2011054820A1 T NN O
of WO2011054820A1 T IN O
white WO2011054820A1 T JJ O
matter WO2011054820A1 T NN O
ischemia WO2011054820A1 T NN O
. WO2011054820A1 T . O

Preparation CN103550162A T NNP O
method CN103550162A T NN O
of CN103550162A T IN O
targeted CN103550162A T JJ O
ferroferric CN103550162A T JJ O
oxide-porphyrin CN103550162A T JJ O
containing CN103550162A T VBG O
composite CN103550162A T JJ O
nanoparticles CN103550162A T NNS O
. CN103550162A T . O

Benzothiazole CN102532055A T NNP O
derivative CN102532055A T JJ O
compounds CN102532055A T NNS O
, CN102532055A T , O
compositions CN102532055A T NNS O
and CN102532055A T CC O
uses CN102532055A T NNS O
. CN102532055A T . O

Sulfonamide EP1650199A1 T NNP O
derivative EP1650199A1 T JJ O
having EP1650199A1 T VBG O
isoxazole EP1650199A1 T JJ O
ring EP1650199A1 T NN O
. EP1650199A1 T . O

A EP1650199A1 A DT O
compound EP1650199A1 A NN O
represented EP1650199A1 A VBN O
by EP1650199A1 A IN O
the EP1650199A1 A DT O
general EP1650199A1 A JJ O
formula EP1650199A1 A NN O
( EP1650199A1 A ( O
I-A EP1650199A1 A NNP O
) EP1650199A1 A ) O
: EP1650199A1 A : O
wherein EP1650199A1 A NN O
R1 EP1650199A1 A NNP O
is EP1650199A1 A VBZ O
hydroxy EP1650199A1 A JJ O
and EP1650199A1 A CC O
the EP1650199A1 A DT O
like EP1650199A1 A JJ O
; EP1650199A1 A : O
R2 EP1650199A1 A NNP O
is EP1650199A1 A VBZ O
optionally EP1650199A1 A RB O
substituted EP1650199A1 A VBN O
lower EP1650199A1 A JJR O
alkyl EP1650199A1 A NN O
and EP1650199A1 A CC O
the EP1650199A1 A DT O
like EP1650199A1 A JJ O
; EP1650199A1 A : O
R3 EP1650199A1 A NNP O
is EP1650199A1 A VBZ O
hydrogen EP1650199A1 A JJ O
atom EP1650199A1 A NN O
and EP1650199A1 A CC O
the EP1650199A1 A DT O
like EP1650199A1 A JJ O
; EP1650199A1 A : O
R4 EP1650199A1 A NNP O
is EP1650199A1 A VBZ O
optionally EP1650199A1 A RB O
substituted EP1650199A1 A VBN O
arylene EP1650199A1 A NN O
and EP1650199A1 A CC O
the EP1650199A1 A DT O
like EP1650199A1 A JJ O
; EP1650199A1 A : O
R5 EP1650199A1 A NNP O
is EP1650199A1 A VBZ O
a EP1650199A1 A DT O
group EP1650199A1 A NN O
represented EP1650199A1 A VBN O
by EP1650199A1 A IN O
the EP1650199A1 A DT O
formula EP1650199A1 A NN O
: EP1650199A1 A : O
or EP1650199A1 A CC O
R6 EP1650199A1 A NNP O
is EP1650199A1 A VBZ O
optionally EP1650199A1 A RB O
substituted EP1650199A1 A VBN O
aryl EP1650199A1 A NN O
and EP1650199A1 A CC O
the EP1650199A1 A DT O
like EP1650199A1 A JJ O
, EP1650199A1 A , O
its EP1650199A1 A PRP$ O
optically EP1650199A1 A RB O
active EP1650199A1 A JJ O
substance EP1650199A1 A NN O
, EP1650199A1 A , O
their EP1650199A1 A PRP$ O
pharmaceutically EP1650199A1 A RB O
acceptable EP1650199A1 A JJ O
salt EP1650199A1 A NN O
, EP1650199A1 A , O
or EP1650199A1 A CC O
a EP1650199A1 A DT O
solvate EP1650199A1 A JJ O
thereof EP1650199A1 A NN O
; EP1650199A1 A : O
and EP1650199A1 A CC O
a EP1650199A1 A DT O
metalloproteinase EP1650199A1 A NN I-UN
inhibitor EP1650199A1 A NN O
containing EP1650199A1 A VBG O
them EP1650199A1 A PRP O
. EP1650199A1 A . O

Acarbose EP1871393A2 T NNP O
methods EP1871393A2 T NNS O
and EP1871393A2 T CC O
formulations EP1871393A2 T NNS O
for EP1871393A2 T IN O
treating EP1871393A2 T VBG O
chronic EP1871393A2 T JJ O
constipation EP1871393A2 T NN O
. EP1871393A2 T . O

The EP1871393A2 A DT O
present EP1871393A2 A JJ O
invention EP1871393A2 A NN O
is EP1871393A2 A VBZ O
directed EP1871393A2 A VBN O
to EP1871393A2 A TO O
a EP1871393A2 A DT O
method EP1871393A2 A NN O
for EP1871393A2 A IN O
treating EP1871393A2 A VBG O
chronic EP1871393A2 A JJ O
constipation EP1871393A2 A NN O
in EP1871393A2 A IN O
a EP1871393A2 A DT O
subject EP1871393A2 A NN O
in EP1871393A2 A IN O
need EP1871393A2 A NN O
of EP1871393A2 A IN O
such EP1871393A2 A JJ O
treatment EP1871393A2 A NN O
comprising EP1871393A2 A VBG O
administering EP1871393A2 A VBG O
to EP1871393A2 A TO O
the EP1871393A2 A DT O
subject EP1871393A2 A NN O
a EP1871393A2 A DT O
dosage EP1871393A2 A NN O
formulation EP1871393A2 A NN O
comprising EP1871393A2 A VBG O
a EP1871393A2 A DT O
therapeutically EP1871393A2 A RB O
effective EP1871393A2 A JJ O
amount EP1871393A2 A NN O
of EP1871393A2 A IN O
acarbose EP1871393A2 A NN O
, EP1871393A2 A , O
or EP1871393A2 A CC O
a EP1871393A2 A DT O
pharmaceutically EP1871393A2 A RB O
acceptable EP1871393A2 A JJ O
salt EP1871393A2 A NN O
thereof EP1871393A2 A NN O
, EP1871393A2 A , O
and EP1871393A2 A CC O
at EP1871393A2 A IN O
least EP1871393A2 A JJS O
one EP1871393A2 A CD O
pharmaceutically EP1871393A2 A RB O
acceptable EP1871393A2 A JJ O
ingredient EP1871393A2 A NN O
to EP1871393A2 A TO O
control EP1871393A2 A VB O
the EP1871393A2 A DT O
release EP1871393A2 A NN O
of EP1871393A2 A IN O
the EP1871393A2 A DT O
acarbose EP1871393A2 A NN O
, EP1871393A2 A , O
wherein EP1871393A2 A NN O
following EP1871393A2 A VBG O
administration EP1871393A2 A NN O
, EP1871393A2 A , O
the EP1871393A2 A DT O
dosage EP1871393A2 A NN O
formulation EP1871393A2 A NN O
releases EP1871393A2 A VBZ O
the EP1871393A2 A DT O
acarbose EP1871393A2 A JJ O
distal EP1871393A2 A NN O
to EP1871393A2 A TO O
the EP1871393A2 A DT O
gastrointestinal EP1871393A2 A JJ O
sites EP1871393A2 A NNS O
at EP1871393A2 A IN O
which EP1871393A2 A WDT O
acarbose EP1871393A2 A NN O
is EP1871393A2 A VBZ O
absorbed EP1871393A2 A VBN O
. EP1871393A2 A . O

Sustained CN101229119A T VBN O
release CN101229119A T NN O
ocular CN101229119A T JJ O
implant CN101229119A T NN O
for CN101229119A T IN O
treating CN101229119A T VBG O
solid CN101229119A T JJ O
tumors CN101229119A T NNS O
. CN101229119A T . O

The CN101229119A A DT O
sustained CN101229119A A JJ O
release CN101229119A A NN O
excipients CN101229119A A NNS O
essentially CN101229119A A RB O
include CN101229119A A VBP O
macromolecule CN101229119A A NN O
polymer CN101229119A A NN O
which CN101229119A A WDT O
has CN101229119A A VBZ O
a CN101229119A A DT O
biotic CN101229119A A JJ O
capacitability CN101229119A A NN O
and CN101229119A A CC O
can CN101229119A A MD O
be CN101229119A A VB O
degraded CN101229119A A VBN O
and CN101229119A A CC O
absorbed CN101229119A A VBN O
, CN101229119A A , O
mainly CN101229119A A RB O
relating CN101229119A A VBG O
to CN101229119A A TO O
PLA CN101229119A A NNP O
, CN101229119A A , O
and CN101229119A A CC O
PLGA CN101229119A A NNP O
; CN101229119A A : O
the CN101229119A A DT O
release CN101229119A A NN O
regulator CN101229119A A NN O
is CN101229119A A VBZ O
selected CN101229119A A VBN O
from CN101229119A A IN O
one CN101229119A A CD O
or CN101229119A A CC O
combination CN101229119A A NN O
of CN101229119A A IN O
mannitol CN101229119A A NN O
, CN101229119A A , O
sorbitol CN101229119A A NN O
, CN101229119A A , O
xylitol CN101229119A A NNP O
, CN101229119A A , O
oligosaccharide CN101229119A A RB O
, CN101229119A A , O
chitin CN101229119A A NN O
, CN101229119A A , O
potassium CN101229119A A NN O
salt CN101229119A A NN O
, CN101229119A A , O
sodium CN101229119A A NN O
salt CN101229119A A NN O
, CN101229119A A , O
hyaluronic CN101229119A A JJ O
acid CN101229119A A NN O
, CN101229119A A , O
collagen CN101229119A A NN O
, CN101229119A A , O
chondroitin CN101229119A A NN O
, CN101229119A A , O
gelatin CN101229119A A NN O
and CN101229119A A CC O
albumin CN101229119A A NN I-UN
. CN101229119A A . O

Pharmaceutical CN102716113A T JJ O
composition CN102716113A T NN O
comprising CN102716113A T VBG O
curzerene CN102716113A T NN O
. CN102716113A T . O

Medicinal CN103520725A T JJ O
composition CN103520725A T NN O
for CN103520725A T IN O
treating CN103520725A T VBG O
emesis CN103520725A T NN O
. CN103520725A T . O

The CN103520725A A DT O
invention CN103520725A A NN O
provides CN103520725A A VBZ O
a CN103520725A A DT O
medicinal CN103520725A A JJ O
composition CN103520725A A NN O
containing CN103520725A A VBG O
a CN103520725A A DT O
neurokinin CN103520725A A JJ I-UN
1 CN103520725A A CD I-UN
( CN103520725A A ( I-UN
NK-1 CN103520725A A NNP I-UN
) CN103520725A A ) I-UN
receptor CN103520725A A NN I-UN
antagonist CN103520725A A NN O
, CN103520725A A , O
a CN103520725A A DT O
5-hydroxytryptamine CN103520725A A JJ I-UN
3 CN103520725A A CD I-UN
( CN103520725A A ( I-UN
5HT-3 CN103520725A A JJ I-UN
) CN103520725A A ) I-UN
receptor CN103520725A A NN I-UN
antagonist CN103520725A A NN O
and CN103520725A A CC O
adrenocortical CN103520725A A JJ O
hormone CN103520725A A NN O
. CN103520725A A . O

The CN103520725A A DT O
medicinal CN103520725A A JJ O
composition CN103520725A A NN O
adopts CN103520725A A VBZ O
a CN103520725A A DT O
NK-1 CN103520725A A JJ I-UN
receptor CN103520725A A NN I-UN
antagonist CN103520725A A NN O
, CN103520725A A , O
a CN103520725A A DT O
5HT-3 CN103520725A A JJ I-UN
receptor CN103520725A A NN O
antagonist CN103520725A A NN O
and CN103520725A A CC O
adrenocortical CN103520725A A JJ O
hormone CN103520725A A NN O
as CN103520725A A IN O
active CN103520725A A JJ O
components CN103520725A A NNS O
, CN103520725A A , O
is CN103520725A A VBZ O
added CN103520725A A VBN O
with CN103520725A A IN O
certain CN103520725A A JJ O
auxiliaries CN103520725A A NNS O
with CN103520725A A IN O
specific CN103520725A A JJ O
spices CN103520725A A NNS O
and CN103520725A A CC O
proportion CN103520725A A NN O
to CN103520725A A TO O
prepare CN103520725A A VB O
and CN103520725A A CC O
develop CN103520725A A VB O
an CN103520725A A DT O
oral CN103520725A A JJ O
preparation CN103520725A A NN O
according CN103520725A A VBG O
to CN103520725A A TO O
a CN103520725A A DT O
technical CN103520725A A JJ O
means CN103520725A A NNS O
specified CN103520725A A VBN O
in CN103520725A A IN O
the CN103520725A A DT O
invention CN103520725A A NN O
. CN103520725A A . O

The CN103520725A A DT O
invention CN103520725A A NN O
aims CN103520725A A VBZ O
to CN103520725A A TO O
provide CN103520725A A VB O
a CN103520725A A DT O
medicinal CN103520725A A JJ O
composition CN103520725A A NN O
preparation CN103520725A A NN O
which CN103520725A A WDT O
can CN103520725A A MD O
prevent CN103520725A A VB O
and CN103520725A A CC O
treat CN103520725A A VB O
emesis CN103520725A A NN O
more CN103520725A A RBR O
conveniently CN103520725A A RB O
by CN103520725A A IN O
utilizing CN103520725A A VBG O
the CN103520725A A DT O
NK-1 CN103520725A A NNP I-UN
receptor CN103520725A A NN I-UN
antagonist CN103520725A A NN O
, CN103520725A A , O
the CN103520725A A DT O
5HT-3 CN103520725A A JJ I-UN
receptor CN103520725A A NN O
antagonist CN103520725A A NN O
and CN103520725A A CC O
adrenocortical CN103520725A A JJ O
hormone CN103520725A A NN O
, CN103520725A A , O
thereby CN103520725A A RB O
improving CN103520725A A VBG O
the CN103520725A A DT O
compliance CN103520725A A NN O
of CN103520725A A IN O
a CN103520725A A DT O
patient CN103520725A A NN O
. CN103520725A A . O

Tetrodotoxin CN101317846B T NNP O
formulation CN101317846B T NN O
for CN101317846B T IN O
drug CN101317846B T NN O
rehabilitation CN101317846B T NN O
, CN101317846B T , O
pain CN101317846B T NN O
ease CN101317846B T NN O
. CN101317846B T . O

Selective US20110184033 T JJ O
Ligands US20110184033 T NNP O
for US20110184033 T IN O
the US20110184033 T DT O
Dopamine US20110184033 T NNP I-UN
3 US20110184033 T CD I-UN
( US20110184033 T ( I-UN
D3 US20110184033 T NNP I-UN
) US20110184033 T ) I-UN
Receptor US20110184033 T NNP I-UN
and US20110184033 T CC O
Methods US20110184033 T NNP O
of US20110184033 T IN O
using US20110184033 T VBG O
the US20110184033 T DT O
Same US20110184033 T NNP O
. US20110184033 T . O

Potent US20110184033 A NN O
and US20110184033 A CC O
selective US20110184033 A JJ O
ligands US20110184033 A NNS O
for US20110184033 A IN O
the US20110184033 A DT O
dopamine US20110184033 A NN I-UN
3 US20110184033 A CD I-UN
( US20110184033 A ( I-UN
D3 US20110184033 A NNP I-UN
) US20110184033 A ) I-UN
receptor US20110184033 A NN I-UN
are US20110184033 A VBP O
disclosed US20110184033 A VBN O
. US20110184033 A . O

The US20110184033 A DT O
D3 US20110184033 A NNP I-UN
receptor US20110184033 A NN I-UN
ligands US20110184033 A NNS O
have US20110184033 A VBP O
a US20110184033 A DT O
structural US20110184033 A JJ O
formula US20110184033 A NN O
( US20110184033 A ( O
I US20110184033 A PRP O
) US20110184033 A ) O
wherein US20110184033 A NN O
X US20110184033 A NNP O
is US20110184033 A VBZ O
C═O US20110184033 A NNP O
or US20110184033 A CC O
SO2 US20110184033 A NNP O
, US20110184033 A , O
R1 US20110184033 A NNP O
is US20110184033 A VBZ O
C1-6 US20110184033 A NNP O
alkyl US20110184033 A NN O
, US20110184033 A , O
R2 US20110184033 A NNP O
is US20110184033 A VBZ O
aryl US20110184033 A JJ O
, US20110184033 A , O
heteroaryl US20110184033 A NN O
, US20110184033 A , O
aryl US20110184033 A NN O
, US20110184033 A , O
— US20110184033 A NNP O
( US20110184033 A ( O
CH2 US20110184033 A NNP O
) US20110184033 A ) O
1-3aryl US20110184033 A CD O
, US20110184033 A , O
or US20110184033 A CC O
— US20110184033 A NNP O
( US20110184033 A ( O
CH2 US20110184033 A NNP O
) US20110184033 A ) O
1-3heteroaryl US20110184033 A CD O
, US20110184033 A , O
and US20110184033 A CC O
n US20110184033 A NN O
is US20110184033 A VBZ O
0 US20110184033 A CD O
or US20110184033 A CC O
1 US20110184033 A CD O
. US20110184033 A . O

Methods US20110184033 A NNS O
of US20110184033 A IN O
using US20110184033 A VBG O
the US20110184033 A DT O
D3 US20110184033 A NNP I-UN
receptor US20110184033 A NN I-UN
ligands US20110184033 A VBZ O
in US20110184033 A IN O
the US20110184033 A DT O
treatment US20110184033 A NN O
of US20110184033 A IN O
diseases US20110184033 A NNS O
and US20110184033 A CC O
conditions US20110184033 A NNS O
wherein US20110184033 A VBP O
modulation US20110184033 A NN O
of US20110184033 A IN O
the US20110184033 A DT O
D3 US20110184033 A NNP I-UN
receptor US20110184033 A NN I-UN
provides US20110184033 A VBZ O
a US20110184033 A DT O
benefit US20110184033 A NN O
also US20110184033 A RB O
are US20110184033 A VBP O
disclosed US20110184033 A VBN O
. US20110184033 A . O

Composition WO2009086934A1 T NN O
for WO2009086934A1 T IN O
treating WO2009086934A1 T VBG O
scalp WO2009086934A1 T NN O
and WO2009086934A1 T CC O
skin WO2009086934A1 T NN O
. WO2009086934A1 T . O

Application CN101513399B T NN O
of CN101513399B T IN O
T-2 CN101513399B T NNP O
toxin CN101513399B T NN O
in CN101513399B T IN O
the CN101513399B T DT O
preparation CN101513399B T NN O
of CN101513399B T IN O
drugs CN101513399B T NNS O
for CN101513399B T IN O
treating CN101513399B T VBG O
bone CN101513399B T NN O
cancers CN101513399B T NNS O
and CN101513399B T CC O
myeloproliferative CN101513399B T JJ O
disorder CN101513399B T NN O
. CN101513399B T . O

Tablet CN201625211U T NNP O
capsule CN201625211U T NN O
filled CN201625211U T VBN O
with CN201625211U T IN O
Dihydroergocryptine CN201625211U T NNP O
mesylate CN201625211U T VBP O
A CN201625211U T NNP O
tablet CN201625211U T NN O
and CN201625211U T CC O
caffeine CN201625211U T JJ O
tablet CN201625211U T NN O
. CN201625211U T . O

Combined WO2009096377A1 T VBN O
use WO2009096377A1 T NN O
of WO2009096377A1 T IN O
angiogenesis WO2009096377A1 T NN O
inhibitor WO2009096377A1 T NN O
and WO2009096377A1 T CC O
taxane WO2009096377A1 T NN O
. WO2009096377A1 T . O

Medicinal CN101264329A T JJ O
composition CN101264329A T NN O
for CN101264329A T IN O
diminishing CN101264329A T VBG O
inflammation CN101264329A T NN O
and CN101264329A T CC O
ease CN101264329A T NN O
pain CN101264329A T NN O
and CN101264329A T CC O
preparation CN101264329A T NN O
and CN101264329A T CC O
use CN101264329A T NN O
thereof CN101264329A T NN O
. CN101264329A T . O

Fat WO2007116981A1 T NNP O
accumulation WO2007116981A1 T NN O
inhibitor WO2007116981A1 T NN O
. WO2007116981A1 T . O

Disclosed WO2007116981A1 A VBN O
are WO2007116981A1 A VBP O
: WO2007116981A1 A : O
an WO2007116981A1 A DT O
agent WO2007116981A1 A NN O
for WO2007116981A1 A IN O
inhibiting WO2007116981A1 A VBG O
the WO2007116981A1 A DT O
accumulation WO2007116981A1 A NN O
of WO2007116981A1 A IN O
a WO2007116981A1 A DT O
fat WO2007116981A1 A NN O
in WO2007116981A1 A IN O
an WO2007116981A1 A DT O
adipocyte WO2007116981A1 A NN O
, WO2007116981A1 A , O
which WO2007116981A1 A WDT O
comprises WO2007116981A1 A VBZ O
a WO2007116981A1 A DT O
milk-derived WO2007116981A1 A JJ O
phospholipid WO2007116981A1 A NN O
as WO2007116981A1 A IN O
an WO2007116981A1 A DT O
active WO2007116981A1 A JJ O
ingredient WO2007116981A1 A NN O
; WO2007116981A1 A : O
a WO2007116981A1 A DT O
beverage/food WO2007116981A1 A NN O
for WO2007116981A1 A IN O
inhibiting WO2007116981A1 A VBG O
the WO2007116981A1 A DT O
accumulation WO2007116981A1 A NN O
of WO2007116981A1 A IN O
a WO2007116981A1 A DT O
fat WO2007116981A1 A NN O
in WO2007116981A1 A IN O
an WO2007116981A1 A DT O
adipocyte WO2007116981A1 A NN O
, WO2007116981A1 A , O
which WO2007116981A1 A WDT O
contains WO2007116981A1 A VBZ O
a WO2007116981A1 A DT O
milk-derived WO2007116981A1 A JJ O
phospholipid WO2007116981A1 A NN O
; WO2007116981A1 A : O
an WO2007116981A1 A DT O
agent WO2007116981A1 A NN O
and WO2007116981A1 A CC O
a WO2007116981A1 A DT O
beverage/food WO2007116981A1 A NN O
for WO2007116981A1 A IN O
inhibiting WO2007116981A1 A VBG O
the WO2007116981A1 A DT O
accumulation WO2007116981A1 A NN O
of WO2007116981A1 A IN O
a WO2007116981A1 A DT O
visceral WO2007116981A1 A JJ O
fat WO2007116981A1 A NN O
, WO2007116981A1 A , O
each WO2007116981A1 A DT O
of WO2007116981A1 A IN O
which WO2007116981A1 A WDT O
comprises WO2007116981A1 A VBZ O
a WO2007116981A1 A DT O
phospholipid WO2007116981A1 A JJ O
having WO2007116981A1 A VBG O
sphingosine WO2007116981A1 A NN O
or WO2007116981A1 A CC O
a WO2007116981A1 A DT O
derivative WO2007116981A1 A JJ O
thereof WO2007116981A1 A NN O
as WO2007116981A1 A IN O
an WO2007116981A1 A DT O
active WO2007116981A1 A JJ O
ingredient WO2007116981A1 A NN O
; WO2007116981A1 A : O
and WO2007116981A1 A CC O
an WO2007116981A1 A DT O
agent WO2007116981A1 A NN O
and WO2007116981A1 A CC O
a WO2007116981A1 A DT O
beverage/food WO2007116981A1 A NN O
for WO2007116981A1 A IN O
promoting WO2007116981A1 A VBG O
the WO2007116981A1 A DT O
increase WO2007116981A1 A NN O
in WO2007116981A1 A IN O
blood WO2007116981A1 A NN O
adiponectin WO2007116981A1 A NN I-UN
level WO2007116981A1 A NN O
and/or WO2007116981A1 A IN O
inhibiting WO2007116981A1 A VBG O
the WO2007116981A1 A DT O
decrease WO2007116981A1 A NN O
in WO2007116981A1 A IN O
blood WO2007116981A1 A NN O
adiponectin WO2007116981A1 A NN I-UN
level WO2007116981A1 A NN O
, WO2007116981A1 A , O
each WO2007116981A1 A DT O
of WO2007116981A1 A IN O
which WO2007116981A1 A WDT O
comprises WO2007116981A1 A VBZ O
a WO2007116981A1 A DT O
phospholipid WO2007116981A1 A JJ O
having WO2007116981A1 A VBG O
sphingosine WO2007116981A1 A NN O
or WO2007116981A1 A CC O
a WO2007116981A1 A DT O
derivative WO2007116981A1 A JJ O
thereof WO2007116981A1 A NN O
as WO2007116981A1 A IN O
an WO2007116981A1 A DT O
active WO2007116981A1 A JJ O
ingredient WO2007116981A1 A NN O
. WO2007116981A1 A . O

Cellulose-based US20100178332 T JJ O
fine US20100178332 T NN O
core US20100178332 T NN O
particle US20100178332 T NN O
and US20100178332 T CC O
process US20100178332 T NN O
for US20100178332 T IN O
producing US20100178332 T VBG O
the US20100178332 T DT O
same US20100178332 T JJ O
. US20100178332 T . O

Method CN101525391B T NNP O
for CN101525391B T IN O
extracting CN101525391B T VBG O
amylase CN101525391B T NN O
from CN101525391B T IN O
liquorice CN101525391B T NN O
and CN101525391B T CC O
application CN101525391B T NN O
thereof CN101525391B T NN O
. CN101525391B T . O

Hydroxy-methyl CA2749218C T JJ O
isoxazole CA2749218C T JJ O
derivatives CA2749218C T NNS O
as CA2749218C T IN O
gaba CA2749218C T NN O
a CA2749218C T DT O
modulators CA2749218C T NNS O
. CA2749218C T . O

The CA2749218C A DT O
active CA2749218C A JJ O
compounds CA2749218C A NNS O
of CA2749218C A IN O
the CA2749218C A DT O
present CA2749218C A JJ O
invention CA2749218C A NN O
have CA2749218C A VBP O
affinity CA2749218C A NN O
and CA2749218C A CC O
selectivity CA2749218C A NN O
for CA2749218C A IN O
GABA CA2749218C A NNP I-UN
A CA2749218C A NNP I-UN
a5 CA2749218C A NN I-UN
receptor CA2749218C A NN O
. CA2749218C A . O

Monatin WO2012169661A1 T NNP O
polyvalent WO2012169661A1 T NN O
metal WO2012169661A1 T NN O
salt WO2012169661A1 T NN O
crystal WO2012169661A1 T NN O
. WO2012169661A1 T . O

Method WO2008034535A1 T NNP O
for WO2008034535A1 T IN O
treating WO2008034535A1 T VBG O
skin WO2008034535A1 T NN O
by WO2008034535A1 T IN O
administering WO2008034535A1 T VBG O
an WO2008034535A1 T DT O
agent WO2008034535A1 T NN O
that WO2008034535A1 T WDT O
decreases WO2008034535A1 T VBZ O
gmcsf WO2008034535A1 T JJ I-UN
release WO2008034535A1 T NN O
from WO2008034535A1 T IN O
keratinocytes WO2008034535A1 T NNS O
. WO2008034535A1 T . O

Suggested WO2008034535A1 A VBN O
is WO2008034535A1 A VBZ O
a WO2008034535A1 A DT O
method WO2008034535A1 A NN O
for WO2008034535A1 A IN O
preventing WO2008034535A1 A VBG O
and/or WO2008034535A1 A JJ O
soothing WO2008034535A1 A VBG O
dry WO2008034535A1 A JJ O
skin WO2008034535A1 A NN O
or WO2008034535A1 A CC O
reactive WO2008034535A1 A JJ O
skin WO2008034535A1 A NN O
against WO2008034535A1 A IN O
external WO2008034535A1 A JJ O
stresses WO2008034535A1 A NNS O
, WO2008034535A1 A , O
characterized WO2008034535A1 A VBN O
in WO2008034535A1 A IN O
that WO2008034535A1 A DT O
keratinocytes WO2008034535A1 A NNS O
are WO2008034535A1 A VBP O
contacted WO2008034535A1 A VBN O
with WO2008034535A1 A IN O
an WO2008034535A1 A DT O
agent WO2008034535A1 A NN O
that WO2008034535A1 A WDT O
decreases WO2008034535A1 A VBZ O
the WO2008034535A1 A DT O
GMCSF WO2008034535A1 A NNP I-UN
release WO2008034535A1 A NN O
from WO2008034535A1 A IN O
keratinocytes WO2008034535A1 A NNS O
. WO2008034535A1 A . O

Itraconazole CN103083262A T NNP O
tablet CN103083262A T NN O
for CN103083262A T IN O
pets CN103083262A T NNS O
and CN103083262A T CC O
preparation CN103083262A T NN O
method CN103083262A T NN O
thereof CN103083262A T NN O
. CN103083262A T . O

A EP1603537A2 T DT O
novel EP1603537A2 T JJ O
formulation EP1603537A2 T NN O
, EP1603537A2 T , O
omeprazole EP1603537A2 T JJ O
antacid EP1603537A2 T NN O
complex-immediate EP1603537A2 T JJ O
release EP1603537A2 T NN O
for EP1603537A2 T IN O
rapid EP1603537A2 T JJ O
and EP1603537A2 T CC O
sustained EP1603537A2 T JJ O
supression EP1603537A2 T NN O
of EP1603537A2 T IN O
gastric EP1603537A2 T JJ O
acid EP1603537A2 T NN O
. EP1603537A2 T . O

In EP1603537A2 A IN O
one EP1603537A2 A CD O
aspect EP1603537A2 A NN O
, EP1603537A2 A , O
the EP1603537A2 A DT O
present EP1603537A2 A JJ O
invention EP1603537A2 A NN O
provides EP1603537A2 A VBZ O
a EP1603537A2 A DT O
pharmaceutical EP1603537A2 A JJ O
composition EP1603537A2 A NN O
comprising EP1603537A2 A VBG O
a EP1603537A2 A DT O
proton EP1603537A2 A NN I-UN
pump EP1603537A2 A NN I-UN
inhibiting EP1603537A2 A VBG O
agent EP1603537A2 A NN O
and EP1603537A2 A CC O
a EP1603537A2 A DT O
buffering EP1603537A2 A NN O
agent EP1603537A2 A NN O
for EP1603537A2 A IN O
oral EP1603537A2 A JJ O
administration EP1603537A2 A NN O
and EP1603537A2 A CC O
ingestion EP1603537A2 A NN O
by EP1603537A2 A IN O
a EP1603537A2 A DT O
subject EP1603537A2 A NN O
. EP1603537A2 A . O

Upon EP1603537A2 A IN O
administration EP1603537A2 A NN O
, EP1603537A2 A , O
the EP1603537A2 A DT O
composition EP1603537A2 A NN O
contacts EP1603537A2 A VBZ O
the EP1603537A2 A DT O
gastric EP1603537A2 A JJ O
fluid EP1603537A2 A NN O
of EP1603537A2 A IN O
the EP1603537A2 A DT O
stomach EP1603537A2 A NN O
and EP1603537A2 A CC O
increases EP1603537A2 A VBZ O
the EP1603537A2 A DT O
gastric EP1603537A2 A JJ O
fluid EP1603537A2 A NN O
pH EP1603537A2 A NN O
of EP1603537A2 A IN O
the EP1603537A2 A DT O
stomach EP1603537A2 A NN O
to EP1603537A2 A TO O
a EP1603537A2 A DT O
pH EP1603537A2 A NN O
that EP1603537A2 A WDT O
substantially EP1603537A2 A RB O
prevents EP1603537A2 A VBZ O
or EP1603537A2 A CC O
inhibits EP1603537A2 A NNS O
acid EP1603537A2 A JJ O
degradation EP1603537A2 A NN O
of EP1603537A2 A IN O
the EP1603537A2 A DT O
proton EP1603537A2 A NN I-UN
pump EP1603537A2 A NN I-UN
inhibiting EP1603537A2 A VBG O
agent EP1603537A2 A NN O
in EP1603537A2 A IN O
the EP1603537A2 A DT O
gastric EP1603537A2 A JJ O
fluid EP1603537A2 A NN O
and EP1603537A2 A CC O
allows EP1603537A2 A VBZ O
a EP1603537A2 A DT O
measurable EP1603537A2 A JJ O
serum EP1603537A2 A JJ O
concentration EP1603537A2 A NN O
of EP1603537A2 A IN O
the EP1603537A2 A DT O
proton EP1603537A2 A NN I-UN
pump EP1603537A2 A NN I-UN
inhibiting EP1603537A2 A VBG O
agent EP1603537A2 A NN O
to EP1603537A2 A TO O
be EP1603537A2 A VB O
absorbed EP1603537A2 A VBN O
into EP1603537A2 A IN O
the EP1603537A2 A DT O
blood EP1603537A2 A NN O
serum EP1603537A2 A NN O
of EP1603537A2 A IN O
the EP1603537A2 A DT O
subject EP1603537A2 A NN O
. EP1603537A2 A . O

Raf US20110257207 T NNP I-UN
inhibitors US20110257207 T NNS O
. US20110257207 T . O

These US20110257207 A DT O
compounds US20110257207 A NNS O
are US20110257207 A VBP O
inhibitors US20110257207 A NNS O
or US20110257207 A CC O
kinases US20110257207 A NNS I-UN
such US20110257207 A JJ O
as US20110257207 A IN O
Raf US20110257207 A NNP I-UN
, US20110257207 A , O
including US20110257207 A VBG O
compounds US20110257207 A NNS O
that US20110257207 A WDT O
show US20110257207 A VBP O
anti-proliferative US20110257207 A JJ O
activity US20110257207 A NN O
, US20110257207 A , O
including US20110257207 A VBG O
against US20110257207 A IN O
tumor US20110257207 A NN O
cells US20110257207 A NNS O
, US20110257207 A , O
and US20110257207 A CC O
are US20110257207 A VBP O
useful US20110257207 A JJ O
in US20110257207 A IN O
the US20110257207 A DT O
treatment US20110257207 A NN O
of US20110257207 A IN O
diseases US20110257207 A NNS O
including US20110257207 A VBG O
cancer US20110257207 A NN O
. US20110257207 A . O

Compound CN101502593A T NNP O
formulation CN101502593A T NN O
of CN101502593A T IN O
washing CN101502593A T VBG O
lotion CN101502593A T NN O
for CN101502593A T IN O
treating CN101502593A T VBG O
beriberi CN101502593A T NN O
and CN101502593A T CC O
dermatophytosis CN101502593A T NN O
. CN101502593A T . O

Procaine CN102058523A T NNP O
injection CN102058523A T NN O
. CN102058523A T . O

Thiolalkyl US7138543 T NNP O
benzoic US7138543 T NN O
acid US7138543 T NN O
derivatives US7138543 T NNS O
. US7138543 T . O

The US7138543 A DT O
present US7138543 A JJ O
invention US7138543 A NN O
relates US7138543 A VBZ O
to US7138543 A TO O
new US7138543 A JJ O
thiolalkyl US7138543 A NN O
benzoic US7138543 A NN O
acids US7138543 A NNS O
, US7138543 A , O
pharmaceutical US7138543 A JJ O
compositions US7138543 A NNS O
and US7138543 A CC O
diagnostic US7138543 A JJ O
kits US7138543 A NNS O
comprising US7138543 A VBG O
such US7138543 A JJ O
compounds US7138543 A NNS O
, US7138543 A , O
and US7138543 A CC O
methods US7138543 A NNS O
of US7138543 A IN O
using US7138543 A VBG O
such US7138543 A JJ O
compounds US7138543 A NNS O
for US7138543 A IN O
inhibiting US7138543 A VBG O
NAALADase US7138543 A NNP I-UN
enzyme US7138543 A NN O
activity US7138543 A NN O
, US7138543 A , O
detecting US7138543 A VBG O
diseases US7138543 A NNS O
where US7138543 A WRB O
NAALADase US7138543 A NNP I-UN
levels US7138543 A NNS O
are US7138543 A VBP O
altered US7138543 A VBN O
, US7138543 A , O
effecting US7138543 A VBG O
neuronal US7138543 A JJ O
activity US7138543 A NN O
, US7138543 A , O
effecting US7138543 A VBG O
TGF-β US7138543 A JJ I-UN
activity US7138543 A NN O
, US7138543 A , O
inhibiting US7138543 A VBG O
angiogenesis US7138543 A NN O
, US7138543 A , O
and US7138543 A CC O
treating US7138543 A VBG O
glutamate US7138543 A NN O
abnormalities US7138543 A NNS O
, US7138543 A , O
neuropathy US7138543 A JJ O
, US7138543 A , O
pain US7138543 A NN O
, US7138543 A , O
compulsive US7138543 A JJ O
disorders US7138543 A NNS O
, US7138543 A , O
prostate US7138543 A NN O
diseases US7138543 A NNS O
, US7138543 A , O
cancers US7138543 A NNS O
, US7138543 A , O
glaucoma US7138543 A NN O
, US7138543 A , O
retinal US7138543 A JJ O
disorders US7138543 A NNS O
, US7138543 A , O
and US7138543 A CC O
cancer US7138543 A NN O
. US7138543 A . O

Antitumor US20110021517 T NNP O
combination US20110021517 T NN O
comprising US20110021517 T VBG O
a US20110021517 T DT O
morpholinyl US20110021517 T JJ O
anthracycline US20110021517 T NN O
derivative US20110021517 T NN O
and US20110021517 T CC O
demethylating US20110021517 T VBG O
agents US20110021517 T NNS O
. US20110021517 T . O

Compositions EP2773369A1 T NNS O
and EP2773369A1 T CC O
methods EP2773369A1 T NNS O
for EP2773369A1 T IN O
preventing EP2773369A1 T VBG O
and EP2773369A1 T CC O
treating EP2773369A1 T VBG O
oral EP2773369A1 T JJ O
diseases EP2773369A1 T NNS O
. EP2773369A1 T . O

2-3-disubstituted US20050131051 T JJ O
quinuclidiness US20050131051 T NN O
as US20050131051 T IN O
modulators US20050131051 T NNS O
of US20050131051 T IN O
monoamine US20050131051 T NN I-UN
transporters US20050131051 T NNS I-UN
and US20050131051 T CC O
theraperutic US20050131051 T JJ O
and US20050131051 T CC O
diagnostic US20050131051 T JJ O
methods US20050131051 T NNS O
based US20050131051 T VBN O
thereon US20050131051 T NN O
. US20050131051 T . O

Compound CN102018925A T NNP O
preparation CN102018925A T NN O
for CN102018925A T IN O
treating CN102018925A T VBG O
arthritis CN102018925A T NN O
. CN102018925A T . O

Preparation CA2353544C T NN O
that CA2353544C T WDT O
contains CA2353544C T VBZ O
oligosaccharides CA2353544C T NNS O
and CA2353544C T CC O
probiotics CA2353544C T NNS O
. CA2353544C T . O

Anti-inflammatory WO2011153502A3 T JJ O
and WO2011153502A3 T CC O
quorum WO2011153502A3 T JJ O
sensing WO2011153502A3 T VBG O
inhibition WO2011153502A3 T NN O
compounds WO2011153502A3 T NNS O
and WO2011153502A3 T CC O
methods WO2011153502A3 T NNS O
of WO2011153502A3 T IN O
making WO2011153502A3 T VBG O
and WO2011153502A3 T CC O
using WO2011153502A3 T VBG O
them WO2011153502A3 T PRP O
. WO2011153502A3 T . O

The WO2011153502A3 A DT O
invention WO2011153502A3 A NN O
provides WO2011153502A3 A VBZ O
novel WO2011153502A3 A JJ O
compositions WO2011153502A3 A NNS O
based WO2011153502A3 A VBN O
on WO2011153502A3 A IN O
a WO2011153502A3 A DT O
structure WO2011153502A3 A NN O
designated WO2011153502A3 A VBN O
as WO2011153502A3 A IN O
`` WO2011153502A3 A `` O
Honaucin WO2011153502A3 A NNP O
A WO2011153502A3 A NNP O
'' WO2011153502A3 A '' O
, WO2011153502A3 A , O
including WO2011153502A3 A VBG O
Honaucin WO2011153502A3 A NNP O
A WO2011153502A3 A NNP O
variants WO2011153502A3 A NNS O
and WO2011153502A3 A CC O
analogs WO2011153502A3 A NNS O
, WO2011153502A3 A , O
and WO2011153502A3 A CC O
pharmaceutical WO2011153502A3 A JJ O
compositions WO2011153502A3 A NNS O
, WO2011153502A3 A , O
liposomes WO2011153502A3 A NNS O
and WO2011153502A3 A CC O
nanoparticles WO2011153502A3 A NNS O
comprising WO2011153502A3 A VBG O
them WO2011153502A3 A PRP O
, WO2011153502A3 A , O
and WO2011153502A3 A CC O
methods WO2011153502A3 A NNS O
of WO2011153502A3 A IN O
making WO2011153502A3 A VBG O
and WO2011153502A3 A CC O
using WO2011153502A3 A VBG O
them WO2011153502A3 A PRP O
. WO2011153502A3 A . O

In WO2011153502A3 A IN O
one WO2011153502A3 A CD O
embodiment WO2011153502A3 A NN O
, WO2011153502A3 A , O
these WO2011153502A3 A DT O
Honaucin WO2011153502A3 A NNP O
A WO2011153502A3 A NNP O
compounds WO2011153502A3 A VBZ O
, WO2011153502A3 A , O
and WO2011153502A3 A CC O
variants WO2011153502A3 A NNS O
and WO2011153502A3 A CC O
analogs WO2011153502A3 A NNS O
thereof WO2011153502A3 A NNS O
are WO2011153502A3 A VBP O
used WO2011153502A3 A VBN O
to WO2011153502A3 A TO O
ameliorate WO2011153502A3 A VB O
( WO2011153502A3 A ( O
including WO2011153502A3 A VBG O
to WO2011153502A3 A TO O
treat WO2011153502A3 A VB O
or WO2011153502A3 A CC O
prevent WO2011153502A3 A VB O
) WO2011153502A3 A ) O
inflammation WO2011153502A3 A NN O
. WO2011153502A3 A . O

In WO2011153502A3 A IN O
one WO2011153502A3 A CD O
embodiment WO2011153502A3 A NN O
, WO2011153502A3 A , O
these WO2011153502A3 A DT O
Honaucin WO2011153502A3 A NNP O
A WO2011153502A3 A NNP O
compounds WO2011153502A3 A VBZ O
, WO2011153502A3 A , O
and WO2011153502A3 A CC O
variants WO2011153502A3 A NNS O
and WO2011153502A3 A CC O
analogs WO2011153502A3 A NNS O
thereof WO2011153502A3 A NNS O
are WO2011153502A3 A VBP O
used WO2011153502A3 A VBN O
to WO2011153502A3 A TO O
ameliorate WO2011153502A3 A VB O
( WO2011153502A3 A ( O
including WO2011153502A3 A VBG O
to WO2011153502A3 A TO O
treat WO2011153502A3 A VB O
or WO2011153502A3 A CC O
prevent WO2011153502A3 A VB O
) WO2011153502A3 A ) O
inflammation WO2011153502A3 A NN O
. WO2011153502A3 A . O

In WO2011153502A3 A IN O
one WO2011153502A3 A CD O
embodiment WO2011153502A3 A NN O
, WO2011153502A3 A , O
these WO2011153502A3 A DT O
Honaucin WO2011153502A3 A NNP O
A WO2011153502A3 A NNP O
compounds WO2011153502A3 A VBZ O
, WO2011153502A3 A , O
and WO2011153502A3 A CC O
variants WO2011153502A3 A NNS O
and WO2011153502A3 A CC O
analogs WO2011153502A3 A NNS O
thereof WO2011153502A3 A NNS O
are WO2011153502A3 A VBP O
used WO2011153502A3 A VBN O
as WO2011153502A3 A IN O
bacterial WO2011153502A3 A JJ O
quorumsensing WO2011153502A3 A VBG O
inhibitors WO2011153502A3 A NNS O
. WO2011153502A3 A . O

Accordingly WO2011153502A3 A RB O
, WO2011153502A3 A , O
in WO2011153502A3 A IN O
alternative WO2011153502A3 A JJ O
embodiments WO2011153502A3 A NNS O
the WO2011153502A3 A DT O
compositions WO2011153502A3 A NNS O
of WO2011153502A3 A IN O
the WO2011153502A3 A DT O
invention WO2011153502A3 A NN O
are WO2011153502A3 A VBP O
used WO2011153502A3 A VBN O
as WO2011153502A3 A IN O
anti-bacterial WO2011153502A3 A JJ O
agents WO2011153502A3 A NNS O
. WO2011153502A3 A . O

Lofexidine EP1762239A1 T NNP O
for EP1762239A1 T IN O
intraspinal EP1762239A1 T JJ O
administration EP1762239A1 T NN O
. EP1762239A1 T . O

Antibody EP1474120B1 T NN O
having EP1474120B1 T VBG O
a EP1474120B1 T DT O
t-cell EP1474120B1 T JJ O
receptor-like EP1474120B1 T JJ O
specificity EP1474120B1 T NN O
, EP1474120B1 T , O
yet EP1474120B1 T RB O
higher EP1474120B1 T JJR O
affinity EP1474120B1 T NN O
, EP1474120B1 T , O
and EP1474120B1 T CC O
the EP1474120B1 T DT O
use EP1474120B1 T NN O
of EP1474120B1 T IN O
same EP1474120B1 T JJ O
in EP1474120B1 T IN O
the EP1474120B1 T DT O
detection EP1474120B1 T NN O
and EP1474120B1 T CC O
treatment EP1474120B1 T NN O
of EP1474120B1 T IN O
cancer EP1474120B1 T NN O
, EP1474120B1 T , O
viral EP1474120B1 T JJ O
infection EP1474120B1 T NN O
and EP1474120B1 T CC O
autoimmune EP1474120B1 T JJ O
disease EP1474120B1 T NN O
. EP1474120B1 T . O

An EP1474120B1 A DT O
isolated EP1474120B1 A JJ O
molecule EP1474120B1 A NN O
which EP1474120B1 A WDT O
comprises EP1474120B1 A VBZ O
an EP1474120B1 A DT O
antibody EP1474120B1 A NN O
specifically EP1474120B1 A RB O
bindable EP1474120B1 A JJ O
with EP1474120B1 A IN O
a EP1474120B1 A DT O
binding EP1474120B1 A NN O
affinity EP1474120B1 A NN O
below EP1474120B1 A IN O
20 EP1474120B1 A CD O
nanomolar EP1474120B1 A JJ O
, EP1474120B1 A , O
preferably EP1474120B1 A RB O
below EP1474120B1 A IN O
10 EP1474120B1 A CD O
nanomolar EP1474120B1 A JJ O
, EP1474120B1 A , O
to EP1474120B1 A TO O
a EP1474120B1 A DT O
human EP1474120B1 A JJ O
major EP1474120B1 A JJ I-UN
histocompatibility EP1474120B1 A NN I-UN
complex EP1474120B1 A NN I-UN
( EP1474120B1 A ( I-UN
MHC EP1474120B1 A NNP I-UN
) EP1474120B1 A ) I-UN
class EP1474120B1 A NN I-UN
I EP1474120B1 A PRP I-UN
being EP1474120B1 A VBG O
complexed EP1474120B1 A VBN O
with EP1474120B1 A IN O
a EP1474120B1 A DT O
HLA-restricted EP1474120B1 A JJ O
antigen EP1474120B1 A NN O
and EP1474120B1 A CC O
optionally EP1474120B1 A RB O
further EP1474120B1 A JJ O
comprises EP1474120B1 A NNS O
an EP1474120B1 A DT O
identifiable EP1474120B1 A JJ O
or EP1474120B1 A CC O
therapeutic EP1474120B1 A JJ O
moiety EP1474120B1 A NN O
conjugated EP1474120B1 A VBD O
to EP1474120B1 A TO O
the EP1474120B1 A DT O
antibody EP1474120B1 A NN O
. EP1474120B1 A . O

Penem CN101367804B T NNP O
derivant CN101367804B T NN O
containing CN101367804B T VBG O
adamantane CN101367804B T NN O
. CN101367804B T . O

Xylo-oligo CN1977850A T JJ O
saccharide CN1977850A T JJ O
tablet CN1977850A T NN O
and CN1977850A T CC O
its CN1977850A T PRP$ O
preparing CN1977850A T NN O
method CN1977850A T NN O
. CN1977850A T . O

Ophthalmic US20120148519 T JJ O
lens US20120148519 T NNS O
. US20120148519 T . O

Method US20060194855 T NNP O
of US20060194855 T IN O
treating US20060194855 T VBG O
migraines US20060194855 T NNS O
and US20060194855 T CC O
pharmaceutical US20060194855 T JJ O
compositions US20060194855 T NNS O
. US20060194855 T . O

A US20060194855 A DT O
combination US20060194855 A NN O
of US20060194855 A IN O
a US20060194855 A DT O
5HT1B/1D US20060194855 A CD I-UN
agonist US20060194855 A NN O
and US20060194855 A CC O
a US20060194855 A DT O
COX-2 US20060194855 A JJ I-UN
selective US20060194855 A JJ O
inhibitor US20060194855 A NN O
is US20060194855 A VBZ O
useful US20060194855 A JJ O
in US20060194855 A IN O
the US20060194855 A DT O
treatment US20060194855 A NN O
and US20060194855 A CC O
or US20060194855 A CC O
prevention US20060194855 A NN O
of US20060194855 A IN O
migraine US20060194855 A NN O
. US20060194855 A . O

Crystalline WO2008064615A2 T NNP O
and WO2008064615A2 T CC O
amorphous WO2008064615A2 T JJ O
forms WO2008064615A2 T NNS O
of WO2008064615A2 T IN O
rimonabant WO2008064615A2 T NN O
and WO2008064615A2 T CC O
processes WO2008064615A2 T NNS O
for WO2008064615A2 T IN O
obtaining WO2008064615A2 T VBG O
them WO2008064615A2 T PRP O
. WO2008064615A2 T . O

Novel WO2008064615A2 A NNP O
crystalline WO2008064615A2 A NN O
polymorphic WO2008064615A2 A JJ O
Form WO2008064615A2 A NNP O
III WO2008064615A2 A NNP O
of WO2008064615A2 A IN O
rimonabant WO2008064615A2 A NN O
and WO2008064615A2 A CC O
an WO2008064615A2 A DT O
amorphous WO2008064615A2 A JJ O
form WO2008064615A2 A NN O
of WO2008064615A2 A IN O
rimonabant WO2008064615A2 A NN O
. WO2008064615A2 A . O

Crystalline WO2008064615A2 A NNP O
form WO2008064615A2 A NN O
III WO2008064615A2 A NNP O
of WO2008064615A2 A IN O
rimonabant WO2008064615A2 A NN O
is WO2008064615A2 A VBZ O
prepared WO2008064615A2 A VBN O
by WO2008064615A2 A IN O
dissolving WO2008064615A2 A VBG O
rimonabant WO2008064615A2 A NN O
in WO2008064615A2 A IN O
an WO2008064615A2 A DT O
aprotic WO2008064615A2 A JJ O
polar WO2008064615A2 A JJ O
solvent WO2008064615A2 A NN O
such WO2008064615A2 A JJ O
as WO2008064615A2 A IN O
acetonitrile WO2008064615A2 A NN O
or WO2008064615A2 A CC O
tetrahydrofuran WO2008064615A2 A NN O
, WO2008064615A2 A , O
pouring WO2008064615A2 A VBG O
the WO2008064615A2 A DT O
solution WO2008064615A2 A NN O
into WO2008064615A2 A IN O
water WO2008064615A2 A NN O
and WO2008064615A2 A CC O
stirring WO2008064615A2 A VBG O
the WO2008064615A2 A DT O
resulting WO2008064615A2 A JJ O
mixture WO2008064615A2 A NN O
. WO2008064615A2 A . O

Amorphous WO2008064615A2 A JJ O
form WO2008064615A2 A NN O
of WO2008064615A2 A IN O
rimonabant WO2008064615A2 A NN O
is WO2008064615A2 A VBZ O
prepared WO2008064615A2 A VBN O
by WO2008064615A2 A IN O
dissolving WO2008064615A2 A VBG O
in WO2008064615A2 A IN O
and WO2008064615A2 A CC O
alcohol WO2008064615A2 A NN O
of WO2008064615A2 A IN O
formula WO2008064615A2 A NN O
ROH WO2008064615A2 A NNP O
, WO2008064615A2 A , O
wherein WO2008064615A2 A NN O
R WO2008064615A2 A NNP O
is WO2008064615A2 A VBZ O
an WO2008064615A2 A DT O
alkyl WO2008064615A2 A NN O
, WO2008064615A2 A , O
such WO2008064615A2 A JJ O
as WO2008064615A2 A IN O
methanol WO2008064615A2 A NN O
or WO2008064615A2 A CC O
isopropyl WO2008064615A2 A NN O
alcohol WO2008064615A2 A NN O
, WO2008064615A2 A , O
and WO2008064615A2 A CC O
stirring WO2008064615A2 A VBG O
the WO2008064615A2 A DT O
mixture WO2008064615A2 A NN O
. WO2008064615A2 A . O

Rimonabant WO2008064615A2 A NN O
of WO2008064615A2 A IN O
formula WO2008064615A2 A NN O
( WO2008064615A2 A ( O
I WO2008064615A2 A PRP O
) WO2008064615A2 A ) O
is WO2008064615A2 A VBZ O
obtained WO2008064615A2 A VBN O
in WO2008064615A2 A IN O
such WO2008064615A2 A JJ O
a WO2008064615A2 A DT O
way WO2008064615A2 A NN O
that WO2008064615A2 A IN O
an WO2008064615A2 A DT O
ester WO2008064615A2 A NN O
of WO2008064615A2 A IN O
5- WO2008064615A2 A JJ O
( WO2008064615A2 A ( O
4-chlorophenyl WO2008064615A2 A JJ O
) WO2008064615A2 A ) O
-l- WO2008064615A2 A NN O
( WO2008064615A2 A ( O
2,4-dichlorophenyl WO2008064615A2 A JJ O
) WO2008064615A2 A ) O
-4-methyl-lH-pyrazole-3-carboxylic WO2008064615A2 A JJ O
acid WO2008064615A2 A NN O
of WO2008064615A2 A IN O
formula WO2008064615A2 A NN O
( WO2008064615A2 A ( O
III WO2008064615A2 A NNP O
) WO2008064615A2 A ) O
, WO2008064615A2 A , O
wherein WO2008064615A2 A JJ O
R WO2008064615A2 A NNP O
is WO2008064615A2 A VBZ O
a WO2008064615A2 A DT O
Cl-C5 WO2008064615A2 A JJ O
alkyl WO2008064615A2 A NN O
group WO2008064615A2 A NN O
, WO2008064615A2 A , O
phenyl WO2008064615A2 A NN O
group WO2008064615A2 A NN O
or WO2008064615A2 A CC O
a WO2008064615A2 A DT O
substituted WO2008064615A2 A JJ O
phenyl WO2008064615A2 A NN O
group WO2008064615A2 A NN O
, WO2008064615A2 A , O
preferably WO2008064615A2 A RB O
methyl WO2008064615A2 A NN O
or WO2008064615A2 A CC O
ethyl WO2008064615A2 A NN O
, WO2008064615A2 A , O
is WO2008064615A2 A VBZ O
reacted WO2008064615A2 A VBN O
, WO2008064615A2 A , O
in WO2008064615A2 A IN O
a WO2008064615A2 A DT O
solvent WO2008064615A2 A NN O
, WO2008064615A2 A , O
preferably WO2008064615A2 A RB O
in WO2008064615A2 A IN O
a WO2008064615A2 A DT O
solvent WO2008064615A2 A NN O
from WO2008064615A2 A IN O
the WO2008064615A2 A DT O
group WO2008064615A2 A NN O
of WO2008064615A2 A IN O
diethyl WO2008064615A2 A NN O
ether WO2008064615A2 A NN O
, WO2008064615A2 A , O
tetrahydrofuran WO2008064615A2 A NN O
, WO2008064615A2 A , O
dioxan WO2008064615A2 A NN O
, WO2008064615A2 A , O
dichloromethane WO2008064615A2 A NN O
, WO2008064615A2 A , O
acetonitrile WO2008064615A2 A NN O
, WO2008064615A2 A , O
toluene WO2008064615A2 A NN O
or WO2008064615A2 A CC O
their WO2008064615A2 A PRP$ O
mixtures WO2008064615A2 A NNS O
, WO2008064615A2 A , O
or WO2008064615A2 A CC O
in WO2008064615A2 A IN O
an WO2008064615A2 A DT O
excess WO2008064615A2 A NN O
of WO2008064615A2 A IN O
N-aminopiperidine WO2008064615A2 A NNP O
, WO2008064615A2 A , O
with WO2008064615A2 A IN O
N-aminopiperidine WO2008064615A2 A NNP O
with WO2008064615A2 A IN O
catalysis WO2008064615A2 A NN O
by WO2008064615A2 A IN O
at WO2008064615A2 A IN O
least WO2008064615A2 A JJS O
one WO2008064615A2 A CD O
Lewis WO2008064615A2 A NNP O
acid WO2008064615A2 A NN O
at WO2008064615A2 A IN O
a WO2008064615A2 A DT O
temperature WO2008064615A2 A NN O
from WO2008064615A2 A IN O
0° WO2008064615A2 A CD O
C WO2008064615A2 A NNP O
to WO2008064615A2 A TO O
the WO2008064615A2 A DT O
boiling WO2008064615A2 A VBG O
point WO2008064615A2 A NN O
of WO2008064615A2 A IN O
the WO2008064615A2 A DT O
solvent WO2008064615A2 A NN O
or WO2008064615A2 A CC O
mixture WO2008064615A2 A NN O
of WO2008064615A2 A IN O
solvents WO2008064615A2 A NNS O
used WO2008064615A2 A VBN O
. WO2008064615A2 A . O

Pharmaceutical WO2008064615A2 A JJ O
compositions WO2008064615A2 A NNS O
containing WO2008064615A2 A VBG O
the WO2008064615A2 A DT O
above WO2008064615A2 A NN O
forms WO2008064615A2 A NNS O
and WO2008064615A2 A CC O
use WO2008064615A2 A NN O
of WO2008064615A2 A IN O
the WO2008064615A2 A DT O
above WO2008064615A2 A NN O
forms WO2008064615A2 A NNS O
for WO2008064615A2 A IN O
the WO2008064615A2 A DT O
manufacture WO2008064615A2 A NN O
of WO2008064615A2 A IN O
a WO2008064615A2 A DT O
medicament WO2008064615A2 A NN O
the WO2008064615A2 A DT O
treatment WO2008064615A2 A NN O
of WO2008064615A2 A IN O
obesity WO2008064615A2 A NN O
, WO2008064615A2 A , O
for WO2008064615A2 A IN O
curing WO2008064615A2 A NN O
of WO2008064615A2 A IN O
the WO2008064615A2 A DT O
habit WO2008064615A2 A NN O
of WO2008064615A2 A IN O
smoking WO2008064615A2 A NN O
or WO2008064615A2 A CC O
for WO2008064615A2 A IN O
the WO2008064615A2 A DT O
treatment WO2008064615A2 A NN O
of WO2008064615A2 A IN O
Alzheimer WO2008064615A2 A NNP O
or WO2008064615A2 A CC O
Parkinson WO2008064615A2 A NNP O
diseases WO2008064615A2 A NNS O
are WO2008064615A2 A VBP O
also WO2008064615A2 A RB O
described WO2008064615A2 A VBN O
. WO2008064615A2 A . O

Solid US20110306632 T JJ O
Dispersions US20110306632 T NNP O
Containing US20110306632 T NNP O
Kinase US20110306632 T NNP I-UN
Inhibitors US20110306632 T NNP O
. US20110306632 T . O

A US20110306632 A DT O
solid US20110306632 A JJ O
dispersion US20110306632 A NN O
comprises US20110306632 A NNS O
, US20110306632 A , O
in US20110306632 A IN O
essentially US20110306632 A RB O
non-crystalline US20110306632 A JJ O
form US20110306632 A NN O
, US20110306632 A , O
a US20110306632 A DT O
kinase US20110306632 A NN I-UN
inhibitory US20110306632 A NN O
compound US20110306632 A NN O
, US20110306632 A , O
e.g. US20110306632 A NN O
, US20110306632 A , O
N- US20110306632 A NNP O
( US20110306632 A ( O
4- US20110306632 A JJ O
{ US20110306632 A ( O
4-amino-7- US20110306632 A JJ O
[ US20110306632 A NN O
1- US20110306632 A JJ O
( US20110306632 A ( O
2-hydroxyethyl US20110306632 A JJ O
) US20110306632 A ) O
-1H-pyrazol-4-yl US20110306632 A FW O
] US20110306632 A FW O
thieno US20110306632 A JJ O
[ US20110306632 A NNP O
3,2-c US20110306632 A JJ O
] US20110306632 A NNP O
pyridin-3-yl US20110306632 A NN O
} US20110306632 A ) O
phenyl US20110306632 A NN O
) US20110306632 A ) O
-N′- US20110306632 A NN O
( US20110306632 A ( O
3-fluorophenyl US20110306632 A JJ O
) US20110306632 A ) O
urea US20110306632 A NN O
, US20110306632 A , O
dispersed US20110306632 A VBN O
in US20110306632 A IN O
a US20110306632 A DT O
solid US20110306632 A JJ O
matrix US20110306632 A NN O
that US20110306632 A WDT O
comprises US20110306632 A VBZ O
( US20110306632 A ( O
a US20110306632 A DT O
) US20110306632 A ) O
a US20110306632 A DT O
pharmaceutically US20110306632 A RB O
acceptable US20110306632 A JJ O
water-soluble US20110306632 A JJ O
polymeric US20110306632 A NN O
carrier US20110306632 A NN O
and US20110306632 A CC O
( US20110306632 A ( O
b US20110306632 A NN O
) US20110306632 A ) O
a US20110306632 A DT O
pharmaceutically US20110306632 A RB O
acceptable US20110306632 A JJ O
surfactant US20110306632 A NN O
. US20110306632 A . O

Drug EP2231189A1 T NN O
delivery EP2231189A1 T NN O
system EP2231189A1 T NN O
for EP2231189A1 T IN O
administration EP2231189A1 T NN O
of EP2231189A1 T IN O
poorly EP2231189A1 T JJ O
water EP2231189A1 T NN O
soluble EP2231189A1 T JJ O
pharmaceutically EP2231189A1 T RB O
active EP2231189A1 T JJ O
substances EP2231189A1 T NNS O
. EP2231189A1 T . O

Stabilized US20120277173 T VBN O
anthocyanin US20120277173 T JJ O
compositions US20120277173 T NNS O
. US20120277173 T . O

The US20120277173 A DT O
invention US20120277173 A NN O
describes US20120277173 A VBZ O
stabile US20120277173 A JJ O
anthocyanin US20120277173 A NN O
compositions US20120277173 A NNS O
, US20120277173 A , O
methods US20120277173 A NNS O
to US20120277173 A TO O
prepare US20120277173 A VB O
such US20120277173 A JJ O
compositions US20120277173 A NNS O
and US20120277173 A CC O
also US20120277173 A RB O
methods US20120277173 A NNS O
of US20120277173 A IN O
use US20120277173 A NN O
of US20120277173 A IN O
such US20120277173 A JJ O
compositions US20120277173 A NNS O
to US20120277173 A TO O
treat US20120277173 A VB O
various US20120277173 A JJ O
afflictions US20120277173 A NNS O
. US20120277173 A . O

The US20120277173 A DT O
present US20120277173 A JJ O
invention US20120277173 A NN O
describes US20120277173 A VBZ O
unique US20120277173 A JJ O
compositions US20120277173 A NNS O
of US20120277173 A IN O
an US20120277173 A DT O
anthocyanin US20120277173 A NN O
and US20120277173 A CC O
a US20120277173 A DT O
stabilizing US20120277173 A VBG O
compound US20120277173 A NN O
such US20120277173 A JJ O
that US20120277173 A IN O
the US20120277173 A DT O
combination US20120277173 A NN O
of US20120277173 A IN O
the US20120277173 A DT O
two US20120277173 A CD O
components US20120277173 A NNS O
provides US20120277173 A VBZ O
that US20120277173 A IN O
the US20120277173 A DT O
anthocyanin US20120277173 A NN O
does US20120277173 A VBZ O
not US20120277173 A RB O
readily US20120277173 A RB O
undergo US20120277173 A JJ O
degradation US20120277173 A NN O
, US20120277173 A , O
such US20120277173 A JJ O
as US20120277173 A IN O
oxidation US20120277173 A NN O
, US20120277173 A , O
pH US20120277173 A JJ O
instability US20120277173 A NN O
, US20120277173 A , O
etc US20120277173 A FW O
. US20120277173 A . O

Method US8563602 T NNP O
of US8563602 T IN O
improving US8563602 T VBG O
animal US8563602 T JJ O
tissue US8563602 T NN O
quality US8563602 T NN O
by US8563602 T IN O
supplementing US8563602 T VBG O
the US8563602 T DT O
animal US8563602 T JJ O
diet US8563602 T NN O
with US8563602 T IN O
oleic US8563602 T JJ O
acid US8563602 T NN O
and US8563602 T CC O
selected US8563602 T VBN O
tocols US8563602 T NNS O
. US8563602 T . O

Application CN101822663A T NN O
of CN101822663A T IN O
isothiocyanate CN101822663A T NN O
to CN101822663A T TO O
preparation CN101822663A T NN O
of CN101822663A T IN O
medicine CN101822663A T NN O
for CN101822663A T IN O
preventing CN101822663A T VBG O
and CN101822663A T CC O
treating CN101822663A T VBG O
medicine-resistance CN101822663A T NN O
tumor CN101822663A T NN O
. CN101822663A T . O

Antibacterial WO2006101818A1 T JJ O
3',5-disubstituted WO2006101818A1 T JJ O
2,4'-dihydroxybiphenyl WO2006101818A1 T JJ O
compounds WO2006101818A1 T NNS O
, WO2006101818A1 T , O
derivatives WO2006101818A1 T NNS O
and WO2006101818A1 T CC O
related WO2006101818A1 T JJ O
methods WO2006101818A1 T NNS O
. WO2006101818A1 T . O

The WO2006101818A1 A DT O
invention WO2006101818A1 A NN O
provides WO2006101818A1 A VBZ O
an WO2006101818A1 A DT O
antiplaque WO2006101818A1 A JJ O
oral WO2006101818A1 A JJ O
composition WO2006101818A1 A NN O
containing WO2006101818A1 A VBG O
an WO2006101818A1 A DT O
orally WO2006101818A1 A RB O
acceptable WO2006101818A1 A JJ O
carrier WO2006101818A1 A NN O
and WO2006101818A1 A CC O
an WO2006101818A1 A DT O
antibacterial WO2006101818A1 A JJ O
effective WO2006101818A1 A JJ O
amount WO2006101818A1 A NN O
of WO2006101818A1 A IN O
compound WO2006101818A1 A NN O
( WO2006101818A1 A ( O
I WO2006101818A1 A PRP O
) WO2006101818A1 A ) O
. WO2006101818A1 A . O

In WO2006101818A1 A IN O
the WO2006101818A1 A DT O
structure WO2006101818A1 A NN O
, WO2006101818A1 A , O
R1 WO2006101818A1 A NNP O
and WO2006101818A1 A CC O
R2 WO2006101818A1 A NNP O
are WO2006101818A1 A VBP O
independently WO2006101818A1 A RB O
a WO2006101818A1 A DT O
hydrogen WO2006101818A1 A NN O
atom WO2006101818A1 A NN O
or WO2006101818A1 A CC O
a WO2006101818A1 A DT O
lower WO2006101818A1 A JJR O
C1-4 WO2006101818A1 A NNP O
alkyl WO2006101818A1 A NN O
group WO2006101818A1 A NN O
and WO2006101818A1 A CC O
R3 WO2006101818A1 A NNP O
and WO2006101818A1 A CC O
R4 WO2006101818A1 A NNP O
are WO2006101818A1 A VBP O
independently WO2006101818A1 A RB O
an WO2006101818A1 A DT O
alkenyl WO2006101818A1 A NN O
or WO2006101818A1 A CC O
alkyl WO2006101818A1 A NN O
group WO2006101818A1 A NN O
having WO2006101818A1 A VBG O
from WO2006101818A1 A IN O
1 WO2006101818A1 A CD O
to WO2006101818A1 A TO O
20 WO2006101818A1 A CD O
carbon WO2006101818A1 A NN O
atoms WO2006101818A1 A NNS O
, WO2006101818A1 A , O
with WO2006101818A1 A IN O
the WO2006101818A1 A DT O
proviso WO2006101818A1 A NN O
that WO2006101818A1 A WDT O
R3 WO2006101818A1 A NNP O
and WO2006101818A1 A CC O
R4 WO2006101818A1 A NNP O
are WO2006101818A1 A VBP O
not WO2006101818A1 A RB O
both WO2006101818A1 A DT O
2-propenyl WO2006101818A1 A JJ O
or WO2006101818A1 A CC O
n-propyl WO2006101818A1 A JJ O
when WO2006101818A1 A WRB O
R1 WO2006101818A1 A NNP O
and WO2006101818A1 A CC O
R2 WO2006101818A1 A NNP O
are WO2006101818A1 A VBP O
both WO2006101818A1 A DT O
hydrogen WO2006101818A1 A NN O
atoms WO2006101818A1 A NNS O
. WO2006101818A1 A . O

Also WO2006101818A1 A RB O
included WO2006101818A1 A VBN O
are WO2006101818A1 A VBP O
oral WO2006101818A1 A JJ O
compositions WO2006101818A1 A NNS O
containing WO2006101818A1 A VBG O
the WO2006101818A1 A DT O
compound WO2006101818A1 A NN O
( WO2006101818A1 A ( O
I WO2006101818A1 A PRP O
) WO2006101818A1 A ) O
. WO2006101818A1 A . O

Muscarinic US20070265251 T JJ O
Antagonists US20070265251 T NNS O
With US20070265251 T IN O
Parp US20070265251 T NNP I-UN
and US20070265251 T CC O
Sir US20070265251 T NNP I-UN
Modulating US20070265251 T NNP O
Activity US20070265251 T NNP O
as US20070265251 T IN O
Cytoprotective US20070265251 T JJ O
Agents US20070265251 T NNS O
. US20070265251 T . O

The US20070265251 A DT O
present US20070265251 A JJ O
invention US20070265251 A NN O
relates US20070265251 A VBZ O
to US20070265251 A TO O
generally US20070265251 A RB O
to US20070265251 A TO O
the US20070265251 A DT O
cytoprotective US20070265251 A JJ O
activity US20070265251 A NN O
of US20070265251 A IN O
mixed US20070265251 A JJ O
muscarinic US20070265251 A JJ O
inhibition/PARP US20070265251 A NN O
modulation US20070265251 A NN O
and US20070265251 A CC O
in US20070265251 A IN O
particular US20070265251 A JJ O
to US20070265251 A TO O
the US20070265251 A DT O
use US20070265251 A NN O
of US20070265251 A IN O
dual US20070265251 A JJ O
inhibitors US20070265251 A NNS O
of US20070265251 A IN O
M1 US20070265251 A NNP I-UN
muscarinic US20070265251 A JJ I-UN
receptor US20070265251 A NN I-UN
and US20070265251 A CC O
poly US20070265251 A NN I-UN
( US20070265251 A ( I-UN
ADP-ribose US20070265251 A NNP I-UN
) US20070265251 A ) I-UN
polymerase US20070265251 A NN I-UN
( US20070265251 A ( O
PARP US20070265251 A NNP I-UN
) US20070265251 A ) O
as US20070265251 A IN O
neuroprotective US20070265251 A JJ O
medicaments US20070265251 A NNS O
, US20070265251 A , O
particularly US20070265251 A RB O
as US20070265251 A IN O
medicaments US20070265251 A NNS O
for US20070265251 A IN O
the US20070265251 A DT O
prevention US20070265251 A NN O
and/or US20070265251 A NN O
treatment US20070265251 A NN O
of US20070265251 A IN O
neurological US20070265251 A JJ O
diseases US20070265251 A NNS O
. US20070265251 A . O

Application CN101856116A T NN O
of CN101856116A T IN O
coumaroyl CN101856116A T JJ O
spermidine CN101856116A T NN O
type CN101856116A T NN O
compounds CN101856116A T NNS O
or CN101856116A T CC O
plant CN101856116A T NN O
extracts CN101856116A T NNS O
thereof CN101856116A T VBP O
. CN101856116A T . O

The CN101856116A A DT O
invention CN101856116A A NN O
discloses CN101856116A A VBZ O
application CN101856116A A NN O
of CN101856116A A IN O
a CN101856116A A DT O
kind CN101856116A A NN O
of CN101856116A A IN O
coumaroyl CN101856116A A NN O
spermidine CN101856116A A NN O
type CN101856116A A NN O
compounds CN101856116A A VBZ O
shown CN101856116A A VBN O
as CN101856116A A IN O
a CN101856116A A DT O
formula CN101856116A A NN O
I CN101856116A A PRP O
or CN101856116A A CC O
plant CN101856116A A NN O
extracts CN101856116A A NNS O
containing CN101856116A A VBG O
the CN101856116A A DT O
coumaroyl CN101856116A A NN O
spermidine CN101856116A A NN O
type CN101856116A A NN O
compounds CN101856116A A VBZ O
to CN101856116A A TO O
the CN101856116A A DT O
preparation CN101856116A A NN O
of CN101856116A A IN O
alpha CN101856116A A JJ O
1-adrenoreceptor CN101856116A A JJ O
antagonist CN101856116A A NN O
health-care CN101856116A A NN O
food CN101856116A A NN O
, CN101856116A A , O
cyclooxygenase-2 CN101856116A A JJ I-UN
inhibiting CN101856116A A VBG O
health-care CN101856116A A JJ O
food CN101856116A A NN O
and CN101856116A A CC O
prostate CN101856116A A NN I-UN
specific CN101856116A A JJ I-UN
antigen CN101856116A A NN I-UN
( CN101856116A A ( O
PSA CN101856116A A NNP I-UN
) CN101856116A A ) O
inhibiting CN101856116A A VBG O
health-care CN101856116A A JJ O
food CN101856116A A NN O
, CN101856116A A , O
or CN101856116A A CC O
the CN101856116A A DT O
preparation CN101856116A A NN O
of CN101856116A A IN O
health-care CN101856116A A JJ O
food CN101856116A A NN O
for CN101856116A A IN O
preventing CN101856116A A VBG O
and CN101856116A A CC O
treating CN101856116A A VBG O
prostatoplasia CN101856116A A NN O
, CN101856116A A , O
prostatitis CN101856116A A NN O
or CN101856116A A CC O
prostatic CN101856116A A JJ O
cancer CN101856116A A NN O
. CN101856116A A . O

Water-containing WO2010001926A1 T JJ O
composition WO2010001926A1 T NN O
. WO2010001926A1 T . O

Application CN103417550A T NN O
of CN103417550A T IN O
sterol CN103417550A T NN O
phenolic CN103417550A T JJ O
ester CN103417550A T NN O
to CN103417550A T TO O
preparation CN103417550A T NN O
of CN103417550A T IN O
breast CN103417550A T NN O
cancer CN103417550A T NN O
prevention CN103417550A T NN O
and CN103417550A T CC O
treatment CN103417550A T NN O
medicine CN103417550A T NN O
. CN103417550A T . O

Novel US20050107455 T NNP O
tricycloimidazoline US20050107455 T NN O
derivatives US20050107455 T NNS O
method US20050107455 T VBP O
for US20050107455 T IN O
production US20050107455 T NN O
and US20050107455 T CC O
use US20050107455 T NN O
thereof US20050107455 T NN O
as US20050107455 T IN O
medicaments US20050107455 T NNS O
. US20050107455 T . O

Pearl CN101862382A T NNP O
health CN101862382A T NN O
care CN101862382A T NN O
product CN101862382A T NN O
for CN101862382A T IN O
improving CN101862382A T VBG O
sleeping CN101862382A T NN O
. CN101862382A T . O

The CN101862382A A DT O
invention CN101862382A A NN O
belongs CN101862382A A VBZ O
to CN101862382A A TO O
the CN101862382A A DT O
technical CN101862382A A JJ O
field CN101862382A A NN O
of CN101862382A A IN O
health CN101862382A A NN O
care CN101862382A A NN O
products CN101862382A A NNS O
, CN101862382A A , O
in CN101862382A A IN O
particular CN101862382A A JJ O
to CN101862382A A TO O
a CN101862382A A DT O
pearl CN101862382A A NN O
health CN101862382A A NN O
care CN101862382A A NN O
product CN101862382A A NN O
for CN101862382A A IN O
improving CN101862382A A VBG O
sleeping CN101862382A A NN O
, CN101862382A A , O
which CN101862382A A WDT O
is CN101862382A A VBZ O
prepared CN101862382A A VBN O
by CN101862382A A IN O
uniformly CN101862382A A JJ O
mixing CN101862382A A VBG O
pearl CN101862382A A NN O
powder CN101862382A A NN O
, CN101862382A A , O
spina CN101862382A A NN O
date CN101862382A A NN O
seed CN101862382A A NN O
extractive CN101862382A A JJ O
, CN101862382A A , O
American CN101862382A A NNP O
ginseng CN101862382A A NN O
extractive CN101862382A A NN O
, CN101862382A A , O
Griffonia CN101862382A A NNP O
extractive CN101862382A A NN O
and CN101862382A A CC O
VB6 CN101862382A A NNP O
. CN101862382A A . O

The CN101862382A A DT O
invention CN101862382A A NN O
efficiently CN101862382A A RB O
utilizes CN101862382A A VBZ O
the CN101862382A A DT O
active CN101862382A A JJ O
constituent CN101862382A A NN O
of CN101862382A A IN O
natural CN101862382A A JJ O
plant CN101862382A A NN O
extractives CN101862382A A NNS O
, CN101862382A A , O
and CN101862382A A CC O
has CN101862382A A VBZ O
the CN101862382A A DT O
functions CN101862382A A NNS O
of CN101862382A A IN O
tranquilizing CN101862382A A VBG O
and CN101862382A A CC O
allaying CN101862382A A VBG O
excitement CN101862382A A NN O
, CN101862382A A , O
nourishing CN101862382A A VBG O
heart CN101862382A A NN O
and CN101862382A A CC O
clearing CN101862382A A NN O
heat CN101862382A A NN O
and CN101862382A A CC O
relieving CN101862382A A VBG O
fidgetness CN101862382A A NN O
, CN101862382A A , O
can CN101862382A A MD O
prolong CN101862382A A VB O
the CN101862382A A DT O
sleeping CN101862382A A VBG O
duration CN101862382A A NN O
time CN101862382A A NN O
and CN101862382A A CC O
has CN101862382A A VBZ O
excellent CN101862382A A JJ O
function CN101862382A A NN O
of CN101862382A A IN O
improving CN101862382A A VBG O
sleeping CN101862382A A NN O
. CN101862382A A . O

Treatment US20130053336 T NN O
of US20130053336 T IN O
chlamydiaceae US20130053336 T NN O
infections US20130053336 T NNS O
by US20130053336 T IN O
means US20130053336 T NNS O
of US20130053336 T IN O
beta-lactams US20130053336 T NNS O
. US20130053336 T . O

Pharmaceutical US20090239946 T JJ O
compositions US20090239946 T NNS O
of US20090239946 T IN O
HDAC US20090239946 T NNP I-UN
inhibitors US20090239946 T NNS O
and US20090239946 T CC O
chelatable US20090239946 T JJ O
metal US20090239946 T NN O
compounds US20090239946 T NNS O
, US20090239946 T , O
and US20090239946 T CC O
metal-HDAC US20090239946 T JJ O
inhibitors US20090239946 T NNS O
chelate US20090239946 T VBP O
complexes US20090239946 T NNS O
. US20090239946 T . O

The US20090239946 A DT O
present US20090239946 A JJ O
invention US20090239946 A NN O
provides US20090239946 A VBZ O
pharmaceutical US20090239946 A JJ O
compositions US20090239946 A NNS O
of US20090239946 A IN O
an US20090239946 A DT O
HDAC US20090239946 A NNP I-UN
inhibitor US20090239946 A NN O
and US20090239946 A CC O
a US20090239946 A DT O
chelatable US20090239946 A JJ O
metal US20090239946 A NN O
compound US20090239946 A NN O
. US20090239946 A . O

In US20090239946 A IN O
one US20090239946 A CD O
embodiment US20090239946 A NN O
, US20090239946 A , O
the US20090239946 A DT O
invention US20090239946 A NN O
provides US20090239946 A VBZ O
a US20090239946 A DT O
method US20090239946 A NN O
of US20090239946 A IN O
treating US20090239946 A VBG O
cancer US20090239946 A NN O
and US20090239946 A CC O
alleviating US20090239946 A VBG O
the US20090239946 A DT O
side US20090239946 A NN O
effects US20090239946 A NNS O
of US20090239946 A IN O
the US20090239946 A DT O
HDAC US20090239946 A NNP I-UN
inhibitor US20090239946 A NN O
by US20090239946 A IN O
administering US20090239946 A VBG O
the US20090239946 A DT O
pharmaceutical US20090239946 A JJ O
composition US20090239946 A NN O
. US20090239946 A . O

In US20090239946 A IN O
another US20090239946 A DT O
embodiment US20090239946 A NN O
, US20090239946 A , O
the US20090239946 A DT O
present US20090239946 A JJ O
invention US20090239946 A NN O
also US20090239946 A RB O
provides US20090239946 A VBZ O
pharmaceutical US20090239946 A JJ O
compositions US20090239946 A NNS O
of US20090239946 A IN O
metal US20090239946 A NN O
HDAC US20090239946 A NNP I-UN
inhibitor US20090239946 A NN O
chelate US20090239946 A NN O
complexes US20090239946 A NNS O
. US20090239946 A . O

The US20090239946 A DT O
invention US20090239946 A NN O
provides US20090239946 A VBZ O
crystalline US20090239946 A JJ O
compositions US20090239946 A NNS O
of US20090239946 A IN O
metal US20090239946 A NN O
HDAC US20090239946 A NNP I-UN
inhibitor US20090239946 A NN O
chelate US20090239946 A NN O
complexes US20090239946 A NNS O
and US20090239946 A CC O
methods US20090239946 A NNS O
of US20090239946 A IN O
producing US20090239946 A VBG O
same US20090239946 A JJ O
. US20090239946 A . O

Monomers US20130053334 T NNS O
and US20130053334 T CC O
oligonucleotides US20130053334 T NNS O
comprising US20130053334 T VBG O
cycloaddition US20130053334 T NN O
adduct US20130053334 T NN O
( US20130053334 T ( O
s US20130053334 T NN O
) US20130053334 T ) O
. US20130053334 T . O

Silver CN103202317A T NNP O
iodine CN103202317A T NN O
complexing CN103202317A T VBG O
antibacterial CN103202317A T JJ O
agent CN103202317A T NN O
and CN103202317A T CC O
preparation CN103202317A T NN O
method CN103202317A T NN O
thereof CN103202317A T NN O
. CN103202317A T . O

Application CN102327275A T NN O
of CN102327275A T IN O
3- CN102327275A T JJ O
[ CN102327275A T JJ O
4- CN102327275A T JJ O
( CN102327275A T ( O
sulfonyl CN102327275A T NN O
) CN102327275A T ) O
benzene CN102327275A T NN O
] CN102327275A T NNP O
urea CN102327275A T JJ O
compound CN102327275A T NN O
to CN102327275A T TO O
preparation CN102327275A T NN O
of CN102327275A T IN O
antitumor CN102327275A T NN O
medicament CN102327275A T NN O
. CN102327275A T . O

Citicoline CN102078299B T NNP O
sodium CN102078299B T NN O
liposome CN102078299B T NN O
solid CN102078299B T JJ O
preparation CN102078299B T NN O
. CN102078299B T . O

Oxycodone CN103070840A T NNP O
hydrochloride CN103070840A T NN O
slow CN103070840A T JJ O
release CN103070840A T NN O
dripping CN103070840A T VBG O
pills CN103070840A T NNS O
and CN103070840A T CC O
preparation CN103070840A T NN O
method CN103070840A T NN O
thereof CN103070840A T NN O
. CN103070840A T . O

Applications CN103505731A T NNS O
of CN103505731A T IN O
1 CN103505731A T CD I-UN
type CN103505731A T NN I-UN
cysteinyl CN103505731A T NN I-UN
leukotriene CN103505731A T NN I-UN
receptor CN103505731A T NN I-UN
antagonist CN103505731A T NN O
on CN103505731A T IN O
preparation CN103505731A T NN O
of CN103505731A T IN O
medicament CN103505731A T NN O
for CN103505731A T IN O
treating CN103505731A T VBG O
the CN103505731A T DT O
Alzheimer CN103505731A T NNP O
disease CN103505731A T NN O
. CN103505731A T . O

The CN103505731A A DT O
invention CN103505731A A NN O
relates CN103505731A A VBZ O
to CN103505731A A TO O
applications CN103505731A A NNS O
of CN103505731A A IN O
a CN103505731A A DT O
cysteinyl CN103505731A A JJ O
leukotriene CN103505731A A NN O
receptor CN103505731A A NN O
antagonist CN103505731A A NN O
( CN103505731A A ( O
CysLT1R CN103505731A A NNP I-UN
) CN103505731A A ) O
on CN103505731A A IN O
preparation CN103505731A A NN O
of CN103505731A A IN O
a CN103505731A A DT O
medicament CN103505731A A NN O
for CN103505731A A IN O
treating CN103505731A A VBG O
the CN103505731A A DT O
Alzheimer CN103505731A A NNP O
disease CN103505731A A NN O
. CN103505731A A . O

Research CN103505731A A NN O
finds CN103505731A A VBZ O
that CN103505731A A IN O
intracerebral CN103505731A A JJ O
CysLT1R CN103505731A A NNP I-UN
mediates CN103505731A A VBZ O
A CN103505731A A DT O
beta CN103505731A A NN O
aggregation CN103505731A A NN O
and CN103505731A A CC O
dysmnesia CN103505731A A NN O
; CN103505731A A : O
and CN103505731A A CC O
by CN103505731A A IN O
oral CN103505731A A JJ O
medication CN103505731A A NN O
, CN103505731A A , O
CysLT1R CN103505731A A NNP I-UN
antagonists CN103505731A A VBZ O
such CN103505731A A JJ O
as CN103505731A A IN O
pranlukast CN103505731A A NN O
, CN103505731A A , O
zafirlukast CN103505731A A NN O
and CN103505731A A CC O
montelukast CN103505731A A NN O
can CN103505731A A MD O
improve CN103505731A A VB O
mice CN103505731A A JJ O
memory CN103505731A A NN O
impairment CN103505731A A NN O
caused CN103505731A A VBN O
by CN103505731A A IN O
A CN103505731A A DT O
beta CN103505731A A NN O
. CN103505731A A . O

The CN103505731A A DT O
CysLT1R CN103505731A A NNP I-UN
antagonists CN103505731A A NNS O
such CN103505731A A JJ O
as CN103505731A A IN O
pranlukast CN103505731A A NN O
, CN103505731A A , O
zafirlukast CN103505731A A NN O
and CN103505731A A CC O
montelukast CN103505731A A NN O
, CN103505731A A , O
and CN103505731A A CC O
analogs CN103505731A A NNS O
thereof CN103505731A A VBP O
such CN103505731A A JJ O
as CN103505731A A IN O
iralukast CN103505731A A NN O
, CN103505731A A , O
ablukast CN103505731A A NN O
, CN103505731A A , O
imitrodast CN103505731A A NN O
, CN103505731A A , O
pobilukast CN103505731A A NN O
, CN103505731A A , O
cinalukast CN103505731A A NN O
, CN103505731A A , O
verlukast CN103505731A A NN O
, CN103505731A A , O
pemirolast CN103505731A A NN O
and CN103505731A A CC O
ibudilast CN103505731A A NN O
, CN103505731A A , O
have CN103505731A A VBP O
significant CN103505731A A JJ O
protection CN103505731A A NN O
effect CN103505731A A NN O
on CN103505731A A IN O
primarily-cultured CN103505731A A JJ O
mice CN103505731A A NN O
neuron CN103505731A A NN O
damage CN103505731A A NN O
caused CN103505731A A VBN O
by CN103505731A A IN O
A CN103505731A A DT O
beta CN103505731A A NN O
. CN103505731A A . O

The CN103505731A A DT O
CysLT1R CN103505731A A NNP I-UN
antagonists CN103505731A A NNS O
such CN103505731A A JJ O
as CN103505731A A IN O
pranlukast CN103505731A A NN O
, CN103505731A A , O
zafirlukast CN103505731A A NN O
and CN103505731A A CC O
montelukast CN103505731A A NN O
, CN103505731A A , O
and CN103505731A A CC O
the CN103505731A A DT O
analogs CN103505731A A NNS O
thereof CN103505731A A VBP O
such CN103505731A A JJ O
as CN103505731A A IN O
iralukast CN103505731A A NN O
, CN103505731A A , O
ablukast CN103505731A A NN O
, CN103505731A A , O
imitrodast CN103505731A A NN O
, CN103505731A A , O
pobilukast CN103505731A A NN O
, CN103505731A A , O
cinalukast CN103505731A A NN O
, CN103505731A A , O
verlukast CN103505731A A NN O
, CN103505731A A , O
pemirolast CN103505731A A NN O
and CN103505731A A CC O
ibudilast CN103505731A A NN O
, CN103505731A A , O
can CN103505731A A MD O
be CN103505731A A VB O
used CN103505731A A VBN O
for CN103505731A A IN O
preparing CN103505731A A VBG O
anti-AD CN103505731A A JJ O
medicaments CN103505731A A NNS O
. CN103505731A A . O

Mouth-wash CN1919268A T JJ O
medicine CN1919268A T NN O
for CN1919268A T IN O
treating CN1919268A T VBG O
stomatocace CN1919268A T NN O
and CN1919268A T CC O
preparation CN1919268A T NN O
method CN1919268A T NN O
thereof CN1919268A T NN O
. CN1919268A T . O

Disclosed CN1919268A A VBN O
is CN1919268A A VBZ O
a CN1919268A A DT O
mouth-washing CN1919268A A JJ O
gargle CN1919268A A NN O
for CN1919268A A IN O
treating CN1919268A A VBG O
ulcerative CN1919268A A JJ O
stomatitis CN1919268A A NN O
and CN1919268A A CC O
its CN1919268A A PRP$ O
preparation CN1919268A A NN O
, CN1919268A A , O
wherein CN1919268A A VBP O
the CN1919268A A DT O
medicament CN1919268A A NN O
is CN1919268A A VBZ O
prepared CN1919268A A VBN O
from CN1919268A A IN O
the CN1919268A A DT O
following CN1919268A A JJ O
raw CN1919268A A JJ O
materials CN1919268A A NNS O
( CN1919268A A ( O
by CN1919268A A IN O
weight CN1919268A A NN O
portion CN1919268A A NN O
) CN1919268A A ) O
: CN1919268A A : O
yellow CN1919268A A JJ O
corktree CN1919268A A NN O
bark CN1919268A A NN O
25-30g CN1919268A A CD O
, CN1919268A A , O
honeysuckle CN1919268A A JJR O
flower CN1919268A A JJR O
18-20g CN1919268A A JJ O
, CN1919268A A , O
mentha CN1919268A A NN O
, CN1919268A A , O
licorice CN1919268A A JJ O
root CN1919268A A NN O
each CN1919268A A DT O
8-10g CN1919268A A CD O
, CN1919268A A , O
borneol CN1919268A A VBZ O
4-6g CN1919268A A JJ O
. CN1919268A A . O

The CN1919268A A DT O
invention CN1919268A A NN O
realizes CN1919268A A VBZ O
easy CN1919268A A JJ O
material CN1919268A A JJ O
availability CN1919268A A NN O
, CN1919268A A , O
simplified CN1919268A A VBN O
preparation CN1919268A A NN O
, CN1919268A A , O
low CN1919268A A JJ O
cost CN1919268A A NN O
, CN1919268A A , O
and CN1919268A A CC O
quick CN1919268A A JJ O
effect CN1919268A A NN O
. CN1919268A A . O

4- US7572825 T JJ O
( US7572825 T ( O
t-Butyldiphenylsiloxy US7572825 T JJ O
) US7572825 T ) O
pentyl-p-toluene US7572825 T JJ O
sulfonate US7572825 T NN O
; US7572825 T : O
2,2- US7572825 T JJ O
[ US7572825 T JJ O
4-Biphenyl-5- US7572825 T JJ O
( US7572825 T ( O
t-butyldiphenylsiloxy US7572825 T JJ O
) US7572825 T ) O
pentyl US7572825 T NN O
) US7572825 T ) O
] US7572825 T VBZ O
-1,3-propanedithiane US7572825 T NN O
; US7572825 T : O
osteoporosis US7572825 T NN O
, US7572825 T , O
rheumatoid US7572825 T JJ O
arthritis US7572825 T NN O
, US7572825 T , O
cancer US7572825 T NN O
associated US7572825 T VBN O
bone US7572825 T CD O
disease US7572825 T NN O
, US7572825 T , O
Paget US7572825 T NNP O
's US7572825 T POS O
disease US7572825 T NN O
, US7572825 T , O
aseptic US7572825 T JJ O
loosening US7572825 T NN O
of US7572825 T IN O
prosthetic US7572825 T JJ O
implants US7572825 T NNS O
; US7572825 T : O
inflammation US7572825 T NN O
. US7572825 T . O

The US7572825 A DT O
present US7572825 A JJ O
invention US7572825 A NN O
pertains US7572825 A NNS O
to US7572825 A TO O
certain US7572825 A JJ O
ketones US7572825 A NNS O
and US7572825 A CC O
reduced US7572825 A JJ O
ketones US7572825 A NNS O
and US7572825 A CC O
derivatives US7572825 A NNS O
thereof US7572825 A VBP O
which US7572825 A WDT O
, US7572825 A , O
inter US7572825 A NN O
alia US7572825 A NN O
, US7572825 A , O
inhibit US7572825 A NN O
osteoclast US7572825 A JJ O
survival US7572825 A NN O
, US7572825 A , O
formation US7572825 A NN O
, US7572825 A , O
and/or US7572825 A JJ O
activity US7572825 A NN O
; US7572825 A : O
and/or US7572825 A CC O
inhibit US7572825 A VB O
bone US7572825 A JJ O
resorption US7572825 A NN O
, US7572825 A , O
and US7572825 A CC O
more US7572825 A JJR O
particularly US7572825 A RB O
to US7572825 A TO O
compounds US7572825 A NNS O
of US7572825 A IN O
the US7572825 A DT O
formulae US7572825 A NN O
: US7572825 A : O
( US7572825 A ( O
1 US7572825 A CD O
) US7572825 A ) O
( US7572825 A ( O
2 US7572825 A CD O
) US7572825 A ) O
wherein US7572825 A NN O
: US7572825 A : O
Ar1 US7572825 A NNP O
is US7572825 A VBZ O
independently US7572825 A RB O
a US7572825 A DT O
biphenyl US7572825 A NN O
, US7572825 A , O
phenanthryl US7572825 A NN O
, US7572825 A , O
fluorenyl US7572825 A NN O
, US7572825 A , O
or US7572825 A CC O
carbazolyl US7572825 A NN O
, US7572825 A , O
and US7572825 A CC O
is US7572825 A VBZ O
optionally US7572825 A RB O
substituted US7572825 A VBN O
; US7572825 A : O
Ralk US7572825 A NNP O
is US7572825 A VBZ O
independently US7572825 A RB O
a US7572825 A DT O
C2-10alkylene US7572825 A NNP O
group US7572825 A NN O
, US7572825 A , O
and US7572825 A CC O
is US7572825 A VBZ O
optionally US7572825 A RB O
substituted US7572825 A VBN O
; US7572825 A : O
—ORO US7572825 A UH O
, US7572825 A , O
if US7572825 A IN O
present US7572825 A JJ O
, US7572825 A , O
is US7572825 A VBZ O
independently US7572825 A RB O
—OH US7572825 A JJ O
or US7572825 A CC O
—ORK US7572825 A JJ O
; US7572825 A : O
—ORK US7572825 A CC O
, US7572825 A , O
if US7572825 A IN O
present US7572825 A JJ O
, US7572825 A , O
is US7572825 A VBZ O
independently US7572825 A RB O
selected US7572825 A VBN O
from US7572825 A IN O
: US7572825 A : O
—O—RK1 US7572825 A NN O
; US7572825 A : O
—O—C US7572825 A NNP O
( US7572825 A ( O
═O US7572825 A NNP O
) US7572825 A ) O
RK2 US7572825 A NNP O
; US7572825 A : O
—O—C US7572825 A NNP O
( US7572825 A ( O
═O US7572825 A NNP O
) US7572825 A ) O
ORK3 US7572825 A NNP O
; US7572825 A : O
—O—S US7572825 A NNP O
( US7572825 A ( O
═O US7572825 A NNP O
) US7572825 A ) O
2ORK4 US7572825 A CD O
; US7572825 A : O
Q US7572825 A NNP O
is US7572825 A VBZ O
independently US7572825 A RB O
—OH US7572825 A JJ O
or US7572825 A CC O
—OROT US7572825 A JJ O
; US7572825 A : O
wherein US7572825 A NN O
: US7572825 A : O
—OROT US7572825 A NN O
, US7572825 A , O
if US7572825 A IN O
present US7572825 A JJ O
, US7572825 A , O
is US7572825 A VBZ O
independently US7572825 A RB O
selected US7572825 A VBN O
from US7572825 A IN O
: US7572825 A : O
—O—RE1 US7572825 A NN O
; US7572825 A : O
—O—C US7572825 A NNP O
( US7572825 A ( O
═O US7572825 A NNP O
) US7572825 A ) O
—RE2 US7572825 A VBP O
; US7572825 A : O
—O—C US7572825 A NNP O
( US7572825 A ( O
═O US7572825 A NNP O
) US7572825 A ) O
—O—RE3 US7572825 A VBP O
; US7572825 A : O
—O—C US7572825 A NNP O
( US7572825 A ( O
═O US7572825 A NNP O
) US7572825 A ) O
—O—SO3RE4 US7572825 A VBP O
; US7572825 A : O
—O—C US7572825 A NNP O
( US7572825 A ( O
═O US7572825 A NNP O
) US7572825 A ) O
—O— US7572825 A NN O
( US7572825 A ( O
CH2 US7572825 A NNP O
) US7572825 A ) O
n—COORE5 US7572825 A NN O
; US7572825 A : O
—O—C US7572825 A NNP O
( US7572825 A ( O
═O US7572825 A NNP O
) US7572825 A ) O
— US7572825 A NN O
( US7572825 A ( O
CH2 US7572825 A NNP O
) US7572825 A ) O
n—NRN1RN2 US7572825 A NN O
; US7572825 A : O
—O—C US7572825 A NNP O
( US7572825 A ( O
═O US7572825 A NNP O
) US7572825 A ) O
— US7572825 A NN O
( US7572825 A ( O
CH2 US7572825 A NNP O
) US7572825 A ) O
n—NH—C US7572825 A NN O
( US7572825 A ( O
═O US7572825 A NNP O
) US7572825 A ) O
RE6 US7572825 A NNP O
; US7572825 A : O
—O—C US7572825 A NNP O
( US7572825 A ( O
═O US7572825 A NNP O
) US7572825 A ) O
— US7572825 A NN O
( US7572825 A ( O
CH2 US7572825 A NNP O
) US7572825 A ) O
n—C US7572825 A NN O
( US7572825 A ( O
═O US7572825 A NNP O
) US7572825 A ) O
—NRN3RN4 US7572825 A VBP O
; US7572825 A : O
—O—P US7572825 A NNP O
( US7572825 A ( O
═O US7572825 A NNP O
) US7572825 A ) O
( US7572825 A ( O
ORE7 US7572825 A NNP O
) US7572825 A ) O
( US7572825 A ( O
ORE8 US7572825 A NNP O
) US7572825 A ) O
; US7572825 A : O
—O—RPA US7572825 A CC O
; US7572825 A : O
RPA US7572825 A NNP O
, US7572825 A , O
if US7572825 A IN O
present US7572825 A JJ O
, US7572825 A , O
is US7572825 A VBZ O
an US7572825 A DT O
organic US7572825 A JJ O
group US7572825 A NN O
which US7572825 A WDT O
incorporates US7572825 A VBZ O
a US7572825 A DT O
phosphonic US7572825 A JJ O
acid US7572825 A NN O
group US7572825 A NN O
; US7572825 A : O
with US7572825 A IN O
the US7572825 A DT O
proviso US7572825 A NN O
that US7572825 A IN O
if US7572825 A IN O
—OROT US7572825 A NNP O
is US7572825 A VBZ O
—O—RE1 US7572825 A NNP O
, US7572825 A , O
then US7572825 A RB O
RE1 US7572825 A NNP O
is US7572825 A VBZ O
not US7572825 A RB O
a US7572825 A DT O
phenyl US7572825 A NN O
group US7572825 A NN O
substituted US7572825 A VBD O
with US7572825 A IN O
a US7572825 A DT O
sulfonyl US7572825 A JJ O
group US7572825 A NN O
; US7572825 A : O
and US7572825 A CC O
pharmaceutically US7572825 A RB O
acceptable US7572825 A JJ O
salts US7572825 A NNS O
, US7572825 A , O
solvates US7572825 A NNS O
, US7572825 A , O
amides US7572825 A NNS O
, US7572825 A , O
esters US7572825 A NNS O
, US7572825 A , O
ethers US7572825 A NNS O
, US7572825 A , O
chemically US7572825 A RB O
protected US7572825 A VBD O
forms US7572825 A NNS O
, US7572825 A , O
or US7572825 A CC O
prodrugs US7572825 A NNS O
thereof US7572825 A NNS O
. US7572825 A . O

The US7572825 A DT O
present US7572825 A JJ O
invention US7572825 A NN O
also US7572825 A RB O
pertains US7572825 A VBZ O
to US7572825 A TO O
pharmaceutical US7572825 A JJ O
compositions US7572825 A NNS O
comprising US7572825 A VBG O
such US7572825 A JJ O
compounds US7572825 A NNS O
, US7572825 A , O
and US7572825 A CC O
the US7572825 A DT O
use US7572825 A NN O
of US7572825 A IN O
such US7572825 A JJ O
compounds US7572825 A NNS O
and US7572825 A CC O
compositions US7572825 A NNS O
, US7572825 A , O
both US7572825 A DT O
in US7572825 A IN O
vitro US7572825 A NN O
and US7572825 A CC O
in US7572825 A IN O
vivo US7572825 A NN O
, US7572825 A , O
to US7572825 A TO O
inhibit US7572825 A VB O
osteoclast US7572825 A JJ O
survival US7572825 A NN O
, US7572825 A , O
formation US7572825 A NN O
, US7572825 A , O
and/or US7572825 A JJ O
activity US7572825 A NN O
, US7572825 A , O
and US7572825 A CC O
to US7572825 A TO O
inhibit US7572825 A VB O
conditions US7572825 A NNS O
mediated US7572825 A VBN O
by US7572825 A IN O
osteoclasts US7572825 A NNS O
and/or US7572825 A NNS O
characterised US7572825 A VBN O
by US7572825 A IN O
bone US7572825 A NN O
resorption US7572825 A NN O
, US7572825 A , O
in US7572825 A IN O
the US7572825 A DT O
treatment US7572825 A NN O
of US7572825 A IN O
bone US7572825 A NN O
disorders US7572825 A NNS O
such US7572825 A JJ O
as US7572825 A IN O
osteoporosis US7572825 A NN O
, US7572825 A , O
rheumatoid US7572825 A JJ O
arthritis US7572825 A NN O
, US7572825 A , O
cancer US7572825 A NN O
associated US7572825 A VBN O
bone US7572825 A CD O
disease US7572825 A NN O
, US7572825 A , O
Paget US7572825 A NNP O
's US7572825 A POS O
disease US7572825 A NN O
, US7572825 A , O
aseptic US7572825 A JJ O
loosening US7572825 A NN O
of US7572825 A IN O
prosthetic US7572825 A JJ O
implants US7572825 A NNS O
, US7572825 A , O
and US7572825 A CC O
the US7572825 A DT O
like US7572825 A JJ O
; US7572825 A : O
and/or US7572825 A NN O
in US7572825 A IN O
the US7572825 A DT O
treatment US7572825 A NN O
of US7572825 A IN O
conditions US7572825 A NNS O
associated US7572825 A VBN O
with US7572825 A IN O
inflammation US7572825 A NN O
or US7572825 A CC O
activation US7572825 A NN O
of US7572825 A IN O
the US7572825 A DT O
immune US7572825 A NN O
system US7572825 A NN O
. US7572825 A . O

Gaba-ergic CA2160798C T JJ O
modulation CA2160798C T NN O
of CA2160798C T IN O
eye CA2160798C T NN O
growth CA2160798C T NN O
. CA2160798C T . O

A CA2160798C A DT O
composition CA2160798C A NN O
for CA2160798C A IN O
the CA2160798C A DT O
inhibition CA2160798C A NN O
of CA2160798C A IN O
the CA2160798C A DT O
abnormal CA2160798C A JJ O
postnatal CA2160798C A JJ O
axial CA2160798C A JJ O
growth CA2160798C A NN O
of CA2160798C A IN O
the CA2160798C A DT O
eye CA2160798C A NN O
of CA2160798C A IN O
a CA2160798C A DT O
maturing CA2160798C A NN O
animal CA2160798C A NN O
which CA2160798C A WDT O
comprises CA2160798C A VBZ O
a CA2160798C A DT O
pharmaceutically CA2160798C A RB O
effective CA2160798C A JJ O
amount CA2160798C A NN O
of CA2160798C A IN O
a CA2160798C A DT O
gamma CA2160798C A NN O
aminobutyric CA2160798C A JJ O
acid CA2160798C A JJ O
antagonist CA2160798C A NN O
relatively CA2160798C A RB O
selective CA2160798C A JJ O
for CA2160798C A IN O
GABA CA2160798C A NNP I-UN
B CA2160798C A NNP I-UN
receptors CA2160798C A NNS I-UN
in CA2160798C A IN O
the CA2160798C A DT O
cells CA2160798C A NNS O
of CA2160798C A IN O
the CA2160798C A DT O
eye CA2160798C A NN O
, CA2160798C A , O
said CA2160798C A VBD O
antagonist CA2160798C A JJ O
present CA2160798C A NN O
in CA2160798C A IN O
a CA2160798C A DT O
carrier CA2160798C A NN O
or CA2160798C A CC O
diluent CA2160798C A NN O
suitable CA2160798C A JJ O
for CA2160798C A IN O
ocular CA2160798C A JJ O
administration CA2160798C A NN O
. CA2160798C A . O

Agents EP2770992A1 T NNS O
, EP2770992A1 T , O
methods EP2770992A1 T NNS O
, EP2770992A1 T , O
and EP2770992A1 T CC O
devices EP2770992A1 T NNS O
for EP2770992A1 T IN O
affecting EP2770992A1 T VBG O
nerve EP2770992A1 T DT O
function EP2770992A1 T NN O
. EP2770992A1 T . O

One EP2770992A1 A CD O
embodiment EP2770992A1 A NN O
of EP2770992A1 A IN O
an EP2770992A1 A DT O
agent EP2770992A1 A NN O
includes EP2770992A1 A VBZ O
a EP2770992A1 A DT O
cardiac EP2770992A1 A JJ O
glycoside EP2770992A1 A NN O
, EP2770992A1 A , O
an EP2770992A1 A DT O
ACE EP2770992A1 A NNP I-UN
inhibitor EP2770992A1 A NN O
, EP2770992A1 A , O
and EP2770992A1 A CC O
an EP2770992A1 A DT O
NSAID EP2770992A1 A NNP O
. EP2770992A1 A . O

Baccatin US20050085513 T NNP O
III US20050085513 T NNP O
analog US20050085513 T NN O
conjugated US20050085513 T VBD O
to US20050085513 T TO O
cell US20050085513 T VB O
binding US20050085513 T VBG O
agent US20050085513 T NN O
such US20050085513 T JJ O
as US20050085513 T IN O
monoclonal US20050085513 T JJ O
antibody US20050085513 T NN O
through US20050085513 T IN O
a US20050085513 T DT O
link US20050085513 T NN O
from US20050085513 T IN O
the US20050085513 T DT O
oxygen US20050085513 T NN O
atom US20050085513 T NN O
at US20050085513 T IN O
the US20050085513 T DT O
C-7 US20050085513 T NNP O
position US20050085513 T NN O
; US20050085513 T : O
treating US20050085513 T VBG O
cancer US20050085513 T NN O
, US20050085513 T , O
rheumatoid US20050085513 T JJ O
arthritis US20050085513 T NN O
, US20050085513 T , O
transplant US20050085513 T JJ O
rejection US20050085513 T NN O
, US20050085513 T , O
viral US20050085513 T JJ O
and US20050085513 T CC O
parasite US20050085513 T JJ O
infections US20050085513 T NNS O
. US20050085513 T . O

Nanocapsules US20100266676 T NNS O
with US20100266676 T IN O
a US20100266676 T DT O
liquid US20100266676 T JJ O
lipid US20100266676 T NN O
core US20100266676 T NN O
charged US20100266676 T VBN O
with US20100266676 T IN O
water-soluble US20100266676 T JJ O
or US20100266676 T CC O
water-dispersible US20100266676 T JJ O
active US20100266676 T JJ O
agents US20100266676 T NNS O
. US20100266676 T . O

New DE102006006115A1 T NNP O
quinoxaline DE102006006115A1 T NN O
derivatives DE102006006115A1 T NNS O
useful DE102006006115A1 T JJ O
e.g DE102006006115A1 T NN O
. DE102006006115A1 T . O

in DE102006006115A1 T IN O
cosmetic DE102006006115A1 T JJ O
and DE102006006115A1 T CC O
pharmaceutical DE102006006115A1 T JJ O
preparation DE102006006115A1 T NN O
as DE102006006115A1 T IN O
photo DE102006006115A1 T NN O
stable DE102006006115A1 T JJ O
UV-filter DE102006006115A1 T NN O
with DE102006006115A1 T IN O
reduced DE102006006115A1 T JJ O
skin DE102006006115A1 T JJ O
penetration DE102006006115A1 T NN O
potential DE102006006115A1 T NN O
to DE102006006115A1 T TO O
protect DE102006006115A1 T VB O
human DE102006006115A1 T JJ O
skin DE102006006115A1 T NN O
or DE102006006115A1 T CC O
hair DE102006006115A1 T NN O
against DE102006006115A1 T IN O
sun DE102006006115A1 T NN O
radiation DE102006006115A1 T NN O
. DE102006006115A1 T . O

Combination WO2013059638A1 T NN O
treatment WO2013059638A1 T NN O
( WO2013059638A1 T ( O
eg WO2013059638A1 T NN O
. WO2013059638A1 T . O

with WO2013059638A1 T IN O
abt-072 WO2013059638A1 T JJ O
or WO2013059638A1 T CC O
abt WO2013059638A1 T JJ O
-333 WO2013059638A1 T NN O
) WO2013059638A1 T ) O
of WO2013059638A1 T IN O
daas WO2013059638A1 T NN O
for WO2013059638A1 T IN O
use WO2013059638A1 T NN O
in WO2013059638A1 T IN O
treating WO2013059638A1 T VBG O
hcv WO2013059638A1 T NN O
. WO2013059638A1 T . O

For WO2013059638A1 A IN O
example WO2013059638A1 A NN O
, WO2013059638A1 A , O
the WO2013059638A1 A DT O
therapies WO2013059638A1 A NNS O
comprise WO2013059638A1 A VBP O
administering WO2013059638A1 A VBG O
to WO2013059638A1 A TO O
a WO2013059638A1 A DT O
subject WO2013059638A1 A NN O
an WO2013059638A1 A DT O
effective WO2013059638A1 A JJ O
amounts WO2013059638A1 A NNS O
of WO2013059638A1 A IN O
therapeutic WO2013059638A1 A JJ O
agent WO2013059638A1 A NN O
1 WO2013059638A1 A CD O
( WO2013059638A1 A ( O
ABT WO2013059638A1 A NNP O
) WO2013059638A1 A ) O
or WO2013059638A1 A CC O
therapeutic WO2013059638A1 A JJ O
agent WO2013059638A1 A NN O
2 WO2013059638A1 A CD O
( WO2013059638A1 A ( O
=ABT-333 WO2013059638A1 A JJ O
) WO2013059638A1 A ) O
or WO2013059638A1 A CC O
therapeutic WO2013059638A1 A JJ O
agent WO2013059638A1 A NN O
3 WO2013059638A1 A CD O
( WO2013059638A1 A ( O
=ABT-072 WO2013059638A1 A JJ O
) WO2013059638A1 A ) O
or WO2013059638A1 A CC O
therapeutic WO2013059638A1 A JJ O
agent WO2013059638A1 A NN O
4 WO2013059638A1 A CD O
( WO2013059638A1 A ( O
ABT WO2013059638A1 A NNP O
) WO2013059638A1 A ) O
, WO2013059638A1 A , O
and WO2013059638A1 A CC O
an WO2013059638A1 A DT O
inhibitor WO2013059638A1 A NN O
of WO2013059638A1 A IN O
cytochrome WO2013059638A1 A JJ I-UN
P450 WO2013059638A1 A NNP I-UN
( WO2013059638A1 A ( O
e.g. WO2013059638A1 A NN O
, WO2013059638A1 A , O
ritonavir WO2013059638A1 A NN O
) WO2013059638A1 A ) O
. WO2013059638A1 A . O

Oligonucleotide EP2341058A2 T NNP O
Analogues EP2341058A2 T NNP O
. EP2341058A2 T . O

The EP2341058A2 A DT O
present EP2341058A2 A JJ O
invention EP2341058A2 A NN O
relates EP2341058A2 A VBZ O
to EP2341058A2 A TO O
novel EP2341058A2 A VB O
bicyclic EP2341058A2 A JJ O
and EP2341058A2 A CC O
tricyclic EP2341058A2 A JJ O
nucleoside EP2341058A2 A NN O
and EP2341058A2 A CC O
nucleotide EP2341058A2 A RB O
analogues EP2341058A2 A NNS O
as EP2341058A2 A RB O
well EP2341058A2 A RB O
as EP2341058A2 A IN O
to EP2341058A2 A TO O
oligonucleotides EP2341058A2 A VB O
comprising EP2341058A2 A VBG O
such EP2341058A2 A JJ O
elements EP2341058A2 A NNS O
. EP2341058A2 A . O

The EP2341058A2 A DT O
nucleotide EP2341058A2 A NN O
analogues EP2341058A2 A NNS O
, EP2341058A2 A , O
LNAs EP2341058A2 A NNP O
( EP2341058A2 A ( O
Locked EP2341058A2 A VBN O
Nucleoside EP2341058A2 A NNP O
Analogues EP2341058A2 A NNP O
) EP2341058A2 A ) O
, EP2341058A2 A , O
are EP2341058A2 A VBP O
able EP2341058A2 A JJ O
to EP2341058A2 A TO O
provide EP2341058A2 A VB O
valuable EP2341058A2 A JJ O
improvements EP2341058A2 A NNS O
to EP2341058A2 A TO O
oligonucleotides EP2341058A2 A NNS O
with EP2341058A2 A IN O
respect EP2341058A2 A NN O
to EP2341058A2 A TO O
affinity EP2341058A2 A NN O
and EP2341058A2 A CC O
specificity EP2341058A2 A NN O
towards EP2341058A2 A NNS O
complementary EP2341058A2 A JJ O
RNA EP2341058A2 A NNP O
and EP2341058A2 A CC O
DNA EP2341058A2 A NNP O
oligomers EP2341058A2 A NNS O
. EP2341058A2 A . O

The EP2341058A2 A DT O
novel EP2341058A2 A JJ O
type EP2341058A2 A NN O
of EP2341058A2 A IN O
LNA EP2341058A2 A NNP O
modified EP2341058A2 A VBD O
oligonucleotides EP2341058A2 A NNS O
, EP2341058A2 A , O
as EP2341058A2 A RB O
well EP2341058A2 A RB O
as EP2341058A2 A IN O
the EP2341058A2 A DT O
LNAs EP2341058A2 A NNP O
as EP2341058A2 A IN O
such EP2341058A2 A JJ O
, EP2341058A2 A , O
are EP2341058A2 A VBP O
useful EP2341058A2 A JJ O
in EP2341058A2 A IN O
a EP2341058A2 A DT O
wide EP2341058A2 A JJ O
range EP2341058A2 A NN O
of EP2341058A2 A IN O
diagnostic EP2341058A2 A JJ O
applications EP2341058A2 A NNS O
as EP2341058A2 A RB O
well EP2341058A2 A RB O
as EP2341058A2 A IN O
therapeutic EP2341058A2 A JJ O
applications EP2341058A2 A NNS O
. EP2341058A2 A . O

Among EP2341058A2 A IN O
these EP2341058A2 A DT O
can EP2341058A2 A MD O
be EP2341058A2 A VB O
mentioned EP2341058A2 A VBN O
antisense EP2341058A2 A JJ O
applications EP2341058A2 A NNS O
, EP2341058A2 A , O
PCR EP2341058A2 A NNP O
applications EP2341058A2 A NNS O
, EP2341058A2 A , O
strand EP2341058A2 A VBP O
displacement EP2341058A2 A NN O
oligomers EP2341058A2 A NNS O
, EP2341058A2 A , O
as EP2341058A2 A IN O
substrates EP2341058A2 A NNS O
for EP2341058A2 A IN O
nucleic EP2341058A2 A JJ O
acid EP2341058A2 A NN O
polymerases EP2341058A2 A NNS O
, EP2341058A2 A , O
as EP2341058A2 A IN O
nucleotide EP2341058A2 A RB O
based EP2341058A2 A VBN O
drugs EP2341058A2 A NNS O
, EP2341058A2 A , O
etc EP2341058A2 A FW O
. EP2341058A2 A . O

The EP2341058A2 A DT O
present EP2341058A2 A JJ O
invention EP2341058A2 A NN O
also EP2341058A2 A RB O
relates EP2341058A2 A VBZ O
to EP2341058A2 A TO O
such EP2341058A2 A JJ O
applications EP2341058A2 A NNS O
. EP2341058A2 A . O

( US7598244 T ( O
S US7598244 T NNP O
) US7598244 T ) O
-1- US7598244 T NN O
( US7598244 T ( O
3-ethoxy-1-methylpropyl US7598244 T JJ O
) US7598244 T ) O
-3- US7598244 T FW O
[ US7598244 T JJ O
7- US7598244 T JJ O
( US7598244 T ( O
3,4-methylenedioxyphenyl US7598244 T JJ O
) US7598244 T ) O
- US7598244 T : O
[ US7598244 T $ O
1,2,4 US7598244 T CD O
] US7598244 T NNP O
triazolo US7598244 T NN O
[ US7598244 T NNP O
1,5-a US7598244 T JJ O
] US7598244 T NNP O
pyrimidin-2-yl US7598244 T NN O
] US7598244 T NNP O
urea US7598244 T NN O
; US7598244 T : O
preventive US7598244 T JJ O
and/or US7598244 T NN O
therapeutic US7598244 T JJ O
agent US7598244 T NN O
for US7598244 T IN O
immunological US7598244 T JJ O
rejection US7598244 T NN O
and/or US7598244 T NN O
graft US7598244 T NN O
versus US7598244 T NN O
host US7598244 T NN O
reaction US7598244 T NN O
in US7598244 T IN O
organ/bone US7598244 T NN O
marrow US7598244 T NN O
transplant US7598244 T NN O
, US7598244 T , O
autoimmune US7598244 T JJ O
disease US7598244 T NN O
, US7598244 T , O
allergic US7598244 T JJ O
disease US7598244 T NN O
and/or US7598244 T JJ O
inflammatory US7598244 T JJ O
disease US7598244 T NN O
. US7598244 T . O

Uses US20120225030 T NNS O
of US20120225030 T IN O
mammalian US20120225030 T JJ O
cytokine US20120225030 T NN O
; US20120225030 T : O
related US20120225030 T JJ O
reagents US20120225030 T NNS O
. US20120225030 T . O

Medicament CN101579333A T NN O
for CN101579333A T IN O
treating CN101579333A T VBG O
soft CN101579333A T JJ O
tissue CN101579333A T NN O
injury CN101579333A T NN O
and CN101579333A T CC O
arthritis CN101579333A T NN O
and CN101579333A T CC O
gel CN101579333A T JJ O
preparation CN101579333A T NN O
method CN101579333A T NN O
. CN101579333A T . O

Paclitaxel CN1754535A T NNP O
analog CN1754535A T NN O
microsphere CN1754535A T RB O
for CN1754535A T IN O
topical CN1754535A T JJ O
injection CN1754535A T NN O
, CN1754535A T , O
its CN1754535A T PRP$ O
preparation CN1754535A T NN O
method CN1754535A T NN O
and CN1754535A T CC O
uses CN1754535A T NNS O
. CN1754535A T . O

Novel WO2011111738A1 T NNP O
fki-4429 WO2011111738A1 T JJ O
substance WO2011111738A1 T NN O
and WO2011111738A1 T CC O
method WO2011111738A1 T NN O
for WO2011111738A1 T IN O
producing WO2011111738A1 T VBG O
same WO2011111738A1 T JJ O
. WO2011111738A1 T . O

Ganciclovir CN1868449A T NNP O
ophthalmic CN1868449A T JJ O
gel CN1868449A T NN O
and CN1868449A T CC O
its CN1868449A T PRP$ O
prepn CN1868449A T NN O
. CN1868449A T . O

method CN1868449A T NN O
. CN1868449A T . O

Process CA2252986C T NN O
for CA2252986C T IN O
preparing CA2252986C T VBG O
functional CA2252986C T JJ O
recombinant CA2252986C T JJ O
tissue CA2252986C T NN I-UN
factor CA2252986C T NN I-UN
. CA2252986C T . O

The CA2252986C A DT O
present CA2252986C A JJ O
invention CA2252986C A NN O
relates CA2252986C A VBZ O
to CA2252986C A TO O
a CA2252986C A DT O
process CA2252986C A NN O
for CA2252986C A IN O
preparing CA2252986C A VBG O
functional CA2252986C A JJ O
recombinant CA2252986C A JJ O
tissue CA2252986C A NN I-UN
factor CA2252986C A NN I-UN
in CA2252986C A IN O
a CA2252986C A DT O
prokaryotic CA2252986C A JJ O
host CA2252986C A NN O
organism CA2252986C A NN O
. CA2252986C A . O

producing US20080119421 T VBG O
a US20080119421 T DT O
synchronized US20080119421 T JJ O
cells US20080119421 T NNS O
by US20080119421 T IN O
administering US20080119421 T VBG O
a US20080119421 T DT O
cell US20080119421 T NN O
cycle US20080119421 T NN O
arresting US20080119421 T VBG O
drug US20080119421 T NN O
, US20080119421 T , O
then US20080119421 T RB O
adding US20080119421 T VBG O
a US20080119421 T DT O
microtubule US20080119421 T NN O
stabilizing US20080119421 T VBG O
drug US20080119421 T NN O
, US20080119421 T , O
and US20080119421 T CC O
applying US20080119421 T VBG O
mechanical US20080119421 T JJ O
vibrational US20080119421 T JJ O
energy US20080119421 T NN O
ultrasound US20080119421 T NN O
; US20080119421 T : O
drug US20080119421 T NN O
deliverying US20080119421 T VBG O
anticarcinogenic US20080119421 T JJ O
agent US20080119421 T NN O
directed US20080119421 T VBD O
to US20080119421 T TO O
be US20080119421 T VB O
more US20080119421 T JJR O
toxic US20080119421 T JJ O
to US20080119421 T TO O
cancer US20080119421 T NN O
cells US20080119421 T NNS O
than US20080119421 T IN O
normal US20080119421 T JJ O
cells US20080119421 T NNS O
. US20080119421 T . O

Application CN101108173A T NN O
of CN101108173A T IN O
p-hydroxybenzene CN101108173A T JJ O
ethanone CN101108173A T NN O
and CN101108173A T CC O
its CN101108173A T PRP$ O
derivant CN101108173A T NN O
in CN101108173A T IN O
preparation CN101108173A T NN O
of CN101108173A T IN O
agentia CN101108173A T NN O
treating CN101108173A T VBG O
gallstone CN101108173A T NN O
disease CN101108173A T NN O
. CN101108173A T . O

Compound CN103239432A T NNP O
ambroxol CN103239432A T VBD O
hydrochloride CN103239432A T JJ O
composition CN103239432A T NN O
granule CN103239432A T NN O
and CN103239432A T CC O
preparation CN103239432A T NN O
method CN103239432A T NN O
thereof CN103239432A T NN O
. CN103239432A T . O

Methods WO2008011478A2 T NNS O
for WO2008011478A2 T IN O
treating WO2008011478A2 T VBG O
chronic WO2008011478A2 T JJ O
pain WO2008011478A2 T NN O
using WO2008011478A2 T VBG O
3-aryl-3-hydroxy-2-amino-propionic WO2008011478A2 T JJ O
acid WO2008011478A2 T NN O
amides WO2008011478A2 T NNS O
, WO2008011478A2 T , O
3-heteroaryl-3-hydroxy-2-amino-propionic WO2008011478A2 T JJ O
acid WO2008011478A2 T NN O
amides WO2008011478A2 T NNS O
and WO2008011478A2 T CC O
related WO2008011478A2 T JJ O
compounds WO2008011478A2 T NNS O
. WO2008011478A2 T . O

External CN101804136A T JJ O
plaster CN101804136A T NN O
for CN101804136A T IN O
curing CN101804136A T VBG O
scald CN101804136A T NN O
and CN101804136A T CC O
burn CN101804136A T NN O
sores CN101804136A T NNS O
and CN101804136A T CC O
preparation CN101804136A T NN O
method CN101804136A T NN O
thereof CN101804136A T NN O
. CN101804136A T . O

Method US20100029580 T NNP O
for US20100029580 T IN O
Diagnosing US20100029580 T VBG O
Non-Small US20100029580 T NNP O
Cell US20100029580 T NNP O
Lung US20100029580 T NNP O
Carcinoma US20100029580 T NNP O
. US20100029580 T . O

The US20100029580 A DT O
present US20100029580 A JJ O
invention US20100029580 A NN O
relates US20100029580 A VBZ O
to US20100029580 A TO O
the US20100029580 A DT O
constitutive US20100029580 A JJ O
activity US20100029580 A NN O
of US20100029580 A IN O
the US20100029580 A DT O
Hedgehog US20100029580 A NNP I-UN
pathway US20100029580 A NN O
in US20100029580 A IN O
non-small US20100029580 A JJ O
cell US20100029580 A NN O
lung US20100029580 A NN O
carcinoma US20100029580 A NN O
( US20100029580 A ( O
NSCLC US20100029580 A NNP O
) US20100029580 A ) O
. US20100029580 A . O

A US20100029580 A DT O
method US20100029580 A NN O
for US20100029580 A IN O
diagnosing US20100029580 A VBG O
NSCLC US20100029580 A NNP O
by US20100029580 A IN O
detecting US20100029580 A VBG O
the US20100029580 A DT O
level US20100029580 A NN O
of US20100029580 A IN O
a US20100029580 A DT O
component US20100029580 A NN O
of US20100029580 A IN O
the US20100029580 A DT O
Hedgehog US20100029580 A NNP I-UN
pathway US20100029580 A NN O
is US20100029580 A VBZ O
provided US20100029580 A VBN O
, US20100029580 A , O
as US20100029580 A IN O
is US20100029580 A VBZ O
a US20100029580 A DT O
method US20100029580 A NN O
for US20100029580 A IN O
identifying US20100029580 A VBG O
subjects US20100029580 A NNS O
that US20100029580 A WDT O
will US20100029580 A MD O
respond US20100029580 A VB O
positively US20100029580 A RB O
to US20100029580 A TO O
treatment US20100029580 A NN O
with US20100029580 A IN O
a US20100029580 A DT O
Hedgehog US20100029580 A NNP I-UN
pathway US20100029580 A NN O
antagonist US20100029580 A NN O
. US20100029580 A . O

Methods US20100029580 A NNS O
for US20100029580 A IN O
treating US20100029580 A VBG O
subjects US20100029580 A NNS O
with US20100029580 A IN O
cancer US20100029580 A NN O
or US20100029580 A CC O
cancers US20100029580 A NNS O
resistant US20100029580 A VBP O
to US20100029580 A TO O
Hedgehog US20100029580 A NNP I-UN
pathway US20100029580 A NN O
antagonists US20100029580 A NNS O
are US20100029580 A VBP O
also US20100029580 A RB O
provided US20100029580 A VBN O
. US20100029580 A . O

Treating US7094770 T VBG O
hepatitus US7094770 T NN O
B US7094770 T NNP O
, US7094770 T , O
C US7094770 T NNP O
and US7094770 T CC O
D US7094770 T NNP O
; US7094770 T : O
AIDS US7094770 T NNP O
; US7094770 T : O
antiproliferative US7094770 T JJ O
agents US7094770 T NNS O
. US7094770 T . O

Application CN102824354A T NN O
of CN102824354A T IN O
polydatin CN102824354A T NN O
in CN102824354A T IN O
preparation CN102824354A T NN O
of CN102824354A T IN O
pharmaceuticals CN102824354A T NNS O
for CN102824354A T IN O
preventing CN102824354A T VBG O
and CN102824354A T CC O
treating CN102824354A T VBG O
chronic CN102824354A T JJ O
glomerular CN102824354A T JJ O
diseases CN102824354A T NNS O
. CN102824354A T . O

Exopolysaccharides US8088605 T NNS O
delivery US8088605 T NN O
system US8088605 T NN O
for US8088605 T IN O
active US8088605 T JJ O
molecules US8088605 T NNS O
. US8088605 T . O

Sustained-release WO2012139262A1 T JJ O
preparation WO2012139262A1 T NN O
of WO2012139262A1 T IN O
compound WO2012139262A1 T NN O
methoxyphenamine WO2012139262A1 T NN O
. WO2012139262A1 T . O

Removal US20090238897 T NN O
of US20090238897 T IN O
skin US20090238897 T JJ O
changes US20090238897 T NNS O
. US20090238897 T . O

The US20090238897 A DT O
present US20090238897 A JJ O
invention US20090238897 A NN O
relates US20090238897 A VBZ O
to US20090238897 A TO O
the US20090238897 A DT O
field US20090238897 A NN O
of US20090238897 A IN O
skin US20090238897 A NN O
disorders US20090238897 A NNS O
, US20090238897 A , O
particularly US20090238897 A RB O
to US20090238897 A TO O
the US20090238897 A DT O
prevention US20090238897 A NN O
and/or US20090238897 A NN O
treatment US20090238897 A NN O
of US20090238897 A IN O
benignant US20090238897 A NN O
or US20090238897 A CC O
malignant US20090238897 A JJ O
changes US20090238897 A NNS O
of US20090238897 A IN O
the US20090238897 A DT O
epidermis US20090238897 A NN O
visible US20090238897 A JJ O
in US20090238897 A IN O
form US20090238897 A NN O
of US20090238897 A IN O
e.g US20090238897 A NN O
. US20090238897 A . O

nevus US20090238897 A NN O
. US20090238897 A . O

A US20090238897 A DT O
pharmaceutical US20090238897 A JJ O
, US20090238897 A , O
dermatological US20090238897 A JJ O
and/or US20090238897 A NN O
cosmetic US20090238897 A JJ O
composition US20090238897 A NN O
is US20090238897 A VBZ O
disclosed US20090238897 A VBN O
comprising US20090238897 A VBG O
as US20090238897 A IN O
active US20090238897 A JJ O
constituent US20090238897 A NN O
the US20090238897 A DT O
boroxine US20090238897 A NN O
compound US20090238897 A NN O
. US20090238897 A . O

The US20090238897 A DT O
present US20090238897 A JJ O
invention US20090238897 A NN O
further US20090238897 A RBR O
provides US20090238897 A VBZ O
the US20090238897 A DT O
respective US20090238897 A JJ O
uses US20090238897 A NNS O
of US20090238897 A IN O
the US20090238897 A DT O
boroxine US20090238897 A NN O
compound US20090238897 A NN O
in US20090238897 A IN O
medicine US20090238897 A NN O
, US20090238897 A , O
particularly US20090238897 A RB O
in US20090238897 A IN O
the US20090238897 A DT O
field US20090238897 A NN O
of US20090238897 A IN O
skin US20090238897 A NN O
disorders US20090238897 A NNS O
, US20090238897 A , O
and US20090238897 A CC O
in US20090238897 A IN O
dermatological US20090238897 A JJ O
and/or US20090238897 A NN O
cosmetic US20090238897 A JJ O
applications US20090238897 A NNS O
. US20090238897 A . O

Compositions US20110027230 T NNS O
comprising US20110027230 T VBG O
phytoestrogenes US20110027230 T NNS O
selective US20110027230 T JJ O
for US20110027230 T IN O
estrogen US20110027230 T NN I-UN
beta US20110027230 T NN I-UN
receptor US20110027230 T NN I-UN
and US20110027230 T CC O
dietary US20110027230 T JJ O
fibres US20110027230 T NNS O
. US20110027230 T . O

Oral US20110027230 A JJ O
compositions US20110027230 A NNS O
comprising US20110027230 A VBG O
an US20110027230 A DT O
association US20110027230 A NN O
of US20110027230 A IN O
one US20110027230 A CD O
or US20110027230 A CC O
of US20110027230 A IN O
a US20110027230 A DT O
mixture US20110027230 A NN O
of US20110027230 A IN O
phytoestrogens US20110027230 A NNS O
, US20110027230 A , O
selective US20110027230 A NN O
for US20110027230 A IN O
the US20110027230 A DT O
estrogen US20110027230 A NN I-UN
receptor-β US20110027230 A NN I-UN
, US20110027230 A , O
with US20110027230 A IN O
dietary US20110027230 A JJ O
fibres US20110027230 A NNS O
are US20110027230 A VBP O
described US20110027230 A VBN O
. US20110027230 A . O

In US20110027230 A IN O
presence US20110027230 A NN O
of US20110027230 A IN O
pre-cancerous US20110027230 A JJ O
lesions US20110027230 A NNS O
in US20110027230 A IN O
the US20110027230 A DT O
colon US20110027230 A NN O
, US20110027230 A , O
characterised US20110027230 A VBN O
by US20110027230 A IN O
mutations US20110027230 A NNS O
of US20110027230 A IN O
the US20110027230 A DT O
APC US20110027230 A NNP I-UN
tumor US20110027230 A NN O
suppressor US20110027230 A NN O
and US20110027230 A CC O
defined US20110027230 A VBD O
as US20110027230 A IN O
polyps US20110027230 A NNS O
or US20110027230 A CC O
adenomas US20110027230 A NN O
, US20110027230 A , O
the US20110027230 A DT O
oral US20110027230 A JJ O
compositions US20110027230 A NNS O
disclosed US20110027230 A VBD O
can US20110027230 A MD O
be US20110027230 A VB O
in US20110027230 A IN O
fact US20110027230 A NN O
profitably US20110027230 A RB O
used US20110027230 A VBD O
to US20110027230 A TO O
reduce US20110027230 A VB O
the US20110027230 A DT O
number US20110027230 A NN O
and US20110027230 A CC O
volume US20110027230 A NN O
of US20110027230 A IN O
polyps US20110027230 A NNS O
, US20110027230 A , O
and US20110027230 A CC O
to US20110027230 A TO O
prevent US20110027230 A VB O
their US20110027230 A PRP$ O
progression US20110027230 A NN O
to US20110027230 A TO O
neoplastic US20110027230 A JJ O
transformation US20110027230 A NN O
, US20110027230 A , O
reducing US20110027230 A VBG O
their US20110027230 A PRP$ O
degree US20110027230 A NN O
of US20110027230 A IN O
dysplasia US20110027230 A NN O
. US20110027230 A . O

Cataplasma CN101045041A T NNP O
containing CN101045041A T VBG O
ibuprofen CN101045041A T NN O
its CN101045041A T PRP$ O
preparing CN101045041A T NN O
method CN101045041A T NN O
and CN101045041A T CC O
application CN101045041A T NN O
. CN101045041A T . O

Plaster CN102793883A T NN O
for CN102793883A T IN O
treating CN102793883A T VBG O
intervertebral CN102793883A T JJ O
disc CN102793883A T NN O
protrusion CN102793883A T NN O
, CN102793883A T , O
cervical CN102793883A T JJ O
spondylosis CN102793883A T NN O
and CN102793883A T CC O
osteoproliferation CN102793883A T NN O
. CN102793883A T . O

Process US20100029584 T NN O
for US20100029584 T IN O
producing US20100029584 T VBG O
a US20100029584 T DT O
cellulose-based US20100029584 T JJ O
film US20100029584 T NN O
to US20100029584 T TO O
be US20100029584 T VB O
used US20100029584 T VBN O
for US20100029584 T IN O
skin US20100029584 T NN O
and US20100029584 T CC O
tissue US20100029584 T NN O
lesions US20100029584 T NNS O
. US20100029584 T . O

2-mercaptoacetophenone-containing CN103319431A T JJ O
1 CN103319431A T CD O
, CN103319431A T , O
3 CN103319431A T CD O
, CN103319431A T , O
4-oxadiazole CN103319431A T JJ O
derivative CN103319431A T NN O
, CN103319431A T , O
its CN103319431A T PRP$ O
preparation CN103319431A T NN O
method CN103319431A T NN O
and CN103319431A T CC O
antitumor CN103319431A T NN O
activity CN103319431A T NN O
. CN103319431A T . O

Renin WO2009154766A1 T NNP I-UN
inhibitors WO2009154766A1 T NNS O
and WO2009154766A1 T CC O
method WO2009154766A1 T NN O
of WO2009154766A1 T IN O
use WO2009154766A1 T NN O
thereof WO2009154766A1 T NN O
. WO2009154766A1 T . O

Nitric US20120289597 T NNP O
oxide US20120289597 T MD O
amino US20120289597 T VB O
acid US20120289597 T JJ O
esters US20120289597 T NNS O
for US20120289597 T IN O
the US20120289597 T DT O
treatment US20120289597 T NN O
of US20120289597 T IN O
chronic US20120289597 T JJ O
pain US20120289597 T NN O
. US20120289597 T . O

Polyene US20090069396 T NNP O
Oxazoles US20090069396 T NNP O
and US20090069396 T CC O
Processes US20090069396 T NNP O
for US20090069396 T IN O
Their US20090069396 T NNP O
Preparation US20090069396 T NNP O
. US20090069396 T . O

This US20090069396 A DT O
invention US20090069396 A NN O
relates US20090069396 A VBZ O
to US20090069396 A TO O
novel US20090069396 A VB O
biologically US20090069396 A RB O
active US20090069396 A JJ O
polyene US20090069396 A NN O
oxazoles US20090069396 A NNS O
, US20090069396 A , O
their US20090069396 A PRP$ O
pharmaceutically US20090069396 A RB O
acceptable US20090069396 A JJ O
salts US20090069396 A NNS O
and US20090069396 A CC O
derivatives US20090069396 A NNS O
, US20090069396 A , O
and US20090069396 A CC O
to US20090069396 A TO O
methods US20090069396 A NNS O
of US20090069396 A IN O
obtaining US20090069396 A VBG O
them US20090069396 A PRP O
. US20090069396 A . O

One US20090069396 A CD O
method US20090069396 A NN O
for US20090069396 A IN O
obtaining US20090069396 A VBG O
the US20090069396 A DT O
compounds US20090069396 A NNS O
is US20090069396 A VBZ O
by US20090069396 A IN O
cultivation US20090069396 A NN O
of US20090069396 A IN O
Streptomyces US20090069396 A NNP O
sparsogenes US20090069396 A NNS O
NRRL US20090069396 A NNP O
2940 US20090069396 A CD O
or US20090069396 A CC O
a US20090069396 A DT O
mutant US20090069396 A JJ O
or US20090069396 A CC O
variant US20090069396 A JJ O
thereof US20090069396 A NN O
. US20090069396 A . O

8,8-disubstituted-13,13a-dihyrdroberberine CN101870694A T JJ O
derivative CN101870694A T NN O
as CN101870694A T RB O
well CN101870694A T RB O
as CN101870694A T IN O
pharmaceutical CN101870694A T JJ O
composition CN101870694A T NN O
and CN101870694A T CC O
application CN101870694A T NN O
thereof CN101870694A T NN O
. CN101870694A T . O

Proved CN101870694A A VBN O
by CN101870694A A IN O
in-vivo CN101870694A A JJ O
animal CN101870694A A JJ O
experiments CN101870694A A NNS O
, CN101870694A A , O
the CN101870694A A DT O
compound CN101870694A A NN O
has CN101870694A A VBZ O
the CN101870694A A DT O
effects CN101870694A A NNS O
on CN101870694A A IN O
improving CN101870694A A VBG O
the CN101870694A A DT O
carbohydrate CN101870694A A NN O
tolerance CN101870694A A NN O
and CN101870694A A CC O
the CN101870694A A DT O
insulin CN101870694A A NN I-UN
resistance CN101870694A A NN O
, CN101870694A A , O
reducing CN101870694A A VBG O
weight CN101870694A A NN O
, CN101870694A A , O
relieving CN101870694A A VBG O
fatty CN101870694A A JJ O
livers CN101870694A A NNS O
, CN101870694A A , O
and CN101870694A A CC O
the CN101870694A A DT O
like CN101870694A A JJ O
, CN101870694A A , O
has CN101870694A A VBZ O
high CN101870694A A JJ O
bioavailability CN101870694A A NN O
, CN101870694A A , O
enhances CN101870694A A VBZ O
the CN101870694A A DT O
in-vivo CN101870694A A JJ O
pesticide CN101870694A A NN O
effect CN101870694A A NN O
, CN101870694A A , O
and CN101870694A A CC O
has CN101870694A A VBZ O
stable CN101870694A A JJ O
structure CN101870694A A NN O
under CN101870694A A IN O
an CN101870694A A DT O
acidic CN101870694A A JJ O
condition CN101870694A A NN O
. CN101870694A A . O

Stabilizing CN102046202A T VBG O
lipid CN102046202A T JJ O
compositions CN102046202A T NNS O
for CN102046202A T IN O
oral CN102046202A T JJ O
pharmaceutical CN102046202A T JJ O
agents CN102046202A T NNS O
. CN102046202A T . O

Sustained CN102697792A T VBN O
releasing CN102697792A T VBG O
medicine CN102697792A T NN O
for CN102697792A T IN O
treating CN102697792A T VBG O
glaucoma CN102697792A T NN O
and CN102697792A T CC O
preparation CN102697792A T NN O
technology CN102697792A T NN O
of CN102697792A T IN O
same CN102697792A T JJ O
. CN102697792A T . O

Thienopyridine US7067527 T NNP O
derivatives US7067527 T NNS O
, US7067527 T , O
their US7067527 T PRP$ O
production US7067527 T NN O
and US7067527 T CC O
use US7067527 T NN O
. US7067527 T . O

Antisense US20140187601 T NNP O
oligonucleotide US20140187601 T JJ O
modulation US20140187601 T NN O
of US20140187601 T IN O
raf US20140187601 T JJ I-UN
gene US20140187601 T NN O
expression US20140187601 T NN O
. US20140187601 T . O

Oligonucleotides US20140187601 A NNS O
are US20140187601 A VBP O
provided US20140187601 A VBN O
which US20140187601 A WDT O
are US20140187601 A VBP O
targeted US20140187601 A VBN O
to US20140187601 A TO O
nucleic US20140187601 A JJ O
acids US20140187601 A NNS O
encoding US20140187601 A VBG O
human US20140187601 A JJ I-UN
raf US20140187601 A NN I-UN
and US20140187601 A CC O
capable US20140187601 A JJ O
of US20140187601 A IN O
inhibiting US20140187601 A VBG O
raf US20140187601 A JJ I-UN
expression US20140187601 A NN O
. US20140187601 A . O

Methods US20140187601 A NNS O
of US20140187601 A IN O
inhibiting US20140187601 A VBG O
the US20140187601 A DT O
expression US20140187601 A NN O
of US20140187601 A IN O
human US20140187601 A JJ O
raf US20140187601 A NN I-UN
using US20140187601 A VBG O
oligonucleotides US20140187601 A NNS O
of US20140187601 A IN O
the US20140187601 A DT O
invention US20140187601 A NN O
are US20140187601 A VBP O
also US20140187601 A RB O
provided US20140187601 A VBN O
. US20140187601 A . O

The US20140187601 A DT O
present US20140187601 A JJ O
invention US20140187601 A NN O
further US20140187601 A RBR O
comprises US20140187601 A VBZ O
methods US20140187601 A NNS O
of US20140187601 A IN O
inhibiting US20140187601 A VBG O
hyperproliferation US20140187601 A NN O
of US20140187601 A IN O
cells US20140187601 A NNS O
and US20140187601 A CC O
methods US20140187601 A NNS O
of US20140187601 A IN O
treating US20140187601 A VBG O
or US20140187601 A CC O
preventing US20140187601 A VBG O
conditions US20140187601 A NNS O
, US20140187601 A , O
including US20140187601 A VBG O
hyperproliferative US20140187601 A JJ O
conditions US20140187601 A NNS O
, US20140187601 A , O
associated US20140187601 A VBN O
with US20140187601 A IN O
raf US20140187601 A JJ I-UN
expression US20140187601 A NN O
. US20140187601 A . O

Compositions WO2012012385A2 T NNS O
comprising WO2012012385A2 T VBG O
derivatives WO2012012385A2 T NNS O
of WO2012012385A2 T IN O
essential WO2012012385A2 T JJ O
oil WO2012012385A2 T NN O
compounds WO2012012385A2 T NNS O
and WO2012012385A2 T CC O
use WO2012012385A2 T NN O
in WO2012012385A2 T IN O
personal WO2012012385A2 T JJ O
care WO2012012385A2 T NN O
products WO2012012385A2 T NNS O
. WO2012012385A2 T . O

A WO2010012459A3 T DT O
process WO2010012459A3 T NN O
for WO2010012459A3 T IN O
the WO2010012459A3 T DT O
preparation WO2010012459A3 T NN O
of WO2010012459A3 T IN O
solifenacin WO2010012459A3 T NN O
salts WO2010012459A3 T NNS O
and WO2010012459A3 T CC O
their WO2010012459A3 T PRP$ O
inclusion WO2010012459A3 T NN O
into WO2010012459A3 T IN O
pharmaceutical WO2010012459A3 T JJ O
dosage WO2010012459A3 T NN O
forms WO2010012459A3 T NNS O
. WO2010012459A3 T . O

Mangiferin-Berberine US20120094941 T JJ O
Salt US20120094941 T NNP O
, US20120094941 T , O
Manufacturing US20120094941 T NNP O
Method US20120094941 T NNP O
and US20120094941 T CC O
Use US20120094941 T NNP O
Thereof US20120094941 T NNP O
. US20120094941 T . O

Otherwise US20120094941 A RB O
, US20120094941 A , O
the US20120094941 A DT O
present US20120094941 A JJ O
invention US20120094941 A NN O
also US20120094941 A RB O
provides US20120094941 A VBZ O
the US20120094941 A DT O
use US20120094941 A NN O
of US20120094941 A IN O
mangiferin-berberine US20120094941 A JJ O
salt US20120094941 A NN O
as US20120094941 A IN O
AMPK US20120094941 A NNP I-UN
activator US20120094941 A NN O
. US20120094941 A . O

Cyclodextrin CN101721713B T NNP O
inclusion CN101721713B T NN O
compound CN101721713B T NN O
of CN101721713B T IN O
3,5-dyhydroxyl-4-isopropyl CN101721713B T JJ O
toluylene CN101721713B T NN O
and CN101721713B T CC O
preparation CN101721713B T NN O
method CN101721713B T NN O
thereof CN101721713B T NN O
. CN101721713B T . O

Composition CN101564388A T NN O
for CN101564388A T IN O
Danshensu CN101564388A T NNP O
and CN101564388A T CC O
danshinolic CN101564388A T JJ O
acid CN101564388A T NN O
B CN101564388A T NNP O
and CN101564388A T CC O
use CN101564388A T NN O
thereof CN101564388A T NN O
. CN101564388A T . O

Method US20120136058 T NNP O
For US20120136058 T IN O
Increasing US20120136058 T VBG O
The US20120136058 T DT O
Solubility US20120136058 T NN O
Of US20120136058 T IN O
Methionine US20120136058 T NNP O
By US20120136058 T IN O
Mineral US20120136058 T NNP O
Addition US20120136058 T NNP O
And US20120136058 T CC O
Acid US20120136058 T NNP O
Treatment US20120136058 T NNP O
. US20120136058 T . O

Fatty CN1771909A T NNP O
artemisinin CN1771909A T JJ O
emulsion CN1771909A T NN O
and CN1771909A T CC O
its CN1771909A T PRP$ O
prepn CN1771909A T NN O
and CN1771909A T CC O
application CN1771909A T NN O
. CN1771909A T . O

Pineapple CN1569868A T NNP O
flavonoid CN1569868A T JJ O
glycoside CN1569868A T NN O
compound CN1569868A T NN O
and CN1569868A T CC O
its CN1569868A T PRP$ O
use CN1569868A T NN O
. CN1569868A T . O

Inhibitor WO2014085489A1 T NN I-UN
of WO2014085489A1 T IN I-UN
apoptosis WO2014085489A1 T NN I-UN
protein WO2014085489A1 T NN I-UN
( WO2014085489A1 T ( O
iap WO2014085489A1 T NN I-UN
) WO2014085489A1 T ) O
antagonists WO2014085489A1 T VBZ O
. WO2014085489A1 T . O

Provided WO2014085489A1 A VBN O
herein WO2014085489A1 A NN O
are WO2014085489A1 A VBP O
compounds WO2014085489A1 A VBZ O
that WO2014085489A1 A IN O
modulate WO2014085489A1 A VB O
the WO2014085489A1 A DT O
activity WO2014085489A1 A NN O
of WO2014085489A1 A IN O
inhibitor WO2014085489A1 A NN I-UN
of WO2014085489A1 A IN I-UN
apoptosis WO2014085489A1 A NN I-UN
proteins WO2014085489A1 A NNS I-UN
( WO2014085489A1 A ( O
IAPs WO2014085489A1 A NNP I-UN
) WO2014085489A1 A ) O
, WO2014085489A1 A , O
compositions WO2014085489A1 A NNS O
comprising WO2014085489A1 A VBG O
the WO2014085489A1 A DT O
compounds WO2014085489A1 A NNS O
, WO2014085489A1 A , O
and WO2014085489A1 A CC O
methods WO2014085489A1 A NNS O
of WO2014085489A1 A IN O
using WO2014085489A1 A VBG O
the WO2014085489A1 A DT O
compounds WO2014085489A1 A NNS O
and WO2014085489A1 A CC O
compositions WO2014085489A1 A NNS O
comprising WO2014085489A1 A VBG O
the WO2014085489A1 A DT O
compounds WO2014085489A1 A NNS O
. WO2014085489A1 A . O

Organotin CN101851250A T NNP O
hydroximic CN101851250A T JJ O
acid CN101851250A T NN O
compound CN101851250A T NN O
, CN101851250A T , O
preparation CN101851250A T NN O
method CN101851250A T NN O
thereof CN101851250A T NN O
and CN101851250A T CC O
application CN101851250A T NN O
thereof CN101851250A T NN O
. CN101851250A T . O

Fused US20090137575 T VBN O
Tetracyclic US20090137575 T NNP O
mGluR1 US20090137575 T NN I-UN
Antagonists US20090137575 T NNS O
as US20090137575 T IN O
Therapeutic US20090137575 T JJ O
Agents US20090137575 T NNS O
. US20090137575 T . O

In US20090137575 A IN O
its US20090137575 A PRP$ O
many US20090137575 A JJ O
embodiments US20090137575 A NNS O
, US20090137575 A , O
the US20090137575 A DT O
present US20090137575 A JJ O
invention US20090137575 A NN O
provides US20090137575 A VBZ O
tetracyclic US20090137575 A JJ O
compounds US20090137575 A NNS O
of US20090137575 A IN O
formula US20090137575 A NN O
I US20090137575 A PRP O
or US20090137575 A CC O
formula US20090137575 A VB O
II US20090137575 A NNP O
( US20090137575 A ( O
wherein US20090137575 A IN O
the US20090137575 A DT O
various US20090137575 A JJ O
moieties US20090137575 A NNS O
are US20090137575 A VBP O
as US20090137575 A IN O
defined US20090137575 A JJ O
herein US20090137575 A NN O
) US20090137575 A ) O
useful US20090137575 A JJ O
as US20090137575 A IN O
metabotropic US20090137575 A NN O
glutamate US20090137575 A NN O
receptor US20090137575 A NN O
( US20090137575 A ( O
mGluR US20090137575 A NN O
) US20090137575 A ) O
antagonists US20090137575 A NNS O
, US20090137575 A , O
particularly US20090137575 A RB O
as US20090137575 A IN O
selective US20090137575 A JJ O
metabotropic US20090137575 A NN I-UN
glutamate US20090137575 A NN I-UN
receptor US20090137575 A NN I-UN
1 US20090137575 A CD I-UN
antagonists US20090137575 A NNS O
, US20090137575 A , O
pharmaceutical US20090137575 A JJ O
compositions US20090137575 A NNS O
containing US20090137575 A VBG O
the US20090137575 A DT O
compounds US20090137575 A NNS O
, US20090137575 A , O
and US20090137575 A CC O
methods US20090137575 A NNS O
of US20090137575 A IN O
treatment US20090137575 A NN O
using US20090137575 A VBG O
the US20090137575 A DT O
compounds US20090137575 A NNS O
and US20090137575 A CC O
compositions US20090137575 A NNS O
to US20090137575 A TO O
treat US20090137575 A VB O
diseases US20090137575 A NNS O
associated US20090137575 A VBN O
with US20090137575 A IN O
metabotropic US20090137575 A NN O
glutamate US20090137575 A NN O
receptor US20090137575 A NN O
( US20090137575 A ( O
e.g. US20090137575 A JJ O
, US20090137575 A , O
mGluR1 US20090137575 A NN I-UN
) US20090137575 A ) O
such US20090137575 A JJ O
as US20090137575 A IN O
, US20090137575 A , O
for US20090137575 A IN O
example US20090137575 A NN O
, US20090137575 A , O
pain US20090137575 A NN O
, US20090137575 A , O
migraine US20090137575 A NN O
, US20090137575 A , O
anxiety US20090137575 A NN O
, US20090137575 A , O
urinary US20090137575 A JJ O
incontinence US20090137575 A NN O
and US20090137575 A CC O
neurodegenerative US20090137575 A JJ O
diseases US20090137575 A NNS O
such US20090137575 A JJ O
Alzheimer US20090137575 A NNP O
's US20090137575 A POS O
disease US20090137575 A NN O
. US20090137575 A . O

Mixture US20080242645 T NN O
of US20080242645 T IN O
xanthine US20080242645 T NN O
compound US20080242645 T NN O
, US20080242645 T , O
plant US20080242645 T NN O
extract US20080242645 T NN O
containing US20080242645 T VBG O
polyurethane US20080242645 T NN O
powder US20080242645 T NN O
and US20080242645 T CC O
dimethicone US20080242645 T NN O
; US20080242645 T : O
softness US20080242645 T NN O
; US20080242645 T : O
reduced US20080242645 T VBN O
tackiness US20080242645 T NN O
. US20080242645 T . O

Suppository CN101766813A T NN O
for CN101766813A T IN O
treating CN101766813A T VBG O
mammalian CN101766813A T JJ O
endometritis CN101766813A T NN O
and CN101766813A T CC O
preparation CN101766813A T NN O
method CN101766813A T NN O
thereof CN101766813A T NN O
. CN101766813A T . O

Cycloalkylnitrile WO2013040863A1 T NNP O
pyrazole WO2013040863A1 T NN O
carboxamides WO2013040863A1 T NNS O
as WO2013040863A1 T IN O
janus WO2013040863A1 T NN I-UN
kinase WO2013040863A1 T NN I-UN
inhibitors WO2013040863A1 T NNS O
. WO2013040863A1 T . O

Cycloalkylnitrile WO2013040863A1 A NNP O
pyrazole WO2013040863A1 A NN O
carboxamides WO2013040863A1 A NNS O
as WO2013040863A1 A IN O
JAK WO2013040863A1 A NNP I-UN
inhibitors WO2013040863A1 A NNS O
useful WO2013040863A1 A JJ O
for WO2013040863A1 A IN O
the WO2013040863A1 A DT O
treatment WO2013040863A1 A NN O
of WO2013040863A1 A IN O
JAK-mediated WO2013040863A1 A JJ O
diseases WO2013040863A1 A NNS O
such WO2013040863A1 A JJ O
as WO2013040863A1 A IN O
rheumatoid WO2013040863A1 A JJ O
arthritis WO2013040863A1 A NN O
, WO2013040863A1 A , O
asthma WO2013040863A1 A NN O
, WO2013040863A1 A , O
COPD WO2013040863A1 A NNP O
and WO2013040863A1 A CC O
cancer WO2013040863A1 A NN O
are WO2013040863A1 A VBP O
provided WO2013040863A1 A VBN O
. WO2013040863A1 A . O

Medicament CN101912586A T NN O
for CN101912586A T IN O
treating CN101912586A T VBG O
mammary CN101912586A T JJ O
gland CN101912586A T NN O
hyperplasia CN101912586A T NN O
and CN101912586A T CC O
preparation CN101912586A T NN O
method CN101912586A T NN O
thereof CN101912586A T NN O
. CN101912586A T . O

Preparation CN103463487A T NNP O
method CN103463487A T NN O
of CN103463487A T IN O
ointment CN103463487A T NN O
for CN103463487A T IN O
treating CN103463487A T VBG O
oral CN103463487A T JJ O
ulcer CN103463487A T NN O
. CN103463487A T . O

Use US6992073 T NNP O
of US6992073 T IN O
N-acetyl-D-glucosamine US6992073 T NNP O
in US6992073 T IN O
the US6992073 T DT O
manufacture US6992073 T NN O
of US6992073 T IN O
a US6992073 T DT O
medicament US6992073 T NN O
for US6992073 T IN O
treating US6992073 T VBG O
cervical US6992073 T JJ O
erosion US6992073 T NN O
. US6992073 T . O

Ointment CN101797254A T NN O
for CN101797254A T IN O
radical CN101797254A T JJ O
treatment CN101797254A T NN O
of CN101797254A T IN O
beriberi CN101797254A T NN O
and CN101797254A T CC O
preparation CN101797254A T NN O
method CN101797254A T NN O
. CN101797254A T . O

Salicylic WO2013148333A1 T JJ O
acid WO2013148333A1 T NN O
derivatives WO2013148333A1 T NNS O
useful WO2013148333A1 T JJ O
as WO2013148333A1 T IN O
glucocerebrosidase WO2013148333A1 T NN O
activators WO2013148333A1 T NNS O
. WO2013148333A1 T . O

The WO2013148333A1 A DT O
compounds WO2013148333A1 A NNS O
are WO2013148333A1 A VBP O
useful WO2013148333A1 A JJ O
for WO2013148333A1 A IN O
treating WO2013148333A1 A VBG O
Gaucher WO2013148333A1 A NNP O
disease WO2013148333A1 A NN O
and WO2013148333A1 A CC O
inhibiting WO2013148333A1 A VBG O
the WO2013148333A1 A DT O
onset WO2013148333A1 A NN O
of WO2013148333A1 A IN O
Gaucher WO2013148333A1 A NNP O
disease WO2013148333A1 A NN O
symptoms WO2013148333A1 A NNS O
in WO2013148333A1 A IN O
a WO2013148333A1 A DT O
patient WO2013148333A1 A NN O
having WO2013148333A1 A VBG O
a WO2013148333A1 A DT O
GBA WO2013148333A1 A NNP I-UN
gene WO2013148333A1 A NN O
mutation WO2013148333A1 A NN O
and WO2013148333A1 A CC O
for WO2013148333A1 A IN O
treating WO2013148333A1 A VBG O
Parkinson WO2013148333A1 A NNP O
's WO2013148333A1 A POS O
disease WO2013148333A1 A NN O
. WO2013148333A1 A . O

Novel US20110064756 T NNP O
sequences US20110064756 T NNS O
of US20110064756 T IN O
brachyspira US20110064756 T NN O
, US20110064756 T , O
immunogenic US20110064756 T JJ O
compounds US20110064756 T NNS O
, US20110064756 T , O
methods US20110064756 T NNS O
for US20110064756 T IN O
preparation US20110064756 T NN O
and US20110064756 T CC O
use US20110064756 T NN O
thereof US20110064756 T NN O
. US20110064756 T . O

Bis US20130035386 T NNP O
[ US20130035386 T NNP O
thiohydrazide US20130035386 T IN O
amide US20130035386 T RB O
] US20130035386 T NNP O
compounds US20130035386 T NNS O
for US20130035386 T IN O
treating US20130035386 T VBG O
leukemia US20130035386 T NN O
. US20130035386 T . O

Methods WO2012019021A1 T NNS O
and WO2012019021A1 T CC O
pharmaceutical WO2012019021A1 T JJ O
compositions WO2012019021A1 T NNS O
for WO2012019021A1 T IN O
treating WO2012019021A1 T VBG O
adverse WO2012019021A1 T JJ O
or WO2012019021A1 T CC O
deleterious WO2012019021A1 T JJ O
sequellae WO2012019021A1 T NN O
of WO2012019021A1 T IN O
traumatic WO2012019021A1 T JJ O
brain WO2012019021A1 T NN O
injury WO2012019021A1 T NN O
. WO2012019021A1 T . O

New CN102106847A T NNP O
fat CN102106847A T NN O
soluble CN102106847A T JJ O
platinum CN102106847A T NN O
injection CN102106847A T NN O
preparation CN102106847A T NN O
as CN102106847A T RB O
well CN102106847A T RB O
as CN102106847A T IN O
preparation CN102106847A T NN O
method CN102106847A T NN O
and CN102106847A T CC O
applications CN102106847A T NNS O
thereof CN102106847A T VBP O
. CN102106847A T . O

Dirithromycin CN102145008A T NNP O
medicinal CN102145008A T JJ O
composition CN102145008A T NN O
and CN102145008A T CC O
preparation CN102145008A T NN O
method CN102145008A T NN O
thereof CN102145008A T NN O
. CN102145008A T . O

treatment US20080221176 T NN O
of US20080221176 T IN O
diabetes US20080221176 T NNS O
mellitus US20080221176 T NNS O
, US20080221176 T , O
cardiovascular US20080221176 T JJ O
disease US20080221176 T NN O
, US20080221176 T , O
dyslipidemia US20080221176 T NN O
, US20080221176 T , O
artherosclerosis US20080221176 T NN O
, US20080221176 T , O
peripheral US20080221176 T JJ O
vascular US20080221176 T JJ O
disease US20080221176 T NN O
, US20080221176 T , O
inflammation US20080221176 T NN O
, US20080221176 T , O
cancer US20080221176 T NN O
, US20080221176 T , O
and US20080221176 T CC O
diseases US20080221176 T NNS O
of US20080221176 T IN O
the US20080221176 T DT O
central US20080221176 T JJ O
nervous US20080221176 T JJ O
system US20080221176 T NN O
; US20080221176 T : O
1,1,1,3,3,3-hexafluoro-2- US20080221176 T JJ O
{ US20080221176 T ( O
4- US20080221176 T JJ O
[ US20080221176 T NN O
methyl US20080221176 T NN O
( US20080221176 T ( O
phenylmethyl US20080221176 T NN O
) US20080221176 T ) O
amino US20080221176 T NN O
] US20080221176 T JJ O
phenyl US20080221176 T NN O
} US20080221176 T ) O
-2-propanol US20080221176 T NN O
. US20080221176 T . O

This US20080221176 A DT O
invention US20080221176 A NN O
relates US20080221176 A VBZ O
to US20080221176 A TO O
compounds US20080221176 A VB O
that US20080221176 A DT O
are US20080221176 A VBP O
modulators US20080221176 A NNS O
of US20080221176 A IN O
the US20080221176 A DT O
liver US20080221176 A NN I-UN
X US20080221176 A NNP I-UN
receptors US20080221176 A NNS I-UN
( US20080221176 A ( O
LXRs US20080221176 A NNP I-UN
) US20080221176 A ) O
, US20080221176 A , O
and US20080221176 A CC O
also US20080221176 A RB O
to US20080221176 A TO O
the US20080221176 A DT O
methods US20080221176 A NNS O
for US20080221176 A IN O
the US20080221176 A DT O
making US20080221176 A NN O
and US20080221176 A CC O
use US20080221176 A NN O
of US20080221176 A IN O
such US20080221176 A JJ O
compounds US20080221176 A NNS O
. US20080221176 A . O

Stomachic CN101574513A T JJ O
hericium CN101574513A T NN O
erinaceum CN101574513A T NN O
polysaccharide CN101574513A T IN O
health-care CN101574513A T JJ O
capsule CN101574513A T NN O
. CN101574513A T . O

Tissue US20110045075 T NN O
coating US20110045075 T VBG O
for US20110045075 T IN O
preventing US20110045075 T VBG O
undesired US20110045075 T JJ O
tissue-to-tissue US20110045075 T JJ O
adhesions US20110045075 T NNS O
. US20110045075 T . O

Azithromycin CN101428000A T NNP O
auristillae CN101428000A T NN O
and CN101428000A T CC O
method CN101428000A T NN O
of CN101428000A T IN O
producing CN101428000A T VBG O
the CN101428000A T DT O
same CN101428000A T JJ O
. CN101428000A T . O

The CN101428000A A DT O
invention CN101428000A A NN O
discloses CN101428000A A VBZ O
azithromycin CN101428000A A JJ O
auristillae CN101428000A A NN O
and CN101428000A A CC O
a CN101428000A A DT O
preparation CN101428000A A NN O
method CN101428000A A NN O
thereof CN101428000A A NN O
. CN101428000A A . O

According CN101428000A A VBG O
to CN101428000A A TO O
experiments CN101428000A A NNS O
and CN101428000A A CC O
researches CN101428000A A NNS O
of CN101428000A A IN O
researchers CN101428000A A NNS O
, CN101428000A A , O
azithromycin CN101428000A A NN O
, CN101428000A A , O
ethanol CN101428000A A NN O
, CN101428000A A , O
propylene CN101428000A A NN O
glycol CN101428000A A NN O
and CN101428000A A CC O
glycerin CN101428000A A NN O
are CN101428000A A VBP O
produced CN101428000A A VBN O
into CN101428000A A IN O
auristillae CN101428000A A NN O
. CN101428000A A . O

The CN101428000A A DT O
auristillae CN101428000A A NN O
preparation CN101428000A A NN O
has CN101428000A A VBZ O
remarkable CN101428000A A JJ O
pharmacological CN101428000A A JJ O
action CN101428000A A NN O
and CN101428000A A CC O
obvious CN101428000A A JJ O
effect CN101428000A A NN O
on CN101428000A A IN O
treating CN101428000A A VBG O
tympanitis CN101428000A A NN O
. CN101428000A A . O

DPP-IV CN101817833A T NNP I-UN
inhibitor CN101817833A T NN O
. CN101817833A T . O

The CN101817833A A DT O
invention CN101817833A A NN O
relates CN101817833A A VBZ O
to CN101817833A A TO O
a CN101817833A A DT O
hybrid CN101817833A A JJ O
pyrimido CN101817833A A NN O
ketone CN101817833A A NN O
DPP-IV CN101817833A A NNP I-UN
inhibitor CN101817833A A NN O
shown CN101817833A A VBN O
as CN101817833A A IN O
a CN101817833A A DT O
formula CN101817833A A NN O
I CN101817833A A PRP O
as CN101817833A A RB O
well CN101817833A A RB O
as CN101817833A A IN O
salts CN101817833A A NNS O
, CN101817833A A , O
a CN101817833A A DT O
preparation CN101817833A A NN O
method CN101817833A A NN O
, CN101817833A A , O
compounds CN101817833A A NNS O
and CN101817833A A CC O
application CN101817833A A NN O
thereof CN101817833A A NN O
in CN101817833A A IN O
the CN101817833A A DT O
prevention CN101817833A A NN O
or CN101817833A A CC O
treatment CN101817833A A NN O
of CN101817833A A IN O
diseases CN101817833A A NNS O
that CN101817833A A WDT O
benefit CN101817833A A VBP O
from CN101817833A A IN O
the CN101817833A A DT O
DPP-IV CN101817833A A NNP I-UN
inhibitor CN101817833A A NN O
. CN101817833A A . O

A CN101817833A A DT O
preparation CN101817833A A NN O
process CN101817833A A NN O
of CN101817833A A IN O
the CN101817833A A DT O
DPP-IV CN101817833A A NNP I-UN
inhibitor CN101817833A A NN O
is CN101817833A A VBZ O
simple CN101817833A A JJ O
, CN101817833A A , O
easily-obtained CN101817833A A JJ O
in CN101817833A A IN O
raw CN101817833A A JJ O
materials CN101817833A A NNS O
and CN101817833A A CC O
suitable CN101817833A A JJ O
for CN101817833A A IN O
industrial CN101817833A A JJ O
large-scale CN101817833A A JJ O
production CN101817833A A NN O
; CN101817833A A : O
and CN101817833A A CC O
in-vitro CN101817833A A JJ O
and CN101817833A A CC O
in-vivo CN101817833A A JJ O
experiments CN101817833A A NNS O
verify CN101817833A A VB O
that CN101817833A A IN O
the CN101817833A A DT O
DPP-IV CN101817833A A NNP I-UN
inhibitor CN101817833A A NN O
has CN101817833A A VBZ O
very CN101817833A A RB O
good CN101817833A A JJ O
selective CN101817833A A JJ O
inhibition CN101817833A A NN O
effect CN101817833A A NN O
to CN101817833A A TO O
DPP-IV CN101817833A A NNP I-UN
, CN101817833A A , O
nearly CN101817833A A RB O
has CN101817833A A VBZ O
no CN101817833A A DT O
influence CN101817833A A NN O
on CN101817833A A IN O
activities CN101817833A A NNS O
of CN101817833A A IN O
DPP-VIII CN101817833A A NNP I-UN
and CN101817833A A CC O
DPP-IX CN101817833A A NNP I-UN
at CN101817833A A IN O
the CN101817833A A DT O
same CN101817833A A JJ O
time CN101817833A A NN O
of CN101817833A A IN O
effectively CN101817833A A RB O
inhibiting CN101817833A A VBG O
the CN101817833A A DT O
DPP-IV CN101817833A A NNP I-UN
activity CN101817833A A NN O
, CN101817833A A , O
lower CN101817833A A JJR O
toxicity CN101817833A A NN O
after CN101817833A A IN O
prepared CN101817833A A JJ O
medicine CN101817833A A NN O
development CN101817833A A NN O
, CN101817833A A , O
stronger CN101817833A A JJR O
effect CN101817833A A NN O
and CN101817833A A CC O
longer CN101817833A A JJR O
acting CN101817833A A VBG O
time CN101817833A A NN O
compared CN101817833A A VBN O
with CN101817833A A IN O
the CN101817833A A DT O
effect CN101817833A A NN O
of CN101817833A A IN O
a CN101817833A A DT O
medicine CN101817833A A NN O
Alogliptin CN101817833A A NNP O
with CN101817833A A IN O
the CN101817833A A DT O
same CN101817833A A JJ O
mechanism CN101817833A A NN O
and CN101817833A A CC O
shows CN101817833A A VBZ O
excellent CN101817833A A JJ O
effects CN101817833A A NNS O
of CN101817833A A IN O
reducing CN101817833A A VBG O
the CN101817833A A DT O
blood CN101817833A A NN O
sugar CN101817833A A NN O
and CN101817833A A CC O
increasing CN101817833A A VBG O
the CN101817833A A DT O
insulin CN101817833A A NN I-UN
sensitivity CN101817833A A NN O
. CN101817833A A . O

Nanometer CN1732918A T NNP O
preparation CN1732918A T NN O
of CN1732918A T IN O
silybin CN1732918A T NN O
and CN1732918A T CC O
preparation CN1732918A T NN O
method CN1732918A T NN O
thereof CN1732918A T NN O
. CN1732918A T . O

Novel WO2014015830A1 T NNP O
heteroaryl WO2014015830A1 T NN O
and WO2014015830A1 T CC O
heterocycle WO2014015830A1 T NN O
compounds WO2014015830A1 T NNS O
, WO2014015830A1 T , O
composition WO2014015830A1 T NN O
and WO2014015830A1 T CC O
methods WO2014015830A1 T NNS O
thereof WO2014015830A1 T NN O
. WO2014015830A1 T . O

Disclosed WO2014015830A1 A VBN O
are WO2014015830A1 A VBP O
novel WO2014015830A1 A JJ O
heteroaryl WO2014015830A1 A NN O
and WO2014015830A1 A CC O
heterocycle WO2014015830A1 A NN O
compounds WO2014015830A1 A NNS O
of WO2014015830A1 A IN O
formula WO2014015830A1 A JJ O
I-1 WO2014015830A1 A NNP O
, WO2014015830A1 A , O
I-2 WO2014015830A1 A NNP O
or WO2014015830A1 A CC O
I-3 WO2014015830A1 A NNP O
and WO2014015830A1 A CC O
pharmaceutical WO2014015830A1 A JJ O
compositions WO2014015830A1 A NNS O
comprising WO2014015830A1 A VBG O
them WO2014015830A1 A PRP O
, WO2014015830A1 A , O
uses WO2014015830A1 A VBZ O
and WO2014015830A1 A CC O
methods WO2014015830A1 A NNS O
thereof WO2014015830A1 A NN O
for WO2014015830A1 A IN O
inhibiting WO2014015830A1 A VBG O
the WO2014015830A1 A DT O
activity WO2014015830A1 A NN O
of WO2014015830A1 A IN O
PI3K WO2014015830A1 A NNP I-UN
and WO2014015830A1 A CC O
for WO2014015830A1 A IN O
treating WO2014015830A1 A VBG O
inflammatory WO2014015830A1 A NN O
and WO2014015830A1 A CC O
autoimmune WO2014015830A1 A NN O
diseases WO2014015830A1 A NNS O
and WO2014015830A1 A CC O
cancer WO2014015830A1 A NN O
. WO2014015830A1 A . O

Instant CN101015559A T JJ O
gelling CN101015559A T NN O
agent CN101015559A T NN O
for CN101015559A T IN O
treating CN101015559A T VBG O
allergic CN101015559A T JJ O
rhinitis CN101015559A T NN O
. CN101015559A T . O

Dispersible CN101011361A T JJ O
tablet CN101011361A T NN O
of CN101011361A T IN O
bendazac CN101011361A T JJ O
lysine CN101011361A T NN O
and CN101011361A T CC O
its CN101011361A T PRP$ O
preparation CN101011361A T NN O
method CN101011361A T NN O
. CN101011361A T . O

Medicine CN101229228A T NNP O
compounds CN101229228A T VBZ O
for CN101229228A T IN O
treating CN101229228A T VBG O
angiitis CN101229228A T NN O
, CN101229228A T , O
phlebitis CN101229228A T NN O
, CN101229228A T , O
osteomyelitis CN101229228A T NN O
and CN101229228A T CC O
preparing CN101229228A T VBG O
method CN101229228A T NN O
thereof CN101229228A T NN O
. CN101229228A T . O

Adjuvant US20050266024 T NNP O
. US20050266024 T . O

Alcohol-precipitated CN103613680A T JJ O
panax CN103613680A T NN O
japonicus CN103613680A T NN O
polysaccharide CN103613680A T NN O
, CN103613680A T , O
and CN103613680A T CC O
preparation CN103613680A T NN O
method CN103613680A T NN O
and CN103613680A T CC O
application CN103613680A T NN O
thereof CN103613680A T NN O
. CN103613680A T . O

The CN103613680A A DT O
invention CN103613680A A NN O
relates CN103613680A A VBZ O
to CN103613680A A TO O
a CN103613680A A DT O
panax CN103613680A A NN O
japonicus CN103613680A A NN O
polysaccharide CN103613680A A NN O
and CN103613680A A CC O
a CN103613680A A DT O
preparation CN103613680A A NN O
method CN103613680A A NN O
thereof CN103613680A A NN O
. CN103613680A A . O

The CN103613680A A DT O
method CN103613680A A NN O
comprises CN103613680A A VBZ O
the CN103613680A A DT O
steps CN103613680A A NNS O
of CN103613680A A IN O
performing CN103613680A A VBG O
aqueous CN103613680A A JJ O
extraction CN103613680A A NN O
on CN103613680A A IN O
the CN103613680A A DT O
panax CN103613680A A NN O
japonicus CN103613680A A NN O
; CN103613680A A : O
removing CN103613680A A VBG O
protein CN103613680A A NN O
; CN103613680A A : O
oxidizing CN103613680A A NN O
, CN103613680A A , O
and CN103613680A A CC O
performing CN103613680A A VBG O
alcohol CN103613680A A NN O
precipitation CN103613680A A NN O
, CN103613680A A , O
and CN103613680A A CC O
the CN103613680A A DT O
like CN103613680A A JJ O
. CN103613680A A . O

The CN103613680A A DT O
panax CN103613680A A NN O
japonicus CN103613680A A NN O
polysaccharide CN103613680A A NN O
has CN103613680A A VBZ O
a CN103613680A A DT O
remarkable CN103613680A A JJ O
adjuvant CN103613680A A JJ O
activity CN103613680A A NN O
, CN103613680A A , O
wherein CN103613680A A VBP O
the CN103613680A A DT O
60 CN103613680A A CD O
percent CN103613680A A NN O
alcohol CN103613680A A NN O
precipitated CN103613680A A VBD O
panax CN103613680A A JJ O
japonicus CN103613680A A NN O
polysaccharide CN103613680A A IN O
part CN103613680A A NN O
has CN103613680A A VBZ O
the CN103613680A A DT O
strongest CN103613680A A JJS O
adjuvant CN103613680A A JJ O
activity CN103613680A A NN O
, CN103613680A A , O
and CN103613680A A CC O
has CN103613680A A VBZ O
an CN103613680A A DT O
intermediate CN103613680A A JJ O
viscosity-average CN103613680A A NN O
molecular CN103613680A A JJ O
weight CN103613680A A NN O
. CN103613680A A . O

Plant CN103613680A A NN O
polysaccharides CN103613680A A NNS O
are CN103613680A A VBP O
widely CN103613680A A RB O
distributed CN103613680A A VBN O
in CN103613680A A IN O
the CN103613680A A DT O
nature CN103613680A A NN O
, CN103613680A A , O
and CN103613680A A CC O
the CN103613680A A DT O
application CN103613680A A NN O
of CN103613680A A IN O
the CN103613680A A DT O
plant CN103613680A A NN O
polysaccharides CN103613680A A VBZ O
has CN103613680A A VBZ O
a CN103613680A A DT O
better CN103613680A A JJR O
advantage CN103613680A A NN O
due CN103613680A A JJ O
to CN103613680A A TO O
low CN103613680A A JJ O
toxicity CN103613680A A NN O
and CN103613680A A CC O
effectiveness CN103613680A A NN O
, CN103613680A A , O
so CN103613680A A IN O
that CN103613680A A IN O
a CN103613680A A DT O
novel CN103613680A A JJ O
thought CN103613680A A NN O
and CN103613680A A CC O
direction CN103613680A A NN O
can CN103613680A A MD O
be CN103613680A A VB O
found CN103613680A A VBN O
for CN103613680A A IN O
development CN103613680A A NN O
of CN103613680A A IN O
novel CN103613680A A JJ O
vaccine CN103613680A A NN O
adjuvants CN103613680A A NNS O
. CN103613680A A . O

Novel US20120115907 T NNP O
compounds US20120115907 T VBZ O
as US20120115907 T IN O
inhibitors US20120115907 T NNS O
of US20120115907 T IN O
renin US20120115907 T NN I-UN
. US20120115907 T . O

The US20120115907 A DT O
present US20120115907 A JJ O
invention US20120115907 A NN O
relates US20120115907 A VBZ O
to US20120115907 A TO O
novel US20120115907 A VB O
renin US20120115907 A JJ I-UN
inhibitors US20120115907 A NNS O
of US20120115907 A IN O
general US20120115907 A JJ O
formula US20120115907 A NN O
( US20120115907 A ( O
1 US20120115907 A CD O
) US20120115907 A ) O
, US20120115907 A , O
novel US20120115907 A JJ O
intermediates US20120115907 A NNS O
involved US20120115907 A VBN O
in US20120115907 A IN O
their US20120115907 A PRP$ O
synthesis US20120115907 A NN O
, US20120115907 A , O
their US20120115907 A PRP$ O
pharmaceutically US20120115907 A RB O
acceptable US20120115907 A JJ O
salts US20120115907 A NNS O
and US20120115907 A CC O
pharmaceutical US20120115907 A JJ O
compositions US20120115907 A NNS O
containing US20120115907 A VBG O
them US20120115907 A PRP O
. US20120115907 A . O

MAILLARD WO2011105465A1 T NNP O
REACTION WO2011105465A1 T NNP O
INHIBITOR WO2011105465A1 T NNP O
, WO2011105465A1 T , O
α-DICARBONYL WO2011105465A1 T JJ O
COMPOUND WO2011105465A1 T NNP O
DECOMPOSING WO2011105465A1 T NNP O
AGENT WO2011105465A1 T NNP O
, WO2011105465A1 T , O
AND WO2011105465A1 T NNP O
METHOD WO2011105465A1 T NNP O
FOR WO2011105465A1 T NNP O
INHIBITING WO2011105465A1 T NNP O
THE WO2011105465A1 T NNP O
MAILLARD WO2011105465A1 T NNP O
REACTION WO2011105465A1 T NNP O
. WO2011105465A1 T . O

Disclosed WO2011105465A1 A VBN O
is WO2011105465A1 A VBZ O
a WO2011105465A1 A DT O
novel WO2011105465A1 A JJ O
Maillard WO2011105465A1 A NNP O
reaction WO2011105465A1 A NN O
inhibitor WO2011105465A1 A NN O
producing WO2011105465A1 A VBG O
highly WO2011105465A1 A RB O
effective WO2011105465A1 A JJ O
inhibition WO2011105465A1 A NN O
of WO2011105465A1 A IN O
the WO2011105465A1 A DT O
Maillard WO2011105465A1 A NNP O
reaction WO2011105465A1 A NN O
, WO2011105465A1 A , O
and WO2011105465A1 A CC O
a WO2011105465A1 A DT O
method WO2011105465A1 A NN O
for WO2011105465A1 A IN O
using WO2011105465A1 A VBG O
same WO2011105465A1 A JJ O
. WO2011105465A1 A . O

The WO2011105465A1 A DT O
Maillard WO2011105465A1 A NNP O
reaction WO2011105465A1 A NN O
inhibitor WO2011105465A1 A NN O
has WO2011105465A1 A VBZ O
as WO2011105465A1 A IN O
an WO2011105465A1 A DT O
active WO2011105465A1 A JJ O
ingredient WO2011105465A1 A NN O
at WO2011105465A1 A IN O
least WO2011105465A1 A JJS O
one WO2011105465A1 A CD O
terpene WO2011105465A1 A NN O
peroxide WO2011105465A1 A NN O
. WO2011105465A1 A . O

Amidobenzothiazoles EP2670740A1 T NNS O
and EP2670740A1 T CC O
process EP2670740A1 T NN O
for EP2670740A1 T IN O
the EP2670740A1 T DT O
preparation EP2670740A1 T NN O
thereof EP2670740A1 T NN O
. EP2670740A1 T . O

Bicarbonate CN103638041A T NNP O
concentrate CN103638041A T NN O
powder CN103638041A T NN O
for CN103638041A T IN O
direct-on-line CN103638041A T JJ O
use CN103638041A T NN O
and CN103638041A T CC O
preparation CN103638041A T NN O
process CN103638041A T NN O
thereof CN103638041A T NN O
. CN103638041A T . O

Application CN102552453A T NN O
of CN102552453A T IN O
gingerol CN102552453A T NN O
and CN102552453A T CC O
rhizoma CN102552453A T NN O
coptidis CN102552453A T NN O
composition CN102552453A T NN O
to CN102552453A T TO O
preparation CN102552453A T NN O
of CN102552453A T IN O
medicine CN102552453A T NN O
for CN102552453A T IN O
resisting CN102552453A T VBG O
vomiting CN102552453A T NN O
. CN102552453A T . O

1-furylmethyl-3-substituted CN101033226B T JJ O
indolin-2-one CN101033226B T JJ O
derivative CN101033226B T NN O
. CN101033226B T . O

Drug EP2659891A1 T NN O
with EP2659891A1 T IN O
activity EP2659891A1 T NN O
against EP2659891A1 T IN O
the EP2659891A1 T DT O
herpes EP2659891A1 T NNS O
virus EP2659891A1 T VBP O
family EP2659891A1 T NN O
. EP2659891A1 T . O

Gene US20110166212 T NNP O
expression US20110166212 T NN O
and US20110166212 T CC O
pain US20110166212 T NN O
. US20110166212 T . O

The US20110166212 A DT O
present US20110166212 A JJ O
invention US20110166212 A NN O
relates US20110166212 A VBZ O
to US20110166212 A TO O
double-stranded US20110166212 A JJ O
oligonucleotides US20110166212 A NNS O
, US20110166212 A , O
pharmaceutical US20110166212 A JJ O
compositions US20110166212 A NNS O
thereof US20110166212 A NN O
, US20110166212 A , O
and US20110166212 A CC O
use US20110166212 A NN O
of US20110166212 A IN O
such US20110166212 A JJ O
double-stranded US20110166212 A JJ O
oligonucleotides US20110166212 A NNS O
and US20110166212 A CC O
pharmaceutical US20110166212 A JJ O
compositions US20110166212 A NNS O
to US20110166212 A TO O
modulate US20110166212 A VB O
nociceptive US20110166212 A JJ O
signaling US20110166212 A NN O
in US20110166212 A IN O
a US20110166212 A DT O
cell US20110166212 A NN O
or US20110166212 A CC O
prevent US20110166212 A NN O
and/or US20110166212 A JJ O
treat US20110166212 A NN O
pain US20110166212 A NN O
in US20110166212 A IN O
a US20110166212 A DT O
patient US20110166212 A NN O
. US20110166212 A . O

Preparation CN101385714A T NNP O
method CN101385714A T NN O
of CN101385714A T IN O
DHA CN101385714A T NNP O
lipid CN101385714A T JJ O
nano-particles CN101385714A T NNS O
. CN101385714A T . O

The CN101385714A A DT O
invention CN101385714A A NN O
discloses CN101385714A A VBZ O
a CN101385714A A DT O
preparation CN101385714A A NN O
method CN101385714A A NN O
of CN101385714A A IN O
DHA CN101385714A A NNP O
lipid CN101385714A A JJ O
nanoparticles CN101385714A A NNS O
, CN101385714A A , O
the CN101385714A A DT O
preparation CN101385714A A NN O
method CN101385714A A NN O
comprises CN101385714A A VBZ O
the CN101385714A A DT O
following CN101385714A A JJ O
steps CN101385714A A NNS O
: CN101385714A A : O
step CN101385714A A NN O
one CN101385714A A CD O
: CN101385714A A : O
an CN101385714A A DT O
emulsifying CN101385714A A VBG O
agent CN101385714A A NN O
and CN101385714A A CC O
lipid CN101385714A A JJ O
material CN101385714A A NN O
are CN101385714A A VBP O
respectively CN101385714A A RB O
weighed CN101385714A A VBN O
, CN101385714A A , O
the CN101385714A A DT O
emulsifying CN101385714A A NN O
agent CN101385714A A NN O
and CN101385714A A CC O
the CN101385714A A DT O
lipid CN101385714A A JJ O
material CN101385714A A NN O
are CN101385714A A VBP O
heated CN101385714A A VBN O
to CN101385714A A TO O
the CN101385714A A DT O
set CN101385714A A NN O
temperature CN101385714A A NN O
after CN101385714A A IN O
the CN101385714A A DT O
mixing CN101385714A A NN O
, CN101385714A A , O
a CN101385714A A DT O
liquid CN101385714A A JJ O
oil CN101385714A A NN O
phase CN101385714A A NN O
is CN101385714A A VBZ O
obtained CN101385714A A VBN O
after CN101385714A A IN O
the CN101385714A A DT O
melting CN101385714A A NN O
; CN101385714A A : O
step CN101385714A A CC O
two CN101385714A A CD O
: CN101385714A A : O
DHA CN101385714A A NN O
is CN101385714A A VBZ O
weighed CN101385714A A VBN O
, CN101385714A A , O
the CN101385714A A DT O
DHA CN101385714A A NNP O
is CN101385714A A VBZ O
added CN101385714A A VBN O
in CN101385714A A IN O
the CN101385714A A DT O
liquid CN101385714A A JJ O
oil CN101385714A A NN O
phase CN101385714A A NN O
, CN101385714A A , O
a CN101385714A A DT O
uniform CN101385714A A JJ O
system CN101385714A A NN O
is CN101385714A A VBZ O
obtained CN101385714A A VBN O
by CN101385714A A IN O
stirring CN101385714A A VBG O
; CN101385714A A : O
step CN101385714A A NN O
three CN101385714A A CD O
: CN101385714A A : O
water CN101385714A A NN O
with CN101385714A A IN O
the CN101385714A A DT O
temperature CN101385714A A NN O
which CN101385714A A WDT O
is CN101385714A A VBZ O
the CN101385714A A DT O
same CN101385714A A JJ O
with CN101385714A A IN O
the CN101385714A A DT O
set CN101385714A A NN O
temperature CN101385714A A NN O
T CN101385714A A NNP O
is CN101385714A A VBZ O
added CN101385714A A VBN O
in CN101385714A A IN O
the CN101385714A A DT O
system CN101385714A A NN O
, CN101385714A A , O
then CN101385714A A RB O
the CN101385714A A DT O
system CN101385714A A NN O
enters CN101385714A A VBZ O
a CN101385714A A DT O
high CN101385714A A JJ O
pressure CN101385714A A NN O
homogenizer CN101385714A A NN O
which CN101385714A A WDT O
is CN101385714A A VBZ O
preheated CN101385714A A VBN O
to CN101385714A A TO O
the CN101385714A A DT O
set CN101385714A A NN O
temperature CN101385714A A NN O
T CN101385714A A NNP O
and CN101385714A A CC O
at CN101385714A A IN O
the CN101385714A A DT O
set CN101385714A A NN O
pressure CN101385714A A NN O
of CN101385714A A IN O
80MPa CN101385714A A CD O
after CN101385714A A IN O
the CN101385714A A DT O
even CN101385714A A RB O
mixing CN101385714A A NN O
and CN101385714A A CC O
stirring CN101385714A A NN O
; CN101385714A A : O
step CN101385714A A CC O
four CN101385714A A CD O
: CN101385714A A : O
the CN101385714A A DT O
obtained CN101385714A A VBN O
high CN101385714A A JJ O
temperature CN101385714A A NN O
micro-emulsion CN101385714A A NN O
is CN101385714A A VBZ O
cooled CN101385714A A VBN O
to CN101385714A A TO O
the CN101385714A A DT O
room CN101385714A A NN O
temperature CN101385714A A NN O
, CN101385714A A , O
and CN101385714A A CC O
aqueous CN101385714A A JJ O
dispersion CN101385714A A NN O
of CN101385714A A IN O
DHA-NLC CN101385714A A NNP O
is CN101385714A A VBZ O
obtained CN101385714A A VBN O
; CN101385714A A : O
the CN101385714A A DT O
preparation CN101385714A A NN O
method CN101385714A A NN O
adopts CN101385714A A VBZ O
the CN101385714A A DT O
lipid CN101385714A A JJ O
nanoparticles CN101385714A A NNS O
to CN101385714A A TO O
load CN101385714A A VB O
DHA CN101385714A A NNP O
, CN101385714A A , O
thereby CN101385714A A RB O
protecting CN101385714A A VBG O
the CN101385714A A DT O
DHA CN101385714A A NN O
from CN101385714A A IN O
being CN101385714A A VBG O
oxidized CN101385714A A VBN O
and CN101385714A A CC O
covering CN101385714A A VBG O
up CN101385714A A RP O
the CN101385714A A DT O
stinking CN101385714A A VBG O
smell CN101385714A A NN O
of CN101385714A A IN O
DHA CN101385714A A NNP O
oil CN101385714A A NN O
; CN101385714A A : O
furthermore CN101385714A A RB O
, CN101385714A A , O
the CN101385714A A DT O
prepared CN101385714A A JJ O
DHA CN101385714A A NNP O
aqueous CN101385714A A JJ O
dispersion CN101385714A A NN O
can CN101385714A A MD O
be CN101385714A A VB O
conveniently CN101385714A A RB O
added CN101385714A A VBN O
in CN101385714A A IN O
foods CN101385714A A NNS O
, CN101385714A A , O
thereby CN101385714A A RB O
expanding CN101385714A A VBG O
the CN101385714A A DT O
using CN101385714A A VBG O
range CN101385714A A NN O
thereof CN101385714A A NN O
. CN101385714A A . O

Pharmaceutical US20120252756 T JJ O
Compositions US20120252756 T NNS O
and US20120252756 T CC O
Methods US20120252756 T NNS O
for US20120252756 T IN O
Treating US20120252756 T NNP O
, US20120252756 T , O
Controlling US20120252756 T NNP O
, US20120252756 T , O
Ameliorating US20120252756 T NNP O
, US20120252756 T , O
or US20120252756 T CC O
Reversing US20120252756 T VBG O
Conditions US20120252756 T NNS O
of US20120252756 T IN O
the US20120252756 T DT O
Eye US20120252756 T NNP O
. US20120252756 T . O

Inhalant WO2007134966A1 T JJ O
propellant-free WO2007134966A1 T JJ O
aerosol WO2007134966A1 T NN O
formulation WO2007134966A1 T NN O
. WO2007134966A1 T . O

Compressible-Coated US20110129530 T JJ O
Pharmaceutical US20110129530 T NNP O
Compositions US20110129530 T NNP O
and US20110129530 T CC O
Tablets US20110129530 T NNP O
and US20110129530 T CC O
Methods US20110129530 T NNP O
of US20110129530 T IN O
Manufacture US20110129530 T NNP O
. US20110129530 T . O

Special CN1977858A T JJ O
emulsion CN1977858A T NN O
for CN1977858A T IN O
treating CN1977858A T VBG O
coppernose CN1977858A T NN O
. CN1977858A T . O

Methods US20110274739 T NNS O
for US20110274739 T IN O
governing US20110274739 T VBG O
tissue US20110274739 T NN O
growth US20110274739 T NN O
. US20110274739 T . O

Controlled WO2013056326A1 T VBN O
release WO2013056326A1 T NN O
pharmaceutical WO2013056326A1 T JJ O
composition WO2013056326A1 T NN O
containing WO2013056326A1 T VBG O
naltrexone WO2013056326A1 T NN O
and WO2013056326A1 T CC O
topiramate WO2013056326A1 T NN O
. WO2013056326A1 T . O

Preparation CN102895631A T NNP O
technology CN102895631A T NN O
and CN102895631A T CC O
production CN102895631A T NN O
method CN102895631A T NN O
for CN102895631A T IN O
integrated CN102895631A T JJ O
new CN102895631A T JJ O
formulation CN102895631A T NN O
of CN102895631A T IN O
maidservant CN102895631A T NN O
from CN102895631A T IN O
Yue CN102895631A T NNP O
plus CN102895631A T CC O
white CN102895631A T JJ O
atractylodes CN102895631A T NNS O
decoction CN102895631A T NN O
. CN102895631A T . O

Kit WO2009049917A1 T NNP I-UN
ligand WO2009049917A1 T NN I-UN
for WO2009049917A1 T IN O
use WO2009049917A1 T NN O
in WO2009049917A1 T IN O
the WO2009049917A1 T DT O
treatment WO2009049917A1 T NN O
of WO2009049917A1 T IN O
beta-thalassaemia WO2009049917A1 T NN O
. WO2009049917A1 T . O

The WO2009049917A1 A DT O
use WO2009049917A1 A NN O
of WO2009049917A1 A IN O
Kit WO2009049917A1 A NNP I-UN
Ligand WO2009049917A1 A NNP I-UN
and WO2009049917A1 A CC O
, WO2009049917A1 A , O
optionally WO2009049917A1 A RB O
, WO2009049917A1 A , O
a WO2009049917A1 A DT O
steroid WO2009049917A1 A NN O
such WO2009049917A1 A JJ O
as WO2009049917A1 A IN O
Dexamethasone WO2009049917A1 A NNP O
in WO2009049917A1 A IN O
the WO2009049917A1 A DT O
treatment WO2009049917A1 A NN O
of WO2009049917A1 A IN O
β-Thalassaemias WO2009049917A1 A NNP O
is WO2009049917A1 A VBZ O
provided WO2009049917A1 A VBN O
, WO2009049917A1 A , O
as WO2009049917A1 A IN O
are WO2009049917A1 A VBP O
methods WO2009049917A1 A NNS O
of WO2009049917A1 A IN O
treating WO2009049917A1 A VBG O
β-Thalassaemias WO2009049917A1 A JJ O
. WO2009049917A1 A . O

Combination US20050255096 T NNP O
treatment US20050255096 T NN O
for US20050255096 T IN O
acute US20050255096 T JJ O
myocardial US20050255096 T JJ O
infarction US20050255096 T NN O
. US20050255096 T . O

A US20050255096 A DT O
combination US20050255096 A NN O
therapy US20050255096 A NN O
for US20050255096 A IN O
the US20050255096 A DT O
treatment US20050255096 A NN O
of US20050255096 A IN O
acute US20050255096 A JJ O
myocardial US20050255096 A JJ O
infarction US20050255096 A NN O
comprises US20050255096 A VBZ O
administering US20050255096 A VBG O
a US20050255096 A DT O
combination US20050255096 A NN O
of US20050255096 A IN O
a US20050255096 A DT O
thrombolytic US20050255096 A JJ O
agent US20050255096 A NN O
and US20050255096 A CC O
levosimendan US20050255096 A NN O
or US20050255096 A CC O
a US20050255096 A DT O
pharmaceutically US20050255096 A RB O
acceptable US20050255096 A JJ O
salt US20050255096 A NN O
thereof US20050255096 A NN O
to US20050255096 A TO O
a US20050255096 A DT O
patient US20050255096 A NN O
. US20050255096 A . O

The US20050255096 A DT O
combination US20050255096 A NN O
synergistically US20050255096 A RB O
reduces US20050255096 A VBZ O
mortality US20050255096 A NN O
of US20050255096 A IN O
patients US20050255096 A NNS O
with US20050255096 A IN O
acute US20050255096 A JJ O
myocardial US20050255096 A JJ O
infarction US20050255096 A NN O
. US20050255096 A . O

Zoledronic CN102000035A T JJ O
acid CN102000035A T NN O
composition CN102000035A T NN O
for CN102000035A T IN O
injection CN102000035A T NN O
and CN102000035A T CC O
preparation CN102000035A T NN O
method CN102000035A T NN O
thereof CN102000035A T NN O
. CN102000035A T . O

Dibenzothiophene WO2010136778A1 T NNP O
derivatives WO2010136778A1 T NNS O
as WO2010136778A1 T IN O
dna- WO2010136778A1 T JJ O
pk WO2010136778A1 T NN O
inhibitors WO2010136778A1 T NNS O
. WO2010136778A1 T . O

Medicinal CN102949400A T JJ O
composition CN102949400A T NN O
containing CN102949400A T VBG O
glucocorticoid CN102949400A T NN O
and CN102949400A T CC O
NOS CN102949400A T NNP O
( CN102949400A T ( O
Nitric CN102949400A T NNP O
Oxide CN102949400A T NNP O
Synthase CN102949400A T NNP O
) CN102949400A T ) O
inhibitor CN102949400A T NN O
for CN102949400A T IN O
treating CN102949400A T VBG O
nasal CN102949400A T JJ O
inflammation CN102949400A T NN O
. CN102949400A T . O

Biological CN1721004A T NNP O
active CN1721004A T JJ O
antibiotic CN1721004A T JJ O
dressing CN1721004A T NN O
. CN1721004A T . O

the CN1721004A A DT O
constituents CN1721004A A NNS O
of CN1721004A A IN O
the CN1721004A A DT O
medicament CN1721004A A NN O
include CN1721004A A VBP O
silver CN1721004A A JJ O
oxide CN1721004A A RB O
, CN1721004A A , O
silver CN1721004A A JJ O
peroxide CN1721004A A NN O
and CN1721004A A CC O
biological CN1721004A A JJ O
macromolecular CN1721004A A NN O
compounds CN1721004A A NNS O
, CN1721004A A , O
wherein CN1721004A A VBP O
the CN1721004A A DT O
biological CN1721004A A JJ O
macromolecular CN1721004A A JJ O
compounds CN1721004A A NNS O
include CN1721004A A VBP O
collagen CN1721004A A NN I-UN
, CN1721004A A , O
epidermal CN1721004A A JJ O
growth CN1721004A A NN O
factor CN1721004A A NN O
microspheres CN1721004A A NNS O
( CN1721004A A ( O
EGF-PLGA CN1721004A A NNP O
) CN1721004A A ) O
, CN1721004A A , O
hyaluronic CN1721004A A JJ O
acid CN1721004A A NN O
, CN1721004A A , O
heparin CN1721004A A NN O
, CN1721004A A , O
chondroitin CN1721004A A NN O
sulfate CN1721004A A NN O
and CN1721004A A CC O
alginates CN1721004A A NNS O
. CN1721004A A . O

Methods US20060183765 T NNS O
of US20060183765 T IN O
treating US20060183765 T VBG O
cancer US20060183765 T NN O
using US20060183765 T VBG O
an US20060183765 T DT O
FPT US20060183765 T NNP I-UN
inhibitor US20060183765 T NN O
and US20060183765 T CC O
antineoplastic US20060183765 T JJ O
agents US20060183765 T NNS O
. US20060183765 T . O

Disclosed US20060183765 A VBN O
is US20060183765 A VBZ O
a US20060183765 A DT O
method US20060183765 A NN O
of US20060183765 A IN O
treating US20060183765 A VBG O
cancer US20060183765 A NN O
in US20060183765 A IN O
a US20060183765 A DT O
patient US20060183765 A NN O
in US20060183765 A IN O
need US20060183765 A NN O
of US20060183765 A IN O
such US20060183765 A JJ O
treatment US20060183765 A NN O
comprising US20060183765 A VBG O
administering US20060183765 A VBG O
a US20060183765 A DT O
therapeutically US20060183765 A RB O
effective US20060183765 A JJ O
amount US20060183765 A NN O
of US20060183765 A IN O
an US20060183765 A DT O
FPT US20060183765 A NNP I-UN
inhibitor US20060183765 A NN O
and US20060183765 A CC O
therapeutically US20060183765 A RB O
effective US20060183765 A JJ O
amounts US20060183765 A NNS O
of US20060183765 A IN O
one US20060183765 A CD O
or US20060183765 A CC O
more US20060183765 A JJR O
antineoplastic US20060183765 A JJ O
agents US20060183765 A NNS O
. US20060183765 A . O

Squaric US20080312244 T JJ O
Acid US20080312244 T NNP O
Derivatives US20080312244 T NNP O
as US20080312244 T IN O
Protein US20080312244 T NNP I-UN
Kinase US20080312244 T NNP I-UN
Inhibitors US20080312244 T NNP O
. US20080312244 T . O

Compounds US20080312244 A NNS O
of US20080312244 A IN O
the US20080312244 A DT O
formula US20080312244 A NN O
I US20080312244 A PRP O
, US20080312244 A , O
in US20080312244 A IN O
which US20080312244 A WDT O
R US20080312244 A NNP O
, US20080312244 A , O
X US20080312244 A NNP O
, US20080312244 A , O
R1 US20080312244 A NNP O
, US20080312244 A , O
R2 US20080312244 A NNP O
, US20080312244 A , O
R3 US20080312244 A NNP O
, US20080312244 A , O
R4 US20080312244 A NNP O
and US20080312244 A CC O
R5 US20080312244 A NNP O
have US20080312244 A VBP O
the US20080312244 A DT O
meanings US20080312244 A NNS O
indicated US20080312244 A VBD O
in US20080312244 A IN O
Claim US20080312244 A NNP O
1 US20080312244 A CD O
, US20080312244 A , O
are US20080312244 A VBP O
inhibitors US20080312244 A NNS O
of US20080312244 A IN O
CHK1 US20080312244 A NNP I-UN
CHK2 US20080312244 A NNP I-UN
and US20080312244 A CC O
SGK US20080312244 A NNP I-UN
kinases US20080312244 A NNS O
and US20080312244 A CC O
can US20080312244 A MD O
be US20080312244 A VB O
employed US20080312244 A VBN O
, US20080312244 A , O
inter US20080312244 A NN O
alia US20080312244 A NNS O
, US20080312244 A , O
for US20080312244 A IN O
the US20080312244 A DT O
treatment US20080312244 A NN O
of US20080312244 A IN O
cancer US20080312244 A NN O
. US20080312244 A . O

Methods US20130012497 T NNS O
for US20130012497 T IN O
detecting US20130012497 T VBG O
adhd US20130012497 T JJ O
susceptibility US20130012497 T NN O
and US20130012497 T CC O
predicting US20130012497 T VBG O
severity US20130012497 T NN O
and US20130012497 T CC O
long US20130012497 T JJ O
term US20130012497 T NN O
outcome US20130012497 T NN O
of US20130012497 T IN O
adhd US20130012497 T NN O
symptoms US20130012497 T NNS O
. US20130012497 T . O

Bacillus CN103305567A T IN O
calmette-guerin CN103305567A T JJ O
compound CN103305567A T NN O
polysaccharide CN103305567A T NN O
, CN103305567A T , O
and CN103305567A T CC O
preparation CN103305567A T NN O
method CN103305567A T NN O
and CN103305567A T CC O
use CN103305567A T NN O
thereof CN103305567A T NN O
. CN103305567A T . O

Crystalline EP1930011A2 T NNP O
form EP1930011A2 T NN O
of EP1930011A2 T IN O
ibandronate EP1930011A2 T JJ O
sodium EP1930011A2 T NN O
. EP1930011A2 T . O

Folium CN102988724A T NNP O
mori CN102988724A T VBZ O
tablets CN102988724A T NNS O
for CN102988724A T IN O
moistening CN102988724A T VBG O
dryness CN102988724A T NN O
and CN102988724A T CC O
lungs CN102988724A T NNS O
. CN102988724A T . O

5-quinolinone US20110178106 T CD O
and US20110178106 T CC O
imidazopyridine US20110178106 T VB O
compounds US20110178106 T NNS O
and US20110178106 T CC O
use US20110178106 T NN O
thereof US20110178106 T NN O
. US20110178106 T . O

5-Quinolinone US20110178106 A CD O
and US20110178106 A CC O
Imidazopyrimidine US20110178106 A NNP O
compounds US20110178106 A NNS O
are US20110178106 A VBP O
provided US20110178106 A VBN O
that US20110178106 A IN O
are US20110178106 A VBP O
useful US20110178106 A JJ O
for US20110178106 A IN O
inhibiting US20110178106 A VBG O
the US20110178106 A DT O
efflux US20110178106 A NN O
of US20110178106 A IN O
any US20110178106 A DT O
therapeutic US20110178106 A JJ O
agent US20110178106 A NN O
that US20110178106 A WDT O
is US20110178106 A VBZ O
a US20110178106 A DT O
MRP1 US20110178106 A NNP I-UN
substrate US20110178106 A NN O
. US20110178106 A . O

Also US20110178106 A RB O
provided US20110178106 A VBN O
is US20110178106 A VBZ O
a US20110178106 A DT O
method US20110178106 A NN O
for US20110178106 A IN O
screening US20110178106 A VBG O
to US20110178106 A TO O
identify US20110178106 A VB O
additional US20110178106 A JJ O
MRP1 US20110178106 A NNP I-UN
inhibitors US20110178106 A NNS O
. US20110178106 A . O

Adhesive US20120219544 T JJ O
composition US20120219544 T NN O
for US20120219544 T IN O
soft US20120219544 T JJ O
tissues US20120219544 T NNS O
, US20120219544 T , O
adhesive US20120219544 T JJ O
composition US20120219544 T NN O
for US20120219544 T IN O
wound US20120219544 T NN O
dressing US20120219544 T NN O
or US20120219544 T CC O
wound US20120219544 T NN O
dressing US20120219544 T VBG O
composition US20120219544 T NN O
. US20120219544 T . O

Composition CN101301346A T NN O
for CN101301346A T IN O
improving CN101301346A T VBG O
organism CN101301346A T NN O
immunity CN101301346A T NN O
of CN101301346A T IN O
aquatic CN101301346A T JJ O
livestock CN101301346A T NN O
. CN101301346A T . O

Cmet WO2011067189A3 T NNP I-UN
inhibitors WO2011067189A3 T NNS O
for WO2011067189A3 T IN O
treating WO2011067189A3 T VBG O
endometriosis WO2011067189A3 T NN O
. WO2011067189A3 T . O

The WO2011067189A3 A DT O
invention WO2011067189A3 A NN O
relates WO2011067189A3 A VBZ O
to WO2011067189A3 A TO O
the WO2011067189A3 A DT O
treatment WO2011067189A3 A NN O
of WO2011067189A3 A IN O
endometriosis WO2011067189A3 A NN O
using WO2011067189A3 A VBG O
cMet WO2011067189A3 A JJ I-UN
inhibitors WO2011067189A3 A NNS O
, WO2011067189A3 A , O
and WO2011067189A3 A CC O
medication WO2011067189A3 A NN O
comprising WO2011067189A3 A VBG O
cMet WO2011067189A3 A JJ I-UN
inhibitors WO2011067189A3 A NNS O
for WO2011067189A3 A IN O
treating WO2011067189A3 A VBG O
endometriosis WO2011067189A3 A NN O
. WO2011067189A3 A . O

Sulphated EP2786782A1 T VBN O
hyaluronic EP2786782A1 T JJ O
acid EP2786782A1 T NN O
for EP2786782A1 T IN O
treating EP2786782A1 T VBG O
degenerative EP2786782A1 T JJ O
osteoarthritis EP2786782A1 T NN O
. EP2786782A1 T . O

Pyrazole US20080125474 T NNP O
Analogs US20080125474 T NNP O
. US20080125474 T . O

Medium CN101019851B T NN O
chain CN101019851B T NN O
fatty CN101019851B T JJ O
acid CN101019851B T JJ O
liposome CN101019851B T NN O
and CN101019851B T CC O
its CN101019851B T PRP$ O
preparation CN101019851B T NN O
. CN101019851B T . O

Ubenimex CN103142544A T NNP O
capsule CN103142544A T NN O
composition CN103142544A T NN O
and CN103142544A T CC O
preparation CN103142544A T NN O
method CN103142544A T NN O
thereof CN103142544A T NN O
. CN103142544A T . O

Medicinal CN101744833A T JJ O
composition CN101744833A T NN O
for CN101744833A T IN O
treating CN101744833A T VBG O
bacterial CN101744833A T JJ O
vaginitis CN101744833A T NN O
. CN101744833A T . O

The WO2007095784A1 T DT O
triazolyl-containing WO2007095784A1 T JJ O
oxazolidinone WO2007095784A1 T NN O
derivatives WO2007095784A1 T NNS O
, WO2007095784A1 T , O
the WO2007095784A1 T DT O
preparation WO2007095784A1 T NN O
method WO2007095784A1 T NN O
and WO2007095784A1 T CC O
the WO2007095784A1 T DT O
uses WO2007095784A1 T NNS O
thereof WO2007095784A1 T NN O
. WO2007095784A1 T . O

The WO2007095784A1 A DT O
triazolyl-containing WO2007095784A1 A JJ O
oxazolidinone WO2007095784A1 A NN O
derivatives WO2007095784A1 A NNS O
of WO2007095784A1 A IN O
the WO2007095784A1 A DT O
present WO2007095784A1 A JJ O
application WO2007095784A1 A NN O
, WO2007095784A1 A , O
or WO2007095784A1 A CC O
their WO2007095784A1 A PRP$ O
pharmaceutically WO2007095784A1 A RB O
acceptable WO2007095784A1 A JJ O
salts WO2007095784A1 A NNS O
have WO2007095784A1 A VBP O
excellent WO2007095784A1 A JJ O
antibiotic WO2007095784A1 A JJ O
activity WO2007095784A1 A NN O
and WO2007095784A1 A CC O
metabolic WO2007095784A1 A JJ O
activity WO2007095784A1 A NN O
in WO2007095784A1 A IN O
vitro WO2007095784A1 A NN O
or WO2007095784A1 A CC O
in WO2007095784A1 A IN O
vivo WO2007095784A1 A NN O
, WO2007095784A1 A , O
they WO2007095784A1 A PRP O
can WO2007095784A1 A MD O
decrease WO2007095784A1 A VB O
the WO2007095784A1 A DT O
inhibitory WO2007095784A1 A JJ O
activity WO2007095784A1 A NN O
of WO2007095784A1 A IN O
C-5 WO2007095784A1 A NNP O
acetamido WO2007095784A1 A NN O
oxazolidinone WO2007095784A1 A NN O
derivatives WO2007095784A1 A NNS O
to WO2007095784A1 A TO O
MAO-A WO2007095784A1 A NNP I-UN
, WO2007095784A1 A , O
so WO2007095784A1 A IN O
that WO2007095784A1 A IN O
the WO2007095784A1 A DT O
clinical WO2007095784A1 A JJ O
negative WO2007095784A1 A JJ O
reactions WO2007095784A1 A NNS O
of WO2007095784A1 A IN O
these WO2007095784A1 A DT O
medicaments WO2007095784A1 A NNS O
are WO2007095784A1 A VBP O
decreased WO2007095784A1 A VBN O
. WO2007095784A1 A . O

Hydrochloride WO2006024668A1 T NNP O
of WO2006024668A1 T IN O
4- WO2006024668A1 T JJ O
[ WO2006024668A1 T NNP O
[ WO2006024668A1 T NNP O
4- WO2006024668A1 T JJ O
[ WO2006024668A1 T NNP O
[ WO2006024668A1 T NNP O
4- WO2006024668A1 T JJ O
( WO2006024668A1 T ( O
2-cyanoethenyl WO2006024668A1 T JJ O
) WO2006024668A1 T ) O
-2,6-dimethylphenyl WO2006024668A1 T FW O
] WO2006024668A1 T NNP O
amino WO2006024668A1 T NN O
] WO2006024668A1 T NNP O
-2-pyrimidinyl WO2006024668A1 T NNP O
] WO2006024668A1 T NNP O
amino WO2006024668A1 T NN O
] WO2006024668A1 T NNP O
benzonitrile WO2006024668A1 T NN O
. WO2006024668A1 T . O

Relaxin-like US6949506 T JJ I-UN
factor US6949506 T NN I-UN
and US6949506 T CC O
methods US6949506 T NNS O
and US6949506 T CC O
uses US6949506 T VBZ O
thereof US6949506 T NN O
. US6949506 T . O

The US6949506 A DT O
present US6949506 A JJ O
invention US6949506 A NN O
relates US6949506 A VBZ O
to US6949506 A TO O
a US6949506 A DT O
relaxin-like US6949506 A JJ I-UN
factor US6949506 A NN I-UN
, US6949506 A , O
its US6949506 A PRP$ O
derivatives US6949506 A NNS O
or US6949506 A CC O
analogs US6949506 A NNS O
, US6949506 A , O
and US6949506 A CC O
uses US6949506 A VBZ O
thereof US6949506 A NN O
. US6949506 A . O

The US6949506 A DT O
present US6949506 A JJ O
invention US6949506 A NN O
further US6949506 A RBR O
relates US6949506 A VBZ O
to US6949506 A TO O
compositions US6949506 A NNS O
comprising US6949506 A VBG O
a US6949506 A DT O
relaxin-like US6949506 A JJ I-UN
factor US6949506 A NN I-UN
, US6949506 A , O
its US6949506 A PRP$ O
derivatives US6949506 A NNS O
or US6949506 A CC O
analogs US6949506 A NNS O
, US6949506 A , O
and US6949506 A CC O
relaxin US6949506 A VB I-UN
wherein US6949506 A NNS O
such US6949506 A JJ O
composition US6949506 A NN O
exhibits US6949506 A NNS O
an US6949506 A DT O
additive US6949506 A JJ O
or US6949506 A CC O
synergistic US6949506 A JJ O
effect US6949506 A NN O
. US6949506 A . O

Substituted US20100234347 T VBN O
Pteridines US20100234347 T NNS O
substituted US20100234347 T VBN O
with US20100234347 T IN O
a US20100234347 T DT O
Four-Membered US20100234347 T JJ O
Heterocycle US20100234347 T NNP O
. US20100234347 T . O

Pharmaceutical WO2014017569A1 T JJ O
product WO2014017569A1 T NN O
for WO2014017569A1 T IN O
lowering WO2014017569A1 T VBG O
blood WO2014017569A1 T NN O
ldl WO2014017569A1 T NN O
. WO2014017569A1 T . O

A WO2014017569A1 A DT O
pharmaceutical WO2014017569A1 A JJ O
product WO2014017569A1 A NN O
for WO2014017569A1 A IN O
lowering WO2014017569A1 A VBG O
blood WO2014017569A1 A NN O
LDL WO2014017569A1 A NNP O
, WO2014017569A1 A , O
which WO2014017569A1 A WDT O
is WO2014017569A1 A VBZ O
a WO2014017569A1 A DT O
pharmaceutical WO2014017569A1 A JJ O
product WO2014017569A1 A NN O
that WO2014017569A1 A WDT O
contains WO2014017569A1 A VBZ O
a WO2014017569A1 A DT O
compound WO2014017569A1 A NN O
represented WO2014017569A1 A VBN O
by WO2014017569A1 A IN O
formula WO2014017569A1 A NN O
( WO2014017569A1 A ( O
I WO2014017569A1 A PRP O
) WO2014017569A1 A ) O
as WO2014017569A1 A IN O
an WO2014017569A1 A DT O
active WO2014017569A1 A JJ O
ingredient WO2014017569A1 A NN O
, WO2014017569A1 A , O
said WO2014017569A1 A VBD O
compound WO2014017569A1 A NN O
having WO2014017569A1 A VBG O
actions WO2014017569A1 A NNS O
of WO2014017569A1 A IN O
inhibiting WO2014017569A1 A VBG O
the WO2014017569A1 A DT O
expression WO2014017569A1 A NN O
of WO2014017569A1 A IN O
PCSK9mRNA WO2014017569A1 A NNP O
, WO2014017569A1 A , O
lowering WO2014017569A1 A VBG O
the WO2014017569A1 A DT O
amount WO2014017569A1 A NN O
of WO2014017569A1 A IN O
PCSK9 WO2014017569A1 A NNP I-UN
protein WO2014017569A1 A NN O
, WO2014017569A1 A , O
and WO2014017569A1 A CC O
increasing WO2014017569A1 A VBG O
the WO2014017569A1 A DT O
amount WO2014017569A1 A NN O
of WO2014017569A1 A IN O
an WO2014017569A1 A DT O
LDL WO2014017569A1 A NNP O
receptor WO2014017569A1 A NN O
. WO2014017569A1 A . O

Substituted WO2010046388A1 T VBN O
( WO2010046388A1 T ( O
aza WO2010046388A1 T NN O
) WO2010046388A1 T ) O
-1-methyl-1h-quinolin-2-ones WO2010046388A1 T VBZ O
as WO2010046388A1 T IN O
antibacterials WO2010046388A1 T NNS O
. WO2010046388A1 T . O

β-LACTAM WO2006075395A1 T JJ O
ANTIBIOTIC WO2006075395A1 T NNP O
ACTIVITY WO2006075395A1 T NNP O
ENHANCER WO2006075395A1 T NNP O
AND WO2006075395A1 T NNP O
PROCESS WO2006075395A1 T NNP O
FOR WO2006075395A1 T NNP O
PRODUCING WO2006075395A1 T NNP O
THE WO2006075395A1 T NNP O
SAME WO2006075395A1 T NNP O
. WO2006075395A1 T . O

Combating US6887883 T VBG O
angiogenic US6887883 T JJ O
activity US6887883 T NN O
in US6887883 T IN O
a US6887883 T DT O
human US6887883 T JJ O
comprising US6887883 T VBG O
administering US6887883 T VBG O
to US6887883 T TO O
a US6887883 T DT O
chrysanthone US6887883 T NN O
compound US6887883 T NN O
. US6887883 T . O

Continuous US20120100182 T NNP O
Cell US20120100182 T NNP O
Programming US20120100182 T NNP O
Devices US20120100182 T NNPS O
. US20120100182 T . O

Application CN102697756A T NN O
of CN102697756A T IN O
geraniol CN102697756A T NN O
in CN102697756A T IN O
preparation CN102697756A T NN O
of CN102697756A T IN O
drug CN102697756A T NN O
for CN102697756A T IN O
treating CN102697756A T VBG O
vaginitis CN102697756A T NN O
. CN102697756A T . O

Method US20100298758 T NNP O
for US20100298758 T IN O
non-therapeutic US20100298758 T JJ O
or US20100298758 T CC O
therapeutic US20100298758 T JJ O
photodynamic US20100298758 T JJ O
skin US20100298758 T NN O
treatment US20100298758 T NN O
. US20100298758 T . O

Substituted WO2012131501A1 T VBN O
benzimidazole WO2012131501A1 T JJ O
compounds WO2012131501A1 T NNS O
as WO2012131501A1 T IN O
cot WO2012131501A1 T JJ I-UN
kinase WO2012131501A1 T NN O
inhibitors WO2012131501A1 T NNS O
. WO2012131501A1 T . O

Antimicrobials US20090247640 T NNS O
having US20090247640 T VBG O
polyquaternary US20090247640 T JJ O
ammoniums US20090247640 T NNS O
and US20090247640 T CC O
alcohol-bearing US20090247640 T JJ O
amidoamines US20090247640 T NNS O
and US20090247640 T CC O
methods US20090247640 T NNS O
for US20090247640 T IN O
their US20090247640 T PRP$ O
use US20090247640 T NN O
. US20090247640 T . O

Novel US20110059910 T NNP O
aromatic US20110059910 T JJ O
fluoroglycoside US20110059910 T NN O
derivatives US20110059910 T NNS O
, US20110059910 T , O
pharmaceuticals US20110059910 T NNS O
comprising US20110059910 T VBG O
said US20110059910 T VBD O
compounds US20110059910 T NNS O
and US20110059910 T CC O
the US20110059910 T DT O
use US20110059910 T NN O
thereof US20110059910 T NN O
. US20110059910 T . O

Aryl-group-substituted CN1854125A T JJ O
acrylonitrile CN1854125A T NN O
compound CN1854125A T NN O
, CN1854125A T , O
its CN1854125A T PRP$ O
production CN1854125A T NN O
and CN1854125A T CC O
use CN1854125A T NN O
. CN1854125A T . O

Amino CN1566086A T NNP O
acid CN1566086A T VBP O
calcium CN1566086A T NN O
chelate CN1566086A T NN O
, CN1566086A T , O
preparation CN1566086A T NN O
and CN1566086A T CC O
application CN1566086A T NN O
thereof CN1566086A T NN O
. CN1566086A T . O

Use DE102004060041A1 T NNP O
of DE102004060041A1 T IN O
substituted DE102004060041A1 T JJ O
cyclopropane DE102004060041A1 T NN O
acid DE102004060041A1 T RB O
derivative DE102004060041A1 T JJ O
having DE102004060041A1 T VBG O
dopamine DE102004060041A1 T NN I-UN
receptor DE102004060041A1 T NN I-UN
ligand DE102004060041A1 T NN O
activity DE102004060041A1 T NN O
to DE102004060041A1 T TO O
e.g DE102004060041A1 T VB O
. DE102004060041A1 T . O

The DE102004060041A1 A DT O
results DE102004060041A1 A NNS O
showed DE102004060041A1 A VBD O
that DE102004060041A1 A IN O
1R-methoxycarbonyl-2R-hydroxycarbonylcyclopropane DE102004060041A1 A JJ O
exhibited DE102004060041A1 A VBD O
a DE102004060041A1 A DT O
median DE102004060041A1 A JJ O
effective DE102004060041A1 A JJ O
concentration DE102004060041A1 A NN O
value DE102004060041A1 A NN O
of DE102004060041A1 A IN O
0.07 DE102004060041A1 A CD O
mu DE102004060041A1 A NN O
M. DE102004060041A1 A NNP O
- DE102004060041A1 A : O
MECHANISM DE102004060041A1 A NN O
OF DE102004060041A1 A IN O
ACTION DE102004060041A1 A NNP O
: DE102004060041A1 A : O
Dopamine DE102004060041A1 A NNP I-UN
receptor DE102004060041A1 A NN I-UN
ligand DE102004060041A1 A NN O
. DE102004060041A1 A . O

e.g US8044040 T NN O
. US8044040 T . O

3- US8044040 T JJ O
{ US8044040 T ( O
3-Cyano-6- US8044040 T JJ O
[ US8044040 T NN O
( US8044040 T ( O
2,2-dimethyl-propyl US8044040 T JJ O
) US8044040 T ) O
-methyl-amino US8044040 T NN O
] US8044040 T NNP O
-5-fluoro-pyridin-2-ylamino US8044040 T NN O
} US8044040 T ) O
-N-methoxy-4-methyl-benzamide US8044040 T NN O
; US8044040 T : O
via US8044040 T IN O
p38 US8044040 T NN O
kinase US8044040 T NN O
inhibition US8044040 T NN O
; US8044040 T : O
( US8044040 T ( O
anilino US8044040 T NN O
) US8044040 T ) O
( US8044040 T ( O
halo US8044040 T NN O
) US8044040 T ) O
pyrimidine US8044040 T NN O
or US8044040 T CC O
( US8044040 T ( O
anilino US8044040 T NN O
) US8044040 T ) O
( US8044040 T ( O
amino US8044040 T NN O
) US8044040 T ) O
pyrimidine US8044040 T NN O
derivatives US8044040 T NNS O
; US8044040 T : O
rheumatoid US8044040 T VB O
arthritis US8044040 T NN O
, US8044040 T , O
psoriasis US8044040 T NN O
, US8044040 T , O
Crohn US8044040 T NNP O
's US8044040 T POS O
Disease US8044040 T NNP O
, US8044040 T , O
osteoarthritis US8044040 T NN O
or US8044040 T CC O
osteoporosis US8044040 T NN O
. US8044040 T . O

In US8044040 A IN O
one US8044040 A CD O
embodiment US8044040 A NN O
, US8044040 A , O
compounds US8044040 A NNS O
of US8044040 A IN O
the US8044040 A DT O
present US8044040 A JJ O
invention US8044040 A NN O
are US8044040 A VBP O
represented US8044040 A VBN O
by US8044040 A IN O
Formula US8044040 A NNP O
( US8044040 A ( O
I US8044040 A PRP O
) US8044040 A ) O
: US8044040 A : O
Methods US8044040 A NNS O
of US8044040 A IN O
production US8044040 A NN O
, US8044040 A , O
pharmaceutical US8044040 A JJ O
compositions US8044040 A NNS O
and US8044040 A CC O
methods US8044040 A NNS O
of US8044040 A IN O
treating US8044040 A VBG O
conditions US8044040 A NNS O
associated US8044040 A VBN O
with US8044040 A IN O
inappropriate US8044040 A JJ O
p38 US8044040 A JJ O
kinase US8044040 A NN O
activity US8044040 A NN O
or US8044040 A CC O
TNF-α US8044040 A JJ I-UN
expression US8044040 A NN O
utilizing US8044040 A VBG O
compounds US8044040 A NNS O
of US8044040 A IN O
the US8044040 A DT O
present US8044040 A JJ O
invention US8044040 A NN O
are US8044040 A VBP O
also US8044040 A RB O
disclosed US8044040 A VBN O
. US8044040 A . O

Tissues US20080206186 T NNS O
; US20080206186 T : O
20 US20080206186 T CD O
mol US20080206186 T NN O
% US20080206186 T NN O
acidic US20080206186 T JJ O
monmers US20080206186 T NNS O
: US20080206186 T : O
acrylic US20080206186 T JJ O
acid US20080206186 T NN O
, US20080206186 T , O
monoacryloxyethyl US20080206186 T NN O
phosphate US20080206186 T NN O
, US20080206186 T , O
propene-1-sulfonic US20080206186 T JJ O
acid US20080206186 T NN O
, US20080206186 T , O
vinyl US20080206186 T FW O
benzoic US20080206186 T NN O
acid US20080206186 T NN O
, US20080206186 T , O
crotonic US20080206186 T JJ O
acid US20080206186 T NN O
, US20080206186 T , O
itaconic US20080206186 T JJ O
acid US20080206186 T NN O
, US20080206186 T , O
vinylsulfonic US20080206186 T JJ O
acid US20080206186 T NN O
, US20080206186 T , O
vinyl US20080206186 T FW O
acetic US20080206186 T JJ O
acid US20080206186 T NN O
, US20080206186 T , O
citric US20080206186 T JJ O
acid US20080206186 T NN O
, US20080206186 T , O
styrene US20080206186 T NN O
sulfonic US20080206186 T JJ O
acid US20080206186 T NN O
, US20080206186 T , O
sodium US20080206186 T NN O
styrene US20080206186 T NN O
sulfonate US20080206186 T NN O
; US20080206186 T : O
porosity US20080206186 T NN O
of US20080206186 T IN O
at US20080206186 T IN O
least US20080206186 T JJS O
40 US20080206186 T CD O
% US20080206186 T NN O
; US20080206186 T : O
interconnected US20080206186 T VBN O
pores US20080206186 T NNS O
. US20080206186 T . O

Improved CN101088997A T NNP O
process CN101088997A T NN O
of CN101088997A T IN O
preparing CN101088997A T VBG O
Raltitrexed CN101088997A T NNP O
. CN101088997A T . O

Transporter US20060051754 T NNP O
selectively US20060051754 T RB O
transporting US20060051754 T VBG O
sulfate US20060051754 T NN O
conjugate US20060051754 T NN O
and US20060051754 T CC O
its US20060051754 T PRP$ O
gene US20060051754 T NN O
. US20060051754 T . O

It US20060051754 A PRP O
is US20060051754 A VBZ O
intended US20060051754 A VBN O
to US20060051754 A TO O
provide US20060051754 A VB O
a US20060051754 A DT O
liver-specific US20060051754 A JJ O
organic US20060051754 A JJ I-UN
anion US20060051754 A NN I-UN
transporter US20060051754 A NN I-UN
which US20060051754 A WDT O
transports US20060051754 A VBZ O
selectively US20060051754 A RB O
a US20060051754 A DT O
sulfate US20060051754 A NN O
conjugate US20060051754 A NN O
and US20060051754 A CC O
its US20060051754 A PRP$ O
gene US20060051754 A NN O
. US20060051754 A . O

Phenylenediamine US20070293503 T NNP O
urotensin-II US20070293503 T JJ I-UN
receptor US20070293503 T NN I-UN
antagonists US20070293503 T NNS O
and US20070293503 T CC O
CCR-9 US20070293503 T JJ I-UN
antagonists US20070293503 T NNS O
. US20070293503 T . O

The US20070293503 A DT O
present US20070293503 A JJ O
invention US20070293503 A NN O
relates US20070293503 A VBZ O
to US20070293503 A TO O
urotensin US20070293503 A VB I-UN
II US20070293503 A NNP I-UN
receptor US20070293503 A NN I-UN
antagonists US20070293503 A NNS O
, US20070293503 A , O
CCR-9 US20070293503 A JJ I-UN
antagonists US20070293503 A NNS O
, US20070293503 A , O
pharmaceutical US20070293503 A JJ O
compositions US20070293503 A NNS O
containing US20070293503 A VBG O
them US20070293503 A PRP O
and US20070293503 A CC O
their US20070293503 A PRP$ O
use US20070293503 A NN O
. US20070293503 A . O

4-PHENYL-5-0X0-l,4,5,6,7,8-HEXAHYDR0QËIN0LINE WO2006117371A1 T JJ O
DERIVATIVES WO2006117371A1 T NNP O
AS WO2006117371A1 T NNP O
MEDICAMENTS WO2006117371A1 T NNP O
FOR WO2006117371A1 T IN O
THE WO2006117371A1 T NNP O
TREATMENT WO2006117371A1 T NNP O
OF WO2006117371A1 T NNP O
INFERTILITY WO2006117371A1 T NNP O
. WO2006117371A1 T . O

Pharmaceutical EP1076553B1 T NNP O
, EP1076553B1 T , O
hygienic EP1076553B1 T JJ O
and/or EP1076553B1 T NN O
cosmetic EP1076553B1 T JJ O
compositions EP1076553B1 T NNS O
containing EP1076553B1 T VBG O
sea EP1076553B1 T NN O
water EP1076553B1 T NN O
and EP1076553B1 T CC O
uses EP1076553B1 T NNS O
. EP1076553B1 T . O

Composition US20120301513 T NN O
comprising US20120301513 T VBG O
solanum US20120301513 T NN O
glaucophyllum US20120301513 T NN O
for US20120301513 T IN O
preventing US20120301513 T VBG O
and/or US20120301513 T JJ O
treating US20120301513 T VBG O
hypocalcaemia US20120301513 T NN O
and US20120301513 T CC O
for US20120301513 T IN O
stabilizing US20120301513 T VBG O
blood US20120301513 T NN O
calcium US20120301513 T NN O
levels US20120301513 T NNS O
. US20120301513 T . O

2- US6891039 T JJ O
( US6891039 T ( O
4-Fluorophenyl US6891039 T JJ O
) US6891039 T ) O
-1- US6891039 T NN O
( US6891039 T ( O
2-cyclopentylamino-4-pyrimidinyl US6891039 T JJ O
) US6891039 T ) O
-5- US6891039 T NN O
( US6891039 T ( O
piperidino-N US6891039 T JJ O
-2-ethyl US6891039 T NN O
) US6891039 T ) O
imidazo US6891039 T NN O
( US6891039 T ( O
4,5-b US6891039 T JJ O
) US6891039 T ) O
pyridine US6891039 T NN O
, US6891039 T , O
for US6891039 T IN O
example US6891039 T NN O
; US6891039 T : O
MAP US6891039 T NNP I-UN
kinase US6891039 T NN I-UN
inhibitors US6891039 T NNS O
, US6891039 T , O
for US6891039 T IN O
Tumor US6891039 T NNP I-UN
Necrosis US6891039 T NNP I-UN
Factor US6891039 T NNP I-UN
( US6891039 T ( O
TNF-alpha US6891039 T NNP I-UN
) US6891039 T ) O
and US6891039 T CC O
Interleukin-1 US6891039 T NNP I-UN
( US6891039 T ( O
IL-1 US6891039 T NNP I-UN
) US6891039 T ) O
disorders US6891039 T NNS O
such US6891039 T JJ O
as US6891039 T IN O
osteoporosis US6891039 T NN O
. US6891039 T . O

Compounds US6891039 A NNS O
of US6891039 A IN O
formula US6891039 A NN O
( US6891039 A ( O
I US6891039 A PRP O
) US6891039 A ) O
and US6891039 A CC O
pharmaceutically-acceptable US6891039 A JJ O
and US6891039 A CC O
pharmaceutically-acceptable US6891039 A JJ O
and US6891039 A CC O
-cleavable US6891039 A JJ O
esters US6891039 A NNS O
thereof US6891039 A VBP O
and US6891039 A CC O
acid US6891039 A JJ O
addition US6891039 A NN O
salts US6891039 A NNS O
thereof US6891039 A NN O
, US6891039 A , O
wherein US6891039 A VBP O
the US6891039 A DT O
symbols US6891039 A NNS O
are US6891039 A VBP O
as US6891039 A IN O
defined US6891039 A VBN O
are US6891039 A VBP O
MAP US6891039 A NNP I-UN
kinase US6891039 A NN I-UN
inhibitors US6891039 A NNS O
, US6891039 A , O
useful US6891039 A JJ O
pharmaceutically US6891039 A RB O
for US6891039 A IN O
treating US6891039 A VBG O
TNFα US6891039 A NNP I-UN
and US6891039 A CC O
IL-1 US6891039 A NNP I-UN
mediated US6891039 A VBD O
diseases US6891039 A NNS O
such US6891039 A JJ O
as US6891039 A IN O
rheumatoid US6891039 A JJ O
arthritis US6891039 A NN O
and US6891039 A CC O
diseases US6891039 A NNS O
of US6891039 A IN O
bone US6891039 A NN O
metabolism US6891039 A NN O
, US6891039 A , O
e.g US6891039 A NN O
. US6891039 A . O

Hdac WO2014164784A1 T NNP O
inhibitor WO2014164784A1 T NN O
polymorphic WO2014164784A1 T JJ O
forms WO2014164784A1 T NNS O
and WO2014164784A1 T CC O
methods WO2014164784A1 T NNS O
of WO2014164784A1 T IN O
use WO2014164784A1 T NN O
. WO2014164784A1 T . O

Polymorphic WO2014164784A1 A JJ O
forms WO2014164784A1 A NNS O
of WO2014164784A1 A IN O
histone WO2014164784A1 A NN I-UN
deacetylase WO2014164784A1 A NN I-UN
inhibitors WO2014164784A1 A NNS O
( WO2014164784A1 A ( O
HDAC WO2014164784A1 A NNP I-UN
) WO2014164784A1 A ) O
and WO2014164784A1 A CC O
methods WO2014164784A1 A NNS O
of WO2014164784A1 A IN O
making WO2014164784A1 A VBG O
and WO2014164784A1 A CC O
using WO2014164784A1 A VBG O
such WO2014164784A1 A JJ O
polymorphic WO2014164784A1 A JJ O
forms WO2014164784A1 A NNS O
are WO2014164784A1 A VBP O
provided WO2014164784A1 A VBN O
. WO2014164784A1 A . O

9-sulfonyl-9h-purine WO2013000280A1 T JJ O
derivative WO2013000280A1 T NN O
, WO2013000280A1 T , O
preparation WO2013000280A1 T NN O
method WO2013000280A1 T NN O
and WO2013000280A1 T CC O
use WO2013000280A1 T NN O
thereof WO2013000280A1 T NN O
. WO2013000280A1 T . O

Beta-carbolines CN102844029A T NNS O
for CN102844029A T IN O
use CN102844029A T NN O
in CN102844029A T IN O
the CN102844029A T DT O
treatment CN102844029A T NN O
of CN102844029A T IN O
hearing CN102844029A T VBG O
loss CN102844029A T NN O
and CN102844029A T CC O
vertigo CN102844029A T NN O
. CN102844029A T . O

Ofloxacin CN101756926A T NNP O
slow-release CN101756926A T JJ O
tablet CN101756926A T NN O
and CN101756926A T CC O
preparation CN101756926A T NN O
method CN101756926A T NN O
thereof CN101756926A T NN O
. CN101756926A T . O

Compositions US20110218243 T NNS O
and US20110218243 T CC O
methods US20110218243 T NNS O
for US20110218243 T IN O
treating US20110218243 T VBG O
and/or US20110218243 T JJ O
preventing US20110218243 T VBG O
cardiovascular US20110218243 T JJ O
disease US20110218243 T NN O
. US20110218243 T . O

Azatadine-containing CN101810615A T JJ O
composition CN101810615A T NN O
. CN101810615A T . O

For US20080131370 T IN O
prophylaxis US20080131370 T NN O
or US20080131370 T CC O
treatment US20080131370 T NN O
of US20080131370 T IN O
apoptosis US20080131370 T NN O
or US20080131370 T CC O
inflammation-associated US20080131370 T JJ O
disease US20080131370 T NN O
, US20080131370 T , O
diabetes US20080131370 T VBZ O
, US20080131370 T , O
or US20080131370 T CC O
chronic US20080131370 T JJ O
obstructive US20080131370 T JJ O
pulmonary US20080131370 T JJ O
disease US20080131370 T NN O
. US20080131370 T . O

Method WO2008059869A1 T NNP O
of WO2008059869A1 T IN O
degrading WO2008059869A1 T VBG O
polysaccharide WO2008059869A1 T NN O
. WO2008059869A1 T . O

Biphenyl CN102558088A T NNP O
methylene-2-sulpho-4-thiazolone CN102558088A T NN O
compound CN102558088A T NN O
as CN102558088A T RB O
well CN102558088A T RB O
as CN102558088A T IN O
preparation CN102558088A T NN O
method CN102558088A T NN O
and CN102558088A T CC O
application CN102558088A T NN O
thereof CN102558088A T NN O
. CN102558088A T . O

A CN102558088A A DT O
biological CN102558088A A JJ O
activity CN102558088A A NN O
test CN102558088A A NN O
proves CN102558088A A VBZ O
that CN102558088A A IN O
the CN102558088A A DT O
compound CN102558088A A NN O
can CN102558088A A MD O
obviously CN102558088A A RB O
inhibit CN102558088A A VB O
the CN102558088A A DT O
activity CN102558088A A NN O
of CN102558088A A IN O
protein CN102558088A A NN I-UN
tyrosine CN102558088A A NN I-UN
phosphatase CN102558088A A NN I-UN
( CN102558088A A ( I-UN
PTP CN102558088A A NNP I-UN
) CN102558088A A ) I-UN
-1B CN102558088A A NN I-UN
. CN102558088A A . O

Therefore CN102558088A A RB O
, CN102558088A A , O
the CN102558088A A DT O
biphenyl CN102558088A A JJ O
methylene-2-sulpho-4-thiazolone CN102558088A A NN O
compound CN102558088A A NN O
disclosed CN102558088A A VBN O
by CN102558088A A IN O
the CN102558088A A DT O
invention CN102558088A A NN O
can CN102558088A A MD O
be CN102558088A A VB O
used CN102558088A A VBN O
as CN102558088A A IN O
an CN102558088A A DT O
inhibitor CN102558088A A NN O
for CN102558088A A IN O
the CN102558088A A DT O
PTP-1B CN102558088A A NNP I-UN
for CN102558088A A IN O
preventing CN102558088A A VBG O
or CN102558088A A CC O
symptomatically CN102558088A A RB O
treating CN102558088A A VBG O
diabetes CN102558088A A NNS O
mellitus CN102558088A A VBP O
or CN102558088A A CC O
adiposis CN102558088A A NN O
. CN102558088A A . O

Spermidine US20050124554 T NNP O
derivatives US20050124554 T NNS O
for US20050124554 T IN O
the US20050124554 T DT O
treatment US20050124554 T NN O
of US20050124554 T IN O
chronic US20050124554 T JJ O
neurodegenerative US20050124554 T JJ O
diseases US20050124554 T NNS O
. US20050124554 T . O

Compounds US20050124554 A NNS O
of US20050124554 A IN O
the US20050124554 A DT O
general US20050124554 A JJ O
formula US20050124554 A NN O
( US20050124554 A ( O
I US20050124554 A PRP O
) US20050124554 A ) O
: US20050124554 A : O
are US20050124554 A VBP O
useful US20050124554 A JJ O
in US20050124554 A IN O
treating US20050124554 A VBG O
chronic US20050124554 A JJ O
neurodegenerative US20050124554 A JJ O
diseases US20050124554 A NNS O
or US20050124554 A CC O
conditions US20050124554 A NNS O
in US20050124554 A IN O
mammals US20050124554 A NNS O
, US20050124554 A , O
such US20050124554 A JJ O
as US20050124554 A IN O
Alzheimer US20050124554 A NNP O
's US20050124554 A POS O
Disease US20050124554 A NNP O
, US20050124554 A , O
Parkinson US20050124554 A NNP O
's US20050124554 A POS O
Disease US20050124554 A NNP O
, US20050124554 A , O
Huntington US20050124554 A NNP O
's US20050124554 A POS O
Chorea US20050124554 A NNP O
and US20050124554 A CC O
Multiple US20050124554 A NNP O
Sclerosis US20050124554 A NNP O
. US20050124554 A . O

In US20050124554 A IN O
formula US20050124554 A NN O
( US20050124554 A ( O
I US20050124554 A PRP O
) US20050124554 A ) O
, US20050124554 A , O
a=3 US20050124554 A VBD O
or US20050124554 A CC O
4 US20050124554 A CD O
; US20050124554 A : O
b=3 US20050124554 A NN O
or US20050124554 A CC O
4 US20050124554 A CD O
provided US20050124554 A VBD O
that US20050124554 A IN O
a+b≦7 US20050124554 A NN O
; US20050124554 A : O
c US20050124554 A NN O
is US20050124554 A VBZ O
an US20050124554 A DT O
integer US20050124554 A NN O
from US20050124554 A IN O
1 US20050124554 A CD O
to US20050124554 A TO O
5 US20050124554 A CD O
; US20050124554 A : O
d US20050124554 A NN O
is US20050124554 A VBZ O
0 US20050124554 A CD O
or US20050124554 A CC O
1 US20050124554 A CD O
. US20050124554 A . O

Methods US20110003777 T NNS O
of US20110003777 T IN O
Treatment US20110003777 T NNP O
Employing US20110003777 T NNP O
Prolonged US20110003777 T NNP O
Continuous US20110003777 T NNP O
Infusion US20110003777 T NNP O
of US20110003777 T IN O
Belinostat US20110003777 T NNP O
. US20110003777 T . O

The US20110003777 A DT O
present US20110003777 A JJ O
invention US20110003777 A NN O
relates US20110003777 A VBZ O
generally US20110003777 A RB O
to US20110003777 A TO O
the US20110003777 A DT O
treatment US20110003777 A NN O
of US20110003777 A IN O
diseases US20110003777 A NNS O
and US20110003777 A CC O
disorders US20110003777 A NNS O
that US20110003777 A WDT O
are US20110003777 A VBP O
mediated US20110003777 A VBN O
by US20110003777 A IN O
histone US20110003777 A NN I-UN
deacetylase US20110003777 A NN I-UN
( US20110003777 A ( O
HDAC US20110003777 A NNP I-UN
) US20110003777 A ) O
, US20110003777 A , O
for US20110003777 A IN O
example US20110003777 A NN O
, US20110003777 A , O
cancer US20110003777 A NN O
, US20110003777 A , O
with US20110003777 A IN O
Belinostat™ US20110003777 A NNP O
( US20110003777 A ( O
also US20110003777 A RB O
known US20110003777 A VBN O
as US20110003777 A IN O
( US20110003777 A ( O
E US20110003777 A NNP O
) US20110003777 A ) O
-N-hydroxy-3- US20110003777 A NN O
( US20110003777 A ( O
3-phenylsulfamoyl-phenyl US20110003777 A JJ O
) US20110003777 A ) O
-acrylamide US20110003777 A NN O
; US20110003777 A : O
PXD101 US20110003777 A NNP O
; US20110003777 A : O
and US20110003777 A CC O
PX US20110003777 A NNP O
105684 US20110003777 A CD O
) US20110003777 A ) O
, US20110003777 A , O
and US20110003777 A CC O
more US20110003777 A JJR O
particularly US20110003777 A RB O
, US20110003777 A , O
to US20110003777 A TO O
improvement US20110003777 A NN O
treatments US20110003777 A NNS O
of US20110003777 A IN O
such US20110003777 A JJ O
diseases US20110003777 A NNS O
( US20110003777 A ( O
for US20110003777 A IN O
example US20110003777 A NN O
, US20110003777 A , O
cancers US20110003777 A NNS O
, US20110003777 A , O
for US20110003777 A IN O
example US20110003777 A NN O
, US20110003777 A , O
leukemias US20110003777 A NN O
) US20110003777 A ) O
, US20110003777 A , O
which US20110003777 A WDT O
employ US20110003777 A VBP O
prolonged US20110003777 A VBN O
continuous US20110003777 A JJ O
infusion US20110003777 A NN O
( US20110003777 A ( O
e.g. US20110003777 A JJ O
, US20110003777 A , O
prolonged US20110003777 A VBD O
continuous US20110003777 A JJ O
intravenous US20110003777 A JJ O
infusion US20110003777 A NN O
) US20110003777 A ) O
of US20110003777 A IN O
Belinostat™ US20110003777 A NNP O
. US20110003777 A . O

Tumor WO2014087778A1 T NNP O
cell WO2014087778A1 T NN O
selective WO2014087778A1 T JJ O
anticancer WO2014087778A1 T NN O
agent WO2014087778A1 T NN O
including WO2014087778A1 T VBG O
hydroxyalkylated WO2014087778A1 T VBN O
cyclodextrin WO2014087778A1 T NN O
. WO2014087778A1 T . O

The WO2014087778A1 A DT O
purpose WO2014087778A1 A NN O
of WO2014087778A1 A IN O
the WO2014087778A1 A DT O
present WO2014087778A1 A JJ O
invention WO2014087778A1 A NN O
is WO2014087778A1 A VBZ O
to WO2014087778A1 A TO O
provide WO2014087778A1 A VB O
an WO2014087778A1 A DT O
anticancer WO2014087778A1 A NN O
agent WO2014087778A1 A NN O
which WO2014087778A1 A WDT O
includes WO2014087778A1 A VBZ O
as WO2014087778A1 A IN O
an WO2014087778A1 A DT O
active WO2014087778A1 A JJ O
ingredient WO2014087778A1 A NN O
a WO2014087778A1 A DT O
compound WO2014087778A1 A NN O
having WO2014087778A1 A VBG O
excellent WO2014087778A1 A JJ O
tumor WO2014087778A1 A NN O
cell WO2014087778A1 A NN O
selectivity WO2014087778A1 A NN O
and WO2014087778A1 A CC O
novel WO2014087778A1 A JJ O
anticancer WO2014087778A1 A NN O
effects WO2014087778A1 A NNS O
. WO2014087778A1 A . O

The WO2014087778A1 A DT O
purpose WO2014087778A1 A NN O
of WO2014087778A1 A IN O
the WO2014087778A1 A DT O
present WO2014087778A1 A JJ O
invention WO2014087778A1 A NN O
is WO2014087778A1 A VBZ O
particularly WO2014087778A1 A RB O
to WO2014087778A1 A TO O
provide WO2014087778A1 A VB O
an WO2014087778A1 A DT O
anticancer WO2014087778A1 A NN O
agent WO2014087778A1 A NN O
that WO2014087778A1 A WDT O
is WO2014087778A1 A VBZ O
effective WO2014087778A1 A JJ O
against WO2014087778A1 A IN O
leukemia WO2014087778A1 A NN O
and WO2014087778A1 A CC O
is WO2014087778A1 A VBZ O
highly WO2014087778A1 A RB O
safe WO2014087778A1 A JJ O
. WO2014087778A1 A . O

By WO2014087778A1 A IN O
the WO2014087778A1 A DT O
present WO2014087778A1 A JJ O
invention WO2014087778A1 A NN O
, WO2014087778A1 A , O
a WO2014087778A1 A DT O
pharmaceutical WO2014087778A1 A JJ O
composition WO2014087778A1 A NN O
is WO2014087778A1 A VBZ O
provided WO2014087778A1 A VBN O
which WO2014087778A1 A WDT O
includes WO2014087778A1 A VBZ O
hydroxyalkylated WO2014087778A1 A JJ O
cyclodextrin WO2014087778A1 A NN O
as WO2014087778A1 A IN O
an WO2014087778A1 A DT O
active WO2014087778A1 A JJ O
ingredient WO2014087778A1 A NN O
having WO2014087778A1 A VBG O
anticancer WO2014087778A1 A NN O
activity WO2014087778A1 A NN O
. WO2014087778A1 A . O

The WO2014087778A1 A DT O
present WO2014087778A1 A JJ O
invention WO2014087778A1 A NN O
particularly WO2014087778A1 A RB O
provides WO2014087778A1 A VBZ O
an WO2014087778A1 A DT O
anticancer WO2014087778A1 A NN O
agent WO2014087778A1 A NN O
for WO2014087778A1 A IN O
leukemia WO2014087778A1 A NN O
which WO2014087778A1 A WDT O
includes WO2014087778A1 A VBZ O
hydroxypropyl-β-cyclodextrin WO2014087778A1 A NN O
as WO2014087778A1 A IN O
an WO2014087778A1 A DT O
active WO2014087778A1 A JJ O
ingredient WO2014087778A1 A NN O
having WO2014087778A1 A VBG O
anticancer WO2014087778A1 A NN O
activity WO2014087778A1 A NN O
. WO2014087778A1 A . O

Compounds US7354945 T NNS O
as US7354945 T IN O
enzyme US7354945 T JJ O
inhibitors US7354945 T NNS O
, US7354945 T , O
cosmetics US7354945 T NNS O
, US7354945 T , O
antitumor US7354945 T NN O
agents US7354945 T NNS O
and US7354945 T CC O
food US7354945 T NN O
supplements US7354945 T NNS O
. US7354945 T . O

Novel US7354945 A NNP O
compounds US7354945 A NNS O
of US7354945 A IN O
the US7354945 A DT O
formula US7354945 A NN O
I US7354945 A PRP O
in US7354945 A IN O
which US7354945 A WDT O
R US7354945 A NNP O
, US7354945 A , O
X US7354945 A NNP O
and US7354945 A CC O
n US7354945 A RB O
are US7354945 A VBP O
as US7354945 A IN O
defined US7354945 A JJ O
herein US7354945 A NN O
, US7354945 A , O
are US7354945 A VBP O
inhibitors US7354945 A NNS O
of US7354945 A IN O
tyrosine US7354945 A JJ I-UN
kinase US7354945 A NN I-UN
and US7354945 A CC O
can US7354945 A MD O
be US7354945 A VB O
employed US7354945 A VBN O
for US7354945 A IN O
the US7354945 A DT O
treatment US7354945 A NN O
of US7354945 A IN O
tumours US7354945 A NNS O
, US7354945 A , O
for US7354945 A IN O
neuroprotection US7354945 A NN O
and US7354945 A CC O
for US7354945 A IN O
protection US7354945 A NN O
of US7354945 A IN O
the US7354945 A DT O
stress US7354945 A NN O
proteins US7354945 A NNS O
of US7354945 A IN O
the US7354945 A DT O
skin US7354945 A NN O
. US7354945 A . O

Anticancer US20050065213 T NNP O
agents US20050065213 T NNS O
; US20050065213 T : O
endometriosis US20050065213 T NN O
; US20050065213 T : O
psoriasis US20050065213 T NN O
; US20050065213 T : O
vision US20050065213 T NN O
defects US20050065213 T NNS O
. US20050065213 T . O

Methods US20100216853 T NNS O
and US20100216853 T CC O
Compositions US20100216853 T NNP O
for US20100216853 T IN O
Modulating US20100216853 T NNP O
P300/CBP US20100216853 T NNP O
Activity US20100216853 T NNP O
. US20100216853 T . O

Presenilin US7125687 T NNP I-UN
enhancers US7125687 T NNS O
assays US7125687 T NNS O
. US7125687 T . O

The US7125687 A DT O
invention US7125687 A NN O
provides US7125687 A VBZ O
methods US7125687 A NNS O
and US7125687 A CC O
compositions US7125687 A NNS O
relating US7125687 A VBG O
to US7125687 A TO O
pen US7125687 A VB I-UN
polypeptides US7125687 A NNS O
having US7125687 A VBG O
pen-specific US7125687 A JJ O
structure US7125687 A NN O
and US7125687 A CC O
activity US7125687 A NN O
, US7125687 A , O
related US7125687 A VBN O
polynucleotides US7125687 A NNS O
and US7125687 A CC O
modulators US7125687 A NNS O
of US7125687 A IN O
pen US7125687 A JJ I-UN
function US7125687 A NN O
. US7125687 A . O

The US7125687 A DT O
invention US7125687 A NN O
provides US7125687 A VBZ O
isolated US7125687 A JJ O
pen US7125687 A JJ I-UN
hybridization US7125687 A NN O
probes US7125687 A NNS O
and US7125687 A CC O
primers US7125687 A NNS O
capable US7125687 A JJ O
of US7125687 A IN O
specifically US7125687 A RB O
hybridizing US7125687 A VBG O
with US7125687 A IN O
natural US7125687 A JJ O
pen US7125687 A JJ I-UN
genes US7125687 A NNS O
, US7125687 A , O
pen-specific US7125687 A JJ O
binding US7125687 A VBG O
agents US7125687 A NNS O
such US7125687 A JJ O
as US7125687 A IN O
specific US7125687 A JJ O
antibodies US7125687 A NNS O
, US7125687 A , O
and US7125687 A CC O
methods US7125687 A NNS O
of US7125687 A IN O
making US7125687 A VBG O
and US7125687 A CC O
using US7125687 A VBG O
the US7125687 A DT O
subject US7125687 A JJ O
compositions US7125687 A NNS O
in US7125687 A IN O
diagnosis US7125687 A NN O
( US7125687 A ( O
e.g US7125687 A NN O
. US7125687 A . O

genetic US7125687 A JJ O
hybridization US7125687 A NN O
screens US7125687 A NNS O
for US7125687 A IN O
pen US7125687 A JJ I-UN
transcripts US7125687 A NNS O
) US7125687 A ) O
, US7125687 A , O
therapy US7125687 A NN O
( US7125687 A ( O
e.g US7125687 A NN O
. US7125687 A . O

pen US7125687 A JJ I-UN
inhibitors US7125687 A NNS O
to US7125687 A TO O
modulate US7125687 A VB O
APP US7125687 A NNP I-UN
processing US7125687 A NN O
) US7125687 A ) O
and US7125687 A CC O
in US7125687 A IN O
the US7125687 A DT O
biopharmaceutical US7125687 A JJ O
industry US7125687 A NN O
( US7125687 A ( O
e.g US7125687 A UH O
. US7125687 A . O

Process WO2014037563A1 T NN O
for WO2014037563A1 T IN O
preparing WO2014037563A1 T VBG O
cinacalcet WO2014037563A1 T NN O
and WO2014037563A1 T CC O
pharmaceutically WO2014037563A1 T RB O
acceptable WO2014037563A1 T JJ O
salts WO2014037563A1 T NNS O
thereof WO2014037563A1 T NN O
. WO2014037563A1 T . O

Nestorone®/estradiol US20130045953 T NNP O
transdermal US20130045953 T JJ O
gel US20130045953 T NN O
. US20130045953 T . O

Ketone WO2010005384A1 T NNP O
pyridine WO2010005384A1 T NN O
analogues WO2010005384A1 T NNS O
and WO2010005384A1 T CC O
their WO2010005384A1 T PRP$ O
use WO2010005384A1 T NN O
in WO2010005384A1 T IN O
the WO2010005384A1 T DT O
treatment WO2010005384A1 T NN O
of WO2010005384A1 T IN O
cardiovascular WO2010005384A1 T JJ O
disorders WO2010005384A1 T NNS O
. WO2010005384A1 T . O

The WO2010005384A1 A DT O
present WO2010005384A1 A JJ O
invention WO2010005384A1 A NN O
relates WO2010005384A1 A VBZ O
to WO2010005384A1 A TO O
certain WO2010005384A1 A JJ O
new WO2010005384A1 A JJ O
pyridin WO2010005384A1 A NN O
analogues WO2010005384A1 A NNS O
of WO2010005384A1 A IN O
Formula WO2010005384A1 A NNP O
( WO2010005384A1 A ( O
I WO2010005384A1 A PRP O
) WO2010005384A1 A ) O
to WO2010005384A1 A TO O
processes WO2010005384A1 A VB O
for WO2010005384A1 A IN O
preparing WO2010005384A1 A VBG O
such WO2010005384A1 A JJ O
compounds WO2010005384A1 A NNS O
, WO2010005384A1 A , O
to WO2010005384A1 A TO O
their WO2010005384A1 A PRP$ O
utility WO2010005384A1 A NN O
as WO2010005384A1 A IN O
P2Y WO2010005384A1 A NNP I-UN
12 WO2010005384A1 A CD I-UN
inhibitors WO2010005384A1 A NNS O
and WO2010005384A1 A CC O
as WO2010005384A1 A IN O
anti-trombotic WO2010005384A1 A JJ O
agents WO2010005384A1 A NNS O
etc WO2010005384A1 A FW O
, WO2010005384A1 A , O
their WO2010005384A1 A PRP$ O
use WO2010005384A1 A NN O
as WO2010005384A1 A IN O
medicaments WO2010005384A1 A NNS O
in WO2010005384A1 A IN O
cardiovascular WO2010005384A1 A JJ O
diseases WO2010005384A1 A NNS O
as WO2010005384A1 A RB O
well WO2010005384A1 A RB O
as WO2010005384A1 A IN O
pharmaceutical WO2010005384A1 A JJ O
compositions WO2010005384A1 A NNS O
containing WO2010005384A1 A VBG O
them WO2010005384A1 A PRP O
. WO2010005384A1 A . O

External CN201453509U T JJ O
patch CN201453509U T NN O
with CN201453509U T IN O
moxibustion CN201453509U T NN O
effect CN201453509U T NN O
. CN201453509U T . O

Mir-26a-targeted CN102319247A T JJ O
anti-osteosarcoma CN102319247A T JJ O
small CN102319247A T JJ O
molecular CN102319247A T JJ O
compound CN102319247A T NN O
. CN102319247A T . O

The CN102319247A A DT O
small CN102319247A A JJ O
molecular CN102319247A A JJ O
compound CN102319247A A NN O
can CN102319247A A MD O
be CN102319247A A VB O
used CN102319247A A VBN O
together CN102319247A A RB O
with CN102319247A A IN O
a CN102319247A A DT O
tumor CN102319247A A NN I-UN
necrosis CN102319247A A NN I-UN
factor CN102319247A A NN I-UN
( CN102319247A A ( O
TNF-alpha CN102319247A A NNP I-UN
) CN102319247A A ) O
to CN102319247A A TO O
enhance CN102319247A A VB O
the CN102319247A A DT O
tumor CN102319247A A NN O
killing CN102319247A A VBG O
effect CN102319247A A NN O
of CN102319247A A IN O
the CN102319247A A DT O
latter CN102319247A A NN O
, CN102319247A A , O
so CN102319247A A IN O
that CN102319247A A IN O
the CN102319247A A DT O
small CN102319247A A JJ O
molecular CN102319247A A JJ O
compound CN102319247A A NN O
can CN102319247A A MD O
be CN102319247A A VB O
used CN102319247A A VBN O
for CN102319247A A IN O
treating CN102319247A A VBG O
osteosarcoma CN102319247A A NN O
and CN102319247A A CC O
can CN102319247A A MD O
become CN102319247A A VB O
a CN102319247A A DT O
new CN102319247A A JJ O
anti-osteosarcoma CN102319247A A JJ O
medicament CN102319247A A NN O
. CN102319247A A . O

Medicament CN103127157A T NN O
for CN103127157A T IN O
curing CN103127157A T VBG O
upper CN103127157A T JJ O
respiratory CN103127157A T NN O
tract CN103127157A T NN O
diseases CN103127157A T NNS O
of CN103127157A T IN O
poultry CN103127157A T NN O
and CN103127157A T CC O
livestock CN103127157A T NN O
and CN103127157A T CC O
preparation CN103127157A T NN O
method CN103127157A T NN O
thereof CN103127157A T NN O
. CN103127157A T . O

Pharmaceutical US20120251516 T JJ O
composition US20120251516 T NN O
for US20120251516 T IN O
treating US20120251516 T VBG O
cancer US20120251516 T NN O
comprising US20120251516 T VBG O
trypsinogen US20120251516 T NN O
and/or US20120251516 T NN O
chymotrypsinogen US20120251516 T NN O
and US20120251516 T CC O
an US20120251516 T DT O
active US20120251516 T JJ O
agent US20120251516 T NN O
selected US20120251516 T VBN O
from US20120251516 T IN O
a US20120251516 T DT O
selenium US20120251516 T NN O
compound US20120251516 T NN O
, US20120251516 T , O
a US20120251516 T DT O
vanilloid US20120251516 T NN O
compound US20120251516 T NN O
and US20120251516 T CC O
a US20120251516 T DT O
cytoplasmic US20120251516 T JJ O
glycolysis US20120251516 T NN O
reduction US20120251516 T NN O
agent US20120251516 T NN O
. US20120251516 T . O

Pyrrolidine-2-carboxylic WO2014124651A1 T JJ O
acid WO2014124651A1 T NN O
derivatives WO2014124651A1 T NNS O
as WO2014124651A1 T IN O
iglur WO2014124651A1 T JJ I-UN
antagonists WO2014124651A1 T NNS O
. WO2014124651A1 T . O

The WO2014124651A1 A DT O
present WO2014124651A1 A JJ O
invention WO2014124651A1 A NN O
relates WO2014124651A1 A VBZ O
to WO2014124651A1 A TO O
compounds WO2014124651A1 A NNS O
of WO2014124651A1 A IN O
Formula WO2014124651A1 A NNP O
( WO2014124651A1 A ( O
I WO2014124651A1 A PRP O
) WO2014124651A1 A ) O
, WO2014124651A1 A , O
combinations WO2014124651A1 A NNS O
and WO2014124651A1 A CC O
use WO2014124651A1 A NN O
thereof WO2014124651A1 A NN O
for WO2014124651A1 A IN O
disease WO2014124651A1 A NN O
therapy WO2014124651A1 A NN O
, WO2014124651A1 A , O
or WO2014124651A1 A CC O
pharmaceutically WO2014124651A1 A RB O
acceptable WO2014124651A1 A JJ O
salt WO2014124651A1 A NN O
or WO2014124651A1 A CC O
solvate WO2014124651A1 A NN O
thereof WO2014124651A1 A NNS O
, WO2014124651A1 A , O
including WO2014124651A1 A VBG O
all WO2014124651A1 A DT O
tautomers WO2014124651A1 A NNS O
, WO2014124651A1 A , O
stereoismers WO2014124651A1 A NNS O
and WO2014124651A1 A CC O
polymorphs WO2014124651A1 A NN O
thereof WO2014124651A1 A NN O
, WO2014124651A1 A , O
which WO2014124651A1 A WDT O
are WO2014124651A1 A VBP O
iGlu WO2014124651A1 A JJ I-UN
R WO2014124651A1 A NNP I-UN
inhibitors WO2014124651A1 A NNS O
, WO2014124651A1 A , O
and WO2014124651A1 A CC O
hence WO2014124651A1 A RB O
are WO2014124651A1 A VBP O
useful WO2014124651A1 A JJ O
in WO2014124651A1 A IN O
the WO2014124651A1 A DT O
treatment WO2014124651A1 A NN O
of WO2014124651A1 A IN O
psychiatric WO2014124651A1 A JJ O
diseases WO2014124651A1 A NNS O
or WO2014124651A1 A CC O
neurological WO2014124651A1 A JJ O
disorders WO2014124651A1 A NNS O
or WO2014124651A1 A CC O
a WO2014124651A1 A DT O
disease WO2014124651A1 A NN O
or WO2014124651A1 A CC O
disorder WO2014124651A1 A NN O
associated WO2014124651A1 A VBN O
with WO2014124651A1 A IN O
abnormal WO2014124651A1 A JJ O
activities WO2014124651A1 A NNS O
of WO2014124651A1 A IN O
iGluR WO2014124651A1 A JJ I-UN
receptors WO2014124651A1 A NNS O
. WO2014124651A1 A . O

Preparation CN102964400A T NNP O
method CN102964400A T NN O
and CN102964400A T CC O
applications CN102964400A T NNS O
of CN102964400A T IN O
dehydro-lincomycin-free CN102964400A T JJ O
lincomycin CN102964400A T JJ O
hydrochloride CN102964400A T NN O
. CN102964400A T . O

Application CN102302479A T NN O
of CN102302479A T IN O
lycopene CN102302479A T NN O
in CN102302479A T IN O
preparation CN102302479A T NN O
of CN102302479A T IN O
medicament CN102302479A T NN O
for CN102302479A T IN O
treating CN102302479A T VBG O
cerebral CN102302479A T JJ O
ischemia CN102302479A T JJ O
injury CN102302479A T NN O
. CN102302479A T . O

Terbinafine CN102641252A T NNP O
hydrochloride CN102641252A T NN O
solid CN102641252A T JJ O
dispersoid CN102641252A T NN O
and CN102641252A T CC O
tablet CN102641252A T NN O
thereof CN102641252A T NN O
. CN102641252A T . O

Compound CN1739797A T NNP O
recipe CN1739797A T NN O
for CN1739797A T IN O
replenishing CN1739797A T VBG O
collagen CN1739797A T NN O
. CN1739797A T . O

Lamina CN101879187A T NNP O
burn CN101879187A T NN O
and CN101879187A T CC O
scald CN101879187A T NN O
plaster CN101879187A T NN O
for CN101879187A T IN O
expelling CN101879187A T VBG O
pus CN101879187A T NN O
and CN101879187A T CC O
promoting CN101879187A T VBG O
granulation CN101879187A T NN O
and CN101879187A T CC O
preparation CN101879187A T NN O
method CN101879187A T NN O
thereof CN101879187A T NN O
. CN101879187A T . O

Clopidogrel CA2363053C T NNP O
bisulfate CA2363053C T NN O
tablet CA2363053C T NN O
formulation CA2363053C T NN O
. CA2363053C T . O

Separating CN101041652B T VBG O
purified CN101041652B T VBD O
new CN101041652B T JJ O
bisflavone CN101041652B T NN O
compound CN101041652B T NN O
from CN101041652B T IN O
dragon CN101041652B T NN O
's CN101041652B T POS O
blood CN101041652B T NN O
and CN101041652B T CC O
preparation CN101041652B T NN O
method CN101041652B T NN O
thereof CN101041652B T NN O
. CN101041652B T . O

Combination WO2012022740A1 T NNP O
treatment WO2012022740A1 T NN O
of WO2012022740A1 T IN O
multiple WO2012022740A1 T JJ O
sclerosis WO2012022740A1 T NN O
. WO2012022740A1 T . O

The WO2012022740A1 A DT O
present WO2012022740A1 A JJ O
invention WO2012022740A1 A NN O
is WO2012022740A1 A VBZ O
related WO2012022740A1 A VBN O
to WO2012022740A1 A TO O
the WO2012022740A1 A DT O
use WO2012022740A1 A NN O
of WO2012022740A1 A IN O
Vitamin WO2012022740A1 A NNP O
D WO2012022740A1 A NNP O
in WO2012022740A1 A IN O
combination WO2012022740A1 A NN O
with WO2012022740A1 A IN O
Interferon-beta WO2012022740A1 A NNP I-UN
for WO2012022740A1 A IN O
the WO2012022740A1 A DT O
treatment WO2012022740A1 A NN O
of WO2012022740A1 A IN O
multiple WO2012022740A1 A JJ O
sclerosis WO2012022740A1 A NN O
. WO2012022740A1 A . O

Use WO2006063526A1 T NNP O
of WO2006063526A1 T IN O
cymipristone WO2006063526A1 T NN O
for WO2006063526A1 T IN O
treating WO2006063526A1 T VBG O
depression WO2006063526A1 T NN O
. WO2006063526A1 T . O

Novel EP2229390A1 T NNP O
imidazoý1,2-a¨pyridine EP2229390A1 T JJ O
and EP2229390A1 T CC O
imidazoý1,2-b¨pyridazine EP2229390A1 T JJ O
derivatives EP2229390A1 T NNS O
. EP2229390A1 T . O

Imidazo EP2229390A1 A NNP O
[ EP2229390A1 A NNP O
1,2-a EP2229390A1 A JJ O
] EP2229390A1 A NNP O
pyridine EP2229390A1 A NN O
and EP2229390A1 A CC O
imidazo EP2229390A1 A JJ O
[ EP2229390A1 A NNP O
1,2-b EP2229390A1 A JJ O
] EP2229390A1 A NNP O
pyridazine EP2229390A1 A NN O
derivatives EP2229390A1 A NNS O
which EP2229390A1 A WDT O
inhibit EP2229390A1 A VBP O
Btk EP2229390A1 A NNP I-UN
and EP2229390A1 A CC O
are EP2229390A1 A VBP O
useful EP2229390A1 A JJ O
for EP2229390A1 A IN O
the EP2229390A1 A DT O
treatment EP2229390A1 A NN O
of EP2229390A1 A IN O
auto-immune EP2229390A1 A JJ O
and EP2229390A1 A CC O
inflammatory EP2229390A1 A JJ O
diseases EP2229390A1 A NNS O
caused EP2229390A1 A VBN O
by EP2229390A1 A IN O
aberrant EP2229390A1 A JJ O
B-cell EP2229390A1 A NNP O
activation EP2229390A1 A NN O
, EP2229390A1 A , O
e.g EP2229390A1 A NN O
. EP2229390A1 A . O

Medicine US20050261349 T NNP O
for US20050261349 T IN O
prevention US20050261349 T NN O
or US20050261349 T CC O
treatment US20050261349 T NN O
of US20050261349 T IN O
diabetes US20050261349 T NNS O
. US20050261349 T . O

Benzomorpholine US20060040931 T NNP O
derivatives US20060040931 T NNS O
. US20060040931 T . O

Compositions CA2288024C T NNS O
comprising CA2288024C T VBG O
condensation CA2288024C T NN O
polymer CA2288024C T NN O
of CA2288024C T IN O
an CA2288024C T DT O
aromatic CA2288024C T JJ O
sulfonic CA2288024C T NN O
acid CA2288024C T NN O
and CA2288024C T CC O
an CA2288024C T DT O
aldehyde CA2288024C T NN O
for CA2288024C T IN O
preventing CA2288024C T VBG O
pregnancy CA2288024C T NN O
. CA2288024C T . O

Furosemide CN103371967A T NNP O
injection CN103371967A T NN O
and CN103371967A T CC O
preparation CN103371967A T NN O
process CN103371967A T NN O
thereof CN103371967A T NN O
. CN103371967A T . O

Schizonepeta CN103156831A T NNP O
active CN103156831A T JJ O
component CN103156831A T NN O
composition CN103156831A T NN O
and CN103156831A T CC O
medical CN103156831A T JJ O
application CN103156831A T NN O
thereof CN103156831A T NN O
. CN103156831A T . O

Thiazole CN103304559A T NNP O
derivatives CN103304559A T NNS O
comprising CN103304559A T VBG O
pyrazoline CN103304559A T NN O
and CN103304559A T CC O
thiophene CN103304559A T NN O
( CN103304559A T ( O
or CN103304559A T CC O
furan CN103304559A T NN O
) CN103304559A T ) O
structures CN103304559A T VBZ O
, CN103304559A T , O
and CN103304559A T CC O
preparation CN103304559A T NN O
method CN103304559A T NN O
and CN103304559A T CC O
application CN103304559A T NN O
thereof CN103304559A T NN O
. CN103304559A T . O

External WO2011033715A1 T JJ O
preparation WO2011033715A1 T NN O
for WO2011033715A1 T IN O
skin WO2011033715A1 T NN O
. WO2011033715A1 T . O

Pharmaceutical WO2009120052A1 T JJ O
composition WO2009120052A1 T NN O
having WO2009120052A1 T VBG O
a WO2009120052A1 T DT O
synergistic WO2009120052A1 T JJ O
effect WO2009120052A1 T NN O
, WO2009120052A1 T , O
for WO2009120052A1 T IN O
the WO2009120052A1 T DT O
treatment WO2009120052A1 T NN O
of WO2009120052A1 T IN O
high WO2009120052A1 T JJ O
blood WO2009120052A1 T NN O
pressure WO2009120052A1 T NN O
and WO2009120052A1 T CC O
dyslipidemia WO2009120052A1 T NN O
. WO2009120052A1 T . O

The WO2009120052A1 A DT O
invention WO2009120052A1 A NN O
relates WO2009120052A1 A VBZ O
to WO2009120052A1 A TO O
a WO2009120052A1 A DT O
synergistic WO2009120052A1 A JJ O
pharmaceutical WO2009120052A1 A JJ O
composition WO2009120052A1 A NN O
containing WO2009120052A1 A VBG O
an WO2009120052A1 A DT O
angiotensin WO2009120052A1 A NN I-UN
II WO2009120052A1 A NNP I-UN
AT1 WO2009120052A1 A NNP I-UN
receptor WO2009120052A1 A NN I-UN
antagonist WO2009120052A1 A NN O
combined WO2009120052A1 A VBN O
with WO2009120052A1 A IN O
one WO2009120052A1 A CD O
or WO2009120052A1 A CC O
more WO2009120052A1 A JJR O
statins WO2009120052A1 A NNS O
for WO2009120052A1 A IN O
the WO2009120052A1 A DT O
treatment WO2009120052A1 A NN O
of WO2009120052A1 A IN O
high WO2009120052A1 A JJ O
blood WO2009120052A1 A NN O
pressure WO2009120052A1 A NN O
and WO2009120052A1 A CC O
dyslipidemia WO2009120052A1 A NN O
in WO2009120052A1 A IN O
mammals WO2009120052A1 A NNS O
. WO2009120052A1 A . O

Medical US20100266654 T JJ O
composition US20100266654 T NN O
including US20100266654 T VBG O
an US20100266654 T DT O
extracellular US20100266654 T JJ O
matrix US20100266654 T NN O
particulate US20100266654 T NN O
. US20100266654 T . O

New DE102006002649A1 T NNP O
aza-heterocycle DE102006002649A1 T NN O
compounds DE102006002649A1 T NNS O
are DE102006002649A1 T VBP O
tyrosine DE102006002649A1 T JJ I-UN
kinase DE102006002649A1 T NN I-UN
inhibitors DE102006002649A1 T NNS O
useful DE102006002649A1 T JJ O
to DE102006002649A1 T TO O
treat DE102006002649A1 T VB O
and/or DE102006002649A1 T JJ O
prevent DE102006002649A1 T NN O
e.g DE102006002649A1 T NN O
. DE102006002649A1 T . O

- DE102006002649A1 A : O
MECHANISM DE102006002649A1 A NN O
OF DE102006002649A1 A IN O
ACTION DE102006002649A1 A NNP O
: DE102006002649A1 A : O
Tyrosine DE102006002649A1 A NN I-UN
kinase DE102006002649A1 A NN I-UN
inhibitor DE102006002649A1 A NN O
; DE102006002649A1 A : O
Insulin DE102006002649A1 A NNP I-UN
like DE102006002649A1 A IN I-UN
growth DE102006002649A1 A NN I-UN
factor-1 DE102006002649A1 A JJ I-UN
receptor DE102006002649A1 A NN O
inhibitor DE102006002649A1 A NN O
. DE102006002649A1 A . O

The DE102006002649A1 A DT O
ability DE102006002649A1 A NN O
of DE102006002649A1 A IN O
( DE102006002649A1 A ( O
I DE102006002649A1 A PRP O
) DE102006002649A1 A ) O
to DE102006002649A1 A TO O
inhibit DE102006002649A1 A VB O
insulin DE102006002649A1 A NN I-UN
like DE102006002649A1 A IN I-UN
growth DE102006002649A1 A NN I-UN
factor-1 DE102006002649A1 A JJ I-UN
receptor DE102006002649A1 A NN O
was DE102006002649A1 A VBD O
tested DE102006002649A1 A VBN O
using DE102006002649A1 A VBG O
biological DE102006002649A1 A JJ O
assays DE102006002649A1 A NNS O
. DE102006002649A1 A . O

New CN103724342A T NNP O
antifungal CN103724342A T JJ O
drug CN103724342A T NN O
compound CN103724342A T NN O
as CN103724342A T RB O
well CN103724342A T RB O
as CN103724342A T IN O
composition CN103724342A T NN O
thereof CN103724342A T NN O
and CN103724342A T CC O
use CN103724342A T NN O
. CN103724342A T . O

New US20100069350 T NNP O
Pyridine US20100069350 T NNP O
Analogues US20100069350 T NNP O
III US20100069350 T NNP O
. US20100069350 T . O

The US20100069350 A DT O
present US20100069350 A JJ O
invention US20100069350 A NN O
relates US20100069350 A VBZ O
to US20100069350 A TO O
certain US20100069350 A JJ O
new US20100069350 A JJ O
pyridin US20100069350 A NN O
analogues US20100069350 A NNS O
of US20100069350 A IN O
Formula US20100069350 A NNP O
( US20100069350 A ( O
I US20100069350 A PRP O
) US20100069350 A ) O
, US20100069350 A , O
to US20100069350 A TO O
processes US20100069350 A VB O
for US20100069350 A IN O
preparing US20100069350 A VBG O
such US20100069350 A JJ O
compounds US20100069350 A NNS O
, US20100069350 A , O
to US20100069350 A TO O
their US20100069350 A PRP$ O
utility US20100069350 A NN O
as US20100069350 A IN O
P2Y12 US20100069350 A NNP I-UN
inhibitors US20100069350 A NNS O
and US20100069350 A CC O
as US20100069350 A IN O
anti-trombotic US20100069350 A JJ O
agents US20100069350 A NNS O
etc US20100069350 A FW O
, US20100069350 A , O
their US20100069350 A PRP$ O
use US20100069350 A NN O
as US20100069350 A IN O
medicaments US20100069350 A NNS O
in US20100069350 A IN O
cardiovascular US20100069350 A JJ O
diseases US20100069350 A NNS O
as US20100069350 A RB O
well US20100069350 A RB O
as US20100069350 A IN O
pharmaceutical US20100069350 A JJ O
compositions US20100069350 A NNS O
containing US20100069350 A VBG O
them US20100069350 A PRP O
. US20100069350 A . O

For US20080096843 T IN O
crops US20080096843 T NNS O
; US20080096843 T : O
3- US20080096843 T JJ O
( US20080096843 T ( O
2,6-Dichlorophenyl US20080096843 T JJ O
) US20080096843 T ) O
-4- US20080096843 T FW O
[ US20080096843 T FW O
( US20080096843 T ( O
3-pyridyl US20080096843 T JJ O
) US20080096843 T ) O
hydroxymethyl US20080096843 T NN O
] US20080096843 T JJ O
-5-trimethylsilylisoxazole US20080096843 T NN O
for US20080096843 T IN O
example US20080096843 T NN O
. US20080096843 T . O

The US20080096843 A DT O
present US20080096843 A JJ O
invention US20080096843 A NN O
provides US20080096843 A VBZ O
compounds US20080096843 A NNS O
of US20080096843 A IN O
formula US20080096843 A NN O
I US20080096843 A PRP O
: US20080096843 A : O
( US20080096843 A ( O
I US20080096843 A PRP O
) US20080096843 A ) O
along US20080096843 A IN O
with US20080096843 A IN O
methods US20080096843 A NNS O
of US20080096843 A IN O
making US20080096843 A VBG O
the US20080096843 A DT O
same US20080096843 A JJ O
, US20080096843 A , O
compositions US20080096843 A NNS O
thereof US20080096843 A VBP O
, US20080096843 A , O
and US20080096843 A CC O
methods US20080096843 A NNS O
of US20080096843 A IN O
use US20080096843 A NN O
thereof US20080096843 A NN O
, US20080096843 A , O
particularly US20080096843 A RB O
methods US20080096843 A NNS O
of US20080096843 A IN O
use US20080096843 A NN O
as US20080096843 A IN O
fungicides US20080096843 A NNS O
. US20080096843 A . O

Benzonaphthyridines WO2004018465A9 T NNS O
with WO2004018465A9 T IN O
pde WO2004018465A9 T JJ I-UN
3/4 WO2004018465A9 T CD I-UN
inhibiting WO2004018465A9 T NN O
activity WO2004018465A9 T NN O
. WO2004018465A9 T . O

Compounds WO2004018465A9 A NNS O
of WO2004018465A9 A IN O
a WO2004018465A9 A DT O
certain WO2004018465A9 A JJ O
formula WO2004018465A9 A NN O
( WO2004018465A9 A ( O
1 WO2004018465A9 A CD O
) WO2004018465A9 A ) O
, WO2004018465A9 A , O
in WO2004018465A9 A IN O
which WO2004018465A9 A WDT O
R1 WO2004018465A9 A NNP O
, WO2004018465A9 A , O
R2 WO2004018465A9 A NNP O
, WO2004018465A9 A , O
R3 WO2004018465A9 A NNP O
, WO2004018465A9 A , O
R4 WO2004018465A9 A NNP O
and WO2004018465A9 A CC O
R5 WO2004018465A9 A NNP O
have WO2004018465A9 A VBP O
the WO2004018465A9 A DT O
meanings WO2004018465A9 A NNS O
indicated WO2004018465A9 A VBN O
in WO2004018465A9 A IN O
the WO2004018465A9 A DT O
description WO2004018465A9 A NN O
, WO2004018465A9 A , O
are WO2004018465A9 A VBP O
novel WO2004018465A9 A JJ O
effective WO2004018465A9 A JJ O
PDE4 WO2004018465A9 A NNP I-UN
or WO2004018465A9 A CC O
PDE3/4 WO2004018465A9 A NNP I-UN
inhibitors WO2004018465A9 A NNS O
. WO2004018465A9 A . O

Substituted US8791257 T VBN O
pyrrolotriazines US8791257 T NNS O
as US8791257 T IN O
protein US8791257 T JJ O
kinase US8791257 T NN O
inhibitors US8791257 T NNS O
. US8791257 T . O

Antimicrobial US20140080876 T NNP O
and US20140080876 T CC O
radioprotective US20140080876 T JJ O
compounds US20140080876 T NNS O
. US20140080876 T . O

Polyethylene US20100255050 T NNP O
Based US20100255050 T VBD O
Bioactive US20100255050 T JJ O
Agents US20100255050 T NNS O
. US20100255050 T . O

Huperzine CN101190176A T VB O
A CN101190176A T NNP O
derivative CN101190176A T JJ O
xipulin CN101190176A T NN O
preparations CN101190176A T NNS O
. CN101190176A T . O

Use WO2012131142A1 T NNP O
of WO2012131142A1 T IN O
sulphamide WO2012131142A1 T JJ O
derivatives WO2012131142A1 T NNS O
as WO2012131142A1 T IN O
neuroprotectors WO2012131142A1 T NNS O
. WO2012131142A1 T . O

Dendritic US20100247439 T JJ O
nano-antioxidants US20100247439 T NNS O
. US20100247439 T . O

Provided US20100247439 A VBN O
are US20100247439 A VBP O
dendritic US20100247439 A JJ O
nano-antioxidant US20100247439 A JJ O
compounds US20100247439 A NNS O
according US20100247439 A VBG O
to US20100247439 A TO O
Formula US20100247439 A NNP O
I US20100247439 A PRP O
, US20100247439 A , O
which US20100247439 A WDT O
may US20100247439 A MD O
further US20100247439 A RBR O
comprise US20100247439 A VB O
active US20100247439 A JJ O
agents US20100247439 A NNS O
covalently US20100247439 A RB O
or US20100247439 A CC O
non-covalently US20100247439 A RB O
attached US20100247439 A VBN O
. US20100247439 A . O

Further US20100247439 A RB O
provided US20100247439 A VBN O
are US20100247439 A VBP O
compositions US20100247439 A NNS O
comprising US20100247439 A VBG O
the US20100247439 A DT O
disclosed US20100247439 A JJ O
compounds US20100247439 A NNS O
. US20100247439 A . O

Also US20100247439 A RB O
disclosed US20100247439 A VBN O
are US20100247439 A VBP O
cosmetic US20100247439 A JJ O
compositions US20100247439 A NNS O
and US20100247439 A CC O
dietary US20100247439 A JJ O
supplements US20100247439 A NNS O
comprising US20100247439 A VBG O
the US20100247439 A DT O
compounds US20100247439 A NNS O
according US20100247439 A VBG O
to US20100247439 A TO O
Formula US20100247439 A NNP O
I US20100247439 A PRP O
. US20100247439 A . O

The US20100247439 A DT O
invention US20100247439 A NN O
additionally US20100247439 A RB O
provides US20100247439 A VBZ O
methods US20100247439 A NNS O
of US20100247439 A IN O
reducing US20100247439 A VBG O
free US20100247439 A JJ O
radicals US20100247439 A NNS O
or US20100247439 A CC O
oxidative US20100247439 A JJ O
stress US20100247439 A NN O
in US20100247439 A IN O
a US20100247439 A DT O
cell US20100247439 A NN O
, US20100247439 A , O
a US20100247439 A DT O
method US20100247439 A NN O
of US20100247439 A IN O
treating US20100247439 A VBG O
a US20100247439 A DT O
subject US20100247439 A NN O
, US20100247439 A , O
and US20100247439 A CC O
a US20100247439 A DT O
method US20100247439 A NN O
of US20100247439 A IN O
treating US20100247439 A VBG O
a US20100247439 A DT O
condition US20100247439 A NN O
comprising US20100247439 A VBG O
administering US20100247439 A VBG O
the US20100247439 A DT O
compounds US20100247439 A NNS O
according US20100247439 A VBG O
to US20100247439 A TO O
Formula US20100247439 A NNP O
I US20100247439 A PRP O
. US20100247439 A . O

Inhibitors WO2013174947A1 T NNS O
of WO2013174947A1 T IN O
the WO2013174947A1 T DT O
activity WO2013174947A1 T NN O
of WO2013174947A1 T IN O
complex WO2013174947A1 T JJ O
( WO2013174947A1 T ( O
iii WO2013174947A1 T NN O
) WO2013174947A1 T ) O
of WO2013174947A1 T IN O
the WO2013174947A1 T DT O
mitochondrial WO2013174947A1 T JJ O
electron WO2013174947A1 T NN O
transport WO2013174947A1 T NN O
chain WO2013174947A1 T NN O
and WO2013174947A1 T CC O
use WO2013174947A1 T NN O
thereof WO2013174947A1 T NN O
. WO2013174947A1 T . O

Oligopeptide US20080051325 T NNP O
. US20080051325 T . O

New WO2010018484A1 T NNP O
uses WO2010018484A1 T NNS O
of WO2010018484A1 T IN O
diisopropylamine WO2010018484A1 T NN O
derivatives WO2010018484A1 T NNS O
. WO2010018484A1 T . O

Prognostic US20100087441 T JJ O
Method US20100087441 T NNP O
. US20100087441 T . O

Dioxolane US20050256034 T NNP O
analogs US20050256034 T NNS O
for US20050256034 T IN O
improved US20050256034 T JJ O
inter-cellular US20050256034 T JJ O
delivery US20050256034 T NN O
. US20050256034 T . O

Crystalline CN103298819A T NNP O
6,7-unsaturated-7-carbamoyl CN103298819A T JJ O
morphinane CN103298819A T NN O
derivative CN103298819A T NN O
, CN103298819A T , O
and CN103298819A T CC O
method CN103298819A T NN O
for CN103298819A T IN O
producing CN103298819A T VBG O
same CN103298819A T JJ O
. CN103298819A T . O

Macrocycles WO2014022752A1 T NNS O
as WO2014022752A1 T IN O
pim WO2014022752A1 T JJ I-UN
inhibitors WO2014022752A1 T NNS O
. WO2014022752A1 T . O

In WO2014022752A1 A IN O
some WO2014022752A1 A DT O
embodiments WO2014022752A1 A NNS O
, WO2014022752A1 A , O
the WO2014022752A1 A DT O
invention WO2014022752A1 A NN O
relates WO2014022752A1 A VBZ O
to WO2014022752A1 A TO O
inhibitors WO2014022752A1 A NNS O
or WO2014022752A1 A CC O
modulators WO2014022752A1 A NNS O
of WO2014022752A1 A IN O
Pim-1 WO2014022752A1 A NNP I-UN
and/or WO2014022752A1 A JJ O
Pim-2 WO2014022752A1 A NNP I-UN
, WO2014022752A1 A , O
and/or WO2014022752A1 A VBZ O
Pim-3 WO2014022752A1 A NNP I-UN
protein WO2014022752A1 A JJ O
kinase WO2014022752A1 A NN O
activity WO2014022752A1 A NN O
or WO2014022752A1 A CC O
enzyme WO2014022752A1 A NN O
function WO2014022752A1 A NN O
. WO2014022752A1 A . O

In WO2014022752A1 A IN O
still WO2014022752A1 A RB O
further WO2014022752A1 A JJ O
embodiments WO2014022752A1 A NNS O
, WO2014022752A1 A , O
the WO2014022752A1 A DT O
invention WO2014022752A1 A NN O
relates WO2014022752A1 A VBZ O
to WO2014022752A1 A TO O
pharmaceutical WO2014022752A1 A JJ O
compositions WO2014022752A1 A NNS O
comprising WO2014022752A1 A VBG O
compounds WO2014022752A1 A NNS O
disclosed WO2014022752A1 A VBN O
herein WO2014022752A1 A NN O
, WO2014022752A1 A , O
and WO2014022752A1 A CC O
their WO2014022752A1 A PRP$ O
use WO2014022752A1 A NN O
in WO2014022752A1 A IN O
the WO2014022752A1 A DT O
prevention WO2014022752A1 A NN O
and WO2014022752A1 A CC O
treatment WO2014022752A1 A NN O
of WO2014022752A1 A IN O
Pim WO2014022752A1 A NNP I-UN
kinase WO2014022752A1 A NNP I-UN
related WO2014022752A1 A JJ O
conditions WO2014022752A1 A NNS O
and WO2014022752A1 A CC O
diseases WO2014022752A1 A NNS O
, WO2014022752A1 A , O
preferably WO2014022752A1 A RB O
cancer WO2014022752A1 A NN O
. WO2014022752A1 A . O

Combination CN101060830A T NN O
of CN101060830A T IN O
a CN101060830A T DT O
NMDA CN101060830A T NNP I-UN
receptor CN101060830A T NN I-UN
antagonist CN101060830A T NN O
and CN101060830A T CC O
an CN101060830A T DT O
anti-depressive CN101060830A T JJ O
drug CN101060830A T NN O
mao-inhibitor CN101060830A T NN O
or CN101060830A T CC O
a CN101060830A T DT O
gadph-inhibitor CN101060830A T NN O
for CN101060830A T IN O
the CN101060830A T DT O
treatment CN101060830A T NN O
of CN101060830A T IN O
psychiatric CN101060830A T JJ O
conditions CN101060830A T NNS O
. CN101060830A T . O

New WO2009062619A1 T NNP O
crystalline WO2009062619A1 T NN O
diphenyl WO2009062619A1 T NN O
acetidinone WO2009062619A1 T NN O
hydrate WO2009062619A1 T NN O
, WO2009062619A1 T , O
pharmaceutical WO2009062619A1 T JJ O
agent WO2009062619A1 T NN O
containing WO2009062619A1 T VBG O
said WO2009062619A1 T VBD O
compound WO2009062619A1 T NN O
and WO2009062619A1 T CC O
use WO2009062619A1 T NN O
thereof WO2009062619A1 T NN O
. WO2009062619A1 T . O

The WO2009062619A1 A DT O
invention WO2009062619A1 A NN O
relates WO2009062619A1 A VBZ O
to WO2009062619A1 A TO O
a WO2009062619A1 A DT O
crystalline WO2009062619A1 A JJ O
hydrate WO2009062619A1 A NN O
of WO2009062619A1 A IN O
formula WO2009062619A1 A NN O
( WO2009062619A1 A ( O
I WO2009062619A1 A PRP O
) WO2009062619A1 A ) O
wherein WO2009062619A1 A NN O
n WO2009062619A1 A NN O
has WO2009062619A1 A VBZ O
a WO2009062619A1 A DT O
value WO2009062619A1 A NN O
of WO2009062619A1 A IN O
0.5 WO2009062619A1 A CD O
to WO2009062619A1 A TO O
1.8 WO2009062619A1 A CD O
. WO2009062619A1 A . O

The WO2009062619A1 A DT O
compound WO2009062619A1 A NN O
is WO2009062619A1 A VBZ O
suitable WO2009062619A1 A JJ O
e.g. WO2009062619A1 A RB O
, WO2009062619A1 A , O
as WO2009062619A1 A IN O
a WO2009062619A1 A DT O
hypolipidemic WO2009062619A1 A JJ O
agent WO2009062619A1 A NN O
. WO2009062619A1 A . O

Diabetes US6911457 T NNS O
imaging US6911457 T VBG O
probes US6911457 T NNS O
. US6911457 T . O

Compound CN101670094A T NNP O
gentamycin CN101670094A T NN O
sulfate CN101670094A T NN O
soluble CN101670094A T JJ O
powder CN101670094A T NN O
and CN101670094A T CC O
preparation CN101670094A T NN O
method CN101670094A T NN O
thereof CN101670094A T NN O
. CN101670094A T . O

Benzoxazinone WO2011012622A1 T NNP O
derivatives WO2011012622A1 T NNS O
for WO2011012622A1 T IN O
the WO2011012622A1 T DT O
treatment WO2011012622A1 T NN O
of WO2011012622A1 T IN O
glytl WO2011012622A1 T NN I-UN
mediated WO2011012622A1 T VBN O
disorders WO2011012622A1 T NNS O
. WO2011012622A1 T . O

The WO2011012622A1 A DT O
present WO2011012622A1 A JJ O
invention WO2011012622A1 A NN O
relates WO2011012622A1 A VBZ O
to WO2011012622A1 A TO O
benzoxazinone WO2011012622A1 A VB O
derivatives WO2011012622A1 A NNS O
, WO2011012622A1 A , O
processes WO2011012622A1 A NNS O
for WO2011012622A1 A IN O
their WO2011012622A1 A PRP$ O
preparation WO2011012622A1 A NN O
, WO2011012622A1 A , O
pharmaceutical WO2011012622A1 A JJ O
compositions WO2011012622A1 A NNS O
and WO2011012622A1 A CC O
medicaments WO2011012622A1 A NNS O
containing WO2011012622A1 A VBG O
them WO2011012622A1 A PRP O
and WO2011012622A1 A CC O
to WO2011012622A1 A TO O
their WO2011012622A1 A PRP$ O
use WO2011012622A1 A NN O
in WO2011012622A1 A IN O
treating WO2011012622A1 A VBG O
disorders WO2011012622A1 A NNS O
mediated WO2011012622A1 A VBN O
by WO2011012622A1 A IN O
GlyT1 WO2011012622A1 A NNP I-UN
, WO2011012622A1 A , O
including WO2011012622A1 A VBG O
neurological WO2011012622A1 A JJ O
and WO2011012622A1 A CC O
neuropsychiatric WO2011012622A1 A JJ O
disorders WO2011012622A1 A NNS O
, WO2011012622A1 A , O
in WO2011012622A1 A IN O
particular WO2011012622A1 A JJ O
psychoses WO2011012622A1 A NNS O
, WO2011012622A1 A , O
dementia WO2011012622A1 A NN O
or WO2011012622A1 A CC O
attention WO2011012622A1 A NN O
deficit WO2011012622A1 A NN O
disorder WO2011012622A1 A NN O
. WO2011012622A1 A . O

Sitafloxacin CN103156821A T NNP O
hydrate CN103156821A T NN O
tablet CN103156821A T NN O
composition CN103156821A T NN O
and CN103156821A T CC O
preparation CN103156821A T NN O
method CN103156821A T NN O
thereof CN103156821A T NN O
. CN103156821A T . O

Prevention US7238677 T NN O
of US7238677 T IN O
urogenital US7238677 T JJ O
infections US7238677 T NNS O
. US7238677 T . O

Analgesic WO2008120766A1 T JJ O
composition WO2008120766A1 T NN O
. WO2008120766A1 T . O

Pharmaceutical US20110275717 T JJ O
formulation US20110275717 T NN O
comprising US20110275717 T VBG O
diclofenac US20110275717 T NN O
. US20110275717 T . O

Selenized CN102633899A T VBN O
microbial CN102633899A T JJ O
exopolysaccharide CN102633899A T NN O
, CN102633899A T , O
and CN102633899A T CC O
preparation CN102633899A T NN O
method CN102633899A T NN O
and CN102633899A T CC O
uses CN102633899A T VBZ O
thereof CN102633899A T NN O
. CN102633899A T . O

The CN102633899A A DT O
invention CN102633899A A NN O
provides CN102633899A A VBZ O
a CN102633899A A DT O
selenized CN102633899A A JJ O
microbial CN102633899A A JJ O
exopolysaccharide CN102633899A A NN O
and CN102633899A A CC O
a CN102633899A A DT O
preparation CN102633899A A NN O
method CN102633899A A NN O
thereof CN102633899A A NN O
. CN102633899A A . O

The CN102633899A A DT O
preparation CN102633899A A NN O
method CN102633899A A NN O
comprises CN102633899A A VBZ O
the CN102633899A A DT O
steps CN102633899A A NNS O
of CN102633899A A IN O
: CN102633899A A : O
adding CN102633899A A VBG O
micromolecular CN102633899A A JJ O
Rhizobium CN102633899A A NNP O
sp CN102633899A A NN O
. CN102633899A A . O

exopolysaccharide CN102633899A A RB O
to CN102633899A A TO O
nitric CN102633899A A JJ O
acid CN102633899A A JJ O
solution CN102633899A A NN O
, CN102633899A A , O
stirring CN102633899A A VBG O
, CN102633899A A , O
adding CN102633899A A VBG O
selenous CN102633899A A JJ O
acid CN102633899A A NN O
and CN102633899A A CC O
barium CN102633899A A NN O
chloride CN102633899A A NN O
, CN102633899A A , O
adding CN102633899A A VBG O
sulfuric CN102633899A A JJ O
acid CN102633899A A NN O
dropwise CN102633899A A NN O
, CN102633899A A , O
removing CN102633899A A VBG O
precipitates CN102633899A A NNS O
by CN102633899A A IN O
centrifugation CN102633899A A NN O
, CN102633899A A , O
regulating CN102633899A A VBG O
the CN102633899A A DT O
pH CN102633899A A NN O
of CN102633899A A IN O
supernatant CN102633899A A NN O
to CN102633899A A TO O
7 CN102633899A A CD O
by CN102633899A A IN O
sodium CN102633899A A NN O
hydroxide CN102633899A A NN O
, CN102633899A A , O
putting CN102633899A A VBG O
the CN102633899A A DT O
supernatant CN102633899A A NN O
in CN102633899A A IN O
a CN102633899A A DT O
dialysis CN102633899A A NN O
bag CN102633899A A NN O
for CN102633899A A IN O
dialysis CN102633899A A NN O
, CN102633899A A , O
concentrating CN102633899A A VBG O
the CN102633899A A DT O
dialysate CN102633899A A NN O
under CN102633899A A IN O
reduced CN102633899A A JJ O
pressure CN102633899A A NN O
and CN102633899A A CC O
then CN102633899A A RB O
adding CN102633899A A VBG O
edible CN102633899A A JJ O
alcohol CN102633899A A NN O
, CN102633899A A , O
separating CN102633899A A VBG O
out CN102633899A A RP O
selenized CN102633899A A VBN O
microbial CN102633899A A JJ O
exopolysaccharide CN102633899A A NN O
, CN102633899A A , O
and CN102633899A A CC O
collecting CN102633899A A VBG O
and CN102633899A A CC O
freeze-drying CN102633899A A VBG O
the CN102633899A A DT O
selenized CN102633899A A VBN O
microbial CN102633899A A JJ O
exopolysaccharide CN102633899A A NN O
to CN102633899A A TO O
obtain CN102633899A A VB O
selenized CN102633899A A JJ O
micromolecular CN102633899A A JJ O
microbial CN102633899A A JJ O
exopolysaccharide CN102633899A A NN O
. CN102633899A A . O

The CN102633899A A DT O
content CN102633899A A NN O
of CN102633899A A IN O
selenium CN102633899A A NN O
in CN102633899A A IN O
the CN102633899A A DT O
exopolysaccharide CN102633899A A NN O
can CN102633899A A MD O
reach CN102633899A A VB O
586 CN102633899A A CD O
to CN102633899A A TO O
790 CN102633899A A CD O
mu CN102633899A A NN O
g/g CN102633899A A NN O
according CN102633899A A VBG O
to CN102633899A A TO O
measurement CN102633899A A NN O
; CN102633899A A : O
mice CN102633899A A NN O
tests CN102633899A A NNS O
show CN102633899A A VBP O
that CN102633899A A IN O
the CN102633899A A DT O
exopolysaccharide CN102633899A A NN O
has CN102633899A A VBZ O
excellent CN102633899A A JJ O
antitumor CN102633899A A NN O
activity CN102633899A A NN O
; CN102633899A A : O
and CN102633899A A CC O
the CN102633899A A DT O
exopolysaccharide CN102633899A A NN O
can CN102633899A A MD O
be CN102633899A A VB O
used CN102633899A A VBN O
in CN102633899A A IN O
preparing CN102633899A A VBG O
antitumor CN102633899A A NN O
medicines CN102633899A A NNS O
and CN102633899A A CC O
healthcare CN102633899A A NN O
products CN102633899A A NNS O
. CN102633899A A . O

Vitamin CN101536993A T NNP O
D3 CN101536993A T NNP O
microcapsule CN101536993A T NN O
and CN101536993A T CC O
preparation CN101536993A T NN O
method CN101536993A T NN O
thereof CN101536993A T NN O
. CN101536993A T . O

Desloratadine CN101933914A T NNP O
patch CN101933914A T NN O
and CN101933914A T CC O
preparation CN101933914A T NN O
method CN101933914A T NN O
thereof CN101933914A T NN O
. CN101933914A T . O

The US20090136573 A DT O
present US20090136573 A JJ O
invention US20090136573 A NN O
provides US20090136573 A VBZ O
methods US20090136573 A NNS O
for US20090136573 A IN O
making US20090136573 A VBG O
, US20090136573 A , O
delivering US20090136573 A VBG O
and US20090136573 A CC O
using US20090136573 A VBG O
formulations US20090136573 A NNS O
that US20090136573 A WDT O
combine US20090136573 A VBP O
a US20090136573 A DT O
therapeutically US20090136573 A RB O
active US20090136573 A JJ O
agent US20090136573 A NN O
( US20090136573 A ( O
s US20090136573 A NN O
) US20090136573 A ) O
( US20090136573 A ( O
such US20090136573 A JJ O
as US20090136573 A IN O
for US20090136573 A IN O
example US20090136573 A NN O
a US20090136573 A DT O
Rho US20090136573 A NNP I-UN
antagonist US20090136573 A NN O
( US20090136573 A ( O
s US20090136573 A PRP O
) US20090136573 A ) O
) US20090136573 A ) O
and US20090136573 A CC O
a US20090136573 A DT O
flowable US20090136573 A JJ O
carrier US20090136573 A NN O
component US20090136573 A NN O
capable US20090136573 A NN O
of US20090136573 A IN O
forming US20090136573 A VBG O
a US20090136573 A DT O
therapeutically US20090136573 A RB O
acceptable US20090136573 A JJ O
matrix US20090136573 A NN O
in US20090136573 A IN O
vivo US20090136573 A NN O
( US20090136573 A ( O
such US20090136573 A JJ O
as US20090136573 A IN O
for US20090136573 A IN O
example US20090136573 A NN O
tissue US20090136573 A NN O
adhesives US20090136573 A VBZ O
) US20090136573 A ) O
, US20090136573 A , O
to US20090136573 A TO O
injured US20090136573 A JJ O
nerves US20090136573 A NNS O
to US20090136573 A TO O
promote US20090136573 A VB O
repair US20090136573 A NN O
and US20090136573 A CC O
regeneration US20090136573 A NN O
and US20090136573 A CC O
regrowth US20090136573 A NN O
of US20090136573 A IN O
injured US20090136573 A JJ O
( US20090136573 A ( O
mammalian US20090136573 A JJ O
) US20090136573 A ) O
neuronal US20090136573 A JJ O
cells US20090136573 A NNS O
, US20090136573 A , O
e.g US20090136573 A NN O
. US20090136573 A . O

Preferred US20090136573 A NNP O
active US20090136573 A JJ O
agents US20090136573 A NNS O
are US20090136573 A VBP O
known US20090136573 A VBN O
Rho US20090136573 A NNP I-UN
antagonists US20090136573 A NNS O
such US20090136573 A JJ O
as US20090136573 A IN O
for US20090136573 A IN O
example US20090136573 A NN O
C3 US20090136573 A NNP O
, US20090136573 A , O
chimeric US20090136573 A JJ O
C3 US20090136573 A NNP O
proteins US20090136573 A NNS O
, US20090136573 A , O
etc US20090136573 A FW O
. US20090136573 A . O

or US20090136573 A CC O
substances US20090136573 A NNS O
selected US20090136573 A VBN O
from US20090136573 A IN O
among US20090136573 A IN O
known US20090136573 A VBN O
trans-4-amino US20090136573 A NN O
( US20090136573 A ( O
alkyl US20090136573 A NN O
) US20090136573 A ) O
-1-pyridylcarbamoylcyclohexane US20090136573 A NN O
compounds US20090136573 A NNS O
or US20090136573 A CC O
Rho US20090136573 A NNP I-UN
kinase US20090136573 A NN I-UN
inhibitors US20090136573 A NNS O
. US20090136573 A . O

The US20090136573 A DT O
system US20090136573 A NN O
for US20090136573 A IN O
example US20090136573 A NN O
may US20090136573 A MD O
deliver US20090136573 A VB O
an US20090136573 A DT O
antagonist US20090136573 A NN O
( US20090136573 A ( O
s US20090136573 A NN O
) US20090136573 A ) O
in US20090136573 A IN O
a US20090136573 A DT O
tissue US20090136573 A NN O
adhesive US20090136573 A NN O
such US20090136573 A JJ O
as US20090136573 A IN O
, US20090136573 A , O
for US20090136573 A IN O
example US20090136573 A NN O
, US20090136573 A , O
a US20090136573 A DT O
fibrin US20090136573 A JJ O
glue US20090136573 A NN O
or US20090136573 A CC O
a US20090136573 A DT O
collagen US20090136573 A NN I-UN
gel US20090136573 A NN O
to US20090136573 A TO O
create US20090136573 A VB O
a US20090136573 A DT O
delivery US20090136573 A NN O
matrix US20090136573 A NN O
in US20090136573 A IN O
situ US20090136573 A NN O
. US20090136573 A . O

Use WO2006066846A1 T NNP O
of WO2006066846A1 T IN O
thiazolidinone WO2006066846A1 T NN O
derivatives WO2006066846A1 T NNS O
as WO2006066846A1 T IN O
antiangiogenic WO2006066846A1 T JJ O
agents WO2006066846A1 T NNS O
. WO2006066846A1 T . O

The WO2006066846A1 A DT O
invention WO2006066846A1 A NN O
relates WO2006066846A1 A VBZ O
to WO2006066846A1 A TO O
the WO2006066846A1 A DT O
use WO2006066846A1 A NN O
of WO2006066846A1 A IN O
compounds WO2006066846A1 A NNS O
of WO2006066846A1 A IN O
general WO2006066846A1 A JJ O
formula WO2006066846A1 A NN O
( WO2006066846A1 A ( O
I WO2006066846A1 A PRP O
) WO2006066846A1 A ) O
, WO2006066846A1 A , O
in WO2006066846A1 A IN O
which WO2006066846A1 A WDT O
R1 WO2006066846A1 A NNP O
, WO2006066846A1 A , O
R2 WO2006066846A1 A NNP O
and WO2006066846A1 A CC O
X WO2006066846A1 A NNP O
are WO2006066846A1 A VBP O
as WO2006066846A1 A IN O
defined WO2006066846A1 A VBN O
in WO2006066846A1 A IN O
the WO2006066846A1 A DT O
description WO2006066846A1 A NN O
for WO2006066846A1 A IN O
the WO2006066846A1 A DT O
preparation WO2006066846A1 A NN O
of WO2006066846A1 A IN O
pharmaceutical WO2006066846A1 A JJ O
compositions WO2006066846A1 A NNS O
for WO2006066846A1 A IN O
the WO2006066846A1 A DT O
treatment WO2006066846A1 A NN O
of WO2006066846A1 A IN O
pathologies WO2006066846A1 A NNS O
in WO2006066846A1 A IN O
which WO2006066846A1 A WDT O
inhibition WO2006066846A1 A NN O
of WO2006066846A1 A IN O
the WO2006066846A1 A DT O
interaction WO2006066846A1 A NN O
between WO2006066846A1 A IN O
HIF-1α WO2006066846A1 A NNP I-UN
and WO2006066846A1 A CC O
p300 WO2006066846A1 A NN I-UN
is WO2006066846A1 A VBZ O
beneficial WO2006066846A1 A JJ O
, WO2006066846A1 A , O
in WO2006066846A1 A IN O
particular WO2006066846A1 A JJ O
as WO2006066846A1 A IN O
antiangiogenic WO2006066846A1 A JJ O
medicaments WO2006066846A1 A NNS O
for WO2006066846A1 A IN O
the WO2006066846A1 A DT O
therapy WO2006066846A1 A NN O
of WO2006066846A1 A IN O
solid WO2006066846A1 A JJ O
tumors WO2006066846A1 A NNS O
. WO2006066846A1 A . O

Tailored US20080025916 T VBN O
Treatment US20080025916 T NNP O
Suitable US20080025916 T NNP O
for US20080025916 T IN O
Different US20080025916 T NNP O
Forms US20080025916 T NNP O
of US20080025916 T IN O
Mastocytosis US20080025916 T NNP O
. US20080025916 T . O

The US20080025916 A DT O
present US20080025916 A JJ O
invention US20080025916 A NN O
relates US20080025916 A VBZ O
to US20080025916 A TO O
a US20080025916 A DT O
method US20080025916 A NN O
for US20080025916 A IN O
a US20080025916 A DT O
tailored US20080025916 A JJ O
treatment US20080025916 A NN O
of US20080025916 A IN O
mastocytosis US20080025916 A NN O
comprising US20080025916 A VBG O
a US20080025916 A DT O
) US20080025916 A ) O
assessing US20080025916 A VBG O
whether US20080025916 A IN O
or US20080025916 A CC O
not US20080025916 A RB O
a US20080025916 A DT O
c-kit US20080025916 A JJ I-UN
mutation US20080025916 A NN O
at US20080025916 A IN O
position US20080025916 A NN O
816 US20080025916 A CD O
is US20080025916 A VBZ O
detected US20080025916 A VBN O
in US20080025916 A IN O
a US20080025916 A DT O
sample US20080025916 A NN O
of US20080025916 A IN O
a US20080025916 A DT O
patient US20080025916 A NN O
and US20080025916 A CC O
b US20080025916 A NN O
) US20080025916 A ) O
administering US20080025916 A VBG O
a US20080025916 A DT O
specific US20080025916 A JJ O
816 US20080025916 A CD I-UN
mutant US20080025916 A JJ I-UN
c-kit US20080025916 A JJ I-UN
inhibitor US20080025916 A NN O
in US20080025916 A IN O
case US20080025916 A NN O
a US20080025916 A DT O
mutation US20080025916 A NN O
is US20080025916 A VBZ O
detected US20080025916 A VBN O
in US20080025916 A IN O
step US20080025916 A NN O
a US20080025916 A DT O
) US20080025916 A ) O
or US20080025916 A CC O
an US20080025916 A DT O
inhibitor US20080025916 A NN O
displaying US20080025916 A VBG O
efficacy US20080025916 A NN O
on US20080025916 A IN O
c-kit US20080025916 A JJ I-UN
wild US20080025916 A NN O
in US20080025916 A IN O
case US20080025916 A NN O
no US20080025916 A DT O
mutation US20080025916 A NN O
is US20080025916 A VBZ O
detected US20080025916 A VBN O
in US20080025916 A IN O
step US20080025916 A NN O
a US20080025916 A DT O
) US20080025916 A ) O
. US20080025916 A . O

Cycloheptimidazole CA2151443C T NNP O
derivatives CA2151443C T NNS O
, CA2151443C T , O
method CA2151443C T NN O
of CA2151443C T IN O
manufacturing CA2151443C T VBG O
the CA2151443C T DT O
same CA2151443C T JJ O
and CA2151443C T CC O
therapeutic CA2151443C T JJ O
agents CA2151443C T NNS O
containing CA2151443C T VBG O
these CA2151443C T DT O
compounds CA2151443C T NNS O
. CA2151443C T . O

Cycloheptimidazole CA2151443C A NNP O
derivatives CA2151443C A NNS O
of CA2151443C A IN O
following CA2151443C A VBG O
general CA2151443C A JJ O
formula CA2151443C A NN O
, CA2151443C A , O
( CA2151443C A ( O
See CA2151443C A VB O
formula CA2151443C A RB O
I CA2151443C A PRP O
) CA2151443C A ) O
( CA2151443C A ( O
Wherein CA2151443C A NNP O
R1 CA2151443C A NNP O
is CA2151443C A VBZ O
represents CA2151443C A VBZ O
a CA2151443C A DT O
lower CA2151443C A JJR O
alkyl CA2151443C A NN O
, CA2151443C A , O
R2 CA2151443C A NNP O
represents CA2151443C A VBZ O
tetrazole CA2151443C A NN O
) CA2151443C A ) O
method CA2151443C A NN O
of CA2151443C A IN O
manufacturing CA2151443C A VBG O
the CA2151443C A DT O
same CA2151443C A JJ O
and CA2151443C A CC O
therapeutic CA2151443C A JJ O
agents CA2151443C A NNS O
containing CA2151443C A VBG O
these CA2151443C A DT O
compounds.New CA2151443C A JJ O
cycloheptimidazole CA2151443C A NN O
derivatives CA2151443C A NNS O
of CA2151443C A IN O
the CA2151443C A DT O
present CA2151443C A JJ O
invention CA2151443C A NN O
have CA2151443C A VBP O
angiotensin CA2151443C A VBN I-UN
II CA2151443C A NNP I-UN
receptor CA2151443C A NN I-UN
antagonistic CA2151443C A JJ O
activities CA2151443C A NNS O
and CA2151443C A CC O
are CA2151443C A VBP O
therefore CA2151443C A RB O
useful CA2151443C A JJ O
as CA2151443C A IN O
treatment CA2151443C A NN O
agent CA2151443C A NN O
for CA2151443C A IN O
hypertension CA2151443C A NN O
or CA2151443C A CC O
congestive CA2151443C A JJ O
heart CA2151443C A NN O
failure CA2151443C A NN O
or CA2151443C A CC O
intraocular CA2151443C A JJ O
pressure CA2151443C A NN O
lowering CA2151443C A VBG O
agent CA2151443C A NN O
are CA2151443C A VBP O
proposed CA2151443C A VBN O
. CA2151443C A . O

Medical CN1775224A T NNP O
stone CN1775224A T NN O
lotion CN1775224A T NN O
for CN1775224A T IN O
treating CN1775224A T VBG O
skin CN1775224A T JJ O
disease CN1775224A T NN O
and CN1775224A T CC O
its CN1775224A T PRP$ O
preparing CN1775224A T NN O
method CN1775224A T NN O
. CN1775224A T . O

Methods WO2008124210A1 T NNS O
and WO2008124210A1 T CC O
compositions WO2008124210A1 T NNS O
for WO2008124210A1 T IN O
treating WO2008124210A1 T VBG O
or WO2008124210A1 T CC O
preventing WO2008124210A1 T VBG O
infection WO2008124210A1 T NN O
using WO2008124210A1 T VBG O
leukocyte WO2008124210A1 T JJ O
sequestration WO2008124210A1 T NN O
agents WO2008124210A1 T NNS O
. WO2008124210A1 T . O

In WO2008124210A1 A IN O
particular WO2008124210A1 A JJ O
, WO2008124210A1 A , O
the WO2008124210A1 A DT O
methods WO2008124210A1 A NNS O
and WO2008124210A1 A CC O
compositions WO2008124210A1 A NNS O
comprise WO2008124210A1 A VBP O
leukocyte WO2008124210A1 A JJ O
sequestration WO2008124210A1 A NN O
agents WO2008124210A1 A NNS O
that WO2008124210A1 A WDT O
are WO2008124210A1 A VBP O
lymphocyte WO2008124210A1 A JJ O
sequestration WO2008124210A1 A NN O
agents WO2008124210A1 A NNS O
such WO2008124210A1 A JJ O
as WO2008124210A1 A IN O
sphingosine WO2008124210A1 A JJ I-UN
1 WO2008124210A1 A CD I-UN
-phosphate WO2008124210A1 A NN I-UN
( WO2008124210A1 A ( I-UN
SlP WO2008124210A1 A NNP I-UN
) WO2008124210A1 A ) I-UN
receptor WO2008124210A1 A NN I-UN
agonists WO2008124210A1 A NNS O
( WO2008124210A1 A ( O
particularly WO2008124210A1 A RB O
FTY720 WO2008124210A1 A NNP O
) WO2008124210A1 A ) O
, WO2008124210A1 A , O
sphingosine WO2008124210A1 A JJ O
kinase WO2008124210A1 A NN O
inhibitors WO2008124210A1 A NNS O
, WO2008124210A1 A , O
and WO2008124210A1 A CC O
SlP WO2008124210A1 A NNP I-UN
lyase WO2008124210A1 A NN I-UN
inhibitors WO2008124210A1 A NNS O
. WO2008124210A1 A . O

Dipyridamole CN101234094B T NNP O
orally CN101234094B T RB O
disintegrating CN101234094B T VBG O
tablet CN101234094B T NN O
. CN101234094B T . O

Use CA2530116A1 T NNP O
of CA2530116A1 T IN O
roscovitine CA2530116A1 T NN O
for CA2530116A1 T IN O
treating CA2530116A1 T VBG O
lymphocytic CA2530116A1 T JJ O
leukemia CA2530116A1 T NN O
. CA2530116A1 T . O

Therapies US20130034522 T NNS O
for US20130034522 T IN O
treating US20130034522 T VBG O
hepatitis US20130034522 T NN O
c US20130034522 T NN O
virus US20130034522 T NN O
infection US20130034522 T NN O
. US20130034522 T . O

Crystalline WO2013088335A1 T NNP O
form WO2013088335A1 T NN O
of WO2013088335A1 T IN O
cabazitaxel WO2013088335A1 T NN O
and WO2013088335A1 T CC O
process WO2013088335A1 T NN O
for WO2013088335A1 T IN O
preparing WO2013088335A1 T VBG O
the WO2013088335A1 T DT O
same WO2013088335A1 T JJ O
. WO2013088335A1 T . O

Treatment US20080003275 T NN O
of US20080003275 T IN O
Premature US20080003275 T NNP O
Ejaculation US20080003275 T NNP O
. US20080003275 T . O

The US20080003275 A DT O
invention US20080003275 A NN O
relates US20080003275 A VBZ O
to US20080003275 A TO O
methods US20080003275 A NNS O
and US20080003275 A CC O
compositions US20080003275 A NNS O
for US20080003275 A IN O
treating US20080003275 A VBG O
premature US20080003275 A JJ O
ejaculation US20080003275 A NN O
in US20080003275 A IN O
a US20080003275 A DT O
male US20080003275 A NN O
or US20080003275 A CC O
prolonging US20080003275 A VBG O
intercourse US20080003275 A JJ O
comprising US20080003275 A VBG O
administering US20080003275 A VBG O
to US20080003275 A TO O
the US20080003275 A DT O
male US20080003275 A NN O
an US20080003275 A DT O
antidepressant US20080003275 A JJ O
via US20080003275 A IN O
a US20080003275 A DT O
route US20080003275 A NN O
selected US20080003275 A VBN O
from US20080003275 A IN O
the US20080003275 A DT O
group US20080003275 A NN O
consisting US20080003275 A VBG O
of US20080003275 A IN O
mucosal US20080003275 A JJ O
administration US20080003275 A NN O
( US20080003275 A ( O
preferably US20080003275 A RB O
nasal US20080003275 A RB O
, US20080003275 A , O
buccal US20080003275 A JJ O
or US20080003275 A CC O
rectal US20080003275 A JJ O
) US20080003275 A ) O
, US20080003275 A , O
administration US20080003275 A NN O
to US20080003275 A TO O
the US20080003275 A DT O
lungs US20080003275 A NNS O
( US20080003275 A ( O
preferably US20080003275 A RB O
by US20080003275 A IN O
inhalation US20080003275 A NN O
) US20080003275 A ) O
, US20080003275 A , O
local US20080003275 A JJ O
administration US20080003275 A NN O
to US20080003275 A TO O
at US20080003275 A IN O
least US20080003275 A JJS O
a US20080003275 A DT O
part US20080003275 A NN O
of US20080003275 A IN O
the US20080003275 A DT O
male US20080003275 A NN O
genitalia US20080003275 A NN O
( US20080003275 A ( O
applied US20080003275 A VBN O
to US20080003275 A TO O
the US20080003275 A DT O
penis US20080003275 A NN O
for US20080003275 A IN O
example US20080003275 A NN O
, US20080003275 A , O
in US20080003275 A IN O
the US20080003275 A DT O
form US20080003275 A NN O
of US20080003275 A IN O
a US20080003275 A DT O
gel US20080003275 A NN O
) US20080003275 A ) O
and US20080003275 A CC O
combinations US20080003275 A NNS O
thereof US20080003275 A VBP O
. US20080003275 A . O

Acyclovir CN101502521A T NNP O
sustained-release CN101502521A T JJ O
preparation CN101502521A T NN O
composition CN101502521A T NN O
and CN101502521A T CC O
method CN101502521A T NN O
for CN101502521A T IN O
preparing CN101502521A T VBG O
the CN101502521A T DT O
same CN101502521A T JJ O
. CN101502521A T . O

Levorotation CN101429164A T NNP O
benzhydryl CN101429164A T NN O
piperazidine CN101429164A T NN O
derivant CN101429164A T NN O
and CN101429164A T CC O
preparing CN101429164A T VBG O
method CN101429164A T NN O
thereof CN101429164A T NN O
. CN101429164A T . O

Method EP0959896B1 T NNP O
of EP0959896B1 T IN O
producing EP0959896B1 T VBG O
secreted EP0959896B1 T VBN O
truncated EP0959896B1 T JJ O
variants EP0959896B1 T NNS O
of EP0959896B1 T IN O
human EP0959896B1 T JJ I-UN
thyrotropin EP0959896B1 T NN I-UN
receptor EP0959896B1 T NN I-UN
. EP0959896B1 T . O

TSHR EP0959896B1 A NNP I-UN
compositions EP0959896B1 A NNS O
and EP0959896B1 A CC O
methods EP0959896B1 A NNS O
of EP0959896B1 A IN O
use EP0959896B1 A NN O
are EP0959896B1 A VBP O
disclosed EP0959896B1 A VBN O
, EP0959896B1 A , O
useful EP0959896B1 A JJ O
for EP0959896B1 A IN O
diagnostic EP0959896B1 A JJ O
and EP0959896B1 A CC O
therapeutic EP0959896B1 A JJ O
purposes EP0959896B1 A NNS O
. EP0959896B1 A . O

N-alkylpiperdino-4-yl-urea-pyrazole US7157472 T JJ O
derivative US7157472 T NN O
for US7157472 T IN O
treating US7157472 T VBG O
obesity US7157472 T NN O
, US7157472 T , O
metabolic US7157472 T JJ O
disorders US7157472 T NNS O
, US7157472 T , O
eating US7157472 T VBG O
disorders US7157472 T NNS O
and US7157472 T CC O
diabetes US7157472 T NNS O
. US7157472 T . O

The US7157472 A DT O
present US7157472 A JJ O
invention US7157472 A NN O
discloses US7157472 A NNS O
compounds US7157472 A VBZ O
which US7157472 A WDT O
, US7157472 A , O
are US7157472 A VBP O
receptor US7157472 A JJ O
antagonists US7157472 A NNS O
for US7157472 A IN O
NPY US7157472 A NNP I-UN
Y5 US7157472 A NNP I-UN
as US7157472 A RB O
well US7157472 A RB O
as US7157472 A IN O
methods US7157472 A NNS O
for US7157472 A IN O
preparing US7157472 A VBG O
such US7157472 A JJ O
compounds US7157472 A NNS O
. US7157472 A . O

In US7157472 A IN O
another US7157472 A DT O
embodiment US7157472 A NN O
, US7157472 A , O
the US7157472 A DT O
invention US7157472 A NN O
discloses US7157472 A VBZ O
pharmaceutical US7157472 A JJ O
compositions US7157472 A NNS O
comprising US7157472 A VBG O
such US7157472 A JJ O
NPY US7157472 A NNP I-UN
Y5 US7157472 A NNP I-UN
receptor US7157472 A NN O
antagonists US7157472 A NNS O
as US7157472 A RB O
well US7157472 A RB O
as US7157472 A IN O
methods US7157472 A NNS O
of US7157472 A IN O
using US7157472 A VBG O
them US7157472 A PRP O
to US7157472 A TO O
treat US7157472 A VB O
obesity US7157472 A NN O
, US7157472 A , O
metabolic US7157472 A JJ O
disorders US7157472 A NNS O
, US7157472 A , O
eating US7157472 A VBG O
disorders US7157472 A NNS O
such US7157472 A JJ O
as US7157472 A IN O
hyperphagia US7157472 A NN O
, US7157472 A , O
and US7157472 A CC O
diabetes US7157472 A NNS O
. US7157472 A . O

Imidiazo EP1912986A1 T NNP O
-and EP1912986A1 T NNP O
triazolopyridines EP1912986A1 T NNS O
as EP1912986A1 T IN O
inhibitors EP1912986A1 T NNS O
of EP1912986A1 T IN O
11-beta EP1912986A1 T JJ I-UN
hydroxysteroid EP1912986A1 T JJ I-UN
dehydrogenase EP1912986A1 T NN I-UN
type EP1912986A1 T NN I-UN
i EP1912986A1 T NN I-UN
. EP1912986A1 T . O

Novel EP1912986A1 A NNP O
compounds EP1912986A1 A NNS O
are EP1912986A1 A VBP O
provided EP1912986A1 A VBN O
which EP1912986A1 A WDT O
are EP1912986A1 A VBP O
11-beta-hydroxysteroid EP1912986A1 A JJ I-UN
dehydrogenase EP1912986A1 A NN I-UN
type EP1912986A1 A NN I-UN
I EP1912986A1 A PRP I-UN
inhibitors EP1912986A1 A NNS O
. EP1912986A1 A . O

11-beta-hydroxysteroid EP1912986A1 A JJ I-UN
dehydrogenase EP1912986A1 A NN I-UN
type EP1912986A1 A NN I-UN
I EP1912986A1 A PRP I-UN
inhibitors EP1912986A1 A NNS O
are EP1912986A1 A VBP O
useful EP1912986A1 A JJ O
in EP1912986A1 A IN O
treating EP1912986A1 A VBG O
, EP1912986A1 A , O
preventing EP1912986A1 A VBG O
, EP1912986A1 A , O
or EP1912986A1 A CC O
slowing EP1912986A1 A VBG O
the EP1912986A1 A DT O
progression EP1912986A1 A NN O
of EP1912986A1 A IN O
diseases EP1912986A1 A NNS O
requiring EP1912986A1 A VBG O
11-beta-hydroxysteroid EP1912986A1 A JJ I-UN
dehydrogenase EP1912986A1 A NN I-UN
type EP1912986A1 A NN I-UN
I EP1912986A1 A PRP I-UN
inhibitor EP1912986A1 A VBP O
therapy EP1912986A1 A NN O
. EP1912986A1 A . O

Dietotherapeutic CN1739572A T JJ O
nutrient CN1739572A T NN O
for CN1739572A T IN O
preventing CN1739572A T VBG O
and CN1739572A T CC O
treating CN1739572A T VBG O
primary CN1739572A T JJ O
and CN1739572A T CC O
secondary CN1739572A T JJ O
gout CN1739572A T NN O
and CN1739572A T CC O
its CN1739572A T PRP$ O
prepn CN1739572A T NN O
process CN1739572A T NN O
. CN1739572A T . O

5-fluorouracil-sn2-phosphatidyl CN101485887B T JJ O
choline CN101485887B T NN O
copolymer CN101485887B T NN O
as CN101485887B T RB O
well CN101485887B T RB O
as CN101485887B T IN O
preparation CN101485887B T NN O
method CN101485887B T NN O
and CN101485887B T CC O
application CN101485887B T NN O
thereof CN101485887B T NN O
. CN101485887B T . O

The CN101485887B A DT O
copolymers CN101485887B A NNS O
and CN101485887B A CC O
the CN101485887B A DT O
delivery CN101485887B A NN O
system CN101485887B A NN O
of CN101485887B A IN O
the CN101485887B A DT O
copolymers CN101485887B A NNS O
can CN101485887B A MD O
effectively CN101485887B A RB O
enter CN101485887B A VB O
focuses CN101485887B A NNS O
, CN101485887B A , O
and CN101485887B A CC O
can CN101485887B A MD O
be CN101485887B A VB O
subjected CN101485887B A VBN O
to CN101485887B A TO O
enzymolysis CN101485887B A VB O
through CN101485887B A IN O
high-expression CN101485887B A NN O
phospholipase CN101485887B A NN I-UN
A2 CN101485887B A NNP I-UN
on CN101485887B A IN O
the CN101485887B A DT O
focuses CN101485887B A NNS O
to CN101485887B A TO O
metabolize CN101485887B A VB O
active CN101485887B A JJ O
skin CN101485887B A NN O
cancer CN101485887B A NN O
resistant CN101485887B A JJ O
medicines CN101485887B A NNS O
, CN101485887B A , O
namely CN101485887B A RB O
the CN101485887B A DT O
5-fluorouracil CN101485887B A JJ O
, CN101485887B A , O
so CN101485887B A IN O
that CN101485887B A IN O
the CN101485887B A DT O
copolymers CN101485887B A NNS O
and CN101485887B A CC O
the CN101485887B A DT O
delivery CN101485887B A NN O
system CN101485887B A NN O
have CN101485887B A VBP O
the CN101485887B A DT O
advantage CN101485887B A NN O
of CN101485887B A IN O
skin-targeted CN101485887B A JJ O
medication CN101485887B A NN O
of CN101485887B A IN O
skin CN101485887B A NN O
cancer CN101485887B A NN O
, CN101485887B A , O
overcomes CN101485887B A VBZ O
the CN101485887B A DT O
defects CN101485887B A NNS O
that CN101485887B A IN O
the CN101485887B A DT O
water-soluble CN101485887B A JJ O
5-fluorouracil CN101485887B A NN O
is CN101485887B A VBZ O
not CN101485887B A RB O
suitable CN101485887B A JJ O
for CN101485887B A IN O
transdermal CN101485887B A JJ O
administration CN101485887B A NN O
and CN101485887B A CC O
has CN101485887B A VBZ O
low CN101485887B A JJ O
envelop CN101485887B A JJ O
rate CN101485887B A NN O
of CN101485887B A IN O
liposome CN101485887B A NN O
, CN101485887B A , O
easy CN101485887B A JJ O
leakage CN101485887B A NN O
and CN101485887B A CC O
difficult CN101485887B A JJ O
acquisition CN101485887B A NN O
of CN101485887B A IN O
liposome CN101485887B A NN O
with CN101485887B A IN O
superior CN101485887B A JJ O
transdermal CN101485887B A JJ O
carrier CN101485887B A NN O
performance CN101485887B A NN O
, CN101485887B A , O
and CN101485887B A CC O
provides CN101485887B A VBZ O
a CN101485887B A DT O
novel CN101485887B A JJ O
medicine CN101485887B A NN O
source CN101485887B A NN O
for CN101485887B A IN O
clinical CN101485887B A JJ O
medicines CN101485887B A NNS O
. CN101485887B A . O

Application CN1739528A T NN O
of CN1739528A T IN O
monomeric CN1739528A T JJ O
alkaloid CN1739528A T NN O
extracted CN1739528A T VBN O
from CN1739528A T IN O
Hubei CN1739528A T NNP O
fritillary CN1739528A T JJ O
bulb CN1739528A T NN O
in CN1739528A T IN O
preparing CN1739528A T VBG O
medicine CN1739528A T NN O
for CN1739528A T IN O
relieving CN1739528A T VBG O
cough CN1739528A T NN O
, CN1739528A T , O
eliminating CN1739528A T VBG O
phlegm CN1739528A T NN O
and CN1739528A T CC O
relieving CN1739528A T VBG O
asthma CN1739528A T NN O
. CN1739528A T . O

Novel US20120142679 T JJ O
2,3-dihydro-1h-imidazo US20120142679 T JJ O
( US20120142679 T ( O
1,2-a US20120142679 T JJ O
) US20120142679 T ) O
pyrimidin-5-one US20120142679 T NN O
derivatives US20120142679 T NNS O
, US20120142679 T , O
preparation US20120142679 T NN O
thereof US20120142679 T NN O
, US20120142679 T , O
and US20120142679 T CC O
pharmaceutical US20120142679 T JJ O
use US20120142679 T NN O
thereof US20120142679 T NN O
. US20120142679 T . O

Application CN103655540A T NN O
of CN103655540A T IN O
myricetin CN103655540A T NN O
crystal CN103655540A T NN O
compound CN103655540A T NN O
to CN103655540A T TO O
medicament CN103655540A T NN O
of CN103655540A T IN O
nerve CN103655540A T NN O
inhibitor CN103655540A T NN O
. CN103655540A T . O

Epicatechin EP2561767A1 T NNP O
for EP2561767A1 T IN O
alleviating EP2561767A1 T VBG O
symptoms EP2561767A1 T NNS O
of EP2561767A1 T IN O
allergy EP2561767A1 T NN O
. EP2561767A1 T . O

Anti-atopic WO2011083853A1 T NNP O
dermatitis WO2011083853A1 T NN O
agent WO2011083853A1 T NN O
. WO2011083853A1 T . O

Cefodizime CN103271880A T NNP O
sodium CN103271880A T NN O
injection CN103271880A T NN O
and CN103271880A T CC O
preparation CN103271880A T NN O
method CN103271880A T NN O
thereof CN103271880A T NN O
. CN103271880A T . O

Preparation CN103463090A T NNP O
method CN103463090A T NN O
of CN103463090A T IN O
sitagliptin CN103463090A T NN O
metformin CN103463090A T NN O
hydrochloride CN103463090A T NN O
compound CN103463090A T NN O
preparation CN103463090A T NN O
. CN103463090A T . O

Alkanoic WO2010070076A1 T NNP O
acid WO2010070076A1 T NN O
derivatives WO2010070076A1 T NNS O
and WO2010070076A1 T CC O
their WO2010070076A1 T PRP$ O
therapeutic WO2010070076A1 T JJ O
use WO2010070076A1 T NN O
as WO2010070076A1 T IN O
hdac WO2010070076A1 T NN O
inhibitors WO2010070076A1 T NNS O
. WO2010070076A1 T . O

Antifungal US20090270496 T NNP O
compounds US20090270496 T NNS O
. US20090270496 T . O

Administering US6953591 T VBG O
to US6953591 T TO O
a US6953591 T DT O
mammal US6953591 T JJ O
non-toxic US6953591 T JJ O
effective US6953591 T JJ O
T-cell US6953591 T NNP O
function-mediated US6953591 T JJ O
disorder-treating US6953591 T JJ O
amount US6953591 T NN O
of US6953591 T IN O
phosphatidyl US6953591 T NN O
serine US6953591 T NN O
( US6953591 T ( O
PS US6953591 T NNP O
) US6953591 T ) O
carrying US6953591 T VBG O
bodies US6953591 T NNS O
wherein US6953591 T VBP O
progression US6953591 T NN O
of US6953591 T IN O
T-cell US6953591 T NNP O
function-mediated US6953591 T JJ O
disorder US6953591 T NN O
is US6953591 T VBZ O
inhibited US6953591 T VBN O
. US6953591 T . O

Cellulose US20100279982 T NNP O
derivative US20100279982 T NN O
. US20100279982 T . O

COMPOUNDS EP2668168A1 T NN O
FOR EP2668168A1 T IN O
THE EP2668168A1 T DT O
REDUCTION EP2668168A1 T NNP O
OF EP2668168A1 T NNP O
ß-AMYLOID EP2668168A1 T JJ I-UN
PRODUCTION EP2668168A1 T NNP O
. EP2668168A1 T . O

New WO2009049460A1 T NNP O
packaging WO2009049460A1 T NN O
material WO2009049460A1 T NN O
for WO2009049460A1 T IN O
sevoflurane WO2009049460A1 T NN O
. WO2009049460A1 T . O

Non-sedating US20100197709 T JJ O
barbiturate US20100197709 T NN O
compounds US20100197709 T NNS O
as US20100197709 T IN O
neuroprotective US20100197709 T JJ O
agents US20100197709 T NNS O
. US20100197709 T . O

Methods US7465445 T NNS O
of US7465445 T IN O
preventing US7465445 T VBG O
or US7465445 T CC O
treating US7465445 T VBG O
graft US7465445 T NN O
versus US7465445 T NN O
host US7465445 T NN O
reaction US7465445 T NN O
by US7465445 T IN O
administering US7465445 T VBG O
an US7465445 T DT O
antibody US7465445 T NN O
or US7465445 T CC O
portion US7465445 T NN O
thereof US7465445 T NN O
that US7465445 T WDT O
binds US7465445 T VBZ O
to US7465445 T TO O
AILIM US7465445 T NNP I-UN
. US7465445 T . O

An US7465445 A DT O
antibody US7465445 A NN O
against US7465445 A IN O
AILIM US7465445 A NNP I-UN
( US7465445 A ( O
alternatively US7465445 A RB O
called US7465445 A VBN O
JTT-1 US7465445 A NNP I-UN
antigen US7465445 A NN O
, US7465445 A , O
JTT-2 US7465445 A NNP I-UN
antigen US7465445 A NN O
, US7465445 A , O
ICOS US7465445 A NNP I-UN
and US7465445 A CC O
8F4 US7465445 A CD I-UN
) US7465445 A ) O
was US7465445 A VBD O
found US7465445 A VBN O
to US7465445 A TO O
have US7465445 A VB O
a US7465445 A DT O
significant US7465445 A JJ O
therapeutic US7465445 A JJ O
effect US7465445 A NN O
on US7465445 A IN O
arthrosis US7465445 A NN O
, US7465445 A , O
for US7465445 A IN O
example US7465445 A NN O
, US7465445 A , O
rheumatoid US7465445 A VB O
arthritis US7465445 A NN O
and US7465445 A CC O
osteoarthritis US7465445 A NN O
, US7465445 A , O
graft US7465445 A NN O
versus US7465445 A NN O
host US7465445 A NN O
disease US7465445 A NN O
, US7465445 A , O
graft US7465445 A NN O
immune US7465445 A NN O
rejection US7465445 A NN O
, US7465445 A , O
inflammation US7465445 A NN O
( US7465445 A ( O
hepatitis US7465445 A NN O
and US7465445 A CC O
inflammatory US7465445 A JJ O
bowel US7465445 A NN O
diseases US7465445 A NNS O
) US7465445 A ) O
, US7465445 A , O
diseased US7465445 A JJ O
condition US7465445 A NN O
accompanied US7465445 A VBN O
by US7465445 A IN O
the US7465445 A DT O
excessive US7465445 A JJ O
production US7465445 A NN O
of US7465445 A IN O
an US7465445 A DT O
antibody US7465445 A NN O
against US7465445 A IN O
a US7465445 A DT O
foreign US7465445 A JJ O
antigen US7465445 A NN O
triggered US7465445 A VBN O
by US7465445 A IN O
immunological US7465445 A JJ O
sensitization US7465445 A NN O
by US7465445 A IN O
the US7465445 A DT O
antigen US7465445 A NN O
. US7465445 A . O

Adenosine US8188100 T NNP O
derivatives US8188100 T NNS O
as US8188100 T IN O
A2A US8188100 T NNP I-UN
receptor US8188100 T NN O
agonists US8188100 T NNS O
. US8188100 T . O

A US8188100 A DT O
compound US8188100 A NN O
of US8188100 A IN O
formula US8188100 A NN O
( US8188100 A ( O
I US8188100 A PRP O
) US8188100 A ) O
, US8188100 A , O
or US8188100 A CC O
stereoisomers US8188100 A NNS O
or US8188100 A CC O
pharmaceutically US8188100 A RB O
acceptable US8188100 A JJ O
salts US8188100 A NNS O
thereof US8188100 A NN O
, US8188100 A , O
formula US8188100 A NN O
( US8188100 A ( O
1 US8188100 A CD O
) US8188100 A ) O
, US8188100 A , O
or US8188100 A CC O
stereoisomers US8188100 A NNS O
or US8188100 A CC O
pharmaceutically US8188100 A RB O
acceptable US8188100 A JJ O
salts US8188100 A NNS O
thereof US8188100 A NN O
, US8188100 A , O
wherein US8188100 A VBZ O
A US8188100 A NNP O
, US8188100 A , O
U1 US8188100 A NNP O
, US8188100 A , O
U2 US8188100 A NNP O
, US8188100 A , O
R1a US8188100 A NNP O
, US8188100 A , O
R1b US8188100 A NNP O
, US8188100 A , O
R2 US8188100 A NNP O
and US8188100 A CC O
R3 US8188100 A NNP O
have US8188100 A VBP O
the US8188100 A DT O
meanings US8188100 A NNS O
as US8188100 A IN O
indicated US8188100 A VBN O
in US8188100 A IN O
the US8188100 A DT O
specification US8188100 A NN O
, US8188100 A , O
are US8188100 A VBP O
useful US8188100 A JJ O
for US8188100 A IN O
treating US8188100 A VBG O
conditions US8188100 A NNS O
mediated US8188100 A VBN O
by US8188100 A IN O
activation US8188100 A NN O
of US8188100 A IN O
the US8188100 A DT O
adenosine US8188100 A NN I-UN
A2A US8188100 A NNP I-UN
receptor US8188100 A NN I-UN
, US8188100 A , O
especially US8188100 A RB O
inflammatory US8188100 A JJ O
or US8188100 A CC O
obstructive US8188100 A JJ O
airways US8188100 A NNS O
diseases US8188100 A NNS O
. US8188100 A . O

Novel WO2014091239A1 T NNP O
pharmaceutical WO2014091239A1 T JJ O
formulations WO2014091239A1 T NNS O
and WO2014091239A1 T CC O
their WO2014091239A1 T PRP$ O
use WO2014091239A1 T NN O
in WO2014091239A1 T IN O
the WO2014091239A1 T DT O
treatment WO2014091239A1 T NN O
of WO2014091239A1 T IN O
periodontal WO2014091239A1 T JJ O
disease WO2014091239A1 T NN O
. WO2014091239A1 T . O

The WO2014091239A1 A DT O
present WO2014091239A1 A JJ O
invention WO2014091239A1 A NN O
relates WO2014091239A1 A VBZ O
to WO2014091239A1 A TO O
novel WO2014091239A1 A JJ O
treatments WO2014091239A1 A NNS O
of WO2014091239A1 A IN O
periodontal WO2014091239A1 A JJ O
disease WO2014091239A1 A NN O
by WO2014091239A1 A IN O
administering WO2014091239A1 A VBG O
a WO2014091239A1 A DT O
suitable WO2014091239A1 A JJ O
formulation WO2014091239A1 A NN O
of WO2014091239A1 A IN O
a WO2014091239A1 A DT O
cyclophilin WO2014091239A1 A NN I-UN
inhibitor WO2014091239A1 A NN O
. WO2014091239A1 A . O

The WO2014091239A1 A DT O
present WO2014091239A1 A JJ O
invention WO2014091239A1 A NN O
further WO2014091239A1 A RBR O
relates WO2014091239A1 A VBZ O
to WO2014091239A1 A TO O
novel WO2014091239A1 A VB O
pharmaceutical WO2014091239A1 A JJ O
compositions WO2014091239A1 A NNS O
containing WO2014091239A1 A VBG O
said WO2014091239A1 A VBD O
cyclophilin WO2014091239A1 A JJ I-UN
inhibitor WO2014091239A1 A NN O
compounds WO2014091239A1 A NNS O
. WO2014091239A1 A . O

Novel WO2008111669A1 T NNP O
prophylactic WO2008111669A1 T JJ O
and/or WO2008111669A1 T NN O
therapeutic WO2008111669A1 T JJ O
agent WO2008111669A1 T NN O
for WO2008111669A1 T IN O
diabetic WO2008111669A1 T JJ O
neuropathy WO2008111669A1 T NN O
. WO2008111669A1 T . O

Rhamm US20100062000 T NNP I-UN
, US20100062000 T , O
a US20100062000 T DT O
Co-Receptor US20100062000 T NNP O
and US20100062000 T CC O
Its US20100062000 T PRP$ O
Interactions US20100062000 T NNS O
with US20100062000 T IN O
Other US20100062000 T JJ O
Receptors US20100062000 T NNS O
in US20100062000 T IN O
Cancer US20100062000 T NNP O
Cell US20100062000 T NNP O
Motility US20100062000 T NNP O
and US20100062000 T CC O
the US20100062000 T DT O
Identification US20100062000 T NNP O
of US20100062000 T IN O
Cancer US20100062000 T NNP O
Prognitor US20100062000 T NNP O
Cell US20100062000 T NNP O
Populations US20100062000 T NNP O
. US20100062000 T . O

CD44 US20100062000 A NNP I-UN
is US20100062000 A VBZ O
an US20100062000 A DT O
integral US20100062000 A JJ O
hyaluronan US20100062000 A NN I-UN
receptor US20100062000 A NN I-UN
that US20100062000 A WDT O
can US20100062000 A MD O
either US20100062000 A VB O
promote US20100062000 A NN O
or US20100062000 A CC O
inhibit US20100062000 A NN O
motogenic US20100062000 A JJ O
signaling US20100062000 A NN O
in US20100062000 A IN O
tumor US20100062000 A NN O
cells US20100062000 A NNS O
. US20100062000 A . O

Rhamm US20100062000 A NNP I-UN
is US20100062000 A VBZ O
a US20100062000 A DT O
non-integral US20100062000 A JJ O
cell US20100062000 A NN O
surface US20100062000 A NN O
( US20100062000 A ( O
CD168 US20100062000 A NNP I-UN
) US20100062000 A ) O
and US20100062000 A CC O
intracellular US20100062000 A JJ O
hyaluronan US20100062000 A NN I-UN
binding US20100062000 A VBG I-UN
protein US20100062000 A NN I-UN
that US20100062000 A WDT O
promotes US20100062000 A VBZ O
cell US20100062000 A VBP O
motility US20100062000 A NN O
in US20100062000 A IN O
vitro US20100062000 A NN O
and US20100062000 A CC O
whose US20100062000 A WP$ O
expression US20100062000 A NN O
is US20100062000 A VBZ O
strongly US20100062000 A RB O
upregulated US20100062000 A VBN O
in US20100062000 A IN O
aggressive US20100062000 A JJ O
tumors US20100062000 A NNS O
. US20100062000 A . O

The US20100062000 A DT O
use US20100062000 A NN O
of US20100062000 A IN O
labeled US20100062000 A JJ O
Rhamm-binding US20100062000 A JJ O
agents US20100062000 A NNS O
in US20100062000 A IN O
culture US20100062000 A NN O
and US20100062000 A CC O
in US20100062000 A IN O
vivo US20100062000 A NN O
to US20100062000 A TO O
identify US20100062000 A VB O
tumorigenic US20100062000 A JJ O
progenitor US20100062000 A NN O
cells US20100062000 A NNS O
that US20100062000 A WDT O
exhibit US20100062000 A VBP O
an US20100062000 A DT O
aggressive US20100062000 A JJ O
phenotype US20100062000 A NN O
characterized US20100062000 A VBN O
by US20100062000 A IN O
high US20100062000 A JJ O
Rhamm US20100062000 A NNP I-UN
and US20100062000 A CC O
CD44 US20100062000 A NNP I-UN
expression US20100062000 A NN O
is US20100062000 A VBZ O
further US20100062000 A JJ O
described US20100062000 A NN O
. US20100062000 A . O

Methods EP0890105B1 T NNS O
related EP0890105B1 T VBN O
to EP0890105B1 T TO O
Alzheimer EP0890105B1 T NNP O
's EP0890105B1 T POS O
disease EP0890105B1 T NN O
for EP0890105B1 T IN O
diagnosis EP0890105B1 T NN O
, EP0890105B1 T , O
manufacture EP0890105B1 T NN O
of EP0890105B1 T IN O
medicaments EP0890105B1 T NNS O
and EP0890105B1 T CC O
screening EP0890105B1 T NN O
of EP0890105B1 T IN O
substances EP0890105B1 T NNS O
and EP0890105B1 T CC O
beta-amyloid EP0890105B1 T JJ I-UN
related EP0890105B1 T JJ O
peptides EP0890105B1 T NNS O
. EP0890105B1 T . O

Also EP0890105B1 A RB O
described EP0890105B1 A VBN O
are EP0890105B1 A VBP O
methods EP0890105B1 A NNS O
of EP0890105B1 A IN O
therapy EP0890105B1 A NN O
for EP0890105B1 A IN O
Alzheimer EP0890105B1 A NNP O
's EP0890105B1 A POS O
disease EP0890105B1 A NN O
using EP0890105B1 A VBG O
peptides EP0890105B1 A NNS O
that EP0890105B1 A WDT O
bind EP0890105B1 A VBP O
to EP0890105B1 A TO O
the EP0890105B1 A DT O
neurotrophin EP0890105B1 A JJ I-UN
receptor EP0890105B1 A NN I-UN
( EP0890105B1 A ( O
p75 EP0890105B1 A JJ I-UN
< EP0890105B1 A NNP O
NTR EP0890105B1 A NNP O
> EP0890105B1 A NNP O
) EP0890105B1 A ) O
and EP0890105B1 A CC O
competitively EP0890105B1 A RB O
inhibit EP0890105B1 A VB O
the EP0890105B1 A DT O
binding EP0890105B1 A NN O
of EP0890105B1 A IN O
beta EP0890105B1 A NN I-UN
-amyloid EP0890105B1 A NN I-UN
to EP0890105B1 A TO O
the EP0890105B1 A DT O
p75 EP0890105B1 A NN I-UN
< EP0890105B1 A NNP O
NTR EP0890105B1 A NNP O
> EP0890105B1 A NNP O
. EP0890105B1 A . O

Production CN103251934A T NNP O
process CN103251934A T NN O
of CN103251934A T IN O
sheep CN103251934A T NN O
and CN103251934A T CC O
goat CN103251934A T NN O
steroid CN103251934A T VBP O
hormone CN103251934A T NN O
antigen CN103251934A T NN O
twins CN103251934A T VBZ O
vaccine CN103251934A T NN O
. CN103251934A T . O

Furan US20080287430 T NNP O
Compounds US20080287430 T NNP O
Useful US20080287430 T NNP O
As US20080287430 T IN O
Ep1 US20080287430 T NNP I-UN
Receptor US20080287430 T NNP O
Antagonists US20080287430 T NNP O
. US20080287430 T . O

Compounds US20080287430 A NNS O
of US20080287430 A IN O
formula US20080287430 A NN O
( US20080287430 A ( O
I US20080287430 A PRP O
) US20080287430 A ) O
or US20080287430 A CC O
a US20080287430 A DT O
pharmaceutically US20080287430 A RB O
acceptable US20080287430 A JJ O
derivative US20080287430 A JJ O
thereof US20080287430 A NN O
wherein US20080287430 A NN O
X US20080287430 A NNP O
, US20080287430 A , O
Z US20080287430 A NNP O
, US20080287430 A , O
R1 US20080287430 A NNP O
, US20080287430 A , O
R2a US20080287430 A NNP O
, US20080287430 A , O
R2b US20080287430 A NNP O
, US20080287430 A , O
R3 US20080287430 A NNP O
, US20080287430 A , O
and US20080287430 A CC O
Rx US20080287430 A NNP O
are US20080287430 A VBP O
as US20080287430 A IN O
defined US20080287430 A VBN O
in US20080287430 A IN O
the US20080287430 A DT O
specification US20080287430 A NN O
, US20080287430 A , O
a US20080287430 A DT O
process US20080287430 A NN O
for US20080287430 A IN O
the US20080287430 A DT O
preparation US20080287430 A NN O
of US20080287430 A IN O
such US20080287430 A JJ O
compounds US20080287430 A NNS O
, US20080287430 A , O
pharmaceutical US20080287430 A JJ O
compositions US20080287430 A NNS O
comprising US20080287430 A VBG O
such US20080287430 A JJ O
compounds US20080287430 A NNS O
and US20080287430 A CC O
the US20080287430 A DT O
use US20080287430 A NN O
of US20080287430 A IN O
such US20080287430 A JJ O
compounds US20080287430 A NNS O
in US20080287430 A IN O
medicine US20080287430 A NN O
. US20080287430 A . O

Lansoprazole CN102198106A T JJ O
nano-particle CN102198106A T JJ O
frozen CN102198106A T JJ O
preparation CN102198106A T NN O
for CN102198106A T IN O
injection CN102198106A T NN O
and CN102198106A T CC O
preparation CN102198106A T NN O
method CN102198106A T NN O
thereof CN102198106A T NN O
. CN102198106A T . O

NOVEL EP1631823A2 T NNP O
REGULATORY EP1631823A2 T NNP O
MECHANISMS EP1631823A2 T NNP O
OF EP1631823A2 T IN O
NF-kappaB EP1631823A2 T NNP I-UN
. EP1631823A2 T . O

The EP1631823A2 A DT O
instant EP1631823A2 A JJ O
invention EP1631823A2 A NN O
pertains EP1631823A2 A NNS O
to EP1631823A2 A TO O
the EP1631823A2 A DT O
discovery EP1631823A2 A NN O
of EP1631823A2 A IN O
two EP1631823A2 A CD O
novel EP1631823A2 A JJ O
regulatory EP1631823A2 A JJ O
mechanisms EP1631823A2 A NNS O
of EP1631823A2 A IN O
NF-kB EP1631823A2 A NNP I-UN
. EP1631823A2 A . O

The EP1631823A2 A DT O
instant EP1631823A2 A JJ O
invention EP1631823A2 A NN O
demonstrates EP1631823A2 A VBZ O
that EP1631823A2 A IN O
NF-kB EP1631823A2 A NNP I-UN
is EP1631823A2 A VBZ O
regulated EP1631823A2 A VBN O
by EP1631823A2 A IN O
PinI-catalyzed EP1631823A2 A NNP O
prolyl EP1631823A2 A NN O
isomerization EP1631823A2 A NN O
and EP1631823A2 A CC O
ubiquitin-mediated EP1631823A2 A JJ O
proteolysis EP1631823A2 A NN O
of EP1631823A2 A IN O
p65 EP1631823A2 A NN I-UN
. EP1631823A2 A . O

Accordingly EP1631823A2 A RB O
, EP1631823A2 A , O
the EP1631823A2 A DT O
instant EP1631823A2 A JJ O
invention EP1631823A2 A NN O
provides EP1631823A2 A VBZ O
methods EP1631823A2 A NNS O
for EP1631823A2 A IN O
regulating EP1631823A2 A VBG O
NF-kB EP1631823A2 A NNP I-UN
, EP1631823A2 A , O
and EP1631823A2 A CC O
diseases EP1631823A2 A NNS O
and EP1631823A2 A CC O
disorders EP1631823A2 A NNS O
associated EP1631823A2 A VBN O
with EP1631823A2 A IN O
NF-kB EP1631823A2 A NNP I-UN
. EP1631823A2 A . O

Further EP1631823A2 A RB O
, EP1631823A2 A , O
the EP1631823A2 A DT O
invention EP1631823A2 A NN O
provides EP1631823A2 A VBZ O
compositions EP1631823A2 A NNS O
capable EP1631823A2 A JJ O
of EP1631823A2 A IN O
modulating EP1631823A2 A VBG O
the EP1631823A2 A DT O
activity EP1631823A2 A NN O
or EP1631823A2 A CC O
expression EP1631823A2 A NN O
of EP1631823A2 A IN O
NF-kB EP1631823A2 A NNP I-UN
, EP1631823A2 A , O
Pinl EP1631823A2 A NNP I-UN
, EP1631823A2 A , O
and/or EP1631823A2 A VBZ O
the EP1631823A2 A DT O
proteolysis EP1631823A2 A NN O
of EP1631823A2 A IN O
p65 EP1631823A2 A NN I-UN
. EP1631823A2 A . O

DERIVATIVES US20120316176 T NNP O
OF US20120316176 T NNP O
7,8-DIHYDRO-1H-IMIDAZO US20120316176 T JJ O
[ US20120316176 T NNP O
2,1-b US20120316176 T JJ O
] US20120316176 T NNP O
PURIN-4 US20120316176 T NNP O
( US20120316176 T ( O
5H US20120316176 T CD O
) US20120316176 T ) O
-ONE US20120316176 T NN O
and US20120316176 T CC O
METHODS US20120316176 T NNP O
OF US20120316176 T NNP O
USE US20120316176 T NNP O
THEREOF US20120316176 T NNP O
. US20120316176 T . O

Application CN101077341A T NN O
of CN101077341A T IN O
aurantio-obtusifolin CN101077341A T NN O
or CN101077341A T CC O
its CN101077341A T PRP$ O
derivates CN101077341A T NNS O
in CN101077341A T IN O
preparing CN101077341A T VBG O
hypolipidemic CN101077341A T JJ O
drug CN101077341A T NN O
. CN101077341A T . O

N-methylformamide EP2598147A1 T JJ O
solvate EP2598147A1 T NN O
of EP2598147A1 T IN O
dasatinib EP2598147A1 T NN O
. EP2598147A1 T . O

Aryl EP1087946B1 T NNP O
alkanoylpyridazines EP1087946B1 T NNS O
. EP1087946B1 T . O

Said EP1087946B1 A NNP O
compounds EP1087946B1 A NNS O
have EP1087946B1 A VBP O
a EP1087946B1 A DT O
phosphodiesterase-IV EP1087946B1 A JJ I-UN
inhibiting EP1087946B1 A NN O
action EP1087946B1 A NN O
and EP1087946B1 A CC O
can EP1087946B1 A MD O
be EP1087946B1 A VB O
used EP1087946B1 A VBN O
in EP1087946B1 A IN O
the EP1087946B1 A DT O
treatment EP1087946B1 A NN O
of EP1087946B1 A IN O
allergic EP1087946B1 A JJ O
disorders EP1087946B1 A NNS O
, EP1087946B1 A , O
asthma EP1087946B1 A NN O
, EP1087946B1 A , O
chronic EP1087946B1 A JJ O
bronchitis EP1087946B1 A NN O
, EP1087946B1 A , O
atopic EP1087946B1 A NN O
dermatitis EP1087946B1 A NN O
, EP1087946B1 A , O
psoriasis EP1087946B1 A NN O
and EP1087946B1 A CC O
other EP1087946B1 A JJ O
skin EP1087946B1 A NN O
diseases EP1087946B1 A NNS O
, EP1087946B1 A , O
inflammatory EP1087946B1 A NN O
diseases EP1087946B1 A NNS O
, EP1087946B1 A , O
auto-immune EP1087946B1 A JJ O
diseases EP1087946B1 A NNS O
such EP1087946B1 A JJ O
as EP1087946B1 A IN O
rheumatoid EP1087946B1 A JJ O
arthritis EP1087946B1 A NN O
, EP1087946B1 A , O
multiple EP1087946B1 A JJ O
sclerosis EP1087946B1 A NN O
, EP1087946B1 A , O
Crohn EP1087946B1 A NNP O
's EP1087946B1 A POS O
disease EP1087946B1 A NN O
, EP1087946B1 A , O
diabetes EP1087946B1 A VBZ O
mellitus EP1087946B1 A NN O
or EP1087946B1 A CC O
ulcerative EP1087946B1 A JJ O
colitis EP1087946B1 A NN O
, EP1087946B1 A , O
osteoporosis EP1087946B1 A NN O
, EP1087946B1 A , O
transplant EP1087946B1 A JJ O
rejection EP1087946B1 A NN O
reactions EP1087946B1 A NNS O
, EP1087946B1 A , O
cachexia EP1087946B1 A NN O
, EP1087946B1 A , O
tumour EP1087946B1 A JJ O
growth EP1087946B1 A NN O
or EP1087946B1 A CC O
tumour EP1087946B1 A NN O
metastases EP1087946B1 A NNS O
, EP1087946B1 A , O
sepsis EP1087946B1 A NN O
, EP1087946B1 A , O
memory EP1087946B1 A NN O
disturbances EP1087946B1 A NNS O
, EP1087946B1 A , O
atherosclerosis EP1087946B1 A NN O
and EP1087946B1 A CC O
AIDS EP1087946B1 A NNP O
. EP1087946B1 A . O

Semuloparin EP2656851A1 T NNP O
for EP2656851A1 T IN O
improving EP2656851A1 T VBG O
the EP2656851A1 T DT O
survival EP2656851A1 T NN O
of EP2656851A1 T IN O
patients EP2656851A1 T NNS O
with EP2656851A1 T IN O
cancer EP2656851A1 T NN O
. EP2656851A1 T . O

Application CN103212077A T NN O
of CN103212077A T IN O
Erbin CN103212077A T NNP I-UN
inhibitor CN103212077A T NN O
in CN103212077A T IN O
preparation CN103212077A T NN O
of CN103212077A T IN O
antitumor CN103212077A T JJ O
drug CN103212077A T NN O
. CN103212077A T . O

The CN103212077A A DT O
invention CN103212077A A NN O
provides CN103212077A A VBZ O
application CN103212077A A NN O
of CN103212077A A IN O
an CN103212077A A DT O
Erbin CN103212077A A NNP I-UN
inhibitor CN103212077A A NN O
in CN103212077A A IN O
preparation CN103212077A A NN O
of CN103212077A A IN O
an CN103212077A A DT O
antitumor CN103212077A A JJ O
drug CN103212077A A NN O
. CN103212077A A . O

The CN103212077A A DT O
inhibitor CN103212077A A NN O
is CN103212077A A VBZ O
specifically CN103212077A A RB O
a CN103212077A A DT O
compound CN103212077A A NN O
capable CN103212077A A JJ O
of CN103212077A A IN O
lowering CN103212077A A VBG O
expression CN103212077A A NN O
of CN103212077A A IN O
Erbin CN103212077A A NNP I-UN
or CN103212077A A CC O
interfering CN103212077A A VBG O
Erbin-ErbB2 CN103212077A A JJ O
interaction CN103212077A A NN O
. CN103212077A A . O

The CN103212077A A DT O
Erbin-Erbin CN103212077A A JJ O
interaction CN103212077A A NN O
is CN103212077A A VBZ O
crucial CN103212077A A JJ O
to CN103212077A A TO O
tumor-prompting CN103212077A A JJ O
action CN103212077A A NN O
and CN103212077A A CC O
carcinogenic CN103212077A A JJ O
action CN103212077A A NN O
of CN103212077A A IN O
ErbB2 CN103212077A A NNP I-UN
; CN103212077A A : O
the CN103212077A A DT O
ErbB2 CN103212077A A NNP I-UN
dependent CN103212077A A JJ O
cancer CN103212077A A NN O
cell CN103212077A A NN O
proliferation CN103212077A A NN O
or CN103212077A A CC O
tumor CN103212077A A NN O
growth CN103212077A A NN O
can CN103212077A A MD O
be CN103212077A A VB O
inhibited CN103212077A A VBN O
by CN103212077A A IN O
over-expressing CN103212077A A VBG O
a CN103212077A A DT O
PDZ CN103212077A A NNP I-UN
structural CN103212077A A JJ O
segment CN103212077A A NN O
of CN103212077A A IN O
Erbin CN103212077A A NNP I-UN
or CN103212077A A CC O
excessively CN103212077A A RB O
giving CN103212077A A VBG O
tail-end CN103212077A A JJ O
polypeptide CN103212077A A NN O
segments CN103212077A A NNS O
to CN103212077A A TO O
the CN103212077A A DT O
ErB2 CN103212077A A NNP I-UN
in CN103212077A A IN O
the CN103212077A A DT O
cell CN103212077A A NN O
. CN103212077A A . O

The CN103212077A A DT O
invention CN103212077A A NN O
provides CN103212077A A VBZ O
a CN103212077A A DT O
novel CN103212077A A JJ O
way CN103212077A A NN O
of CN103212077A A IN O
treating CN103212077A A VBG O
ErbB2 CN103212077A A NNP I-UN
positive CN103212077A A JJ O
tumors CN103212077A A NNS O
, CN103212077A A , O
i.e. CN103212077A A FW O
, CN103212077A A , O
a CN103212077A A DT O
way CN103212077A A NN O
of CN103212077A A IN O
inhibiting CN103212077A A VBG O
protein CN103212077A A JJ O
stability CN103212077A A NN O
and CN103212077A A CC O
kinase CN103212077A A NN O
activity CN103212077A A NN O
of CN103212077A A IN O
the CN103212077A A DT O
ErbB2 CN103212077A A NNP I-UN
by CN103212077A A IN O
reducing CN103212077A A VBG O
the CN103212077A A DT O
expression CN103212077A A NN O
of CN103212077A A IN O
Erbin CN103212077A A NNP I-UN
or CN103212077A A CC O
interfering CN103212077A A VBG O
with CN103212077A A IN O
the CN103212077A A DT O
combination CN103212077A A NN O
of CN103212077A A IN O
ErBin CN103212077A A NNP I-UN
and CN103212077A A CC O
ErbB2 CN103212077A A NNP I-UN
, CN103212077A A , O
so CN103212077A A IN O
that CN103212077A A IN O
the CN103212077A A DT O
tumor-prompting CN103212077A A JJ O
action CN103212077A A NN O
and CN103212077A A CC O
carcinogenic CN103212077A A JJ O
action CN103212077A A NN O
of CN103212077A A IN O
the CN103212077A A DT O
ErbB2 CN103212077A A NNP I-UN
are CN103212077A A VBP O
inhibited CN103212077A A VBN O
. CN103212077A A . O

Preparation CN103751116A T NNP O
method CN103751116A T NN O
of CN103751116A T IN O
gentamicin CN103751116A T JJ O
sulphate-loading CN103751116A T JJ O
porous CN103751116A T JJ O
hydroxyapatite/PLGA CN103751116A T NN O
( CN103751116A T ( O
poly CN103751116A T JJ O
( CN103751116A T ( O
DL-lactide-co-glycolide CN103751116A T NNP O
) CN103751116A T ) O
microspheres CN103751116A T NNS O
. CN103751116A T . O

Carboxyl- WO2009080555A3 T JJ O
or WO2009080555A3 T CC O
hydroxyl- WO2009080555A3 T JJ O
substituted WO2009080555A3 T JJ O
benzimidazole WO2009080555A3 T NN O
derivatives WO2009080555A3 T NNS O
. WO2009080555A3 T . O

Synthesis US6958145 T NN O
of US6958145 T IN O
cyclic US6958145 T JJ O
compounds US6958145 T NNS O
. US6958145 T . O

Norethisterone-containing EP2520289A1 T JJ O
patch EP2520289A1 T NN O
. EP2520289A1 T . O

N- US7393849 T JJ O
[ US7393849 T NNP O
4-Amidinobenzoyl US7393849 T JJ O
] US7393849 T NNP O
-N- US7393849 T NNP O
[ US7393849 T NNP O
3-phenoxybenzyl US7393849 T JJ O
] US7393849 T NNP O
-3- US7393849 T NNP O
( US7393849 T ( O
4-biphenyl US7393849 T JJ O
) US7393849 T ) O
-alanyl-glycyl-amide US7393849 T NN O
; US7393849 T : O
anticarcinogenic US7393849 T JJ O
, US7393849 T , O
antidiabetic US7393849 T JJ O
, US7393849 T , O
anticholesterol US7393849 T JJ O
agent US7393849 T NN O
, US7393849 T , O
cardiovascular US7393849 T JJ O
disorders US7393849 T NNS O
, US7393849 T , O
osteoporosis US7393849 T NN O
. US7393849 T . O

Sulfonamide US7393849 A NNP O
and US7393849 A CC O
urea US7393849 A JJ O
compounds US7393849 A NNS O
having US7393849 A VBG O
an US7393849 A DT O
inhibitory US7393849 A JJ O
effect US7393849 A NN O
on US7393849 A IN O
Src US7393849 A NNP I-UN
kinase US7393849 A NN O
including US7393849 A VBG O
enantiomers US7393849 A NNS O
, US7393849 A , O
stereoisomers US7393849 A NNS O
and US7393849 A CC O
tautomers US7393849 A NNS O
thereof US7393849 A RB O
, US7393849 A , O
as US7393849 A RB O
well US7393849 A RB O
as US7393849 A IN O
pharmaceutically US7393849 A RB O
acceptable US7393849 A JJ O
salts US7393849 A NNS O
or US7393849 A CC O
solvates US7393849 A NNS O
of US7393849 A IN O
said US7393849 A VBD O
compound US7393849 A NN O
, US7393849 A , O
said US7393849 A VBD O
compound US7393849 A NN O
having US7393849 A VBG O
the US7393849 A DT O
general US7393849 A JJ O
structure US7393849 A NN O
shown US7393849 A VBN O
in US7393849 A IN O
Formula US7393849 A NNP O
II US7393849 A NNP O
are US7393849 A VBP O
disclosed US7393849 A VBN O
and US7393849 A CC O
claimed US7393849 A VBN O
: US7393849 A : O

Use US20120264701 T NNP O
of US20120264701 T IN O
d-ribose US20120264701 T NN O
for US20120264701 T IN O
fatigued US20120264701 T JJ O
subjects US20120264701 T NNS O
. US20120264701 T . O

Ampk US20110118359 T NNP O
activating US20110118359 T VBG O
agent US20110118359 T NN O
. US20110118359 T . O

Composition US20060177423 T NN O
and US20060177423 T CC O
method US20060177423 T NN O
for US20060177423 T IN O
killing US20060177423 T VBG O
of US20060177423 T IN O
tumours US20060177423 T NNS O
. US20060177423 T . O

Bioavailability US20050095293 T NNP O
of US20050095293 T IN O
drug US20050095293 T NN O
independent US20050095293 T JJ O
of US20050095293 T IN O
gastric US20050095293 T JJ O
pH US20050095293 T NN O
; US20050095293 T : O
core US20050095293 T NN O
comprised US20050095293 T VBD O
of US20050095293 T IN O
water US20050095293 T NN O
soluble US20050095293 T JJ O
acid US20050095293 T NN O
( US20050095293 T ( O
s US20050095293 T JJ O
) US20050095293 T ) O
of US20050095293 T IN O
tartaric US20050095293 T JJ O
acid US20050095293 T NN O
, US20050095293 T , O
fumaric US20050095293 T JJ O
acid US20050095293 T NN O
, US20050095293 T , O
succinic US20050095293 T JJ O
acid US20050095293 T NN O
, US20050095293 T , O
citric US20050095293 T JJ O
acid US20050095293 T NN O
, US20050095293 T , O
malic US20050095293 T JJ O
acid US20050095293 T NN O
, US20050095293 T , O
glutamic US20050095293 T JJ O
acid US20050095293 T NN O
, US20050095293 T , O
and/or US20050095293 T JJ O
aspartic US20050095293 T JJ O
acid US20050095293 T NN O
or US20050095293 T CC O
salts US20050095293 T NNS O
; US20050095293 T : O
acid US20050095293 T JJ O
resistance US20050095293 T NN O
; US20050095293 T : O
drug US20050095293 T NN O
delivery US20050095293 T NN O
. US20050095293 T . O

Telaprevir WO2009150194A1 T NNP O
dosing WO2009150194A1 T VBG O
regimen WO2009150194A1 T NNS O
. WO2009150194A1 T . O

Nucleic CN101302511A T NNP O
acid CN101302511A T NN O
molecule CN101302511A T NN O
NRN1SR12 CN101302511A T NNP O
and CN101302511A T CC O
use CN101302511A T VB O
thereof CN101302511A T NN O
in CN101302511A T IN O
anti-cancer CN101302511A T JJ O
medicine CN101302511A T NN O
preparation CN101302511A T NN O
. CN101302511A T . O

